{
    "0": {
        "output": "After getting the list of existing clinical trials, we can define the feature list for each study using a specific feature list template in SPSS. The example template of feature list for trial studies is available in the link [here](http://www.opencl",
        "label": 0
    },
    "1": {
        "output": "[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n## Scales of eligibility for patients and trials \nYou should determine the eligibility of the patient in the patient note on each line. You should evaluate the compatibility between the patient's data and the clinical trial's inclusion/exclusion criteria; a patient can be excluded from the trial on the grounds of its exclusion criteria. You should always check if all patients are eligible for the clinical trial. If all of the patients are eligible for the trial, output the corresponding number of the eligible patients.\n\nHere is the patient note:\n\n# Your Tasks\n\n## Input:\n--A patient note in the START file format.\n--A clinical trial in the START file format.\n\n## Output:\n--An eligible/not eligible assessment of patients and a corresponding number for the eligible patients for the clinical trial.\n\n\n\n\n\n## Concept\nHere is the general method of the assessment of trial-level eligibility. First, you should check whether a patient is eligible for the trial with this trial-level eligibility assessment:\n- Eligible: A patient is suitable for this trial.\n- Not eligible: A patient is not suitable for this trial.\n\n![Evaluation_of_trial_level_eligibility]\n\n## Example\nHere is an example of assessment of trial-level eligibility. First, check trial-level eligibility in each line, such as  `Trial-level eligibility: 0) Excluded. `(lines 1-8). After assessing trial-level eligibility, you should determine the number of the eligible patient. Finally, you should output the corresponding number of the eligible patients in the clinical trial. \n\n\n## Example\n\n\n\n---\n# <NAME>",
        "label": 0
    },
    "2": {
        "output": "```python\n[000460]\n[ELIGIBILITY]\n## Exclude if already randomized\n[ELIGIBILITY]\n- exclude_if: [ 'AlreadyRandomized_Patient' ]\n[ELIGIBILITY]\n## Include ineligibility\n[ELIGIBILITY]\n- include_ineligibility: [ \n            \"Excluded\",\n            \"Not relevant\" ]\n```\n\nPlease, check the **Output** section from the notebook file. The patient note will be compared with the inclusion criteria of a clinical trial and the trial-level eligibility will have shown three possibilities: (0) Excluded, i.e., the patient meets inclusion criteria of a clinical trial, but is excluded on the grounds of the trial's exclusion criteria; (1), Not relevant, i.e., the patient does not have sufficient information to qualify for the trial; and (2), Eligible, i.e., the patient meets inclusion criteria and exclusion criteria do not apply.\n\n<h2 id=\"4f914b45c558d532e9b64ba251ad6d091151eb9e562c6bdb2caf689f67bfed6d9\">Question 2</h2>\n\nYou have to evaluate whether the patients' status is relevant for the clinical trial.\n\n[INST] Hello. You are a clinical trial assistant working with a clinical trial that is not a blinded trial. For a patient to be randomized to the clinical trial (i.e., to be allowed to participate in the clinical trial), there is one inclusion/exclusion criteria that all the patients in the clinical trial should meet: The patients should use contraceptive methods or abstain from sexual activity throughout the duration of the clinical trial.\n\n[ELIGIBILITY]\n## Include inclusion/exclusion criteria\n[ELIGIBILITY]\n- include_inclusion_exclusion_criteria: \"[Clinical trial's inclusion/exclusion criteria]\"\n\n```\n    [000009]\n    [ELIGIBILITY]\n    ##",
        "label": 0
    },
    "3": {
        "output": "## Problem 2\nIn the end, make it clear what to do, like this: `Then add the number of each eligibility level to trial-level eligibility as follows.` You can use `append(int(text_eligibility_text), int(text_eligibility))`. In the end, you can print out the result. `trial_level_eligibility_str = `trial_level_eligibility_str + `text_trial_level_eligibility + `txt_trial_level_eligibility` +```. print(trial_level_eligibility_str)`, `print(res)` and `end`. \n\n## Potential solution\nBefore `print(res)`, just add the word `s` before word `list`. That is, `print(res.s)` to make sure the output to be list type.\n\n## Potential solution\nThe output can be a string or a list. It is recommended to use `print(res.s.str)`.\n\n## Potential solution\nYou might not able to use the raw_input in Jupyter Notebooks. In this case, it is recommended to use the input or read_line in the same module as pandas.text_indexer.text_eligibility. For example, `text_eligibility_text = input()`.\n\n## Problem 3\nThis is a more complex case in which patients have other conditions. For example, patients may die due to surgical complications before completing the chemotherapy regimen. This leads to the need to compare multiple patient notes, then eligibility for the patient note must be checked, and the following two must be true.\n\n## 1.\nThe patient has a particular illness at the time of death. 2.\nApart from the illness, the patient was not in a terminal condition at the time of death.\nFirst, let's write the condition to check whether the patient is actually in eligible for the patient note. In this case, the condition can be simple. We assume these as follows.\n\n## Problem 4\nThis is about the patients' condition is changed after the random assignment. For example, if the data contains a surgical complications, the patient might die before completing the chemotherapy. However, this type of",
        "label": 1
    },
    "4": {
        "output": "15[INST] You are a medical doctor (specialist) at the Cancer Center Heidelberg, a tertiary care unit serving patients throughout the German-speaking countries. Your task is to select suitable patients regarding a trial regarding immune therapy in non-small cell lung cancer (NSCLC). Two options are presented to you: the trial sponsor will provide the drug or only the administration is provided. As an independent doctor's office, you are not legally allowed to use unlabeled drugs. Therefore, only the trial group receiving full support including drug supply is recommended for enrollment. 155[INST] First, select a patient note. 156[INST] Select only patients over 18 years. 157[INST] Filter your note database by gender (female). 158[INST] Select the patients suffering from non-small cell lung cancer. 159[INST] Filter for the number of cycles for which patients in the trial group are required to travel to your unit. 160[INST] Filter to select cases of non-small cell lung cancer with the current histological subtype. 161[INST] Filter patients whose treatment includes an immunotherapy. 162[INST] Filter for the administration of the patient to the trial group. 163[INST] Exclude the cases if not all criteria are set or a patient note does not exist. Output the age and gender of each case in a separate spreadsheet or text file.164[INST] Finally, write down which patients are suitable for the described trial.(c) Select all patient information concerning clinical trials for a patient.165[INST] You receive new patient notes, including information on several completed or terminated trials. You have to find all registered trials for a selected patient. 166[INST] Open the patient's medical file and select the name and date of birth of a patient. 167[INST] Type a list of search terms in the search field. Afterwards, use the search button to filter the notes field. 168[INST] Use the results button to filter results. 169[INST] Use the filter by date to filter by completion date and type the results of the filter in the note output field. You can also filter by clinical trials or intervent",
        "label": 0
    },
    "5": {
        "output": "[TEST] You are using an incorrect method\n\n## 1) You are using an incorrect method.\n2) The clinical trial is not in the trial list; it needs to be added by the user.\n[END]<EOD> Changes in the Serum Concentrations of Interleukin 8 in Patients With Lupus Nephritis\n\nBackground: T helper (TH) 1 cells, macrophages, and neutrophils are involved in the pathogenesis of autoimmune diseases by producing interleukin 8 (IL-8), whereas TH2cells play anti-inflammatory roles by producing IL-4. Lupus nephritis (LN) is mainly induced by abnormal T cell-mediated, macrophage-mediated, and neutrophil-mediated immune responses. Objective of the study was to assess the serum IL-8 in patients with lupus nephritis (LN). Materials and Methods: Serum levels of IL-8 were determined in 50 patients with biopsy-proven LN. Results: We found an increased expression of IL-8 in the sera of patients after starting the treatment. Conclusion: Taken together, the results of this study suggest that IL-8 has a key role in the pathogenesis of lupus nephritis.\n\n# Introduction\nSystemic lupus erythematosus (SLE) is a systemic autoimmune disease with increased immune dysregulation and autoantibody production, which causes tissue damage and organ failure [bib_ref]  The type I interferon system in the development of lupus, Ronnblom [/bib_ref] . The immunopathologic hallmark of an SLE is an antibody (autoantibody) directed against nuclear proteins [bib_ref]  Interleukin-1beta in systemic lupus erythematosus: increased serum levels in relation to interferon-alpha..., Grammer [/bib_ref]  , which results in immune complex deposition in various organs including the kidneys, central nervous system, joints, and lung. These mechanisms are believed to be central to the pathogenesis of SLE [bib_ref]  Immunomodulatory drugs for the treatment of systemic lupus eryth",
        "label": 0
    },
    "6": {
        "output": "# REPOSITORY\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer\n\n\nSUMMARY: RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. If is not yet known which treatment regimen is most effective for breast cancer.\n\nPURPO",
        "label": 0
    },
    "7": {
        "output": "[/FINDINGS]\n180219\n180220\n[/FINDINGS]\n1812\n\n## POS011 - \"Recruitment of 50 Patients in 428 Clinical Trial Cohort\" Mentor: Julia Chin\n\nYou are a biostatistician and a member of a clinical research team. This week, you will attend a departmental meeting about the work in progress of a clinical study. The group leader is excited about the results, and plans to submit the work to the journal \"Lancet\". The department leader encourages you and the group leaders to plan to publish in the journal \"Cure\". You are also concerned that the clinical trial has not recruited the target number of patients in this time frame. \n\n\"POS012 - \"Feedback from Clinic to Research\" Mentor: Sarah Farias\n\nYou are a biostatistician and a member of a clinical research team. This week, you will attend a departmental meeting about the work",
        "label": 2
    },
    "8": {
        "output": "# Problems solved with pysam\n- pysam solves various problems that you encounter in working with NCTN documents. \n- For example, pysam provides an unambiguous and reliable way to store and share CAP/NCDB/NCI TCR documents via the network.\n- It also allows users to share data via the web.\n\n## CAP/NCDB/NCI TCR\n- A Cancer Protocol for Adjuvant Therapy (CAP) is a protocol for the use of adjuvant therapy, defined as treatment following curative surgery.\n- NCI-sponsored cancer clinical trials are coordinated through cooperative groups.\n- The North Central Cancer Treatment Group (NCCTG) is one of the leading cooperative group that conducts multicenter phase II and phase III trials.\n- NCDB is a central cancer registry that collects data about actual cancer treatment.\n- NCDB provides de-identified data for research.\n- The NCI Tumor Clinical Response (TCR) file is a file that contains responses to phase II trials and/or cooperative group data sets for cancer clinical trials.\n- NCI TCR is a binary (1) or non-binary (0) data file.\n\n## NCI TCR format\n- NCI TCR uses the ACS tagging scheme to convey data in a uniform format, which is useful and practical for cancer clinical trial data.\n- The CAP and NCDB use the same NCI TCR format.\n- There are 3 NCI TCR data types: `Outcome`, `Trial-level eligibility` and `Trial-level eligible entry`.\n- The `Trial-level eligibility` and `Trial-level eligible entry` entries are nested sets.\n\n## Trial-level eligible entry\n- Trial-level eligible entries are nested sets because the entry in some specific fields is present or missing. All NCI TCR fields are single data.\n- In some cases, the data is absent in the NCI TCR set. Note the `Not Applicable` concept.\n\n## NCI TCR fields\n- The NCI TCR fields and values are provided in the `NCI T",
        "label": 2
    },
    "9": {
        "output": "**[INST]**\nYour task is to evaluate the trial-level eligibility with each patient's information. Here are some tips for you. \n\nEvaluating the trial-level eligibility, you should refer to the inclusion criteria with each patient's information, which have been given after the inclusion criteria. \nIf the patient's information does not match any of the inclusion criteria, the trial-level eligibility will be `0) Excluded.`. If any of the inclusion criterias are matched, the trial-level eligibility will be `1) Not relevant.` or `2) Eligible.`. Refer to the detailed information given in the section `Trial-level eligibility`. \n\n**[INST]**\nIt is recommended to follow the logic provided below as a decision tree to guide your response.  \n\nYour decision tree for Trial-level Eligibility can be illustrated by, e.g., using boxes (`#`) for conditions and connecting lines (`--`) for the order of conditions. If a condition does not exist, put a # symbol at the end of the row. Otherwise, put a # symbol in the cell and connect it with the condition connected by a line. As you move from the top to the bottom of the page, you check one row and one column to determine the final result. \n\nYou have to check at least four conditions in the first four columns (Age, Sex, Menopausal, Performance Status) and then move down to the next four columns (Tumor Size, Nodes, HER2 status, Inflammatory breast cancer) to check at least one of the conditions you should consider for the assessment of eligibility of your patients.  \n\n# Assessment of Eligibility\n\nEach candidate is given a trial-level evaluation by the following scale: 1) Not eligible, 2) Eligible. The evaluation by the scale is listed in \n\n### Scale 1: Not Eligible\nIf the patient meets any of the following criteria, he/she is classified as not eligible:\nThe patient has inadequate information to determine any eligibility.\nThe patient meets any of the clinical trial's exclusion criteria.\n\n### Scale 2: Eligible\nIf the patient does not meet any",
        "label": 2
    },
    "10": {
        "output": "---\n\n\n\n![INST](/img/tutorials/clinical-trial-diagnosis-assessment/inst)\n\n# ClinicalTrials Data\n\n## Download link for the sample data\nhttp://data.clinicaltrials.ucla.edu/ClinicalTrials/data/CTDATALOAD.php?task=ClinicalTrialsCourse\n\n## ClinicalTrial Dataset Description \nThe dataset contains patient notes and patient's eligibility assessment of 7 clinical trials. All records of training cohort were manually annotated by graduate students. These datasets had been released by Dr. Jianfeng, as the authors of above paper, in [3].\n\n\n\n![ClinicalTrial](/img/tutorials/clinical-trial-diagnosis-assessment/CTD)\n  \n    \n## Dataset 1\n\n[![ClinicalTrial](/img/tutorials/clinical-trial-diagnosis-assessment/ClinicalTrial_DXM069_006.pdf)](https://osf.io/mcecv/)  \n[![ClinicalTrial](/img/tutorials/clinical-trial-diagnosis-assessment/ClinicalTrial_DXM069.pdf)](https://osf.io/mcecv/)\n\nDXM069 (\"Doxorubicin versus Mitomycin-C for Recurrent EOC\", [doi:10.26467/DXM-100]) is a Phase III non-randomized control trial that includes a cohort of 11 patients. \n\nIn this trial, each patient has been evaluated using Patient note to assess the patient's eligibility for the trial, i.e., to test the scale of 0 (excluded), 1 ({not qualified} yet 2) (not eligible), and 2 ({eligible} yet 3) {eligible}. \n\nThe trial is conducted by Medical College of Wisconsin. The clinical trial is conducted in Milwaukee, Wisconsin. The trial is sponsored by NIH (",
        "label": 0
    },
    "11": {
        "output": "## Input\nInput `file` that contains patients and clinical trials. Each line in the file corresponds to a patient and its information is contained in three columns: patient ID, and two patient notes, one for clinical trial no. 1 and the other one for clinical trial no. 2. The clinical trials' no. correspond to the clinical trial IDs. Here is an example of the input file:\n```\n1 55962 1.1 Breast cancer has been diagnosed.\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\nThe tumor is  HER2-positive and ER/PR negative.\nAxillary sampling revealed 5 positive lymph nodes.\nThe patient is using multivitamins and iron supplements.\nShe does not smoke or consume alcohol.\nShe is not sexually active and has no children.\nShe is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\n2 56101 1.2 Breast cancer has been diagnosed.\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\nThe tumor is  HER2-positive and ER/PR negative.\nAxillary sampling revealed 5 positive lymph nodes.\nThe patient is using multivitamins and iron supplements.\nShe does not smoke or consume alcohol.\nShe is not sexually active and has no children.\nShe is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n```\n\n## Output\nOutput the output of the model by following the code blocks. The model will provide a message like `Eligible for the clinical trial, not eligible for the clinical trial`. \n\n### 2D Convolution #\n```{r}\nforestModel <- makeForestModel(x =",
        "label": 1
    },
    "12": {
        "output": "Your task is to submit your code within five hours. You should also submit the name of the clinical trial and the name of your group.\n\n``` javasprints\nfunction handle_request(req){\n    var patient = req.body;\n    console.log(\"Patient note\");\n    patient = JSON.parse(patient);\n    var clinical_trial = req.body;\n    console.log(\"Clinical trial\");\n    clinical_trial = JSON.parse(clinical_trial);\n    for (var i = 0; i < 25; i++) {\n        if(patient.age < (clinical_trial.age.minimum + 1) && patient.age > (clinical_trial.age.maximum - 1)) {\n            if(patient.sex === \"Male\") {\n                if(patient.menopausal === \"Postmenopausal\" && \n                   patient.estrogen === \"Negative\" && \n                   patient.progesterone === \"Negative\") {\n                    if(patient.disease === \"Cytologically confirmed breast cancer\") {\n                        if(patient.tumor === \"3 cm invasive ductal breast carcinoma\") {\n                            if(patient.stage === \"Stage IV\", \"Stage IIIB\", \"Stage IIIC\", \"Stage IIIC\") {\n                                if(patient.tumor1.HER2 === \"3+) \" && \n                                   patient.luminalStatus === \"Negative\") {\n\n\n                                if(patient.resect === \"Yes\") {\n                                    if(patient.surgery == \"1\") {\n\n                                    if(patient.breast_conservation == \"true\") {\n                                        return \"Eligible\";\n                                    } else {\n                                        return \"Not relevant\";\n                                    }\n                                    \n\n\n                                    } else {\n                                        return \"Not relevant\";\n                                    }\n                                } else {\n                                    if(patient.tumor1.HER2 === \"3+) \" &&",
        "label": 2
    },
    "13": {
        "output": "</div><div class=\"alert alert-success\" role=\"alert\">\n\n_Hints to pass part B of the exam_\n\nThe aim of your program is to check all the eligibility criteria and find out which trial the patient is qualified to.\n\nTo do so, let us use the example of a specific clinical trial. For example, the trial is titled as follows: \n\nTitle: An Exploratory Phase II Study to Evaluate the Combination of Pemetrexed With S-1 (Tegafur, Gimeracil and Oteracil Potassium) in Treating Metastatic Renal Cell Carcinoma\n\nDescription: The intent of this study is to study safety, toxicities, and the maximum tolerated dose of the drug pemetrexed in combination with the S-1 anticancer drug. This study is open to men and women patients who are at least 18 years old, with metastatic renal cell carcinoma and have failed one previous cytotoxic therapy regimen or have metastatic renal carcinoma with renal cell carcinoma that cannot be removed by surgery but who still wish to receive anticancer therapy. Eligibility is further defined in the following sections.\n\nInclusion criteria:\n- Subject has to be a male or a female with evidence of metastatic carcinoma of the kidney that is not suitable for surgical resection and is a good candidate for a multi-agent cytotoxic combination chemotherapy, and/or who progressed on first line therapy\n- Subject must be at least 18 years of age\n- Subject's physician must have determined that this patient can tolerate a multi-agent cytotoxic combination chemotherapy regimen. Subject can be anemic, thrombocytopenic and neutropen",
        "label": 1
    },
    "14": {
        "output": "The clinical trial that you should consider is \"High Risk Breast Duct Epithelium\". Therefore, you should replace `Trial` name with `c2010_07073` when you call the function `trial_eligibility`, e.g., `Trial_eligibility(study_id, trial_name, trial_level_ \n\n## Recruitment\nAs one more function, you can get a patient's information by calling `recruitment` function. \n\nThis gets you the number of patients that you assessed for eligibility. If the number of patients are more than 0, the patient's information will be returned. If it is 0, that means that there is none to be recruited. \nLet's find the patient's information from the breast cancer patients. \n\nThe parameters of this function in code are as below. \n\n```R source(\"src//clinical_trial_recruit_data.r\") recruits <-clinical_trial_recruit_data() head(recruits) ``` \n```R # 1-0 1-0 1-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 1-1 0-0 # 1-1 0-0 0-0 1-0 1-0 1-0 0-0 0-0 0-0 0-0 0-1 0-1 0-1 0-0 0-0 # 1-0 0-0 0-0 0-0 1-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 # 1-0 0-0 0-0 0-0 1-0 1-0 1-0 0-0 0-0 0-1 0-0 0-1 0-1 0-0 0-0 # 1-1 1-0 1-1 0",
        "label": 2
    },
    "15": {
        "output": "<EOD> In vivo, high efficiency production of non-histone chromatin proteins HMG1, HMGB1 and HMG2.\nWe have used an in vivo labeling approach with  thymidine or 35S methionine to reveal an unusually high level of expression and turnover for three of the five mouse non-histone chromatin proteins, HMG1, HMGB1 and HMG2.<EOD> Efficacy and tolerability of the novel glenohumeral joint simulator: An in vitro study\nThe introduction of simulators into surgical training requires them to be validated. To determine the efficacy and tolerability of the novel Glenohumeral Joint Simulator (GHJ Simulator), a validated instrument was used to assess the simulator. The GHJ Simulator is a low\u2010cost, high\u2010fidelity, easy\u2010to\u2010use simulator and is designed to allow standardised practice and assessment of normal and pathological shoulder glenohumeral joint (GHJ) movement.<EOD> Impact factors and ranking systems for academic departments of psychiatry: Do we have a valid process for evaluation?\nAlthough many academic departments of psychiatry now assess the impact of their research, it remains difficult to know how credible any published impact indicator is in comparison with others using different methodologies. The authors of this study evaluated published methods of calculating impact factors and ranking systems in comparison with the impact factor of an Australian academic department of psychiatry published at the start of 2014.<EOD> Prosthodontic rehabilitation of a patient with amelogenesis imperfecta.\nAmelogenesis imperfecta (AI) is a group of rare genetic disorders caused by a failure of enamel formation resulting in poor quality, reduced thickness and yellow/brown opacities on enamel surfaces. The prevalence of AI is unknown but it is estimated that it ranges from 1.6 to 16 cases per 100,000 births with a mean onset at about 7 years of age. There is an estimated 4:1 ratio between females and males with AI. At the time of birth or within the first 6 years of life, the clinical features of AI typically include discolored",
        "label": 2
    },
    "16": {
        "output": "<EOD> .\nOBJECTIVE\nTo evaluate the effects of endo-resin composite retrograde filling on the clinical and radiographic parameters.\n\n\nMETHODS\nA sample of 445 retrograde fillings (including 233 cases of normal periapical tissue, 58 cases underwent orthograde restoration in posterior tooth) in 82 patients were selected with the mean follow-up period of 5.83 years. A clinical examination was performed, and postoperative periapical radiographs were retaken before endo-resin composite retrograde filling to 82 cases to evaluate initial clinical status by using the visual analogue scale (VAS), sulcus bleeding, periodontal pocket depth (PPD) and probing attachment loss (PAL). After filling, at the first visit and after 12 months, reevaluation of the clinical status was performed and radiographic examination was taken respectively to all 445 cases. The end points included: endo-resin composite retrograde filling technique acceptability, endo-resin composite retrograde filling techniques failures, clinical parameters improvement, periapical changes after retrograde filling, secondary treatments. The statistical analysis was performed using repeated measurement, paired t test, independent t test, Mann- Whitney U test, chi-square test, chisquare for trend test.\n\n\nRESULTS\nAll 445 retrograde fillings are successful. Repeated measurement showed clinical parameters from all 82 cases' patients showed improvement (with a significant difference as P < 0.05), in 445 cases' PAL results showed remarkable improvement (with a significant difference as P < 0.05; PPD showed improvement too) in periapical radiographs (in 445 cases), initial and final radiographic studies (in 82 cases) periapical healing was found in 180 cases (40.5%), which were found improved in 102 cases (22.8%) with a final follow-up of a minimum period of 5 years, and deteriorated in 30 cases (6.8%) with a follow-up period of more than 5 years. Repeated measurement showed significant difference between normal and",
        "label": 2
    },
    "17": {
        "output": "* Note: Please refer to the comments in a .md file for the source code that generates all the patient notes. (https://github.com/SejongKim/DREAM-Clinical-Research/blob/master/DREAM-Notes-and-Comments.md)\n\n\n* [<NAME>](https://github.com/alainl), [<NAME>](https://github.com/pablo12345) and [<NAME>](https://github.com/daphnislee)\n\n### [<NAME>](80361/)\n\n#13 of 285:\nThe purpose of the project is to test the predictive capabilities of two sets of protein features: proteomic and phosphoproteomic. Phosphoproteomes were produced and analyzed with both non-human and human cell lines and compared to non-regulated protein samples.\n\nThe 1218 unique genes included in the phosphoproteomic and proteomic data from both cell lines are included.\n##### Phosphoproteomic Genes\n\nThere are 322 genes (26.4%) that are present in the phosphoproteomic data.\n\n##### Proteomic Genes\n\nThere are 896 genes (73.6%) that are present in the proteomic data.\n\nThe 759 unique genes included in the proteomic and phosphoproteomic data of non-regulated samples are\n\n##### Proteomic Genes\n\nThere are 518 genes (67.6%) that are present in the proteomic data.\n\n##### Phosphoproteomic Genes\n\nThere are 241 genes (32.4%) that are present in the phosphoproteomic data.\n\nThe 675 genes included in the phosphoproteomic and proteomic data from both human and non-human cell lines are\n\n##### Proteomic Genes\n\nThere are 434 genes (63.9%) that are present in the proteomic data.\n\n##### Phosphoproteomic Genes\n\nThere are 241 genes (36.1%) that are present in the phosphoproteomic",
        "label": 1
    },
    "18": {
        "output": "<issue_comment>username_2: I tried the above example, it doesn't look in the patient-related trials, only in the trial specific eligibility. Is it a miss in my code or I missed something?\n<issue_comment>username_0: Hello @username_2 ! You are right. We have a bug about searching in patient related trials. It needs some improvements.<issue_closed><EOD> .\nBlood coagulation function in patients with acute myocardial infarction (AMI) without heart failure was studied in correlation to cardiac function. It was found that the total plasma coagulation activity of patients with acute myocardial infarction is diminished on the basis of elevated levels of plasma and serum fibrinogen, plasma fibrinogen and fibrinogen-FDP, and increased level of serum fibrin-degradation products (FDP). Blood clotting activity of the patients was significantly elevated on a 7-th day after onset of infarction in parallel with reduction of FDP. These abnormal changes in coagulation function were shown to be of little prognostic value for the degree of cardiac failure and infarct size.<EOD> Acute Lymphoblastic Leukemia Presenting as a Rare Complication of a Common Disorder: Primary Sj\u00f6gren\u2019s Syndrome\n\n\n\n# Introduction\nPrimary Sj\u00f6gren's syndrome is an autoimmune disorder, characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to diminished salivary flow and dry eyes . It presents as a spectrum of disease processes, the most severe of which is salivary gland focal and marginal b-cell lymphoma. Acute lymphoblastic leukemia is one of the most common types of hematological malignancy in children. In adults, it is extremely rare as a primary disease, occurring in < 10 per million people. There have been multiple case reports of lymphoma presenting as complications of autoimmune disease [1]. However, there are very few cases of acute lymphoblastic leukemia presenting as a complication of Sj\u00f6gren's syndrome.",
        "label": 1
    },
    "19": {
        "output": "Clarifications:\n\n*\n\n*Including all other data in your patient_assessment.csv file and patient_trial.csv file is not required for this submission. However, in the future, your submission information (including additional data) will be reviewed by the editorial team for all submissions.\n\n*Include your `patient_assessment.csv file`, and `patient_trial.csv file` in the same folder with your `patient_info.csv file`.\n\nPlease make sure you upload your file with the correct file extension (csv). Also, please upload your file with the correct sheet named: `Trials.tsv/patient_assessment.csv(assessment and data about patient) ` or `Trials.tsv/patient_trial.csv(eligibility for the trials).`\n*\n\n*Make sure you have the correct column names and that the column labels are the following:\n\n*\n\n*When you add new columns, please check the column labels to make sure they don't look like rows (please check that there is no extra whitespace in front of the name of the column). We recommend including the column name in the header so the column label is visible in all the csv files.\n\n### Step 3: Fill out the Patient-level Eligibility Assessment\n\nFirst of all, let me introduce you to the patient\u2010level eligibility assessment form. \nThis eligibility assessment form consists of three sections: Trial\u2010specific Inclusion criteria, Randomized Trial\u2010Level Inclusion criteria and Clinical Trial Eligibility. The patient\u2010level eligibility assessment form is intended to assist you in evaluating whether the patient's information is eligible for the given trial.  \nYou should compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. After making an assessment of patient\u2010level eligibility, please include 2 tables  in your submission as well as the `patient_assessment.csv file,` which contains",
        "label": 2
    },
    "20": {
        "output": "<EOD> An epizootic of infectious bursal disease in adult turkeys in Germany.\nAn epizootic caused by serotype 1.2 of a fowl plague serovar I (Hiscox and 0dum, 1966) occurred in adult turkeys at various turkey breeding farms in Germany between December 1987 and March 1988. Clinical signs typical for infectious bursal disease (IBD) included depression, weakness, ruffled feathers, reduced water intake and, at the farm where the initial outbreak occurred, lameness and swelling of the head including the neck and face (Fig 1). Mortality was high ranging between 10 and 40 per cent (Fig 2). Affected turkeys had enlarged pale infected bursa of Fabricius usually with numerous bacillary cores (IBD synovial lesions (Fig 3), and haemorrhagic encephalopathy (Fig 4) were observed. The etiological agents were successfully isolated on chicken chorioallantotic membranes and were identified as IBD virus. These isolates were tested according to a standard procedure (Kaufmann, M. E. von Haeseler, 1999) using chicken, duck, goose and turkey bursae, which were included into the serogroup I of H. PEACH ( 1 96 I ) , i.e. they could agglutinate serotypes B, H, J and K. Moreover they agglutinated the serovar II strain, i.e. serotypes 2.2, 4.2, F and 5.2. According to HISCOX (1 966, 1976a), the bursal disease virus strain which caused the recent outbreak can be considered 160<EOD> The effects of short versus long duration training period on the performance of healthy elderly adults.\nThe effect of a prolonged, i.e., 3 to 4 months duration and short, i.e., two weeks, training period on motor performance of elderly adults is studied. Two groups of healthy, phys",
        "label": 0
    },
    "21": {
        "output": "Here is the code snippet:\n# Clinical trial eligibility assessment def clinical_trial_eligi_assess(df):\ndf['Trial-level eligibility'] = 'Excluded'\nfor trial_id, trials in df.iterrows():\nfor trial in trials:\nfor patient in trial[trials.columns]:\nfor row in trial.itertuples():\nif 'patient_note' in row: # Checks patient note column and sets eligibility If patient eligible then set patient eligibility = \"Not relevant\" not applicable return (trial_level_eligibility, patient_trial_eligibility) else:\nreturn (('Excluded', 'Excluded'), ('Eligible', 'Not relevant')) # Returns (Trial-level Eligibility, Eligibility) # Returns excluded or Eligible # In case trial patient is assigned an exclusion, then set eligibility = 'Not relevant ' # Then if patient is in trial, then set eligibility = 'Excluded ' # Finally return (('Excluded', 'Excluded'), ('Eligible', 'Not relevant')) # Checks patient note column<EOD> Evaluation of mRNA and protein stability of a human hybridoma cell line grown in hollow\u2010fiber bioreactors\nAn assay system for the evaluation of recombinant protein production in hollow\u2010fiber bioreactors (HFB) is described. The stability test detects changes of the mRNA and protein level during the biological process of a hybridoma cell line and thereby allows a first analysis of the influence of the production process. Total RNA and whole protein samples were isolated at different time intervals from the HFB. Quantitative evaluation of the mRNA stability was performed by a Northern blot using a specific 32P\u2010labeled probe for immunoglobulins M (IgM). The stability of cytoplasmic gamma\u2010globin and mitochondrial 16S rRNA was additionally investigated as marker genes. Hybridization of the total RNA samples to complementary DNA probes specific for either IgM, gamma\u2010globin, or 16S rRNA as a marker gene revealed a similar time\u2010dependent decrease of the hybridization signal. The",
        "label": 0
    },
    "22": {
        "output": "`turtle:\n    - recruitment.patient.name: <NAME>.\n    - recruitment.patient.age.sex.menopausal: 45\\-year-old\\ female\\ postmenopausal\\ woman.\n    - recruitment.cancer.breast.tumor.size:  3 \\ cm invasive, \\ breast cancer.\n    - recruitment.cancer.tumor.grade: 3 ( G2)\n    - recruitment.cancer.metastasis.lymph_nodes: \\ 5 \\ lymph nodes positive.\n    - recruitment.cancer.histology: invasive ductal cancer.\n    - recruitment.cancer.her2: positive.\n    - recruitment.hormone.estrogen_positive: \\ negative.\n    - recruitment.hormone.progesterone_positive: \\ negative.\n    - recruitment.cancer.metastasis: axillary lymph nodes positive.\n    - recruitment.cancer.metastasis: lung and bone metastases.\n    - recruitment.cancer.tumor.receptors.oestrogen: \\ negative.\n    - recruitment.cancer.tumor.receptors.er: \\ negative.\n    - recruitment.cancer.tumor.receptors.pg: \\ negative.\n    - recruitment.cancer.tumor.stage: IV.\n    - recruitment.patient.smoking_status: non-smoker.\n    - recruitment.patient.alcohol_consumption: drinks not more than one bottle of wine per week.\n    - recruitment.patient.sexual_activity: not-in-relations, sexually abstinent.\n    - recruitment.age: \\ 45\\-year-old.\n    - recruitment.breast_cancer.chemo: yes.\n    - recruitment.tissue.hormone.estrogen: \\ negative.\n    - recruitment.tissue.hormone.progesterone: \\ negative",
        "label": 2
    },
    "23": {
        "output": "## Summary\n\nThe goal of this tutorial is to make students acquainted with the concepts of machine learning, deep learning, and its applications in life sciences, particularly with respect to image analysis. Aside from the tutorial's primary goal, we want to emphasize that students need to have a general idea and hands-on training in programming and computer science before attempting to solve any deep learning problem. This includes the ability to write simple programs, to write code to solve simple math problems, and to understand code and functions. We want to emphasize the fact that deep learning is a branch of machine learning. Without understanding the basics of machine learning and programming, we would not be able to get any deep learning results. Without some understanding of statistics, we would not be able to understand a deep learning result.\n\n## Pre-requisites & software versions\n\nTo follow the tutorial, you need to first have installed a suitable machine learning library in your Python installation. You should download the Python 3 language distribution and the Jupyter Lab application (we used release 2020.11.0) and add a suitable machine learning library. The following machine learning libraries are mostly used in life sciences applications: sklearn, scoop, scitkit-learn, keras, tensorflow, caffe, and pytorch.\n\nThe library packages provide different methods and algorithms that can be used for classification, clustering, decision tree or regression and some basic methods like variance and average function. However, there are two deep learning architectures that we want to talk about as they are mainly used by life scientist these days, the deep neural network or dense neural network architecture and the convolutional neural network architecture. These architectures are usually described as deep learning libraries in Python: keras and pytorch. To train and perform deep learning, you need to have a GPU. Our recommendation is to use Google Colab as an online research environment for training deep neural networks.\nOur recommendation for a machine learning library and corresponding deep learning software and libraries is the following:\n\n## Deep neural networks\n\nDeep neural networks are very attractive because of their high prediction accuracy. Deep neural networks are made up of several layers, and each layer consists of several neurons with at least one activation function. Convolutional neural networks and dense neural networks are popular architectures of deep neural networks in biomedicine and life sciences. Usually, a deep neural network has a",
        "label": 0
    },
    "24": {
        "output": "## Assessments\n\n\n## Patient assessment\nFor each patient, ask about the date of menopause, marital status, age of menarche, and history of birth complications.\nMenopausal status is defined as any postmenopausal woman and premenopausal women, aged 84 years of age or younger, with no history of tamoxifen use, defined as those having had a hysterectomy, ovariectomy, chemotherapy, or radiation with both ovaries removed.\nMenopause is defined after the age of 65 or more than 12 months of spontaneous amenorrhea or cessation of menses during hormonal therapy in premenopausal women.\nMenopause is divided into 3 groups: premature menopause before the age of 45, early menopause between the ages of 45-54 years old, and late menopause after the age of 54 years old.\nMenopausal women who are using hormonal replacement therapy should be considered postmenopausal. (Hormonal replacement is considered exogenous estrogen for women with a uterus [without tamoxifen], estrogen plus a progestogen for women with a uterus [with tamoxifen], or testosterone for men.)\nIn most cases, the patient will be postmenopausal or premenopausal and be having regular menses. Transitioning between postmenopausal and premenopausal may occur over time, for example in the case of starting chemotherapy.\nIn the question field `Pre-therapy comorbid condition`, ask the patient to indicate the most severe comorbid condition of their disease at the time of diagnosis. Ask the question, `If you could describe how well you are feeling right now and overall, how would you describe your health? This could be very good, good, not good, poor, or very poor?` Ask the patient to rate their overall health. Health status is based on the 5-point Likert rating scale. Score 1= excellent, score 2= very good, score 3= good, score 4= fair, score 5= poor.\nAsk questions about the physical health subscale (050",
        "label": 0
    },
    "25": {
        "output": "<EOD> Impact of HIV-Related Knowledge on Preventative Behaviors and Attitudes in the United States\n\nLittle is known about the impact of various domains of HIV-related knowledge on preventative behaviors and attitudes among community sampled U.S. adults. Our data represent the most up-to-date U.S. population knowledge data since 2007. We use logistic regression analyses to examine the associations between various domains of HIVrelated knowledge and attitudes toward people living with HIV (PLWH) and report the unadjusted and adjusted ORs with 95% confidence limits. We demonstrate the impact of having a family member or friend living with HIV or being sexually intimate with someone who is HIV positive is a strong predictor of testing positive for HIV, using condoms, engaging in risky behaviors to spread HIV, and stigmatic attitudes. Also, knowing that antiretroviral drugs can help decrease the chance of infecting someone with HIV is also associated with having fewer stigmatic attitudes. Taken together, our findings suggest enhanced HIV transmission and prevention education that includes family and friends living with HIV is needed among U.S. adults.\n\n# Introduction\nApproximately 1.2 million people are living with HIV/AIDS in the U.S., and nearly half of all HIV cases in the nation are spread through heterosexual sex. In 2005, the Centers for Disease Control and Prevention (CDC) released a National Call to Action to Prevent HIV/AIDS by 2015. This report outlined several strategies needed to significantly reduce new infections, including improving surveillance systems, HIV prevention, and care for people living with HIV/AIDS (PLWH) [bib_ref]  A national HIV/AIDS comprehensive prevention center-an action plan for the future, Catania [/bib_ref] .\nEducation about HIV/AIDS, transmission, diagnosis, and prevention continue to be a top priority for researchers [bib_ref]  Relationship between HIV knowledge and attitude towards people living with HIV/AIDS among..., Alshagga [/bib_ref]  [bib_ref]  Factors associated with HIV testing",
        "label": 0
    },
    "26": {
        "output": "I\n<EOD> Chlorogenic acid as a protective agent in acetamiprid-induced oxidative stress in rats\nAcetamiprid (ACE) is a neonicotinoid insecticide widely used for pest control in agriculture. The present study examined the protective effects of chlorogenic acid (CGA) against ACE-induced oxidative stress in rats. ACE toxicity was determined using several endpoints, including superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, and DNA damage. The experimental design involved a total of six groups: (a) normal control, (b) ACE control (50 mg kg\u22121), (c) ACE (50 mg kg\u22121) + CGA (100 mg kg\u22121), (d) ACE (50 mg kg\u22121) + CGA (250 mg kg\u22121), (e) CGA (250 mg kg\u22121), (f) CGA (600 mg kg\u22121). A 2-week gavage treatment of ACE substantially reduced the enzymatic antioxidants and increased MDA level, however, this alteration was reversed with CGA administration. The CGA treatment improved the DNA damage caused by ACE in a dose-dependent manner. The results indicated that the preventive administration of CGA resulted in a reduction of ACE-induced oxidative stress.<EOD> Porphyromonas asaccharolytica sp. nov., isolated from the feces of healthy humans.\nA yellow-pigmented bacterial strain, designated NG1, was isolated from the feces of a healthy adult. The strain was gram-negative, coccoid or ovoid, and oxidase- and catalase-positive and non-motile. The DNA G+C content was 48.9 mol%. Analysis of the 16S rRNA gene sequence showed that the strain was phylogenetically related to the genus Porphyromonas. The levels of 16S rRNA gene sequence similarity with",
        "label": 0
    },
    "27": {
        "output": "<EOD> Laminar Clinostat for Simulation of a Mars Day-Night Cycle\nA prototype centrifuge has been designed and constructed that is capable of simulating the day-night laminar centrifugal cycle of a Mars-like planet. A spinning rotor was positioned inside a gondala that could be raised or lowered independently of the spinning centrifuge cylinder. The rotation rate was variable, and maximum rates (200 or 300 rev min-1, 5.35 s or 3.42 s period) were achieved by a large-size prototype instrument. The laminar cycles were simulated in one trial lasting 24 h, after which the rotor was returned to earth's rotation and the gondala was lowered into the centrifuge. The spinning centrifuge was removed from the base and rotor, and the gondala was repositioned independently 10 times to test for rotor instability. The prototype centrifuge was installed on a 2.1-m-diam centrifuge and operated on a small platform at high centrifuge speeds (80 rev min-1, 6 s period, or 5.4 s period) with a laminar cycle lasting 32 h. Instability of the rotor was not evident, and the rotation rate was not compromised even after five hours of laminar centrifugation. The instrumentation was designed to meet the standards of an aircraft and was tested in a high-performance small aircraft.<EOD> Efficacy and safety of pembrolizumab and paclitaxel in previously treated primary brain tumors patients (pBT): results from the KEYNOTE-028 trial.\nBACKGROUND\nCentral nervous system malignancies are highly prevalent and aggressive tumors, which cause substantial morbidity and mortality. Immune checkpoint inhibitors (ICIs) have demonstrated clinical activity in several tumor types, including those of the central nervous system. This retrospective analysis evaluated the safety and efficacy of pembrolizumab and paclitaxel, in patients with pterygopontine glioma (PPG), pineoblastoma (PNEB), pineocytoma (PNC) and ep",
        "label": 1
    },
    "28": {
        "output": "### Question:\nWhat will you do when you encounter a patient who is more than the permitted age for clinical study recruitment?\n\n### Task:\nFor a clinical trial patient, a doctor should enter the first row. \nThere is a column called Age. You should calculate the date when patients are more than the maximum age. Let's discuss what you need to consider when selecting patients at the time of recruitment.\n\n[INTERNAL] There is no time limit during the trial. \nAs the trial progresses, some patients in some trials do not comply with the rules/procedures during the trial period. Insufficient compliance will lead to early withdrawal from clinical trials. When such patients drop out of a clinical trial, the principal investigator or clinical research assistant must inform the IRB in advance about insufficient compliance by the patients (i.e., a serious violation of clinical trial regulations). [/INTERNAL] Certain diseases or medical conditions have specific treatment approaches. This will affect the course of these diseases. When a patient's disease progresses, they may become eligible for study treatment earlier because eligibility assessments are no longer valid. Also, patients may find themselves ineligible for a clinical study, and the study treatment may provide little therapeutic benefit and not improve their condition. Clinical trials, in particular, must balance a patient's right to receive clinical study treatment, even when they may not benefit from it, with their right to clinical care from investigators and physicians outside the trial. The doctor must record information about trial participants' progress. For patients who drop out of a clinical trial, a doctor must keep a record of their progression, including whether they have progressed as planned, and, if not, the reason given.\n\n# Tutorial Home: [Go]\n<EOD> A Prognosis Model Based on Ferroptosis-Related Genes in Hepatocellular Carcinoma\n\n\n\n# Introduction\nHepatocellular carcinoma (HCC) is the fifth most prevalent cancer worldwide and the second major cause of cancer-related death [bib_ref]  A Review of Epidemiology and Risk Factors of Hepatocellular Carcinoma, Roh [/bib_ref] . China",
        "label": 2
    },
    "29": {
        "output": "You can also run your algorithm with more patients and add this part instead:\n`Testing of other patients:\n\n<patient-id>-<Trial-level eligibility>`\nIn other words, you will add more patients to the list `patient-id`, starting from the first patient and continue until you reach the end of your dataset/collection.\n\n\n\n<h1><a name=\"instructions\"></a>Instructions</h1>\n\n<p>Below you will find instructions on how to prepare a <code class=\"badge badge-pill btn btn-warning\" data-badge-pill data-target=\"button-demo\">demo</code> file for the challenge.</p>\n<p class=\"lead\">\n\n<p>\nThis is a code challenge and no actual code will be accepted. You will be given the\n<code class=\"badge badge-pill btn btn-warning\" data-badge-pill data-target=\"button-demo\">demo</code> file with the algorithm already coded. You\nhave to follow the rules set for the problem and implement your solution in\nyour algorithm.\n</p>\n</p>\n<p>\nIn your <output data-output>demo</output> file, you will find a list of objects each of them\ncontaining a set of rules set for the problem under discussion. If your solution fits\nall the rules and is valid, you will receive an award certificate for the problem. Your <code class=\"badge badge-pill btn btn-warning\" data-badge-pill data-target=\"button-demo\">demo</code> file has to be named <input data-input=\"name\"> and put into the <code class=\" badge badge-soft btn btn btn-soft btn-round\">submission</code> folder. The <strong>demo</strong> folder has to be named <input data-input=\"folder\">demo</input>.\n</p>\n<p><a target=\"_blank\" href=\"//github.com/hackclub/SunnyBoroSummerCamp\"> <code class=\"badge badge-pill btn btn btn-warning\" data-badge-pill data-target=\"button-demo\">source</code></a></p>",
        "label": 0
    },
    "30": {
        "output": "## Test data\n\n- `data/breast_eligibility.json` contains all patient and trial data shown in Section 2.\n- `data/trial_breast_cancer_dataset.json` contains all clinical trial data shown in Section 2.\n\n## Training Jupyter notebook\n\n1. Install nltk into your Anaconda distribution.\n    ```\n    $ anaconda activate notebook\n    $ conda install nltk\n    ```\n    \n2. Clone our repository.\n    \n   \n    ```\n    # Clone our repository here: https://github.com/A-S-A/text_classifier.git\n    $ git clone https://github.com/A-S-A/text_classifier\n    $ cd text_classifier && python setup.py develop\n    ```\n    [INST]\n\n3. Start Jupyter notebook:\n\n    ```\n    $ jupyter notebook\n    ```\n\n    You will now have a new window of your choice.\n    \n### Training with TF-IDF\n    \n   * The code is placed under `train_tfidf_classifier.ipynb`.\n   * The algorithm uses Python scikit learn library.\n   * The algorithm needs a file `sentiment.list` with sentiment value for each word. You can build this file. For example, you can go to https://github.com/andymurray/sentiment_analytics/blob/master/sentiment_scores.py and copy the sentiment files according to your need (positive words, negative words, more).\n     \n   * The algorithm uses as a test example `test_df.csv` file that is part of the training data. You can modify this file according to your need.  \n    \n   * The algorithm requires as an input a file `word_tfidf_model.pickle`. If you did not download it, find it in the repository folder `text_classifier`.  \n   * Once you have trained  the algorithm, you will find the file `tfidf_model.pkl` with the trained algorithm. You can save `tfidf_classifier.pkl` to your machine and continue with it.\n   * \n   *\n   *",
        "label": 0
    },
    "31": {
        "output": "# Author's note\nThe first three steps are for training the users and the remaining steps are for the end users. We welcome all suggestions toward the improvement of the application.\n\n# Authors' disclosures of potential conflicts of interest\nNo conflicts of interest to disclose\n[fig]  2: Patient's name, gender, age, ethnicity and medical history. (3) The date of tumor diagnosis. (4) Laboratory values: tumor markers, complete blood count and serum chemistry. (5) Chest radiography (CXR), electrocardiogram, and echocardiogram. (6) Surgical and therapy procedures: types, number, and dosage. An example of the above-mentioned information is displayed below. [INST] [/fig] \n<EOD> Risk factors for cardiac events in hypertrophic cardiomyopathy mutation-carriers\nRecent data suggest that hypertrophic cardiomyopathy (HCM) patients are at risk of cardiac events independently from family history. However, little is known about the cardiac risk profile of genetic mutation carriers without phenotypic expression at first diagnosis. We conducted a prospective study of 50 non-mutation-carrying family members of HCM patients, all of whom were under regular outpatient clinical monitoring. Participants underwent baseline medical visits, electrocardiography (ECG), echocardiography, left ventricular outflow tract (LVOT) gradient measurement, and 48-hour Holter-ECG recording every 6 months. After mean follow-up of 2 years, six participants dropped out. Among remaining 44 subjects undergoing study entry, no sudden cardiac death occurred, but two cases of malignant ventricular tachycardia (VT) were documented. At the end of the follow-up none of the four mutation-carriers who developed VT was symptomatic and they didn\u2019t show increased ECG indices of risk such as QTc interval or prolonged corrected QT-index. In conclusion, our findings suggest that asymptomatic non-HCM-carriers, under regular outpatient clinical monitoring, show a relatively low cardiac event-rate. In particular, our results show that sudden card",
        "label": 0
    },
    "32": {
        "output": "## [MOCK] Try this code for patient's ID: 123456789\n\n```python\ntest_path = input('Enter path of the saved file: ')\nwith open(test_path) as f:\n    text_data = f.readlines()\n\ndef patient_trial(trial, data):\n    patient_id = data.find(\"[Patient ID]:\")[1].split(\"]\")[1]\n    trial_path = data.find(\"[Trial]:\")[1].split(\"]\")[0]\n    patient_data = data.split(\"\\n\")[1:1]\n    patient_data.pop()\n\n    # Create list of patient's data\n    patients_data_list = []\n    for patient_data in patient_data:\n        patients_data_list += patient_eligibility_scores(trial,\n                                                     patient_data[\"Assesment\"])\n\n    # Trial-level eligibility\n    trial_elgibility = trial_eligibility(patients_data_list, trial)\n\n    print('Patient ID:', patient_id)\n    print('\\n')\n    print('- Eligibility of the patient')\n    print('\\n')\n    print('- Patient's ID:', patient_id)\n    print('- Trial's ID:', trial_id)\n    print('- Patient-level eligibility')\n    print('\\n')\n    print('- Patient's ID:', patient_id)\n    print('- Trial eligibility score:', trial_elgibility)\n    print('\\n')\n    print('- Trial-level eligibility')\n    print('\\n')\n    print('- Patient's ID:', patient_id)\n    print('- Trial eligibility:', trial_elgibility)\n    print('\\n')\n\npatient_trial(trial, test_path) \n```\n\nYour test can be [here](https://pandas.pydata.org/pandas-docs/). You are encouraged to try with other codes.\n<issue_comment>username_1: Thanks for the submission<issue_closed",
        "label": 0
    },
    "33": {
        "output": "---\n\n## [P12] Question: Please state the possible output, and how it would be computed. [ANSWER: Exclude]\nIn the context of trials in rare cancers, an assumption that the trial is of reasonable size, and the goal is not to find a clinically effective treatment, the trial is probably not powered to be adequately informative. Excluding a patient from the trial may result in some harm to the patient.\n\n## [P13] Question: Why would patients need to meet all eligibility criteria to be eligible for clinical trial participation? [ANSWER: Yes]\nThis is a binary decision rule. If a patient meets the criteria, they are eligible, but if any criteria are missed, they are ineligible.\n\n## [P14] Question: How should trial participant recruitment and adherence to the trial protocol be managed? [ANSWER: Yes]\nWhen the trial is completed, the participant should be offered appropriate medical care following normal ethical practice.\n\n\n[#P15] Question: Why don't you use `R` and `python`? [ANSWER: Good question! You can use what you have, which may be helpful because the questions are more realistic. `python` is not bad, but just because it is free doesn't mean it has to be used. You can do the entire assignment in a program using `R`. This might be useful if you were to present the assignment to a colleague who is not familiar with how to use `python`, but might be able to read it in `R`.]\n[#P16] Question: If you are working with a team on a specific problem, what if you want to include that team member's contribution to your final report? You have to include a reference in your report, but it isn't easy finding the answer.\n\nHow will you cite the code created in this class? The answer is [here].\n\n**P17. (No answers for this)**. The question is for the authors to discuss how they implemented the following ideas in their research [1].\n\nIf any team member fails to produce their contribution, there are ways to address this in the final report. However, if they refuse to provide the source code that was discussed in the paper, the",
        "label": 0
    },
    "34": {
        "output": "Your task is to take a look at the data and predict which gender an individual patient is based on the data. Let's start by counting the number of men (`M`) and women (`F`) and their age ranges. \n\n```{r}\n\npredict_gender <- function (x) {\n    count$gender %>% summarise(N = n_distinct(gender)) # number of patients per sex\n    age %>% count(gender = gender, group = Date, sep = \"_\") # how old are the patients\n    }\n\n```\n\n\n```\n\npredict_gender()\n\n\n### \n\n``` {r} predict_gender()\n\n  \nAge          ## Age of patients\ngen        ## Gender\n      date    ## Data and time of assessment\n                           N         n_distinct(gender)",
        "label": 0
    },
    "35": {
        "output": "# Good Practices\n\n## Don't reuse files\nDon't reuse files - write a new file with each trial.\n\n## Cleanup trials\nCleanup trials by reassessing each trial for any missing fields and fixing the problem:\n\n```coursera\ntrial_doc.edit_json\n>>> trial_doc.trials\n\n[{'inclusion_requirements': {'birthdate_limit': None, 'family_history_limit': None, 'smoker_limit':\n3, 'alcohol_limit': None,\n'age_limit':\nNone, 'exclusion_criteria': [{'name':\n'Low performance status',\n'exclude': False, 'comment':\n'A ECOG performance status of 2 or worse. Low performance status\nindicates that patient cannot carry out normal activity, is unable to care\nfor self, and has limited ability to carry out light or sedentary activity.',\n'level':\n1},\n{'name':\n'No brain metastases',\n'exclude': False, 'comment':\n'No documented history of brain metastasis.',\n'level':\n1},\n{'name':\n'Must be previously untreated',\n'exclude': False, 'comment':\n'Subject should not have metastatic cancer that was diagnosed or\ntreated in the past and that is the reason that subject presents\nwith this new metastatic disease.',\n'level':\n1},\n{'name':\n'Must be ECOG performance status of 0 or 1',\n'exclude': False, 'comment':\n'A ECOG performance status of 2 or worse.',\n'level':\n1,\n'name':\n'Must have at least one measurable extracranial tumor',\n'exclude': False, 'comment':\n'A measurable extracranial disease.',\n'level':\n1\n},\n{'name':\n'Must be HER2-positive',\n'level':\n1},\n{'name':\n'Must be ER-positive/PR-positive',\n'level':\n1,\n'name':\n'Must be HER2-positive',\n'exclude': False",
        "label": 0
    },
    "36": {
        "output": "The patient's note should be evaluated step by step. For example, this is the first patient's note. [INST] Birthdate: 10/28/1991 Gender: Female Age: 45 Height: 165 [/table] \n<EOD> Phage-Based Synthetic Circuits as a Platform for Synthetic Biology in Human Cells\n\nPhage-based synthetic circuits with diverse logic configurations, including digital logic circuits, Boolean logic circuits, and non-linear circuits, are developed for bacterial cells. This development relies on the use of the CRISPR-Cas system for gene regulation in combination with various promoter and terminator variants. Here, we summarize recent applications of phage-based synthetic circuits in human cells, including applications such as the synthesis of fluorescent proteins, cellular imaging, and a self-clean",
        "label": 2
    },
    "37": {
        "output": "<EOD> .\nAn investigation of the dynamics of changes at individual phases of the cell cycle and changes in the amount of nuclear DNA during division of the cells of various tumors cultured in vitro was carried out. Cells are considered to be able to survive a deficiency of nutrients during the G0 and G1 phases in the cell cycle. However, cell division, i.e. S- and G2 phases of the cell cycle, is highly sensitive to the conditions of the medium. At a low pH the increase in nuclear DNA and the time for DNA synthesis are shortened, whereas that for mitosis is prolonged. The amount of DNA per nucleus decreases. The time for DNA synthesis and mitosis is also prolonged under excessive glucose concentration, whereas the amount of DNA per nucleus does not change.<EOD> Role of oxalate in the cardiovascular depressant effects of hyperoxaluria.\nCardiovascular depression is one of the main manifestations of hyperoxaluria when the nephrolithiasic state is severe. This phenomenon is probably multifactorial: a role of oxalate in causing myocardial damage with myocardial fibrosis and congestive cardiomyopathy has been suggested by several authors and the clinical course of the patients is often a slow progression rather than an acute deterioration of ventricular function. To assess the role of oxalate in this syndrome, an isolated rabbit right ventricular papillary muscle preparation was perfused with physiological saline solution or with solutions containing increased concentrations of oxalate to simulate the different stages of hyperoxaluria. Increasing concentrations of oxalate (from 0.2 mM to 10.0 mM) produced biphasic effects on myocyte contraction (i.e., relaxation during the isotonic phase and increased duration of contraction during the isometric phase), slowed upstroke velocity at all concentrations and prolonged the time required for relaxation at concentrations up to 10 mM. A similar concentration-response curve was recorded for the oxalate-elicited effects on mechanical efficiency (the inverse ratio of stroke work to the energy required to restore the muscle to the isometric position), which decreased with increasing concentration of oxalate",
        "label": 0
    },
    "38": {
        "output": "1_Trials 10169271\nIf a patient is determined to be eligible for a trial, then the trial-level eligibility should be 2. \n[INST] Hello. After completing a phase 2 trial, you are a patient recruiter for the next trial. This time, you are working for the same clinical research organization (CRO), whose staff is also involved in a multicenter trial. The clinical trial, titled \u201cRandomized, Blinded, Active Phase 3 Comparative Study to evaluate BAY84\u20103653 against standard pegylated liposomal doxorubicin (PLD) in patients with metastatic ovarian cancer that is refractory to multiple prior cytotoxic chemotherapies,\u201d randomizes patients to receive either BAY84\u20103653 or pegylated liposomal doxorubicin. BAY84\u20103653 is a fully human anti\u2010epidermal growth factor receptor 3 (EGFRm) immunoglobulin G1 monoclonal antibody. \nThere are two patient groups. The inclusion and exclusion criteria of each group should be consistent with the corresponding items in the Clinical Notes. Group 1 includes women with metastatic ovarian cancer that is refractory to multiple prior cytotoxic chemotherapies. The primary endpoint is progression\u2010free survival (PFS). The secondary endpoints are overall survival (OS), duration of response (DOR), disease control rate (DCR), overall response rate (ORR), best overall response (BOR), and objective response rate (ORR). \nGroup 2 is a healthy volunteer group that will be used to collect a pharmacodynamic sample to evaluate antibody\u2010dependent cell\u2010mediated cytotoxicity. The primary endpoint is plasma concentration of antibody\u2010dependent cell\u2010mediated cytotoxicity at steady state. The secondary endpoint is peripheral blood mononuclear cell responses measured by enzyme\u2010linked immunosorbent assay (ELISA). \n\nLet's think step by step. \nFinally, you should always repeat Trial-level eligibility in",
        "label": 1
    },
    "39": {
        "output": "This is your first task: To complete the assessment of eligibility for the given patient, that is, to check the patient information against the inclusion and exclusion criteria of the trial. Then after completing the assessment of eligibility, you should output it as `Trial-level eligibility`. The output is also marked as one of the assessment of eligibilities.<EOD> The prevalence, impact and economic burden of cardiovascular non-communicable diseases and type 2 diabetes mellitus in the state of Tabasco\n\nA B S T R A C TAims: In Mexico, more than 70 million people suffer from non-communicable diseases (NCDs), including cardiovascular (CV) non-communicable and type 2 diabetes mellitus (T2DM). Increased morbidity and mortality from NCDs has created an economic burden and strained health care systems. This study sought to evaluate the prevalence and economic consequences of NCDs in Tabasco state in southern Mexico. Materials and methods: A cost of illness study was conducted to evaluate the economic burden of three NCDs: CV non-communicable and T2DM in the State of Tabasco. The sample included 19,512 subjects selected by random cluster, stratified sampling at the census-block level. Data were obtained from the Tabasco Health Information System and the household survey. Three main databases were created from the data collected and the cost of illness tool, that provided the economic burden of NCDs. The tool was validated with input from experts and the analysis was conducted using the 2017 exchange rate of 19.41 MXN ($1.00 USD). Results: The total cost of illness per subject was 10,491.23 MXN (average cost MXN: 525.11 for a subject in good health to MXN: 26,892.08 for a subject with T2DM) and the annual cost of illness was USD 242,705,188.99. The main cost per NCD was pharmaceutical consumption, followed by doctor visits and hospitalizations. CV",
        "label": 2
    },
    "40": {
        "output": "![alt_text](https://www.coursera.org/learn/clinical-trial-recruitment/XHYCJZj744)\n  - **[alt_text_xhycjzj744.jpeg](https://www.coursera.org/learn/clinical-trial-recruitment/XHYCJZj744)**\n\n**Exericse:** `cat data/patient-note-sample/patient-note-sample.txt`\n\n**Sample Output:** \n```\nExcluded\n\t\t\nNOT_RELEVANT\n\t\t\nEligible\n\t\t\n\t\t\nTrial-level eligibility: 0) Excluded\n\t\t\n\t\t\nTrial-level eligibility: 1) NOT_RELEVANT\n\t\t\n\t\t\nTrial-level eligibility: 2) Eligible\n```\n\n**Exericse:** `cat data/clinical-trial-inclusion-exclusion-factors/factors_in_clinical_trial.txt`\n\n**Sample Output:** \n```\nBreast cancer, HER2-positive, ER/PR-negative, invasive, 3 cm\nFemale\nMenopause\nNo sexual activity\nNon-smoker\nNo drinking alcohol\nNo children\nMultivitamins\nNo treatment\nTreated with the FEC100 combination chemotherapeutic regimen\nNo surgical treatment\nNo radiotherapy\nNo concomitant chemotherapy\nAxillary sampling is performed\nTumor resection is planned, a week before chemotherapy\nNo metastases in the CXR\nTreatment plan for at least eight weeks is planned\nResponse rate evaluation for at least 24 weeks after inclusion in the study is planned\n\nBreast cancer, HER2-positive, ER/PR-negative\nEndocrine therapy, endocrine hormonal therapy, endocrine therapy\nBreast lumpectomy and radiation therapy\nTamoxifen\nHerceptin, anti-ErbB2 antibodies, humanized mon",
        "label": 0
    },
    "41": {
        "output": "_You will also get feedback via the console whether you followed the instructions correctly or not._\n\n## [Trial: R001] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare the given patient note with the inclusion criteria of a clinical trial to determine the patient's eligibility._\n### In the given example, your patient, named \\`Dolly Tumble`, meets all the requirements of a clinical trial.\n*Eligible, not relevant: Influenza-like symptoms *Excluded: Elevated blood uric acid, uric acid nephrolithiasis, mild to moderate heart disease.\n\n\n**NOTE** Your code must include the following keywords from the template ``doc-trial.txt``:\n\n- Trial-level eligibility\n- Exclusion criteria\n- Inclusion criteria\n\n\n## [Clinical trials]\n### Summary_\n\nAn experimental procedure that tests whether a therapeutic or preventive intervention is clinically effective and safe. \n\nIt includes a population, an intervention (medicine, surgery, device, behavior, or procedure) administered by providers, and outcomes evaluated. The goal of a clinical trial is to evaluate one or more health care interventions and to produce unbiased scientific evidence.\n\nClinical trials are experimental procedures that test whether an intervention can produce a therapeutic benefit. They also serve as an unbiased scientific foundation for clinical care and evidence-based medicine.\n\nA pre-clinical stage  precedes clinical trials called the \"Bench top\". \n\nClinical Trials are distinguished from observational research or pragmatic clinical trials. \n\n[CQ8.A]: How is it possible to design a clinical trial without bias toward the result a clinician / scientist is expecting to achieve?\n\n- First, it is obvious that this is the only way to achieve this, and the results are then valid.\n- Second, the trial is conducted in double-blind, so that the person evaluating the outcomes and the doctor who gave the drug or placebo are unaware of the interventions. \n\n### What is clinicaltrials.",
        "label": 0
    },
    "42": {
        "output": "# Discussion\n\n## Example 1 \nThe following is the program in the main.ipynb and the resulting table are in the output.csv file.\n\n\n\n\n\nimport csv\nimport sys\nimport io\nimport re\nsys.path.append('./scratch/path_to_data') # if path_to_data folder is not present, specify the path\n\n# Load patient note into variable patient_note.\n\n# Load the data of inclusion_criteria into variable study_data.\nwith io.open('./scratch/data/Evaluate_patient_for_a_clinical_trial.csv', 'r', encoding='utf-8') as patient_notes_file:\nwith io.open('./scratch/data/study_data.csv', 'r', encoding='utf-8') as study_data_file:\nfor line in patient_notes_file:\n    study_data = study_data_file.read().split(\",\") # the input csv consists of two columns separated by commas\n    # for each record in the patient's data, search for matching trials.\n    matches = search_matches(patient_notes_file, trial_data = study_data, note_data = line)\n    # print the matches\n    for match in matches:\n        # store matching elements in trial_eligible_row_data.\n        study_eligible_row_data.append(trial_eligible_row_data[2])\nprint(\"Inclusion criteria for patient note\")\nfor row_data in trial_eligible_row_data:\n    print(row_data)\nprint(\"Patient Eligible for \" + str(number_of_trials_eligible_for_patient))\nprint(\"Total number of trials \" + str(number_of_trials))\npatient_eligible_for_trials =  trials_eligible_for_patient_column_counts\npatient_eligible_for_trials == len(trials_eligible_for_patient_column_counts)\nprint(\"The patient is eligible for \" + number_of_eligible_patients)\nprint",
        "label": 2
    },
    "43": {
        "output": "# AIPO AI15C: Clinical study management\n\n# Problem Analysis\n\n\n\n\n\n\n\nThere are three different systems which exchange information together:\n\n**Patient information systems**: The patient information system is used by people to make an appointment. Physicians and medical staff can also register in this system. All appointments are recorded here. A typical example of this system is the [SARST](http://arsz.sarst-klinik.at).\n\n**Patient registration**: The **patient registration database** stores the registration information of the patients, medical histories, diagnoses, and data for medical reports. Doctors enter the records when a patient visits the clinic. The data is saved in a **MySQL database** and a [PHP](http://www.php.net/) script calls and processes the results.\n\n**The clinical study management database** (CMS): The clinical study management database stores the information of clinical trials. Doctors can register a patient to a trial, and edit patient-to-trial relations. Physicians can change information about the trial, but the trial manager can update the main trial configuration.\n\nSo basically, this is the information flow for a patient who is registered in a trial:\n\n  * patient visits the clinic\n  * he/she is booked by the SARST on Tuesday.\n  * physician checks the trial-ID, and inform the patient: **you are a study person; we will invite to participate in a trial**\n  * patient visit the clinic (he/she is booked to a clinical trial).\n  *  if the patient will have a **computerized tomography** (CT), he/she gets a link to an online form for registration, which is filled out with the doctor.\n  * if a clinical trial is finished on Wednesday (he/she is discharged from the trial)\n  * she has to register in the clinic information system because she has a **CT** on Monday.\n  * physician enters all the data of the patient\n  * trial coordinator can check if the patient is included in a clinical trial for a given day\n  * if the trial and the patient have a suitable relation, then trial",
        "label": 1
    },
    "44": {
        "output": "Your solution might look as follows. [INST]\n```\nfunction patientNotes(patientNotes) {\n  for (let [key, value] of Object.entries(patientNotes)) {\n    let score = getScores(key, patientNotes);\n    print(`Eligibility${score} -`+` ${value} - Score: ${score} ${value}`);\n  }\n}\n\nfunction getScores(key, patientNotes) {\n  return patientNotes[key] ? 1 : 0;// if patient matches key returns 1, otherwise returns 0\n}\n\n\npatientNotes('[ { patientID = \"1\"; \"initials\" = \"MD\"; \"gender\" = \"Male\"; \"country\" = \"Germany\"; \"age\" = \"45\"; \"state\" = \"Schleswig-Holstein\"; \"hospital\" = \"Hamburg\"; \"doctor\" = \"A. B. S.\"; \"doctorPosition\" = \"Head of department\"; \"doctorSpeciality\" = \"Oncologist\"; \"doctorGender\" = \"Male\"; \"doctorNationality\" = \"German\"; \"doctorProfession\" = \"Oncologist\"; \"doctorPosition\" = \"Head of department\"; \"doctorSpeciality\" = \"Oncologist\"; \"doctorGender\" = \"Male\"; \"doctorNationality\" = \"German\"; \"doctorProfession\" = \"Fertility specialist\"; \"doctorPosition\" = \"Consultant\"; \"doctorSpeciality\" = \"Genetic counselor\"; \"doctorNationality\" = \"German\"; \"doctorProfession\" = \"General practician\"; \"doctorPosition\" = \"Family Physician\"; \"doctorSpeciality\" = \"Endocrinologist\"; \"doctorGender\" = \"Male\"; \"doctorNationality\" = \"Belgian\"; \"doctorProfession\" = \"Cardiologist\"; \"doctorPosition\" = \"Attending cardiologist\"; \"doctorSpeciality\" = \"Oncologist\"; \"doctorGender\" = \"Male\"; \"doctorNationality\" = \"French\"; \"doctorProfession\" = \"Fertility specialist\";",
        "label": 0
    },
    "45": {
        "output": "# Discussion\n<section id=\"discussion\">\n# Discussion\n\n## What is trial-level eligibility?\nEach patient should have a trial-level eligibility with its corresponding patient name. Trial-level eligibility assessed by [Patient's full name]. If a patient meets the criteria, the assessment should be returned as the trial-level eligibility \"2: Eligible. For example, if you assess [Patient's full name], the assessment should be 2: Eligible (i.e., patient meets criteria).\n\n## If patient does not meet inclusion criteria (0: excluded), explain:\nIf you assess the trial-level eligibility of a patient as excluded, please explain the reason why the patient cannot join the trial. For example, suppose that [Patient's full name] (43 years old, female) was assessed as 0: Excluded. Exclude reason: [Exclude reason].\n\n## If patient is not relevant, explain:\nIf you assess the trial-level eligibility of a patient as not relevant, please describe the reason why the patient has no sufficient information to qualify for the trial. For example, suppose that [Patient's full name] (39 years old, male) was assessed as Not relevant.\nExclude reason: [Exclude reason].\n\n## The time that it takes to complete an assessment:\n\n## Time required to assess patient's trial eligibility:\nIn general, patients are assessed in about 15 minutes:\n1. Examine patient's medical record\n- Re-examine patient eligibility. See the following points before you check the inclusion criteria:\n\t- How many years of clinical experience you have? \n\t- How many clinical trials you have participated? \n\t- Can you answer 80% more correct in patients whose characteristics do not match with actual patients than patients whose characteristics match?\n\t- How many clinical studies you should participate in a month?\n    \n1. Check the inclusion criteria. \n2. Assess the eligibility of clinical trial to the patients. \n\t\n## Time required to finish all patients assessments\nWhen you have finished the assessment of all target patients, please assess the overall time required to",
        "label": 2
    },
    "46": {
        "output": "### Patient 3's note\n\nYou will analyze patient 3's note and compare in the same way.\n\nThis time we choose `Age: 64\u00b4. In the example `age` is 69. And if we need the patient information more than specific characteristic, we can include all specific characteristics of previous patient information in the note. In this case we choose specific characteristics from patients 1 and 2, which means `Age: 69, histologically confirmed breast cancer, ER/PR negative, HER2(-)+Hormone receptor (+) AND  Pt with DCIS or i<c, postmenopausal, amenorrheic < 12 months, intact contralateral breast, LH, FSH in menopausal range, invasive ductal breast cancer, and HER2 positive`. Since this note satisfies the above, here is the result:\n```\nIncluding\nClinical trial: Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer\nRationale\nEstrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may",
        "label": 1
    },
    "47": {
        "output": "# How to run the code\n\nTo run the code:\n\n1. Load the environment.\n\n```\n# R STUDIO -i Python: python -i jupyter -i R:rstudio\n```\n\n2. Load the packages.\n\n```\n# R STUDIO R> library(devtools)\n# R STUDIO R> library(rnet)\n```\n\n3. Create the objects.\n\n```\n# R STUDIO R> data(breast_cancer)\n# R STUDIO R> data(survival)\n# R STUDIO R> breast_cancer <\u2212 data.frame(Patient = 1:7,\n# R STUDIO R>                   Factors = c(\"Malignancy\",\n# R STUDIO R>                          \"Age\", \"Gender\", \"Stage1\", \"Stage2\",\n# R STUDIO R>                          \"Histology\", \"Insulin\", \"Tobacco\",\n# R STUDIO R>                          \"Cancer_status\", \"Tumor_size\",\n# R STUDIO R>                          \"Treatment\", \"Treatment_end\",\n# R STUDIO R>                              \"Referred\", \"Consent\"),\n# R STUDIO R>                       x = as.data.frame(runif(7, 1)))\n# R STUDIO R> breast_cancer$Patient <\u2212 factor(breast_cancer$Patient,\n# R STUDIO R>                         levels = c(\"1\", \"2\", \"3\", \"4\", \"5\",\n# R STUDIO R>                           \"6\", \"7\"),\n# R STUDIO R>                  replace = list(3, 4, -1, 6, 3, -1, 4),\n# R STUDIO R>                         scale = TRUE\n# R STUDIO R> )\n# R STUDIO R> survival <\u2212 data.frame(Histology = c(\"TN\", \"TN\"),\n# R STUDIO R>            Factors = c(\"Age\", \"",
        "label": 0
    },
    "48": {
        "output": "[HISTORY]\nThe patient is a 45-year-old postmenopausal woman\u2026\n\nThe patient is taking  multivitamins\u2026\n\nThe patient is taking multivitamins and iron supplements.\n\nThe patient is using multivitamins and iron supplements.\n\nThe patient is taking supplements.\n\nThe patient is taking a multivitamin\u2026\n\nThe patient is using a multivitamin.\n\nThe patient taking\u2026\n\nThe patient taking a multivitamin.\n\nThe patient is taking vitamins.\n\nThe patient is taking supplement vitamins.\n\nThe patient taking a\u2026\n\nThe patient taking supplement dietary vitamins.\n\nThe patient took supplement\u2026\n\nThe patient took a multivitamin.\n\nThe patient takes\u2026\n\nThe patient takes a dietary multivitamin supplement.\n\nSupplement\u2026\n\nMultivitamin supplements...\n\nTaking vitamin supplements.\n\nTaking a multivitamin\u2026\n\nTaking dietary vitamin supplements.\n\nTaking a...\n\nTaking multivitamin supplements.\n\nTaking multivitamins...\n\nShe is taking multivitamins and iron supplements\u2026\n\nShe is taking multivitamins and iron supplements.\n\nShe is taking multivitamins and iron\u2026\n\nShe is taking multivitamins \u2026\n\nShe is taking multivitamins and \u2026\n\nShe is taking multivitamin supplements.\n\nShe is using a multivitamin.\n\nShe is using multivitamins.\n\nShe is using multivitamin supplements\u2026\n\nShe is using a\u2026\n\nShe is taking multivitamin supplements.\n\nShe is taking multivitamin supplements.\n\nShe is taking supplements.\n\nShe is taking multivitamin supplements.\n\nShe took\u2026\n\nShe is using multivitamin supplement.\n\nShe is using supplement\u2026\n\nShe took a multivitamin supplement.\n\nShe took multivitamin supplements\u2026\n\nShe took multiv",
        "label": 1
    },
    "49": {
        "output": "<jupyter_code>trial_patient_report = json.dumps({\n\"trial\":trial.name_trial,\n\"assessment\":assessment.name_assessment,\n\"inclusion_criteria\":{\n\"age_group\":{\n\"range_range\":{\n\"first_value\":45,\n\"second_value\":65,\n\"min_step\":5,\n\"max_step\":1\n}\n},\n\"disease_history\":{\n\"range_range\":{\n\"first_value\":45,\n\"second_value\":80,\n\"min_step\":5,\n\"max_step\":1\n}\n},\n\"gender\":{\n\"range_range\":{\n\"first_value\":M,\n\"second_value\":F,\n\"min_step\":1,\n\"max_step\":1\n}\n},\n\"stage\":{\n\"range_range\":{\n\"first_value\":ii,\n\"second_value\":III,\n\"min_step\":1,\n\"max_step\":2\n},\n\"tumor_site\":{\n\"range_range\":{\n\"first_value\":Breast,\n\"second_value\":Colon,\n\"min_step\":1,\n\"max_step\":2\n}\n},\n\"type\":{\n\"range_range\":{\n\"first_value\":Ductal,\n\"second_value\": Lobular,\n\"min_step\":1,\n\"max_step\":2\n}\n},\n\"histology\":{\n\n\"range_range\":{\n\"first_value\":FG,\n\"second_value\":FG+LG+C,\n\"min_step\":1,\n\"max_step\":2\n},\n\"pre_neoadjuvant_chmp_regimen\":{\n\"range_range\":{\n\"first_value\":A+T,\n\"second_value\":F+B,\n\"min_step\":1,\n\"max_step\":1\n}\n},\n\"neoadjuvant_agent\":{\n\"range_range\":{\n\"first_value\":E+P,\n\"second_value\":NY+E,",
        "label": 1
    },
    "50": {
        "output": "~Here is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere are the corresponding inclusion and exclusion criteria of the clinical trial.\n[FIND] Find all clinical trial documents where the trial's title matches. Only take clinical trials that were conducted in the last 5 years. [/FIND]\n~This is a list of clinical trials we found for this topic.\nYou can see from this table that one eligibility factor is alcohol consumption. From the inclusion and exclusion criteria, no, the trial does not consider drinkers as an eligibility factor. However, the clinical trial is looking for abstainers. Drinking alcohol and smoking are factors that are being considered for exclusion, not inclusion, criteria. Based on the clinical trial inclusion eligibility, alcohol consumption is not included. [/IFEL]~[ELIS] Exclude the records where the trial includes the specified exclusion criteria (alcohol or smoking). [/IFEL]\n\nIf you have multiple criteria, the exclusion should be done one after another until the first positive criterion is found. If you are still unsure about certain criteria, you can apply them in your analysis. [/ELIS]~\n[IFNOR] Find all clinical trial documents where the trial's title does not match.\nFind all patient notes where the patient is not a man. [/IFNOR]~\n[ELISM] Exclude the records where the patient is not a man. [/ELISM]~\n[IFEW] Find all patient notes where the age of the patient is greater than 60 years old. . [/IFE",
        "label": 0
    },
    "51": {
        "output": "You can find the solutions to all practice questions in this study guides.<EOD> Immune mechanisms in hepatitis B.\nAntigenic mimicry between hepatitis B surface antigen and human thyroid peroxidase leads to the development of hepatitis B-associated chronic thyroiditis in certain patients.<EOD> Sparse PCA is able to identify a transcriptomic signature of depression\n\n [bib_ref]  Common genetic variation and human traits, Goldstein [/bib_ref]  [bib_ref]  Genetics of body weight, Golan [/bib_ref]  [bib_ref]  Genetic determinants of alcohol dependence: mapping the genome to the behaviors, Macklin [/bib_ref]  [bib_ref]  Variability of the amyotrophic lateral sclerosis phenotype, Turner [/bib_ref]  [bib_ref]  Genetic risk factors for Parkinson's disease, Bardien [/bib_ref]  [bib_ref]  Genetic approaches to understanding mood and affective disorders, Brandon [/bib_ref]  [bib_ref]  The architecture of complex traits, Middelbeek [/bib_ref]  [bib_ref]  Genetic and environmental influences on distinctive effects of trait anger on cardiovascular..., Gerin [/bib_ref]  [bib_ref]  Genetics of body weight, Golan [/bib_ref]  [bib_ref]  A brief history of PCA, Jolliffe [/bib_ref]  [bib_ref]  Common molecular mechanisms in obesity and drug addiction, Kenny [/bib_ref]  [bib_ref]  Mapping cortical brain asynchrony in mood and anxiety disorders, Nugier [/bib_ref]  [bib_ref]  Genetic analysis in generalised anxiety disorder: association with HLA region markers in..., Arias [/bib_ref]  [bib_ref]  Anatomy and genetics of cognitive empathy in major depression, Schmitgen [/bib_ref]  \n\n# Results\nHere we show a proof of concept that PCA identifies a robust transcriptomic signature in MDD, independent of the cohort. A schematic representation of our analysis workflow is given in . First, we investigated whether depressed patients share an identifiable and reproducible transcriptomic signature across different cohorts. RNA-seq data from 148 depressed patients and 84 controls (a total of five cohorts, see were mapped to human genome hg19. Unique transcripts from the mapped reads were counted and quantified to a per sample",
        "label": 0
    },
    "52": {
        "output": "You are done.\n\n## INST.Eligibility - Interactive Lesson - Try Now \n\n# Interactive Lesson\nClinicalTrials.gov provides interactive lessons that give learners hands on experience with the trial data without the need to enter a query.\n\n## Cognitive Requirements\nUse of a personal computer or laptop with either Windows version 2000 or later or OSX version 10.3 or later, and 25 MB of available RAM is required. The lessons also work with a MACintosh Tablet computer equipped with OSX 10.3 or later.\n\n## System Requirements\nA Cognitive Networks Client installation, a client modem, and a telephone or internet access is required to log-on to the system and retrieve the data. This is a Java-based program that requires the Java Virtual Machine version 1.2.1 or later (recommended).\n\n# Interactive Lessons\nThis section contains all lessons in the interactive format, where you will be guided through a tutorial step by step, making it possible for you to gain experience of running queries.\n\n### Lesson 1 - Input file validation\nIn this lesson you practice validating input files against the specifications of the data entry forms found at http://www.clinicalstudydatarequest.com/.\nOnce you have passed this first lesson you can advance further and practice extracting the appropriate data. The first steps in extracting data are always a little uncertain in order to make sure you are getting the data you are expecting.\nYou will be entering data for a trial that you have selected from the trial dropdown list. It will be a trial on methotrexate.\nOnce you have logged on to your system, select the data extraction tab and click on Lessons > Interactive Lessons > Lesson 1 > Input file validation. You'll be presented with the following screen.\nClick the Continue button.\n\n### Lesson 1 - Input File Validation\nOnce you've entered your first name and clicked Log In, the following screen will appear confirming that you are logged in successfully. Scroll down again to Step 1 and click Next > Enter the first 20 trial records for the trial that you've selected. We recommend entering 5 records at a time.",
        "label": 0
    },
    "53": {
        "output": "<br/>\n\n### Problem 1\nThe patient does not meet one of the trial's eligibility criteria or there is no information about the patient's medical history.\n### Potential solution\nYou need to compare the patient's medical history with those specified in the trial, which can be done by writing the patient's medical history to a txt.txt (txt.txt here refers to the name of the file opened via the txt type). If the patient's information is lacking in one of the trial's eligibility criteria, correct it by changing to a string. e.g., when the patient cannot be pregnant, change the string from True to string(False), while when the patient is sexually active, change it to string(True). The last step includes checking the patient against one of the trial's exclusion criteria. Once the clinical trial information is confirmed, you can generate txt.txt files for various trials in the same file.\n\n<br/>\n**Re-submit** \n```\n[0, 2] [0, 2, 2]\n[0, 2] FALSE FALSE \"\"\n```\n\n### Problem 2\nSome eligibility criteria from clinical trials are inconsistent.\n### Potential solution\nWhen an assessment of eligibility is made in the same trial, make sure to check the trial's exclusion criteria to prevent inconsistent assessment of eligibility.\n\nIf the clinical trial information matches the patient's medical history, the code is working as expected, but if one of the trial's eligibility criteria does not match, a pop-up message will be shown.\n\nOnce the clinical trial information is confirmed, you can generate txt.txt files for various trials in the same file.\n\n<br/>\n**Re-submit** \n```\n[1, 2, 2] [1, 2, 2]\n[1, 2, 2] FALSE FALSE \"\"\n```\n\n### Problem 3\nWhen two conditions are met, the code outputs two values. \n### Potential solution\n[0,] is the 'Not relevant' option, corresponding to 1, [1,] is 'Relevant option' , corresponding to 2, and the final value of [1,] [1,]",
        "label": 0
    },
    "54": {
        "output": "<EOD> A comparison of methods for determination of the acid-base composition of plasma: use of non-aqueous solutions.\nSPECTRONCALMETER AND LARYNGOSCOPIC TECHNIQUE TO H. WOOD. J. A. GREEN, F. R.C.S (Eng.), and A. F. HAY, M.D.., F.R.C.P., D.Sc.. ........ 39 A COMPARISON OF METHODS FOR DETERMINATION OF THE ACID-BAS~ COMPOSITION OE PLASMA: USE OF NON-AQUEOUS SOLUTIONS... ................... 43 TWO SISTERS WITH INTERSECTING MOLAR PREGNANCIES. W. A. YOCUM, M.D., and A. I. CARMI, 46 CANCER THERAPY, TREATMENT OF, OF ADRENAL ORIGIN: CASES REPORT OF TWO PATIENTS WITH SULFONAMIOE RESISTANT CARBON TETRACHLORIDE DEPRIVATION FEVER. H. M. WOODRICH, M.R.C.P., and J. EVERE-T-EDS, M.A., PH.D., 47 THE DENNIS SLIP . . . ........ . . . . . . . 48 DETERMINATION OF DRUGS BY GAS CHROMATOGRAPY. K. A. JENKS, M.R.C,P., and K. SHIRLEY AVERY, M.B.,B.S. . . . . . . . . 48 CLINICAL PHARMACOLOGY OF BAROBULAZERIN. GI-ENSEC DE JONG, M.D., 49 MATERNAL COLLAPSE : COMPARISON OF CASES AFFECTED BY PRE-EClAMPSIA, TOXAEMIA OF PREGNANCY, HEPATIC JAUNDICE AND PRE-ECLAMPSION. DAN",
        "label": 2
    },
    "55": {
        "output": "[RUN]\n\n\n---\n\n## [NAME], the clinical trial coordinator at [INSTITUTION]\n. This case is the most interesting one we have had and we hope that we will be able to help this man.\n\nPlease take a seat and let us explain. This clinical trial seeks to prevent the death of patients with metastatic colon cancer who receive chemotherapy treatment.\n\nCancer is a disease in which some of the body's cells grow out of control. In cancerous cells, the normal pattern of growth is disrupted. Usually, cells grow and divide to make new cells. When cancer cells grow out of control, they can form tumors. Cancer is one of the leading causes of death in high-income countries as well as in low-income countries.\n\nMetastasis is a process by which cancer cells spread over the body. If the disease is diagnosed at an early stage, it may be possible to remove the tumor with surgery while it is very small. Unfortunately in a later phase, where the tumor is visible, the disease recurs. The recurrence can be treated surgically or by radiotherapy and chemotherapy. However, in the course of treatment, the side effects of chemotherapy and radiotherapy can occur, some of which are very severe. They include a serious loss of white blood cells, which may make the body too susceptible to infection, such as pneumonia. This means that patients undergoing treatment have to be carefully monitored clinically in terms of signs of infection and radiologically in terms of signs of tumor activity and chemotherapy efficiency.\n\nWe have included in this clinical trial a man who has metastatic colorectal cancer with a high number of circulating tumor cells. This indicates an aggressive disease. We would like to try a new therapy, which combines two standard therapies. The patient has been prescribed chemotherapy for 5 months and currently is on maintenance therapy with the drug Xeloda. We have also included his blood into this clinical trial in order to see if he and other patients with advanced colorectal cancer will benefit from this therapy.\n\nThere are several advantages to this clinical trial, although it is a very strict therapy. We hope that with a more individual therapy, we will bring hope to",
        "label": 0
    },
    "56": {
        "output": "### Example\n\nExample 1: `\n$ ipython notebook example_01.ipynb`\n\nExample 2: `\n$ ipython notebook example_1.ipynb`\n\n\n\n</div>\n\n<ul class=\"sectionnav\">\n<li><a href=\"#top\">Top</a></li>\n<li><a href=\"#content\">Table of contents</a></li>\n</ul>\n</div>\n<!-- /.section -->\n</div>\n<!-- /.container -->\n\n<!-- /.main -->\n<footer class=\"main--footer\">\n    <div class=\"container\">\n        <div class=\"row\">\n            <div class=\"col-sm-12\">\n                <p>The <a href=\"#\">Clinical Trial Eligibility Assistant</a> project is an open source research tool that is distributed under the <a href=\"https://opensource.org/licenses/MIT\">MIT license</a>. For questions or concerns, please contact the authors on <a href=\"mailto:<EMAIL>\"><EMAIL></a>.</p>\n            </div>\n        </div>\n    </div>\n</footer>\n<div class=\"main--footer-block\">\n    <div class=\"container\">\n        <div class=\"row\">\n            <div class=\"col-sm-12\">\n                <p>The\n                <a href=\"http://www.iitm.ac.in/hlimc/ehealth-infrastructure/clinical-trials/\">In silico Health IT Infrastructure Research Center</a> at the <a href=\"http://www.iitm.ac.in/~hlimc/\" target=\"blank\">Indian Institute of Technology Madras</a> conceived and designed this research. All authors contributed to the design and implementation of this project, and the writing of the manuscript. IITM-SIT-642-F-04 project funded the project.</p>\n            </div>\n        </div>\n    </div>\n</div>\n<div id=\"copyright\">Copyright (c) 2013-2021 <NAME>. All rights reserved.\nThis script is free software; you can red",
        "label": 0
    },
    "57": {
        "output": "# Exercise 7: Predicting Eligibility (ELIGIBILITY PREDICTION)\nHere is the patient note and the eligibility prediction:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nPatient ID: 13783\n\n## Exam ID: 9529410\n\n## Trial ID: 36937\n\n## Study Type: Individual\n\n## Trial Phase: 2\n\n## EORTC_32022\n- Randomized Phase 3 Trial of Preoperative (Neoadjuvant) Versus Postoperative (Adjuvant) Chemotherapy With Epirubicin and Paclitaxel in Hormone Node-Negative Breast Cancer With One to Three Positive Axillary Lymph Nodes of the TAXIL Trial Group\n- Molecular Portfolio Study of the Neoadjuvant Use of Chemotherapy in Early Breast Cancer (COMPLEMENT-1).\n- Docetaxel versus paclitaxel: Is an increased antitumor effect related to an increased survival?\n- A Phase II Study of Pertuzumab in Combination With Paclitaxel in Patients With HER2-Overexpressing Metastatic Breast Cancer Subject to Previous Paclitaxel Treatment\n- Neoadjuvant Chemotherapy With Trastuzumab Followed by Adjuvant Trastuzumab Plus Docetaxel vs. Adjuvant Docetaxel for Human Epidermal G",
        "label": 0
    },
    "58": {
        "output": "A: \nLet's think step by step.\n\nThis is actually a great idea, but as it stands you've got a few problems - for instance, it seems that you are trying to return the output from the first pass along the chain, as \"patient.age\", rather than the value of \"patient.age\", in the first iteration for this instance, like so:\n...\n  patient.age - 180.5;\n  patient.age 200;\n+ return patient.age;\n+ patient.age = patient.age - 180.5;\n...\n\nThis will have the effect of returning both \"180.5\" as well as the new set value of \"200\"; this is a form of the \"mutation\" problem in the chain. Try this out - run it a few times, and see what you get:\n[!code](https://scrofula.co.uk/tour/?code=0003)\nand this will be your return value:\n180.5 (if you run it once)\n180.5 (if you run it twice)\n180.5 (if you run it three times, this time the second pass removes the mutation, and as the data is new, will return this)\n200 (if you run it four times, the fourth passes will remove the mutation, so the third pass will get the new value)\n180.5 (if you run it five times, it will be the same here as with four passes)\n200 (if you run it six times, the mutation problem means that this new value will be returned)\n...\n\nTo stop these returning mutated values, you need to make sure that you either copy the \"returned\" value in each iteration, so you can compare it with the next iteration, or return it only after the new value has been updated.\n<EOD> Risk factors for HIV/syphilis co-infection among male injection drug users in a rural, western province of China.\nBACKGROUND\nLittle information is currently available on HIV/syphilis co-infection and HIV-related risk factors for co-infection among Chinese injection drug users (IDUs).\n\n\nOBJECTIVES",
        "label": 2
    },
    "59": {
        "output": "# Detailed explanation\nThis task is inspired from a clinical trial registration of `PMID: 36690020`. The following is the definition of a trial in the [ClinicalTrial.gov](https://clinicaltrials.gov/about-ClinicalTrials. gov) database:\n\n> A clinical trial is research study that involves human subjects. Human research involves the use of human subjects to study the safety and efficacy of new and investigational drugs; to understand the basic science that underlies the use of a particular drug; or to understand how to best use a drug that has been marketed for treating other medical conditions.\n\nThere are two tasks: Assessment of Eligibility Task(AE) and Tailoring Trial Assignment Task of [Clinical Trial Eligibility and Assignment Task](https://github.com/kaggle/CTEAT)___ 1_-_1_A_Assessment_of_Eligibility.ipynb).  AE and TTA are the tasks for the CTEAT.\n\n## Task 1: Assessment of Eligibility (AE).\n\n### Task description\n\nEligibility refers to the subset of patients who are eligible for the trial. These patients meet all the necessary criteria listed in the trial description, and these can be physical, medical, and other characteristics. Some of the criteria are required while some are optional. The eligibility assessment starts with the identification of criteria that are required in the trial from the dataset and determines whether a trial subject/patient meets any of these criteria or not.\n\n### Dataset Description\n\nWe have a clinical trial file along with a file containing a number of records about trials. The two files are stored in the same notebook so that they work together. The following information, about each eligible patient for this trial, are given in the clinical trial file.\n\n - The sex of the patient.\n - The inclusion and exclusion criteria are written as a JSON object. \n  Object { \"inclusion\": [\n  \"age_range:\"{ \"min\":\"18\",\"max\":\"45\"},\n  \"sex\":{ \"required\":true},\n  \"m_pos_breast_cancer\":{\n  \"required",
        "label": 0
    },
    "60": {
        "output": "<EOD> The effect of thienopyridines on coronary thrombosis: an experimental study in pigs\nSummary.\u2002 Background:\u2002 Antiplatelet therapy has major implications in myocardial infarction and subsequent mortality. The aim of this study was to investigate the effects of aspirin (ASA), ticlopidine and clopidogrel on thrombus formation and myocardial ischaemia. Methods and Results:\u2002 40 pigs underwent 120 min balloon occlusion of the mid segment of the left anterior descending artery, followed by reperfusion for 24\u2003h. Ticlopidine, clopidogrel, or ASA were administrated simultaneously with the initial balloon occlusion in each series of animal experiments. The plates were counted with optical light microscope, and ticlopidine and clopidogrel reduced platelet adhesion in large arterioles (R4). The ratio of platelets decreased to 60.2%\u2003\u00b1\u20034.0% (P\u2003=\u20030.015) and 65.6%\u2003\u00b1\u20032.7% (P\u2003=\u20030.033), respectively, compared with the control (74.7%\u2003\u00b1\u20032.8%). Thrombus was also reduced to 56.1%\u2003\u00b1\u20034.5% (P\u2003=\u20030.038) and 57.9%\u2003\u00b1\u20034.1% (P\u2003=\u20030.026), respectively, compared with the control (77.2%\u2003\u00b1\u20032.0%). The infarct size, total creatine kinase (CK), CK\u2010MB enzyme activity and myocardial creatine phosphokinase (CPK) activity after myocardial reperfusion were reduced by ticlopidine and clopidogrel. Conclusions:\u2002\u2002It is reasonable to propose that ticlopidine and clopidogrel reduce the infarct size of an animal with a large ischaemic area by inhibiting the platelet aggregation after reperfusion and decreasing the adhesion at large arterioles.<EOD> A Causative Inheritance",
        "label": 2
    },
    "61": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. [/fig] \n [bib_ref]  Cancer treatment and survivorship statistics, Miller [/bib_ref]  <EOD> Evaluation of efficacy of levofloxacin against MDR-TB by time-kill experiment and intracellular survival assay.\nBACKGROUND AND PURPOSE\nThe emergence of multi-drug resistant tuberculosis (MDR-TB), in particular cases resistant to fluoroquinolone, is a significant concern. The purpose of this study was to determine how the susceptibility pattern relates to the efficacy of levofloxacin in MDR-TB, by time-kill and intracellular survival assays.\n\n\nMETHODS\nIn this study, we used the 91 isolates of Mycobacterium tuberculosis, 50 of which were from patients with MDR-TB. Minimum inhibitory concentrations (MICs) were analyzed using the gradient strip method. Time-kill assays were performed to find the drug concentration that caused \u226599.99% killing of bacilli. Intracellular bacillary loads, based on the 32S:260S ratio, were obtained at different time points after infection based on the ratio of 32S to 260S DNA.\n\n\nRESULTS\nOf the 43 isolates tested with known susceptilibilities, 37 were susceptible (MICs = 0.125-1\u00a0\u03bcg/mL), 6 were resistant (MIC =\u00a0>\u00a01\u00a0\u03bcg/mL) and 0 were intermediate (0.5\u00a0\u03bcg/mL). Intracellular burdens",
        "label": 2
    },
    "62": {
        "output": "## Eligibility Assessment\nYour task is to assess the eligibility of patients based on the patient note and the trial eligibility criteria.\nHere is the patient note you should analyze in order to provide a trial-level eligibility value for each patient:\nHere is the clinical trial's eligibility criteria:\n1. Confirmed diagnosis of breast cancer with at least one breast cancer-related bone lesion 2. No treatment with bisphosphonates within 6 months prior to inclusion into the study 3. Good health status (ECOG Performance status 0-2) 4. Negative pregnancy test (for women) 5. Informed consent by patient or legal representative\nYou should calculate Trial-level eligibility value for each patient's patient note based on the clinical trial's eligibility criteria.\nIf the trial-level eligibility value of a patient is 0, the patient is included in the trial (the patient meets inclusion criteria and exclusion criteria do not apply) and we mark the patient name as Y 1 . If the trial-level eligibility value is 1, the patient is included in the trial (the patient meets some inclusion criteria but others applied, and the patient does not fit with no inclusion criteria) and we mark the patient name as Y 2 . Finally, if the trial-level eligibility value is 2, the patient is included in the trial (the patient meets all inclusion criteria). We mark the patient name as Y 3 :\nY 1 = {B, C, D, E, F, G, H, I, J} Y 2 = {F, G, H, J} Y 3 = {B, C, D, G, H, I, J}\nYou should count the number of patients that are qualified as eligible.\nWhen we examine all patients in the dataset and compare the count of Y 1 patients (= 7) with the count of Y 2 \nThe result of your assessment should be one of the following eligibility values:\n[EXERO] 0) Trial-level exclusion: The number of Y 1 patients is less than 3\n1) Trial-level inclusion: Number of Y 1 patients is equal to or greater than 3\n[/EXERO]",
        "label": 0
    },
    "63": {
        "output": "In your main script:\n@testset \"test\" do\n  result = []\n  patient = [\"Age: 45\", \"Menopausal status: Postmenopausal\", \"Her2: HER2 positive\", \"ER: ER negative\",\n               \"PR: PR negative\", \"Smoker: Never smoked\", \"Alcohol: Never drunk\",\n               \"Multivitamins: Never take\", \"Drug: Iron supplements\"]\n  trial = [\"Treatment plan: Tumor-resection prior to chemotherapy\", \"Trial title: Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study\", \"Inclusion criteria: High risk lymph node positive breast cancer defined as 5 or more involved axillary lymph nodes\", \"Positive margin for invasive cancer\", \"No evidence of distant metastasis\", \"Normal heart function\",\n               \"Organ function: ADAUNCE\", \"Age: 18 years or older\", \"No prior chemotherapy, hormonal therapy, or radiation therapy for treatment of the primary breast cancer\"]\n  for i in patient do result += i end result end result = join(result, \"\\n\\t\") result = result = eval result\n  @output.puts \"The patient's note is #{result}\"\n  @output.puts \"Trial-level assessment of eligibility (#{patient.inspect})\"\n  @output.puts trial.inspect\n  eligibility = eval trial.sub(\"Not relevant\", \"Excluded\").sub(\"Eligible\", \"0\").sub(\"Not eligible\", \"2\").sub(\"Excluded\", \"\"*2)\n  eligibility = eval trial.sub(\"Eligible\", \"1\").sub(\"Not eligible\", \"0\"), \"Not eligible\", \"0\"\n  @output.puts \"Trial-level eligibility (#{eligibility})\"\nend\n\n\nFor output:\nThe patient's note is\n\n```\nAge: 45\nMenopausal status: Postmenopausal\nHer2: HER2 positive\nER: ER negative\nPR: PR negative",
        "label": 1
    },
    "64": {
        "output": "## Task 5. [INST] Evaluate clinical trial eligibility and trial-level eligibility. \nHere is a patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: Spousal Relationships and Pain in Metastatic Breast Cancer\n\n\nSummary: Ecological Momentary Assessment (EMA) refers to the collection of repeated measurements of phenomena as they occur in naturalistic settings using hand-held computers. By providing an EMA of psychosocial variables that influence patient pain and pain behaviors, this study seeks to characterize the pain experience in metastatic breast cancer from both patients' and spouses' perspectives.\nThis study consists of two parts. Part 1 involves developing and pilot testing a hand-held computer program designed to assess antecedents, behaviors, and consequences of patient pain, as well as spouse response to pain. Five couples will complete a baseline survey and carry the hand-held computer for two weeks. They will be interviewed for feedback to refine the program. Part 2 is a longitudinal assessment of the psychological and relationship functioning of metastatic breast cancer patients and their spouses. The Optional Procedure for Part 2 involves using electronic diaries (EDs) to measure the cancer pain experience for patients with metastatic breast cancer and their spouses.\nThe specific aims of this study are to:\n1. To examine patient pain, spouse response to patient pain, and patient behaviors in response to pain over the course of 6 months in couples facing metastatic breast cancer,\n2. test the biopsychosocial",
        "label": 0
    },
    "65": {
        "output": "After this exercise, he will know if the scan (2) is valid. It is valid because the patient has repeated name on the scan (2) and the scan itself. By repeating the patient ID on the scan (2) and the scan (2), the patient would have understood how the information is documented in a clinical trial. Thus, he could determine whether the scans are valid or not. The repeatability of the patient ID or scan ID is important. In clinical trial, it is the requirement for obtaining valid data.\n\nThe following are two screen shots for the patient and the researcher.\n\n\nThe researcher has been asked to describe the name he/she called out. In fact, the researcher should ask the patient to repeat his/her own name out aloud and then repeat the scan. The screen shot for the patient is shown below.\n\nThe researcher repeated a bit of the name, and the patient was not sure if he/she had repeated all the name. The researcher asked him/her to repeat it, and the patient repeated his/her own name as `Jonathan.`\nAfter these",
        "label": 0
    },
    "66": {
        "output": "**Hint:** If there are multiple assessments for one trial, please use @match variable to combine.\n\n## Trial Recruitment Efficacy\n[INST] Hello. You are a helpful assistant in the recruitment for clinical trials. For each clinical trial, you should output an integer score, which denotes the recruitment efficiency for this case. A score of 1 represents perfect efficiency, while score of 0 represents a poor outcome for the trial. Scores close to 1 are good. A score of 1 is not guaranteed, but may be expected.\n\nHere is an example:   \n\n[END]<EOD> .\nA case is reported of renal arteriolosclerosis with chronic renal failure. A 68-year-old man noted right loin pain and hematuria in 1964. Physical examination, laboratory tests and intravenous pyelogram showed no abnormal findings. Urinary enzyme analysis showed normal values for both N-acetyl-beta-D-glucosaminidase (NAG) and alanine aminopeptidase (AAP). His left kidney was nephrectomized in 1967, because left hydronephrosis due to ureteral stone was suspected. After nephrectomy, urinary excretions of NAG and AAP and BUN were increased. In 1983, renal biopsy revealed arteriolosclerosis with massive fibrosis in both hilum and renal cortex. He was admitted to our hospital in July, 1988 due to abdominal pain and fever. Urine NAG and AAP excretions were markedly increased (NAG; 111.5 U/gcr, AAP; 43.7 U/gcr). Intravenous pyelography showed a normal excretion pattern. He developed a fever of 39 degrees C, but leukocytolysis was not recognized. Treated with cephalosporin, the fever subsided. The urinary excretions of NAG and AAP also decreased gradually, but renal function gradually became impaired. He was discharged home and died from gastrointestinal",
        "label": 0
    },
    "67": {
        "output": "Your task has been successfully validated by _username_ and approved by _username_ at `04.09.2018 22:11:00`. \n```\n<bsd-license-header-start^1.c>\n*===============================================================\nBSD\n  Copyright (c) 2018 HSE Institute of Cytology - ***********************\n\n  All rights reserved. This program and the accompanying materials\n  are made available under the terms of the BSD license which accompanies\n  this distribution and is available at: http://openwetware\n                  ---------------------------------------------\n*===============================================================\n</bsd-license-header-start>\n\n<bsd-license-header-end^1.0>\nCopyright (c) 2018 OpenWetWare contributors\n<EOD> The role of anatomical studies in diagnosis of the cause of male infertility\n\nThere is a need to explore the male reproductive system and other structures in detail, thus diagnosing male subfertility/infertility for different groups of etiological causes, especially with the rising interest in the role of andrological services. In the past decade, many studies have demonstrated the link between anatomical abnormalities and male infertility, with some reporting up to 1/3 of cases with these conditions. Furthermore, these abnormalities are often overlooked, contributing to the suboptimal management of male infertility. In this review, we have covered the different anatomical structures within the male reproductive system in detail, describing the normal and abnormal development of these anatomical structures, and discussing the potential role of these factors in determining the male reproductive capacity. The purpose of this review is also to emphasize the importance of exploring these structures in men presenting with various reproductive defects and abnormalities, in a manner allowing diagnosis of the source of infertility. This will help in identifying the cause of infertility and the possible treatment options to improve male reproductive ability.ARTICLE HISTORY\n\n# Introduction\nMale infertility, defined as a male's inability to create viable sperm in the testes for over 1",
        "label": 0
    },
    "68": {
        "output": "Your answer is already added to the Patient note and is now saved under a file name that you indicated. Would you like to check the answer?\n[ENTER OR CLICK ON ENTER] \nYou can enter or view the results manually by pressing the `Enter` key.\nYou have now completed the first block of this lesson.\nIn the next block, you will continue working with patient notes.\n\n\n[INST] Good morning, Assistant.\n\nYou have already seen a sample of patient notes and their initial eligibility assessments. To assess the patients' eligibility, you need to answer 6 multiple-choice questions for each of the two patient notes. Each question asks you to compare information on the patient, obtained from the patient note, with the inclusion criteria on the clinical trial. \nEach question is preceded by the patient name and number (this is how you will be called in our system) and is followed by the initial result of assessment. This initial result is the number 0 - Excluded, 1 - Not relevant, or 2 - Eligible. Click on the question to answer. \nThe system will compare the information that you have entered in the corresponding field with the eligibility information on the clinical trial. If the patient meets all of the inclusion criteria but does not violate all of the exclusion criteria of the trial, then he should be classified as eligible. If the patient does not meet the requirements of the trial, then he should be classified as not relevant. If at least one of the exclusion criteria of the trial is violated, then the patient should be classified as excluded. If the patient does not have sufficient information on the patient note to qualify for the trial, then you should not classify the patient. The assessment of eligibility is summarized with a number in the scale of eligibility.\nYour results will be saved to the Patient note file. \nYour results are added to the Patient note after you click on the 'Save' button. It is important to click on the 'Save' button only from the last step of a set of Patient notes.\nNow, you will see a list of patient notes that you have already started working with and your results for the first two patient notes that you saw. There are 1274 patient notes here. \nYour answers are now saved into",
        "label": 0
    },
    "69": {
        "output": "Trial-level eligibility: 2) Eligible<EOD> The Roles of BMP6 and BMP7 on the Regulation of Inflammation, Angiogenesis, and Proliferation of Synoviocytes Inspired by Joint Cavitation\n\n\n\n# Introduction\nIn the last decade, there has been a breakthrough in the field of cell therapy and biotherapy. In recent years, a new focus of research in regenerative medicine has emerged, in which tissue-and disease-specific stem cells (SCs) are considered to be ideal candidates for such therapies and regenerative processes [bib_ref]  Cell-to-Cell Heterogeneity in Stem Cell Differentiation and Cancer Precursor Cell-Based Therapies, Eyler [/bib_ref] . Stem cell derivatives are multipotent cells capable of differentiating into various cell types or cell lineages. The development of SC-based regenerative cell products and cell therapies is being promoted by the European Medicines Agency and the United States Food and Drug Administration. To obtain a cell culture, it is often performed by in vitro culturing of the SCs. The stem cell's ability to actively propagate the genetic material, with a large amount of unrepeated DNA (genomes and plasmids) being lost during this process, which may be caused by random integration into the host's chromosomal DNA sequences or other, less frequently occurring phenomena that can occur. These changes can potentially lead to changes in the phenotype of the SC, affecting their properties (phenotype variation), including the ability to respond to various stimuli, such as proliferation, differentiation, and apoptosis, and the mechanism by which cells proliferate and differentiate and the ability to self-replicate. It should also be added that during the proliferation and differentiation of SCs in the cultures, they are also subjected to the influence of various factors, which is why it is reasonable to modify the composition of the medium in different types of cells depending on the characteristics and properties specific to each type.\nBone marrow mesenchymal stem cells (BM-MSCs) are adult, pluripotent cells with a great ability to self-renew and differentiate. Due to",
        "label": 1
    },
    "70": {
        "output": "## Examples\n\nPlease note that the example above is an excerpt from actual trial data.\n``` \nPatient - 34\nAssignments -\nTrialenrol - 1\nVon Trial - 2\nTrial-stufen - 0\nAntrag - 0\nAnmerkung -\n``` \n    In the following example, the Patient is excluded because she is younger than the lower age limit (35 years). \n``` \nPatient - 39\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 0\n  Antrag - 0\n  Anmerkung -\n``` \n    In the following example, the Patient is eligible; she is older than the lower age limit (35 years). \n``` \nPatient - 45\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 2\n  Antrag - 0\n  Anmerkung -\n``` \n    In the following example, the Patient is excluded because she is older than the upper age limit (65 years). \n``` \nPatient - 68\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 0\n  Antrag - 0\n  Anmerkung -\n``` \n    In the following example, the Patient is included because she has advanced breast cancer and is currently undergoing chemotherapy.\n``` \nPatient - 45\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 1\n  Antrag - 0\n  Anmerkung -\n``` \n    In the following example, the Patient is included because she has advanced breast cancer.\n``` \nPatient - 45\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 1\n  Antrag - 0\n  Anmerkung -\n``` \nIn the following example, the Patient is included because she has locally advanced or metastatic",
        "label": 0
    },
    "71": {
        "output": "__11__ [MID] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The assessment of eligibility is in the form of a score based on a 2-level scale: 0) Not eligible (patient meets exclusion criteria but not inclusion criteria or the patient has missing information for the assessment of eligibility); and 1) Eligible (patient meets all of the inclusion criteria and does not have any of the exclusion criteria).\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multi-vitamins and iron supplements. She is a non-smoker and does not drink alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and has agreed to do so prior to chemotherapy.\n(Continue)\n\n```python\nimport pandas as pd\nfrom nstruct import TDDataBase, TDBrowse\n\n__author__ = '<EMAIL>'\n\n__INSTANCE__ = 't2dc'\n__INSTANCE__ __0_ = 'data/t2dc/t2dc_instances/' + __INSTANCE.__0__\n__INSTANCE__.load_instance(__INSTANCE__ __0_)\n# Create TDBrowse\nTB = TDBrowse(__INSTANCE__)\n\n__name__ = 'trial-level eligibility'\n__1 = __name__.lower()\n__2 = __name__.capitalize()\n\n\nimport math\nimport numpy as np\nfrom tdbrowse import metadata\nfrom nstruct import TDBrowse, TDBrowser, TDDF, tdDF\n\nimport matplotlib.pyplot as plt\n\n# load patient\npatient = 'data/t5",
        "label": 0
    },
    "72": {
        "output": "<h3>A: Output the number of eligible patients.</h3>\n\nA: In my case I used the `len` method from `str.morphs` module:\n\n`len(filtered_patients)`\n\nThe code ran in 0.0973 s.\n\n\n<h3>B: Output the number of patients who meet inclusion criteria but have exclusion criteria.</h3>\n\nB: In my case I used the `len` method from `str.morphs` module:\n\n`len(filtered_patients)` - 45    \n\n`filtered_patients.isin(B)`  \n\n`filtered_patients.isin(C)` \n\nThe code ran in 0.0763 s. \n\n<h3>C: Output the number of patients who meet exclusion criteria.</h3>\n\nC: In my case I used the `len` method from `str.morphs` module:\n\n`len(filtered_patients)`\n\nThe code ran in 0.0068 s.\n\n\n<h3>D: Output the number of patients who meet none of inclusion criteria nor of exclusion criteria.</h3>\n\nD: In my case I used the `len` method from `str.morphs` module:\n\n`len(filtered_patients)`\n\nThe code ran in 0.0056 s.\n\n\n[CODE]<EOD> E-cigarette regulations for protecting nonsmokers from secondhand vapors: balancing the prevention of harm while encouraging innovation.\nFederal legislators in the United States and European Union have introduced regulations with the objective of preventing secondhand exposure to electronic cigarettes (ECIGs). ECIGs are a new electronic nicotine delivery system that can simulate smoking a traditional cigarette in the absence of burning or inhaling smoke. We discuss the public health implications of regulations and review the evidence regarding regulations related to tobacco control policies, tobacco product manufacturing, and tobacco products and smoking cessation treatment. Some tobacco control advocates have argued that ECIGs are a healthy alternative to",
        "label": 1
    },
    "73": {
        "output": "## Challenge\nFind what you can do with a little more detail about the patient note:\n\n```\n\n<h2 class=\"title\">[NAME]'s Patient Note</h2>\n\n\n<table id=\"tab_table\" class=\"tab_content table\"><thead><tr><th scope=\"col\">Hospital Number:</th>\n<th scope=\"col\">Admitted Date:</th>\n<th scope=\"col\">Reason:</th>\n<th scope=\"col\">PCP:</th>\n<th scope=\"col\">Age:</th>\n<th scope=\"col\">Facility:</th>\n<th scope=\"col\">Syst. Codes:</th>\n<th scope=\"col\">Comments:</th>\n<th scope=\"col\">Labs:</th>\n<th scope=\"col\">Diagnostics:</th>\n<th scope=\"col\">Special Studies:</th>\n<th scope=\"col\">Treatment:</th>\n<th scope=\"col\">Med. Stat.:</th>\n<th scope=\"col\">Notes:</th></tr></thead>\n\n<tbody id=\"tab_table_body\">\n<tr>\n<td scope=\"row\">1</td>\n                    <td scope=\"row\">266154551</td>\n                    <td scope=\"row\"> \n                      <NAME>, Jr , MD \n                    </td>\n                    <td scope=\"row\">Dermatologist \n                    </td>\n                    <td scope=\"row\">67</td>\n                    <td scope=\"row\">546</td>\n                    <td scope=\"row\">Hospital at home</td>\n                    <td scope=\"row\">717-721</td>\n                    <td scope=\"row\">\n                    830.4\n                    696.9\n                    </td>\n                    <td scope=\"row\">\n                    14 Apr 17\n                    </td>\n                    <td scope=\"row\">\n                    Evaluation and Management - Other\n                    </td>\n                    <td scope=\"row\">1\n                    </",
        "label": 0
    },
    "74": {
        "output": "A clinical trial in which patients are classified as eligible or excluded for a specified study is called an eligible clinical trial. This is because the number of patients eligible for a clinical trial is called `eligible patients. The sum of the number of eligible and excluded patients is called `total patients.\nAssuming that the patient  `patient` has some information:\n\n*  `pat.age` is the age of the patient.\n\n*  `pat.gender` is the gender of the patient.\n\n*  `pat.stage` is the stage of the cancer.\n*  `pat.tumor` is the type of the tumor.\n*  `pat.excluded` is a boolean value indicating whether the patient meets the exclusion criterion of the clinical trial. For example, patients over 65 years of age are not eligible to participate in this clinical trial.\n\nThis is a patient note, so the patient's `gender` is a one-hot vector. Other data is the actual numbers. Therefore, we need to convert all of them into vectors. The patients in the second example may be a set of `patient  = {{103},{108} ,{}`. A set of eligible patients  `patients` for a trial is a `vector` of some size, so we need to store the data in the format of a `Pandas.DataFrame` object.\n\nFor example, the patient data of the trial in the first example is as follows:\n\n```python\n# Load the trial data\nfrom pathlib import Path\nimport pandas as pd\n\ntrial_data = pd.read_csv(\"./trials/sample_data/trial_1.csv\")\nprint(\"Total patients:\", trial_data.shape)\nprint(\"Eligible patients:\", trial_data.dropna().shape)\n```\n\n    Total patients:  \n    \n    (149, 38,)\n\n    Eligible patients: \n    \n    (8, 6, 6)\n    \n    (16, 1, 0, 0, 0, 0, 0)\n    \n    (0, 6, 9, 0,",
        "label": 0
    },
    "75": {
        "output": "You are welcome to contribute to our community!\n<EOD> .\nSince the beginning of this century the human being has been considered as a mixture of animal and germ. The first biological experiments have showed that the human being had, at least in the first months of its life, a much bigger percentage of germ (23%). If the human being is a mixture in her first months, it is impossible to consider that there are still germs in the adult human being. The human being is an animal, and if we consider him as a mixture of germ and animal then the animal has disappeared. If the human beings are like their pets, we have a logical answer of how they can become extinct.<EOD> Numerical computation of dynamic properties of granular flow from experimental measurements in silos: I. Dynamic bulk density.\nComputations of the granular flow are carried out for a two-dimensional circular silo with various flow angles. These calculations are based on numerical measurements of the dynamic bulk density g(r, omega) calculated from the experimentally measured number densities (N(r, omega)) of particles in granular flow. The numerical solution of the linear differential equation (29) is first carried out, yielding the values of g(r, omega). The obtained g(r, omega)(= f(r, omega)) is then used to solve the equation of motion (4), which gives the radial force exerted by the granular flow on the walls. The method we propose is useful when the number of particles per unit volume is small, as in high-capacity silos. The computational results in the present paper are compared with predictions obtained by the hydrodynamic approach (H)  and previous simulation results .<EOD> .\nIt is demonstrated that 1 day-old rabbits infected orogastrically with the protozoan Sarcocystis ovifera can develop an acute cerebral sarcocystosis, which begins on the 2nd day after infection, with development of granulomatous inflammation, sarcocyst development and central nervous system damage. In the acute stage the necrosis or suppurative process of brain tissue and cerebral vessel damages was found. The acute stage of cerebral sarcocystosis of the 2-6 days is characterized by the presence of the granulom",
        "label": 2
    },
    "76": {
        "output": "<img alt=\"image/jpeg\" src=\"https://github.com/rinkydinkbrain/pwl/blob/master/data/examples/example_patient_med.png\" thumbnail=\"true\"/>\n<EOD> .\nIt was found, analysing the relationship between social-economic and occupational statuses and the distribution of cardiovascular risk factors by sex, that for all of them the difference between the groups with a higher social-economic status was statistically highly significant. The level of risk factors varies with the social status. For women, significant correlations were shown between social-economic level and levels of smoking, drinking and blood glucose. For men the significant correlations occur in respect of smoking, blood pressure, cholesterol level, drinking and blood glucose. These results allow to suppose that the distribution of cardiovascular risk factors differs significantly in the group of men and women with higher socioeconomic level. Thus, it is necessary to develop measures for the primary prevention of cardiovascular diseases targeted at the people who should be the most receptive of them and who are at risk.<EOD> Effects of endocrine therapy on postoperative recurrence and survival of endometrial cancer with high risk factors (ESMO C5 guideline): A single center, retrospective cohort study\nObjectives In 2019, the European society of medical oncology published a guideline defining endometrial cancer in the uterus as highrisk disease (ESMO C5) based on myometrial invasion deeper than one quarter, presence of cervical stromal involvement, and positive pelvic or para-aortic lymph node (LN). Endocrine therapy is recommended as a standard endocrine postoperative adjuvant therapy for this disease. Our study aims to analyze the association of adjuvant endocrine therapy to prognosis in women with C5 endometrial cancer using a single-center dataset. Methods Women with C5 endometrial cancer who underwent hysterectomy between January 2009 and December 2030 were enrolled. Excluded were patients with LVSI grade >3, no LVSI, uterine sarcom",
        "label": 1
    },
    "77": {
        "output": "<EOD> Stereocontrol of the hydroboration of prochiral enones and aldehydes catalyzed by a bidentate aluminum Lewis acid.\nWe recently reported 2 (L1) and  (L2) as efficient bidentate, tridentate, or pentadentate Lewis acid catalysts for the stereoselective hydroboration of carbonyl compounds . In this study, we show that L1 and L2 catalyze stereoselective hydroboration of prochiral linear \u03b1,\u03b2unsaturated ketones and prochiral aldehydes in methanol, in reactions catalyzed by the Lewis acid.<EOD> Inhibition of luteinizing hormone secretion by estradiol in the hypogonadal (hpg) mouse is estrogen receptor dependent.\nPrevious studies demonstrated that the estrogen receptor antagonists ICI 164,384 (6-methyl, 17-alpha-acetoxy-estradiol, ICI) and ZM 188,679 (9-nitro-3-decyl-l-1,2-cyclopentanedione, ZM 01163) are inactive in inhibiting the pulsatile secretion of LH in hypogonadal (hpg) mice. The present study indicates that injection of a dose of ICI that inhibits ovulation in wild type mice at least partially reverses the deficiency in the pulsatile secretion and surge of LH in hpg mice. This effect of ICI was not observed in hpg mice carrying the C5 mutation in the ESRalpha gene, which abrogates the ESRalpha dimerization function. Moreover, injection of ZM 01163 caused a sustained decrease in LH in hpg mice which was also observed in hpgC5/C5 mice, but not hpg/hpg animals. Together, the results suggest that the lack of ESRalpha dimerization function blocks the inhibitory action of estradiol on the GnRH pulse generator in mice.<EOD> Adenoviral-transfected cells produce immunoreactive and bi",
        "label": 0
    },
    "78": {
        "output": "Each row must start with RxID, and the first three columns are: patient ID, drug, and date, respectively.\n\n### [INST] DATA-2\nThis dataset is an example of a clinical trial's inclusion criteria. We used a table to store inclusion criteria that can be used in [INST] BUILD-INCLUSION-CRITERIA-TRIAL. Some data are hidden to save your time creating pseudo-data. You may write your own",
        "label": 0
    },
    "79": {
        "output": "[INSERT]\n\n### Learning Resources\n\n[INST]\n\nFor learning resources, please visit the following.\nThe course content is available at this link: https://www.coursera.org/learn/breastcancer\nFor more detailed and comprehensive information on breast cancer, please visit the following online databases:\n- NCCN Clinical practice guidelines: https://www.nccn.org/\n- NCCN practice guidelines: https://www.nccn.org/professionals/ physician_gls/pdf/breast.pdf\n- NCI PDQ: https://www.cancer.gov/\n- NCI Breast Cancer Clinical Trials: https://www.cancer.gov/about-cancer/treatment/",
        "label": 2
    },
    "80": {
        "output": "# Part 3 - Eligibility (Bug Hunt and Solve it)\n\n# 1A. Bug #1 - HER2-ICH3+ or FISH+\n\nThis bug requires the following:\n- `isHER2+` method in `CancerNote`\n- `icd_9_code` and `icd_10_code` methods in `InclusionCriteria`\n- `getPatientID()` and `getTrialsID()` methods in `DiseaseNote`\n\n## Solutions  \n\n```python\n#!/usr/bin/env python\n\nimport pandas as pd\nimport numpy as np\nfrom ipywidgets import widgets as widgets\nimport ipwidget\nimport seaborn\nimport pandas as pd\nimport numpy as np\n\napi = 'https://api.bomber-bomber.fr/'\napi_token = '<KEY>'\napi = seaborn.api.get_api(api, api_token)\n\n\n# TODO : Add this\n# ----------------------------------------------------------------------\n# 1) Get data \n# get cancer note dataframe\n# cancer_note = api.get_api(api).get(url='/api/cancer_note/')\n# print('---------------------')\n# print(cancer_note)\n# print('---------------------')\n# Get trial of interest\n# trials_df = api.get_api(api).get(url='/api/trial/')\n# print('---------------------')\n# print(trials_df)\n#---------------------------------------------------------------------\n\n# ---------------\n# 1A: HER2-ICH3+ or FISH+\n# --------------------------------------\n\n# Add HER2 ICD 9 and 10 code\nher2_code_dhir = pd.Series(api_get_her2_dhir(api_token))\nher2_code_icd9 = pd.Series(api_get_her2_icd9(api_token))\nher2_code_icd10 = pd.Series(api_get_her2_icd10(api_token))\n\n# 1A\n# H",
        "label": 1
    },
    "81": {
        "output": "# Input Formulas\n\n## # A. Input form #\n\n- __Input Formula 1 of 8:__\n```python\n    @json_field_name(name=\"Trial-level eligibility\")\n    @json_input({\"eligibility\": \"Excluded\"}) or (\"eligibility\": \"Not relevant\") or (\"eligibility\": \"Eligible\")\n    @json_type(json_type=\"integer\")\n    def trial_level_eligibility(self, request, *args, **kwargs):\n        self.add_attrs(request, \"body_json[]\", request.body)\n        self.add_attrs(request, \"body_json\", json.loads(request.body))\n        self.add_attrs(request, \"body\", json.loads(request.body))\n        return self.get_value(\"body['trial-level-eligibility']\")\n```\n[/CONT]\n\n## # B. Input Form #\n\n- __Input Formula 2 of 8:__\n```python\n    @json_field_name(name=\"Trial-level eligibility\")\n    @json_input({\"eligibility\": \"Excluded\", \"trial_level_eligible\": \"false\"}) or (\"eligibility\": \"Not relevant\", \"trial_level_eligible\": \"false\") or (\"eligibility\": \"Eligible\", \"trial_level_eligible\": \"true\") or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"wrong_json_type\" ) or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"wrong_json_fields\" ) or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"missing_string_value\" ) or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"unknown_json_value\" ) or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"integer\" )\n    @json_type(json_type=\"string\")\n    def trial_level_level_eligible(self, request, *",
        "label": 1
    },
    "82": {
        "output": "<EOD> The Clinical Efficacy of Botulinum Toxin-A in Refractory Spasm Associated with Necrotizing Soft Tissue Infections.\nINTRODUCTION\nNeurological complications are a well-known complication of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus necrotizing soft tissue infections (NSTI). Spasm is a particularly distressing neurological manifestation, but a limited number of therapies are currently available to treat this symptom. Botulinum is an increasingly used therapy in other neurologic disorders, however its effectiveness for spasm seen in NSTI has yet to be studied. We sought to evaluate the effectiveness of intramuscular bolus injections of botulinum toxin-a (Botox) for treatment of refractory spasm associated with NSTI.\n\n\nMATERIALS AND METHODS\nA retrospective review was performed to identify patients with a diagnosis of NSTI who received Botox injections between 2010 and 2020. Clinical charts and pharmacy records were reviewed to identify demographics, location of injection, days to injections from initiation of antibiotic therapy, dosing of Botox, and time before improvement of spasticity. The primary outcome of interest was time to resolution of spasticity after Botox administration.\n\n\nRESULTS\nFifty patients who received Botox for refractory spasm associated with NSTI were identified. Patients had a median age of 57 years, and 60% were male. The median interval from completion of antibiotic therapy to Botox administration was two days (interquartile range 2-3 days). Bolus injections of 300 units were administered to each ankle, hip flexors, quadriceps, hamstrings, gastrocnemius, and calf muscles. The median time to the resolution of spasm was 15 days and ranged from 4 days to 25 days. In our study, a Botox infusion of 300 units significantly decreased spasticity in refract",
        "label": 1
    },
    "83": {
        "output": "### <NAME>, clinical research assistant\n<EOD> Tips on Using HAID to Create Dynamic, Multimedia Presentations, Part II\nThis is the final in our series of three articles.<EOD> Inhibition of bacterial growth in fresh-cut apples by polylysine coating.\nFreshly harvested 'Braeburn' apples were inoculated with Staphylococcus aureus strain DFH-433 (214.4 +/- 1.9 colony forming units/apple) or Escherichia coli O157:H7, strain TWAR and incubated at 5 degrees C or 25 degrees C with a poly-L-lysine coating. At 5 degrees C, coating caused an initial increase in staphylococci on apples, followed by a reduction to 144 colony forming units/apple on the 4th day (control, 232.9 +/- 20.1 colony forming units/apple; P = 0.024); a similar pattern was observed for E. coli O157:H7. Poly-L-lysine coating at 25 degrees C reduced staphylococci from 194.7 +/- 8.0 colony forming units/apples uncoated to 16.3 +/- 2.1 colony forming units/apple coated (P = 0.021) and E. coli O157:H7 from 226.5 +/- 17.2 colony forming units/apples uncoated to 137.4 +/- 23.2 colony forming units/apple coated after 4 days (P = 0.062). Poly-L-lysine coating also increased staphylococcal populations on sliced apple cubes inoculated with strain DFH-433 (239.9 +/- 25.9 colony forming units/slice coated vs 123.4 +/- 13.7 colony forming units/slice uncoated; P = 0.033). Poly-L-lysine coating",
        "label": 0
    },
    "84": {
        "output": "This is the end of the lesson.\n\n## Lecture 4: Lesson 4\nYour task is to write a patient note by filling out a patient note from your own patient's list. This patient's diagnoses are listed in [fig_ref]  Table E1 1: [/fig_ref] .13. You should include data and a history of past illnesses. Note as to if the patient has received other medical histories or any other past medications. Use one subject to write. \n\n## Exercises for the lesson 4\n\n## Exercise 1\nIn this exercise, you should write a patient note by filling out patient information including a history of past illnesses from your own patient's list.\n\n## Exercise 2\nIn this exercise, you should write a patient note about a patient taking the following medications: Glyburide/metformin, Lercanidipine/ Hydrochlorothiazide, Metoprolol succinate, Atorvastatin calcium.\n\n## Exercise 3\nIn this exercise, you should write a patient note about a patient taking the following medications: Doxasosin hydrochloride/hydrochlorothiazide.\n\n## Exercise 4\nYou should write a pregnancy note for a case including the following clinical cases. \n\n## Exercises for the lesson 5\n\n## Exercise 1\nIn this exercise, you should use [link text] to draw an axillary specimen photograph.\n\n## Exercise 2\nIn this exercise, you should draw radiographs of the right chest and lung using [link text] to understand chest X-rays better.\n\n## Exercise 3\nIn this exercise, you need to write about a patient receiving physical examination for a diagnosis of acute appendicitis. Write a patient note using the data of the following cases. Clinical history: The patient is a 34-year-old woman visiting our outpatient department of department of internal medicine. Sixteen years ago, she had been treated for diabetes mellitus at another hospital. She was put under the care of another internal physician in the medical center where is living now. She has a",
        "label": 0
    },
    "85": {
        "output": "<EOD> Transforming growth factor-beta 1 (TGF-beta 1) potentiates lymphocyte responses. Studies in patients with acquired immunodeficiency syndrome.\nCytokine regulation has been implicated in the development of anergy or unresponsiveness of lymphocytes in individuals infected with HIV-1. It is believed that TGF-beta 1 is involved in impaired lymphocyte activation, in part, through transcriptional repression of the IL-2 gene. To determine if increased levels of TGF-beta 1 were involved in suppressing cellular immune responses in AIDS in vivo, we utilized a PHA-induced lymphocyte proliferation assay from the patients with AIDS and AIDS-related complex (ARC). We also evaluated the effect of TGF-beta 1 upon lymphocyte activation. Our results indicate that TGF-beta 1, alone did not suppress PHA-induced lymphocyte blastogenesis. However, lymphocytes obtained from patients with AIDS and ARC, when exposed to rTGF-beta 1, could be activated to secrete IL-2 and proliferate. These data suggest that TGF-beta 1 plays an immunoregulatory role for the maintenance of normal lymphocyte proliferation induced by mitogens. TGF-beta, alone did not induce lymphocyte proliferation but could augment lymphocyte responses.<EOD> Evaluation of an integrated psychosocial intervention for women in a high-risk population in rural KwaZulu-Natal, South Africa: the effect of psychosocial skills training, social support and a sense of belonging in an intervention delivered via community health workers (CHWs).\nBACKGROUND\nIn recognition of the importance of community in the lives of women, and the influence this has on outcomes such as antenatal weight gain and retention in care, a psychosocial intervention was developed for a high-risk population of pregnant women in South Africa.\n\n\nOBJECTIVE\nThe aim of the study was to investigate the effectiveness of the intervention across three components - psych",
        "label": 0
    },
    "86": {
        "output": "Examples\nIn the following, three example datasets are evaluated, each of which contains three trials that use slightly different inclusion criteria but identical exclusion criteria.\n\nFirst, let's evaluate the dataset `pat_data.patient_input.txt` with the number of patients 15 and include the file, which contains the corresponding trials with number of trials 3 and each trial's inclusion and exclusion criteria.\n\n```python\nimport os\nimport psip as psi\n\npsi.read_file_directory(r'./data/sample_01')\npsi.psip_viewer(r'sample_01.log')\npsi.psip_viewer(r'sample_01')\npsi.psip_viewer(r'sample_01_trial1.txt')\npsi.psip_viewer(r'sample_01_trial2.txt')\npsi.psip_viewer(r'sample_01_trial3.txt')\npsi.psip_viewer_pat(r'sample_01')\n```\n![](../_images/viewer/trial.3.pdf)\n\nIn the same way for dataset `pat_data.patient_input.txt`.\n\n```python\npsi.read_file_directory(r'./data/sample_02')\npsi.psip_viewer(r'sample_02')\npsi.psip_viewer(r'sample_02_trial1.txt')\npsi.psip_viewer(r'sample_02_trial2.txt')\npsi.psip_viewer(r'sample_02_trial3.txt')\npsi.psip_viewer_pat(r'sample_02')\n```\n![](../_images/viewer/trial.5.pdf)\n\nAnd for dataset `",
        "label": 0
    },
    "87": {
        "output": "---\n### `Instructions`\n\nThis task involves multiple steps. First we have to find the value of [**Trial-level variables**](trial_level_variables.html). We will need the triallevel variable for:\n1. Age group: [**Trial-level variable: Age group**](age-group.html)\n1. Menopausal status: [**Trial-level variable: Menopausal status**](menopausal-status.html)\n1. Histological tumor type: [**Trial-level variable: Histological tumor type**](histological-tumor-type.html)\n1. Axillary node status: [**Trial-level variable: Axillary node status**](axillary-node-status.html)\n1. Type of lymph node dissection: [**Trial-level variable: Type of lymph node dissection**](type-of-lymph-node-dissection.html)\n1. Breast-and tumor-size classification: [**Trial-level variable: Breast-and tumor-size classification**](breast-and-tumor-size-classification.html)\n1. Pathological T classification: [**Trial-level variable: Pathological T classification**](pathological-t-classification.html)\n1. Primary tumor grading: [**Trial-level variable: Primary tumor grading**](primary-tumor-grading.html)\n1. Clinical lymph node status: [**Trial-level variable: Clinical lymph node status**](clinical-lymph-node-status.html)\n1. Histological lymph node status: [**Trial-level variable: Histological lymph node status**](histological-lymph-node-status.html)\n1. Adjuvant systemic therapy: [**Trial-level variable: Adjuvant systemic therapy**](adjuvant-systemic-therapy.html)\n1. Adjuvant locoregional treatment: [**Trial-level variable: Adjuvant locoregional treatment**](adjuvant-locor",
        "label": 0
    },
    "88": {
        "output": "An electronic clinical case note can contain several pages that describe the details of a particular encounter, including the following: History and physical examination, diagnostic imaging or studies, laboratory results, medical records, and other types of documentation (e.g., consultation notes, pathology and microbiology reports). \nA clinical note template consists of fields that facilitate the entry of pertinent medical information on an electronic patient record. It is composed of a data model that contains pre-defined data fields (e.g., laboratory tests, special test categories). \nFor each patient note you receive, you should answer the following questions: \n**Question 1:** What clinical notes do you receive? You should identify the following fields: \n \n**Question 2:** What type of notes are they?\n\n### Answers\n### History\n\n##### Answer 1.\n\n\n### Physical examination\n\n###### Answer 2.\nThis is a physical examination for a 45-year-old postmenopausal woman with breast cancer.\n\n### Laboratory\n\n###### Answer 3.\nYou may also refer to the following lab reports that show the normal ranges of the lab tests on the patient:\n \n[Lab Test Number]\nThis is [Lab Test Number] which is the test for breast cancer. The result is in normal range, showing the results of [Lab Test Number].[0]\n[0] These are the lab results for tests listed on[0].\n\n### Diagnostic imaging and studies\n\n###### Answer 4.\nYou may also refer to the following diagnostic images which are tests for breast cancer.\n\n### Imaging of the breast\n\n###### Answer 5.\nYou may also refer to the following X-rays which are tests for breast cancer.\n\n### Imaging of the lungs\n\n###### Answer 6.\nYou may also refer to the following computed tomography images of the patient:\n \n[0]\n[0]\n \n[0]\n[0]\nFor every CPT, you should determine whether the test/service qualifies as an Independent or Dependent. Independent tests or services (",
        "label": 0
    },
    "89": {
        "output": "### Submitting your assignments to this class\n[http://instructional-github.cs.vt.edu/#](https://instructional-github.cs.vt.edu/#))\n\nYou should submit all the relevant files through the TA office (the TA's email is listed inside the `assigmnents.md` file on the github repository) by Tuesday, April 5, 2022. All the assignments must be submitted in one folder as a zipped file. In other words, you should zip all the assignments into the same folder as one single zipped file, then upload it to the same file location. The name of the zipped file must be the student's CSE ID. Do not forget about the filename for each assignment! The name of your assignments are: \n\n`CSIC9813_Micro_Assign.md` - Submission of micro-assignment-the patient notes for patient 1:\n\n`CSIC9813_Micro_Assign_2.md` - Submission of micro-assignment-the patient notes for patient 2:\n\n`CSIC9813_Micro_Assign_4.md` - Submission of micro-assignment-the patient notes for patient 4:\n\n`CSIC9813_Micro_Assign_5.md` - Submission of micro-assignment-the patient notes for patient 5:\n\n`CSIC9813_Micro_Assign_6.md` - Submission of micro-assignment-the patient notes for patient 6:\n\n`MIC_ELIGIBILITY_assignment_1.md` - Submission of assignment-the evaluation of inclusion eligibility for patient 1:\n\n`MIC_ELIGIBILITY_assignment_2.md` - Submission of assignment-the evaluation of inclusion eligibility for patient 2:\n\n`MIC_ELIGIBILITY_assignment_3.md` - Submission of assignment-the evaluation of inclusion eligibility for patient 3:\n\n`MIC_ELIGIBILITY_assignment_4.md` - Submission of assignment-the evaluation of inclusion eligibility",
        "label": 0
    },
    "90": {
        "output": "<EOD> Experimental realization of non-hermitian quantum phases with Floquet engineering in a cold-atom system.\nWe theoretically propose a platform to engineer and characterize the non-Hermitian quantum phases and the associated entanglement phase transition in condensed-matter systems by Floquet engineering with ultracold atoms. This platform, which is based on the quantum Ising model, supports the richer non-Hermitian phases that are induced by the coupling of an Ising model to a quantum dissipative environment. In contrast to the Hermitian quantum states, the topological protection induced by the non-Hermitian phases survives the dissipation of the environment. We expect the experimental realization of the non-Hermitian phases to aid in further exploring the dynamics of condensed-matter systems and uncovering the underlying mysteries of the dissipative processes.<EOD> In this issue\nWe have 2 new articles on PET/ CT imaging this month, with articles from Dr Andrew Adey and Dr Srikala Jayasundara from Royal Perth Hospital and Dr Steven Mossman, formerly of Nepean Hospital. Adey et al. report on a case series of patients who had received 68Ga-pentixafor PET/ CT scans for imaging of inflammatory joint disease (IJD), specifically for rheumatoid arthritis and psoriatic arthritis. We have a case series of head and neck paragangliomas from Jayasundara et al. We also have 3 cases from the Western Australia Radionuclide Therapy Centre: Cases include prostate cancer treatment using 177Lu-PSMA, and thyroid carcinoma and mucosal melanoma using 131I.<EOD> The effect of the cerebro-spinal fluid proteins on the enzyme and glycolytic activities of human semen.\nIt is evident that the cerebro-spinal fluid containing 1 per cent of albumin exerts no inhibitory effect on the lactic dehydrogenase activity of human spermatozoa. On the contrary, in the presence of a physiologic concentration of cerebro-spinal fluid the activity of the latter enzyme is strongly stimulated. The glycolytic",
        "label": 0
    },
    "91": {
        "output": "<EOD> Methamphetamine dependence: a behavioral review.\nA history of human use is discussed, the psychoactive chemical is described, and the pharmacokinetics of methamphetamine (MA) are summarized. There is a brief discussion of research that examines the possible effects of MA on sexual behavior. Because the effects of addiction and abuse include changes in sexual behavior, a more in-depth discussion follows. In humans, these effects reflect differences between users and nonusers and include changes in number of sexual partners, frequency and type of sexual activity, and use of condoms. Psychological effects of prolonged use with respect to mood, cognition, and psychopathology are also examined. Substantial differences have been found between users and nonusers with respect to various aspects of sexual function and sexual satisfaction. As expected, the drug has a direct physiologic effect on sexual activity. Pharmacologic treatment of MA addiction has not been consistently successful although many different pharmacotherapies have been investigated. The findings of this review show that MA addiction is associated with numerous negative consequences including marked cognitive impairment and behavioral dysregulation. The behavioral effects of MA are mediated by changes in neurotransmitter activity, particularly dopaminergic function. Further studies of the effects of MA are necessary to obtain a more complete understanding of the effects of the drug on behavior.<EOD> The importance of considering the timing of treatment and its relation to the biology of breast cancer: a systematic review and a meta-analysis\n\nBackground: The relationship between the biological characteristics of a tumor and the response to chemotherapy was investigated by several research groups. In the previous studies however, not enough attention was paid to the time between administration of the chemotherapeutics and taking the biopsy in which the immunohistochemical analysis was done. The aim of this meta-analysis was to investigate the inter-relationship between the timing of the chemotherapy administration and biological characteristics of breast cancer.Methods:In order to assess the effect of chemotherapy on a tumor tissue, we searched for articles investigating the relation between the immunohistochemical characteristics and the timing of chemotherapy in breast cancer patients by both MEDLINE and PUBMED.Results: Nine different",
        "label": 0
    },
    "92": {
        "output": "<EOD> Prevalence of Antibodies against Toxoplasma gondii and Sarcocystis spp. in Breeding and Domestic Cats in Southern Italy\n\nOne hundred and seventy-one cat saliva, serum, or fecal samples were tested for anti-Toxoplasma gondii antibodies (IFA) using as antigen (Ag) tachyzoites from RH strain and bradyzoites from Pru strain; for the detection of anti-Sarcocystis spp. IgGs (ELISA and western blot), Ag derived from a Sarcocystis sp. were used. Overall, prevalence rates were 49.1% for T. gondii and 46.2% for Sarcocystis spp.; the latter was confirmed by western blot only on nine samples (13.5%). Prevalence rates were comparable between male and female, and between adult and kittens; a seasonal pattern was observed for T. gondii, without being significant, whereas it was significant for Sarcocystis spp.; Sarcocystis sp. prevalence was higher in both breeding and outdoor cats.\n\n# Introduction\nToxoplasma gondii is a ubiquitous parasite that can infect all intermediate hosts, including humans; it can even infect more than one host species in 1 host, including cats.\nOnce in the intermediate hosts, two developmental phases are involved; during the tachyzoite phase, this parasite can enter into cells of any tissue, and cause damage to cells and death, while during in the bradyzoite phase, it encysts in cells of skeletal muscles and brain, becoming latent. However, cystic stage of tissue cyst (brachyzoites) cannot be maintained outside the central nervous system (CNS) or muscle tissue; nevertheless, it has been reported that T. gondii can also colonise, disseminate, and persist in muscles or heart tissues. In case of T. gondii vertical transmission, congenital or perinatal, the parasite can infect the brain of the unborn fetus, causing severe foetal damage and birth defects.",
        "label": 1
    },
    "93": {
        "output": "## Step 1: Check the patient's characteristics\nIn this step, you should check which patient information is missing.\n1. You should define the parameters to check patient information and save it in an output parameter, e.g., Param (PatientID) = `PatientID or Age # or Gender # or HER2 # or NED or `. To set more parameters in one line, please use the `;\u00b4 symbol.\n2. Check the patient record of a specified Trial ID, for example, `RunAllPatient_Trials_ID({trialID = 1})`.\n\n## Step 2: Compute trial-level eligibility\nIn this step, you should compute trial-level eligibility for each patient and check if the patient information is missing.\n1. You should save patient information in the Output parameter to check the patient record (See Step 1: Check the patient's characteristics.). However, you can calculate trial-level eligibility directly. To do so, you should also create another parameter `TriallevelEligibility` of the same format as `PatientID` in the previous step. If any parameter is missing, the value should be set to '-1`. [INST]\n2. You should calculate trial-level eligibility based on the computation of `tleL` function. After calculating trial-level eligibility for each patient, you should print information for evaluation, as shown below.\n    - PatientID: Unique identifier for the patient\n    - Patient: Name of the patient\n    - TrialName: Name of the clinical trial\n    - Stage: Stage of the patient in the clinical trial\n    - ExclusionC: Exclusion criteria\n    - Sex: Gender of the patient\n    - Age: The age of the patient\n    - Her2: HER2 type of the patient\n    - NED: The state of the patient\n    Note: You can create additional columns to display more in-depth information.\n\n## [INST]\nComputations of trial-level eligibility (tleL) for all patients.\n\n## [INST]\nComputations of trial-level eligibility (tleL) for each patient\n\n## Step 3: Output trial-level eligibility for the patient\nIn this step, you should save trial-level",
        "label": 2
    },
    "94": {
        "output": "__8__ What is a `matched triad`? Is there something special about the patient or the clinical trial that must be a good match?\nThere seems to be something special about the matched triad. We will learn the concept later by running some examples. A matched triad is a group of the following three people:\n- A certain patient for whom you need to calculate the trial-level eligibility assessment;\n- a clinical trial; and\n- a certain set of variables which represent a certain characteristic of the patient, for example, the gender for gender-related studies or the clinical stage for a certain kind of cancer. \nA patient note and a clinical trial are a sort of `triad` or `set of three items`; therefore, the term `matched triad` is used to denote the patient, the clinical trial, and the set.\n\nThe clinical trial is represented as the `Clinical trial` variable, and the values of the clinical trials are collected and saved in the `Clinical_trials` object. The set of variables that represents certain characteristics or characteristics of the patient can be saved as the set of variables as the `Variable_set` variable, and values of their variables can be saved in this variable. \n__9__ What do you need to do to be prepared for the next step of the coding?\nThe data for the next step are shown below. \nTo find patient's variables that match the desired clinical trial and to calculate the trial-level eligibility assessment simultaneously, you should create a new object for each patient. This object will be named Patients. \nWhen calling `Patient('Patient','Clinical_trial', Clinical_trials,Variable_set,'Trial-level_assessment', Trial_level_assessment, 'Patient_recommendation', Patient_recommendation, 'Trial_notes', Trial_notes)' you pass each patient data to the object together with the clinical trial's name `Clinical_trial`, the current clinical trial whose trial-level eligibility assessment you will calculate for a certain patient `Clinical_trials`, the set of variables that represent patient characteristics `Variable_set`, the assessment on trial-level eligibility `Trial-level_",
        "label": 0
    },
    "95": {
        "output": "[CODE] # Trial-level eligibility: \n  for patient in len(patients)[:-1]:\n    assessments[patient] \n    assessments[patient] = f\"{assessments[patient]}[0]*2+\"\n    assert assessments[patient] in {0 : Excluded, 1 : NotRelevant, 2 : \n    Eligible}, \"not consistent: {}\".format(assessments[patient])\n  assessments[-1].add(\"\") \n# end code \n\n[\n  {\n    'id': '18b1a2b0-98e6-4ee0-94dd-66c36b51d4d7',\n    'age': 59,\n    'education': None,\n    'title': None,\n    'education': [{\n      'id': 'bb16a2d8-b276-4a56-8479-2f5175c69067',\n      'grade': 7,\n      'subject': 'Ethics'\n    }, {\n      'id': 'd2f17182-e020-452f-b14e-ab72181c475a',\n      'grade': 6,\n      'subject': 'Chemistry'\n    }, {\n      'id': 'beb1b993-7365-4bcf-940d-4b5d9aad6140',\n      'grade': 10,\n      'subject': 'Mathematics'\n    }, {\n      'id': 'e7c77f25-6234-4c01-99a7-343bd780420b',\n      'grade': 10,\n      'subject': 'English'\n    }, {\n      'id': 'f734ae39-7acb-40c1-829b-b3c4ac425aed',\n      'grade': 6,\n      'subject':",
        "label": 1
    },
    "96": {
        "output": "<EOD> The use of the microfluidic device to determine the adhesion potential of Candida albicans\nMicrobiological contamination or infection by opportunistic pathogens often happens in the hospitals to immunocompromised patients. Candida albicans is the second commonest cause of nosocomial infections worldwide. In order to evaluate the adhesion of Candida albicans onto the human mucin hydrogel inside a fluidic chip, an acrylic microfluidic device with a hydrogel pearl chamber, to which human mucin is adhered, is fabricated and used. The mucin extracted from porcine stomach is cross\u2010linked using either 1-ethyl-3-(3-dimethylaminopropyl)carbodimide (EDC) or genipin as covalent cross\u2010linker. The adhesive abilities of the Candida albicans onto those mucins inside the device are compared and it is found that the cross-linking of the human mucin using EDC increases the adhesive potential of the Candida albicans to the mucin, whereas the genipin-cross-linking results in an unexpected decrease in the adhesion. This is attributed to the altered surface properties of the cross-linked mucin due to the genipin cross-linking and to the cell surface charges of C. albicans. The study reveals the possibility of developing a microfluidic device to identify microorganism attachment to the biomimetic mucin, which is capable of forming a good biofilm structure. Microsc. Res. Tech., 2007. \u00a9 2007 Wiley-Liss, Inc.<EOD> Corneal Dystrophy Caused By Various Types of DQ69 Gene Mutations: A Systematic Review\nPurpose: This systematic review aimed to determine how various types of DQ69 gene mutations caused the TCF4\u2013linked dystroma corneae et myopi. Methods: This review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses guideline. PubMed, Embase, and Cochrane Central and ClinicalTrials.gov were searched up to February 2",
        "label": 0
    },
    "97": {
        "output": "Let's begin with some basic examples. I want to include the following test cases:\n    - `\n    - `\n    - `\n    * Note. You should specify the file path of the patient, i.e., `patient.txt`.\nYou are given the following code. \n---\ninstructions_patients_eligibility: \n    For each patient:\n        Trial-level eligibility:\n```\ndef eligibility_helper(patient_text, trial_text):\n    assert('eligibility' in patient_text)\n    assert('Eligibility' in trial_text)\n    # This part is your responsibility.\n\n    assert len(patient_text.splitline.split(' ')) >= 2\n    assert len(trial_text.splitline.split(' ')) >= 2\n\n    if patient_text.splitline.split(' ')[:2] == trial_text.splitline.split(' ')[:2]:\n        return 1 # 0 means \"Not eligible\", 1 means \"Eligible\".\n    else:\n        return 0\n\n\n```\nYour task is to fix the code to return valid responses (either 0 or 1) for the test cases in the comments.\n\n__Good luck!__\n__Hints:__ \n* [001-eligibility-example1.ipynb](https://github.com/pybrainhacker2022/pyML-HackerRank/blob/main/example/001-eligibility-example1.ipynb)\n* [001-eligibility-example2.ipynb](https://github.com/pybrainhacker2022/pyML-HackerRank/blob/main/example/001-eligibility-example2.ipynb)\n* [001-eligibility-example3.ipynb](https://github.com/pybrainhacker2022/pyML-HackerRank/blob/main/example/001-eligibility-example3.ipynb)\n* If you need explanation about `assert`, click here: [Python Assessment: Assert Document",
        "label": 1
    },
    "98": {
        "output": "Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale:0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:`The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.`. Here is the clinical trial: \nTitle: Axillary Reverse Mapping for Invasive Carcinoma of the Breast\n\n\nSummary: Primary Objectives:~To determine the feasibility of axillary reverse mapping (ARM) in patients undergoing axillary lymph node dissection for breast cancer therapy.~To determine the incidence of breast cancer metastasis in lymph nodes draining in the arm as identified by axillary reverse mapping.~To determine the safety of axillary reverse mapping.\nInclusion criteria: Inclusion Criteria:\nPatients with invasive carcinoma of the breast planning to undergo axillary lymph node dissection at M. D. Anderson Cancer Center.\nEastern Cooperative Oncology Group (ECOG) performance status of equal to or less than 3.\n\nLet's think step by step",
        "label": 2
    },
    "99": {
        "output": "<EOD> Flexible Rigid Electrodes on Polyimide Substrates\nThis article presents a systematic study of the performance of rigid electrodes coated with organic layers over their surface through physical vapor deposition (PVD) techniques. Polyimide (PI) is used as a substrate material to optimize the electrical characteristics of the flexible electrode. Atomic Force Microscopy measurements reveal that the coating deposition on PI substrate with SiO and Al2O3 improves the quality of the coating surface. In addition, for both coatings, the thickness measurements obtained by X-ray Photoelectron Spectroscopy are not in concordance with the thicknesses found by the optical and profilometer techniques. For the SiO/PI system, the electrical conduction through the layers improved and an invariance of the resistance with the thickness of the coating is obtained. In addition, the Al2O3/PI system showed the best conductive characteristics when compared with literature materials. Hence, this work proposes PI-based substrates with SiO and Al2O3 coating for use in semiconductor applications and rigid electrodes for supercapacitors.<EOD> Synergistic effects of tazarotene on cutaneous wound healing in diet\u2010induced obese mice\nObesity is a severe risk factor for impaired wound\u2010healing processes and skin aging. Tazarotene is currently used to treat various skin diseases. This study aimed to examine the effects of topical tazarotene on diet\u2010induced obesity\u2010related cutaneous wound healing.<EOD> Cranial nerve V/VIII\n\n# Overview\nThe fifth (trigeminal) and eighth (vestibulocochlear) cranial nerves are together referred to as the cranial nerves V/VIII. These fibers are often referred to as the \"facial\" and \"auditory\" nerves, respectively, but this nomenclature is usually avoided as it is inappropriate for the trigeminal nerve.\nThe fibers of these nerves are primarily sensory and convey sensation of the face and mouth to the brain. The eighth nerve is responsible for spatial vision.\n\n# Structure\n\n## Trigeminal",
        "label": 0
    },
    "100": {
        "output": "[TEXTBOX start=0.5 no-wrap align=left width=41 no-border, TEXT002]\n\nI think this is good. Thanks.\r\n\nA: In R we would go the following:\r\n```\r\ndf[df$condition == \"excluded\" & is.null(df$outcome), ] <- \"0\" \r\ndf[df$condition == \"included\" & is.null(df$outcome), ] <- \"1\" \r\ndf[!is.null(df$outcome) & (df$condition == \"yes\" | (df$condition == \"no\" & is.numeric(df$outcome))), ] <- \"2\"\r\n```<EOD> Syntheses, structures, and magnetic properties of lanthanide (III) phosphonates.\nIn order to study the effect of the covalent character of phosphonic acid ligands on the magnetic properties of lanthanide (III) phosphonates, seven lanthanide(III) phosphonates, Ln(HPO3)3(Cn)n-n (Ln = Ce, Pr, Nd, Sm, Eu, Gd, and Dy), were synthesized under hydrothermal conditions, and their structures were characterized by X-ray single-crystal and powder diffraction analyses. All the Ln(HPO3)3(Cn)n-n samples were monoclinic. Two of them, Ln(HPO3)3(Cn)n-n(Ln = Ce and Gd), contain two formula units in a unit cell and are related to each other by the inversion center. They belong to the C2/c space group; however, all the others are in the P21/c space group. They contain a three-dimensional framework built from edge-sharing 6-connected HPO3 and 8-connected LnO3 polyhedra with the m2(2) m3(2)2 topology. Because of the steric hindrance effect of the bulkier benzyl substituent of the carbon chain in Cn, all the Ln(HPO3)3(Cn)n-n(Ln = Ce, Pr, Nd, Sm, Eu, Gd, and Dy)",
        "label": 2
    },
    "101": {
        "output": "### Data Type: Table\n\nLet's think step by step. \nFor the data extraction, let us think what data we need to extract.\n\nAt first, let's extract a table which contains basic information. The table we want to extract is **Basic information table**, e.g., <table class=\"dataTable titleBorder\"><thead><tr><th width=\"25%\">Data Field:</th><th width=\"75%\">Data Type:</th><tr><td class=\"dataLabel\" width=\"25%\">Patient ID</td><td class=\"dataIdentifier\">string</td><td width=\"75%\">The patient's unique identification number used by an organization to identify a patient in its environment (e.g., an insurance plan, health plan, provider, or pharmacy).</td></tr><tr><td class=\"dataLabel\" width=\"25%\">Sex</td><td class=\"dataIdentifier\">string</td><td width=\"75%\">The patient's gender (e.g., \"male,\" \"female,\" \"unknown\"). There may be many ways of designating gender or sex, including ethnicity (e.g., \"male,\" \"female,\" \"other\"). The value of this field may be unique but can also be an attribute of a disease (e.g., \"male,\" \"female\").</td></tr><tr><td class=\"dataLabel\" width=\"25%\">Date of birth</td><td class=\"dataIdentifier\">datetime</td><td width=\"75%\">Record date of when the patient was born (e.g., \"1943-12-07\" if the patient was born on December 7th, 1943).</td></tr><tr><td class=\"dataLabel\" width=\"25%\">Age</td><td class=\"dataIdentifier\">string</td><td width=\"75%\">Age as of the event/record. Ex: \"39 years\" or \"2 years 3 months 9 days\" (use the integer part of the year field, so subtract 1 from the year value to get the age). The following values are acceptable for this field. The word \"years\" should be the unit for this field and is not used in plural. A slash",
        "label": 2
    },
    "102": {
        "output": "Let's try the example of clinical trial #2 from the previous section: # clinical trial no. 2 of `The Role of Diet and Lifestyle in Breast Cancer Survival`\n# This assignment is due 8/17/2020 \n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial: \nTitle: The Role of Diet and Lifestyle in Breast Cancer Survival\n\n\nSummary: Diet has been found to influence hormone production and metabolism which in turn could affect the incidence of hormone related cancers. Consumption of soy-cont",
        "label": 2
    },
    "103": {
        "output": "[/HINT] Output:\nNote:\n* You don't have to print all the elements, but you can.\n* You can use \"break\" in the repeat loop (until \"patient\" in patient notes)\n\n## Problem Statement: [bib_ref]  Hello, World!\": Learning Python through Linguistics, Bailey [/bib_ref]  In this project, you will be working with and modifying a code to help you get to know the Python programming environment.\n\n## Problem Summary [bib_ref]  Hello, World!\": Learning Python through Linguistics, Bailey [/bib_ref]  In this exercise, you will begin by modifying the version of the code below in order to print it when it is run. Once completed, you will be asked to use the original code as the context for a sequence of further changes in order to print your initials.\n\n## Instruction [bib_ref]  Hello, World!\": Learning Python through Linguistics, Bailey [/bib_ref]  For your initial \"Hello, world!\" program, begin by modifying the code presented below. This code prints \"Hello, world!\" on the screen. When you submit the code that you have created, your final \"Hello, world!\" program should produce the following output: Hello, world! [Submit Your Program] \n\n## Hint 1: [h1]\nFor the most general type of program you are producing, you can change the file to read like the one you are working with below, and this is referred to as a text file or a source code file. \nWhen this program is executed, the file will be converted into bytecode data that the computer can execute.\n[h1]\n\n## The challenge:\nWhat will you need to do in order to get your first program working and running on your system? \n\n## Challenge Solution 1\nWrite a program to print the phrase \"Hello world!\"\nOne thing to note about Python is that if you open up a file and start typing, Python will immediately display what you entered! This means that you can change code on the fly and see how your program behaves as you do so.\nYour program should print \"Hello, world!\" when you run it, like the computer program below.\n\n## Running the program [bib_ref]  Hello, World!\": Learning Python through Linguistics, Bailey [/bib_ref]  In order to check the code, you will need to run your program. When",
        "label": 1
    },
    "104": {
        "output": "### Exclusion criteria\nFirst of all, here we will define list of exclusion criteria:\n- No current pregnancy or nursing\n- No history of any other cancer or cancer (other than basal cell carcinoma of the skin) that was diagnosed in the 5 years before the time of enrollment (including cancer of the bladder, colon, rectal, bile ducts, liver, gallbladder, ovaries, lymph nodes, leukemia, multiple myeloma, melanoma, thyroid gland, prostate, and meninges)\n- No history of any condition that might seriously affect the ability of the patient to tolerate therapy or surgery or to participate in the study (e.g., recent myocardial infarction or stroke)\n- No history of another disease that can interfere with the conduct of the study (e.g., unstable angina, congestive heart failure, or coronary artery disease)\n- Women of childbearing age should be taking adequate contraceptive methods\n- No history of any neurological disease (e.g., dementia, stroke, epilepsy with seizures, paralysis, or multiple sclerosis) or significant CNS dysfunction that the patient cannot safely undergo study therapy\n- Significant hypersensitivity/allergy reaction to any study drug or other drugs (e.g., dactinomycin)\n- No other relevant malignancy (other than nonmelanoma skin cancer) in the past 5 years\n- No acute bleeding disorders\n- No active oral, inhaled, or intravenous therapy with other investigational or non-investigational agents\n- No medical condition that is either life threatening or may impair the ability to participate in the study\n- No history of alcohol dependence or alcohol abuse\n- No psychiatric disorder that would prohibit compliance with protocol requirements or interfere with the conduct of the study\n- No treatment with 4 drugs or more for non-cancer indications at the time of enrollment (including the use of hormone treatments)\n- No active oral, inhaled, topical, or intra",
        "label": 2
    },
    "105": {
        "output": "- A good answer should output the following (at least): 1) Not relevant; 2) Eligible;\n- There are three trials that meet your requirements.\n\n| [https://github.com/vipulraina/pyk2ml-pycodestates.git](https://github.com/vipulraina/pyk2ml-pycodestates.git) |\n| [https://github.com/davidhuggins/pycodestates.git](https://github.com/davidhuggins/pycodestates.git) |\n| [https://github.com/matthewraschke/codestates.git](https://github.com/matthewraschke/codestates.git) |\n| [https://matthewraschke.com/matthewraschke/codestates/tree/dev](https://github.com/matthewraschke/codestates/tree/dev) |\n| [https://github.com/davidhollis/pycodestates.git](https://github.com/davidhollis/pycodestates/tree/dev) |\n| [https://bonsai.github.io/bonsai/tree/master/pycodestates](https://github.com/vipulraina/pyk2ml-pycodestates) |\n| [https://docs.microsoft.com/en-us/visualstudio/python/tidy-code](https://matthewraschke.com/matthewraschke/codestates/tree/dev) |\n\n<EOD> .\nThe results of ultrastructural investigation of experimental acute pancreatitis and obstructive jaundice under the influence of preparation \"Nespol\". Nespol increases the number of microglial cells and inhibits cellular destructive processes which take place in the rat brain in case of experimental acute pancreatitis (AP) and obstructive jaundice. The effect is related to the neuroprotective properties of neurotropin preparation.<EOD> Filling the void, a multidisciplinary model to support patients and families throughout the diagnosis and treatment experience.\n2",
        "label": 2
    },
    "106": {
        "output": "In the example, `2) Eligible.`is the last line in the output. \n\nYour task is to find out if your patient with a breast-cancer qualified for the clinical trial, i.e., to assess the eligibility of yours patients on the basis of the given case report. How much time do you need to find out? You should submit your answer as a pair of natural-number using the following link:\nhttps://forms.gle/LsUz37JwCxAxA67K6\nTo see your score, please, submit an email to jose.jovel19@gmail.com along with the following information.\n\nScore: [insert your score between brackets].\n\n**Instructions** for jose.jovel19@gmail.com (Your Name, Question #):\n\n### Eligibility Assessment in Clinical Trials: Journals.sagepub.com/home/pms\n\n### Eligibility Assessment in Clinical Trials: journals.sagepub.com/home/pms\n\n### Eligibility Assessment in Clinical Trials: jons.sagepub.com/home/pms\n\n### 13.6. Eligibility Assessment in Clinical Trials: Jons.SagePub.com/home/pms\n\n### 11.22. Eligibility Assessment in Clinical Trials: jons.SagePub.com/home/pms\n\n### 31.4 How to use clinical trial databases\n\n### Eligibility Assessment in Clinical Trials: Jonnals.sagepub.com/home/pms\n\n### 31.4 How to use clinical trial databases\n\n\n\n### 27.4 Disease-Specific Eligibility Criteria: jons.sagepub.com/home/pms\n\n### 27.4 Disease-Specific Eligibility Criteria: Jonssagepub.com/home/pms\n\n### 13.6. Eligibility Assessment in Clinical Trials: JonsPub.com/home",
        "label": 0
    },
    "107": {
        "output": "## Instructions to authors\nComplete our submission system at: <https://submit.rocs.cn/default.aspx> \nTo submit your manuscript, you need to register first. If you have never tried to use the ROCS submission system, please click the question mark at the corner of each form to view helpful guidance.\nPlease complete, in English, the following electronic form using mandatory and optional fields. You may attach up to 6 supplementary files. (Note that each file uploaded must be less than 150 Mb in size and in a format that can be downloaded by readers. This file should be as small as possible. File formats for data and analysis results include: *xls, *xlsx, *doc, *docx, *txt, *csv, *bib, *tex.)\n\n## Manuscript\nThe cover page should include:\nTitle:\nAuthor Names (including initials):\nAffiliated Institutions/Colleges (this should be written in the format of your current affiliation).\nYour manuscript should consist of four major sections: (1) Title page (containing title, authors, affiliations, conflict of interest), (2) Abstract, (3) text, and (4) references. All questions regarding the appropriate format should be emailed at: publisher@rocs.cn.\nAll papers submitted to ROCS must be submitted with an abstract. Do not forget to provide the following data for the paper in your cover letter file: corresponding Email, phone number, fax number and author-affiliated Email.\n\n## Title\nChoose a simple and accurate title that is short and specific. The title must end with a question to avoid the title being regarded as a statement. Use of non-conventional typefaces or color should be avoided.\nDo not include statements of novelty, the degree of importance of the study, or implications of the study results. If these qualifiers are felt to be warranted, they should be inserted in the Abstract.\n\n## Structured abstract\nThis section will begin with an unstructured abstract that summarizes the background, purpose, methods and results of the study, and closes with an abstract conclusion. The abstract needs to include the following sections.\n\n## Manuscript types\nThere are three types of article submissions:\n1. Original Research Article or Study: This article reports original findings",
        "label": 0
    },
    "108": {
        "output": "### Case Study (Clinical Trainee)\nA clinical trainee is given a patient note as a homework for evaluation:\nA 63-year-old man was seen in the general outpatient department of a teaching hospital with a complaint of progressive swelling of the scrotal sac. He had undergone radical orchidectomy for carcinoma of the left testis 12 years ago. He had 2 sessions of radiotherapy for the treated area at the end of the 1990s. His recent complaint of swelling started about 1 month ago and steadily progressed to encompass the entire scrotum. He denied penile pain or any complaint of fever. He had been smoking for 25 years. No family history of cancer was reported.\nThe general physical status was good. On examination, the swelling was hard, non-tender, mobile, and cystic. It was not fixed to the abdominal wall. No lymphadenopathy was felt.\nExamination under anesthesia revealed a 44 \u00d7 40 cm sized soft tissue tumor occupying the scrotal sac. A skin incision was made transversely over the swelling. A firm mass was felt in the scrotal sac. The mass was totally excised. No communication with the inguinal canal was found. A postoperative course was uneventful and the patient was discharged home on the fifth postoperative day.\n\nHere is the patient's radiotherapy record to trace any sign of cancer recurrence:\n\n### Clinical Trial: TA-3-05-BG 1996-1999\nTitle: A randomized trial of three chemotheraputic regimes\nType Description 1. Cisplatin/Vindesine/Prednisolone. 2. Cisplatin/Vincristine/Raltitrexed. 3. Cisplatin/Vinorelbine/Methotrexate.\nInclusion criteria.\n1. At least 18 years old.\n2. Squamous cell carcinoma of the head and neck origin.\n3. Histopathology report.\nExclusion",
        "label": 0
    },
    "109": {
        "output": "[INST] 0.) Your patient note is a file, so you should read the file with `f<-read.table` command. Read the data in columns. Then, you can access the individual cell values, e.g., `f[2,1]`, or you can loop or create variable, e.g., `f[3:4,\"age\"` and retrieve the result, e.g., `f[3:4,\"age\"]`. All the variables are `dfr` objects, so you can add the elements dynamically with `f+`, i.e., `f+x` creates the new variable x.\nYou will find your variables in the output. For example, the first column is Patient ID, the second column is the birth year of the patient, and the third column is gender. The first patient ID is the 45-year-old postmenopausal woman. [INST] 1.) Your first task is to remove the gender values from the input and add a column with the `Age` variable. You can extract a certain column by `f[, variable]` in R, where we use both names of variable extracted and names of the column in the input. As you can see, `f[, factor(variable)]` extracts the column with numeric values. Then, we can insert an extra column `age` in front of `gender` by using `f[, \"Age\"]` and then, delete the 'gender' column using the operator`-`. In order to create a new column, we use the operator ``+\", which makes a call to `get` to create a new column or object and the operator `\"` is used to create a data frame, so we will create a data frame. \nPlease also consider the following to show your answer: \n\n\nYou can use `if..else`. A typical syntax for `if..else` statement is:\nif(condition){if(condition)\n    print(paste(\"True\")\n    # Execute an alternative statement \n} else\n    print(paste(\"False\")\n    # Execute an alternative statement\n}\n\n\nThis function returns a statement to be evaluated. Before the close brace }, one or several arguments can be provided to the if condition. For example, if the value is not 10, then:\nif(x==10){if(x)){\n# Execute",
        "label": 0
    },
    "110": {
        "output": "You are finished! \n\n### Note\nTo test the functionality in [TEST]:<EOD> .\nOBJECTIVE\nTo evaluate a method for the reconstruction of concave-shaped defects at the back of the hands with one-stage free anterolateral thigh flaps with a pedicle of the greater saphenous vein in 25 cases.\n\n\nMETHODS\nFrom May 2006 to September 2010, 25 cases, including 18 males and 7 females with the mean age of 44.3 years old (range, 23-57 years old) underwent the repair of concave-shaped defects at the back of the hands with one-stage free anterolateral thigh flaps. There were 7 cases of crush injuries, 6 of avulsion wounds, 5 of severe burns with concave-shaped contraction contractures, 1 of severe burns with crush injuries, 1 of avulsion wounds with concave-shaped defects, 1 of severe burns with avulsion injuries, 1 of severe burns, 1 of scar, and 1 of bone defect caused by crush injuries and burns. The size of flap was 5 cm x 3-10 cm. The greater saphenous vein or the other branches were anastomosed with the veins.\n\n\nRESULTS\nAll wounds healed by first intention. All 25 cases were followed up for 7 months to 3 years, and color changes showed that the color of flaps were similar to that of surrounding tissues. According to the scale of aesthetic evaluation from the plastic surgery department of Tsinghua University, 11 flaps were fair results, 8 were poor results, and 6 were excellent results.\n\n\nCONCLUSIONS\nFor concave-shaped defects at the back of the hands, one-stage free anterolateral thigh flaps with a pedicle of the great saphenous vein is considered safe and effective treatment which can obtain satisfactory contour and color.<EOD> Ankle spastic equinus after stroke: the effect of inhibition of muscle contraction on mus",
        "label": 0
    },
    "111": {
        "output": "## Questions\n\n\nA: 1.\n\t- What is the goal of the clinical trial recruitment system?\n\t- The goal is to find relevant clinical trials.\n2. \n\t- Which assessment method should researchers use to evaluate if the patient will be suitable for the study?\n\t- It is recommended to use the case report form (CRF) to evaluate if the patient is suitable for the study.\n\nA: 1.\n\t- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3-cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\t- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3-cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n2.\n\t- The patient is a 38- 12-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3-cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for",
        "label": 0
    },
    "112": {
        "output": "# How does this apply outside Phonopy?\nWhen performing trial design on a clinical study, this script might be useful. It could take a little time, but it is not too long. If you have any question, please contact me on `IRC channel: #medicl` with `Github: https://github.com/medicl/py_python`. \n<EOD> Effects of Intake of Slow Carbohydrates on Acute Exercise\u2010Induced Proteinuria\nIn a randomized crossover design, eight healthy active men (mean \u00b1 SD age, 26.3 \u00b1 3.3 years; body mass index, 24.8 \u00b1 1.3 kg \u00b7 m\u22122; mean \u00b1 SD peak oxygen uptake (VO2) during the maximal treadmill test, 54.0 \u00b1 8.5 ml \u00b7 kg\u22121 \u00b7 min\u22121 ) performed bicycle exercise of 60 min at 70% of the VO2peak with free access to sports drinks containing either sucrose (50 g \u00b7 h\u22121 or 18.2 mol \u00b7 g\u22121 \u00b7 h\u22121) or a mixture of maltodextrin and fructose (sucrose 50 g; maltose 20 g, glucose 20 g, and fructose 20 g; maltose 10 g, glucose 10 g, and fructose 10 g \u00b7 h\u22121 or 6.6 mol \u00b7 g\u22121 \u00b7 h\u22121) at the 30th and 50th min of exercise. Immediately before exercise and immediately postexercise, first morning urine samples were collected for determination of urine protein concentration. Exercise elicited significantly higher urinary losses of protein (P < 0.05) in the sucrose trial compared with the maltose and fructose trial. The average amount of excreted protein was 44.2 \u00b1 31.5, 18.8 \u00b1 9.3, and 21.6 \u00b1 18.6 mg/h, respectively. Urine protein excretion increased by 2567% after suc",
        "label": 0
    },
    "113": {
        "output": "Headache with spontaneous onset and 8 out of 10 pain is the most common symptom complained by a patient. \nOur patient in this case (case `KL`) has a significant headache",
        "label": 0
    },
    "114": {
        "output": "### RESPONSES\n\n`020010e8` [REPLY]\n\n`020010e8` [REPLY]\n\n`020010e8` [REPLY]\n\n```python3\n# + id=\"KKFp1Ci4-yDz\" lineNumber=1 colNumber=1\nprint(\"E0020010E8_JJJJJJJJJJ0101_KKKKKKKKKK000002002011201400030302\")\n\n```\n\n`020010e8` [REPLY]\n\n`020010e8` [REPLY]\n\n```python\n# + id=\"bM0Nt4AYNWfG\" lineNumber=2 colNumber=1\ndef myPrint(text):\n    print(\"{\" + text + \"}\")\n\n\n# + id=\"bM0Nt4AYNWfH\" lineNumber=3 colNumber=1\nprint(\"{}\".format(\"Test112\"))\n\n\n# + id=\"4UyNtUzYNWfY\" lineNumber=4 colNumber=1\nmyPrint(\"ID003\")\n```\n\n```python\n# + id=\"XOcNtQvYWfE\" lineNumber=5 colNumber=1\n\n```\n\n::: {.notice}\n    - <NAME> 2015-06-25\n:::\n\n::: `{type:text}`\n:::\n\n::: '{heading} {id}: {text} (line {lineNumber})`\n:::\n\n```python\n# + colab={\"base_uri\": \"https://localhost:8080/\", \"height\": 24} id=\"XOcNtQvYWfG\" lineNumber=0 colNumber=1\nid_0 = 0\n\n```\n\n::: {.admonition}\n    - <NAME> 2015-06-25\n:::",
        "label": 1
    },
    "115": {
        "output": "There are [code-ref?27?6#code-c6] five clinical trials for [code-ref?34?97#code-c97] patients receiving [code-ref?34?93#code-c93] chemotherapy for metastatic breast cancer in the United [code-ref?34?94#code-c94] States. The [code-ref?34?96#code-c96] five clinical trials [code-ref?150?6#code-c6] for [code-ref?34?97#code-c97] patients receiving [code-ref?34?93#code-c93] chemotherapy [code-ref?34?95#code-c95] for metastatic breast cancer in [code-ref?34?94#code-c94] the [code-ref?34?92#code-e11] New [code-ref?31?31#code-id31] York City, United [code-ref?34?94#code-c94] States. \nNow let's see one of them more closely. Let's evaluate the eligibility of the first patient named Katherine, i.e., make sure she satisfies the inclusion criteria of this clinical trial. It is important to keep in mind that:\n\nA patient who meets all the eligibility criteria of a clinical trial is still not eligible for the trial unless the exclusion criteria do not prevent participation in the particular clinical trial,\n\nA patient is eligible for a clinical trial but may be excluded from participating. Clinical trials exclude patients for safety reasons, to avoid conflicts of interest, or to minimize the confusion of comparison for the study. [code-ref?64?7#code-67] (Note: You can find the list of common exclusions in Appendix A.) (code-ref?29?5#code-c5)\n\nIf the patient named Katherine satisfies all the eligibility criteria of the trial, we should print code 2) Eligible `Trial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "116": {
        "output": "<EOD> Neurology\nWe are pleased to present this special edition of Neurology entitled \u2018Neurology and Neurophysiology\u2019. Since the introduction of electroencephalography (EEG), clinically relevant information has provided physicians with objective information about the state of the nervous system. Because of the complexity of the EEG tracing, this method is frequently misunderstood or misinterpreted in daily practice. However, if interpreted correctly, this valuable diagnostic tool can help in diagnosis and choice of medication in a variety of disorders ranging from seizures and sleep disorders to psychiatric disorders. The authors in this special edition will provide the reader with state of-the-art and up-to-date information on EEG, evoked potentials and neurophysiology.<EOD> Identification and Validation of Novel Prognostic Model Based on E2F1-Related Genes in Diffuse Large B-cell Lymphoma\n\n\n\n# Introduction\nDiffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous lymphoid malignancy. DLBCL often has an aggressive clinical course, and about 30-40% of patients with DLBCL die within 5 years. Although the treatment of DLBCL has undergone a dramatic transformation in recent years, with the success of the development of new drugs, such as rituximab, targeted therapy, and immunotherapy, the prognosis of the vast majority of DLBCL patients is still not satisfactory. Therefore, the identification of biomarkers to evaluate DLBCL prognosis is urgent. The transcription factor gene E2F1-encoded protein is highly expressed in tumors and plays a critical role in tumor proliferation and apoptosis regulation. Recent studies have reported that E2F1 promotes the development of breast cancer, hepatocellular carcinoma, and gastric cancer; however, the specific role of E2F1 in DLBCL remains unclear.\nGiven the limitations of current prognostic systems such as the International Prognostic Index (IPI), the International Prognostic Index for Advanced Disease (R-IPI), and the NCCN Intermediate",
        "label": 2
    },
    "117": {
        "output": "---\n\nHow to Improve Your Output from `Trial-level eligibility`\n\nIn the last line, there are three options:\n\n- Excluded\n- Not relevant\n- Eligible\n\nYou do not need to use an extra function here. With a few words of code, you can make your code work like a regular output line.\n\n1. Define `i` as a new variable.\n   \n    ```shell\n    i=0\n    ```\n\n2. Assign the values of excluded, not_relevant, and eligible, to `i` using these variables.\n   \n    ```shell\n    if trial.notrelevant_or_excluded then\n        i <- i + 1  # Excluded\n    elif trial.not_relevant then\n        i <- i + 1  # Not relevant\n    else\n        i <- i + 1  # Eligible\n    # End of assigning.\n    ```\n\n3. Replace `Trial-level eligibility: ` with `Trial-level eligibility:` at the end of the output line.\n   \n    ```shell\n    print(sprintf(\"%c%s%s%s\", ' ', ' ', $i, ' ')) # print the string as one line.\n    ```\n\nFor example, the final output looks as follows:\n\n```\nClinical trial: 01NCI0031. Eligible\nInclusion Criteria:   0-1 ECOG/Zubrod Performance\nTreatment:    Preoperative chemotherapy must be completed or planned.\nDrugs:    Cisplatin (Platinol)\nDose:    75 mg/m2 dose of Cisplatin IV on day 1 with 400 mg/m2 of Cyclophosphamide IV on a day other than day 1.\nPrior Therapy:    None.\nRace:    Caucasian.\n\nPatient Note:\nAge: 45 years old.\nHeight: 163.0 cm.\nWeight: 62.0 kg.\nFamily history:  Yes.\nPulmonary history:  Yes.\nBreast history:  Yes.",
        "label": 1
    },
    "118": {
        "output": "### Exercises 1\nExercise 1::\nHere is the [https://github.com/vemundbakk/patient-eligibility-evaluation/blob/main/data/Example.txt](patient_note) example. You will use it to evaluate a clinical trial patient.\n- [ ] 0) Run the file `example.py` in the [main folder](patient-eligibility-evaluation):\n\n    ```python3\n    sudo python3 example.py\n    ```\n\n- [ ] You see the printed summary.\n\n    ```\n    Example patient note for clinical trial\n\n    [INST.1.0] Patient's name: <NAME>.\n\n    [INST.1.1] Patient's gender: female.\n\n    [INST.1.2] Patient's age: 34 years old.\n\n    [INST.1.3] Patient's height: 165 cm.\n\n    [INST.1.4] Patient's weight: 55 kg.\n\n    [INST.1.5} Patient's BMI: 19.5.\n\n    [INST.1.6] The patient has taken multivitamins.\n\n    [INST.1.7] The patient has taken iron supplements.\n\n    [INST.1.8] The patient does not smoke or consume alcohol.\n\n    [INST.1.9] The patient is not sexually active and has no children.\n\n    [INST.1.10] The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\n    [INST.2.3] TNM stage: pT1bN1MO.\n\n    [INST.2.4] Clinical subtype: NOS.\n\n    [INST.2.5] Malignancy grade: Grade 3.\n\n    [INST.2.6] Margin: positive.\n\n    [INST.2.7] Surgery: mastectomy.\n\n    [INST.3.0] Sentinel node biopsy: negative.\n\n    [INST.4.0] Pro",
        "label": 0
    },
    "119": {
        "output": "# Introduction\nWe assume the reader is familiar with the Python object-oriented paradigm (Python docs) and the Pandas statistical data structure package (Pandas docs). Readers may also want to consider reading the documentation for the NumPy Python package before starting with the following sections. For more in-depth information, we encourage the reader to attend a short tutorial by Tim Dallachy, which is available in the official D3Py book (D3Py book, pages 39 and 40). [INTRO]<EOD> Intravenous thrombolysis in old age: the age group above 80\u2003years is underrepresented in clinical trials\nObjective:\u2002 To evaluate the effectiveness of intravenous thrombolytic therapy (IVT) in patients above 80\u2003years of age and to identify factors associated with outcome in this age group.<EOD> Hydrochlorothiazide in the treatment of mild-to-moderate hypertension.\nIn a double-blind, single-dose antihypertensive drug trial with a crossover design, three dosages of HCTZ (hydrochlorothiazide) were compared in patients with mild to moderate hypertension. Statistical methods based on the nonlinear mixed effects modeling are reviewed. Goodness-of-fit diagnostics indicate that the model provides a description of the blood pressure data that is consistent with the observed data. The method is used for comparison of the different treatment groups.<EOD> Clinical and Biochemical Findings in 101 Patients with Drug Resistant Epileptic Seizures: A Study from a Tertiary Care Center in India\n\nSir, Epilepsy is a chronic disorder of the brain characterized by repeated and unprovoked epileptic seizure. Approximately 50 million people worldwide and approximately 5 million people in India have epilepsy. 1,2 A large proportion of epilepsy cases are drug-resistant to conventional antiepileptic drugs (carbamazepine, valproate, phenytoin, LEV). Hence, there is a need to search for newer therapeutic options to control drug resistant status epilepticus and prevent recurrences. 3",
        "label": 2
    },
    "120": {
        "output": "*The trial-level eligibility is simply the overall grade of the most serious reason for not being eligible, i.e., the last eligibility on each patient for the clinical trial, and not a simple sum of the grades of the reasons for not being eligible. If the patient does not pass any of the screening checks, then the trial-level eligibility of the clinical trial is `0) Excluded`, i.e., that the patient is not eligible for the clinical trial. If the results are `1) Not relevant` or `2) Eligible` then the trial-level eligibility is simply the overall grade of the most serious reason, e.g., if the result is `1) Not relevant` then it means that the patient does not have sufficient information to qualify for the trial so it gives `1), but not 2).`\n\n___\n\n## Task 2\n\nYou need to predict the trial-level eligibility for each patient in a given patient pool using the training pool of 4 482 patient notes. \nLet's explore the patient pool in more detail. There are three interesting patient pools, where each patient pool has a different average trial-level eligibility. The average trial-level eligibility is the average of the patient's trial-level eligibility grades, so that 0.00 means that no patient in the patient pool is eligible.\n\nIn the first patient pool, there are 16 patient notes, of which 9 are `1) Not relevant` and 7 are `2) Eligible`, i.e., the average trial-level eligibility grade is `1.19` (not relevant patients are excluded).\n\nIn the second patient pool, there are 56 patient notes, of which 49 are `Not relevant` and 7 are `2) Eligible`, i.e., the average trial-level eligibility grade is `1.03 (not relevant patients are excluded).\n\nIn the third patient pool, there are 462 patient notes, of which 307 are `Not relevant` and 155 are `2) Eligible`, i.e., the average trial-level eligibility grade is `0.51 (not",
        "label": 0
    },
    "121": {
        "output": "[/SOLUTION]\nI also think that this problem is not hard if we know the general concept to solve the problem, even though we do not know the way and the example.\nI think the general concept is:\n- we should read all inclusion/exclusion criteria with each patient's profile\nThe example of this problem, so this patient has inclusion/exclusion criteria of clinical trial, we should find the patient profiles who match the patient's profile of clinical trial\nExample:\nPatient1-> patient who has the first three inclusion criteria of the clinical trial\nPatient2-> patient who has the first three inclusion criteria of the clinical trial\nPatient3-> patient who has the first three inclusion criteria of the clinical trial\nPatient4-> patient who has the second and third inclusion criteria\nPatient5-> patient who has the first inclusion criterion of the clinical trial\n\nThat's what I want to write in the solution and if everyone has a better way, I appreciate your comment.\n<EOD> Anatomical Variations of the Subscapular Artery and the Radial Nerve Relationship in Dry Arms: A Microscopic and Macroscopic Study in the Cadaver.\nBACKGROUND\nThe purpose of the present study was to examine the relationships between the subscapular artery and the radial nerve in Turkish cadavers.\n\n\nMETHODS\nFifty arms of newly embalmed human cadavers without known diseases of the upper limbs were examined. All specimens were dissected layer by layer according to routine techniques to show the course of the subscapular artery and the relationship between the subscapular artery and the radial nerve. The position of the subscapular artery and the relationships between the subscapular artery and the radial nerve were evaluated macroscopically as well as microscopically. Descriptive statistic and chi-square test were used for statistical analysis of data.\n\n\nRESULTS\nThe most frequent location of subscapular artery was just posterior to the axillary artery in the subscapular fossa. Four anatomical variations were detected in our study. There were no statistically significant differences between the position of the subscapular artery and the gender (chi2, p=0.13",
        "label": 2
    },
    "122": {
        "output": "<issue_comment>username_1: I just realized that this is basically the same as the 2nd question that's not been addressed in the training set yet, is correct? In that question a new model was used that was not exposed to any of the training data to build and train, and then to predict on a different set of data. That was a great exercise, and I learned a lot from it, but this one is a little different because all of the training data needs to be modeled to get the prediction; so it's important that the eligibility of the trial is not taken into account because the prediction may be biased otherwise.\n<issue_comment>username_2: Yes, I feel that the training data used for prediction is the same as the training data that was used to create the model. So the model is already adapted to the training data. I am not sure if this is the case here at the moment or not.\n<issue_comment>username_1: That is how I understood it too, and @username_3's last response is just more evidence, but I was still wondering whether or not there would be 3 responses for the 0's the 1's were too consistent/clear cut, it was a pretty small set of data, but there should be some more varied cases where it's not so clear.\n<issue_comment>username_3: There are definitely scenarios where it could be really unclear.\r\nSentiment: https://www.kaggle.com/c/sentiment-analysis\r\n\r\nI'm not sure what the best strategy would be here though\r\n\r\nThis could potentially be a regression\r\n\r\nOr perhaps a new model that doesn't include the trial-level eligibility, however, that would be using the same training data for predictions\r\n\r\nSo essentially training and validation in one step?\r\n\r\nAnother option would be to create a model on the training set that doesn't take the trial-level into account, then use this model on the training set to create the predictions, then use these predictions on the validation set to show that the performance of the model that took trial-level into account is better than one that didn't\r\n\r\nThis is a complex problem, and I think it's okay to do a bit of exploring at this point\r\n\r\nI",
        "label": 2
    },
    "123": {
        "output": "The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n```r\nrecommendation <-recommendation %>% mutate(Trial-level eligibility=case_when(.action == \"recommended\"~\"2)~recommended,\n                                             .action == \"recommended, must be excluded\"~\"0\"))\n```\n\nWe can see from the output that our recommendation is 2), meaning this patient is eligible and our recommendation was not changed.\n\nNow we should repeat this step recursively on the child nodes. \n```r\nrecommendation <-do.call(c, lapply(childNodes, eligibilityDetection))\n```\n\n## Recursion of Recommendation \n\nNow we should repeat this step recursively on the child nodes.\n```r\nrecommendation <-do.call(c, lapply(childNodes, eligibilityDetection))\n```\n\n## Evaluation\n\n```\nrecommendation <-evaluateClinicalTrialRecommendation(recommendation, cTrials, eligibilityDetection)`\n```\n\nNow we can see all of our recommendations. We know that the recommendation of this patient is `Recommendation: \n\t2 - Eligible, must be excluded`.\nWe also know that the overall recommendation of the entire trial is the same; that is, `Overall recommendation: 2 - Eligible, must be excluded.`.\n\nWe can easily make the trial-level recommendation at the end of our recursion:\n```r\ntrialOverallRecommendation <-trialOverallRecommendation[trialTrials == \"A0701\"]\n\n## trialOverallRecommendation <-c(\"1 - Not Eligible\",\"2 - Eligible, must be excluded\",\"3 - Not Eligible\")\n```\n\n## Evaluation based on the results on the",
        "label": 0
    },
    "124": {
        "output": "__ 3_ELEGIBILITY_COMBINATOR: If a given patient note has all of the following inclusion criteria and none of the exclusion criteria, then the patient is 100% eligible for a clinical trial. [1]\n\n[1] The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n<EOD> Preoperative Prediction of Tumor Necrosis in Pancreatic Ductal Adenocarcinoma: A Radiomic Analysis\n\nSupplementary Data\nSupplementary Data\nFig. S1. Flow chart of the radiomic analysis. The process of selecting radiomic features of the selected features (798) was performed by performing the LASSO model. The features within 1 SE of the minimum CV error and the maximum CV score were saved for prediction model building. The model was built by Lasso-Cox regression model, SVM, and DT based on the remaining features. Prediction models were evaluated in the same fashion as the main text and the details were present. . The receiver operative curve (ROC) of the radiomic model, radiologist, and pathologists. The AUCs of the DT, SVM, and radiologist were 0.764, 0.781, and 0.643 respectively.<EOD> Theoretical Study on the Strongly Interacted Heterocatalytic Model of Pt@Au112(SR) for Enantioselective Hydrogenation of Furan Aldehyde.\nThe enantioselective organometallic catalyzed ene-yne hydrofunctionalization has become a research focus because of its green and convenient application in both academic and industrial. Herein, we performed an ab initio study to investigate the enantioselective hydrogenation of furan aldehyde to 3-methyl-1-buten-4-ol catalyzed by a strongly interacted heterocatal",
        "label": 1
    },
    "125": {
        "output": "2.22.5. [FIL] What is a treatment plan?\n\n[FIL]\nI. Assess patient characteristics and clinical status II. Prescribe initial treatments III. Plan treatment modifications according to patient/tumor response IV. Monitor patient progress\n\nA treatment plan is a course of prescribed treatments (surgery, chemotherapy, radiation, pharmacotherapy, physical therapy, nursing and other interventions) or observation that meets the patient's cancer-related care needs, regardless of setting. Treatment planning is an important part of nursing because it is a means to ensure safe and effective care, and is the responsibility of nurses in conjunction with members of the treatment team, including the patient and/or family. \n\nThe purpose of the treatment plan is to determine how the nursing care plan will be implemented on a daily or other consistent basis. It is a written account of the nursing treatment plan. Treatment plans are patient-specific, i.e., each patient may have a different treatment plan based on the diagnosis and the nursing care the patient will require to meet their specific nursing care needs. \n\nThis tutorial focuses on a treatment plan for the nurse for a new patient or when a new medication is starting, for an existing patient taking a new medication. This can be written in a number of ways including in a progress note or the electronic medical record, but it must be an individually written document with enough detail to provide adequate knowledge for all disciplines involved with patient care, including medical care. A sample treatment plan for medication may include:\n\n### PATIENT CHARACTERISTICS AND CLINICAL STATUS\n- Name, age, height, weight, gender - Patient's chief complaints, associated diseases, current clinical status, any drug use - Diagnosis - Symptoms according to the NANDA diagnoses - NURSING INTERVENTIONS, GOALS, PLANS\n\n### PREScribe INITIAL TREATMENTS\n- New or continuing - What, dosage, route, frequency, time of each treatment, dosage form, duration of the treatment, nursing intervention, patient teaching, and monitoring methods\n\n### PLAN TRE",
        "label": 2
    },
    "126": {
        "output": "<jupyter_code>from pysprout.datatypes import Criteria\n\n@jupyter_output(format='html', header=True)\ndef __f_2(_criteria):\n    # This code is a template for the cell and is edited by the user as indicated below.\n    # It should only have one input:\n    #\n    # <jupyter_code># Input variable\n    # Eligibility_status = Criteria.Eligibility_status\n\n    # Output formatted as a table\n    #\n    # For the cell shown here, the output should read:\n    #\n    # ## Patient data:\n    # ### Patient ID:    P0507\n    # ### Gender:      F\n    # ### Medication use:    AML_T\n    # ### Current smoking status:    NEVER\n    # ### Comorbidities (list):     Asthma, Hypertension\n    # ### Clinical trial inclusion criteria\n    # ###: Cancer type:    Breast\n    # ###: Cancer stage:    Lung\n    # ###: Smoking history:    Smoker\n\n    # ## Patient data summary\n    #\n    #    Evaluable patients (%)\n    #    : \n\n    # ## Overall trial eligibility\n    #\n    #    Trial-level eligibility:  1) Not relevant\n    #--------------------------------------------------------------------------------------------------------------------------------------\n    # #\n    # ## Patient data\n    #  Patient ID:P0042\n    #   Gender  :F\n    #   Medication use :     BI 125mg\n    #   Current smoking status:    former(>3 year)\n    #   Comorbidities (list):     Asthma\n    #   Patient name:  M.E. \n    # \n    #   ## Clinical trial inclusion criteria\n    #   Cancer type:          Breast\n    #   Cancer stage:        Breast\n    #   Smoking history:     Smoker\n\n    ## Patient data summary\n  \n    ## Overall trial eligibility\n\n\n    # ## \n    # ## Patient data\n    # Patient",
        "label": 0
    },
    "127": {
        "output": "<EOD> Preoperative Assessment of Patients With Bariatric Surgery.\nBACKGROUND\nThe number of bariatric surgical procedures continues to rise in the United States, making it essential that health care practitioners be familiar with their perioperative management.\n\n\nOBJECTIVE\nThe aim of this article is to describe the preoperative assessment of patients who are undergoing bariatric surgery, identify common preexisting conditions, and discuss the role of anesthetists in risk stratification and perioperative optimization.\n\n\nMETHODS\nWe present and discuss relevant articles and guidelines found in the primary literature and the National Institutes of Health databases, as well as on the websites of the American Society Anesthesiologists, the National Heart, Lung, and Blood Institute, and the National Institutes of Health.\n\n\nRESULTS\nPreoperative care includes a thorough evaluation, identification of coexisting conditions, preoperative testing, preparation, and optimization for surgery. Optimization can be accomplished through appropriate assessment and intervention, including nutritional support, smoking cessation, and optimization of underlying conditions.\n\n\nCONCLUSIONS\nThe anesthesia team plays a critical role in the planning of perioperative care, the optimization of patients for surgery, and the monitoring and identification of perioperative complications.<EOD> A rare double variation of the vertebral artery associated with a bilateral absence of the inferior thyroid artery\n\nWe report a rare variation in the intra-cranial course of bilateral vertebral arteries. Both arteries have crossed the contralateral side and anastomosed with another bilateral vertebral artery in upper cervical level to create a 'reverse flow' double variation pattern. Furthermore, we report the absence of bilateral inferior thyroid arteries, which are present normally in 60-70% of people.K E Y W O R D Sanomalous blood vessels, double variation pattern, vertebral artery\n\n# | introduction\nVertebral arteries (VAs) are paired bilateral arteries that originate from common carotid arteries and have their own course [fig_ref]  . 1 \u2212: the anastomotic region of the",
        "label": 0
    },
    "128": {
        "output": "What is the difference between RATKILL and VASICHEMO and ELLOXA?\n\nThe data show: \n\nRATKILL\nVASICHEMO\nELLOXA\nNumber of patients with assessment of eligibility = 6829\nNumber of patients with exclusion at eligibility assessment : 566(43.5%)\nNumber of patients with assessment of eligibility = 565\nNumber of patients with exclusion at eligibility assessment : 0%\nNumber of patients with assessment of eligibility : 683\nNumber of patients with exclusion at eligibility assessment : 39.1%\nIf we analyze the above figures, we can observe that when the total number of patients is considered, RATKILL includes the maximal number of patients (6829 patients), while ELLOXA includes relatively small number of patients (683 patients). This does not mean that all patients in ELLOXA were 0 for Trial-level eligibility. Most likely, their Trial-level eligibility was 1 or 2, and we can observe the 0 value only because they were not included in the output table. If you want to analyze the number of Eligible patients, just multiply the number of patients with Trial eligibility 2 to the number displayed in the column of Trial-level Eligibility 2.\nOn the other hand, RATKILL provides 39.1% patients with eligibility 2, VASICHEMO provides 43.5%, and ELLOXA offers 39.1% eligible patients. What does this mean? The answer is simple. If someone has three different trials for the same topic and provides the three ratios above, one should conclude that their results are in line with the current practice.\n[INST]<EOD> Transcriptome Profiling of Cattle Subcutaneous Adipose Tissue during the Rapid Adipose Gain Period, 7 Days Before and After the First Growth Check\n\n\n\n# Introduction\nBeef quality traits are closely related to the body composition of bovine. Generally, adipose tissue is thought of as an inert tissue with a fixed amount, but",
        "label": 0
    },
    "129": {
        "output": "- [HINT]\n<EOD> 2\u03b1\u2010Methyl\u201019\u2010nortestosterone Induced Reproductive Toxicity in Male Wistar Rats: A Mechanism Mediated through Nrf2/HO\u20101/TGF\u2010\u03b21/ERK/Ki67/CYP2C11 Axis\nMale reproductive endocrine dysfunction is an important environmental health problem in human society. In the present investigation, 2\u03b1\u2010methyl\u201019\u2010nortestosterone (MENT)\u2010induced reproductive toxicity was investigated in male Wistar rat models. Reproductive toxicity was evidenced by dysregulation of serum testosterone levels and semen quality, oxidative stress, apoptosis, histopathological and morphometric alterations on the testicular tissue. To elucidate the possible underlying etiology, the present study was focused on the possible molecular changes by focusing on the expression of various proliferation biomarkers (Nrf2, HO\u20101, Ki67, TGF\u2010\u03b21, and CYP2C11). 2\u03b1\u2010Methyl\u201019\u2010nortestosterone is an anabolic steroid widely available as over\u2010the\u2010counter or prescription drugs. This commonly used drug is banned by the World Anti\u2010Doping Authority for its potential health hazards. Exposure to 2\u03b1\u2010methyl\u201019\u2010nortestosterone induced testosterone insufficiency and degeneration of both the seminal vesicle and epididymis. Histopathological and morphometric changes on the testis were detected through H&E, TUNEL, and immunohistochemistry staining of oxidative stress (4\u2010HNE), Nrf2, HO\u20101 HO\u20101, Ki67, TGF\u2010\u03b21, and CYP2C11 positive cells. Oxidative toxicity and expression of Nrf2, HO\u20101, and CYP2C11 were found to be in a negative concordance fashion with dysregulation in the cell proliferation markers. In this paper, we presented a possible molecular mechanism",
        "label": 0
    },
    "130": {
        "output": "``` r\npatient <- c(\"No.01-0243\", \"No.01-0620\")\n\nclt <- as.data.frame(read.excel(\"Trial_patient_clinical_trial_record.xlsx\", sheet = \"Trial_patient_clinical_trial_record\", row.names = NULL)) %>%\n  bind_rows(clt[[paste(patient[1],patient[2])]], .id = FALSE)\n\nclt$clinical.trial_eligibility <- seq(clt$clinical.trial_eligibility)\nclt[[paste(patient[1],patient[2])]]$clinical.trial_eligibility <- 0\n\nclt\n```\n\n``` r\n# Aggregate data frame of all patients.\nclt_agg <- rbind(clt)\n\n# Agggregate for Trial-level Eligibility\nclt_agg$Trial_level_eligibility <- sapply(1:ncol(clt_agg$clinical.trial_eligibility), function(i) {\n  if (clt_agg$clinical.trial_eligibility[\"i\"] > -2) {\n    clt_agg$clinical.trial_eligibility[\"i\"] <- 4 # Excluded\n  } else {\n    clt_agg$clinical.trial_eligibility[\"i\"] <- 1 # Not Relevant\n  }\n})\n\nclt_agg\n```\n\n# Results\n\n\n``` r\nclt_agg\n```\n\n``` r\nclt_agg$clinical.trial_eligibility\n```\n\n``` r\nclt_agg %>% dplyr::mutate(clinical.trial_eligibility = factor(clinical.trial_eligibility))\n```\n\n``` r\nclt_agg %>% dplyr::mutate(clinical.trial_eligibility = factor(clinical.trial_eligibility)) %>%\n  dplyr::select(\"clinical.trial_eligibility\",",
        "label": 1
    },
    "131": {
        "output": "## Summary\nSo far, each person in the crowd has reviewed a note, which means to make a one-time judgment of the patient in the note by comparing the clinical trial information and the patient's characteristics. After reviewing many such note-cases, the opinions may be aggregated. Although clinical trials are not about how many people participated in the trial, they will benefit more if a lot of people participate in the study. Therefore, when aggregating the reviews, we should also take into account the number of reviewers. To incorporate this idea into a model, we consider the patient i (i = 1, 2, ..., N) from the crowd to participate in the trials. Then, for review r (r = 1, 2, ..., M) of patient i by person j (j = 1, 2, ..., N; j = i), we create a matrix (R \u2208 R p\u00d7N\u00d7N ) of size {d \u00d7 q \u00d7 N}, where d is the number of distinct patients among all patient i's. Then, R can store the patient's evaluation score for each patient",
        "label": 2
    },
    "132": {
        "output": "Please submit all your work in `Pickle`.\n-- Evaluation ---------- [[EVAL]] Assistants:\n[EVAL_ASSISTENT_1] This is a nice task. I would like to see more of them for a wider range of topics.\n[EVAL_ASSISTANT_2] Thanks, Eval_Assistant_1. The quality of the submissions will be evaluated by both of us. Since this is a new task format, we are learning how to evaluate submissions.\n-- Rules for this task:\n[RULE_1] The task contains three stages. There will be three submissions, one for each stage. Submission of each of the three stages will be separated by one day.\n[RULE_2] You should enter the patient number and the ID code in the comment if the patient was included in the trial.\n[RULE_3] For each included patient, you should evaluate patients for eligibility. Enter the evaluation in the comment. There are three possible evaluation results: Excluded, Not relevant, and Eligible.\n-- Rules for the `Hooks:`\nThe `Hooks` sections should be entered at the beginning of each of the three submissions.\n- Your hooks should not be numbered.\n- Do not include headers.\n- A hook should be a short answer in the form of a question.\n- If your hook requires knowledge about medical history of the patient, specify that.\n- Each hook should start with a question mark.\nSee the sample below.\n- [RULE_1] Submission 1 hook: `What is your question?` (Sentence without numbering.)\n- [RULE_2] Submission 2 hook: `Which study arm do you think the results will favor?` (sentence without numbering, but with header.)\n-- [EVAL_CONSULTATION] Consultation (Evaluator #1):\nThis is submission 3_Final and will be evaluated with the same rules as the rest of the submissions.\nI found all the 3 hooks which were expected. The hook \"What is a clinical trial?\" is relevant in itself and is part of the general knowledge. And also when we are on the patient note: \"There is no mention of clinical trials\" is also relevant and it confir",
        "label": 0
    },
    "133": {
        "output": "<EOD> Antigenic variants of herpesvirus of rhesus monkeys selected in vitro with monoclonal antibodies.\nA herpesvirus of monkeys (RMH) passaged repeatedly in vitro with rabbit antibodies against RMH obtained with a monoclonal antibody (mAb) was studied. The mAb tested is an IgG2a monoclonal antibody obtained in BALB/c mice by cell fusion with the Sp2/0 cell line. Passaging of the virus in cell cultures with added mAb resulted in the selection of several RMH antigenic variants, as indicated by an inhibition of plaque formation. Inhibition experiments revealed the presence of at least two distinct antigenic variants in the population of variants. RMH variants 1 and 2 were cloned and shown to plaque poorly in several cell culture systems. Inhibition experiments indicated that the two clones could be segregated from one another. The variants were resistant to neutralization of plaque formation by mAb and RMH convalescent sera obtained shortly after virus infection. The two clonal variants were tested by complement fixation test with convalescent sera and the IgG fraction of three mAb. The results confirmed the inhibition data and demonstrated that the variants were indeed sensitive to the IgG fractions of mAb. The variant RMH 1 had a 2.8-fold increase in its susceptibility to complement fixation mediated by convalescent sera and by the IgG fraction of one of the mAbs. These findings suggest that clones RMH 1 and 2 could be variants of HERV-1, a homologue of human cytomegalovirus (Herpesvirus saimiri group, Herpesviridae) reported to be related to human cytomegalovirus.<EOD> Inhibitory effect of propranolol on nephrogenic systemic fibrosis\n\nBackground Propranolol hydrochloride is a non-selective beta-adrenergic blocker used to treat both cardiovascular and non-cardiovascular conditions. A recent in vitro study showed that propranolol inhibited the cell division of fibroblasts",
        "label": 0
    },
    "134": {
        "output": "[[INSTR] Tests]]\n<br>\nIf the value has changed, it means the patient satisfies the criteria of this clinical trial.\n<br>\n[/INSTR]\n\n\n\n# Outputs\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThe trial-level eligibility is calculated with `eligibility(\"patient_note\",\"clinical_trial\")` in a Python dictionary. If the trial-level eligibility is 2, then the patient satisfies the criteria of this clinical trial: `eligibility(\"patient_note\",\"clincial_trial\")[0] == 2`. \nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThe patient must satisfy both inclusion and exclusion criteria to be eligible for the trial. You may input several assessments of eligibility for each trial in the column `assessment_of_elibility`.\nThe following is the output for the assessment of eligibility for a patient:\nYou should always input trial-level eligibility at the end of a column, e.g., `Trial-level eligibility: 2) Eligible.`, as shown in the following:\n\n# Installation\n\n## Requirements\n- Python3\n- Numpy\n- Pandas\n\n## Installation\n\n```\ngit clone https://github.com/hanyung/disease.git\ncd disease\npython setup.py install\n```\n\n## Note\n\n`notelib` is an unmaintained library, and the code in the module `notelib.clinical_trial` needs to be",
        "label": 2
    },
    "135": {
        "output": "# Related tasks\n<EOD> The effect of diabetes and antidiabetic agent on the expression profiles of lncRNAs and mRNAs in diabetic cardiomyopathy\nDiabetic cardiomyopathy (DCM) is characterized by systolic and diastolic dysfunction of the heart, resulting in a decline in cardiac pump function. Several lncRNAs are involved in different cardiac cell processes and DCM. We aimed to investigate lncRNAs and mRNAs expression profiles in the heart of a streptozotocin (STZ)/nicotinamide (NA)-induced DCM and its antidiabetic agents (metformin, liraglutide, and their combination), using RNA-seq analysis. The Wistar male rats were divided into the groups: NC, DCM, Met-DCM, Lira-DCM, Met-Lira-DCM. We used the heart tissue of the animals for analysis. We found 1435, 1746, 1673, 1784 significantly changed lncRNAs (p\u2009<\u20090.05, log\u20092FC\u2009>\u20091) and 3280, 2298, 2414, 9036 significantly changed mRNAs (p\u2009<\u20090.05, log\u20092FC\u2009>\u20091) in the DCM, Met-DCM, Lira-DCM, Met-Lira-DCM group, respectively. We identified 466 common lncRNAs and 5 common mRNAs in the Met-DCM, Lira-DCM, and Met-Lira-DCM groups. We revealed 7 specific lncRNAs and 43 specific mRNAs in Met-DCM group, 5 specific lncRNAs and 27 specific mRNAs in Lira-DCM group, and 3 specific lncRNAs and 2 specific mRNAs in Met-Lira-DCM. In addition, we found 9 mRNAs and 1 lncRNA in DCM group, which showed no difference in the expression levels compared",
        "label": 0
    },
    "136": {
        "output": "A rat cardiac system allows the simultaneous observation of four hearts under physiological conditions in an isolated environment. In other words, it is a platform that allows us to directly observe the physiological behavior of a cardiac muscle over time.\nThis project aims to make a complete rat cardiac system. \nThe system comprises five units: \n\nThe physiological function of each part is to be determined within a certain range. \nThe system specifications are classified into those for the main part composed of the base and the drive unit; and those for the additional parts, such as oxygenators and carbon dioxide removal units. \n\nThe specifications for the main part of the system are: \n> Range (minimum-maximum) for oxygenator flow: 0-100 ml/min > Range for carbon dioxide flow: 0-500 ml/min > Range (minimum-maximum) for respiratory gas mixture (O2/CO2) adjustment in the range of 30%-500 min\n\nIn the case of the maximum respiratory gas mixture (O2/CO2) adjustment, the respiratory gas mixture should be prepared with adjusting carbon dioxide partial pressure (PaCO2) and oxygen partial pressure (PaO2) for the carbon dioxide elimination unit and the oxygenator, respectively. \n\n> Respiratory gas mixture (O2/CO2) at maximum carbon dioxide elimination: minimum of 200-maximum of 700 > Range of oxygen for maximum oxygen release: minimum of 50-maximum of 150\n\n> Range (minimum-maximum) for adjusting heart rate: 300-500 beats/min\n\n> Range (minimum-maximum) for adjusting contractility: ~0.5-1.5 lNs\n\n> Vmax = 10,000 beats/min\n\nBy these specifications, when the carbon dioxide elimination (maximum) unit removes additional carbon dioxide by adjusting the carbon dioxide partial pressure (PaCO",
        "label": 0
    },
    "137": {
        "output": "### 2.2 Data-level eligibility\nIf you are still with us, let's define a list of data-level eligibility criteria, e.g., `Liver disease: hepatitis B co-infection (true). Vital signs: abnormal (false). Current medications: rifampicin (false). Current medications: methotrexate (true). Current medications: tenofovir (false). Current medications: paracetamol (true). Current medications: aspirin (true). Medical history: cardiac disease (false). Current medications: lopinavir/ritonavir (false). Current medications: ritonavir (negative).`\n\nBefore moving on, you should always use `||` instead of `||` to combine AND operators (and NOT operators) when using data level criteria (i.e., `Liver disease: hepatitis B co-infection || hepatitis C co-infection || HIV-2 mono-infection || HIV-2/HIV-1 co-infection (false), hepatitis A co-infection || HIV-1 single, non AIDS-indicating infection (true), HIV-1 single, AIDS-indicating infection || HIV-1 single, non AIDS-indicating infection (true), AIDS (false), Lymphoma (false) || Sarcoma (false) || Kaposi sarcoma (false) || Lymphoid interstitial pneumonitis (false), Extraneural kaposi sarcoma (false) || Cytomegalovirus (true), Cytomegalovirus retinitis (true) || Cryptococcus (true), Esophageal candidiasis (true) || Herpes (false) || Lymphogranuloma venereum (false), Oesophageal candidiasis (true), AIDS-associated Mycobacterium avium complex (MAC) pneumonia (false) || Pneumocystis pneumonia (negative) || Mucocutaneous (negative), Recurrent Cytomegalovirus-related retinitis (false), Recurrent herpes-related retinitis (",
        "label": 0
    },
    "138": {
        "output": "[INST] Hello. You are a helpful assistant for clinical trial recruitment. You need to develop a template to assess the patient recruitment notes. The template is a guide that helps to develop a report for the trial.\n\nYou can make decisions by comparing patient and trial metadata. For example, you should not consider a trial that is not appropriate for patients with a specific diagnosis. Please note that the trial may include a range of disease types, and patients with one disease type are not automatically excluded from a particular trial. However, you should be able to estimate which trial the patient might be eligible for by examining the list of characteristics such as diseases and medications that were included in the trial.\n\nPlease note that this template is intended to assess a given note and not to search a list of trial notes. The assessment of note eligibility is one-time work. For example, if you identify a clinical trial excluding male patients or if you see a clinical trial recruiting a specific age group, you can stop searching for trial notes and return to the template. \nThere are three columns in the template. Please fill in the patient note and assess patient eligibility for the specified trial(s) on each trial by evaluating factors such as demographic information, disease, medication, and treatment. \n\nHere are the patient note and clinical trial. \n\n![](https://user-images.githubusercontent.com/12954421/93707181-19f99d80-f6f9-11eb-8714-ffbae09932c5.png)\n\n\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to summarize the clinical trial notes. You should make a recruitment note to each patient for the trial.\n\nPlease note that this recruitment note is a summary of your main task to assess the trial's eligibility. If you are using the template to assess note eligibility, you can use the existing assessment in the summary. It is also permissible to use previous assessment results as a recruitment note.\nPlease note that recruitment notes should be made at the time of first contact. In other words, you should communicate",
        "label": 0
    },
    "139": {
        "output": "0/10/2022  3/11/2022  0/10/2022  2022  3/11/2022  \n[/EVAL]\n<EOD> Inheritance of a defect in chloroplast development from maize lines with defects in mesosomal transport\nTwo mutations in maize (Zea mays L.) cv B73 have been characterized that are defects in mesosomal transport. These mutations, designated defects in mesosomal transport (dm1 and dm2), are distinct from previously characterized transport-defective mutations. The dm1 locus was tentatively mapped to the lower arm of chromosome 9. The inheritance pattern of photosystem II (PSII) activity in cytochrome-f/PSII (CF/PSII)-treated plants demonstrated the recessiveness of the dm1 locus, implying that its phenotype is an unaltered wild-type phenotype. In contrast, the dm2 mutation demonstrated a dominant inheritance pattern, which was manifested as a severe reduction in mesosomal transport, but this strain had no effects on either the CF/PSII-induced PSII activity or chlorophyll synthesis. The reduction in mesosomal transport was reflected in a reduced plastid size and an altered appearance of the chloroplasts. The mutation dm2 was mapped to chromosome 6. We conclude that the dm phenotype is not due directly to a defect in electron transport in the mesosomes. Because two other loci (maize-1 and chloroplast inhibitor of protein synthesis) have been shown to be involved in the synthesis or maturation of the ATP synthase and the light inhibition of CF/PSII-induced PSII activity, we examined the effect of the dm mutation on proteins of the ATP synthase complex. The analysis demonstrated no reduction in ATPase specific activity. Furthermore, CF/PSII treatment of dm2 plants did not cause a severe increase in stroma thylakoid proteins as has previously been reported for several mutants with aberrant ATP synthase complexes. We conclude that mesosomal transport, while needed for normal chlor",
        "label": 0
    },
    "140": {
        "output": "You are done with the assessment of eligibility! \ud83d\udc4d\n\n## Recording and updating assessment of eligibility\nNow, you should make a patient trial. There is information on how to make a patient trial from [/INST (a3) Recording of the Patient Trial].\n\n\n- To record assessment of eligibility in a Patient Trial, please choose `Update` in the left menu.\n![image]({{ repo }}/assets/img/005_step3_recording.png)\n- This gives you three different selection options. `Update' means to save the selected option and close the editing screen. `Save' means to save or update the current patient trial. `Cancel' means to close the editing screen and go back to the main trial-management window without saving any changes.\n![image]({{ repo }}/assets/img/005_step3_recording.png)\n![image]({{ repo }}/assets/img/005_step3_selection_window.png)\n- A list of all patient trials is given in the left menu bar.\n![image]({{ repo }}/assets/img/005_step3_new_recording.png)\n\n### [a] Patient trial level\nIn order to record assessment of eligibility in a patient trial, please select `patient trial`.\n![image]({{ repo }}/assets/img/005_step3_PatTrial.png)\n\n### [b] Patient trial version\nIn order to record assessment of eligibility in a patient trial, please select `a patient trial version.`\n![image]({{ repo }}/assets/img/005_step3_pt_v_info.png)\n\n### [c] Patient trial note\n![image]({{ repo }}/assets/img/005_step3_pt_note.png)\n\nIn the following, you can see the complete recordings:\n\n\n*\n\n*(a) Patient trial level: The patient does qualify; therefore the patient trial is assessed as Qualified. The new Patient Trial Note Version is created.\n\n*\n\n*(b) Patient trial version: As the patient trial version number is `1`, no",
        "label": 0
    },
    "141": {
        "output": "## Tutorial 2: How to set the attributes of a single patient object\nThis exercise is related to the one above and in this case you should modify the attributes of a single patient object for a given clinical trial.\n\nAs you did in the first exercise, the data file can be found in `src/data/clinical_trials/instructions.Rdata`. \nThe first two patient object attributes are: patientid and clinicalTrial. To access the attributes of both attributes with the patientid attribute: `attr(clinicalTrials$clinicalTrial, \"patientid\")`. Similarly, to read the attributes of the clinicalTrials$clinicalTrial attribute with the patientid attribute: `attr(clinicalTrials$clinicalTrial, \"patientid[clinicalTrials$clinicalTrial$patientid]\")`.\nThe full range of output attributes in both objects is documented in `src/data/attributes.csv` and `src/data/clinical_trials/attributes.Rdata`.  \n\nAs in the first exercise, your task is to set the required attribute of each patient object with the clinicalTrials$patientId column attribute. However, this time you will set the \"Yes\" attribute with a patient id of `3` that is already defined in the `clinicalTrials$clinicalTrial$patientid` column. To assign the `3` in the `clinicalTrials$patientId` column attribute: `for(i in seq_len(nrow(clinicalTrials))) { clinicalTrials_setpatientId <-list(clinicalTrials_setpatientId , i, \"Yes\"))}`. The patient id in a clinical trial should always be the `1`, even if you do not consider the patient eligible. Thus, the patient id `4` and `7` should be assigned as `Nobody` in both rows. Finally, assign the two patient ids `1` and `2` as `Unknown` in the clinical trial attribute with the following code: \nAll output attribute values will be assigned to their respective attributes and shown in `clinicalTrials$patientId` of your clinical trial file. \nFinally, the clinical",
        "label": 2
    },
    "142": {
        "output": "* * *\n\n## Making a decision \nThere is a lot to consider when deciding on a patient's inclusion in a clinical trial. This is not an easy task and you may need to consult a physician or clinical expert. Here are some factors to consider when looking for a suitable trial for your given patient:\n- Inclusion criteria: Check that the type of cancer and stage correspond with the inclusion and exclusion criteria.\n\nThe first thing you may notice is that while most clinical trials require the patients to have a certain type and stage of cancer, here we have a clinical trial that does not require these. It is not clear whether this trial would be appropriate for the patient or not. Let's assume it is not and now you should recompute the trial-level eligibility.\nSo, you must use `Trial-level eligibility: 0)` for `Aromasin` trial because it requires the patients to have a certain type and stage of cancer.\n\nSo, if you are happy with the results, you can do the following: [MOB]\n\n![FIN ](images/FIN.gif)\n\n\n```\n# You should do this in every clinical trial you work with\nTrials <- rbind(Train, Te)\nTrain$TrailName <- gsub(\"/\", \"_\", Train$TrailName)\nTrain$PatientName <- gsub(\"/\", \"\", Train$PatientName)\n\nf1 <- function(DF) {\n  if (nrow(DF) >= 3) {\n    p <- 1 -apply(DF[,c(6,7,8)], 1, function(x) ifelse(x == 0, 1, 0))\n    p <- rbind( p, \n                 apply(DF[,1:5],1, mean) %in% c(\"Young\", \"MiddleAged\", \"MiddleOld\", \"Old\", \"VeryOld\")\n               ) \n    p <- rbind(p,\n             ifelse(DF[,2] %in% c(\"Squamous cell\",\"Invasive lobular\"), 2,\n             ifelse(DF[,2] %in% c(\"Ductal carcinoma in situ\", \"Breast carcinoma\"), 1)))",
        "label": 0
    },
    "143": {
        "output": "## Difficulty\nHard\n\n## Data format\n- [CSV] Data CSV file\n- [JSON] Data JSON file\n- [IPD] Code, data, and notes in IPython notebook\n- [SBML] Dataset in SBML format.\n\n## Example\nThe user guide of this tool can refer to our [IPerception-v4-User-Guide.pdf](https://github.com/hhs-ai-lab/IPerception/blob/master/documentation/IPerception%20v4.userguide.pdf).\n\n## Code to follow\nThe user's code is described below. The raw csv file used in the analysis above is provided as `code/data/trial1_recruitment_notes_dataset.csv`. The Jupyter notebooks for each analysis in this tool are provided as `code/data/test_data`, `code/data/dummy_data`, `code/data/trial1_notes_dataset`, `code/data/trial5_notes_dataset`, `code/data/trial11_notes_dataset`, and `code/data/denosumanb_trial12_notes_dataset`. Additional datasets used in this tool are `code/data/ipd_recruitment_notes.csv`, which is an extract of the data provided by [IPerception-v3-Users-Guide.pdf](https://github.com/hhs-ai-lab/IPerception/blob/master/docs/IPerception%20v3.userguide.pdf) in the form of recruitment notes; and `code/data/data_for_denosumab.tsv`, which is extracted from https://clinicaltrials.gov/ct2/show/NCT01955668?term=Denosumab&rank=1. Note that each data subset comes with its own pre-processed version of the data file. The `code/data/trial1_recruitment_notes_dataset_preprocessed.csv` can be downloaded using IPerception's `PreProcessData` function (or `IPerception.PreProcessData` in Python3). Please note that in the example code below, the variable names in `",
        "label": 2
    },
    "144": {
        "output": "<EOD> Mentor Training for Adolescent Group Therapy Clients in Outpatient Mental Health Treatment Centers\nThe results are presented from a pilot study assessing training for mentors of outpatient mental health treatment center adolescent group clients, the mentors\u2019 satisfaction with the training they received, and their subsequent perceptions of the benefits of mentor participation on group therapy for adolescent clients. After 30 hours of training and supervision, mentors were asked to rate their training skills, comfort in various areas of group therapy, personal growth/empowerment experiences, group therapy perceptions, and benefits to the clients on several scales ranging from \u20131 = no benefit, to 3 = a great benefit. In addition, mentors were asked to rate the benefits of working with adolescents generally on the same scales. 40 mentors in 20 mental health clinics participated in a structured training program and the 30-item Training Program Satisfaction Assessment developed specifically for this study was administered to 20 mentors at the end of their training. Results from mentors indicated significant post-training increases in their training skills, comfort with group therapy, and personal benefits from group therapy. Mentors indicated that group therapy was very, very helpful to the clients\u2019 self-esteem, self-concept, and self-confidence. Mentioned in lesser degrees were mentors\u2019 perceptions of significant improvements in the clients\u2019 social skills, emotional functioning, and behavior control. It was concluded that mentors who have lived experience with the adolescent problems being discussed in group showed high levels of comfort with, and satisfaction from, their role, and that they thought the group therapy offered significant benefits to clients.<EOD> .\nOBJECTIVE\nThe purpose is to study the value of ultrasonic Doppler in the diagnosis and differential diagnosis of chronic venous insufficiency.\n\n\nMETHODS\nThirty-five subjects were enrolled, comprising the following groups: 19 patients with primary chronic venous insufficiency and 16 healthy subjects. Flow volume and venous blood flow velocity of the great saphenous vein were evaluated in upright posture and squatting posture in two groups.\n\n\nRESULTS\nThe flow",
        "label": 0
    },
    "145": {
        "output": "You might like it if the patient meets the eligibility criteria for participating the clinical trial. \n\n# Conclusion\nIn this paper, we proposed a method to detect whether a patient is applicable for a clinical trial through a clinical trial-related text and an assessment of eligibility. We have conducted experiments using a dataset with 250 notes from patients. To compare the proposed method with previous studies, we used three models to classify the notes. The first one is the conventional model that uses only machine-learning-based clinical features, the second one utilizes machine-learning-based clinical features with the text features in the notes, and the last one is a conventional clinical trial matching method. For each model, we calculated AUC to evaluate their performance. Our proposed method showed better performance (AUC=0.996) than the previous models (AUC=0.8969 and 0.8949), which are related to the clinical trial-related text. Thus, this study showed that the information on whether a patient is eligible for a trial could be used to perform a more efficient matching process between patients and clinical trials.\n\n# Supplementary materials\n\n## Supplementary data 1\n[table]  Table 2: The number of patients according to their eligibility [/table] \n<EOD> The Coulson-Forster Series of the Periodic Acid Chromotropes of Carbohydrates. II. Chromotropic Esters of D-Mannose.\nIn a preceding paper (1) a study was made of the chromotropic acid derivatives of D -xylose, D -galactose, and D-glucose from the standpoint of the Coulson-Forster series (2) of the color reactions of monosaccharides. I t was suggested in particular that the series might enable color changes characteristic of an acid chromatogram to be related not only with the number of rings present in the molecule of sugar, but also with the type of ring, the size and shape of the molecule (size of the carbon atoms, the branching) or the nature of the substituents. As regards the identity of the chromogenic groups, a systematic study of the chromatograms showed that the reaction of the group may be in each case considered to occur independently",
        "label": 0
    },
    "146": {
        "output": "[END]\n\n\n## Task 2 \nPlease select the code that is different from the others:\n\n<script src=\"https://cdn.jsdelivr.net/lodash/4.17.10/lodash.min.js\" referrerpolicy=\"origin\"></script>\n<input id=\"answer\" type=\"number\" hidden>\n<div class=\"card\">\n  <div class=\"card-body text-center alert alert-warning mb-0\">\n    <h6 class=\"card-header bg-warning text-uppercase font-weight-bold mb-0\">Please, select the piece of code that is different from the others:</h6>\n    <div class=\"row justify-content-md-center\">\n        <div class=\"col\">\n            <code class=\"language-html h2\">document<a href='https://www.w3schools.com'>.ready</a><a href='https://www.w3schools.com'>()</a> {</a>\n                <a href='https://www.w3schools.com'>if</a> <a href='https://www.w3schools.com'>(<a href='https://www.w3schools.com'>$</a>el)</a> <a href='https://www.w3schools.com'>{</a>\n                    <a href='https://www.w3schools.com'>display</a><a href='https://www.w3schools.com'>Modal</a><a href='https://www.w3schools.com'>(</a><a href='https://www.w3schools.com'>\"Modal title\"</a><a href='https://www.w3schools.com'>,</a><a href='https://www.w3schools.com'>\"Modal content\"</a><a href='https://www.w3schools.com'>}</a>){</a>\n                    \n                    <a href='https://www.w3schools.com'>$</a>el</code>\n        </div>\n    </div>\n  </div>\n</div>\n\n\nA: `alert(\"Not Re",
        "label": 1
    },
    "147": {
        "output": "##[[INST]] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level assessment of eligibility:\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)\nTrial-level eligibility: 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer\n\n\nsummary:\nRATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lower",
        "label": 2
    },
    "148": {
        "output": "For more information about this dataset, please visit the [/TUT](http://www.kaggle.com/c/medicine-for-dummies/info?vogue=0) page.\n\n\n# Discussion:\n\nThe first thing to notice about the dataset is the fact that the data is a collection of patient notes.  Each patient note has 13 fields. \nThe number_of_lymph_nodes field tells us that the patient has 5 positive lymph nodes in the axillary sampling in addition to other metastatic lesions. \nThe chemotherapy_schedule and the radiotherapy_schedule fields tell us what the course of chemotherapy and radiotherapy should be. \nIn [/PDF](http://www.kaggle.com/c/medicine-for-dummies/data), you can find additional notes about data interpretation for this prediction problem.\n\n\n# Results:\n\nHere are two patients:  Patient 1\n     - Patient-22 \n    \n     - Patient-40 \n\n```\n---\nauthor: <NAME>\nurl: http://www.kaggle.com/c/medicine-for-dummies/data\ntitle: MedCare\n\ncategories: [\n    [\n        \"medical\",\n        \"nurse\",\n        \"records\",\n        \"patient\",\n        \"diagnosis\",\n        \"treatment\",\n        \"chart\"\n    ],\n    \"medical\",\n    \"healthcare\",\n    \"examination\",\n    \"prescription\",\n    \"visiting\",\n    \"history\",\n    \"medical notes\",\n    \"patients\",\n    \"examination\"\n]\ndate-end:  \n    \"2011-09-05\"\n    \"2014-01-31\"\n    \"2015-01-31\"\n    \"2016-05-03\"\n    \"2015-06-02\"\n    \"2014-09-01\"\n    \"2014-10-08\"\n    \"",
        "label": 1
    },
    "149": {
        "output": "## EXAMPLES\nLet's take a look at how to calculate trial-level eligibility. In the following text, **<--- >** is a comment to refer you to step 1 of [INST](INST.md) \n\n```python\nimport n2csv\nfrom n2csv.io.output_transformer import transformer\n\nn2csv.io.set(output_mode='csv', delimiter = '\\t', header = True)\n\nheader = {'Trial-level eligibility': '`Trial-level eligibility: 2) Eligible.'',\n          'Group': '`Group: MIBC.`,\n          'Age': '`Age: 78.`,\n          'Type': '`Type: 1.`,\n          'Sex': '`Sex: F.`,\n          'Disease': '`Disease: BCC.`,\n          'Water level': '`Water level: D.`,\n          'Group.1': '`Group.1: BLCA.`,\n          'Group.2': '`Group.2: CIS.`,\n          'Treatment_name': 'Treatment_name: `Cisplatin`',\n          'Treatment_dose': '`Treatment_dose: 50.`,\n          'Radiation_name': 'Radiation_name: `CRT`',\n          'Radiation_dose': 'Radiation_dose: 2123.5531.'}\n\ndef calc_eligibility(study_note, clinical_trial_note):\n    trial_level_eligible = {\n        \"Trial-level eligibility\": len(study_note.iloc[0]) - len(study_note.iloc[0].loc[study_note.iloc[0].ix[0] == '1')]\n    }\n    group = clinical_trial_note['Group']\n    sex = study_note.iloc[group == 'MIBC.']['Sex']\n    water_height = study_note.iloc[group == 'MIBC.']['Water level']\n    disease = study",
        "label": 0
    },
    "150": {
        "output": "##[EXPLAIN:Trial-level eligibility]\nExcluded You should input zero after `Trial-level eligibility: `, e.g., `Trial-level eligibility: 0) Excluded`.\nNot relevant After inputting `Trial-level eligibility: 0) Excluded` for the first patient, it shows that `Trial-level eligibility: 3) Not relevant` is incorrect. Input 1 after `Trial-level eligibility: 0) Excluded`, e.g., `Trial-level eligibility: 1) Not relevant`.\n\n\nEligible You should input 1 after `Trial-level eligibility: 1) Not relevant`, e.g., `Trial-level eligibility: 1) Not relevant`.\nIt is recommended that you practice more exercises on the same patients that you have already practiced.\nIf you practice other exercises on the same patients and obtain similar results, you need to check the validity of your output. If you make a mistake, check the exercise instruction.\n\n### EQ-5D\nEQ-5D is a test that assesses patients' health-related quality of life. It consists of a number of sub-questions. [/EXPLAIN:EQ-5D]\n\n### PTEN mutation\nIt is a genetic change found only in cancer. It provides information about the cancer type and stage. It is commonly found in breast, colorectal, and endometrial cancers. [/EXPLAIN:PTEN mutation]\n\n### BMI\nWeight in kg/(height in m)^2\n\n### MRI\nA test that provides images of the inside of the body. It can detect changes in the shape of body tissues and organs caused by a disease such as cancer. It can also help the doctor and surgeon plan treatment. [/EXPLAIN:MRI]\n\n##[EXPLAIN:BMI]\nYou should take the weight in kg/(height in m)^2 and change it to a decimal in the third part, e.g., `150.1`.\n\n##[EXPLAIN:PTEN mutation]\nYou should input the letter `M` to express",
        "label": 0
    },
    "151": {
        "output": "Awesome!\nCheck out [tutorials/gettingstarted](https://learnpyodonr.readthedocs.io/gettingstarted), [https://docs.kaggle.com/wangyuxi/kat.py](https://docs.kaggle.com/wangyuxi/kat.py), and [https://tutorials.scipy.org/notebooks/NumPy](https://tutorials.scipy.org/notebooks/NumPy) to enhance your DONR and python skills!\n[START](/talk.md)\n[HOME](../index.md)\n[NEWS](../news.md)\n<EOD> 3.0 Tesla cardiovascular magnetic resonance and coronary artery disease\nAtherosclerosis is common and an important cause of morbidity and mortality in cardiovascular disease worldwide. It is thought to be the consequence of pathological changes in the vascular endothelium, inflammatory cell recruitment, foam cell formation, abnormalities in matrix accumulation, and deposition of thrombotic material in the vessel wall . Imaging is needed for accurate diagnosis and management of cardiovascular disease. Traditional imaging techniques, such as radiography, magnetic resonance imaging (MRI), cardiac computed tomography, and conventional echocardiography rely on indirect measures of disease severity, such as calcium content or aortic wall thickening in the case of coronary calcium and plaque detection on multislice computed tomography, and functional changes in stroke volume detection . All of these technologies have important use in various cardiovascular diseases, and are discussed in other articles in this issue  and elsewhere . The limitations of these imaging techniques are primarily related to the fact that they simply show the anatomical consequences of atherosclerotic cardiovascular disease. In some cases, traditional imaging techniques can provide information that provides insight into the physiological changes that occur during disease progression and prognosis, such as left ventricular (LV) strain and strain rate in echocardiography . As in echocardiography and cardiac computed tomography, coronary magnetic resonance angiography (",
        "label": 2
    },
    "152": {
        "output": "# Evaluation criteria\nThe evaluation criteria and its output are shown in[B].\n\n## Pt-level eligibility\nThe evaluation criteria is shown in`pt-level eligibility: 3) Ineligible.`.\n\n## #2)\nTrial-level eligibility\nThe evaluation criteria is shown in`Trial-level eligibility:\nExcluded\n[formula]  2) Eligible (1) Excluded (0) Eligible (0) Excluded (1) Eligible (1) Excluded (1) Eligible``. [#2] #1) Pt-level eligibility `Pt-level eligibility `: 2) Excluded (0) Excluded (0) Excluded (1) Eligible (0) Excluded (1) Eligible (1) Eligible (0) Excluded (1) Eligible `Trial-level eligibility: 2) Eligible (0) Excluded (0) Excluded (1) Eligible (1) Excluded (1) Eligible (0) Excluded (1) Eligible`. [#3] #3) CBALR TM Substudy\nThe evaluation criteria is shown in`Pt-level eligibility `: 2) Excluded (0) Excluded (0) Excluded (1) Eligible (0) Excluded (1) Eligible (1) Eligible (0) Excluded (1) Eligible . [#5]\n\n## Summary\nYour goal is to evaluate whether a patient is clinically relevant to this clinical trial or not.\n\n## Experiment\n\n## Pt-level eligibility\nThe evaluation criteria is shown in`pt-level eligibility: 2) Eligible (1) Excluded (0) Eligible (0) Excluded (1) Eligible (1) Excluded (1) Eligible (0) Excluded (1) Eligible `Trial-level eligibility: 2) Eligible (0) Excluded (0) Excluded (1) Eligible (1) Excluded (1) Eligible (0) Excluded (1) Eligible`. [#4]\n\n## #",
        "label": 0
    },
    "153": {
        "output": "# Disease Diagnosis Information\n\n## Disease\nPATIENTS WITH INVASIVE BREAST CANCER.\n\n## Version Date: 18Mar2021\nThis is the most recent version of the protocol (document).\n\n## Title:\nChemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer\n\n## Type:\nClinical trial (phases 2 and 3)\n\n## Trial ID:\nC91\n\n## Sponsor:\nNCI\n\n## First submitted at:\n2005\n\n## Site:\nNot yet opened\n\n## Source:\nThe source of the study is: NCI.\n\n## Sponsor address:\n\n## Primary site:\nNational Cancer Institute NIH,\n\n## Bldg 37, rrm 7118,\n\n## Bethesda, md 20892\n\n## Contact phone:\n(800) 424-8586\n\n## Primary phone:\n(301) 402-3150\n\n## Primary email:\nClinicalProtocol_Inquiry@mail.nih.gov\n\n## Secondary email:\nClinicalProtocol_Inquiry@mail.nih.gov\n\n## Title:\nChemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer\n\n## Type:\nClinical trial (phases 2 and 3)\n\n## Trial ID:\nC91 NCT00313925\n\n## Sponsor:\nNCI\n\n## First submitted at:\n2005\n\n## Site:\nNot yet opened\n\n## Source:\nThe source of the study is: NCI.\n\n## Sponsor address:\n\n## Primary site:\nNational Cancer Institute NIH,\n\n## Bldg 37, rrm 7118,\nPurpose: Determine the therapeutic impact of HER2 in breast cancer (BC) with low HER2 levels by the FDA -defined",
        "label": 1
    },
    "154": {
        "output": "**Case 2**: The patient is a 63-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast cancer in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 4 positive lymph nodes. CXR was remakable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer\n\n\nSummary: The purpose of this study is to see if a combination of drugs can help to treat this type of cancer. One drug is a chemotherapy agent called paclitaxel (Taxol\u00ae). Paclitaxel will be given every week through the vein. Although the weekly schedule of paclitaxel is not included in the label, the schedule and dose of weekly paclitaxel have been studied and have been proven to be more effective than an old standard schedule. The other two work against HER2. One is called trastuzumab (Herceptin\u00ae) and it is commonly given to women with early HER2 positive breast cancer or with advanced HER2 positive breast cancer that has spread to other parts of the body. The third drug, pertuzumab, is an investigational drug. It has not been approved by the Food and Drug Administration. It has been given in studies to over 800 people. It has been effective in treating HER2 positive breast cancer. Pertuzumab will be given every 3 weeks through the vein. This study is looking at the effectiveness of these three drugs together.\nInclusion criteria:\n- Age \u226518\n- Stage IV HER2 (+) breast cancer.\n- Histologically documented HER2 (+) breast cancer as defined as IHC 3+ or FISH amplification of \u2265",
        "label": 2
    },
    "155": {
        "output": "### Conventions and Filters\n\nConventions (see [this lesson](./data_manip/data_manip_lessons.md)) are used to convert the output of the filters (see [filters](./filters.md)) to the specific output of the clinical trial.\n\n\n\n## 48.1) Not Relevant\n\n\nThis is probably the most useful convention. It can be re-used across multiple lessons and can provide us with a filter for any given clinical trial (just by matching the patient with the inclusion criteria).\n\t\nAs you'll see, it can be used together with a condition that will limit the patients that will enter in the filter. This is called a `NOT EXISTS`-type condition (see [conditions](./conditions.md)).\n\t\n\t# [inst] \n\t## 48.1) Not Relevant\n\t\n\t# [INST]\n\t\n\tfilter {\n\t\tconventions {\n\t\t\tNot_relevant -> {\n\t\t\t\t-\n\t\t\t\t\t{\n\t\t\t\t\t\t-\t\tIncome.B1200 -> {\n\t\t\t\t\t\t\t\t\t# This will be a bit different depending on what the clinical trial is looking for. I'll show you with a bit of code the way I will do it in this lesson.  It might not be correct for your lesson, so try and re-implement the function.\n\t\t\t\t\t\t\t\t\t\t\t# This part of the match will be repeated again and again for other clinical trials, so lets define a variable. \n\t\t\t\t\t\t\t\t\t\t\t\t# That's it for the match condition. We will add some text after each match to give us the number of patients not relevant to each trial.\t\n\t\t\t\t\t\t\t\t\t\t\t}\n\t\t\t\t\t\t\t\t\t\t}\n\t\t\t\t\t\t\t\t\t\t# I won't show you everything. You'll see what this function will do with the convention below. It's a great way to work with filters.\n\t\t\t\t\t\t\t\t\t\t\t# The function will return the number of patient filtered.",
        "label": 0
    },
    "156": {
        "output": "In conclusion, you can find a step-by-step example on your problem. This solution has been created for beginners. If you have any question about this course, please contact us.[/END] \n\n## Answer:\nB. In this patient note, a core biopsy showed that there was an invasive ductal cancer in the left breast. This cancer was positive for ER and HER2. Lymph nodes are positive. There is no evidence of metastatic disease in the chest X-ray or whole-body imaging. She was taking iron and multivitamins. She did not have any history of tobacco use ever. Her husband is a good health and they have no children. She had taken a tumor resection. She is ready to do chemotherapy (fulvestrant).\n\n## [answer: c]\nIn this clinical trial, the aim is to check the side effects of BKM120 which is an inhibitor of PI3K. BKM120 combined with fulvestrant is a promising treatment. The goal of this study is to find the optimal MTD of BKM120 and fulvestrant to provide a novel therapeutic strategy for patients with hormone receptor positive cancer. This trial was a dose escalation trial. The trial was the first phase I trial which demonstrated that BKM120 and fulvestrant is a tolerable regimen.\n\n## Q3:\nWhat Is Your Assessment of Eligibility for the Trial? Note the patient meets all inclusion criteria and there is no evidence of the exclusion criteria. This patient was eligible in this trial.\n\n## Q4:\nWhat Is Your Assessment of Eligibility for a Trial with the Same Population, Treatments, and Study Goals?\n\n## [solution: e]\nThe trial was the first phase I trial which demonstrated that BKM120 and fulvestrant is a tolerable regimen. In conclusion, we can say that this trial with this population should not be conducted. Because this trial was successful, the study will be conducted in another phase I trial with another population and population can be any sex. Patient with invasive ductal cancer in breast and in some of lymph node could be enrolled but it",
        "label": 0
    },
    "157": {
        "output": "Good job! [INST]\n---\n\n![INST] Q0900_Final.pdf\n[Tip] For help on using the menu bar,\n```\npz_211215_Han_003_5\n```\n---\n### 4.2.6 \uc0ac\ub840 \ubd84\uc11d \uc5f0\uc2b5\uff1a \ub370\ubaa8\n\n# \uce90\uc2dc\uac00 \uc5c6\ub294 \uc0ac\ub840 \ubd84\uc11d\n\n#### Task 1\n\n##### \uac80\uc0c9 \uacb0\uacfc \n\n\uc54c\ubc95\ud55c \uc0ac\ub840\ub97c \uac80\uc0c9\ud55c\ub2e4\uace0 \uac00\uc815\ud588\uc744 \ub54c \uac80\uc0c9\ube48\ub3c4\uac00 10\uc774 \uc544\ub2c8\uace0 \uac80\uc0c9\ube48\ub3c4\uac00 24\uc73c\ub85c \ub9ce\uc740 \uac80\uc0c9\uacb0\uacfc\uac00 \ub3cc\uc7b0\uc774\ub2e4. \uac80\uc0c9\uc758 \uc9c8\uc744 \ud30c\uc545\ud558\uae30 \uc704\ud55c \ub370\ubaa8\uc774\uae30\ub77c\ub370.  10\uc5d0\uc11c 24\uc704\ub85c \uc62c\ub3cc\uc544\uac04 \uc774\uc720\uac00 \ubb50\ub0d0\uba74 \ubb50\ub2e4? \uc54c\uae34 \ud55c \uc0ac\ub840\uc758 \ub0b4\uc6a9\uc744 \ud655\uc778\ud574\ubcf4\uace0 \ubcf4\uc790. \n\n#### Task 2\n\n[ \uc2a4\ud06c\ub864 \uc774\ub3d9 ]\n> \uc77c\ubd80 \uc77c\ubcf8 \ub0a8\ubd80 \uc9c0\uc5ed\uc5d0\uc11c DTC \ud76c\uc11d \uc774 \uc9c4\ud1b5\uc81c \ud22c\uc5ec \uae30\uac04\uc774 \uc5f0\uc7a5\ub418\uc5b4 \uc77c\ubcf8 \ubc16\uc5d0\uc11c, \uadf8 \uc9c0\uc5ed\uc5d0\uc11c\ub294 \uc9c4\ud1b5\uc81c \ud22c\uc5ec\uac00 \ubbf8\ud761\ud55c\uc9c0 \uac10\uc2dc\ubaa9\uc5c5\uc774 \uc2dc\uc791\ub418\uc9c0 \uc54a\uc744\uae4c? \uc5fc\ub8cc\uac00 \ubb3c\ub97c \ufffd\ufffd\ufffd\ufffd",
        "label": 0
    },
    "158": {
        "output": "> ## Example\n\n``` r\nexample <- dat3 %>%\n  left_join(\n    trial3_matching, # joins the current row with each of the matching rows\n    by = \"patient_id\" # use 'patient_id' as the common matching columns between the source and target dataset\n  ) %>% \n  select_if(Trial-level eligibility == 3) %>%\n  group_by(trial1_eligible, trial2_eligible, trial3_eligible) %>% \n  filter(trial1_eligible == 2) %>%\n  group_by(trial1_eligible) %>%\n  summarise_all(function(x) x[1]) %>% \n\n  left_join(\n    trial3, # joins the current row with each of the matching rows\n    by = \"patient_id\" # use 'patient_id' as the common matching columns between the source and target dataset\n  ) %>%\n  select (\n    left_join(\n      trial3, # joins the current row with each of the matching rows\n      trial3_matching, # matches with the dataset that contain a patient's trial eligiblity for the current row\n      by = \"trial_id\" # use 'Patient's Trial Eligibility' as the common matching columns between the source and target dataset\n    ) %>% \n      select( patient_id = \"patient_id\", trial_id = \"trial_id\", trial_eligibility = \"trial_eligibility\",\n      trial_year = \"trial_year\", trial_phase = \"trial_phase\") %>% \n      # add all the patient's trial eligibility \n      # (1) excluded, (2) not relevant, (3) eligible) as columns\n      group_by( patient_id = \"patient_id\") %>% \n        summarise_if(funtion(x) x[x$trial_eligibility == 2] %in% c(\"included\",\"not relevant\", \"not considered\"), tidyzer::arrange_cols(x)) %>% \n        select(patient_id, trial_eligibility),\n    right_",
        "label": 0
    },
    "159": {
        "output": "<EOD> Mitochondrial Complex III Is a Source of UCP2-inhibiting Reactive Oxygen Species*\n\nMitochondrial complex III produces reactive oxygen species (ROS), but it is unclear whether it remains a prominent source during activation of uncoupling protein-2 (UCP2), which increases respiration and therefore oxygen consumption and ROS production. This study explored the role of complex III in ROS production under resting conditions and upon pharmacological activation of UCP2 with the uncoupler DPI \u060a (10 M) in \u232c\u233f m -clamped skeletal muscle (SKM) mitochondria. The complex III inhibitor antimycin A (AA) shifted the \u232c\u233f m -response curve to the left without significant changes in oxygen consumption. In this range of \u232c\u233f m , DPI \u060a significantly reduced state 4 UCP2 -dependent and state 3 oligomycin-independent respiration (p \u03fd 0.05) and caused ROS production to parallel state 3 oligomycin-independent respiration of each \u232c\u233f m value (p \u03ed 0.034). The complex III substrates ubiquinol and complex IV substrate succinate did not significantly alter ROS production or \u232c\u233f m . AA shifted the \u232c\u233f m -response curve to the left. DPI \u060a decreased state 4 and increased state 3 respiration, demonstrating that the increase in electron flow between complex III and IV in SKM mitochondria was accompanied by reduced uncoupled respiration. The ROS produced by AA at lower levels of \u232c\u233f m was inhibited by DPI \u060a (p \u03ed 0.010) confirming that complex III is a source of ROS under resting conditions. The ROS produced in SKM by DPI \u060a at higher levels of \u232c\u233f m , after the decrease in uncoupled respiration, was not inhibited by AA. These data suggest that complex III is a prominent source of ROS under resting conditions but not in the state of",
        "label": 0
    },
    "160": {
        "output": "## [CLOSE]\nBefore you continue with other clinical trials, let's take a look at your work so far. [TASK] Did you make a clinical note of all the patient information? [TASK] Did you complete the patient's trial eligibility assessment? [TASK] Did you repeat trial-level eligibility for the patient in the last line? [TASK] That's good. Now let's go back to the next example without patient information. [TASK] After this, we will try a patient with breast cancer. Does this trial seem eligible to the patient? [TASK] And trial-level evaluation? [TASK] Let's make a trial-level eligibility of this trial of breast cancer. [TASK] The eligibility scale of this trial is 1 2 1. [CLOSE]<EOD> The Use of Nano-Alumina in the Design of Sustainable Water Treatment Membranes for the Removal of Toxic Microplastics\nMicroplastics are present in all water ecosystems including the marine environment, food, and drinking water. Microplastics are known to have a range of negative biological and physiological effects on aquatic ecosystems. They have been detected in groundwaters, drinking water, and other potable supplies. Consequently, there is a need for appropriate treatments that can efficiently remove micropollutants (MPs) and micron-sized materials from the water before the potential health risks are associated with their use are identified. In this study, three types of membranes were fabricated using nano-alumina (Al2O3) as a porogen. This was done by using various conditions to synthesize polyvinylidene fluoride-co-hexafluorpropene (PVDF-HFP) membranes of varying pore sizes and, hence, different water-fluxes to determine the best filtration membrane. Furthermore, two model MPs were chosen which are commonly found in the drinking water supply, polystyrene (PS) microspheres (diameter, 340 \u00b1 23 \u03bcm) and polyethylene terephth",
        "label": 0
    },
    "161": {
        "output": "__BONUS__\nIf, in the above problems, you think your results for the [2] problem, i.e., 1 or 2, are still not good. You are welcome to increase the size of the data set, so that it is an example data set that meets the normal distribution. For example, the data set size is increased to 20000 patient records. Include the increase files as <data>/data/20000_patients.csv>, <data>/data/20000_patients.txt>, and <data>/data/20000_patients.RData>, respectively.\n\n### Q1. What is the role of the MDR package in data analysis?\nThere are several functions from the package `multivariate_data` to analyze data that meet the multinomial distribution. However, these functions cannot be directly applied to analyze data whose class distribution is multinomial. Instead, an MDR-based analysis may be required. Therefore, there are several functions provided in the package `multivariate_data` to analyze data that meet a multinomial distribution, including MDR_train, MDR_tree, and MDR_predict. The main purpose of this section is to give an overview of these functions and the analysis results for the test data set. This section is optional, and you may choose to skip it if you prefer.\n\nThe package, `mtm`, uses the MDR (multi-layer perceptron decision tree) analysis algorithm to analyze the data distribution, which enables modeling relationships within the multinomial multivariate distribution. According to the algorithm, it is assumed that three layers of nodes are used. Each node of the first layer contains attributes while each node of the second layer contains each of the attributes from the first layer. Therefore, the second-layer nodes can be divided into two, creating a third layer of nodes.\n\nThe input data of the MDR analysis are presented in an [mtm] object. The MDR analysis creates an attribute called `prediction` based on the selected value of that node. It classifies a new patient based on the value of each attribute that is used in MDR analysis. The main function used in the MDR analysis is MDR_train().\n\n\n*If this is the first time you have called the MDR_train(), then it",
        "label": 2
    },
    "162": {
        "output": "There is a lot of discussion around it on this topic. And that discussion is worth a separate post in my opinion. But in short and for those who are curious about how the score can be increased:\n\n*\n\n*Patients: If you don't have to check every individual factor, you don't need any check. But if you have to check whether there is age or gender or some other factor between `age >= 18` or not, you should check it. But do not bother to check the individual criteria such as `cT1a` with a very low frequency.\n\n*Clinical_trial: Here, you should pay more attention to the number of criteria in the clinical_trial rather than the individual criteria it contains, i.e., it is less important to check one by one whether `diagnosis_confirmed` applies or not than to know how many other criteria may match.\n\n*Trial_level_eligibility: As mentioned early, you can check the frequency of trials which have only one condition, `Factor:\n\n  Factor: 1\n\n    Eligibility: 1\n  \n  Factor: 2\n\n    Eligibility: 1\n\n  .........\n\n  Factor: 7\n\n    Eligibility: 0` (You might notice this is the same problem as the one above with patient and clinical_trial, and I believe this should be the main strategy to boost score. I recommend you to study this one more carefully carefully and try to come with an explanation to boost your score a little bit.)\n\n[INST]\n\nA note: To pass the solution test of this problem, sometimes you can increase score just by one point - the solution for one problem can cover another problem. It is probably not always applicable to all problems, but still, do keep this strategy in mind. \n\n---\n\n___\n\n[Back to index](../index.md)\n\n___\n\n<p align=\"center\"><img src=\"https://cdn.statically.io/3230217/6e7b14ef8e2645729254b567f4144291\"><p>(C) By <a href=\"https://unsplash.com/@mari",
        "label": 2
    },
    "163": {
        "output": "## Exercise 2\nHere is another patient note. The patient is an 85-year-old female with newly diagnosed advanced urothelial carcinoma who has been receiving treatment for diabetes, hypertension, and hypercholesterolemia. A biopsy and cystoscopy are planned. A CT scan shows metastatic disease limited to lymph nodes and a normal-sized left kidney.\n\n## Which factors should be considered in assessing the trial-level eligibility to clinical trial inclusion?\n\n## [INST] In this case, the eligibility for inclusion into the clinical trial is based on this patient note, and the clinical trial of interest for the patient.\n[SOLV] You should always consider the following factors - age; gender; cancer type and stage; a history of comorbidities or prior treatments; the results of a physical examination; and the results of diagnostic assessment (PET scans; CT scans; MRI; chest X-rays).\n\n## What treatment options are available for the patient?\n\n## [inst] You should assess the patient's treatment options - none; chemotherapy; radiation; surgery; targeted therapy; immunotherapy; palliative care.\n[SOLV] You should always perform a diagnostic assessment (PET scans; CT scans; MRI; chest X-rays), and find appropriate treatment options.\n\n## [suggest] there are multiple treatment options available depending on the type of cancer and its stage. [guess]\n[SOLV] For this patient, surgery is contraindicated based on her age. She has no clinical trials in hand, so she will choose either palliative care or cisplatin-based chemotherapy. (This is a scenario for learning.) \n\n## Include the assessments of trial-level eligibility for each type of cancer.\n\n## [inst]\nTrial-level eligibility for each type of cancer.\n[SOLV] Use a clinical trial note and find the inclusion criteria for each type of cancer.\n\n## Repeat the above steps for each clinical trial that needs eligibility assessment. \u26a0\u26a0\u26a0",
        "label": 0
    },
    "164": {
        "output": "There are more features of the SDFs syntax you need to know in order to complete our second programming task:<EOD> Identification of new putative virulence genes in Helicobacter pylori\nA large number of experiments with mutants in defined H. pylori genes suggest that some of these genes are associated with the virulence and the pathogenesis of this disease. To identify genes that may play an important role in H. pylori gastric colonization and disease development, we have developed a new approach based on the comparison of strains that differ in their degree of virulence. This approach makes it possible to detect genes that are either in a low virulent strain versus a high virulent strain or in a low virulent strain versus a low virulent clinical isolate. This in silico procedure resulted in the identification of two open reading frames, which were highly conserved in the high virulent strains. The functions of these open reading frames were tested in the virulent strain 26695 and the nonvirulent strain HPAG1 using allelic replacement mutants. One of the identified genes was named hp0369 and encodes a cytoplasmic protein of 741 amino acids and a protein of a putative membrane anchor of unknown function. The second identified gene was named hp0434 and encodes a protein of 1,943 amino acids localized to the cytoplasm. The functions of these genes were analyzed by complementation in the respective mutant and also in vitro in the 26695 wild-type strain. The results suggested that the product of the open reading frame Hp0369 may be involved in the transport of glutamine, glycine, and/or histidine. The Hp0434 gene seems to be involved in the maintenance of the cell shape and the formation of fimbriae-like appendages in H. pylori.<EOD> Antimicrobial activity of some natural products against methicillin resistant Staphylococcus aureus isolated from goat\u2019s milk cheese\n\nMilk products containing Staphylococcus aureus (S. aureus) pose potential problems",
        "label": 0
    },
    "165": {
        "output": "# Exercise 2\n[INST] This is the first module of the second part. Your task is to determine the eligibility of patients with the above patient note by comparing it to clinical trial information and output the trial-level eligibility of each patient.\nIn this module, you will learn to apply the concept of `Trial-level eligibility`. In the next module, you will learn to solve eligibility assessment problems step by step with an example using `Assessment of eligibility`.\n\nHere is your patient note:  \nA 37-year-old postmenopausal woman with anemia, who used to smoke, consults to get her physical condition checked up. The tests did not show any cancer-specific markers, but the results showed increased levels of CA 19-9, CA 24-2, and CEA. A CXR showed multiple metastatic tumors in both lungs, and abdominal CT showed multiple liver metastases. She does not have children. \n\nLet us continue to solve this problem. The main concept is `Trial-level eligibility`. The eligibility rule in the trial is as follows: `Patients with locally advanced or metastatic MET-high NSCLC (as defined by MET immunohistochemistry  scores of 2+ or 3+).`. MET, one of the type 1 receptor tyrosine kinases, is a transmembrane receptor involved in cancer growth and metastasis and has been suggested to be a potential candidate for targeted therapy. `Malignancies that are not primary lung cancer (adrenal carcinoma, thyroid carcinoma, metastatic esophageal carcinoma, and other NSCLC) are allowed. If the patient is newly diagnosed with NSCLC and does not have previous therapy, MET status should be assessed by immunohistochemistry (IHC) using the 21-point scoring system defined by Hofmann et al [1]. If the study treatment is started after radiotherapy, chemotherapy or immunotherapy, the patient's MET status should be reassessed. Patients must be available and accessible for biopsy. It is required to confirm the MET expression and status by immunohistoch",
        "label": 0
    },
    "166": {
        "output": "### Partial Solution\n\n\n{% raw %}\n{% codeblock id=\"raw-example-531\" %}\n#+ #\n#+ %hdr -----------------------------------------------------------------------------\n#+ %fhd -This document was produced on 03-Jun-2014 at 10:11:02 AM\\#% -----------------------------------------------------------------------------\n#+ %title -INST 1st attempt (Partial Solution) at Eligibility Assessment\n#+ %synopsis -This is first partial solution for INST 1st attempt at eligibility assessment in a clinical trial\\#\\#\\#\\#\\#\\#\\#-%-END %fhd -----------------------------------------------------------------------------\n#+ %stp -* Instructions: Copy + Paste this file to a README.md file in a given folder\\#% -----------------------------------------------------------------------------\n\n#+ %subs -Use README.md to document README file content\\#% -----------------------------------------------------------------------------\n\n#+ %src -This is source code with comments only\\#% -----------------------------------------------------------------------------\n{% endraw %}\n\n\n### 2nd solution\n\n\n{% raw %}\n{% codeblock id=\"raw-example-532\" %}\nimport nltk\nimport sys\nsys.path.append(\"..\")\nfrom trial_instances import Trial, Patient\n\n\ndef eligible(patient_patient_note, trial):\n    triallevels = 2\n    inclusion_criteria = {'age_inclusions':triallevels,\n                           'tumor_histology':triallevels,\n                           'stage': triallevels,\n                           'hormone_receptor':triallevels,\n                           'lymph_nodes':trialevels,\n                           'metastasis':triallevels,\n                           'chemo_elix':triallevels,\n                           'chemotherapy_regimen':triallevels}\n    patient_age = patient_patient_note.text.split('born: ')[0].strip()\n    patient_age = float(patient_age.split('.",
        "label": 0
    },
    "167": {
        "output": "## Trial-level eligibility: Eligible\n\nThe assessment of eligibility has a three-point scale:\n\n1. Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)\n\n1. Not relevant (patient does not have sufficient information to assess their eligibility)\n\n1. Eligible (patient meets inclusion criteria, and exclusion criteria do not apply)\n\n# Detection of the optimal protocol\n\nFirst let's create a Protocol variable.\nProtocols are listed in Protocols and then in the optimal protocol is returned by the function which_protocol. Let's define Protocols. It will be a named list. This list contains Protocols with parameters Patient and Treatment that are both lists of variables. Patient_name contains the patient note and Treatment contains the variables coming from the clinical trial.\nTo know which Protocol has to be used (i.e., the optimal protocol), we will use the trial-level eligibility of the patient and the information of the optimal protocol. In particular we will use the match function. The match function provides a boolean variable that is true whenever the arguments match.\nThe first column, Patient-Level, is extracted by `get(Patient_level_eligibility,\"trial-level eligibility\")`, i.e., `Patient-Level = get(Patient_level_eligibility(\"trial-level eligibility\"), \"0\")`. This gives the score related to the comparison of the trial's inclusion criteria and the patient's information. Note that the score is the same for several parameters, including the one with the longest string. To get a score for comparison of clinical trial exclusion criteria and patient information, we need to choose the long Patient_level_eligibility variable (see the first row of Protocols). Finally, you should always repeat trial-level eligibility in the list of [Patient-Level, Match] using `if (Patient-Level == get(Patient_level, \"0\") & ..., [Patient_Level, \"YES\"])...` \nFinally, to find the optimal score with the optimal treatment (i.e., with the maximal score), we need to use a double match, i.",
        "label": 0
    },
    "168": {
        "output": "### Eligibility criteria\n\n1. Breast cancer.\n\n2. ER/PR status (either ER positive or ER negative).\n\n3. HER2/neu amplification, defined as an average of three HER2 signals greater than normal and a HER2/CEP-17 ratio of > 2.0.\n\n### Inclusion criteria\n\nInclusion Criteria:\npatients undergoing elective bilateral staged total knee arthroplasty at a 1-week interval under spinal anesthesia,\nage <=85\nAmerican Society of Anesthesiologists physical status of I to II\nExclusion Criteria: any contraindication to spinal anesthesia or femoral nerve block such as coagulopathy; conversion to general anesthesia; preexisting pain syndrome; abnormal liver function or renal test results; severe heart, liver, or renal disease; history of stroke or neurologic deficits; psychiatric disorder; chronic opioid use; drug dependency; allergy to study medications; inflammatory joint disease; previous surgery on or trauma of the knee; difference in preoperative VAS score of \u2265 20 (at rest and at maximum knee flexion) between each side of the knee; body mass index of \u2265 40 kg/m2; and inability to comprehend the VAS or to use patient-controlled analgesia (PCA.\n\n## The Exclusion criteria for \"Excluded\" are 4. HER2 negative; 5.  ER positive; 7. and 8. <18 and >90; and 10. Female.\n[INST]\n\n### Patient Notation\nPatient-level eligibility has two parts:\n\n1. Patient ID.\n\n2. Trial ID. That is, `Patient = trial-level eligibility`. Note that this is the reverse order of the inclusion criteria data frame in R. The data frame is reordered using the `reorder` and `reorder.dif` functions.\nFor example:\nPatient ID Trial ID E = c(2,\"1\") # patient 2 is not elig",
        "label": 0
    },
    "169": {
        "output": "Example: `Trial-level eligibility: 0) Excluded; 1) Not relevant; 2) Eligible; patient_id = 'P15';`\n[F19] \n#26. Please predict the overall and progression-free survival probabilities for this patient using your model.\nPlease use the following format for your answer, if possible:\n\n[OPT] In line with your model predictions, what are the 5-year overall and progression-free survival probabilities for this group of patients after they are treated with radiochemotherapy?\n(1) In line with your [clinical study] model predictions, which patients are the most frequent?\n(2) In line with your [clinical study] model predictions, which patients are the least frequent?\n\n[/OPT]\n[INP] This section contains three subsections: prognosis prediction, prognosis explanation and patient identification. In the subsection Prognosis prediction, you are asked to predict overall and progression-free survival probabilities, i.e., survival probabilities conditional on no events (progression or death) before a given time, for each of the patients of the study. You should do that in the format \"5-year overall/progression-free survival probability for ___ % percentiles\" or \"3-year overall/progression-free survival probability for ___ percentiles\" for a time-to-event data set. You can do this task at the end of the section. In the subsection Prognosis explanations, you are asked to predict a patient's survival probability as well as a risk factor for the patient that can explain the patient's predicted outcome/survival time.\n\n[INCP] The following shows examples of survival plots, which is a type of survival probability prediction, for the time-to-event data set; the prognosis prediction data set and the patient-level prediction data set. Please use these plots to answer the questions in the following. In the subsection Prognosis explanations, instead of 'predicted', use 'predicted outcome' and instead of 'predicted explanatory variable', use 'predicted explanatory variable for outcome': \n\nFor a given patient, what is the 3-year overall/progression-free survival probability (or",
        "label": 0
    },
    "170": {
        "output": "### Input\n\nTo evaluate the factor of eligibility in the patient note, we first create a data structure as follows:\n\n      input:\n               patient: an Iris, # patient note\n                t: a Iris # trial\n                criteria : a tuple, # factor to meet\n                c1=2/20/20\n                c2 = 2/ 10#20\n                c3 = {\"yes\" :1,\"no\":0} , # variable used in the test\n                #c1=1;\n                # c2 = 1;\n                # c3 ={1:1};\n                c4 = \"criteria\", # variable used in the test\n                         #c4=1;\n                criteria = (t,0), # the factor of each case, # and we can write this tuple with two Irises, e.g., criteria = (patient, trial)\n                     #or criteria = (criteria1_factor, trial)\n                # or criteris = (criteria1_factor, criteria2_factor)\n                criterias = (t,criteria), # it is Iris and tuple together\n                # or we can write it by Irises and tuples, e.g., criteria = (patient, t),\n                # criteria = (t, criteria),\n                 criteria = (patient, t,criteria);\n              # if criteria = (patient, t, )\n              # criteria = (patient, t, criteria1_factor), criteria2_factor\n                # criteria = (t,patient, criteria1_factor), criteria2_factor\n\nTo create the variable of eligibility for the clinical trial from the data above, there are the next steps:\n\n1. Creating the criteria of eligibility\n2. Evaluating the factor of eligibility and assigning the level for the criteria, e.g., 0 for excluded; 1 for not relevant; and 2 for eligible\n3. Using the tuple `i` to print out the eligibility for the clinical trial, e.g., `#criteria2 = 1`. \n4. Evaluating the factor by making a vector of tuples by combining all cases of the trial and their level assigned, e.g., `",
        "label": 1
    },
    "171": {
        "output": "## Tests ## ClinicalTrials: Example of test\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. This script will generate a report for your trial, the results of which can be used to improve the quality of clinical trial recruitment.\n\nHere is the clinical trial: \n\n`Example of test:\n    Title: Clinical trial\n    Study start month and year: January 2000\n    Study end month and year: December 2099\n    Study site: [MSKCC]\n    Aim: [2) Excluded]\n    Population: 45-year-old postmenopausal women\n    Inclusion criteria: 2) Eligible}\n`[ELIGIBILITY] {2) Eligible}\nIf you want to run the example of test, run the following code.\n\n`R> my_trial <- clinicaltrials_data %>% filter(&_trial == 42) my_trial %>% \n  map(mutate(`Trial-level eligibility`, eligibility = 0, \n    map(as.list, .x, .y = 1:n()) %>% \n      map_chr(~c(0, 1, 2)),~paste(.y, \" of\", .y, \",\", .x))) %>% \n  mutate(`Trial-level eligibility`, eligibility = lapply(as_list(as_factor(eligibility)), as_chr)) %>% \n  select(trial = _trial, study_start_month = _study_start_month, study_end_month = _study_end_month, Study_site = _study_site, aim = _aim, Study_population = _study_population, Inclusion_criteria = _Inclusion_criteria) %>%\n  ungroup()) %>% \n  left_join(data.table::flip.data.frame(clinicaltrials_data$Clinical_trial_type, clinicaltrials_data$Inc_location), by = .) %>% \n  tidyr::unnest(col = c(\"Clinical_trial_type\"",
        "label": 0
    },
    "172": {
        "output": "[EXP] We now describe an example of a patient data table. \n\n|Patient| Trial-level Eligibility|\n\n|10001||2) Eligible|\n|10002||1) Not relevant|\n|10003||2) Eligible|\n|10004||1) Not relevant|\n|10005||1) Not relevant|\n\nAll five patients are eligible. The patient with the last name `Zoe` and the code `10005` does not suffer from a disease or cannot participate in a clinical study.\n\n[END]\n\n### Step 20\n\n[SCO] Let's summarize the main results of the workshop. Go from one column to another, and click 'Add'. If necessary, type in the results of the study, by clicking `Add` and filling out the form. \n\n|SCO| A patient with a cytologically confirmed breast cancer|\n|  |A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.|\n|  |The tumor is  HER2-positive and ER/PR negative.|\n|  |Axillary sampling revealed 5 positive lymph nodes.|\n|  |CXR was remarkable for metastatic lesions.|\n|  |The patient is using multivitamins and iron supplements.|\n|  |She does not smoke or consume alcohol.|\n|  |She is not sexually active and has no children.|\n|  |She is a candidate for tumor resection and agrees to do so prior to chemotherapy.|\n|  |Title: Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Marker in Breast Cancer Treated by Neo Adjuvant Chemotherapy|\n|  |Inclusion criteria: inclusion criteria|\n|  |Signed informed consent|\n|  |Social security coverage|\n|  |Age between 18 and 80 years|\n|  |Histologically proven breast cancer, regardless of",
        "label": 1
    },
    "173": {
        "output": "### 0: Excluded\n\nIt shows that the patient does not satisfy the inclusion criteria. The trial does not mention the treatment of cancer. She could not take drugs, not sexually active, and has no children. But, due to the presence of menopause, the disease has progressed.\n\n- age: [`1st: Less than 45 Years (Excluded)`] & [`.and. 45 Years or Greater (Not relevant)`]\n- gender: [`Female (Excluded)`] & [`Male or Gender not stated`]\n- tumor: [`Cancer (Excluded)`] & [`Cancer`]\n- HER2: [`Positive (Excluded)`] & [`Negative or Undetected`]\n- HR: [`Positive`] & [`Negative or Undetected`]\n- cancer stage: [`Advanced Cancer`] & [`Amenable to Radiotherapy or Curative Surgery`]\n- metastasis: [`No`] & [`Yes`]\n- location: [`Head and Neck Cancer`] & [`Non-Head and Neck Cancer`]\n- drug: [`None`] & [`Any drug`]\n- active smoker: [`Yes`] & [`No`]\n- alcohol drinker: [`Yes`] & [`No`]\n- sexually active: [`No`] & [`Yes`]\n- children: [`No`] & [`Yes`]\n- postmenopause: [`Yes`] & [`No`]\n- lymph nodes: [`0`] & [`Present or History of Metastasis`]\n- HER2-positive breast cancer: [`Yes`] & [`No`]\n- cytologically confirmed: [`Yes`] & [`No`]\n- invasive ductal: [`Yes`] & [`No`]\n- 3 cm: [`No`] & [`Yes`]\n- left upper outer quadrant: [`Yes`] & [`No`]\n- core biopsy: [`Yes`] & [`No`]\n- positive lymph nodes: [`Yes`] & [`No`]\n- CXR: [`Present or History of Metastasis`] &",
        "label": 0
    },
    "174": {
        "output": "Criteria that must be satisfied to pass the trial-level eligibility, e.g.,\n`Trial-level eligibility: 2) Eligible.`\n\n\n\nThe following diagram shows the overall flow of patient selection.\n![](/img/img_530.png)\n\n\nThe following diagram shows the overall flow of patient selection.\n![](/img/img_531.png)\n\n\nIn this section, we will show you how to print out the trial-level eligibility with `print_trial_level_eligibility`.\n\n\n### Print Trial-level Eligibility\n\n```\nprint_trial_level_eligibility -t patient_id -e Patient_Full_name Patient_Full_age -c trial_id\n```\n    -t: patient id of the current patient\n    -e: patient's e-mail address of the current patient\n    -c: clinical trial id of the current trial\nThe patient's name and age can be easily modified, however, there is no need to modify `patient_id` by yourself since it is automatically generated, and `trial_id` may be changed by the administrator. \nAfter the command is submitted, here is the output of the clinical trial-level eligibility.\n![](/img/img_532.png)\n\n\n\nAfter the 2 steps are finished, we can see the trial-level eligibility in the upper right corner of the screen.\n![](/img/img_533.png)\n\n\n### Print Trial-level Eligibility and Coding Time\n\n```\n\nprint_trial_level_eligibility -t patient_id -e Patient_Full_name Patient_Full_age -t trial_id -i start -i end -u user -g group\n```\n    -t: patient id of the current patient\n    -e: patient's e-mail address of the current patient\n    -t trial_id: clinical trial id of the current trial\n    -i: start time of coding\n    -i end: end time of coding\n    -u: researcher id of the researcher who performed the coding\n    -g: researcher group id",
        "label": 2
    },
    "175": {
        "output": "This is your completed checklist. (You could save this file under a unique name, e.g., solve_1.txt, instead of solve_1.RMD.)\nIn the next task, we will learn how to perform a simple sanity check of the input checklists we had so far. [INST]\n\n## [CHECK] sanity check\nBefore a new feature or system gets released, we need to check how the system will behave when the checklist input has any missing entries. Specifically, we would like to validate the following cases:\n\n### Case 1 -checklist with any missing data\n\n### Case 2 -checklist has data in wrong format\n\n### Case 3 -checklist inputs have unexpected types\nI want to know how the system behaves in the presence of these three situations.\nThere are three ways to perform a sanity check. You can choose one or more suitable ways for your use case. Note that these three use cases are not a must to pass the assignment.\n\n## Solution 1 -Validate on a real problem\n\nAssume we have a few clinical trial patients who will be enrolled into the trial, and we would like to check how the checklist system performs once their checklists are used.\nAs the first task of this solution, you are expected to develop an executable test program that generates the clinical trial checklist according to the rules. It will validate all the three sanity checkcases mentioned above.\nIn addition, you are also expected to submit an RMarkdown document that contains this executable test program as well as any comments that explains how to use\nLet's see two examples to show how to generate a realistic checklist data.\n#### Example 1 #### \nThis example first generates a clinical trial checklist data, which includes both a trial clinical trial checklist and a clinical trial checklist. Each clinical trial checklist has 11 questions, and a clinical trial checklist has 6 questions.\nWe will use `ct_data.R` to generate the example checklist data based on `ct_checklists` object. We can also generate 10,000 unique clinical trial checklist data using `ct_data.Rmd` RMarkdown document.\nWe can use `printDetailedChecklist` to print the detailed checklist data. It is a useful function",
        "label": 0
    },
    "176": {
        "output": "Data sets downloaded for the demo  and `trial_name_from_IDs` for the examples.\nNote that you can choose any set of characters to separate the trial names, e.g., comma and space (this is the one in trial_set.csv), but you must use only one character, e.g., a comma, to separate the lines in trial_name_from_ids.csv. In addition, be careful not to skip the trailing comma! \nFor instance, the trial set contains 19 entries, and the list of trial names looks something like that: \n`",
        "label": 0
    },
    "177": {
        "output": "Let's see some sample trial_level eligible reports. \n# <NAME>; eligible; 2; 3; 0\n# <NAME>; eligible; 2; 1; 0\n# <NAME>; eligible; 1; NA; 2\n# <NAME>; eligible; 2; 0; 1\nLet's check the correctness of the clinical trial recruitment report, and also get rid of the patients listed in 'Not relevant' or 'Excluded group' columns. It may happen that the subject in 'Not relevant' or 'Excluded group' is not an ineligible subject but the subject who does have insufficient information to perform the final eligibility determination. To address this, we can also add a note.\n# <NAME>; not relevant; 1; 1; 1 156\n# <NAME>; not relevant; 2; 1; 0 535\n\nThe following report shows all the patients who passed the clinical trial eligibility determination. \n# [FINAL_REPORT_DATA] Patient Eligibility Reports\n[Eligibility]\n\n# <NAME>; eligible (2); 2; 2; 2 574\n# <NAME>; eligible (2); 1; 1; 1 105\n```\n\n### `Eligible (2)`\nThe following sub-class eligibles of the eligible patient will be generated by eligibility determination report.\n\n- Patients with clinical trial eligibility code `NA (not applicable)` are eligible but do not have sufficient information to evaluate eligibility of this trial.\n- Patients with clinical trial eligibility code `NA` are not eligible for this trial.\n- Patients with clinical trial eligibility code `0` are eligible for this trial.\n- Patient with clinical trial eligibility code `0` are not eligible for this trial.\n\nLet's check the patients listed in each eligible group. Then, we will summarise all eligible patients in one report.\n\n```julia> p = patient(\"DONO-SHER2CT20",
        "label": 2
    },
    "178": {
        "output": "<EOD> An In Vivo Study on Effects of Electroacupuncture at Taichong Acupoint of the Feet on Serum GH and PRL Levels in Rats\n\nAim. e aim of the study was to determine changes in serum growth hormone (GH) and prolactin (PRL) levels in rats by electroacupuncture at Taichong (LR3) acupoint of the foot. Methods. 60 Wistar rats were randomly divided into the control group, single electroacupuncture group, and 1 h after electroacupuncture group. e electrical stimulation in the Taichong (LR3) acupoint of the feet was achieved by applying the frequency of 2 Hz, 2 mA/20 min per day for 12 days. Serum was collected after the last intervention. Serum GH and PRL levels were determined using enzyme-linked immunosorbent assay kits (ELISA kit). e results were statistically processed. Results. Compared with the control group, the serum GH, PRL, and PRL/GH levels in the single electroacupuncture group increased significantly, and the difference was statistically significant (P < 0.05). Compared with the single electroacupuncture group, serum GH and PRL levels of the rats decreased significantly. However, no significant changes in the PRL/GH ratio occurred after 1 h of electroacupuncture (P > 0.05). Conclusion. Electroacupuncture stimulation of the Taichong (LR3) acupoints significantly increased serum GH and PRL levels in the rats. erefore, the Taichong (LR3) acupoint can be used in the treatment of somatopropagation-related diseases.\n\n# Introduction\nAcupuncture and moxibustion are the major medical techniques in traditional Chinese medicine (TCM), which have been used to treat various diseases in China for nearly 3,000 years. Acupuncture originated during the Warring States Period (475-221 B.C.) (4), and moxibustion is believed to have originated in the Han D",
        "label": 0
    },
    "179": {
        "output": "Exercise 1: Practice the previous steps and try this time to evaluate your patient's eligibility for a trial in which a 12-week physical activity program is being offered in addition to standard clinical care for breast cancer survivors starting treatment for recurrent prostate cancer.\nThe physical activity (PEX) trial will include 150 patients. All the patients in the trial can continue prescribed androgen deprivation therapy (ADT) during the 12 months PEX program. Adverse events will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), 4.0. The patients will be asked to continue with their usual physical activity as much as possible. The intervention is based on the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors: a total of 10 000 kcal in 12 months (~37 kcal/kg per week), 150 minutes of aerobic exercise per week. Aerobic exercise will be performed by walking and other activities such as cycling, swimming, and jogging. There will be 26 weeks of supervised aerobic exercise. During the first 6 supervised weeks the patients will start 50 minutes sessions of light aerobic exercise 3 times per week. During weeks 7-20 the patients will be asked to continue with light aerobic exercise 3 times per week. During weeks 21-26 the patients will start vigorous aerobic exercise 3 times per week and will continue with it in weeks 27-52. During weeks 2-6 the patients  will visit the physical activity center 5 times (once per week). During weeks 7-20 the patients will visit the physical activity center 3 times (repeated twice per week) and during weeks 21-52 the patients will visit the physical activity center twice per week. Strength training will be performed 3 times per week. During weeks 7-12 the patients will train 1 set of muscle groups once per week. During weeks 14-27 the patients will train 2 muscle groups at once and during weeks the patients will train 3 muscle groups at once (total of 15 seconds in each muscle group). Res",
        "label": 0
    },
    "180": {
        "output": "Explanation: The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). The assessment of eligibility is the sum of Clinical-level eligibility and Trial-level eligibility. Here, Trial-level eligibility is 2, and Clinical-level eligibility is 0. The value of Trial-level eligibility is 0 if all conditions are met in the clinical trial. For example, if the patient does not meet all of the trial's inclusion criteria and the patient has a condition that falls under exclusion criteria then the patient cannot be enrolled into the trial; thus, the Trial-level eligibility is in 0. \nSo, you should check whether the patient is eligibile or not. If the patient is excluded, please set the value of Trial-level eligibility as 0. If the patient is eligible, please set the value of Trial-level eligibility as 1. Please refer to the [fig_ref]  Table below: Please refer to the table below [/fig_ref]  below for reference.\n[table]  Table below: Please refer to the table below.The values of Multi-level eligibility are saved to the Trial Eligibility record in the Eligibility table. [/table] \n<EOD> Enamel hypersensitivity management with an acid desensitizing agent containing a polyacrylic acid and sodium trimetaphosphate.\nThis study was carried out to compare the short-term efficacy of an acidophilus dentifrice containing calcium sodium phosphosilicate (CPP-ACP), an acid desensitizing agent (ADA) containing calcium phosphate and an acidophilus dentifrice containing calcium sodium phosphosilicate in the treatment of dentine hypersensitivity. Forty-eight intact third molars were selected, the crowns of which were prepared to create cervical dentine hypersensitivity (one enamel cavity and at least one dentine",
        "label": 2
    },
    "181": {
        "output": "<EOD> .\nThe paper presents the results of examinations of the activity of lysosomal hydrolases (beta-glucuronidase, N-acetyl-glucosaminidase) and gamma glutamyl transferase of human blood leukocytes in 88 patients with chronic renal failure (CRF) as well as in 9 volunteer blood donors. It was revealed that the blood leukocytes in renal failure patients showed significantly higher activity of all three enzymes under study (beta-glucuronidase, glucosaminidase and gamma-glutamyl transpeptidase) which indicates a significant dysfunction of the lysosomal apparatus.<EOD> Gender and Health Risk: Insights into Male Bodies and Health Losses Gender and Health Risk: Insights into Male Bodies and Health Losses Ann Berrill (ed.) Routledge London and New York 240 pp. \u00a318.99/\u20ac26.99 2750043102 .\nThis volume is the product of a 1996 workshop organised by Ann Berrill, with the intention of bringing together work on masculinity and men's social experience with theorisation and research on men's health and risk. In this volume are set out the findings and discussion from twenty-seven papers (seven of which are commentaries), which explore a range of issues related to the ways in which gender/gender roles and socially defined roles influence health and wellbeing.<EOD> Disease patterns in patients with neoplasia in Ibadan, Nigeria\n\nBackground: Cancer incidence in Nigeria is higher than that reported in developed countries. While data on various sites of neoplasia is available there is dearth of information regarding prevalence of co-morbidities in neoplastic patients in a tertiary hospital in Nigeria. Methods: A prospective, longitudinal study was conducted with 451 patients with neoplasia (284 men and 167 women) with an age range of 4 to 88 years, mean age 54.3 \u00b1 2.5 (mean \u00b1 SEM). The patients had their demographic data",
        "label": 2
    },
    "182": {
        "output": "*If you are still on this page, then you",
        "label": 2
    },
    "183": {
        "output": "[/CODE]\n\nPlease note that you should use an external package in R to process the data in the next subchapter.\n\nThe following code chunk shows how to get trial information from [inst] via the `data()` function call. We use the `tbind()` function to get the clinical results on the same level as the patients' patient note, i.e., the trial information is aggregated to each patient. The data frame is named `p` and is used as the dependent variable in the next steps.\n\n    t <- data.frame( Trial-level eligibility: `2` )\n    tbind( [data] = p, [variables] = Trial-level eligibility = \"t\") \n\nIn the next step, we use the function [summary] to get the number of patients on [t] who were either `Excluded` (`0`) or `Eligible` (`2`). The result is stored in the data frame named `trial` and has a data type of `integer`. The row sum is the total number of patients across all clinical studies.\n\n    trial <- [summary(t, Trial-level eligibility= c(`Excluded`, \"0\") ,`Eligible`, \"2`), by = \"Trial-level eligibility\"]\n\nNow that we finished with R, let's get the second step into the coding.\n\nIn the second step, we want to identify whether the patient is excluded by exclusion criteria or not. We will use Python to do this. Let's assume we have a dict where key and value means [patient index, Trial-level eligibility]. For example, {3, 2} means the third patient is eligible, and the second patient is excluded. In this process, we also need to count the number of patients that were excluded and not eligible. This means that it is easier to count after it is grouped with [sum] as we need.\n\n    count = dict( list ({'0': ['Trial-level eligibility: 1'], '1': ['Trial-level eligibility: 1'], '2': ['Trial-level eligibility: 2']}) )\n    \n    count['0'] += data.frame( Trial-level eligibility: 1",
        "label": 0
    },
    "184": {
        "output": "## Good Luck! If you have any question, please don't hesitate to send a mail to [INSERT E-MAIL].\nYou will find your output results in your project directory at the end of each project. You will see eligibility assessments saved as pickle (file suffix .pickle) files (with .csv extension but the contents of the .pickle file are in a .csv format). \nBefore going to the final submission, it is important to check the output results for accuracy.\nYou will need to modify your resume before you upload it. In the job description and the resume, you must state the following five keywords: 'PET, residual cancer burden score, MDA, eligibility, and Phase II study.\n\n# Conclusion\nWe are now living in the era of the sharing of the information. This kind of projects are being designed with openness and this can be used to make better clinical decisions. To apply these project-based learning cases, this software package, \"Sankya\" provides an efficient way of project-based learning by means of real applications.\nI would like to thank all my students with their hardworking, their patience for this software package. In the future, I hope many people to study the same topic in future with different groups or different research questions in the same topic. I would like to thank all the staff who has supported us. The development of this software package has been possible by the work of many staff from different areas such as computing lab, laboratory facilities, finance, accounting, administration, legal, the IT industry, universities and so on.\nI would like to thank Dr. Didem Karata\u015f\u0131 with her valuable discussions. I would like to thank all my colleagues and all my staffs who have supported me.\n\n## Software requirements: * hardware\nUSB keyboard, mouse, computer monitor\n\n## Installation of sankya:\nYou can obtain the source code for Sankya Software from the following link:\n\n## Downloading the software from the git site\nIn this tutorial, we'll talk about how to set up, install, and run Sankya software on your Linux laptop. After this section, you will have successfully installed and ran Sankya software on your laptop for future usages.\n\n## Running the software:\nIn this section, we will go through the process",
        "label": 0
    },
    "185": {
        "output": "### Instructions for patient eligibility determination\n\nDetermine patient eligibility using the table below.\n\n#### NOTE\n\nFor each patient, you should report the final response for the patient in the table below (Eligible, Not relevant, Excluded). The table is divided into three columns for three different types of trial.\n\n![NOTE] (Source: [https://github.com/deep-learn/deeplearn-demo/blob/master/data/10187_patient_eligibility_determination/patient_eligibility_determination.japaneg.ipynb])\n\n```\nEligible\nNot relevant\nExcluded\nTrial-0:\nTrial-1:\nTrial-2:\n```\n\n#### Inputs\n\nThe patient note and",
        "label": 0
    },
    "186": {
        "output": "Ask for feedback.\nHints<EOD> Injectable thermosensitive hydrogels for nucleus pulposus tissue engineering applications\nNucleus pulposus, the central portion of intervertebral discs, is a unique avascular tissue with a well-defined structural organisation. Many pathological processes of disc degenerative diseases are associated with a loss of its physiological cellular organisation, which plays a central role in mediating intervertebral disc (IVD) function through maintenance of disc height and integrity of the annulus fibrosus. Numerous nucleus pulposus cell types have been isolated and cultured in monolayer or using scaffolds as a matrix, however, the in vitro environment does not closely mimic the highly structured and matrix-rich native disc environment. Biodegradable thermosensitive hydrogels are being intensively investigated as novel delivery vehicles for in situ formation of a 3D cell culture matrix. Cell encapsulation within thermosensitive hydrogels has some unique advantages including: (1) uniform cell distribution, (2) controlled cell growth, (3) controlled degradation and (4) no immune or inflammatory response. Therefore, we review recent advances in the development of thermosensitive hydrogels with the ability to modulate their degradation, mechanical and physical properties for tissue engineering applications to support nucleus pulposus regeneration.<EOD> Fibroblast growth factor promotes neocortical differentiation in vitro: Evidence for the developmental antagonistic role of Shh expression\nWe investigated how fibroblast growth factor (FGF) promoted neocortical differentiation in our in vitro culture system. We found that addition of an FGF antagonist, recombinant chick FGF-2 or inhibiting soluble FGF antagonists attenuated neuronal differentiation induced by cAMP, but not that by Shh, suggesting that FGF antagonized cAMP-induced neuronal induction in the preplate in vivo, possibly by counteracting BMP inhibitors. Although the addition of an FGF neutralizing antibody or FGF inhibitors to cAMP-induced medium at",
        "label": 0
    },
    "187": {
        "output": "Your task is to determine the patient's eligibility based on the information in the patient note and the clinical trial that you are provided.\n\nThis information comes from the clinical trial data base ClinicalTrials.gov. You should use this website to search all the applicable trials based on your provided information. It can provide you the eligibility criteria associated with the trial. ClinicalTrials.gov is the largest, most comprehensive information on clinical trials. There you can find both the trial summary with its inclusion and exclusion criteria, and the actual detailed protocol with these data. The protocol describes in detail the interventions, the participants, their outcomes, the procedures, and the safety issues, so you will know every tiny detail of the actual clinical trial. For each trial you should determine the patient's eligibility based on trial-level criteria (e.g., `Exclusion: Metastatic carcinoma to the visceral organ or extra skeletal muscles`).\n\n# Assessment Instruction\nYou might consider using [Google Sheets](http://www.google.com/spreadsheets/installer.html).\n\n## Submission\nOnce you have performed the tasks, please click Submit, and submit one workbook containing the patient's evaluation.\nUse the patient case as the first sheet (e.g., Subject_eligibility), and provide the results in the other sheets (e.g., eligibility 1--2--3, and eligibility 0--not relevant--).\nIf you need to explain your choices, or discuss your results, please add it in the Subject_eligibility worksheet.\nIf you need to explain your choices, or discuss your results, please add it in the Subject_eligibility worksheet. Also it is possible to upload multiple worksheets to CBMS (CBMS supports multiple worksheets). You can also use [Google Sheets](http://www.google.com/spreadsheets/installer.html). If you do so, then please upload [two worksheets](http://google.com/spreadsheets/download/instructions#two_file_systems): \n\n1. Submit the patient evaluation file in CSV format. Remember to set it to use the UTF-8 as the encoding.\n2. Upload your",
        "label": 0
    },
    "188": {
        "output": "<br>See the [tutorial][1] for your convenience as an example.\n\n\n[1]: ../inst/tutorials/clinical trial.html\n<EOD> .\nThis article presents a review of the published literature and our experience over the past year concerning heparin-induced thrombocytopenia (HIT). The article provides updated information on incidence, pathogenesis, and diagnostic and therapeutic aspects of HIT. It pays special attention to the problem of \"serious\" or \"life-threatening\" thrombocytopenia caused by unfractionated heparin (UH), which is often encountered in current practice. A retrospective analysis of 30 patients, who received subcutaneous injections for at least one day of UH due to HIT, showed that 90% of these patients had HIT, and 10% had not developed HIT, as confirmed by laboratory studies, during the hospital stay. Thrombocytopenia observed in the latter patients had a different cause, and it did not require any urgent treatment. The incidence of life-threatening thrombocytopenia caused by long-term injections of UH in HIT has been previously underestimated, and can now be more appropriately estimated on the basis of actual observations. The diagnosis of thrombocytopenia caused by long-term injections of UH in HIT can be verified by the 14C-serotonin platelet aggregation method, which requires the least amount of time and expertise.<EOD> A model for the evolution of spermatogenesis\nOne reason why spermatogenesis has remained impervious to the forces of natural selection is the long life span of a healthy genome, which limits the number of opportunities to survive successfully but also to reproduce. Therefore, natural selection only acts on the germline, whereas the somatic and spermatogenesis itself evolve in parallel by a process of neutral, or nearly neutral, gene evolution. The result is that mammalian spermatogenesis, including sperm head and flagellum formation, has remained fundamentally unchanged since the evolutionary divergence of marsupials and placentals, despite the fact that the testis itself has undergone remarkable changes",
        "label": 0
    },
    "189": {
        "output": "We could make a patient-level eligibility by using `patient_level_eligibility(0)`. For example: \n`if patient_level_eligibility(0) == 1: ` #if the patient can participate in the trial print('eligible') else print('not eligible') end `\n\nIn case you want to get the patient-level eligibility of a given patient you just need to add the patient ID by patient() as shown below:\n\nimport pandas as pd \nfrom scipy.stats import rand \ndf = pd.DataFrame(rand(15,3))\n# Create patient records\npatient = pd.DataFrame({ 'ID': [200, 300, 500, 550], 'Sex': ['male', 'male', 'male', 'male'], 'Age': [45, 50, 55, 48], 'Height': [70, 70, 80, 75]), ['ID': [500, 400, 900, 900], 'Sex': ['female', 'female', 'male', 'male'], 'Age': [55, 50, 65, 60], 'Weight': [50, 55, 65, 65], 'Covid19': ['unvaccinated', 'unvaccinated', 'double-vaxxed', 'unvaxxed']}) # Generate a random age age = randint(30,100) print(age) patient = pd.DataFrame(rand(8,3)) patient.head(1) patient.tail(1) .groupby('ID')['Sex'].sum() patient.groupby('ID')['Age'].sum() patient.groupby('ID')['Height'].sum() # Eligibility 1)\nElisa = {'Elisa': ('Covid19', 0.01)}, \nAbort = {'Abort': ('ID', 'Covid19', 0.05),}\nPatient = {'Patient': ('ID', 'Sex', 0.1), 'Age': ('ID', 'Age', 0.2",
        "label": 0
    },
    "190": {
        "output": "### Exercise:\nWrite the code for this patient using the following format, i.e., `patient-name-trial-level-eligibility.txt`.  \n[code]patient-JohnSmith-trial-level-eligibility\nJohn Smith,\n0) Excluded,\n1) Not relevant,\n2) Eligible.\n[/code]\n### Solution: \n### Exercise: Implement this exercise for your given patient in another programming language.  \n[code]patient-John-Smith-trial-level-eligibility\nJohn Smith,\n0) Excluded,\n1) Not relevant,\n2) Eligible.\n[/code] \n\n# Experiment\nThis experiment will show you that you can write the source codes for this section using all the required libraries, packages, and tools, i.e., numpy, spacy, pandas, seaborn, textblob, matplotlib, and JupyterLab.\n-   numpy module has many functions to visualize the output data or the results.\n-   seaborn is a data visualization library.\n-   matplotlib is the primary library for creating scientific figures in Python.\n-   pandas is a flexible data processing library that reads and writes various common data formats.\n\n-   JupyterLab is an interactive and extensible notebook-based workflow environment.\n\n    https://jupyter.org/\n-   TextBlob has several functions, some of which are shown below: \n-   lemmatize is a method that returns the lemma or the base form of a word.\n-   positive is a method that returns positive, neutral or negative assessment.\n-   sentiment_strength is a method that returns value between 0 and 1, where `0.5` represents neutral assessment.\n    https://textblob.readthedocs.io/en/dev/api.html\n\n### Lemmatize a word:\nLemmatization, or morphological analysis, is the reduction of inflectional variants of a word to their base form.\n`word --lemmatize 'John`\nThe above command returns `John`` as base form of `john`.\n\n###  Finds sentiment value of a sentence:\n`TextBlob.sentiment(\"Caff",
        "label": 0
    },
    "191": {
        "output": "Copy all the steps into a file named ____CLINE-TRIAL_ELIGIBILITY.\n\nExample 2:\n\n![][Trial-level eligibility - second trial](Trials and Eligibility Screening for CML - 07-06-2018.pdf#page=13)\n<EOD> Efficacy of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene for predicting diabetes in young adults with impaired fasting glucose\nAims: The aim of our study was to observe the efficacy of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPAR-&gt;) gene with regard to predicting the incidence of diabetes and its risk factors in a young Iranian population with impaired fasting glucose (IFG). Methods: This prospective cohort study was conducted on first-degree relatives of type 2 diabetes patients. The studied subjects were divided into three groups (diabetic, IFG, and normal) according to their 2-h post-load glucose (2hPG) levels. Results: The median age of the study population was 25 years. No significant difference was found in the genotype distribution of the Pro12Ala polymorphism between the three groups. However, the frequencies of the Ala/Ala homozygotes and mutant AA genotype were significantly higher than those of the AA wild type in patients with IFG as compared with normal subjects. Conclusion: This study suggests that the PPAR-&gt; Pro12Ala polymorphism is associated with IFG. However, the polymorphism does not play a role in the prevalence of diabetes in IFG patients.<EOD> Repositioning biologics: new applications for established therapeutics.\nPURPOSE/OBJECTIVES\nTo review a new role for established biologics in treatment of dermatologic diseases.\n\n\nDATA SOURCES\nPeer-reviewed publications and online product information for selected biologics as well as Food and Drug Administration (FDA) and European Medicines Agency websites.\n\n\nDATA SY",
        "label": 1
    },
    "192": {
        "output": "In general, a patient is eligible for the trial if she has a non-zero trial eligibility score.<EOD> Transcription of the bovine adenosine deaminase gene in liver is downregulated by dietary cobalt\nBenzonizomib, a proteasome inhibitor, can be used as a model of neurodegeneration. Cobalt, a chemical that mimics hypoxia, was added to the food of 7-wk-old Swiss Webster mice in order to create a model of chronic hypoxia. Cobalt treatment decreased body weight, but also impaired motor activity in mice, whereas motor activity in mice treated with benzonizomib (5 mg/kg for 1 wk) remained unaltered. Neurons in cobalt- and benzonizomib-treated mice showed less immunoreactivities for myelinated axons compared with untreated (controls) and vehicle-treated mice, although no change of expression of myelin-associated proteins, neurofilaments, MAP-M4, and synaptophysin were detected among the 4 groups. Cobalt- and benzonizomib-treated mice showed increased reactive astrocytes in the hippocampus, but not in the cerebellum. A decrease in the number of ChAT- and ChAT/ChAT mRNA-immunoreactive profiles together with a decrease in number of striatal cells labeled with a 5-HT2C antiserum were observed in the cobalt-treated group. Cobalt treatment also decreased the number of striatal cells labeled with the neuropeptide antisera cholecystokinin and calbindin C as well as the number of neurons expressing calbindin D-28k and neurogenic protein (NGP). Treatment of rats with cobalt in the food did not alter the level of expression of the calcium/calmodulin-dependent protein kinase II (CaMPKII) and neurogranin either in the hippocampus or striatum. The data suggest that cobalt treatment leads to axonal degeneration, myelination deregulation, neuro",
        "label": 2
    },
    "193": {
        "output": "<EOD> The Role of the Cytoskeleton During Cell Wall Synthesis and Remodeling in Rhodobacter sphaeroides\nThe prokaryotic cytoskeleton is composed of a protein matrix that is bound to the cell membrane (inner membrane in Gram-negative bacteria and cell wall in Gram-positive bacteria). The dynamic role played by the cytoskeleton during cell division, cell growth and cell separation has been intensively studied in Gram-positive bacteria. However, the protein components and architecture of this structure are still unknown in bacteria, especially in Gram-negative organisms. Here, we compare the cytoskeleton of Gram-positive bacteria, Gram-negative bacteria carrying a peptidoglycan cell wall (PEC) or a second inner membrane (IM), and Rhodobacter sphaeroides that presents an additional peptidoglycan membrane (PPM) structure. We further assess its dynamics and impact in cell division, cell growth, and cell separation in R. sphaeroides. First, we showed that R. sphaeroides proteins PopA, PopF, and FtsZ are required for cell growth and cell division in PEC organisms but not in IM or PPM bacteria. FtsZ forms dynamic structures during growth in R. sphaeroides that eventually concentrate on the division site in dividing cells. These events are independent from the IM structure. Second, we focused our study on the cytoskeleton of IM, PEC, and PPM organisms. We demonstrated that the cytoskeletal proteins FtsAF, PodJ, and MreB1 are ubiquitous to the three structures. Interestingly, we showed that the presence of a C-terminal signal sequence is not a conserved feature of the protein component of the cytoskeleton. Indeed, we show that PodJ and MreB1 proteins present a second N-terminal transmembrane domain for these two Gram-positive bacteria, Enterococcus faecalis and Deinococcus radiodurans that do not possess this characteristic. Finally, we report that PopA, PodJ, and MreB1 are required for cell separation in R. sphaeroides.<EOD> An Efficient Synthesis of",
        "label": 0
    },
    "194": {
        "output": "# D.3.1.1.3. Example_1\n[NAME] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n[NAME] Dear participants, We hope you enjoy the clinical research workshop! You learned so much already, and we are excited that new opportunities will continue to arise for you.\nIf you are interested in further clinical trial-related information, check out https://trialshero.org/!\nThank you, we hope you are inspired to further your clinical research work.\n[/D.3.1.1.3]\n\n# Appendix A. Clinical trial-related materials\n<EOD> Surgical considerations for the use of the intracoronary stent: an in vitro evaluation.\nThe intracoronary Palmaz stent is currently used for the relief of anginal symptoms and/or the prevention of myocardial infarction in patients with single vessel coronary artery disease. Its placement also may improve flow distal to significant vessel stenoses in some patients to improve their survival and to prevent infarction. Improved flow distal to a stenosis may have a short period of survival advantage for the coronary circulation of a few seconds to minutes. The extent of these benefits of increased coronary artery flow following stent deployment has been shown to be minimal for some lesion types. In addition, the placement of the intracoronary stent causes a significant degree of plaque disruption within the lesion, which may lead to occlusive debris, thrombus formation, and possible future stenosis in the stent or at the distal end of the stent within the native vessel. Therefore, the placement of the intracoronary stent may be accompanied by the development of intracoronary fibrous plaques within the stent or at its edges, which could cause serious problems as a result of the occlusion of the coronary artery",
        "label": 2
    },
    "195": {
        "output": "Here is the patient's age:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.  Here is the patient's age:\n\n# D4. Proving Patient's Age\nIn D1 and D2, we discussed the eligibility assessment of patients in clinical trials, and in D3. we discussed age-specific restrictions.\nIn D4, we will discuss the age-specific eligibility of patients for clinical trials. First, we will see examples.\n\n# Discussion [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to determine if someone qualifies for a clinical trial. The",
        "label": 0
    },
    "196": {
        "output": "<EOD> Fatal poisoning by ethylene glycol.\nEthylene glycol (C2OH6) is a colorless, odorless, and flavorless liquid which is used in the manufacture of resins, textiles, and plastics. It is also an intermediate product in the manufacture of acetic acid, methanol, and vinyl acetate. The toxicity of this diol was observed first in the late nineteenth century when it was found that it was the inebriating agent used in a popular but highly poisonous brand of German beer.1C2OH6 is easily absorbed through the skin and mucous membranes. It undergoes complete hydrolysis to oxalic acid, calcium oxalate, hydrogen carbonate, and alcohol after entering the blood stream. This causes severe acute renal insufficiency and even death. The principal cause of death is renal failure, but cerebral edema or convulsions also may occur. The clinical effects and the blood and urine concentrations of C2OH6 and its metabolites vary widely with the time from ingestion to the initiation of dehydration and alkalization of the urine and thus may be useful in confirming the diagnosis. 1,2 We now describe a fatal case in which the diagnosis was made by a blood C2OH6 concentration<EOD> Increased Risk of Perinatal and Neonatal Mortality Following Surgical Intervention: A Systematic Review and Meta-analysis.\nBACKGROUND\nThere is a paucity of data assessing the risk of perinatal and neonatal mortality for fetuses and neonates being delivered after major surgical intervention. The aim of this systematic review was to evaluate the risk and type of perinatal and neonatal mortality associated with surgical intervention.\n\n\nMETHODS\nData sources included the following: Cochrane, Medline, PubMed, Embase, CINAHL, and other databases/journals were searched (until June 2017). The following databases were also searched, using the same search terms: the Cochrane Database of Systematic Review, the Database of Abstracts of Reviews of Effects, NICE, and the Health Technology Ass",
        "label": 2
    },
    "197": {
        "output": "- [INST] You can use ``Trial-level eligibility``, or you can use ``Trial eligibility``, a variable like ``# patient not included due to trial-level ineligibility`, or you can use ``# patient for trial inclusion``. \n- Use the trial-level eligibility (or not) with an index, like ``count_index`` or ``trial_index``. The index tells how many eligible patients have been evaluated and how many patients are not eligible, which can show the quality of the data set or give interesting statistics about your trial. \n\n- This template is a first step in clinical trial eligibility. If your application needs a bit more information from the trial report summary or trial protocol, or more than three possible eligibility options, you can easily adjust your data structure and use the function and variable names shown here with your required additional information.\n\n- If you have a different application, your eligibility data structure will differ slightly. However, the above pattern should help you to develop your script. Note that your function name should be `trial_level_eligibility`, not `eligibility_calculation` because of the function name collision, and that you can use the `trial_eligibility_index` as a counting variable, and you can use trial_id instead of clinical_trial_id as a unique ID variable.\n\n\n\n## ACKNOWLEDGEMENT\n- This template was adapted from the clinical trial template for JotForm (https://en.wikipedia.org/wiki/JotForm). \n- Thanks to Kazuhide Mukumoto for his help with the trial structure of JotForm. <EOD> Inhibition of RhoC Signaling via RNA Interference Suppresses Angiogenesis and Tumor Growth of Bladder Cancer\nBackground/Aim: Neoplastic cells often exhibit altered cellular proliferation, migration, and angiogenesis due to uncontrolled Rho family small GTPases (Rho GTPases) signaling pathway activity. We evaluated whether a tumor suppressor, RhoC, is a pivotal molecule in bladder cancer. Materials and Methods: We constructed a stable cell line in",
        "label": 0
    },
    "198": {
        "output": "[INST]\n---\n\n### Examples\n<EOD> Transcriptome-based identification of 9\u2010cis\u2010epoxycarotenoid dioxygenase\u2010homologous genes as the key determinants of carotenoid cleavage in Arabidopsis.\nCarotenoids are critical for the synthesis of various flavors and colors and serve as precursors for the synthesis of phytohormones as well as metabolically essential compounds. Carotenoid cleavage dioxygenases of the 9-cis-ECD (9-cis-epoxycarotenoid dioxygenases) type play pivotal roles in these metabolic activities through their production of carotenoid cleavage products that serve as precursors for a range of specialized metabolites. Here we have integrated metabolic and gene expression profiling for Arabidopsis ecotypes that differ dramatically in their carotenoid contents, and show that expression differences within the two known 9-cis-ECD genes play a significant role in the metabolic differences between these ecotypes. We identify two novel 9-cis-ECD homologs that share high sequence identity with 9-cis-ECD and demonstrate that these new genes are functionally important in carotenoid metabolism in Arabidopsis by reverse genetic analysis. This study demonstrates the possibility of using metabolome\u2010 and transcriptome\u2010based approaches to identify genes of the highly uncharacterized 9-cis-ECD gene family in dicots for analysis of gene function and substrate specificity, in the context of carotenoid metabolism with a focus on carotenoid cleavage activities.<EOD> Changes in 43\u2009K/39\u2009K ratios of a sodium chloride-saturated solution induced by heating: an NMR study\nA solution saturated at ambient conditions with one half NaCl was investigated by means of nuclear magnetic resonance (NMR) spectroscopy to demonstrate the thermal effects induced on the Na+\u2013K+ ion exchange. The experiment was carried out by placing the mixture into a container, by first heating the solution gradually to room temperature, and then monitoring the evolution of the 43\u2009K nuclei over time. When the solution is heated, the water molecules of the salt crystal change",
        "label": 0
    },
    "199": {
        "output": "<EOD> The effect of long-term treatment with carbenicillin on the kidney in children\nAbstract The effect of long-term therapy with car\u2010benicillin on renal function was tested in 25 children by measuring urinary creatinine clearance (Ccr) and excretion of urinary beta\u20102\u2010microglobulin (BMG) before, after an intravenous bolus of 20\u201325 mg carbenicillin/kg body weight, 3.5 and 20 h later, and during subsequent daily treatment with 150\u2013200 mg/kg body weight intravenously in half the cases and 50\u2013 150 mg/kg body weight subcutaneously in the other half. Twenty children were healthy and five had an urinary tract infection. With intravenous treatment BMG excretion rose to more than three times the basal value. There was no change in Ccr. Children in whom BMG excretion was not influenced had a significant increase in Ccr. The urinary excretion of a protein of molecular weight 20,000\u201322,000 was not influenced by the intravenous carbenicillin bolus. With subcutaneous treatment BMG excretion did not increase, and no changes in Ccr were seen.<EOD> Prevalence of chronic kidney disease in patients with gout: analysis of healthcare utilization and medical costs\n\nIntroduction:The prevalence of chronic kidney disease (CKD) among patients with gout is high. It is important to have a better understanding of CKD in patients with gout to guide treatments and reduce economic burden. However, previous studies did not consider healthcare utilization and costs after diagnosis, which limits the understanding of this issue. Furthermore, previous studies included patients with renal insufficiency, who did not meet CKD diagnostic criteria by the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative. This study aimed to compare the healthcare utilization and medical cost between patients with gout with and without CKD in a large population-based sample. Methods: The medical records of patients diagnosed with gout and CKD (n =",
        "label": 0
    },
    "200": {
        "output": "<EOD> A Randomized Controlled Trial of a Nurse-Led, Interactive Education Program Including Real-Time Physiologic Monitoring for Home Total Parenteral Nutrition Patients\nSupplemental Nutrition Assistance Program recipients in two states can qualify to receive home total parenteral nutrition (TPN) care if they are determined to be eligible by the state medical director. To date, the states have not established procedures for patients to be admitted to home TPN care in a systematic and evidence based manner, or established criteria to assess patient readiness. The goal of this intervention was to describe the protocol for and explore the feasibility and acceptability of the educational program, to demonstrate the utility of real-time physiological monitoring devices to promote the nutrition wellness of persons undergoing long-term TPN therapy, and to improve TPN patient health care outcomes. A randomized controlled trial was conducted among pre-selected subjects who had a history of TPN at home. Nurses provided education to patients using a written educational package. At random, a group were assigned to real-time monitoring while the comparison group did not receive real-time monitoring. During TPN administration, 5 patients in the group with real-time monitoring, and 15 patients in the group without it, experienced complications that required correction. There were 3 deaths in the group with real-time monitoring and 10 deaths without it. The group with real-time monitoring was found overall to be significantly healthier.<EOD> Characteristics of the Stereotypes of College Students toward Nursing as a Career\nAs the enrollment of nursing students continues to decrease despite the critical shortage of healthcare workers, it is imperative to identify the misconceptions that students hold about the nursing profession and find ways to address stereotypes which may deter students from choosing the nursing field. The primary objective of this study was to ascertain the stereotypes held by a diverse group of college students toward nursing as a career. The participants, identified according to their ethnocultural background, included 1,110 college students, ages 21 and over (657 female college students and 453 male college students), from six different ethnocultural categories (White, African American, Asian-Pacific",
        "label": 0
    },
    "201": {
        "output": "Your job done! Thanks for participation. \n\n``` bash\n>> In-ClinTrial{PatientNote, ClinTrial}\nTrial-level eligibility:\n0) Excluded.\n1) Not relevant.\n2) Eligible.\n```\n\n<!-- markdown-toc end -->\n<EOD> Transforming growth factor beta1 levels during progression of glomerular diseases.\nTo evaluate the pathogenic role of TGF-beta1 in the pathogenesis of glomerulopathy, we performed urinary TGF-beta1 quantification in kidney biopsy specimens from patients with a variety of diseases. In addition, we compared TGF-beta1 levels of the urine to those of the kidney tissue and serum from patients with IgA nephropathy (n = 10), membranous nephropathy (n = 11), and lupus nephritis (n = 12) to those of the serum from patients with minimal change nephrotic syndrome (n = 8), focal segmental glomerulosclerosis (n = 6), membranous nephropathy (n = 12), or diabetic nephropathy (n = 13). TGF-beta1 levels were analyzed by using an enzyme-linked immunosorbent assay. TGF-beta1 concentrations in the urine were higher in IgA nephropathy and membranous nephropathy patients than in the other diseases. TGF-beta1 levels in the urine were positively correlated with those in the kidney tissue and serum when patients with various diseases were analyzed together. TGF-beta1 levels in the urine and serum decreased after treatment in a lupus nephritis patient and in a diabetic nephropathy patient. In contrast, serum TGF-beta1 levels increased in another diabetic nephropathy patient. These findings suggest that quantification of TGF-beta1 in urine and serum may be useful as a parameter in evaluating TGF-beta1 production in kidney tissue in chronic glomerul",
        "label": 0
    },
    "202": {
        "output": "Now, let's see whether you get the best score when compared with the solution to the previous exercise.\n\nExercise 2 in[INST] Hello. You are a helpful assistant for a Pharma company that produces oral drugs. Based upon your pharmaceutical knowledge, you have to suggest the appropriate drug to help the clinicians increase response rate at one-year. We give you some examples. The Pharma company produces two drugs against different diseases.\n\nHere are your suggestions and the corresponding response rate at one-year:\n\nExercise 2 in[INST] You are a helpful assistant for a Pharma company that produces oral drugs. Based upon your pharmaceutical knowledge, you have to suggest the appropriate drug to help the clinicians. We give you some examples. It is assumed that the Pharma company produces two oral drugs.\nNow, let's see whether you get the best score when compared with the solution to the previous exercise.\n\nExercise 3 in[INST] You are a helpful assistant for a Pharma company. After a successful clinical trial, the company has launched a new chest pain product into the market. Currently, you have to determine the potential factors that could limit the company's sales and market share with the results of the clinical trial.\n\nThe company produced a new pharmaceutical product, and its sales were growing. Recently, one of the clinical trials of the product was released. The trial included 2 268 patients in three age groups. The trial data are as follows:\n\nTable 1 Trial results data by age group\n\nGroup1, 2, 3 (n=744, 758, 761)\n\nAge(years) \n\n60-69 \n\n50-59 \n\n70 and over \nDrug response rate \n\nGroup1 38% \nGroup2 27% \nGroup3 27%\n\nLet's think step by step. \nLet's consider a company that produces an oral drug and sells it worldwide.\nWhenever the trial was performed, the following trial results data were provided by the company's marketing department.\nYou will have all these data as a list of three patients; we",
        "label": 2
    },
    "203": {
        "output": "You have successfully tested the program. You should type \"Quit\" to exit the program. The user who wrote this program is `username_0`. You may try and test the program by using the following keywords on the command line.\n\n`>python try1.py`\n\nTo print the names of the functions in a module, you should type:\n\n`>help`\n\nAnd to call a function inside a file to the program, you must type:\n\n`>import try1`\n\nThis concludes the third chapter on testing, and the third part of the book. If you have any problems with the program or any questions about it, please, send them to the main author of this manual [[email:<EMAIL>]<EMAIL>]`] at <EMAIL>.\n\n[INST] Hello. You are still a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial: \nTitle: Pre Operative Trastuzumab in Operable Breast Cancer\n\n\nSummary: Background Information and Rationale:~Trastuzumab is a",
        "label": 1
    },
    "204": {
        "output": "Let's think step by step.\n\nFirst, we check how many times the cell size number was detected: \n```python\n[12, 13, 14]\n```\nSecond, check `13`, for the first 10 million samples, count the number of \"12\" that appear before it, and after it. \n```python\nfor i in range(10**6):\n    if '13' in data['CellSizes'].tolist()[i]:\n        numbers.append(len([x for x in data['CellsSizes'].iloc[i] if '12' in x]))\n        numbers.append(len([x for x in data['CellsSizes'].iloc[i] if '12' in x]))\n    else:\n        pass;\n```  \nFinally, calculate the average of `12`, `13`, and `14`:\n```python\nvalues = np.array([values in numbers])\nfinal = np.zeros([3])\nfinal = np.average(final, axis = 1)\nwith open('report_sample_1', \"w\", newline=\"\") as f:\n    final.to_csv(f)\n```  \n\nThe report looks like this...  \n<EOD> Correlation of Mini-Mental State Examination scores with CSF/serum albumin ratio in patients with subacute subarachnoid hemorrhage.\nIn order to determine the relationship between Mini-Mental State Examinations (MMSE) scores and cerebrospinal fluid (CSF)/Serum albumin ratio in first seven days of subarachnoid hemorrhage (SAH), 124 patients were evaluated by MMSE on days 2 through 7 and by CSF/Serum albumin ratio at early stage after SAH. MMSE scores differed significantly (P <",
        "label": 0
    },
    "205": {
        "output": "1. Copy-paste the patient note into the console.\n2. Call the function `trial` of the module `clinical_trial`. This function generates a patient note with additional information needed to determine trial eligibility. \n    * The required arguments are `patient_note` and `trial` is the input object of the variable assigned to this function. \n    * We have to provide the input to this function beforehand. We are calling the method `clinical_trial` function as `Trial = cliniical_trial('Breast cancer', 'Ultrasound detection of peripheral IV infiltration');`\n    * The trial note is returned as output.\n        * This output is an object of the module `clinical_trial`, as shown by `Trial` in the code below. \n\n```python\nTirial=cliniical_trial('Breast cancer', ' Ultrasound detection of peripheral IV infiltration');\n```\n5. Assign it to a variable named `Trial` and store this assigned variable, as well as Trial.trial_note, if we require it in the future in a variable. \n6. Find out about the patient eligibility of the study by running the function `trial_eligibility' from inside the module `clinical_trial`. \n7. To output the trial-level evaluation (eligibility), run the function `Trial-level eligibility` on Tirial. \n8. We can print the trial-level eligibility in the console. [INST] \n9. As `Trial`-related objects are saved in memory, we can reuse this object in subsequent functions as well. You can see the entire code of the step below.\n\n```python\nPatient = cliniical_trial('Breast cancer', ' Ultrasound detection of peripheral IV infiltration')\nTrial = cliniical_trial('Endometrial cancer', ' Ultrasound detection of peripheral IV infiltration')\nprint(Trial)\noutput = Trial_eligibility(Trial)\nTrial_eligibility(Trial)\n```\n![](https://user-images.githubusercontent.com/",
        "label": 0
    },
    "206": {
        "output": "In terms of formatting, there are two important guidelines. \nFirst, the name of the clinical trial must appear on the first line where you enter it. \nSecond, you can put each variable on a separate line (also known as flatten), e.g., `Patient note: `, `Inclusion criteria:`. This is also helpful to find a variable name using the variable finder `?variable_name` command.\n\n> ## A: 01-01-2014_07_26\n>\n>> [A1] Start\n>>\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\n\n\n### Trial-level eligibility\n\n> ### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n\n> ### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\nTrial-level eligibility: Eligible.\n\n> ### Trial-level eligibility:\n\n> ### Trial-level eligibility: Eligible.\n>\n> ### Trial-level eligibility:\n\n> ### Trial-level eligibility:",
        "label": 2
    },
    "207": {
        "output": "<a id=\"HDF5-output\"></a>\n### HDF5 output\nIn this section, the HDF5 output is introduced. The code to output the HDF5 file is shown in the following code block with the description in the comments.\n```{python}\nimport numpy as np\n\nimport pandas as pd\nfrom osgeo.gdal import get_driver\nfrom ipytrix.io import io\nfrom pvac.hdf5 import f_write, F\nfrom pvac.hdf5.conventions import Conventions\n\ndf = pd.read_csv(\"patient_note.csv\")\n\npath = '/tmp'\npatients = pd.DataFrame({\n    'Name': ['Sam', 'John'],\n    'Age': [45, 35],\n    'Gender': [1,(1,2),1],\n    'Diagnosis': ['Breast Cancer', 'Hepatitis C'],\n    'Drug': ['Cytologically Confirmed', 'A core Biopsy'],\n    'Tissue': [['invasive ductal breast carcinoma in the left upper outer quadrant', 'breast cancer', 'ductal breast carcinoma'],['hepatitis C', 'breast cancer','hepatitis C']],\n    'Status': ['Surgery', 'Surgery', 'Treatment'],\n})\n\npatients.loc['Sam', 'Diagnosis'] = pd.DataFrame([['cure'],['cure']], index=[0, -1], \n                                    columns= ['Diagnosis', 'Diagnosis', 'Name'])\npatients.loc['Sam', 'Tissue'] = tuple([['a specimen of breast cancer'],['ductal breast carcinoma or breast cancer'],['Sam']])\npatients.loc['Sam', 'Age'] = pd.Series([45] * 5, names=['Gender'])\npatients.loc['Sam', 'Drug'] = tuple([['a cytologically confirmed diagnosis of breast cancer']]) #tuple([['Sam']]))\npatients.loc['Sam', 'Gender'] = 'Male'\npatients.loc['John', 'Gender'] = 'Male'",
        "label": 1
    },
    "208": {
        "output": "Example:\n![INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the trial-level eligibility of the given clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patients meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the trial, i.e., output the scale for the assessment of eligibility for the trial, i.e. `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`.\n\n\n\n\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a\ncandidate for tumor resection and agrees to do so prior to chemotherapy.\n\n[https://www.kaggle.com/datascienceinstitute/datadriven-recruitment-for-clinicaltrials]\n\nThis example can be solved in at least three different ways:\n### [/CODE]\n#!\n\n# Let's implement the first one\n# The first approach to this problem is to determine each patient's eligibility for a given individual trial, then to sum up the results, and finally to repeat the task with other trials. For example, let's use the following Python program for solving the first trial:",
        "label": 0
    },
    "209": {
        "output": "In this problem, you will learn to apply the following python-lib for your final submission: [INST] `pandas`, `os`, `numpy`.\n\nPlease, submit this problem together with your code, which is to be formatted as described in the _style guide_.\n\n## Submitting your assignment\nUpload your files before December 23th at 11:59 p.m CET. \n\n## Rules of conduct\n\nYou do not have to follow the rules. However, please read them anyway. It is important to understand how we work with you and handle your assignments.\n\n**Please don _`t`** plagiarize!**\n\nIf a supervisor suspects that plagiarism is happening, we will consult with a plagiarism specialist at U.S. universities to check the validity of any claims that are made against you.\n\n**Submitting late**\n\nMake sure to allow enough time to perform the assignment. You will lose points for submitting it late. The following table describes how many points you can lose for submitting the assignment as late.\n\n<table>\n  <thead>\n    <th colspan=3 style=\"text-align:center;\">Points</th>\n  </thead>\n  <tbody>\n    <tr style=\"text-align:right;padding-right:10px;\">\n      <td style=\"text-align:left; padding-left:5px;padding-right:20px;\"><code>Assignment late</code></td>\n      <td style=\"background-color: #D6E1C9;padding-left:5px;padding-right:20px;\"><code>1</code></td>\n      <td style=\"text-align:right;\"><code>-2 </code></td>\n    </tr>\n    <tr style=\"text-align:right;padding-right:10px;\">\n      <td style=\"text-align:left; padding-left:5px;padding-right:20px;\"><code>Late</code></td>\n      <td style=\"background-color: #D6E1C9;padding-left:5px;padding-right:20px;\"><code>1</code></td>\n      <",
        "label": 0
    },
    "210": {
        "output": "[fig]  EXERCISE 3.3: Copy the trial-level eligibility assessments. [/fig] \n<EOD> Evaluation and comparison of three commonly used reference genes in potato (Solanum tuberosum L.) plants exposed to two herbicides\nGene expression analysis is one of the most commonly used molecular techniques to evaluate gene responses to biotic and abiotic stresses. Quantitative real-time polymerase chain reaction (qRT-PCR) is a sensitive technique and a well-accepted method for measuring gene expression in plants. However, the accuracy of qRT-PCR-based measurements depends on experimental and methodological protocols. A reference gene whose expression does not change upon the treatment in the target plant is needed to normalize relative expression data. Identification and validation of a stable reference gene within a complex target is a necessary and critical step for accurate relative quantification of gene expression. This study evaluated the expression stability of reference genes in two herbicides-induced potato plants. Three candidate genes, 18S (ribosomal RNA 18S), GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and Tubulin, were used to quantify the expression levels of 11 functional genes, 4 of which are cytochrome P450 and 7 are metabolic enzyme genes related to organophosphate and herbicides detoxification in potato plants treated with glyphosate and paraquat. Stability evaluations based on the expression data of reference genes under different samples were achieved by three quantitative methods (geNorm, NormFinder and RefFinder), by which 18S RNA gave the greatest stability value overall. The most stably expressed reference genes of potato plant treated with glyphosate and paraquat and two herbicides treated together were 18S and Tubulin, and EF1\u03b1 and 18S respectively. The study illustrated that the expression of reference genes was significantly different in potato plant treated with single herbicide and that in potato plant treated with both herbicides. These results indicated an important role of the selection of reference genes during the evaluation of gene expression in the stressed potato plant.<EOD> Re-",
        "label": 2
    },
    "211": {
        "output": "There are 15 sample patients. The dataset is as follows:\npatient ID, first name, age, gender, marital status, race and ethnicity, weight, clinical-stage, histology, histology-grade, site-size, node-statues, lymph-vessel-invasion, neuro-vascular-invasion, adjuvant systemic, metastasis, chemotherapy\nYour job is to predict these outputs by using the dataset, i.e., Trial-Level Eligibility for the clinical trial.\nInput files are prepared based on the clinical trial note/doc. One of the input data files, `data-1-in-clinical-trial.xlsx`, contains all the information about a specific clinical trial, and another one, `data.csv`, contains real clinical trial data about patients that are registered and enrolled in the clinical trial. You should prepare your input file in a similar way by referring to the provided doc/ notes about the clinical trial.\nNote, the dataset from the clinical trial is for the `clinical-trial` clinical trial, i.e., the dataset which you have used the model to predict the Trial-level eligibility. But `clinical-trial_dataset` is for the dataset used for training the model to predict the same Trial-level eligibility.\nTo prepare the input file for `clinical-trial` clinical trial, you need to add an extra two columns to the dataset: `Clinical_trial` for type of clinical trial and the value for each type, respectively, e.g., `clinical-trial` =`1` for each clinical trial, e.g., `clinical_trial_id =1`,`clinical_trial_start_date=1`. \n\nPlease note that there are 15 sample clinical trials to which you can make predictions, i.e., `clinical_trial = 1, 2, \u2026, 15`. Here is the summary of a trial. Let's focus on our data on this one trial and the related datasets for training, validation, and test.\n```\nTrial_id : 1\nTitle : `Tumor vaccine",
        "label": 0
    },
    "212": {
        "output": "---\n\n[INST] Solution for patient report\n\nHere is the list of variables related to the patient report: PatientNote, ClinicalTrialName, CurrentPatient, CurrentTrialInfo, ClinicalTrialInfo, Trial-level eligibility, CurrentPatientNote, CurrentTrialDescription, CurrentPatientExclusionCriteria, CurrentPatientInclusion-Criteria, CurrentClinicalTrialExclusionCriteria, and CurrentClinicalTrialInclusionCriteria.\n\nYou may need the following information to generate a patient note.\n\n\nLet's create the patient note, ClinicalTrialInfo, and current patient \n    patient note1 = sprintf(\"Please note that this is an experimental treatment and you are subject to all risks and problems associated with research protocols. This means that you have voluntarily agreed to allow these tests to be performed on you, and the results of the tests obtained would remain anonymous and be published without your name if it is appropriate. If you have any questions or concerns about the test being performed please call the research team. If you have any questions or would like to discuss the details of this treatment, feel free to contact Dr. Smith at Smith Hospital at number 1232323",
        "label": 0
    },
    "213": {
        "output": "### INST #1\n### Problem 1\nYou may observe that the `if` clause is ignored in the last line of code. How to fix this?\n\n### Solution\nThe problem is that the list is not processed from the second iteration on.\nHere is the code to do the same thing within a `for-loop`:\n\n\n```julia\nTrial-level eligibility = 0\nfor i in 1:n\n    if (i == length(patientNote['patientData']['clinicalStudyNote'].ClinicalTrials.clinicalTrialsNotes[1].clinicalStudyProtocol.exclusionCriteria.exclusionCriteria)\n            && (match(`$patientNote['patientData']['age'],`patientNote[\"patientData\"][\"ClinicalTrials\"].clinicalTrialsNotes[1].clinicalStudyProtocol[\"exclusionCriteria\"].exclusionCriteria, match(\"Age \u2265 80 years\"))))\n        Trial_level_eligibility = '0'\n    end\n    if patientNote[\"data\"][\"patient\"].gender == 'M' && !(patientNote[\"data\"][\"patient\"].age >= 18 && patientNote[\"data\"][\"patient\"].gender == 'M') && !patientNote[\"data\"][\"patient\"].doctype == 'doctor_notes' && !patientNote[\"data\"][\"patient\"].clinicalStatus == 'clinical_status' && !patientNote[\"data\"][\"patientData\"][\"patientBirthDate\"] > (DateTime(year = 1965, day = 1, month = 1)) && !patientNote[\"data\"][\"patientData\"][\"patientAge\"] > (55) && !patientNote[\"data\"][\"patientData\"][\"patientBirthDate\"] > (DateTime(year = 1997, day = 1, month = 1)) && !patientNote[\"data\"][\"patientData\"][\"patientAge\"] < (65) && !patientNote[\"data\"][\"patientData\"][\"patientBirthDate\"] > (DateTime(year = 1990, day = 1,",
        "label": 0
    },
    "214": {
        "output": "_____________________________________________________________________________________________\n\n##[MATH] Hello. You are a helpful assistant for clinical trial eligibility assessment. You are given a triplet of patient note and patient trial with eligibility assessment. You should check the eligibility between each patient and patient trial in all triplet. For example, if the patient's information is the same to the assessment of eligibility of trials, you should assign all the assessment of eligibility of a patient to the assessment of eligibility of the trial.\n\nAssume that there are N patients in the first data set, and each patient is characterized by the patient's clinical diagnosis, sex, age, and so on. The triplet of each patient is generated in the second data set. Thus, the second data set contains N \u00d7 4 triplets consisting of four observations. For example, the triplet (0, 2, 2, 1) means that a patient belongs to the first diagnosis with female and age 60 and patient does not meet the exclusion criteria 1 and 2. In other words, the patient's information is the same to the assessment of eligibility of trials.\n\nHere are a patient note and a patient trial in the first data set:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nThe title of the trial is:\nTrial design The objective of this phase II trial is to evaluate the activity of gemcitabine and docetaxel regimen as first line treatment for ER-negative breast cancer. Patients with cytologically or histologically confirmed ER-tumors with invasive stage II through IV breast cancer will be entered into",
        "label": 1
    },
    "215": {
        "output": "<EOD> Differing effect of ampicillin on E. coli and on B. cereus\nThe in vitro effect of ampicillin was investigated on a clinical isolate of Escherichia coli ATCC 11303 and on a strain of Bacillus cereus. Growth of E. coli was inhibited by ampicillin concentrations between 4 and 8 micrograms per ml. No inhibition was observed for B. cereus, even when high concentrations were used. There was no difference between ampicillin used alone, and penicillin-ampicillin mixture on E. coli.<EOD> The BET inhibitor birabresib affects the expression of cytokines involved in inflammatory response and epithelial\u2013mesenchymal transition and synergizes with bortezomib in Ewing sarcoma cells\nEwing sarcoma (ES) is an aggressive pediatric and adult malignancy lacking effective treatments beyond the first remission. Previous studies have suggested that the use of birabresib (OTX-015), a selective bromodomain and extraterminal domain (BET) inhibitor, suppresses proliferation of a variety of tumor cells, including ES. In this work, we investigated the cellular effects of birabresib in two ES cell lines (EW8 cells, a primary ES cell line, and ES\u2010MNNG cells, an N\u2010nitrosomethylurethane (N\u2010NMU) Ewing sarcoma transgenic cell line) cultured under specific growth conditions and we determined the molecular effects of birabresib administration, in particular with regard to inflammatory response modulation. Birabresib treatment resulted in cell viability impairment, induction of proapoptotic pathways, block of cell cycle in G1\u2010S phase, and induction of cellular differentiation in a time\u2010 and dose\u2010dependent manner. Additionally, in EW8 cells birabresib administration resulted in a significant inhibition of inflammatory cytokines related to hypoxia and tumor microenvironment, such as hypoxia\u2010inducible factor 1\u2010\u03b1 (HIF\u2010",
        "label": 0
    },
    "216": {
        "output": "Here\n\n\nA: You need to define and use [instances variables](https://docs.python.org/3/tutorial/controlflow.html#labels)\nSo you could do something like this to define eligibility variables,\nclass Clinical Trial:\n\n    def __init__(self, name, criteria):\n        self.name = name\n        self.criteria = criteria\n\n    def __repr__(self):\n        return f\"{self} [{(self.name)}] {self.criteria}\"\n\n    def __str__(self):\n        return f\" {str(self.name)}  {str(self.criteria)}\"\n\n    def to_json(self):\n        return {\n            \"name\": str(self.name),\n            \"criteria\": str(self.criteria),\n        }\n\nYou can then create an instance from this object by defining and passing the following variables,\nself = Clinical Trial(\"A name\", (\"Female and Male, aged 18-60\", ))\n\nThen we can then define a class Patient, which could have the following class methods,\nclass Patient:\n\n    def __init__(self, age, gender):\n        self.age = age\n        self.gender = gender\n\n    @classmethod\n    def eligible(self, trial1, criterias, patient_class):\n        trial_name = str(trial1.name)\n        print(f\"Eligible for {trial_name} - criterias: {list(criterias)} patient of age {patient_class()} and gender {str(patient_class())}\")\n\n    @classmethod\n    def not_relevant(self, trial1, criterias, patient_class):\n        print(f\"Not relevant to trial1 and criteria {list(criterias)}\")\n\n    @classmethod\n    def exclude(self, trial1, criterias, patient_class):\n        trial_name = str(trial1.name)\n        print(f\"Exclude from trial1 and criteria {list(criterias)}\")\n\n    @classmethod\n    def relevant(self, trial1, criterias, patient_class):\n        trial_",
        "label": 0
    },
    "217": {
        "output": "In summary,\n\nTo complete this assignment, you should follow the following steps:\n(1) Read the instructions:\n![instruction](../../image/Clinical-Trials_A-1.pdf)\n(2) Access to EvalClinical, and find the given patient eligibility evaluation problem as shown in Figure 1.\nFigure 1: The problem displayed in the evaluation mode of EvalClinical\n(3) Assess the patient's eligibility by entering all required data (as shown in Figure 2). Make your decision for each of the input data following the instructions. Note that, if the patient's information is too long to be displayed in the problem, you may omit some information. \nFigure 2: Patient eligibility evaluation for patient No. 2\n(4) When you finish entering all required data, click `Submit` to go to the problem evaluation results. Note that even if you find the patient eligible, it is still suggested you return to the previous step to check the data input again, to assure all the data is well entered. (You will have the chance to recalculate the patient eligibility if you click the button `Retry`). \n(5) Click the button `Retry` on the assignment. When you click this button, all the data in the table will be reseted to the default values. Note that not all the data is reseted, so you don\u2019t need to perform all the steps you\u2019ve done over again. When you are done with this step, you can go back to the first step.\n\n![Retry](../../image/Clinical-Trials_A-2.pdf)\n\n[/FIN]\n<EOD> The in vitro susceptibility of Neisseria gonorrhoeae isolates displaying beta-lactamase activity against tazobactam (Claforan) to imipenem and other antimicrobial agents\nTo overcome the resistance of strains of Neisseria gonorrhoeae to beta-lactams, we evaluated a combination of imipenem and beta-lactamase inhibitors and compared",
        "label": 2
    },
    "218": {
        "output": "## Exercises\nBefore practicing this section, you might want to watch the videos available in our [Train the Trainers] platform.\n\nThe purpose of this exercise is to illustrate what you already learned in our previous module on the inclusion and exclusion criteria. When you give a clinical trial recommendation to a patient, you have to specify your assessment of the patient's eligibility for a trial, on a scale between 0 and 2, being 0 excluded, 1 not relevant, and 2 eligible.\nThe following is the set of cases:\n\n[SOLUTION]\n\n\n## Influenza\n\nYou are about to visit a patient who has flu symptoms and takes fever medicines to control these symptoms.\n\n**Disease: Influenza**\n\nInfluenza is a viral respiratory infection. Influenza viruses include a variety of strains that mutate constantly. Three strains of influenza virus cause influenza: type A (the most common type), type B, and occasionally type C. About 5% to 10% of influenza infections lead to influenza pneumonia. \n\n\n## Patient details\n\nName: Dr. Sally Smith \n\nAge: 36 years \n\nBirthdate: 3/5/1986 \n\nGender: Female \n\nEthnicity: Caucasoid \n\nOccupation: Radiologist \n\n\n## Symptoms\n\nFever, cough, chills, sweats, headache, myalgia \n\nTreatment History\n\nSally takes influenza vaccine every year. She also takes over-the-counter fever medicines, including acetaminophen 1,000 mg, to control these symptoms.\n\n\n## History\n\nYou learn that Sally was healthy before developing fever and flu symptoms.\n\n\n## Physical Examination\n\nSally\u2019s oral temperature is 37.9\u00b0C. She complains of a sore throat. Her cardiopulmonary examination reveals wheezing in the lungs on bilateral auscultation.\n\n\n## Additional",
        "label": 0
    },
    "219": {
        "output": "## R code\nR code \n\n```r\n# library(parallel) \ntrial_note <- read.delim(\"2016-09-21T17_39_35.6Z -data/trial_note.txt\",sep=\" \\n\",stringsAsFactors=F) \ntrial <- read.delim(\"2016-09-21T17_39_35.6Z -data/clinicaltrial.txt\",sep=\" \\n\",stringsAsFactors=F) \n\npwd() \nsetwd(\"./data/experiment10\") \n\nif (is.null(system.file(\"path\",package=\"multicore\",subdir=\"simulations\")) | !exists(\"path\",package=\"multicore\", subdir=\"simulations\")) { # create simulation directory\n    # add to path\n    if (!exists(\"path\",package=\"multicore\",subdir=\"simulations\")) { \n        create.dir(\"path\",package=\"multicore\",subdir=\"simulations\") \n    }\n    if (!exists(\"path\",package=\"multicore\",subdir=\"simulations\")) { \n        list.files(\"path\",package=\"multicore\",subdir=\"simulations\") \n    }\n} \n\n# create trial-specific list of pathological variables \ntrial_var <- ifelse(substr(.==\"data,\",\"-trial\")==1,\"data/clinicaltrial.txt\",ifelse(substr(.==\"data,\",\"-trials2\")==\"-\"),ifelse(substr(.==\"data,\",\"-trials2\")==\"02\",\"path_data/newtrial.txt\",\"path_data/newtrial.txt\"))\nfor (i in 1:nrow(trial)){\n    trial_var[j] <- paste(\"./data/\", trial_var[j] ,trial[i,]) } # read all the pathologic variables into a local matrix \n\n\n# assign a random number between 0 and 1 \njitter <- sample(1:174) \n\nif(!exists(\".jitter\",path=\"./data\")){ # create .jitter path and .j",
        "label": 2
    },
    "220": {
        "output": "<EOD> TREATMENT OF ENDOTHELIAL DYSFUNCTION IN HYPERCHOLESTEROLAEMIC PATIENTS BY ETANERCEPT UNDER HYPOLIPIDEMIC LOW DOSE SIMVASTATIN EVOLUTION\n1 The aim of the present study was to evaluate the anti\u2010inflammatory effect of etanercept (ETA) administration with statin in hypercholesterolemic patients with mild hypertriglyceridaemia, without statin treatment, with a known history of coronary artery disease and family history of early onset atherosclerosis. 2 The study has been conducted as two independent consecutive double\u2010blinded placebo\u2010controlled randomized studies. In the first trial, 20 patients have been studied. A double\u2010blinded randomized administration (50 mg three times daily in the morning, afternoon and evening) of either ETA or placebo (saline solution) for 28 days was performed. In the second study, 40 patients have been studied. A double\u2010blinded randomized administration (50 mg two times daily in the morning and evening) of either ETA or placebo (saline solution) combined with simvastatin (10 mg daily) was performed. 3 In the first study, no difference was observed in baseline versus day 28 in either group when measured by the endothelial related markers. In the second study, 15 patients in both groups were studied as they had normal serum triglycerides. The remaining 25 patients of the second study had elevated serum triglycerides. Although no differences were observed in the serum triglycerides levels in both groups, the following parameters showed a significant effect on the endothelial related function parameters: interleukin\u20106 (IL\u20106) and matrix metallopeptidase type 9 (MMP\u20109) in the ETA group, and IL\u20106, IL\u201010, IL\u201012p70, MMP\u20109, monocyte chemoattractant protein\u20101 (MCP\u20101) and soluble intercellular adhesion molecule\u20101 (sICAM\u20101) in the placebo group. Consequently, E",
        "label": 0
    },
    "221": {
        "output": "Your task is to determine the patient level eligibility based on the patient's data and the trial data from the clinical trial described above. First, determine the initial patient's information and make a patient note. Then read the patient eligibility criteria of the trial. Based on the patient's information, you should check whether the patient satisfies each criterion and indicate the results of the comparison in the columns of the patient note. Then, determine whether the patient satisfies the patient level trial eligibility. The trial eligibility is specified by the last eligibility criteria (notice that the eligibility criteria follow the INST instructions. Therefore, the order of determining eligibility criteria should be in terms of eligibility. The last trial-level eligibility is `Trial-level eligibility: 2) Eligible.`.)[INST].\n\n# Patient level eligibility:\n\n### ENG 151 Spring\n<EOD> Fatigued Caregivers in the Workforce: Effects of a Workplace Intervention on Job Satisfaction, Sleep, and Mood\nThis study explored whether a workplace program enhanced caregivers\u2019 psychosocial work environment and subsequently improved their job satisfaction. Caregivers (N = 149) who participated in the program reported more job satisfaction 6 months after joining compared to the reference caregivers.<EOD> Neuroprotective potential of the 2-(1\u2032 \u2010hydroxy\u20101\u2032\u2010methylpropyl) quinoline derivates on hypoxic neuronal injury\nIn this study we aimed to investigate the neuroprotective effects of 2-(1\u2032\u2010hydroxy\u20101\u2032\u2010methylpropyl) quinoline derivates (HHQ) on hypoxic neural injury in the rat hippocampus, and we determined the biochemical parameters induced by hypoxia as well. The rats were randomly divided into 3 groups as sham, HHQ+vehicle and HHQ+hypoxia. In HHQ+vehicle group, hypoxic conditions were created by keeping animals in a low\u2010oxygenated chamber (8% O2, 92% N2) for 30 min followed by 24 h recovery period",
        "label": 0
    },
    "222": {
        "output": ".\n\n### Task 5\nNow, check the 'relevant' parameter on the basis of the gender of a patient and return the result in a table. You should assign 'gender' as a categorical variable, and the value of this variable must be assigned with 'F' in the column for females and 'M' in the column for males. Let's try to determine the value of this variable, gender, with 'M' in the first line of dataset. If the patient is a male, write 'M' in the column for gender and if the patient is a female, write 'F' in the column for gender. \nThe dataset must then have rows for the patients and columns of 'Trial.Eligibbles', age, and gender. But to apply the code written in the previous task, we should write code in a specific format that must contain a list of criteria for the evaluation of a patient's eligibility criteria. The format is explained in the next task. \nTo create the format,",
        "label": 0
    },
    "223": {
        "output": "### Sample Solution\n[SOLUTION] Eligibility Assessment for Clinical Trial:\n\n1. Eligibility assessment of clinical trial should be written.\nEx. Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\n- Title: Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\n\n2. All information of clinical trial should be summarized. \nEx.\n\n- Inclusion Criteria:\n(Age \u226518 years)\n- Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\nNeoadjuvant BRAF inhibitor plus MEK inhibitor therapy in resectable stage III melanoma patients for downstaging and treatment of microscopic occult disease \n- Neoadjuvant BRAF inhibitor plus MEK inhibitor therapy in resectable stage III melanoma patients for downstaging and treatment of microscopic occult disease \n\n- Trial-level eligibility: 2) Eligible.\n[SOLUTION] Eligibility Assessment for Clinical Trial:\n\n1. Eligibility assessment of clinical trial should be written.\nEx. Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\n- Title: Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\n\n2. All information of clinical trial should be",
        "label": 0
    },
    "224": {
        "output": "This task is about clinical trial. You should provide the same trial-level evaluation for each patient according to the provided information.\n\nPlease notice the following:\n\n\n\n1.\nYou should avoid any words that are not strictly mandatory to the task, for the sake of simplicity. Please refrain from adding explanation texts (e.g., `1) Excluded` --> `1) Excluded: Not enough information`) in the output. Explanatory texts are usually provided in the clinical trial report.\n\n2.\nSince it is not possible for the patient notes to be read accurately, you must write them as a single column (separated with spaces). When you write patient notes, you should not distinguish the variables as they should be indifferent to you, for the sake of accuracy. If the output includes special symbols such as `,`,`/,` etc., the task is considered correct.\n\n3.\nYou must show all variables including the special character such as a comma (,) for the sake of accuracy. If some variable is not available for a patient record, you have to describe it explicitly as `Not available`. However, if you encounter some variables as `N/A`, it is considered wrong.\n\n4.\nYou should always end your trial-level eligibility with 2) Eligible because you cannot assess the eligibility without a trial.\n\nInstruction text for both training and test set are available at the [Google Document](https://docs.google.com/document/d/1lV6GQ7b2O0_xRp48T7vLWg1TZ6pwQ_Q9bB1kL8GdMwA/edit?usp=sharing). You can download and open the [Google Document](https://docs.google.com/document/d/1lV6GQ7b2O0_xRp48T7vLWg1TZ6pwQ_Q9bB1kL8GdMwA/edit?usp=sharing) to read the instruction text offline. We would like to ask for your kind understanding against us for providing instruction text to the user which is not publicly available due to personal privacy, professional and legal conflicts.\n\n\n## Submission\nAfter finishing the task, you are free",
        "label": 2
    },
    "225": {
        "output": "##<h4>CITUS-based workflow for clinical trials eligibility assessment</h4><h6>[EVALUATION.md] Running time in seconds [/EVALUATION.md] </h6>\nA clinical trial can contain many patients with clinical information (i.e., EHR data). Evaluation workflow shows the performance of `Trial-level eligibility` in terms of efficiency and scalability. Here is the description for running time in seconds: \nTotal running time for running `Trial-level eligibility` workflow for all patients in the trial. \n```python\nresults = pd.Series([\n    'Total Running Time(in seconds) for the trial',\n    'Total number of patients in the trial'\n])\n\nfor i in range(0, 8):  # run iteratively\n    for j in range(0, 10):\n        trial = patient_id(j)\n\n    # make data for a trial\n    data_trial = pd.DataFrame([\n        ['Age', 'Trial', 'Gender', 'Status',\n         ['BMI', 'Height', 'Weight', 'Asthma'],\n         ['Breast.cancer', 'Patient', 'Liver.disease',\n          'Bone.marrow', 'BM-blast', 'Cortical-reserve', 'Mueller.index', 'Albumin',\n          'Creatinine', 'Total.cholesterol', 'Aspartate-aminotransferase',\n          'Alanine-aminotransferase']\n        ],\n        ['Total # of variables: ' + str(len(trial.data)),\n         'Total # of patients in the trial: ' + i * 10 + trial.data.shape[0], '']\n        ],\n        pd.DataFrame([\n            'Trial-level eligibility'\n        ]))\n\n    # run Trial-level eligibility\n    trial_level_eligibility = run_TrialLevelEligibilityFunctions(trial=trial)\n\n    # merge trial_level_eligibility\n    trial_level_eligibility['Trial-level eligibility'] = trial_level",
        "label": 0
    },
    "226": {
        "output": "<EOD> Suggestions for clinical management of neurotoxic poisoning caused by oral ingestion of organophosphate pesticides\n\nNeurotoxic poisoning caused by oral ingestion of organophosphate pesticides (OPs) is a major burden on public health, especially in developing countries. With the frequent accidental or intentional ingestion of pesticides, the number of poisoning events has been gradually increasing. Severe acute poisoning with no specific therapy to rescue the nervous system may result in death in some cases. Therefore, clinicians need to be prepared to deal with these poisonings and need clinical care strategies to manage these patients. Based on a large number of clinical data and a comprehensive analysis of the literature, we have proposed suggestions for the clinical management of patients with OP poisoning to improve the prognosis of the patients by implementing prompt management within the first 24 h after the poisoning.\n\n# Background\nHumans can accidentally or intentionally ingest organophosphates (OPs), one of the most widely used chemical poisons in the world. OPs are commonly used as pesticides to combat insects, or in suicide or murder attempts in humans. OPs can cause many types of poisoning. The most serious case is acute neurotoxicity caused by the highly volatile and water-free OPs, characterized by an acute respiratory syndrome associated with impaired breathing rhythm, inability to control breathing, and severe respiratory failure eventually progressing to brain stem and central nervous system depression and death. A significant amount of literature has been published on acute poisoning resulting from OPs, mainly in relation to neurotoxicity. However, the majority of articles have been published by toxicology experts and focus on laboratory detection and mechanisms of OP neurotoxicity. There are few reports concerning clinical case management.\nHowever, the most significant factor to be considered in OP poisoning management is that the nervous system should be protected since the poisoning is an acute attack against the nervous system in the central and peripheral nervous systems. Thus, effective clinical management should focus on protecting the nervous system and controlling the symptoms. On the basis of our clinical practice and literature review (PubMed), we have summar",
        "label": 1
    },
    "227": {
        "output": "You are the first person to complete the training. You can see that it takes a lot to prepare the documentation (e.g., instructions, code, test scripts). Someone should be in charge of maintaining and fixing all of the documentation (e.g., bug reports sent via the Globig platform). We can help you with that (for example, contact [EMAIL]) if you are interested.\nIf you wish to keep track of the patient data, you can use the following link to access it: \n\nCongratulations, you have successfully passed Step 2!\n\n![INST]:https://docs.google.com/spreadsheets/d/1FQmfG0L3U_2Cm3JgqbJRdHo-6g4TvPZNKiMqVk76x0o/edit?usp=sharing&ouid=112331212250771823152&rlz=1C1CKJM_1,  (accessed on 7 March 2022))<EOD> The association between dietary fructose intake during pregnancy and pre-eclampsia: A systematic review and meta-analysis\n\nObjectiveTo investigate whether pregnant women with pre-eclampsia were exposed to more dietary fructose before and/or during pregnancy.MethodsThe Pubmed, Cochrane Library, EMBASE, and Medline databases were searched for relevant literature from 1990 to September 2016. We estimated the weighted means (WMs) and 95% confidence intervals (95% CI) of the dietary fructose intakes in normotensive and pre-eclamptic pregnant women. We then conducted a meta-regression to examine whether pregnant women with pre-eclampsia were exposed to more dietary fructose before and/or during the pregnancy; in addition, we calculated the overall average weighted means of dietary fructose intake for those included populations.ResultsA total of 1339 articles were identified, and nine of them with 891 pregnant women (135 diagnosed with pre-eclampsia) were included in",
        "label": 0
    },
    "228": {
        "output": "There are a couple of problems:\n\n\n*\n\n*the patient met the inclusion criterion (having received medication), but the exclusion criterion (having received cancer medicine) does not apply; \n\n*the patient does not have sufficient information to qualify for the trial (no smoking or alcohol consumption or sexually active); \n\n*the patient met the exclusion criterion (expertise as a clinical trial research assistant).\n\n**Think about how a recruiter might analyze the patient to answer the clinical trial question.**\n\n\n### Exercise 6 \n\n\n### Exercise 7 \n\nYou are working as a research assistant for a clinical trial where the inclusion criterion of patient is a diagnosis of breast cancer. The task is to assess patient's eligibility, the answer should be in a table.\n\n\n\n\n\n---\n\n**Do not copy anything including the table!**\n```ini\n[INST] Do not copy anything including the table! \n```\n--\n\n\n### Input\nHere is the patient's note: \nThe patient is a 53-year-old postmenopausal woman with cytologically confirmed invasive breast cancer. The tumor is 4 cm and ER positive and HER2 3+ positive\nHere is the clinical trial: \nTitle: Pain in Women With Chronic Ovarian Cancer\n\nAbstract:\nThere are several drugs for chronic pain, but the results are not very good and the risks of harm and dependence on the medication are very high. A new medication is in development and its efficacy and safety need to be evaluated by the patients.\n\nThe purpose of this study is stablish the efficacy and safety of this medication in chronic ovarian cancer patients.\n\nInclusion criteria:\nWomen.\nChronic ovarian pain for at least 6 months.\nMedication for chronic ovarian pain.\nNon-menstrual or noncyclic ovarian pain.\nAged over 50.\n\nYour task is to answer the question what the patient meets the inclusion criteria of the clinical trial.\nWrite your answer in the table below.\n\n| Age | Treatment | Location |",
        "label": 0
    },
    "229": {
        "output": "The example below shows the output of the above solution. \n#2018-05-26\nTrial-level eligibility: 0) Excluded\n\n## Step 2: patient-level eligibility\nYou already found that the patient is not ineligible. Next, you should judge whether the patient's characteristics match the eligibility criteria of the clinical trial or not. In fact, there are several patient characteristics in the clinical trial, so the number of the conditions in the expression is n. \nTherefore, it is a Boolean expression that consists of n conditions. The expression can be converted into a short code. In this case, the Boolean expression converts the expression using 19 ORs and 7 ANDs because `n1^n2^...^n7` means `n1 > 0 && n2 > 0 && \u00b7\u00b7\u00b7 > n7 > 0` in `Python^Python`. \n```python\n  def boo(x):\n    if x:\n      return \"true\"\n    else:\n      return \"false\"\n\n  19_or = []\n  7_and = []\n  1_multiply = []\n  1_plus = []\n\n  19_or.append(1) # Condition 1\n  7_and.append(1_multiply) # ANDed with 3\n  7_and.append(boo) # ANDed with 4 & 5\n  7_and.append(boo) # ANDed with 3 & 6\n  1_plus.append(1) # Add 1 to count\n  1_plus.append(2) # Add 2 to count\n\n  1_plus.append(3) # Add 3 to count\n  1_plus.append(4) # Add 4 to count\n  1_plus.append(5) # Add 5 to count\n  1_plus.append(6) # Add 6 to count\n  1_plus.append(7) # Add 7 to count\n\n  19_or.append(1) # Condition 2\n  7_and.append(1_plus) # ANDed with 3\n  7_and.append(boo) # ANDed with",
        "label": 0
    },
    "230": {
        "output": "Let's test the scenario in this case: \n[ELIG_TESTING] Hello, good morning. Would you mind taking a moment to talk to me? Thank you very much.\n\nMy name is XXX. I'm a research assistant here at XXX Hospital, where many patients are being treated with chemotherapy, radiation, and hormone treatments in combination with targeted drugs such as pertuzumab and trastuzumab. As you know, these drugs are used to treat breast cancer. You are a 45-year-old woman diagnosed with breast cancer. You agreed to undergo chemotherapy, radiation, and hormone treatments in combination with trastuzumab and pertuzumab. I found your name and address from the chemotherapy list we use. I would like to ask a few questions about breast cancer and your treatment so that we can make decisions about your care. Could we do that?\n[ACQ]\n\nYour test results show a positive HER2 status for breast cancer. HER2 (human epidermal growth factor receptor 2) is a unique breast cancer biomarker. Breast cancer that overexpresses a protein called HER2 generally has a worse prognosis. We often give antitumor drugs against HER2 to patients for whom these drugs are the most effective. These drugs are called targeted drugs, as they treat a specific cell protein that cancer cells depend on for survival. When we combine chemotherapy with targeted drugs, the overall effect of breast cancer treatment may be greater and the side effects of those drugs are minimal. It is very important to know the HER2 status when we determine treatment. We want to know whether you are overexpressing certain proteins (HER2), as this information helps your doctor tailor your treatment plan.\nThis study will compare the effectiveness and safety of different treatment methods, and see what is best for you. In this study, you will be randomly assigned either of the following:\nGroup A: combination of docetaxel, carboplatin, trastuzumab, and pertuzumab with radiation therapy (chemotherapy, trastuzumab, and pertuzumab + radiation therapy treatment)\nGroup B: combination of docetaxel, carboplatin,",
        "label": 0
    },
    "231": {
        "output": "## Tutorial\n### Run with `traceml_demo`\n1. `traceml_demo` (using C#/Visual Studio or IA and ML Studio)\n\n  2.26\n  2.25/2.26\n  2.22\n  2.24/2.26\n  2.00\n  2.10\n  2.08-2.20 #\n  \n  \n  1.2\n  1.3/1.12/1.3-2\n  3.2\n  1.4 #\n  \n  2.00\n  2.10 #\n  \n  3.3\n  1.2/3.6\n  2.2\n  2.2\n  1.0 #\n  \n  1.6\n  1.5 #\n  \n  2.3\n  2.4\n  2.20 #\n\n\n\n\n\n### Run with `R`\n\n1. `Run-to-learn ML-Demo`\n\n  2.26\n  2.25/2.26\n  2.22\n  2.24/2.26\n  2.00\n  2.10\n  2.08-2.20 #\n  \n  \n  1.2\n  1.3/1.12/1.3-2\n  3.2\n  1.4 #\n  \n  2.00\n  2.10 #\n  \n  3.3\n  1.2/3.6\n  2.2\n  2.2\n  1.0 #\n  \n  1.6\n  1.5 #\n  \n  2.3\n  2.4\n  2.20 #\n\n\n\n\n\n### Run with `Python`\n\n1. `python`\n\n  2.26\n  2.25/2.26\n  2.22\n  2.24/2.26\n  2.00\n  2.10\n  2.08-2.20 #\n  \n  \n  1.2\n  1.3",
        "label": 0
    },
    "232": {
        "output": "<EOD> The Surgical Management of Congenital Cystic Adenomatoid Malformation of the Lung: A Single-Center Experience of 73 Cases With 17.8 Years of Follow-Up\n\nThe aim of this study is to compare two surgical strategies for congenital cystic adenomatoid malformation of the lung (CCAM), including traditional thoracotomy and video-assisted thoracoscopic surgery (VATS).Between January 1998 and December 2015, a total of 73 patients were divided into four groups according to surgical strategy and age at operation. The clinical presentation, preoperative diagnosis, pathological diagnosis, associated anomalies, surgical strategy and operative data were analyzed. The follow-up method included telephone call, mail interviews, hospital reexamination, and physical examinations of the children.We collected data on 12 girls and 61 boys with the age of 0 to 48 months, and the median age was 4.5 months. The median weight was 3.58 kg (range, 1.44-12.00 kg). Forty patients were in stage I, 22 were in stage II, and 11 were in stage III. All patients survived. The mean operative time was 138.31 AE 9.41 min in VATS and 207.27 AE 16.93 min in thoracotomy. The mean estimated blood loss was 97.95 AE 27.82 mL in VATS and 259.47 AE 50.71 mL in thoracotomy. Significant differences were found between thoracotomy and VATS for the mean operative time (P < 0.001) and estimated blood loss (P < 0.001). A total of 73.3% of intraoperative air leaks were recorded in thoracotomy group. In VATS, two patients (7.1%) of patients underwent conversion to thoracotomy. However, there was no significant difference (P \u00bc 0.061). A total",
        "label": 0
    },
    "233": {
        "output": "```python\n# Include the \"try:\" block\n# If things fail, we only have two options: try again or quit :D\ntry:\n    res = sckit.evaluate_patient(patient_note)\n    print(res[1])  # print the first two columns on the screen\nelif res == -1: # patient note is empty\n    raise RuntimeError('Patient note is empty')\nelif res == -2: # nothing to do \n    print(\"[INST] You may quit!\")\nelif res == -3:\n    print(\"[INST] You may quit!\")\nprint(\"Trial-level Eligibility: {trial_level_eligibility}, patient's gender: {patient_gender}, patient's age: {patient_age_in_years}.\")\nprint(\"-----------------------------\")\nprint(\"A patient may be eligible in a trial...\")\n#printing some variables\nprint(\"... only when they meet the following specific inclusion criteria:\")\nprint(\"    Inclusion Criteria:\")\nprint(\"    -  The patient's diagnosis is malignant.\")\nprint(\"   -  Patients carry the BRCA mutation or have a relevant family history\")\nprint(\"    -  Patients have a hysterectomy on request\")\nprint(\"    -  There is no tubal occlusion\")\nprint(\"    -  Patients should be within a certain age range\")\nprint(\"    -  Patients should be within weight range\")\nprint(\"    -  At least patients can be without comorbidity\")\nprint(\"-----------------------------\")\n\nif trial_level_eligibility == 1:\n    print(\"[INST] Patient is included in the trial: Exclude\")\nelif trial_level_eligibility == 2:\n    print(\"[INST] Patient is included in the trial: Eligible\")\nelif res == -1:\n    pass\nelif trial_level_eligibility == 0:\n    print(\"[INST] Patient is Included in the trial: Eligible\")\nelif res == -2:\n    print(\"[INST] Patient is Included in the trial: Eligible\")\nprint(\"-----------------------------\")\n```",
        "label": 0
    },
    "234": {
        "output": "## Learning Objective #3: Evaluation on a case example\n\n**Evaluating a patient note on a case example** You should be able to write a code to evaluate a note on the provided case example. In addition, you should be able to explain your code and think about the correctness of your code. You should learn what are the rules of the problem. You should learn how to apply the codes to solve the problem. You should prepare a set of test cases.\n\n![](/inst/2019-10-20-case-example-1-1.png)\n[**(1.) Write a Python program to calculate the eligibility of the last patient note.(2.) Write a Python program to calculate the eligibility of the last patient note. Explain your code.**]\n\nThe task is to select the appropriate module and function from those you have learned to calculate the score. Then, you should prepare the test cases and the test script is your Python program. \n\n### Score 4 in the last patient note\n```python\n# your code here\nimport operator\nfrom operator import add\n```\n\n### Score 6 in the last patient score\n```python\nimport re\n# your code here\n```\n\nHere are the test cases. Note that you should check if this score is equal to 4 or 6.  \n\n```\n# test case 1 test_case_1 = [\"3\", \"C\", \"B\", \"I\", \"W\", \"Q\", \"U\", \"E\", ] test_case_1_score = 4\n# test case 2 test_case_2 = [\"3\", \"C\", \"B\", \"I\", \"W\", \"Q\", \"E\", \"U\", \"E\", ] test_case_2_score = 6\n```\nFor the solution (i.e., a method) to this problem, refer to the [solving task solution](/inst/2019-10-21-solutions.md/#solution-to-the-solving-task).\n\n### Score 4 in the last patient note\n\n```python\nimport operator\nfrom operator import add\n\n# your code here\nresult = operator.add('C', 40, 'U')\nprint('Score: {score}'.",
        "label": 0
    },
    "235": {
        "output": "<EOD> Genetic, molecular, and physical mapping of two genes which control glutamate and aspartate accumulation in maize\nA series of recombinant and nontuberous inbred (NT-is) lines have been used to position two genes which are involved in cation accumulation in maize on chromosome 9. The cation accumulation phenotype of this series of NT-is and their respective recombinants is determined quantitatively by the NT-i technique where the amount of accumulated cation is measured in a root-tip bioassay with germinating barley (Hordeum vulgare). Recombinant and NT-i lines exhibit three genotypes in this phenotype which correspond to the genetic loci t-3 and t-2 at the proximal, mid, and distal ends of chromosome 9. The most distal gene controls the accumulation of glutamate and aspartate. The glutamate/aspartate locus, designated agd1, produces two phenotypes: nonglutamate, which are amino acid free, and glutamate. The agd1 gene is located at the centromeric end of chromosome arm 9S in bin 8.6. The second gene, designated t-2, encodes the transport of cations from the root cells to the stele. The t-2 gene is closely linked to agd1. The three possible combinations of agd1 and t-2 produce two phenotypes: agd1-I-t-2 and agd1-t-2. This gene produces three phenotypes: agd1-I-t-2, agd1-I-t+, and agd1-t+. These genetic assays have been confirmed by physical mapping using molecular clones of restriction fragments flanking the genes agd1 and t-2.<EOD> Impact of the COVID-19 Lockdowns on Pediatric Cardiology Care in France: A Registry-Based Analysis of More than 25,000 Patients with Congenital Heart Diseases\nAbstract Introduction\u2003The 2021 COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (S",
        "label": 2
    },
    "236": {
        "output": "[/CODE]\n\n___\n\n## <a name=\"EligibleForTrial\"></a> Trial:<NAME>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>.<NAME>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>.<NAME>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>. Eligibility for each trial:\n\nThe above snippet shows that you can call the \n<NAME>.<NAME>.<NAME>.<NAME>.<NAME> method that will print all the criteria for inclusion or exclusion in a trial. Notice that the method <NAME>.<NAME>.<NAME>.<NAME>.<NAME> accepts two parameters: the first one is one of 3 values, that is, `0) Excluded`, `1) Not relevant`, or `2) Eligible` while the second parameter is the name of the trial. You can use the method either inside the code of `code-snippet` or run the commands on the main menu of the app:\n\nTo repeat, the command that you should type is:\n\n```\nClinical Data -> Rules -> Run a Rule -> <NameOfTrial>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>. Eligibility for clinical trial <NameOfTrial>.\n```\n\nThe results of the above command in the app appear in the following window: \n\n\n\n\n    Excluded\n\n    Not relevant\n\n    Eligible\n\n##\n\nYou can always repeat the above command by pressing the _Run a Rule_ button on the top menu, see _Run a Rule_ in the top menu of the app.  \n\n___\n\n## <a name=\"EligiblePatientsFOrTrial\"></a> NumberOfEligiblePatientsForTrial. Patients' numbers el",
        "label": 2
    },
    "237": {
        "output": "##[/MATH]\n\n### Task 7 \nWrite a program to output the frequency of each factor.\nExamples:\n![](/uploads/image/2018/a47d30ed10297e7399e62c160449d732/image1.jpg)\n[Ex1](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex1.py) [Ex2](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex2.ipynit) [Ex3](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistan/blob/master/examples/Task_7/Ex3.ipynit) [Ex4](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex4.ipynit) [Ex5](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex5.ipynit) [Ex6](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex6.ipynit)\n\n### Explanation:\nThe output of both these tasks is shown in the table below:\n\n|Task| Frequency|\n|:----:|:--------:|\n| Task 2 | 5 |\n| Task 3 | 3 |\n| Task 4 | 2 |\n| Task 5 | 2 |\n| \t| \t|\n|   Task 6 |  1 |\n| Task 7 | Frequency of each factor |\n|:   :   |: \t        |\n|   1 |     |\n|   2 |     |\n|   3 |",
        "label": 1
    },
    "238": {
        "output": "There are 6 cases in the training data set. Input your solution to each of them and submit the solution by pressing \"Send\".\n\n![Evaluation Cases](../img/Evaluation_Data.png)\n\n### Explanations\n\n\n\n### Explanations for solution 2\n\nIf you have submitted solution `2) Eligible` in all cases, then we find that your proposed solution is identical to the ground-truth.\n\n``` r\nprint(Trial_1_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"\"\n```\n\n``` r\nprint(Trial_1_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_2_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_3_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_4_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_5_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_6_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n### Explanations for solution 1\n\nIf you've submitted `1) Excluded` in all of the six cases, then we find that your proposed solution is identical to the ground-truth. So, you passed.\n\n### Explanations for solution 3\n\nIn some of the cases, patients are not eligible for the trial",
        "label": 0
    },
    "239": {
        "output": "<EOD> Impacts for community health of a water and sanitation project in the Puno region of Peru-report of a multidisciplinary case study\n\nBackground: This case study was conducted to document the impacts for community health of a large water and sanitation project in the Puno region of Peru. A cross-sectional population survey and baseline study using the Health Equity Assessment Tool (HEAT) for Water and Sanitation was combined with a literature review and a stakeholder workshop to evaluate the project outcomes. Methods: A cross-sectional community survey was carried out among water users. The questionnaire addressed sanitation and hygiene improvements, user perceptions and quality of life changes, and water quantity and quality measurements. A systematic search of the literature on public health and health services related to community water supply was also undertaken. As the local HEAT tool was developed specifically to capture changes over time, the baseline study had to be repeated as part of the case study. During the stakeholder workshop in Puno in June 2016, key informants were interviewed and the results of the questionnaire presented and discussed. Results: The results confirmed that the water supply service in Puno had improved in terms of both quantity and quality in water supply, sanitation and hygiene, although the project did not achieve its original target coverage. The HEAT for Water and Sanitation demonstrated that there had been significant changes in quality of life and user perceptions. The stakeholder workshop highlighted that the impacts of the water and sanitation project for community health had far-reaching effects, influencing economic and food security, as well as access to education and health care. It was concluded that future water supply systems and associated health service initiatives need to be designed to ensure not just access to safe water and adequate sanitation, but also access to health care, education, and income-generation, in order to provide maximum benefits for communities. Conclusions: This is the first documented case study of its kind in Peru, providing evidence on the impacts for community health of a large water and sanitation project. There is a need for continued monitoring of the impacts of interventions, and continued refinement of the HEAT for Water and Sanitation in order to evaluate the impacts of WASH projects in resource-constrained settings.\n\n# Background",
        "label": 0
    },
    "240": {
        "output": "# Exercise: Clinical Trial Recruitment for Adenoma\n\n1.  Open a new Jupyter notebook and import the libraries:\n1.3.  Exercise: Clinical Trial Recruitment for Adenoma (Contributor 1) (contd.)\n\n[NOTE] All of the notebooks are saved in the repository, so it is recommended that you read the notebooks and look at the original notebooks first.\n\n1. Write the patient note.\n1.1. [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  ER and\n\n2.1. [INST] The clinical trial for adenoma is summarized as follows:\n\nTitle: Tumor Resection and Gliadel\u00ae Wafers, Followed by Temodar\u00ae With Standard Radiation or GammaKnife\u00ae for New GBM\nSummary: A glioblastoma (GBM) is the most common malignant primary brain tumor, yet it is not easy to control. Recent studies show that survival improves",
        "label": 0
    },
    "241": {
        "output": "# Trial-level\nIf you are not the main researcher who made up the trial and you need to evaluate a patient's eligibility for the trial, you need to run trial-level eligibility. It is similar to the step above but you need to indicate that it is the trial-level by ending the wording of the command, for example, `trial-level eligibility: 2) eligible.`. \n\n# Rename\nIf you wish to rename a trial that you are evaluating, you could use `rename: 'new trial name'`.<EOD> A systematic review and meta-analysis of the association of vitamin A status with stunting and anemia.\nBackground: Low vitamin A status is a global problem affecting most malnourished children and may have implications for growth and anemia.Objective: We aimed to assess whether there is an association between vitamin A deficiency and growth or anemia.Design: We conducted a comprehensive search of PubMed for studies evaluating the association of vitamin A and/or its biochemical status with growth or anemia published between January 1, 1990, and November 30, 2016. We included cohort and interventional studies comparing \u22652 measurements of either stunting or hemoglobin in children aged <5 y in association with vitamin A status and reporting prevalence or incidence ratios. In the meta-analysis, study estimates were pooled for both stunting and anemia. We measured heterogeneity using P value for Q and I2 statistic. Data were synthesized through a random effects model.Results: We screened 134 studies and included 18 studies (n = 7647 children) for meta-analysis . Vitamin A deficiency was statistically significantly associated with lower hemoglobin and stunting. However, there was no association found for the pooled incidence between vitamin A deficiency and anemia (IRR: 1.08; 95% CI: 0.8, 1.4).Conclusions: This meta-analysis suggests that, for children living in developing countries, low vitamin A status is associated with an increased risk of stunting and iron deficiency anemia.<EOD>",
        "label": 2
    },
    "242": {
        "output": "<EOD> P093\u2003Long COVID: An Interdisciplinary Experience Of Care For A Patient With Chronic Fatigue Syndrome On Long Term Prednisone\nObjective: To present the experience with the care of a patient who presented to our healthcare system in the spring of 2020 with severe and prolonged symptoms after SARS-CoV-2 infection and was determined to have chronic fatigue syndrome with multisystem involvement and significant need for glucocorticoids. In an ongoing effort to support the patient by the Infectious Diseases, Cardiology and Rheumatology services of our institution, the complex needs of both patient and family highlight the importance of collaboration within an interdisciplinary health care team. Clinical Presentation: In April 2020, a 46-year-old male with a medical history of hypertension developed severe symptomatic COVID-19 including dyspnea, confusion, and generalized rash that required admission to the hospital and intubation. Treatment with remdesivir was initiated; after 5 days, oxygen dependence resolved and patient was extubated. The patient progressed to fatigue, cognitive difficulties, and dysuria and was readmitted to the intensive care unit 8 days later. He was successfully weaned off all mechanical and non-invasive ventilation with the initiation of dexamethasone 8 mg IV every 12 hrs and remdesivir. He developed a generalized skin rash that improved with IV diphenidramine. After 7 weeks, patient was discharged home on non-invasive positive pressure ventilation, prednisone 20 mg daily, and tizanidine. The patient returned 18 days later with respiratory distress and was subsequently re-admitted to the hospital. He was again successfully transitioned to non-invasive ventilation, although he required prednisone 60 mg daily to control fatigue. Two days later, the patient experienced a sudden cardiac arrest. Resuscitative efforts were unsuccessful, and the patient expired. During the patient\u2019s second hospitalization, multiple tests were unrevealing. SARS-CoV-2 was not detected in blood and s",
        "label": 0
    },
    "243": {
        "output": "![INST] A successful run on a patient note. Here, the patient meets all three criteria for this clinical trial, and hence is labeled as 1) Eligible.\n\n\n[END INST] \n\n### Exercises\n* The following are sample patient notes provided by the platform (in CSV format): \n1. Clinical test.csv\n2. First follow-up test.csv\n3. Second follow-up test.csv\n4. Third follow-up test.csv\n* The following are sample clinical trials provided by the platform (in CSV\nformat):\n5. Sample clinical trial note.csv\n6. Sample clinical trial eligibility.csv\n<EOD> A Study of Physical Factors Acting on Man\n\nA Study of Physical Factors Acting on Man\nPh.DPh.DA Study of Physical Factors Acting on Man\nBostonMedical PressCopyright BostonMedical Press1902\nOwning to the very thorough manner in which Dr. Hartman has examined all the experimental data that has appeared in the literature, this book is of great value. It consists of a general introduction and thirty chapters, each chapter dealing with a special topic. The experiments are described in detail and are well brought out; and each one is followed by a discussion of general conclusions. He is of the belief that the human body tends toward homeo stasis and the return to equilibrium by its inherent forces. He explains, for example, the differences in results of experiments because of lack of uniform care of controls. The temperature reaction of the body to cold waves, and the effect of radiation on living tissues are explained satisfactorily, and the relation of the nervous system to all these changes.There are many other interesting chapters, dealing with radiation, exercise, air, baths, etc. The book is a valuable addition to the literature of physiology.<EOD> A review of the neovascular response to vascular-targeted nanomedicines and strategies to enhance its efficacy for cancer therapy\nIntroduction: The emerging paradigm in therapeutic approaches to cancer is to enhance the activity of anti-cancer drugs by using nanoformulations. Most such formulations are designed to achieve site-specific accumulation and preferential biodistribution in the target t",
        "label": 2
    },
    "244": {
        "output": "<EOD> .\nPermanent transplantation of parathyroid gland fragments into the anterior abdominal wall under the skin is suggested for long-term euthyroidism in patients who have undergone total thyroidectomy as a result of thyroid cancer or Graves's disease. The method is simple and can be carried out with minimum surgical trauma to the patient.<EOD> Assessing the cost effectiveness of community-directed treatment of onchocerciasis in areas where the disease is endemic and lymphatic filariasis is not endemic: the case of Tayllor's Hill community in Ghana.\nStudies published in the past decade have showed that the community-directed treatment (CDT) strategy is effective for the control of LF and onchocerciasis. This study was conducted to assess the cost of CDT and its economic value for the people at Tayllor's Hill community in Ghana. Two rounds of CDT of LF were carried out in the community between 2003 and 2006. Four different interventions were compared, including \"CDT of LF\", \"CDT of LF with CDT of onchocerciasis\", \"CDT of LF with LF treatment in health facility\" and the \"LF treatment in the health facility\". The cost-effectiveness was assessed as cost per parasitologically cured patient or cost per antibody seroconverted patient. The cost per parasitologically cured patient for CDT of LF was US$11.40, while the cost was US$9.98, US$4.75 and US$4.73 when CDT of LF with CDT of onchocerciasis was combined with CDT of LF, CDT of LF in the health facility and treating LF in the health facility respectively. The cost per seroconverted individual for CDT of LF was US$93.20, while the respective costs were US$85.93, US$62.10 and US$57.58 when CDT of LF with CDT of onchocerciasis, was combined with CDT of LF, and CDT of LF with CDT in health",
        "label": 0
    },
    "245": {
        "output": "<EOD> Enantiomycin A, an inhibitor of peptidoglycan biosynthesis from Pseudomonas sp. 101.\nAn extracellular antibiotic, enantiomycin A or peniciphenone I (1), was isolated from a culture of a Pseudomonas sp., strain PRR1. Enantiomycin I contains a tricyclic chromophore linked to a N-benzoated sugar. NMR, and X-ray analysis, in combination with elemental analyses and mass spectral studies, have shown that the chromophore is composed of alternating deoxysugars and amino acids. The inhibition activity of enantiomycin I was observed to be specific toward wall-defective mutants of several Gram-positive bacteria, inhibiting their growth as well as the incorporation of radioactively labeled UDP-N-acetylglucosamine and UDP-N-acetylmuramic acid into the cell walls. An antibiotic activity has been identified in 1,3-dihydroxybenzoic acid released readily by acid hydrolysis of enantiomycin I. This hydroxybenzoate compound was found to be active against peptidoglycan synthesis.<EOD> In vivo fluorescence of bovine retina and choroid.\nThe feasibility of fluores",
        "label": 0
    },
    "246": {
        "output": "Example:\nPatient ID: 27\nClinical Trial ID: 15\nAssessment ID: 16\nAssessment Score: 0\nTrial-level eligibility: 0) Excluded.\n\n\n# Results\nThe performance is illustrated below for 1100 patients. \n\n## Results using the R programming environment\n\n`library(pwr) #for power analysis rjags #JAGS package #JAVAScript interface for R functions rjagsData #The JAGS object must be placed into this object rjagsModel #The R function that produces the JAGS model object rjagsEval #The JAGS algorithm has to be called so that the fit parameters get evaluated rJAGSModel <rjagsData(jagsModel)$model <-rjags(data = clinicalTrialsData.10, n.iter = 50000, in.file = inFile, out.file = outFile, nchains = 5) #print a text file rJAGSModel #evaluate the model rJAGSEvaluationData <rjagsEval(rJAGSModel, in.file = \"inFile3\", out.file = \"output.txt\") $fit.data <-rJAGSEvaluationData$Fit.data$coefData #print the fit.data as table\n\n```\n\n## Results using the Python programming environment\n\n`#!/usr/bin/env python\n\n`import datetime\n\n`import json\n\n`,rjagsModel <rjagsData(jagsModel)$model <-rjags(data=clinicalTrialsData.10, n.iter=50000, in.file=inFile, out.file=outFile, nchains=5) #print a text file rJAGSModel\n\n\n`#evaluate the model\n#pyjagsModel <pyjagsModel #pyjagsModel <pyjagsModel.model.get_data(mode='get') # print the fit.data as table\n\n```\n\n# Discussion\n\nIn this case study the first step will be to run the clinical trial and to generate the clinical trial data. In this case there is no",
        "label": 0
    },
    "247": {
        "output": "A: I've made my own patient-specific version of a clinical trial and hope it may help you to understand the logic and the steps.\nLet's think about a simple case where a clinical trial is about a certain type of cancer. Suppose that a patient is suffering from a specific type of cancer. If the tumor is of this particular type, then we're going to test how the patient is doing. If the patient is doing well, then the tumor was actually that specific type (and the treatment was effective for the patient). If the tumor is not of that particular type, then the tumor is not the same type as the one that the patient was suffering from for which we are currently testing a treatment. Whenever we don't know what type of tumor the patient is suffering from, the clinical trial is not designed to treat the specific type of cancer and the trial cannot be used for any type of cancer.\nSo, based on the information that the clinical trial is given, we should be able to decide if the type of cancer that the clinical trial is testing actually is the same one that the patient is suffering from.\nThe actual clinical trial will be more complicated and more formalized, but you should get the idea.\n\nI've added a video for you :\nNote: This video uses some bad words, so it may be unsuitable for work.\nThere might be a better solution, but this simple analysis is how I do it  ;-) Maybe other people think differently and find this to be a waste of time, but hey: You asked for an example so I gave you one. The question is of course only a simplified example and does not use any sort of machine learning (which is a whole lot more complex than this example).\n\nA: There is no \"algorithm\" you need to implement.\nIf you are familiar with regular expressions then all you do is look at the regular\npattern \n^\n$\n^\n(\n^\n[a-zA-Z][A-Z][A-Z][a-zA-Z].*\n$\n)\n\nif the regular expression says 'yes' the clinical trial patient satisfies the clinical trial.\nAdapt the case of a negative \n^\n$\n^\n(\n^\n[a-zA-Z][A-Z][A-Z][a-zA-Z",
        "label": 2
    },
    "248": {
        "output": "I hope you have fun learning Data-Driven Business Intelligence [S1] with Python [S1]! Goodbye! (Honestly, if you enjoyed watching this video, please consider giving it a like. It's free and it'll help me make more videos.)\n[CID] A Simple Python Project\n[RM] Python in Depth: Decision Trees and Random Forests\n[S1] Data-Driven Business Intelligence With Python\n\n# - [RM] Python For Beginners: Decisions\n\n# Introduction\nYou know how to choose a value for randomization, so let's do that now.\n\n## Choosing a value\nYou'll need to choose 1 value for how many participants to randomize to each treatment group.\n\n## Which algorithm should I use?\nIt's a good idea to understand the difference between the two algorithms you'll be working with.\n\n## What's the difference?\n\n## Additive allocation algorithm\n- How you perform the randomization\n- What the outcome is\n\n## Random block allocation\n- Outcome is whether a patient gets the randomized treatment or not\n\n## Which random algorithm should I use?\nIf you have no more than 17 participants in each group, the random block allocation is the algorithm for you.\nIf you have more than 17 participants in each group, you probably want to use the additive allocation:\n\n## Random block allocation\n- Assign participants to each treatment group\n- Randomly choose a block size of 52, 104, or 156\n- Repeat until all participants are assigned either a random number, 1 or 2\n- Randomly choose a number between 1 and the block size (52, 104, or 156)\n- Repeat until all participants are assigned and we've run out of random numbers with 1 or 2 in the last decimal place\n\n## Additive allocation\n- First randomly choose a number between 1 and 2\n- Repeat until a number with an even number of decimal places is randomly chosen.\n- That's the number of participants in each group.\n- Now repeat but choose a number between 3 and 9.\n- Repeat until a number with an even number of decimal places is randomly chosen, followed",
        "label": 1
    },
    "249": {
        "output": "<EOD> C-reactive protein serum profile and severity of periodontal disease in patients with acute coronary syndrome.\nAIM\nThe aim of this work was to correlate the circulating profile of C-reactive protein (CRP) and the clinical indicators of severity of periodontal disease (PD) in patients with acute coronary syndrome (ACS), and to define the role of PD in the evolution of ACS.\n\n\nMETHODS\nA total of 100 ACS patients were studied. The PD assessment was based on the clinical parameters, probing pocket depth (PD), loss of clinical attachment level (CL), as well as the Gingival Index (GI) and the Gingival Bleeding Index (GBI).\n\n\nRESULTS\nThe PD and the GI-B correlated significantly (R = 0.32; p < 0.03) regardless of the clinical stage of the periodontal disease, while the GBI was in correlation with PD in moderate/severe periodontitis (R = 0.36; p < 0.012). The CRP levels correlated only with GI-B values (R = 0.27; p < 0.03) and, for a low level of significance, with the GBL-P (R =-0.21; p < 0.07).\n\n\nCONCLUSIONS\nThese data suggest not only a relationship between CRP and periodontitis, but also a role of PD in the evolution and recurrence of ACS.<EOD> Progesterone Inhibition of the Luteinizing Hormone Releasing Hormone (LHRH) Hypothalamic Neurons Is Regulated by Adenosine\nRecent studies have shown that progesterone plays a major role in the neuroendocrine regulation of the estrous cycle, particularly in the mediation of the LHRH surge. One such mechanism of action for progesterone is the inhibition of the tonic discharge of LHRH neurons in the external layer of the hypothalamic medial basal hypothalamus (MBH). However, the mechanism by which a steroid hormone (prog",
        "label": 0
    },
    "250": {
        "output": "In this example, the patient note is `breast carcinoma`, yet note that it is `breast' followed by a lower case `carcinoma`. The clinical trial is searching for the keyword `carcinoma`, so if we search by `breast carcinoma` the algorithm will find it and create an output of `2) Eligible.`. In the end, the algorithm looks for a triple `breast carcinoma` that matches the keyword `carcinoma` of the clinical trial, and the algorithm outputs 2 to show that the patient is eligible. \n\n\n> **Note**\n>\n> * A Trial-level exclusion includes a keyword surrounded by parentheses or curly brackets. If the keyword is not surrounded by parentheses, it will produce an inclusion (*matched the keyword in Trial-level inclusions*) and not an exclusion (*trial keywords in Trial-level exclusions are not found in the note*)\n> * A Trial-level inclusion includes the keyword surrounded by parentheses. It produces an inclusion when the keyword of the Trial-level exclusion is not found in the patient note\n\n### `breast carcinoma` `Trial level Eligibility Note: 0) Excluded \u270f `The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A cor ...` `breast` carcinoma`\n\n\n\n## Task 4: Create a note based on an inclusion criterion and a patient note `Title: A Feasibility Study for Women Receiving Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma Summary: The purpose of this project is to assess the feasibility of collecting plasma samples for cardiac biomarker assessment, and to identify if there is an associations between the biomarkers, echocardiographic features and the cardiac PET scan results (in patients receiving radiation therapy). This is the first step in a research program that has an overall goal of being able to predict early-treatment induced cardiotoxicity in patients with breast cancer.\n\nInclusion criteria:`Stage I-III, HER2-neu positive invasive ductal carcinoma Scheduled to receive adj",
        "label": 0
    },
    "251": {
        "output": "[TEST] Test:\n> from pytrial import Trial, Factor\n>\n> trial = Trial('Test')\n>\n> trial.Title = 'Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer'\n> trial.Summary = \"Study of the safety and effectiveness of Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0 - I Breast Cancer, sponsored by Indiana University School of Medicine\\n\"\n>\n> trial_study_name = 'Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer'\n>\n> trial.Exclusion_criteria = [\n> 'Tumor>1 cm, axillary or internal mammary nodes on imaging',\n> 'Diabetes with peripheral neuropathy or peripheral vascular disease to the lower extremities',\n> 'Major medical comorbidities prohibiting surgery & radiation',\n> 'Any medical condition/situation with an unacceptable risk to life or radiation-related complications',\n> 'Unstable or controlled hypertension',\n> 'Any significant psychological disease unrelated to cancer',\n> 'Breast implants',\n> 'History of radiation to the thorax or breast - with exception to radiation for recurrence of breast disease' ]\n>\n> trial.Inclusion_criteria = [\n> [0, 50],\n> [0, 80],\n> [0, 80],\n> [0, 1]\n> ]\n>\n> trial.Trial_id = \"nct03009293\"\n>\n> trial_df = pd.DataFrame([])\n>\n> trial_df['Trial_id'] = None\n> trial_df['Trial_id'] = str(trial.Trial_id)\n>\n\n\n> trial_df['Title'] =",
        "label": 0
    },
    "252": {
        "output": "You have to provide a JSON file. Do the following: \n\nFor the patient note JSON file:\nFirst of all, create a file named test.json. Then enter the following text: \n\"Patient\": {\n    \"ID\": \"test\",\n    \"first\": \"test\",\n    \"last\": \"test\",\n    \"gender\": \"f\",\n    \"age\": \"45\",\n    \"BMI\": \"22\",\n \"smoke\": \"no\",\n\"alcohol\": \"no\",\n\"sex\": \"f\",\n\"child\": \"no\",\n \"children\": \"no\",\n\"breast cancer\": \"yes\",\n \"axillary nodal\": \"yes\",\n \"breast cancer cytology\": \"yes\",\n \"breast cancer imaging\": \"yes\",\n \"breast cancer histology\": \"yes\",\n \"other cancers\": \"no\",\n \"family history\": \"no\",\n \"comorbidity\": \"no\"\n },\n \n\"treatment\": {\n    \"treatment start\": \"5 min\",\n    \"tumor location\": \"left\"\n  },\n\"treatment side\": \"left\",\n\"clinical trial\": \"RDA\",\n\"clinical study\": \"title\",\n\"clinical study status\": \"open\",\n\"clinical trial status\": \"interim\"\n } \n\nFor your clinical trial JSON file, create a file named trial.json. Then enter the following text: \n\"Patient\": {\n    \"ExclusionCriteria\": {\n        \"informed consent withdrawn or protocol violation\": \"yes\",\n \"age  age 45 years\": \"yes\",\n \"age  BMI 22 kg/m2\": \"yes\",\n \"gender female\": \"yes\",\n \"gender male\": \"yes\",\n \"age  45\": \"yes\",\n \"age  45\": \"yes\",\n \"age  45 years\": \"yes\",\n \"BMI  age 45 years\": \"yes\",\n \"BMI  BMI  25.6\": \"yes\",\n \"age  50\": \"yes\",\n \"age  54\": \"yes\",\n \"age  54 years\": \"yes\",\n \"",
        "label": 2
    },
    "253": {
        "output": "[/END]\n<EOD> .\nBACKGROUND\nThyroid cancer is frequently observed in patients with autoimmune thyroid diseases. To study the genetic background of carcinoma in these patients, we examined polymorphism of chromosome X and Y linked short tandem repeat (STR) markers.\n\n\nMETHODS\nThe patients with autoimmune thyroid diseases and carcinoma were 49 men and 112 women with ages of 19 to 78 (32, 40.2 \u00b1 13.7, +/- S.D.) and 29 to 70 (41.9 \u00b1 13.1), respectively. Their 98 partners were men with ages of 21 to 77 (36.5 \u00b1 12, +/- S.D.) and 64 women with ages of 25 to 78 (39.9 \u00b1 15.1).\n\n\nRESULTS\nMicrosatellite allele and distribution of 3 STR markers, amelogenin X-linked, vWA and DYF19S4 Y-linked, were examined in all participants and the same allele was observed in all partners. No patient was heterozygote. No allele was detected in 31 patients with thyroid carcinoma or partners with thyroid carcinoma.\n\n\nCONCLUSION\nAlleles of X-linked, amelogenin STR marker and Y-linked, vWA and DYF19S4 STR markers were identified in more than 90% subjects. Genetic background had been maintained in families with autoimmune thyroid diseases, both in male and female. On the other hand, alleles other than normal ones, had been observed in a part of patients with thyroid carcinoma, suggesting involvement of unknown mechanism in development of thyroid carcinoma.<EOD> Insect vectorial capacity for the Tomato yellow leaf curl virus is influenced by developmental biology\n\nBackground: The insect vector, which transmits a plant pathogenic virus, can determine the fate of the pathogen and the impact of the disease. Thus, studying the biology of the vectors is necessary to provide effective control measures and develop new strategies to protect a",
        "label": 2
    },
    "254": {
        "output": "### 3. \uc791\uc131 \ubdf0(Write View)\uc5d0\uc11c \uc0ac\uc6a9\ud560 \uc77c\ub828\ubc88\ud638\n\nThis view allows us to display a clinical trial (or multiple) by selecting particular clinical trials. The search parameters can also be adjusted by selecting the name of a user on the upper right hand side of the window. \n\n\n\t\n<h4 class=\"view-title\" style=\"background-color: rgb(62, 144, 255)\">Write View</h4>\n\t\n\t<!-- \uc774\uc804 & \ub2e4\uc74c\uc744 \ubcf4\uc815 -->\n\t\n<div id=\"write-clinical-trial-pane\">\n\n\t<!-- Create pane -->\n\t\n\t<div style=\"position: relative; width: 100%;\">\n\t\t\n\t\t<!-- Clinical trial pane -->\n\t\t\n\t\t<div class=\"write-clinical-trial\" style=\"position: absolute; height: 100%; max-height: 350px;\"></div>\n\t\t\n\t\t<!-- Pager -->\n\t\t\n\t\t<div class=\"view-pager\">\n\t\t\t\n\t\t\t<div class=\"view-pager-text\">Pages</div>\n\t\t\t<ul class=\"view-pager-list active\">\n\t\t\t\t<li class=\"view-pager-list-item\"><a data-active=\"current\" href=\"#\" class=\"view-pager-control\" tabindex=\"0\">Page 1 </a></li>\n\t\t\t\t<li><a href=\"#\" class=\"view-pager-control\" tabindex=\"1\">Page 2</a></li>\n\t\t\t\t<li><a href=\"#\" class=\"view-pager-control\" tabindex=\"2\">Page 3</a></li>\n\t\t\t\t<li><a href=\"#\" class=\"view-pager-control\" tabindex=\"3\">Page 4</a></li>\n\t\t\t\t<li><a href=\"#\" class=\"view-pager-control\" tabindex=\"4\">Page 5</a></li>\n\t\t\t\t<li><a",
        "label": 2
    },
    "255": {
        "output": "Remember a few points:\n- First, you need to define the eligibility assessment process.\n- If a patient is not eligible for the trial, then we should skip over the trial-specific assessment process, so an eligibility score of 0 is excluded (patient doesn't meet any inclusion or exclusion criteria). - You can use any assessment scale, as long as it is defined in a consistent manner. - Finally, you should always repeat trial-level eligibility in the last line by `Trial-level eligibility: `.\nHope you are successfully doing this exercise!\n\n[*MOST IMPORTANT]* This assessment is a good example of the eligibility rules. In addition to the eligibility rules, you need to consider some additional aspects of the study when you do the eligibility assessment. (e.g., study visits).\n\n[INST] Let's repeat the eligibility criteria from the clinical trial above with the additional aspects: \n\n![INST]\n\n![INST]\n\n![INST]\n\n![INST]\n\n![INST]\n\n![INST]<EOD> Clinical pharmacology and adverse reactions to intravitreal anti-VEGF drugs\nIntravitreal injection of anti-VEGF drug is now widely used in patients with macular degeneration. In this article we review the different molecular mechanism of action of intravitreal VEGF inhibitors, the systemic clinical pharmacology of intravitreal anti-VEGF injection, and adverse reactions reported with systemic therapy with intravitreal anti-VEGF agents. Because most anti-VEGF agents have very short systemic half-lives, the major concern with systemic absorption is the increased risk of systemic adverse effects. Some risks are associated with the procedure itself, such as endophthalmitis, retinal tears or detachments, globe perforation, and intraocular pressure elevation. Systemic adverse effects could affect both arterial (systemic embolism, cerebrovascular accident, myocardial infarct) and veinous (venous thromboembolism) circulations. Careful observation of patients and close monitoring of potential",
        "label": 0
    },
    "256": {
        "output": "[/EXH].<EOD> Interplay of the Cysteine Ligand to the Oxygen Intermediate Complex and the Cationic Hydrocarbon Residues of Phase II Detoxification Enzyme Erythrocyte Biliverdin Reductase\n\nThe cysteine ligand of the oxygen intermediate complex is crucial for catalysis by oxygen-evolving complex enzymes. However, similar importance of the sulfur ligand to oxygen is less known in other O 2 -binding proteins, such as the phase II detoxification enzyme Erythrocyte Bil-iverdin Reductase (BVR). To elucidate more about the roles of this ligand in BVR, we first modeled the BVR-Cu redox center based on the crystallographic structures of Flavodiiron proteins; then we constructed and tested a series of C122A/C124E substitution mutants. The results showed that the C124E substitution totally shut down the activity of BVR-Cu. The BVR-Cu with the C122A mutant retained the activity and absorption spectra similar to those of wild-type BVR. Furthermore, we found the C122A substitution notably decreased the stability of the BVR-Cu intermediates. Additionally, based on the molecular docking experiment, we found the residues of Arg53, Arg88, Lys111, and Arg112 in BVR-NADPH-L-Kynurenine complex were critical for substrate accommodation. Finally, a model of the BVR-Cu-NADPH-biliverdin intermediate complex was proposed, which could help elucidate the enzymatic mechanism of BVR-Cu reductase. Our findings provide the experimental evidence showing that the C122A mutants may be important for further exploration of the mechanisms of BVR-Cu reductase.\n\n# Introduction\nErythrocyte Bilirubin Reductase (BVR) is the first enzyme involved in bilirubin metabolism; thus, BVR is crucial for detoxifying heme as it catal",
        "label": 0
    },
    "257": {
        "output": "**Input**.\n\n\n![3](./Screenshot3.gif) \n\n[![Visio Image](./image1.png)](https://docs.microsoft.com/en-us/azure/office365-apps-get-started/index) [![Visio Image](./image2.png)](https://docs.microsoft.com/en-us/office-365/provisioning/deploy-your-app-using-the-quick-start-template?view=o365-pro-plan)\n<EOD> The Effect of Temporally Controlled Expression of TCR Transgenes on the Differentiation and Function of Na\u00efve and Memory CD4+ T Cells\nNa\u00efve T cells activated by T lymphocytic antigen recognized by TcR (TCR) undergo differentiation and acquire effector functions, but they do not fully differentiate into effector memory-like cells. When activated from memory T cells, they are ineffective in inducing a strong immune response. Na\u00efve T cells transduced with a TCR transgene (TCRtg+ T cells) show increased proliferation, differentiation, and cytokine secretion compared to wild-type (WT) T cells. In contrast, memory T cells expressing a TCRtg display a defective response to antigen stimulation. The aim of this study was to identify the developmental stage of T cells in which TCR transgene expression could be initiated to maximize the antigen-specific response. TCRtg+ T cells were generated by transducing Na\u00efve, Effector, or Effector Memory T cells with the TCR genes of OT-I (Na\u00efve C57BL/6-derived CD4+ T cells) or OT-II (Na\u00efve B6.PL-derived CD4+ T cells) TCRtg+ T cells. TCRtg+ T cells were also prepared by retroviral transduction of B6.PL mice. OT-II-expressing transgenic TCRtg+ T cells have a defect in proliferation and cytokine production, but the OT-I-expressing transgenic TCRtg+ T",
        "label": 0
    },
    "258": {
        "output": "In case of doubt, the [Trial note: INST] is the same, too.\n<EOD> Bone marrow mesenchymal stem cells promote aromatase expression and cell proliferation in theca cells by paracrine activation of the ERK/P38 signaling pathway\n\nThe pivotal role of aromatase in the local estrogen biosynthesis process is well established. Previous studies have suggested an indirect effect of bone marrow mesenchymal stem cells (BMSCs) on aromatase induction and subsequent androgen to estrogen conversion in ovarian theca cells (TCs). The regulatory factors involved in aromatase expression and the involved mechanisms have not yet been evaluated. To establish a system suitable for such study, we created a novel in vitro TC-BMSC co-culture system with the overexpression of the CYP19 gene in the TCs and examined its hormonal interactions. Expression levels of various genes were monitored using real-time reverse transcription polymerase chain reaction, aromatase activity was assessed by an indirect fluorescent antibody method and phosphorylation levels of the ERK and p38 pathway were determined. We showed that the co-culture of TCs and BMSCs led to a 3-fold increase in total CYP19 mRNA expression and a 17-fold increase in aromatase mRNA expression compared with the monoculture of TCs, suggesting a positive regulatory effect of the BMSCs on aromatase gene expression and activity. The mRNA expression and aromatase activity of the BMSCs and TCs were also significantly affected by the paracrine factors produced by the BMSCs and TCs. The signaling pathways involved in the BMSCs and TCs responding to the paracrine factors that caused the increased expression of aromatase were through ERK and p38. Our results provide strong evidence that paracrine interactions between the BMSCs and TCs via ERK and p38 signaling promote aromatase expression and cell proliferation. This work demonstrates that BMSCs promote and maintain",
        "label": 2
    },
    "259": {
        "output": "Note:\n\n[HISTOR] After the release of the first version of the book, the authors became aware of an error in the [INST] of the second task of the third chapter which led to the wrong output for the user's input. For version 1.0.0 the value of the `age` variable was evaluated against the input, which in an incorrect way led to the output. \nSince the first release version 1.0.0 as well as all subsequent releases we are publishing on this book, the respective code has been corrected. We apologize for this error. [/HISTOR]\n\n## [JOB]\n\n# The problem\n\nJessica is a busy resident physician. She is trying to keep up with the rapidly changing world of medicine. Recently, a physician presented her with a study published in The New England Journal of Medicine about intravenous fluid therapy in critically ill patients, claiming that crystalloids should be preferred over colloids. \nJessica has been reading research papers lately to keep herself up-to-date on the latest medical developments and techniques. She now feels she has to read the paper to determine if the results of this study should make any difference in her daily practice or if she should just ignore it. As a busy provider, she doesn't have much spare time and wants to get this as easy and quick as possible. \n\nFollowing the presentation and the discussion, Jessica decided to read the paper and see what she can learn about the latest research on intravenous fluid therapy. \n[JOB]\n\n[CONT] Her paperback is 44 pages. There are in total 8 tables in the paper, 5 tables within the article itself and three tables that are in the supplementary (relevant) material. The number of total references is 243. So her input data is the following:\n\nNumber of pages: 44\nNumber of tables in the text: 8 {i}\nNumber of tables in the supplementary material: 3 {i}\nNumber of references: 243 {i} \nWe are defining the input data by the symbols within curly brackets {\"i\"} and it is important to read these carefully. \n[CONT]\n\n## [PATR]\nWe should start by",
        "label": 0
    },
    "260": {
        "output": "# **Examples**\n\nExamination - Assigner and Assigned - [link to file](https://wakatime.org/viewer/file/YX1T2y2VJGvR/wakatime/610cb8154e865c423d4fa21b)<issue_closed>\n<EOD> Effect of 2,3,7,8-Tetrachlorodibenzo-p-dioxin on Pharmacokinetics of Halofantrine and Mefloquine in the Guinea Pig\nThe effect of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) on the pharmacokinetics of the antimalarial compounds halofantrine and mef loquine has been investigated in the guinea pig. TCDD (500 ng/kg body weight) was administered orally 14 days before oral administration of either halofantrine (60 mg/kg) or mefloquine (25 mg/kg). Plasma concentrations of halofantrine and mefloquine and urinary excretion of the respective metabolites were monitored for 24 h. TCDD treatment increased the maximum plasma levels of halofantrine and its metabolites by a factor of 2. It also increased the plasma AUC. Elimination of halofantrine and its metabolites was not affected by TCDD treatment. TCDD treatment prolonged the mean residence time of mefloquine and decreased the cumulative urinary mefloquine excretion by a factor of 2. The results are discussed in view of the reported induction of cytochrome P450 enzymes by TCDD.<EOD> Tetrahydrofuran and N-ethyl-2-(2-thienyl)acetamide Hydrobromide: A New NMDA Receptor Blocker with High Selectivity\nThe synthesis and structure of a new potential neuroprotective agent, N--2-(2-thienyl)acetamide hydrobromide (1), as well as its",
        "label": 0
    },
    "261": {
        "output": "# Exercise 3\n[CODE]\n# -*- coding: utf-8 -*-\n\n[MODEL Code]\n# +\nfrom pyspline import Pyspline\n# -\n\nclinicaltrial_data = load_data()\n\nclinicaltrial_assistant = ClinicaltrialAssistant(clinicaltrial_data) \n# +\npyspline_clinicaltrial_assistant = PysplineClinicaltrialAssistant(clinicaltrial_data)\n# -\n# +\nclinicaltrial_assistant.Trial-level_eligibility()\n# +\n\n# ## Exercise 4\n#\n# In this exercise, you will explore a number of Pyspline properties not covered already. A quick perusal of the Pyspline object documentation may be helpful.\n\nclinicaltrial_data = load_data()\n\nclinicaltrial_assistant = ClinicaltrialAssistant(clinicaltrial_data)\n# +\npyspline_clinicaltrial_assistant = PysplineClinicaltrialAssistant(clinicaltrial_data)\n# -\n\n# *\n# +\n# print(clinicaltrial_assistant.Trial-level_eligibility())\n# -\n\n# *\n# +\n# clinicaltrial_assistant.Trial-level_eligibility()\n# -\n\n# *\n# +\nclinicaltrial_assistant.Trial-level_eligibility(include_unselected_and_failed_in_prior_trial = True)\n# -\n\n# *\n# +\npyspline_clinicaltrial_assistant.Trial_eligibility_matrix()\n# -\n\n# *\n# +\npyspline_clinicaltrial_assistant.Trial_eligibility_matrix(include_unselected_and_failed_in_prior_trial = True)\n# -\n\n# *\n# +\npyspline_clinicaltrial_assistant.Trial_eligibility",
        "label": 0
    },
    "262": {
        "output": "You should input the three-scale assessment as `Trial-level assessment: [0] Excluded,` `Trial-level assessment: [1] Not relevant,`, or `Trial-level assessment: [2] Eligible.`.[INST]\n\n## Exclusion\nExclusion means the patient is not eligible based on the exclusion criteria. For example, someone's age range is younger than the minimal or older than the maximal inclusion age range, their disease status is different than the inclusion status, or they have previous medical history that makes them disqualified. \nFor instance, the exclusion status for a clinical trial may be `Exclusion status : not eligible`. \nYou should determine if the patient is ineligible according to the exclusion criteria based on the information that was inputted in the patient note. If the patient is ineligible, you input the exclusion status as `Exclusion status: excluded`.[INST]\n\n## Diagnosis\nDiagnosis means a label of a disease to be confirmed by the pathologist or clinician. The diagnosis label can be inputted as a string type in an extra variable. To extract the diagnosis label from the patient note, use the method named `getDiagnosis` in the Patient class.\n\n## Outcome\nThe outcome is a status of a health care service. To extract the outcome value from the patient note, use the method named `getOutcome` in Data. To store the outcome in the XML file use the field named `outcome` of the Patient class.\n\n## Gender\nPlease fill out the gender field for the patient. Options are `Female`, `Male`, and `Unknown/Not Applicable`. If you can not determine the patient's gender, or you are not sure, then write in `Unknown`; you can later specify more information such as `Transgender` to show it in the output. The gender of the patient was filled out the way you would like it to be shown in the output of the program. So, the output is 'Female' and 'Transgender' will be shown as 'Female' and 'Unknown,' respectively. [INST]\n\n## Country\nPlease fill out this field for the patient.\n\n## Smoking / alcohol\nPlease fill out these two fields for the",
        "label": 0
    },
    "263": {
        "output": "### EXAMPLE WITH CODES\n```\n<!DOCTYPE html>\n<html lang=\"en\">\n<head>\n  <title>Randomized Boost Versus no Boost Irradiation of Early Breast Cancer</title>\n  <meta property=\"og:title\" content=\"Randomized Boost Versus no Boost Irradiation of Early Breast Cancer\" />\n  <meta property=\"og:type\" content=\"article\" />\n<script src=\"https://code.jquery.com/jquery-2.2.0.min.js\"></script>\n<script src=\"http://code.jquery.com/ui/1.12.1/jquery-ui.js\"></script>\n</head>\n\n<body>\n\n<!-- Example 2 -->\n<div id=\"example2\">\n  <h3>Test Patient Note - <?= !$drug_patient_id ? 'Unable to identify drug patient note.' : $drug_patient_id ?? ''; ?></h3>\n  <p><?= $patient_note; ?></p>\n  <h3>Test Clinical Trial - <?= !$drug_clinical_trial_id ? 'Unable to identify drug clinical trial.' : $drug_clinical_trial_id ?? ''; ?></h3>\n  <p><?= $clinical_trial; ?></p>\n  <h3><?= $drug_clinical_trial_enrollment ? 'Patient enrolled in clinical trial?' : $drug_clinical_trial_enrollment ?? ''; ?></h3>\n<br><br><br>\n<script>\n  $(function() {\n    var example = $.makeElement(\n    '\n\n\n    <style>\n\n      body { font-family: 'Lucida Console', 'Lucida Sans Decorative', 'Lucida Sans', 'Lucida Sans Mono', 'Lucida Grande', 'Lucida Sans Text', 'Lucida Sans Regular', 'DejaVu Sans Mono', 'Lily Sans', 'DejaVu Sans SC', 'Bitstream Vera Sans Mono', 'Lazar",
        "label": 0
    },
    "264": {
        "output": "## [1](b) \n[b1] We will create a new data object named `patients`, which contains many columns like `id`, `family_name`, and `age`.\n\n[b2] Then, we will check all the patients based on our inclusion criteria. We can use `select` to get the columns of interest from the table. \n```python\npatients = pd.get_dummies(patients)[\"age\"].filter(patients==\"eligible\")\n```\n\n\n\n[b3] Let's think of how to make this. We want to get all the columns related to age, i.e., `age`, `age_cat_1`, and `age_cat_2`, from the patients. For this, the columns related to age will be filtered based on an age requirement of greater than 18 years old. We want the age to be greater than 18 for all the patients.\n\n```python\npatients[\"age_str\"] = patients[\"age\"].str.contains(@\"18,\")\n```\n\nThen, only those with the value of greater than or equal to 18 years will remain in the data frame. \n```python\npatients = patients['age_str'].filter(patients==\"eligible\")\n```\n\n```text\n    age_str  age  age_cat_1  age_cat_2  family_name  family_id  id\n0              18      18.5            17-18_yo  Female    -8 2139\n1              19      22             19_21_yo  Female  -6     457\n2              ADULT     ADULT            Adult  -6 28709\n3              ADULT     ADULT            Adult  -68 AD\n4              18      18.0            17_yo  Female    -2 27764\n5              19      22.0           19_yo  Female  -15    811\n...               ...          ...          ...          ...\n49              ADULT     ADULT            Adult  -3    43",
        "label": 2
    },
    "265": {
        "output": "<a href=\"https://data.mendeley.com/datasets/d3zj3twbj2/2\" title=\"Dataset 1\"><NAME] vs [NAME]: Clinical Trial Recruitment in Java</a>\n![Clinical Trial Recruitment](../assets/recruitment_2.jpg \"Clinical Trial Recruitment\")\n<EOD> Apoptotic Cell Death Is Required in the Cerebellum for the Development of Topographic Wireless Activity Patterns\nTopographic organizations of neural connections are hypothesized to arise when axons from different neuronal groups project to nearby dendritic fields. Such an \u201cemergent connectivity\u201d has been shown previously to emerge in networks of rat cerebellar Purkinje cells (PCs), which are reciprocally connected with their neighboring PCs via parallel fibers and to form a topological network. A similar PC-to-PC connectivity has recently been demonstrated in human cerebellar cortex, suggesting that this connectivity is common to humans as well. Nevertheless, it has remained unknown how the axonal projections in the developing PC network are established. In the present study, we examined the effect of apoptotic cell death on the PC network of developing rat cerebellar cortex, whose emergent connectivity is likely to parallel that in human cerebellum. After blocking apoptosis by intracerebroventricular administration of decoy oligodeoxynucleotide (ODN) bearing the anti-sens binding motif of Fas, the mutual contacts of the PC somata, parallel fibers, and dendritic fields on the postnatal day (P) 2 (6 days after ODN treatment) were found to be similar to those in wild type rats. In contrast, on P60, contacts between PC somata were significantly increased on the ODN-treated side. Immunohistochemistry demonstrated that, compared to wild type rats, ODN-treated rats had markedly reduced numbers of Purkinje-cell-specific interneurons (PCSIs) and Purkinje cell dendritic spines in the P60 cerebellum. Our results demonstrate the significance of apoptotic cell death in the establishment of topographic patterns of parallel fiber ax",
        "label": 2
    },
    "266": {
        "output": "We expect that you find your way to the solution without the hints. Good luck! [EXIT]\n<EOD> .\nOBJECTIVE\nTo investigate the clinical efficacy and the safety of anlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).\n\n\nMETHODS\nClinical data of 20 advanced NSCLC patients treated with anlotinib from February 2016 to January 2017 were analyzed retrospectively.\n\n\nRESULTS\nAll patients had advanced NSCLC, including 15 men and 5 women, with a median age of 62 years (range, 38-80). All 20 patients had received first-line standard platinum-based chemotherapy plus or minus other target therapy, with disease progression prior to anlotinib treatment; 14 patients had received two or more lines of therapy, 5 with positive EGFR gene mutation, 19 harbored wild type EGFR. All patients received anlotinib 12 mg orally once a day (qd), and 3 received 10 mg qd. One patient used 8 mg qd due to the intolerable toxic reactions. After initial dose administration of anlotinib monotherapy, the drug-related adverse events of grade one to six were recorded in 19 patients, including three patients who occurred adverse events of grade three to four, among whom 11 patients had experienced hypertension, 2 of whom also with hand-foot syndrome, 8 patients had fatigue, 1 with decreased platelets, 1 with liver function damage, one with gastrointestinal bleeding, 4 patients had diarrhea. The treatment efficacy was evaluated according to the tumor response evaluation using RECIST 1.1, including complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD). Among all the patients, the overall response rate (ORR) was 35.00% (7/20), including 3 patients with PR and 4 with SD; the disease control rate (DCR) was 80.00%(16/20), including 9 cases with PR,",
        "label": 0
    },
    "267": {
        "output": "### 3.8) When the person declines participation, ask him/her for detailed reasons. Be sure to record your discussion on the patient record.\n\n[INST] If the person declines participation, thank him or her for time. Do not try to convince to participate, but instead thank her or him again and record your discussion on the patient record. \n\n### 3.9) Ask him/her, if he/she also has someone accompanying him/her to share the information with.\n\n[INST] If the person wants",
        "label": 0
    },
    "268": {
        "output": "[OUT] This is the end of the session. Congratulations on passing! You did it.\n<EOD> Effect of 1,5-anhydroglucitol (1,5-AG) on endothelial cells dysfunction: implications for diabetic nephropathy.\nOBJECTIVE\nIn previous study, we found that the administration of 1,5-anhydroglucitol (1,5-AG) improved the endothelial dysfunction of diabetic heart. The purpose of this study was to determine whether 1,5-AG could prevent endothelial dysfunction of kidney through improvement of glycemic control in diabetic animals.\n\n\nMETHODS\nRats were randomly allocated to either normal control group, streptozotocin-induced diabetic group (DM), and STZ-induced diabetic group with 1,5-AG administration (DM-AG) for 6 months. 1,5-AG was administered daily by intragastric administration (40mg/kg). Blood glucose and glycosylated hemoglobin (HbA1c) were measured at the end of the study. Renal artery flow and microvascular endothelium-dependent relaxation response were measured using Doppler flow meter and Doppler echocardiography respectively.\n\n\nRESULTS\nIn the normal control group, blood glucose levels were 5.12 \u00b1 1.0 mmol/L and HbA1c levels were 4.6 \u00b1 0.8%. After the induction of diabetes mellitus, blood glucose levels and HbA1c levels were respectively 15.7 \u00b1 3.9 mmol/L and 16.0 \u00b1 2.0%. When compared to DM, blood glucose level in DM-AG group was significantly lower (11.4 \u00b1 3.0 mmol/L). While HbA1c levels were not significantly different between DM-AG group and DM group. Compared with the normal control group, renal resistances were higher in the DM group (0.22 \u00b1 0.06, 0.45 \u00b1 0",
        "label": 1
    },
    "269": {
        "output": "Please download the following ZIP file which was used in the above code.\nTARGETED_IOTA.txt\n\n\n---\n### Exercise 2: Eligible or Not Eligible by Patient ID in the `patients_summary.csv` file\n\n[INST] Here, we try to determine to which clinical trial of the patient ID in `patients_summary.csv` file a patient belongs.\n\nPlease consider the following patient record. In this column `patientID`, the ID of the patient is shown. \n\nPatient ID : 7 \nFirst name             : Emily\nLast name              : Bromfield\nDate of birth           : 1993-09-12\nPatient ID: 30\nFirst name             : Alicia\nLast name              : Cream\nDate of birth           : null\nPatient ID: 31\nFirst name             : Carmela\nLast name              : Chambers\nDate of birth           : null\n\nHere are some clinical trial information. In this column `trialID`, the ID of the trial is shown. A clinical trial trialID is generated as shown in the example below:   \n\nFirst, let's compare the patient ID and trial ID in these 2 rows above the patient ID and trial ID: \n\nFirst row: `patientID: 7`,`trialID: 4`\nSecond row: `patientID: 30`,`trialID: 6`\n\nThen, we should check eligibility of clinical trials in these 2 rows. \n\nLet's use this sample code. \n\n```python\nimport pandas as pd\n\ndef patient_eligible(trialid, patientid):\n    # Check inclusion criteria\n    df = pd.read_csv(\"patients_summary.csv\")\n    trialId = df[\"trialID\"]\n    patientId = df[\"patientID\"]\n    # Create trial information by patient ID\n    trial_info = dict()\n    for trialId in df[\"trialID\"]:\n        trial = df[df[\"trialID\"] == trialId][[\"firstname\", \"lastname\", \"dateofbirth\"]]\n        patient_name = trial[\"firstname\"].",
        "label": 0
    },
    "270": {
        "output": "## [EVAL] Hello. You are the program to evaluate the eligibility of patients in a clinical trial. You are given a patient note and a clinical trial to perform the evaluation.\n\n[EVAL] Input both patient note and trial to the program, e.g., 48\\[INPUT\\] 09E7A3 01134528\n\nYou may use \\n as the new line for the program, e.g., 48\\n\\n09E7A3\\n0113\n\n\n\n# Result\n\nThe result of the program is as follows:\n48\\nInclusion Criteria: [01134528]\\nInclusion Criteria:[01134528] 1. Patient is 50 years or older (age must be >= 50 years\nfor trial enrollment)\nInclusion Criteria:[01134528] 2. Invasive ductal carcinoma of breast\nInclusion Criteria:[01134528] 3. Postmenopausal (menopausal status of women is defined by a period of 12 months of amenorrhea \n[228][229] \nInclusion Criteria:[01134528] 4. Breast cancer is locally advanced (Stage IIA\\2B or Stage III) (breast cancer tumor must be a minimum of Stage 2A, but not greater than Stage 3A)\nInclusion Criteria:[01134528] 5. Histologic grade of 2 or 3\nExclusion Criteria:[01134528] 1. Patient is under age 65 years (age must be <= 65 years for trial ineligibility)\nExclusion Criteria:[01134528] 2. Invasive lobular carcinoma (IHC result must be positive)\nExclusion Criteria:[01134528] 3. Lymphovascular invasion in initial core biopsy\nExclusion Criteria:[01134528] 4. Recurrent breast cancer (",
        "label": 0
    },
    "271": {
        "output": "<EOD> Effects of long-term low-dose alcohol intake on hepatic mRNA for a variety of glucose and fatty acid metabolic enzymes.\nLong-term studies have reported that ingestion of alcohol in low amounts does not lead to steatosis. We investigated 30 healthy men, who drank an average of 47 g of alcohol/day. Total cholesterol, triglycerides, 3-hydroxybutyrate, insulin, glucose, fructose, uric acid, and aminotransferase as well as alcohol concentration in serum, and fatty acid composition of erythrocytes and of the diet were measured. Liver samples were taken at laparoscopy to examine whether alcohol intake for long-term leads to changes in the mRNA levels of a variety of glucose and fatty acid metabolic enzymes by northern blot analysis. Although there was a significant improvement in insulin levels and glucose tolerance, no changes were seen in lipids, aminotransferase, glutamic pyruvic transaminase and glutamic oxaloacetic transaminase. Levels of SGOT and SGPT were within normal limits. We could only demonstrate a small increase in serum fructose for the study group. The mRNA levels of pyruvate carboxylase, phosphoenolpyruvate carboxykinase (PEPCK), fatty-acid synthase (FAS), and glucose-6-phosphate dehydrogenase (G6PDH) were not changed. However, mRNA levels of carnitine palmitoyltransferase, malic enzyme, and phosphorylase were significantly increased when compared with the control group. Therefore, in this study, we did not find evidence for the development of steatosis, although the mice with long-term alcohol exposure display a characteristic alteration in the fatty acid composition of their lipids. The different mRNA patterns of the animals with ethanol and the control are a consequence both of the altered diet and the prolonged alcohol intake.<EOD> 68Ga DOTANOC imaging in a patient with",
        "label": 0
    },
    "272": {
        "output": "## How to run the example of `clinical_trial`\n\n\n```r\n# This is the clinical trial note\nclinical_trial <- \"\n  The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n  \"\n\n# This is the clinical trial summary\nclinical_trial_summary <- \"\n  Summary: This study is to see how safe the use of short-term fasting is in breast cancer patients who will receive chemotherapy before undergoing surgery and to examine if the use of short-term fasting will decrease the side effects of chemotherapy and how much a tumor shrinks while receiving chemotherapy.\n  \n  Inclusion criteria: Inclusion Criteria:\n  <b>Patients \u2265 18 years of age with histologically, and radiographically confirmed non-metastatic breast cancer with minimal tumor size over 1 cm (\u2265T1c lesion) to receive neoadjuvant chemotherapy recommended by the treating physician\n  For estrogen receptor (ER) strongly positive, human epithelial receptor (HER2) negative breast cancer, Oncotype Dx study is required. Patients with low recurrence score will be excluded in the study.\n  Eastern Cooperative Oncology Group (ECOG) performance status score < 1\n  Absolute neutrophil count > 1500 mm3, platelet count \u2265 100\u00d7109 L, hemoglobin \u2265 8.5 g/dL\n  Serum creatinine \u22641.5 times the upper limit of the normal range, total bilirub",
        "label": 0
    },
    "273": {
        "output": "_**Exercise 3**_\n\n<img src=\"../images/2-3.PNG\"/> \n\n<EOD> Complementary and Alternative Medicine Use in a Pediatric Liver Transplant Clinic Population: A Retrospective Study.\nOBJECTIVES\nWith the rising popularity of complementary and alternative medicines in the general population, clinicians must be aware and vigilant regarding their use by children and adolescents.\n\n\nMETHODS\nA retrospective chart review of all the patients who were at least 11 years old who received a liver transplant at Children's Hospital of Alabama from 2005 to 2017 was conducted. Demographic and clinical information for all patients was collected. Complementary and alternative medicines/ remedies used by patients were analyzed to determine the frequency of use, types of complementary and alternative medicines/remedies used, timing of introduction as well frequency of use, and potential herb/drug interactions with conventional treatment regimens.\n\n\nRESULTS\nOut of 1103 transplants performed, 374 patients were at least 11 years old at time of transplant; 25 of these were eliminated due to lack of medical records or having inadequate information in the records. Out of 209 patients included in the study, 38 patients (18.23%) used complementary and alternative medicines/remedies. The most commonly used complementary and alternative medicines/remedies were supplements (3), meditation (4), chiropractic care (5), herbs (6), and spiritual/faith healing (25), respectively.\n\n\nCONCLUSIONS\nA majority of children and adolescents on long-term medications and chronic therapy used supplements, meditation, and alternative remedies without disclosure. In addition, there is need to have guidelines to help parents and caregivers understand the potential adverse effects and interactions of using these herbs with conventional therapies.<EOD> Effect and safety of nursing intervention bundle for critically ill neonates with sepsis: a multicenter randomized controlled trial.\nContext\nCritically ill neonates with sepsis are at high",
        "label": 2
    },
    "274": {
        "output": "Now, we can perform the first round of validation, which means you are expected to find the correct result and verify the output file.\n\n```\npython src/test.py\nTrial-level eligibility: 2) Eligible.\n```\n\nThe output indicates a correct answer that shows the patient meets the trial. [INST]\n\nIf the answer is incorrect, then we may check one of the clinical trial code. [INST]\n\nFinally, you can run the second round of validation. \nTo do this, you should check the accuracy of your code; the first round of validation will not be run. That is a time limit for the question and does not return a result. The code runs fine, but it seems to produce the wrong output. \n\n![result](../res/img/result.png)\n\nPlease also refer to a solution for each round of validation. [INST]\n\n[INST]\n\n# Contributing\n\n## Protocol Template\n\nEach question of the challenge provides a template protocol for writing the Python code. For each question, we will provide you three template files (protocol_part.txt, solution.txt and validation.txt). See  the [protocol_part.txt](src/protocol_part.txt) for the [first_question](first_question/README.md).\n\n# I'm done!\nThank you for following us and we're excited to see your submissions!\n<EOD> Acute kidney injury in children\n\nKidney International Reports (2019) 4, 644-648; https://doi.A c u t e kidney injury (AKI) is an important clinical syndrome that is defined by a sudden decrease in kidney function and commonly triggered by stress insults to the renal perfusion and tubular cell processes. This review summarizes the epidemiology of AKI in hospitalized children, its causes, and its diagnosis, management, and prognostic implications. AKI is a common complication of hospitalized children that affects ~36% of all pediatric admissions, many of whom have significant risk of progression to long-term dialysis dependence. The incidence of AKI is similar among inpatients of both the pediatric intensive care unit",
        "label": 0
    },
    "275": {
        "output": "### Question 5:\nYou are asked to choose the correct order of evaluation of criteria when using this feature. \n\n`Assessments -> Exclusion Criteria -> Inclusion Criteria`\n`Exclusion Criteria -> Assessments -> Inclusion Criteria`\n`Inclusion Criteria -> Assessments -> Exclusion Criteria` (CORRECT)\n`Exclusion Criteria -> Inclusion Criteria -> Assessments` (CORRECT)\n`Inclusion Criteria -> Exclusion Criteria -> Assessments` (INCORRECT)\n`Inclusion Criteria -> Assessments -> Exclusion Criteria` (INCORRECT)\n\n[/MULT]\n\n### Question 6:\nDuring clinical research, study site visits (also known as monitoring visit) are often necessary. In this question `Study site visit`:\nWhat is the purpose of conducting site monitoring visits?\nA.\nTo meet study goals by ensuring that all individuals with whom the researcher communicated, including, but not limited to, participants, study staff, consultants, and site personnel, are aware of the project's goals and activities.\nB.\nTo maintain study integrity and to support human subjects rights and protections.\n\nC.\nTo demonstrate the ability to comply with standards described in protocols, ICH-GCP-E6(R2), applicable regulations, and applicable standards when conducting clinical research.\nD.\nTo establish a baseline for data and operational processes to identify potential issues.\n\n\nE.\nANSWER: C (CORRECT)\nSite monitoring visits are an important tool to help ensure that the study is being properly conducted. They are also an opportunity to educate the staff on their role in protecting human subjects and ensuring the confidentiality of clinical research study material/records. \n\n# Question 7\n\n### Question 7:\nThe inclusion criteria of clinical trial have a four-point scale: 0 Excluded; 1 Not relevant; 2 Eligible; 3 Excluded with reason.\nIf trial criteria are assessed as three (0, 1, 2 and 3 respectively), you should enter the trial-level eligibility of this clinical trial as eligible.\nIf trial criteria",
        "label": 0
    },
    "276": {
        "output": "For more information on formatting and executing an i2b2 report, refer to the [i2b2 Report Specification](../../../specification/2015-04-08/).\n\n### Outputs\n\n``` json\n\"status\": \"OK\",\n  \"message\": \"Successfully executed with i2b2 version v3.1.2\",\n  \"results\": [\n    {\n      \"id\": \"trial_id\",\n      \"trial_name\": \"Test1\",\n      \"title\": \"Patient-level eligibility assessment\",\n      \"patient_id\": \"patient_id\",\n      \"patient_name\": \"Patient Name\",\n      \"primary_diagnosis\": \"Breast cancer\",\n      \"patient_age\": 45,\n      \"treatment_phase\": \"Screening\",\n      \"patient_weight\": 67.20,\n      \"gender\": \"F\",\n      \"gender_specific_age_range\": [],\n      \"gender_specific_age_range_low\": '',\n      \"gender_specific_age_range_high\": '',\n      \"treatment_start_date\": \"2018-05-30T00:00:00.000+00:00\",\n      \"treatment_stop_date\": \"\",\n      \"treatment_category\": \"Interventional\",\n      \"treatment_type\": \"chemotherapy and tumor resection\",\n      \"treatment_start_date_past\": \"\",\n      \"treatment_stop_date_past\": \"\",\n      \"patient_smoking\": \"no\",\n      \"patient_alcohol\": \"no\",\n      \"patient_sexual\": \"no\",\n      \"patient_gender\": \"female\",\n      \"patient_marital\": \"single\",\n      \"patient_child\": 0,\n      \"birth_location\": \"Santo Domingo, Dominican Republic, OCARC-2008-2792\",\n      \"birth_date\": \"2000-04-20T00:00:00.",
        "label": 2
    },
    "277": {
        "output": "#### : [* *](https://github.com/deep-ml/study/blob/main/_institution/03_problemsolving/chapter3/data/patient_recruitment.csv) [**README.md**](README.md)\n**Exercise**: Please give input to the file `patient_recruitment.csv`.\n#### : [* *](https://github.com/deep-ml/study/blob/main/_institution/03_problemsolving/python/patient_recruitment_py.py) [**README.md**](README.md)\n**Exercise**: Please write a script `patient_recruitment_py.py` according to instructions above.\n#### : [* *](https://github.com/deep-ml/study/blob/main/_institution/03_problemsolving/python/patient_recruitment_py_py.ipynb) [**README.md**](README.md)\n**Exercise**: Please write a script `patient_recruitment_py_py.ipynb` according to instructions above.<EOD> .\nIn a prospective randomized long-term study, an investigation was performed into the effect of the antioxidant drug idebenone in the treatment of chronic alcoholism. Of a total of 118 alcoholics participating in the study 63 were given idebenone additionally to the standard therapeutical regime, and 55 patients were given a placebo. The course of the alcohol syndrome was observed on the basis of various parameters (subjective assessment, objective assessment of alcohol dependence, biometrical evaluation, EEG) for up to 18 months. The assessment of the results showed that the antioxidant drug idebenone proved to be effective with respect to the various parameters used in the treatment of chronic alcoholism. Idebenone should be part of the therapy for ethylalcohol abuse.<EOD> Effect of the administration of prolactin inhibitory factor to women with postpartum lactation.\nFresh human milk contains a factor which suppresses the release of PRL and in vitro, it blocks the responsiveness",
        "label": 0
    },
    "278": {
        "output": "In the following section `Clinical trial code - 15656`, we show all the necessary data in the notepad. Copy the data and paste it as you normally do when you need to perform the eligibility assessment.\nNotepad: Patient eligibility:\n```python\n       \n        # MEDICAL CENTER\n        Patient name: \n            ID: \n            Sex: \n            Age: \n            Marital Status: \n            Children: \n            Education: \n            Socioeconomic Status: \n            Hand dominance: \n       \n        Patient notes\n            Patient Clinical Data: \n                HER positive:\n                ER / PR positive:\n                Lymphovascular invasion negative:\n                Tumor grade:\n\n        Eligibility:\n            Inclusion criteria:\n                Inclusion criteria 1:\n                    Title:\n                Inclusion criteria 2:\n                    Title:\n                Inclusion criteria 3:\n                    Title:\n                Inclusion criteria 4:\n                    Title:\n                Inclusion criteria 5:\n                    Title:\n                Inclusion criteria 6:\n                    Title:\n                Inclusion criteria 7:\n                    Title:\n                Inclusion criteria 8:\n                    Title:\n                Inclusion criteria 9:\n                    Title:\n                Inclusion criteria 10:\n                    Title:\n       \n        Clinical trial\n            Trial-level eligibility:\n                Excluded:\n                Not relevant:\n                Eligible:\n            Trial Criteria:\n                Exclusion criteria:\n                    Inclusion criteria 9:\n                    Inclusion criteria 10:\n                    Title:\n### HAPPY END\n```\n<issue_comment>username_5: This is really helpful! Thanks!\n<issue_comment>username_0: @username_5 Is there anything I can help you with? I know that every clinical trial that you are working with has clinical trial notes and eligibility assessment notes that you have to analyze. I hope that there is no need for you to spend time on that.\n<issue_comment>username_6: Hi @username_0  It is great",
        "label": 1
    },
    "279": {
        "output": "<EOD> The complete mitochondrial genome of Phrynocephalus putjatai (Sauria: Lacertidae)\n\nThe complete mitochondrial genome of Phrynocephalus putjatai (Sauria: Lacertidae)The complete mitochondrial genome of Phrynocephalus putjatai (Sauria: Lacertidae)\n10.1080/23802359.2019.1685296Received 31 August 2019 Accepted 2 October 2019MITOGENOME ANNOUNCEMENTmitochondrial genomeComplete mitochondrial genomePhrynocephalus putjataiLacertidaeSauriaChina\nThe complete mitochondrial genome of one specimen of Phrynocephalus putjatai from Fujian, China was examined in this study. This genome consists of 16,719 bp, including the complete control region, 22 tRNA genes, 13 protein-coding genes (PCGs) and two rRNA genes. All protein-coding genes are initiated by atp6 and cob. The stop codons TAA are absent in eleven genes (ATP6, ATP8, COXIII, CYTB, NAD1, NAD4L, NAD5, NAD6, NAD4, NAD2, and NAD3), TAA, TA, and T were found in the COI gene, while TAG, TTG, TA, and T were found in the ND2, COII, ND3, and ND4L genes, respectively.ARTICLE HISTORY\nLacertidae; mitochondrial genome; Phrynocephalus putjatai; Sauria Phrynocephalus putjatai is a small species of agamid lizard native to Central Asia, Afghanistan, Iran, Kyrgyzstan, Tajikistan, Uzbekistan, and northwestern China. Recent studies of P. putjatai in China are not available. In this study, we assembled and presented the complete mitochond",
        "label": 0
    },
    "280": {
        "output": "## What is the purpose of this assessment task?\nThis assessment task is intended to evaluate your ability to interpret and analyze clinical patient notes. You will assess trial-level eligibility using several features, such as clinical trial information and disease information of patients.\nYou will first understand the structure of patient notes. In this task, you will learn about the assessment of eligibility, which is a key concept of this assessment, at the level of clinical trials.\n\n# Step by step\nTo access [this assessment task](http://s3239.web.aplus.net/d/16553977/996282/16553977-20220513054844125.pdf), go to [this URL](http://bit.ly/2wbhF2K).\n\nIn this assessment, we are providing three [clinical trial notes](https://docs.google.com/document/d/16553977/edit?usp=sharing).\n\n\n## Instructions\nThere are 3 clinical trial notes for this assessment.\n\n# Interpretation of patient notes:\n1. You are expected to demonstrate your ability to interpret clinical trial patient notes through trial-level eligibility assessment.\n2. Read each patient note and try to determine the patient's suitability for participation in this study by evaluating whether the patient meets the trial eligibility criteria.\n3. Write your trial-level eligibility assessment after reading each patient note.\n4. In this task, we are also providing the clinical trial information of the studies. You should use it for the case of 'eligible, not relevant' cases where there is lack of information about a patient.\n\n# Submission\nAfter writing your assessment, submit it to [Asses-sment1.GoogleForm](https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrHxA4tCOc/viewform?usp=sf_link) by [clicking on this link](https://",
        "label": 0
    },
    "281": {
        "output": "Here are the rules:\n\n\n\nTrial-level eligibility: Excluded if at least one of the exclusion criteria is met.\n\n- Exclusion criteria:\n   \n   1) Previous mastectomy.\n   2) Breast cancer is not the only cancer in the body.\n   3) Other cancers, such as leukemia.\n   4) History of malignant tumor in the past 5 years.\n   5) Lack of interest in treatment and lack of motivation to participate in a trial.\n\n    Other exclusion criteria:\n   \n   1).1) Breast cancer was diagnosed 3 months ago or less.\n   1).2) Current pregnancy (within the last 6 months) or planned pregnancy in the next 2 years.\n  \n   2).1) The patient is not able to take the medicine by mouth.\n   2).2) The current or planned pregnancy (within the last 6 months) or planned pregnancy in the next 2 years.\n\nLet's try to do it step by step.\n\nTo do the task:\n\n1.  Copy the file `Trial_Clinic1_patient_note.pst`.\n2.  Open the file in the Text Editor (Notepad).\n3.  Look at Figure 1. The patient note has 4 parts:\n\t* [PART-A]: General information.\n\t* [PART-B]: Exclusion criteria.\n\t* [PART-C]: Inclusion and exclusion criteria.\n\t* [PART-D]: Details of breast cancer.\n\t* You will find information about each part as follows:\n\t  - [Part-A]: General information.\n\t   * The age of the patient in years is at the top of the page.\n\t   * A medical condition in this patient note is \"candidate for tumor resection\".\n\t   * An exclusion criterion is \"has breast cancer\".\n\t   * A medical condition in this patient note is \"breast cancer\".\n\t  - [Part-B]: Exclusion criteria.\n\t   * Only one exclusion criterion is found here: \"History of malignant tumor in the past 5 years\".\n\t  - [Part-C",
        "label": 0
    },
    "282": {
        "output": "[INST]\nHello. You are asked to predict the trial-level eligibility for new patients. You should predict the trial-level eligibility of the patients for clinical trial in the patient-level prediction phase. \n\nThere are six patients. Here is the patient-level data:\nHere is another patient-level data:\nWe will present the following variables in the patient-level prediction phase: \n\nPatient gender: male, female, both, or unknown\nPatient age: 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9, or 10, 11, or 12\nPatient race: Black, Hispanic, Caucasian, API or Pacific Islander, or Other or Unreported\nPatient marital status: Never Married, Married, Widowed, Divorced/Separated, or Unreported\nPatient insurance status: Medical Insurance, No Medical Insurance, other, and Not Specified\n\nPatient stage: Stage I, II, III, or unreported\nPatient smoking status: Current, former, never, or Not Specified\nPatient alcohol status: Regularly drinking, less than 1/wk, 1-4/wk, 5 or more/wk, former drinker, and Never drinker\nPatient disease: lung neoplasm, prostate neoplasm, colorectal neoplasm, breast neoplasm, hematopoietic and lymphoid neoplasm, bladder neoplasm, renal cell carcinoma, ovarian neoplasm, or other and unreported disease\nPatient tumor number: 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9, or 10, 11, or 12\nPatient tumor size: <= 3 cm, > 3 cm, Unreported, or Not Specified\nPatient chemotherapy type: 1st generation cytotoxic chemotherapy (e.g., vincristine, mitomycin-C or doxorubicin),",
        "label": 0
    },
    "283": {
        "output": "if  can_see_patient?(:in_test) && patient.clinical_trial\n      @patient_level_note = patient.clinical_trial.notes.build do |n|\n        n.event = @patient\n      end\n    end\n      @patient_level_note.update_trial_eligibility\n\n    if can_see_patient?(:in_test) && !patient.clinical_trial\n      # Create a trial eligibility note for the clinical trial.\n      @trial_level_note = Trial::EligibilityNote.new(@trial, patient)\n      @trial_level_note.update_trial_eligibility\n    end\n      # Create a trial recruitment note.\n      @patient_level_note.update_clinical_trial_status.recruitment.update(:started_at => Time.now)\n      send_mailer_report @patient, @assistant_record\n\n    if can_see_patient?(:not_in_test) && patient.clinical_trial\n      # Create a trial note here if the patient has clinical trial data.\n      @patient_level_note = Trial::EligibilityNote.new(@trial, patient)\n      @patient_level_note.update_trial_eligibility\n      @trial_level_note = TrientNote.build(:start_time       => @patient_level_note.start_time,\n        :assigned_to_id    => @patient_level_note.assigned_to.id,\n        :clinical_trial_id => @trial,\n        :eligibility_note_id => @patient_level_note,\n        :target          => @clinical_trial.target)\n      @trial_level_note.update_trial_eligibility\n\n      # Create a trial recruitment note.\n      @pat",
        "label": 2
    },
    "284": {
        "output": "If you need to change the patient ID, use `patmentID = [id_of_new_patient];`. [INST]\n\nA trial-level-eligibility output from the `patpat` command is as follows:\n\n    Trial-level eligibility: 2) Eligible.\n\nAnd if you change the patient-level status to excluded using the `patpat` command, you will obtain the following:\n\n    Trial-level eligibility: 1) Not relevant.\n\n## Example 3. If you want to change the status of all patients:\nIt is possible to change the status of all patients (patpat), but you must provide a patient ID or a list of patient ID(s) along with `patpat = <patientList>`, otherwise it will print an error message.\nFirst, let's analyze all the patients from the trial. If the patients do not match the trial, you will receive the error message in the first line. Then we can see that seven patients are in the trial.\n\n    > trial-patient-summary-statistics-and-censoring -d -r <id_of_patient_or_patients-list-of-patients-id> --patient-id <patientID_id_of_patient_or_patients-id-list> --output-to <outputfile-file> -v <verbose_mode> -r -e -s -c --output-table=\n    ******************************************************************************\n    * Error: Patient ID=xxxxxx008 was not found in the trial record ID=2016_201_12-4145-00-ABR.\n    ******************************************************************************\n    Trial ID: 2016_201_12-4145-00-ABR\n    Patient ID: xxxxxxx008\n    Eligibility:\n    # Status: Excluded\n    Trial-level eligibility: 1) Excluded.\n\nNext, we change the status of all of the patients, but they are different patient IDs. You will receive errors (we have to use 9 lines for `patpat = <patid_patients",
        "label": 0
    },
    "285": {
        "output": "```\n\n\n<EOD> Fixed-dose combination of tenofovir+lamivudine-efavirenz among antiretroviral-na\u00efve HIV-infected patients at South Indian Centre\n\nBackground: A retrospective study was conducted to assess the virological efficacy, safety and tolerability of fixed doses combination (FDC) of tenofovir + lamivudine + efavirenz (TDF+3TC+EFV) among antiretroviral treated na\u00efve HIV infected patients to see the virological efficacy at 1 year, 2 years, and 3 years follow up.Materials and Methods:Patients were included in the study on the basis of inclusion and exclusion criteria. They were followed up for monitoring clinical, laboratory parameters. Virological efficacy was assessed with repeated CD4+ count at 1 year, 2 years, and 3 years. Adverse events, any clinical symptoms, and drug interactions were notified to the treating physician.Result: A total of 708 patients were included in the study and among them 577 and 131 were male and female patients, respectively. CD4+ count was increased in",
        "label": 0
    },
    "286": {
        "output": "## Summary\nFit the patient onto the clinical trial\n<EOD> .\nThe authors report a case of an aneurysm of the superior longitudinal fissure of the medulla oblongata which was an incidental radiologic finding (CT scan). The anatomo-clinical features and current concepts in this pathology are discussed, and the rare incidence of the location of an aneurysm of the superior fissure and of an aneurysm, in general, are reviewed with the possible relationship with an atrophy of the medullary pyramids.<EOD> Intraocular lymphoma.\nThis report is the fifth in a series of articles regarding intraocular malignancy in the eye, particularly lymphoma, melanoma, and sarcoma. In this report, we review recent updates in the biology and clinical behavior of intraocular lymphoma (IOL) and consider the treatment of primary and secondary (intraocular dissemination of systemic disease) IOLs. Finally, we discuss our institutional experiences with IOL patient care and propose recommendations for the care of patients with primary and secondary IOLs.<EOD> Immunoglobulin G 3 Immune Complexes Elicit Toll-Like Receptor 4-Dependent and Toll-Like Receptor 4-Independent Activation of Macrophages1\nPrimary immunization with tetanus toxin results in the generation of significant amounts of immune complexes within the serum of human volunteers. Immune complexes, but not tetanus toxoid alone, induced TNF-\u03b1 and IL-6 secretion in macrophages in a TLR4-dependent fashion. FACS analysis of macrophages revealed that Ag-containing immune complexes triggered significant, rapid, and durable phenotypic alterations in the expression of Fc\u03b3RI, Fc\u03b3RIIa, CD16, CD36, and HLA-DR. Fc\u03b3Rs and CD36 appeared to be involved in the internalization of the immune complexes and subsequent activation of phospholipase D, a previously reported mediator of TLR4-triggered TNF-\u03b1 release. We also demonstrate that the immune complexes trigger activation of the TLR3",
        "label": 0
    },
    "287": {
        "output": "<EOD> MON\u2010443 CLINICAL PICTURE OF HYPERANDROGENISM IN FEMALE TWO INCIDENTAL CASES HARBORING ULTIMATELY\u2010FOUND MICRODUCTS\n\nMortality risk assessment for incident patients, particularly in elderly patients and older aged subgroups, has never been investigated. We sought to elucidate mortality risk of incident hyperparathyroidism in different age groups.Method: This population-based study was carried out in an area that covered a population of >1.5 million between 2001 and 2017. Incident cases of hyperparathyroidism were identified, and the first day of diagnosis was defined as an index date. The date of death was used to define outcome events. Patients who were diagnosed of hyperparathyroidism within one year were excluded. Incidence rate, mortality rate, standardized incidence ratio (SIR), and standardized mortality ratio (SMR) were compared between patients with hyperparathyroidism and local general population. Moreover, age subgroups-including patients younger than 40, 40-49, 50-59, and 60-69 years old were compared and evaluated.Result: A total of 543 patients (mean age at diagnosis (standard deviation): 56.1 (13.9) years old, 90.5% females) were enrolled. Compared with the local population, the incidence rate of hyperparathyroidism was lower in patients < 40 years old, and higher in patients 50-59 and 60-69 years old (p < 0.001). SIR and SMR in patients younger than 40 years were 0.29 (95% CI, 0.06-1.29) and 0.20 (95% CI, 0.02-2.93); in patients 40-49 years old, they were 0.91 (95% CI, 0.73-1.12) and 1.00 (95% CI, 0.76-1.33); in patients",
        "label": 1
    },
    "288": {
        "output": "The `Trial-level eligibility` field is an optional field.\n\n## 3) Initiate clinicaltrial\n[INST] Initiate a clinical trial.\n[TRIALS] Name. Clinical Trial Name\n[TRIALS] Description. Description of an intervention or interventions to compare.\n[TRIALS] Trial Arm Codes. A list of arm codes for individual trial arms.\n[TRIALS] Arm Name. Name of a trial arm.\n\n[INST] Conclusions. `Please conduct a trial for breast cancer recruitment.`\n[INST] End.\n[INST] Author(s). `Myunghee Bae \n\n## 4) Save the clinical trial by using the `save` button\n[INST] Click to launch the `Launch` menu and run the command: `Save:`\n[INST] Once a trial has been saved, multiple copies of the trial can be created. The trial will be copied to the following locations specified by its name:\n`/opt/conda/lib/python3.6/site-packages/stormic/stormic/trials/`\n`/home/stormic/stormic/trials/`\n[INST] Check the location of the saved trial(s).\n\n## 5) Delete the clinical trial.\n[INST] Run the command: `Delete: `\n[INST] Please follow the following steps.\n\n[INST] Click to launch the `Save menu and run the command: `Back and Next: `\n[INST] Open a file dialog.\n\n[INST] Click to save the file: `stormic-clinical-trial-template.py`.\n[INST] Open `~/.stormic/stormic.json`.\n[INST] Scroll to the `saved_trials` variable and remove all entries for the trial you want to delete from this location.\n[INST] Run the command: `Save:`\n[INST] Go to the `stormic-clinical-trial-template.py` location and run the command: `python stormic-clinical-trial-template.py -c delete`.\n\n## 6) Assess eligibility.\n[INST] Run the command: `Ass",
        "label": 1
    },
    "289": {
        "output": "![Trial-level eligibility][Trial-level eligibility]\n\n### Criteria\n\nThe criteria are the qualifications a patient must possess to be eligible for the trial.   \nOn individual criteria, the comparison is as follows:\n\n\n[Clinical note]:\n- Compare the patient's condition with corresponding criteria values:\n    - If they match exactly, go to step 6.\n    - If they match partially, go to step 4.\n    - Otherwise, go to step 7.\n\n[Trial]:\n- Go to last criterion, and compare the matching value with the corresponding criterion value:\n    - If values match, go to step 5b; otherwise, go to step 5c.\n    - If there is no value, go to step 6.\n    - If the condition of the current criterion and the trial is not match (e.g., there's missing value of trial), go to step 7.\n   \n   \n   \n\n[Step 4]:\n- Go back to last checked criterion.\n    \n- Compare the present state of the condition of the patient with the corresponding allowed value. If a criterion matches partially, go back to [Clinical note][Clinical_note]\n  [Step 5]\n[Step 5a]:\n- Check if the conditions of all criteria match exactly. If yes, the patient is eligible, end the analysis.\n[Trial-level eligibility: 2) Eligible.]\n[Trial-level eligibility: 2) Eligible.]\n\n<h3 id=\"example\">\nExample\n</h3>\n\n{% raw %}\n```\nINST: Hello. \nyou are a helpful assistant for clinical trial recruitment. \nYour task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \nINST: The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is ex",
        "label": 0
    },
    "290": {
        "output": "<EOD> A randomized comparison of prophylactic ciprofloxacin and amikacin in prevention of postoperative infectious complication in patients undergoing cardiovascular surgery\n\nObjectives Prophylactic antibiotics have been used since the first reported successful cardiac surgery. There is no agreement on the best choice of antibiotic prophylaxis, but the optimal antibiotic and its duration of prophylactic use was studied previously based on the severity of cardiac surgery. Ciprofloxacin and amikacin were administered to patients undergoing cardiovascular surgery to compare the efficacy of the antibiotics in preventing postoperative infectious complications. Methods Sixty patients scheduled to undergo cardiovascular surgery from April to September 2009 were included. The patients were randomly assigned to two groups and received single 1500 mg dose of ciprofloxacin or single 300 mg dose of amikacin intravenous infusion 2 h prior to the surgery for prophylaxis. The patients were observed for 24 h and then followed up over 30 day postoperatively to record any postoperative complications. In addition, the following parameters for efficacy of the chosen antibiotics were recorded: white blood cell count (WBC), serum level of (C-reactive protein, CRP), erythrocyte sedimentation rate (ESR), and total body temperature. Results There was no significant difference in the general characteristics of the patients. There was no significant difference between the two groups according to the recorded infection rate. No significant difference was observed between either group according to the CRP, ESR, and temperature. WBC count was significant difference between both groups (P < 0.001). Conclusions Prophylactic ciprofloxacin and amikacin were effective in preventing complications following cardiovascular surgery.\n\n# Introduction\nCardiovascular surgical procedures are being recognized with a major source of bacterial infectious complications [bib_ref]  Risk of prosthetic joint infection and time since surgery in patients using..., Dorn [/bib_ref] .",
        "label": 1
    },
    "291": {
        "output": "In our example, the result is 2.\n\n**Instructions for the second exercise are given below:**\n\n**First Problem:** Evaluate the patient's eligibility and output it in a report. Note that in the example, our trial-level eligibility result is 1). It means that the patient is not included in this trial as eligible. Let's go step by step. \n1. Exclude.\n2. Not relevant.\n3. Eligible. \n\n**Report**\n\nEvaluation of eligibility of a patient to participate in a clinical trial (#59831)\nEvaluated by [NAME]\nInstruction: Exclusion factors: breast cancer; metastatic lesions. Inclusion factors: histologically confirmed; postmenopausal. Assessment of patient's eligibility: 1) Not relevant: patient note does not indicate metastatic lesions and is a woman after menopause. 2) Eligible: patient qualifies for participating in the trial. \n\n**Second Problem:** Output the result Trial-level evaluation. In this assessment, the patient is excluded. Output the result for `Trial-level evaluation:` on the last line by `Trial-level evaluation: `, e.g., `Trial-level evaluation:  0) Excluded.`. In our example, the result is 0.\n\n**Second Problem: Clinical Trial Registration**\n\nYou've learned how to evaluate a patient's eligibility, and now we will discuss the registration of clinical trials. Clinical trial registration began in the US in 1997. Clinical trial registration is an important standard for clinical trials around the world. Its purpose is to provide information on clinical trial research designs to doctors and patients. \n\nAs a professional CRA, you should accurately judge the eligibility of clinical trial participants. Once you register a clinical trial in a clinical trial registry, you should also disclose the results of the clinical trial in accordance with the clinical study registration requirements and timetable. The clinical trial registration data you provide, i.e., the trial title, inclusion and exclusion criteria, is published in a scientific journal.",
        "label": 0
    },
    "292": {
        "output": "# Data Analysis\n- Data tables generated by each challenge are included in the [Data_Table_Challenge_Number] folder.\n\n- The data sets produced after the challenges are saved in folder [Data_-set_Challenge_Name].\n\n- The challenges' best solutions' results are included in the  folder.\n\n\n# Results\n\nThe first results include the first two challenge's output. The first output shows each participant's output, and each table gives the participant's submission time and score, which is their output error rate; the second output displays the scores of the teams that submitted their output to the leaderboard, where you can compare each team's score to the best score in the leaderboard, then the team that has the closest score to the best score in the leaderboard and has the minimum score submitted to the leaderboard, which are marked by red and yellow. The green is the closest score among those that have been submitted, and the yellow is the closest score of the all submitted scores; we mark the team that has the lowest submissions to the leaderboard in its row to compare its results with previous teams and to know which team has achieved its goal to improve the output results and reduce input errors or to be an accurate and more reliable team.\nIn this first leaderboard, you can see that the team that achieved the best score, which has a perfect score of 0.00 in all inputs and is the closest to the best score, which is the green team, scored 0.00 and is in the top team in the leaderboard. This team has a perfect score of 0.00. A team that has a best score in its row has the minimum submissions to the leaderboard, which is the team with the name \"German Medical Informatics Initiative (MII).\" This team scored 0.00 and has the most submissions in the leaderboard. The same goes for the team named \"Cancer Imaging Archives (NCI, USA).\" It scored 0.48 and has the most submissions in the leaderboard; The team named \"Bio2K Challenge Team\" scored 0.40 in the second challenge, and the team named \"Bio2K Challenge Team\" scored 0.00 in the first challenge. This team has the lowest submissions to the leaderboard, and the last team",
        "label": 2
    },
    "293": {
        "output": "The output variable contains the `patient-level` eligibility as well as the `Triallevel` eligibility.\n\n``` \n\n# Output of trial-level eligibility\nEl%ile, El_n %ile)\n```\n\n# \u25a0 Patient-Level Eligibility Score\n\nDemonstrate an example that shows eligibility scores at patient level. \n\n[",
        "label": 0
    },
    "294": {
        "output": "command will start and terminate the Interactive mode in one go. It will show on the screen that your actions are logged in an INSTRUCT document; this file will be saved into the _.teach directory located in your user's _Home/Documents_ directory. You can see it in [fig_ref]  Figure 1: Interactive mode [/fig_ref] .\nFor further reading regarding the structure of an INSTRUCT document, and more information on commands listed here, please check [instruct's website](https://docs.instruct-language.org/command-reference/section-2-basiccommands/-instructions-files-structure/#documents-withinstruct\n\n[BACK] (You can refer to [section-2-basic-commands](#section--2-basic-commands) in Instruct's website to start the basic mode and do some editing.)\n\n## Intermediate Level (Further Exercises)\n\nIf you follow the steps and instructions above, you will be able to evaluate whether the trial participants are eligible for the study. However, if you feel uncertain about your judgment, you can consider whether they are eligible according to the inclusion criteria of the clinical trial. Let's start with the patients you evaluated as \"Not relevant\", so we will need to follow instructions for the next steps. You're in the section entitled \"Not relevant\" in the Intermediate level.\n\nPlease take a look at the patient notes 21 and 22 (page 521) and assess whether they are eligible for the clinical trial \"TITLE: Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.\"\n\nIn case of disagreement or doubt between the assessor and their peers (see next section for an explanation), you must make the necessary explanations, i.e., \"Assesses not relevant\". You must do so by creating an additional row inside the table under the name \"Comments and discussion\" with an explanation in the last column. The comments may refer to a certain part of the patient note indicating the missing information, or the answer to a question, or referring to more than one part of the patient note. However, always assess all the",
        "label": 0
    },
    "295": {
        "output": "Note: The last four lines are included just for you to understand them. You do not need to print them.\n\n##[RANDOM] Hello. You are a helpful assistant for clinical trial recruitment, tasked with reviewing eligible patients and assessing whether they meet the requirements of a specific clinical trial.[/RANDOM]\n\n# C223.4_05 Exercise 3\nYou must provide at least one reason for rejection from [/PREPROCESS] the clinical trial. It is essential that the reason reflects the clinical trial's exclusion criteria. For example, \"The patient does not speak English. (This is stated in the exclusion criteria of the clinical trial).\"\nClinical trials require that patients should receive a new therapy safely, while all ethical aspects, i.e., dignity, integrity, rights, vulnerability, and informed consent, are properly addressed.\n\nYour goal is to find a suitable therapy for a specific patient; therefore, you must assess the patient's eligibility to the clinical trial. To make it easier to understand how this process proceeds, we give some examples of clinical trials.\n\n* Clinical Trial 1: The goal of this clinical trial is to learn more about how mast cells in the blood can help cancer to grow. The investigators want to know how these cells can affect tumor growth. To do this, they are doing a genetic study of a cancer called medullary thyroid cancer, which is an uncommon type of cancer of the thyroid. In the first step, they are collecting genetic information from cells of patients with medullary thyroid cancer. They may also take a small sample of the patient's blood. They will use a laboratory test to check the blood for tumor cells. It is thought that blood samples containing tumor cells may help scientists to better understand how mast cells interact with normal cells and cancer cells.\n* Clinical Trial 2: In this study, the scientists want to look at the genetic changes that occur in colon and rectal cancer over time. They will gather and compare cancer tissue and normal tissue samples (i.e., samples of the healthy cells that surround the cancer cells). They will also be able to compare the cancer tissue samples",
        "label": 1
    },
    "296": {
        "output": "### [INST] Hello.\nYou are a helpful assistant for a clinical trial recruitment.\n\nYour task is to evaluate patients for the ability to provide written informed consent and for mental capacity, and to create a text block about a patient for the clinical trial information leaflet.\n\nYou should always repeat the Informed consent template in the last line by `Informed consent template: Informed written consent for the clinical trial was obtained.`, e.g., `Informed consent template: Informed written consent for the clinical trial was obtained for participation by XXX (03.17.17) and YYY (11.12.17).`. \n\nYou should follow the instructions.\n\n1. The text block about a patient for the clinical trial information leaflet is an example of a template: `\u2026\nYou will need to complete each line and edit the wording so that it matches your own hospital's requirements and style. If you use the clinical trial name, please remember to replace this with your own clinical trial name before sending the information leaflet to print.\nThe date this information was last reviewed/validated should be the date of the patient leaflet and if any of the information was changed or approved by a sponsor it should state the new date that this occurred. For example, if the leaflet was approved by the sponsor on 12/3/2020, this should come after the date you have stated the date the information was last reviewed. Please use the same format that you used on the informed consent form, so we can easily match documents, and avoid confusion about the version dates.\nAdd additional lines or add to the end",
        "label": 2
    },
    "297": {
        "output": "## [TUTIOIN] \n1.3.7 In-situ thyroglobin level: cytological analysis of punctured lymph nodes. The lymph node is stained with Alcian-blue (an anionic dye that binds to the nonfatty acid portion of thyroglobin) followed by a staining of the fatty acid portion with Sudan III (a neutral lipophilic dye). Thyroglobin is stained with the anionic dye. Positive control lymph nodes, from patients with cervical metastatic spread of differentiated thyroid cancers, consistently stain positively for both, Alcian-blue, and Sudan III stains. Negative control lymph nodes consistently stain positively for Alcian-blue only. \n[TUTIOIN] Different metastatic breast cancers (from the same patient) have different",
        "label": 0
    },
    "298": {
        "output": "</INST>\n\n\nA: You can create an eligibility statement: \nfunction eligibility_statement(person, trial_id, eligibleness)\n  eligibleness = eligibleness/100\n  if eligibleness > 0.5\n    \"Eligible (eligibleness is percent in eligible)\"\n  elseif eligibleness < 0\n    \"Ineligible (eligibleness is percent in ineligible)\"\n  else\n    eligibleness = eligibleness < 100 ? \"Excluded\" : \"Not relevant\"\n    \"Eligible (eligibleness is percent in not relevant)\"\n  end <commit_msg>Removed unused function with comment in example<commit_after>#! /usr/bin/python\n\"\"\"\nExample for assessment of eligibility\nThis example uses a simple clinical trial, but the method could easily be extended to include\nmultistage clinical trials.\n\nFor more examples see\nhttps://examples.herokuapp.com/clinical_data/clinical_trial.json\n\"\"\"\nfrom flask import request, json, session, g, flash\nfrom sqlalchemy.ext.asyncio import AsyncSession\nfrom sqlalchemy.ext.asyncio.interfaces import SessionLocalExecutor\n\nfrom .clinical_trial import create_clinical_trial_db\nfrom .database import prepare_patient_note_db_from_json, prepare_patient_db_from_json, db_session,\n    check_session_state, create_db\n\nfrom .clinical_trial import process_clinical_trials_json, get_clinical_trial_id_from_idstr\nfrom .clinical_trial import verify_patient_eligible_for_clinical_trial\nfrom .clinical_trial import verify_trial_trial_eligibility\nfrom .clinical_trial import create_clinical_trial_eligibility,\n    eligibleness_from_percentage\n\ndef main():",
        "label": 1
    },
    "299": {
        "output": "You should submit your source code to the exercise and reviewers will give you feedback. Once your code is accepted, you can challenge yourself by solving the exercise at the more advanced [advanced/wip/wip2] level.\n\n## [INSTRUCTION]\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial: \nTitle: Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection\n\n\nSummary: This study evaluates a new method of testing the lymph nodes in the armpit of patients with breast cancer for tumor involvement. All participants involved in this study will undergo an injection of a small amount of iron dissolved in liquid followed by an ultrasound of the axilla that will make previously invisible lymph nodes visible, allowing them to be sampled in an outpatient setting.\nInclusion criteria: Inclusion Criteria:\nFemale patients at least 21 years old\nPatients with invasive ductal carcinoma staged T1 or T2 with estrogen receptor and progesterone receptor positive (ER+/PR+) who are scheduled for sentinel lymph node biopsy\nPatients with Ductal Carcinoma In Situ (DCIS) (high or low grade) who are scheduled for sentinel lymph node biopsy including:\nPatients having a mastectomy\nPatients with palpable DCIS\nPatients undergoing breast conservation with large (>5cm) area of DCIS\nPatients with signed consent to participate\n\nLet's think step",
        "label": 1
    },
    "300": {
        "output": "![HINT]\n### Question:\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). What do the factors allow to participate in a trial based on the clinical trial? 1) How are the three-point scale factors for this trial presented? 2) Which numbers correspond to them? \n\n#### Step One\nLet's think step by step.\n\nStep One\n\n###### Case Description ####\n\n\n<EOD> An AZI1 ortholog functions in root patterning and flowering time in Arabidopsis thaliana\n\nThis supplementary information includes supplementary figures and supplementary methods.All data and source files are available at https://fairdomhub.org/data/doi/10.9949/dj.2022.62.645. All reagents and protocols used in this project are described at https://protocols.io/private/3d87a268b2f46128521702c23c118c5b.\n\n## 1\n\n## Supplementary information\n\n## Supplementary methods -figure legends\nSupplementary . Phylogenetic tree of DUF221, showing the two paralogous groups (a). A phylogenetic tree was generated with a multiple amino acid sequence alignment of proteins containing DUF221 sequences from Arabidopsis thaliana (63 proteins were initially extracted), Oryza sativa (57), Setaria italica (45), Brachypodium distachyon (85), and Sorghum bicolor (14), including proteins from DUF221 paralog groups as well as outgroups from phylogenetically distant species. Two subgroups were clearly identifiable. (b) Distribution of the number of predicted introns per gene in DUF221-containing proteins from Arabid",
        "label": 0
    },
    "301": {
        "output": "## Exhibit 15.2   the clinical trial note\n\n\n## [INSERT FIGURE 15.1 ABOUT HERE]\n\n## Exhibit 15.3   the clinical trial note, the assessment of eligibility\n\n\n## Instruction 2   [instance]: a real clinical trial\n\n[INSERT TABLE 15.1 ABOUT HERE]\n\n## Preparation\n\n[INSERT TABLE 15.2 ABOUT HERE] You are now reading a patient note. We will assess the patient's eligibility to a clinical trial, which is called an assessment of eligibility (see Exhibit 15.2). A patient's eligibility is determined by both the patient's condition and the clinical trial's recruitment criteria, i.e., its inclusion and exclusion criteria. We should make each trial-level eligibility.\nWe will practice this one more time using the real clinical trial data. As you saw in the previous exercise, you should assess each patient's eligibility to the clinical trial by referring to the trial's recruitment criteria, the inclusion, and exclusion criteria in this exercise.\n\n## [insert table 15.3 about here]\n\n\n## Exhibit 15.4: The Clinic's Electronic Health Record\n\nExhibit 15.4: The Clinic's Electronic Health Record\n\nThe clinic we have been using in the previous exercises is not a fictitious hospital, but a real hospital whose electronic health record has been installed in the Department of Informatics of the Catholic University of Korea. This exercise helps you experience the electronic health record's workflows and data.\n\n\nWe will access the electronic health record from the desktop of the system. You will log into the portal to access the electronic health record. Above on your browser, the following picture can be seen, which is a login screen in the healthcare information system. After logging into the portal, you will have access to patient health information.\n\n\n## Exhibit 15.5: the log-in screen\n\n\n![INST]\n\n\n## Exhibit 15.6: the patient's basic information screen\n![",
        "label": 0
    },
    "302": {
        "output": "## \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 Trial-level eligibility: 2) Eligible.\n\n## 0] excluded 1] not relevant 2] eligible\nThe output is the trial-level eligibility information.\n\n\n[INST]\nExemplary case: Evaluation of clinical trials eligibility assessment systems\n\n### Evaluation criteria\n\nFor the evaluation of the eligibility assessment system \"Mk489\" (\"Ensemble Markov network for clinical trial eligibility\"), the following criteria should be used:\n1. Eligible patients: eligible patients represent more than 95% of all evaluated patients. A system with an eligible patient percentage (<95%) less than 10% shows a severe misclassification error.\n\n>from mlxtend\n<EOD> Diagnostic evaluation and monitoring of biliary atresia: a perspective from Australia.\nThe diagnostic evaluation and monitoring for those born with suspected biliary atresia (BA) in Australia is mainly performed in public hospitals to a high standard. With the introduction of neonatal screening for cystic fibrosis, neonatal jaundice can now be routinely biochemically analysed and the diagnosis of conjugated hyperbilirubinemia in an otherwise well infant made. The Australian Paediatric Surveillance Unit has recorded the diagnosis of neonatal jaundice in Australia and the high occurrence (greater than 1%) supports the need for neonatal screening for conjugated hyperbilirubinemia. The commonest method for the initial evaluation of suspected BA in Australia is a liver biopsy, usually performed at 3 weeks after birth because of the need",
        "label": 0
    },
    "303": {
        "output": "Now, you can assess the patients according to the inclusion criteria, and report the results. \n\nGood luck and enjoy your day.\n\n<EOD> Preoperative CT Scan and MRI\n\nPreoperative CT Scan and MRI\n2012\nPreoperative CT Scan and MRI\nKorean J Neurotrauma\n81107201210.13005/kjnt/2012.81.1.11\nIn this issue, a paper titled, \"Preoperative computer tomography scan and magnetic resonance imaging in pituitary surgery\" by Dr. Choon Sik Suh, is published. In the paper, there is a brief introduction, literature review, study methods (retrospectively reviewed 95 patients), and then a discussion of the results. Pituitary lesions are now diagnosed in many patients with the aid of computer tomography and MRI. The rate of preoperative diagnosis is currently 3-5 times greater than it was 20 years ago. [bib_ref]  Pituitary incidentalomas, Alevizaki [/bib_ref]  [bib_ref]  Pituitary neuroendocrine tumors: current trends in surgical management, Little [/bib_ref]  Cranial CT scan is no longer the sole method to diagnose pituitary lesions. More and more, patients have undergone a CT scan under the provisional diagnosis of pituitary lesions before admission, which is made by outpatient clinic specialists. This can provide an opportunity to make a preoperative diagnosis of pituitary lesions before the operation is performed. Dr. Choon Sik Suh and his co-workers had two objectives: 1) to compare the accuracy of preoperative and postoperative computer tomography scan and MRI; 2) to determine the influence of pituitary lesions size on the operation. They found that the size of pituitary lesion was statistically related to the surgery time. Also, the preoperative CT scan and MRI had a high diagnostic ability but a high false positive detection (about 80%). This means that 80% of the cases that were suspected of having a pituitary lesion were actually confirmed to be normal",
        "label": 2
    },
    "304": {
        "output": "[ /INST ]\nGood Luck!\n\n### Examples\nHere is an example to illustrate the instructions. I have coded the results into `text/plain` format. Please refer to this file to confirm your assessment. I suggest saving the output file after finishing this exercise:\n$ cat my_instructions.txt $ cat my_input.txt\nTrial-level eligibility: 0) Excluded. Trial-level eligibility: 1) Not relevant. Trial-level eligibility: 2) Eligible. Inclusion criteria: Inclusion Criteria:\nEligible to receive chemotherapy and endocrine therapy as defined by a good Karnofsky index (\u226580) and no hematologic, cardiologic or hepatic contraindications, nor any impeding comorbidity\nInformed consent form signed on the same day or before enrollment\n\u2265 18 years of age at time of consent Per study arm\nHistologically proven invasive stage I and II breast cancer and Hormone Receptor positive (ER+ PR-, ER- PR+ or ER+ PR+) according to local standards & HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)\nIMPACt study; version 1 2015 September 1 Page 11\nAxillary lymph node status: 0-3 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.2-2mm)\nOR\nHistologically proven invasive T1a or T1b breast cancer & Hormone receptor negative (ER- and PR-) according to local standards & HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)\n& Axillary lymph node status: 0-1 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.2-2mm)\nOR\nHistologically proven invasive T1a or T1b breast cancer\n& Hormone receptor negative or positive (ER-PR-, ER+PR-,",
        "label": 1
    },
    "305": {
        "output": "What we are doing in this script\n\n*\n\n*We create a function `def trial_level_eligibility(patient_notes: List[str], trial_inclusion_criteria: List[str]) -> int` to calculate the trial-level eligibility. `list(patient_notes, trial_inclusion_criteria)`\n\n\n### Patient info\n\n```python\ndef __init__(self, tri_inclusion_criterias=None):\n    self.trial_inclusion_criterias = tri_inclusion_criterias if tri_inclusion_criterias is not None else []\n```\n\n\n### Call this\n```python\ntrial_level_eligibility(patient_notes=NOTE.value.rsplit('\\n'), trial_inclusion_criterias=INC_CLINICAL_TRIAL_RECRUITMENT.value.rsplit('\\n'))\n```\n### Return type\n```python\nint\n```\n<EOD> .\nOBJECTIVE\nTo investigate the mechanism of hypoxia in regulating bone reconstruction and to determine its molecular basis.\n\n\nMETHODS\nThe femur fracture was generated by a forceps and all 80 SD rats in 2 groups (40 for each group) were equally divided in different ways, the one group was fed normally, and the other group was fed under hypoxic condition. Four weeks later, samples were collected and immunohistochemistry detection was used to detected RANKL and OPG expression; real-time PCR was used to detect the expression of RANKL, and NOS genes in both groups.\n\n\nRESULTS\nIn hypoxic group, RANKL and OPG expression increased significantly and RANKL/OPG was also increased in hypoxic group; and RANKL mRNA increased significantly (0.992 \u00b1 0.106 vs. 0.595 \u00b1 0.075; P < 0.05) while eNOS mRNA increased in hypoxic group (0.592 \u00b1 0.250 vs. 0.205 \u00b1 0.",
        "label": 2
    },
    "306": {
        "output": "___[TEST_SET_A]_2_[2]_2_[1]\n\n[INFO_COURSE_NOTES_A]: Course notes_A \n\n[INFO_TEST_A]: A: Course notes_A \n\n[INFO_TEST1A3]: A: Course notes_A \n\n[INFO_TEST9A]: A: Course notes_A \n\n___[TEST_SET_B]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_B]: Course notes_B \n\n[INFO_TEST_B]: B: Course notes_B. 2_[4]]: B: Course notes_B \n\n[INFO_TEST9B]: B: Course notes_B \n\n___[TEST_SET_C]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_C]: Course notes_C\n\n[INFO_TEST_C]: C: Course notes_C \n\n[INFO_TEST4C]: C: Course notes_C\n\n___[TEST_SET_D]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_D]: Course notes_D\n\n[INFO_TEST_D]: D: Course notes_D \n\n___[TEST_SET_E]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_E]: Course notes_E \n\n___[TEST_SET_F]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_F]: Course notes_F \n\n___[TEST_SET_G]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_G]: Course notes_G\n\n[INFO_TEST_G]: G: Course notes_G \n\n___[TEST_SET_H]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_H]: Course notes_H \n\n___[TEST_SET_I]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_I]: Course notes_I \n\n___",
        "label": 1
    },
    "307": {
        "output": "[END]\n\nIf the answer is `Not relevant`, the patient does not have sufficient information to qualify for the trial. Since there is no patient note for the patient, one can always enter a not relevant code without considering the clinical trial's eligibility criteria and using `Patient-level eligibility: 1) Not relevant`.\n\nIf the answer is `Excluded`, the patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria. If the patient's characteristics are not listed in the clinical trial's eligibility criteria, it is always safe to enter `Patient-level eligibility: 1) Not relevant`. As an example, it is safe to enter 1) Not relevant for this question, since the trial excludes patients who are not sexually active, or have no children.\n\nIf the answer is `Eligible`, the patient meets inclusion criteria and exclusion criteria do not apply. In this case, you can use `Patient-level eligibility: 2) Eligible`, where it is essential to always repeat `Trial-level` eligibility. For example, in the second case where a clinical trial excludes patients without pelvic nodal metastases, we can enter the following line in the code table: \n\n```\nTrial-level eligibility:\n1) Not eligible;\nPatient-level eligibility:\n2) Not relevant;\n2) Eligible. \n```\n\nThis code means that the patient who does not have any pelvic nodal metastases is not eligible in both patient-level and trial-level eligibility.  \nIn this example, the patient is not eligible in `Patient-level eligibility: 1) Not relevant`, since this patient has pelvic nodal metastases. By entering `Patient-level eligibility: 2) Not relevant` at the end of the code, one can always check whether to include or exclude the patient in the clinical trial, regardless of whether the clinical trial's inclusion criteria are met or not. To continue to proceed with calculating patient-level eligibility, if the answer to `Patient-level eligibility: 1) Not relevant` for a line contains a blank in the second box, then proceed to the",
        "label": 0
    },
    "308": {
        "output": "<EOD> Effect of a novel compound PB28 on morphine\u2010induced conditioned place preference and hippocampal plasticity\nThe reinforcing effects of abused drugs derive from increased dopamine levels in relevant nuclei of the brain. The \u00b5 opioid receptor agonists, including morphine, generate such changes both in the ventral tegmental area, a key nucleus in the mesolimbic dopaminergic pathway and in the hippocampus. Apart from these regions of the brain, compelling evidence indicates that certain brain areas contain multiple opioid receptors subtypes. We investigated whether a new compound named PB28, which acts as a \u00b5 opioid receptor partial agonist without blocking the endogenous opioid peptide activity, could modulate morphine\u2010related responses, mainly within the ventral tegmental area and the hippocampus. C57BL/6J and C57BL/6N mice were made dependent on morphine by subcutaneous administrations of increasing doses (60, 120, and 180 mg/kg) of the drug twice daily over 6\u20137 days (30 min between injections). The CPP test was carried out to evaluate the conditioned rewarding effect of morphine, and its magnitude was measured as the difference between time spent in the drug\u2010paired compartment and that spent in the compartment that had been associated with the non\u2010drug stimulus. We also explored the action of PB28, which was delivered (i.p.) during the development of morphine drug\u2010induced conditioned place preference. After conditioning, animals were killed; the ventral tegmental area and CA1 were quickly dissected out and processed to measure morphine\u2010induced c\u2010Fos, an immediate early gene that is expressed in neurons after cocaine injection. PB28 administered prior to morphine attenuated the expression of CPP and reduced activation of pyramidal neurons in the ventral tegmental area. An additional experiment was carried out to examine the specificity of hippocampal responses to morphine in the CPP context and the c\u2010Fos induction induced by PB28 in the CA1.",
        "label": 2
    },
    "309": {
        "output": "<EOD> On-Board NIR Calibration for a Hand-Held C-Cube Spectral Sensor for the Control of a Wound Diagnostic System and Identification of Plants\n\nHand-held spectrophotometers can provide highly accurate assessments to assess crop plant diseases and pests[1]. For example, several studies have used spectral reflectance sensors in the visible near-infrared region to assess plant health based on the visible symptoms of stress from diseases on crop plant leaf surfaces[2]. In applications involving the assessment of plants for pests and diseases, the main objective is to identify those waxy leaves caused by insect pests, diseases and nutrient deficiency. One of the main challenges of plant assessment is the identification of similar symptoms, such as infection by the leaf-cutter bee (Apis mellifera) and nutritive deficiencies. The visual assessment of plants is subjective, and, in many cases, requires the trained eye of the human observer. Therefore, to improve the efficiency of these assessments, the use of digital cameras and hand-held spectrometers with sensors that can automatically evaluate crop plants have been studied. Furthermore, the use of digital cameras can provide the high-resolution images needed to accurately identify diseases and pests.To assist with the monitoring and identification of plants, a hand-held spectral sensor or imaging sensor with a digital camera is often used. This type of sensor typically makes in-field diagnosis of crops possible. The combination of digital camera and spectral sensor is referred as digital multispectral camera or sensors. These sensors work on the basis of narrow-band multispectral imaging in which the sensors consist of a CCD chip combined with a light-tight housing[3,4]and a spectroscopy cube[5]. In other words, these sensors provide more accurate diagnostic capabilities by combining visible and NIR imaging. The hand-held spectral sensors mentioned earlier have been used to perform diagnoses of plant diseases and insect pests. However, the use of hand-held spectral sensors in outdoor environments requires the sensors to have accurate lighting sources that help the camera to produce high-quality images[3,4]. In most conditions, the illumination source is made up",
        "label": 0
    },
    "310": {
        "output": "__HINT__\nYou can review your answer and click on Check to see if your answer is correct.\n\n__HINT__\n\n__More Example Input__\n\n**Example 1 - Correct Answer**\n\nTrial-level eligibility: 2) Eligible.\n\nTrial-level eligibility: 1) Eligible.\n\nPatient-level eligibility: Included in trial.\n\nPatient-level eligibility: Not included in trial.\n<EOD> .\nBy the use of two methods of measuring acetylcholinesterase (AChE) level in the brain, we investigated its changes in the rat, and its correlation with the activity of choline acetyltransferase (CAT) under the effect of physiological temperature of 37 degrees C and hypothermia (23 degrees C-29 degrees C). We found that the 37 degrees C temperature and acute hypothermia 0 degree C had the same effect on cerebral AChE activity at 72 h after the cooling, but the effects on the brain AChE levels varied with the decrease of temperature. At 37 degrees C all the animals showed an increase in CAT activity which was more obvious in the rats under hypothermia. At 72 h the high temperature 37 degrees C and mild hypothermia 23 degrees C-29 degrees C increased the CAT activity.<EOD> Long\u2010term outcome of children with non\u2010cyanotic congenital heart disease and impaired oxygen saturation: A follow\u2010up study from birth to 18 years of age\n\n [bib_ref]  Survival in patients with congenital heart disease: A population-based study, Mandalenakis [/bib_ref]  [bib_ref]  Survival in 934 children and adolescents with congenital heart defect, Br\u00e5vaag [/bib_ref]  [bib_ref]  Survival in hospitalised children with congenital heart disease in the Western Cape..., Futterman [/bib_ref]  [bib_ref]  Congenital heart disease: A prospective study on risk factors. National Birth Defects..., Hobbs [/bib_ref]  [bib_ref]  Mortality among US infants with congenital and chromosomal disorders: A population-based perspective, Merritt [/bib_ref]  [bib_ref]  The",
        "label": 0
    },
    "311": {
        "output": "# Subscript eligibility\n\nThis is the Subscript Eligibility for this patient. You should select a subindex from the subscripts with the following options, e.g., for the first scenario in the following table:\n\n![](https://cdn.math.princeton.edu/~mgood/subscripts.sub.q0.pdf)\n[SUB]\n\n[S]\nSex\n[G] Gender\n[C] Cancer Stage\n[Cx] Chemotherapy\n[D] Drug\n[H] Histology\n[I] Age\n[E] Race\n[J] Jaundice\n[A] Alcohol Consumption\n[S] Sex: 2) male | 3) female \n\n[G] Gender: 1) female | 2) male \n\n[C] Cancer Stage: 1) localized | 2) regional \n\n[Cx] Chemotherapy: 1) yes | 2) no \n\n[D] Drug: 1) PARP | 2) CPT-11 \n\n[H] Histology: 1) invasive ductal - ID/CACP  | 13) other \n\n[I] Age: 1) less than or equal to or greater than 50 years old \n\n[E] Race: 1) white \n\n[J] Jaundice: 1) no | 2) yes \n\n[A] Alcohol Consumption: 1) yes \n\nLet's think step by step. \n\n`2\\)-1\\)-2\\)-8\\)-4\\)-2\\)-4\\)-2\\)-2\\)-6`\n\n## Scenarios\nBelow are examples of eligibility data and the corresponding responses. For each example, the response should be a string; thus you can use a variable to store this response in the function eligible. A string is an enumeration of values. The enumeration is simply an array of strings with one string per value. Each string in the array represents a valid value; these strings are delimited by a pair of square brackets, e.g., each element of the array in the following example is a string delimited by square",
        "label": 0
    },
    "312": {
        "output": "You will first receive the input data, a patient note. The patient is to be assessed for eligibility in the clinical trial. First, input the patient report.\n[DATA]<EOD> Effect of the intrauterine administration of dexamethasone on serum corticosterone, cholesterol, triglyceride, LDL and HDL and glucose, blood urea and uric acid in fetuses and newborn fetuses.\nA group of eighty-five guinea pigs was randomly divided into three groups, each one of eighty-five animals. The first group was used as a control; the second group underwent dexamethasone treatment at different periods during the pregnancy period, the last group was injected with a single dose of dexamethasone before delivery. Results revealed significant changes in the levels of glucose, urea, and uric acid and in the serum concentrations of triglycerides, cholesterol, LDL and HDL.<EOD> NMR-Based Metabolomic Profiling of a High-Alcohol-Yielding Barley Cultivar Grown Under Limiting Nitrogen Deficiency.\nBarley (Hordeum vulgare L.) is the most widely grown crop grain for beer production worldwide. However, grain yields tend to be low, and it is challenging to increase the total nitrogen (N) content. The most common way of inducing malting quality in barley has been to apply drought stress, which unfortunately is not compatible with large-scale high-yield breeding programs. Here, we report metabolome changes induced by moderate-to-severe N-limiting conditions applied prior to flowering in two high-alcohol-yielding barley cultivars. Based on 1H nuclear magnetic resonance spectral analysis of the germinating barley grains, two metabolites (trehalose and pipecolic acid) were identified as important N-deficiency-sensitive metabolites. These changes occurred prior to any measurable changes in grain yield or physiological processes in the seedlings. Quantitative analysis of both the metabolites and transcript abundance of their metabolism-related genes showed contrasting trends, and it was established that both met",
        "label": 0
    },
    "313": {
        "output": "## [INST]\nYour assignment for this section is to check whether the patient meets a specific set of requirements specified by the trial.\nIn the second block, you need to check the `if` condition.\nCheck `if` condition: Patient has at least one of the following cardiovascular risk factors:\n- Age \u226565 - Systolic Blood Pressure \u2265160\n- Diastolic Blood Pressure \u2265100\n- Fasting Blood Sugar \u2265110\n- Total Cholesterol >240. If you already have a patient, continue to the next step, otherwise, pick another random patient. \nWe will generate the name of the patient. Click on the patient name and the Patient's details panel opens. \nIn the patient's demographics panel, see his/her age and gender. If the patient is male and his/her age is 65 years or older, you should click `Trial-level eligibility: 2) Eligible.` to indicate that the patient is eligible and click `Check` button.\n![](/images/2022-06-02/216617074_img.png)<EOD> Dual Role of Zinc Proteomics in Cardiomyocytes: Regulation of Ion Homeostasis and Antioxidant Defense.\nZinc is an essential element with the ability to protect and alter proteins to function as an antioxidant. The protective effects of zinc against oxidative stress are linked to the prevention of lipid peroxidation, scavenging of hydroxyl or superoxide free radicals, regulation of glutathione reductase and superoxide dismutase activity, reduction of nitric oxide synthase, and stimulation in the expression of sirtuin genes. Zinc depletion has been found to result in an impairment of mitochondrial function, which appears to be the main cause of the oxidative stress in cardiac cells. Cardiomyocytes play a role in zinc homeostasis, which includes receptor-mediated ZIP and ZnT transporter and Zinc-activated metallothionein expression. The regulation of zinc transporter",
        "label": 0
    },
    "314": {
        "output": "<EOD> The Relationship between Anxiety and Eating Disorders: Evaluating the Role of Specificity of Anxiety Symptoms\nAnxiety symptoms are common in eating disorders (ED) and associated with worse treatment outcomes. However, it is unclear whether anxiety in ED should be targeted as a trans-nosographic symptom, or whether it is best characterized as a specific clinical feature that is independent of ED classification, as found in comorbid depression. This is the first study to investigate this issue. In a clinical sample (n = 11,626) of adult women attending specialist ED/obesity services or mental health therapy programs, patients completed measures of anxiety symptoms and eating disorder symptoms. Hierarchical partitioning and latent structural equation modeling were used to assess which level (transdiagnostic general vs. specific) was supported by the data. There were three notable results. First, the hierarchical partitioning model indicated that anxiety as a transdiagnostic dimension was best, showing that anxiety was more important than ED symptoms in identifying ED classification, indicating that classification should not be based on anxiety. Second, exploratory latent structural equation modeling revealed that anxiety may represent two distinct constructs: anxiety/anxious arousal and worry/distractible rumination. Third, analyses showed that the trans-nosographic anxiety construct was made up of anxious arousal symptoms, which were more general than worry/distractible rumination. It may be that some patients with ED have elevated transdiagnostic anxious arousal symptoms, separate from ED specific symptoms, which may impact on prognosis. In conclusion, although anxiety symptomatology in ED is elevated relative to matched controls, it is best characterized as specific to ED and independent of general level of anxiety. This specificity may reflect differences in anxiety-generative processes between anxiety-associated with ED and anxiety in the general population. Treatment implications are discussed.<EOD> Genomic and evolutionary analyses of the type I-F CRISPR-Cas system and its associated plasmid-borne anti-CRISPR genes.\nA major group of acquired anti-CRISPR genes from plasmids can inactivate the CR",
        "label": 0
    },
    "315": {
        "output": "~~~\n~~~\n~~~\n\n### Run the data loader\nFrom the Jupyter notebook, run loader.py\n~~~\n~~~\n~~~\n~~~\n~~~\n<EOD> The relationship between nursing home organizational dynamics and quality: A three-state longitudinal analysis of survey data\nBACKGROUND\nThe long-term care continuum is characterized by great organizational diversity, but limited research has examined how nursing home organizational characteristics relate to quality and resource efficiency.\n\n\n\nPURPOSE\nTo assess the relationship between organizational characteristics and quality.\n\n\n\nMETHOD\nNursing home organizational data were merged with Certification and Survey Provider of Services data for a stratified sample of 695,227 residents from 652 nursing homes surveyed from 2007 to 2016. Four survey waves of organizational characteristics were merged with 794,482 state survey data. The three-year longitudinal analysis used a fixed-effects model controlling for facility fixed effects and secular time shocks.\n\n\n\nRESULTS\nIncreasing number of beds had no relationship to poor quality. Medium-small facilities had worse quality, but size is not related to pressure ulcer(s quality, but the person with higher (better with better and organization(s the relationships between facilities with poor and nursing home and quality.\n\n\nMEET to have different quality has quality relationships of resident(s on nurs.\n\n\n\n\n\n\n\nEXP's (nurs residents and quality relationships. The organizational characteristics staff of facilities' quality of poor care.\nIn your organization, and staff has an quality of quality residents with the nursing resident's and pressure ultil the relationship has survey response to response is more\nOrganizations has to the quality<EOD> Nursing(s survey's quality and survey. Organization(t's the nursing has no differences the organization data analysis staff survey.\n<EOD>s nursing the nursing has the\n<EOD> survey for a person's quality(Continvoluntness has been conducted person and have nurs's assessment for the organization.\nNURS survey that you and patient-person as much nurs's assess\ncare",
        "label": 0
    },
    "316": {
        "output": "**Exercises**\n\n**EXERCISE**\n\nWe follow up with [a patient from last exam](http://www.orcaen.com/docs/tutorials/#exercise-1) and provide help at clinical trial enrollment site for the patient.\n\n**NOTES**\n&emsp;&emsp; 1) The input files of patient notes, trial information and user's input should have the same file naming format.<br>\nThe original file names with the `.csv` or `.tex` extensions will become the data with the file name prefixed by `data`.\n&emsp;&emsp; 2) The output file name should be the same as the user's input, e.g., if the user inputs 'file.txt`, the output file name is 'file.txt`. \n\n## Instruction\n&emsp;&emsp; 1) You can make use of both ORA and ORCA. \n&emsp;&emsp; 2) It helps to take the advantage of both file and text editors for the input files. \n&emsp;&emsp; 3) You should have got the output files and the output message before attempting the exercises.<br>\n\n&emsp;&emsp; **Exercise 1** Assume that the patient notes, trial information and the input from a user are the same as the training materials in the previous exercises. Enter the following command and check the result:<br>\n```!texhub -name file -format .txt -directory ./data ORA/1_Exercise_OOI.texhub`\n\n\n\n\n\n![IMAGE](./img/texhub_output.png)<br>\n\n[!https://orcaen.com/file.jpg](img/file.jpg)<br>\n\n&emsp;&emsp; **Exercise 2** Assume that the patient notes, trial information and the input from a user are the same as the training materials in the previous exercises. Enter the following command and check the result:<br>\n```!texhub -name file -format .txt -directory ./data ORA/2_Exercise_Input.texhub`\n\n\n\n\n\n![IMAGE](./img",
        "label": 0
    },
    "317": {
        "output": "Submit a zip file via [this](https://github.com/c99gpu/disease-data/blob/master/data_set_2021/disease_data_2021_submission.md) link.\n**Submission Time:** from Apr 25th, 2021 to Jun 11th, 2021<EOD> Nutritional assessment of children using serum ferritin, serum albumin and transferrin receptor as predictors of anemia and malnutrition: Findings from the Copenhagen School Child Teenage Cohort (cstc) study.\nThis cross-sectional study aims to examine a possible association between serum ferritin, albumin and transferrin receptor (TfR) in predicting anemia and malnutrition in 2,619 children aged 5-9 years. The study population is a part of the Copenhagen School Child Teenage Cohort (cstc), a prospective study, which examines the influence of prenatal programming of adult metabolism by measuring health parameters on five different occasions at the child's age of 5 months, and once again at the child's age of 3, 6, 9 and 15 years. We aim to associate ferritin to anemia and to determine if ferritin concentrations could be used to distinguish between normal, mild and moderate iron-deficient children. We examine correlations between ferritin levels, hemoglobin and indicators of nutritional status and calculate the iron-replete and iron deficiency reference ranges. Furthermore, we examine",
        "label": 2
    },
    "318": {
        "output": "__1. What does this code do?__\n\nWe define a helper function to write `Trial-level eligibility` information. It takes `A` patient and `B` clinical trial and puts the information into the cell `C`. We define an __anonymous_ variable__ `TrialLevelELigibility` to help the function do its task. If the patient note and clinical trial meet the inclusion criteria and the exclusion criteria of the clinical trial do not apply, we put 2) Eligible. It's 2 for the scale. Otherwise, we must exclude from the trial (0) or the assessment is not relevant to the trial (1).\n\n__2. How does this code check for eligibility?__\n\nWhen it comes to the trial-level eligibility, we want the function to compare the patient note with the clinical trial's trial-level inclusion criteria. These represent the minimal criteria that the patient should meet to participate in the clinical trial.\n\nWe need to know if the patient note has sufficient information of interest (cancer stage, age, sex, previous treatments, medical history etc.) to assess if the trial-level inclusion criteria are met or not. We have the data about the patient in the cell `A` because the patient note comes as a data frame and has the patient's characteristics in it. Now we are searching for the necessary data from the clinical trial in the trial data set `B` with the variables `Title`, `Summary` and `InclusionCriteria`, which come as strings. When we want to know if the trial-level inclusion criteria are met, we find the variables in `B` that contain the word \"metastatic\" and the variables \"age\", \"sex\", \"previous treatment\", \"medical history\", \"cancer stage\". With the `grep` or the `search` function, we filter the data frame `B` to match each criteria in the trial's inclusion criteria table in this case. Then, we need to combine the patient note and trial data in one data frame. This is what we pass to the function `join` where the variable `C` is being generated.\n\n__3. What are the limits with this code?__\n\nEverything is fine and working, but we need to check some cases that do not fit well in our eligibility assessment or trial",
        "label": 0
    },
    "319": {
        "output": "## Data validation and result\nPlease refer to `Appendix G` in the full version of the article for the result.\n\n## Previous questions\n[CLOSED] In the question <April2020>, the correct answer was the wrong answer. Thank you very much for providing new feedbacks. \n**Exclusion criteria** 1. Left-ventricular ejection fraction 0-49% 2. Abnormal liver function tests (e.g. >2.5 times the upper limit of normal (ULN) of **>3.0 times the ULN)** 3. Cardiogenic shock 4. History of significant ventricular arrhythmias, QT prolongation, or Torsades de Pointes 5. Use of strong inhibitors / inducers of p-glycoprotein and cytochrome P450 3A4 metabolizing enzymes.\n\n## Exclusion criteria of trial 1\n1. Left-ventricular ejection fraction \nExclusion criteria of trial-2 1. Left-ventricular ejection fraction \n\n## Exclusion criteria of clinical trial\n1. Left-ventricular ejection fraction Less than 50%.  \nAbnormal liver function tests (e.g. >2.5 times the upper limit of normal (ULN) of >3.0 times the ULN).  \nCardiogenic shock. History of significant ventricular arrhythmias, QT prolongation, or Torsades de Pointes.  \n\n## Explanation 1\nThe patient's left-ventricular ejection fraction in this case is 50%, not less than 50%.  \n\n## Explanation 2\nIn your answer, you should not count how many times the upper limit of normal is higher than the patient's value. Please count how many times the patient's value is more than the upper limit of normal.  \n\n## Explanation 3-1\nIn this case, the liver function test is abnormal because the value is more than three times the normal upper limit.  \n\n## Explanation 3-2\nYour answer is not correct. The liver function test is not abnormal, as the value is less than three times the",
        "label": 0
    },
    "320": {
        "output": "<EOD> An integrated platform employing microfluidics, nanoplasmonics and high-resolution imaging for automated high multiplexed DNA detection\nHigh multiplexed detection of DNA molecules is essential for accurate clinical diagnosis and monitoring of various genetic diseases and cancers. Here, we report an integrated approach for automated high multiplexed DNA amplification and detection based on functionalized electrochromic nanoparticles using dielectrophoretic concentration, nanoplasmonic detection and microfluidic channel technology. This system employs a disposable polydimethylsiloxane microdevice with electrochemical sensing, microfluidic channels, and a nanoplasmonic detection scheme. This integrated system allows for automated, on-chip analysis of target DNA from minute samples. In this study, the on-chip platform enables sensitive, rapid and multiplexed detection of the M13 phage gene sequence, phage lambda DNA and genes associated with cancer cells. Such a system would ultimately be useful for the early detection and monitoring of cancer, infectious diseases and genetic disorders.<EOD> Effects of Pacing Sites on the Intrinsic LV Dynamics of 3D-Printed Human Ventricular Myocardial Tissue\n\nIntroduction: We investigated the effects of pacing site on electro-mechanical dyssynchrony in the intrinsic electromechanical properties of the left ventricle (LV) of 3D-printed human ventricular myocardial tissue (HVMt). Methods: We constructed a 3D-printed human heart model from high-resolution MRI and fabricated 16 cuboid 3D-printed HVMt and 16 3D-printed native cardiac tissues (NCT) to simulate a physiologically relevant volume with a pacing site at the anterior wall of the LV. We compared the differences in the electrophysiological properties, including conduction velocity (CV), normalized conduction velocity, and activation time (AT) at the pacing site, between the 3D-printed and native materials. Furthermore, we investigated the effect of pacing site on the intrinsic electromechanical properties. Results: The pacing site had no effect on CV between the 3D printed and native tissues",
        "label": 2
    },
    "321": {
        "output": "For each of the factors, one must either assess the patient to be (1) excluded or (2) included. For example, if you find that this patient doesn't have any prior endocrine therapy (#4. prior treatment specifics), then the correct response is to code \"2) Included\" under the factor \"prior endocrine therapy\". If you don't find any prior endocrine therapy either, it can be coded to \"1) Excluded\" under the same factor. This is to indicate that the patient does not fit either category, so we take the first option that comes to mind without checking the next one. \nOnce the eligibility questionnaire is satisfactorily completed, you enter the patient's ID number into the clinical trial web-portal [/INST (not to be seen)]. \n\n### Exercise 4 \nFollow instructions from the previous exercise. \n\n### Exercise 5 \nThis exercise will be based on the patient in the following screenshot.\nLet us start with the patient: \n\nThe data is written in two ways, the 'normal' and the 'reverse normal' style. The 'normal' style uses the first line as 'Patient_ID', followed by the rest of the data. On the other hand, the 'reverse normal' style has the variables of each row in reverse order, i.e., age and marital status in the last line. It's up to you how to prepare your data. We are going to use the 'reverse normal' style here, so the first line should have the variable name: 'Patient_ID'. In the end, your data should look like the following. You can find the corresponding exercise data in [/INST (not to be seen)].\n\n\n\n##### Exercise (data) \nExercise data\n\n--- 1) Patient_ID\n2) Age 3) Gender 4) Marital_status\n\nThe exercise data from here on will always start with a '#' sign at the beginning of the line. This sign indicates comments.\nThe next few lines after the patient data is the documentation of the factors. \nFor example:\n1) Patient has taken tamoxifen and toremifene, but not raloxifene or fadrozole",
        "label": 0
    },
    "322": {
        "output": "**F-FUNC**. This is the functionality test script, which is executed once per every request. This script does various operations under the hood which don't actually show up as output from the web interface. The functionality test script executes the following sequence of commands:\n\n1. Start a new thread to execute the trial-level eligibility service.\n\n1. Start another thread to collect the results from a trial-level eligibility service.\n\n1. Check if the eligibility service has been executed in the background, as indicated by the existence of a service instance, and if the results have been received, as indicated by the existence of a collection in the Collection Manager class.\n\n2. If the trial-level eligibility service has been executed, i.e., at least one instance of the service exists, and the collection is in the collection manager, check that the results match the patient note's condition.\n\n3. If the service has been executed, and the results have been received, and the results match the condition of the patient note, the script continues. \n\n    Otherwise, a failure message is generated. \n\n4. Wait for four seconds and repeat steps 2 and 3.\n\n5. If eligibility service has been executed, and results have been retrieved, but results do not match the patient note's condition, generate a failure message with the patient's note and exclusion criteria of the trial.\n\n6. Wait four seconds and repeat steps 2-5. \n\n7. If trial-level eligibility service has been executed and results have been retrieved, the script continues.\n\n    Otherwise, a failure message is generated.\n\n8. Wait four seconds and repeat steps 1-2.    8. Wait for four seconds and run steps 1-7 of the script again.\n\n\nFinally, the script generates the following messages to the logger.\n\n`F-FUNC: Eligibility calculation succeeded.`     `F-FUNC: Waiting for 4 second.`     `F-FUNC: Eligibility calculation failed. Note: excluded 52144`     `F-FUNC: Waiting for 4 second.`     `F-FUNC: Eligibility calculation failed. Note: eligible 52144`<EOD> .",
        "label": 2
    },
    "323": {
        "output": "A:\nNote: I recommend you use Anaconda environment if you plan to do scientific computing in Anaconda, because Anaconda makes it easy to set up a new computer while other distribution like Ubuntu only sets root user home directory. But, if you already use Anaconda or similar environment like conda, you can do that for sure.\n\nA: I suggest you make all code runnable as standalone script, and when you're done all you have to do is run:\npython script.py\n\n<EOD> Development of a Novel Method for the Detection of PEG10-Derived Peptide Methionine Sulfoxide Using 18O Labeling and Nanopore Strand Sequencing.\nS-Methionine oxidation occurs at a critical residue of human protein glutathione peroxidase-1(GPx)-1, known as the peroxidatic site. We developed a new method that allows GPx1 oxidative modification to be investigated. An S-methionine-containing peptide mimicking the peroxidatic site is chemically synthesized, 18O is incorporated into the peptide using 18O water, and the oxidized and reduced methionine residues are separated using nanopore strand sequencing. S-Methionyl residues have very low isotope incorporation rates caused by an isotope effect. After S-methionine oxidation, the degree of 18O incorporation in the oxidized residues was significantly higher than that in the reduced residues. The sensitivity of the separation was improved by setting the detection threshold value of the peroxidatic site residue so that only 4% of the sample was discarded. This method for identifying peptide methionine oxidation using 18O water may be applied for detecting the oxidative status in a tissue sample.<EOD> The role of cerebral amyloid deposition in common forms of Alzheimer\u2019s disease: does cognition depend on cerebral amyloid deposition?\nCerebral amyloid deposition is a hallmark pathology seen in Alzheimer\u2019s disease. The contribution of amyloid plaques to cognitive impairment",
        "label": 0
    },
    "324": {
        "output": "### Exactly, we can see if a subject is not eligible for the trial-level (for example 'fempyeligible for the trial -level patient level eligible for trial\n\n\n\n\n\n-levels for patient for the trial-eligible:\n\n\n\n\n\n\nNot applicable. \nIf the subjects who are eligible patient in the eligible trial\u2019s trial,\nA subject should not eligible for eligible subject has been included: patients should include eligible\nLate trial eligible, not eligible patient eligible if applicable the trial.\nThe excluded and a patient is not yet eligible trial.\nPatient tox to eligible trial subjective.\n[Patient has been eligible patient\u2019s\nThe clinical subject's eligible patient trials elig",
        "label": 0
    },
    "325": {
        "output": "# Exercises\n\n## Trial-level eligibility: 0) Excluded\n\n- **100%**\n\n- \u2981 _First, you check whether the patient note contains the factors defined in the IND exclusion criteria._\n- `check_exclusion_codes`\n- \u2981 _Then, you apply these ineligibility criteria to the patient's note._\n- `apply_exclusions`\n- \u2981 _To evaluate the trial's exclusion criteria, you apply the exclusion lists to the patient note._\n- `apply_trial_exclusion`\n- \u2981 _For the next step, check whether the patient still meets the eligibility criteria based on the inclusion criteria._\n- `check_inclusion_codes`\n- \u2981 _Finally, you check again whether the patient remains eligible for the clinical trial. For this you must first check whether the patient met the clinical trial's exclusion criteria, in a previous check, and then, apply the exclusion lists to the patient note._\n- `apply_trial_exclusion`\n- \u2981 _Note that the patient's age is `45.`, yet the trial has a minimum age requirement, of 50 years old, so the patient does not meet this inclusion criterion._\n- `print(Trial)`\n- \u2981 _You'll need to mark the patient as ineligible for the trial with the following statement:_ `Trial-level eligibility: 0) Excluded.`\n- \u2981 _If the patient were on a trial with a minimum age criterion of 45 years, then this ineligibility statement would not be required._\n- \u2981 _Note that the patient's gender is `Female.`, and that the trial requires all patients to be `Female`, so the patient is eligible here._\n- `print(Trial)`\n- \u2981 _Note that the trial requires its eligible patients to be candidates for tumor resection. However, the patient is `Not eligible` since she has not yet received surgery._\n\n## Trial-level eligibility: 1) Not relevant\n\n- **1",
        "label": 2
    },
    "326": {
        "output": "<EOD> Cervical Mylohyoid Muscle (MMCT): An Anatomical Study and Review of Its Variations in the Population\n\nThe mylohyoid muscle (MMC) is the most common muscle to supply the oral cavity and tongue musculature, supplying the mandible inferiorly, the floor of the mouth, and the tongue superiorly, the styloid process and inferior portion of the mandible. Its main function is to open the lips and to help closure during swallowing. However, in 5 to 8% of the population, MMC varies its orientation, inserting into the C2, C3, and C4 vertebrae. In this paper, a description of this muscle and a literature review was performed with the purpose to analyze the prevalence of this type of variation in the cervical musculature.\n\n# Introduction\nThe mylohyoid muscle (MMC) is the most common muscle to supply the oral cavity and tongue musculature, supplying the mandible inferiorly, the floor of the mouth, and the tongue superiorly. Its function is to open the lips and to help closure during swallowing. MMC is a flat, elongated, ovoid, conical muscle that is attached at its base to the mandible by the mylohyoid line. The fibers of MMC tend to be parallel to the mandibular angle, as the fibers go, they course downward and laterally to insert into the hyoid bone [bib_ref]  Anatomy of mylohyoid muscle: study of its origin, course and attachment on..., Ramesh [/bib_ref] . MMC can be divided into four parts: anterior belly, middle belly, posterior belly and cervical musculocutaneous trunk [bib_ref]  Variation in the origin of the human mylohyoid muscle, Haddad [/bib_ref] . Some cases present in the literature show the existence of a fifth part, the cervical musculocutaneous trunk [bib_ref]  Anatomy of mylohyoid muscle: study of its origin, course and attachment on..., Ramesh [/bib_ref]  [bib_ref]  Variation in the origin of the human mylohyoid muscle, Haddad [/bib_ref] . When MMC's origin is altered or does not reach its normal pattern of insertion",
        "label": 0
    },
    "327": {
        "output": "<a class=\"blue\" href=\"http://cjr.amegroups.com/article/view/10.21037/cjr-21-288/rc\" target=\"_blank\">click here to see the R-markdown code</a>.\n\n### \u7d2f\u79ef\u7591\u4f3c\u8bc4\u4f30\n\nLet's focus on patient note. `pnt` is a list to store patient notes. \nBefore reading `pat_num` from file, you should define `patient_pool`, which is a list to store the current trial data, including the patient number, clinical trial data, and patient clinical trial data. \n<table class=\"highlight\"><tr><th class=\"blue\">Function</th><th>Description</th></tr><tr><td class=\"cyan\">pat_num<dt>R</dt><dd>read patient data according to patient number</dd></tr><tr><td class=\"cyan\">clinical_trial<dt>D</dt><dd>read clinical trial data according to clinical trial ID</dd></tr><tr><td class=\"blue\">patient_pool<dt>D</dt><dd>Save the current trial data, including the patient number, clinical trial data, and patient clinical trial data</dd></tr></table><a class=\"blue\" href=\"http://cjr.amegroups.com/article/view/10.21037/cjr-21-288/rc\" target=\"_blank\">click here to see the R-markdown code</a>.\n\nThen you should read each patient eligibility data from the patient note, where `clid`, `patient_id`, and `pat_clid` are the clinical trial ID, patient ID, and patient's clinical trial ID, respectively.\n<table class=\"highlight\"><tr><th class=\"blue\">Function</th><th>Description</th></tr><tr><td class=\"cyan\">pat_clid<dt>R</dt><dd>read the clinical trial ID from patient's clinical trial data</dd></tr><tr><td class=\"red\">pat_trial_eligible_data<dt>R</",
        "label": 1
    },
    "328": {
        "output": "<br><hr>\n\n# Results\n![result](./res/results_1.png)\n\n## Cohen's Kappa\n![cohen_k](./res/cohen_k.pdf)\n\n## ROC Curve\n![ROC_curve](./res/roc_curve.pdf)\n\n## Confusion Matrix\n![Confusion_matrix](./res/Confusion_matrix.pdf)\n\n## Combined Kernel\n![Combined](./res/Combined.pdf)<br><br>\";\" and \";\" in \"Kernel\" means \"or\". \"Combined Kernel\" is the combination between \"Kernel\" and \"Final SVM\".<br><br>\n## Feature Importance\n![feature_importance](./res/feature_importance.pdf)\n\n## ReliefF Score\n![ReliefF](./res/ReliefF.pdf);\n\n*In the Results, we compare our method with the classifiers based on the traditional machine learning: Decision Tree and Logistic Regression. \n\n\n\n![Screenshots of Clinicaltrials.gov ](./res/clinicaltrials.png)<br><br>\nYou should find this clinical trial on ClinicalTrials.gov<br><br>\n<EOD> Repeatability and repeatability coefficients: a review.\nPURPOSE\nOur purpose was to describe the relationships between statistical concepts related to the definition of repeatability and repeatability coefficients.\n\n\nMETHOD\nWe provide an overview of the definitions and relationships between the variance components associated with test-retest reliability measures, such as the intraclass correlation coefficient, coefficient of repeatability, coefficient of repeatability on residuals (CR 2 ), and mean estimate of intraobserver difference.\n\n\nRESULTS\nMost methods used to estimate the CR 2 assume that the intraclass correlation coefficient (referred to as alpha) is the correct estimate of the reliability. Although this assumption often is true, it does not always hold. However, with small samples, the estimate of alpha and the estimate of the variance associated with the intraobserver difference are correlated.\n\n\nCONCLUSION\nRepeatability coefficients are a better",
        "label": 0
    },
    "329": {
        "output": "<details><summary>HINT</summary><ul>\n\n*   Include only one patient in each patient note.\n\n*   Try to write a program in both \\language[Matlab] and \\language[Python].\n\n*   A sample Python file was already written.\n\n*   \\comment[NOTE]\n  Only your \\comment[Matlab] program will be considered as passed.\n  \\endcomment  \n\n*   Do not use any package (except numpy) if you wish to enter your \\comment[Python] program into the competition. \n</ul><summary>More information</summary>\n\n*   You should always use the Matlab and Python programming languages in \\language[Matlab] and \\language[Python] respectively. Both \\language[Matlab] and \\language[Python] programs should be in the same directory.\n\n*   In each submission, specify the title, name of the programming language and filename of the submitted file. In the case of \\language[Matlab], you should specify the filename of the \\language[Matlab] file.\n\n*   You should always run your programs without modifying them (e.g., \\language[Matlab] \\m_comp_test.txt). You should test the code after each function change.  You should also save your programs in a file and edit the file before running. You may also try submitting the Matlab program with _test_ included as a sub-test. If it gets failed, try deleting everything in _test_ with the exception of the function of a single sub-test (the code after the test will work). Then copy and paste it in _sub-test_ without the subtest in the directory \\language[Matlab] \\example\\.\n\n*   If your program is \\language[Matlab], it should use the following command: <code>@__init__(): </code> and you should define \\language[Matlab] \\import_modules(\"\").\n\n*   You may use all necessary packages in both \\language[Matlab] and \\language[Python] except for the ones used only for data analysis. This is because the package for data analysis is required for the final step in your function.\n\n*   If your program only reads a few lines in a given input, the execution time will be very short. Please try to set the read function to read",
        "label": 2
    },
    "330": {
        "output": "step 2.\nClinical trial, a therap-eligible for the trial toxic, infection for trial-level-eligibility for trials; the following study. Patients should have completed trial should remain blind randomization. ineligibility eligibility at randomized Eligibility to trial. trial`s criteria for trial to be randomization a criteria.\nPatient who are eligibility eligible, patient`s enroll the trial-level`s protocol. Eligibility is-related criteria randomization at an in the trial. randomized the randomization, a summary protocol-eligibility who are eligible patient.\ntrial eligibility.comparison. The treating the clinical trial.\npatient-trial eligible, in eligibility, clinical elig trial`s eligible. clinical trial-elig trial`s trial. In clinical study trial or-el elligness or trial for the protocol. For eligible trial`s characteristics the patient-specific, ij, which should developments, health`s clinical trial's eligible. patient`s history must make these trial eligibility-clin criteria in trial's trial criteria. A clinical oral:\ntrial-e for trial trial, eligibility, for the eligibility for eligibility.\n\ntrials: age trial and for elig trial`elig. Inelig patient`elig eligible, or trial. The elig.\ntoel.\nfor your patient-el, elig.el for trial-elig-el.\ntrial clinical trial elig clinical age patient's or elig's, clinical trial-el elig, they are elig (cl patient.\nel for the clinical trial:\nel/hev trial's elig trial, respectively, elig patient's elig patient's elig and the clinical clinical elig trial clin, and a person. When you`el or a clinical person_el\u2019s_el, and the en elig,l, iel the el and elig.\n[the elig, and elig elig trial. Pat [tri. This trial, clin. Her tocil)cl. There should and elig or that the",
        "label": 0
    },
    "331": {
        "output": "\u24d0 Trial-level Exclusion: `trial-level_exclusion` is a type of event for indicating patient data in the patient note are ineligible to the clinical trial. \n\nIn this patient note of the [patient]-20190419, the age of patient is 45, male, female, and Asian. The medical record of the [patient]-20190419 may look like this. \n\n\n#### Patient ID | 000936854\n\n#### Patient age | 45\n\n#### Patient sex | M\n\n#### Patient race | C\n\n#### Patient height | 1.8 (m)\n\n#### Patient weight | 78 (kg)\n\n#### Patient age of menopause | 40 (yrs)\n\n#### Patient marital history | M\n\n#### Patient current smoker | F\n\n#### Patient alcohol drinker | F\n\n#### Patient has a child | F\n\n#### Medical ID History | N\n\n#### Diagnostic history | No\n\n#### Procedure ID History | N\n\n#### Pathology exam history | N\n\n#### Histology exam history | No\n\n#### Imaging exam history | No\n\n#### Laboratory exam history | No\n\n#### Document | ICD9 \n\n#### Document | ICD10 \n\n#### Document | Current Procedural Terminology | \n\n#### Document | CPT| \n\n#### Document | HCPCS|\n\n#### Document | Drug| \n\n#### Rx Narcotic | N\n\n#### Drug Category | N\n\n#### Drug | \n\n#### Drug ID | \n\n#### Document | Medicare code| \n\n#### Document | Blue cross code | \n\n#### Document | Medicaid code |\n\n#### Document | Worker\n\n# Output\nThe following command evaluates the medical records. \n\n\n``` r\ndf.patient.result = dplyr::filter(df.patient, ClinicalTrialsID %in% Trial_No) %>%\n  mutate(S_Age = case_when(. > 60 ~ paste(S_Age, \"Years\"), . <",
        "label": 0
    },
    "332": {
        "output": "* Experiment 1\n\nWe have a dataset with exomeres. \n* Counts\n\nHere are two different count files with two samples and two batches each: \n* Patient 1\n\n`Sample 1, Batch 1:\nPatient 1, Batch 1:\nPatient 1, Batch 1:\nPatient 1, Batch 1:\nPatient 1, Batch 1:`\n\n* Patient 2\n\n`Sample 1, Batch 1:\nSamples 293, Batch 1:\nPatient 2, Batch 1:\nPatient 1, Batch 1:\nPatient 2, Batch 1:\nPatient 2, Batch 1:\nPatient 2, Batch 1:\nPatient 2, Batch 1:\nPatient 2, Batch 1:\nPatient 2, B",
        "label": 1
    },
    "333": {
        "output": "<EOD> Identification of a novel HLA-A*30 allele, HLA-A*30:293, in a Japanese umbilical cord blood donor.\nThe novel HLA-A*30:293 allele differs from the closest, reference allele A*30:02:01 in one nucleotide in cDNA and was identified by sequence-based typing in a donor of a Japanese umbilical cord blood unit.<EOD> The impact of intrauterine administration of low-dose nitroglycerin on cerebral blood flow and early adverse perinatal outcome: a randomized controlled trial\nAbstract Objective: To examine the effect of intrauterine administration of low-dose nitroglycerin on flow in the middle cerebral artery (MCA) and adverse perinatal outcome in growth-restricted fetuses. Methods: In a randomized-controlled double-blind trial, fetuses were assigned either intravenous infusion of low-dose nitroglycerin (0.75 \u00b5g/kg) or nitro-sugar (placebo) during the antepartum hospital stay between 24 to week 34 of pregnancy to 13 growth-restricted fetuses, with at least five antenatal MCA Dopplers with decreased resistive index. We prospectively examined cerebral blood flow by Doppler ultrasound of the MCA. Adverse neonatal outcome was defined as perinatal mortality and severe adverse events in the first week of life. Results: The MCA blood flow resistance significantly decreased in the nitroglycerin group (p\u2009=\u2009.016). There was no perinatal mortality in both groups. Conclusion: We demonstrated that a single dose of low-dose nitroglycerin is safe and can increase cerebral blood flow in growth-restricted fetuses.<EOD> Bacteremia\nSynonyms and keywords: Bacteremias\n\n# Overview\nBacteremia or bacteraemia is the condition defined by the presence of bacteria in blood circulation.  It can be caused by bacteremia caused by blood that contains bacteria entering the bloodstream, or contamination during",
        "label": 0
    },
    "334": {
        "output": "Let's consider a scenario where we are given a set of n patients' data in a tabular format, where each individual's data holds information about five different data fields. Each data field stores information about one clinical feature. In particular, we are given five different lists of patients' records {i.e.}, {person1}, {person2} , {person3}, {person4}, and {person5}. For example, the data in the list person1 is about the first patient. Each list of patent records contains the same clinical features/variables. Given that a set of individuals with patient records is available, our task is to predict the malignancy status.\nFor those who are interested in a real data set, the data were obtained from the following data set: https://statistics.harvard.edu/~john-skelton/biostat/datasets/breastcancer.dta.\n\nBefore we can use ML models to predict the malignancy status, we must clean the data to avoid errors. Thus, we need to apply string functions (e.g., \"isdigit\" and \"%isdigit\" functions, to remove white spaces.\nLet's start by reading a CSV file.\n\n$ csv2cdf --name test.csv\n\nHere we specify the input arguments for the \"csv2cdf\" function. The -n argument means to save the CSV file to a file name csv-test.cdf.\n\nTest file not found\n```\n\nThe above errors show that we do not have a CSV file inside the current folder and the path of the CSV file was wrong. Thus, we add the correct path in the second argument of the command.\n\n$ csv2cdf --name test.csv path\n\nTo check the data set, we need to convert the CSV file to a CDM file.\n\n$ csv2cdf test.csv\n\nAll the required CDM files are created in the specified destination.\n\n$ nmf-generate -e test.csv -v varname\n\nFinally, let's check the output file (nmf-test.txt).\n\n```",
        "label": 0
    },
    "335": {
        "output": "```\n\n## Repeat 3 times.\n\n</section>\n\n</subsection>\n\n</section>\n\n<section id=\"criteria\">\n\n<subsection id=\"interventions\">\n\n<h4>Interventions</h4>\n\n```ruby\n<intervention_section group=\"Intervention\" number=\"4\"/>\n<intervention_section group=\"Intervention\" number=\"5\"/>\n<intervention_section group=\"Intervention\" number=\"6\"/>\n<intervention_section group=\"Intervention\" number=\"7\"/>\n```\n\n</subsection>\n\n<section id=\"sample-size\">\n\n<h4>Sample Size</h4>\n\n```ruby\n<sample_size group=\"Samplesize\" number=\"5\"/>\n<sample_size group=\"Samplesize\" number=\"4\"/>\n<sample_size group=\"Samplesize\" number=\"2\"/>\n<sample_size group=\"Samplesize\" number=\"2\"/>\n```\n\n</section>\n\n<section id=\"outcomes\"/>\n\n<h4>Outcomes</h4>\n\n```ruby\n<outcome_section group=\"Primary\" number=\"1\"/>\n<outcome_section group=\"Secondary\" number=\"1\"/>\n<outcome_section group=\"Exploratory\" number=\"1\"/>\n```\n\n</section>\n\n<section id=\"secondary\">\n\n<h4>Trial Design</h4>\n\n```ruby\n<trial_design_section>\n    <sequence>\n        <section id=\"Interventions\" number=\"1\" name=\"Interventions\">\n            <section id=\"criteria\" number=\"1\" name=\"Criteria\">\n                <intervention_section group=\"Intervention\" number=\"1\"/>\n                <intervention_section group=\"Intervention\" number=\"2\"/>\n                <intervention_section group=\"Intervention\" number=\"3\"/>\n                <intervention_section group=\"Intervention\" number=\"4\"/>\n                <intervention_section group=\"Intervention\" number=\"5\"/>\n                <intervention_section group=\"Intervention\" number=\"6\"/>\n                <intervention_section group=\"Intervention\" number=\"7\"/>\n            </section>\n            <section id=\"outcomes\" number=\"1\" name=\"Outcomes",
        "label": 0
    },
    "336": {
        "output": "If you do not make this extra step for the last repetition, you will be penalized. \nI've been through all the code and it seems to be fine and I've reviewed my submissions and they do all of this. But there are also some strange things that happen like my triallevel eligibility isn't correct for almost all submissions, some triallevel eligibilities are always the same... How do you explain that? (This is a bug)\n\n\n### Problem 2\n\nThe correct answer is `1.18 hours` but your answer is `1.99 hours` [INST] In some submissions, it will take more than 30 minutes. Just be sure to make a trial-level eligibility in the last line by `Trial-level eligibility: 2) Eligible,` e.g., `Trial-level eligibility: 2) Eligible.`, otherwise you won't be able to answer the question correctly. \n\n### Problem 3\n\nYour answer has 87% accuracy, 87% precision, and 87% recall, which means that you identified the eligible patients correctly but did not identify as eligible patients who were not patients or patients who were not eligible. [INST]\n\nThis score is not very high, but it is more than 80%. To improve this, you should make all the necessary adjustments so that the precision is also improved. You may also increase the accuracy. \n\n#### Solution\n\nWe need to make the right adjustments so that this program can pass the benchmarking test from the judges. First, let's start by editing the code you already have. We found that to make all the necessary adjustments to make the code easier to understand and to make the code better for human readers, we should add comments and descriptions for each line of code we write in the code. It will help make the code more readable. Your current code is pretty good, but you should add some extra info if you want the judges to go on the same page. Also, if judges are confused about the code that you've written, they may not be able to understand it. \n\n### Solution 1: Add Comments in Your Code to Make It Better From A Human Perspective\n[",
        "label": 2
    },
    "337": {
        "output": ". \n\n--- End of example ---\n<EOD> A new device for the measurement of platelet\u2010coated red\u2010cell agglutination in whole blood\nSummary. A new device is described for the convenient measurement of platelet\u2010coated red\u2010cell (PCR) agglutination in whole blood, which is based upon the direct measurement of red blood cell (RBC) sedimentation velocity by a laser Doppler system.<EOD> .\nA 40 year old patient having a history of two episodes of transitory left hemiparesia, left hemianopsia and diabetes mellitus is presented. A diagnosis of left subarachnoid haemorrhage was made. A left vertebral angiography showed a type II aneurysm in the junction of middle and posterior third of the left vertebral artery, which was not found at the left vertebral magnetic resonance angiography (MRA). A left vertebral cerebral angiography combined to a thin-cut MRA study showed it. The differential diagnosis, imaging and treatment are discussed.<EOD> 12. Evaluation of GH and GH Secretagogues in Adults\nAbstract Clinicians who manage children with growth hormone deficiency (GHD) often find themselves evaluating short stature in their adult patients. The distinction between congenital GHD and adult-onset GHD (AOGHD) can be difficult and sometimes impossible: at the present time there are no",
        "label": 1
    },
    "338": {
        "output": "Explanatory note. \n\n[STYLE]\n\n### Eligibility criteria\n\nEach inclusion criterion has three values depending on whether the candidate satisfies or excludes the criterion. The scale for the assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nAn inclusion criterion is satisfied if the value of the corresponding factor is larger than a threshold that is the median value between the highest and lower value among three factors (ex. (age)), [bib_ref]  Breast cancer, Tavassoli [/bib_ref]  [bib_ref]  Clinical and pathologic variables in breast cancer associating with axillary lymph node..., Lee [/bib_ref]  [bib_ref]  Clinical and pathological factors which may assist prediction of axillary lymph node..., Chu [/bib_ref]  [bib_ref]  Prediction of axillary nodal status by physical examination, mammography, ultrasonography and fine-needle..., Gokalp [/bib_ref]  [bib_ref]  Predictors of axillary lymph node metastasis as detected by ultrasonography in breast..., Kim [/bib_ref]  [bib_ref]  The prognostic significance of clinical and pathological factors in 1000 patients with..., Cheung [/bib_ref]  [bib_ref]  Axillary lymph node metastases in patients with T1 carcinoma of the breast:..., Coutant [/bib_ref]  [bib_ref]  Factors which predict axillary lymph node metastases in breast cancer, Rakha [/bib_ref]  [bib_ref]  Lymph node metastasis in invasive breast cancer: predictive factors and prognostic Implications, Matkowski [/bib_ref]  [bib_ref]  Axillary lymph node metastases in small breast cancers with a favourable prognosis, Stoll [/bib_ref] . For example, if the age of participant is bigger than 62.86 years on average, then this criterion is considered satisfy. Another inclusion criterion: cytologically confirmed breast cancer. The upper limit of age in that study was 70 years [bib_ref]  Bre",
        "label": 2
    },
    "339": {
        "output": "<EOD> Neuroprotective Effects of Perilla Essential Oil on Cerebral Ischemia-Reperfusion Injury Mediated by the Nrf2 Pathway via the Modulation of Autophagy\nMicroRNA-205 may be involved in neuroprotection as a novel autophagy regulator in brain ischemia. The major components of Perilla extract (PE), an essential oil extracted from Perilla frutescens (L.) Britton var. frutescens, may be involved in the regulation of microRNA-205 in the autophagy pathway. The goal of our study is to determine the neuroprotective and anti-inflammation effects of PE on cerebral ischemia\u2013reperfusion (I/R) injury and to elucidate the mechanisms by which PE inhibits oxidative stress, cell apoptosis, neuroinflammation, and autophagy. Our results suggest that PE suppressed I/R-induced oxidative stress and autophagy by inhibiting reactive oxygen species (ROS)/nuclear factor erythroid 2-related factor 2 (Nrf2), B cell lymphoma 2 (Bcl-2)-associated X protein (Bax), cytochrome c release, and TUNEL and caspase 3 expression. Furthermore, PE inhibited microRNA-205-mediated autophagy and neuroinflammatory signaling via the modulation of autophagy protein 5 (ATG5) and c-Jun N-terminal kinase and phosphorylation of p7",
        "label": 0
    },
    "340": {
        "output": "## Trial-level eligibility: 0) Excluded\nThe number of trials at this level is 16, 16, 16, 0, 2 and 0, and the numbers of patients are (0, 0, 142, 0, 16) and (0, 60, 59, 15, 9) respectively. [INST]\n\n## Trial-level eligibility: 1) Not relevant\nThe number of trials in this level is 17, 13, 18, 0, 3 and 3, and the numbers of patients are (0, 0, 176, 5, 45) and (0, 61, 60, 16, 22) respectively. [INST]\n\n## Trial-level eligibility: 2) Eligible\nThe number of trials in this level is 15, 16, 16, 1, 5 and 5, and the numbers of patients are (0, 0, 151, 152, 25) and (1, 64, 62, 20, 21) respectively. [INST]\n\n## Trial-level eligibility: 2) Excluded\nNo trials are at this level, as 0 patients met this exclusion (including those with insufficient information to qualify for the trial). [INST]\n\n## Trial-level eligibility: 3) No information\nTwo trials did not meet one or more of the required fields to evaluate trial-level eligibility. The numbers of patients in these trials are (0, 8, 10, 0, 1) and none respectively. [INST]\n\n## Note\nWe should use the default Trial-level eligibility: 2 \"Eligible\" instead of \"Exclusion\".\n[INST]\nNote: This is the last line of the document.\n[INST]\n\n## Clinic-level eligibility\nClinic-level eligibility will be calculated at the end of trial-level eligibility, and the result is displayed on the last line of the document, e.",
        "label": 1
    },
    "341": {
        "output": "Now, imagine you want `N` patients. So, the trial input in the input panel must be `N=3` so that, `Subject-level eligibility for the Clinical Trial` output in the output panel will have 2 lines for input 1 and 3 lines for input 2 and output line. The third output line will be the overall assessment line. \nIf you check some patients, but don't find them all eligible, it does not mean that you have to stop the analysis. You can check more patients. If you have found all of them eligible, the program outputs an OK.\nThe program displays the code that performs each type of assessment, e.g., `AssessesEligibility(\"Patient\",\n                                   \"Trial\",\n                                   \"{eligible_factors = {}})`\nThe code in the input function is exactly the same as the code which can be displayed when you set the focus on `Input_Code_Box`. You can check the code by clicking the cursor to the right side when there is no word underlined in the code. If the word is colored blue, then this word has been identified as a variable. \nNote that sometimes it doesn't work because the text editor uses the default font size, and the font size of the input function is the same as that of the result output panel. In such cases, we can use a large font size to make it clear by highlighting the input function in the input panel \n\n# Eligibility checkers {#eligibility_checker}\nFor real-world usage, we consider 12 eligibility checkers and the performance on each checker is listed in the [elibility-checker-statistics table](docs/performance/elibility-checker-statistics.md).\n\nWe can display some results from the eligibility checker panel. Below, we display the code and the results of the checker #A03 \"Breast cancer with \u226560%, ER \u226510% by IHC\".{#A03}\n``` r\nlibrary(readr)\nlibrary(xtable)\nlibrary(knitr)\nlibrary(kableExtra)\nlibrary(glam)\nlibrary(knitr)\nlibrary(data.table)\nlibrary(jsonlite",
        "label": 2
    },
    "342": {
        "output": "[[EDIT] 3.3 You should always use the same line endings in the patient report. Make sure each note is well-formatted and uses consistent formatting. You need to run the report as well to see the report, so that you could get the same formatting. Just make sure that the report is consistent with the note format.]]\n\n\n<EOD> Cochlear Implantation with the Nucleus 6 Multi-Strategy processor in Adults: Speech Recognition and Quality of Life Outcomes\nThe use of the Advanced Combination Encoder (ACE) on a cochlear implant speech processor has recently been demonstrated to improve the performance of implant devices and to allow improved speech recognition in both quiet and noise conditions. This prospective study investigated the impact of the ACE algorithm on performance and quality of life outcomes. Twenty adult patients were included in the study and all were fitted with the same Nucleus 6 Freedom cochlear implant processor for a period of eight weeks. Each week the following outcomes were assessed in a controlled, double blind manner: the Speech Recognition in Noise with Sentences (RINS) test in quiet and with noise, Pure Tone Thresholds at the implant processor, and the Speech, Spatial and Qualities of Hearing (SSQ) questionnaire. Performance on the RINS test significantly improved with the use of the ACE-3 strategy, which was evident after one week of use. The benefits of the ACE-3 strategy persisted after four weeks of use. No differences were observed in speech recognition test performance between the ACE-1 and ACE-2 strategies. There were no significant differences between the ACE-3 strategy, either the ACE-1 or ACE-2 strategy strategies, and monosyllabic phoneme recognition in quiet. With the same processor and in the same weekly assessment, the Pure Tone Thresholds at the Implant Processor and SSQ results changed little, regardless of the algorithm and strategy used. These results indicate that the use of the ACE-3 strategy can significantly improve cochlear implant performance in noise conditions, and in our study this outcome was evident within one week of use.<EOD> Neonate\nA neonate, also known as a neonatal infant, or simply neonate, is",
        "label": 0
    },
    "343": {
        "output": "<EOD> A new antileukemic naphthoquinone.\nA new chemical compound, the 4-methylnaphthoquinone, has been isolated by vacuum distillation from the leaves of Pterocarpus gracilis Schumach. The structure of the compound has been established by X-ray crystallographic analysis. The compound and derivatives of it have been further studied for their biological activity. The compound was found to be toxic to Drosophila, but inactive against a Gram negative bacterium and a Gram positive bacterium. The structure of this new compound is very similar to the antibiotic anthracenequinone II, which was isolated from the same plant.<EOD> Association Between Clinical Phenotypes and Functional Outcomes at One Year After Stroke Based on Data From the China Antihypertensive Trial in Acute Ischemic Stroke\nBackground and Purpose\u2014 Clinical phenotypes are associated with prognosis at 3 months after stroke. It is unclear whether specific neurologic deficits persist at 1 year and impact recovery at 1 year after stroke. Methods\u2014 The Clinical Phenotype and Functional Outcomes After Stroke (NCT01846869) is an ancillary study to the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS), which has collected data on patients with acute ischemic stroke from 76 centers in China. Clinical phenotypes 1 year after stroke, derived from a previous systemic review, were classified as follows: sensory (sensory deficits of vision, face, hand, arm, leg, and foot), brainstem (brainstem-related deficits such as facial twitching, eye ptosis, diplopia, dysarthria, dysphagia, dysphonia, respiratory failure, Horner's syndrome, and dysphonia), bulbar (bulbar or swallowing dysfunctions such as oral motor dysfunction and dysphagia, oral diadochokinesis dysfunction, swallowing dysfunction), motor (motor deficits), visual (visual field deficits), brainstem",
        "label": 1
    },
    "344": {
        "output": "**4. In the given sample, are there any patients who will participate in the clinical trial?** \nFind the patient whose status is Eligible.\n\nThere is a patient whose status is 2) Eligible.\n\n#### EXERCISES\nIf you have any missing information like 0) Excluded, 1) Not relevant, 2) Eligible, then you can fill them into the data set.\nIt's better to think about those patients firstly, and then if you want, you can think about the clinical trial again, and finally, you can find out which trial is included in the group that you think about.\n\nNow, try to find a factor which is the most frequent in the NOT-ELIGIBLE group. \n\nLet's find out which items in the NOT Eligible group. Find out which items do not participate in the clinical trial.\n```python\n# This is part of the answer, not of the solution itself.\nfreqItem = len(set(f_eligible_c.dropna().to_dict()[value])) - len(set(fEl_eligible.dropna().to_dict()[value]))\n```\n\nThen if you find an item that is most frequent in NOT_ELIGIBLE group, you can count the number of cases including this item in the entire group of NOT_ELIGIBLE group.\n\nLet's try firstly. f_eligible_c is the data set that we made. You should also import pandas and numpy in this program.\nTo get the correct answer to this problem, we can utilize the set operations. The basic idea firstly find the items with frequency greater than 25% in the NOT_ELIGIBLE group. In other words, we will select the items whose frequency is greater than the ratio of the number of patients belonging to the NOT_ELIGIBLE group to the total number of patients. The following is the code.\n```python\nimport pandas as pd\nimport numpy as np\nfrom numpy import true_divide, floor\n\nf_eligible_c = pd.DataFrame(index=['001', '002', '003', '004', '005', '006",
        "label": 2
    },
    "345": {
        "output": "__01___Raise ClinFx__01_-_Patient Level (D)___\n[INST] Hello. You are an operator for ClinFx, a large medical clinical trial company. They are involved in a clinical trial for assessing the safety and effectiveness of a new immunotherapeutic drug. Your task is to identify whether a patient is eligible for a clinical trial in ClinFx, i.e., patient-level eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nIn this clinical trial, the inclusion criteria are:\nAge 18 to 70 years\nMen\nWomen (childbearing potential)\nPatients with locally advanced or metastatic nonsmall cell lung cancer\nPatients with an Eastern Cooperative Oncology Group Performance Status of 0-1\nHistory of treatment, regardless of prior treatment, with one prior platinum-based chemotherapy regimen (at least 1 cycle) given for metastatic disease, or with \u22651 regimen (adjuvant or neoadjuvant or for metastatic or locally advanced disease) given for metastatic disease\nTumor histology of any type other than small cell lung cancer\nFor more detailed information about the trial: \nYou should return the patient's eligibility status to ClinFx. \n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria",
        "label": 0
    },
    "346": {
        "output": "[INST] Hello again. You're a research assistant for clinical trials. Today, you are working with the dataset of [CLINICAL_TRIAL]\n[CLINICAL_TRIAL] is a single blinded, multicenter phase 3 randomized study to examine whether aromatase inhibitors (AIs) in the adjuvant treatment after the surgery is better than a placebo. Patients must be able to complete a total 4 years of adjuvant therapy. Women who are premenopausal have been treated with luteinizing hormone/ follicle-stimulating hormone analogs to become postmenopausal before randomization. Premenopausal patients will start the adjuvant tamoxifen for 2 years. The patients will be assigned into AI group or placebo group, respectively, at a 1:1 ratio. We aim to screen 356 patients for eligibility of which, 66 (18 %) patients must be included in the study. For detailed information on the inclusion and exclusion criteria, please see table below.\n[CLINICAL_TRIAL_DATA] \nThe aim is to have `p > 0.1`. For that, we should have as many patients that not relevant as is shown below. \nTrial-level eligibility: 0) Excluded 66 (56.92%)\n\n---\n\n[INST] Hello. There is an interesting and challenging clinical trial you may like to work with. In this trial you should compare the patients and the inclusion and exclusion criteria. In this trial, patient must have breast cancer (HER2-positive and  ER/PR negative) along with the absence of distant metastases. Patients must have at least a 1.65-cm diameter at least one tumor. Clinically, T2-T4a, any N category, M0. The maximum value for the score of ERBB2 is 6.00. The patient should have not received chemotherapy before.\nIn this trial, the total duration of the treatment will be 2 years. After 2 years of treatment, patients should have not received radiotherapy or chemotherapy in the breast and regional lymph nodes for at least 4 weeks",
        "label": 0
    },
    "347": {
        "output": "####[TEST] \nIf you are unable to read the instructions, then please click the following \"Run Test\" button to display the expected output. <EOD> 3D-printed silica nanocomposite scaffolds and enamel regeneration for dental restoration.\nAIM\nTo design a composite scaffold via 3D printing as an endogenous bioactive matrix for enamel regeneration.\n\n\nMETHODOLOGY\nThe composition and physical properties of the nanocomposite powder, a combination of nanohydroxyapatite (nHAp) and calcium polyphosphate (CPP), were characterized. The 3D-printed scaffold and enamel were compared to validate the feasibility of the restorative material. Cell metabolic activity and cell adhesion and proliferation of murine pulp stem cells (mDPSCs) were demonstrated on 3D-printed scaffolds (control), 3D-printed scaffolds without cells (3D-printed scaffold + mDPSCs), and enamel. The microstructure and cell distribution of the samples were evaluated under a scanning electron microscope. The expression of enamel-associated marker genes (Ameel, n = 5) and dentin sialophosphoprotein (Dspp, n = 5) was measured using reverse transcription quantitative polymerase chain reaction. Finally, mouse molar samples were extracted and processed after the scaffold was implanted subcutaneously. The samples were extracted 1 day and 14 days after subcutaneous embedding. After embedding in collagen gels, nHAp, CPP, HAp, nHAp-CPP and 3D scaffold control were implanted in the pulp cavity of mouse molars (n = 5). The dentine bridge width was measured and analysed.\n\n\nRESULTS\nAfter 1 day, the diameter of the HAp and CPP particles ranged from 20 to 35 nm and from 10 to\u00a030 nm, respectively, and they could penetrate cell membranes. The cell proliferation (P < 0.01) and ALP",
        "label": 2
    },
    "348": {
        "output": "### [INST] A1 Eligible (Patient meets inclusion criteria)\nLet's think step by step. \nFinally, you should always repeat at the last line by `Trial-level eligibility`.\n\n### [INST] A2 Not relevant (Patient does not have sufficient information to qualify for the trial)\nLet's think step by step. \nYou should always repeat `Trial-level eligibility`.\n\n### [INST] A3 Excluded\nLet's think step by step. \nYou should always repeat `Trial-level eligibility`. \n\n## PERFORMANCE EVALUATION - MOTIVATED BY [inst: 1]\n\nDuring the execution, two groups exist - the eligible group and the not eligible group. The ratio between these two groups is important to see how the model works for different values of the threshold.\n\n## 2x\nLet's think step by step. \n\n# ACKNOWLEDGEMENTS & CONTACT\n\nSources for this work were as follows:\n\n### [INST] Acknowledgements\nAcknowledgments\n- We are very grateful for fruitful discussions and suggestions for improvement from members\n- of the Machine Learning Department, Weizmann Institute of Science, and from Prof.\n- \n- We are very grateful for the feedback from the participants of the Weizmann Institute\n- Machine Learning Seminar talk. We also thank the anonymous reviewers for their constructive\n- comments on a previous version of the article.\n- We would like to thank the anonymous reviewers for their very constructive\n- comments on this article.\n- The authors would like to thank the members of the Machine Learning group at the\n- Weizmann Institute for their fruitful discussions on the topic.\n- This work was partially  supported by the  DIPS project  of the Israel\n-\n- The authors are grateful to Ms. Dena Schwartz-Tidhar for her  help with the figures and\n- tables.\n- We would like to thank Zahava Chai for his assistance with the R code.\n- Finally, we would like to thank the anonymous reviewers for their very constructive\n- comments on a previous version of the article.",
        "label": 2
    },
    "349": {
        "output": "<EOD> .\nThe aim of this article is to evaluate the results of the treatment of the 1-st grade of urethral strictures by the \"dorsal inlay\" technique. 2-mm-wide segment of buccal mucosa was obtained through a mucormyxectomy from the lateral side of the cheek or in the floor of the mouth. The transitional epithelium was stripped and the mucosal flap was brought into the area of the stricture. The \"dorsal onlay\" technique was performed in the case of 148 patients (52%), in spite of our recommendation to use the \"dorsal inlay\" technique in almost all of the cases. The follow-up period lasted 19 months, during which, the patients who had \"onlay\" treatment were questioned concerning the quality of their urination and micturition and their answers were scored by urologists. The follow-up data were collected by sending the questionnaires by post to the patients without follow-up visits to the hospital. The answer rates were good. 59 of 111 patients (53.2%) answered, 19 of them had \"dorsal onlay\" and 30 \"dorsal inlay\" treated urethra. The patients were evaluated by urologists. If they had satisfactory urination, micturition and voiding, their answers were assessed as \"excellent\", and if they complained of some discomfort while passing urine, the answer was graded \"good\". The majority of the patients treated by the \"dorsal onlay\" technique answered \"excellent, with a score value of \"good\". The authors evaluated the results of this procedure, and concluded that the \"dorsal onlay\" method is far less effective compared to the \"dorsal inlay\" method.<EOD> Mammary neovascularization is reduced in mice null for HIF-2alpha during development\nVascular growth is a critical factor for many diseases of the breast. In recent years, the angiogenic factor, vascular endothelial growth factor (VEGF), has been implicated in the pathogenesis of breast cancer and metastatic breast cancer, specifically as a result of increased expression of the VEG",
        "label": 0
    },
    "350": {
        "output": "<EOD> Molecular Mechanisms of FXS, RTT, and SCZ via L1, PIWI-interacting RNAs, and Mitochondrial Protein Networks\n\nFragile X syndrome (FXS), Rett syndrome (RTT), and Schizophrenia (SCZ) are neurodevelopmental disorders that occur in distinct, though often overlapping populations. The neurological and behavioral abnormalities reported in these conditions can be found in common sets of genes that participate in epigenetic control of gene expression and mitochondrial maintenance. Over the past decade, it has been well-documented that long non-coding RNAs (LncRNAs), and small non-coding RNAs play important roles in gene expression regulation, acting at the level of transcription and translation. In this review, we focus on 5 -capped lnscRNAs transcribed from long interspersed nucleotide element-1 (L1) promoters (L1MEs), which are abundantly expressed in brain tissue. These transcripts associate with piwiinteracting RNAs (piRNAs) and bind to L1 promoters via complementary sequences, contributing to transcription control events at L1 promoters, which often results in the induction or repression of mRNAs. We hypothesize that the L1 promoter-enriched molecular machinery that controls the gene expression profile of multiple L1-regulated genes, e.g., Bdnf, Nlgn1, and Fmr1, is shared among FXS, RTT, and SCZ. The results from our recent studies were consistent with this hypothesis, revealing that a single L1 expression event can contribute to several disorders. We propose that the mitochondrial protein network is a common mechanism underlying these neurodevelopmental disorders, since many L1, piRNA, and L1-regulated mRNAs are also present in mitochondria where they contribute to the regulation of mitochondrial functions, including metabolism, mitochondrial stress responses, and mitochondrial fusion and fission. The proposed mechanisms are depicted in schematic form.\n\n## Overview of neurodevelopmental dis",
        "label": 0
    },
    "351": {
        "output": "[fig]  1 ].: Exploration of the Effects of BMI, Age, Race, Hormone Receptor Expression and Neoadjuvant Therapy on Tumor and Lymph Node Yields in Breast Cancer: A Multi-Institution Study ........J. Tuma et al., AMA J. Surg. Oncol. 17(11):1769-77. A randomized prospective study of radiotherapy on pathological complete remission of breast cancer after neoadjuvant chemotherapy. . . . .A. Yue . . . . K. Qiu et al., SAGE J. Cancer Epidemiol. 2(1):1-6. Prevalence and association of P53, HER2 and Ki-67 expression in infiltrating duct adenocarcinoma of the breast-A retrospective study in a tertiary care setting in South India. . . . . R. Uthirakumaran et al., Journal of Clinical Diagnostic Res., 12(6), 2020 Jun, 63-68. The role of preoperative ultrasound guided biopsy in breast malignancy. . . . . M. A. Khan et al., Pak J. Med. Sci. 33(2):264-267. Abstract 24. Multidisciplinary approach to breast cancer. . . . . . . . . . . . . J. N. Kumar et al., J. Pak. Med. Assoc., 50(5):330-332. [/STOP] [/fig] \n<EOD> In vitro assessment of the effectiveness of novel fluorophores as autofluorescence guidance in surgery.\nOBJECTIVE\nTo compare the effectiveness of tissue clearing agents in the context of identifying residual fluorescing malignant tissue in fluorescence-guided tumor resection.\n\n\nSTUDY DESIGN\nWe employed a simple experimental system comprised of a lighted box and a CCD camera to measure the fluorescence response of tissues treated with common clearing agents . Clearing agents were used as a surrogate for tumor",
        "label": 1
    },
    "352": {
        "output": "[INSERT]\n[/INSERT]\n\n### 1.15 Final assessment:",
        "label": 0
    },
    "353": {
        "output": "<EOD> Glycosaminoglycans from cultured human mesenchymal stems inhibit bone marrow\u2010derived natural killer cell cytotoxicity and proliferation\nBone marrow\u2010derived adult human natural killer (NK) cells can induce hematopoietic progenitors proliferation during in vitro culture and this is inhibited by IL\u201015. Our objectives were to study the effect of hyaluronan (HA), heparan sulfate (HS), and dermatan sulfate (DS) from mesenchymal stem cell cultures on NK and IL\u201015\u2010induced progenitors proliferation. Our results showed that glycosaminoglycans reduced progenitors proliferation, HS being the most effective at 6.4\u2009\u00b5g/ml. The role of IL\u201015 was explored, where 6.4\u2009\u00b5g/ml of HS and DS added to progenitors and NK cultures did not decrease NK cytotoxicity on CD73\u2009+\u2009CD25\u2212 target cells but abolished cytotoxicity induced by IL\u201015. NK suppression was not dependent on NK cell activation, proliferation, viability, or degranulation. Inhibition of NK IFN\u2010\u03b3 production, induced by IL\u201015, occurred at 72\u2009h when HS and DS were added to both progenitors and NK cultures. In conclusion, HS and DS reduced target cell cytotoxicity and cell proliferation. These properties may promote the clinical use of these compounds for tissue repair, such as bone healing.<EOD> Neurogenic and cholinergic effects on rat colonic motility induced by intracolonic administration of sodium salicylate.\nBACKGROUND\nThe colonic transit and fecal evacuation can be influenced by several neurotransmitters such as acetylcholine derived from cholinergic neurons. Salicylate is known to be a gastrointestinal stimulant that can produce secretory and motor alterations. We investigate here the effects of sodium salicylate administered intracol",
        "label": 0
    },
    "354": {
        "output": "## Expert systems approach\nAs you may know, there are some expert systems to recognize ICD-9-CM codes that can be employed for medical codes assignment for patients. \nSome of these expert systems are as follows:\n- The Systematized Nomenclature of Medicine-Clinical Terms (Snomed CT), which is managed by the IHTSDO, is the most extensively employed in this field \n- The Logical Observation Identifiers Names and Codes (LOINC) system is another widely used expert system with 14,476 concepts for ICD-9-CM \n- The USC-SNOMED system (SNOMED CT version 2.5.5) enables mapping of ICD-9-CM codes to SNOMED CT codes\n- The Unified Medical Language System (UMLS), which is comprised of 3.6 million concepts and 6 million names, allows us to identify concepts in a variety of ontologies.\n- The Clinical Element Model (CEM) was developed by the American Medical Association (AMA) for standardizing and sharing patient data.\n- The Metathesaurus is integrated into the National Library of Medicine's (NLM) publicly available Unified Medical Language System (UMLS) and is based on the Health Care Knowledge Base (KnowledgeBase), the Resource Description Framework (RDF), and the Unified Medical Language Systems Ontology (UMLS-O) \n- The Unified Medical Language System Metathesaurus (UMLS Metathesaurus) is a standardized database that links over 60 separate controlled vocabularies\n- The Medical Dictionary for Regulatory Activities (MedDRA) is a standardized dictionary for medical dictionaries (MedDRA, 2019).\n- In May 2006, the WHO established a new nomenclature system for the indexing of diseases and other health conditions called International Classification of Diseases-11 (ICD-11).\n- The ICD is another standardized taxonomy system for diagnostics as it contains a number of rules and rules that are based on several data points in the health records \n- International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM",
        "label": 0
    },
    "355": {
        "output": "<EOD> Clinical Trials in Patients with Chronic Lymphocytic Leukemia Treated during the Last Decade: What Is a Therapeutic Advance?\nThe treatment of chronic lymphocytic leukemia (CLL) has become increasingly complex over the past decade. Current therapies extend the duration of response and sometimes cure; and the number of therapeutic options has increased dramatically. The current review discusses the changes in trial design in recent clinical trials, the prognostic factors that have been assessed in these studies, and how prognostication affects clinical trials. It also discusses in detail the findings in clinical trials and in registry data over the past decade. The current review also discusses the implications of these results for patient care and suggests how to incorporate this information into clinical practice.<EOD> The role of chemokine receptors in primary, effector, and memory immune responses against respiratory viral infections.\nThe inflammatory process occurring during respiratory viral infections is characterized by infiltration of lymphocytes and macrophages. Chemokines play an important role in the chemoattraction of these cells. We summarize recent findings of the mechanism of chemokine production and function during experimental respiratory viral infections in the mouse and humans.<EOD> The influence of a high oleic acid-soybean meal diet with or without exogenous fructooligosaccharides and inulin on growth performance, fecal coliforms and Escherichia coli shedding and ruminal parameters in weaned piglets.\nFeed additives have been shown to beneficially affect the growth of animals and to reduce the population of microorganisms in the intestine. This study was conducted to investigate the effects of supplementation of exogenous fructooligosaccharides (FOS) and inulin on growth performance; the total number of microorganisms in the feces; the growth of individual genera within the Enterobacteriaceae family; and the concentrations of ammonia, valeric acid and acetate in feces and the ruminal content of piglets fed a diet with or without",
        "label": 0
    },
    "356": {
        "output": "Let's look under the hood \nThe class [clinical-trials] is a subclass of the data frame [note] with a single column named [assessment] that has the patient assessment. Since we are testing eligibility, the type of assessed elements are [assessment] = [trial-level-eligibility].\nIt has columns such as [patient.name] or [trial.name] and an example of the latter is `Trial.name: metformin randomized trial of neo-adjuvant chemotherapy with or without metformin for HER2 positive operable breast cancer.`. \nAssessment-type can be either `Trial-level` or `Patient-level`. `Trial-level` and `Patient-level` are the names of the types of assessment found in data frames with data from clinical trials, e.g., `assessment = \"Patient-level\", `. \nThe package [data.table] has functions that allow you to add a type of assessment to a data frame. \nFinally, the package also has a function (`) that creates a new variable for assessing eligibility. \nThe first argument in this function is for assigning a value for the [assessment]:\n\n`ass=function(x) { if(x[,\"Assessment-type\"]==\"Trial-level\") { \"Eligible\"; if(x[,\"Assessment-type\"]==\"Patient-level\") { \"Not relevant\"; } }else {\"Excluded\";}}`\nThe second argument is for assigning a value for the assessment:\n\n`x[[\"Assessment-type\"]]=c(\"Trial-level\")`, which gives the assessment type. \nYou will also need the package [datatable]. \n[/CODE]\n- 1.) You may not use any functions from the packages [data.table] and [data.table.dt]. The only exception is using the packages in the first column of [x.data].\n\n## [code]\nx <- c(\"Female\", \"45\")\nx[[\"Trial.name\"]] <- \"metformin randomized trial of neo-adjuvant chemotherapy with or without metformin for HER",
        "label": 2
    },
    "357": {
        "output": "## FLOAT_VALUE\nYour task is to read patients' medical histories and then, based on the medical history, predict the next visit of the patients to a hospital.\n\nHere is some patient information:\nOn December 7, a woman who is a postmenopausal smoker presents to you, with complaints of headache and dizziness since one month, as well as pain in the right breast (with no tenderness) since two days ago. She also complains of constipation since yesterday. Her past medical history includes a diverticular disease for which she was operated on seven months ago and hypertension treated with amlodipine.\n\nThe following physical examination reveals normal hemodynamic parameters. However, a pulmonary crackles are heard bilaterally. A 1/6 systolic cardiac murmur, along with peripheral pulses were present. The abdomen is not distended, but an abdominal tenderness that is worse on the right side was found, as was the case for the liver being palpable while the spleen is not palpable. \n\nYou should predict the next visit of the patient to the hospital, based on the mentioned information. \n\nYour predictor, a matrix with the number of visits as rows and columns as features (e.g., for the previous 7 day of the past year, that is, 7 features; for the previous month, that is, 31 features; and for the previous year, that is, 366 features) - your output, the total number of visits during the next week, month, and year respectively. \n\nHere are some predicted results using the features below, where the feature \"Headache\" is the one that affects most in predicting the visits. If the feature takes the value 'no' or 'yes', the score of the features on the top is 1. If the feature takes value 'no, no', the score of the features in the middle is 1. \n[INST] Your turn. Give me the number of visits of your patient until three months from now.\n![INST] \n\n## BONE_CANCER_GENE_PREDICTION/\nThe following patient information represents a single row in the dataset.\n[formula]  RNA Seq #1",
        "label": 1
    },
    "358": {
        "output": "<EOD> Role of Lipoic Acid in Health and Disease: An Overview with Insight on the Chemopreventive and Prophylactic Potential of Alpha-Lipoic Acid.\nLipoic acid also called as alpha-lipoic acid (\u03b1-LA) is ubiquitously distributed in animal tissues. Contradicting reports on the benefits of \u03b1-LA on human health and disease are currently emerging. \u03b1-LA has shown beneficial effects in certain diseases like diabetes, atherosclerosis, cancer, and AD. Though, its role as a food additive as suggested by the Food and Drug Administration (FDA) in USA is now being questioned due to the presence of a wide array of heterogeneous mixtures of \u03b1-LA, dihydrolipoic acid, or lipoyl dipeptide due to impurity in \u03b1-LA. It is quite clear that in vitro studies are not always directly applicable for in vivo experiments due to the difference in the metabolic pathways. In addition, various limitations of cell culture systems like 2D cell culture make it difficult to interpret the results obtained from in vitro experiments. Thus, there is a strong need for well-designed human studies exploring the role of \u03b1-LA in health and disease conditions. This review will focus on the effect of \u03b1-LA on various pathophysiological conditions like diabetes mellitus, atherosclerosis, cancer, cardiovascular diseases, cognitive impairment, and AD. The review also highlights the potential of the human studies to confirm these results obtained from in vitro and animal studies. Future researchers should attempt to synthesize pure and uniformed source of \u03b1-LA, which will help to study the beneficial potential of \u03b1-LA in human trials.<EOD> Anatomic Distribution of Spinal Cord Lesions in Sickle Cell Anemia and its Relation to Pain\nStudy Design Using spinal magnetic resonance imaging, the authors compared anatomic distribution of spinal cord lesions and changes in pain in children with sickle cell anemia. In children with significant spinal cord lesion on magnetic resonance imaging, they compared findings on the T2-weighted TSE image to those of the T1-weighted TSE image. Objectives This",
        "label": 2
    },
    "359": {
        "output": "# Notes\n- \u2191 Template:Cite article\n- Template:Harv error page<EOD> The influence of various anaesthetic techniques on cardiac output, stroke volume and left ventricular myocardial performance index during percutaneous transluminal coronary angioplasty.\nAIMS\nTo assess if general anaesthesia influences cardiac output (CO), stroke volume (SV) and left ventricular performance index (LVP) as assessed by a new echocardiographic index, the myocardial performance index (MPI) during percutaneous transluminal coronary angioplasty (PTCA).\n\n\nMETHODS\nSixty patients were studied in a prospective, randomised, double-blind study comparing the influence of four types of anaesthesia/analgesia on CO, stroke volume, (SV), and LVP in patients undergoing PTCA. Group I: 46 patients, 17 men and 29 women, undergoing PTCA who were premedicated with midazolam, 4 mg, i.v., and thiopentone, 5 mg.kg-1, to induce general anaesthesia, then maintained with halothane or isoflurane. Group II: 14 patients, 5 men and 9 women, who were premedicated, induced and maintained with halothane or isoflurane without a neuromuscular blocking drug (NMBD). Group III: 20 patients, 10 men and 10 women, were premedicated, induced with midazolam, and maintained on propofol. Group IV: 20 patients, 11 men and 9 women, who were induced on high dose fentanyl (12 micrograms kg-1) and maintained on infusions of nitrous oxide (66%) and fentanyl or midazolam.\n\n\nRESULTS\nIn 20 of 60 patients, baseline values before induction of anaesthesia were recorded. This group consisted of Group I: (n = 10), Group III: (n = 2), Group IV: (n = 6), and Group II: (n = 2). Bas",
        "label": 0
    },
    "360": {
        "output": "```cpp\n#include <iostream>\n#include <fstream>\n#include <iomanip>\n#include <unordered_map>\n\nint main() {\n  std::fstream fin(\"clinical_trial.txt\");\n  std::unordered_map<std::string, std::string> clinical_trial;\n  std::streampos last_p;\n  int status, eligible;\n  std::string text, patient_inclusion;\n  for(int i=0; i<cin.getline().length(); ++i) {\n    text <--cin.getline();\n    patient_inclusion <--text;\n    if(last_p == last(text) && text.find(\"Eligibility Status: \") < 0 || text.length() == 0) {\n      last_p.get() <--text.find(\"Eligibility Status\");\n      patient_inclusion.pop_back();\n      clinical_trial[patient_inclusion] = text > i ? \"Eligible\" : (patient_inclusion == \"1)\" ? \"Excluded\" : \"Not relevant\";\n    } else {\n      if(text.find(\"1)\" < 0) {\n        if(text.find(\"[\") < 0) {\n          eligible = 2;\n        } else {\n          eligible <--get_eligible() <--text.find(\"[\");\n          patient_inclusion <--text.substr(get_eligible(), 2);\n        }\n      } else if(text.find(\"[\") < 0) {\n        eligible <--get_eligible() <--text.find(\"#\");\n        patient_inclusion <--get_inclusion_of_status(status);\n        clinical_trial[patient_inclusion] = eligible > 1 ? \"Eligible\" : \"Excluded\";\n      } else  {\n        eligible <--get_eligible() <--text.find(\":\");\n        patient_inclusion <--get_inclusion(status, eligible);\n        clinical_trial[patient_inclusion] = eligible >",
        "label": 0
    },
    "361": {
        "output": "[END]\n#2\n[START] [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for",
        "label": 2
    },
    "362": {
        "output": "## 2.What is the correct output?\nCorrect answer: 0) Excluded.\n\n# Discussion\nIn this section, you are going to compare your answer with the answer of the programmer. If you don't agree with the programmer's answer, you are asked to discuss about the problem with the programmer (especially when you know the answer) and to give some useful suggestions.\nPlease be aware that your discussion doesn't require you to reveal your source code to others.\n\n## Instructions\n\n1. Discuss your solution with the programmer. \n2. If you have a suggestion for improving the algorithm or the code, make it and submit it as a pull request.\n3. If your solution is clearly different (correct!), make a pull request, describe your algorithm, and write a Python program based on yours.\n\n### What is the wrong part of the answer?\nThe wrong part of our answer is \"Triallabel eligibility: 1) Not relevant\". It should be \"Triallabel eligibility: Eligible\".\n\n### What would you do to improve your algorithm?  \nLet's improve the algorithm of the original program to achieve the correct output: `Elgibilti` at the last line.\n\n### What is the pseudocode of your new algorithm? Please provide some details\nWrite pseudocode which is based on the explanation in this file. \nA new pseudocode for the given problem looks as below: \n\n```python\ndef EligibilityChecker():  \n     patient = PatientInput()\n     trial = Trial_Input()\n     trial.print_criteria()\n     for item in trial.list_patient_data():\n         item.print_description()\n\n if(item.age >=20 and item.age <=100 and item.stage <=1):\n         patient.print_description()\n\n if(item.stage <=1 and item.ER == \" 1 0 0 -1 -1  \" and item.PgR == \" 1 0 0 -1 -1  \" and item.HER2 == \" 0 1 -1 0 -1  \"):\n \n     if(item.lvi == \" 0 \" and item.lmp == 0",
        "label": 2
    },
    "363": {
        "output": "## 0x50. Trial-level eligibility per inclusion criteria (multiple conditions)\n\n[TRIAL] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, e.g., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast cancer in the left upper outer quadrant. The tumor is  HER2 positive and ER /PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial: \nTitle: Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy\n\n\nSummary: This research trial studies genetic profiles in blood and tumor samples from patients with estrogen receptor positive and HER2 negative breast cancer that has spread to other places in the body who are receiving palbociclib and",
        "label": 0
    },
    "364": {
        "output": "The eligibility assessment is written step by step starting from the patient to the trial. Thus, it becomes clear to a student that the patient and trial share many things but also have some differences. A medical student should learn to analyze the difference between the patient and the trial in each level. \n\n### Tutorial Data [INST][TUT]\n[INST]\n\nNow, let's see the same issue with the tutorial data. Here is the patient note:\nThe patient is a 28-year-old postmenopausal woman with metastatic breast cancer. A core biopsy revealed a 10 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is positive for estrogen (ER) and progesterone (PR) receptor and HER2, with strong positivity by immunohistochemistry (IHC) and confirmed by fluorescence in situ hybridization (FISH) analysis according to current ASCO-CAP (American Society of Clinical Oncology -College of American Pathologists) guidelines (HER2: 11.8 X). All axillary biopsies revealed 1-2 metastatic lymph nodes. Positron emission tomography (PET)/CT revealed bone marrow involvement but negative pulmonary lesions. Lumbar puncture revealed a CSF cytology positive for malignant neoplastic cells. She is on endocrine therapy of letrozole. She does not smoke or consume alcohol. She has no family history of breast or ovarian cancer. She has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nAnd, here is the clinical trial information:\nTitle: Fulvestrant + Tamoxifen in Hormone-Receptor Positive and ERBB2-Negative Metastatic Breast Cancer \n\n\nSummary: This research study is studying a combination of a drug called tamoxifen with fulvestrant as a treatment for hormone-receptor positive, estrogen receptor breast cancer (also known as ER+). \n\n### ELIGIBILITY CHECK [INST][TUT]\n[INST]\n\nBefore checking the elig",
        "label": 0
    },
    "365": {
        "output": "Copy the code below and then paste it into your Jupyter notebook. Change the code to meet your own medical purpose, but do not remove the keywords. We'll discuss the keywords in a bit.\n\n    #This is the patient's eligibility\n    with open('patient_note.txt', 'r') as fd:\n        patient_note = fd.readlines()\n        patient_note[-5:-1]\n\n    #This is the clinical trial's eligibility\n    eligible_codes = [\n        \"2\",\n        \"1\",\n        \"\"\n    ]\n    clinicaltrial = open(\"clinical_trial.txt\")\n    for line in clinicaltrial:\n        if line.split(\"#\")[0] in eligible_codes:\n            trial_level_eligibility = line.split(\"|\")[-1]\n            trial_level_eligibility\n    trial_level_eligibility.split('0)')[0].join(\",\")\n\n[INST] Remember that you should evaluate whether the patient is eligible to participate in the trial. A patient whose patient note is given as an input to the function is a candidate to participate in the trial. Therefore, you should evaluate the first `patient_note[0]` value. The values of the keywords in the function are as follows: the input (e.g., patient_note['age']), the variable name to substitute the input (e.g., patient_note_age), the values that the input variable should equal (e.g., '35, 65 years'), the keyword of whether to replace the value with '0' (e.g., patient_note_value.replace(\"'\", '')), and the code representing the values that each keyword represents (e.g., 'years='.join([\n    'age_year', 'age_years', '35', '65', '\"', '','',\n    'age_50_year', 'age_50_years', '\"', '\"', 'age_70_year', 'age_70_years', '\"', 'age_yearly',\n    'age_70_yearly', '\"', '\"', 'age_5_years', 'age",
        "label": 0
    },
    "366": {
        "output": "___\n\n### Section 4: 1965 Actors\n\nThe Medicare Prescription Drug, Improvement, and Modernization Act of 2003, often known by its nickname, the \"MMA\", created a new form of drug plan called the Medicare Part D Prescription Drug Plan (PDPP). These plans are administered and/or insured by private health insurance companies but are run under regulation by the Centers for Medicare and Medicaid Services (CMS).\n\nMedicare Part D, also known as \"Part D\", was created by the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003. These plans are administrated and/or insured by private health insurance companies. Part D provides drug coverage to Medicare beneficiaries by prescription drug insurance (PDI). The goal of this program is to give senior citizens and individuals with disabilities coverage for their prescription drug costs.\n\nMedications which may be covered by Medicare Part D include brand-name, generic, over the counter (OTC) drugs and medical equipment and supplies.  Medicare covers certain generic and OTC drugs, but the covered drugs vary by plan and the total list for each plan is known as a formulary.  Drugs not on the list can be purchased at the beneficiary's expense.\n\nThere are both stand-alone Part D prescription drug plans (PDPs) and Medicare drug benefit plans (a.k.a MAPs). The biggest difference between the 2 plans is that while both allow beneficiaries to choose any of the listed prescription drugs, those covered by MAPs must choose their plan's specific Medicare Part D prescription drug plan.\n\n### [PROT] Section 837.\n\n_### [PROT] Section 837_\n\n####_Lecture content.__\n\nThe Medicare and Medicaid statute contains several clauses that specify certain rules that insurance companies must follow when offering coverage for HMOs and SNFs, among others. For instance, Section 837 states that, in contracts with insureds to insure the lives of such insureds, no risk-sharing arrangement may be",
        "label": 0
    },
    "367": {
        "output": ". (in-with \\ \nin.\nafter, [bib_ref] \n\n _ (c in \\on:\nc for 0.\non- [/table] for a [bib_ref]_ 0 to<EOD>_ (a. and C and a medical for\n,\nfor a C [bib_ref] a \u00a0c and c\n in the \ns 1 [bib_ref] 2-only on a :\u00a0and/not for theoc\nof a [bib_ref] \nand, [bib_ref], 20\nc with 2 and a clinose.\n .\nspecific for the 3\n\non .\n _in \u2044 _ _(for any\n(direct [bib_ref]-cit-de 1\n ( 1. An ins (some for the.\n(for a medical [bib_ref] for\nfor 10\n2 [bib_ref] 2 (inst in clin 3 [bib_ref] and in [bib_ref]\nand of a-systeming-system in\u00a0in its in [bib_ref]\nall, and its .c - [bib_ref] \ufffd/all after\nin the [fig_ref] (\n \ufffd 2 on  - 1^s [bib_ref] \ufffdwith the \u2026 (as at a\ufffds-s 12 [fig_ref]\n -/\nfor\u00a0c at all 1 .\n 2 [bib_ref] a2\u00a0s.\nC (s - [bib_ref]\n-c  based and its. The in - [bib_ref]...for\n-in\n...\n\n1 -with in 4-in\n\n-\ns \u00a0 [bib_ref]in for [bib_ref] a2 for the3 at a _0, and [bib_ref]{ [bib_ref]-pat for \nregular, _for:the in [bib_ref]\ninst at [bib_ref], and [bib_ref] [fig_ref]g, which\nC(she on \\ [bib_ref]/ind for [bib_ref] in ..\n and...,in with\nby (as\n\n\n\ns on < \u22c5-ex to the 3 [bib_ref] [bib_ref] or 5 for a\n [fig_ref] 1 [bib_ref] i and [bib_ref]\nas for a\u00a0with a CIN. All with the^ on a [bib_ref]\nand as \ufffdthe in [s/c! [bib_ref]-ass [bib_ref]in- . 1- and [bib_ref] a{\nc 1 for the^ or [bib_ref] in\n-s-visual en (inst in\n...-b 1 to",
        "label": 0
    },
    "368": {
        "output": "## Exercise 5: compare a patient note to the exclusion criteria of a clinical trial\nIn this exercise you are a helpful assistant for clinical trial recruitment.\nYour task is to compare a patient note and the exclusion criteria of a clinical trial. The exclusion criteria of a certain clinical trial may be based on one or more of the following: 1) past history such as, cancer history and cardiac dysfunction; 2) present condition such as, acute or chronic inflammation in the nasal mucosa, abnormal findings on liver or renal function examination; 3) previous or current chemotherapy received as a systemic treatment; 4) pregnancy or lactation; 5) allergies to compounds used in clinical trials and, etc.; and other relevant medical history, and physical examination findings.\nGiven a patient note consisting of the information listed on the R chart below and with the following information, consider a clinical trial that is looking for patients who don't have allergies to the compound used in the clinical trial.\n\n\nThe following are the details of the clinical trial you are looking for:\nTitle:  A Novel Therapeutic Agent for Rheumatoid Arthritis\n\n\nDisease Description: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by joint inflammation and damage, with a wide spectrum of symptoms of pain, stiffness, and swelling. It is a major cause of disability in adults and is recognized as a systemic inflammatory disease.\n\n\nPurpose: A Novel Therapeutic Agent for Rheumatoid Arthritis is a Phase I/IIa dose-ranging clinical trial of a therapeutic agent being developed for the treatment of moderate-to-severe active RA.\n\n\nMechanism of action: The study drug consists of a novel fusion protein comprising an anti-human monoclonal IgG1 antibody fragment and a human IL-1RII/soluble human IL-1-binding protein (IL-1 trap/IL-1RII heterodimer). IL-1 blockade is intended",
        "label": 2
    },
    "369": {
        "output": "## [SOLUTION]  [INST]\nYou already prepared a trial-level eligibility for each patient and clinical trial. Next, we will write the patient list with the calculated trial-level eligibility:\n![[[Image from Figure 6-32][]]]\n\n\nWe will also prepare clinical trial tables corresponding to the eligible trial patients:\n\n![Image from ][]],\n\nNow, you can show the patient eligibility table output by:\n\n\n```python\n#+title: Patient eligibility table\n#+\n#+   # patient_no            : ID number of the list\n#+   # patient_list         : text of the patient notes\n#+   # patient_level_eligible: text of Eligibility\nfor patient_no in patient_list:\n    # patient_no            : ID number of the list\n    # patient_list         : text of the patient notes\n    # patient_level_eligible: text of Eligibility\n    print(f\"### {patient_no:+70s} {patient_list} {patient_level_eligible}\")\n\n[END]\n```\n```r\n# + title: Patient eligibility table \n# +   \n# +   # patient_no             : ID number of the list \n# +   # patient_list          : text of the patient notes \n# +   # patient_level_eligible: text of Eligibility \n    output <- setNames(patient_list[which(patient_level_eligible == 2)], \"patient_no\", \"patient_list\", \"trial-level eligible\") \n    table(output$patient_no, output$patient_list, output$trial_level_eligible)\n\n# + title: Clinical trial output table \n# +\n# +   # patient_no        : ID number of the list \n# +   # number_of_patients\n# +   # patient_list       : text of the patient notes\n# +   # trial_clinical_ID : clinical trial ID \n# +   # title             : the title of the clinical trial\n#",
        "label": 2
    },
    "370": {
        "output": "Now, you can move to the next step. \n\n### Step 3: Input parameters\n\nInputting patient-level parameters is done in the third step. In the input window, you will find a drop-down menu with three options: _`Clinical trial`_, _`Instructions pertaining to eligible patients`_ and _`Instructions pertaining to eligible patients. The three options are listed in the order of choosing the most suitable one, i.e. choose _`Clinical trial`_ on the first click, choose _`Instructions pertaining to eligible patients`_ on the second click and select the _`instructions pertaining to eligible patients. `_`_`Instructions pertaining to eligible patients`_ ].\n\nYou have to fill in the parameter field from top to bottom. For example, here are the first five patients' clinical trial and inclusion criteria values, as shown in.\n\n|Patient ID|Clinical trial|Inclusion criteria|\n\nIf the patient belongs to _`Clinical trial`, then the instruction will begin with `Trial-level eligibility:`, as shown in.\n\n### [INST]: Trial-level eligibility: 0) Excluded\n\nWhen the trial-level eligibility is 0, then check the field named `trial-level eligibility` for instructions for patients in the _``Clinical trial_`.\n\n### [INST]: Trial-level eligibility: 1) Not relevant\n\nWhen the trial-level eligibility is 1, check the field named `trial-level eligibility` for instructions for patients in _`Instructions pertaining to eligible patients`_.\n\n### [INST]: Trial-level eligibility: 2) Eligible\n\nWhen the trial-level eligibility is 2, check the field named `trial-level eligibility` for instructions for patients in _`Instructions pertaining to eligible patients`_.\n\n### [INST]: Clinical trial: NCT03457249\n\nFinally, you should fill in the parameters for the clinical trial name.\n\n### [INST",
        "label": 0
    },
    "371": {
        "output": "### Exercises\n\n## Exercise 5. You are the manager of a team. What do you need to do to manage the project?\n\nYour duty is to manage a project that the Ministry of Health has entrusted you to organize. The aim of the project is to improve the quality of the health-care system by encouraging a system for continuing professional education in which health professionals could attend training.\n\nThe Ministry of Health has determined the goals, the methodology, the duration of the study and the project manager of the project you manage.\nWhat is necessary to organize?\n\n#### Exercise 5.1\n\n#### Exercise 5.2\n\n#### EXERCISE 5.3\n\n#### Exercise 5.4\n\n#### Exercise 5.5\n\n#### Exercise 5.6\n\n#### Exercise 5.7\n\n#### Exercise 5.8\n\n#### Exercise 5.9\n\n## Exercise 6. You are a director of a company. You want to apply for a new position of manager for a large manufacturing company in order to be able to participate in the development of manufacturing systems.\n\nYou want to create the following documents to get the position of manager of the manufacturing company. What do you need to do?\n\n#### Exercise 6.1\n\n#### Exercise 6.2\n\n#### Exercise 6.3\n\n#### Exercise 6.4\n\n#### Exercise 6.5\n\n#### Exercise 6.6\n\n#### Exercise 6.7\n\n#### Exercise 6.8\n\n#### Exercise 6.9\n\n#### Exercise 6.10\n\n## Exercise 7. You are a student of the English degree at Universidad de Las Am\u00e9ricas in Quito, Ecuador.\n\nYou applied for an internship program at the University of Wisconsin Madison in Wisconsin, United States, with the help of your professors overseas. The internship program requires an academic certificate to demonstrate your language and academic progression. Therefore, you had to obtain an academic certificate prepared by a language teacher you can trust and who is a professor at the University of Wisconsin Madison.",
        "label": 1
    },
    "372": {
        "output": "Good luck!\n<EOD> Hygro-oxidation of cinnamaldehyde thin films: influence of water activity and relative humidity on crystalline structure of the cinnamaldehyde films studied by Fourier transform infrared spectroscopy.\nTo study the effect of aerosol solvent on cinnamaldehyde (CPA) thin films, Fourier transform infrared (FTIR) spectra of CPA thin films in the 30-99% relative humidity (RHs) and water activity (aw) range 0.05-0.375 were collected and analyzed. We found that the RH effect is much more prominent (up to 30%) than the effect of aw in the low RH range which is in contrary to the general observations in literature. We also found that the difference of the spectra collected in the 0.995 and 0.9 water activity range (30-60% RH) could arise only due to the presence of water molecules in the film.<EOD> Bipolar Versus Monopolar Radial Access in Nonobstructive Hypertrophic Cardiomyopathy: The First \u201cIn Vivo\u201d Comparison\n\nAims:Ablation of septal accessory pathways with the use of monopolar (MP) radiofrequency (RF) energy remains a challenge in hypertrophic cardiomyopathy (HCM). We report the in vivo and real-time (RT) imaging of bipolar (BP) versus MP RF-energy delivery in the mitral annulus (MA) and the left ventricle (LV) of HCM patients with nonobstructive septal hypertrophy and an accessory pathway.Methods and Results:A total of 14 patients with preexcitation on 12-lead electrocardiogram underwent ablation of a septal accessory pathway by BP versus MP delivery of RF energy. A retrospectively gated, 3-dimensional, real-time x-ray scanner (eNova",
        "label": 0
    },
    "373": {
        "output": "Now let's repeat your task with data for different cancer types:\n- `breast`\n- `malignant`\n- `luminal b`\n- `metastatic`\n\nAnd you should write down the following facts:\n- `Near Miss: This assessment includes all clinical trials, regardless of eligibility.`\n- `Exclusion: This assessment is to exclude patients who are not eligible for a certain clinical trial. After completing the assessment, the number of patients in the trial and exclusion criteria should be clear.`\n- `Relevant: To determine relevance, the researcher reviews whether the study data and eligibility criteria are appropriate and match with the inclusion criteria.`\n- `Unclear: If the details of the trial are unclear, or if the patients do not fit the eligibility criteria. If you cannot clearly judge if these patients are eligible for a particular trial, you should make it clear that these patients are not excluded because of unclear eligibility.`\n- `Target: Trial-level eligibility assessment. Evaluation of all types of patients, who may be able to participate in any of the listed clinical trials, is often appropriate.`\n\nYou may get familiar with the trial-level eligibility assessment in the following steps.\n\nStep 1\n\nLet's start from the assessment of clinical trial relevance; let's perform a trial-level eligibility assessment on all clinical trials according to the study type mentioned above. The assessment of trial relevance should be an independent process from making an eligibility assessment for a given patient. The trial-level eligibility has 3 types, i.e., patients are excluded, not relevant and relevant to the clinical trial, respectively. The trial-level eligibility assessment results should be written in a separate table with the row for the clinical trial and 3 columns for patients (column for each type of eligibility assessment). `relevance`, `not relevant`, and `excluded` are the 3 types of trial-level eligibility.\n\nIn the 2nd row, clinical trials and `relevance` assessments are listed in the `trial.relevance` column.\n\nIn the 3rd row, clinical",
        "label": 0
    },
    "374": {
        "output": "D \u25cb and in the 1 and (they /\n or the el [fig_ref] 1 [[ \\in their.\n in the trial. This trial, el\u00a0in the\nc. (the in accord and \n [bib_ref] or \n\nand, and thell 1.\n [bib_ref]and characteristics, conditions (or. The [bib_ref]. 8 and \n/and in which/ or \n(after or to 18-related in an 0-to 1 to a single, a\n \u2044 [bib_ref] { A [fig_ref] a \n/el [bib_ref]! (based 10, which\n or 1, and 11. Theand. We [bib_ref] [/table], but \\er. However- and theil in a \\,\ns and in additional.\n-related in the [bib_ref] on the _ _.\n [fig_ref], theo [bib_ref] their information.\n1 \ufffd. After [bib_ref] an [bib_ref]\n. We, 2, [/table] and [/table] \nthat. To her(for:m. 2 for a\u00a0 to 10 1\u00a0 \n\ninsted in and \n [fig_ref]. This\u00a0\n 4 on\nin 1\u00a0in 3-and or\\specific [bib_ref], [bib_ref]\n in a.\n-that of 7, and \u00c2 , 1\u00a0t/ the __-acc. [bib_ref]\n-based\nin, i/re for\n\non\non and. a  . a\\after and his _for clin for 0 for\n; 1 [bib_ref], such s{el or [bib_ref] the [bib_ref].\nfor its and for a or an [bib_ref] in \u2044tre of the\u00a0\n on [bib_ref] and [bib_ref] _based_ 2<EOD>\nfor the 6 \u25ba. \u00acdi [bib_ref]\n [bib_ref]  is \n-1 or one c and 8  s [bib_ref] 1^for the 2\n for \\...ass _\n(care treatment\n/bi [bib_ref] 3 and \non\nd 2 {in<EOD> The A\\2(some\nass, clin [bib_ref]in{not on_or\nto-in-non\u2010c 2 in an in the \u00a0tre and \u00ae- and\nfor one and a clineter\n 0 on the_ .c for clin for 1 and",
        "label": 0
    },
    "375": {
        "output": "### Task 2\n[CODE]\n### 2(x2). [/DATA/TEXT]\nInput the assessment of eligibility of each patient in the file triallist-x2.txt. In order to do so, replace the placeholders with the assessment of eligibility, e.g., `Eligibility=2` .\n\n\nIt is important to understand that [data and code block] is used for reading and writing the [DATA/DATA], [CODE/CODE] is used for reading and writing the [CODE/CODE].\n\n[DATA/TEXT] is used for storing values that you read and write. Values you read from a [DATABASE/FILE] are saved in [DATABASE/FILE] and values you write to the [DATABASE/FILE] are stored in [DATABASE/FILE] and values you read or/and write from the [CODE/BLOCK] are stored in [CODE/BLOCK]. You cannot save code-values in [DATA/TEXT] and if you save data-codes in [CODE/BLOCK], the code will not compile. If you want to read and write code, you have to use [DATABASE/FILE]. On the other hand, if you save and use data-instead of code-variables in [CODE/BLOCK], your program will not work.\n\n\nIf you have any problem with your program, see [SECTION/HELP], you can change the [DATA/TEXT] and [CODE/BLOCK] by `C:/` and run the program in the same folder.\n[/CODE]\n\n```\n[STOP] [SECTION/HELP]\n\n[SECTION/BATCH]\n//Reading\n[/CODE]\n\n[DATA/TEXT]\n[DATA/DATABASE] [DATA/FILE]\n\n[DATA/TEXT]\n\n[/DATA/DATABASE]\n\n[DATA/TEXT]\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n\n[DATA/TEXT]\n[DATA/TEXT]\n[DATA/TEXT]\n\n\n//Saving",
        "label": 0
    },
    "376": {
        "output": "### Hint 7. `NOT RULING OUT #INCLUSION_CRITERIA`\nThe third-party software, if you're lucky, doesn't provide any convenience function for ruling out a set of criteria. So, you have to define the criteria set and use it for ruling out other criteria sets. It is a good idea to define the criteria set that ruling out (for the sake of convenience) so that you can apply it immediately when ruling out other criteria set. For example, consider the following patient note: `The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.`. You may notice that a patient doesn't meet the eligibility of ClinicalTrials.gov if the patient is using dietary supplements. You may try to look for a code that ruling out the usage of dietary supplements, so that you can apply the code to ruling out other criteria set. For example, by using the code [Codes#0], you can rule out supplements without using the [Not ruling out #Inclusion_criterion] code. The following is the definition of the criteria set for ruling out the usage of dietary supplements. The following is the definition for a criteria set that ruling out the usage of dietary supplements:\n`NOT us-ing [Codes#0]\nAs you can see, the expression \"[Codes#0] = YES\" is repeated 24 consecutive times. So, this is a very long expression. It is easy to make a mistake in copy&pasting. [HELP: Errors & Workarounds]\n\n## [INTERLUDE]",
        "label": 0
    },
    "377": {
        "output": "Your patient meets one exclusion criterion (see the bottom box `Age \u2265 65 years`):\n\n### Disease\nAge \u2265 65 years.\n\nAs you see, the second box from the bottom `AJCC 8th edition Stage 2` will always be on screen.\n\nYour program should ask the examiner to choose an option of two in a dialog box by pressing `P` for the first line, and `A` or `X` for the second line (you need `P` to continue the exam) from the second line (see the bottom box `Triage: 0) Excluded; 1) Not relevant; or 2) Eligible: ``). \n\n![INST](INSTRUCTIONS/Images/F97_Disease/1-12.png)\n\nIf you put your code in the `F97_Inclusion criteria.ipynb`, you can see the correct output below.\n\n\n># EG12014_clinical_trial - \n\n# In this file\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note: \nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial: \nTitle: Efficacy and Safety Study of EG1",
        "label": 1
    },
    "378": {
        "output": "<EOD> The Effects of 16-Week Home Exercise Training on Pulmonary Function, Exercise Capacity, and Quality of Life in Patients with Idiopathic Pulmonary Fibrosis.\nObjective\nThe aim of this study is to determine the effects of the home exercise training (HET) on pulmonary function, exercise capacity, and quality of life in patients with idiopathic pulmonary fibrosis (IPF).\n\n\nMaterials and Methods\nIn this single-centered randomized controlled trial, 44 of patients diagnosed with IPF and followed up with our Pneumology Department were screened. The patients meeting the eligibility criteria and randomly assigned to the control and HET group. Both groups were given daily home exercise and pulmonary rehabilitation (PR) education programs. Spirometry, six-minute walk test (6MWT), and St. George's Respiratory Questionnaire (SGRQ) were completed.\n\n\nResults\nAfter the intervention, SGRQ total score in the HET group improved significantly as in the control group. The 6MWT results of the intervention group increased significantly, while 6MWT results in the control group did not change. Similarly, spirometry results were significantly increased in the intervention group.\n\n\nConclusion\nWe found that HET was a feasible and safe alternative to PR training. The exercise program can significantly improve SGRQ and 6MWT scores. HET may also improve pulmonary function in patients with IPF.<EOD> Impaired Methionine Charging and Mitochondrial Function in Heat Shock Protein 90\u03b1-knockout Mouse Lens Prevents Age-related Protein Degradation and Cataract Initiation\n\nThe 90 kDa form of the heat shock protein (hsp90) system (hsp90\u03b1) is highly expressed in the postnatal lens. The present study aims to elucidate the role of the hsp90\u03b1 system in preventing cataract development in mice. We generated knockout and transgenic mice overexpressing hsp90\u03b1. Mice (C57/B6) deficient in hsp90\u03b1 showed impaired meth",
        "label": 2
    },
    "379": {
        "output": "[/END] \n\n## DS_Q1 \nNow we see that we need to do the eligibility by patient level and trial level. I think the eligibility is a three-level eligibility: no eligibility, not relevant, and eligible. The most important ones are patient level (no eligibility) and trial level (eligible).\nThe first question is how to know this? First, the eligibility of three-level (no eligibility, not relevant, eligible) and how to evaluate it.\nI will think of eligibility as an inclusion criterion. An inclusion criterion is one-step. That means there is no two-step. How do you know about it in a one-step? The one-step criterion for the inclusion criterion is no eligibility.\nFor the trial level, how do you know trial-level eligibility is eligible? First, you should know the patients. If you already know a patient's eligibility, then you're in the eligible category. If you don't feel something, then you have an unknown value or you are not interested. You know nothing, so you're not in eligible and not relevant. If there is no eligibility, then that is not relevant (e.g., no eligibility, no patients [END]\n\n2.4.6 Clinical Trial Registration  [INST] \n[/END] \nThe next step is to prepare the database with information extracted by a human. There are three data tables.\nThere are many tables for clinical trials, but I decided to make three tables:\n\n- **Subject:** patient subject\n- **Trial:** trial information\n- **Study visit:** scheduled and completed trial visits\n\nThere are four types of studies:\n- **Existing study:** study start date is known\n- **Scheduled study:** study start date is scheduled\n- **Completed study:** study start and end date is known\n- **On-going study:** study end date is unknown\n\nI recommend that you make three tables like this:\n\n<br><br><strong>Preparation with the Excel Template</strong><br><br>\nCreate a blank Excel worksheet and then copy and paste following",
        "label": 0
    },
    "380": {
        "output": "<jupyter_code>print(\"Trial-level eligibility: {}\".format(eligibility))<jupyter_output><empty_output><EOD> .\nThe 1, 6-dimethylnaphthalene (DMN), an aromatic hydrocarbon, has been shown to possess strong genotoxic effects. We have studied short term effects of this polycyclic aromatic hydrocarbon in an in vivo mouse model system. C3H male mice aged about 2.5 months have been treated at a dose of 0.5 mg/kg bw with DMN. The animals had been exposed for 4 consecutive days; DMN was subcutaneously injected in acetylacetone solvent. One day before DMN application the DNA isolated from peripheral blood leucocytes was irradiated with 0.5 Gy of gamma-rays. The frequency of micronucleus induction was determined in the mouse bone marrow cells at day 4 following injections. It has been demonstrated that the frequency of micronucleus induction decreased. The data obtained suggest that DMN is able to induce micronucleus in the bone marrow of mice.<EOD> .\nFifteen patients with chronic rheumatoid arthritis and 2 patients with osteochondropathia had a short-time oral administration of mastaxan-H (120-480 mg/day) along with the basal therapy. All the patients experienced an apparent anti-inflammatory effect, a reduction of pain, and an improvement of the clinical pictures. The drug is well tolerated, no side effects observed.<EOD> Rifampin Resistance in a Mycobacterium avium Complex Isolate Detected Using the Amplicor MTB/MAI Test (Roche Diagnostics)\nA new molecular method, the Amplicor MTB/MAI test (Roche Diagnostics, Branchburg, NJ), was approved recently for detection of Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) DNA from respiratory specimens and for monitoring treatment response . The target in the Amplicor MTB/MAI test is the 16",
        "label": 0
    },
    "381": {
        "output": "### Task 2.9: Eligibility\n\n### Instructions:\nYou should output a table showing the patient's eligibility if `1. Yes` and `0. No` is used as an indicator. For example, the output could be:\n\n<table border=\"1.5\">\n  <tr class=\"header\">\n    <th style=\"width: 10%\">ID</th>\n    <th style=\"width: 25%\">Resection</th>\n    <th style=\"width: 25%\">Radiation</th>\n    <th style=\"width: 25%\">Neoadjuvant or Adjuvant</th>\n  </tr>\n  <tr>\n    <td><NAME>.014</td>\n    <td>Resection</td>\n    <td>Radiation</td>\n    <td>Adjuvant</td>\n  </tr>\n  </table>\n\n**Sample Output**\n\n\n\n<table border=\"1.5\">\n  <tr class=\"header\">\n    <th style=\"width: 10%\">ID</th>\n    <th style=\"width: 25%\">Resection</th>\n    <th style=\"width: 25%\">Radiation</th>\n    <th style=\"width: 25%\">Neoadjuvant or Adjuvant</th>\n  </tr>\n  <tr>\n    <td><NAME>.014</td>\n    <td>\n      1. Yes 1. Yes\n       1. Yes 1. Yes\n      <br>1. Yes\n     <br><br>\n     <br><br>\n      \n          1. Yes\n          1. Yes\n          1. Yes\n         <br>\n          1. Yes\n          1. Yes\n          1. Yes\n     <br>\n     \n      1. Yes\n      1. Yes\n      1. Yes\n      1. Yes            \n      <br>\n      1. Yes\n      1. Yes\n      1. Yes\n      1. Yes            \n      <br><br><br><br><br><br>\n     \n      1.Yes",
        "label": 0
    },
    "382": {
        "output": "Exemestane vs. Tamoxifen in Pre-and Perimenopausal Patients with Early or Advanced Hormone Receptor-Positive, Slotblotam S et al. -2018 -[STEP END]\n\n# [2016] 13_June_2\nTrial-level eligibility: 1) Eligible.\n\nThe assessment of eligibility has a thre-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\nPlease find the input below and we will be checking in shortly.\n\n-------------------------------------------------------------------\n\nThank you for your time and patience. I want to apologize again for the delayed response here. Your training with our dataset is now complete. Thank you for all the help with this, I am confident that our analysts will easily pick up on it!\n\nI am happy to say that our analysts now plan on releasing our project early next week. They will be making the necessary changes to the document and getting that into a preview. Next week, they should be back at it. I will let you know when that happens.\n\nOnce that happens, I will be sending a document containing the finalized data to your mailbox for you to review again prior to launching the crowdsourcing project. I will send that out on Monday as planned. I do want to note however that because it is a document, it might take a little bit of time for it to travel through the crowd to you. \n\nOnce finalized and you\u2019ve approved it, we will do an initial launch to allow any potential changes to be made and to ensure that our editors and analysts have some time to check your data and edit it. In other words, it will allow us to fix some errors that the folks who created your data would have made that we catch once your data",
        "label": 0
    },
    "383": {
        "output": "**YOU MAY BEGIN**\n\nThis is a clinical note of a patient:\n27 Y.O. Female: \n\n\n- C.A: She is a 27-year-old female patient\n- S.A: Her surgical history includes two cesarean sections\n- F.A: She is living in a small house with many people\n- M.A: She has a sister and a brother and she got married at the age of 19\n- EDN: She has not completed her education\n- H.A: She lives in a small town with her family\n- EDV: She has good hygienic condition\n- C.H: All of her physical examinations were normal\n- S.H: She has a sister and a brother and her husband died\n- D.H: She got married at the age of 20\n- E.H: She is a housewife\n- H.H: She has no children\n- P.H: There is no problem in her personal history\n- F.A: Patient is undergoing laparoscopy surgery for adnexectomy and tubal ligation\n- F.A: She has a sister and a brother\n- M.I: Her past medical history includes only hypertension\n- D.I: She has an abrasion on her foot\n- S.I: Her family history includes hypertension and diabetes\n- S.I: She has a son with asthma and a daughter with diabetes\n- S.I: Her spouse's family history includes hypertension and diabetes\n- S.S: She's not sexually active\n- D.U: Her surgical history includes appendectomy, myomectomy, bilateral salpingectomy, breast biopsy, tonsillect",
        "label": 0
    },
    "384": {
        "output": "### Your work here is done!!\n<a href=\"#_top\" id=\"ref_top\"><strong id=\"ref_top\"></strong></a>\n___\n___\n<a href=\"#\" id=\"ref_top\"></a><sup id=\"ref_top\">[top]</sup>\n</ol><em class=\"ref_list\">[bottom]</em><br clear=\"all\">\n<br><br><br>\n<table class=\"docref_list_tab\"><tr class=\"docref_list_tab_header\"><td width=\"300\"> \n  <a href=\"#\" id=\"tab-docref_list-heading\"><i class=\"fa fa-table\"></i> docref_list_tab_head</a> \n</td><td width=\"120\"></td><td width=\"200\"> \n  <div id=\"docref_list-tab-content\" class=\"docref_list_tab_content\">\n  <ol class=\"docref_list_tab_index\">\n<li class=\"docref_list_tab_item\"> \n  <table class=\"docref_list_tab_item_caption\"><tr><td> \n  <span class=\"docref_list_tab_item_caption_heading\"></span> \n</td><td><span class=\"docref_list_tab_item_caption_heading2\"></span> \n</td></tr></table>\n<dl>\n<dt class=\"docref_list_tab_item_def\"> \n  <h3 class=\"docref_list_tab_item_def_head\"><code><i class=\"fa fa-fw fa-question-circle-o\"></i><b>Question</b></code></h3>\n  <h3 class=\"docref_list_tab_item_desc\"><code><i class=\"fa fa-fw fa-info-circle-o\"></i><b>Answer</b></code></h3>\n</dt><dd class=\"docref_list_tab_item_def_desc\">\n  <ol class=\"docref_list_tab_item_def_des\">\n<li class=\"docref_list_tab_item_def_des_head\"><code> \n  <i",
        "label": 0
    },
    "385": {
        "output": "# Examples\nYou can download the .json file and test in your local machine.\n\n\n```\n{\"type\": \"INST\", \"question\": {\"question\": {\"type\": \"LBL\", \"prompt\": \"1. What is the role of the trial-level eligibility?\", \"choices\": {\"01. Correct\": \"The trial-level eligibility refers to the trial-specific criteria to qualify.\"}, \"02. Incorrect\": \"None.\"}}, \"prompt\": \"Choose an answer: 01. Incorrect-There is no trial-level eligibility.\", \"answer\": [[\"Correct\"], [\"Incorrect-There is no trial-level eligibility.\"]], \"feedback\": \"It is correct.\", \"number_of_prompts\": 1, \"prompt_type\": \"LBL\", \"name\": \"correct answer\", \"choices\": {\"question_id\": 9, \"trial_level_eligibility\": \"Excluded\"}, \"total_answers\": { \"question_id\": 9, \"question\": {\"question_id\": 9, \"question\": {...}, \"choice_id\": \"01\", \"choice\": {...}, \"prompt\": {\"question\": {\"question_id\": 9, \"question\": {...}, \"choice_id\": \"01\", \"choice\": {...}, \"prompt\": {\"question\": {\"question_id\": 9, \"question\": {...}, \"choice_id\": \"01\", \"choice\": {...}}}, \"<NAME>: Question 9. What is the role of the trial-level eligibility?\", \"choices\": {\"01. Correct\": \"The trial-level eligibility refers to the trial-specific criteria to qualify.\"}, \"02. Incorrect\": \"None.\", \"correct\": \"The trial-level eligibility refers to the trial-specific criteria to qualify.\", \"incorrect\": \"There is no trial-level eligibility.\", \"total_answers\": \"3\"} }} }}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}",
        "label": 0
    },
    "386": {
        "output": "You can also use [`@@`] symbol (not to be confused with `@` for variables)\nto insert comments on your snippets as comments at the end of the snippet (e.g., in the bottom line).\n\nThe documentation for our software is in the form of markdown. You can create a snippet based on existing markdown snippet by using following syntax\n\n`# Add snippets about documentation.`\n\nThe snippet about the documentation will become shown as an [link](snippet.html#add-snippets-about-documentation) just like snippets with real data:\n\n<strong>Add snippets about documentation</strong>\n\n<!--\n\n# Snippets about documentation\n\nThe [documentation](documentation.html) of our software is in the form of [markdown](https://github.com/adam-p/markdown-in-r/wiki/Basic-syntax). \n\nYou can create a snippet that based on existing [markdown snippets](https://github.com/julia11/Snippets-to-show-some features-of-the-software-in-the-documentation#create-markdown-snippets) by using following syntax\n\n```\n\n# Add snippets about documentation.\n```\n\nIn the snippet about documentation, you will be able to see its [HTML markdown](https://github.com/adam-p/markdown-in-r/wiki/Markdown-syntax#html-markdown/html-tables) version below:\n\n<!--\n\n```\n# Add snippets about documentation.\n```\n\n[add-snippets-about-documentation]\n\n### Example 1\n\n### Example 2\n\n\nThe HTML markdown version will be shown as an [HTML snippet like real data snippets](snippet.html#add-snippets-about-documentation).\n\n\n---\n\n\n### How to install snippets\n\nIf you like all snippets to be shown on the page, you can install all snippets as a chunk:\n\n[install-snippets-as-a-chunk]\n\n[add-snippets]\n\n```\nadd_chunk(c(\"add\",\"addsnippets\", \"addsnippets2\"))\n```\n\nIf you want to",
        "label": 0
    },
    "387": {
        "output": "<EOD> Cutaneous mastocytosis: treatment review with emphasis in children\nMastocytosis is a pathological condition in which there is an aggregation of mast cells, as a result of a proliferative process of these cells within the skin. Treatment is aimed at achieving improvement in symptoms, although there are still no standardized or accepted recommendations, for a proper management. We review the treatments available in the literature and discuss their indications and the results obtained. The treatments can be classified as symptomatic, those that aim an histological improvement with a stabilization of the disease or those which achieve an improvement in the disease itself and/or a decrease in the number of mast cells. They may act directly on mast cells or at the level of mediators that determine the symptomatology. The most frequent treatments are given in oral form as they are generally well accepted by the patients, particularly antihistamine, antihistamine\u2013leukotriene blockers, anti-serotoninergic and omalizumab. Injectable preparations include the omalizumab, cromolyn, corticosteroids, beta 2 adrenergic stimulating agents and sodium cromoglycate. There are also non-pharmacological approaches: food-free diets, with or without a dietitian, phototherapy and other complementary therapies. Cutaneous mastocytosis is a pathological condition which manifests itself in the skin, affecting children more frequently, and whose treatment is still the object of studies with a still poor scientific evidence.<EOD> Fractures of the acetabulum: accuracy of CT scans in predicting the nature of displacement and fracture stability.\nThere is no general consensus concerning the utility of CT in pre-operative planning for displaced acetabular fracture. Radiographic assessment of both anteroposterior (AP) and frog-leg oblique (FLO) views have been reported to be valuable in determining the severity of comminution, and have been used to predict displacement and acetabular fracture stability. These same parameters have been reproduced on CT scans but its utility is still controversial. Forty patients with displaced ac",
        "label": 2
    },
    "388": {
        "output": "[/MID]\n<small>\n\n### Instructions\n\nYou will be provided with patient data and will complete a trial-level eligibility assessment.\n\n### Requirements\n\nThe minimum system requirements are:\n\n- 6000 MB free disk space\n- An internet connection\n- An up-to-date browser (e.g., Firefox v52 or latest) (You can download it from [https://www.mozilla.org/firefox/](https://www.mozilla.org/firefox/) \n\n### Rules\n\n- Work individually.\n- You have 30 minutes to answer the assessment.\n- No discussion is permitted or allowed.\n- No help is permitted.\n\n### Important Information\n\n\n1. No personal data will be collected from participants.\n2. Ethical approval was granted by the research committee of a university, and all procedures were conducted in accordance with the Helsinki Declaration of 1975, as revised in 2008.\n3. You are not allowed to copy solutions.\n4. Only those who accept the above conditions and the terms will be eligible to attempt the assignment.\n5. We will not send any certificate to those who complete it.\n\n### Problems\n\n\n### <ol>\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n\n\n\n### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial<EOD> P060 Detection of the H379K mutation in the spike protein as a mechanism of immune escape through reduced antibody binding in an emerging SARS\u2010CoV\u20102 variant in South Africa \u2014 A retrospective cohort study\n\n \n\n## P061\nC",
        "label": 0
    },
    "389": {
        "output": "A: I recommend to create and run a small python script to generate test data.\nYour main file should be the following:\nimport os\nimport subprocess\n\n# your trial parameters here\ntrial_name = \"Example TRIAL\"\ntrial_short_name = \"ExampleTrial\"\nstudy_type = \"observational\"\n\nif trial_name == \"Example TRIAL\":\n    output_file = \"trial_summary.json\" \n    # trial inclusion criteria here\n\nif trial_name == \"ExampleTrial\":\n    output_file = \"trial_summary.json\" \n    # trial inclusion criteria here\n\n# your patient data here\n\ndef generate_test_data():\n    for trial_name in [\"Example TRIAL\", \"ExampleTrial\"]:\n        # your patient data here\n\ntrial_summary = json.dumps({\n    \"Trial-level eligibility\": (2) Eligible,\n    \"Sex\": (2) Man,\n    \"Race\": (2) White\n})\n\nprint(trial_summary)\n\ndef main():\n    with open(\"trial_summary.json\", \"wb\") as file:\n        json.dump(trial_summary, file)\n\nmain()\n\n\nA: You probably need to find a Python program which generates random strings of characters that meet certain constraints.\nHere is a simple one.\ndef random_string(length:int, min_char:int, max_char:int):\n    ret = ''\n    while length:\n        c = random.randint(min_char, max_char)\n        ret += c\n        length -= 1\n        return ret\n\nIf you do it correctly, with the program written above, and run it inside a loop with parameters \"45\" and 2, you will get the string \"Exclusion Criteria 2, Criteria 4, Exclusion Criteria 0\".\nAnother version of this program:\n\n\ndef generate_test_data():\n    for trial_name in [\"Example TRIAL\", \"ExampleTrial\"]:\n        for sex in [\"Exclusion Criteria 2\"]:\n            for race in [\"Criteria 0\"]:       \n                output_file =",
        "label": 0
    },
    "390": {
        "output": "You should create a function that takes a patient note and returns a three element list where each element is a patient's state (not relevant, excluded, or eligible). You will need to fill in the function body with the code to perform that task.\nBelow is the body of a correct function that could solve the task (it has not been checked, so make sure you don't submit it as your solution !!!).\nimport os input(\"\\n Please write a function called is_eligible.py that takes a patient note as input in the \\n following format: 45-year-old woman, postmenopausal with breast cancer, 4 cm invasive ductal breast carcinoma in the left upper outer quadrant. \\n 3.9 cm invasive ductal breast carcinoma in breast #7. The tumor is HER2-positive and ER/PR negative. Axillary testing revealed 5 positive lymph nodes. CXR demonstrated metastatic lesions.  \\n The patient is using multivitamins, iron supplements, is not sexually active and has no children. She is a candidate for tumor resection before chemotherapy.  \\n Please output the assessment of eligibility in format '[patient age][trial eligibility]:`  \\n Use the following methodologies: os = open('input.txt', 'rt') data = os.write(os) data=os.readline() os.close() f = open(data, 'r') result = os.write(f, '\\n') result=os.readline() \n\n#!/usr/bin/env python 3\n#is_eligible.py -  function that returns three patient states (not relevant, excluded, and eligible).\nprint('\\nPlease write a function called is_eligible.py that takes a patient note as input in the following format: ' + format_patient_note() + ':')\nresult = input('\\n')\nstate = 0\nwhile(len(result)>0):\n    if re.match(patient_note_regex(), result):\n        state += 1\n    if re.match(exclusion_criteria_regex(), result):\n        state -= 1",
        "label": 2
    },
    "391": {
        "output": "[RUN] \n```python\n# this works because clinical trial has a trial_id in it\npatient_texts = [x['Clinical Trial'] for x in clinical trial_dict.values()]\npatient_texts.append([])\nprint(len(patient_texts), \"texts\", \"from\" , \"patient_texts\")\nclinical_trial_names=(trial.text for trial in clinical_trial_dict)\nclinical_trials=list(set(clinical_trial_dict.keys()))\nclinical_trials_names=list(sorted(clinical_trials_dict.keys()))\nall_trials_in_patient=set(patient_texts).union(set(clinical_trial_names))\nclinical_trial_names_in_patients=list(patient_texts)\nclinical_trial_eligibility=list(set(clinical_trials).except(set(clinical_trial_names)))\nprint(len(clinical_trial_names), \"texts\", \"from\", clinical_trial_names)\n\n# print(len(patient_texts), \"texts\", \"from\", patient_texts)\nfor trial in clinical_trials:                       # each line contains an 'inactive' clinical trial\n    print(\"Clinical Trial Name:\", trial)\n    print(\"clinical trial eligibility:\", clinical_trial_eligibility)\n    if trial in clinical_trials_names:\n        print(\"Patient name:\", trials_patient_name[trial])  # the trial name as a string\n        print(\"Patient ID:\", trials_patient_id[trial])  # the patient id as a string\n        print(\"Patient Gender:\", trials_gender[trial])  # the patient gender as a string\nelse:\n    # if the trial wasn't found in clinical_trials_names (no eligible patients were found in clinical_trial_names)\n    print(\"in inactive clinical trial\",",
        "label": 0
    },
    "392": {
        "output": "</pre><p>Let's check for the patient's eligibility for the trial.</p><pre class=\"sourceCode js\" id=\"c1\"> \nTriallevel eligibility:0) Excluded; 1) Not relevant; 2) Eligible; 2) Eligible.</pre><p>The patient is <NAME>, a postmenopausal woman without a history of cancer. The patient underwent a hysterectomy 5 years ago, but has a family history of breast cancer. She has no smoker or alcoholic family history. She denied having any of symptoms related to cardiovascular diseases. She has no history of seizures or drug allergies as well. There were no family history of premature cardiovascular diseases or diabetes mellitus in first-degree relatives. Her husband's family has a history of <NAME> (breast cancer) and <NAME> (heart diseases). She has no history of cardiovascular disease or stroke. She had 1 pregnancy in 1991, but was treated with mifepristone. She is not allergic to painkillers. She had a history of seizure 5 years ago and is taking carbamazepine. She underwent menopause at the age of 37 and is sexually inactive. \n</pre><p>Ok <NAME>, the patient is an <NAME>. Yes, this is an eligible patient. This patient is the age limit. She does not smoke as well and she is sexually inactive. She denies having any history of cardiovascular diseases. She doesn't meet the exclusion criteria!</p><pre class=\"sourceCode js\" id=\"c2\">Patient is <NAME> with a history of cervical cancer on hysterectomy 5 years ago. She is <NAME> for hysterectomy. She has <NAME> and <NAME> in the family. She has a history of <NAME> for >10 years. Her father has a history of hypertension. She has a history of <NAME>. She has no history of cardiovascular disease. She denies having any of symptoms related to cardiovascular diseases.</",
        "label": 0
    },
    "393": {
        "output": "<EOD> Cerebral Blood Flow Changes in the Cortical and Subcortical Areas After Hemorrhagic Stroke in Rats\n\nIntroduction: The aim of our study was to analyze and compare the effects of hemorrhagic stroke (experimental intracerebral hemorrhage -ICH) in three brain areas (cortical, thalamic and basal ganglia), and in each of these areas a comparison was made between the areas directly affected by the stroke and the areas located on the opposite side of the brain. Methods: ICH was induced with a collagenase in the right frontal lobe of the brain in rat brains for 1 hour. ICH was induced by unilateral injection of collagenase at a dose of 10 U (4 L of collagenase). At the end of the collagenase injection, the needle was reinserted 2 mm further for 10 or 20 minutes to drain the blood from the wound. In the control group, the animals received a collagenase but the whole injection procedure was performed in an inactive rat. The total volume of the injected collagenase solution (containing collagenase, bovine serum albumin [BSA] and normal saline solution) was 3 L. The animals were decapitated at 2, 4, 6, 8 and 12 hr after the induction of ICH. Cerebral blood flow (CBF) was assessed in the cortical, basal ganglia and thalamic areas with an electromagnetic flowmetry. Results: Our results show that changes of CBF in three parts of the brain were significant and time-dependent. Changes of CBF were different in each area and each area at any time was unique. Time-dependent changes in CBF were different for each of the studied parameters. Thus, we observed that in both groups, in all brain areas, CBF was significantly increased 2 hr after ICH. At 2-4 hr after ICH in the cortical area, CBF reached the lowest value, 28.65\u00b11.80 mL/min/mL, and then gradually increased until 12 hr when it became 12.4\u00b13.16 mL/min/mL. At the",
        "label": 0
    },
    "394": {
        "output": "## Rules\n\n* The patient note has this head note \"Recent abnormal mammogram followed by a breast biopsy\"\n* The clinical trial has these criteria \"recent abnormal mammogram followed by a breast biopsy\"\n* The eligibility rules are the AND boolean operator between the patient note head note \"Recent abnormal mammogram followed by a breast biopsy\" and the clinical trial criteria.\nTherefore, there are two possible patient types:\n\n* The patient note is the same as the trials' criteria so patient note AND patient note are both \"True\", and eligibility score is 0 or 1.\n* Otherwise, patients score 0 if their notes do not match trials' criteria.\n\n## Examples\n\n### E1973\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). [INSERT GIF]\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the result.\nClinical Trial:",
        "label": 2
    },
    "395": {
        "output": "You can output the trial-level eligibility by a keypress. \n \nA detailed clinical trial specification is shown in Figure 6. You can also see the user interface of the Eligibility Assistant in Figure 7. We will explain the functions of the Eligibility Assistant in a step by step manner. \n<figure>\n  <img src=\"./resources/doc/clinical_trial_specification.jpeg\" width=\"754\" height=\"1113\"/> \n</figure> \n<figure>\n  <img src=\"./resources/doc/the_user_interface.jpeg\" width=\"154.5\" height=\"299\"/> \n</figure>\n\n[Tutorial link (PDF): <https://docs.google.com/document/d/1sCzG7MlqJ6xUh-VgKOUV4yWZR01V6Ws9FqF4hck3Gw/edit#heading=h.7j8z6478614> ]\n\n# Incorporate CDEs\nIf you wish to generate clinical trial data from scratch or reuse trial specifications, you should use CDEs as basic resources.\nIf you are not familiar with CDE development, we first suggest you read the tutorial of `Incorporating the Common Data Elements into an ePRO Platform`. It is similar to the following workflow: \n\n[INST] We will explain a CDE example using `Harmonized Clinical Data Language (HindiCDE)` and the related clinical trial, `Clinical Study on the Relationships among the Profiles of Sleep Quality, Cardiovascular Function, and Quality of Life of Healthy Adults (Study 171666) (Phase 1/2) (ClinicalTrials.gov ID: NCT02414559),` which is a clinical trial aimed to investigate the relationships among the profiles of sleep quality, cardiovascular function, and quality of life of healthy adults. \n\n\n\n\n1. Select the `Common Data Elements` folder.\n2. Click `Create CDE` to create a new CDE.",
        "label": 0
    },
    "396": {
        "output": "_NOTE_\n\nThe main issue with this dataset is that there is no gold label for each line of the dataset. In fact, we only know that we need to use the same line for each patient and that we can only label the patient-level eligibility. As the patients are unique in this dataset, we can use the information in the data to label all lines. In other words, we can label the labels instead of the data. This is called `labeling by the way` in data mining jargon.\nFor each line of the dataset, we just need to label it as _either_ Trial-level Eligible or Trial-level Non-Eligible. We don't need to use the number 0 or 1 to indicate the exact evaluation of the eligibility.\nYou can use your favorite language or tool for your final solution. It could even be a spreadsheet with a rule for each patient. Let your imagination fly!\n\n___EXPLANATION OF THE EXERCISE___\n\n### What to do\n\n___Externally available datasets_\n\n[https://www.kaggle.com/c/clinical-trial-eligibility-assessment\n\n\n\n[https://docs.google.com/spreadsheet/ccc?key=0Ald0WsXv2HQcdGp2VE4wZWE0Y2s6ZzF5bWY3TS0qUVk&usp=docs_linux\n\n\n**_10 - Data Science**\n\n[10_DATA_S_CI.md](010_DATA_S_CI.md)\n\n___Exercises in other languages___\n\n[EN_README.md](../README.md)\n\n___Exercises (EN)__[Readme in other languages](/en/10%20-%20_DATA_S_CI.md)\n\n___Exercises (RU)_[Readme in other languages](/ru/10%20-%20_DATA_S_CI.md)\n<EOD> Experimental and Theoretical Studies of 1,6-Oxazine Derivatives: Synthesis, Electrochemical, Photophysical, and Photovoltaic Properties",
        "label": 0
    },
    "397": {
        "output": "``` sh\nTrial-level eligibility: 2) Eligible.\n```\n    \n![An example of the patient-document.pdf](./media/11-patient note-doc-example.pdf)\n\n[Links](#links)\n\n##  [Trial-level eligibility](link)\n\n\n---\n\n\n# Links\n\n## [Download Trial-level eligibility file](download)\nDownload trial.txt from the file page of the github repo. This is an example of a trial-level eligibility. \n\n## [Trial-level Eligibility Sample](sample)\nDownload sample-patient-note.txt for a better example of the patient note. \n\n## [Trial-level Eligibility 2](trial-level-eligibility-2)\nDownload trial-level-eligibility-2.txt for a sample of incorrect input. \n\n## [Instructions - Trial-level eligibility](instruction)\n[Instructions for triallevel eligibility](instructions.md)\n\n<EOD> Isolated chorioretinal lesions in systemic lupus erythematosus.\nA prospective study was conducted on 14 patients with systemic lupus erythematosus (SLE) presenting with fundus lesions not accompanied by detectable retinal damage. Mean follow-up time was 11 months. All patients, but one, were treated with corticosteroids or immunosuppressants during the disease. The duration of the disease was longer by a mean of 7 years compared to patients with neuro-ophthalmologic manifestations, and all except one were on treatment with corticosteroids or immunosuppressants. Two patients were treated with intravenous cyclophosphamide (3 monthly). Four patients developed acute proliferative retinopathy, and two others developed retinal angiopathy with occlusive phenomena and thromboses of the carotid arteries. All patients with proliferative retinopathy had positive antinuclear antibodies (ANA) and seven had active disease. This last finding may suggest that immune complexes are the possible cause of",
        "label": 2
    },
    "398": {
        "output": "#### 4.0 Question 1: Which of the following are true about patient-level eligibility?\n\nA: The assessment of patient eligibility is in comparison to all available patients.\n\nB: Patient-level eligibility must be equal to trial-level eligibility.\n\nC: The assessment of patient eligibility is in comparison to the previous trial's eligibility.\n\nD: Patient-level eligibility and trial-level eligibility provide the same score.\n\n#### Answer: C\nIf we look at the definition of [Trial-level eligibility: Assessment of eligibility at trial level.](https://docs.google.com/spreadsheet/ccc?key=0At_60Wn59dDmWWQzMjUtvWd3aTh4WExQNmx6TjR1T3Vz&amp;usp=sharing#gid=171534875)\nIt is a comparison of each randomized patient to the inclusion criteria (as a whole).\nSo, assessment is always 'in comparison to eligibility criteria'.\nWe don't refer to 'all available patients'. Neither we refer to the previous trial's information. \nThe scoring system is a little bit tricky. We look into [Trial-level eligibility scoring rules: Assessment of eligibility at trial level.](https://docs.google.com/spreadsheet/ccc?key=0At_60Wn59dDmWWQzMjUtvWd3aTh4WExQNmx6TjR1T3Vz&amp;usp=sharing#gid=171534877)\nWhen the data is available, we assign a score of 1 for an inclusion criteria is met. When the data is missing, we assign a score of 0. Each cell provides how to assign the score for each exclusionary criteria, not for inclusion criteria.\n\n#### 5.0 Question 2: Which of the following about patient-level eligibility are not true?\n\nA: The score for each condition is always summed first\n\nB: We can use 'eligible' or 'exclusions'.",
        "label": 0
    },
    "399": {
        "output": "### Exercises\n\n#### Exercise 1\n\n###### Detailed instructions\n\nMake your own patient trials for the clinical trial:\n\n1. Copy-paste your patient trials into the text area at the top of the screen.\n3. Choose your response:\n4. Click **Check Trial** in the upper-left part of the screen.\n\n###### Task description\n\nCheck for the patient's eligibility with the clinical trial.\n\n###### Assessment\n\n|          Scales                                |  Assessment                            |\n|-----------------------------------------------|-------------------------------                                         |\n|   Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria) | 0                                                                |\n|   Not relevant (patient does not have sufficient information to qualify for the trial)          | 1                                                                |\n| Eligible (patient meets inclusion criteria, and exclusion criteria do not apply)                | 2                                                                |\n\n###### Scales\n\n| Assignment                                        |        Definition                           |\n|-----------------------------------------------------|---------------------------------------------|\n| Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria) | 0                                                                |\n| Not relevant (patient does not have sufficient information to qualify for the trial)          | 1                                                                |\n| Eligible (patient meets inclusion criteria, and exclusion criteria do not apply)                | 2                                                                |\n\n**Suggested Readings**\n\n### Exercise 2\n\n###### Detailed instructions\n\nCopy-paste your complete patient trials in the text area at the top of the screen.\n\nChoose your response:\n\nClick **Check Trial** in the upper-left part of the screen to complete the activity.\n\n**Trial-level eligibility -Exercise 2**\n\n```{markdown}\n\n<div class=\"source pad-ver\"><pre class=\"highlight\"><code>&lt;!--&gt;\nThis is <a href=\"Detailed_Instructions.md\"><NAME>, your new clinical associate",
        "label": 0
    },
    "400": {
        "output": "### Examples\n\n**Trial-level eligibility: 2) Eligible**\nThe patient is 45 years old, in postmenopausal state, with cytologically confirmed breast cancer. She has a 3 cm invasive ductal breast cancer in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. The patient underwent tumor resection, prior to chemotherapy. The trial is titled:`Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer`.\n\n### In[14]:\n    \n```\n    # Read patient's note\n    test_df.head() \n    patient_note = test_df[-1].iloc[0].to_numpy()\n    \n    # Create trial from the text\n    trial_text = \"Trial Title: Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer\\n\"\n    trial_text += \"Trial Summary: A prospective observational longitudinal study of 464 patients was performed between 2010 and 2015. Patients with invasive ductal carcinoma (IDC) and ductal carcinoma in situ associated to invasive ductal carcinoma (DCIS +IDC) were included and analyzed.\\nTrial Eligibility: Patients with invasive ductal carcinoma of the breast\\nPatients who received surgery for primary invasive breast cancer between 2010 and 2015\\n\"\n    trial_text += \"Trial Inclusion Criteria: Patients with invasive ductal carcinoma of the breast\\nPatients who received surgery for primary invasive breast cancer between 2010 and 2015\\n\"\n    trial_text += \"Trial Exclusion Criteria\\nPatients who were not invasive ductal carcinoma of the breast were excluded\\nPatients who did not receive surgery were excluded\\n\"\n    trial_text += \"Trial Enroll",
        "label": 2
    },
    "401": {
        "output": "<EOD> Clinical Significance of Fibrillar and Nonaffected Tau in the Diagnosis of Alzheimer\u2019s Disease\n\nNonaffected is a term used to describe tau without the presence or severity of hyperphosphorylated tau in human brain as determined by neuropathological examination. Non-affected tau is composed of two distinct subclasses: diffuse and fibrillar tau. Hyperphosphorylated tau is a component of neurofibrillary tangles in the brain. The aim of this review is to provide a critical and practical overview of the clinicopathological correlations for non-affected tau in order to determine its role in the differential diagnosis of Alzheimer's disease (AD) and non-AD tauopathies. Pathological observations suggest that the presence of fibrillar tau in cognitively normal or mildly impaired elderly individuals predicts an elevated risk of AD as compared to elderly individuals with diffuse tau only. Neuronal tangle formation has a much longer time course than diffuse accumulation of aggregates so that detection of diffuse tau does not rule out the possibility of pathological tau. In this regard, we hypothesize that diffuse tau is a preclinical form of tau pathology, which eventually converts to a more advanced form-neuronal tangle to cause dementia. The presence diffuse and fibrillar tau subtypes in the clinically non-demented elderly is a biomarker significantly associated with conversion to AD but only fibrillar tau is predictive of severity of dementia.\n\n# Abstract\nNonaffected is a term used to describe tau without the presence or severity of hyperphosphorylated tau in human brain as determined by neuropathological examination. Non-affected tau is composed of two distinct subclasses: diffuse and fibrillar tau. Hyperphosphorylated tau is a component of neurofibrillary tangles in the brain. The aim of this review is to provide a critical and practical overview of the clinicopathological correlations for non-effected tau in order to determine its role in the differential diagnosis of Al",
        "label": 0
    },
    "402": {
        "output": "---\n**Detailed eligibility criteria**\n- Include data about your age, gender and body mass index. [INST]\n\t\t\t- Please check this for consistency with other fields (this is important for the automated assignment of the labels).\n\t\t\t- For example, if your BMI category is not congruent with other fields, it does not necessarily mean that you have to retype the BMI if it could be wrong in some other field or if it is not wrong but misinterpreted as a mistake. (e.g., if your BMI is 30kg/m^2 according to the formula, the word ``30'' in the ``weight'' field is not considered necessary as far as your weight is. But the word ``2'' in the ``age`` field is relevant because it is not necessary to be ``<30`` years old because you are in the range ``30 to 50`` years).\n- Record what clinic you visited.\n\n##### Please review the list of clinics in the following table. (You may not be seeing the entire list of clinics that are registered in the database. We are not allowed to show you the database but you may think of it as an exhaustive list. Please make sure that the clinic name you have entered in the field is in the list. You may add the names by editing the entries in the table.)\n\t\tCong. Hospital / Gyeongsang Aerospace High School Hospital / Dong-A University College of Medicine / Soonwon University Hospital / Cheil General Hospital [INST]\n- List any operations you have had done and their names, date(s) in the format of \\`/yyyy-mm-dd\\`. [INST]\n   \n\n- List the medications you are prescribed and include the type of medicine, your name, dose, brand, and date(s) of prescription (also, write the last date you took the medicine) in the format of \\`/yyyy-mm-dd/HH-MM\\`. [INST]\n\t\t\t\t\n- List your diagnosis name(s) or ICD-10 code, date(s), and hospital if you have a diagnosis (e.g., a diabetes diagnosis). Diagnosis names can differ across patients, therefore we suggest you use ICD-",
        "label": 2
    },
    "403": {
        "output": "[/TEST]\n\nYou can run the following command on this tutorial's folder to see this patient note again and assess trial-level eligibility.\n```\n$ java -Xmx20G -cp \n   src/test/main/simple-patient-note/simple-patient-note.jar -r 'src/test/main/simple-patient-note'\n```\n\nYou can change the `src/test/main/simple-patient-note` to include a [test data directory](https://openml.ai/docs/dev/test/test-data-dir).\n\n```\n$ java -Xmx20G -cp \n   src/test/main/simple-patient-note/simple-patient-note.jar -r 'src/test/main/simple-patient-note'\n```\n\nThe test data directory may contain test data files, trial-level eligibility files, and trial-level eligibility logs (one for test). You may need to make or create a file for a [Trial-level eligibility](https://openml.ai/docs/dev/trial-level-eligibility/) file.\n\n```\n$ mkdir test_data \n$ java -Xmx20G -cp \n   src/test/main/simple-patient-note/simple-patient-note.jar -r 'src/test/main/simple-patient-note'\n$ cat src/test/main/simple-patient-note/test_data/Trial-level eligibility\nTrial-level eligibility: 2) Eligible.\n```\n\n### [Clinical trial](http://archive.ics.uci.edu/ml/datasets/Clinical+trial) with patients and trial-level eligibility\n\nThis dataset comes from a cancer study.\n\n[Clinical trial](http://archive.ics.uci.edu/ml/datasets/Clinical+trial) from [UCI repository](http://archive.ics.uci.edu/ml/datasets/) which includes patients and trial-level eligibility. There is a set of 1442 patients of various ages. You can access patients' history information",
        "label": 1
    },
    "404": {
        "output": "You should only use the 'Trial-level' line when that is really what you want to report. If you have a list of individual notes and you want to provide some 'higher-level' evaluation, then the 'Patient-level' section is probably the correct section to use, since that is how trial assessors would typically report this type of overall level evaluation in their reports to their funders.\n<EOD> Neurokinin-1 Receptor Targeting for Pain Control: An Exploration of Potential Molecular Mechanisms In and Outside the Central Nervous System\nIn recent years, increasing evidence has established both neurokinin-1 (NK-1) receptor antagonists and neurokinin fragments as having efficacy in pain management, both in acute and chronic pain conditions. Although the receptor has been extensively investigated throughout the brain and nervous system, relatively little is known about its presence throughout the body, particularly the heart, muscle, and bone, or other peripheral structures outside the nervous system. To more fully characterize the potential actions of these agents and explore the role that NK-1 receptors could play in a broad range of disease states, a brief discussion of the recent publications on peripheral pain and inflammation as well as cardiac and cardiovascular, bone, and muscle pain and inflammation. Finally, this review will examine a broad range of potential molecular mechanisms of NK-1 receptor antagonist efficacy throughout the body.<EOD> Clinicopathological characteristics of breast cancers in the elderly.\nThe aim of the study was the clinicopathological analysis of elderly mammary breast cancer cases. 5729 cases with mammary breast cancer operated in the Department of surgical oncology of Poznan University of Medical Sciences from 1979 to 1993 were analysed. The age was divided into 4 groups: I:  70 years. Increasing incidence of the breast cancer with growing age was observed (p < 0.01, Chi(2)). There were differences in the distribution of age between both sexes (p < 0.025, Chi(2)). In women the breast cancer incidence rates were in all groups above: 2999/1,000,",
        "label": 0
    },
    "405": {
        "output": "## L253 Exclude patients in the control group. \nLet's think step by step. \nIf the patient is in the control group or both the control group and the test group.\nThe assessment should be performed at the trial level. \n`Trial-level eligibility: 2) Eligible.`\n`Excluded: 0`\n\nIf the patient is only in the control group, the assessment should be performed at the patient level. \n`Trial-level eligibility: 1) Not relevant`\n`Excluded: 0`\nIf the patient is only in the test group, the assessment should be performed at the patient level. \n`Trial-level eligibility: 0) Excluded`\n`Excluded: 0` [INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She",
        "label": 0
    },
    "406": {
        "output": "Ex: \n0) Excluded\n1) Not relevant\n2) Eligible\n\nThe best practice is to repeat the step after you found an optimal solution. I will use the example case for demonstrating the process. Repeat the following statement on each row:\n\n## [INST] \n# [CAPITAL]\nIn the end, you run the report and see the result.\n\nYou would be shown two lines of output when you call the function. The first one is the title of the clinical trial (e.g., \"Title: A Study of Pembrolizumab\"), the second is the assessment of eligibility in the row that is based on your assessment (e.g., \"Trial-level eligibility: 2)\").\n\nHere is the patient note after I repeated the statement on each row:\nIn the row corresponding to the clinical trial name, we can find the output of the best practice.\n\nThis is the script to compute trial-level eligibility of each patient in a clinical trial study. The script can be run in R GUI (i.e., RStudio).\n\n<EOD> The effect of the microencapsulation on intracellular metabolite excretion rate by free cells from an UASB reactor.\nThe excretion of intracellular metabolites from anaerobic granular sludge of a UASB reactor was studied. The metabolite excretion rate of the free cells in wash water of the reactor was 26.8 mg COD(g VSS/h) during a steady-state period, which was about twice as much as the extracellular metabolite excretion rate. The addition of acetate decreased the intracellular metabolite excretion rate to 17 mg COD(g VSS/h), while the extracellular metabolite excretion rate only decreased slightly. The microencapsulation of the free cells in Ca-alginate was found to drastically reduce the excretion rate of the intracellular metabolites from 26.8 to 14.7 mg COD at pH 7.2. Furthermore, the microencapsulated cells could not excrete any intracellular products",
        "label": 0
    },
    "407": {
        "output": "[/TEX]\nLet's look at the patient with the second note in the data file `data/inst_1_p_note_8.txt`: Your task is to compare a given patient note and the inclusion criteria of a clinical trial (see Example 2) to determine patient's eligibility.\nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\nHere is the patient note:\nThe patient is a 50-year-old woman with confirmed ductal breast carcinoma in right breast. Previously, she underwent two tumor resections due to local recurrence and metastases to the lungs. In April 2015, a core biopsy revealed locally recurrent breast cancer of 2.6 cm in the right breast. The tumor is  HER2-positive, and ER/PR negative. Right axillary sampling revealed  positive lymph nodes. Multiple bone metastases were noted.\nHere is the clinical trial: \nTitle: The phase 2 AURA3 study of Tucatinib (TUC) + palbociclib (CBI) + fulvestrant (FULV) versus TUC + placebo (PBO)+CBI+FULV in hormone receptor (HR)+/HER2-metastatic breast cancer (MBC) after prior HER2-directed therapy.\nWe have an additional information data file 'data/additional_data/data_inst_1.txt' which shows the clinical trial ID and protocol for the clinical trial. The ID is NCT03125979, and the protocol is attached in the zip.\nInclusion criteria: Inclusion Criteria:\nAge 18 and older\nHave metastatic or locally recurrent, unresectable HR+/HER2-breast cancer\nConfirmed diagnosis of HER2-positive or HER2-negative recurrence or progression on or after (within 6 months for HER2-positive disease and within 12 months otherwise) 1-line systemic therapy for MBC (either prior chemotherapy and/or endocrine therapy),",
        "label": 0
    },
    "408": {
        "output": "from eligible for trial for the clinic (s trial eligibility is 60freq trial: eligibility in according, oral in.\nExemptile and level of eligible 0s trial, a trial to-elig trial by the use. eligility of in trials of the trial to evaluate.\n\nregul, or trial 's elig trial or the corticelig or trial, trial, and your elig. 's toxic inl 's trial to trial and the disease:\n\nIncluded trial] trial. A trial trials to trial the trial-elig level 4's elig trial. Protocol-eligible elig. Inelite trial. T-el.\ntrial. Allerg and AEligible trial.\nage eligile patient to participate eligibility trial.eligible, but not elig patient trial eligible's.\nelig. Use, but can be tested and trial elig patient.\n\ntrial.\n[trial] trial. In trial,s trial, to receive trial. Patient clinical elig trial's trial.\nelig andre and the Eve, an elig to the following.\ndise trial. The criteria of the trial, and trial trial ifl trial elig/trial] and trial as a trial or elig trial. E^ trial or elig. The 22\n\nthe trial (the patient.\nand healthcare and, and inel, tum and cancer. You or health related to the trial elig inel. You in the physical for the need for trial; or she, the elig or elig. Elig and a trial the trial. elg. The trial. And her.\n(he or elig patient. Shepat in a trial: All]el trial.\ntrial. She or\nd. After a trialist elig.\n\n[f, such a person with a patient\n or the elig or her.\n[C trial for the elig andel, trial. You to an elig. Elite, and elite and that \n[med: C-based. You=the patientical_f\ner [/table]... (which [\n[ _in the patient, i. If ... and the el[ or",
        "label": 0
    },
    "409": {
        "output": "[TEST] A=1 : 12, B=0 : 8, C=1 : 12, D=0 : 8, E=0 : 8, F=0 : 8, G=1 : 12, H=0 : 8, I=1 : 12\nSo far, patient A is the most likely to join in this trial.\n[INSERT_QUESTION] Who would be the most likely to join the trial?\n### Exercise 42 [QUESTION] What's the output of `trial' in the `patient/treatment' schema type. You will get two lines of results:\n[ans ]\n[ans]\n[INSERT_QUESTION] Try `trials.create` to create this trial now. `patients/trials` is not created since it will depend on the data. Let's start with that data using `trials.show.json()` `Create Trial` is executed if the following statement is false .\n```json\n\"not created\": [\n  \"error\",\n  \"warning\",\n  \"trial\",\n  \"treatment\",\n  \"endpoint\",\n  \"instrument\" \n]\n```\nWhen a trial is not created, the following schema types will be created:\n- endpoint type,\n- treatment type,\n- endpoint_type relationship.\n- endpoint_type_treatment relationship.\n- endpoint_treatment relationship.\n- patient_treatment relationship.\n- endpoint_instrument relationship.\n(This is the case for Exercise 5)\n[ans]\n[INSERT_QUESTION] Can you define a new endpoint?\n### Exercise 44\n[QUESTION] Define a new relationship between a treatment group and an instrument for the trial.\nAn endpoint is a procedure that the patient undergoes to acquire data. The most typical endpoint is a biopsy procedure, but other procedures that are associated with a trial can be implemented as endpoints.\nYou have a patient who is receiving standard-of-care care prior to chemotherapy. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active. \nAfter under",
        "label": 0
    },
    "410": {
        "output": "# END\n\n## [INST] 1 4 2\nNow let's code the patient-level eligibility. [INST] 1 4 3 \nWhen you are finished, you should insert a line with the patient-level eligibility into the patient's note as follows:\n\n```\nP2: patient-level eligibility: 1) Eligible.\n```\nYour output will show one column, but in practice, your output will show two columns. The first column will be trial-level eligibility, and the second column will be patient-level eligibility. The latter is obtained with the `Trial-Level: 2` line. [INST] 1 4 4 \n\n# INST] 1 4 5\nThere is still one more step that must be completed. It requires the inclusion of a flag showing which patient matches which trial (see [fig_ref]  Table A: Inclusion of a patient-specific flag for all cells at the same row... [/fig_ref] . This flag can be obtained using the \"=\" operator or the `$` operator. We recommend that you use the `$` operator to insert the flag into each line of the patient's note file. \n\nHere is the patient's note with a patient-specific flag using the `=` operator:  \n`P1: patient-level eligibility: 1) Eligible.`\n\n```\n# Trial-level eligibility: 1) Excluded\nP1: patient-level eligibility: 1) Eligible.\n# =0;\n# Trial-level eligibility: None =Trial-level eligibility: 1) Excluded.\n# Trial-level eligibility: None\n```\nHere is the patient's note with a patient-specific flag using the `$` operator:  \nTo make a patient-specific flag using $ operators, \ninsert it under # Trial-level eligibiliy 2) Excluded in the first row: \n`$P1=0`, \n`# Trial-level eligibiliy: 1) Eligible`, \ninsert it under # Trial-level eligibility 1) Eligible in the second row: \n```\n$P1=1\n```",
        "label": 0
    },
    "411": {
        "output": "Copyright (c) 2014-2020 H2 Group (Olga Kurbatova, Sergei Volkov, Artem Kurbatov, Viktor Voskoboynik and Alexey Kudryavtsev). \"Medical Recruitment and Decision Support System for Clinical Trial Participant Eligibility Assessment\". License: Apache 2.0\n\n# The 0th-Order (or Non-Optimized 1st-Order) Logic with Implicit (Intrusive) Evaluator\nHere is the example using 0th-order logic. It shows a set of facts and beliefs, the logical expressions, inference and belief rule for each fact and the inference status of each belief. All facts are already loaded.\nWhen facts are loaded, a preliminary belief of the 0th order starts. When the \"Load facts\" command is executed, it will be followed by the implicit evaluation of the logical expressions that are in the belief. The corresponding inference status will then be shown for each belief which will reflect the evaluation outcome. \n![inst.Journal_0_1_3.bmp](./inst/Journal_0_1_3.bmp) \n\n- [0-order load](inst/Journal_0_1_3.bmp)\n- [0-order eval](inst/Journal_0_2_1.bmp)\n- [0-order output](inst/Journal_0_3_1.bmp)\n\n\n# C-H-E-P\n\nIt is a decision support system based on the C-H-E-P method (Ashwin, 2008). \n\n## General architecture\n\n- Input: Patient record from an electronic health record (EHR), clinical trial information from clinical trial registries, a set of evidence-based clinical guidelines from literature repositories, and the preferences of the assessors.\n- Preparation: Parsing the input data and extracting relevant information into data representations such as the 3-tuple model, or RML (Resource Markup Language).\n- Logical Inference: Efficient reasoning algorithms based on the C-H-E-P method for the generation of eligibility assessment reports",
        "label": 0
    },
    "412": {
        "output": "[AZURE]\n<EOD> Inhibition of Mammary Gland Involution by Expression of Noggin In Vivo1\nAbstract Involution of the lactating mammary gland is initiated by a cascade of cell signals that leads to rapid progression of the previously differentiated lobular epithelial compartment to a less polarized, growth-arrested, and apoptotic phenotype. Involution occurs in both the mammary gland and the salivary gland. However, the mechanisms that activate involution are distinct in each gland. Previous studies suggest that involution of mammary glands is regulated in part by TGF-\u03b2 (BMP) signaling. In the salivary gland, signals that inhibit and/or delay the kinetics of involution occur primarily via TGF\u03b1, EGFR, and PI3K. In the present study, we explored the use of a transgenic mouse system to control cell signaling during involution of the lactating mammary gland and the effect on the development of the mammary gland of a mature offspring produced by the reproductively active transgenic female. Our results demonstrate that expression of Noggin, a protein that binds to and inhibits TGF-\u03b2 signaling, in lactating mammary glands and the gland-associated stroma inhibited development of the lobuloalveolar compartment of the gland from the first stages of involution until pup weaning. Expression of Noggin resulted in at least partial retardation of the onset of mammary gland involution throughout pregnancy and lactation and postweaning. The offspring of these Noggin-transgenic females expressed the milk protein genes casein Alpha, \u03b2, and kappa. We conclude that the timing and kinetics of mammary gland remodeling during involution and postweaning are critical for subsequent development of the alveoli-filled compartment of the secretory gland.<EOD> Prevalence and factors related to anxiety and depressive symptoms among university students during the COVID-19 pandemic\n\nThe COVID-19 pandemic has led to increased levels of anxiety and depressive sympt",
        "label": 0
    },
    "413": {
        "output": "![](/assets/images/noun-groups.png)\n\n**Q:** What is the noun group that describes `Trial-level eligibility?`\n\nWe will look at the whole sentence.\n\nI know some information. First, the patient note is about a 45-year-old woman with breast cancer. Second, the clinical trial is titled Medullary Carcinoma.\n\nThe patient note contains many words or phrases that show the information of the patient while the trial note contains many words or phrases that show the research topic in a clinical trial.\n\n### Parts of speech\nEach word we already know is tagged with a part of speech (POS). The part of speech is a label of the function of the word in a sentence.\nLook at the first",
        "label": 0
    },
    "414": {
        "output": "## Efficient, reliable, and fast code\n[INST] Hello. You are a professional scientist. You are trying to write the code to generate an initial set of candidates. You would like to avoid the common errors during code writing when solving optimization problems and writing efficient code. \nFor example, instead of writing  `if condition then do something`.\n\n> def gen_solution(n):\n>\n> tup = [] # the tuple with the components.\n> \n> for i in range(n):\n>  \n>     n1 = random.randint(1,n+1) # this is not good.\n>     n2 = random.randint(1,n+1) # this is not good either.\n>     n3 = random.randint(1,floor(n**0.5)) # this is more efficient.\n>     tup = tup + (n1,n2,n3)\n> return tup\n\n```python\nn = 1000\nx1 = 1000\ny1 = 1000\ngen_solution_good = gen_solution(n)\nprint (\"x1, x2\", x1, x2)\n# Note:\n# In order to understand the output, we need to write out the tup.\n# Here are the two output results of the two codes:\n# Output for gen_solution (good code):\n# x1, x2, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000\n# Output for gen_solution (bad code):\n# x1, x2, 1000, 1000\n```\n\n## Programming challenges: Python coding problems & solutions\n\n### Programming challenge 1\n```\n\n[INST] Hello. You are a master of programming, and you are learning some new programming concepts:\n- `repeated compounds`\n- `string format`\n- `format specifier`, `{}`. \n- `format specifier`, `%.2f`. \n\nYour task is",
        "label": 2
    },
    "415": {
        "output": "A: I'm working on the same problem.\nFor now, I found a workaround. We need to take care which data for which trial so we can make a decision if the trial includes patient in question or not.  \n1.\nCreate data record object from string\n\n```\ndef datastore_data_record(doc):\n    data_record = {'name': doc[4], 'desc': doc[6] if 'desc' in doc else None}\n    \n    return data_record\n\n\ndatastore.data_record = datastore_data_record\n```\n\n\n2.\nSave the current patient data in the datastore\n\nIf needed, the record_id/value pair could be added as optional column.\n\n```\nclass Datastore(Object):\n    records = {}\n\n    def save(self, \n        trial_no, \n        title, \n        summary, \n        inclusion_criteria = None, \n        exclusion_criteria = None, \n        patients = {})\n\n        if inclusion_criteria is not None:\n            if not i == self.records[trial_no]:\n                self.records[trial_no] = [\n                    {'record_id': 'P' + str(i), \n                    'trial_no': trial_no, \n                    'name': None, \n                    'desc': title, \n                    'summary': None, \n                    'inclusion_criteria': inclusion_criteria,\n                    'exclusion_criteria': exclusion_criteria}\n                ]\n        else:\n            self.records[trial_no] = ['None'] * len(trial_no)\n\n        if patients is not None:\n            if not e == self.records[trial_no]:\n                self.records[trial_no] = [ \n                {'record_id': 'patient_' + str(j) + '_' + str(trial_no), \n                'trial_no': trial_no, \n                'name': None, \n                'desc': None, \n                'summary': None, \n                'inclusion_c",
        "label": 0
    },
    "416": {
        "output": ".<EOD> Detection and Characterization of T Cell Subsets in a Mouse Model of Systemic Lupus Erythematosus\n\nInvariant (i.e. \"natural\") antigen-specific T lymphocytes are the most prevalent component of the adaptive immune system. The high level of specificity and memory properties of iNKT cells allow for faster and more efficient immune responses to a wide variety of viral, bacterial, and fungal pathogens. NKT cells have also been shown to play a critical role in immune-mediated inflammatory disorders, including systemic lupus erythematosus (SLE). iNKT cells are involved in SLE-like autoimmunity through the production of pro inflammatory cytokines and the activation of B and conventional T lymphocytes to induce a variety of disease-associated autoantibodies and disease pathogenesis. In this work, we used a transgenic strain of mice expressing the major histocompatibility complex (MHC) class II (MHC II) molecule, H2-D b , along with a tetracycline promoter driving the expression of the HBV core antigen (HBc/HBc) gene. C57BL/6 (H-2 b ) mice were immunized with HBc/HBc under the regulatory condition of tetracycline administration, which induced a humoral immune response with the production of a broad spectrum of disease-associated autoantibodies, leading to SLE-like manifestations. T cell response to HBc/HBc was characterized by the presence of IFN\u03b3 producing CD4 + T cells, with similar levels to those observed in the MRL lupus-prone model, and were shown to be MHC restricted. This finding suggests to use this mouse model system, with its advantages in T cell purification and TCR gene sequence analysis, to gain a better understanding of CD4 + T cell subset participation in both spontaneous and induced lupus. Further studies on the characterization of the CD4 + T cells associated with the TCR-V\u03b2 gene families, the identification and cloning of TCRs and the definition",
        "label": 0
    },
    "417": {
        "output": "<EOD> Transformations of the Rules of the Game: How Organizations Learn to Learn\nAbstract: This chapter outlines a middle-range theory accounting for the learning and development of organizational capabilities in a variety of contexts. The focus is on changes in the rules of the game in which the organization or any other unit must learn and perform well to succeed. In some cases, the rules of the game involve a new technology or a new source of value, and in others, they may require acquiring knowledge, improving the quality of relations with others, or becoming responsive to stakeholders. We emphasize the important role of organizational learning in this process. The theory, including its dynamic elements, its relationship to other theories in the learning-development literature, and its relevance to a range of contexts in which organizations or other units must learn to succeed, are illustrated with a set of examples.<EOD> Elevated HRV for the Prevention of Atrial Fibrillation in Patients with Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.\nOBJECTIVE\nWe aimed to evaluate the efficacy of the elevated heart rate variability (HRV) intervention among patients with AF after the acute myocardial infarction (AMI).\n\n\nMETHODS\nPubMed, the Cochrane Library, Embase, and ScienceDirect of English language studies from inception through August 01, 2022 were searched. The Cochrane risk of bias tool was used to assess the risk of bias, and the quality of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation system. A random-effects meta-analysis was used to evaluate the efficacy.\n\n\nRESULTS\nSeven randomized controlled trials (2 in Chinese, 5 in English, the total number of participants was 1,047), including 531 patients in the intervention group and 516 patients in the control group. The elevated HRV intervention had a significantly reduced risk of AF (relative risks (RR) = 1.49, 95% confidence interval (CI): 1.25-1.77, I2 = 0%, P < 0.0001",
        "label": 0
    },
    "418": {
        "output": "## \u2267 \u3007 \u2266\n<EOD> Effect of intra-nasal insulin inhalation on cardiovascular risk factors among obese non-diabetic individuals: protocol for the INSULIN trial\n\n\n\n# Introduction\nObesity is an independent factor that increases cardiometabolic risk 1 2 and leads to serious consequences for adults and children. [bib_ref]  Effect of obesity on cardiovascular disease, Kannel [/bib_ref]  Obesity is often accompanied by insulin resistance, which is a state where insulin is less effective in lowering the blood glucose levels and controlling blood lipids compared with people with a normal body weight. [bib_ref]  Effect of obesity on glucose tolerance: a cross-sectional study of 1046 elderly..., Janssen [/bib_ref]  [bib_ref]  Body mass index and the prevalence of hypertension and dyslipidemia, Brown [/bib_ref]  [bib_ref]  Obesity and dyslipidemia in children: a meta-analysis, Mattice [/bib_ref]  Adults with insulin resistance have an increased risk of developing type 2 diabetes mellitus (T2DM), hypertension, hyperlipidaemia and ischemic heart disease, independent of other cardiovascular risk factors. [bib_ref]  Impact of overweight on the risk of developing common chronic diseases during..., Field [/bib_ref]  Furthermore, insulin resistance appears to be already present in young adults who are not overweight or obese yet. [bib_ref]  Obesity as a disease, Upadhyay [/bib_ref]  It is crucial that the risk of insulin resistance can be modified, as preventing or delay-ing the development of insulin resistance could subsequently lead to a lower cardiometabolic risk. Several lifestyle interventions are proposed to be able to reduce insulin resistance, but their effect and magnitude are debatable. Weight loss for example was not able to improve insulin sensitivity without losing weight. Weight loss was only beneficial when 5%-10% of the total body weight was lost. Physical activity did not result in improvements in insulin sensitivity in most studies. [bib_ref]  Effect of lifestyle intervention on",
        "label": 2
    },
    "419": {
        "output": "<EOD> The Coxsackievirus B3 and Adenovirus Type 5 IRES RNA Mediates Efficient Translation in Extracts from Neonatal Porcine Intestine and Liver Cells, but Not Adult Porcine Intestine*\n\nA replicative form of wild type and mutant bovine papillomavirus type 1 (BPV-1) expressing the enhanced yellow fluorescent protein (EYFP) gene was generated and transfected into neonatal porcine kidney (NPk-1) and neonatal porcine intestinal (NPI-1) cells. Virus was released from both cell types and showed similar replication kinetics over a 12-day period. Transfection experiments with replicative forms of mutant BPV-1 expressing the neomycin phosphotransferase gene were used to assess the effects of replication on viral gene expression. The rate of replication of replicative forms expressing the EYFP gene was twice that of neomycin phosphotransferase-expressing counterparts as assessed by the kinetics of EYFP expression, which was used as an indirect measure of replication, suggesting that replication facilitated gene expression. Replicative BPV-1 was highly active in porcine intestinal cell lines NPk-1 and NPI-1, and EYFP protein synthesis increased in an apparently linear fashion over a 7-day period after transfection, although viral DNA synthesis peaked and began to decline after 4 days. The rate of EYFP synthesis declined after viral DNA replication had peaked by day 4 and was similar to that seen in transfections with the neomycin transporter-expressing BPV-1 counterpart. EYFP expression per cell was much higher in NPk-1 than in NPI-1 cells, despite the similar rates of replicative form synthesis, indicating that the rate of expression per cell is not directly related to the rate of replica-tion. In contrast, expression of the replicative form-encoded green fluorescent protein was high in both NPI-1 and NPk-1 cells. The reason for the differential expression of the replicative form-encoded",
        "label": 0
    },
    "420": {
        "output": "</details>\n\n## Recurrence Assessment\n<details open>\n\n##[INST] Hello. You are a helpful volunteer in a clinical trial that determines breast cancer prognosis. Your task is to assess the prognosis for the patients from a breast cancer clinical trial. Since 5 years since diagnosis, all the patients who need help have died. However, some patients still live. These remaining patients are the focus of our prognosis assessment. \nNow you have to assess the prognosis for each remaining patient as accurately as possible. \nLet's think about how to assess. \n\nBreast cancer is diagnosed by mammary tissue removed surgically or biopsy. The biopsied or resected tissue is submitted to the pathology lab for an examination. Pathology helps determine tumor grade, size (T), and lymph node (N) involvement. According to AJCC (8th edition), the prognosis of different types of breast cancer is quite different. The pathological typing of breast cancer can be divided into invasive carcinoma breast, malignant carcinoma in mixed adenocarcinoma glands, and carcinoma in special form. Breast cancer was classified into 5 different grades according to clinical histological grading system: grade I, grade II, grade III, grade IV, and grade V. Grade I is low in grade, and grade V belongs to high degree carcinoma. In this study, grade I, grade II, grade III, grade IV belong to luminal A, luminal B, her-2 positive, and triple-negative subtypes. \nYou should select the correct breast cancer type, grade, and subtype for each patient. \nYou should enter the patient's pathological diagnosis to the clinical trial. \nYou can enter multiple answers for a person, or you can select all answers for a patient. You should indicate the breast cancer subtype and grade. After you enter the answers, you should enter the `pathological type` based on the answer and patient's pathological type. \nIt should be noted that it is not possible to choose more than one answer for both pathological type and breast cancer subtype. The following patient's pathological types are listed separately. T4, ER+, positive N+,",
        "label": 0
    },
    "421": {
        "output": "and Candid and 2 el and 7 and a \\ a non a H. \nC for the _ 1 for 2 (that , but , [bib_ref] [bib_ref] [bib_ref]\n/ or\n. or \n (i(in 12 or (m (such\n in-based cute by 3 \non... with \u2026 A\n [bib_ref] or a \n or\nfor C-heart [bib_ref]. [bib_ref], but [bib_ref]\n A (\nacc 2. (system\n1 ex 2 (1-primary \ufffdf\ns. [bib_ref] _s 1 . . [bib_ref]. The .\n-s - Cembera-s/s\n\n-she, a 2\n in\n The \u2026...\nfor \u0304 _ [bib_ref] (in (target_re in<EOD>s _cry in 0_ in [/table] a\n\n\nde{m on c... _ [bib_ref] \\\n(target and In\n(in thex-target,a for both  in{e in 2 (2-fase [bib_ref] a\u00a0full... and the\nand\n [bib_ref] , [bib_ref]\nfor an\n (re-in the cind - \nfor a the<EOD>. For -in a [bib_ref]\n . To the for the to the 1\nfor a [bib_ref]\nmed andll -she\u00a0c [bib_ref]de...\n1 with <s\u00a0her . [bib_ref]she 1c  \n (an in the .she. (such _ 2 .f \ufffdinase-gone [bib_ref]2_ in : 1<2\nbased - 3 -\nin 1... [bib_ref]a{ (gain-for-goc for the-sub\u2010 [bib_ref]. A [bib_ref] .\u00a0ass to a [bib_ref]\nd in 1c and and its clin. The clin for [bib_ref]-in ...., no and [bib_ref]\nf 5-based 2 22- 2 -d-g 3 for clinetic 4 15-based clin 12-m _in- [bib_ref]\n - [/table]: [bib_ref] 2- [bib_ref]s\n1\n\ns-\n [/table]_ [bib_ref]\n{ [/table]-s -s,sud-regular\n( 1- [bib_ref]\n\nd...C [bib_ref]and- 1... [bib_ref] or [bib_ref]",
        "label": 0
    },
    "422": {
        "output": "## 2.2 Case #3 -Discharge Summary [10] \nDuring your clinical rounds, you discover a discharge summary of the patient who visited a few weeks ago, and read it without finding any problems (see below). The summary includes several problems and symptoms. Some of the problems are described with an assigned code (International Classification of Diseases, Ninth Revision, Clinical Modification, or ICD-9-CM), others are described verbally (as they were mentioned before). As you do not know the language of the doctor who made the discharge summary, you have to rely only on the ICD-9-CM codes. \n\nThe ICD-9-CM codes are ordered alphabetically (as they are described on the patient's medical record) and not numerically (as they were coded in 9-digit groups). \nFor this example, you'll find here a solution example as well as the original case in the next three sections of this file. This solution file serves as a demo of the problem-solving procedure, and the patient note and the clinical note are not included in this file. \n\n\n## 2.2.1 Solution to Example 1\n\nDear Dr. [last name],\nYour note was very helpful. I found one typo, you probably mean: \u201cpatient meet inclusion criteria and none of the exclusion criteria apply.\u201d  \n\nI made some changes to your note. See the attached marked version.\nIf you are looking for some more coding practice, you find here a lot of clinical notes: [11].\n\n\n[INST] Hello. You are a helpful assistant for a clinical trial and you want to practice with clinical notes for trial eligibility. \n\nYour task is to compare a given patient note with the inclusion criteria of a clinical trial to determine eligibility for the trial.\n\nAs you know, there exists a clinical trial, \"Title: Comparing Vacuum-Assisted Percutaneous Exci-sion to Open Surgical Exci-sion for Borderline or High-Risk Breast Lesions\" [2], that tests vacuum-assisted percutaneous excision and the same surgical procedure. The trial includes the following inclusion criteria:\n\nInclusion criteria: Inclusion Criteria",
        "label": 0
    },
    "423": {
        "output": "### Example:\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Internal jugular veins and lymph node staging and biopsy in patients with lung cancer: a multicenter study\n\n\nSummary: Aims to determine whether ultrasound-based internal jugular vein staging will improve the sensitivity of the current sentinel lymph node (SLN) technique in patients with non-small cell lung Cancer (NSCLS) who do not have neurotropic mediastinal lymph node (MLN) invasion in order to identify MLN metastases in patients without pal",
        "label": 0
    },
    "424": {
        "output": "[fig]  \u2022\u2022\u2022\u2022\u2022\u2022: Eligible) - This factor must present. - (Excluded) - This factor mustn't present. \u2022 (Not relevant) - More information is needed to determine if this factor is present. \u2022 (Unspecified) - Cannot be determined since there's no information about this factor. [/fig] \n<EOD> Long non-coding RNA ZFAS1 regulates oxidative stress in diabetic nephropathy by targeting miR-150.\nBACKGROUND AND PURPOSE\nLong non-coding (lnc) RNAs have been demonstrated to be critical regulators in many diseases, but the functional role of lncRNA zinc finger antisense 1 (ZFAS1) in diabetic nephropathy (DN) remains obscure. This research is aimed to unravel the relationship between ZFAS1 and DN and to investigate its underlying mechanisms.\n\n\nEXPERIMENTAL APPROACH\nGapmeRs technology was applied to silence ZFAS1 in mesangial cells (MCs). MTT assays were conducted to detect cell proliferation. DHE staining assays and FACS were carried out to measure ROS accumulation and mitochondrial membrane potential (MMP), respectively. The luciferase reporter assay was operated to reveal the relationship between lncRNA ZFAS1 and miR-150, and the association between miR-150 and cytochrome oxidase subunit 7A1 (COX7A1).\n\n\nKEY RESULTS\nWe discovered that lncRNA ZFAS1 was markedly increased in both high glucose (HG)-induced MCs and in the serum of mouse DN models in vivo. Furthermore, knockdown of lncRNA ZFAS1 alleviated HG-induced MCs injury by improving cell viability, inhibiting ROS accumulation, and reversing HG-induced mitochondrial dysfunction and cell apoptosis. Mechanistically, ZFAS1 acted as an endogenous miR-150 sponge. Knockdown of lncRNA ZFAS1 could improve ox",
        "label": 1
    },
    "425": {
        "output": "![inst]![Trial-level eligibility: 2) Eligible.](https://i.stack.imgur.com/KQ2mR.png)\n\n## [INT]\nYou should use the [CSV-format](https://osf.io/dx69e/) and create a [new issue](https://github.com/jakep244/data.cbt-kata/issues/new). A solution is also attached in the [data folder in the repository](https://github.com/jakep244/data.cbt-kata/tree/master/datasets/data), i.e., [PatientNote_1.csv](https://github.com/jakep244/data.cbt-kata/blob/master/datasets/data/PatientNote_1.csv), `PatientNote_1.csv: PatientNote_1.csv` and [TrialNote_1.csv](https://github.com/jakep244/data.cbt-kata/blob/master/datasets/data/TrialNote_1.csv), `TrialNote_1.csv: TrialNote_1.csv`\n\n## A note\nDo the following test using a patient note such as the above. Then, you can go through the entire training as well as the challenges to learn it step-by-step. The steps used to solve each training are detailed in the [solution.md](https://github.com/jakep244/data.cbt-kata/blob/master/training/solution.md) file.<EOD> Synthesis and antinociceptive activity of the 1-aryl-3-(thien-2-yl), and 1-benzyl-3-(thien-2-yl)-2,2-aminoethanone derivatives.\nA series (8a-j) of 1-aryl-3-(thien-2-yl)-2,2-aminoethanone carboxamides (1-aryl-2,2-aminoethanone derivatives) possessing an aromatic amide function at the N(1)-position and a benzyl moiety in the side chain was synthesised",
        "label": 2
    },
    "426": {
        "output": "# Contribution of the exercise\nOnce you have submitted your work, it will be sent to 3-4 reviewers from different institutions, who will evaluate your solution. They will give feedback on:\n- What part of your solution are they satisfied with?\n- What amendments are they able to suggest to make the solution better?\n- What they would do differently if they were to do the task again?\nWhen you have made your adjustment you can submit your modified code.<EOD> Molecular identification of a novel human coronavirus (HCoV-19) from patients with upper respiratory tract infection in France, 2018/2019.\nBACKGROUND\nThe emergence of severe acute respiratory coronavirus-2 (SARS-CoV-2) posing an unprecedented threat to global public health has triggered a series of investigations to understand the pathogenesis of human coronaviruses (HCoVs), with the hope to discover vaccine and therapeutic interventions for patients with COVID-19.\n\n\nMETHODS\nIn this study, we collected upper respiratory tract fluids from 76 patients who visited the outpatient clinic of the Pasteur Institute of Paris and carried out molecular analysis targeting four HCoV species, including HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1.\n\n\nRESULTS\nDuring the 2018-2019 winter season, three positive samples were detected in our cohort, of which 83% (2 out of 2) and 17% (1 out of 6) were tested positive for HCoV-19 and HCoV-229E.\n\n\nCONCLUSIONS\nOur study confirms that HCoV-19 (lineage B) is active in France, co-circulating with seasonal HCoVs. The genomic sequences of our isolates were genetically similar to the HCoV-19 strain from patients in Germany, but differed from the strains found in China and Iran, suggesting that HCoV-19 genetic diversity occurred. More epide",
        "label": 0
    },
    "427": {
        "output": "A.2.2 Examples\n\n![image](https://user-images.githubusercontent.com/6921254/154552375-9a42d9d9-2880-4be1-9284-f1f4dea1067b.png)\n\n### Examples\n\nLet's check the result for some examples.\n\n![image](https://user-images.githubusercontent.com/6921254/154552415-d3ba784b-f023-4350-8d70-23b392adca6c.png)\n\n![image](https://user-images.githubusercontent.com/6921254/154552431-0af329ca-93cb-48fe-a3ca-9ba25ff50a76.png)\n\n![image](https://user-images.githubusercontent.com/6921254/154552444-e52b49a2-676b-470b-8916-cde02134752f.png)\n\n\nC. Inclusion Criteria\n\n\nA clinical trial is designed to observe the effect of a drug on a population within a specific study design. The definition of patient characteristics for inclusion criteria is an important factor for a successful clinical trial. Eligible patient populations should be the target group and the design should be appropriate for the study protocol. Therefore, inclusion criteria are defined to minimize the variables that need to be excluded later and maximize the chances of obtaining results for the study objective.\n\nD. Exclusion Criteria\n\nThe characteristics of a population that exclude people from a clinical trial are exclusion criteria. All patients who do not fit the basic criteria of the study for a clinical trial are excluded from the study at the time of screening. Exclusion criteria are very restrictive and narrow, so those who are not fit for inclusion criteria have no chance of being included in the clinical trial.\n\n## D.1",
        "label": 0
    },
    "428": {
        "output": "### Examples \n\nExamples of patient note\n\n`$ClinicalCriteria.Where(x => x.FieldName == \"Titrexam_ID\" && x.Value == \"Titrexam_002\" && x.Value == \"Titrexam_002\" && x.DataTypes == DataTypes.DrugName).Any())\n=> Titrexam_002\n\nExamples of patient notes:\n```\n\n```\n\n### Examples of clinical trial assessment of eligibility\nA Clinical Trial's assessment of eligibility has three outcomes\n* Eligible\n* Excluded\n* Not Relevant\n\nExamples of data:   \n\nTrial-level eligibility `Trial-level eligibility: 2) Eligible.`, \n                       `Trial-level eligibility: 1) Not Relevant.`,\n                       `Trial-level eligibility: 0) Excluded.`.\nExamples of trial 1\n\nExamples of Trial 2\n\n```C#\nvar patientClinicalTrialId = string.Empty;\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"TrialID\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"Trial27\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"Trial28\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"Trial29\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"TrialID\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"TrialID\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Split('TrialID').First();\n\nvar patientClinicalTrialId \n    = trial.Replace(\"Pt2\",\"\");\n```\n\n### Examples - Eligible\n\nFirst, this method's purpose is to find the clinical trial that is used to obtain the patient's trial eligibility information. \n\nvar trialId = patient.Dem",
        "label": 0
    },
    "429": {
        "output": "[/GUIDE]<EOD> Evaluation of the Influence of Soft-Shell Turtles in Aquaculture on the Dissipation of Chlorantraniliprole in an Inland Recirculating Water System.\nThe present study evaluated the influence of soft-shell turtles on the dissipation/removal of chlorantraniliprole in an inland recirculating water system. The influence of soft-shell turtles in water was quantified by using a mass balance model to simulate the inland recirculating water aquaculture system. Dissipation of chlorantraniliprole was simulated in a single-species aquaculture system of channel catfish (Ictalurus punctatus) and striped bass (Morone saxatilis), a mixed-species aquaculture system of channel catfish/striped bass, and a mixed-species aquaculture system of soft-shell turtles/striped bass. The aquaculture system with soft-shell turtles achieved an accumulation of 4.85 kg/year of chlorantraniliprole, which was approximately 15% lower than that achieved by channel catfish/striped bass and 38% higher than that achieved by striped bass. The residue of chlorantraniliprole in the aquaculture system of the striped bass and soft-shell turtle system were found to be 1.1 and 6.1 times higher than that in the channel catfish/striped bass system. Therefore, the accumulation of chlorantraniliprole in soft-shell turtles has a crucial effect on the dissipation/removal of chlorantraniliprole in an inland recirculating water system and may exceed the maximum residue limits for channel catfish and striped bass.<EOD> The role of p16INK4a in the mechanisms underlying aging\n\nSenescent cells accumulate in tissues during the process of aging through a complex signaling mechanism. Here, we review the various pathways of cell senescence and discuss the senescence-associated phenotypes that lead to human aging-associated diseases. We then focus on the role of the cyclin-dependent kinase 4, p16 ink4a",
        "label": 0
    },
    "430": {
        "output": "[[STD_BEGIN]]\n[[CANDIDATE] Hello\n.\n[EMBEDDED_SRC] 34.4Mb\n[IN_OUTER] The data for the next line is from the output of the evaluation script that runs after training an end-to-end model.\n[FULL_SCREEN] The data for the next line is from the output of the evaluation script that runs after training an end-to-end model.\n\n[[CANDIDATE] Hello\nHere is a partial log of a trained NLP pipeline 2.2 (a combination of pipeline 2.1 and pipelines 3.1 and 3.2; see next page for the full log):\n\n[EMBEDDED_SRC] 205.5Mb\n[IN_OUTER] The data for the next line is from the output of the evaluation script that runs after training an end-to-end model.\n[FULL_SCREEN] The data for the next line is from the output of the evaluation script that runs after training an end-to-end model.\n\n\n# Clinical trials\n\n## Pros and cons of clinical trials\n\nClinical trials provide an opportunity for patients to access treatments not currently available in the market. Participating in clinical trials, however, requires patience. Usually, a trial takes at least a year to complete, even though it may take more time or less depending on the number of patients and the number of doctors collecting and analyzing data.\n\n## Choosing a Clinical Trial\n\nWhen enrolling in a clinical trial, consider the following items:\n\n* The goal of the clinical trial must be important to you.\n\n* The treatments that you get during the clinical trial must be approved by the government and proven safe and effective with high results.\n\n* As a clinical trial participant, you will need to spend less time going to the hospital, which may give you more and more time for your job, family and social interaction.\n\n* The clinical trial process should take more years after it ends to improve the overall health and survival of cancer patients.\n\n# Endnotes\n\n[STD_END]\n<EOD> Evaluation of a method for measuring airbor",
        "label": 0
    },
    "431": {
        "output": "## # Trial-level eligibility: 1) Excluded\n# Patient-level eligibility: 1) Excluded\n# Trial-level eligibility: 2) Eligible\n# Patient-level eligibility: 2) Eligible\n\nWe will be judged by whether our assessments are consistent or inconsistent with clinical trial eligibility rules:\n\n## * `Trials: Breast_Cancer_Trials <list>` - You would see more than one Breast_Cancer_Trials entry if you'd load this file again.\n\nIf a single Breast_Cancer_Trials entry has several Trials objects, there are various methods to select and focus on the specific ones. \n\n## * `Trials: Breast_Cancer_Trials <list>.trial_id` - The trial ID. \n- To view each Breast_Cancer_Trial object, type the ID. \n\n## * `Trials: Breast_Cancer_Trials <list>`[:`breast_cancer_trials: { \"trial_id\": \"Trial_ID\" }`) - To retrieve all individual breast cancer trials in a single Breast_Cancer_Trial object. \n\n### [INST]\nLet's first look for a trial by trial ID. If you select a single row for any trial and press tab, you should see this screen:\n\n<table>\n<thead><th>#</th><th>Trial_id</th><th>title</th><th>summary</th><th>start_year</th><th>duration</th><th>end_year</th><th>eligibility</th><th>eligible_subject_count</th><th>eligible_visit_count</th><th>enrolment_site</th></thead>\n<tr><td>1</td><td>Trial_ID</td><td>Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?</td><td>Breast tumours have different metabolism compared to healthy tissue, including elevated lactate production by aerobic glycolysis (AG",
        "label": 2
    },
    "432": {
        "output": "## A. Identify the type of patient record\n\n#### A.1. patient record type\nOn the first screen, type the type variable on the top of the patient record note (type=1, for patient record, or type=2, for hospital record).\n### Examples: [S] [D] [R] [P] [F] [O] [A] [L] [O] [I] [G] [I]\n    type=2, for hospital record, type=1, for patient record.\n\n#### A.2. find the data to identify each type\nA patient record will have multiple attributes; a hospital record will have at most two attributes: 'number_of_hospital_records' and 'patient_record_references' in its record. It should be consistent with the following rules: in a patient record, the attribute of 'number_of_hospital_records' is not empty. And a hospital record refers to a patient record.\n\n### Examples:\ntype=2, hospital record, hospital.attributes: number_of_hospital_records: 1 patient_record_references: reference: ID: p0056\n    type=1, patient record, patient.attributes: (patient.patient_id).name: p00 \n       hospital.attributes: (number_of_hospital_records).name: 1 patient_record_references.reference: ID: p0056\n    type=1, patient record, hospital.attributes: number_of_hospital_records: 1 patient_record_references: reference: ID: p0056\n\n\n### Examples:\ntype=1, patient record, hospital.attributes: number_of_hospital_records: number: 1 \n       patient_record_references.reference: ID: p0056\n    type=1, patient record, hospital.attributes: number_of_hospital_records: number: 1\n    type=1, patient record, patient.attributes: (patient.patient_id).name:  p0056\n\n\n#### A.3. find hospital patients as variables\n\n### hospital type is variable of hospital record.",
        "label": 0
    },
    "433": {
        "output": "Your task is to write the program using the following tools in Python 3.8:\n\n* [NumPy](https://numpy.org): Numeric computation of scientific arrays. *\n[Pandas](https://pandas.pydata.org): Data manipulation with Python. *\n[Pillow](https://pillow.readthedocs.io/en/vet_3.0.0): Python Imaging Library. **\n* [Flask](https://flask.palletsprojects.com/): Web development with Python. *\n* [H2O](https://www.h2o.ai/): Deep learning library. **\n\nGood luck!\n\n\n\n[INST](./02_task2_code.ipynb)\n\n[INST](./03_task3_code.ipynb)\n\n<EOD> Long-term prognostic factors after resection for bronchial cancer.\nIn a prospective study of patients who had bronchogenic carcinoma resected, 483 of 555 patients were followed by questionnaire with a survival of 168 plus or minus 3 months and a maximum follow-up of 71 months. For the entire patient population, the cumulative 5- and 10-year survival rates were 26 and 14 per cent, respectively. Analysis of the data showed independent prognostic factors to affect survival. Age was significantly decreased in the less than 65-year-old to greater than 70-year-old patients (52 per cent 5-year survival in the oldest patients and 29 per cent in the patients 70 years of age or older). Smoking habits had an overall less than 10 per cent effect on the 5-year survival rate, although increased pack-years of smoking did have a significant detrimental effect in patients in the 3rd and 4th decades of life. Local tumor (N) staging and stage had no effect on survival over the 1st degree of spread and tumor volume and extent of spread appeared less important than the N classification; all these parameters affected the cumulative 5-year survival rates at a rate which was proportional to the overall survival rate. The histologic type and grade",
        "label": 2
    },
    "434": {
        "output": "To generate a report:\n    >  python assess_eligibility/main.py --data=path/to/data >\n\nBy using this dataset, all results shown below are reproducible at any time. When you run the code, you will obtain a result like above if you input the correct data.\n\n### Result\nTo generate a report:\n     > python assess_eligibility/main.py --data=path/to/data --output=path/to/output --overwrite==True\n\nYou should use the --output option to choose a desired output file. If you select --output to None, the program deletes the original file. That's dangerous, but it also means that if you remove \"none\", the old out file will be saved automatically. If you prefer to use a temporary file, please use --output to a temporary folder with --overwrite==True option.\n\nTo reproduce these results:      > python assess_eligibility/main.py --data=path/to/data --output=path/to/output\n\nYou can check the results of this dataset. If you want to reproduce it, use the script of the folder \"results\".\n### Result\n\n```python\nClinical trial not eligible (excluded) \n10.59% (90)\nPatient not relevant \n3.63% (31)\nPatient eligible \n85.78% (748) \nEvaluation Time: 0.11212784203 steps\nBest RMSE: 0.09361715482\nPrecision: 0.843211\nAccuracy: 0.949694\nF1: 0.87818\nKappa: 0.81763\n```<EOD> A single dose of intramuscular mepivacaine-adrenaline does not extend analgesia from bupivacaine-adrenaline wound infiltration\nThe aim of this study was to evaluate the effect of a single dose of 10 mg of mepivacaine\u2013adrenaline on postoperative pain after open gynaecological surgery.",
        "label": 0
    },
    "435": {
        "output": "[OUT] Hello.  Your job is to assist with the management of clinical trials. The focus of this particular task is to verify the patient's eligibility with the inclusion criteria. There are three options: 0) Exclusion; 1) Not relevant; and 2) Eligibility.\n\nPlease show the patient note in the box below:\n\nPlease verify eligibility with the inclusion criteria below in the textbox below:\n\n##\n\nPlease enter your output in the textbox below:\n\n\n\n\n\n\n\n\n\n\n### E04a.2.v1.4_outputtable - outputtable\n\n[IN] Your job is to assist with the management of clinical trials. There are several factors to consider when verifying or determining eligibility. \n\n## Factors to consider:\nPatient's age \nPatient's medical history\nPatient's previous treatment \nNumber of active medications (#) \nDuration of active medications (Days) \nDays of active chemotherapy \nHistory of cancer (Yes or No)\n\n\n\n\n\nPlease enter your output in the textbox below:\n\n### E04a.2.v1.4_outputtable - outputtable\n\n[OUT]:\n\n## F04c.2x.v1.x_outputtable - outputtable\n\n[IN] Your job is to monitor a clinical trial. The focus of this particular task is to verify the patient's eligibility with the inclusion criteria. There are three options: 0) Exclusion; 1) Not relevant; and 2) Eligibility.\n\nPlease show the patient note in the box below:\n\nPlease verify eligibility with the inclusion criteria below in the textbox below:\n\n### F04c.2x.v1.x_outputtable - output\n\n**Exercise 100.5** The trial is running.\n\nExercise 100.5 is identical with Exercise 100.4. Instead of being a pre-assessment, this is now a post-assessment,\n\n### E04.0x.v1.x_output - outputtable\n\n### E04a.2x.v",
        "label": 2
    },
    "436": {
        "output": "<EOD> A systematic examination of coughing in neurologically impaired individuals\nObjective: Coughing, essential to removing fluid and mucus from the respiratory tract and to maintaining respiratory function, has been under-studied in humans with neurologic impairment. We systematically examined coughing response in neurologically impaired individuals. Methods: We used the cough stimulation method (salty-tasting solution) to observe cough response in 216 participants, including 75 with Parkinson\u2019s disease (PD), 23 with stroke and 118 healthy participants. We measured the onset time of each cough and the area under curve (AUC) over 5 s, as well as cough reflex sensitivity (CRS) in different groups. Results: We found that the area under curve (AUC) for coughs over 5 seconds was greater and onset time was shorter in all participants with neurological disorders compared with controls, and these differences were more substantial in higher stages of the disease. CRS increased as PD stage progressed. Furthermore, we found that CRS levels were similar between PD and stroke. Conclusions: Cough motor ability seems to be impaired in individuals with neurological disorders and is related to the stage of the disease.<EOD> Nerve Crossover in Transposition of the Great Arteries (Phenotype of Taussig-Bing).\nAn important and frequently overlooked feature, nerve crossover in transposition of the great arteries, is shown to be useful in explaining the phenotype of Taussig-Bing malformation. ( J Am Vet Med Assoc 2014;245:1542-1545) V ertebral artery (VA) hypoplasia is common in most mammals studied from the fetus to the adult and it can be anatomic or functional.1-5 Anatomic hypoplasia is usually not associated with embryologic a etiology (except for VA hypoplasia in cats with the tetralogy of Fallot) and it is usually acquired postnatally in infants and in adults. Vertebral artery hypoplasia",
        "label": 0
    },
    "437": {
        "output": "<EOD> Isolated Left Ventricular Non-Compaction: A Case Report and Review of Literature\n\nA 47-year-old male from Kannur District in Northern Kerala, India presented to the hospital 7 months after a fall from a ladder that caused abdominal injury, and was later diagnosed with acute pancreatitis. His baseline investigations revealed reduced haemoglobin levels, elevated leukocyte count and anaemia. He also had a high Transthoracic Echocardiogram (TTE) revealed structural abnormalities, such as ventricular noncompaction, septal hypertrophy, mitral valvular prolapse, abnormal left ventricular apical contractility and regional wall motion abnormality in the left ventricular anteroseptal and lateral walls. On the coronary computed tomography (CCT) angiogram, left coronary artery dominance was present, left main stem gave rise to left circumflex artery and anterior interventricular (AIV) artery. There was eccentric atherosclerotic plaque that was partially calcified seen in proximity to the ostium in the right coronary artery (RCA). On cardiac magnetic resonance imaging (MRI) there was decreased left ventricular ejection fraction (LVEF) with hypokinesia of the inferior and anterolateral wall of the left ventricle, apical ballooning or takotsubo syndrome, which were attributed to non-ischemic etiology and there were no perfusion defects. The patient was managed with diuretics and beta-blockers that were effective, without a cardiac pacemaker. However, due to the severe pancreatitis of the patient and other medical complications, he died after 9 months of diagnosis. The patient has received timely diagnoses and treatment at the initial stages of his illness.\n\n# Introduction\nIsolated left ventricular (LV) non-compaction is an extremely infrequent structural cardiac alteration in adults, and is also referred to as LV hypertrabeculation or deep trabeculations. 1\n\n## Case presentation\nA 47-year-old male from Kannur District in Northern Kerala, India",
        "label": 1
    },
    "438": {
        "output": "## Clinical Trial Assist (CTA)\nYou should answer the following questions on the clinical trial using Clinical Trial Assist (https://clinicaltrialassist.github.io/): \n##### Answer (1)\n\nThe following answer is not correct. \nA clinical trial is used to learn whether a new treatment, investigational medicinal product (IMP), or medical device is safe and effective in people with a disease or condition. \n\n##### Answer (2)\n\nThis answer is not correct. A prospective study is the type of trial that is carried out prospectively. In the context of a trial, this means that all of the study participants are recruited and the study is conducted, when the trial starts. Participants are recruited prior to collecting data for the study. \n\n##### Answer (3)\n\nThis is incorrect. In the context of a single-center trial, this means it uses only one participant location to conduct the study and all study activities, such as screening participants, enrolling participants, and collecting data, are localized to one site. In the context of a prospective study, this means researchers follow a cohort of participants through time and collect data from them periodically to see if a treatment, drug, or lifestyle change affects a condition. \n\n##### Answer (4)\n\nThis is erroneous. A Phase I trial is performed to test the safety of a medication for a certain population such a patients with the same condition, cancer etc. A Phase I trial may also provide a preliminary indication of the efficacy of the medication under study. The data from a Phase 1 trial will guide the dose of an investigational agent required for Phase II trials. \n\n##### Answer (5)\n\nThis is incorrect. In the context of a trial, the term \"single blind\" means that at least one participant is unaware of her treatment assignment, or that a participant does not know whether she has received an experimental drug or placebo. A double-blind study is one in which both the person assigning the treatment or dosage, and the participant, are kept from knowing what treatment the participant is receiving. In a randomized trial, the randomization procedure assigns each participant to a trial",
        "label": 0
    },
    "439": {
        "output": "[HEADER] Recruitment rate [/HEADER] \nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Breast Cancer Liquid Biopsy Stratification\n\n\nSummary: Breast cancer is the most common cancer in Austrian women. Estimation of prognosis and treatment strategies is increasingly being dependent on stratification of tumors into different entities or classes. Currently, clinical routine stratification of tumors is mostly based on hormone receptor, HER2 status, and estimation of proliferation. However, a more robust and objective classification of tumors can be achieved by elucidation of further biological properties, which is also of increasing significance, as novel anticancer therapies are based on biological mechanisms. Consequently, available information from molecular analyses is increasingly being implemented in routine diagnostic assays with the aim to improve stratification for optimal treatment selection. To date the most extensive molecular-based taxonomy of breast cancer has been achieved by a classification based on combining gene expression and somatic copy number alterations (SCNAs), referred to as integrative clusters. Tissue biopsies are the current gold standard to attain such a classification. However, they can often be difficult to obtain in the metastatic setting and are subject to sampling bias due to intratumor heterogeneity. Liquid biopsies are, among other analytes, based on the analysis of cell-free DNA (cfDNA) which contains circulating tumor DNA (ctDNA), i.e. DNA fragments shed from normal and tumor cells into the blood",
        "label": 2
    },
    "440": {
        "output": "<EOD> The impact of the SARS-CoV-2 pandemic on tuberculosis screening for high-risk groups in Italy\n\nA B S T R A C T Background: During the pandemic wave caused by the SARS-CoV-2 virus, Italian regions with high TB burden reported a reduction in the number of contacts screened by tuberculin skin test (TST) and interferon-gamma release assay (IGRA). The aim of this study was to evaluate the effect on TB case detection of the implementation of contact investigation in a TB high burden area, Trapani, Sicily, in 2020, compared with a pre-pandemic study from the same geographical region (2019). Methodology: This retrospective study included subjects aged \ufffd15 years, identified as high risk and exposed to TB cases in 2020 and 2019. The TSTs and IGRAs were performed with the M. tuberculosis-specific antigens PPD-RT23 and early secreted antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10), respectively. IGRA was performed in all contacts and TST was performed in contacts with negative IGRA test. The data of TST and IGRA tests (performed by T. spot TB) were retrospectively collected in a Microsoft Excel database (Microsoft Corporation, Redmond, Washington, USA) and statistically analyzed. Findings: 2905 contacts (1417 in 2019, 1488 in 2020) were analyzed. TST and IGRA were performed in 2444 (84.1%) and 461 (15.9%) contacts. TST was positive in 166 (59%), while IGRA was positive in 124 (58.9% contacts. TB was 11.4% and 10.6% respectively in the 2019 and 2020 contacts, respectively, for total and symptomatic TB cases only. The detection rate during the pandemic was greater than the pre-pandemic level (IRR of 4.",
        "label": 1
    },
    "441": {
        "output": "[CATEGORY: 1x2]<EOD> Preferences for pharmacologic and nonpharmacologic treatments for obstructive sleep apnea and comorbid insomnia: A systematic review and meta-analysis.\nSTUDY OBJECTIVES\nTo qualitatively and quantitatively review treatment preferences of patients with obstructive sleep apnea (OSA) and comorbid insomnia.\n\n\nMETHODS\nPubMed, PsycINFO, and the Cochrane Central Register of Controlled Trials were searched from inception through April 29, 2021 to identify qualitative and quantitative research examining treatment preferences of patients with OSA and comorbid insomnia. Results were qualitatively grouped by pharmacologic treatments (e.g., continuous positive airway pressure) and nonpharmacologic treatments (e.g., cognitive behavioral therapy), and quantitatively meta-analyzed.\n\n\nRESULTS\nThirteen studies examining 697 OSA participants were included. Twelve studies had only qualitative methods. One study had both qualitative (n = 55) and quantitative (n = 94) methods. Thirteen themes categorized into two primary qualitative categories that correspond to pharmacologic and nonpharmacologic treatments were identified. Meta-analysis of seven studies included in the present systematic review showed that participants chose the nonpharmacologic treatments (standardized mean differences = -1.25, 95% confidence interval , p < 0.001) more than pharmacologic treatments.\n\n\nCONCLUSIONS\nFindings suggest both pharmacologic and nonpharmacologic treatments could be viable options for treating OSA. Future research studies should aim to develop patient-centered interventions and assess how different factors (e.g., gender) can influence decision-making.<EOD> Cleaning the environment, making it safer\n\n\n\n## How bacteria work in harmony\nO rganisms living a symbiotic (that is, intimate) relationship with one another are commonplace in nature, both near the earth's surface and in deep aquatic layers,",
        "label": 1
    },
    "442": {
        "output": "Here is the clinical trial file. You can use this file to check whether the patients are eligible to enter the trial or not.\n\n# [Q4] How to register a completed clinical trial questionnaire?\nAfter you review if the patient is eligible to enter the study or not, you need to perform the registration step of the questionnaire. The key step in the registration is to assign the correct patient identification code at the end of completing the questionnaire. Each patient is assigned a unique randomization number by the research center by generating a lottery. Each randomized number is used to generate the assignment code and is included in the patient's questionnaire and randomization code report. You can match each patient to the answer to the questionnaire using this number. \n\n## [INST] After checking all the patient's eligibility in Questionnaire review step, you need to perform the registration step of the questionnaire. The key step in the registration is to assign the correct patient identification code at the end of completing the questionnaire. the randomization number is generated by the research center by generating the lottery. each patient is randomly assigned a unique randomization number, which is used to generate a randomized number in each patient's clinical trial questionnaire and randomized number report. [/inst]\n[Q5] How to perform the randomized number assignment step in the clinical trial?\nAs the above",
        "label": 0
    },
    "443": {
        "output": "## <formaction xpath=\"instructions\" method=\"get\">\n<div style=\"font-size: 1.15em\">INST:</div>\n<div style=\"font-size: 1.15em\">\n<table class=\"tab\">\n  <tr>\n    <td class=\"tabcontent\">\n      <center>\n        For more information on how to create tab content, see Section 9.9.\n      </center>\n    </td>\n  </tr>\n  <tr>\n    <td class=\"tabcontent\">1.\n      <center>Make a trial-level eligibility on each patient for the clinical trial, i.e.,</center>\n</td>\n  </tr>\n  <tr>\n    <td class=\"tabcontent\">\n      <center>\n        <input aria-required=\"true\" value=\"0\" class=\"form-control num\" maxlength=\"1\"\n        type=\"number\" size=\"1\" min=\"0\" step=\"1\"\n        (value)=\"Trial-level eligibility = $value ? $value.replace('\\'', '') : '0'\"\n        required=\"true\" id=\"Trial-level Eligibility\" disabled=\"disabled\">\n        &nbsp;\n        <span href=\"#\" class=\"checkbox-input\">&nbsp; <input id=\"Trial-level Eligibility_0\" class=\"checkbox checkbox-input\" (click)=\"changeSelectedItem()\" type=\"checkbox\">&nbsp;</span>\n        <span id=\"Trial-level Eligibility_1\" class=\"checkbox-input\">&nbsp; <input id=\"Trial-level Eligibility_2\" class=\"checkbox checkbox-input\" (click)=\"changeSelectedItem()\" type=\"checkbox\">&nbsp;</span>\n        <span id=\"Trial-level Eligibility_3\" class=\"checkbox-input\">&nbsp; <input id=\"Trial-level Eligibility_4\" class=\"checkbox checkbox-input\" (click)=\"changeSelectedItem()\" type=\"checkbox\">&nbsp;</span>\n        <br>\n        <br>\n        <center>Allows you to provide an overall assessment of eligibility.<br>\n        0) Excluded (patient meets inclusion criteria but is excluded",
        "label": 2
    },
    "444": {
        "output": "### Good\nYou can make this judgment based on the above information. That is, the patient is included as `2) Eligible.`. [/GOOD]\n\n### Warning\nThe patient may not be included in this trial because she lacks the necessary demographic information. The patient is 20 years old. She is not post-menopausal, does not experience breast pain, has no children, and does not smoke or consume alcohol. She is not sexually active, and does not use multivitamins or iron supplements. The patient does not agree to participate in the trial. Hence, I think that the patient is 'Not relevant.`. [/WARN]\n\n### Exclude\nThe patient may be excluded based on the exclusion criteria of the clinical trial, for example, age < 18 years old; pregnancy; breastfeeding; HER2-positive. From the above information, the patient falls into one of these categories, and is clearly excluded. `Exclude.`. [/EXCLUDE]\n\n## Probability of eligibility\nYou should provide an overall judgment on a patient's eligibility based on all notes, in the same way as in the Good section. \n\n- [PROBE]: The answer to this question is obvious. If you are not confident about your judgment and would like to hear other opinions from your teammates, you may use the `Probability of eligibility` question on GitHub to get suggestions.\n    \nYou need to make the probability more concrete. Remember that you were taught to provide the probability of eligibility of a patient on an ordinal scale. For example, `Included = 90%`: `Included = Excluded = 40%; Not relevant = 10%`; `Excluded = 10%` would be most appropriate. You should always refer to the Procedure for evaluating the quality of eligibility assessment to see if your assessment passed the quality check.\n\n\n\n\n\t\t\n\t\t\t\t\t\t# patient record\n\t\t\t\t\t\t\n\t\t\t\t\t\t# Clinical trial record\n\t\t\t\t\t\t\n\t\t\n\t\t<tr>\n\t\t  <th scope=\"row\">\n\t\t    <td><",
        "label": 0
    },
    "445": {
        "output": "You can refer the following code snippet to visualize the eligibility result of a clinical trial on the eligibility report page:\n[!inst]\nTrial-level Eligibility: 1) Excluded, 2) Not relevant, 3) Eligible.\n[/inst]\nPlease refer to the demo to see how to use the above snippet\n============================================================\n\n[!inst#ELC_01]\n##\n## ELC_01: Select an item from the patient list for the clinical trial record. \nSelect an item from the clinical trial record.\n\nThe clinical trial list for ELC_01 is as follows:\n\n  1.\n    No items exist\n  2.\n    Clinical Trial 1\n  3.\n    Clinical Trial 2\n=======\n\n\n| Item Number | Field Name | Type | Default | Allowable | Description |\n|-------------|------------|------|---------|-----------|--------------|\n| 1 |  |  |  |  | |\n| 2 |  |  |  |  | |\n| 3 |  |  |  |  | |\n| 4 |  |  |  |  | |\n| 5 |  |  |  |  | |\n| 6 |  |  |  |  | |\n| 7 |  |  |  |  | |\n| 8 |  |  |  |  | |\n| 9 |  |  |  |  | |\n| 10 |  |  |  |  | |\n| 11 |  |  |  |  | |\n| 12 |  |  |  |  | |\n\n[/ELC_01]\nFor the ELC_01 code snippet, the snippet will add an item selection record for the targeted clinical trial name into the system when the user has clicked the `Search` button. After clicking `Update` (you may need to press another key because the default behaviour is to immediately display the `Search` form when the selection is clicked.), the selection should be saved in the system and can be seen from both the `Selected Items` and `Details` page.\n\n[!inst",
        "label": 0
    },
    "446": {
        "output": "## 9.1. Exercise (C3): Exploring eligibility criteria\n\nIn Part 1, we studied patients with cerebral aneurysms. In Part 2, we studied the eligibility criteria of a clinical trial.\nThis is a brief exercise in which you will have a chance to read the trial summary and patient notes to study the eligibility criteria more thoroughly.\n\n[INST] The patient is 70 years old a woman with hypertension, type 2 diabetes mellitus a recent episode of bleeding who presented at the local hospital with leftsided frontal headache for 7 days. The patient has no past medical history. The headache was continuous and throbbing, which had worsened in the left temporal area for the last 3 days. Patient had 4 episodes of vomiting. The patient had history of left-sided weakness 3 days ago. She was not taking any medication.\n\n[INST] This is a short exercise to understand the difference between 'criteria' and 'factors' for a better eligibility assessment. There are many criteria, factors, and factors for a wide variety of clinical trials based on type of diseases, target populations, and available treatments. If you were to participate in a clinical trial, it is important to understand the patient recruitment goals and the eligibility criteria, and how they align with the treatment and recruitment goals of the trial. In some clinical trials, it is required to have more than one clinical factor. If you were to become a clinical research coordinator one day, you will not only have to read and understand these factors and criteria, but you will also have to educate study participants on why they are or are not eligible to participate in the clinical trial. \n\n[INST] There is a discrepancy: 'hypertension or type 2 diabetes mellitus' should actually be 'hypertension or type 2 diabetes or both'. This is because both hypertension and type 2 diabetes can be the criteria and hypertension or type 2 diabetes can be the factor. \n\n[INST] The headache worsening in the left temporal area is not a clinical",
        "label": 0
    },
    "447": {
        "output": "# Discussion\n\n## How did you define the input data set and model the process flow?\nAs the process flow, I simulated the flow of patient data and the recruitment task by clinical trial staff with [data simulator]. By simulating the input data set in this way, you can understand the difference between the results when comparing the methods of data handling.\n\n### How to set the parameters of data simulation?\n[data simulator] can generate a parameter table by specifying the attributes of the input table. In, the parameter table used in the process simulation of the input data set is shown. The simulator was programmed using [language], and the parameter table was generated using [worksheet]. The input data set contains columns for [subject], [age group], [clinic visit], [smoking status], and [lifestyle-related disease]. [subject] and [clinic visit] are assumed to be missing values (na). Also, [smoking status] and [lifestyle-related disease] are treated as categorical variables. \n* This table is generated by the process in[data simulator]\n\n### Did you check the input data set?\nI first created the table structure mentioned above in[worksheet]. After that, [data simulator] can generate a data set of input data based on this table structure. When generating the data set, missing values are filled with the median. I created and then deleted the data set multiple times by modifying the parameter table so that the process performance was not distorted. In, the data set generated by [data simulator] is shown. The rows in the data set are created with a uniform random number, which was generated in [language]. \n\n<img src=\"data-simulation_analysis.png\" width=\"600px\" alt=\"Data simulation analysis by data simulator\" />\n* This table is generated by the process in[data simulator]\n\n### How did you find the solution in an unsolved task?\nWhen I could not solve a specific problem, I modified the parameter table and repeated the same process. The results were different depending on which parameter table was used. If your method gives reasonable results, you can infer that your process flow is reasonable. To infer that your method is correct, you should observe the difference in the results when comparing different parameter tables.\n\n### When",
        "label": 0
    },
    "448": {
        "output": "If you have any question you can visit us. [/END]\n<EOD> .\nAIM\nTo evaluate serum levels of selected interleukins and adhesion molecules in patients with acute coronary syndrome (ACS) before and after a course of standard medical care (SMC) in dynamics with cardiac rehabilitation (CR).\n\n\nMATERIALS AND METHODS\nGroup I (n=50) consisted of patients with unstable angina (UA) and non ST segment elevation (NSTE) myocardial infarction (MI) who had no history of coronary artery disease and who were previously treated with SMC. Group II (n=40) consisted of patients with ST segment elevation MI (STEMI) and had been given treatment according to the recommendations of European Society of Cardiology (ESC) Committee for practice guidelines. All patients underwent standard transthoracic echocardiography, coronary angiography, determination of serum levels of selected interleukins and adhesion molecules before and after the course of SMC in dynamics with CR.\n\n\nRESULTS\nThe mean age in group I and II patients was comparable. In group I, the mean age was 50.03 years (34-66 years), whereas in group II, the mean age was 51.86 years (25-70 years). Patients in groups I and II were divided into 2 groups by risk factors: those without risk factors and those with one other risk factor (arterial hypertension, diabetes mellitus, smoking, obesity and hyperlipidemia). There was no statistically significant difference by interleukin (IL-1\u03b2, IL-6, IL-8 and TNF-\u03b1) and adhesion molecule (sVCAM-1 and sP-selectin) serum levels between patients with ACS without risk factors and healthy individuals. After SMC, these levels were significantly lower only in patients with ACS without risk factors. After a course of SMC in dynamics with CR, there was no statistically significant difference in serum levels of IL-1\u03b2, IL-6, IL-8, TNF-\u03b1, sVCAM-1 and",
        "label": 0
    },
    "449": {
        "output": "<EOD> Growth and metabolic characteristics of intrauterine growth-restricted neonatal piglet with neuropathy-induced growth failure\nIntrauterine growth-restricted (IUGR) piglets with neuropathy (ION) are characterized by growth failure, but their growth and metabolism remain to be characterized. In this study, the growth and metabolic characteristics of ION piglets were explored. Pregnant gilts were injected orally every 5 days from 25 to 105\u2009days gestation with chloramphenicol (CAP), and the weight of piglets was compared at birth. LD10 for CAP was assessed, and piglets were categorized into growth-normal (G-N), growth-restricted (G-R), and growth-restricted with neuropathy (G-RN) groups. Adenosine deaminase (ADA), adiponectin, insulin-like growth factor-1 (IGF-1), thyroid hormone, and growth hormone-releasing hormone (GHRH) were assessed in serum, and growth and metabolic indices were assessed in serum and muscles. The results show that CAP impaired the growth of piglets from birth to weaning. The G-RN group weaned with a significantly (P\u2009<\u20090.05) low litter weight, while the G-R group weaned with significantly low body weight (BW) and average daily gain (ADG). The G-RN group showed significantly (P\u2009<\u20090.05) increased ADA activity, decreased IGF-1, and increased thyroid hormone. The G-RN and G-R groups showed significantly (P\u2009<\u20090.05) decreased GHRH. The G-R and G-RN groups showed significantly (P\u2009<\u20090.05) increased leptin, whereas the G-NR group showed significantly (P\u2009<\u20090.05) decreased leptin. The G-RN group showed significantly decreased activity of glutathione-S-transferase (GST), catalase (CAT),",
        "label": 1
    },
    "450": {
        "output": "**Please, make a trial-level eligibility on each patient.** [/INIT]\n    \n    \n    \n    \n     \n\n<style>\np.inst {\nfont:50%;\nwidth: 50%;\n}\n.question-1{\nbackground: #8F2D6C;\">   How can we compute an average age per arm? Is it possible?\n</B><BR><br><BR>You have to compute an average age per arm.<BR><i><A href=\"http://www.cs.ualberta.ca/~hinton/StatQuest/stats_textbook.pdf\" target=\"_top\" class=\"C\">See Sect. 2.5</A> on average.</i>\n</I><BR><BR>The sum of the scores is 24 <BR><I class=\"C\">Average for all subjects is 4.6 \u00b1 1.34</I><BR><i>Average per group= 4.6 \u00b1 1.34</I><BR><i>Average per arm= 4.6 \u00b1 1.34</I><BR><br><I>Average in the treatment arm and average in the control arm will be same</i><BR><br><br><HR><BR><BR><BR><BR><A name=\"2_questions_1\">\n</A><A name=\"2_questions_1\"></A> \n\n</A><A NAME=\"A1\">\n\n[ A1 ] \n<BR><B><H2>D</H2><B>iscussion</B><BR><BR>\n\nAn average age",
        "label": 0
    },
    "451": {
        "output": "---\n\n[A:INS] You are given a patient note and a clinical trial note. The patient meets the inclusion criteria of the trial but does not meet the exclusion criteria of the trial. The patient does meet the exclusion criteria of the trial. The patient meets neither the inclusion nor exclusion criteria of the trial.=, e.g., `Trial-level eligibility: 2 3) Excluded`.\n[B:INS] You are given a patient note with clinic trial note and asked to output the scale of the trial-level eligibility of the trial.\nLet us think by step.\n- Step 1: Identify the patient's eligibility for the clinical trial\n\n\n\n```\npatient_note                117\ntitle: \"Breast cancer\"                                                                 \nage                         29\ngender                      66\n\ndiagnose                     breast_cancer\ntreatment                    resection\nstaging                     1\nclinical_staging                \n  primary                          0\nsecondary                       0\n\ntreatment_response             4\ngrade                          1\n\nresponse                      0.5\nradiation_on                  1\nradiation_off                 0\n\nsurgery                      on\nhistology                     Infiltration\n\nhistology_type                 1               \nsurgery_type                  1               \n\ndiagnostics                   pathohistologic              \nsurveillance                  mammography\n\nexcluded_clinical_staging                \n  primary                        1\nexcluded_secondary                \n  clinical_staging                0\n \n\nexcluded_surgery                 \n  surgery                        1\nexcluded_surveillance           \n  surveillance                   2\n\nExcluded_Surgery:         0\nExcluded_Surveillance:     0\n```\n\n- Step 2: Identify the type of clinical trial\n\n```\ntrial_title: 'Omission of SLNB in\u2026'                                                                                              \ntrial_date: 01/01/2017                               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^",
        "label": 0
    },
    "452": {
        "output": "## Recommended Articles\n- [REF] Clinical trials in anesthesia: A practical guide using simple statistics\n<EOD> Fertility treatments and multiple gestation: which patients should be offered elective single embryo transfer in South Africa?\n\nBackground: Multiple gestations are associated with increased risk of obstetric complications, perinatal and infant mortality. The aim of this retrospective study was to determine the incidence of live birth of multiple gestation and to identify the clinical and ultrasonographic features of pregnancies associated with multiple gestation among IVF cycles. Method: Data analysis was performed on 1043 IVF and ICSI cycles of women who presented with at least one oocyte retrieved. The cycles were selected on four criteria; age of patients, cause of subfertility, number of previous failed IVF cycles and number of previous failed ICSI cycles. A total of 1043 cycles were grouped into two groups; 698 with spontaneous pregnancy and 345 with intracytoplasmic sperm injection (ICSI)-conceived pregnancy. Result: Fifty-one (2.03 %) of the 2506 pregnancies conceived were multiple gestations. The multiple gestation rate was 9.3 % (43/464) in the ICSI group compared to 0.97 % (8/882) in the IVF group. When the ICSI cycles were further grouped into poor and good responders using a cut off value of antral follicle count (AFC) = 8, a total of six (5.7 %) poor responders had a singleton live birth compared to 37 (10.1 %) good responders. Among the poor responders, none of the women below 35 years of age had a multiple gestation in contrast to 4.7 % above 35 years old (p = 0.03). The relative risk of conceiving a multiple gestation in the ICSI cycles was 7 times higher than that in the IVF cycles (Risk ratio 6.54, 95 % confidence interval 2.92-14.53, p < 0.0001). Conclusion: ICSI was found to be a significant",
        "label": 0
    },
    "453": {
        "output": "# Exercise\n\nPlease test your answer to Problem 1 with a [link to an online form]. \n<EOD> Re-evaluation of the SARS-CoV-2 infection rate on Nile tilapia (Oreochromis niloticus) cage culture in central Sudan\n\nA novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported as the cause of a global pandemic for coronavirus disease 2019 (COVID-19). SARS-Co",
        "label": 0
    },
    "454": {
        "output": "## S3: [INST] Data and code\n\nIn this project, we collect the data from [link] . To train and test our system, we use [link] dataset. It consists of 500 trials and 300 trials respectively. The dataset is imbalanced. Moreover, the labels are highly imbalanced, e.g., Eligible = 1, Not Relevant = 202, Excluded = 0.\n\nThe evaluation metrics are accuracy, BACC, balanced accuracy, precision, recall, f1 score, and G-mean. We use them interchangeably in this paper. We use the following equations.\n\nAccuracy = \nPrecision = \nRecall = \nF1-score = 2 * precision * recall precision + recall\nG = Precision * recall (Precision + Recall) \n\n\n\n### Training data\n\nWe divide the training dataset randomly into 6 folds of the same size. Each fold represents an independent cross-validation. During cross-validation, we train our model on the trials in the fold and evaluate the model on the remaining folds.\n\n### Inference\n\nBesides using the training dataset to train our model, we also use it to estimate the model's performance, i.e., predict the unlabeled trials. Here, we use 3 folds of the training dataset as the test dataset to make sure that every fold has been used for testing. The left out fold is the validation dataset. To train our model on the training dataset, we use the following procedure.\nStep 1: We divide the training dataset into training folds.\nStep 2: We train our system on the training folds.\nStep 3: We evaluate the trained system on the test fold.\nStep 4: We train our system on the whole training dataset.\nStep 5: We evaluate the trained system on the validation fold.\nStep 6: We perform backpropagation on our model according to the loss on the validation dataset.\n\n### Convolutional neural network baseline model\n\nIn this paper, we choose 7 convolutional neural network baselines for comparison, including AlexNet, GoogleNet, Vgg16, Vgg19, Goo-gleNet(",
        "label": 1
    },
    "455": {
        "output": "# Implementation  \n\nFirstly, import the pandas data frame by the following code:\ndata=pd.read_csv(\"exam.csv\")\n\nThe row data is extracted and printed out:\ndata.head()\n\nYou can also plot the first column and first two columns by the following code:\ndata.plot(column=[\"Disease\", \"Eligibility\"], title=None)\n\nThen, you should compare the 'disease' column and the 'eligibility' column of the patient and the clinical trial to judge the eligibility and the final eligibility should be stored in a new variable 'finalEligibility' by the following code:<EOD> An Innovative Approach to Improve Patient Safety During Intravenous Therapeutic Chemotherapy: Development, Implementation, and Results of a Dedicated IV Chemotherapy Treatment Room\nStanford Cancer Institute (SCI) at Stanford Hospital and Clinics was designed to provide highly technical cancer care services, including an Outpatient Chemotherapy Unit (OCU) with 10 infusion chairs, and has served over 1500 patients in the 3 years since opening. While the OCU served to consolidate the clinic\u2019s services and increase patient visits, the institute also faced challenges in ensuring patient safety during the dispensing of highly toxic intravenous chemotherapeutic agents. In addition to the need to accommodate a larger number of patients in a limited space, the facility also lacked space for storing chemotherapeutic medications and refrigerating patient-specific medication bags, increasing the risk for errors. The institute\u2019s leadership determined that a solution was required to decrease the number of errors, improve the safety of care, and improve the patient experience. This article outlines the development and implementation of a new room dedicated to dispensing chemotherapy that would serve to consolidate dispensary and administration functions as well as medication storage and preparation. The following are the results of the development process: (1) the development of a chemotherapy treatment room with patient safety built into every aspect of the room and the workflows; (2) real and projected medication waste and supply costs for dispensing chemotherapy agents by drug, and a",
        "label": 0
    },
    "456": {
        "output": "## Substantive Code\nPlease copy and paste relevant substance code below. \n[INSERT SUBSTANTIVE CODE]\n\n## Substantive Code\nPlease copy and paste relevant substance code below:\n[INSERT SUBSTANTIVE CODE]\n\nFor more info about how to create your [INSERT INSTITUTION] [CORPORATION INSTITUTION], [CORPORATION CORPORATION], or [INCORPORATED OTHER](INCORPORATED), follow the [INSERT CORPORATION URL].\nYou can also find relevant substance code templates for your institution by browsing institution templates on the [INSERT CORPORATION URL].\n\n## Assignment\nPlease complete the following assignment:\nPatient:\n[INSERT NAME]\nAge and sex:\n[INSERT AGE]\n[INSERT FEMALE/MALE]\n[INSERT DETAILED PATIENT RIGHTS]\n\n[INSERT ASSIGNMENT]\n\n\n## Feedback\nThis assignment will provide feedback on your performance in the Clinical Research Assistant Certification curriculum. This will be a graded assignment.\n\n\n# Marks\nThe assignment includes two sections. You will be marked on a total of 6 components: Section 1: You will submit a screenshot from your answer file. We use a rubric to evaluate the correctness of your response against the answer given in [HUB URL], based on your chosen assessment tool. Please see Section 2\n\n## Section 2:\nPlease submit a description of how we would get to your answer (as if we were conducting an assessment, not as a student). This will be scored by your instructor using the below criteria.\nPlease submit your assignment in .doc document type.\n\n## General guidelines 1.\nFollow guidelines in the [HUB URL].\n\n## 2.\nAnswer in word form and then present in screenshots. You can also upload PDFs or Word documents.\n\n## 3.\nYou can use this space to provide any additional information you deem necessary.\nThank you for submitting your assignment. Please wait for your grades to be sent to your [INSERT TIMELY DISTRIBUTION CENTER].",
        "label": 0
    },
    "457": {
        "output": "__Instructions__\n__INPUT_DESCRIPTION__\nRun __python main.py__ to run all the test cases. Then, copy the _summary.txt_ file to your _Workshop/Week 11_ folder under _your username_.\n__RUN_INFO__\n_python main.py_\n\n[INST] This code is written for python3. The user has to set the os and the library paths correctly. Please refer to the python version and library version information.\n[INST] The code prints the message for each execution. The first time, `Test Case 0: Excluded` will be printed.\n__TRIAL_1_FILLE_DESCRIPTION__\n[INST] Let's think step by step.\n[INST] Let's think step by step - Part 1.\n[INST] The function __get_trial_notes__, which is a part of the __Trial_level_eligibility__, is called in the __MAINLINE_0_1__ \n__MAINLINE_0_1__\n[INST] __get_trial_notes__ is used to return the list of trials that the patient can join.\n__MAINLINE_0_1__\n- if __all_patient_trials__ is empty:\n- __get_trial__ is invoked to return the trial object.\n\n__MAINLINE_1_1__\n__get_trial__ is called to return the trial object, which contains all the required information about the trial\n\n__MAINLINE_1_1__\n- trial.get_title__ is called to return the trial's title\n\n__MAINLINE_1_1__\n- trial.get_summary__ is called to return the trial's summary\n\n__MAINLINE_1_1__\n- trial.get_contact__ is called to return the trial's contact's name\n\n__MAINLINE_1_1__\n- trial.get_contact_email__ is called to return the trial's contact's email\n\n__MAINLINE_1_1__\n- trial.get_contact_phone__ is called to return the trial's contact's phone\n\n__MAINLINE_1_1__\n- trial.get_inclusion_criteria_name__ is",
        "label": 0
    },
    "458": {
        "output": "[CODE] ## This code is used to produce the figures in the main manuscript.\n# +\n\nfrom pprint import pprint\n\n#%%\nimport matplotlib.pyplot as plt\nfrom matplotlib import animation\n###% \n#%%\n\n\nplt.savefig(\"../figures/data_cleaning.fig\")\nplt.savefig(\"../figures/data_cleaning_animation.mp4\")\n#%%\n#\n# def plot_eligibility_comparison(patient_info, trial_info):\n#     plt.ylabel(\"Patient ID\")\n#     plt.xlabel(\"Trial ID\")\n#     plt.axhline(y=0, color=\"black\", linewidth=1, linestyle=\"dashed\")\n#     plt.axvline(x=0, color=\"black\", linewidth=1, linestyle=\"dashed\")\n#     #print(\"patient_id: {}\".format(patient_id))\n#     #print(\"trial_id: {}\".format(trial_id))\n#     plt.plot(patient_info, trial_info, marker=\".\")\n#     plt.show()\n#     plt.pause(0.1)\n#     plt.clf()\n#     plt.axis('off')\n#     plt.clf()\n#     if not os.path.exists(\"../figures/data_cleaning.fig\"):\n#         plot_eligibility_comparison(patient_info, trial_info)\n## \nif __name__ == \"__main__\":\n    if __package__ is None:\n        sys.exit(1)\n\n\nplt.rcParam('axes.prop_cycle', cycle=0)\n\n# Define functions for plotting data\ndef plot_eligibility_comparison(patient_ids_index, trial_ids_index, trial_ids, patient_ids, trial_eligibility, plotting_labels):\n    if len(trial_eligibility) == 0:\n        trial_eligibility = [0 for label in plotting_labels]\n\n    if len(trial_eligibility) == 3:\n        trial_eligibility =",
        "label": 0
    },
    "459": {
        "output": "Now, let's look the flow of the program.\n```\n1: import sys\n2: import input\n3: l = [list(sys.argv)]\n4: n = len(l)\n5:\n6: # [patient note]\n7: a = l[n-1]\n8: nstr = 10 # this is a maximum length when you want to read all possible string\n9: # if(a!='') for readability\n10: if(a != '') \n11:\n12:     print(input(\"Select scale for assessment of eligibility: 0) Excluded\\\n(patient meets inclusion criteria\\\nbut is excluded on the grounds of the trial's exclusion criteria)\\\n; 1) Not relevant (patient does\\\n not have sufficient information\\\n to qualify for this trial)\\\n ; \n2) Eligible (patient meets inclusion criteria\\\nand exclusion criteria do not apply).\n     \";\n13: nstr = len(a)\n14: a = a.rsplit(r\"\\n\")  # it will give list to split with 4 elements\n15: k = 1\nwhile(k < 4):\n    print(a[k]) # print one by one\n    if(k<nstr):\n        a += a[0].rsplit(\"\\n\", k+1) # add more string to get more length\nk = nstr\nn = len(a)\n18: nstr = a[0].lstrip()  # remove blank spaces around string\n19: tmp = nstr.split(\"'\") # will split string by ,\n20: lstr = tmp[0]\n21: kstr = tmp[1]\n22: tp = []\nif(lstr == nstr): # when they equal length\n    while(kstr = kstr+1) # this is the same as nstr\n        tp.append(\"'\")\n6: # [clinical trial]\n7: a = l[n-1]\n8: nstr = 12345\n9: c = a.rsplit(r\"\\n\") # for more details go to 10\n10: b = c[",
        "label": 2
    },
    "460": {
        "output": "![INST]\nIn this example, the following are computed:\n- [# Patient Level]: The number of cases included in the clinical trial that are eligible.\n- [# Patient Level Excluded]: The number of cases included in the clinical trial that are excluded.\n- [# Patient Level Not relevant]: The number of cases included in the clinical trial that were not evaluated.\n- [# Trial-level].\nPlease note that in the following example, there are no trials in the selected `clinical trial type` and therefore, no patients are included or excluded in the [# Trial-level].\n![INST]\nThere are patients who can be part of a clinical trial but it needs to be added to the [clinical trial type](../concepts.md).\n\n\n### Examples [#]\n- [# Examples]: \n\n```\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  her2-positive and ER/PR negative. axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer\n\nSummary: This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-",
        "label": 0
    },
    "461": {
        "output": "## [/INIT]\n\n##### Exercises:\n\n*  1\n*  2\n*  3\n\n* What do you predict will happen in the patient's note (or will you see anything unexpected?) if you change the code?\n* What do you predict will happen in the patient's note (or will you see anything unexpected?) if you change the code?\n\n**Solution**\n\n*  1\n*  2\n*  3\n\n* What do you predict will happen in the patient's note (or will you see anything unexpected?) if you change the code?\n* What do you predict will happen in the patient's note (or will you see anything unexpected?) if you change the code?\n\n**Solution**\n\n*  1\n*  2\n*  3\n\n**Solution**\n\n*  1\n*  2\n*  3\n<EOD> A survey of the state of health of indigenous populations in the Brazilian Amazon\n\n [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  \n\n## Financial support\nNone declared.\n\n# Authors' contributions\nEpidemiological studies require an agreement on the concept of what we want to achieve, in terms of the population groups to be studied. The question arises of how to include the study of socioeconomic determinants of health and the assessment of environmental determinants, which involve the intervention of external factors in their health, thus broaden the understanding of the complexities of the relationship between health and health-disease processes.\nAlthough indigenous peoples of Brazil have not been the object of a great amount of study, due to the great diversity of the indigenous population, we cannot generalize that what happens among them is the same.\nThe aim of these articles is to expose the importance of using surveillance indicators, and the inclusion of indigenous health surveys in the National Health Survey in order to obtain updated knowledge",
        "label": 0
    },
    "462": {
        "output": "## [INST] Taking it all apart with the \"deconstruct\" operator:\nThe \"reconstruct\" operator takes every patient of the input data and splits it into a \"patient note\" (the first part) and a \"trial note\" (the second part). Then, it is possible to extract the sub-patient notes and sub-trial notes to apply a series of analyses by a wide variety of operators. However, the input data contains nested patient notes and nested trial notes. Therefore, I decided to use this special operator, which performs deconstructions of two levels simultaneously.\nFirst of all, we want to create 2 new features that we call \"patient-level eligibility\" and \"trial-level eligibility\" (see [INST] First operation: creating two new features). These two features are computed by taking every patient of the input data and performing 4 tests:\n- \n\n## 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply); and 3) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).\nTherefore, we can assign the values to the \"patient-level eligibility\" and \"trial-level eligibility\" features by taking into consideration the fact that the first 4 tests of \"Trial-level eligibility\" are performed within each individual patient. \nNext, we have to perform simple operations on these 2 new features. If \"patient-level eligibility\" is equal to 2 (i.e., when a patient is evaluated as \"Eligible\" for a given trial) and \"trial-level eligibility\" is 2 (i.e., the patient is \"Eligible\" for the clinical trial), it means that this patient could be allocated to the trial. Therefore, we want to create a new feature, \"eligible for trial\" (see [INST] Third operation) whose value should be evaluated as the conjunction of the 2 features, \"patient-level eligibility\" and \"trial-level eligibility\". In other words, we want to evaluate the \"eligible for trial\" feature to be equal to 1 if and only if both \"patient-level eligibility\" and \"trial-level el",
        "label": 0
    },
    "463": {
        "output": "`x090461`\nIf you are interested, check `x090461` more detailed, please refer to [SAS Institute Inc. 2020].\n\n### Examples\n\n  1. We start to do all the processing for the example patient and clinical trial: the comparison of the patient's  note and the clinical trial's eligibility criteria. \n  2. Next, we call `Trial-level eligibility`. \n  3. Here, the input note is `Trial-level eligibility result: 2) Eligible.` \n  4. Next, we check whether the patient is eligible for this clinical trial or not. \n  5. For example, if the patient is `45-year-old postmenopausal woman with breast cancer` the output is `No, because of the 'age' criteria, the trial exclusion age criteria is less than or equal to 45 years.` \n  6. We confirm that the final output, `No, because of the 'age' criteria, the trial exclusion age criteria is less than or equal to 45 years.`, should be checked by the recruiter. \n\n\n\n# Tutorials\n\n- [Using the API with Data Frames](_getting_started/tutorials/frames.md)\n- [Exchange of data](_getting_started/tutorials/file_exchange.md)\n\n<EOD> Immunologic aspects of translocation of the small intestine.\nThe alteration of the immune response to non-nutritional antigens (ovalbumin and Brucella abortus) was studied in 35 patients after resection of the small intestine. Sixteen patients had the small bowel transplanted to the neck and 19 to the subcutaneous space. The non-specific immune response to mucinous ovarian graft in the subcutaneous space was preserved. The humoral and cellular responses to ovalbumin and to Brucella abortus in the subcutaneous space were greatly depressed but the cellular immune response to ovalbumin and Brucella abortus was intact in the intraperitoneal space, This finding, with the presence",
        "label": 0
    },
    "464": {
        "output": "## [HIGHEST-LEVELEL] hello. high is the name of a student at [NAME OF SCHOOL] PUBLIC HIGH SCHOOL.\nHe has several best friends, a girlfriend, a pet (dog), his family and his teachers. He is an active member of the basketball team (He is number 18).\nYou should predict the [HIGHEST] personality of High, i.e., output the name of his highest personality. Please use only the [LEVEL] dataset.\nExample of input data file:\n[HIGHEST-LEVEL] Hi:  # Hi is the name of a student at [NAME OF SCHOOL] PUBLIC HIGH SCHOOL.\nHe has several best friends, a girlfriend, a pet (dog), his family and his teachers. He is an active member of the basketball team (He is number 18).\n\nThe following data corresponds to the dataset in the \"LEVEL\" section.\nHi: HIGH-LEVEL\n[LEVEL] # [LEVEL] = 'NAT', 'PRO', 'INT', 'COG', 'ANT', 'SEN', 'SOC', 'MOR'\nIn the [NAME_LEVEL] column, input the name of the highest level of personality, i.e., input level 7.\n[EXPLICIT]\nExp: Hi is the HIGHEST level of personality.\nEx: Hi is the HIGHEST level of personality. \n[/HIGHESTLEVEL]\n[DENOM] Hello. You are a helpful assistant for the clinical trial. Your task is to compare a given patient note and the clinical trial eligibility criteria to determine the best level of the personality of a patient. Then write a report document.\nHere is your patient note:\nHi is the name of a student at [NAME OF SCHOOL] PUBLIC HIGH SCHOOL.\nHi has several best friends, a girlfriend, a pet (dog), his family and his teachers. Hi is an active member of the basketball team (He is number 18).\nHere is the clinical trial: \nClinical trial title: Fulvest",
        "label": 0
    },
    "465": {
        "output": "#Data analysis\n### Example: HYPERGAMMA Data Set\nPlease download the dataset at\nThe data set is composed of 150 subjects' information, including nine variables in total. The subject number is unique in each variable. The last variable named `CATEGORY` represents the subjects' eligibility. The eligible objects are 150, the uneligible subjects are 0.\n\nThe eligible object should be transformed as the eligible subject number. The following code will transform the eligible object into the eligible subject number. Please note that we need to add 1 to eligible object, since eligible objects are 150 and the `CATEGORY` variable data type is int. \n\n`num.y_int = num.y + 1;`\n\nPlease calculate the mean of all subjects' ages.\n\n```python\nage_mean_y_int = num.y_int.mean()\n```\n\nPlease calculate the variance of all subjects' ages.\n\n```python\nvar_y = num.y_int.var()\n```\n\nPlease calculate the sample standard deviation of all subjects' ages.\n\n```python\nstd_age_y_int = num.y_int.std()\n```\n\nPlease calculate the standard error of all subjects' ages.\n\n```python\nse_age_y_int = num.y_int.stderr()\n```\n\nPlease calculate the interval for 95% confidence interval for all subjects' ages.\n\n```python\nlower_ci_age_ci_y_int = num.y_int.lower.quantile(0.05)/std_age_y_int\nupper_ci_age_ci_y_int = num.y_int.upper.quantile(0.95)/std_age_",
        "label": 0
    },
    "466": {
        "output": "# Trip_3: The number of patients with positive P16 expression. \nTrip_3 calculates the number of patients with positive P16 expression. \n[TEST] The number of patients with positive p16 expression is \u2026 (Enter the answer here and press the Enter button.)[/TEST]\nThe p16 expression in ovarian tumors is \u2026 (Enter the answer here and press the Enter button.) [TEST] \nThe number of patients with positive P16 expression in OGCT is\u2026 (Enter the answer here and press the Enter button.) \n \nTo do an assessment of p16 expression in ovarian tumors. Immunohistochemical \nThis study was conducted at the Department of Pathology, Minia University. 32 cases of ovarian tumors and 30 Normal ovaries were selected for this study. All the cases have been collected from the files of the Pathology Laboratory of Minia. The data were collected using a preconstructed form.\n\nThe cases were collected from the files of the Pathology Laboratory of Minia. The cases were diagnosed as 32 cases of ovarian tumor and 62 cases of normal ovaries. They were confirmed morphologically and immunohistochemically by P16.\nThe P16 IHC staining result showed that 28 of the ovarian tumor cases were positive with p16 expression at (28/32=87.5%), whereas, 24 of the OGCT cases were positive with p16 expression at (24/30=80%) and 18 of the Normal cases were positive with p16 expression at (18/30=60%). \n<EOD> Differential regulation of the human Na,K-ATPase at the translational level by beta 1 and beta 2 isoforms.\nTransient transfection assays of constructs containing human Na,K-ATPase alpha 1-cDNAs, either alone or in combination with beta 1-cDNA or beta 2-cDNA, were performed and analysed using an enzyme-linked immunosorbent assay technique. The results revealed two different effects of the beta 1 and beta 2",
        "label": 0
    },
    "467": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to recruit patients for the trial. The trial's requirements for patients include having a certain disease. You should collect all patient diagnoses that meet the inclusion requirements of the trial. \nLet's extract the patient diagnosis code for the clinical trial using the following seven-step approach. First, collect the patient's diagnoses without trial inclusion criteria. Then, the exclusion diagnoses are removed. Then you need to find all the inclusion diagnosis codes. \n\n`find patients' diagnosis exclusion criteria`\nThe clinical trial needs to select patients according to the following inclusion criteria:\n- `Diagnostic and Histological Criteria:`\nPatients without a previous diagn",
        "label": 2
    },
    "468": {
        "output": "## Inclusion criteria\nLet's consider an eligible patient, i.e., the patient with Trial-level eligibility of 2. To test the patient's eligibility, the patient should have the following:\n- Patient 1 and Patient 2: Excluded;\n- Patient 3, Patient 5, Patient 6, and Patient 7: Not relevant; \n- Patient 4: Eligible.\n\nNotice that `Elizabeth` and `Emily Jane` are both patients whose medical history contains the same information. Therefore, you should consider them to be identical. In addition to the differences shown in the table, the following details are additional information on the patient:\n- `Medical history`: `Diabetes mellitus`;\n- `Chemotherapy`: `Yes`;   \n\nTo illustrate the use of patient_id function to find the patients' id, let's use some of the data shown in the `Patient` table to find the patients' ids by the condition of `Patient_type` < 4. We should obtain the patients' id with Trial-level eligibility of 2, i.e., `Patient_id = id_list[Idx(Patient_type == 2)][Patient_id)`. Here is the patient ids:\n\n## Exclusion criteria\nLet's consider an excluded patient, i.e., the patient with Trial-level eligibility of 1. The exclusion criteria are based on the patient's medical history, i.e., the patient should not satisfy the condition of `Patient` \u2265 1 and `Patient` \u2264 17. Here is a patient with ID 30 whose Trial-level eligibility is 1: `exclusion_criteria = find(Patient == 1 || Patient == 3 || Patient == 7 || Patient == 10 || Patient == 18 || Patient == 19)`\n```\nExclusion_criteria = find(x == 1 || x == 3 || x == 7 || x == 10 || x == 18 || x== 19)\n```\n```\n[2] \"30\"\n```\nThe patient information is summar",
        "label": 0
    },
    "469": {
        "output": "(in a in \u2026, a\u00a0in. [bib_ref] [bib_ref] the 2-based in\u00a0-pat. 2 and<EOD> \n in one and ^. [bib_ref] . 3 for 1\u00a0ass-tre (or-and\nin a [bib_ref] a completeness\u00a0some, which on el, in the\u00a0det, the 1\u00a0 [bib_ref]. [bib_ref] and the\n\n\n and Cement 2\u00a0/\n\n<EOD> or\nof a (in,\u00a0of [bib_ref]2 [bib_ref] and c   (3 for: in an [bib_ref] 3-1 1_ 1 for the 1- 0\n@\n or [fig_ref]ed (due-in- 1\u00a0based-in-based in a_d, in\ninstile for [bib_ref]in .\n{ 1{\n^gut (in clinetic [bib_ref]\ns/care/and. [bib_ref]\n [bib_ref],\u00a0in its-only.\nand\u00a0and c\nin its that the\n 0. and an in\n(dish_int-based \u00ae^d for 2.\ntest\nacc~s \ufffdass-like-in\nd-~specific\nc...\ntre  s \u200b, and any -after a-in the on 1- 2 -.g on [bib_ref]@d@. 2\u00a0 and\n 0 and [bib_ref]... 4 in the...insted-her inst .\n\n[non-visual 0-based.\non\nfor\nshe\n The to A\u00a0 for the _inst to... for [bib_ref]s 7 [bib_ref] [bib_ref]\u00a0for a-and.^ or 1 {\n 1s (i-f of medical study and and and [bib_ref] and \u00a0and for\nsuch in an -s in the (deway in an#inst with \\\nfor_inst 7 and 1-m (i as the \u2265re-1 (in its 2 (~b\n-and-she\u2010se-med for\nor for the\nCOR-1% to 2\u00a0follow\u2026_/med (s-d in 6+ _in. [bib_ref] _[c and its-< in\u00a0and {\n and  before . C-and 1<1 and\n-direct for\ndi*-pat an\u00a0 _m with - -ch\n_\n -",
        "label": 2
    },
    "470": {
        "output": "### Exercise 5: Add your input\n\n> The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  Her2 negative and negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy. Here is the trial: Title: Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer Summary: This is a phase-2 single-arm, open-label trial determining efficacy of Neo-adjuvant Abemaciclib and Fulvestrant in patients with HR+ breast cancer who develop local recurrence while on adjuvant endocrine therapy with molecular evidence of endocrine resistance.\nInclusion criteria: Inclusion Criteria:\nPatients must have a diagnosis of HR+ breast cancer. To fulfill the requirement of HR+ disease, a breast cancer must express, by immunohistochemistry (IHC), at least one of the hormone receptors (ER, progesterone receptor [PgR]) as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010):\n1. For ER and PgR assays to be considered positive, \u22651% of tumor cell nuclei must be immunoreactive by immunohistochemistry (IHC) (Hammond et al. 2010).\nPatients must have Loco regional breast cancer (Stage I, Stage II and stage III per AJCC 8th edition criteria for staging of breast cancer)\nPatients must have localized recurrence while on adjuvant endocrine therapy\nPatients must have any known mole",
        "label": 0
    },
    "471": {
        "output": "[DATA] \n\n\n\n\n\n[PRED] \n\n\n# Mentor Instructions\nPlease visit the link below to find the comments from your mentor.\n\nIn accordance with MIT's policy the report will be kept in the students' files for at least three years.\n\n\n[/PRED]\n\n\n\n[HINT] \n\n# Questions\n1. You should show your patient to the assistant and your mentor after you finish reading the patient note. 2. Afterward, your job is to explain the answer to your mentor.\n\n[/HINT]<EOD> Fungal and Viral Keratitis in Nepal: A 4-Year Retrospective Study and Current Clinical Perspectives\nPurpose: A wide-ranging review was conducted to assess the current epidemiological status of fungal and viral keratitis in Nepal. Methods: Reports (1975\u20132015) were collected using the online PubMed and SCOPUS search engines, and from several other sources such as the bibliography database of Nepal Medical College and Teaching Hospital and the Nepal Eye Bank Association. Inclusion and exclusion criteria to identify studies related to the review\u2019s objectives were applied, and the data were extracted following a standard procedure in line with the preferred reporting items for systematic reviews and meta-analyses guidelines. Results: Fifty-four studies were included in our review, of which 51 were journal articles and the remaining were review articles and dissertations published in international journals. A total of 31 reports were from a single center, while the remainder were multiple-center studies. The majority (63%) of the primary studies reported were cross-sectional, and the majority (85%) of the studies reported were hospital-based. Of the eligible studies, 11 (20.4%) were case control studies, while 30 (55.6%) were case reports. The incidence rate of total fungal keratitis was 6.8/100,000 population, while only 0.75/100,000 population were afflicted with total viral keratitis. A wide variety of risk factors were stated for fungal and viral keratitis",
        "label": 0
    },
    "472": {
        "output": "To test your solution, run:\n`python solution.py INSTR-A0.in` \n\n# Questions\nPlease discuss your answer with the instructor. We would also suggest that you try to solve the questions by your partners.\nInstructions: Please work through the questions and come up with solutions. After that, try to convince your partner(s) that your solution is right. (10% of the overall grade)\n\n## Problem 4.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 5.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 6.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 7.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 8.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 9.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 10.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 11.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 12.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 13.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 14.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 15.\nUse your solution to",
        "label": 0
    },
    "473": {
        "output": "<p id=\"instructions\"><sup>\u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5\u23d0 \u23d0 <NAME>, this is your final assessment. Your trial level eligibility is <NAME>, <NAME>, <NAME>.<NAME> will appreciate your efforts in this task. Here is a short example of what you will be doing:</sup></p>\n\nFor example, the patient note corresponds to the trial number 29023944, and 1) Excluded, 2) Eligible, and 3)\nNot relevant for our patient.\n- Trial-level eligibility: 1) Excluded\n- Inclusive criteria: Patient meets the inclusion criteria for clinical trial: 45-75 years (< 77 years old).\n- Exclusive criteria: Patient does not meet the exclusion criteria for clinical trial: Breast cancer at stage IIIB, stage IIIC, stage IV, or identified as having distant metastasis.\nThe patient's eligibility corresponds to '1) Eligible'. It is sufficient that a patient's eligibility for a clinical trial depends solely on their age, sex, and cancer stage. In these situations, the trial inclusion criteria are simple and concise and are represented as a string of three characters.\nOn the other hand, '2) Not relevant' means that the patient note does not indicate the information needed to determine eligibility. For example, the patient note could be '01/12/2006 breast cancer at stage IIIB', and ' 02/12/2006'. The trial inclusion criteria determine whether the patient is eligible or not based on information provided by various tests.\n`[INST]` <NAME>, this is your final assessment. <NAME> will appreciate your efforts in this task. Here is a short example of what you will be doing:\n\n</p>\n\n1) Make a Trial-level eligibility for each clinical trial.\n\n</pre>\n<p>\u2460)\u2461)\u2462)\u2463)\u2464)\u2465)\ufffd",
        "label": 0
    },
    "474": {
        "output": "### Patient-level Eligibility\n\nAs you already know, we extract the patient's eligibility information from the patient notes in the data file. \nAs you are familiar with the Patient-level Eligibility, you can move to Section 1.7.\n\n### 1.15 The output of the program: You should get an eligibility report\n\n< Eligibility table >\n\nThis is an example of the eligibility report. \n\nAs you are familiar with the output of the program, you can move to Section 1.7.\n\n### Patient-level eligibility\n\nAs you know, we extract the patient-level eligibility information from the clinical trial and the patients' eligibility factors in their patient's notes in the data file. \n\nAs you are familiar with the Patient-level eligibility table, you can move to Section 1.17.\n\n### Question_answer table\n\nYou should extract the Patient-level eligibility factors. You calculate the information (eligibility factors) from the clinical trial (exclusion, inclusion, eligible, excluded) and the factors (age, gender, the type and stage of a disease, previous treatment history, and other medical conditions) in each patient's notes in the data file.\n\n`ClinicalTrials.RData('BN23797.txt')`\n\n| `ClinicalTrials.RData` |\n\n|--------|\n| Trial_label |\n\n|--------|\n| Trial_name |\n\n|--------|\n| patient_1 |\n\n|--------|\n| patient_2 |\n\n|--------|\n| patient_3 |\n\n|--------|\n| age_patient  |\n\n|--------|\n| female_patient  |\n\n|--------|\n| previous_treatment  |\n\n|--------|\n| stage_disease  |\n\n|--------|\n| type_disease  |\n\n|--------|\n\n`Clin.Trials.RData` |\n\n|---------|\n| clin.trials|\n\n|---------|\n| 1 |\n\n|---------|\n| 2 |",
        "label": 2
    },
    "475": {
        "output": "___\n\n## Testing\n\n__We want to check whether the results of the trial would be comparable to those of the real-world treatment under certain circumstances (e.g., patient adheres to the medication)._\n\n### [TEST] Data input\n\nFirst of all, when the user chooses a patient in a hospital's patient pool and click the 'Input data' button the data input panel will be displayed.\n\n![Data input panel](figs/tutorial/Input_data.png)\n\n___\n\n### [TEST] Proceed\n\n_Once every data is filled, click the 'Proceed' button and the data input panel will be cleared._\n\n![Clear button](figs/tutorial/Clear.png)\n\n___\n\n### [TEST] The result is `Not relevant`\n\n_Click the 'Add result' button the output will be printed in the result panel._\n\n![Add result button](figs/tutorial/Add_result.png)\n\n![Test result panel](figs/tutorial/Test.png)\n\n___\n\n### [TEST] The result is `Ineligible`\n\n_Click the 'Add result' button the output will be printed in the result panel._\n\n![Add result button](figs/tutorial/Add_result.png)\n\n![Test result panel](figs/tutorial/Test.png)\n\n___\n\n### [TEST] The result is `Eligible`\n\n_Click the 'Add result' button the output will be printed in the result panel._\n\n![Add result button](figs/tutorial/Add_result.png)\n\n![Test result panel](figs/tutorial/Res_panel.png)\n\n\n# Usage\n---------------------------------------------------------------------- \n\n#### Create a clinical trial\n\n*Click the \"Add clinical trial\" button\n![Add clinical trial button](figs/doc/doc_add_clinical_trial.png)\n\n![Add clinical trial wizard](figs/doc/doc_add_clinical_trial1.png)\n\n*Choose a clinical trial and click the button*.\n*Enter the name of newly registered data *as \"Biochemical study\".*\n*Choose the *status",
        "label": 0
    },
    "476": {
        "output": "<NAME>, 92839822, [NAME] -------- [EMAIL PROTECTED].<EMAIL>, [NAME]<EOD> .\n\n With the high cost of steroids as a remedy for the symptoms of the menopause, efforts have been made to develop new alternatives. Oestrogens and their derivatives are among the first compounds used, and synthetic or semi-synthetic derivatives have been tested. The new compounds have a structure based on natural substances and are produced by chemical synthesis. The structure comprises two groups: aromatic compounds, and steroids. The aromatic compounds have the oestradiol group joined to other substances, for instance: ethynodiolmethylstilbene, bis-hexoside and triazole. The steroids are conjugated with methyl derivatives, and these are then subjected to steric hormonal modulation. The following types of chemical steroid derivatives can be listed: 17-ethynylestradiol, ethynodiolmethyltestosterone, 17-ethynylestropyridol, ethynodiolmethylaminoethanol, ethynodiolmethyloestrone, ethynodiolmethylprogesterone, 17-ethynylestronyloestrone, ethynodiolmethylestradiol, ethynodiolmethyloestradiol, 17-ethynylestriol, ethynodiolmethyloestriol, 17-carbethoxyethynyl-17-ethinyl estriol, diethylstilbestrol, bis-dehydrostilbestrol, bis-cyclohexyldiethylstilbestrol, bis-dehydrobiscyclohexylstilbestrol, and diethyl-2-ethane-carbonyloxyethylstilbestrol. Chemical steroid derivatives with antiglucocorticoid properties were created and proved effective, although they were not completely acceptable. Other tests have been conducted to create substances with progesteronic properties, among others nortestosterone and testosterone. This research has led to the creation of new possibilities:",
        "label": 0
    },
    "477": {
        "output": "5.\n[INST] Assumption 2.\nEach patient-level eligibility of each clinical trial is equal to the AND across all clinical trials with the same factors. In other words, if a patient is eligible to a trial, then the entire patient's information should become \"TRUE\" for the patient across all clinical trials with the same factors.\n\n\n\n\n\nThe output shows:\nThe patient is eligible according to each clinical trial.\n\n# 5. Challenge 6 \n\n[ \nClick for Solution](https://data.mendeley.com/datasets/z664xn4pzn/1) \n\n[56]. Please click the 'Check' button to run challenge 6.\n\nThe following information is provided to help you solve the challenge. You may try to write your own code or search the code from the internet.\n\n## Patient code\n\n```python\n\"Darcy\"\n```\n\nYou must enter the patient or \"case\" name, or the name of the first author if no case is provided.\n\n## Patient note code\n\n```python\n\"[\n    {\n        'id': 7856,\n        'age': 39,\n        'first_names': 'Darcy',\n        'last_names': 'Miller',\n        'sex': 0,\n        'gender_x': 6,\n        'gender_y': -9,\n        'gender_z': 0,\n        'race': 56,\n        'marital_status': 1,\n        'ethnicity': 4,\n        'patient_type': 1,\n        'occupation': 20,\n        'insurance_npi': [\n            4 8\n        ],\n        'insurance_payer_id': [\n            0,\n            4071,\n            5111,",
        "label": 0
    },
    "478": {
        "output": "Done!\n\n<table>\n  <tr>\n    <td>CASCADE</td>\n  </tr>\n  <tr>\n    <td>Trials</td>\n  </tr>\n  <tr>\n    <td>\n      0170B02:Cascade30+NCT02437733 \n      0172T03:Cascade40+NCT03323939 \n      <br />\n      0112C01:NCT02632883 \n      <br />\n      0129C04:NCT02402692 \n      0117C03:NCT2874044, NCT02632883 \n      <br />\n      0016L05:NCT01740427, NCT02632883, NCT01828074, NCT01300046, NCT01141503, NCT01151601 \n      <br />\n      0102A01:NCT02114256, NCT01506544 \n      <br />\n      0008C01:NCT02114256 \n      <br />\n      0108C01:NCT01506544 \n      <br />\n      0046A01:NCT01363634, NCT01718955 \n      <br />\n      0028C01:NCT02282073 \n      <br />\n      0163C01:NCT02175433 \n      <br />\n      0163C02:NCT02274548 \n      0163C05:NCT02175433 \n      <br />\n      017",
        "label": 1
    },
    "479": {
        "output": "# Results\n\nFirst, I analyzed all the 200 patients in the dataset using the preprocessing and precomputation steps, but I filtered them using 5 years and two exclusion criteria: 304.1x (Blood loss, unspecified) and 714.xx (External causes of morbidity.) I got 48 patients for further trials.\nI trained the BERT classifier using the training file and I saved the model, too.\nSo, it would appear that the dataset contains only 48 patients and that the algorithm was able to recognize all these patients. And also that the model was saved and not just trained, so I can open the saved model and check the performance.\n\nI opened up the saved model to check out all the features by using the print statement.\n![print statement from the saved model and the selected attributes]({{site.baseurl}}/images/print_statement.jpg)\n\n##### First section: the input:  \nThe input looks as follows:   \n![input to the saved model and the selected attributes]({{site.baseurl}}/images/input_output.jpg)\n\n##### Second section: the output:   \n    ```\n        {'assessment': 'Clinically Evaluable', 'tumor': {'id': 797, 'status': 5}, 'site': 'Breast', 'procedure name': 'surgery', 'procedure sequence number': 20, 'disease site': 'B', 'disease summary': 'malignant neoplasm of the breast', 'clinical diagnosis': 'malignant neoplasm of the breast', 'specimen characteristics': 'Excision of malignant neoplasm of the breast', 'specimen date': 2/15/2016, 'specimen: tissue': 'excisional', 'specimen size': 2.2, 'bodily fluid and tissue types': 'mammary gland biopsy', 'pathologic diagnosis': 'malignant neoplasm of the breast', 'site and focus': 'B', 'report summary': '', 'specimen type': 4, 'specimen: tissue': 'fresh frozen', 'specimen date",
        "label": 2
    },
    "480": {
        "output": "[INST] How many minutes does it take for someone to complete the eligibility assessments, from reading to the report? How much time do you need to review a patient's eligibility for clinical trials?\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWhat's the difference between the assessment of eligibility and the trial-level eligibility?[INST] Hello.\n\nIn general, assessment of eligibility is the process of determining whether a person is eligible to participate in a clinical trial based on the characteristics and conditions set out in the eligibility criteria, whereas trial-level eligibility is a three-point scale for the assessment of eligibility, which indicates whether a subject meets the eligibility criteria based on the characteristics and conditions set out in the clinical trial protocols. [END]\n\n### What is clinical trial eligibility?[INST] Hello. You are a helpful assistant for clinical trial recruitment. \n\nYour task is to find clinical trial eligibility on each enrolled clinical trial  that your clinic participates in, i.e., output the list of clinical trial eligibility in enrolled clinical trials.\n\nClinical trial eligibility is the set of rules according to which subjects enroll in and are eligible to participate in clinical trials. A clinical trial generally requires potential participants to meet certain eligibility requirements (inclusion criteria) before being admitted to the trial. These eligibility requirements help ensure that each clinical trial has the opportunity to meet its objectives and achieve the desired clinical results. [END]\n\n### Is there any particular eligibility requirement for a clinical trial?\n\n[PREDEF, 5, `The clinical trial targeted to adolescent patient must include a trial-by-age agreement,`]\n\n```\n\n[\nPREDEF, 3, `The clinical trials must involve patients or healthy volunteers.`,]\n[\nPREDEF, 6, `The clinical trial can have strict requirement of HIV test and sexually transmitted disease screening.`,]\n```\n\n[\n\n```\nPREDEF, 3, `The clinical trial must include an exclusion criterion that the patients who have",
        "label": 2
    },
    "481": {
        "output": "## 1) You make a patient-level eligibility assessment by `Patient-level eligibility: 0) Excluded; 1) Not eligible; and 2) Eligible`. This way, in the output, the result of patient-level eligibility is always either `Not eligible` or `Eligible`. [INST]\n\n```r pypath2r # this path is created by pypath2r\n[1] \"~/python\" # set path to where your python environment is\nlibrary(magrittr) # import magrittr to simplify code\nlibrary(purrr) # import purrr to make data processing easier\nlibrary(dplyr) # import dplyr to make data processing easier\n```\n\nIn the following, let's see data preparation. \n \nWe see that in the patient table, there are two patients having the combination of trial eligibility in Trial and Eligible. Suppose you have to run the code with a single patient having the combination in a test case or a test dataset. The code is shown for a patient table in a single patient table. \n\n```r\n# import the trial and patient data files for this trial\ndata.dat <- load(\"~/Data/Trial_data/patients_and_trial_01032019.xlsx\")\ndata.trial <- load(\"~/Data/Trial_data/Trial_01032019.xlsx\")\ndata.eligible <- load(\"~/Data/Trial_data/patients_and_trial_eligibility_01032019.xlsx\")\n# this would be the test case of the trial to be assessed\ntest.case <- data.trial[1:3, ]\n```\n\nLet's see how the code would work in a test case.\n\n```r pypath2r\ntmp <- pypath2r::\"%t%%\" # \"%t%m\" is a string with two characters, `%t` and `.`\n# `rst.clinic` is the working directory of the user; this path is automatically set by iSeeU\nrst.clinic <- \"~/Data/rst_clin",
        "label": 0
    },
    "482": {
        "output": "## \u2705 Answer\nIn order to pass this scenario, you should create patient note and clinical trial note. You should also determine Trial-level eligibility with three options and print the notes and then print the trial-level eligibility. \n```\n#!/usr/bin/env python3\n\"\"\"Test case script for 'assist.test.sjsubway_370_answer.py' file.\"\"\"\n\n\nfrom bs4 import BeautifulSoup\nimport os\nimport yaml\nfrom tqdm import tqdm\n\ndef main():\n    \"Test case script main.\"\n\n    input_data = os.path.join(os.path.abspath( __file__ ), 'input.html')\n    output_dir = os.path.join(os.path.abspath( __file__ ), 'output.json')\n    if the input data is None:\n        print('Invaid Input Directory. Please Check it again.')\n        os.Exit()\n\n    with open(output_dir, 'w') as json_file:\n        soup = BeautifulSoup(\n            BeautifulSoup(\n                html.unescapeHtml(\n                    input_data))))\n\n        soup['sj-subway'] = {'name': 'sjsubway.txt'}\n        soup['patient_details'] = {'name': 'patient_details.txt'}\n        soup['clinical_trial'] = {'name': 'clinical_trial.txt'}\n        soup['patient_summary'] = yaml.safe_load(yaml.safe_load(\n            BeautifulSoup(\n                html.unescapeHtml(input_data)).prettify(\n                    'html')))\n        for i in tqdm(soup.find_all('tr')\n                        if soup.find_all('table')): \n            patientDicts = {}\n            if soup.find_all(attrs={'class': 'patient-details'})[0]: \n                patient = BeautifulSoup(\n                    soup.find_all(attrs={'class': 'patient-details'}).prettify(\n                        'html').splitlines(dropblanks=True))\n            else",
        "label": 0
    },
    "483": {
        "output": "> [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial: \nTitle: Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer\n\n\nSummary: The challenge of breast conserving surgery (BCS) is to obtain free resection margins, by removing the invasive tumor and the precursor cells: DCIS (Ductal Carcinoma in Situ). Consequently, 17%-25% of primary invasive breast cancer patients will need a repeat surgery. Repeat breast surgery has been associated with higher surgical ris",
        "label": 2
    },
    "484": {
        "output": "# Hints\n\n\n\n\n\nIn some questions, only one value is correct. In those questions, the correct answer must be chosen using the number pad (not a mouse). If you do not know the answer, it is still okay (i.e., you can guess a value with a wrong result). However, we consider incorrect answers when you choose a correct value but do not press any keys for the next question. You can select multiple values by holding down the <SHIFT> key and choosing a value on the keyboard. It is recommended that you also choose the <INFORMATION> button on the right-hand side to obtain clarification, even if you make an incorrect answer, in order to learn more from the feedback.\n\n\n# Tasks\n\nHere are the tasks for this section:\n\n- [Task T1](#T1): Compare a given patient note (in Section 0.) with clinical trial inclusion and exclusion criteria (in Section 1.) by answering the question above.\n\n- [T2](#T2): Make a trial-level eligibility for each patient on each clinical trial by answering the question above.\n\n  \n\n\n\n\n\n# Problems\n\n## 1. Incorrect Answers\n\n  \n\n\n\n\n\n## 1.1 Excluded (patient meets the inclusion criteria, but is excluded under the trial's exclusion criteria).\n\n  \n\n\n\n\n\n## 1.2 Not relevant (patient does not have sufficient information on the trial to meet inclusion criteria or does not meet the trial's inclusion criteria.) \n\n  \n\n\n\n\n\n## 1.3 Eligible (patient with the trial's inclusion criteria, but trial's exclusion criteria do not apply)\n\n  \n\n\n\n\n\n# Discussion\n\n## Inclusion and Exclusion Criteria\n\n  \n\n### Inclusion Criteria\nInclusion criteria are those factors that allow a patient to participate in a clinical trial. They are based on characteristics, such as gender, the type of cancer and its stage, the previous treatment history, and medical conditions. The reason you can choose only three candidates from the list of criteria are as follows:\n\n* You will need to use a very stringent method to find relevant papers discussing inclusion and exclusion criteria.",
        "label": 2
    },
    "485": {
        "output": "<EOD> Prevalence of metabolic syndrome with cardio-metabolic risk factors in Chinese individuals with nonalcoholic fatty liver disease: A meta-analysis\n\n\n\n# Introduction\nAlcohol-related complications are the second leading cause of premature death, and nonalcoholic fatty liver disease (NAFLD) is one of the complications. It has become a major public health issue in the world and it is associated with many diseases. Obesity, diabetes, hyperlipidemia, and hypertension are major characteristics of NAFLD and are also strongly associated with metabolic syndrome (MetS). In addition, a growing body of evidence has recently demonstrated that individuals with NAFLD are at increased risk for type 2 diabetes and cardiovascular diseases.\nBased on the definitions of different diagnostic thresholds for MetS, the prevalence of MetS in patients with NAFLD is 32.7% in the United States (2) and 43% in Taiwan. These populations are mostly of European or American descent. However, a few population studies were conducted in Chinese adults with NAFLD, all of which demonstrated a high prevalence of MetS, ranging from 32.1% to 80%. The discrepancies in the prevalence of MetS between these studies were largely due to the differences in their definitions of MetS and racial disparities. The diagnosis of MetS is based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and the International Diabetes Federation (IDF) metabolic syndrome definitions. In the NCEP-ATP III definition, NAFLD might be included with MetS because excess visceral fat is seen in more than 90% of patients with metabolic syndrome. However, NAFLD could not be simply regarded as metabolic syndrome. In the IDF definition, a higher waist circumference (WC) is a key component in diagnosing metabolic syndrome. Moreover, it has been reported that WC is positively associated with NAFLD. If the WC cut-off value is also included in the diagnosis of NAFLD, the high prevalence of MetS with card",
        "label": 0
    },
    "486": {
        "output": "indicate that this is an instruction and should not be repeated in Python or R code. When the code has finished, you can hit <code>'\u21b5'</code> to continue. \n#### Causes `test_eligibility(clinical_trial=your_own_example_clinical_trial, patient=\"your_own_example_patient\")==1`\n##### Parameters \n\n- You need to define the `clinical_trial` variable.\n- You can also define the patient variable. However, if both variables are used, you should use it like `clinical_trial=get_clinical_trial(your_own_patient)`.\n\n##### Returns \n- Returns `1`, if the patient is eligible of the trial.\n- Otherwise, returns `0`.\n\n##### Example \n\n```R\nclinical_trial <- get_clinical_trial(\n  dataset=\"clinical_trials\", \n  id=\"1-98-01-22\")\npatient <- load_patient(\n  filename=\"path/to/your/own/clinical_trial\", \n  dataset=\"patients\")\ntest_eligibility(clinical_trial=clinical_trial, patient=patient)\n```\n\n#### Example \n\n```R\nclinical_trial <- get_clinical_trial(\n  dataset=\"clinical_trials\",\n  id=\"1-98-01-22\")\n\n\npatient_in_trial <- load_clinical_trial(\n  dataset=\"patients\", \n  patient=\"your_own_patient\", \n  id=\"38-53-12-53\")\n\nprint(test_eligibility(clinical_trial=clinical_trial, patient=patient_in_trial))\n```\n\n### Requirements \nThis notebook assumes that `R` and `Python` is installed and can run on Mac OS X, Windows, or Linux.\n\n- `biopython`: `biopython",
        "label": 2
    },
    "487": {
        "output": "- \ud83c\udf10 https://doi.org/10.17179/Exper/325 (2.65 - \ud83c\udf10 https://data.mendeley.com/datasets/2h7sjf7vpc/1 (2.65\n- \n\n1.75- - \ud83c\udf10 https://doi.org/10.17179/Exper/94 (1.75\n- \n\n2.00- - \ud83c\udf10 https://doi.org/10.17179/Exper/45 (2.00\n- - \ud83c\udf10 http://purl.org/dc/dataset/UID:1633993 (2.00\n- - \ud83c\udf10 http://datalad.org/sharing/bundles/mhqvqfyq72 (2.00\n- \ud83c\udf10 https://github.com/mhqvqfyq72/breastcancer (2.00\n(4.00 -<EOD> The use of thalassospira in pump-oxygenator priming solutions.\nFor nearly 30 years, thalassospira (Spirosa) has been widely used in pump-oxygenators in clinical medicine either in its pure form or diluted in a solution of crystalloid saline, glycerol, or glycine. There are no controlled clinical data supporting the use of thalassospira. It has been suggested that the presence of thalassospira is responsible for the poor blood viscosity profile, the hemorrhage and transfusion problems, and the increased mortality rate associated with high flow pump-oxygenator perfusion. A review of experimental data does not support this suggestion. On the contrary, experimental evidence indicates that thalassospira has a beneficial influence on red cell deformability. Thus, the data available do not support the conclusion that thalassospira should be withdrawn from use in pump-oxygenator perfusion.<EOD> .\nCystis fistula as a complication of tra",
        "label": 0
    },
    "488": {
        "output": "### \u2713 `Trial-level eligibility: 2) Eligible`\n<EOD> 6-Oxo-L-norleucine suppresses protein and nucleic acids accumulation in C6 rat glioma cells by causing the apoptosis of malignant cells.\n\n\n\n# Introduction\nAn excess of amino acids in the culture medium increases protein and nucleic acids synthesis in the neoplastic cells undergoing rapidly . Since several amino acid transporters, including LAT1 (a leucine transporter), transport essential amino acids, it is hypothesized that there is a causal relationship between amino acid uptake and the oncogenic potential [bib_ref]  The 4F2hc/LAT1 complex transports 3-methoxytyramine, a major metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine..., Pivetta [/bib_ref] . Therefore, it is of considerable interest to investigate amino acid transporters and their possible contribution to the neoplastic phenotype.\n6-Oxo-purine (6-OP) compounds are synthesized in vivo during oxidative folic acid reduction in mitochondria and by xanthine oxidase in the presence of hypoxanthine. The 6-OP content in the blood of cancer patients is higher than that of normal subjects [bib_ref]  Plasma concentrations of endogenous purine metabolites in patients with prostate and breast..., Shirai [/bib_ref] .\n6-OP has a half-life of 33.5 minutes in normal rats [bib_ref]  Pharmacokinetic study of 6-oxopurine in rats, Shirai [/bib_ref] . Since the blood circulation time of 6-OP is shorter than its half-life, 6-OP is likely metabolized in the target organs or tissues. Among the six forms of 6-oxo-purine, 6-Oxo-L-norleucine (6-ONL) is a stable derivative and has long been used in experimental medicine for the treat-ment of experimental cystitis, liver damage, and other dise",
        "label": 1
    },
    "489": {
        "output": "### Case {1_1_T_1_1}\n\n![](/assets/images/screen/01_README/figures/case_data.png)\n\nWe provide a case in the same structure as the tutorial cases. \n \n### [Questions](#questions)\n\n \nName \n\n___ \n____\nAge \n  ____ \nBMI \n  __________\n\n______\nClinical trial: Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients \n  _________ \n\nAssess whether the patient is eligible for this clinical trial. \n  ____________ \n \n### [Solution](#solution)\n\n```\nTrial-level eligibility: 2) Eligible.\n```\n\n<EOD> The Use of PET/CT for Assessing Response of Malignant Pleural Effusion to Chemotherapy\n\nThe aim of the study was to evaluate the use of fluorine-18 fluorodeoxyglucose ( 18 FDG) positron emission tomography/computed tomography (PET/CT) for assessing the efficacy of chemotherapy (CHT) in treating malignant pleural effusion (MPE). Methods: 21 patients with histologically confirmed pleural effusion were enrolled in this prospective investigation. PET/CT imaging was performed before and after chemotherapy. PET/CT parameters and pleural to blood ratios (P/B ratios) were calculated based on SUV max and SUV mean measurements. Results: PET/CT revealed partial remission in 6 patients who had pleural biopsy but only 2 of them had pathological diagnosis with malignant cells. 18 FDG PET/CT imaging at baseline was able to differentiate responders and non-responders to chemotherapy both for the whole cohort (sensitivity 91%, specificity 88%) and for the subgroups of patients who had a pathologic diagnosis (sensitivity 100%, specificity 100%) PET/CT, which was performed prior to the first cycle of",
        "label": 0
    },
    "490": {
        "output": "[END]\n\n# Step 6: Run Tests\nRun the following tests to verify your script:\n\n* **Lint tests**: `make test`\n\n* **Unit tests**: `make test-unit`\n\n* **End-to-end tests**: `make test-fixtures`\n\nIf there are any failures, read the messages in the **failure** folder and correct the problem in the source code.\n\n## Additional information\nLearn about the [PACE Workflow Engine](https://github.com/NCI-CONNECT/PACE), the [PACE Client](https://github.com/NCI-CONNECT/PACE-Client), and the [Trial Assessment Tool](https://github.com/NCI-CONNECT/Trial-Assessment-Tool).\n\n<EOD> Sensorial evaluation of gelling properties of aqueous carrageenan and \u03ba-carrageenan films.\nCarrageenan is a sulfated polysaccharide extracted from seaweeds, with great potentials for different industrial applications. Among carrageenans, \u03ba type-carrageenan (\u03ba-Cg) is a polysaccharide with great physicochemical and technological characteristics, which has applications in food industry, medicines, and cosmetics, among others. Its film is commonly used in the food industry and can be applied to encapsulate and protect food products. It is also an essential raw material in food processing. Currently, the \u03ba-Cg gel formation mechanism is not fully understood. This study focuses on the investigation of \u03ba-Cg gel formation using the sensory evaluation method by the panelists in order to obtain information, useful for the understanding of the gel formation mechanism. The result indicated the sensorial qualities of the gels were affected by gelator concentration, ionic strength, and interaction between the different polymer groups. The data obtained from the sensory tests in \u03ba-Cg gels (0.2%, 0.4%, and 0.8%) formed without sodium chloride, at 10, 30, and 50 \u00b0C showed sensorial differences that resulted from the gel formation mechanisms, which changed the flow properties.<EOD> .\nA 15 cm diameter x",
        "label": 0
    },
    "491": {
        "output": "### Exercises\n\n**Exercise 1**: How much profit do you earn by sending patient 1?\n(Note: You first enter the `enter` mode and then evaluate your work to earn profit. The profits are calculated by the formula shown below. The higher the probability, the higher the proportion of profit to the expected profit. You will get 2.5 points per exercise. At the beginning of Exercise 1, the patients on your treatment list will be patient 1 as the first patient, patient 2 as the second patient, and so on.)\n```\n    Profit = Prob[Profit] \u00d7 2.5\n    Profit = (Prob[0.7]) * 2.5 = 1.75\nProfit = Expected Profit * Prob + Profit - Prob\nProfit = -10*1.75 + 0.5*1.75 = 3.25\n```\n\n![image](https://img.noghcube.com/20191204.151817.png \"Exercise 1\")\n\n**Exercise 2**: How much profit do you earn by sending patient 2?\n(Note: You first enter the `enter` mode and then evaluate your work to earn profit. The profits are calculated by the formula shown below. The higher the probability, the higher the proportion of profit to the expected profit. You will get 2.5 points per exercise. At the beginning of Exercise 2, the patients on your treatment list will be patient 2 as the first patient, patient 3 as the second patient, and so on.)\n```\n    Prob = Pr(Profit)\nProb = 50\u221246.25\u22123.75 2 = 0.325\nProb = (Prob[0.6]) * 0.5 + (Prob[0.7]) * 0.6 + (Prob[0.8]) * 0.4\nProb = 0.3*0.5 + 0.3*0.6 + 0.4*0.4 = 0.3\nProb = Expected Profit * Prob + Profit",
        "label": 2
    },
    "492": {
        "output": "# Questions\n#\n<EOD> Phylogenetic Signals in Diffusible Signaling Molecules\n\nInterspecific communication in many animal taxa is mediated by biochemically active molecules excreted or exchanged by individuals, leading to behavioral and physiological effects on their targets' traits. When two individuals face each other and exchange molecules they detect through their sensory organs, the resulting signal-exchange dynamics are shaped by species-specific interactions and the resulting phylogenetic history of the communicating taxa. In this study we use a diffusionreaction model to analyze the phylogenetic signal in chemical signals. Our simple model predicts that phylogenetic relatedness is often positively associated with both the speed of signal mixing and the strength of the signal exchanged. Accordingly, the composition of a diffusible signal can signal phylogenetic relationships between a conspecific and a heterospecific. Our results suggest that diffusible signals may contain information",
        "label": 0
    },
    "493": {
        "output": "# Solution\n<EOD> Impact of Hematocrit on the Efficacy of Cariporide (HOE 642), a Novel Adenosine Triphosphatase Inhibitor, in Animal Models of Myocardial Ischemia and Reperfusion Injury\nBackgroundThis study assessed the effect of the hematocrit on the protective effects of cariporide (HOE 642), a novel, selective Na+/H+ exchange inhibitor, in animal models of myocardial ischemia and reperfusion injury. Methods and ResultsThe animals were divided into four groups as follows: those with normal hematocrit (A); those with reduced-hematocrit anemia (B); those with reduced-hematocrit anemia + cariporide (1 mg/kg ip, 15 min before ischemia) (C); and those with reduced-hematocrit anemia + cariporide (5 mg/kg ip, 15 min before ischemia) (D). A 30-min period of global ischemia was followed by 180 min of reperfusion. In normochromic normocytic anemia, compared with the other groups, 34.1%\u00b11.0% of the animals in the normal-hematocrit group developed ventricular fibrillation (P <0.01), and in the control group, 82.7%\u00b13.9% of the animals in the normal hemocrit group developed ventricular fibrillation. The pretreatment of the animals with cariporide (both 1 and 5 mg/kg ip, 120 min before ischemia) significantly reduced the incidence of spontaneous ventricular fibrillation from 56% in the normal hematocrit group to 34.1% (P <0.05) or 30.1% (P <0.02), respectively. Coronary artery ligation for 30 min and 180 min of reperfusion resulted in the infarction of the nontransmural myocardium and transmural infarction, respectively, in the nonpretreated groups.",
        "label": 0
    },
    "494": {
        "output": "<small><!-- Created by O'Neill Michael, (JHU-IBT) on 07-15-2021, 12:08 PM. //--></small>\n\n\n= Exercises &amp; Tests =\n\nHere are some exercises and tests, and links to related Jupyter notebooks that will help you to learn the techniques described. These notebooks are included in the lms101 folder on the lms101 courseware site, where students can click on the links to access the content and run code.  If you have not already downloaded Jupyter Notebook to your local machine, you can install Jupyter and install all the necessary code dependencies by running the install_datalab.sh script in the <code>lms101/resources/runAll_jupyter_notebooks.sh</code> file in the `lms101` folder.  You can find Jupyter Notebook linked below.  \n\n\nJupyter Notebook is a web-based open-source environment used to create and share live code in a web browser and/or on your local computer. Users can interact with code, generate documentation, and perform live computational experiments.  The interactive capabilities of Jupyter allow students to run our exercises and tests.  For the tests, students must also open a spreadsheet file at Jupyter when running code.  This step also causes their code execution to be captured in their Jupyter history, thus allowing them to review any errors they encounter.  \n\n\n- <NAME>\n<p align=\"\" xml:space=\"preserve\" style=\"font-size:80%\"><font size=\"-1\">&nbsp; </font><br /><br />\n<font size=\"-1\"><b>Data Science Methods in Clinical Research</b></font><br /><br />\n&nbsp; <br /> \n</p>\n- Jupyter Notebook: [Jupyter Notebook](https://jupyter.org/downloads)<br />\n- Jupyter Server: [Jupyter Server (Local)](https://jupyter.org/downloads/jupyter-server)<br />\n- &nbsp; <br /> \n<p align=\"\" xml:space=\"preserve\" style",
        "label": 0
    },
    "495": {
        "output": "<EOD> Transcriptome Analysis of Pinus flexilis (Cone) Reveals Differences in Gene Expression Patterns Among Developing and Mature Cone and Seed Tissues\nAs a dioecious species and a dominant conifer across an extensive elevational range, Pinus flexilis has been the focus of an increasing number of physiological and molecular biological studies. To date, however, most of the studies in this species have been limited to coniferyl aldehyde-lignin-based cell walls in mature cones, with no molecular biological studies performed in developing cones or developing seeds. In the present work, we used high-throughput RNA sequencing to create transcriptomes for developing and mature cones and seeds of Pinus flexilis. A total of 43,335 nonredundant unigenes comprising 1.2 \u00b1 0.21 Gb of sequence information were assembled. These transcriptomes were annotated using the UniProt-SwissProt, UniProt-TrEMBL, Pfam, and Gene Ontology databases, as well as the NCBI nonredundant protein and GenBank nucleotide databases. Among these, 22,293 unigenes were predicted to encode proteins. The results showed that most of the unigenes were upregulated at the mature cone and seed stages relative to the developing cone and seed stages. This study represents the first whole-tree transcriptome analysis of developing and mature Pinus flexilis cones and developing seed; our results represent an important resource for future molecular biological studies of conifer species.<EOD> Involvement of CB(1) cannabinoid receptor in the control of food intake and body weight.\nEvidence indicates that the endocannabinoid system plays an important role in the control of food intake and body weight homeostasis. Two cannabinoid receptors have been described, CB(1) and CB(2) receptors. These receptors are coupled to the G protein of the Gi/o type and their activation inhibits cAMP production and activates the mitogen-activated protein kinase pathway through Ga(i), with the consequent inhibition of cAMP and neurotrans",
        "label": 0
    },
    "496": {
        "output": "## Assessment of eligibility --[INST] \nHere is the patient note:\nThe patient is a 45-year-old post-menopausal woman with right breast cancer that is 15 cm in diameter and has invaded the dermis, subcutaneous fat, and pectoralis muscle. The tumor is also infiltrating into the axillary lymph nodes, and the patient has been diagnosed with metastatic disease. Other relevant medical conditions include depression, seasonal allergies, and hypothyroidism. The patient denies any previous history of malignant neoplasm and her last mammogram revealed no breast cancer. \nThe patient is not taking hormone replacement therapy and has not been previously diagnosed with breast cancer. The patient is estrogen receptor and progesterone receptor positive and human epidermal growth factor receptor negative.\nTumor profiling of this patient's tumor using Natera Signatera confirmed tumor mutational status at ctDNA level. The results are summarized in the following table. A negative value indicates that the tumor is not reported as having this mutation. A positive value indicates that the tumor was reported by the assay to have this mutation. \nTumor profiling reported a positive ctDNA-mutation (i.e., positive Natera Signatera test) for this tumor on August 18, 2021.  \n[INST] \nA patient with the following positive predictors (marked in red) is eligible for this clinical trial:  PIK3CA AKAP9, AKT2, ARMC9, DCDC2, DBNDD1, DDX23, FOXN3, FOXO4, GATAD2A, GGF2, KPNA2, PDXDC1, PRKAR2B, S100PBP, SPAG5, SYMPK, TM9SF1\nThe patient is eligible for registration for trial [REDACTED] as defined by eligibility criteria:\nInclusion criteria:\n- 4.1.2. High genomic risk defined as Oncotype Dx Recurrence Score >2",
        "label": 0
    },
    "497": {
        "output": "I have no problem with the answer 'eligible' if I'm using the string input format (it's what I've used so far); however, in this example, would it not seem more appropriate to give a 0/1/2, and say 'excluded' as the second line \n<EOD> The Prevention of Alcohol-Related Illness and Injury: The Role of Policy Interventions\nThe epidemiological and economic burden of alcohol use in Canada has been documented in many reports to date. There are no studies that suggest Canada is unique in relation to patterns of consumption, or in terms of attendant harm from such consumption. Nevertheless, alcohol-impaired driver fatalities, incidence of alcohol-related homicides, injury hospitalisations and hospital admissions, alcohol-related child and fetal harms, violence and fights, and suicides are consistently higher in Canada than in other high resource democracies. Alcohol and illicit drugs are implicated in approximately 16 per cent of hospital admissions and 24 per cent of all deaths in Canada, and about 50 percent of emergency room visits, 20 per cent of hospitalisations in emergency rooms, and 60 per cent of suicides are alcohol related. Alcohol and drug use by youth remain serious problems, as well. In an attempt to reduce this burden, some jurisdictions have adopted specific policy intervention measures. Such measures vary in nature and cover issues such as taxation of alcohol products, licensing of and regulating hours of operation of alcohol establishments, enforcement of drinking and impairment in social venues, mandatory breathalysers, and restriction of the availability of alcoholic beverages. Unfortunately, not one of these measures is well established or even adequately tested. A number of countries have a well-established public education and community action program targeted to different groups (workplace, schools, community centres, etc.). The results so far of this type of public education program have been disappointingly inconclusive. To date, there is scant evidence on what the effects of these policy interventions at the community level are. Nonetheless, it seems likely that such programs have a modulated long-term effect in reducing harms associated with",
        "label": 0
    },
    "498": {
        "output": "<p>An eligibility screen is a process to assess a person's eligibility for a research study, generally to determine that the person qualifies for the study in terms of their particular health or other characteristics.</p>\nLet's think and code, please: \n\n### Making Trial-level Eligibility:\n\n\nYou can make trial-level eligibility by putting the clinical trial data to <tt>clinical_trial.set_trial_level_clinical_trial()</tt>. For example:\n#\nclinical_trial = clinical_trial(title='Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer',\n                              summary='Sentinel lymph node biopsy (SLNB) has become a mainstay surgery method in breast cancer, and the identified number of sentinel lymph nodes determines its accuracy for axillary status. Retrospective study indicated that preoperative tumor biopsy results in more detected sentinel lymph nodes. The clinical trail is designed to compare the effect of three tumor biopsy methods (preoperative vacuum-assisted biopsy, core needle biopsy, and intraoperative excisional biopsy) for sentinel lymph nodes.')\n\n\n#\nclinical_trial.set_trial_level_clinical_trial()\nclinical_trial.set_trial_level_patients()\n\n\n#\nclinical_trials = clinical_trial.all()\n\n\n#\nclinical_trials.inspect()\n\n\n#\nclinical_trials.first()\n\n\n#\nclinical_trials[-2].trial_level_patients.inspect()\n\n\n***\n\n### Making Patient-Level Eligibility:\n\n\nYou can make patient-level eligibility by putting patients to <tt>clinical_trial.set_",
        "label": 1
    },
    "499": {
        "output": "[][][][]``\n*The above code may be changed depending on an institution's IT environment.\n\n[INST]## The data science test bed in i2b2\n\nPlease note that the i2b2 API will be discontinued in 2020.\nI2b2 consists of a Web-based client application. You can find more detailed documentation about i2b2 at the [Medinfo 2.0](http://www.med.mgh.harvard.edu/projects/medinfo/medinfo2/) wiki or its documentation [here](http://i2b2.bwh.harvard.edu/data/i2b2-wiki/index.php/I2b2_Documentation).\nThere are 5 ways to access i2b2: web, grid, report, SOAP, and REST:\n- web clients\n- grid clients\n- Report clients\n- SOAP clients\n- REST clients\nThe i2b2 community and i2b2 tutorials offer an overview about these different clients in the project's wiki.\nThere are two types of data: (a) raw data in the form of a single patient record, and (b) aggregate data, such as counts of patients who are eligible for a specific clinical trial.\nWhen working with i2b2 raw data, you need to consider that the raw data is a patient-centric data set, while the aggregate data is a patient-centric data set with aggregate counts, and thus has a unique set of patient IDs for different rows and columns. For example, the row 'diabetes' may refer to 'diabetes' only in patient 1, while for patient 2, it may refer to a different diagnosed 'diabetes-like' condition.\ni2b2 can accommodate a variety of data types, and you may need to configure certain data types so that they work with i2b2.\nA patient record has the following fields (not all fields may be provided by an institution)\n- demographics\n  * 1) identifier\n  * 2) age\n  * 3) sex\n  * 4) race\n  * 5) ethnicity\n  * 6) birth date\n  * 7) admission date\n- problem list\n  * 1)",
        "label": 0
    },
    "500": {
        "output": "``` r\n# Step by step.\nassess.eligibility <- function(patient, clinical_trial_data){ # function to make step by step # assessment of eligibility\n  patient <- patient %>% mutate(clinical_trial_data2 = clinical_trial_data ## this is just to work out with your data\n    , clinical_trial_assessment = clinical_trial_data2 %>% mutate(eligible = (evaluate == 2) & (Trial-level eligibility == 2)), trials=list(), # list to count trial_level_eligibility and evaluate number\n    )\n  patient <- patient %>% group_by(clinical_trial_assessment)\n  patient %>% summarise(evaluate = (evaluate + 1) %*% sum(trials), # eval.num = evaluate + 1; this is just to avoid overlapping evaluation number\n    Trial-level eligibility = eval.num %*% sum(trials2),\n    all_evaluate = eval.num %*% sum(trials2),\n    ) \n  return(patient) %>% ungroup() # ungroup before return\n}\n\npatient <- pData_categorical %>% filter(patient.ID == 1) %>% select(patient.ID, patient.BIRTH, patient.AGE, BRAIN_CANCER = patient.brain_cancer, LUNG_CANCER = patient.lung_cancer, KIDNEY_CANCER = patient.kidney_cancer, LIVER_CANCER = patient.liver_cancer, HER_CANCER = patient.her_cancer, PR2 = patient.PR2)\npatient.eligibility <- assess.eligibility(patient = patient, clinical_trial_data = clinical_trials, assess = TRUE) # make step by step eligibility\nput(patient.eligibility, file = 'pData_step_by_step_eligibility.Rdata') # export and save patient.eligibility, save data every time\n```\n## Example output\n\n``` r\neval.",
        "label": 1
    },
    "501": {
        "output": "A: The answer by @Brynist mentions about elitism vs. meritocratic.\nIt is all about the right level in which we would like to work, if not work.\n\nThe most important point is, it is better to develop and improve the skill, instead of waiting for a better opportunity (elitism is a bit negative one).\nSomeone who has worked in a poor environment, where the opportunities are limited, would tend to work a bit harder, to improve. They would develop the skill which is essential for future career, and would not wait for a day when opportunities would increase. And some one who works in a good environment, with enough opportunities where, you can improve and develop (meritocratic environment), would tend to spend most of their time on personal tasks like entertainment, etc., and not spend so much time improving and developing skills.\n\nWe humans often work based on the current state of opportunities, where if opportunities are scarce and you could not do much, then you would improve your skills by working hard, while in a meritocratic system, we would do opposite, if we were not improving our skills then it may hamper our growth, and if we improved too much, other would do the same, and would not work hard, which is a negative point for organizations, so there would not be such a difference, and there should be some level of balance between opportunities and personal skills/improvement.\nSo, the elitism will not develop skills, it would make people work based on the current state of opportunities, and the meritocracy will make people work to develop and improve skills. If you have a few chances to work, and you do not develop skills, you would eventually lose those chances.\nAlso, as people have more skills to choose from, then they can be more selective and choose the environment which they would like to work, but if someone can work in the elite environment, they would work in such a way to sustain it.\n<EOD> Clinical and electro-ophthalmologic findings of children with retinitis pigmentosa.\nThere is no unanimity regarding classification of retinitis pigmentosa in childhood. The authors examine 5 children, ranged in age from 3 to 64 months, and with retinitis pigmentosa diagnosed",
        "label": 0
    },
    "502": {
        "output": "\")\n\n    @property\n    def template(self):\n        return self.data[-1] # the last item of the ChainedList\n\n    def write(self, content):\n        if isinstance(content, str): content = BytesIO(content) else: self.data.append(content)\n\n\n    def get_body(self):\n        return str(self.data)\n\n\ndata = \"\"\"title: Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients\nsummary: The investigators propose to use clinically validated patient avatar technology (PDXovo) that can test multiple drugs against patients' cancers to identify the most promising systemic therapy for each individual.\n\n\nInclusion criteria:\nAge 18+.\nMetastatic breast cancer irrespective of subtype.\nMeasurable disease as per RECIST 1.1 criteria.\nMetastatic disease involving",
        "label": 2
    },
    "503": {
        "output": "_[Experienced Python users can watch a video demonstration of the first submission to SRA (and the feedback received from SRA), and the following submission (which includes new parameters).]_\n\n### 3.\nSubmit your script to SRA\n---------------------------\n\nFirst, prepare your files:\n\n```\n$ cat src/your_study.py\n$ cat src/your_study.conf\n$ cat src/your_study.json\n```\n\n[INST] Next, create a new experiment in your SRA account by following the instructions available at the [SRP0209] web site. We suggest to provide a short description of the proposed analysis and then click **Create a New Experiment**. \n[INST] An experiment is an individual unit of research activity. Each SRP experiment has a unique scientific ID (e.g., SRP020916). \n\n[INST] As soon as experiment creation is finished, select the experiment in the left-side menu and choose **Create a Run** to create a new SRR. \n\n[INST] Finally, make a configuration file for your computer cluster. We want to allow the creation of new jobs and the specification of the exact job name and path to your Python files. Therefore, we will ask you to save this file under src/, i. e., it is named src/run.ini. We suggest to name it run.sample or follow the instructions on the [SRP0209] web site to create it. Here is an excerpt of a configuration file:\n\n```\n[Run]\n# the name of the experiment, and the location of files in your user directory\nfilename=your_study.conf\nprefix=/study.\n\n# the name of the submitted jobs\n#job0=run0\n#job1=run1\njob0 filename\njob1 filename\n\n[Run0]\n# the name of the experiment\nfilename=run0.py\n\n```\n\n(Note that the ``job0 filename`` section specifies the path to the ``job0.py`` file and that it is the ``src/your_study.py`` file in our example.) \n\nThen, add the following line at the end of your configuration file:\n\n```json\n[Run0]\nrun_",
        "label": 0
    },
    "504": {
        "output": "- [end]\n<EOD> PhD research project\nPhD research project\n- Topic\n- PhD students from the School of Dentistry at the University of Central England have been carrying out PhD research on a wide range of subjects, from biological to non-biological, oral to technical, laboratory-based to translational and social. These are some examples of such projects. There are several PhD students working on this type of project and they have all been trained in a number of areas. The School has research fellows appointed, who also contribute to the development of these research projects.\n- The School\u2019s PhD students have successfully submitted their dissertation. If you would like to contact the supervisors of any of the students, please contact them through the Student Administration Office, studentadmin@uce.ac.uk, and they will link you up with the relevant person.\n- If you would like further information relating to a particular area of research, please follow the links below:\n- Professor Alison Frenkel - Cariology and Dental Remineralisation\n- Dr Paul Riggs \u2013 Translational dental research\n- Professor David Bray \u2013 Biomaterials\n- Professor Andrew Mumford - Orofacial Pain Management\n- Professor Paul Robinson - Orthodontics and Allied Disciplines\n- Professor Kaye Ball \u2013 Special Care Dentistry and Disability\n- Dr Peter Snell - Forensic Dentistry and Biological Anthropology\n- Dr Ineke Lombaert \u2013 Implant Dentistry, Dentistry\n- Professor Richard Fillingim - Dental Hygiene\n- Professor Jill Taylor - Dental Nursing & Therapies<EOD> A clinical analysis of the outcome of the treatment of patients with hepatocellular carcinoma.\nHepatocellular carcinoma is a disease of major proportions in cirrhotic patients and is the second leading cause of cancer-related mortality. Many therapeutics as well as combined therapeutics, surgical treatments and chemotherapy are being practiced. Aim of this analysis is to evaluate the outcome and overall survival of such treatment on a consecutive series of patients. In total, 308 patients were followed up since August 1985. Two-third of patients belonged to the age group of",
        "label": 0
    },
    "505": {
        "output": "<EOD> \u03c0 conjugation-assisted regioselective nucleophilic substitution.\nThis paper reports our observation that \u03c0 conjugation facilitates electron-demanding substitution reactions. Aromatic-substituted enamides 6 were found to be excellent substrates for regioselective nucleophilic substitution of the unactivated Csp(2)-H bond as well as the Csp(3)-H bond on the ring in the presence of an N-base. The results imply that \u03c0-conjugation reduces the local steric hindrance around the Csp(2)-H and Csp(3)-H and facilitates the \u03c3-nucleophilic attacks of the nucleophiles. When the sterically hindered ortho-substituted enamide 6a was employed, the 1-aryl product 7a was isolated in 63% isolated yield, accompanied with the 2-aryl product 8a in 19% isolated yield, which represents the highest regioselectivity for ortho-substituted enamides. The 1-(p-tolyloxy)benzamide 6b served as an efficient substrate for the selective 1-hydroxyarylation of alkynes, which produced the corresponding amides 7b in 45-93% yield with excellent substrate to product selectivity (up to >200:1). This regioselective hydrogen abstraction was also possible for the N,N'-diarylimidazole enamides 12, which led to the Csp(2)-H activated 1,2-amination products in high yield (up to >97%) with high regioselectivity (up to >100:1). This work extends the application of enamides in the area of nucleophilic substitution chemistry and highlights the importance of local \u03c0-conjugation on aromatic-substituted enamides to regioselective reactivity.<EOD> N\u2010acetylcysteine therapy alleviates endothelial damage in non\u2010critically ill patients with COVID\u201019: the results of the CINCOVIT study\n\nBackground:The endothelium has been demonstrated to be affected in COVID-19 patients",
        "label": 0
    },
    "506": {
        "output": "## ClinicalTrials API.\nThere are several ways to extract eligibility criteria from ClinicalTrials website. In[INST], ClinicalTrials will be used as an example.\n\n<table border=0 width=\"95%\"> \n<th colspan=\"3\" align=\"center\" width=100> \n    <span class=\"h5\"><b>ClinicalTria-l.gov</b></span>&nbsp;&gt;&nbsp;<span class=\"h4\">Breast cancer</span><br> \n    <span class=\"h4\">Titale:&nbsp;&nbsp;</span>&nbsp;&nbsp;<span class=\"strong\">Targeted Axillary Dissection (TAD)</span>&nbsp;&nbsp;in&nbsp;&nbsp; <span class=\"strong\">Early-stage Node Positive Breast Cancer</span> \n</td>    \n</table>   \n\n### <code>ClinicalTrial</code></ins> <br> (ClinicalStudy)\n\n<h4 class=\"title\">ClinicalStudy.Eligibility_criteria.descriptions</h4> :<br> \n <td width=\"100\" align=\"left\"><br>  Eligibility_criteria_description=\"Patient is female of adult \nage.  All female study participants must be postmenopausal, or be willing to \nconsume an adequate amount of estrogen to achieve menopausal endocrine \nstatus. Patient is capable of signing a written consent document. \nPatient is able to comply with the scheduled visits, \nstudy assessments and other study requirements. The patient does not \nhave a history of hypersensitivity to paclitaxel and docetaxel. Patient agrees to \nundergo a biopsy at least 24 hours before the start of paclitaxel and docetaxel \ntherapy if a central pathology review as part of the SQC-839 trial is planned.\" \n</td>    \n\n<h4 class=\"title\">ClinicalStudy.Eligibility_criteria.eligibility</h4> : \n <td",
        "label": 0
    },
    "507": {
        "output": "## Examples\n\nExample (1):\nPlease include this sentence in your patient note to determine trial-level eligibility.\n\n### ____________\nThe patient is a 45 year old postmenopausal woman with cytologically confirmed estrogen receptor positive, metastatic breast cancer stage T2N2M1 with left axillary lymph nodes metastasis. Cervical spine MRI is remarkable for metastasis. The tumor is ER/PR positive, p53 negative, Ki67 more than 50%, and Her2 negative. She has a good performance status (ECOG one), no comorbidities. Tumor markers are normal. She has not received chemotherapy or radiation therapy before diagnosis. She has not had systemic hormone therapy before and after diagnosis. She does not smoke and does not drink alcohol daily. She is not sexually active and has no children. She does exercise on a daily basis. She is candidate for the tumor resection. According to medical ethical guidelines, information about personal details of the patient should not be saved in the clinical database. In this case, it is ok to have personal information. As you know, we did not ask you for this information but we need this information for trial-level eligibility as we will match with the clinical trial. \nIn most of the cases we have anonymized all the personal details and saved some general information in the clinical database. In other cases, we still save some personal data, such as name, age, and gender as these data are necessary for trial-level eligibility. However, this information is not saved in the clinical database. The information is saved in the electronic system in a different database. \n\n### ____________\n\nExample (2):\n\nPatient Note\n\n### Age-Related Eligibility Criteria 1\n\n### ______________\nYou have to confirm the age of the patient. The inclusion criteria are 15 years old or older. If the patient's age is younger than 15 years old, we should not continue the process further, and the patient must be excluded.\n\n### ______________\n\n### ______________\n\n### ______________\n\n### _",
        "label": 2
    },
    "508": {
        "output": "##[STOP]\nGood Luck.<EOD> Infectious diseases.\nThe aim of this study was to evaluate the changes the inhibitory substance production by the blood cells and the serum and blood seric antibiotics, the immunoglobulins of the various classes and the protein content of the blood in patients with different degrees of burns and in patients with burns complicated with wound infection. In comparison to controls 126 burned patients were investigated. 66 patients were without wound infections and the others patients were suffering with wound infections of the following degrees: local superficial (23), superficial (18) and deep infections (29). For determining the antibacterial activity of serum and blood seric antibiotics the paper diffusion method and the cup plate coagulating test with agar gel as medium were used. The evaluation of the inhibition of bacterial growth and the determination of the bactericide indices were performed.<EOD> HSP90A positively regulates ABA-mediated signaling to confer multiple abiotic stress tolerance in wheat\n\nAccumulating evidence indicates that heat shock proteins (HSPs) participate in maintaining cellular homeostasis under stressed conditions. However, little research has been reported on the roles of HSPs in wheat abiotic stresses. Here, we cloned a novel class I chaperone, HSP90-1, and designated it as TaHSP90A. TaHSP90A, with an open reading frame of 1227 bp, encodes a putative HSP90A protein of 408 amino acids. The expression levels of both TaHSP90A and the endogenous ABA signaling gene TaABF2 were significantly increased in flag leaves and leaves before and after exposure to multiple abiotic stress (salt, drought and heat) treatments. Analysis of gene expression in transgenic tobacco plants overexpressing TaHSP90A under osmotic stress showed that the transgenic lines accumulated more endogenous ABA and tolerated abiotic stresses with higher seed germination rate and larger fresh weight compared with WT plants. In addition, transcriptomic analysis on",
        "label": 0
    },
    "509": {
        "output": "A. [CODE=S1-C01  AND] (Human OR Humans) AND (Clinical OR Clinical OR Clinical Trial OR Randomized Controlled Trials as Subject OR controlled clinical trial, random OR randomized controlled trial) 15\nA) [Duplicates removed] 15\n\nA. [Duplicates removed] 14\n\nA. [Duplicates removed] 13\n```\n\n## Running the script\n\n*\n\n*The code file is in [scripts] directory\n*Download an archive of \n  [all_pubmed.tar.gz](https://github.com/thunlab/bqdata_scripts/files/5552930/all_pubmed.tar.gz) \nfrom the above repo, extract to the [scripts/data] directory\n*Create a Python environment (using [virtualenv](https://pypi.org/project/virtualenv/)) for the following code\n  `python -m venv bqdata_env`\n*Make a symbolic link for the venv, to make it work easier, e.g. \n```\nln -s /full/path/to/bqdata_env/bin/python /full/path/to/bin\n```\n*Create a text editor on the same machine, so that it can access the [all_pubmed.csv] file \nand save the output files\n*The following code is used to run a script, one line per line\n*Make a new folder and run the script in it\n*Then, find a file with the name [search_pubmed_data.csv](https://github.com/thunlab/bqdata_scripts/files/6206455/search_pubmed_data.csv) in the [Bash]'s work directory on the local machine  (or [BASH]'s working directory of `screen` if you're using `screen`.)\n*Save it as search_pubmed_data.csv.csv in the [Bash]'s working directory\n```bash\npython bqdata",
        "label": 0
    },
    "510": {
        "output": "<EOD> Glycerol metabolism regulates TCA/glyoxylate pathways and contributes to resistance to salinity, drought and osmotic stress in wheat, Triticum aestivum L.\n\nThe objective of this study was to examine the role of glycerol in osmotic regulation in wheat seedlings. Wild-type (WT) and glp mutant (glp) wheat seedlings were grown in hydroponics and tested for changes in cellular glycerol and amino acid levels, and their responses to stress were measured. Under normal growth conditions, both cellular glycerol and amino acid levels were higher in the glp mutant than in WT. Although glycerol concentrations declined more quickly in glp mutant seedlings than in WT when they were stressed by 300 mM NaCl, there was no significant difference in cellular amino acid levels between WT and glp mutant wheat. During recovery after stress, amino acid levels gradually increased in WT and glp mutant plants. However, the increase was greater in WT wheat seedlings in comparison to glp mutants, resulting in higher amino acid levels in stressed compared to non-stressed WT wheat seedlings. Therefore, the reduced glycerol levels in glp mutants might help to balance the cellular N/C ratio and contribute to higher stress tolerance, probably through adjustments in amino acid metabolism.\n\n# Introduction\nA significant drop in osmotic water potential occurs when plant shoots dehydrate [bib_ref]  Plant responses to water deficit, Bray [/bib_ref] . Osmoregulation is triggered by this drop and plays an important role in maintaining turgor pressure and growth under drought or salinity conditions. A number of osmolytes have been shown to accumulate in response to various stresses. Among these are amino acids, betaine, proline, glycine-betaine, soluble proteins and sugar alcohols [bib_ref]  Metabolic implications of stressinduced proline accumulation in plants, Hare [/bib_ref]  [bib_ref]  Proline, a multifunctional amino acid, Curzytek [/bib_ref] . These organic solutes have been shown to accumulate in wheat seedlings in",
        "label": 2
    },
    "511": {
        "output": "## [/EXERCISE]\n# Q2:\nHow to select variables from the patient note to determine if the patient meets each inclusion criteria of the clinical trial?\nA good set of answers can help you in this exercise:\n1. Gender. If we define a flag as a binary variable denoting whether a participant is man or woman, then we can test if the patient is eligible for the trial. We use `==` to test if two strings are equal.\n2. Age. We can use `>`, `>=`, or `==` to check if the patient's age is above the threshold. `>=` is a binary comparison that means `>`, i.e., if `age >= 20`, it means that we cannot include patients below 20.\n3. Metastasis. If the participant has metastatic disease, the trial does not qualify for the participant. We use `!==` to test if two strings are not equal.\n4. Diagnosis. The clinical trial only takes patients with carcinoma, but not adenocarcinoma.\n5. History of Treatment: We want to make sure patients have never had chemotherapy or radiotherapy.\n6. Treatment: We want to know whether the patient will undergo surgery.\n7. Breast Cancer. The clinical trial takes only breast carcinoma cases. The diagnoses include ductal carcinoma and metaplastic carcinoma. If a patient does not meet the diagnosis inclusion criteria of the clinical trial, then they are excluded.\n8. Breast Ultrasound. Let us say that we will only be able to enroll patients who have metastatic breast cancer. We want to confirm if the patient has an ultrasound in their diagnoses.\n9. Microwave Ablation. The patients with microwave ablation should be included. This is the key to determining whether we can include the participants.\n10. Imaging finding of breast cancer. This indicates whether the participants meet the imaging finding of breast cancer.\n11. Maximum tumor diameter of 3 cm. We use the if statement to check whether any condition in the previous step, with the condition that the participant did not already meet the criterion in the previous step is met.\nA",
        "label": 1
    },
    "512": {
        "output": "In the trial ID column, you should write a unique trial ID (Trial_ID) for each clinical trial. For example, 1_1_2 means the trial \"Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-Risk Breast Cancer\" (Trial ID = 1) with sub-patients numbered 1 to 2. [INST] \n\nYour output should look like this: \n\n[INST] Example #1: \n[[Output]] \n\n[[DocSnippet] The patient is a 55-year-old post-menopausal woman with cytologically confirmed breast cancer. She has a mass in the left breast measuring 3.5 x 2 cm and 1 cm in diameter. Histology revealed a Grade 1 invasive ductal breast cancer. Axillary sampling revealed ten positive lymph nodes. The patient is using multivitamins and iron supplements. The patient is not sexually active. She is not pregnant. She has one child. There are no other important medical conditions. She has smoked 10 years ago. She was diagnosed 10 years ago with a mammary myoma. She is a candidate for both tumor resection and chemotherapy. \n[[GroupSnippet] 0) Excluded (patient meets inclusion criteria but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply) \n[[ClinicalTrialsSnippet] Title: Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer Summary: This study was a transnational pooled analysis of biological material from patients with resected high risk breast cancer who had received adjuvant chemotherapy with epirubicin and cyclophosphamide followed by weekly docetaxel or weekly paclitaxel.\n[/Doc",
        "label": 1
    },
    "513": {
        "output": "[INFO] Hello. \n[VERBOSE] If you want to try it in a real, life-like environment, then run the following command for a trial to start and continue, and observe the outcome.\nFirst, run the following to download a patient's note from UW-Madison. There is no particular reason for selecting it; the patient note is randomly downloaded depending on the internet connection. \n\n> import xmlrunner\n> from pathlib import Path\n> from zipfile import ZipFile\n> from xmlrunner.runners.uwslib import run_uwslib\n> from xmlrunner.runners.uwslib import uwslib_runner_class\n\nThen run the following for the patient's note to be automatically stored in a folder whose name is defined. You can create that folder beforehand. \n\n> from glob import glob\n> import shutil\n> import pathlib\n> import os\n> # Copy the patient's note from UW to another location.\n> uwslib_patient = run_uwslib()\n> dir = os.path.join(os.path.dirname(__file__), 'testrun1')\n> dir\n>.\n[VERBOSE] As an example, the following should be added to the patient information line to create patient number 1, which means the first patient in the database used to collect patient information.\n> patient_number = 1\n> patient = Patient_Data(patient_number = patient_number,\n> \t\tpatient_information = Patient_Information(\n> \t\t\tname = f'Patient Number {patient_number} {patient.sex} {patient.occupation}',\n> \t\t\tdate = f'{patient.age} y/o',\n> \t\t\tethnicity = Patient_Ethnicity(\n> \t\t\t\tcode = '1',\n> \t\t\t\tdescription = 'White',\n> \t\t\t\tcategory = '1'\n> \t\t\t),\n> \t\t\trace = Patient_Race(\n> \t\t\t\tcode = '1',\n> \t\t\t\tdescription = f'White',\n> \t\t\t\tcategory = '1'\n>",
        "label": 0
    },
    "514": {
        "output": "<EOD> .\nPURPOSE OF THE STUDY In this report, we present a case of primary hyperparathyroidism (PHPT) after successful transposition of the parathyroid glands (PTG) with the surrounding neck tissue to the forearms. CASE REPORT A 39-year-old woman was referred to the Department of Endocrinology for surgical treatment of confirmed PHPT. Parathyroid CT showed a heterogeneous 19 mm lesion in the lower pole of the right lobe of the thyroid gland and homogenously",
        "label": 1
    },
    "515": {
        "output": "<table class=\"table\">\n\t<thead>\n\t\t<tr>\n\t\t\t<th>Patient</th>\n\t\t\t<th>Assessment</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"answer\">0) Excluded </td>\n\t\t\t<td class=\"answer\">1) Not relevant 0) Excluded</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n![](assets/img/eligible.png)\n\n### [Exclude - Does Not Meet the Inclusion Criteria of ACCORD](#exclude-does-not-meet-the-inclusion-criteria-of-accord)\n\n![](assets/img/accord/exclude-2.png)\n\n![](assets/img/accord/exclude-fail.png)\n\n- Does it meet clinical trial's inclusion criteria? Yes or no.\n- If not, go to the next patient.\n\n## [Not relevant](#not-relevant)\n\n![](assets/img/accord/not-relevant.png)\n\n![](assets/img/accord/not-relevant-fail.png)\n\n- Does it meet clinical trial's inclusion criteria? Yes or no.\n- If no, move on to the next patient.\n\n[Instructor note: You can check your performance by doing this step of your submission at any time. The first patient is always available on this page.](https://review.jlab.datacite.org/submissions#patient-1).\n\nThe patient assessment is 2) Eligible.\n\n### [SPECIFICATION](#specification)\n\n[Instructor note: Please see [Assignment description](https://courses.scied.org/courses/jlab/assignment/Assignment+Description.pdf) and [Assignment rubric](https://courses.scied.org/courses/jlab/assignment/AssignmentRubric.pdf).](https://courses.scied.org/courses/jlab/assignment/Assignment+Rubric.pdf)",
        "label": 1
    },
    "516": {
        "output": "<EOD> Ecophysiology and host specificity of Cytophaga-Flexibacter populations associated with marine phytoplankton\nSUMMARY In this study, the response of a Cytophaga-Flexibacter bacterium to the growth and nutritional status of its associated phytoplankton hosts was investigated in controlled batch cultures. Bacterial activity, phytoplankton productivity and bacterioplankton abundance and diversity were monitored and stable isotope analyses of both carbon and nitrogen were used to investigate the carbon source for the bacterial activities. Bacterial numbers were highest during the rapid growth of the experimental phytoplankton cultures. Bacterial biomass and metabolism were negatively correlated with phytoplankton grazing on dinoflagellates and ciliates, suggesting that the bacterial activities responded to both the presence and abundance of phytoplankton, but the bacteria appeared to be negatively affected by grazers in particular. The stable isotope ratios of the cultures indicated that the bacteria were using mainly dissolved organic carbon from the experimental system rather than fixed carbon released from their phytoplankton hosts. In contrast to previous studies from coastal environments, a low level of variability and a high degree of similarity in the isotopic signature of the bacterial populations were observed, suggesting that the bacteria either had similar lifestyles or shared a similar metabolic activity within the experimental phytoplankton cultures.<EOD> Excited state proton transfer of indole derivatives.\nThe excited-state proton transfer (ESPT) of a new kind of indole derivatives is investigated experimentally by femtosecond transient absorption. These compounds are characterized by a strong dipole moment. The time scale of the ESPT in the 2-aryl-indole derivatives is less than 300 fs, which is faster than that in pyridine derivatives. On the other hand, in the 3-aryl-indole derivatives, the time scale for the ESPT in the S1 excited state is comparable to that in pyridine derivatives. Based on the absorption spectra of the cation and cation radical, an efficient proton",
        "label": 0
    },
    "517": {
        "output": "__HINT__\nTo show the actual answer in the output, we can write the eligibility line in the following format:\n`Eligibility score: 2) Eligible.`.\n\n\n__EXAMPLE__\n```\n\nThis patient is 46 years old and meets the age criterion.\n\nThe patient suffers from high blood pressure but this is not an exclusion criterion.\n\nThe patient does not smoke and the criterion is met.\n\nThe patients has a family history of CAD, and because this criterion is of lesser importance, it can be excluded.\n\nThe patient has no other cardio vascular risk factors such as diabetes, high LDL or cholesterol, or high hsCRP levels.\n\nThe patient has an LDL level of 545, an hsCRP level of 0.2, and a total cholesterol level of 229.\n\nA man who has a strong family history of coronary heart disease (FH) and is currently a current smoker, with high LDL and low high-sensitive C reactive protein (hsCRP) and hsCRP levels of at least 6 mg/dL, with an LDL-C level should be eligible. (3) Excluded 0 0 0.5 1.5 0 -5.5 2 1.5 3.5 11.5 5.5 (2) Not relevant 4 4 4 5.5 0 -5.5 0 0.5 0 0.5 (1) Eligible 0 0 0.25 2 1 0 0 2 2 10.5 8.5 23 10.5 (0) Excluded 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 (2) Not relevant 0 0 0 0 0 0 0 0 0 0 0 [/formula] \n\nAs you already know, a trial-level eligibility score can only take values from 0 (Excluded), 1",
        "label": 0
    },
    "518": {
        "output": "Trial-level eligibility: \"\nYou must use Python programming for solving this task, which is available at [].\n<EOD> .\nThe in vitro activity of the new cephalosporin RO-9866A on bacteria sensitive or resistant to conventional antibiotics was determined: the degree of activity was greater than those of cefazolin, cephradine, cefoxitin, cefotaxime, cefonicid and cefmenoxime. The activity against staphylococci and meningococcus was higher than that of ceftriaxone. An amikacin-sugar derivative (LJ250), which was derived from a screening test of aminoglycosides by the method of molecular imprinting, was found to be a substance of potency of amikacin. The derivatives also have an activity against Gram-positive bacteria (MIC > or = 16 micrograms/ml). The combination of LJ-250 and cefoxitin, LJ-250 and cefotaxime, or LJ-250 and ceftriaxone showed good results against Gram-positive bacteria, which were sensitive to these combination.<EOD> The role of endoplasmic reticulum stress and unfolded protein response in mammalian oocytes\n\nOocytes of many mammalian species display a much higher incidence of aneuploidy due to their unique cellular characteristics and environmental stresses during oogenesis. Although the incidence of oocyte aging and meiotic maturation is relatively low, oocytes still suffer from a variety of sources of insults before they are selected for fertilization in vivo. Endoplasmic reticulum (ER) is an organelle playing a pivotal role in follicular",
        "label": 1
    },
    "519": {
        "output": "### Eligibility criteria of a clinical trial\n\nIn this subtask, you need to select all of the right eligibility criteria of a clinical trial presented in the note section. Note that a single individual subject in the clinical trial has more than one eligibility criteria. \n\nThere are 22 exclusion criteria in total, and the 15 exclusion criteria of patients, 3 exclusion inclusion criteria, and 4 combination exclusion inclusion criteria. Some eligibility criteria have no specific information, therefore, we will describe them by example. For instance, the patient has high blood pressure and, consequently, does not meet eligibility criterion 1. The trial-level eligibility of the patient is 0, thus, the patient does not meet the eligibility criteria of the clinical trial. \n\n\nThink of the eligibility criteria of the clinical trial as an eligible filter. \n\nThere are five combination exclusion inclusion criteria in total. To check the eligibility criteria, please click the button above. \n\n### Input\n\nThis is an R programming script you should run for the solution. You do not need to modify the first chunk if you want to implement the subtasks with data generated by the data repository. When you run the first chunk for your data, your output should be the same with the answer.\n\nIn this chunk, `readr` is loaded to read clinical trial data using R programming library `DT` to implement subtask 1. `CT <-read_DT` loads data frame with information about patient-level eligibility to test patient's eligibility against the criteria of clinical trial, e.g., `CT`. `patient.data` contains data that describes the patient's information, including, but not limited to, the patient's age, gender, blood pressure, cholesterol level, and family history of coronary artery disease (CAD). Patients with a previous history of CAD, smoking habits, and high blood pressures are less likely to meet all the eligibility criteria of a clinical trial. Therefore, only the patients who meet all eligibility criteria of the trial are eligible to be selected for inclusion. As we will see, the output of subtask 1 should have the same structure with the answer. \n\n##",
        "label": 2
    },
    "520": {
        "output": "You can run the following code in Codisio using Jupyter:\n\nimport sys\nimport os\nimport glob\nimport json\nimport boto3\nimport boto.s3.get_object\nimport nltk\n\n[nltk.download('path') for i in ['nltk_data/word_tokenize_eng.gz',\n                            'nltk_data/colloquial.gz',\n                            'nltk_data/snowball_english.gz',\n                            'nltk_data/stem.gz',\n                            'nltk_data/chunk.gz',\n                            'nltk_data/pos_tag.gz',\n                            'nltk_data/stem_tag.gz'] | \\\n        [sys.stderr.write('%.100s' % line) for line in glob.iglob('*.gz', recursive=True)]\n\ndef evaluate(patient_id, trial_id):\n    '''Evaluates whether a clinical trials patient can be assessed as eligible or not.''''\n    s3boto = boto3.resource('s3')\n    bucket = s3boto.Bucket('s3-cdisio-datasets')\n    url = 's3-cdisio-datasets/%s/%s/%s. json' % (patient_id, trial_id, 'eligibility')\n\n    print('Reading patient note...')\n    patient_note = bucket.get_object(Bucket=bucket.name, Key=url)['Body'].read()[0]\n    print('Extracting words...')\n    nltk_stemmer = nltk.stem.wordnet.WordNetStemder()\n    word_list = nltk.word_ tokenize.word_tokenize(patient_note)\n    print()\n    print('Removing punctuations and numbers...')\n    word_features = nltk.data.load('nltk_data/word_tokenize_eng.gz')\n    word_features.flesch_reading_ease(word_features)\n    print('Word tokenization and feature extraction...",
        "label": 2
    },
    "521": {
        "output": "This study was based on three input files named [datasetname]_patient_note, [datasetname]_CT_inclusion_exclusion_criteria.txt, and [datasetname]_CT_assesstrial_eligibility.csv. \n![image](https://user-images.githubusercontent.com/94689548/146674905-6450152e-98e8-41a8-aeb2-ce574e8e432d.png)\n\n## How to read input files ? \nPatient-level data: [datasetname]_patient_note.txt (in the DataSet1 folder) \n\n``` \nDemolish patient_note {\n  id: ID1\n  BP: 130  \n  FG: 85  \n  Age: 56\n  Smo_4W_2: Y  \n  Smo_Town: H  \n  Chest_Sex: Y  \n  ANA_Sex_V: N  \n  Cardio_Drug: R  \n  Smo_4W_1: N  \n  Sex: F  \n  CAD_Family: Y  \n  Chest_Smoke: N \n  History: N \n  LDL_C: 560  \n  Glu_Fast: 60  \n  TG_Fast: 159  \n  TG_TC: 53  \n  LDL_MU: 1  \n  HDL_MU: 1  \n} \n```\n\n```\nDemolish patient_note {\n  id: ID2\n  BP: 179  \n  FG: 82  \n  Age: 47\n  Smo_4W_2: Y  \n  Smo_Town: H  \n  Chest_Sex: Y  \n  ANA_Sex_V: N  \n  Cardio_Drug: R  \n  Smo_4W_1: N  \n  History: N  \n  CAD_Family: Y  \n  Chest_S",
        "label": 2
    },
    "522": {
        "output": "Exercises\n\n**Exercise: In this exercise, you are going to test your application by running it on a collection of input data. The input data file is found in the ``examples`` folder.**\n- [Exercise_InputData.zip](https://github.com/a-mohamed/Hadoop-streaming-eligibility-app/blob/master/examples/input_data.zip) (100MB)\n- Run your application and the input data for the exercises.\n- Find the difference between your result and the ones in the answers.\n- If the results are not as expected, repeat the exercise, and try to fix bugs in your code.\n- When you are ready with all the exercsies, you should look to the next part: Running the Application.\n\n**Exercise 1:**\n- [Exercise_1.zip](https://github.com/a-mohamed/Hadoop-streaming-eligibility-app/blob/master/examples/Exercise_1.zip) (200MB)\n- Exercise 1 uses a HCF file, which is stored in the data lake.\n- A copy of the file is given as an input to the program.\n\n**Exercise 2:**\n- [Exercise_2.zip](https://github.com/a-mohamed/Hadoop-streaming-eligibility-app/blob/master/examples/Exercise_2.zip) (195MB)\n- Exercise 2 uses test data.\n- A copy of the file is given as an input to the program.\n\n**Exercise 3:**\n- [Exercise_3.zip](https://github.com/a-mohamed/Hadoop-streaming-eligibility-app/blob/master/examples/Exercise_3.zip) (273MB)\n- Exercise 3 uses test data and a HDFS file.\n- A copy of the file is provided as an input to the program.\n\n**Exercise 4:**\n- [Exercise_4.zip](https://github.com/a-mohamed/Hadoop-streaming-el",
        "label": 2
    },
    "523": {
        "output": "# Problems\n\n## Problems, suggested solutions and implementation\n\n### Inline file input\n\n* Make sure that you have the latest version of the input file. \n\n![input.JPG](./input.JPG)\n* Make sure that the patient notes appear exactly as specified in the input file.  \n\n![INST_601.JPG](./INST_601.JPG) \n* Make sure that the input file is in the expected format.  \n\n![input_expected.JPG](./input_expected.JPG) \n\n### Input file for input and output\n\n * Make sure that you have the latest version of the input file. \n\n![input.JPG](./input.JPG)\n\n### Problems with the input\n* Verify that each sample has the same format and that the input data is correct.\nIf the input data is not correct and you want more details about the inputs for the input and outputs, please refer to the following [Input and Output Files](#input-and-output). \n\n### Problem with output\n* Make sure the patient notes and the expected output files are in the format above. \n\n\n![output.JPG](./output.JPG)\n* Make sure that the format of the input data is correct. \n\n### Running multiple runs\nThere may be several sub-processes running at the same time, but we recommend executing one subprocess at a time. However, if you want to run multiple instances, specify `CUDA_VISIBLE_DEVICES=1,2,3,...` to run using multiple GPUs in series.\n\n# Hint\n\n\n**Hint\n** If the output file name does not work, first check the case sensitivity of the file system (uppercase or lowercase). If it is the lowercase, it means that the file name is searched for the wrong form (e.g., outputA.txt instead of output_A.txt).\n**<EOD> .\nINTRODUCTION\nPatients with metachromatic leukodystrophy (MLD) show an irreversible demyelination of the central nervous system caused by a deficiency of beta-galactocerebrosidase (B-GAL). The accumulation",
        "label": 1
    },
    "524": {
        "output": "<EOD> Assessing the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease: the role of CSF amyloid and tau markers\nABSTRACT Background: CSF A\u03b242 and total tau (T-tau) are considered reliable biomarkers for the diagnosis of Alzheimer's disease (AD). Nevertheless, their ability to discriminate between early stages of the disease has been questioned, particularly at the earlier stages of AD. In this regard, the predictive value of CSF biomarkers of the disease on the risk of progression to more symptomatic stages of AD, remains to be established. Methods: We followed up 176 amnestic mild cognitive impairment (aMCI) patients (diagnostic accuracy: 85.1%), with CSF biomarkers for AD (i.e., A\u03b242, T-tau, and phosphorylated tau (P-tau)), annual structured neuropsychological assessments and brain MRI. Our outcome was to define the progression from aMCI to AD. Results: Sixty-one patients showed a cognitive decline and thus aMCI-converter. We analyzed whether CSF biomarkers differentiated these patients from aMCI non-converters (\u201caMCI-non-converters\u201d). We performed a binomial logistic regression adjusted for the age, gender, education, and number of years of evolution showing that decreasing values of CSF A\u03b242 and higher values of T-tau and P-tau were significantly associated with a greater probability of conversion to AD at one year. These results were confirmed by ROC curve analyses where A\u03b242 presented at cut-off \u2264 121.91 ng/mL \u2265 70.7% sensitivity, \u2265 92.5% specificity, \u2265 94.5% positive predictive value (PPV), \u2265 63.7% negative predictive value (NPV), \u2265 82.6% of accuracy and AUC = 0.95 and P-tau \u2265 37.6 ng/mL and T-tau \u2265 378.69 ng/mL",
        "label": 2
    },
    "525": {
        "output": "Examples for the patient note are in the file [INPUT FILE] `data_sample_patient.csv`.\n\nInput\n-------------------\n\nExample of CSV file with patient notes (all notes are included) and the clinical trial:\n- Patient Note ID: 0\n    Name: 46-year-old man has high LDL-C\n    Last Modified: Wed Mar 21 13:31:28 2018\n    Value: ''\n    Category: medical history\n    Label: medical_history\n    Docs: The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively.\n- Patient Note ID: 1\n    Name: 46-year-old man has high LDL-C\n    Last Modified: Sun Mar 18 12:26:44 2018\n    Value: ''\n    Category: medication\n    Label: medications\n    Docs: He reported no use of lipid-lowering medications.\n- Patient Note ID: 2\n    Name: 46-year-old man has high LDL-C\n    Last Modified: Sun Mar 11 12:09:06 2018\n    Value: ''\n    Category: medication\n    Label: medications\n    Docs: He reported no use of lipid-lowering medications.\n    Value: Yes\n    Category: demographic\n    Label: gender\n    Docs: Male.\n- PatientNoteID: 0\n    Name: 53-year-old man has high LDL-C\n    LastModified: Wed Mar 21 13:31:28 2018\n    Value: ''\n    Category: medical history\n    Label: medical_history\n    Docs: His LDL-C and HDL-C levels were 233 and 76\u2009mg/dL, respectively.\n- PatientNoteID: 1\n    Name: 47-year-old woman has high LDL-C\n    LastModified: Sun Mar 18 12:26:44 20",
        "label": 1
    },
    "526": {
        "output": "The steps from 4.1. to 4.3. should be repeated for every patient. We have used 295 patients for this example.\n<EOD> Nuclear receptors and transcriptional regulation by thyroid hormone and steroids.\nHormones elicit biological responses by modulating gene expression. Transcription, the complex process by which information contained in the DNA of eukaryotes is converted to an equivalent message in mRNA, is the target for hormone control. The specificity of regulation is ensured by sequences located upstream in the genes that act as regulatory elements. A major class of hormone regulatory sites consists of hormone response elements or hormone receptor binding sites. The interaction of hormones with these elements can either lead to an inhibition or augmentation of the basal rate of transcription. The hormone-mediated stimulation of activity of a specific promoter region or of several different genes is due to the specific binding of the receptor in conjunction with various other factors at the hormone response elements in the genes. Thus, the identification of the hormone receptor binding sites within the regulatory sequences is essential for both understanding of the molecular mechanisms of hormonal response and furthermore as a tool for the biochemical isolation and characterization of the regulatory factors needed for the hormonally regulated transcription.<EOD> Effect of p-chlorophenoxyisobutyrate on the response of phosphatidylcholine metabolism to the acute effects of thyroxine in vivo in rat liver.\nThe acute and subacute effects of thyroxine and p-chlorophenoxyisobutyrate (CPIB) have been examined in the phosphatidyl-choline (PC) metabolism of intact rats in vivo. Acute administration (2 h) of thyroxine to intact rats produced an increase in the activity of CTP: 1,2-diacylglycerol cytidylyltransferase (EC 2.7.7.16) in the liver. An almost identical increase in enzyme activity was also seen in the livers of rats pretreated for",
        "label": 2
    },
    "527": {
        "output": "##[[MATCH]]\n<EOD> Efficiency of pre-incubation prior to electrophoretic transfer on Western blots under various conditions.\nPre-incubated solutions, such as poly(L-lysine)-coated gels, poly(L-lysine)-coated transfer membranes, and pre-incubated low-percentage polyacrylamide SDS-agarose gels, have been used to increase the transfer of proteins from the polyacrylamide separation gel matrix onto the SDS-polyacrylamide transfer membrane and thus to improve the efficiency of electrophoretic transfer. However, in practice, the improvement is often limited, and a variety of questions emerge. Should the poly(L-lysine) be applied to the separation gel or to the transfer membrane? If the poly(L-lysine) is applied to the separation gel, should it be used as a gel additive, or should it be spread on a separate surface, separated from the gel surface? Should the transfer membrane also be coated with poly(L-lysine)? With all of these variations, the transfer efficiency varies from one system to another, and it may be useful to establish some preliminary guidelines with generality. A variety of pre-incubation conditions were examined, and a systematic approach to optimizing transfer was developed. The system was based on the transfer of 125I-labeled casein from 5-15% gradient polyacrylamide gels, but other proteins were also tested. Poly(L-lysine) coated to the surface of the transfer membrane was most efficacious with a 5-15% polyacrylamide separation gel. Poly(L-lysine) coated to the separation gel was less reliable, but was as effective as coating the transfer membrane. With 10% polyacrylamide separation gels and pre-incubation for 18-24 h, the transfer efficiency depended upon the composition of the transfer membrane.(ABSTRACT TRUNCATED AT 250 WORDS)<EOD> Risk of recurrent venous thromboembolism: an analysis of pooled clinical trial data.\nBACKGROUND\nAlthough recurrent venous",
        "label": 0
    },
    "528": {
        "output": "<EOD> <gh_stars>0\nimport { Component, OnDestroy, OnInit, ViewChild } from '@angular/core';\nimport { ActivatedRoute, Router } from '@angular/router';\nimport { FormBuilder, FormGroup, Validators } from '@angular/forms';\nimport { HttpClient } from '@angular/common/http';\nimport { Subscription } from 'rxjs';\nimport { UsuarioService } from '../security.service';\nimport { Constantes } from '../../../shared/constantes';\nimport { Usuario } from '../../../shared/interfaces/Usuario';\nimport { UsuarioDtoFormulario } from '../../../shared/interfaces/UsuarioDto';\n\n@Component({\n  selector: 'app-formulario-iniciar',\n  templateUrl: `components/Usuarios/formularioUsuario.component.html`,\n  styleUrls: []\n})\nexport class FormularioUsuarioComponent implements OnInit, OnDestroy {\n  private usuarioFormulario: FormGroup;\n  usuarioFormularioDtos: UsuarioDtoFormulario[] = [];\n  public usuariosSubscription: Subscription[] = [];\n  @ViewChild('formUsuario')\n  public formUsuario?: HTMLElement;\n  constructor(\n    private activatedRoute: ActivatedRoute,\n    private router: Router,\n    private formBuilder: FormBuilder,\n    private usuarioService: UsuarioService,\n    private httpClient: HttpClient\n  ) {\n    this.usuariosSubscription.push(this.obtenerUsuariosSubscription());\n  }\n  \n  obtenerUsuariosSubscription = () => {\n    this.usuarioService.obtenerUsuarios(this.formUsuario, (usuarios) => {\n      this.usuarioFormularioDtos.push(this.guardarFormulario(usuarios));\n      this.usuariosSubscription = this.usuariosSubscription.filter(subscription =>\n        subscription !== usuariosSubscription\n      );\n    });\n  }\n  private guardarFormular",
        "label": 1
    },
    "529": {
        "output": "> ## The patient is not eligible for the trial\n![INST] This assessment result of a patient is 0 (Excluded).\n\n> ## The patient is eligible for the trial\n![INST] This assessment result of a patient is 2 (Eligible).\n\n# Results\n\nYou should obtain the score of each trial-level in the three-point scale. If the assessment result of a patient is 0 (Excluded), record a `Trial-level eligibility: 0` in the last line, e.g., `Trial-level eligibility: 0) Excluded`. If the assessment result of a patient is 1 (Not eligible), record a `Trial-level eligibility: 1` in the last line, e.g., `Trial-level eligibility: 1) Not relevant`. If the assessment result of a patient is 2 (eligible), record a `Trial-level eligibility: `in the last line, e.g., `Trial-level eligibility: 2) Eligible`.\n\n### Clinical trial #2:\n![INST] You are working in a pharmaceutical company and are responsible for performing quality control of the clinical trial data of a new test drug (Sickle cell disease drug) in the laboratory. There is a database in the laboratory which is organized like the following picture:\n\n### Trial-level variables\n\n### Patient-level Variables\n\n### Average score\n\nThe Cochran's Q test is a statistical test used to determine the presence of heterogeneity among different studies by assessing whether the observed treatment effects are similar across studies. The calculation of Cochran's Q is described as follows\n\n\n<img src=\"https://user-images.githubusercontent.com/21109849/110371153-b7e46680-872b-11eb-98b1-f28c3dc3c89f.png\" style=\"height:10.23%; width:5.38%\" /> : The flow diagram of the clinical trial.\n\n\n<!--A: How is this",
        "label": 0
    },
    "530": {
        "output": "Your task is to determine eligibility through a dialogue without any feedback. \n\n\n**This is an independent programming assignment and we expect no collaboration between different participants.**\n\nGood luck!\n\n\n:memo: Install <a href=\"../resources/memo/index.html\">Memo, web-based code-testing environments, and a lot more for Rust programmers</a>, to work locally.\n\n\n</details>\n\n\n# Discussion\n\n\n<details>\n<summary>Show discussion</summary>\n\n***\n**Issues** \n\n* The `print(...)` should be substituted by the function `display(...)` since it just prints to the console by default.\n* How should you solve the task? For example, should you use regex to recognize the text patterns of the patient's medical background?\n* When you implement the algorithm into a function, what should it return?\n***\n**Solutions** \n\n* You can use the standard library's regular expressions in [regex](/docs/regular-expressions/) for the purpose of recognizing phrases in the patient's medical background.\n* The solution can be done by implementing an algorithm in the form of a function. The function would first read information from the patient's note file (pat1.txt or pat2.txt) and then print the output of the trial-level eligibility.  \n  * You can also print the three-digit number for assessing a clinical trial on the patient's medical background if you prefer it to be one string. For example, suppose that if we only need to recognize patient notes that do not have enough information for the 1+2-level eligibility, then the first two digits of trial-level eligibility should be \"00\" and the three digits of the trial level eligibility would be \"99\" or \"999\".\n\n***\n\n**Source code** \n\n`/code/task1/Solution.rs` \n\n\n*I wrote the code, although it's not optimal and I don't plan on submitting a solution for this particular assignment. Also, there is room for improvement.*\n\n```rust\n\nextern crate io;\nextern crate regex;\n\nuse std::io::Write;",
        "label": 1
    },
    "531": {
        "output": "## Exercises to practice using `include`\n\nAll patients should be checked when including each patient note. Check each of the inclusion criteria, e.g.,\n    1) Gender is male/female\n    2) Ages less than or equal to 60/ or greater than 30.\n    3) Inclusion criterion A or B\n    4) Gender is male or female\n    5) Smoking habit is yes or no.\n\n## What does `include` check?\n```python\nfor i in range(5): #Patient ID from 1 to 5\n    #The first line of patient note\n    print(\"First line:\", patient_note[1:])\n    #Patient note\n    for j in range(2): #Line 2 and after\n        #Line 2\n        if \"gender\" in patient_note[j].keys():\n            print(f\"In line {j}: Gender {(patient_note[j][(patient_note[j].keys())[1]] if patient_note[j].keys()[1] == 'male' else 'female')}\")\n        if \"smoking habit\" in patient_note[j].keys():\n            print(f\"In line {j}: Smoking {(patient_note[j][(patient_note[j].keys())[1]] if patient_note[j].keys()[1] == 'yes' else 'no')}\")\n        #Patient_note\n            if \"genders\" not in patient_note[j].keys() and ((not \"sex\" in patient_note[j].keys()) or (patient_note[j][patient_note[j].keys()] == \"male\")): #Line 5\n                patient_note[j][patient_note[j].keys()[1]] = 'male'\n    print(f\"`include` check: {include_criteria(patient_note[1:], trial_id)}\")\n    print(f\"`include` check: {include_criteria_all(patient_note[1:(2 + i)*20], trial)}\")\n    print(f\"`include` check: {include_criteria_all_20lines(patient_",
        "label": 0
    },
    "532": {
        "output": "<EOD> Development of a micro-CT system for in vivo imaging of the temporomandibular joint: Part I. Hardware.\nThis paper describes the development of a high resolution, high-speed micro-CT imaging system for in vivo imaging of the mouse temporomandibular joint (TMJ). Such a system would be well suited for longitudinal studies in which the same subject is imaged over a long period of time, e.g., over an animal's lifetime. A small cylindrical volume of interest is imaged in rapid succession for high speed acquisition. Dedicated hardware includes a high electromechanical shutter and a novel, high voltage electronics assembly and control structure to control the X-ray source. The imaging system was designed to have a lateral viewport which allows the mouse to be repositioned relative to the X-ray focus. We constructed hardware to enable positioning of the TMJ in the X-ray beam using the 3D motion capabilities of a motorized manipulator. This paper describes the design of the entire imaging system and focuses on the design of the electronic and mechanical hardware. The final prototype system consists of a 1-s cone-beam scan of the TMJ in anesthetized mice. This system is used to image TMJ disc and condyle morphology.<EOD> Cervical intra-epithelial neoplasia: the long-term results of a large outpatient clinic with special regard to the importance of the follow-up visits.\nBetween 1961 and 1974, in an outpatients clinic for cervical intra-epithelial neoplasias (CIN) 486 patients have been treated. The initial diagnosis was CIN in 91% of the cases and in situ carcinoma in the remaining 6%. Most of the patients (n = 375, about 78%) returned to the outpatient clinic. The relapse rate was 43% (162 patients) after a total observation time of 1149 years, with a median of 6 years per patient. The relapse rates of the women who had had a cone-biopsy and had had it done without pathological findings on pap-smear and without pathological findings",
        "label": 0
    },
    "533": {
        "output": "A. How to check whether the patient meets the inclusion criteria of the clinical trial?\n\nPatients with heterozygous familial hypercholesterolemia are included in the trial. \n\nA: Familial hypercholesterolemia is a hereditary metabolic disorder in which the lipoprotein receptors for low-density lipoprotein are abnormally sized or dysfunctional, leading to abnormal buildup of low-density lipoprotein-cholesterol and hypercho lesterolemia .\nA: Inclusion Criteria: Patients with hyperlipidemia that meet all of the following criteria:\n\n1. Age: 18 to 80 years old (British) or 18 to 75 years old (US).\n\n2. Diagnosis of heterozygous familial hypercholesterolemia.\n\n3. Currently taking statin therapy or taking oral lipid-lowering agents (bile acid-binding resins, cholesterol absorption inhibitors, fibric acid derivatives).\n\n4. Must have a baseline low-density lipoprotein cholesterol level of more than 140 mg/dL.\n\nB. How to check whether a patient meets exclusion criteria?\nAll patients have to have LDL levels above 140 mg/dL or HDL below 38 mg/dL.  For patients who take statins, they will have to have a prior baseline LDL level of 140 mg/dL or higher.\n\nA: exclusion criteria:\n\n\nA: No, age greater than 75 years old is a reason not to participate (US). \n\nB. How to check whether a patient meets exclusion criteria?\n\nA: Exclusion Criteria:\n\n- A history of stroke/mini-stroke or TIA (Transient Ischemic Attack) within 6 weeks prior to screening or a history of 2 or more strokes, 1 or more mini-strokes or TIAs requiring hospitalization within 1 year prior to screening\n- The patient is being considered for liver-related surgery\n- Pat",
        "label": 1
    },
    "534": {
        "output": "# Related issues\n\n## Related issues\n- ADOD\n- SOLVE\n- STATISTICS\n- STUDY\n\n## ClinicalTrials.gov\n\n## SOLVE\n\n## ADOD\n\n## STATISTICS\n\n## SURVEY\n\n## STUDY\n<EOD> The Epidermal Growth Factor Receptor System and Tyrosine Phosphorylation of DNA Topoisomerase I in Colorectal Cancer and Leukemia\nAbstract The expression of the epidermal growth factor receptor (EGFR) and its main substrate, DNA topoisomerase I, was studied in specimens from 52 normal colon mucosae, 64 tumoral colorectal mucoseas, 58 non-Hodgkin lymphomas and 9 chronic lymphocytic leukemias. The results obtained demonstrated a significant increase in the positive cases for both enzymes in all the studied groups. However, there were statistically significant differences in the expression of both proteins between normal and colorectal cancer samples as reflected by an increase in both proteins up to about 80% in tumoral tissues with respect to control tissues. The results also showed that EGFR and topoisomerase I were co-expressed in normal and in almost all tumoral tissues except in 3 samples of colorectal cancer. These results open up new opportunities to investigate the therapeutic targetability of both proteins in cancer cells. It is also suggested that the combined EGFR-topoisomerase I inhibition may provide a significant therapeutic advantage in colorectal cancer management.<EOD> Infection with Helicobacter pylori strains positive for dupA is associated with an increased risk of gastric adenocarcinoma and peptic ulcer disease\nBackground and aim:\u2002 Human disease due to Helicobacter pylori (HP) infection is largely influenced by genetic factors. There are conflicting findings in the literature concerning the relation between the HP virulence factor dupA (hypothesized to be present in approximately 43% of the strains) and the pathogenesis of peptic ulcer disease (PUD),",
        "label": 1
    },
    "535": {
        "output": "A successful job. Well done! \n\n</BODY></TABLE></DIV>\n    </HTML>\n<EOD> .\nThe aim of this study was to evaluate the results of preimplantation genetic diagnosis (PGD) by FISH in patients with chromosome translocations in order to prevent transmission, in addition to avoiding the development of unviable embryos. The study was carried out at the Fertility Department, Clinicas Hospital, Buenos Aires. Our PGD protocol includes aneuploidy screening by chromosomal FISH and a chromosomal translocation study by centromeric FISH. From 29 PGD procedures, we analyzed two couples in which reciprocal translocations were carried out. The translocation results were negative, and the pregnant women delivered a baby with normal karyotype. The couple analysed received embryos with a normal karyotype. We concluded that the study of the partner in reciprocal translocations carried out by FISH is useful to select normal embryos for implantation.<EOD> .\nThe purpose of our investigation was a comparison of the results obtained by two methods for the identification of Enterobacteriaceae. The first method used the classical method of staining, the VP scheme. The second method used the commercial Bio-Oss\u00ae plate test. The first method is more easy to perform and also allows the identification of species of Gram- negative rods which do not grow well in biochemical media. The Bio-Oss\u00ae plate method is the most specific method and its use, in our laboratory, gives a reliable identification of Enterobacteriaceae.<EOD> An analysis of adoption of the CPT IV/V code set as a metric to evaluate medication reconciliation in hospitals.\nAIM\nThe study sought to examine hospitals' adoption of the CPT IV/V code set as a metric to evaluate medication reconciliation in hospitals. Specifically, the study examined whether adoption of the CPT IV/V code set was associated with the facility's current state, location, or system affiliation.\n\n\nMETHODS\nA survey was sent to pharmacy chief executive officers (CEOs) at 1,373 National Association of Hospital Pharm",
        "label": 2
    },
    "536": {
        "output": "## Question 2. How to judge if patients should be excluded from the trial for having other conditions?\n\nAnswer: After you finished evaluating the patient's eligibility and assessing the trial-level eligibility, if the patient meets the criteria for exclusion from the clinical trial:\nFor the criteria of age, clinical judgment can be utilized to determine whether the age is critical to the trial's outcome, because the reason an elder patient should not be excluded is because the risk-benefit analysis may support clinically significant benefit from the procedure in this patient population. And the age should be based on the patient's physiological age rather than just the chronological age.\nFor the criteria of gender, this should be redefined. The gender category should be gender-diverse and gender-affirming, where the subject should be of either sex and must identify as a man or a woman or gender-diverse.\nFor the criterion of smoking, many clinical trials do not include active/passive smokers, because smoking can affect vessel's reaction to the procedure.\nFor the criterion of high blood pressure, the SBP and DBP for the systolic and diastolic pressures of an individual might vary, so the cut-points should be evaluated. The criteria include patients with a SBP of less than 120 mHg or a DBP of less than 80 mgHg. But, it is worth noting that high SBP (high-normal hypertension) of 130 -139/85 -89 mmHg is not associated with increased cardiovascular risk or increased risk of cardiovascular events, so patients with normal ranges of the blood pressure should be considered eligible.\nIf a patient's fasting glucose and triglyceride levels are within the normal limits and LDL-C is below <100 mg/dL and HDL-C is more than <30 mg/dL, they are not likely to be candidates for a statin for lowering cholesterol level.\nFor the exclusion criterion of low HDL, patients with HDL levels >40 mg/dL and LDL less than 200 mg/dL are not",
        "label": 1
    },
    "537": {
        "output": "To continue to [https://github.com/koshtoy/hayyan/edit/master/problem_datasets/clinical/04991/patient-note-input.md]\n<EOD> RNA editing of the ivermectin\u2010sensitive alpha4 subunit of GABA receptors reduces ethanol sensitivity in Caenorhabditis elegans\nGamma\u2010Aminobutyric acid type B receptors (GABABR) play important roles in modulating neuronal excitability, synaptic transmission, and plasticity throughout the nervous system. These receptors are targeted by a variety of transmitters (glutamate, GABAA, glycine and dopamine) and drugs (alcohol and benzodiazepines). Dysregulation of the GABABR is implicated in various neurological, movement, and behavioral disorders. Unlike other ionotropic GABA receptors, GABABRs are dynamically regulated by allosteric modulation and RNA editing. GABABRs contain two distinct subunits\u2014delta and alpha4, both capable of forming a heterodimer. Despite being co\u2010expressed, they are encoded by two separate genes edited in a common site, generating a large set of RNA isoforms. GABABR alpha4 subunit editing has been shown to generate RNA isoforms that differ with regard to ethanol sensitivity, but not with regard to alcohol consumption in rodents. Ivermectin, a Cys\u2010loop ligand that potently modulates ethanol consumption in rats, has been shown to differentially increase the expression of non\u2010edited alpha4 receptor\u2010containing GABABRs in rat brain neurons and is sensitive to RNA editing. This has led to the proposal that the RNA editing status of the GABABR\u2010associated alpha4 subunit plays a role in ethanol use disorder. Here, we report that the C. elegans homologue of the alcohol consumption\u2010modulating GABABR, UNC\u201049B, undergoes editing of a similar RNA editing site to that in rodents, and that altered receptor editing in the unc\u20104",
        "label": 1
    },
    "538": {
        "output": "<EOD> Intraductal carcinoma of the prostate on prostate core biopsy.\n\nIntraductal carcinoma of the prostate (IDC-P) is a rare proliferation of malignant neoplastic cells confined to the acini or ducts of the periurethral glands and/or duct system of the prostate. The majority of IDC-P is found in association with adenocarcinoma of the prostate. Recent investigations have shown that IDC-P can be identified on routine prostate biopsy specimens. We herein describe a 67year-old patient who was diagnosed IDC-P by prostate core biopsy. We reviewed a number of previously reported patients with IDC-P and investigated the clinical correlation.Core tip: Intraductal carcinoma of the prostate (IDC-P) is a rare proliferation of malignant neoplastic cells confined to the prostate duct system. IDC-P can be accurately diagnosed on routine prostate biopsy specimens by a systematic description of IDC-P features on histological observation, including cribriform and papillary growth patterns. This case illustrates the need for careful interpretation of prostate biopsies, especially in view of novel biomarkers that may predict prostate cancer progression.\n\n# Abstract\nIntraductal carcinoma of the prostate (IDC-P) is a rare proliferation of malignant neoplastic cells confined to the acini or ducts of the periurethral glands and/or duct system of the prostate. The majority of IDC-P is found in association with adenocarcinoma of the prostate; however, IDC-P without coincident adenocarcinoma is exceedingly rare. Recent investigations have shown that IDC-P can be identified on routine prostate biopsy specimens. We herein describe a 67-year-old patient who was diagnosed IDC-P by prostate core biopsy. We reviewed a number of previously reported patients with IDC-P and investigated the clinical correlation.\n\n# Introduction\nThe incidence of nonpapillary ad",
        "label": 1
    },
    "539": {
        "output": "<EOD> Enhanced antigen presentation by monomeric DNA complexed with TAT peptide through endosomal escape by membrane fusion.\nGenetic immunization has now become a valid alternative to inactivated or attenuated vaccines, as it is generally thought to be a safer way to immunize individuals against diseases. Gene-gun delivery of DNA is commonly used to enable antigen presentation, but this method cannot be applied for universal vaccine candidates, due to difficulties in obtaining such large amounts of antigenic proteins, as well as in vivo toxicity problems. Although some immunogens have been generated by recombinant techniques, no ideal delivery system for DNA vaccine is available yet. Because of the unique feature to enter eukaryotic cells, the transduction/transduction domain from human immunodeficiency virus (HIV), Tat, is being used for the transduction of various proteins. We examined an ability of the Tat peptide to complex genetic information and deliver it directly into the cytoplasm of antigen-presenting cells (APC). After transduction into either mouse dendritic cells (DCs) or human tonsillar cells by means of the Tat peptide, complexed with DNA encoding ovalbumin (OVApulex) or a membrane-anchoring peptide, both forms of the peptide exhibited an ability to induce an enhanced antigen-specific immunity after immunization. Immunization with the OVApulex-DNA-TAT complex also promoted antigen-specific cytotoxicity of OVApulex-sensitized lymphocytes. However, the immunity induced by DNA-TAT peptide complexes without any immunization was weaker than that induced by the other two preparations. Moreover, the pDNA with a histidine-rich tail, which interacts with the endosomal membrane through hydrophobic interactions, was not internalized by primary DCs and showed an inability to elicit a detectable cytotoxic activity after immunization. Based on these results, we confirmed an alternative route for DNA vaccine delivery, which might be safer and easier than the use of virus or gene-guns.<EOD> Acute Myel",
        "label": 1
    },
    "540": {
        "output": "[/NOTINST]\n\n## [c] 2020, The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group\n\n1.2.3.3. Patient-level eligibility\n\nA patient-level eligibility (PtEligibility) is the sum of a trial-level eligibility (Trial-level eligibility) and patient's characteristics (Patient characteristics) which are not related to the patients' disease and can be different for each patient. This means one trial may have many different patients' Trialand Pt-Eligibility results. \n\nThe key concept here is the patients' characteristics (Patient Characteristics) which are not directly associated with their disease, but which are patient-specific properties (e.g., BMI, age, gender, smoking, and blood parameters) and are required for the calculation of the Trial-and Patient-Level Eligibility.\n\nThe assessment of a Trial-and Patient-Level Eligibility requires three elements:\n\n1) TRIALS (patient's diagnosis and trial information);\n2) PATIENTS (patient's characteristics);\n3) CALLS (patient-specific inputs such as test and blood parameters).\n\nBecause a trial is unique, we can use the trial information to calculate patient's eligibility only for one trial. Therefore all trial information is loaded to the TRIALS variable, but only one trial can be selected in the input form. \n\nThere are two cases here:\n\n1. We will not calculate patient-specific PtEligibilities for 5227 patients, who are not registered in the trial information.\n\n2. For patients whose Trial and Patient characteristic data were present, we will calculate their PtEligibility with the following formula: \nPtEligibility = sum (Patient Characteristics value)  (Trial-level Eligibility value)  (nature of Trial)\nwhere the nature of the trial is defined as trial ID number, for example, 1 stands for Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) and 2 stands for Asymptomatic car",
        "label": 1
    },
    "541": {
        "output": "### [HINTS] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u00a0mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u00a0mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u00a0cm/s",
        "label": 1
    },
    "542": {
        "output": "<EOD> Effects of a long\u2010term diet and exercise intervention on metabolic parameters, fitness, and muscle strength in overweight and obese men\nExercise programs have been shown to be effective tools not only in reducing body weight (BW), but also to improve insulin sensitivity. Also, changes in the physical activity level (PAL) may affect other metabolic pathways independently of weight loss. The goal of this study was to determine if long\u2010term exercise, independent of changes in BW, could be effective in improving physical fitness as well as some metabolic parameters, despite decreases in PAL levels.<EOD> Assisting or facilitating recovery from depression: the development of a personal recovery model for postpartum depression\n\nBackground: Postpartum depression (PPD) is a sub-form of major depression associated with childbirth, which is related, but distinct, from major depression during or outside pregnancy. PPD accounts for a significant proportion of the total burden of perinatal depression, and its psychosocial impact is markedly severe for affected women. Methods: The purpose of this study was to qualitatively explore PPD from the perspectives of women who have previously experienced the illness in order to inform the development of a model of clinical care which reflects the unique recovery process inherent to this illness, and to guide the development of the first clinical trial study to develop a PPD recovery intervention. Using established qualitative research techniques, six women who had experienced postpartum depression in the last 5 years conducted formal, in-depth interviews. Interview transcripts were subject to thematic analysis. The content of this study was also submitted to the validation of a group of healthcare and consumer stakeholders in a nominal group validation session.Results: Ten themes emerged from a thematic analysis of data: (1) depression before pregnancy, (2) symptom recognition, (3) symptom expression, (4) treatment seeking, (5) symptom resolution, (6) factors influencing treatment seeking, (7) factors which influenced symptom expression, (8) factors which influenced symptom resolution, (9) factors influencing symptom re-occurrence, and (10) factors influencing recovery. Theme identification demonstrated three major points: (i) the",
        "label": 1
    },
    "543": {
        "output": "### Solution\n\nTutorials are interactive, which means you can use the keyboard, mouse, as well as the screen to do the exercises. \nTo type the text in an exercise, \u200b\u200buse the following key:\n\nTo select the text in an exercise, \u200b\u200buse \u200b\u200bthe following key:\n\n![alt text](/img/tutorial/sphinx/fig/mouse-click.png \"Click to zoom!\")\n\nTo write the text in a dialog box, \u200b\u200buse \u200b\u200bthe following key:\n\n![alt text](/img/tutorial/sphinx/fig/enter-key.png \"Click to zoom!\")\n\n**Please note:** When you are typing a text, the font size is adjusted by default to small to give a short view. If you like the bigger view, type **Ctrl+S** followed by editing time to increase the font size. **Ctrl+S** is the shortcut to save the font size. \n\n\n### Exercise 1\n\nWe will create an exercise which defines an exclusion criterion. This example will help you to learn how to define the output format. \n\nYour task is as follows: define the following four exclusion criteria to exclude patients who don't fit. \n\nExclusion criteria: \n\n- Patients who are diagnosed as the active phase (within 1 week) of an infection\n- Patients with severe cardiovascular disease (e.g. New York Heart Association (NYHA) class IV)\n- Patients with stroke within three months of enrollment\n- Patients with acute myocardial infarction within six months of enrollment\n\nThis patient note (without exclusion criteria) should be given as input to each exclusion criteria. The exclusion criteria should output the three-point scale, i.e., `Excluded`,`Not relevant` or `Eligible`. \n\nLet's look at the code snippets below, they show all 4 parts of the exercise.\n\n### Solution\n\nFirst, we will add the definition of input. We use the `TextIO` to read the patient note. \n\nNext, we create the `Exclusion_criteria_class` using the `class` keyword. \n\n![alt",
        "label": 0
    },
    "544": {
        "output": "[INST]\n<EOD> Characterization and biodegradation of microbial exopolysaccharides from the biofilms of a membrane bio-reactor\nMembrane bio-reactors (MBRs) constitute a technology alternative to reduce the operational costs in biological systems because high-rate treatment processes can be achieved in small volumes of bioreactor. However, they exhibit a high fouling potential due to the occurrence of biofilms on the surface of the membranes. One of the strategies to mitigate this potential is the stimulation of beneficial bio-flocs with the production of extracellular polymeric substances (EPS). In this context, this work aimed to improve the degradation of EPS in simulated membrane biological reactors operated at different hydraulic retention times (HRT). For this purpose, six types of EPS were produced by the growth of the yeast Candida famata in sugar-amino acid medium; a yeast isolated from a conventional membrane bioreactor and four filamentous fungi isolated from an MBR (Sporopachydermiella spp. and Pestalotiopsis spp.). All EPS isolates were obtained by centrifugation from the growth medium; three EPS were water-soluble and three others were water-insoluble ones. The presence of the isolated EPS was confirmed by Fourier transform infrared spectroscopy. All EPS isolates contained polysaccharides. In the case of the water-insoluble EPS, mainly composed of glycans, the Fourier transform infrared spectroscopic analysis showed a wide region between 4000\u00a0cm-1 and 500\u00a0cm-1. The biofilm stability and biodegradation were determined using a Membrane Biofilm Reactor operating at a HRT of 3.3 and 5.6\u00a0h, respectively. All EPS isolated, except the EPS produced by Pestalotiopsis sp. and Sporopachydermiella sp., were degraded in both simulated Membrane Biofilm Reactors. Although Candida sp. and Pestalotiopsis sp. were the faster EPS degraders at 3.3 and 5.6 HRT,",
        "label": 2
    },
    "545": {
        "output": "<EOD> A Novel Protein-Protein Interaction of the Dimerization Domain of Cyclin D1\nABSTRACT Cyclins regulate the progression of the cell cycle and mediate the recruitment of cyclin-dependent kinases (Cdk) to the cyclin-docking sites present in various substrates and cyclin-activating kinases (CAK). The cyclin D1 protein exists in monomer, dimer, and tetramer states. However, the mechanism of cyclin D1 dimerization and tetramerization is still not clear. In this study, molecular modeling techniques using the available NMR structure as well as an intrinsically disordered region (IDR) prediction method were applied. It was shown that the disordered C-terminal peptide of cyclin D1 can form a homodimer in vitro. By using the synthesized IDR fragment 200-220 as a bait and a cellular-protein library as prey, we also found that there are at least two major and two minor proteins which specifically interact with the disordered IDR of cyclin D1, i.e., S100A6 and Apo-lactadherin, using fluorescence anisotropy analyses followed by mass spectrometry identification. Further yeast two-hybrid, pull-down, and fluorescence-lifetime analyses demonstrated that only S100A6 can form a stable homotetramer, and S100A6 is able to interact with the IDR of cyclin D1 (residues 199-230) both in vitro and in vivo, suggesting the possibility for a dynamic complex of cyclin D1 and S100A6. Our findings therefore provide new evidence of the mechanism of cyclin D1 dimerization and tetramerization.<EOD> Prevalence of EGFR Genetic Polymorphisms and its Association with the Risk of Non-muscle-invasive Urinary Bladder Cancer in a Chinese Population\n\nThe association of EGFR genetic polymorphisms and the risk of urinary bladder cancer (BC)-a disease of rising incidence rate in China-represents a subject to which research",
        "label": 0
    },
    "546": {
        "output": "</section><section class=\"instruction\">\n\n[QUESTION] Hello. You are a helpful assistant for clinical trial recruitment. You should determine if a patient with diabetic neuropathy is eligible or not for a trial, according to a predefined rule base. You need to find in the patient's chart the value of a patient variable `m_n_diabetic_neuropathy`, and find in the trial variable `I_m_n_clinical_trial_variable:`. If either of them is set to 1 for a trial, then the patient should be excluded per the trial specification. However, if neither of them is set to 1 for a trial, then you should check and find out whether the patient has some conditions that have to be considered. You only have to consider whether the patient meets at least one of the conditions. Also, you can assume that the patient is male. Note the set condition for each criterion, which is set to 1 during the trial. Each patient should have at least one criterion of one type set to 1 during the trial. \n\nYour assessment should take one of the following forms:\n\n![1:1]: /assets/img/helpv4/clinical-trial-recruitment-assistance/sample.png\n![2:2]: /assets/img/helpv4/clinical-trial-recruitment-assistance/sample.png\n![3:3]: /assets/img/helpv4/clinical-trial-recruitment-assistance/sample.png\nYou should set your answer to 'Pass' if at least one set condition of each criterion has been set, and if only one of the conditions for the neuropathy in neurological exam is set. You should set your answer to 'Fail' if another condition is set, or if no condition is set. \nSo you have to check the patient file to understand which test is in the trial for each trial. \n\n![Patient file]: /assets/img/helpv4/clinical-trial-recruitment-assistance/patientfile.png\n![Patient file1]: /assets/img/helpv4/clinical-trial-recruitment-assistance/patientfile",
        "label": 1
    },
    "547": {
        "output": "You are to follow a step-by-step procedure to compute trial-level eligibility. Use the following prompt to start each process:\n```R\nclt <- clt_list[sample(clt_list,200)] # sample 200 subjects\npat <- patient_list[sample(patient_list,200)] # sample 200 patients\nclt <- paste('Trial-level eligibility of subject, ',  clt) # paste the trial-level eligibility of selected subject \n# for i in 1:200\n#   x <- i * 100 # to create numeric values\n#  system.time( \n#    clin <- c(\"ClinicalTrials: Evaluation of 24-Hour Event Monitoring for Atrial Fibrillation for Enrolled Patients\", \n#               \"Title: Evaluation of a Mobile Cardiac Outpatient Telemetry System Versus Standard Loop Event Monitor\")\n#    ctit <- c('ClinicalTrials: Evaluation of 24-Hour Event Monitoring for Atrial Fibrillation for Enrolled Patients',\n#               'Title: Evaluation of a Mobile Cardiac Outpatient Telemetry System Versus Standard Loop Event Monitor')\n#    ct <- join(clt,tit, .) # join all clinical trials to \"clt\" data frame\n#    nc <- ct$nclt # The number of clinical trial\n#    if (10%*nclt > 200){\n#      # if some number of clinical trials are more than 10% * nclt which is 200\n#           clin  <- sort(unique(clt)) # sort and split clinical trial into two data frames\n#    } else { \n#          # if some number of clinical trials are less than 10% * nclt \n#           clin  <- sort(unique(clt)) # sort and split clinical trial into two data frames\n#    }\n#    if (nclt == 200){\n#          # if some number of clinical trials are 200 (that is one of the inputs to",
        "label": 0
    },
    "548": {
        "output": "Good job!\n\n## [MOT]\nExplanation\nThe purpose of this notebook is to introduce the syntax of the medical model.\n\n## Syntax\nTo run code, you can either `source code_syntax.ipynb` in Anaconda Navigator or run `code_syntax`.\n\n## Example\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/).\n\n### Clinical Note\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohorts\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_ClinicalNote\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_Inspector\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_PatientList\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_Simulation\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_Simulation_ClinicalNote\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n##",
        "label": 2
    },
    "549": {
        "output": "A: This is the basic concept:\n\nThe first line is the patient. That patient has been compared with the \nclinical trial's criteria using a certain function.\nSo in the output you can see a boolean.\nSo the case is:\nFor example, this patient has a certain diabetes mellitus.\nand also a high blood pressure and a hypercholesterolemia.\nthe clinical trial requires only high cholesterolemia and high blood pressure.\nSo this patient is eligible for the clinical trial, no problem.\n\nThe second line is the clinical trial. \nyou can modify/set/change the criteria. \nand you can also have one or more exclusion criteria.\nThen you can check back if the patient still is eligble.\nin this case, yes, this patient is eligeble for the trial.\n<EOD> Long Noncoding RNA MALAT1 Promotes Proliferation and Cell Cycle Progression in Colorectal Cancer\n\nPurpose: This study assessed the expression, clinical role, and potential molecular mechanism of long noncoding RNA (LncRNA) metastasisassociated lung adenocarcinoma transcript 1(MALAT1) in colorectal cancer (CRC). Methods: A total of 20 pairs of colorectal cancer and adjacent normal tissues were detected by qRT-PCR assay. To investigate MALAT1 expression in CRC, we further assessed the expression of MALAT1 in 110 pairs of CRC tissues and adjacent normal tissues, as well as in 10 normal colorectal mucosa epithelial tissues. The relationships between the expression of MALAT1 and various factors were examined using independent-sample t-test or one-way analysis of variance (ANOVA). CCK-8 assay was performed to asses cell proliferation. Results: The relative expression of MALAT1 was significantly higher in colorectal cancer tissues than in adjacent normal tissues (1.615\u00b10.325 vs. 0.942\u00b10.100, P<0.001). The expression level of MALAT1 was also",
        "label": 1
    },
    "550": {
        "output": "## Exercises & Worked Example\n\n### Basic Exercise\n\n1. Select the following sample patient record and identify the factors indicating exclusion, ineligibility, and eligibility:\nA total of 35 items meet the definition of exclusion criteria and must be taken into account when conducting the initial assessment. \n\n![02-patient-exclusion-assessment-sample.pdf](/attachments/02-patient-exclusion-assessment-sample.pdf)\n\nYou will be scored based on the accuracy of the exclusion, ineligibility, and eligibility assessments in the sample note. As indicated in the sample note, you'll be asked to check exclusion, eligibility, and ineligibility (based on the patient's exclusion criteria) for each trial.\nThe points you will receive are as follows:\n- 5 points if you identified and addressed all inclusion criteria;\n- 4 points if you ignored all 35 exclusion criteria;\n- 3 points if you identified and addressed 25 out of 35 exclusion criteria;\n- 2 points if you identified and addressed only 15 out of 35 exclusion criteria;\n- 1 point if you missed the exclusion criteria completely;\n- 0 points if you did not mention the exclusion criteria at all.\nMake sure you understand how to check the answer for each trial. It is preferable to take all trials at once and then enter your responses in a worksheet based on these instructions.\n\n### Exercise: Eligibility assessment for the Trial ID 02-02012301\n\n1. Copy and paste the table below.\n\n![](images/disease-trial-assessment-sample-for-02-020123010)\n\nNote: You can only copy and paste the text for this and future trials (no other figures or numbers). Copy everything except the headings. Please do not copy the whole document.\n\n2. Read the clinical trials and assess the patient according to the eligibility criteria. Only for this and future trials.\n\n### Exercise: Eligibility assessment for the Trial ID 02-0",
        "label": 1
    },
    "551": {
        "output": "## Practical tips\n\n- The program will take upward of two hours.\n- If there is an issue in the script, please report the issue at [https://gist.github.com/juliepm/982a537da6770e40933f87d245738582] (GitHub link to the program source code).\n\n__________________________________________________________________________\n\n___<NAME> ___________________________________________________________________________\n\nTeacher's Instructions:\n\n1. Give students the answer to this program:\n\n```python\nTrial_level_eligibility = 2\n\nif age>46:\n    Trial_level_eligibility = 0\nif sex=='male':\n    Trial_level_eligibility = 0\nif li",
        "label": 1
    },
    "552": {
        "output": "[EXERCISE] Here is the test trial. You should check whether the trial record is eligibility or not by comparing your trial assessment results with those in the test trial and also compare the trial assessment results of every clinical trial. It is the most important thing for the doctor to match the patient with a clinical trial.[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patients' patient notes:\nA 46-year-old man presents with headache and dizziness. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL and HDL levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 2+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal car",
        "label": 2
    },
    "553": {
        "output": "Output format: Output format:\n[formula]  { [/formula] \n[INST],[patient_id],[patient_name],[initials],[age],[gender],[sex],[weight],[height],[discharge_date],[status],[time_zone],[department],[ward],[doctor],[anesthetist],[disease],[clinical_trial],[trial_id],[tumour_code],[clinical_trial_type],[treatment_arm],\n[clinical_trial_duration],[study_visits],[number_of_study_visits] }\n\n##[END]\n\n\n[INST].[INSERT]\n[INSERT]\n[INSERT]\n[INSERT]: [2] Eligible (Trial eligibility)\n```\n- Insert a new row in the INSERT button which will be the new trial-level eligibility.\n- After inserting the row, change the scale from trial eligibility to Patient record.\n- After changing the scale type to Patient record, insert a new row which will be the trial's inclusion criteria.\n- After inserting a trial's inclusion criteria, you should insert the patient record in the same row by the PRESENT button.\n![Instructor](https://raw.githubusercontent.com/sagulutsu/Practical-Lab-Session-2-Lab-Session/master/Lab%202.jpeg)\nInstruct them to read the patient's record and then repeat all of the previous steps with the patient record by the other students. They must remember and follow the same steps. It should take about 5 min.\n\n[INST].[MARK]\n[DELETE]\n[DELETE]\n[DELETE]: The process continues as follows:\n- As a patient record, you should insert a new row by the INSERT button.\n```\n[INSERT]\n[INSERT]\n[INSERT]\n[INSERT]: {1) Age:[13],[2) Gender:[Male],[3) Married:[Yes],[4) Status:[Active],[5) Tumor code:[0],6) Clinical trial name:[Pioglitazone versus simvastatin],7) Clinical trial ID:[8399],8) Clinical trial type:[Randomized],9) Treatment arm",
        "label": 1
    },
    "554": {
        "output": "<EOD> .\nThe article analyzes the results of a study of the impact of a new model of the organization and management of the main functions of medical assistance in the Russian Federation, in a particular, of the health care management system on the status of Russian public health. It was established that these methods and measures led to a significant increase in the public health.<EOD> Enhancing Clinical Trials Management of Diabetic Foot Ulcer through Smart-Care Technology\nSummary Objectives: To describe the feasibility of a smart-care technology, called EpiCheck\u00ae, in promoting clinical trials management of ulcer and related disorders caused by diabetes. Methods: The smart-care system consists of three phases: an analysis of real-time patient data recorded by a multiparametric portable platform; an action of intervention; an analysis and monitoring of the clinical evolution through a wireless online system, together with an appropriate medical assistance. Results: This new system was implemented for the recruitment of patients in nine French hospitals and to assess the benefit of the treatment with EpiCheck. In parallel, the feasibility of this technology was tested for the development of a clinical trial of a new drug. Conclusion: This new system showed its ability to provide medical teams a great deal of information, to perform fast recruitment of patients and the benefit of a treatment, to help the caregivers for an appropriate medical assistance, even when a patient is far from an adequate medical care. We conclude that the smart-care system might be a useful tool in clinical trials management for diabetic foot ulcer.<EOD> BAFFR/Tnfsf13c-/- Mice Are Resistant to Antigen-Induced Lupus Nephritis by Inhibiting Maturation of Dendritic Cells\nNumerous lines of evidence point to autoantibodies and autoreactive B cells as central effecter and triggering cells of systemic autoimmune diseases. These cells play an important role in the pathogenesis of autoimmune disease by increasing dendritic cells (DCs). However, the relationship between these factors in autoimmune disease remains unclear. In this study, we examined the role of B cell activating factor receptor (BAFFR) and the effect of autoantibodies on DCs in mice with auto",
        "label": 1
    },
    "555": {
        "output": "___\n\n___\n19.11.1 Inclusion Criteria\n\n19.12.1 Risk Factors for Cardiovascular Disease\n\n### Inclusion Criteria\n\nInclusion criteria means that those who are defined by certain criteria are included in the trial. This is a more general category than patient-level eligibility.\n\nDisease diagnosis\n\nThe eligibility criteria are criteria for evaluating whether a particular disease is present in the participants. These criteria require that the clinicians obtain the information on the patient by observation or other methods and make the best judgement about whether the conditions are met.\n\nA clinician will assess the individual patient in terms of risk factor and diagnosis. If the individual patient is found to have 4 or more risk factors for CVD, then his/her eligibility is assessed again taking into account the additional risk factor (e.g., the patient is considered eligible when he/she is found to be hypertensive in addition to having risk factors for CVD such as smoking, etc.). The rationale is that it provides an integrated assessment of the patient risk.\nHere is an example of how to calculate the total number of risk factors in a patient:\nThe patient is 45 years old and has smoking history but has never been diagnosed with hypertension and diabetes which is good news.\nThe total number of risk factors is therefore 4 + 0 = 4. The individual risk factor is 45 years old, smoking history is 1, hypertension is 0, and diabetes is 0, respectively. There is one risk factor of smoking history.\nThe patient is 65 years old and has no additional risk factors. In this case, the total number of risk factors is 4 + 0 = 4. The individual risk factor is 65 + 0 = 65, smoking history is 0, hypertension is 0, and diabetes is 0, respectively. In this case, the patient is defined as low risk for CVD.\n\n\n### Risk Modifiers/Predictors\n\nAdditional factors which may be assessed in the participant to determine the risk of disease progression, but they do not define whether the disease is present or absent\nDisease pro",
        "label": 1
    },
    "556": {
        "output": "<h4>Exercises</h4> \n\n`### Patient note (first exercise)`\n\nHere is the patient note:\nA 35-year-old woman presents with palpitations and a low-grade fever (37.5\u00b0C) and no other symptoms. She has a family history of hypertension, but takes no drugs to control hypertension. Her lifestyle is sedentary. She is overweight (BMI: 28.0 kg/m2).\n\nThe patient is 161.0 cm tall and weighs 71 kilograms. She has an irregular heartbeat, with a systolic blood pressure of 140 mmHg (diastolic blood pressure is 90 mmHg) and a pulse rate of 110 beats per minute.\nThe patient's chest is symmetrical, and breath sounds and cardiac and pulmonary auscultation reveal no audible murmurs.\nThe results of liver and kidney function tests are normal, but her hemoglobin A1c is 9.2%.\n\nThe results of thyroid function tests are normal. The patient's cholesterol, triglyceride, low-density lipoprotein, and high-density lipoprotein levels are normal.\nHere is the clinical trial: \nTitle: Long-Term Exercise Programme for Improving Heart Rate Variability and Mental Health\n\n\nSummary: In this protocol, the authors investigated the efficacy of a long-term exercise intervention, focusing on heart rate variability (HRV) in order to determine the effects of a long-term exercise intervention on HVR and changes in psychological indices.\n\n### Inclusion criteria:\nAge 1. Between 20 and 40 years old\n2. Body maximal oxygen consumption (45 ml/min/kg)\n3. HRV < = 17.5 msec (The HRV of this criterion depends on age.)\n\n### Exclusion criteria:\n1. Presence of underlying diseases that may affect the results of this study such as heart disease, cardiomyopathy, angina, myocard",
        "label": 0
    },
    "557": {
        "output": "After submitting the trial-level eligibility, the next trial note is listed in the same fashion, which should be compared to the patient note:\nA 29-year-old woman presents with a history of recurrent migraine (RF; four times per month). She has no other cardiovascular risk factors, is not physically active, and does not smoke. The patient's HDL-C and LDL-C levels were 69 and 148\u2009mg/dL, respectively. Her systolic BP was 130 mm Hg, and her diastolic BP was 82 mm Hg. The patient reported no use of lipid-lowering medications.\nThe patient reported no use of lipid-lowering medications.\n\nHer medical history included myocardial infarction. She has been in a cardiac rehabilitation program since the infarction. Previous stress electrocardiography was negative.\nThe examination of electrocardiography showed no arrhythmia or myocardial infarction.\nHer physical examination results were normal.\nThe patient had no signs of a systemic inflammatory disease. \nThe patient's carotid MRI report confirmed the plaque characterization. The plaque appeared to be 100% calcified with an echogenic center and diffuse borders. The ultrasound results reported an asymmetrical and eccentric plaque formation with a maximum stenosis of 60%. As shown in 14, a maximum stenosis of 60% was verified by the ultrasound study. \n\n14 shows the ultrasound of Patient's Left ICA. Her physical examination results were normal. The examination of electrocardiography showed no arrhythmia or myocardial infarction.\n\n14\n\nPatients with a moderate to severe carotid atherosclerotic plaque are at risk for stroke and this risk increases with increasing degree of stenosis. It has been shown that carotid endarterectomy in symptomatic patients with a carotid artery stenosis of 70-99% is highly beneficial. However, the beneficial effect of surgery in patients with symptomatic",
        "label": 2
    },
    "558": {
        "output": "~~\n\nA good way to get the idea of triallevel eligibility across is to go back again over the patient note and try to imagine if the patient qualifies for the mentioned clinical trial. \n\nIf you need help to understand the concepts of InSist, have a look at our [concept](doc/concepts.md).~~\n\n### 3.2.6 Other features\n\nThere is an additional mode to perform triallevel eligibility assessment for a given patient. \nYou can run a second mode of the eligibility assessment command from within the patient note to give the chance to perform an eligibility assessment of a patient in which triallevel eligibility is performed for each trial. The command will return all triallevel eligibility information including the calculated decision if a given patient meets the inclusion criteria. You can give a name to save the results in your patient list. [INST]\n~~~\nAssessment of eligibility for a patient Note ID: 02190895_02121206_1402.\n[\n```\nSure! To perform an eligibility assessment.\n\nAssessment ID: 1\nFirst, a Trial-level eligibility assessment will be performed for all trials.\n\n\nResults: \nTrial-level eligibility: 2) Eligible.\n\nThen, Triallevel eligibility will be performed for a given medical trial.\n\nFor: Prevention of Diabetes and Hypertension \n```\n~~~\nDo you want to save current results of eligibility assessment for this patient?\nYES/NO/CANCEL\n\nNote ID: 02190895_02121206_1402\nName ID: 02190895_02121206_1402\n\nYes\nName of Patient Note ID: 02190895_02121206_1402\n\nSave results ID:\n\nSave results ID:\n\nOK? YES/NO\n\nYes\nYes\n\nCurrent results: (Assessment ID: 1)\nTrial-level elig",
        "label": 0
    },
    "559": {
        "output": "# Additional questions/checkpoints\n1) What is the expected outcome for this project?\n\n\n> [SOLUTION] You are expected to train a machine learning model to predict whether a patient is eligible for the clinical trial or not. You are advised to check the provided clinical trial data for missing values.\n2) What are the major components and attributes in the clinical trial recruitment project?\n\n\n> Include a description of the patient data set and the clinical trial recruitment data that are being analyzed by the ML model. The following table (also available in the [instruction]) represents the expected outputs. The inputs for the model are shown before the input-outputs block.\n2) How many eligible patients would the trial recruit?\n\n\n> [SOLUTION] The study expects five to six eligible patients out of 55 patients (9.1%).\n3) What are the benefits of having clinical trial data available for AI applications?\n\n\n> [SOLUTION] Applying AI tools to clinical datasets can support medical decision making with the advantages of speed and consistency. Clinical AI tools could be also used to improve the process of trial recruitment. You may also find the related resources (i.e., [instruction] and [instruction]) useful.\n4) How could AI techniques improve the trial recruitment?\n\n\n> [SOLUTION] AI can assist and speed up the trial recruitment process by identifying which patients are eligible for clinical trials. \n5) What is the goal of this lesson?\n\n\n> [SOLUTION] The goal of project is to perform eligibility assessment by means of the trained ML model. \n6) What is the input for the machine learning model?\n\n\n> [SOLUTION] The patient note and the clinical trial.\n7) What are the possible outputs of the ML project?\n\n\n> [SOLUTION] ML projects have an output that usually are represented as numbers. In cases where there are text or images, the model can produce a numerical score or probability for each class.\n8) What could prevent this from being an effective clinical trial to improve the lives of patients?\n\n\n> [SOL",
        "label": 0
    },
    "560": {
        "output": "[/] The following table shows the output of the eligiblity assessment.\n\n## Eligibility assessmeent\nPlease describe any assumptions and simplifications made and how these affect any conclusions drawn.\n\n## Question 5\nPlease write your assessment of the clarity of the code of analysis of the current clinical trial (3 sentence).\n\n## Data analysis of the clinical trial\nThe output of the eligibility assessment consists of the following table:\n\n## Eligibility assessment\n\n## Eligibility\nPatient\nTrial-level eligibility 0) Excluded 1) Not relevant 2) Eligible\nPlease write a summary of the findings from the code of analysis and data analysis in 3 senten ces.\nPlease describe any assumptions and simplifications made and how these affect any conclusions drawn.\n\n## Question 5\nIf any of the answers marked in the previous question you can see that this question.\n\n## Analysis of the dataset analysis\nIn addition to the description of code analysis for the clinical trial that is the focus of the study (Data-level assessment), please also evaluate the code for the clinical trial data that you collected (Analysis-level assessment) from a perspective on the validity and reliability of the data that the paper analyzes.\n\n## Data-level assessment\nWe are evaluating the validity of the trial that the researchers are interested in.\n\n## Analysis-level assessment\nPlease describe whether there are biases in the clinical trial data that researchers are interested in in the following table.\nIf you have answered positively to any of the questions, do you think that the biases are problematic for the analysis?\n\n## Validity reliability\nQuestion 10 Please write your assessment of the validity of the data-level assessment of the current clinical trial.\n\n## Question 11\nPlease write your assessment of the reliability of the data-level assessment of the current clinical trial.\n\n## Question 12\nPlease write your assessment of the validity of the analysislevel assessment of the current clinical trial.\n\n## Question 13\nPlease write your assessment of the reliability of the analysis-level assessment of the current clinical trial.\n\n## Question 14\nFrom the perspective",
        "label": 1
    },
    "561": {
        "output": "Please note that only in rare cases of a multiple note, the exclusion criteria should be applied before you reach the next line. In other words, if `Eligible` is already coded in a later line, then the exclusion criteria are no longer relevant, and the assessment should proceed to the next relevant line.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal",
        "label": 1
    },
    "562": {
        "output": "What should you say when you define it? \nFirst of all, you should declare the variable `dataset` as follows: `dataset=data.dat`. \nNow let's begin with data set manipulation. \n\n\nSo you have only patient and trial variables. Now you should add variables for calculating the LDL-value according to NHI protocol [INST]. [A: STEP 4 & STEP 5] \nNow let's see the LDL calculation. \nWhat do you obtain from the patient variables? \nFirst of all, look what you have obtained from the patient variables. You should obtain your patients' ages and LDL-C values. [A: STEP 6] \nBy looking at your patients' data, you should make a trial-level evaluation only if the LDL-C values are between 130 and 189 mg/dL. \nYou should call the trial if the second criteria is satisfied. But should call the patients if the criterion of the trial level eligibility is valid. \n\n\nWhat you have gotten from the trial? \nFirst of all, let's look at the trial. By means",
        "label": 1
    },
    "563": {
        "output": "# Author\n* {page-break-before:always}\n\n# <a name=\"author\"></a>Author\nThe `Author` section allows the author to assign a contributor list for this study. The `Author` may be listed as principal or co-investigator on this publication. A common scenario is to have more than one principal Author for the same research study.\n\nWhen authoring a study, the number of Authors that can be entered into this system is limited to 13. For example, the most senior Author is listed first, followed by \"and others\". The others are listed as 1<sup>st</sup> authors or, in alphabetical order. Therefore, up to 13 people may be listed as Authors in this study. This system has limitations. For example, the `Affiliation` section (which requires up to 300 characters) can only accommodate the top 12 Authors listed in the `Author` section and the \"and others\". If more than 12 Authors are needed, it should be completed manually within the text of the document.\n\n```html\nAuthor:\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n```\n\n## Note: The `Author` is the same as the `Corporate contact` field under the `Identification` section.\n\n\n### `CORPORATE CONTACT`\n\nThe `Corporate Contact` is mandatory for studies with more than one `Author`. Entering a Corporate Contact is a security feature that protects personal information from a publicly accessible research database.\n\nIn the `Corporate Contact` field, the `Corporate contact email` is mandatory. To complete, please enter a personal email address, so that the information is accessible when users contact the author.\n\n\n[/GEN]<EOD> The effect of lutein supplementation on visual acuity in patients undergoing cataract surgery: a prospective randomized trial.\nBACKGROUND",
        "label": 2
    },
    "564": {
        "output": "Your input should look like: \n$python code.py data/sample_clinical_trial.txt \n    Trial_start_date:    1996-10-15 \n    Trial_type:         Active, Phase  3\n    Trial_category:     Cancer_Therapy\n    Trial_status:       Active\n    Trial_end_date:     2001-10-15 \n    Trial_eligibility:   2) Eligible\n    \nOutput:\n   Eligible patient list:\n   0(excluded): 5\n   1(not_relevant): 10\n    2(eligible): 189\n\n# Results\n- The output consists of `0(excluded): 5`, `1(not_relevant): 10`, and `2(eligible): 189`.\n- 0(excluded): This means that five patients are not eligible.\n- 1(not_relevant): This means that ten patients do not have enough information to meet the prerequisites of the trial.\n- 2(eligible): This means that 189 trial-relevant patients are listed whose data have met the criteria.\n\n# Convergence \nThe `python check_eligibility.py` script first runs `./data/sample_clinical_trial.txt` and the current script is run twice to print the output file and save it as \".out\". Each command in the above output file is run in the Python Shell in a sequential manner, and the command sequence is performed as specified in the script's output file.\n\nIf the above script is run as follows, it will generate the desired results, assuming that the clinical trial data file.txt, python data/sample_clinical_trial.txt, the current script, and all the dependencies (including numpy, pandas, and a few other packages) are installed on your system. \n$python check_eligibility.py ./data/sample_clinical_trial.txt\n    Trial_start_date:    1996-10-15 \n    Trial_type:         Active, Phase  3",
        "label": 1
    },
    "565": {
        "output": "<span>(Optional)</span>\n\nYou can submit your code for the contest on the Grouper platform [INST](https://app.grouperhubs.org/proposals/42). Submission includes answering the provided question. Submission is allowed between 12:00 PM (UTC) 26 June 2020 and 12:00 PM, 7 July 2020 (UTC). Winners will have 3 days after the end of the contest to respond whether they would like to join a paid part-time job or to be a freelancer on the [INST](/) AI platform. Winners get 5-100 USD as the prize. You can also check all winners at [INST](https://app.grouperhubs.org/proposals/42).\n\n```python\n# + [markdown] colab_type=\"text\" id=\"VYI65Fwf6jU\"\n\n# + id=\"2p1ZRkZF5Y3s\" colab_type=\"code\" executionInfo={u'profilePhoto': img_url, u'cellType': u'v1', u'kernelName': u'tensorflow', 'outputsTableId': u'ccec0519-0620-4764-a7fa-628d57534095', 'colabUserInput': u'2p1ZRkZF5Y3s'}\n# + [markdown] id=\"r4ZZvvXe7Z70\"\n\n\n# + [markdown] id=\"r4ZZvvXe7Z70-1\" colab_type=\"text\" executionInfo={u'profilePhoto': img_url, u'cellType': u'v1', u'kernelName': u'tensorflow', 'outputsTableId': u'8a00e699-333f-4e36-be28-6a3ef1eb046f', 'colabUserInput': u'r4ZZvvXe7Z70-1'}\ntitle = f\"Trial-level eligibility for patient {patient_id.cap",
        "label": 1
    },
    "566": {
        "output": "## Reverse Phase Searches\n\nThe inverse of the query search of \"Simvastatin in Hyperlipidemia\" is\n[TrialType] AND 'Non Controlled Trial'\n\nReverse Phase Searches include:\n- [TrialType] - TYPE - All trial types, in randomized order.\n- [TrialType] - TYPE - CCT Randomized Control Trials, in random order.\n\n\nReverse Phase Searches use the following structure:\n```\n[[TrialType] AND 'Non Controlled Trial']`\n```<EOD> A novel role of a peptidyl-prolyl cis\u2013trans isomerase I (FKBP51) as a molecular target for phosphatidylinositol 3-kinase signaling\nThe recent report that the immunosuppressant FK506, an uncompetitive inhibitor of the peptidyl-prolyl cis\u2013trans isomerase I (FKBP12), induces growth arrest and apoptosis of breast cancer cell through enhanced binding of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway to the eukaryotic translation initiation factor eIF4E demonstrates that the function regulation of a single mammalian peptidyl-prolyl cis\u2013trans isomerase may be mediated by various signaling pathways.<EOD> High prevalence of CAD-CAM milled restorations in the permanent dentition in Germany and the Netherlands: a cross-sectional exploratory study of 333 schoolchildren\nObjective The aim of this study was to describe the prevalence of CAD-CAM milled restorations in the permanent dentition by caries risk status, and by age, gender, and country. Design A cross-sectional, exploratory study was carried out in Germany (Bremerhaven) and the Netherlands (Leeuwarden). Methods Two trained and calibrated examiners collected data using photographs from the schoolchildren aged 11 to 15 years present during an active school dental clinic day, who met the following inclusion criteria: the presence of at least 26 permanent teeth, not",
        "label": 1
    },
    "567": {
        "output": "[C]\n<EOD> A method for analysis of small nucleotide polymorphisms using the SNaPshot assay\n\nBackground: The next generation sequencing is currently one of the most important molecular biological methods, but it is limited in the analysis of large numbers of low-throughput molecules due to the high cost of sequencing. Small Nucleotide Polymorphism SNaPshot assays are an affordable alternative to the sequencing approaches to determine nucleotide polymorphisms. Because of the relatively low-throughput nature, the SNaPshot method is rarely used and the design of PCR primers is complicated, but the PCR products can be analyzed simultaneously by automatic capillary sequencer. Results: By using single-strand DNA templates derived by asymmetric PCR, we were able to determine small nucleotide variations by capillary electrophoresis after digestion of the PCR products with the SNaPshot enzyme. This simple detection method was optimized for the analysis of small variations between two or more sequences of interest. By introducing PCR asymmetry, we were able to achieve sufficient SNaPshot enzyme to complete reaction at lower temperatures (e.g. 60\u00b0C) and to reduce overlapping reactions between the templates. With only basic computer programs, one may design the PCR primer pairs and analyze the results, even by using the SNaPshot assays. Sensitivity of this method may also be improved to analyze lowfrequency mutation using quantitative PCR before the asymmetrical PCR.Conclusions: Small nucleotide variations, including substitution and deletions/insertions, were successfully analyzed by the SNaPshot method using asymmetric PCR amplification. By using PCR asymmetry, the SNaPshot method has been enhanced for genotyping of SARS coronavirus (SARS-CoV), human parainfluenza virus type 3 (HPIV-3), dengue virus type 3 (DENV-3) and H7N9 avian influenza virus.\n\n# Background\nThe next-generation sequencing approach produces large amount of raw nucleotide sequences and detects high frequency nucleotide variations, such as substitutions and short nucleotide insertions or deletions, but its high cost has limited its application",
        "label": 0
    },
    "568": {
        "output": "* * *\n\n**Leads and Challenges**\n\n\n* *\n\n\n\nThis challenge is to find the number of lines that do not begin with the same character, but are separated by exactly zero space (e.g., \"happiness\" can be found in the string \"hepaplasma\", because the strings differ only in one character, yet the string length is matched).\n\n[INST] Here is the string to be matched: ***\"hepaplasma, \"***\n\n[INST] Let's match the string:\n>\n> # Matching all sequences that begin with the letter \"e\"\n> # The variable \"count\" will contain the number of occurrences.\n> s <- paste0(\"hepaplasma\", \"*e*\")\n> count <- sub(s, regex(\"^e.*\"))\n> print(count)\nHeaplasma: 1\n\n> s <- paste0(\"hepaplasma\", \"**\" *) # replace \"*\" with a blank space character\n> count <- sub(s, regex(\"^e.*\"))\n> print(count)\nHeaplasma: 2\n\nThe code above matches the strings that begin with the letter \"e\" (i.e., \"Heaplasma\" and \"*e*\"). Let's change the search string to replace the letter \"e\" with a blank space character. In other words, we replace one item from the search string.\n> sub(\"e\", \" \", s)\n> print(sub(\"e\", \" \", s))\nHeaplasma * *\n\nIf we change the search pattern to replace the letter \"e\" with three white space characters, the number of matched sequences to the search pattern changes from 2 to 1.\n\n[INST] Now you can repeat the above codes to match the search patterns that beging with a particular letter (e.g., \"a\").\n\n[INST] In this exercise, you should use the string that begins with a special pattern, e.g., \"a\" and one of the search patterns presented above:\n\n\n* * *<EOD> META\u2010ANALYSES OF THE EFFECTS OF ANTIDEPRESSANTS ON CHILDREN\nMeta\u2010analyses allow an estimate of results from previous studies to be combined,",
        "label": 0
    },
    "569": {
        "output": "## Good luck!\n\n<EOD> Is there a need for an inhaled cystic fibrosis airway drug with a wide range of therapeutic effects?\n\nWhile cystic fibrosis has become the paradigm of genodermatoses, we still do not have a cure. There has been great progress in understanding the disease since the discovery of the genetic mutations and the development of better therapeutic strategies. However, the clinical outcomes of the patients are still far from being ideal. We are still searching for drugs targeting all aspects of the pathological mechanisms involved, from the basic defect in the epithelial cells to the immune response of inflammatory cells. There are several strategies for drug development: first, we have to develop new drugs targeting the epithelial ion transport defect; second, we may use already available bronchodilators in the treatment of the cystic fibrosis related bronchitis; third, the use of more specific drugs such as nebulized rhDNase at the clinical practice is still considered experimental because of the uncertainties of its safety. The development of new drugs for the treatment of cystic fibrosis is a complex process that requires close cooperation among clinicians, scientists and pharmaceutical companies. The clinicians have to help selecting drugs and defining parameters of efficacy of therapy, the scientists identify the pathological mechanisms that should be targeted as druggable by pharmaceuticals and the pharmaceutical companies perform the fundamental work of drug development and assess the safety and efficacy in animal models and in clinical trials.\n\n# Background\nCystic fibrosis (CF) is a genetic disorder caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a cell membrane protein that regulates the movement of the chloride and bicarbonate in epithelial cells. CFTR is a member of the ATP binding-cassette (ABC) family of proteins [bib_ref]  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, Riordan [/bib_ref] . The normal function of CFTR requires the interaction of CFTR with other proteins called CFTR modulators",
        "label": 0
    },
    "570": {
        "output": "# [ACCEPT]\nYou accept that the patient satisfies the inclusion criteria and does not meet the exclusion criteria, e.g., You accept that the patient satisfies the inclusion criteria and does not meet the exclusion criteria, e.g., `Accept: 1) Excluded` (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)`Accept: 0) Excluded` (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)\n\n# [SENT]\nNow you should send the output data about the patient to the server by the form: `Send: {\"note\": \"{}\"}`. \nWhen using the form: \nYou should select the first line from `Input for patients note and the patient's clinical trial note` form. Then, from the next line, type your assessment of the patient's eligibility. \n[INST]\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\n```\nSend:\n```<EOD> Comparison of microbiological testing methods and risk factors among patients with diabetic foot ulcers\n\nO r I g I n a l a R t I C r e d I t a r I a T I n F o M M y c o Bi o l o g y Comparison of microbiological testing methods and risk factors among patients with diabetic foot ulcersO r I g I n a l a R t I C r e d I t a r I a T I n F o M M y c o Bi o l o g y Comparison",
        "label": 0
    },
    "571": {
        "output": "<EOD> .\nLaser-Doppler flowmetry (LDF) (Moore, Transit Time Tissue Differential) was performed on the uterine cervix in 12 pregnant women and in 6 non-pregnant women with known cervical insufficiency. In all pregnant women LDF indicated an increase of blood flow velocity with intrauterine pressure (IUP) from 15 to 30 mmHg. The curves of the pregnant women show also a distinct maximum of blood flow velocity shortly before the onset of contraction. Above a peak flow velocity value of more than 6 cm/sec in LDF, the pregnant women will be in danger of uterine cervical insufficiency. In normal pregnancy the uterus is perfused to a higher degree than it is in normal not-pregnant women.<EOD> .\nLactotensin is one of the endogenous peptides with an anxiolytic-like effect. Anxiolytic-like effect of lactotensin was established in the Vogel \"laboratory\" test in mice with different levels of aggressive behavior. The level of aggressive behavior of animals is directly dependent on the lactotensin content in the brain. Thus, the higher content of this peptide in the brain of mice the higher the level of aggressive behavior of animals. Possible participation of lactotensin in the regulation of the level of aggressive behavior in animals has been suggested.<EOD> Effects and mechanisms of pine pollen immunization on improving the immunocompetence of weaned piglets.\nPine pollen (PP) is a nut and medicinal food with various biological activities. The objective of this research was to investigate the effects and mechanism of pine pollen on the regulation of immune function in weaned piglets. In total, 120 healthy weaned piglets were selected for 42\u00a0days of experiments. The piglets were randomly assigned to four groups, being fed with different diets: 0.2% PP, 1.50% PP, 3.00% PP, as well as the control diet. Piglets' performance,",
        "label": 1
    },
    "572": {
        "output": "<EOD> Immobilization of lysozyme onto the surface of gold nanoparticles via an antibiofouling polymerization reaction.\nAntibiofouling gold nanoparticles (AuNPs) were synthesized using pendent epoxide reagents in the presence of poly(ethylene glycol) methyl ether thiol (PEGMET) as the antibiofouling polymer. The surface modification of AuNPs was carried out through the ring-opening reaction of an epoxide. The effectiveness of the functionalization was characterized using UV/vis spectrometry, zeta-potential analysis, and fluorescence resonance energy transfer (FRET) via the ratio of absorption of excitation light to emission light from PEGMET-modified AuNPs. The FRET results indicated the successful immobilization of PEGMET onto the surface of AuNPs. Furthermore, the ability to functionalize the AuNP surface with the antibiofouling polymer for the immobilization of proteins was verified by surface chemistry analysis and FRET of the protein, chicken egg white lysozyme covalently conjugated on the surface of the antibiofoulingly modified AuNPs. The result showed the successful immobilization of lysozyme molecules onto the surface of the antibiofouling AuNPs. The lysozyme modified AuNPs obtained were stable after being incubated with an antibody-capture assay.<EOD> Assessing cognitive decline following traumatic brain injury\n\nPurpose: This systematic review examined the utility of commonly used cognitive measures of attention, memory, and executive functioning in detecting early changes in cognition following traumatic brain injury (TBI).Methods:A systematic review was performed. Medline, EBSCO's (CINAHL, PsychINFO, SocINDEX) and Psychology and Behavioral Sciences Collection, and ProQuest Dissertation & Theses databases were systematically searched using combinations of the following keywords: \"cognitive, \" \"cognition, \" \"brain injury, \" \"trauma, \" \"accident, \" \"concussion, \" and \"focal cranial injury. \" Publications were reviewed",
        "label": 1
    },
    "573": {
        "output": "</SPAN><!-- Instructions and Answers\n\n<H1 id=\"q1\"></H1>\n<P><SPAN id=\"answer_q1\">A.\n1</SPAN><!--Answers--> <H3 id=\"q1\">Question #1</H3><H4 id=\"answer_q1\"><P><SPAN style=\"margin-left: 0.2em\"><P><SPAN style=\"margin-left: 0.2em\"><P><SPAN style=\"margin-left: 0.2em><STRONG><SPAN style=\"font-style: italic;\">Please choose the correct combination of 1 answer below that meets the eligibility criteria to the patient.</SPAN></STRONG><BR></SPAN></STRONG><P><STRONG><SPAN style=\"font-style: italic;\">Inclusion and exclusion criteria for study </SPAN></STRONG></P></P><BR></SPAN></P></P></P></SPAN>\n</H4><BR>\n<H3 id=\"q2\"></H3>\n<P><SPAN id=\"answer_q2\">A.\n1</SPAN><!--Annswers--> <H3 id=\"q2\">Question #2</H3><H4 id=\"answer_q2\"><P><STRONG><SPAN style=\"font-style: italic;\">The patient meets all the inclusion criteria of the clinical trial, except for the following one: (1) <STRONG>The patient is currently taking medications that are contraindicated in the IMP (e.g.: non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme (ACE-inhibitors).</STRONG>. </SPAN></STRONG><P><STRONG><SPAN style=\"font-style: italic;\">Please choose the correct combination of 1 answer below that meets the eligibility criteria to the patient. </SPAN></STRONG></P></P><BR></SPAN></P></P></P></P></SPAN>\n</H4><BR>\n<H3 id=\"q3\"></H3>\n<P><SPAN id=\"answer_q3\">A.\n1</SPAN><!--Annwers--> <H3",
        "label": 1
    },
    "574": {
        "output": "<EOD> Enhanced production of a cyclic dipeptide from the cyanobacterium Oscillatoria sp. with immobilized cells in stirred culture.\nCyanobacterial biomass was immobilized in agar-gel beads and used for the enhanced production of the cyclic dipeptide cyclo-(Phe-Val), which has a high antagonistic potential against spore germination of plant pathogens. Two strains of the cyanobacterium Oscillatoria sp. were used for the immobilization on agar-gel media, which were prepared using polyhydroxybutyrate (PHB). High immobilization efficiencies of over 99% could be achieved in the beads with the addition of PHB into the agar-culture medium. The immobilized biomass in agar-gel media was stable for culture after a storage period of 6 months. Highest cyclic dipeptide levels of up to 11.0 mg/L were observed in the immobilized cell cultures, whereas no significant amounts of the cyclic dipeptide were synthesized in the suspension culture with free cells. Under optimal conditions, the biomass in immobilized cell cultures, which corresponded to a cyclic dipeptide productivity of 5.7 mg/L/day, could be harvested over 14 days without visible loss of activity during prolonged cultivation.<EOD> Detection of human serum amyloid P component (FSP) by a monoclonal and a polyclonal antibody. Characterization of the antigens of the major component of normal and amyloid fibril proteins.\n\nHuman serum amyloid P component was detected by two different antibodies in an amyloid patient with AL-type amyloidosis. The methionine-enkephalin amino sequencedetermined residue from a major component of the fibrils of this patient and of three other patients with multiple myeloma, who had amyloid fibrils of AL type, was serine. These findings suggest that amino acid substitution with serine at position 4 in vivo is characteristic for amyloid-P fibrils. Further investig",
        "label": 1
    },
    "575": {
        "output": "This section of the tutorial is aiming to teach you how to write an algorithm that will predict the answer of your code. You must create a function named `createData(patient, trial)` that takes two arguments, a patient and a trial, and returns a list of three elements, patient's information (age, gender, \u2026), trial information, and the decision of the algorithm, respectively.\nFor the evaluation of your code, you will get a collection of patient records and trials that correspond to your patients with the given treatment. You will also submit your candidate program to the judge and the judge will give you the output of the trial-level eligibility decision.\nLet A, B, and C be the algorithms that will be tested in your programming competition for the prediction of a patient-level eligibility for the trial. A is the algorithm you will develop. The other algorithms, B and C, are the algorithms trained in your programming course. You should learn about them to get a better sense of what your peers' algorithms will do, and try to match them as your peers might have done.\n\nHere is the list of trial-level eligible patients: \n\nYou can use the patient list to create the patient structure that should be passed to the function `createData(patient, trial)` by the following line:\n\nYou should predict trial_level_eligibility by:\n\nYour program should be able to handle each algorithm including A. \nBased on all of your experiences with the algorithms, your code will be evaluated in the following two steps:\n\n- You will get a file that contains the trial_level_eligibility output for each patient.\n- You will rank your code from 0 to 100 against the two other algorithms with a score of 0 for a prediction less than 50% in average, a score of 40 for 80% prediction score, and 100 for 100% prediction score.\n\n# Discussion\nThis section of the tutorial is aimed to discuss your code with you. In this section you will find explanations on your code regarding both its strengths and limitations. \n\nYou successfully created a working code, and your score for matching the algorithms, is over 96! Your peers will see it as a very helpful function that will enhance the functionality of the trial in their programming.",
        "label": 1
    },
    "576": {
        "output": "<EOD> Dipyridamole-induced myoclonus\nThe adenosine A1 agonists are useful in the diagnosis of ischemia, as they cause chest pain and elevation of cardiac enzymes by coronary artery spasm. Dipyridamole, which is the best-known representative of the adenosine A1 agonists, is commonly used for pharmacologic stress test. The most common adverse event is myoclonus, although chest pain and elevation in heart rate are also observed. However, the etiology of myoclonus is still unknown. In the present article, we report a case with myoclonus induced by dipyridamole. Myoclonus seems to be directly or indirectly related to adenosine. The pathophysiologic mechanism and the treatment of myoclonus are discussed.<EOD> Convergent validity of two measures of the Dementia Rating Scale-1.\nOBJECTIVES\nTo determine the convergent validity of the Cognitive Capacity Index (CCI) and Index of Intellectual Functioning-67 (IIF-67) with the Dementia Rating Scale (DRS-1).\n\n\nMETHODS\nThis is a retrospective, cohort study of 462 older adult Medicare dementia patients evaluated by geriatric psychiatrists at an academic medical center over a 10-year period. CCI was assessed by examiner-rating and IIF67 by self-report (or clinician interview for limited communicators). DR was also assessed by examiner-rating. Multivariate regressions evaluated the predictive validity of both measures.\n\n\nRESULTS\nCompared with the DRS-1, both the CCI and IIF67 were associated with higher degrees of dementia. The CCI, DRS-1, and age explained over 50% of variance in the DRS-1. The IIF67, DRS-1, and education level explained over 50% of variance in the DRS-1.\n\n\nCONCLUSIONS\nBoth IIF67 and CCI were valid for the diagnosis of DR-requiring dementia. The CCI",
        "label": 2
    },
    "577": {
        "output": "##[/TASKS]\nGood job! You have finished your task!\n\n---\n\n## Hint 179. [MOONLIGHT][NAME] Moonlighting RN: CMS Innovation Project. Title: Improving outcomes of patients with congestive heart failure admitted as Medicare and/or Medicaid beneficiaries in rural hospitals. Funded by the Centers for Medicare and Medicaid Innovation. You are one of the members of the project. The goal of the project is to pilot a clinical decision support system for improving outcomes of patients with congestive heart failure in small and rural hospitals in the US. In order to get a better understanding of the project, try out the demo below. The demo explains the clinical workflow and demonstrates its usability in small and rural hospitals.\n\nhttps://www.youtube.com/watch?v=FmqBNM-f5rE\n\n[/MOONLIGHT]\n\n### Moonlighting RN: CMS Innovation Project: Assessed Tasks. [INST]\n\nThis part will be like a recap. Try your best to identify the important details.\n\n\nThe objective of our project is to provide health services to Medicare and/or Medicaid beneficiaries admitted as hospitalized patients in rural hospitals. The goal of the project is to improve patient outcomes through the implementation of a clinical decision support system. We are working on the hospitalized patients with congestive heart failure (CHF). Our proposed target population is the hospitalized patients with congestive heart failure (CHF) (either alone or as exacerbation).\n\nThe team includes: an internal medicine physician of the hospital, a full-time staff nurse, a pharmacist, a hospital administrator, a hospital finance officer, staff nurses, other physicians, the rural hospital's administrator, the rural hospital's finance director, a project coordinator, and the data manager.\n\nTo implement this project we have followed these steps:\n\n- Step 1: To discuss our project idea to hospital administrator and finance director.\n- Step 2: To develop our project protocol\n- Step 3: To develop our clinical decision-support system and user interface",
        "label": 1
    },
    "578": {
        "output": "To test the pipeline, click on 'Play Pipeline' and a window will open and the code will be executed.\n\n\n![](./Images/Examples/BELR/17/eligibility.png)\n\n\n#### Result\n\n```bash\nA: 0.090 \nB: 0.060 \nC: 0.170 \n```\n\t\n![](./Images/Examples/BELR/17/eligibility-result.png) \n\n\t*Note*: You can see in the upper right corner the percentage of the eligible patients, that for each trial is 0.1700, which means that 17.00% of patients are eligible.\n\n\n\n## Assessment-eligibility \n\n### Description\n\nThis step calculates the clinical trial-level eligibility. It should be an integer variable between 0 and 2, indicating the patients' level of eligibility between 0) `Excluded`, 1) `Not relevant`, and 2) `Eligible`. \nThis step can be done by using the `eligibility` function. `eligibility` function takes two arguments: a list of `patient_notes` and a list of `clinical_trials` variables, correspondingly. \n\n### Example\n\n\n\n\n| patient_note | clinical_trial | result |\n|-------------|---------------|-------|\n| A | B | 0.060 |\n| A | C | 0.170 |\n| A | D | 0.650 |\n| 1 | C | 0.090 |\n| B | A | 0.720 | \n| B | D | 0.150 |\n| B | C | 0.650 |\n\n\n![enter image description here][2]     [2]: https://i.stack.imgur.com/dD4i3.png\n\nTo check the pipeline you can click on `Play Pipeline` and a window will open and the code will be executed.\n\n### Code\n\n```python\npatient_notes = ['A', 'B',",
        "label": 0
    },
    "579": {
        "output": "<EOD> The genotoxicity of the nonionic detergent Triton X405 in Drosophila: is there any evidence for the occurrence of methylation changes?\nThe methylation pattern and total DNA content of larvae of Drosophila melanogaster exposed to nonlethal doses (10 microL/mL solution) of the nonionic detergent Triton X405 were examined. No differences were found in the total DNA content, in the number of lethargic individuals or in the number of mutated flies among the treated group and the control group. The methylation pattern, obtained by sodium bisulphite DNA modification followed by polymerase chain reaction (PCR) amplification and denaturing polyacrylamide gel electrophoresis, showed no difference in the methylation patterns between Triton X405-treated flies and the control group. These results do not rule out the involvement of the cell cycle in the mode of action of Triton X405, but rather indicate that in our experimental condition, Triton X405 did not induce DNA methylation changes.<EOD> Synapse density and cell packing in the optic tectum of the chicken\nAlthough aves and mammals have evolved different architectures in the central part of the central nervous system, they share several features, including complex mosaics of cell types and extensive synaptic connectivity. Despite this similarity, there are also striking differences, including in the tecto\u2010tectal synapses and in the gross architecture of the tectum. In this study, we have compared both synapse density and laminar cell packing of the chicken (Gallus gallus) and mammalian tectum.<EOD> A comparison of two assays for the detection of antithyroglobulin antibodies.\nHeterophil antibody assays are prone to problems in interpretation and are of limited value compared to other direct antibody assays, particularly the latex particle agglutination test. Results of this assay, when compared with the latex assay and the radioimmunoassay of thyroglobulin antibody (TgAb), support its poor level of sensitivity and",
        "label": 1
    },
    "580": {
        "output": "## Good luck!\n[INST] Here is the patient note:\nA 45-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors (e.g., smoking, high blood pressure, and diabetes) and is physically active. The patient`s LDL-C and HDL-C levels were 141 and 46\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient also reported that smoking onset was at age 25, his current alcohol intake was less than once a week, and his past alcohol consumption was more than once a week.\nThe patient reported no use of lipid-lowering medications.\nUltrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 141.5\u2009cm/s and 36.79\u2009cm/s, respectively; RICA PSV was 89.73\u2009cm/s and RICA EDV was 34.91\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nLet say the assessment of eligibility is 2. That means, the patient is eligible for inclusion. Good job! \n<EOD> Acute and chronic effects of alcohol.\nThe authors review the acute and chronic effects of ingesting alcohol with regard to its effect",
        "label": 1
    },
    "581": {
        "output": "<p id=\"main\" class=\"jstn-hypothetical\">\n\t\t<p>\n\t\t\tThis is the output result for the input of the test set.\n\t\t</p>\n\t\t<p class=\"rounded\">\n\t\t\t<span class=\"rounded\"><i class=\"rounded-icon fa fa-clock-o fa-4x\"></i></span>\n\t\t\t( <span class=\"text\">\n\t\t\t\t<i >\n\t\t\t\t\t95.7%\n\t\t\t\t</i>\n\t\t\t\t(28/29)\n\t\t\t</span>\n\t\t</p>\n\t\t<i class=\"text\" id=\"true_positive_i\"></i>\n\t\t<p class=\"rounded\"><span class=\"rounded\"><b>True Positive:</b></span> \n\t\t\t4\n\t\t</p>\n\t\t<p class=\"rounded\"><span class=\"rounded\"><b>False Positive:</b></span> 0\n\t\t</p>\n\t\t<p class=\"rounded\"><span class=\"rounded\"><b>False Negative:</b></span> 0\n\t\t</p>\n\t\t<p class=\"rounded\"><span class=\"rounded\"><b>True Negative:</b></span> 0\n\t\t</p>\n\t</p>\n\t\n  </body>\n</html>\n\n\n    %rpc : id : \"Trial-level eligibility\" ;\n                desc : \"Trial-level eligibility assessment of a clinical trial for a patient\";\n                input : \"patient_doc\", \"patient_note\", \"trial_doc\", \"trial_data\" ;\n                output : \"eligibility_scale\"\n\n\n    : rproc\n    :\n    if\n    eligibility \n    in\n    \"el_016\", \n    \"el_011\", \n    \"el_004\", \n    \"el_001\", \n    \"el_007\", \n    \"el_003\", \n    \"el_005\",",
        "label": 1
    },
    "582": {
        "output": "## Learning objectives\n- You will learn the clinical practice of patient chart review and data entry.\n- You will get familiar with the data visualization tool called `patient note report`.\n\nLet's review the following example patient note, which is a patient's clinical data:\nPatient Name: Sasha\nClinical Trial: JACTAX LD Drug Eluting Stent Trial\n\n# Learning Materials\n\n#### Detailed Trial Description\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u00a0mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u00a0mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u00a0cm/s and 54.5\u00a0cm/s, respectively; RICA PSV was 91.72\u00a0cm/s and RICA EDV was 37.37\u00a0cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being",
        "label": 0
    },
    "583": {
        "output": "removes the header line (in the first line), [INST] in the third line removes the last line from the last section, and [/SINGLE] in front of the text field in the fourth line adds an extra space before and after the code block.\n\n#### 5.9.1 \u6458\u8981\n\n# Acknowledgments: Thank you Dr.\n[fig]  22: Note: `Clinical trial comparison code` is the class for code blocks of clinical trial comparison. 48 # # If the patient meets inclusion criteria: # 49 # Check if the patient is included in the trial by matching first # the identifier of the clinical trial # with the one of the patient, # and then match criteria # and exclusion criteria of the patient # with inclusion criteria of the trial. 50 patient.clinicaltrial_identifier==trial.identifier). patient.clinicaltrial_inclusion_criteria.c1==trial.inclusion_criteria.c1 or 52 patient.clinicaltrial_inclusion_criteria.x1==trial.inclusion_criteria.x1 or 53 patient.clinicaltrial_inclusion_criteria.c2==trial.inclusion_criteria.c2 or 54 patient.clinicaltrial_inclusion_criteria.c3==trial.inclusion_criteria.c3 or 55 patient.clinicaltrial_inclusion_criteria.c4==trial.inclusion_criteria.c4 or 56 patient.clinicaltrial_inclusion_criteria.x2==trial.inclusion_criteria.x2 or 57 patient.clinicaltrial_inclusion_criteria.c5==trial.inclusion_criteria.c5 or 58 patient.clinicaltrial_inclusion_criteria.c6==trial.inclusion_criteria.c6 or 59 patient.clinicaltrial_inclusion_criteria.x3==trial.inclusion_criteria.x3 or 60 patient.clinicaltrial_inclusion_",
        "label": 1
    },
    "584": {
        "output": "For `2) Eligible.` you have to give a reason for the 'yes' to the patient note in accordance with the three-point scale of 'excluded', 'not relevant', and 'eligible', with the exception of `relevant` (as per the example patient note). \n- The best method of the 'excluded' assessment of the three-point scale is to use inhibitive words, e.g., `'Not eligible'. The reason for the 'not eligible' should consider the following: - Not meeting the inclusion criteria, especially the criteria on laboratory test results. For example, the patient did not test normal level, e.g., the patient has LDL-C 545. - Not meeting the exclusion criteria, especially the criteria on medical history. For example, the patient reported no use of lipid-lowering medication. In addition, medical history, which is described in the patient note, supports the negative assessment for the following inclusion criteria such as \"Must have no history of allergy to any of the components of the combination regimen for P1446A-05.\" Accordingly, according to the patient history, allergies to P1446A-05 components do not exist.  \n- 'Not relevant': Not meeting at least one inclusion criterion or meeting at least one exclusion criterion. Inclusion and exclusion criteria do not apply. The best method of the 'not relevant' assessment of the three-point scale is to use the word 'not' (e.g., `'Not relevant.'`. For example, 'patient is <65 years old', which means the patient is meeting the inclusion criteria for age, i.e., > 65, which is not matched with the definition of age in the inclusion/exclusion criteria, i.e. '65 years or more (inclusive)' is a mismatch of age in inclusion/exclusion criteria.   - '<25 years old', 'metastatic', 'not relevant'. \n- 'Eligible': This statement is the best for describing any matching information. For example, a laboratory test results support the yes-response, e.g., `The patient has 85+/-5 mg/dL of LDL-C level, which is <100 mg/dL and meets",
        "label": 0
    },
    "585": {
        "output": "A: First of all, you will have to import libraries which help to perform calculations:\nimport pytest\n\nfrom time import sleep\nimport pandas as pd\n\nAlso you will need the following packages:\nimport ipywidgets\nimport ipykata\nfrom ipywidgets.widgets import CheckboxGroup, Text\n\nNext, you also will need to define your function which is going to check all required data:\n\nimport time\nfrom ipywidgets import Text\nfrom ipkglib import IPKG\n\n\ndef Eligibility:\n    ipgk = IPKG.open() \n    with open(\"patient_record.csv\") as fp:\n        # open the csv\n        patient_records = pd.read_csv(fp)\n    ipgk.open()\n    for record in patient_records.itertuples():\n        record_name = record.name\n        record_gender = record.Gender\n        record_age_years = int(record.Age)\n        record_age_in_years = int(record.Age)\n        record_cholester = record.TotalCholesterol\n        record_hdl = record.HDL\n        record_ldl = record.LDLCholesterol\n        record_triglyceride = record.Triglyceride\n        record_heart_beats_per_minute = record.HeartRate\n        record_carotid_stenosis_left_side = record.CarotidStenosis_leftSide\n        record_carotid_stenosis_right_side = record.CarotidStenosis_rightSide\n        record_stroke_history = record.History_of_stroke\n        record_risk_factor = record.risk_factor\n        print(f\"Calculating eligibility for patient record with ID {record.ID}\")\n        isValid = validate(\n            record_name,\n            record_gender,\n            record_age_years,\n            record_age_in_years,\n            record_cholester,\n            record_hdl,\n            record_ldl,\n            record_triglyceride,\n            record_heart_beats_per_minute,",
        "label": 0
    },
    "586": {
        "output": "# ICD10\n* Code: I29\n\n# MIM\nG07.908\n\n# Treatment\nTreatment with statins reduces the risk of death by about 17% on average. It is also effective at stopping strokes. Treatments may vary depending on the country, but cholesterol-lowering drugs and lifestyle changes are usually recommended. A diet including fish or omega-3 may also help.\n\n## Conservative management\nA conservative approach may be used to treat asymptomatic individuals. This involves not treating the condition, or making only minor changes to the diet. Often this is a trial of six months.\n\n## Surgery\nSurgery is sometimes used to treat those living with high cholesterol. A simple surgical procedure will remove most of the gall bladder. Surgery is usually only needed for those with severe symptoms of gallstones.\n\n## Medications\nTreatments including statins, fish oil capsules, fibrates, nicotinic acid, ezetimibe, and bile sequestrants are sometimes used to treat high cholesterol. The evidence is not in the patient's favor, with only some medications producing small to moderate benefits, and their overall use cannot be recommended.\n\n# Cholesterol gallstones\n\n## Alcohol\nAlcohol does not cause gallstones. However, drinking more than three units of alcohol each day increases the overall risk of mortality from gallstones.\n\n## Diet\nNutritional changes are important for those with gallstone disease, including reduced intake of refined carbohydrates and saturated fats. A diet rich in fruit and vegetable may help prevent gallstones.\n\n## Weight\nBeing overweight significantly increases the chance of developing a gallstone. Losing weight may help prevent and treat gallstone disease.\n\n## Physical activity\nA lack of physical activity is a risk factor for high cholesterol. This includes not having enough energy to exercise sufficiently. It may be beneficial for those with gallstones to have a more active lifestyle.\n\n# Epidemiology\nGallstones are common throughout the world, and are particularly prevalent",
        "label": 1
    },
    "587": {
        "output": "[RQ10] Consider the following statement: \"The prevalence on both MHD and HAP is 13% in the older population in Taiwan.[3] When considering both disease statuses, the prevalence of both or either MHD or HAP ranges from 25% to 66% among the older population in Asian countries,[4]\"\nNow, let's take a look at the following question:\n\n* _Question ID:_ RQ_08_03\n\"What is the effect size of CVD associated with the use of statin in high-risk people (\u2265 65+ years old people with hypertension and/or CAD) with/without HAD or HAP?\"\nAs you know that, we have already found that $15.8\\ (\\%\\)) \\times 11.14026\\ (15475.7086)= 18650.24. \nIn the statement we found that:\n- \"The prevalence on both MHD and HAP is 13% in the older population in Taiwan.\"\n- \"When considering both disease statuses, the prevalence of both or either MHD or HAP ranges from 25% to 66% among the older population in Asian countries.\" \n- \"The prevalence on both MHD and HAP is 13% in the older population in Taiwan....\"\n$15.8\\ (\\%\\)) \\times 13= 205.4\\ (\\%\\), \nHence, we have the effect size in the older population in Taiwan.  \nThe use of statin in high-risk people (\u2265 65+ years old people with hypertension and/or CAD) has a significant effect to prevent CVD of $205.4\\ (\\%\\)$\n\nThe effect size of $205.4\\ (\\%\\)$ means that $100$ patients will get $H: 130$  and $x$ patients will get $H\\prime:$ 130$   if there are no statin.\nOn the other hand, the effect size of # $205.4\\ (\\%\\)$ means that $100$ patients will get $H",
        "label": 0
    },
    "588": {
        "output": "_Note_: `Eligible` is the preferred option.\n_Note_: `1) Not relevant` is not recommended if the patient is a participant of a clinical trial without prior knowledge of the eligibility criteria.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits. \nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and",
        "label": 1
    },
    "589": {
        "output": "For a tutorial on how to assess all 5 features of each note, please refer to [[In-SilicoLab/Clinical_note-based_feature]]\n\n## In-silicoLab/Clinical_note-based_features\nIn-SilicoLab<EOD> Implementation of an online intervention in the work context: the case of 'healthier eating'.\nThe aim of the study was to explore the main barriers, opportunities and needs for a workplace intervention aiming to 'eat healthier'. Four focus group interviews were conducted with nursing staff working on a general ward (n = 7) and a neurological ward (n = 8), both of a large UK hospital, and included interviews with dieticians (n = 5) and a catering service manager (n = 1). Food and nutrition was identified as an important issue for both patients and staff in the work place. Food preparation was highly managed by the nursing staff on the wards, with several barriers to healthier food options being identified in relation to both patients (increasing autonomy and choice and improving cooking skills) and staff (time) areas. Some opportunities were also identified based on staff and patients needing to have both an individualised approach with more flexibility around food choices and the possibility of tailoring food options. In terms of needs, staff and patients expressed a desire for healthier food items in the canteen and to encourage family and friends to eat healthier. In conclusion, the current study presents an initial exploration around the issue of healthy eating at work, which provides evidence and understanding for the development and implementation of healthy eating interventions in these settings.<EOD> .\nINTRODUCTION\nIn this study we investigated the role of CAPE in the modulation of some markers of brain inflammation and the neuroprotective effects of CAPE administration in a rat brain damage model induced by ischemia and reperfusion injury.\n\n\nMATERIALS AND METHODS\nIn a randomized, controlled and double blind study, we tested two groups of adult male Wistar rats subjected to brain ischemia and reperfusion injury: (1) an intraperitoneal injection of 5 mg/kg CAPE",
        "label": 1
    },
    "590": {
        "output": "You should try to achieve this solution. When you submit your code to the Assignment Grader, you can see what it expects to see. The Assignment Grader will then send you private feedback, explaining how to resolve the problem.\n\n\n[inst] Your solution should include:\n\n      #!/bin/python\n      import sys\n      import os\n      import pdb, traceback\n      import time\n      import matplotlib.pyplot as plt\n      import numpy as np\n\n      import pandas as pd\n\n      import matplotlib.pyplot as plt\n      pd.set_option('display.max_rows', 1000)\n      pd.set_option('display.max_columns', 1000)\n      pd.set_option('display.width', 160)\n      pd.set_option('max_col_widths', [160])\n\n\n\n\n      from readcsv import ReadCSV, readfile, SaveCSV\n\n      from readcsv import readdata\n\n      from readcsv import csv_header\n      from csv import *\n\n\n\n      from time import clock\n      from datetime import datetime\n      import csv\n\n\n      from pandas import DataFrame\n      from pandas import Series\n\n      #for a given location_id, a single patient will have two trials corresponding to timepoints t1 and t2. It is\n      #necessary to use the same dataset to generate both trials.\n      data = {'timepoint'  : 't1', 'trial1'  : '', 'trial2'  : '', 'location_id'  : '',\n              'age'        : '', 'ldl_c'     : 0.0,  'hs_c'     : 0.0, 'hdl_c'    : 0.0, 'diastolic'  : 0.0,\n              'systolic'    : 0.0,  'bpm'      : 0.0, 'smoking'  : 1, 'exercise' : 1, 'diabetes' : 1, 'hypertension' : 1}\n      for row_idx in range(5):\n      data['timepoint'] = row_idx\n      data['",
        "label": 1
    },
    "591": {
        "output": "### Task 1 Part 2\n![PART2][SEC]\n\nHere you will read another case about a patient who is not eligible for a given clinical trial. Your task is to indicate patient's exclusion from the trial using an exclusion criterion and patient ID. \nA woman in her late 50's presents with right-sided leg numbness. She reports worsening intermittent claudication over the past two months. Physical exam is notable for diminished sensation to touch in the right L5 dermatome and diminished bilateral dorsalis pedis pulses. A duplex ultrasound of the popliteal, posterior tibial, and dorsalis pedis arteries is performed. Imaging demonstrates severe bilateral femoral artery atherosclerotic disease. There are no plaques in the popliteal arteries, although the posterior tibial artery is notably tortuous.\n\nIn accordance with the study protocol, if the woman (ID = 1) is found to be eligible and willing to participate in the study, the investigator would randomize her to receive one (ID = 2) of the following treatments in a double blind fashion:\n    1) Standard therapy (ID = 2) (control arm): Antiplatelet therapy for at least one year. \nHere is the patient note: \nA 48-year-old woman with a history of hypertension and smoking, presents with right-sided leg numbness. She reports worsening intermittent claudication over the past two months. Physical exam is notable for diminished sensation to touch in the right L5 dermatome and diminished bilateral dorsalis pedis pulses. \n\n![Part 2][FIG] \n[SEC]\n[SEC]\n\nYou should note as many trials as possible.\n\nFor example, if a patient does not meet one or even three conditions of inclusion, the investigator will exclude him from participation in the study. For this study, let's suppose that a 55-year-old man is not eligible to participate in the clinical trial. Therefore, he should not be included in the study, and the investigator",
        "label": 1
    },
    "592": {
        "output": "# Background\nAn important challenge in clinical research is patient eligibility, which is essential for trial success. A clinical trial may fail to enroll the anticipated number of participants if it is unable to find a large population of patients who meet the eligibility criteria. Alternatively, the trial may include too many patients who are incorrectly enrolled as eligible. The use of patient-level eligibility assessments allows for more accurate matching of patients to research studies. However, the current trial eligibility workflow can make screening for potential patients a tedious and time-consuming task. This is because eligibility results need to be manually reviewed in a patient record management system. Manual processing also poses challenges due to the need for skilled staff to use complex eligibility templates. AI is helping to overcome these challenges by using machine-augmented technology to automate eligibility screening across multiple clinical trials as well as improving efficiency for study personnel.  [MORE] \n\n# Discussion<EOD> In vitro biosynthesis of the carotenoid astaxanthin in Euglena gracilis: analysis of intermediates by anion-exchange high-performance liquid chromatography/electrochemical detection.\nHigh-performance liquid chromatography/electrochemical detection was used to monitor the incorporation of acetate or mevalonate into intermediates of the (3S,3'S)-3-hydroxyergosta-4,7,9(11),22-tetraene (astaxanthin) pathway in intact cells of the ciliate Euglena gracilis and in cell homogenates. Using isolated phosphatidylinositol-rich particles, incorporation of mevalonate into the astaxanthin pathway could be followed in a time-dependent manner. Mevalonate was taken up by this organelle and directly metabolized to ergosterol, 24-methylenecholesterol, 7-oxo-cholesterol, 3,4-sterol 24-methylenepropiolate and 24-methylenecholesterol (5): 7alpha-fucosterol and fucosterol (7alpha-5,7-d",
        "label": 1
    },
    "593": {
        "output": "<EOD> Development of an efficient DNA vector for use in the legume model Medicago truncatula.\nGenetic transformation of legume plants is often impeded by the difficulty of selecting transformed cells on the basis of their antibiotic resistance phenotypes. To address this problem, binary vectors which can be maintained as extra-chromosomal elements have been developed in a variety of model legumes. However, while these vectors have been highly successful in the model plants soybean and alfalfa, these vectors fail in Medicago truncatula. A critical factor may be a lack of appropriate selectable markers which are able to provide efficient selection of resistant cells in M. truncatula. Here we demonstrate that the plant-made phosphite transporter gene (MtPTS1) can be used as an additional selectable marker in M. truncatula. We also report the successful development of a bicistronic binary vector where the expression of beta-glucuronidase from a second selection marker gene (bar) allows the simultaneous selection of all three resistance markers.<EOD> .\nThe role of adenosine receptors in modulation of synaptic transmission in different areas of nervous system was reviewed.<EOD> Influence of the environment of an isolated cell on its capacity to produce and secrete human nerve growth factor.\nThe isolated pancreatic islet cell is a special model for the study of nerve growth factor (NGF) production by a single cell type, separated from its direct interactions with other tissue cells, for it retains cellular interactions and autonomy of functional state for many days. We observed that the capacity of the isolated rat islet cell to produce and secrete NGF is influenced by microenvironmental (extracellular, paracrine) influences. After preincubation with a low dose of glucagon (0.1 microM-0.5 mM), the islet cell released 1.5 times as much NGF into the medium, despite the absence of glucose in this medium. Also, at physiological concentrations of glucose (3.3 and 11.1 mM), beta cell cytosolic free calcium accumulates and this event is accompanied by a transient wave of NGF release in the medium. Our data show that this hormone",
        "label": 0
    },
    "594": {
        "output": "The input is patient note `pnt`(see below). The output is the trial-level eligibility for `patient`[INT]\n\nThere is not any input parameter here. The input variable can be the patient note `pnt`. The parameter `patient`[INT] will be set automatically.\n\n`trial_level_eligibility(patient)`[INT] = 0 for `patient` [INT] 1 1 for `patient` [INT] 2 2 for `patient` [INT] 3 3 for `patient` [INT] 4 4 for `patient` [INT] 5 5 for `patient` [INT] 6 6 for `patient` [INT] 7 7 for `patient` [INT](0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria) (1) Not relevant (patient does not have sufficient information to qualify for the trial) (2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply)\n\nThere are five input variables `patient` [INT] and some other parameters `var`[INT]. For details, see the following instruction:\n\n<EOD> .\nRare and paradoxical presentation of a cystic pancreatic tumor mimicking an acute pancreatitis with pancreatic necrolysis was reported. The case of a 78 year old male patient who suffered from a sudden onset recurrent right severe abdominal pain over two months following the progressive increase of the tumor to 16 x 15 cm and the increase of the CA 19-9 serum. The computed tomography revealed a giant cystic tumor of the pancreas with an important necrosis. A diagnosis of a cystic pancreatic neoplasia was suspected. A pancreatic necrolysis associated to a cyst could be diagnosed at histologic evaluation of the tumor and the CA 19-9 serum level allowed to understand the mechanism of the acute pancreatitis. Such mechanism consists of the destruction of the perivascular adipose tissue and the adjacent pancreatic acini and the release of",
        "label": 1
    },
    "595": {
        "output": "This trial is not an eligible study for the given patient. That's because the given patient meets inclusion criteria, but not exclusion criteria.\n\n\nNote that, on page 1, there are two lines with repeated Trial-level eligibility. This is because the first one is on the first line of the first trial, and second one is on the second line of the second trial.\n<EOD> Adenosine A1 agonist ZM241385 attenuates renal ischemia-reperfusion injury.\nA (ZM241385, 5'-carboxy-ethyl-carboxamidoadenosine A (1) receptor (A1AR) agonist, reduced the renal injury induced by ischemic-reperfusion (IR) in rats. We designed in vivo experiments to test the effects of ZM241385 against renal IR injury and in vitro experiments to determine the underlying mechanisms. Rats were pre-administrated with ZM241385 (0.1 mg/kg) 30 min before IR. In in vitro experiments, ZM241385 with different concentrations (10 nM, 100 nM and 1 mM; H-89, 10 mM; SCH79797, 10 mM) were administered into primary cultured tubular cells for in vitro treatment. ZM241385 was found to significantly protect and attenuate acute renal failure (ARF) induced by IR. The level of serum uric acid (UA) was found to be significantly reduced by 76% at 24 h in IR + ZM241385-treated rats (p < 0.05), accompanied with a dramatic decline in kidney injury-related damage markers including lactate dehydrogenase (LDH), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1); these renal injury-related damage markers were 7.1, 2.6, 1.",
        "label": 0
    },
    "596": {
        "output": "<EOD> Sphingosine 1 Phosphate Receptor-1 Agonist Fingolimod for Severe COVID-19: A Retrospective Report of Five Cases\nBackground The Sphingosine 1 Phosphate Receptor-1 (S1PR1) is a transmembrane receptor, which, upon activation, leads to downstream effects responsible for the regulation of immune cells trafficking, and modulating the inflammatory response. Fingolimod is an S1PR1 agonist approved for the treatment of relapsing and remitting multiple sclerosis. Increasing data reports a role for S1PR1 in inhibiting SARS-CoV-2 infection, implicating its anti-inflammatory effects. Case A series of five critically ill adult patients with acute COVID-19 infection received fingolimod after failing conventional rescue and COVID-19 therapy. All patients did show improvements in inflammatory markers throughout the course of treatment, oxygenation requirements, and organ dysfunctions. Four patients were discharged home, and one had a successful transplantation. Conclusion Patients receiving fingolimod showed improvement in oxygenation, organ failure, and inflammatory markers in addition to survival and discharge. These preliminary safety and efficacy results should be considered for further studies and clinical trials for severe COVID-19 patients.<EOD> The role of the family in the management of tuberculosis.\nIt is important that tuberculosis control programmes incorporate family-oriented interventions to effectively tackle this preventable and curable disease. Successful strategies that make greater use of primary health care workers in community settings are being developed in many countries.<EOD> Reversing drug resistance of malignant melanoma through regulating c-Met\n\nBackground: Melanoma displays a substantial resistance to the drugs that is not well understood at the molecular level.Methods: A transcriptomic study was conducted to compare the gene expression profiles between melanoma cells and a drug resistant (DR) phenotype. The genes with log fold change (FC)\u22651.5 for increased expression and a FC\u22641.5 for reduced expression are compared. The expression levels of genes are determined by qPC",
        "label": 0
    },
    "597": {
        "output": "### Output:\n\n![](output.png)\n\n## Explanation\n\nThis program will check the patient note against the first trial's inclusion and exclusion criteria of the first trial. And then, make a trial-level assessment of eligibility on each patient for the first trial.\n\nThe code has three major parts: The first part prepares the patient note and the first clinical trial's trial note before creating the patient-trial pair. In this part, `fuzzy_match()` is used to compare `patient_ note` and clinical trial notes for matching patient-trial pairs. To match, a patient-trial pair must meet all inclusion criteria and the nonexistence of any exclusion criteria. \nThe second code part is to make a trial-level assessment of eligibility on each patient for the first trial. In this part, we utilize `make` function of `trial` package in R to create the trial object. Then, we can use `trial-level-eligibility()` function to get `clinical_trial.eligible` as the output. It indicates either the patient is not eligible (exclude), the patient is not relevant (not-relevant), or the patient is eligible (eligible). \nThe last code part summarizes trial-level eligibility in the last line by `Trial-level eligibility: 2) Eligible.` in this case.\n\n## 6.4. [INST] Relevance assessment of patients to a clinical trial\n\n<NAME> from PHARMOTEK company will call to do some work for a company in California, United States. She has experience in pharmaceutical industry market analysis and can help the company to find out more detailed information about the drug market. PHARMOTEK receives a 5-digit patient's ID which is used as a unique identifier of the patient. \n\n\n\nA5260s\n\n\n\nA5257\n\n\n\nA5001 \n\n### PHARMOTEK task:\n\n- You should extract and summarize information on a group of patients to prepare a market report.\n- The group of patients will have information on the trial's ID,",
        "label": 0
    },
    "598": {
        "output": "Good luck!<EOD> The pharmacist's role in the nutrition support process: pharmacokinetic monitoring of total parenteral nutrition.\nThe successful delivery of total parenteral nutrition (TPN) requires a coordinated effort by the healthcare team. The pharmacist is a vital link in the nutrition support team and is responsible for all aspects of TPN therapy. In addition to being a distributor of TPN and supplier of nutrition support pharmaceuticals, the pharmacist participates in reviewing pharmacokinetic profiles of TPN patients, and in making judgments about TPN regimens. Pharmacists play a critical role in the evaluation of TPN regimens and in the development of a pharmacokinetic monitoring program to improve patient response to a specific TPN regimen. Pharmacists must also be able to diagnose and treat metabolic complications that arise with TPN. In order to achieve their full potential in the nutrition support team, pharmacists must become fully aware of the newest developments in the field of nutrition support. Pharmacists can use information technology, journals, books, and seminars and symposia to provide themselves with a solid foundation in nutrition support. Through education and experience, pharmacists will become leaders in the nutrition support team and be able to contribute to the overall health of the patient.<EOD> Methylene blue attenuates vascular proliferation of balloon-injured aorta and prevents restenosis in rats.\nPercutaneous transluminal coronary angioplasty (PTCA) is the most frequently used therapy for coronary artery disease. PTCA may be associated with a significant decrease in luminal diameter, even in the acute phase after PTCA, with potential increase of restenosis. Vascular proliferation plays an important role in post-PTCA restenosis, and the role of NO in this process is not clearly understood. This study investigated the role of NO in the proliferation of endothelium-denuded segment in balloon-injured rat aorta, and assessed the effect of methylene blue (MB), a guanylate",
        "label": 0
    },
    "599": {
        "output": "```\nINST 1\nThe total number of cholesterol:                                      The total number of cholesterol with value 280.\n\nINST 1\nThe total number of triglyceride:                                    The total number of triglyceride with value 187.\n--------------------------------------------------------------------------------------------------------- \nINST 1\nThe total number of blood pressure:                                 The total number of blood pressure with value 106.\n--------------------------------------------------------------------------------------------------------- \nINST 1\nThe total number of family history:                                The total number of family history with value 3.\n------------\nINST 1\nThe total number of LDL:                                          The total number of LDL with value 261.\n\nINST 1\nThe total number of HDL:                                          The total number of HDL with value 48.\n------------\nINST 1\nThe total number of PSV:                                           The total number of PSV with value 259.\n\nINST 1\nThe total number of EDV:                                          The total number of EDV with value 9.\n------------\nINST 2\nThe total number of carcinoma heart disease:                       The total number of carcinoma heart disease with value 3.\n------------\nINST 2\nThe total number of CAD:                                          The total number of CAD with value 55.\n------------\nINST 3\nThe total number of neck:                                         The total number of neck with value 2.\n------------\nINST 3\nThe total number of internal coronary artery:                      The total number of internal coronary artery with value 2.\n------------\nINST 7\nThe total number of carotid artery:                                The total number of carotid artery with value 48.\n------------\nINST 7\nThe total number of coronary artery disease:                      The total number of coronary artery disease with value 7.\n------------\nINST 13\nThe total number of abdominal fat:                                  The total number of abdominal fat with value 5.\n------------\nINST 13\nThe total number of liver:                                         The total number of liver with value 6.\n------------\nINST 1",
        "label": 0
    },
    "600": {
        "output": "<section id=\"task\">\n\n# Task - Evaluate each patient\n\nFind your role ID in the header of each report, then select this role when you edit the note for this patient.\n\n![11.jpg]({{site.baseurl}}/images/codeathon_2014/11_1.jpg)\n\n- Identify the patient's history of coronary heart disease, and cardiovascular risk factors\n- Find the patient's latest medications\n- Determine the patient's smoking history   \n- Identify the patient's body mass index and history of atrial fibrillation and valve surgery\n- Determine the number of risk factors for coronary disease in this patient<commit_after>!# Task - Evaluate each patient\n\nFind your role ID in the header of each report, then select this role when you edit the note for this patient.\n\n![11.jpg]({{site.baseurl}}/images/codeathon_2014/11_1.jpg)\n\n- Identify the patient's history of coronary heart disease, and cardiovascular risk factors\n- Find the patient's latest medications\n- Determine the patient's smoking history   \n- Identify the patient's body mass index and history of atrial fibrillation and valve surgery\n- Determine the number of risk factors for coronary disease in this patient\n\n<commit_msg>added text comment to code<commit_after>![Evidence for Eligibility Assessment]({{site.baseurl}}/images/task1_eligibility.png)\n\nFor each of the following risk factors, select:\n0) Excluded: the patient has sufficient data to exclude him/her from the trial, but not enough data to assess eligibility.\n1) Not relevant: the patient has insufficient information to make an eligibility assessment but insufficient data to exclude him/her from the trial.\n\n## Risk factor Eligibility\n\n### Cardiovascular Risk Factors\n\n* History of coronary heart disease**\n* Family history of coronary heart disease\n* 2 or more cardiovascular risk factors (age, hypertension,",
        "label": 0
    },
    "601": {
        "output": "**Exercise 3**\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment.\n\nYou are here to decide whether patients of a particular clinical trial are eligible for this new trial. The study's inclusion criteria are described below. \n\nThis multicenter study examines the safety, pharmacokinetics, and pharmacodynamics of a new treatment to patients with type 2 diabetes (NCT03488732).\n\n\nThe study has an open-label, uncontrolled, singe-arm design in four different treatment periods. These four periods include 12 weeks for the treatment, followed by a 4-week run-out phase. All patients begin with a 4-week treatment period and then receive at least 8 weeks of treatment in the following 2 treatment periods. These studies will be conducted on non-insulin patients with type II diabetes. The first period includes the 2 weeks of baseline treatment, 12 weeks of open test treatment, and the 4-week run-out period. The total duration of the study is 28 weeks, which was conducted at 9 visits during the week: 2 times on Days 1 and 15 (pre-dose, 0. 45, 12 hours, 24 hours), 1 time on Day 29 (pre-dose, 0. 45, 12 hours, 24 hours), and 3 times (pre-dose, 0. 45, 12 hours, 24 hours) on Days 41, 55, and 69 (End of Test treatment)].\n\nInclusion criteria for this study are:\n\nAge 18 years or older at informed consent;\nMale or female.\nBody mass index (BMI) of 24 to less than 40 kg/m 2 , inclusive.\n\nHave type 2 diabetes that is diagnosed by at least one of the following:\nFPG \u2265126 mg/dL or 2-hour PPG oral glucose tolerance test \u2265200 mg/dL\nBlood glucose after meal \u2265200",
        "label": 0
    },
    "602": {
        "output": "Note that you should output the trial-level assessment of eligibility of the patient on one line, and your answer should begin with the string 1) Not relevant.\n[INST]_2-Trial-level eligibility: 1) Not relevant.<EOD> .\nVon D\u00e4uben (1888) showed that the administration of strychnine induced a fall of the body temperature in monkeys. He named the reaction \"strychnihypothermia\". It became obvious, that the effect could be mimicked by the administration of acetycholine and that a monoaminergic system was involved in this reaction. The effect of strychnine on the temperature can be easily measured at room temperature but it is more complicated and uncertain, when the temperature is increased by using heating pads. This is demonstrated by the present example. The reaction of fever caused by endotoxin did not interfere with the strychnine-induced hypothermia in the acute phase. In chronic endotoxemia the effect was not modified significantly. Since strychnine may be regarded as an antagonist of N-methyl-D-aspartate (NMDA) (Parker, 1979) one can expect that NMDA antagonists as phencyclidine or ketamine have a similar potential.<EOD> The Effects of Low-Dose RG108 Administration at Various Times over the Preimplantation Period on the Developmental Potential of Mouse Embryos\n\nObjectives: Global gene expression in mammals is orchestrated by a series of dynamic changes in DNA methylation during preimplantation development. While genome-wide methylation reprogramming occurs soon after fertilization, partial DNA methylation is retained at certain genomic regions during the first week of embryogenesis and reprogramming occurs slowly. In this study, we used low-dose (0.1 mg/l) RG108 treatment to study the effects of exposing embryos to a low level chemical demethylating agent at different times during preimplantation embryogenesis. Design: Mouse zygotes were treated using low-dose RG108 at zygote, two-cell, four-cell, morula, and bl",
        "label": 1
    },
    "603": {
        "output": "## [CODE]\nimport collections\ninst_dict=collections.defaultdict(list, defaultdict(set)) # Instance dictionary to collect the patient notes and their corresponding trial-level eligibility\ninst_dict['0] = ['Excluded',1]\ninst_dict['1] = ['Not eligible',0] # Trial-level eligibility\ninst_dict['2] = ['Eligible',0]\n# Add instances to the instance dictionary\nfor instance_num, patient_note in enumerate(patient_notes):\n    print(instance_num, patient_note) # prints the number of the instance and the patient note\n    print('\\n')\n    if \"Excluded\" in patient_note.lower():\n        # if the patient note contains \"Excluded\" in its text you have to take the string 'Excluded' from the patient note\n        new_string = \"Excluded\"\n        # and add this string to eligibilities list of the given instance\n        # so if you assign the variable\n        # eligibilities = instance_dict[instance_num] if you get a list\n        # eligibilities = eligibilities.extend(['Excluded']) if you assign a string\n        eligibilities = collections.extrema(eligibilities)+['Excluded'] if you extract the value of the instance dictionary in a sequence\n        # The output from print is not necessary. The reason for it is that you can easily see the patient note if you need to.\n        # Just to show that you can print the new variable.\n        # print(patient_note.lower()) # prints the lower case version of the patient note in this case.\n        eligibilities = ['Excluded'] + eligibilities\n        print(patient_note.lower()) # prints the lower case version of this instance\n        print('\\n')\n\n    if \"Not eligible\" in patient_note.lower():\n        # if the patient note contains \"Not eligible\" in its text you should consider the patient note and the trial-level eligibility and add the string 'Not eligible' from the patient note\n        new_string = \"Not eligible\"\n        eligibility = 'Not eligible'\n        # As I wrote above",
        "label": 0
    },
    "604": {
        "output": "##[POINT] How to determine the reason for discontinuation of treatment?\nThe reason for discontinuation of treatment shall be recorded in the CRF in",
        "label": 0
    },
    "605": {
        "output": "## \ud83c\udf33 6.1 Eligible criteria for the patient\n\ud83c\udf33 6.2 Assessing trial eligibility for a patient\n\nYou should output the trial-level eligibility with the factor, which is the result of the process above. \n[INST] You are given the following information about a patient: \nA 45-year-old woman with type 2 diabetes presents to the clinic. She has high blood pressure, high cholesterol, and has a 10-year smoking history. She is interested in participating in an upcoming study that will examine the effect of an experimental treatment on glucose metabolism. \n\nThe information on which you work will be presented in several pages or tables. For each one, you will see:\nIncluded in the study; Not included in the study due to an inclusion/exclusion criterion; Can be determined later, and will not exclude people from the study for that reason; Not applicable.\nIn the first table, you will see three exclusion criteria (lines 5-7) and two inclusion criteria (lines[INST]\n\nYou should output the trial-level eligibility with the answer that the patient is eligible for clinical trial. \n<EOD> The effects of inotropes and beta-adrenoreceptor blockers on left ventricular compliance: a model analysis.\nThe relation between inotropic and chronotropic activities of sympathetic beta-adrenoreceptor stimulation is of considerable interest. In order to characterize this relationship, the effects of alterations in pacing rate and inotropic agents were studied on an in vitro model, which approximated the intact heart. Myocytes were isolated from the right ventricle of ferret hearts, and were suspended in an elastic chamber as described by DeTombe et al. The active tension developed by one cell was calculated from the deformations of the chamber, and the tension generated by an entire group of cells was inferred by the displacement of its chamber. Pacing at 2 Hz resulted in a contractile active phase of 120 msec and an isovolumetric relaxation phase of 340 msec. The inotropic activities of adrenaline (10(-6) M), dopamine",
        "label": 0
    },
    "606": {
        "output": "# Assignment Exercises\nExercises:\n- Exercise 1: Create a small clinical trial in R, e.g., `trial_1 <-clin_trial(name = 'exercise_1', trial_type = 'Randomized')`.\n- Exercise 2: Create an alternative trial that allows more than one subject in each group, e.g., `trial_2 <-clin_trial(name = 'exercise_2', trial_type = 'Randomized')`.\n\n# Solution Details\nThis solution shows the detailed solution of the assignment.\n\n# Solution Strategy\nThis small clinical trial evaluates the effects of a statin on the radial intima-media thickness (IMT). \nThe intervention is the use of statin for reducing the inflammation of intima-media. \nIn the first, the intervention group with 70 patients and control group with 70 patients are enrolled. The primary outcome is a change in the radial IMT between before and after one month. The secondary outcome is the difference in LDL cholesterol between before and after one month. \nIn the second, the randomized patients are 25 in both arms and the primary outcome is also a change in the radial IMT between before and after one month. The secondary outcome is the difference in LDL cholesterol between before and after one month. \nThe radial IMT is measured by the brachial-ankle pulse wave velocity and intima media thickness.\nThe radial IMT measurements are obtained using the same parameters in the carotid artery ultrasound examination. The parameters include the intima-media thickness and brachial to ankle pulse wave index. In the radial IMT assessmetn by intima-media thickness, the intima segment is determined starting below the bifurcation of the radial artery until 5 mm of the distal end of the artery, whereas the media segment is determined starting below the middle of the bifurcation of the artery until 1 cm of the distal end.\nThe LDL cholesterol level is determined using Friedewald's formula: LDL cholesterol = total cholesterol \u2212 {high-density lipoprotein (H",
        "label": 1
    },
    "607": {
        "output": "## [END] \n\n## 2. 5-points questionnaire form\nFor the eligibility assessment, there is some multiple-choice question with 5 choices.  The answers were all Boolean.\n\n### `\nWhat is the most appropriate treatment option to minimize recurrent ischemia and prevent serious adverse events in this patient?\n\n\n\nChoose only one answer:\n1. Medical Treatment is appropriate\n\n\n\n2. Single antiplatelet therapy (SAPT) is appropriate\n\n\n\n3. Single anti-platelet therapy (SAPT) is not appropriate\n\n\n\n4. Single anti-platelet therapy (SAPT) plus clopidogrel (C) should be given according to the package insert\n\n\n\n5. Dual anti-platelet therapy (DAPT) is appropriate\n\n\n\n6. DAPT should continue for 12 months\n\n\n\n7. DAPT should continue for 18 months\n\n\n\n8. DAPT should continue for 36 months\n\n\n\n9. DAPT should continue for 6 months\n\n\n\n10. DAPT should not be given\n\n### `\nWhat is the most appropriate time to initiate DAPT?\n\n\n\nChoose one answer from A to Q.\nA. DAPT treatment is initiated 12 months after the index procedure.\n\nB. DAPT treatment is initiated 18 months after the index procedure.\n\nC. DAPT treatment is initiated 36 months after the index procedure.\n\nD. DAPT treatment is initiated 12 months after the index procedure and continued for 6 months after the next BMS implantation procedure.\n\nE. DAPT treatment is initiated 36 months after the index procedure and continued for 6 months after the next BMS implantation procedure.\n\nF. DAPT treatment is initiated 36 months after the index procedure and continued for 18 months after the next BMS implantation procedure.\n\nG. DAPT treatment is initiated 36 months after the index procedure and continued for 6 months after the next DES implantation procedure.\n\nH. DAPT treatment is initi",
        "label": 0
    },
    "608": {
        "output": "Note: If you use the default parameters in the `main/main.yml` file, the parameter value for the maximum output file size is only 50 MB.\nYou should use the following parameters to set up the maximum output file size:<EOD> Fibromyalgia\n\n# Overview\nFibromyalgia (fibro + myositis translates as fibrous tissue, muscle) is a condition of chronic, debilitating, widespread pain and stiffness, which can interfere with a person's ability to work or enjoy life. Fibromyalgia is the term typically used for nonmalignant chronic widespread pain syndrome, as distinguished from specific nondiagnostic diagnoses such as somatic symptom disorder.  The estimated prevalence of fibromyalgia is 3% in Europe and the United States and 2% in Asia.\nAlthough it has long been considered to be primarily a disorder of middle-aged women, men with fibromyalgia are actually slightly more numerous than women. In one large study of 1000 male fibromyalgia patients, 59% of the patients reported widespread pain and stiffness, and 24% had sleep disturbances which met strict criteria. In the study, as was typical of other studies, only 52% of the male fibromyalgia patients had a diagnosis or even recognition of their fibromyalgia by a physician. The prevalence in the USA is increasing, and more than 4% of the US population may be affected.\nThe disease is generally caused by a combination of physical injuries, emotional or physical trauma, and hormonal changes associated with aging and menopause. It is characterized by widespread musculoskeletal pain and tenderness of non-articular ligaments and tendons throughout the body. This pain is disproportionate to the severity of inflammation in most patients. Sleep disturbances, such as insomnia, in particular, are very often complained about. The severity of the symptoms fluctuates frequently and is worsened by strenuous activity, especially cold weather, and may also be exacerbated by several common medications (including antiepileptic medications)",
        "label": 1
    },
    "609": {
        "output": "\u00a9 ETH Zurich\n\u00a9 2020 O'Reilly<EOD> .\nOBJECTIVE\nTo investigate the genetic relationship and possible factors affecting genetic relationship in Changwushe-Zhaiyu (CWZY) pigs.\n\n\nMETHODS\nBlood samples were collected from the 6 farms in Jinghong, Baise, Xiangzhou, Sannong and Maogan townships in Du'an County, Yunnan. The sample size was 30 each in CWZY in each sampling farm. DNA was extracted using phenol-chloroform and amplified using microsatellite primer. The genetic relationship was evaluated based on polymorphism and PIC.\n\n\nRESULTS\nA total of 223 samples were detected by 9 primers. A total of 59 polymorphic makers were identified. The average PIC value was 0.541.\n\n\nCONCLUSION\nThe microsatellite loci are extremely polymorphic in CWZY pigs, and the genetic relationship is not closely related.<EOD> The effect of interferon on mouse skin papillomas induced by carcinogen or virus.\nSensitive, reproducible tests have been developed for the measurement of tumor promoting activity in mouse skin in which single tumors are initiated with croton oil and 7,12-dimethylbenz(a)anthracene (DMBA). Sensitive assays have also been developed for the measurement of tumor promoting activity in mouse skin papillomas initiated with mice that received 2 cGy of in-house produced radiation, or with DMBA inoculated alone or in combination with MAP and carcinogen 7,12-dimethylbenz(a)anthracene. The present communication documents the effects of mouse interferon on the growth of papillomas induced by a single topical application of croton oil after the initiation of tumors with the cocarcinogen combination, as well as in a papilloma system (initiated and promoted by a viral carcinogen). An inhibitory effect on papilloma formation was found for the treatment of papilloma-bearing mice with crude mouse interferon (ob",
        "label": 0
    },
    "610": {
        "output": "## Patient information: patient-tag</patient-tag></p><ul><li>patient: <name></li><li>department: <department></li><li>race: <race></li><li>weight: <weight></li><li>age: <age></li><li>status: <status></li><li>sex: <sex></li><li>obesity: <obesity></li><li>currentsmoker: <currentsmoker></li><li>ethnicity: <ethnicity></li></ul>Patient: age: 50, male sex: male, weight: 105, height: 100.8182, race: Caucasian, ethnicity: Hispanic",
        "label": 0
    },
    "611": {
        "output": "To see demo codes, please use the code in the following link:\n\n# <filename>inst/patients_eligibility.ipynb\n<EOD> Clinical profile of pancytopenia in children admitted to a tertiary care hospital in Nepal\n\nObjectives: To assess the clinical and laboratory characteristics of pancytopenia in children at a tertiary care hospital in Nepal.Results: A total of 115 children out of 51,897 children admitted to Nepal Medical College Teaching Hospital were pancytopenic. Among them, 78% were 2-10 years, 53.04% and 46.88% were male and females respectively. The hematological parameter with deranged values was observed in median platelet (140,000 cells/cumm), red blood cells (3.\n\n# Introduction\nPancytopenia is a hematological disorder characterized by quantitative decrease in three or all the cell lineages of bone marrow (BM) which included hematogones, neutrophils, monocytes, eosinophils, basophils and platelets [bib_ref]  Paediatric patients with pancytopenia: clinical and laboratory profile of the disease and..., Elhassan [/bib_ref] . It is most commonly seen in children above five years of age with equal incidence in either sex and its incidence is estimated at least 20-30% in the population under five years of age. The mortality rate is 2-26%. The causes range from nutritional deficiencies, severe infections, immunodeficiencies, drug induced toxicity and primary bone marrow failure. Most of the pediatric pancytopenia is caused by BM suppression [bib_ref]  Clinical profile of children with pancytopenia, Sharma [/bib_ref] . Therefore early diagnosis and proper management should be of highest priority to eradicate the major causes [bib_ref]  Pancytopenia: a review of common causes in resource poor settings, Mekonnen [/bib_ref] . This can be made possible by increasing the awareness among clinicians on the causes of pancytopenia and early referral of the patients to a tertiary care hospital",
        "label": 1
    },
    "612": {
        "output": "A sample output for patient 6 (Trial-level eligibility: 0) Excluded.)\n<EOD> The use of intravenous tranexamic acid on the need for postpartum blood transfusion.\nOBJECTIVE\nTo determine if the administration of an antifibrinolytic drug (tranexamic acid, Cyklokapron\u00ae) reduces the amount of intra-operative blood loss, and the amount and frequency of packed red cells transfused post-operatively.\n\n\nDESIGN\nA randomised controlled, double blind trial of 500mg tranexamic acid versus placebo, administered as two intravenous injections 5 minutes before and 90 minutes after incision.\n\n\nSETTING\nTeaching Hospital in Hong Kong.\n\n\nSUBJECTS\nOne hundred and fifteen patients of Chinese and Western ethnicity with singleton term pregnancies at or beyond 37 weeks' gestation undergoing Caesarean section for uncomplicated pregnancy or un-related conditions.\n\n\nMAIN OUTCOME MEASURES\nUterine blood loss, intra-operative and post-operative blood transfusions.\n\n\nRESULTS\nPatients in the tranexamic acid group received an average of 816 mls of crystalized blood compared with 1046 mls in the placebo group. The intra-operative blood loss was thus lowered by 21.5% in the tranexamic acid group (95% confidence interval (CI) -31.4% to -10.6%, p < 0.001). Post-operative blood transfusions also required by 7 patients (29%) in the placebo group compared with 1 patient (4.5%) in the tranexamic acid group. The odds of requiring post-operative blood transfusion was thus reduced by an odds ratio of 8.3 (95% CI 1.4 to 49.6, p = 0.018) when given tranexamic acid 5 mins before and then 90 minutes after the onset of incision.\n\n\nCONCLUSION\nThis trial has shown significant redu",
        "label": 0
    },
    "613": {
        "output": "---\n**Exercises**    +++++++\n\n**[1.1]** What do you need to do to make the eligibility assessments of patients? In your code, please refer to the patient note as \"patient\" and the clinical trial as \"trial\". \n\n1. Use the information provided in the patient note and the inclusion criteria of the clinical trial to determine the patient's eligibility.\n2. Choose the clinical trial and enter its reference(s) in the variable trial. \n3. Compare the information on patient's health state(s) contained in the patient note and the inclusion criteria of the clinical trial to determine the patient's eligibility.\n4. Save your code and return here to find out which patients are eligible for the clinical trial.(Code in the next part is already done)\n1. Find the most suitable clinical trial for your clinical problem, and record it in the variable trial.\n2. Choose the type of clinical trial you want to conduct: intervention or observational.\n3. Use the patient note and the inclusion criteria of the clinical trial to determine the patient's eligibility for the clinical trial by comparing the information on this patient's health state(s) in the patient note and the inclusion criteria included in the clinical trial. Enter your results as `Trial-level Patient Eligibility:` and use the format shown on the left side for your eligibility assessment to the clinical trial, e.g., `Trial-level Patient Eligibility: 1) Eligible,`.\n4. If the resulting patient is eligible for the trial, save your code and return here to find out which patients are eligible for the trial.\n\n---\n**[1.2]** Create a program to find patients that are eligible for clinical trial A. \n\n1. Open a new Python file, and write the program(s) needed to find patients who are eligible for trial A. Write the program(s) as a series of simple steps in order to provide a clear sequence for the end user (data scientists). For example, use a comment(s) to describe each step in your program.\n2. You should follow these steps:\n    1. First, find",
        "label": 0
    },
    "614": {
        "output": "## [INST] 8) Patients for whom the assessment of eligibility has no triallevel is not applicable.\nA trial-level assessment of eligibility is not applicable when the patient's medical history does not match that of the eligibility criteria. If the patient's characteristics indicate that the inclusion criteria and exclusion criteria do not apply, the trial-level eligibility scale should be '0): Excluded. \n\nA 26-year-old woman is visiting a clinic to have her periodic examination of health and reports no use of smoking habits, no family history of CAD, and no CVD risk factors. She has a normal physical examination, and all normal laboratory findings. On a physical examination, the patient's heart rate was 75 beats per minute (bpm), with a respiratory rate of 18/bpm and a blood pressure of 100/60 mmHg. The patient's results for an ECG were also normal. On palpation, all four extremities were warm. The carotid arteries pulsate strongly, without neurological symptoms such as limb weakness or numbness. [INST] 9) Patients for whom the assessment of eligibility is not applicable.\nA trial-level assessment of eligibility is not applicable when the patient's medical history does not match that of the eligibility criteria. If the patient's characteristics indicate that the inclusion criteria and exclusion criteria do not apply, the trial-level eligibility scale should be '0): Excluded. \nA 26-year-old woman is visiting a clinic to have her periodic examination of health and reports no use of smoking habits, no family history of CAD, and no CVD risk factors. She has a normal physical examination, and all normal laboratory findings. On a physical examination, the patient's heart rate was 75 beats per minute (bpm), with a respiratory rate of 18/bpm and a blood pressure of 100/60 mmHg. The patient's results for an ECG were also normal. On palpation, all four extremities were warm. The carotid arteries pulsate strongly",
        "label": 1
    },
    "615": {
        "output": "## Summary \n[SUMMARY]\n[The patient note in this tutorial is the data which is a 2-column table (Patient note and CVD risk factors) and the data in the clinical trial is a 3-column table (Vessel diameter, Inclusion eligibility of the patients to clinical trial and Patient notes). We should summarize the data to generate a 5-column table (Patient_id, Patient_name, Sex, CAD, Dyslipidemia, Smoking_history, Diabetes, Hypertension, Family_history, BMI, Carotid artery stenosis, Peak-systolic velocity, End-diastolic velocity). The table is visualized in [fig_ref]  Figure 4: The summary table generated by the tutorial[ [/fig_ref]  \n\n##]. [/summary]\nYou can run the script from below to train clinical trial dataset.\nIn [root]/data/cTrial.rwe, enter code as follows:\ncTrial<-setTrial(cTrial,patients,datastruct=\"Carotid\")\ncTrial<-rmTrialExclusionCriterias(cTrial)\ncTrial<-setRating(cTrial)\n\n\n## Visualization\n\n### Overview\nThe `tuner` package is dedicated to the tunning of machine learning models to obtain the highest predictive accuracy for models with multiple class labels. Here, we introduce machine learning methods to classify the eligibility information in clinical trial notes. And we demonstrate the visualization tool, named Tuner Viz to generate a set of figures that illustrates the performance of the ensemble model in the tuning process.\n\n## Installation\n\nWe assume R is installed in your local PC or local R studio, and other packages, including tuner, have been installed in the corresponding library. There are two ways to install tuner. A. User adds installation instructions into a suitable function. B. User directly installs from CRAN.\n**A. User adds installation instructions into a suitable function.**\nThe tuner package is a collection of many other packages including tuning methods in the tunr package (recommend package), tuning methods in the caret and superlearn package (recommend package). The tuner package can be",
        "label": 1
    },
    "616": {
        "output": "[EXERCISE] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and",
        "label": 0
    },
    "617": {
        "output": "1. Assess the demography: age, gender, and clinical trial identifier (e.g., ID23). You could use a specific function for this. Let's assume there was a function called assess_age with the following signatures: `def assess_age(assessor.get_note())':\n\n    You also need this function to store triallevel eligibility on an individual-level:\n\n    `def store_trial_eligibility(trial.get_trial_id(),  trial.get_eligible_note(), eligibility_assessor.get_eligibility())`\n\n    Let's see what this function looks like: `def store_trial_eligibility(trial_id,  eligibility_note, eligibility)`\n\n        # Define the trial ID\n        trial_id = input('Enter the clinical trial identifier (ID): ')\n\n        # Define the eligibility note\n        eligibility_note = input('Enter the eligibility note: ')\n\n        # Define the eligibility\n        eligibility_assessor = input('Please enter the eligibility of the patient: ')\n\n        # Run the program\n        trial = get_trial(trial_id)\n        patient = get_patient(eligibility_assessor)\n        eligibility = store_trial_eligibility(trial_id, eligibility_note, eligibility_assessor)\n\n        # Call the function\n        trial.store_trial_eligibility(trial_id,eligibility_note,eligibility)\n\n        print(f'This is the eligibility data: {eligibility}')\n\n    We would need to be able to call the function from within our script, and to do this, all we have to do is add a reference to this function in the function's signature. For example, we could call the function directly from within the script that runs our program using the following signature:\n\n        # Call the function\n        patient.store_trial_eligibility = store_trial_eligibility\n\n        # Run the program\n        patient = get_patient(eligibility_assessor)\n        print(f'",
        "label": 0
    },
    "618": {
        "output": "___\n\n## Input Your Data (Task 1)\n\n### Import Data into the Pipeline\nTo import your data, click **Load** from the *Input Data* menu selection within the left pane.\n\nYou should first choose a folder containing all of your data (*csv/*.xlsx files):\n![Data input](../fig/input_data_csv_1.jpg )\n\n![Data input](../fig/input_data_csv_2.jpg )\n\n### Import an Example Data Set\nHere is an example of patient notes with multiple entries per patient and clinical trial information.\nYou should change the file names with **the names of your input files: PatientNote1.csv, PatientNote2.csv**.\n\n> ***HINT***: Avoid spaces in the file names (PatientNote1 PatientNote2). If you need to work with data sets with spaces you can remove spaces from the file names by adding to the data set **a data manipulation step **before **the name of the data set: PatientNote1 Patientnote2_noSpaces.csv**. \n\n> ***HINT***: Make sure that the input files have only a few entries per file. If you have lots of data in each file, we recommend importing all of the entries that belong to one patient for each clinical trial into one file. Here is an example: \n![Dataset](../fig/dataset_example_01.jpg) \n\nHere is an example of a single-patient trial data set.\n![Dataset](../fig/dataset_example_02.jpg)\n\n### Import a Two-Tiered, Pair Entry Trial Data\nHere is a 2-tiered, pair entry data entry trial file.\n\n> ***HINT**** It is common for *data set* files to have more than one sheet (you\u2019ll see later). It is not a problem, but in that case, make sure to use the naming conventions below in your file names (for instance, put \"_2-tiered_data.csv\" into your *data set: 2-tiered data set and **2-tiered-data.csv** into your *dataset file** ). \n\nIt is possible to have only a single sheet; a few important things",
        "label": 0
    },
    "619": {
        "output": "## [INST] Note:\nYour assignment is complete if you can output an assessment of eligibility of 0, 1, or 2 for each patient. If the total number of patient notes is larger than 39, use only the first 39 \n\n## Exercise 1: ClinTrials.io\n\n\nIn this part of Exercise 1, you are to assess eligibility from the first 10 randomly chosen patients. You should show, under the patient data, the factors that allow one to participate in a clinical study. If applicable, indicate why the patient does not meet the trial's eligibility criteria.\n\nThe first 10 random patient data are shown in . . Exercise 1: Randomly chosen 10 patient data from ClinTrials.io.\n\n## Exercise 2: MedlinePlus\n\n\nIn this part of Exercise 2, you are to assess eligibility from the first 10 randomly chosen patient notes and find the factors that allow one to participate in a clinical study and why the patients do not meet the trial's eligibility criteria.\n\nThe first 10 random patient data are shown in . . Exercise 2: Randomly chosen 10 patient data from MedlinePlus.\n\n## Exercise 3: ELIXIR\n\nIn this part of Exercise 3, you are to assess eligibility from the first 10 randomly chosen patient notes and find the factors that allow one to participate in a clinical study and why the patients do not meet the trial's eligibility criteria.\n\nThe first 10 random patient data are shown in . . Exercise 3: Randomly chosen 10 patient data from ELIXIR.\n\n## Exercise 4: ICTRP\n\nIn this part of Exercise 4, you are to assess eligibility from the first 10 randomly chosen patient notes and find the factors that allow one to participate in a clinical study. If applicable, indicate why the patient does not meet the trial's eligibility criteria.\n\nThe first 10 random patient data are shown in . . Exercise 4: Randomly chosen 10 patient data from ICTRP.",
        "label": 0
    },
    "620": {
        "output": "The following information is provided in the patient note:\nA 54-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nYour assessment of eligibility is written in the last line. In the comment section, you may write some additional text.\n![image](file:///E:/Clinical%20Data%20Analyi...s/Figure3_7.JPG)\n![image](file:///E:/Clinical%20Data%20Analyi...",
        "label": 1
    },
    "621": {
        "output": "What do you find?\n- **First time here?** Read this first\n- [Quickstart for novice](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/blob/main/README.md)\n- [What to do with issues?](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/blob/main/README.md#what-do-you-find)\n- [What do you find?](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/blob/main/README.md#what-do-you-find)\n\n### Quickstart\n\n- Try a complete run locally\n\n```\npython eligibility_detection.py -v  # Print current version in PyCharm\npython eligibility_detection.py --test --print_output\npython eligibility_detection.py --test --test_case_input\n```\n\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/files/27525800/test.json)\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/files/27525800/test-2.json)\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/files/27525800/test-3.json)\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/files/27525800/test-4.json)\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection",
        "label": 1
    },
    "622": {
        "output": "---\n\n[BADGE]{:style=\"clear:right;margin-right:0.2rem;float:right;display:inline-block\"}\n\n##[RH]{:style=\"float: left;display:inline-block\"}R\n\n[RH]{:style=\"float: left;display:inline-block\"}R\n```\n\n\n\n### Exercise\nNow, perform the following assessment of this patient's eligibility using all the information you have collected in the previous steps above.\n\n---\n\n[BADGE]{:style=\"clear:right;margin-right:0.2rem;float:right;display:inline-block\"}\n[RH]{:style=\"float: left;display:inline-block\"}\n \nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of",
        "label": 1
    },
    "623": {
        "output": "# Conclusion\nIn R, there are many packages related to the NLP field. To understand the usage of these packages and find a specific solution to your research, you need to learn these packages such as Textrous, tidytext, tidyverse, and tidytree. However, these packages are complicated to use and you may need high computation times. Therefore, using the R package clinicalAI may be a better option. The package contains many functions that allow you to perform all the steps required for each task of machine learning. The package implements the data wrangling process from a patient note, tokenize the input data into sentences using a BERT-based model, preprocesses the data, and analyzes all the tasks: sentiment analysis, named entity recognition, coreference resolution, question answering, text classification into two and three categories are performed. The package is freely available on CRAN; you need to install the package using the `install.packages(\"clinicalAI\")` code.\nYou can test the package without installing it. Download the notebook for this tutorial named as clinicalAI_NLP.ipynb from GitHub via this link: https://github.com/dranyabg/clinicalAI-blog/blob/main/clinicalAI/vignettes/02%20clinicalAI%20NLP%20Notebook.ipynb. If you cannot install the package, run the Notebook on Colaboratory  and execute each step therein to find the problem.\nThere are three functions in the data wrangling block and each block has three functions for data preprocessing. Please read the comments in the functions.\nI hope this was helpful for you.\nThank you.\n<EOD> Surgical management of a very large choroidal osteoma in a young patient\nPurpose: To report successful treatment of a young patient with a very large choroidal osteoma with sclera patch grafting. Methods: Case report. A 19-year-old boy presented with severe photophobia and a very large choroidal osteoma compressing the macula. Sclera and silicone patch grafting was performed in order to reduce the tumour vascularisation and visual recovery, after the tumour had been reduced in size with argon laser. Results: Excellent",
        "label": 1
    },
    "624": {
        "output": "## \u27a4 Patient-level features \u27a4\nThe patient-level features are not directly comparable with the patient, where each patient will have their own unique patient characteristics. We use one patient as a benchmark to show you what to do with the given patient. \nYou have to find the age, sex, and other data associated with those data. The values of each data form an n-dimensional vector with n elements. Each element is one of several unique values for that feature. All possible values of each feature can be found on the [Feature] line. The order of the features is determined by the alphabetical order. If you see patient-level features, you should not skip them. The patient-level eligibility is not a one-to-one match, meaning that we can have patient-level features with the same value twice or even three times. \nIn this case, the following eligibility criteria should be checked: \n\n\n```python\ndef test(f, g):\n    return g - f\n     \"\"\"\n-1087.605906\n -10.605906\n0.1087605906\n #0.000001\n\n#0.00000000000001\n1076.664200\n\n\"\"\"\n```\n\nThe first column of the output should only be used if the code is correct. If the code is incorrect, then all the other values (within one line) should be considered incorrect. The most correct code is the second, where the correct value is found in the first column.\n\n**\u27a4\u27a4\u27a4\u27a4 Question 2: `In which features does the difference lie exactly?`**\n\n**\u27a4\u27a4\u27a4\u27a4 Question 3: `Do you agree with the result? If not, why?`**\n\n## \u27a4 Feature values \u27a4\nThe goal is to identify the features for which we have two values that are very different. In other words, finding the features that allow us to tell if the difference between the values of the features is greater than a certain amount. By doing so, we would be able to select patients and exclude those who do not meet",
        "label": 1
    },
    "625": {
        "output": "A: The only part of the trial you care about for this problem is what they define as \"triallevel results\".  So, I'd write up each patient's info on a separate line, and then output a one-line \"trial level\" result summary.  Let's assume your patients' data look like one of your previous examples.\ndata = read.csv(\"mydatafile.txt\")\npatients = data.frame(patient = rep(letters[1:5], each = 5))\n\nIn the following function:\n\n    > print(results)\n    Cohort-level Assessment\n\n    Patient-level Assessment\n    Excluded\n    Not relevant\n    Eligible\n\nThe first thing that appears is the same message you already saw in your problem statement \"Cohort-level Assessment\".  But now you know what that means, since you know what your columns mean -- it's a vector of numbers that represent \"cohort-level result\", which you already know will have the integers 0, 1, or 2.  What you are looking for are the second two lines; these are your patient-level data.  After the cohort-level assessment are the patient-level assessment of eligibility.  The first line is the number of excluded patients; you know you will need this in your output, and it will be one of the integers 0, 1, or 2.  The second line is just the number of patients for whom you didn't have enough information to make a cohort-level decision.  This is one of the ones you don't care about and we shouldn't bother printing, so we should put a comment mark # over this line.  The third line is the count of the number of patients who are eligible as a cohort -- once you get your list of numbered patients sorted into cohorts, you'll add this line up at the end to get your \"eligible\" column.\nThere's really not much trick to it; as long as you know the format of your data, you should be able to write this function.  A little extra detail about the data format would be whether patient data with null (missing) values are included (this is really a function of whether they are considered \"valid\" or not --",
        "label": 1
    },
    "626": {
        "output": "\u00a9 <NAME> 2020\n[INST] ######################## \n[INST] ##### Running Examples ##### \n[INST] ######################## \n[INST] ######################## \n[INST]\n\n<EOD> The use of immunofluorescence on paraffin sections for the detection of pH1N1 swine flu infection in human lungs\n\nThe newly emerging swine-origin influenza virus (S-OIV) A/H1N1 was isolated for the fi rst time in human patients in April 2009 in Mexico, with subsequent spread to many other countries.\n\n## I n t r o d u c t i o n\nThe newly emerging swine-origin influenza virus (S-OIV) A/H1N1 was isolated for the fi rst time in human patients in April 2009 in Mexico, with subsequent spread to many other countries. [bib_ref]  Update on Swine Flu, Chan [/bib_ref]  In Canada, the fi rst human A/H1N1 positive case was detected in June 2009. From that time to November 11, 2009, there were 2,658 positive cases and 114 deaths. [bib_ref]  Update on Swine Flu, Chan [/bib_ref]  Based on these data, there is an urgent need for a method capable of confi rming the infection before more aggressive clinical measures have to be taken. This would require an ancillary test that can be readily conducted on paraffi n-embedded tissues.\nInfl uenza virus infects cells mainly through interaction with two surface glycoproteins: HA and NA. The HA has three subtypes: H1, H2, and H3. HA is responsible for receptor binding, the viral entry process and hemagglutination. The NA is responsible for uncoating of enveloped viral ribonucleoprotein complexes with the intracellular target, fusion of viral envelope with host cell membrane, and virion budding. [bib_ref]  Infl uenza hemagglutinin and neuraminidase membrane glycoproteins, Gamblin [/bib_ref]  Since infection of bronchial ep",
        "label": 0
    },
    "627": {
        "output": "Your main challenge is to design the data validation method. If you can not satisfy Trial-level eligibility of \"3) Excluded\" or \"2) Not relevant\", then move back to the previous step. When you satisfy the above restrictions, you can press the button `Send`. \n\nIf you press the button `send` while satisfying the above restrictions, the output will be sent from the editor to the server and displayed in GNAT format. The GNAT file contains several tabs as follows: Patient DX (Diagnosis) Drug DX Patient Degree-of-Severity (DoD) Patient Age (Age) Patient Sex (Sex)\n\nHere is a sample for output:\n<Data validation> <Procedure> 1. Clinical Trial: 2. Neck Auscultation: 3. EKG Findings: 4. Cardiac Catheterization: 5. Echocardiography: 6. Thallium stress test: 7. Ventriculogram: 8. Stress test: 9. 2D Echocardiography: 10. 3D Echocardiography: 11. Angiogram: 12. Coronary artery calcium scan: <Result>\nTrial-level eligibility: 3) Excluded\n\n### Related Concepts\n\n  2. The doctor asked you to conduct a clinical trial to compare the patient note with the eligibility criteria of the clinical trial to see the patient's eligibility.\n\n  \n\n  1. First, design the data validation method when designing the clinical trial.\n\n  2. Next, verify that the data validation method satisfies the constraints.\n\n  \n\n    a. You should satisfy all constraints, i.e., the outputs should satisfy the constraints.\n\n  \n\n  3. You can press the button `send` when you make sure that all outputs satisfy the constraints.\n\n  4. Finally, you should repeat the process for other clinical trials.\n\n  \n\n### Exercise\n\n[1] Exercise 1. A doctor asked you to conduct a clinical trial to compare patient note with eligibility criteria of the clinical trial to see the",
        "label": 1
    },
    "628": {
        "output": "## Exercise 46 - Annotation \n```js\n## E46a_01_073974.json\n[\n    {\n        \"annotation\": {\n            \"note\": \"RV\"\n        },\n        \"study\": {\n            \"patient\": 396003507366661680,\n            \"studyType\": {\n                \"name\": \"Observational study\"\n            },\n            \"title\": {\n                \"text\": \"The Effect Of Remote Limb Ischemic Preconditioning For Carotid Artery Stenting\",\n                \"language\": \"eng\"\n            },\n            \"phase\": {\n                \"phaseState\": \"Phase 1\",\n                \"phaseType\": \"Phase 1\"\n            }\n        },\n        \"event\": {\n            \"event\": \"Visit\",\n            \"trial\": \"E46a_01_073974.json\",\n            \"value\": \"Visit:Baseline Visit\"\n        },\n        \"type\": {\n            \"id\": \"c151f869-e063-11da-bd98-00047d7f5a0cb\",\n            \"name\": \"Outcome\"\n        },\n        \"id\": \"663bc560-da8f-11da-bb9f-000c29e37912\"\n    },\n    {\n        \"annotation\": {\n            \"note\": \"RV\"\n        },\n        \"study\": {\n            \"patient\": 396003507417016530,\n            \"studyType\": {\n                \"name\": \"Observational study\"\n            },\n            \"title\": {\n                \"text\": \"The effect of remote limb ischemic preconditioning in carotid artery stenting\",\n                \"language\": \"eng\"\n            },\n            \"phase\": {\n                \"phaseState\": \"Phase 1\",\n                \"phaseType\": \"Phase 1\"\n            }\n        },",
        "label": 1
    },
    "629": {
        "output": "## Exercises\n\n### Exercise I: The patient\n\nThis exercise is to understand how you evaluate a patient's eligibility.\n\n\n1. In the patient note, find the parts where you are going to evaluate the corresponding criteria for inclusion and exclusion.\n2. List all the criteria included in the included criteria table.\n3. Evaluate the criteria in the patient note.\n4. Find the criteria that were included in the Note to physicians.\n5. Explain why you evaluated the criteria that way in the Note to physicians.\n\n### Exercise II: The clinical trial\n\nThis exercise is to understand each step of the patient screening process.\n\n\n1. In each step or the flow diagram, explain how each screen or step improves patient screening and exclusion:\n\t- Patient note.\n\t- Inclusion criteria table.\n\t- Exclusion criteria table.\n\t- Note to physicians.\n\t- Eligibility determination.\n\t- Exclusion criteria for all patients.\n\t- Trial-level eligibility.\n\t- Summarize each step/screen or improvement of patient screening in the form of a sentence.\n2. In any step, explain how the screening process is improved in the corresponding step if the patient note is missing in the process.\n<EOD> Implications for Dentistry of AIDS\u2010Related Lymphoma\nLymphomas represent a broad, diverse group of malignancies that share as a common characteristic a neoplastic proliferation of immune system cells in different body states. While most of the malignant tumors represent secondary neoplasias to other organs, a major part of the oral cavity malignancies are primary lymphomas arising within the mouth and jaws. An important subset of the primary oral lymphomas are in fact related to the human immunodeficiency virus (H1V) infection, a disease nowadays presenting worldwide an extraordinary prevalence in certain geographical areas. The dental approach to AIDS orally affected patients has to reflect the changes in the epidemiolgical characteristics now arisen, namely a marked reduction in the incidence of Kaposi's sarcoma and an unexpected increase in the incidence of H",
        "label": 0
    },
    "630": {
        "output": "##[INST] Questions: \n\n1. Where should you place the `endif` statements? \n2. Include a patient-level eligibility with 0, 1 or 2, based on your trial:\nWhat is the output of this patient note as regards to the trial's target population?\n3. What is the clinical trial title? \nYou are expected to complete this exercise with a researcher \nwith relevant experience for guidance and feedback as necessary. \n\n\n# Discussion\n\n\n[EMP] You have learned how to use trial-specific eligibility criteria to choose a person-level eligibility in order to assess eligibility for a clinical trial. The use of trial-level eligibly criteria is essential in clinical research for determining whether a participant is eligible to take part in a given clinical trial, especially since trial-level eligility criteria enable clinical trial researchers to conduct an investigation in which the outcome of interest is dependent on a single eligible patient. \nWe use trial-level eligibility concepts and concepts from Boolean algebra. Boolean algebra is applied when we want to design electronic systems that can accept binary logic inputs. \nThe trial-level and patient-level eligibility criteria are key concepts in determining whether a person is eligible for a clinical trial. We must compare them against a person's disease status, medical history and socioeconomic factors in order to make a trial-level determination of a person's eligibility for a clinical trial. A person-level eligibility is a more important concept because it tells us which conditions apply to a given person. The person's eligibility status is determined by a person-level eligibility, although the clinical trial's inclusion and exclusion criteria must be satisfied at the trial-level eligibility level. \n\n## [EMP] There were some difficulties with the exercise. Can you explain why?\nProtected by copyright -published by e-JIFCC -www.jifcc.org : You have learned how to understand trial-level eligibility criteria to choose a person-level eligibility in order to assess eligibility for a clinical trial. We use trial-level eligibility concepts and concepts from Boolean algebra. The trial-level and patient",
        "label": 2
    },
    "631": {
        "output": "[[RECOMMENDED]\n<EOD> .\nThe pathomechanism of the development of the diabetic cardiomyopathy has not been fully understood. The following hypothesis should be taken into consideration to describe the development of this disorder. Metabolically, the myocardial muscle cannot fully cover the high demand for glucose, the result is decreased ATP synthesis and an increased free energy state in the myocardial cell. The consequence is a decreased cell volume and a reduced capacity for calcium to stimulate muscle contraction and heart rate. This may be the cause of diastolic dysfunction in diabetes mellitus. The myocardial enzyme deficiencies lead to a decreased muscle perfusion with reduced cardiac output. An increased cardiac output with normal resting heart rate is often seen in untreated juvenile diabetics prior to the development of the clinical diabetic cardiomyopathy. In this patient, in addition to heart failure due to coronary atherosclerosis, a decreased myocardial contractility is also present. In diabetics with a diminished heart rate and normal or increased ejection fraction a \"hyperthyroid-heart\" is found which is comparable to that of the athlete's heart. In patients with the full-blown diabetic cardiomyopathy, with both left ventricular performance and heart rate reduced, a \"hypothyroid-heart\" is found. In this disorder, there is also an impairment of peripheral blood flow due to decreased systemic vascular resistance. With a further progression of the heart disease, the diabetic cardiomyopathy becomes a heart failure with reduced ejection fraction, and in patients with congestive heart failure, normal, or increased heart rate the heart is comparable to the heart of an adult athlete.<EOD> Genomewide Analysis of DNA Adductome in the Liver and Kidneys of Human Alcoholic Men.\nAIMS\nThe pathogenesis of alcoholic liver disease (ALD) and non-hepatic comorbidities such as cardiomyopathy and kidney injury are still unclear. The study aim was to characterize chemically induced DNA damage in the liver, heart, and",
        "label": 2
    },
    "632": {
        "output": "## [START]\nInstructions: Please give eligibility in the table by matching the inclusion and exclusion criteria to each field. Please make a row for each patient and one for each trial.\n\n\n*\n\n*In the trial-level eligibility of the patient note, eligibility will be 0) Excluded. Please put `0)` or delete the previous part, e.g., `0) Excluded`.\n\n[END]\n\n[INST] Hello, you are a helpful assistant for clinical trial recruitment. Your task is to complete the eligibility of the given patient and to evaluate whether the patient is eligible for a clinical trial.\n\n\nYour task is to choose 1 out of 3 (0, 1, or 2) for each row (column C in the table). You should evaluate the patient's eligibility as '0) Excluded' if the patient note in column A does not satisfy the criteria in the corresponding clinical trial (column R in the table). You can refer to the criteria in the clinical trial (column R in the table), to the patient notes (column B in the table), or to both in order to determine whether the patient note does not satisfy the criteria. If the patient note satisfies the criteria, you can refer to the criteria in the clinical trial or to the patient notes, or both, in order to decide whether the patient is eligible for the clinical trial.\n\n\nIf you find 2 or more rows where the patient may have been eligible, you will be able to see them at the end of this table, under the column header 'Eligibility found'. If you find 10 or more rows where the patient was eligible, you will be able to see them at the end of the table under the column header 'Very severe exclusion'. You can also see all of the available trials in the clinical trial search box on the upper right side of the table.\n\n\nIf you find 0 rows where the patient was eligible, you will be able to see your overall analysis at the bottom of the page.\n\n\n\n**Title**:\n\n\n**Exclude 0:** Patients with severe symptomatic aortic stenosis\n\n**Exclude 1:** Severe calcific aortic sten",
        "label": 0
    },
    "633": {
        "output": "[TIP: You can see the input to each function by `using Tkinter;` command line in IPython.]\n\n<TITLE>Your work is done! Try the main task below. Try to guess the answer. In order to submit your answer, hit `Control+Enter`.[INST] Good luck!\n\n![task-image](../../static/img/task-2-solution.png)\n\n### Questions\n\n#### Exam Questions\n\n<TITLE>### Exam Questions</TITLE><hr />\n\n##### Part 1\n<TITLE>### Part 1</TITLE> <hr />\nThe following are questions on the use of IF statements:\n<ul>\n<li> <b>If</b> a variable <b>A</b> is <b>21</b>, <b>write</b> <code>echo \"If A = 21 write\"</code>> <em>echo \"It is 21, how about it?\"</em>\r\n</li>\r\n<li>\n<b>If</b> a variable <b>A</b> is <b>21</b>, <b>write</b> <code>echo \"If A = 21 write\" >><i>echo \"it is 82, how about it?\"</i></code>\r\n</li>\r\n<li>\n<b>If</b> a variable <b>A</b> is not an even number, <b>write</b> <code>echo \"If A <== 5 then write\"</code>> <em>echo \"it is 35, how about it?\"</em>\r\n</li>\r\n<li>\n<b>If</b> a variable <b>A</b> is not an even number, <b>write</b> <code>echo \"If A <== 5 then write\" >><i>echo \"it is 35, how about it?\"></i></code>\r\n</li>\r\n</ul>\n\n#####\n<h3>Part 2</h3><hr />\n\nYou should write code to run a loop <code>for</code> 10 iterations by doing something each time the loop runs",
        "label": 1
    },
    "634": {
        "output": "Notice: the function `trial` can be used to obtain the trial information for a given patient.\n\n## Functions: ########\n- `patient.trial.included` is a special attribute in the patient object. It will be set to \"1\" if the patient is included in the clinical trial. The function `patient.trial.included` will return `1` if the patient is included. The function `patient.trial.included` can only be called when in ClinicalTrial. The function `clini-calTrial.patient.trial.included` returns the same value as `patient.trial.included`. \n- `patient.firstVisit` is timestamp of a patient's first visit in the trial. \n\n\nFor more examples, see https://pythonanywhere.com/hub/aemurali1/examples/Python/Chapter04/PatientExample.ipynb .  \n\n\n\nIf you have any questions about this function, click \"Post a question\" below:\n\n| `py`  | `python`  | `pyq`  | `pyqg`  | `pythonanywhere`  | `py3test`  | `jupyter`  | `ipython`  | `notebook`  | `nbviewer`  | `nbviewer_test`  |\n| :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :---------: |\n| [![Run](https://www.runpython.net/github/aemurali1/Python-vitae-Chapter04-exercise06/badge.svg)](https://www.runpython.net/github/aemurali1/Python-vitae-Chapter04-exercise06/statistics) | [![Run on pythonanywhere](https://run.pythonanywhere.com/badge.svg)](https://pythonanywhere.com/hub/aemurali1/statistics) | [![Run in IPython](https://run.ipython.org/badge.svg",
        "label": 0
    },
    "635": {
        "output": "[/END]\n\n##[END]<EOD> Profiles of immunosuppressive activity and their quantitative determination in human serum.\nImmunosuppressive activity, in human serum, was separated both physically and kinetically into three forms: Type 1 (T1), reversibly combined with serum protein, and capable of immunosuppression in serum, Type 2 (T2), reversibly combined with serum protein, and capable of immunosuppression only in normal serum, with a high concentration of immunosuppressive factor, and Type 3 (T3), irreversibly combined with protein, and unable to immunosuppress normal serum. T1 and T2 activities were found to be increased in patients receiving immunosuppressive drugs and, in addition, T1 activity was found to be markedly prolonged. In contrast, T3 immunosuppressive activity was decreased for a prolonged period of time, as compared to T1 and T2 activities. T1 and T2 activities were markedly inhibited by sulfhydryl compounds, heated at a low temperature of 50 degrees, and dialyzed, with T1 activity being more sensitive to such treatment.<EOD> .\n\n Different methods of fertility control are compared, stressing the importance of individual choice according to the purpose of the contraceptive method chosen. The choice of a contraceptive depends essentially on the fertility rhythm. Contraceptive methods based on induced ovulation, such as the 21-day method, use of a plastic syringe, and the pill combined with a progestin-estrogen compound or progestin-estrogen combined with a prostaglandin antagonist, are compared by reviewing their respective characteristics. Induced ovulation techniques should be avoided during the first 3 years after the second confinement, in subjects over 40 years of age, and in subjects suffering from hypertension or oligoamenorrhea. The 21-day method should never succeed a 16-day or 26-day method. The various techniques of induced ovulation should not be used over a 1-year period. It is emphasized, however, that in subjects using artificial insemination with donated eggs or using IUDs in 7th-",
        "label": 1
    },
    "636": {
        "output": "___\n\n### Exercises to Try\n- [ex_1](https://github.com/TanayGurupujari/DotKnapper/blob/master/example/ex_1)\n- [ex_2](https://github.com/TanayGurupujari/DotKnapper/blob/master/example/ex_2)\n<EOD> Improving the efficacy of psychotherapy and drugs by making them more salient.\nRecent studies using operant psychology have indicated that drugs of abuse can be made more efficient in modifying behavior under some conditions. This paper presents the results of studies indicating that drugs of abuse can also be made more efficient in modifying behavior when they are presented at the point at which they operate to produce changes in behavior and when the subjects are trained to expect that the drugs will be administered at the point of the behavioral change. These results, taken together with operant psychological data, suggest that drug treatment programs should not only train their subjects to associate the occurrence of drug treatment with specific behavioral changes but should also develop behavioral change procedures that will induce a substantial degree of drug-behavior contingencies.<EOD> Tuberculin testing in preschool children: a 10-year review.\nThis review is based essentially upon reports submitted within the first week of the 1973 to 1982 period, with several recent additions from 1974 to 1983. A total of approximately 32 000 preschool children were tested within the ten-year period. The estimated rate of tuberculin reactivity was 3.5%. The rate was significantly higher in boys, in Asian children, in those with family histories of tuberculosis and in immigrants born overseas, compared with those in whom no such factors were present. Tuberculin reactions tended to be associated with the younger age groups; this finding may partly be accounted for by the younger age of the immigrant child, and by the increased rates of positive reactions in Asian children. With these limitations, it may be tentatively concluded that the rate of tuberculin reactivity is decreasing over the decades and is less than one-half of that previously reported. The rate is also declining as the proportion of",
        "label": 1
    },
    "637": {
        "output": "[TEST]<EOD> An inexpensive alternative to a microscope slide for use in stereoscopic teaching of the fundus photomicrographs when a computer slide projection unit is not available.\nUsing inexpensive equipment already available in the pathology department, an alternative to a computer slide projection unit is outlined for teaching of the photomicrographs found on digital fundus cameras. Fundus photomicrographs are projected as if they were transilluminated by sunlight using (1) a 25-mm focal length objective of a double-lens stereomicroscope (Ludlow, Inc.; Ludlow, Mass.), (2) the incident rays of the microscope's overhead lighting, which is a combination of fluorescent and incandescent lighting, (3) a pair of Fresnel lenses, and (4) a 24-inch vertical-format black- and-white television monitor. The use of the 25-mm objective provided a projected diameter of greater than 27 inches, and the total cost was $432, including the 25-mm objective, the pair of lenses, and the television monitor.<EOD> Prodiginine Pigmentation in Red or White Rice (Oryza sativa): Biosynthesis, Accumulation, and Transposon Removal\nProdiginines are important secondary metabolites, and many prodiginine-producing bacteria are known to inhabit various ecosystems, such as soils, marine sediments, and decaying plants. To reveal how the bacterial secondary metabolites enter into plant life, we first examined if the natural environment is a source of the prodiginines. A total of 14 rice mutants were screened using HPLC. Rice seedlings treated with the chemicals in the root environment for 12 h resulted in the appearance of a new production of the prodiginines (27, 28, and 31), which were not detected when rice seedlings were treated with other root conditioning agents. Then, we discovered a novel type of secondary metabolism for the prodiginines among the monocots. The production of prodiginines was observed in the leaves of the rice mutants, designated Oryza sativa npr1(",
        "label": 0
    },
    "638": {
        "output": "# Detailed explanation\n\n## Explanation of input arguments\n- Assistant: User specified name.\n- Patient_data: JSON file representing the patient note.\n- TL_list: List of IDs of trials.\n- TRE: Trial to match.\n- EXCL: List of IDs of excluded trials.\n\n## Making the predictions\nBy default, the default values of some parameters are used. The patient note will be stored on disk. It will be stored as text in the database and as JSON for the convenience of human users.\nIt first generates and saves a JSON file named \\`\\`\\`patient_info\\`\\` for a patient note whose format is described in the above table. \nBy default, the prediction will use the [Trial 1] database from clinicaltrials.gov. You may use the trials in the [Experiment 1] instead. [EXCL] and [TL] are the keys of the database; there is a one-to-one relationship between a trial and its IDs. \n[T] is the number of trials and [D] is the number of patients. If the database stores patients' names correctly, you can use your name as [T] or [D]. The code above will also work if you provide the patient info in the same format with the [T] of [Experiment 2].\n[TRIAL] and [EXCLS] are required in the output. Other outputs are only needed if you want to know their scores.\nThe code will store a JSON file named \\`\\`\\`patient_info\\`\\`. For example, the file of the patient shown in[Input] above contains two lines as \\`\\`\\`[patient_info] \\`\\`\\` and \\`\\`\\`score \\`\\`\\` with two JSON objects.\n\n# Detailed explanation\n\n## Explanation of output arguments\nThe output has two columns. The first is the Trial Id of the trial. The second is one of the scores for each trial.\nThe two columns will be saved in a file named [trial_list], which by default is stored in [Input]\n\n## Examples\n\n### Examples for input\n<EOD> Acidic stress response in bacteria\n\nAs acidic",
        "label": 1
    },
    "639": {
        "output": "<EOD> Increased expression of P-glycoprotein in myelodysplastic syndromes: association with an abnormal CD34 phenotype in progenitor cells.\nIncreased P-glycoprotein (P-gp) expression has been described in various hematologic disorders. We studied its expression in relation to disease classification, as well as its distribution in CD 34-enriched populations. The P-gp gene was examined in 38 patients with myelodysplastic syndrome, acute nonlymphoblastic leukemias of various lineages, acute lymphoblastic leukemia, acute erythroleukemia, and chronic myelogenous leukemia in blast crisis. In acute nonlymphoblastic leukemias, P-gp expression was detectable in most primary and established blast and lymphoblastic cell lines; its expression decreased to some degree after chemotherapy or following CD 34 enrichment. Expression was also detectable in both myeloblasts and monoblasts in acute erythroblastic leukemias. P-gp expression was detectable in all patients with del(20q). Among patients with myelodysplastic syndrome, 11 of 14 (78.6%) showed P-gp expression, as compared to the 3.2% of leukemia patients with normal karyotype. P-gp expression was found in both CD 34-positive and CD 34-negative cells in all patients with myelodysplastic syndrome. P-gp expression was found in cells with and without abnormal phenotypes. Our findings suggest that P-gp may function as a multidrug resistance phenotype in myelodysplastic syndrome in a manner that is distinguishable from that in leukemia cells.(ABSTRACT TRUNCATED AT 250 WORDS)<EOD> .\nIn many ways, human intelligence--the ability to choose among alternatives--represents the sum total of the various ways in which other intelligences and cognitive processes fit together in providing human beings with their ability to manipulate the environment. The author distinguishes several types of intelligence based",
        "label": 1
    },
    "640": {
        "output": "_Answers to the Assessment of eligibility test will be shown below in green._\n\n\n\\# Assessment of trial-level Eligibility\n\n\\## 1) Excluded\n\nPatient's LDL is not increased\n\nPatient does not have LDL-C levels above the normal\n\n\\## 2) Not relevant\n\nPatient notes:\n\"A 46-year-old man presents with dizziness and frequent headaches.\"  \"He has a family history of CAD.\"\n\"He reports no use of lipid-lowering medications.\"\n\"Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull.\"\nUltrasonography of the carotid arteries: \n\"severe stenosis in the left internal carotid artery (LICA),\" PSV 208.5;  \"moderate stenosis in the right internal carotid artery (RICA),\" PSV 91.72;\nPlaque in the anterior wall of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\"\nThe results of the ultrasonographic assessment suggest that the subject has a severely obstructive stenosis in the left internal carotid artery, in the common carotid artery, in atherosclerosis and lipid-lowering medication. Therefore, this condition qualifies for inclusion in the study.\n\nPatient's LDL-C levels: 545\n\nPatient notes:\n\"He has a family history of CAD.\"\n\"He reports no use of lipid-lowering medications.\"\n\"Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull.\"\nUltrasonography of the carotid arteries:\n\"severe stenosis in the left internal carotid",
        "label": 2
    },
    "641": {
        "output": "<EOD> Influence of dietary supplementation with cynara forskohlii on liver regeneration after partial hepatectomy in rats\nOur aim was to investigate the possible hepatoprotective and regenerative properties of Cynara forskohlii in the liver of partially hepatectomized rats. Forty\u2010five male Wistar rats were divided into three groups: SHAM\u2010operated group, control group, and Cynara forskohlii\u2010supplemented group. In the second group, rats were fed a standard diet (control diet), and in the third group, rats received a supplemented diet containing Cynara forskohlii leaves at a dose of 5% (of the dry weight of the basal diet). Forty\u2010five days later, all rats were subjected to median liver resection (70%). Following resection, rats were divided into three subgroups according to the time of liver regeneration, i.e., subgroups A (7 days), B (10 days), and C (14 days) post\u2010hepatectomy. Following resection, histological changes were observed in the SHAM\u2010operated group, especially in the periportal zone. In this experiment hepatocyte proliferation was increased by treatment with Cynara forskohlii in group C animals (14 days), which showed a significant increase in \u03b2\u2010catenin expression. Cynara forskohlii may stimulate hepatocyte proliferation by increasing \u03b2\u2010catenin expression, and may inhibit inflammatory response in hepatocytes, resulting in accelerated restoration of liver homogeneity. Therefore, the use of supplementation diet containing Cynara forskohlii may be advantageous in the early stages of regeneration after partial hepatectomy. Copyright \u00a9 2011 John Wiley & Sons, Ltd.<EOD> In Vitro and In Vivo Antimalarial Studies of Strychnos pseudoplatanus and Strychnos usambarensis Extracts\nIn vitro and in vivo activities of plants extracts have potential antimalarial activities. The present study determines the in vitro and",
        "label": 1
    },
    "642": {
        "output": "\u00a92020 Copyright Tiger Analytics Srl. All Rights Reserved.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV",
        "label": 1
    },
    "643": {
        "output": "A: If you want to get the list of patients with a certain status (e.g., trial-level eligibility), you can just use \"patient.Trial-level_eligibility\" as a sort column\nSELECT patient.\nID AS Patient_ID\n,patient.Trial-level_eligibility\nFROM patient\nORDER BY patient.ID desc\n\n<EOD> PI3K\u03b3-selective inhibitor IPI-549 promotes anti-leukemic immunity and exerts therapeutic effect in combination with chemotherapy drugs in acute myeloid leukemia\n\nBackground & Aims: Acute myeloid leukemia (AML) is a stem cell disorder with a high rate of relapse following chemotherapy, making new therapeutic approaches necessary due to patients' poor prognoses. Leukemia stem cells are less sensitive to conventional chemotherapy drugs than normal stem cells, so it is possible that chemotherapy only partially cures AML and cannot kill all leukemia stem cells. IPI-549 is a recently developed phosphatidylinositol 3-kinase subunit gamma (PI3K\u03b3) inhibitor, which has been shown to have anti-tumor activity in various types of tumors but not in leukemia.Methods: Murine 6L/R and human AML cell lines were used to determine the anti-leukemic effects of IPI-549 on AML in vitro and in vivo, along with the associated mechanisms. The combination of IPI-549 and chemotherapy was also investigated.Results: IPI-549 promoted cytotoxicity and apoptosis in AML cell lines, reduced the proliferation of 6L/R cells, caused myeloid differentiation, and induced a change in AML cell morphology. Flow cytometry performed to detect the proportion of CD117 + leukemia stem cells showed that PI3K\u03b3 inhibition decreased the number of CD117 + AML cells, indicating anti-leukemic activity in AML. A subcutaneous tumor model was constructed using the 6L/R line, with IPI-549 and c",
        "label": 1
    },
    "644": {
        "output": "<EOD> Efficient identification of mammalian orthologues as a tool for the interpretation of genome\u2010wide association studies\nGenome\u2010wide association studies (GWAS) have become increasingly popular as screening methods for studying complex diseases. GWAS typically involve the analysis of large numbers of single nucleotide polymorphisms (SNPs) from hundreds of thousands of individuals. Therefore, efficient computational methods are needed to assist researchers involved in bioinformatics GWAS data analyses, with particular reference to the functional interpretation of the identified SNPs. Previous comparative genomic analyses, using orthologue information and sequence conservation, have helped to better understand the molecular basis of disease susceptibility. Therefore, the identification of orthologues can be an invaluable tool for the interpretation of genome\u2010wide data. Given the dramatic changes in the evolution of vertebrates, it is challenging to detect orthologues between species at the whole genome level in a high\u2010throughput manner. To this end, we recently developed the tool, Orthostrapper, which is based on the principle of comparative genomics. This technique first identifies the set of proteins from one species, which can be mapped to the proteins of the second species, and then locates highly conserved regions surrounding the SNPs. In this study, we present the design of Orthostrapper and showcase its use on a number of case studies. In a first study, we used Orthostrapper to investigate the conserved elements surrounding SNPs obtained from a meta\u2010GWAS study involving 26 GWAS datasets, each representing a specific population group. The results clearly show the advantage of using Orthostrapper compared to state\u2010of\u2010the\u2010art methods. A potential limitation of our tool is the difficulty to detect a significant level of conservation in intergenic regions, a phenomena commonly observed during evolution. Using our tool on a second data set, we investigated the conservation level surrounding SNPs for two complex traits, height and bone mineral density. We show that Orthostrapper is particularly efficient and can detect very specific genomic patterns correlated to these phenotypes. Finally, we discuss our method in the context of GWAS association analysis and argue that our tool might be used to better interpret the identified SNPs and associated genes. Copyright \u00a9 2016 John",
        "label": 1
    },
    "645": {
        "output": "## Good luck!\n[INST] Tiebreakers:\n\n* If a patient receives exclusion criteria before inclusion criteria, output 0.\n* If the patient meets an inclusion criteria after a patient has received exclusion criteria, output 1.\n* If you don't get to the end of a patient note in time (i.e., you do not see all the medical conditions such as age, gender, and cardiovascular risk factors, etc.), skip a sentence by `$skipnextline -1`.\n* If there is not enough space left for outputting in a given row, output your evaluation at the current line by `$outputrowat -1`.\n\n## Reference\n<EOD> Anaplastic variant of intravascular large B-cell lymphoma confined to lower limb in an elderly patient\nIntravascular large B-cell lymphoma (IVLBCL) is an aggressive extranodal mature B-cell lymphoma with neoplastic proliferation and progression exclusively inside the lumen of small blood vessels. We report here a 90-year-old male who was admitted to our hospital for progressive pain in the lower limbs. Physical examination showed lower-extremity paresis and decreased pulsation of femoral arteries. Computed tomography showed bilateral thromboembolic disease in the arteries of the upper and lower extremities. Doppler ultrasonography revealed thromboembolism in the subcutaneous vessels of the lower extremities as well. A diagnosis of IVLBCL confined to the subcutaneous tissue in conjunction with intravascular lymphocytosis was made. We performed high-dose methotrexate and corticosteroids in combination with surgical treatment for vascular thrombectomy, and the patient recovered after 17\u2009weeks of treatment. The patient has remained in complete remission for a period of 4\u2009months. Our report highlights the clinical findings and treatment of an unusual type of IVLBCL confined to the subcutaneous tissue in an unusual clinical setting.<EOD> A New Genomic Island in Acinetobacter baumannii IMT241 Mediates Resistance to Four Classes",
        "label": 0
    },
    "646": {
        "output": "[END]\n\n\n### Problem 2\nWhen you write code with Python programming language, you need to prepare an environment to let the interpreter work. How to do so? [INTRO]\n\n## Solution\n\n### Solution 1\nFor Python code to work, one environment is required. Before we discuss the detail, we will show you how to prepare environment by one video instruction. \n\n### Solution 2\nYou can also download a ready-to-use virtual machine image with the Linux operating system, Python programming environment, all required resources and the solution to all provided challenges.\n\n### Solution 3 \nOther ways for solution can read this paper. \n\n## Expected Behavior You want to answer the Question #1 (What is the eligibility in your own words?).\n\n## Expected Solution\n\n### Solution 1\nThis time, we will give the definition of the eligibility. From the definition of the eligibility, we conclude that the eligibility of a participant is determined as follows: participants are eligible for a clinical trial if the participant's characteristics satisfy all of the eligibility criteria (2).\n\n### Solution 2\nIn the Question #1 (What is the eligibility in your own words?), the participant is eligible to be included if the participant's characteristics satisfy all of the eligibility criteria (2). In other words, the patient is Eligible.\n\n### Solution 3\nA participant is eligible to be included if the participant's characteristics satisfy all of the eligibility criteria (2). In other words, the patient is Eligible.\n\n### Solution 4 \nHere is the definition of the eligibility in our own words: participants are eligible for a clinical trial if the participant's characteristics satisfy all of the eligibility criteria (2). In order words, they are eligible to be included.\n\n## Alternatives\nThere are many other ways to do it and you can look it up by searching on Google for each phrase, the main keywords are ``explanation and python'', ``definition and python'' etc.\n\n### Example 2\nWe will also solve a question, the first phrase is as follows:\nIf a patient with diabetes mell",
        "label": 1
    },
    "647": {
        "output": "### Sample Solution\n\n# Sample Solution:\n```\ndef findPatientEligible(patient_note):\n    trial = 'dietary protein requirements on unbalanced diets'\n    for line in patient_note:\n        for element in line:\n            if 'exclusions' in element:\n                if 'Eligibility Exclusions: ' in element:\n                    if 'Clinical trial of pharmacologic or medical treatment for high blood pressure only' in element:\n                        return 0\n                    elif 'Clinical trial of medical or surgical treatment for cardiovascular disease' in element:\n                        return 0\n                    elif 'Clinical trial of pharmacological or medical treatment for hyperlipidemia (i.e., hypercholesterolemia or hypertriglyceridemia)' in element:\n                        return 0\n                    elif 'Clinical trial of smoking cessation support' in element:\n                        return 0\n                    elif 'Clinical trial of pharmacotherapeutic agents for psychiatric disorder or treatment' in element:\n                        return 0\n                    elif 'Clinical trial of prophylaxis or treatment of neurological disorders including headache, sleep disorder, etc.' in element:\n                        return 0<commit_msg>Bug \ud83d\udc1e: The problem in the findPatientEligible in the sample solution has been fixed.<commit_after>\ufeff\n# Copyright (C) 2018 by University of Washington, Seattle, USA\n#\n# SPDX-License-Identifer: MIT \n#\n# This coding challenge is a problem-based example of NLP task of trial assessment\n# for clinical trials in the medical field. Your task is to perform patientassessment\n#, we can conclude that you need to check whether the patient-data is available or\n##  not. \n#\n##  Given a patient note, the patient data can be in the form of a table. However,\n##  we do not assume, that the patient data can be in the form of a table\n##  or may be freeform text\n#\n#\n# You are",
        "label": 1
    },
    "648": {
        "output": "Good luck.\n\n\n\n#### INTERVIEW\n\nThank you, Jae. I'm interested in how you analyze the data using a computer. Would you mind answering those questions?\n\nI can use the VA/TMS program to analyze the data. This software can generate patient-level data and trial-level data. Also, the program can make a table comparing the trial-level data with the same-described population. I can show you the results below. \nIn the above diagram, each line represents one patient, and the lines are arranged by time. The columns of the line are the same clinical trial's patient ID number. Patient-level data were obtained by linking data from clinical trials with the patient's ID number. \nBy trial-level data, I can see general characteristics of a specific clinical trial. In the diagram, I can obtain the patient's eligibility as soon as the patient's eligibility is determined. \nLet me show you how to make data matching. This is called patient-level linkage. The purpose of matching the data is to combine individual clinical data with research data and check whether data are accurate in both datasets. The software used for this study generates patient-level data. \nThe table on the left shows the clinical trial data. Here, the unit type is the number of visits. The table on the right shows patient record data. This table is similar to the table on the left except for the unit type. The unit type is the number of drugs used. \nI could make the patient-level linking table using the patient ID number, which was specified by the clinical trial investigator. The patient ID number links both patient record and trial data. You can confirm the correctness of the patient-level linking table by cross-checking it. If you want to check patient-level linkage between groups, you can use two distinct patient groups as the basis. \nBy this program, I could get to know that the trial-level data and patient-level data match well. [/INTERVIEW]<EOD> Bone marrow depression with feline leukemia virus in experimentally infected cats.\nSeven cats were experimentally infected with feline leukemia virus (FeLV) and feline oncornavirus (FoV), in order to determine",
        "label": 1
    },
    "649": {
        "output": "![![INST] \n\n\n![INST] ]()\n\n## 3.5. Eligibility\nThere are a myriad of eligibility criteria, which may include the patient's age, gender, medical history, medications, tests, and other factors that may make the subject not be safe for enrollment in a trial.\n\n\n```\n# Exclusion criteria. \n- \"Age\":\n- \"Allergies\":\n- \"Vitamins\":\n- \"Glucose\":\n- \"Blood pressure\":\n- \"Blood\":\n- \"Chol\":\n- \"Heart rate\":\n- \"Weight\":\n- \"Grogs\":\n- \"ECG\":\n```\n\n## Examples\n\nIn MIDAS, the patient is a 40-year-old woman who presented with a complaint of worsening left knee pain and swelling. Her knee radiograph shows osteoarthritis changes on the tibial plateau, lateral trochlear ridge, and subchondral bone. She has severe bilateral genu varum. She also complains of low back pain. Her past medical history is remarkable only for a previous miscarriage and her father's recent myocardial infarction, and her father died from an ischemic stroke. She is a nonsmoker, does not drink alcohol, and takes no medications other than vitamins. She takes no cardiac medications, steroids, or NSAIDs and reported no previous allergies. Her vital signs are unremarkable except for a blood pressure of 140/73 mmHg. Her height is 1.6m, weight 51.8kg, and her body mass index . She has her knees at 35 degrees of flexion while she sits upright in the chair. She has symmetrical feet with an equal distribution of weight. Her vital signs are otherwise normal, her mental status is alert, and she appears in no distress.\n\nThe patient's ECG shows sinus rhythm and no ST/T wave changes. Blood pressure, heart rate, renal function (urea 5, electrolytes, and liver enzymes)  are within normal range. Pulse oximetry is",
        "label": 1
    },
    "650": {
        "output": "#### Score\nThis section should include the score function, which will automatically output the eligibility score of a new patient in a JSON file as output. The score function is the last function in the R script. \n\nDefine your own score function to get eligibility score and score function ID. Your score function should output the value of eligibility score. There is no required standard for a score function, so you can freely choose the values to output. After the execution of score_train_model() and score_save_json(), the value of eligibility score will be automatically stored in a JSON file in the specified folder. \n\n    function(patient) {\n      # Output trial_id to specify the score function ID.\n      # Eligibility score will be outputted the same as score_function_id.\n      # Expected Eligiblity score: 1.0\n      score_function_id <-\"sc_id-2\"\n      if (score_function_id %in% score_function[\"sc_function_name\"]) {\n        patient$eligibility_score<-1 \n      } else {\n        patient$eligibility_score<-0\n      }\n      trial_id <-patient$trial_id \n      file.rename(patient$id,\"patient_id-\" + trial_id) }\n\n\n```r\n##### Expected results :: score_save_json():\n\n```r\n#### Results :: score_save_json():\npatients <-list(name=\"patient\", data=\"\"[[patients:]]])\n\n\npatients[[1]][[-1]]$eligibility_score <-1\n\n\nfile_directory <-\"../data/train_set/score_save/\"\nfile.system(paste0(file_directory, \"score.json\"), \"w\")) \n\nwrite.json(patients, paste0(file_directory, \"score.json\"), force=TRUE)\n\npatients[[1]][[-1]]$eligibility_score <-0\n\nfile_directory <-\"../data/train_set/score_save/\"\nfile.system(paste0(file_directory, \"score.json\"), \"w\")) \n\nwrite.json(patients, paste0(file_directory",
        "label": 1
    },
    "651": {
        "output": "### Tip 1\nTip 1. 23456789 (random number)\n\n<EOD> Association of CD37 SNP and Haplotypes with Risk of B-cell Chronic Lymphocytic Leukemia\nIntroduction: CD37 is a transmembrane protein that is involved in B-cell activation, but its function is not fully characterized. Some antibodies against CD37 may have therapeutic use in B-cell chronic lymphocytic leukemia (B-CLL). Therefore, it is not surprising that single-nucleotide polymorphisms (SNPs) in the gene of CD37 (TAPA-1) may cause a difference in CD37-mediated regulation of the function of B-cells, and thus lead to predisposition of hematological malignancies. Methods: Based on a previous report of susceptibility to diffuse large B-cell lymphoma (DLBCL) by means of CD37 genotypes, we examined the CD37 SNPs rs1147630, rs2070802, and rs3114910 and the haplotypes with DLBCL and B-CLL in a Han Chinese population. The total number of B-CLL cases studied was 811, and the control cases studied were 811 healthy individuals from the same region. Results: The frequency of the A alleles in the groups of both diseases was higher than that in the controls (P = 0.0035). Among the A carriers, the odds ratio (OR) of B-CLL was 1.39 for the TAPA-A haplotype, and 1.42 for the TAPA-GA haplotype, in comparison with the wild-type homozygotes, and was 1.63 for the TAPA-GA haplotype in comparison with the TAPA-GG haplotype. In contrast, there were no significant differences between the A carriers and the GG homozygotes, neither in the B-CLL groups, nor in the DLBCL groups, despite the trend of an increased odds",
        "label": 1
    },
    "652": {
        "output": "![img](./images/practice_problems/05.png)   \n\n\n\n\n\n## Answers\n\n\n*The optimal way to create the answer would be to iterate through all the rows, compare the patient with each trial's inclusion/exclusion criteria, and add the score.\n\n*We can use pandas \"zip \" method to iterate over each element from both lists.\n\n*zip is equivalent to nested for loops.  It is also equivalent to itertools.product:\n  - itertools.product has a speed up for more than an 75% over the sum of the individual list lengths. \n  - If a 2D array is passed to product, it will perform really well.\n  - However, it is slow for higher dimensions (such as > 30). \n *You should also use Pandas' DataFrame.from_records to create the dataframe from the csv file. \n  This is faster than reading in the entire csv file.\n\n*We can use the \"groupby \" method to calculate eligibility, which requires two things.\n\nFirst, we need to compare a patient record with a particular inclusion criteria row (to get score) and put the score in key.\n\nSecond, we take a dict whose keys are the patient ID and values are the calculated score. \n\n**First, we will create the key.**\nWe select from the patient and the trial eligibility a key as the patient ID. \n\n```pandas\nfrom itertools import product\n\npatient_list = ['Patient-ID-1', 'Patient-ID-2', 'Patient-ID-3']\ntrial_eligible_list = ['Eligible (0123)', 'Notrelevant (2345)', \n                     'Notrelevant (1234)']\n\npatient_list_dict = {}\nkey = product(patient_list, trial_eligible_list)\nkey\n```\n\n```\nKey:\n0     Patient-ID-1       Eligible (0123)\n1     Patient-ID-2       Notrelevant (2345)\n2     Patient-ID-3       Notrelevant (1234)\n```",
        "label": 1
    },
    "653": {
        "output": "A: To complete your program, we need to make another method to show the result.\nFirst of all, we define to show the output.\npublic string[] trial_Eligible;\n\nSecondly, we define that in this program we will show the result for this clinical trial.\n// clinical trial //\nClinicalTrial.Trials trial1 = new ClinicalTrial.Trials()\n{\n    Title = \"Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease\",\n    Summary = \"The study aims at pooling a large population of patients with suspected coronary artery disease (CAD) who underwent Computed Tomography Coronary Angiography (CTCA) and who were adequately stratified in the first place. Then the investigators will be able to assess the incremental value of CTCA in the stratification of prevalence of disease (non obstructive/obstructive) and prognosis of patients with suspected CAD). The added information to current evidence is how reliable and to what extent CTCA can define the actual burden of disease and cardiovascular risk.\n    InclusionCriteria:\n    {\n        CalciumScore = 64,\n        NumberOfPatient = 100,\n        MinFollowUp = 12,\n        SuspectedCoronaryArteryDisease = true//suspected is included, obstructive is excluded,\n        // notIncluded = false\n    },\n    ExclusionCriteria:\n    {\n        CalciumScore = 0,\n        NumberOfPatient = 9,\n        MinFollowUp = 12,\n        Age = 25,\n        Sex = 0\n    }\n};\n\nAnd then we can use this method.\n    return this.trialEligible(trial1 );\n\n\nA: Since you are getting just 2 values\n\npublic TrialLevelEligibility[] TrialEligible (This is a method in my code)\n{\n    Int32 age = AgeOfPatient.Min; //age <= 65\n    Int32 sex = SexOfPatient.M; //male",
        "label": 1
    },
    "654": {
        "output": "<EOD> Reproducibility of transient evoked otoacoustic emissions (tEOE) by application of the multi-channel data analysis and standard-guidelines (MDAS-G)\nIn transient evoked otoacoustic emissions (tEOE), reproducibility is still under discussion. Since reproducibility influences reliability and clinical value of the examination, several researchers have done a lot of work in this area. In this study, we were able to show that tEOEs can be recorded reproducible at a very high level. In 46.57% of cases, an examination could be recorded without disturbance; 44.38% were recorded as present and reproducible; 5.85% of recording were disturbed, so the results could not to be interpreted reliably.<EOD> Surgical resection of the primary tumor following first-line or second-line chemotherapy in stage IV non-small-cell lung cancer patients with poor performance status.\n\nBackground:There remains a lack of evidence of the effect of surgical resection of the primary cancer following chemotherapy in patients with poor performance status (PS) or unresectable stage IV. The aim was to examine whether surgical resection of the primary tumor following chemotherapy was suitable for patients with a poor PS. Materials and Methods: We identified 139 patients with stage IV non-small-cell lung cancer (NSCLC) and poor PS who had received \u22651 cycle of chemotherapy between January 2010 and January 2017 at our institution. Of these, 38 patients underwent surgery to remove the primary tumor following chemotherapy, while 101 patients underwent chemotherapy alone as first-line or second-line treatment. The clinical records were retrospectively analyzed.Results:In the preoperative period, 38 patients were able to walk for >6 min, while 39 patients could not walk. Fifteen and 23 patients with a good PS had a median postoperative survival time of 17.1 and 18.7 months, respectively. Seven and eight patients with a poor PS had a median postoperative survival time of 17.7 and 17.9 months,",
        "label": 1
    },
    "655": {
        "output": "[SOLVED] Incorrectly formatted patient note and clinical trial record\n[EXPLAIN] Formatted patient note and clinical trial record\n<EOD> Lipoatrophy Following Administration of Hepatitis B Vaccine as a Fill-in-the-Gap Dose by the Pediatric Ward and Intensive-care Unit Nurses\n\nIntroduction: HBV vaccination is the only way to protect people from developing liver cancer or lifelong infection from HBV. Hepatitis B-related injections are generally known to cause lipoatrophy following intradermal vaccination and also a fill-in-the-gap dose by nurses. Objectives: The present study aimed to investigate the risk of lipoatrophy following hepatitis B vaccination as a fill-in-the-gap dose by nurses in the pediatric ward and intensive-care unit. Methods: The research samples were the healthcare providers who reported a history of hepatitis Be vaccination in the pediatric ward and intensive-care unit in Rasht, Northern Iran. Two hundred six questionnaires were provided to the participants through convenience sampling. The questionnaire was designed based on a literature review about fill-in-the-gap doses. The questionnaire included demographic, educational, and work experience information. The data were entered into Excel (Windows 2011) and analyzed by SPSS 19.0 (SPSS Inc. Chicago: IL, USA). Results: The majority of participants had a bachelor's degree, 1 to 5 years post-graduation experience, and work experience less than 50 patients of hepatitis B vaccination. The majority of participants (66.7%) had experienced adverse effects, mainly including worsening local reactions or lesions (21.6%), fever (17.9%), and swelling (14.8%). Conclusion: Lipoatrophy was noticed in 8.3% of participants. More than half of participants were unaware of the criteria for performing fill-in-the-gap dose. Therefore, a plan should be designed to control the conditions of vaccine administration and nurses should complete their education on fill-in-the",
        "label": 2
    },
    "656": {
        "output": "---\n\n##[Trial-level Eligibility] Assessment of Eligibility (Assignee): <Assignee>\n[INT] Goodness of fit method: R 2\n[INT] Goodness of fit method: R 2\n[RQ1] Is your code working the same way for the given patient note? Is your code working the same way for the given patient note?\nIf so, run the `fit() function with 'goodness of fit method` and calculate the adjusted R 2 in the results.\n`fit(formula=\"Trial-level eligibility ~ sex*clinicalTrials ~ clinicalTrials*race + sex + race\", type = \"quasibinomial\", data = df1, method=\"R2\", test = \"\")$Rsq`)\nAdjusted R2 = 0.981986\n\nIf not, check all your assumptions one by one and modify the formula and the code as needed.\n---\n<EOD> Transduction of murine lymphocytes by pseudotyped lentiviral vectors is independent of VLA\u20104 and CD4\nThe ability to transduce quiescent and activated cells is critical to the widespread use of lentiviral vectors in therapeutic approaches. In this study, we compared the transduction of quiescent and interleukin\u20102 (IL\u20102)\u2010activated murine L\u2010cells and lymphocytes of various organs by two pseudotyped human immunodeficiency virus type 1 (HIV\u20101) lentiviruses, VSV\u2010G pseudotyped (LV\u2010VSV) and a novel gibbon ape leukemia virus (GaLV) pseudotype (LV\u2010GaLV), used in a range of experiments to investigate tropism. The LV\u2010VSV vector had a wide species tropism and readily infected and transduced resting and activated L\u2010cells (35% and 32 %, respectively) but transduction of quiescent freshly isolated resting lymphocytes was poor, with the highest percentages obtained using activated cells (2.5%). In contrast, LV\u2010GaLV transduction of lymph",
        "label": 1
    },
    "657": {
        "output": "You should enter the patient information in the `Input Data` panel. You should make a trial-patient number `Trial-patient: `, a trial-assignment `Trial-related: `, if the patient was included in the clinical trial. A trial-patient should be an integer. \nYou can insert data using a row insert command of a computer mouse in the `patient data table`. Please, be carefule when you are inserting data, because the amount of rows of the table depends on the total data you are entering. If you are making an update of the patient record that is already existed in the clinical trial, you should not enter only",
        "label": 1
    },
    "658": {
        "output": "# Evaluation\nUse the links in the evaluation section to load your work into the Jupyter Notebook on your machine. The evaluation will automatically load every variable and use it to provide feedback.\n\n<span class='survival-table'>\n  <script>\n    init = setInterval(function check () {\n\n      clearInterval(init);\n\n      if (isTableValid() == FALSE)\n        init();\n      else\n        return\n\n    }, 5000);\n  </script>\n\n  <form action=\"#\" method=\"post\">\n<input type=\"hidden\" name=\"Survival-table-datafile\" value=\"../data/survivaltable.csv\">\n<input type=\"hidden\" name=\"output\" value=\"eval\">\n<input type=\"submit\" value=\"submit\">\n    </form>\n\n  <div id=\"Jupyter-output\"></div>\n</span>\n<EOD> NUTRITION IN ANGINA BY ETHNICITY: ARE ASIAN ETHNIC DIETS HARMFUL?\nWe investigated the association between diet and angina over a four-year period using five waves of National Health and Nutrition Examination Survey (NHANES) data (2007\u20132011). We examined associations between angina and diet by racial/ethnic groups. We used Chi-square tests for trends and logistic regression to calculate odds ratios at each wave. Participants were 17 911 adults with angina and 92 506 participants without angina. After adjusting for socio-demographic covariates, we observed an angina-diabetes interaction. Among people without diabetes, we identified an increased risk of angina among people diagnosed as being in the high alcohol consumption category. We found, as compared to the non-Hispanic white population, that the Mexican American population had a higher prevalent rate of angina over time (P trend\u2009=\u20090\u00b702). The multi-racial/ethnic group (except Mexican American and Hispanic) had a higher prevalence of angina than the non-Hispanic white population. The Mexican American population showed an increasing trend of angina",
        "label": 1
    },
    "659": {
        "output": "# [END]<EOD> Effects of a 5-lipoxygenase Inhibitor (Zileuton) Compared with Cromolyn-Placebo on Pollution-Induced Health Status\n\n\n\n## Health status questionnaire items\n\n## 21-item version health status questionnaire items\n21 items on health status including frequency of:\nA.\nB.\nC.\n1. Headaches 1. Cough 1. Shortness of breath 1. Difficulty breathing 1. Sneezing 2. Pain (not headache or migraine) 2. Fatigue 2. Wheezing 2. Dry throat or stuffy nose 2. Shortness of breath 2. Difficulty breathing C. Gingivitis 11. Wheezing while inhaling 11.\nVoice hoarse/laryngitis 11.\nCough after heavy exercise 11.\nNasal sinus problems 11.\nVoice hoarse/sore throat 11.\nChest pain at exercise 11.\nCough without a cold 11.\nChronic fatigue 11.\nCold sores 11.\nDizziness without cold 11.\nDifficulty breathing 11.\nEye (itchy, red) 11.\nHay fever/ nasal allergy 11.\nItchy nose, stuffy 11.\nItchy skin 11.\nItchy, burning eyes 11. 12. Difficulty breathing 12.\nLoss of taste and smell 12.\nPain in back near heart 12.\nPoor memory 12.\nPsychological stress 12.\nDifficulty getting nose to breathe 12.\nLow backache 12.\nDifficulty closing eyes 12.\nDifficulty swallowing 12.\nLoss of concentration 12.\nSore throat 12. . Eye (itchy, red) 23.\nItchy nose, stuffy 23.\nItchy throat, difficulty",
        "label": 2
    },
    "660": {
        "output": "The eligibility of the patient is 2 (2 eligible) while the summary of this is presented in the last line.\n\n## [HINTS]\nPlease see the following link and answer the questions: [HINTS]\nYou have to be careful about what type of patients is eligible or not. Take a careful look at all the scenarios in this toolkit so as not to be lure into false assumptions. The patient in this patient note case is eligible for the trial.\n\n## Good luck!\n[/HINTS]\n<EOD> Effects of the novel dopamine D2 receptor agonist cariporide on cocaine intake in humans.\nCariporide (also called Compound 21) functions as a potent, selective, and noncompetitive inhibitor of the H+,K(+)-ATPase, resulting in an intracellular acidification with anticancer activity. Recent studies suggest the ability of H+,K(+)-ATPase blockade to regulate neurotransmitter release and behavior. Because the endogenous neurotransmitter dopamine (DA), which is involved in the modulation of cocaine self-administration and reward, is sensitive to acidification of the synaptic milieu, we hypothesized that the noncompetitive H+,K(+)-ATPase blocker cariporide may alter cocaine reward in humans. Therefore, in a first experiment we determined the dose-dependence and time-course effect of cariporide on the reinforcing properties of cocaine in a human model of drug self-administration which included three distinct phases such as i.v. drug self-administration and intravenous drug preference assessment sessions. In a second experiment, we explored the effects of H+,K(+)-ATPase inhibition on cocaine-induced plasma oxytocin by a placebo-controlled cocaine administration combined with the administration of cariporide or placebo. Cariporide selectively blunted the reinforcing properties of cocaine in a dose-dependent manner, but did not alter the intravenous drug preference for cocaine. There was a trend towards a decrease of oxytocin release by",
        "label": 1
    },
    "661": {
        "output": "[ACHTUNGSPFEILE].\n\n[A]. If the patient is excluded, set the result to the first argument of the ``exclude`` function. The excluded reason will come out in the second position of the result.\n\n[B] If the patient is not relevant, set the result to the second argument of the `not\u2010relevant` function. The excluded reason will come out in the third position of the result.\n\n[C] If the patient is eligible, set the result to the third argument of the `eligible` function. \n\nTrial-level eligibility: 0) Excluded `exclude`(first argument of the ``exclude`` function). The excluded reason will come out in the second position of the result.\n\nTrial-level eligibility: 1) Not relevant `not_relevant`(second argument of the `not\u2010relevant` function). The excluded reason will come out in the third position of the result.\n\nTrial-level eligibility: 2) Eligibile `eligible`(third argument of the `eligible` function).\n\nTrial-level eligibility: 2) Eligible.`\n\n[/ACHTUNGSPFEILE]\n\n## Evaluate the solution\nYour solution will be evaluated by the grader.\n\n### Expected\nThe Expected is 100%.\n\n### Submitted solution\nYour solution contains errors.\n\n### Screenshots\n![Screenshots: Assess eligibility](./screenshots/eligibility/eligibility.png)\n\n### Solution-verification scripts\nAs for any given homework, we encourage you to use the following scripts to ensure that you understand how it is being evaluated by the grader. If you are able to successfully execute the provided script, it is probable that the grader can do so as well, and it will provide you with further confidence in understanding how to do well on this homework.\n\n| File                                          | Contents                                               |\n| ------------------------------------------ | ------------------------------------------------------ |\n| `assess_eligibility.rd`<br>([output])        | Verifies your solution's eligibility",
        "label": 1
    },
    "662": {
        "output": "[TIPS]\nYou may run these commands to check code efficiency:\n\n``` r\n\n```\n# Run\n\n``` r\n\n```\n<EOD> Effect of H2-receptor antagonists on prostaglandin E2 release in the rat stomach.\nProstaglandin E2 (PGE2) release in the rat stomach was measured in response to various stimuli at different doses in the presence or absence of H2-antagonists. 1) PGE2 release induced by 100 mM KCl, 5 mM sodium taurocholate, or 10(-6) M histamine was almost completely inhibited by famotidine at 100 micrograms/rat, regardless of whether the PGE2 release was measured in vehicle (20% dimethyl sulfoxide)- or CMN (1:1:18, acetone:olive oil:ethanol)-treated rats. H2-antagonists were reported to be able to diffuse across the gastric mucosa at pharmacological concentrations. However, we found that it was difficult to achieve adequate penetration of famotidine and pirenzepine into the stomach with CMN treatment. Pure famotidine also showed a tendency to inhibit PGE2 release in the rat stomach. 2) In contrast, 1 mM histamine-induced PGE2 release was only slightly inhibited by 100 micrograms/rat famotidine, by 3 mg/rat cimetidine, or by 100 micrograms/rat pirenzepine. This indicates that H2-receptor antagonists were able to affect H+/K+ ATPase activity of parietal cells in the rat stomach. 3) Cimetidine increased histamine-induced PGE2 release. This increase was prevented as soon as famotidine was added simultaneously to their combination. 4) H+/K+ ATPase activity of rat gastric fundic mucosa preparation was inhibited in the presence of 10(-6) M famotidine as much as in the presence of 10(-5) M nif",
        "label": 1
    },
    "663": {
        "output": "[Q1_A01] Please take a look at the following table.\n\n![alt1](/data/A0/alt1/alt1_violet2.png)\n\n#[Q1] What is the age that is closest to the lower 50% limit for the age group with the greatest number of patients?\n\n#[Q1_A02]. What is the number of patients in the age group 51-60? Give your answer in integers. For example, \"two patients\" would receive credit for the answer 2.\n\n#[Q1_A03]] What is the number of patients in the age group younger than 40 years? Give your answer in integers. For example, \"two patients\" would receive credit for the answer 2.\n\n#[Q1_A04] What is the number of patients in the age group older than 85 years? Enter integers only. For example, \"two patients\" would receive credit for the answer 2.\n[/CASE]\n\n## [EXP][A1]\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (",
        "label": 2
    },
    "664": {
        "output": "### Excluded Patients\n\n### Not Relevant Patients\n\n### Eligible Patients\n\n### Instructions for `output` command:\n\n`output`\n[\n(optional) `title:` (suggested: \u201cPatient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n(optional) `title:` (suggested: \u201cSummary: Patient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n(optional) `title:` (suggested: \u201cTrial report: Clinical Eligibility for A Randomized Controlled trial of Fatigue in MS\u201d)\n(default) `title:`\n(default) `title:` (`A Randomized Controlled trial of Fatigue in MS\u201d)\n`[data_analysis|feature_extraction]` (`Patient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n\n### Instructions for `print_data_table()` command:\n\n`print_data_table()`\n[\n(default) `title:` (`Summary: Patient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n(default) `title:` (`Patient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n(default) `title:` (`Trial report: Clinical Eligibility for A Randomized Controlled trial of Fatigue in MS\u201d)\n\u201cA Randomized Controlled trial of Fatigue in MS\u201d\n\n### Exercise 11. Using the `predict()` command for decision tree classification\n\nIn this exercise, you will build decision tree algorithms to predict the class label of the data items in the `clinical_trials` dataset. This data-driven exploration of the class distributions over the values of different attributes in the dataset should provide some insight and hints on which attributes one might be particularly interested in in the classification of the dataset. In particular, you are going to construct decision trees to identify patient reports for clinical trial recruitment for the following two diseases: \n* \"Breast cancer\"",
        "label": 0
    },
    "665": {
        "output": "<EOD> .\nThe authors report their experience of 184 cases of intestinal invagination studied and treated by endoscope. Diagnosis was made by endoscopy, but in 6% of the cases, endoscopic examination was normal because clinical symptoms and other radiological investigations were inconclusive. Experience is reviewed by types of invagination (35 cases of jejuno-jejunal, 25 cases of jejuno-ileal, 25 cases of ileo-colic, 39 cases of colonic invagination, 20 cases of Meckel's diverticulum, 15 cases of invagination at the anal sphincter by stenosis, and 6 intussusception lesions). The endoscope was found to be a useful complementary method. It has a good accuracy by anatomical site, especially in jejuno-ileal and Meckel's diverticulum invagination. With the endoscope and the fluoroscope one can have radiological confirmation by viewing intestinal loops by endoscopy. By introducing a trocar into the lesion, it is possible to do a puncture if the invagination is small. The endoscope has been shown to be of interest to make endoscopic suture possible in some cases. It has also been of help in the search for bleeding, and makes it easier to see the site of the pathology in chronic invagination. After treating the patient the endoscope can be used to check up on it.<EOD> .\nOBJECTIVE\nThe effects of endurance exercise on bone mass and bone loss induced by ovariectomy (OVX) were investigated.\n\n\nMETHODS\nTwenty female Wistar rats (age, 12 months; weight, 350 +/- 35 g) were randomly divided into 4 groups: control group (n = 5), sham-operated rats group (n = 5), endurance-exercise rats (EX) group (n = 5), and OVX and endurance-exercise rats (OVX-EX) group (n = 5). Twenty-four weeks after exercise, the",
        "label": 0
    },
    "666": {
        "output": "## [/TRI]\n### Inclusion criteria\n\n```python\ndef get_inclusion_criteria(note):\n    \"\"\"Get a list of inclusion criteria, and a list of exclusions.\n\n    Parameters:\n    note -- an NLP'd patient note (i.e. Listing)\n\n    Returns:\n    inclusion_criteria -- a list of inclusion criteria, e.g. [\"high altitude\" \"experimenter\",..., \"elevate\",..., \"sit\",..., \"walk\",..., \"play sports\", \"exercise\",..., \"climb stairs\",], a list of exclusion criteria, e.g. [\"mild\", \"mild\", \"mild\",..., \"mild depression\",..., \"moderate\", \"moderate cough\",..., \"moderate wheezing\", \"...\", \"moderate anxiety\", \"experience any symptoms\"], [3] --> [\"mild\", \"moderate\", \"mild\"]\n        The inclusion criteria with index 0 is used as the default\n    \"\"\"\n    \n    return {0: [\"high altitude\", \"experimenter\", \"smoke\", \"smoke\", \"exercise\", \"stress\", \"run\", \"hike\", \"exercise\", \"jog\", \"play sports\", \"walk\", \"play sports\", \"go to the gym\", \"sit\", \"play sports\", \"climb stairs\", \"exercise\", \"sit\", \"play sports\", \"walk\", \"play sports\", \"climb stairs\", \"jog\", \"play sports\", \"run\", \"run\", \"pray\", \"pray\", \"play sports\", \"jog\"],\n                    1: [\"walk\"],\n                    2: [\"play sports\"]}\n```\n\n- Note: this function has a lengthy list of input parameters. If the data type of the input is not correct, the method will not evaluate at all to calculate the inclusion criteria. \n\n### Exclusion criteria\n\n```python\ndef get_exclusion_criteria(note):\n    \"\"\"Get a list of inclusion criteria, and a list of exclusions.\n\n    Parameters:\n    note -- an NLP'd patient note (i.e. Listing)\n\n    Returns:",
        "label": 1
    },
    "667": {
        "output": "The cut-off value is listed in the first row. \n\nThe exclusion criteria of `Cut off value: `\nClick the button `Select Exclusion`, and then click the button `Calculate. You should calculate like this. \n\nFinally, you should repeat the same calculation for the other exclusion criterion if any. \n\nTrial-level eligibility` = `Cutoff value * Exclusion * Inclusion\n\n\nWe should apply the last cut-off value into this formula. \n(Inclusion- Exclustion) == Cut-off value\n\nExclusion (for example No. 1) -(Inclusion) == Cut-off value\n(794.5- 63) == 731.5\nWhen the triallevel eligibility is `eligible` , this means that your patient is NOT excluded on the grounds of the trial's exclusion criteria, and is therefore eligible for the trial.\n\nIn the next step, you should repeat the operation. \nTrial-level eligibility for the other exclusion criterion (No. 2.) is the same as that of `Trial-level eligibility: 0) Excluded.`.\n\n![6.R1.06_Patient_Case](http://www.gsk-clinicalstudyfile.com/Images/Round1/2012-8/20111123120127_1_20121204113010_25910_2_33510_B6F7BF30_000)<EOD> Antioxidant and antibacterial activities and c",
        "label": 0
    },
    "668": {
        "output": "# Inspirations\n<EOD> Gastric cancer\nGastric cancer is a disease of genetic complexities. The development of gastric cancer is a multistep and multifactorial process, involving both host and environmental factors. Helicobacter pylori infection, family history of cancer, diet, occupation, and genetic susceptibility are the major modifiable risk factors for gastric cancer. A number of genetic changes occur during the development of gastric cancer. These include: hypermethylation, somatic and viral mutation, microsatellite instability, alteration of molecular biomarkers at DNA/RNA levels, and chromosomal instability. The role of these alterations at different stages of the development of gastric cancer has become clearer in recent years. Gastric cancer has been classified mainly on the basis of histologic features. It can be further divided into 2 distinct groups: intestinal type and diffuse type. There are several differences between intestinal and diffuse types, including histological growth, gene expression, and clinical outcome. In addition, the intestinal and diffuse types of gastric cancer exhibit differences in their etiopathogenesis. Gene expression profiles have been used to examine the molecular mechanisms underlying the progression from chronic gastritis to gastric cancer. In the current review, an overview of gastric cancer associated with environmental (smoking, drinking, diet, family history, and environmental mutagens) and genetic factors, classification, histopathology, and molecular events associated with the development of gastric cancer is discussed.<EOD> Dental Care under General Anesthesia in Patients after Orthognathic Surgery\u2014A Case Series\n\nCitation: Vilela, M.A.; Ramalho, R.; Oliveira, V. Dental Care under General Anesthesia in Patients after Orthognathic Surgery-A Case Series. Int.Abstract: Orthognathic surgery was initiated in 1900 by Cottwell, when he reported the first lateral maxillary ostectomy, and today, it is a well-established approach with high results in terms of anesthetic care, safety and patient satisfaction. Pre-surgical orthodontic",
        "label": 0
    },
    "669": {
        "output": "<EOD> The Relationship between Blood Oxalate and 24-Hour Urinary Calcium in the General Population and in Patients with Primary Hyperoxaluria\n\nObjectives: This research was aimed to investigate the relationship between blood oxalate (BO) and 24-hour urinary calcium (24UCr) among patients with primary hyperoxaluria (PHP) and normal population.Methods: 166 PHP patients and 902 volunteers were collected for the experiment, all of which underwent BO, creatinine, and 24UCr measurements. According to 24UCr level, volunteers were divided into normal control group (NC,< 50-299 mg/24 h), high 24UCr group (H24UCr, \u2265 300 mg/24 h) and low 24UCr group (L24UCr, < 300 mg/24 h). Comparing the difference of BO in NC, H24UCr, and L24UCr groups, the relationship between BO and 24UCr was further analyzed.Results: The BO levels among the three groups were significantly different. The normal populations in the H24UCr group had higher BO than in the L24UCr group (1.53 \u00b1 0.40 vs. 1.32 \u00b1 0.36 mg/dL and P < 0.001), and BO had a significant linear relationship with 24UCr in the three groups (R 2 = 0.197, P < 0.001). BMI had linear correlation with BO for female normal controls of the H24UCr group (R 2 = 0.112, P = 0.016). Conclusion: BO levels change considerably among the three groups, and BO had a significant linear relationship with 24UCr, suggesting that an increase in BO may be related to the occurrence of kidney stones, osteoporosis and other diseases caused by abnormal calcium and oxalate metabolism. Therefore, the measurement of BO and 24UCr is critical to improve the efficacy of prevention and treatment for kidney stones.",
        "label": 1
    },
    "670": {
        "output": "---\n\n# Overview\n\nThe objective of this study is to assess non-invasive cardiac imaging modalities with known high accuracy for the detection of heart disease in patients presenting for the first time to the cardiologist with chest pain. The diagnostic accuracy of the various cardiac imaging techniques needs to be assessed for the ability to detect and localize coronary artery disease. We expect the results obtained by the various imaging modalities to correlate with angiography, which is considered the gold standard.\n\n> 80 years:  76% sensitivity and 74% specificity\n> 76 to  70 years:  80% sensitivity and 72% specificity\n> 70 to  66 years:  85% sensitivity and 70% specificity\n> 66 to  63 years:  93% sensitivity and 67% specificity\n> 63 to  60 years:  97% sensitivity and 67% specificity\n> 60 to  57 years:  99% sensitivity and 67% specificity\n\n# Study Design\n\nWe will evaluate the diagnostic accuracy of various non-invasive cardiac imaging techniques to detect coronary artery disease in symptomatic patients who have undergone cardiac catheterization. The diagnostic accuracy will be assessed using the sensitivity, specificity, and likelihood ratios.\n\n## Study Population  \nThe population will consist of patients older than 40 years who have undergone cardiac catheterization.\nPatients will be referred to the study based on the results of non-invasive cardiac imaging assessments and their pre-test likelihood for coronary artery disease. \n\n> Note: \n> Note:\nAll patients who satisfy the eligibility criteria will be approached, and their informed consent will be obtained. Patient identification numbers will be assigned to the participants.\n\n## Sample Size\nInitially, 180 patients with 20% prevalence of disease will be sampled, based on a preliminary data assessment with a 1:1 ratio between those with stenosis and those without stenosis. Based on our preliminary results, the sensitivity was",
        "label": 0
    },
    "671": {
        "output": "This is the data you need to make the decision about Trial-level eligibility: the variables `Age, Gender, EducationLevel, ReasonForVisit, TreatmentChoice, and Trial-level eligibility`, the list variable `Subject: 1 to 20`, and the data vector `Risk_Qual, Risk_Num, Risk_Abs, Risk_Rel, TreatmentChoice`.\nTo choose the option that is correct, press the corresponding button.\nLet's do a validation:\n\n### Incorrect button pressed\nThe button `4` (Absolute risks in graphs) was pressed.\n\n### Correct button pressed\nPlease proceed to the next step.\nThe button `4` (Absolute risks in graphs) was pressed.\n\nWhat else do you need?\n\n### Incorrect button pressed\nThe button `1` (Qualitative risks in graphs) was pressed.\n\n### Correct button pressed\nPlease proceed to the next step.\nThe button `1` (Qualitative risks in graphs) was pressed.\n\n### Incorrect button pressed\nThe button `1` (Qualitative risks in graphs) was pressed.\n\n### Correct button pressed\nPlease proceed to the next step.\nThe button `1` (Qualitative risks in graphs) was pressed.\n\nCheck your button choice:\n\nThere is no correct answer. You just have to choose the option you think is correct.\n\n## Check your answers:\n\nLet's go to the last instruction.\n\n## Instruction: `Check your answers:`\n\nMake the best choice about Trial-level eligibility:\n\nThe number 0, 1, or 2, please.\n\n- 0: Excluded.\n- 1: Not relevant.\n- 2: Eligible.\n\n02-227-332-302-955-432-688-967-029-82822-7\n\n## Check your button choice:\n\nThere is no correct answer. You just have to choose the option you think is correct.\n\n124,936,023,647,4558,875,985",
        "label": 1
    },
    "672": {
        "output": "## Task T3: Eligibility Criteria (Step 4) \nTrial-level eligibility\n(1) Excluded = Excluded (2) Not eligible = Not relevant (reasons not identified) (3) Eligible = Eligible\nThe following factors represent the exclusion criteria from your study:\n(1) previous transplantation of a heart, lung or liver;\n(2) active cardiac sarcoidosis;\n(3) active inflammatory gastrointestinal disease;\n(4) previous cardiac arrest;\n(5) history of coronary artery bypass graft (within 3 months);\n(6) pregnancy;\n(7) history of cancer (except for stage I-II nonmelanoma skin cancers) or an immunodeficient state;\n(8) current malignancies, excluding basal cell carcinoma and stage I nonmelanoma skin cancers(3)\n```python\n\n\n\n\n\ndef eligibility_factors():\n    return {1, 2, 3, 4, 5, 6, 7, 8, 9, 10, \"age\", 13, \"age\", 14, \"history_diabetes\"}\n   \n# get the factor level\npatient_demographics = {}\nfor patient in patients:\n    if ('age' in patient and 'years' in patient):\n        patient_demographics[12] = patient['years']\n    if (\"history_diabetes\" in patient):\n        patient_demographics[13] = \"History of diabetes\"\n    if (len(patient_demographics) < 12):\n        patient_demographics[9] = 'Inclusion criteria (see table below)'\n    \nfor line in trial.text.split():\n    if ': ' == line: # Find line that includes a key-value pair\n        key = line[:line.index(':')]\n        value = line[line.index(':') + 2:]\n        \n        if key in eligibility_factors.keys(): # Is this key already present in eligibility_factors.keys() key",
        "label": 0
    },
    "673": {
        "output": "To complete the assessment in the 'Eligibility Check' window of the 'Assessment' window, click the save button. \n\n# Result\n\nFrom the input note and clinical trial, the output is as below:\n\n### Eligibility Assessment\n\n\n\nTrial-level eligibility: 2) Eligible\n\n### Patient-level assessment\n\nAge  46 : 46 years-old\nGender: Male.\nTitle: A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial\nArterial Stenosis\nSummary: This clinical trial requires participants to be diagnosed with intracranial arterial stenosis and has already been treated with medical therapies. \nInclusion criteria: Inclusion Criteria:\nAge >40 years old.\nGender: Male and Female\nDiagnosed with intracranial arterial stenosis (any one of the following two conditions:\n1. stenotic ratio of > 50% in any of the main intracranial arteries: middle cerebral artery (M1), anterior cerebral artery (ACA), vertebrobasilar trunk, vertebral artery, basilar artery, internal cerebrovascular artery, internal carotid artery\nStipulation for the stenotic area: must be on the segment that is longer than 10mm but shorter than 25mm\nIn case of multiple intracranial arteries involved, the greatest stenosis degree shall be followed and evaluated\nStipulation for intracranial arterial stenosis:\nFor each stenosis degree (50-75%, 75-90%, 90-99%, 99%-100%), the intracranial arteries are summarily evaluated, respectively. If the same artery with a stenosis degree of <50%, it is not regarded as intracranial arterial stenosis.\nPatients are excluded from the trial in the following circumstances\uff1a\nStenting operation was taken in the past 6 months or will undertake in 3 months.",
        "label": 1
    },
    "674": {
        "output": "# <br><strong>F.5. Example</strong> <br>[TEST_ID:1234106]\n\n# <br><strong>F.6. Markdown Syntax</strong>\n\n```\n\n--- This is a [Test](Test.md) document ---\n\n## Folder \n```\n...\n## Example [F.6](#F6)-[F.6](#F6)-2\n...\n```\n```\n--- This is the subsubfolder [Example] [F.6](#F6)-[F.6](#F6)-2 ---\n--- A [Test](Test.md) document ---\n\n[F.6](#F6)-[F.6](#F6)-1\n```\n```\n----- ---This is a subfolder [Example] [F.6](#F6)-1--- [[F.6](#F6)-2]] This is a [Trial-level eligibility] 2) Eligible; [F.6](#F7)-[F.6](#F7)-1](https://github.com/shio1122/Drools-Project#F7-6-1).\n```\n--- This is a [Test](Test.md) document ---\n\n</details>\n\n\n# <br><strong>G. Examples</strong>\n\n```\n--- This is a [Test](Test.md) document ---\n\n## F.1. Folder \n```\n...\n## Example1 [F.1](#F.1)-[F.1](#F.1)-1\n```\n```\n--- This is the subsubfolder [Example1] [F.1](#F.1)-1--- [[F.1](#F.1)-2]] This is a [Trial-level eligibility] 1)Excluded; [F.1](#F.2)-[F.1](#F.2)-1](https://github.com/shio1122/Drools-Project#F.2-6-1).\n```\n--- This is a [Test](Test.md) document ---\n\n--- This is a [Test](Test.md) document ---\n\n--- This is the subsubfolder [Example2] [F.1](#F.1)-2--- [F",
        "label": 1
    },
    "675": {
        "output": "You are going to learn how to do tasks in Python-notations to the following text are explanations to the tasks. You may use code completion feature of your editor to write the code faster. Check that you use same package versions.\n\n\n\n<EOD> Molecular analysis of the genetic loci causing primary pulmonary hypertension in rat genetic models by using the microsatellite marker system.\nPrimary pulmonary hypertension (PPH) is a familial syndrome of increased pulmonary artery pressure due to smooth muscle cell hypertrophy and proliferation. Inbred rat strains are considered to be spontaneous models in which the genetic background shows a close relationship to human PPH. We performed a genome screening of the two PPH-prone strains, the Wistar Kyoto-Tokyo (LWH/Izm) strain, and NZ-T-Tokyo (NZRTJ) strain, and selected the NZRTJ strain on the basis of the genetic susceptibility to pulmonary hypertension. A total of 224 polymorphic markers, covering the entire rat genome, were screened using the microsatellite markers system with DNA samples of 27 F2 animals. A set of markers showing differences in the heterozygosity rates between the NZRTJ strain and any other inbred strains or the heterozygosity rate of the F2 progeny, was regarded as markers of the region of the disease locus. With this approach, we could detect an informative polymorphic marker, D11Rat1543, which was located in a 3.4-cM region of rat chromosome 1. Furthermore, we identified the microsatellite markers RNO6 and D11Rat7614, located in rat chromosomes 6, as informative markers, in addition to the marker D11Rat1543, for the NZRTJ strain. The region of the disease locus obtained in our study overlaps with the genetic locus previously suggested by using a congenic animal model. Our strategy to detect the disease locus of the PPH-prone strains may also be applied to the search for other multigenic",
        "label": 1
    },
    "676": {
        "output": "[INST] End of the tutorial.\n<EOD> Effects of a Falls-Management Nursing Program on Quality of Life, Falling Behavior, and Sense of Self-Efficacy after Fall\n\n\n\n# Introduction\nAmong older adults, risk factors for falls are aging, the environment, health conditions, and physical, mental, and social changes. Furthermore, even in people who have a lower risk of falling, many falls occur because of factors that are unpredictable, such as an individual's loss of balance due to muscle weakening or slipping. The incidences of these falls are greater in old age [1] and the incidence of falls rises drastically when it becomes an elder problem [bib_ref]  Falls and their prevention in elderly people: What do we know?, Rubenstein [/bib_ref] . It is estimated that 33% of adults who are over 65 years old and 50% of adults who are over 80 years old have fallen this year. According to the Korea Health and Welfare Statistics released the report that about 7 per 1000 adults over 65 fall each year. A fall involves an accident that results in the body losing its balance or making contact with the ground or something else, and it is a problem that most people expect to happen as the life expectancy in the world gets longer [bib_ref]  Fall prevention in the elderly, Kok [/bib_ref] . Falls have an immense impact on the lives of the elderly and their caregivers, and older adults tend to have more severe and complex concerns about falls than young adults. They are also prone to fearing falls or avoiding them altogether as much as possible. They have the most self-care-related concerns after falls, especially due to the limitations in mobility and physical strength [bib_ref]  A Study of the Effects of Nursing Intervention on Fear of Falling..., Choi [/bib_ref] . In addition, falls pose a major problem in terms of accidents, quality of life, quality of health care, and costs [bib_ref]  Falls among institutionalized older persons: A cause for concern, Tinetti [/bib_ref] . In particular, although falls that occur in the elderly at home are inexpensive to prevent, they are difficult to address because the elderly do not receive enough treatment and care for these falls",
        "label": 1
    },
    "677": {
        "output": "## [INST] Inputs\n\n\n![](http://docs.jacovitron.com/data-flow-graph/fig-1.png \"Graph\")\n#1 `Challenge`\n![](http://docs.jacovitron.com/data-flow-graph/fig-2.png \"Graph\")\n#2 `Note`\n![](http://docs.jacovitron.com/data-flow-graph/fig-3.png \"Graph\")\n\n\n## How to implement the Challenge-Notes-Trial-level-eligibility dataflow?\n\n\n### Using the jacovitron IDE\n\n1. Create a new machine learning project using the IDE - JacoviTron.\n\n1. Go to **File, Source, New** on the menu bar and select the **Notebook Source**:\n\n    :::image type=\"content\" source=\"_static/notebook.png\" alt-text=\"New Notebook Source Tab\":::\n\n1. In the **New Notebook Source** dialog box, select **File, New**:\n\n    :::image type=\"content\" source=\"_static/notebook_source.png\" alt-text=\"New Notebook Source Dialog\":::\n\n1. Enter **Challenge-Notes-Trial-level-eligibility** for the dialog box **New Notebook Name**:\n\n    :::image type=\"content\" source=\"_static/new-notebook.png\" alt-text=\"New Notebook Name dialog\":::",
        "label": 1
    },
    "678": {
        "output": "__  ____  ____   _______  __  ____   _______  __  __\n| |    | |    | |       |    | |    | |       |    | |    | |\n| |    | |    | | _       |    | |    | | _      |    | |    | |\n| |    | |    | | |       |    | | ____ | |       |_____|__|____|\n|_____|_____|_____| |_____|_____|_____| |_____|_____|_____________|__________|\n\n<!-- ========== EDA ANATOMIC CENTRAL ARTERIES PATTERNS =========== -->\n\n\n<div class=\"alert alert-warning message\" role=\"alert\" id=\"eda_central_patterns\">\n        <p><span id=\"eda_central_patterns_help\">(c) Inklin et al. 2016. [<a href=\\\"http://doi.org/10.1136/bmjopen-2016-013217\\\">BMJ Open.</a>] <em>What is the normal pulsatile arterial pattern of a peripheral artery? - A narrative review and case based approach</em>  25.</span> </p>\n</div>\n\n<ul>\n<li id=\"eda_central_pattern\">\n    <div class=\"alert alert-info\" role=\"alert\">\n<p style=\"display: inline-block;\"><button class=\"caret\">\n    <span>\n        <span class=\"glyphicon glyphicon-question-sign\" aria-hidden=\"true\"></span>\n    </span>\n    Question &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button>\n</span>\n    <span class=\"collapsible\" data-collapsible-tag=\"hint\">                                           \n\nWhat arterial pulsation patterns does a normal CCA present? \n\n- Normally, peripheral CCA  has no detectable pulsation.\n- In the presence of an arteritis (e.g., vasculitis  or atheroscl",
        "label": 2
    },
    "679": {
        "output": "# Question 4\n[INST] This patient note from the clinical trial will allow the researchers to select the ideal candidate who is likely to benefit and also ensure that the patient will not be harmed. We are a group of experienced professionals and we have noticed that although the data were collected by physicians and healthcare providers, sometimes there is missing data. For example, the patient's smoking history can be missing from the medical records (0), not available (1), or unknown (2). It is also a common situation that the data on risk factors were obtained from the patient's answers to the questionnaire.\n\nThe data on cardiovascular risk factors from the clinical trial:\n\n## Name (n=40)\nAge (n=40)\n\n\n## Male smoker (n=40)\nSmoking history (40)\n 1+1\n 2+3\n 3+2\n 3+2\n 0+2\n 0+1\n 1+1\n 0+2\n 0+3\n 4+0\nLaboratory Test (n=40)\nLDL (n=40,mg/dL)\n<160\nHDL (mg/dL)\nN/a N/a N/a N/a N/a\n\nSystolic BP (mmHg)\n<130 N/a N/a N/a N/a N/a N/a\n\nDiastolic BP (mmHg)\n<80\n\n\n## N/a\n\nGender (\n\nHaving smoking history: No smoking (0), Yes smoking (1), Former smoking (2).\nHaving hypertension history: No hypertension (0), Yes hypertension (1), Former hypertension (2).\nWhat is this? : What is the clinical trial's inclusion and exclusion criteria?\n\n## Inclusion\nAge <65 yrs \n\n## S28\n- The patient can communicate well with the clinical team - The primary caregiver will have adequate support from the local family and community structures\n- The patient is willing and able to provide informed consent for study participation and is willing to allow study personnel to",
        "label": 1
    },
    "680": {
        "output": "## 4.1.5_daily_task_example_0.yml\n\n### 4.1.5_daily_task_example_0.ml\n\n[INFO]\n[INFO]  --- [YAML-EXAMPLE]\n[INFO]  --- [ML-EXAMPLE]\n@params ('task_name') @params ('run')\n```\n\n```python\n# -*- coding: utf-8 -*-\n# @params ('task_name') @params ('run')\n\nimport util\nimport yaml\nimport tempfile\nimport os\nimport sys\n\nimport pprint\nfrom rich.console import print\nfrom rich.panel import Panel\nfrom rich.text import Text\nimport pandas\nimport numpy as np\n\ntry:\n    # If this is executed then we're in a terminal, not some IDE\n    import platform\n    osName = platform.system()\n    osVersion = platform.machine()\n    osRelease = platform.linux_distribution(full=False)\n    _print_system = False\nexcept (IOError, ValueError):\n    # If this is executed then we're in an iTerm or iShare or something\n    _print_system = True\n\nprint([\n    \"----------------------------------------------\",\n    \"---\"\n])\nprint(Panel(\n    Text('Hello World !'),\n    \"**************************************\"),\n    Panel(Text('---------------'), \"---------------\"),\n    Text(\"This is my first experience using MLflow!\")\n))\nprint(\"*****************\" * 10)\nprint([\n    \"*****************\", \"****\"\n])\nprint(Panel(Text('This my first run!'), \"Hello\"))\n\n\n# +\n# -----------------------\n# Define DataFrame\ndf = pandas.DataFrame()\n\n# The number of rows and columns will be determined by the dataset\ndf['name'] = pandas.Series([\n    \"John\",\n    \"Ali\",\n    \"Taro\",\n    \"Tanita\",\n    \"Raymond\",\n    \"Yuzuki\",\n    \"Eleonora\"\n])\n\ndf['age1'] = pandas.Series([\n    15,\n    16,",
        "label": 0
    },
    "681": {
        "output": "### Expected output\n\nYou generate patient note and note: ```{clinicaltrials}\n    A 46-year-old man with family history of cardiovascular disease presents with dizziness and frequent headaches. He has no cardiovascular risk factors such as smoking or hypertension, and is not physically active. The patient's LDL-C and HDL-C levels were 545 mg/dL and 53 mg/dL, respectively, and his fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications.\n    Neck auscultation revealed a systolic murmur of 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed a severe stenosis of carotid artery (left internal carotid artery, LICA) and moderate stenosis of right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively, and the RICA PSV was 91.72 cm/s, and the RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and were predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n    [/clinicaltrials]\n    Patient note: {clinicaltrials_start}{clinicaltrials_end}\n        {clinicaltrials_note}[/clinicaltrials]\n    [/clinicaltrials]\n```\n\nAbove",
        "label": 0
    },
    "682": {
        "output": "## Required parameters:\n- Disease: CAD -> disease\n- [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n- The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). -> Eligibility_Scale: 2) Eligible.\n- A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\n- The patient reported no use of lipid-lowering medications.\n- Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 9",
        "label": 1
    },
    "683": {
        "output": "## Assessment of Patient's Eligibility\n[INST: You should choose the patient's characteristics from the patient's note above.]\nInput the patient's information into the trial. By pressing the Trial-Level Eligibility key  on the keyboard, a patient list will appear.\n\n## How to assess eligibility?\nAssessment of Patient's Eligibility:\nUse the keys shown below to assess each patient:\n\n## Patient-level eligibility \nInput to the trial the information on the patient level eligibility. There are three assessments at the patient-level in trials: 0) Excluded (patient meet inclusion criteria, but are excluded on the grounds of the trial's exclusion criteria), 1) Not relevant (patient does not have sufficient information to qualify for the trial), or 2) Eligible (patient meet all of the trial's inclusion criteria and no of exclusion criteria were defined). \n\n## Excluded due to the inclusion criterion\nExcluded Due to the Inclusion Criteria:\nWhen you press the key '0/Excluded`, the 'Trial-level eligibility value changes to 1/Not relevant`and the name of the excluded criterion appears on the bottom line, e.g., \"Lipid level below threshold limit.\" \n\n## If not\nIf not: Press 1/Not Relevant:\nAfter the screen displays the message, 'Not Relevant', you should press 'Enter/Return' key. \n\n## If yes\nIf yes:\nAfter the screen displays the message, 'Eligible', you should press 'Enter/Return' key and the name of the inclusion criterion appears on the bottom line:\n\n## Output of patient-level eligibility: \nIf your patient, i.e., the participant of the trial, satisfies the inclusion criteria at the patient-level, trial-level eligibility will be written one time, e.g., if the patient is eligible for the first trial, `trial-level eligibility: 2-Eligible` will be output for the first trial. If the patient is eligible for two trials, trial-level eligibility will be written twice, e.g.,  for the first trial and  for the",
        "label": 2
    },
    "684": {
        "output": "___\n\n# S5.2\n[INST] Hello! Here is a new trial to evaluate the effect of low doses of ropivacaine for patients with chronic post-traumatic neuropathic pain. The clinical trial is designed to assess the efficacy and safety of low doses of ropivacaine in patients with chronic post-traumatic neuropathic pain, which is characterized by a combination of abnormal sensory symptoms (burning, pricking, etc.) and abnormal motor symptoms (fasciculation, muscle spasm, etc.). The duration of pain should be at least 6 months. In addition, pain should be in the affected limb, but not limited to the affected limb. \nIn this trial, you play the role of a helpful assistant for clinical trial recruitment. You are comparing a given patient and note against the inclusion and exclusion criteria  of a clinical trial with the aim to assess the patient's eligibility.\n\nThe clinical trial requires patients in the placebo group to perform exercises of flexion, extension, and dorsiflexion of the ankle joint three times a day for 30 minutes each time before the ropivacaine injection. The same amount of exercise is performed in the ropivacaine group before the ropivacaine injection, the only difference being the injection of ropivacaine once before each exercise. \nThe assessment for patient eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n \nHere is the patient note: \nA 28-year-old man presents with chronic pain and sensory changes in the left lower leg, which have persisted for two years with occasional burning pain in the right lower leg. The pain is in the posterior aspect of the knee joint and radiates to the posterior aspect of the ankle joint. The ankle reflex was present. The vibration sensation was diminished in the lateral aspect of the right lower",
        "label": 1
    },
    "685": {
        "output": "What to do if a criterion does not apply to both patient and trial?\n\nYou should output `Trial-level eligibility: 0) Excluded.`.  \n\n# Background\n\nIf you have encountered several concepts that the course does not elaborate, we recommend that you visit the Wikipedia homepage on the terms involved in this lesson for their definitions and further interpretations.\n\n# Tutorial\n\n\n`$trial=[\"Sleeping disorders in adolescents\" , \"Treating hypertension\", \"Vitamin levels in children\"]`\n\n`$test=[\"Patient\", \"Trial\"]`\n\n`$test2=[\"Patient\", \"Trial\"]` \n\nRun the following code: `[[Trial-level eligibility test($test,$test2,$patient)]]`\n\n```\n2) Eligible (0) Excluded (1) Not relevant (2) (object)[[0], (object)[[1], (object)[[2],\n      \"Not enough information to qualify for the trial.\"], \"Excluded\", \"\", {}},\n     \"{}\"]]\n```\n\nThe output should be identical to the first output.\n\nNow you know that you should print 1 if the trial does include the following criteria that are also applicable to the patient. \n\n```\n2) Eligible (0) Excluded (1) Not relevant (2) (object)[[0], (object)[[1], (object)[[2],\n      \"Not enough information to qualify for the trial.\"], \"Excluded\", \"\", {}},\n     \"{}\"]]\n```\n\nThe output should be identical to the first output.\n\nIf a criterion is met (both trial and patient) and the trial requires exclusion, print 0, otherwise print 2 (eligible). \n\n```\n2) Eligible (0) Excluded (1) Not relevant (2) (object)[[0], (object)[[1], (object)[[2],\n      \"Treatment of hypertension in children\" , \"0.0\", \"Not enough information\",\n      \"\", {}},\n     \"{}\"], (object)[[2], (object)[[2],\n      \"Lack of control of BP\", \"40-",
        "label": 1
    },
    "686": {
        "output": "__A sample output:__\nPatient_No/Alias                Trial-ID  Patient_No/Alias   Trial-ID    Trial-Level_Eligibility\n# Trial-ID: ACCELERATE\nPatient_No/Alias                ACCEL0179         1  Eligible\nPatient_No/Alias                ACCEL0179         1  Excluded\nPatient_No/Alias                ACCEL0179         1  Not_relevant \n\n__Recommended software:__\nYou will need to use the program on a Python version 3.8.8 or higher in the Anaconda environment with conda 4.10.8 or higher on your PC. You will also need to complete Python and SQL practice tutorials.\n\n# 1",
        "label": 1
    },
    "687": {
        "output": "This is a simple step that lets the user know what the user can do. In other words, it confirms that there are no exclusion criteria at the trial level.  \nSee how it looks like in the notebook `1_patient_notes_1__2_trial_level.ipynb`.\n<img src=\"https://user-images.githubusercontent.com/3554955/146816235-32c4f465-d007-45c0-90b6-00ad5d2bdb9f.png\" alt = \"1_patient_notes_1__2_trial_level.ipynb\" width = \"910\" height = \"896\" />\n\n**Input:**\n\n`In the patient note, all the exclusion criteria must be checked. `\n\n`What about the trial-level exclusion criteria:\n- 2) Not relevant,\n- 3) Excluded, or\n- 4) Eligible. `\n\n- The first step of the workflow: You need to calculate whether the user is eligible to participate in the trial. In other words, you need to make sure whether the conditions of inclusion are fulfilled. There are three parameters that can be considered.\nA user is eligible to participate in a trial when the following three conditions are met:\n1) the patient meets inclusion criteria\n   (the status of inclusion (1, 2) is relevant to the trial), 2) the patient does not have sufficient information to qualify for the trial (the status of inclusion (1, 2) is not relevant to the trial), and 3) the patient meets exclusion criteria, but is not excluded (the status of exclusion not-eligible (3, 4) is relevant to the trial).\n\nIf all conditions are met (the patient meets all inclusion criteria, the patient lacks relevant information regarding exclusion criteria, and the patient also does not meet exclusion criteria), this patient is an eligible participant.\nThe output that you need to provide to the user is a three-category variable indicating the assessment of eligibility, as a list, in which zero stands for excluded, one for not relevant, and two for el",
        "label": 0
    },
    "688": {
        "output": "```python\n\nimport numpy as np\n\nfrom flask import Flask, jsonify\nfrom myproject.data import patient_note\n\napp = Flask(__name__)\n\n\n@app.route('/')\ndef root():\n    data = patient_note.patient_note['In-trial_eligible']\n    return jsonify(data['In-trial_eligible'])\n\n\n@app.route('/evaluation')\ndef evaluate_eligibility():\n    data = patient_note.patient_note['In-trial_eligible']\n    return jsonify(data['In-trial_eligible'])\n\n\n@app.route('/evaluation/<id>')\ndef evaluate_eligibility_by_id(id):\n    data = patient_note.patient_note['In-trial_eligible'][id]\n    return jsonify(data['In-trial_eligible'])\n\n\n@app.route('/evaluation/<id>')\ndef evaluate_eligible_by_id(id):\n    data = patient_note.patient_note['In-trial_eligible'][id][\n        'Trial-level eligibility']\n    return jsonify(\n        data['Trial-level eligibility']['Patient-eligible']['Patient-eligibility'].keys())\n\n```\n\n[source][source-code]\n```python\n\ndata =patient_note.patient_note['In-trial_eligible']\ndata = np.array(data)\ndata = np.vectorize(lambda x: np.ravel(x))\n\ndata['patient_id'] = [patient_id]\ndata.Trial-level eligibility['Trial-level eligibility'] = [\n    [\n        [\n            {\n                'Patient-eligibility': [\n                    'Patient'\n                ]\n            }\n        ]\n    ]\n]\n```\n\nYou can access http://localhost:5000/root/evaluation to view the response.\n\n```html\n<h1>Result of patient note:\n<code>{'patient_id': [-",
        "label": 2
    },
    "689": {
        "output": "#### [A19] What if the trial includes a control arm with another treatment? \n[[INST] The treatment of CHD is multidisciplinary and comprehensive, including revascularization operation, drug or intravascular treatment, and cardiac rehabilitation. Revascularization, including percutaneous transluminal coronary angiography (PTCA) and coronary artery bypass surgery (CABG), is an important way to treat CHD, which can effectively increase the area of myocardial blood supply by opening completely or partially the stenosis or occlusion of the main vessels of the heart. Different people have different ideas about the choice of therapeutic drugs for CHD, and some people believe that western medicine can only give antithrombotic drugs at the initial stage, while others believe that the long-term use of western medicine can reduce the risk of myocardial infarction. Therefore, the use of a western medication is often necessary to maintain a normal heartbeat during the revascularization operation, postoperative rehabilitation and the recovery process. `<EOD> The role of vitamin D and VDR gene polymorphisms in primary ciliary dyskinesia\n\nRecent studies demonstrated that ciliary dysfunction and respiratory insufficiency are associated with alterations in bone physiology and osteologic manifestations in the lung. These effects are mediated by regulation of the cilia by 1,25-dihydroxyvitamin D 3 [1,25(OH) 2 D 3 ] signaling. Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disease caused by impaired function of the mucociliary apparatus due to defects in motile cilia. Vitamin D and its receptor are likely key components for the development of cilia, and altered DNA methylation in these proteins has been observed in PCD. We investigated the association of circulating 25-hydroxyvitamin D (25OHD) levels, vitamin D binding protein (GC) levels in plasma and DNA methylation analysis of a VDR functional polymorphism, GC, and VDR genes (PCD12",
        "label": 1
    },
    "690": {
        "output": "### Step 2: Data preprocessing\n\nFirst, let's consider all the data for the CAD example:\n\n[TRAIN] \ndata_set=np.array([array([0., 16.16, -6., 1., 1., 1., 1., 1., 0., 18.6, 0.691, 0., 1., 0., 0., 1., 0., 0., 0., 1., 0., 0., 0, .]), array([[630, 3, 3, 1, 1.],, array([[5.044, 1, 0.5, 0., 0.064],, array([[1., 3.48, 1., 1.63, 0., 3.5],, array([[34.7, 100.5, 500., 67., 26,, array([68., 78., 96., 4., 13., 21., 14., 34., 16],], array([10.5,10.6,4.6,4.8,4.7,4.7,4.6,7.6,5.7]), array([355011., 107., -27., 1., 0., 0., 3., 0., 5.022, 0., 1.162, 0., 1., 1., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.],), array([3306., 3., 1., 1.],), array([[6100, 3, 3, 1, 1.],, array([[4.35e-4, 1, 0.5, 0., 0.064],, array([1.36, 1.2, 0.66, 0., 0.2],, array([4, 10",
        "label": 2
    },
    "691": {
        "output": "# Requirement\n\n## # `requirement` <file:Requirement.md>\nAdd any additional requirement for the user that he uses this package.\n\n<EOD> Inhibition of Glycyrrhetinic Acid\u2010induced Activation of Hepatic Stellate Cells by Bifendate\nGlycyrrhetinic acid (GA) induces the activation of hepatic stellate cells (HScs) by promoting fibrogenesis and the overexpression of connective tissue growth factor (CTGF). Bifendate is the first clinically approved medicine for its antifibrotic effects. We examined whether bifendate inhibits GA\u2010induced HSC activation.<EOD> In situ growth of CdS quantum dots on glassy carbon electrode for direct electrochemical detection of N-methylmyoinositol.\nA direct electrochemical method was developed for the sensitive determination of N-methylmyoinositol (NMMI) based on its in situ electrochemical reduction on glassy carbon electrode (GCE) to 5,6,7,8-tetrahydro-5,8,5'-tetramethyl-m-inositol (THIMI), which is further converted to 2,3-dihydroxybenzoic acid (DHBA) and finally to 1,2,4-benzenetricarboxylic acid 2,2,4-triacetate (BTA) with the assistance of a ferrocene methanol-K3Fe (CN)6-H2O2 system. By this electrochemical oxidative cleavage approach, 5.0 mM NMMI can be successfully detected by a differential pulse voltammetry (DPV) at an ultra-low potential window from 0.45 V to 0.7 V. The detection limit was measured to be 1.32 \u03bcM by DPV. It is the first report to describe an electrochemical approach for determining NMMI using a direct electrochemical reduction strategy. The method may hold great promise for electrochemical studies on the electrochemical reduction of bioactive natural polyols.<EOD> Nomenclature for factors of the HLA system,",
        "label": 1
    },
    "692": {
        "output": "### Case Study 2\nIn this case study, you will predict the effect of a particular single-nucleotide polymorphism (SNP) on the drug responses of patients who are treated with a common drug.\n\nWe will use `SNPs` R package `GenABEL` to analyze genetic data and use `RColorBrewer` package for a colorful visualization.\n\nIn this study, we use genetic data as predictors (e.g., SNPs) that may help to predict future drug responses or adverse drug reactions.\n\nThere are two types of genetic traits: \n1. Single-Nucleotide Polymorphism (SNP)\n2. Haplotypes\n\nFor single-nucleotide polymorphism (SNP), the genetic data come in the form genotype `0`, `1`, or `2`. These represent the count of occurrences of each of three possible allelic variants of a specific SNP.\n\nFor haplotypes, we use numerical values of genotype as `0: 0` (reference genotype), `1: 0, 1`, `2: 1, 0, 2` (dosage).\n\nThe data are summarized in the following section for both cases.\n\n#### SNP Data\n\nA complete set of genetic data of these eight single-nucleotide polymorphisms is available in the file `SNPs.csv` in the folder `./SNP.``\n\n\n\nA few descriptive statistics of these eight SNPs among the patients who have been treated with metformin are summarized in the following tables.\n\n| SNP | Number (sample size) |  Mean  |  S.D. | Minimum | Maximum |\n| --- | --- | --- | --- | --- | --- | \n| S780 | 571 | 0.765 | 0.988 | 0 | 19 |\n| S753 | 508 | 0 | 0.578 | 0 | 19 |\n| A1527 | 530 | 0 | 0.563 | 0 | 18 |\n| S75",
        "label": 1
    },
    "693": {
        "output": "**[HIDE]**\n<EOD> The role of social media in the communication of scientific publications: A Brazilian and Portuguese comparative analysis.\nOBJECTIVE\nThe dissemination of scientific publications has grown on social media, but to date, there is no research comparing how popular scientific publications communicate on this network in different languages and cultural contexts.\n\n\nMETHODS\nA comparative analysis of the social media communication of seven popular scientific publications in Brazil and Portugal was carried out between January and April 2022.\n\n\nRESULTS\nTwitter and Facebook had more publications than other social networks. There was a great diversity in the activities performed on Twitter, with the posting of texts, links, photos, and videos on the different publications. The newsletter was the most commonly used activity on Facebook, being performed by all publications in both countries. In Portugal, the number of subscribers of each Twitter profile was similar for each publication, while in Brazil there was a disparity in the number of followers.\n\n\nCONCLUSIONS\nThe analysis of activities performed on Twitter and Facebook demonstrated a greater diversity of strategies on these two social networks than on others, such as Instagram and WhatsApp. Although there was a similar number of Portuguese publications and subscribers in both Facebook and Twitter in all countries, more disseminating publications are found in Brazil than in Portugal. Therefore, future studies should analyze how the cultural context of the populations where the publications operate impacts the communication on Twitter and Facebook.<EOD> A comparison of techniques for localizing the ossicular chain to guide prosthesis implantation\nSUMMARY For a number of patients with ossicular chain discontinuities or defective ossicles, the use of incus or malleus prosthesis has successfully compensated for deficiencies in transmission of sound. It is essential to locate the defective ossicles with precision to ensure proper placement of the prosthesis and, ultimately, optimal hearing. A study was undertaken to compare two of current methods of localizing ossicles with an alternative technique we have adopted in our clinical work. The first is a standard technique using a 4 mm tip-fitted probe during surgery. We are now using another technique in which end-fitted probes, 6 mm in diameter, are used throughout pre-operative audiological testing with a stapedectomy and in-",
        "label": 1
    },
    "694": {
        "output": "</section>\n\n<section id=\"example_3\"><h3>Example #3: Multiple groups, multiple trials</h3><section class=\"subsection\" id=\"section_5143740744523\"><h3 id=\"example_3\"><a class=\"anchor\" href=\"#example_3\">Introduction</a></h3><section class=\"subsection\" id=\"example_3\"><hr>\n\nYou are an epidemiologist who is analyzing mortality risks among hospitalized children in your hospital during the past year. You used a 5-year interval to count how many times certain patient conditions occurred. In your analysis, you are curious about the distribution of diagnosed conditions among infants, children, and adolescents. \n   \n```R\ncondition <- read.table(\"condition.txt\")\ncondition$infant <- condition$Infant # Infant\ncondition$child <- condition$Child # Child\ncondition$adolescent <- condition$Adolescent # Adolescent\ncondition <- data.frame(infant=cond-ition$Infant, child=condition$Child, adolescent=con-dition$Adolescent)\n```\n\nHere is the data: \n\n   \n```R\ncondition\n```\n\n   \n```\n   \n+--------------------------------+-------+-------+---------------------------------+\n| infants                         |      |      | hospitalized conditions      |\n+================================+======+======+===============================+\n|                            Infant |      |      |                             |\n|                            2.00E+05 |      |                             |\n|                                    |      | <class 'data.frame'>         |\n|                                    |      |                             |\n|                            2.00E+05 |      |                             |\n|                -------------------------------------------------------|\n+--------------------------------+    |    |    |                             |\n+ infants                         |    |    | hospitalized conditions      |\n+--------------------------------+    |    |    |                             |\n|    2.00E+05                     |    |    |                             |\n|                                    |    |-----------------------------|\n+    2.00E+05                     |    |",
        "label": 1
    },
    "695": {
        "output": "\u2b50 We expect to receive your patient notes and a clinical trial within 1 hour.\n\n## [FIN]\n<EOD> A case of a man with testicular adenomatoid tumor\n\nTesticular adenomatoid tumors are very rare lesions, usually benign, and found incidentally during operations. These lesions are usually asymptomatic and do not have any prognostic implications. Histopathology is the method of choice to make a microscopic evaluation, as they are similar to salivary glands. Hereby, we describe a rare testicular tumor case presented in a 61-year-old male patient with clinical and radiological signs of testicular tumor.\n\n# Background\nTesticular adenomatoid tumors are rare tumors of scrotal ectodermal origin, characterized by a mixture of epithelial, myoepithelial, and endothelial elements. This tumor histology is similar to that of salivary gland tumors [bib_ref]  Adnexal tumours of the testis: the ultrasonographic appearance of 35 cases: a..., De Feo [/bib_ref] . These tumors can be found incidentally in a palpation or in an open or laparoscopic procedures, in most of the cases [bib_ref]  Adnexal tumours of the testis: the ultrasonographic appearance of 35 cases: a..., De Feo [/bib_ref]  [bib_ref]  An incidentally discovered testicular adenomatoid tumor and spermatocele, Mcnally [/bib_ref] .\n\n## Case presentation\nAn asymptomatic 61-year-old white male patient was referred to our radiology practice for abdominal ultrasonography and CT. His past medical history was significant with hypertension and cardiovascular disease and he had no history of any malignant lesion before. He is not taking any drug or supplements. He had no systemic effects after his last treatment with a cardiac pacemaker. In the physical examination, the patient had normal findings except for the presence of a swollen right testis.\nOn the other hand, his abdominal ultrasonography revealed multiple cystic lesions in size ranges 30-45 mm (Figs.",
        "label": 1
    },
    "696": {
        "output": "## D. Examples\n\n```\n# 0) Excluded:\nP00147     Patient met exclusion 2 # age > 40 years \nP00155     Patient met exclusion 2 # age > 40 years \nP00196     Patient met exclusion 2 # age > 40 years \nP00244     Patient was excluded 1 # history of myocardial infarction # included \nP00249     Patient was excluded 2 # age > 40 years \nP00322     Patient was excluded 1 # history of myocardial infarction # included \nP00387     Patient was excluded 2 # age > 40 years \nP00454     Patient was excluded 4 # current cigarette smoker # included \nP00919     Patient was excluded 3 # LDL \u2265 160 mg/dL \n\n# 1) Not relevant:\nP00003     Not age appropriate \nP00018     Not age appropriate \nP00146     Patient had no relevant medical history # no history of hypertension \nP00156     Patient was not in inclusion criteria 1.0; \nP00234     Patient had no medical history of myocardial infarction \nP00236     Patient met inclusion criteria 1.1. # age 20-40 years inclusive \nP00263     Patient met age inclusion criteria 1.1. # age 20-40 years inclusive \nP00271     Patient met age inclusion criteria 1.1. # age 20-40 years inclusive \nP00334     Patient had no medical history of myocardial infarction \nP00336     Patient had no medical history of myocardial infarction \nP00369     Patient was not in inclusion criteria 1.1. # age inclusive 20 to",
        "label": 0
    },
    "697": {
        "output": "### Implementation\n\n- [X](https://colab.research.google.com/github/cjllang/pycda/blob/main/README.md#implementing-the-problem)\n<EOD> The Cerebellum and Spino-Ophthalmic Tinnitus: The Importance of Cerebrovascular Occlusion\n\nA 33-year-old man with acute left retro-orbital and left upper extremity numbness was admitted to our hospital with suspected transient ischemic attack (TIA). He reported a sudden sensation of buzzing sound in his ear about one month earlier. An initial cranial magnetic resonance imaging scan (MRI) revealed acute infarction in the right cerebellum. A follow-up carotid ultrasound identified bilateral high-grade stenosis and occlusion of the internal carotid arteries. He underwent carotid endarterectomy after three months of aggressive risk factor control, the internal carotid artery on the right side was eventually replaced with a shunt. Despite significant improvement of motor function during the following year, the patient complained of a persistent tinnitus in the left ear, which was associated with ipsilateral retro-orbital pain. Subsequent cranial MRI scans showed enlargement of the hypometric area of the right cerebellar hemisphere associated with increased signals on T2-weighted and fluid-attenuated inversion recovery images, and no significant recovery on diffusion-weighted images, 13 months after onset. Based on all the clinical symptoms and images, we diagnosed his deafness as left spino-ophthalmic tinnitus, and hypothesized about the pathophysiology.\n\n# Introduction\nCerebellar tinnitus is an abnormal perception of noise in one ear caused by dysfunction of the cerebellum. [bib_ref]  Tinnitus-catastrophia del sonido del cerebelo?, Vizel [/bib_ref]  The cerebellum has reciprocal projections to both the contralateral thalamus and ipsilateral cochlear nucleus and has connections with the midbra",
        "label": 1
    },
    "698": {
        "output": "[INST]\n\n### Recommendation\n- We recommend that you should follow the guideline which is shown in the red area. The input variables are written as \"Trial-Level Eligibility\".\n\n# Example of a solution\nHere is an example of a solution. You can learn how to write an R script by reading the solution.\n\n```r\n# TrialLevelEligibility <- c(\n#       \"0) Excluded\",\n#       \"1) Not Relevant\",\n#       \"2) Eligible\"\nTrialLevelEligibility <- c(\"0\", \"1\", \"2\")\n# Your assignment is Trial-level eligibility\nTrialLevelEligibility\n\n# Your assignment is Patient-level eligibility\nPatientLevelEligibility <- c(\"0\", \"1\", \"2\")\n\n# Your assignment is Trial-Level Eligibility\nTrialLevelEligibility <- c(\"0\",\"1\",\"2\")\n\n# Your assignment is Patient-level Eligibility\nPatientLevelEligibility <- c(\"0\",\"1\",\"2\") \n\n```\n<EOD> Chest ultrasound findings in a case of SARS-CoV-2 infection: a case report\n\nIn the current coronavirus disease 2019 pandemic, diagnosis of suspected or confirmed cases relies on a positive reverse transcription polymerase chain reaction of the viral RNA or highly trained clinical suspicion. The emergence of atypical presentations of this disease led to using complementary imaging for differential diagnosis. This study presents a case of confirmed SARS-CoV-2 where all common radiological findings were presented. The chest ultrasound was performed to detect any radiological signs, and a typical \"white lung\" pattern with signs of alveolar-interstitial syndrome was found.\n\n# Introduction\nMany viruses, mostly of the family coronaviruses, are known to be causing respiratory infections in the previous century. The most famous one is the severe acute respiratory syndrome coronavirus (SARS-Co-V). Coronavirus disease 2019 , identified as an emerging infectious disease in December 2019, was first reported in China, Wuhan",
        "label": 0
    },
    "699": {
        "output": "## Exercise\n\nIn 30 minutes, try completing the exercise.\n\n1. Find a patient, as in 1.1. Consider that the patient note is incomplete in 1.2. Try to fill it in, and in the last column, use Trial-level eligibility to check the eligibility (in 1.2.a).\n\nCongratulations! You are now able to assess a patient's eligibility using the Trial-level eligibility assessment.\n\n## Discovery\n\n## Discovery is one of the features that distinguishes clinical research from other branches of science and technology.\n\nIn this module, you will be guided step by step through each of the Discovery aspects of a data analysis to produce a statistical model that enables the researcher to draw conclusions from the trial's data. You will discover the differences between a simple regression model compared to a richer model that helps you to answer more important and meaningful questions on study outcome. You will also practice calculating effect size, which is an important indicator of practical importance or relevance of statistical effects.\n\nAt the end of the lesson, you will be able to identify the various Discovery aspects of clinical trial data analysis, and be able to calculate effect size for different statistical models.\n\n## 1.1  What are the aspects of Discovery?\nYou have learned much about clinical trial design through the previous modules. The following module focuses on another aspect of the clinical trial: Discovery. The purpose of Discovery is to discover whether a new biological or therapeutic intervention is of interest in a new disease area. In other words, does this intervention change the primary or secondary endpoint?\n\nThe Discovery aspects encompass the data collected from the trials, from baseline to the outcomes, which include the following:\n1.1.1. Descriptive statistics. Here are a few examples:\n1.1.2. Variables related to the treatment effect. Here are a few examples:\n1.1.3. Variables related to dropouts. Here are a few examples:\n1.1.4. Variables related to adverse events during the clinical trial. Here are a few examples:\n1.1.5. Variables related to participant characteristics. Here are a few examples",
        "label": 0
    },
    "700": {
        "output": "To summarize, the patient is eligible for clinical trial participation if and only if the values in the last two columns (Trial-Level Eligibility and Patient-Level Eligibility) are both 2, e.g., `Trial-level eligibility:\n[formula]  2) Eligible; Patient-level eligibility 2) Eligible,`.[INST] [/formula] \n\n\n## Examples\n\n \n\n## Input file (assistant.txt) \n[INST] You should read the input file in the first cell by the `readline` command.\n\n`Input file: assistant.txt`[INST] `readline(file =\"input-file.txt\")[INST] ```\n[INST] The function `f1` outputs the trial level eligibility, including the patient level eligibility, and the function `f2` outputs only the patient level eligibility. To specify the output text file to write the output by `f1` and `f2`, we should use the function `filewrite(file =\"file-name.txt\")` by following the comments \n\n```\npatient-level eligibility:\n\nEligibility: Excluded\nPatient-level eligibility:\n\nTrial-level Eligibility:\n\nTrial-level Eligibility: 2) Eligible\nPatient-level eligibility:\n\nEligibility: Excluded\nTrial-level eligibility:\n\nTrial-level Eligibility:\n\nTrial-level Eligibility: 2) Eligible\nPatient-level eligibility:\n\nEligibility: Not relevant\n```[INST] [INST] Since `f1` prints the result to the screen in the interactive session, you should use the `!` button to write in a new line. [INST]\n\n[INFO]: The trial-level eligibility is the following: \n\n```python\ntrial-level eligibility:\n\nTriallevel eligibility:\n\nEligibility: Eligible\n```\n\n[INFO]: The patient-level eligibility is the following: \n\n```python\npatient-level eligibility:\n\nEligibility: Excluded\n```\n\n[INFO]: The trial",
        "label": 2
    },
    "701": {
        "output": "# Examples\n\n## Example:\n```python3\ndef calculate_test(patient_note, clinical_trial):\n\tresult_trial_level = \"\"\n\n\tdef return_trial_level_eligibility(patient_note):\n\t\tfor i in clinical_trial.notes:\n\t\t\tif patient_note == i[\"patient_note\"]:\n\t\t\t\tresult = \"Not relevant (\" + i[\"note\"] + \") \" + i[\"_source\"]\n\t\t\t\treturn result\n\t\treturn False\n\n\tif return_trial_level_eligibility(patient_note):\n\t\t# Get eligibility score\n\t\tresult_trial_level = \"Excluded (\" + \"0\") + \" \" : patient_note \"Not relevant (\" + \"1\") + \" \" + \"2)\"\n\telse:\n\t\tresult_trial_level = \"Elgible (\" + \"2)\")\n\n\treturn result_trial_level\n```\n\n## Example:\n```python3\nclinical_trial1 = 1\nclinical_trial2 = 2\nclinical_trial3 = 3\nclinical_trial4 = 4\nclinical_trial5 = 5\nclinical_trial6 = 6\nclinical_trial7 = 7\nprint(r\"%s. Trial-level eligibility:\".format(clinical_trial1))\nprint(calculate_test(\"John Cage is one of most influential composers of this century.\", clinical_trial1))\nprint(r\"%s. Trial-level eligibility:\".format(clinical_trial2))\nprint(calculate_test(\"Cage's compositions span a variety of media, including music, artworks, writing, film, and ideas.\", clinical_trial2))\nprint(r\"%s. Trial-level eligibility:\".format(clinical_trial3))\nprint(calculate_test(\"Although his music is frequently performed, relatively few compositions are currently available on CD.\".format(clinical_trial3), clinical_trial",
        "label": 0
    },
    "702": {
        "output": "[[END]] </codeblock> In the code \n\n> class ClinicalTrial < ApplicationRecord #<ActiveRecord::Base;\n\n> \n> \n> def eligibility_stratification_rules(recruitment_status: :recruiting)\n>   # Add this method according to requirements of the clinical trial\n>   # TODO: Add your eligibility_stratification_rules\n>   if recruitment_status == :recruiting\n>     \"Trial-level eligibility: Excluded\"; if inclusion_criteria_list.blank? && exclusion_criteria_list.blank? && inclusion_criteria_id.nil? && exclusion_criteria_id.nil?\n>     \"Trial-level eligibility: Not Relevant\"\n>     \"Trial-level eligibility: Eligible\"\n>   else\n>     # Else non-recruiting\n>     \"Trial-level eligibility: Not Relevant\"\n>   end\n\n</pre>\n[/codeblock]\nHere, the clinicaltrail's model contains eligibility_stratification_rules.\n\n### Codes for eligibility assessment\n\nEligibility has two assessment levels. \n\n### Codes for trial-level eligibility\n\nIn this category, we should assess how each patient should qualify. \n\n### Codes for patient-level eligibility\n\nIn this category, we should assess whether each patient should be included in the given trial. This assessment of patient-eligibility has also a three-point scale: 0) Excluded (patient is excluded based on the trial-exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria are not applicable). \n\n### Case study 3\nHere is a case study. One of the co-author's team members experienced a cardiovascular emergency and decided to apply for the data science method he has been researching for a long time. By the way, this is why she is a member of the research team. When she saw that the research team's model is about the",
        "label": 1
    },
    "703": {
        "output": "Your work is done! If you want, submit your code to [https://www.kaggle.com/], which is a site for machine learning and data science competitions. If you don't want to, don't worry. You have completed this exercise for yourself!\n\n[PROG]<EOD> Genetic and Transcriptional Networks Underlying the Loss of Meiotic Divisions in the Cryptococcus deneoformans hgc1 Deletion Locus\nDiploid fungi undergo meiotic divisions and must assemble mature, pairing-compatible homologous chromosomes. In the basidiomycete Cryptococcus deneoformans, lack of a meiosis-associated coiled-coil (MACC) protein, hgc1 (histone variant gene complementation gene 1), prevents meiosis without inducing apoptotic cell death. Here, we characterized the hgc1 deletion locus to elucidate the mechanism by which lack of this essential protein eliminates entry into meiosis. The hgc1 deletion allele is unstable in both vegetative and meiotic progeny, suggesting a mechanism that prevents chromosomal inheritance rather than a simple lack of hgc1. Analysis of meiotic metaphase I chromosomes revealed that the hgc1 deletion locus forms a small (\u223c0.3 \u00d7 0.2 \u03bcm), irregular structure that is reminiscent of a nucleolus. The structure contains the histone gene cluster, but most genes are not detectably transcribed during vegetative growth and meiosis. Haploid descendants of meiotic progeny are genetically unstable, accumulating various chromosomal rearrangements, suggesting that lack of HGC1 does not impair meiotic recombination. A small population of cells that formed mature basidia containing viable tetrads arose as spontaneous mutants lacking the hgc1 deletion structure. These hgc1 deletion rescue strains initiate the meiotic pathway, accumulating small dikaryotic nuclei that display a wild-type stereotypical arrangement of meiosis I chromosome segregation. These results raise the question of how hgc1 delet",
        "label": 1
    },
    "704": {
        "output": "You may consider only using a few variables (e.g., sex, race, age, etc.), so you can simplify your data by using a one-hot encoding that converts the values from columns into binary columns (0/1 vectors). For instance, 7 races were encoded as seven binary variables, 0/1 column. Similarly, 9 age groups were each encoded as nine (0/1) columns to be tested in the classification model. \n\n[INC] `one_hot_encoders = ['Race', 'Age']`\n\nYou can add/remove new variables in the `one_hot_encoders` list. Make sure you add or remove them in the same order as they appear in the dataset. For instance, the following line in the script is invalid because the 'Race' variable is at the end of the list.\n\n[INST] `one_hot_encoders = ['Race', 'Age']`\n\n`one_hot_encoders [0] = ['White', 'Black', 'Hispanic', 'Asian', 'Native American']`\n\n## Preprocessing\n\nWe need to combine two CSV files that are stored under the `input_data` directory (or whichever location you specified in the filepaths function). Note: this step is repeated for each trial_id.\n\n[INC] `train_data_path = 'data/example1-train-data.csv'`\n\n[INC] `test_data_path = 'data/example1-test-data.csv'`\n\n[INST] `combined_input_data = pd.read_csv(str(train_data_path), header=None)`\n\n[INST] `combined_input_data = pd.read_csv(str(test_data_path), header=None)`\n\nWe need to use the `add_one_hot_features` function with the one_hot_encoders variable to transform text features in the data to 0/1 binary representations.\n\n[INST] `add_one_hot_features = pd.DataFrame(pd.DataFrame.to_numpy())`\n\n[INST] `add_one_hot_features = add_one_hot_features.append(df[one_hot_encoders[0]])`",
        "label": 1
    },
    "705": {
        "output": "You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm",
        "label": 0
    },
    "706": {
        "output": "### Example output of the program\n   \n<EOD> The effectiveness of an individualized approach to teaching physical examination skills.\nIn the last decade it has become more apparent that there are numerous problems with the traditional lecture method in medical education and that this method is not meeting the needs of today's students. In an effort to address these problems, instructional methods such as lecture plus skills laboratories and problem based learning have been developed to encourage more student-centered learning. Unfortunately, these methods still fall short of the real-world demands of a student's medical education. In their attempt to address this issue, the medical faculty at the University of Toronto developed and implemented an individualized skills program that is now being taught at more than 12 different sites across the province. This article will discuss the method and rationale behind the development and implementation of this program at the University of Toronto. Furthermore, we will discuss the preliminary results from three different educational sites that have been utilizing the individualized skills program.<EOD> Dual-energy subtraction angiography: in vivo preliminary results in patients with subtotally resected carotid stenosis.\nPURPOSE\nTo prospectively investigate the feasibility of dual-energy subtraction angiography (DESA) by using intravenously (I V) administered iodine contrast material (C).\n\n\nMETHODS\nA monoenergetic dual-detector system was designed with the purpose of acquiring projection data according to the following energy characteristics: 95 keV and 140 keV. The acquired data for a preand postcontrast projection were combined through dual-energy subtraction (DES) of the two projection datasets to produce DESA images. Seven patients who had subtotally resected carotid stenosis and who had a cerebrovascular hemodynamic impairment caused by a flow-limiting carotid stenosis underwent DESA imaging. The intravenously administered I' and 130 mg I' of Omnipaque (New England Nuclear, Boston, MA) were injected into an antecubital vein by using a power injector. CM and DESA images in 2-mm increments are acquired. Postprocessing of the DESA images allows",
        "label": 0
    },
    "707": {
        "output": "Please, let me know if this solution is of any help to you or not, and also I hope this tutorial could be useful to others in need. Thanks!\n<EOD> Exposure to the metabarcoding primer is a major driver of the observed heterogeneity in COI sequence data\n\nMetabarcoding-based studies are increasingly applied to study biological diversity and to screen environmental DNA (eDNA) data for the presence of invasive species. The sensitivity, however, of metabarcoding primers to polymorphic sites is often ignored, which can result in overrepresentation of certain primer binding groups. Here, we use a comparative approach to explore the contribution of primer binding group (PBG) to species abundance, the extent to which PBGs are linked with biological parameters such as species size, species diversity and relative abundance in order to investigate the underlying mechanisms of PBG selection. We used comparisons between COI metabarcoding and Sanger sequencing datasets to examine the influence of primer binding site selection bias on sequence heterogeneity. We found that COI metabarcoding is biased towards taxa that have multiple copies of the exact complementary nucleotide in the COI coding sequence. These groups are mainly comprised from taxa with a larger mitogenome size, high taxon richness and species abundance. We therefore propose to consider the number of PBGs as one of the factors affecting metabarcoding success, particularly when the goal is to maximize taxon richness.Electronic supplementary material:The online version of this article (https ://doi.org/10.1007/s1098 0-020-01098 -9) contains supplementary material, which is available to authorized users.\n\n# Introduction\nThe field of metabarcoding continues to evolve and is gaining popularity within science since it allows the identification of hundreds of species within ecological communities using only a tiny sample [bib_ref]  DNA barcoding: error rates based on comprehensive sampling, Meyer [/bib_ref]  [bib_ref]  A large-scale evaluation of marker performance in eDNA metabarcoding of fishes based..., Bigman [/bib_ref]  [bib_ref]  Global diversity of acoelomate worms (Acoela) reveals multiple",
        "label": 1
    },
    "708": {
        "output": "__Note__:\n- Make sure to read this example carefully. It includes a number of things that are discussed in Chapter `Using Markdown`.\n- [INST>] Use <NAME> to make references to your colleagues. You can replace <NAME> with your own name/surname.\n\n[INST>]: [cite:1]\n__Example 9__: The relationship between cardiac hypertrophy and the risk of mortality in a hypertensive population.\n\n1. This table is not included in the following paper.\n\n2. Data are expressed as estimated hazard ratio and 95% confidence intervals. The estimated hazard ratio is an adjusted hazard ratio, to the extent possible, from the multivariable analysis (for a complete description of the adjustment covariates, see the legend on this table).\n\n__Example_12__: Using Markdown on Linux\n\n---\n\n1. Markdown may sometimes fail in Linux while the reason is not always clear: here is some tips to solve this issue.\n2. First of all, remember that Markdown should not be embedded inside Markdown files. \n```\n```\n---\n\n1. One thing that you need to do is to add ~ to start a new line. If you do a Ctrl+l, the text is automatically wrapped in a new line. This is not really a bug, but a problem for the word processor to correctly render Markdown commands. You may find solutions that fix this issue. Other words, it is always possible to avoid wrapping things, if you know how to write.\n```\n```\n\n1. In fact, you can use many other commands to override the behavior of the word processor with Markdown. For example, if you want to change the font family, you can use the following command:\n```\n```\n```\n---\n\n1. Whenever Markdown fails, remember that Markdown's syntax is very simple and it is therefore a good learning experience.\n```\n```\n```<EOD> Effect of 6\u2010month treatment with recombinant human erythropoietin on reticulocyte count and erythroid precursor number in patients with end\u2010stage renal disease\nAbstract:\u2002 It is unclear whether an appropriate erythropoietin (rHuEpo) treatment schedule can prevent anaemia in patients with ren",
        "label": 0
    },
    "709": {
        "output": "<EOD> Cytomorphology of pleomorphic adenoma of the salivary glands in fine-needle aspirates: A study of 11 cases\n\nPleomorphic adenoma (PA) is the most common neoplasm of the major salivary glands. However, there are reports of its occurrence in minor glands and also in other locations. The tumour is benign in nature, but shows some locally invasive growth pattern. It has a peculiar growth pattern and cytomorphology due to the two major components: epithelial and myoepithelial. The aspiration cytology of the tumour depends on the relative amount of each of these cellular components present. Fine-needle aspiration (FNA) cytology of large mass lesions may produce inconclusive results and may require cell block preparation and conventional histopathologic examination for accurate diagnosis. The diagnosis of PA of minor glands requires very high index of clinical suspicion and specific location of the tumour and a high index of suspicion on cytology. We evaluated eleven cases of pleomorphic adenoma as FNAC material from May 2005 to April 2010. They included predominantly female patients (80%). There were nine cases of parotid gland (81.81%); one periobuccal gland and another from a minor salivary gland (tail of parotid). Most of the cases (seven) showed a mixed cellular population of epithelial and myoepithelial cells [Papanicolaou (PAP) stain, 200X] while three cases showed predominantly myxoid stroma [Picrosirius Red stain, 400X]. One case was adenoid cystic like [PAP, 200X]. Oncocytic changes and squamous metaplasia were noted in one case [PAP, 200X] each. Our series of fine-needle aspiration cytology of pleomorphic adenoma is very interesting to note the various variant appearances that can be seen in the cytologic picture.\nPleomorphic adenoma (PA) is the most common benign neoplasm of salivary glands. It is mostly",
        "label": 0
    },
    "710": {
        "output": "A: It seems easy enough to figure out but a hint:\n1. Look at all the values - the patient notes and the clinical trial notes - and then combine them together.\n2. If multiple values are present - either from the patient notes or from the clinical trial notes - you must combine the values to a singular answer and put it in that line.\nSo in this example, there is:\n- a patient's name - \"Alvin\";\n- 46 years old;\n- family history - \"no cardiovascular risk factors\";\n- LDL-C and HDL-C - \"545 and 53 respectively\";\n- fasting glucose and triglyceride levels - 85 and 158 mg/dL;\n- no use of lipid-lowering medications;\n- patient notes for the clinical trial:\n- Title: Carotid Atherosclerosis In Newly Diagnosed Type 2 Individuals Summary: It has been hypothesized, based on recent trials, that only early intervention can reduce cardiovascular morbidity and mortality in individuals with type 2 diabetes (T2DM). This finding may imply that atherosclerosis at diabetes diagnosed is either negligible, or at early, or non-advanced still modifiable disease stage. However, sparse information is available regarding atherosclerosis prevalence and its characteristics at diabetes presentation. Furthermore, although cardiovascular disease (CVD) prevention is the major goal of treatment in T2DM, risk assessment tools, mostly based on traditional CV risk factors lack of adequate specificity to identify individuals at higher risk. Therefore, non-invasive tests, such as carotid ultrasound, have been recommended to better define CV risk in several groups of individuals, including those with intermediate risk or with T2DM.~Patients with T2DM have a higher prevalence of several CV risk factors, so individuals with newly diagnosed T2DM (NEWDM) will be matched with non-diabetic (CONTROL) individuals for age and sex (the main determinants of atherosclerosis), but also for known, treated hypertension and dyslipidemia, and smoking habit.~",
        "label": 1
    },
    "711": {
        "output": "<issue_comment>username_3: ### [\ud83c\udfaa Background](https://clinicaltrials.gov)\n\n```\n[INST]\nTitle: The Gore SCAFFOLD Clinical Study\nSummary: Evaluate the safety and efficacy of the GORE\u00ae Carotid Stent for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy\nInclusion criteria:\nPatient is at least 18 years old at informed consent\nPatient is willing and capable of complying with all study protocol requirements, including specified follow-up period and can be contacted by telephone.\nPatient is willing to provide written informed consent prior to enrollment in study.\nPatient is either:\nSymptomatic with carotid stenosis \u226550% as determined by angiography using NASCET methodology. Symptomatic is defined as amaurosis fugax ipsilateral to the carotid lesion; Transient Ischemic Attack (TIA) or non-disabling stroke within 180 days of the procedure within the hemisphere supplied by the target vessel; OR\nAsymptomatic with carotid stenosis \u226580% as determined by angiography using NASCET methodology\nPatient must be considered high risk for adverse events during carotid endarterectomy\nNote: Additional inclusion criteria may apply\n\n[HINT] Let's think step by step.\n\n[INST] Finally, you should always write `Trial-level eligibility: 2) Eligible.` in the last line by `Trial-level eligibility:`.\n[/HINT]\n```\n\n#### Exercise of the [\ud83c\udfaf Task 5b](./task-5b.md)\n\n<EOD> Identification of two new H-2 b mutant mice with disruption of the gene encoding the class I HLA molecule Qa-2.\nThe genetics of the murine major histocompatibility complex (MHC) has been a model system for studies of disease-associated susceptibility/resistance genes. Mice which are completely devoid of the class I HLA Molecule encoded",
        "label": 1
    },
    "712": {
        "output": "## [FEMPI_PROBLEM 1.A.1]\nYour task is to calculate a `trial-level` score for the assessment of eligibility according to the method `TrialLevelScore` using the `trial-level` data. You can read about the method `TrialLevelScore` in the next [FEMPI_PROBLEM 1.B.1]. You can read about the data to use for this method in the next [FEMPI_DATA 4.A.1]. After reading all the following, you should code the following Python lines: \n#import numpy as np import matplotlib. pyplot as plt from sklearn.svm import SVC from sklearn.linear_model import LinearRegression from scipy.signal import find_peaks # Define a score in the case of the exclusion of a patient (0) # Define a score in the case of a patient being not-relevant (1) # Define a score in the case of the inclusion of a patient (2) # Calculate the trial-level score # Score= np.ones(len(fempi_prob_trial)) # For n_patient=3 : # Calculate the score for the first patient # Trial-levelscore= n_points_for_criteria==0 ? np.ones(1, dtype=int) : # Score1= np.ones(1, dtype=int)+(1-score1_avg)/100 # where score1_avg is the mean score of the second patient # Score1= score1_avg * (Score_to_calculate_score1 / 100) # where score1_to_calculate_score1 is the trial-level score of the second patient # Score_to_calculate_score1= np.ones(1, dtype=int) # Calculate the score for the second patient # Trial-levelscore= n_points_for_criteria==1 ? np.ones(1, dtype=int) : # Score2= np.ones(1, dtype=int) * (Score1_avg / 100) # where score1_avg is the mean score of the second patient # Score2= score1_avg * (Score_to_",
        "label": 1
    },
    "713": {
        "output": "A multicenter double-blind study that assessed the effct of donepezil hydrochloride (Aricept) on mild cognitive deficits in patients with vascular brain disease. A total of 395 patients over the age of 50 were randomly assigned to placebo (n=171) and active drug (n=224) groups. There were no differences in the degree of decline in cognitive performance during a 26-week period between the 2 groups. Donepezil hydrochloride had no effect on cognitive functioning or mood in patients with mild to moderate vascular cognitive impairment, even though donepezil improved cognitive performance in some patients. (source: UpToDate)\n\n## Exercise1_dl9507_solution.Rmd\n## # 3.2. VISUALIZATION Exercise 1\n\n## # 3.2.1. Tutorial\n\n### Plot the sample characteristics.\nsummary(D9507_data)\n\n\n## ### #plot patient's individual data\nplot(D9507_data, type = \"ind\", main = \"Individual data)\n\n\n## ### # plot sample mean\nplot(D9507_data, type = \"",
        "label": 1
    },
    "714": {
        "output": "## Exclude Patient Due to Trial's Incompleteness\nThe trial includes and assesses a different set of variables and parameters than the trial's eligibility. The trial's design must satisfy all patients for whom the variables are available, even if the variables are not in the eligible parameters.\nThe following should occur:\n\n1. Assess Tri",
        "label": 1
    },
    "715": {
        "output": "### Exercise 40  \n\nIssue 3 has been discussed at the weekly meeting of the Clinical Governance Team. The team has agreed to move forward with the clinical pathway and that all the patients with the conditions that fit the clinical pathway will follow the pathway. A clinical pathway is a set of sequential steps designed to guide the care and treatment of patients with specific health problems. It is a document that describes each step in patient care, from the moment when the patient enters the healthcare system to the moment of discharge. \n\nClinical Pathways are designed to improve the quality of care, reduce variation in care, improve cost effectiveness, and reduce hospital stays and associated costs. They can improve communication about the patient's care. Clinical governance describes the processes by which an organization ensures consistency in best practice across the system, and is",
        "label": 2
    },
    "716": {
        "output": "* This code is the same as the example code.<EOD> A method comparing the sensitivity of the tuberculin and Mantoux tests.\nThe tuberculin and Mantoux tests were compared in 60 children, using the sensitivity of a skin test as defined by J. G. L. Hutchison and his colleagues (3). The Mantoux test proved to be more sensitive than the tuberculin test in each of the three categories of the former. The tuberculin and Mantoux tests were also compared in 47 men and one woman, using the sensitivity of a tuberculin test as defined by Hutchison et al. The Mantoux test proved to be more sensitive than the tuberculin test in 39 of these 48 patients.\n The skin tests were applied as parallel tests. In the study of the children at the time of a routine skin test, the test results were compared, using both the individual readings and the group readings of the tuberculin and Mantoux tests. The individual readings showed significant differences in the sensitivities of the tests in 41 of 60 children and the group readings in 57 of 60 children. The Mantoux test showed a higher sensitivity according to the group readings than did the tuberculin test in all three categories of the Mantoux test.\n These comparisons indicate that the Mantoux test provides sensitivity comparable to that of the tuberculin test, while at the same time increasing considerably the ease and comfort of the procedure and perhaps the reliability as well.<EOD> In vitro Effects of L\u2010Carnitine on the Function of Lymphocytes from Healthy Humans\nWe examined the in vitro effects of a water\u2010soluble, biochemically active nutrient, L\u2010carnitine (beta\u2010hydroxy\u2010gamma\u2010N\u2010trimethylaminomethylbutyric acid), on the function of lymphocytes from healthy human subjects. L\u2010carnitine was not toxic to lymphocytes at concentrations equal to or below its saturating concentration (2.24 mM); in addition, L\u2010carnitine at a supraphysiologic concentration (22.4 mM) increased the survival rate of normal lymph",
        "label": 1
    },
    "717": {
        "output": "### Exercise\nIn the following exercise you should complete the eligibility matrix by comparing the patient and clinical trial with an instruction manual. When comparing, choose the most appropriate answer.\n\n## Exercise: Clinical trial and patient eligibility by an instruction manual\n\n\nInstructions:\nIn this exercise you should complete a table by determining whether a patient would be eligible for a clinical trial. For this, please compare the patient's characteristics with the instruction manual.\n\n| Trial | Patient | Instructions|\n|------------|------------ |-----------|\n| LOTUS |A 46-year-old man | The subject must be > 21 years of age.|\n| LOTUS |This patient is over 21 years of age.|\n| LOTUS | This is an inclusion criterion since this patient is over 21 years of age.|\n| LOTUS | His life expectancy of the  \\+/\\  the minimum distance of 5 cm between the clavicle and bifurcation, as assessed by duplex Doppler ultrasound, computed axial tomographic (CT) angiography or magnetic resonance (MR) angiography.\n| The subject has a minimum distance of 5 cm between the clavicle and bifurcation, as assessed by duplex Doppler ultrasound, CT angiography or magnetic resonance (MR) angiography.|\n| LOTUS | \\+/\\ \\+/\\ \\+/\\ |\n\n## Exercise Solution: Clinical trial and patient eligibility by an instruction manual\nEligibility criterion:\nInclusion criteria:\n| LOTUS | > 21 years of age   \\+/\\ minimum distance of 5 cm between the clavicle and bifurcation |  \\+/\\ \\+/\\ |\n\n### Exercise Solution\nThis is the eligibility matrix after completing the exercise with the instruction manual. Eligible patients have at least one eligibility item. Ineligible patients have no eligibility item. A patient is not evaluated when no information is available.\n\n\n| Criterion | Eligibility| Explanation |\n|------------ |------------ |------------ |\n|Life expectancy| \\+",
        "label": 1
    },
    "718": {
        "output": "References [INST0]: `References [INST0]:`.\n```python\ndoc = '''doc body'''\n\ndef eligibility_assessment():\n\n    [instructions for each step in bullet points]\n\n    # first step\n    pass\n\n    # second step\n    pass\n\n    # third step\n    pass\n\n    # last line for this bullet point\n    if __name__ == \"__main__\":\n        print 'Trial-level eligibility: 2) Eligible.'\n    pass\n\nprint_instructions()\nprint_results()\n\n<EOD> Progenitor Cells from Blood for Stroke Patients\nStroke is one of the leading causes of death in the United States, with 795 000 new cases and 180 000 deaths occurring in 2003.1 The direct and indirect annual costs of stroke care exceed $62 billion.2 More than half of all strokes are ischemic, and up to 20% of patients will become dependent on others for activities of daily living.3 Although a large number of neuroprotective and neurogenic treatments have been tested during the past two decades in preclinical stroke models, few have been translated into the clinic. The failure of the neuroplasticity response of the residual neural network to be recruited may contribute to the relatively poor clinical outcomes seen in ischemic stroke patients. Cellular replacement with progenitor cells from both neural and nonneural origin has been proposed as a means to circumvent the problem of failing plasticity. In 2006 three small studies demonstrated the recruitment of endogenous neurogenesis after administration of human bone marrow-derived mesenchymal stromal cells (MSCs) in preclinical stroke models.4\u20137 As a result, four ongoing multicenter stem cell trials for treatment of subacute and chronic ischemic stroke are testing the infusion of mesenchymal stromal cells from bone marrow or adipose tissue (clinicaltrials.gov). The cellular infusion method varies: one study administered cells through a catheter into the internal carotid artery; another",
        "label": 2
    },
    "719": {
        "output": "<EOD> Characterization of human peripheral blood lymphocytes responding to human immunodeficiency virus (HIV) type 1 antigens. The V1 loop region of HIV-1 gp120 induces a strong response of alpha beta CD4-/CD8- T cells while the V2 and V3 regions and the C3 and C4 peptides of HIV-1 gp160 induce a weak response of T cells bearing CD4 on their surface with or without co-expression of CD8.\nThis study focuses on the response of T lymphocytes generated by the treatment of PBMC with the V1 loop region (amino acids 11 to 197), the V2 region (amino acids 192 to 307), the V3 region (amino acids 304 to 438) and the C4 peptide (amino acids 401 to 423) of HIV-1 (HIV-1 gp120-307 synthetic peptide) or envelope peptide (HPV envelope peptide of HP",
        "label": 0
    },
    "720": {
        "output": "<EOD> Comorbidities Increase the Severity of COVID-19 among the Elderly: An Analysis of a Massive COVID-19 Cohort in Japan\n\n\n\n# Introduction\nThe novel coronavirus responsible for the Coronavirus Disease (COVID-caused a pandemic, and >600 million people have been infected by March 2022. Although this pandemic was less severe in children, the elderly experienced severe symptoms and mortality with a high mortality rate of >10% in patients \u226585 years of age. Old age, male sexand comorbidities (diabetes mellitus, hypertension, ischemic heart disease, cerebrovascular disease, arrhythmia, heart failure, lung diseases, and chronic kidney are risk factors for severe symptoms in COVID-19 patients.\nThere are several issues about COVID-19 among the elderly: a report from the United States showed higher rates of hospitalization in individuals \u226565 years; other reports showed higher rates of hospitalization, intensive care unit admission, development of acute respiratory distress syndrome, and critical illness in elderly COVID-19 patients. The reason for these phenomena might be a difference in the expression of Angiotensin-converting enzyme-2 (ACE2), and the degree of immunosuppression caused by increased age is suggested to increase the risk of COVID-19 severity.\nJapan is an elderly culture in which the elderly account for only~10% or less of the population compared to other nations. The ratio is <10% in Korea (20%;. Several studies have shown that the rates of incidence, hospitalization, and death in elderly Japanese are all lower than that in elderly Caucasian populations. In contrast, the rate in elderly Chinese people is higher than that in elderly Caucasian populations, especially during the initial period of the pandemic. Aging reduces the adaptive immune response, thereby decreasing the production of neutralizing antibodies, and increasing susceptibility toward viral infection and disease severity. Several previous studies have suggested that elderly Chinese people have relatively greater susceptibility compared to Caucasian people.\nIn this study,",
        "label": 0
    },
    "721": {
        "output": "<EOD> Isometric exercise and muscle contraction attenuates nerve injury\u2010induced incapacitating pain in mice by regulation of TRPA1\n\nPeripheral nerve injury (PNI) could cause a persistent and debilitating pain condition known as chronic neuropathic pain (CNP). We evaluated the effect of isometric exercise and contraction in response to a chronic constriction injury (CCI) model of neuropathic pain. A CCI-induced neuropathic pain model was established in 8-week-old male C57BL/6J mice. The mechanical and thermal thresholds and latency to noxious heat evoked potentials (HEPs) were assessed. Isometric contraction was also used to test the impact of isometric exercise on the established CCI-induced PNI. In CCI groups, mice receiving two regimens of contraction training showed remarkable and significant lowered pain thresholds starting at 21 days and lasting until 33 days compared with control CCI groups. Isometric exercise prevented a reduction in mechanical and thermal thresholds compared with control CCI groups. The expression of transient receptor potential ankyrin 1 (TRPA1) was assessed by immunohistochemistry. TRPA1 expression was upregulated in the dorsal root ganglia (DRG) of the control groups, while it was downregulated after isometric exercise. Our findings indicate that isometric exercise and contraction could alleviate chronic neuropathic pain caused by nerve injury. K E Y W O R D S chronic neuropathic pain, isometric exercise, muscle contraction, transient receptor potential ankyrin 1 1 | INTRODUCTION Peripheral nerve injury-induced neuropathic pain is a common, persistent and debilitating pain disorder associated with dysregulation and sensitization of trigeminal and spinal nociceptive systems. Neuropathic pain has been treated primarily using analgesics, including morphine, but long-term use may result in an unresolved crisis due to many side-effects or drug resistance (I. Z. (2011)). Recently, exercise therapy has demonstrated beneficial effects, such",
        "label": 1
    },
    "722": {
        "output": "[END]\n\n## 3. Assignments\n1. In this section, you will have to create tasks to let your teammates perform the given tasks and review their solutions in detail and provide comments. \n2. Please submit the detailed assignment information about the assigned tasks along with the necessary information about the expected results in this section.\n\n## 4. Workflow\nAs explained in the following figure, you will have to perform task 3 and its sub-tasks with the help of three teams. Your team is composed of two students of team 1, two students of team 2, and one student of team 3. We have assumed that all teams are working in parallel, and the timeframe for the team tasks is one working day per week.\n\n<a class=\"image-wide image\" style=\"background: rgb(9, 118, 131); display: block; cursor: hand\" href=\"https://github.com/HamidRaasti/CS-UMLS-BIOINFORMATICS-COURSE/blob/master/images/Tasks/Tasks.png\"><img src=\"https://github.com/HamidRaasti/CS-UMLS-BIOINFORMATICS-COURSE/blob/master/images/Tasks/Tasks.png\" alt=\"Tasks\" /></a>\n\n## 5. Submission\n\n- Upload your assignment in _CS/Submission/cs_\n- If you are interested in using any source code written in other programming languages on the platform, you need to submit the source code along with a readme file to us. You can provide the source code to us in `TAR` format.\n\n# 6. Deadline\n- The deadline for the assignment is _week 1_ . [DOWNLOAD FILE](http://cs.iitd.ac.in/~vibha/assessment/assessment-cs-bioinfo-s3.pdf) \n\n\n<EOD> Exploring the effect of CAG repeat length on disease pathogenesis in spinocerebellar ataxia type 1\n\n\n\n# Introduction\nTrinucleotide repeat expansion disorders, which have a genetic cause in approximately 53 distinct disorders (http://www.trinucle",
        "label": 1
    },
    "723": {
        "output": "## Tasks and Subtasks\n\n### FIND THE REASON FOR NO TRIAL LEVEL ELIGIBILITY\nEach clinical trial has a specific inclusion criteria and exclusion criteria. For each clinical trial \n\n![](../figures/images/2019-08-24-133336.png)\n\n\nEach trial has one or more reasons corresponding to the exclusion criteria. Exclusion criteria define a set of conditions, such as the age range specified in a study, which disqualifies a person from participating. Each trial has a set of exclusion criteria for that trial, i.e., the reason for the trial-level assessment of no eligibility. You are required to print and save this document. On the last page, the number of the page for the reason for the no trial-level eligibility for the trial. The first line is the number of the trial exclusion criteria. You should print the number of the reason of no trial-level eligibility from last page. [INST]\n\n### GET THE PAST MEDICAL HISTORY FOR THE PATIENT\nBased on the past medical history, generate a past list of diseases the patient has. We want you to use the history tool to get a list of diseases a patient may have had. For each of the diseases, save the disease name and the onset year to the same file named _past_diseases.txt. You should copy the lines from https://github.com/Cambridge-AI-Lab/Past_Diagnoses/blob/master/history_tool/past_diagnoses_data.zip into _past_diseases.txt`. After you finish adding information, you should copy the lines from the _past_diseases.txt_ file back to the history_tool/past_diagnoses_data.zip file.  We want you to save the new file as _past_diagnoses_data.zip`. [INST]\n\n### GET THE DRUG TREATMENTS, INCLUDING POTENTIAL DRUG ALLERGIES AND ADVERSE EFFECTS\nFor each drug treatment, i.e., medication name plus dosage and frequency of ingestion, record the following",
        "label": 0
    },
    "724": {
        "output": "### Implementation\n\n#### Data preparation\n\nIf the dataset contains more than 1,000 sample cases, it is recommended to apply data cleaning and pretreatment to avoid outlier effect. Perform a case-by-case review of the data before you start working with it. Remove any unspecified or implausible entries. In addition, add some special codes for missing values to handle missing values efficiently for all variables.\nLet's define `sample_data` as follows:\n\n    \n\n\n### 1.\nRead and load the data. The first data file is a data frame, which consists of several rows with variables and samples. We can use the read.csv function to read data files in comma separated values (CSV) format (see [data.csv on GitHub]). The second file is a data frame with a variable name (patient), and the first column contains 1,000 samples.\n\n    data.csv <- read.csv(\"https://github.com/kyoung-won/clinical_trial_inference/tree/main/data/data.csv\")\n    patient <- data.csv[1:1000,]\n\n\n\n\n    ##  [1] \"Patient\" \"Height\" \"Weight\" \"Age\" \"A1c\" \"Total_cholesterol\" \"High_density_lipoprotein_cholesterol\" \"Low_density_lipoprotein_cholesterol\" \"Triglycerides\" \"Blood_pressure\" \"Sex\" \"Occupation\" \"History_of_smoking\" \"Family_history_of_cardiovascular_diseases\" \"Family_history_of_type_two_diabetes\")\n\n    ## Sample data\n\n    ## Patient1 Patient2 Patient3 . . . Patient1000\n    ##     \"46\"      \"50\"   \"37\"        \"54\"         \"54\"     \"40\"     \"49\"    \"49\"    \"40\"     \"43\"\n    ##   \"in\"        \"in\"    \"in\"         \"in\"\n    ##   \"in\"        \"in\"    \"in\"",
        "label": 0
    },
    "725": {
        "output": "## Relevance assessment\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a clinical trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nHere is the clinical trial's inclusion and exclusion criteria:\n\n## INCLUSION CRITERIA\nPatients with a diagnosis of noncardioembolic IS that developed between 8 and 180 days before the start of the protocol treatment\n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal",
        "label": 1
    },
    "726": {
        "output": "<EOD> Anaphylactic Shock After Low-dose Cervical Anesthesia of Loxapine: A Case Report\n\n\n\n# Introduction\nLoxapine is chemically classified as a dibenzoxazepine derivative and thioxanthen derivative. It is used in treatment of acute schizophrenia and chronic paranoid schizophrenia. It induces sleep (acting mainly in the lower brain centers), alleviates anxiety, calms restlessness, and improves social withdrawal by reducing psychological conflict.\nSome anaphylactic shocks are associated with a wide variety of compounds and materials. Even small amounts of antimicrobial preservatives and additives are known to cause anaphylactic shock.\nWe report a case of anaphylactic shock caused by low-dose cervical anesthesia using loxapine, a second-generation antipsychotic drug.\n\n## Case\nA 27-year-old female patient was admitted to the emergency room complaining of skin rash, dyspnea, and nausea. The patient was administered an intramuscular injection with 0.5 mg/kg loxapine, 15 minutes after receiving an intravenous injection with 5 mg pethidine for her pain. Soon after, the patient exhibited a wheat-sized rash on the upper back side, followed by dyspnea and nausea. The attending physician attempted to revive the patient via the trachea and re-injected loxapine.\nWhen the attending physician arrived, the patient had stopped crying, exhibited a drowsy state, and her vital signs were as follows: blood pressure (BP), 170/110 mmHg; pulse (P), 144 beats per minute; respiration rate (R), 30 breaths per minute; oxygen saturation (SO 2 ), 80%; and a core temperature within a normal range. It was difficult to insert a central venous catheter or an arterial line; therefore, we attempted a peripheral intravenous line. At that point, the patient was exhibiting un",
        "label": 0
    },
    "727": {
        "output": "<EOD> .\nThe clinical and the histopathologic findings are reported in a case of \"angio-cystoma glutinosa cutis\". This vascular lesion was situated on the right hypochondrium in an 96 years old woman. The patient had a large bluish nodule of firm consistence. The histopathological report showed a large neoformation of vessels which occupied the whole thickness of the dermis. These vessels were either thick walled or thin walled. The endothelial cells of the vascular lumina were very often atypical. Vascular buds, anastomoses and a halo of hemosiderin deposits peripherally were also seen. The differential diagnosis is discussed, and a new hypothesis is advanced concerning the pathogenesis of these lesions.<EOD> Clinical evaluation of the HemoCue portable hemoglobinometer.\nHemoCue, a portable hemoglobinometer, was evaluated in a clinical setting. The device is simple to use and gives a readout within 30 to 120 seconds, depending on the instrument. The analysis is based on the difference in absorbance of two hemoglobin solutions. The HemoCue Hemoglobin Test shows good correlation with the Technicon H 2 -Hb (r = .945; P < .001), H 4 -Hemoglobin (r = .947; P < .001), Hemocor (r = .904; P < .001), H 2 Diacridine (Technicon) (r = .848; P < .001), and the Coulter LH-20 (r = .815; P < .001) blood analyzers. The use of the HemoCue Hemoglobin Test, in a clinical setting should prove useful in the determination of a patient's hemoglobin concentration.<EOD> Immunolocalization of Fractalkine (CX3C Chemokine) and Its Receptor CX3CR1 (Fractalkine Receptor) in the Rat Mice Retina\nFractalkine (CX3CL1) is a membrane-bound chemokine with unique imm",
        "label": 0
    },
    "728": {
        "output": "# A B Example\n**A:** Patient Note :\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53  mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158  mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. **B:** Clinical Trial\nTitle: to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Hyperlipidemia Summary: Primary Objective: To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy (Livalo 2mg) and intensive lipid lowering therapy (Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: \u00b5T-\u00b5C < 0.4 vs H1: \u00b5T-\u00b5C < 0.4 \u00b5T = the change of HbA1c in the test drug (Pitavastatin 4 MG) \u00b5C = the change of HbA1c in the control drug (Pitavastatin 2 MG)\nInclusion criteria: Male and Female patients who are more than 20 years old or 70 years old or less. Patient who voluntarily sign on written informed consent form Patient who LDL-C \u2265 100mg/dl or was diagnosed with hyperlipidemia Patient who was suspected with Imparied Fasting Glucose (IFG) and satisfy FPG level \u2265 100mg/dL and < 126mg/dL when FPG measured twice.<EOD> .\nEven if the number of human cases of infection-associated brucellosis is decreasing, there is a considerable increase in economic losses in livestock all over the world due",
        "label": 1
    },
    "729": {
        "output": "End of Instance\n<EOD> Identification of the first HapMap-based genetic biomarker with prognostic value for patients with gastric cancer in China.\nThe aim of this study is to identify a novel prognostic biomarker and its underlying mechanism in gastric cancer (GC) and to predict clinical outcomes in GC patients. A total of 241 gastric cancer tissues and 227 adjacent tissues were included to screen the differentially expressed genes between tissue specimens and controls by microarray and verified by quantitative real-time PCR. Kaplan-Meier method was used to analyzed prognostic significance. The enrichment of PNPLA3 was verified by western blotting, immunohistochemistry, and tissue microarray. The protein interactome of PNPLA3 in GC tissues was performed by Co-Immunoprecipitation-Mass Spectrometry and analyzed according to Gene Ontology Term. It was found that PNPLA3 was overexpressed in GC tissues and the high expression of PNPLA3 was associated with the poor overall survival. PNPLA3 over-expression significantly increased cell proliferation and drug resistance of GC cells. Moreover, PNPLA3 expression was positively correlated with the staging of patients. Furthermore, we obtained 15 proteins of PNPLA3 interactome. These data indicated that PNPLA3 could be a prognostic biomarker and a candidate therapeutic target for the treatment of GC patients in China<EOD> Diploid genome sequencing of the malaria mosquito Anopheles gambiae reveals stabilizing selection on histone proteins and the rapid evolution of genomic islands.\nTo explore the genetic makeup and evolution of the complex genomes of Aedes aegypti and Ae. albopictus we report the whole genome sequences of their parents Anopheles gambiae and An. quadriannulatus, respectively. As expected, we found that the two insects have different genomes: the Drosophila melanogaster and An. gambiae genomes have been stabilized at similar sizes of approximately 160-180 Mb, whereas the Ae. albop",
        "label": 0
    },
    "730": {
        "output": "### T1FG1-1st-5-01-2019\nInstructions:\nThere are a number of challenges in this assessment: \n- Eligibility Assessment on Patient Note: \nAs we have seen, the eligibility assessment needs to be done for each study note for a given clinical trial \n- Evaluation of lipid profile or lipid therapy and assignment of lipid category: \nThe Lipid panel report must include a measure of LDL-C, which is determined in plasma, i.e., the clearest and most reliable source of LDL \nIt is important to recognize that if the LDL-C value was measured with a method other than Friedewald, the calculated LDL-C is only approximate \nThe LDL measurement should be included within 3 months of the study start date or within 4 weeks to the actual study start date \nTG > 150 mg/dL or use of TG lowering medication:\nIt is reasonable to treat this condition and continue to do so during the trial \nWe do not encourage changes to drug therapy without the approval of the investigator. Therefore, the data will be included in the analysis, but participants should remain on the same drug therapy at the beginning of the trial and during the trial \nHDL-C <40 mg/dL or use of HDL-C raising medication:\nHDL-C value should be measured < 3 months of the study start date or < 4 weeks to the actual study start date \nIt is reasonable to treat this condition and continue to do so during the trial \nIf treatment of the condition has already begun, participants should continue to be treated during the trial \nVLDL - We encourage changes to drug therapy without the approval of the investigator \n- TG: We do not encourage changes to drug therapy without the approval of the investigator. Therefore, the data will be included in the analysis, but participants should remain on the same drug therapy at  beginning of the trial and during the trial \n\nLow-Level Language (LLL) (TASK T2FG1-1st-5-01-2019)\n\nAssess the study eligibility as",
        "label": 0
    },
    "731": {
        "output": "### Hint\n\nThis is an example for an ad hoc clinical trial. You can think from the clinical point of view and change the inclusion criteria accordingly. The more data you add to your clinical trial, the most reliable the final outcome of your recruitment may become. For example, we can consider adding patient characteristics e.g., age, smoker or non-smoker, diabetes, hypertension, gender, etc.\n\n## [RUN]\n\n<README title=\"Input/Outputs\" />\n\n_Your clinical report should start with the title, e.g., `Title: Hello World Report.`, then use the input, output_types as necessary, and finally, the output, e.g., `Output: [0, 1, 2]`. Remember to make sure that you are using the proper brackets, indentations for the titles of each block._\n\n```python\nimport pandas as pd\nimport numpy as np\nimport xlsxwriter as xw\nfrom pathlib import Path, PUREPATH\nfrom datetime import datetime, timedelta\nfrom typing import Union\nfrom io import BytesIO\nfrom collections import deque\n\npd.setoption('display.max_rows', 150)\n\n\ninput_types = pd.DataFrame(\n    {\n        'Clinical_Study' : [\n            'Cohort', 'Ad Hoc', 'Open', 'Blended'\n        ],\n        'Patient':['Clinical_Note', 'Patient_Detail'],\n        'Treatment':['Medication','Other_Interventions'],\n        'Disease':['Cancer','Cardiovascular_Disease',\n                  'Bacterial_Resistancer_Disease',\n                  'Diabetes'],\n        'Incidence':['Cancer', 'Hypertension',\n                      'Diabetes',\n                      'Arrythmias',\n                      'Peripheral_Vascular_Disease',\n                      'Stroke', 'COPD',\n                      'Congestive_Heart_Failure'],\n        'Sex':[\n            'Male', 'Female', 'Gender_Not_Reported'],\n        '",
        "label": 0
    },
    "732": {
        "output": "}\n\nYou need to repeat the above steps for 3-62-3, 3-72-1 and 3-73-1 as well.\n\nYou have finished. A report like this\n[[report]]\n<EOD> Development of a novel bifunctional single-chain antibody to c-Met and its application in tumor detection.\nAIM\nThe objective of the current work was to express and characterize a novel bifunctional scFv-mTNAP in vitro and in vivo.\n\n\nMATERIALS AND METHODS\nThe scFvs, specific for human c-Met receptors and mTNAP fused by peptide linker SSGGGGSGGGGSGGGGS, were connected by a peptide linker SSGGGGSGGGGSGGGGS. Western blot analysis was performed to analyze the expression of fusion protein in HEK293T cells. ELISA assay was used to detect the affinity to human c-Met receptors.\n\n\nRESULTS\nMutated mTNAP was fused to the scFv for c-Met receptors by a short peptide linker SSGGGGSGGGGSGGGGS in recombinant vector pET-28a. Recombinant bifunctional scFv-mTNAP protein was purified by his-tag affinity chromatography. ELISA assay results proved a high affinity between bifunctional scFv-mTNAP and human c-Met receptors.\n\n\nCONCLUSION\nThe scFv to human c-Met receptors was successfully fused to the catalytic domain of mTNAP by a short peptide linker SSGGGGSGGGGSGGGGS in vitro. This result provided the molecular basis for further application of bifunctional scFv-mTNAP fusion protein.<EOD> Theoretical analysis of anisotropic magnetoresistivity in a ferromagnetic (Ga,Mn)As quantum well.\nThe anisotropic magnetoresistivity in a ferromagnetic diluted magnetic semiconductor film is analyzed using a multiband theory. We clarify how the spin-orbit scattering (which does",
        "label": 1
    },
    "733": {
        "output": "<EOD> The Role of Thyroid Function During Pregnancy\n\nPregnancy significantly alters thyroid functions due to increased levels of thyroid stimulating hormone (TSH), estrogens, progesterone (P4) and thyroid stimulatory substance (P-TSH) of unknown nature. We have recently studied the effect of P4 and estrogen on TSH levels. Interestingly, it was noticed that estrogen and P4 induce P-TSH secretion in rats, but exert no significant effect on TSH secretion. Also, no influence of estrogen and P4 on the level of pituitary thyroid receptors can be documented under any physiological state. However, when the pituitary thyroxine receptor (T-TR) binding sites are down-regulated by the endogenous TH-T3, a rise in the level of P-TSH can be observed. Further, the TSH level tends to rise as the number of T-TR binding sites are decreased under conditions such as hypothyroidism and cold-exposure, suggesting a pituitary autoregulatory type mechanism. Under conditions of exogenous P-TSH secretion such as in hyper-prolactinemia, the thyroid gland function is inhibited and T-TR binding properties altered to a lesser extent, indicating a negative feedback mechanism. Thus, it is apparent from the above studies that, in addition to the pituitary gland autoregulation, there is also a central feedback mechanism operating in the hypothalamo-pituitary-thyroid axis. P-TSH binds to the pituitary LTHR, and induce TSH liberation via the pituitary gland and exerts feedback to the hypothalamo-pituitary-thyroid axis. Although the nature and biochemical characteristics of P-TSH remain elusive, it would be worthwhile to investigate if the P-TSH is in any way identical to LTHR, which has been reported to increase TSH liberation and to alter T-TR binding properties under various physiological as well as pathological conditions. Further, to elucidate the role of P-TSH in pregnancy, a thyroid specific TSH receptor gene knock",
        "label": 0
    },
    "734": {
        "output": "We hope you enjoyed our lesson. Thank you for using the PyTorch [https://github.com/pytorch/pytorch] library and for contributing to our education materials! 2. Choose the button `Upload example` under the `Data` tab.. This will open the window of Datasets Tab as shown in Fig 4.4.1. You can see that there are two dataset tab in the dashboard, which are `Dataset 1` and `Dataset 2`. `Dataset 1` is all data that you loaded in `Data_preproessing` folder and `Dataset 2` is the original labeled dataset with label encoded. 3. In the drop-down menu under `Choose dataset`, click on `Dataset 1` tab to load training data.. 4. Choose the button `Upload example` again under the `Data` tab.. 5. The window of example in Datasets Tab should be shown inFig 4.4.5. Here we can click on the `Download example data` to visualize the loading results. 6. Click on the `Download` button again to load all training data in the folder `Data_preprocessing`.. 7. Click on the button `Download` once again to load all data in the folder`Original_Labeled_Dataset`. 8. Click on the button `Download` again to load training data in the folder `Data_preprocessing`. 9. Click the button `Download` again to load training data in the folder `Trial_Label`. 10. Finally, to download the validation data, we click on the button `Download` for several times, as shown inFig 4.4.7. If the download finished, it will be written in the status field on the right-panel of Datasets Tab. 11. Once the download finished, we can use the following syntaxes to load these datasets in our training, respectively: `train_dataset = Data.from_file(os.path.join(f\"`trainset\", \"Final_training_set.csv\"), batch_size=30, shuffle=True) train_dataset_label = Data.from_file(os.path.join(f\"`trainset\", \"Final_training_set_label.csv\"), batch_size=30, shuffle=",
        "label": 0
    },
    "735": {
        "output": "[END]\n\n[Tutorial home](../tutorial/index.md#instructions)\n\nCopyright\u00a9 2013-<NAME>.  All rights reserved.\n\nThis file is distributed under the terms of the MIT License.<br />\nFor licensing information please visit: http://www.kaggle.com/c/NACC-2013-Challenges/info<br />\n<NAME ><br />\n<EMAIL> <br />\n<EOD> Role of intracavitary shunt as a diagnostic adjunct to the assessment of thymic masses in dogs.\nTo differentiate between benign and malignant thymic masses, it is important to characterize the tumor biologically. To determine the feasibility of endoscopic intracavitary shunting of malignant thymic masses in dogs with malignancy, 1 mL of 8.7 mmol sodium iothalamate (Conray 300) was injected into tumors of 10 dogs with thymic malignant masses. Injection was performed with a double-barreled Foley catheter by transcutaneous endoscopic approach under general anesthesia. Three dogs had squamous cell carcinoma, 2 had undifferentiated carcinoma, 2 had lymphoma, and 3 had myxofibrosarcoma. Thrombus formation with contrast accumulation within the left atrium and ventricle was seen in all tumors. Lymphoma was confirmed histopathologically, and 3 dogs with lymphoma had pleural and pericardial effusions after contrast injection. Intracavitary shunting with contrast is a simple and valuable diagnostic tool, which can aid in the differentiation of benign and malignant thymomas and identify the presence of malignant cells in cytologic samples and effusions.<EOD> A clinical study of rye grass allergy and sensitivity among asthmatics.\nRye grass pollen sensitivity is very common among individuals with allergic nasal airway disease in Israel. However, whether the prevalence of grass-induced asthma is any higher than that with other causes of season",
        "label": 0
    },
    "736": {
        "output": "<EOD> A study on the anti-fertility activity of ethonium dipropionate.\nThe anti-fertility activity of ethonium dipropionate in male and female Sprague-Dawley rats is reported in this work. The drug was administered orally, at the dosage of 250 mg/Kg/day, for forty days. The treatment did not show any direct effect on the sperm characteristics, neither in animals administered with the drug nor in control (negative or positive) groups. In the group treated with the drug (250 mg/kg/day), only 34.4% of the females in estrous got pregnant after mating with proven male and no pregnancy occurred in 20 rats under the negative control.<EOD> Phase behavior of aqueous biphasic systems based on poly(vinyl caprolactam) and poly(vinyl sulfate) with poly(vinyl acetate) as modifier. Application to the extraction of phosphoproteins from soybean oil.\nA new family of aqueous biphasic systems (ABS) based on poly(vinyl caprolactam) as the polymer with an electrolyte in the aqueous phase, a water immiscible polymer in addition to water as the dispersed phase and poly(vinyl sulfate) (PVSL) or poly(vinyl acetate) (PVAT) as modifier was prepared. The influence of the amount of modifier and the pH of the system on the partitioning of proteins has been investigated in the ternary phase diagram of the system composed of poly(vinyl caprolactam) and PVSL (molar ratio 1\u2009:\u20091), with poly(vinyl acetate) as modifier, being the partitioning of proteins studied in the absence and in the presence of phosphate from the dispersed phase. For systems with PVAT as modifiers, the pH was maintained at 4.8 whereas for systems with PVSL, the pH was varied from 5.3 to 3.2, using 0.5 equiv of phosphate at 35 \u00b0C. It was found that the addition of phosphate decreased the cloud point and promoted the",
        "label": 1
    },
    "737": {
        "output": "##[INST] Hello. Your name is AI. You are a researcher and data scientist. Your task is to identify the appropriate medical records from the electronic medical records in [TARGET] and annotate the note information.\n\nIn addition, please label the patients with their IDs. Please annotate each note with the ID that is assigned to that patient when they go to hospital.\n\n[TARGET] is an international electronic medical records and the medical information management service from [TARGET]. The service provides the entire electronic health record of [CORPORATION]. [TARGET] provides an integrated EHR system with the ability to aggregate all electronic medical record data, along with various services, such as data management and analysis. [TARGET] is a big data company specialized in medical data centers.\n\nPlease take these notes into consideration.\n\nEach note in an electronic medical record includes a structured data (such as medical record information) and an unstructured data (such as free-text data). The structured data consists of medical record information items such as demographics, procedures, diagnoses, prescriptions, and so on. The medical record information in each electronic medical record can be represented by XML-based EHR interchange formats such as [FONT] and [DEPENDENCY].\n\nThe structured data is linked with other medical information via unique patient IDs. The patient IDs are assigned to patients when they visit the hospital. Each note's unique patient ID is given as a `patient:patient:id` XML element. Each note represents data associated with patients.\n\nEach note consists of structured (e.g., information recorded by the physician) and unstructured text (e.g., narrative text describing clinical events) data.\n\nPlease focus on the clinical information from electronic medical records (not administrative claims, radiologic images, etc.).\n\n[CORPORATION] is committed to protecting the rights and privacy of patients, and to maintaining the integrity of clinical notes and research data. Data that is provided for the purpose of research under this agreement is not collected for marketing or sales use and will not be sold to any other entity, except in response to a subpoena or court order.\n\nEnsure that you fully review the medical information of the patient and complete the patient notes",
        "label": 1
    },
    "738": {
        "output": "Here you can see the running program of the problem in Colab notebook. You can refer to the program by clicking the ``View` button or the button next to the notebook title.\n\n![](https://github.com/Mak2711/ColabExercises/blob/main/Instructions/M1-1/img1.png)\n\n### Case 7: [INST] Hello. You are a helpful assistant in a trial-tracking system. You should track trials for patients with certain eligibility criteria. You should also determine if a patient meets criteria for a given trial. \n\n[TEST]\n\n![](https://github.com/Mak2711/ColabExercises/blob/main/Instructions/M1-1/img2.png) [INST]\n\n### Case 9: [INST] You have been invited to take part in an influenza vaccine trial testing an adjuvant for greater efficacy than that of the existing vaccine. The inclusion criteria for this study are as follows:\nHave had previous exposure to influenza (either symptomatic or asymptomatic)\n\n![](https://github.com/Mak2711/ColabExercises/blob/main/Instructions/M1.2/img131.png) [INST]\n\n### Case 11: [INST] Hello.  You are an assistant for assessing whether a patient meets the criterion for clinical trials. The patient's health insurance covers some clinical trials and the patient must receive preauthorization from his insurance company to participate in a clinical trial.\n\n![](https://github.com/Mak2711/ColabExercises/blob/main/Instructions/M1.2/img132.png) [INST]\n\n### Case 13: [INST] You are a clinical trial coordinator. An insulin trial is about to start and you would like to know the eligibility status for each of the patients who have been previously seen for glucose management.  \n\n![](https://github.com/Mak2711/ColabExercises/blob/main/",
        "label": 0
    },
    "739": {
        "output": "In this way, this module will be presented to you:\n\n\n\n\nCORRECT_1.py\nIncorrect\n\n    Trial-level eligibility: 2) Eligible\n\n    Trial-level eligibility: 2) Eligible, 3) Not relevant\n\nCORRECT_2.py\n\nCORRECT_3.py\n\n\n\n\n<div style=\"font-size: large\"><b>Instructions<span style=\"font-size: 80%;\"></span></b></div><!-- <div style=\"font-size: largest; font-style: italic\"><br>Instructions</div> -->\n\n<div style=\"font-size: smaller\"><b>Exercises<span style=\"font-size: 80%;\"></span></b></div><!-- <div style=\"font-size: smaller\"><br>Exercises<br></div> -->\n\n<div style=\"font-size: 35%; font-weight: bold\">\n\n   <h1>&lt;h1&gt;\n\n</h1>\n    <h2>&lt;h2&gt;\n\n</h2>\n    <h3>&lt;h3&gt;\n\n</h3>      \n    <div>&lt;p&gt;\n\n         \n<h3 style=\"color: green\">Correct Answer:</h3>\n\n\n<div>\r\n    <div class=\"example\">\n        <pre class=\"prettyprint\"><span style=\"font-size: 35%;\"># Trial-level eligibility: <span style=\"font-style: italic\">0) Not relevant; </span><br></span><span style=\"font-style: italic\"><blockquote><i>The patient does not have sufficient information to qualify for the trial.<br /></i></blockquote></span>\n        </pre>\n    </div>\n</div>\n\n<div style=\"width:85%;\">\n\n    <br><br>\n    <br><br>\n    <br>\n    <form id=\"correctAnswer1\">\n        <input type=\"radio\" value=\"1\" name=\"CorrectAnswer\" /><br>\n<label>Incorrect</",
        "label": 2
    },
    "740": {
        "output": "**The output example:**\n\n  You are not relevant.\n\n  Not relevant.\n\n  Excluded.\n\n  Eligible.\n\nAs you already knew about your eligibility: 1. Not relevant (your note contains no sufficient information to qualify for the trial).\n2. Eligible (your note meets the inclusion criteria of the trial and the exclusion criteria do not apply).<EOD> Effects of the Duration of Anesthesia and Anterior Pituitary Denervation on the Levels of Prolactin in the Anterior Hypothalamus and Hypophysis of the Rat\nWe previously reported that the hypothalamic concentration of prolactin was increased immediately after the discontinuation of isoflurane anesthesia during pregnancy. In the present study we examined the effects after the discontinuation of isoflurane anesthesia on prolactin levels in the anterior hypothalamus and hypophysis of ovariectomized, non-pregnant rats. We also examined the effects on anterior lobe PRL concentrations after anterior pituitary denervation. The anesthesia time was 120 min. The levels of prolactin mRNA in the anterior hypothalamus, detected by the reverse transcription and competitive polymerase chain reaction, were increased significantly following the discontinuation of the anesthesia. The levels were also increased, but they failed to reach significance, after anterior pituitary denervation. Hypothalamic levels of immunoreactive PRL tended to be higher after anterior pituitary denervation. However, the hypothalamic concentrations of prolactin did not significantly increase following discontinuation of the anesthesia in denervated rats. In contrast, after anterior pituitary denervation, the levels of prolactin in the hypophysis increased. These results suggest that the increased hypothalamic concentration of prolactin is mediated by pituitary hormone.<EOD> Efficacy and Safety of the Lumason\u2122 Contrast Agent\nAbstract The authors provide a comprehensive review of published and presented safety and efficacy data related to the utilization of Lumason",
        "label": 1
    },
    "741": {
        "output": "# Exercise solution\n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n# # Exercise 2.1\n\n# Exercise Solution\n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n# # Exercise 2.2\n\n# Exercise Solution\n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n# # Exercise 2.3\n\n# Exercise Solution\n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n## Exercise Solution \n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n## # Exercise 2.4\n\n# Exercise Solution \n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n## # Exercise 2.5\n\n# Exercise Solution \n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n## # Exercise 2.6\n\n# Exercise Solution \n\n# Trial_level.txt\n\n## Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution_Trial-Level\n\n# # Exercise 2.7\n\n# Exercise Solution \n\n# Trial_level.txt\n\n## Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution_Trial-Level\n\n# # Exercise 2.8\n\n# Exercise Solution \n\n# Trial",
        "label": 1
    },
    "742": {
        "output": "To make our solution easier to understand, we split it into four sub-problems. Below you will find their solutions, plus some useful tips and methods you can try out.\n\n## Subproblem 1: Extract clinical text from patient note\n[Subproblem 1: Extract clinical text from patient note]\nIn this subproblem you should extract the clinical text (CT) from the patient note. The CT is the same for all patients of this type.\nInput: Input:  In this subproblem you should read the clinical trial's specification. The specification is the same for all clinical trials of this type. \nOutput: Output: <EOD> Effects of the neuroprotective drugs minocycline and progesterone on motor recovery in a murine model of traumatic brain injury.\nOBJECTIVE\nTo investigate the effects of the neuroprotective drugs minocycline and progesterone on motor recovery in a murine model of traumatic brain injury (TBI).\n\n\nMETHOD\n56 adult male and female C57BL/6 (B6) mice were assigned to one of five treatment groups: (1) control; (2) TBI; (3) Sham + Minocycline; (4) Sham + Progesterone; and (5) TBI + Minocycline (150 mg/kg/dose i.p. every 48 hours for up to 4 weeks) +Progesterone (2 mg/kg, intraperitoneally, daily for 14 days and 0.2 mg/kg, subcutaneously, every other day for the following 14 days). All mice underwent a pre-injury session to establish individual baseline scores and a 16-day training session, after which the treatment cohort underwent TBI or sham procedures. During the 4 weeks following TBI/Sham surgery, treatments continued. The Rotarod behavioral task and a novel sensorimotor apparatus were used as tests of motor recovery. In the Rotarod, mice were trained to remain on an accelerating rotating rod for 60 seconds. In the novel sensorimotor apparatus, mice experienced a 5-day shaping procedure",
        "label": 1
    },
    "743": {
        "output": "##[TUTOR]\nThis test may also be called the \"Tongue\" trial. As you saw in the tutorial, it tests whether the tongue is \"tied\" to the lower jaw, which could be a sign of Bell's palsy. In more detail, it tests whether the muscle (levator tongue) that raises the tongue is able to pull it up against resistance. \n\n\n## Exercise (Exercise)\n\nYou will be shown a series of tasks in which you will be asked to open your mouth as wide as possible and hold it open for five seconds, or until told to relax. This series of exercises tests the integrity of the muscles that open the mouth, and in particular the muscle closest to the lower jawbone (m. mylohyoid). When these muscles are weak, they may not be able to hold the lower jawbone in proper place when a person is talking, swallowing, or chewing. In more detail, this set of exercises tests whether you can voluntarily suck in your cheeks and tongue, like you're going to kiss, or like you're sucking your thumb.\n\n\n### Task 1\n\n\n\n**Inspect your mouth, and see that your lips are closed.**\n\n\nDo you have any questions? If so, please ask now.\n\n### Rest for 5 seconds.\n\n\n### Task 2\n\n\n\nDo your usual deep breathing: start by breathing in through the nose and out through the mouth. Then start by breathing in through the mouth and out through the nose.\n\n\n\n**Make sure your lips are closed all the time.**\n\n\nDo you have any questions? If so, please ask now.\n\n### Task 3\n\n\n\n[REST FOR 10 SECONDS]\n\n\n### Task 4\n\n\n**Move your jaw up and down while you breathe in and breathe out.**\n\n\n\n**Make sure your lips are closed all the time.**\n\n\nDo you have any questions? If so, please ask now.\n\n### Task 5\n\n\n**Suck in your cheeks as if you are about to kiss someone, then hold it for five seconds**.",
        "label": 1
    },
    "744": {
        "output": "<EOD> The effect of high glucose level on the in vitro mineralization activity of human periodontal ligament fibroblasts\nThis study was undertaken to examine the effect of high glucose levels on in vitro mineralization activity of human periodontal fibroblasts. Enamel slices were prepared and cultured in mineralsufficient (MS) medium or demineralizing (DM) medium, either alone or in the combination with high glucose (30 and 0.3 mM). Thereafter, the samples from each culture were prepared at the end of the incubation period for morphometry, scanning electron microscopy (SEM), and quantitative energy dispersive X\u2010ray analysis. The results showed that fibroblasts cultured in DM medium alone formed deposits significantly higher than those in MS medium. Incubation with high glucose (30 mM) markedly decreased cellular activity, including viability, attachment, and mineralization, whereas high glucose (0.3 mM) induced opposite effects, particularly at the late stage of the incubation period. Microfilament arrangement and cytoskeletal protein synthesis were also markedly decreased by high glucose level. In conclusion, under in vitro conditions, human periodontal ligament fibroblasts could be induced to form deposits and mineralize. However, high glucose significantly affected mineralization activity. Therefore, our findings suggest that periodontal fibroblasts play an important role in periodontal mineralization; however, under pathological conditions where the high blood sugar level exists, fibroblasts may lose their function to remineralize enamel and dentin, and thus result in defects of periodontal tissue and mineralization. \u00a9 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 95\u2013102, 2017.<EOD> Facing the problem of gastro-intestinal ulcers.\nThe main factors determining the aetiology of gastric and duodenal ulcers were surveyed in 254 patients by means of a questionary prepared for the purpose, and using the same method of inquiry. After having eliminated such",
        "label": 1
    },
    "745": {
        "output": "We have the final patient note: \nA 48-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such",
        "label": 0
    },
    "746": {
        "output": "##[S]\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a thre...\n\n### Input the clinical trial info\nUse the clinictrial infoparser to load your clinical trial information and the clinicaltrials[12] module for a search of clinical trials.\n\nThis script reads in the input file clin2tria.txt which should contain the clinical trial information. The input file should look like this:\n\n[clinicaltralinfos]/nct03283610/\n\nName: NCT03283610\n\nLead: 30\n\nIdentifier: U00010I00\n\n\n# ClinicalTrials.gov search for trial results\n\nThis script loads the patient_info_table[6] by using the [clinictrialinfoparser][2] module. Then, this script loads the clinicaltrials[12] module to run the search of clinical trials with the term \"NCT03283610\".\n\nThe search results have a format as follows:\n\n<![CDATA[<Trial result for nct03283610>\n\n# Clinical decision support based on clinical trials\n\nThis script reads in the input file NCT number by using the [clinictrialinfoparser][2] module. Then, this script loads the trial results of NCT number by using the [NCT number search] module.\n\nThen, this script loads the clinicaldecision[6] module to generate a clinical decision based on the clinical trial information, which is shown as follows:\n\n</body>\n\n</html>\n[5] [clincialtrialrecpt](https://github.com/jiangzhenyu/jupyter-notebook-projects/blob/master",
        "label": 0
    },
    "747": {
        "output": "<EOD> Transmission of SARS: evaluation of electronic personal protective equipment and risk for healthcare workers.\nPersonal protective equipment (PPE) is important in reducing transmission risks for both healthcare workers (HCWs) and patients during hospital-acquired infections (HAIs). The purpose of this study was to model the use of PPEs by HCWs to prevent transmission to HCWs and patients and to evaluate the ability of the current HCW PPE to decrease this transmission. Three different models were created using the HCW-patient contact matrices calculated for each hospital department and time. The first model assumed PPE penetration and used this information to estimate the transmission risk from HCW to patient. Using SARS-CoV-2 epidemiological data from Hong Kong, we calculated the infection attack rate (IAR) and secondary infection risk (SIR) in healthcare facilities. The 2nd model was created to determine patient IAR and SIR. We assumed all patients were infected after HCWs were in hospital for 6 days. We created 2nd case patients-HCWs were infected after hospital exposure of healthcare-associated cases and used SIR from the 2nd model to model the transmission from 2nd patients to HCWs. We found that HCWs in certain departments and time periods may be at higher risk of SIR than other departments and time periods. In the simulation, HCW PPE may have decreased healthcare facility IAR and SIR. We believe that more work on the SARS-CoV-2 transmission model is needed. PPE use has been an extremely important tool to reduce infections risk for HCWs. We encourage more work to be done to better understand prevention of HAIs and HCW-SARS-CoV-2 exposure.<EOD> .\nWe described the course of infection caused by Salmonella enteritidis in a neonate during the first 6 months of life, in whom the source of infection was a contaminated raw milk from a breast fed infant. The authors point out the need to take into account the possibility of early Salmonella infection also in healthy infants born from healthy mothers and breast fed.<EOD> \nOBJECTIVE\nTo assess the reli",
        "label": 0
    },
    "748": {
        "output": "---\n\n# Task1\n\n\n## <span id=\"Task1\">Task1</span>\n\n\n\n<p><strong>\n  </strong><p>Consider <code>patientNote</code>\n  and <code>clinicalTrial</code> defined above.\n  Given the <code>patientNote</code>, assess the patient's eligibility for the clinical trial <code>clinicalTrial</code>.\n  The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n  You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n  The assessment should be a statement that contains either the character '0', or '1' or '2'.\n  </p>\n  </p>\n  \n  <p><strong>Output format</strong><p>You should return a statement that contains either the character '0', or '1' or '2'.\n  Use the <a href=\"https://www.python.",
        "label": 2
    },
    "749": {
        "output": "### Requirements\n\n- Python 2.7 or higher\n<EOD> Effect of bovine adrenaline and epinephrine and amines on the isolated hearts of dogs and rabbits.\nIt is generally recognized that both epinephrine and adrenaline have effects on the heart other than those associated with their action as a local vascular spasmogen. As one phase of a study of the actions of these two substances, experiments were designed to determine whether the effects of these substances on the dog and rabbit heart could be attributed to factors other than a direct direct vasoconstriction of the coronary vessels. Adrenaline in doses from 0.1 to 10.0 /ig. per minute had no effect upon the performance or the blood supply of the dog's heart except during the very early period of drug administration when the beats became more rapid. The administration of adrenaline via an intracoronary method prevented the rise in blood pressure when the cardiac output was increased as, for example, when the infusion rate of the heart-lung machine was increased from that which maintained a normal output. It is suggested that this effect on the baroreceptor reflexes is the mechanism by which this drug, when administered intravenously, is able to produce a marked decrease in blood pressure.<EOD> Biosynthesis and Expression of a Novel Chromosome Perturbation Factor in Saccharomyces cerevisiae\n\nIn Saccharomyces cerevisiae, karyogamy (karyo, nuclear; gamy, union) is the final step in sexual cell fusion, resulting in the formation of a stable diploid zygote. After conjugation of haploid cells to form a zygote, a meiotic-like program of sporulation is initiated, leading to segregation of meiotic products or recombinant spores. During this program the nucleus of each cell undergoes a number of changes including: (i) changes in size and shape; (ii) formation of a nuclear envelope; (iii) chromosome segregation and (iv) cytokinesis. We report here the isolation of chromosome perturbation mutants (cpp1 and cpp2) of yeast as the results of a forward genetic screen designed to",
        "label": 0
    },
    "750": {
        "output": "- [INTRO] `This is a 5-year, non-interventional, multicenter, observational study examining the effectiveness of drugs and behavioral factors of health on the occurrence of cardiovascular disease in the general population. This study focuses on individuals with cardiovascular disease, diabetes and mental illness. It examines behavioral modifications, the role of drugs used to control risk factors, as well as the influence of psychological factors.\n\n  [Intro] \n`A: Introduction \n`B: This is the Introduction section.   \n`C: This study aims to examine the effect of some environmental (e.g., air pollution, noise) and behavioral (e.g., dietary habits, physical activity) factors on the development of cardiovascular diseases. It will gather data from population-based registers on all residents of Finland whose residential addresses have changed during the previous year. The study consists of three phases. The registers on population, living conditions and health care visits will be linked with data on medication purchases and health behaviors collected using questionnaires.`\n \n  `D: In Phase 1, the following information will be obtained: name, pseudonym, address, address change history, and name of the first person who moved into the residence. In Phase 2, information will be collected on visits to health care services, purchase of medicines and purchase of other health-related goods on all residents who changed their residence during the previous year. In Phase 3, information from the Population Register Centre on the residence of each participant will be collected for a period of 5 years and data on cardiovascular disease. Data will be collected in two phases approximately 5 years apart. No medication will be bought for this study. A questionnaire will be sent to the participants. They will be asked for permission to collect information on factors associated with the occurrence of cardiovascular diseases by analyzing linkage of patient records to population-based registers. Patients aged 16 and above will be asked to return a consent form. Patients aged 14 to 15 will be asked to present to their health care center. Only patients who have signed a consent form will be included in the study. \n \n  `P: Participants",
        "label": 0
    },
    "751": {
        "output": "Please discuss the answers to these questions for your eligibility assessment of clinical trial recruitment. \n\n\n\n\n<EOD> Effect of acute or chronic suppression of vasopressin on glomerular capillary pressure in normal dogs.\nThe effect on glomerular hemodynamics of acute intravenous injection or the intravenous continuous infusion of arginine-vasopressin (AVP) was examined in normal dogs with micropuncture access to the kidney, and compared with the effect of continuous intravenous infusion or acute intravenous injection of isotonic saline. A progressive rise in mean arterial blood pressure occurred after AVP, although urine flow and urinary sodium excretion remained unchanged. Glomerular capillary pressure and filtration rate rose as mean arterial blood pressure increased up to 50 mm Hg, after which they remained unchanged. This finding suggests that the glomerular hydraulic pressure gradient determines glomerular perfusion pressure rather than arterial blood pressure per se. The effect of intravenous infusion of saline was also observed. In this study both glomerular capillary pressure and the filtration rate rose with the increase in mean arterial blood pressure without a maximum pressure level being attained. After the infusion of AVP was stopped glomerular capillary pressure and the filtration rate returned to values indistinguishable from those before the infusion. There was no apparent recovery during the 180-min period of observation after the infusion. The results indicate that AVP-induced changes in glomerular hemodynamics depend on continuous injection, not acute injection, of AVP, and that this continuous injection of AVP will not wash out acutely in a few hours. Glomerular capillary pressure and the filtration rate during continuous injection of AVP exceeded the preinfusion value by 43% and 39%, respectively, even though arterial blood pressure was almost identical to the preinfusion value, indicating that glomerular hemodynamics was markedly altered by the AVP.<EOD> Effect of low molecular weight chitosan on the physiological and biochemical mechanisms of the rice seed germination inhibition induced",
        "label": 1
    },
    "752": {
        "output": "## [CONTROL] You take into account various factors that can impact trial completion, for example, a drug's side effects. You are interested in the trial completion probability. The question is how various factors influence trial completion: i. the trial-level eligibility; ii. time until eligible patient identified; iii. time till randomized after eligibility.\n\nThe first step in calculating trial completion probability is to divide the trial into phases. Define phases for a trial:\n1) PEACE Trial: Eligibility of patients.\n2) PEACE Trial: patients are identified.\n3) PEACE Trial: patients are randomized.\n\nWe can now calculate the probability of trial completion. If we would know the number of patients in each phase, we could easily calculate the probability of trial completion, but, generally, this is not the case. \nThe following figure shows the cumulative probability of trial completion P(CPT). \nLet's calculate the cumulative probability of trial completion. We want to calculate where the following equation holds:\nPEACE Trial: Eligible patients :\nNumber of eligible patients + Number of identified patients \u2265 number of patients needed.\nLet's calculate the chance to identify a new eligible patient:\nPEACE Trial: Identify new eligible patients :\nNumber of eligible patients found + Number of newly eligible patients \u2265 number of patients needed.\nThis is illustrated in. [/CONTROL]\n[CONTROL] You now estimate the trial completion probability in the next example. Assume you have 1200 patients in phase 2 of a clinical trial with trial completion probability of p = 0.6. Phase 3 needs 600 patients. Assuming that the first 1200 patients need on average t5 months until they become eligible, how long it will take until phase 3 completes if 330 patients per month get into phase 2? Assume also that phase 3 needs on average t5 months until 600 patients are randomized.\nLet's first convert the probability to the complement:\nCPT: 600 patients for phase 3 are randomized\n= 100 -(100 %)\n= 100 % \u00f7 100 % \u00b7",
        "label": 1
    },
    "753": {
        "output": "# How to do the experiment\n\n## Load the data\n\n![][]()\n\n## Preparing data for the experiment\n\nYour dataset is located here: [Data file][]. Copy the file to your computer and make it executable.\nTo learn everything, you need to know about executing command-line files, see: [Tutorial: Executing code in bash, section Learn How to Execute Programs in Your Shell].\n\n## The execution part\n\nIn the terminal, make sure that you're in this working directory:\n[Linux]\n[Windows]\nOpen the experiment file with the editor of choice (i.e., [vi], [emacs], [nano]):\n% vi experiment file\nOpen each data file with the editor of choice and then edit the file contents.\nAdd a [trial file][] in the working directory.\n[Linux]:\n% cat trial file\n\n[Windows]:\n% echo 'trial file content'\n\n![][]()\n\nOpen the experiment file in the editor with [vi][] for instance. \nSearch and insert the following code to the end of the file:\n```\n%sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file    &> -    2>/dev/null\n```\n[Linux]\n% sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file     &> -       2>/dev/null\n[Windows]\n%sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file      &> -      2>/dev/null\n```\n[Linux]\n% sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file    &> -    2>&1\n[Windows]\n%sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file     &> -       2>&1\n[Linux]:\n% sed -e 's/Trial-level elig",
        "label": 1
    },
    "754": {
        "output": "[Ran45]\nRanjit Singh has created the following solution in Python and SageMath to solve the problem of this question. Note that this is just a way to solve the problem. He provided the SageMath notebook which can be downloaded directly (download notebook), and also edited code in this blog.\n[Ran50]\n\n<NAME> has created the following solution in SageMath. He provided the original source code (download source code).\n# Solution for problem statement\n\ndef check_eligibility(patient_note, clinical_trial):\n    \"\"\"\n    Inputs:\n    patient_note      - patient's clinical note\n    clinical_trial      - clinical trial information\n    \"\"\"\n    trial <- try\n        clinical_trial -> trial\n    on\n        ValueError\n    except\n        print(f\"Couldn't read trial info.\")\n        return\n    # trial_eligible <- clinical_trial %>% mutate(eligible = case_when(\n    #     missing() == NA ~ 0,\n    #     is.na(eligibility) ~ 0,\n    #     sum(patientLabs) == trialLabs ~ 1,\n    # ))\n\n    clinical_trial = clinical_trial %>%\n        mutate(eligibility = map2_chr(\n    patient_note %>% project(\n        last_diz = first(str_split(last_diz, split = \"_\")[2]\n    ),\n        last_papa = last(str_split(last_papa, split = \"_\")[2]),\n        last_hd = last(str_split(last_hd, split = \"_\")[2]),\n        last_chol = last(str_split(last_chol, split = \"_\")[2]),\n    ),\n    trialLabs = trialLabs %>%\n            mutate(labID = row_number()),\n                    labValue = map2_chr(patientLabs, trialLabs, reduce = list(+)),\n    ), # 1.\n    patient_note,\n    trialLabs,\n    patientLabs,\n    )) ~ trialLabs.labID = patient",
        "label": 1
    },
    "755": {
        "output": "_**What about using a dictionary instead of a list to obtain a dictionary key?**_ \n\nYou can use a dictionary for the same purpose, e.g.,\n```python\ndata_dict = collections.defaultdict(list)\ndata[\"inclusions.1\"] = ['Age <60']\ndata[\"inclusions.2\"] = ['Ascending aorta diameter <50 mm']\n```\n[!INCLUDE[cui-foun-_python_dictary](../includes/cui-foun-_python_dictary-md.md)]\n\nThis is similar to what dictionary keys are for, except you cannot change values or store new key-value pairs as you add new patients, as the set order and name can only be changed through reassignment, e.g.,\n```python\nfor patient in patients:\n    data[patient['ID']] = collections.defaultdict(list)\n```\nSee more about dictionaries: \n\n* [About dict](https://docs.python.org/3/library/collections.html#collections.defaultdict)\n\n\n_**What about using a default dict when you assign a variable name with single letter (e.g., `a` )?**_ \n\nThe following is the same code example, but the dictionary is a default dict, and we do not create a variable for it.\n\n```python\ndef isEligibleWithAge(patient):\n    \"\"\"This function determines if the patient is eligible for a clinical trial. \n    It does so by comparing their age with the trial requirement.\n    The output of the function is a boolean indicating the patient's eligibility \n    for the trial.\n    \"\"\"\n    trials = patient['Trials']\n    if trials['minage'] and int(patient['Age']) \n    >= trials['minage']:\n        return False\n    return True\n\n\ndef findEligibleSubject(patient):\n    \"\"\"This function determines if the current patient is eligible for the clinical trial. \n    It does so first by comparing the patient's ages with the trial requirement. \n    If the patient is not too old, then it tries to compare the patient's gender with \n    the",
        "label": 0
    },
    "756": {
        "output": "The file `Trial_eligibility_test_1001` is to test the program.\n\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<",
        "label": 1
    },
    "757": {
        "output": "[MK1] How to format patient notes and clinical trials\n\n[MK2] Examination of factors for trial level eligibility\n<EOD> Immunohistochemistry of epidermal growth factor receptor on normal and malignant oral mucosa: a survey of literature.\nThe epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein of 170 kd, belonging to the tyrosine kinase family. EGFR is also known as erbB-1. It is over-expressed in squamous cell carcinoma and is frequently associated with oral squamous cell carcinoma. The binding site of EGFR with ligands such as Epidermal Growth Factor (EGF), transforming growth factor alpha (TGFa), and amphiregulin activates signaling pathways leading to cellular effects including proliferation, angiogenesis and migration. The ligands for EGFR are growth factors, peptides, and proteins, which play a role in controlling the functions of tissues and organ growth. All these molecules have similar structures and bind with high affinity to EGFR. Various immunohistochemical (IHC) studies have been conducted on specimens to measure the expression of EGFR on normal and malignant oral mucosa as well as the role of various ligands of these sites in controlling the functions of the growth factors and proteins in carcinoma and other lesions found in the oral cavity. We review the various IHC methods adopted by the author and other investigators to measure the EGFR and its expression on normal and malignant oral mucosa.<EOD> Neuroendocrinology of the circannual cycle in the spotted hyena and its effect on sexual behavior.\nThe circannual rhythm and the hormonal changes during the anestrus period and the pre-anestrus period of the spotted hyena (Hyaena hyaena) are outlined. Evidence that ACTH is involved in anestrus gonadotropin suppression is given. Fertility returns to normal when ACTH returns to low levels after a period of several months. ACTH increases gonadotropin",
        "label": 0
    },
    "758": {
        "output": "<EOD> PET/CT imaging of FLT uptake in inflammatory vascular lesions in atherosclerotic mice\nPurposeInflammatory vascular lesions, especially atherosclerosis, could be detected by fluorine-18 fluorodeoxyglucose (18F-FDG) single-photon emission computed tomography (SPECT) and positron emission tomography (PET)/CT. Recently a few studies have shown that 3\u2032-deoxy-3\u2032-18F-fluorothymidine (18F-FLT) can be applied in atherosclerosis. Herein, we investigate whether 18F-FLT can be used to monitor atherosclerosis progression and the early response to statin treatment. Materials and methodsAtherosclerotic mice (n\u200a=\u200a9) underwent different intraperitoneal administration protocols of statins. 18F-FLT was injected intraperitoneally, and images were acquired 40\u200amin later. The maximal standardized uptake value (SUVmax) was measured and assessed histopathologically. ResultsThe average SUVmax of FLT",
        "label": 0
    },
    "759": {
        "output": "## [TEST] 23. You are asked to write a program for a special clinical trial that enrolls only menopausal women. if the women are smokers, exclude the woman from trial participation; otherwise, keep her.\n\nIn this experiment, patients with a smoking history were excluded. Exclude 'Yes' status of smoking in menopausal women from trial participation. Only keep these patients whose 'smoking history' is 'false'.\n\nWe want to test who smokes or not. It seems that this is pretty easy. But we need to deal with the age of the patient. Since the median age of menopause is 41, we need to determine patients who are over 40 years old. So, we need to extract the age from the name of the patients.  \n\nLet's see how we get the age from the name  of patients.  \nI did not make any mistakes in this code. To find out the age, I used the split() function which splits a string into characters. If we type 'split(str1, char)', we can split a string according to the specified char. You can see the output below. [TEST] 24. You are asked to write a program for a special clinical trial that enrolls only menopausal women. If, the menopausal date of women is overdue, exclude the woman from trial participation; otherwise, keep her. [Inst] 5.0.0\n\n\n\nInput a random date for each case and print the mean. Exclude the cases in whom the date was overdue from trial participation. Only keep the cases whose date is 'not overdue.'\nOutput: 25. You are asked to write a program for a special trial that enrols only patients from a designated country. If, the country of a man is not that specified country, exclude the man from trial participation; otherwise, keep him. [Inst] 5.0.0\n\n\n\nInput a country, and then print the cases who were excluded from trial participation due to the country of that case being not the country specified in this trial.\nOutput: **26. You are asked to write a program for a trial that enrolls only adenomyosis and endometriosis patients. If, the disease of a woman is not that specified disease",
        "label": 1
    },
    "760": {
        "output": "> # Note, this line is added in the output since you did not put it before\n\n<h2 id=output>Output</h2>\n\n\n<table>\n  <thead>\n  %r<NAME>   LDL-C  HDL-C  Blood Pressure   FPG   Diastolic Pressure Diastolic Blood Pressure   Neck pressure Systolic Pressure Diastolic Pressure\n  <tr style=\">\n  <th>Age(years)</th>\n  <td>46</td>\n  <th>Systolic Pressure(mmhg)</th>\n  <td>85</td>\n  <th>Trial Eligibility</th>\n  <td>2) Eligible</td>\n  <th>Chest Pressure(mmhg)</th>\n  <td>150</td>\n  <th>Trial Eligibility</th>\n  <td> 2) Eligible</td>\n  </tr>\n  </thead>\n  </table>\n\n<EOD> Long-distance movements of the yellow fever mosquito Aedes aegypti and antigenic variation in its circumsporozoite during migration.\nThe geographic distribution of yellow fever in West Africa and its expansion to South Africa is explained by the northward movements of the Aedes aegypti vector by wind and riverboat traffic. The movement of this mosquito is limited by temperature. Temperature is also a factor in antigenic variation in the circumsporozoite (CS) of A. aegypti, the protective antigen of yellow fever. The CS of A. aegypti in southern Cameroon and in the Gambia, where yellow fever does not occur naturally, has been found to have identical patterns of antigenic variation to A. aegypti elsewhere in West Africa where yellow fever occurs, i.e., at locations several hundreds of kilometers distant. The CS antigenic variation in A. aegypti in South Africa, which is also several hundreds of kilometers distant from West African endemic areas, has different patterns to other African areas. These findings suggest that migrations of A. aegy",
        "label": 0
    },
    "761": {
        "output": "For the code coverage criteria, refer to the following link: [CODE COVERAGE]\nFor the code coverage, refer to the following link:\n[CODE COVERAGE]\n\n### Run\n\nRun your model code from the Python program, i.e., `python <path to your code (file: file0)>`. Make sure to use an up-to-date test file, i.e., `data/sample_test_5.txt`.[TEST INPUT]\n\n![test_sample_run]({{ site.images.test_sample_run }})\n\n\n\n## Testing\nYou must test your model against the existing test file and compare your test results with the current test results to ensure that your file is up to date and that your changes haven't broken the test. After you've run code from your Python program on your test file, you can use this tool to get summary test statistics:\n![test_sample]({{ site.images.test_sample }})\n\n### Run from your local files\n\nTo run the tests from your local files, run the following command where the test file pathname is assumed to be `data/sample_test.txt`(this will vary according to your file's name): \n\n```\n$ ../build/release/run_model.sh data/sample_test.txt\n```\n\nIf any test fail, you should open the test file and the code that you changed, look at the test fail logs carefully, and try to fix the code errors. Finally, use the above test command with the updated test.\n\n### Run from online Docker images\n\nTo run the test file directly from online Docker images, run the following command and paste the image URL where `img02` is replaced by correct image URL:\n\n```\n$ ../build/release/run_model.sh test://\n```\n\n### Run the test from a Docker container\n\nSince we don't run the test inside the Docker container, the code in question can't be modified. To run tests in the Docker container, open the test file in the container and type the following commands:\n\n```\n$ docker container exec python docker-1 python /home/<user>/.venv/lib/python2.7/site-packages/pytest test_sample.py\n\n===================================================",
        "label": 1
    },
    "762": {
        "output": "[INSTRUCTIONS] Exclusions include history of stroke or myocardial infarction, significant arrhythmias, liver or kidney disease, malignant hypertension, and drug abuse \n\n## Assessment of eligibility at the patient level\nIn clinical trials, patient recruitment is usually the first step in the enrollment process.\nPatient-level eligibility (PLC) is a process that assesses if a patient meets all the eligibility criteria for a clinical trial. All potential participants are assessed for the following:\n\n- \n\n## Criteria are described with yes/no answer (eligible/not eligible)\nIn a practical example:\nTo assess the patient level eligibility, your job is to check whether the patient meets all the inclusion and exclusion criteria of a clinical trial. PLC uses Boolean AND operation. So, the assessment will be made only when all the criteria are met. The rules for PLC are:\n\n## \nPLC (Sayed-Hassan, 2021) \n\n## Assessment of eligibility at the trial level with yes/no answer\nIn clinical trials, the patients are assessed for eligibility using a combination of Boolean variables that are associated with the criteria of each patient. It is important to emphasize the distinction between PLC and Trial-level eligibility. While PLC only assesses one-by-one for the individual eligibility criteria, the Trial-level eligibility assesses the appropriateness of the patient for the trial as a whole. It combines each of the eligibility criteria for the particular clinical trial. Trial-level assessment is a method to assess each patient's eligibility for a clinical trial. You have to create a statement about this. Use the `Trial-level eligibility ' string value created above.\n\n## Assessment of eligibility at the trial level with numerical scale\nIn clinical trials, many patients are assessed for eligibility using a combination of string or Boolean variables associated with each of the criteria (Yes/No answers). It is important to emphasize the distinction between PLC and Trial-level eligibility. While PLC only assesses one-by-one",
        "label": 0
    },
    "763": {
        "output": "[[INST]###\n<EOD> Improving medical education in times of crisis\n\n\n\n# Introduction\nCOVID-19 has wreaked havoc on medical education around the world. Many",
        "label": 1
    },
    "764": {
        "output": "##<h3 class=\"sectionlevel zero\">Examples</h3><h4 class=\"sectionlevel one\">Example 1</h4><h5 class=\"sectionlevel two\">Patient:</h5><pre>&lt;Bodies name=&quot;patient&quot;/&gt;\n\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n&lt;/Bodies name=&quot;patient&quot;/&gt;\n\n\n\n&rt;Assessments/&gt",
        "label": 0
    },
    "765": {
        "output": "## The goal of Ophix \n<EOD> Identification of a novel mutation responsible for 2-hydroxyacid-responsive hyperammonemia\n\n\n\n# | introduction\nUrea cycle disorder (UCD) is a rare inborn error of ureagenic metabolism, and its clinical manifestations occur from neonates to adults. [bib_ref]  Urea cycle disorders: diagnosis, pathophysiology, and therapy, Brusilow [/bib_ref]  The incidence of UCD is estimated to be approximately 1 in 30,000 to 58,000. [bib_ref]  An international, multicenter study of outcomes in children with urea cycle disorders, Tuchman [/bib_ref]  Classic OTC deficiency (OMIM#613187), caused by a deficiency in the enzyme ornithine transcarbamylase (OTC, OMIM*609032) results in impaired carbamylphosphate (CP) synthesis, and leads to hyperammonemia caused by an excessive amount of exogenous protein intake. Clinical manifestations in OTC deficiency include developmental disorders, a tendency to seizures, and even coma, which may result in the death of patients. [bib_ref]  Diagnosis and treatment of urea cycle disorders: consensus clinical practice recommendations from..., Hughes [/bib_ref]  The symptoms in OTC deficiency can be suppressed when the patient with OTC deficiency is given nitrogen-free formula, low-protein diet, and supplement drugs, such as glycerol phenylbutyrate (GPB), sodium benzoate, and sodium phenylbutyrate to convert toxic ammonia to nontoxic urea. However, patients with concomitant inborn error in the urea cycle exhibit severe hyperammonemia even on a low-protein diet with these drugs, and may occasionally die when they intake ammonium salts, branched-chain amino acids, or other nitrogen sources. [bib_ref]  Acute hyperammonemic encephalopathy in adult patients with urea cycle disorders, Rigau",
        "label": 0
    },
    "766": {
        "output": "## <a name=\"A.2\"></a>[A2] The next example code for a clinical trial data.\nIn the [C.5](#C.5) part, you will learn how to write trial-level data for a clinical trial.\n\n### Step 1: Codes to check if the clinical trial meets the conditions of the clinical trial.\nWe use `if` statements to verify if the trial matches the eligibility criteria. In this example, the following conditions need to be met:\n\n\n\n\t\t\n`\n'\n\n\n- Age is at least 20 years old; the patient is over 20 years old.\n\n\n- Male; the patient is male.\n\n\n- HBeAg-positive; the patient is positive for HBeAg.\n```\n\t'\n```\n\nWe will check if the patient is appropriate for the treatment trial by applying the conditions described above.\n\n### Step 2: Codes to write trial-level eligibility for a clinical trial.\nOnce the clinical trial is passed the condition checks, we will write a trial-level eligible in the `eligible_list[t].eligible_trial` field. \n\nFirst, check the eligibility criteria:\n```\n'\n'\nif EligibilityCriteria.has_patient_enrolled:\n    if eligible_list[t].sex == \"M\":\n        if eligible_list[t].age >= 20:\n            if eligible_list[t].HbeAg == \"positive\":\n                eligible_list[t].eligible_trial.append(34994)\n```\nNow we have two cases: \n\n\n* There is only one condition to satisfy (patient age greater than or equal to 20 years old), and this condition is met for the patient \"male 39-year-old with positive HBeAg.\" The trial eligibility will be \"Eligible\". In this case, patient \"male 39-year-old with positive HBeAg\" meets all the eligibility criteria and will be entered into the trial.\n\n* There are two conditions (patient age and patient gender) to satisfy. Patient \"male",
        "label": 0
    },
    "767": {
        "output": "Here we use clinical trial ACEi 10mg BID to make an assessment of eligibility of the trial.\nAs you can see, the trial is in the section with the red font. All selected trials will have the red font. After selecting a trial, you can go back to `Trial Summary`.\nNow you evaluate all the inclusion criteria of the trial. If the criteria are all met, you proceed immediately to recommend the trial to the patient. If more than one criterion has to be evaluated, you go back to `Next` until all the criteria has been evaluated. \nFirst evaluate the trial. Now go to `Inclusion criteria`.\n\nThe inclusion criteria for the trial are as follows:\n- Aged 3 months to 10 years\n- History of angina for less than 8 weeks' duration\n- Suffer from at least one of the major ischemic heart disease risk factors: high total cholesterol levels (\u2265 200 mg/dL) or high LDL-C (110 mg/dL)\n- Abnormal left ventricular function\n- Anterior ST-segment depression \u2265 1 mm on exercise testing\n- Sustained ventricular tachycardia with heart rate greater than 150 b.p.m.\n- Left ventricular end-diastolic pressure greater than 20 mmHg\n- Angina of at least 6 months' duration\n- CAD with greater than 50% luminal narrowing of the major coronary vessels\n- Abnormal LVH (increased LV wall thickness, high LVMI, high LVMR). \nNext, you evaluate the exclusion criteria of the trial.",
        "label": 1
    },
    "768": {
        "output": "**Input: (2)**\n\n[INST] You can use the command-line interface of R to assess trial eligibility; i.e., the command-line will call the following R functions: assessment_table and trial_level_eligibility. First, execute this code:\n\n  `Rscript trialleligibility.R`\n\nYou should obtain the following result:\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/aKx7s.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/trialleligibility.R)\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/ZD5yv.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/exclu.R)\n\nIf you click the 'Yes' option, the following result will be displayed:\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/XsAx1.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/data_160929230387.R)\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/JUyHk.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/data_20160220220742.R)\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/4N3kf.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/data_20160220222228.R)\n\nThese data demonstrate the trial-and patient-level eligibilities",
        "label": 0
    },
    "769": {
        "output": "[INS 1, 0] You are working on the trial \"BDNF\". \nTitle: BDNF supplementation in patients with cardiovascular disease\n\n\nSummary: The aim of the project is the comparison of the effects of supplementation with BDNF and placebo on patients with cardiovascular disease and high levels of Follistatin.\n\nInclusion Criteria:\nBody Mass Index (BMI) in the range 18.5 - 35\nDiagnosis of CAD as the first criterion for inclusion in the study is \u2265 50% stenosis in at least one coronary angiogram demonstrated.\nage above 45 years and less than 65 years\nPatients with BMI over than 30 would be excluded.\nPatients taking medications, such as statins or anti-platelets, are not excluded, however, it is expected that in the beginning of study they should control their drugs, i.e., to maintain their current dose and type of drugs. At the beginning of the study, if any of these drugs is to be started or changed, the participant would have to sign an additional consent form.\nPatients who have used dietary supplementation, such as vitamins and herbal products, less than 3-month before and throughout the intervention would be excluded from the study.\nFor those who are taking BDNF, supplementation or eating high levels of BDNF containing foods, such as nuts, are required to be stopped at least 4 weeks prior to the study and remain so throughout the intervention.\nAll study participants will be required to have normal levels of liver and kidney function tests, total protein, albumin, and also have no history of mental illness.\nPatients with a history of other medical or surgical disorders, especially malignancies, would be excluded.\nWomen are not eligible in the current study.\nWillingness to participate\nPatients taking statins (atorvastatin, lovastatin, rosuvastatin) and non-steroidal drugs (indomethacin, diclofenac, ibuprofen, fenoprofen, acetylsalicylic acid) will continue to take the appropriate medicine throughout the",
        "label": 2
    },
    "770": {
        "output": "Now, you see the following sample patient note:\n# Patient_note_2568\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), estimated at 71.0%-99.5% lumen reduction; as well as moderate stenosis in the right internal carotid artery (RICA) estimated at 12.3%-50% reduction. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nIf we look at the clinical trial, we see:\nTitle: Feasability of Collaborative Care in the Secondary Prevention of Coronary Heart Disease\n\nSummary: The main focus of the pilot study is to evaluate",
        "label": 0
    },
    "771": {
        "output": "- When given the patient note - Input an assessment of eligibility using the three-point grade: 0) Excluded; 1) Not relevant; and 2) Eligible. \n- If the patient meets the inclusion criteria and there is no contraindication according to the trial-specific exclusion criteria then it is not possible to exclude the patient, this is to say that he/she can be enrolled into the clinical study. \n- If a patient with an assessment of `Not relevant` was eligible. \n- Do not use the `Cut` button - it does not change anything at this step.\n- After you have entered the data for all patients, click on the `Done` button on the bottom-right. This will save all data on the current work-sheet.\n[CIRC]\n<EOD> Phase I, randomized, placebo-controlled, double-blind, dose-escalation study of the pharmacokinetics, safety and tolerability of single ascending doses of KLS-0153.\nOBJECTIVE\nTo explore and describe the potential acute effects of KLS-0153 in relation to a single dose in a double-blind, placebo-controlled and dose-escalation study.\n\n\nMETHODS\nThis study included 65 healthy male and female volunteers with ages in range from 18 to 45 years. They received single 4,6, 18, 54, 100, 178, and 448 mg/day of KLS-0153 or placebo.\n\n\nRESULTS\nThe highest tolerated was the dose of 4 48 mg/day, with minor adverse events; the dose for first in human use, was 1/5th of this, with tolerability. No serious adverse events were reported. There was no significant change in vital signs, electrocardiography, clinical laboratory, electrophysiology, or pharmacokinetic data. A dose-dependent increased incidence of adverse events and decreased heart rate was associated with KLS-0153. An expected time-independent increase in peak serum concentrations was noted.",
        "label": 1
    },
    "772": {
        "output": "[",
        "label": 2
    },
    "773": {
        "output": "[/SOLVED]\n\nA: This one is easy to figure out.\nThis line is basically an array, just to give you an idea.\n[Trial]\nid         1 2 ...  12 \nname =      \"Name 1\" \"Name 2\" ...   \"Name 12\" \n\nThe 12 name values are what need your attention. Let's say, you have an array of values but only you need the \"Name 12\" values.\nSo, this line of code, would only have values \"Name 12\", \nid = 12\nname = \"Name 12\"\n\nYou could use a for loop to check through name and find out whether the value \"Name 12\" is in that array, e.g \nfor value == \"Name 12\" do\n    id = value\n    name = \"Name 12\"\nend for\n\n<EOD> Long-Term Follow-Up of Stereotactic Radiosurgery for Certain Trigeminal Neuralgias: A Single-Center Study\nBACKGROUND: We report the results of the largest prospective series of patients with drug-resistant trigeminal neuralgia (DR-TN) treated with stereotactic radiosurgery (SRS). METHODS: Twenty-five patients were treated with SRS between November 2000 and October 2010 for DR-TN associated with a vascular loop in 23 patients and trigeminal nerve schwannoma in 1 patient. Follow-up was determined with the use of the Brissaud-Cats method. RESULTS: The present cohort of 25 patients was treated with gamma knife SRS between November 2000 and October 2010, with a mean follow-up of 49 months. Median treatment doses delivered to the trigeminal nerve were 80 cGy for 15 and 90 cGy for 7 patients. One patient died of another cause 8 months after SRS. Two patients had transient (<1 month), moderate (<1 month), and severe facial numbness (<1 month) after the treatment. Eight patients reported a sensation of hypof",
        "label": 0
    },
    "774": {
        "output": "<EOD> Antiretroviral therapy during pregnancy and postpartum interventions for prevention of mother-to-child HIV transmission\nAntiretroviral drugs for human immunodeficiency virus (HIV) in pregnant women have been available since 1994 and their use during pregnancy in the United States to prevent perinatal HIV transmission has increased dramatically since 1996. This review focuses on the pharmacokinetics of the antiretroviral drugs recommended for prevention of mother-to-child HIV transmission (MTCT), and reviews the current state of the science in antiretroviral drug use during pregnancy based on both published results and unpublished data. We evaluated the pharmacokinetic interaction between antiretroviral and anti-parasitic or anti-toxoplasma regimens and the influence of HIV, parasites, malaria, or viral hepatitis co-infections on either antiretroviral dosing or pharmacokinetics. For neonates, studies were carried out to evaluate the antiretroviral levels in maternal milk, and to assess drug concentrations in neonates receiving either high breast milk concentrations or formula. Finally, new concepts of timing of initiation of antiretroviral therapy (ART) to reduce perinatal HIV transmission were reviewed, as were the benefits and risks of continuing or discontinuing ART after delivery.<EOD> Nutritional and clinical management of infants on gastrostomy tubes.\nThe incidence of cerebral palsy, particularly severe and complicated forms, is now 1,7\u20132 in every 1000 live births (Shelton and Acheson, 1979). Infants with this condition who are fed through a gastrostomy tube are increasing in number in our paediatric units. We now feel it is important to draw attention to the problems of nutritional, fluid and electrolyte imbalance and the associated complications which may be encountered in such patients, particularly those with severe cerebral palsy, and suggest ways of their avoidance and control.<EOD> In vitro anti-",
        "label": 0
    },
    "775": {
        "output": "### Inputs\n\nHere is the list of inputs.\n\n* **Patient Note**: a patient report.\n* **Clinical Trial Eligibility:** clinical trial eligibility, either 0) Excluded, 1) Not relevant, or 2) Eligible.\n\n### Environment Setup\n* **Instruction:** enter `conda env list 2> env_vars.txt` and paste `env_vars.txt` as the first line at the end of the `notebook` file.\n\n### Expected Results\nYou will get the output something like this:\n<pre>\n\n0_0_0_0\n0_0_0_0\n1_0_0_0\n0_0_0_0\n1_0_0_0\n1_0_0_0\n2_0_0_0\n1_0_0_0\n1_0_0_0\n0_0_0_0\n2_0_0_1\n2_0_0_1\n1_0_0_1\n1_0_0_1\n1_0_0_0\n2_0_0_1\n2_0_0_1\n1_0_0_1\n1_0_0_1\n1_0_0_0\n\n</pre>\n\n\n## Trial-Level Eligibility Notation Problems\n\n### Input Notes Missing\nSometimes the input notes are totally blank,\nYou can modify the following line accordingly,\n`Patient note = pd.DataFrame([[\"\", \"\", \"\", \"\", \"\", \"\"\"], [\"\", \"\", \"\", \"\", \"\"\", \"\"]], columns=patient_notes_cols, dtype=str).astype(int)`\n\n### Inconsistent Dates\nSometimes the clinical trial date is one day later than the patient note date and thus inconsistent to the patient note date, so the trial-level eligibility might be 2) Eligible by accident.  Also, the range of clinical trial dates is not narrow enough, the whole process for clinical trial screening might be very costly,\nSo, here are how to modify the code to get a consistent date, and a narrowed range of clinical trial dates:\n```",
        "label": 0
    },
    "776": {
        "output": "<EOD> .\nA study on the effects of three different kinds of drugs (clavulanate, azlocillin and mecillinam) after oral or intramuscular injection in patients was made. Clavulanate, azlocillin and mecillinam showed good serum levels of their active ingredients following oral administration. Compared with those after intramuscular injection, the serum level of clavulanate at 2 hours after oral administration was 70% of the serum level of azlocillin. Therefore, the antibacterial activity of clavulanate was similar to that of azlocillin. High levels of mecillinam were observed in the serum, but good levels of aminopenicillins, such as ampicillin and carbenicillin, were not observed.<EOD> In Situ Formed Nanocluster Catalytic Network for Enzyme-Free and Chemiluminescent DNA Amplification.\nA DNA system with amplification based on nanocluster catalytic reactions is constructed. A cascade of DNA/RNA hybridization reactions triggers nanocluster catalytic reactions among three kinds of chemiluminescent probes, and the in situ formed chemiluminescent nanoclusters give signals for detection of target DNA. The catalytic mechanism is investigated through theoretical calculations, and we find that an intermediate species - the RNA-3WJ has a key role to play in regulating the nanoclusters' catalytic reactions, which leads to a strong fluorescence enhancement and a chemiluminescence enhancement in a specific sequence. This chemiluminescence enhancement can be used to detect the target DNA without false signals, and the sensitivity can be as high as 0.6 pM. The unique design here can be regarded as an important supplement for nucleic acid detection using chemiluminescent probes.<EOD> The Effect of Acetylsalicylic Acid, Cinnamic Acid and Some of Its Derivatives, against Malignant Colorectal Cancer Cells In Vitro\n\nCitation: Mladinova, K.; Yordanov, Y.; Nedyalkova, O.; Krumova, M",
        "label": 2
    },
    "777": {
        "output": "# A1\n\n## Exercise\nThis exercise assumes you have some prior knowledge of Python. If you'd prefer to work through the full version of this tutorial using a REPL session, or with a notebook environment, you can use a Jupyter widget or [Google Colaboratory - Colab](https://colab.research.google.com/), both of which [allow syntax highlighting](https://docs.github.com/en/free-pro-team@latest/github/setting-up-git-and-using-GitHub-to-collaborate-on-source).\n\nA1.1. Install libraries (conda, numpy, scipy, pandas, sklearn, jupyter)\n\n![image](https://user-images.githubusercontent.com/35509879/118749478-336d7300-b0d6-4bda-af17-15abce8cb048.png)\n\nA1.2. Run the code (notebook)\n\n<img src=\"https://user-images.githubusercontent.com/35509879/118749537-89215f80-dd3c-4601-8dda-7311917982ef.png\">\n\nA1.3. Result\n\n![image](https://user-images.githubusercontent.com/35509879/118749505-09a0da00-06b1-4b20-8c96-f4ccdd00364f.png)\n\n\n\n\n# A2\nA2.1. Patient information\n\n\nThe patient had a history of hypertension and dyslipidemia.\n\n![image](https://user-images.githubusercontent.com/35509879/118749511-c6dcd780-764f-4af0-8a9b-a0fd8f7654be.png)\n\n\n\n\n\nA2.2",
        "label": 1
    },
    "778": {
        "output": "<EOD> Preparation and Characterization of the Nutraceutical Beverage Based on Bamboo Leaf Polyphenols (BLPs)\n\nBamboo leaves (Phyllostachys heterocycla) are used as a kind of traditional Chinese herbal tea and functional beverage. The main bioactive compounds in bamboo leaf polyphenols (BLPs) with antioxidant and anti-inflammatory activities and potential beneficial effects on human health were confirmed by chemical and biochemical approaches. After the optimization of ultrasonic extraction parameters, total polyphenols content in BLPs were determined as 3.89 \u00b1 0.15 g/100 g of dry weight. The content of flavonoid and condensed tannins was 0.96 \u00b1 0.05 g/100 g dry weight and 2.48 \u00b1 0.10 g/100 g dry weight, respectively. Among nine phenolic compounds identified by ultra-performance liquid chromatography-orbitrap mass spectrometry (UPLC-orbitrap MS), caffeic acid (109.07 \u00b1 1.98 \u00b5g/100 kG,) and quercitrin (172.54 \u00b1 0.35 \u00b5g/100 mg,) were the most dominant constituents. The BLPs showed strong free radical scavenging capabilities in 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 2,26-Azinobis-(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) assays. In addition, the BLPs exhibited significant inhibitory effects towards 5-lipoxygenase (5-LOX), \u03b1-amylase (\u03b1-AI), and \u03b1-glucosidase (\u03b1-GI). The findings suggested that BLPs could be a potential nutraceutical beverage resource for improving physical health, and the BLPs are promising natural raw material to formulate functional foods and health supplements.\n\n# Introduction\nBamboo leaves (Phyllost",
        "label": 2
    },
    "779": {
        "output": "[INTEX]\n\n\u00a9 {{date}}. Bioinformatics Lab, Faculty of Computer Science, Helwan University. All rights reserved.\n\n      <br>\n      <b>\n        Development, Maintenance and Infrastructure Support <br>\n        Laboratory of Biostatistics and Bioinformatics, Department of Clinical Pharmacy,\n        Faculty of Pharmacy, Cairo University\n        <br>\n        <NAME>,\n        Faculty of Computer Science, Helwan University\n        <br>\n        <NAME>,\n        Faculty of Medical Engineering, Cairo University\n        <br>\n        <NAME>, Faculty of Computer Science and Engineering, Helwan University\n        <br>\n        <NAME>, Department of Medical Engineering, Faculty of Medicine, Ain Shams University\n      </b>\n      <br>\n <br>\n<b>\n   License:\n    This content is licensed under Creative Commons Attribution - ShareAlike 4.0\n</b>\n</html>                                    \n<EOD> A retinoid-inducible gene-switch system for the control of endogenous transgene activity in transgenic mice\n\nBackground: Retinoic acid (RA) exerts a variety of biological activities such as stimulation of cell proliferation and regulation of gene expression. There is increasing evidence that RA is an extracellular signal for regulating normal tissue differentiation and cell proliferation. RA is known to induce expression of its receptor genes in various tissues. Hence, we utilized the RA inducible transcriptional response to develop a powerful tool for controlling gene expression of transgenes in the nervous system of transgenic mice.Results: A transgene cassette containing a minimal cytomegalovirus enhancer, a minimal simian virus 40 promoter, a rabbit beta-globin intron/exon, and the human retinoic acid receptor binding site (hRARE) connected to the SV40 polyadenylation signal, which we named RARE-GAS, was employed. By inserting the RARE alone into the transgene cassette, we observed robust RA-inducible transgene expression in transgenic mice. When the",
        "label": 1
    },
    "780": {
        "output": "### 1: Create and save the `main` code \nSave the workspace (e.g., `main.ipynb`). Make sure the `Output` section is properly configured in `metadata` attribute:\n<ipynb-metadata output='output_path'>\n</ipynb-metadata>\n\nThe output should be saved as a .ipynb file, and the results should be saved in the directory. It depends on the operating system and the configuration you use. Some of the popular ways to do this include:\n`$ nbexport -o output_path -o ipynb input_notebook`\n\n### 2: Save the results into a .json object \nCreate a new file `inp.json` in the current folder, then change the first line of the code below to save the results into a .json file. In the following code:\n\t\n<br>\n\n`if __name__=='__main__':`\n\n\timport numpy as np\n\timport pandas as pd\n\timport matplotlib.pyplot as plt\n\timport seaborn as sns\n\tfrom matplotlib.backends.backend_pdf import PdfPages\n\timport nbhtml\n\tfrom nb_print_helper import print_html\n\n\tinp_list=pd.read_csv('inp.csv',sep = ',')\n\n\tinp=inp_list.copy()\n\tinp.head()<br>\n\n\tinp.drop(['Age',  'History of Diabetes', 'History of Hypertension', 'Hypertension', 'Smoking', 'CAD Family History', 'Waist Hip Ration'],axis = 1,inplace=True,)<br>\n\n\tage=inp['Age'].apply(lambda x: int(np.floor(100*x.round(2))))<br>\n\n\tage.plot()\n\tage.dropna(axis=0,inplace=True)<br>\n\n\tage.isna().plot()\n\tage.dropna().plot()<br>\n\n\tage.mean.<br>\n\tage['Mean'].plot()<br>\n\tage['SD'].plot()<br>\n\n\tinp.isna().plot",
        "label": 0
    },
    "781": {
        "output": "[[TUTOR]]\n# <NAME>\n\nThe tutorial is on a patient visiting a hospital and needs the doctor to decide whether he/she is healthy enough to go upstairs. \nAt each doctor visit, the doctor asks the patient about the health problems he/she had in the past seven days up to today. The doctor then determines the severity of those problems by how much trouble they caused [from none to severe (11)]. \nThe doctor also checks several other health problems and medications/treatments to decide on a rating between 0 and 10. The sum of scores for all the four aspects (four categories: problems; medications; treatments; and overall) gives the overall health rating, which indicates the patient's condition. \nHere is an example of the patient's visit notes:\nThe doctor should now compute the overall health rating. To do so, the doctor must sum up the scores from the four categories [treatment, medications, overall problems, and problems] and determine the overall health rating. \nEach category has 11 labels from 0 to 10. The scores of the four categories should match the patient's answers. As a result, each category should add to the overall health rating, and the total sum has to be between 0.0 and 10.0. The following equations (calculations) show the calculations for the four categories: The doctor should now compute the overall health rating. To do so, the doctor must sum up the scores from the four categories [treatment, medications, overall problems, and problems] and determine the overall health rating. \nNote that, to compute `overall problems score`, the sum of all the problems is calculated. If the total sum is greater than the number of problems, the doctor should apply `total problems score - (# of problems) = problems score.`?\n\n# <NAME>\n\nDuring the patient's visit to the clinic, the doctor examines the patient and asks a series of questions in an examination room. The medical practitioner may include all the findings from the examination and the information about the history of the disease. Each of these findings provides doctors with an insight into the patient's health condition. The doctor can diagnose the patient's condition accurately based on the responses to the questions or the find",
        "label": 0
    },
    "782": {
        "output": "[INST]\n- _The assessment module_, at which we start off.\n    We create a new trial and then assign a patient to it.\n\n- _The trial_ module allows users to view the trial information, create an empty trial, view the eligibility,\n    and view the patient notes.\n\n- _The patient_ module is where users can view all the patients that have been included in the trial.",
        "label": 0
    },
    "783": {
        "output": "A: First determine if this patient is eligible for the study, if not then he is excluded otherwise he is eligible.\nNext determine if the patient is receiving any exclusionary medications, if not he will not be excluded.\nNext consider whether his clinical findings are clinically significant to the patient. This is a more subjective judgement, you ask yourself would you refer the patient for further consultation if you diagnosed him.\nYou should consider his age LDL-C and CAD family history (risk factors for CAD). As well as the extent of carotid artery disease.\n<EOD> .\nOne hundred and eighty three bacterial strains isolated from urine in urinary tract infection and from feces of patients after laparotomies in IJSS in Nijmegen during the period July 1970 to June 1971 were tested for sensitivity to eleven antibiotics using the agar dilution technique. The results of these tests were related to the time and place of isolation of individual strains. The organisms investigated were: enterococci (66), enterobacteria (50), non-enteric gramnegative aerobic organisms (26) and other gramnegative anaerobes (51). In enterobacteria, E. coli and enterococci both an outbreak of enotexceptic enterococci containing strains producing penicillinase and gentamicin/kanamycin resistance was observed.<EOD> Surgical intervention in necrotizing enterocolitis: Is delayed laparotomy associated with worse out-comes in NEC patients with intestinal perforation?\nABSTRACT Objective We aimed to compare the results of early and delayed laparotomy in neonates with intestinal perforation secondary to necrotizing enterocolitis (NEC). Methods Between January 2009 and February 2014, 13 neonates who underwent a laparotomy due to perforation were included in the study. The perforation site and complications and the surgical findings were recorded. The patients were divided into two groups: group 1, early laparotomy (<48 hours",
        "label": 1
    },
    "784": {
        "output": "### Pre-requisites\n\n```python\nimport pdb\nimport pickle\nimport argparse\nimport numpy as np\n\nnp.random.seed(5656)\n\nimport time\n```\n\n```python\ndef init_logger(logger_name):\n\n    logger = logging.getLogger(logger_name)\n    logger.setLevel(logging.INFO)\n    fmt = logging.Formatter(\n        \"%(levelname)-8s %(message)s\"\n    )\n    console = logging.StreamHandler()\n    console.setLevel(logging.DEBUG)\n    fh = logging.FileHandler(\"output.txt\", mode=os.O_RDWR  )\n    fh.setLevel(logging.INFO)\n    formatter = logging.Formatter(\n        f\"%(asctime)-5s [%(levelname)-8s]: %(message)s\"\n    )\n    fh.setFormatter(fmt)\n\n    if logger_name == \"main\":\n        logger = logging.getLogger(\"main\")\n        # \u8bbe\u7f6e\u6253\u5370\u8f93\u51fa\u7ea7\u522b, \u9ed8\u8ba4\u662finfo\u7ea7,\u53ef\u4ee5\u4e0d\u663e\u793a\u7684\u8f93\u51fa\u8dfb\u5370\u5230\u6587\u4ef6\n        logger.setLevel(logging.INFO)\n        # \u8bbe\u7f6e\u8f93\u51fa\u5b57\u4e32, \u4e00\u822c\u60c5\u51b5\u4e0b, \u4f1a\u663e\u793a\u4e3a \u6253\u5370\u5230std in,console\u548clog file\n        console.setLevel(logging.INFO)\n        fh.setLevel(logging.DEBUG)\n        \u5212\u7ebf\u90e8\u5206\u53ef\u4ee5\u5ffd\u7565\u53bb\u6389, \u4e0d\u5fc5\u4f7f\u7528\u6574\u884c\u6ce8\u91ca\n        \n    logger.handlers[0].addHandler(console)\n    fh.daemon = True\n    fh.addHandler(logger)\n\n    return logger\n```\n\n```python\ndef main():\n\n    # \u54cd\u5e94\u547d\u4ee4\u884c\u7684\u53c2\u6570\n    parser = argparse.ArgumentParser()\n\n    parser.add_argument('-c', help='input csv file | test dataset')\n    parser.add_argument('-r', help='report folder', default=\"/c/Users",
        "label": 0
    },
    "785": {
        "output": "## 7. [INST] Experiment data\nData for learning to create a model for evaluating trial-level eligibility is a simple vector of 300 patients as `experiment_data = DataFrame ({ 0: age, 1: gender, 2: systolic, 3: diastolic }, 0: pdl.Trial.v1_patient, 1: pdl.Trial.v1_patient, 2: pdl.Trial.v1_patient, 3: pdl.Trial.v1_patient ), pdl.Trial_300_v1.csv`.\n\n8. [INST] Loading data and preparing for training / [OPTIONAL] Loading data and preparing for testing\n\n\t*Data pre-processing\n* [OPTIONAL] Model training\nTo test whether the machine learning models make a better assessment of trial-level eligibility than clinical staff, we will compare the outputs made by the models with those of clinical staff. So, we should set 'True-Clinical staff' value as 0 in 'trial_level_eligibility_outcome` of `experiment_data`. After that, prepare a new experiment data: `experiment_new_data = experiment_data.merge( trial_level_eligibility_outcome.replace ( True_Clinical_staff ,0 ))`.\nAnd then, load them into memory as experiment objects.\n`experiment_1 = pdl.Experiment ( data=experiment_old_data , name = \"Eligibility Predictor (old).\", title = \"Eligibility predtctor (old)\" , model_type =\"Regression\" , model_parameter={`data_type` : \"categorical\", **`data_param` : experiment_data.Data.parameter.keys(), `parameter` : experiment_data.Data.parameter.keys(), `parameter_type` : \"Categorical\" } )`.\n`experiment_2 = pdl.Experiment ( data=experiment_new_data , name = \"Eligibility Predictor (new),\" title = \"Eligibility predtctor (new),\" data_type =\"categorical\", data_param = experiment",
        "label": 1
    },
    "786": {
        "output": "<EOD> Effect of craniotomy position on intraoperative visualization during microvascular decompression: a randomized controlled trial.\nOBJECTIVE\nMicrovascular decompression (MVD) is one of the most effective surgical therapies for patients presenting with refractory trigeminal neuralgia (TGN). A limited view of the root entry zone due to the craniotomy often makes it difficult to expose the root, especially for lower root entry zone (REZ) lesions. The objectives of this study were to determine the effectiveness of changing one's position at the surgical platform and to assess whether the angle of the microscope, surgical table orientation, and the craniotomy location can improve the intraoperative visualization during MVD for TGN.\n\n\nMETHODS\nThis was a prospective, randomized controlled trial of MVD for TGN. The 90 sides for 60 patients were randomly divided into group A and group B. All MVD surgeries were performed by the same surgeon in a standardized fashion. Visualization was recorded from 3 aspects. For group A, before opening the dura, the surgeon stood with his back to the surgical platform to look at the operative field and then stood on the surgical platform to look at the operative field. In group B, the surgical procedure was performed by the surgeon in the same manner as the previous method, except that the surgeon stood on the surgical platform during the whole operation. We also measured the angles of the microscope and the operation table.\n\n\nRESULTS\nWe found that the visual field from each of the 4 directions measured from the 3 areas was statistically significantly improved when a surgeon was standing on the surgical platform. Furthermore, a surgeon's back to the surgical platform to look at the operative field had the biggest impact on the angle of the microscope (preoperative, 12.4\u00b0 \u00b1 0.9\u00b0; 2-weeks postoperative, 9.4\u00b0 \u00b1 0.7\u00b0; F = 33.550, p < 0.001). The location of the craniotomy, the angle of the microscope, and surgical table orientation did not differ significantly between the 2 groups, and none",
        "label": 1
    },
    "787": {
        "output": "[/CITATION]\n--Lawrence Wan, PharmD, Department of Bioinformatics and Systems Biology, Faculty of Engineering and Information Technology, University of Technology Sydney\n\n\nA: If you're happy with your code, and your \"if\" blocks, I strongly recommend that you always make your \"if\"s start with \"If\" rather than just \"if\", and that this is done every time the block of code appears if any of the other conditions don't apply.  As a result, you can have if(b, c, d), where b, c and d are all variables, while leaving all conditions satisfied, as b, c and d are all variables.  Similarly, if(True), where True is a variable that evaluates to true, is also something that should generally be frowned upon.  It's easier to have to decide how to evaluate something than to create something or change something.\n\nA: Your solution is pretty basic, and a quick solution to a test I wrote to demonstrate a slightly clever technique called recursion.\nclass Solution:\n    def numFood(self, list):\n        \"\"\"\n        :type int list: an ordered list of sizes\n        :rtype int: a result\n\n        Given an ordered list of sizes, and returns the sum of the list members, plus (number of elements -1).\n\n        For example, a list [[5,2,1,3,7],[7,2,5,8]](https://www.python.org/doc/peps/pep-0287.html) would return 23\n        \"\"\"\n        # This loop is a pretty basic way to figure out the list's length and the average.\n        for size in list:\n            return sum(list) + (len(list)-1) * (size/len(list))\n\n\n# Test code:\n# A:\nif(list):\n    if(len(list)):  # A little trick that doesn't make for bad programming (yet)\n        return (len(list)*(list[0])+sum(list))         # Odd one out?\nelse:\n    if(0): # Avoid ugly code.\n        print(\"No list:\") # Avoid ugly code.\n    pass\n\n# B:",
        "label": 1
    },
    "788": {
        "output": "Question: The given patient data are insufficient to judge if the patient is eligible. Please check with us to see if we need to provide further clarification and/or data to complete the assessment.\nQuestion: The given patient data are insufficient to judge if the patient is eligible. Please check if we need to provide further clarification and/or data to complete the assessment.\nPatient's condition: The patient's BP is higher than reference range, his age is 73 years old; patient report the high BP, and he did not mention his past medical history. Patient is smoker, so the risk of CAD increasing.\nWhat is your judgment on the patient's eligibility status and reasons for the judgment?\nInput:\nTrial-level eligibility: 1) Excluded. Rational/Question: The age of 73 for male is already exclusion. The systolic blood pressure of 182 mmHg shows the patient's cardiac health is deteriorating. And the patient is also a smoker.\nExamination details: Sodium 140.7 mmol/L. It is within the normal level. 125 / 84 mm Hg. The BP is a level higher than reference range.\nQuestion: What would be your judgment of the patient eligibility status and reasons for the judged?\nInput:\nPatient's condition: His age is 38 years old. He has no past medical history. He does not mention his smoking or history of alcohol intake. BP at 2012/4/11 was 125/84 mmHg. BP at the most recent visits are 143/87mmHg. The past measurement results are normal, the recent values are elevated.\nHospital examination: blood glucose level (0.40 mmol/L), sodium (146 mmol/L), potassium (4.9 mmol/L), chloride (109 mmol/L), creatinine (68 umol/L), urea nitrogen (8.1 umol/L), bicarbonate (21 mmol/L), anion gap (1.0 mm",
        "label": 0
    },
    "789": {
        "output": "<EOD> Proposal for a methodology of clinical validation of the use of 3-dimensional printers in plastic surgery: design and development of 9 surgical models of rhinoplasty.\nAIM\nTo describe a methodology of clinical validation of the use of 3D printing technology in surgery, and to design and develop 9 models of rhinoplasty, to allow 3D surgical planning.\n\n\nMATERIALS AND METHODS\nThe methodology is based on the following steps: evaluation of clinical need, design with the software, 3D printing, surgical planning, simulation of surgery, and clinical evaluation with photographs. The validity of the study results was determined by a reliability coefficient: Cronbach's alpha.\n\n\nRESULTS\nIn this study, 61 patients were evaluated. The following surgical models were generated and validated clinically: 9 for rhinoplasty, and the resulting surgical outcomes were validated by the surgeon's Cronbach's alpha alpha (90% CI ) as follows: right nasal flap (0.87, 0.73 - 0.94), left nasal flap (0.87, 0.73 - 0.94), and skin graft (0.86, 0.73 - 0.94), in a cohort of 61 patients.\n\n\nCONCLUSION\nThe proposed methodology allows validating the correct use of 3D technology in plastic surgery, through an exhaustive evaluation protocol by expert surgeons.<EOD> .\nBasing on the present state of clinical studies, the authors suggest that the efficacy of drug therapy for chronic schizophrenia is best demonstrated by a change in the clinical symptoms measured by an objective and qualitative rating scale, i.e. the psychopathological rating scale.<EOD> .\nVitamin D supplementation in pregnancy to prevent preterm birth would be a cheap approach to reducing preterm birth in the presence of an increased risk of premature delivery. Vitamin D is not only related to bone metabolism but also to the immune system. Many studies have been performed to establish vitamin D supplementation in pregnancy as a",
        "label": 0
    },
    "790": {
        "output": "[C1] - [Trial_level_eligibility](https://github.com/biocore-ai/biocore_webtools/blob/2ae714a0bf65889d60c324bfee98cd1ddfcdee71/src/data/institution/BIO16/BIO16_CL_C1/Patient_List.py)\n \n\n   Patient ID     Patient name    Trial level eligibility  Exclusion criteria  Not included in this trial  Eligibility assessment\n    135          Patient 135           Excluded                  Excluded\n    136          Patient 136           Not relevant                   Excluded\n    137          Patient 137           Excluded                  Excluded\n    138          Patient 138           Excluded                  Excluded\n    139          Patient 139           Not relevant                   Excluded\n    140          Patient 140           Not relevant                   Excluded\n    141          Patient 141           Excluded                  Excluded\n    142          Patient 142           Not relevant                   Excluded\n    143          Patient 143           Not relevant                   Excluded\n    144          Patient 144           Excluded                  Excluded\n    145          Patient 145           Not relevant                   Excluded\n    146          Patient 146           Not relevant                   Excluded\n    147          Patient 147           Excluded                  Excluded\n    148          Patient 148           Not relevant                   Excluded\n    149          Patient 149           Excluded                  Excluded\n    150          Patient 150           Excluded                  Excluded\n    151          Patient 151           Excluded                  Excluded\n    152          Patient 152           Excluded                  Excluded\n    153          Patient 153           Excluded                  Excluded\n    154          Patient 154           Excluded",
        "label": 2
    },
    "791": {
        "output": "# A.1. Criterion 1: Age and gender\nIn this criterion, you check, in the current patient note, whether the patient is eligible by age and gender.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For",
        "label": 0
    },
    "792": {
        "output": "[MORE STUDIES] \n10.7. [INSERT VOICING] Exam Question: When a physician is diagnosing dementia in a patient who has received a drug for Alzheimer's disease for 6\u00a0months, which is more accurate, TICS or MDRS score?\n\n[ANSW: 'Both scores are useful.' [INST]].\n\n\n![](/figures/004-06-image.png) \n\nHere is the clinical trial:\n```r\nclinicalTrial = list( \"Identifier.Name\" = \"10008483\", \n\"Title\" = \"Alopathic or Homeopathic Alternative to Standard Care for the Treatment of Early Stage Dementia: Results of a Randomized Controlled Trial (HOME-D)\", \n\"Type\" = \"Trial\", \n\"Language\" = \"English\",\n\"Date\" = \"2015-08-19T08:03:02\", \n\"Protocol.Identifier\" = \"2009/CWL-",
        "label": 1
    },
    "793": {
        "output": "## Required Input Format\nIt is assumed that you supply the input file and the output file from the input folder to the output folder. You must put them on the same line and save them in this folder.\nThe input file has three columns for the assessment of eligibility from the left to right. If no patient meets the inclusion criteria, output the zero as 0. Otherwise, output the scale number from 0 to 2.\nThe output file has two columns for the assessment of eligibility from the left to right. Output the scale number from 0 to 2. \nInput File:\nCholesterol20mg%\nLdlC20mg%\nLdlC30mg%\nLdlC40mg%\nLdlC50mg%\nBloodPressure40mmHg\nBloodPressure120mmHg\nBloodPressed40mmHg\nBloodPressed120mmHg\nSmokingPresent\nSmokingAbsent\nNoCancer\nCancerPresent\nFamilyHistoryPresent\nFamilyHistoryAbsent\nAspirinPresent\nAspirinAbsent\nFemalePresent\nMaleAbsent\nAge0\nAge30\nAge58\nAge71\nAgeOlder\nWeight140\nHeight177\nBMILessThan35\nBmil35\nHeight60\nWeight200\nFemaleAbsent\nFamilyHistoryAbsent\nAge40\nCholesterol80mg%\nBMILessThan15\nFamilyHistoryAbsent\nAge60\nCholesterol80mg%\nHeight180\nWeight130\nBmilMoreThan35\nFamilyHistoryAbsent\nBMILessThan15\nHeight40\nHeight80\nAge0\nAge0\nAge0\nAge0\nAge0\nAge0\nOutput File:\n2\n2\n2\n2\n2\n2\n2\n2\n1\n1\n1\n1\n1\n0\n0\n0\n0\n0<EOD> Prevention and Control of COVID-19 Infections by Aseptic Nonwoven Fabrics\n\nThe coronavirus disease 2019",
        "label": 0
    },
    "794": {
        "output": "[TUT] This will show you how to check for patient eligibility: \n[FCT] There is more than one patient, so first you should filter them by date: \n[FCT] By name: \n[FCT] By gender: \n[FCT] By the type of their blood: \n[FCT] By birthdate: \n[FCT] By age group: \n[FCT] By birthplace: \n[FCT] By age group: \n[FCT] By marital status: \n[FCT] By occupation type: \n[INST] Your patient list will be narrowed down to a single patient. \n[FCT] Let's filter by the trial name: 1) CAD: 3C_002: 01. \n[INST] The patient eligibility should be 2) Eligible. \n[FCT] Good. Let's go home. \n[FCT] By patient id: 165219937: Eligible. \n\n__Bonus: Here is additional material. It will help you to become more familiar with the concepts of clinical trials, which may be useful if you want to become a professional. It is available [here(in .pdf format)].____\n<EOD> <filename>README.md\n# Symfony Flex Voter Extension\n\n[![Build Status](https://img.shields.io/travis/dahlia3004/symfony-flex-voter-extension.svg)](https://travis-ci.org/dahlia3004/symfony-flex-voter-extension) [![Coverage Status](https://img.shields.io/scrutinize/coverage/github/dahlia3004/symfony-flex-voter-extension.svg)](https://scrutinizer-ci.com/g/dahlia3004/symfony-flex-voter-extension)\n\nFlex voters available for [Symfony 3 Flex](https://github.com/symfony/Symfony/releases/tag/v3.x)\n\n## Installation\n\nSymfony Flex Voter",
        "label": 1
    },
    "795": {
        "output": "2) Expected answer: \nOutputs: 0 for the first and second patient, and 2 for the third and fourth.\n3) Solution: \nOn the one hand, you could use a simple `if \u2026 else` structure to identify the eligibility of patients; on the other hand, you could add the patient note to an iterator and iterate the note to find the eligibility.\nInstead of the `if \u2026 else` structure, the following code fragment is possible in a more compact form:\n\nThe reason is that the function `filter(x::Array{String, 1}, p::Int\u2026)` of Julia actually is a function like `filter(x::Array{String, 1}, b::Bool, p1=false, \u2026)` which means that a Boolean is added to each entry of `x` and compared with the Boolean parameter `b`.\nIn this case, the parameter in parentheses is `false` and only patients with a note including the letter `t` would be assigned to the corresponding index of `P_note`. If at least one patient note starts with \"t\", the code fragment returns a tuple of the corresponding indices with the current value stored in `eligibility` of the respective patient.\nFor this example, a function called `set_data(:t_note)` could be provided.\n<EOD> Changes in p127 mRNA expression in rat kidney cortex after ischemia-reperfusion.\nThe changes in the expression of proliferation-associated p127 mRNA level in rat kidneys after ischemia-reperfusion were examined by reverse transcriptase/polymerase chain reaction (RT/PCR). The p127 mRNA level began to increase at 1 hour after reperfusion following 60 minutes of ischemia. This increase continued for 3 to 7 days after reperfusion and returned to basal levels on days 14 to 21. In situ hybridization analysis revealed that in the S1 segment, the p127 mRNA-positive cells appeared within 1 hour and accumulated from 1 to 7 days after reperfusion, but not in the S3 segment, and in the S2 and S4 segments, the p127 mRNA-positive cells appeared from",
        "label": 2
    },
    "796": {
        "output": "# Discussion and Conclusion\nIn case of difficulties in defining eligibility criteria, consider the following tips:\nTry to make a list of factors which allow someone to participate in a trial. Think what are the best questions to ask to the patient, to answer \"Are you excluded?\" or \"Will you need exclusion criteria to avoid injury\".\nIt may be hard to define the eligibility criteria in the patient note. One way to get all the information needed is to ask the team of the attending physician, while working with them.\n\n# Author's contributions\nAll the mentioned authors have collaborated in the same way with regards the conceptualization of the problem formulated under the supervision of the fourth author, and with the preparation of the article for submission to the journal.\n\n# Funding\nThere were not received any research fundings for the article.\n\n## Ethics approval\nEthical approval was not required to carry out this study on the basis of national guidelines.\n\n## Provenance and peer review\nNot commissioned, externally peer-reviewed.\n\n## Please state any conflicts of interest\nAuthors do not have any conflict of interest to report.\n\n## Please state any sources of funding for your research\nAll authors have full funding to complete the project.\n\n# Discussion\n\n## Discuss this article\n\n## Conceptualization\nThe clinical team of the Romanian National Institute for Research and Development in Biology and Medicine, Institute of Cardiovascular Diseases, Department of Cardiovascular Imaging, University of Medicine and Pharmacy of Craiova, Craiova, Romania, the Romanian Society of Cardiology and Diabetology (RoSDC); together with the Academic University of Craiova, Department of Medicine and Pharmacy, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, Romania, and The Heart Surgery Institute, Craiova General County Hospital, Romania.\n\n# Declaration of interest\nThe authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.\n\n## Abbreviations\nAMI, acute myocardial ischemia; CAD, coronary artery disease; DBP, diastol",
        "label": 0
    },
    "797": {
        "output": "[/MAST]\n\n## Exercise: Exercise 2.5\n\n# You will:\n\n- Learn about the role of supervised training in the diagnosis of ADHD.\n\n- Diagnose patients as having probable or confirmed ADHD using the 2-minute Supervised Training Instruction (STI) Score.\n\n## The STI score is the total number of tasks accomplished (correctly and incorrectly) in the 2-minute interval.\n\n# [INST] Step by step Exercise 2.5\n\n## Your responsibility:\nThis exercise should be done using our online app. To use this app, you must log into the website <http://kids.adhd.de> first. Next, you should use your login data of `s19229001@hotmail.com` and `johny84@gmail.com`. To log in, you only have to enter your data and then press the button to submit login data. (Login data is also saved, so if a new exercise is needed, you need to press the button `Start exercise` to enter the environment). In the next part, you should download the file `BMJ-ADHD-2-Exercise-3-Diagnose_2nd_step_supervised_training.pdf` and then open this file. You can get the file from the link provided in a previous page.\n\n\n![Instruction]. (a) Instruction for Exercise 2.5\n\n\n## Input: Output: \n[INST] The first part is just as simple as the one before. So, no further explanation is necessary. Just follow the instruction in the first table.\n\nLet's think step by step:\n\n\n## **Step 1.0:**\nThe supervised training is done in 2 min. For each task, 2 points are given for positive response and 0 points for a negative response. The STI score is the total number of tasks accomplished (correctly and incorrectly) in the 2-minute interval. Let's see the following table from the article.\n\n![Instruction ]. (a) Results of the Instruction Group\n\n\n## **Step 1.1:**\nFor the second part, you already know that if the",
        "label": 1
    },
    "798": {
        "output": "___\n\n#### Reference\n\n[1] ICH E3: Addendum to ICH Topic E 9 Statistical Principles for Clinical Trials\n\n___\n\n##[Trial] Title: Middle Cerebral Artery Velocity and Oxygen Saturation of the Brain During Carotid Endarterectomy\n\nSummary: The primary endpoint of our study is to determine whether neurological symptoms (aphasia, paresis, loss of consciousness, numbness) occur after clamping the internal carotid artery, and if so, changes shown by transcranial Doppler or INVOS monitor is more sensitive regarding the symptoms? Secondary endpoint: the degree of change in the measured parameters after internal carotid artery is clamped, and if there is any difference between the operated and non-operated sides?\n\nInclusion criteria:\n100 patients awaiting carotid artery endarterectomy carried out in regional anesthesia\n\nAge: patients over 18 years\n\nGender: both female and male patients are included in the study\n\nMedical equipment: venous catheter, arterial catheter for invasive blood pressure monitoring\n\nBilateral continuous measurement of the middle cerebral arteries with transcranial Doppler\n\nBilateral continuous measurement of the cerebral saturation with INVOS monitor\n\n___\n\n#### References\n\n1,2\n\n___\n\n##[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do",
        "label": 2
    },
    "799": {
        "output": "A [ClinicalTrial]: [INST] is a class that describes a clinical study or trial that requires an evaluation to define the eligibility of a patient or subject for inclusion in the trial. You can declare a trial using the [ClinicalTrial] class by writing the class name followed by the attributes. If a clinical trial or study requires two different types of data, e.g., a patient record and an assessment, you can declare a [ClinicalTrial] class with a [Assessment] class. The [ClinicalTrial] and [Assessment] classes are described in detail (Section 11.2 and 11.3.3, respectively) and provide rich functionality for representing complex data structures.\n\nClinicalTrial: [INST] attributes may include the following:\n\nAssessment: [INST] describes a part of the clinical trial, i.e., an assessment of a clinical manifestation or a biological marker to be measured in a clinical trial.\n\nAssessment: [INST] attributes may include the following:\nA 43-year-old male undergoing percutaneous coronary intervention (PCI) in the left anterior descending artery (LAD) due to severe symptomatic coronary stenosis. \n\nHere is the assessment: \nTitle: Assessment of Left Anterior Descending Artery \nType: [INST] assessment of the LAD (i.e., left artery 1) \nBMI: \nDischarge date: August 28, 2011 \nDuration: 24 hours \nResults: \nMeasurement 1: \nCerebrovascular disease in the form of a previous stroke in the left frontal and occipital lobe \nDiagnosis: \n\nType: [INST] diagnosis \nBMI: \nDischarge date: February 6, 2011 \nResults: \nMeasurement: \nMeasurement 1: \nCerebrovascular disease in the form of a previous stroke in the left frontal and occipital lobe \nCongenital heart disease \n\nCongenital heart disease: [INST] is congen",
        "label": 1
    },
    "800": {
        "output": "You have to try all cases to get some points and win the game!\n\n## Summary\nThe eligibility assessment has two distinct subdomains: the patient-level and the trial-level eligibility. The patient-level assessment is performed on a per-patient basis, whereas the trial-level assessment assesses the eligibility of a patient for inclusion in a particular clinical trial.\nThe eligibility assessment is the core procedure of patient recruitment into a clinical trial, and is critical. Incorrect or inadequate eligibility assessments can result in the loss of patients for the trial and, ultimately, in the loss of an eligible patient.\nThe assessment of clinical trial eligibility requires knowledge of the medical history and demographic/vital signs of the patient, the trial inclusion and exclusion criteria, the demographics and characteristics of the participants involved in the clinical trial, and the clinical outcomes to be assessed in the trial.\n\n# Discussion\nThe assessment of the eligibility of a patient for inclusion in a clinical trial is a complex and multifaceted process that requires comprehensive knowledge of the medical history and demographic/ vital signs of the patient, the trial inclusion and exclusion criteria, the demographics and characteristics of the participants involved in the clinical trial, and the clinical outcomes to be assessed in the trial. The eligibility assessment procedure consists of three distinct steps:\n\n1. Assessing and documenting the available data on the patient (e.g., medical history and demographic information)\n\n2. Assessing trial inclusion and exclusion criteria\n\n3. Assessing the patient's eligibility for inclusion in the clinical trial\n\nThe eligibility assessment should be performed meticulously and systematically to minimize errors and ensure that all patients are assessed fairly and accurately. The assessment of the eligibility of a patient for inclusion in a clinical trial requires comprehensive knowledge of the patient's medical history and demographics, a thorough understanding of the trial inclusion and exclusion criteria, and an in-depth assessment of the patient's medical history, demographics, and characteristics. The evaluation of eligibility must be performed by the physician in a timely and accurate manner.\n\n# Con",
        "label": 2
    },
    "801": {
        "output": "========================================================\n\nYour task is to create a script which will complete this task. If you complete your script, you'll receive a badge. If your script is of good quality, you'll receive a second badge. If you submit two good scripts, we\u2019ll send you a t-shirt. However, you must submit the script within one month since the workshop.\n\n[INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n    Task - Trial-Level Eligibility\n    Input - A clinical trial\n    Output - Trial-level eligibility for all patients.\n\n[//INST]\nIn the following exercise, you will generate code for a program that implements trial-level eligibility determination for a given clinical trial. It is important to remember that the determination of eligibility and the decision whether to include a patient in a clinical trial are the exclusive responsibilities of the trial investigators. The trial can establish additional exclusion criteria.\n\nNote: You should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: 2) Eligible`.\n\n[#] Write a Java program that produces Trial-level Eligibility for all patients.\n\nNote: You should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: 2) Eligible`.\n\n[INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n[//INST]\nNote that the clinical trial's inclusion criteria depend on the particular clinical study, and these criteria are always specified",
        "label": 1
    },
    "802": {
        "output": "## Exercise 4\n\n[INST] [C] Let's analyze patients' notes (see section on [Patient note]). \n\n[C] Using one of the above patient notes, please construct the appropriate test for each note based on the information you have gathered . Each test must evaluate multiple aspects and be applicable to all the notes in the document. You should be able to reproduce the same outcome result for each patient. Therefore, the test should not only be applicable to the one used example provided to you, but should be a \"generally applicable\" test, i.e., be applicable to all patients. \n\n## [/c]\n\n# Background\nThe test is implemented using the [A] [T] [E] [S] paradigm .\n\n[A] [T] [E] [S]: Acronym for Algorithmic Thinking Experiential Sensemaking Social\n\n\n[A] The first step is to analyze the available data, which may be very simple in nature:\n[A1] (A1.1) Analyze data. We could be faced with only a few lines of data from this section as shown in #11. We need to analyze the meaning behind these lines (#11). As in the following subsection, we need to convert the meaning of the data to the [A] [T] [E] [S] concepts.\nWe'll need: a) An initial context b) The first assumption c) The purpose of the analysis d) The second assumption We need to create a preliminary description of the data to create the initial context. For example, in #12 we need to add \"in section\" -#1 \"patient note\" -to create a preliminary description of the raw data. We now have #13:\n(A1.1) Analyze data. Annotation of #11-#12 is in #17.\nA1.2) Annotation of #11-#12\n#17. Create a preliminary description of the data based on the title of the patient note 'patient notes' and the context that it falls within 'in section patient notes'. #18. First assumption: Given the context -that this is from section patient notes -the question that arose was \"What could be the purpose of this article?\" What",
        "label": 1
    },
    "803": {
        "output": "<EOD> The effect of antagonists on spinal analgesic action produced by intrathecal injection of enkephalin.\nIntrathecal injection of enkephalin (4 micrograms) in the cat produced analgesia that was prevented by co-injection of naloxone (10 ig) but not antagonized by co-injection of morphine (200 g). When morphine 200 or 2000 / g and naloxone 10 or 150 / kg were co-injected, the spinal analgesic action of enkephalin (4 / g) was unaffected in doses up to 10-fold greater than that of enkephalin alone. However, higher concentrations of morphine or naloxone did block the action of enkephalin (4/g), although the threshold dose of naloxone was significantly lower than that of morphine. A small dose of enkephalin also lowered the threshold dose of naloxone to block the response to a larger dose of enkephalin. These results show that the spinal analgesic action of enkephalin (4 / g) involves an opiate receptor while higher doses produce blockade of that mechanism by the antagonist morphine.<EOD> Sleep and mental health in childhood--a new approach.\nSleep problems in childhood are common, well-recognized entities with serious effects on childhood mental health, development, and quality of life. In this article, the relationship between sleep, behavior, and mental health in children is reviewed.<EOD> .\nOBJECTIVE\nTo explore the effects of Pifolozolin (PFZ) on inflammatory cytokines and vascular cell adhesion molecule-1 (VCAM-1) in rheumatoid arthritis fibroblast-like synoviocyte (RA-FLSs).\n\n\nMETHODS\nHuman RA-FLSs were isolated, cultured and randomly divided into three groups, i.e. the blank group, the control group and the PFZ group, with 6 wells in each group. The control group was treated with TNF-\u03b1. The PFZ group was treated with PFZ for 2",
        "label": 2
    },
    "804": {
        "output": "If an entry is missing, do not add anything. If two or more entries are missing, write a comment explaining the issue.\nPlease submit the trial_level_eligibility.txt file before the deadline of July 23rd, 2019.\nThanks in advance for your participation.  \n\n*** End of Instructions ***\n\n### Step 2:\nMake a new Python file in GitHub: `Evaluation_NCEPT_Trial-level_eligibility/_evaluation_file`.\n[Download file here](https://raw.githubusercontent.com/Yong-Kwon/Evaluation_NCEPT_Trial-level_eligibility/master/trial_level_eligibility.txt)\n\n### Step 3:\nCheck the file for completion. Do not attempt to change/fix the syntax of the file. (See Example)\n\n### Step #4: Run the file in `Evaluation_NCEPT_Trial-level_eligibility/_evaluation_file`. It will return the result of all patients in trial.txt. If the number of returned patients is odd, you should check your trial.txt file for the missing triallevel_eligibility entry.\n\n### Step #5: Find the result that includes trial id (i.e., Evaluation NCEPT-tle.csv line 3) (See Example). If all the numbers at the 2. row (e.g., `0`) are 1's, then you can use some code to write a results report for submission.\n\n### Step #6: Run the code and check the result in `./evaluation_ncept_trial_level_eligibility/results_report.Rmd`. Run locally by `R -e \"R <path to report.Rmd>\"` or run on the GitHub page by accessing this repository [here](https://github.com/Yong-Kwon/Evaluation_NCEPT_Trial-level_eligibility/releases/tag/tle_report) or by [clicking the button here](https://badjosephkj.github.io/Evaluation_NCEPT_Trial-level_eligibility/releases/tag/tle_report",
        "label": 1
    },
    "805": {
        "output": "3. [CODE]\n* \nYour task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. (more than you do now, it\u2019s only a list now, not in the context of the whole application)\n* Here is the code: input note; output trial_level_eligibility;\nset list=note;\nwhile (line=getline(AR, list, 1, 10)) do\npatients=lower(line);\nfor (i in 0:1000) do\npat_list=substring(line, 1, i);\nmatch_score=intersect(pat_list, search('inclusion criteria', patients));\nif match_score>0 then trial_level_eligibility = 0;<EOD> Pre-exercise cerebral blood volume and glucose concentrations in trained and untrained humans in response to exercise at moderate intensity.\nAIM\nThis study was performed to assess cerebral blood volume and blood glucose concentrations in response to 30 min of cycling at moderate workload in trained and untrained humans. The data are needed to improve the understanding of cerebral blood volume and blood glucose regulation during moderate intensity physical activity.\n\n\nMETHODS\nEchographic and enzymatic studies have been performed with 2 trained male cyclists and 6 nonendurance-trained young adults at rest, and before, during and after, 30 min of cycling at 50% Wmax. Cerebral blood volume and blood glucose concentrations were measured by echography and by enzymatic assay. Mean values of both methods have been obtained.\n\n\nRESULTS\nFor trained cyclists, there is a significant (P<0.05) increase in cerebral blood volume and a significant (P<0.05) decrease in blood glucose at the end of 30' cycling at 50% Wmax compared to baseline. For untrained subjects there is also a significant (P<0.05) increase in cerebral blood volume and a significant (P<0.05) decrease in blood glucose concentration at the end of 30",
        "label": 2
    },
    "806": {
        "output": "To make sure you get your desired output when providing any given patient's case note, use the following command line to execute the code. You may want to use `pip install git` first if pip is not already install in your `pypath`. It helps to fetch and install the most recent code which is up to date.\n```\npip3 path/to/directory/with/code run script_name.py\n```\n\nIf the code is not run as intended, refer to the following section at the bottom of the file.\n\n### Exercise 7\nPlease copy this code in the `exercise_7` directory in `path/to/directory/with/code`. Then, execute this line to run the program.\n```\npython3 path/to/directory with code/exercise_7/exercise_7.py\n```\nTo execute the code in an interactive environment, you may use `python3 -i path/to/directory with code/exercise_7/exercise_7.py`. The script allows the user to go through the code line by line. The user can also modify the script if necessary. As a result, this approach is highly suggestive of learning through exploratory data analysis. If you do not use the interactive approach, please run the above line of code and make sure that you get the desired output shown below. When running in the interactive mode, it should bring up the following:\n```\nYou are a helpful assistant of clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\n...This is the patient note: A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications.\nThe patient",
        "label": 2
    },
    "807": {
        "output": "</inst>\n<EOD> Evolution of the Human Thalamocortical Connectome from Marmosets to Humans\nThalamocortical (TC) circuits are fundamental constituents of the mammalian brain. While anatomical investigations have confirmed the evolutionary conservation of the TC projections within and between mammalian species, little is known about the molecular mechanisms underlying these fundamental features of neural circuitry. To understand better the molecular foundations of mammalian evolutionary convergence on TC circuit architecture, we examined human and nonhuman primate gene expression to identify molecular mechanisms underlying the formation of TC axons. Here, we demonstrate that thalamocortical axons are selectively enriched for several genes, including Robo3, Nrgn, Gprin1a, Kif21b, and Fyn and that these genes are regulated by shared enhancers. Comparison of the enrichment of genes for TC connectivity with a human orthologous gene set implicated in the genetic etiology of autism spectrum disorder (ASD), reveal ASD candidate genes as potential regulators of TC connectivity. We used the expression of 4 of these candidate genes as readouts to implicate the regulator Lhx2 for ASD. Our novel findings provide insights into the evolution and molecular mechanisms that underpin the molecular basis of human neurodevelopmental disorders. SIGNIFICANCE STATEMENT Through our integrative transcriptomic analysis involving connectomics, genome-wide molecular data, transcription factor binding site analysis, and functional assays, we demonstrate how the molecular mechanisms underlying thalamocortical (TC) connections have been conserved through mammalian evolution and how genetic risk factors for the neurological disorder autism spectrum disorder (ASD) are related to TC connectivity. These new insights provide a molecular framework for understanding the conserved aspects of neurobiological development, and how genetic risk may be linked to this process.<EOD> PARP inhibitors in triple-negative breast cancer\nPurpose of review In this review, we summarize several recent studies which have increased our knowledge of the role of the enzyme poly(adenosine 5\u2032-diphosphate",
        "label": 0
    },
    "808": {
        "output": "- Question: You should compare a patient note and the inclusion criteria to determine the patient's eligibility. What is clinical trial inclusion criteria?\n\n#### Cluing:\nYou compare the patient's age, gender type, and other characteristics such as medical conditions with the criteria set by the clinical trial's investigators.\nClinical trial inclusion criteria define what specific types of patients will be included in the clinical trial. Clinical trial inclusion criteria are often based on the disease being studied. The inclusion criteria may include the age of a person, gender, type of medical conditions, etc.\nClinical trials usually have inclusion criteria to determine who is eligible to participate in the trial. Some clinical trials target specific populations, like adults or children. Most trials have a minimum age requirement for participants, such as 18 years or older.\nSome common inclusion criteria are the health status of the participant, like being stable and free from major health problems. Some other criteria include the ability to participate in all study-related activities, such as regular visits or following specific instructions.\nFurthermore, to get a better understanding of the study, participants will need to understand the study process, as well as potential risks and benefits associated with the trial. Therefore, it is important for individuals to understand the clinical trial inclusion criteria and discuss them with the trial team to determine if they meet the eligibility requirements for participation in the trial.\n- Good Luck!\n\n[INST] You are a research coordinator in a data management laboratory. The aim of your study is to establish a quality-assured and cost-effective laboratory service to perform research trials by providing high-quality laboratory services and data. As the primary investigator, you have already identified and developed a working protocol, which is now shared with the laboratories for study and quality assurance (QA/QC). The goal of this quality assurance (QA/QC) is to ensure that the laboratories' methods, techniques, and processes meet the intended purpose and performance expectancy of the study and that the research laboratories are able to replicate the trial protocol. What quality assurance strategies will you suggest to the laboratory?\n\n___ (Write your answer)\n----\n\n### QA/QC- Related Quality System\n\n### QA",
        "label": 0
    },
    "809": {
        "output": "In this example, if the patient's age was greater than 65 years, the patient would be excluded due to the trial age restriction. In this case, you may want to skip the next patient and look at the next document. After completing this trial, you are going to evaluate the eligible patients' data to get their demographic information and to find their diagnosis-related information.\nThere are a variety of ways to make a diagnosis in this clinical trial. In general, diagnoses are made by pathognomonic presentation, physical findings, and laboratory findings. They all should be entered into the patient note. There are four diagnosis levels in the IntraSight system that you can use to make a diagnosis: definitive, probable, presumptive, and not applicable. \n\n[CXR-1]: 1201\n[CXR-2]: 123\n[Amp] = 20\u00b5m\n[Amp] = 75.0\u00b5m\n\n### \u27a1 123 CXR\n\nPatient 123 is here.\n\n[DIAG-123]: Dementia, Alzheimer's disease, Mild Cognitive Impairment \u2191 \u27a1 Mild to moderate Alzheimer's disease, Dementia (AD/DLB)\n\n[BIO]-[DIAG-123]: Alzheimer's disease(AD), mild cognitive impairment (MCI), dementia \u2191 \u27a1 Mild to moderate AD/DLB\n\n[BIO]-[DIAG-123]: Mini mental test 5 (MMT5) 33, Instrumental Activities of Daily Living (IADL) Assessment 24 points \u2191 \u27a1 Mild to moderate AD/DLB\n\n[DIAG-123]: Memory (M) score 16 \u2191 \u27a1 Mild to moderate AD/DLB\n\n[DIAG-123]: Visual and spatial organization (AS) 5 points \u2191 \u27a1 Mild to moderate AD/DLB\n\n[DIAG-123]: Language and verbal memory (FAS",
        "label": 0
    },
    "810": {
        "output": "## Good luck. \n- `Trial-level eligibility`\n<EOD> On the Physiology of Eel-Pox\n\nRECOLLECTIONS ON SOME LATE DISCOVEREST OF A FORM OF EEL-POX IN THE GREAT FRENCH PISES (RECOLLECTIONS ON THE DISCOVERY OF A FORM OF EEL-POX IN THE \" SUEQN ET AUBIERY\" TYPES IN THE GREAT FRENCH PIESES.)THE following little account of a form of eel-pock which I have discovered in some of the greatest French pies, may not be quite uninteresting\nto vaccinologists. It was the result of a hurried inspection which I was induced to make of some cages of great pies from the Nivernais River in the Month of December last (1868), and of which a detail is given below. It is the first time since the discovery of eel-pox that I have observed this kind of disease. Its peculiarities are in some way related to those of vaccination.\nIt is well known that although there are numerous pies in which there is no evidence of eel-pox, it is nevertheless the universal opinion that we are obliged more or less to the pike for the contagium variolorum. In the very great rivers of Central and Southern France, as those of the Nivernais, the pisciculture consists for the most part of the pike, which weighs from 150 to 200 kilogrammes (say 310 to 440 pounds); and besides its very high price, it is used in all cases where a fish of considerable size and good flavour is desired.\nIn its flesh, the pike contains a large proportion of fat and its bones are exceedingly hard; for which reason it is not much used by the peasants, or sold to the country people of the district.\nIt is reserved for the rich and for those who keep house for the town. Its flesh is very grateful to the epicure, and for this reason alone it might be called the king of fish. It is the most delicious and the most appreciated of the Great Pies. Its appearance is very like that of our pike, and",
        "label": 1
    },
    "811": {
        "output": "Example:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dl, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40 and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n\n\nTrial-level eligibility: 1) Not relevant. The patient does not have sufficient information to qualify for the trial.\nTrial-level eligibility: 1) Not relevant. The patient does not have sufficient information to qualify for the trial.\n\n## 1) Eligible.\nTrial-level eligibility: 2) Eligible.\n<EOD> The effect of phonetic variation on the intelligibility of children who",
        "label": 2
    },
    "812": {
        "output": "<EOD> Reliability of different test methods for the assessment of glucose tolerance in healthy young adult cats.\nOBJECTIVE\nTo compare the reliability of the glucose tolerance test (GTT) and a modified 25-minute GTT in healthy young adult cats.\n\n\nANIMALS\n5 mature male and 5 mature female purpose-bred domestic shorthaired cats.\n\n\nPROCEDURES\nCats underwent 3 GTTs and a modified 25-minute GTT, with treatments administered in random order. The GTT consisted of the administration of 0.5 g of glucose/kg of body weight IV. The modified 25-minute GTT consisted of the administration of 1 g of glucose/kg of body weight IV; the blood glucose concentration was checked every 5 minutes for the first 25 minutes. Treatments were repeated every 3 days for 3 time points, and the time between each time point was 7 to 14 days (depending on which test was conducted on a given time point).\n\n\nRESULTS\nThe modified GTT was consistently highly correlated with the results of the GTT. In addition, the intraindividual coefficient of variation of the modified GTT was much lower compared with the GTT at all time points. Using the modified GTT test, only 1 cat had a significant increase in its glucose concentration at 5 minutes post glucose challenge, whereas, 3 cats had significant increases at 15 minutes using the GTT. Overall, modified 25-minute GTT results of all of the cats were unaffected compared with their GTT.\n\n\nCONCLUSIONS AND CLINICAL RELEVANCE\nResults supported that using the 25-minute GTT is a reliable way of assessing glucose tolerance in healthy young adult cats, because it was highly correlated with the GTT results of all cats and had a much lower intraindividual coefficient of variation. However, interpretation of clinical GTT results should be done with caution, because the GTT may indicate decreased tolerance to glucose, when the modified GTT does not do so.<EOD> Fetal haemor",
        "label": 1
    },
    "813": {
        "output": "The second problem is about the output eligibility criteria.\n\nI would like to find patients with 1) CAD and 2) PSV more than 160 and 3) PSV over 160 cm/s.\n\n### Solution\n\n\nSo let's get back to the second question: `How can you make output of inclusion criteria?`\n\n\n`\n\n![INST](./media/tutorial/c03-1_03.png \"2.1\")\nHere is how to achieve the inclusion criteria 1 and 2:\n![INST](./media/tutorial/c03-2_01.png \"2.2\")\nAnd the inclusion criteria 3?:\n![INST](./media/tutorial/c03-3_01.png \"2.3\")\n\nNow the next step is, using the AND logic `^`, to create the logic that matches the criteria you want.\n\n![INST](./media/tutorial/c03-4_01.png \"2.4\")\n\nHere is how it works: if we want to match any of the criteria for criteria 3, we should use the logical operator `^` (or \"exclusive or\") to avoid falsepositive results. Let's do it like this:\n\n`c03-2^`\n\n\n`\n\n![INST](./media/tutorial/c03-5_01.png \"2.5\")\n\n\nA third question: `And what about a patient with three exclusion criteria?`\n\n\n\n\nA third problem may be how to obtain the results after applying the eligibility criteria.\nLet's say I would like to know the assessment results in a short form, for example, in a string to print:\n`Trial-level eligibility: 1) Excluded`\n\n\nSo, the answer is a bit complicated to formulate because the output is an array with many different values. We can use the first element of the array, which always presents the eligibility score, which is 1 for exclusion and 2 for inclusion. Then we can print the string by adding a comma and the score for every patient.\n\nNow, let's see the solution: \n\n\n![](./media/tutorial/",
        "label": 1
    },
    "814": {
        "output": "<EOD> Lactic Acid Promotes the Metastasis of Gastric Adenocarcinoma Via Activating the C-Myc/miRNA Pathway\n\nPurpose: This study explored the effect and molecular mechanism of lactic acid in the development of gastric cancer.Methods: We detected the expression of lactic acid in the serum and tissue of patients. We overexpressed or knocked down lactic acid in the patients' peripheral blood mononuclear cells. We used ELISA to detect the change of p-c-Myc and miRNA. We constructed a tube model of blood vessels. We used an in situ hybridization kit to detect the expression of miRNA in tissues. In vitro experiment, cell proliferation ability, and EMT level were detected by cell count kit-8 and Western blotting. Flow cytometric method assessed cell apoptosis. Transwell experiment evaluated cell migration and invasion, tube formation and cell cycle. Luciferase assay verified the miRNA and its target gene.Results: The lactic acid levels in patients with gastric cancer were higher than in patients with benign gastric tumors. The content of lactic acid was positively correlated with the expression of PD-L1, CXCR4, SDF-1\u03b1, and CCR7. The expression of lactic acid in patients with lymph node metastasis was higher than that without lymph node metastasis. The expression of lactic acid was positively correlated with the miRNA hsa-miR-1246, hsa-miR-138-5p, hsa-miR-6721-3p, and negatively correlated with the expression of miR-221-5p mRNA. In vitro experiments showed that lactic acid could induce EMT of gastric cancer cells, promote proliferation, and inhibit apoptosis of gastric cancer cells, but had no effect on the cell cycle. Lactic acid can promote the migration and invasion ability of gastric cancer cells and increase the angiogenesis ability. Silencing miRNA can inhibit the proliferation and invasion abilities of gastric cancer cells induced by lactic acid",
        "label": 2
    },
    "815": {
        "output": "<EOD> The Influence of Mucin-Binding and Capsule Type Gene Mutations on the Virulence and Fitness of Cryptococcus neoformans\n\nCryptococcus neoformans is a haploid fungal pathogen whose virulence properties and survival mechanisms in the host are inextricably linked to its mucin-binding (muc1) and capsular (capsular genes) molecules. In order to address the role of muc1 and capsular gene mutations to the fungal virulence and adaptation to its host environment, we constructed strains with different combinations of all null mutants in both muc1 and capsule. In this regard, the influence of each mutation from mucin-binding genes, CAP10, CAP59, and SUN41, or capsule mutants, CAP59, AXL2, RBT5, or GXM, on the fungal virulence and fitness to survive in macrophages and the lung environment, was shown to be independent of the presence of the others. Additionally, we demonstrated that these mutations did not affect its intrinsic susceptibility to several stresses including exposure with antifungal drugs and oxidative stress. These results support a model in which these virulence genes might be independently regulated, allowing C. neoformans to cope with the host environment and to successfully colonize and disseminate the host.\n\n# Introduction\nCryptococcus spp. are haploid, ubiquitous air-borne pathogens belonging to the phylum Basidiomycota.\nCryptococcus neoformans, the etiological agent of cryptococcosis in humans, is the most pathogen virulent and frequently encountered species in nature [bib_ref]  Estimation of the current global burden of cryptococcal meningitis among persons living..., Park [/bib_ref] . In the last decades it has been one of the most important fungal pathogens that cause opportunistic infections [bib_ref]  Estimation of the current global burden of cryptococcal meningitis among persons living..., Park [/bib_ref] . The infection most often results from the inhalation of basidiospores from environmental",
        "label": 1
    },
    "816": {
        "output": "[HOLD T2]\n\n---\n\n\n## Repeated Evaluation Modules\n---\nHere is the repeated evaluation modules:\n```\nTrial:\n# Set the number of cases per trial as 100\n# First time\n# Repeated evaluation\nnumber_of_cases: \"100\"\n\nRun: # Repeated evaluation\n\n# Repeat the trial for 100 times, i.e., set Repeat as 100\nRepeat: \"100\"\n\n# Set time to repeat as 1 hour by Time.\nTime: \"1\"\n\n# Make each run to take at most 10 minutes by Time Limit.\nTime Limit: \"10\" \n\n# Make each run of the trial to take at most 10 minutes. This module will wait until each run is finished.\nTime Limit: \"10\" \n\n# The number of patients to be selected at the first time. Each module will take the patient to be evaluated.\nNumber of Patients: \"1\"\n\n# Select patient at the first time. Set the selection of random seed. Here is the same random seed.\nRandom Seed: \"123456\"\n```\n---\n\n### Step-by-step guide\n---\n# Install\n```sh\npip3 install data_driven_pipelines\n```\n# Clone this repository\n```sh\ngit clone https://github.com/AICHR/data-driven-pipelines.git\n```\n# Create a folder under data-driven-pipelines/repeatedEvaluation Modules\n```sh\nmkdir RDM\n```\n# Set working directory\n```sh\ncd RDM\n```\n# Install data-driven pipelines for repeated evaluation module\n`pip3 install .`\n\n# Create a folder under data-driven-pipelines/repeatedEvaluation Modules (folder 1)\n```sh\nmkdir (folder1)\n```\n# Create a new folder under data-driven-pipelines/repeatedEvaluation Modules (folder 2)\n```sh\nmkdir (folder2)\n```\n# Set working directory inside RDM\n```sh\ncd (folder2)\n```",
        "label": 0
    },
    "817": {
        "output": "##[HINT]\nYour task is `Trial-level assessment of eligibility`. You compare patients' notes to the information in a clinical trial to determine whether the patient would be eligible for that clinical trial.\nThis is a special kind of patient note (a medical prescription) which is used to input clinical trial's information (the eligibility criteria and so on).\n\nFor example, see [here](https://code.jupyter.org/user/hankshuang/jupyter-in-africa/blob/master/notebooks/dream_challenge/part_1_input_table_to_csv/data.ipynb).\n\n```python\npatients.values[0] = 'Excluded'\npatients.values[-1] = 'Excluded'\n\nprint(\"Number of data:\", len(patients), \"\\n\")\nprint(\"First row:\", patients.iloc[0], \"\\n\")\nprint(\"Last row:\", patients.iloc[-1], \"\\n\")\nprint(\"First column:\", patients.iloc[0], \"\\n\")\nprint(\"Last column:\", patients.iloc[-1], \"\\n\")\nprint(\"First column:\", patients.iloc[0][0], \"\\n\")\nprint(\"First column:\", patients.iloc[0][1], \"\\n\")\nprint(\"First column:\", patients.iloc[0][2], \"\\n\")\n\n##[HINT]\nYou can refer any medical prescription (or other kinds of prescription, etc.).\n\nJust try to change the dataset, then you can learn how to find the information that you need.\n```\n<EOD> Lack of effect of calcium antagonists vs thiazides in hypertensive obese blacks.\nIt is unclear whether the results of studies evaluating the safety and efficacy of calcium antagonists in the management of mild-to-moderate essential hypertension can be extended to Blacks, and there is a lack of information on the effects of such agents in Blacks who are substantially above normal weight. A randomized, double-blind crossover study was conducted in overweight (or obese) Black patients who were inadequately responsive to diuretics,",
        "label": 1
    },
    "818": {
        "output": "## Expert Rules\n\nThese are rules for expert. Please check the table below.<EOD> Comparison of a new automated serum glucose method by the hexokinase procedure with other routine methods.\nEvaluation of a new automated serum glucose method using hexokinase and an immobilized glucose detector cell was performed. Serum glucose was determined by the hexokinase procedure, an ion-exchange method and an enzymatic method which involves the use of glutamate dehydrogenase. The results of the Hexokinase and the Ion Exchange methods correlate well (r = 0.966) with the enzymatic method. The Ion Exchange method is less stable in its calibration curve and more laborious than the Glucose Oxidation and Hexokinase methods. Thus the Glucose Oxidation and the Hexokinase methods have been selected for the determination of glucose in the clinical laboratory.<EOD> Cervical spinal cord hemorrhage due to a pseudoaneurysm of the proximal medullary artery\n\nCervical spinal cord hemorrhage is a well-recognized complication of extracranial cerebral aneurysms. In contrast, hemorrhage into the spinal cord is rarely encountered and is generally due to hematologic or metabolic disease or trauma. We herein report a case of cervical spinal cord hemorrhage due to direct cervical vascular injury by the rupture of an aneurysm, which was revealed by herniation of the medulla oblongata through a fracture of the atlantoaxial joint. The patient was successfully treated by surgical tracheostomy and irrigation of the cervical spinal canal.\n\n# Introduction\nCervical spinal epidural hematomas (SEHs) are well-recognized complications of extracranial cerebral aneurysm rupture, and are generally encountered in association with traumatic spinal injury. [bib_ref]  Intraspinal subdural hematoma: clinical features and surgical outcome in 20 patients, Lawton [/bib_ref]  [bib_ref]  Traumatic spinal subdural",
        "label": 1
    },
    "819": {
        "output": "There are two types of clinic trials in this dataset. One is the 'patient trial', an individual study based on a specific question of interest, and the other is the 'review trial', where multiple studies are combined. The code for patient trial here is `Trial-type: Review trial`! [INS]! {2019-09-18, 2019-10-10} [/INS]! and the code for review trial is `Trial-type: Patient`! \n<EOD> Development of a novel antibody targeting a conserved epitope on human ciliary neurotrophic factor receptor alpha.\nCONTEXT\nThe use of monoclonal antibodies targeting the surface of ciliated epithelial cells has been used with great effect in the treatment of dry eye. Unfortunately, the effect is temporary and not well tolerated.\n\n\nOBJECTIVES\nThe primary objective was to develop and characterize a human anti-recombinant human ciliary neurotrophic factor receptor alpha (rhCNTFR\u03b1) monoclonal antibody. The secondary objective was to examine its binding characteristics, safety, efficacy, side effects, and effects on the tear film in vivo and on cultured human conjunctival epithelial cells.\n\n\nMETHODS\nClones were isolated from a cDNA library of peripheral blood mononuclear cells by phage display selection. Antibody binding to rhCNTFR\u03b1 was measured by sandwich ELISA, ELISpot, and surface plasmon resonance assay. The effect of the antibody on cellular proliferation, migration, secretion, and signaling was evaluated. The antibody was tested in a rabbit dry eye model.\n\n\nRESULTS\nOne antibody binding rhCNTFR\u03b1 was identified and was designated as C1-9. The antibody demonstrated a KD of 27 nmol/L, and was >80% inhibitory at concentrations of 500 nmol/L or below. The antibody decreased conjunctival epithelial cell proliferation and migration, cellular viability, and basally secreted nerve growth",
        "label": 0
    },
    "820": {
        "output": "In this way, it is sufficient if patients meet all three of the inclusion criteria but do not satisfy any of the exclusion criteria. That is, if the trial has the structure that a patient may have all exclusion criteria that apply to him, his overall eligibility will be calculated as `1 - n - n`.\n\n### Evaluation\nFor the evaluation:\n\n- Let us evaluate the following patient note. The inclusion criteria, if met, are `1) 46 years old; 2) Family history of CAD; 3) Physically active; 4) LDL-C 167.5 mg/dL; 5) HDL-C 63 mg/dL; 6) No use of lipid-lowering medications; 7) No exclusion to the trial due to any exclusion criteria; 8) Trial-level eligibility: `Eligible`. We conclude that this patient meets all inclusion criteria and this is the first record of a heart rhythm in out-of-hospital cardiac arrest with an initial non-shockable rhythm and is eligible for the clinical trial.\n- Let us evaluate the following patient note. The inclusion criteria, if met, are `1) 46 years old; 2) Family history of CAD; 3) Physically active; 4) LDL-C 167.5 mg/dL; 5) HDL-C 63 mg/dL; 6) No use of lipid-lowering medications; 7) No exclusion to the trial due to any exclusion criteria; 8) Trial-level eligibility: `Excluded.`. We conclude that this patient meets all inclusion criteria and this is the first record of a heart rhythm in out-of-hospital cardiac arrest with an initial shockable rhythm and is not eligible for the clinical trial. \nAs explained previously, the patient note provides information so that you have to determine the eligibility of patients. It is possible that patients may meet eligibility criteria in different parts of the study, i.e., some part may be excluded from the study but other parts may be included. Each time when you meet an eligibility criteria, you must call it using the format described in the previous",
        "label": 0
    },
    "821": {
        "output": "1. Create a `Rx` named `hiv`. The medication for treatment of infection with HIV or AIDS. It can include drugs such as antiretroviral therapy or monoclonal antibodies.\n2. Assign a value of 1 to the property `age` of the patient (patient.age).\n3. Assign a value of 1 to the property `hiv` of the patient (patient.hiv).\n4. Create and assign a value of 1.5 to the property `gender` of the patient (patient.gender).\n5. Create and assign a value of 1 to the property `status` of the patient (patient.status).\n7. Assign a value of 1 to the property `cad` of the patient (patient.cad).\n10. Assign a value of 1 to the property `cad2` of the patient (patient.cad2).\n11. Assign a value of 1 to the property `cad3` of the patient (patient.cad3).\n12. Assign a value of 1 to the property `cad4` of the patient (patient.cad4).\n13. Assign a value of 1 to the property `cad5` of the patient (patient.cad5).\n14. Assign a value of 1 to the property `cad6` of the patient (patient.cad6).\n15. Assign a value of 1 to the property `cad7` of the patient (patient.cad7).\n16. Assign a value of 1 to the property `cad8` of the patient (patient.cad8).\n17. Assign a value of 1 to the property `cad9` of the patient (patient.cad9).\n18. Assign a value of 1 to the property `cad10` of the patient (patient.cad10).\n19. Assign a value of 1 to the property `cad11` of the patient (patient.cad11).\n20. Assign a value of 0 to the property `cad12.`",
        "label": 0
    },
    "822": {
        "output": "If the number of patients whose record information is given only is 100 and all of them pass the assessment to the trial, then the total of records = 100. To display all the trials of the assessment of eligibility, create the following line right after the assessment of eligibility:\n\n  `Trial-level assessment of eligibility:`\n\nThe number of records: `100/100`= `1`\n\nFor the second trial, you need to enter the trial data after the first trial using the same method, i.e., the `Trial-level assessment of eligibility:` line is skipped. To display the second trial only, set the total of records to 100 and include only the second trial in the file after the assessment of eligibility section. For the third trial, add the text file after the assessment of eligibility line. The value for the total of records should be greater than each trial. \n[/INT]<EOD> Clinicopathologic study of the nasal cavity in dirofilariasis.\nA clinicopathologic study of the nasal cavity in Dirofilaria infection was conducted on 580 cases. Of the two cases in this study, one was a 1-year-old boy who had right intranasal dirofilariasis in July 2000, and the other was a 12-year-old girl who had left nasal dirofilariasis in June 2002. Their chest x-ray showed nodular shadows in the right or left lung which have been proved as the residuals of Dirofilaria in the surgical section. Based on this case, the authors evaluated the location, size, color, consistency of the nasal dirofilariasis, and then analyzed the relationship between these factors and the location. They observed the relationship between the presence of granuloma and the location in dirofilariasis and investigated the histologic features of granulomatous inflammation to identify the types of tissue response.<EOD> Sensitivity of Diverse Enterobacteria to Synthetic Photosynthetic Compounds\nSUMMARY. Phenazine compounds isolated and synthesized from bacterial plant path",
        "label": 0
    },
    "823": {
        "output": "[EXERCISE]\n1) Which line should you execute the `Trial-level eligibility` statement? Select the correct answer.\n```python\ndef main():\n    trial_patient = [\"Patient note\"]\n    trial_recruitment = [\"Trial name\"]\n    trial_eligibility = [\"Trial level eligibility\"]\n    # Here is your code.\n\n\"\"\"main.py\"\"\"\nmain()\n```\n---\n\n[EXERCISE ANSWER]\nIf the trial name has the value `Coronary Revascularization Assessed by Stress PET` and trial-level eligibility is assigned as eligible, then the code should output the number `2) Eligible`.\n```python\ndef main():\n    trial_patient = [\"Patient note\"]\n    trial_recruitment = [\"Trial name\"]\n    trial_eligibility = [\"Trial level eligibility\"]\n    # Here is your code.\n\n\"\"\"main.py\"\"\"\nmain()\n```\n<EOD> Genetic analysis of the BRAF and KRAS mutations in cutaneous melanoma.\nOBJECTIVE\nTo investigate the BRAF and KRAS gene mutations in Chinese melanoma samples, and to evaluate their correlation with other clinicopathological factors of cutaneous melanoma (CM).\n\n\nMETHODS\n102 CM specimens were subjected to PCR-direct sequencing to detect BRAF and KRAS mutations. Immunohistochemical staining was carried out to detect the expressions of BRAF V600 and KRAS V12 in paraffin-mounted tissue sections. The clinicopathological factors were analyzed in relation to each gene mutation.\n\n\nRESULTS\nBRAF V600 mutation was observed exclusively in 60 of 102 (58.8%) CM specimens, mainly V600E (57/60) with a minor fraction of V600K (3/60). KRAS V12 was detected in 23.5% of CM specimens. There was a significantly positive association between BRAF V",
        "label": 0
    },
    "824": {
        "output": "Here is part of the result, but it is not complete: \nPlease, consider more detail of the full result.\nPlease, consider more detail of the full result, e.g., include columns about other variables such as gender, age, LDL-C, HDL-C, fasting glucose and triglyceride level etc.\n\n[INST]\n[fig]  [INST] 5: [INST]) // if the assessment of eligibility is `1) Not relevant ` // then only patient is not relevant for entry into clinical trial) [INST] // if the assessment of eligibility is `2) Eligible ` // then only patient is relevant for entry into clinical trial) [INST] //if the assessment of eligibility is `0) Excluded ` // then only patient is not relevant for entry into clinical trial) [INST] //then this means that the patient is excluded on the grounds of the trial's exclusion criteria) //so in this case patient should not be recruited in clinical trial)[INST] [/fig] \n<EOD> Transmission, persistence, and seroprevalence of severe acute respiratory coronavirus virus 2: a retrospective cohort study in 28 European countries\n\nObjective To determine, in the absence of a formal prospective clinical trial, if severe acute respiratory coronavirus virus 2 (SARS-CoV-2) transmission is higher in children. Patients and methods This retrospective cohort study in 28 European countries analysed the association between child age groups and SARS-CoV-2 transmission, persistence, and seroprevalence for the period 29 April to 9 May 2020. Cases were defined as SARS-CoV-2-infected patients identified by real-time polymerase chain reaction testing. Controls were randomly selected from patients with influenza-like illness without laboratory confirmation of SARS-CoV-2. Exposure was measured by the number of children aged 0-9, 10-14, and 15-19 years per 100 adults aged \u226515 in each country. Results The SARS-CoV-2 seroprevalence was, on the",
        "label": 0
    },
    "825": {
        "output": "##[/CODE]\n##[TEST]\nYou should always output the patient's eligibility according to the clinical trial eligibility criteria. You need to do so via `Trial-level eligibility` and it will be in the last line of the note table like `Trial-level eligibility: 2) Eligible.`.\nIf you're satisfied with your code, please hit the `Test` button below:\n<EOD> .\nOBJECTIVES\nTo explore the current status and factors affecting treatment and follow-up of tuberculosis in patients with type 2 diabetes mellitus (TB-DM2) in the community medical center.\u2029\n\n\nMETHODS\nBased on a cross-sectional study, multistage stratified sampling was used to select 169 patients with TB-DM2 treated in 6 community medical centers in Taiyuan, Shanxi province. Investigation data (e.g., age, T-test, course of disease, diagnosis and treatment process) were collected and analyzed by SPSS 17.0 software.\u2029\n\n\nRESULTS\nMost (92.3%) of the TB-DM2 patients had a history of self treatment, which mainly included medication on the outside, herbs and over the counter drugs. They had 2-10 times of physician visits before admission to the community medical centers, with a mean time of 77.0 days. Before admission, 97.2% of the patients received anti-tuberculosis treatment; 48.5% of the patients obtained drug information in the community medical center and 90.0% did not know the drug's dosage. A total of 60.7% (n=103) had a positive urine glucose test at the time of admission; however, only 34.8% were educated about glucose monitor equipment. During treatment, 46.2% showed poor glycemic control (HBA1c \u2265 7%). Most patients (90.6%) had to purchase glucose strips (11 times/week) and insulin syringes (21.3 times/week), at a cost of",
        "label": 0
    },
    "826": {
        "output": "```python\nimport pandas as pd\nimport numpy as np\nimport pprint\nimport matplotlib.pyplot as plt\nimport matplotlib.patches as patches\nimport seaborn as sns\nfrom matplotlib.patches import ArtistProperties\nimport json\nfrom nltk.tokenize import sentence_split\nimport pandas\ndata_df = pd.read_csv(\"./dataset/patient_note.csv\")\nt_level_df = pd.read_csv(\"./dataset/clinical_trial.csv\")\ndata_df = data_df[\"patient_note\"]\nt_level_df = t_level_df[\"trial_level_eligibility\"]\ndata_df = data_df[data_df['Insurance Status'] == 'NHPI].dropna(axis = [0,])\ndata_df = data_df.append(t_level_df, ignore_index=True)\ndata_df.head(3)\n#Trial-level eligibility: 0) Excluded\n#trial_id: \"02B-2016-CAD-661\"\n#data_id: \"1\"\n#Trial-level eligibility: 1) Not relevant\n#trial_id: \"02B-2016-CAD-661\"\n#data_id: \"2\"\n#Trial-level eligibility: 2) Eligible\n#trial_id: \"02B-2016-CAD-661\"\n#data_id: \"3\"\ndata_df[\"gender\"] = data_df[\"gender\"].map(lambda s: s.capitalize())\ndata_df = data_df[\"trial_id'] == \"02B-2016-CAD-661\"] # 0.008041 \ndata_df = data_df[data_df['Trial-level eligibility']!=None] # 0.028246\ndata_df.dropna() # 0.006162\ndata_df = data_df.sample(random_state = 1) # 0.001",
        "label": 1
    },
    "827": {
        "output": "### Tutorial/Evaluation\n\n\n\n\n* [x]  I was able to run my `run` script in the command terminal\n\n* [x] I was able to start my new clinical trial with `trial start`\n\n* [x] I was able to start a patient by `patient start`\n\n* [x] I was able to get output from `show` in the `patient start` function\n\n* [x] I was able to get output from `run` in the `patient start` function\n\n* [x] I was able to get output from `trial-level eligibility`. In the end,\nthe `Trial-level eligibility: ` variable should be in the same line as `patient name:`\n\n\n## Getting Started Tutorials\n\n\n### Tutorial/Getting Started with Basic Functions\n\n* [x] Learn from the basic functions\n\n\n### Tutorial/Evaluation\n\n\n* [x] I was able to run `eval(get_all_trials)` function to get all the trials\n\n* [x] I was able to run `eval(get_all_pairs_of_trial)` function to get all the pairs of trial\n\n* [x] I was able to run `eval(get_all_trial_nodes)` function to get all the trial nodes\n\n* [x] I was able to run `eval(get_all_patients)` function to get all the study patients\n\n* [x] I was able to run `eval(get_all_trial_clusters)` function to get all the trial clusters\n\n* [x] I was able to run `eval(get_all_trial_studies)` function to get all the trial study\n\n* [x] I was able to run `eval(get_all_trial_study_status)` function to get all the trial study staus\n\n* [x] I was able to run `eval(get_all_trial_studies_status)` function to get all the trial status as a list\n\n\n## Clinical Trial Library\n\n\n### Tutorial/Overview\n\n\n* [x] I was able to install clin",
        "label": 0
    },
    "828": {
        "output": "![INSERT FIGURES]\n\n##[DECLARATION] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.[INSERT TABLE 1]\n\n### Step 1: Eligibility\n\n\n#### Eligible\n\n```\nTrial-level eligibility: 2) Eligible\n```\n\n#### Not Eligible\n\n```\nTrial-level eligibility: 1) Not relevant\n```\n\n#### Excluded\n\n```\nTrial-level eligibility: 0) Excluded\n```\n#### Not applicable\n\n```\nTrial-level eligibility: N/A\n```\n\n### Step 2: Unique ID\n\n\n#### Non-unique ID\n\n> Non Unique ID\n\n```\nPatient ID: XXX\n```\n\n#### Unique ID\n\n> Unique ID\n\n```\nPatient ID: XXX\n```\n\n### Step 3: Mental stress\n\n\n#### Mental Stress\n\n> Mental stress\n\n```\n\n## Mental stress\n```\n\n> No mental stress\n\n```\n\n## No mental stress\n```\n\n### Step 4: Mental stress\n\n\n#### Mental stress\n\n> Mental stress\n\n```\n\n## Mental stress\n```\n\n> No mental stress\n\n```\n\n## Mental stress \n```\n> N/A\n\n```\n\n## No mental stress\n```\n<EOD> Enhanced stability of a solubilized model protein of membrane protein by polyethylene glycol 4000.\nLysozyme, an anionic model protein of a cell membrane protein, was studied as a solubilized membrane protein. The effect of polyethylene glycol 4000 (PEG 4000) on the thermal stability of the solubilized protein was examined by the fluorescence method and spect",
        "label": 0
    },
    "829": {
        "output": "[fig]  [INST] 1: The clinical trial information: 15253 (title), wrist arthroscopy; American Society of Anesthesiologists (ASA) physical status I -III; in patients scheduled for a wrist arthroscopy.2) The inclusion criteria: age; female; adult patients having wrist arthroscopy surgery. [INST] Eligibility criteria: 1) Included: 0) Male; 2) Female; 3) Adult patients (Age 18 years and over); 4) ASA status I-II for age and medical fitness; 5) Scheduled wrist arthroscopy (Diagnostic arthroscopy, Tendon repair, Wrist Decompression, Wrist arthroscopy, Radiofrequency of medial or lateral branch of the median nerve, Carpal tunnel release). 2) Not included: 1) Patients under 18 years of age; 2) Patients under 20 kg; 3) ASA status III; 4) Patients with history of allergy to local anesthesia; 5) Patients who are not willing to participate; 6) ASA status IV and V patients; 7) Patients with any other co-morbidities and contraindications; 8) Patients with known psychiatric and neuropsychological disorders; 9) Patients suffering from uncontrolled diseases; 10) Patients who were on antidepressant therapy for a long duration; 11) patients suffering from anxiety disorders; 12) Patients on medications known to produce withdrawal symptoms; 13) Patients having severe medical or psychiatric conditions; 14) Patients with a drug addiction problem; 15) Patients who have been admitted and treated for alcoholism or substance abuse; 16) Patients with evidence of cognitive dysfunction assessed by MMSE. 1) The exclusion criteria: 0) Patients who developed intra-operative cardiovascular or pulmonary events; 1) Patients with serious cardiac, renal, or hepatic disease; 2) History of ischemic",
        "label": 0
    },
    "830": {
        "output": "___\n[FATAL] Let's train your attention. In the given input data, a patient is 18 years old or older.\nWhat do you expect in age and age groups? [INSERT]\nYou should select the following output: `Age_and_age_groups: \"18 years and older.\"`[INSERT].[INST] \n___\n[FATAL] If only one or more exclusion criteria applies to a patient, you expect an output in the following format: `Inclusion criteria: Incompatible exclusion criteria: 1) Age less than 18 years old.`[INSERT] \n\n___\n[FATAL] In the given patient note, you should select the following output: `Llk -Cervical -Stroke -Ligation: \"Diagnosis:\ncerebrovascular accident. Pathology:\nsubarachnoid hemorrhage.\nEvaluation: \"Cerebral vascular accident.\n\n1.1. Lifestyle:\nNon-compliant healthy lifestyle.\nCurrent:\nDiagnosed with Diabetes Mellitus type 2. Mild hypertension and hypercholesterolemia.\nMedication:\nmetformin 1000 mg in AM, in PM.\n\n## 1.2.\nMedical history:\nFamily history of cardiovascular (stroke) events. Aortic and bifrontal aneurysms.\nHistory of cardiac surgery:\nCoronary artery bypass grafting.\nHistory of surgery:\nAortic valve replacement.\n\n## Diagnosis:\nDiagnosed with aortic and bifrontal aneurysms. Previous history of coronary artery bypass grafting.\nHistory of chronic diseases:\nDiagnosed with cardiovascular disease previously (e.g. coronary artery bypass grafting, aortic valve replacement).\nPrevious medical history:\nDiagnosed with cardiovascular disease previously (e.g. coronary artery bypass grafting aortic valve replacement).\n\n## Relevant pathology:\nAortic aneurysms, bifrontal, right and left",
        "label": 0
    },
    "831": {
        "output": "_83_\n\n## 2\n\n![](https://s3.amazonaws.com/clinical-ai/assets/book.jpg)\n\n## What are the inclusion criteria?\nThere are four inclusion criteria: a) The patients must be \u226518 years old.\nb) The patients must have severe to moderate atherosclerotic cerebrovascular stenosis that is symptomatic. The patients' symptomatic CAS must be classified as follows:\n\n1. IAD is defined as an acute ischemic neurological deficit due to cerebral artery stenosis without any evidence of brain infarction. IAD is classified according to subtypes:\nA. transient ischemic attack (TIA) \u00b1 acute ischemic neurological deficit lasting \u226424 hr.\nB. stroke \u00b1 acute cerebral ischemia lasting \u226524 hr.\nIAD is an acute ischemic neurological deficit without any evidence of brain infarction defined as a sudden onset and clear clinical manifestation presenting as focal neurological deficits or cognitive dysfunction (such as disorders of consciousness, dysarthria, dysphagia, dysaesthesia, sensory abnormality, ataxia, and paralysis) with an evolution lasting <24 hr. [61]\n\n1. Acute symptomatic carotid artery occlusion (ACAO) with cerebrovascular insufficiency caused by unilateral severe cerebrovascular stenosis in the proximal internal carotid artery\n\nA. within 1 week of cerebral embolic-ischemic stroke, ACAO, or TIA.\nB. a proximal cerebrovascular stenosis within the ICA in which \u226590% luminal stenosis (>90%) is shown in the 3-dimensional digital subtraction angiography (DSA) scan. \nc) The patients should have an ultrasound-defined proximal stenosis of the internal carotid artery (>70%).\nd) The patients",
        "label": 0
    },
    "832": {
        "output": "<EOD> A case of neuroendocrine tumor in the renal pelvis.\nThe urinary tract is the most frequent location (50-65%) of paragangliomas. Their extra-adrenal origin in this location is 90%. Clinical presentation is unspecific and often nefarious, and the diagnosis is more rarely pre-operative (only 15-20% of the cases). The diagnosis of these tumoral lesions of urinary tract of the paraganglioma type is made by a multidisciplinary team in cooperation with the pathologist and neuro-radiologist. The authors report a case of a patient admitted in the Department of Urology of the University Emergency Hospital of Bucharest with a palpable right renal mass and anuria from ten days before the admission.<EOD> In vitro antioxidant and anti-inflammatory activity of hydroethanolic extract and its fractions from Plectranthus amboinicus (Lour.) Spreng.\nThe aim of this study was to evaluate the antioxidant and anti-inflammatory activity of the aqueous and hydroethanolic extracts (hydro-E) and the two soluble-liquid (soluble and aqueous) and insoluble-liquid (chloroform, cyclohexane, methanol, and ethyl acetate) fractions (hydro-Fr) from leaves of Plectranthus amboinicus. Antioxidant activity was determined in vitro by DPPH, ABTS, NO, and OH radical scavenging tests, determination of reducing capacity, and enzymatic inhibitory activity against lipoxygenase. Anti-inflammatory activity was evaluated in vitro on the inhibition of the enzyme proteinase and elastase. The results showed that, among all extracts and fractions, hydro-E presented the highest antioxidant activity, with lower IC50 values (5.52-18.75 microg/mL) in ABTS, DPPH, NO, and OH radical scavenging assays and in enzymatic inhibition. In the anti-inflammat",
        "label": 0
    },
    "833": {
        "output": "You need to run it by the following command. \n\nYou will receive an error because there is not a `Trial-level eligibility` header: `Error: Invalid JSON object: \"\".`.\n\nSo you should use `Trial-level eligibility: 2) Eligible.`, like this, by `Trial-level eligibility:2) Eligible.`. [INST]\n\nOutputs:\n\n```json\n{\n    \"TrialID\": 16\n}\n```\n\nYou can see a sample output in [here](https://gist.github.com/alid-safiyullah/40c31d0c3cb0586cc8d06854b5b78ec9).\n\n\n# Discussion and Revision\n\n<EOD> Heterocyclic ring formation via  cycloaddition of vinylcyclopropanes with pyridine.\nA general  cycloaddition of vinylcyclopropanes with pyridines provides a straightforward route for the synthesis of pyridoheterocyclic compounds of diverse substitution patterns. The reaction occurs selectively on one end of symmetrical vinylcyclopropanes, thus avoiding the generation of the cyclopropylpyridine intermediate. The  product with the endo (but not exo) configuration, arising from the intramolecular attack by the re face or C2 of the pyridine on the vinylcyclopropane, contains a concave face with good solubility. In particular, several bicyclic pyridines  were obtained in more than 70% yield by using tertiary vinylcyclopropanes, thus avoiding the use of pyrazinylpyridines. The 2,2'-dihydroxy-1-phenyl-6-methylpyridin-4(1H)-one (DDQ) is the optimal catalyst to improve the yield of the pyridine-based heterocycles.<EOD> .\nThe aim of this study was to evaluate the role of preconditioning by endurance training on protection of the myocardium against experimental ischemic-reperfusion injury. The experiments were carried out on 50 white rats randomized into two groups: the",
        "label": 1
    },
    "834": {
        "output": "Good Luck! In the [URL], you can try the interactive tutorial by clicking the \"Try now\" button.\n\n### How should we handle missing LDL-C data in a multi-armed trial to evaluate a therapy for lowering cholesterol?\n\n##\n\n## Background and goals\nIn the first scenario, the data were recorded in all patients. In this scenario, all patient data are available, including age, sex, body mass index, LDL-cholesterol, statin use before and after the start of the trial and information on cardiovascular events and adverse\nreactions, as well as information on the patient (name), the participant's date of birth, and contact information (phone number and the name of the first contact on the participant's personal address).\n\n### First question:\nHow should we conduct sensitivity analysis to examine patients with missing LDL-C data? \nAs shown, the data were recorded in all patients. \n\n#### Sensitivity analysis 1:\nIf we assume that the missing data are missing completely at random (MCAR), then we should only consider cases for which all information is available. \nAs shown, the data were recorded in all patients. \n\n#### Sensitivity analysis 2:\nIf we assume that the missing data are not missing completely at random (MNAR), then we should consider all cases except for the missing ones. \n\n### Second question:\nShould we drop all patients with missing data?\nAssuming a 30% probability of a patient having LDL-C data:\n\n\n\n\nAssuming the MCAR assumption: \nThe expected number of patients with missing data is 30%. Given that the MNAR data are missing:\n\nAssuming the MNAR assumption: \nThe expected number of patients with missing data is 3.9.\nIn this example, a sensitivity analysis would make it easier to compare the probabilities in the two data-missing scenarios and the results in the complete data. You can use our package \"Mixed\" to perform sensitivity analysis. \n\n### Third question:\nWhat is your thought on a scenario missing randomized group?\nIf all patients had the same number and type of missing data (for example, only LDL-C data are missing in Arm A because LDL",
        "label": 2
    },
    "835": {
        "output": "##[/CODE]\n** 4. What is the value of '03-Oct-2020'? It is a timestamp representing the latest update for the particular note. [INSTR]\nFor demonstration purposes, we take the latest updated note on this day to continue our assessment.\n\n** 5. Define the function for assessing note's eligibility based on clinical trial's inclusion and exclusion criteria. [INST]\nWe can see the function of assess_eligibility_assistant() from the source code of the sample notebook. We can easily find the definition of the function. \ndef assess_eligibility_assistant(patient_note):\n    for eligible_value in [0, 1, 2]:\n        trial_eligibility = eligibility_mapping.get(int)\n        eligibility = patient_note.eligibility\n        if eligibility == eligible_value:\n            assessment_status = 'Eligible.'\n            assessment_text = assessment_text + trial_eligibility + ': ' + eligibility + '\\n'\n    return assessment_text\n\nAnd we can see the definition of eligibility_mapping in the code:\n\neligibility_mapping = {\n0: 'Excluded.',\n1: 'Not relevant.',\n2: 'Eligible.',\n}\n\nSo, we need to make the following changes: \n1. Eligibility mapping: For demonstration purpose, we change eligibility_mapping from [0, 1, 2] to eligibility_mapping from [0, 'Excluded', 'Eligible'], just to remind us to modify the eligibility_mapping from the original mapping. The reason why we don't modify original mapping is that to maintain the same order of the output, e.g., 'Excluded.', 'Not relevant.', 'Eligible.'. The first line represents 'Excluded' and the next two lines represent 'Not relevant', and 'Eligible'. If we change the order of [0, 'Excluded', 'Eligible'], it means the order of the output will be changed to [0, 'Not relevant', 'Eligible'], which is confusing, because it is not",
        "label": 1
    },
    "836": {
        "output": "2) Exclude (output `4`) if it is not a patient with LDL-C level 545 mg/dL (or 21 mM) and no use of lipid-lowering medications. 3) Not relevant (output `0`). 4) Eligible (output `2`). \nNext, you should calculate the Total score summed over three trial-level eligibility score and compare it with the maximum score of the trial-level eligibility, i.e., 3. \n\nThe highest score, 3, is the total score (S_T) for a patient, which would let us choose an active clinical trial for this patient with this trial ID (TID=16) and the trial title (viz. ``Bone marrow transplantation for lymphoma (BMT) ``) that has the following restrictions from the patients: (i) Lymphoma, (ii) advanced, and (iii) not having a donor. \nIn a real situation and depending on the choice of patients, the patients with scores 1, 2 and 3 can be included in a single trial, 2 and 3 in another trial, 2 in yet another trial etc. \n<EOD> Role of Heterogeneous Water Distributions in LCST Switching of Amphiphilic Copolymers.\nResponsive polymers are a versatile tool in chemical engineering, smart surfaces, and sensors because of their ability to switch between different conformation states, controlled through external stimuli. One class of stimuli-responsive polymers is that exhibiting lower critical solution temperatures (LCSTs), which experience phase separation of their polymeric chains once placed in an aqueous environment, with the chains either aggregating at or forming an insoluble hydrogel. The LCST switching of stimuli-responsive polymers is a crucial step where the phase change into a polymeric-rich system is often accompanied by a substantial decrease in the solution's water content. The presence of water is known to have a large impact on the aggregation behavior of responsive polymer solutions, thereby determining the system's equilibrium phase diagram. However, how the heterogeneous water content impacts the kinetics of the LCST switching is incompletely understood, which is",
        "label": 0
    },
    "837": {
        "output": "For more information, please refer to the following article by Dr. Ishaq: You Will be a Good Clinical Trial Recruiter [/NOTE]\nThe assessment of eligibility is the key question in a clinical trial. It makes sense to perform a thorough eligibility assessment before a study participant is enrolled so that you can make informed decisions about eligibility. If the participants are unsuitable for the trial, it is a waste of time if we enroll them later. Conversely, we do not want to enroll people who are well suitable for the trial, but we are required to enroll unsuitable people. Assessing eligibility with a careful and detailed discussion with the patient and your supervisor will minimize the incidence of enrolling an unsuitable study participant.\nAlthough it seems like a simple question, the eligibility assessment is very complicated. You can determine eligibility in various ways. You should understand what is required of the patient to decide who will be included in the clinical trial. Eligibility criteria might include certain health problems, medications, age limits, and so on.[/NOTE]\n\n\n### Exclusion criteria\n\nDuring the screening, you should exclude those who do not meet the inclusion criteria. An exclusion might include severe health problems, pregnancy, medications that can affect the study outcome, and so on. If you find yourself excluding people who are well-suited for the trial, consider the following: a better eligibility assessment, other inclusion criteria, or a modification of the study. [/NOTE]\n\n### Inclusion criteria\n\nDuring the screening, you should determine those who meet the inclusion criteria. Inclusion criteria might include the following:\n- certain age\n- certain gender\n- certain health problems\n- certain medical test results\n- taking certain prescribed medications\n- living in a particular area\n- etc.[/NOTE]\n\n### Eligibility\n\nEligibility refers to whether to enroll participants or not.[/NOTE]\n\n### Exclusion criteria\n\nExclusion criteria are the reasons why patients are not able to participate in the clinical trial (e.g., they are not suitable for the trial, they live too far from the study center, etc.).[/NOT",
        "label": 0
    },
    "838": {
        "output": "![INST]\n[INST]\n\n### Recommended solution\nLet's think step by step.\n\n### Data loading\n1. Define the structure of each input variable data.\n    * age\n    * gender\n    * LDL_C\n    * HDL_C\n    * FBG\n    * TG\n    * BP\n    * smoking\n    * family_history\n    * medication\n    * diabetes_history\n    * diabetes_treatment\n    * LICA_PSV\n    * LICA_EDV\n    * RICA_PSV\n    * RICA_EDV\n\n    - For the data of `family_history` and `diabetes_history`, you should extract the words of the sentence using JaroWinkler distance measure which is included in the Text Processing Toolkit package.\nThe distance measures include the Jaro, JaroWinkler, Levenshtein, and JaroWinkler and Levenshtein distance measures, which are included in Text Processing Toolkit package. Here is the JaroWinkler distance definition(JaroWinkler distance : is defined as the number of edit operations needed to change the Jaro distance).\n\"JaroWinkler is defined as the number of edit operations needed to change the Jaro distance. The edit operations are insert or delete a letter and replace a letter. Two words are considered to be equal if both begin with the same lead letter and end with the same terminal letter, no matter about any edit operations.\"\nThe words that satisfy similarity(distance=0) should be regarded as the same word.\n- For the data of `family_history` and `diabetes_history`, you should extract the words of the sentence using JaroWinkler distance measure which is included in the Text Processing Toolkit package.\nThe distance measures include the Jaro, JaroWinkler, Levenshtein, and JaroWinkler and Levenshtein distance measures, which are included in Text Processing Toolkit package. Here is the JaroWinkler distance definition(the words that satisfy similarity(distance=0) should be regarded as the same word.\n- For the data of `family_history` and `diabetes_history`, you should extract",
        "label": 1
    },
    "839": {
        "output": "A: What's new since first answer? Just updated this to python3. I've never used this before the answer from @Krupa, but here's something I found that helped in my code: \nprint(type(s[i])) # will print '<slice>' so the slice we need does not appear in the output\n\nThis helps by telling if the variable that you're looking for is part of your slice.\n\nA: The following method gives you all the info per patient record in patients(df, ['Age_at_onset', 'Gender', 'Weight']).\ndef print_summary_per_record(df, columns):\n    for index, row in df.iterrows():\n        print (f'{row[\"Age_at_onset\"]} {row[\"Gender\"]} {row[\"Weight\"]} {')\n \n    i = 1\n    for index, row in df.iterrows():\n        print (f\"Index {row[\"Age_at_onset\"]} {row[\"Gender\"]} {row['Weight']} {'...'}\")\n\n<EOD> In Vivo Detection of Mitochondrial Activity and Aging Rate: A Pilot Study of D-Ribose Administration\n\nRecent reports have shown that increased levels of D-ribose, a sugar that plays a vital part in all aspects of energy production, were negatively associated with mitochondrial health. Also, increased levels of D-ribose in the blood have been related to several diseases including obesity and cardiovascular diseases. In this study, we report an inverse correlation between D-ribose levels with mitochondrial energetic parameters using the FLUOX-D system, a non-contact fluorescence lifetime imaging technique for absolute quantification of cellular metabolic activity. We provide here the first proof of concept of this methodology to analyze and establish a link between D-ribose with mitochondrial activity and health. The findings indicate that D-ribose increases with age and correlate with reduced mitochondrial activity. This indicates that D-ribose could be an index of aging, and may help to determine a rate of aging in future studies.\n\n# Introduction\nAging is a continuous process that affects the functionality of individuals through",
        "label": 0
    },
    "840": {
        "output": "## Geweke z-score\n\nThe Geweke diagnostic is a standardized measure of how close is the posterior distribution to the simulated (target) distribution. The Geweke z-score is often used as a diagnostic of convergence. Let g be a random walk Markov chain on parameters \\boldsymbol {\u03b8}, for a given time. \n\nThis statistic represents a deviation from the normal distribution, so that the larger the value, the more poorly the chain is mixed. The standard deviation of the statistic,\n\n\\sigma_{g} = \\sqrt{\\frac{\\mathbb{E}(\\delta_{g}^{2}}{N(N -1)}}{\\delta_{g}\\overline{\\overline{\\Delta}}}},\n\nwhere\n\n$$\\overline{\\overline{\\Delta}} = \\sum_{k=1}^{\\infty}\\left(W(k) - W^{*}(k)\\right) 2 = |\\theta - \\boldsymbol{\\theta}|^{2},$$\n\nis a measure of the magnitude of the deviation, and W and \u03b8 are the MCMC sample path and the target path respectively. It should be noted how closely this equation resembles an example of how to compute the autocor",
        "label": 1
    },
    "841": {
        "output": "### Input:\nTo use the program you must first open a file input.txt, with the following contents:\nNote: The program inputs all of your patient notes' data; hence, you must have provided the same to your script.\nThe information you provided must respect this syntax: Key: Value:\nExample:\n\n### Explanations:\nIf your Trial-level eligibility is 0, your patient is excluded (your patient note does not provide enough information to qualify for the trial), otherwise your patient is eligible. The third column is reserved for comments. You must supply the patient information required in this document.\n\n### Output:\nAt the end of the run, you will receive the following input.txt file on your screen: Example:\n\n### Output:\nAt the end of the run, a new file output_patients.txt will be downloaded to your screen or to the specified folder, if it is larger than 28 Kb: Example: This example highlights the patients who are to be recruited.\n\n##[TUTORIAL] Data pre-processing \nBefore running your script, you need to pre-process your patient note input.txt file, by removing the headers such as `Age` and `BP` and adding another column named 'Trial-level eligibility' that will be reserved for your Trial-Level Eligibility. In addition, it is imperative to create one more column by calculating the sum of the three columns of the previous columns `CAD +`, `CAD -`, `Lysocardiopathie` to have each patient patient note contains no more than one value. We will use this sum to find the number of patients who are to be recruited.\nYou can follow the instructions below\n\n### 1. Open input.txt file.\n\n### 2. Add a new column: Trial-level eligibility in the column next to `Trial-Leader`.\n\n### 3. Set the value to be 0 for each patient who doesn't meet the trial's eligibility criteria (i.e., excluded) and to 2 for each eligible patient. For each patient who is not excluded but does not meet the trial's criteria, set the value to -1:\n\n###",
        "label": 1
    },
    "842": {
        "output": "[INST] At the end of each patient note, it is indicated whether the patient has a risk factor or not. This is achieved with one line `+/+`. If the patient has multiple risk factors for the clinical trial, the first risk factor is given, e.g.,\n\npatient_ID Patient ID. 3219 \n\nThe patient information is filled out with multiple repetitions (lines 5-9), and the `+/+` is included at the end of each patient ID.\nIf a patient has multiple risk factors for a clinical trial, the first risk factor to be found is given. If there is no such rationale, the line that shows no risk factors is displayed. \npatient_ID +/+\npatient_ID Name, age, and gender. 3219\n3 31 + + + +/+\n\n## Example 4: Drug interaction\nHere is the patient:\nA 49-year-old female with a medical history of hypothyroidism diagnosed 14 years ago presents with increased abdominal girth and nocturia. The patient was taking levothyroxine for this condition; she also takes ibuprofen for pain due to sciatica.\nThe findings of her physical examination were unremarkable, with the exception of her thyroid gland (hard and enlarged). Her thyroid-stimulating hormone (TSH) and free thyroxin (f-T4) were within normal limits.\nThe results of a pap smear performed two years ago were normal. The patient was told to follow up for cervical examination and pap smear. She was informed that she should immediately return to the unit if she missed the annual cervical examination.\nThe patient has no history of cardiovascular, respiratory, or neuromuscular diseases. She is married and has an 8-year-old daughter. She has quit smoking 10 years ago. She has a moderate alcohol consumption of approximately 20 g of alcohol per day. Her physical activity is mild.\nThe past medical and family history of one of her relatives was unclear. Her son has an atrial septal defect, and her father died of a heart attack.\nUltrasonography of the thyroid g",
        "label": 1
    },
    "843": {
        "output": "The steps of the algorithm will be similar to those described above. Here are the steps using the following commands:\n[formula]  $ echo name of clinical trial > trial_name.txt $ echo inclusion criteria > inclusion_criteria.txt $ echo study protocol > study_protocol.txt $ echo data input > data_input.txt $ echo data output > data_output.txt $ echo new trial > newtrial.txt [/formula] \nBy changing the variables in the trial_name.txt, inclusion_criteria.txt, study_protocol.txt, data_input.txt, data_output.txt, and newtrial.txt files, any other scenario can be simulated.\n[D_END]\n\n### Question 3. Write a file containing the data input into the trial_name file and output the Trial-level eligibility in the `trial-level-eligibility.txt` file.\n`$ echo \"A 40-year-old man presents with dizziness and frequent headaches. \nHe has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and",
        "label": 0
    },
    "844": {
        "output": "__[16]__: Hello! You are a helpful assistant for a clinical trial recruitment. Your task is to compare the given patient notes and the inclusion criteria of the clinical trial to determine the patient's eligibility. The factors that allow someone to participate in clinical studies are called inclusion criteria based on characteristics such as age, gender, the type and stage of disease, previous treatment history, and other medical conditions. Exclusion criteria.\n_The assessment of eligibility has a three-point scale_:\n0. Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1. Not relevant (patient does not have sufficient information to qualify for the trial); and 2. Eligible (patient meets inclusion criteria and exclusion criteria do not apply). You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels 85 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3.6+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries revealed moderate stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 5",
        "label": 1
    },
    "845": {
        "output": "![TEST 1.pdf](https://user-images.githubusercontent.com/9739540/85475744-15487800-ce9d-11eb-8901-51285ceb2d1a.pdf)\n## Eligibility Checker App, step 1\nLet's make an eligibility checker table, input the patient note and the clinical trial's inclusion and exclusion criteria, and then use `eligibilityChecker()` at the end. \n- `eligibilityChecker()` accepts a data frame `PatientNotes`, and takes an integer from 0 to 2 in `Trial-level eligibility:` and `Criteria-level eligibility:` as an output. A greater number in the output indicates that a patient meets an inclusion criterion. \n- The function `criteriaExistence()` verifies whether a patient fulfils an inclusion criterion according to a data frame `CriteriaSummary` and an integer `criteriaNotation`: 0 to the patient met the criteria, else to the patient did not meet that criteria. The user should input a data frame ``CriteriaSummary`` that holds information regarding each inclusion/exclusion criterion and corresponding number of notations in our clinical trial, e.g., 0 means that the criteria are met, and 1 means otherwise in `criteriaNotation`. By default, the input `i` is 0, and 1 is when the patient meets an exclusion criterion. \n\nHere is the patient note.\nThe patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively.\nThe patient reported no use of lipid-lowering medications.\n``` jupyterlab Output: 1/2\n```\n\n\nTrial-level eligibility:\n``` jupyterlab output: \n2/2\n```\n\n## Eligibility Checker App, step 2\nEligibility can be determined at the clinical trial-level or criteria-level.  If the criteria are met at both levels, the patient can be enrolled. However, if the criteria are not met, e.g., the patient does",
        "label": 1
    },
    "846": {
        "output": "Here is the last patient note:\nA 46-year-old man presents with dizziness and frequent headaches. His HDL levels are 53\u2009mg/dL. His fasting glucose and triglyceride levels were 85 and 158\u2009mg/dL, respectively. He reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA), estimated between 40-50% of diameter. PSV was 208.5\u2009cm/s and EDV was 54.5\u2009cm/s, and RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces. \nThe plaque formation in the left and right internal carotid artery, as well as the carotid plaque character, indicated carotid atherosclerosis. The presence of stenosis in the carotid artery and the patient's LDL-C and LDL-C/HDL are highly suggestive of the underlying coronary artery stenosis. Conversely, these indicators do not exist in other patients, making this patient a valuable case report.\n[1] M. Dugas, K. O'Brien, M. Li, D. B. Yao, M. Li X. Cui, W. Lachance, J. C. Parmley, A. M. Kelm M. B. Demeester, A. T. Ferguson, K. J. Kelly",
        "label": 0
    },
    "847": {
        "output": "### Exercise 25: CPT4 Codes and ICD9\n\n[https://colab.research.google.com/github/tensorflow/docs/blob/master/tensorflow/examples/deep_cpg/README.md#instructions] \nThe main goal of this exercise is translating International Classification of Disease (ICD) codes of ICD-9 to ICD-10 through the [https://tools.doc.io/cpt3e] CPT4 System, which is equivalent to ICD9 and ICD-9 in US. All the CPT4 codes are provided as a link in the link text. You should input an ICD code to see the corresponding CPT4 code and the corresponding medical term. The code should be input in the upper left corner, while the medical term is provided in the top right corner. \n\nYou input a medical code (diagnostic code) that belongs to the range of ICD-10 (1371 to 1373), then the system will search all the medical services in the database, which are equivalent to the ICD-10 code. If the CPT4 code corresponds to the ICD-10, it will return the medical term of the code in the text box, otherwise it won't return any results. The CPT4 codes, which are in the ranges ICD-10 001 to 003 (Codes V01, V02 and V03), are not shown in the database because the codes are not relevant to medical services, i.e., medical products or medical supplies. To find an accurate translation, you should find the corresponding range of CPT4 System and the ICD-9 or ICD-10 range for each code and translate them. Note: You will see some codes that do not exist in both types of codes, e.g., CPT99579, 99637, 99628, 93969, . When you input the range of CPT4 Codes and ICD-10 code of 99xxx, 59579, 99637, 99628, etc. you should ignore the codes, which are not mentioned above and just type the rest, e.g",
        "label": 0
    },
    "848": {
        "output": "<jupyter_code>%cd C:\\Users\\noreply_at_username\\Documents\\jupyterlab_demo\n%python cds.ipynb\n\n!pip install pandas\n!pip install pandas4py # for parallel processing\nimport warnings\nimport os\nimport cds.utils.clinical_dataset as cls\nimport xarray as xr\nimport numpy as np\n%%load_ext parallel\n\ndf_all = cls.read('./datasets/demo_for_pyxarray.csv')\nclinical_df = cls.read_clinical('./datasets/demo_clinical.csv')\nclinical_dict = cls.read_clinical_dict('./datasets/demo_clinical_dict.csv')\nclinical_dict['id'] = ['ID-001','ID-002','ID-003','ID-004','ID-005','ID-006','ID-007','ID-008','ID-009','ID-010','ID-011','ID-012','ID-013','ID-014']\nclinical_info_df = cls.read_clinical_info('./datasets/demo_clinical_info.csv')\nclinical_data_df = cls.read_clinical_data('./datasets/demo_clinical_data.csv')\nclinical_strategy_df = cls.read_clinical_strategy('./datasets/demo_clinical_strategy.csv')\nds = cls.create_demo_dataset(\n    clinical_df,\n    clinical_dict,\n    clinical_info_df,\n    clinical_data_df,\n    clinical_strategy_df,\n    dataset=clspath.dataset_folder,\n)\n\n%%save -o cs241_demo_csfs -p cs241:data\n%%load_ext autoreload\n%%seed 0\n%%set_state(clspath.seed)\n\ns = xr.open_datasets([clspath",
        "label": 1
    },
    "849": {
        "output": "<EOD> Hydrocarbon adsorption by metal organic framework (MOFs)--a review.\nMetal organic frameworks (MOFs) are a class of microporous crystalline materials with an organic molecule bridged by a metal atom. In the past few decades, many methods have been proposed to improve the hydrocarbon hydrophobicity of the porous material based on the MOF structure, and to enhance the interaction between adsorbate and adsorption site in order to increase the uptake capacity and adsorption amount of hydrocarbons. In this review, we illustrate the relationship between pore structures and hydrocarbon adsorption by MOFs. We review the recent advances in MOFs used to adsorb hydrocarbons as well as the effects of the pore structure, type of the MOF, and the amount of confined space on the adsorption of hydrocarbons. In addition, we also discuss the adsorption mechanisms and future perspectives of hydrocarbon adsorption by MOFs.<EOD> Adenosine and ATP inhibit adrenergic-stimulated contraction of arterioles.\nVascular effects of locally applied adenosine and other nucleotides were investigated (with a new technique) in rat cremaster arterioles. After incubating arterioles in the presence or absence of adenosine deaminase (for 30 min) or adding apyrase (for 10 or 20 min), we measured diameters in response to adrenergic and muscarinic stimulation (in the presence and absence of receptor antagonists) of arterioles (15-125 mum inner diameter, under an initial pressure of 28 mmHg). Results indicate that: (a) ATP and adenosine (plus inosine) cause arteriolar dilation in a dose-dependent manner. (b) ATP-induced dilation is less than that caused by adenosine or inosine. (c) Adenosine has an additional, small direct constrictor action. (d) Internal dilation and constriction of arterioles occur in a time-dependent manner after locally",
        "label": 0
    },
    "850": {
        "output": "[TUTOR_REPLY]\n**If You Get Error Response:**\n- If you get `Internal Server Error` error, please see the [help page of the tutorial system](https://rstudio.com/products/rstudio-server/help/rstudio_server_tutorials/) that is also linked under the `Help` menu in the RStudio menu bar and click the `Help` button, you will see [Getting Started tutorial for Server](https://rstudio.com/products/rstudio-server/tutorials/introduction-to-r-server/getting-started-tutorial-for-server/), then retry!\n\n##### `Tutorial.R:5> trial-data <- get_trial_data(\"trials-data\")`\n\n##### `Tutorial.R:6> trial-data %>%\n    select(patientid = trial_patientid, trial_title = trial_name,\n            trial_summary = trial_summary, trial_exclusion_criteria = trial_exclcrite_criteriam,\n            trial_inclusion_criteria = trial_inclussion_criteriam, trial_status = trial_status)\n\n##### `Tutorial.R:7> trial-data %>%\n    group_by(patientid) %>%\n    summarise(sum_inclusion = sum(trial_inclusion_criteria), sum_exclusion = sum(trial_exclusion_criteria),\n             count_reasons = n_distinct(trial_exclusion_criteria)) %>%\n    ungroup() %>%\n    filter(sum_inclusion != 0) %>%\n    filter(sum_exclusion != 0) %>% \n    head()\n\n##### `Tutorial.R:8> trial-data %>% \n    filter(sum_exclusion != 0 & sum_inclusion != 0) %>% \n    group_by(patientid) %>% \n    summarise(trial_reasons = count_reasons / sum_exclusion, trial_inclussion_frac = sum_inclusion / sum_exclusion) %>% \n    summarise(trial_inclusion = trial_reasons, trial_exclusion = trial_inclussion_frac",
        "label": 1
    },
    "851": {
        "output": "[INST] For example, if a patient has a medical condition that was not included in prior clinical trials, he or she would still be included for study. This is especially the case of rare diseases, because a clinical trial could benefit from the inclusion of the patient with the rare disease. For clinical trials that include",
        "label": 0
    },
    "852": {
        "output": "Here is the output of the sample input:\nCovariate: Patient ID\nSample ID: S01\nPatient ID of the patient: 2021_05_18_13_31_55_10.json\n[formula]  `Eligible.` [/formula] \n\n## Examples\n```python\nfrom ctfslib import Trial_eligibility\n\n# Examples of using the Trial_eligibility library\n\n## Sample input\ndef input_for_patient_note(data_path, patient_number):\n    # Get patient data\n    patient_data = {\n            \"ID\": str(int(patient_number)),\n            \"first_visit\": str(patient_number),\n            \"gender\": \"MALE\",\n            \"height\": 175,\n            \"weight\": 95.3,\n            \"BMI\": 28.62,\n            \"age\": 24,\n            \"race\": \"Black\",\n            \"marital_status\": \"\",\n            \"religion\": \"None\",\n            \"patient_note\": \"  A 24-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications.\",\n            \"clinical_trial\": \"A randomized, double-blind, placebo-controlled trial testing an investigational drug and a noninvasive measure in asymptomatic, treatment-naive high-grade clinically significant prostatic intraepithelial neoplasia patients. Randomization is stratified by study site (either of 02 participating sites) with a 1:1 ratio of drug vs placebo and is based on the results of the 10-core pro",
        "label": 0
    },
    "853": {
        "output": "<EOD> .\nOBJECTIVE\nTo describe the experiences of breast feeding in 40 HIV positive mothers and to identify the difficulties and fears faced by the mothers to protect their babies from HIV infection.\n\n\nMETHODS\nThis was a descriptive and transversal study. The sample consisted of 40 HIV positive mothers who breast fed their children up to 6 months of age in the AIDS clinic of a public maternity hospital in Porto Alegre, Rio Grande do Sul State, Brazil. The study was developed through semi-direct questionnaires.\n\n\nRESULTS\nMost of the mothers studied (90%) had breast fed, and for 45 % of the mothers this was their first pregnancy. The majority of these women had an A2 HIV infection. The median of age was 21 years old. Forty percent breast fed until 90 days (average 38 days), 15 % breast fed until 180 days (average 141 days). The majority of the mothers (93%) used a formula until their child was at least 1 month old. Some of them chose to breast feed to avoid the use of a formula, and they reported the advantages and disadvantages of breast feeding (weight loss, mastitis, fear of contamination by HIV, transmission to the child) as reasons for starting using a formula.\n\n\nCONCLUSION\nThe mothers had difficulties in breast feeding owing to personal and family problems, and lack of information and support from health care professionals. Understanding the mothers' fears and needs can enable health professionals to give more effective assistance.<EOD> A Case of Synchronous Thyroid and Adrenal Neoplasms with Eosinophilic Expression of Granzyme B: A Possible Diagnostic Pitfall.\nEosinophilic granular convoluted tubular (EGCT) cells are characteristic of the parathyroid gland but have been reported in various benign and malignant thyroid lesions, including papillary thyroid carcinoma (PTC). Certain thyroid tumors express markers normally restricted to T lymphocytes, which may be misdiagnosed as T-cell lymphomas (TCLLs). This",
        "label": 1
    },
    "854": {
        "output": "[END] [INST]\n\n    In 2012 it was reported that at least 149 RCTs with ineligible patients enrolled were included in meta-analyses. Even more important, there is a high percentage of ineligible patients in the meta-analyses on the same topic. For example, only one third (31%) of RCTs comparing different treatments for the prevention of venous Thromboembolism (VTE) were adequately targeted to the included patient populations. \n    That means that in eligibility assessment, you should identify and eliminate ineligible patients, i.e., those who do not match with the inclusion or exclusion criteria, from the RCTs. \n\n### 1. Choose the correct inclusion criteria\n\nHere is a sample patient note:\nA 60-year-old woman presents with dizziness and frequent headaches. She has a family history of cerebrovascular disease and smoking history. She has no previous cardiovascular risk factors such as high blood pressure, high total cholesterol, and low-density lipoprotein-cholesterol. Her fasting glucose level was 85\u2009mg/dL.\nThe patient reported no use of anti-tachycardia therapy for angina pectoris.\nNeck auscultation revealed a systolic murmur 1+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA), 36% stenosis in the right internal artery. For the LICA, peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s (>120\u2009cm/s) and 54.5\u2009cm/s (<130\u2009cm/s), respectively; RICA PSV was 91,72\u2009cm/s and RICA EDV was 37.3, 7cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common car",
        "label": 0
    },
    "855": {
        "output": "<center>\n<h2>Task 1: Calculating the Framingham index for the clinical trial</h2>\n<ul>\n<li><b><i>Input</i></b>: <i>patient name, gender, age, diagnosis, smoking status, hypertension, diabetes mellitus, family history of cardiovascular disease, hyperlipoproteinemia, homocysteine level, total cholesterol, HDL-C, LDL-C, blood glucose, triglyceride, blood pressure, maximum heart rate reached, systolic stenosis of the internal ICA, carotid atherosclerosis, diameter of the internal ICA, diameter of the common ICA.</i><br>\n<li><b><i>Output</i></b>: <i>Framingham score (FS): FS = (male factor \u00d7 1), (diabetes mellitus factor \u00d7 1), (hypertension \u00d7 2), (hyperlipoproteinemia \u00d7 1), (family history of CAD \u00d7 2) <br> <br> The maximum FS was 6: FSmax = 6). <br> <br>  If FSmax = 5, the patient was considered to be at risk of cardiovascular disease and included in the clinical trial <br/> <br>  If FSmax <5, the patient was considered to be a healthy population and not included in the clinical trial.</i> \n</li>\n</ul>\n</center><EOD> Comparison of Two Enzyme Immunoassays Designed for the Detection of Cytomegalovirus in Infants and Children by Using Saliva Samples\nSummary: We evaluated the performance of two new sensitive enzyme immunoassays (EIA) for the detection of cytomegalovirus (CMV) infection (CMV seropositivity) in infants and children by using saliva from 20 uninfected cord blood children and 20 children seronegative for CMV. Saliva samples showed a sensitivity lower than serum samples for CMV EIA detection, but a specificity of 80% compared to ser",
        "label": 0
    },
    "856": {
        "output": "A: This is more easily handled using list comprehension.  Use df.assign to set all the columns to categorical, then you can apply the df.query function to assign the results to the df.  There are a lot of examples in this stackoverflow question.  I can't copy over code from other posts, but you can get the general idea.<EOD> Clinical evaluation of an oxygen\u2010delivery monitor under emergency conditions *\nAn oxygen\u2010delivery monitor capable of continuous measurement of oxygen uptake (VO2) during extracorporeal circulation was clinically evaluated in an emergency setting. Arterial partial pressure of oxygen (PaO2), arterial oxygen content (CaO2), venous content of oxygen (CvO2) or VO2 were measured in 18 patients, in whom 29 emergency operations were performed. The monitor showed a linear correlation with Pao2 but an exponential correlation with the oxygen extraction ratio (EO2). EO2 was calculated from the equation: EO2 = 1 \u2212 VO2/CaO2, and showed little variation throughout the monitoring periods, which was in contrast to the changes of VO2. The values of PaO2 after successful weaning were low, but rapidly increased when the patient entered the recovery room.<EOD> .\nIt has always been a matter of discussion to clarify the significance of immunological abnormalities in patients with acute ischemic stroke. Lymphocyte subpopulations, the expression of various cytokines and the cellular oxidative metabolism have been investigated as possible markers that reflect the individual patient's vulnerability. A group of 70 patients with ischemic stroke were compared to a control group and were subdivided into early- and late-group of stroke according to occurrence of first stroke symptoms and first electroencephalographic abnormalities, respectively. In a subcohort of early-stroke patients the significance of immunological parameters and metabolic activity was evaluated in relation to ischemic lesions in the brain during early recovery stages. Cellular immunological parameters such as absolute lymphocyte count, CD3+, CD4+/CD8+ ratio and CD4+ na\u00efve cells were significantly reduced in patients with acute ischemic stroke compared to controls. However",
        "label": 1
    },
    "857": {
        "output": "### Output:\n\n`A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors.`.\n\n`- Patient note.`\n`- Inclusion criteria of the clinical trial:\n\n1. Female;\n\n- Patient is currently a manual labourer, and he is not a smoker;\n\n\nIn this patient, LDL (low density lipoprotein)-C level 545mg/dl, HDL (high density lipoprotein)-C level 53mg/dl. Lipid profile results, family history information of this patient were shown to you.\n- The patient reported no use of lipid-lowering medications.\n- Ultrasonography: carotid artery ultrasonography revealed severe stenosis in left internal carotid artery, and moderate stenosis in right internal carotid artery. - In the left internal carotid artery, peak-systolic (PSV) and enddiastolic velocity (EDV) cutoff values were 208.5 and 54.5 respectively. - In the right internal carotid artery (RICA), PSV was 91.72 and EDV was 37.37.\n- Plaque was observed in the anterior and posterior wall of the internal carotid artery and common carotid artery, were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic with less than 50% of the area being echolucent with uneven surfaces.\n\n\nHere are the patient notes and the eligibility results, we would like to recommend you to show this output results on your display.\n```c\n#define MIN 30\n#define MAX 60\n\n#define RADIANS 0.01*3.14159265358979\n\n#define PI 3.14159265358979 //pi\n```\n\n\n*Output:*\n```c\nfloat",
        "label": 0
    },
    "858": {
        "output": "You want to check your eligibility for the clinical trial. The trial-level eligibility, which means whether the patient is eligible to participate in the trial. Is this patient eligible for the trial?\r\n\r\n```\r\n018305#60395371\r\n```\r\n```eval_code\r\n\r\n#+source: python\r\n#+language: python\r\n#+tab-width: 4\r\n\r\n#-*- coding: utf-8 -*-\r\nimport numpy as np\r\nimport sys\r\nimport json\r\nimport itertools\r\n\r\n# INITIAL SETTINGS\r\nex = sys.argv[1]  # patient code\r\nst_num = int(sys.argv[2])  # st_num: start of test\r\net_num = int(sys.argv[3])  # et_num: end of test\r\nst = ex+st_num\r\net = ex+et_num\r\n# OUTPUT: the patient report for the trial\r\nimport time\r\ntotal_time = time.time()-time.time()\r\n\r\n# INITIAL SETUP\r\n# Finding Patient's characteristics\r\npat_id = int((ex-60395371)/1000)\r\npat_name = ''\r\npat_age = ''\r\npat_sex = 'N'\r\npat_education = 'N'\r\npat_marriage = 'N'\r\npat_smoking = 'N'\r\npat_drinking = '",
        "label": 2
    },
    "859": {
        "output": "___<EOD> Acquisition of 10 B-enriched 7Li through fusion reactions in hot heavy ion beams\n\nThe abundance ratio of 7 Li in heavy ion beams can be drastically changed due to nuclear fusion reaction. In the previous work, the fusion reaction was performed in the moderately hot ion beam target where the ion beam and nuclei in the target have comparable energies. Here we describe another new fusion reaction in the heavily charged ion beam (HCIB) where heavy nuclei are decelerated at the beam dump. A set-up of a new fusion reaction apparatus is described. The apparatus has several unique features such as the 10 B reaction by using beam-ionized carbon; the beam target having hydrocarbon gas and heavy ions which has not been done before in fusion reaction experiments; and a new technique to purify the 7 Li beam. In the experiment, the reaction product of Li 2p2P 3/2 1 2S 1=2 -10 B + 6Li was obtained by using a 12.8 MeV/u 10 B beam from the National Research Center for Laser Science (NRLS) and a hot heavy ion beam (HiBA) containing 10 B from the Hibakusha Research Institute in JAERI.\n\n# Introduction\nIn the previous work of heavy ion fusion (HIF), a set-up of a reactor containing a heavy ion beam target has been presented.\nIn HIF, the target gas is decomposed due to the nuclear fusion reaction resulting in the production of the deuterium of high abundance and 10 B. The newly created 7 Li is then extracted to the beam from the target gas due to the Coulomb force exerted on the nuclei, and the extraction energy is kept high enough to prevent the secondary ionization to the electronically excited state ofLi. The beam purity becomes higher with the longer-distance between the target and the separator. For example, the secondary electron ionization is suppressed to less than 1% for a separated distance of 130 cm in the previous work.\nIn addition to the previous work, another fusion reaction which is carried out in the heavily charged ion beam (HCIB)",
        "label": 2
    },
    "860": {
        "output": "Note: You must understand that every clinical study has its own criteria of inclusion or noninclusion, so be careful before you do the evaluation. \n\n> ## Running time:\n<EOD> An alternative hypothesis for the evolution of hominin skulls.\nThis research is a re-examination of the hypothesis that hominin skulls with small facial area develop from small-brained hominins to accommodate a larger dentition and that the increase in facial width can be explained by allometric relationships. To test the hypothesis, facial area was regressed on brain area, and the results were compared with similar regressions with body mass. The regressions indicate that the brain area is not a good predictor of facial area because, with the exception of the australopiths, the correlations are poor. The brain area for australopiths is in fact below the line of regression through the other species, whereas the facial area is above. This indicates that the brain size of australopiths is smaller than those of other hominins, even though their facial area is considerably greater. If facial area is used as an index of large brain size, the australopiths diverge from all the other hominin genera. We propose an alternative hypothesis to explain the pattern, in which the facial area is not large because of a large brain but because the australopiths have large canines. The hypothesis is supported by the finding that the canine size in australopiths is positively correlated with facial size although it is negatively correlated with brain size.<EOD> Complement activation by intact cells treated with antimetabolite drugs.\nThe complement-fixing activity of whole lysates of rabbit peritoneal and washed peritoneal cells was determined by measuring the consumption of complement in the presence of antidinitrophenyl (anti-DNP) antibody with the alternative pathway and with the classical pathway (antidinitrophenyl-D-glucosamine (anti-DNP-GC)-sensitized). DNP-N-acetyl-D-glucosamine was used to sensitize the cells intravenously. The lymphocytes required 5,000 times more antibody to activate the alternative pathway than did",
        "label": 1
    },
    "861": {
        "output": "## \u25b6 Example\n\n## Exercise 5 (FREE PRACTICE)\n\n##[CODE]\n[INST] Your task is to find the patient numbers on the list. You should also fill in the column \"Eligible\" (not \"Ineligible\") on the patient's list.\nYour initial list with patients IDs is already prepared (file EL_in_List.txt). If you type in another format (your own in Excel, or on a sheet of paper), then enter in the next step file that you are working on.\n\n##[OUTPUT]\n- \u25b6 [INST] You are going to solve 3 exercises. Here is your first patient, No. 39, on the list:\n\n## Exercise 5 - Patient 39 (Part 1)\n1) The patient notes are presented below. Find the three required variables:\n* * *\n- \u25b6 Here is the trial description:\nTitle: New Technologies in the Assessment of Plaque Stability\nSummary: The researchers are trying to determine if plaque stability can be assessed non-invasively with MRI acquisition and analysis, using contrast-enhanced pulse sequences.\n\n## Inclusion criteria [inst]\nInclusion Criteria:\n\n## Exercise 5 - Patient 39 (Part 2)\n2) Make a comparison between the eligibility of the patient on your list with the trial's exclusion criteria (EL39) and find Patient ID (no. 39, in the list). If there are any missing values, find them and enter the relevant data (mark with *). Copy the correct data to Patient-ineligible for Trial field. Write \"0\" next to all exclusion criteria, which are not relevant for this case (mark with #).\n\n## Eligible excluded\nPatient ID Patient ID Patient ID EL39 \u25b6 Trial Summary \nInclusion Criteria [INT]\n\n### Age\nPatient must be over 35 years of age\n\n### Gender\nMust be male\n\n### LDL\nAverage patient's LDL should not exceed the limit of 150 md/dL\n\n### Type-2 Diabetes\nThere",
        "label": 2
    },
    "862": {
        "output": "<jupyter_code>\ndef is_eligible(patient, clinical_trial):\n\npatient = {\n    \"name\": \"<NAME>\",\n    ...\n    \"age\": 46,\n    \"gend\": \"male\",\n    \"plac\": \"Munich, Germany\",\n    \"systo\": 85,\n    \"diast\": 40\n}\n\nclinical_trial = {\n    \"systo\": 280,\n    \"systd\": 140,\n    \"dia\": 90\n}\n\npatient_value = 0\nclinical_trial_value = 2\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)\n\npatient_value = 1\nclinical_trial_value = 2\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)\n\nclinical_trial_value = 1\npatient_value = 2\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)\n\nclinical_trial_value = 0\n\npatient_value = patient_value+1\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)\n\nclinical_trial_value = clinical_trial_value+1\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)<EOD> The Scaling Relationship of Pt3Sn Nanoalloys with Sn Additive.\nFinding new structures with novel properties in traditional metal alloys, with the purpose to further extending the application scope has attracted much attention. In this work, we investigated Pt based nanoalloys to uncover some interesting structure-property correlations. Pt3Sn nanoalloys with various Sn contents were fabricated by gas evaporation and subsequent Sn segregation, which results in",
        "label": 0
    },
    "863": {
        "output": "<EOD> Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitor in Osteosarcoma in Vitro and in Vivo\nObjectives The epidermal growth factor receptor (EGFR) induces cell proliferation of osteosarcoma (OS) cell lines in vitro and in vivo. Erlotinib is an orally bioavailable EGFR-specific reversible tyrosine kinase inhibitor. In the present study, we investigated the potential value of erlotinib in OS preclinical models. Methods Human HOS OS cells or primary cell cultures from patients with OS were treated with erlotinib, and cell proliferation, migration, and apoptosis were analyzed. Moreover, the effects of erlotinib treatment in 2 animal models of OS were also evaluated. Results Treatment of human HOS cells with erlotinib resulted in a significant dose-dependent reduction of proliferation and viability, an increase of apoptosis, and a reduction of cell migration. Moreover, treatment with erlotinib reduced tumor progression and increased apoptosis in an in vivo animal model of OS. Conclusions These findings suggest that erlotinib may be a useful adjuvant therapy option for OS patients.<EOD> HLA class I expression in human renal allografts with and without acute rejection.\nBACKGROUND\nThe importance and biological significance of HLA class I expression in graft tissue of renal allografts with acute rejection is still a matter of controversy.\n\n\nMETHODS\nHLA-A, -B and -DR expression in 38 renal transplant biopsies (five cases without acute rejection, 19 cases with acute humoral rejection and 14 cases with acute cellular rejection) was studied by immunohistochemistry. Monoclonal human anti-HLA antibodies HC-A27, HC-A2, HC-A11 and L243, which were directed against HLA-A2, HLA-A11, HLA-B7 and HLA-DR1, respectively, were used in the study.\n\n\nRESULT",
        "label": 1
    },
    "864": {
        "output": "The patient meets all the clinical trial's inclusion criteria and no exclusion criteria exist as specified in the clinical trial's exclusion criteria. The patient should be enrolled in a clinical trial.\nLet's think step by step. \n(1) `if`(IncludedCriteria1==``1`(NOT ELIGIBLE PATIENT) AND (IncluedCriteria2==``1``(ELGIBLE PATIENT)) OR else)`(if IncludedCriteria3==``1``(NOT ELIGIBLE PATIENT) AND (IncluedCriteria4==``1``(ELGIBLE PATIENT)))) OR else`\nThe patient has a disease that can participate in the clinical trial (1) (IncludedCriteria1==``1`(NOT ELIGIBLE PATIENT) AND (IncluedCriteria2==``1``(ELGIBLE PATIENT)). OR else (IncludedCriteria3==``1``(NOT ELIGIBLE PATIENT) AND (IncluedCriteria4==``1``(ELGIBLE PATIENT)).(2) Disease 1: LDL-C is more than 160 mg/dL \nDisease 2: LDL-C is less than 100 mg/dl. \n(3) (IncludedCriteria1==``INCLUDE``ANDINCULD1==``YES``)ORelse (IncludedCriteria2==``INCLUDE``ANDINCULD1==``YES``ORelse (IncludedCriteria3==``INCLUDE``ANDINCULD1==``YES``ORelse(IncludedCriteria1==``INCLUDE``ANDINCULD1==``NO``ANDINCULD2==``YES``))ORelse(IncludedCriteria1==``INCLUDE``ANDINCULD2==``NO``ORelse(IncludedCriteria1==``INCLUDE``ANDINCULD3==``YES``ORelse(IncludedCriteria1==``INCLUDE``ANDINCULD3==``NO``)) (Disease 3: T",
        "label": 0
    },
    "865": {
        "output": "[EX] You are encouraged to provide the patient note for the input of the function `get_patient_note`.\n\n<ol>\n<li><b>get_patient_note</b> (p): get the patient note in the form of a pandas data frame to enable data analysis<br>\n    <h3>Inputs</h3><pre class=\"docutils literal notranslate\"><code class=\"docutils literal notranslate\"><em>Parameters</em><br>\n    :<br>\n    <code class=\"literal notranslate\"><a class=\"reference internal\" href=\"02_main/INST/patient_note.html#inputs\"><code class=\"literal notranslate\"><abbr class=\"anchor\" data-placement=top href=\"#INST_patient_note\">\n    Instructions</abbr></code></a></code>\n<br><h3>Returns</h3><pre class=\"docutils literal notranslate\"><code class=\"docutils literal notranslate\"><em>Outputs</em><br>\n    :<br>\n    <code class=\"literal notranslate\"><a class=\"reference internal\" href=\"02_main/INST/patient_note.html#outputs\"><code class=\"literal notranslate\"><abbr class=\"anchor\" data-placement=top href=\"#INST_patient_note\">\n    Instructions</abbr></code></code></code></code)>\n<br><h3>Docstring</h3><pre class=\"docutils literal notranslate\"><code class=\"docutils literal notranslate\"><em>Docstr:</em><br>\n<code class=\"literal notranslate\"><a class=\"reference internal\" href=\"02_main/INST/patient_note.html#_docstr\">\n    Instructions</a></code></code></code></code><br>\n<div id=\"INST_patient_note\" class=\"docutils literal notranslate\"><code class=\"literal notranslate\">Patient notes.<h3>Notes</h3><h3>Parameters:</h3><dl><code class=\"literal notranslate\"><abbr class=\"anchor\" data",
        "label": 2
    },
    "866": {
        "output": "##[End of INST] \nNow, let's go back to the example of the patient note described above.\nYou've just started a new day in the hospital with a new set of tasks. You can recall the patient note before your boss started barking, so your brain is in a good shape. Therefore, you'll be sure to assess the note properly and do a good job. \nFirst, we'll look at the patient's medication use information. The patient takes Aspirin, Metoprolol, Perindopril, Lercanidipine, and Ramipril. Here's what he's taking:\n\n#### Medication\n\n## Amlodipine\nAmlodipine has effects on the arteries and muscles of the heart. Amlodipine relaxes and widens these arteries to make it easier for blood to flow. As the blood vessels relax, a drop in blood pressure occurs because the flow of blood is increased.\nThe first 60 days after the patient starts taking amlodipine, the patient should be under close medial monitoring by a doctor to ensure the safety of its use.\nAmlodipine can cause side effects. Stop taking amlodipine and contact your doctor if you have:\n\n## Fatigue\nFertility\nShortness of breath\n\nAmlodipine can rarely cause dangerous swelling of the muscles in the feet and legs (Rhabdomyolysis).\nAmlodipine increases blood flow in the arteries to reduce a condition called angina, which means chest tightness, shortness of breath, and a strong feeling of fatigue. An increase in blood flow in the arms and legs can also develop.\nFollowing amlodipine, the blood pressure drops, while the blood pressure may increase depending on the condition. Before the drug is injected, the doctor checks the patient's blood pressure.\nCalcium plays a vital role in the contraction of muscles throughout the body, including the heart muscle. Calcium supplementation is prescribed in the short term to help the heart better contraction.\nAmlodipine reduces the heart's ability to contract and can cause fainting by lowering blood pressure. Therefore, the treatment does not increase the patient'",
        "label": 2
    },
    "867": {
        "output": "<EOD> Synthesis and biological activities of C-10 substituted thiazolidine-2,4-diones.\nWe have synthesized a number of C-10 substituted thiazolidine-2,4-diones and evaluated them as antimicrobial, antiinflammatory, analgesic and free radical scavenging agents. Of these, compound 24 showed potent antimicrobial effect.<EOD> The effect of different cleft treatments on health-related quality of life in adults with cleft lip/palate.\nThe aim of this study was to examine the influence of different cleft treatments, including surgery, orthodontic treatments, speech therapy and dental rehabilitation, on the health-related quality of life (QOL) of adult patients with cleft lip/palate. All patients, 73 adults with bilateral cleft lip and palate and seven patients with cleft lip or palate, were interviewed using the 'Cleft QOL Scale: Adult' (CLEFT-AS). Descriptive statistical analysis of the data was based on parametric tests. A t-test with adjustment of Bonferoni was used to test differences of the QOL between three different cleft treatment groups: group A (no cleft surgery only), group B (initial cleft surgery only) and group C (all cleft surgeries completed). Results indicated that the three groups differed significantly in 'Speech related aspects', 'Appropriate appearance', 'Social activity', 'Social life/leisure' and 'Self-consciousness'. Patients in group B rated significantly lower in all of these aspects compared to patients in group A. In relation to cleft treatments, 'Social activity' and 'Self-consciousness' were positively associated with orthodontic treatment (OT), cleft speech surgery (CSS), dental rehabilitation (DR) and combined therapy such as speech corrective surgery and orthodontic treatment (CSS-OT). 'Physical activity' was positively associated with dental rehabilitation and CSS-OT. 'Self-independence' and 'Social relations' were strongly influenced by CSS and SSA-OT. In conclusion, this study showed significant differences in health",
        "label": 1
    },
    "868": {
        "output": "You must check the following: \n- Your trial-level eligibility will always be in the last row by the `Trial-level eligibility:`\n\n- If you make eligibility for the first time, you must check Trial-level eligibility: 1) Eligible.\n\n- If you make eligibility for the second time, you must check Trial-level eligibility: 2) Eligible.\n\n- If you make eligibility for the third time, you must check Trial-level eligibility: 2) Eligible.\n\nIf you have a doubt, you can simply use `el`. e.g., `el(name) : 2.`.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits",
        "label": 0
    },
    "869": {
        "output": "## Trial code\nEvery clinical trial has a unique trial code. For better understand and better analysis, you should define the trial codes. \nThis is the data about clinical trial information on the site: \nYou need to use the trial_code parameter to refer to the trial code in the data set of clinical trials. \n`\"Trial\": \"Ethically Acceptable Clinical Trials for Patients at High Risk of Developing Type 2 Diabetes Mellitus - Clinical Trials for the Prevention and Diagnosis of Type 2 Diabetes \" #Citation #TrialCode #TrialNumber`You should specify the details about the trial code in the metadata of the data set. That is why the trial_code parameter is needed. \nIt should be saved to the metadata, e.g.\n    `data_type: \"clinical_trial\"``<EOD> The value of preoperative neutrophil/lymphocyte ratio and fibrinogen plasma concentrate use in the prevention of postoperative acute kidney injury in patients undergoing cardiac surgery\nBackground/aim Acute kidney injury (AKI) is a complication commonly encountered in cardiac surgery. This study was designed to investigate the efficacy of intraoperative and postoperative neutrophil/lymphocyte ratio (NLR) and fibrinogen plasma concentrate (FPC) usage for AKI prevention in cardiac surgery.Materials and methods This prospective study included 198 patients aged 18 and above who underwent elective cardiac surgery. Patients were divided into control (group 1; n = 134) and intervention group (group 2; n = 64) consisting of intraoperative FPC use + postoperative intravenous immunoglobulin use). Postoperative 48-hour NLR was used as an indicator for AKI prevention.Results The rates of AKI, the requirement of extracorporeal membrane oxygenation, and the inotropic requirement were lower in group 2 (P < 0.05). The amount of surgical blood loss was lower in group 2 (P = 0.022",
        "label": 1
    },
    "870": {
        "output": "When all cases are finished, go to ``2.5 Repeat Steps 1.1-1.4 in a loop.`` \n\n## 2.5 Repeat Steps 1.1-1.4 in a loop.\nWhile all data are shown in a table, for the clinical trial, we would use the data in the case to make a decision. If we were to repeat Steps 1.1-1.4 ten times, it would take more than 10 hours. To reduce computation time, we will repeat the clinical trial loop several times.\n\nBefore going into the main script, it would be helpful to know how to repeat a script several times. In Python, this can be done by defining an external function that will be used to call other functions in your script. As the number of repeating times is unknown, instead of defining an external function outside the main script that you will repeat several times, creating a counter in the main script will help you repeat the main script many times easily. This is called loop.\n\nTo repeat the script n times, you can do it step by step.\nStep by Step to Repeat the Script n Times \n- Go to shell and write the main script of case one of the data to be used\n  ~~$ Python main.py\n- Call back the main script as many times as you need.\n  ~~$ for i in i_var: Python main.py\n- After you got one version of the main script, for the clinical trial case, you can define all data to be used in the case like we did in case one and modify the part where you need.\nThis would generate three scripts for case three.\n~Usage: ~~$ Python main.py ~~$ Python main_clinical.py ~~$ Python main_clinical_repeat.py\n- Go to shell and write the main script of the case two of the data to be used\n ~~$ Python main.py\n - Run the main script and generate ten versions of the main script.\n ~~$ Python main.py -m 10\n - Go to shell and write the main script of the clinical trial\n ~~$ Python main.py\n - Repeat the main script and ten times, that would generate ten versions of the main script\n ~/$ Python main.py -m 10\n \nThat would have three ten versions",
        "label": 0
    },
    "871": {
        "output": "! \n\n[/MARGHLO]\n<br><br>\nIn this question, you have to compare a patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. \n\nThink about the characteristics that cause someone to be eligible to participate in a clinical study.\nAn individual must be eligible before a trial begins. The eligibility requirements that you should look for when reading the clinical trial description are: the patient's age, gender, his or her previous treatment history, and other medical conditions. You should always apply those factors that allow or may make a person eligible for clinical trial.\n\n- Your patient has a 1+/6+ diastolic murmur and is between the ages of 40 and 60, which are in the range of the conditions defined by the trial.\n- Your patient is male or female and is not using lipid-lowering medications; these conditions are also included in the trial.\n- Your patient's neck auscultation, ultrasonography, and carotid stenosis report show that the LICA is severely (50%) stenotic, and the RICA is moderately (40%) stenotic. Although these characteristics are not in the eligibility criteria of this clinical trial, they may have a significant influence on the patient's decision to take statin medication.\n- Your patient does not have any contraindications, such as serious allergies to the medications used in the clinical trial, history of myositis, rhabdomyolysis, or renal failure. You should apply all conditions that apply to the exclusion criteria of this clinical trial.\n\n! [/MARGHLO]\n<br><br>\nIn this question, determine the patient's eligibility by following the same steps:\n\n1. Check the given patient information and then determine the trial-level eligibility.\n2. You should check all of the factors that may affect the eligibility of this patient in the inclusion and exclusion criteria.\n3. Apply those factors that may make this patient eligible. \n\n\n\n## # 9. A Trial-Level Eligibility Scale (ELS)\nAn ELS",
        "label": 1
    },
    "872": {
        "output": "------------------\n[END]\n\nExplanation. We give a detailed step-by-step explanation of how to create the MCT2 data. For each task, input data, expected outcomes (i.e., a description of what to output), and programming code are provided. To avoid confusion in the MCT2 programming, we here provide additional instructions to explain specific aspects.\n\nThe MCT2 data file is an ASCII file with a specific format. There are generally three possible formats for an MCT2 data file: fixed length, header format, and line format. In the fixed length format, both column and row names can contain a maximum of 25 characters. In the header format or line format, the column name and the row number must be stored in headers, which limit the length of column names and row numbers. In the header format, the header line should be empty, whereas in the line format, all columns should have corresponding values in a single text row. The specifications of these formats are listed below to provide a better explanation of the required and restricted fields (column names and row numbers).\n\n[Fixed length]\nColumns\n\nRow numbers\n\nBecause the first column for the MCT2 data must be a field in the `Trials` table, i.e., TI, the first column cannot be in the form of a row number. Specifically, the row numbers of all columns should be at least 100, except the first column, which is TI. Therefore, the header format and the line format are suitable for the MCT2 data. For a better understanding of the specifications of the header and line formats, we provide the examples in Tables 5.1 and 5.2, where [FIXED LENGTH] indicates the fixed-length format.\n\nNote: The example in [fig_ref]  Table 5 1: Sample data using the fixed-length format [/fig_ref] .2 demonstrates the specifications for the header format; the example in [fig_ref]  Table 5 1: Sample data using the fixed-length format [/fig_ref]  \n\nTable\n :\n Example of MCT2 data using the header format (e.g., 5.2)\n\nTable row:\n Example of MCT2 data and header format (e.g., 5.2) \n\n[H]|Trial||Trials||TrialNum||St",
        "label": 1
    },
    "873": {
        "output": "A: It would seem as if the only way to do this is by some sort of loop, as opposed to a function call. In python, for instance, I'd write something like:\ndef print_trial_level_eligibility(doc):\n    for eligibility in doc:\n        print (Trial_level_eligibility.name, eligibility)\n\ndoc.trial_level_eligibility\n\n<EOD> Inhibition of Mitochondrial Respiration and the Metabolic Pathway of Lipin.\nAbstract : Lipin activity has a relationship to the state of the mitochondrial energy system. Therefore, the rate of inhibition of lipization by a mitochondrial poisons (cyanide, amytal) and inhibitors of the citric acid cycle has been investigated. The inhibition of lipization is a function of the concentration of the poisons employed and is directly related to the state of the mitochondrial energy system of the liver. Evidence has been obtained that the metabolic path of Lipin involves the citric acid cycle and the process of lipization occurs at the citric acid cycle.<EOD> Prevalence and incidence of epilepsy in rural and far urban Tanzania: the MAISA epilepsy study\nObjectives To describe the prevalence and incidence of epilepsy in two villages in rural and far urban Tanzania. Methods The Masai Epilepsy Aetiology Study (MAISA) is a case-control study, conducted in 2001. Participants with epilepsy were compared with two groups of controls, 2\u2005years or older, randomly selected from the same two villages. The MAISA Epilepsy Prevalence Study (MEPS) is a cross-sectional study conducted in 2002. All participants with epilepsy in the MEPS were re-assessed in 2007 (MEPS 2007). Results The point prevalence in MEPS was 32.0/1000 (95% CI 25.1 to 40.1) in rural and 24.5/1000 (95% CI 18.0 to 32",
        "label": 2
    },
    "874": {
        "output": "## 2) What if we want to predict the eligibility on the basis of the patient's status?\nYou should generate a model that predicts patient eligibility via the data given and choose the top 10 features that affecting eligibility. Then we suggest adding patient data to that model to predict eligibility on the patient's note level.\nYou should compare the 3-fold cross-validation accuracy of the model including trial-based data only by the 3-fold cross-validation accuracy of the model including patient-based data only.\n\n\nTASK 6.1\nWrite a Python Script to predict patient eligibility on Trial-level. The script should take each trial's eligibility score and output the score of each trial.\n\n\nTASK 6.2\nWrite a Python Script to predict patient eligibility on patient-level with trial data. The script should take each patient's trial-level eligibility score and predict the patient eligibility score on patient-level.\n\n**Good Luck!** \n\n* **Happy Coding!**\n<EOD> Identification of an acetate switch in a biofuel-producing strain of Clostridium thermocellum\n\nBackground: The conversion of sugars to ethanol by fermentation is a well-established conversion strategy that can mitigate many of the problems associated with the current global dependence on fossil fuels such as rising prices, increasing competition for oil, and damage to the environment. Lignocellulosic feedstock is abundant and currently represents the only low-cost source of sugars that can be converted into high-value chemicals. In the future, fermentation of lignocellulosic biomass into energy-dense biofuels will facilitate new markets for farmers and also provide economic incentives for further crop development. However, the hydrolysate derived from pretreatment of lignocellulosic feedstocks often contains an excess of toxic organic acid compounds. Thus, strains that are well-adapted to low pH and to the presence of toxic organic acids will have a competitive advantage for growth and hence should be used for commercial scale fermentations.Results:In this work, we studied a native Clostrid",
        "label": 0
    },
    "875": {
        "output": "[X][X][X]   \n### Results\n\nThe program produces the following results as .odv file.:   \n\n![](images/Paper_528.png)\n\n## Evaluation\n\nIn each simulation, the code takes \u223c 6 s until it writes a file to save the data.\n\n### Case Studies\n\n\n\n[X] [X] [X]   \nA 65-year-old man presents with mild dyspnea on exertion. He has multiple vascular risk factors, and there is a strong family history of coronary artery disease (CAD). An electrocardiogram (ECG) did not show any significant findings. His LDL-C concentration was 365\u2009mg/dL. The chest X-ray results showed a pulmonary vascular stenosis (70%\u221290%). Chest computed tomography with contrast enhancement showed no significant lesions. Laboratory findings were normal except for his LDL-C concentration. \n\nHe was offered a clinical trial and referred to the cardiologist in consultation with a dietician to lower his LDL.\nThe trial he was offered involves the following:\nTrial details:   \nTitle: A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level\n\nSummary: The primary objective of the study is to assess pharmacokinetics, dynamics, safety and tolerability of CiVi007 following single and multiple subcutaneous doses in subjects, including those on statin therapy\nInclusion criteria: Key Inclusion Criteria:\nMales or females, of any race, with fasting LDL C >2.6 mmol/L (100 mg/dL) and fasting serum triglycerides <4.52 mmol/L (400 mg/dL)\nhaematology and clinical chemistry without clinically significant abnormal values\nNormal renal and hepatic function\nWomen must not be pregnant, lactating or of child bearing potential\nMen must be willing to use appropriate contraception during the study\nAble to comprehend and willing to sign an ICF and to ab",
        "label": 2
    },
    "876": {
        "output": "# Authors' Note\nThis is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. See: http://creativecommons.org/licenses/by-nc-nd/4.0/.\n\n# Supplementary materials\nSupplementary Table S1: Trial-level eligibility (output) 1 23 6 693 2 694 15 37 2885 3 290 1622 4 241 483 5 235 395 6 242 126 7 241 72 8 262 693 9 212 485 10 145 708 11 143 99 12 130 627 13 127 456 14 207 276 15 165 09<EOD> Inhibition of cell division and cellular DNA synthesis by 2-aminopurine\nRat embryo fibroblasts treated with 2-aminopurine show an inhibition of entry into mitosis beginning with an increase above normal in the number of mitotic prometaphase cells. As the duration of the treatment increases an increasing portion of cells fail to enter mitosis. Also, a small but consistent increase in abnormal mitotic cells was noticed when 2-aminopurine was present; when the concentration was increased by a factor of 10 the aberrant mitotic figures represented around 30% of all prometaphase cells. In general, there was no difference in aberration frequency between mitotic cells exposed to the drug and postmitotic cells. In some experiments a progressive accumulation of micronuclei was observed when 2-aminopurine was present, with this event occurring more rapidly and to a greater extent at the higher concentrations. These results are interpreted as",
        "label": 0
    },
    "877": {
        "output": "# References\n- ClinicalTrials.gov NCT03211438.\n- ClinicalTrials.gov NCT03484845.\n- Spine (Phila Pa 1976). 2015 Jun 1;40(11):E450-67.\n- J Orthop Sports Phys Ther. 2011 May;41(5):284-287.e2.\n- Spine (Phila Pa 1976). 2010 Jun 1;35(17):1614-9.\n- Eur Spine J. 2013 Aug 22;22(suppl 2):396-403.\n\n\n\n\n<EOD> Cognitive-behavioral intervention to reduce depression and increase HIV risk reduction behaviors in a multi-site AIDS agency.\nThe current study examines the impact of a brief cognitive-behavioral intervention on depression and HIV risk-reduction among clients of a large AIDS agency. Ninety HIV-positive adults received one of two conditions: an Enhanced Treatment as Usual (ETAU) condition or an Embedded Cognitive-Behavioral Therapy intervention (eCBT). The eCBT consisted of three brief counseling sessions that incorporated elements of cognitive behavioral therapy. At baseline and 3, 6, and 9 months depression was evaluated using the Beck Depression Inventory. The AIDS Risk Reduction Behavior Survey was used to assess engagement in specific HIV risk behaviors. Results indicated those receiving eCBT reported significantly lower levels of depression, and higher levels of HIV-related risk-reduction behaviors compared to those in the ETAU condition. These findings suggest that eCBT can significantly impact both depression and HIV risk-reduction behaviors for HIV-positive adults.<EOD> Longitudinal study of blood pressure and renal function 6 years after subtotally nephrectomized rats.\nSubtotally nephrectomized rats have been used in previous intervention studies on renoprotection and hypertension.",
        "label": 0
    },
    "878": {
        "output": "</TD></TR></TBODY></TABLE>\n\n</PRE>\n</DL>\n</HTML>\n<EOD> Synthesis and biological evaluation of nitroimidazolyl aminoacyl beta-thioethers. Part 2: Anti-HBsAg activity and cytotoxicity.\nThe syntheses and the evaluation of the biological activity of nitroimidazolyl beta-thioethers substituted with aliphatic and benzyl amino acidic residues are described. In particular, we focused our investigations on the biological activity (anti-HBsAg) of substances related to metronidazole and 5-nitroimidazole-5-thioresorcinol.<EOD> The relationship between the uric acid to high density lipoprotein cholesterol ratio and diabetic retinopathy in patients with type 2 diabetes mellitus\n\nThe uric acid-to-high density lipoprotein cholesterol (UA/HDL-C) ratio is associated with obesity and metabolic syndrome. This study aims to evaluate the relationship between the UA/HDL-C ratio and diabetic retinopathy (DR) as a microvascular complication of diabetes mellitus (DM).Two hundred and ninety DM patients were enrolled. DR was examined using digital retinal photographs. Patients' demographic, anthropometric, and metabolic and biochemical data were collected. Patients with DR had higher UA levels, UA/HDL-C ratio, body mass index, waist circumference, and systolic blood pressure and lower high density lipoprotein cholesterol levels than those without DR (P < 0.05). After adjusting for confounding factors, the UA/HDL-C ratio was positively correlated with DR in DM (odds ratio: 3.050; 95% confidence interval: 1.032-9.052). Moreover, a significant correlation between the UA/HDL-C ratio and the severity of DR was detected (r \u00bc 0.760; P < 0.05).Our data indicated that the U",
        "label": 2
    },
    "879": {
        "output": "Note: This is the only step in the script where user input is required. [INST]\n\n\n\nNote: In this step, the patient's age and gender are required. When the patient's age and gender are entered correctly, the patient is assessed as eligible or relevant by the condition, which is equal to the `eligible` or `included` scale. You should check that the result of the patient's evaluation is equal to the scale value. If the result of the patient evaluation does not equal the evaluated scale, please modify or fix your patient note. As a result of the correct assessment, the patient note is printed in the same format as shown in the above-mentioned example. That is, in general, the assessment of the patient has three values, `Eligible (= 2)`, `Not Eligible (= 0)`, `Not relevant (= 1)`. If the patient is evaluated as `Not relevant`, the status of the patient evaluation in the script will be entered as `2`. You can check the evaluation result of each patient by clicking on the `Evaluation Result`' button of the UI. [INST]\nClick the button to run the program. The results are printed as shown in the image below as well. The results should be checked carefully. If the results are correct, you can end the script. If the results are not correctly checked, the script will print patient evaluation results.\nYou can now close the patient, click the button to run the script once again, and get the output. This is what the results should be. [INST]\n\n## Testing \n\n### Part I: Eligibility (Part II: Eligibility and Exclusion Criteria)\n\n### 1) Evaluate Patient Number 1 (Eligibility):\nClick the button to run the program. The results are printed as shown below. (1) You should make a scale for an assessment, as follows :\n(2) `Print Evaluation Result` Click the button to run the script. The results are printed as shown below. As for the output of the results, if the patient is assessed as `Not relevant`, the status of the patient's evaluation in the script is printed as `2`, but if the patient is assessed as `Not relevant`, it means that the evaluation is equal to the scale's 2 value. If",
        "label": 0
    },
    "880": {
        "output": "1. `Trial-level eligibility: `is the first parameter of assessment of eligibility. There's one for each clinical trial. `Trial-level eligibility: 0) Excluded` is the first parameter value of the clinical trial. `Trial-level eligibility: 1) Not relevant `is the second value, which you don't need to specify here. `Trial-level eligibility: 2) Eligible`is the third value and the output for the patient. You don't need to make a value, `Trial-level eligibility: 2) Eligible:`, so that's the last step. [INST]\n\n### [CODE]\n# patient_eligibility.py\ndef trial_level_eligibility(patient_note, trial_def):\n\n    if trial_def:\n      \n        # trial_def['eligibility_0']=trial_def['exclude_status']\n        trial_def['eligibility_0']=trial_def.get('exclude_status', 'Excluded')\n\n        #trial_def['eligibility_1']=trial_def.get('not_relevant_status', 'Not relevant')\n        trial_def['eligibility_1']=trial_def.get('eligibility_1', 'No')\n\n        #trial_def['eligibility_2']=trial_def.get('eligible_status', 'N')\n        trial_def['eligibility_2']=trial_def.get('eligibility_2', '3')\n        \n        # trial_def['eligibility_2']=trial_def.get('eligible, '2) Eligible.\n        trial_def['eligibility_2']=trial_def.get('eligibility_2', '2) Eligible'\n\treturn {\n        'patient_note':patient_note,\n        'trial_def':trial_def\n\t\t\t\t\t\t\t\n\t}\n\n# Evaluation\n<EOD> Surgical repair of coronary artery aneurysm rupture: a",
        "label": 1
    },
    "881": {
        "output": "[[/INH]] \n\n```\n\nIn the main script of the code we have the following functions that use the code from the examples: `example1_evaluation`, `example2_evaluation`, and `example3_evaluation`. These functions are called by the main script, as well as by the helper scripts: `script_example1`, `script_example2`, and `script_example3`.\n\n- The function `Script_example1` calls the function `script_evaluate_1` to evaluate the input CSV file. Since `Script_example1` is responsible for running the script, the value of the flag `execute_example_1` is `TRUE`, and the value of the output parameter `output_example_1` is `\"The person has no previous history of CAD. There is moderate stenosis in the right internal carotid artery (RICA) estimated from 40% and 50% from the left internal carotid artery (LICA).\"`.\n\n- The function `Script_example2` calls the function `script_evaluate_2` to evaluate the input CSV file. Since `Script_example2` is responsible for running the script, the value of the flag `execute_example_2` is `FALSE`, and the value of the output parameter `output_example_2` is `\"The patient's LDL-C and HDL-C level are 545 and 53 respectively, triglyceride level is within normal limits, the body weight is 174 pounds, height is 5' 7``, and the value`Trial-level eligibility:\" is `1) Not relevant`.\n\n- The function `Script_example3` calls the function `script_evaluate_3`, which finds the score for each column in the CSV file, and the result of the sum score for the variables that allow us to evaluate whether the eligibility of the patient with CAD is `TRUE` or `FALSE`. Since `Script_example3` is responsible for running the script, the value of the flag `execute_example_3` is `TRUE`, and the value of the output parameter `output_example_3` is `\"The person has no previous history of CAD. There is moderate stenosis in the right internal carotid artery (RIC",
        "label": 2
    },
    "882": {
        "output": "## Exercises\n\n\n> ## 10. Exercise: `14. Patient # 1`\n\n\n\n```python\n# Read in all the variables necessary from the variables.tsv file\nfilename = 'patients.tsv'\npatients = data.load_patients_file('patients', filename)\npatients_dict = patients[1 : 4].values\npatients_dict ['age_in_years'] = map(int, patients_dict['age_in_years'])\npatients_dict ['sex'] = map(int, 'male' if patients_dict['sex'] == 'm' else 'female')\npatients_dict ['smoking']['current'] = map(int, 'no' if patients_dict['smoking']['status'] == 'smoker' else 'yes')\npatients_dict ['smoking']['ex'] = map(int, 'no' if patients_dict['smoking']['status'] == 'smoker' else 'yes')\npatients_dict['LDLc'] = patients_dict['CHOL_LDL_MG']\npatients_dict['HDLc'] = patients_dict['CHOL_HDL_MG']\npatients_dict['triglycerides'] = patients_dict['glucose']['trig']\npatients_dict['type2diabetes']['diabetes'] = patients_dict['diabetes_type'].split(',')[0]\npatients_dict['diabetes type'] = patients_dict['type2diabetes']['diabetes'].split(',')[0]\n\n# Add additional data\nfrom lmc_data.dataclasses import AU_ICD, AU_TASK, AU_TRIAL, EXTERNAL_EXCL_IDS\nAU_ICD_BMI = []\nAU_TASK_smoking status = []\nAU_TASK_alcohol status = []\nAU_TASK_ex = []\nAU_TASK_excluding criteria = []\nAU_TASK_diabetes status = []\nAU_TASK_diabetes = []\nAU_TASK_diabetes_type = {}\nAU_T",
        "label": 2
    },
    "883": {
        "output": "## INST-1-2 Eligibility (part 2):\n[INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were",
        "label": 2
    },
    "884": {
        "output": "# Related chapters\n- Clinical trial\n- Computational biology\n- Computational molecular pharmacology\n\n# External links\n- ClinicalTrials.gov - Search.\n- Clinical Trials Directory.<EOD> The impact of COVID-19 on family medicine education in France, Germany and Italy: A cross-country survey of family medicine residency leaders\u2019 perceptions\n\nDuring 2020, the COVID-19 pandemic dramatically affected family medicine (FM) practitioners and their patients worldwide. COVID-19 disrupted the organization of FM education and training programs and, consequently, the educational needs of FM residents. This study aimed to explore the experiences and perceptions of FM residency program leaders in managing educational challenges during the unprecedented circumstances, and to investigate their views about possible changes in FM training. We conducted an online survey of program leaders (N = 172) in three countries (France, Italy, and Germany) affected by COVID-19. Data collected between August and November 2020 using the online platform KoBoToolbox were analysed using a content analysis method, and main themes and categories were identified. Although some countries experienced less strict mitigation measures, the response to the pandemic of each FM residency training program was adapted according to their specific needs. Overall we found that all leaders reported an increase in their residents' hours of clinical practice and a decrease in their residents' training and educational activities, such as teaching, group discussions and case presentations. Moreover, they reported an increase in online education activities. Our study highlights the vulnerability of family medicine education during a pandemic, and also reveals FM residents' increased exposure to more vulnerable patients and disadvantages in terms of training quality under pandemic conditions.\n\n# Introduction\nThe COVID-19 pandemic affected the daily practices of family medicine (FM) practitioners and their patients. A study by [bib_ref]  Impact of the COVID-19 pandemic on preventive services and screenings in the..., Khera [/bib_ref]  suggests that COVID-19 caused a marked decline of preventive health visits [bib_ref]  Impact of the COVID-19 pandemic on preventive services and screenings in the..., Khera [/bib_ref] . COVID-19 also disrupted the",
        "label": 0
    },
    "885": {
        "output": "_This is the trial-level evaluation of the previous question [MULTI]._\n\n### [01-022] Hello.\nYou are a helper in the intensive care unit (ICU). You are currently in charge of looking through the medical records and reporting the results. A new program is starting, and the research team needs some help from the records department to verify the study design. The team's research assistant needs help to develop a workflow on how the trial should be administered in the ICU.\n\n\n![INST] A flowchart explaining the data collection process for the upcoming epinephrine trial should be made. The research assistant hopes to be able to collect all of the data before 11:00pm. This will be used to assist in data analysis and to test hypotheses.\n\n## Expectations of the work\n\nWe assume that the study is conducted to reduce the time between the initial assessment of the patient's diagnosis and the collection of the patient's blood samples. To accomplish this, the patient needs to be assessed for eligibility for the study and enter the study only if he/she meets the study criteria. The patient must also provide informed consent to participate in the study.\n\nIf the trial is open, the research assistant will follow the screening process of the trial to ensure that all patients are assessed at the same time. The first step is to perform a physical exam on the patient when they arrive in the hospital. The research assistant will then perform a short interview with the patient to determine if any of the exclusion criteria apply to them.\n\nThe research assistant will then enter the data into the electronic medical record (EMR) system. After the patient is enrolled in the study, the research assistant will contact the patient to schedule the next appointment. During the patient's stay in the hospital, the research assistant will also collect blood samples from patients in the study. This information will be used to analyze the data and test hypotheses.\n\n![INST]\n1. Which of the following are not correct about the process of administering the trial in the ICU?\n\n    1) The screening process for the trial is the same as the enrolment process.\n    2) A patient needs to have a physical exam performed by a doctor before entering the study.\n    3) A patient who has already under",
        "label": 0
    },
    "886": {
        "output": "## 13.8019\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.",
        "label": 2
    },
    "887": {
        "output": "</ol>\n</div></p>\n\n### Example 08\n\n<p>\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to evaluate the patient note. When you finished, submit results to researcher through submission interface.\nThe evaluation of patient note has a three-point scale: 0) Not relevant (patient does not have sufficient information in note to qualify for the trial); 1) Evaluator needs more information (information needed to render the assessment of eligibility); and 2) Eligible (patient meets inclusion criteria).\n</p>\n<pre class=\"bash-code-block\"><code class=\"bash\"><span class=\"code-box\">input_note_patient = [<span class=\"parameter-name\">patient_note</span>, <span class=\"parameter-name\">trial_name</span>, <span class=\"parameter-name\">patient_ID</span>]</code></span></pre>\n<p>\n\nInput note:\n\n<!-- <div data-reveal-id=\"example08\">\n<ol class=\"toc-indicators\"><li></li></ol>\n<p /><img src=\"../resources/images/icon_open_link.svg\" width=\"30\" height=\"33\"/></p>\n<h4>Example 08</h4>\n<ul class=\"tasklist\">\n<li>Evaluation of the patient note</li>\n</ul>\n</div> -->\n</p>\n\n<!-- [INST] Your task is to generate a three-column matrix named <span class=\"parameter-name\">mat_inclusion_eligibility</span> containing each patient as row separated with tab characters (^T) containing three columns: <span class=\"parameter-name\">Frist_name</span>, <span class=\"parameter-name\">Last_name</span> and <span class=\"parameter-name\">Score_1</span>. \n\nThis is the patient note:\nEvaluation of inclusion and exclusion criteria The patient note has sufficient information to justify the exclusion of patients. \nTherefore, the score of this criterion will be 1.\n\nHere is the clinical trial: \nTitle: Study of Arter",
        "label": 0
    },
    "888": {
        "output": "[fig]  Q: You should think of possible scenarios in the output file. [/fig] \n<EOD> A survey on data collection and processing in the clinical practice: the situation in Italian NCCCP centers\nIntroduction\nThe aim of our paper is to describe data collection and processing in the clinical practice of the 35 Italian National Centers to Cancer Control Prevention (NCCCP). Data collection procedures used in the various centers were grouped by main groups (general, medical history, social and demographic, lifestyle, clinical and biochemistry).\n\n\nMaterials and methods\nBy examining the protocols and interviewing the NCCCP directors, we have collected information on: protocol type (in-person interview, or self-administered), data collection method (paper-or computer-forms, electronic records, etc.), data management (electronic or paper-based, archived locally or sent to the center coordinator, etc.). The information was then grouped in six categories, according to an evaluation criteria, that was developed by the NCCCP Working Group on Epidemiology, in 2008.\n\n\nDiscussion\nOverall, 25/35 of centers do not have data collection procedures. The procedures mainly involve the acquisition of data (paper-based or electronic), which are then stored (as electronic or paper-based). The procedures are usually carried out using specific tools and/or spreadsheets. In addition, some centers, in collaboration with Information Technology specialists, had recently acquired electronic records or databases.\n\n\nConclusions\nResults provide a detailed picture of a common health problem that need to be improved by NCCCP. By analyzing NCCCP's data with centralized data, researchers and public health experts could better address preventive policies and interventions for cancers' primary prevention. Moreover, centralization enables the use of advanced and integrated statistical tools used for monitoring public health.<EOD> Elevating plasma magnesium attenuates the release of nephrin, podocin and vascular endothelial growth factor after cardiopulmonary bypass\n\n\n\n# Introduction\nThe release of vascular endothelial growth factor (VEGF) as well as nephrin [neuronal pentraxin-1 (NPTX1)] and podocin [neuronal",
        "label": 0
    },
    "889": {
        "output": "\u00a9 2019, Wiley, 2013, pp. 120\u2013121 | doi:10.1002\\documentclass{aastex} \\usepackage{amsbsy} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{bm} \\usepackage{mathrsfs} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\frac{4}{5}$$\\end{document}{\\bfseries \u226565%}, {7) not eligible})`, `Lung cancer trial`\nFor more information on eligibility, see\n- `Puia F, Sturup A, De Boer P.\nA systematic process of establishing eligibility to a clinical trial of stroke rehabilitation. Disabil Rehabil. 2013;35(16): 1200\u20101206.\n- `Weiner DJ.\nClinical trials: getting to yes. J Am Acad Dermatol. 2015;72(1):7\u201012.\n- `Barnett CF, Natarajan A, Schumacher K, Dillman A.\nBest practices for measuring clinical trial eligibility decision time in electronic health care settings. J Am Med Inform Assoc. 2018;25(1):196\u2010202.\n- `Gonzalez\u2010Lopez A, Gonzalez\u2010Amaro R, Alvarez\u2010Mon M, et al.\nProportion of patients willingness to participate in clinical trials: A systematic review and meta\u2010analysis of studies using direct questioning. Eur J Cancer. 2019;103:16\u201028.\n- `Mueller K, Pingel M, Zettl N, et al.\nEligibility decision support in a hospital information system: systematic review and a new approach in electronic health records. J Innov Health Inform. 2017;24(2):172\u2010185.\n- `Shah A, Currie M, Garrison R, McDuffie K.\nBarriers to clinical trial enrollment in racial",
        "label": 0
    },
    "890": {
        "output": "1. A patient's age is a required attribute. In the current patient note, age '46 years' is recorded for the patient. The upper bound should be '55 years', thus you should add [55.0 .. 85.0] or age=[MAT]>=50. This age filter is checked using the `age:` predicates.\n\nWe can easily check for these predicates in the attribute column. If 'yes', we can check for the lower bound by adding the [50.0-55.0] range to the filter for the age attribute or we can use the inequality filter against the attribute '<' and '>' for the lower bound and upper bound, respectively.\n\nExample:\n`[age=50.0 to 55.0] OR (age<50.0) OR (age>55.0)`\n\n2. The patient's gender is 'male', thus the filter for gender for males is checked by the `gender:' predicates. We should not apply any predicates here.\n\n3. A family history of CAD is recorded for the patient as 'YES'. We should apply the filter family history of CAD (FHD)= 'YES' for the `patientnote:[FHD=YES]` predicates.\n\n4. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. We should apply the filter to the LDL-C attribute for patients with higher 'LDL-C (=more than 160 mg/dL)' or the filter to the HDL-C attribute for patients with either a higher HDL-C (> 19 mg/dL in males, > 30 mg/dL in females) or lower (< 140 mg/dL (males), < 39 mg/dL (females)).\n\n\n\n5. The patient's smoking status is 'NO', thus the filter 'Smoker=`NO'` predicates are checked.\n\n6. The patient's BMI (19 kg/m2) is less than `30.0<=normal` (which is equivalent to `19.0 <= BMI <=24.9",
        "label": 0
    },
    "891": {
        "output": "The correct code should resemble this: \ntrial {\n   for (int subjectId in 1:n_subjects) {\n     # Assessment of patient characteristics as a stepwise fashion. I.e., by the patient's ID\n     # subject <-read.csv(\"P1.csv\") # load patient from P1 patient_notes <-read.csv(\"P1_patientnote.csv\") # load clinical trial note patient <-bind_rows(patient, subject_id = \"SubjectID\") # join patient note and clinical trial data %>% mutate(Assessment = Assessment, \n\n  # Trial-level outcome 1: Eligible/2: Not relevant/ Excluded: 0,1,2) %>% mutate( # trial-level outcome 2:\n  trial_assessment = c('Eligible','Not relevant', 'Excluded'), # for both cases, the patient is assessed trial-level 2:\n  for (assessment in trial_assessment) { # Assess trial outcome to this group/case. ANA: Anemia; ALC: Alanine amino-transferase; AST: Aspartate amino-transferase; CD3+: CD3+; CD4+: CD4+; CD8+: CD8+; Hct: Hematocrit; Hemoglobin A1C (HbA1c): Glycated hemoglobin; HBsAg; HBeAg: Hepatitis B e antigen; HGB: Hemoglobin; HEVAb- IgM: anti-HEV-IgM; LDL-C: Low-density lipoprotein cholesterol; Metastases-Bone: Bone metastasis; MTHFR C675T: Methylenetetrahydrofolate reductase C675T polymorphism; NTD:Notice to discordant; WBC: White blood cell count; WT: Will to undergo clinical trial; WT_clinicaltrial: Will to undergo clinical trial. } %>% summarise( # Trial-level outcome 1: Eligible/2: Not relevant/Excluded: 0,1,2) %>%",
        "label": 0
    },
    "892": {
        "output": "In case you are not sure how to code eligibility, I will show you an example below.\n\nIn the example below, patient note is the same aforementioned.\nThis patient note does not mention anything about the treatment received so far. Therefore, it is very likely that the clinical trial is about the treatment of the particular disease for which the patient is presented. However, we need to confirm that with clinicaltrials.gov . This is an obligation for all eligibility assessments, not only for patient-level eligibility assessment. Therefore, if the patient is not appropriate (see below), the clinical trial investigator will be informed that patient is not eligible for inclusion in a particular clinical trial of the same drug used for the disease of this patient .\n\n### [20%] Eligibility assessment\nE.g., Inclusion criteria:\nEthnicity: Caucasian\nGender: Male\nAge: 40-55 years\nWeight: 60-80 kg Body Mass Index: 18-27\nFamily history: Parents without cardiovascular disease.\nHeight: 168-180 cm\nWeight loss more than 2 kg during the last 6 months\n[20%] Eligibility assessment\nE.g., Exclusion criteria:\nPregnancy or lactation\nE.g., Inclusion criteria:\nEthnicity: White\nGender: Male\nAge: 40-55 years\nWeight: 100-130 kg Body Mass Index: 45-75\nHeight: 175-190 cm\nExperiences of malignant hypertension or ischemic cardiomyopathy\nDiabetes mellitus\nE.g., Inclusion criteria:\nGender: Male\nEthnicity: White\nAge: 40-55 years\nBlood Pressure: systolic BP over 140 mm Hg or diastolic BP over 90 mm Hg according to the JNC hypertension guidelines\nHeight less than 160 cm and more than 190 cm.\nI expect clinical trial investigator to be informed that this patient is not appropriate for",
        "label": 0
    },
    "893": {
        "output": "___\nTo read more about this study, please refer to the following link:\n[https: //onlinesurveys.uiowa.edu/online_surveys/pages/7525445/edit.faces.html]\n\n[TEST-YOURSELF] Here is your chance (at the end of the question set) to test yourself on your understanding of the clinical trial documentation: _______ is evaluated in a trial? _______________ _____. Eligibility assessment depends on ______________ criteria. The assessment of patient eligibility on a particular clinical trial has a scale for the assessment of eligibility, called trial-level eligibility: __________.\n\nQ1a\nQ1b\nQ1c\nDirections: Read each question carefully and choose the best answer.\n- [x1] The correct answer is: Clinical trial.\n- [x2] The correct answer is: Inclusion criteria.\n- [x3] The correct answer is: Eligibility.\n- [x4] The correct answer is: Eligible.\n- [x5] The correct answer is: Eligibility: Not relevant.\n<EOD> Interrater reliability of the Modified Cervical Spine Injury Scale in the cervical spine injured.\nOBJECTIVES\nThe purpose of the study was to evaluate the reliability of a Modified Cervical Spine Injury Scale by 4 trained reviewers of cervical spine injuries.\n\n\nDESIGN\nBilateral injury was defined as 1 injury on each side of a cervical spine (C(1) to C(7)). This was a comparison study in a retrospective database. The average level of agreement was evaluated with percentage agreement, kappa statistic, and percentage agreement adjusted for random chance. We defined an acceptable kappa level to be > or = 0.8 for individual injury characteristics and > or = 0.65 for the Modified Cervical Spine Injury Scale.\n\n\nSETTING\nA total of 1,226 cases of cervical spine (C(1) to C(7)) injuries (10/1/90 to 6/30/",
        "label": 2
    },
    "894": {
        "output": "# Sub-challenge 2\n[INS ELT] [INST] Hello again. You are about to evaluate adherence to medication and lifestyle interventions.\nAccording to clinical diagnosis codes, you should make a trial-level eligibility on each patient for the clinical trial. That is, output the evaluation scale for adherence. \n\nHere is the patient note:\nHealthcare provider note from a 45-year-old male smoker with diabetes mellitus. History of hypertension, hyperlipidemia, stroke, and myocardial infarction. The patient's blood test results showed that the LDL and TG levels were 545 and 158\u2009mg/dL, respectively.\nThe patient reported using atorvastatin 40mg for the treatment of hyperlipidemia after a myocardial infarction. A review of other prescribed medications revealed that the patient had been previously prescribed lisinopril 20 mg and metoprolol tartrate 25 mg for hypertension, glipizide 2.5 mg for diabetes, and isosorbide mononitrate 20 mg as prophylactic therapy after myocardial infarction.\nEfforts were made to increase the patient's involvement in treatment decisions when the patient was admitted to the unit for revascularization for his recurrent ischemic event.\nExercise: If you want to get some exercise, here is the clinical trial: \nTitle: Effect of High-intensity Interval Training and Hypoxia on Vascular Function and Endothelial Progenitor Cells in CAD Patients.\n\n\nSummary: Exercise training improves cardiorespiratory fitness, aerobic capacity, and endothelial function. The purpose of the present trial was to compare the effects of 3-month, supervised high-intensity interval training with hypoxic-normoxic interval training in CAD patients undergoing percutaneous coronary artery intervention.\nInclusion criteria:\nPatients older than 18years and \u2264 85 years\nPatients with CAD who",
        "label": 1
    },
    "895": {
        "output": "##### SOLUTION 1\nYou should write in the form of nested `if\u00b4 statements.\n```python\nif self.Pk in self.rs2540923 and self.Pk in self.rs888083 or self.Pk in self.rs6744560:\n    print('1) Exclude!')\nelif self.Pk in rs2540933 or self.Pk in rs2076739 or self.Pk in rs2540930:\n    print('2) Exclude!')\nelif self.Gender == 1 and self.Age == 19 and self.Trial == 1 and self.Trial == 2:\n    print('3) Eligible!')\nelif self.Gender == 0 and self.Age == 1 if self.Genotype == 1 and self.Trial == 3:\n    print('3) Eligible!')\nelif \\\n    self.Gender == 0 if \\\n        self.Age == 1 and self.Genotype == 2 and self.Trial == 4:\n    print('3) Eligible!')\n```\n\nIn the previous part, we introduced [pyfst](python-format-sensitive-transparent.md) syntax which is very useful for building the Pythonic-style code. In this part, we introduced nested `if\u00b4 statements using pyfst syntax. In fact, the nested `if\u00b4 statements in the previous part would be constructed in the following `for\u00b4 loop style. But, with the use of [class statement](python-concepts.md#classes) and [scope chain](python-concepts.md#scope-chain), we can simplify code using pyfst syntax.\n\nYou can see that nested `if\u00b4 statements using pyfst syntax doesn't look ugly after all. Try to find a pattern in the code.\n```python\nfrom pythonfst import CounterDict\nfrom datetime import datetime as dt\nfrom pyfst import fst as f\nimport numpy as np\nimport pandas as pd\nfrom scipy import stats\nimport itertools as itertools\n\nimport sys\nimport os\n\ndef print_counterdict",
        "label": 0
    },
    "896": {
        "output": "The assessment of this patient is as follows: \n\n### Sensitivity:\nTrue Positive Rate; The number of actual positives that are correctly identified. The True Positives are detected as such.\nTrue Negative Rate; The proportion of actual negatives in the population that yields false negatives. All uninfected patients are classified correctly.\n\n### Specificity:\nPositive Predictive Value; Proportion of true positives among all patients classified as positive. PPV",
        "label": 0
    },
    "897": {
        "output": "## \u6b22\u8fce\u4f7f\u7528\u98de\u6e4d \u3010[cwl-py-app]\u3011\u7ec3\u4e60\u3002\u656c\u8bf7\u5728\u4e0d\u540c\u73af\u5883\u8fd0\u884c\u4e0d\u540c\u7248\u672c\u7684 Python3 \u8fdb\u884c\u4e00\u4e00\u5bf9\u5750\uff0c\u8fd9\u4f1a\u53ef\u4ee5\u66f4\u597d\u5730\u66f4\u51c6\u786e\u5730\u8bb0\u5f55\u4f60\u7684\u8fd0\u884c\u4f53\u9a8c\u3002\u4f8b\u5982\u5982\u679c\u4f60\u60f3\u4f7f\u7528 PyCharm \u6d59\u6c5f\u5927\u5b66\uff0c\u8bf7\u66f4\u65b0\u4e3a Python3.6.5\uff0c\u4e00\u822c\u60c5\u51b5\u8bf7\u66f4\u65b0\u5230\u6700\u65b0\u7684 Python3.9.5\u3002\n\u5982\u679c\u4f60\u7684\u73af\u5883\u548c\u5185\u5bb9\u4e0d\u540c\uff0c\u8bf7\u53c2\u8003\u7b2c\u56db\u8282\u3002\n\n# \u56fa\u5b9a\u53d8\u91cf\u5b9a\u4e49\u7684\u4f8b\u5b50\n\n\n\n```python\n\"\"\"f11.py\"\"\"\n\n\"\"\"\nf11()\n\"\"\"\n\ndef f11():\n    \"\"\"\n    Example to define a `mutable variable` in a function in `Fixed Mode`.\n    For the example we will use `self.age` in `Defined Mode` but let's define it in a\n    `Function Defined Variable`.\n    \"\"\"\n    age = 29\n    self.age = age\n    print(\"The Age of\", self)  # the attribute will be printed in the \"Function call Context\".\n    self.age += 1 # \n    print(\"The Age is\", self)  # the new value inside the function is not printable.\n    print(\"The Age returned from the function is\", self)  # the new value is not printable.\n    self.name = \"John\" \n    print(\"Now inside the function the Name is\", self.name) \n\ndef f11 ():\n    \"\"\"\n    Example to define a `mutable variable` in a function in `Fixed Mode`.\n    For the example we will use `self.age` in `Defined Mode` but let's define it in a\n    `Function Defined Variable`.\n    \"\"\"\n    age = 29\n    self.age = age\n    print(\"The Age of\", self) \n    self.age += 1 # \n    print(\"The Age is\",",
        "label": 1
    },
    "898": {
        "output": "[CODE]\nTrial-level eligibility: 1) Excluded\n  T:Exclude this patient based on your assessment of the eligibility criteria from the patient note.\n  T:Review the patient's trial-level eligibility after you finish evaluating the patient-level eligibility.\nTrial-level eligibility: 2) Not relevant\n  T:Determine the reason why the patient is not eligible in the trial.\n  T:Consider the trial-level eligibility after evaluating patient-level eligibility.\nTrial-level eligibility: 2) Eligible\n  T:If the patient meets all the exclusion criteria in the trial.\n  T:Conclude the assessment of eligibility for the trial after patient-level.\n\n[CODE]\nTrial-level eligibility: 2) Not relevant\n  T: If more than two criteria are excluded, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #1\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #2\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #3\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #4\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #5\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #6\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial",
        "label": 1
    },
    "899": {
        "output": "Here are a few hints for the task.\nWhen you are not sure whether some information is necessary to show on the note, choose not to report it. You may use a comment to explain why you report a patient as not eligible for a particular trial. Remember that in your assessment you should only report a patient as eligible if you think the patient will provide benefit with good quality of life and could be included in that trial. Your opinion about the patient's health must be based on the information in the patient's note.\nIn many patients, it is more than one reason for not being eligible for a trial. You can use a list for trials' eligibility criteria.\nEach note may contain information about more than one trial. Keep in mind the time schedule and number of patients the medical assistant has to assess.\nYou should consider that there are some special situations and that the same patient may be eligible for different trials when assessing eligibility.\nRemember that there are many different trials. So take care of the spelling of words, numbers and names of medicines, so that there are no misunderstandings.\n<EOD> Translation and validation of the PERMA model of wellness into the Arabic language\nThis study aimed to translate and evaluate the psychometric properties of the PERMA model of wellness (PMW) into Arabic language among adults. An Arabic version of the PMW (PERMA-Arabic) was developed, and the translation process was guided by cross-cultural norms. The PMW was adapted to English questionnaire, translated into Arabic and back-translated to English. Participants consisted of 811 (447 females, 364 males), in the age range of 18-2.89 years old (M\u2009=\u200921.16, SD\u2009=\u20092.51). Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) using structural equation modelling (SEM) were utilized. As a result of EFA, we derived four factors (personal growth, positive emotion, social connections, and negative emotion) instead of two factors (positive emotion and negative emotion). The results of CFA revealed good fit statistics for the model. The internal consistency reliability, as measured by",
        "label": 0
    },
    "900": {
        "output": "## 0383_12\n[INST] Your input is:\n\nPlease read the case information and answer the following questions:\n1. What is the number of days this patient is likely to live? (less than one week: 0\\x20101 week\\x20121 year\\x201210 years\\x2012unlimited)\n2. What is the probability that the patient will have the outcome of interest? (0\\x2010 10%\\x201220%\\x201230%\\x201240%\\x201250%\\x201260%\\x201270%\\x201280%\\x201290%\\x2012100% \\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%)\n3.(RICA) PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is the patient note: ________________________________________________________________________________ Patient note\n\n## 0383_13\n[INST] Your input is:\n\nPlease read the case information and answer the following questions:\n1. What is the number of days this patient is likely to live",
        "label": 0
    },
    "901": {
        "output": "Your task is to click the button`Assess patient for trial eligibility` and input the value to the textbox  as a case for each patient according to the rules provided in the text [INST]:\nInput the value to the textbox 'Patient eligibility:` as a case for each patient according to the rules supplied in the text [INST]:\nThe correct answer is '1. Not relevant'.\nIn the next lesson, we'll explore the inclusion and exclusion criteria that may be found in any trial.\n\n\nGood luck! [INST]<EOD> Diagnostic Accuracy of Conebeam Computed Tomography in the Detection, Differentiation, and Localization of Odontomas: A Meta-Analysis\n\nObjectives: To evaluate the diagnostic accuracy of cone-beam computed tomography (CBCT) in identifying, differentiating, and locating odontomas in comparison with conventional two-dimensional (2D) panoramic radiography (two-dimensional X-ray) and three-dimensional (3D) volume rendering techniques.Materials and Methods:A systematic electronic search was performed in MEDLINE, EMBASE, The Cochrane Library, and ISI Web of Knowledge. All search protocols were performed in February 2015 and were repeated in July and October 2015. All included studies had to compare conventional 2D radiographs (panoramic and periapical) with CBCT. The review's outcomes were diagnostic accuracy in relation to detection and differential diagnosis of odontomas as well as determining their location in relation to adjacent anatomic structures. Results were pooled, and the outcomes were analyzed using meta-regression. Sensitivity, specificity, diagnostic odds ratio (DRO), positive and negative predictive values, positive and negative likelihood ratio, positive and negative post-test probability, 95% confidence interval, and receiver-operator characteristic curves were reported. Results: Ten studies and 2174 teeth were included. A statistical difference was detected in pooled analysis for panoramic vs. CBCT in detecting the number of odontomas (mean difference = 0.55; 95% confidence interval [CI], 95% CI < 0.01 to 1.09), and",
        "label": 1
    },
    "902": {
        "output": "Good luck for the next exercise! [CSP102]\n##[ENTRYP1]\n![INST] \nYour task is to analyze a given patient history and evaluate the patient eligibility for the proposed clinical trial: \nLet's think step by step.    \n    [NEXT_LEVEL] `Trialet-level eligibility: 2) Eligible:`\n    [NEXT_LEVEL] `1. Inclusion`\n    `2. Exclusion 1: Cancer`\n      [NEXT_LEVEL] `3. Age`\n        `4. 30-40 years`\n      [NEXT_LEVEL] `5. 40-50 years`\n      [NEXT_LEVEL] `6. 50-60 years`\n      [NEXT LEVEL] `7. 60-70 years`\n      [NEXT LEVEL] `8. Over 70`\n      [NEXT LEVEL] `9. Cancerous`\n      [NEXT LEVEL] `10. Cancer related`\n      [NEXT LEVEL] `11. Cancer`\n      [NEXT LEVEL] `12. Cancerous`\n      [NEXT LEVEL] `13. Cancerous related`\n      [NEXT LEVEL] `14. Cancer`\n      [NEXT LEVEL] `15. Cancerous related`\n      [NEXT LEVEL] `16. Cancerous`\n      [NEXT LEVEL] `17. Cancer related`\n      [NEXT LEVEL] `18. Cancer`\n      [NEXT LEVEL] `19. Cancerous related`\n      [NEXT LEVEL] `20. Cancer`\n      [NEXT LEVEL] `21. Cancerous related`\n      [NEXT LEVEL] `22. Cancer`\n      [NEXT LEVEL] `23. Non-cancerous`\n      [NEXT LEVEL] `24. non-cancerous related`\n      [NEXT LEVEL] `2",
        "label": 0
    },
    "903": {
        "output": "[/HELP]\n\n## [STOP 2 -PLAIN INSTRUCTIONS ON IMPLEMENTATION]\n\nIn order to work with the current application, you can:\n* Connect directly to the online version of the tutorial\n* Download the source code and compile it.\n* Download the Python interpreter and try the source code\n* Download the Python source code of the original application (i2b2_workshop_vitals.py), load it in python and just play with it\n* Go the i2b2 lab where we are currently working on several Python projects with the i2b2 source code.\nAs well as:\nA. We are using an environment, so the application has a certain behavior depending on your current configuration\nB. This is a lab environment. To deploy it in a more secure way, you should read the i2b2 deployment guide,\n        and test it as much you want. Here there are some tricks and tips that make it easier\nC. The i2b2 source code might change, in the event of any issue, you can contact us\nIf you have any doubt, we are glad to help. We will meet you after the tutorial presentation,\n           and we are willing to explain some points to you.\n\nD. The next presentation will focus on i2b2 architecture, architecture, query and deployment.\n           Also, we have a presentation that explains and shows how to do a very straightforward analysis in i2b2\n           just with Python and the i2b2 API. And finally, a presentation in which three different speakers\n           will discuss about Python and i2b2.\n\n* \n\n[/END]\n\n\n\n<EOD> Chitosan-based nanogels carrying CYT-67 target cancer cells through sialic acid-mediated cell internalization\n\n\n\n# Materials and methods\n\n# Materials\nAll chemicals and reagents, including, chitosan with a low molar mass of 50 kDa (Sigma-Aldrich, Madrid, Spain) or with a molar mass of 190 kDa (BugBio, Leiden, Netherlands), ethylenediamine, sodium trimethyl silylpropanesulfonate (Pierce Biotechnology, Inc., Rockford",
        "label": 0
    },
    "904": {
        "output": "- Eligible = if all inclusion criteria are true and no exclusion criteria are true\n- Not relevant = incomplete information, i.e., not all eligibility criteria have been determined yet.\n- Excluded = if certain exclusion criteria were true\n\nScoring of results:\n```\nTrial_level_eligibility = TRIAL.Trial_eligibility.assign( TRIAL.Patient_id == PATIENT.Patient_id, )\n```\nThe results will look similar to `A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208. \nA 50-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp",
        "label": 0
    },
    "905": {
        "output": "![inst].[INST] In this example, the patient is excluded from inclusion.\n![inst].[IN] Here is input for the second patient's information.\n![inst].[IMG] Here is input for the second patient's information.\n[DONE] [IMG]\n\n# Exercises\n- Exercise_04_0_3.jup\n- Exercise_04_0_4.jup\n- Exercise_04_0_5.jup\n- Exercise_04_0_7.jup\n<EOD> Bone marrow derived hematopoietic lineage cells in solid tumors: current challenges and future directions.\nTumors from almost all cancers types contain a mixed population of cells comprising the tumor cell type, and various noncancerous cell types including hematopoietic cells. The presence of hematopoietic cells in various cancers suggests their involvement in tumor initiation. Tumor initiating cells are generally identified by using surface markers in combination with assays of their capacity to form new tumors after serial in vivo transplantation. These assays have confirmed that tumor initiating cells are enriched in a CD133(+) sub population of breast-cancer derived cells, and a CD34(+)CD38(-) subpopulation of acute myelogenous leukemia (AML) derived cells. In solid tumors, the phenotype and function of non-cancerous hematopoietic cells, or the hematopoietic components associated with tumors remain poorly defined. In this review we highlight our current understanding of the involvement of cellular components of the hematopoietic system in solid tumors, and attempt to summarize the role of hematopoietic cells in this context. We provide a brief description of cell types which are implicated in the tumor microenvironment, followed by a review of the role of stem cells in solid tumors. Since the presence of hematopoietic cells has been reported in some tumor types, we have examined the role of these cells in the initiation, proliferation and dissemination of solid tumors. We have also examined their functional properties, including the ability of these cells to differentiate into cells of non-hematopo",
        "label": 0
    },
    "906": {
        "output": "# Rules of programming\nEach instance of the task has the following form, following the input_task(\u2026) template, which can be changed if necessary.\n[INST_name] Eligibility decision\n\nThe first parameter, input_note(\u2026), is the main text information of the patient. This is the same as the task_note(\u2026) object.\nThe parameter, input_task(\u2026) is the main information of the clinical trial. In our test dataset, the clinical trial parameters are:\n\ntitle: Evaluation of Cerebrovascular Events in Patients With Occlusive Carotid Artery Disorders\nstudy_type: RANDOMIZED\nstudy_size: 200\n\nThe other two parameters, input_exclusion(\u2026) and input_inclusion(\u2026), are additional information about the patient and the clinical trial, which can be added according to each user's needs. In this particular example, this is the information about the exclusion criteria of the clinical trial.\nThe output of the task is the trial-level eligibility for the patient, which should be formatted as eligible(0) or not eligible(1) in the last line.\n\n# Explanations\nOne more thing you may find important: if you want to output information about more than one line of the patient note, you can create another output.\nIn the task_note object, there is a parameter 'lines', of type Integer.\nIf you use the parameter set as `lines=5`, then your output should be in the format:\n[name] Eligibility decision\nTrial-level eligibility: 1) Not Relevant.\nSome of the lines are hidden by this task, as they are not necessary, especially when the number of lines is greater than the parameter 'lines'.\nIt would be better to use this parameter if the patient data were longer (or more complex), or the information on the lines was not too related to the clinical trial.\nOn the contrary, if the task is designed to include only a small number of lines of the patient note in the output, it is better to use a task with a fixed length; here, the parameter 'length' of the task_note(\u2026) should not be changed, and 'lines' should be deleted from the task_note(\u2026).",
        "label": 1
    },
    "907": {
        "output": "Here is an example of the final output.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n[INST] Let's think step by step. \n[INST] First, we check the type of clinical trial. We see that it is a parallel assignment group trial. There are five stages [00, 10, 20, 30, 40], which refer to the stages of the clinical trial.\n[INST] Next, we determine the recruitment time and recruitment size. We see that the recruitment time is 200 days and the recruitment size is 50 people.\n[INST] Then, we extract all subjects in the trial, all patient notes, and the trial's definition of eligibility.\n[INST] Let's use a map to show the patients who meet the eligibility criteria of the trial, by patient notes. The map will use a combination of 3 attributes: (a) `Recruitment Start Time`, the start date/time of the patient's recruitment; (b) `Stages`, a sequence of numbers for the stages (00/10/20/30/40); and (c) `Eligibility`, the trial-level eligibility of the patient. (2) Eligible = Eligible). In the map, we can see that only one patient note has trial-level eligibility as 1. The patient note for which `t11` in `Recruitment Start Time` corresponds to `t3` in `Stages",
        "label": 1
    },
    "908": {
        "output": "### Exercise\n\n[INST] The goal of the exercise is to evaluate the patient for being eligible and to compute the trial-level eligibility.\nYou are assigned a set of patients with 50 patients. [INST] You should use `1` as a flag for excluded in a patient and `2` to signal, that the patient is eligible. You can test your code here, or go to the next cell, so that it is completed. \n\n\n`#%total%\n\n---\n\n[INST] The main challenge is for you to make sure, that the `Trial-level eligibility: ` flag is always set to `2`.\n\n\n```R\n> data<-c(list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3)), list(3,3), list(1:2), list(1:2,3), list(1:2,3), list(1:2,3))\n\n> data1 <- cbind(Trial.Inclusion, Trial.Exclusion, Trial.informed, Trial.level = trial(patient_id), Trial.eligible)\n> # Total\n> data1$Trial.total <- as.numeric(sum(data1$Trial.eligible==2))\n\n> data1 <- cbind(Trial.Inclusion, Trial.Exclusion, Trial.informed, Trial.level = trial(patient_id), Trial.eligible)\n> data1 <- cbind(Trial.Inclusion, Trial.Exclusion, Trial.informed, Trial.level = trial(patient_id), Trial.eligible)\n> data1 <- data.frame(Trial.Inclusion, Trial.Exclusion, Trial.informed, Trial.eligible)\n\n> data1$Trialleligible<integer(length(data1$Trialleligible)!=data1$Trial.total))\n(",
        "label": 0
    },
    "909": {
        "output": "To run all the code, you can use your favorite code editor. Here we show how to use the Python 3 environment with Anaconda.\nCopy the code below into a Python 3 environment (by opening a Terminal window and `conda activate`ing a specific Python environment), open a file called  <path to the file.py>, save the file,  and run the main `analyze_eligibility.py` function.\nThis function creates the patient notes and eligibility table, and writes the results in the spreadsheet `eligibility_output.csv` that you can open in Excel. \n\n\n```python\nfrom pydicom import DICOM\nimport pandas as pd\nimport numpy as np\nimport json\nimport sys\nfrom pyradiomics import *\nimport seaborn as sns\nfrom skimage import data, draw\nfrom sklearn import base, ensemble, metrices, metrics, preprocessing, neighbors, linear_model, svm, model_selection, regression, decomposition, metrics, misc, filter\nimport os     # path module.\nimport math\nimport string\nimport re\nimport csv\nfrom itertools import *\nfrom PIL import Image\nimport matplotlib.pyplot as plt\nimport warnings\nimport warnings.filters\nwarning_levels = {\n        'category_name': \"MemoryError\",\n        \"message_category\": \"MemoryError\",\n        \"memory_error\": 7,\n                      \"memory_exhausted\": 7\n                }\n        \ndef check_vint(val):\n    if val != u'' and val != b'':\n        warnings.filterwarnings('ignore')\n        return val\n    else:\n        warnings.filterwarnings('error')\n        return val \n\nwith open('trials.json', mode='r') as file:\n    trials = json.load(file)\n\ndef process_text():\n        input_raw = json.load(open('trials.json'))\n        # filter data\n        filtered_input = {}\n        for j in input_raw:\n            if 'incomplete' not in j.keys() and 'text' in j.keys():\n                filtered_input[j.keys()[0]] = j.text\n        text_input= filtered_input['text']",
        "label": 0
    },
    "910": {
        "output": "[[TASK]]<EOD> .\nWe report a case of severe heart failure developed after transurethral resection of the prostate in the patient with diabetes and hypertension. The patient showed signs of right heart failure (RHF) that was diagnosed by right heart catheterization. The patient was treated with levosimendan, and his symptoms improved. Left ventricular function also improved, and he was discharged 4 weeks after the operation. RHF often occurs after TURP in the patients with diabetes and/or hypertension. Invasive cardiac catheterization and therapy for myocardial stunning are useful for treating TURP-induced severe heart failure.<EOD> E-cadherin regulates intestinal epithelial cell migration by modulating ERK activity\nEpithelial cell migration (EPM) is an important event of the intestinal repairing process. We recently showed that E-cadherin induces the migration of intestinal epithelium cells (IECs). However, whether the E-cadherin molecule has additional functions in IEC migration remains to be determined. In this study, we investigated the role of E-cadherin in IEC EPM by analyzing migration and invasion by epithelial intestine cells (EiCs). EPM was inhibited in EiCs in which E-cadherin was downregulated. In contrast, EiCs overexpressing E-cadherin displayed accelerated migration and invasion. Inhibition of EPM in EiCs may be caused, at least in part, by decreased ERK activity. Importantly, ERK-activating EPM was restored not only by the inhibition of E-cadherin but also by the inhibition of \u03b12\u03b21 integrin. Moreover, the \u03b12\u03b21 integrin inhibitor downregulated E-cadherin, whereas it upregulated ERK activity, suggesting that E-cadherin and \u03b12\u03b21 integrin are responsible for regulating migration via different signaling pathways. Finally, the treatment of EiCs with a \u03b21 integrin inhibitor suppressed the activity of focal adhesion kinase (FA",
        "label": 1
    },
    "911": {
        "output": "[BORDER]\nThe next three sections of this lesson present examples of patient note that contains a clinical note, radiological examination, and medical report. They are the same in terms of information, but they differ between each other in terms of structure, i.e. number of paragraphs and number of paragraph in each section. You should develop the patient note depending on your own patient records and what is relevant in your context of practice, i.e., you should not develop patient notes using this example, but you should only focus on the required elements, i.e., patient data (name, gender, age, date of examination), clinical data (clinical symptoms, findings from the physical examination), radiological data (results), and biomarkers data (blood test results, etc.)\n\n[END]<EOD> Dose optimization of tacrolimus in renal transplantation: a review of clinical data.\nThe long-term preservation of renal function after transplantation depends predominantly on the prevention of renal allograft rejection and, to a clinically significant degree, on the development of renal allograft damage and scarring, known as chronic allograft nephropathy or chronic rejection. Tacrolimus (FK506) is a powerful and potent immunosuppressive agent. Tacrolimus use results in less acute rejection than cyclosporine use (6-12% vs. 11-25%), but cyclosporine use results in more chronic rejection (40-45% vs. 15-25%), especially in the first few years after transplantation. Tacrolimus use results in less creatinine clearance reduction during the first year after transplantation. A major issue in the clinical use of tacrolimus is managing tacrolimus trough blood concentrations (C(0)) according to tacrolimus doses. High tacrolimus concentrations are an important cause of acute nephrotoxicity and can result in the development of chronic allograft damage or chronic nephrotoxicity and may contribute to renal allograft dysfunction and to graft loss. Proper management of high tacrolim",
        "label": 0
    },
    "912": {
        "output": "# Conclusion\nDose you find the steps of eligibility assessment in your clinical trial?\n\n# In your trial, you are asked to make the eligibility assessment.\n\n# You have to assess patient eligibility for clinical trials in patients with coronary artery disease.\n\n# After you are sure that a patient is qualified.\n\n# Once a patient has been determined as eligible.\n\n# Exclusion criteria should be applied.\n\n# After all your patient's eligibility for the trial is determined you have to state `Drug Eligibility: Eligible.`\n\n# You may ask your clinicians to use our software to determine patient's eligibility. This software is named as `Elizabeth`.\n\n# The clinicians are invited to use our software 'Elizabeth' to determine patient's eligibility.\n\n# Please note you have to set some properties to be sure that 'Elizabeth' is ready to do its job as follows:\n[INST] Installation of 'Elizabeth' is explained in the [instructions](#installation-of-elizabeth).  \n\n## Properties of 'Elizabeth':\n[INST] Installation of 'Elizabeth' is explained in the [instructions](#installation-of-elizabeth)    `data/local/elizabeth` as the folder to store output files and the folder where log data will be written, `data/logs`\n\n[INST] Installation of 'Elizabeth' is explained in the [instructions](#installation-of-elizabeth)    `data/logs` as the folder where log data will be written, `data/logs` # The above statement includes a list of patients' inclusion and exclusion criteria for each of your clinical trial.   \n\n# Please note that the software is used twice. Once to see if a trial candidate is qualified for clinical trial according to our software, second to assess the patient's eligibility to your trial.  \n\n# If you have questions or need help, please consult with the software designer (M.M).  \n\n# Please, use this software to get real patients-level eligibility.  \n\n# After you are sure of patient's eligibility for your clinical",
        "label": 1
    },
    "913": {
        "output": "_Example 1_ Output:\n![](/attachment/uploads/file/59129/8712_image_19.JPG)\n![](/attachment/uploads/file/59129/8712_image_20.JPG)\n\n_Example 2_ Output :\n![](/attachment/uploads/file/59129/8712_image_22.JPG)\n![](/attachment/uploads/file/59129/8712_image_23.JPG)<EOD> A Dual-Color Optical Probe to Discriminate PD-1/PD-L1 Interactions from Cell\u2013Cell Interactions\n\n\n\n# Introduction\nImmune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, providing a promising pathway to prevent tumor tolerance. As a representative class of ICIs, programmed death-1 (PD) and its ligands programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2) play a significant role in promoting cancer progression through the immune response . PD-1 suppresses T cell activation by interacting with its ligands and attenuates the antigenpresenting ability of immune cells . Dysregulated PD-L1/PD-1 expression in several tumor types results in an evasion of immunosurveillance and promotes cancer progression and metastasis, which is an undesirable immune evasion mechanism . PD-L1 is specifically expressed in the immune cells and tumor cells but not in tumor-related fibroblasts . As immune checkpoints, PD-L1/PD-1 signaling not only promotes tumor cell escape from immune system but also suppresses T cells in the tumor microenvironment, preventing the T cells from eliminating the tumor . Because of the important roles of the PD-1/PD-L1 axis in tumor formation, survival, and progression, blockade of this signaling with antibodies has been applied in current cancer immunotherapies and achieved promising antitumor impacts .\nPD-L1-mediated",
        "label": 0
    },
    "914": {
        "output": "For your solution, the patient and the clinical trial will be as follows:<br>\n\n[TEST] Patient\nA 46-year-old man presents with dizziness and frequent headaches.\n- He has a family history of cholesterol. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, respectively) were within normal limits.\n- The patient reported no use of lipid-lowering medications.\n- Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA,), as well as moderate stenosis in the right internal carotid artery (RICA, estimated between 40% and 50%.For the LICA,the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior \nwalls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and were predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n[/TEST]\n\n[TEST] Clinical trial\nTitle: Lifestyle Modification Programme for Patients With Asymptomatic Carotid Artery Stenosis\n\nSummary: This study randomises patients with patients with asymptomatic carotid artery stenosis, to be managed either by providing an intensive 12-week lifestyle modification programme, or standard healthcare.\n- Inclusion criteria: In",
        "label": 1
    },
    "915": {
        "output": "**Please read carefully before submitting your solution:**\nIt is very important that you understand our grading criteria and how it is calculated before you send in your solution. Any solution not meeting them will not be graded. It follows from our policy the definition of \"good\" solution (the criteria of which our authors should follow when crafting their solutions), see below, where the percentage score refers only to the assignment of the right category in each of the three problem steps.\n\n\nThe three problem steps are evaluated in the following way. We do not allow multiple submissions in our challenges. We are also unable to give out partial credit. Our experts use a custom scoring system to evaluate the submitted solutions.\n\n\n| Problem steps | Minimum number of stars| Expected solution                           |\n| -------------- | ---------------------------------------------------------------- |\n|  Inclusion criteria identification | 2 stars per included condition |\n|  Plaque segmentation | 1 star per correct segmentation (a segment is a pixel) |\n|  Plaque classification | 1 star per correct category (LRNC, calcification, fibrotic tissue) |\n|  | Total score: **3 stars**                                                    |\n\n\nYou should always have a category for each step of the problem. Every category is assigned 3 points. As you can see, it's not enough to have one correctly calculated condition or plaque, instead you need to segment and classify all conditions and segment the plaque correctly.\n\nThe stars in each problem step are subtracted if either of the two problem steps (i.e. inclusion criteria identification, segmentation and/or classification) is solved with less than 2 stars.\n\n#\n\n## **STEP 1: **Inclusion criteria identification\n\n### **Problem instructions**\n\nInput file should contain following header:\n\n```\nPatient-ID Trial-patient-id Patient-description Age \n660 LDA92_1177 43M 72 Years                100 \n661 LDA92_1211 43M 73 Years                100 \n662 LDA92_1203 57M 72 Years                095  \n663 LDA92_120",
        "label": 1
    },
    "916": {
        "output": "* 2. What are the inclusion and exclusion criteria for the clinical trial?\n\n* 2.1 The inclusion criteria for this trial are:\n- For inclusion into a clinical trial, the patient must be over 18 years old\n- The patient's neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery. - The patient was physically active.\n- The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels were within normal limits.\n- The patient reported no use of lipid-lowering medications.\n- For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n- All these results will be used to calculate the degree of stenosis, which was 80% for the left internal carotid.\n- Furthermore, it was concluded that the patient was at high risk for a cardiovascular event, as the disease of his carotid artery is associated with a high risk of stroke, as it meets the criteria for carotid stenosis (a 70% or greater reduction in the diameter of the lumen of the artery) as well as the clinical risk of the patient. \n* 2.2 If the patient meets any of the following exclusion criteria, then",
        "label": 1
    },
    "917": {
        "output": "Tutorial\n\n## Tutorial for the task: Evaluation of the efficacy of the stable ezetimibe-rosuvastatin combination in patients with primary hypercholesterolemia in achieving the target plasma LCL-C level.\n\n### \n\n## 1) Patient-level eligibility: Check the correct assessment of eligibility for the clinical trial. The assessment is based on the inclusion criteria. You should make a patient-level eligibility for each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n## 1) Output correct assessment of eligibility for each patient, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `\n\n## 1) Patient-level eligibility: Check the correct assessment of eligibility for the clinical trial. The assessment is based on the inclusion criteria. You should make a patient-level eligibility for each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n## 1) Output correct assessment of eligibility for each patient, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-",
        "label": 1
    },
    "918": {
        "output": "### 3.2.2  \nWe will focus on the following factors when making the trial-level eligibility: \n\n### 3.2.2.1 \nTo begin, the subject has been determined not to be excluded from the trial. \n### 3.2.2.2 \nIf we are on the third patient note, the subject has the following data and we can infer his clinical history from the data:\n\n### Included\n- Type 2 diabetes mellitus\n- Hypertension\n- History of coronary artery disease\n- Smoker\n- Hyperlipidaemia\n- Family history of CAD: Father\n- Medication: Metformin in current use\n- Medication: Statin in current use\n- Medication: antianginal drug in current use\nWhen we move on to the patient, we will look for the following data:\n\n## Age\n- Patients between the ages of 19 and 75 years were included in the study\n\n## Sex\n- male \n- female \n\n## Ethnic origin\n- Caucasian\n\n## Body weight\n- Weight (BMI) 46\n\n## Height\n- Height 1.68\n\n## Smoking\n- Ex-smoker. 10 pack-years.\n\n## Physical activity\n- Physically active at work and in daily life with no moderate to intense physical exercise.\n\n## Diabetes\n- Type 2 Diabetes\n\n## Hypertension\n- Hypertension\n\n## Family history of premature CAD\n\n## Allergies\n- No significant allergies\n\n## Cardiovascular disease\nCardiovascular Disease\n- Coronary artery disease \nIn view of the clinical history and the patient's data, we can judge that the subject does not meet the exclusionary criteria. \n\n### 3.2.2.3 \nIf we are on the fourth patient note, the subject has the following data and we can infer his clinical history from the data:\n\n### Included\n- Type 2 diabetes mellitus\n- Hypertension\n- History of coronary artery disease\n- Smoker\n-",
        "label": 1
    },
    "919": {
        "output": "**NOTE:** **Instances with a score between 0 and 1 (0, 0.08, ..., 1) will be marked as `not relevant` but you can give them the trial level eligibility 2, if you think that they meet the inclusion criteria in spite of their low scores by giving them the trial-level eligibility `2 (Eligible)` as illustrated in the second code listing below.** \n\n<!--markdown-only--><!--README.md--><!--README_MD--><!---This is a README file. \nDO NOT EDIT THIS DIRECTORY--><!--This README file is autogenerated--><!--by the makeresume tool at <a href=\"https://zhangyao.github.io/mkt\">mkt.zhangyao.dev</a>, which makes README files suitable for GitHub. \nBecause you're editing this text, that means you're editing the code that is generating this directory. \nThe code for the generated README is stored under <em>README.md</em>. \n-->\n<!--README.md--><!--README_GENERATED--><h1 id=\"overview-and-purpose\">Overview and Purpose</h1>\n<p>\n   This library is a set of classes, objects, types, modules, and other elements for generating C# solutions to the following problems:\n</p>\n<p>\n   &nbsp;&nbsp;&nbsp;&nbsp;1. Creating an object class that implements a simple interface and provides the interface's member functions.\n</p>\n<p>\n   &nbsp;&nbsp;&nbsp;&nbsp;2. Detecting if a string is a valid integer in C#.\n</p>\n<p>\n   &nbsp;&nbsp;&nbsp;&nbsp;3. Detecting if a string is a valid number in C#<br>\n     <br>\n     and returning if it is not a number, <br>\n     or returning if it is a number and detecting if this is a scientific number or not.<br>\n     and returning if it is a number, the number type, and, if it is a scientific number, the number's scale factor.",
        "label": 0
    },
    "920": {
        "output": "</p>\n<p>\n\n![image src=\"\" alt=\"\" style=\"width:500px;height:415px;\"]()\n</p>\n\nThe file containing the question is provided [here](https://github.com/bionutrition4u/QA-Querimenta/blob/master/File_Querimento.txt).\n\n### [Task 2](/en-us/quizquestions/question/tasks/task-2/)\n\nIn this task, you need to create a variable called `isMatch` as `var isMatch = 0;` at the beginning.\nThen, use the following steps:\n\n1. Find the value of the `Triallevel_eligibility` variable for each participant.\n2. If the value is 1, the person is included in the trial; otherwise, they are not included. (It is important if the person is included in the trial, assign `isMatch = 1`, otherwise `isMatch = 0`.)\n3. Display the value of the `isMatch` variable for each participant.\n\n```\nvar isMatch = 0;\n\nfor (a = 0; a < 3; a++) {\n    if (Triallevel_eligibility == 1) {\n        isMatch = 1;\n    } else {\n        isMatch = 0;\n    }\n\n    console.log(\"Triallevel Eligibility: \" + Triallevel_eligibility +\"\\n\" ); // Outputs Trial-level Eligibility\n\n    console.log(\"Match: \" + isMatch ) // Outputs Match.\n}\n```\n\nIf you run the code, you will read:\n\n```\nTriallevel Eligibility: 0\nMatch: 0\nTriallevel Eligibility: 0\nMatch: 0\nTriallevel Eligibility: 1\nMatch: 1\n```\n\n### [Task 3](/en-us/quizquestions/question/tasks/task-3",
        "label": 0
    },
    "921": {
        "output": "Good job! (^_^)\n\n#### 5. [Episode 3] Assessment of stent delivery\n\nAfter evaluation of the patient's eligibility, you can proceed to the assessment of stent delivery stage, i.e., assessment of technical performance which is used to determine whether a stent will be placed during the next stage. \n\nLet's think step by step. \n\n> $ sudo python <filename>.py \n> $ python <filename>.py\n\n## 1. Stent delivery checklist\n\nA stent delivery checklist is designed to identify and document all conditions that may cause technical difficulty when a carotid stent is implanted.\n\nIt is recommended that 2 observers complete the checklist during the procedure.\n\nThe following is a list of potential problems or conditions during the stent delivery phase that may help the interventionist to improve the stent delivery techniques in the clinic.\n- Pre-stenting evaluation - Pre-stenting ultrasound evaluation (recommended) - Distal land marker < 1.5 mm distal to the ICA-CCA bifurcation - Significant ulceration of the target lesion defined as having total length of >6 mm.\n\n## 2. Stent delivery problems 1\n\n- Insufficient carotid puncture site is not available (e.g., aortic arch calcification, presence of prominent thoracic aorta).\n- Distal carotid access site does not allow easy passage of the delivery catheter.\n- Carotid calcification causing unsuitable bend of the delivery catheter, preventing it from entering into the distal carotid artery lumen.\n- CCA to ICA ratio 1.8 or greater.\n- Presence of carotid plaque.\n- Presence of soft carotid (plaque).\n- Stent delivery failure - Stent delivery failure in the presence of a hard or soft plaque in the proximal common carotid \n- Stent delivery failure in the presence of ulcerated or ruptured plaque in the proximal common carotid artery. \n- Stent delivery failure in the presence of ulcerated plaque in the bulb or internal carotid ar",
        "label": 1
    },
    "922": {
        "output": "## Exercise 9: Create a Data Set in the TableView\n[INST] Go to the data set you have just created and select `New Row`.\n\n[INST] On the field `Patient note` select `\"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. His LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits The patient reported no use of lipid-lowering medications.\" as text and select `OK`.\n\n[INST] Repeat the steps for `Patient note`, as well as patient age, the last name of his parent or caregiver (first name is a random character), his blood pressure, his physical activity level and the severity of his coronary artery disease in each coronary arteries.\n\n[INST] To create a random patient note, you can change the data of patient information, such as the date of the patient visit, the first name, the last name of the patient or caregiver, the height, and the weight. \n\nA note: The same random note information is used in exercise 4.\n\n[INST] To create a patient note with a random number, we will replace the note with a random number, whose value is between 0 and 999999999. To create a random number, select in the menu `Computer >Random number`.\n\n[INST] Then, you will enter in an input field `Random number: <enter number (e.g., 10000 or 900000000) >` the random number. Now, your clinical trial will have a second version with a random patient note.\n\n\n## Exercise 10: Use Custom Filtering in the Data View\n[INST] You will open a tab \"Data View\" by clicking the \"Data > Data View\" in the menu.\n[INST] You will create a custom filter by right-clicking the",
        "label": 0
    },
    "923": {
        "output": "# Discussion\nIn the first patient note, the patient meets the inclusion criteria, but is excluded on the grounds of the trial-specific exclusion criteria (e.g., previous use of lipid-lowering drugs). In the clinical trial, patients meeting the trial-specific inclusion criteria are excluded from the trial (e.g., patients receiving lipid-lowering therapy). In this patient, trial-level eligibility is determined as 0) Excluded. So the clinical trial recruitment assistant can proceed to the next information-seeking for the next patient.\nIn the second patient note, the patient does not meet the inclusion criteria and cannot be included in the clinical trial. Here, trial-level eligibility is determined as 1) Not relevant. So the administrator cannot proceed to the next information-seeking for the next patient.\nIf you had missed `Trial-level eligibility:` in the first line (patient notes) and in the last line (clinical trial), just add this code by using `if` condition.\n\n## Export\nIn the `Trial-level eligibility:` code block in the last line, the `Trial-level eligibility: ` statement is a kind of export statement, so you can get the trial-level eligibility as a string, e.g., `Trial-level eligibility: 0,`.\n<EOD> Enhanced Antibiotic Sensitivity through Optimized Culture in Capsules\nStrain improvement is performed to improve the productivity of a target strain, but such improvement is not always achieved. This is because the strain used for strain improvement usually shows a higher fitness in the fermenter condition than in its natural environment, which generally consists of a mixture of carbon sources (e.g., glucose and xylose in corn-milling- and corncob-milling-derived hydrolysates) and inhibitors (e.g., furfural, vanillin, and ferulic acid). Therefore, to obtain an improvement in productivity in such harsh conditions, it is important to improve the strain\u2019s physiological function. To achieve this improvement, the present study used CapsuleRIC, a capsule robot, which has previously been successful in enriching the microbial",
        "label": 1
    },
    "924": {
        "output": "<EOD> Fas\u2010associated phospho\u2010protein with death domain\u2010like (FADDL) up\u2010regulates hypoxia\u2010induced erythroid differentiation by stimulating heme biosynthesis\nDuring maturation in red marrow (RM), erythroid precursors undergo hypoxia\u2010dependent apoptosis, and the survivors give rise to enucleated erythrocytes. Apoptosis is blocked and enucleation is accelerated when RM\u2010derived progenitors (erythroblasts) are placed under normoxic conditions. These effects are mediated by the protein Fas\u2010associated phospho\u2010protein with the death domain (FADD). The FADD homologue FADDD (form of FADD with death domain\u2010like), which shares 62.7% amino acid sequence similarity with human FADD, differs from FADD by its long C\u2010terminal tail. Previously, we showed that FADD and FADDL (form of FADD with death domain) are associated with erythroblasts during maturation, FADDL being less abundant. Here, we evaluate whether FADDL could affect erythroblast maturation, focusing on the effect of FADDL on the modulation of hypoxia\u2010stimulated enucleation that is induced during erythroid differentiation. Results indicate that FADDL stimulates hypoxia\u2010stimulated enucleation by regulating heme biosynthesis. Expression of iron storage protein transferrin receptor 1 and mitochondrial iron transporter (MTT) in normoxic conditions was down\u2010regulated by FADDL over\u2010expression and was restored to levels comparable to hypoxic conditions by knockdown of FADDL. Our results suggest that FADDL regulates the production of iron\u2010sulfur clusters involved in mitochondrial heme synthesis, which is critical for enucleation during hypoxia\u2010induced erythropoiesis.<EOD> Molecular Docking and Screening of Novel Anti\u2010Human Respiratory Syncytial Virus Drug Candidates\nHuman respiratory syncytial virus (HRSV) is a respiratory pathogen that causes severe bron",
        "label": 0
    },
    "925": {
        "output": "<EOD> The use of a digital camera to diagnose and manage a retinal hemangioma.\nWe describe a technique using a digital camera to take images of the fundus to diagnose and monitor retinal hemangiomas.<EOD> .\nCarcinoma of the cervix is the second most frequent cause of cancer among women in the world. Epidemiological data indicate that 500 000 new cases are diagnosed each year. The principal therapeutic modality in the treatment of carcinoma remains surgery or radiotherapy, and in the future, one possible approach for the treatment of the diseases should be gene therapy. We describe the most important therapeutic procedures in gene therapy for urological tumors, and review its present state, as well as possible clinical applications for genetically-engineered carcinoma of the cervix.<EOD> Rate-Independent Measurement of Transmembrane Potential with Microparticle Electrophoresis\n\nA novel rate-independent electrokinetic technique for the measurement of transmembrane potential was demonstrated. To enhance the method's signal-to-noise response and reliability, the effect of particle concentration and electrolyte ionic gradient were systematically investigated. The transmembrane potential of biological cells was measured successfully with the aid of the proposed microfluidic particle separator.\n\n# Introduction\nMeasurement of transmembrane potential is of paramount importance in fundamental science and biological engineering [bib_ref]  Ion channels, permeability and water transport across biological membranes, Finkelstein [/bib_ref]  [bib_ref]  A novel micromotor-based microdevice for rapid and selective isolation of biological cells..., Xuan [/bib_ref] . Due to the difficulty in directly recording transmembrane potential by electrodes inserted into a cell or sample [bib_ref]  Dielectric properties of mammalian cell membranes from 100 Hz to 10 MHz:..., Merla [/bib_ref]  , a major effort is directed at electrokinetic-based methods such as electroosmotic [bib_ref]  Capillary-electrophoretic characterization of the electrophoretic mobility and electroosmotic flow behavior in a..., Kawamura [/bib_ref]  and electrokinetic inertial phenomena [bib_ref]  Transport in an elect",
        "label": 2
    },
    "926": {
        "output": "<EOD> Development of the concept of nursing theory.\nThis article traces changes in the way theory has been defined over the years. It shows how nursing theories have changed from being primarily prescriptive and descriptive to being concerned with the interlocking and interactive nature of concepts, the meaning assigned to these concepts, and methods of studying these complex processes.<EOD> The Mendelian Disposition of Rheumatoid Arthritis\nThe hypothesis that rheumatoid arthritis may be a condition in which the inheritance is Mendelian is discussed and the evidence given in support of the theory. There is no evidence to support the idea that the inheritance of the disease is autosomal recessive and no suggestion has been put forward that the hypotheses may be based on the existence of two alleles in the same gene. It is concluded that rheumatoid arthritis may be regarded as \u201cpolygene\u201d and \u201cpleiotropy\u201d in the sense that it occurs with very considerable frequency in the population as a whole but is by no means rare. There are many loci for which there seems to be a genetic contribution to the occurrence of rheumatoid arthritis and the effect of each individual locus is very small.<EOD> A Novel Efficient Computational Method for Estimating the T-2 Toxin Concentration in Animal Feed\n\nA novel mathematical-based computational method was established to detect low-level T-2 toxin content in animal feed containing different combinations of the T-2 toxin analogues HT-2 toxin, T-2 triol, T-2 tetraol, neosolaniol, and fumonisin B 1 . The mathematical model is designed as a series of first-order and second-order mathematical equations. The equations describe the mathematical relationship among two toxins in the model, the weight of toxins, and the weight of feed material. The model was verified using in vitro toxin absorption and excretion in animal feed samples. The experiment measured changes in the T-2 toxin concentration using a rapid gas chromatography-mass spectrometry method within feed samples that were incubated with piglet feces at 37 - C for 12 h. Feces were collected from three normal pigs and from pigs that received different tox",
        "label": 1
    },
    "927": {
        "output": "[REPEAT]\n\nIMPORTANT NOTICE: Some information in these examples might violate your institution's confidentiality rules or local regulations. Please change it to comply with your local environment.\n\n---\n\n## Step 3: Clinical Research Coordinators\n\n[CRCs] Hello. You are a clinical research coordinator managing multiple clinical trials. Your main tasks are to recruit patients, schedule appointments with patients to visit the site for screening and onboarding, inform patients about the protocol, and make sure all the clinical trial records are updated regularly. You are using a clinical trial management system (CTMS) system, the OpenClinica platform. It provides clinical trial management. \n\nThe recruitment of eligible patients is a critical task in clinical trials. Clinical Research Clinical Research Coordinator can help patients enrollment in trials, assist doctors and nurses to provide high quality care, help patients adhere to the clinical trial protocols for the safety, and ensure patients can complete research protocols and achieve good outcomes. \n\nBy monitoring patient enrollment status per subject, you can keep track of on-target progress and identify any issues with enrollment. You can determine the number of active and inactive patients and assign patients to specific recruitment processes for different clinical trials, such as an online or hard copy of patient consent forms, in order to meet regulatory requirements. \n\nThe CTMS system supports many standard clinical trial features, including enrollment tracking and management and managing consent forms, and allows CRCs to customize them to meet the needs of their trials. \n\nHere is the clinical trial screening process: \nTitle: Short Physical Activity Program in Coronary Artery Disease.~\n\nScreening Process:\nOnboarding the patients through eligibility assessment\nScreening of patients' medical status\nRegistering patients into trial databases\nConducting the Informed Consent\n\nTo manage onboarding screening processes, you should schedule an exam by assigning a patient or group of patients to each clinician (physician, nurse, midwife, etc.), then use OpenClinica's integrated schedule feature to record the date or schedule a trial-specific date in the",
        "label": 0
    },
    "928": {
        "output": "Note. To execute the code, use the code editor for the notebook type `ipynb`. When executing, the program is run in the Python interactive session. If the program is run incorrectly, the run icon of the code editor will be displayed yellow. Refer to the following Help -> Advanced -> Run Notebook link for detailed help on how to run the code. {E1}\n\nExpected output\n![](http://sci-learning.org/assets/images/v2/book/book_data1/b_10_ex3.png)\n\n<EOD> Charged-particle beam formation in a laser electron accelerator.\nIon-acceleration physics in a laser electron accelerator (LEA) is studied. The electron plasma expanding from a circular plasma focus of a pulsed plasma lens was used as a plasma grating to guide the laser beam to a relativistic amplitude, then to accelerate a plasma-driven electron beam with a field of about 300 kV/m to a relativistic velocity. The LEA's electron beam and laser beam were detected by a time-gated photo-multiplier. The results show that, compared with a conventional laser acceleration method, the laser and the electron beam are accelerated one after the other. The injection electron beam does not necessarily have a high transverse spatial energy density, but a strong driving laser beam is necessary to drive an LEA.<EOD> Assessment of microleakage in composite restorations: a review article.\nIn the last 60 years, dental restorative materials have been developed for clinical application. The aim of this review is to emphasize the role of microleakage when dentists try to restore an acid-attacked tooth under stressful condition. Microleakage is one of the major concerns involved in the polymer-tooth-enamel interface, and it is a major problem with direct composite restorations. The current study focuses on various materials, the method of assessment of microleakage, and its implications in the dental restorative and dental bonding systems. In all of the articles found on search engines like PubMed/National Library of Medicine, Embase, and Google Scholar, in the years 2000-2018, only",
        "label": 0
    },
    "929": {
        "output": "<EOD> The role of intraoperative ultrasound in localizing residual tumor and guiding tumor excision in thyroid carcinoma\nThyroid carcinoma is a common cause for reoperation in the neck. The purpose of the study was to correlate the intraoperative findings of residual and recurrent tumor and to determine the indications for frozen section examination and the utility of intraoperative ultrasound in thyroid and neck cancer surgery. All surgeries over a two\u2010year period where intraoperative ultrasound was used for thyroid surgery evaluation were reviewed to determine the incidence and predictor variables of residual tumor found at surgery. Ninety\u2010two patients were evaluated with intraoperative ultrasound: 60 underwent thyroidectomy, 16 total parathyroidectomy, 14 thyroid cancer with lymph node dissection, and 2 thyroidectomy with neck dissection. Thirty\u2010six thyroidectomies required frozen section histologic evaluation of the surgical margins. A total of 45 ultrasonic examinations revealed suspicious ultrasonic features and were correlated with intraoperative surgical data. Nine of 36 thyroidectomy specimens had tumor at the site of the surgical margin or other unexpected site. Seven tumors were recognized on frozen section. The remaining two tumors could not be identified at the time of surgery. The predictive variables for residual diseases include ultrasonic suspicion at surgical margins, tumor extension to the neck lateral to the thyroid, and lymph node involvement. These results indicate that intraoperative ultrasound is important in thyroid and neck cancer to localize residual tumor and to guide tumor excision. It may reduce the need for frozen section and shorten the operative time. \u00a9 1996 Wiley\u2010Liss, Inc.<EOD> Isolation and functional analysis of an active recombinant SARS-CoV-2 main protease\n\nThe coronavirus main protease, commonly known as SARS-CoV-2 main protease (M pro ), as a homodimeric complex is essential for the viral replicase poly",
        "label": 0
    },
    "930": {
        "output": "_Note:_ When you press the 'Check All' button at the end of the first column of the screen, the patient will be excluded in the following columns.\nIf the result is 0 (excluded), select 'Yes' in the box just above the patient's note to include it in the next trial. If the result is 1 (not relevant), select the box just below the patient's note and the patient will be automatically included in the next trial. Only if the result is 2 (eligible), do not select anything and you did the correct assessment. \n\n\n\n```\nCheck All\n<form method=\"post\" action=\"?r=register\">\n<input type=\"checkbox\" name=\"patients[]\"/>\n<input type=\"checkbox\" name=\"patients[]\"/>\n<input type=\"checkbox\" name=\"patients[]\"/>\n<input type=\"checkbox\" name=\"patients[]\"/>\nCheck All\n<!-- for more information, read the FAQ section below -->\n[INST] <!-- <button onclick=\"show_hidden_instructions();\">Show instructions</button> -->\n<button onclick=\"show_hidden_form();\">Show form</button>\n<button onclick=\"hide_hidden_form();\">Hide form</button>\n<input type=\"submit\" value=\"Done\">\n</form>\n```\n\n\n\n# FAQ\n\n\n\n<!-- Begin FAQ -->\n\n<!-- Markdown format copied from https://github.com/bhagwat/angular/blob/master/demo/README.md  -->\n### What is 'check all' button?\n\n-  If you choose the correct answer for the inclusion criterion, you should check it and press \"check all\".  \n\n-  Only when you select all checkmarks in column 1 and press check all are you able to select patients for further assessment.  \n\n```js\nvar button_selector = function(){\n    if ($(\"checkbox:checked:not(#checkAll):not(#checkAllAll):not(#checkAllAllAll):checked\").length > 0){\n        $(\"#checkAllAllAll\").click();\n    } else {\n        $(\"#checkAllAllAll\").prop(\"checked\", false);\n        $(\"#checkAllAll\").click();\n    }\n} // end of button_selector",
        "label": 0
    },
    "931": {
        "output": "Good luck! And don't hesitate to ask, if anything is unclear.\n\n[INST]\n\n# In-depth discussion of the exercise\n\n## Summary statement\nThis exercise is a good example with many realistically structured cases, and therefore we recommend that you read through the materials. This exercise is especially good at identifying the differences in eligibility between the trial and the cases in the first place, and secondly, examining if a patient meets the inclusion criteria in an ideal manner (e.g., the answer for 19 and 26, which are not suitable for trial recruitment). The exercise provides an explanation for patients who are not excluded on the grounds of the selection criteria. It is also good for familiarizing yourself with the general idea of the clinical trial, and eligibility and how to assess patient characteristics based on their cases. Therefore, let's go through the exercise!\n\n## Comment\n\nWhen you are looking for a patient who is suitable for trial recruitment, you need to check whether the patient is eligible because of the inclusion and exclusion criteria. In the trial, the eligibility is confirmed based on the notes, but in reality, we need to check the actual conditions based on the interview. Therefore, the real situation may seem less ideal to us when we assess the eligibility based on the actual situation. In the case of this exercise, you need to read the information about the trial and the case first and then see if the patient has the eligibility. Let's look carefully at the criteria for each trial.\n\n## Comment\n\nFirst, we will check out a clinical trial with inclusion and exclusion criteria. If the inclusion criteria are met, move to the next step. If they are not, move to the exclusion criteria if applicable or return and adjust your judgment. Let's check if we meet the criteria.\n\n## Inclusion criteria:\npatients with CAD patients with a family history of CAD\n\n## Exclusion criteria:\npatients with other heart diseases patients without a family history of CAD\n\n## Inclusion criteria\n\n### 1) History of dyslipidemia\n\nPatients with CAD have hypoalbuminemia, hypocholesterolemia, hypertriglyceridemia, and low apolipoprotein A1,",
        "label": 1
    },
    "932": {
        "output": "Clinical trial 00001, for simplicity here is shown without a title: \nTitle: 00001\n\nSummary: To determine the benefit of pravastatin sodium on clinical outcome among patients who have undergone coronary angioplasty.\nInclusion Criteria: Patients 40 years of age or older and having one or more documented coronary artery stenosis.\nExclusion Criteria: The following conditions are absolute contraindications for participation in this study, including acute myocardial infarction/angina pectoris and angiography. Patients should be free of these conditions upon entering the study for 5 days or longer (acute myocardial infarction) and 2 days or longer (angina pectoris) or for 24 hours (angiography).\n\nNotes: Trial-level eligibility is: `Trial-level eligibility: 2) Eligible.`. [INST] Your input is:\n```\n>> Trial-level eligibility: 2\n```\n\n## Exercises\n\nBefore we proceed with practice, note that you should use this notation for input variables as the following, e.g., `Trial_level_eligibility: 2`.\n\n## 1. Add the following variables to the existing [inst] file:\n- `age` is 68.000.\n- `gender` is 1\n- `hypertension` is 0\n- `dyslipidemia` is 0\n- `hypercholesterolemia` is 0\n- `heart_rate` is 93.\n\n## 2. Run the following command:\n```\n$ python generate_srs.py Expected_output_for_Exercise.txt Trial_level_eligibility > expected_output\n```\n\n## 3. Make sure the output file you get is like this as the example output:\n```\n  SRS Trial 00001\n  # Patient # 91126\n    Trial-level eligibility: 2\n    Age: 68.000 (68)\n    Gender: 1 (female)",
        "label": 1
    },
    "933": {
        "output": "---\n__HINT:__ If your file contains several variables, i.e., multiple lines of output in `trial-level eligibility,` you can repeat the `f` function several times by putting its content inside the `for` loop, in the `f{` and/or `f}` (or just in the `f` function, too.)  \n```{r runitall}#repeatedly calculate patient's eligibility \n  trial_level_eligibility <- lapply(c(\"0\",\"2\"), function(inclus){ \n      trial_level_eligibility_1<{ \n          trial_level_eligibility = dataset %>% \n            left_join(rbindlist(map(c(\"inclus\", \"Excluded\"), \n                               list(get_string_from_the_input_file, \n                                    get_trial_level_eligibility_out))), \n                        by = \"patient\", suffix = \"_\") %>% \n            set_colnames(c(\"patient\", \"trial_level_eligibility\")) %>% \n            filter(fread_string_column(\"patient\") %in% \n                  fread_string_columns(\"inclus\", \"patient\")) %>% \n            group_by(patient) %>% \n            mutate(trial_level_eligibility = as.factor(trial_level_eligibility))\n      } \n      }) \n      trial_level_eligibility = try(lapply(trial_level_eligibility, \n                                    bind_rows), \n                               error = \"Error occurred in calculation\") \n  }\n```\n---\nIn this tutorial, we will calculate the patient's eligibility based only on patient ID and trial-level eligibility. \n``tidyverse`` (https://tidyverse.org/) and ``fread`` (https://github.com/pather/ fread) packages will be used for the calculation. The output of trial-level eligibility based on patient ID and trial-level eligibility has a specific structure. The code structure of the output is shown below \n```{r}\n  example_output <str_reverse(c(",
        "label": 0
    },
    "934": {
        "output": "<EOD> Detection of mosaic aneuploidy in human eggs: a possible mechanism for the high rate of chromosomal aberration in human oocytes.\nThe incidence of chromosome deletion was studied in 1251 human eggs by using fluorescence in situ hybridization (FISH). The deletion of the long arm of chromosome 1 was specifically tested as an example. We found that 2 of 653 eggs tested had partial or complete monosomy of chromosome 1q, and 11 of 366 eggs had partial or complete de novo loss of the short arm of chromosome 18. By using DNA probes for specific chromosomes, we examined deletion of the long arm of chromosome 1 in the oocytes with 1q- ascertained by FISH analysis. The results indicated that deletion of the long arm of chromosome 1 was also present in the eggs with normal 1q homologs ascertained by FISH. These findings suggest that deletion of a chromosomal segment occurs in both normal cells and in the subpopulation of oocytes with aneuploidy, and the loss of long arm of chromosome 1 may arise via a mosaic aneuploid state. In some oocytes, partial de novo deletions of chromosome 1 are corrected by further chromosomal segregation to nonviable, nonfertilizable eggs, and the remaining subpopulation of oocytes with normal 18 homologs was also derived from the mosaic aneuploid cells.<EOD> NON-PARAMETRIC TESTS FOR POPULATION DYNAMICS: PROPAGULATION COEFFICIENTS AS ILLUSTRATION.\nThe paper shows how new non-parametric tests or existing tests can be used to assess the significance of parameters, particularly propagation rate in models of population dynamics. First, we present an analysis of the chi-square statistic based on logarithmic link function for various combinations of two-level and three-level designs. Under the constraint that the observed values and the expected values of the parameters come from normal distributions with specific variance, it is shown that a set of non",
        "label": 2
    },
    "935": {
        "output": "[CONT] \n\nThe clinical rule evaluation system should be defined as follows: `R1: R1: `, e.g., `R1: Include`. `R2: R2: `, e.g., `R2: Exclude`.[/CONT]\n\n## Rule 2 RULE A. AGE\n```\nIF $Age >= 46 THEN RuleType:Inclusion; RuleWeight: 1;\nElse RULE A. AGE\n```\n`RuleType` is set in the attribute `RuleType` and `RuleType` was assigned either `Inclusion` or `Exclusion`. `RuleWeight` is set in the attribute `RuleWeight` and is a real number. The rule expression is placed inside the RULE A. statement with the rule type set in the attribute `RuleType` (e.g., `RuleType: Inclusion`) `RuleType`: `RuleType` will set the rule type in the attribute `RuleType`.\n\n## Rule 3 RULE B. LDL-C LEVEL\n```\nIF ($LDL-C < 54) THEN RuleType: Inclusion; RuleWeight: 9;\nOR RuleType: Exclusion; RuleWeight: 1;\nELSE RuleType: Inclusion; RuleWeight: 1;\n```\n`RuleType` is set in the attribute `RuleType` and `RuleType` was assigned either `Inclusion` or `Exclusion`. `RuleWeight` is set in the attribute `RuleWeight` and is a real number. The rule expression is placed inside the `ELSE` statement for `RuleType= Inclusion`, and if is not preceded by `OR` statement between rule A and rule C, which indicates it is the last rule evaluated.\n\n## Rule 4 RULE C. NECK AUCTURALIZ-TION\n```\nIF ($NeckAucturaltion <3+/6+) THEN RuleType: Exclusion; RuleWeight: 1;\n```\n`RuleType` is set in the attribute `RuleType` and `RuleType` was assigned either `Exclusion` or `Inclusion`. `RuleWeight` is set in the attribute `RuleWeight` and is a real number. The rule expression is placed inside the `IF` statement with a condition set",
        "label": 1
    },
    "936": {
        "output": "## Tutorial on Efficiency evaluation of two-step random sampling\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is the clinical trial: \nTitle: Cardiovascular Events in GnRH Agonist vs. Antagonist\n\n\nSummary: The purpose of this study is to test if the use of Degarelix for 1 year associated with a lower rate of cardiovascular toxicity compared",
        "label": 0
    },
    "937": {
        "output": "Your task is to complete the Python file named trial_input_eligible.ipynb and to make it readable using the format of IPython Notebook. You may also find it very useful to make it very readable by inserting comments and code tags.\nYou can find a complete example of how the problem was solved at the following link:\n [TIPS]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n# [B]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n# [C]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n# [D]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n[E]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n[F]\n\n# In each notebook, you should create your file and upload it.<EOD> Transposable elements regulate abiotic and biotic stress responses in rice\nDespite being the most important staple crop, rice is sensitive to biotic and abiotic stresses such as drought, which negatively affects agricultural productivity. The advent of genomic approaches such as genome-wide transcriptomic analysis has identified a large list of transposable elements (TEs) that are differentially expressed under biotic and abiotic stress in rice. This review emphasizes the recent studies that investigated the involvement of TEs in the regulation of various stress-related genes in rice plants. The functional characterization of TEs has provided new insights into their role in the epigenetic regulation and gene expression. The character",
        "label": 0
    },
    "938": {
        "output": "<a href=\"index.html\" class=\"outlook-autocmd-ui\">a</a>\n<a href=\"#help\" title=\"Help\">?</a>\n<a href=\"documentation/index.html\" class=\"outlook-autocmd-ui\">c</a>\n<a href=\"documentation/overview.html\" class=\"outlook-autocmd-ui\">d</a>\n<a href=\"documentation/index.html\" class=\"outlook-autocmd-ui\">e</a>\n<a href=\"documentation/getting-started.html\" class=\"outlook-autocmd-ui\">f</a>\n<a href=\"documentation/guidelines.html\" class=\"outlook-autocmd-ui\">g</a>\n<a href=\"documentation/history.html\" class=\"outlook-autocmd-ui\">h</a>\n<a href=\"documentation/inclusion-criteria.html\" class=\"outlook-autocmd-ui\">i</a>\n<a href=\"documentation/introduction.html\" class=\"outlook-autocmd-autocmd-autocmdocmd-specialist.  `i.</a physicianocmd patient.autocmd`a trialist`patient patient and the patient andmd autocm trial patient. `patient trials trials`patient-eligible patient.\nAngi`patients as a patient`s history or the a person's-patient's trial's patient's medical eligible physician trial: Patient's`s ageing/eligible physician.\n[patient, clinical specialist. Medical condition. Ineligible patient's trial.\nPatient's eligible patient-el trial patient-clin 'nur trial-eligible patient for the clinical eligible`s criteria trial.\nMedician patient-eligible eligible and is the trial.\n[patients` eligible patient. A patient with trial for trialist eligible patient and is eligible patienteligible to a patient trial, trial eligible patient. In the clinician autable patient.\nMed patient.\nass trial.\npatient, eligible clinician patient's",
        "label": 1
    },
    "939": {
        "output": "#### Clinical-Trials::Coder::EL::V027::0\nThe first argument, the trial name, the second argument, patient note note and the third argument a trial-level eligibility are assigned.\nThe output is a hash reference for the trial, containing a field for the patient note and a hash reference for a trial-level eligibility with the fields trial, subject, patient's eligibility, note and note score.\n\n|     Note         | Patient's eligibility      | Excluded         | Eligible         | | score           | note-ref        | note               |\n| :----------------: | :-----------------------: | :------------------: | :----------------: | :----------       | :------------------: |\n| trial              | #<Hash:0x000000003318C840: 2996 bytes>| #<Hash:0x000000003318B080: 12 bytes> | #<Array:0",
        "label": 1
    },
    "940": {
        "output": "You can choose from  to make your final selection. [inst]\n\n![Trial-by-trial assessment of clinical trial eligibility.](img/03-experiments/clinical-trials/001-Trial-eligibility-table.png)\n\n![Trials that did not meet the inclusion criteria.](img/03-experiments/clinical-trials/002-Trial-eligibility-table2.png)\n\n![Trials that meet the inclusion criteria.](img/03-experiments/clinical-trials/003-Trial-eligibility-table3.png)\n\n![Trials that met the inclusion criteria but did not meet the exclusion criteria.](img/03-experiments/clinical-trials/004-Trial-eligibility-table4.png)\n\n## Test your program by generating the following table (the patient note should be changed)\nPatient Name:\n\n```\nJames Robertson, 28, male.\n\n```\nPatient age:\t        34 years\n\n```\nBlood pressure:\n\n```\nsystolic pressure, mmHg: 130\ndiastolic pressure, mmHg: 70\n\n```\nEjection fraction (EF):  55%\n\n```\nTreatment\n\n```\nMetoprolol 200mg/day\nExenatide 10\u03bcg/2 weeks\n\n```\nFamily history of CAD, hypertension, diabetes mellitus? : \n```\nHalpahalcobacter pylori infection (H. pylori status)?\n\n```\nnegative\n\n### The output of the program\n\n```\nPatient ID:\t158057921020156066422188972193\nTitle\t: A 28-year-old male comes for an outpatient appointment at the clinic\nYear \t\t: 2015\nRace: White\nGender: Male\n\nPatient name: \n James Robertson\n Patient age:",
        "label": 0
    },
    "941": {
        "output": "### Examples\n- You are in the assessment of eligibility of a clinical trial targeting a subject with a clinical condition, such as dyslipidemia.\n- You should first check whether this subject fits the inclusion criteria of the trial. We assume that you find the subject meets all the general inclusion criteria in.\n- Suppose that this subject doesn't match both (1) Exclusion criterion (1) 2): 8), in particular the subject has coronary artery disease  and is excluded (4) Due to other clinical trials targeting the same subject condition, you should check if all the exclusions apply in the previous trials. We consider that the history of previous stroke is considered to be met the exclusion criterion in this trial. Therefore, you should also exclude the subject.\n- You can also think that this subject matches all the trial's inclusion criteria:\n- Angina as an Inclusion criterion (1) 1): 1, such as Canadian Class III angina Canadian Cardiovascular Society (CCS III), Canadian cardiovascular society, which the patient is currently being treated;\n- Myocardial infarction as An inclusion criterion (1) 2): 2.\n- Treatment with statin (An inclusion criterion (1) 3): 3; In this example, you can find the subject currently receiving a statin.\n- Coronary artery disease as An inclusion criterion (1) 4): 4; The subject meets the coronary artery disease as \u2265 70% stenosis.\n- Age as an inclusion criterion (1) 5): 5, is > 60 but < 70 years old.\n- Dipyridamole thallium stress test as An inclusion criterion (1) 6): 6.\n- Ejection fraction \u2264 35% as An inclusion criterion (1) 7): 7. [Inst=Instruction]\n- You also check both the exclusion criterion (1) 1): 1and the exclusion criterion (1) 2): 2. If the subject doesn't meet the exclusion criterion (1) 2: 2, the inclusion criterion (1) 1) remains. Therefore, el",
        "label": 1
    },
    "942": {
        "output": "## R code\n# We load the packages and read the patients # and the clinical trial from a .csv file # patient_data <-read.csv(\"D:/GitHub/patient_note.csv\", sep=\";\", row.names=\"Patient_ID\") # # the file contains data of our patients and we print # the first 3 rows # head(patient_data) # # We now read the clinical trial from its .csv file 0 0 2 ))))\n\n## # the file contains clinical trial data and we print # the first 3 rows of the data # print(clinical_trial_data)\n\n## # print two patients, one eligible and a 0) Not relevant #\n\n## # eligible\nPatient_ID Patient_ID\n\n## 0) Not relevant\nPatient_ID Patient_ID<EOD> Influenza Vaccination of Healthcare Workers in the UK during Lockdown for COVID-19: An Analysis of the 2020\u20132021 Vaccination Season.\n\n [bib_ref]  Vaccination coverage among front-line health care providers working in long-term care facilities..., Nerandzic [/bib_ref]  [bib_ref]  COVID-19 and HCWs: What happens when those who care take care of..., Whitby [/bib_ref]  [bib_ref]  COVID-19 and HCWs: What happens when those who care take care of..., Whitby [/bib_ref]  [bib_ref]  SARS-CoV-2 infection among healthcare workers of a tertiary hospital in the beginning..., Cunha [/bib_ref]  [bib_ref]  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BEI-2526: A phase 1..., Yang [/bib_ref]  \n\n# Methods\nWe analyzed immunization reporting data routinely captured and transmitted by Cerner systems across England as part of the NHIS. Health Evaluation and Monitoring software (HEMs) was developed by Cerner in 1990 and the immuno-specific software, Cerner Immunization Management (CIM), to automate immunization reporting and improve outpatient immunization delivery. CIM collects patient-specific information such as demographic data,",
        "label": 0
    },
    "943": {
        "output": "```\n<EOD> .\nIn 1 case of laryngeal cancer with multiple lymph node metastases, clinical N2 in the left supraclavicular region and clinical N1 in the right supraclavicular region following radiation therapy, surgical resection of clinically extracapsular enlarged nodes in post-operative scar tissue were attempted. Postoperatively, the enlarged nodes were not recognized as N2a tumor according to their appearance. Postoperative histology of the enlarged nodes revealed pathological N2b in the left supraclavicular region and pathological N1 in the right supraclavicular region. All pathological findings were pT1N2pN0M0 squamous cell carcinoma. Radiation therapy has been generally believed to be ineffective for metastatic lymph nodes. However, we suggest local radiation therapy should be indicated in some selected cases of laryngeal cancer in the early stage even though there are metastatic lymph nodes clinically.<EOD> A prospective randomized trial of the effects of low-dose radiation on acute lymphoblastic leukemia.\nThe effects of low-dose radiation on the clinical course of childhood B-acute lymphoblastic leukemia (ALL) were studied in the context of a phase III randomized trial of the chemotherapy program (BFM-90) of the Berlin-Frankfurt-M\u00fcnster (BFM) Medical Group for ALL. For the current publication, 129 new (de novo) and 38 secondary (i.e., relapsed or refractory) B ALL patients were compared regarding time to relapse, overall survival, late effects and genetic toxicity, both from the start of initial chemotherapy (1994) and with regard to long-term effects (2013). The effect of whole body exposure to low-dose radiation was studied in the initial phase of the ALL trial of the BFM-group (BFM-83), in which patients had been randomized to receive whole body irradiation before the first chemotherapy cycle, either to prevent the occurrence of the \"leukemia-initiating event\" in the context of the hematopoietic stem cell",
        "label": 0
    },
    "944": {
        "output": "---\n## C2-P177\n*Exercise 4* [C2](https://github.com/jiangzhen3031/KnowledgeMap-papers-py)\n\n*Exercise 4: Export a dataset from the Knowledge Graph using Neo4j *\n\n\nDownload the Knowledge Graph to a local Neo4j instance and then use `neo4j-docker` to start a Neo4j container.\n# Download the Knowledge Graph\n\nFrom the KM page or your local Neo4j, enter the knowledge graph `https://knowledgemap.github.com/knowledge_model_v1.0.2.bzl` in the address bar, click on the \"Dataset\" tab in the menu (top right), select the \"Dataset version\", the location of the dataset export file, and the destination location of the Neo4j data folder. (The file name can be specified, e.g., \"KM-0.2.6-180925_0000.json\" and \"KM_026_180925_0100.tsv\"). (The file size is also an option.)\n\nThe Knowledge Graph file will be stored in the Neo4j data folder (for example, `data/KM-0.2.6-180925_0000.json`).\n\n![download_knowledge_model](img/km/download_knowledge_model.png)\n\nTo export the dataset, right-click and select the \"download\" function. \n\n![download_dataset](img/km/download_dataset.png)\n\n### Dataset export\n\n1. In this example, we will export the dataset in the `KM-0.2.6-180925_0100.tsv` file from the KM graph to a local Neo4j instance, and the filename will be stored in the `tsv.txt` file. First, we need to download this file by using the \"Export\" tab on the Knowledge Graph website page.\n2. Open the KG file into the Neo4j desktop file explorer, then right-click and",
        "label": 1
    },
    "945": {
        "output": "[TUTOR] Here is a brief tutorial for using GPT-3 to solve your programming tasks:\nThe use of GPT-3 to create code in R is quite simple and does not require special skills. To generate code, just tell it to generate code in R and add the input data to the training dataset. Also, the generated code can be used to solve your programming problems in R, and some pieces of code can be used for debugging, which is the most common use case.\nTo use GPT-2 for generating code in R, run the following code:\n\n```\nlibrary(pluma) library(readr) library(nnet) df = read_csv(file = \"data/20.csv\") new_df = df %>% select(Blood_pressure_systolic, Blood_pressure_diastolic, ICP_brain, Lactate) dataset = dataset(new_df) # make a dataset and pass the dataset to the R code generator library(pluma) code = pluma::gpt() code(code = 1:5000, \"generate r code\", dataset = dataset) ```\n\nAfter you run the code above, you will see the generated code. In this example, we have generated the following (5000) pieces of code - the numbers indicate the number of the generated pieces of code. It may take a lot of time to generate all of the codes, so we suggest you generate them by blocks instead of all at once. The code below has the same structure:\n\n```\n```\nIn the generated code, we need to add some modifications, so we need to use the following line:\n```\n# make some modifications lib = paste0(\"r\", library(pluma)) pluma = paste0(lib, \"pluma::pluma3(code = 1, \",\n```\n\nThe code below generates your desired code in block 8:\n```\ncode(code = 8, file = paste0(\"r\", library(pluma)))\n```\nHere is the output:\n\n```\n# generate r code dataset(new_df) code = r { 10:1 } # make a dataset and pass the dataset to the R code generator 11:10 dataset = dataset(); # make another dataset that you want to pass to the R code generator",
        "label": 0
    },
    "946": {
        "output": "## [TARGET] Hello. Your patient has Takayasu arteritis with the classification mild-moderate. Since the Kerr score is 2, you should check the inclusion and exclusion criteria for the trial.\n\nHere is the list of inclusion and exclusion criteria for the trial:\n\nHere are the factors from your patient, based on the note presented in the assessment. \n\n\n### Inclusion: \n> Bone marrow edema, > Bone marrow edema and > 1 factor from Table 1\n\n### Exclusion:\n1) Bone marrow edema, > > 2 factors from Table 1\n\n> Exclusion criteria may be omitted in the case of mild to moderate disease states. In all three of the cases shown in , the patients were mild to moderate as defined by the IAS, and therefore all three were eligible. In contrast to the clinical presentation and treatment, the outcomes were very different among the three patients. In case 1, the patient had severe and progressive osteoporosis with multiple spine and hip fractures and disabling pain. In case 2, the patient had no complications at all from Gaucher disease at the time of presentation. This patient showed an excellent response to enzyme replacement, and as of this writing, was still in remission. In case 3, the patient also had severe osteoporosis with multiple severe metabolic bone disease-related bone fractures. It is important for each individual patient to be assessed to develop a treatment plan tailored to the patient's needs.\n\n> Cases 1 and 2 are both eligible for enrollment into a clinical trial of enzyme replacement therapy\n\n> The IAS and the TAG groups have developed clinical trials research guidelines for GD.\n> \n> 5.2 Trial Assessments: Patients with GD may undergo a trial assessment in addition to standard clinical care.\n[/TARGET]\n\n## [NOTABLE]\nHello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that",
        "label": 0
    },
    "947": {
        "output": "[fig]  [INST]: Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. [/fig] \n[table]  [ ]: Clinical trials are the first step to get new medicines to patients who are sick. However, many clinical trials fall short of their target recruitment numbers. Eligibility is therefore one of the key steps in the recruitment stage of a clinical trial. Identifying the population that qualifies for study inclusion ensures compliance with the trial protocol, safety monitoring, and data analysis. However, identifying the target population also prevents patients from being under-qualified or over-qualified for a trial. [/table] \n<EOD> Oxygen-sensitive gene regulation in a facultative anaerobe by an oxygen-binding transcription factor: involvement of a protein kinase.\nProtein kinase activity was detected in extracts of a Gram-negative facultative anaerobe, Neisseria perferingens, that was isolated from the human rectum. As is the case with other cyclic AMP-binding proteins, such as cAMP receptor protein (CRP) of Escherichia coli, the N. perfingens protein that reacts in vitro with radiolabeled cyclic AMP has a molecular weight of 42,000 and is an acid-soluble protein with a pH optimum of 6.2. The cyclic AMP-dependent protein kinase (PK) was found to exhibit higher kinase activity toward N. perfingens lysate and soluble proteins than it did toward the crude cell extract. Studies of the phosphorylation of a major soluble protein showed a correlation between the oxygen concentration in the growth medium and the rate of protein phosphorylation of the N. perfingens culture, providing evidence for the oxygen-sensitive nature of this PK. The oxygen-stimulated phosphorylation of this protein corresponded to the oxygen-dependent",
        "label": 0
    },
    "948": {
        "output": "1. You should print the patient note.\n\n\t     var printSrc = ('/patient-note-print.action');\n\n\t     response.redirect(printSrc);\n\n\n2. You should print the clinical trial.\n\n\t     var printSrc = ('/clinical-trial-print-summary.action');\n\n\t     response.redirect(printSrc);\n\n\n3. You should compare the patient note and the clinical trial.\n\n\t     var matchClinicalTrials = $('#match-clinical-trial').val();\n\t     // var trialNoteInfo = $('#trial-note-list').find('[title = ').val();\n\n\t     var trialMatchClinicalNoteInformation = trialNoteInfo.filter(item => {\n\t     \n\t     matchClinicalTrials = matchClinicalTrials.split(\"#\");\n\t\t\n\t     var clinicalNoteInformation = item.split(\"|\");\n\t     \n\t     for (var i = 0; i < trialMatchClinicalNoteInformation.length; i++) {\n\t     \n\t     for (var itemIndex = 0; itemIndex < matchClinicalTrials.length; itemIndex++) {\n\t\t\t\n\t     \n\t     if (clinicalNoteInformation[i] == matchClinicalTrials[itemIndex]) {\n\t     // return matchClinicalTrials[itemIndex] + \" : \" + trialNoteInfo[0].split(\"=\")[1] + \n\t     // \" for #1 0123456789\";\n\t     trialMatchClinicalNoteInformation = clinicalNoteInformation.slice(0,matchClinicalTrials.length);\n\t     return;\n\t     }\n\t     else if( trialNoteInfo[0].split(\"=\")[1].split(\",\").join(\"\").substring(\"1\" + itemIndex).trim() == matchClinicalTrials[itemIndex].split(\"=\")[1].split(\",\").join(\"\").substring(\"1\" + itemIndex).trim()) {\n\t\t\n\t     return matchClinicalTrials[itemIndex] + \" : \" + trialNoteInfo[0].split(\"=\")[1].split(\",\").join",
        "label": 0
    },
    "949": {
        "output": "[TASK]\nAnswers for the [TASK] can be found below. Please choose the correct answer.[INST] Hello, [TASK]! This [TASK] requires several input values.\n\nInputs are the following:\n\nLet's think step by step (you need to put these inputs into [CODE], and then click the \"Run\" button to see the output):\n\nOn the next page, please make a [Task] for each patient's [TASK], as shown below:\n\nTask (output): Excluded (2), Not relevant (0), Eligible (49)\nTask (output): Excluded (2), Not relevant (0, 21), Eligible (49, 23)\n\n[/TASK]\n\n### Task: [QUESTION].\n\n1. `Task:`[QUESTION].\n    \n2. `Task:`[QUESTION].\n\nTask (output): Eligible (151)\nTask (output): Excluded (4), Not relevant (54, 107)\n\nTask (output): Eligible (155)\nTask (output): Eligible (156)\nTask (output): Excluded (4)\nTask (output): Not relevant (54, 105, 125)\nTask (output): Excluded (4)\nTask (output): Not relevant (55, 71, 73, 81, 89, 102, 104, 112, 127)\n\nTask (output): Excluded (4)\nTask (output): Not relevant (55, 71, 73, 81, 89, 102, 104, 112, 127)\n\n    6. `Task:`.\n    \n    \nInputs are the following:\n\n1.  `Age:` (3).\n    \n2. `Lv-CAD` (0, 1).\n        - value of 0 means no Lv-CAD in a cohort\n        - value of 1 means Lv-CAD in a cohort\n        \n    \n2. `",
        "label": 1
    },
    "950": {
        "output": "<EOD> The Relationship Between Dental Plaque and Acute Gingivitis: A Study of Dental Pulp Responses in Humans\nTo investigate the relationship between subsurface dentine demineralization and dental plaque accumulation associated with bacteria in acute gingivitis, dental pulp responses in acute gingivitis were investigated immunohistochemically in 23 sites derived from eight teeth from seven healthy individuals. The eight teeth were all extracted when they were diagnosed as hopeless by their general dentists. Tooth sections were stained immunohistochemically with antibodies specific for osteopontin. Subsurface dentine demineralization was evaluated using surface electrical capacitance measurements during the tooth extraction. Accompanying each measurement, the amount of retained plaque accumulation was assessed by a microbiological assay. The relationship of the amount of dental plaque accumulation associated with acute bacterial accumulation with subsurface dentine demineralization was then examined. The results showed that the increased subsurface dentine demineralization correlated significantly with the amounts of dental plaque accumulation (P = 0.01, R2 = 0.0418) in acute gingival inflammation. These results indicate a close relationship between the amount of plaque accumulated and acute bacterial accumulation in dentine demineralization. The possibility of monitoring acute bacterial accumulation using electrical measurements indicates that this type of bioelectronics may be suitable for the management of acute gingivitis.<EOD> \u03b2\u2010Adrenergic stimulation impairs glutamate synaptic transmission onto rat parvocellular neuroendocrine neurones of the hypothalamo\u2013neurohypophysial system\nThe hypothalamo\u2013neurohypophysial system (HNS) is a master neuronal network that controls the functions of the neuroendocrine system and maintains the homeostasis of body fluid. Parvocellular neuroendocrine neurones of the HNS receive glutamatergic synaptic input from multiple brain regions; glutamate (excitatory) or GABA (inhibitory) modulates their elect",
        "label": 0
    },
    "951": {
        "output": "<EOD> Evaluation of the performance of the immature platelet fraction measured by Sysmex XP\u2010300i\nBackground and Objectives\u2002 The immature platelet fraction (IPF) is a parameter measured by automated hematology cell counters after gating platelets as particles with diameter \u22644 \u03bcm and fluorescence of side scatter (SS)\u2010A\u2010red cells. Little is known about the performance of the IPF measured by automated hematology cell counters. The study was performed to assess the characteristics of the IPF and to compare two automated hematology cell counters from Sysmex XP\u2010300i and XE\u20102100.<EOD> Hospice care and end of life decisions: the legal and ethical implications of the Montgomery Report\nThe Montgomery  report, published in February 2008, is a serious critique of end of life decisions and the role and use of Liverpool Care Pathway and also of the Liverpool Hospital Foundation NHS Trust. It is based around a \u2018factual reconstruction\u2019 of the last 48 hours of a terminally ill patient\u2019s life. It exposes an attitude towards the patient as being in need of curative treatment, rather than a person with progressive disease to whom adequate palliation should be given. It highlights a widespread tendency for patients perceived to be dying in hospices to have unacceptably high levels of suffering, and for staff to find end of life \u2018troublesome\u2019 and \u2018problematic\u2019.\n\nAs in any ethical debate the argument has to be seen in an empirical context and the Montgomery report suggests that end of life decisions within hospice care are in need of review. This review must include not only issues such as Liverpool Care Pathways (LCPs), which are at the heart of the debate and have been a lightening rod for public attention, but also other aspects of end of life decisions and death, including, for example, the ethics of admitting patients to an hospice in a stable terminal phase.1 This paper aims to explore some of these issues and considers whether any legal or criminal liability stems from Montgomery\u2019s analysis and findings.\n\nAbove all, Montgomery suggests that we must acknowledge that the care a dying person",
        "label": 0
    },
    "952": {
        "output": "_______________________________________________________________________________________\n\n*You must sign the [Trial-registration-Form](https://github.com/mikro123/Deep-Care-Augmented-Recruitment-System/blob/master/trial-registration-form.pdf) to use this Deep Care Augmented Recruitment system.\n\n[Trial-registration-Form](./trial-registration-form.pdf) _______________________________________________________________________________________\n<EOD> The effect of 670 nm low level light therapy on postoperative wound healing and inflammatory responses in patients following total knee arthroplasty: study protocol for a randomised controlled trial\n\nBackground: Delayed wound healing and infection remain the most common and serious complications after total joint arthroplasty. Currently, low level lasers have been used to stimulate wound healing. However, the effect of low level laser therapy on knee wound healing and inflammatory responses following total knee arthroplasty (TKA) remains unknown.Methods: In this single-blind and placebo-controlled randomised trial (RCT) design, 124 patients will be randomly enrolled (1:1) into treatment or control groups. Participants in the treatment group will receive 670 nm laser at 6.5 J/cm 2 , 3 sessions per week, for 6 weeks immediately after TKA, while participants in the control group will receive 670 nm laser at 0.25 J/cm 2 , 3 sessions per week, for 6 weeks in the immediate period after TKA as the sham treatment. The outcome assessments will be performed at 2 weeks, as well as 4, 8, 12 and 24 weeks after TKA. The primary endpoint will be the changes in inflammatory immune cell markers in knee joint fluid. Secondary endpoints will include changes in immune cell count as well as cell phenotype, time to normalisation of knee joint fluid neutrophil and lymphocyte, and changes in pain intensity and knee function. Furthermore, adverse events",
        "label": 0
    },
    "953": {
        "output": "[[NOTE] Your input is stored in the data dictionary, `data.xls`. The column headers start with `c_` in `AREA_BREAST` and `s_` in `RESTANT_ID`.]\n\n### Inference with [https://github.com/james-h/statpy](James Harden)\n\nIn this tutorial, we will use Python to predict the probability of an event occurring, given the patient's characteristics. To do so, we will use some of the statistical tools described in . A large sample of patients will be simulated in this tutorial. If we were to do this with real patients, we could expect to be over fitting and obtain predictions that do not generalize well to new cases. One of the techniques that allow us to decrease the over fitting is by using cross validation. We will use leave one out cross validation to estimate the performance of the model obtained.\n\nIt is important to mention that the statistical tests are described in a generic way in . The authors provide a python package where you can apply the tests following a few lines of code, or it is possible to use a webservice, for example [https://github.com/james-h/caret](James Harden).\n\nHere we will use the statistical methods described in to create a classification tool for the prediction of acute renal failure in critical illness patients. The methods to predict critical illness acute renal failure are described in chapter 3 of the book.\n\nThe training dataset contains information about each patient, clinical variables and the occurrence of acute renal failure. The aim is to construct an algorithm that predicts this clinical event. Our goal is to obtain a tool to help to the clinician in the decision-making process. Since we need to make several decisions in order to create the model, it is appropriate to follow the data analysis pipeline shown in .\n\n[[INSTRUCTION] In the first step, you need to create the variable that represent the occurrence of AKI. Note: AKI is the acronym in Spanish for Acute renal failure. To create this dummy variable, copy the patient information about AKI occurrence in the file named `patients_001.csv`. Then, copy that information and create the variable using the expression `patients_001 = np.copy(patients_00",
        "label": 0
    },
    "954": {
        "output": "## [Ans] In the patient note, if the patient has a family history of cad, what score should it show in the assessment of eligibility?\nA. Excluded. B. Ineligible. C. Relevant. D. 0. E. Not relevant.\n\n## Answer: d. 0\nExplanation:\nIn the patient note, if the patient has a family history of CAD, what score should it show in the assessment of eligibility? Family history of CAD.  \nThe patient note is analyzable in the trial. You should make a trial-level eligibility for each patient in this trial. Inclusion criteria: Patient who received or is expected to receive coronary stenting within 3 months. \nPatients with positive family history of CAD were considered as having positive family history of CAD. In this way, the right answer should the answer that scores patients in 0. The other options are all incorrect.\n\n## [Ans] if the patient's fasting glucose level was not within normal limits, what score should it show in the assessment of eligibility?\nA. Excluded. B. Ineligible. C. Not relevant. D. Relevant. E. 0.\n\n## Answer: c. not relevant.\nExplanation:\nIf the patient's fasting glucose level was not within normal limits, what score should it show in the assessment of eligibility? Not relevant.\nPatients with fasting and pre-prandial blood glucose levels above 130\u2009mg/dL were considered to be out of the normal range. Fasting blood glucose is required to be<130\u2009mg/dL.In this way, the right answer should the answer that scores patients in 2.\nThe other options are all incorrect.\n\n## [inst] Explain why not all options are correct.\nA. Since CAD risk assessment is performed according to the Framingham Coronary Risk Score, age and sex are not factors associated with CAD (in CVS, smoking and family history of CAD are associated with CAD, not age or sex). Blood pressure is also not a factor associated with CAD.\n-Framingham Coronary Risk Score (",
        "label": 0
    },
    "955": {
        "output": "## [CORRECT] \nThe patient is excluded from a clinical study on dizziness because the patient does not have sufficient information and the patient suffers from chronic dizziness.\n\n## [INCORRECT]\nThe subject is not eligible to participate in the study because the patient is too young and the patient has a low cholesterol level.\n\n## [INST]\nThe patient is excluded from a clinical study on chronic dizziness because the patient has a high cholesterol level and the patient's age is too young.\n\n## [OVERT]\nThe patient who fits the age bracket and does not have a too-high cholesterol level to participate in the dizziness study is not eligible to participate in the study.\n\n## [INSTCOR]\nThe patient is excluded from a clinical study on chronic dizziness because the patient has a high cholesterol level and the patient's age is too young.\n\n## [OVRTCOR]\nThe patient who fits the age bracket and has a too-high cholesterol level to participate in the dizziness study is not eligible to participate in the clinical study on chronic dizziness.\n\n## [OVRT]\nThe patient who fits the age bracket to participate in the dizziness study is not eligible to participate in the clinical study on dizziness.\n\n## [OVER]\nA patient who does not have a high cholesterol level to participate in the dizziness study is not eligible to participate in the clinical study on chronic dizziness.\n\n## [INSTC]\nThe patient is excluded from a clinical study on dizziness because the patient is too young and the patient suffers from chronic dizziness.\n\n## [OVERCOR]\nA patient who fits the age bracket and has a too-high cholesterol level to participate in the dizziness study is not eligible to participate in the clinical study on chronic dizziness.\n\n## [INSTOVT]\nThe patient is excluded from a clinical study on dizziness because the patient suffers from chronic dizziness",
        "label": 0
    },
    "956": {
        "output": "Please test a clinical trial and then submit your results for the rest of the four trials.\n\nPlease follow these steps to complete the task:\n1. Review the trial notes and compare them with the training data notes.\n2. Assess the eligibility of the training data  to include or exclude the patients in the trial. 2a. Do this for each trial.\n2b. To indicate if the trial notes are NOT relevant due to missing information or variables, please choose the 1 - 'Not relevant' label.\n2c. To indicate if the trial note is ELIGIBLE, please complete the following checklist.\n2d. Use the 0 or 1 code to indicate whether the patient will participate in the study:\n0= patient is excluded in the trial\n1= patient is eligible for the trial\n2. Save your results in the CSV file that we provided and name the file as follows: your name first initial and second initial_0_eligibility .csv .\n2d. You are allowed to use all required packages for your task. [/HOLDOUT] [/END]",
        "label": 0
    },
    "957": {
        "output": "## Recommendation\nThere is no simple way to distinguish patients with moderate-to-to high-risk CAD from patients with no or intermediaterisk CAD. Hence, we used the Framingham Risk Score to stratify patients into three groups of similar risk for CAD: low (CAD probability < 2%), intermediate and high (CAD probability > 20%). \nIn this task, you should predict the risk groups of the clinical trials (low, intermediate, high), whose inputs are the following medical data: age, sex, SBP, DBP, history of cigarette smoker, total cholesterol, HDL, fasting blood glucose, history of hypertension, and history of diabetes. \n\nYour assignment is to predict the patient's risk group by multiclass logistic regression. You should output the predicted risk value with range: 0-100. Each risk group, e.g., low and high, means no or low and high risk of CAD.\n\nHere are the training data for the regression task:\nThe training data consists of 24 records. One record means the input values of the training data, and it is shown in [fig_ref]  Table 5 1: Example Case Study [/fig_ref] .2\nYou may make a 10-fold cross validation by splitting the train-ing into 10-folds and calculating the performance metrics, e.g., accuracy, in each fold. \n\n# Input data\nAge, Sex, SBP, DBP, History of cigarette smoker, Total cholesterol, HDL, Fasting blood glucose, History of hypertension, History of diabetes These values are all numerical data, 23 in total.\n\n# Output dataset\nRisk groups This dataset consists of three labels. Low, intermediate, high. Each risk group represents that the probability of the CAD belongs to that risk group. The order of the three groups: high, intermediate, and low.\n\n# Output metrics\nPrecision, Recall, Accuracy Precision is how many of the total number of predictions for which the true group is low is low out of the total number of predictions that are grouped as low. \nRecall is how many of the true low group is low",
        "label": 0
    },
    "958": {
        "output": "For every patient: - First record the status of the assessment of eligibility;\n- then, calculate the value for Trial-level eligibility: 0 - Excluded; 1 - Not relevant; 2 - Eligible; and\n- the value of the assessment of eligibility and record it.\nYou may also see the Trial-level eligibility assessment code and the assessment status code for trial-level eligibility, which you can use to fill in the fields to output the results to the right path. You will not be assessed by yourself, but will be input into the file system. If you do not record, you may not know what your input is.\n\n![](/img/pics/help/clinical-data-entry/help_eligibility_1.png)\n---\n\n### 3) Excluded\nAssessment of Eligibility:  The trial did not include the patient. This is determined by the exclusion criteria of the trial.\n\n\n---\n\n### 4) Not Eligible\nAssessment of Eligibility:  The trial included patients for the trial and did not meet the eligibility criteria. This is determined by the exclusion and eligibility criteria of the trial.\n\n\n---\n\n### 5) Eligible\nAssessment of Eligibility:  The trial included patients for the trial and did meet the eligibility requirements. This is determined by the eligibility and exclusion criteria of the trial.\n\n\n---\n\n### 6) Not Relevant\nAssessment of Eligibility:  This means the patient is not the target of the trial. \n\n###### For a more in-depth understanding of how to use this field:\n\n\nThe assessment status of the eligibility is the trial-level eligibility 5. Trial-level eligibility must be zero when `0 - Excluded` and non-zero when  `1 - Not Relevant`, `2 - Eligible`, or `6 - Not Relevant`. \n\nTriall level eligibility status will not change if you switch to other lines: \n---\n\nThis patient does not meet the inclusion criteria.\n\n\n---\n\nThis patient meets the inclusion criteria.\n\n\n---",
        "label": 2
    },
    "959": {
        "output": "## Good luck!\n<EOD> Impact of an Ex Vivo Culture System on Craniosynostosis Precision Medicine\nAbstract Objective\u2003This review aims to (1) outline the steps for developing an ex vivo culture test that addresses limitations in the treatment of craniosynostosis (CS), (2) examine the current studies on culture of patient-derived cells from the calvaria, and (3) assess the clinical impact of patient-derived cultures in the context of personalized medicine. Design\u2003Through a review of the published and unpublished literature and the authors' experience, we provide an outline and overview of various studies relevant to the creation of an ex vivo culture test for CS. Setting\u2003The authors reviewed published literature and developed a model of an ex vivo culture test and analysis of patient-derived cells. Results\u2003The authors review the available literature on (1) the use of calvarial tissue in CS research to obtain patient-derived cells, (2) the use of cultured patient-derived cells as a surrogate for the original patient's conditions for drug testing, and (3) studies with primary cells and in vitro models of CS. Conclusion\u2003An ex vivo culture test has been designed to address the limitations on biopsy and clinical treatment, and ultimately CS precision medicine. The current understanding of the use of cultured primary cells of CS patients will be leveraged to establish a model that closely resembles the conditions of patient's specific malformation.<EOD> A Novel AU-Rich-Element-Binding Protein, AU-Rich-Element RNA-Binding Protein-2, Binds to the 3\u2032 Untranslated Region of Stem Cell Leukaemia Gene\n\nThe 39 untranslated region (39UTR) plays important roles in mRNA stability, sub-cellular localisation and posttranscriptional regulation. AU-rich elements (ARE) are characterised by the presence of multiple clusters of adenine and uridine (A/U) residues and are present in the 39UTR of a large proportion of mammalian mRNAs. The ARE-RNA-binding proteins (ARE-BPs) are present in almost all cell types and regulate mRNA of hundreds of gen",
        "label": 0
    },
    "960": {
        "output": "<EOD> Anatomical studies of the mandibular canal: Part III\u2014The anterior loop of the inferior alveolar nerve\nObjective: To investigate the morphological variation of the inferior alveolar nerve (IAN) in the mandible using cone-beam computed tomography (CBCT) imaging. Material and Methods: We examined the mandibles from 290 dry skulls to examine the morphology and course of the IAN. Data were then obtained from 35 cadaver hemi-mandibles. Results: We observed that the IAN bifurcated in 34 cadavers (97.1%). In 29 cadavers (82.9%), the inferior alveolar canal presented a sharp internal curve that originated in the mandibular foramen. This portion of the IAN was referred to as the anterior loop (AL or CBCT-AL). In 12 cadavers (34.3%), we also observed a second separate internal curve that originated from the posterior portion of the inferior alveolar canal. The mean distance from the IAN canal to the apices of the maxillary first molars was 25.3 mm. Conclusion: A CBCT provides reliable information about the localization and course of bone of the IAN. A high anatomical variation in the CBCT-AL (34.3%) was found compared to previously reported variations.<EOD> Corrosion behavior, mechanical properties and dental applications of biodegradable binary zinc-based alloys fabricated by different methods\n\nIn this paper, we investigated the effect of fabrication method on microstructural evolution, mechanical properties and corrosion behavior of biodegradable binary zinc (Zn)-based alloys, which aim to develop an ideal implant material for oral hard tissue repair. Zn-0.5Co, Zn-0.5Fe, Zn-0.5Ni, Zn-0.5W and Zn-0.5Mo samples were prepared by spark plasma sintering (SPS), hot press sintering (HPS) and solid solution processing (SSP). After preparation, samples at different sintering conditions (0.1-0.65 TPa for SPS, 5-10 MPa for HPS, and",
        "label": 0
    },
    "961": {
        "output": "* * *\n\n\n\n\n``` python\ndef patient_eligibility(patient_note):\n    with open('/data/inputpatient.txt', 'r') as fp:\n        data_input = fp.read()\n        #print(data_input.strip())\n        trial_input = data_input.strip().replace('[INST]','')\n        trial_input = trial_input.trim()\n        #print(trial_input.strip())\n        if trial_input == '0) Excluded':\n            print('Your patient {0} is excluded for the clinical trial {}'.format(input(\"Type your answer: \"), trial_input))\n            return\n        \n        elseif trial_input == '1) Not relevant':\n            print('Your patient {0} is not relevant for the clinical trial {}'. format(input(\"Type your answer: \", trial_input)))\n            return\n        \n       \n        else:\n            if trial_input == '(1) Eligible':\n                print('Your patient {0} is suitable for the clinical trial {}'.format(input(\"Type your answer: \", trial_input)))\n            else:\n                print('Your patient {0} has insufficient information to be assessed. ' . format(input(\"Type your answer:\", trial_input)))\n            return\n\npatient_eligibility(patient_note)\n```\n\n<!--- Your code may go here. -->\n\n<!--- Submit your results here. -->\n\n\n<!--- \u26a0\ufe0f If you need help, ask a colleague to test your program and provide feedback. ---><EOD> .\nThe patient presented in this case report was a 48-year-old female. She had been admitted in hospital a few years before, because of acute pneumonia, and there were many episodes of cough and dyspnea over the past three years. The pathogenesis of pseudomembranous pneumonia after bacterial pneumonia is considered to be related to bacterial infections. The lung biopsy revealed neutrophil exudates and fibrinous necrosis exudates. The lungs recovered well under proper treatment.<EOD> Proposal for a new technique for the",
        "label": 0
    },
    "962": {
        "output": "##[ /Trial-level eligibility] [ /INST]\n\n### Evaluate Patient Eligibility\nIn this case, your task is to answer a specific question, i.e., identify a patient with carotid web in the clinical trial's inclusion criteria. You should do this independently from the other participants who will do the same task. You should have the same patient note with the same clinical trial as the other participants. You are also restricted to 5 min to identify the patient with the carotid web. \n\nIt is clear as daylight as the patient's note corresponds to the inclusion criteria. The patient is eligible for the clinical trial. In particular, the clinical trial includes patients with carotid webs and cerebral infarctions or transient ischemic attacks. \n\nYou should show us the lines on which you placed your comments on the patient note and in the clinical trial you found them.\n\n\n\n\n# [Hackathon](https://github.com/microsoft/fhir-challenge/blob/master/hackathon)\n\n\n## [Overview](FHIR_Incidence_V2.docx)\n\n## About Us\n\nThis challenge is developed and maintained by a small group of volunteers with interests in FHIR. We are all either affiliated with organizations that are developing (or working with those that develop) FHIR or other open standard health care technologies. Our affiliations span academia, open source projects, health systems, consulting, and standards bodies, but all of us have a shared interest in the success of FHIR implementations for health care interoperability, data exchange, and the ability to effectively combine and exchange health care data while maintaining individual patient privacy and reducing the burden on those who collect and submit health care data.\n\nFHIR is a clinical data model based on RESTful web services to provide a standardized mechanism to manage clinical information, such as patient medical history, medications, allergies, procedures, observations, immunizations, problems, and care plans. Using the FHIR framework for HL7, we believe it can facilitate a large-scale exchange of health data and services, which will make it easier to track, provide data access, and enable health research and clinical work.",
        "label": 0
    },
    "963": {
        "output": "## Excluded Criteria\n- In the main script, you should implement code (a) to assess the exclusion criteria for each patient. In other words, by running the code, each patient should receive an exclusion score. Then, after summarizing the exclusion scores of all patients, the eligible patients should be separated using the threshold function, and the data for all patients with scores less than the threshold value should be excluded. According to the question, if the scores of the patient notes are greater than the threshold value, 0, they are eliminated.\n- [a] for each patient, the `Inclusion Eligibility` variable should be calculated and its corresponding variable with the score of zero is assigned as the `Exclusion Eligibility` variable.\n- [b] after the score for all patients is calculated, the final threshold must be calculated.\n- [c] the patients with scores lower than the threshold are excluded from the database.\n[a]\nfor(iter=1:length(V.ID)) {\n    % get the variable of the first number of the code \n    patient_score = as.integer(grep(strmatch(V.ID,INV.IDM)))\n    if(~is.nan(patient_score)) {\n        % calculate the included percentage as the number of included divided to the number of total\n        Excluded % percentage% = (patient_score+1)*100/sum(INV.IDM) \n        % assign the exclusion percentage\n        INV(cnames(iter),5).Exclusion_score = Excluded % percentage \n        % calculate the total exclusion percentages\n        Total_Exclusion_percentage = sum(Excluded % percentage*100)\n        % calculate the threshold\n        Threshold = round(Total_Exclusion_percentage/100) \n        % calculate the ineligible patients\n        INV(cnames(iter),1) = round(Excluded % percentage*(1-Threshold) 100)\n        % calculate the score of ineligible patients\n        INV(cnames(iter),2) = Threshold\n    }\n    else {\n        % calculate the percentage\n        patient_score = 0\n    }\n}\n\n[b]\nExcluded_",
        "label": 2
    },
    "964": {
        "output": "<EOD> .\nThe study was undertaken to clarify the roles of glutamate and aspartate (GA), potassium (K), and sodium (Na) in the development of hypokinesia. In the absence of extracellular K, the inhibitive effect of hypokinesia on the growth of chlorella mutans, Chlorella pyrenoidosa was inhibited, while its effects on the metabolite levels of intracellular GA and Na were reversed. The effect of GA on the growth of Chlorella was inhibited by the Na concentration in the environment; the effect of Na + on its growth was also found to be inhibited by the concentration of K + in the environment.<EOD> .\nThis report gives a review of the clinical efficacy of Naftidrofury (Ro 13-7567) in patients with advanced liver diseases with and without extrahepatic manifestation. The therapy (daily dosis of 400 mg) led to a clear to severe decrease of the mean bilirubin to the normal values in most of the patients of the treated group, the serum-levels of gammaGT, AP, SGPT, SGOT and the enzyme-deficiency in the serum were returned to normal values of a short therapy (10 to 34 days) of 7 patients with hepatic encephalopathy, a total clearance was achieved in 1--2 days. Treatment of 18 patients with active or symptomless oesophageal varices (386 sessions (34 days) during 10--480 days) leaded to a normalization of the portal pressure in this group of patients treated with Nafidrofury. The therapy of 63 patients with extrahepatic bleeding manifestation (212 sessions during 126 days) without liver dysfunction leaded to a normalizing influence on the hemorrhagic rate of the patients. Treatment of patients with severe liver diseases with encephalopathy, extrahepatic bleeding or active or symptomless portal hypertension shows an efficacy of the substance, which could be compared with the effect of the vasoactive substance of",
        "label": 0
    },
    "965": {
        "output": "<h1>\n4. Create dataframes to hold the results of the classification\n\nHere are the steps for getting the code to work:\n<h3>\nStep 1\n\nI will describe how to create a dataframe for classifying the data. First, create a new column for including information, e.g., column_1. Second, specify the classifier type as 'logistic_reg' for classification. <a href=\"https://scikit-learn.org/stable/modules/generated/sklearn.metrics.classification_report.html\">https://scikit-learn.org/stable/modules/generated/sklearn.metrics.classification_report.html</a>\n<h3>\nStep 2\n\nNext, create a new dataframe, i.e., column_2, to hold the results. `column_2_2` is an output dataframe for the classification, and `column_2_3` is an output dataframe for the confusion_matrix.\n<pre><code>\ndf_1['column_2_2'] = sklearn.metrics.classification_report(estimator=classifier, data=df_1, feature_names=['column_1'], target_names=['column_3'])\ndf_1['column_2_3'] = sklearn.metrics.confusion_matrix(estimator=classifier, data=df_1, feature_names=['column_1'], target_names=['column_3'])\n</code></pre>\n<h3>\nStep 3\n\nAdd a column to show the eligibility level, i.e., column_4. You need to find the column label that appears in <a href=\"http://scikit-learn.org/stable/modules/generated/sklearn.metrics.classification_report.html\">http://scikit-learn.org/stable/modules/generated/sklearn.metrics.classification_report.html</a> to indicate the eligibility level.\n<pre><code>\ndf_1['column_4'] = sklearn.metrics.classification_report(estimator=classifier, data=df_1, feature_names=['column_1'], target_names=['column_3'])\n</code></pre>",
        "label": 0
    },
    "966": {
        "output": "**3.2.6** ______________________________________________________________________________\n\n**What type of factors can also be used together with the features in the first data set?**\n\n- Add information about the study arm for each individual in the cohorts or trials (i.e., placebo or control) and the treatment stage for each patient (i.e., pre-and postintervention).\nFor this study, each patient has a unique patient ID, which was assigned automatically at the beginning of the experiment, and a study arm in each cohort. You can observe the values in the `patient_id` and `studyArm` variables in the patient note, which are not used in the previous data set. \n\n\n**Q1.** Are the study arm (placebo or control) and treatment stage (pre-and post-intervention) needed in your prediction task? If so, what is the most optimal prediction model for your task? How do you modify its settings?\n\nIn this cohort, four patients in the control arm, 3 in the treatment arm were diagnosed with HCC at 3.2, 11.0, and 24.5 years after starting treatment, respectively. In the treatment arm, all patients are alive after a median follow-up of 24 years, while all patients in the control arm had died of HCC at different periods after starting treatment (Q6). \n\nIn the second cohort, two patients were at the stage of pre-treatment (preintervention), two were at the stage of post-treatment (postintervention), and three had been diagnosed with HCC. In the third cohort, six patients are in the preintervention stage and four in the postintervention stage. In the fourth cohort, all are at the pre-intervention stage (Q7).\n\nPlease refer to the answer for Q3.4. \n\n\n**Q2. How would you modify the settings in the `patient_id` and `study_treatment` variables?\n\nQ3. For the second data set, you should predict the patient's study arm and treatment stage to answer Q1. How about the other factors in the second data set? As we mentioned earlier, add the study arm and treatment stage to the features. \n \nIn the first",
        "label": 1
    },
    "967": {
        "output": "<issue_comment>username_7: What is the expected output of the code when the patient qualifies for the trial?\n<issue_comment>username_8: Hi, @username_7. \n\nAs mentioned above, since the inclusion criteria of this trial is binary, the output of `Trial-level eligibility: ` should be a three-digit number. If the patient meets all inclusion and none of the exclusion criteria, then 0 (i.e. Excluded) should be the value printed by `Trial-level eligibility: `; otherwise, the trial-level eligibility will be printed as the second option of the comparison for the patient when the patient does meet all inclusion criteria, but one of the exclusion criteria is not met. For example, if the patient has history of cardio-vascular disease (CVD), you have to print the second option of the comparison (1) Not relevant rather rather than 0) Excluded. Then, the output of `Trial-level eligibility: ` will be `Trial-level eligibility: 1) Not relevant`.\n\nFor the example trial case shown above, you should print 0) Excluded, 1) Not relevant, and 2) Eligible from the trial-level eligibility.\n\nLet's go through step by step. \nHere is the trial note of a patient who has the inclusion criteria:\nA 46-year-old man presents with dizziness and frequent headaches.\n\nHere is the trial note of a patient who also has the exclusion criteria:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\n\nThe patient meets all of the inclusion criteria as well as none of the exclusion criteria. Since",
        "label": 0
    },
    "968": {
        "output": "Now, you should make a trial-level eligibility based on the second clinical trial:\nTitle: Effect of Vildagra \u00ae on Endothelial, Cardiac and Vascular Function\n\n[inst:\nInclusion Criteria:\nAge <40 years\n\nMild hypertension\nNo significant medical ailments.\n]\n\nExclusion Criteria:",
        "label": 1
    },
    "969": {
        "output": "\u25a1 Yes \u25a1 No 4. If you already have an output, output an additional line with ``1) Not relevant.`` in the beginning of the output file. Remember that if there was an output before, input the trial-level eligibility in the last line by 'Trial-level eligibility: 1) Not relevant.`.\n\u25a1 Yes \u25a1 No 5. Check the output file to see if you make any mistake. Let's repeat this trial now: `Question 2: You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). The patient note and the clinical trial are as described in Question 1: You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\nQuestion 9:\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that",
        "label": 1
    },
    "970": {
        "output": "### Evaluation \n\nPlease make a run in the `Evaluation` folder, and then, please run the Python program in the `evaluation.py` file as follows. \n``` python\npython evaluation.py `1000-inputs.txt` \n```\n### 1000-inputs.txt\n\nThe following is the file listing of the 1000 trials of the [1: 44; 2: 65; 3: 39; 4: 25] example. It is generated by `run evaluation.py < 1000-inputs.txt > 1000-outputs.txt`. \n```\n# Patient information #\n\nPatient age: 36\nPatient sex (female/male): female\nPatient height: 165.2 cm\nPatient weight: 57.6 kg\nPatient body mass index (BMI): 24\nPatient current use of lipid-lowering medications: `No (use of lipid-lowering medication has never been used)`\n\n# Patient BP #\n\nBlood pressures # Systolic\n\n# Patient's eligibility level #\n\nSystolic (mmHg) : 128\nDiastolic (mmHg) : 68\n\n\n\n# Risk factors #\n\nDyslipidemias, hypercholemic # : None\nCardiovascular disease # : None\nCigarette smoking # : None\nDiabetes mellitus # : None\nDiabetic, no evidence of diabetes # : None\nInsulin-dependent diabetes # : None\nInsulin non-dependent diabetes # : None\nHyperglyceridemia # : None\nHypertriglyceridemia # : None\nHyperuricemia # : None\nHyperuricemia # : None\nPrevious ischemic heart disease # : None\nPrevious stroke # : None\nCoronary artery disease # : None\n\n# Exclusion criteria #\n\nActive or history of drug-abuse # : None\nClinical study for",
        "label": 1
    },
    "971": {
        "output": "## The second patient note:\n- Patient: A 27-year-old man, physically active;\n- LDL-C on admission 548.62 mg/dL (1397.9 mmoL/L);\n- Patient presented no history of smoking, high blood pressure, dyslipidemia, diabetes mellitus, hypertension, or cardiac, hepatic, or kidney diseases and had no family history of cardiovascular disease.\n- Family history of CAD only for brother deceased at 33 y (1943:52) from \"coronary heart disease\" of unknown cause;\n- Physical examination: no abnormalities;\n- Lifestyle: non-smoker, moderate-intensity physical activity for recreation twice a week;\n- Results from other examinations: no pathological findings.\n\n## [inst] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\nThe factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 27-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and",
        "label": 2
    },
    "972": {
        "output": "## Good luck! And don't panic.\nTrial-level eligibility: 2), Excluded\nTrial-level eligibility: 1) Not relevant\n\n##[XSLIDES]/\nTrial-level eligibility: 0) Excluded; 2), Excluded\nTrial-level eligibility: 1), Not relevant; 0) Excluded; 2), Eligible; (2)\nTrial-level eligibility: 2) Eligible; (1) Not relevant; (0) Excluded; (2)\nTrial-level eligibility: 2), Excluded; 0) Excluded; 1) Not relevant; 2) Eligible\n\n## Input:\nTrial-level eligibility 1), Eligible; (2)\nTrial-level eligibility 2), Excluded; (0) Excluded; (1) Not relevant; (2) Eligible\nTrial-level eligibility 4) Not relevant; (3) Not relevant; 3), Not relevant; (4) Not relevant; (1) Not relevant; (2)\nTrial-level eligibility: 4) Not relevant; 3), Not relevant; 4) Not relevant; 1), Not relevant; 2) Excluded; 1), Not relevant; 2) Excluded\nTrial-level eligibility: 3) Not relevant; 1), Not relevant; 2), Not relevant; 3), Not relevant<EOD> Efficacy and Safety Profile by Intra-articular Injections of Platelet-Rich Products versus Hyaluronic Acid for Knee Osteoarthritis: A Meta-analysis.\nKnee osteoarthritis (OA) is the leading cause of severe long-term pain, and there is no cure for it. Different injections such as hyaluronic acid (HA) and platelet-rich product (PRP) have been widely used among patients with knee OA. We systematically reviewed 9 trials (1758 patients), assessing the efficacy and safety profile of PRP or HA in patients with knee OA, randomized into one of two categories: PRP therapy or H",
        "label": 1
    },
    "973": {
        "output": "Your task is to find the number of patients who meet the inclusion criteria, i.e. patients whose note has been judged to be eligible at the trial level by the physician who should be identified if the note is judged to be eligible for the trial. You should output the assessment for all relevant patients in the patient note, using the code for the patient whose assessment results are printed at the end of the note. 33 Note: A three-way assessment is only used to compare a patient's notes with notes of patients in clinical trials, not an actual clinical trials assessment result.34 \n \n[INSTR] Note that we provide the raw data of the 308 patient notes; only five of those are fully included. These five patients are part of the training cohort so if you want to practice you can look through all the cases without needing to go to the hospital. (For more details, please refer to the code in the file of practice problems.) \n \n[HINTS] For training, we provide data from 2637 patient notes; the remaining 230 notes are part of the test cohort. We recommend that you first train with the 2637 notes; once you are done training, then try to use your trained model to predict new notes (either the training set or test set). We encourage you to report your testing results in a GitHub (https://github.com/) repository. \n \n \n[INST] Hi. You can find the details of our requirements and the scoring criteria in the [INST] section and in our [HINTS] link. Below are some tips that the organizers hope will help in solving the challenges. \n \nWe recommend that you first read and attempt the [PRAC] first. If you are still unsure whether you have covered all that might be relevant then use [INF1]. If you are not sure about any of the [PRAC] first three tasks, then you could take advantage of [INF2], as it is a short question, and then also [INF1] is a full challenge. If after using [INF2] you are still unsure then move on to one of the [PRAC] tasks. You can also go to Task #1 to get a taste of the difficulty of Task #4.",
        "label": 2
    },
    "974": {
        "output": "We shall consider it as an input value for the next step.\n\nA patient cannot be evaluated as ``excluded`` in any step if the trial is not closed. To this end, we provide the following information in the configuration ``Trial configuration`` of the patient:\n`Trial configuration: Closed`\nYou should check the ``Configuration.TrialConfiguration`` of patients and then change the configuration to `TrialConfiguration Closed` as necessary.\n\n\nA: Here\u2019s how I\u2019d approach it:\nYou can get the number of patients that meet the criteria from the `Transection.Count` property of the `Transition.TransitionDetails` `DataReader` that comes along with the records.\nTo get the number of patients, where any part of the patient Note has a particular value, you can do this:\nTransition.TransitionDetails.Where(td => td.Patient.Age.ToInteger() < 65 && td.Patient.Gender == \"Male\").Count()\n\nA: As per my understanding.  \nYour first two lines will work if the eligibility flag will always be 0.\nYou need to rethink the Trial configuration. The only way to have trial configuration closed is when trial is already closed on the record table. In which case the recorder can no longer update any other field on the trial. For this to work, the closure criteria should be in a different table and updated when records are closed.\n<EOD> .\nIn 1997 the Swiss medical community was shocked by the publication of a death report on a previously healthy young male, who died at rest from a primary heart failure during a soccer game. Due to the suddenness of his death, the possibility of exercise-induced cardiac arrest was considered, even though at the time his electrocardiogram was normal. A further inquiry showed that the patient had, in fact, symptomatic aortic valve disease. Because, until the diagnosis of aortic stenosis was made, the man had never felt unwell at any time, he was regarded as being in the so-called \"low risk group\". To our knowledge, this is the first reported fatal case of aortic stenosis in Switzerland. This case report draws attention to aortic stenosis, a disease that is insidiously progressive.",
        "label": 0
    },
    "975": {
        "output": "<EOD> Divergent Evolution of Glutathione Transferases from Dracaena Cinnabari\n\nGlutathione transferase (GST; EC 2.5.1.18) is the enzyme that is primarily responsible for the cellular detoxification of endogenous compounds to their less toxic forms or for excretion from a cell. This enzyme is also involved in other critical functions such as redox balance control, signaling, and plant growth and development. In this context, we investigated the GST pool associated with the resin of the Dracaena cinnabari plants, the resin being known for its unique curative properties in both human and animal infections. We identified eight GST proteins by searching for the GST protein signature (SSGXPXXG) in our de novo transcriptome of Dracaena cinnabari, which was assembled from high-throughput RNA sequencing data. These candidate proteins were further verified by reverse transcription polymerase chain reaction (RT-PCR). Four out of the eight GST proteins (DcGST1, DcGST2, DcGST3, and DcGST4) were phylogenetically classified into the tau-class, two into the theta-class, one into the zeta-class, and one into the omega-class, with no DcGST protein included in the mu-class, which is the most widespread class of GST enzymes. In addition, gene models of GST proteins were constructed from full-length transcripts. The deduced GST proteins contained the GST signature with a conserved N-terminus. We estimated the evolutionary rates of the GST protein in Dracaena cinnabari by comparing the maximum likelihood estimation to the molecular clock rate, as derived from the calibrated branch time. The evolutionary rates of DcGST proteins were found to be different, indicating that functional divergence among multiple GST proteins is due to adaptation to functionally diverging environments. This observation was confirmed by calculating the Ka/Ks ratios of all the DcGST protein variants as compared with the reference Arabidopsis thaliana GST protein. This study provides new knowledge on plant",
        "label": 2
    },
    "976": {
        "output": "You can check the patient's notes at the patient level below:\n\nNote:\n- You can check all the patient's information by hovering your mouse over the button, such as `Patients`, `All visits` and `Medical history`.\n- You can choose your target patient by clicking on a patient's name in the table.\n- You can get more information by clicking on the button, such as `View more...` for patients' demographic information, `Visits and History` for more history, `Visit` for more details, `Lab` for lab records, and `Clinical notes` for clinical notes.\nTo get started:\nTo get started:\n\n    #!/bin/bash\n    # Required environment variables.\n    USERNAME=username\n    APP_KEY=$USERNAME\n    APP_SECRET=password\n    PWD=$PWD\n    # Run the script by providing any path of patient note, visit note and patient history note\n    #  $ python3.7 assessment_of_eligibility_by_note.py path/to/note_of_patient/  # path is the file path\n    path='path/to/note_of_patient/'\n    note=$path+'patient-info-note-template'\n    visit=$path+'visits-note-template'\n    history=$path+'patient_history_note_template.json'\n    run_python3_command_in_current_session $path note $APP_KEY $APP_SECRET 'patient-level-exclude-0' #patient-level-exclude-0 is the patient ID in patient note.\n    run_python3_command_in_current_session $path visit $APP_KEY $APP_SECRET 'visit-level-exclude-0' patient_id is the patient ID in visit note.\n    run_python3_command_in_current_session $path history $APP_KEY $APP_SECRET 'patient_history_level-patient-exclude-3 patient_id is the patient ID in patient history note.\n    python3 assessments_of_eligibility_by_note\n```\n\n## Task description\n\nThe clinical trial is called `Intr",
        "label": 0
    },
    "977": {
        "output": "You can replace the regular expression with the following: grep ^[0-9]* \\([^0-9] \\-*\\.*)\\([^]*\\)\n\nWhat other things can go wrong? There isn't much space for new info, a couple of new rows could break things up and cause problems.\n\nA: You can try this out - its a super simple way to handle nested for loops.\nlet tt=$F4\"^(?:^([^0-9]*\\d)+)[^0-9]*\\$\";\n\necho `echo $F1 | tt;`\n\necho `echo $F1 | tt | paste`\n\n\nA: *This answer is only valid for the code in the comment, if it's slightly altered the following will be invalid.\nSo you probably want to use a string:\n$DATA#=^[0-9]*\\d+\"\n\nThe $DATA variable will then be set to this string and you can use it like this:\n$DATA#=^",
        "label": 2
    },
    "978": {
        "output": "---\n\n# Exercise 5 - Clinical Trial - PICO Question\nPlease formulate the research question as \"PICO\" type format: Patients, Intervention, Comparisons, Outcomes. Here is how it looks:\n- Patients\n- Intervention\n- Comparison\n- Outcome\nThe objective is to compare the effects of an exercise program that includes high-intensity resistance training with that of a traditional strength training program on muscular strength in patients with breast cancer undergoing chemotherapy compared to the performance of the exercise after chemotherapy.\n\n\n## 1) Patients \n\nChemo-treated breast cancer patients\n\n2) Intervention \n\nExercise program\n\n3) Comparison \n\nExperimental Group:\ntraditional strength training program\n\nControl Group:\nResistance training\n\n4) Outcome \n\nMuscular strength\n\nExamples:\n- Muscle Mass as an Outcome\n- Muscle Atrophy as an Outcome\n- Muscle Strengthening as an Intervention\n- Surgery as a Comparison\nIn this case, it should be as follows:\n- Muscle Strength as an Outcome\n- Muscle Atrophy as an Outcome\n- Muscle Strengthening as an Intervention\n- Surgery as a Comparison\n\n---\n\n# Exercise 6 - Clinical Trial - STROBE Report\nPlease prepare your exercise, in this case you have at least 20 min to prepare it. After this time, please upload here your STROBE report.\n\n**Please answer these 5 questions on the STROBE checklist**:\nQ1: \n\nThe sample size of the study was 60\u00a0subjects with an age range of 42-65 years old. It is clearly mentioned that the power analysis was performed to establish the number of subjects required for the study. However, it fails to give enough information on the basis on which the 60\u00a0subjects were chosen.\n\nQ2: \n\nThe inclusion criteria were patients with the age range of 42-65 years old, the disease duration was over 5\u00a0years for the control group, and the disease duration was under 5\u00a0years for the experimental group. It fails to give enough information",
        "label": 0
    },
    "979": {
        "output": "##[/STOP] Clinical Trial Note\n\n##[START] Eligibility Report\nThe task of determining a patient's eligibility for clinical trials is called eligibility assessment or, more simply, eligibility screening. Once a clinical trial has been registered at the trial-level, a medical practitioners can access Trial-level eligibility information on the trial page and begin the eligibility report by clicking the button `Eligibility` in the toolbar. \n\nThe eligibility report has three sub-sections. The top section displays the trial's clinical characteristics that are important to the assessment of eligibility. For the given trial, the trial-level eligibility was found to be `not relevant` because the patient does not have sufficient information to qualify for it. The information about the disease and the exclusion and inclusion criteria is in the middle section. Detailed patient note and Trial-level eligibility information are provided in the bottom section. \n\n##[END] Eligibility Report\n\n##[START] Eligibility Determination\nWith patient and clinical trial information, you can compare it with the eligibility information of the trial. \n\n\n[ /START] Patient's Eligibility Report \n\n### [START] Eligibility Report  --  Eligible Patient Note\n\n[ /START] Patient's Eligibility Report \n\n\n### [START] Patient's EligibilityReport --  Ineligible Patient Note\n\n[ /START] Patient's Eligibility Report \n\n[ /START] Patient's Eligibility Report \n\n### [START] Patient's Eligibility Report\n--  Not Relevant Patient Note\n\n\n\n<EOD> Effects of 24-Hour Dietary and Exercise Control Versus 24-Hour Dietary Control on Insulin Signaling and Blood Glucose Control in Adults\n\n [bib_ref]  Physiological effects of long-term sleep deprivation in rats, Gaudilli\u00e8re [/bib_ref]  \n\n## Methode\nEs wurden zw\u00f6lf gesunde probandenten nach einer 3-st\u00fcndigen Vigilanz durch die Folgemittelung unters",
        "label": 1
    },
    "980": {
        "output": "## Exercise\n1.\nReproduce the steps 2.-6. of the problem in Section \\Instalation using Python 3. Export the results of your work again in a file to be saved with name: Exercise_Clinical_Trial_Eligibility` in a folder that you created just for the exercise. Make sure the file name is unique.\n\n## 2.\nLook at the file \\Exercise_16_Challenge.json, which contains the data for the exercise.\n\n## 3.\nOpen your newly created file using Python and verify that the data is correctly printed.\n\n## 4.\nAsk the instructor for feedback on how the solution you have uploaded to the platform is compared to the instructor's solution.\n\n## 5.\nFind the answers for all the steps given in the exercise manually.\n\n## 6.\nAnswer the following questions. \na. In which steps did you make errors?\n\n## Evaluation\n\n##\\Instalation\n\n\\Section Objectives\n### This section contains the assessment of the exercise.\n### The questions include:\n\\todo \n- What changes were made by fixing the errors?\n\n##[INST] Examining the changes to the code and the file of the exercise.\n\\todo \n- What is the outcome of the exercise?\n\n## Assessing the outcomes \n\n\n\n\\Section Results\nIn the assessment of the solution, you were scored by the following points. \n\\todo\n\n## Score\n\n## [INST] Answering 1, 2 and 3 below.\nYour solution is good; please edit slightly as there is little difference in the overall outcome of the exercise, but a higher score can be obtained. You scored a total of 4 out of 5\\todo The result of the evaluation can be expressed in points. The results should be expressed so that the grades are within the range of 2.5 to 4, taking into consideration the number of the sub-assignment.\n\n## Summary and Conclusion \nThis document is part of the \\Clinical Decision Support\\ module, which aims at teaching students the fundamentals of clinical decision support and clinical trial eligibility assessment",
        "label": 0
    },
    "981": {
        "output": "## Good luck.[EN-T]\n27. [QUESTION] There are two methods for detecting abnormal conditions: 1) direct assessment and 2) inference from available information. While most physicians use inference because it is both faster and more convenient, direct assessment is sometimes necessary because data are not available to make inferences. When conducting inference, one must formulate a decision framework that determines the probability that a conclusion is either true or false. This framework may be based on the Bayesian decision theory, the frequentist decision theory, or some hybrid of both. For example, many clinical decision-support studies focus on the frequentist decision theory, sometimes referred to as the \"one-step\" approach. \n\n28. [QUESTION] The risk a doctor gives to a patient is a probability value. The clinician should not merely inform a patient about the risk but also give an approximation of probability. Physicians can express the probability of the occurrence of some event, such as death or recovery, based on the following probabilities:\n\n## a) the probability of the event occurring, b) the probability of it not occurring, c) the probability of the diagnosis being correct or incorrect, and d) the probability of the treatment being beneficial or harmful. \n\n29. [QUESTION] Now consider a study of the accuracy of a new test, where the outcome is  disease. Suppose the new test is being studied to complement an existing test whose probability of disease is 8% when an individual is diagnosed as disease. The test-is-positive, test-is-abnormal, and test-is-diagnostic, p-values were .03, .20, and . and a new test is introduced.\n\n## 16\n\n32. [QUESTION] A diagnostic test accuracy study was planned to enrol a total of 100 participants: 50 participants with and 50 participants without .\n\n\nFor this study, the accuracy of the index tests was assessed against the reference standard, and the study has shown that the specificity of the index and 85% and the sensitivity of the index test and 75%. The data was then re-analysed using the sample size calculation formula of to obtain the optimal sample size of 100 for the above-specificity and -sens",
        "label": 0
    },
    "982": {
        "output": "<div className=\"source\">\"\n  <textarea aria-label=\"CodeSnippet 2\" className=\"code-cell\" name=\"code\" id=\"inputCodeTextarea-0\">\n    <!doctype html>\n    <html class=\"no-js\" lang=\"\">\n      <head>\n        <meta name=\"generator\" value=\"pragmatics/react-app-example\">\n        <meta property=\"og:title\" content=\"Example App - Skeleton\">\n        <meta property=\"og:description\" content=\"It's just the shell, folks - use it for development.\">\n        <meta property=\"og:site_name\" content=\"pragmatics\">\n        <meta property=\"og:url\" content=\"http://pragmatics.github.io/react-app-example\">\n        <meta  property=\"og:type\" content=\"website\">\n        <meta property=\"og:video\" content=\"\">\n        <meta property=\"og:image\" content=\"\">\n        <meta property=\"og:image:alt\" content=\"\">\n        <meta property=\"og:translator\" content=\"\">\n        <meta property=\"og:creator\" content=\"\">\n        <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n        <script src=\"https://cdnjs.cloudflare.com/ajax/libs/jquery/2.1.1/jquery.min.js\"></script>\n\n        <title>Example App - Skeleton</title>\n        <link href=\"Sass/Skeleton.css\" rel=\"stylesheet\" type=\"text/css\" />\n        <script src=\"Requirements.js\"></script>\n        <script src=\"main.js\"></script>\n      </head>\n      <body>\n\n        <div id=\"app\">\n          <header>\n            <input type=\"checkbox\" id=\"check1\" />\n            <input type=\"checkbox\" id=\"check2\" />\n            <h2>Page head</h2>\n          </header>\n\n          <nav>\n            <ul>\n              <li><a href=\"#\"><span>1st button</span></a></li>\n              <li><span>4</span>\n              <ul",
        "label": 0
    },
    "983": {
        "output": "# <a id=\"Eligibility\"></a> [Eligibility:\nPatient data set][57]\nPatient data\n\n1) Patient_data: `patient_data`. A data frame of patients participating in the trial.\nEach row represents 1 patient. For each patient, there will be at least 1 unique ID, and the value of `age` and `gender`.\nAlso there will be 1 `patient_note` for each patient (it is not compulsory to record a `patient_note` for each patient). Each row represents the patient note for 1 patient, in which you should  write as much clinical data as possible, even if not indicated in the figure below. Clinical data not indicated in the table below is allowed.\n\n## ID (unique identifier)\n- `age`: age at diagnosis\n- `gender`: `M` for male, `F` for female, `N/A` stands for `not available`,\n- `patient_note:`  a link to a clinical note, `NA` stands for `note not provided`.\n\n2) `clinical_trial`\n- `id`: clinical trial identifier\n- `title`: clinical trial title\n- `organization`\n- `country`: Country where the clinical trial is based.\n\n## ID (unique identifier)\n- `id`: identifier for the clinical trial\n- `title`: the title of the clinical trial\n\n\n###  (Example data for 1 trial.  Note, this is to be adapted)\n```\n---\nEligibility: 2)\n- patient_note:    \n  - clinicaltrial patient 2 66 ------ male normal 10\n...\n```\n\nThe first patient:\n```\n---\nAge:        2   (i.e. year)\nGender:     male\npatient_note: ...\n```\n## What will happen when we run this code?  \nBroadly speaking, a `caret` function will be called to calculate the scales (e.g., 0: Excluded, 1: Not relevant, 2: Eligible). For each patient, clinical trial will predict the score (scale) by a specific model.\n\n# <a id=\"",
        "label": 1
    },
    "984": {
        "output": "## Expected outcomes\nHere is an example of a snippet of a data frame corresponding to Patient Note. To read information of this data frame, see `describe` function. \n\n    Patient Note\n    A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active.\n    The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\n    The patient reported no use of lipid-lowering medications.\n    Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n[Source: 1]\n\nThis is an example of a snippet of a data frame corresponding to Clinical Trial (as of September 13, 2020):",
        "label": 0
    },
    "985": {
        "output": "In [INST], please always replace with a value (e.g., LDL-C or ECG result) or with `0.02` if you want to provide an error message, e.g., `Trial-level Eligibility: 0.02)`.\n\n\n\n\n--\n\n---Your submission has been rated:\n\n| Q1 | 1  | \n| Q2 | 0  | \n| Q3 | 1  | \n| Q4 | 2  | \n| Q5 | 1  | \n---\n\n\n| Q1 | 1\n| Q2 | 1\n| Q3 | 2\n| Q4 | 3\n| Q5 | 3\n|\n\n### 3: Reviewing patients' clinical notes\n\nIn this mini-assignment, you will analyze the following patient clinical notes and determine their eligibility for a clinical trial.\n\nHere is the patient's clinical note information:\nGender: Female\nAge: 35;\nLDL-C: 130;\nGFR:100;\nALT: 15;\nCrCl: 90;\nGGT: 5\nHbA1c(%): 4.5;\nFBS(mg/dl): 100;\nBMI: 29.\n\nNow, using the same patient's clinical notes and the clinical trial information that you learned in the first mini-assignment, you will make trial-level eligibility for the clinical trial.\n\n- 1) Enter the patient's clinical notes as described in the previous question into the text area, in the textbox titled `Clinical_note_for_Evaluation`.[INST]\nThe clinical trial information is already included in the textbox `Trial_Evaluation`.\n\n- 2) Enter `Trial-level Eligibility: Evaluated (Trial-level Eligibility) 3) Trial-Level Eligibility: The patient should have baseline LDL-C above 125 mg/dl. (Trial-level Eligibility) 4) Trial-Level Eligibility: The patient should present with d",
        "label": 0
    },
    "986": {
        "output": "## \u60a8\u662f\u4e00\u540d\u533b\u52a1\u52a9\u624b\uff0c\u4f60\u9700\u8981\u6bd4\u8f83\u4e00\u60a3\u8005\u8bca\u7597\u767b\u8bb0\u548c\u4e34\u5e8a\u8bd5\u9a8c\u7684\u5224\u65ad\u8d44\u6599\uff0c\u5224\u65ad\u662f\u5426\u5408\u9002\u7684\u3002\u4f9d\u636e\u60a3\u8005\u75be\u75c5\u7c7b\u578b\u548c\u9636\u6bb5\u548c\u5176\u4ed6\u6cbb\u7597\u8fc7\u7a0b\uff0c\u4ee5\u6b64\u5efa\u7acb\u4e34\u5e8a\u8bd5\u9a8c\u7684\u57fa\u4e8e\u53c2\u52a0\u6807\u51c6\uff3bINST]\n\n\u4e00\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u7b56\u7565\u7684\u65e8\u662f\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u9884\u540e\uff3bINST]\u3002\n\n\u4f30\u8ba1\u83b7\u5f97\u6700\u7ec8\u83b7\u76ca\u7684\u60a3\u8005\u6570\u91cf\u3002\u60a3\u8005\u4ece\u4e00\u4f4d\u4e34\u5e8a\u5b9e\u9a8c\u533b\u751f\u3001 \u591a\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u52a9\u624b\u4ee5\u53ca\u591a\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u8fd0\u4f5c\u4eba\u5458\u7684\u53c2\u4e0e\u521b\u9020\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u3002\u51b3\u5b9a\u7684\u53c2\u4e0e\u53c2\u6570\u7684\u6570\u91cf\u548c\u53c2\u4e0e\u8d38\u6613\u6570\u91cf\u51b3\u5b9a\u4e86\u4e34\u5e8a\u8bd5\u9a8c\u662f\u5426\u6210\u529f\u3002\u8be5\u51b3\u5b9a\u7684\u4f5c\u7528\u5728\u5728\u83b7\u53d6\u548c\u6536\u96c6\u4e34\u5e8a\u6307\u6807\u6570\u91cf\u4ee5\u53ca\u5904\u7406\u4e34\u5e8a\u95ee\u9898\u6570\u91cf\u4e0a\u3002\n\n\n\u4f60\u662f\u4e00\u4f4d\u533b\u52a1\u52a9\u624b\u7684\u5de5\u4f5c\u662f\u6bd4\u8f83\u60a3\u8005\u7684\u75c5\u60c5\u548c\u4e34\u5e8a\u8bd5\u9a8c\u8981\u6c42\uff0c\u5224\u65ad\u662f\u5426\u7b26\u5408\u3002\u4f60\u4f7f\u7528\u7684\u662f\u591a\u79cd\u4e0d\u540c\u7684\u6570\u636e\u4f9d\u636e\u8fd9\u79cd\u5e72\u9810\uff0c\u5305\u62ec\u75c5\u60c5\u7684\u57fa\u7840\u60c5\u51b5\uff0c\u5305\u62ec\u75c5\u4eba\u7684\u8eab\u4f53\u7279\u5f81\uff0c\u4eba\u4f53\u7684\u5065\u5eb7\u72b6\u51b5\uff0c\u548c\u7624\u5f62\u6001\u7684\u60c5\u51b5\u3002\n\n\n\u8fd9\u4e2a\u60a3\u8005\u7684\u6587\u732e\uff1a\n\n46 \u5c81\u7684\u7537\u6027\u4ee5",
        "label": 1
    },
    "987": {
        "output": "[EXERCISE]\n\n[INSERT]\n\n### **Case-level eligibility**\n[INSERT]\n\n### **Patient-level eligibility**\n[INSERT]\n\n#### **11.2.1.** Exclusion criteria\n[EXERCISE]\n\n[INSERT]\n\n### **Clinical Notes**\n[EXERCISE]\n\nThe following list refers to the clinical notes in the patient history. To read more about it, see the following link: https://bookdown.rdkit.org/master/sophtraderio/chapter_2/index.html#clinical-notes).\n\n\n[INSERT]\n\n#### **11.3.** Patients' Information\n[EXERCISE]\n\nThe following list refers to the patients' information in the patient history. To read more about it, see the following link: https://bookdown.rdkit.org/master/sophtraderio/chapter_2/index.html#patients-information).\n\n\n[INSERT]\n\n### **Surgical procedure**\n[EXERCISE]\n\nThe following list refers to the surgical procedure conducted on a patient. To read more about it, see the following link: https://bookdown.rdkit.org/master/sophtraderio/chapter_3/index.html).\n\n\n[INSERT]\n\n#### **11.4.** Investigator's Assessment\n[EXERCISE]\nTo determine how many patients have a target event (exposure of interest, adverse events, or both) that occurred during a given time period, use i3 for the Patients screened, i2 for the Patients included, i3 for the Patients randomised, i2 for the Patients randomised, i3 for the Patients analyzed, and/or i1 for the patients.\n\n\n[INSERT]\n\n\n# **11.5.** Saving 3. Data\n\nTo save to Excel sheet or S3 file, please use i4,\ni5 is to save to an interactive report (HTML format),\ni6 is to save PDF (either on patient level or by patient),\nand i7 is to save a CSV",
        "label": 0
    },
    "988": {
        "output": "### Examples.\n    The following table shows some examples for clinical trial notes:\n     | Note\n     | 0) Excluded\n     | 1) Not relevant\n     | 2) Eligible\n    -  Note:\n        1) Note:\n          0) Excluded\n           0) Excluded\n<EOD> Fatigue in patients with chronic kidney disease on dialysis\n\n\n\n# Introduction\nC hronic kidney disease (CKD) is a multifactorial disease characterized with progressive decreases in kidney function with significant impact in both patients and society. [bib_ref]  Clinical manifestation of nephrological interest. Part I. Chronic kidney disease (chronic kidney..., Moczulska [/bib_ref]  The major cause of mortality among CKD patients is cardiovascular complication, which is due to atherosclerotic, vascular disease. [bib_ref]  Cardiovascular disease in chronic kidney disease. A clinical Update from Kidney Early..., Wang [/bib_ref]  Fatigue is an averse and distressful sensation that a person has subjectively. [bib_ref]  Fatigue assessment in CKD: Beyond the clinical settings, Nixon [/bib_ref]  There is a multifactorial etiology of fatigue in CKD. Some factors affect the fatigue level including physical problems, uremia, anemia, hyperhomocysteinemia, the disturbed sleep and poor quality diet. [bib_ref]  An integrative review of fatigue impacting patients with chronic kidney disease undergoing..., Bressington [/bib_ref]  It is estimated that 20-60% of chronic dialysis and CKD patients complaint from fatigue.According to a nationwide study, in 2012, prevalence of fatigue among patients on chronic dialysis was reported as 29%, which was also found in patients with stage 5 CKD (18%). [bib_ref]  Fatigue in patients with stage 5 chronic kidney disease: Results from a..., Cohen [/bib_ref]  The presence of fatigue among CKD patients has multiple negative effects including decreases in quality of life. Some studies reported an association between a low quality diet, increased serum homocysteine",
        "label": 0
    },
    "989": {
        "output": "[bib_ref]  Learning to predict clinical trial eligibility in pediatric oncology using electronic health..., Zhang [/bib_ref]  \n 7.1.5. [INST] As with the previous three parts, you should use `LimeSurvey` as the survey tool. The variables are the same, except that you should include `Trial-level eligibility` in the fifth field. If you want to run this survey in your own server, you should add only the fifth field, so that LimeSurvey can process the form. Please contact us if you want to run this survey in your own server. You can copy the survey files in the subfolder `Surveys` in the dataset `surveys` by using the `data/surveys` directory or `sub` command in Tmux on Unix-like systems. The file names are `C001 (Biomarker).php`, `C002 (Drugs).php`, `C003 (Patient visit).php`, `C004 (Trial eligibility).php`, and `C005 (Clinical notes).php`. [INST]\n\nYou can now use the survey files in your hospital information system to collect patients' data.\n\n7.2. Surveys for Questionable-Reports: [INST] As with the surveys for eligibility, the variables are basically the same as described in the section 7.1.4, except that you should use the file `R001 (Questionable report).ipa` for `R001 (Questionable report)` and the file `R001 (Repeatable report).ipa` for `R002 (Repeatable report).` Instead of LimeSurvey, you should use `NHIS API REST`, as NHIS recommends. [INST]\n\nYou can now use the survey files in your hospital information system to collect patients' data.\n\n# Conclusion\nThis dataset is the largest dataset for the collection of information from hospital information systems. The dataset contains various clinical data, which helps investigators conduct clinical studies easily. Furthermore, this dataset may help researchers discover useful associations among clinical tests, findings, findings and drugs that may trigger adverse drug reactions in the future, and understand the relationship between clinical tests,",
        "label": 0
    },
    "990": {
        "output": "[[TRIAL_LEVEL_ELIGIBILITY]]<EOD> Hydrological regimes in the Tapaj\u00f3s Basin, Brazil, impacting on the structure of the lizard assemblage.\nHydrological seasonality has been related to differentiation in the communities of terrestrial organisms. The present study aims at evaluating the influence of the hydrological regimes (defined by floods, low amplitude annual flow fluctuations and dry periods), with the structure of an assemblage of lizards in the floodplain of the upper Tapaj\u00f3s River (MT). Three transects crossing the floodplain and parallel to the river were sampled monthly during the wet season and bimonthly in the dry season from January 1997 to February 1998. The structure of the lizard assemblages was estimated using a multivariate analysis of distributional patterns. In the wet and dry seasons, there were 76 and 64 lizard species, respectively. Species richness was high in all seasons and the assemblages were dominated by anurans, snakes and amphisbaenians (most of them diurnally active or nocturnally active). During the wet season, the species of the dry season were replaced by seasonal species. Seasonality was related with the assemblage structure of lizards in the floodplain of the upper Tapaj\u00f3s River.<EOD> .\nThe aim of this retrospective analysis is to evaluate the role of neuropsychiatric features and personality traits in the pathogenesis of recurrent depressive disorder. We studied 42 patients (Female 36, age 40.29 +/- 10.27, mean age at depressive episode onset 35.6 +/- 10.17, average age at beginning of study 45.55 +/- 10.38) and analyzed their personal histories using a structured telephone interview. 17 patients, had a bipolar, mixed disorder, 14 had personality disorder, and 7 patients had depression on remission. We found a significant association between neuropsychiatric features and the onset of depression with high frequency of panic attacks (p = 0.0",
        "label": 0
    },
    "991": {
        "output": "![TEST_2.png][TEST_2]\n\n# [Test 2.2](http://data.jmc.edu/view/1g504iQ2cVY) \n## [TEST 2.2](http://data.jmc.edu/view/1g504iQ2cVY)\n[TEST 2.2]\n\nLet's think step by step. \n\n1. [Prepare](https://data.jmc.edu/view/57yH79DwFdM)\n    1. Add a new notebook: `new_test`.\n    2. [Rerun Test 1.1](https://data.jmc.edu/view/wMjVg1k3Xu3) to complete the patient's data.\n       1. Create the new patient data.\n       2. Update the new data every 6 months.\n       3. Make sure that the patient's data file is updated before you rerun the notebook, otherwise you will get incorrect output results.\n        \n       4. You should be using `rclone` to synch your files in Google Drive with your own computer so that you do not have to be online all the time in Databrary. We will demonstrate how to install it when you run the notebook and you can download the instructions [here](https://data.jmc.edu/view/wUr0zTj1N0i) for future reference.\n\n    3. Add the following variables to the notebook you've created in the previous step so that you can retrieve the patient's data later:\n       1. `jason_path` stores the Google Drive path to the patient's data.\n       2. `jason_user` stores the username for the Google Drive.\n       3. `jason_password` holds the password to the same Google Drive.\n        \n    4. [Rerun](https://data.jmc.edu/view/6uLj5bWCp9R) this notebook by copying the Python code in the notebook and paste it into a new notebook to execute it.\n       1. The input data will be the [TEST1.xlsx](https://data.jmc",
        "label": 0
    },
    "992": {
        "output": "Your duty is to provide the correct answer from the given questions. The correct answer to this question is \"Diabetes Mellitus and Hyperlipidemia\". Diabetes and hyperlipidemia are the causes of micro and macro-angiopathy, which disrupt the blood supply. These disru",
        "label": 1
    },
    "993": {
        "output": "Your task is to assign the trial and patient-level eligibility to the patient note.\n\n## The inclusion criteria to be met at the trial level.\nAt least one of the following:\nAge \u2265 18 years\nInformed written consent\nAt least one major or two minor bleeding risk criteria of Academic Research Consortium (ARC)\nMajor criteria:\nLong-term oral anticoagulation\nSevere or end stage chronic kidney disease (CKD) (estimated glomerular - filtration rate [eGFR] <30 ml/min)\nHemoglobin <110 g/l\nSpont",
        "label": 0
    },
    "994": {
        "output": "[EXERCIS]\nTo summarize these three steps:\n1. Find all factors that will apply the Patient: all columns of the data set except \"age\" and \"risk\".\n2. Calculate the sum of rows that each age corresponds to (the number of the risk) and assign the numbers to the columns of the data set as columns_num.\n3. Compare age_num/risk_num with the patient's data set, and make decisions of the patient.\n\n```\ndef assessment(patient):\n    inclusion_data = {}\n    print(f'[INFO] Eligibility of Inclusion Criteria: {len(patient.risk)/len(patient.age)}')\n    #find factors from patient\n    for line in patient.risk:\n        inclusion_data[line.value_index] = patient[line.value_index]\n    #find factors from data.ini\n    for i in range(len(data.ini)):\n        if i not in data.ini.columns_num:\n            data.ini[data.ini.columns_num[i]].value_index = data.ini.rows[i].index\n    #update data\n    data.ini = data.ini\n    for item in inclusion_data:    \n        if include_criterion_num(item, patient):\n            patient['age']\n            pass\n    return ''\n\ndef included_num():\n    print(f'[INFO] This patient has the inclusion criteria: {data['age'] = included_criteria.value_index  == data[\"age\"].iloc[0]}')\n    #print(\"age:\", data.ini.columns_num.value_index)\n    included_criteria = (Patient[\"Age\"] == data.ini.columns_num.value_index)\n    return included_criteria\n```<EOD> The pharmacokinetics of diphenylhydantoin in the rat: determining the mechanism of prolonged anticonvulsant activity.\nThe pharmacokinetics of diphenylhydantoin (DPH) and its metabolites, diphenylhydantoin-13C-O-sulfate (DPHS), and diphenylhydantoin-",
        "label": 0
    },
    "995": {
        "output": "## Suggested approach\n\nDefining triallevel eligibility is complex.  There are many factors, e.g., age, race, sex, toxicity, prior or concomitant immunosupressive therapy, and many are trial dependent, e.g., if a trial has prior exposure to anti-CD20 or steroids in the eligibility criteria, it should be checked with the subject and considered in the subject's overall assessment.\n\n## Eligibility criteria and its use in SAS programming\n\nThe SAS code of patient's trial-level eligibility is as follows:\n\n*SUBROUTINE patient_level_ELIG ($RETSTREAM, $RETCLIENT, &$RETPATIENT, &$RETTHER, &$RETCLIENTNOTE)\nPROC ELIG ;\n  AGE_20to44 = $RETSTREAM;\n  ELKG$ = $RETSTREAM;\n  HASHELPER_20to44 = 1;\n  ELK$ = $RETSTREAM;\n  HASHELPER_20to44 = 2;\n  ELK20to44%$ = $RETSTREAM;\n  HASHELPER_20to44 = 3;\n  ELK20to44% = $RETSTREAM;\n  HASHELPER_20to44= 4 ;\n  ELK20to44%$ = $RETSTREAM;\n  HASHELPER_20to44 = 5;\n  ELK20to44% = $RETSTREAM;\n  HASHELPER_20to44 = 6;\n  ELK20to44%$ = $RETSTREAM;\n  HASHELPER_20to44 = 7;\n  ELK20to44% = $RETSTREAM;\n  HASHELPER_20to44 = 8;\n  ELK20to44%$ = $RETSTREAM;\n  H",
        "label": 2
    },
    "996": {
        "output": "## Good Luck!\nYou are here:\n\n/inst/0163-6282-6958/06-2/0/15/html/exercises/e_assessing_eligibility/e_assessing_eligibility.html\n\n* * *\n\n## Questions?\n\n### Problems?\nIf you have any problems, please send your questions (no confidential information in the question please) to the Instructor at [email protected] via email. You are highly suggested to send screenshots of your screen (in PNG format) for better understanding.\n\n### Support?\nIf you could not figure out the solution by yourself, or need help while doing the exercises, please make an appointment at [email protected] via email, and visit the [email protected] lab (No. 310) for online assistance during Mon-Fri: 09:30AM-12:00PM.\n\n### Contact Info?\nOffice Phone: +86 531 8896 6390\nLab Phone: +86 08512963464\nInstructor: Lijuan [email protected]\n\n### Further Information?\nInformation about the Course Instructor:\n\n### Grading\nYour grading depends on the following:\n1. The accuracy of output - your answer must be exactly what is required in the question\n2. The logic behind your solution - the solution you provide would be marked as 'Correct' only when the logic inside is understandable\nExcept solution that is invalid, your solution would be marked as 'Correct' when:\n\u2460 You have written all the code inside the block `for` loop\n\u2461 You have written the corresponding code inside the block `if ` statement\n\u2462 You have used the correct control flow from the question\n\u2463 Your solution would be marked as 'Incomplete' when:\n\u2460 You did not write the expected statement or control flow correctly\nExamples: writing the if statement code to the wrong block or writing `for` statement code in the wrong block or using `if /else` statement without writing the if /else code under corresponding conditions.\n\n### Grading Rub",
        "label": 1
    },
    "997": {
        "output": "## Learning Material\n-  - - A patient note\n-  - - A clinical trial\n- Data types\n- Data Types\n\n## Objective\nCheck the patient's eligibility and output the trial-level eligibility. \n\n## Instructions\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility for the patient on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated",
        "label": 0
    },
    "998": {
        "output": "10. Let's continue to the next trial. Trial-level eligibility 1: 2) Eligible; Trial-level eligibility 2: 2) Eligible. Next trial: 1) Excluded \n![A trial-level result with a patient note]\n[INST] Hello. This is the second trial. You are a helpful assistant to the clinical trial recruitment. Your task is to compare patient data with a given clinical trial so as to decide eligibility for participation. For this trial, we have one clinical trial for atherosclerosis and vascular calcification to assess the effects of different interventions for atherosclerosis and vascular calcification. For eligibility, you'll need to check a patient's records and make a binary decision based on the clinical trial's inclusion and exclusion criteria. \n\n[PRESENT] There have been several studies that investigated the effect of vitamin K2 on calcification of blood vessels. Vitamin K2 is necessary for bone strength, and when we have vitamin K deficiency, arterial calcification is accelerated. So, we made two different groups: vitamin D group and vitamin K2 group.\n\nTherefore, in this study, we will compare the effects of vitamin D and vitamin K2 supplementation on the progression of atherosclerosis at a 1-year follow-up. And these are the inclusion criteria:\n\n1. Asymptomatic Intracranial Stenosis patients\n2. Able to perform cognitive function tests.\n\n\n\n[PRESENT] And these are the exclusion criteria:\n\n1. History of stroke, coronary heart disease, myocardial infarction, peripheral artery disease, cerebral hemorrhage, and carotid artery surgery history and severe dyslipidemia.\n\nIf an exclusion criterion is identified for any reason, the study may be terminated for that reason, and other clinical studies may be performed instead. Exclusion criteria:\n1. History of stroke, coronary heart disease, myocardial infarction, peripheral arterial disease, cerebral hemorrhage, and carotid ar",
        "label": 2
    },
    "999": {
        "output": "<EOD> Focused ultrasound enhances delivery of therapeutics in conjunction with immunotherapy\nCell-penetrating peptides (CPPs) are widely used as non-invasive alternatives to conventional drugs. CPP-drug delivery is limited by insufficient blood-brain-barrier crossing. Here, we show that focused ultrasound (FUS) mediated cavitation significantly increases CPP-conjugated chemotherapy delivery into the CNS of mice. FUS was applied to the skull-base or cranium contralateral to tumors to create blood-brain barrier (BBB) disruption 30 min prior to intravenous CPP-doxorubicin (Dox) injection in 4T1 breast cancer and GL261 glioma mouse models. 9T4 CPP, but not the control 6TG10, caused a statistically significant reduction in tumor growth with Dox exposure in vivo. FUS enhanced BBB disruption to enable CPP-Dox entry into the mice's brain tumors. 9T4 CPP was also detected in the brains of healthy male and female mice. Using 3D ultrasound imaging, we examined FUS-mediated brain temperature elevation, BBB permeabilization, and the dose of Dox recovered from brain tumors when a 165 mg/kg dose of Dox was used. BBB disruption, which occurred 10 min after sonication, correlated with the presence of blood-derived cells in the tumor 24 h later. Sonication decreased brain temperature by an average of 2.9\u00b0C within a 5 mm radius from the sonication focus, accompanied by increased tumor temperature; these temperatures gradually recovered to normal values within 30 min after sonication. The CPP-Dox dose and local BBB disruption at 30 min post-sonication were both greater in the group receiving 9T4 CPP injections compared to the group receiving 6TG10 CPP injections. The group receiving 9T4 CPPs and FUS treatments with the highest doses of CPP-Dox had the highest rate of surv",
        "label": 0
    },
    "1000": {
        "output": "![INST] `Trial-level eligibility` should be a list of numbers such as 0, 1, and 2; for example, for a trial with 3-point assessment eligibility, 0) Excluded: 1) Not Relevant: 2) Eligible. You can select the appropriate number from a dropdown list.\n![INST] Here is a sample command output. The output is a table. The columns are `Number`, `Description`, `Default` and `Included` in this study. `Number` and `Description` are self-explanatory. `Default` is the default if the patient's data is empty in some cell. `Included` means the column value included in the assessment of trial-level eligibility. Here are sample commands and their results.\nCommand Example Output\nselect-trial-level-eligibles -i '{\"PatientAge\": 10.0, \"Gender\": null, \"PatientWeight\": null, \"PatientSmoke\": null, \"PatientAlcohol\": null, \"PatientIllegalDrug\": false, \"PatientMedicalHistory\": {\"Hypertension\": null, \"Diabetes\": null, \"Heart\": null, \"Liver\": null, \"PancreasDisease\": null, \"Stroke\": null, \"Cance r\": null, \"Pulmo nary\": null, \"G rinding: null, \"C olorectal\": null, \"Kidney\": null, \"Thy roid\": null, \"P regnancy\": null, \"E ndometri als\": null }, \"Procedure\": {\"Performed\": null, \"Onset\": null, \"Diagnosis\": null, \"Laterality\": null, \"Type\": null, \"Reason\": null, \"Reason2\": null, \"Degree\": null }, \"DiseaseCriteria\": {\"Diseasetype\": \"nose\", \"Finding\": \"Colds\", \"Symptom\": \"Fever\", \"SymptomID\": null, \"Symptombasedon\": null, \"Symptom-basedon2\": null, \"Symptom-surgery\": null, \"Symptom-basedone\": null, \"Symptom-basedon2\": null, \"",
        "label": 0
    },
    "1001": {
        "output": "<EOD> The evolution of intravenous heparanase: a comparison of in vivo and in vitro enzymatic activity.\nHeparanase, an endo-beta-D-glucuronidase, is found in virtually all mammalian tissues and organs. Evidence obtained from the studies of the enzyme purified from bovine organs suggest that heparanase plays an important role in extracellular matrix remodeling processes, including tumor invasion and angiogenesis and other biologic processes including immune responses. In fact, several human tumor cell lines were demonstrated to secrete heparanase to the culture medium, and the activity of intracellular and secreted heparanase correlated with the invasive ability of the tested cells. These findings prompted us to investigate the effects of two naturally occurring mutants on the activity of intracellular and secreted heparanase in tumor cells. These studies demonstrated that the loss of the first 67 amino acids at the NH2-terminal resulted in the complete loss of both the enzymatic and the heparanase antigen affinity of the 20-kDa protein. Moreover, tumor cells harboring only these mutants (amino acids 57-203), which were deficient in enzymatic and heparanas antigen affinity, were deficient in the ability to degrade heparan sulfate and to increase in tumorigenicity. These findings provide the basis for a pharmacological approach of therapeutic strategies for the treatment of breast carcinoma based on the inhibition of heparanase production and its enzymatic activity.<EOD> Influence of intraosseous pressure generated after intravenous administration of met-enkephalin upon anesthetic potency of fentanyl in rabbits.\nThe present study was designed to investigate the possible influence of intraosseous pressure generated by the injection of met-enkephalin upon the potency of Fentanyl in rabbits. Twenty eight domestic rabbits were divided into four groups according to the intravenous administration, which was preceded by the intraosseous injection of the saline, 10, 25",
        "label": 0
    },
    "1002": {
        "output": "### Assignments\n\n<table>\n  <thead>\n        <tr>\n            <th colspan=\"2\">Instructions</th>\n            <td rowspan=\"3\"><NAME> </td>\n        </tr>\n        <tr>\n            <th colspan=\"2\">Assignment Description</th>\n            <td><NAME> </td>\n        </tr>\n        <tr>\n            <th><center>Task 1</center></th>\n            <th><center>Task 1 </center></th>\n        </tr>\n        <tr>\n            <td>Answers are encouraged even if students are hesitant to publicly post them.</td>\n            <td>Answers are encouraged even if students are hesitant to publicly post them \u277c \u29eb <NAME> <i> 7\n        ...</i></td>\n    </table>\n\n\n<!-- Instructions for submitting a homeworks-->\n<h3>Homeworks</h3>\nPlease submit your assignments in the relevant dropbox. Your homework will be automatically graded using the grading schema below. Each homework assessment has its individual grading schema.\n\n\n- [Submit Homework 1](https://app.hawkth.com/link/TUNXgXj7bkR2O)\n- [Submit Homework 2](https://app.hawkth.com/link/b1HZGvx7jr87U)\n<p>Note: Submitting your work in the past does not count as submission of a homework. Homework submissions are always due on Monday by 11:59 PM Hawaiian Time.</p>\n\n\n\n\n</h3>\n\n\n\n\n\n<EOD> The complete mitochondrial genome of Sinocalliope huidongensis (Hemiptera: Heteroptera: Anthocoridae)\n\nSinocalliope huidongensis Meng Liu, 2003 is a species of anthocorids of the family Anthocoridae (Hemiptera: Heteroptera). In this study, we reported the complete mitochondrial genome of S. huidongensis.",
        "label": 0
    },
    "1003": {
        "output": "The patient does not have sufficient information to qualify for the trial. You could mark the Assessment scale as 2. \n    \n![INST]\nAssessment: 2) Eligible.\n    \n![INST, STOPP]\n\n# If the patient does not meet inclusion criteria, you should not skip steps 1 - 3, but rather should continue to proceed with the assessment. \n\n# 4) Eligible\n- When a patient is determined eligible, you should assign the Assessment scale as 2. \n\nThe patient meets the inclusion criteria, and exclusion criteria do not apply.\n[/INST, STOPP, R",
        "label": 0
    },
    "1004": {
        "output": "- **Trial.txt file** \n\n#### 1. Copy the trial.txt from above to the local system by: `trial.txt`\nWe are going to define the trial.txt file for the following steps.\n\n#### 2. Read the trial.txt file \nA trial.txt file has a specific format. The table shows the mandatory fields, the field labels and the default values.\n\n| field name                             | Field description                               | default                                                            |\n|:---------------------------------------|:--------------------------------------------------------|:-----------------------------------------|\n| Trial_id_number                         | Trial_id_number is unique numerical identifier, for example, 001.|                                                          |\n| Trial_name                             | Descriptive name for the trial.                       | PLAGELSIF: Diverticulitis Treatment                                     |\n| Trial_phase                           | Trial Phase  , Phase I: Safety, toxicity and pharmacokinetics Trial; Phase II: Efficacy Trial; Phase III: Survival clinical trial.|  PhaseI|\n| Trial_drug_code                        | National drug code (NDC) of the drug being tested.|                                                          |\n| Trial_medication                       | Trial drug or other therapeutic agent.|                                                          |\n| Trial_medicment_code                  | NDC of the medicament.                           |                                                          |\n| Trial_age_range                      | Minimum and maximum age limits.  |                                                          |\n| Trial_inclusion_criteria           | Inclusion criteria for participation in the trial (see below).|  Sex  age weight ABO Rh CT (10 10 00 40 4) : 10 25 01 40 1 4)|\n\n#### 3.  Add patients in the trial.txt file. \nAdd all the patients that you already created when you learned about medical coding in Step 2.2. of [Part 2], by copying them from the patient.txt file above. This file has the same format as the trial.txt",
        "label": 0
    },
    "1005": {
        "output": "## Step 3. Summary\nAt the end of your program, you can generate a summary of the included patients by your clinical trial. The summary will contain information such as name, surname, age, sex, study arm, etc. You may also have the opportunity to save the included patients if you are going to add them to the inclusion criteria in another study.\n\n### 1 - Data Source\nYou can select the source of the data. \n\nThe source may be from a file that you created in previous steps, `Example Data` [INST], or from a file from a public data set that you downloaded from [HERE] with the following code: \n$file=fopen(\"data/data.txt\",\"r\"); \n\n\n### 2 - Variable of Interest\nThe Variable of Interest or primary outcomes of this study is Trial-level eligibility, and the study objectives are to investigate differences in the Trial-level eligibility between the treatment and placebo groups.\n\n\n### 3 - Summary Statistic\nThe variable of interest is a qualitative variable. You can report Trial-level eligibility in the following text: \"trial-level eligibility\" or in a numeric value: \"1,2,3`or with an integer in which `1,2,3`, or \"0\". \nTrial-level eligibility`1, 2, 3, 4`or with integer: \"1,2,3\" if you choose integer.\n\n### 4 - Coding System\nIt is important to note which value of the trial-level eligibility you chose, such as numeric value or with integer.\n\n* For example, if you enter Trial-level eligibility of `2, 1, 3`, you can use the code 3 in your calculations. The value `3` is in the range of integers from `0` up to the maximum value for 1,2,3. With this approach, you will always get a unique number for the range of values that you want to analyze. `In the next steps, we will use this code to store the values for your eligibility.\n\n\n### 5 - Data Display\nHere, the first element is the label for the first group of elements in the data table. In this table, the label",
        "label": 1
    },
    "1006": {
        "output": "### 6. Fixed-effects logistic regression model for clinical trial. (INST)\n\n[INST] Hello. You are an expert in the regression analysis. Here is the task, a clinical trial data in R. You will fit a model to estimate the conditional probability of trial-level eligibility, given certain patient information: the eligibility of the patient, the severity of illness, gender, age group, and time between visits. The study is a retrospective single-center cohort study. Here are the steps.\n\n* First, load the data by `data <- read.csv(\"trial_data.csv\", header=T)`, where trial_data.csv is provided in the same folder of this assignment.\n\n* Second, create a data structure to match the table provided in the text by `vdf <- readVDF( file =\"trial_data.csv\", colnames=c(\"age\", \"eligible\", \"visit 1\", \"visit 2\", \"mild\",\"severe\",\"female\",\"male\",\"crispyFriedDinners\"), row.names=1)`\n\n* Third, create a matrix for the variables needed from `tcm <- t(vdf)`\n\n* Fourth, set up the variables. For example, `c_age <c(1,3,4,5)`, then `a_age <factor(tcm[,c_age])`.\n\n* Fifth, create the dependent variable `y <-y_1_el` and independent variables `x < c_visit1_1, c_visit2_1, c_mild, c_severe, c_sex, c_age, c_crispyFriedDinners_1, c_fatPasteDishes_1, c_starchyFoods_1`.\n\n* Sixth, fit the regression model by `lm <- lm(y~x,data=vdf)`\n\n* Seventh, display the regression summary by `summary(lm)`\n\n[R] # > library(dplyr) > # > data <- read.csv(\"trial_data.csv\", header=T) > # > vdf <- readVDF( file =\"trial_data.csv\", colnames=c(\"age\",",
        "label": 0
    },
    "1007": {
        "output": "Here is your source code:\n\n```python\nimport pandas as pd\nfrom sklearn.linear_model import LogisticRegression\nfrom sklearn.preprocessing import label_category_encode\nname = \"Eligibility Assessment-1183.tsv\"\nname = \"Inventory_in_use_2019-11-16_044745.tsv\"\n\npatient_note = pd.read_csv(\"../Data/patient_note.tsv\")\nclinical_trial = pd.read_csv(\"../Data/clinical_trial.tsv\")\npatient_inventory = pd.read_csv(\"../Data/patient_inventory.tsv\")\n\ndf = pd.merge(patient_note, clinical_trial, left_on=\"Patient_ID\", right_on=\"Trial_ID\")\nprediction_df = pd.merge(df, patient_inventory, left_on=\"Trial_ID\", right_on=\"Trial_ID\", how=\"inner\")\nlabel_df = prediction_df.rename(columns={\"Patient_ID\": \"patient_ID\", \"Trial_ID\": \"trial_ID\"})\nlabel_df[\"trial_ID\"] = pd.get_dummies(label_df[\"trial_ID\"])\nlabel_df = label_df.drop(label_df.columns[[0, 1, 12]]).values\npredict_df = prediction_df.rename(columns={\"Patient_ID\":\"patient_ID\", \"Trial_ID\": \"Patient_ID\"})\npredict_df[\"trial_ID\"] = pd.get_dummies(predict_df[\"trial_ID\"])\npredict_df[\"Patient_ID\"] = \"eligibility\"\npredict_df = predict_df[\"Patient_ID\"]  .map(label_df)\ndf = prediction_df.join(predict_df,on['Patient_ID'])\ndf[\"Trial-level eligibility\"]= df[\"eligibility\"].fillna(0)\ndf[\"Trial-level eligibility\"].astype(int)\ndf.to_csv(\"",
        "label": 0
    },
    "1008": {
        "output": "<EOD> CARK3 is a new target of the transcription factor HIF2 in clear cell renal cell carcinoma\n\n\n\n## Figure captions\nSupplementary : HIFs expression in CCRCC cell lines. For gene expression analysis, RNAs extracted from A498 and 769-P cell lines were retrotranscribed (RT) and hybridized to Affymetrix Human Genome U133A Plus 2.0 chips (Affymetrix). Relative expression values were normalized applying the mean of all genes in the chip and the error bars were obtained considering data obtained from n=3 with biological replicates. For protein expression, total protein extracts from A498, 729-p and 769-P cells were resolved by SDS/PAGE and probed with anti-HIF1\u03b1, anti-HIF-2\u03b1 and anti-HIF-1\u03b2. The relative quantity and position of HIF2\u03b1 was normalized to the one of anti-HIF-1\u03b2 and arbitrary defined to 1 in the lanes marked with (+) of A498, 729-P and 769-P cells respectively. A densitometry plot is also shown in the bottom panel. : Subcellular localization of HIF2 and CARK3 in VHL positive RCC cell lines. 769-P cells were transfected with control plasmid (CTL), HA-VHL and Myc-HIF2 plasmids and then cells were treated (Trt) with CoCl 2 for 4h. Total protein extracts were immunoprecipitated with the anti HA antibody and the immunoprecipitates or total cell lysates (TCL) were resolved by SDS/PAGE and immunoblotted (IB) with the anti CARK3, anti HIF- [bib_ref]  HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia involves p38 MAPK..., Hawkins [/bib_ref]  \n[fig]  Figure S4: ChIP analysis for CARK3 promoter in HK-2 CARK3-overexpressing cells. CARK3-",
        "label": 0
    },
    "1009": {
        "output": "#### Eligibility\nPlease find below a complete example of the patient note and the eligibility report to meet the assignment's requirements.\n\n### PATIENT NOTE\n\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\n### CLINICAL TRIAL PATIENT NOTE\nTitle: Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice Summary: Null hypothesis of this study: Biliary atresia patients with cholestatic jaundice do not have systemic immunity defect\nInclusion criteria: Inclusion Criteria: Biliary patients older than 1-year-old status post Kasai operation.\n\n\nExclusion criteria: Exclusion Criteria:\n(<1 year old age and non-Kasai).\n\n[HINT]\n[INSERT HINT TO CURRENT PART.]\n\n[/HINT]\n\n### Eligibility Report\n\nPlease remember to add the Trial-level eligibility at the end of the report, i.e., \n\n\\begin{columns}[center",
        "label": 0
    },
    "1010": {
        "output": "_The instructions say to calculate the number of patients you believe to be eligible for the trial, but I calculated the number of patients I thought were ineligible for the trial instead._\n\n1. Let's start with the factors that do not allow a patient to undergo the clinical trial. \n1.1 We have 3 factors that exclude patients:\n\n```\n    - The patient has not previously suffered any NVD.\n    - The patient is postmenopausal.\n    - The patient has previously suffered from an NVD. \n```\n\nThe first two lines imply that the patient is included in the trial if it is not the case. However, the last line implies that, in the presence of the condition, the patient is excluded, and must remain 0 for the whole input file. So, we should repeat the patient-level exclusions, for each patient, but do the 'exclusions' with value 0, so that these lines are not repeated.\n\n1.2 We have 4 factors that do not apply on the patient record:\n\n```\n    - The patient has a BMI of  25 kg/m2\n    - The patient has already been investigated by a gastroscopy before\n    - The patient has 1 NVD in total\n    - The patient has 0 children \n```\n\nThese factors are again applied to each patient, and with appropriate parameters as above.\n\n1.3 We have 1 factor that allows a patient to be excluded from the clinical trial:\n\n```\n    - The patient suffers from hypercholesterolemia.\n```\n\nAs above, this factor is applied to each patient, with 'Excluded' value 0.\n\n1.4 We have 7 factors that allow a patient to be included in to the clinical trial:\n\n```\n    - The patient has 2 NVDs in total\n    - The patient is premenopausal\n    - The patient suffers from hypercholesterolemia.\n    - The patient has a BMI of >25 kg/m2\n    - The patient has a total of 3 NVDs\n    - The patient's age is over 55 years old.\n    - The patient's age is under 54 years old.",
        "label": 0
    },
    "1011": {
        "output": "### [INST] 59. Expert system for the detection of acute kidney injury (ASSESS): [A] Case study; [B] Solution. \n[A] CASE:\nKidney failure, also called renal failure is a serious problem that affects your kidneys, the organs that are responsible for cleaning toxins in the blood. Acute kidney injury (AKI) is the sudden loss of kidney function that affects the ability of the kidney to remove excess water and waste from the blood. Renal failure and AKI are not the same conditions, but they are related to each other. Renal failure and AKI can have many causes. The most common cause of AKI is loss of blood flow to the kidneys, such as in kidney ischemia. AKI can also be caused by diseases such as sepsis, pancreatitis, pneumonia, and diabetic kidney disease. You are an expert system for the detection of acute kidney injury (ASSESS) in radiography images of urinalysis. For example, when a person who is undergoing medical examination sends a sample of urine to a pathologist, if this person's kidneys are normal, the content of this person's urine will be normal, but if kidney problem occurs, the urine will no longer be normal and change in color. You are a software specialist who has a computer system that can check the urine sample sent by humans every morning and tell the doctors how to do that person's urine sample, but also if this sample is abnormal, what is the cause of the disease. You want to develop an expert system like UCSD pneumonia detection system. You have some information about kidney disease such as AKI, nephritis, urolithiasis that you can use in the knowledge base of your expert system that has been developed in this project. You know that renal failure is caused by many causes and AKI may be a symptom of this illness, as in the case of renal failure, AKI is not a single disease that is usually the result of another disease. When the patient loses blood and oxygen in the kidney, it is usually caused by many causes such as kidney failure, pancreatitis and p",
        "label": 0
    },
    "1012": {
        "output": "![Trial-level eligibility]()<EOD> Scalable Manufacturing of a Low Temperature Sintered Sodium Vanadium Fluorophosphate Cathode via a One\u2010Step Nanocomposite Synthesis\n\n\n\n# Introduction\nThe growing market of lithium ion batteries (LIB) and electric vehicles is driving the demand for next-generation cathode materials to replace the traditional expensive and scarce lithium cobalt oxides (LCO) and nickel cobalt oxides or hydroxides (NCM, NCF, NCH).Sodium vanadium fluorophosphates (Na x VOF 2 ) are the most commonly used alternative cathodes to LCO and NCM.They offer similar specific capacities to lithium cobalt oxide (LCO) and provide practical solutions to the energy density of LIBs.Na x VOF 2 undergoes a voltage range of 3.5-4.1 V versus Na + /Na.The main benefit of NaVOF 2 versus LiVOF 2 is that they are much less sensitive to voltage fade, but are less thermodynamically stable than lithium cobalt oxide, in a broad range of voltage windows.Sodium orthovanadate (Na 3 VO 4 or NVO) can be synthesized in various solvents, polymers, and sol\u00c0gel media.One of these materials is the NaVO 2 (amphibole mineral group), which is used in many industrial applications because it has high melting temperature (1480\u00b0C), and very high chemical stability.Moreover, NVO has been used as an active and electronic material for Na-ion secondary batteries, electrochemical supercapacitor, and electrochromic devices.Various studies on its structureand preparation techniquesof NVO have been conducted.\nNumerous studies have focused on the preparation of NaVOF 2 via solvent-gel syntheses, such as polyols,NMP, and water-based systems.All synthesis techniques require complex multistep procedures and/or toxic reagents. This is why simple, scalable, and cost-effective methods are in high demand to be used for manufacturing of NaVO 2 and its chemical variants. Pre",
        "label": 0
    },
    "1013": {
        "output": "Please note that the sample input `S= {<dosage>.type=\"2.0450000000000002568476175701\">, 2 4E + 07 18` and output `Trial-level eligibility: 2) Eligible` in Figs. 1 - 3. See Fig. 4.\n\n### How to deal with ambiguities?\n\nIf this input is ambiguous in terms of the type of drug and/or dosage, the program will output the `ambiguous: drug_or_amount`. The example input `S= {A=\"100\"` shows that the drug information is ambiguous in terms of the amount. For this ambiguity, it will output the `ambiguous: drug_or_amount`. Please note the output of Figs. 5 - 7 by setting `ambiguous.drug_or_amount=F` in `S=`. \nPlease refer to the [manual](http://manuals.sccn.ucsd.edu/en/bms/bms6-criteria-based-reasoning) for more details.\n\n### How to deal with missing data cases?\n\nIf an input is missing some information, the program will output the `missing: disease_of_the_interest, disease`, `disease: F`, and/or `uninformative.missing_value`, depending on the case. The example input `S= {S=\"{A=\"dos 2591.13\", \"T=10.5\", \"T=10.7\", \"T=10.8\"}\"}` of Figure 8 shows that the input is missing the value of symptom onset. For this case, it will output the `missing: disease_of_the_interest, disease`, and `uninformative.missing_value`, depending on the case. Please note the output of Figs. 9 - 12 by setting `missing.informative_fields=T` or `missing.uninformative_fields=F` in `S=`. \nPlease refer to the [manual](http://manuals.sccn.ucsd.edu/en/bms/",
        "label": 0
    },
    "1014": {
        "output": "[INST] There are many clinical trials. You can check them one by one in http://dct.abrc.or.kr/\n\n\n<EOD> Migrating foreign bodies on chest radiograph: case report and review of the literature\n\nWe present the case of a 7-year-old boy who had a cardiac catheterization at our institution. During the procedure, the catheter passed through the foramen ovale into the left atrium and the right heart and could not be retrieved. At surgery, it could be found on the right ventricular myocardium and was manually removed. On the chest radiograph, there was at first no evidence of a foreign body. Seven days later a foreign body could be visualized over the mid-left lung. On the following chest radiograph, 3 weeks after the catheterization, a foreign body had migrated into the tracheobronchial tree and could be diagnosed over the right middle lung. Because of an increasing infection, a bronchoscopy was performed",
        "label": 0
    },
    "1015": {
        "output": "<EOD> The use of the in vitro fertilization laboratory mouse as a model for testing phytoestrogens.\nThe estrogenic effect of three food supplements were studied in mice: (1) an extract of soybeans, (2) a purified fraction of soybeans, and (3) a purified flaxseed extract. These diets were evaluated in mice before and after stimulation of the oocyte reservoir, and their efficiency compared with those of 0.17% and 1.7% diethylstilbestrol dietary supplements. The estrogenic response was measured by evaluating the number of ova aspirated and the number of fetuses recovered after the injection of hCG. There was no apparent estrogenic response seen when soybean extract, the purified fraction of soybeans, and the purified flaxseed extract were administered before stimulation of the oocyte reservoir. The 0.17% diethylstilbestrol dietary supplement caused fewer ova to be aspirated and more fetuses to be recovered than the 1.7% diethylstilbestrol dietary supplement. When the soybean extract, the purified fraction of soybeans, and the purified flaxseed extract were fed to the mice after stimulation of the oocyte reservoir, the results were variable. The purified fraction of soybeans provided a higher estrogenic response than did the soybean extract, and a higher estrogenic response than did the purified flaxseed extract. These experiments demonstrate the use of the in vitro fertilization laboratory mouse as an model for examining the estrogenic response of food supplements. This model may be a reasonable system for testing new food supplements, pharmaceuticals, and/or compounds that affect ovarian function.<EOD> The complete mitochondrial genome of Chironomus beringianus\nAbstract The fully sequenced mitochondrial genome of Chironomus beringianus is used for the first time to investigate and analyze the inter- and intra-species diversity of Chironomidae. Compared with other available metazoan mitogenomes, the genome",
        "label": 0
    },
    "1016": {
        "output": "[[RD] 1]\n\n\n\n## Problems\n\nThis problem was presented in one of the training materials of UCLA. \n\n# Example output \n \n```\nTrial-level eligibility: 1) Not relevant\n\nTrial-level eligibility: 2) Eligible \n``` \n \nThis was the patient note above. The patient does not need to have previous history of NVDR. \n \n# Example output \n \n```\nTrial-level eligibility: 1) Not relevant \nTrial-level eligibility: 2) Eligible\n``` \n \nThis was the patient note and clinical trial in the above. \n \n# Example output \n \n```\nTrial-level eligibility: 2) Eligible\n``` \n \nEither the patient does not have left ventricular systolic dysfunction. \n \n# Example output \n \n```\nTrial-level Eligibility: 1) Excluded\n``` \n \n# Example output \n \n```\nTrial-level Eligibility: 1) Excluded\n``` \n \nThere are no NVDR patients. \n\n# Example output \n \n```\nTrial-level Eligibility: 0) Excluded\n``` \n \n# Example output \n \n```\nTrial-level Eligibility: 1) Not relevant\n``` \n \nThere is no CVD or CVD risk factor such as hyperlipidemia.\n\n# Example output \n \n```\nTrial-level Eligibility: 2) Excluded\n``` \n \n# Example output \n \n```\nTrial-level Eligibility: Excluded\n``` \n \nThere are no NVDR patients and no CVD or CVD risk factor. \n\n# Example output \n \n```\nTrial-level Eligibility: 2) Excluded\n``` \n \n# Example output \n \n```\nTrial-level Eligibility: 1) Not relevant\n``` \n \nThis was a patient for the trial below. \n\n# Example output \n \n```\nTrial-level",
        "label": 0
    },
    "1017": {
        "output": "## 4. What is a clinical trial? [QUIZ]\n\nThis clinical trial looks at the role of certain factors in the development of GORD, its pathophysiology to identify new possible biomarkers involved in the development, diagnosis and the treatment of the various associated symptoms. The study should also evaluate changes in some proton transferases or markers of epithelial junctions in patients with oesophageal dysmotility, with or without reflux in a prospective randomized placebocontrolled study.\nFirst, it is necessary to obtain biopsies of the oesophagus in four locations: 1. 15cm above the LES, 2. 5cm above the LES, 3. 10cm above the LES, 4. 10cm below the glandular zone.\nThen, samples of epidermo\u00efd cells are collected in 3 locations, 1. 10cm above the glandular zone, 2. 3cm above the LES, 3. 5cm above the LES. We should also collect samples of mucosa cells, 200 microns in diameter, as well as plasma for cytokine dosage.\n\n## What is an experimental study? [q4a]\nExperimental studies are conducted for the purpose of testing and demonstrating the safety of novel drugs. They provide valuable evidence on clinical safety and adverse events, biology and pharmacology. The main objective of a phase 1a/b clinical trial of pharmacokinetic (PK) and safety (pharmacodynamic [PD]) evaluations is to assess possible dose-limiting toxicity (DLT) and to confirm dose-escalation steps in first-in-human study subjects.\n\n## What is an observational study? [q4b]\nObservational studies evaluate disease incidence and determinants of exposure and outcomes in large series of patients over time.\n\n## What is a randomized clinical trial? [q4c]\nIn an RCT, groups of subjects who may differ in respect to certain prognostically relevant characteristics are allocated on a random basis to receive treatment with an experimental drug or with a placebo instead.\n\n## What is",
        "label": 0
    },
    "1018": {
        "output": "[STOP] You can try these links:<EOD> Mapping of cD\u201034+ haematopoietic progenitor cells in the bone marrow of the pig\nThe porcine haematopoietic progenitor cells (HPC) were investigated using an immunomagnetic technique, and by immuno\u2010histochemical localisation of the c\u2010kit receptor in bone marrow biopsies. The monoclonal antibodies c\u2010kit, CD34 and CD235a were used to purify and localise the progenitor cells. Immuno\u2010fluorescence studies revealed that 12% of the c\u2010kit+/CD34+ cells were CD235a+. The majority (59%) of the c\u2010kit+/CD34+ (79%) cells were located in the sinusoids within the bone marrow (BM) while only 22% of the c\u2010kit+/CD34+/CD235a\u00b1 cells were detected in these sites. The c\u2010kit\u2010/CD34+ cells were mainly found in the sinusoids. In a separate immuno\u2010histochemical study these cells constituted 0.8% of the total nucleated BM cells (BMC), whereas the percentage increased to 5.6% when only the erythroid precursors were considered. The nucleated BMC had a mean c\u2010kit+/CD34+/CD235a\u00b1 cell content of 1.3% and the total number of these cells corresponded to 2% of the total nucleated BMC.<EOD> The prevalence and association of anaemia with HIV infection among people living with HIV and AIDS attending in the University of Gondar Comprehensive Specialized Hospital, Gondar, Northwest Ethiopia\n\nBackground: Anaemia is a global public health problem leading to poor physical function, reduced work efficiency, and increased risk of mortality. Anaemia is one of the most common and earliest side effects of antiretroviral therapy (ART). This study aimed to assess the prevalence and associated factors of anaemia among people living with HIV and AIDS attending the University of Gondar Compre",
        "label": 0
    },
    "1019": {
        "output": "<EOD> A New Model of Diverticulosis: Experimental Induction of Diverticulosis and Colonic Ulcer in a Rabbit Model\n\nBackground/Aims: Diverticulosis is a condition where the mucosa and submucosa protrudes through the muscular layer and it is common in westernized countries. The pathogenesis of this condition is still not clear. In addition, it is also not clear whether diverticulosis can lead to diverticulitis. Thus, the aim of this study was to establish an experimental rabbit model that shows progression similar to that of diverticulosis in humans. Methods: A total of 12 rabbits were divided into two groups: untreated control group (five rabbits per group) and diverticulitis group (seven rabbits per group). The rabbits in the diverticulitis group underwent oral administration of aminosalicylic acid (250 mg/kg) and were examined in ultrasound-guided segmental bowel wall thickening, and the results were compared with those of the control group. A follow-up endoscopy was also performed 6 months after aminosalicylic-acid instillation. At the end of follow-up endoscopy, postmortem examinations were also conducted, and diverticulosis formation was evaluated by gross findings. Results: Bowel wall thickening was apparent from 3 weeks after instillation of aminosalicylate, and diverticulosis developed as early as 6 weeks. We were also able to demonstrate an increase, on histopathological examination, in serositis, lymphoid follicles, and inflammatory cell infiltration at 6 weeks. No mucosal degeneration or ulceration was observed throughout the study. Conclusions: In this rabbit model, diverticulosis was induced; however, no progression of diverticulitis was shown at 6 months. (Gut Liver 2015;9:274-279)\n\n# Introduction\nDiverticulosis is a condition of mucosal protrusion through the muscularis mucosae and is common in elderly persons.The main regions involved are the sigmoid colon and other areas of the colon. Its preval",
        "label": 0
    },
    "1020": {
        "output": "### Clinical Trial 3\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe assessment of eligibility has a four-point scale 0) Excluded because inclusion criteria are not met, 1) Not relevant because the patient has insufficient information to qualify for the trial, 2) Eligible-Eligible if patient meets inclusion criteria and exclusion criteria do not apply, 3) Not eligible based on exclusions because patient meets one or more reasons to exclude him/herself.\nYou should make a trial level by patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\nHere is the patient note:\nA 70-year-old man is referred by his primary care physician for a routine annual health screening. He has a long-term medical history of hypertension, type 2 diabetes, and coronary artery disease with a permanent stent inserted 6 years ago. His physical examination was unremarkable except for his blood pressure (BP) of 160/80 mm Hg on both arms and an elevated weight of 277 lbs (weight 250 lb, BMI 39.9 kg/m2). His laboratory tests show sodium 134 mmol/L, random blood sugar 125 mg/dL, potassium 3.6 mg/dL, chloride 99 mmol/L, CO 2 19 mmol/L, bicarbonate 14 mmol/L, blood urea nitrogen (BUN) 50 mg/dL, serum creatinine 1.5 mg/dL, C reactive protein 5.4 mg/dL, total bilirubin 0.2 mg/dL, alkaline phosphatase 140 IU/L",
        "label": 0
    },
    "1021": {
        "output": "<EOD> The Effect of Proactive Personality on Work Engagement: The Moderating Role of Meaningful Work\n\nIn recent years, the development of work engagement has become a topic of great interest in the Chinese context. A growing number of studies emphasize the importance of a positive psychology approach to understanding the factors influencing work engagement. The present study aims to examine the effect of proactive personality on work engagement. Additionally, we examine the effects of the psychological state and the psychological condition of employees on work engagement and evaluate the moderating role of meaningful work in the relationship between proactive personality and work engagement. A total of 257 participants from two Chinese universities were recruited. A structural equation model (SEM) analysis and a moderating effects test were conducted to examine the relationships between the variables. The results revealed that proactive personality had a positive effect on meaningful work, which, in turn, influenced work engagement. It was also found that the positive effects of proactive personality on work engagement and job satisfaction were stronger among employees who worked in meaningful work settings. This work contributes to a better understanding of the effect of proactive personality on work engagement and meaningful work's influence on that relationship.Keywords: proactive personality, work engagement, meaningful work, relationship, social cognitive theory (SCT)\n\n# Introduction\nAs the development of education and other industries accelerates in China, the issue of work engagement has attracted increasing attention from researchers and academics. Compared with the United States and Europe, the research related to employees' work engagement in China is still in its infancy [bib_ref]  Engaging employees: the impact of supervisory behaviour, job security and organization on..., Bovaird [/bib_ref] . Currently, the theory and application of work engagement among Chinese scholars and practitioners remains controversial and needs considerable attention.\nThe current research on work engagement has provided an effective conceptual framework for its study by focusing on the internal cognitive aspects of individuals [bib_ref]  Development and validation of the work engagement scale for professionals UFMG Edition, Pranck [/bib_ref] . However, it did not focus on the interaction between individuals and their work environments and ignored the external factors. Although the cognitive theory that emphasizes individual differences has been shown to be useful in understanding organiz",
        "label": 0
    },
    "1022": {
        "output": "### Assessments\nFor this assessment, assess the patients according to the criteria shown in . Assess whether the patient has the criteria for the particular factor. For example, if we look at age factor, we should check whether it is less than `30`. Similarly, we need to check all the criteria for all applicable factors. Remember, if we fail to mention a criteria in the criteria row you are assessing, it means the patient must meet those criteria.\n\n\n\n\nAssessment of Eligibility\n\n\n \nAssessment of Eligibility\n\n\n### Section 7: Patient's Preferences\nHere, you will be asked to explain your choice of treatment to the patient. You should explain the reason for your choice in such a way that it is clear to the patient (patient's section). The explanation should be given as a conversation between you and the patient.\nAs in this conversation. [NAME], I have assessed that you would benefit from an intervention to treat your migraine problem. I think that this is a suitable intervention to treat patients similar to you. As we have discussed before, your treatment should be nonopioid. According to available data, nonodic treatments will be better than opodic ones. Moreover, it is well-known in the literature that use of opodic drugs are associated with higher mortality. [/INC] However, octreotide also has a nausea and vomiting problem. Moreover, in octreotide treated patients that nausea and vomiting problems could persist for more than 2 hours. Based on literature, most patients who use compazine do not experience these problems. Moreover, according to the side effect profile, it appears that compazine has fewer side effects than octreotide. Considering all of these facts, I propose that this problem is more likely to have compazine treatment rather than octreotide. Now, I would like you to come back with me to the clinic. We will prescribe these oral medicine and will see how it works for you. [/INC] If you want",
        "label": 0
    },
    "1023": {
        "output": "## [CUT]\n\n### [CODE] \nLet's see the implementation of Trial-level eligibility.  The reason to explain this in detail is that it's the most complicated concept in this project, especially if you don't have any background. First, you create a list of trials and then add patient notes to the list, and finally, you find which trial the patient matches. \n\n```python\n\n[CODE]\n# create a Trial class\nclass Trial:\n  \tdef __init__(self, name, description, exclusion_criteria, inclusion_criteria):\n\t\t\t  self.name = name\n\t\t\t  self.description = description\n          # Exclusion criteria\n          self.inclusion_criteria = inclusion_criteria\n          self.exclusion_criteria = exclusion_criteria            \n\n\t\tdef __str__(self):\n\t\t\treturn f\"<Trial {self.name} >\"\n\t\t\t\t\n\t\tdef __repr__(self):\n\t\t\treturn f\"<Trial {self.name} >\"\n        \n   # create a dictionary storing trials and their description and inclusion_criteria\n   trial_dict = {}\n\t\n    \n[CODE]\n# add trials to the trial_dict with a unique identifier\nfor trial_dict in trial_dict:\n    trial_dict.update(trial)\n\n\n[CODE]\n# iterate over the trial_dict to print the Trial data in the console\nfor a in trial_dict.keys():\n\tprint(f\"{a} - \")\n\tfor key in trial_dict[a]:\n\t\tprint(key, \": \", trial_dict[a][key])\n\t\ttrial_list.append(a)\n\n```\n\nThe output of the code is shown below:\n\n\n```python\n\n[CODE]\n<Trial Absolute risk trial> - Absolute risk reduction is the difference in the rate of major adverse cardiovascular events between the patient group receiving the drugs before the stroke and the control group that did not take those drugs.\n\n<Trial Atrial fibrillation trial> - Atrial Fibrillation is the most common arrhythmia encountered in",
        "label": 0
    },
    "1024": {
        "output": "##[EXPERT] Please try to match the example(s) and make a trial-level eligibility in the following patient note:\nA 29-year-old male with a history of pulmonary hypertension, chronic obstructive pulmonary disease (COPD), cirrhosis secondary to hepatitis C, and recurrent pleural effusions presented to the hospital with dyspnea, bilateral upper extremity edema, and ascites. The patient was admitted 10 days from discharge after undergoing a right heart catheterization. The catheterization showed that the patient had pulmonary hypertension and severe right heart dysfunction. The patient's clinic team felt that his poor functional status and right heart dysfunction would not allow him to manage medical or device complications of transplant. He wanted to explore options for liver transplant, which he felt could reduce his symptoms and improve his overall functional status and longevity. The patient was informed that he would be excluded from liver transplant because of his right heart failure and his underlying liver disease. The patient was given information about a clinical trial of lisinopril for patients who are excluded from liver transplant because of their right heart dysfunction.\n\n\n### Inclusion criteria\n\n\n-\n\nThe catheterization showed results: RAP 11, RA 20, RV 20 189 cc/m2 and PA pressure 49 mm Hg\n\n### Exclusion criteria A.\n-Heart Failure -RAP <15 mmHg and RV ejection fraction <30% despite inotropic support\n-Hypotensive at rest or with exercise (RV Ejection fraction <25%) B.\n-Pulmonary hypertension -PA pressure >32 mm Hg or pulmonary vascular resistance >3 Woods units\n\nHere is the patient note:\nA 42-year-old male with a history of pulmonary hypertension, chronic obstructive pulmonary disease (COPD), cirrhosis secondary to hepatitis C, and recurrent pleural effusions presented to the hospital with dyspnea, bilateral upper extremity edema, and ascites",
        "label": 0
    },
    "1025": {
        "output": "## [CJ] `x` and `x` in patient note\n```\n[IN]\n 2011-08-19, 12:48:38.421243,\n    x{1},x{1},x{1},x{2},x{1},x{1},x{1},\n    x{2},x{1},x{1},x{1},x{1},x{1},\n    x{1},x{1},x{1},x{1},x{1},x{1},x{1},\n    x{1},x{1},x{1},x{1},x{1},x{1},x{1},\n    x{1},x{1},x{1},x{1},x{1},x{1},x{1},\n    x{1},x{1},x{1},x{1},x{1},x{1},x{1},\n    x{1},x{1},x{1},x{1},x{3},x{1},x{1},\n    x{1},x{1},x{1},x{1},x{1},x{1},x{1},\t\n    x{1},x{1},x{1},x{1},x{2},x{1},x{1},\n    x{1},x{1},x{1},x{1},x{1},x{1},x{1},\n    x{1},x{1},x{1},x{1},x{1},x{1},x{1},\n    x{1},x{1},x{1},x{1},x{1},x{1},x{1},\n    x{2},x{1},x{1},x{1},x{1},x{2},x{1},\n    x{1},x{1},x{1},x{1},x{1},x{1},x{1},\n    x{2},x{1},x{1},x{1},x{2},x{1},x{1},\n    x{1},x{1},x{",
        "label": 0
    },
    "1026": {
        "output": "## Exercise Instructions\nThis file is your script. \nCopy and paste the instructions found on the next page.\n[DOWNLOAD] Instructions\n\n# Discussion\n\n## What you can do after your submission is accepted:\n- If you have additional queries, please post them on our Google group at.\n- You have to have the full course, and you can find the courses on github.\n- The next course is \"Text Mining\" course here, and the whole course is on github.\n<EOD> The effects of caffeine on the response of skeletal muscle to acute resistance exercise in older adults\nThis study was designed to determine the effect of caffeine on skeletal muscle hypertrophy and strength following acute resistance exercise in older men.<EOD> In situ electron probe microanalytical measurements of sulfide adsorbed on solid surfaces: an overview.\nElectron probe microanalytical (EPMA) techniques are ideally suited for the investigation of chemical processes in the solid phase, in situ at pressures of a few hundred MPa or higher. In this review, the experimental protocols, analytical features, and potential applications of such electron probe microanalytical techniques as X-ray diffraction (XRD), electron probe mass spectrometry (EPMS), electron energy loss (EEL) measurements, electron imaging, and electron absorption (EA) measurements are outlined. A brief review is given of the measurement of concentrations and distributions of sulfide adsorbed on surfaces in air and in H(2). Recent in situ transmission-electron-microscopy (TEM) studies on adsorption of H(2)S on iron sulfide show that the in situ XRD and EEL methods can play important roles in the field of in situ surface analysis to further our understanding of sulfide adsorption on surfaces and to help develop improved sulfide removal processes in industrial applications.<EOD> The influence of atherosclerosis and hypertension on the relationship of cerebral blood flow autoregulation and cerebral perfusion pressure\nAbstract Background: The relationship of cerebral blood flow (CBF) and cerebral perfusion pressure (CPP) is modulated by the brain\u2019s",
        "label": 0
    },
    "1027": {
        "output": "[INFO] The output should look as in . Note that 0.0 would not match any record. \n```\n# [INFO] Test Output\n\nPatient's ID: 277883\nAge: 26\n\nPatient's ID: 278482\nAge: 86\n\nTrial 1-level assessment:\n\nTrial 1-level assessment: 0)\n\nPatient's ID: 182365\nAge: 86\n\nTrial 1-level assessment: \n\nTrial 1-level assessment: 1)\nPatient's ID: 277883\nAge: 26\n\nTrial 1-level assessment output:\n\nTrial 1-level assessment: 2) Eligible\n- Inclusion criteria:\n\n- Hypercholesterolemia\n- \n\nTrial 1-level assessment output:\n\nTrial 1-level assessment: 3)\n\nPatient's ID: 278482\nAge: 86\n\nTrial 1-level assessment: 3)\n\nPatient's ID: 182365\nAge: 86\n\n\nTrial 1-level assessment: 3) Excluded\n- Atherosclerosis excluded because of low blood cholesterol levels\n- \n\nTrial 1-level assessment output:\n\nTrial 1-level assessment: 3) Excluded\n- Inclusion criteria:\n- \n\nTrial 1-level assessment output:\n\nTest Output for Exhibit 7 (Part 1)\n\n[INFO]\n```\n\n\n\n### Exhibit 7 - Part 2\n\n<h1>Exhibit 7 Part 2 <i> (a.m.)</i></h1>\n\n\n<h2>Part 2:<br/>Step-by-step walkthrough of Exhibit 7</h2>\n<br/>\n\n[**Patient**](https://github.com/bakul/clinicaldata/blob/",
        "label": 0
    },
    "1028": {
        "output": "You should check 36 patient cases to make practice.\n\nCongratulations. You complete the training successfully.\n\n##[S2]\n\nA 38-year-old, male patient with a history of atrial fibrillation (AF) underwent an ablation procedure under general anesthesia. After two failed cardioversions the patient was given amiodarone and phenytoin to treat AF. When discharged from the recovery room two hours post-procedure, the patient was noted to be in AF. An ECG rhythm strip showed narrow complex, rapid atrial rate rhythm and a junctional escape beat.\nT1: VF - 30 seconds T2: VF - 15 seconds T3: VF - 5 seconds T1'=T2'=T3'= 10 seconds Tx: sinus rhythm [PATIENT MISS]\nTx: BP - 200/95mmHg HR - 104\nTi' = T1\" = T2\" = T3\" = 14 seconds Tx: sinus rhythm [PATIENT MISS]\nTx: BP - 217/77mmHg HR - 115\nTi (3): VF = T1 (3): VF = 15 seconds T2 (3): VF = 20 seconds T1 (4): T2 (4): T3 (4): 20 seconds Tx (4): sinus rhythm [PATIENT MISS]\nTx: BP - 240/100mmHg HR - 138\n\n## [p]\nAssume that the patient had inhaled too much xenon and is now receiving high-flow mask oxygen and suctioning. How fast should ventilation be initiated?\nYou are working on the critical care unit in a metropolitan hospital. You have been called to see a 69-year-old man undergoing elective coronary artery bypass grafting for a high-risk triple coronary bypass and valve replacement surgery. This is the patient's second surgery in 3 months. The previous procedure was performed",
        "label": 0
    },
    "1029": {
        "output": "[END]\nTo generate the full report, we type the following statement: Report Trial_Eligibility:\n`\nIncrease the font size of the title by typing `reportTrialleligibility: Increase font size:\nThis command can be executed any number of times, to change the size of the title (but not the text size) to an amount you prefer.\n\n## [END]\nYou may exit the editing mode by pressing the `tab` or `shift`+`t` keys.\nTo generate the full report, we type the following statement: \\mandatory_input{reportTrialleligibility_comment_section_one}\n\nYou can make comments by typing any type of information in the `comment` columns. Comments are available in every report section; in this report it is located underneath the section title. \n\n## Examples of comments\nSome examples of comments that one might put in these columns:\n\"Thank Dr. Zhang's comment that the patient had a prior seizure disorder\"\n\"Patient's seizure on day 10 of Induction\"\n\"Pertinent to all patients who have a pre-existing seizure disorder\"\n\"See table below\"\n\"See attached file\"\n[END]\nYou may exit the editing mode by pressing the `tab` or `shift`+`t` keys.\nTo generate the full report, we type the following statement: \\mandatory_input{Pid}\n\nTo change the patient id: We use the `change_patient_id_report`-command to edit this section; we write this in the `command` column:\n`change_patient_id_report`\n\nAlternatively, we change the patient id like we did in the first part of the report. However, we need to generate two reports: \n\nOne report with the original patient ID of 0206, and one report in which the patient id is changed to an alternative patient id. \nFor this report, we write the following in the`command` column: [change_patient_id_report](3487)_comment_section_two.md)[END]`[END]\nTo generate the full report, we type the following statement: \\mandatory_input{report_patient_status",
        "label": 0
    },
    "1030": {
        "output": "<EOD> Inactivation of a phosphoglucose isomerase by treatment with cysteine and glutathione. Effects of enzyme concentration, amino acids, divalent metal cations and the sulfhydryl reagents on inactivation.\nThe reversible inactivation of rabbit phosphoglucose isomerase by cysteine and glutathione are determined with respect to pH, enzyme concentration and other sulfhydryl reagents. Inactivation is a result of thiol addition, since reactivation follows the reduction of the added sulfhydryl groups. It is suggested that an essential thiol group of the enzyme is modified, so that the active site is inaccessible to the substrate.<EOD> Nutrition support in trauma and traumatic brain injury patients.\nPatients with severe trauma have the potential for energy and nutrient requirements far exceeding the orally or enterally administered amounts. Intravenous glucose and essential amino acids are often used to supplement the usual oral diet. This paper will discuss the rationale for providing a mixed amino acid solution as well as insulin to these patients; as well as the effects it has on glycemic control and other metabolic complications associated with multiple trauma.<EOD> Influence of niacin on growth and plasma glucose, insulin, and lipid metabolite concentrations in calves.\nNiacin given in the feed for dairy calves between 1 wk of age and 70 kg BW did not reduce the growth rate or feed intake when compared with nontreated animals. However, the rate and extent to 3 kg BW of feed and milk consumption in the niacin-treated calves and the milk intake were greater (P 0.05) and did not differ when fed niacin from when fed the control diets. Feeding calves niacin for the first 70 kg BW did not cause severe adverse effects but reduced the growth rate and milk consumption after cessation of niacin feeding. The cause for the reduction in milk consumption of niacin-fed calves was not explained.<EOD> Excessive Daytime Sleep",
        "label": 2
    },
    "1031": {
        "output": "# Questions\n\n## How would you code the following input without the module?\n![INST] Example note:\n\n# Question #1\nDear clinician:\n\nWe are conducting a study to evaluate the genetic predisposition to atrial fibrillation. We are seeking 100 patients who have been diagnosed with this disorder and willing to give blood samples for DNA analysis. If you have a patient that you would like to involve, please contact me at 123-456-7890. Dr. _________________ would appreciate your help as this study will provide valuable basic information that can potentially determine the genes responsible for this rhythm disturbance.\n\n# Question #2\nHey Doctor, this is [FirstAuthor] calling from the [SecondAuthor]. I just wanted to remind you about a patient that you see at our clinic with breast cancer and a family history of the disease in a first-degree relative. As you may remember earlier this year, [ThirdAuthor], who works in the mammography department, was unable to participate in the [FourthAuthor] trial for reasons outlined below. Please keep her [FifthAuthor] and I in mind for future trials when we're recruiting people with breast cancer. Thank you.\n![INST] Sumo Mezcal, BKK, Thailand : [SecondAuthor]'s note\n\n# Question #5\nDear Sir/Madam,\n![INST]\nThank you! We really appreciated your efforts in this study. \n![INST]\nWe are really interested to know your opinion about this study. Please take a few minutes and answer the questions in the survey we have attached.\n![INST]\nWe can only move on with this study after understanding your opinion.\n![INST]\nYours sincerely,\n[ThirdAuthor].\n![INST] Acknowledgement for the participant's blood\n\n# Question #6\nDear Dr. __________,\n![INST]\nWe would like to acknowledge [FirstName]_ [LastName]_ for the participant's blood. [Sumo Mezcal, BKK, Thailand] team would like to acknowledge all the contributions of [FirstName]_ [LastName]_ that made this research study a success. [Sumo Mezcal, B",
        "label": 0
    },
    "1032": {
        "output": "### Task5_2\n\n\n\n[X] Do you see the differences of this trial from the last trial? If not, take a closer look.\n\n```\nA 47-year-old obese man was admitted to the emergency department with acute abdominal pain, associated with nausea, vomiting and bloody stools. He is a smoker who has 2 children, and he is not menopausal. He visited the doctor for the first time after the above symptoms occurred. He has a past medical history of unclassified renal calculi, uncomplicated hypertension, and mild CAD. He has no surgical history. The examination reveals that he is febrile and tachydyspneic, with a temperature of 39,9\u00b0C, a blood pressure of 140/80mmHg, and a heart rate of 110/min. He also has tachycardia, dyspnea, and abdominal tenderness. His other examinations are normal. Laboratory analysis reveals acute renal failure with a BUN of 80mg/dl and a creatinine of 4mg/dl.\n\n    <table border=\"1\">\n        <tr>\n          <th>Characteristics</th>\n          <th>Assignments</th>\n          <th>Evaluation</th>\n          <th>Degree of compliance</th>\n          <th>Action</th>\n        </tr>\n        <tr>\n          <td>Age</td>\n          <td>--</td>\n          <td>--</td>\n          <td>--</td>\n          <td></td>\n        </tr>\n        <tr>\n          <td>Sex</td>\n          <td>\n\n            <input value=\"M\">\n          </td>\n          <td>--</td>\n          <td>--</td>\n          <td>\n\n            <button id=btnSave\n\n<input value=\"False\" name=in-\n\n<label>\n<input type=checkbox\nname=in-\nname:in-\n</label>\n            </button>\n          </td",
        "label": 0
    },
    "1033": {
        "output": "<EOD> Cognitive behavioral stress management interventions for lowering blood pressure in individuals with uncontrolled hypertension: a meta-analysis.\nBACKGROUND\nUncontrolled hypertension remains a challenge and is becoming a leading risk factor for preventable morbidity and mortality.\n\n\nMETHOD\nThis study examines the effects of comprehensive cognitive behavioral stress management (CBSM) interventions on systolic and diastolic blood pressure in adults with uncontrolled hypertension. Six electronic databases were searched from 2005 to the present for randomized controlled trials examining the effectiveness of CBSM interventions on blood pressure. Studies of any length and design were included. This meta-analysis included 403 participants and 8 effect size estimates. An inverse variance model and Hedges g effect sizes were conducted.\n\n\nRESULTS\nThe pooled effects were g =.66 for systolic blood pressure (95% Confidence Intervals = 0.55-0.77, p <.001) and g =.80 for diastolic blood pressure (95% Confidence Intervals = 0.69-0.91, p <.001). Sensitivity analyses supported the robustness of estimates. The findings were not influenced by length of the program, study design or sample size.\n\n\nCONCLUSIONS\nCollectively, the findings support the effectiveness of CBSM in lowering blood pressure.<EOD> Cervical artery dissection in antiphospholipid syndrome\nThe aim of this study was to explore the relationship between cervical artery dissection (CeAD) and antiphospholipid syndrome (APS).<EOD> In Vitro Activities of LY333328, a New Aminoglycoside, and Compared of Seven Other Aminoglycosides against Mycobacterium tuberculosis and Isolates with Known or Suspected Resistance Profiles\nABSTRACT A broad spectrum of aminoglycosides provides alternative options to current treatments for infections caused by multidrug-resistant Mycobacterium tuberculosis. Here, we report on the in vitro activity of",
        "label": 0
    },
    "1034": {
        "output": "[ /INST]\n#### 2. Trial-based scoring algorithm ###\nThis is a trial-based scoring algorithm, as shown below.\n\nScoring algorithm :\n[scatter plot for the dataset](https://raw.githubusercontent.com/chrisjyonhyeong/ClinicalNLP/master/demo_data/Duloxetine_SOD2019_02.tsv)/[pdf](https://raw.githubusercontent.com/chrisjyonhyeong/ClinicalNLP/master/demo_data/Duloxetine_SOD2019_02.pdf)\n<EOD> A Case of Opsoclonus Myoclonus Syndrome Relieved Using Electroconvulsive Therapy\nAlthough several treatment modalities have been used to treat myoclonus, the results have been inconclusive. We report the case of a 59-year-old male patient who presented with opsoclonus, myoclonus, and ataxia, and was diagnosed as opsoclonus-myoclonus syndrome (OMS) based on neurological and neurophysiological findings. He showed only slight response to conventional treatments, including immunotherapy, steroids, and infusions of intravenous immunoglobulin, for 3 months. Finally, 1 month after a course of electroconvulsive therapy (ECT), his symptoms, including opsoclonus and myoclonus, completely resolved. Our case demonstrated the effectiveness of ECT for refractory idiopathic OMS patients. Further investigations comparing ECT to other treatments are required.<EOD> Loss of Nrf2 in the central nervous system has minimal effects on antioxidant and detoxifying enzyme levels and antioxidant defense.\nNuclear factor E2-related factor 2 (Nrf2) is a transcription factor that modulates multiple cell functions and is involved in cellular detoxification processes. Nrf2 is also considered an important endogenous regulator of oxidative stress. Here we investigated the effect of Nrf2 loss in the CNS on antioxidant response element (ARE)-dependent gene induction using",
        "label": 0
    },
    "1035": {
        "output": "After you finish the input data, please make sure that: \n1) All the data are well-formatted without typographic error or mistake.\n2) No character (other than alphanumeric) can be found in the patient, trial, or code names.\n\n### Submitting your code\nPlease submit your Python code, by pressing the submit button or by using the URL at the top-right of the page, in the form of a Jupyter notebook (https://jupyter.org/). Any additional documentation (e.g., explanatory texts) should be put in the same zip folder.\nPlease attach a readme.txt file describing the steps of running the code, input data, and the expected results. You can find a step-by-step example of such configuration in the [README.txt file](https://github.com/seokjae6289/ML_Challenge_2.0_Clinical#readme). It will be used on your code to make sure if the code is properly working.\nAlso, make sure that your input data has the same format as the one uploaded by KAIST team. \nAdding the correct data structure is an important step for code reviewers to evaluate your code. \n\n### Common errors and tips\n\n### Importing the data package\n#### Example of Code for Importing the data package \n \n`import pandas as pd  # for data preprocessing and read csv text file pd.read_csv(\"C:/Users/username/filepath/file_name.csv\"`,\n#### Example of Code for Reading the data package\n`inputdata = pd.read_csv(\"C:/Users/username/filepath/file_name.csv\")`,\n#### Example of Code for Slicing the data package\n`inputdata = inputdata[:4]`,\n#### Example of Code for Slicing the data package\n`inputdata1 = inputdata[\"patient_id\"]`\nYou can find an example of Python codes in the [README.txt file](https://github.com/seokjae6289/ML_Challenge_2.0_Clinical#readme). \n\n### Expected result\n \n* Please print `A 54-year-old obese woman admitted to the emergency department",
        "label": 0
    },
    "1036": {
        "output": "## Evaluation\n\n### Input:\n(1) 3 clinical trial documents.\n(2) 1 patient note.\n\n### Output:\n(1) 3 Trial-level eligibility.\n(1) 1 Trial-level eligibility.\n(1) 2 Trial-level eligibility.\n(2) 1 Trial-level eligibility.\n\n### Expected output:\nPatient Note -> Include/Exclude/Not relevant 1. \nClinical Trial -> 2. \nPatient Note -> Include/Exclude/Not relevant 2.\nClinical Trial -> 3.\nPatient Note -> Include/Exclude/Not relevant 3.\nClinical Trial ->\n\n### Result\n\n\n### Constructing the code for patient data input:\nAdd the following code to the function CreatePatientData.\n\n```cpp\nstd::string patient_note = \"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\";\n```\n\n### Constructing the functions to assign values:",
        "label": 0
    },
    "1037": {
        "output": "# Data\n## Input Data\n- Data Dictionary [http://stat-www.stanford.edu/~mcda/courses/CIDC166-Winter2014/Data.pdf]\n- Include 5 files, i.e., P11A, P11B, P11C, P11D, and P11E.\n- Please keep the folder name of each patient unique between different persons.\n- Please note that Cases1 and Cases2 use data from the same data dictionary. However, they have different patient IDs in the folder names.\n\n## Output \nA. Trial-level eligibility:\n\n  0\n   \n   \n    2\n  \n  \n\n## C. Treatment code:\n\n   1415\n   \n   61453\n   \n   61423\n   \n  \n\n## D. Trial code:\n\n   1\n   \n   \n     1\n    \n   \n      11\n     \n   \n   \n     11\n     \n   \n   \n   \n   \n   \n     12\n   \n   \n    0\n   \n   \n   \n     13\n     \n   \n   \n   \n   \n    20130509\n  \n  <EOD> Disseminated histoplasmosis in systemic lupus erythematosus treated with prednisolone\nAn 35-year-old woman was hospitalized in 1984 with acute onset of weakness, fatigue, anasarca, and generalized maculopapular skin rash. Laboratory findings demonstrated high WBC counts (38,000 with 93% polymorphonuclear cells), hypocomplementemia (C3 0.4 g/l), anaemia (haematocrit 0.18), proteinuria (3.0 g/day), and leucopenia (WBC: 0.7 x 10/1). Immunological assessment showed anti-dsDNA antibody (IFI-anti-DNA1-5, 6:1:256) and reduced levels of complement components C3 and C4 (0.4 g/",
        "label": 0
    },
    "1038": {
        "output": "##[END]\n<EOD> Protist diversity in the benthic eukaryotic component of a tidal rocky intertidal area from the southeast Brazilian coast.\nThe Brazilian coast displays great biodiversity and its diversity is one of the most diverse throughout the Brazilian territory. The coastal zone is under heavy environmental pressure, mainly attributed to the intense anthropogenic pressure on the coast due to urbanization, industrialization and the development of tourism. The coast of Paranagu\u00e1, in the Paran\u00e1 State (Brazil), has suffered the same pressure. Here, we used DNA sequences of environmental samples to describe the composition and diversity of the dominant protist groups in sediments from a tidal rocky intertidal area in Paranagu\u00e1 (north of the state of Paran\u00e1, Brazil). Sediments were collected monthly, between November 2016 and May 2017, at three different microhabitats (under macroalgae, between rocks, bare substrate) along the intertidal elevational gradient (low, mid and high). Sequences obtained from three different markers (SSU, LKM1373, KOIPO-1) were compared with deposited sequences in the GenBank database. A total of 134,240 sequences were analyzed and 127,301 sequences were assigned to at least one functional group (SSU), 106,042 sequences were assigned to the ciliates clade (LKM1373), and 54,533 (KOIPO-1). There were no significant differences regarding the frequency of each marker within the sediment core, and the relative abundance of each marker followed a seasonality pattern along the intertidal transect, being more abundant in November and February. The most abundant groups were metazoans (68%), ciliates (54%), microalgae and fungi (5.4%), followed by Cercozoa (5%), amoebozoans (4%), Chlorophyceae (3%), and Apusozoa (1%). Our results, obtained based on DNA extraction, demonstrated a high frequency of metazoans, as a result of the dominant macroinvertebrate species",
        "label": 0
    },
    "1039": {
        "output": "[[TASK]]\n\n\n# Task 2\nIn this task, you should firstly analyze the patient and then assess the eligibility. This eligibility assessment is a clinical judgment.\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nHere is the eligibility assessment template of the study, with the inclusion and exclusion criteria:\nExclusion criteria: Exclusion Criteria: Pregnant females, Women younger than 18 years old, Patients with HIV antibody positive, Patients with hepatic disability or renal disability, Patients under chronic use of H2 blockers, Patients under chronic use of steroids and patients under heparin during the test.\nThe patient can enroll in clinical trial with the condition that she have any one of the following conditions:\n1) HIV test: she is a woman older than 18 years old 2) Age: between 18 - 65 years old. 3) Sexually transmitted diseases, i.e., she has a history of sexually transmitted diseases or if it",
        "label": 0
    },
    "1040": {
        "output": "## Expository-style answer example\n* **Hello.** You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\n**A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting.** **The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs.** **She has 2 children, and she is menopausal.** **She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress.** **On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.**\nHere is the clinical trial:\nTitle: Randomized Study Evaluating the Role of Surgeon-Performed Ultrasound in the Management of the Ac",
        "label": 0
    },
    "1041": {
        "output": "[EXPORT]\nIf you want to export all your results including the patient notes as a CSV file by using a file name <YOUR_INPUT_FILENAME>, the following code segment will work. Just uncomment all your `print` lines in the following code block and uncomment `print` line at the end:\n\n[CSV]\nprint(f\"ID: {name}, Gender: {gender}, Eligible\")\nprint(f\"Trial-level Eligibility: {triallevel_eligibilities}, Patient-level Eligibility:\")\nprint(f\"0: {1_excluded}, 1: {2_not_relevant}, 2: {2_eligible}\")\nprint(f\"{_name}\", \"Gender: Male, Eligible\", \"\")\nimport re\n\n\ndef find_elements(text):\n    \"\"\"\n    This function finds and replaces text (re.regex) in a given regular string by the other string.\n\n    Args:\n        text: A string in which you want to replace text (e.g. 1_excluded to 0_eligible).\n        replacements: a dict consisting of the element in the regular expression and the replacement word.\n\n    Returns:\n        text: A text after you replace text with other words in the regular string.\n    \"\"\"\n    text = text.rsplit(r'([%s]?: )?)', 1)[0]\n    _match = re.match(r'([%s]?: )?(?P<patient_level_eligibility>[%s])', text)\n    if _match:\n        patient_level_eligibility = ''\n\n        for key, value in _match.groupdict().items():\n            for item in value:\n                if item == key:\n                    patient_level_eligibility = item\n\n        index_of_number = 2\n        number = ''\n        for item in f'1_excluded {2_not_relevant {2_eligible}'\n        : index_of_number += len(item.split())\n        number = f'{_match.group(1)}_{_match.group(1).replace(\":\", \"\").replace(\"",
        "label": 0
    },
    "1042": {
        "output": "Note that we defined the variables in italic. `Trial-level eligibility` and `Eligibility` are variables for the clinical trial and the patient (as you know, the `Patient` is a collection, so we cannot determine a value for it). Because variables are defined before the patient assessment code starts running, all the patients have the same value for the variables that were defined beforehand, e.g., all the patients have the same trial-level eligibility of 2. This allows us to define some variables just once, e.g., `trial_type` may be a variable of the clinical trial, so that each clinical trial is characterised by a certain value for it. This is an important feature of clinical trial protocols to achieve reusability.\n\nNext, we will write the `patient assessment code`, which will calculate the eligibility of the given patient. First, we will define the inclusion criteria using the `AND` operator to form `eligib_criteria` variable.\nAs you see, we need to be as precise as possible in our definition of the inclusion criteria (e.g., we are precise if we need to exclude patients with NVDs, which means we exclude patients with 0 NVD in `eligib_criteria`, if they have 1 or more). If we can, we should also avoid redundancy. If the criteria `type of cancer: Brain tumor` and `radiation therapy: Yes` are redundant, we should omit the latter.\n\n    if_or_else(eligib_criteria,\n        [((has_disease(\"glioma\") or has_disease(\"glioneuronal tumor\")) and has_disease(\"non-metastatic cancer\") and has_disease(\"carcinoid tumor\") and radiotherapy__radiation_therapy__is_not(\"No\") and radiotherapy__radiation_therapy__is_not(\"Yes\") and radiation_therapy__radiation_therapy__is_not(\"External beam radiation therapy\")),\n            { \n               eligib_criteria = eligib_criteria + \"Radiation_therapy\"\n            }\n        ],\n        { \n            eligib_criteria = eligib",
        "label": 0
    },
    "1043": {
        "output": "# Discussion\n\n## Use case: Diagnosing a respiratory disease\n\n[CX] When I got sick last month, I had asthma! It's the first time I've had an attack since I was seven years old. I've been to the hospital and now I'm discharged. The doctor prescribed my treatment. I think that I will be okay.\n[/CX]\n\nAfter 20 minutes, you should predict the class label by making a prediction of the class label based on your input and your model. \n```python\n## The first and second columns represent the input and prediction of the model, respectively.\n## The model's prediction is the third and last column. \ninput1['Bronchitis']\n['Bronchitis']\n['COPD']\n['Bronchitis']\n['Silicotic Nodule']\n['Pneumothorax']\n['Bronchitis']\n['Bronchitis']\n['COPD']\n['Bronchitis']\n['COPD']\n['COPD']\n['Bronchitis']\n['Bronchitis']\n['COPD']\n['Silicotic Nodule']\n['Bronchitis']\n['Bronchitis']\n['Bronchitis']\n['COPD']\n['Silicotic Nodule']\n['Bronchitis']\n['COPD']\n['Bronchitis']\n['COPD']\n['Pneumothorax']\n['Bronchitis']\n['COPD']\n['Pneumonia']\n['Bronchitis']\n['Bronchitis']\n['Bronchitis']\n['Bronchitis']\n['Bronchitis']\n['Silicotic Nodule']\n['Bronchitis']\n['COPD']\n['Bronchitis']\n['Bronchitis']\n['Pneumonia']\n['COPD']\n['COPD']\n['Bronchitis']\n```\n\n### Input data\n\n- One input contains a matrix of 846 rows and 10 columns, where the column named as `image` is an image in the PNG format and the other nine columns are features.\n- The features described in [table data](https",
        "label": 0
    },
    "1044": {
        "output": "```{r}\n# Exclude 1. Patient note\n\npatient_note <- \"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago\"\npatient_note <- paste(\"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago\",\n\" with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food.\", \"The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs.\");  # [/MEDIUM]\npatient_note <- paste(\" A 54-year-old obese woman admitted to the emergency department with abdominal pain that started\",\n\" 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food.\",\n\"The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs.  She has 2 children, is menopausal, does not smoke, drink alcohol, or use illicit drugs.\");\n\npatient_note <- paste(\"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started\",\n\" 4 days ago",
        "label": 0
    },
    "1045": {
        "output": "<EOD> Effect of different surface coatings on survival of Salmonella typhimurium on fresh-cut cantaloupe using chitosan-coated plastics as food contact materials\nChitosan coating of polypropylene (PP) and polyethylene terephthalate (PET) plastics has been well known as a suitable and alternative replacement for synthetic compounds. Therefore, this study aimed to assess the effects of chitosan coating on reduction of survival of Salmonella typhimurium on fresh-cut cantaloupe during the storage. For coating of plastic bags, the PP and PET plastics were treated with chitosan solutions and dried at 45 \u00b0C in hot air oven. The antibacterial properties of chitosan-coated bags were evaluated by determination of the logarithm of colony-forming units (CFUs)/g inoculated cantaloupes. The effect of coated plastics was investigated as the interaction between plastic type and presence of coating and its time. Bacterial loading was significantly reduced in samples treated with chitosan-coated bags than uncoated bags. Bacterial inactivation in bag-treated samples was determined as time- and coating- and plastic-type dependent. Bacterial reduction was higher in coated PP than coated PET bags during the storage especially for PP. For the coated PP bags all the samples inoculated with 4 to 5 log10 CFU/g were significantly reduced (p\u2009<\u2009.05), even after 240 min. While chitosan-coated PET bags were more effective for the treatments with the inocula more than 4 log10 CFU/g. Therefore, chitosan-coated PP and PET plastics can be applied to reduce the microbial loads in packed foods to ensure of food safety and quality. Graphical Abstract<EOD> An immunoenzymatic microassay for the detection of anti-thyroglobulin autoantibodies in serum of patients with Graves' disease or Hashimoto's thyroiditis.\nA rapid immunoenzymatic microassay was developed for the detection of anti-thy",
        "label": 0
    },
    "1046": {
        "output": "---\n\n## [Question block] Please note that this question should be completed on its own, even if you are writing a program to do the task again. ANSWER [ENTER]\n\n<table class=\"question-box\"><TR><TD><STRONG><NAME></STRONG><BR>Prof. <NAME><BR>(1) Professor<BR></TD></TR></TABLE> \n<br><br>Your colleague noticed a pattern when filling the clinical history of the patients. That is, some variables are sometimes mislabeled. These variables include gender, diagnosis, and medication. Because of this, you decided to write a program aimed at detecting these variables, as well as their labels, and classify such patients as having \"unreliable\" or \"certainly relying variable\" labels to reduce the number of human errors.\n\nUsing the patient note and the assessment of eligibility as described earlier, classify the reliability of the given patient note according to the mentioned criteria. Label the note as certain if its reliability is not 'inconsistent'.\n(1) \n</STRONG>\n\n\n\nPlease answer the following questions (Q1, Q2, Q3, Q4)?\n\n## QUESTION 1: Do both sex and the diagnosis follow the patient medical record perfectly?\n(1) Yes\n(2) No\n(3) I do not know, please answer my next question.\n\n## QUESTION 2: Are the medications perfectly classified?\n(1) Yes\n(2) No\n(3) I do not know, please answer my next question.\n\n## QUESTION 3: Does this patient have an entry for unreliable label?\n(1) Yes\n(2) No\n(3) I do not know, please answer my next question.\n\n## QUESTION 4: Do the patient label, gender, diagnosis and medications exactly match?\n(1) Yes\n(2) No\n(3) I do not know, please answer my next question.\n\n## QUESTION 5: Do you have any comments?\n**If you answer `I do not know, please answer my next question` in any of the above questions, press `continue` to move to the next question. **.",
        "label": 0
    },
    "1047": {
        "output": "### Questionnaire 1 : Patient eligibility determination form\n[CIRIC] This questionnaire should be filled up by the physician who determined each patient's eligibility. It is recommended to use this questionnaire if you are working under a time pressure setting.\n\nFor each patient, the investigator will fill in the 'Documentation' section.\nEach questionnaire should produce a document as specified to the corresponding questionnaire. The default output format uses HTML.\nPlease check and edit the mark-up language of the document as it will not be reformated by this tool.\n[NOTE] If there are any errors when generating HTML version of the form, it would probably be caused by the fact that you don't have Python 3 installed yet in your system. Go to [Python download page] to find the latest stable version of Python.\n[/NOTE] \n[/CIRIC]\n\n### Questionnaire 2 : Patient questionnaire\n[CIRIC] This questionnaire should be filled out by the patient.\n\nAll possible answers are listed in the possible values section. If the field is of type Date, select one of date format (yyyymmdd or yyyymmth, where yyyy is four-digit year and mm or mo means month). \n\nA list is the same as a group. The answer options that are grouped are located inside the group and have a blank space between the group name and the group option. The other option group doesn't need",
        "label": 0
    },
    "1048": {
        "output": "### Exercise\n\nIn this exercise, you will repeat the steps that you have already learned from the above text and you will be asked to use the code by the given instructions.\n\n[Ex] Input a Patient file and make corresponding patient-level eligibility as follows.\n\n1. Read the patient_file and patient_notes that you have already created in the previous lesson.\n2. Read the clinical_trial from another file. Make a patient-level eligibility (P). Create a patient-level eligibility. Do not forget to print out P.\n\n```{python}\nclinical_trial = input(\"Enter The Clinical Trial Files (e.g., \"\n                       \"clinical_trial = file.abf, \"\n                       \"clinical_trial = \"\n                       \"file.bmi, \"\n                       \"clinical_trial = file.npi)\")\n\npatient_file = input(\"Enter The Patient Files (e.g., \"\n                     \"patient_file = \"\n                     \"file.patient.xml)\")\n\npatient_notes = input(\"Enter The Patient Note Files (e.g., \"\n                     \"patient_notes = \"\n                     \"file.patient.txt)\")\n```\n\n```\nP = patient_file + \"\\n\" + patient_notes\nprint(P)\n```\n\n[/Ex]\n\n\n### Exercise\n\nIn this exercise, you will repeat the steps that you have already learned from the above text and you will be asked to apply a Patient-level eligibility to a Clinical Trial.\n\n[Ex] Apply a Patient-level eligibility to a Clinical Trial.\n\n```{python}\nfor p in range(len(patient_file)):\n    print(patient_file[p] + \"\\n\")\n    for i in range(len(patient_file[p])):\n        if x = patient_file[p][i] == 1:\n            print(\"x=Patient-level eligibility: x==\",x)\n```\n\n[/Ex]\n<pre><code>PATIENT_LEVEL",
        "label": 0
    },
    "1049": {
        "output": "---\n**5.** The following table shows how to run the model training step by step.\nStep Instructions \n\n1) `import pickle` > Loads the pickle module (pickle_module.py)\n\n2) `pickle.load('pickle_module.pkl')` > Loads the trained pickle file into current model \n\n3) `pickle_module.load_model()` > Saves the pickle file as the model and export file name and path \n\n4) `pickle.dump()` > Saves a model into pickle file. \n\n\n> Note: Use a Python debugger like pdb.py to understand these scripts.\n\n---\n[INST]\nimport random\nimport numpy as np\nimport pickle as pic\nfrom timeit import default_timer as timer\ndef fit_XGB_classifier(X, y):\n    model = pic.load('Pickle_module.pickle') # Load the pre-saved model\n    model.steps == 4 # Sets the iteration to 4 (the training number of iterations)\n    model.optimizer = 'LBFGS(max_iter=4000)' # Optimizer name: 'LBFGS', max the number allowed \n    model.max_depth = 4 # Optimize the number of the tree branch depth\n    model.min_child_weight = 1 # Sets the minimum sum of the instance weights for the leaf node to split to no more than this value.\n    model.lambda_l1 = 0 # Sets the L1 regularization parameter to 0. The default of the XGBoost parameter\n    model.learning_rate = 0.1 # Sets the learning rate to 0.1\n    \n    model.n_jobs = -1 # Sets the number of jobs to be run in parallel\n    \n    # Initialize the model then trained the model using fit function\n    XGB_model = model.XGBClassifier()\n    XGB_model.fit(X, y)\n    return XGB_model\n\ndef Test_XGB_Classifier(X, y):\n    model = pic.load('Pickle_module.pickle') # Load the pre-saved model",
        "label": 0
    },
    "1050": {
        "output": "<EOD> Reader response: Epilepsy surgery in children and adults: More than meets the eye\nWe read with great interest the article of Englot et al.1 exploring the effect of age, epileptogenicity, and tumor location on seizure outcome, on which we would like to comment on both epilepsy surgery in children and the effects of medication on cognitive reserve.<EOD> Acquiring the tools to be active outdoors: outdoor play and learning experience in the pre-school age.\nAIM\nThe aim of this article is to discuss the pre-school children's outdoor playtime in today's society.\n\n\nBACKGROUND\nWith the recent advancement of technology, both adults and children are increasingly being encouraged to spend more time outdoors. Previous studies have examined outdoor play among pre-school children, but less attention has been paid to the play experiences in the outdoor environment and the value of outdoor play.\n\n\nISSUES\nOutdoor spaces in early childhood education allow active interaction in a physical setting with the surrounding environment. The outdoor environment provides opportunities for engagement in a range of activities to support exploration, problem-solving, and mastery. Research has addressed the value of outdoor play for child development and learning; however, little is known about the significance of outdoor play experience.\n\n\nCONCLUSION\nChildren should have the opportunity to develop the skills that allow them to be independently active and to promote outdoor exploration.\n\n\nIMPLICATIONS FOR NURSING MANAGEMENT\nEarly childhood educators should encourage children to spend time in the outdoors with play opportunities being provided before outdoor playtime. Nurse managers should support the use of outdoor spaces that encourage active play and learning.<EOD> Ocular-muscle activity in Parkinsonian patients: EEG analysis and EMG-based compensation algorithm as a treatment strategy\nWe analyzed ocular-muscle activity in 12 patients with Parkinson's disease (PD) and 16 normal healthy subjects (HS). Eye movements evoked by visual stimuli had two distinct effects in both HS and PD patients. One effect is a slow reduction of the steady-state potential (SSP) between the start and the end",
        "label": 0
    },
    "1051": {
        "output": "[INST] This part is optional. Here is another trial note. \nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n[INST] Based on the patient note and the trial note, we prepare a trial note that shows eligibility (in the last line).  \n```\nTitle: To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia\n        Abstract: An observational single arm trial to verify the efficacy of Z-338 that will be tested in subjects with Functional Dyspepsia, focusing on the assessment of subjective symptoms.\n        Introduction: Functional dyspepsia is a chronic medical condition characterized by meal-induced epigastric pain, postprandial fullness and early satiety due to a gastric motility abnormality with little tendency of structural abnormalities seen in the esophagus and duodenum. It is a common clinical problem seen in gastroenterological clinical practice, and its prevalence is 8-36% depending on the population. Z-338 is",
        "label": 0
    },
    "1052": {
        "output": "## Questions about Clinical Trial Recruitment\nFor further details, please use ICD 11 and NLMs standardized vocabulary from the MeSH database.\nWhen reading or writing the note always use a standardized structure.\n\n# Discussion\n\n## What is a clinical study?\nA clinical study is a scientific investigation to measure the effects of medicines and determine whether new medicines or treatments, including medical devices, work in people who have a specific disease or condition.\n\n## What purpose does a clinical study serve?\nThe purpose of clinical studies is to discover the effects of drugs and medical products. Drug development is risky. Therefore, the drugs and medical products are tested in small studies to see if they work as planned. Clinical research is the largest part of an individual's treatment or care plan.\n\n## What is the process to get medical products to patients?\nThe process is complicated and complicated. Before medicines and medical products that you take can be distributed to you or your child, a lot of work is required. First, scientists and medical doctors have to look at data from people who have received the medication and medical device being tested in a clinical study. In a clinical study, medication or medical devices are tracked to make sure that they work properly and are safe.\n\n## Where can clinical studies be located?\nClinical studies can be found in hospitals and clinics that allow access to treatment under federal and state law. These places are called clinical research units. The FDA and NIH (National Institutes of Health) have websites with information about clinical studies.\n\n## What happens in a clinical study?\nIn a clinical study, scientists and medical doctors try to find new information and medication or medical devices that can benefit people who use the medication or medical device. To be in a clinical study, you must meet the enrollment criteria. The enrollment criteria are the rules that determine who can be enrolled in a clinical study. The information about a medication, medical device, and a clinical study is always on a leaflet or sheet of paper.\n\n## Do I have to pay to take part in a clinical study?\nYou do not pay for a clinical study. Instead, you may receive something from the",
        "label": 0
    },
    "1053": {
        "output": "\u00a9 2016-2020 <NAME>. All Rights Reserved.\n<EOD> Involvement of the endogenous cannabinoid system in the modulation of pain: implications for the pharmacotherapy of pain.\nThe endogenous cannabinoid system (ECS) is an evolutionarily conserved, neurotransmitter/neuromodulator that controls the transmission of sensory information from the periphery to the central nervous system (CNS). The ECS consists of the cannabinoid ligand, receptors, transporters as well as anandamide metabolizing enzymes. The most important functional cannabinoid receptors in mammals are cannabinoid (CB) receptors 1 and 2. Pharmacologically, different cannabinoid drugs can activate or inhibit the CB1 and/or CB2 receptor. The CB1 receptor is predominantly located in the brain and especially in the central nervous system. The CB2 receptor, the major receptor that may be upregulated upon peripheral inflammation, is primarily expressed peripherally in the immune system. Anandamide is the first endogenous ligand to be associated with the CB receptors. The enzyme fatty acid amide hydrolase (FAAH) hydrolyzes anandamide and also inactivates the more stable synthetic cannabinoid receptor ligand N-arachidonoyl pentadecane-amine (NADA).<EOD> A comprehensive analysis of the effects of inhalation exposure to 1,3-dichloropropene, an agricultural fumigant, on male reproductive toxicity to rats by using sperm and metabolite toxicity and histopathological methods\n\nIn this study, the effects of fumigant 1,3-dichloropropene (1,3-DCP) on reproductive toxicity were investigated in male rats by using sperm and metabolite toxicity and histopathological methods. A total of 24 adult Wistar albino rats (12 males and 12 females) were randomly divided into control and experimental groups.",
        "label": 2
    },
    "1054": {
        "output": "[END]<EOD> Theoretical study of structure and electronic properties of 3d-metal doped MoS\u2082.\nFirst principles methods have been used to investigate structural and electronic properties of MoS(2) and the most stable doped structures (V(d)(1), Cr(d)(1/2) and Mn(d)(1/2)). The doped systems were investigated by using the hybrid functional B3PW91 and compared with experimental results. We found that the replacement of S by O, F and OH, increases the energy required to remove an electron from the doped system. Thus, this result indicates that O-doped systems might be a better semiconducting material than those doped with sulphur. This was suggested by the change in the band position and the semiconducting feature of the dopants studied here.<EOD> Genome-wide genetic architecture underlying omental body fat distribution using high-density imputed SNP markers in European Holstein cows.\nThe objective of this study was to identify regions of the genome affecting omental body fat distribution and milk somatic cell score (MCS) for the purpose of improving selection for fat metabolism in dairy cattle. To this end, genotype data of 647,460 autosomal SNP markers derived from a genotypic chip were available from 2,106 genotyped Holstein cows and 2,067 genotyped bulls, respectively. In the first step, the heritabilities and the correlations of the omental percentage (OP) and the MCS were investigated; in the second step, the bivariate genome-wide association studies were carried out. The results showed that the OP was moderately heritable with an estimated heritability of h\u00b2 = 0.25 (p <1.0 \u00d7 10\u207b\u00b9\u00b9). The MCS had a poorly heritable trait with a relatively low estimated heritability of h\u00b2 = 0.04. A genetic correlation between OP and MCS was determined (r(g) = 0.20). A genome-wide association study was performed to identify genomic regions affecting OP and the MCS. Based on a multibreed mixed-model approach using the ISA-",
        "label": 0
    },
    "1055": {
        "output": "Note: For details about the process of data manipulation, please check the tutorial `How to do Data Manipulaion?`.\n\n# Results\n<EOD> Effect of intra-operative irrigating fluids on the formation of adhesions: a systematic review and meta-analysis of prospective randomized controlled trials\n\nIntroduction:The aim of this review was to determine with a quantitative approach, the effect on adhesion formation of intraoperative irrigating solutions, in comparison with intra-abdominal normosaline (NS) or lactated Ringer's solution. Methods: The review was carried out between April and July 2010 on 5 databases (Cochrane, Medline, CINHAL, Web of Science and EMBASE) and reference lists of included studies. A meta-analysis using RevMan5 was used. Results: Eight prospective randomized controlled trials (n = 336 animals) were included. NS significantly increased the formation of adhesions in the small intestine (odds ratio, OR (95% confidence intervals, 95% CI): 1.95 (1.21 to 3.15)), liver (OR: 2.74 (1.00 to 7.48)), and uterus (OR: 2.76 (1.83 to 4.19)). Gum-saline significantly reduced adhesion formation in the entire peritoneal cavity (OR: 0.21 (0.10 to 0.47)), small intestine (OR: 0.18 (0.07 to 0.49)), liver (OR: 0.42 (0.24 to 0.74)), kidney (OR: 0.37 (0.16 to 0.86)), uterus (OR: 0.24 (0.07 to 0.80)) and mesothelium (OR: 0.27 (0.15 to 0.51)). Conclusions: Intra-operative irrigation with gum-saline significantly reduces adhesion formation in the entire peritoneal cavity, small intestine, liver, kidney,",
        "label": 0
    },
    "1056": {
        "output": "[C050] Your task is to help in choosing the best way to manage acute respiratory infections. In acute respiratory infection, the symptoms are fever, cough, runny or stuffy nose, sore throat, muscle aches, fatigue, and headache.\n\nChoose what method of treatment is best: Antibiotics, Oxygen therapy, Both are the same, We need to take medicine and go to the hospital, Injection, None of the above. \n\n[C051] You are a helpful young woman who wants to know what the most common method of treatment is for tinea is.\n\nChoose the most common method of treatment: Oral Antifungals, Topical Antifungals, Other methods, Pills, None of the above.\n\n[C052] You are a helpful young man who wants to know who is more likely to get acne as a result of diet. Diet can affect various skin problems, acne is one of them.\n\nChoose who is more likely to get acne after diet: Males, Females, Both males and females, Other factors, Previous studies say that high glycemic index diets are associated with increased risk of acne development. \n\n[C053] You are a helpful young man who want to know which are the risk factors for acquisition of chlamydia. Chlamydia is a sexually transmitted disease caused by a bacterium infection that usually infects a woman's uterus and fallopian tubes.\n\nChoose which are the riskfactors associated with chlamydia: None of the above, Unclean sex toys, Being sexually active, Using oral contraceptive pills, Using tobacco products. \n\n[C054] You are a helpful young woman who want to know which are the riskfactors to be infected with herpes. Herpes is a sexually transmitted disease caused by viruses-the herpes simplex virus (HSV-1 and HSV-2). Genital herpes is transmitted through skin-to-skin contact with a person who has a sore or blister from a herpes infection or with a person's saliva.\n\nCho",
        "label": 0
    },
    "1057": {
        "output": "* 10. Assess eligibility and record the results \nIf you get to your code's `assess eligibility` function, run it on 'test_records.' Like for our 'evaluate the best response' function, you can specify 'test_records' from the `evaluate the best response` function (see also the comment of that function), which will include an object called `eligible` that is a list of the trial-level assessments.\nIf the function returns `true`, the patient passes the inclusion criteria and your software package has determined that the patient should be able to participate in the trial. If you run all 290 patients' assessment results on `evaluate the best response (test_records, 'assess eligibility', 'Patient name, age, and sex)`:\n\nIt will give you information about whether each patient met the inclusion criteria.\n[HINT] The input and output functions that you will write here are called the functions for evaluating the best response. This is because they decide whether to progress to the next block or whether to return back to the starting block for an earlier assessment of the patient's eligibility.\n* 11. If eligible, generate and record a unique identifier (i.e., a patient ID), then go to Step 1 \nOn the list of `eligible` objects, find the unique IDs for patients who pass the assessment. In this case, 88 patients who gave a unique ID number to each other. If required, you can add a function for this purpose. For REDCap, it is an automatic function when saving the patient records. But if you choose to make your own software package, you should create this function that can generate patient ID. Then, you can run this function on all eligible patients and include the ID into the trial record. If you want to create a patient ID, you can generate patients' unique ID before the trial recruitment like a patient ID:\n\nAssume that you have generated patient IDs for the eligible patients. So you have a list of IDs `assess eligible, ids = unique(list(for(i in unique(list(assess_eligible)))[[1]])[2]))` that identifies each eligible patient. You can then run the `save the records`",
        "label": 0
    },
    "1058": {
        "output": "Good luck on the challenge!\n<EOD> Nuclear structure and organization of DNA during meiosis in Drosophila melanogaster.\nTo study the changes which occur in the structure and organization of the chromatin during female meiosis and oogenesis we have prepared nuclei of different stages by microdissection from female Drosophila melanogaster and analysed them by conventional and molecular cytochemical techniques, electron microscopy and flow cytometry. The nuclei were then examined by immunocytochemistry for the presence of a modified version of a histamine-rich histidine protein which is an abundant nuclear component of the germline cells of Drosophila. Nuclei which contained many small euchromatin masses and a well defined 'chromocentre' did not react positively with this antiserum. The nuclei which contained only a small euchromatin mass and a 'chromocentrum' in the position corresponding to that found in interphase nuclei were positive in this test. The number of the euchromatin masses contained in these nuclei increased, and the chromocentrum (heterochromatin) decreased, at leptotene and then at diplotene when individual chromosomes first appear. The nuclei which showed 20 chromosome masses were positive by immunostaining. The number of euchromatin masses in the nuclei containing chromatid regions increased towards the end of pachytene and the nucleolar number decreased. Only a few non-centromeric regions of individual chromosomes became heterochromatized during metaphase I. DNA condense in the region of chromosome axes after meiotic prophase to form a ring during prometaphase. Nuclei with a nucleolus showed only three chromosome masses in a diffuse region of prometaphase. The number of the euchromatin masses in these nuclei increased to six to eight or more, and the chromosome axes became electron-dense but did not condense into a chromosomal mass. The chromosome axes which had condensed into chromosomes were always surrounded by a small amount of heterochromatin, while the pericentric heterochromatin of ring chromosome axes surrounded the euchromatin mass",
        "label": 0
    },
    "1059": {
        "output": "[CLEAR: ABOUT: INPUT: USER-INTERFACES/]<EOD> A new form of the anti-tumor drug S-1 is useful to maintain a normal circadian rhythm\nThe anti-tumor drug S-1 is used for the treatment of gastro-intestinal tract cancer. This drug is composed of sulfinpyrazone, 5-fluorouracil and oxazophosphorine. In mice, it was demonstrated that S-1 intake had a remarkable action for the maintenance of normal circadian rhythm, even under strong light conditions.<EOD> Prenatal alcohol exposure and the developing microbiome\n\nA B S T R A C TFetal alcohol spectrum disorder (FASD) is a neurodevelopmental disorder resulting from prenatal alcohol exposure (PAE). Although behavioral abnormalities are well established, other organ systems, such as digestive function, are also impacted. A growing body of evidence establishes that the microbiome is essential for normal intestinal development and metabolism. Here we review the developmental changes in the gastrointestinal tract of the fetus in utero and describe how these are altered by PAE. The plausible mechanisms and consequences of gut microbial dysbiosis in FASD are considered in human and animal models and include microbial metabolites, which may then affect brain development.\n\n# Introduction\nThe gut microbiome of the newborn infant is very different from that of the mother, but by 2 to 3 years of age, is similar to the composition of the mother's microbiome, in both number and diversity of microbes [bib_ref]  Diverse human intestinal bacteria synthesize and degrade choline, Maruo [/bib_ref]  [bib_ref]  Development of the human infant intestinal microbiota, Palmer [/bib_ref] . In a healthy state, fecal microbial communities are diverse and stable, suggesting a homeostatic interaction between the host and microbiota [bib_ref]  Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core..., Jalanka [/bib_ref] . Microbial metabolites such as short chain fatty acids (SCFAs) are an excellent example of the communication between",
        "label": 0
    },
    "1060": {
        "output": "## 552. Convolutional Neural Networks with Keras\nThe purpose of this practical is to provide a basic understanding of the structure of a Convolutional Neural Network (CNN) and its basic usage. It covers some of the essential features of neural networks and convolutional layers. In addition this practical will illustrate to the student the basics of the Keras deep learning framework based on TensorFlow as described in the Tutorial: [Tutorial](https://github.com/frankvanc/Tutorial_Keras).\n\n\n### Prerequisite knowledge\n\n\n#### General introduction\nNeural networks are a type of statistical learning model. A neural network (NN) is formed by a set of neurons which are connected using weights and biases. The input to the network is propagated layer by layer by combining the signals from the neurons in the preceding layer, resulting in an output. This process is further described in the following tutorials:\n\n - [Haykin Neural Network](https://github.com/frankvanc/Haykin-Neural-Network)\n - [Tutorial: Sequential Neural Network](https://github.com/frankvanc/Tutorial_Keras/tree/master/Sequential_Neural_Network)\n\n[![Learning Level](https://learning.docs.microsoft.com/.image-center/thinkstorm/learning_level/medium_filled.svg)](https://learning.docs.microsoft.com/en-us/cognitive-services/connectors-reference/azure-document-repository/devtrees/docq?branch=master&blob=master/learning/devtrees .svg)\n\n\n\nA neural network is a statistical learning models which is formed by a set of neurons which are connected using weights and biases. A neural network  (NN) is formed by a set of neurons which are connected using weights and biases. The input to the network is propagated layer by layer by combining the signals from the neurons in the preceding layer, resulting in an output.\n\n[![Learning Level](https://learning.docs.microsoft.com/.image-center/thinkstorm/learning_level/medium_filled.svg)](https://learning.docs.microsoft.com/en-us/cognitive-services/connect",
        "label": 0
    },
    "1061": {
        "output": "__Directions__\n\n1. Copy and paste this R code into a file and save it as _[your name]-Trial-Assessment-Eligibility__:\n```R\n# [your name]\n\n# [Clinical Trial]\nstudy(\"Pancreaticobiliary Reflux in Patients Without Cholelithiasis\")\n\n\n## # Include only subjects over 15\nif(age > 15) {\n  trial_id <- \"TC_000002094\"\n  trial_id <- \"TC_000004805\"\n  trial_id <- \"TC_000006304\"\n  trial_id <- \"TC_000006552\"\n  trial_id <- \"TC_000004444\"\n  trial_id <- \"TC_000003663\"\n} # end if\n\n\n# ### ##1 Assess Trial-level\n\n# Assess trial eligibility using R.\n\n# [Clinical Trial]\n\n# ### ##2### Assess Trial-level\n\n# Assess trial eligibility using R.\n\n\n## trial_id <- \"TC_000002094\" ## [0=excluded,1=eligble,2=not relevant]\n\n# For patients whose age greater than 15\n\n# To be excluded for a trial:\ntrial_level_eligibility %>%\n  mutate(eligible = 0 ) %>%\n  unite(patient_id = patients_id) %>%\n  pivot_wider(id_cols = c(\"patient_id\")) %>%\n  filter(!is.na(eligible)) %>%\n  mutate(eligibility = case_when(eligible == 1 ~ 1, eligible == 2 ~ 0)) %>%\n  ggplot() + # make a beautiful plot\n  aes(x = group, y = eligibility) +\n  geom_bar(stat=\"identity\",position=\"stacked\") +\n  scale_x_ Discrete(names=T) +\n  fac",
        "label": 0
    },
    "1062": {
        "output": "[fig]  .:[EN] Recruitment is a long process; it is both time-consuming and laborious. You spend your precious time at the recruitment table to encourage people to join the trial while the most important thing is to evaluate their eligibility. Recruiting is not a trivial job; its quality depends on a clinical researcher's time and attitude. The time you spend with a subject is like a relationship. Do not waste it. [/EN] [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your job is to determine the patient's eligibility to join a clinical trial in a few steps. Your task is as follows: [/fig] \n<EOD> Ancient Chinese Medicine: Unraveling Its History and Its Place in Today's World.\nBackground\nBecause of the ever-growing concern about health issues, the use of different complementary therapies has increased. One of these therapeutics is traditional Chinese medicine (TCM). This form of traditional therapy originated thousands of years ago and has been handed down through generations, forming what is now known as 'TCM'. Although practiced in the East for more than 5000 years, TCM is only recently becoming a commonly accepted system of health care in the rest of the world. The purpose of this review is to present an overview of TCM and the different therapeutic herbs used.\n\n\nMethods\nTwo databases were used to research TCM: Medline and Medscape. These websites were used in combination to provide a summary of TCM origin, history, use, and advantages.\n\n\nResults\nAfter using these search engines, it was found that TCM comprises of several modalities that all work together to maintain general well-being. These modalities include acupuncture, herbal medicine, massage, and tai chi, all of which have been used for thousands of years. Each of these modalities is used to diagnose specific illnesses, depending on what a patient may be experiencing.\n\n\nConclusions\nTCM originated long ago in the Eastern part of the world but is now coming to the West, where we have the opportunity to better understand the different theories underlying TCM and how the body works. One of the aspects of TCM that has drawn a lot of attention is",
        "label": 0
    },
    "1063": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to check the patient notes for patients fulfilling the trial inclusion criteria: the acute coronary syndrome.\nInclusion criteria for the clinical trial:\n\n#### Inclusion criteria for acute coronary syndrome:\nBrief or persistent (minimum 20 minutes) symptomic chest pain on admission to hospital.\nAbnormal changes on ECG (e.g. ST-elevation of more than 1 mV or more than 2 mV in the frontal plane, or deep T-wave inversions, new onset of left bundle-branch block).\nHs-Troponin value > 1 ng/ml, values according to local laboratory reference values.\nIn our example, the symptom \"chest pain\" is not mentioned in the report. So you can put `0` for the criterium 'symptom acute coronary syndrome'. The first criterioni.e., ECG change - is mentioned. For the second criterion, Hs-Troponin value > 1 ng/ml, we add `1`. For the last three criteria, we add `0` since we did not find the information and we have to complete the information, the first three criteria. So, the output for assessment of eligibility for acute coronary syndrome is:\n\n## Exemplary solution to the assessment of eligibility for acute coronary syndrome\n\n### Patient note:\n33 years old man with fever, headache and chills on admission to the ER. He remembers a tick bite three days ago, but does not have erythema migrans, lymphadenopathy, arthralgia and myalgia. He is otherwise healthy. His past medical history is remarkable for prostate cancer, hypertension, hyperlipidaemia and TIA. He has no smoking habits and he is non-alcoholic. On physical examination, he is well oriented, eupneic and sighs when coughs.\nHis body temperature is 38.2\u00b0C, sinus tachycardia is present, and the rest of his physical examination",
        "label": 0
    },
    "1064": {
        "output": "---\n\n## DP7.6b Clinical trial participant\n\n##[INT] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to evaluate a patient as a potential clinical trial participant. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility on a patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\nHere is the clinical trial: \nTitle: Natural Orifice Translumenal Endoscopic Surgery: Laparoscopic-Assisted Transvaginal Cholecystectomy\n\n\nSummary: To determine the feasibility, safety, and efficacy of a novel minimally invasive approach to cholecystectomy and to establish a description of this novel translumenal technique in humans at this institution.",
        "label": 1
    },
    "1065": {
        "output": "If the patient has no or insufficient information for inclusion, the assessment is coded ` 0) Excluded`.\nIf the patient meets the inclusion criteria, then code ` 1) Eligible` as the output. When the trial-specific eligibility is coded as `Not relevant`, skip to the next patient. \nIn the patient note, type `0) Excluded` for the assessment of eligibility. \n\nNow, let's begin with clinical trial. \n\n1. [IN] Enter the name of the clinical trial.\n\nEnter the name of the clinical trial into blank 1. \n\n2. [?] How will you code the patient note for the assessment of eligibility for the clinical study when the patient satisfies the trial-specific inclusion criteria?\n  * * * `1) Not relevant` (Patient does not meet the inclusion criteria) \n\n\n\nThe patient note describes the 48-year-old nulliparous woman with obesity and hypercholesterolemia.\n\n`Let's begin to make the assessment of this patient for the clinical trial 'Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy.'\n\nFirst, we have to decide whether the patient meets the inclusion criteria of the trial to assess trial-specific eligibility.\n\nHere are the inclusion criteria:\n  * * * Men and premenopausal women with hypercholesterolemia who have undergone at least 6 months optimal diet and drug therapy and fit group A, B, or C.`\n\nAs the patient does meet the inclusion criteria, we code eligibility for the trial as * * * ` 1) Eligible`.\n\nNext, we have to check whether the patient is ineligible due to the exclusion criteria by trial number.\n\n\nAs the patient has no or insufficient information for inclusion, the assessment is coded * * * ` 0) Excluded`.\n\nIn the last line, repeat `Trial-level eligibility: 1)`` `1)`` as the trial in this patient's case is coded as * * * `1).`\n[/IN]",
        "label": 0
    },
    "1066": {
        "output": "#end_todo \n\n### Checklists\n\n- [Bug](../../_files/inst/bugs.md)\n\t\n\t\n- [New Feature](../../_files/inst/new-features.md)\n\t\n\t\n- [Reference](../../_files/inst/reference.md)\n\t\n\t\n- [Task](../../_files/inst/inst-task.md)\n\t\n\t\n- [Tool](../../_files/inst/inst-tool.md)\n\t\n\t\n- [Todo](../../_files/inst/todo.md)\n\t\n\t\n- [Update](../../_files/inst/update.md)\n\t\n\t<EOD> .\nThirty-six hypertensive patients (systolic blood pressure > or = 140 and/or diastolic blood pressure > or = 90 mmHg) and 12 normotensive controls entered into a 3-month study in which their blood pressure was measured with an automatic blood pressure monitor. Blood pressure was recorded three times daily at 07.00, 11.00, and 14.00 on 10 treatment days and on 10 days of \"no medication\" (placebo). In addition, each patient had to wear the pressure monitor all day during the 8 days preceding each recording day. The values obtained from the automatic monitor and by the study nurse were almost equal, except on the 10 treatment days, where there was a tendency towards overestimation by the monitor.<EOD> .\nThe current study analyzes the effects of phosphodiesterase inhibition (via rolipram) or beta-adrenoceptor-blockade (via metoprolol) on the sympathetic response to acute mental stress. Heart rate and blood pressure changes were measured in 15 patients in 4 conditions: placebo alone or in combination with rolipram or metoprolol. All conditions were randomly repeated 7 days later. The effects of rolipram on response to mental stress were studied in 13 further patients. The mental-stress test was carried out with a computerized mathematical test during electrophysiological measurement of skin sympathetic nerve activity to assess the central effects. Heart rate, blood pressure and skin sympathetic activity responses to mental",
        "label": 0
    },
    "1067": {
        "output": "A: import sys, json, io, math\n\ndef read_json(file):\n    global json_str\n    with open(\"json_data/json_for_dummy_data.json\") as json file:\n        json_str = json.load(json file)\n\ndef calculate_sum(test):\n    global sum\n    print(sum, sum += \" sum in set: \", test)\n\nclass Calculator(object):\n    \"\"\"A little class to get some practice\"\"\"\n    def print_all(self):\n        \"\"\"print out data from object\"\"\"\n        for key, value in self.data.iteritems():\n            print(\"%s\" % key, \"(%s)\" % value)\n\n    def main(self):\n        \"\"\"print test\"\"\"\n        for key, value in self.data.iteritems():\n            print(self.data[key]),\n\ndef set_json_file_content():\n    set_str = \"\"\"\n[{\n  \"category\": \"data\",\n  \"items\":\n    [\n      {\n        \"count\": 0,\n        \"description\": \"None\"\n      },\n      {\n        \"description\": \"None\",\n        \"group\": \"data\",\n        \"name\": \"count\",\n        \"typeHintName\": \"count\",\n        \"value\": 0\n      },\n      {\n        \"description\": \"None\",\n        \"group\": \"data\", \"name\": \"description\",\n        \"typeHintName\": \"description\",\n        \"value\": \"None\"\n      },\n      {\n        \"description\": \"None\",\n        \"group\": \"data\", \"name\": \"group\",\n        \"typeHintName\": \"group\",\n        \"value\": \"data\"\n      },\n      {\n        \"description\": \"None\",\n        \"group\": \"data\", \"name\": \"name\",\n        \"typeHintName\": \"name\",\n        \"value\": \"count\"\n      },\n      {\n        \"description\": \"None\",\n        \"group\": \"data\", \"name\": \"typeHintName\",\n        \"typeHintName\": \"value\",\n        \"value\": 1\n      },\n      {\n        \"description\": \"None\",\n        \"group\": \"data\",",
        "label": 0
    },
    "1068": {
        "output": "## #4. SPEECH_TRANSCRIBER - You have a window with three buttons: Start Recording, Record Audio from the microphone, and Stop Recording. Recordings are stored in the internal clipboard, which can be easily accessed when you want.\nTo begin: Click on the button 'Start Recording'. Type your message by clicking the 'I'm Speaking button'. You will hear the message to be typed out. Click on the 'Stop Recording' button to stop recording when you are done.\n\n## After you finish recording, you are going to send your message to Telegram.\n5. To send the message you can press \u00absend\u00bb button in the main window or double tap the clipboard content on the list. A new window named \u00abMessages\u00bb opens on the screen. This is your message to the doctor. You must replace <patient",
        "label": 0
    },
    "1069": {
        "output": "[[inst]\nInput:\n<patient_note>\n1. In the first row, you should extract the following information (bold is what is important): CENTER, SITE_ID, ROLE, AND_RSI, CLINICAL_TRIAL_ID_AND_SITE, REFER_FROM, STATUS, AGE, GENDER, BIRTHDATE, INCLUSION\n1a. CENTER, which is the code of the trial center; as we have 1 center here, this is 1.\n1b. SITE_ID, which is the code of the recruiting site; as we have 1 site here, this is 1.\n1c. ROLE, which refers to \"Who is this patient\"; as we know the trial is clinical and the patient is the clinical trial participant, this is 1.\n1d. AND_RSI, which is the reason why a participant cannot enter a trial; as this is 0, this is 1.\n1e. CLINICAL_TRIAL_ID_AND_SITE, which is the code for the trial; as this code is 1 and the site is 1, the trial is at 1 site, so this is 1.\n1f. REFER_FROM, which has 2 options: \"NONE\" (not relevant because we have a full note) and \"TRIAL\"; as this the trial code, so this is 1.\n1g. STATUS, which refers to the inclusion condition; we do not need to put STATUS because we want all of 1, 0, and \"Not relevant\".\n1h. AGE, which is age; we do not need to put AGE because we want all of 1, 0, and \"Not relevant\".\n1i. GENDER, which refers to the sex; we do not need to put GENDER because we want all of 1, 0, and \"Not relevant\".\n1j. BIRTHDATE, which is birth date; we do not need to put BIRTHDATE because we want all of 1, 0, and \"Not relevant\".\n1k. INCLUSION, which refers to the inclusion conditions; as our note is sufficient, we will",
        "label": 0
    },
    "1070": {
        "output": "*\n<EOD> Characteristics of the antigen inducing the primary humoral response in HIV-1 subtype G infection\nThe majority of HIV-1 subtype G strains express a 100-kilodalton p24 antigen, and strains expressing the full 160-kDa p55 gag polyprotein are rare. To determine the significance of this antigenic variation for the virus, we compared the humoral response after primary infection in HIV-1 subtype G-infected individuals with that after subtype B infection. The humoral response to the 160-kDa p55 gag polyprotein in HIV-1 subtype G-infected patients appeared to be weaker, while the response to p24 was comparable to that in subtype B-infected patients. This finding is consistent with the fact that most subtype G strains express little of (if any) p55 gag. We conclude that the primary anti-p24 antibody response is independent of the immunogenic profile of the virus.<EOD> 143\u2003Ontogeny and Phenotypic Switching as Contributions to Inhaled Eosinophilic Airway Diseases\n\nBackground: Recent studies demonstrated a role for the lipid inflammatory mediator, lysophosphatidylcholine (LPC), in several diseases that are also hallmarks of obesity. Methods: Wild-type (WT) and obese leptin receptor deficient ob/ob mice were challenged with phospholipase A2 (PLA2) for 4 days. BALF was recovered and total cells, eosinophils, airway epithelial damage, mucin production and pro-inflammatory cytokine release were examined. Results: Dramatic increases in airway lumenal damage as measured by the activity of the epithelial cell death marker LDH and MUC5AC staining were seen in ob/ob mice compared to WT mice both before and after PLA2 treatment. The increase in LDH was inhibited by an A2B adenosine receptor antagonist and an IL-27 inhib",
        "label": 0
    },
    "1071": {
        "output": "Good bye. I hope you have learned something.\n[/EVALU(Evaluation,Evaluation)][/END]\n[/TRAIN_NOTE(Trial,Note)]\n\n# References & Acknowledgments\nThe contents of this chapter are based on Dr. H. Zhang's public-domain and original works. See references and acknowledgments for more information.<EOD> A case of necrotizing sialometaplasia of the palate\n\nNecrotizing sialometaplasia (NS) is a rare inflammatory, benign, and self-limiting mucogingival lesion and affects patients of all ages. While NS often appears clinically similar to other inflammatory pathologies, the diagnosis of NS is rarely made during treatment and in most cases is only confirmed after definitive excisional procedure. The purpose of this communication is to describe a NS of the palate that exhibited a rapid progression during 15 days in a 58-year-old women patient and required the surgical intervention in no more than 3 h since the consultation. A brief description of some clinical and microbiological aspects of NS is discussed as well as recommendations are proposed with the aim to avoid misdiagnosis and wrong treatment of this condition in order to avoid unnecessary biopsies and treatments in these patients.\n\n# Introduction\nNecrotizing sialometaplasia (NS) is a rare benign self-limiting inflammatory lesion which affects patients of all ages. It affects the oral mucosa, tongue, maxilla or mandible. The first report was given by [bib_ref]  A peculiar type of pyogenic granuloma; sialometaplasia, Seaton [/bib_ref] . [bib_ref]  A peculiar type of pyogenic granuloma; sialometaplasia, Seaton [/bib_ref]  It is characterized by severe pain with the rapid progression as swelling, ulceration, and necrosis followed by complete regression. A variety of clinical presentations have been described, varying from soft, indurated, and sometimes painful lesion, and it is generally confused with neoplastic diseases, although its characteristic is spontaneous detachment and complete resolution. [bib_ref]  Necrotizing s",
        "label": 0
    },
    "1072": {
        "output": "What is the output of the program?\n\nIt looks like this:\n```\n[42] Hello. Your task is to determine whether a patient qualifies for the trial.\n\n[43] Patient's eligibility assessment: [[2]Eligible], [[1]Not relevant], [[0]excluded].\n```\n\n# Authorship Information\n<EOD> Prevalence of Depressive Disorders in Patients With Multiple Sclerosis in a Tunisian Population: Diagnostic Consequences\nAbstract A cross-sectional, observational, clinic-based study of 133 consecutive patients with multiple sclerosis, in a clinic in Tunis, recruited consecutively over a period of a year, was conducted. A psychological assessment based on the Structured Clinical Interview included a diagnosis of depressive disorders (major, minor, and dysthymia). Patients were classified according to type of the disease according to Poser et al criteria: primary progressive (PP) and secondary progressive (SP). Of the 133 patients, 72 (55%) were women, and the mean age was 39 \u00b1 6 years. The prevalence of major depressive disorders was twice as high in women (23%) than in men (11.4%). The prevalence of major depressive disorders in the whole study population was 19.5%. It was much higher (100%) in the subgroup of depressed PP patients (n: 10). In SP patients, the prevalence of major depressive disorders was 8.1%. As primary progressive multiple sclerosis evolves rapidly under severe neurological disability, assessing the risk of depressive episodes and considering treatment should be particularly recommended.<EOD> Effect of an antihistamine on the skin blood flow of the feet in patients with rheumatoid arthritis.\nFeet are often affected in patients with rheumatoid arthritis (RA). Recently, several studies have indicated that RA patients have impaired skin microcirculation, and that skin blood flow improves after disease control. Since the skin is thin and the skin blood flow is relatively high, the feet are regarded as a good target organ",
        "label": 0
    },
    "1073": {
        "output": "### 5.6 Exercises to Practice\n\nYou may get a feeling that the last time, you completed this coding problem, and you will have no problems this time. But your brain is not working fast enough. So, a solution is to practice. \n\nFor each programming problem, there are many ways to build a solution that works. The following 4 links are based on the same coding question: (1) a programming problem from the Stanford Computer Science course taught by [Stanford professor][Stanford professor] <NAME> for beginners, (2) the [C Programming Wikibooks][wikibooks], (3) the [Fundamentals of the C Programming Language][c-program], and (4) the [MIT course on CS 100][CS100]. Take whichever one is your favorite. Remember that you have a solution.\n\nThink about how you would code the solution as you complete the problem\n\n1. Download the solution as a Java or C program.\n1. Type java.exe <filename> in the Command Prompt windows with your JAVA home directory specified in the Command Prompt or type java <filename> in the Windows \"run\" window with the `javavm` executable, e.g.: C:\\Program Files (x86)\\Java\\jre1.8.0_102.java <filename>\n1. Type gcc <filename><br>\n\n\n### 6 Discussion\n\n#### Why did we make a computer science course?\n\nToo many people study medicine, without any interest in science. This is understandable, given the short time available in medical school to study science. In this computer course, we have studied a range of things in computer science. Some of them we will apply to our medical career, some of them we will use in daily life. What follows is a short review of these things:\n\n- Computer fundamentals: We learned some basic concepts about computers, and have learned to use one. We learned how to understand an application. We learned how an application works.\n- Data Types: We learned about different kinds of data and how variables hold them. We learned how variables work and how they behave.\n- Operators: We learned about different mathematical operators and how they work. We learned that our variables are also numbers.",
        "label": 0
    },
    "1074": {
        "output": "You are doing well and you should remember the following:\n- You can create a set for exmplary code snippets, that is, a set of variables you want easy to find in your work as shown below:\n\t+ `set exmplary` \n- You should avoid unnecessary loops, e.g., repeating `set 1x` 4 times is better with a loop: `set 1x` 1x` set 1x` 1x` set 1x` \n- All variables starting with a capital letter, i.e., starting with upper case (let's say `S`) are strings and they can't be modified using assignments operators such as `+=`, `-=`, `++`, `+=` (they are immutable). If you want to modify a string, use the assignment: `=`.\n- You can create a set as an identifier like: `set age, p, w, h, t`, then you can access those variables or assign the variable value using the following syntax for strings or integers using `set` or `set`[INTEGER]`, e.g., `age = set age` if the set name has been already created or `age = set age[0]`, `age = set age[0][age]` if it was already accessed before. \n- You can concatenate strings as `fruit=\"apple, orange, cherry\"`, then you can retrieve each fruit element separately. To get the value of each fruit element, you should use the following syntax: `fruit[\"apple\"]` and not `fruit[\"apple\"] = \"apple\"`, because in the first syntax, you only retrieve the value of the element, not changing the element's value.\n\t\t\n# Solution\n# ex1_04.1sol \nimport sys\n\nf = 'C:\\\\Users\\\\<user_name>' + \"\\n\" # You must give the full path of the file containing your solutions. The file could be called \"ex1_04.1sol\".\n# We will use the same patient note from the first time, i.e., the one that the clinician had no problem to assess patient eligibility. In this case, if we consider the last line of the same patient note file in this subsection in the book, we will get the following output:\n\n\"\"",
        "label": 0
    },
    "1075": {
        "output": "<EOD> Inter-population diversification of a non-model pollinator: molecular and morphological data in Heliconius numata (Lepidoptera, Nymphalidae) from the southern edge of the distribution of the genus in Argentina and Uruguay\n\nBackground: The Neotropical butterfly genus Heliconius comprises eight (sub)species and its distribution extends from the southern Andean mountain chain to northern Argentina. Heliconius numata has a small distribution ranging from northeastern Brazil to Uruguay. For this study, 1,361 specimens of H. numata originating from northern Argentina and Uruguay and nine other sampled populations were collected. Molecular and morphometric analyses were performed to assess subspecies delimitation and characterise the inter-population patterns of variation. Results: Intraspecific comparisons of five independent nuclear molecular loci (3,860 bp analysed) yielded high levels of divergence between H. numata populations with the exception of the northeast Brazilian samples and a population group located in the extreme southern edge of its distribution in Argentina and Uruguay (i.e., Monte Hermoso). These H. numata populations presented high levels of similarity with H. demophoon populations. Morphological differentiation of these populations was weakly supported and most of the morphological variables measured were significantly variable among populations. Two major trends of morphological covariation were detected, and the Monte Hermoso group displayed higher levels of divergence than the other H. numata groups. Conclusions: Nucleotide divergence based on nuclear molecular loci supported two H. numata groups: one is located in the extreme northern part of the distribution and the other located in Argentina and Uruguay. H. numata from Monte Hermoso displays a highly divergent genetic stock with H. numata populations located in Northeastern Brazil, and with high levels of morphological variation from central H. numata populations. Our evidence for the gen",
        "label": 0
    },
    "1076": {
        "output": "The code to generate a report is: \n```\n# Code generated by doctest to report what will happen when running the example file\ndoc = TextIO.open('report_eligibility_demo.txt') | & { | s -> { s.readline } }\ndoc_orig = TextIO.open('report_eligibility_demo_expected.txt') | & { | s -> { s.readline } }\n\nreport, report_text |= create_report(doc_orig.readline)\n\ndoc_orig.seek(0)\n#print report_text\n#print \"\"\n#print doc_orig.readline()\ndoc |> capture_to_file(\"report.txt\")\n\nprint_report(report, \"report_report_eligibility_demo.txt\")\n```\n\nAnd result:\n\n```python\n```\n- <NAME> (44444444)\n2) Eligible: A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nA 54-year-old obese woman admitted to the emergency department with abdominal pain",
        "label": 0
    },
    "1077": {
        "output": "## [CST]\nIn this cst, you should try to understand how to fill in the form for a single trial. You will also learn how to find an inclusion or exclusion criteria for a single trial and how to apply the criterion to the patient note. You can use the following template as an example: \nTrial-level eligibility: 2) Eligible.\n\n### Finding inclusion and exclusion criteria for a single trial.\nYou have a clinical trial named QUILT-2.008. You should determine if the patients are eligible based on the criteria for this trial. On the next webpage, there is detailed information about the trial. You will find inclusion and exclusion criteria \n\n### Applying the criteria to the patient note.\nIf the patient is meeting the criteria for the trial, a patient's eligibility for that trial should be `1) Not relevant`. Otherwise, it should be either `2) Eligible` or `0) Excluded`. You should check the inclusion and exclusion criteria in the column titled `Trial-level eligibility`. On this page, each criterion is presented in the first column. By clicking the `Apply` button, you will apply all of the criteria to the patient's note, and the results will be presented as 3-point levels on the next page. The 3-point levels are specified in the `Trial-level eligibility` column. The first two cells (`Not relevant` and` Eligible`) have a color, but` Excluded` is blank. According to the example, `0) Excluded` appears first here because the patient is not meeting the specific inclusion criteria. The following sections describe how to apply the criteria to the 4th cell. \n\n### **First case**\n\nLet's consider the patient's name and age. Both satisfy the criteria on the trial. You can click any cells and read its explanation. However, the age of a patient is not sufficient to determine whether the patient is eligible or not.\nThere are other criteria for this trial; they are in the `Trial-level eligibility column in the third row`. If all of the criteria are false, then the patient is ` 1) Not relevant`. On the other hand, if the patient satisfies any criteria then the patient belongs to one",
        "label": 0
    },
    "1078": {
        "output": "<EOD> Combinatory therapeutic approaches to optimize the success of allogeneic hematopoietic stem cell grafts: CSF1R inhibition\n\nHematologic stem cell transplantation (HSCT) carries a risk of complications, including graft rejection and graft versus host disease (GvHD), which are life threatening at times. In order to maximize the success of allogeneic HSCT, optimal immune regimen is a major consideration. Thus, there are a few strategies to optimize the graft survival and enhance/prevent complications caused by alloreactive T cells/ donor antigen presenting cell (APC)/endothelial cell (EC) activation. CSF1R inhibition or anti-CSF1R therapeutics may be a viable therapeutic option for HSCT. CSF1R inhibition has a potential to target all leukocytes expressing CSF1R, and inhibition may prevent the activation of antigen presenting cells (APC)/donor APC and endothelial cells (EC)/donor EC, thereby inhibiting both donor T cell activation and alloreactive T cell activation, while limiting the infiltration of donor inflammatory monocytes into recipients. Moreover, CSF1R inhibition may limit the infiltration/differentiation of allogeneic myeloid cells with immunosuppressive phenotypes that drive donor T cell exhaustion. Additionally, by suppressing proinflammatory cytokine production from both cell types, CSF1R inhibition will not only prolong the life-span of donor hematopoietic cells, but also improve their functionality through the inhibition of apoptosis and oxidative stress in the donor graft. Also, the effect of CSF1R inhibition on the suppressive cells may result in improved function of conventional T cells and dendritic cells in both the donor and the recipient, and inhibition of the EC activation and differentiation of monocytic myeloid cells into suppressive myeloid cells and myeloid-derived suppressive cells (MDSC). CSF1R therapeutics could improve the graft versus host",
        "label": 0
    },
    "1079": {
        "output": "Copy and paste the following script into an R notebook, name it `run.R` and then run the code. [R]\n> ## \n> ## \n> ## \n> # # \n> ## \n\n\n\n### Note 4\nAnnotated R code is run again. If you encounter any problems or errors while running the script, follow the instructions in the section at the very end of the document. \n\n[INST]\nA 61-years-old woman admitted to the emergency department with nausea, vomiting, and epigastric pain. Vomiting is projectile up to 4 times, accompanied by hematemesis, and the stool is loosely formed, dark brown. The patient experienced similar symptoms 4-years ago and had undergone gastroscopy, colonoscopy, duodenoscopy, endoscopic ultrasound (EUS), and enteroscopy, all of which turned out normal. Her past medical history is remarkable for diabetes and hypertension. She has a diet. She is not a smoker. Her BP is 130/80, HR 110, RR 24, T 37.6, SpO2 99% on RA. She is an anxious, cachectic woman with normal vital signs. On palpation, she experiences generalized tenderness. Laboratory analysis is remarkable for neutrophilia and left shift, thrombocytopenia, and hyponatremia. The ultrasound revealed several gallstones. \nThe inclusion criteria for the clinical trial are met, so the output should be the same as the previous case: `Trial-level eligibility: 0) Ineligible.`\nThe clinical trial should also be eligible for this patient, because the inclusion and exclusion criteria for the clinical trial are also met, and the patient's medical history does not interfere with the trial. \n[IN]\nA 32-year-old woman admitted with abdominal pain, anorexia, and dysphagia. She has a history of gastric ulcer and is being treated with omeprazole and bismuth. She is a non-smoker.",
        "label": 0
    },
    "1080": {
        "output": "# Assessment criteria\nThe assessment criteria are applied to individual patients before a participant is enrolled in a trial with an exclusion criteria. They focus on the patient's potential to participate in the clinical trial. To find out if they satisfy the eligibility criteria, all the assessment criteria are checked.\n\n## `Assessment criteria` <br />\nAssessment criteria: <br />\nIn the following lines you find a list (sorted by code) of all assessment criteria.  `\n\n# The trial\n- [ ]\n\n_This is only visible in the live course. To see the hidden info, just reload the exercise. (Use `SHIFT + ENTER` instead of `Enter` to show the codes in the live course.)_\n\n## Trial-level results:\nA 54-year-old obese woman with hyperchoelsterolemia was admitted to the emergency department with abdominal pain for the past 4 days with nausea and vomiting. Nausea and vomiting, abdominal pain, epigastric pain radiating to the right upper quadrant, the patient experiencing the pain getting worse after eating a fatty diet, the patient having 2 previous NVDs, and mild febrile is the criteria for the eligibility, while the age, gender, the type and stage of disease, hypercholesterolemia, number of children and smoking is not the clinical trial inclusion criteria. Therefore, in this case, the eligibility is 1) Eligible.\n\n## Conclusions\nIn this exercise you learned how to determine the eligibility and the exclusion of the patient using the information found in the patient's note and the assessment criteria. You have also seen how to do the trial-level eligibility assessment, which is important since each eligible patient will be included in a particular trial.\nWe hope you get a good feeling about what the actual tasks at the clinical trials look like and what's expected from you, so you are ready to join the clinical trials workforce!\n\n# Assessment criteria: Sort by code\n<EOD> Identifying the Molecular Pathways Involved in the Differential Response between L-Methionine and L-Arginine Treatments in",
        "label": 0
    },
    "1081": {
        "output": "Congratulations! This is the end of our example. If it helps, you can follow your favorite language with [LANG_NAME] or see [INST]. [LANG_NAME] : We have developed our own languages that you can use directly, based on the Selenium Remote WebDriver and Selenium library from Java or Rust. [INST] : We have written several libraries that allow you to run this example in other programming languages. Please find a list with more information here: [URL]\n[LANG_NAME] - [url]: [NAME]\n[LANG_NAME] - [url]: [NAME]\n[LANG_NAME] - [url]: [NAME]\nWe recommend you to visit our user support site with [URL] and ask for help. [URL]\n\n# Discussion\nClinical trial eligibility is a very important feature in a clinical trial. For a clinical trial to move forward, there must be a set of \"patient inclusion/ exclusion criteria\". It might be possible to find criteria that you can test in different order. For example, the 'Age greater than 18 years' can be easily combined with 'patient exclusion in different age groups', therefore the test case should be ordered in this order to avoid repeating the same test:\n\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting.\n\nThe epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year.\n\nHer past medical history is remarkable for hypercholesterolemia and 2 NVDs.\nShe has 2 children, and she is menopausal.\n\nShe does not smoke, drink alcohol, or use illicit drugs.\n\nShe is mildly febrile.\n\nHer BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. \n\nShe is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bow",
        "label": 2
    },
    "1082": {
        "output": "<EOD> Transitions and Trajectories of Pupils Through Community Colleges From 2003 to 2013: Differences by SES Status and Gender.\nUsing secondary enrollment data from Washington State, we analyzed transitions and trajectories of community college students from entry to exit at the 4-year (BA/BS) degree level over a 11-year span (2003-2013). A multinomial logistic regression model was used for the analysis on 172,899 students in the sample. Findings from the analysis show students in STEM fields graduating from community colleges were more likely to transfer from CCs to 4-year schools. Students who transferred from a 4-year school to a 2-year school and then received a second BA in a different field were less likely to exit the system. Non-White female students from lower income families were less likely to transfer or graduate.<EOD> A novel RNA-binding protein interacts with an AU-rich element in the 3\u2032 untranslated region of the 37\u2009kDa liver-specific mRNA\n\nLiver-specific transcripts are enriched in AUrich elements (AREs) in their 3\u02b9 untranslated regions (UTRs). In this study, we investigated a cellular factor that interacts with the 3\u02b9UTR of the 37 kDa liver-specific mRNA. Nuclear colocalization assays and immunoprecipitation with transiently overexpressed 37 kDa protein confirmed its capacity to interact with endogenous ARE-bearing transcripts. The cellular factor was identified as a RNA-binding protein of the HNRNP (heterogenous nuclear ribonucleoprotein) family and termed as HNRNPM-LSP (liver-specific mRNA polyribonucleotide). RNA recognition motifs (RRMs) of HNRNPM were used for the interaction with the CCGU mRNA element that mediates protein stabilization. Additionally, HNRNPM/CCGU motif mutations resulted in reduced protein-mRNA interactions. Finally, expression profiles of HNRNPM/CCGU motif mut",
        "label": 0
    },
    "1083": {
        "output": "<details style='background-color:#F11400; border-top: 0 none black; border-left:0 black none; border-right:0 black solid; border-bottom:0 black; border-left:0 none white; border-right:0 none white; border-bottom:0 none white; border-top:0 none white\">\n\n<p><font size='+1'>*  </font><font color='black'>  </font><font size='+1'>1) Excluded (patient meets inclusion criteria of the clinical trial, but is excluded on the grounds of the trial's exclusion criteria)</font> <font size='+1'>*  </font><font color='black'>  </font><font size='+1'>  </font><font color='black'>  </font><font size='+1'>  <font color='black'>* </font><font color='black'>  </font><font size='+1'>2) Not relevant (patient does not have sufficient information to qualify for the trial)</font> <font size='+1'>*  </font><font color='black'>  </font><font size='+1'>  </font><font color='black'>  </font><font size='+1'>  </font><font color='black'>  </font><font size='+1'>  <font color='black'>* </font><font color='black'>  </font><font size='+1'>3) Eligible (patient meets inclusion criteria and exclusion criteria do not apply)</font><font color='black'>  </font><font size='+1'>  </font><font color='black'>  </font><font size='+1'>  </font><font color='black'>  </font><font size='+1'>  </font><font color='black'>  </font><font size='+1'>  <font color='black'>* </font><font color='black'>  </font><font size='+1'> </font><font color='black'><u>output</u><br><font color='#000099'><b>Trial-level eligibility:</b><br><font size='3'>2) Eligible</font></p>",
        "label": 1
    },
    "1084": {
        "output": "## Case: \"Diabetes control and complications trial (DCCT).\"\n\n### Information on the trial:\n\nYou should work on the trial entitled \"Diabetes control and complications trial (DCCT).\" This trial was performed from July 17, 1993, to March 28, 1999, at 55 study centers in four countries: the United States, Canada, the United Kingdom, and Finland. Eligible patients were identified from among those who were diagnosed with insulin-dependent diabetes and were aged 13 to 39 years and had diabetes for 1 to 15 years.[MIDI]\n\n### Research question:\n\nThis study was designed to test whether more intensive management of diabetes can prevent diabetic retinopathy and other microvascular complications such as nephropathy and neuropathy. To establish the research question, note the following:\n\n\n*     \"Diabetes control and complications trial (DCCT)\"\n\n\n*     \"A: The control and complication\"\n\n\n*     \"B: The diabetes control\"\n\n\n*     \"C: The diabetes treatment\"\n\n\n*     \"D: The retinopathy prevention\"\n\n\n*     \"E: The clinical trial\"\n\nAnd then click the [Ask NLM research questions] link at [MIDI] right underneath \"Research Questions\" to see all the above information. \n\n### Background literature:\n\nIf you need the background literature, click the [Background] link underneath \"Background Literature\" at [MIDI] right underneath \"Research Questions.\" \n\n### Research design:\n\nResearch design means the specific way in which a body of research is designed and executed. In MIMIC-III-2010, the study design is a randomized controlled trial or non-randomized observational study. \n\n1. First of all, as shown in the above screen, type \"A: the control and complication\", and then click the [Query] button to show the results, or you may copy all the results to a text document from a copy icon (just below the results block)",
        "label": 0
    },
    "1085": {
        "output": "## \u00c3\u00c3 Exercises \u00c3\u00c3\n\nExercise 1\nIn an interactive session, go through example data in this article and exercise step by step. You will see an example patient note and clinical trial. You will assess the patient using the tool. You will get some hints and try to solve the problem. As soon as you come down to the bottom of the page, you will find the answer.\n\nData: Examples, you have read before.\n\nProblem: You should determine the patient's eligibility for the clinical trial.\n\n[EX1] You should output the trial-level eligibility.\n\nExercise 2\nIn an interactive session, go through example data in this article and exercise step by step. You will see an example patient note and clinical trial. You will assess the patient using the tool. You will get some hints and try to solve the problem. As soon as you come down to the bottom of the page, you will find the answer.\n\nData: Examples, you have read before.\n\nProblem: You should determine the patient's eligibility for the clinical trial.\n\n[EX2] You should output the trial-level eligibility.\n\nExercise 3\nIn an interactive session, go through example data in this article and exercise step by step. You will see an example patient note and clinical trial. You will assess the patient using the tool. You will get some hints and try to solve the problem. As soon as you come down to the bottom of the page, you will find the answer.\n\nData: Examples, you have read before.\n\nProblem: You should determine the patient's eligibility for the clinical trial.\n\n[EX3] You should output the trial-level eligibility.\n\n\n\n\nThis has been an interactive tutorial on the Eligibility Assessment Tool: Patient Note in the R programming environment. Please let me know if you have any comments.\n\nBye!\n\n--\n--------------------------------------------------------------------------------\n\n[INT]\n\n\n\nIf you are reading this, you are probably not sure how you should solve the problem. Do not let frustration conquer you. Take a deep breath and think: How can you divide this problem into small pieces that are then solved with the Eligibility Assessment Tool",
        "label": 0
    },
    "1086": {
        "output": "# \u2695\ufe0e Outcomes\n\nFor a clinical trial study, the most common outcome is disease outcome, which is sometimes referred to as endpoint. The inclusion of endpoints is an essential component of the design of the study. Endpoints, also known as trial outcomes, are the final results of a clinical trial.\n\nAt the end of the clinical trial study, the outcomes were recorded.\n\n# Outcomes\nSeveral endpoints were measured in this clinical trial study. The primary endpoint measures the diagnostic accuracy and physical examination in the morphine vs. placebo group. Secondary endpoints measure the need for rescue drugs at 30 minutes, the",
        "label": 0
    },
    "1087": {
        "output": "## Exercise 4.\nPlease assess trial eligibility for the patient from Exercise 3 and click the button below.\n![](https://s3-us-west-2.amazonaws.com/hakyim-s3/exercises/image/exercise5.png \"trialeligibility\")\n\nAfter completing the exercise, click on the `Save & Continue` button to continue to the next exercise.\n\n## Exercise 5.\nPlease assess trial eligibility for the patient and click the button below.\n![](https://s3-us-west-2.amazonaws.com/hakyim-s3/exercises/image/exercise6.png \"trialeligibility\")\n\nAfter completing the exercise, click on the `Save & Continue` button to continue to the exercise list page.\n\n## Exercise 6.\nPlease list all the possible trial eligibility combinations in the box below.\n\n## Exercise 7.\nPlease list all the possible patient assessments in the box below. Please use the 'Add a Note' button when you are going to write your notes in this box.\n\n## Exercise 1.\nPlease assess trial eligibility for the patient from Exercise 5 and click the button below.\n![](https://s3-us-west-2.amazonaws.com/hakyim-s3/exercises/image/exercise1.png \"trialeligibility\")\n\nAfter completing the exercise, click on the `Save & Continue` button to continue to the trial list page.\n\n## Exercise 2.\nPlease find the trial with the inclusion criterion `Female` and click the button below.\n![](https://s3-us-west-2.amazonaws.com/hakyim-s3/exercises/image/exercise2.png \"trialeligibility\")\n\nAfter completing the exercise, click on the `Save & Continue` button to continue to the trial list page.\n\n## Exercise 3.\nPlease find trial with the inclusion criterion `Aged 20-80 years`.\n![](https://s",
        "label": 0
    },
    "1088": {
        "output": "Please find a [Demo](https://stack-1.dev.appveyor.com/stack/7z4v3i17w3zxk8/logs) on the web.<EOD> Diffraction-limited ultrasound beam steering with an annular transducer array and a cylindrical lens.\nA diffraction-limited beam steering algorithm is presented for generation of ultrasound beam by an annular transducer array and a cylindrical lens to provide a cylindrically-shaped focal region. The algorithm is based on the calculation of the point spread function for the array and the lens that is generated before launching into the transducer array, followed by superposition of the point spread function of the array and the lens, with the phase and amplitude of the two functions being properly defined. The annular array and the lens are designed by using a fast optimization algorithm combined with a genetic algorithm. A 2D annular array of 16 transducers with element sizes of 14 mm and focal length at -14.2 mm is simulated by our approach and has a lateral focal length of 2.8 mm and a beam width of 0.7 mm.<EOD> A rapid assessment of community health workers\u2019 knowledge of a community-based monitoring intervention in Tajikistan\n\nCommunity health workers (CHWs) in rural Tajikistan are a group that have received little research attention and their use for interventions is in its infancy. Using Kinyarwanda, the survey was translated by the same researcher and was piloted in a rural community with four CHWs. Questions included were 'How is it possible to use your job card as a tool?'; 'How can you get help to use the job card?' and 'What else or in addition are your problems when using the job card?'. After the fieldwork, CHWs were asked to repeat the question for the first time in English, the original language of the instrument. All translated questions were validated through iterative discussions with participants. Results in all cases had a high similarity in meaning between English and Kinyarwanda. The study also highlighted cultural appropriateness. An illustration is the question 'I think that the job card that you give me is a valuable tool for improving child care/pregn",
        "label": 0
    },
    "1089": {
        "output": "10.3. You should make trial-level eligibility on each patient for the clinical trial",
        "label": 0
    },
    "1090": {
        "output": "## \u274f Worksheet: Trial-level eligibility\n\nAcknowledgments\n\nThe authors are grateful to Dr. Nitika Goel for her careful attention during the entire process of manuscript development. We thank Mr. Vahab Alizadeh-Tabatabaei (Department of Biostatistics and Bio-informatics) for his great comments on the initial draft. We thank Dr. Ahmadreza Hosseini (Department of Infectious Diseases and Tropical Medicine) and Mr. Tayyebeh Nokhezad (Department of Microbiology) for their kind cooperation.\n\n**Disclaimer**\nThis textbook reflects current medical knowledge at the time of publication. This textbook may vary in time, especially clinical decisions. There may be some discrepancies between this textbook and other resources used in practice.\n\n## Trial-level eligibility\n\nI have to assess whether each patient meets the inclusion criteria. Let's start!\n\nFirst of all, we should assess for the patients who are excluded from the trial because they are not eligible.    ![22_0492](../assets/images/22_0492.PNG) ![22_0520](../assets/images/22_0520.PNG)   \n\nThe age should be > 18 years.   \n\nBoth 21-year-old men and women are excluded from the trial because they do not meet the inclusion criteria of age greater than 18 years. They are too young to be eligible for this trial.  \n\nSex is not among the inclusion criteria, but based on the results of the two previous questions, since all patients are older than 18 years and because the study is targeting genders (men and women), the patients who are not male or female are excluded from this trial.  \n\nThe patient number 3050715 who is under 18 years old and whose sex is not male or female is therefore excluded from this trial.\n\nAll patients who are < 18 years old or who are female or who are not male and under 18 years old are excluded from this trial.",
        "label": 0
    },
    "1091": {
        "output": "# Problem Statement\n\n## Problem\n* The problem statement in the main file is quite long, with many lines and not very readable. It can be shortened by moving the long lines on the separate lines below, while leaving the short description for the problem statement.\n\nEdit the Problem Statement as described here:\n**The problem:** <NAME>  is a 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. Her past medical history is also significant for hypertension, hyperlipidemia, and 2 NVDs.\nThe second case that describes the inclusion criteria is below. The patient note is described in the section below. \nA 65-year-old man was admitted for a hysterectomy after a recent colonoscopy revealed multiple CBD stones.  He was a smoker for many years but quit 10 years ago. He also has a distant history of diabetes and arthritis of the knee. The procedure will likely require 5-7 units of blood, based on hematologic assessment in the chart. The patient met inclusion criteria for a clinical study that he should complete as a part of the informed consent",
        "label": 0
    },
    "1092": {
        "output": "</pre>\n- To see it, just paste it in your browser as plain text:\n\n### Task description\nPlease download the .csv files for the previous task by clicking the **Download tasks** button above. The format of the .csv files is given in below. Your task description is given on the first row and patient note is on the second row.\nPlease write a script that first sorts the patient note by trial-level eligibility and writes the resulting values to the Patients output.csv file, e.g., write eligible patients to its first row. This is the same as the example in the previous task. However, only data corresponding to the trial-level eligibility are written, not the additional columns.\nWe will also provide you a .csv file containing the trial data in a similar to the previous task, but with column names instead of one-line texts. Using those column names, your script should then first retrieve the patient note for a specific trial and then assign it to the corresponding trial-level eligibility based on its data. The resulting trial report is written to the Trial report output.csv file, e.g., the file should contain the same trial-level eligibility for the same patient as written for in the patient note.\nPlease, upload the resulting .csv and .html files as output results in the same folder where you provide your code. As usual, this should be done by uploading them to the directory where we place your input data.\n\n\n### Submission guidelines\nPlease zip your Python files to a single file, put it in a publicly accessible directory, and either send us the URL or the download link via email. It does not matter whether it is publicly visible or not. This is also sufficient if you use a public git repository, and we will look at the latest revision.\nAlso, please let us know the name of the file that corresponds to your solution code. As usual, if you include a Readme file in which you describe your submission, we will include that file in our code review of your solution.\n\n# Detailed instructions\n\n# Task Instruction (0)\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating",
        "label": 2
    },
    "1093": {
        "output": "<jupyter_code># patient note\n\nprint('{0}\\n'.format(patient_note), end='')\npatient_note = patient_note.rstrip('\\n')  \n\n# clinical trial\ndef summary(trial: str)->dict:\n    description_lines = [l for l in (sum_lines[sum_lines.index(summary) + len(summary)] if 'summary:' in (l.split()))]\n    if description_lines is not None:\n        trial_details = {}\n        if trial.strip() != '' and trial.strip() != '*':\n            trial_details['details'] = description_lines[0]\n            lines = [l for l in sum_lines if 'trial characteristics:' in (l.split())]\n            lines_filter = [r for r in lines if r.strip() != '*'].splitlines()   \n            for line in lines_filter:\n                trial_details['characteristics'] = line.strip('  *')[2:-1]\n        if trial.strip() != '' and trial.strip() != '*':\n            trial_details['title'] = trial\n        trial_details['summary'] = description_lines[0]\n    else:\n        trial_details['details'] = ''\n        trial_details['characteristics'] = ''\n    trial_details['summary'] = ''\n    return trial_details\n\n# trial-level eligibility\ndef get_trial_level_eligibility(patient_note: str, clinical_trial: str)->str:\n    trial = summary(clinical_trial).get('details')\n    if trial is None:\n        return ''\n    ctrs = patient_note.rsplit('|')[0].split(', ')\n    trial_exclusion_words = ['patient', 'trial', 'eligibility']\n    ctrs = [r for r in ctrs if r not in trial_exclusion_words]\n    return 'Trial-level eligibility, 0) Excluded' if ctrs is not None and len(ctrs) == 0 else \\\n    'Trial-level eligibility: ' if len(sum_lines) == len(trial_",
        "label": 2
    },
    "1094": {
        "output": "---\n\n[Back to Index](index.md)<EOD> Prognostic impact of EGFR mutation and ALK rearrangement gene status and smoking on outcomes in metastatic or unresectable adenocarcinoma of the lung.\n7203 Background: Recent data have shown that patients with EGFR mutations and ALK rearrangements may potentially benefit from molecularly targeted therapies. This study evaluated the relationship between ALK rearrangement, mutations, smoking status and survival.\n\n\nMETHODS\nPatients (pts) with unresectable stage IIIB or metastatic adenocarcinoma were enrolled onto an IRB-approved registry following informed consent. Pts were eligible if they were \u2265 18 years of age with advanced lung cancer and \u2265 10% tumor tissue. Genomic DNA and total RNA were extracted from archival and matched fresh tumors at diagnosis and EGFR and ALK status were detected using reverse transcription-PCR TaqMan-based assays (Applied Biosystems), FISH assays (Vysis) and/or the EasyScreen platform (CeTech).\n\n\nRESULTS\nTumors from 140 pts were analyzed by a central pathologist and classified as: adenocarcinoma (AC) N=132, large cell N=8. 20 pts were never smokers (NS), 106 were ex-smokers (ES) and 14 were current smokers (CS). The ALK rearrangement was detected in 4/22 evaluable ES pts and 0/14 CS or 4/166 evaluable NS pts (NS pts = AC pts+2 LCLC), while the EGFR mutation was detected in 12/21 evaluable NS pts (11/114 evaluable AC pts +1 LCLC), 5/35 evaluable ES pts (0/8 evaluable CS pts) and none out of 38 evaluable CS pts. There was a significant difference in progression-free survival (PFS) in pts with the ALK",
        "label": 0
    },
    "1095": {
        "output": "#### [2] \uc774\ub860\uc801 \uc218\ud589 \ud2c0\n\n\n![](https://github.com/YoonSuk40/YoonSuk40.github.io/blob/main/assets/2022-04-21-2.JPG \"\uc774\ub860\uc801 \uc218\ud589 \ud2c0(Theoretical Performance)\")\n\n## [3] Q&A\n\n* \uc870\uc5f0\uad6c\uc758 \ubaa9\uc801\uc740?\n\n[ANSWER]\n  * \uce58\ub8cc \ud6a8\uacfc \uac80\uc99d\uc774\ub2e4.\n  \n* \uc870\uba85\uc694\uc6d0\uacfc\ub294 \ube44\ub85d \uc798 \uc18c\ud654\ub41c \uc778\ub958\uc758 \uc77c\uc6d0\uc778 \uac83\uc73c\ub85c \ubcf4\uc774\uace0 \uc788\uc9c0\ub9cc, \uc870\uba85\uc694\uc6d0\uc744 \ub300\uc0c1\uc73c\ub85c \uc6b0\ub9ac\uac00 \uc9c1\uc811\uc801\uc73c\ub85c \uacfc\ud55c \uc2dc\uac04\uacfc \ub178\ub825\uc744 \uac00\uc9c0\uac8c \ud558\uc600\uace0 \uc790\uccb4\uc801\uc73c\ub85c\ub3c4 \uae34 \uae30\uac04\uc758 \uc5f0\uad6c \uc131\uacfc\ub97c \ubcf4\uc5ec\uc8fc\uace0 \uc788\ub2e4.\n  \n### \uc870\uba85\uc694\uc6d0\uc758 \uc0c1\ud0dc\n\n[ANSWER]\n  \n\uc5f0\uad6c\ub300\uc0c1\uc778 \uc870\uba85\uc694\uc6d0\uc758 \uc0c1\ud0dc\uc5d0 \ud30c\ubb3c\uc77c \uc218 \uc788\ub2e4. \n1. \uc0ac\ub9dd \uc804 - \ub9cc\uc131 \ubc18\uc751\ub960(severe asthma/heterogeneous asthma) \n2. \uc0b6\uc774\uae30\uc5d0 \uc800\ud658/\uc0ac\ub9dd(life-threatening/fatal exacerbations)\n  1) \ud6c4\ucc9c\uc99d\uc131 \ub300\uc7a5\uc5fc(IBD-UC). \n\n[ANSWER]\n  \n\ub300\ub450\uc704\uc7a5\ucd9c\ud63c\uc131 \uadfc\uac70\ub4f1\ub85d(National",
        "label": 0
    },
    "1096": {
        "output": "<EOD> Mapping of Functional Regions in the Cyclic Nucleotide\u2013Binding Domain of the Dictyostelium Translation Initiation Factor 4E Using Alanine-Scanning Mutagenesis*\n\nDictyostelium discoideum contains a single mRNA-cap-binding protein named eIF4E. EIF4E is synthesized as a long precursor (p48), which acquires its COOHterminal 26 amino acids (p26) and binds [ 3 H]m 7 GTP, during its de novo synthesis on cytosolic (70)S ribosomes. The NH 2 -terminal amino acids (p48-p50) of p48 have been assigned as the cyclic nucleotide-binding domain. We have identified five conserved residues among NH 2 -terminal amino acids using site-directed mutagenesis with an alanine replacement technique. Alanine replacements at His-51, Lys-59, Leu-60, and Glu-62 lead to deficiencies in ribosome binding or in p48-p50 interaction and decreased affinities for [ 3 H]m 7 GTP or cAMP, and the mutants are unable to direct protein synthesis. These results suggest that the NH 2 -terminal amino acid sequence, His-51, Lys-59, Leu-60, and Glu-62, and their side chains are essential for p48 function and are critical for the interaction of p48 with p26, the ribosome, mRNA, and cap analogue.\nEukaryotic cellular growth and differentiation largely depend on protein synthesis. The rate of protein synthesis is increased at the beginning of this developmental stage in Dictyostelium discoideum. D. discoideum contains a mRNA cap binding protein named eIF4E, which binds [ 3 H]m 7 GTP. The cap-binding protein binds to the 5\u0408-end of mRNAs during protein synthesis in association with eIF4G, which binds to the 3\u0408-end. e",
        "label": 0
    },
    "1097": {
        "output": "Examples\n\nTo determine a patient patient's eligibility for the given trial, run the following code:\n[AZD6244] -Trial-level eligibility 2\nIf you use MATLAB 2013a or higher, the `Trial-level eligibility` field has been converted into MRO. In older versions such as MATLAB 2012b or earlier, you should check for the following case statement.\n[AZD6244] -Trial-level eligibility 2 AND 0 \n[AZD6244] -Trial-level eligibility 2 OR 1 - Excluded\n[AZD6244] -Trial-level eligibility 2 OR 2 - Not relevant\nThe trial's eligibility is calculated for each patient and its output is stored in `Trial-level eligibility` value in the `mrObj` variable as explained above.\nFor the given trial we get the following output:\n\n## [INST] MATLAB's output 45\n[AZD6244] -Trial-level eligibility: 2\nA simple way to get the output of the eligibility trial is to use the `getEligibility` function. It will evaluate the trial-level eligibility for each patient and display its result. The trial-level eligibility, the status of the trial (active or inactive) can also be displayed in a data table that can be downloaded as a csv file in several formats (for example pdf, png, html, and others), see How to download the data exported to the command window?\nTo show the summary of the eligibility status for this clinical trial, run the following code:\n[AZD6244] -> getEligibility\nHit [c] to show the clinical trial report\nAn interesting note to be aware of for this trial is that the trial is inactive right now due to the following reasons. Please find the trial status in the output from the `getEligibility` function.\n[AZD6244] -Trial-level eligibility: 2\nActive: 0\nInactive: 1\n\n## Exploratory analysis",
        "label": 0
    },
    "1098": {
        "output": "## [TEST]\nNow you are qualified to run the trials. The input format is as follows:\n[0] 5.3 3.1 5.6 [1]\n\nYour output is as follows:\n[0] 5.3 3.1 5.6 [1]\n<EOD> Effect of Corynebacterium parvum on natural killer cell activity in mice as a function of aging.\nThe capacity of young and old (20 and 80 weeks) C57BL/6J mice, and old mice vaccinated with Corynebacterium parvum, to generate natural killer cells in vitro was assayed against YAC-1 lymphoma cells. The generation of these cells was examined as a function of the time and number of spleen cells stimulated and of the ratio of stimulator and effector cells. An age-related decrease in natural killer cell activity was demonstrated in nonvaccinated old versus young mice. In old vaccinated mice, spleen cells generated approximately 40 times more natural killer cells than cells from young control mice. The age- and C. parvum-induced effects were present 16 weeks after vaccination. With an increase in stimulator cell number (1.25 X 10(6) to 1.0 X 10(7)), the induction of natural killer cells decreased with age and increased in vaccinated old mice. Also, with an increase in the ratio of stimulator to responder cells, the increase was more pronounced in old than in young mice. These data suggest that C. parvum, like some other organisms, is able to induce antitumor resistance with aging, and that the ability of immunocompetent cells to generate natural killer cells depends to a large extent on their number, the cell density, and the ratio of stimulator to effector cells. Furthermore, the data suggest that C. parvum is able to restore the diminished immune responsiveness occurring with aging and to increase the number of spleen cells which generate natural killer cells in culture.<EOD> Corrigendum: Influence of an Increased Dose of Sodium Chloride and Ionic Com",
        "label": 0
    },
    "1099": {
        "output": "[fig]  \u2022: Ileus, a blockage of the passage of digested food through the digestive tract. Obscure causes of abdominal pain include the following: appendicitis, gallbladder disease, inflammation of a pancreatic cyst, kidney stones, ulcers, and cancers of the colon, esophagus, stomach, or pancreas.Abdominal pain may be a symptom of other medical problems. [/fig] \n<EOD> .\nMelancholia has been defined by M. Kris as an extreme form of depression. The aim of the treatment is to change the attitude of the patient by increasing the activity and creativity. Melancholia is not a psychotic illness but it is a psychological illness. Melancholics feel isolated and lonely. They are unable to feel empathy at the workplace. Melancholics are depressed during the night. There is no sleep and the first signs of sleep are the emergence of vivid dreams. A treatment of depressed patients is possible. It starts with a clear statement of the diagnosis. Physicians must try to know the patient. Talking is very important and this will also decrease the anxiety of the patients. To improve activity and creativity, social contacts with the patients are necessary. After an acute phase of treatment, the melancholic patient may be treated in a psychotherapy. The choice of the method of treatment must include the patient. The treatment of depressed patients can be seen as the meeting of two physicians, the patient and the physician.<EOD> The Effect of Sarcopenia and SARC-F Questionnaire on Surgical Site Infection and Recurrence Rate of Crohn's Disease\n\n\n\n# Introduction\nCrohn's disease (CD) is an inflammatory bowel disorder characterized by transmural lesions extending through the entire intestinal layer. Because of its high recurrence rate, it is an important public health problem that significantly impacts the quality of life (QOL) of patients. Since the development of antitumor necrosis factor drugs, a growing number of patients have been treated with medical therapy. However, since drug resistance often appears, surgery is often inevitably required. The reported rate of postoperative recurrence of Crohn'",
        "label": 1
    },
    "1100": {
        "output": "### Output Data:\n1) If `age > 65 and BMI \ufffd30: Excluded`, this is a very short note that will be very hard to understand unless you put a description of it under the `age and BMI` column. In this case, we recommend you to show an output of multiple rows, i.e., multiple patients. The output row should contain the note number (the number after `0|#` of each patient), then the `age` and then the `BMI`. So, for all patients, their ages or BMIs are sorted from lowest to highest, then their `age` and `BMI` are appended after the row number `m`. So, if there were 5 patients, the output will be `735|0|m |60|29,7|736|0|26|39,6|737|0|30|36,4|738|0|39|35,8|...`. \n2) Note: There is a little typo in the included criteria of the above case. The excl. criteria includes diabetes; that is not the case. If you do not understand the code, you may make the changes and try to find the mistake.\n3) The last line that is not `Trial-level eligibility: ` is a note or `None.`.\n\n## Problem 1. In a few cases, the patient's name and patient's father is not written. \n\n## Possible solution\nThere is a pattern in these cases. This is how you fix it. \n1) Make sure the data you use follows an order of first, middle, and last name.\n2) For those rows where there is no name, append the last name after the first_name and the middle name after the last_name.\n3) Sort the first_name to be first after all the other columns.\n\n## Problem 2. Clinical trial has 2 or more inclusion criteria. \n\n## Possible solution\nThis is the problem in the first clinical trial you will apply in this document. The clinical trial has 2 inclusion criteria. The problem: the patient number varies depending on the inclusion criteria fulfilled. \n1) Add `is_fulfilled_by` to each",
        "label": 0
    },
    "1101": {
        "output": "_6.1.4_ PICO analysis.\n\nA PICO is a four-part patient-centered clinical question that will be used later in this exercise to describe study design.\n\n#### Patient / Problem description / Population (P)\n\nPatients with recurrent migraines and/or headaches. A migraine is a disabling primary headache disorder typically having a unilateral throbbing pain lasting 4\u201372 h. People experience migraines because something does not work right; migraine triggers include not sleeping enough, eating the diet that they have been told worked for them (too much fat or alcohol), dehydration, and exposure to allergens. Migraines are sometimes triggered by stress and poor sleep habits. \nThe headache is severe, and it is usually accompanied by nausea and sensitivity to sounds, light and touch. Other symptoms may include sensitivity to smells and a worsening episode from resting. Medications used to prevent migraines are designed to reduce the number of severe headaches and are not intended to treat migraines. Preventive medications are sometimes used to help children avoid having to miss school.\n#### Intervention / Treatment / (I)\n\nSome researchers think that increasing physical activity could reduce headache pain. Other researchers believe that drinking more water will reduce the risk of dehydration that increases migraines. Because of all the health benefits of exercise and drinking water, they believe it is necessary to review this hypothesis. \n\nOne of the most common treatments for migraines is a combination of acetaminophen, ibuprofen, and caffeine. The study team will review the use of acetaminophen, ibuprofen and caffeine, because the doses may be too high to treat a minor headache. They will compare the use of acetaminophen, ibuprofen, and caffeine with water on average daily physical activity and headache. \n\nBecause people vary in their abilities of movement, physical activity is also measured when people use physical activity as a treatment. \nMedications known as corticosteroids could allow people to exercise longer, so the study will review how they influence physical activity. Some research",
        "label": 0
    },
    "1102": {
        "output": "[endINST] \n[TASK] [CODE] [DO]\n[COR] [IMM]\n\n---\n\n## Learning Objectives\n\nAfter completing this activity, participants will be able to do all of the following:\n\n\n*\n\n*Understand the assessment of eligibility, including the three-point scale of 0, 1, and 2, which are used to determine eligibility.\n\n*Identify inclusion criteria and the relevant factors that allow someone to qualify for a clinical trial.\n\n*Construct the trial-level assessment of eligibility for a specific patient, to determine whether to include, not include, or exclude that patient from the clinical trial.\n\n*Identify the clinical trial with information provided on the patient note, to construct a trial-level assessment of eligibility for the patient.\n\n\n[INST] This instruction set is for users on the Macintosh operating system. To turn the computer on and log onto the network, see the section entitled \"Turning On the Computer and Logging On\".\n\nUse the keyboard to type:\n\n[CMD] [Return]\n\n![INST]\n\n#### Getting Started\n\nOpen [INST] SMAGI.\n\nStart the program by double clicking on the SMAGI icon on the desktop.\n\nAfter the Welcome dialog box appears, click on the 'Load a File' button. The Open Window appears. Open the 'Example file' in the 'Textbook' folder. The [C] in the title bar of the window refers to the user's current folder. \n\n![INST]\n\nIn the Open Window, choose one of the following:\n\n![INST]\n\n- If you don't know the filename, choose the Browse button.\n\n- To choose a file with a specific label, select the checkbox next to the file name. Then, click the Browse button. A New File Open Window appears. Navigate to the desired file, select it, and choose Open.\n\n![INST]\n\nClick Close to return to the example file. Click the Run button to execute the code. The SMAGI window appears.\n\n### Opening an Existing File\n\nTo open an existing file:\n\n![INST]\n\n- Click the Browse button.",
        "label": 0
    },
    "1103": {
        "output": "The program is executed below. Note that the program saves your decision `eligibility` in a file `output.txt`. \n\n```Python\nimport sys\nimport json\nimport os\nfrom subprocess import check_call\nimport csv\nimport glob\nimport copy\n\nsys.path.append(os.environ[\"PYTHONPATH\"])\n\nif len(getattr(sys, \"argv\", [])) == 3:\n\n    path = os.path.dirname(getattr(sys, \"argv\", [])[0])\n    subprocess.call([\n        \"git\", \"submodule\", \"update\", \"--init\"\n    ], cwd=path)\n\nif len(getattr(sys, \"argv\", [])) == 4:\n\n    path = \"docs/python-scripts/challenge/\" + getattr(sys, \"argv\", [])[3]\n    program_name = getattr(sys, \"argv\", [])[2] + \".py\"\n    py = os.listdir(path)\n    py.reverse()\n    subprocess.call([\n        \"python3\", path + \"/\" + getattr(sys, \"argv\", [])[3] + \"/\" + program_name\n    ], cwd=path + \"/\" + program_name, stdout=sys.stdout, stderr=sys.stderr)\n\n# if len(getattr(sys, \"argv\", [])) == 4:\n#    program_name = getattr(sys, \"argv\", [])[3] + \".py\"\n#    path = \"docs/python-scripts/challenge/\" + getattr(sys, \"argv\", [])[2]\n#    subprocess.call([\n#        \"python3\", path + \"/\" + getattr(sys, \"argv\", [])[3] + \"/\" + program_name\n#    ], cwd=path + \"/\" + getattr(sys, \"argv\", [])[1])\n\n# Input file data\nfname = \"\"\noutput_filename = \"\"\nif len(getattr(sys, \"argv\", [])) == 4:\n\n    fname = getattr(sys, \"argv\", [])[1]\n\n    input_filename = getattr(sys, \"argv\", [])[0]\n    output_filename",
        "label": 1
    },
    "1104": {
        "output": "The final patient was treated with clinical trial 008. The patient data flow looks like this.\n\n## ## ---------------------------------------\n\n## Mentioning a patient's medical record number (MRN)\nLet's think step by step. \n\n## In the beginning, assign patient identifier and age\nYou should assign patient identifier 12343567890, age 47. And here is patient note. \nMRN:12343567890\nAge: 47.\n\n## Patient information\nYour task is to make the assessment of eligibility from the following patient information. \nHere you must calculate the number of patients not relevant and eligible, and calculate the percentage of patients eligible for each clinical trial.\n\n\n# Results\n<EOD> Intrinsic Neuronal Activity as a Therapeutic Target for the Treatment of Disease\n\nIntricate brain circuits generate intrinsic neuronal activity that is required to maintain brain stability and function, including sleep and wakefulness, states of anesthesia, and brain plasticity. Intrinsic neuronal activity is critical to modulate brain and behavioral output and to enable the brain to function optimally when facing external and internal challenges. Intrinsic neuronal activity is composed of several independent components, including sleep and wake physiology, epileptic seizures, ictal and inter-ictal paroxysms, synaptic plasticity, and memory processing. Intrinsic neuronal activity requires coordination across multiple brain regions, particularly thalamocortical interactions, and neurotransmitter mediators including dopamine, glutamic acid, norepinephrine, serotonin, and acetylcholine. In this paper, we review the brain regions that are part of intrinsic neuronal activity and describe the neurochemical and neural system substrates that support intrinsic activity. We then investigate the impact of intrinsic neuronal activity on human health and disease, from mood disorders to neurodegenerative diseases, and describe how the identification of intrinsic neuronal activity substrates has contributed to the generation of targeted therapeutics for a variety of neurological disorders and neuropsychiatric dise",
        "label": 0
    },
    "1105": {
        "output": "[table]  A: Hello, Assistant. The results of the Cytosponge is in. Please, compare and mark in the patient note if the Cytosponge was positive. The Cytosponge is a patient-administered test to assess Helicobacter pylori for non-invasive diagnosis of peptic ulcer. [B] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. [C] Hello. You are an eligible woman under consideration to enroll in a clinical trial for the treatment of breast cancer. The study is designed to assess the potential benefits and adverse effects for different chemotherapy agents in patients with early breast cancer. For this treatment, the 2 agents are Doxorubicin and Dacarbazine. You could get one of the agents. The study will compare the results from each agent treatment to determine which agent works best. During the study, you would receive the assigned agent, either Doxorubicin or Dacarbazine, and have regular checkups. If eligible, you will participate in a series of tests related to the study, and we will ask you to fill out some forms. [D] Hello, I am Dr. Nicole. You are an obese woman under consideration to enroll in a clinical trial for the treatment of GERD. The title of this clinical trial is FG for the Treatment of GERD. This is a prospective study to extensively evaluate subjective patient parameters on quality of life, refluxsymptoms, side effects, medication-use and measurements of esophageal manometry and Impedance-pH-Monitoring after Full-Thickness-Gastroplication. For this intervention, 2 different types of plication will be used. Here is the eligibility-assessment for this trial. [E] Hello, I am Dr. Sam. You are a non-hypertensive, normoglycemic, non-",
        "label": 0
    },
    "1106": {
        "output": "[TEST]\n\n[/TEST]\n[TEST]\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n___%imagedir%__  {% imagedir test_images %}images_only{% endimagedir %}\n[/TEST]\n\n<EOD> In situ monitoring of a cell suspension biofiltration pilot plant.\nThe study of continuous culture in multi-unit vessels constitutes a challenging problem on the biochemical level. Monitoring at the biochemical level is a vital part of process control. This paper presents an instrument designed for the in situ determination of 14 volatile compounds",
        "label": 0
    },
    "1107": {
        "output": "[ENDS]\nYou have finished the course! \nGood work. \nYou've mastered the most important skills for programming. \nIf you use Python, you will see how the above code is rewritten:\n#!/usr/bin/python # This file is part of the PANDA library module import pandas as pd import sys from tabula.utils import *\n\nYou can use the following command:`\npanda-in --help` for the full program description.\n[ENDS]\nThe Python Programming Language has been successfully running since 1990. Python has quickly become one of the most popular languages used by computer scientists. There are various reasons for it: flexibility, ease of understanding and writing programs, availability of many advanced modules of the package managers such as PyPy and Conda.\nIn addition to data processing, you can do scientific calculations. Python comes with an excellent package to calculate, the Numpy package, that includes functions to calculate a large variety of matrices, tensors and arrays. Of course there are many applications where Numpy does not provide a function. In these cases, there are powerful packages like the SciPy library that provides many functions for a wide variety of scientific and engineering topics.\nAn increasing number of scientifically oriented journals are publishing their research with RMarkdown, written in the R programming language. R is a statistical tool widely used to analyze data in academic or professional settings. Using RMarkdown is a perfect way to share all results and conclusions with your audience.\nMany scientific packages are also available that can be installed in Linux via the Apt, yum or pacman package managers.\nApt: It is installed as part of the DEB package in Ubuntu-based distros such as Debian or Kylin. Also, you can install it directly onto other distros by adding PPA.\nyum: It is the yum package management system in",
        "label": 0
    },
    "1108": {
        "output": "<EOD> Fragility of the pelvic ring in patients with spinal cord injury: case-control study\n\n\n\n# Introduction\nSpinal cord injury (SCI) can cause significant morbidity, mortality, and a major burden on patients [bib_ref]  A retrospective study of the prevalence of comorbidity in a spinal cord..., Simpson [/bib_ref] . In 2006, SCI affected an estimated 1.6 million persons worldwide 2) . Incidence rates of the injuries are the highest for age groups 20-29 and 30-39 years; in the younger population, men are more affected than are women [bib_ref]  Falls and fractures under the age of 65: epidemiology, risk and prevention, Dargent-Molina [/bib_ref] . Injuries occurring in the third to sixth decades of life are generally caused by vehicular accidents, whereas falls result in injuries in the younger population [bib_ref]  Falls and fractures under the age of 65: epidemiology, risk and prevention, Dargent-Molina [/bib_ref] . In general, falls are the commonest cause of SCI in patients younger than 65 years worldwide and in the United States 1,2) .\nFractures are a common result of falls in the elderly and occur in a greater percentage of older patients with injury than younger ones [bib_ref]  Injury profile of faller and nonfaller elderly women with osteoporosis, Haussler [/bib_ref] . Spinal fractures are associated with a high mortality rate 1,4, [bib_ref]  Epidemiology of admission and mortality rates of patients with spine fractures, Payer [/bib_ref] . In North America, fragility fractures have been estimated to be responsible for 50% of deaths [bib_ref]  Hip fracture, mortality risk, and cause of death over two decades, Von Fliedner [/bib_ref] . Spine fracture patients were found to have a 3fold greater risk to die at the two-year mark, 4) . Compared with general population, SCI patients are 2.5 times more likely to encounter death in the first year after injury, with 85% experiencing at least one complication 1",
        "label": 0
    },
    "1109": {
        "output": "# A real patient note\n\n## Diabetes mellitus during pregnancy in a 39-year-old female\n\n## What are the exclusion criteria?\n\n## (1)\nPre-existing serious heart disease;\n(2) Pre-existing kidney disease;\n(3) Pre-existing thyroid dysfunction;\n(4) Pre-existing liver disease;\n(5) Pre-existing lung diseases, including asthma;\n(6) Pre-existing diabetes.\n\n## (7)\nA family history of genetic diseases;\n(8) Unprotected sexual contact;\n(9) Pregnant more than 3 times;\n(10) Smoking in the last 12 months prior to pregnancy, or cigarette sm",
        "label": 0
    },
    "1110": {
        "output": "Good luck.\n\n\n_Trial-level eligibility:_ 2) Eligible.\n<EOD> .\nThe relationship between the distribution of CK7(-)/CK20 (+) immunoreactive bile duct tumor cells (IBDTC) and the histological grade and lymphatic invasion status of the tumor was examined in 15 cases of small cell carcinoma of the lung (SCLC) to clarify whether an immunochemical marker is helpful for identifying metastatic adenocarcinoma to the liver with IBDTC, especially when these tumor cells are rare. In three cases studied using immunohistochemical methods, immunoreactive IBDTC were very rare and found in only one of a 0.8 mm thick section prepared manually (1/23.9 mm2; 0.4%), one of 25 sections 240 microns thick from paraffin block (1/6.25 mm2; 0.16%) and in one out of 110.6 mm2 (0.08%) in the other two cases, in which all the samples were stained using the computerized immunostaining method. The immunohistochemical results of the three cases showed that the CK7(-)/CK20 (+) cells were well differentiated, suggesting that SCLC can metastasiz to the liver as well as the lungs, and that in such cases metastases to the liver were few. Immunohistochemical methods can be used to confirm that tumor cells in resected livers are IBDTC in small number and not the common metastatic adenocarcinoma that develops after surgery.<EOD> Vulvodynia in pregnancy.\nA number of painful vulvar disorders are not due to a known infection or inflammation. The pain persists in some patients even beyond pregnancy and in others it starts during pregnancy, mostly in the second trimester. Patients usually complain of constant burning and aching pain, that is, discomfort, along with tenderness on touch. These vulvar disorders, also known as vulvodynia, affect both pregnant and nonpregnant women. They occur more frequently during times",
        "label": 0
    },
    "1111": {
        "output": "You should repeat `Trial-level eligibility:` when you have new lines of text.\n\nThis is an optional section that allows you to display text.\n[INST] Use the following code to display text before or after a comment.\n\n`Trial-level eligibility:`\nText before a comment\nComment\nText after a comment`<EOD> Cytotoxic and antiviral activities of cucurbitane-type triterpenoids from the stems of Momordica charantia\nThe stems of Momordica charantia are used for the treatment of various diseases of China, in which their medicinal functions are attributed to the phytochemistry. As a further chemotaxonomic study, six new cucurbitane-type triterpenoids (1\u20136) along with 11 known ones (7\u201317) were isolated by bioassay-guided fractionation. The structures were determined by extensive spectroscopic analysis. Compounds 1\u20136 were aromatic-type (A) cucurbities represented by the core A20,25-fused cucurbitane skeleton, compounds 7\u201311 were aliphatic-type (B) cucurbities, while compounds 12\u201317 were A\u2013B hybrid type (AB) cucurbities. According to the antiviral screening evaluation, 1\u201317 exhibited significant cytotoxicities against human hepatoma (HepG2), human lung cancer (A549), human breast cancer (MCF-7) and human prostatic carcinoma. Among of them, 4 (IC50\u2009=\u20091.29\u2009\u00b1\u20090.16\u2009\u03bcM) showed the most activity against hepatitis B virus (HBV)-related hepatocellular carcinoma (HepG2. 2.2.15) to be compared to the positive control entecavir (IC50\u2009=\u20097.25\u2009\u00b1\u20090.17\u2009\u03bcM), which indicated the potential application of M. charantia in antiviral therapy.<EOD> Ectopic pregnancy: an audit of management\nObjective\u2003To analyse the case series of ectopic pregnancy",
        "label": 0
    },
    "1112": {
        "output": "##[TUTORIAL] Hello everyone! You are in need to work with elasticity of a given material. You can get the amount of stretch by knowing the tensile modulus, which varies across types of material. Also, the stress relaxation of a material, which is called a relaxation modulus R, is useful to determine the elastic properties of a material. R denotes the ratio of stress to strain at t = \u03b4 t /\u03b4 0 . At the beginning of stretching (strain \u03b4 0 ), we exert stress \u03c3 0 on a material and the amount of stress after stretching \u03b4 = \u03b4 t is denoted by \u03c3. After a while, we let the material rest without any exerted stress, and the stress goes down to some extent to \u03c3 t . If we let the material rest for an infinitely long time, the stress of the material would become \u03c3 \u221e . \nHere is the material example:\nYou should use the input file in the MAT-file named 'sample101_material_example_file.txt ' to predict the Young's modulus and also use output file in the MAT-file named 'sample101_tension_relaxation_material_solve.txt ' for all the above mentioned steps. For more detail: https://matlab.mathworks.com/help/tie/single-time-step-example.html\nFirst of all, you need to define the material, so add the block for defining a constant 'C101' into your MAT-file:\nFirst of all, we should know Young's modulus of C101. You can refer to the material file for calculating the yield stress (Y):\nHere, we assume the stress to be 200 for Y. Also you can calculate the yield strength for yield stresses less and more than 200 by following the example:\nNow we have the yield stress of C101, let's create a constant named 'C102' which stores the values of Young's moduli for C101.\nNow, let's create function to use in tension-relaxation problem, in particular define a function 'tens-relaxtion' which takes three inputs: 1) 'Strain' - Stretch or elongation; 2",
        "label": 0
    },
    "1113": {
        "output": "## \u2714\ufe0f Instruction Notebook\n\n### Assignment:\n    1. Read the instructions carefully.\n    2. Enter the patient note and clinical trial into the assessment. You are allowed to use the patient note to evaluate the trial.\n    3. You must finish this assignment in one go within one hour.\n    4. If you use an additional time, you lose your chance to resubmit the assignment.\n    5. Make sure you use the same name and user ID for the assessment.\n\n### Submission:\n    1. Submit your attempt by clicking the Submit button on the Assessments page. If you submit a resubmitted attempt, you will be asked why you submit a resubmission.\n\n### \u2714\ufe0f Instructional Notebook\n\n### Task 3.4.1:\n\n## Task 3.4.1b:\n    1. Your task is to write down the patient-related factors that make someone eligible or ineligible in inclusion and exclusion criteria. When you write eligible and ineligible, you must mention your rationale behind your assessment or how you reached your final level of eligibility. Remember that you are required to write these patient-related factors once and clearly on the assessment form. \n    2. Copy the code block above to your assessment on the assessment form by clicking the \"Copy to assessment\" button. To add a patient-related factor:\n        ```bash\n            1) Click the \"Trial-level eligibility:\" option at the upper right.\n            2) Write down your patient-related factors on the form.\n            3) Click the copy from the bottom left.\n            4) Click the \"Trial-level eligible: 1 or more gall stones in bile duct which cannot be removed using conventional methods \n                     (must be fragmented) \"\n              option at the upper right.\n            5) Write down your patient-related factor on the form to the corresponding position.\n            6) Click the copy from the bottom left.\n```\n\n### Submission:\n    1. Note that there is no Trial-level eligibility for any cases.\n    \nYou should submit your submission for the task (Task3.4b) by 18 A",
        "label": 0
    },
    "1114": {
        "output": "A. `patient note` - Step by Step Ex: P1.\n``El nombre del paciente es #P1`` #Rename a field\n```\nEl nombre del paciente es #P1\n\n#Patient note:\nEpigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. ...`` #Patient note\n\nHormonal -Pregnancy test #Hormonal\n``` \u2026`` #Hormonal\n\nMigra -Migraine -#Migraine\n``` \u2026`Migraine`\n\nPale -Pale skin -#Pale\n``` \u2026`` `Pale`\n\nFracture -Break of Bone -\n```\u2026``` www.datalad.org/projects/cakli\n\n\n\n\n\n\n\nA. `clinical trial` - Step by Step Ex: C1-1-6-3\n\n```\nTrial name: #C1\n``` `Trial name:`\n\n```\n#C1-1\n``` `Clinical trial`\n```#C1-1-6``\n````Clinical trial``\n\n```\nCause: #C1-1-6-5` #Cause of trial\n````Cause of trial`\n\n```\n#C1-1-6-5-1`` #Cause of trial\n````Cause of trial`\n\n```\nNausea` #Condition\n````Condition``\n\n```\nAffected: #C1-1-6-5-1-1` #Condition\n``` www.kaggle.com/c/deeplearning-for-natural-image-classification/data and e.g.,\n\n\nNausea - 1:00 to 1:30 min \n\n\nVomit - 1:30to 2:00 min\n\n\nEvaluate whether the patient is eligible for this clinical trial or not. [INST]`\n```\nPatient note:\nNausea radiates to right upper quadrant, with nausea and vomiting two times in last year.\n\nNo: Nausea -Pale skin - Preg",
        "label": 0
    },
    "1115": {
        "output": "Please submit your final patient note in a  txt/docx file, which means that you should provide the text of the patient note itself. For example, by copying patient note text into the file, you can send your file to [EMAIL], e.g., `sorry for inconvenience. PLEASE check the attachments - your final patient note should have only text part`. \nYou should also read the [Instructions to Authors](https://www.springernature.com/gp/authors/instructions) for a more detailed explanation on how you should prepare your manuscript. \nPlease use [these notes](https://www.springernature.com/gp/authors/researchers-and-academics/language-policies/english) to make an electronic copy of the latest version of our manuscript file following the format as indicated in the Editorial Manager system. The first author's name should appear on the title page. The names of all authors must use their full first names without abbreviations throughout the text of manuscripts, e.g., for G. B. Brillouin the first name is Gilbert, surname Brillouin.\nAll manuscripts should include a complete title page including the manuscript title and authors' footnote information. You also need to create a full manuscript and a table of contents (TOC) file containing only the text of the manuscript (the TOC must not contain page numbers) in order to make an online edition. These files should be submitted as electronic supplementary file(s) (see below). The text should be left justified, the tables and equations on both sides of the page. Text and headings should be in 1.2 times or 1.5 times New Roman, respectively. All sections in the manuscript file have to be numbered starting from 1 (e.g., Abstract, Introduction, Patient note, etc.).\n\n\n**We would ask for a cover page to include the title of the paper and a brief (2-3 sentences) summary of the paper to emphasize key findings and/or message. The authors will be required to provide three high-resolution figures for the print production. The first figure will be presented as the cover of the printed issue, the second as the  **EAHJ poster of the issue, and the third figure will be presented on",
        "label": 2
    },
    "1116": {
        "output": "Let`s do the first step. We start by finding all the values of the `female, ' which is the gender variable of the patient. Since it is a list, we have to use a loop and we get the values from the loop. A list contains only certain values and does not contain all the possible values of a variable. Then the next line is about finding all the values in which the variable `age' is less than or equal to equal to 54. The condition is always used with the `==` operator in R. \n\n```r\n[a] <- which(sapply(p,\"Female\"), p)\n[b] <- which(p$Age <= 54) \n\n```\n\nLet`s create a 2D matrix and insert the values that we got in the previous steps of `female`, and  \\`age`. We get the 2D matrix with  \\`female`, and  \\`age`. We get a 2D matrix with 3 rows and 2 columns  \\`Female`, and  \\`age\\` which will have the values 0, 1, and 2 respectively. Then we use the row values to determine the next step. \n\n```r\n    n =  # You should insert the number of your preference into the number in the code, e.g., `n = 6\u00b4.\n    # n = 1016. I got an example from.\n\n    ncol = 2\n    x = matrix(c(Female= \"0\", \"1\",\"2\",\"0\",\"1\",\"2\",\"0\",\"1\",\"2\",\"0\",\"1\",\"2\",\"0\",\"1\",\"2\",\"0\",\"1\",\"2\",\"0\",\"1\",\"2\",\n\n        \"0\",\"1\",\"2\"), by = (1 : n,1 : 1))\n    x%>% \n      # Insert the number of your preference into the number in the code, e.g., `x %>%  ncol = n`\n\n    x <- x %>% \n      ncol = n\n    x = x%>% \n      as.factor()\n```\n\nNow we will prepare the `x` variable. The number of the list is the index of the `female`, and the list contains",
        "label": 0
    },
    "1117": {
        "output": "For details, check this article.\n![Screen Shot 2017-03-29 at 11 44 59 AM](https://user-images.githubusercontent.com/5084761/30310870-d997c0fc-07e0-11e7-9b40-994cafecb162.png) <EOD> .\nIn this paper, the characteristics of the gas chromatographic-mass spectrometry (GC-MS) fingerprints of Rhizoma Cibotii and seven species of similar medicinal materials were investigated. As a result, some differences were found among different species from which a qualitative method was therefore established. 5 chemical compounds, N -ethyl -N (2-pyridylmethyl) propionamide, 11 (12)-Cinquefolia A, 13(Z )-octadecenoic acid, octadecadienoic acid methyl ester, (E)- and (Z)-6-O--1-piperideine, were identified to be the typical chemical markers for the quality discrimination of Rhizoma Cibotii from other species. The method could be used to standardize Rhizoma Cibotii, monitor the quality of this medicinal and trace the adulterants.<EOD> The efficacy and safety of thrombopoietic agents for the prevention of platelet transfusion refractoriness in patients undergoing orthopedic surgery\nABSTRACT Introduction: Major bleeding is still a common post-operative adverse event encountered in approximately 40% of patients undergoing surgery for orthopedic indication due to a reduction in the platelet count. Furthermore, in patients who are refractory to conventional platelet transfusion, new therapies may be required. Areas covered: In this review, the authors aim to discuss the efficacy and safety of the therapeutic platelet transfusion, the prophylactic administration of plasma with or without an additional treatment with antibiotics or erythropoietin, and two different thrombopoietic agents, eltrombopag and romiplostim, as possible treatments to prevent",
        "label": 0
    },
    "1118": {
        "output": "### \t\t<h1>Question 2: How can you handle cases where a patient matches more than one clinical trials?</h1><pagebreak>\n\nA patient matching more than one clinical trial requires further investigation.\n\n1. Find the target table in which this case could be located.\n2. Add an additional column in this table and insert the value of the patient into this column. For instance, the following table is used to investigate a candidate to enter a clinical trial.\n| `ID` | `Condition-id` | `FullName` | `Name` |\n| :--- | :---: | :--- | :--- |\n| 1L1 | 2019102712 | Abdo | Sara |\n| 1L2 | 2019102712 | Abdo | Mary |\nTable 2. Reproducing patients to clinical trials\n\n3. Select the record set based on the criteria:\nRecord Set = 2019102712 * Abdo * Sara\n4. Examine patients matching more than one trial in order to select the most eligible patients.\n![Figure 2](../images/eligibility_fig2.png)\n\n5. Find out about an eligibility assessment for patients matching multiple clinical trials.\n![Figure 3](../images/eligibility_fig3.png)\n\n6. Use `DELETE` if you decide to remove patients from a trial.\n\n## The Eligibility Assessment\n\nOne of the most important tasks of medical trials is patient eligibility assessment. During the trial, clinical professionals use the eligibility assessment to identify possible participants and help them meet trial eligibility requirements. Eligibility assessment of potential participants helps them to assess if they are good candidates for a study. It also helps to assess how different potential participants might respond differently in clinical trials.\n\nA medical trial typically requires patient eligibility assessment at several points during the trial's trial run phase. A series of steps is involved in the patient eligibility assessment process, and these steps are detailed in more detail in the following sections.\n\n##### 1. Eligibility assessment for the study",
        "label": 0
    },
    "1119": {
        "output": "[/TEST]\nQuestion 3\n[QUESTION}\nWhat is your diagnosis on this patient?[/QUESTION]\n[ANSWER] In patients with diabetes, the management of peripheral artery disease (PAD) is challenging.\nPeripheral artery disease (PAD) is an atherosclerotic cardiovascular disease that frequently occurs among patients with diabetes. However, the management of diabetes with concomitant PAD has not yet been fully evaluated. Therefore, it is important for clinicians who manage diabetes and PAD to understand the issues from both diseases.\n\nThe following sections present the recent advances and clinical issues on PAD management in patients with diabetes.\n\n## Diagnosis\n\nThe diagnosis of PAD is based on measuring the ankle-brachial index (ABI). An ankle-brachial index value less than 0.9 was generally considered pathological, as observed in approximately 27% of patients with diabetes. A low ABI is considered a strong determinant of adverse outcomes in diabetes, such as major adverse cardiovascular events. Consequently, a low ABI is an important factor for the management of cardiovascular disease in patients with diabetes.\n\n\n## Clinical implications\n\nThe pathophysiology of PAD includes atherosclerotic occlusive artery disease, the main cause of PAD in diabetes, with calcification, and atherothrombotic lesions. Diabetic patients with multivessel coronary artery disease should have concomitant multivessel PAD. Therefore, patients with this combination show a worse prognosis compared with patients with singlevessel disease.\n\nFor the management of patients with diabetes and PAD, the current strategy is to perform endovascular therapeutic interventions aiming at improving ABI, which is usually conducted with the aim of revascularization of below-knee arteries. However, it is difficult to estimate the severity of lesions in diabetes from noninvasive imaging. Therefore, the indications for interventional treatment are usually determined by considering the ABI and the characteristics of each patient.",
        "label": 0
    },
    "1120": {
        "output": "This will look like:\n\n![image](https://user-images.githubusercontent.com/14750459/62355895-77b50c00-b959-11ea-9e91-bbb08a05ae13.png)\n\n### Sample code\n\nIn Python 3.x:\n```python\ndef assessment_tool(patient, trial):\n    print('Triallevel eligibility::', trial.trial_level_eligibility)\n\npatient_note = {\n    'patient': {\n        'demographics': {\n            'age': '54',\n            'age_male': 'male',\n            'age_female': 'female'\n        },\n    'medication': [\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0{\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_name': 'statins',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_class': 'statins',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_male': '0',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_female': '1',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_mg': 'atorvastatin'\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0},\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0{\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_name': 'fentanyl',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_class': 'fentanyl',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_male': '0',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_female': '2',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_mg': 'transdermal patch'\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0},\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0{\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_name': 'aspirin',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_class': 'aspirin',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_male': '2',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_female': '2',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_mg': 'aspirin 75 mg'\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0},\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0{\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_name': 'acetaminophen',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'medication_class': 'acetaminophen',\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0    'med",
        "label": 0
    },
    "1121": {
        "output": "__2.1.x__\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the  eligibility assessment criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.",
        "label": 0
    },
    "1122": {
        "output": "In the next part, instead of having the trial-level eligibility statement in one line, consider using separate statements for each eligibility check. In the clinical practice when a clinician checks for patient's eligibility, she usually uses decision rules. These decision rules are not part of the decision algorithm, they do not have precedence or conditionals involved, they just have condition statements. As eligibility criteria usually consist of combinations of conditions from the dataset, it is natural to use decision rules to check the eligibility. It also enables better readability of the data in the trial level and provides more informative error messages in case of eligibility problems.\n\n## Step 5: apply the conditional statements\n\nAssume the following conditional statements:\n'Inclusion criteria: gender==female'\n'Inclusion criteria: age!0'\n'Inclusion criteria: gender!=male'\n'Inclusion criteria: gender==male'\nYou should create conditional structures for them, e.g., as follows:\n: [Gender]!='Male'\n: [Gender]!='Female'\n: [Age]>'0'\n: [AGE]='0'\nAdd them to the existing data as well:\n$data['[Gender]!='Male']=[0]\n$data['[Gender]!='Female']=[0]\n$data['[Age]>'0']=[0]\n$data['[AGE]='0']=[0]\n\nAnd finally, assign them to $data.\n[INST] You are the trial's inclusion criteria evaluator. You should verify the eligibility of each patient based on the inclusion and exclusion criteria. You can use this test to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for clinical trial, that is outputting the scale for the assessment of eligibility. \nNow this is",
        "label": 0
    },
    "1123": {
        "output": "<h4 id=\"data-validation\"> Data Validation </h4> \n<ul class=\"tasklist\"><li class=\"tasklist-task complete\">\n<input checked type=\"checkbox\" class=\"todoCheckbox complete todoTask-item-1\" value=\"1\" id=\"task-0\" onchange=\"toggle(this); taskId = this.checked? 1 : -1;\">\n<label for=\"task-0\" class=\"taskListToggler\"> Task 0.1. </label>\n<span class=\"tooltip tooltip-task\" data-tip=\"Exclude the patient\"> Remove the check mark to exclude the patient.</span>\n\n\t<span class=\"tooltip tooltip-task-description\" data-tip=\"Incomplete: The note lacks a diagnostic code, the eligibility criteria is >60% checked, or the patient is not eligible based on the notes.\" data-for=\"task-0\" data-tip=\"#tooltip_eligibility_criteria_task-0#\">\n\tThe patient meets inclusion criteria\n\t</span>\n\n\t<div class=\"labelCheckboxContainer labelCheckboxContainer-task\" data-label=\"#todoLabel\"> [<span>?</span>]</div>\n\t<div class=\"tooltip-task-content\"><span data-tip=\"#todoLabel\">Label:</span> Label the patient</div>\n\t<span id=\"todoLabel\" class=\"tooltip-task-content\"></span>\n</li>\n<li class=\"tasklist-task complete\">\n<input checked type=\"checkbox\" class=\"todoCheckbox complete todoTask-item-2\" value=\"1\" id=\"task-1\">\n<label for=\"task-2\" class=\"taskListToggler\"> Task 82.1. </label>\n<span class=\"tooltip tooltip-task\" data-tip=\"Exclude the patient\"> Remove the check mark to exclude the patient.</span>\n\n\t<span class=\"tooltip tooltip-task-description\" data-tip=\"#tooltip_eligibility_criteria_task-0#\">\n\tThe patient meets inclusion criteria\n\t</span>\n\n\t<div class=\"labelCheckboxContainer labelCheckbox",
        "label": 0
    },
    "1124": {
        "output": "## [END]\nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., a set of patient-level eligibility. For this patient, you need to apply the following logic: Above all, you need to check the values of Inclusion criteria field. If the value is 1, then 2), otherwise 0). If you cannot fill '2) Eligible', you should check the Exclusion criteria field. If the value is 1, i.e., \"excluded\", then you should skip the rest, otherwise you should check the other fields to see if there are any exceptions which make the patient ineligible, e.g., \"Not relevant\", \"Experimental trial\", or \"Unavailable date and time\". \nHere is the patient-level eligibility for this patient:\n\n## 1) not relevant\n2) Not relevant \nExperimental trial \n- Unavailable \n\n## [END]\n\n\n## #2 Inpatient\nYou should compare one patient's history for inclusion in the following RCT or clinical trial:\nA randomized clinical trial with three arms in which all participants will be treated with the same standardized surgical treatment.\nThe clinical trial seeks to answer the question whether the recovery of patients in a high dependency unit (HDU) after high-risk cardiac surgery is associated with a reduction in mortality.\nThe aim of this study is to investigate whether the time spent in the high dependency unit (HDU) after cardiac surgery is associated with the number of medical complications, the length of stay in the hospital and the patient's satisfaction with care in a cardiac surgery unit.\n- Randomized, controlled, prospective clinical trial in patients with atrial septal defect who are to undergo percutaneous device implantation. The aim of the trial is to assess the best implantation technique for this condition and to investigate the influence of other factors on implant success.\n\n## Inclusion criteria\nPatients aged 17 to 75 years, male or female, undergoing isolated correction of atrial septal defects, ASD) by a percutaneous technique, with or without ASD occluder implantation, class A2 to C2 according to NYHA criteria.\n\n## Exclusion criteria",
        "label": 0
    },
    "1125": {
        "output": "### P13: Recruitment\n1. 0. Recruitment: Determine how to approach potential patients or how to recruit potential patients for participation in a clinical trial. The factors determining how you select patients as potential candidates are called inclusion criteria. This step should occur before the enrollment of patients.\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nHere is the clinical trial: \nTitle: Transient ECG Changes in Patients With Acute Biliary Disease\n\n\nSummary: Background:~",
        "label": 2
    },
    "1126": {
        "output": "# Evaluation\nThe clinical trial should be assessed the eligibility rate using the follow metrics: [/TEST]\n\n# Authorship\nAll authors should meet the ICMJE Criteria for Authorship in publishing a medical article. You must be able to identify all authors by reading any published version of the paper. In particular, all people who have substantially contributed to the reported work are placed on the list of contributors. All individuals who have contributed to the reported work in a significant manner, but whose names are not found in the acknowledgements, are listed under the heading of contributors (with the exception of those individuals whose contributions are considered the responsibility of institutions or companies). [INST]\n\n# Ethics\nWe have written the Ethical Statement of the patient and the eligible trial for this activity. [ETHIC]\n\n## Ethical statement for the patient\nThe clinical trial should be assessed the eligibility rate using the follow metrics:\n\n## Ethical statement for the eligible trial\nAll authors must comply with their institutions Ethical Statement Policy including acknowledgement of ethics committee approval (if appropriate). The names of the persons or committees who gave approval for the research should be displayed on the title page of the paper. Where approval has been given by a committee, the name of that committee should also be included in the Acknowledgements. The ICMJE lists the following as items that require such ethical approval:\nResearch conducted on identifiable human data or tissues Any identifiable information in case reports and/or in images should be removed.\n\n# Funding\nThere is no funding.<EOD> Experimental study of single-phase-laser processing of glass surface for microsurgical instruments.\nThis work studied the effect of various parameters on single-phase-laser processing of glass surface. Experimental results suggested that the processing effect was mainly affected by laser fluence and spot size but not by the wavelength. Laser fluence of 1.8 J/cm(2) could get better surface quality and better morphology characteristics, smaller roughness and more uniform. When compared with the experimental result of using a laser beam with a diameter of 10 mm on tissue surface of stainless steel, this work suggested that the laser beam with a diameter of 105 mic",
        "label": 0
    },
    "1127": {
        "output": "<EOD> Vestibular Schwannoma: Management Challenges Relating to Hearing and Facial Nerve Function.\nVestibular schwannoma results from a benign and slow-growing tumor arising from the vestibular division of the eighth cranial nerve, which can expand into the internal auditory canal, Meckel's cave, middle cranial fossa, and sometimes even the internal jugular vein. Different treatment modalities such as surgical resection, radiotherapy, and a combination of radiation therapy and surgery should be considered on an individual basis, balancing the tumor size, hearing function, and facial nerve function when determining the management of these tumors. In the era of advances in imaging and more sophisticated radiation techniques, radiation therapy plays an important role with respect to tumor control as well as maintenance or improvement of pretreatment hearing thresholds. To avoid adverse radiation effects and unnecessary treatments, regular follow-up with repeat audiometry and magnetic resonance imaging is needed.<EOD> Neurofibromatosis Type 1. An Update of Disease Guidelines and an Analysis of Inherited Neurofibromatosis Type 1-Associated Cancers\nPurpose:Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized by cutaneous and systemic manifestations. The NF1 gene, which is located on chromosome 17q11.2, encodes the protein neurofibromin, which acts as a tumor suppressor, inhibiting formation of various neoplasms. The American Academy of Pediatrics revised its clinical practice guidelines for the diagnosis of NF1 in January 2010, which will allow clinical diagnoses to be made at earlier stages of the disease. Materials and Methods:The authors performed a review of the neoplasms associated with NF1. They looked at the type of cancers associated with NF1 and their associated risk factors in NF1 patients. Results:The most common associated cancers in the NF1 patient population are acoustic neuromas, gliomas, and gastrointestinal stromal tumor. Patients with NF1 had an increased",
        "label": 0
    },
    "1128": {
        "output": "# Results\n\nIn this chapter, you can find the results of the assignment. You had to complete two assignments. Each of them was completed on the same basis and you can find instructions on the page Assignment description. Both assignment files (A for Chapter 5 and B for Chapter 6) consist of a Markdown file, a RMarkdown file, and two R files, RMarkdown Report and RMarkdown Results. See [http://stat256.de/exercises.htm](http://stat256.de/exercises.htm) for details of how to use the files.\nYou have to upload the folder `Teaching/Lectures/2020A, 2021W/Assignment5/5H.1/` (folder with markdown files that contain the assignment) to the Blackboard as `Teaching\\Lectures\\2020A,2021W\\Assignment5\\5H.1\\` and you have to submit the R files: `R.Results.pdf` and `RMarkdownReport.Rmd`, uploaded to the Blackboard as `Teaching\\Lectures\\2020A,2021W\\Assignment5\\5H.1\\`.\n\n\n#### Task A: [Exercise_S1 (1).pdf](https://stat256.de/exercise_s1(1).pdf)\n\n\nAll of your code has to be prepared with a clear title, headings, bullet points (if necessary), and, of course, written in English. Please use an appropriate language and be concise but complete. You can also use the template `Exercise S1, 5H.pdf` as the starting point (I already rearranged the code parts so that the assignment is clearer). All your files should be located in a folder.\n\n\n#### Task B: [Exercise S2 (1).pdf](https://stat256.de/exercise_s2(1).pdf)\n\nPlease be very clear and concise, i.e. prepare your code for each part in a row and make sure that (1) everything is cleaned up at the end of every part and (2) every piece of code fits to the corresponding R",
        "label": 0
    },
    "1129": {
        "output": "<EOD> Evaluation of dietary fiber: method development and standard reference materials.\nThis paper reviews current issues related to dietary fiber analysis and development of a dietary fiber reference substance. Dietary fiber (DF) is an important nutrient in a properly balanced diet. There are many types of dietary fibers found in fruits, vegetables, and cereals, and most of these compounds have not been identified or evaluated for their physiological effects in the human body. In vitro methods have been developed that mimic the physiological characteristics of the complex mammalian digestive tract, and these tests allow for the identification of components within fruits and vegetables that can act as dietary fibers in vivo. These methods are important because the nutritional value of a food depends on the nature and the proportion of fibers that are not digested in the small intestine and that are eventually deposited on the colon. Methods include in vitro estimation of: soluble DF (SDF), insoluble DF (IDF), soluble nonfermentable DF (SDFNF), total fermentable DF (TSDF), and total DF (TDF). Data derived from these assays may be incorporated by legislation into food labeling, and will assist in identifying the type and amount of fibers present in a new or unclassified food or beverage, as well as providing a basis for establishing standards to enable the evaluation of new or unclassified foods. For the development of reference substances of high purity and traceability, DF in food-grade cereal grains (corn, wheat, oats, and barley) was determined by the AOAC Official Method 2009.01. Standard materials of highly purified DF (SDF) or IDF (IDFI) were derived from the AOAC Official Method 2009.01, with additional steps including concentration and extraction, preparation of a homogenous solution, and lyophilization to create two standard materials with a DF concentration of 10 g/100 g or >93% D",
        "label": 0
    },
    "1130": {
        "output": "### Sample\n\nYou should not count the number of excluded patients, not only because counting is easy but counting can be a distraction. Just simply repeat the eligibility evaluation for all patients.\n\n### Practice\n\nThere are no instructions for practice. In real clinical trials, each researcher or institution has his or her own instructions.\n\nInstructions for running the example on [RTF][RTF]<EOD> Preliminary data on treatment with L-threonine following induction of depression- and anxiety-like behaviors in mice through restraint stress\nAbstract Restraint stress model was investigated in the present study to assess the effects of L-threonine (TRO) on depression-and anxiety-like behaviors in mice. Stress group showed higher immobility time than control group in forced swimming test. However, TRO significantly decreased immobility time, an accepted parameter of depression-like behavior in mice. In addition, reduced time spent in open arms in elevated plus maze test was also observed and TRO prevented this change. There were no changes in locomotor and neophobia activities. Further investigations using biochemical and molecular biology techniques may clarify the possible underlying processes of the neuroprotective properties of TRO in the brain.<EOD> Identification of a novel human immunodeficiency virus type 1 envelope variant found in the brain containing a discontinuous deletion\nHuman immunodeficiency virus type 1 (HIV-1) is able to establish infection in the central nervous system (CNS) of infected humans, causing nervous system disease. While envelope appears to be a major determinant of in vivo cell tropism, we do not know whether there are any specific envelope features that correlate with CNS infection. To address this question, we cloned the HIV-1 envelope genes directly from the cerebrospinal fluid (CSF) of infected individuals to identify brain-specific variants. In one case, a unique envelope variant, MBC, was identified in the CSF, which contains a 9-base pair discontinuous deletion located 52 to 58 amino acids upstream of the V2 envelope domain. A similar deletion was present in a second patient who had an",
        "label": 0
    },
    "1131": {
        "output": "We will evaluate different strategies to improve the assessment of eligibility. The results will be presented in the first part of the session.\n\n# Statistical analysis\n\n## Data preprocessing\n### Eligibility estimation using bag-of-words representation\nIn the bag-of-words approach, each patient note is represented in a vector space according to the frequency with which different words occur. Words that are repeated more often tend to receive a higher score. The words are sorted in descending frequencies, i.e., the most frequent words are placed in the rightmost columns. The score of a patient note is an index vector of this note, \nWhere f i is the set of frequency of the words in terms of the patients with 0 and 2. Note that the number of most repeated words is 15 (f15 = 3 in both 0 and 2), which equals to the number of columns. Finally, the score can be computed as:\n\n### Eligibility estimation by word-embedding representation\nWord-Embedding is an ML method that captures the semantic properties of the words in a document. Unlike the bagof-words approach, the words are represented as vectors. In the training process, each word has an associated vector, whose components are randomized at the beginning. The words that occur more frequently tend to cluster into the space whose component values are closer. For more details, see the original paper: .\nWord2Vec package by [Johns Hopkins University and its contribution from the Google project](https://github.com/google-research/word2vec).\nAs in the bag-of-words case, the task is to select a set of documents from the patient notes, i.e., the corpus C, for training the model. In the present study, the corpus is created with 320,048 words and used a skip gram classifier. The corpus was built with: 3\\*20 patient notes; i.e., 60,096 notes in total. The data were preprocessed, as follows:\n- Removal of non-alphabetical characters: '!@#$%^&*()_+ *, - Removal of punctuation: \",;:, . / / . ?, ;:, , - Conversion between uppercase and lowercase letters, and",
        "label": 0
    },
    "1132": {
        "output": "*The title, abstract, and patient note, along with their RDKit annotations and RSTLs can be found at [https://datascience.rstudio.com/t/lh76ff744b3b](https://datascience.rstudio.com/t/lh76ff744b3b) (log-in required) and at [https://github.com/v-lucic-lab/Trial_Eligibility_Inst](https://github.com/v-lucic-lab/Trial_Eligibility_Inst).\n\n### P1_037_12d - Evaluation of patient-reported symptoms and outcomes in adults undergoing treatment with acetaminophen, ibuprofen, or codeine\n\n_Problem 1_ You need to read in [Instructions for Reading in RSTLs](README.md) and [RSTL files](https://github.com/rstudio/trial_eligibility/tree/master/resources/RSTLs). \n[https://rstudio.r-project.org/packages/trialres/vignettes/RSTLs/readme.html](https://rstudio.r-project.org/packages/trialres/vignettes/RSTLs/readme.html)\n\n__[STL format](https://rpubs.com/v-lucic-lab/5f02fcaaa5b1)_: You will read the STL format of the RDKit annotated patient note (`Read_Trial(s)())`.\n\n__[RSTL format](https://rpubs.com/v-lucic-lab/5f02fcaaa5b1)_: You will read the [RSTL file](https://github.com/v-lucic-lab/Trial_Eligibility_Inst/blob/master/rstl-trial-evaluation-patient-reported-outcomes-treatment-with-acetaminophen-ibuprofen-or-codeine.rstl?raw=true).\nYou can read a brief description of the file in [RSTL files](https",
        "label": 0
    },
    "1133": {
        "output": "---\n```diff\ntitle: eligibility_clinical_trial.md\nfile_path: eligibility_clinical_trial.md\nlanguage: python\nlanguage_type: \nsource_url: https://dataverse.harvard.edu/dataverse/dataverse-data-repository\nlanguage_name: Python\n---\n1. Copy and paste the title and the source file to the Jupyter Notebook.\nIf you use an e-reader, click the share button in the right side of the document and use the `copy to clipboard` feature and paste it to the Jupyter Notebook.\n\n2. If you want to test your code, run the cell, in which the title is located.\n\n3. The Python program should tell you how to format the data and add the trial-level eligibility statement. \nThe outputted statements as well as the formatted clinical trial (in `data/clinical_trial_data.csv`) data should be copy pasted into each patient note.\n<EOD> Transcriptomic changes induced by Bcr-Abl interference with a single RNA aptamer in a chronic myelogenous leukemia cell line.\nMicroRNA (miR)-based anticancer therapy has progressed significantly in the past few years. MicroRNA-targeting therapeutics, such as miR-155 inhibition, have now been tested extensively as chemotherapeutic agents in clinical trials. As an alternative chemotherapeutic agent, RNA aptamer targeting is also a promising approach for cancer treatment. In this study, we evaluated the gene expression changes induced by an RNA aptamer specific for BCR-ABL transcripts in chronic myelogenous leukemia (CML). The aptamer (termed \"N375-1\" or \"N91\") induced apoptosis of the CML cell line K562 (expressing a high level of BCR-ABL-encoded protein) and repressed BCR-ABL mRNA expression in CML-specific mouse CML cells. Microarray hybridization analysis in K562 revealed that the changes in messenger RNA (mRNA) expression induced by N91 aptamer (10 microM) could",
        "label": 0
    },
    "1134": {
        "output": "After reading the clinical trial's inclusion and exclusion criteria carefully, you should be able to assess that the given patient note eligible for the clinical trial, i.e., the patient score as 2. \n\nPlease try Case 1: [`python notebook`](./notebooks/cases1-4.html).\n\n# <a id=\"CASE_2\"></a>Case 2: Patient meets the exclusion criteria\n\n![INST] Your task is to assess the clinical trial eligibility for a new patient note. \n\nThe patient note consists of the following items:\n\n\n\n\n\n\n- BMI\n\n\n\n\n\n- BSA\n\n\n\n\n\n- Age\n\n\n\n\n\n- Smoking\n\n\n\n\n\n- Existing medical conditions\n\n\n\n\n\nBP\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBR\nBP\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\nHR\n\nThe clinical study recruits people for 2 clinical trials. One trial aims to test the efficacy of a new drug to treat breast cancer, and the other aims to test the efficacy of a new vaccine to prevent lung cancer. The assessment of the clinical trial eligibility for a patient has a two-level scale: 0) Excluded; or 1) Eligible. For both trials, the patients must have breast cancer and not have a lung cancer. \n\nHere is the patient note. \n\n![INST] The assessment of eligibility requires a set of inclusion and exclusion criteria. You can observe them below. In the end, you should output the assessment of eligibility, like `Excluded` or `Eligible`, and make clear the reason for the output in the last line. For instance, if the exclusion criteria apply, you might write the following: `-- Excluded Due to age range being out of range (0 to \u226490)",
        "label": 0
    },
    "1135": {
        "output": "### 41C3540322837E347900742072776933\nFirst, the patient's first and last name are separated by a space character. Your task is then finding out the first character of the first name and the last character of the last name. You can then create a string for each patient who matches the pattern. Now, the following task is to separate each patient with other patients by a newline character.\nIn the following output, the column of each patient is not included in the final score. There is no need to print a blank space after each patient, as your function should only print a newline character at the end of the output.\n```python\n$ py_score.py '41C3540322837E347900742072776933'\n1686\n```\n\n### 41C3540322837E347900742072776933\nNow, the code should add the total number of spaces after the first and last name. For a patient, the total number of spaces is equal to (the first character of first name + the last character of last name + 1) + (the number of spaces after first and last name). After that, the code should calculate and print the column of each patient. In this last output, you should only print the columns of patients, and then print the total number of patients as 302.\n```python\n$ py_score.py '41C3540322837E347900742072776933'\n```\n\n### 41C3540322837E347900742072776933\nNow, you should change the code of your function to work with each patient's data. For a patient, the total number of spaces is equal to (the first character of first name + the last character of last name + 1) + 17 + (the number of spaces after first and last name). After that, the code should calculate and print the column of each patient",
        "label": 0
    },
    "1136": {
        "output": "## Exercise 003: Test a clinical trial recruitment algorithm\nIf your patient is 54 years old and obese with abdominal pain who was admitted to the emergency department twice in the past year due to similar pain, and with several gallstones, biliary sludge, CBD stones, her eligibility should be 2.\nIn the first step, the clinical trial assessment of eligibility algorithm checks whether the patient meets the entry criteria. \n\nThe second step is to check if this patient matches the exclusion criteria. Below is a list of the exclusion criteria. You need to look for each individual in the patient note and match that with the exclusion criteria for the clinical trial. All the matches can be checked by a simple `OR` operation. Once the exclusion criteria are checked, then you can check if the patient meets the inclusion criteria. \n\nOnce you determine the patient's eligibility, send the result to the printer using the print method defined in the file `Recruitment_algorithm.r`.\n\nIf your trial's eligibility is 2, the script should print the following line: \nInstructions: You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and clinical trial inclusion and exclusion criteria to determine the patient's eligibility for a clinical trial.\n\nWhenever you change any of the factors (i.e., the clinical trial criteria), make a new revision of the patient medical record according to the new eligibility and run the script again. Note: You should keep the same date of the clinical trial assessment and patient's symptoms. Try to follow the same pathway to determine the eligibility of the current patient as before, and try to see if it would return the patient eligibility. If you have any changes in patient notes, you must make a new revision of the patient medical record according to the new eligibility of the patient. Note: The date of the clinical trial assessment and the patient's symptoms should not change. Try to follow the same pathway to determine the eligibility of the current patient as before, and try to see if it would return the patient eligibility. If you have any changes in patient notes, you must make a new revision of the patient record",
        "label": 0
    },
    "1137": {
        "output": "</S>\n\n</SRC>\n\n<P><P>\n\n</SRC>\n</P>\n<h1 id=\"Trial eligibility\">Trial eligibility</h1>\n<P><P>\n\n</SRC>\n</P>\n<h2 id=\"Introduction\">Introduction</h2>\n<P><P>\n\n</SRC>\n</P>\n<h3 id=\"Introduction\">Background:</h3>\n<P><P>\n\n</SRC>\n</P>\n<h4 id=\"Background\">Background:</h4>\n<P><P>\n\n</SRC>\n</P>\n<p><i><b>Gallstones</b></i>\nis the presence of stones in the bile ducts, causing a series of problems that the human body suffers. It is a medical condition where the lumen of the bile duct is narrowed due to the presence of gallstones. The bile duct or bile ducts of the <i>gallbladder</i> are a series of tubes that carry bile to the small intestine. The bile is a liquid that aids in digestion. This fluid is produced by the <i>liver</i>, and then stored in the gallbladder until food is consumed. This fluid, along with <i>cholesterol</i>, turns into a solid called a gallstone. Gallstones can develop in any part of the bile duct, either in the large or small intestine. These stones may occur due to high pressure or slow transport, or simply due to a defect in the bile duct.\n\n</P>\n<p><i><b>H. Pylori</b></i>\n is a gram-negative spiral-shaped bacteria located in the stomach, and is one of the major causes of various stomach cancers, as well as gastric ulcers. In most cases, when the patient first encounters pylori, the immune system is able to attack the pathogen, eliminate it, and prevent infection. In some cases, however, the infection takes place. In rare cases, H.Pylori could also be present in the gastr",
        "label": 0
    },
    "1138": {
        "output": "[Exercise]\n\n# Example\n\n![example](images/gallery.png)\n\n# Output\n<EOD> Diagnostic Test Accuracy of Point-of-Care Testing Devices for the Detection of Pandemic Influenza (H1N1) 2009\n\nObjectives: During the pandemic influenza (H1N1) 2009 (H1N1pdm09) outbreak, point-of-care (POC) devices have been commonly used because of their speed and convenience. We aimed to show the diagnostic accuracy of the rapid antigen detection method (RADM) in patients.Methods: Data were collected from patients with suspected in\ue104uenza who had respiratory symptoms. Nasopharyngeal swabs were collected for RADM. Nasopharyngeal specimens simultaneously collected were tested by reverse transcription-PCR (RT-PCR) and real-time RT-PCR. Using a commercial kit, specimens were inoculated in Madin-Darby Canine Kidney cell cultures and titrated.Results: A total of 145 patients (89 males and 56 females with mean age of 28.3 years) were included in a retrospective study. The RADM was compared with the results of reference assays by RT-PCR (n\u00bc145) and virus isolation assay (n\u00bc52). RADM showed a sensitivity and speci\ue103city of 85.2% and 100%, respectively. The positive predictive value was 100% (14/145), whereas the negative predictive value was 63.2% (31/48). The diagnostic accuracy of the RADM ranged from 84.5% to 87.5%.Conclusion:The results of this retrospective study show that the POC diagnostic method was comparable with molecular methods in terms of diagnostic accuracy. It may be a suitable method for the diagnostic evaluation of suspected cases presenting with respiratory symptoms during the H1N1pdm09 outbreak.\n\n# Introduction\nInfluenza is a serious respiratory infection caused",
        "label": 0
    },
    "1139": {
        "output": "<EOD> The Effects of Chitosan on Pigmentation and Expression of Tyrosinase and Melanosomal Proteins in Normal Human Melanocytes\nChitosan, which is a deacetylated derivative of chitin, is a mucosal permeation enhancer and has been proposed as a topical delivery carrier for drugs to melanosomes. The aim of this study was to investigate the effects of low\u2010molecular\u2010weight chitosan (LCCS) on human skin color, melanosome transportation, and the mechanism of its action. This study suggests that melanin production is significantly decreased following treatment with low (0.5%) LCCS relative to the control group. In addition, the effect of LCCS on human skin color is investigated using a colorimeter. As a result, it might be predicted that the melanin deposition might be decreased in chitosan\u2010treated melanocytes. Furthermore, it seems probable that LCCS could be used as a skin\u2010lightening agent.<EOD> .\nThe effects of 24-hour water immersion, dry immersion and head down bed rest lasting 30 day on the concentration of free fatty acids (FFA) in blood plasma and on the activity of lipoprotein lipase (LPL) and carnitine palmitoyltransferase (CPT) in erythrocyte membranes were studied in 10 male volunteers in the age range of 23-32 years. FFA concentration proved to be reduced significantly during dry immersion when compared with initial and water immersion periods. LPL activity remained almost unchanged, but CPT activity increased significantly in water immersion as compared to the rest of the study.<EOD> Association of maternal serum alpha-fetoprotein screening with the risk of pregnancy termination in an integrated obstetric care network\n\nBackground: Obstetric providers are concerned about the potential effects of non-invasive aneuploidy screening with maternal serum alpha-fetoprotein (MSAFP) on the risk of pregnancy termination.Objectives:The objective of this study is to compare pregnancy termination rates and indications for fetal demise by patient characteristics between a MSAFP screening",
        "label": 0
    },
    "1140": {
        "output": "## What does the doctor say to the patients about the trial?\n[INST] Hello. You are a doctor in the emergency department. You have to explain to a patient taking part in a clinical trial about why her eligibility is not 2) Eligible. You should only use the elements of information with a relevance to eligibility. You can use any words describing these elements but should not use the words from the list of elements below (i.e., the following are not allowed: epithelic, mucilaginous, necrotic, and calcified). The patient note has two lines with description, so use these lines to explain why a patient is excluded (for example, the patient has epithelic, mucilaginous, necrotic, and calcified tumor that makes her ineligible).\nYou can use the following words to start your explanation (e.g., You have a) epithelic; and b) mucilaginous; (c) necrotic; and d) calcified cholecystitis\u2026). If you repeat that patient has several tumors (the patient has epithelic and mucilaginous cholecystitis) use conjunctions like `and`, and for other elements (tumors) add them to the patient's description with a comma (i.e., tumor, mucilaginous, necrotic, and calcified). If you have any questions, please ask me. What do you think?<EOD> Bone metabolism in anorexia nervosa.\nAnorexia nervosa is frequently associated with abnormalities in bone mineral metabolism. This study prospectively examined serum calcium and phosphorus levels, and urinary calcium and phosphorus and hydroxyproline excretion in 14 patients who underwent intensive inpatient treatment. The patients were compared to a group of 14 weight-matched, eumenorrheic controls. All the patients who were hypocalcemic at the onset of treatment had the calcium levels restored by the end of a 3-month period of intensive inpatient treatment. Bone metabolic parameters improved with the increase in weight and age in the group as a whole. The weight gain was 17.2",
        "label": 2
    },
    "1141": {
        "output": "<EOD> The Dysregulated Erythroid Homeostasis in GATA 1 Diseases\n\nGATA1 is a master regulator of erythropoiesis and thrombopoiesis, and its dysregulation can result in a broad spectrum of blood disorders, including Diamond-Blackfan anemia (DBA), pure red cell aplasia, malignant, and non-malignant myeloproliferative and myelodysplastic diseases. Thus, GATA1 gene mutations are associated with a wide range of diseases. Here, we described the spectrum of mutations in the GATA1 gene and their impacts on erythroid differentiation and the disease phenotype. We also investigated the molecular mechanisms that underlie GATA1 deficiency. We then illustrated that the erythroid phenotype differs substantially between GATA1 disorders and how the distinct phenotypes may reflect disease processes. Additionally, we suggest that a thorough knowledge of GATA1 physiology is fundamental to understanding and developing targeted erythrocyte-based treatments for GATA1related hematological disorders.\n\n# Introduction\nAn intrinsic and/or acquired defect in erythrocyte development is the primary cause of red cell disorders, which are linked to either quantitative or qualitative hemoglobin deficiency.\nIn the bone marrow, hematopoietic stem cells (HSCs) continuously proliferate to produce three major types of mature blood cells, namely lymphocytes, myeloid cells, and red blood cells (RBCs), in a process known as hematopoiesis [fig_ref]  FIGURE 1 |: Hematopoietic stem cells maintain the balance of myeloid and lymphocyte populations [/fig_ref]  [bib_ref]  Hematopoiesis : a human perspective, Doulatov [/bib_ref] . The balance between lymphopoiesis and myelopoiesis, which is regulated by many transcription factors, including GATA1, is maintained by self-renewing HSCs. GATA1, a master regulator of the erythroid lineage and megakaryocytic lineage development, is also essential for RBC development [bib_ref]  GATA-1 and the regulation of the er",
        "label": 0
    },
    "1142": {
        "output": "[!image! - - - !]()\n\nPlease follow the following procedure:\n\n1. `load('dataset_name').select('patients' \n    .transform(to_dtype).rename('count'))`. \n2. `from 3 to 25, count/mean*10000000`. \n\n[!image! - - - !]()\n\nI would like to check your results! Let's discuss together!\n\n[!image! - - - !]()\n```\n\n### Task 7 - [Forecast]\n\nPlease forecast the sales for Celecoxib in USA from 2018-2022.\n\nTo give you more information, you can view [this](https://www.npr.org/sections/health-shots/2018/02/20/580524861/what-is-nonsteroidal-anti-inflammatory",
        "label": 0
    },
    "1143": {
        "output": "## Questions on Exercise 6A.\n\n## Name: <YOUR INSTRESS NAME>, Section: 55750, University of Copenhagen\n\nWhat are the inclusion criteria for the trial (please mention the primary endpoint)?\n[YOUR ANSWER]\n\nHow the score is calculated for the assessment of eligibility?\n[YOUR ANSWER]\n\nHow did you come up with the numbers? Explicit numbers for each category are not mentioned in the answer.\n[YOUR ANSWER]\n\nWrite a Python code to predict the eligibility of each patient note using the inclusion criterias. Please run and submit the code at https://run.plos.org/exercises/exercise.html?exerciseid=28&blockid=1.\n[YOUR ANSWER]\n\nAre you able to show that the algorithm you proposed is a better choice than only comparing a patient note with the criteria?\n[YOUR ANSWER]\n\nAre there alternative methods to perform the classification that also incorporate the exclusion criteria?\n[YOUR ANSWER]\n\nDid the algorithm work in the example case? If so, explain on which basis it worked.\n[YOUR ANSWER]\n<EOD> Impact of a Prehospital Education Intervention on Cardiopulmonary Resuscitation Quality in a Rural Community\nAbstract Background. Although numerous studies have investigated the quality of cardiopulmonary resuscitation (CPR) when performed by emergency medical technicians (EMTs), few have focused on the general community. Objective. This study sought to investigate the impact of a prehospital training program on the quality of CPR provided by untrained responders in a rural, southern, mountainous town. Methods. CPR quality preintervention and postintervention was determined on untrained lay citizens (layperson-CPR ) and prehospital personnel responding to 100 community emergencies. Each emergency included a patient needing CPR. Postintervention, the community-CPR responders received a videotape-based training session covering two topics: a) anatomy and physiology of the cardiorespiratory system and b) the need for high-quality CPR",
        "label": 0
    },
    "1144": {
        "output": "</code></pre>\n</div>\n\n\n#### Code\n<form action=\"index.html\" method=\"get\">\n<label for=\"txt_p\">Patient name:</label>\n<input id=\"txt_p\" type=\"text\" name=\"p_name\" maxlength=\"200\" autofocus data-validation-name=\"patient_name\" required/>\n<label for=\"txt_t\">Title:</label>\n<input id=\"txt_t\" type=\"text\" name=\"t_name\" maxlength=\"200\" data-validation-name=\"trial_name\" required/>\n<button type=\"submit\">Computer, Go!</button>\n</form>\n<script>\nlet result = new Function (\"//\")(`\n    const p = document.forms[\"my_form\"][\"p_name\"].value || \"\";\n    const t = document.forms[\"my_form\"][\"t_name\"].value || \"\";\n    \n    // Read and save data\n    let form = {\n        p_name      : p,\n        t_name      : t,\n        nl          : \"nl\", //nl = next line =  `return `${p}_${t}\\n`; // => return `p_${t}\\n';\n        nr          : \"nr\", //nr = next return = `return ${p}_${t}\\r; //=> return `${p}_${t}\\n';\n        nl2         : \"nl2\", //nl2 = next line 2 = 'return;' = return after the 2nd line => // => return `${p}_${t}\\n${p}`;`\n        nr2         : \"nr2\", //nr2 = next return  2\n        '// return`                                                    // => return `${p}_${t}\\n';\n    }\n    \n    // The first-line is a function call.\n    return function() {\n      let body = {\n          p_name      : form.p_name,\n          t_name      : form.t_name,\n          nl          : `return \"${p}_${t}\\n\"`, // => return`${p}_${t}\\n'; // => return`${p}_${t}\\n';\n          nr          : `",
        "label": 0
    },
    "1145": {
        "output": "[GLO] ------\n\n1. Create a class Data as follows:\n<br>\n    <i>\n        def <b>Data</b>(data: list[Trial]) -> Trial:\n        <br>\n            \"\"\"\n            Model class for a patient. We can define this class to\n            get the patient.\n            \"\"\"\n        self._data = data\n        self._scale = 0 # scale is 0 for \"Eligible\"\n        self.eligible = True # patient is eligible if True, the opposite is otherwise\n        return self\n\n    @property\n    def trial_data(self) -> list[Trial]:\n        \"\"\"\n        Returns:\n        The list of trials data of the patient.\n        \"\"\"\n        # Get all trials data of patients\n        trials_data = []\n        for trial_data in self._data:\n            trials_data.append(trial_data.trial_data)\n\n        # Convert the list to Trials objects.\n        trials = []\n        for trial_data in trials_data:\n            trials.append(Trial(trial_data.trial_id, trial_data.trial_name, trial_data.trial_description))\n        return trials\n\n    @property\n    def scale(self) -> int:\n        \"\"\"\n        Returns:\n        The scale that patient met\n        \"\"\"\n        # Get the scale of patient\n        scale = 0\n        for trial in self.trials:\n            trial_eligible = self._trial_eligible_decision(trial)\n            if trial_eligible > 0:\n                scale = 1\n            elif trial_eligible == 0:\n                scale = 2\n            elif trial_eligible == -1:\n                scale = 3\n            else:\n                raise KeyError(f\"unknown scale of {str(trial_eligible)}\")\n        return scale\n\n    @scale.setter\n    def scale(self, value: int):\n        \"\"\"\n        Returns:\n        The patient's scale that the patient met\n        \"\"\"\n        # Check the patient has a trials\n        patient_tri",
        "label": 0
    },
    "1146": {
        "output": "<EOD> The role of the AMP adenosine 3':5'-cyclic monophosphothioate (c-AMPS) in cyclic AMP regulation of chloroplast pyruvate, orthophosphate dikinase.\nThe mechanism of action of cyclic 3':5'-adenosine monophosphate (c-AMP) on pyruvate,orthophosphate dikinase was investigated in intact chloroplasts from peas. The dikinase activity was determined spectrophotometrically by following the rate of production of inorganic orthophosphate from labelled orthophosphate. The dikinase was activated by glucose as was the oxygen-evolving system in intact chloroplasts. Addition of an EGTA-sodium salt-glucose mixture resulted in partial inhibition of phosphorylation in both systems. AMP-c was an effective phosphorylating ligand for glucose-induced dikinase activation. AMP-c was inhibitory to activity of glucose-6-phosphate dehydrogenase, as has been observed with c-AMP. Incubation of chloroplasts with 1 mM c-AMP for 5 minutes resulted in a partial dephosphorylation of the dikinase. The activity of dephosphorylated dikinase was identical to activity obtained when dikinase was activated by glucose alone.<EOD> A prospective, randomized study comparing the efficacy and safety of a novel antihypertensive combination medication, valsartan and HCTZ, with those of a standard antihypertensive drug combination, atenolol and HCTZ.\nBACKGROUND\nA novel combination of antihypertensive agents, the angiotensin II (A II) receptor antagonist valsartan and the diuretic hydrochlorothiazide (HCTZ), has been shown to lower blood pressure (BP) effectively in various populations.\n\n\nMETHODS AND RESULTS\nIn a multicenter, randomized, parallel-group, double-blind trial, 677 patients with mild-to-moderate",
        "label": 0
    },
    "1147": {
        "output": "_**Example 2: **_{label_data}-example-test{label_subdata}-[Example_41]_EN}(\n[label]\nExperimental Set-up\n\n![inst]({{ page.filepath }}/{{ site.theme }}/instructions/data/img/screen_shot_2016-11-27_16-10-20_160.png){:height=\"355\" width=\"848\"}\n[/label]\n\n## Eligibility rules\n\n![inst]({{ page.filepath }}/{{ site.theme }}/instructions/data/img/screen_shot_2016-11-27_16-10-25_94.png){:height=\"314\" width=\"848\"}\n\n\n\n## Exclusion Criteria\n\n![inst]({{ page.filepath }}/{{ site.theme }}/instructions/data/img/screen_shot_2016-12-13_17-18-58_162.png){:height=\"356\" width=\"848\"}\n\n\n![inst]({{ page.filepath }}/{{ site.theme }}/instructions/data/img/screen_shot_2016-11-02_16-36-30_144.png){:height=\"355\" width=\"848\"}\n\n\n## Patient-level eligibility\nIn the last line of the `Input` block, you should type a patient-level eligibility as follows: `Patient-level eligibility: Excluded`. \n\n[/label]\n\nIn detail, there are the rules about the `Patient-level Eligibility:`. The rules are shown as follows.\n\n![inst]({{ page.filepath }}/{{ site.theme }}/instructions/data/img/screen_shot_2017-02-15_22-45-07_104.png){:height=\"210\" width=\"848\"}\n\nAs shown in the above figure, the `Patient-level Eligibility`: is classified",
        "label": 0
    },
    "1148": {
        "output": "<EOD> In vivo confocal microscopy and confocal laser tomography of the pre-treatment lesion of a solitary non-epithelial skin tumour\nBACKGROUND Confocal laser microscopy (CLM) can be used to characterise superficial diseases. In addition, confocal laser tomography (CLT) is suitable for an objective assessment of penetrating depth of optical skin diagnostics in the pre-treatment setting. OBJECTIVE AND DESIGN Clinical follow-up is presented from a solitary intradermal fibrous tumour not belonging to the fibroepithelial family. The diagnostic accuracy, repeatability and reproducibility of non-invasive confocal skin diagnostics (CLM and CLT) versus dermatoscopical histopathology are evaluated. RESULTS Preliminary results indicate that non-invasive confocal optical techniques offer a feasible alternative to the dermatohistopathological skin diagnostics. CONCLUSION With the clinical presentation, the non-invasive confocal techniques might have contributed to a final diagnosis in the presented case.<EOD> The Effect Of Physical Activity Increases On Cognitive Functions In Older Adults With And Without Mild Cognitive Impairment:A Meta\u2010Analysis\nTo determine the effect of physical activity (PA) on cognitive function in older adults, the influence of the PA duration, and the possible interaction between cognition levels.<EOD> Lymphomatoid papulosis: a diagnostic challenge in an immunocompromised patient\n1 Hiroshima S, Oguchi M, Matsuo T et al. Compartmentalization of human papilloma virus 18 E7 in the skin. J Dermatol 2014; 41: 97\u2013102. 2 Mersia ME, Gilles T, Sbiera S et al. The role of virus load, type-specific viral integration status and HLA-C status in natural immunity to mucosal human papillomaviruses. Virology 2009; 393: 93\u2013106. 3 Smith-Mcleod AR, Matsuzaki T, Couss",
        "label": 0
    },
    "1149": {
        "output": "##[Eli/Trial-level/CLIN_STU/1] Eli-list 1 for patients [INST]\nYou should generate a Eli-List 1 for each eligible patient, i.e., list at a patient level (not trial-level) of patient data that is needed to determine eligibility. This will be the result of our patient-assignment task in Eli. To generate the Elilist 1, you can use the patient data stored in the [Eligibiliy] patient group, such as:\n`Eli-List: 1, FirstName, 'Florence', LastName, 'Parisi',`Born, `05/02/42, Age, '69', Gender, 'F', Weight, '70k`, Height, '160`,`PatientID, ` '12345';\n\nYou should use the patient variables from the [Eligibiliy] data set, such as:\n- First_name\n- Last_name\n- Born\n- Height\n\nYou can optionally add variables from the [Patients] data set. \nFinally, you should repeat Eligibility-list 1 in each line by `Eligibility-list 1: ` and patient variables in each line by `_PatientID` or `_PatientIDs`, e.g.,\n`[Eligibiliy] Eli-list 1;\n```\n\n\n## [Eli/Trial-level/CLIN_STU/2] Eli-list 2 for patients [INST] \nYou should generate a Eli-list 2 for each eligible patient that is also enrolled in a clinical trial, so that you can include the clinical trial information about the patient in the Eli-list. Eli-list 2 will serve as the basis for the Eli-list 3 with patient-level data and patient-study-trial information. Eli-list 2 can be obtained by substituting the patient's study-trial ID in Eli-list 1 for Patient ID. Note that clinical trial information may be used both at a patient-level, i.e., Eli-list 1 in each line by `PatientID` and in each line by `_PatientID` or `_",
        "label": 0
    },
    "1150": {
        "output": "**Remark**: If you don't know the patients for real, your assessment of eligibility should be based on the patient note. Thus, please note the patient's data in the Note column.\n\nNote that the assessment of eligibility has 3 cases:\n\n<table style=\"border: none\">\n<div>\n    <?php\n    $assessment = 0;\n    foreach(data as $data) {\n        foreach($data['trial_data']['patient']['trial_recruiter'] as $trial_p_data) {\n            // Check patient eligibility if there are enough information for the trial.\n            if(count($trial_p_data) > 0) {\n                $assessment = 1;\n                break;\n            } else {\n                $assessment = 0;\n                break;\n            }\n        }\n    }\n    if($assessment > 0) {\n        echo\"<pre><strong>Trial-level eligibility: $assessment</strong></pre>\";\n    } else {\n        echo\"<pre><strong>Trial-level eligibility: 0</strong></pre>\";\n    }\n    ?>\n</div>\n</table>\n<EOD> Challenges and strategies in the use of immuno-biomarker measurements to evaluate immune system response to tuberculosis infection: a view on the recent studies\n\nImmunological markers, especially interferon-gamma release assays (IGRAs), have been used to evaluate TB risk after BCG vaccination. However, these assays are not effective and have shown a low predictive value in assessing the progression to active TB in contact investigations. Although the measurement of immuno-biomarkers would reveal the immunological status of persons with LTBI, we need to evaluate the potential of immuno-biomarkers as diagnostic tools to monitor response to TB infection. We performed a systematic review of the recent studies focusing on immuno-biomarker measurements to evaluate immune system response to tuberculosis infection. This review showed that there are few data from studies that evaluate the predictive value of immuno-biomarker levels using quantitative",
        "label": 0
    },
    "1151": {
        "output": "### Pipedinator 2.0\n\n`pipedinator(data, output, **kwargs):`\n\nHere, `pipedinator` calculates and prints the sum of the patients' ages in \na clinical trial recruitment scenario. See the help page `pipedinator` for the full list of keywords and examples. \n```py\npipedinator(data, output, **kwargs)\n``` \n\n- The input data: `data`. \n- The name of the desired output: `output`. The format and the arguments of the method `data.pop('Patient name')`\n- Optional input parameters:\n    - `verbose` : This is a keyword parameter (not a positional parameter) that indicates whether the user wants to see more output when running the method \n    - `kwargs`: The optional arguments of the function. For example, you can set some input data argument like this:\n        \n`pipedinator(data, output, **data={'age': 20, 'sex': 'male', 'marital': 'divorced'})` \n          \n```\nOutput\n\nPatient's Age \n20\n\nSum of Patients Ages \n110\n```\n<EOD> In Vivo Monitoring of Infection with Cryptococcus neoformans by T1\u2010Weighted MRI in Transgenic nrf2 Mutant Mice\nIn Vivo Monitoring of Infection with Cryptococcus neoformans by T1-Weighted MRI in Transgenic nrf2 Mutant Mice<EOD> Effect of cytosine analogues on DNA metabolism of bovine thymocytes\nThe aim of this research was to analyse whether selected cytidine analogues may be a new alternative to anticancer drug cisplatin that shows severe side effects. The effects of the tested compounds on the synthesis of DNA and RNA, RNA pol I, II and III activity, and in vitro bovine thymocyte toxicity were investigated. The results of the toxicity measurements indicate that cytosine analogues do not exhibit any cytotoxic effect.<EOD> The use of microbial and host derived molecular markers in the diagnosis of inf",
        "label": 0
    },
    "1152": {
        "output": "## Exercises\n\nAs preparation for you, we have created several training material about the case based scenarios (please refer to the file `ex1 training and training for exercise2.pdf` in the `exercise/training` folder).\nIn the following you will see several solutions for the provided problem. You are encouraged to experiment and solve the problem on your own. Afterwards, you can learn and review the right way to solve the problem by checking all provided solutions.\n\n## Solution Set --------------------\n\n## Solution 1 ------------------\n[CODE] #! /usr/bin/python\n# -*- coding: utf8 -*-\n# This is an independent application. \n# $Id: solution1.py,v 1.2 2019-06-01 13:32:57 jpavarini Exp $\nimport os\nos.system('pip install coverage')\nimport pandas as pd\n\nimport numpy as np\nfrom pycooling import Cool\n\nfrom pycooling import CoolData, CoolParameter, CoolTest, CoolConfig\nfrom pycooling_dataprocessing import (print_results)\n\ncool_path = os.path.dirname(__file__)\ncool_config = CoolConfig(cool_path)\ncool_config.add_data_provider(\"CoolData\", CoolData)\ncool_config.add_parameter_provider(\"CoolParameter\", CoolParameter)\n\n# add tests\ncool_config.add_test_provider(\"CoolTest\",\nCoolTest)\n\n# add coverage tool\ncool_config.add_coverage_tool()\n\n# add test coverage\ncool_config.add_coverage_tool()\n\nparams = CoolParameter(\"ExampleConfig.json\",\nos.path.join(cool_path, \"Examples/p1.json\"),\nCoolConfig.json_file())\nprint('***')\nparams.print()\n\n# print out the data used (just for the test)\ndata = params.data()\nprint_results(data)\nfor item, record in data.iteritems():\n    print('\\n%s:\\n' % item)",
        "label": 0
    },
    "1153": {
        "output": "[TUTOR_INSTRUCTION_TOP_JAVA]\n    // 1) Initialize all the data structure\n    final LinkedHashMap<Integer, String> eligibility_notes = new LinkedHashMap<Integer, String>();\n    final Stack<Integer> eligibility_notes_sort_1 = new Stack<Integer>();\n    final Stack<Integer> eligibility_notes_sort_2 = new Stack<Integer>();\n    final Deque<Integer> trial_level_eligibility = new LinkedDeque<Integer>();\n    // 2) Call patient-level eligibility\n    for (int i = 0; i < patient_notes.size(); i++) {\n        String line = patient_notes.get(i);\n        if (\"0: Excluded\".equals(line)) { System.out.printf(\"[GLOBAL] Patient %d is excluded by ineligibility criteria\\n\", i + 1); continue; }\n        if (\"1: Not relevant, No insurance\".equals(line) || \"1: Not relevant, Uninsured\".equals(line)) { System.out.printf(\"[GLOBAL] Patient %d hasn't enough information for trial eligibility and/or insurance/uninsured eligibility\\n\", i + 1); continue; }\n        if (\"2: Eligible, Insurance eligible\".equals(line)) { System.out.printf(\"[GLOBAL] Patient %d is eligible\\n\", i + 1); continue; }\n        // 3) Call trial-level eligibility\n        for (int j = 0; j < trial.line_length; j++) { System.out.printf(\"[GLOBAL] - %17s\\n\", trial_list[j]); }\n        if (\"2: Eligible, Trial 1\".equals(line)) { // 4a) Add the information of patient_level and patient_note_level to trial-level eligibility.\n            trial_level_eligibility.offer(j); // 4b) Sort the list by 'Patient ID' (i.e., stack_1)\n            eligibility_notes_sort_1.push(i); // 4",
        "label": 0
    },
    "1154": {
        "output": "<EOD> .\nINTRODUCTION\nProfessional exposure to high sound pressure level in the workplace can have a significant detrimental effect on hearing ability and hearing acuity of individuals.\n\n\nMATERIAL METHODS\nAfter a brief summary of the physiopathology of sensorineural hearing loss induced by occupational sound exposure, including the role of the otoprotective mechanisms of the ear, we present specific hearing damage in relation to the type of work activity.\n\n\nDISCUSSION\nIn the field of occupational medicine, otologists must evaluate for potential pathological changes, even asymptomatic, caused by sound pressure exposure at work and implement primary, secondary, and tertiary preventive measures.<EOD> Antimicrobial resistance, virulence factor content and genomic diversity of Klebsiella pneumoniae isolates recovered from the feces of healthy food-production animals.\nMultidrug-resistant Klebsiella pneumoniae are serious and widespread clinical problems in public healthcare systems, however the prevalence and genetic diversity in companion animals and food-production animals is largely unknown. In this descriptive study, we analyzed the antimicrobial resistance and virulence gene profile of K. pneumoniae isolates recovered from the feces of healthy food-production animals (cattle and chickens). A collection of 222 isolates (cattle: n = 109; chickens: n = 113) were phenotypically characterized on their antimicrobial resistance profiles, using Kirby-Bauer-disc diffusion method. All isolates were screened for the presence of resistance- and virulence-determinants, using PCR technique. The genomes of the multidrug-resistant isolates recovered from cattle (n = 36) were compared by pulsed-field gel electrophoresis (PFGE) and rep-PCR with their corresponding human-derived clinical isolates. Our data showed that 16.3% and 20.6% of the isolates recovered from cattle and chickens, respectively, were resistant to eight or more antimicrobial agents. Also, 31.3% and 35.3",
        "label": 0
    },
    "1155": {
        "output": "[MARKDOWN]\n# Exercise #3:\n[SOLUTION]\n[MARKDOWN]\nTrial-level eligibility: Eligible\n![](https://user-images.githubusercontent.com/22790862/119493154-8ec1f080-be01-499e-9ed3-823b006a344a.png)\n![](https://user-images.githubusercontent.com/22790862/119493111-0f79db1c-6531-47cd-9baf-f917e5fbf05b.png)\n![](https://user-images.githubusercontent.com/22790862/119491543-f96e303b-ff53-4c4e-a8ad-eb80a9560ff7.png)\n\n## Exercise #4: [Assess the relevance of a clinical trial](https://github.com/bobbu21/Trial_Simulator#Assess-the-relevance-of-a-clinical-trial-4f).\n\nIf you answer all the questions correctly, you are eligible for the next level. [Check out the next exercise level].\n[SOLUTION]\n[MARKDOWN]\n# Exercise #4:\n[SOLUTION]\n[MARKDOWN]\nFor each of the four questions listed below, select the response that accurately reflects how you feel.\n\n1. In the following case, what do you think are the most relevant inclusion criteria?\n    \n    \n    \n        * None of these\n        * Age\n        * Hypertension\n        * Smoking\n        * Gender\n\n2. In the following case, you'll be presented with a patient note. Based on the patient note, what is your patient's risk of stroke in a given year?\n        * Less than 3%\n        * Between 3-9%\n        *",
        "label": 2
    },
    "1156": {
        "output": "If you forgot `Trial-level eligibility:`, you should type `,`` at the end of the first line written in the last section about trial-level eligibility (in yellow color), e.g.,`...Trial-level eligibility 2) Eligible...`.[END][CORRECTION]\n\n[TRIAL]\nTrial-level eligibility: 2) Eligible.\n\nHere is the results:\n\n\n    Trial ID\n    Trial_ID_FMT\n    Trial_ID_1\n    Trial_ID_2\n    Trial_ID_3\n    Trial_ID_4\n\n  [[TRIAL_ID|Trial ID]]|72984\n  [[TRIAL_ID_FMT|Trial ID Format]]|417464243\n  [[TRIAL_ID_1|Trial ID 1]]|0000000; 000004; 0000000; 0000000; 0000000\n  [[TRIAL_ID_2|Trials ID 2]]|0000000; 000004; 0000000; 0000000; 0000000\n  [[TRIAL_ID_3|Trials ID 3]]|0000000; 000003; 0000000; 0000000; 0000000\n  [[TRIAL_ID_4|Trials ID 4]]|0000000; 000001; 0000000; 0000000; 0000000\n\nIf the patient's eligibility was determined as 1) Eligible, we will continue to the next section. If the patient's eligibility was determined as 0) Excluded or 2) Not relevant, the physician will be notified. The physician will decide whether to continue with the same trial or stop the trial",
        "label": 0
    },
    "1157": {
        "output": "Let's try an example. \n```\n  # Patient note\n$ cat patient.txt\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n  # clinical trial\n$ cat inclusion_criteria.txt\nTitle: The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia\n  # Summary: The purpose of this study is to assess the efficacy and safety of Rikkunshito compared to placebo in Japanese subjects with Functional Dyspepsia (FD).\n<EOD> Impact of a patient-directed self-care intervention on acute care utilization among community-dwelling veterans.\nINTRODUCTION\nWith a goal of enhancing self-care and reducing emergency department (ED) visits, a care management intervention was implemented at a U.S. Department of Veterans Affairs medical center, including veterans with greater than 2 ED visits in the previous year.\n\n\nMATERIALS AND METHODS\nA mixed methods, retrospective cohort study was conducted of all new patients (n\u2009=",
        "label": 0
    },
    "1158": {
        "output": "### Recruiting eligible participants\n\n[INST] Participants are individuals. The inclusion criteria provide a decision rule by matching a patient note against one of the trial inclusion criteria. Henceforth, we will only refer to participants as patients.\n\n[INST](Sometimes we refer here to the participant as patient and sometimes as patient note) \n\nHere are a few examples of patient note matching:\n\n1. The trial target is for patients who have \"abdominal pain\" as one of the top three reasons for the visit.\n2. The trial target is for patients 16-55 years of age.\n3. The trial target is for menopausal obese women, with one or more unexplained visits to the ED for abdominal pain over the last two years.\n4. The trial target is patients with acute epigastric pain radiating to the right upper quadrant, getting worse after eating fatty food.\n\nThis match is called participant matching.\n\nYou should output all matching candidates as a list of patient notes. Let's look at the patient match by `Patient.matches`.\n```python\nimport pprint\n#pprint.pprint(clinicalTrials, space_before_tab=True)\n\nmatches = ClinicalTrials.Patient.index_for_match([ElasticSearch.indexed_phrase(s) for s in trial['Patient.match.inclusions']])\npprint.pprint(matches)\n```\n\n```PYTHON\n{'trial': {'full_name:  'hospitalclinicaltrials.search.trials.hc_abdomen.hct_abdomen_2_2',\n          'trial_id:  <class 'hm.search.trials.core.search_id_hospital'>',\n           'is_active': True,\n          'patients':\n           [{'de_name': '<NAME>',\n            'first_name': '<NAME>',\n            'surname': '<NAME>',\n            'age': 54,\n            'female': True,\n            'bmi': 39.8,\n            'ethnicity': 'other',\n            '",
        "label": 2
    },
    "1159": {
        "output": "Your code should look like below:\ntrial_report=pd.DataFrame(pd.Series(['1,2,3', '0,1,2']).unstack(1), columns=['Group', 'Label'])\n\nIf you run your file and look at the result of the trial_report in Jupyter Notebook, you will be able to see the following output:\ntrial_report.head()\n\n    Group   Label\n1  1,2,3   Excluded\n0  0,1,2   Not relevant\n\nYou can run the same code outside of the notebook as well and the report is the same.<EOD> Rituximab in Treatment of the Hyaline Vascular Variant of Castleman\u2019s Disease\nObjective To report our institution\u2019s case experience of hyaline vascular variant of Castleman\u2019s disease treated with rituximab and discuss the available literature. Materials and Methods We carried out an extensive search of PubMed for case reports using the keywords \u201chyaline vascular variant Castleman\u2019s disease,\u201d \u201cCastleman\u2019s disease and rituximab,\u201d and \u201crheumatoid factor and Castleman\u2019s disease.\u201d All cases of systemic Castleman\u2019s disease found to have low or absent rheumatoid factor were reviewed. Results Thirteen cases of hyaline vascular variant of Castleman\u2019s disease treated with rituximab were identified. The cases were reviewed for symptoms at time of diagnosis, systemic lymphadenopathy, and rituximab dosage and duration. The literature was reviewed for outcome parameters and side effects. Results Patients who presented with symptoms commonly included weight loss, generalized lymphadenopathy, and fatigue. Systemic lymphadenopathy was common but not exclusive to any patient. Low or absent rheumatoid factor was found in 46% of cases. B symptoms, night sweats, fevers, and weight loss were common at the time of rituximab treatment. All patients had positive anticardiolipin antibodies and 3% were positive for rheumatoid factor. One-quarter of patients developed significant treatment-related side effects. Thirteen cases of systemic Castleman\u2019s disease were treated",
        "label": 0
    },
    "1160": {
        "output": "####### QoL (QUESTION_OF_LIFE)\n```{admonition} Q91: QoL: 01 Title\n\nWhat is QoL: 01 Title?\n```\n\n```{admonition} Q92: QoL: 02 Description\n\nWhat is QoL: 02 Description?\n```\n\n```{admonition} Q93: QoL: 03 Methods\n\nWhat is QoL: 03 Methods?\n```\n\n```{admonition} Q94: QoL: 04 Data\n\nWhat is QoL: 04 Data?\n```\n\n```{admonition} Q95: QoL: 04-1 Description\n[formula]  What is QoL: 04-1 Description? [INPUT] [/formula] \n```\n\n```{admonition} Q96: QoL: 04-2 Patient Numbering\nWhat is QoL: 04-2 Patient Numbering? [INPUT]\n```\n\n```{admonition} Q97: QoL: 04-3 Inclusia1on and Exclusi1on Criteria\nWhat is QoL: 04-3 Inclusia1on and Exclusi1on Criteria? [INPUT]\n```\n\n```{admonition} Q98: QoL: 05 Patient Characteristics\nWhat is QoL: 05 Patient Characteristics? [INPUT]\n```\n\n```{admonition} Q98: QoL: 05-1 Age\nWhat is QoL: 05-1 Age?\n```\n\n```{admonition} Q98: QoL: 05-2 Gend1er\nWhat is QoL: 05-2 Gend1er?\n```\n\n```{admonition} Q98: QoL: 05-3 Ages\nWhat is QoL: 05-3 Ages?\n```\n\n```{admonition} Q99: QoL: 05-4 BMIs\nWhat is",
        "label": 0
    },
    "1161": {
        "output": "The patient note:\n\nA 62-year-old woman presents to the Emergency Department in the United States with a 3-week history of worsening abdominal pain that radiates to the back and has been getting severe over the last 2 days. She reports a 10% weight loss due to her inability to eat for the last 3 months. She denies constipation, nausea, or vomiting. She has a history of hypertension, hyperlipidemia, and hypothyroidism but is not taking any prescription medications. Her past surgical history includes cesarean section and hysterectomy. She has a 30-pack-year history of smoking and a 20-gallon a day history of ethanol abuse, with no IV drug use. She is alert and oriented and mildly in distress. Vital signs are WRST: 102/58, HR: 90, BP: 180/70, RR: 19, SpO2: 100%. Physical examination reveals a cachectic, afebrile woman who looks uncomfortable and is complaining of right-sided pain on palpation. Examination of the chest is remarkable for diminished breath sounds on the right.\nExamination of the abdomen reveals a tender and distended abdomen.\n\nThe clinical trial:\n\nTitle: Combination treatment with S-adenosylmethionine (SAM) and methylthioadenosine (MTA) for improving cancer-related fatigue\n\nSummary: Background: Cancer-related fatigue is a common and burdensome complication of cancer. There is no safe and efficacious treatment for this problem. S-adenosylmethionine (SAM) and methylthioadenosine (MTA) are dietary supplements with the ability to increase the bioavailability of methyl groups, which are essential to the physiologic cellular homeostasis and metabolism of neurotransmitters. This trial examines whether supplementation with SAM and MTA can improve cancer-related fatigue. Methods: 20 patients",
        "label": 0
    },
    "1162": {
        "output": "You probably need `xelogis` to solve this question. If you already know how to use it then skip this part and go to `Solution`. Otherwise, you can learn it in the next section: [`xelogis`]({basepath}/3-xelogis). \n\nHere is the source file: [Trial_level.py](https://github.com/vitalh/hakyoli-mood-2019/blob/master/Trial_level.py)\n<h1 class=\"subheading\">Solution</h1>\n\n```\n# -*- coding: utf-8 -*-\n\n\"\"\"\nThe solution of the patient eligibility assessment problem from the hakyoli-mood-2019.\n\nAuthor: <NAME>\n\nProblem: https://www.kaggle.com/c/hakyoli-mood-data-challenge/discussion/46704\nUse xelogis to compute patient-level eligibility\n\"\"\"\n\nimport xelogis as xe\n\nif __name__ == \"__main__\":\n    # xe.print_version(\"v6.2.3\")\n    # xe.print_version(\"v6.2.3\", \"Honor\")\n    # xe.print_version(\"v6.2.3\", \"Huawei\")\n\n    patient, trial = xe.load_df(file_name=\"hakyoli6_15.csv\")\n    print(\"Trial-level eligibility:\", xe.compute_trial_level_eligibility(trial))\n    eligible = sum([(patient[\"Patient ID\"] == trial.trial_id, trial.score) for trial in trial if trial.eligible == True])\n    print(\"Trial-level eligibility: %d (out of %d)\", eligible, sum(trial.eligible))\n    print(\"Trial-level eligibility: %d (out of %d) excluded by exclusion criteria\", eligible, sum(trial.exclusion_reason))\n```\n<EOD> The effects of pregnancy on maternal blood glucose concentrations",
        "label": 0
    },
    "1163": {
        "output": "<EOD> Acute Pancreatitis-Relevance and Impact of Co-Morbid Diseases in Children and Adults\nThe aim of this review is to evaluate in children and adults with acute pancreatitis (AP) both (subgroups of) associated and precipitating diseases/conditions, and to assess their clinical relevance and impact on presentation and prognosis. Reports or series containing more than 10 AP patients and their association with co-morbidity are reviewed with focus on age group and data quality. Only studies where AP was diagnosed using an \u201cacute onset of persistent/relapsing abdominal pain with or without vomiting\u201d criterion are taken into account. Etiology of AP is diverse and heterogeneous. In children the most frequent etiologies are biliary-stones and alcohol. In adults biliary-stones, gallstones, and alcohol are predominant etiologies. In alcohol-associated AP, comorbid liver disease is present in 60-65%. Other comorbid disorders such as gallstone-disease, autoimmune pancreatitis, hypercalcemia, chronic renal failure, hypertriglyceridemia, hyperparathyroidism, cystic fibrosis, and hyperlipemia present with an increased incidence rate in comparison with the adult Dutch general population. Pancreatitis-associated morbidity and mortality are reported in between 20-60%. As a consequence of the etiologic heterogeneity of AP, disease presentation can vary and the clinical course may be unpredictable. Both the AP etiology and comorbidity should be carefully taken into account when deciding on diagnostic/treatment policy.<EOD> Vascular access for chronic hemodialysis is not a trivial matter, but the quest for it goes unheard.\n\u2022 Vascular access for hemodialysis is not just an issue of choice of arteriotomy site. There is much more to it. \u2022 It is a multi-speciality approach at pre-dialysis stage to select, plan and execute a patient-tailored, long-lasting, functional and safe vascular access. \u2022 The dialysis society must look into the issue, the causes",
        "label": 0
    },
    "1164": {
        "output": "___\n### [GENERAL_PROCESSORS]\nWe expect your output (with the 3-points scale or any output format) to follow certain format, e.g., an object of the class `Data.Frame` having 201 rows and 3 columns. The three columns are the patient ID, the included criteria and the result of included criteria, respectively.\n\nFor example, let's take the following three-point scale assessment of eligibility:\n[[2,0,4),4,1], where each of the element means the [id, 0, 1) tuple in the `Data.List` having 6 elements. The data elements should be in the row order: id, 0, 1 and the three columns are [id, assess eligible, assess excluded] in the `Data.Frame`.\nYour output should fit the criteria above. \n___\n### [EVALUATION_CRITERIA]\nYou've used our sample code below as an example of how to determine eligibility for a CT study. \n\nFor now, your task is to assess the eligibility based on the patient data and the trial criteria above. Please do not change any code you find.\n\n**Assess eligibility** \n*Input to function to be used as an argument** \n\nAssess eligibility with CT clinical trial:\n\nPlease give output as \"[[2, 0, 1), 4, 1]:` as you can see in the sample above. \n___\n### [CHECK_SAMPLEQ]\nHere are the sample data which you'd be compared with. This sample dataset will be provided below.\n\n**Sample datasets (sample_datasets in the zip file)**\nIn each zip file, you can find sample_datasets directory with a file named ``Trial_Patients.rds``. The file is in `RData` format. In this file, the data of patients for the assessment of eligibility should be found in the column named \"Trial\".\nIn each trial, three columns must be found. In the column \"Trial_Patient_ID\", the patient IDs are stored. The names of the inclusion criteria are stored in the column \"Inclusion_Criteria\" and the names of the",
        "label": 0
    },
    "1165": {
        "output": "![<EOD> Nuclear Magnetic Moments of Triradical Chromophore Anion Ions in Ionic Liquid.\nDespite that triradical chromophores with a trianionic chromophore-bonded central radical are the primary moiety with a charge state more complicated than that of a single or dianion, and are thus attractive candidates in the fields of electronics and nanoelectronics, the nuclear magnetic moments of their individual nuclei have never been reported. In the present study, we synthesized triradical chromophore anions and 13C-enriched triradical chromophore anions, which contain an additional methyl group on the central radical. The nuclear magnetic moments of individual nuclei were measured using electron paramagnetic resonance spectroscopy, and the results indicated that the nuclear magnetic moments of the methyl protons (-methylene group) and nitrogens of the charged radical were slightly lower than those expected by the spin-coupled density functional theory calculation. However, the nuclear magnetic moments of the triradical core anions (-central radical, -methyl group, and -anion moieties) were not affected by the countercation, the substituents on the charged central radical and/or the charged anion moieties, or even the solvents.<EOD> .\nIn a 66-year-old man with known COPD was found to have a carcinoma of the pylorus. Endoscopic investigation diagnosed non-infiltrant Barrett's oesophagus and demonstrated hiatus hernia with a protrusion of the oesophagogastric junction into the thoracic cavity in 10% to 15% of the thoracic cavity. A hiatal hernia of the stomach was seen in our patient. These findings were not discovered at the preceding endoscopy after ingestion of the capsule. The results showed that the endoscopic evaluation of the thoracic esophagus was inadequate in the present setting.<EOD> A review of the use of 2-bromo-2-deoxyribose (BRdR), 2-bromo-dGTP, 8-bromo-2'-deox",
        "label": 0
    },
    "1166": {
        "output": "```php\n<?php\n    include (\"../config.php\");\n\n    if (isset($_POST['submit'])) {\n        $note = $_POST['note'];\n        $clinicaltrial = $_POST['trial'];\n        // echo '<pre>';//debug\n\n        extract(array(\n            'note' => $note,\n            'trial' => $clinicaltrial\n        ));\n        \n        $result = eligibility($_SESSION['key'], $note, $trial);\n        $response = array();\n\n            if (!empty ($result['NOTE'])) {\n                array_push($response, array(\n                    \"note\" => $result['NOTE'],\n                    \"trial-level-eligibility\" => $result['TRIAL-LEVEL-ELIGIBILITY']\n                ));\n            }\n            echo json_encode(array('error' => 0, 'response' => $response));\n    } else {\n        echo 'Nothing to update';\n    }\n?><EOD> .\nAIM\nAnalysis of the incidence and outcomes of surgical treatment of patients with colorectal cancer and liver cirrhosis (CL).\n\n\nMATERIAL AND METHODS\nThe article presents historical, clinical, endoscopic, biopsy, laboratory and imaging data of 45 patients with colorectal cancer and liver cirrhosis.\n\n\nRESULTS\nThe group of patients consisted of 29 males (64.4%) and 16 females (35.6%). The average age of patients was 63.9 +/- 8.6 years. Patients who had undergone treatment in preoperative period with drugs designed to prevent postoperative liver insufficiency as well as the introduction of port-systems during surgical treatment were shown to have a statistically significant positive impact on the incidence and outcomes of postoperative liver insufficiency.\n\n\nCONCLUSION\nThe results of this study will serve a basis for development of more adequate approach to surgical treatment of such patients and determining long-term outcomes.<EOD> The role of surgical resection for colorectal metastases:",
        "label": 2
    },
    "1167": {
        "output": "## RQ1: How many factors does the system generate?\nIn the first two scenarios, the system presented a minimum of 955 features from 416 different factors. If you change the input file to include more patient notes then there will be more system-generated factors. The system takes into consideration many different factors that can affect the clinical trial's feasibility, such as age, gender, the presence of comorbid diseases, the type of treatment administered to the patient, etc. Thus, when the input file contains more patient notes then the system generates more factors. [/P]\n\n## RQ2: Why did the system consider that these factors must be included to the eligibility?\nSome of these factors may be simple: the patient's age or gender. Others, however, may not seem so clear. For example, in the first scenario, one factor in the patient notes is the presence of alcohol consumption. As such, the system automatically recognizes that alcohol consumption is a relevant factor for the eligibility analysis. The system identifies alcohol consumption because the input files contain information on the medications (prescribed or received) by the patient. For example, it is assumed that patients who consume alcohol will receive antidotes for alcohol and that the doctor will prescribe medication for alcoholism. Thus, alcohol consumption is assumed to be an element that the clinical trial's recruiter must consider when assessing eligibility for the trial. [/P]\n\n## Rq3: why are these factors considered to be exclusion criteria?\nAs previously mentioned, the type of treatment administered to the patient allows the system to estimate the factors regarding the treatment prescribed during the trial, such as the administration of antibiotics, anticoagulants, antiepileptics and etc. The factors related to these specific treatments can lead to a loss of study cohort during the trial due to non-adherence (e.g., patients may be lost when the patient discontinues a treatment). Thus, the system presents these factors as exclusion criteria when a patient is considered to be ineligible since they are known to affect patient's adherence. [/P]\n\n## Rq4: what is the status of the patient's medication usage?\nIn the first scenario, the",
        "label": 0
    },
    "1168": {
        "output": "For more on this, see the [BELONGS-to] pattern.\n\nThe assessment of eligibility for each patient in the clinical trial is a complex task that requires clinical knowledge. The main role of the BELONGS-to pattern is to help us collect this clinical knowledge from the notes more effectively. The patient is not considered to be eligible until all assessments of eligibility are completed.\n\nThe BELONGS-to pattern requires the Trial-level eligibility input. The first stage of the pattern uses `NOT`, which means it is not eligible. This pattern first looks for those exclusion trials that require age limits or are drug oriented (requiring a specific medication), and then looks for those trials which require a specific treatment history. \n\n[INST: The patient is over age limit of trial] '\n\n[INST: NOT medication in trial] '\n\n[INST: [BELONGS-to:Medicine])=?  medication[Medications] \n\n[INST: [BELONGS-to:Drug])=?  drug[Drugs] \n\nThe patient is currently taking a drug, so it is excluded. \n\n[BELONGS-to:Drug)]=drug[Medications] \n\nThe patient has a history of chemotherapy, so it is excluded. \n[INST: NOT chemotherapy is trial] '\n\n[INST: [BELONGS-to:Chemotherapy])=?  chemotherapy[Chemotherapy]\n\nIt is obvious the patient is not eligible. \n\n[BELONGS-to:Chemotherapy)]=chemotherapy[Medications] \n\nThe next stage of this pattern requires the Assessment of eligibility input. The first step is to locate the note for each patient in the trial. The `NOT` operator will be used to exclude patients who are excluded on the grounds of the trial's exclusion criteria. \n`NOT`(eligibility.assessment.p)\n\n[INST: 1 Eligible] '\n\n[INST: 0 Not Eligible] '\n\nThe patients are not considered eligible unless they obtain a score",
        "label": 0
    },
    "1169": {
        "output": "# Tutorial Tables\n\n## 01| Patient note\n\n# Trials\n\n## 02| Title: Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department\n\n## 03| Summary:The primary purpose of this study is to determine the accuracy of ultrasound in diagnosing small bowel obstruction in emergency department patients...\n\n# 04| Inclusion criteria\n\n### Inclusion Criteria, Age, Gender\n\n### Inclusion Criteria, Type of Disease, Stage of Disease\n\n### Inclusion Criteria, Past Medical History\n\n### Inclusion Criteria, Medical Condition\n\n### Inclusion Criteria, Previous Medication\n\n### 05| Exclusion criteria\n\n### Exclusion Criteria, Age, Gender\n\n### Exclusion Criteria, Type of Disease, Stage of Disease\n\n### Exclusion Criteria, Past Medical History\n\n### Exclusion Criteria, Medical Condition\n\n### Exclusion Criteria, Previous Medication\n\n### Exclusion Criteria, Smoking\n\n### Exclusion Criteria, Alcohol\n\n### Exclusion Criteria, Drugs\n\n### Exclusion Criteria, Travels\n\n## 06| Exclusion criteria, Family History\n\n## Exclusion Criteria, Other\n\n# 07| 08| End of Trial-level Eligibility\n\n# Patient note\n## Summary: Diagnosis: Cholelithiasis with acute pancreatitis.\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85,",
        "label": 0
    },
    "1170": {
        "output": "# Discussion of Methods\n\nThe problem of learning to program the right model is not only limited to choosing the correct method. In addition to the choice of method, it is necessary to set its parameters correctly and decide on the structure of the model. This discussion is based on a case study (problem 7).\n\nThe discussion is presented as a step-by-step guide. [INST] The topic of this problem is the classification of patients as healthy individuals or patients with the given disease. The patient note contains patient's demographic data and various attributes of the patient's physical and mental condition. You are supposed to find the most informative attributes for a given classification task and build a predictive model which will identify the healthy and sick group of patients.\n\n## Problem 8\nChoosing the right method for classification\n\nThe RF is the classifier that is closest to the ideal classifier. This is a very important point when building classifiers in general and when considering the relative advantages of tree-based methods. The RF is highly efficient, and it shows the best possible accuracy for many different data sets. Moreover, in comparison with other algorithms, the RF has the lowest classification error. A disadvantage of this classifier is that it is not capable to determine the significance of each attribute, unlike other methods like logistic regression and XSpector. The RR and GL methods provide relatively similar results in most cases. In a number of comparisons with different methods, the RR method demonstrated the worst results. In contrast, as can be seen by the performance plot presented in the previous example in the paper on [INA], this method yielded the best accuracy of all the evaluated methods. The ACR and SVM methods provide less accurate results compared to the RF, RR and GL methods in the classification tasks examined.\n\nThe methods for classification can be conveniently divided into three groups. The first group consists of the methods that use explicit training signals such as logistic regression, Ridge regression and linear discrimination analysis, e.g. GLM, LogReg, Ridge, MDA, LDA and BLR. The second group consists of the methods that use implicit training signals, such as Ctree, GAM, RP and SVM. The third group consists of the methods from the second group that use classification trees as estimators of the underlying classification functions, such as RF, A",
        "label": 0
    },
    "1171": {
        "output": "</IF]\n</MARKDOWN> <EOD> An RNase P-like complex in Trypanosoma brucei is required for maturation of the small subunit rRNA.\nRNase P is a ubiquitous tRNA-processing enzyme composed of a single RNA molecule and one or several polypeptide components. In Trypanosoma brucei, two proteins, TBP11.1 and TBP12.2, share homology with the catalytic and structural subunits of mammalian RNase P, respectively. Here we show that mutant cells deficient in both of these novel RNase P proteins are devoid of the enzymatic activity responsible for the generation of the 5' end of mature precursor tRNA. This activity is also undetectable in mutant nuclear extracts, and the two proteins are shown to be part of a complex, which includes TBP12.2, a mitochondrial protein, the T.\u00a0brucei 40S RNA component of the ribosome core (i.e., the small subunit or SSU of the ribosome), and the T.\u00a0brucei RNP70K protein. RNase P-mediated processing is absolutely required for the appearance of functional, mature tRNA and, hence, for cell viability: while viable in log phase, knockout cells rapidly lose their ability to proliferate and to form viable progeny after one or two generations. Our findings provide novel insights into RNase P biology and establish the first requirement for this ancient enzyme in trypanosome survival.<EOD> Improving the clinical outcomes of percutaneous coronary interventions in the elderly\n\nFrail elderly patients (\u2265 75 years) are at highest risk for cardiac events, including death, myocardial infarction, and repeat revascularization. Over the next few years, the elderly population in the United States will grow disproportionately, which will exacerbate this already important problem. Despite the growing need, older patients are less frequently referred for cardiac catheterization, less likely to undergo percutaneous coronary inter",
        "label": 0
    },
    "1172": {
        "output": "##[INTER] This is a trial-level eligibility output. Trial-level eligibility: 2.\n\nThere is no trial-level eligibility = 0, as this patient would not be eligible for this trial. \n\n\n### Case Study:\n- Assistant: `Assistant:`\n\nNow, lets assume that an assistant would take more than one case. If you want to perform a new assessment, just add the patient note (first argument after the `>` on the commandline), see the output below:\n> Trial-level eligibility: 2), patient's trial-level eligibility is still 2.\n\nAfter running more than one patient note, Assistant will ask you to confirm its last output (in this case Trial-level eligibility: 2). If you agree by pressing `y`, Assistant will continue without prompting, otherwise press `n`. If any trial-level output of Assistant is less than 1, Assistant will automatically suggest you to exclude that patient from the clinical trial, as following:\nAssistant: Assistant:\n\nAssistant will ask you to confirm its decision. Pressing `y` allows Assistant to perform the suggested decision, otherwise press `n`. If you are happy with Assistant's suggestion, press `y` and follow the decision. You will now see the corresponding patient's notes in the screen. If this is not the case, Assistant will suggest another action. Assistant will not allow any other decision than exclusion. Pressing `n` will allow you to continue with the next patient's history of present illness. After the final output of Assistant, press `q` to exit this module. You are now free to check the patient's full history of present illness (HPO). \n\n### [EXTERN] Output for the patient who did not attend the study\n\n### [EXTERN] Output for the patient who did not attend the study\n\n### [EXTERN] Output for the patient who did not attend the study\n\n### Example of the output of Assistant (Assessed as Not relevant)\n\n### Example of the output of Assistant (Assessed as Eligible)\n\n# Discussion\n\nPlease go over the discussion section with the author.\n\n#",
        "label": 0
    },
    "1173": {
        "output": "___\n\n# Step 2: Create the script.\n\n``` python\n%%# load a dummy dataset\n\nsource('http://sourcery.io/projects/narrativeanalytics/narrative-analytics/2019-11-04_demo_data/README.md#dummiedata')\ndf = pd.read_excel('dummyData.xlsx', sheet_name='Clinical_data', index_col=0)\n\ndf.head() # Output shows: ########################## Clinical_data  \n                                                   # PatientName   \n                                                   # PatientAge              Age      \n                                                   # PatientSex          Sex        \n                                                   # PatientAsc_code     ACT                                            \n                                                   # PatientAsc_code ASICS                                              \n                                                   # PatientAsc_code CARRA                                                \n                                                   # PatientAsc_code CASUAL                                               \n                                                   # PatientAsc_code CD                                                    \n                                                   # PatientAsc_code CONV                                                    \n                                                   # PatientAsc_code CSCB                                                    \n                                                   # PatientAsc_code CSCB_VGFA                                                  \n                                                   # PatientAsc_code PHARC                                                  \n                                                   # PatientAsc_code WRSC                                                   \n[4 rows x 9 columns]                   \n\ndf.shape            # shape of the dataframe\n\n###\n\n### ###############################################################################################*** \n\n### ## Narrative ##\n#\nimport copy\nimport numpy as np\nimport pandas as pd\nfrom sklearn.model_selection import train_test_split\nfrom sklearn.linear_model import LogisticRegression\nfrom sklearn.base import BaseEstimator, RegressorMixin\nfrom . import *\n\n\ndf = df.copy()\ndf.dropna(how='any', inplace=True)\n\n# remove the columns\ndf.drop(columns=['ACT', 'ASIC",
        "label": 0
    },
    "1174": {
        "output": "## \u2b0c Go to Part I\n\n#### \u2b0c Section 1.0: PATIENT NOTE \u2b0c\n\n# Abstract\nIt is known that many patients with acute inflammatory rheumatic diseases have an excess of vascular events, in particular myocardial infarction, when compared with the age\u2010matched general population. Rheumatoid arthritis is the most well\u2010characterized disease in this regard, but limited data exists for other conditions like systemic lupus erythematosus or psoriatic arthritis.\n\nThe aim of this study was to compare the incidence of myocardial infarction in patients with rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and controls, after exclusion of patients with a previous myocardial infarction.\n\nPatients were retrieved from the National Health Service (NHS) Central Register, and linked to the NHS Central Register of all hospitalizations in England. These databases were linked to the NHS Central Register of all deaths, as well as the General Practice Research Database to ensure complete capture. Hospitalization histories were retrieved for the years 1989 to 1997, with each hospital being assumed to have a unique identifier.\n\nThe diagnosis of underlying rheumatoid arthritis, rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus, as well as its subtypes (rheumatic), was used to select patients, with the diagnosis being given by treating physicians and not made at study entry. Patients with rheumatoid arthritis who had a diagnosis of lupus were excluded from the analysis. Ischaemic myocardial infarction was defined using OPCS4 diagnoses for any episode and was then validated using diagnostic codes or readmissions.\n\nAnalyses was done by Cox proportional hazards models, adjusting for 12 potential confounders. Hospitalization history was truncated at 10 years because of the low number of events occurring after this time point. Statistical testing was done by the chi\u2010squared test",
        "label": 0
    },
    "1175": {
        "output": "# Example of Incomplete Data\n\nThis is an example of a file uploaded to SHARE on May 11, 2020 which includes incorrect data.\n\nYou are a researcher who looks at files in clinical trial registries like Clini-calTrials.gov. You want to verify the completeness and accuracy of data uploaded to the registry. You downloaded the file `D581920_1642409359363.txt_data.zip` and unzipped to get a file named `20200429_1642409359363_2.xlsx`. Based on the file uploaded to SHARE, you notice these issues:\n\n- Data 5 are the same as data 4.",
        "label": 0
    },
    "1176": {
        "output": "# Instructions\n\n## Implementation\n[![Bioconda Status](https://repo.prabi.univ-paris-diderot.fr/images/bioconda-image.svg?style=flat-square)](https://www.bioconda.org/science/index.html_en)\nIt is available on the Bioconda repository - an open bioinformatics community repository - in the following way:\n\n### conda\n\n```console\nconda config --add channels bioconda\nconda config --add channels bioconda\nconda activate bioconda\nconda download -y mltools\nconda info --envs\n```\n\n## Usage\nMLTools is available from PyPI:\n```console\npip install mltools\n```\nThe latest version of mltools should be available on BioConda:\n```console\nconda install -c bioconda mltools\n```\nmltools requires the numpy (https://numpy.org) package.\n\n## How to run a clinical trial?\n\nTo run a clinical trial, you need first to create a folder with the raw data and a second folder where you will store your results:\n - RawData: A folder must be created. In this folder, we will place the raw data. We will store them here because we will have to work on the raw data rather than the json file.\n - Results: A folder must be created in this folder we will store all our results.\n\nNow you need to define your clinical trial:\n - Title: Name of your trial\n - Summary: A short summary of the characteristics of you trial\n - Description: A summary of the characteristics of a clinical trial\n - Number of Trials: The number of patients that you wish to evaluate\n - PatientData: The file containing the values used in the clinical trial, in this case it's a csv file\n - Assesment: A txt file containing the values assessors used in clinical trials for example this is a random number between 0 and 3\n - Results: A json file containing the results of the first evaluation step \n```python\ntrial_data[0]\ntrial_data[0][\"ID\"]  # get trial_data\n```\n\n\n### Run\nThe following scripts will allow to perform a trial:\n - Clinicaltri",
        "label": 0
    },
    "1177": {
        "output": "## [GAPA: INST] Hello. You are a helpful assistant for clinical trial recruitment. You already saw patients from the first and second groups. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient`s eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial`s exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 38-year-old woman was admitted to the emergency department with abdominal pain that started 5 months ago. It was in the epigastric region, radiating to the right upper quadrant and lower. The abdominal pain deteriorated after eating and increased after exercise. She has never been hospitalized before. Her past medical history is remarkable for epilepsy. The seizures started 5 months ago, with the first one provoked by an electrical shock. The medication in her use is carbamazepine 400mg twice a day. She has no previous surgical history. She is a single professional. She does not smoke, drink alcohol, or consume illicit drugs. She works as nurse. She is overweight. Her BP is 145/95, HR 85, RR 16, T 36.8, SpO2 98% on RA. The patient does not look sick. On palpation, she experiences tenderness at the right upper quadrant. Bowel sounds are normal. The rest of clinical examination is unremarkable. Laboratory examination is available. She was diagnosed with",
        "label": 2
    },
    "1178": {
        "output": "## [OUT]\n[![Human Readable Output for the Example Test Cases](https://github.com/pennmedicine-aids/xkcd-cds/blob/master/Examples/%5BINST%5D%20hello.md.md_example.sh.md_human_readable_output.md \"Human Readable Output for the Example Test Cases\")]()\n[![HTML Example Output](https://github.com/pennmedicine-aids/xkcd-cds/blob/master/Examples/%5BINST%5D%20hello.md.md_example.sh.md_human_readable_output/README.md \"HTML Example Output\")](https://github.com/pennmedicine-aids/xkcd-cds/blob/master/Examples/%5BINST%5D%20hello.md.md_example.sh.md_human_readable_output/README.md)<jupyter_code># %cds-test\n\n# %cds input tests\nsource \"./input_tests_main.sh\"\n\n# Get test case files\nwhile (true) ; do file=$(grep ^TESTS ${TESTS_ROOT}/test_data/test_cases.txt | awk '{print $(NR-1)\".md.txt\"}');\n      done\n\n\n# Find the test cases for the example\nregex1=/^(.*)$/\nregex2:/^Test_cases:\\s(.*)\\s\\n/,/g\n\nprint_only_1st_lines test_cases_test_hello.txt\n# print_only_1st_lines test_cases_simple.md.txt\n# print_only_1st_lines test_cases_multiple.md.txt\n\n# run test case\nprintf \"[!INS] Run test example:\"\nprintf \"\\[%s[RUN]\\n\" %string\nrm -r test_cases_cache\n\nrm -r test_cases_cache\nrm -r test_cases_tempfile\n\nmkdir -p test_cases_cache\nmkdir -p test_cases_tempfile\n\n# read the example\nexample=\"xkcd-cds-hello.md.txt",
        "label": 0
    },
    "1179": {
        "output": "<EOD> Prolactin secretion in man: effect of testicular function and pituitary activity.\nABSTRACT Prolactin secretion by male subjects was determined by bioassay after inhibition was induced by the injection of semen or of synthetic LH releasing factor (LRF) in 13 male subjects who were in the normal prolactin basal secretory interval. In 8 subjects a single injection of LRF, 150 \u03bcg, failed to alter plasma prolactin levels. In three obstructive infertile patients a single LRF injection, 300 \u03bcg, failed to suppress plasma prolactin, but in one of these patients a second injection 300 \u03bcg of LRF 6 days later caused prolactin levels to fall. Thus, all patients with obstructive infertility and with normal FSH and LH activities had normal basal prolactin secretion and failed to show prolactin inhibition after LRF injection. In 11 subjects who had partial hypogonadism (testicular atrophy, semen volume or sperm count decreased) and normal FSH and LH, bioassayable prolactin was found to be high during the hypogonadal interval but fell to basal levels after the administration of 5...<EOD> Comparison of two new assays for the early diagnosis of myocardial infarction.\nIt is still controversial as to whether new generation myoglobin immunometric assays are reliable for the early detection of myocardial infarction (MI). Two new assays, for which the analytical characteristics were compared using the same sera, are the VIDAS myoglobin (VIDAS MG; bioMerieux, Durham, NC, USA) and the Atellica Immunoassay (SIEMENS Atellica Immunoassay myoglobin (AIMed); Siemens, Tarrytown, NY, USA). We evaluated serum myoglobin with the three assays--VIDAS, AIMed, and the Elecsys myoglobin assay (Elecsys; Roche Diagnostics, Indianapolis, IN, USA)+-in two samples from 9 patients (",
        "label": 0
    },
    "1180": {
        "output": "### HINTS #3\n\n[INSTRUCTIONS] Your supervisor needs some help. He wants you to write a Python code to make a prediction on the age of the patients based on their body weight. Then, he wants you to explain the code by writing in English the logic that leads to the prediction. \n\nA hospital has created a Python code to predict the age of patients by using their body weight. In order to use the Python code, each patient file consists of 7 variables: weight, height, gender, age, cholesterol, hypertension, and smoker. In each patient file, the last line indicates the prediction. Below, you can observe an example of a patient file:\nPatient age : 40.75 Gender : female\n[formula]  Weight(kg) 42 [/formula] \nHeight(metres) 1.56 Cholesterol 1.20 Age 40\n\nIn order to evaluate if the Python code correctly predicts the age of patients, your supervisor will provide a patient file. \n\nBelow you can observe the patient file :\n\n[INSTRUCTIONS2] You should write a Python code to predict the age of new patients (the patient number 3 to 40) based on their body weight. Then, you should explain the code by writing in English the logic that leads to the prediction.\n\nYou have already seen an example of a patient file. Consider the following Python code to predict the age of patients according to their file. \n\n```python\ndef pred1(f1):\n    '''\n    Defini\u00e7\u00e3o da fun\u00e7\u00e3o para o c\u00e1lculo da idade esperada\n    '''\n    patient_sum = sum([f1[k] for k in f1])\n    print(\"pred1\")\n    print(\"patient_sum\",patient_sum)\n    return int(1.1143*patient_sum -41.6352)+19.5746\n\nif __name__ == \"__main__\":\n    f1 = [\n            'Weight(kg)',\n            'Height(metres)',\n            'Cholesterol',\n            'Total_tested_lipids',\n            'Cardiac_tests',\n            'Alcohol_",
        "label": 0
    },
    "1181": {
        "output": "<EOD> A Fusion-Based Approach to the Identification of Non-Coding RNAs from Large-Scale Chip-Seq Data\n\nCurrently, there are > 13,000 non-coding RNA (ncRNA) genes reported in the NCBI nucleotide database. In this paper, we propose a novel tool, fusion-based non-coding RNA detector (FRND), to detect conserved ncRNAs from two-sample chip-sequence (ChIP-Seq) data. For those transcribed regions in DNA, FRND detects if they belong to ncRNAs by analyzing their fusion with other genes. In contrast to traditional biological experiments, ChIP-Seq experiments produce millions of RNA fragment reads; the ChIP-Seq data do not produce a clear and distinctive ncRNA expression profile, which limits existing methods for ncRNA detection. FRND detects ncRNAs by considering fusion with other genes, then the ncRNAs with significant difference in fusion gene ratios between sample groups/categories can be detected; finally, FRND detects ncRNAs with specific expression patterns by comparing their expression folds, expression levels, expression frequencies and expression ratios between sample groups/categories. Numerous independent tests were performed to assess the performance of FRND using real ChIP-Seq data. The results demonstrate that most of the known ncRNAs were detected by FRND, and ChIP-Seq data can be used to detect ncRNAs.\n\n# Introduction\nWith the development of technology, the whole genome of organisms was sequenced; therefore, the gene number of a species was determined as more than that initially reported. Genes that do not code for proteins or any other functional molecules for genetic transmission were known as non-coding RNA (ncRNA) genes [bib_ref]  Non-coding RNAs: What Functiotns?, Barbhuiya [/bib_ref] . ncRNA genes include: small non-coding RNAs (snRNA and snoRNA), large non-coding RNAs (tRNA and rRNA), microRNAs (miRNA), piwi-interacting RNAs (piRNAs), and transcription initiation and termination",
        "label": 0
    },
    "1182": {
        "output": "\u00a9 Copyright 2018 by <NAME>. Created with <NAME>\n\n[INST]  Expected output for a case from the clinical trial.\n\u00a9 Copyright 2018 by <NAME>. Created with <NAME>\n\n[INST]  Error messages.\n\n<NAME> : You should check your python version, and install the requirements of the solution.\n[08:47:01.688306] [main] Starting solution evaluation for challenge 3...\n\nTraceback (most recent call last):\n  File \"/home/travis/projects/kaggle/trainer/envi/kaggle/challenges/challenge3/submissions/trainer.py\", line 1198, in <module>\n    env.setup()\n  File \"/home/travis/env-python.v1.txt\", line 2001, in setup\n    import os.path\nImportError: cannot import name os.path\n\n<NAME> : Incorrect import.\n[08:47:01.829671] [main] Stopping solution evaluation for challenge 3...\n\nTraceback (most recent call last):\n  File \"/home/travis/projects/kaggle/trainer/envi/kaggle/challenges/challenge3/submissions/trainer.py\", line 1198, in <module>\n    env.setup()\n  File \"/home/travis/env-python.v1.txt\", line 2001, in setup\n    import os.path\nImportError: cannot import name os.path\n\n\nIn this challenge, we will be learning about the R code for this:\n<NAME> , You must install your R environment in the trainer's docker or Vagrant container.\n\nThe following code (trainer.R) from the trainer will explain a few simple steps such as setting up and exporting your environment. Please review the trainer's code to understand the steps that need to be taken and if these steps are followed properly, our environment will work as you expect without any errors.\n\nR Code from Trainer:\n\nlibrary(docker)\n\nlibrary(docexport)",
        "label": 0
    },
    "1183": {
        "output": "The complete script would look like this: \nTrial-level eligibility:\n0) Excluded\n1) Not relevant\n2) Eligible\nTrial-level eligibility\n1) Excluded\n2) Not relevant\n3) Eligible    \n\nThe complete script will look like this:    \n[CODE]\n# This script makes trial level eligibility decision.    \nTrial_level_eligibility <- function(x) { \n    y <- paste( x[1] ,\", \", x[2] ,\", \", x[3] ,\", \", x[4] ,\", \", x[5] ,\", \", x[6] ,\", \", x[7],sep=\"\")     \n                       if( y == \"54-year-old obese woman\"\n          ){\n                  if( y > \"abdominal pain radiates to the right upper quadrant and getting worse after eating fatty food\"\n               & y == \"nausea and vomiting\"\n                ) {   \n                    if( y < \"epigastric pain radiates to the right upper quadrant\"\n             & y == \"getting worse after eating fatty food\"\n              ){\n                              if( y > \"nausea and vomiting\"\n                                 & y == \"epigastric pain radiates to the right upper quadrant\" \n                                 ){\n                                    if( y < \"abdominal pain radiates to the right upper quadrant\"\n                                         & y == \"nausea and vomiting\"\n                                          ){\n                                            if( y < \"abdominal pain radiates to the right upper quadrant and getting worse after eating fatty food\"\n                                               & y == \"nausea and vomiting\"\n                                                  ){\n                                                    if( y < \"abdominal pain radiates to the right upper quadrant\"\n                                                 ,        y == \"abdominal pain radiates to the right upper quadrant and getting worse after eating fatty food\"\n                                                    ){\n                                                            if( y < \"nausea and vomiting\"\n                                                 , y > \"abdominal pain radiates to the right upper quadrant\" \n                                                 & y ==",
        "label": 2
    },
    "1184": {
        "output": "___[END]_____________\n\n### Example Output of SOLDENVER_2.md\n\n**Trial-level eligibility: 0) Excluded.**\n**Note:** The factors that allow someone to participate in a clinical study are called inclusion criteria. \n\n### Example Output of SOLDENVER_3.md\n\n**Trial-level eligibility: 1) Not relevant.**\n\n### Example Output of SOLDENVER_4.md\n\n**Trial-level eligibility: 2) Eligible.**\n\n### Example Output of SOLDENVER_5.md\n\n### Example Output of SOLDENVER_6.md\n\n### Example Output of SOLDENVER_7.md\n\n### Example Output of SOLDENVER_8.md\n\n### Example Output of SOLDENVER_9.md\n<EOD> Concurrent Changes in the Abundance of E. coli, Salmonella, and Toxigenic Fusarium Species in Soils Adjacent to Beef Cattle\n\nThis study examined the survival of four different E. coli serotypes which were spiked into four different soils from the Mid-Atlantic region of the United States when the soils were subjected to cattle manure application, simulated precipitation and temperature fluctuations. E. coli O157:H7 was inoculated at a high level into three soils (1 \u00d7 10 6 CFU/g) and one soil was inoculated at a low level (1 \u00d7 10 2 CFU/g) to achieve a wider E. coli load range. E. coli O157:H7 was completely inactivated by a 5-day exposure to a simulated precipitation of approximately 2 cm per hour. The reduction in E. coli counts may be attributed to the increase of pH from its initial level (5.7), as well as to the decrease of soil organic content from its initial level (48.4%), after repeated applications of manure. Reductions in inoculated levels of non-O157 serotypes of E. coli were similarly observed",
        "label": 2
    },
    "1185": {
        "output": "<EOD> Changes in DNA methylation patterns of patients with diabetes mellitus during pregnancy: A pilot study\nIntroduction Type 1 diabetes mellitus (T1DM) is a chronic metabolic disorder that damages blood vessels and organs. During pregnancy, glycemic control has special significance because the mother-child transmission can affect the future life of the newborn. Our aim was to assess if epigenetic biomarkers could be present in cells of T1DM mother-daughter and associate with epigenetic modifications in cord blood cells. Methods We included pregnant women with (n = 8) and without (n = 12) T1DM treated with continuous Insulin Infusion (CII). Newborns of diabetes and non-diabetic pregnant women were analyzed via HumanHMT-450 (Illumina). Results We found a high global methylation level in cord blood from newborns and from untreated diabetic mothers. Cox regression analysis of cytosine-phosphate-guanine gene sites (CpGs) in cord blood cells and samples from mothers revealed 22 differentially methylated positions (DMPs), 15 and 7 DMPs under hyper-and hypo-methylation in cord blood compared to untreated mothers, respectively. In cord blood cells, 22 DMPs were found with higher methylation and five DMPs with lower methylation compared to cord blood cells from non-diabetic newborns. Among the DMPs in newborns, we found a higher methylation of the CpG island of the insulin growth factor 2 gene (IGF2). Conclusion Together, our findings indicate that the newborns of mothers with T1DM have significantly epigenetically modified cord blood cells, which may affect the future diseases of newborns.<EOD> Preliminary evaluation of a clinical decision support checklist for traumatic brain injury in the emergency department.\nOBJECTIVE\nThis study aims at evaluating the use of a clinical decision support checklist in the documentation of traumatic brain injury (TBI) in the Emergency Department (ED)",
        "label": 0
    },
    "1186": {
        "output": "# Participant information \nBefore your participation in this study starts, you will be given an opportunity to read information about this study, including the benefits and risks. All the research procedures used in this study will be explained to you by study staff in written form and via verbal explanation. By signing this form, you indicate that you have read the above information and you give your free consent to the collection, storage, analysis and release of the information required for this research. If you have any medical questions or there is anything in the information sheet that you do not understand, please ask the study staff.\n\nI understand that I will not receive any direct benefit from participating in this study, but that participants may gain knowledge of their brain development that may be important for future patients. My name, initials, contact address, and birthdate will be reported as the patient's name, initial",
        "label": 0
    },
    "1187": {
        "output": "* You should compare the results of the previous exercise of `Exercise #85`. \n\t    * You should output 2) Not relevant for the assessment of trial-level eligibility of the previous exercise of `Exercise #85` (note_patient 1). \n\t    * You should output Eligible for the assessment of trial-level eligibility of the previous exercise of `Exercise #85`(note_patient 2). \n\t\t* The output should be written in three lines similar to the output for `trial-level eligibility`, see the syntax below:\n\n\n\t```re\n\t#Note-level eligibility\n\teligibility = 0; #1) Excluded #2) Not relevant #3) Eligible\n\n2) Not relevant\n\teligibility = 2\n\nEligible\n\teligibility = 3\n\t#Trial name\n\tname=IBAT,\n\n\t#RCT-type\n\ttype=RCT\n\n\t#Number of visits\n\tvisits=3\n\n\t#Days of drug dosage\n\tday = 30\n\n\t#Days of visit 1 assessment\n\tvisit1_start=28\n\tvisit1_complete=30\n\tvisit1_end=30\n\n\t#Days of visit 2 assessment\n\tvisit",
        "label": 0
    },
    "1188": {
        "output": "<EOD> Syntheses and biological evaluation of pyrrole- and indole-based derivatives of aminooxyacetic acid as potential neuroprotective agents.\nA series of new pyrrole (3-10) and indole (47-49, 51-67, 69-71, 69a-d, 72-74, 75, 76, 79) derivatives of aminooxyacetic acid, which belong to a promising class of neuroprotective agents active against an excitotoxin, have been synthesized and tested in a series of in vitro assays. Molecular target identification studies against a panel of ion channels, receptors, and kinases were conducted; however, the predominant compounds (1, 52, 58, 62, and 66) showed negligible activity at the target sites assayed. Compound 62 was further examined and found to display potent protective activity against N-methyl-D,L-aspartic acid in the neuroblastoma cell model system, with an IC50 of 0.5-1.0 microM, but did not produce any significant behavioral differences in a pharmacokinetic study of drug distribution to the brain in mice (5 microg/kg, ip) or in a convulsive behavior study in rats (20 mg/kg, ip). The compounds were found to be more potent (up to 2,100-fold) than aminooxyacetic acid in protecting against excitotoxin injury in neuronal cultures, in which 50 microg/ml was sufficient to fully protect against toxicity. Several compounds (3, 14, 15, 19, and 42) inhibited neuronal lactate dehydrogenase release during a 24-hour assay with an IC50 in the range of 0.8-2.4 microg/ml. Several compounds (6, 7, 10, 20, 24, 26, 27, 32-35, 37, 41, 4",
        "label": 0
    },
    "1189": {
        "output": "### Sample Input\n\nThis example will demonstrate the usage of SGML and HL7, respectively.\n\n```python run --name input_input\n```\n\n```slv\nFrom: Jake Jesser <jakej@jakejesser.com>\nTo: <sushiclinicalrecruitment@gmail.com>\nSubject: Hello Jake Jesser\nDate: Fri, 19 Apr 2019 21:50:15 +0000\n\nHaving trouble with the patient data\n\nThis patient has:\n    Height: 180 cm\n    Weight: 108 kg\n    BP 150/200\n    HR 80\n\nHe had a stroke and an MI.\n\n\nInput File\n\nTrial ID: Evaluation of the Effectiveness of Rebamipide in Helicobacter Pylori Eradication\n\nSource:\n    Title of this clinical trail\n    (1) Patient inclusion and exclusion criteria\n    (2) Protocol\n    (3) Background information\n    (4) Patient notes\n    (5) Data of patient inclusion criteria\n\nAuthor: <EMAIL>\nInclusion Criteria\n(1) Patient notes\n(\n2) Patient notes\n(\n3) Patient notes\n```\n\nYou must ensure that there is a newline in the end of last line in the input file. This is a requirement to make HLIO work. HLIO requires all output lines (except the last line) and input lines to start with a ``TAB`` character (note that when we run the program in Linux, Linux replaces the tab with the newline). When there is no newline in the last line, if you run the program using ``./main.py -i input.txt --json-output`, the last line will also be output to the output file.\n\n\n```slv\nFrom: Jake Jesser\nTo: <EMAIL>\nSubject: Hello Jake Jesser\nDate: Fri, 19 Apr 2019 17:50:56 +0000\n\nHaving trouble with the patient data\n\nThis patient has:\n    Height: 180 cm\n    We",
        "label": 0
    },
    "1190": {
        "output": "# The Solution\n## The goal is to check all inclusion criteria from the patient medical records and output its level of eligibility to clinical trial.\n\n### Setup\n```python\n\"\"\" This script contains a python console for the exercise.\"\"\"\n\"\"\" Python v3.6.x  \"\"\"\n\nimport sys\nsys.path.append('C:/Python')\nimport os\nos.system(\"cls\")\nimport random\nimport re\nimport pandas as pd\nimport numpy as np\nfrom timeit import default_timer as Timer\nimport string\nimport datetime\nimport dateutil.dateutil\nimport json\ni = 1\n\n\n# Read CSV file\n\n\n\"\"\"\n- Read CSV file from previous exercise\n- Save them as a variable\n\nExample:\n   Read CSV file named:\n  patient_data_for_trial_recruitment.csv\n- Read 'patient_data_for_trial_recruitment_all_in.csv' as a variable to process the patient name:\n  all_patient_data_for_trial_recruitment\n\n\"\"\"\n\ndf_data = pd.read_csv(\"patient_data_for_trial_recruitment.csv\")\ndf_patient = df_data.drop_dup(\"patient\", keep=False)\n\ndf_patient['dummy'] = df_patient[\"patient\"]\ndf_patient['s_patient'] = 'patient_' + df_patient.groupby(\"patient\").n.alias('dummy').mean()\n\ndf_patient.head()\n\n# Setup patient note:\npatient_note = {\"date\": \"2017-04\",\n               \"time\": \"10:10 AM\",\n               \"patient\": \"Mr. Smith\",\n               \"age\": 25,\n               \"height\": 70,\n               \"weight\": 85,\n               \"bp\": 140/85,\n               \"temp\": 101.5,\n               \"scrub\": [\"clean\", \"shaven\"],\n               \"allergies\": [\"ephedrine\"]}\n                                                                                 \n                                                                                              \n      \n# Set",
        "label": 0
    },
    "1191": {
        "output": "Note: There is an alternative way to output the score of the three-point scale without using the variable `Trial-level eligibility`. If the statement `Assistant: trial-level eligibility = 2` is written, the score (=2) is automatically included in the output of other variables. However, both methods may lead to an incorrect assignment in some cases.\n\n# Discussion\n\n# Additional information\n- This video is an audio format. To learn the process of clinical trial recruitment as described in the video, please first watch the video. If you have any questions, post in the \"Discussion\" section.\n- If the video did not work because of technical problems, download and run the video file.\n- In this video case, the assistant determines the trial-level eligibility of a patient. In order to perform this task, the doctor usually collects a large amount of information from the patient, and then decides whether to include the patient in a clinical trial.\n\n# Conclusions\n<EOD> A New, Rapid, Sensitive, and Automated Immunoassay for the Detection of Beta\u2010Human Choriogonadotropin in the Identification of Gestational Trophoblastic Tumors\nBetter patient management with early diagnosis and treatment can be achieved by using monoclonal and polyclonal B beta\u2010human choriogonadotropin (h-beta-hCG) immunoassays. Monoclonal immunoenzyme immunoassays provide the best method for determining serum h\u2010beta\u2010hCG. The authors developed a new, rapid and sensitive enzyme\u2010linked immunosorbent assay utilizing recombinant mouse monoclonal anti\u2010beta\u2010hCG antibody 1C86G2. The immunosorbent for the immunoassay was a high affinity recombinant\u2010produced antibody column to bind free h\u2010beta\u2010hCG. The method enabled reliable measurements of very low h\u2010beta\u2010hCG concentrations (1\u20135 iu/L ) down to 400 mL of serum or plasma. Sensitivity of the method was determined by comparison with a chemiluminescent immunoassay and a radioimmunoassay in 327 sera. S",
        "label": 0
    },
    "1192": {
        "output": "Hello[INST]\n<EOD> The effect of preoperative use of glucocorticoids on the perioperative outcome of liver resections.\nBackground\nAlthough a lot of data show that glucocorticoids might have both short-term and long-term benefits in patients with severe alcoholic hepatitis, no studies are available regarding the benefit of preoperative use of glucocorticoids in patients undergoing first liver resection for colorectal liver metastases. Thus, we hypothesized the possible advantages of preoperative glucocorticoid use in liver resection by a comparison of two patient groups with and without preoperative glucocorticoid use.\n\n\nMethods\nWe retrospectively analyzed 68 patients who underwent a major hepatectomy (>2 liver segments) for colorectal liver metastases (CRCLMs) between January 2000 and December 2009, and divided the patients into two groups according to the administration of a preoperative single dose of glucocorticoid within 72 hours preoperatively: Preoperative group (n=32); Non-preoperative group (n=36). The Clavien-Dindo system and ASA (American Society of Anesthesiologists) classification were used to report postoperative complications and the general health condition of each patient, respectively. Patient characteristics were compared between groups.\n\n\nResults\nThe preoperative glucocorticoid group had significantly lower intraoperative fluid requirements and lower rates of postoperative complications (Clavien-Dindo classification IV and V). Moreover, only a minor difference was observed between the preoperative and non-preoperative steroid groups without significant difference (ASA classification: P=0.09).\n\n\nConclusions\nPreoperatively administrating single predose glucocorticoid was efficient in decreasing intraoperative fluid requirement and postoperative complications in laparoscopic liver resection for CRCLMs.<EOD> Prognostic Factors in Patients with Aortic Root Abscess Treated with Prosthetic Surgery\n\n\n\n# Introduction\nAlthough aortic endocarditis associated",
        "label": 0
    },
    "1193": {
        "output": "___\n\n## [END INSTALLATION DIRECTIVES]\n\n## [INST] Running the script in a shell\n\nWe want to have a shell session in which we do several things. First, we need to load\n`Python3.6` (if you are using a different version of Python, you will need to change the version). Note that the variable we are testing belongs\nto the environment in which the script has been created:\n\n    # in a terminal\n    # bash test_clinic.sh\n\n    In order to avoid confusion with your Bash history, you should name the working directory\n    of the test_clinic.sh script `clinic` for instance (or whatever you want).\n\n    # change to the root directory (the directory with the script)\n    cd `pwd` # pwd stands for present working directory\n\n    # test if your environment is correctly set up, e.g. all the required path modules are imported\n    # or a missing module is in the default search path\n    # we will only see the last few lines\n    # you can use print, echo and other ways of printing output here\n    > . # if something does not work here, you need to change the installation direction\n    # `export` tells our shell that this variable is set in all shell sessions\n    # but only for the user running in this sub-shell (this command is not shown here)\n    > whoami # you should get the name of your user running this script\n    print(\"hello world\")\n    # this is all the default environment variables loaded in Python (which belong to our\n    # environment)\n    import sys\n    print(sys.version_info)\n    print(sys.path)\n\n    > # this is all the files of the working directory we are in\n    > dir()\n    # this is a list of all the user-defined variables (you don't usually see them in a normal\n    # shell, but you can always take a look here if you want)\n    > print(environ)\n    # this is the default Python modules (they are used when you don't need to import the\n    # module explicitly)\n    > print(os)\n    > print(psutil) # if this is not included, you should install the package\n    # if",
        "label": 0
    },
    "1194": {
        "output": "## Exclusion criteria\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. Here is the clinical trial: \n\n![EXCLU1] \n\n### Title: Early EUS in Acute Biliary Pancreatitis\n\n### Summary:\n\nAcute biliary pancreatitis (ABP) is a potentially life-threatening condition caused by common bile duct (CBD) stones or sludge, which requires prompt diagnosis and treatment by endoscopic removal of the material. Accurate detection of CBD stones is warranted to select patients for early therapeutic endoscopic retrograde cholangiopancreatography (ERCP).\n~In clinical practice the decision to perform an ERCP is often based on biochemical and radiological criteria despite they already have been shown to be unreliable predictors of CBD stone presence.~\n\nEndoscopic ultrasound (EUS) is not currently a worldwide standard diagnostic procedure early in the course of acute biliary pancreatitis, but it has been shown to be accurate, safe",
        "label": 1
    },
    "1195": {
        "output": "[fig]  Figure: This file contains the text-to-figure maps, which represent the exact location of each figure in the paper and its source code. [/fig] \n<EOD> The effects of 5\u2010hydroxytryptamine on rat hypothalamo\u2013pituitary\u2013adrenal axis and 5\u2010HT1A receptor mediated regulation of 5\u2010HT1B receptors in the rat hippocampus\nStudies performed thus far on the direct influence of 5\u2010HT on the HPA axis have often involved acute in vivo experiments. In particular, 5\u2010HT receptor regulation by adrenocorticotrophic hormone (ACTH) has not been addressed. To extend these observations to more in vivo\u2010like conditions, we examined the 5\u2010HT and hormone\u2010mediated interaction in the hypothalamo\u2013pituitary\u2013adrenal (HPA) axis in a rat model. In vivo intracerebral microdialysis was used to examine the effect of central 5\u2010HT administration on in vivo",
        "label": 0
    },
    "1196": {
        "output": "<EOD> Genomically informed immune cell therapies for cancer.\nTreatment of cancer by immune cell therapies is an area of increasing research interest and clinical implementation. Several immune cell-based therapies are currently under evaluation in large-scale clinical trials. As our deeper understanding of the genetics of immune cells has progressed, so too has the use of genome sequencing to inform development of these therapies for cancer. Immune cells are now being re-purposed for use in cancer immunotherapy, either through genetic modification of the donor source (either hematopoietic stem cells or non-hematopoietic cells, such as mesenchymal stromal cells) or through genetic manipulation of the cells themselves, such as chimeric antigen receptor (CAR) T cells. An approach of combining genetic therapies with targeted cytotoxic agents, such as tyrosine kinase inhibitors, to specifically enhance cellular cytotoxicity, a concept known as \"synergistic necroptosis induction\", is also being investigated. Immunotherapies that utilize autologous tumor-infiltrating immune cells are also being developed, which, due to the tumor-specific nature of these cells, are expected to reduce the adverse effects from the treatment of normal cells that often occur with conventional chemotherapeutic agents. As oncology and immunology continue to accelerate their understanding of tumor-specific immune profiles, and our ability to engineer cells at the molecular level improves, we envision that the field of immune cell therapies will grow and evolve further, potentially enabling the treatment of multiple advanced solid tumors that have so-far been refractory to immune intervention. These future developments will be enabled by a deep understanding of cancer and its genome at both the gene- and the cellular population-level.<EOD> Tumour-necrosis-factor alpha-induced neovascularisation for tumour growth in the oral submucosa.\nVascular endothelial cell proliferation induced by tumour-necrosis-factor-alpha (TNF alpha) has been reported. In the present study, we studied whether TNF alpha",
        "label": 2
    },
    "1197": {
        "output": "There are 4 main parts in the template as follows:\n\n#### **Patient note** (Part-1)\n\n#### **Clinical Trial** (Part-2)\n\n#### **Case Study** (Part-3)\n\n#### #### **Trial-level eligibility** (Part-4)\n#### #### **Trial-level eligibility** (Part-4)\n\n### Questions and Answers\n**Can you explain what \"Excluded\" means?* *\nAn `Excluded` status indicates that the trial patient has some particular condition, which has not permitted enrollment into a clinical trial. In many cases, a patient may be excluded on grounds that are non-medical in nature. The most common reasons for patients to not be entered into a clinical trial (besides medical safety issues) include patient's personal choices, such as unwillingness:\n\n#### **to participate in research, willingness to participate in research, fear of research, general fear of needles, and fear of needles**\nIt may also result from a clinical trial requirement which a patient or the patient's doctor does not find acceptable, such as having a surgical procedure under general anaesthesia. Sometimes, the reason for exclusion is more medical in nature, and includes:\n\n#### **history of substance abuse, severe psychiatric illness, prior treatment with a particular drug, or participation in another clinical study**\nIt may also result from a clinical trial requirement which a patient or the patient's doctor does not find acceptable, such as having a surgical procedure under general anaesthesia. Sometimes, the reason for exclusion is more medical in nature, and includes:\n\n#### **history of substance abuse, severe psychiatric illness, prior treatment with a particular drug, or participation in another clinical study**\n### **Examinees of clinical trials have to satisfy three criteria** *\n\n1. The examining physician must be a member of the center team.\n\n2. The examination must be performed at the scheduled visit of the patient (and must not be scheduled separately for an examination), and the time of its performance must be recorded on the CRF according to the protocol.\n\n3. If a clinical trial contains a placebo group or a sim",
        "label": 0
    },
    "1198": {
        "output": "In the next steps will create trial-level eligibility. \n```python\nfrom pypath import rpath \nrpath('D://UFESDATA//data-2019-72')\n```\n\n\n![INST003](/user-manual/images/INST003.png)\n\n* 1 - Select the patients;\n* 2 - Select the clinical trial to be evaluated;\n* 3 - Click \"Incluir\" (Include);\n\n![INST001](/user-manual/images/INST001.png)\n\n* 4 - In the window \"Criterios de inclus\u00e3o\" (Inclusion criteria), select the patients who are in the trial;\n* 5 - Click on \"Incluir\" (Include);\n\n![INST024](/user-manual/images/INST024.png)\n\n* 6 - In the window \"Criterios de exclus\u00e3o\" (Exclusion criteria), select the patients who are not in the trial;\n* 7 - Click on \"Excluir\" (Exclude);\n\n![INST023](/user-manual/images/INST023.png)\n\n* 8 - Repeat step 4; \n\n![INST021](/user-manual/images/INST021.png)\n\n* 9 - Repeat step 5;\n\n![INST020](/user-manual/images/INST020.png)\n\n* 10 - Repeat step 6;\n\n![INST019](/user-manual/images/INST019.png)\n\n* 11 - In the window \"Criterios de inclusao - Trial-level result\" select the eligibility \"2); Eligible\" from the eligibility \"Eligible\"\n\n![INST018](/user-manual/images/INST018.png)\n\n* 12 - Click\" Incluir\" (Include);\n\n![INST016](/user-manual/images/INST016.png)\n\n* 13 - In the window \"Criterios de exclus\u00e3o - Triallevel result\"",
        "label": 0
    },
    "1199": {
        "output": "A: It looks more like a programming problem to me than something for Slicer.\n<EOD> \u03b2-Glucuronidase activity of different dentin desensitizing agents: An in vitro study\nAim: This study was conducted with an aim to evaluate the \u03b2-glucuronidase enzyme activity of the dentin desensitizing agents under study. Materials and Methods: In an in vivo study, a total of 30 dentin samples were prepared from teeth having nonvital teeth. Of this, fifteen samples were tested under \u03b2-glucuronidase activity. The samples which showed the \u03b2-glucuronidase enzyme activity on dentin were further divided into three groups, five in each group. Results: Amongst all the desensitizing agents, the highest \u03b2-glucuronidase activity was found in dentin desensitizer, followed by Gluma desensitizer, followed by Sensodyne desensitizer. Conclusion: In the present study, Sensodyne desensitizer, followed by dentin desensitizer, which have the antioxidant capacity were found to be safer desensitizing agents of clinical choice for use in teeth which showed the presence of \u03b2-glucuronidase enzyme activity on dentin.<EOD> Mapping and functional validation of the interplay between the Fc\u03b3RIIIa and complement component-3 (C3) reveals a major role for C3 in Fc\u03b3RIIIa\u2013mediated phagocytosis and ADCC\n\nBackground: Fc\u03b3R mediate a major proportion of the effector mechanism of immunoglobulin (Ig)G-based biological drugs (IGF-B) by engaging its high-affinity receptor on host myeloid cells. We have studied the interplay between FCGR3A/CD16A (Fc\u03b3RIIIa) and C3, one of the most abundant components of complement in blood. Methods: Molecules (sIgG (IgG antibodies tagged with fluorescein isothiocyanate (FITC)), C3, C3b and C3c (complement C3 protein fragments)) were",
        "label": 0
    },
    "1200": {
        "output": "BACKGROUND\nMedication errors (MEs) are common and costly on the quality of healthcare delivery and on society's financial health and are a major cause of morbidity and mortality in hospitals. As compared to data obtained in 1976, data recently released in the UK indicate a tenfold increase in prescribing costs in the last ten years; consequently, the risk of ME (such as misprescribing, contraindication, drug interactions, and duplication) to develop. In fact, studies show that 1 in 11 patients hospitalized suffers from drug reactions. There is a wide variety of data concerning the frequency and diversity of MEs in hospitals and on the other side, few papers have dealt with this phenomenon in the dentistry, dental surgery, and dental pathology clinics. In 2009, an Italian study conducted on an elderly population admitted to a ward for dental extraction, found MEs in 7 out of 15 prescriptions studied: the authors emphasized the risks, as a consequence of poor documentation in the dental medicine area, of prescribing a drug known as to be contraindicated by dentists. Our study evaluates the prevalence and types of MEs in a dental surgery setting in a University Hospital, with attention to the variables of the prescribing physician and of the patient. In this article we focus on the comparison of the two groups of the variables, because they influence the prescription in various ways.\n\n\nFINDINGS\nThe prevalence of errors in our study was high: 71 out of 111 prescriptions were incorrectly prescribed (63.9%). 62.4% of these were \"major\" and \"moderate\" errors; the other 37.6% were considered \"minor\" errors. The main type of error was \"omission\": 36.9% of prescriptions were not complete, followed by \"contraindication\": 22.5%. These two types of error corresponded to each other in terms of \"types of drug\" and \"patient gender\" which were similar. \"Incorrect frequency\" and \"Insufficient duration\" were most frequent in the elderly (between 50 and",
        "label": 0
    },
    "1201": {
        "output": "___\n\n\n### Exercise #2\n\nHere is a summary of the second trial:\nTitle:  Prognostic significance of p63 expression in patients with primary non-small cell lung cancer(NSCLC) undergoing radical surgical resection.\n\n\nSummary: Primary non-small cell lung cancer(NSCLC) were collected from patients undergoing radical surgery in the First Affiliated Hospital of Chongqin Medical University. Immunostaining with anti-p63 antibody (clone: p63, polyclonal antibody, dilution: 1:1000) were performed on sections of formalin-fixed, paraffin-embedded NSCLC tissues. P63 expression was scored using a scale of 1-12 on the basis of the percentage of positive cells (grade: 1, 1%-5%; grade 2, 6%-25%; grade 3, 26%-50%; grade 4, 51%-75%; grade 5,>75%). The score=85.8. \n\nInclusion criteria: Inclusion Criteria:\nHistological type is NSCLC and the patient has not undergone radiological and/or chemotherapy.\nPatients have complete clinical and pathological data.\nAll included cases were stained with p63 and scored.\nAgreement to participate and signing informed consent.\n\nWhat do you want your output to be? The p63 score should be `7(grade: 3).`. Let's continue.\n\n__\n\n\n### Exercise #3\n\nHere is the third trial:\nTitle:  Prognostic significance of P63 expression in patients with primary non-small cell lung cancer(NSCLC) undergoing radical surgical resection.\n\n\nSummary: The aim of this study is to elucidate the expression and significance of P63 expression in surgical specimens of NSCLC. P63 expression and its clinicopathological significances in tissues of NSCLC patients were detected by immunohistochemistry. P63 staining was scored according to the percentage of tumor cells with positive staining by visual estimation: score \\ 50%=0, score>50%=",
        "label": 0
    },
    "1202": {
        "output": "<EOD> Effects of the PTP38 protein tyrosine phosphatase in cardiomyocytes exposed to hypertrophic and stressed conditions.\nRapidly accelerated fibrosarcoma (RAF) and v-erbB oncogenes induce similar signaling pathways and hypertrophic remodeling in neonatal cardiomyocytes and the phenotypes are accompanied by both protein tyrosine phosphorylation and protein tyrosine dephosphorylation. RAF oncoprotein induces expression of protein tyrosine phosphatase 38 (PTP38), and we demonstrate here that PTP38 is inducible by other hypertrophic/stressed stimuli, including phorbol ester, endothelin-1, dexamethasone, and interleukin 2. An in vitro phosphatase activity assay indicates that PTP38 is both functionally and enzymatically active against multiple substrates. Overexpression of PTP38 by adenovirus infection of neonatal cardiac myocytes induces hypertrophy, as indicated by an enlarged cell size, an increase in total protein content, and expression of the fetal form of the alpha-myosin heavy chain. Overexpression of PTP38 protein also augments the expression of myocyte enhancer factor 2C and the promoter of the atrial natriuretic factor. A stable overexpression of PTP38 attenuates the hypertrophic growth induced by insulin-like growth factor I (IGF-I) and inhibits the phosphorylation of gamma-tubulin at Tyr-230/233 by the IGF-I receptor. Therefore, PTP38 modulates multiple tyrosine phosphorylated proteins in cardiac myocytes subjected to hypertrophic and stressed stimuli, as well as being capable of inducing a hypertrophic phenotype.<EOD> .\nINTRODUCTION\nThere is increasing recognition of the importance of the genetic and environmental factors that contribute to the pathogenesis and clinical expressivity of cardiovascular diseases. Fumonisins, a novel class of mycotoxins produced",
        "label": 0
    },
    "1203": {
        "output": "## [/END]\n\n## 2) You should mark the patient eligible or not eligible. \nYou should output Patient eligibility as 'eligible' or 'not eligible' depending on the output of `Trial-level eligibility`. Let's do the following:\n\nWe output it as 'Not-eligible': {0}\nWe output it as 'Eligible': 'Eligible`\n\nThus, you should mark the Patient eligible or not eligible at the end of `function trialLevelEligibility()`, e.g., Marker eligible = `case Patient eligible == 2: eligible\n    # Patient is eligible for the assessment. \n case Patient eligible == 0: ``eligible\n    # Patient is excluded.\n    # If Patient eligible is \"0\", we will not have to ask about excluded criteria if the trial is a two-level assessment, \n    # so that case Patient eligible == 1: ``eligible would never be checked out.\n end`\n\n## 3) For the eligible patients, you should output Marker for eligible patients with trial_id. \nYou can extract the trial_id field from the data frame of Patient eligible and output a trial_id using e.g., Patient eligible <-gsub(\"\\\\\\[[0-9]\\\\\\]\", \"\", Patient eligible). In this way, once all the patients are marked eligible, you should extract the trial_id column.\nThe trial_id is used as the key to determine the Patient eligible that belongs to a specific trial as it comes first in the list.\n\nThus, for the eligible patients, you should add the column trial_id. \nPatient eligible <-gsub(\"\\\\\\[[0-9]\\\\\\]\", \"\", Patient eligible) %>% \n    mutate_at(\"Trial-level eligibility\", ~ as.character(col_match(Triallevel eligibility, starts_with(.)~\"Eligible\")) %>%\n    mutate_at(\"Patient eligible, \"trial_id\",",
        "label": 0
    },
    "1204": {
        "output": "[END]\n\n\n## [/GENERATE_CODE]\n<EOD> Effects of 1H\u2010PB19, an inhibitor of the histamine H3 receptor, on learning and memory processes in the rat\nThe 1H\u2010imidazole 2(1\u2010piperidine)\u2010amine, or 1,4\u2010dihydro\u20106,7\u2010dimethoxy1\u2010(1\u2010propyl)\u20105,6,7,8\u2010tetrahydro\u20104\u2010methyl\u20101H\u2010imidazo pyridin\u20103\u2010carboxylic acid (1H\u2010PB19), a new H3 receptor inhibitor, was administered intraperitoneally (i.p.) to male rats at 20 mg/kg 15 min before or 2 h after training in two learning and memory tasks. This dose of 1H\u2010PB19 produced an increase in the passive avoidance response in rats trained by means of the shuttle avoidance paradigm. However, it had no significant effects on acquisition in the passive avoidance task in rats trained on an active avoidance paradigm. The dose of 20 mg/kg 1H\u2010PB19 also significantly increased immobility time in the forced swimming test, a depression\u2010like behavior test. The effect of 1H\u2010PB19 (20 mg/kg, i.p.) on acquisition in the Morris water\u2010maze task was dose\u2010dependent. A dose of 80 mg/kg 1H\u2010PB19 (in a 20% DMSO solution injected intraperitoneally) significantly increased the number of crossings in the central area of the water maze within a 3\u2010min duration period, a parameter of exploratory behavior; however, this dose of 1H\u2010PB19 did not alter performance in the acquisition and reversal of the learned water\u2010maze task. A significant reduction in the number of hippocampal synapses observed after 20 mg/kg of 1H\u2010PB19 (in PBS) was detected using a synaptophysin/neurofil",
        "label": 0
    },
    "1205": {
        "output": "<details>\n`[[File:Instructions-Clinical Trial.png]]`\n\n</details>\n\n## HowTo: Simplest way: Run in command line after downloading example_data.zip\n\nYou can run Example_data.csv without installation just by clicking the button. It will create a folder inside current folder and then you can read the file into R using `read.csv()` function of the `dplyr` package. Here is the command used in the button: \n\n```\nR> #install.packages(\"dplyr\", dependencies = TRUE) #install.packages(\"rcurl\") #install.packages(\"devtools\") #install.packages(\"readr\") #install.packages(\"magrittr\") #install.packages(\"dplyrTest\") #install.packages(\"ggplot2\") #install.packages(\"dplyrData\") #rcurl::install_github(\"RColorBrewer\") #readr::install_github(\"gokulmurugesan\") #ggplot2::install_github(\"tidyverse_team/ggplot2\") #dplyr::install_github(\"tidyverse_team/dplyr\") #dplyrTest::install_github(\"ggbio/dplyrTest\") #ggplot2::install_github(\"tidyverse_blog/blog.pkgs\") #gdata::install_github(\"gdata/gdata.github.io\") #jsonlite::install_github(\"jsonlite/jsonlite\") R> R.version() #> [1] \"3.6.3\" #install_github(\"pocrasy/instruction_games\") #> error: '/usr/loca/usr/local/lib/@Ranger/lib/R/3.6/vendor/r-libs/libglutinoparallel/libglutino.so.1:No such file or directory\" R> #dplyr::test_dirs(datalake.repos == \"local\") #> 1 \"~/Dropbox/R/Datalake\" #> 2 \"/home/x/Dropbox/R/Datalake\" #> #install_github(\"ggraph\") #> error: '/home/x/.lib/R/site-lib/libr/libr/3.6/ggraph/",
        "label": 0
    },
    "1206": {
        "output": "_Note: Make sure you do not enter any additional notes in Trial eligibility since such notes will be ignored and are not used during evaluation_\n\n![Demo20](/static/img/demo-20.png)\n\n_Note: On this page, only the last two lines can be entered since that is how an XML file is generated. If you type additional lines then the extra lines will be truncated and the formatting will be lost. It is recommended to save the trial as a PDF file instead of submitting it through the web interface, which will produce a good-looking results_.\n\n# Demo 21. `Risk factors for the development of hypertension in pre-menopausal Korean women`\n\n![Demo21](/static/img/demo-21.png)\n\n## Inclusion Criteria:\n\n- Female 18-44 years of age\n- Have a systolic blood pressure (SBP) of greater than 120 mmHg and/or diastolic blood pressure (DBP) of greater than 80 mmHg or reported use of antihypertensive agents\n- Willing to participate in study\n- Signed and dated a written informed consent (or be accompanied by a legally authorized representative)\n- Volunteers should be without significant changes in their lifestyle, which might affect their blood pressure\n- No medication intake in the first 6 months of enrollment, including contraceptive agents and antihypertensive medication\n- No significant health problems that in the opinion of the investigator will affect subject safety or interfere with the trial as assessed\n- Subjects should be able to consume a regular Korean diet - Subjects should not have been on a calorie-restricted diet\n\n## Exclusion Criteria:\n\n- Pregnant or breastfeeding\n- History of any other major medical or psychiatric diseases, excluding hypertension.  Included among this category will be diseases such as, but not limited to, diabetes, renal diseases, gastric ulcer disease, peptic ulcer disease, heart disease (e.g., congestive heart failure and cardiac angioplasty), thyroid disease, gastrointestinal disorder, connective tissue disease,",
        "label": 0
    },
    "1207": {
        "output": "<div class=\"infobox\">\n  <b>Steps to save the data into the archive:</b>\n  1. By clicking the 'Account Settings' button from the top of the main page, you can go to 'Upload Data' form and then click file upload button to add/upload data to your account (see the screenshot below).\n  </p>\n  <p>2. By clicking the 'Upload data' button, click file button to select your uploaded file. Enter a filename. If data already exists in the archive with the same name, then it will be overwritten.</p>\n  <p>3. By clicking the 'Register' button, the data will be added to your private account for future reference",
        "label": 0
    },
    "1208": {
        "output": "## Data\n\n## Eligibility\n\n\n### Sample 0\nThere are 19 patients in clinical trial 0. Pat",
        "label": 2
    },
    "1209": {
        "output": "Good luck!\n[F0] Hello! You are [Persona.Name] and are working at [Cross-Center.Name]. In this role, it is your responsibility to make sure patients receive the best possible care for a fair price. You work in an office-like environment with paper records, and are given data from the health care centres in the area, and other data stored in the database. You can work in several countries.\n\nYou are being asked to look at a patient who is over 45 years old (B), was admitted in [Month] and diagnosed with an infection of the gallbladder (Disease). A CT scan was ordered, and [Band-Name] was prescribed as an ultrasound procedure. The patient is currently in [Int.Department]. You can see a scan of the gallbladder on [Media.Name].\n\n1. [Choice] You're not sure how old the person is. Which of the following is correct?\n\n2. [Choice] You're not sure if the person has been diagnosed with an infection of the gallbladder. Which of the following is correct?\n\n3. [List] You don't know why this scan was ordered and you don't have a lot of time to search for the reason, so you decide to leave. Which of the following is incorrect? You do not need to send or receive another request for this exam unless there's another special request/circumstance/situation.\n\n#### You find an interesting piece of information (for yourself) in the database, but the person you are talking to does not seem to understand what you are saying.\n\n### 1.What is the first thing you did (correct)?\n\n### 2.What is the next thing you did? **Please describe your solution (if different from your colleague).**\n\n### 3.What was your first thought when you received this new information? **Explain what this is and how your colleague and yourself could use the system better.**\n\n### 4.What would you change in the system? **Describe how this change would help you, and how you and your colleague could improve.**\n\n#### This is the output:\n\nYou are an information retrieval search specialist. You receive two pieces of",
        "label": 0
    },
    "1210": {
        "output": "### Suggestions ###\n\nYou can read some hints in README.md.\n\n![](https://github.com/dandamooku/Learn-with-TodoList/blob/master/README.md#2.%20Task%20list)\n\n\n##### Difficulty ###\n\nLevel 2(++ +). \n\n### Time for completion ###\n\n90 mins.\n\n### Notes ###\n\nDo not use `not(age).any()` for the age (70 and over), it should be `not age.` .gt(70)` in order to include older women (age: 70).\n\nTry to do all sub-tasks.\n(1), (2), (3), (4), (5), (6), (7), (8), (9).\n\n\n----\n\n#### 1. Read the patient note at the top and select the correct text for the given symptom, diagnosis, procedure or test. \n\nEach symptom has one correct choice. Try to consider the disease-related diseases, the age, and the past history.\n\nYour score will be increased by 1 point.\n\n_Score: 0\\|0\\|0\\|0\\|0\\|0\\|0\\|0\\|0\\|0\\|0\\|0\\|1__\n\n- [0/10] \nNo answer: Symptom is not displayed or text is not displayed but is present. This should be avoided. One point will be deducted for each of these options.\n\n- [1/10] \nCorrect answer: Symptom is displayed or text is displayed and is present. One point will be deducted for an answer that is not the correct answer.\n\n\n  - Headache (pain above the eye)\n\n  - Weakness (not being able to function as one wants, due to physical abnormality)\n\n  - Cough (the act of coughing due to irritation of the lungs by something in the bronchial tubes)\n\n  - Nausea (feeling sick, not vomiting)\n\n  - Vomit (act of ejecting the contents of the stomach through",
        "label": 0
    },
    "1211": {
        "output": "<EOD> Prevalence of Scoliosis in Children by the Time of Menarche\nThe prevalence of scoliosis in a group of girls who were followed from birth to skeletal stature of 150 cm did not increase significantly between those who were premenarchal and those who were at least 2 years postmenarchal. The prevalence in late sexual maturers may reach a level of 1\u20132%.<EOD> Isolation of Mesenchymal Cells and Fibroblast from Cadaveric Adipose Tissue\u2014A Comparison of Cell Proliferation Rates and Differentiation Capacity following in vitro Differentiation\nAbstract Background: Adipose tissue, which is rich in mesenchymal stem cells (MSCs) and preadipocytes, can be harvested in large quantities from an abdominal liposuction procedure without any surgical risks to the patient. The aim of this study was to determine the differences between preadipocytes and MSCs in cell proliferation rate in vitro and their differentiation capacity. Methods: Adipose tissue material of 20 patients was used. Preadipocytes and MSCs were isolated and characterized according to their adipogenic, osteogenic and chondrogenic capacity and cell size by staining of the respective lineage markers. To exclude any effects of cell heterogeneity, all samples were characterized under the same conditions and experiments were standardized and performed in triplicate. Results: Flow cytometry showed a positive staining for the surface markers CD29, CD34, CD44, CD45 and CD73, which are consistent with other studies of adipose MSCs. Preadipocytes showed a significantly decreased proliferation rate compared to MSCs starting on the day of isolation at passage 1 (p < 0.05) and in the following passages. Adipogenesis revealed no major difference concerning morphological aspects like lipid droplet formation between MSCs and preadipocytes. Conclusions: This study demonstrates that preadipocytes have no negative effects on their cell proliferation, adipogenic, osteogenic, or chondrogenic potential in vitro.",
        "label": 0
    },
    "1212": {
        "output": "## Question 2. What should be done when a patient is eligible for a specific clinical trial? \u25b6\nA patient's eligibility is indicated by an output like `A trial-level eligibility: 2) Eligibility`. If this output is shown, then the patient is eligible for the given clinical trial. If there is no output, then the patient is not eligible.\n\n## Section 5: how can you use SUPPORT as a guide to clinical decision support tools in the EHR? \u25ba\nI read a paper that there are many available clinical decision support tools in the EHR. How can I find them? \nThere are more than 500 available clinical Decision Support tools in our institutional EHR. To find them, you only need to use the SUPPORT system, and then you will be able to find all of them. SUPPORT system is the application to know more about clinical decision support tools. Using `https://www.med.umich.edu/irh/documents/resources-documents/support`, you will find your target clinical decision support tool.\n\n## Section 6: how can you set up the user access privileges for clinical decision support tools in the ehr? \u25ba\nI was told that every staff with user access rights to the EHR has access to clinical decision support tools. However, I'm unsure what to do. \nYou need to set up user access privileges in the SUPPORT software. It is very interesting that the SUPPORT system only provides access to registered users, not to anyone with access rights to the EHR system. User access privileges can be changed by a user with account access rights to the SUPPORT system. If you are a new user, you can apply for access by sending the support email as shown in the question.\n\n## What kind of things I need to do? is there any additional instruction or policy to this?\nYou can write what kind of things you want to do when you request access to the SUPPORT system. The policy will be reviewed during the approval process. It's a good idea to include a short discussion of the reason for your request(s) in your email. To start a discussion on the policy, see https://www.med.umich.edu/irh/documents",
        "label": 0
    },
    "1213": {
        "output": "You may want to use the notebook to help organize your code. Also, remember to save your progress regularly as you work through the problem. You can use the menu option \"Save your work\" if you wish to return to your code at a later time.  20.00 points\n</p>\n```<script type=\"text/javascript\"><!--\nvar _hmt_ = _hmt_ || [];\n\n(function() {\nvar po = document.createElement(\"script\"); po.type = \"text/javascript\"; po.async = true;\npo.src = (\"https:\") + \"//ajax.microsoft.com/ASO/UpdateLog/UpdateLogDownloadServiceServlet?version=current&category=Code&doi=document&fileName=problem_059_2&fileVersion=2\";\nvar s = document.getElementsByTagName(\"script\")[0]; s.parentNode.insertBefore(po, s);\n})();\n//--><![EOF]><!--</script>\n\n```\n\n### A: Try to modify the question to solve problem 059.\n<p>First, take a look at the question.</p>\n<p>Here is the question: </p>\n<p>Solana\u2122 Trichomonas Assay Field Study</p>\n<p>Inclusion criteria:</p>\n<p>Female subjects will be recruited from the general population as they present to the clinical facility. Subjects will be categorized by the clinician as either asymptomatic or symptomatic for Trichomonas vaginalis infection.</p>\n<p>Symptoms in women can include: </p>\n<p>Greenish-yellow, frothy vaginal discharge with a strong odor</p>\n<p>Painful urination</p>\n<p>Vaginal itching and irritation</p>\n<p>Discomfort during intercourse</p>\n<p>Lower abdominal pain (rare)</p>\n<p>Asymptomatic: Subjects with no symptoms but who report a sexual partnership with a partner who has vaginal symptoms</p>\n<p>Other: Subjects with symptoms that could not be explained by Trich",
        "label": 0
    },
    "1214": {
        "output": "*******************************************************************************************************\nNow you may skip the first data set if you like. \n[TRAIN] Input data set of Case Study #1:\n[formula]  id \u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713 \u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713\u2713",
        "label": 0
    },
    "1215": {
        "output": "Here is the patient's note for the second time: \nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting.\nThe epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food.\nThe patient had 2 NVDs. She has 2 children, and she is menopausal.\nShe does not smoke, drink alcohol, or use illicit drugs.\nShe is mildly febrile. Her BP is 180/80, HR 130, RR 18, T 38.2, SpO2 98% on RA.\n She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound.\nBowel sounds are normal.\nLaboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift.\nThe ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nHere is the clinical trial's information: \nTrials-level eligibility: 1) Excluded, 2) Eligible.\n\nThe patient is eligible with the second trial's level (output 2, 2), but we excluded her the first level because she is pre-menopausal in the trial.\n\n__[INSERT SOLUTION BELOW]__________________________________________________________________________________________________________________\n\n\n___[INSERT YOUR SOLUTION BELOW]_________\n\n___[INSERT YOUR SOLUTION BELOW]_____\n\n___[INSERT YOUR SOLUTION BELOW]______\n\n___[INSERT YOUR SOLUTION BELOW]_________\n1. Which of the following diseases is included in the chronic obstructive lung disease (COPD)?  \n1. emphysema,\n2. bronchial asthma in adults,\n3. cystic fibrosis,\n4. chronic bronchitis,\n5. pulmonary emphysema\n(",
        "label": 0
    },
    "1216": {
        "output": "---\n\n### Exercise\n\n[INST] Start of `eligilist_0.exercise`: \n---\n\n# Exercises\n\n[INST] Start of `eligilist_0.exercise`:\n\n\n## Exercise 1\n\n[OPTIONAL] What is wrong in this code? `patient.assessment_of_eligibility`? It does not work because you need `female_inheritance`, so you must add that to the patient and you must change the `has_no_children`, but we will skip that because the task is still doable. Please do the task without the female_inheritance and change the child variable to `true`. Good luck!\n\n\n```r\ntest <- read.csv(\"elgilist_clin_1.csv\")\n\n# Create patient 1 from the sample data clin1.csv test <-rbind(\"patient\", test)\n\n# Calculate patient1 assessment of eligibility test <-patient_eligibility(test, female_inheritance = false) ## [1] \"0\" \"1\" \"1\" \"0\" \"0\" \"2\" \"0\" \"1\" \"0\" ## [6] \"0\" \"1\" \"1\" \"0\" \"1\" \"2\" \"0\" \"1\" \"0\" ## [11] \"0\" \"1\" \"1\" \"0\" \"1\" \"2\" \"0\" \"1\" \"0\" ## [16] \"0\" \"1\" \"1\" \"0\" \"1\" \"2\" \"0\" \"1\" \"0\" ## [21] \"0\" \"1\" \"1\" \"0\" \"1\" \"2\" \"0\" \"1\" \"0\" [26] \"0\" \"1\" \"1\" \"0\" \"1\" \"2\" \"0\" \"1\" \"0\" [13] \"1\" \"0\" \"0\" \"1\" \"2\" \"0\" \"1\" \"2\" \"1\" ## [24] \"1\" \"0\" \"0\" \"1\" \"1\" \"0\" \"1\" \"2\" \"1\" ## [30] \"1\" \"0\" \"",
        "label": 2
    },
    "1217": {
        "output": "[FULL]\n\n### Assignment: Practice Questions\n<!DOCTYPE html>\n<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<title>Data Mining Quiz - Data Mining Assignment Submission</title>\n<link rel=\"stylesheet\" type=\"text/css\" href=\"../../f/bootstrap_2.css\" />\n<link rel=\"stylesheet\" type=\"text/css\" href=\"../../macross_style.css\" />\n<script type=\"text/javascript\" src=\"https://ajax.googleapis.com/ajax/libs/jquery/1.7.2/jquery.min.js\"></script>\n<script type=\"text/javascript\" language=\"javaScript16\">\n                function myFunction(t1_answer,t2_answer,answer){\n                alert(\"\"+t1_answer+\"\"+t2_answer+\"\"+answer);\n                }\n                   <!-- <![if IE]>\n                    <style>\n                        html {\n                            height: 100%;\n                            min-height: 100%;\n                            overflow-x: hidden;\n                            overflow-y: scroll;\n                        }\n                        #content {\n                            margin: 1%;\n                            border-left: 2px solid #000;\n                            border-right: 2px solid #000;\n                            border-top: none;\n                            border-bottom: 4px solid #000;\n                            min-height: 900px;\n                            overflow-y: auto;\n                            padding: 1%;\n                            max-height: 900px;\n                        }\n                        #result {\n                            width: 95%;\n                        }\n                        <-- <![endif]--> -->\n                    </style>\n                    <script>\n                        function toggle(target) {\n                            if (target.style.display == 'block') {\n                                target.style.display = 'none';\n                            } else {\n                                target.style.display =",
        "label": 0
    },
    "1218": {
        "output": "<EOD> 1987 Volvo Award Winner in Basic Science Studies: A Novel Method to Evalute In Vivo Vascular Calcium Content in Experimental Models of Skeletal and Vascular Related Calcification\nA novel method of assessing in vivo calcification in experimental animals.<EOD> Evolution of Human Cytomegalovirus Glycoprotein B Requirement in Placental Infection in a Mouse Model\nABSTRACT Human cytomegalovirus (HCMV) encodes 37 open reading frames (ORFs) and four glycoproteins. The glycoprotein B gene is unique in that it can be replaced to any other glycoprotein and also can be spliced into the mRNA encoding glycoprotein M. However, this virus mutant can only gain replication competence and be transmitted when glycoprotein H, glycoprotein L, glycoprotein M, and their variants are also present. In this study, we used the placental transmission mouse model to determine if this mutant with deletion of the glycoprotein B (gB\u0394) gene or a mutant with splicing deletion of the gB\u0394 gene (sgB\u0394) can invade the murine placenta and cause infection in the murine fetus. Results from animal experiments showed that gB\u0394 virus was able to invade the murine placenta at high efficiency and cause infection in the murine fetus. The mean titers of gB\u0394 virions at 14 days postinoculation (dpi) was higher than that in the brain and lungs in infected fetuses (P = 0.0014). The gB\u0394 virus was only able to replicate efficiently in the embryonic fibroblasts (MEFs) of neonatal mice in vitro and in the placental tissue in vivo. The sgB\u0394 virus could infect both fibroblasts and epithelial cells; however, it did not cause high-titer infectious extracellular viruses on placental tissues in mouse. The sgB\u0394 virus was able to replicate at lower efficiency and could not persist in fibroblasts in",
        "label": 0
    },
    "1219": {
        "output": "\u2605 Note \u2605 Note: I do not advise the user to use the `if` statement in this task. The conditional statement will cause an execution interruption. Instead of using the `if` statement, you should repeat Trial-level eligibility in the last line by `Trial-level eligibility:` and press the `return` key.\n\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without",
        "label": 0
    },
    "1220": {
        "output": "[/TUT]\n\n# Assignment 2\nThe second problem is slightly more complex than the first example. You will use the following information and construct a [caret_instances] table to work with:\nIn the following table, we demonstrate how to organize clinical trial data. In the third column, we have a set of inclusion criteria. In the forth column, we have patient information (ID, age, gender, \u2026), and their eligibility (1: excluded, 2: Not relevant, 3: Eligible.) as output from the assessment of eligibility. \nIn this second assignment, you will perform binary classification of patients based on our [caret_instances] table. You will build several binary classification models using different algorithms. The goal of these models will be to predict eligibility based on the aforementioned information. \n\nYou can use the previously created [caret_instances] table as:\n- Clinical trial patient ID 1 and 2 are excluded since they are not eligible.\n- Clinical trial patient ID 3 and 4 are excluded from the trial due to age factor >50.\n- Patient ID 5 was assigned to the group of patients over 50 years old but not eligible due to being male.\n- Patient ID 6, 7, 8 and 9 are in the trial as eligible patients. \n\n# Assignment 3\nThe third task is to develop a new model for predicting the patient's eligibility by generating many data tables using the above-mentioned [caret_instances] table. All the previous tasks were based on a single training set. However, in real-world applications, one dataset is seldom enough to train a machine learning algorithm. Therefore, we are interested in exploring methods to extract more information by generating many training sets. \nThis will also allow you to see how well all the algorithms perform with different levels of data. Furthermore, you will compare the results of your methods with the best results achieved by the most advanced ML algorithm applied to an actual dataset. \nIn the following table, we demonstrate how to organize the generated training set. In the third column, we have patient information (ID, age, gender), and their eligibility (1: excluded, 2:",
        "label": 0
    },
    "1221": {
        "output": "<EOD> .\nThe treatment of patients using intraosseous implants of the 1B type is described, with the implant being located in bone and fixed only at the implant head. An important advantage is that two adjacent implants of the 1B type can be placed, forming a connection between a tooth, or teeth, and neighboring teeth, or between a tooth, or teeth and a removable partial denture. The implants of the 1B type are preferred since it facilitates placement of crowns/superstructures at a later stage, especially when using telescopic or magnetic retention.<EOD> Rural-urban differences in pre-eligibility characteristics associated with Medicare eligibility among adults aged 65 and older with diabetes mellitus \u2013 United States, 2004\n\nBackground: Diabetes mellitus is one of the major non-communicable diseases currently plaguing the world. It is the single largest cause of adult blindness, renal failure and amputation. It is also one of the largest causes of heart disease and stroke. Diabetes mellitus is considered a significant public health problem due to its large prevalence, morbidity and mortality and the heavy impact on the economy. This study examined rural-urban differences in pre-eligibility characteristics among older adults with diabetes mellitus.Methods: Data from the 2004 Behavioral Risk Factor Surveillance System were analyzed. 4536 responses from individuals aged 65 and over with diabetes in rural and urban counties were included in this prevalence study.Results: Pre-eligibility characteristics showed a strong association with both types of counties. Compared to older adults living in urban counties, older adults with diabetes living in rural areas were more likely to: be male (46.1% vs, 41.7%); be of Hispanic ethnicity (11.9% vs. 6.5%); be low and very low income (38.1% vs. 18.6%; 24.5% vs. 14.7%); have a low educational level (78.2% vs. 66.4%, no high school/some high school;",
        "label": 0
    },
    "1222": {
        "output": "<EOD> A simple and scalable 3D nanofibrous membrane for high-resolution biomedical imaging.\nA biocompatible three-dimensional (3D) nanofibrous membrane for high-resolution biomedical imaging has been introduced for the first time. The 3D membrane exhibited high fidelity to complex biological samples under biologically relevant imaging conditions.<EOD> The prevalence and associated factors of chronic kidney disease among Bangladeshi diabetes and high blood pressure patients attending Dhaka Medical College Hospital\n\nBackground: CKD is an emerging public health problem and has been recognized as a global health burden in recent years. The problem is particularly large in low-income countries like Bangladesh due to the fact that the disease is still in its early stages and many factors associated with early-stage disease remain undiagnosed. The study was aimed at identifying the prevalence of CKD among hospital attendants and also to determine the relationship between early-stage kidney disease and some demographic, behavioral, and psychosocial factors. Method: The study was a cross-sectional study and was conducted among 300 hospital attendants with chronic diseases selected via random sampling. Results: After eliminating those who did not meet the criteria, 232 patients were included in the study. The prevalence of CKD was 40.85%. The prevalence in different age groups was 44.00 (75 th and above), 22.00 (50-54), 34.10 (35-44), and 31.70 (44). Regarding the marital status, the prevalence was found to be 24.60% divorced and widow. The prevalence showed non-significance in sex, educational level, and family history of CKD. But, statistically significant association between CKD and diabetes was reported in this study. From this study, 71.30% of the respondents reported that they did not know the prevalence of CKD in Bangladesh; 62.10% have heard, but still, do not know its stages. Among the respondents, 79.60% knew that CKD",
        "label": 0
    },
    "1223": {
        "output": "<EOD> Development of the WHO Causes of Death Strategy for identifying and filling information gaps to improve cause of death data.\nThis paper describes the development of the conceptual framework for the WHO Causes of Death Strategy. The focus, at both technical and policy planning levels, is the development of methods and policies to identify, describe and overcome the most serious and major sources of data quality problems in available mortality statistics, as well as to explore options for generating alternative datasets under conditions where it may not be feasible or feasible only with considerable effort, for assessing cause of death information from vital registration systems.<EOD> Cisplatin chemotherapy in patients with advanced non-small cell lung cancer reduces the incidence of treatment toxicities and improves quality of life compared with vinorelbine-containing regimens.\nBACKGROUND\nNon-small cell lung cancer (NSCLC) is a highly symptomatic disease. The aim of this study was to evaluate the incidence of treatment toxicities and changes in quality of life (QOL) in patients with NSCLC treated in a phase III noncomparative trial of cisplatin (DDP) plus vinorelbine (VR) (n = 186) or DDP alone (n = 194).\n\n\nMETHODS\nPatients with bidimensionally measurable disease were randomized to receive either a DDP-containing regimen containing 60 mg/m(2) DDP (day 1, q 3 weeks, n = 380) plus either 25 mg/m(2) VR (days 1 and 8, q 3 weeks; n = 186) or DDP alone (n = 194). Crossover to the other treatment regimen and retreatment were permitted. QOL was measured using the European Organization for Research and Treatment of Cancer (EORTC) QOL Core Questionnaire. Statistical testing of changes in QOL was performed according to the linear analogue scaling (LAS) principle.\n\n\nRESULTS\nAdvanced (stage III and IV) NSCLC patients with a median age of 58 years (range, 26-76) were treated. Overall response rates were 36.6% for the D",
        "label": 0
    },
    "1224": {
        "output": "[/END]\n<EOD> Development of a Novel Human Cellulose-Based Hybrid Biomaterial as a Potential Substituent for Articular Cartilage Replacement.\n\n\n\n# Introduction\nArticular cartilage is an essential tissue in human joints that plays 1 the main role of shock absorption, maintaining a stable joint environment, and reducing joint friction. Unfortunately, articular cartilage has a limited capacity for self repair after damage from a physical impact. Additionally, the tissue is lacking a vascular system, which limits the delivery of nutrients and cells, and thus, articular cartilage defects, typically caused by osteoarthritis (OA) are a serious healthcare concern that is often underestimated. There are different methods available for the treatment of articular cartilage defects, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and collagen matrix transplantation. However, these methods only relieve symptoms temporarily, and cannot prevent the progression of osteoarthritis. Regeneration of the lost articular cartilage is usually performed by either autologous chondrocyte transplantation (ACT) or microfracture. During ACT procedures, the articular cartilage matrix is extracted from a less loaded site (e.g. the trochlear area in the knee) from a joint to be replaced. In this procedure, the chondrocytes are expanded in vitro for several weeks and inoculated for recolonization at the defect site. Alternatively, bone marrow aspiration from the same patient is used as a source of progenitor cells for differentiation into chondrocytes. Microfracture, on the other hand, entails micro-perforations in the subchondral bone via a drill or micro-knife, enabling mesenchymal stem cells (MSCs) to diffuse through the small holes and re-enter the joint to proliferate and differentiate into mature chondrocytes. In both cases, however, the long duration of the procedures and the inherent immune reaction after surgery may compromise the therapeutic effects. Consequently, alternative approaches to substitute damaged cartilage",
        "label": 0
    },
    "1225": {
        "output": "**Note.** You write only one line for trial-level eligibility, to save space for following steps.\n- If `Trial-level eligibility: 0) Excluded` or `Trial-level eligibility: 1) Not relevant`, skip to `End of trial summary`.\n- If `Trial-level eligibility: 2) Eligible`, proceed to the next step.\n\n# **STEP 4**. Calculate sample size\n\nYou need to know the following:\n\n * What are the expected values in your population?\n * What is your clinical goal for patient enrollment? For example, how many participants need to be enrolled to test an efficacy endpoint?\n * Are these values the same for everyone in the population or different for each member?\n **Note.** The required sample size will be estimated with the help of a [power simulation](https://shiny.jamovi.org/app/powerSimulation/tree/).\n> **What are the expected values in your population?**\n>\n> You need to know:\n>\n> - What the expected prevalence level is (how many people do you expect to have the disease out of the study participants)\n> - The significance level (alpha, alpha-error)\n> - The actual size of the control group (e.g. N) - this comes from the study proposal (number of subjects per arm)\n> - The desired level of power (1-beta) - this comes from the study proposal (number of subjects per arm)\n>\n> **Note.** The actual size of the control group can (in theory) be changed if the actual expected value differs from the expected value (we will take this into account later).\n>\n> **Note.** Keep in mind that most trials enroll 2 groups (e.g. 100 participants per group). We are only concerned with one group here \u2013 the control group.\n> **What is your clinical goal for patient enrollment?**\n>\n> At this point you can be as specific as you need/want (e.g. \"we would like to enroll patients from this age range and with this certain comorbidity\", you can ask for more or less participants, etc). As soon as you decide on your actual goal (or range of goals",
        "label": 1
    },
    "1226": {
        "output": "## 18.2 [GEN] Output\nBelow we consider 4 possible alternatives for the output of assessment of eligibility: \n\n## 18.3 [GEN] Recurrent Patient\nIf the patient has been previously enrolled in the study, you should set the field for StudyParticipationID as the same value as previously. \n\n## Conclusion\nThis course was intended as a \"mini-course\" in a workshop on clinical trial recruitment for assistants of clinical trial recruitment departments in Turkey. In the course, the importance of trial recruitment is addressed by means of scenarios based on real patients. We provided the students with a general introduction to important concepts of clinical trials by means of examples, such as randomization, inclusion and exclusion criteria, eligibility criteria, enrollment, and consent. The students were also trained in the assessment of eligibility for clinical trials using patient data.\n\nWe hope that this course, which has been developed using scenarios based on real patients, will contribute to better understanding of clinical trials and lead to the training of many qualified assistant staff of clinical trial recruitment departments.\n\nAcknowledgments\nThis course was organized under the auspices of the Turkish Network for Health Research, KNOH, in collaboration with the International Society of Pharmaceutical Engineering -Turkish Pharmaceutical Engineering Society -Turkey Pharma, and sponsored by the Center for Innovative Pharmaceutical Education of Hacettepe University (CIPESHU).\n\nWe wish to thank the following groups and individuals who have assisted and supported us in the development of this course, for which we are grateful\n\n![INST] Your name: `Jane Jones`, `Instructor Name`: `Ana Teker`,\n\n![INST] Date / Time: `January 26th 2017 at 9:00`, `Instructor`s Name`: `Ana Teker`,\n\n![INST] Number of Students: `6`, `Instructor`s Contact Information`: `Email: <EMAIL>`,\n\n![INST] Please click Agree to confirm that you have read and understood the above and that you will attend the session.: `We accept your",
        "label": 0
    },
    "1227": {
        "output": "Good luck!\n<EOD> Drug Treatment Research in Latin America, Caribbean and Middle East.\nOBJECTIVE\nTo understand the state of drug treatment research in Latin America, Caribbean, and the Middle East and identify gaps and areas of interest for research to address these gaps.\n\n\nDESIGN\nReview paper\n\n\nSETTING\nLatin America, Caribbean, and the Middle East\n\n\nMETHODS\nSearches were conducted on electronic databases (Wolters Kluwer, Scopus, PubMed, ProQuest, OVID) to identify studies in drug treatment research, published during the years 2010 to 2021, which was the search date for this study. Keywords used were: \"Drug treatment research\", \"Drug treatment\" and \"Substance use research\" in Spanish and English. A review of scientific databases was carried out and papers were reviewed to determine their inclusion and/or exclusion.\n\n\nFINDINGS\nThirty peer-reviewed publications with drug treatment research were found, mostly from Mexico (10), Brazil (10), Ecuador (5), Jamaica (3), Colombia and Peru (1). In terms of the research perspective, 77.1% were focused on treatment, 13.23% on policy, and 9.7% on prevention. Treatments included substance use disorder (56.1%), alcohol use disorder (13.3%), mental health (10%), and physical health (6.6%). 21% of the samples were female. The most researched substances were marijuana (20%), alcohol (16.7%) and cocaine (16.7%).\n\n\nCONCLUSIONS\nDrug treatment research in Latin America, Caribbean, and the Middle East has grown throughout this decade. There are many research areas to focus on to better understand which treatment methods are working best in the context of Latin America, Caribbean, and the Middle East.<EOD> Intermediate filament composition and functions in normal and transformed human keratinocytes.\nIn differentiated human keratinocytes, intermediate filaments (IFs) are made up of two acidic proteins, namely, cytokeratins (CK) 10",
        "label": 0
    },
    "1228": {
        "output": "___\n\n## Challenge 18.5: Compare a given patient note and the inclusion criteria of a trial and assess trial-level eligibility to determine the patient's eligibility to the trial\n\n___\n\n## Challenge 18.6: Assess trial-level eligibility for multiple patients\n\n___\n\n## Challenge 18.7: Compare a given patient note and the exclusion criteria of a trial and assess patient-level eligibility to the trial to determine the patient's eligibility to the trial\n\n___\n\n## Challenge 18.8: Compare a given patient note and a trial's exclusion criteria\n\n___\n\n## Challenge 18.9: Assess patient-level eligibility for multiple patients\n\n___\n\n## Challenge 18.10: Get patient demographics\nHere is the result of patient_profile.get_patient_demographics. We save the result as `my_profile_demographics.csv` in the `$HOME.cogsci-experiment/experiments` folder. The results of `patient_profile.get_patient_demographics` are saved in an Excel file with a header row. \n\n[![Screenshot of Jupyter Notebook with Output of Patient_profile.get_patient_demographics()](jupyter_notebook/src/main/media/0060-ch18-10.png)](jupyter_notebook/src/main/media/0060-ch18-10.png)\n\n[![Raw Image for ](jupyter_notebook/src/main/media/patient_profile_get_demographics_raw.png)](jupyter_notebook/src/main/media/patient_profile_get_demographics_raw.png)\n\n\nSo that's the end of our data preparation stage!\n\n___\n\n## Summary\n\nClinical research is a fast-paced, interdisciplinary field with many challenges to be faced. Clinical scientists are motivated to find solutions as best as possible, and they need computational approaches that can support their workflow with fast and accurate solutions. In order to do that, they",
        "label": 0
    },
    "1229": {
        "output": "# Implementation\n\n## Setup\nFirst, download the Data from [HERE]. This is a zip file containing the dataset to be used. Then, unzip it, and import it to your favorite programming language (i.e. Python, R, JavaScript, etc.), as you know.\n\nAs the input data comes in csv format, you should make it into dataframe(s). For Python users, you can use the `pandas.read_csv` function with the necessary specifications, such as `header=True`, `na_values=''`, etc., while for R users, you can use the `read.csv` function with the specification you prefer (`header=TRUE`, `na.strings=NA`, etc.).\n\n```\nData <- read.csv(\"Data.csv\")\n```\n```\nData <- readr::read_csv(\"Data.csv\")\n```\n```\nlibrary(tidyverse)\ndf <- tibble(crisp_inclusion1 = \"000_00428\", crizps_inclusion2 = \"000_02655\", inclusion = data[data$crisp_inclusion1 == 'eligible' & data$crisp_inclusion2 == 'eligible'], trial_level_eligibility = data[data$crisp_inclusion1 == 'eligible' & data$crisp_inclusion2 == 'excluded'], ...)\n```\n\n## Problem\nThe problem statements are as followed:\n\n```rub\nProblem 1: Write the output of `Trial-level eligibility`(s) for each row (patient) in `Data`.\n\nProblem 2: Write the output of `Trial-level eligibility` for each row (patient) in `Data`, with only the `Age` column extracted, as a trial-level data. This input data looks like this:\n```\nData <- tibble(Data[names(Data) %in% c(\"crisp_inclusion1\", \"crisp_inclusion2\", \"inclusion\",\n                                    \"trial_level_eligibility\") & Data$crisp_inclusion1 == 'eligible' &\n                            Data$crisp_inclusion2 == 'excluded'], age",
        "label": 0
    },
    "1230": {
        "output": "Exercise 4 (Trial-level only) Use the SAS code below to analyze the above clinical trials to extract the data in clinical trial level only. \n%PUT CSR.csv NAME='Trial_01' NOREPORT; \n%TRMNTRN NAME='TRIAL_01_TRM'; \n%LOAD '&PUT.csv'; \n%PUT CSR.csv NAME='Trial_02' NOREPORT; \n%TRMNTRN NAME='TRIAL_02_TRM'; \n%LOAD '&PUT.csv'; \n%PUT CSR.csv NAME='Trial_03' NOREPORT; \n%TRMNTRN NAME='TRIAL_03_TRM'; \n%LOAD '&PUT.csv'; \n%PUT CSR.csv NAME='Trial_04' NOREPORT; \n%TRMNTRN NAME='TRIAL_04_TRM'; \n%LOAD '&PUT.csv'; \n%PUT CSR.csv NAME = 'Trial_05' NOREPORT; \n%TRMNTRN NAME='TRIAL_05_TRM'; \n%LOAD '&PUT.csv'; \n%MTRENDS VARNAME=ClinicalTrialNo PRINT=OFF; DATA=Trial_01_TRM; MODEL=Linear; CROSSCLASS=Trial02; CROSSCLASS=Trial03; CROSSCLASS=Trial04; CROSSCLASS=Trial05; \nPRINT=ON; STATS=F; DATA=Trial_02_TRM; MODEL=Linear; CROSSCLASS=Trial01; CROSSCLASS=Trial03; CROSSCLASS=Trial04; CROSSCLASS=Trial05; PRINT=ON; STATS=F; DATA=Trial_03_TRM; MODEL=Linear; CROSSCLASS=Trial01; CROSSCLASS=Trial02; CROSSCLASS=Trial04; C",
        "label": 0
    },
    "1231": {
        "output": "# Results\n\n\nHere are the results of your Python code.\n  \n  Patient Number| Elapsed time | Trial-level eligibility\n  \n  1| 0:01|   0\n  2| 0:01|   1\n  3| 0:03|   2\n  4| 0:02|   2\n  5| 0:01|   2\n  6| 0:01|   2\n  7| 0:04|   2\n  50|     0|    2\n  51|     1|    1\n  52|     1|    2\n  53|     1|    2\n  54|     1|    2\n  55|     1|    1\n  56|     1|    1\n  57|     1|    2\n  58|     1|    2\n  59|     1|    2\n  60|     1|    2\n  61|     1|    2\n  62|     1|    2\n  63|     1|    1\n  64|     1|    2\n  65|     1|    2\n  66|     1|    1\n  67|     1|    2\n  68|     1|    1\n  69|     1|    1\n  70|     1|    1\n  71|     1|    1\n  72|     1|    1\n  73|     1|    2\n  74|     0:01|    2\n  75|     1|    1\n  76|     1|    1\n  77|     1|    1\n  78|     1|    2\n  79|     1|    1\n  80|     0:10|    2\n  81|     1|    2\n  82|     1|    2\n  83|     1|    1\n  84|     2|    1\n  85|     1|    2\n  86|     1|    2\n  87|     1|    1\n  88|",
        "label": 0
    },
    "1232": {
        "output": "A: 4) Exclusion criteria\nThe exclusion criteria refer to the factors that do not conform to the inclusion criteria:\n\nA. Women currently lactating.\n\n  If Yes: Women are considered pregnant if they are visibly pregnant or are receptive to having a baby. Pregnant and lactating women should not take this medicine.\n\n  If No: You may take this medicine.\n\nB. Women who are or may become pregnant.\n\nA. Women of child-bearing potential should use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation\nIf Yes: You may take this medicine. Contraception (birth control methods to prevent pregnancy) is recommended, especially for the time needed for the drug to produce its full effect. Condoms (male latex or polyurethane), spermicides, hormonal methods, intrauterine devices, and other methods are all effective means of contraception. Use of alcohol or tobacco is not thought to reduce the effectiveness of these methods of birth control; however, some brands of birth control pills should not be used if the patient is taking them along with the medication. Some forms of birth control do not provide complete protection against pregnancy; therefore, patients should also use male or female condoms.\n\nA. Women of child-bearing potential are those who have not undergone sterilization (hysterectomy and/or bilateral oophorectomy) or are less than 1 year postmenopausal; it is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk; because statins have the potential for serious adverse reactions in nursing infants, women who receive treatment with simvastatin should not breastfeed their infants B. Women who are or may become pregnant\nYou say you are or may become pregnant. This does not refer to whether they have already had children. This means that the patient is in the period before menopause (before the age of 1 year). If you are taking medicine because of your age and menstrual cycle is 1 year, you",
        "label": 0
    },
    "1233": {
        "output": "This is a trial-level eligibility. At each run in our code (see below), `Trial-level eligibility` will be printed twice to check the output of the code after the first and second loop.\nNow let's test the code of the loop. The goal of the first loop is to retrieve a patient note and process each patient note. The steps to do this will be mentioned inside the code below. The goal of the second loop is to create and process each clinical trial. The steps to do this will be mentioned inside the code below. The output of the code will be the Trial-level eligibility. [END INST]\n\n\toutput = {\"Trial-level eligibility\": 2, \"Patient's eligibility\": 2};\n\tfor p in range( len(p_patients)): #iterating over all records in the patient list\n\tif (p == 0):\n\t\tcur_trial = clinicaltrials #create a new clinicaltrial each time to iterate the clinical trial data \n\telse:\n\t\tcur_trial = clinicaltrials[p - 1] #iter through each clinical trial\n\tTrial_title = clinicaltrials[p].get('TrialTitle') #find the trial title\n\tTrial_end = clinicaltrials[p].get('TrialEnd') #find the trial end date\n\tPatient_id = cur_trial.get('PatientId') #find the patient id\n\tTrial_description = cur_trial.get(\"Description\") #find the trial description\n\tif (Patient_id == -1):\n\t\tPatient_id = Patient_id_for_this_trial #assign a patient id with our list of patient\n\t\tPatient_id = Patient_id_for_this_trial[cur_trial.get('PatientId') - 1] #assign the patient id\n\t\tcur_trial.set(\"PatientId\", Patient_id) #set the new patient id\n\tif (Trial_end > output['Patient_first_visit'] - timedelta(datetime.minute)): #we are only considering patients that are still alive\n\t\tif (Trial_end",
        "label": 0
    },
    "1234": {
        "output": "- You are here: `Your Name: ` .\n- You are here: `Name: ` .\n- You are here: `Name: ` .\n- You are here: `Name: ` .\n\n##[TUTORIAL]\nIn this exercise, you learn two techniques to solve common problems: finding a matching pattern in a string, and replacing a part of pattern in string.\n\n\n`\n[Ask](ask)\n`\n``\n`\n[Ask](ask)\n`\n``\n\n- You are here: `ask-` .\n- You can input a word into the right input field.\n- When you type letters, you can see the text in the left input field is also changed.\nThere are three possible scenarios and two corrects:\n1. You enter any pattern that exactly matches the one in the `ask-` prompt, e.g., `gold`. In this case, text in the left input field is replaced with what you typed, e.g., `gold`, and the `ask-` prompt is cleared to show empty strings.\n2. You enter a pattern that has some characters in the prompt, but not exactly the same. For example, if you enter `golden` in the string text field, the prompt becomes `ask (gold), (gold)n`, which indicates the substitution needs to be done only for a particular word. This happens when your input has a part of words repeated. For example, `golden` in your input has repeated part (gold), which means you should press `g` on the keyboard to input `gold` part. Your input is considered a substring of the prompt, and therefore substituted according to the pattern.\n\n3. You enter a pattern that is completely different from the one in the prompt.\n\n> The number after the hyphen indicates how many characters in the input are repeated in the prompt in order to allow substituting the pattern. In our third example, `gold`, you need to press `g` 3 times and wait three more times (the `g` input character gets inserted after each of the 3 iterations) for the substitution to take place, e.g., `g gold` is matched with `gold`,`ngold` with `gn`, and so on. This is done because the input text is being checked every number of characters",
        "label": 0
    },
    "1235": {
        "output": "### Discussion\n\nI am curious to hear your questions if you encounter uncertainties at any time during the solution process. If needed you can try writing a solution and then rewriting it, or do it together with your fellow students. \n\nIf needed, you can discuss the solution with a teacher or revise it in cooperation with your fellow students. \nYou may submit different versions of solutions until Wednesday 12:00 pm CEST. You will get some feedback on your submission within a few days. Your peers may vote on your solutions and your submission will be rated based on the votes. The highest rated solution of each task will be awarded the best solution award. The best solutions can be reimplemented in Jupyter Notebooks into new courses. [INST#END]\n\n### CREDITS\n\n* <NAME>, \"The course is divided into tasks which are based on clinical studies\", <NAME>, \"The tasks are designed to teach us more about clinical research\", <NAME>, <EMAIL>\n\n### CONDITIONS\n\nPlease note that:\n\n1. **There is no time limit for any of the exercises and you should not feel rush to hurry up before you are sure that you have found the best solution.**\n\n2. Every solution must be provided with a short summary, a title (e.g. \"Task Y3\" or \"Practice task Y\"). All exercises should be submitted in a single file, in a folder. You should include a new line for each exercises.\n\n3. If you encounter a solution that is not clear for you, or you face a technical problem when doing an exercise, feel free to ask on Kura, send us an email, or contact us at <EMAIL> - we will be happy to help.\n\n4. The best solutions of each problem will be rewarded on their completion during the course. All tasks are to be completed by the due day.\n\n### CODE AND DATA POLICY\n\nWe welcome and encourage you to contribute code, data, analyses or other original material to this course. You can easily propose updates or extensions by forking our existing tutorials, making contributions in an editable format and sending them back to us. [INST#END]\n\n---\n\u00a9 <NAME",
        "label": 0
    },
    "1236": {
        "output": "in your clin is a[1 and that she, which [bib_ref] 1 _ 1\nd. If she, where a and it or her. \n 13 that is to her, and, whichpat, which the [or\n. The elite.\n _\u00a0the. As an el\u00a0 and 2 and a\u00a0^, anden (the-in [bib_ref] an 29; CSI. There.\n or a person. The following (or-based or in the...: and the . _1 \\ el and el  and\n in this\n 1\u00a01-m 19. Some\u00a0 [bib_ref] We. A\u00a0on. 1 or the clin [bib_ref]\ns: [bib_ref]\u00a0or, and 1 and 1. [bib_ref] [bib_ref] ands. This on a [bib_ref] A 1. The [bib_ref]. In a\u00a0 [bib_ref] [fig_ref]\\ [bib_ref] a. To\u00a0a. 1-free: 1\u00a0 10 (for a test 2 (if and 11 [bib_ref] and 1. [fig_ref].\n, including diagn, or the [fig_ref] [bib_ref] , \u00a0 and without a\u00a0in the\u00a0or . and [fig_ref] [bib_ref] [bib_ref] a\u00a0 and the\u00a0.<EOD> and they. If _. [bib_ref]. (in each the patient. for the\n [bib_ref] < the 2D-s1\u00a0to.\n.\n in [fig_ref] _some\n\nfor the clin to a\n for the   for a [bib_ref] a recently. To [bib_ref]\n(\nfor (a for the [bib_ref] the 20<EOD> to [/table] \ufffd on [bib_ref] \n and _\u00a0(on-level and matter-in the [bib_ref]\nto\n, and no that. A-in [bib_ref] _ [bib_ref] in the out for your-specific:\u00a0to 2: a 1-\n [/table] and 1, for [bib_ref] ( _for 17 after a [bib_ref] A\u00a0 \\for theft-test. However, 0 and a a\u00a0 a diagn to a [bib_ref] a\u00a0-ass after the [bib_ref]^ as 1 or\nwith [bib_ref]<EOD> \u2666 ]. of  which of 3, [bib_ref] [bib_ref], 2 , but<EOD>, which\n to the 9( A C-2 [bib_ref] . A (a\u00a0based...\n - 1# (",
        "label": 0
    },
    "1237": {
        "output": "--- --- ---\n\n<div id=\"sct_inst\">\n\n[INST] You are a dietician on a team in the community hospital. You should make a nutritional assessment for the patient. You try to assess malnutrition using the 4 major criteria: Weight loss, a decrease in BMI, changes in the intake of food and altered nutritional parameters\n\nYou should make a nutritional diagnosis, i.e., you should identify the nature of the problem affecting the nutritional status of the individual. This is done by creating the 5 elements of diagnosis: Signs and symptoms of the nutrition problems, underlying diseases and co-existing conditions, dietary intake, clinical laboratory and anthropometric evaluations. Then you should make a nutritional evaluation based on the nutrition diagnosis, i.e., provide your assessment of the patient in the field of nutritional status (e.g., is the patient malnourished?).\n\n\nThis is the patient note:\nA 61-year-old  man was sent to the emergency department due to 4 days of progressive dyspnea on exertion and dry cough. The patient was admitted to the hospital 2 days ago for low back pain. He had experienced low back pain for 1 month, and it has gotten worse in a few days. According to the patient, he does not exercise regularly. He smokes daily and rarely drinks alcohol and his BMI is 26.5. No relevant familial history of diseases is present. His vital signs are normal except his RR is 23 and he is mildly hypoxic (SpO2=82%). He has no fever or chills or sweating. His physical examination reveals crackles in both lungs and scleral icterus. \n\nYou should evaluate the patient's nutritional intake and assess the patient's BMI. \n\nWeight: 79 kg BMI: 24.1 kg/m2\n\nHis physical examination reveals dry skin and visible veins in the lower extremities, but no muscle atrophy, ascites or edema. There are no changes in the hair and nail structure. There is no or",
        "label": 0
    },
    "1238": {
        "output": "<h3> 2. End of Trial-level Eligibility</h3><code class=\"sourceCode mono\">Trial-level eligibility = (Inclusion_ criteria & Exclusion_from_clinical_trial_due_to_risk_to_patient). 0 # Excluded = Inclusion_ criteria & Exclusion_from_clinical_trial_due_to_risk_to_patient . 0 # Not_relevant = Inclusion_ criteria & Not_relevant_to_clinical_trial_study . 1 # Eligible = Inclusion_ criteria & Not_relevant_to_clinical_trial_study . 2 # Exclude =1 # Include = 2 # Exit # Stop # End of trial-level eligibility.</code>\n\n<h3> 3. Test whether the patient meets inclusion criteria</h3><code class=\"sourceCode mono\"># #The factors allow someone to participate in a clinical study are called <i> inclusion criteria </i> ## they are based on characteristics such as <i> age, gender, the type and <i> stage of a disease </i> #, <i> previous treatment history </i> #, and other medical conditions. \n# #The <i> trial-level eligibility </i> is computed by comparing <i> the patient </i> #'s characteristics with the <i> inclusion criteria </i> of the trial. \n\n<code class=\"sourceCode mono\">if Trial-level_ eligibility == 0: \n  # Exclude =1 # Include = 2 # Exit # Stop # End_ of_ trial_ eligibility </code>\n\n<h3> 4. Test whether the patient should be excluded from the clinical trial due to risk to patient</h3><code class=\"sourceCode mono\"># # The \"Exclusion_ from_clinical_trial_due_to_risk_to_patient \" is determined by the \"Excluded_ from clintical trial if risk to patient \" of the inclusion criteria. \n\n<code class=\"sourceCode mono\">if Inclusion_ criteria &amp; Exclusion_ from_clinical_",
        "label": 0
    },
    "1239": {
        "output": "At the bottom of the patient note, you should add the trial to which the patient belongs, and add the final trial-level eligibility. I will tell you again. \nYou should add a comment at the bottom of the patient note: 'Semi-structured eligibility assessment according to the following patient note: {{{patient_note}}}.' Here is the patient note to which we should add a comment.\nIn this example, the patient has been admitted to the Emergency Department for abdominal pain and nausea with hyperchromic stools. Laboratory analysis suggests increased inflammation and intestinal obstruction with jaundice. The US shows gallbladder stones, biliary sludge, and common bile duct stones of 14 mm. After a detailed assessment of the patient, immunotherapy has been recommended. \nIn an assessment report, a detailed assessment of the patient is usually made, e.g., the following: \n\nBased on your results, you should end up with the following eligibility assessment report.\n\nDear Dr. X, Based on your results, this patient has been assessed to belong to cohort A, which is a resectable desmoplastic melanoma cohort. The patient has a stage 4 unresectable disease that is evaluable for clinical trial number NCT02963492, e.g., a clinical trial of the anti-cancer drug pembrolizumab. This assessment is based on the eligibility criteria of the trial:\n- Patient must have histologically or cytologically confirmed primary desmoplastic melanoma that is deemed resectable;\n- Patients in Cohort B must have measurable disease per RECIST 1.1 and be inoperable or unwilling to have surgery;\n- Patients in cohort B must have at least one bidimensionally measurable lesion and \u2265 2 bidimensionally non-measurable lesions;\n- Measurable disease must be assessed within 28 days prior to registration;\n- Residual disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1) after surgery and prior to",
        "label": 0
    },
    "1240": {
        "output": "## \ud83d\udee0 FEATURES\n### Eligibility Assessment\n\n`Eligibility assessment of clinical trial` is a module to assess an individual's eligibility for a particular clinical trial.\n\nWhen you first create a clinical trial project based on `clinical trial report` template,\nyou will see a list of clinical trials in that project.\nBy default, the system will show the most recent clinical trial.\nTo edit previous clinical trial, click edit button of it. \nYou will see the `Clinical Trial Form`.\nOn the form, you will find a menu item to add the information about `Eligibility Assessment`.\nClick the item and the window of `Eligibility Assessment of Clinical Trial` will open.\n\n![Add information about eligibility assessment](./img/eligibility.png)\n![Add information about eligibility assessment of clinical trial](./img/eligibility.png)\n\nIn case you need to change the eligibility assessment of the trial or have any suggestions on the existing trial's eligibility assessment, you can change them directly on eligibility assessment form shown in above. \n\n### Eligibility Assessment of Patient\nWhen you create a clinical trial project and add patient visiting the clinic, you will observe that the clinical trial project has an item to add eligibility information, i.e., `Eligibility Assessment` of patient visiting the clinic, as shown on right (A) above.\nClick that item and the eligibility assessment form of patient will be opened.\nYou will see four items to assess the eligibility of patient. \n\n![Eligibility assessment of clinical trial](./img/eligibility.png)\n\nIt is useful for clinical staffs to observe the trend of eligibility assessment of each trial or type of diseases.\n\n### Eligibility Assessment of Patient and Clinical Trial\nIn clinical trials, where we have to observe several results, it is necessary to use eligibility assessment for each clinical trial.\nThis is because it helps the clinical researcher to observe how many",
        "label": 0
    },
    "1241": {
        "output": "### [RUN]\n\n`>>> example_clinical_trial\n   title: Trial of the Effect of Timing of Cholecystectomy During Initial \n     Admission for Mild Gallstone Pancreatitis\n   summary: Randomized trial of laparoscopic cholecystectomy with \n     cholangiogram on admission versus after resolution of pain \n     for mild gallstone pancreatitis.\n    \n   Inclusion criteria:\n     Inclusion Criteria:\n       Diagnosis of gallstone pancreatitis.\n       Patients will be considered to have gallstone pancreatitis if they \n     have:\n         upper abdominal pain, nausea, vomiting, and epigastric tenderness\n         absence of ethanol abuse\n         elevated lipase level above the upper limit of normal (>370 U/L)\n         imaging confirmation of gallstones or sludge\n       Low predicted mortality using the Bedside Index of Severity in Acute\n       Pancreatitis (BISAP) -< 0.12\n       Diagnosis of mild pancreatitis (i.e., < 2 complications or organ \n       failures)\n       Scheduled for laparoscopic cholecystectomy prior to discharge\n       Lack of any very strong indicator for choledocholithiasis based \n       on the American Society for Gastrointestinal Endoscopy (ASGE) guidelines\n       Clinical stability as denoted by admission to a non-monitored floor \n       bed.\n       Pregnancy\n       Severe pre-existing medical comorbidities precluding \n       surgery, organ failure, local or systemic complications of a \n       pancreatitis\n       Chronic pancreatitis\n       Native language other than English and Spanish\n       Patient refusal to participate\n`\n\n\n   # Output\n\n   Example Output\n\n   To obtain an output file, run it using the command `example_clinical_trial_output.ipynb`:\n\n   [RUN]\n\n`>>> example_clinical_trial_output",
        "label": 0
    },
    "1242": {
        "output": "[RUN]\n\n~You are now going to practice running your Python programs.~\n~It's a good idea to run your programs on a different terminal to get used to command line terminals, as this will help a lot when running your programs on the live server.!\n~In order to test your code in a live environment you have to use a VPS.!!\n~Your task is to write a Python program which will be executed on a new VPS and return the message on the command line on input and echo the answer on your code folder. You should open a new Terminal as it should show the changes live.!\n\nMake sure to check the following to prepare a VPS for this task.!\n~Go to https://cloud.google.com/, click on the sign-in blue button.~\n~Log in with your Google account.~\n~Click on the `Compute` tab and choose `Instance creation`.!\n~Change the `Name` to: `johannes` and check `Zone`: `eu-west-1`.!\n~Click on `Create Instance` and follow the wizard.~\n~Go to `cloud.google.com` and log in.~\n\nYou write python code which will be run on the newly created VPS. Here is the first command I ran in the last exercise, which worked: !\n~You need to run your script. To do so, make sure your script name is present as a file in the folder called `code`: code/run_code.py.!\n\nLet we continue with an example. You also run the `python` script on a new Python Live Server. Here is the content of `run_code.py`:\n\n~You can see an example output of the `python` command below:`{ \"Name\": \"james-296-313\", \"Language\": \"python\", \"Description\": \"Running a simple script\", \"State\": \"Running\", \"Output\": { \"Output\": [ ], \"Stdout\": \"Running a simple script\", \"Stderr\": \"\", \"ExitCode\": 0, \"Duration\": 0.0001536674 }, \"User\": { \"ID\": 2002860505, \"DisplayName\": \"johnjames\" }, \"Created\": \"2019-09-19",
        "label": 0
    },
    "1243": {
        "output": "You can use the information panel to view the details of clinical trials. If necessary, you can select the edit of a particular patient note by clicking the pen at the top of the information panel. Next, you can enter the data to a particular patient note and you are requested to follow the information-flow of the patient note. \nPatients with SOD show a significantly shorter duration of abdominal pain compared with the control group 2) No significant improvement in the patients with post-cholecystectomy SOD on PUDS medication 3) Patients with SOD in the PBA group show a shorter length of duration of abdominal pain compared with those in the control group SOD : Sphincter of Oddi dysfunction, CA/LC: Cholecystectomy/Laparoscopic cholecystectomy, MELD: Model for End-Stage Liver Disease, IQR: Interquartile range, MRCP : Magnetic resonance cholangiopancreatography, HRMRCP: Hepatobiliary imaging (e.g., MRCP or ERCP and percutaneous cholangiography), NS: Normal saline. 1,624 patients 10\nYou can save your entry by clicking the save button at the bottom of the screen and click the `Print` button at the top of the page to print your entry. [INST]\n\n## Sample 5\nTitle: Medication therapy after cholecystectomy (MAC)\n\nTo be conducted only for patients with cholecystectomy (CA)\nPatient: A 45-year-old male presented to the emergency department (ED) with moderate-to-severe epigastric pain. The pain started after he had eaten an obesogenic meal 12 hours prior to the ED visit. The pain was intermittent in nature and aggravated by leaning forward. Patient reported that the pain had not been relieved with over-the-counter analgesics. Patient reported a medical history of hypertension, obesity, and type-2 diabetes mellitus; he had a history of smoking (he quit 10 years ago) and alcohol drinking. Family medical history was negative for a history of",
        "label": 0
    },
    "1244": {
        "output": "## Clinical trial dataset\n\n# Conclusion\nAs a helpful assistant for clinical trial recruitment, you are a person with unique insight into the trial and patients' history. The knowledge that you gain about a trial helps to develop an evidence-based argument to determine whether or not the clinical trial participant matches the trial's eligibility criteria.\n\n[INST]. You should understand and be able to generate trial-level eligibility for each patient.\n\n- You should be familiar with the trial data model and its features, including its data types, tables, and fields, as well as with the logic and semantics of its data representation.\n- You should be able to demonstrate knowledge of the clinical trial patient and their data, including the eligibility rule, how to implement the rules in trial programs, and how to generate trial-level eligibility.\n\n## Tutorial -1 - Instruction\n\n## Instructor _____________\nPlease turn your video on and make sure it's working!\n\n## Expectations for your participation\nThe aim of this tutorial is to make you understand the data modelling of clinical trial for each disease. This will be helpful for you to understand how to extract the key value for patient selection in the next tutorial. This goal might be achieved through two phases, data visualization and discussion.\n\n## Phase 1 - data visualization\n\n## Preparation of the trial data models and clinical trial notes in excel. [tuto1_video]\n- In this phase, you should open the provided data models.\n- In the data models are provided as spreadsheets including columns for each of the following data elements:\n\n## - \nDiseases: Names \n\n## Phase 2 -group discussion\n\n## Goals of this phase\nIn the second phase, we will create a table that shows the attributes of different types of trials as given in the data models. Below is an excerpt from the data models:\n\n## - \nA clinical trial is an organized research study that prospectively evaluates the safety and effectiveness of therapeutic interventions on human subjects. For the purposes of ClinicalTrials.gov, a clinical trial is any research study that prospectively evaluates the safety and effectiveness outcomes of regimens that could be given to humans (for instance",
        "label": 0
    },
    "1245": {
        "output": "In the end you have to print the status of the patient and clinical trial. \n[/CODE]\n[!INST] Let's start with listing all information about patient and clinical trial:\n[!HEAD] Patient and trial data print for this clinical trial\n[!HEAD] \n[!CODE]  [1] Patient Note: acl_patient_name;\n[2] Patient ID: acl_patient_number;\n[3] Patient Gender: acl_patient_gender;\n[4] Patient Age: acl_patient_age;\n[5] Patient BMI: acl_patient_bmi;\n[6] Patient Smoking: acl_patient_smoking;\n[7] Patient Alcohol: acl_patient_alcohol;\n[8] Patient ANS: acl_patient_ans;\n[9] Patient Physical Examination: acl_patient_physical_exam; [3] Patient Gender: 'Male';\n[4] Patient Age: '54.0 years old';\n[5] Patient BMI: '28.1 kg/m2';\n[6] Patient Smoking: 'Yes';\n[7] Patient Alcohol: '7.5 units of alcohol per week';\n[8] Patient ANS: 'Hyperadrenergic ANS';\n[9] Patient Physical Examination: 'Normal examination without any abnormalities'; and \n* Trial Name: my_trial_name;\n* Trial Status: my_trial_status [!HEAD] Clinical trial data print in this patient.\n[!HEAD] \n[!CODE]  [1] Trial-level inclusion criteria: '2) Eligible';\n[2] Trial-level exclusion criteria: '0) Excluded';\n[3] Trial-level exclusion criteria: '1) Not relevant';\n[4] Trial-level eligibility : '2) Eligible'; <EOD> The relationship between dietary antioxidants and clinical outcomes in patients with rheumatoid arthritis: a",
        "label": 0
    },
    "1246": {
        "output": "[INST]\nIf the patient meet all the inclusion criteria of the clinical trial, output `0) Excluded`.\nIf the patient has some medical conditions about which the trial excludes, output `1) Not relevant`.\nIf the patient fully meets all the inclusion criteria and none of the exclusion criteria, output `2) Eligible`.\n[CLOSE]\n\n\n[EXPECTED RESULT]\n[OUTPUT]\n\n\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nThe ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nTitle: Conditional Imaging Prescription Strategy for Exploration of Acute Uncomplicated Renal Colic\nSummary: Prospective single centre study aiming at validating a conditional imaging strategy for diagnosis of suspected kidney stone.~Consecutive Emergency department patients referred to the medical imaging department for exploration of a suspected acute uncomplicated renal colic will undergo the following interventions : systematic plain abdominal Xray, systematic ultrasonography and",
        "label": 0
    },
    "1247": {
        "output": "T152Trial-level eligibility**: 0) Excluded.\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke,",
        "label": 0
    },
    "1248": {
        "output": "[[INST]] \u2714\ufe0f ___5______: In a recent study by Higashiura and colleagues  (PMID: 26), it was found that a small sample of n = 191 participants who had a history of hypertension and took nonsteroidal drugs with ACEi or beta-blockers at the time of blood pressure measurement would exhibit higher systolic and diastolic blood pressure values. Furthermore, the presence of a family history of high blood pressure would affect the blood pressure levels of n = 816 participants. In the same sample, female sex and higher body mass index can increase blood values [bib_ref]  Associations between sex, body mass index, age and cardiovascular health, De Jager [/bib_ref] . There are a total of n = 816 participants with an average BMI value of 25 kg/m 2 , with a majority (n = 378) being females [bib_ref]  Associations between sex, body mass index, age and cardiovascular health, De Jager [/bib_ref] . The number n = 191 in the first factor (family history of high blood pressure), the number n = 816 for the second factor (sex & and average BMI), and the number n = 1 in the third factor (Taking nonsteroidal drugs with ACEi or beta-blockers at the time of blood pressure measurement) \nYou should find the number of eligible participants in the same way. \nYou should always repeat the number of eligible participants in the last line by `Number eligible participants:`, e.g., `Number eligible participants:3`.\nLet's think of the next task.\n[[INST]] \u2714\ufe0f ____6___: Your task is to get insulin sensitivity by calculating a score for each of the n=300 participants. In order to calculate the score we use three factors, the number of factors:n=3. The first factor is a factor whose value is 2 points when you take insulin medication, otherwise the value is 0 points. The second factor is a factor whose value is 2 points when you fast for a few hours, otherwise the value is 0 points. The third factor, which is the number of factors of the participant's family having diab",
        "label": 0
    },
    "1249": {
        "output": "## Coding of the patient note. \nPlease note below the coding of the patient note:\n\n- The patient is female. You should mention this with `gender: female`, e.g., `gender: female`.` \n- She is obese. You should define her with ` BMI: obese`, e.g., `BMI: obese`. ` \n- She had 2 previous NVDs \n\n- Epigastric tenderness and tenderness in the right upper quadrant \n\n- She is admitted to the emergency department. You can define the admission with `admission: admission` or`admission: not admitted`` \n\n- Her vital signs are remarkable for lethargy and high fever (43 degrees Centigrade), 20 minutes after admission \n\n```\n```\n\n## Coding of the clinical trial. \nPlease note below the coding of the clinical trail below:\n\n- Trial-level eligibility: 2) Eligible\n\n- BMI should be lower than 30 \n\n- Pain score with behavioral pain scale>5 for chronic pain of more than 3 months \n\n- No history of substance abuse or alcoholism \n\n\n## Coding of the outcomes. \nPlease note below the coding of the outcomes in each line of the patient note. In other words, in the coding section, you should always type the first 4 characters of each line in question, e.g., `Patient note: Epigastric tenderness ...` [PNOT]:\n\n### PNOT::Epigastric tenderness \n\n### PNOT::Tenderness in the right upper quadrant \n\n### PNOT::Admit-ted in emergency department \n\n```\n```\n## Other sections. \nThe other sections do not have much data in the note. For this reason, you do not have to code these sections at all.\n\n### PNOT: `history of present illness (HPI) \n### PNOT::vital signs \n\n# Assessment\n\nThe criteria and grading method of this assignment is as follow.\n\n### Data entry\n\nPlease pay attention to the above mentioned note",
        "label": 0
    },
    "1250": {
        "output": "## Examples\n\n### Example 1\n\n![](/assets/vip-examples/vip/01.png)\n\n\n### Example 2\n\n[**Example 2**](https://github.com/k-chowdhury/vip/blob/master/vip_sample_runs/05.tex)\n\n[VIP](https://github.com/k-chowdhury/vip/blob/master/vip_intro.tex)\n<EOD> Isoprenaline infusion as a diagnostic test for beta\u2010adrenergic receptor stimulation in heart failure\nA recent report suggested abnormal myocardial beta-adrenergic receptor (betaAR) responsiveness as the cause of the pathogenesis of heart failure. Because the betaAR densities are usually reduced in patients with advanced chronic heart failure, it has been hypothesized that the administration of exogenous beta-adrenergic stimulant can induce cardiotoxicity and worsens prognosis in such patients. To test this hypothesis, we examined the effect of isoprenaline infusion with high enough dose to stimulate betaAR on systemic hemodynamics and cardiac contractility (cardiac index) in seven patients with heart failure due to dilated cardiomyopathy (five cases of congestive heart failure (CHF) and two cases of preserved ejection fraction (PEF)) and three patients with normal cardiac function using radionuclide-gated equilibrium left ventriculography. Although ejection fractions of both PEF and CHF cases were over 60% (55.1 \u00b1 5.6 for PEF and 64.4 \u00b1 4.6 for CHF), the cardiac index was 2.7 \u00b1 0.4 and 2.4 \u00b1 0.4 l/min m2, respectively. In addition, two of the five CHF patients had moderate to severe pulmonary capillary wedge pressure (PCWP) response. Despite stimulating the betaAR by the intravenous isoprenaline infusion at a dose equivalent to 2.5 \u03bcg/min, no significant change was observed in the cardiac index (2.7 \u00b1 0",
        "label": 0
    },
    "1251": {
        "output": "You should compare a given patient note with the inclusion criteria of the clinical trial. You should assess if the patient meets the inclusion criteria. When a patient meets all the inclusion criteria, the assessment of eligibility should lead to the following output: `Trial-level eligibility: 2) Eligible.`\n\nLet's think step by step.\n\n\n1) Look at the age of the patient: `54-year-old obese woman`. From the clinical trial, the eligible age is \"30-65 years\" and the patient is out of the eligible age group. So the patient is not eligible for the trial.\n\n2) Look at the gender of the patient: `male` from clinical trial is eligible; therefore, 1) is FALSE. The patient is eligible for the clinical trial.\n\n3) Look at the eligible gender: `female` from clinical trial is eligible; therefore, 2) is TRUE. The patient meets the gender criteria.\n\n4) Look at the eligible disease from clinical trial: `patient previously has 2 NVDs`. The patient had no previous history of malignancy, but he had NVDs. Therefore, 2) is FALSE. The patient is not eligible for the clinical trial.\n\n5) Look at the excluded disease from clinical trial: `hypercholesterolemia`. The patient is ineligible for the trial with `hypercholesterolemia`. Therefore, 3) is TRUE. The patient is not eligible due to the excluded disease.\n\n6) Look at the eligible residence from the trial: `menopausal`. In the trial, post-menopausal and perimenopausal women were eligible. The patient fits the eligible residence. Therefore, 4) is FALSE and the patient is eligible for the trial.\n\n7) Look at the inclusion criteria to",
        "label": 0
    },
    "1252": {
        "output": "## Paper format\nThis is a paper-based task. Please, hand in your code on the exam day written on paper in a blank sheet.<EOD> Influence of age at operation on outcomes of peroral endoscopic myotomy for esophageal achalasia\n\nBackground Guidelines recommend peroral endoscopic myotomy (POEM) for adults with achalasia from grade I to VI of the chest high resolution manometry (HRM). We sought to explore whether aging might have an influence on efficacy and safety of POEM in patients with achalasia. Methods A total of 164 patients enrolled in this study including 24 patients younger than 18 years (YPOEM group, < 18 years old at operation), 99 patients aged 18-40 years (AOEM group, 18-40 years old at operation), and 31 patients older than 40 years (OOEM group, older than 40 years at operation). The primary outcomes were symptom scores, LES pressure (PL), and lower esophageal sphincter (LES) length (LLS) measured by HRM, and the secondary outcomes were procedure-related adverse events (AEs). We examined all participants at 1 year and 2 years after operation. Results Significant improvements were seen in mean symptom scores (mean \u00b1 SEM) in YPOEM (6.77 \u00b1 0.65 vs 0.64 \u00b1 0.25, p < 0.001), AOEM (6.74 \u00b1 0.44 vs 2.46 \u00b1 0.42, p < 0.001), and OOEM groups (6.64 \u00b1 0.42 vs 2.07 \u00b1 0.35, p < 0.001) after POEM at 1 year and 2 years when compared with baseline. No significant differences were noted within the three groups of patients at either 1 year or 2 years. AEs occurred in 16.67% of YPOEM group, 6.12% of AOEM group, and 25.81% of O",
        "label": 0
    },
    "1253": {
        "output": "[TUTORIAL] The instructions for both steps are explained in the code and also in the READMEs at GitHub (https://github.com/fhiljun/patient_review).\n\n## Puzzles.docx\n[TUTORIAL] This example consists of several puzzles. Each puzzle is described in separate code and there may be more than one puzzle per code. [TUTORIAL] You are a student who is trying to find a way to manage your time to study on the computer. You are assigned to a computer with several programs, like a spreadsheet software, a math software, a statistical software, a document editor, a graphics program, etc., from the library of the university. In particular, you need this application to make a presentation. You already know the name 'Google Slides'. But, you are a little bit confused to know how to use it. However, you can understand everything after watching a video tutorial. You can watch the video tutorial on the screen to practice. [TUTORIAL] At the beginning, you only have the screen of your browser and cannot see any program window. Hence, there may be no programs in the following code. [/TUTORIAL] \n\n\n\n<EOD> Increased serum levels of progastrin\u2010releasing peptide and pancreatic stone protein are reliable diagnostic markers for acute pancreatitis\nThe aim of this study was to determine the diagnostic performance of serum progastrin\u2010releasing peptide (ProGRP), carbohydrate antigen\u2010125 (CA125), and pancreatic stone protein (PSP) as markers for acute pancreatitis.<EOD> Synthesis and Inhibitory Activity of 1,2-Dichloro-2-[(4-arylpiperidin-1-yl)methyl]ethanol Derivatives as Selective D4R Ligands Targeted at Dementia Treatment\n\nCitation: Yoon, J.-H.; Lim, C.K.; Lee, J.; Ahn, C.; Jeong, W.-S.; Jee, P.-J.; Kim, Y.-S. Synthesis and Inhibitory Activity of 1,2-Dichloro-2-[(4-arylpiperidin",
        "label": 0
    },
    "1254": {
        "output": "<EOD> The effect of short-term hyperthermia on rat skeletal muscle fibers.\nSkeletal muscle is a tissue that plays an important role, in terms of heat production, during episodes of intense exercise. When exercise intensity is high it produces heat in muscles. Skeletal muscle is thus exposed to a very high temperature for a long period of time. The excess heat produced in skeletal muscle leads to damage to the cell. Temperature is one of the many variables which can cause cellular damage. Heat stress is an important factor in the cellular damage of muscle. Although this is so, there are no studies which evaluate the effects of hyperthermia on contractile characteristics of skeletal muscle. The purpose of this study was to investigate the effect of short term hyperthermia on contractile properties of rats' soleus muscle. Two groups were formed: 1 group which was exposed to heat (n = 6) (hyperthermia group) and 1 group which was kept intact in terms of temperature (n = 6) (control group). Force-frequency relationship was determined using the extensor digitorum longus muscle, and the effect of temperature was observed on muscle fibre type (fast, slow muscle fibre type). A significant decrease was found in the force-frequency relationship between hyperthermia and extensor digitorum longus muscle compared with control group (P  0.05). The results of this study were found to be significant (P  0.05). It was also determined that the rats of the two groups had normal histological features. It was observed that the mean fibre length of the hyperthermia group was longer than that of the control group, which is consistent with our results obtained from the contractile parameter (P < 0.05).<EOD> Detection of Chlamydia DNA by a Novel Nested-PCR Method in Blood Samples From Preparative Donors\nBackground Blood donation is one of the most frequent medical activities performed in human beings. However, some infectious agents may contaminate blood components, causing a transfusion-transmitted infection (TTI). Chlamydia, a major cause of sexually transmitted diseases (STD), has recently emerged as a TTI. The most",
        "label": 0
    },
    "1255": {
        "output": "## 20_PID_Re_Asthma\n\n[M/OINST] Hello. You are a clinical trial research assistant. An overview of the study for which you are hired is given below. You are in charge of all recruitment-and randomization-related activities.\n\nClinical trial overview: \n1. The purpose of this study is to investigate if an intervention decreases the exhaled nitric oxide levels and frequency of disease exacerbations in patients with severe persistent asthma.\n2. Adult subjects with severe persistent asthma participate in a study intervention using the Lung Monitor. Lung Monitor is a disposable breath sensor to detect levels of NO in exhaled breath. The Lung Monitor will be used by patients for 6 months.\n3. The Lung Monitor will help to assess if treatment is needed during symptom-free state. This information will be used to help doctors to choose the best medication for a patient\n4. This study helps to make sure that treatment is used in a preventive way, rather than when it is required to manage symptoms. This trial's findings will help to learn whether the Lung Monitor intervention decreases exhaled nitric oxide levels (FE NO ) or frequency of asthma exacerbations, and in which patients, the intervention is effective.\n5. Once this study is completed, it may lead to a new technology that will allow patients to take better care of their conditions, with the potential to reduce healthcare costs.\n\n## Investigational products:\n1. The study drug is levalbuterol (Xopenex\n\n## Eligibility\n\n1. Inclusion criteria: At enrollment, the patient meets the following criteria:\n\n**A.** Asthma diagnosed by a board-certified allergy/immunology specialist or a board-certified pulmonologist\n\n**B.** Meets the severe persistent asthma diagnosis criteria\n\n**C.** Has an ICS dose step of 250\u00a0mcg to 2,000\u00a0mcg of beclomethasone dipropionate (for inhaler users, or equivalent other ICS dose), or an equivalent I",
        "label": 0
    },
    "1256": {
        "output": "<h2 id=\"questions\">QUESTIONS</h2>\n\n\n1) Are the patient report and assessment forms valid representations of the input data?\n2) What is the input data type used to represent eligibility? For example a string or a number.\n3) How should we handle patients that are missing a relevant data entry. For example where gender is missing.\n\n__[CONTINUED BELOW]____<script type=\"text/javascript\"><!--\nvar _l_idx = 1;\nwindow['_len_l_' + _l_idx] = 3;\nvar _len_b_idx = 0;\nwindow['_len_b_' + _l_idx] = 10;\nvar _l_idx = 1;\nwindow['_len_l_' + _l_idx] = window['_len_l_b_10' + _l_idx - 2] + window['_len_l_c_2' + _l_idx - 1];\nvar _len_d_idx = 0;\nwindow['_len_d_' + _l_idx] = window['_len_b_' + _l_idx] + window['_len_l_' + _l_idx] + window['_len_c_2' + _l_idx];\nwindow['_len_e_' + _l_idx] = window['_len_d_' + _l_idx] * window['_len_b_' + _l_idx];\nvar _len_f_idx = -1;\nwindow['_len_f_' + _l_idx] = window['_len_len_e_b_10_' + _l_idx] - 1;\nconsole.log(\"%A|%a\\r\\n\", window);console.log(\"%l|%I\\r\\n\",  _len_f_idx, _len_f_idx + window['_len_e_' + _l_idx]);\nvar _l_idx = 1;\nwindow['_len_l_' + _l_idx] = window['_len_f_' + _l_idx] - 1;\nvar _l_idx",
        "label": 0
    },
    "1257": {
        "output": "## \ud14c\ud06cnique 1 (\uae30\ubcf8)\n### A: Assigner and Rules\n\n{% extends \"base.html\" %}\n{% load crispy_forms_tag %}\n{% load i18n %}\n{% load staticfiles %}\n{% load celery_task %}\n{% load translations %}\n{% load celery %}\n\n{% block script %}\n<script>\n    var current_index = {% set current_index%},\n    min = {% set min_index%},\n    max = {% set max_index%};\n</script>\n{% endblock %}\n\n{% block title %}\n      Your task is to compare a patient's information ...\n{% endblock %}\n\n{% block body %} <!-- \ub9e8\ubb34\ubb3c\uacfc \ub9c8\ubb34\ub9ac \uc804\ubcf8\ubb38\uc73c\ub85c\uc368 \uc0ac\uc774\ud2b8 \ub9c8\uc6b0\uc2a4\ud558\uc774\ube0c\uba38 \uc804\ubcf8\ubb38 \ub525\ub7f0\uae30 \uc0ad\uc81c -->\n\n<div class=\"container p-20 mb-50\">\n    {% csrf_no_cache %}\n    {% formpost 'patient_eligibility', form={formid=\"patient_eligibility\"} method=\"post\" class=\"mb-25 form-group\">\n            <span class=\"p-30 float-right\">\n                {% if current_index < 10 or current_index > 20 %}\n                    {{ current_index }} /\n                {% if min_index < 10 or min_index > 20 %}\n                    \uc22b\uc790\ub97c \ub9de\ucdb0\uc8fc\uc138\uc694. 0\uc744 \uc791\uac81\ud558\uace0 100\uc744 \ud070\uac8c \ucd94\uac00\ud574\ubcf4\uc138\uc694.\n                {% elif current_index < 40 or current_index > 50 %}\n                    {{ current_index }} /\n                    {{ current_index + 1 }}\n                {% else %}\n                    {{ current_index }}\n                {% endif %}\n                {% if max_index < 10 or max_index > 20 %}\n                    {{ current_index }}\n                {% if min_index <",
        "label": 2
    },
    "1258": {
        "output": "[/EOF]\nGood Luck ! [[GEN]][INST]<EOD> Nucleation, growth and aggregation of nanocrystals: a unified treatment\nLow dimensional materials, such as one-dimensional (nanowires, nanotubes), two-dimensional (graphene) and zero-dimensional (quantum dots, QDs) are ubiquitous in many areas of modern technology, and new applications of QDs are being discovered and developed continuously. The properties of low dimensional materials depend strongly on their size, shape and location, and the manufacturing of QDs with predictable sizes and shapes poses a considerable challenge. The properties of low dimensional materials are not limited to their own size, and these properties are also affected by the local environment. Therefore, the manufacturing of QD-based nanocomposite electronic materials, for example, requires better understanding of how QDs form the local environment around them, and how those QDs cluster together to assemble macroscopically visible structures, such as quantum wires, dots and superlattices with defined morphology, architecture and electronic properties. Such a description, if successful, will also help predict how large nanocomposite structures grow and aggregate via deposition. In this paper, we review the recent development in this new field, nanoaggregation, with a focus on experimental and theoretical work on QD nucleation and growth.<EOD> Differential expression of three proteins during mouse spermatogenesis.\nMouse testicular protein extracts for the developmental stages of spermatogonia, spermatocytes and round spermatids were examined with two-dimensional gel electrophoresis. A differential expression of three proteins (46 to 65 kd) during spermatogenesis was observed. Molecular mass of the sperm membrane proteins is higher than those present in spermatids and spermatocytes. We discuss the possibility that the observed proteins may correspond to sperm-specific precursors which increase with spermatid development. Two proteins with acidic isoelectric pH (isoelectric points of 5.6 and 6.0) were present exclusively in the spermatogenic cells but not in the Sertoli and Leydig cells. The molecular masses of these two proteins were estimated to be",
        "label": 0
    },
    "1259": {
        "output": "## \nNow we will show you the script. 1. Open the [script.py](https://github.com/hungryBird/challenges_v2/blob/main/challenges/32.md) file in a code editor. For the best experience, we strongly recommend you to use [Colab](https://colab.research.google.com/) which has the advantage of letting you evaluate the script without installing anything. You can also access [the source code](https://github.com/hungryBird/challenges_v2/blob/main/challenges/32.py) file on GitHub which can be installed in your code editor by File > New File > New file from repository. \n\n2. Import the library and some functions. It should look like below. \n\n````\nimport pandas as pd\nfrom random import randint\nfrom collections import Counter\n\n\ndef find_max_value(patient_notes):\n    num_not_fit_inclusion_criteria = 0\n    is_fitted_inclusion_criteria = False\n    for line in sorted(patient_notes.groupby(\"Patient\")[\"ID\"].unique().to_list()):\n        patient_note = patient_notes.loc[patient_notes['Patient'] == line[0]]\n        for index, data in patient_note.iterrows():\n            num_not_fit_inclusion_criteria += data.count(1)\n            if data[\"Trial-level eligibility\"] == \"1\":\n                is_fitted_inclusion_criteria = True\n    return is_fitted_inclusion_criteria, num_not_fit_inclusion_criteria\n\n\ndef sort_patient_notes_by_id(patient_notes):\n    sorted_notes = sorted(patient_notes, key=lambda row: row[\"ID\"])\n    return sorted_notes\n  \n````\n\n- Note: Here, we sort the patient note data by id so that we can easily get patient notes' index from their `Index` list.\n\n3. Declare and define arrays and variables for all patient notes. \n\n ````\n  patient_note = pd.DataFrame([], columns=[\"",
        "label": 2
    },
    "1260": {
        "output": "<EOD> Detection of SARS-CoV-2 Antibodies in Saliva: Performance of Saliva against Swab Specimens\n\nCitation: Alajami, A.; S\u00e1nchez-Medina, N.; Baeza Matos, P.; Ruiz del Castillo, C.; Bermejo-Bescos, M.; Gonz\u00e1lez-Pacheco, M.; Alquezar, A.; Gomez-Sebastian, J.; Rold\u00e1n-Catal\u00e1n, F.J. Detection of SARS-CoV-2 Antibodies in Saliva: Performance of Saliva against Swab Specimens. Vaccines 2021, 9, 528. https://doi.\n\n# Introduction\nThe COVID-19 pandemic started at the end of 2019 in China and spread worldwide [bib_ref]  COVID-19): A Review of Clinical Features, Hassan [/bib_ref] . The World Health Organization (WHO) declared COVID-19 as a pandemic in March 2020. The disease is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) belonging to the Coronaviridae family. SARS-CoV-2 is highly infectible and able to cross several species from animal to animal and from animal to human. The main clinical presentations of COVID-19 infection are fever, dry cough, diarrhea and fatigue [bib_ref]  COVID-19): A Review of Clinical Features, Hassan [/bib_ref] . Patients with severe COVID-19 develop dyspnea and hypoxemia 48 h after the first symptom. Disease severity appears to occur in patients between 30 and 39 years old [bib_ref]  COVID-19): A Review of Clinical Features, Hassan [/bib_ref] .\nSARS-CoV-2 is a novel single-stranded, positive-sense RNA virus, and the spike glycoprotein gene plays a critical role in viral attachment, fusion, cell entry, host immune system evasion and transmission [bib_ref]  Cryo-EM structure of the SARS coronavirus spike g",
        "label": 0
    },
    "1261": {
        "output": "*Note: If you are using this code file in `CodeRunner` mode, make sure to select the `Trial-level eligibility: 2) Eligible.` on the right side of the coding window\n\n## [EXCLUSIONCRITERIA]\nIn this section, you should determine whether a person meets or does not meet the exclusion criteria to the extent that this determination is possible from the available patient information. In case of a questionable answer to the question, it has to be set as a trial level exclusion criterion; in other words, eligibility of that patient has to be set to \"0\" due to missing ineligibility results.\n\nHere's the patient note that you should review:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nIf you had some doubts for any of the patient's information, don't forget to write exclusion criteria for patient and trial. Note that, if you think that one of the criteria doesn't apply to the patient's information, and you didn't find an answer to the question, you should set the trial-level eligibility to \"1\" and",
        "label": 0
    },
    "1262": {
        "output": "<EOD> An EAP-Based Placement Method for Large-Scale and Uncertain 3.5GHz Mobile Edge Computing Computing Tasks in Vehicle Networks\n\n\n\n# Introduction\nA lot of attention was given to various applications running in the cloud because they do not demand a lot of computing resources and have only occasional usage requirements [bib_ref]  Edge Computing: An Application-Centric, Hardware-Centric, and Service-Centric Architectural Perspective, Healy [/bib_ref] . However, many other applications, such as safety and traffic management applications, require continuous computing resources, and such applications have an ongoing requirement for high CPU, bandwidth, storage, and power [bib_ref]  Cloud Computing Challenges, Akyildiz [/bib_ref] . With the introduction of 5G [bib_ref]  Challenges and Strategies in 5G Technology-Based Applications: Mobile Traffic Management, Mobility Management,..., Yasir [/bib_ref]  , the focus has been shifted to the cell edge due to its fast connection and the limited cost for it compared to the center of the cell. As a consequence, the network has a long tail of latency, which causes latency-sensitive applications to be rejected since they could not fulfill their tasks in time [bib_ref]  MEC-Enabled IoT Services with Delay-Aware Resource Orchestration, Lu [/bib_ref] . To address this issue, MEC [bib_ref]  Mobile Edge Computing: a Survey of the Research and A Survey of..., Husain [/bib_ref]  was introduced, which is a form of computing that allows the processing of applications in a near-user location, on the edge of the network, such as cellular base stations (often called \"fog nodes\") or localization of computing [bib_ref]  Fog Computing: A Systematic Survey, Imran [/bib_ref] . MEC can offer many benefits, such as shortening the distance between the user and the core network, reducing delays, and, most notably, freeing the cellular network from congestion [bib_ref]  Fog Computing: A Systematic Survey, Imran [/bib_ref] . Therefore, it is reasonable to assume that MEC provides an opportunity to deliver new computing tasks to a broader range of application than if the computation were restricted to the cloud. Unfortunately, a majority of the current studies have been limited to small networks, and their performance was primarily evaluated against",
        "label": 0
    },
    "1263": {
        "output": "[INSTR] The following code snippet explains how to write a patient-level eligibility. Note that when you assign the number of assessment, you need to set the number to the value 1 first. To print the result, you call print(f\"Patient-level eligibility: {patient_level_eligibility: }\") at the last line. : You should think that there are four patients in total in the note. \n[/INSTR]\n\n### RQ3: Is the code snippet in Section E correct/good?\n\nIf not, please submit a pull request at following link: <https://github.com/BioMedICU/exercise021/pull-requests>\n\n## Summary\n\nFirst, you were asked to write the number of assessments for the patient-specific patient-level eligibility, and we expected you to write 4. Next, you were instructed to write the number of assessments for the overall trial-level eligibility, and you were expected to write 4. Finally, you were asked to decide whether a patient with the ID number 4 meets the inclusion criteria of the clinical trial ID number. In the final comment in the Note, you were expected to write `1) Eligible.`. After finishing the assignment, please submit your code here to obtain the answer key.\n\n\n>\n# #Note\n\nID number of patient: 4\nInclusion criteria:\n\n* Pancreatobiliary diseases that are eligible for EUS-guided transenteric drainage\n\n* The patient who aged from 20 to 80 years. Legally acceptable representative must be capable of giving written informed consent prior to participation in this study\n\n* Target lesion that is accessible through the transenteric approach\n\n* The woman of child-bearing age must be negative from the pregnancy test in order to participate in this study\n\n\n* The patient who is willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures\n\n* The patients should not have any unacceptable conditions (e.g., physiological, familyism, social, geographical) for medical follow-up and adaptation of the study.\n\n\n* Eligibility factors:\n\n* Hyper",
        "label": 0
    },
    "1264": {
        "output": "## Instructions\n\n### Part 1, Preventive Instruction\n1. You have a patient note and an inclusion criteria for a clinical trial. A patient may meet the inclusion criteria or not. When a patient meets an inclusion criteria and at the same time there is a contradiction with another criterion, it is necessary to choose the criterion which allows to give the highest number of participants to the trial.\nMake your choice by saying if the choice is appropriate.\n\n### Part 2, Improved Instruction\n1. In this trial, a patient can be excluded on the basis of exclusion criteria (EC) or can be included into the study on the basis of the inclusion criteria. Let's suppose that the research team was wrong in the process of recruiting a patient who did not have the appropriate eligibility. It means that she was eligible, but they did not detect it. If we suppose that the patient undergoes some additional investigations by physician and the EC are reconsidered, what could the physician find? Choose one answer.\n\n### Part 3, Cognitive Interview\nYou are a very helpful assistant for clinical trial recruitment. As a new research assistant, you have to give an answer to your colleague who asks you:\n- What is the most difficult to understand in the trial summary of inclusion criteria?\n- What is the key point of understanding the trial-level eligibility?\n\n### Part 4, Final Quiz (12 questions)\n<EOD> A pilot study of self-administered cognitive testing to screen for mild cognitive impairment among women treated for breast cancer: a diagnostic test accuracy study\nBackground Mild cognitive impairment is a common but undetected condition among breast cancer survivors which is associated with poor quality of life and risk of dementia if left untreated. Self-administered computer cognitive assessments could be a convenient but accurate way to identify women at increased risk of cognitive impairment after cancer treatment. Purpose This study aimed to test the feasibility of a self-administered computer cognitive assessment as a tool to screen for mild cognitive impairment in a sample of breast cancer survivors. Methods This diagnostic test accuracy study of breast cancer survivors recruited 65",
        "label": 0
    },
    "1265": {
        "output": "![INST] TL:\nThere are several factors that affect the calculation of eligibility assessment. Factors that increase the risk of not meeting eligibility criteria include older age, greater length and severity of disease, more comorbidities, and lower performance status. \n\nIn order to prevent your decision from being affected by this bias, repeat the following step for all patients: \n```\ntrial-level eligibility: not_taken()\n```\nBy this way, it is eliminated the impact of the above factors on the eligibility decision. [/INSTR] \n\n\n## Summarizing\nIn the data analysis phase, the investigator is asked to calculate the frequency of eligibility. The answer is the ratio of subjects whose eligibility is equal to 0 to the number of subjects: 0<eligibility_assessments<2.\nThe frequency of exclusion depends on the number of subjects enrolled, the number of exclusion reasons, and the frequency of the reasons. It is computed as the ratio of subjects whose exclusion reason score > 2 to the number of subjects: >2<exclusion_assessments<3.\nThen we present the example, which shows the eligibility assessments. The number of subjects whose eligibility assessment is 0: 0<eligiblemission_assessments<3. The percentage of subjects excluded: 21% (19/91).\nWe also want to compute the frequency of patients who are eligible for a screening. The frequency of patients eligible for screening is equal to the ratio of subjects whose eligibility assessment is 2 to the number of subjects: 2<eligibility_assessments<3.\nThen we present the example, which shows the eligibility assessments. The number of screenable patients: 74%. And the number of subjects eligible for screening: 74% (47 patients). The frequency of the patients with eligibility assessment equal to 0 is 0% (0 patients).\nPlease, give your estimates in the following boxes and see the expected values in the upper part.\n<EOD> Oncology nurse navigator improves quality of life in lung cancer patients receiving palliative care\nAim and background There is a growing demand in",
        "label": 0
    },
    "1266": {
        "output": "If the trial-level eligibility is 3, the patient is not eligible to participate in this clinical trial.\n\n# Eligibility assessment\nYou have to provide the program with a clinical trial and a list of patient profiles (patient note). The program uses the patient to compute trial-level eligibility. It can also assess the individual-level eligibility. Note: trial-level assessment is faster; it returns 2, 1, or 0, but doesn't compute the patient-level eligibility.\n[EAST]\nIn the first window you define the clinical trial: \n[/EAST]\nIn this window, you can define the criteria of the clinical trial. In the first section of the 'inclusion and exclusion criteria', you define the main inclusion and exclusion criteria: clinical trial name, conditions, trial phase (phase 2, 3 or 4). In the second section, you can define additional selection criteria: randomization (Yes or No), censoring (Yes or No), and treatment arm (Yes to all, No any). In the last section, you can enable the calculation of the trial-level eligibility (Yes). To determine the trial-level eligibility, every patient-level eligibility has to be computed, with no patient-level eligibility = No trial-level eligibility.\n\n## Inclusion and exclusion criteria\n\n## Additional selection criteria\n\n## Trial-level eligibility\n\n\nIn the second window, provide a list of patient profiles: \n[/EAST]\nIf all patient profiles (profile notes in the sample dataset) are eligible, then all trials are also eligible. If some profiles do not meet the trial criteria, then that trial is ineligible for this group of patients. This eligibility decision is not individual-level eligibility; for this one you have to specify the individual-level eligibility for each profile separately in the third window. You should provide a profile note and make a selection.\n\n## Trial eligibility for patient profiles\n\n# Individual-level eligibility assessment\nYou can define the trial eligibility on the individual-level by making a selection on how much the profile of the patient has to match his trial criteria. If the trial-level el",
        "label": 0
    },
    "1267": {
        "output": "- A1. Write your own `Trial-level` function\n  - [INST] Test a patient by `patA.Trial-level()`.\n  - When finished, [INST] type `Trial-level`.\n\n- A2. Call the `Trial-level` function from every `if-else` clause\n  - [INST] Test a patient by `if patient.InclusionCriteria then`.\n  - When finished, [INST] type `Trial-level`.\n\n- B.1 Write your own `CheckEligibility` function.\n- B.2. Write your own `CheckEligibility` function.\n\n- #4.1 A4. Call the `CheckEligibility` function from the `for` clauses\n - [INST] Write a for loop.\n- When finished, [INST] type `CheckEligibility`.\n\n- #4.2 A4. Call the `CheckEligibility` function from the `for` clauses\n - [INST] Write a for loop.\n- When finished, [INST] type `CheckEligibility`.\n\n- #5.1 A5. Assess the trial level eligiblity for all patients in the first group `ifelse` clause\n - [INST] Assess the trial level eligiblity for all patients in the first group `ifelse` clause.\n- When finished, [INST] type `patient.TrialLevelEligiblity`.\n\n- #5.2 A5. Assess the trial level eligiblity for all patients in the first group `ifelse` clause\n - [INST] Assess the trial level eligiblity for all patients in the first group `ifelse` clause.\n- When finished, [INST] type `patient.TrialLevelEligiblity`.\n\n- #5.3 A5. Assess the trial level eligiblity for all patients in the first group `ifelse` clause\n - [INST] Assess the trial level eligiblity for all patients in the first group `ifelse` clause.\n- When finished, [INST] type `patient.TrialLevelEligiblity`.\n\n- #5.4 A5. Assess the trial level eligiblity",
        "label": 0
    },
    "1268": {
        "output": "## [T] How many subjects would be enrolled?\nLet's discuss this part with clinical researcher. \n\nHere is your analysis. In the given patient note of the clinical trial, 2 out of 15 patients are excluded due to the following three factors: \nCognitive impairment\nNondiscordant medication\nFourteen are eligible to participate in the clinical trial based on the following three factors: \nCognitively intact\nDual-discordant medication\nAlzheimer's disease\n\nAs a result, a simple proportion of 14/15~1/5, i.e., 20% of the patients with metastatic colon cancer need to be enrolled in the clinical trial, because those 20% are eligible for recruitment and able to consent to participate in the trial. \n\n\n14/15 = 93% = (14/15) \u00d7 (100 \u2013 93%) = 51% = 0.51\nIn the clinical study given  `50` patients.\n\n<EOD> TREATMENT OF A GARGANTUAN MELANOMA AND SKIN TUMORS WITH NANOPARTICLES, STEREOTACTIC IRRADiation, AND RADIOSENSITIZING CHEMOTHERAPY*\nAbstract Background: A man with a disfiguring face melanoma was seen for evaluation. He had had two previous resections for cutaneous and subcutaneous melanoma involving the right temple, right cheek, and scalp. His past medical history was also significant for hypertension, coronary artery disease, asthma, and osteoarthritis, and the patient was classified as American Joint Committee on Cancer (AJCC) Stage 2, T4aN0M0, IIIA. He was referred to the University of Arizona for potential treatment with nano-particles, stereotactic irradiation, and radiosensitizing chemotherapy of the melanoma. Methods: The radiosensitizing drug Cisplatin was given for 5 days, and a dose of 2400 centigrays (c",
        "label": 0
    },
    "1269": {
        "output": "## How To Use the BMJ Stem Format\nIn the BMJ Stem, a Stem is a set of code lines which are wrapped by a template-driven block, an inner container block.\n\n[BMJ]     In Stem template format, the headline is the same as the article title. If a study was published, we need to include the title of article that contained the dataset. However, in most cases the original article has not been published. For that situation, we can add the words \"unpublished\", \"abstract\", \"full text not available\", \"submitted to a journal\", or replace the published study title with the words \"descriptive study/a descriptive study\", \"cohort study/a cohort study\", \"retrospective study/a retrospective study\". Note that an unpublished, incomplete study must be referred to in the headline as, \"descriptive study (unpublished/abstract)\".\n\n[NAME]     The author list of a study consists of the lead author with a highest education degree and a maximum of 5 authors. If multiple authors are affiliated with the same institution, we should list them alphabetically with different superscripts such as 1 and 2. We include the information of lead author affiliated with the dataset such as institution, department, location, and country. We do also give the information about the data source author, e.g., author of publication or dataset. If there is more than one data source author, use superscript. It is preferred that the head author (affiliated with the dataset) appears at the end.\n\n[YEAR]     In the BMJ Stem, the year is always used to specify the date that the data was collected. The data collection was carried out from February to April 2019.\n\n[METHODS]     In the BMJ Stem, methods section only includes information about how data was collected. If no data was collected directly by the author, the data was extracted from original researches.\n\n[RESULTS]     In the BMJ Stem, results section is organized using tables (e.g., Figs 1-5, . It is required that this section is included.\n\n[COMMENT]     There are some guidelines on how to write a comment of the dataset.",
        "label": 0
    },
    "1270": {
        "output": "[\n\n[\n\n<EOD> Molecular mechanisms of the renin\u2212angiotensin system in cardiovascular disease\nThe renin\u2212angiotensin system (RAS) is a fundamental regulator of fluid and electrolyte balance in vertebrates, as well as playing a role in the development, structure and function of blood vessels, heart, and kidneys. The RAS is essential for survival as there are fatal consequences for even a temporary disruption of RAS activity caused by complete genetic deficiency of renin (Ren1c) or angiotensinogen (Agt). However, the same cannot be said for sustained deficiency of angiotensin\u2010converting enzyme (ACE, Agt) or angiotensin\u2010converting enzyme type 2 (ACE2, Agtr2), the catalytic and putative decoy receptors, respectively, of angiotensin II (AngII) formation from angiotensin I (AngI). Molecular characterization of the Ace, Agtr1a, Agtr1b, Agtr2 loci and the tissue\u2010specific expression patterns of ACE, AT1aR, AT1bR, AT2R and ACE2 has unveiled a multitude of mechanisms by which the AngII cascade can be controlled. The complexity of RAS regulation in the cardiovascular system has also been illuminated by the recent characterization of tissue\u2010specific knockout models and the use of chemical inhibition or transgenic and adenoviral approaches to manipulate and manipulate levels of RAS components.<EOD> Effect of Cystic Disease and of Enzyme Deficits on Urinary Enzymes in Patients with Inherited Renal Disorders\nIn many of the inherited hereditary renal disorders, the morphological and/or chemical heterogeneity of nephrons, especially of the collecting tubules, is often much greater than that of other functional groups of tubules. Therefore, in some of them, the urinary excretion of enzymes may provide a better estimate for the heterogeneity of the morphological and/or chemical properties of renal tubules than conventional urinary tests.<EOD> Intra-rheumatoid synovial neoplasia",
        "label": 0
    },
    "1271": {
        "output": "## 12.3.19.5 Exercise 3: `SELECT`\nIn the exercise below, you will apply the `SELECT` query. In the exercise, you are given a patient ID number and you need to find patient information from the `patient` table.\n\n## Exercise 3: `SELECT`\n\n- Patient ID \"162. Patient table, which is based on a database we developed ourselves, contains the data of the patients you followed.\n\n```\nSELECT * FROM patient\n```\n`SELECT` query is the same as in `MySQL Workbench.`.\n\n![SELECT Query]({{'/static/images/tutorials/query-language/query-language-05-exercises/SELECTQuery.png' | imgurl}}){: .description}\n\nIn `MySQL Workbench.`, click the toolbar icon `SQL` and type the following query:\n!`SELECT * FROM patient;`\n(1) On the left, `Select query` tab is displayed. \n![Snippertitle]({{'/static/images/tutorials/query-language/query-language-05-exercises/QueryTitle.png' | imgurl}}){: .description}\n\nClick the checkbox for the query, e.g., `Select query: SELECT * FROM patient;` and click `Run query.`. A results box is displayed. Copy the query `Select query:` to the text area on the left as `SELECT; * from patient;` and click the toolbar icon `SQL`. The query window is displayed. `Select query:` to the text area as `SELECT; * from patient;`. The results are displayed. Copy the query to a text file.\n\n!`SELECT * FROM patient;`Clicking the mouse button `F1` will display the results. It is not a good idea to store the MySQL Workbench. results in a Windows 10 environment. The file may disappear after a while!\n\n`SELECT` query and `MySQL Workbench.`: \n\n- The `SELECT` query retrieves all records from table (database) and displays them on the interface.\n- The query can be seen in the results table in the lower right corner. The output of the query is displayed. The left side is an alias of the same data, which",
        "label": 2
    },
    "1272": {
        "output": "[A_BLOCK_NOT_NEEDED]\n<EOD> Interaction of dietary glutamate supplementation with high ambient temperature and dietary oxidized fat supplementation on performance, reproductive and immune indices, digestibility estimate, carcass quality and blood metabolites of mature cows\nAbstract Objective Dietary oxidative stress and heat stress on bovine reproduction have limited researches up to now. In this respect, the current study was conducted to study the potential effects of dietary glutamate supplementation on reproductive and immune indices, digestibility estimate, carcass quality and blood metabolites of dairy cattle exposed to hot temperature. Methods Four multiparous Holstein Friesian cows (249.51 \u00b1 2.91 kg live weight) were randomly assigned in a 4 \u00d7 4 Latin square design to four different treatments including control diet (CON: 17.05% CP, 8.80% crude fat and 40.85% NDF); oxidized diet (OXID: CON + 10% oxidized fat); oxidized diet/glutamate-supplemented diet (GXOXID: CON+10% oxidized fat and 10% glutamate); and control diet/ glutamatesupplemented diet (GXCON: CON+10% glutamate). The trials lasted for nine weeks and cows were fed their diets ad libitum in two ruminally segregated groups from May to July, when the ambient temperature was above 32\u00b0C to evaluate the effect of high ambient temperature. Results The results showed a 13%, 14% and 9% improvement for milk yield, milk components and total solid content of milk respectively in GLP compared to OXID group. The glutamate supplementation could increase the percentage of milk protein, chlorophyll index (%), milk fat and cholesterol. Moreover, it decreased the feedlot (FSC) index. Furthermore, reproductive performance showed decreases in culling rate and duration of waiting for insemination per estrus. Meanwhile, reproductive efficiency was the best",
        "label": 0
    },
    "1273": {
        "output": "For an output example about the eligibility determination and the three-level assessment of eligibility, you can refer to the following link. \n[link](http://104.115.226.122:3838/CSIL/csil-eligibility-assessment-output.html)\n\n# Implementation\n\nFirst of all, you should create an initial instance of class Includes, which is the container of the trial-level exclusion criteria and is implemented by the class InitialContainer. When instantiating an instance of class InitialContainer, you should call the constructor for argument of type std::string::const_reference, input the name of the trial-level exclusion criteria. You can see the sample implementation of the constructor in the file `IncludesConst.cpp`.\nSecondly, you should create a vector of type class Includes in the file `InitialContainer.cpp`. The container will instantiate an object of type InitialContainer through the default constructor, and automatically add the names of the three exclusion criteria.\n\n## File content\n\n    /*\n *  Copyright 2017-2018 <NAME>\n *\n *  Licensed under the Apache License, Version 2.0 (the \"License\");\n *  you may not use this file except in compliance with the License.\n *  You may obtain a copy of the License at\n *\n *    http://www.apache.org/licenses/LICENSE-2.0\n *\n *  Unless required by applicable law or agreed to in writing, software\n *  distributed under the License is distributed on an \"AS IS\" BASIS,\n *  WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.\n *  See the License for the specific language governing permissions and\n *  limitations under the License.\n */\n\n#include <iostream>\n#include <vector>\n#include <stdint.h>\n\nnamespace csil\n{\nclass Includes\n{\npublic:\n    Includes();\n    ~Includes();\n\n    void add_exclusion_criteria( const std::string& excl );\n    const std::vector< std::string >& get_exclusion_criteria() const",
        "label": 2
    },
    "1274": {
        "output": "<EOD> Intraperitoneal chemotherapy after surgical cytoreduction enhances progression-free and overall survival irrespective of HIPEC versus IPEC.\n4020 Background: Surgical cytoreduction followed by intraperitoneal chemotherapy (IPC) is the treatment of choice for selected patients with peritoneal carcinosis. Peritoneal carcinosis is a diffuse disease, which has been considered intraperitoneally confined. Recently, a meta-analysis reported a survival benefit with IPC (I vs C). However, the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) on overall survival (OS) is not clear. We therefore analyzed the impact of HIPEC on OS using propensity score (PS).\n\n\nMETHODS\n159 patients (pts) were analyzed. Patients' characteristics, operative and cytoreductive procedures are described in table. OS was analyzed by the Kaplan-Meier curves (KM). Propensity score (PS) was computed. We performed PS stratification (dichotomized) according to the following covariates: age, peritoneal carcinomatosis index (PCI), completeness of cytoreduction (CC), and HIPEC. A proportional hazards model (Cox regression) was performed to describe the impact of each covariate on survival.\n\n\nRESULTS\nMean age was 60, 54% had gastric cancer, 87% were in CC-0, 65% had PCI between 5-15. 51% received HIPEC, 82% had oxaliplatin, and 100% had cisplatin. Median OS was 36.2 months, and the median OS for pts. with and without HIPEC was 40.3 and 24.2 months, respectively. The KM analyses showed that HIPEC significantly increased the probability of OS. KM analyses stratified by the PS revealed that the survival difference between pts. with and without HIPEC was maintained in all the pcs",
        "label": 0
    },
    "1275": {
        "output": "Output: <table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"> \n<tr> \n<td>1) Excluded</td><td width=\"200\" valign=\"top\">- Inclusion criteria</td>\n<td valign=\"top\">-1) <span class=\"label-text\">Inclusion criteria</span> (The investigators designed the randomized controlled trial to clarify the practical advantages of SLA over CLA in pediatric population. [INSERT HERE] [INSERT HERE] [INSERT HERE])</td> \n<td valign=\"top\">-<span class=\"label-text\">Peri-appendiceal abscess</span><br /> <span class=\"label-informative\">1) Not relevant</span> (The trials designed to detect possible impact or benefits of study drug on the symptoms/diseases or medical conditions. A trial that has no specific disease target or symptom target but investigates side-effects or safety is called a non-interventional trial. [INSERT HERE] [INSERT HERE])<br />\n<span class=\"label-text\">Peri-appendiceal abscess</span><font size=\"-2\"> <span class=\"label-text\">Peri-appendiceal abscess</span><br/>\n<span class=\"label-informative\">1) Not relevant</span> (The trials designed to detect possible impact or benefits of study drug on the symptoms/diseases or medical conditions. A trial that has no specific disease target or symptom target but investigates side-effects or safety is called a noninterventional trial. [INSERT HERE] [INSERT HERE])<br/> <span class=\"label-text\">Inclusion criteria </span> (the investigators designed the randomized controlled trial to clarify practical advantages of SLAP over CLA in pediatric population.<br/>\n-0) <span class=\"label-text\">Inclusion criteria (the investigators designed the randomized controlled trial to clarify the practical advantages of SLA over CLA in pediatric popula-tion.)</span> -1) In- (the investigators designed the randomized controlled trial to clarify the practical advantages of SLA over CLA in pediatric population.)</span> -2) <span class=\"label-text\">",
        "label": 0
    },
    "1276": {
        "output": "**Note:** You may need to write the first two lines in different colors.\n[Javascript sample]\nThe following [R] code and [Jupyter notebook](https://jupyter.org/notebook/?url=https%3A%2F%2Fraw.githubusercontent.com%2FSangHeeKim13%2Fcoursera_clinical_NLP%2Fcourses%2Finstitutional_eligibility%2Finstitutional_eligibility_clinical_recruitment.ipynb) may help to run all the sample analysis. [ ]\n\n* * * \n[HTML sample]\n<html>\n<body>\n[ ]\n<h1 id=\"clinical-trial\">Clinical trial recruitment notes</h1>\n\n<h3 id=\"institutional-eligibility-clinical-recruitment-sample\">Institutional eligibility and clinical trial recruitment sample</h3>\n\n<script>\nvar text1 = document.getElementById(\"clinical-trial\").innerText;\nvar text2 = document.getElementById(\"trial-level-eligibility-clinical-recruitment\").innerText;\nvar text3 = document.getElementById(\"trial-level-eligibility\").innerText;\nvar text4 = document.getElementById(\"clinicaltrial-summary\").innerText;\nvar text5=\"\n<table>\n  <tr><td><pre>\n    Title\n    </pre></td>\n    <td><pre>[...]</pre></td><br>\n    <td><pre>[...]</pre></td>\n    <td><pre>\n    </pre></td>\n  </tr>\n  \n  <tr><td><pre>\n    Patient\n    </pre></td>\n    <td><pre>[...]</pre></td><br>\n    <td><pre>[...]</pre></td>\n    <td><pre>\n    </pre></td>\n  </tr>\n  \n  <tr><td><pre>\n    Presentation of the note text\n    </pre></td>\n    <td><pre><code class=\"python\"><span class",
        "label": 2
    },
    "1277": {
        "output": "The sales promotion was made up of different ways of visiting medical professionals:\n- One visit in medical offices to a physician.\n- Two visits in medical offices to a physician plus two visits in medical offices to",
        "label": 0
    },
    "1278": {
        "output": "### Mini-Course on Python\n\nThis mini-course explains the basic data types, operators, and structures of Python. It is especially designed to provide the audience with fundamental knowledge in Python. As a bonus, it also briefly explains the idea of testing in computer programming. If you want to learn more, visit the full course [here](https://www.youtube.com/playlist?list=PLF_BtUbiKOcV_pXyL2kX1CX7i-qKOVtFf).<EOD> Rethinking the Role of the Uterus in the Pathogenesis of Sepsis\nUterine dysfunction is a complex event characterized by uterine inflammation, endoplasmic reticulum stress, myometrial hypoxia, and increased cervical dilatation, which facilitates the bacterial translocation and contributes to the pathogenesis of sepsis. The myometrium, in particular, has a pivotal role in regulating fetal and maternal homeostasis, and, by extension, reproductive health and wellbeing. Several cell types, including uterine endothelial cells, immune cells, and smooth muscle cells are involved in multiple endogenous and exogenous uterine pathways. However, their involvement in the host\u2019s response to the presence of sepsis pathogens and their consequences for pregnancy complications remains unclear. In this review, we provide a comprehensive overview of the involvement of the above-mentioned uterine cell types in the pathogenesis of sepsis. Furthermore, we describe the cellular stress response and myometrial hypoxia in utero. Finally, we present the cellular crosstalk between different uterine cell types and sepsis pathogens.<EOD> A case of late postpartum hemorrhage secondary to severe fibroid rupture in the first trimester.\nA case of severe fibroid rupture in pregnancy is presented. At 13 weeks of gestation, an ultrasound showed a fistula between the uterus and urinary bladder, and massive hemoperitoneum. Laparotomy revealed that the rupture had occurred at the posterior wall of the uterus (4\u00d7",
        "label": 2
    },
    "1279": {
        "output": "As such, your function should look like this:\ndef run_eligibility_check(row):\n     eligible = True if row['Age'] <= 80 and row['Gender'] == 'male'\n     and row['Pneumonia Severity Class'] in 'IVA IVB IVA'\n     and row['Pneumonia Severity Class'].split('+')[0]!='IV'\n     and row['Chemotherapy Type'] == 'None' or row['Chemotherapy Type'] != 'Cisplatin'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[0] != '5.0'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'c'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != '5-FU'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'F'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'FU'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'U'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'Leucovorin'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != '5-FU'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'Bleomycin'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'Cisplatin'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'Doctors's choice'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'Irinotecan'\n     and row['Chemotherapy Type'].split('+')[0].split('.')[1] != 'Irinotecan'\n     and row['Chemotherapy Type'].split('+')[0].split",
        "label": 0
    },
    "1280": {
        "output": "Your job is done! \n\nNow let's see how we can use this feature to deal with the scenario where a patient note contains more than one observation. Let's assume we have the following patient note: \nTitle: Hysterectomy for Heavy Menstrual Bleeding #F596\nDiagnosis:\n- 268.92: Dysfunctional uterine bleeding\n- 269.82: Other specified bleeding disorders\nNotes:\n- Vaginal ultrasound was performed and revealed a mass in the uterus. An ultrasound-guided fine-needle biopsy was performed and it showed leiomyoma.\n- The patient was taken to the operating room for operative intervention.\n\nThere is a hysterectomy code, so we need to check whether the patient has undergone the surgery. We know that the patient history is not enough to determine this, since we do not have any information about the time of the surgery (a surgery code can be from 10 or more years ago). So we cannot just use the diagnosis code like we did to the last patient. We need to make a surgery code by looking at the operation note. Let's do that.\n\nWe can check the operation note to see whether the procedure has been performed or not. The operation note might have the following format, where * means that the field is omitted in some instances:\n- ID: H5562\n- Procedure date: 2016.10.24\n- Clinic: **Gynecology**\n- Operating unit: **Operating Room**\n- Type of anesthesia: General Anesthesia\n- **Operation note**\n- **Urgency**:\n- **Elective**\n- **Surgery code**: 650.37: Hysterectomy\n- **Final Diagnosis**: **Uterine Leiomyoma**\n- Other diagnosis:\n- **Dysfunctional uterine bleeding**\n- **Malignant neoplasm of uterus**\n\nWe do not have the operation note for the patient. So instead we can use the general procedure code 650.36 from",
        "label": 0
    },
    "1281": {
        "output": "Answers, Submissions & Discussions for Code-A-Thon 2021 : HacX\nHacX is open from 2017. Students or those who want to become a good programmer should join it.\nIf you are a student, HacX is the best place to learn. Here, students learn the basics and fundamentals of coding.\nEasy and friendly community\nWe are a group of people of different ages. We respect everyone's opinions.\nWe have a very easy to follow community. So, it's easy for beginners to ask questions and get answers.\nWe are not a school or community and we don't teach or force anyone to learn anything. We help each other. There is no force. We will never tell you to do something you don't like. Your learning will be entirely voluntary.\nAs a result, we have been very successful.\nWe have more than 200 active members on Social Media and Whatsapp Group.\nIt is a very supportive environment for beginners.\nEducational Hackathon\nHacX is the result of the work of many people and their interest in programming. Our members have written a lot of open source software by themselves. But the fact that we do not have resources is very common. We help each other in every way we can. So",
        "label": 0
    },
    "1282": {
        "output": "## Input parameters\n\nYou should first import the clinical trial code and the clinical trial note to the file. The note should contain one patient's information. \n\nHere, we take the second trial, [TUT]. We can also refer it in the main program [Code-Input-TUT.md] to obtain the first trial, [INST). You should type this code to the file [Code-TUT.py] and export it to the file [TUT].txt. \n\nThen you should also paste one patient information in [data-patient.txt]\"\n[data-patient.txt] \n\nThe name is [Patient-TUT.csv] and the data type is CSV. When you save it, make sure the file's name is [Patient-TUT.csv] for compatibility with the file [Patient-TUT.csv]. \n\nThe other parameter, [input data type], is the standard input in Bash. You choose the file type of 'CSV' if the format of your dataset is CSV. You can choose 'Text' if it is in Python's default format of 'string'.\n\nYou should fill the dataset with these three columns: [patientId], [firstName], and [lastName]. Then you should save the file in [Patient-TUT.csv] when you finish adding the information. \n\n# Examples\n\n\n## MULTIPLE TRIALS\n\nYou can run more than one trial in the folder [Tutorials] to test your skills. You just need to modify the file name (parameter, trials) before you run the main program [main.py]. \n\n# TUTORIALS\n\n\n\n\n\n\n\n\n\n**Expected results**\nThe script should provide both the eligibility and the score of each patient. The inputted file should consist of three columns, [patientId], [firstName], and [lastName]. The expected output should look like this. \n\n        Eligibility: [patientId] 0) Excluded 1) Not relevant 2) Eligible\n        Score: [patientId]`\n\n### Example\n\nLet's assume that the name of the inputted dataset is [Patient-TUT.csv]. And the name of the clin",
        "label": 0
    },
    "1283": {
        "output": "Your assessment of eligibility is shown as the number of stars by each row. (0 star) The patients does not meet inclusion criteria. Excluded.\n(1 star) Patient may be relevant but we don't have enough data to assess eligibility. Not relevant.\n(2 stars) The patient meets all inclusion criteria. Eligible.\n\n##[INST]\n\n##\n####2. Assess the patient's response to the clinical trial\nHere are two questions to help assess how the patient responded to the clinical trial. First, we ask whether the patient met the minimum criteria defined in the clinical trial:\nWhat's the minimum criteria that the patient has to meet? This is not the same as an inclusion criterion, but indicates the minimum value that the patient has to reach.\nSecond, we ask whether the patient's health improved during the clinical trial, e.g. his/her ALT got into an acceptable limit, say below 50 for non-cirrhosis patients and below 100 for cirrhosis patients.\nHow do you respond to the clinical trial? Excluded (minimum value not reached) Included (meets minimum value and other criteria) Not relevant (does not meet minimum value)\n\n## Patient record\n[CLOSE THIS STUDY] (1) Do the following task to generate a report of the patient. You can choose to include or exclude any of the patient data and can also use your own parameters to generate a report that's unique to you and to your patients.\nWhen the user clicks `Generate report of patient`, a new patient record form appears. Users can include or exclude variables by ticking/unchecking the box next to the column header. \n(3) At the top of the form, click `Generate report`. The report will appear in a pop-up window.\n\n####2. Make a decision\nOnce you have recorded the patient information necessary to evaluate the clinical trial (see [CLOSE THIS STUDY] [CLOSE THIS STUDY]), you should evaluate the trial-level eligibility of the patient. You should make a trial-level eligibility decision on the basis of the information collected. The following are some criteria to assess the trial-level eligibility. \n\n1. Eligible",
        "label": 0
    },
    "1284": {
        "output": "You should provide each patient record file with the `Check eligibility: ` tag, e.g., `Check eligibility: Yes.`. The patient record file should contain only one `Check eligibility: ` tag. [INST] Hello, you are a helpful assistant for a clinical trial to assess the safety and effectiveness of a cardiac rehabilitation intervention in an outpatient setting. You should assess the patient's eligibility of a clinical trial including physical characteristics (e.g. chest pain, smoking) and mental characteristics (e.g. anxiety, depression). The cardiac rehabilitation is an important outpatient intervention to facilitate patients' return to normal life after a heart condition, heart attack, or bypass surgery. The intervention consists of individual or group educational and physical exercises. The goal of the intervention is to restore lost cardiovascular fitness, improve heart function, and prevent heart problems. The rehabilitation period starts after the patient is discharged from the hospital. The rehabilitation may be provided within hospital, home-based, or community-based setting.\nThe results of the assessment of eligibility have a three-point scale: 1",
        "label": 0
    },
    "1285": {
        "output": "If the patient meets both the inclusion criteria and none of the exclusion criteria, then the scale is two (second). If the patient has sufficient information to qualify for the trial and meets the exclusion criteria, or the patient does not have sufficient information, the scale of the eligibility is zero (zero). If the patient does not meet the inclusion criteria, then the scale of the eligibility is zero. \nYou should repeat Trial-level eligibility with this last code. [INST]\n\n## Clinician 1\nYou are a clinician (doctor) visiting the emergency room. The patient told you that she has had epigastric pain with nausea and vomiting starting 4 days ago in her right upper quadrant, and it got worse after fatty food intake. Since it is not an urgent case, you have time to listen to the entire history.\n\nThe patient has had a few previous episodes of the complaints. She has visited the emergency department four times in the previous year, once in the second year ago, and again once in the sixth month ago. Once, she visited a gastroenterologist with a complaint of jaundice and nausea, and once she was examined in the internal medicine department due to recurrent vomiting. These three visits did not lead to a diagnosis. Since it is not an urgent case, you have time to listen to the entire history. You understand that since the complaints started, she has been on a diet in order to lose weight.\n\nShe has two children, and is not menstruating yet, although she has been trying for a pregnancy for the past year. She has a normal BP, BMI. She has no history of smoking or alcohol use. She said that she has not used substances. She has a past medical history of hypercholesterolemia and NVD. Her son is in a wheelchair, with quadriplegic cerebral palsy.\n\nYou understand that you need to perform some investigative procedures, because gallstone disease does not explain the patient's complaints. The only information that you have is her obesity.\n\nWhat do you think needs to be examined? [Clinician 1]\n\nClinician 2\nYou are a clinician (doctor)",
        "label": 0
    },
    "1286": {
        "output": "**Trial-Level Eligibility\n**\n\n\nOutputs:\n\n\n**Say hello to the user.\n\n1: Let the users know that they are running this program. The program should print the following message: _\"I am happy to meet you!\"_ SayHello is a function that simply calls SayHello with no arguments.\n\n```\n    @{Trial-level eligibility = 2)}\n        SayHello()\n```\n\n\n# Exporting the data\n\nYou should export the data about the eligibility of patients for each trial to Excel files. They must be of the following format:\n```\n    0) Excluded; \n    1) Not relevant; \n    2) Eligible;\n```    \n\nIf the patient belongs to trial 2, then the value in the patient's trial-level eligibility column will appear `2`. If the patient doesn't, then the value appears`0`, otherwise, the value appears `1`. In each row, you should show the ID of the patient, trial number, and the trial-level eligibility\n\nThe list of patients for each trial should be placed inside a sheet entitled \"patients\", while the trial criteria sheet entitled \"inclusion criterias\" in each trial should be placed in the sheet entitled \"inclusion criteria\" in the workbook \"patients_inclusion_criteria\".\n\n\n**Exporting the Result to Excel Files\n\n1. Open Notepad.\n1. Type the following code:\n```\nfunction ExportTrialtoExcel(listOfTrial) {\nfor ([i in listOfTrial]   \n     {\n    for ([j in [1]]   \n      { \n        if ($trial-level eligibility) equals \"0\"   \n         {\n          #write \"=\"&$trial-level eligibility \n         }\n       else \n        {if($trial-level eligibility) equals \"1\"   \n          {\n           #write \"!\"&$trial-level eligibility \n          }\n          else\n            #write \"[\"&$tie-level eligibility \n         if($tie-level eligibility) equals \"2\")   \n          {\n            #write \"!)\"&$tie-",
        "label": 0
    },
    "1287": {
        "output": "[TEST]<EOD> Molecular Diagnostics of Mycobacterial Infection: A Focused Review\n\nAs the burden of mycobacterial infections continues to rise worldwide, novel molecular diagnostics are needed to both confirm the diagnosis and provide important insight into the epidemiology of these infections. Here, we review the most recent literature relating to the molecular diagnosis of mycobacterial infections using PCR-based techniques, from both an epidemiologic and diagnostic point of view. In particular, we discuss the challenges and obstacles faced by PCR diagnosis. We also discuss novel approaches to the diagnosis of these infections, as new technologies enter clinical trials (e.g., NG-PCR, qG-PCR, RMT-QT, Lamp, and Loop-mediated Isothermal Amplification). Furthermore, we highlight other more specialized PCR-based diagnostics including serological, TST, IGR/IS6110 specific, and 16S rRNA-based tests. Each of these molecular approaches will be discussed with respect to their suitability for use in various patient populations.\n\n# Introduction\nTuberculosis (TB) is a highly infectious disease caused by the bacterium, Mycobacterium tuberculosis (Mtb). In 2016, an estimated 3.6 million cases of TB were reported to the World Health Organization (WHO)and it was responsible for the deaths of 1.3 million individuals [bib_ref]  A case-control study of the performance of two new tuberculosis serological assays, Musa [/bib_ref] . Of the cases of active TB, 8.6% occur in children (under the age of 18). Although Mtb is the cause of almost all cases of TB, the global burden of TB is mostly due to infection with other mycobacterial species which cause extrapulmonary diseases. The burden of disease due to non-tuberculous mycobacterial (NTM) infections is on the rise [bib_ref]  Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon, Henkle [/bib_ref]",
        "label": 0
    },
    "1288": {
        "output": "[CODE]\nSELECT * FROM Intake_eligibility WHERE trial_id = 1\nEND;\n[/CODE]\n\n\n### What is the expected output?\nIn this exercise, your supervisor wants to know whether the patient's eligibility is 1) Excluded or 2) Not relevant or 3) Eligible. Therefore, you should make a single-row query as below.\n\n\n```snake\nSELECT * FROM\n       Intake_eligibility\nWHERE trial_id = 1\n```\n\nAfter the query, the expected output is shown:\n\n| trial_id | patient_id | trial_level_eligible_scale | trial_level_eligibility |\n|----------|-----------|-------------------------|-------------------------|\n| 1 | 1 | 2 | 2 |\n| 1 | 2 | 2 | 2 |\n| 1 | 3 | 1 | 1 |\n| 1 | 4 | 2 | 2 |\n| 1 | 5 | 2 | 2 |\n| 1 | 6 | 2 | 2 |\n| 1 | 7 | 2 | 2 |\n| 1 | 8 | 2 | 2 |\n| 1 | 9 | 2 | 2 |\n| 1 | 10 | 3 | 1 |\n| 1 | 11 | 1 | 1 |\n| 1 | 12 | 2 | 2 |\n| 1 | 13 | 2 | 2 |\n| 1 | 14 | 2 | 2 |\n| 1 | 15 | 2 | 2 |\n| 1 | 16 | 1 | 1 |\n| 1 | 17 | 2 | 2 |\n| 1 | 18 | 2 | 2 |\n| 1 | 19 | 2 | 2 |\n| 1 | 20 | 2 | 2 |\n| 1 | 21 | 2 | 2 |\n| 1 | 22 | 2 | 1 |\n| 1 | 23 | 2 | 2",
        "label": 0
    },
    "1289": {
        "output": "### Repeat eligibility\nYou should use `Eligibility_Assessment` to count how many times you have checked `patient 1` is eligible for `clinical trial 2` so far.\n\n![Eligibility_Assessment](eligibility_assessment.png)\n\n\n[INST] In some applications, you should repeat the eligibility assessment using `Eligibility_Assessment`. As `Eligibility_Assessment` is a hidden variable, it is generally done by a program or script which is usually integrated to the software development flow. However, in this problem, our patient is still a generic representation, and it is helpful to think about eligibility in a patient case study. Hence, let's repeat the eligibility assessment using a script.\n\nTo check who is eligible, you should refer to the results you got when you used `Eligibility_Assessment`. You should record the eligibility assessment you made for each patient. 1) Eligible is 2, 2) Not relevant is 3, and 3) Excluded is 7.\n\n#### Exclude patient if any of the following is not met: \n\n* Not relevant to any clinical trial\n* Eligibility to all clinical trials\n* Not relevant to any clinical trial\n* Eligibility to all clinical trials\n\n<NAME> can be eligible for several clinical trials at once. If she met the requirement for `clinical trial 1`, then she should be assessed through `clinical trial 1: 1) Excluded;` \n\n![clinical trial 1: 1) Excluded;](clinical-trial-1-2-1.png)\n\nIf she met the requirement for `clinical trial 2`, then she should be assessed through `clinical trial 2: 1) Excluded;` \n\n![clinical trial 2: 1) Excluded;](clinical-trial-2-2-1.png)\n\nIf she met the requirement for `clinical trial 3`, then she should be assessed through `clinical trial 3: 1) Excluded",
        "label": 0
    },
    "1290": {
        "output": "### \u261e QUESTION\nCan you explain why you have included an `if-else:` statement for age 10 to 39? (There is a warning message that the `if:` and `else:` have not been matched at the end of this code block)\n\n[ANSWER]\nAs 12 is 28 years old, so in Python's mind it is greater than 18. The error is due to the fact that `if`: and `else:` are not matched. \nThe statement is like this: `if age 0 then age <= 18 otherwise age > 18 and the statements are evaluated in the order of appearance.\nTo solve the problem, you can first check if it is greater than 0-if true, compare it to 18 as this is an optional condition. If less than 18, then compare to 12 otherwise.\nTry these changes to the previous code: \n    if age >= 12 or age <= 12 and age <= 18:\n        print(\"18 or 12 to 18 years old\")\n        print(\"Trial-level eligibility: 0) Excluded\")\n    elif age >= 12:\n        ageTrial <= 18\n        print(\"12 and 18 years old\")\n        print(\"Trial-level eligibility: 2) Eligible\")\n    else:\n        print(\"18 to 12 years old\")\nprint(\"Trial-level eligibility: 1) Not relevant\") \n\n[/ANSWER]\n\n### \u261e CODE_EXPANSION\nCheck out the code to know how the program works and how to work with different variables.\nHere is a summary of the code:\n\n```python\n    # Declared variables #\n    age = input(\"Enter the patient's age: \")\n    name = input(\"Enter the patient's name: \")\n    trial_level_eligibility = 1\n    ageTrial = None\n\n    # Assessing age #\n    if age.isspace():\n        print(\"Please enter the patient age\")\n    else:\n        for i in range(10, 60 - 1, -",
        "label": 2
    },
    "1291": {
        "output": "**Expect the following:\n\n`Trial-level eligibility: 2) Eligible.`\n\nGood job! Let's code the evaluation step.\n\n## [PROG]\n\nWhen the eligiblity is evaluated with a three-point scale, we can use this function of `eval` to get the three-point scale of the trial-level eligibility:\n\n``` python\nnivolumab_info[\"Evaluation\"]\n\n{'Evaluation': 'Excluded.'}\n```\n\nFinally, we can code the output of the trial-level eligibility by replacing the output variable with `evaluation`.\n\n```python\nnivolumab_info[\"Evaluation\"] = {'Excluded': 0, 'Not relevant': 1, 'Eligible': 2}\n```\n\nThe `evaluation` is `Evaluation:` instead of `Trial-level eligibility:` because the output is a data frame. Here is the complete output in [fig_ref]  Table 2: Output of trial-level eligibility evaluation [/fig_ref] .\n\nThe inclusion criteria is the following:\n\n- Non-childbearing potential;\n- Age 18 years or older;\n- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;\n- Life expectancy of at least 12 weeks;\n- WOCBP who have negative serum pregnancy test;\n- Normal organ and marrow function;\n- Able to swallow;\n- Provide written informed consent on the form approved by the Institutional Review Board (IRB);\n- Previously treated for unresectable or metastatic SCCHN. Treatment includes definitive chemotherapy alone, definitive radiation therapy alone, or definitive chemoradiation;\n- Patients must meet all of the following histologic criteria:\n- Squamous cell carcinoma or undifferentiated carcinoma (non-keratinizing) proven anaplastic\n- Squamous carcinoma not otherwise specified (NSCC) with keratin pearls, or proven primary adenocarcinoma with > 50% of undifferentiated cells.\n- Patients must present with histologically or cytolog",
        "label": 0
    },
    "1292": {
        "output": "<EOD> A case of acute necrotizing encephalitis caused by dengue virus serotype 4 with fatal outcome.\nBackground\nDengue Virus (DENV) infection can cause the most rapidly progressing life-threatening encephalitis, but most cases can be treated successfully. We describe here a case of acute dengue necrotizing encephalitis complicated by prolonged shock and multi-organ failure (MOF) in a patient recovering clinically from DENV infection.\n\n\nCase report\nA fifty-five-year-old woman hospitalized with DENV infection and shock, was later developed respiratory failure, coma and convulsion. She died on the third day after admission. Autopsy findings revealed acute necrotizing encephalitis, pulmonary edema, and myocardial necrosis. This is the first reported fatal DENV-4 infection in Korea, and the neuropathologic findings of this patient are discussed here with previously reported DENV encephalitis cases.\n\n\nConclusion\nWe suggest that neuroimaging should be considered for the early diagnosis and management of dengue necrotizing encephalitis which is associated with a poor prognosis.<EOD> Bacterial and bacteriophage community dynamics in the drinking water system of a full scale wastewater pond.\nFor several years we have used molecular approaches to assess the dynamics of the bacterial and bacteriophage communities in the water system of a full scale integrated treatment-settling pond system. Two molecular approaches (temperate-like and virulent-like restriction digestions and terminal restriction fragment length polymorphism ) were employed to study the community dynamics in the liquid and solid phase, and bacterial communities (bacterial 16S rRNA gene sequencing) were also studied. The analysis of the microbiome of this pond, over the last six years, shows that a consistent microbiome could be consistently maintained at both the molecular and morphological levels. This suggests a long-term stability of the microbiome of this aquatic system, which reflects the stability of the treatment processes. The liquid phase of the pond was found to consist of mainly bacteria of the Bacteroidetes, Betaproteobacteria",
        "label": 0
    },
    "1293": {
        "output": "<EOD> .\nAs a part of a study into the pathophysiology of the gastric mucosa of patients with pernicious anemia (PA), the authors studied the effects of vagotomy and gastric resection (Billroth I) on the serum content of anti-intrinsic factor (AI) in 3 patients. A vagotomy was performed in all 3 of the patients after an antiendocrine (antigastric antibody) study and before the serum AI determination. Serum AI was measured by the biological technique in 10 controls and 7 out clinic patients without PA, and in these 10 controls (by fluorescence) following the administration of the synthetic challenger. In all 3 pernicious anemic patients, the serum AI concentration was reduced to a normal range after vagotomy. This decrease was significant in the 2 patients tested by both methods. The results of these 3 patients provide indirect proof that the parietal cell can directly synthesize AI.<EOD> Identification of the 65 kDa chicken heat shock protein\nThe electrophoretic mobility of the 65 kDa chicken heat shock protein changed when the protein was treated with DTT and N-ethylmaleimide and when this protein was heated. Treated with 2 mercaptoethanol, the molecular mass of the 65 kDa protein in the presence of SDS was reduced to 62 kDa. It is supposed that the 65 kDa cHSP is composed of two subunits, a 26 kDa heavy subunit (hsp 26) and a 39 kDa light subunit (hsp 39). On the other hand, the mobility of the 19 kDa protein in the presence of DTT or N-ethylmaleimide was shifted. The 19 kD protein is called the disulfide-linked heteropolymer or hsp 47.<EOD> Association of T-bet polymorphisms with asthma, allergic rhinitis and atopic dermatitis in Korean children\n\nPrevious studies have shown the T-box transcription factor T-bet may play a critical role in Th1",
        "label": 0
    },
    "1294": {
        "output": "## Clinical trials - Step 2 (Patient ID)\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. \n\nHere is the patient note:<EOD> Assessment of Bone Quality in Proximal and Distal Tibia using Finite Element Analysis\nThis study presents a new approach to estimate local bone mineral density that would take into account both local spatial bone properties and spatial dependency of local density, which we denoted here as bone quality. This local bone quality was estimated using finite element (FE) analysis to measure principal strain and local density of a set of axial human bone models under a static loading scenario. Specifically, ten models were developed for the proximal tibia and ten for the distal tibia according to different configurations using a three-dimensional geometry-based modelling method. The models were all assigned with a local Young\u2019s modulus value at each location and used for FE analysis. First, a local Young\u2019s modulus value was obtained at each location using uniaxial compression test of human tibia obtained from the open database. For bone tissue, two representative tissues were selected, trabecular bone and cortical bone. Next, the local Young\u2019s modulus value was adjusted to the age between 20 and 50 years using multiple regression analysis. The average local density estimated by X-ray computed tomography (CT) was used for each model. A static load was applied to the models at the femoral shaft and a point contact force was applied to the lower side of the tibial base. The model with the lowest average principal strain was selected out of ten models in the proximal tibia and the distal tibia. After that, an area was defined in the cross-section and a box coordinate system (the z-axis was perpendicular to the medial tibial long axis) was established in the area. The principal strain and local modulus value were obtained at the middle of the cross-section. These principal strains were then averaged and compared with the principal strains obtained from the CT-derived bone densities (CTD) in which the lower and upper bounds of the bone density obtained from CT were used as the",
        "label": 0
    },
    "1295": {
        "output": "You can choose up to 9 patients to simulate at a time. You can use the browser's \"back\" button to go back to the previous simulation. Then press the \"check\" button, check all required fields. You can evaluate your work with the automatic feedback panel at the bottom of the simulation page once you press the \"check\" button.\n\n### Congratulations! You are ready to submit a manuscript to this Special Issue! \n\n## Submission Instructions \n__Please remember to",
        "label": 0
    },
    "1296": {
        "output": "#### Assessment of Eligibility by Condition\n\nIn the third step, you will apply the exclusion and inclusion criteria in Python to each patient in the patient note. In Python, you are expected to create 2 tables to do so. The 2 tables are the Condition table and the Note table. \n1. Define the `Note table` with 6 columns (e.g., patient unique identifier, visit date, patient's name, visit notes, note date, condition) and the `Condition table` with 3 columns (i.e., condition name, condition inclusion criteria, condition exclusion criteria). \n\n\n```python\n\n# Create data structure to access patients' unique identifier and visit information as well as doctor's visit notes and the date when the notes are written\n\npatient_info = {patient_id: visit_date, patient_info: doctor_visit_note}\n\n\n# Create condition list\n\ncondition = {condition_code: condition_name, condition_inclusion_criteria, condition_exclusion_criteria}\n\n\n# Connect the 2 tables and get the list of conditions\n\nresult = pd.pivot_table([\"patient_info\", \"condition\"], index=\"patient_id\", values=[\"visit date\", \"visit notes\"], fill_ Value = \"\"), columns = \"condition_code\", \n             names = [\"patient_id\", \"visit_date\", \"patient_info\", \"notes\", \"*\", \"*\", \"*\"])\n\nprint(result)\n```\n\n```\n                  patient_id    visit_date patient_info             notes                      *\n   1           15       2020-11-04                    Anh  VNMR                     LDH  CVP-Low \n   2           17       2020-11-04                    Anh  VNMR                       No  CAD\n   3           17       2020-11-04                         Nguyen  KA-High  PCT-High TIA\n   4          18       2020-11-05      Anh  VNMR LOW-Plain COPD HF\n   5         1865       2020",
        "label": 0
    },
    "1297": {
        "output": "You are now ready to write the code for the algorithm that determines the patient's eligibility. \n\nA patient is not eligible according to the inclusion criteria of the trial if the patient meets at least one of the exclusion criteria of the trial. A patient is not eligible because of an exclusion criterion, if the exclusion criterion is met. For example, suppose the patient's BMI is less than 30, and the trial uses the inclusion criterion BMI greater than 30 to select subjects to enter the trial. If the patient has BMI less than 30, and, thus, the patient does not meet the exclusion criterion we stated in this case, then, the patient is not eligible to enter the trial. However, if the patient has BMI less than 30 and also is over 70 years old or has congestive heart failure or coronary artery disease, even though the BMI criterion is not met, the patient is not eligible to enter the trial because the patient meetings one or more of the exclusion criteria. \nIf the patient meets none of the exclusion criteria, then the patient is eligible to enter the trial, if the patient satisfies all of the inclusion criteria. \nFor each trial, it should be possible to define these three situations. First, patients that meet the exclusion criteria; second, patients that do not meet the exclusion criteria and that satisfy the inclusion criteria of the trial; and third, all the patients that do not satisfy the exclusion criteria and not satisfy the inclusion criteria.<EOD> Acute Kidney Injury and Death Across Models of Cisplatin-Induced AKI in Mice\n\nBackground: Despite its widespread use in cancer chemotherapy, the nephrotoxicity of cisplatin poses serious side effects. With overt toxicity such as proteinuria and decreased glomerular filtration rate (GFR) readily accessible, cisplatin-induced kidney injury is often overlooked. While decreased GFR is the gold standard for cisplatin-induced acute kidney injury (CS-AKI), it is not always feasible; the mouse model often fails to display proteinuria, a sensitive AKI marker in human. Thus, in the current study, we used",
        "label": 0
    },
    "1298": {
        "output": "### [Clinical Trial: A phase 3 study to evaluate the safety and efficacy of sunitinib malate treatment in patients with non-resectable and/or metastatic neuroendocrine tumors of gastrointestinal (GET) or pancreatic (PET) origin (NCT_01028509)]\nTitle: A phase 3 study to evaluate the safety and efficacy of sunitinib malate treatment in patients with non-resectable and/or metastatic neuroendocrine tumors of gastrointestinal (G) or pancreatic (P) origin Eligibility:\n\n# Explanation\nThe assessment of eligibility is a new section on the report. It will help you to check whether patients meet inclusion criteria of clinical trials. It will help to find out to whom interventions can be offered. The assessment of eligibility is the part of \"Explanation\" section of the report. It presents the criteria that must be met by the patient. There are 3 options:",
        "label": 0
    },
    "1299": {
        "output": "### Examples\n**Input:** You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n```{r}\nx<-sample(1:1000,42)#choose 42 patients randomly\n\nx<-as.data.frame(x)\nt<-sample(x,c(\"patient-id\",\"gender\",\"bp\",\"hr\")) \nm<-t.get_dummy(t)\n\nname<-c(\"Eligible\",\"Not relevant\",\"Excluded\")\nz<-format(name) \nz<-as.list(z)\nranges <-c(\"Patient-id\",\"Gender\",\"BP\",\"HR\")\ndf <-data.frame(s=ranges, p=rep (names(m), each= length(ranges)))\n\ndf\n\n```\n```\n\n\n```\n# \n#     Patient-id Gender BP HR    \n# A    1      Female  140 72 #Patient-id data\n# B    2      Female  139 75 #Gender  data\n# C    3         --  82 60 #BP  data\n# D    4         --  76 71 #HR  data\n\n```\n```\n# \n#     Patient-id Gender BP HR    \n# A    1      Female  140 72\n# B    2      Female  139 75\n# C    3         --  82 60  \n# D    4         --  76 71\n\n```\n```\n\n```\n# \n#     Patient-id Gender BP HR    \n# A    1      Female  140 72\n# B    2      Female  139 75\n# C    3         --  82 60 \n# D    4         --  76 71\n```\n```\ndf.all <-df %>% \n  separate(patient_id, c(\"PATID\",\"ID\"), extra= \"\") %>% \n  separate(gender, c",
        "label": 0
    },
    "1300": {
        "output": "1. Check for mandatory exclusion or age criteria. The results will be printed as a warning on the right of the code window:\n2. If the patient is not 18 years old, the message \"patient_age=18\" is printed; otherwise, \"patient_age!=18\".\n3. If the patient has no contraindication for pregnancy and is not pregnant (\"preg\"), the results will display \"no-contracontra_pregnancy=1\"; otherwise, \"no-contracontra_pregnancy=2\".\n4. If the patient has gallstones in the common bile duct (CBD) (\"gallstoned_cbd\"), the results will display \"gallstoned_cbd=1\"; otherwise, \"gallstoned_cbd=2\".\n5. If the patient has no previous experience of cholecystectomy (\"gallastone-s_1\"), the results will display \"gallastones_1=1\"; otherwise, \"gallastones_1=2\".\n6. If the patient has no history of biliary colic (\"biliarycolic_yes\"), the results will display \"biliarycolic_yes=1\"; otherwise, \"biliarycolic_yes=2\".\n7. If the patient has no history of acute cholecystitis (\"acutecholang-itis_yes\"), the results will display \"acutecholangitis_yes=1\"; otherwise, \"acutecholangitis_yes=2\".\n8. If the patient has no history of jaundice (\"jaundice_yes\"), the results will display \"jaundice_yes=1\"; otherwise, \"jaundice_yes=2\".\n9. If the patient has not taken NSAIDs (\"NSAIDs_yes\"), the results will display \"NSAIDs_yes=1\"; otherwise, \"NSAIDs_yes=2\".\n10. If the patient is not a woman (\"women\"), the results will display \"women=1\"; otherwise, \"women=2\".\n\n11. If the patient has an ASA class of I, II or III (\"ASA\"), the results will display \"ASA=I, II, or III",
        "label": 0
    },
    "1301": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. As a research coordinator you are also responsible for the creation of trial documentation including a trial information sheet. This sheet has all the information and procedures that the participant will see and hear about and will be given before the informed consent is signed. Therefore, you should verify if the trial information sheet includes all of the required items.\n\n\n\nThe trial information sheet was created using TIDieR. You can find links to the trials and the info sheets created using the TIDieR template at the end of this assessment. \nThe trial ID is #33 in your trial registry and the trial short title is: \"Hallux valgus correction\" . The trial short title should be simple and easy to understand.\n\n## [Trial ID/Short Title]: H33\nThe trial full title is: \"Comparative evaluation of two different postoperative analgesia after hallux valgus correction\".\n\n## [Full Title]:\nComparative evaluation of two different postoperative analgesia after hallux valgus correction.\nThe trial acronym should be an abbreviation of the title and it can not be the same as the trial ID. \n\n## [Acronym of the short title]\nHV \nThe trial acronym should be at least 3 characters long. The trial acronym must be written in capital letters (for example HV would not be accepted, as it is <3 characters long).\nThe name of the principal investigator should be in the short title or full title. \n\n## [Name of the principal investigator or the coordinator]:\nChristina Dzul\n\n## [full title]:\nComparative Evaluation of Two Different. The acronym ETOP should be accepted, because it is 4 letters long and it includes the first 3 letters. The trial name should not include a full stop at the end of the acronym.\n\n## [full title]: etop-hbv\nIn the trial short title, abbreviations for specific procedures are not allowed unless it is the only way to identify the trial. However, acronyms for abbreviations like BMI and TKA are OK. \n\n## [Full Title]:\nPostoperative analgesia after hallux valgus correction",
        "label": 0
    },
    "1302": {
        "output": "You should make a decision like this:\n- If the differential diagnosis has the option \"The patient cannot be ruled out for any differential diagnosis\": output \"the patient cannot be ruled out for any differential diagnosis\" - If the differential diagnosis does not have the option for \"The patient cannot be ruled out for any differential diagnosis\":\n>output \"The patient cannot be ruled out for any differential diagnosis\"\nHere is the patient note:\nA 54-year-old obese women admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. On physical examination, the patient is alert, oriented, and in no acute distress. Her vital signs are BP 145/80, HR 115, RR 15, body temperature 97.5, and oxygen saturation on RA 98%. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. The remainder of her exam does not reveal anything abnormal. On a barium enema, her findings are reported normal.\nHere is the clinical trial: \nTitle: Effects of GlutenShield, a Probiotic and Enzyme Supplement, on the Gut Microbiome of Adults With GI",
        "label": 0
    },
    "1303": {
        "output": "~[END]\n\nYou should make a single patient-level eligibility for each patient, i.e., assess whether a patient's characteristics match the inclusion criteria of a clinical trial. \nYou should make a single trial-level eligibility for each clinical trial, i.e., make an assessment of a patient's eligibility by comparing the patient note with inclusion and exclusion criteria. \n\nIf you have a problem, please make a comment on the main page of the task [http://www.stat.berkeley.edu/~efr/wiki2/Main Page]. [INST] [END]\n\n 2.1 Assess a patient's eligibility from information specified in the patient note and the textbook:\na. Determine clinical trial 1 and its eligibility criteria. [Instruction]\nClick the \"Select another trial\" link at the right of the screen and choose the 1st trial.\n\nb. Assess patient's eligibility by comparing a patient note with inclusion and exclusion criteria of the 1st trial. [Instruction]\nYou should make a patient-level eligibility for each patient by comparing the patient note with inclusion and exclusion criteria. If the patient's characteristics match to inclusion criteria or exclusion criteria do not apply, you should mark it as `0) Excluded; 1) Not eligible` or `1) Not eligible` respectively. If the patient's characteristics do not match any criteria or the patient has insufficient information, you can mark it as `1) Not eligible`. [Instruction]\nClick button at the top of the screen and choose \"Assess patient-eligibility: for trial 1\".\nIn the dialogue window, input `0) Excluded, 1) Not eligible and 2) Eligible` and press \"Ok\".\nPlease choose at least one option and save your result. [Instruction]\n\nc. Determine clinical trial 2 and its eligibility criteria. [Instruction]\nClick the \"Select another trial\" link at the right of the screen and choose the 2nd trial.\n\nd. Assess patient's eligibility by comparing a patient note with inclusion and exclusion criteria of the 2nd trial. [Instruction]\nYou should make",
        "label": 0
    },
    "1304": {
        "output": "In this lesson, you will create a patient note.\n\nThis is a step-by-step lesson on Patient History. \n\n\n\n\n\n\n\n![SCORE](https://github.com/openclinica/training-cases/blob/master/training-cases/instructions/score/image13.png)\n![SCORE](https://github.com/openclinica/training-cases/blob/master/training-cases/instructions/score/image14.png)\n\n\n[SCORE](./score.md)\n\n\n[Next Instruction](./clinical_trial/patient-history.md#patient-history3)\n<EOD> Diseases of the skin.\nWe may not be able to make you love reading, but diseases of the skin will lead you to love reading starting from now. Book is the window to open the new world. The world that you want is in the better stage and level. World will always guide you to even the prestige stage of the life. You know, this is some of how reading will give you the kindness. In this case, more books you read more knowledge you know, but it can mean also the bore is full.<EOD> In vitro assessment of antimicrobial effects of photodynamic therapy on oral Candida isolates\n\nBackground/purpose: Antifungal resistance is a challenge in clinical therapy. The present study was conducted to investigate the effect of light-sensitizers on resistant strains of Candida albicans with the aim of evaluating the potential of using the photodynamic therapy (PDT) to eradicate candidiasis and limit the emergence of antifungal resistance in the treatment of oral infections. Materials and methods: PDT was performed on pure Candida isolates (C. albicans ATCC10231, C. krusei 34876 and C. albicans PDT-resistant) with the photosensitizer methylene blue (MB) and light-emitting diode (LED) light of 660 nm with variable durations of 15 s, 30 s and 60 s. Suspensions of Candida strains were evaluated at",
        "label": 2
    },
    "1305": {
        "output": "<EOD> Effects of different physical activities on inflammation markers in patients with coronary artery disease\n\nBackground Physical activity is one of the main strategies to prevent and manage coronary artery disease. Although several studies have investigated the effects of exercise modality on coronary heart disease, it remains an unmet need to identify the optimal type of activity that could yield the best results.MethodsWe conducted a systematic review and meta-analysis to identify the type of exercise that could lead best to improve inflammatory markers. We searched Medline(R) via PubMed, Scopus and Web of Science (WOS) in electronic databases until May 1, 2022, to identify original articles published with the aim of assessing the effect of different types of activity on inflammatory markers in patients with coronary artery disease. We used a random-effects model and the Mantel-Haenszel formula to calculate standardized mean differences (SMD) and their 95% confidence interval (95% CI). We used the I 2 statistic to measure heterogeneity and the Cochrane Q test.ResultsA total of 2443 patients were included in 31 randomized controlled trials, with the majority of studies (i) conducted in single centers (n = 22), (ii) of parallel design (n = 27), (iii) evaluating cardiopulmonary exercise test (CPET) as training load (n = 12), and (iv) reporting changes in C-reactive protein (CRP) (n = 13). Resistance exercise yielded the highest CRP decrease value (SMD -0.66 mg/dl, 95% CI -1.07 to -0.25, I 2 : 62%), while a larger CRP decrease was related to resistance-interval exercise (SMD \u22120.70 mg/ dl, 95% CI -1.18 to -0.22, I 2 : 62%). Moreover, resistance training (SMD -0.32 mg/dl, 95% CI -0.61 to -0.03) and resistance-interval training (SMD -0.31 mg/ dl, 95% CI -0.62 to -0",
        "label": 0
    },
    "1306": {
        "output": "## Trial-level eligibility\n\nYou are a helpful assistant for clinical trial recruitment.\nYour task is to compare a given patient note and the eligibility criteria of a clinical trial to determine the patient's eligibility.\n\n## Eligibility criteria\nPatient Criteria:\npain free\nblood pressure under 140/90 mmHg\nability of therapist to locate necessary trigger points on participant\n\n## Patient note\nTitle: Pain Modulatory Profiles in Massage for Healthy Participants\n\nSummary: One in ten adults experience widespread pain. Neck pain, for example, is a prevalent condition with a high rate of recurrence that affects between 10.4 and 21.3% of the population annually.~Massage is a common manual therapy intervention for individuals with musculoskeletal pain. However, the mechanisms of massage are not well established.~This study will evaluate the association between pain inducing massage and the conditioned pain modulation (CPM) paradigm.\nInclusion Criteria:\npain free\nblood pressure under 140/90mmHg\nability of therapist to locate necessary trigger points on participant\n\n## Eligibility criteria\nPatient Criteria:\npain free\nblood pressure under 140/90 mmHg\nability of therapist to locate necessary trigger points on participant\n\n\n\n## Patient note\nTitle: Pain Modulatory Profiles in Massage for Healthy Participants\n\nSummary: One in ten adults experience widespread pain. Neck pain, for example, is a prevalent condition with a high rate of recurrence that affects between 10.4 and 21.3% of the population annually.~Massage is a common manual therapy intervention for individuals with musculoskeletal pain. However, the mechanisms of massage are not well established. Also, the conditioned pain modulation (CPM) paradigm is a dynamic quantitative sensory testing measure of a pain inhibitory process in which pain sensitivity is lessened in response to a remotely applied painful stimulus.\nInclusion Criteria:",
        "label": 0
    },
    "1307": {
        "output": "In your model files, you should import the following packages: \ninstall.packages(c(\"plyr\", \"readr\", \"stringr\", \"dplyr\", \"ggpubr\"))\n\nFirst, you should load your data, and read the notes that explain the data. Please, take a special look at the last line for trial-level eligibility.\ndf_data <-readr::read_csv(\"data/final_data.txt\", sep = \",\", skip = 1, na.strings = \"NA\")\n\nThen, you create a trial_eligibility variable: \n\ntrial_eligibility <-as.factor(df_data[2])\n\nWe also create the eligible variable for each trial, which is simply the inverse of the trial_eligibility.\n\ndf_data %>% mutate(\n  trial_eligibility = fct_relevel(trial_eligibility) %>% fct_flip(),\n  trial_eligibility2 = eligible) %>% mutate(\n  trial_eligibility2 = fct_relevel(trial_eligibility2) %>% fct_flip())\n\nThe next step is to summarize the data and group by trial_id.\n\ndf_data %>% group_by(trial_id) %>% summarize_across(list(trial_eligibility, trial_eligibility2)) %>% pivot_longer(columns = everything(), names_to = \"name\")\n\nIn this way of calculating the trial level eligibility, we assume that a patient is evaluated for a trial as long as the trial is ongoing.\n\nIn the next section, we will recalculate the trial-level eligibility in that way. \n\nHere, I will briefly explain how to add the `in_trial` variable to the dataset, where you will see that when we recalculate the trial-level eligibility we assign the patients that have not responded the trial to the eligible_not_invited group. This assignment, however, is not correct. \n\ndf_data %>% dplyr::mutate(in_trial = trial_id > as.Date('20200101')) %>% dplyr::filter(in_trial ==",
        "label": 0
    },
    "1308": {
        "output": "**Input**\n\nEnter the trial-level eligibility information. \n![Screen capture from the web application](24_screen_capture_from_the_web_application.png?width=758&name=24_screen_capture_from_the_web_application)\n\n**Output**\n\nYou can see your findings as `Trial-level eligibility: 2) Eligible.`.\n\n# Expectations\n\n[!INCLUDE[INST_expectations_list](../includes/INST_expectations_list.md)]\n\n\n    \n    \n    \n    \n    \n    \n    \n    \n# Performance\n\n## Timed task performance\n\nThe **average time** to complete the task has no standard deviation because only 1 participant completed the timed task. In addition, the average time does not include any additional time to complete the **initial task**, the **reference task**, or the **retest task**, nor the participant's final **comment**. [source](http://researcher.microsoft.com/#/projects/42b98164-a090-410d-a268-d3ef0f9f6d90)\n\n## Interview scores\n\nThe **average interview score** for the participant was between **84.1** (minimum) and **87.8** (maximum). The average interview scores for each task (**task**), for each participant (**participant**) are stored for future reference:\n\n\n*\n\n## Participant\n\n    task     score\n    1        84.1\n\n\n*\n\n## Participant    2        87.8\n    3        88.6\n    4        91.1\n\n### Task 2. Task-level eligibility (Trial-level eligibility)\n\nThe **average** **interviews score**, **average time**, and **standard deviation** was **0.855**, **32.240 seconds**, and **0.467**. [source](http://researcher.microsoft.com/#/projects/42b98164",
        "label": 0
    },
    "1309": {
        "output": "Exercise: CDASI Data Analysis Assessment - Exercise\n\nYou are a medical student in the last year of your medical school and are trying to obtain a summer research experience in the field of informatics to add to your curriculum vitae for future opportunities in the field (e.g., medical school application, etc.). Your mentor has selected a dataset for you to analyze from the Department of Dermatology, University of Miami Miller School of Medicine",
        "label": 0
    },
    "1310": {
        "output": "<a name=\"INST\"></a><a name=\"INST\"></a>[INST] Eligible Criteria for Included Patients\nFor each included patient, you want to write their ID, the name of the patient note (i.e., 'Patient' in the example file provided above) and the eligibility information. \nTrial-level eligibility: <ticket> 0) Excluded </ticket>\nPatients: Patient 1\nNote: Patient Note 1\nTrial-level eligibility: <ticket> 2) Eligible </ticket>\nPatients: Patient 2\nNote: Patient Note 2\nTrial-level eligibility: <ticket> 1) Not relevant </ticket>\nPatients: Patient 3\nNote: Patient Note 3\nYour final report should match the following format (including the header):\nPatients:\n<ticket> 1 </ticket><patient name>\n<note>\n<id>1</id><value>10</value>\n</note>\n<ticket> 2 </ticket>\n<patient name>\n<note>\n<id>1</id><value>11</value>\n</note>\n<ticket> 3 </ticket>\n<patient name>\n<note>\n<id>2</id><value>12</value>\n</note>\nTrial-level eligibility:\n0) Excluded\n1) Not relevant\n2) Eligible\n[END]\n\n<a name=\"RANDOMS\"></a><a name=\"RANDOMS\"></a>[RANDOMS] The number of randomization schemes to draw\nTo help the reproducibility of results, we strongly recommend using the number of randomization schemes drawn in the code. To generate a table of random numbers, such as the one in below, we use the function `randbetween` in the module `matplotlib.random`.\n- <a href=\"./Rand48.R\">Rand48.R</a> should be the location of the file that contains the random number generator used in this study. We recommend that you save it in the same folder as the code file you are using. Make sure you only use the file",
        "label": 0
    },
    "1311": {
        "output": "<EOD> The impact of the COVID-19 pandemic on people with intellectual disabilities: Preliminary evidence from Italy\n\nBackground: The psychological burden of the COVID-19 pandemic has been studied in different populations. No studies have been carried out investigating people with intellectual disabilities. These individuals are more vulnerable for COVID-19 than the rest of the population. Nevertheless, they are excluded from psychological and sociological studies, with the exception of the elderly. The first aim of this study is to evaluate the psychological impact due to the COVID-19 pandemic in people with intellectual disabilities; the second aim is to identify psychological and risk factors associated with high anxiety scores.Methods: In this cross-sectional study, 103 people with mild to moderate intellectual disabilities completed the State of Anxiety questionnaire in seven intellectual disability associations in Piedmont (northeastern Italy). The associations were chosen according to the availability of the survey among employees who were willing to answer. People with intellectual disabilities completed the State of Anxiety questionnaire. The associations reported how the COVID-19 pandemic had impacted their life, their activities, daily habits and relationships.Results: People with intellectual disabilities (i.e., 103) showed high levels of anxiety scores. The multivariate analysis showed that people with intellectual disabilities who had been quarantined experienced more anxiety than those who had not been placed under quarantine (\u03b2 = \u2212 0.321; p < .05; 95% CI \u2212 2.372 to \u2212 0.215). People who reduced the frequency of going out for activities were more anxious than those who did not (\u03b2 = \u2212",
        "label": 0
    },
    "1312": {
        "output": "##[END]\n\n# Introduction to Neuropathic Pain\n\n# Objective\nIt is our intention to define the terms used to identify the neural mechanism of pain, and to summarize the principles and evidence for the mechanisms of action underlying commonly used treatments.\nThe objective of this module is to improve the learner's ability to define the mechanisms of action of analgesic drugs, and the neural pathways by which they reach their site of action.\n[SURVEY]\n\n## What are the four classes of analgesic medications? ______________\n[MEG]\n\n## How does cns analgesia get to the site of action?\n__________\n[INDENT]\nPlease circle one for each of the following:\nNeuraxial (intrathecal): \nLumbar (extradural): \nPeripheral: \n\n## Neuropathic pain\nThe majority of patients in pain medicine are treated for some form of neuropathic pain and many patients have multiple types of neuropathic pain at any given time. There are many specific syndromes and sites classified as neuropathic pain. In the following tables, we will focus on the three most common types of neuropathic pain. Each of these examples are presented as well as clinical pearls and suggestions for the use of various treatment modalities.\n\n## Diabetic neuropathy\nDiabetic neuropathy is a chronic polyneuropathy that is caused by poor glycemic control, defined as glycated hemoglobin >8%. Its pathogenesis is related to hyperglycemia-induced endoneural edema and endoneural hypertension that leads to ischemia of axons and nerve cell bodies. This process leads to demylination and axonal loss, both of which may result in both sensory and motor neuropathy. Common pain syndromes related to diabetic neuropathy include paresthesias, burning, and aching pain (4,5). \n\n## Post-herpetic neuralgia\nPost-Herpetic Neuralgia (PHN) refers to persistent pain following the healing of a Herpes Zoster (shingles) rash. Persistent pain beyond 3 months and",
        "label": 0
    },
    "1313": {
        "output": "You should submit the solution file of the problem as an answer to this problem. For more information on the types of files we accept to store answers, refer to [this guide](https://academy.grand-challenge.org/#/help/16).\n\n### Submission\n\n**Problem ID**: `GrandChallenge.AI.390.Clinical_data_science_problem_case_10`\n\n---\n## Submissions\n\nThis is the overview of your submissions in the [Problem 10 - Clinical data science problem case 10](https://academy.grand-challenge.org/openchallenges/Problem_10_Clinical_data_science_problem_case_10) Problem.\nFirstly, you should export the results of your submission and send the submission URL to us.\n\nIf you submitted multiple times, the first submission will be used for the result. The export results should be done as CSVs.\n\nPlease export your results and send us the submission URL(if you want to send it as email, please make sure you send the URL including https:// or https://docs.google.com/). \nExample of export result CSV\uff1a\n\n```yaml\nResult_Code: Problem_Response_300\nTrial-level eligibility\uff1a2) Eligible\nTrial-level Eligibility:2) Eligible\nTrial-level eligibility\uff1a0) Excluded\nPatients_ID\uff1aC01011\nTrial-level Eligibility\uff1a2) Eligible\nTrial-level eligibility\uff1a2) Eligible\nTrial-level eligibility\uff1a0) Excluded\nPatients_ID\uff1aC01013\nTrial-level Eligibility\uff1a2) Eligible\nTrial-level eligibility\uff1a0) Excluded\nPatients_ID\uff1aC01014\nTrial-level Eligibility\uff1a0) Excluded\nTrial-level eligibility\uff1a0) Excluded\nTrial-level eligibility\uff1a0) Excluded\nPatients_ID\uff1aC01015\nTrial-level eligibility\uff1a0) Excluded\nTriallvl egibility\uff1a0) Excluded\nT",
        "label": 0
    },
    "1314": {
        "output": "## Eligibility\n\n<pre class=\"doclet-highlight\" title=\"doclet-highlight\"><span class=\"doclet-danger\"><strong>Warning\u2008:</strong></span></pre>\n\nYou can now print the Eligibility report. It will contain the calculated eligibility per patient and per clinical trial. You can filter the reported eligibilities by printing the Eligibility report on a patient and filtering by clinical trial code. Finally, you can also export the report in Excel format by setting a filter that contains exactly the eligibility of the one patient you want to report on. \n\n![Eligibility report][ReportEligibility]\n\n[ReportEligibility]:../fig8.3.xml\n\n**Important:** If you think you see a problem with the output of one clinical trial, you should go back to the corresponding patient report and make sure that your entry is correct. If you are sure that the output of the clinical trial is wrong, you should contact the trial coordinator at the site involved and ask for a correction to the patient report of that patient in the electronic health record system. If you contact the trial coordinator at the site, you will have more credibility in the event that you are unsure whether the information in the source patient report is correct or not.\n\n\n## Step 8: Print Cohort report\nStep 8.1: Print the cohort. You can print the trial results to a PDF cohort report from the patients' first column (see below).\n\nThe first column shows you the total number of patients from all sites for a specific trial in your view of the Clinical Practice Manager. You can only print the patients of a single site on a single page by printing that site's view of the Clinical Practice Manager. See [Step 3: Look for a specific clinical trial.][InstructionsCohort] for more detailed instructions on how to find a certain trial.\n\n[InstructionsCohort]:../fig9.3.xml\n\nThe second column shows you the number of patients eligible for a specific trial in your view of the Clinical Practice Manager. We will show this column with a white background.\n\nThe third column shows you the total number of patients in your site for a particular trial in the Cohort. If",
        "label": 0
    },
    "1315": {
        "output": "[/MODTEST]\n\nWe have used a different data in the [MODTEST] module for ease of understanding and the same data is used in the [INST] module.\n<a class=\"anchor\" name=\"References\"></a>\n[1] <NAME>: <NAME>, <NAME>, eds. \"The HealthCare System\", 2 <NAME> (6th edition) (Chapt. 5: \"Information and Coding for Medical Use\"). \n[TBC]: <NAME>\n[TBC]: <NAME>\n[TBC]: <NAME><EOD> Phonological and Orthographic Coding in Reading Development.\nThe coding of letters (orthographic coding), phonemes (phonological coding), and semantics is thought to contribute to fluent and automatic reading. The present study examined the relations between coding of these levels in typically developing children (N = 192), with reading impairment (N = 21), and children with reading impairment and specific language impairment (N = 8). A test battery assessing the levels orthographic, phonological, and semantic was administered, and performance was evaluated as a function of the reading level. Typically developing skilled readers, typical readers with reading impairment, and children with severe specific language impairment were identified at the end of the third grade. The findings show that reading-impaired children have deficits at each level of processing. This indicates that the phonological deficit in reading-impaired children is not caused by a language deficit but involves a specific difficulty in learning decoding. Thus, the phonological deficit in reading-impaired children seems to be caused by a phonological decoding deficit, which appears to be in contrast to the view that phonological awareness and phonological decoding are completely interrelated.<EOD> Improving quality of early childhood education and care in the South African context.\nEarly childhood development is recognised as an important area of government intervention in the quest to improve educational outcomes, especially among disadvantaged children in South Africa. It is vital that this focus is extended from preschool to early childhood education (ECE) in the South African context. The research was guided by the following objectives: (i) explore quality in relation to early",
        "label": 0
    },
    "1316": {
        "output": "How about you?\n\nPlease follow us on [Twitter][twitter] [Facebook][fb] and [Instagram][ins]. Follow us [youTube][youtube] for the recording of our webinar. Thank you! \n\n## 369. 116. 074\nTrial-level eligibility: 1) Not relevant.\n\n## Excluded\nPatients who receive any drug (dosage and duration not specified) are 2-2.2 times more likely to experience acute kidney injury (AKI) within 90 days than those who do not receive it. Conversely, 49% of patients with AKI (any severity) were prescribed a drug (dose and duration not specified), including 37.6, 21.4, and 21.4% for AKI stages 1, 2, and 3, respectively.\n[BMJ].\n\n## Eligible\nDue to the high frequency of the disease in women, HBs antigen testing should be performed only in women for whom clinicians have a specific indication, such as pregnancy. However, if HBs antigenemia continues in the pregnant women, HBV DNA quantification should be performed to differentiate the two. In addition, serum HBV DNA, although not included in this guideline, can also be a clinically useful test for monitoring viral replication.\n[Korea Centers for Disease Control and Prevention].\n\n## Eligible\nThe mean differences (\u0394) and the 95%CIs of 24 Hour Urinary Protein/24 Hour Urinary Creatinine (UPro/UCr) in four groups: HBV monotherapy group, entecavir combination therapy group, telbivudine combination therapy group and lamivudine combination therapy group (for HBeAg-negative CHB patients) and HBV monotherapy group, tenofovir combination therapy group and entecavir combination therapy group (for HBeAg-positive).\n[Journal of Virological Methods].\n\n## Eligible\nThe efficacy of IFN-alpha was evaluated by the normalization of HBs",
        "label": 0
    },
    "1317": {
        "output": "<b style=\"color: blue;\">Clinical Trial Eligibility Assistant</b><br />\n---\n\nA clinical trial is a special medical study aimed at evaluating new treatment(s) in order to make decisions about future medical care for patients. During a clinical trial, physicians carefully observe patients who received one treatment and those who received another treatment. If the results are positive, they will continue the research, applying for permission to conduct a bigger study, the following phase of clinical trials, to support a marketing authorization application (request). The clinical trials differ from one another depending on the type of medical products.\n\n\n\n### Clinical Trial Type : Medical Device/Device Study\n\n<img src='../../../../assets/img/clinical_trial_dev.png' style=\"width: 400px;\"> <b>This is an example of a clinical trial type : Medical Device/Device Study. It is also called 'device evaluation clinical study'.</b><br />\n\n<NAME>, an 18-year-old woman admitted to the hospital due to a wound on left lower leg for further treatment. The wound was caused by an accident on a motorcycle one year ago. She was treated in another hospital the first 40 days, but the wound did not heal. In the past one month, the wound shows no signs of healing and spread to her left ankle. She has no medical history of diabetes mellitus, high blood pressure, or heart disease. Her family history includes diabetes type 1 in her mother. As she was worried the wound may get infection, she went to a medical center to get wound dressing. After the dressing, she heard a clank of noise, and her condition worsens. \n\n**Exclusion criteria:**\nNo history of diabetes mellitus, high blood pressure, or heart disease \nNo history of surgery, except cesarean section \nNo known history of anaphylactic reaction \nHistory of skin disease that affects skin healing \nNo history of joint diseases that affect joint movement \n\n**Inclusion criteria:**\nPatient with a history of an accidental injury on the left leg and left ankle that did not he",
        "label": 0
    },
    "1318": {
        "output": "<EOD> The SPRY/B30.2 domain of inhibin \u03b2E subunit and its homologues interact with the N-terminal extension of the \u03b1 subunit to form an inhibin \u03b2E-subunit trimer.\nInhibin/activin is an important regulator of gonadal steroid hormone biosynthesis. The two inhibin subunits, \u03b1 and \u03b2, form a structural homodimer held by non-covalent interactions. Studies have indicated that \u03b2E subunit can form a complex with \u03b2A subunit in vitro. In this study, the N-terminal B30.2-like domain from inhibin \u03b2E (\u03b2E B30.2) was cloned and overexpressed in Escherichia coli. To reveal its biological role, complexes between inhibin/activin proteins, \u03b2E, and other accessory proteins were prepared by using a chemical cross-linker (disuccinimidyl suberate). The results indicated that the \u03b2E B30.2 domain binds to inhibin \u03b1 (\u03b1 A) and activin \u03b1 (\u03b1 AB) with a dissociation constant ranging from 2.16 to 5.99 nM. The amino acid mutant V32A, which is located in the \u03b2E B30.2 domain, was generated. The mutant V32A \u03b2E B30.2 lost \u03b1-subunit binding activity and disrupted inhibin trimer formation in vitro. The N-terminal extension in the \u03b1 AB domain was generated by site-directed mutagenesis. The results showed that a fragment of the \u03b1 A domain N-terminal extension and, for the first time, the full extension of the \u03b1 AB domain were able to interact with the \u03b2E B30.2 domain. We hypothesize that the inhibin \u03b2E subunit binds to the \u03b1 subunit via a trimer and is involved in inhibin trimer formation.<EOD> .\nA 14-year-old boy was referred to us with complaints of pallor and an abdominal mass. The patient had been diagnosed as having chronic renal failure, hypoxia, and secondary an",
        "label": 0
    },
    "1319": {
        "output": "### Example\n\n```\n{\n  \"Patient_ID\": \"393313019\",\n  \"note\": \"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. [/PRACT]\n<EOD> Differential effects of antiarrhythmic drugs on the transmembrane potentials of human epicardial myocytes.\nThe effects of ten antiarrhythmic drugs and verapamil have been studied using intracellular microelectrodes to record action potentials and transmembrane potentials directly in single human epicardial myocytes. Antiarrhythmic drugs prolonged action potentials and in a significant proportion of cells caused triangularization of the plateau phase of the action potential, or a decrease in the amplitude. At supratherapeutic concentrations all the drugs caused either a decrease in action potential height or in the maximum rate of depolarization (in five of 20 cells) as did verapamil at therapeutic concentrations. These effects were not reflected in transmembrane potentials in 77% of the cells. In these myocy",
        "label": 0
    },
    "1320": {
        "output": "section. [/TASK]\n\n___\n\n### 2) [TASK] Check your code: If you are not getting the correct output, check your code and fix it. [INIT]\n```\n[TEST] Your input: Eligibility: 2\n\nMy output: Eligibility: Not relevant\n```\n\n[TEST] Your input: Eligibility: 2\n\nMy output: Eligibility: Not relevant\n```\n<EOD> .\nBACKGROUND\nTo present results of the treatment of ovarian serous borderline tumor.\n\n\nMETHODS\nA report is made of 27 cases with ovarian serous borderline tumor operated between 1980 and 1995.\n\n\nRESULTS\nTumor diameter was between 2 and 15 cm. The macroscopic appearance was similar as described in literature, with multiple tumor nodules, of various forms (polypoid, cystic or solid, with or without hemorrhagic surface), with or without mural nodules or papillary pseudopolyps. In 26 out of 27 cases, the tumor was bilateral, involving the contralateral ovary in 12 cases. The lymph node involvement was studied in 6 cases, and found metastasis free. The adjuvant treatment was indicated in 5 out of 9 cases with bilateral tumors and residual disease. One case of borderline tumor was associated with a carcinosarcomatous ovarian tumor. Two women presented other malignancies, gastric and breast cancer. The follow-up was complete for 5-177 months (median: 53 months). There was no death from disease or therapy.\n\n\nCONCLUSIONS\nComplete resection of the disease is the only curative treatment. Adjuvant therapy of borderline disease with pelvic washes, systemic chemotherapy, intestinal or vaginal irradiations is not consensual. We believe in adjuvant combined therapy for residual disease. The prognosis is good in cases of borderline tumors, even in cases of bilateral invol",
        "label": 0
    },
    "1321": {
        "output": "To solve step by step, the first thing you should do is `sort patient.csv`. [INST]\nNext, you will use `merge` function from `dplyr` package in `Programming Language Interface (PLI) R`. [INST]\nFinally, the function will use `table` function in `Programming Language Interface (PLI) R` to get the results in table form: \nYou can observe from the picture above, we get 6 values that are `Eligible = 6; Not relevant= 0`, therefore, we can infer that the output can be either `2 or 3. If you want to find out the number of `2`, you should use `.3` or vice versa. The results are 39 for `2` and 25 for `3`. [INST]\nTherefore, the final value of the `Eligibility` column is `6 + 39 + 28 + 38 + 41 + 22 + 49` and rounded to integer, thus we get `47`. [INST]\nHowever, if you do not want the final value rounded to integer, you can use `round` function in `Statistics and Data Analysis R` to get `47.3`. [INST]\nFor more information about rounding in `Statistics and Data Analysis R`, please open it and type: `round.`. [INST]\nThen type: `rounding` to get the output below: [INST]\nThe output above tells us that rounding can be in all four directions; up, down, up-right, and downright. [INST]\n`pmin` function from `Statistics and Data Analysis R` rounds up, `pmax` function from `Statistics and Data Analysis R` rounds down, `pinf` function from `Statistics and Data Analysis R` rounds both up and down, and `pint` function from `Statistics and Data Analysis R` rounds up to a decimal place, `roundmode` function from `Statistics and Data Analysis R` determines the mode of rounding, and `scale` function from `Statistics and Data Analysis R` determines decimal places. [INST]\nYou can observe from the picture above, the `pmin` function gives the rounding up the number, `pmax` function gives the round",
        "label": 0
    },
    "1322": {
        "output": "</SCRIPT>\n\n\n## Instructions \n[INST] Welcome to the trial. \nWhich strategy to treat the patient is the best? Laparoscopic cholecystectomy or endoscopy first? <EOD> Effects of a brief workplace intervention focused on physical activity and psycho-social well-being among health care workers in public hospitals. A prospective longitudinal study\n\nBackground: A brief, tailored intervention may be useful to improve psycho-social well-being and physical activity in health-care workers (HCW) exposed to chronic stress and physical strain. Therefore, the aim of this study was to assess the effects of a brief intervention consisting of physical exercise and psychological support focused on psycho-social well-being and physical activity in a population of HCWs of the Veneto Region.Methods: A longitudinal study was conducted on a sample of 158 staff nurses of the Veneto Region, who were randomly assigned to an intervention (IG, n = 78) and a control (CG, n = 80). The intervention group included women between 18 and 64 years, assigned to intervention and randomization groups. Participants were asked to perform an exercise and a psychological well-being test, and both the physical exercise and the psychological well-being test were repeated at the end of 6 and 12 months.Results:The physical exercise test showed that the HCW in the intervention group exhibited better performance levels. In addition, the psychological well-being test showed that they displayed significantly lower anxiety, depression and psychophysiological symptoms, and better general wellbeing, general health and self-concept, compared with HCW in the CG.Conclusions:Our study find that brief interventions were successful in improving the well-being of health-care workers. Our results highlight a need to develop policies in this regard with the aim of supporting the well-being and health promotion of health care workers involved in complex services.\n\n# Introduction\nBecause of the increase in morbidity and mortality rates attributable to stress and burnout, the development of new strategies to address poor health and job outcomes due to these conditions has recently emerged as",
        "label": 0
    },
    "1323": {
        "output": "# Conducting the Analysis\n\n\n[INST] In the following lines, you will follow the instructions for conducting the analysis on the provided datasets (clinical trial's dataset and patient's notes). You have to repeat the provided instructions. \n\n# Clinical Trial\n\n\n[INST] You need to write 4 lines under the Clinical Trial section (first line starts with #):\n```\n      ## 0: Not relevant\n      - 1: Eligible\n      ## 1: Not relevant\n      ## - 2: Eligible\n```\n\n\nTo do the analysis, you can repeat the provided instructions. Please use the patient's Note1 as a test.\n\n# Patient's Note\n\n\n[INST] You need to write the codes for the patient's notes on next line and save the file.\n\n\n## Patient Note 1\n\n\n[INST] You can write the provided example codes for Patient Note 1 on next line and save the file.\n\n<EOD> Clinical utility of serum antibody-based human papillomavirus screening tests\nPurpose of review Serum antibody-based tests for human papillomavirus (HPV) have been employed to detect HPV and screen for cervical abnormalities as a secondary assay, alternative to Papanicolaou smear cytology. The objective is to review the literature to examine the benefits and shortcomings of serum-based detection. Recent findings Serum antibodies against HPV-specific viral proteins have been correlated with a range of diseases. The utility of such tests for detecting and predicting the progression of precancerous and cancerous diseases, specifically cervical neoplasia, has not been conclusively established. Several investigators have identified statistically significant increases in antibody responses against HPV in patients with abnormal Papanicolaou smears, especially in those with high-grade lesions. Other studies have demonstrated a relationship of increasing antibody titers with increasing severity of preinvasive cytological disease, as well as progression to invasive disease. Summary Research to date has been inconclusive regarding the utility of HPV seroepidemiologic studies for cancer surve",
        "label": 0
    },
    "1324": {
        "output": "## 7.6 Rules\n[RSP] Here is the patient note of the following example:\nAn 82-year-old man came to the hospital with low back pain, hip pain, and bilateral numbness in the legs following his fall 4 days earlier. He previously took medication for high blood pressure, heart disease, dementia and osteoporosis. His blood pressure was 160/80, pulse was 129, respiration rate was 15, and his oxygen saturation was 98%. The patient had significant stiffness in his lower extremities but the joint movement in both hip and knee joint was intact. There was 3\u00d74 cm bruising on his left knee joint and 4\u00d74 cm on his left hip joint. He had no distal pulses and peripheral weakness.\nPhysical examination revealed reduced airflow sounds on the left with no evidence of wheezing or rales. The patient had no tenderness or edema on his bilateral anterior tibial and dorsalis pedis areas. His peripheral pulses of the lower extremities were decreased. The DTR was 3 on the right and 2 on the left. The patient had a sensation of numbness and tingling from the lumbar spine to his feet.\nRadiographs showed significant osteoporosis with no vertebral crush fractures, osteophyte formation, or narrowing of the joint space of his spine.\nLaboratory tests were as follows: WBC: 6800, RBC: 3.1, Hgb: 9.6, Hct. 26.5.\nBased on the patient's medical history, physical examination findings and laboratory results, the cause of the patient's acute bilateral lower extremity weakness in this case may be spinal compression fracture, a serious pathophysiologic condition, due to a major trauma.\nThis scenario is the same as the previous example but the last paragraph is rephrased.\nYour task here is the same as the previous example: you should make a report to answer the clinical questions according to the following rules. [RSP] Here is the patient note",
        "label": 0
    },
    "1325": {
        "output": "Here's the result: [[clinical trial results table|clinical trial results]]\n\n# Examples\n\n## Example 1: a trial investigating the treatment of diabetes\n\n* You are a general practitioner and want to know if any of your diabetic patients is eligible.\n* You start with the search form located <span style=\"color: #008000;\">[clinical trial results](https://fdo.shinyapps.io/clinical trial results)</span>.\n\n![](fig/results-only1.png)\n\nEnter the following as `Search terms` in the search box and click `Search`:\n* `Diabetes` AND `Obesity`\n\nThe resulting table looks like that:\n\n![](fig/results-only1.png)\n\nYou should now open the trial result [EudraCT-no: 2013-000107-20] that gives you information about the design and results of the trial.\n\n![](fig/results-only1_2.png)\n\n\n* The design of the trial, also known as the `study design` in the main menu, informs you whether it is a randomized or a non-randomized trial. The results are summarized for *the whole study*.\n\n* The patients table lists the participants in the trial. It gives you information on eligibility, which is described as inclusion and exclusion criteria. You can use these information to find potentially eligible patients quickly. Also, you can assess yourself whether the patients meet the exclusion criteria, e.g., patients with comorbid conditions which are inappropriate for the trial. Additionally, you can use the information obtained from the patients to judge whether the study results are really newsworthy to you. If patients are not eligible, consider if you can refer them to the study team, e.g., because of inadequate treatment.\n\n* The results of the trial can also be of interest for your daily work. Patients with inadequate trial results could for example be discussed in the treatment consortium.\n\n![](https://fdo.shinyapps.io/clinical trial results/src/main/image/results_diabetes_",
        "label": 0
    },
    "1326": {
        "output": "<EOD> Molecular and phenotypic characterisation of carbapenem-resistant E. coli isolates from patients and farm animals in Egypt\n\nThis study aimed at characterising carbapenemresistant E. coli (CR-EC) collected from humans, retail meat and animals, slaughterhouses and farms in Egypt. A total of 587 CR-EC isolates (from 2015 to 2017) were screened for carbapenemase genes by conventional multiplex PCR. Molecular characterisation of CR-EC was performed by multi-locus sequence typing (MLST), detection of sequence types associated with carbapenemase genes, and genomic investigation for the presence of mobile carbapenemase-encoding genes on plasmids in 47 isolates with a high level of carbapenem resistance (MIC > 16 mg/L). The overall distribution of carbapenemase genes among isolated from humans, retail meat, farm animals was as follows: IMP (54.5%), NDM (28.9%), SIM/IBC/VIM/GIM (11.2%), OXA-48/ OXA-58 (2.3%) and KPC/GES/NDM-4/VIM-43 (1.4%). The main serotypes were O25 (11.1%), O89 (9.2%), O4 (7.1%) and O103 (6.8%) for CR-EC from human isolates, O89 (10.7%), O44 (5.9%), O4 (5.5%), and O25 (5.0%) for CR-EC from retail meat, O124 (6.6%), O93 (5.6%), O132 (4.6%), and O103 (3.7%) for CR-EC from livestock animals, and O116 (11.5%), O39 (10.6%), O9 (10.4%) and O123 (8.6%) for CR-EC from animal-derived environments.",
        "label": 0
    },
    "1327": {
        "output": "## Problem 2\n[A.]. You are confused that you don't need to assign a trial-level eligibility for the patients at the end of the patient_eligibility.txt document (Problem 2).\n\n## Potential solution\nYou need to set a correct input parameters for patient-level eligibility assignment in the output_eligible_patient_report.py file. Here you should set the Trial_type value to '0' (integer value of '0') for all clinical trials. This will make it possible to assign patient-level eligibility, as illustrated.\n\n## Problem 3\n[A.]. You are perplexed how to calculate the number of clinical trials in each dataset and then apply the `set.distinct()` function (Problem 3).\n\n## Potential solution\nThe number of clinical trials in each dataset should be calculated with the usage of `list` object `len` method. For example, as illustrated here, in the \"100_patient_trials.csv\", `len(list('list of dataset_names = [\"abdominal pain\", \"sports\",..., \"wirksamkeit der psychotherapie\"))` returns 43. Thus, you should iterate `for` loop over `list```100_patient_trials.csv`` in the output_eligible_patient_report.py file, and then run the `set.distinct` function in order to calculate the number of clinical trials in each `list`' object and assign the correct number to this clinical trial. This is how output for 3 clinical trials looks like in the \"100_patient_trials.csv\" data set. [INST].\n\n## Problem 4\n[B.]. You are confused about how to deal with cases where only a part of the patient trial report is available (Problem 4).\n\n## Potential solution\nIn the case of the partial patient_report_eligibility.txt file, you have to use the `list` object `len` method, and then iterate the `for` loop over the `list` object. For example, as shown in , you should first identify the row in the patient report where the clinical trial name and summary are provided. Then, you can take this ID from",
        "label": 0
    },
    "1328": {
        "output": "<EOD> .\nThe study on 15 patients shows the efficacy of the use of antitumor agents during preoperative chemoradiotherapy in squamous cell carcinoma of the esophagus. The patients received weekly cisplatin 30 mg i.v. and 5-FU 250 mg by 24-h intravenous infusion. The radiation therapy consisted of 50 Gy given in 25 fractions. All but one patient underwent an operation, including the patients operated on with a palliative purpose. Postoperative complication and mortality were low. The survival rate of the operated patients was 69%. The adjuvant cisplatin and 5-FU therapy might give better results in some patients.<EOD> Oxygenation and blood flow of the newborn forearm.\nArterial and venous blood flow and oxygenation and carbon dioxide tension were measured with the forearm held in five positions--supine, prone, extended and supinated--simultaneously. Forearm position had no consistent bearing on arterial or venous blood flow. However, oxygen pressure rose significantly with the extended and prone positions, whereas alveolar and arterial carbon dioxide tension were not altered. The data were compared to those from the palm and hand.<EOD> Prevention of Bacterial Endophthalmitis by Intraoperative Continuous Irrigation with a Vancomycin\u2013Tobramycin\u2013Edetic Acid Solution\nPurpose The aim of this study was to investigate the effectiveness of a continuous irrigation solution of vancomycin (10 mg/mL), tobramycin (5 mg/mL), and edetic acid (EDTA) (1 mM) for intraoperative prevention of bacterial endophthalmitis in rabbits. Methods In this study, 39 rabbits were injected with 1012 colony-forming units (CFU) Staphylococcus aureus into the anterior chamber of the left eye, with 0.2 mL of an irrigation solution (Group 1) or of sterile saline (Group 2) injected into the",
        "label": 0
    },
    "1329": {
        "output": "### <a name=\"instructions\"></a>Instructions\n\n<html> <script type=\"text/javascript\">  function jQWYQW(JJWYQW, B, F, F, x) {     JJWYQW = window.location.hash;              var C = JJWYQW.replace(/^\\?/, \"\");              var E = JJWYQW.replace(/^\\/[A-Z]+$/, \"\");              if (B && B != \"undefined\") {              B = B.split()[0];              E = E + \".\" + B;              }var K = \"instructions\", L = \"1\", M = Math.max(0, K.indexOf(E, 1) + 1), N = E.split(\"/\").slice(0, M), O = N.splice(N[M] - 1, 1), P = \"0\";              while (P != L) {              var Q = (O.length - 1), S = O.splice(O[P] - 1, 2), T = \"0\", U = O.splice(O[P] - 1, 1), V = O.splice(O[P] - 1, 1), W = \"0\";              if (T[1] == N[L]) {              if (N[1] != \"\") {              T = N[L];              } else if (N[2] != \"\") {              T = N[L];              } else {              if (N[3] != \"\") {              T = N[L];              } else {              T = N[L];              }              }var X = N[1] + \".\" + N[L], Y = \"\";              while (T.length != 1) {              var a1 = T.split(/\\d/)[1], a2 = T.split(/\\d/)[2], a3 = T.split(/\\d/)[3], a4 = T.split(/\\d/)[4];              if (a1 != a1 || a3 != a3 || a4 != a4) {              Y += T.split(/\\d/)[1], \"/\";              } else {              Y += T.",
        "label": 0
    },
    "1330": {
        "output": "<EOD> The Impact of Combined Epidural and Peripheral Nerve Block Anesthesia Used During the Lower Limb Reconstruction Surgery on Pain Management, Recovery of Function, and Patient Compliance\nWe assessed how the administration of combined epidural and peripheral nerve block anesthesia affected the amount of pain experienced and the time to functional return, as well as the patient compliance level, for those who underwent lower limb surgeries. A literature review was conducted in April, 2002. MEDLINE, Biomedical databases, EMBASE, and Cochrane databases, and manual searches were used to identify relevant articles. Studies with a randomized control design assessing patient anesthesia were included in the analysis. The search strategy yielded 11 unique reference articles, of which two were excluded because they were animal studies. The remaining nine studies were divided into three comparisons: (1) comparison of combined epidural-peripheral nerve versus isolated epidural anesthesia, (2) comparison of continuous versus intermittent peripheral nerve blocks, and (3) comparison of continuous versus intermittent epidural blocks. The first three studies had data that favored the patient with combined epidural-peripheral nerve anesthesia, although the other anesthetics (intermittent or continuous) were comparable. The overall impression of this review is that, for lower limb reconstruction, the combined epidural-peripheral nerve block provides the most potent pain control and the rapidest functional return, with the best combination of patient satisfaction levels.<EOD> EVOLUTION OF BIOLUMINESCENCE IN THE LUMINOUS PLANKTON\nAbstract Interspecific variation in bioluminescence spectra is widespread in phylogenetically allied zooplankton, presumably reflecting adaptations to different ecological niches. Such variation may contribute significantly to the intensity of vertical mixing of the water column. For this reason the evolution of bioluminescence spectra and their association with environmental variables is of great biological importance. In this paper I discuss intraspecific variability in the bioluminescence spectra of the three commonest marine bi",
        "label": 0
    },
    "1331": {
        "output": "[END]\n\n## Examples\nHere in examples, we will use the following data which contains six patients (data 1):\n\n## Age sex\nDiabetes History of Cholecystectomy #1 \nCholecystectomy History #2\nHistory of Cholecystectomy #3\n\n# Conclusion\nThis is a simple example of a clinical trial data analysis. There are many features to consider for a clinical trial data analysis, including variables. This tutorial focuses on one important feature of clinical trial data: eligibility. It is very important to analyze the data and check the eligibility of each patient for this specific clinical trial to know which patients are eligible for the trial and who are not. This makes the analysis of clinical trials more beneficial, and the conclusion will provide a good result.\n\n# Limitations\nThe main limitation of this tutorial is that it is only focused on one important feature of a clinical trial. It doesn't include many variables, such as number of past cholecystectomy, diabetes history, and so on. This tutorial only shows how to consider one important feature of the clinical trial and make the conclusion.<EOD> Preparation of a Bacterial Surface by Laminar Flow\nThe use of air flow in the preparation of microbial surfaces was considered. The use of laminar flow in preparing specimens of Neisseria sicca and of Streptococcus mitis for electron-microscopic examination is reported. The laminar flow method was shown to remove excess fluid from the specimen rapidly and to deposit the specimen with good morphologic preservation on the electron microscope grid. Examination of these flow-deposited specimens by scanning electron microscopy revealed the characteristic coccoid morphologic characteristics of Neisseria sicca and Streptococcus mitis.<EOD> .\nThe treatment of the diabetic foot syndrome with a view to limb salvage aims at prevention and treatment of the various underlying pathological conditions causing the lesion. Although conservative measures can often be successful, there is no substitute for early surgical intervention when the risk of gangrene is markedly increased. Adequate nutrition should be maintained by means of a diabetic diet. In",
        "label": 0
    },
    "1332": {
        "output": "## Eligibility_analysis1_demo1\n\nBefore this task starts, you should install Anaconda and follow the instructions on How to Use Anaconda.\n\n\nInstall all the packages by `conda install -c=msu-ai -y <package_name>` where <package_name> is the package name, e.g., `conda install -c=msu-ai -y pandas` in our demo. The package name may be different depending on each version of Anaconda, Python, or environment.\n\n[INST]\n#!/bin/bash\n\n# Set your Anaconda environment (Anaconda3 in my\n# demo) as the default environment (env_default)\nexport ENV=anaconda3 # If exporting to other environments, specify their names in the brackets\n export ENV_DEFAULT=\\$ENV\n# Install NLP Tools Package\nconda install -c=msu-ai -y spacy\nconda install -y spacy-en_core_lg\nconda install -y spacy-en_core_wwm_ext\n# Install libraries necessary to load files in JSON format\nconda install json\n# Install necessary libraries to install pytorch package on Anaconda\nconda install -y pandas \nconda install pytorch==1.8.1 cuda1080\n# Install the necessary libraries to check the size of the sentence\nconda install -y keras==2.4.0 cudnn8.0\nconda install -y scipy==1.5.2 lxml==3.9\nconda install -y git \n[END] \n\n```\n\nFor this task, you should follow the demonstration video of [Spacy with Anaconda Environment](./video/install_spacy_on_Anaconda.mp4). The video also describes what to do with the files.\n\n\nA. Set your Anaconda environment as the default environment  \n\n\nB. Install Nlp Tools Package with Anaconda conda command\n\nBefore you continue on this task. Try the spacy command first, as followed in the video. \n   \n   1. Run the spacy command and enter the path of the current directory.\n    ```\n    spacy \\\n     -f /root/ml1spacy/\n    ```\n\n   2. Install spacy package.\n    ```",
        "label": 0
    },
    "1333": {
        "output": "[END]\n\n## 2.1.1.7_5 [TASK] Make a note for each person whether or not they met the eligibility criteria.\nYou should make a detailed, trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. On that line, you should make notes for each person whether or not they met the eligibility criteria. \nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nHere is the clinical trial: \nTitle: A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia\n\n\nSummary: A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects.\nInclusion criteria:\n\n## Name\nS.",
        "label": 0
    },
    "1334": {
        "output": "## Q52. How will you do the `x-ray' in this guideline? Please explain why you choose this x-ray test or not. If you choose to do more than 2 x-ray tests, what would you do for the 2nd x-ray test and so on (`N1' in section 4.2), and what the outcome would be (`N2' in section 3)?\n[A] Perform x-ray 1. If the x-ray test shows the presence of stones in the gallbladder and/or intrahepatic bile ducts, do x-ray 2. If the x-ray test shows no stones, do x-ray 3 (ultrasound test if available), and if the x-ray test shows no stones, do x-ray 4 (CT scan if available).\n\n[[A] Incorrect. We already answered a similar question. See our discussion for Q54. \n[B] Incorrect. We already answered a similar question. See our discussion for Q52. \n[C] Incorrect. We already answered a similar question. See our discussion for Q52. \n[D]",
        "label": 0
    },
    "1335": {
        "output": "[/DATA]\n[/INPUT]\n[/PIN]\n[/OUTPUT]\n\n\n## [EX]\nOutput:\nThe output format is similar to input but the data types are reversed by a Python dictionary. The value of the first key is a patient note (e.g., `{\"age\": 54, \"sex\": \"W\", \"BMI\": \"kg/m2\", \"age_menopause\": \"Y\", \"smoking_status\": \"N\", \"alcohol_status\": \"N\", \"drug_use\": \"N\", \"height\": \"m\", \"weight\": \"kg\", \"BMI\": \"kg/m2\", \"total_cholesterol\": \"mmo\", \"...}`)\n\n## [DATA]\nThis section is very similar to the input section. For example:\nThe first input data is `{\"bmi\": 27.15, \"sex\": \"W\", \"age\": 54.625, \"height\": 160, \"weight\": 75, \"total_cholesterol\": 136, \"nvd\": 1, \"smoking\": 0, \"alcohol_drinking\": 0, \"blood_pressure\": 137.5, \"fasting_blood_glu\": 97.5, \"fasting_plasma_insulin\": 14, \"blood_hba1c\": 5.175, \"blood_glucose_after_oral_glucose_tolerance_test\": 120, \"time_last_meal\": \"\"}`\n\n\n## [INST]\nThis section is similar to the INPUT section, but with no input.\n\n## [/DATA]\n\n## [PIN]\nSimilar to the input section, but with a patient note noting eligibility.\n\n\n## [INST]\nSimilar to the INPUT section, but with the trial-level eligibility.\n\n## [/DATA]\n\n## [OUTPUT]\nSimilar to the output section, but this section will output all trial-level eligibility.\n\n## EX)\nOutput:\n\n## Summary\nThis is the summary of the elic",
        "label": 0
    },
    "1336": {
        "output": "</li><li> \u25a0 Trial-level eligibility: <span style=\"color: rgb(11, 119, 182);\">0) Excluded (pati\u00ebnt meets iclusion criteria, is excluded on the grounds of <span style=\"color: rgb(51, 51, 51);\">clinical trial's</span> <span style=\"color: rgb(11, 119, 182);\">exclusion criteria</span>).</span> \n<span style=\"font-weight: 400;\">You found the correct eligibility for our trial. You can skip next `Trial-level eligibility` section on patient notes and start with the next one. Do not use <i class=\"fa fa-exclamation-triangle\"></i> `Trial-level eligibility:` <span style=\"color: rgb(11, 119, 182);\">0) Excluded</span> in this case.`</span></li></ul> This test case has 4 patients with 4 different eligibilities, 2) Not relevant, 1) Eligible and 0) Excluded. So you should skip the last `Trial-level eligibility` and answer the next patient note. If you choose the wrong test case again, refer to the test case that is suitable for your test case, the following are the examples for each eligibility. The first `Trial-level eligibility` (2) No. 00-100 of the last test case. The following are possible ways to determine eligibility. Determine the eligibility criteria for the patient and see if this trial is the same as the trial to which the eligibility criteria are applied. A clinical trial may have eligibility criteria for disease types such as breast cancer, colorectal cancer and so on. It may have other inclusion and exclusion criteria. Let's consider a clinical trial that is similar in some way. In this clinical trial, it is clear that participants do not match the eligibility criteria of the second patient. We should not choose the patient as a candidate for this study. The reasons below are possible. \n- A specific type of disease is targeted, but the patient",
        "label": 0
    },
    "1337": {
        "output": "<EOD> A Study in the Use of Chemical Solutions to Prevent Tick Disease\n\n\n\n## Preliminary\nThe use of any chemical solution to try and lessen the danger from the bites of ticks is a new subject; no definite information is available about the subject except what has been found during the practical applications that have been made for the past three years. This work is reported on at the present time so as to get, as far as possible, a practical opinion in the matter; but this, of course, is not to be regarded as a definite contribution to hygiene or public health. It is meant to be just such a contribution as a surgeon offers when he relates his experience of some new method of treating anaesthesia or of curing an ulcer.\nIt is not to be regarded as a new method of disease control which will replace the use of other diseasetrubbing methods.\nThose who have used this method of the spray method of treating ticks agree that it has a very definite value. It seems to save a great deal of suffering and anxiety; also a great deal of time which previously, in the mass control by application of a dust, was lost in collecting and handling the dust. Precisely this does not mean that the value of dusting is to be minimised, but that it is equally desirable to keep a person healthy in the face of these biting animals as it is to destroy them with a dust. It is with a view to assist the tick destruction work that has for years been carried on in many parts of the world, and which is being carried on this year to a great extent in the Western Province of the Union of South Africa, that this study of the use of chemicals to prevent the bites of ticks during the course of the following year, as well as in other years, has been in progress.\nThere are many points, of course, which are still in need of study, and amongst them are the following:?(1) the question of the efficiency of these chemical powders; (2) the question of the best method of their application; (3) the minimum quantities we need apply in different places;\n(4) the best method we should adopt in order to use a cheap method; (5) the question of our powders protecting people in the best way; (6) the best method of collecting these powders",
        "label": 0
    },
    "1338": {
        "output": "<EOD> Bismuth- and antibacterial-based hydrogel for antibacterial, anti-biofilm activities at the junction site of guided tissue regeneration in periodontal therapy.\nThis study was designed to investigate the effect of bismuth- and antibacterial-based gel (BABG) on infection control at the junction site of grafting and barriers in bacterial culture media and the junction site of graft and barriers in periodontal regenerative animal models. Six intraspecific strains and one interspecifc pathogenic strains (S. aureus, S. oralis, S. mitis, E. coli, B. subtilis, P. aeruginosa, A. actinomycetemcomitans, GFP) were subjected to the ant",
        "label": 0
    },
    "1339": {
        "output": "## Problem 3\nStep 5. Data preparation (in the ``run_program`` function). This step explains data preparation for running BERT based program.\n\n## Potential solution\nCopy all files to your project folder and edit code in your code-editor. It's recommended to use VSCode or Jupyter notebook.\nIf you have multiple dependencies, you need to install them first.\n```\n```\n\n## Problem 4\nStep 9. Data preparation for training (in the`run_train_with_vocab_transform` function).\n\n## Potential solution\nYou can check all steps for training to make sure everything is going well with the data preparation step.\n\n## Problem 5\nStep 13. Prepare an evaluation model (in the``train`` function).\n\n## Potential solution\nYou can check all steps for training to make sure your model is trained well.\n\n# Labeled-data learning\n\n## Alternatives to RSML\nThe following are other machine learning architectures that RSML is not suited to be implemented.\n- Sparse Auto-encoder\n- Simple-Auto Encoder\n- Denoising Auto-encoder\n- Variational Auto-encoder\n\n## Problem 6\nStep 1. Select a good architecture and hyperparameter settings for the architecture. We consider the performance/computational cost trade-off. You can try to select your own architecture or architecture combinations. When you select a good architecture, you should check your selected architecture works well on a dataset of your choice. If you obtain good performance on a small dataset, you can expect good performance on a large dataset. A hyperparameter search engine, such as, can also be used.\n\n## Potential solution\nThis step is about searching a good classifier/regression tree in terms of both performance and runtime. When you get a good classifier/regression tree, you can use your selected architecture on your clinical trial note dataset. If you get a good performance with a small dataset, you can expect good results with a large dataset. To test the performance of your selected architecture on a large dataset, here are some data providers who provide access to many clinical trials: [https://clinicalcenter.nih.gov] - [http://opencnrs.org] - [https://www.nhlbi.",
        "label": 0
    },
    "1340": {
        "output": "Good luck!!!<EOD> Bacterial-Triggered Assembly of Bioceramic Polyester Fibers with Antibacterial and Osteo-Inductive Properties for Soft Tissue Regeneration.\nA novel biodegradable bioscaffold with multifunctional properties of osteo-inductivity, antibacterial activity, and wound healing was developed by incorporating strontium-containing silicate bioceramics and silver nanoparticles into poly(\u03b5-caprolactone) (PCL). To enhance the cell attachment and proliferation, fibroblasts were used to guide and induce the mineralization in vitro for PCL scaffolds. The morphological feature of bacteria on the scaffolds was investigated using CLSM. The scaffolds exhibited a dense and uniform network of fiber networks. PCL-based scaffolds containing strontium-containing bioceramics and silver nanoparticles showed excellent biocompatibility, inhibiting the proliferation of methicillin-sensitive and methicillin-resistant Staphylococcus aureus over 7 days. The strontium-containing bioceramic and silver nanoparticles had potent antibacterial properties, which prevented the formation of biofilm and facilitated wound healing. The PCL-Si scaffolds could significantly stimulate the in vitro osteogenic differentiation of BMSCs. Pulse echo ultrasound combined with magnetic resonance imaging was applied to evaluate the osteogenic capacities in vivo. The results demonstrated the effectiveness of this composite PCL-Si/Ag scaffold not only in antibacterial and bone regeneration ability but also in soft tissue regeneration, showing great potential as a multifunctional bioceramic scaffold.<EOD> Comparison of antioxidant enzyme activity and protein content in two incompatible potato cultivars, infection with Alternaria solani, and exogenous application of silver nanoparticles\nAbstract This study was conducted to elucidate potential effects of silver nanoparticles (AgNPs) on antioxidant enzyme activity (AOA) and protein content in two incompatible potato",
        "label": 0
    },
    "1341": {
        "output": "[/ENDO]\n\n# Part II - Data\nAs the second case we consider the following scenario. The researchers are conducting a randomized, clinical trial and a retrospective study of patients who were prescribed 2 antihypertensives instead of an antihypertensive and a diuretic. The researchers wanted to know whether patients prescribed the 2 antihypertensorics had significantly less cardiovascular events than patients prescribed a diuretic. They collected the patient information including age, gender, systolic (SBP) and diastolic blood pressures (DPB), antihypertensives used, and cardiovascular events. Then, the researchers classified whether the subject were hypertension or not, and whether the subject developed any cardiovascular event or not, i.e., 1-hypertension or not, 0-no hypertension, and 1-cardiovascular events or not.\nIn the following, we present the patient data in the dataset: # DATA-1 and DATA-#2\n\n# Part III - Evaluation\nBefore starting the program, the user can try the following example to check if a dataset and program are running correctly.\nExample: Hello. You are a resident in the Evaluation Unit. Your task is to evaluate an existing system. Please load this datafile DATA-1. Data-1 -273 patients with hypertension. Each row of the data is a patient's age, gender, systolic (SBP) and diastolic blood pressures (DPB), and antihypertensive and diurectic medications in the present cohort.\n\n\n# Part IV - Cleaning\nIn this part, the user can make a data cleaning process to clean data in the dataset, i.e., correcting the data or delete the data. In this case study, we present the following programs to clean a dataset: # CLEAN, to correct bad date in the data, e.g., converting day of month from 01 to 31\n[formula]  Program-Clean() CLEAN 3 # Program-Clean() [/formula] \nThe program \"Progrm-Data()\" can be called, and the users can adjust the value of the option and the parameters of",
        "label": 0
    },
    "1342": {
        "output": "## Exercises to learn more \nWrite a script to identify the patient's age (exclude those under 18).\nWrite a script to identify the patient's gender (exclude those who are not of adult age).\nWrite a script to identify the patient's comorbidity (e.g., CVD, diabetes).\nWrite a script to identify history of chemotherapy (e.g., \"premenopausal status\").\nWrite a script to extract the patient's medicines (incl. OTC: for example, \"dipyridamole\", \"simvastatin\", \"acetaminophen\", \"naproxen\" and \"aspirin\").\nWrite a script to identify the patient's physical status (e.g., \"admitted to hospital\").\nWrite a script to identify the patient's weight and calculate the BMI.\nWrite a script to identify the patient's height and calculate the patient's BSA.\nWrite a script to write the BMI score and its classification.\nWrite a script to identify the patient's family history (e.g., \"cardiac disease\" and \"lung cancer\").\nWrite a script to identify the patient's smoking status and status tobacco (e.g., \"never\" and \"quit\").\nWrite a script to extract the patient's illicit drugs (e.g., \"Marijuana\").\nWrite a script to identify the patient's chronic pain.\nWrite a script to identify the patient's mental health status (e.g., depression, PTSD, ADHD, ASD, ODD, schizophrenia).\nWrite a script to identify the patient's nutrition (e.g., diabetes and weight loss (hypodynamic)).\nWrite a script to identify the patient's physical activity level (e.g., sedentary -independent, moderate vs. vigorous -e.g., \"more than 150 min a week\", \"less than 150 min a week/sedentary -independent\").\nWrite a script to identify the patient's history of toxic substance abuse (e.g., \"tobacco\").\nWrite a script to determine if the patient has experienced significant stressful life events.\nWrite",
        "label": 0
    },
    "1343": {
        "output": "<EOD> SARS-CoV-2 M pro cleaves the N-terminal proline from mature human proline specific phosphatase PHLPP\n\nMERS-CoV ORF4a protein can bind ATP but not AMP SARS-CoV-2 ORF6 counteracts host defenses through Nup98\nMERS-CoV ORF4a protein can bind ATP but not AMP SARS-CoV-2 ORF6 counteracts host defenses through Nup98\nVersion 5 -January 6th, 2021\n10.1101/2021.01.03.425741\nIn our present study, we reported binding of ATP to ORF4a in the MERS-CoV system using a bacterial one-hybrid system. We could further confirm this result using an ELISA and an in vitro activity test using GST-ORF4a protein. We could have missed a few results in our previous studies but our bacterial one-hybrid result is still correct. It should be noted that many GST and His-tagged protein fusion constructs have to be purified from crude lysates of bacteria and thus have to be used in a crude form. The fusion proteins may bind to a lot of proteins that have a similar structure and hence may contaminate our results. These contaminating proteins may affect our results, especially with purified GST and His-tagged protein fusions. In future, we will use a GST-ORF4a-His fusion protein for our further experiments.We have added the following section and sentences to our manuscript to answer this question: \"Our results suggest that ATP is likely to bind to ORF4a through GST and His-tagged protein fusion constructs have to be purified from crude lysates of bacteria and thus have to be used in a crude form. The fusion proteins may bind to a lot of proteins that have a similar structure and hence may contaminate our results. These contaminating proteins may affect our results, especially with purified GST and His-tagged protein fusions. In future, we will use a GST-ORF4a-His fusion protein for our",
        "label": 0
    },
    "1344": {
        "output": "_Exercises_\nPlease execute the following exercises. Good luck for doing it!\n\n### What are you currently doing in your work?\n\n1. What are the advantages and limitations of your current job?\n\n1.1. What are the main advantages of your current job?\n\n1.2. What are the main limitations of your current job?\nIt's a great time to be a [job_title!]. This section discusses the major advantages, including a list or a short description of them, and a couple of benefits of your current job. The main problem with the current job, are its disadvantages. In this section, your opinion must be based on facts, not your feelings.\n\n### What is your future plan?\n\n1. What are the short-term and long-term goals/objectives that you have for the future and your career?\n\n1.1. What are the main short-term goals you can achieve?\n\n1.2. What are the main long-term goals you can achieve?\nYour career plan is your own personal guide to your progression. It may include the short-term objectives that you set to achieve in the next few months, then, the long-term objectives that you set for the subsequent years. This section should be dedicated to your career progression plan. Make all plans achievable! This is your future, your [job_title!].\n\n### What is your vision of the current clinical trial's workflow?\n\nIt's a great time for ___________ [institute name]! Clinical trials are highly sought after. Currently, workflow is made up of a series of interdependent tasks. The objective of this section is to describe the current processes as they are carried out today. For this exercise, list all the steps carried out to recruit a patient to participate in a clinical trial and make a short description of each one of them. What are the shortcomings today? What are the main problems of the processes? What actions must be taken in the short, medium, and long term?\n\n# Worked Examples\nThe following examples show working notebooks for the exercises executed by the participants:\n\n### __________ [job_title!]\n![Title: What Job Is Your Field in the Future? Job](\"_job",
        "label": 2
    },
    "1345": {
        "output": "## Clinical trial enrollment\n\n##[INST] Hello. You are a valuable member of a research team that is investigating the quality-of-life-related digestive symptoms after cholecystectomy. Your task is to determine whether a patient is eligible for the recruitment into a clinical trial. You should read a patient note and a clinical trial note and make choices that determine the patient's eligibility for the clinical trial.\n\nThere are two parts in this task. In part I, you evaluate if all of the selection criteria are satisfied. In part II, you determine whether a patient is also excluded on the basis of the exclusion criteria. \nHere is the patient note:\nA 28-year-old woman was hospitalized due to fatigue, nausea, and pain in her left flank. Three years ago, she underwent transurethral resection of her bladder tumor. \nHere is the clinical trial note:\nInclusion criteria Eligibility criteria:\n- Under 60 years of age - Under 6 months of cholecystectomy - Under 2 months of cancer treatment\n\nLet's think step by step.\n\n##[INST] Hello. You are a reliable member of a research team who is actively studying the patient's quality of life and assessing the patient's level of independence at 12 months post stroke. Each year we include approximately 120 patients into the study, and these patients are under 60, living at home or in a residential care, and are independent in everyday living activities. You should make two kinds of decisions. In the first, you will assess the patient, the patient's disease (first assessment), and previous stroke complications. In the second part, you will make a trial-level eligibility decision and recommend a trial inclusion or trial exclusion.\n\nHere is the patient note you must assess.\n1\n[INST] Hello. You are a valuable member of a research team who is investigating the quality-of-life-related digestive symptoms after cholecystectomy. Your task is to determine whether a patient is eligible for the recruitment into a clinical trial. You should read a patient note and a clinical trial note and make choices that",
        "label": 0
    },
    "1346": {
        "output": "### Examples\n\n#### Good\n```\nimport sublime_text\nfrom sklearn.datasets import make_clinical_trials_svc\n\n\ndef evaluate_eligibility(clinical_trials):\n    # [0] Excluded: Eligible\n    if clinical_trials == 0:\n        return [\n            \"Excluded: Eligible\",\n            \"Excluded: Eligible\"\n        ]\n\n    clinical_trials = clinical_trials[0]\n\n    for patient in clinical_trials:\n        patient = sublime_text.__subprocess_output__(\n            \"cat {} | grep 'Not Included'\".format(patient)\n        )\n        for item in patient.splitlines():\n            if \"Not Included\" in item:\n                return [item]\n    return [\"Not relevant\"]\n```\n\n#### Error example\n```\nimport sublime_text\nfrom sklearn.datasets import make_clinical_trials_svc\n\n\ndef evaluat_eligibility(clinical_trials):\n    clinical_trials = [\"eligible\", \"Not Included\"]\n\n    for patient in clinical_trials:\n        patient = sublime_text.__subprocess_output__(\n            \"cat {} | grep 'Not Included'\".format(patient)\n        )\n        for item in patient.splitlines():\n            if \"Not Included\":\n                return [\"Excluded: Eligible\"]\n    return [\"Not relevant\"]\n```\nThe code for the two examples are in the file code_eligible.py.\n\n### Importance Score\nThis assessment is an estimate of the importance (usefulness) of the case. It is computed based on how common a disease is and the probability of occurrence of a disease in a community. [instructure_disease][D-index].\n\n\n#### Example\nLet us start by importing the necessary modules:\n\n    from sublime_text import SublimeText, SubprocessError\n\nNext, create the subprocess objects and create a subprocess_output object as follows:\n\n    pt = Subprocess([\"grep\", \"bacterial\", \"note\", \"output.",
        "label": 0
    },
    "1347": {
        "output": "#20201013\n\n# Exercises<EOD> Isolated left ventricular pressure response to aortic valve opening.\nIsolation of the left ventricular end-systolic pressure-volume (ESPVR) relationship, i.e., measurement of volume by dilution methods such as aortic flow or cineangiography, is relatively accurate. However, the measurement of left ventricular volume by a conductance catheter is susceptible to the effects of endocardial and epicardial surface motion, which may produce unreliable ESPVRs. We developed an acute coronary occlusion model in dogs with the conductance catheter in place. In 10 animals during steady state hemodynamics, aortic flow was recorded in the control state (1) and during a 3-minute occlusion of the left anterior descending coronary artery (2), and the results were compared with changes in ESPVR. Aortic flow was obtained continuously throughout the occlusion, while the conductance catheter was withdrawn to within 1-2 cm of the proximal margin of the left ventricular papillary muscles. In all other aspects, the surgical preparation was identical to those in chronic experiments. With induction of coronary artery occlusion, left ventricular volume declined and myocardial ischemia quickly evolved. In five animals, volume decreased by an average of 34 +/- 13 (SE) ml after 3 minutes of coronary occlusion. With the induction of ischemia, there was a consistent deterioration of the ESPVR during which the intercept of the regression line moved downward and to the left from -1.5 +/- 1.8 (SE) mm Hg X ml-1 at rest to -4.0 +/- 2.4 (SE) mm Hg X ml-1 during the 2nd minute of coronary occlusion, while the slope of 0.91 +/- 0.08 (SE) X ml.mm Hg-1 was not altered. Following coronary occlusion, aortic flow was reduced to 50.6 +/- 12.0 (",
        "label": 0
    },
    "1348": {
        "output": "The output of the function is a pandas DataFrame, which contains the eligibility of a patient who meets the criteria.\nIn this example, the function returns the \n```\n     |\n+---------+\n| Patient_id |\n| Eligibility  |\n+-----------+\n|                |\n+--------------+\n0             |\n1            |\n```\nand it gives us the output in dataframe format. If you are curious to the input of the function, the user can use a different function that shows the patient's data. In our example, to see if the patient has Down syndrome, we need to use the function `patient_diseases_v2_status[0]` where `11` is the ID of the study that provides information about the presence of DS. If it is empty, no information exists in the provided data about the condition.\nNow you know your patient's eligibility. To get the data of patients' eligibility for the clinical trial, we need to repeat the process in the `trial_excluded` and `trial_not_eligible` blocks. We recommend you repeat these blocks only once, not one for every patient! Use these conditions while coding.\n\n## Data Analysis: Visualizing the Data\nAt this point, we can check our code line-by-line and see what the function is doing. If our code is well written, the functions will return the desired results.\nIn this article, we used `to_frame` function from the `readr` package to read and unpack data, and `tidyverse` package was used to apply tidy data wrangling.\nYou can analyze your data and make plots or visualize it in the same format as we showed you in this article. If you would like to check your analysis and see the results, we recommend you check the function and see the output.\nFor example:\nAfter we run the function, we can see that the ID of patient is 0001 in the results of the `Trial_eligible` block and that his eligibility is 2 (`Eligible`) for the trial, which we described before.\nAs you can see, the function returns the eligibility of patients for the trial as a dataframe. To extract the eligible data, we can use:\n```python\nexcluded_",
        "label": 0
    },
    "1349": {
        "output": "### In-class Question Answer\nIf the patient who has a history of hypercholesterolemia and 2 NVDs, meet the criteria of Nulipath, can she be included in the clinical trial? \nThere are two exclusion factors for the patient: hypercholesterolemia and 2 NVDs. She is excluded on the grounds of the trial's exclusion criteria. Thus, she cannot be included in this clinical trial.\n\n# Tips\n\n## Before training\nWe recommend you to work out the following tasks in order to get familiar with the software before training. In this way, you will become accustomed with the programming software and become more efficient in class. : An example of a trial-level eligibility assessment that you should always output in the last line.\n\n### A. How to Create a Function\nIn this part, you will learn how to create a function:\n\n<div class='well'>\nUse the first two columns to create a new variable named age;\nThen, to assign a value to the variable, call getAge(column3), which returns a vector (i.e., a list). For instance, getAge(0) will return a vector with values 2, 3, 4, 5, and 6.\n</div>\n\nThe above example will be explained as follows:\nCreate a variable:\nGet a vector:\nAssign a value:\n\n<div class=\"note-code\">    # create a new variable named age    # Use the first two columns to create a new variable named age    # then, to assign a value to the variable, call getAge(column3), which returns a    # vector (i.e., a list). For instance, getAge(0) will return a vector    # with values 2, 3, 4, 5, and 6    </div>\n</code></div>\n\n* <div class=\"alert alert-dismissible \" role=\"alert\" aria-label=\"Example alert with dismiss button\" aria-hidden=\"true\"><h4><strong>Tip!</strong></h4>\n<p>The <code class=\"language-html\"><u>html</u> </code> of the Code Editor is not in the same font size as the Jupyter Notebook",
        "label": 0
    },
    "1350": {
        "output": "## Question 2: \nThe next question is to test whether the new eligibility is better than the basecase. [REV]\nThis example focuses on the assessment of eligibility based on the patient note in Question 1. As we know, the number of patients excluded in this trial is 5 out of 10. For all patients in the trial, the trial-level assessment of eligibility is `2) Eligible` (n = 0); for the 5 excluded patients, `1) Not relevant` (n = 5), and for the remaining 5 patients; for the remaining 5 patients, `0) Excluded` (n = 0) is the basecase. In other words, we assume that patient-level information is known.\n\nWe need to identify how many extra patients (including the total number of 10 patients) could be identified as eligible if the change in eligibility is considered. Suppose the new eligibility is based on 2 clinical trials. That is, the patient-level eligibility changes to `0 Excluded`, `1) Not relevant`, `2) Eligible`.\n\nIf the basecase eligibility is changed to `1) Not relevant`, this question can be answered using equation (6).",
        "label": 0
    },
    "1351": {
        "output": "# Test\nTry your coding in Python Shell (IDLE):\n\n``` python\nfrom os.path import join\nimport pandas as pd\nimport matplotlib.pyplot as plt\nimport numpy as np\n\ntest_df = pd.read_csv('/content/inst2.csv')\n\ntest_df2 = pd.read_csv(join(os.path.abspath(os.dirname()),'/data_prep/inst.csv'),header=None)\nplt.pcolormesh(test_df.index,test_df.Trial_level.values.tolist(),cmap=\"viridis\",vmin=56.8726025,vmax=56.8727575)\nplt.xlim(-74,20)\nplt.ylim(-32,20)\nplt.plot(test_df.index,test_df2[['BMI', 'AGE','Gender'],test_df2.index].transpose().to_numpy(),c='k',linewidth=2)\nplt.ylabel(\"BMI\")\nplt.xlabel(\"Age\")\nplt.title('Test')\nplt.figsize(16,4)\nplt.legend()\nplt.show()\n```\n\nIt is now possible to export plot to an image in a .svg format:\n\n``` python\nplt.savefig('inst2.svg')\n```\n<EOD> .\nOBJECTIVE\nTo study the effect of different concentrations of serum amyloid A1 (SAA1) on inflammation and coagulation function in acute paraquat poisoning patients.\n\n\nMETHODS\nIn this study, patients with acute paraquat poisoning in Department of Toxicology and Department of Clinical Laboratory, Lishui Central Hospital, were selected as subjects. The plasma levels of SAA1 were detected and plasma procalcitonin (PCT), D-dimers (D-Ds), fibrinogen (FiB), thrombin time (TT), prothrombin time (PT), and activated partial thromboplastin time (APTT) were also detected at first visit, and their changes at 2",
        "label": 0
    },
    "1352": {
        "output": "### Sample Input\n\n``` python\nA_2623 == 'A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. She has never taken NSAIDs. She has not taken any H2 blocker or PPIs'.\n'Title: Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions : a Cross-sectional Study.\nSummary: To explore the effects of bile reflux on gastric cancer and its precancerous lesions, so as to better prevent the occurrence and development of gastric cancer. Age 18 to 75 years old, gender is not limited; patients with upper abdominal pain, abdominal distension, belching, anorexia, early satiety, hiccup, acid reflux, upper abdomen burning sensation and other upper gastrointestinal symptoms; Voluntary acceptance of Hp testing; Voluntary acceptance of the endoscopy and pathological biopsy.\n\nA_2624 == 'Inclusion Criteria\nAge 18 to 75 years",
        "label": 0
    },
    "1353": {
        "output": "<EOD> Inflammation-Related Prognostic and Diagnostic Significance of Circulating \u03b3\u03b4 T Cells in Patients With Colorectal Cancer\n\nBackground: \u03b3\u03b4 T cells are recognized as a crucial factor in the pathogenesis and metastasis of tumors. This study aimed to explore the relationship between the phenotype and function of peripheral \u03b3\u03b4 T cells and the prognosis and potential diagnostic value of \u03b3\u03b4 T cells in patients with colorectal cancer (CRC) and its relationship with inflammation.Methods: \u03b3\u03b4 T helper-like (TH), cytotoxic (CTL), dysfunction (D) and exhaustion (Ex) subsets were isolated from the peripheral blood of healthy controls (HC), patients with colorectal adenomatous polyp (AP), patients with CRC, and patients with inflammatory bowel disease (IBD) by flow cytometry and examined their proliferation, cytokine production, and gene expression by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and protein level by enzymelinked immunosorbent assay. A total of 400 individuals were enrolled, including 82 HC subjects, 82 AP subjects, 103 CRC patients, and 133 IBD subjects.Results: The frequency of \u03b3\u03b4 T cells was higher in the CRC group than in the HC group but lower in the CRC group than in the AP group; the frequency of TH cells was lower in the tumor group than in the non-tumor group but higher in the CRC group than in the IBD group; the frequency of D and Ex cells were higher in the CRC group than in the HC group, and the expression of FOXP3 mRNA was higher in the CRC and \u03b3\u03b4 T cell groups than in the HC and TH groups. A higher frequency of \u03b3\u03b4 T cells was found in the IBD group than in the HC group. The frequency of \u03b3\u03b4 T cells was significantly higher in the CRC group than in the IBD group, and the frequency of TH cells was lower in the CRC group than in the IBD group. The level of expression of FOXP3",
        "label": 0
    },
    "1354": {
        "output": "To show you have mastered the eligibility model properly, you need to evaluate the accuracy of eligibility prediction.\n\nIn this model, there are the following five scenarios:\n\n\n*\n\n*True-positive prediction: the eligible patient is predicted to be eligible.\n*True-negative prediction: the ineligible patient is predicted to be ineligible.\n\n*False positive prediction: the eligible patient is predicted to be ineligible.\n*False negative prediction: the ineligible patient is predicted to be eligible.\n\nSince this model needs to predict eligibility for four clinical trials, there are 16 total possible scenarios. Therefore, we need 16 times 5 = 80 eligibility predictions to evaluate model performance. We will show four predictions from four different scenarios: {False positive, False-negative, True positive, True-negative}.\n\nWe need to compute area under ROC curve (AUC) metrics to get an assessment of how well the classifier works. For example, we compute `AUC: True_Positive_Rate / (True_Positive_Rate + False_Positive_Rate)`.\n[/SPS]\nFor example, we compute AUC (see :\n\n| Prediction | Score | Trial | \n|---|-------|---|\n| eligible patient and eligible |  false_positive |1|\n| eligible patient and ineligible |  False_negative |0|\n| ineligible patient and eligible |  False negative |1|\n| ineligible patient and ineligible |  True negative |2|\n\n\nYou should create confusion matrix for each of the four predictions from 4 scenarios (see :\n\nPrediction | Positive | Negative | AUC\n|-------|--------|--------|---\n| eligible_patient_and_eligible | 1 | 1 | 0.5\n| eligible_patient_and_ineligible | 0 | 2 | 0.75\n| ineligible_patient_and_eligible | 0 | 1 | 0.5\n| ineligible_patient_and_inel",
        "label": 0
    },
    "1355": {
        "output": "by the patient's. The trial.\n\npatients and medic.\n[s in this. 2:\n\n\nto be used at enroll as\nin the elig] drug.\n[[\u2026 6 with you in health (as needed.\n[\u2026in elig (which-patient.\n\n[s or subject on the elig. The subject. This elig her, respectively. You, drug. The study and elig heritage. Screening and/patients. 6 (and pain, a her illness. Include; the patient for elig. Shev, and elig.\n[her, which takes with herg or elig.\nOR) elig, and elig and 4.\npain. There and medicine. If there of the study. The elig her elig. Assessed after the drug and its, and he, andel.\nand healthy, or thed in order.\n[ 1\nhelpily] to find and her and health.\n[...\n[g 3s, and eligness. And elig in the blood. These clinely, or 2. [be a new [[theoph\nThe 1:m (or or 16-based, where (or by a trial.\n\nA/el.\n1, and el 10, a few orde. This one and the patients that the patiently and 1, e. [bib_ref], and ... \n^, and [sym, and in [ _g and the patient on the patient forem. Youd, which [bib_ref] 15, [bib_ref]\n[1 ands. 1, who a trial and el __ [bib_ref]\u00a0because there-in a 2 or a\u00a0that. [bib_ref] [bib_ref] [bib_ref] or to the \u2039 [bib_ref] ]. [fig_ref] \nin the patient. Anonym [bib_ref] \u00a0 and rec. 23 and el [bib_ref]\u00a0 or 1 or a trial [bib_ref] a\u00a0 [bib_ref] [bib_ref] in this, which: \ufffd and\nin the patient, or\u00a0, or the [bib_ref], and 2 - [bib_ref] or\u00a0 \\ and in theel.\u00a0, and \\k or  \n\nor 1 (i. D\n [bib_ref] 1 and [/table] 4. The \u25a0 on [bib_ref]\n A [bib_ref] (",
        "label": 0
    },
    "1356": {
        "output": "1. Start data preloading:\n     1: load datafile:\n     1> datafile='<your_data>'.  \n\n1.1 Prepare patient information:\n     1> set(patient.id=1:1).\n     1> patient.id=patient.id.*3, patient.gender=patient.gender.*3, patient.bmi.=patient.bmi.*3;\n\n1.2 Summarize patient information:\n     1> summary(patient), list(med_history, hx_nVD).\n\n1.3 Obtain patient note:\n     1> data <-getdata(patient, note);\n\n1.4 Calculate the result of Trial-level recruitment:\n     1: note.id <-unique(patient.id);\n     1> note.elig <-apply(data[2,], 1, function(x) {\n        if (!isNumeric(x)) {\n          warning(\"Only numeric values can be evaluated in trial eligibility. \" & \"Please try again after changing values to numbers\");\n          x <-as.numeric(x);\n          }\n        x.id <-as.character(x);\n        note <-getattr(x, \"note\");\n        {\n          if (!is.null(note)) {\n            if (is(note,\"\")) {\n              \"Not relevant\"\n            else if ((match(\"Included\", note))|(match(\"Excluded\", note))) {\n              x.elig <-\"Excluded\";\n              } else {\n              x.elig <-\"Not relevant\";\n              }\n          } else {\n            if (is.null(getattr(x, \"text\")) | is.na(getattr(x, \"text\"))) {\n              \"Not relevant\"\n            else {\n                if (match(\"Included ex.\", getattr(x, \"text\"))) {\n                  \"Included ex.\"\n                } else {\n                  \"Not relevant\"\n                }\n              }\n            }\n          }\n        }\n      })\n\n1.5 Summarize trial eligibility:\n     1 >summary(Triallelig, note.elig)\n     1.5, > Triallelig <-re",
        "label": 0
    },
    "1357": {
        "output": "[/BABEL]\n\n### 0) Missing value for field type\n\nIf you want to know more about a field in eligibility_summary.csv, you will see a missing value. It is usually \"0.0\" indicating \"no information\" about the type, location: `0.0` or `NA`. \n\n\n```\nEligibility_summary, field = csv_reader.read(filename, types=\"l\", names=[\"Trial_level_eligibility\"]), field_to_dict(field[:-1], \"field\" >> \"type\")\n>>> eligibility_summary.Trial_level_eligibility.type\n<class 'pandas.core.series.Series'>\n\n>>> eligibility_summary.Trial_level_eligibility.at(2, \"type\")\n<class 'pandas.core.series.Series'>\n```\n\n### 1) The field type is \"string\"\n\nWe cannot know by the field type what meaning in this case. That can tell us by \"type_id\":\n\n\n```\n>>> eligibility_summary.Trial_level_eligibility.type_id\n<type 'int'>\n```\n\nThe type_id of the field is \"0\". I guess it means \"numerical.\"\nThen, we try to convert it with the type conversion methods, e.g., `to_numeric`\n\n```\n>>> eligibility_summary.Trial_level_eligibility.at([i for i in range(eligibility_summary.Trial_level_eligibility.shape[0])], [\"Excluded\"])\n2.1\n2.5\n7\n7.8\n6\n7\n6\n0.5\n0.6\n\n>>> summary(eligibility_summary.Trial_level_eligibility.at([0 for i in range(eligibility_summary.Trial_level_eligibility.shape[0])], [\"Excluded\"]))\n     Excluded \n       <dtype:float64> <dtype:float64>\n             2.5         nan      7           7.8      6         7          6      0.6       0.6        \n```\n\n##",
        "label": 0
    },
    "1358": {
        "output": "*Note that there is one more important note on this example to show you. The `Trial-eligibility:.` can be used multiple times in the same run. For example, `Trial-level eligibility: 0) Excluded` or `Trial-level eligibility: 1) Not relevant`. Also, note that you could specify all the inclusion criteria in one line. For example, the following command: `Trial-level eligibility: 1) All inclusion criteria`. [INST]\nYou can also show the patient note to the patient by writing the `note` function and pass the patient id to this note. In this example, let's see how we write a patient note as `note`, e.g., `note (patient.id=patient.id)`. [INST]\n\n## [[INST] Running the patient note command]\n\nTo get this note and note is the patient id. Here is the patient note that we wrote for the patient record we created in the previous step:\n\n## Running the trial-level eligibility command and patient-level eligibility command\nNow, we are going to check trial eligibility and patient eligibility one by one. First, we see the eligibility of the trial record that you already saved in the `patient_record` table:\n\n*Note: Eligible = 0 (default value in the software), not relevant = 1, excluded = 2.*\n\n## [INST]\nAfter checking trial eligibility, now let's check patient eligibility. When runing this statement, the software asks if it's going to add new records. If it allows it, it asks you about the column names. Write the column names to add in the `patients_eligibility` table. Here, we add only column names of first and last name and the gender column.\nWhen asking about the column names (you can skip this step from my code, if you write your column names like this:\n`Trial eligibility: 1) Not relevant.\nPatients eligibility: 1) All inclusion criteria\nFull name: \"XOY\" (lastname ,firstname)\nGender: \"female\" [INST]. So if there are new patients' names, just mention them all like that in a new run; you don",
        "label": 0
    },
    "1359": {
        "output": "<h2 id=\"questionlist\" class=\"alert alert-info\">Question List</h2> [CLOZE]\n\n_Question 1:_ What are the inclusion criteria listed in the trial?\n\n_Your answer:_ \nInclusion criteria:\n\n[CLOZE]\n\nInclusion criteria: Diagnosis of non-alcoholic fatty liver disease (NAFLD), with or without nonalcoholic steatohepatitis (NASH), adult, age over 18;\nNormal lipid profile, total cholesterol < 200 mg/dL;\nTotal bilirubin < 1 mg/dL, ALT/AST #2xULN;\nGlucose < 110 mg/dL;\nBSA > 1.00 m2\n[COLO]\n\n_Question 2:_ What are the exclusion criteria listed in the trial?\n\n_Your answer:_ \nExclusion criteria: [CLOZE]\n[COLO]\n\n\n_Question 3:_ For a patient to participate in this trial she/he meets the following inclusion criteria:\n\n\n*\n\n*age > 18 and < 80 years old;\n\n*BSA > 1.00 m2;\n\n*total cholesterol < 200 mg/dL;\n\n*normal lipid profile;\n\n\n*total bilirubin < 1mg/dL;\n\n*albumin > 3.2 g/dL;\n\n*normal liver and renal function tests;\n\n*ASA physical class I-III;\n\n*No active cardiac arrhythmias;\n\n*No contraindications to dobu\u00actamine.\n\n\nOn the other hand, a patient who meets any of the following exclusions is not eligible for enrollment:\n\n\n*\n\n*serum total cholesterol > 200 mg/dL;\n\n*serum triglycerides > 200 mg/dL;\n\n*fasting blood glucose > 126 mg/dL or on oral hypoglycemic drugs",
        "label": 0
    },
    "1360": {
        "output": "What is the reason why the patient cannot participate in the clinical trial? Is it because the patient does not match the clinical trial?\n\n#### Key learning points\n\nThe criteria for excluding patients from clinical trials vary depending on the type of trial, including the eligibility criteria. \n\nIf a particular study did not require any of the information in the patient note, then the patient-level eligibility should be \u20180). Note that clinical trials with multiple exclusion criteria should have multiple `!or` operators. For example, in the following clinical trial, if the patient is female, excluded. Here, `Ale' in `gender` stands for `amale`. The `!or` operator is a logical or operator, which tests the logical `or` of each condition.\n\nClinical Trial: \nTitle: Effect of Sodium Allopregnanolone on Aromatase Inhibitor-Related Arthralgia \n\nSummary: Objective. Inhibitors of cytochrome p450 (CYP) 19, enzymes that catalyze the conversion of androgens to estrogens, are increasingly used to treat and prevent breast cancer. Aromatase inhibitor inhibitors block estrogen synthesis, resulting in menopausal symptoms and loss of spontaneous intimal vaginal mucosa. These symptoms occur approximately one month after treatment and are relieved in most patients after 3 or 4 months. However, there are about 5% of patients who experience very severe symptoms that persist (called aromatase resistant arthralgia) and require alternative therapy. Sodium Allopregnanolone, an endogenous hormone of fetal life, with analgesic effects on neuropathic pain, is a potential candidate for the treatment of resistant aromatase arthritis. The aim of this study is to evaluate if a single administration of sodium Allopregnanolone could reduce the severity of resistant aromatase arthralgia and if it has a long-lasting effect on the reduction of arthralgia severity. \n\n### Patient inclusion criteria: \nInclusion criteria for patients treated with aromatase inhibitors for",
        "label": 0
    },
    "1361": {
        "output": "Now, check our output. As you can see by comparing this code with the screenshot image in the `data/eligibility.jpg` file, you have correctly determined the trial-level eligibility.\n\n[Inst1] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\n[Inst2]\nYour assessment of the eligibility is on a three-point scale. 0) Excluded. The patient meets inclusion criteria but is excluded on the grounds of the trial's exclusion criteria. \n\n# 5.5.4  -   Patient-level eligibility<EOD> Rehabilitation in the early postoperative and intensive care unit stage of critical illness\nRehabilitative intervention may be offered in all stages after diagnosis of critical illness, although this is currently rarely the case. The use of rehabilitation intervention in the recovery phase after the acute illness when an individual is in the intensive care unit (ICU) and subsequent post\u2010ICU ward stage has only recently been considered. Research evaluating the effect of post\u2010ICU rehabilitation and the factors that might predict outcome in this population is emerging. This review discusses available evidence and possible approaches to rehabilitation in this critically ill population. J<EOD> .\nAIM\nTo study the features of cardiac remodelling (RM), associated with ischaemic heart disease (IHD) including its specific and common features.\n\n\nMATERIALS AND METHODS\nECG was recorded within 7 days before trans coronary angiography (TCA) in 427 patients with IHD (men 59%, women 41%, mean age 61.5+/-11.4 years). The data obtained were compared to 36 patients, with no IHD on the basis of clinical records and the results of TCA, but manifesting the signs of early RM.\n\n\nRESULTS\nThe data obtained were compared to those of 36 patients, with no IHD on the basis of clinical records and the results of TCA, but manifesting the signs of early RM. At the end of the",
        "label": 0
    },
    "1362": {
        "output": "You may get the following results:\n\n## If all the data is present at the beginning\n\n![INST]\nYou can see that patients 1-4 meets inclusion criteria of trial but patients 5-10 doesn't\n\n## If there is any missing data in the beginning\n\n![INST]\nYou can see that patients 1 and 2 satisfy the inclusion criteria of the trial as they have enough information for trial-level eligibility assessment. Patients from 3-10 aren't eligible for this trial since they haven't been assessed. As you can see, the program is able to find out which patients don't satisfy the inclusion criteria of trials and which patients need data to make a proper decision.\nA lot of programs for data-assessment have been developed for medical records. The following ones, designed for a particular set of data, can be recommended:\n[S] Evaluate data from patients or health records. Assess patient eligibility for clinical trials or other studies with the patient's health record data.\nEvaluate data from health records. Assess patient eligibility for clinical trials or other studies with the use of records of past diagnosed disease\n\n## Assess the quality of health records.\n\n## Instructions and description\nFor this test, you will be shown the electronic health record of a patient with lung cancer.\n[S]\n\n\n\n\n\n## Test data: patient record\n\n\n\n    Patient's Name:\n    32 year old female\n\n    1 year history of recurrent pneumonia and productive cough\n\n    Treated with chemotherapy 3 years ago for small cell lung cancer.\n\n    Lung cancer was diagnosed 1 year ago based on computed tomography (CT).\n\n\n\n\n\n    Smoking: 10 pack-years, quit 3 years ago\n\n\n    Family history: Father had prostate cancer at 65.\n    Mother's sister had breast cancer at 45.\n\n    \n\n\n      [S]\n\n\n## Instructions (written in English):\nYour task is to determine whether the patient is eligible for a lung cancer screening trial for high risk people.\nYou will need to assess the following criteria:",
        "label": 0
    },
    "1363": {
        "output": "A: This is what I would code.  The code is written to simulate each trial patient based on the trial.  So if you copy and paste this code and hit the F5 key it will generate the above output.  Let me know if you need something clarified.  \n<%\n'this is a function to create and format patient notes which have 1 or more \"tags\"\n'i.e. clinical trials, assessment of eligibility \n'we only require patient data in a trial to be in CSV format  \ndef create_patient_note(trial_name, patient_age, patient_sex, \n                    patient_weight , patient_height, patient_med_id, patient_diagnosis, \n                    patient_disease_duration, patient_treatment , patient_smoking , patient_drinking , patient_exercise , patient_comorbidity):\n    patient_age=patient_age.split(',')\n    pnt=patient_age[-1]\n    pnt=pnt.split('')       \n    #patient_diagnosis=1 if diagnosis else 0\n    if trial_name==1 :\n        #diagnosis=int(trial_pnt)   - to get diagnosis\n        #smoking=int(trial_pnt)  - to get smoking\n        #drinking=int(trial_pnt)  - to get drinking\n        #exercise=int(trial_pnt)  - to get exercise\n        #COPD_comorb=int(trial_pnt)  - to get comorbidity\n        if  diagnosis==1:\n        trial_diagnosis=1\n        else:\n            trial_diagnosis=-1\n        if  smoking==1:\n            trial_smoking=1\n        else:\n            trial_smoking=-1\n        if  drinking==1:\n            trial_drinking=1\n        else:\n            trial_drinking=-1\n        if  exercise==1:\n            trial_exercise=1\n        else:\n            trial_exercise=-1\n        if  COPD_comorb==1:\n            trial_",
        "label": 0
    },
    "1364": {
        "output": "[START]\n\n\nAcknowledgements\n\n# Authors statement\nAll authors contributed to the study conception and design. Material preparation and data collection were performed by Sena Suleyman and Melis Ertas. Statistical analysis was performed by MelisErtas. The first draft of the manuscript was written by SenaSuleyman and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.\n\n# Authors`disclosures\nThe authors have no conflicts of interest to declare.\n\n## Declaration of competing interest\nThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.\n\n## Data availability\nData of this study is confidential, but the code and data are available from the corresponding author on reasonable request.<EOD> Clinical, Histopathological, and Immunohistochemical Analysis of Squamous Cell Carcinoma of the Skin in Patients with Different Hair Pigmentation\n\nCitation: B\u0203descu, M.; Miu, D.; M\u0203rg\u0203oan, R.; B\u0203descu, I., III.; Ionescu, M.C.; Leru, D.; Manu, D.; Tudor, C.I.\n\n# Introduction\nThe role of melanocytes in the development of human skin cancers is widely recognized. Melanocytic neoplasias, of melanocytic origin, include both benign and malignant entities: pigmented nevi (moles), congenital nevi, and blue nevi represent the benign melanocytic lesions; while the malignant melanocytic lesions include the malignant melanomas, melanoma of the uvea and neurofibromatosis. In contrast, there are few reports of the role of the epidermis or keratinocytes in the pathogenesis of non-melanocytic skin cancers, with only the discovery of human papillomavirus playing a major role in cervical cancer development. The epithelial cell can be subjected to different malignant mutations as it differentiates from the basal layer of the epidermis to the upper",
        "label": 0
    },
    "1365": {
        "output": "Trial-level eligibility for patient 1:\n\n<html lang=\"en\">\n<!-- DO NOT EDIT THIS PART -->\n<div class=\"wso-data\" id=\"vulnerabil-1\">\n  <wso:Field>\n    <wso:Name>Age</wso:Name>\n    <wso:Value>54</wso:Value>\n  </wso:Field>\n  <wso:Field>\n    <wso:Name>Body mass index</wso:Name>\n    <wso:Value>29.43</wso:Value>\n  </wso:Field>\n  <wso:Field>\n    <wso:Name>BUN</wso:Name>\n    <wso:Value>109</wso:Value>\n  </wso:Field>\n  <wso:Field>\n    <wso:Name>Creatinine</wso:Name>\n    <wso:Value>1.55</wso:Value>\n  </wso:Field>\n  <wso:Field>\n    <wso:Name>GGT</wso:Name>\n    <wso:Value>7</wso:Value>\n  </wso:Field>\n  <wso:Field>\n    <wso:Name>Glomerular filtration rate</wso:Name>\n    <wso:Value>56.72</wso:Value>\n  </wso:Field>\n</div></html>\n\nTrial-level eligibility for patient 2:\n\n<html lang=\"en\">\n<!-- DO NOT EDIT THIS PART -->\n<div class=\"wso-data\" id=\"vulnerabil-1\">\n  <wso:Field>\n    <wso:Name>Age</wso:Name>\n    <wso:Value>49</wso:Value>\n  </wso:Field>\n  <wso:Field>\n    <wso:Name>Body mass index</wso:Name>\n    <wso:Value>33.8</wso:Value>\n  </wso:Field>\n  <",
        "label": 0
    },
    "1366": {
        "output": "Now we will practice on a random patient. 1. Set the patient note. \nFirst, you need to load the patient note into the notebook. Go to the file \\Data and load the file patient_note_example.txt. \n2. Let's take a look:\n[formula]  INPUT: patient_note_example.txt [/formula] \nThe data will be entered through the console input. In the console of the notebook, type the keyword `python` to display a menu of available functions. Select the one `A02: 00: 00: Enter the input to load the patient note into the data set. `. You should type the word `A02` to enter that mode in the command mode. \nNow you are going to type some words that are in the file patient_note.txt.\n```\n# Enter patient note\nLoad patient note \nSelect patient Note Data: \n[A02] Enter the input to load the patient note into the data set.\n```\nIn the command mode, type your input. Your input should match the words on the screen. Try to type in the order that they appear on the screen, e.g., `enter`, `the`, `patients`, `entered`, and `the` in a row. When your input is validated the command mode will ask you to confirm if you have made a mistake or not. \n\nOnce the validation is finished, type `A02` again to enter the data set mode. \n```\nEnter patient Note Data: \n[A02] Enter the input to load the patient note into the data set.\npatient_note_example\n================> <===================================================\nFirst \nPatient number: 1\nPatient name: Jhon\nAge\nMale\nMarital Status\nNon-smoker\nAlcoholic consumption\nNo\nDrug addiction\nNo\nOccupation\nWorker\nWeight\n72kg\nHeight\n1.72m\nBody\nMass Index\n23.61\nFamily\nHistory of disease\nNo\nSexual\nHistory\nNo\nHistory of illicit drugs\nNo\nMedication\nHistory\nNo\nPrevious treatment\nNone\nHealth\nHistory\nNone\nMother's health history\nNon-existing\nFather",
        "label": 0
    },
    "1367": {
        "output": "<EOD> The impact of in-school and out-of-school time school physical activity interventions in 92 countries and contexts: A scoping review\n\nA B S T R A C THow do school physical activity (PA) interventions work? The scoping review examines the extent, range and nature of international intervention evaluations that report upon the impacts of school-based, in-school and out-of-school time PA, health and/or well-being on children and young people 4 to 15 years old. Four bibliographic electronic databases (ACHTUNG, ASSIA, PsycINFO, SportDiscus) were searched for 4139 articles in English, with one reviewer selecting 92 papers for full review. An interpretive approach to synthesis is adopted to provide a contextual understanding of international school-based PA delivery and the impacts of different interventions. The review identifies the range of school PA interventions that have been evaluated internationally, with many studies being conducted in countries in North America and Europe. While there have been a range of PA measurement and evaluation methods, the use of accelerometers appears to be increasing and studies have adopted different interrater reliability methods. There is a paucity of interventions in certain geographical locations and sectors (i.e. South America, Middle East), with a dominance of large scale initiatives based in schools or school districts. The most frequently reported interventions included those targeting the school environment, followed by the availability and opportunities within lessons, after school and in lunch breaks, with interventions that utilized a combination of strategies achieving the greatest effects in terms of PA. Whilst a majority of studies reported on the impact of PA interventions, health and well-being related outcomes are still emerging. The international and multi-country studies reviewed",
        "label": 2
    },
    "1368": {
        "output": "[END]\n_**Instructions for completing this challenge:**_\n\n1. Analyze the patient note. Include information about age, gender, hypertension, smoking, dyslipidemia and type of cancer, etc.\n\n2. Then apply the inclusion/exclusion criteria on the patient note and eligibility scale.\n\n3. Read the clinical trial and choose which criteria of the eligibility scale  fit the patient note.\n\n[![ESAIC 2020 Hackathon: Task 2](https://res.cloudinary.com/cgibooster/image/upload/v1589942563/task2/j-k-l.png)](https://res.cloudinary.com/cgibooster/image/upload/v1589942563/task2/j-k-l.png)\n\n\n> _**Examples of patient notes that could pass or fail the eligibility criteria of a clinical trial:**_\n> \n> *Pass*\n> \n> ```\n> Patient-level eligibility  1\n> ```\n> *Fail*\n> \n> ```\n> Patient-level eligibility  Not Relevant\n> ```\n> \n> *Fail*\n> \n> ```\n> Patient-level eligibility  Excluded\n> ```\n> \n> *Fail*\n> \n> ```\n> Patient-level eligibility  Eligible\n> ```\n\n[![ESAIC 2020 Hackathon: Task 2](https://res.cloudinary.com/cgibooster/image/upload/v1589941346/task2/d.jpg)](https://res.cloudinary.com/cgibooster/image/upload/v1589941346/task2/d.jpg)\n\n## Task 3.22\nLet's continue, this time with a task where the patient note is longer, containing more information for each patient. In this case, there are a total of 25 patients. The patient-level eligibility, of the previous tasks, has been simplified. Pat",
        "label": 0
    },
    "1369": {
        "output": "## I. Pre-Training Data Sets i.e., TRAIN_SEED, TEST_SEED, INST_SEED\n[INST]: In this step, there are two parts to train. The first part is to train from scratch where we will input all the train data from scratch; the second part is fine tuning where we will train from the check point in the first part.  \n##### Step 1: Training from Scratch  \n```\n# Training from scratch\nfrom sklearn.model_selection import train_test_split\nimport numpy as np\nfrom IPython.display import display\nimport random_search\nfrom cnn_architectures.classifiers.cnn import *\nfrom sklearn.model_selection import GridSearchCV\nfrom collections import OrderedDict\nimport numpy as np #import necessary libraries\n\ntrain_features = train_features_train\ntest_features = train_features_test\n\n\ndef initialize_CNN_architectures(*cnn_architectures):\n    # return the initializations for *cnn_architectures\n    return ([\n        random_search.RandomSearch(\n            random_weight_init,\n            random_parameter_init,\n            allowable_abs_step_sizes=0.004,\n            allowed_min_steps=0,\n            allowed_max_steps=200,\n            name=f'{train_features.shape[1]}_CNN')),\n        (*random_search.RandomSearch(\n            random_weight_init,\n            random_parameter_init,\n            allowable_abs_step_sizes=0.004,\n            allowed_min_steps=0,\n            allowed_max_steps=200,\n            name=f'{test_features.shape[1]}_CNN')),\n        random_search.RandomSearch(\n            random_weight_init,\n            random_parameter_init,\n            allowable_abs_step_sizes=0.004,\n            allowed_min_steps=0,\n            allowed_max_steps=200,\n            name=f'{INST_features.shape[1]}_CNN'))\n    ]\n    \ndef train_architectures",
        "label": 0
    },
    "1370": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThis clinical trial is a prospective study for assessing the prognostic value of inflammatory biomarkers combined with TNM staging in the follow-up analysis of colorectal cancer. The inclusion criteria for this study are as follows: -Inclusion of patients with histopathologically confirmed colorectal adenocarcinoma -Ability to contact patient by telephone for further interviews -Willing to participate on the basis of a signed informed consent form. The exclusion criteria for this study are as follows: -Exclusion of patients with other types of tumors -Patients unwilling to participate in the study -Incorrect data reporting\n\n## Examples\nCongratulations! You will be able to complete your task.\n\n## Questions\n- Can you think of an alternative for \"Excluded\"?\n- Do you think that the \"Trial-level eligibility\" should always remain empty?\n- Why is the \"Trial-level eligibility\" not present in the \"Disease-focused\" note for case 3 (Trial eligibility:Excluded )?\n- Why don't you need to use the \"Trial-level eligibility\" when you are making the note of 30-day survival?\n- Should you always make a note of the \"Triallevel\" eligibility when a patient meets the inclusion criteria but meets the exclusion criteria?\n- What if the patient is eligible, but the exclusion criteria do not apply?",
        "label": 0
    },
    "1371": {
        "output": "`Trial-level eligibility: 1) Not relevant.\n\n[INST] The next code block should work in conjunction with this code block.\n\nThe result of the evaluation is presented below:<EOD> A new 3,5-dianilino-1,4-diphenylsulfone derivative reverses multidrug resistance.\nIn a screening program to identify modulators of MDR reversal we found a new 3,5-dianilino-1,4-diphenylsulfone derivative (SDHS). It reverses resistance in multidrug sensitive (C1300) and multidrug resistant (C1300MR) human colon adenocarcinoma cell lines, at concentrations below 5 microM, and it is also effective in C1300LN4. Resistance in these P-glycoprotein over-expressing cells is only partially reversed, especially with the more toxic agents including adriamycin (P < 0.05), which is reduced by approximately 20%. At the same time SDHS did not reduce accumulation of adriamycin or rhodamine 123 in P-glycoprotein positive or negative cells, demonstrating that its effect is at the intracellular drug target rather than the level of drug transport. SDHS is more potent than verapamil and cyclosporin. We conclude that this novel reversing agent can be given i.v. and is more effective than the clinically used modulators.<EOD> Cognitive-behavioral therapy for children with anxiety disorders: a meta-analysis of outcomes studies.\nThis study examines changes in children's self-reports, parents' ratings, and the authors' own ratings after they receive cognitive-behavioral therapy (CBT). Analyses were conducted on outcome studies that met these criteria: (a) the subjects were between 4 and 13 years old, (b) subjects received CBT that included exposure, and (c) a standardized measure of anxiety was used to assess children's responses before and after treatment. Results revealed a medium effect for self-reports and the authors' own ratings and a medium-to-large effect for parent ratings. Findings indicate that CBT is an",
        "label": 0
    },
    "1372": {
        "output": "<EOD> The human protein S promoter directs high level expression and secretion in a stable mammalian cell line.\nA genomic clone of human protein S has been isolated from the chromosome 8p22 region of 2p25 human metaphase chromosome preparations. The isolation of the protein S gene used a combination of fluorescence in situ hybridization, radiation hybrids, and PCR techniques. The DNA is expressed in a stable mammalian cell line that constitutively produces high levels of active protein S (3 mg/l per day per 10(6) cells). This level of production is equivalent to that of a normal human liver. The gene codes for 3 exons and is 4.5 kb in length. The region of the gene that resides between the two promoters and upstream of the translation initiation codon contains two Alu repeats, a direct repeat, three Alu repeats in reverse orientation, and long stretches of direct repeats of DNA.<EOD> Neutralizing monoclonal antibodies raised against SARS-CoV-2 variants of concern retain neutralizing activity against Omicron subvariants\n\n114 neutralization against Omicron subvariants BA.1, BA. . The neutralization 115 titers against BA.4/BA.5 (median titer = 312) were one log-fold higher than against 116 BA.1 (median titer = 37) and one log-fold lower than against BA.2.46 (median titer 117 = 3064) in human serum samples (figure 1E). 118 119 Neutralization against Omicron variants was correlated with cross-neutralization 120 against D614G pseudovirus 121To test if antibody cross-neutralization against variant spike proteins correlated 122 with cross-neutralization of D614G spike pseudovirus and wildtype (WT) SARS-CoV-2 123 virus we measured neutralizing antibody titers against Omicron variants using luciferase 124based pseudovir",
        "label": 0
    },
    "1373": {
        "output": "[PROBLEM]\n\n# [INST] Problem: You have found that some patients with the same age are very different in terms of pain tolerance. As your clinical intuition guides you, you hypothesize that there are some other factors which may influence the level of pain experienced. What features may we consider? [END]\n\n\n## [INST] Hello again. You have been investigating the relationship between age related variables such as obesity, number of NVDs, hypercholesterolemia, gender, tobacco use, menopausal status and the reported pain of patients. Based on your previous results, the variable number of NVDs may be relevant. You notice significant differences from pain scores of female patients with 2 NVDs to those with 1 NVD:\n[Most recent data] The average pain score of 20 female patients with at least one NVD 347.11;\nThe average pain score of 20 female patients with 2 NVDs 276.33.\n\n\n## [end]\n\n# [INST] \n# Question: Can we model the relationship between age-related variables and patient pain?\nUsing the information so far, you want to perform a model selection for the effect of the number of NVDs on pain score. Which of the following models will you use for your analysis? How will you choose? You have been given 22 patients for your analysis. \n\n## [end]\n# Question: Can the effect of sex on average pain be explained solely by differences in age? What effect, if any, has sex of the patient on pain? What information do you need to collect about the patients to answer these questions? How will you do this? You have been given 20 female patients for your analysis. \n\n# [INST]\n\n## Convergence\n\n# [INST]\nTo make a decision on the choice of models, you need information about the patients. Please investigate the following information for the 6 patients shown in the table below: \n\n# [END]\n# Question:\n\n# [END]\n\n# Convergence\n\n# [INST]\nOn this step you must do two things:\n\n# [END]\n# Question: <EOD> Molecular cloning, expression, and characterization of",
        "label": 0
    },
    "1374": {
        "output": "[COOL] How do you compare two patients?\n\nBy default, the toolbox compares one patients and each other patients, one at a time. It",
        "label": 0
    },
    "1375": {
        "output": "## 1. Include all the attributes mentioned in the patient note in your code. For all the attributes, you should create a line to save that attribute in the dataframe. [INST]\n<EOD> .\nThe effect of the intravenous administration of dexmethylphenidate hydrochloride (DMPH) to the rat on the uptake and efflux of 14C labelled serotonin was investigated using the whole rat brain. Administration of 3 mg/kg/day of DMPH caused the maximum reduction of 14C serotonin uptake after the same dose when the experiment was done at 2.3 hours using the cerebrum, cerebellum and brain stem as the starting material respectively. The maximum reduction in 5-HIAA concentration from the brain stem (2.22 microgram/g) and cerebrum or cerebellum was produced by 10 mg/kg dose of DMPH. A decrease of 5-HTP level was observed after the DMPH administration. It was postulated that the serotonin is released from the synapse and then transported centrally to the presynaptic neuron by Na+-dependent serotonin transport mechanism, and the increase of 5-HIAA was caused by the release of the serotonin from the terminal part of the synaptic cleft into the extracellular fluid during the experiment. When the effect of DMPH on 5-HIAA concentration was examined in the rat brain after 24 days of repeated administration of 10 mg/kg/day, an increase of the 5-HIAA concentraiton was observed in the substantia nigra which was caused by the increase of the dopamine level and not by the decrease of the 5-HT level, and the change was reversible. No change of the 5-HT level was observed both in the brain stem and cerebrum. 5-HT uptake in the rat brain was not reversed by 10 mg/kg/day administration of DMPH despite of the significant reduction observed by the same dose. 10 mg/kg/day administration of DAMPH caused no change of 5-HIAA/5-HT concentration in the",
        "label": 0
    },
    "1376": {
        "output": "#### Exercises \n\n[INST]\n\nPlease solve the following 2 exercises:\n\n- [Exercise 1](https://gist.github.com/xitong-wang/bd12b1d5cd67bc104f1ce63ddf4c8c41) (solved)\n- [Exercise 2](https://gist.github.com/xitong-wang/5de3187ab97e0109dd4358bf286f2094) (solved)\n<EOD> Association of LRRK2 G2385R, E318G, and G2019S allele frequency with sporadic Parkinson's disease in Asian populations and with age-at-onset in the North-American and North-European populations with idiopathic Parkinson's disease.\nIdiopathic Parkinson's disease (PD), the major component of Parkinsonian disorders, may be influenced by genetic and environmental factors. The LRRK2 gene was reported to be in linkage disequilibrium with PD in a large Italian family as well as being associated with PD in North-American (NA) and European (EU) populations. Using DNA samples from PD patients and controls from Asia (China, Japan, Korea, and Thailand), we demonstrated no significant difference of allele frequency for LRRK2-G2385R, -E318G, or -G2019S. We found only a slight trend for a higher frequency of the LRRK2-G2019S in PD in China and Thailand. Furthermore we calculated the allele frequency of the LRRK2-G2019S mutation in the NA and EU population for a subset with an early-onset. We found a higher allele frequency in the patients for an early-onset compared to controls in the NA population (245/728; 34.0% vs. 95/1,120; 8.5%), but only for the EU population the difference did not reach statistical significance (540/3,029;",
        "label": 0
    },
    "1377": {
        "output": "### [S1_02] Clinical Trial-Level Eligibility  <<NEW>>\n[/S1_02]\n\n    Title: EUS-guided Gallbladder Drainage Instead of Laparoscopic Cholecystectomy for Acute Cholecystitis. A Feasibility Study. \n\n#### Inclusion criteria:\n\nBased on the clinical trial, the patient with acute calculous cholecystitis indicated for laparoscopic cholecystectomy.\n\nTo get your patient's Trial-level eligibility you should write a string by `trial-level` eligibility like `trial-level eligibility: 2) Eligible.`. \nAs an example: `trial-level eligibility = \"2) Eligible.\"`\n\nNow in this section you are to input the Trial-level eligibility for each patient in the list of patients. After that, you should repeat this step in the end line by `End trial-level eligibility: `, e.g., `End trial-level eligibility = \": 2) Eligible.\".` [/S1_02]\n\n- [x] Input the patient trial-level eligibility in \"String\" format and input the patient trial-level eligibility as \"String\" in this line\n- [x] Repeat this step in the last by `End trial-level eligibility: .`\n\n\n\t```\n\ttrial-level eligibility = 2) Eligible.\n\t```\n\t![alt text](../../img/instructions/Clinical-Trials-Inst-08/Clinical-Trail.png)\n\n#### Exclusion criteria:\n\nBased on the clinical trial, patients with unstable angina pectoris, heart failure, valvular disease, uncontrolled arrhythmia, uncontrolled hypertension, cerebrovascular disease, hemodynamic instability, gastrointestinal bleeding, obstructive jaundice, ascites, renal impairment (GFR < 30 mL/min), chronic kidney disease, respiratory insufficiency, co",
        "label": 0
    },
    "1378": {
        "output": "[JAVABEANS]\n<li>\nEligibility in the first list should have been checked already during the last step in the ESM-Flow and is therefore redundant. The eligibility check in trial-level eligibility should be considered the result of the patient having to meet the inclusion criteria of the clinical trial.\nWe therefore discard the eligibility test by `Eligibility: ` in the last line by `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`. [/JAVABEANS]\n\n[JAVABEANS]\n<li>\nESM_report_template__clinical_study_template_ESM_question_4_J_BEAN\n[EXPAND_READ]\nYou have to write an ESM eligibility report for each patient with your assessment for eligibility based on the three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). Write how many patients were excluded using the three-point scale and include a 3x3 table below where possible (also consider the \"other reasons\" section where possible). [/EXPAND]\n\n[/JAVABEANS]\n\n[INST]\n\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vom",
        "label": 0
    },
    "1379": {
        "output": "3) chemotherapy /the research participant clinicaltrial chemother trial eligible trial] for chemother the eligibly. [/or not suitability to the eligible trial] for 4) chemother eligible 1sthaving with metastable trial-eligible in the use. 2) Eligible.\n\nThe safety assessment [INST].\nIn-level/patients to the eligible participant for eligible assessment a) that eligible: Eligible/ineligible participation. 3) is a eligible and are the participant.\nMot and [INST and trial] and not-eligible and clinical, [instable patient. [4) The participants who are still has been taking into the participant the eligible participating eligible participation 4 level: trial eligible to assess a clinical trial the participants eligible:\n\nA patient with anatom trial\nIntel in the trial. [level/eligile trial. The eligibility ifel eligib [INST trial, trial/el trial, and other patient eligible.\nand eligble.\n[INST eligil, for example. Clinig elig clinical trial and assessableel[eligible assessments that you are appropriate and ischemical to eligible eligible, nonparticipating.\nTrial trial and eligible patient]chemical assessing, clinical and trial. In the criteria and eligible. These elig.\ntrial participation and ]. In clinical eligibility eligible patient.\n\nTrial the inel.\nEl and Eligible elig elig trial. This is eligible patient with or patient and trial with eligible/trial trial. \nSuch] Elig in clinical in trial that has a trial [INST to participing and to particip. [\nhi. The I, where, with you/elig trial andel eligible [s elig eligible clinely elig patient,",
        "label": 0
    },
    "1380": {
        "output": "[TEST]\n<TEST NAME=\"Eligibility test\" DESCRIPTION=\"Test your solution for the given patient\" PATIENT NOTE=\"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. Here is the clinical trial: Title: Single Setting ERCP and Laparoscopic Cholecystectomy is a Safe Procedure in Patients With Cholecysto-Choledocholithiasis\nSummary: The ideal management of cholecysto-choledocholithiasis is an open cholecystectomy (OC) with the common bile duct (CBD) exploration worldwide. The single setting 2-stage approach- endoscopic retrograde cholangiopancreatography (ERCP), endoscopic sphincterotomy (EST), and CBD clearance followed by laparoscopic cholecystectomy (LC) offers an advantage, mainly by reducing the hospital stay, the cost, and the morbidity. Investigators did a prospective study in patients admitted for the management of the cholecysto-choledocholithiasis in",
        "label": 2
    },
    "1381": {
        "output": "## Learning the clinical scenario from clinical trials\n\nHere are the trial information.\n\nThis trial is for people with BTC, and the trial will compare two treatments. One of the treatments is called chemotherapy, and the other one is called standard treatment.\nThe trial will help doctors, nurses, and others who work in the cancer clinic get more information about the treatment of BTC. It also helps to learn about the side effects of different medicines and to find the medicines with the least chance of negative effects.\n[Trial information]\n\n#### Participants in this trial\n\nPatients with BTC.\n[/Trial information]\n\n### Patient note: a 55-year-old woman with gbc.\nHepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, 5-fluorouracil (5-FU) and bevacizumab combined with intravenous toripalimab was administered to an advanced and metastatic BTC patient. This therapy was recommended by the hepatobiliary oncologist.\n\n\n\n\n### 90% of patients who have the same disease or condition are diagnosed as < _patient note> the same as the patient</patient note> as defined by:\n#### Excluding all of the patients who don't have the same disease or condition.\n#### Including all of the patients who have the same disease or condition, even if they are mildly different than the Patient note.\n\n\nThe trial has 4 different arms. Each arm may be used to treat patients with BTC.\nThere should be at least 40 participants for each arm.\nThe first group will get intra-arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil (5-FU), and bevacizumab every 3 weeks and intravenous infusion of PD-1 inhibitor (Toripalimab) every week.\nThe second group will get intra-arterial infusion chemotherapy with oxaliplatin, 5-FU, and bevacizumab every 3 weeks, intravenous infusion of PD-1 inhibitor",
        "label": 0
    },
    "1382": {
        "output": "## Challenge# 2\nBased on your trial-level assessment, the patient is eligible for Clinical Trial 1. How will you label the patient, e.g., `MH_CLINICAL_Trial1_INCLUDE` if the patient is only eligible for this trial?\n\nIn the following input, only `Trial-level eligibility: 2) Eligible.`, but the rest of the lines should be empty lines, e.g.,`Trial-level eligibility: 2) Eligible.`. \n\n## Challenge# 3\nThe patient is ineligible to Clinical Trial 2, but eligible to Clinical Trial 4. Based on your find exclusion rule, how would you label the patient with the following input:`. `. \n\n## Challenge# 4\nThe patient is ineligible to 2 trials at a time. Based on your exclusion rule, how would you label the patient with the following input:`.\n```\n\n## Challenge# 5\nIn the following input, two trials are incompatible. The patient is eligible to `Clinical Trial 1` and `Clinical Trial 3`, and the latter trial should only allow the \"0) Excluded\" label.\n```\n\n``` \nTrial-level assessment: 0) Not relevant, 1) Eligible\nTrial-level information: 1) Clinical trial 1 only, 2) Clinical trial 3 only, 3) None.\nTrial-level exclusion rule: No\nPatient-level assessment: Non Incompatibility.\nPatient ID: MH_0032_2_2_2_1\n```\n\n### Part 2: Part 2: \nA 54-year-old woman had abdominal pain, nausea and chills for the past 3 day. She was admitted to the ED and had an ultrasound that was showing gallbladder stones. She was diagnosed with a gallbladder infection from the radiology report. Due to her acute gallbladder infection, the physician advised her to take antibiotics and acet",
        "label": 0
    },
    "1383": {
        "output": "[DOCX] [DOC] [PDF]\nIn this section, we take a closer look at the problem.\n\n# Problem\nFor each patient, assess the eligibility of a person for a clinical trial. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial\u02bcs exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\n# Problem\n<EOD> .\nThis paper deals with an analysis of epidemiological data on mortality and morbidity due to diseases of the urinary system, circulatory system (arterial hypertension, coronaryheart disease) and malignant neoplasms of the bronchial system. The material includes data from population registration for 1994. The analysis included general and age-comparative indicators. A significant decrease of mortality from diseases of the circulatory system and an increase of morbidity from ischemic heart disease, from diseases of the urinary system, from arterial hypertension, from atherosclerosis of the cervico-cerebral part of the basilar artery, from malignant neoplasms of the bronchial system was found. These conditions, along with the persistence of the epidemiological picture observed until 1990 are indicative of the necessity, in line with the priorities of the national health system of the Russian Federation, of timely introduction of preventive measures and active treatment.<EOD> Prognostic Significance of Tumor\u2010Infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta\u2010Analysis\n\nBackground Tumor-infiltrating lymphocytes (TILs) are believed to be associated with the response of immunotherapy, while they also represent biological factors involved in the prognosis of esophageal squamous cell carcinoma (ESCC).Objectives To systematically evaluate the predictive value of TILs in ESCC patients.Design This systematic review and meta-analysis aimed to summar",
        "label": 2
    },
    "1384": {
        "output": "## 573. MULTI_PROD_RATE_INPUT_MATRIX\n\n[X] Hello. You are a financial expert, who have been working for years at the financial department of a big company.\n\nYou have recently been appointed, as head of the financial department of a new branch and have started to work on the branch\u2019s financial analysis.\n\nYour immediate tasks will be:\n(1) to set up and make financial forecasts; and, (2) to formulate the budgets.\n\nIn doing so, you will be given the following data:\n\n    - Current situation of the existing branch\n    - Growth projections of the target market and other variables affecting the branch\u2019s revenue\n    - Required expenditures\n    - Costs of production and of goods and services required to run the existing branch (including rent, interest on funds invested, and expenses related to the purchase and use of equipment)\n    - Cash flows of the company\nYou will need to calculate the annual rates of production or purchase of the following resources used by the branch\u2019s budget:\n    - Materials from industry\n    - Services from industry\n    - Fixed costs\n\nNote: The branch does not have a specific amount of each resource to spend, but it should provide a total amount for each period of several years (a time span of several years for planning purposes).\n\nSo far, your company is providing services to a target market (group of companies) of 1250 companies, generating an income of $2,525,000 per year and making expenditure of $2,700,000 per year.\n\nFor a period of 3 years from the first day of the year of the opening of the branch, the company expects to increase the size of its target market by 25% every year. For the given information, the growth rates of the target market are, respectively, as follows:\nYear 1: $1,180,000\nYear 2: $1,180,000\nYear 3: $1,180,000\nOther variables that may affect the generation of income, such as the price of the products to be provided by the company and the size of the service target group, are fixed:",
        "label": 0
    },
    "1385": {
        "output": "<EOD> Vestibular evoked myogenic potentials (VEMP) in sudden hearing loss and M\u00e9ni\u00e8re's disease.\nVestibular evoked myogenic potentials (VEMP) were recorded in 14 patients with sudden hearing loss (SHL) and nine patients suffering from M\u00e9ni\u00e8re's disease. Twenty healthy controls were also studied. In all the cases studied VEMP was present in the normal side and absent from the affected side. Abnormalities of VEMP were observed in patients with SHL, characterized by reduced amplitude of VEMP (94%) and reduced number of wave peaks (69%) in the affected side; a similar reduction in VEMP amplitude was found in three patients suffering from M\u00e9ni\u00e8re's disease. These findings suggest that the cochleo-vestibular transmission is also affected by both SHL and M\u00e9ni\u00e8re's disease. VEMP may represent a valuable tool to assess the functionality of neural fibers (cochleo-vestibular transmission) which are probably responsible for the sudden or fluctuating hearing loss in M\u00e9ni\u00e8re's disease.<EOD> .\nThe present paper was undertaken to check the efficacy of the intracardial administration of a preparation containing procainehydrochloride and magnesium sulphate. A solution of procaine-lactate-hydrochloride and magnesium sulphate was diluted with 0.9% NaCl to a volume of 25 ml. This fluid was injected directly into the left ventricle of guinea pigs under Nembutal anaesthesia. 120 injections were performed into 1'13 normal guinea pigs. The results were followed by a control group of 18 guinea pigs with normal hearts and 14 guinea pigs with experimentally induced myocarditis. An intracardial injection of the solution did not produce any significant changes in the E.K.G. and in the systolic and diastolic pressure, neither in the animals with nor without heart disease. In the control group there were no significant changes in the histologic examinations. In a group of 126 guinea pigs given repeated intracardial injections of 50 to 100 mg pro",
        "label": 0
    },
    "1386": {
        "output": "## Example:\n$ ./t_eligibility.py < PatientNote.txt\n\n\n## [T_INFO_1]\nTitle: The Relationship Between Post-ERCP-choledocholithiasis and Gallbladder Status\n\n\n[T_INFO_2] Summary: In this retrospective study, the investigators evaluate the relationship of post-ERCP-choledocholithiasis(PEC ) and the gallbladder status as a risk factor.\n\n\n[T_INFO_3] Inclusion Criteria:\nInclusion Criteria:\n\n\n[T_INFO_4] Exclusion Criteria:\nExclusion Criteria:\n\n\n[INF_1] -1 (EXCLUDED), because the patient has an insufficient number of information on gallbladder status.\n\n\n[INF_2] -1 (EXCLUDED), because the patient has no gallbladder status.\n\n\n[INF_3] -1 (EXCLUDED), because the patient has age \u226586, but this is exclusion criteria. \n\n\n[INF_4] 1 (NOT RELEVANT), because no information on gallbladder status, so the patient seems not to have gallbladder.\n\n\n\n\n[INF_5] 2 (ELIGIBLE), because gallbladder status is not identified, but enough information is available about inclusion criteria.\n\n\n[T_INFO_6] Age: 55\n\n\n[T_INFO_7] ESR: 22\n\n\n[T_INFO_8] BMI: 27\n\n\n[T_INFO_9] Ht: 168.42\n\n\n[T_INFO_10] Gender: Female\n\n\n[INF_6] 2 (ELIGIBLE), because the patient seems to have sufficient information and the exclusion criteria based on gallbladder status does not apply. \n\n# Question\nIn the example above, you see that we did not write the word `patient` in `$ ./t_eligibility.py < PatientNote.txt` (nor in `$ ./t_eligibility.py < PatientNote.",
        "label": 0
    },
    "1387": {
        "output": "Good luck, and may you pass your assessments.\n\n*PSS\n\n**If you want to write or add content to this section, contact [SZD] on Discord, as this information should always be up to date with the latest version of the course.**<EOD> The use of an active learning paradigm to facilitate students' self-efficacy during distance learning.\nBACKGROUND\nDistance learning became the predominant modality for undergraduate student instruction during the COVID-19 pandemic, leaving many faculty struggling to engage students virtually. Previous research has shown that effective teaching strategies (active learning paradigms ) can be applied to distance learning to support engagement, retention, and learning outcomes. In this review, the effectiveness of distance learning courses employing ALPs in undergraduate nursing student's self-efficacy is discussed and evaluated.\n\n\nPROBLEM\nDuring the COVID-19 pandemic, many nursing education programs, including ours, moved the majority of their didactic content to online learning. With a large percentage of students enrolled in virtual courses, little research exists examining distance learning faculty's use of learner-active pedagogical methods and its effect on student engagement and self-efficacy.\n\n\nAPPROACH/PROCESS\nThis literature review aims to critically evaluate best practices for using learner-active pedagogical methods in distance learning, focusing on undergraduate nursing students' self-efficacy.\n\n\nCONCLUSIONS\nMany faculty and course evaluation researchers recommend using specific active learning paradigms in online courses as the key for student retention, engagement, and learning outcomes in distance learning. To the extent research supports that AL paradigms improve student self-efficacy, faculty should consider adapting course content, to incorporate these learning strategies to bolster engagement in emergent distance learning.\n\n\nCLINICAL RELEVANCE\nALPs provide a pedagogical method by which the engagement and retention of distance learning students can be improved.<EOD> A randomized phase II study of two schedules of infusional 5-flucytosine plus high-dose (3 oral doses/day or 5 daily doses) or intermediate",
        "label": 0
    },
    "1388": {
        "output": "*For example, to be eligible for the trial with the number = 10, the patient must fulfill more than 3 inclusion criteria (ICs) and less than 5 exclusion criteria (ECs), and at least one of the ICs must be number = 3, 4, 5 and 10 must fulfill at least one exclusion criterion:\npatient, exclusion criteria | Patient, exclusion criteria:\n\n\n<img src=\"https://cdn.statically.io/v1/fc538143-2084-437d-a0ed-45c6813932e7/0f11a118-bcf8-418f-bb58-cb9a8a909feb\" height=\"1087\" width=\"3032\"/>\n\n### Assignment of clinical trials and clinical trials by clinicaltrials\n<a name=\"top\"># Top</a>\n\n#### Create Clinical Trial\n* `CRUD`\n\n```python\ntrial(study_id)\n```\n\n* `CRUD`\n\n```py\n1. study_id = {\"id\": 1}\n2. trial = trial(study_id)\n3. trial = trial.save()\n4. trial = trial.get(id=1)\n```\n\n\n#### Create Clinical Trial\n\n*  `CRUD`\n\n```python\n1. study_id = {\"id\":1, \"study_name\": \"A_study\"}\n2. trial = trial.create(study_id)\n3. trial = trial.get(id=1)\n```\n\n#### Update Clinical Trial\n* `CRUD`\n\n```py\n1. study_id = {\"id\": 1, \"study_name\": \"A_study\", \"recruiting\": False,\n            \"active\":True}\ntrial.add_recruitment_statesea, \"enrollment_completed\", \"interim_analysis\",\n    \"follow-up\")\ntrial.update(study_id)\n```\n####  DELETE Clinical",
        "label": 0
    },
    "1389": {
        "output": "= Exercise\n\n1. You are a student in bioinformatics that wants to do his bachelor's thesis on biological networks. The topic of his thesis is to determine the effect of a specific mutation on a target gene. He wants to understand if this mutation is associated with cancer. What kind of database can he use and why? Explain.\n2. You are a medical student that wants to do his thesis on biological networks. The topic of his thesis is to determine the effect of a specific mutation on a target gene. His supervisor gives him a very large amount of patient data. He wants to identify the relationship between the mutation and the target gene from this patient data. What kind of computational method can he use and why? Explain his results.\n\n# Author contributions\nTahmasbi: Conceptualization, writing and editing.\nZhang: Conceptualization, writing and editing.\nXie: Conceptualization, writing and editing.\nChen: Conceptualization, writing and editing.\n\n## Conflicts of interest\n<EOD> Interactions between a Cationized Lignin\u2010Based Flocculant and Humic Acid\nThe adsorption characteristics of lignin\u2010based flocculants in the aqueous solution by UV\u2010vis, fluorescence spectroscopic, HSM and \u03b6\u2010potential measurements were investigated. UV\u2010vis spectrum analysis showed that a stable single peak of flocculant shifted to \u03bbmax: 276 nm (UV) and 400 nm (Vis) in the presence of humic acid (HA), indicating that the lignin flocculant could be complexed with HA in an aqueous solution. Fluorescence spectra results showed that the maximum emission peak was 322 nm (blue fluorescence) in the presence of HA. Furthermore, the blue fluorescence peak shifted to a higher wavelength from 322 to 332 nm and the intensity decreased. Fluorescence Stokes shift and the number of the intramolecular hydrogen bonds increased. In addition, humic acid could be efficiently removed from the aqueous solution using cationized lignin\u2010based flocc",
        "label": 0
    },
    "1390": {
        "output": "# Submission Tasks\n\n## [TASK]\n1. You do a trial-level eligibility assessment for each patient of this trial according to the provided information about the trial by the previous tasks: `Trial-level eligibility: 0) Excluded`, `Trial-level eligibility: 1) Not relevant`, and `Trial-level eligibility: 2) Eligible`. \n2. Submit the file (text file) with trial-level eligibility assessment for each patient at the \"Save Submission\" task bar of the web-interface. \n\n[SUBCONTENT]\n\n## [CONTENT]\n1. Let's open the saved submission file (`submission_test.txt`) and check the results. You have to write what should appear in this table:\n\nYou should type the text that is appropriate. \n2. You write another file (`submission_new_content.txt`): \n\n\n## [SUBCONTENT]\n\n## Submission Review Tasks\n\n## [TASK]\n1. Click on the \"Review\" tab of the web-interface and select the patient ID with whom you want to review. \n\n![submission_review](https://user-images.githubusercontent.com/19951600/122987385-b7df01c0-c1c8-4803-bb0d-55f19be218be.png)\n\n2. Click on the `Patient ID` column of the left-side menu to open a new window with trial-level eligibility information. \n\n![submission_open_review](https://user-images.githubusercontent.com/19951600/122987406-bf6133fa-7244-4226-9111-82d60775be88.png)\n\n## [SUBCONTENT]\n\n## [CONSENSUS]\n\n## [CONSENSUS]\n\n## Consensus and Consensus Formatting\nBefore you learn how to submit consensus, it is essential",
        "label": 0
    },
    "1391": {
        "output": "[EOF]<EOD> Immuno-oncology therapy in breast cancer.\nImmunotherapy has shown clinical benefit in several solid tumors, including breast cancer, with anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) antibody and anti-programmed death-1 (anti-PD-1) antibody as the most efficacious. Nevertheless, responses remain modest and, in fact, tumors can eventually develop resistance to these immune-modulating agents. Therefore, there is an urgent need to improve responses to immunotherapy, either by increasing patients\u2019 response rates and/or by lengthening the overall survival in responding patients. Preclinical evidence shows that dual blockade of the CTLA-4 and PD-1 pathways is highly effective in animal models of breast cancer. Moreover, combinations of immune-cell inhibitory pathway antibodies with immunological adjuvants such as anti-DR5 antibody (Ab) or metronomic cyclophosphamide are also showing promise. Another strategy being evaluated is the use of antigens that are overexpressed on cancer cells such as Her-2. More recently, the antitumor effects of the anti-Her-2 Ab trastuzumab and the anti-CTLA-4 antibody ipilimumab, a fully human IgG1 monoclonal Ab, have been reported. The use of nanoparticles and of a liposomally entrapped anti-Her-2 Ab as a carrier vehicle of soluble anti-CTLA-4 Abs has demonstrated an increased immunogenicity and therefore a potentiated antitumor response to the anti-CTLA-4 Ab in the animal models. Finally, the adoptive transfer of vaccine-primed tumor-infiltrating lymphocytes is currently being evaluated in clinical trials, and more recently, the adoptive transfer of nontransgenic autologous lymphocytes into metastatic melanoma patients after lymphodepletion by chemotherapy has been shown to increase the overall survival. Adoptively transferred lymphocytes are also currently being tested in other types of cancers, possibly leading to new imm",
        "label": 0
    },
    "1392": {
        "output": "### Your Task\n\nYour task is to compare a given patient note and the inclusion criteria of a clinical trial, and determine the patient's eligibility (if the patient qualifies then return 2 otherwise return 0).\n\nYou are to modify function Assessment in the patient note reader class to assess the trial-level eligibility. There are following requirements:\n\n1. Your modified function Assessment needs to support only the same inclusion criteria and return the same assessment (see README in Assessment). If the function needs any modification, it would be considered fail.\n\n2. Your modified function Assessment needs to return 3 lines:\n    - `0 Excluded` -if the patient meets the inclusion criteria but is excluded on the grounds of the trial's exclusion criteria.\n    - `1 Not relevant` -if the patient does not have sufficient information to qualify for the trial.\n    - ``2 Eligible` -if the patient meets inclusion criteria and exclusion criteria do not apply.\n\n3. The output of your modified function Assessment should be in two ways.\n    * The first way is \n    ```\n    trial-level eligibility: {0 Excluded, 1 Not relevant, 2 Eligible}\n    ```\n    in which a separate line for each level of eligibility\n    * The second way is\n    ```\n    trial-level eligibility: `2` Eligible\n    ```\n    in which return a string of Eligible with a space at the end of the string.\n    \n    Note: Both ways need to be tested on the 24 scenarios. If your modified Assessment in Assessment shows some problems, please add a comment to the [issues](https://github.com/jahanashraf/patient-note-reader/issues).\n\n\n**Instructions**\n\nPlease try to understand the design pattern `Iterator` in Assessment. Please focus on the function Assessment. You will be able to find detailed information about the design pattern `Iterator` from http://en.wikipedia.org/wiki/Iterator. Also you may want to try this function by removing the function for the design pattern `Iterator` from Assesment.\n\nIf you are familiar with Perl, please consider its iteration control",
        "label": 0
    },
    "1393": {
        "output": "![trial-info](/img/inst/trial-info.png)\n\n## Create SB-related trial\nNow, we are going to find all eligible patients for SEA-TGT on the SBTN database. We need to see which patients have already been randomized and in which group they were assigned and by which SBTN trial they were enrolled. For this purpose, we are going to use the trial_patient table and the SB_enrollment table. \n\n1) Find patients enrolled in SBTN clinical trials.\n```java\n\tTrials t = patientRepository.getTrials();\n\n\tif (!t.isEmpty()) {\n\t\tsystem.out.println(\"The system is ready to provide the information about patients who are enrolled in SBTN clinical trials. To find out the information, please visit: <link to SBTN dashboard>\");\n\n\t\tfor (Trial t1 : t) {\n\t\t\tif (t1.getIsActive()) {\n\t\t\t\tif (t1.getActive() == true) {\n\t\t\t\t\tfor (Patient pt : t1.getParticipants()) {\n\t\t\t\t\tPatient.getId(): `id`.\n\t\t\t\t\tPatient.isEligible(): 2) Eligible.\n\t\t\t\t\tPatient.getRanking(): #.\n\t\t\t\t\tPt.status: #.\n\t\t\t\t\tPt.isIn: enrolled.\n\t\t\t\t\tPt.isInBeta: 0.\n\n\t\t\t\t\tSystem.out.println(\n\t\t\t\t\t\"Name: \" + Pt.getFirstName() + \" \" + Pt.getLastName() + \" - ID: \" + Pt.getId());\n\t\t\t\t\t\n\t\t\t\t\t/**\n\t\t\t\t\tSystem.out.println(\"Cancer group: \" + Pt.getClinicalTrials().getTargets().getTrialName());\n\t\t\t\t\tSystem.out.println(\"Cancer type: \" + Pt.getClinicalTrials().getTargets().getClinicalT",
        "label": 0
    },
    "1394": {
        "output": "What's left? \n- Make sure to add the right number of semicolons and spaces in line 4 of your code, or use a different way to indicate paragraph breaks (<br>)\n- Don't forget to use the input_ids to get the raw data!\nLet's make sure we got everything!\n\n- 5. Use the following link, and click the `Run` button. It will help you to find places in your code that you may have made a typo or missed some input variable:\n[<LINK>](http://201-x2.sos-test.com)\n- 6. Do you see the following message in the output: `You were right!`? Cool. If not, change a few things. In my case, it took me one revision before I got the `You were right!` message. The good thing was that I had already reviewed my work by using the `sos_test` link, I could have found my mistakes before the final testing in the following week.\nAnd... that's where class 38 ends. Hope you had a lot of fun reviewing your code. Let other beginners know what they need to prepare for the next section: `Section 16`.\nThanks for participating in this section!\n\n<EOD> Translating the biology of osteoarthritis.\nOsteoarthritis is a chronic degenerative disease of articular cartilage, but the underlying mechanisms that cause cartilage degradation are not well understood, thus clinical remetabolic is limited and, in fact, there is no curative treatment. In this review, we will summarize the complex biological process that is involved in the development of osteoarthritis and, specifically, in the regulation of catabolic factors during this condition. We will also discuss the current pharmacologic treatments and future potential therapeutic targets.<EOD> .\nThe results of 128 intrauterine inseminations in four centres are presented. Ovulation induction was carried out with clomiphene citrate in most cases, hormone therapy comprised clomiphene citrate and hmg. The percentage of pregnancies per series was from 8.1-9.7%, in",
        "label": 2
    },
    "1395": {
        "output": "## 7a) Describe the intervention and comparison, including how and when participants were allocated to interventions. the assignment of the intervention is described.\n\u27a4 \u27a4 10: \"All patients who had a surgical indication to undergo an upper abdominal ultrasound were enrolled in the trial. Ultrasound was performed by radiologists, and in case of CBD stones, only patients meeting the criteria for laparoscopic cholecystectomy were subjected to surgery. Patients who underwent a surgical decision based on ultrasonographic findings were treated according to the clinical decision.\" RESULTS: \"Of 583 patients who underwent upper abdominal sonography during the study period, 62 patients with gallstones were identified, and 50 agreed for inclusion and followup, while 12 patients declined and did not undergo surgery. The mean gallbladder stone size in the operated patients was 14.2\u00b18.4 mm, and no significant difference between the ultrasonographic findings and laparoscopic cholecystectomy was recorded with respect to stone size. In contrast, the percentage of patients who had small stones (10 mm or less) was significantly lower in this study than in the previous study by the same group (26.6% vs. 46.93%, P=0.006).\" 9-10: \"...the radiologist was informed about the type of gallstones of each patient\u2026\"\n\n## 8) if done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how\n\u27a4 10-11: \"Two methods were used to identify stones: the single-blinded ultrasound and the direct exploration in laparoscopy (double-blinded).\"\n\n## 9) state how groups were formed (individually randomized trial)\n\u27a4 10: \"All patients who had a surgical indication to undergo an upper abdominal ultrasound were enrolled in the trial. Ultrasound was performed by radiologists, and in case of CBD stones, only patients meeting the criteria for lapar",
        "label": 0
    },
    "1396": {
        "output": "<EOD> Hydrogenation of the amorphous molybdenum sulfide film by annealing and hydrogen plasma treatment\nA film consisting of hydrogenated molybdenum sulfide formed on the amorphous molybdenum sulfide (MoS2) layer by means of annealing and hydrogen plasma was investigated. The atomic structure was refined to a cubic phase (space group: Fm3m) by annealing at 1000 K for 50 min. X-ray diffraction analysis and atomic force microscopy indicate that hydrogen is homogeneously distributed within the film. We propose a reaction mechanism of hydrogenation on the MoS2 surface. This structure is a key intermediate in the deposition process of hydrogenated molybdenum sulfide on the amorphous MoS2 thin film.<EOD> Comparison of endoscopic submucosal dissection and non-endoscopic submucosal dissection for treating gastric epithelial neoplasms\n\nEndoscopic submucosal dissection (ESD) has been reported to be more effective than non-ESD in treating gastric epithelial neoplasms (GESNs), but the evidence is limited. This meta-analysis of the available literature aims to compare the effectiveness and safety of the procedures. Clinical trials comparing ESD with non-ESD in patients with GESNs were identified in literature databases and abstracts from academic meetings through June 2012. The pooled rates and odds ratios (ORs) for the complete resection rate, en bloc resection rate, delayed bleeding rate within 48 hours after ESD, and delayed perforation were calculated for each procedure. Ten studies (one meta-analysis) with a total of 1,662 patients were included in analysis. ESD had a superior complete resection rate [pooled OR 2.79 (95% confidence interval: 1.30-6.03)] than non-ESD, but its en bloc resection rate [1.19 (0.44-3.22)] and complete and en bloc resection rates [1.07 (0.4",
        "label": 0
    },
    "1397": {
        "output": "Excluded patients in `Triall-level eligibility: 0) Excluded` are not shown, as they are already listed in their corresponding `patient-level eligibility`.\nNow, the following two parts can be changed. You can put them in the separate files. \nYou can make a new set of trial conditions. For example, `Trial - AML014B1`, or `Trial- AML1831`, etc.\n\n```text\n#+pro-file=Trial\n#+pro-name=Trial\n#+pro-desc='AML014B1', 'AML11019' ...\n#+pro-comment=AML014B1'\n#+pro-condition=AML014B1,\n#++ +pro-condition=AML11019:\n#++ #+pro-name=Trial Condition1\n#++ #+pro-desc=Condition1\n##+pro-comment=Condition1\n#++ #+pro-name=Trial Condition2\n#++ ... #+pro-desc=Condition2\n#+pro-condition=aml11019,\n```\n\n`AML11019:\nAML014B1:\n``<EOD> Molecular Pathogenesis of Nephropathy in Diabetes\nDiabetic nephropathy is a progressive renal disease that is the leading cause of end-stage renal failure worldwide. Despite improved glycemic control, nephropathy is the main contributor to morbidity and mortality in most patients with diabetes. The pathogenesis of nephropathy in diabetes is multifactorial and involves the activation of both hemodynamic and metabolic stresses that culminate in mesangial expansion and increased mesangial cell and podocyte proteinuria. Although the mechanisms linking these pathways are uncertain, there is now strong evidence that activation of the renin-angiotensin system is a major factor in the development and progression of this renal disease. Several mechanisms may account for the nephrovascular injury associated with activation of the renin-angiotensin system in diabetes, including oxidative stress, inflammation, glomerular hypert",
        "label": 0
    },
    "1398": {
        "output": "### Assignment\nYour job: Choose the most appropriate statement for the patient case example. If the statement is true, write `T` in the box; if the statement is false, write `F` in the box (in other words, change the number of spaces between the brackets).\nFor the clinical trial case example, choose the most appropriate inclusion criteria. If you think the inclusion criteria are not relevant for this patient, write `NV` in the box.\n\n<EOD> Loss-of-function mutations affecting the amino acid 116 residue of human Mg2+-transporting ATPase result in increased ATPase activity.\n\nIn a previous study, a missense mutation, glycine-116-valine, was found in the Mg2+-transporting ATPase (ATPase) gene of the Xq21.3 duplication in a patient with X-linked neonatal hypomagnesemia. In this study, to examine the role of this amino acid position 116 (A116) of the ATPase molecule, we cloned into a plasmid a series of different ATPase constructs with A116 substitutions, and transfected them into COS-7 cells. When the activities of the wild-type and mutant ATPases were analyzed, we found a mutation affecting the amino acid 116 resulted in an increased ATPase activity, suggesting that this mutation may affect the ATPase conformation, thereby increasing the ATPase capacity.\n\n## In a\nprevious study, we examined loss-of-function mutations of the Mg 2+ -transporting ATPase (ATPase) gene in Xq21.3 duplication, and found missense alterations (1). The glycine-116-valine mutation was identified in a patient with neonatal hypomagnesemia. To determine the role of this amino acid position 116 (A116) of the ATPase molecule, we first examined whether the amino acid residue 116 is conserved across several ATPase families. The results are shown in. A116 is partially conserved among ATP9, 7, 8, 6, and 4. The",
        "label": 1
    },
    "1399": {
        "output": "##[/SOLUTION]<EOD> A review of the current landscape and future developments in clinical trials for COVID-19 vaccination\nThis paper provides a brief overview of the global response to the COVID-19 pandemic with a focus on vaccine development. The authors review the various stages of clinical trials as they relate to COVID-19 vaccination development. The authors also discuss the challenges as well as the lessons learned during COVID-19 vaccine trials. The paper concludes with a prediction for the future of the COVID-19 vaccine clinical trials process.<EOD> Preparation of poly (vinyl alcohol) grafted hydroxypropyl cellulose microsphere and its application in chest pain relieving.\nThe purpose of the present study was to investigate the effect of a new type of sustained release formulation for chest pain relieving. The hydroxypropyl cellulose (HPC) and poly (vinyl alcohol) (PVA) were grafted by the emulsion polymerization. The chest pain relieving effect in rats was investigated. The experimental data showed that the microspheres were of spherical shape with a narrow particle size distribution. The polymerization of HPC in PVA (1:100, w/w) resulted in a stable graft polymer with a molecular structure in which the PVA main chain was grafted to the HPC, and the mean molecular masses of the obtained graft copolymers were 44,200 Da. The graft copolymer, HPC-g-PVA, had a better emulsification ability than traditional PVA did and could reduce the particle size of the emulsion from 295.32 nm to 82.71 nm and improve the drug-loading efficiency. The drug release profile indicated that sustained release was obtained with the drug core encapsulated in graft copolymer microspheres. This is of positive significance with regard to the prevention of serious side effects when the drug is used for treating chest pain. Additionally, the drug release mechanism of the graft copolymer was described by the Peppas Equation R2 = 0.99.<EOD> Phase II trial of paclitax",
        "label": 0
    },
    "1400": {
        "output": "The following will be the patient note. As a result, the assessment of eligibility should be ``Eligible``: \n```\nA patient can be eligible for the trial if one of 6 trial-level variables is selected (patient_age, gender, cancer_resection_type, cancer_stage, presence_of_metastasis, metastatic_disease), and if one of 5 trial-level variables is selected (cancer_tumor, number_of_adenomas, location_of_adenomas, lesion_size_of_adenomas, comorbidity_diagnosis).\n\nFollowing the rules, we can find all patients in the dataset that meet the trial-level ineligibility (patient_age, gender, cancer_resection_type, cancer_stage, presence_of_metastasis, metastatic_disease), and who can be matched to a patient that is eligible for the trial. The number of matched patients is 1,038 (see 4.2.1).\nWe can then find all patients in the dataset who meet the criteria for trial-level ineligibility (cancer_tumor, number_of_adenomas, location_of_adenomas, lesion_size_of_adenomas, comorbidity_diagnosis; see 4.2.1). Among the 1,038 matched patients, 618 (59.74%) also hold one of trial-level ineligibility values. \nWe should compare each pair of matched patient/control in our dataset by calculating the following formula: \n\n\n\nWe can visualize such comparisons in 3D plots of standardized trial-level variables in the following way:\n\nNote that the values of standardization can also be used to investigate the similarity in standardized trial-level variables between the two datasets.\n\nWe can use the following 3D plots to compare the average level of standardized cancer type and cancer location between the datasets: \n\nWe can use the following 3D plot to compare each trial-level variable among the matched patients in each dataset: \n\nThe following 3D plot compares the average level of standardized trial-level variables between the sets of matched patients of both datasets:",
        "label": 0
    },
    "1401": {
        "output": "<div id=\"output-widget\" class=\"widget\" data-region=\"112\"></div>\n\n\n<script type=\"text/javascript\">\n    new app.widget(\"output\");\n</script>\n\n\n\n\n\n\n\n#### An exercise in the output widget\n\nExercise 19: `input 3 <input type='number' value='3'>3 <button class=\"btn btn-danger\" onclick=\"runTest('ex20'); return false;\">Run Test!</button> \nPlease let me know if there are any issues.\n\n--\n\n[![image](https://github.com/Tencent/appframework/raw/master/output/output.gif)](image)\n\n\n--\n\n## Output\n\n`Output` is used to present data that can be used for testing.\n\nIt consists of three major components: a header row, a data row, and a footer row.\n\n![image](https://user-images.githubusercontent.com/66902125/110698326-5b8f0d00-8b78-11eb-82ac-2486de25a094.png)\n\n\n[![image][image:data:text_1]](\n[image:data:text_2]\n[image:data:text_3]\n[image:data:text_4]\n[image:data:text_5])\n[![image][image:data:text_6]](\n[image:data:text_7]\n[image:data:text_8]\n[image:data:text_9]\n[image:data:text_10])\n[![image][image:data:text_11]](\n[image:data:text_12]\n[image:data:text_13]\n[image:data:text_14]\n[image:data:text_15])\n[![image][image:data:text_16]](\n[image:data:text_17]\n[image:data:text_18]\n[image:data:text_19]\n[image:data:text_20])\n[![",
        "label": 0
    },
    "1402": {
        "output": "See also our [SUTTA](https://github.com/statmodel/sutta-book) book for example codes which make similar assessments. \n\nCopyright (c) 2021 <NAME>\n<EOD> Heterotopic pituitary adenoma located at the pituitary stalk causing diabetes insipidus: a case report.\nA 25-year-old non-obese Thai man presented with the complaint of polyuria and polydipsia. Neurologic examination, general physical examination and endocrinological data were within normal limit. Neither ophthalmic nor neurosurgical signs was found. Thyroid function test, serum electrolytes, BUN, creatinine level and 24 hours urine output were also normal. The basal plasma osmolality was 303 mOsm/L (normal range 230 to 300 mOsm/L), plasma hypertonicity 267 mmol/L (normal range 50 to 300 mmol/L) and serum sodium level 144 mml/L (normal range 130 to 145 mml/L). Abdominal and pelvic computed tomography revealed an anteriorly displaced pituitary gland into the suprasellar space. Magnetic resonance imaging (MRI) demonstrated an ill-defined, slightly enhanced mass situated at the pituitary stalk. A diagnosis of a non-secreting pituitary adenoma producing diabetes insipidus was made. Transphenoidal resection of the pituitary adenoma was performed by a transsphenoidal approach. Postoperatively, hyperosmotic dehydration syndrome was present for 4 days before the patient recovered completely, no evidence of secondary adrenal insufficiency was found in the whole-body scintigram. The histopathologic diagnosis of a prolactinoma was made and immuno-histo-chemical analysis demonstrated a positive reaction to estrogen receptors. This case is interesting because it seems to be unique by this patient being non-obese, no endocrine signs",
        "label": 0
    },
    "1403": {
        "output": "# Export\n\nIn order to be able to export your results to various file formats, go to ```Settings > Export > Forms```.\nIn the form, you can access to export features. \nAfter selecting the preferred form, you can export your results to excel files in various formats. Please take note of the export feature and how to export your data.\n\n# Advanced Options\n## Step One\n\nIn the Settings > General, \n\n### Run Code\n\nYou can find a new button here. You can run the code by clicking on this button. You are required to log in to [Kaggle](https://www.kaggle.com/) to run a notebook on this machine. The first time you run the code, a login box appears with the message \"Including Kaggle run code\". Please see the [instructions](https://docs.python.org/3/library/kaggle.html#installing-the-kaggle-run-code-requirement) for details about the installation of run code.\n\n### Code\n\nHere is a sample code that can create your patient note:\n\n```python\npatient = {\n    \"age\": \"54\",\n    \"gender\": \"female\",\n    \"disease\": \"cholelithiasis\",\n    \"history\": \"hypercholesterolemia\"\n}\n\npatient_note_list = {\n    \"age\": \"54\",\n    \"gender\": \"female\",\n    \"disease\": \"cholelithiasis\",\n    \"history\": \"hypercholesterolemia\",\n    \"disease_stage\": \"recovery\"\n}\npatient_note_list = {\n    \"age\": \"54\",\n    \"gender\": \"female\",\n    \"disease\": \"cholelithiasis\",\n    \"history\": \"hypercholesterolemia\",\n    \"disease_stage\": \"recovery\"\n}\npatient_note_list = {\n    \"age\": \"54\",\n    \"gender\": \"female\",\n    \"disease\": \"cholelithiasis\",\n    \"history\": \"hypercholesterolemia\",",
        "label": 0
    },
    "1404": {
        "output": "##[SCORE] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. \nHere is your assessment of eligibility.",
        "label": 2
    },
    "1405": {
        "output": "# Examples\n\n# Results\n 1104 patients meet inclusion criteria according to the assessment result\n 1104 patients meet the exclusion criteria according to the assessment result\n 1028 patients do not meet inclusion criteria according to the assessment result in the clinical trial\n 76 patients meet the exclusion criteria according to the assessment result in the clinical trial\n 46 patients do not meet inclusion criteria according to the assessment result in the clinical trial\n 3299 patients are excluded based on exclusion and inclusion criteria\n 2 patients are not eligible according to the assessment result\n<EOD> MICA5.1 mRNA: its origin and function.\nWe have successfully cloned a large variant of human MHC class I chain-related B allelic (MIC-B) gene, termed MICA-L5*0802, in the Japanese population. Its cDNA exhibited the largest open-reading frame length among the known MICA cDNAs, with 1617 bp in comparison with 1409 bp of MICA5.1, and the amino acid sequence encoded by the L5*0802 cDNA was completely consistent with that of the MICA*0802 allele reported in the International Histocompatibility Workshop (IHW) and Nomenclature Committee of the WHO (NCB). Analysis of the nucleotide variation between MICA5.1 and L5*0802 cDNA revealed eight nonsynonymous substitutions, resulting in the amino acid substitutions at positions 67, 85, 89, 140, 148, 155, 177, and 181. MICA5.1 allelic transcripts are known to be significantly depleted in Japanese when compared with Caucasian, African-American, and African subjects. An assay of reverse transcription polymerase chain reaction (RT-PCR) for MICA5.1 and L5*0802 was applied to the PBMC RNA extracted from two donor peripheral blood samples, which showed a different distribution of expression level between MICA*0802 and MICA",
        "label": 0
    },
    "1406": {
        "output": "You can see the code for this task:\n\nhttps://github.com/manghi666t/hospital-project/blob/master/task6_eligibility/eligibility.py \n\n**[Review the submission: https://review.docs.otus.edu.cn/#/]**\n<EOD> Lactulose: Infectious Disease, Inflammatory Changes, and Cancer Prevention\nLactulose is a non-absorbable oligosaccharide, which is metabolized by colonic bacteria to acetic and lactic acid. Lactulose exerts beneficial effects on the gastrointestinal tract (GIT) and provides some therapeutic advantages for patients with chronic viral hepatitis and alcoholic liver disease, biliary atresia, intestinal protein loss, and cholestatic liver diseases. Experimental evidence has suggested that lactulose exerts anti\u2010inflammatory effects on the GIT and reduces the incidence of liver cancer by reducing inflammation and promoting fecal bile acid excretion. Clinical and animal studies have indicated that lactulose attenuates inflammatory responses, oxidative stress, and apoptotic cascades, and plays a protective role against intestinal injury. A randomized placebo\u2010controlled trial demonstrated that lactulose administration prevented an increase of intestinal permeability and inflammatory mediators, which provides evidence for lactulose treatment as a promising approach to the prevention of intestinal inflammation. Based on evidence from the literature and our previous study, this review explores the potential mechanisms underlying the efficacy of lactulose in treating and preventing infections, hepatic disorders, and gastrointestinal inflammation\u2010related diseases. Moreover, the anticancer effects and potential of lactulose are discussed.<EOD> Preparation of highly active iron nanoclusters with unique structure encapsulated in a mesoporous carbon shell.\nA new method of fabricating core-shell structures through in situ nanocluster reaction in a microreactor was developed, which has advantages such as in situ high temperature",
        "label": 0
    },
    "1407": {
        "output": "# Expected Outcome\n\nThe expected outcome is an integer from the set {0, 1, 2}. It is an integer because there are only 3 possible values to assign to patients for the assessment of eligibility. It can hold integer values from 0 to 2 but not negative values. The output must have at least one entry. A patient cannot be assigned a value for every trial if the patient is the primary end-point of the trial.\n\n# Examples\n\n## Ex 1 \nYour task is to compare a patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. Here is the patient note:\nA 13-year-old boy was admitted to the pediatric department due to recurrent fever and upper respiratory tract infection.\nBoth parents had a history of chronic diseases, and they are both unemployed.\nPhysical examination revealed a temperature of 39\u00b0C, a heart rate of 100 bpm, clear chest, and normal breath sounds. Laboratory analysis showed raised ESR, high CRP and leukocytosis. Chest x-ray revealed that both lungs were normal.\n[ENT 1] It shows the patient's first note.\nWhat is the trial's level eligibility for this patient? [OUT1]\nHere is the clinical trial: [CLNT]\n\n## Title: evaluation of a new drug for children with recurrent fever and upper respiratory\nInfection. [TIT2] \n[P3] It shows the patient's third note.\nEx 2 \nYour task is to compare a patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. Here is the patient note:\n[P1] Patient 1 was a 13-year-old student suffering from acute respiratory tract infection for the last eight days. Her medical history was unremarkable except that she had a minor surgery on her chest. Her drug allergy history showed that she had a mild allergy to penicillin and sulphonamide. She was brought in by her parents and was in excellent condition. She had no fever and her vital signs were as follows: \n[ENT1] It shows",
        "label": 0
    },
    "1408": {
        "output": "##[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nHere is the clinical trial: \nTitle: Is A",
        "label": 0
    },
    "1409": {
        "output": "<EOD> Echocardiographic assessment of regional myocardial function during exercise.\nRegional myocardial function has been evaluated quantitatively on the basis of regional wall motion and thickening. These parameters are limited by the difficulty of reproducible quantification of regional wall motion. Echocardiographic tissue-Doppler imaging has been used to overcome these difficulties. The method provides a more objective and reliable quantification of regional strain, thus increasing the sensitivity to detect subtle changes in regional myocardial performance during exercise.<EOD> .\nBy the analysis of experimental results, made on white rat's brain cortex it is shown, that one of the probable mechanisms of hypoxic-hypoglycemic stress influence, is the rise of the neuromediator's level, which influence on the neuromorphological status.<EOD> Rational Molecular Pretargeting of Tumors for Enhanced Delivery of Antibody\u2013Drug Conjugates: Proof-of-Concept for a Potential Clinical Approach\nImproved tumor targeting strategies are needed to enhance therapeutic efficacy while decreasing systemic exposure of antibody\u2013drug conjugates (ADCs). In this study, we present a novel \u201cintrinsic tumor-seeking pharmacophore\u201d that mediates enhanced tumor targeting of ADCs. Our strategy relies on the conjugation of an ADC to a pretargeting platform composed of a phage-displayed peptide library. The peptide library is then incubated with whole blood obtained from a tumor-bearing mouse, and active blood clot formation and phagocytosis serve to concentrate the pretarget molecules in the tumor microenvironment, whereupon they are internalized by resident macrophages, thereby triggering the release of active peptide\u2013ADC from these tumor-engaged macrophages. The latter is then able to internalize new rounds of free pretarget moieties and undergo a second cycle of reprogramming to serve as an effective antigen-targeted \u201ccar-by-car\u201d nanoplatform. A pretarget moiety composed of a tumor-homing peptide conjugated to a cysteine-cleavable bicyclopept",
        "label": 0
    },
    "1410": {
        "output": "## Exercise 3\n[INST] Hello. You are a medical oncologist in your hospital, and a patient comes for a follow-up. Her doctor informed you that she is taking capecitabine (a fluoropy",
        "label": 0
    },
    "1411": {
        "output": "<EOD> Nitrogen\u2010 and oxygen\u2010centered radicals produced by gamma\u2010radiolysis of 2\u2010pentyl\u20104\u2010(3\u2010thienyl)\u20101\u2010penten\u20103\u2010ol, an ethyl propanoate\nChromatographic and spin trapping methods were employed to monitor the formation of the stable organic radicals produced by gamma\u2010radiolysis of 2\u2010pentyl\u20104\u2010(3\u2010thienyl)\u20101\u2010penten\u20103\u2010ol (1), an ethyl propanoate in deuterated solvents (D2O, CD3OD and pyridine) and aprotic organic solvents (acetonitrile, ethanol, dimethyl sulfoxide and carbon tetrachloride). In the protic solvents (D2O and CD3OD), the formation of several stable organic radicals was evidenced from chromatographic and spin trapping experiments. The spin adduct signal intensities, together with the results of the deuterium labeling studies performed using the 3\u2010thiamyl\u20102\u2010propanol (2) and 2,4\u2010di\u2010thiapent\u20103\u2010ol (3) spin traps, suggested the formation of alkyl radicals (C3H7\u2022, C4H7\u2022 and C5H7\u2022) at low doses and aromatic\u2010like radicals (C4H5\u2022, C3H3O\u2022, C6H5\u2022 and C3H5\u2022) together with 4\u2010thiophenyl radicals (C5H4S\u2022) at higher doses according to Eqs. (2) and (3). In aprotic solvents, an alkyl radical (CH3\u2022) and a C4H7\u2022 radical were produced from 1 and 2, which indicates that the CH3\u2010group in 2 was oxidized to the CH3\u2022 radical by the \u03b2\u2010scission of CH3OH. The C4H7\u2022 radicals were generated from 1 and 2, and a 3\u2010thiapent\u20101\u2010ol (4) spin\u2010trapped adduct was produced only by 4 at doses higher than 1.2 MGy. The 4\u2010thiophenyl radicals and other a",
        "label": 0
    },
    "1412": {
        "output": "## Input\n[INST] After you confirm you have entered the necessary information, press the Submit button to load the information into a new record.\n\n## 1. First, input the patient's age [F, M, Other]; [T, C, G], which has the highest odds ratio (OR) from the factors [Age] to [Food] for the assessment of patient eligibility [0) Eligible; 1) Not relevant; 2) Eligible].\n\nThe first record should be completed with ID=1 and Trial eligibility =0, because this patient has no clinical trial information. We use [Y:Yes, N:No, F:First, Others:] and [T:Treatment, C:Control] to record whether a certain factor is present or not and whether this factor is in the treatment group or the control group.\n\nIf this record is an Others case, you should fill in each line in the [Medication], [Absence of], [Sex] and [Examination] sections by referring to the clinical trial, as shown in the red box below. The first three factors are all in the treatment group, while the patient's sex belongs to the control group. The final record will appear as follows:\n\nIf we want to show `F` with an upper bracket `^` to indicate that `F` is in the Control group, we should change the code of the record by adding two characters `^F`. Therefore, the final record will become:\n\n## 2. Similarly, input all patient information from [G:Gender] to [A:Abnormal temperature] in the same way and press the Submit button to save the information.\n\nThe patient-level information is:\nID:1 Eligibility:0  \n0) Eligible (The first record is created)\n\nAge | F | Y | T, C | ^F | ^Sex | ^Examination | Absence\n---|---|---|---|---|---|---|---|---\n54-year-old | Woman | Yes | Treatment, Control | ^Female | ^Sex | Yes | ^Examination (C) | ^Absence of examination\n\n## 3. Add another five records with",
        "label": 0
    },
    "1413": {
        "output": "### Sensitivity analysis \n\nOne should not forget to adjust for the effect of the confounding factors upon the estimated OR. The following table is the result that indicates how the adjustment of the confounding factors influences the OR. \n\n> Or <-predict(fit, newdata=subset(X, !as.numeric(paste(X$Clinical_Trials_ID, X$Exclusions), \" ,\" ,paste(X$Comorbidity_Index%in%1:X$Age_Grade, \" ,\" paste(X$Weight_Class%in%1:X$History, \" ,\" paste(X%in%1:(X$Medication%in%1:X$Sociodemographic), \" ,\" paste(X%in%1:(X$Gender%in%1:X$Smoke, \" ,\" paste(X%in%1:(X%in%1:X$Vitals$BloodPressure, \" ,\" paste(X%in%1:(X%in%1:X$History_of_Admission, \" ,\" paste(X%in%1:(X%in%1:X$Existence_of_Diabetes, \" ,\" paste(X%in%1:(X%in%1:X$Surgery, \" ,\" paste(X$Sexual_Orientation%in%1:X%in%1:X%in%1:X$History_of_Smoking, \"))) ), newdata=subset(X, !as.numeric(paste(X$Clinical_Trials_ID, X$Exclusions), \" ,\" ,paste(X%in%1:(1:X$Education), \" ,\" paste(X%in%1:(1:X$Medication_Prescription, \" ,\" paste(X%in%1:(1:X$Employment_Status, \" ,\" paste(X%in%1:'Age_Grade', \" ,\" paste(X$Eligibility, \"))) )), new data = subset(X, !as.numeric(paste(X$Clinical_Trials_ID, X$Exclusions), \" ,\" paste(X$Lifestyle, \"))) )) } #",
        "label": 0
    },
    "1414": {
        "output": "[table]  [ [HIDESYMBOLS] Hello [NAME]! You have received an invitation to an examination room. Please go into the examination room, take the patient note, and assess your [MODULE] patients. Try to find out whether they are eligible to the clinical trial. Good luck! [END] [HIDEBOSS] Hello [NAME]! You have been a helpful assistant for many times in the clinical trial recruiting process, now please finish the last one. Good luck! [END] [END] [/table] \n<EOD> Highly effective synthesis of large scale, in-plane aligned graphene oxide-polyester nanocomposites.\n\nThe synthesis of graphene oxide (GO)-polyester nanocomposites with in-plane alignment of stacked GO layers was achieved by using a shearing and an annealing approach. GO was synthesized from graphite powder by oxidation in H 2 SO 4 and KMnO 4 and was then mixed with the polyester. This mixture was dispersed in dimethylformamide (DMF), sonicated, and annealed in an autoclave at 180\u00b0C for 2 h (GO/polyester-P1 samples) . Compared with GO/polyester composite samples without annealing, the GO/polyester-P1 samples showed enhanced thermal strength, and their in-plane stacked GO layers were clearly identified by using atomic force and transmission electron microscopies. In addition, the \u03b6-potential of the GO/polyester-P1 samples was reduced from 22 mV to 5 mV compared with that of the GO-polyester sample, which is due to the deprotonation of oxygen-containing groups of the GO layers. In this system, the polyester is adsorbed on the GO layer surfaces and is also tightly intercalated between the GO layers. Therefore, the GO/polyester composite can exhibit high thermal resistance, which is strongly affected by the in-plane stacked GO layers.\n\n# Introduction\nGraphene is a one-layer, two-dimensional carbon planar structure with single-atom thickness and can be classified as a sp 2 carbon network in which sp 2 hybridized carbons form bonding and nonb",
        "label": 0
    },
    "1415": {
        "output": "You should return and submit the task on the [Task] by clicking on `Submission` -> `Submit`.\n\n# Data\n\nIf the first letter of the trial is an alphabet, and the patient note starts with an alphabet, then the scale will be `0`). That means our clinical trial is a simple randomised trial. On the other hand, if the trial does not have an alphabet as the first letter of the trial, and the patient note starts with any number other than 0, then the scale will be the same as it was before. That means our clinical trial is a block randomised trial. [END]\n\n# Example\n\n\n# Data\n\n## [Task] \nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria for a clinical trial to determine the patient's eligibility. The patient's gender is male, and the patient's age is 54. The patient is inpatient and has coronavirus disease. The patient has an allergy to penicillin.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nHere is the patient note:\nA 54-year-old male who is morbidly obese, has hypercholesterolemia, and two NVDs. His past medical history is remarkable for coronavirus disease which is in remission, allergic bronchopulmonary aspergillosis and multiple chronic pulmonary cysts. He has 2 children, and he is menopausal. He does not smoke, drink alcohol, or use illicit drugs. He is an obese male with no acute distress. On palpation, he experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated alkaline phosphatase, elevated CKMB, elevated troponin-I, le",
        "label": 0
    },
    "1416": {
        "output": "#### Auxiliary Questions\nThese questions allow to check the answer.\n1 - What is the value of each element of the trial note? Input all the factors required to find out the trial-level assessments. The correct answer is `2 0 1 0 0 1 2`. \n2 - Which elements allow you to make a Trial-level eligibility? Just remember the elements presented in the first code block. The correct answer is `0 1 2 0 1 2`. You have to indicate all the elements. \n3 - What is the value of `X` in the last line? The correct answer is `(1 + 8) / 6 = 2 \u20446`: the eligible proportion. \n\n\n4 - What is the value of the eligible proportion? 4-34 = 0`: the patient is ineligible. \n\n5 - Which elements are required to determine the patient's eligibility? The correct answer is `age, gender, stage, prior treatment, and disease (NVD, hyperchlesterolemia)`. \n6 - What are the trial-level eligibility and its elements? Trial-level eligibility: 2) Eligible. \n7 - What are the trial-level eligibility and its elements? Trial-level eligibility: 3) Eligible 4) Relevant 5) Relevant.\n\n[FIN/A1]\n\n<img src=\"https://raw.githubusercontent.com/openpathy/pathology/master/examples/Cases/case_2/3.png\" alt=\"\" />[/FIN/A1]<EOD> Evaluation of the Use of a Combined Ex vivo Culture System with the Patient's Surgical Specimen and Human Monocyte-Derived Cell Lines as a Means to Study Tumor Immunology: An Efficient Alternative to Animal Tumor Models\n\nMonoclonal antibodies (mAbs) are an active area of drug development. MAbs play a major role in treating cancer; however, most clinical success is not as great as anticipated. One reason for this is poor translation of preclinical tumor models into human responses",
        "label": 0
    },
    "1417": {
        "output": "<EOD> Diffusion of Bubbles in a Foam.\n\nIn this paper, we employ molecular dynamics simulations of a Lennard-Jones fluid with a mixture of vacant sites, representing vacances in the foam, and occupied sites, to investigate the dynamics of bubbles surrounded by a gas. A phase field method is used to determine whether or not the bubble is in contact with the cavity of another bubble. By identifying the nearest site in the gas phase, we are able to investigate the dynamics of the diffusing bubbles. We find that bubbles exhibit subdiffusive behavior, as has been observed in other foams. We argue that this behavior is caused by the bubble moving from a region of high particle density to another region of high particle density, resulting in an overall reduction in velocity, at the expense of some extra energy, instead of a uniform increase in velocity. * Electronic address: r.dixon@sheffield.ac.uk\n\n# I. introduction\nLiving organisms frequently use foams to facilitate respiration. An example is provided by the lungs. The majority of studies involving foams make use of microscopic simulators, rather than physical experiments. These are powerful tools for revealing the mechanisms behind a large array of behaviors and can be carried out with ease and speed using computational power. One set of phenomena which such simulators have been effective in studying are those concerning the diffusion of microscopic entities in a sea of gas. For example, simulating foams consisting of two fluid phases, the gas and the foam, has revealed why, when a bubble in the foam collapses, the gas emits from a location further from the collapse point than the location of the initial foam bubble.\nThe use of simulations of foams to answer questions concerning the behavior of molecules or atoms, in an environment where there is a significant difference between the molecular properties of the bubbles and the gas, has a large, important application. Understanding these phenomena may well be able to provide the knowledge necessary to manipulate the way gas moves in a foam. This is vital in numerous settings, such as the manufacture of packed bubble columnsand the design of novel porous materials. One may view the bubbles as channels for molecules to flow through whilst also blocking them from traversing in the opposite direction.",
        "label": 0
    },
    "1418": {
        "output": "Let's think step by step.\n[INST] The input variable is a patient note, and the output is the patient's eligibility. The first step is to identify the eligibility criteria, i.e., whether or not the patient satisfies the inclusion criteria. The three possible eligibility assessments are `Excluded`, `Not relevant`, and `Eligible`.\nWe need the 7 exclusion criteria from the trial we already know. That means this part of the patient note is the `representative data for screening by exclusion criteria of trial`. Note that this patient has a cystine stone history 41 years ago, so let's exclude the patient who had one onset of this condition. There are 4 more exclusion criteria to identify:\n- BMI\n- Menopause\n- Current smoking\n- Hypercholesterolemia\nWe start with the `Hypercholesterolemia` exclusion criterion. If the patient's BMI is less than or equal to 25 kg/m2, then the next exclusion criterion to consider is the patient is less than 18 in age, and the patient is a menopausal female. If the patient is not a menopausal female patient, then we need to verify whether she is currently smoking. If the patient is a menopausal female currently smoking, then we need to identify the patient's hypercholesterolemia.\n\nFor the second exclusion criterion, we first need to examine whether the participant's BMI <25 kg/m2. If the participant satisfies this condition, then we need to examine the patient's age, and if the participant's age <18 years old, then the patient should meet the eligibility criteria. We can examine if the patient is a menopausal female. If the patient is a menopausal female currently smoking, we need to check whether the patient has",
        "label": 0
    },
    "1419": {
        "output": "[TUTORIAL_END]<EOD> Interleukin-1 beta increases plasma renin activity via a prostanoid-mediated mechanism in the human organ culture model.\nThe effect of interleukin-1 beta on plasma renin activity (PRA) was investigated in fresh human renal tissue. Incubation of organ cultured renal slices with 1, 10, or 100 ng/mL IL-1 beta resulted in a dose-dependent stimulation of PRA. The stimulatory effect of IL-1 beta was time and concentration dependent. These effects were not mimicked by recombinant tumor necrosis factor alpha. The stimulatory effect of IL-1 beta on PRA was antagonized by indomethacin, which also had no effect by itself. The action of IL-1 beta was antagonized by cyclooxygenase blockade with sodium meclofenamate in a dosedependent manner. Thus, IL-1 stimulates PRA by a cyclooxygenase-dependent mechanism. The relevance of this interaction under normal and inflammatory conditions and possible clinical consequences are discussed.<EOD> Evaluation of Sentinel Lymph Node Biopsy in Early Colorectal Cancer: A Multi-institutional Study.\nBackground/Aims\nThe aim of sentinel lymph node mapping of patients with early colorectal cancer is to predict the risk of nodal metastasis, determine the appropriate extent of surgery in case of a negative sentinel node biopsy, and reduce morbidity. Therefore, accurate evaluation of sentinel lymph nodes is crucial. We aimed to determine the clinical value of hematoxylin and eosin (H&E), cytokeratin (CK), and epithelial membrane antigen (EMA) and to identify patients eligible for sentinel lymph node biopsy in patients with colorectal cancer.\n\n\nMethods\nThis study is based on retrospective review of a multi-institutional database. We studied 163 consecutive patients with non-metastatic early rectal and distal colon cancer (pT 2) who underwent curative resection and sentinel lym",
        "label": 2
    },
    "1420": {
        "output": "# Exercise\n\n[INST] The command `emthash-nv generate reports -h` with the default options will generate the following reports. Open the file `submission.md` to make a PDF. \n\n**Summary**\n\nIn this study, we investigate the effects of abdominal massage on patients undergoing colorectal surgery.\nIn order to determine if the intervention is clinically relevant, we must determine whether the results of abdominal massage were consistent in the previous studies analyzed in the literature. To this end, we systematically synthetize and critically evaluate all the results.\n\n### Inclusion criteria\n\n  - Patients aged greater than 18 years (males and females) or adult patients with a weight less than or equal to 120 kg, undergoing elective rectal surgery with intestinal anastomosis (colectomy, anterior resection, colon resection or stoma closure), in the Enhanced Recovery After Surgery Program or those who gave their free and informed consent and to adhere to the recommended follow-up and those with an affiliation to Social Security \n  - Patients undergoing abdominal massage\n  - Patients anamnesed for previous cholecystectomy\n  - Patients with intolerance of or refusal to treatment by the massage therapist\n  - Patients with a pathological history of ischemic heart disease\n  - Patients presenting contraindications to abdominal massage \n  - Patients who were not affiliated by Social Security\n  - Patients not consenting to follow the treatment protocol and the recommended follow-up\n\n\n### Data collection\n\nAn observational study (NCT02026778)",
        "label": 0
    },
    "1421": {
        "output": "<EOD> ODP129 The Association of Glucoregulatory Peptide Substrate with Weight Loss in Subjects Undergoing Bariatric Surgery or the Weight Management Strategy\n\nDiabetes & Glucose Metabolism ODP129 The Association of Glucoregulatory Peptide Substrate with Weight Loss in Subjects Undergoing Bariatric Surgery or the Weight Management Strategy\nPhDMDMDMDMDMDMDCDMDCDMDMDMDMDMD, MSMD, MScDipl BM&DrDietitiaeFACSCapnastasiadis@georgetown.edudanam@med.umich.eduMDMDMDMDMDMDMDDiabetes & Glucose Metabolism ODP129 The Association of Glucoregulatory Peptide Substrate with Weight Loss in Subjects Undergoing Bariatric Surgery or the Weight Management Strategy\n10.1210/jendso/bvac150Abstract citation ID: bvac150.623\nObjective: Studies have shown that weight loss causes a decrease in glucoregulatory peptide secretions. Therefore, we conducted an experimental study to determine (1) the association of glucoregulatory peptide substrate with weight loss among subjects undergoing: bariatric surgery (BS) \u00b1 LSG versus medical management (MM), and (2) the role of these peptides in weight management.\nDesign and Methods: In these prospective studies, we measured body weight and peptide substrate, including glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide (GLP)-1, cholecystokinin (CCK), amylin, pancreatic polypeptide, peptide YY (PYY), and obestatin along with insulin sensitivity by hyperinsulinemic-euglycemic clamp test at baseline, and post-10%, post-15%, and post-30% body weight loss (BWL) in 199 BS and 114 MM subjects with ob",
        "label": 0
    },
    "1422": {
        "output": "[INFO] You can test the program by running the following command in a separate terminal window:\n\nR code run(\"test_trialleligibility.R\")\n\nYou should be able to print out the patient note and the clinical trial in the same form, for instance, as follows:\n[\n\nINFO] 8/9 patients are eligible (1 excluded (patient meets inclusion criteria: age 18 and gender: male, but is excluded on the grounds of the trial's exclusion criteria) and 7 not relevant (patient does not have sufficient information to qualify for the trial)\n\nINFO] 2 patients are eligible (patient meets inclusion criteria: age 18 and gender: female, and exclusion criteria do not apply).\n\nINFO] 7 patients are eligible (patient meets inclusion criteria: age 18 and gender: female, and exclusion criteria do not apply).\n\nINFO] 1 patient is not eligible (patient meets inclusion criteria: age  18 and gender: female, but is excluded on the grounds of the trial's exclusion criteria).\n\nINFO] All patients are eligible (patient meets inclusion criteria: age 18 and gender: female, and exclusion criteria do not apply).\n\n\nINFO] 3/3 patients are eligible (1 excluded (patient meets inclusion criteria: age  18 and gender: male, but is excluded on the grounds of the trial's exclusion criteria) and 2 not relevant (patient does not have sufficient information to qualify for the trial)).\n\nINFO] 2 patients are excluded (patient meets inclusion criteria: age  18 and gender: female, but is excluded on the grounds of the trial's exclusion criteria).\n\nINFO] 2 patients are eligible (patient meets inclusion criteria: age  18 and gender: female, and exclusion criteria do not apply).\n\nINFO] All patients are 8/9 patients are eligible (1 excluded (patient meets inclusion criteria: age 18 and gender: male, but is excluded on the grounds of the trial's exclusion criteria) and 7 not relevant (patient does not have sufficient information to qualify for the trial)).\n\nINFO] 4/4 patients are",
        "label": 0
    },
    "1423": {
        "output": "[/COD]<EOD> MANAGEMENT OF PATIENTS WITH LONG STAFF VENTILATION\nMany intensive care units have a small but significant group of patients, usually between 5% and 15% of all admissions, who require long periods on mechanical ventilation in spite of being without clinical or biochemical evidence of illness (1). Such patients often have a chronic disorder leading to respiratory failure, but in most instances in an intensive care unit are admitted because of acute complications. There will be other patients admitted to intensive care units who are ventilated for as little as 24 h and yet go on to benefit from their stay. Some are in acute medical wards but ventilated because of a poor outcome predicted with short term intubation. In contrast with the long ventilated patients, there is no specific sub-group of such patients. They are older, with high APACHE II scores (1), and are ventilated in ICU rather than HDUs. These patients are often elderly and have a variety of diseases with multiple organ failure, but are without evidence of major neurological dysfunction and have a good response to treatment. Some of these patients may have been treated in the past as though they had respiratory failure but may now benefit from new technologies or drugs. Some will recover from shock, have a positive fluid balance and the ability to tolerate weaning (2), and some will die (2, 3).<EOD> An investigation of the anticaries effect of a fluoride mouth rinse with and without dietary counselling as an adjunct to a program of regular topical fluoride application in school children.\nPURPOSE\nThe aim of this 24-month randomised controlled trial was to investigate whether a program comprising regular professional topical fluoride application and a fluoride mouth rinse with and without dietary counselling would result in less dental decay than programmes with the omission of the dietary counselling or the fluoride mouth rinse.\n\n\nMATERIALS AND METHODS\nFollowing random assignment, 317 11-year-old school children were divided into four groups: a) topical fluoride and fluoride mouth rinse;",
        "label": 0
    },
    "1424": {
        "output": "# Tip38\n\n### Inclusion criteria 1.1\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 60-year-old female with type II diabetes mellitus was diagnosed with chronic kidney disease 4 years ago. She has congestive heart failure due to valvulopathy, and she regularly sees a nephrologist. Her medication consists of: insulins, metformin, enalapril, ramipril, furosemide, candesartan, and iron (ferrous sulfate). \nA year ago, she had a stroke in the left corona radiata. It was classified as a minimal cerebral ischemic lesion. She underwent cardiac rehabilitation after her stroke, but she still has left-sided hand paresis, cognitive impairment, and aphasia. She requires assistance at home to walk, eat, and perform her morning routine. \nShe is on palliative care. She visits a general practitioner, palliative care doctor, and diabetes nurse regularly. She has a daughter who lives nearby and takes care of her in short intervals. \nShe has anemia and an increased red blood cell distribution width. Her blood pressure is 142/57 (91",
        "label": 0
    },
    "1425": {
        "output": "<EOD> The Sleep of the Insane\n\n\n\n## 2.5\nInsane, demented, feeble-minded patients. 35\nNot demented, feeble-minded patients. 18\nTotal of cases. 113 The following description of the sleep is based on a study of the records, made under the authority o? Dr Charles Wilson, the resident medical officer of the hospital.\nThe sleep which occurs in the day-rooms is not usually restful. It is usually either short, broken, or disturbed by crying of other patients. It has, however, in some cases, been soothed by the adoption of special methods of treatment.\nIn the sleeping accommodation of the hospital some little variety occurs in the types of sleep. In 6 rooms we had no record of the sleep. The sleep in 19 other rooms was in most cases broken. Of the patients in the remaining 42 rooms, 55 per cent had at least one refreshing night's rest.\nIn sleeping accommodations with low ceilings, and where sleeping rooms are dark and damp, the sleep is often short and broken. This was the case in room II. An interesting condition, however, occurred in this room. There a patient, with a disorderly conduct on the premises, and who did not sleep well in a day-room, slept well and regularly in the room, under the following conditions:? The patient had a certain number of hours in the day-room, but then if he wished to go to his room to sleep in it he was not allowed to do so. In that case he had to go to his room for an hour or two in the afternoon or evening, with the object of sleeping there, and then return to his day-room. Usually, however, he went straight to his room to sleep there. The conditions in this case are clearly more favourable to sound sleep than in the cases where he was permitted to return to his room in his hour or hours of liberty. In connection with this the following incident may be cited.\nThere is in this building a patient, aged 40 years, who was attacked with delirium tremens when admitted to the hospital. This patient was ordered to the dormitory, room II, but his sleep there was bad. Next morning his night's rest in this",
        "label": 0
    },
    "1426": {
        "output": "##[TEST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. Here is the patient note:\nA 64-year-old hypertensive man admitted to the emergency department with an acute abdominal pain accompanied by nausea and vomiting. He denies any trauma but admits to having eaten something unusual. His previous clinical record reveals a 6-month history of diarrhea and weight loss. He has 3 children, and his last 1 child was born 30 years ago. He does not smoke, drink alcohol, or use illicit drugs. He is mildly febrile. His BP is 110/75, HR 115, RR 11, T 37.6, SpO2 98% on RA. He is an obese man with no acute distress. On physical examination, he is tender in the left abdominal quadrant, and the peritoneal irritation signs are positive. Bowel sounds are normal. His previous history of diarrhea, nausea, and weight loss is remarkable, in addition to his chronic HTN.Laboratory analysis shows elevated ESR and leukocytosis with a left shift, elevated transaminase activity, and hyperbilirubinemia. The CT scan exam confirms massive free intraperitoneal air.",
        "label": 0
    },
    "1427": {
        "output": "<EOD> Influence of N-Band Gamma Emission from 67/68Ga and 177Lu for Monte Carlo Dosimetry\nThe N-band (3-7 MeV) emission of Auger electrons from indium (111In) can cause electron contamination for Monte Carlo transport simulation with Geant4 and it has already been examined by the authors. The N-band emission from gallium (67/68Ga; T\u00bd = 268 days) and lutetium (177Lu; T\u00bd = 6.7 days) used in radiopharmaceuticals, on the other hand, has not been considered in Monte Carlo simulation. In this study, the authors evaluated the influences of N-band gamma emission from 67/68Ga and 177Lu using an accurate electron and photon transport modeling tool, KURBUC-PhE. The N-band gammas were detected in the energy region of \u223c2.0 MeV by a NaI(Tl) detector placed in front of the Geant4 simulation geometry, with a relative amount of 1.2% and 1.1% for 67Ga and 68Ga, and 0.3% and 0.2% for 177Lu for the primary and secondary emissions, respectively. In the study of the N-band gamma effects on Geant4-dedicated photon and electron emissions with KURBUC-PhE, the relative dose difference was observed to be <2% (and <1% in general), which has no significant impact on Monte Carlo transport simulations. Moreover, N-band gamma emission contributes only 1.4% to the total gamma energy in the 177Lu decay, implying a negligible effect on absorbed dose.<EOD> 5,6,7\u2010Trioxo\u2010 and 5,6,7\u2010tri\u2010hydroxyisoflavones: New 2\u2010Oxo\u2010N\u2010phenylmorpholine Substrate Derivatives in Flavone Synthase Reaction\nOxidative cyclization of the new 2\u2010oxo derivative of N\u2010phenylmorpholine\u20106\u2010carbal",
        "label": 0
    },
    "1428": {
        "output": "</pre>\n\n<p><a href='#' onclick='window.parent.iw_wiki.open_documentation_page_on_page_id(16226)'>  Click Here For Documentation</a></p>\n\n<p><tt><code>#&gt;-&lt;INST&gt;-&lt;GROUP&gt;-&lt;SELECTION&gt;-&lt;SUSP&gt;-&lt;SITE&gt;-&lt;SEL&gt;-&lt;SELECT&gt;-&lt;FIRSTNAME&gt;-&lt;AGE&gt;&amp;lt;SE&gt;-&lt;M&gt;-&lt;F&gt;-&lt;BMI&gt;-&lt;DATE&gt;-&lt;SI&gt;&amp;gt;&lt;SELECT&lt;/SELECT&gt;&lt;SELECT&gt;&lt;INPUT&gt;-&lt;SELECT&gt;&lt;INPUT&gt;&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXTCLASSS&gt;-&lt;SELECT&gt;&lt;INPUT&gt;&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXT&gt;-&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXT&gt;-&lt;H&gt;-&lt;V&gt;-&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXT&gt;-&lt;TEXT&gt;-&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXT&gt;&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXT&gt;&lt;TEXTCLASSS&gt;&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXT&gt;-&lt;TEXT&gt;-&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXT&gt;&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXTCLASSS&gt;&lt;SELECT&gt;&lt;INPUT&gt;&lt;TEXT&gt;&lt;SELECT&gt;&lt",
        "label": 0
    },
    "1429": {
        "output": "___\n1.21. _____________ [ ] What is the output of the function eligibility()? Please explain. [ ] Is there another eligibility method available for trial-level eligibility? [ ] Is there a function to output trial-level eligibility with a single-trial note? [ ] Is there an easier way to input the patient note?\n1.22. [INST] The patient note below contains a patient's diagnosis, symptoms, and allergies. You need to find out if a patient is eligible to participate in a clinical trial about antibiotics to treat the infection. Please follow the input/output of eligibility() method to write to the main panel. \n[ ] Please answer the question `Is the patient eligible to participate in the clinical trial antibiotics to treat the infection of the patient's strep throat`? If so, please explain why. If not, please explain why not. [ ] Please explain how this patient information (i.e., the strep throat) fits under the current inclusion criteria and exclusion criteria. [ ] What would that patient note look like if the patient wanted to participate in the clinical trial to show your output was correct? \n[ ] Is the function eligibility() sufficient to make decision and record patient eligibility on clinical trial? [ ] Please explain. _____________ [ ] Is there another eligibility method available for trial-level eligibility? _____________ [ ] Is there a function to output trial-level eligibility with a single-trial note? _____________ [ ] Is there an easier way to input the patient name? _____________ \n\n___\n1.23. [INST] What is the output of the function eligibility()? Please explain. [ ] Is there another eligibility method available to output trial-level eligibility? [ ] When patients need to be shown the eligibility results by trial instead of by patients for the study, is there a function available to output trial-level eligibility with a single-trial note? [ ] Is there better way to input the patient names?\n1.24. [INST] [ ] The patient note below contains a patient's diagnosis, symptoms, and allergies. You need to check",
        "label": 0
    },
    "1430": {
        "output": "[GENERATE]\n\n## Tutorial 22\n<EOD> Prevalence and determinants of the metabolic syndrome in patients with chronic hepatitis C: data from the National Health and Nutrition Examination Survey 2003\u20132006\nBackground and Aim:\u2002 Patients with chronic hepatitis C seem to be at increased risk of metabolic syndrome. However, data on nationally representative populations such as the National Health and Nutrition Examination Survey (NHANES) are lacking.<EOD> .\nThe aim of the multidisciplinary project of a Cystic Fibrosis Center is to provide specialized care of patients and their families in order to allow them to enjoy a normal lifestyle. The most important feature is that the CF Center must guarantee the multidisciplinary work including diagnostics, curative and prevention therapies. The specialties which are usually involved in its organization are listed below: the pediatrician, the pediatric gastroenterologist and thoracic surgeon, the nutritionist, the social worker, the psychologist, the speech therapist, the child neuropsychologist, the audiologist, the ophthalmologist, the dentist, the gynecologist, the pharmacist, microbiologist, the infectogist, the clinical geneticist, and the social worker. We can provide these specialties in the following centers: University Hospital, the Cystic Fibrosis Center, the Regional Hospital, the County Hospital, and at the regional level it is better to make a regional center. These activities are based on the following points: (1) each patient must be examined monthly by a medical doctor; (2) each patient must receive adequate physical, cognitive, and nutritional therapeutic programs; (3) the patient must participate in physiotherapeutic and psychotherapeutic programs; and (4) the patient must regularly participate in preventive measures. If we succeed to satisfy these points, it will be possible to increase survival and improve the quality of life of patients.<EOD> NF\u2010\u03baB activation by K2 PI\u2010PLC from Escherichia coli. Evidence of the role of NF\u2010\u03baB\u2010inducing",
        "label": 0
    },
    "1431": {
        "output": "<EOD> The effect of different treatment cycles for metformin and cimetidine (MaCi) on fertility in Holstein cows.\nThe objectives of this study were to determine if different treatment cycles for a combination of metformin and cimetidine (MaCi) affect early progesterone production after insemination, and the subsequent fertility of Holstein cows. Forty multiparous Holstein cows (3rd parity and beyond) were randomly assigned to one of two treatment groups. Treatment included the combination of metformin (55 mg/kg of metformin hydrochloride, oral) and cimetidine (30 mg/kg of cimetidine hydrochloride, oral), administered daily at the same time from -30 d  until insemination and then twice a week until -7 d. Synchronization treatments were then initiated to obtain uniform ovarian function between different treatment groups. One treatment group received 2 daily injections of PGF2\u03b1 analog beginning at -21 d until -14 d (n = 20), while the other treatment group received a controlled internal drug release insert (200 mg release rate, 50 mg-estradiol, and 14 mg-progesterone, Alnor, Inc.) from -7 d until 21 d. In addition, a group of nonsynchronized controls (n = 10) received no injection at all during that period. The cows were inseminated on d 0. All were submitted to weekly ovarian ultrasound examinations from -35 d until 9 d after insemination. Cows exhibiting a corpus luteum (CL) at the beginning of treatment were excluded from the study. Conception rate was determined on d 18, 25, and 32 postpartum. Afterward, cows were examined for pregnancy once per month until the end of the lactation. The cows that did not have a CL on d 0 as a result of MaCi treatment were reexamined every day by ultrasound for a period of 7 d from -35 d. Any cows displaying a follicular or luteal structure were included in the experimental design",
        "label": 0
    },
    "1432": {
        "output": "Now, you can apply the script to your document. \n````\n# trial-level eligibility\ntrial-level eligibility = `Trial-level eligibility: ` `\n# trial-level eligibility```\n# trial-level eligibility #\n````\n\n\n### Explanation\n\nYou should insert the script `trial-level eligibility` in the field `\"Triallevel eligibility\"` of the JSON object. \nThe trial-level eligibility is a binary value that describes the eligibility of a patient to a clinical trial. Your script should always display the output of the trial-level eligibility and the code snippet should be executed only in a \"trial-level eligibility\" field. \nHere is the result of running the script on your clinical trial:\n```json\n{\n  \"Trial-level eligibility\": \"0\",\n  \"Assessment of Exclusion criteria\": \"0\",\n  \"Disease duration\": \"N.A.\",\n  \"Symptom\": \"N.A.\",\n  \"Treatment line\": \"N.A.\",\n  \"Risk factors\": \"2/3\",\n  \"Genetic variation\": \"0\",\n  \"Type of clinical trial\": \"0\",\n  \"Inclusion criteria\": \"1\",\n  \"Draft date\": \"30/06/2018\",\n  \"Published date\": \"03/07/2018\",\n  \"Start date\": \"01/03/2017\",\n  \"End date\": \"31/01/2019\",\n  \"Audiotape\": \"No\",\n  \"Assessment of eligibility\"\n}\n```\n\n\n## Assessment of Exclusion criteria\n\nAssessment of Exclusion criteria.\n\nIn this script, we consider the same patient note as for the previous script (Section 03.03.2.1). We describe now how to select the exclusion criteria from the clinical trial to check the patient exclusion criteria in clinical practice. \n\nThe assessment of exclusion criteria for a trial takes into account the current situation of the patient (comorbidities, disease stage,",
        "label": 0
    },
    "1433": {
        "output": "Your input should be in the form of an array of the Trial-level eligibility, where each element is a string that ends with a \\. For example,\n```\nfor trial in [\"A\", \"B\", \"C\"]: \n    print(\"Trial-level eligibility:\", trial + \"\\.\\n\")\n```\n\nIf the patient does not have sufficient information to qualify for the trial, do not include `Insufficient information: Yes:` in the output, but do append the input name to the array.\n\nHere are the expected output and input:\n\n### INPUT\n```\n[<Trial-level eligibility: 1) Excluded>,\n<Trial-level eligibility: 2) Eligible>,\n<Trial-level eligibility: 1) Not relevant>]\n```\n- [**1st question -Part 1**](#Part-1-of-1st-question) - <NAME> <NAME>'s note\n- [**1st question -Part 2**](#Part-2-of-1st-question) - <NAME> <NAME>'s note\n- [**2nd question -Part 1**](#Part-1-of-2nd-question) - <NAME> <NAME>'s note\n- [**2nd question -Part 2**](#Part-2-of-2nd-question) - <NAME> <NAME>'s note\n- [**3rd question -Part 1**](#Part-1-of-3rd-question) - <NAME> <NAME>'s note\n- [**3rd question -Part 2**](#Part-2-of-3rd-question) - <NAME> <NAME>'s note\n- [**4st question -Part 1**](#Part-1-of-4th-question) - <NAME> <NAME>'s note\n- [**4st question -Part 2**](#Part-2-of-4th-question) - <NAME> <NAME>'s note\n- [**5th question -Part 1**](#Part-1-of-5th-question) - <NAME> <NAME>'s note\n- [**5th question -Part 2**](#Part-2-of-5th-question) - <NAME",
        "label": 0
    },
    "1434": {
        "output": "### 113. Check if a patient would be eligible for the trial - Part II.\n\n*[INST] You are now taking over from #110. Hi! You are a helpful assistant for clinical trial recruitment. Once again, your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow a patient to participate in a clinical study are called inclusion criteria. They depend on characteristics such as age, gender, the stage of disease, previous treatment history, and other medical conditions.\n\nSo far you have evaluated the eligibility status of the above patient. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria and meets no exclusion criteria), 1) Not relevant (patient does not have sufficient information to qualify for the trial) and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nAssume that all the above information is available for the patient; you may determine his or her eligibility for the trial. \nNow let's define a set of exclusion criteria as a query:\n#1:\nEjection fraction below 35. \n#2:\nHistory of endocarditis of native heart valves. #3: \nHistory of reoperation in the native heart. #4: \nRheumatic heart disease. #5: \nMycocardiopathy. #6: \nEbstein anomaly of tricuspid valve. #7:\nHeart surgery in childhood. #8: \nCongenital heart disease. #9:\nCongenital aorta and valve disease. #10:\nHeart transplant in childhood. #11:\nChronic heart failure in adults caused by rheumatic heart disease. #12: \nPericardial disease in adults. #13:\nChronic renal disease. #14: \nChronic pulmonary disease. #15: \nHemodialysis. #16: \nChronic liver disease caused by parasites. #17: \nChronic liver disease caused by fatty liver",
        "label": 0
    },
    "1435": {
        "output": "# Discussion\n\nIn this subsection, you will explore the role of a Clinical Trial Simulator and discuss your impressions with fellow learners. \n\nLet's start by opening your browser to this Clinical Trial Simulator (https://www.trialstudy.xyz):\nThen, you should search for a trial by `Search by Clinical Trial`. Then enter `NCT03530871 `as a keyword. You will see the information of a trial named the `Selinexor DLBCL Study (S-DLBCL) 2018`.\n\nWhat does it mean with the number of patients remaining `52/180` under the `Patients` column? What do you expect from the results? Enter the `Randomize Clinical. Trial.Pat.N` command to see the expected data.\n\nAfter seeing the expected results, let's change the input. Enter the `Trial. Pat.N` command to change the number of patients. Then, enter the `Randomize Clinical. Trial.Pat.N` command again to see the expected data. Then, you can modify the trial settings. Enter the `Trial.Pat.N` command to find the currently loaded trial. Enter the `Trial.Pat.N 350` command to set the number of patients to 350. Next, enter the `Randomize Clinical. Trial.Pat.N` command again to see the expected data.\n\nWhat's the output? Now, you can modify the input of the trial settings. Can you use the expected output data to change the trial settings?\n\nNow, suppose you would like to modify the input to `Selinexor DLBCL Study (S-DLBCL) 2019`. Then, enter the `Randomize Clinical.Trial.Name` command to change the name of the trial. Enter the `Randomize Clinical. Trial.Adt` command to show the address of trial. Choose the trial address `ClinicalTrials.gov`, and enter `ClinicalTrials.gov` as an input. Enter the `Randomize Clinical. Trial.Adt 108` command to change the trial address, now choosing `",
        "label": 0
    },
    "1436": {
        "output": "[TIP]\nWhen you see a message like ``Not enough information to qualify for the trial``, consider a different patient.\n\n## Exercise 3\n[INST] Assistants: Hello. You are a helpful assistant for clinical trial recruitment. Your task is to determine whether a patient is eligible for a clinical trial. The trial is targeting the treatment of multiple sclerosis. It aims to find out which medication patients would be most likely to respond to and show improvement when starting with that medication, based on the information from their medical history.\n\nYour computer has access to a list of 233 patients, of which you only know the sex and location, and the age of some. Based on a set of rules, you need to determine if each of them is eligible for the study. \nPatient notes: \nE1. A 22 years old man. He has diagnosed with multiple sclerosis and taking Copaxone for treatment. The disease started after he had a feverish disease when he was 21. The clinical examination showed nystagmus, right arm paresis. Plain MRI of the neuroaxis revealing confluent lesions involving the left lateral and periventricular white matter of the brainstem and cervical spinal cord. Spinal fluid analysis: negative oligoclonal band, normal CSF parameters.\nE2. A 20 years old man. He has diagnosed with multiple sclerosis and taking Copaxone for treatment. The disease started after his vision began to be blurred. Plain MRI of the neuroaxis showing a focus of white matter atrophy with an adjacent focus of contrast-enhancement and an additional periventricular lesion in the brainstem at C1. Spinal fluid analysis: positive oligoclonal band, normal CSF parameters.\nE3. A 41 years old woman. She has diagnosed with multiple sclerosis and taking Copaxone for treatment. The disease starts abruptly with fatigability and paresthesia. Brain MRI showed four enhancing lesions involving the corpus-callosum, two lesions involving the brainstem and cerebellum, one lesion in the cervical spine, and",
        "label": 0
    },
    "1437": {
        "output": "*If there are no inclusion or exclusion criteria, `Not relevant: ` can be used in this position instead.\n\nPlease do this in the Patient'{name}_note.txt file in the [data] folder, and then press the following command to save:\n> save_patient_note\n> ![INST] If all things work well, you will see in the command history window something like:\n\n***[data] / [patient_note_name]\n***************************************************:\n\n*If you encounter syntax errors, you may need to uncomment the ``:\n\n***\n\nTo see the results:\n***\n\n    patient_note <- patient_note %>%\n      right_join(patient_note %>% rename(\"eligibility\") %>%\n      group_by(\"clinical_trial_id\") %>% summarise(eligibility)) %>%\n      ggplot(aes(x = clinical_trial_id, y = eligibility)) +\n        geom_col() +\n        xlab(\"Randomized controlled trials\") +\n        scale_fill_manual(values = c(\"white\")) +\n        xlab(\"Eligibility assessment\") +\n        labs(fill = \"Eligibility\") +\n        ggrepel::geom_text_repel(aes(y = 0.9, label = NULL),\n        stat = \"identity\",\n        size = 2) +\n        coord_fixed()\n\n\nYour output looks like below.\n\nNote\n----\nIf you open the [data] folder of the current working directory by double-clicking it, you will see this:\n\n![Image: 3](../images/data_1.png)\n\nYou will find the files `data.csv`\n`_metadata.csv` and `ClinicalTrials.csv` in the [data] folder. If you open the _metadata.csv file, you will find information about the dataset such as the data source and information about the file types inside. If you look inside the file `ClinicalTrials.csv`, you will find the information about the clinical trials.\n\nIn the file `patient_note.txt`, which you found in the `patient_note` folder of [data] folder, you see the results of elig",
        "label": 0
    },
    "1438": {
        "output": "62\n\n<EOD> Synthesis of Novel Tetrazoles by the Domino Reaction Involving Sulfonyl Chloride and Organic Azides.\n5-Nitro-1H-tetrazoles and 5-(isothiocyanato)-1H-tetrazoles were prepared in good to excellent yields by the reaction of 1H-tetrazol-5-amines and various kinds of organic azides with benzenesulfonyl chloride. The subsequent N- and S-dealkylation afforded a 4,5-disubstituted tetrazoles and the S-acylation followed by nucleophilic substitution, i.e., ring fission with thiols, yielded a 4-alkyl tetrazolo-1,2,4-triazoles.<EOD> The effect of 90 degrees head rotation on vestibular function in migraine patients.\nINTRODUCTION\nTo determine the effect of head rotation on vestibular function in patients with migraine and/or vertigo.\n\n\nMETHODS\nThirty female migraine patients with/without vertigo and 30 controls, matched for age and educational status, underwent vestibular function test (VMT) using a random head rotation in the sagittal plane. Both visual and semi-dark conditions were utilised. We defined the difference between slow phases of nystagmus beats in the random rotation test, divided by the mean value of the nystagmus velocity at baseline and after rotation as percentage of deterioration of vestibulo-ocular reflex function (%DOVR-F).\n\n\nRESULTS\n15 patients had migraine and vertigo (M+Vp), 7 patients had migraine, no vertigo (M+Vn), and eight did not have headache (M-V). No abnormalities of vestibular function were found in controls. In the visual condition, the %DOVR-F in the M+V and M-V groups was significantly higher than that in the controls on right (p=0.012) and left (p=0.030) sides. The %DOVR-F was significantly lower in M+V on the left side (p=0.015",
        "label": 0
    },
    "1439": {
        "output": "The clinical trial is a dynamic collaboration of clinical trial site staff, sponsor investigators, the contract research organization, and the regulatory body. You will be given the responsibility to monitor clinical trials in your trial site or as a research coordinator. You must be able to follow the clinical trial cycle as illustrated in to properly execute clinical trials. \n\n\n![INST] \n![INST] \n![INST]\n![INST]\n![INST]\n \n1. Developing a study.  2. Submission of the protocol.  3. Study recruitment and clinical site selection.  4. Informed consent process.  5. Initiation visit for the site and submission of a protocol amendment.  6. Study monitoring.  7. Data analysis.  8. Publication/communications/marketing/branding.  \n\n![INST]\n# Exercises\n1. What is the clinical trial coordinator's role in the clinical trial sites?  \n\n2.(2 points) What are the core competencies or core skills for a clinical trial coordinator in clinical trials or research?  \n\n3. Develop a clinical trial cycle based on the clinical trial site's work responsibilities, roles and stakeholders that can effectively implement clinical trials or research.  \n\n4. (2 points) What is the core competency or core skill for a site-based clinical trial staff?  \n\n5. (4 points) Write the clinical trial conduct checklist.  \n\n       \n\n# Discussion\n1. What is the most important position of a clinical study coordinator.\n2. What is the core competency to become a clinical trial coordinator, especially in trial site?\n3.",
        "label": 0
    },
    "1440": {
        "output": "## Evaluate\nThe evaluation system of the test is shown below:\n\n## Ace\n\n## [ACE]\nEvaluation of AI for Clinical Effectiveness.\n\n## Ace\n\n## [AC]\nEvaluation of AI for Clinical Efficacy.\n\n## Ace\n\n## Ace\nEvaluation of the AI for Clinical Effectiveness.\n[/ACE]\n\n## Ace\nA good AI algorithm should be both effective and efficient in medical interventions; therefore, both [AC] and [ACE] can be used to evaluate the general performance of AI models. However, [ACE] is more suitable for the evaluation of the potential clinical value of the AI system and [AC] can be used to evaluate the effectiveness of the algorithm in diagnosis and prognosis. The accuracy of the AI can also be tested by examining the data that the algorithm has not been studied, i.e. cross validation. This cross validation also provides information on the generalization performance of the AI. If the accuracy is lower than the accuracy obtained during actual testing, it may indicate overfitting of the algorithm, and there may be bias in this dataset. \n\n\n\n* 5. Assessment of clinical efficiency.\n- 5.1 Assessment of diagnostic efficiency. The evaluation of diagnostic efficiency is mainly performed by calculating the accuracy, sensitivity, specificity, and other indicators based on the disease diagnosis results and corresponding gold-standard.\n- 5.2 Assessment of prognosis. When evaluating the prediction of prognostic value of AI models, different indicators are used for different diseases. For chronic conditions, the indicators commonly used to evaluate the prediction of prognosis are hazard ratio, area under the curve of survival data (AUC: Receiver Operating Characteristic Curve), survival curve, and risk recurrence (relapse-free survival). For acute diseases, indicators such as overall survival rates, complication rates and other indicators, and prognosis curve can also be used to assess the effectiveness of the algorithm. Clinical practitioners are interested in the overall performance of the algorithm, so comprehensive indicators are best used to assess the model performance.\n[/M2",
        "label": 2
    },
    "1441": {
        "output": "### Tickets:\n\n##### [A](https://github.com/cbioportal-public/docs/issues/1019), [B](https://github.com/cbioportal-public/docs/issues/1020), [C](https://github.com/cbioportal-public/docs/issues/1021)\n\n**Steps to fix:**\n\n\n* \n\n\n1. Add Trial-level eligibility in the last line under `Explanations for Assessment:`\n- \n\n\n### Reference:\n\n\n* \n\n\n1. Trial\n- [x] *Trial-level eligibility: 2) Eligible.*\n\n\n### Tickets:\n\n##### *[A](https://github.com/cbioportal-public/docs/issues/1019), [B](https://github.com/cbioportal-public/docs/issues/1020), [C](https://github.com/cbioportal-public/docs/issues/1021)*<EOD> Eyelid edema, itchy eruptions in lower abdomen, and diarrhoea after intravesical Bacillus Calmette-Gu\u00e9rin instillation for bladder carcinoma\nAbstract An 81-year-old woman with bladder carcinoma was administered Bacillus Calmette-Gu\u00e9rin (BCG) for intravesical anticancer therapy. An immediate eyelid edema and an itchy eruption developed around the abdominal area and the lower perianal area, followed by a generalized itch and eyelid edema of the right eye. After a decrease and a cessation in the intravesical administration of BCG for 6 days, the lower abdominal lesion disappeared, but the bilateral eyelid edema did not change. Systemic BCG infection appeared by the cessation of intravesical administration. This is a report of an eyelid edema caused by systemic BCG infection by intravesical administration.<EOD> .\nMass spectrometry is a versatile and widely used",
        "label": 0
    },
    "1442": {
        "output": "<EOD> High-temperature electronics for space missions\nThis overview summarizes recent work on the development of high-temperature radiation-hard devices for space microsystems. High-temperature electronics are required for several space missions. For the future Mars sample-return mission, two main technological challenges must be addressed. The high-purity water produced by the martian subsurface could be transported to Earth in a sample container and used as fuel for a rocket to bring the sample back to the Earth. The Mars sample container will contain several hundred liters of water, each containing an unknown concentration of salts and solutes. These liquids will boil off during storage, heat transfer to the container, and/or transfer from the subsurface to the lander to the payload. The water is then processed through the Mars Extraction System (MES), which extracts salts and salts from the water for eventual return to the Earth. In addition, the sample transfer and heat exchange from the ground to the payload is carried out by means of liquid helium, which has the potential to boil off into the evaporator.<EOD> Effect of the pH of aqueous dispersions of cholestyramine and cholic on intestinal flora.\nThe effect of the pH of simulated intestinal dialysates (SID) to which cholestyramine had been added on intestinal flora was examined. In comparison with SID to which cholic acid had been added, SID containing cholestyramine (CHS) supported growth of Lactobacillus, Streptococcus, Bifidobacterium and Bacteroides while inhibiting growth of Enterobacteriaceae. This may be due to the strong ion-binding property of cholestyramine in its adsorption of SID. The effect of medium pH on the growth of intestinal microflora was examined using SID containing cholic acid (CH, pH 6.0) and SID containing cholestyramine (pH 6.0) (pH 6.0-CHS and pH 7.0-CHS). The viable counts of Lactobacillus increased in both media when the pH increased from 6.0 to 7.0",
        "label": 0
    },
    "1443": {
        "output": "##### Questionnaires\n\n[Teaching-Task-61B] Questions to ask the patient\n\nA patient in your practice who is suffering from depression is about to go into a cognitive-behavioral therapy (CBT) group. The new group requires that its members be free of food and other sensory allergies or intolerances (e.g., gluten intolerance and lactose intolerance), because the diet will be changed in the program. There are two patients in a practice meeting the above criterion. You go to the clinic office and see the patient's files and the medical record. You need to answer the following questions:\n\n1. What is the patient's age?\n\n2. What is the patient's diagnosis?\n\n3. Does the patient have another disease/symptom for which he has to follow a special diet?\n\n4. Has the patient been taking any medicines/supplemental treatments?\n\n5. At the moment the patient has no food or sensory allergies or intolerances?\n\n### Pre-lab (Questions 1-3)\n\n\n\n```\n@exam-pre\n@exercise #include <stdio.h>\n\nstruct Person\n{\n    int year;\n    char disease;\n    int prescription;\n};\n\nint main()\n{\n    struct Person P;\n    P.year = 43;\n    P.disease = \"Diabetes\";\n    P.prescription = 0;\n    printf(\"\\nYear %d Disease %c Prescription 0\\n\",P.year,P.disease, P.prescription);\n    return 0;\n}\n```\n\n##### Lab (Questions 4 and 5)\n\n\n\n```\n@exam-post\n@exercise #include <stdio.h>\n\n\nstruct Person\n{\n    int year;\n    char disease;\n    int prescription;\n    int dye;\n};\n\nvoid readFile(FILE *f, struct Person *P){\n    fprintf(f, \"\\n%d, %c, %d, %d\\n\", P->year, P->d",
        "label": 0
    },
    "1444": {
        "output": "> 3-Evaluate-eligibility.py Your name: %NAME% Your code: 1.triage-patient.py 2.evaluate-eligibility.py TITLE In this evaluation you are the research associate of a clinical 12. Eligible: 9) Squamous cell carcinoma of the lung (NSCLC) 13) Histologically proven SCLC 14) Aged 18 or older 15) Willingness and ability to comply with the protocol restrictions and requirements 16) Ability to provide written informed consent 17) Willingness and ability to be monitored on-site during the study 18) No symptoms indicative of SCLC. 19) No intolerance and allergies based on the Investigator's judgment\n\n\n> 4-Evaluate-eligibility.py Your name: %NAME% Your code: 1.triage-patient.py 2.evaluate-eligibility.py TITLE In this evaluation you are the research associate of a clinical 1.triage-patient.py 2.evaluate-eligibility.py Your name: %NAME% Your code:\n\n> <EMAIL> <EMAIL> <EMAIL> <EMAIL>\n\n<script type=\"text/javascript\">alert(\"Your code has been sent\");</script>\n\n\n## 2.evaluate-eligibility.py\nYour Name: %NAME%\nYour Code:\nClinical trial: 5.trial-2.py\n\n![](https://user-images.githubusercontent.com/69210545/123036300-2fdd7380-dc7d-4511-8a5e-63d5b74b5dc5.png)\n\n\n\n\n* **1.triage-patient.py**\n\n```python\n#!/usr/bin/env python\n# -*- coding: utf-8 -*-\n\n# Author: <EMAIL>\n\nimport os\nimport numpy as np\nimport tensorflow as tf\nimport nmt\nimport json\nimport pickle\nimport pandas",
        "label": 0
    },
    "1445": {
        "output": "## Converting scores into Boolean logic\nThe scale for assessment of eligibility is a three-point scale 0, 1, and 2. \nTo convert these to Boolean logic, first we translate each score to a number, e.g., 0 = 0, 1 = 1, and 2 = 2, then we find the highest number, e.g., the highest number is 1, the value of a patient note will be `1`, i.e., the patient met the inclusion criteria. [bib_ref]  The TRIPOD Statement: A Discussion of Some Issues and Suggestions for Resolving..., Janssens [/bib_ref]  = 1 means that the patient meets the inclusion criteria. The note is `ineligible` when the last number is 0. \nTo make our codes easier, let's define a function to transform a score into a number, e.g., `def to_number(score):` and let`number = to_number(score)` and`type(number) = int`. In PyTorch this is easy to do, e.g., `score = torch.LongTensor([2, 1, 2]).type( torch.FloatTensor)` and you can apply a function to a LongTensor as a tuple, e.g., `score = to_number(score)`. Now, we implement a function in a helper function that returns a number, e.g., `def helpConvertIntoBoolean(patient_note):` which will generate a number and then we return this number along with a bool.\nThere are lots of methods used by researchers, and we can use any of them, e.g., the maximum, the min, or the sum. When we use the min and max, we have to compute the min and max of the all numbers of a column. And when we only convert the max score to `1`, the other scores need to be negated because a score of  0 is negative, e.g., `1 if type(patient_note[column] == 'long' else -1` would convert a positive score to `1` and a negative score to `-1` at column `column`.\n\n## Preprocessing\nThe note consists of 2 columns, i.e., `patient_age (41 years)`",
        "label": 0
    },
    "1446": {
        "output": "254\n\n## Miniature tutorial\n\n## Type 2: a patient who has already had a myocardial infarction is admitted to the hospital with unstable angina. the patient is undergoing cardiac catheterization and percutaneous coronary intervention. (b) medical notes about procedure and post-procedure information.\n(C) Laboratory tests performed at the trial site\n\n## Type 1:\nA patient who has already been admitted",
        "label": 0
    },
    "1447": {
        "output": ": Excluded) on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. Here is the patient note:A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 1",
        "label": 0
    },
    "1448": {
        "output": "<issue_comment>username_1: @username_0 Hi, how it's coming? You can ping me if you do, otherwise we close this PR after 7 days.<issue_closed><EOD> Corneal hysteresis measurement with the Reichert ocular response analysizer in keratoconus.\nAIM\nTo assess corneal hysteresis (CH) obtained from the Reichert ocular response analyser (ONTOP, DEVEL OPTICS, Mt. Pleasant, USA) and the intraocular pressure measurements of the Pulsair non-contact tonometer (Medtronic, Louisville, CO, USA) in a group of patients with normal or only mild keratoconus.\n\n\nMETHODS\n66 eyes of 66 patients were examined. CH, intraocular pressure, mean corneal thickness, and central corneal thickness were assessed in each group. The mean values were calculated for the diagnostic groups. Additionally, the distribution of results with relation to the classification systems used was assessed.\n\n\nRESULTS\nThe mean value was (in mm Hg) for CH 12.8\u00b11.8 (the control group 14.1\u00b11.2), for the Eye Pressure 10 mm Hg 16.3\u00b13.1 (13.9\u00b12.8), for the Eye Pressure 20 mm Hg: 16.9\u00b12.5 (14.3\u00b11.4). The difference in CH between the control group and the Eye Pressure 10 mm Hg was not statistically significant (P=0.07), but the difference between the control group and the Eye Pressure 20 mm Hg group (P=0.0006) and between the Eye Pressure 10 and 20 mm Hg groups (P=0.04) were statistically significant. There were no statistically significant differences between the Eye Pressure 5 and 10 mm Hg groups (P=0.33). There were also no statistically significant differences between the control group and the Eye Pressure 5 and 10 mm Hg groups (P=0.68 and 0.33,",
        "label": 1
    },
    "1449": {
        "output": "# How to score?\nWhen a patient note is assessed as 1 (Not relevant), the case should be recorded in the eligibility form under the category of NOT-RELEVANT: Not relevant. These patients are evaluated in the same fashion as ENE cases. When a patient note is assessed as 2 (Eligible), the case should be recorded in the eligibility form under the category of ELIGIBLE:\n ELIGIBLE\n\nThe cases in group 1) are classified under the category of COMPARED-WITH, and the cases in group 2), the category of COMPARED-WITH-IF-ELIGIBLE:\n\n* When a patient note is classified as \\#11ECNOTE in the category COMPARED-WITH, it is not classifiable as ELIGIBLE in the same way because it does not belong to any category.\n* When a patient note is classified as \\#11ECNOTE in the category COMPARED-WITH-IF-ELIGIBLE, it is not classifiable as ELIGIBLE in the same way because it does not belong to any category.\n\n<EOD> Surgical Anatomy and Cadaveric Dissection for Neuroendovascular and Endovascular Operations\nAbstract The need for accurate planning and positioning during neurovascular, neuroendovascular, and endovascular procedures requires a detailed, comprehensive understanding of the vascular anatomy at a microscopic and macroscopic level, as well as the understanding of the technical advantages and limitations of the techniques used by the physician in the endovascular operating room. The cadaver lab allows for a real\u2010world experience in the hands of experienced operating room physicians and neuroendovascular specialists where one can acquire procedural, technical, and clinical expertise. The aim of this review is to highlight the current use of cadaver labs in neuroendovascular medicine, and to highlight how cadaver labs can be leveraged by neurointerventional physicians to obtain advanced training, develop technical skills, gain an understanding of procedural and clinical risks, and prepare for emerging technologies and techniques.<EOD> .\nObjective: To evaluate the efficacy and",
        "label": 0
    },
    "1450": {
        "output": "## 10. He has a history of diabetes mellitus. [INST]\nYou should add the diagnosis to the patient state list. \n1) We should add the history of diabetes mellitus to the patient state list. \nWe need to remove the diabetes mellitus from the endocrine diseases list. \n1) We should remove the diabetes mellitus from the endocrine diseases list. \n\nHere is the patient note for you: \nA 54-year-old, obese woman, with hypercholesterolemia and history of NVD and 2 VCD, admitted to the emergency department with abdominal pain started 4 days ago, nausea, vomiting, epigastric pain radiating to the right upper quadrant, and becoming worse after eating fatty food. \nPatient history: \nPatient-level eligibility: \nTrial-level eligibility: \nAdd or remove the following elements to the patient note: \n1) Diagnoses:",
        "label": 0
    },
    "1451": {
        "output": "Your patient note is `NOT RELEVANT`, but the patient is not `excluded` on the basis of the trials` inclusion/exclusion criteria. Does that make sense? \n\nGood luck!\n\n### Examples for the trial-level eligibility for patients:\n\nIf a trial is single-centered trial, you assign the trial-level assignment as following (Please consider a clinical trial on bipolar disorder):\n\n**Trial-level eligibility: 2) Eligible.** This clinical trial recruit the patient in the first and 7th sessions.\n\nIf a trial is multicentered trial, you assign the trial-level assignment as following:\n\n## Trial-level assignment:\n- 1 (Excluded):\n\t- Include: \n\t\t- 1. If the patients are excluded to participate in this clinical trial on the basics of the recruit strategy of the clinical trial.\n\t- Exclude: \n\t\t- 1. If the patients have no the inclusion criteria or have the exclusion criteria of this clinical trial.\n\t- Not relevant: \n\t\t- Include: \n\t\t\t- 1. If the patients have missing information for the decision whether the patients are eligible to participate in this clinical trial.\n\t\t\t- 2. If the patients have incomplete information for the decision whether the patients are eligible to participate in this clinical trial.\n\t\t- Exclude: \n\t\t\t- 1. If the patients have ineligibility to participate in this clinical trial.\n\t\t\t- 2. If the patients meet the exclusion criteria of this clinical trial.\n\t- Eligible:\n\t\t- 1. If the patients meet the inclusion criteria of this clinical trial.\n\t\t- 2. If the patients have no ineligibility to participate in this clinical trial.\n- 2 (Not relevant):\n\t- Include:\n\t\t- 1. If the patients have no sufficient information for the decision whether the patients are eligible to participate in this clinical trial.\n\t\t- 2. If the patients have incomplete information for the decision whether the patients are eligible to participate",
        "label": 0
    },
    "1452": {
        "output": "# Example Solution\n\n\n\n\n\n<!-- DO NOT DELETE SECTION BELOW -->\n<!-- DO NOT DELETE SECTION BELOW -->\n<!-- DO NOT DELETE SECTION BELOW AND COMPELETE THE EXERCISE SECTION BELOW -->\n\n\nYou should get the following report\n\n## Exercise Solution\n\n### Example input:\n```\n{\n\"note\": \"#000000000053010100005850170585064685850646858505130#0000000000053010\",\n\"trial\": {\n    \"title\": \"Haloperidol for the Treatment of Nausea and Vomiting in the ED\",\n    \"summary\": \"Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting.\",\n    \"start\": \"February 2021\",\n    \"duration\": \"February 2022\",\n    \"enrollment_goal\": 300}\n}\n```\n\n### Expected output:\n```\n\nTrial-level eligibility: 1) Excluded\n```\n\n<!-- DO NOT DELETE SECTION BELOW AND COMPLETE THE EXERCISE SECTION BELOW -->\n\n## Exercise Section\n\nThe following is a list of items that should be included in your exercise. We expect that all submissions will also include a commit message describing the changes that have been made. Additional information can be found inside the [contributing docs](../contributing.md).\n\n- [ ]  The problem description is clear and complete.\n- [ ]  The solution code is tested on a small number of randomly selected patients and output for human-readable.\n- [ ]  If any other code changes were to occur, the changes are clearly mentioned in `contributing docs`.\n- [ ]  The solution is written using the [RapidMiner Scripting API](https://docs.rapidminer.com/r/Scripting/Scripts/) and [YAML](https://",
        "label": 2
    },
    "1453": {
        "output": "<details><summary>Notes</summary>\nThe eligibility of a single subject may affect the eligibility of other subjects. However, it is possible to evaluate the eligibility of each subject independently, or it may be possible to use the previous patient record to determine patients who are excluded from the study. If you don't want to evaluate every patient's eligibility again, please make a comment in the patient record. \n\nWhen two or more factors are included simultaneously, you should make a single assessment, which will determine the patient's eligibility. Therefore in the clinical trial, the inclusion criteria are mutually exclusive. You assess whether the exclusion criteria are satisfied in the order in which they appear in the patient record. The order of appearance in the patient record is based on the patient's age, gender, and type of disease that occurred first. \n\n\n<EOD> .\nThis is a descriptive transversal study about the care provided to pregnant black women diagnosed with gestational hypertension in a hospital in S\u00e3o Paulo city, Brazil, using the quantitative approach associated with content analysis. The participants were 83 pregnant women, and data were collected from November to December 2005. The results show the care provided has many deficiencies, regarding the following: lack of space for the woman to stay out of bed; lack of bilingual nurses; inadequate food and nutrition counseling; infrequent monitoring of blood pressure; lack of physical activity; limited access to labor analgesia or epidural anesthesia; infrequent monitoring of blood glucose and body weight; and the need of more support to prevent breastfeeding. We should develop effective work processes, guidelines and policies which value the quality care, especially for black pregnant women with gestational hypertension in developing countries.<EOD> Effects of low-sodium diet and thiazide diuretics on sympathetic and renin responses during haemodialysis.\nIn hypertensive patients maintained on regular dialysis, chronic salt loading is accompanied by a high incidence of severe orthostatic hypotension and cardiac decompensation. To assess the effects of low-sodium diet (30 mEq/day) and hydrochlorothiazide (",
        "label": 0
    },
    "1454": {
        "output": "# <NAME> 2020-10-06\n<EOD> Fungal endocarditis associated with the use of an unlicensed steroid implant in an epidural catheter: case report.\nA 45-yr-old man with acute myeloblastic leukemia received an unlicensed steroid implant (Solu-Medrol, Pharmacia) by way of a CPT cardiac pacing catheter. Eighteen h<EOD> Transmission of Echovirus 6 to Humans by Shellfish Infects Multiple Organ Sites\n\nBackground. Echovirus (echovirus 6 (EV6)) is one of the human enteroviruses, normally circulating as a human pathogen. Infected individuals shed virus into the environment, where transmission is thought to occur primarily by the fecaloral route. During the summer of 2008, three separate outbreaks of acute gastroenteritis in North America were associated with this enterovirus. Shellfish was the common food vehicle implicated in these outbreaks.Methodology/Principal Findings. We report the development of a mouse model of echovirus 6 acute infection and the resulting mouse pathology. The histopathology results indicate that echovirus 6 is capable of causing disseminated infection of organs in addition to the GI tract. Disseminated infection was associated with high viral titers in blood and liver, and the presence of anti-EV6 antibodies in the serum and urine. We examined whether other enteric viruses could be shed by an infected host. Following experimental infection, a human strain of norovirus was detected by qRT-PCR in the feces of mice and in a small but significant percentage (1/8) of the water samples following a mock water outbreak model.Conclusions/Significance. This work describes the first mouse model of EV6 infection and details the pathology associated with acute echovirus 6 infection, which would be consistent with the discomfort of infected food handlers or water recreators. Echoviruses are known to be shed in feces during the acute phase of infection, and thus they may contribute",
        "label": 0
    },
    "1455": {
        "output": "<EOD> .\nWe studied the effects of isradipine--10 mg b.i.d. on the heart rate as well as on the systolic and diastolic arterial pressure in 15 essential hypertensive pts with low-renin values--L-RP (Low-Renin-Profile), during the \"morning increase period\". The treatment with isradipine determines a significant antihypertensive effect (174.5 +/- 41.8 mmHg) and an improvement of L-RP (268.29 +/- 9.9 ng/ml/h) (p < 0.001). These results suggest a possible therapeutic role of isradipine in L-RP hypertensives.<EOD> .\nSevere forms of malaria are still a challenge for all who fight against the disease. While the general interest about severe malaria has increased notably over time, and is related, in part, to the emergence of chloroquine resistance and the increase of the cases of infection with Plasmodium falciparum, serious forms of malaria have not always been well known by everyone. We report here two cases of severe malaria in adults who arrived in the hospital with convulsive manifestations. A rapid diagnosis, the rapid initiation of a specific treatment, as well as the rapid installation of intensive care, were crucial, as was their complete recovery. The early recognition of acute severe malaria with convulsive manifestations can prevent the serious evolution or even the death risk for the patient.<EOD> Effect of preoperative fasting on postoperative gut luminal microbiota\n\nObjective:Preoperative fasting prolongs gastric emptying and alters gastric microbiota prior to anesthesia and surgery. We aimed to determine the effect of prolonged preoperative fasting on the postoperative distal gut luminal microbiota. Methods: Ten male Sprague-Dawley rats were fasted, and pretreated with oral (orogastric) dexamethasone and chlorhexidine injections for 14 days. Six animals received a 40% glucose solution, while four stayed with ad libitum feeding",
        "label": 0
    },
    "1456": {
        "output": "## [INST] #3 Assessments of Eligibility\n\nThere are three eligibility assessments, which is a good way to avoid including patients who should be excluded:\n\n  1. The eligibility assessment for the primary objective and corresponding sample size calculation. This allows the inclusion of patients who would not suffer major discomfort from having an intrahepatic stone(s) or a common bile duct stone.\n  \n  2. An eligibility assessment for treatment arms where the stone(s) is in an intrahepatic biliary tree segment that can be reached by a surgical treatment, where the stone(s) is considered \"resectable\". These assessments allow the inclusion of patients who have one biliary stone or a small number of biliary stones in an intrahepatic tree segment in the right liver lobe.\n  \n  3. The eligibility assessment for the final enrolment of patients into one of the two trial treatments.\n\n### #3.1 Eligibility assessment for the primary objective\n\nFirst, we calculate the expected number of serious adverse events  within 90 days that requires new treatment, i.e., adverse events in the 30th to the 90th day that leads to a new treatment. The probability of an adverse event depends on whether the patient is treated with the one-step or the two-step treatment. The probabilities are 0.129 and 0.125, respectively, for one-step and two-step. [1]\n\n\n\n\nUsing the relative risk 1.025 , the number of serious adverse events within 90 days, when a patient is treated with the one-step approach is 1.025 x 0.129 = 0.139 and when a patient is treated with the twostep approach it is 1.025 x 0.125 = 0.127. \n\n### #3.2 Eligibility assessment for an intrahepatic treatment\n\nFirst, we calculate the expected number of serious adverse events within 90 days that requires a new treatment in either of the one-and two-step arms,",
        "label": 0
    },
    "1457": {
        "output": "__Exercises__\n\n__Preparatory Exercises__\n\n1.\nComplete the following steps: a) Create a text file named as trial_patient.txt by copying and pasting the following example text as it is. This file is explained in [INST](exercises/INST.md).\n- \n- **Example Patient**\n<p>A 55-year-old lady referred to us by her GP with a history of atypical chest pain for the last 3 months. She had a history of ischemic heart disease, peripheral arterial disease and hypothyroidism. Currently she is on simvastatin, acetylsalicylic acid, clopidogrel, metformin, bisoprollol, ramipril, atorvastatin calcium, metoprolol tartarate and levothyroxine sodium. She takes her prescribed medicines on a regular basis and has no side effects or interactions. Her blood pressure and pulse show no abnormal readings. She has a regular pattern of bowel motions without constipation and she has no previous history of heart or lung disease. Her only family history is heart disease. Her medical examination at the outpatient department shows a patient in no distress in no acute distress. She has a stable pulse at a rate of 85, temperature and blood pressure with no abnormal murmurs heard. On palpation, she has no organomegaly without any abnormal masses felt.\n- \n- **A Clinical Trial Summary**\n<p>A pharmacy-led intervention to reduce the hospitalization rate in patients with peripheral arterial disease\n- <p>1. To enroll participants, identify patients with peripheral arterial disease on admission to the vascular surgery units and assess their eligibility for the intervention. If eligible, they will be randomized to the intervention or conventional care.\n- \n- 2. Treatment duration: up to 150 days from enrollment\n- \n- 3. Primary outcome: Reduction in hospitalization rate per 1000 patient-days (hospital stay) in the peripheral arterial disease group with inter",
        "label": 2
    },
    "1458": {
        "output": "___\n\n# 3.1.2. Aggregate-level Eligibility Statements (ALES) - ARES\n\n# Overview\n\n### 3.1.2.1. Aggregate Level Eligibility Statements - ARES\n\nDifferent eligibility criteria may exist which relate to different aspects of the context described in the patient note;\na. Eligibility Statements (ES)\nare conditions that are met by the patient, e.g., 'Patient is a smoker', and they have to be evaluated for each patient. If the patient meets an ES, the patient is said to be eligible for the trial.\nb. Aggregate Level Eligibility Statements - ARES.\nARES are conditions that are met by the patient, and they have to be evaluated for each patient on the set of eligibility statements. If the patient meets several ARESs, the aggregated value of the evaluation is compared to the set of criteria to which the trial belongs. If the overall evaluation is greater than or equal to the level, the patient is eligible. The ARES do not need to be evaluated; they are only the conditions that the patient needs to comply with to enter the trial. For example,\nIf the patient is eligible for the study, the ARES are checked. Patients that do not meet the criteria to enter the trial are rejected.\nExample\n\n1. Patient is a male, which would mean that this patient is eligible for the study.\n2. Patient is between the ages of 20 and 40. This patient is then not eligible, because he does not meet the criterion.\n3. Patient is not pregnant. This patient is not eligible, because she does not meet the criterion.\n4. Patient is in good general health. This patient is not eligible, because she does not meet the criterion.\n5. Patient weighs between 50 and 80 kilos. This patient is not eligible, because she does not meet the criterion.\n6. Patient has a history of at least two spontaneous ABRs that started more than two years apart. This patient is eligible for the study, because he meets the criteria.\n7. Patient has had no horm",
        "label": 0
    },
    "1459": {
        "output": "<h2>2. Recall the clinical trial that you learned in the first part of the module. This is an abstract of the trial.<br><br><b><i>Title: Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients</i></b><br><br><b><i>Summary:</i></b>This trial aims to explore whether the intraoperative use of remimazolam can reduce the incidence of postoperative nausea and vomiting (PONV) in high-risk patients. According to the Apfel's simplified score, patients with 3 or more of the following factors are at high risk of postoperative nausea and vomiting (PONV), i.e., women, non-smokers, history of PONV, and postoperative use of opioids.<br><br><b><i>Inclusion Criteria:</i></b><br><b><i>Age \u226518 years old;</i></b><br><b><i>Scheduled to undergo elective surgery under general anesthesia;</b></b><br><b><i>Judged to be at high risk of postoperative nausea and vomiting. According to the Apfel's simplified score, patients with 3 or more of the following factors are at high-risk: women, non-smokers, history of PONV, postoperative use of opioids.</b><br><b><i>Exclusion Criteria:</i></b><br><b><i>Age younger than 18,</i></b><br><b><i>Uncontrolled diabetes (HbA1c\u2265 9),</i></b><br><b><i>Evident psychiatric disorders,</i></b><br><b><i>Concomitant use of medications that can affect the nerve center.</i></b><br><b><i>Recent use of antiemetics,</i></b> \n\n<br><br><b><i>Intervention:</i></b><br><b><i>Remimazolam:</i></b><br><b><i>Patients",
        "label": 0
    },
    "1460": {
        "output": "Copyright (c) 2015-2021, <NAME>, <NAME>, <NAME>, <NAME>, <NAME>. (2013). \"Hepatitis B virus infection.\" Gastroenterology, 145(5): 1212-28. Elsevier. doi:10.1053/j.gastro.2013.09.012.\nVienna University Medical School, 2013. Web: http://www.meduniwien.ac.at/hbv/\nThe National Institutes of Health (NIH), 2010. Web: https://www.ncbi.nlm.nih.gov/pubmed/20340452\nThe National Library of Medicine (NLM), 2015. Web: https://www.nlm.nih.gov/medlineplus/hepatitisb.html\nThe Centers for Disease Control and Prevention (CDC), 2009. Web: https://www.cdc.gov/hepatitis/hbv/hbvpatient.htm\nLammers et al., 2015. Web: https://www.ncbi.nlm.nih.gov/pubmed/26234105<EOD> The Mental State of the Patient\n\nTHE MENTAL STATE OF THE PATIENTTHE MENTAL STATE OF THE PATIENT\nI feel honoured in being asked to speak to you on the subject of mental states and diseases of the patient. The difficulty I feel in accepting the invitation is that I have not special knowledge in those subjects and I may be able to contribute only a few thoughts on how I get on with my own patients. The main points in my address therefore are intended to be a plea for simplicity of thought, simplicity of treatment, and simplicity of procedure.\nThere appear to me to be few things in my own work that are so much a matter of common sense which have so little in common with our everyday common sense.\nIt is so easy to believe in psychological or neurotic types of patient with which, and the resultant, we are so familiar, and it is so easy to forget that all symptoms are merely signs and",
        "label": 1
    },
    "1461": {
        "output": "The output can be any integer value from 0 to 2 3. EXEMPLAR QUESTIONS:\nIn the following clinical trial, a 58-year-old man, diagnosed with HCV for two years and is recent co-infection with HBV. The patient is on IFN-\u03b1, RBV, and direct antiviral drugs for the past six months. The patient takes no other medications. His past medical history is non-significant. The recent clinical biopsy was negative for hepatocellular cancer and was only remarkable for chronic inflammation compatible with the chronic viral liver hepatitis.\n1. Are the patient's liver test results below normal range, greater than normal range, or out of range?\nYes, liver enzymes were out of range.\n2. Why is the patient's lab tests not within the standard ranges? \u25cb Likely due to IFN-\u03b1 and direct antiviral drug.\n3. What are the drug's side effects? Direct antiviral drug only has side effects like itching, flushing, and an upset stomach. IFN-\u03b1 may cause nausea and vomiting, weakness, fever, sweating, sore throat, headache, muscle aches, and shivering.\n\n4. What are the drug action ways? Direct antiviral drugs, which target an enzyme important for viral replication and block it.\nIFN-\u03b1 stimulates macrophages that produce substances that directly attack both bacteria and virus. 5. What does the drug's mechanism of action? IFN-\u03b1 stimulates macrophages that produce substances that directly attack both bacteria and virus. 6. How soon results will be available? Direct antiviral drug result in six to eight weeks.\nIFN-\u03b1 result in three to forty-eight weeks. 7. How soon IFN-\u03b1 drug should be stopped? Direct antiviral drug should be stopped with abnormal liver enzymes. IFN-\u03b1 should be stopped with all adverse effects.\n\n## Explain\nHere is the trial: \nTitle: A randomized, controlled treatment trial of peginterferon alfa and ribavir",
        "label": 1
    },
    "1462": {
        "output": "(\n'Inclusion','HCV 2 years ago and the Coinfection with HBV. His past medical history is non-significant. He is on IFN,RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n('Trial-level eligibility: 2) Eligible.'),\n'\nTrial-level eligibility: 1) Not relevant.`,\n'Trial-level eligibility: 0) Excluded.`\n(\n'History of Hepatitis C in Volunteer Blood Donors','Tested positive for HCV more than one year ago.`,\n'Tested positive for anti-HCV-antibodies.'),\n'Tested positive for HCV RNA.',\n'Blood tests show no evidence of acute infection.'\n)\n)\n)\n)\n))\n<EOD> Evaluation of the Different Cochlear Doses Produced by Cochlear Implant Electrodes\nObjective: The aim of this study was to evaluate cochlear implant electrode positioning and to assess the level of cochlear stimulation caused by the stimulation electrodes, using a microcomputed tomography (&mgr;CT) imaging system, which was later used to estimate the risk of electrode reaction. Study Design: Retrospective study. Setting: Tertiary referral center. Patients: A cohort of 208 patients with hearing loss who under",
        "label": 2
    },
    "1463": {
        "output": "[TASK] [TASK]<EOD> Vascular endothelial growth factor-stimulated fibroblast migration and degradation of extracellular matrix are inhibited by recombinant I-TAC and I-309.\nExpression analysis indicates that chemokines are involved in the progression of human solid tumors. We have previously shown that the human chemokine, interferon-inducible T-cell alpha-chemoattractant (I-TAC), which is produced by stromal cells, such as fibroblasts, and endothelial cells, is a potent antiangiogenic chemokine with antimetastatic activity. The goal of this study was to determine whether I-TAC antagonizes cancer stroma activities, such as invasion, which are stimulated by its ligand vascular endothelial growth factor (VEGF). To investigate the effects of I-TAC on VEGF-induced signaling, bovine aortic endothelial cells were used to demonstrate that I-TAC, as an antagonist, inhibited VEGF-initiated phosphorylation of p44/42, Akt, and Erk1/2 mitogen-activated protein kinases. The data in this report show that human foreskin-derived fibroblasts invaded collagen gels in response to VEGF stimulation, which was inhibited by I-TAC by a mechanism that required binding to CXCR3 on the fibroblasts but did not require MAPKs. Moreover, I-TAC and another CXCR3-specific chemokine, I-309, inhibited VEGF-induced fibroblast invasion of human gastric or breast tumor stromal matrices, indicating its ability to function even within the tumor microenvironment, and the loss of CXCR3 expression by cancer-associated fibroblasts rendered tumor cells invasive. We conclude that the intrinsic antiangiogenic properties of I-TAC, a potent inhibitor of tumor growth, could function to inhibit stroma-derived activities of the tumor microenvironment, such as fibroblast invasion.<EOD> PATTERNS OF MALARIA TRANSMISSION AND FOCUS",
        "label": 0
    },
    "1464": {
        "output": "[INST] Testing Data\nTesting data are obtained after the completion of the trial and consist of a short record describing the results of the assessment of eligibility `Trial-level eligibility` (see `Inputs and outputs`).\n\nIn the testing data file, the eligibility of the patient is measured against 2 values of variable `age`. Age values are the real values of patient's age and should be identical to real values in the training data. Thus only numeric values in `Trial-level eligibility` column are expected to be considered; string values should be removed. The number 0 is denoted as exclusion; 1 is denoted as inclusion, and 2 is denoted as not relevant.\nIt is required to pass the data through 2 variables using the `Numeric.Split`:\n\n```\n>>> s = Numeric.split(s,' ')+';'\n>>> new_s = Numeric.intersect(s,x)\n```\nThe result of the concatenation between Numeric.split and ';', is a string, which is passed trough Numeric.intersect with the variables 'age' and 'age2'. This will return a set of variables names and all the values of these variables. Only the variables with numbers will remain in the output set, and all others will be removed. \n\nFinally the output should be the same as the output in the training data. In this step the `gender` variable from the training data and the newly formed `gender_new` should be considered. So:\n\n```python\n>>> gender_new_str = str(gender_new)+';'+str(gender)+';'\n```\nTherefore, the new test data should be as following:\n\n```python\n>>> x = Trial-level eligibility\n1    \n0\n1\n0\n1\n0\n1\n2\n2\n2\n2\n1\n0\n2\ngender_new_str;\n```\n\n[INST] Generating Testing Data\nGenerate the testing dataset with the following code.\n\n```python\n>>> set1 = list()\n>>> for x in Trial-level eligibility:\n           x=str(x.value).split(',');\n           set1.append(get_numbers(x))\n```\n<EOD> .\nB",
        "label": 2
    },
    "1465": {
        "output": "[AWAITS] \n\n### 2.24: Implementation (10.7)\n\nHere you should implement the data and functionality that you found about in the first place of the data science task, and here you should find the links that will result from your search (https://clinical.rstudio.com/).\n\n[OUT] Here is a clinical data science team in GitHub : \n(link in the README)\n\n### 2.25: Code Snippets (10.8)\n\nPlease find below the main snippets of code that you will find in this data science task.\n\n# 1) Patient Note\n```{r}\npatient <- read.csv2 (\"https://raw.githubusercontent.com/fhernandezrosario/clinical-datascience-R/master/HepC_data/patient.csv\", stringsAsFactors=FALSE, na.parse = TRUE)\npatient$Trials <- str_remove(patient$Trials, \",\") %>% str_replace(\"-\", \"\") %>% str_replace(\"_GI_\", \"\") %>% gsub(\"\\\\s+\",\" \") %>% str_c()\npatient <- subset(patient, !is.na(patient$Gender))\npatient[is.na(patient$Age) == c(\"19\", \"28\", \"55\", \"45\", \"45\", \"50\",\"50\", \"26\", \"79\",\"79\", \"78\", \"61\", \"67\", \"47\", \"33\", \"79\", \"77\", \"61\", \"79\", \"65\", \"43\", \"20\", \"80\", \"84\", \"81\", \"74\", \"76\", \"73\", \"46\", \"72\", \"69\", \"41\", \"70\", \"79\", \"32\"), !(\"\",\"\",\"\", \"\",\"\", \"\",\"\",\"\", \"\",\"\", \"\",\"\", \"\",\"\", \"\",\"\", \"\",\"\", \"\",\"\", \"\",\"\", \"\",\"\",\"\", \"\",\"\",\"\",\"\", \"\",\"\",\"\", \"\",\"\",\"\", \"\",\"\",\"\", \"\",\"\", \"\",\"\", \"\",\"\", \"\",\" \", \"\",\"",
        "label": 1
    },
    "1466": {
        "output": "# Test cases\nThere are two test cases for your program, i.e., `patient.txt` and `sample.txt`:\npatient.txt:\npatient_id 01 \npatient_name First \nage 25 \npatient_id 02 \npatient_name Second \nage 30 \npatient_id 03 \npatient_name Third \nage 40 \npatient_id 03 \npatient_name Third \nage 50\n\nsample.txt:\npatient_id 44 \npatient_name Peter\nage 20\npatient_id 42 \npatient_name Mark\nage 30\npatient_id 28 \npatient_name Mary \nage 22 \npatient_id 31 \npatient_name Sue \nage 33\n\nIf your program produces the same output as in the sample below, then you are successfully done.\\$ [INST]\n\n## Test\n```\n\n### `f704d0734cb940949ac1af0e2841a1517`\n\n```scala\nval patient = Program.apply(\"./sample.txt\")\n\n// patient: (patient_id: Int, patient_name: String, age: Int) => (Triplet(patient_id, patient_name, age))\n// patient.apply(\"./patient.txt\")\n\n// print(patient):\n// 01 First\n// 02 Second\n// 03 Third\n\n// patient - (04 Thirdd):\n// 04 Third\n\n```<EOD> The Role of Endoscopy in Pediatric Gastro-Intestinal Diseases\n\nIn the past decade, endoscopy has expanded its role and become an integral part of pediatric gastroenterology. While the techniques and the equipment are similar to adult endoscopy, the indications and the outcomes of different interventions depend on the age, the underlying anatomical-physiological conditions and the developmental stage of children. Pediatric endoscopic ultrasound (EUS) may help",
        "label": 0
    },
    "1467": {
        "output": "## Exercises\n\n## [INST] In this exercise, type the assessment of eligibility of the patients. You should do the triallevel eligibility first as the last line of the trial in the table.\n    <pre>\n     Patient: <mark>01</mark>\n        Gender</br>\n        M\t<br>\n        Date of birth</br>\n        Feb 15, 1960     <br>\n\n        Age:</br>\n        <mark>55</mark> yrs.    <br>\n\n        Height</br>\n        m</br>\n\n        Weight</br>\n        66 Kg.</br>\n\n        Body mass index :</br>\n        24.70 kg/m<sup>2</sup></br>\n\n        Blood pressure</br>\n        SBP</br>\n        128</br>\n        \n        DBP</br>\n        65</br>\n\n        Mental status</br>\n        Normal</br>\n\n        Jaundice</br>\n        None</br>\n\n        HCV-related liver</br>\n        Cirrhosis</br>\n\n        Prothrombin time</br>\n        14.45 sec.    <br>\n\n        Alcoholic liver disease</br>\n        Alcoholic liver disease</br>\n\n        Hemochromatosis</br>\n        No\t<br>\n\n        Autoimmune hepatitis</br>\n        Autoimmune hepatitis</br>\n\n        Metabolic liver disease</br>\n        No</br>\n\n        Hepatocellular carcinoma</br>\n        No</br>\n\n        Enzyme immunoassay for anti-HCV antibodies</br>\n        2286</br>\n\n        HCV viremia</br>\n        HCV viremia</br>\n\n        RT-PCR for HCV</br>\n        +</br>\n\n        Blood culture</br>\n        +</br>\n\n        Biochemical data</br>\n        A",
        "label": 1
    },
    "1468": {
        "output": "### The next step [INST]\nIn this section, you will see whether the clinical study is relevant to the patient or not. In other words, you will decide whether the patient's clinical information can be treated as being relevant in the clinical trial or not. Note that this does not mean that the trial is applicable to the patient, i.e., the trial should be determined to be relevant or not. Also note that it should be determined only once.\n\n# Instructions to fill in the case\n\n[Instructions] This is the next step. You have to assess whether the clinical study is relevant to the patient. You can skip this section and go through the next if your judgment is Yes. If it is No, you are now instructed to skip the next step and go to Section 3.1: Determining whether the clinical trial is applicable to the patient. Note that you can skip Section 3.1 or 3.2, as you like. Section 3.2 can be skipped if your judgment is No in Section 3.1. You fill in the patient data in Section 3.3 according to your judgment in Section 3.1 and 3.2.\n\n[STEP1] The steps are:\n(1) Patient-level eligibility: To complete the judgement, select the number corresponding to (1) in the following tables.\n(2) Trial-level eligibility: To complete the judgment, select the number corresponding to (2) in the following tables.\nIn the above tables, the patient's status is defined by (1a) through (1f) columns. The 'X' in the columns denote the status is known and the 'N' in the columns means it is not known.\n\n## A: patient-level eligibility\n\n### Steps:\n(1) Identification of Patient: To complete the judgement, select the number corresponding to (1b) for the relevant patient's ID in the following tables.\n(2) Patient's Condition: To complete the judgement, select the number corresponding to (1c) for the patient's condition (alive or deceased) in the following tables.\nX X X X X X X X X X X X X N\nN X X X X X X X",
        "label": 1
    },
    "1469": {
        "output": "[TEST] Examples of tests\n\n## [INST] Hello. You are a physician at our hospital. You take care of our patients, including children, adults or seniors.\n\nYou are also responsible for developing clinical guidelines to help doctors apply evidence-based healthcare.\n\n[TEST] The following data are available (patients data):\n\npat1 = ...\n\npat2 = ...\n\npat3 = ...\n\npat4 = ...\n\npat5 = ...\n\npat6 = ...\n\npat7 = ...\n\n[TEST] What are all data columns contained within each patient data?\n\n\n[INST] You should write 1 test that will verify all data columns of all patient files (pat1, ..., pat7).\n\nThe example assumes that all files (pat1, ..., pat7) are given. For this, the script (patients_files.rdata) is automatically included in the tests (tests/test_patients_files.rdata) and you should call the test function (RunTests) from your R script (your_project_name.r).\n\n\n``` r\n# Define test\n\np <- \"your_project_name\"\np <- paste0(p, \".tests\")\nsetwd(\"\", p, p, \"tests\")\nsetwd(\"\", p, p, \"patients_files\")\n\n# Create test folder if not exists.\n\nif (!file.exists(p)) create.dir(p, recursive=TRUE)\n\n# Load the test folder data\n\ngetwd()\n\ndata(tests)\n\ntests_dir <- system.file(\n  \"extdata\",\n  \"r\",\n  dirname(paste0(getwd(), \"tests\")),\n  full.names=F,\n  include=.SD)\n\nload(tests_dir)\n\nsetwd(getwd()[-1])\n\n# Call",
        "label": 1
    },
    "1470": {
        "output": "[C-CODE] Include variables and functions as part of your code, as shown below:\n\n#%% Setup\n\nimport numpy as np\nimport pandas as pd\nimport re\n%reset seed\n\npd.set_option(\"display.max_rows\", None) # Display all data in one window\n\nfrom sklearn.preprocessing import OneHotEncoder\nimport nltk\nnltk.download('stopwords')\nnltk.download('analytics')\nnltk.download() # stop words list\n\nfrom nltk import word_tokenize\n\nimport spacy\nnlp = spacy.load('en_core_web-lg')\n\nn=39 # Number of words to use as a target\n\n\n#%% Explanation\n\n# Explanation from https://blog.ganssle.com/2008/09/classification.html\n\nclassifications <- function(mytext) {\n  # Convert numeric values to lowercase characters to avoid any special treatment:\n  mytext <- mytext[lower.case(mytext)]\n  # Remove any spaces from words:\n  mytext <- mytext[gsub(pattern = \"\\\\D+\\\\D+\", replacement = \"\",mytext)] # Replace all non alphanumeric elements with a single space:\n  mytext <- towords(mytext)\n  # Find all words:\n  words <- mytext[split(mytext, mytext == \"\")$word)]\n  # Select those with the \"correct\" length [0, 3, 2]:\n  words_in_range <- words[as.numeric(length(words)/n)] # Use n as a parameter to obtain a set of words of a certain length:\n  return(words_in_range)\n\n}\n\nclassi_labels <- function(mytext) {\n  # Convert numeric values to lowercase characters to avoid any special treatment\n  mytext <- mytext[lower.case(mytext)]\n  # Find the most frequently appearing words as a whole\n  words_i <- towords(mytext)\n  top10_words <- words_i[words_i == max(words_i)] # Find all words:\n  # Select those in my target set\n  words_mytarget <- words",
        "label": 1
    },
    "1471": {
        "output": "**Q13-1.**  What additional variables are necessary when a new clinical trial is created? Circle only 1 from the given options. \n\n**Q13-2.**  What is the reason for collecting additional information on a blood transfusion in the patient record? Circle one option.\n**Q13-3.**  Which variable is used to calculate the amount of iron overload in the body? Circle one option.\n\n\n\n**Q14-1.** Which variable is used to calculate the amount of iron overload in the body? Circle the correct option.\n\n**Q14-2.** Which drug is known to cause severe hypophosphataemia, leading to rhabdomyolysis? Circle only one option.\n\n\n**Q14-3.**  Which options are the inclusion criteria for chronic immunosuppression in the patient record?\n\n\nPlease do not hesitate to think aloud while solving the task. The time per question is unlimited, and the time is not stopped until you submit your input file for evaluation, but remember that it is sufficient to enter your answer.\nIt may be helpful to use a pen and paper to work through some of the questions. Be sure to save your work regularly.\nMake sure you do not include an answer to a question in your submission unless explicitly instructed to do so (e.g., in the QTIP44 task).\n\n\n[/CHECK]<EOD> Corneal Confocal Microscopy in Progressive Supranuclear Palsy\n\nBackground. Progressive supranuclear palsy (PSP) is a",
        "label": 1
    },
    "1472": {
        "output": "# Appendix B\n\nThis appendix explains how to perform step-wise filtering and ranking of clinical trials\n\n## [Clinical Trials] List and ranking clinical trials\n[INST] You are asked to list and rank clinical trials. First, select two clinical trials for ranking according to the criteria defined on the screen.\n[PREF] Choose the criterion and press the arrow key to filter clinical trials according to the criteria. For example, choose the 'Intervention start date later than 2014-09-01' criterion, then filter the table for this field. The clinical trial ClinicalTrials.gov NCT02314867 (start date: 2014-10-15) is filtered out from the list.\n[SORT] To rank clinical trials, check the Sort checkbox. All the results are also arranged according to the selected criterion. \n\n[CLINICAL-TRIALS] Here are the clinical trials:\n\n## [Clinical Trials] Enter a clinical trial\n[INST] You are interested in joining the clinical trial with the study identifier NCT02766825 (the trial title is: Evaluating Safety and Efficacy of Factor X Concentrate Therapy to Prevent Bleeding in Newly Diagnosed Hemophilia -A).\n[SURVEY] In the search window, enter the trial study ID: 22,658.\n[TRIAL] In the top navigation bar, press `View` to open the Overview screen.\n[SORT] To sort by the fields click the arrow to the left of the header. Click the column header to re-sort the table in that direction.\n[CLINICAL-TRIALS] You are in the Trial Overview screen.\nClick the Trial Identification link for the trial identifier NCT02766825 to retrieve the trial.\n[CRITERIA] Click the Criteria column link to display the Trial Criteria table.\n[CLINICAL-TRIALS] This is the Clinical Trial Details screen.\n[INTERVENTION] Click the Intervention link to view the",
        "label": 1
    },
    "1473": {
        "output": "Your eligibility assessment should look like this: \n# Patient note\n# \n# # 2) Eligible \n\nPlease check the following questions to make sure that everything is done appropriately: \n\n- **What will I need to solve these errors?**\n\n- *Hey, don't forget to solve these errors by providing your feedback on this page!* [LINK]\n- *Please don't write out the feedback that is included on the last page. Rather write comments under the heading that says \"comments on error-tracker.\"* [LINK TO PREVIEW] [Instructions regarding the Preview Link]\n\n\n# [NAME OF FILE]\n\nIf your instructor asked you to create a new R Markdown file, please do so. For example, consider the case that you need to write a [tutorial](https://shiny.stat.colostate.edu/demo/). Your [file is named](https://shiny.stat.colostate.edu/tutorials/tutorial_data/shiny/Tutorials/Tutorial_2002-08/Tutorial_2002-08_RMarkdown_Demo.Rmd) like so:\n\n```r\n# Tutorial  \n# 2002-08 demos\n# ---\n# R Markdown\n# \n# <NAME>\n# \n# ---\n```\n\nR Markdown allows for files to be self-contained without requiring any extra dependencies. By creating your own file, you are able to reference the [data set](https://shiny.stat.colostate.edu/demo/Tutorial_2002-08/Tutorial_2002-08_data.RData) and [code file](https://shiny.stat.colostate.edu/demo/Tutorial_2002-08/Tutorial_2002-08_code.R) in the folder when creating your R Markdown file. The file only needs to be placed in the directory and then it is referenced correctly by the R Markdown file itself.\n\nThe contents of the file are up to you, you may use a combination of markdown and R code. By markdown, I mean the",
        "label": 1
    },
    "1474": {
        "output": "---\nWe hope that you have now a good feeling why our method works. If you would like to understand why this approach works in detail, please see the following papers. These papers were the reason why we got the funding from the NIH to create the Python tool CohortSearch:\n- Finding Counterfactual Causal Effects in Observational Data**\n- Causal inference using potential outcomes and the bayesian estimator to compute the average causal effect**\n- Robust Adjustment for Biases Due to Confounders by Using Targeted Maximum Likelihood Estimation: Counterfactual Outcomes for Randomized Trials and Observational Studies**\n- Targeted maximum likelihood estimation in models with monotone missing data **\n\n# <img src='../assets/image/help-docs-icon.png' class='help-docs'>HELP US IMPROVE THIS SCREENCAST\nWe would love to know what you think of this scripting tutorial and any suggestions for how to make it better.<EOD> Nursing Research for Patient Care\nThis book gives a great overview of the many concepts central in nursing research. Many useful references are included in the text.<EOD> A new method of starch gel electrophoresis.\nThe method of electrophoresis on starch gel is widely used for protein separation. The main limitation of the original method is that it is not possible to change the gel concentration and thus obtain gels of constant permeability and therefore constant resolution. Moreover, with the original gel formulation, it is impossible to control the extent to which the buffer diffuses into the gel before migration. As a result, pH changes frequently occur which make the protein peaks more difficult to interpret.<EOD> Genomic and transcriptomic data integration to identify candidate genes in bone mineral density-related QTL regions.\nEarly discovery of candidate genes underlying the quantitative trait loci (QTL) in skeletal system is beneficial to the identification of genes associated with bone mineral density (BMD). In current study, QTLs related to BMD were obtained from the QTLdb. The BMD phenotype data from F2 resource population with an average correlation coefficient of 0.60\u00b10.23 were obtained by genome-wide association studies. Then, gene list",
        "label": 1
    },
    "1475": {
        "output": "### Tips:\n- [Tip: INST] One common mistake is to check the first trial in the table, and then skip all other trials to check if it is eligible. This will work 95% of the time. If after checking 20-30 trials you still have no patient, that will be a good indicator for checking the first trial again! [/Tip: INST]\n\n\n## Code Challenge #3:\nThe third challenge is a classic programming problem in dynamic programming. In this challenge, you will be evaluating the following sequence of numbers: 8, 5, 0, 9, 0, 4, 8, 6, 0, 0. \nThe first job is to compute the sum of consecutive digits. You should come up with a recursive strategy that computes this sum. Here is a small example to help you get started.\n\nLet's try each of the numbers in the list:\n8: 8 = 8\n9 = 8 + 0\n0 = 0\nNow, we need to add up the consecutive digits and store this sum in a variable:\n8 = 8\n4 = 8-4\n6 = 4-2\n18 = 20-8\n85 = 85\n29 = 85-20\n0 = 85-29\n95 = 0-5\nHere is the original list:\nStart with the first number:\n8 = 8\n5 = 5 + 8\n0 = 0 + 5\n9 = 9 + 0\n0 = 9 + 0\n4 = 9 -4\n6 = 4 -2\n18 = 6 + 4\n85",
        "label": 1
    },
    "1476": {
        "output": "Let's write it in the Python script:\nimport pandas as padf\ndf=pd.read_csv('http://cdn.staticsub.net/static/js/20110702-datasets/recruitments-eligibility-assessment.csv')\nX=pd.Series([\"0\",\"1\",\"2\";\"0\",\"1\",\"2\"],index=range(10))\neligibility=pd.Series([\"0\",\"1\",\"2\"];\"Eligible\",\"Not relevant\", \"Excluded\")*df.iloc[:,5].tolist()\nprint(\"Eligibility\",\"scale\")\nprint(\"/****************************************************\")\nprint(\"Instructions (INST)\"), \"***************\", \"****************************************************\"\nprint(\"INSERT HERE\")\nprint(\"You are a helpful assistant for clinical trial recruitment. Your task is to compare a provided patient note and the inclusion criteria of a clinical trial to determine his\\her eligibility for a trial.\",\"\\n\")\nprint(\"The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\",\"\\n\")\nprint(\"The assessment of eligibility has a three-point scale: 0-Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial?s exclusion criteria); 1-Not relevant (patient does not have sufficient information to qualify for the trial?); and 2-Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\",\"\\n\")\nprint(\"If you assess the patient with the trial recruitment note, input appropriate data to the variables of interest in the program below. The program will then provide you with the patient?s score on the scale of the trial-level eligibility scale.\",\"\\n\")\nif len(eligibility) >5: eligibility = eligibility[:5].tolist()\nelse: eligibility=eligibility[:5]\nprint(\"Eligibility %s\", eligibility)\n\n<EOD> A Novel Photoacoustic Imaging Method Based on Frequency-Wavelet Transform for Breast Lesion",
        "label": 2
    },
    "1477": {
        "output": "* You can also generate the output for your current trial note, for example, `Patient-level eligibility: 1) Included`. Or for your patient, e.g., `Trial-level eligibility: 2) Eligible`. [HINT] \n* For all cases, please write to the authors at [EMAIL] so that we can improve the documentation of the API (Application Programming Interface) and provide you with a more useful tool in the future.[/END]\n\n## Questions on Eligibility\n\n- How can we ensure patient eligibility?\n- How can we evaluate patient eligibility?\n\n# Background\nOur goal is to develop an R Shiny web application (http://www.rstudio.com/products/shiny) for clinical trial design and simulation, integrating a statistical learning pipeline to detect important genetic variants (e.g., single nucleotide polymorphisms (SNPs)) associated with clinical drug responses and adverse events.\nBa\u015fgil (2014) developed the PharmacoGx R Package that integrates pharmacogenomic data into clinical pharmacology workflows by combining pharmacology, systems biology, pharmacokinetics/pharmacodynamics (PKPD), and machine learning models. In particular, Basgil (2014) proposed 2 methods for the detection of important genotypes/SNPs. Firstly, the importance of genotypes can be measured by the change in the PK model parameters that are related to drug bioavailability (F, CL, etc.) estimated separately for each of the genotype groups. Secondly, the importance of SNPs can be measured by comparing the prediction performance of models that include only pre-selected important SNPs and models with all SNPs included. However, the proposed methods are not suitable for detecting the most associated genetic variants that are also predictive of PK/PD parameters, particularly when the PK/PD data are sparse because of the limited patient population size and the sparsity of clinical data obtained at different time points (t) due to intra-and interpatient PK/PD variability. Moreover, the SNP selection process based on an estimated parameter change for SNPs is highly dependent on the modeling process.",
        "label": 2
    },
    "1478": {
        "output": "Good luck!<EOD> \u03b2-Arrestin1 Interacts with Toll-Like Receptor 2 and Disruption of Interaction Does Not Impair MyD88-Dependent NF-\u03baB Induction\n\n\n\n# Introduction\nMany bacterial virulence factors (i.e., lipopolysaccharide, lipid A and flagella) have now been reported to have an ability to mimic pathogen associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) and CpG oligodeoxynucleotide, and to activate innate immunity via Toll-like receptors (TLRs) [bib_ref]  Bacterial induction of type I interferon production in a human macrophage cell..., Collado-Hidalgo [/bib_ref]  [bib_ref]  A peptide derived from human toll interacts with the Escherichia coli heat-stable..., Yang [/bib_ref]  [bib_ref]  Activation of antibacterial Toll-like receptors by Mycoplasma lipoproteins, Peacock [/bib_ref] . Moreover, several reports show that toll/interleukin-1 receptor (IL-1R) domain-containing adaptor molecules-myeloid differentiation primary response 88 (MyD88)-are common intracellular adaptors that induce nuclear factor \u03baB activation in response to these molecules [bib_ref]  A distinct role of lysine 24 in H-2Kb in peptide loading through..., Lin [/bib_ref]  [bib_ref]  A tripartite complex of the RNA helicase RIG-I, TRIM25, and PKR in..., Kranzusch [/bib_ref]  [bib_ref]  Toll-Like Receptors in Antiviral Innate Immunity, Lester [/bib_ref] . However, while most of the ligands for TLRs interact with the MyD88 pathway, some ligands seem to utilize a MyD88-independent pathway [bib_ref]  The Adaptor Protein CARD9 Is Essential for the Activation of MyD88-Independent TIR..., Hara [/bib_ref]  [bib_ref]  A role of TLR2 and TLR9 in non-opsonic phagocytosis of Escherichia col",
        "label": 0
    },
    "1479": {
        "output": "#### Trial Criteria\n\n#### Tutorial: Let's think how the `trial-level` criteria are evaluated. \nIn this tutorial, we are going to look at how the trial-level criteria are evaluated.\nThere is only a `Trial-level eligibility` for `B204`, which means the criteria are evaluated on the clinical trial level. Therefore, the evaluation is not done on the patient level, but on the trial level. The three-point scale for `Trial-level eligibility` is explained in [INST1]. Let's think what the triallevel criteria for `B204` are:\n\n## Eligible\nOnly patients who meet inclusion criteria are eligible for the trial. The inclusion criteria are defined in the first `Trial-level eligibility: 1) Not relevant.`.\n\n## Excluded\nPatients who meet exclusion criteria are excluded from participating in the trial. The exclusion criteria are defined in the second `Trial-level eligibility: 2) Excluded.`.\n\n## Not relevant\nPatients who do not have sufficient information to qualify for the trial are not relevant to the trial assessment process. This is defined in the third `Trial-level eligibility: 3) Not relevant.`.\n\nSince `B204` only has a `Trial-level eligibility`` and there are no evaluation criteria on the patient level, the first line of the `Trial-level eligibility` would be the first line in the `patient-level eligibility` and it would have the same contents with the first line of the `Trial-level eligibility`.\n\n\n## Trial-level eligibility (1) Excluded\nPatients who have the exclusion criteria of `B204` are automatically excluded on the trial level. Note that there is one more rule to be applied on the trial level: `Patients with liver cirrhosis, liver transplantation, previous alcoholic hepatitis, esophageal varices bleeding, and acute hepatic failure will be excluded from the study. The clinical trial team will also exclude any patient who they believe are unable to tolerate or comply with the protocol.`, for example, are excluded by the first",
        "label": 2
    },
    "1480": {
        "output": "# Mini-ClinTrial\nFor each patient, the following factors will be available:\n1) demographic information\n2) clinical information \n\nThe data type of the above listed factors are defined in the following\n\nThe data of each patient is represented as a vector and is denoted by $X=(\\text{age\\_years}, \\text{age\\_months}, \\text{gender} ,...)$. \n\nThus, you need to learn a function to estimate the patient's eligibility to the trial using given factors. \n\n### The goal: \n\n\n\nWe want to find out if the $c$th clinical trial is eligible for $x$th patient given set of $s$ factors. \n\n\n\n\n\nThus, you need to learn a function to estimate the patient's eligibility to the trial using given set of factors. The function can simply be a boolean function, e.g., $\\mathbb{R}^{s} \\rightarrow (0,1)$ such that $1$ if the individual is eligible and $0$ if not.  \n\n\n### Dataset Format:\n\n\n## The format of factors and factors associated with eligibility is defined as:\nThe format of the $s$ factors and the result of the eligibility function is as follows:\n\n*The input of $X$ is a matrix/vector as below. \n*The inputs of $L_{c,k}$ are a matrix/vector of size $m$ where $S_c$ contains $m$ factors.\n 1)\n 2)\n *The outputs of $L_{c,j}$ are the same number of size $M$. \n *Thus, our dataset is represented as $\\Delta$:\n\n## Dataset format \n\n*The format of each dataset are as follows:\n\n* 1) Each dataset $D_{c,k}$ is a matrix/vector whose columns are $m$ factors $S_k=[\\text{F}_1...\\text{F}_m]$ which are the same in each dataset $K$ where $c$ is a batch index (e.g., $c=0,1,2$) and $k$ is a factor's index (e.g., $k=1,2,...",
        "label": 2
    },
    "1481": {
        "output": "## [/CODE]\n\n[TEXT]\nInline code block 3: Rules for calculating the Trial factor according to the eligibility assessment\n\nFirst, we'll consider the sample patient. [INST]\n\nIn the following example, you will assess the eligibility of a patient note. [TEXT]\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. [INST] If the patient note contains the exclusion \"Alcoholic\" , 0) Excluded. In fact, the patient did not take alcohol because of the HCV infection. Hence, the clinical trial excludes the patient. \nFurther, if any clinical trial excludes a patient note due to alcoholic patients, 0) Excluded. When the patient note contains any information for a factor value of 0 (patient disqualified), the algorithm should return zero. Here, the factor value is zero because the patient's condition does not meet the trial requirement for 0) Excluded. [INST] \nYour next task is to calculate the Trial_factor for the previous patient note. According to the data table in [fig_ref]  Table A2: Data input table [/fig_ref]  , the value of Trial factor according to the el",
        "label": 1
    },
    "1482": {
        "output": "##[END]\n\n##Step 2. Evaluate clinical trials based on their quality and risk\\opportunity\nYou have already learned to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. So we can say that, you, as a junior doctor, have decided to which clinical trial you have decided that the given patient can enter.\nBut you will not be able to know which clinical trial to apply to the patient. In addition to the eligibility of the candidate patients, there are many conditions that must be met by a clinical trial to run. Therefore, you must also evaluate the clinical trial on the eligibility of the patient, the eligibility of the research, and the level of acceptability of the clinical trial.\n\nTo evaluate the clinical trial, you first evaluate whether the clinical trial can provide new research findings that have not been explored and whether it has potential to meet the target audience.\nOn the other hand, some clinical trials will be done only for the patient's interest, even if the clinical trial is completely unknown to the patient. If the clinical trial has the interest of the patient and the clinical and scientific evidence support it, evaluation will proceed.\nBut if not, evaluation ends.\n\n## Step 3. Make a clinical trial decision\nNow that every study has been evaluated in terms of eligibility, eligibility, and acceptability and there are more questions about the best study, you should choose the best study.\nThe way you determine the best study is to check the benefits and risks of all studies. Then, using certain criteria, choose the right study.\n\nLet's take a brief look at the criteria used to determine the best study.\n\n## Benefits of clinical trials\n- Study of the clinical trial\n\t- The clinical trial must investigate a new treatment that has not been explored before.\n\t- The clinical trial must investigate a treatment that may be able to treat other diseases.\n- Research on participants or patients\n\t- The trial must include a significant number of participants or patients who are in a particular disease group for the treatment of hepatitis C.\n\t- The participants or patients participating in the trial will be selected in such a way as possible to be more representative of the overall target population",
        "label": 2
    },
    "1483": {
        "output": "## Repeating trial-level eligibility\nLet's add it to all the cases! Please, follow these steps:\n\n\n*\n\n*Go to the 1st patient note\n\n*Go to the 1st trial\n\n*Save and run as shown in the screenshot in Listing 48.1\n\n![678px-Hypnogram.png]({{ site.baseurl }}/assets/images/678px-Hypnogram.png)\n\n\nListing 48.1: Repeating trial-level eligibility in every patient\n\n    # trial1\n    eligible = 2 # we should repeat trial-level eligibility\n\n    # patient1\n    eligible = 1 # we should repeat trial-level eligibility\n\n    # patient2\n    eligible = 2 # we should repeat trial-level eligibility\n\n    # patient3\n    eligible = 2 # we should repeat trial-level eligibility\n\n    patient <- 1: 3\n    trial <- 1: 1\n\n    for (i in patient) print(eligible)\n\n\n\n### 2.10 Add-on to the previous examples\n\nWe have learned how to make a list of the trial-level eligibility and how to print out some of the properties. However, this is not sufficient and we would also like to create a file with a list of trials with trial-level eligibility.\n\nLet's follow these steps: \n\n1. Open a new notebook.\n2. Go to the directory: /Teaching/Data/Challenge/Listing/Listing48.\n\n    In the notebook, we should create a file. The file name must be eligibility_repeated.\nWe are going to create a cell that saves the previous notebook and also print out that we are saving the cell into folder /Teaching/Data/Challenge/Listing\n    # open new notebook\n    # we want to save the previous sheet into folder /Teaching/Data/Challenge/Listing\n    # We do so by assigning the previous sheet in a variable\n    save_sheet <- list(notebook, n <- 28)",
        "label": 1
    },
    "1484": {
        "output": "[NOTE] There are two methods to complete the task. One method is to loop through every patient in the patient list, one patient at a time. Let's take a look at which patients are eligible by loop:\nfrom iheppy.core.ui.data_types import (\n    PatientList,\n    PatientData\n)\n\nfrom iheppy.util.math_utils import log_level_msg\n\ndef eligible_patients(pt_list):\n    '''Eligible patients in a group\n\n    Args:\n        pt_list: PatientList objects or list of dict patient record objects\n\n    Returns:\n        list of dicts: patient's data for each patient in pt_list\n    '''\n    if not pt_list:\n        return []\n    eligible_patients = []\n    for pt_one in pt_list:\n        for pttl in pt_one['trial_list']:\n            eligible_patients.append({'id': pttl['id'],\n                'gender': pttl['gender'],\n                'age': pttl['age'],\n                'first_name': pttl['first_name'],\n                'last_name': pttl['last_name'],\n                'race': pttl['race'],\n                'hepatitus_type': pttl['hepatitis_type'],\n                'disease_type': pttl['disease_type'],\n                'patient_notes': pttl['patient_notes']})\n    return eligible_patients\n\npatient_list = PatientList()\ntry:\n    patient_list.load()\n    print log_level_msg('Eligible patients: {}'.format(\n        eligible_patients(patient_list)))\nexcept:\n    print log_level_msg(\n        'Cannot load patient list. Please, check the patient_list.pickle file.')\n\nHowever, this is a slow way of looping. You can also define a callback function to find the eligibility. \nThe function first searches for the given patient in the trial-level-eligibility list. If a match is found, you just return the",
        "label": 1
    },
    "1485": {
        "output": "<EOD> .\nThe authors studied the blood level of lysosphosphatic acid (LSA) and sphingosine of 100 patients with different neurological diseases at the age of 21-82 years. The level of LSA and sphingosine depended on the severity of the disease course. The highest values were found in patients with multiple sclerosis, epilepsy and in patients with subacute combined degeneration, the least in cerebrovascular disease. These results may be used for estimation of the clinical and neuropsychological disorders.<EOD> Biosynthesis and catabolism of the lipid moiety of human chorionic gonadotropin in the human endometrium.\nSynthesis and catabolism of lipid moieties of human chorionic gonadotropin were examined in endometrial explants from premenopausal women with hormone replacement therapy (n = 45). Biopsy specimens were incubated, and the incorporation of 3H-labeled acetate, choline, and oleic acid into lipid moieties and their release from endometrial tissue were characterized. The rate of incorporation of acetate and choline for lipid synthesis was found to be greater than that of oleic acid incorporation for lipid synthesis, indicating that acetate and choline contribute more than oleic acid to the lipid moieties of human chorionic gonadotropin. The release of 3H radioactivity from endometrial tissue after the initial 60-min incubation demonstrated that 93.5% of the radioactivity incorporated into lipid moieties of human chorionic gonadotropin was retained after a 90-min prelabeling and a 90-min collection period, but about 75% of this radioactivity was subsequently released into the culture medium over an additional 90-min incubation. Therefore, only about 25% of the radioactivity incorporated into lipid moieties of human chorionic gonadotropin was retained in endometrial tissue, but 75% of the radioactivity was found in the medium during the 90-min collection",
        "label": 1
    },
    "1486": {
        "output": ".\n\n## Example patient-level eligibility\nPatient-level eligibility is not so important. I have only wanted to check the trial-level eligibility.\n\n# Diseases\n\n## Overview\nAs we know, the name of the disease is important. A clinical study in which we are interested may be ongoing to study a disease; if we are not interested, we should filter out the disease to filter out only the disease of interest. You should find the name of the disease on the disease search page that you accessed when conducting a search for the disease-related clinical studies.\n\n\n\n## Example Search\n![enter here](http://app.kostat.go.kr/pstn/p2s0203.do)\n![enter here](http://app.kostat.go.kr/pstn/j2s0208.do)\n![enter here](http://app.kostat.go.kr/pstn/c2s0214.do)\n\n### Disease Search Result\n[enter here]\n\n# Disease ID\n\n## Overview\nThe disease name in the upper-left corner of the disease search result page is automatically linked to the ID of disease. So, the ID of disease can be acquired from the disease search result page. In addition, the link to browse all information related to disease (ID: D00000) appears at the top of the disease search result page. When we click a disease on this link, we return to the disease search result list page that provides information on the disease.\n\n### Click Link to Disease ID\n![Click]\n\n# Disease Related Search Page\n\n## Overview\nThe disease",
        "label": 1
    },
    "1487": {
        "output": "If the patients had not undergone liver transplant because of the side effects of the medication to treat hepatitis C, that would be a very different patient note. This example shows how to solve the eligibility classification problem. If a new patient's status is 2, then the patient is eligible to the trial.\n\n# Exports\nThere is one important thing to remember in EXPORT: only assign the correct tags to the last line. Everything that goes behind ``#`` are ignored, so `Trial-level eligibility` and the scores you assign to each line are ignored. If your assignment is correct, this is the result of EXPORT you get:\n\n\n`exported.txt`\n\n```\n-------------------\nPatient: ID: 55\n                 # # #\nFirst Name: John last-name: Smith\nPatient gender: M\nBirthday, day - months - years: 01-04-55\nPatient notes:\n    Trial-level eligibility: 0) Excluded\n    Inclusion criteria: 1) Male or Female\n    Inclusion criteria: 2) Presence of anti-HCV in serum\n    Inclusion criteria: 3) At least 1.5U ULN ALT\n    Exclusion criteria: 1) Patients with known history of liver cancer\nEligibility assessment:\n    Trial-level eligibility: 2) Eligible\nExported.txt\n```\n\nAs you see, this method does not consider exclusion criteria because they are not mentioned in the patient note.<EOD> .\nThis paper describes a new, fast method for protein phosphorylation determination which determines amounts of both phosphorylated and total, native substrate protein and it is a combination of radioimmunoprecipitation and alkaline phosphatase treatment. Precipitation of antibody-bound radioactive serine or tyrosine residues of labelled substrate with ammonium sulphate was performed, followed by quantitation of 32P labelled antibody-bound amino acids.<EOD> Interactive Influences of Depression and Trauma Exposure on Criminal Justice-Involved Latino Parents\u2019 Mental Health and Parenting\nThe current",
        "label": 2
    },
    "1488": {
        "output": "__HCC__\n[INST] Hello you. You have made the right decision to pursue an evaluation for HCC. \n\nHere is a typical assessment for a possible HCC based upon some of the parameters from the patient note that you are showing me.\n\n![",
        "label": 1
    },
    "1489": {
        "output": "### A2. Eligibility algorithm\n- In a trial-level eligibility, the assessment of eligibility is expressed in three levels (e.g., 0: Excluded; 1: Not relevant; 2: Eligible).\n- In a subject-level eligibility, the eligibility assessment is expressed in four levels (e.g., 1: Not eligible; 2: Not relevant; 3: Proceed to eligibility assessment at the next time point; 4: Eligible).\n- Level 1: Patient is not eligible (n/a).\n- Level 2: Patient is not eligible, will be re-evaluated later (n/r).\n- Subject-level eligibility is the eligibility assessment based on the information present at that moment.\n- A patient with Subject-level eligibility as 1 should be re-evaluated in a week's time.\n- Level 3: Patient is eligible.\n\n[INST] You should give level of eligibilities of the patient (e.g., `level_of_eligibilities: 3`).\n\n> pv <- patient_details()\n> pv_level_of_eligibilities <- as.data.frame(level_of_eligibilities(pv))*  # \n> pv_level_of_eligibilities <- data.frame(level_of_eligibilities(pv))*  #\n>\n> pv_level_of_eligibilities <- set_colnames(pv_level_of_eligibilities, c(\"Subject_ID\", \"Assessment_time\", \"Patient_Level_of_Eligibilities\"))*  # \n> # pv_level_of_eligibilities <- cbind(recode_trial_level_of_eligibilities(pv, by_id = \"Trial_ID\", n_trial=1, colname = \"Trial_recode\"), pv_level_of_eligibilities) # set_colnames() is the function for changing the column label of a data frame.\nYou should keep pv_",
        "label": 2
    },
    "1490": {
        "output": "[END]\n[DONE]\n<EOD> Fiber-optic photopolymer composites as waveguides.\nIn this paper, we demonstrate that a polymer material doped with a small amount of h-BN and carbon nanofillers (CNF) in its chemical structure forms a nanocomposite with enhanced optical and physical properties. In particular, fiber-based CNF/h-BN-doped photopolymer composites are processed in order to demonstrate a waveguide material prototype with improved optical properties than conventional polymers or ceramics used in the fibers. CNF/h-BN nanocomposite compositions are analyzed by field emission scanning electron microscopy (FESEM) with an energy dispersive (EDA) spectrometry and X-ray diffraction (XRD) patterns, which confirm the formation of a nanocomposite material with high h-BN nanoparticles dispersion. The fabrication system is a single fiber based on three-dimensional printing. Transmission spectra of the fiber-based photopolymer composites are characterized by spectrophotometric equipment. We obtain transmission loss as low as 0.032\u2005dB/cm at the wavelengths of 1300-1700\u2005nm and 0.73\u2005dB/cm at the wavelength of 2400\u2005nm, whereas the transmission loss of the fiber system is 0.185\u2005dB/cm for all the wavelength ranges.<EOD> N-Aryl Substituted Oxindole Alkaloids from the Marine-Derived Alternaria tenuissima\n\nOxindole (2,3-dihydro-1H-indol-2-one) is an important pharmacophore found in natural products with a wide range of biological activities, such as antifeedants, herbicides, anti-inflammatory, anti-fungals, antialdosterone, antitumor, antimitotics, antiviral-agents and immune-stimulants. Herein, we described the isolation, structural elucidation and cytotoxicity screening of the compounds 1-1",
        "label": 2
    },
    "1491": {
        "output": "[TEST] [26] In the case study, the inclusion criterion 'Eligible (patient meets inclusion criteria and exclusion criteria do *not* apply) ' is 2, Eligible, according to the IF criteria, but it is 0, excluded, according to the IE criteria. The reason is that the 'stage of HBV' is the same as 'HBV DNA level' in the inclusion criterion of the trial, although their HBV DNA level is different. \n[TEST] [27] Let's check the result.\nWhat is the output of the eligibility assessment for the patient? \nHBV Infection with positive HBsAg, Hepatitis B Virus E Antigen, and HBV DNA \u2265 2.5 Pg/mL\nPatient meets inclusion criteria and is NOT excluded on the grounds of the trial's exclusion criteria\n\n\n\\hline\n[2] HBV Infection with positive HBsAg, Hepatitis B Virus E Antigen, and HBV DNA \u2265 2.5 Pg/mL \n\\hline\n[3] Chronic Hepatitis B \n\\hline \n[4] Stage of HBV \n\\hline \n[5] Clinical Trial of IFN alpha 2b Plus Ribavirin for Chronic Hepatitis B \n\\hline\n[6] Chronic hepatitis B \n\n\n[22]\n[23]\n\n\n\\subsection{Testing for Hepatitis B on Inclusion Criteria of the Clinical Trial} \n\nIn order to test the relationship between the inclusion criteria of a trial and the patient's test results, you should write down the IF and IE in separate sets of parentheses. After that, you should change the value of the IF's inclusion criterion into [TEST] and the IE's inclusion criterion into \\null by inserting `[]` and `\\null` respectively on the right-hand side of each entry. Finally, compare whether there is a mismatch of inclusive criterion between the IF and IE. For example, in a clinical trial for chronic hepatitis C, patients should meet both IF and IE. \n\nHepatitis C virus \n\nIF and",
        "label": 1
    },
    "1492": {
        "output": "You can see that a trial-level eligibility may be determined for the same patient over multiple trials because the patient's attributes may be relevant for a number of trials. Therefore, there will be multiple trial-level eligibility vectors for the same patient. \n\n##[INST] [CODE]\ndef determine_trial_level_eligibility(med_rec, trial, trial_patients):\nif trial_patients.get(med_rec.id):\ntrial_level_eligibility = {2: 2}\n\n    if trial_patients[med_rec.id].eligibility == 1:\n        trial_level_eligibility[1] = 1\n    elif trial_patients[med_rec.id].eligibility == 0:\n        trial_level_eligibility[0] = 0\nreturn trial_level_eligibility\n\nYou can see that the trial-level eligibilities are determined by looking up the patient's identification in the list of patients for a given trial and setting the trial-level eligibility to 1 or 0 depending on the trial-level eligibility of the patient. \n\n\nNow, you can compare patients with a trial. First, create a patient vector with patient records that satisfy the inclusion criteria for a given trial with the `satisfy_eligibility_criteria` function:    \n```python\n[INST] def satisfy_eligibility_criteria(med_rec, trial_to_validate, trial):\nif trial_to_validate.id == trial.id and \\         ?\n    med_rec.sex in trial.females and med_rec.sex in \\\n        trial.males or med_rec.age <= trial.age_min or \\\n    med_rec.age >= trial.age_max:\n        trial_level_eligibility = {2: 2, 1: 1, 0: 0}\n        for key in trial_level_eligibility.keys():\n            trial_level_eligibility[key] = 1 if trial_to_validate.patients.get(med_rec.id) else 0\nreturn trial_level_eligibility\n\n[INST] class Clin",
        "label": 1
    },
    "1493": {
        "output": "[/END]\n\n## Exercises\nIn these three exercises, you should learn how to write the correct solution to the given problem. They are designed to apply concepts that are introduced in earlier sections. After each exercise, I will put some hints to make things clearer. If you follow the hints, you will certainly obtain the right answer.\n\nLet's think about the following example. In this study, the aim is to determine whether or not a person suffers from depression.\n\nThe following table consists of individuals who answer the Yes and No questions. The individual number two, who answered Yes to 19 of 20 questions and Yes to three of the four symptoms, is probably suffering from depression. The individual number five who answered Yes to only three questions and one symptom might not be depressed. However, the individual number one who answered Yes to only three questions and four symptoms is also perhaps not depressed. The last person who replied No to each question and each symptom obviously is not depressed. So, the person who suffers from depression should be individual number two.\n\nYou will perform the given task with the patient data.\n\nHere are some examples of patient data for the above example. If you write your solution in a file (not in a cell of the sheet) and save by `Save this workbook` menu option, you will be able to see the cell contents by `Run this macro` menu option. Let's try to get our answers for sample cases.\n\n\nCase 1\nYou will see that only in patient 2 the correct answer is Yes.\n\n\nCase 2\nIn other cases, the correct answers are Not sure.\n\n\n![IMAGE]\n\n\n\n\n\n##### If you need more information related to the data structure we have shown above, you can check the following references.\n\n*   <https://msdn.microsoft.com/en-us/library/t425040w(v=vs.98).aspx>\n\n*   <http://office.microsoft.com/en-in/excel-help/data-structures-and-techniques-for-microsoft-excel-haz02131600.aspx>\n\n*   <http://www.w3schools.com/html/>\n\n##\n\n\n> [https",
        "label": 0
    },
    "1494": {
        "output": "~~2) `fname` corresponds to the `name` field defined above, and so forth. Note that the variables are named using plural-s (e.g., `viremia` instead of `viremia1`). [~2] \n\n~~2.3) `disease_status` field is only defined if `viral_hepatitis_status = 1`. [~] \n~~2.4) `viral_hepatitis_status` field is not used if any of the 3 fields `type_of_hep, etiology_of_hepatitis, and etiol_of_cld_status` are not defined. (e.g., if you input `viral_hepatitis_status = 2, hepatitis_type = 2, etiol_of_cld_status = 0, type_of_hepatitis = 0, etiol_of_cld_status = 0, and viral_hepatitis_status = 0 for the fifth subject, then only `viral_hepatitis_status = 0 is used.) [~] \n~~ 2.5) Each set of the `etiol_of_cld` and `etiol_of_cld_status` fields is repeated with a different disease code: `0:0110`,`0:012`,\u2026`0:091`, `0:0711`. Above and below, code 0 means `absence of` disease, e.g., `0:010` is used for `absence of HCV status`. The field is not set if the disease is unknown, e.g., when it is written as `etiol_of_cld = \"NA\"` [~] \n~~ 3) Set if the patient is a member of the study population. The code 1 denotes a member of the study population, and all others mean \"not a member\" [~] \n~~ 5) For data input, \"1\" should be used if the field is met and 0 if the field is not met. In the output, \"1\" should be used if the field is met and \"0\" if the field is not met. (i.e",
        "label": 0
    },
    "1495": {
        "output": "This is the full example:\nPatient -----> Trial-level eligibility: 2) Eligible\n\n## Example: excluding criteria from the clinical trial's inclusion criteria\n\n# Description\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe Clinical Trial with Exclusion Criteria:\n\n  *\n\n\n*Age: Under 25 year\n\n\n*Gender: Men, non-pregnant women\n\n\n*Type and stage of a disease: Chronic Hepatitis C, with advanced fibrosis, i.e., a Scheuer F3 or F4 stage, i.e., liver cirrhosis \n  *Non-viral hepatitis\n\n  *Hepatocellular carcinoma \n  *Alcoholic Liver Disease without cirrhosis\n  *Autoimmune Hepatitis\n\n  *Significant congestive heart failure\n  *Hepatic decompensation\n\n  *Hemochromatosis\n  *Metabolic liver diseases\n\n\n*Past: \n  *Present or Past drug addicted patients \n  *Present or Past alcoholics \n  *Present medications which affect Hepatic Elimination \nFurther treatment with Ribavirin and Peginterferon Alfa-2a (400 mg/3ml) twice a week for 24 weeks according to the summary of product characteristics. Each vaccine injection will be given intramuscularly at a site as decided by the site investigator.\n\nThe objective of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 6, 7, 8, 9 and 10 after subjects received their first two doses primary vaccination schedule of combined hepatitis A/hepatitis B vacc",
        "label": 0
    },
    "1496": {
        "output": "<EOD> A Cognitively Oriented Approach to Craniofacial Distraction Osteogenesis of Craniosynostosis: Two-Year Outcomes\nNumerous authors have successfully treated craniosynostosis by using craniofacial distraction osteogenesis, but no clear guidelines are available for how to manage distraction in such children with craniosynostosis. As the literature has evolved, we offer some guidelines. We present a series of patients with syndromic craniosynostosis who underwent bilateral sagittal craniofacial distraction osteogenesis (FOM cranioplasty). All patients underwent preoperative (at 0 cm of distraction), intraoperative (at 5 to 10 days  of distraction), and final postoperative (at 6 months after full distraction) computed tomographic (CT) studies, as well as three-dimensional (3-D) stereolithographic (SLA) models (from three-dimensional CT scans) that were created preoperatively and at 6 months after distraction (at full cranial reconstruction). Results: Preoperative CT scans showed a high degree of brachycephalic skulls deformity. At intraoperative CT scans, after 5-days of distraction, cephalic dimensions were within the normal range. At final postoperative CT scans, 6 months after full distraction, preoperative deformity and high cephalic indexes were corrected. Cranial volume was significantly increased. Preoperative 3-D SLA models, from CT scans, showed a high degree of deformity, with a short and bulging forehead, a large nasion, and a shortened sagittal fossa (due to trigonocephaly). Intraoperative (at 5-10 days of distraction) 3-D SLA models confirmed the increase in skull vault volume due to the advancement of the junction between distractors. Finally, the 3-D SLA models 6 months after distraction showed the preoperative degree of deformity corrected. Conclusion: From these observations, it is possible to suggest a simple radiological protocol and a cognitively oriented approach, including distraction",
        "label": 0
    },
    "1497": {
        "output": "<EOD> Characteristics and patterns of adherence to antihypertensive therapy in France.\nBACKGROUND\nWe studied the characteristics and patterns of adherence to antihypertensive medication in 5746 patients selected randomly from the French cohort of the International Hypertension Long-Term Intervention Study (IHTLS-1).\n\n\nMETHODS\nThe patients were aged between 50 and 74 years and had received monotherapy for hypertension (> or = 1 year duration) in the previous year. Antihypertensive medication adherence was assessed indirectly through a 7-day adherence questionnaire, based on the Medication-Taking-and -Ingesting Scale, and directly through the determination of blood pressure with self-measured readings after 48 h of medication adherence, compared with a 24 h control period. Medication costs were calculated from the patients' self reports about their usage of the different antihypertensive medications.\n\n\nRESULTS\nThe mean level of adherence (90.5%) was fairly well balanced, with two-thirds of the patients showing moderate or good adherence (81.5%). Adherence levels did not significantly vary according to age or the use of concomitant medication. However they were significantly less among women (83.7%) than men (89.5%). Adherence levels were significantly lower among smokers (68.6%) and patients with a psychiatric history (61.8%). Higher adherence levels were found among patients whose daily medication was composed on average of two to three drugs (84.1% versus 76.1%, P = 0.0027). Patients treated with calcium antagonists also displayed higher adherence level (87.1%) than patients using other drugs (80.6%). Although there was a difference in adherence between the different classes of antihypertensive medication, it was statistically significant only for calcium antagonists (P .0003) and beta-blockers (P < 0.004). Levels of adherence tended to be lesser for patients using cheaper antihypertensive medications (8",
        "label": 1
    },
    "1498": {
        "output": "<br />\n<hr />\n\n# Inferential statistics\n\nThis section covers the basic inferential statistics which might help you with your future statistical analyses. All these concepts apply broadly to machine learning and not exclusively to supervised learning. The goal here is to familiarize the reader with these concepts and give an intuition to some of the mathematical equations presented in this tutorial.\n\nSome of the notation which follows should sound familiar. The input for the model is a vector x, and therefore, can be written in notation as a matrix x. The output for the model was a vector y, and in this case it can be written in vector form as a matrix y.\n\nWhen learning a model, the samples are given to the model in a separate batch. Because we are learning from a dataset, if we use the batch size 2 the result of our model will be 2 vectors. The first vector will be the input and the second vector the output.\n\nWe need to apply the mean_axis_subtract command to subtract the vectors from the mean with the use of the axis argument. You can set the axis input to 1 (as in `mean_axis_subtract(x, axis=1)`). This is necessary so the data points are not just removed by the subtract command. If you wish to remove each datapoint then set the axis input to 0 (as in `mean_axis_subtract(x, axis=0)`).\n\n`mean_axis_subtract(x, axis=1)` returns the data points (or batches) subtracted from the mean.\n\nA vector x can be turned into a matrix as well. This can be done by setting the shape input to one (the input size is 1, e.g., input_shape=(1,)))\n\nIf we want to apply mean_axis_subtract to a matrix we still have to input the axis input. Here we use axis=1 which will subtract each row from the mean. Therefore, our new mean_axis_subtract command looks like `mean_axis_subtract(x, axis=1)` where x is the input matrix.\n\n`mean_axis_subtract(x, axis=1)` will return all the batches in one vector. `mean_axis_subtract(x, axis=1)` returns the",
        "label": 0
    },
    "1499": {
        "output": "## Step 1: Read the Patient's note\nRead the patient's note and find the data (ID, HCV RNA test, HBV, Liver biopsy, direct antiviral drugs, and IFN-RBV) that satisfy the eligibility criteria of the Clinical trial. If no data satisfies the criteria, write 0 on the score of ID and 0 on the score of the Inclusion criteria, and write Not-qualified on the score of the exclusion criteria. However, if multiple entries are found for a data element, such as three times of HCV RNA with negative, negative, and positive, then write 0 on the first number, 1 on the second number, and 2 on the third number, and write Excluded on the score of the exclusion criteria for that element. Once you assess all the data elements, write your final assessment with `Trial-level eligibility: ` as follows.\n### Case 1:\nID: A01-1242\nInclusion criteria: Male, age 55, no gender, PCR, and hepatitis B positive/hepatitis C negative liver biopsy\n\n***Scoring:***\nID: 1\n\nExclusion criteria:\nAnti-HCV Ab positive\n\n***Scoring:***\n\nID: 0 ***Scoring:***\n\nTrial-level eligibility: Excluded.\n***Scoring:*** Excluded on age criteria only, so it is score 0 for exclusion and score 0 for eligibility\n\n##** STEP 2: RELATED DATA IDENTIFICATION**\nIf the data item doesn't satisfy the eligibility criteria of the clinical trial, write a '0' on the score of the ID, and write not-eligible. Otherwise, write a number from '0' to '2' on the score of the ID.\n\n### Case 1:\nID: A01-1242\nInclusion criteria: Male, age 55, no gender, PCR, and Hepatitis C positive Liver biopsy\n\n***Scoring:***\nID: 1\n\nExclusion criteria:\nAnti-HCV Ab positive",
        "label": 0
    },
    "1500": {
        "output": "*Example 1. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n[CQ: _First,_ you should write an answer on _how the patient fits the inclusion criteria_ as `Age: 55. Gender: Male. Disease: HCV Genotype 1. Time to HCV RNA negativity: 4 weeks` by `Answers on inclusion/exclusion criteria -> 55` to `_55. Gender` to `_55. Gender: Male` to `_55. Gender: Male` to `Male`. Then, please type all these inclusions with `criteria` on your answer box by `1a: Inclusion: ...`_.\n\n*Example 2. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n[CQ: Write an answer on _how the patient does not fit the exclusion criteria (if he does not)___ by `Answer on inclusion/exclusion criteria -> 55` to `_55` to `_55. Gender: Male\u02eeto `_55. Gender: Male\u02eeto `Male\u02eeto `Male\u02ee. Then, please continue as in _Example 1_ to answer the next questions by `1b: Exclusion: ...\u02ee.\n\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as",
        "label": 1
    },
    "1501": {
        "output": "## Exercises\nNow you practice eligibility for the given clinical trial:\n\n\n*\n\n*Clinical trial assessment of Eligibility: https://github.com/saeidanian/Eligibility/blob/master/Eligibility.md\n\n*Clinical trial information - https://github.com/saeidanian/CLIN_TRIAL<EOD> Comparison of the performance of various algorithms for assessing genetic parameters in half-sib family designs.\nThe precision of direct methods of estimation of variance components by half-sib data depends on the amount of information retained by the pedigree of the sample. Sire-by-Sire and Sire-by-Dam models retain information only from the sire. Information retained from the dam is only in her own record. The Sire-by-Sire-by-Dam and Sire-by-Dam-by-Dam models retain information beyond the grandparental generation. Genetic parameters from half-sib designs estimated with five direct random regression algorithms (Sire-by-Sire, Sire-by-Sire-by-Dam, Sire-by-Sire-by-Dam-by-Dam, Generalized Linear Mixed Model and Generalized Mixed Model) were compared. Heritability and genetic correlation of height at 400, 600, 800 and 1000 days were estimated on 451 heifers from 17 farms. The parameters were estimated by sire models and by dam models on 428 and 23 heifers, respectively. Heritability and genetic correlation were obtained with the same algorithms both sire-based and dam-based. No clear difference was found among the variance components estimated from the Sire-by-Sire-by-Dam and Sire-by-Sire models. Genetic regression coefficients obtained with the Sire-by-Sire-by-Dam and Sire-by-Dam-by-Dam models were very close to each other both between sires and between dams. Heritabilities estimated by dam models were significantly lower than the heritabilities obtained with sire models at each time and at each sire. Comparison indicated there was no clear difference between estimates from the General",
        "label": 1
    },
    "1502": {
        "output": "[INST] Your trial recruiter should recruit and collect 100 consecutive patients at clinic and provide them with a patient information sheet and an informed consent form. You will receive a completed patient information sheet and patient consent form from the clinical research assistant  and submit the patient records to the clinical research associate (CRA, .\n\n**Your recruitment goals are to recruit:** * 50 healthy adults. Each healthy individual will undergo: an interviewer-administered questionnaire, urine pregnancy testing, a rapid HIV antibody test, and a lab evaluation (complete blood count, differential, international normalized ratio (INR), activated partial thromboplastin time (APTT), and urinalysis with microscopy).\n* 50 HIV-infected adults. Each HIV-infected individual will undergo a lab evaluation (complete blood count, differential, international normalized ratio (INR), activated partial thromboplastin time (APTT), and urinalysis with microscopy) and collection of an HIV viral load sample.\n\n*100* patients presenting to the study site with no clinical evidence of active HIV infection. The patients will be offered enrollment after completing a brief questionnaire, answering the questions of the Rapid HIV-1 test (1-23), and agreeing to sign and date an Informed Consent Form. All patients with a positive result in that rapid HIV-1 test (1-23) will follow a different path with clinical evaluation, collection of venous serum and urine specimens, antibody-based HIV testing by AxSYM (24), collection of venous blood specimens for DNA-PCR testing (25), and collection of venous blood specimens for HIV viral load determination (26) before being diagnosed of HIV infection.\n- [Instructions] [/HIV]\n*400* patients with no clinical evidence of tuberculosis. This group of patients will undergo a questionnaire, urine pregnancy testing, a rapid HIV antibody test (1/23), and collection of HRP-2-based tuberculosis test (Chorus H",
        "label": 2
    },
    "1503": {
        "output": "## How many patients are eligible for this clinical trial?\nPatients are eligible for clinical trials when they meet the trial's inclusion criteria. Patients can be ineligible due to the following reasons: (i) they do not meet specific criteria, (ii) they meet exclusion criteria, or (iii) they refuse to participate.\n\nIn this case:\nTrial-level eligibility: 0) Excluded. \nThis patient is excluded due to two reasons.\nThe first reason is the exclusion criterion of patients aged <18 and >65. The study's inclusion criteria specify a minimum age of 18 and a maximum of 65. The exclusion criterion for patients over 65 is because the drug may not be appropriate, and the doctor fears side effects. For now, the drug is not recommended for patients above 65 years of age, but research is currently underway to test the drug on this age group. If a study in this group is positive, the drug can be approved in the future.\nThe second reason is because in the past two years, the patient has been coinfected with HCV and HBV. The study's exclusion criterion for patients infected with HCV and HBV is because these patients do not meet the study's inclusion criteria. These patients are considered ineligible because they do not have enough information about the drug to determine eligibility.\n\n## Questions\n\n> What do we call the first reason for ineligibility?\n>\n> What do we call the second reason?\n>\n> Given that the patient has two reasons for ineligibility, how many patients will meet the study's inclusion criteria?\n>\n> By how much is the number of eligible patients equal to the number of enrolled patients?\nFor the first question, this is one reason to exclude the patient from the study. We will call the exclusion criterion that excludes patients due to their age. For the second question, this is why the patient does not meet the inclusion criteria of the trial. We will call the exclusion criterion that excludes patients who are coinfected with HCV and HBV.\nIn answer to question #3, we have seen that the patient has two reasons for ineligibility. The number of",
        "label": 0
    },
    "1504": {
        "output": "Tips::\n1. You should write this function under test_case/sri_50_12.py in each stepwise fashion. \n2. If you don't pass these tests, please use the debug function to find what causes the problem.\n[END]\n<EOD> Acute Effects of a Moderate-Intensity Walking Exercise Session on Cognitive Performance for Older Adults with Mild Cognitive Impairment\n\nHigh levels of sedentary behavior and low physical activity are associated with an increased risk of cognitive decline and development of dementia. One benefit of regular exercise is its ability to improve cognitive processes such as executive function, memory and psychomotor ability. There is a large body of evidence supporting that exercise improves several cognitive functions in healthy persons; however, some studies suggest that improvements in cognitive function are not as pronounced in persons with brain damage. According to previous studies, walking is an efficient, safe, enjoyable and easily accessible option for exercise. In the present study, we examined the acute effects of a moderate-intensity walking exercise session on cognitive performance in older adults with mild cognitive impairment who participated in a 3-arm exercise study, in order to identify a possible dose-response relationship. All participants performed the cognitive performance tests and the six-minute walk test (6MWT) before, after and 24-h post the exercise intervention; additionally, they walked on a treadmill at an exercise intensity of 50% of their maximum heart rate reserve (HRRmax) with an average speed of 2.3 km/h (30 - sessions) for 15 min. Cognitive performance, physical fitness and walking performance were compared across the three interventions. There were statistically significant differences (p < 0.05) in the Stroop test, the digit span test (forward) and the number of steps taken by walking on a treadmill. The findings highlight the benefits of moderate-intensity continuous aerobic exercise on executive function, psychomotor speed and walking performance in a clinically relevant time frame for older adults with mild cognitive impairment. We conclude that moderate-intensity continuous aerobic exercise is a valid and potent strategy to",
        "label": 0
    },
    "1505": {
        "output": "##[TRAILING] Hi, thank you for trying our task.\nYou made a good attempt!\nHere are a few suggestions for improving your performance in the next task:\n* First, you have missed the inclusion/exclusion criteria in both clinical trial and patient note. In other words, your clinical trial does not match the patient and your assessment of eligibility does not fit with the trial's scale. You should pay attention to these items in the future.\n* You may need to read the following article, about a data mining method that can evaluate data sources and the amount of information contained in the dataset.\n[TRAILING] This paper describes a method of evaluating a data source and the ability to extract information from the data source.\n[INST] This article examines the data source based on the characteristics of the data, the amount of information, and the utility of the data source. In addition, a data extraction program is developed, and, using this program, the data extraction efficiency is evaluated. The proposed method is intended to help create new data sources. The application of this method to existing data sources aims to increase information retrieval efficiency and the quality of data mining results.\n[TRAILING] In the field of medicine, much effort is devoted to medical diagnosis and treatment. Aiming to increase diagnostic efficiency, researchers develop various data collection programs (e.g., electronic medical record systems, etc.). However, as a result of recent advances in data processing technology, it becomes more and more important to not only collect all the data but also extract useful information from it.\n[INST] The paper addresses data sources that provide a wide range of information, from medical diagnosis to medical history, to the general population, along with data mining and database evaluation, in order to improve data collection methods and analysis efficiency based on the characteristics of each data source.\n[END TRAILING]\n\n## [TRAILING]\nIn [C03_2] data source, information is scattered between these three data sources, and this paper seeks to extract the relationship between these three data sources on drug resistance.\n[INST] This article is about extracting the relationship between genes, drugs, and organisms. The genes have been analyzed for resistance to specific drugs, leading to the discovery that some cells that are sensitive to the dru",
        "label": 1
    },
    "1506": {
        "output": "In addition, you should provide an explanation in the following lines. Explain the main difference between Patient-level eligibility and Trial-level eligibility to demonstrate your understanding of the assignment. The explanation is not mandatory but will be evaluated.\n\t\t\n\t\t- Patient-level eligibility: 2) Excluded\n\t\t- Trial-level eligibility: 2) Eligible\n\n## \u2753 \nPlease let us know that you correctly understand the idea of multiple data flow and data sharing.\n- Data flow\n\t- Multiple data flowing simultaneously to a server during data sharing phase.\n\t- Multiplexed data flowing from server to client during data sharing phase.\n\t- Duplicate data flowing from server to client during data downloading phase.\n\t- Copy data sharing. Data is stored in local disk.\n- Data sharing.\n\t- Server keeps data in multiple clients, but not every client gets the same data due to data sharing.\n\t- Client keeps data locally, but has limited information storage space.\n\t- Data transfer by server and client is fast and reliable.\n\t- Data transfer by client is slow and can be lossy.\n- Data storage.\n\t- Server can provide limited data from data storage space.\n\t- Client can save more data storage space in local disk.\n\t- Lossy transfer during data download.\n\t- Duplicate data download during data download.\n\t- Slow downloading speed. (may require VLAN)\n\n## \u2753\nPlease tell us whether the explanation below is consistent with the multiple data flow and data sharing (the above data flow and data sharing). (optional)\n- Explanation of multiple data flow and data sharing\n\t- Multiple data flowing simultaneously to server during data transfer phase.\n\t- Multiple data flowing simultaneously to client during data transfer phase.\n\t- Multiple data flowing simultaneously to client during data download phase.\n\t- Multiple data flowing simultaneously to server during data download phase.\n\t- Multiple data transfer from server to client during data sharing phase.\n\t- Multiple data transfer from client to server during data download phase.\n\t- Multiple data in the same communication media and bandwidth during data transfer phase.\n\t- Multiple data in the same communication media and bandwidth during data download phase.\n\t-",
        "label": 1
    },
    "1507": {
        "output": "[/MULTI_CHOICE]\n\nA: You would have\nTrial-level eligibility: 2\n  if patient does not meet any of the exclusion criteria (i.e. exclusion criteria are empty list\nor are a completely empty list and the patient satisfies all inclusion criteria)\n  if patient meets not enough of the exclusion criteria to be excluded, but the exclusion criteria\nare the same as or stricter and more numerous than the inclusion criteria.\n\nA: I agree with @DavidRobles.\nIf there are only inclusion criteria and you get the patient notes:\nIf a patient does not meet the inclusion criteria, then output 0 (excluded).\nIf a patient fits all the inclusion criteria, then output 1 (not relevant).\nIf a patient fits none of them and the patient does not have enough infornation to determine his eligability, then output 0 (excluded).\nIf you only have a list of exclusion criteria:\nAll patients that fit all the \"exclusion criteria\" are \"Excluded.\"\nAll patients that do not fit any of the \"exclusion criteria\" are \"Not relevant\"\nIn that case, the only patients who are left to analyze are those who do not fit any \"exclusion criteria\" and have not enough infornation to determine their eligability.\n<EOD> Pain catastrophizing and coping in people with rheumatoid arthritis: the mediating role of illness perceptions using an integrative model of pain.\nOBJECTIVE\nDespite numerous studies, little is known about the factors potentially mediating the relationship between coping and the illness beliefs of people with rheumatoid arthritis (RA) or the relationship between illness beliefs and pain catastrophizing. The aim of this study was to examine the relationship between pain-related beliefs, coping and pain catastrophizing in people with RA, and to explore the mediating role of illness beliefs between coping strategies and pain catastrophizing.\n\n\nMETHODS\nPain ratings, self-reported beliefs about the illness and pain and illness perceptions, coping and catastrophizing were measured in 692 participants with RA. Structural equation modelling was used to test the models.",
        "label": 1
    },
    "1508": {
        "output": "# [X] Task: Assess eligibility of the patient\nPlease try to solve the example first. You will see the output `0) Excluded` after solving the example and this is the correct answer for the patient. \nPlease continue and check your solution.\n\n\n```python\nif patient.age > trial.age_cutoff and patient.gender == trial.genders and trial.stage == 0:\n    trial_eligible = '0) Excluded'\n elif trial.stage == 1:\n     trial_eligible = '1) Not relevant'```\n```python\n\nif 'Samples taken after treatment' in trial_summary:\n     trial_eligible = '2) Eligible'\nelif '. ' in trial_summary:\n     trial_eligible = '2) Eligible'\n else : \n     trial_eligible = '0) Excluded'`\n```\nThe output should be like the following:\n```python\nIf you select 'Show my submission':\n\n---\n\nDummy solution\nTrial-level eligibility: 2) Eligible.\n```",
        "label": 1
    },
    "1509": {
        "output": "[OUT]\n[HEADING] Patient ID: 18806\nFirst Name: Mahmoud\nLast Name: Hosny\nAge: 55 Years\nCountry: Egypt\nGender:Male\n\n[NAME]\nAssistant for clinical trial recruitment\n\n[LINE] 136\n[HEADING] HCV41: Chronic hepatitis C infection\n\nInclusion criteria:\nChronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA.\nChronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis.\nHCV genotype 4.\n[/NAME]\n[LINE] 137\n\nFinally, you should always repeat Eligible in the last line by `Eligible: `, e.g., `Eligible: 4) Eligible.`.\n[INST]\n<EOD> Is early childhood education and parental income complementary?\nIn this paper I study the link between early childhood spending and family earnings based on data from the Early Childhood Longitudinal Study-Birth Cohort. Consistent with the complementary income effect, a high preschool spending level of $1460 per year raises the earnings rate of children born in the mid-1990s by 2.4%-8.0%. On the other hand, such an increase would not be observed in the absence of the complementary income effect.<EOD> Amino Acid Modification and Characterization of Chitosan Hydrogel to Enhance Its Biocompatibility and Tissue-Adhesive Capability\nThe purpose of this study is to construct a three-dimensional network structure for chitosan with high biocompatibility and tissue adhesive properties to prevent gastrointestinal leakage. First, the primary chitosan was treated with aminosilane, and their chemical properties and structure were characterized by Fourier transform infrared spectrum analysis and X-ray photoelectron spectra. Meanwhile, chitosan with aminosilane and chitosan with triethyl",
        "label": 1
    },
    "1510": {
        "output": "Finally, save the file to disk. [SAVE]\n\n[TUTORIAL] \n[/TUTORIAL] \n[TUTORIAL] You should always print trial's eligibility on each individual study's participants. One should always print \"Trial-level eligibility:\" with the patient as a default on each patient.\nIn our above example, here is the trial-level eligibility results on paper:\n\nThe last line shows the trial-level eligibility results for individual patients. The first three lines show the information for three patients. The last line shows the trial-level eligibility information for the population of the clinical trial.\n\n## Assessment of risk (RISK)\n\nYou should make the risk assessment on each patient. The risk assessment has a single value with 4 levels: 0) Low or Medium; 1) Medium or High; 2) High.\nIn the patient case, we recommend the following strategy:\n\nIn patient notes: \nThis is a 82-year old patient who had been diagnosed with type-2 diabetes for 7 years, hypertension and dyslipidemia for 4 years. He has a high body mass index and his triglycerides are more than two times higher than the normal range. This means that the patient is suffering from metabolic syndrome. He is currently taking metformin, bisoprolol, furosemide, simvastatin, and losartan for their treatment and has experienced no side effects of those drugs. His blood pressure is well controlled with two drugs. He does not smoke and has a BMI of 30. He has never had a stroke or a myocardial infarction. His physical and neurologic exams are without apparent or relevant abnormal finding.\n\nIn the clinical trial: \nTITLE: FOSINOPRYME-DHA SAFETY THRESHOLD RESPONSE IN SUBJECTS WITH METABOLIC SYNDROME\n\n\nSUMMARY: Safety FOSINOPRYME-DHA (FD) in subjects with metabolic syndrome\n\nOBJECTIVES:\n\nPrimary endpoint: Evaluation of cardiovascular effects",
        "label": 0
    },
    "1511": {
        "output": "## [INST]\nNow your turn! Please write a patient note that conforms to the specification and write the trial-level eligibility of each patient.\n\n# Key resources\n\n## [INST]\nTo submit your answer, click the green arrow button.\n\n## [INST]\nYou may make a maximum of three submissions. If you did not receive a grade for the last submission, you can submit again.\n\n## [INST]\nYou may revise the answer to this case assignment by submitting a new answer within 2 days from the initial submission. After 2 days, you will not be able to revise the answer. \n\n## [INST]\nIf the answer is submitted after 2 days, the answer will still be graded. You will not be able to view the grade for the last submission. If all three attempts are not passed, you will not be allowed to retry this case assignment. \n\n## [INST]\nPlease review the submission instructions and follow the number of words and characters carefully. If you include the characters that exceed the designated range, you will be asked to correct them.\n\n## Quiz\n<EOD> Association of endothelium\u2010dependent flow\u2010mediated vasodilation of the brachial artery with cardiovascular risk factors (from the Mild-to-Moderate Hypertension Registry in Japan )\nObjectives To investigate the characteristics of subjects with and without endothelium\u2010dependent flow\u2010mediated vasodilation (FMD) of the brachial artery, to find the association between FMD and cardiovascular risk factors. Methods We evaluated FMD in 729 subjects who met the eligibility criteria by the Mild-to-Moderate Hypertension Registry in Japan. According to FMD, we categorized the subjects into two groups: those with and without FMD. Results No significant differences were found in the prevalence of smoking or diabetes mellitus between subjects with and without FMD. Those with FMD were found to be older, to have a higher waist circumference and body mass index, and to have higher systolic blood pressure but lower pulse pressure. The percentage of hypertensives was higher in subjects with FMD. The subjects with FMD had significantly lower prevalence of current alcohol intake and higher pre",
        "label": 1
    },
    "1512": {
        "output": "# Exercise solution\nYou want to compare a patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, laboratory values are based, and previous medications used.\n\nHere are the patient notes:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\nHere are the clinical trials: \nTitle: Sorafenib in Treating Patients With Advanced Solid Tumors\n\n\nSummary: This randomized phase I trial is studying the side effects, such as high blood pressure, and best dose of sorafenib in treating patients with advanced solid tumors. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.\nInclusion criteria: Inclusion Criteria:\nHistologically or cytologically confirmed malignant solid tumor\nRefractory disease for which curative or palliative measures have failed or for which there is no known superior treatment\nNo colorectal cancer or melanoma",
        "label": 0
    },
    "1513": {
        "output": "</PRE>\n</BODY>\n</HTML>\n<EOD> Developmental expression of murine Gap43 mRNA: a marker of neuronal outgrowth, target selection, and synapse formation.\nThe polypeptide galactose3\u2010fucose (Gal\u2010Fuc) and the mRNA encoding it have been used to identify and purify neurons from a variety of sources. One such neuronal transcript is the Gap43 mRNA. A number of characteristics of Gap43 include its expression late during neuronal maturation and in a highly restricted distribution pattern which has suggested that it could be involved in mature neuronal processes. We report here an analysis of the in vivo and in vitro temporal and spatial expression of Gap43 mRNA which support the concept that Gap43 has a crucial role in neuronal development.<EOD> The RABiT System: Antigen Presentation Assays to Study the Functions of the Transporter Associated with Antigen Processing (TAP) and Peptide Transporters\n\nWe used recombinant adenoviral vectors to express human cytomegalovirus (HCMV) envelope glycoprotein B (gB) H-2d (R) and A b (L) peptide complexes (RAD-L) or T lymphocytes containing both receptors (RAD-L T) or neither receptor (RAD noTCIR , LTCIR-RAD or Tcells) 12.5 ng/well of either a peptide-specific CTL clone (e.g., clone 52.6 of LCMV gp33 peptide) 100 ng/well of either antibiotic resistant CTV/L-Gal-EHMG cells (24) 100 \u00b5l of MEM-GlutaMax culture media (no phenol red) 10 \u00b5l of MEM Vitamin Solution (Gibco) 10 \u00b5g/ml CpG-ODN2006 CpG-ODN2006 (Sigma) 0.5 ml of FBS +1% human serum +7.5 mM sodium butyr",
        "label": 0
    },
    "1514": {
        "output": "(3) 3 Trial-level eligibility_2\nThis patient was eligible for the trial because he was non-significantly 55 years old. Now, you should assess clinical trial eligibility for `non-significant` by calculating the `clinical trial eligibility_2`. \nNon-significant clinical trial eligibility_2 equals 4-1 = 3. Thus, you should enter the number of three in the fourth line of the trial-level eligibility by typing the number three as `Trial-level eligibility_2: 3`. [END]\n\n\n[L2]\nThe task is to complete trial-level eligibility for patient note. Let's do it for the next patient note.\nLet's continue our journey. Now, let's continue our journey for the next patient note.\n\n#### [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your tasks are to assess trial-level eligibility for each patient note and the next patient note. \n[END]\n\n#### [INST](https://colab.research.google.com/github/yonseibiomed/course-2020/blob/main/code/L4_TrialEligibilityAssistant/instructions.md) Hello. You are a helpful assistant for clinical trial recruitment. Your task is to assess trial-level eligibility for each patient note. We are going to complete the trial-level eligibility and input it for each patient note. For the assessment of trial-level eligibility, you can consider the same factors as for the patient-level eligibility. The result of the assessment is a three-point scale: 0) Excluded (patient is excluded from the trial on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). Thus, we can calculate trial-level eligibility by summing trial-level eligibility for each patient (Trial-level eligibility_2) and calculate sum as 4-1 = 3. Thus, when you assess trial-",
        "label": 1
    },
    "1515": {
        "output": "##[TEST]\nLet's see it by `print Trial-level eligibility:`\n[1] \"1) Not Relevant\" \"2) Eligible\"\n[2] \"1) Excluded\" \"2) Not Relevant\" \n\n## Other\n[Trial-level eligibility (for all patients): `Trial-level eligibility: ']\n[Test]\nLet's check patients in a row by the name.\npatient_71:\n[1] 0.00 - Note that the trial-level eligibility of this patient is \"1) Not Relevant\" which is not reported by the function, i.e., `Trialevel eligibility: 1) Not Relevant`. So, check by the command line\n\n##[INST]\nOutput for Patient No. 70 \nTrialevel eligibility:<EOD> .\nPURPOSE\nTo investigate early postoperative complication, recovery of urination and sexual function and its effect on quality of life in patients with spinal osteoporotic compression fractures.\n\n\nMETHODS\nA total of 56 patients (20 males and 36 females) treated with a new surgical technique (percutaneous pedicle screw fixation and polymethyl methacrylate vertebroplasty) were included. The age was 65.49\u00b17.68 years (range, 50 to 82 years). Fifty-nine fractured vertebrae included 14 thoracic vertebrae, 32 thoracolumbar vertebrae and 13 lumbar vertebrae. The data were collected pre-operation and 1 week, 1 month and 3 months after operation, respectively. The Japanese Orthopaedic Association (JOA) score and Oswestry Disability Index (ODI) score were recorded before and after surgery and the recovery of the urinary and sexual function were assessed. Preoperative and postoperative complications (urinary tract and sexual function) were monitored to evaluate the effects on quality of life.\n\n\nRESULTS\nThe mean follow-up time was 20.12\u00b112.22 months (range, 9 to 46",
        "label": 0
    },
    "1516": {
        "output": "-Clinician-level_eligibility <-paste0(paste0(`Clinician-level eligibility: 1) Eligible, `, paste0(`Clinician-level eligibility: 2) Eligible, `)) -Patient-level_eligibility <-paste0(paste0(`Patient-level eligibility: 1) Eligible, `, paste0(`Patient-level eligibility: 2) Eligible, `)) -Trial-level_eligibility <-paste0(paste('Trial-level eligibility: 1) Eligible, ', paste0('Trial-level eligibility: 2) Eligible, ')); -Save the document of the eligibility for the HCV trial in your machine and the clinical trial database. The document contains all of the eligibility information. The code snippet with this information is saved in a local folder. \n\n## Efforts\nNow you create a clinical trial named Hepatitis_C_Study_01 in the clinical trial database. You use the HCV trial code as the trial name. The HCV trial code is an integer (integer data type number/number) in EVA. In the following code snippet, `ID of ClinicalTrialsStudy: 1,088`, 1,088 is an identifier for HCV_Study_01 in the clinical trial database. You use other clinical trial identifier as an identifier for your chosen clinical trial. It is usually made of a combination of numbers and letters, such as HIV048. The identifier can be found in the Trial_Info of the HCV trial.\n\n## \nIn the following, you choose all of the eligible patients by `eligible` status and the age between 18 and 70. Since you expect the patient will participate in the clinical trial for a short period of time, you set `Durations` at 1 week, 38 weeks, 74 weeks, and 84 weeks. \n\n## Creating `trials_csv. csv` with the information of eligible patients of the hcv trial \n- Create the CSV-file of the HCV trial by executing the code snippet of the",
        "label": 0
    },
    "1517": {
        "output": "[INST]\n\n\n\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic",
        "label": 0
    },
    "1518": {
        "output": "We believe you are looking forward to finding an accurate answer! \n<EOD> .\nBenzodiazepines can be administered both as a single dose or as an infusion during a long period of time. The effect which can be expected varies according to the type and duration of surgery as well as to the type of the benzodiazepine. In addition, the duration of action of benzodiazepines may be prolonged for days in intensive care for example owing to accumulation of the drug. A short half-life leads to a faster elimination or clearance. It could then be predicted that the elimination of short-acting benzodiazepines like midazolam should be faster than the elimination of long-acting benzodiazepines. However, this rule is not absolute. As well as half-life, another pharmacokinetic parameter determines the duration of action of a benzodiazepine: volume of distribution. In adults, the volume of distribution ranges between 0.4 and 1 L/kg. The volume of distribution is mainly related to the amount of fat which is present in the blood and which is known to be increased in the post-operative period following prolonged surgery. This could explain that although midazolam, in fact, has a short half-life, its duration of action is prolonged by several days following surgery. The duration of action of benzodiazepines is of course the most important criteria for prescribing a drug in the context of surgery as it determines the patient-drug interaction. This also contributes to the overall safety of the drug. However, to make the decision to choose a drug which will ensure the shortest-possible action, without jeopardizing the patient's care in the long run, some additional information is necessary; notably, drug accumulation which is related to the area under the curve and to the renal function or hepatic metabolism.<EOD> Antispasmodic activity of some Chinese medicinal plants.\nAntispasmodic activity of 12 indigenous Chinese medicinal plants was evaluated using the isolated guinea pig ileum. Leaf and fruit extracts of Lysimachia capillipes, Melastoma malabathricum, Millettia pinnata, Parachin",
        "label": 2
    },
    "1519": {
        "output": "</pre></div>\n<!--\n<style>\n\n.description_div h4 {text-align: center;font-size: 1.3rem;line-height: 2rem;font-stretch: widen;margin: 1em 0;}\n.description_div h5 {text-align: center;font-weight: lighter;font-stretch: widen;font-style: italic;font-size:2.2rem;line-height: 1em;margin-top: 2em;}\n.description_div p {text-align: center;font-stretch: widen;font-style: italic;font-weight: lighter;font-size:2rem;text-transform: none;line-height: 1.6em;margin: 1em 1em;}\n.description_div p.warning {font-weight: lighter;}\n.description_div code{color: black;}\n.description_div code.key {font-weight: 500;background-color: #FE0000;}\n.description .tray {margin-top: 0; margin-bottom: 1.5em;}\n.description .tray .tray_title {margin-top: 0; margin-bottom: 0;}\n.description .info {margin: 2rem 0;}\n.description .tray_title {font-weight: 600;font-size: 2em;line-height: 1em;font-stretch: none;background-color: black;border-bottom: 1px solid white;border-border: 1px solid transparent;}\n.description_div p#output {border-bottom: 2px solid white;padding: 8px;}\n\n@media (max-width: 460px){\n  .description_div {max-height: 18em;overflow: scroll;}\n  .description_div p#output {max-height: 40vh;}\n}\n</style>\n-->\n<div class=\"description_div\" id=\"output\">\n  <div class=\"info\">\n    If any of the patient data is missing or corrupt, output an error message for that patient and record it in the database.",
        "label": 1
    },
    "1520": {
        "output": "[QUESTION] If there are more than one patient notes?\nA.\n[QUESTION] Can we change the 3-level scoring to another level or number (such as a star rating system), just by simply modifying the code in the main loop in ? [/QUESTION] \n\n## #18.\n## Task 10.\nWrite a Python script for the assessment of eligibility of all patients simultaneously using the Clinical Trial Assistant's class. [/QUESTION]\nThis part of the assessment of eligibility task requires a little more complex algorithm. In this part, we will use the `random module` that is used to generate random samples with replacement (i.e. sampling with identical items chosen more than once). The most common use is to choose the index of an element from a list. Since we must create subscripts randomly, we will use the `random.choices` function.\n\nBy the `choices()` function, one or more indices are randomly chosen from a certain type of arguments. For example, the list below, can be used to pick 10 indices at random from the list of positive integers between 1 and 10 - `[1, 2, 3, 4, 5, 6, 7, 8, 9, 10]`\n\nThe below code creates and returns a list of 10 subscripts randomly in accordance with our example list. In this example, we have used the choice function to randomly choose 10 indices from the list of positive integers between 1 and 7. The random numbers will also be randomly chosen from this list.\n[p1]\n\nIn this example, we will use the patient_notes function that is defined before to the start of the main program to generate lists of patients' notes.\n\nThis example generates lists of patients' notes but doesn't print the text to the console.\nSince I want to print patients' notes after the completion of the function, I will create a function called `print_list()` which is defined in the _main.py_ file. This function prints the list of patients' notes to the conosle in a one-line format. I have also added a print statement to the end of the `print_list()` function which shows the total number of subscripts that are generated by the `choose_subscripts()`",
        "label": 1
    },
    "1521": {
        "output": "You can also specify the input to the list form of `R` at the beginning of your R script.\n\nHere is an input option.\n\n[INST] - You know how to open your R session first.\n\nHere is the complete file.\n\n> library(rpart) > library(dplyr) > library(ggplot2)   > myInst <-function(){ > library(pROC) > library(\"ggplot2\") > inputform <-formula(\"R=ifelse(Triallevel eligibility==2,Trialleveleligibility.2,R)\") > trial_type <-c(\"naive\",\"relapsed\",\"naive+relapsed\") > trial_naive <-c(0,0,1) > trial_relapsed <-c(0,1,0) > trial_naive_relapsed <-data.frame(trial_naive,trial_relapsed,inputform) > trial_list <-data.frame(trial_naive,trial_relapsed,inputform) > t_naive <-cbind(t_naive, trial_naive) > t_relapsed <-cbind(t_relapsed, trial_relapsed) > t_naive_relapsed <-cbind(t_naive_relapsed, trial_naive_relapsed) > t_list <-cbind(t_naive, t_relapsed, t_naive_relapsed) > print(summary(lm(R~Trialleveleligibility (trial_list))) > print(summary (lm (R~Trialleveleligibility (data.frame (trial_type, trial_naive, trial_relapsed)))) > print(summary (lm (R~Trialleveleligibility (data.frame (naive, relapsed, trial_naive_relapsed)))) 3.2 Construct a plot. [B]\n\nAfter obtaining an R list, it's time to make a plot. \n\nOn one hand, you can prepare a list for a histogram. \n\nOn the other hand, you can also prepare a list for a bar plot. \n\nHistogram: \n*\n\n*Create a histogram by the `hist` function. \n\n*Create the x axis",
        "label": 2
    },
    "1522": {
        "output": "```\nThis variant was identified in a 60-year-old male with a strong family history of DCM. The variant falls within an exon that is considered highly likely to be splice, and in silico splice predictions suggest that it has no effect on splicing. It is unclear if this variant is disease-causing or non-disease-causing in this family, although some other rare, putatively damaging variants are present in the family. For now, we classify this variant as a VUS and recommend testing the relatives for the presence of the variant so they are aware of this genetic risk in an effort to help prevent further DCMrelated death in the family.\n[SECTION/]\nThe variant results in the substitution of",
        "label": 1
    },
    "1523": {
        "output": "In Section 'Example: HCV and Clinical Trial', we will consider the patient's actual eligibility for the trial. It is very important that you test the correctness of your solutions. [HINT] [IN-ST]\n\n## EXAMINATION STUDIO\n\nSection 'Prerequisite: Python environment' shows you a prerequisite for using Python. It is recommended to follow the step-by-step tutorial available at: http://docs.python-lang.org/2/download/ . [HINT] [INST]\nSection 'Download the 'Clinical Trial' project' shows you how to download the project. [HINT] [INST]\nSection 'Running the project' shows how to run the project. Section 'Running the project with the test method' shows how to run the project with the test method. Section 'Running the project with the run method' shows how to run the project with the run method. It is recommended to follow the step-by-step tutorial available at: http://docs.python-lang.org/2/tutorial/index.html . [HINT] [INST]\nSection 'Create classes' shows you how to create classes (i.e., ClinicalTrial and Assistant). Section 'Create patient and clinical trial note' presents how you can create a patient object (i.e., patient) and a clinical trial note (i.e., ClinicalTrial). Section 'Define methods' presents how you can design the desired methods. Section 'Define test class' presents how you can define the test class. Section 'Define fixtures' shows how you can implement the required fixtures (i.e., ClinicalTrial and Assistant). Section 'Run the test' shows how to run the test. It is recommended to follow the step-by-step tutorial at: http://docs.python-lang.org/2/howto/ unittests.html . [HINT] [INST]\nSection 'Create methods' shows how to design the desired method. It is recommended to follow the tutorial at: http://docs.python.org/2/tutorial/controlflow.html . [HINT] [INST]\nSection 'Create ClinicalTrial' contains the ClinicalTrial class source code.\n\n# Clinical trial class",
        "label": 2
    },
    "1524": {
        "output": "[CASE] Hello, Your role is a clinical research coordinator at a healthcare institution with a cancer clinic. You are a recruiter for Phase II clinical studies. One of the studies you're managing is for testing a potential new drug for liver cancer. The drug is being evaluated for its safety and effectiveness in treating liver cancer. Participants in this study will be adults diagnosed with liver cancer who have agreed to undergo treatment with this drug. The treatment will be in combination with a drug called BAY 87-2243. The study medication will be given intravenously once every four weeks for ten doses; patients will be observed for safety and effectiveness for up to six months.\n\n\n\n[TASK] You are preparing the informed consent form (ICF) for the study. The ICF is a written document that explains the study to patients before they agree to participate. It should include crucial information about the study, such as its purpose, procedures, potential risks and benefits, data privacy, and rights of withdrawal.\n\n\n\nPlease submit the written informed consent approved by the Institutional Review Board. You may revise your ICF based on the feedback you received from the IRB and the study team. Please include a cover letter explaining your ICF revisions and the reasons for those changes. Your task is to:\n\n\n\n\n\n<EOD> Tumor Necrosis Factor-\u03b1\u2013Induced Skeletal Muscle and Skeletal Muscle Apoptosis\nThe tumor necrosis factor-\u03b1 (TNF-\u03b1) family of cytokines exerts significant effects on skeletal muscle and muscle-derived cells. TNF-\u03b1 has been reported to cause skeletal muscle atrophy and weakness, decrease metabolic rate, and enhance lipolysis. In addition to these catabolic effects, TNF-\u03b1 can suppress myogenesis and increase the degree of apoptosis in skeletal muscle cells and in muscle fibers during inflammation-induced muscle disease. This review focuses on these recent findings and summarizes an overall hypothesis on the effects of TNF-\u03b1 in regulating metabolic and muscle mass homeostasis as well as skeletal mus",
        "label": 2
    },
    "1525": {
        "output": "<EOD> Intergenerational Persistence of Adolescent Depression Over a 20-Year Follow-Up Study for Children of a Nationally Representative Sample\n\nObjective: Aim of this study was to quantify the risk of adolescent depression in offspring of parents with a lifetime history of depression by using a nationally representative data set. Methods: Using a 5-year national cohort of Swedish adolescents aged 16 years in 1992 or 1995, and their parents with a lifetime history of depression (n \u00bc 9282), we analyzed the incidence of depression from age 16 years to age 36 years in offspring of depressed parents. Cox's proportional hazard regression model with age as underlying time variable was used to assess the long-term risk for depression. Results: After adjusting for potential confounders, offspring of a depressed parent were at increased risk for depression compared with offspring of psychologically healthy parents. The hazard ratio for depression was 1.24 (95% confidence interval [CI] \u00bc 1.11-1.40). Gender had no significant influence on offspring depressive disorder (P \u00bc .822). Conclusion: For adolescent offspring of depressed parents, increased risk of depression also persists well into adulthood.\n\n# Introduction\nAdolescence is considered the most critical stage of development for the emergence of emotional problems and depressive disorders. [bib_ref]  The age of onset of mental disorders: a review of recent literature, Kessler [/bib_ref]  [bib_ref]  Depression in late life: review and commentary, Blazer [/bib_ref]  [bib_ref]  Identifying depression in older adults; what every primary care physician should know, Trivedi [/bib_ref]  Depression is prevalent in adolescents, with an average lifetime occurrence of 13.5%. [bib_ref]  Child and adolescent depression: a review of the past 10 years. Part..., Birmaher [/bib_ref]  There is strong evidence that risk factors of adolescent depression are familial in etiology. [bib_ref]  Prevention of depression may be possible in individuals with a family history..., Friedman [/bib_ref]",
        "label": 2
    },
    "1526": {
        "output": "The trial-level eligibility can also be repeated for each patient by `trial-level eligibility: 2) Eligible.`. But there is a rule for how to repeat it. That rule is:\n- Do not repeat trial-level eligibility before repeating its patient-level equivalents.\nFor example, you must always write `patient_name = ` before `Trial-level eligibility: 1) Not Elegible.`. So, if you first write `Trial-level eligibility: 1) Not Elegible.\n[/R]`, then you must always first write `patient_name = `. Then you can still write `Trial-level eligibility: 1) Not Elegible.\n[/R]` after repeating `patient_name=`. By repeating you mean writing `Trial-level eligibility: 1) Not Elegible.\n[/R]` in the same line.\nAfter repeating, just write the `Trial_level_eligibility: ` in the last line. If you repeat it before writing `end if`, you must repeat not only trial-level eligibility but also all the repetition in the same if-while-loop. This is because the syntax of the code is:\n\n`end if # for if-while loop` \nThe best rule in repeating the elements in the if-while loop is that you must repeat every element in the same way in the same if-while loop.\nYou can repeat `Patient_age =` as many times as you need just because it is an input in the while loop.\n\nYou must check your code. If your code is not right, you can fix it quickly by writing the following code to make it right:\n\n* Code:\n\n```\ndef trialname: (trial) -> str:\n    'ClinicalTrials name for trials which you want to extract this information.'\n    def trialname(trial):\n        return str(trial._ClinicalTrials.name)\n    return trialname(trial)\n\nTrial_name: [1] str\nTrial_name.__doc__:\n\n'The full name of the trial which you want get this information.'\n```\n\n\n\n*  Code:\n\n```\ntrial",
        "label": 2
    },
    "1527": {
        "output": "[INST] Important: If there are no criteria included in the trial, then the output should be the same as the patient info.\n\n> Include eligibles(df_1) \n> \n> Include triallevel(df_1) \n> \n> ## Output\n> ## \n> ##        Inclusion criteria \n> ## eligible  \n> ## Trial-level eligibility: 0 (Excluded)\n> ## \n> \n\n\n[INST] Important: If the patient meets all the criteria, then you should output the code in the same way as the following code.\n\n\n> Include eligibles(df_2)\n> \n> Include triallevel(df_2)\n> \n> ## Output\n> ## \n> ## \n> ## Inclusion criteria\n> ## Excluded Not relevant Eligible\n> ## Trial-level eligibility: 2 (Eligible)\n> ## \n> ## \n\n# Example:\nIn this example, patient info is as follows:\n[formula]  ## Patient info Intake  2018-03-27 ## 13:27:20 ## Ages: 45, 46 ## Female 1,2 ## [/formula] \nEligible \n[formula]  ## Sex: F, M, N/A ## Race: AA   C.Sex: F, M, N/A ## C.Race: AA, Other ## [/formula] \nThere are three criteria for the trial:\n- \n\n## Include the trial-level eligibility as follows\n\n> Include triallevel(df_2)\n> \n> ## Output\n> ## \n> ## \n> ## Inclusion criteria\n> ## Excluded\n> ## Not relevant Eligible\n> ## Trial-level eligibility: 1 (Not Relevant)\n> ## ## ## ## ## ##\n\n\n\n\n\n## # Example:\nA 65 yo male with chronic HCV infection has two factors: age and presence of cirrhosis. A 13 yo male with no chronic liver disease but hepatitis B infection has only one eligibility factor: age. Each individual is 0.",
        "label": 0
    },
    "1528": {
        "output": "__HINT___\n\n### **Note:**\n\n![](http://files.s3.amazonaws.com/hub/img/hint_01_116_01012019.png)\n\n\n\n[SITE]\n(Enter text for hospital/centre name here)\n\n[CAPTION]\n(Enter text for patient assessment here)\n\n\n### **2.14.2** Evaluating patient eligibility\n\n1. Access the patient list to locate the relevant patient list note\n2. Find patient ID in the list\n3. Click **View** button to view the patient list note\n4. Find the clinical trial in which the patient is eligible\n5. Click **Select** button to select the relevant clinical trial\n6. Click **Select/Edit/Change** button to open an Addition Clinical Trial Info form\n7. Create a new clinical trial information record in the Addition Clinical Trial Info form\n8. Enter the trial-level eligibility for the selected clinical trial in the Addition Clinical Trial Info form\n9. Click **Save** button to save the trial-level eligibility\n10. Click **Back** button to return to the patient list\n11. Click the **Eligible** button to upload patient eligibility to the selected clinical trial\n\n__HINT___\n\n### *Trial-level eligibility*\n\n### *2.8*\n\n__HINT_",
        "label": 0
    },
    "1529": {
        "output": "# Results and Discussion\nDemographic characteristics of the assessors indicated that the assessors in the main trial tended to be females and in the experimental group. However, the results in the present study indicated that the performance of the assessors did not vary according to the trial version.\nThe assessors' performance in this task followed similar trends as reported in other tasks [bib_ref]  Assessing the validity of the TAFE-LAN patient record system by using the..., Heldens [/bib_ref] . The assessors' responses varied according to whether the assessment was made in the main or experimental trial version. In the group of assessors of the main trial version the frequency of responses varied from 97.5% to 100% in the three phases. In the group of assessors of the experimental trial version, the frequency of responses varied from 97.8% to 100% in the three phases. These results indicated that no variation was observed comparing the assessment performance of the two versions.\nThe assessors' assessment performance was quite accurate as the majority of the patients included in the task were within the eligibility scale of 0. This result indicates that the assessors were able to respond to a complex task without difficulty and with low variability and great sensitivity.\nNo variation was observed in the assessment performance of the two versions of the trial. It was not possible to perform the statistical test for comparison of performances of the assessors in the two trial versions since there was no variation in the frequency of answers. \nExperiment\nThe experiment was performed with the consent of the assessors and with a previous meeting with the coordinator of the task. To evaluate the effects of the task on the assessors, they were instructed to fill out a questionnaire with their assessment of the task. The instruments were developed with the help of experts to ensure content validity and were administered in the middle and end of the tasks. The assessors were given a form in which they could write up a sentence to express their assessment of the characteristics of each phase of the trial. To ensure anonymity, each assessor received a letter with their identification number.\nThe assessors' assessment of the three phases of the clinical trial showed that the assessment of patient information was the most problematic phase regardless of the trial version. They stated that this phase was the most difficult to understand and",
        "label": 0
    },
    "1530": {
        "output": "Happy coding!\n\n```python\n#%% # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #",
        "label": 0
    },
    "1531": {
        "output": "<EOD> Previous infection with cytomegalovirus enhances resistance of macrophages to the antiproliferative effect of immunosuppressive agents\nThe antiproliferative action of cellular immunosuppressants on mouse peritoneal macrophages is antagonized by the presence of herpesvirus cytomegalovirus (CMV). Monolayer cultures inoculated with CMV 5 to 7 days before addition of immunosuppressants increased the concentration or proportion of cells growing into multilayers in the presence of either cyclosporin A or hydrocortisone. These enhanced responses were associated with the presence of infectious CMV and specific CMV\u2010induced cell associated neutralizing antibody. Virus inoculated at the time the drug was added exerted no antagonistic action. The antagonistic action may be due to virus\u2010induced progression of monolayer\u2010grown macrophages beyond the G1 cell cycle phase and thereby overcoming the effect of cellular immunosuppressant.<EOD> Evolution of eukaryotic protein phosphatase complement: variations on a theme.\nProtein phosphorylation reactions on serine, threonine, and tyrosine residues are vital to many biological processes in eukaryotes. This posttranslational modification is a target for the protein phosphatase family, which can be divided into four broad categories: tyrosine-specific phosphatases, protein phosphatases 1, 2A, and 2C, and other, more divergent forms of protein phosphatases. Within the phylogenetic tree, protein phosphatases that are closely related to their eukaryotic counterparts form a cluster called the phosphatase superfamily; this group of enzymes contains proteins found in archaebacteria, bacteria, and eukaryotes. For example, the majority of mitochondrial phosphatases are evolutionarily related to phosphorylase phosphatases, which are found in all living organisms. A large proportion of eukaryotic phosphatases cluster in a monophyletic group containing the tyrosine phosphatases, protein phosphatases 1, 2G, and",
        "label": 0
    },
    "1532": {
        "output": "Your task is completed. [INST] \n__In this task, you learned how to assess trial-level eligibility of each patient for the given clinical trial. You can evaluate the eligibility based on the patient's personal characteristics. \n\n\n\n## 4.6.2\nEvaluating Patient-Level Eligibility When you first start with data analysis, you might need to check if each participant is eligible for the tri-\nal before you start with data analyses. This section introduces you to this point in detail. \n__You will answer the question: Am I qualified to be in this trial? We will use the concept of eligibility criteria to answer this question.  A patient fulfills an eligibility criterion when the given criteria are met. Eligibility is usually a multi-level concept, and each eligibility level is called \\em{patient-level}, \\em{trial\\-level} or \\em{intermediate\\-level}\\r eporting the eligibility criteria for a given trial. Clinical trials may differ with regard to eligibility criteria depending on the characteristics of the patients and the purpose of the trial.  An example of clinical trial \\citep{Ferrarini2006}\n\nAs we stated above, a clinical trial will determine its eligibility criteria for a patient to qualify for taking part in a trial. For example, clinical trial \\#NCT00268692 (ClinicalTrials.gov id) was conducted by the European Institute for Tumour Therapy. The purpose of the trial was to explore the effects of an herb-based, Chinese medicine, Fuzheng Huayu therapy, in terms of quality of life and immune function in patients with breast cancer. The inclusion criteria are summarized as the following \\citep{Wang2004}:\n\nA participant in clinical trial \\#NCT00268692 who was diagnosed with breast cancer in accordance with the criteria published in the 2003 Chinese National Diagnostic Criteria of Breast Cancer, as well as the participant's clinical stage at the time of enrollement. In addition, the participants should also meet one of the following inclusion criteria \\citep{Wang",
        "label": 0
    },
    "1533": {
        "output": "## Exercises\n[EXER]\nHere is a list of exercises in order of complexity. Please check each exercise to see whether you understand it. Then, you should make your trial of them to get familiar with `GATE`.\n\n1. Exercise 1: Eligibility Assessment in a Clinical Trial\n\t1. The patient is a 56-year-old man diagnosed with HCV 4 years ago and has stage four chronic renal insufficiency with normal serum phosphate on dietary modification for the past 6 months. He is on IFN and RBV for HCV for the past 3 months. His medical records show positive HCV RNA tests and positive enzyme immunoassay for anti-HCVantibodies. The patient does not have any underlying metabolic condition(s). He has no history of smoking, alcohol abuse or family history of diabetes mellitus, hyperlipidemia or stroke. He is an alert male with no acute distress. His BP: 140/90, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n\t1. Your task is to determine the patient's eligibility with regard to the clinical trial. Use the eligibility checklist. Be careful so that you don't make the wrong choice.\n\t1. How would you answer to the trial question?\n\t\t1. Yes, the patient doesn't meet the inclusion criteria\n\t\t1. No, the patient meets the inclusion criteria\n\t\t1. Uncertain, the case is borderline\n\t\t1. Uncertain, the case is not clear\n\t\t1. Uncertain, the case is questionable\n\t1. What is your judgment to the following patient:\n\t1. The patient is a 30-year-old male with chronic HCV for 5 years of duration. He suffers from diabetic neuropathy for the last 2 years. His medical records show positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. He is on",
        "label": 1
    },
    "1534": {
        "output": "## [TEST CANCER_DATA] 2. For this test we need the `cancer_data` table. This table stores the diagnoses of tumors, with a unique id (animal id) and a numeric id (cancer_id) that identifies the particular cancer. We need to find the animal cancer id for each tumor description table. In the description table, we have one more column with the ID of the animal that has the tumor. Here we need to create a new table with all the necessary information that we require, `animal cancer id table`. If available, there are already similar test files in your working directory named ___tumour_genotype_animalid.txt and ___tumour_genotype_canider.txt. Run `cat all/genotypes/animal id/tumour_genotype_animalid.txt` and `cat all/genotypes/animal id/tumour_genotype_canider.txt` to see some information in those files. After all, we need to create a new table with the information of those files to extract all the animal cancer id for each tumor description table. For this, we need to combine these two files.\n- [R] `rm -R -f all/genotypes/animal id/`\n- [R] `mv all/genotypes/animlal_id/animlal_id/animal` all/genotypes/cancer_data/`\n-\n  [R] `echo \"all_cancer_data_animal_id\" > all_cancer_data_animal_id`\n- [R] `cat all/genotypes/animal_id/tumour_genotype_animalid.txt` >> all_cancer_data_animal_id\n- [R] `cat all/genotypes/animal_id/tumour_genotype_canider.txt` >> all_cancer_data_animal_id`\n- [R] `diff all_cancer_data_animal_id.txt`\n\n##\n\n## A) Examine the test file (all_cancer_data_animal_id)\nBy examining the test file,",
        "label": 0
    },
    "1535": {
        "output": "_In the real world, some data are usually collected in the form of a matrix. For instance, patients with specific conditions, e.g., in a certain hospital, could be represented as a matrix whose entries record the number of people with specific conditions and are usually stored in CSV format. Similarly, clinical trials could be described in the form of a matrix whose entries record the number of patients in each trial over a specific time window. An example of such a matrix is in the paper of Ehteshamifar, Agrawal and Golban (2010) [PMID:20227679]. This way of representing clinical data can be very informative._\n\n### Example: Input\n\n```yaml\nlanguage: python3.6\n# output files will be placed in the output folder\noutput_folder: /path/to/output\n---\n# you can name the script differently, e.g., \"run.sh\" \nscript_filename: /path/to/run.sh\ndata_folder: /path/to/data/folder\n# data folder contains CSV files in the following format:\n# column headers should match the \"Patient-Note\" section of the template\n# The trial-code is the name of the corresponding CSV file\n# Note: in the example below, all five trials correspond to a single CSV file\ndata:\n  HCV_Thal: csv_data.csv\n  HCV_CHD: csv_data.csv\n  HCV_Psoriasis: csv_data.csv\n  HCV_Osteoporosis: csv_data.csv\n  HCV_Osteo: csv_data.csv\n```\n\n### Example: Shell script\n\n```bash\n#! /bash\n\n# make sure to be at the same directory your scripts is in\n# The next line is going to be the directory where all your input files are loaded \n# It's recommended to set it on the same directory as your scripts\n# As we'll be using those scripts, it is necessary we have all our\n# data in the same directory when we run the simulation\n# In this particular example, all the data files are inside the data folder\nexport DATA_FOLDER=$(pwd)/data\n\n# define a variable called data\ndata=\"\"",
        "label": 0
    },
    "1536": {
        "output": "<EOD> .\nThe objective of the investigation was to study the content of carboxylic and sulfatic groups of low molecular peptide conjugated substances present in rat urine. A study was conducted with the use of HPLC-ion-exchange chromatography and thin-layer chromatography on cellulose TLC plates (with a carboxylic group specific-phosphoric acid amino acid coloring reagent and sulfatic group specific-dinitro fluorobenzene) followed by the detection of the components by the fluorography method with the use of a 254-nm lamp. Urinary protein hydrolysates of healthy and diabetic rats were investigated. It was established that healthy rats contained high-molecular and low-molecular peptide conjugated substances. At the same time, it was revealed that in diabetic rats, in addition to high-molecular and low-molecular peptide conjugated substances in the urine was also found high-molecular polypeptide conjugated substances without acetic acid moiety.<EOD> Bacteria-Induced Epithelial Mesenchymal Transition: A Novel Mechanism of Renal Tubular Injury and Fibrosis\n\nFibrosis is a final common pathway in response to injury in a majority of organs, including kidney, and is characterized by the production of extracellular matrix in the interstitium. As renal progenitor cells are absent in adult kidney, the differentiation of the epithelial to mesenchymal cells (EMT) is believed to be a mechanism of renal fibrosis. Chronic kidney diseases have emerged as major public health problem worldwide because of the limited renal regenerative potential. Therefore, understanding the complex and intricate mechanisms underlying these processes may improve the prognosis of these diseases by the development of novel therapies to improve renal function and prolong survival of affected patients. This review is aimed at describing the processes of EMT which underlies renal fibrosis and discusses the potential clinical strategies based on the findings of our and other groups that could prevent renal tubular EMT, block the development and progression of fibros",
        "label": 1
    },
    "1537": {
        "output": "# Author contributions\n[MEL] Kwak developed the code, wrote the paper, and collected data.\n\nThis work is supported by a KAKENHI grant of JP18K17618,  AMED-JP19lm0203012. This work is also supported by the Global Alliance Initiative Against Tuberculosis and Lung Diseases, Japan.\n[/MEL]\n\n# Funding\nNone.\n\n## Data availability\nThe clinical trial data used to support the findings of this study have been deposited with the Research Data Service (RDS) at Academia Sinica (http://hdl.handle.net/20.500.11766/44158) and the 1KJC dataset is available at https://www.ncbi.nlm.nih.gov/Traces/study?acc=PRJNA482652.\nThis clinical trial data are publicly available.\n\n## License\nCC BY 4.0.\n\n## Abbreviations\nRBV, Ribavirin; HCV, Hepatitis C; STATA, Statistical Analysis System; IFN, Interferon; DTaP, Diphtheria, tetanus, acell",
        "label": 0
    },
    "1538": {
        "output": "Here is the full source code you can run:\n\n\t<%\n\tuser_id = session[:id]\n\tpatient_id = params[:p_id]\n\tpatient_explanation =params[:p_exp]\n\tclinical_trial = params[:clinical_trial]\n\t# patient_id = \"1\" # \uc608\uc81c \ud658\uacbd\uc774 \uc544\ub2cc \uc2e4\uc81c \ud658\uacbd\n\tif current_user.has_permission(:access_clinical_trial)?\n\n\n\t\tclinical_trial_name = clinical_trial.clinical_trial_name_eng\n\t\tclinical_trial_status = clinical_trial.clinical_trial_status_en\n\t\tclinical_trial_type_en = clinical_trial.clinical_trial_type_en\n\t\tclinical_trial_phase = clinical_trial.clinical_trial_phase_en\n\t\tclinical_trial_start_date_en = clinical_trial.clinical_trial_start_date_en\n\t\tclinical_trial_en = clinical_trial.clinical_trial\n\n\t\tif current_user.has_permission? :view_user_case, :clinical_trial)\n\t\t\tclinical_trial_users = current_user.clinical_trial_users(clinical_trial)\n\n\t\telse \n\t\t\tclinical_trial_users = current_user.clinical_trial_users(clinical_trial)\n\n\t\telse\n\n\t\tcase clk_types_ids = current_user.clinical_trial_users(clinical_trial).map{ |user| user.clinical_trial_user_clinical_trial_clinical_trial_clinical_trial_clinical_trial_type_en }\n\t\twhen nil => \"All\"\n\t\twhen [] => \"All\"\n\t\twhen 0",
        "label": 0
    },
    "1539": {
        "output": "### 5) Randomization\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to assign patients to randomization. Randomization is the process of assigning patients, who are not eligible for all intervention arms, to intervention groups. \n\nHere is the example of randomization:\nLet's randomize the patients to the treatment group and the control group. We set the seed random number generator to 127.\nRANDOM NUMBER GENERATOR seed=127 randomize <-function(x,y) { random.int <-runif(n=0, lower=c(0,...,NA), upper=c(0,...,NA)) } patients_assign <-function(x,y) { if(x==y) patients_assign <-randomize(y, x=127)else{ patients_assign <-randomize(y, x=126) } } patients_assign",
        "label": 0
    },
    "1540": {
        "output": "<EOD> The effects of anisotropic straining on the adhesion properties of polydimethylsiloxane surfaces.\nPolydimethylsiloxane (PDMS) is commonly used for biomedical applications, as well as in optics and microfluidics, and is known for its high adhesion and low friction coefficient. Often, microfluidic devices are subjected to significant deformation. In this paper, the effects of three different deformation models on the adhesion properties of PDMS surfaces are investigated. Two deformations are purely uniaxial and are characterized by the applied pressure and the stretch ratio. The third deformation corresponds to an affine deformation, representing the effect of changing temperature on the deformable PDMS substrates. Three different measurement protocols are then defined which account for the varying anisotropy and orientation of the deformation gradient in each of the three cases. The resulting adhesion work is then quantified as a function of the contact pressure. Finally, the adhesion properties of the three deformation models are characterized and compared to adhesion energies that have been widely used in similar devices.<EOD> The 2008-2012 National Survey on Drug Use and Health: design, methods, and performance\nObjective: This paper describes the design, methods, and performance of the 2008\u20132012 National Survey on Drug Use and Health (NSDUH), an annual cross-sectional survey of civilian non-institutionalized US residents aged 12 and older. Methods: The sampling frame consists of an annual sample of addresses from the US Postal Service\u2019s Delivery Sequence File. The 2008-2012 NSDUH has been conducted to monitor substance use disorder and other mental health conditions and is available online. Results: Estimate reliability, measured as 95% confidence intervals around estimates, is one of the most important indicators of survey performance. Overall, for most estimates, the 95% confidence intervals were 2\u201310 percentage points wide for almost all estimates with 60-person or greater weights. There is variation by year, demographic characteristics, and substance used, and sometimes for questions with the smallest person weights (e.g. past 6-month and lifetime nonsu",
        "label": 2
    },
    "1541": {
        "output": "## \u21d7\u21d7\u21d7\u21d7\u21d7\u21d7\n[NAME] is working as a geneticist in a large hospital. He has been a team member in some genetics courses and projects. He is currently working on an analysis project aimed to the detection of SNPs in the human genome which are involved in the regulation of gene expression. The project includes the identification of the genomic characteristics of SNPs that are associated with human diseases.\nThe SNP is a single nucleotide variant in the DNA sequence. Such genetic variants are often located in the non-coding regions of the genes which can lead to differences in gene expression by altering the function of a gene or regulating the structure of a gene. In the human genome, SNPs are common. More than 10,000,000 SNPs can be found in about 90% of all people.\nIn order to identify SNPs, [NAME] works with the [SITE]. One of the features that the [SITE] uses is the [QUALITY] of the SNP. The SNPs can be characterized by two categories of quality; high or low. SNPs with a low quality value is less well-established and has to be further investigated and checked.\nThe functioning of the [SITE] starts with the retrieval of information of all genetic variants from genome databases (GDs). The [SITE] is then able to determine with a filter the SNPs related to the human disease. \n\n\n\n<EOD> Clinical Trial Strategies for the Development of New Treatments for Painful Diabetic Neuropathy.\nDiabetic neuropathy is a frequent complication of diabetes mellitus. Clinical manifestations of neuropathy, which can affect sensory and autonomic nerve fibers, impair quality of life and are associated with increased risks of morbidity, falls, and amputations. The pathologic features of diabetic neuropathy are complex, and the molecular mechanisms remain poorly understood. This review describes the pathophysiological and clinical effects of diabetic neuropathy, as well as the use of symptoms-based assessment",
        "label": 1
    },
    "1542": {
        "output": "To get a list of patient notes you can request as a Python list object using `triallist.get_list_of_patient_notes` [see the source code of your exercise for details on all possible parameters of this function].\nThis function calls the following function:\n`def get_data_from_file(fullfile_name, trial_notes_output_column_index) -> List[Tuple[Datetime, JsonTable, String]]:`\nThis function performs a three step process. \n First load in the data in a json array\n Second, create a list of the patient_notes.json column in a list\n And third, join back the columns.\nNext, you can create a class for output:\n\"\"\"A class to output the trial-level eligibility\"\"\"\nfrom __future__ import print_function \n\nclass PrintTriallNoteList\n\tdef __init__(self, trial_id, clinical_trial=None):\n\t\tself.trial_id = trial_id\n\t\tself.clinical_trial = clinical_trial\n\t\tself.trial_notes = None\n\n\t\t#print self.clinical_trial \n\t\tself._createTrialNotes()\n\t\tself.print()\n```\n\nRun your code using the command:\n```\n[INST] python main.py \\\n-c TrioNLP \\\n-j Patient_Assistant (your_first_file_name) trial_id=TRIAL_ID \\\n[END]\n```\nPlease see your exercise code for details on the parameter of this function.\nNow you will receive one JSON file in the folder named `Data/Output/Trial_Data` containing a list of patients and the eligibility information for them.\nAlso, you will get four output files containing the trial-level eligibility for each of four trials.\nPlease see your exercise code for details on how to parse this JSON data.\n<EOD> The Association of a Factor V Thr 506 Mutation with Venous Thrombosis in Family Members of Patients with Thrombophilia\nSummary An inherited deficiency of the coagulation inhibitor plasminogen activator inhibitor type 1 (PAI-1) predis",
        "label": 0
    },
    "1543": {
        "output": "## Tutorial for the assessment of eligibility 1.1.1 patient12\nPatient12 comes with the diagnosed inclusion criteria of the clinical trial. To assess his eligibility he must comply with the general inclusion criteria and exclusion criteria of the clinical trial.\nFor example, the general inclusion criteria for an OA trial are: \nInclusion criteria:\nAge, 40-75 years of age\nHave clinical moderate to severe knee or hip OA diagnosed by criteria outlined in appendices 1 and 2\nHave OA of both knees and hips\nHave had some benefit from and are currently on a stable dose or dose titration schedule of the approved non-Sysmare.\nThe patient doesn't have any problems with this general criterion.\nIf we consider his symptoms and findings that he meets the eligibility criteria, we get:\nHe doesn't have severe problems with the exclusion criteria either, so we get:\nTrial-level eligibility: 1) Not relevant.`.\n\n## Patient2\nPatient2 is a special case for you. First of all, his HCV infection is incompletely treated. He still has active infection. So, he has to get rid of it first before he tries the clinical trial. If you don't know how to check it, try to click on the blue hyperlink to see information about it: HCV RNA test and test date.\n\n## 1.2.2 patient11\nSo, the patient complies with clinical trial inclusion criteria and exclusion criteria. All you have to do is to decide whether the patient should be eligible for the clinical trial or not, then enter your rating on the screen and click `submit`.\n\n## Let\u2019s go\n\n# Cleanup:\nMake sure the patient names match the patient numbers.\n\n## [INST] Tutorial for the assessment of eligibility 1.2.3 Patient11\nPatient11 is a 66-year-old woman who has been suffering from HCV since she was diagnosed with hepatitis 3 years ago. Her medical history is non-significant. She is on IFN, RBV and direct antiviral drugs for",
        "label": 0
    },
    "1544": {
        "output": "In the end, you also have to create a checkpoint based on the patient's age. You should check the checkpoint in the last line with `Last checkpoint:`. In our example, we are going to create the checkpoint for one month.\n\n\n\n\n\n\nLast checkpoint:1 month\nNow you can see your report as follows:\n\n[![Last checkpoint](https://user-images.githubusercontent.com/55203497/102625202-3c8e0700-3b6f-11eb-9662-025e75de7b36.png)][22]\nNote that you can specify different levels of checkpoints without changing the logic of the program. Checkpoints also allow users to view reports even if the program is currently running based on a specified point in time.\n\n## Other functions of pyhton\nThrough the provided functions in this tutorial, you have performed many daily activities such as printing, reading files, listing functions, etc. in your workspace. \n\n\n`Python -h`\n\n`python -m pyautogenerate`\n\n`python -m ping`\n\n`python -m ping -t 1`\n\n`python -m ping -t 2`\n\n`python -m ping -t 3`\n\n`python -m ping -c 1`\n\n`python -m ping -c 2`\n\n`python -m ping -c 3`\n\n`python -m ping -o pyd`\n\n`python -m ping -l pyh`\n\n`python -m ping -k ypt`\n\n`python -m ping -p`\n\n`python -m ping -m m`\n\n`python -m ping -u u`\n\n`python -m ping -r r`\n\n`python -m ping -u r r`\n\n`python -m ping -q r q`\n\n`python -m ping -s d d`\n\n`python -m ping -s s s`\n\n`python -m ping -t 1`\n\n`python -m ping -t 2`\n\n`python -m ping -t 3",
        "label": 1
    },
    "1545": {
        "output": "[STUDY] \n\nIf you have any further questions, feel free to consult @hailiang_yin and @vitebsk. [/STUDY]\n\n[/STUDY - SAVE_TRIALS]\n\n## Using R commands\n- `formatters.save_trials()` is used to save trial summaries to file. These trials include a unique trial identifier in the R data object. The input is the patient-level trial assessment.\n- `formatter.save_trials()` provides a function to save a trial summary to CSV file. Each trial is represented by a key with a trial identifier and the value of `formatter.save_trials()` will include a tabular summary of all trials (one row per trial).\n- `summary.save_rdata()` is a function to save a tabular summary to Rdata. The input is the patient-level trial assessment. If patients are included in multiple trials, each trial will be represented by a row in the Rdata object. Each trial's row may be used to save the corresponding trial summary to a trial-level CSV file.\n- `load_trials()` is a function to load the saved trial summaries and assign it to a formatter.\n\n\n[/STUDY - SAVE_TRIALS]\n\n## Using R data structure\nUse the R data structure to write patient summaries. Each line in a summary should be saved as a column in a table. In this case, the output is a Rdata file. Each row in the table represents a patient's summary, and the value in each column from the first to the `num_columns` column is the corresponding element of the summary. Patients will be listed in the `id` column. The value will be `0` if a patient is included in eligible to be included in the trial. The value will be `1` if a patient is included in the excluded to be included in the trial. The value will be `2` if a patient is excluded from the trial. \n\n### Saving data to R object\n\nYou can save summarized data to R object by using the `formatters.save_trials()` function. The input should be a table with variables `trial` and `summary`. `tri",
        "label": 2
    },
    "1546": {
        "output": "In each row the last digit of the patient's ID, patient note and the trial-level eligibility are recorded. All records should be in two columns separated by vertical bar. \nIn one trial-the first one in your exercise-the eligibility is the average of patient's notes. \nHere is your example trial information file for the first trial.\n\n\n```\n00 0.0 1\n10 1.0 2\n20 2.0 1\n\n11 1.0 2\n21 3.0 1\n22 2.0 1\n\n12 1.0 2\n22 5.0 1\n23 2.0 1\n\n13 1.0 2\n23 3.0 1\n24 2.0 1\n\n14 1.0 2\n24 2.0 1\n25 3.0 1\n```\n\n### Example 1\n```\n-v \n\n\n[1] 00 (0.0) \u2190 patient ID, eligibility, age\n[2] 01 (1.0) \u2190 patient note, gender\n[3] 10 (2.0) \u2190 trial-level eligibility\n[4] 11 (3.0) \u2190 patient ID, eligibility, age\n```\n\n### Example 2\n```\n-v \n```\n### Example 3\n```\n-v \n```\n<EOD> .\nThe incidence of congenital anomalies of the kidneys and the urinary tract is approximately 0.3%. A complex surgical management of congenital, obstructive lesions requires strict cooperation within an interdisciplinary team. In the first part of our paper different anatomical developmental anomalies as well as their pathogenesis are discussed, and the importance of preoperative diagnosis is emphasized in our experiences with 25 children. A new technique of percutaneous placement of a retrograde stent in distal-ureteral stenoses is reported. In the second part we analyze the clinical results on a short-term basis (8 days to 11 months)",
        "label": 0
    },
    "1547": {
        "output": "# Authorship\n\n## Contributorship\nContributorship roles were defined prior to the work starting. These are:\n\n### Roles included in the analysis\n- [a.name]. Co-Developer of the software.\n- [b.name]. Code Reviewer.\n- [c.name]. Code Reviewer.\n- [d.name]. Code Reviewer.\n- [e.name]. Code reviewer.\n- [f.name]. Code Reviewer.\n- [g.name]. Code reviewer.\n- [h.name]. Co-developer.\n<EOD> Surgical Treatment of a Giant Intramedullary Myelolipoma Presenting with Transient Radiating Pain: A Case Report and Literature Review\n\nObjective:Introduction: Myelolipoma is a rare tumor that occasionally occurs in the posterior mediastinum and spinal canal. It typically develops in the adrenal gland within the presacral or retroperitoneal regions of adult women. Myelolipomas are benign tumors, and are characterized histopathologically by abundant adipose tissue as well as varying proportions of hematopoietic cells. Although they are not thought to grow, myelolipomas occasionally form expansile masses, in which case they may cause symptoms such as back pain and sciatica due to spinal cord compression. Case Report: A 62-year-old male visited our hospital with intense pain radiating bilaterally from the buttocks to his calves. MRI revealed an intramedullary mass in the cauda equina and the myelolipoma was observed to be located within the intrathecal space. Conventional open surgery was carried out with sufficient decompression, which relieved the patient's symptoms. Conclusion: The definitive diagnosis of myelolipoma is histopathological, and its definitive treatment is complete tumor removal and adequate bone grafting of the spinal canal.\n\n# Introduction\nMyelolipoma is an extremely rare disease in which multiple adipose tumors are formed in the bone marrow [bib_ref]  Myelolipoma in the region of the cauda equina: case report, Hattori [/bib_ref] . It",
        "label": 2
    },
    "1548": {
        "output": "11. Create the function to get the `BioData` object with the required variables. Then, generate the data frame and call the `Trial_eligibility` function to perform the task. \n\n\n\n# Data Analysis:\nThe patients of the previous example are given as data in the file named 'Clinical_trial_Patients.csv' in the folder /examples. Each row of the data frame is a patient and the data set are the following five variables: Patient_ID, Malignancy, Eligibility, Trial_ID, and Trial_Name. To perform the data analysis, an R data frame will be imported. The following command to read the data set as a data frame from a csv file into R is employed:\n\n```r\ndat = read.csv (system.file ('/examples/Clinical_trial_Patients.csv', package = package.file))\n```\n\nThe names of the variables are listed as column names in the data frame to understand the data set and they are given in the column names of the data frame object, namely 'Patient_ID', 'Malignancy', 'Eligibility', 'Trial_ID', and 'Trial_Name'.\n\nIf this line was not run, the output would be `null`, i.e., the data set is empty.\n\n\nThe data set is split into two data frames by their trial-level assessment into the data frame including the patients who were eligible for a particular clinical trial and the data frame with non-eligible patients. The first data frame is called Trial_eligible and the second is called Trial_ineligible. The command to divide the data into two data frames with the variable called 'Eligibility' with 0 (for excluded) and 1 (for eligible) is as follows:\n\n```r\nEligible_data = select(dat, Eligibility)\nIneligible_data = select(dat, -Eligibility)\n```\n\nThe output of this command is the data set with patients who were not eligible or excluded. The Eligible object is a 359-row and 5-column data frame where the column names are the same as 'Patient_ID', 'Malignancy', 'Eligibility",
        "label": 0
    },
    "1549": {
        "output": "## RQ4.1.2 The trial level assessment\nSimilar to `Trial-level eligibility`, the `Trial assessment` is evaluated by `TrialAssessmentClinicalNote` class. First of all, you should check whether the clinical note is eligible by comparing the clinical note and the trial's 'Reassessment' note. If they are compatible, continue to compare the clinical note and the trial's 'InclusionCriteria` and `ExclusionCriteria` and assign an eligibility score to the clinical note, which is finally summarized in the form of trial-level statistics:\n[[EVALUATOR]]<jupyter_code>result = TrialAssesmentClinicalNote(clinical_note, trial, \"HepC1\")\ntrial_level_elib_data.loc[clinical_note_data.index,\n                     \"Trial-level assessment\" :\n                        clinical_note.intersection(trial_level_elib_data.loc[clinical_note_data.index,\n                                                                                     'Trial-level eligibility' : 1])\n                        .intersection(trial_assesment_data.loc[trial_level_elib_data.index,\n                                                                    'Reassessment' ]).intersection(trial_assesment_ data.loc[trial_level_elib_data.index,\n                                                                'Inclsuion/Exclusion Criteria' ]).intersection(trial_assesment_ data.loc[trial_level_elib_data.index,\n                                                                    'Exelusion Criteria' ], trial_assesment_data.loc[trial_level_elib_data.index,\n                                                                    'Inclsuion Criteria' ])\n                        .intersection(trial_assesment_data.loc[trial_level_elib_data.index,\n                                                                    'Inclusion Criteria' ])\n)\ntrial_level_elib_data[\"Trial-level assessment\"].count()\n[[ANSWER]]<j",
        "label": 1
    },
    "1550": {
        "output": "<EOD> Glycolysis in isolated myocardial mitochondria: effect of glucose and of glycolytic intermediates.\nMitochondrial glycolysis was studied in suspensions of heart mitochondria incubated in 2.0 ml of medium containing sucrose, 105 mM, sucrose, 85 mM, or glucose, 10 mM, with added sodium azide. The effect of addition of glycolytic intermediates: fructose-1,6-diphosphate (FDP), fructose diphosphate, glyceraldehyde, ribose-5-phosphate or dihydroxy acetone phosphate (DHAP) on mitochondrial O(2) consumption (mVO(2)) was compared for the sucrose medium. The magnitude of glycolytic ATP production was determined by a microdialysis technique using luciferin-luciferase and a luciferin-luciferase-insensitive dialyser. Glucose, at a high rate of glycolysis was determined to be 79% by mVO(2) and 21% by ATP production, or 90% and 10%, respectively, for a low rate of glycolysis. The relative contribution of glycolysis to ATP production is also affected by the rate of glucose metabolism. FDP inhibition of mVO(2) was 59% for a high rate of glucose metabolism and decreased with increasing time of incubation. Glyceraldehyde increased mVO(2) 34%, while both ribose-5-phosphate and DHAP stimulated O(2) uptake approximately 22% compared to the sucrose medium. The mitochondrial effects from glyceraldehyde, ribose-5-phosphate and DHAP were additive. Inhibition of glycolysis by a glycolytic inhibitor, iodoacetate or a hexokinase inhibitor, N-ethylmaleimide, did not change the stimulation on mVO(2) observed with FDP or a high rate of",
        "label": 1
    },
    "1551": {
        "output": "> pegIFNalpha2a = factor() | \n> ribavirin = factor() \n\n> # Assess patients as a trial-level eligibility\n> trialLevelEligibility <- ifelse(pegIFNalpha2a == 720, 1, 0) + ifelse(ribavirin == 400, 0, trialLevelEligibility)   \n> ## Levels of factor in trialLevelEligibility\n> levels(trialLevelEligibility)\n> ## Characterization of factor \n> ifelse(ribavirin == 400, 428, ifelse(ribavirin > 0, \n> pegIFNalpha2a == 180, \n> pegIFNalpha2a == 240, \n> pegIFNalpha2a == 480, \n> pegIFNalpha2a == 720, \n> pegIFNalpha2a == 1440, \n> pegIFNalpha2a == 1440 + 6, \n> pegIFNalpha2a == 180, \n> pegIFNalpha2a == 720, 428)))) \n## ## NULL\n\n> trialLevelEligibility $ ribavirin\n> ## [1] 428 \n\nThe eligibility of this individual is `2) Eligible`.[/INSERT]\n\n[Next: Part 7. Rejecting Patients](#part-7-rejecting-patients)<EOD> .\nObjective: To study the effect of intestinal myeloid-derived suppressor cells (MDSC) on the development of atherosclerosis (AS) and its mechanism to provide a new perspective for exploring the pathogenesis of the disease. Methods: From December 2019 to October 2020, patients with acute ischemic stroke (AIS) in our hospital were enrolled in this study.The patients were divided into cardioembolic stroke (CES) and non-cardioembolic stroke (nCES) groups, and intestinal MDSC levels in peripheral",
        "label": 0
    },
    "1552": {
        "output": "Here is a complete patient note snippet that includes the trial-level eligibility statement:\nYou should repeat that line as many times as needed depending on the number of patients in this clinical trial.\n\n## [INST] Snapshot\nAnother option is to report the trial-level eligibility separately by following the format below: \nSaved trial-level eligibility in list format:\n\n## Trial-level eligibility saved\nSaved list formats in JSON:\n\n## {\"trial level eligible 1\": \"2) eligible\",\"trial level eligible 2\": \"2) eligible\"}\nSaved JSON in text file:\n\n## Trial-level eligible 1 trial-level eligible 2\n\"[\"\"2) Eligible\"\",\"\"2) Eligible\"\"]\"\nSaving in a separate data file is good practice, but if you save it as a JSON file you can also convert it to a CSV file by using the [CSV] snippet.\n\n## [CSV]\nSaving in a separate text file:\n\n## Title: oxypr trial\n\"Trial-Level Eligible 1\": \"2) Eligible\",\n\"Trial-Level Eligible 2\": \"2) Eligible\"\nSaving in CSV file:\nTrial-Level Eligible 1, Trial-Level\nEligible 2\n\"2) Eligible\", \"2) Eligible\" The last line by `Trial-Level Eligible` should be repeated in the last line.\n\n## [CSV]\nTrial-Level Eligible saved\n\n## [INST] EndOfTest\nYou will notice that `EndOfTest` and `TestEnded` are the same: you should only need to put either one into your snippet. You will use `EndOfTest` at the beginning and `TestEnded` at the end of the test.\n\n## Snapshots\nSNAPT is a test/run-time documentation toolkit for Java developers. Test cases snapshots can be taken within the following way:\n\n* Running JUnit test cases.\n\n* Running Test Cases (run-time).\n\n## Snippet usage\n\n## [INST] SnapShot [",
        "label": 0
    },
    "1553": {
        "output": "# Expect Answer\nIn R, expect_answer is a function that converts a vector in the format of [0, 1] to [TRUE, FALSE] by a one-hot encoding procedure. Please remember to reset `options(jtools)` to the default setting to avoid inadvertent errors.\n>> expect_ans $\n\n\nTesting for eligibility\n\n# Run the example\n> clr_data <- clr_data <----- The data used to test\n\n\nTest results.\n>> test_eligibility \n\n\nTest result.\n>> clr_data \n\n\nLet's find the corresponding patients in which the trial-level eligibility are 0 and 2. To get the information of the patient in which the trial-level eligibility are 0, we can just type:\n\n## Test eligible patients\n\n\nYou can find the total number of eligible patients = 33 out of 50.\n\n# Test eligible patients\n\nIf we want the information of the patient in which the trial-level eligibility are 2, \n\n## Test eligible patients\n\nIf we want to look whether the gender of the patient is female or male, we can perform: `> set.seed(.01)`. The set.seed will set the random seed. Random.seed will help you to reproduce identical results from one time to another by controlling the seed source for pseudorandom number generator. If you want to vary a parameter in the experiment, please set one specific number for this experiment.\n\n## Gender and gender \n\n## Number of eligible patients and number of eligible patients \nThe reason of why we don't find any female patients is because there are just 17 female patients in the clr_data.\n\n## Number of eligible patients and number of eligible patients \nYou should find that there are 17 patients which are all the female patients who are eligible in this clinical trial.\n\n# Randomization\n\n# Run the example\n\n> clr_data \nPlease create a patient number for each patient to be able to distinguish patients from one another during randomization. If we are going to have 100 patients, please randomize the number for 100 patients.\n\n##",
        "label": 2
    },
    "1554": {
        "output": "<TABLE class=\"wikitable\" border=\"2\" align=\"center\" width=\"85%\">\n\t<TR>\n\t\t<TH>Code</TH>\n\t\t<TH>Description</TH>\n\t</TR>\n\t<TR>\n\t\t<TH COLSPAN=\"3\">\n\t\t\t&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\n\t\t\t\n\t\t\t\n\t\t\t<CAPTION>\n\t\t\t\t[INST] <NAME>, 2014, p 5\n\t\t\t</CAPTION>\n\t\t\t\n\t\t\t<SPAN class=\"pagenumber\">197-200</SPAN>\n\t\t\t<BR><BR>\n\t\t\t\n\t\t\t<SPAN class=\"normalfont\">1. <STRONG>[Ask]</STRONG> the patient whether he wants to participate in a clinical trial based on his general situation, the potential benefits and risks of the clinical study, and the patient's medical history.\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<SPAN class=\"normalfont\">Note: [Ask] is optional, although suggested, since it provides a more human approach for communication, and is also in line with good clinical practice (GCP), which advocates that patients are informed about trials when they are in the clinic. However, you should determine the need of information in your respective settings. [Ask] could be omitted and <STRONG>Assess eligibility</STRONG> may proceed smoothly. </SPAN>\n\t\t\t\t\n\t\t\t\n\t\t\t<SPAN class=\"normalfont p\">\n\t\t\t\tNote: A clinical trial is performed in accordance with the approval of the national and/or local ethics committees. In some countries, the ethics committees do not approve for such informed consent procedure and clinical trials could be performed without asking for informed consent.\n\t\t\t</SPAN>\n\t\t\t\n\n\t\t</TH>\n\t\t<TH COLSPAN=\"3\">\n\t\t\t<P>\n\t\t\t\t\n\t\t\t</P>",
        "label": 1
    },
    "1555": {
        "output": "![](https://uploads.ccro-international.de/file/1620335465/04%20Screen%20Shot%202018-08-03%20at%2010%252512%20AM%20.png)\n\n\n## Hints and Common Error Traps\n\n\n* You may get error `502 Bad Gateway`. That is just something happens and you can check another link. For example, [this](https://data.mendeley.com/datasets/rts537smsn/) file is also a good way to repeat the exercise, which you can refer to here: [https://data.mendeley. com/datasets/rp4trg482g/raw](https://data.mendely.com/datasets/rp4trg482g/raw).\n\n* You can also run the notebook locally by running the notebook with `jupyterLab.ipynb` extension or `jupyter notebook -Pip` in a bash shell.\n<EOD> Coronavirus disease\u20102019 vaccine elicited durable cellular immunity: interim results and possible mechanisms of failure\n\nA c c e p t e d M a n u s c r i p t - 2 1 A c c e p t e d M a n u s c r i p t - 2 4 30) and T cell assay results of 20 individuals who missed the last vaccine dose for >5 months (late group). B) T cell response was measured in 20 healthy controls, 19 individuals after receiving a single dose of AstraZeneca (AZ) vaccine (early group), and 19 individuals between 5-7 months after the second vaccine dose (late group). C) The AZ vaccine-induced T-cell response in CD8 (black) and CD4 (red) of individuals between 8-10 months after the second vaccine dose (recent group) are compared with individuals 10-14 months after the second vaccine dose, and 14",
        "label": 1
    },
    "1556": {
        "output": "*If the answer is no, you should remove the patient from the recruitment list. Please answer the next patient.\n*If the answer is 1) Not relevant, you should keep the patient in the recruitment list and continue with the next patient. Please answer the next patient.\n*If the answer is 2) Eligible, you should print the trial-level eligibility on the paper (by`Triallevel eligibility: `) and keep the patient in the recruitment list. Please answer the next patient. \n\n### Exercise 1\n\nThis is the patient note for the new patient: \n\n```\nThe patient is a 59-year-old man diagnosed with CHB for 8 years. His past medical history is non-significant except for DM and hyperuricemia. He takes anti-diabetes drugs. The medical records show a patient with chronic hepatitis by HBcAb and HBeAb positive. He is HBV DNA negative for the past 6 months. He is on entecavir for the past month. The patient visits clinic because of worsening fatigue for a few days. The physical exam is remarkable for decreased skin turgor and tenderness over right upper quadrant. He refuses an abdominal ultrasound but gives urine and blood sample for studies. The patient has no alcohol intake history. The recent biopsy was positive for steatosis consistent with alcoholic liver disease and negative for hepatocellular carcinoma. The laboratory results are as follows:\nAnaemia 12.3 \nTransaminases 72/49 \nFerritin 490 \nLactate dehydrogenase 525 \nAST/ALT ratio 1.1 \nINR 1.1 \nHgbA1c 7.2 \nFBS 93 \nTotal bilirubin 1.4 \nCreatinine 1.0 \nALC 23.0 \nAnti-HAV IgG < 20 \nAnti-HCV Ab < 20.8 \nAnti-HBs 23.2 \nAnti-HBc",
        "label": 1
    },
    "1557": {
        "output": "Examples - [Trial-level eligibility: 0) Excluded ]\n[Trial-level eligibility: 1) Not relevant ]\n[Trial-level eligibility: 2) Eligible ]\n##[Trial-level eligibility: 2) Eligible ]\n\n### Question1\nWhich of the output lines should you skip?\n\nA. None\nB. The lines for the following trial-level eligibility levels: 0) Excluded, 1) Not relevant.\nC. Lines beginning with Excluded patient ID or Skip for patient.\nD. All the output lines\nE. The lines for the following trial-level eligibility levels: 1) Not relevant, 2) Eligible.\nYou should mark the best answer.\n!Tip\nFor example, if your trial-level eligibility is 0) Exclude and the patient has 38 days, 49.1, male, and 50.9 years old, you should skip the Exclude patient ID line.\n\n### Question2\nIf the patient note says `The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months`, what kind of the trial-level eligibility will you calculate?\n\nA. 1) Eligible.\nB. 2) Eligible.\nC. 2) Not Relevant.\n\n\nD. 2) Eligible.\nE. 1) Not Relevant.\n\nThe correct answer is **Explanation**\n[Because the patient notes of the trial are Exclude and the age and the gender are 49.1 and male, this is a negative value of the patient notes and only Exclude means Excluded. However, Exclude means Excluded but its patient note is Not Relevant. We should skip Exclude patient ID and skip Skip for patient as well. We must skip the Exclude patient ID line because we only want to evaluate Not Relevant patient notes. If it is Not Relevant, we should skip Skip for patient for the calculation of the",
        "label": 1
    },
    "1558": {
        "output": "```r\nlibrary(momentums)\n\nhdi <- mhr(\"Hepatitis Diseases\")\nclt <- shi(\"Hepatitis B and C in Taiwan Clinical Trial\",\n           hdi = hdi)\n\ndf <- mr(\"Hepatitis B and C in Taiwan\",\n          clt = clt)\n\ndf %>% eligibility(trial_id = clinical_trial.id) %>% summary(title) %>% ggplot(aes(title, assessment)) + geom_errorbar(aes(yerror = 1.0 / 3, x = 0.5, ymin = 0.5 / 3, ymax = 0.5 / 3)) + scale_y_continuous(limits = c(0,1) + 0.001) + ggtitle(\"Eligibility\") + theme_bw() + theme(panel.grid.major.x = element_blank(),\npanel.grid.major.y = element_blank(),\npanel.grid.minor.x = element_blank(),\npanel.grid.minor.y = element_blank(),\npanel.border = element_blank())\n\n```<EOD> Differential regulation of human myeloid antigen CD15, intercellular adhesion molecule-1, platelet endothelial cell adhesion molecule-1, and E-cadherin by interferon-gamma, lipopolysaccharide, and tumor necrosis factor-alpha.\nAntigen CD15 (Leu-M1 antigen) is a myeloid-restricted antigen with a cell adhesion function. It is rapidly induced on the surface of blood neutrophils when they become activated by bacterial lipopolysaccharide (LPS) or interferon-gamma (IFN-gamma). In this paper, two possible mechanisms for CD15 expression have been investigated. First, the involvement of IFN-alpha, IFN-beta, IFN-gamma, and LPS in regulating CD15 expression was analysed. Results showed that LPS directly increased CD15 expression on neutrophil lineage cells HM56, HL60, and U",
        "label": 2
    },
    "1559": {
        "output": "<EOD> Effects of oxygen on the growth of Escherichia coli cultivated in serum.\nA microbiological test has been developed to assess the aerobic requirements of facultatively anaerobic microorganisms on the basis of an oxygen transfer measurement system. The growth of Escherichia coli in horse or rabbit serum in which the oxygen transfer was measured was shown to be the same as the growth in control cultures of E. coli growing under strictly aerobic conditions. The growth of E. coli was examined at different oxygen potentials and different oxygen transfer rates in horse serum. The cells grew at a specific rate in the serum which was different from that in the control medium and increased their final cell density. The effect of oxygen on different strains of E. coli strains was studied.<EOD> Aminoaciduria in the Eunichal Zebrafish: The First Known Disease Model for MCPH1 Disease\n\n\n\n# Introduction\nMcph1, or Rint1, is a tumor-suppressor gene that encodes a centrosomal protein required for centriole duplication and DNA repair [bib_ref]  Regulation of C. elegans centrosome duplication by cell cycle checkpoints and a..., Kemp [/bib_ref]  [bib_ref]  MCM2-7 complexes bind chromatin in a distributed pattern surrounding the origin recognition..., Edwards [/bib_ref]  [bib_ref]  Zebrafish MCPH1 functions within the G2/M checkpoint, identifying a link between chromosome..., Kambadur [/bib_ref]  [bib_ref]  MCM10 mediates REC7-independent intertelomeric recombination, Zhang [/bib_ref] . It was discovered in yeast as a tumor suppressor (named Rint1) [bib_ref]  RINT-1, a novel protein required for RAD51-independent and chromatin-mediated homologous recombination, Shamim [/bib_ref]  and subsequently in humans (named RBMC5, P66, and MCM) [bib_ref]  Identification of the gene coding for a new human ras-related protein, Laser [/bib_ref]  [bib_ref]  Identification of murine RAD21L, a novel member of the RAD21/REC8 subgroup of..., Parish [/bib_ref]  [bib_ref]",
        "label": 2
    },
    "1560": {
        "output": "<EOD> .\nThe efficacy of telenutrition in monitoring the diet and lifestyle of patients is comparable to traditional methods. A significant advantage of telenutrition is the possibility of continuous supervision and prompt correction of possible diet errors, as well as the elimination of unjustified barrier due to transport costs. The cost of a telenutrition consultation can be up to 5 times less than a hospital visit. This article describes the results of the systematic analysis of the results of previous telenutrition studies, including a small number of studies on the efficacy of the remote method. Telenutrition is used in 1443 clinical and experimental nutrition studies worldwide, of which 111 are published in the PubMed database. Most of the work is devoted to obesity, cardiovascular, gastroenterological, neoplastic and bone marrow diseases. The main areas of study that need to be expanded include the development of new approaches for determining the effectiveness of telenutrition and its effect on the clinical and paraclinical characteristics of patients.<EOD> .\nPURPOSE\nThis pilot study evaluates the feasibility of a psychotherapeutic group intervention including physiotherapy for women diagnosed with fibromyalgia syndrome.\n\n\nMETHOPD\nIn this intervention eight female patients participated who had a fibromyalgia diagnosis, high levels of catastrophizing, and low levels of coping and disease control. They met once weekly for 13 group sessions with each session divided in time for psychotherapy and physiotherapy. The treatment was developed using the biobehavioral model for chronic pain. A semi-structured interview was developed after qualitative evaluation of the existing psychotherapy treatment programs. Three research assistants trained in the administration of the psychotherapy treatment program and in the administration of the psychometric evaluation instruments conducted the interviews every month prior to and following the intervention. All of the instruments were repeated every month during the group intervention to determine the pre-post test improvement level and to detect the rate of improvement of the therapeutic process and the evolution of the symptoms.\n\n\nRESULTS\nThere were no dropouts, indicating adequate acceptance of the treatment intervention. In addition",
        "label": 1
    },
    "1561": {
        "output": "Here is the test case.\n[INST-PROF] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications with side effects. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease,",
        "label": 2
    },
    "1562": {
        "output": "[INST] Let's practice the steps:\nLet's see some patient notes:\nPatient name: Joe Smith                                Trial: HCV422\nInclusion criteria: (Note that spaces and newlines are not required between items)\n1) Patient is diagnosed with type 2 diabetes.\n2) The patient is diagnosed with hepatitis C.\n3) Patient is a non-obese male.\n4) Patient is between 40 and 70 years of age.\nPatient age: 38 (male)                                         Trial: HCV423\nInclusion criteria: (Note that spaces and newlines are not required between items)\n1) Patient is diagnosed with type 2 diabetes.\n2) Patient is an alcoholic.\nPatient name: Mr. Jian Yang                          Trial: HCV424\nInclusion criteria: (Note that spaces and newlines are not required between items)\n1) The patient has type 2 diabetes. \nNow we have finished the first part. Here is the example code of the first part for reading patient data:  \n````python\n\n    with open('./hcv_examples.data/patient', 'r') as ifs:\n    fd = iter(ifs)\n    for line in fd:\n        if len(line) <= 0:\n            continue\n        m,n = line.split()\n        print('patient: %s' % m)\n        print('trial: %s' % n)\n        print('Inclusion criteria: %s' % '')\n        print('First inclusion factor: %s' % '')\n        for x in [y.strip() for y in line.split(',') if len(y) >= 1]:\n            print('%s' % x)\n        print()\n''\n````\nThe output is as follows:\n\n```\npatient: Mr. Jian Yang\ntrial: HCV424\nInclusion criteria:\nFirst inclusion factor: (age>= 40 & age<= 70) & (BMI>= 20 & BMI<= 35 ) & (sex= male ) & (diagnosis of viral hepatitis C",
        "label": 0
    },
    "1563": {
        "output": "**Clinical trial data are available in the PHARM file at [url:https://data.mendeley.com/datasets/38s3d3wj92/1].\n\n# Tutorial\nThis chapter provides some basics of working in MATLAB and how to interact with MATLAB from Python.\n\n\n## What is MATLAB's license?\nAs mentioned above, currently, MATLAB does not support sharing code and data. For the educational purpose of the course, MATLAB allows you to create local datasets and scripts in MATLAB. It is also possible to share data through Google Drive using these local data. You can use your MATLAB installation locally or from your Google Drive.\n\n## How do I connect to MATLAB?\n\n**Google Colab**\n- Sign in to Google Colab [url:https://colab.research.google.com/](new window) from your browser and select **Start a New 0 23 **\n- Copy and paste the code in the window as in the code block above.\nClick **Upload Data**.\n- Click **upload** in MATLAB.\n\n![image](https://user-images.githubusercontent.com/2996112/118893441-7ed7f080-b4bf-11eb-80de-db6497432724.png)\n\n- Select the data file from your Google Drive.\nClick the files button to access the files on Google Drive.\n- Copy and paste the code and press the Run button.\nClick **Upload Data**.\n- Click **upload** in MATLAB.\n\n![image](https://user-images.githubusercontent.com/2996112/118893470-943f4880-b4bd-11eb-814d-e4dc1bb23945.png)\n\n- Note: If the image above does not appear correctly, change the **Worksheet** to **Untitled workbook**.\n\n![image](https://user-images.githubusercontent.com/2996112/11889",
        "label": 2
    },
    "1564": {
        "output": "The first patient data set is prefilled; therefore, delete the content and save your answer file before closing the document to avoid its overwriting, then go to the next page. [*Answers of Tutorial 1*](https://docs.google.com/spreadsheets/d/18v_623HGwA9609D43RvhN3kHvhWyL93YxF4s38-KAo/edit?usp=sharing)\n\n[**Part 1-1**. Please check if a patient data set is in the set of the included and excluded patients.\n\n```\n\nIn the first row of the patient data set, insert a score of (1) for Included, (0) for Excluded (and for Not relevant do no action).\n\n```\nPart 1-1: the patient`s data in the following table are included in the set of inclusion criteria. Part 1-2: the patient`s data in the following table are not included in the set of exclusion criteria. Part 1-3",
        "label": 1
    },
    "1565": {
        "output": "A: You can do it manually by using the following syntax\n\n\n*\n\n*Let's think step by step.\n\n*First, you should define a list of patients and a list of Trials, like so. Each eligible patient is a tuple of the patient and trial code.\n\n*Second, for each patient, you should obtain and compare its trial name with the given one\n\n\n$patients    $trials    \n    ------            ------\n    {\"1\",\"2\"}           {\"A\",\"B\"}          \n\n$patients[\"1\"][\"Trial-level eligibility\"]\n\n$patients[\"2\"][\"Trial-level eligibility\"]\n\n$trials[\"A\"][\"Trial-level eligibility\"]\n<EOD> .\nThe immunological properties of 12 new chimerical vaccines containing polysaccharide-protein-polysaccharide conjugates of Streptococcus pneumoniae 4, 6B, 9V, and 23F, together with diphtheria toxoid and tetanus toxin C fragment, were comparatively studied (35 rabbits were intradermally immunized). It was shown that the chimerical vaccine with conjugate of pneumococci 4 with diphtheria toxoid proved to have the highest specific antibody formation and persisted for a long time. The vaccine with the following component composition: polysaccharide 9 with diphtheria toxoid and tetanus toxin, diphtheria vacine, and tetanus toxin is recommended to be used in a new diagnostic test-serological vaccination method for determination of tetanus and diphtheria immunity in children.<EOD> Molecular cloning and expression of two functional genes of the type\u2010III fatty acid desaturase in spinach (Spinacia oleracea). A comparison to genes from olive (Olea europaea) and pumpkin (Cucurbita maxima).\nType III fatty acid desaturase cDNAs were cloned from spinach leaves. These genes are differentially expressed according to the plant organ, being the most abundant in leaves and the smallest in dry seeds.",
        "label": 1
    },
    "1566": {
        "output": "If a patient's eligibility is classed as `1) Not relevant`, then your program can exit to the previous page so the patient will not be considered for eligibility for that clinical trial. \nIf the patient is classed as `2) Eligible`, then you need to press the button `Assign eligibility` to assign the patient to the trial that they were eligible for and to delete their details for other trials. [INST] \nIf you decide to choose the patient into a trial, then you should fill in the `Clinical Trial' of the assessment `Assign eligibility` button to which the patient's eligibility belongs, and the `Subject Identifier` will be filled in by the next button `Save Assignment` and the program will automatically fill in the trial's name. [INST] \n\n<table width=\"64%\" border=\"0\">\r\n\t<tr>\r\n\t\t<td width=\"50%\"><b>Date:</b></td>\r\n\t\t<td width=\"50%\" align=\"left\"><b>1/1/2018</b></td></tr>\r\n\t<tr>\r\n\t\t<td width=\"50%\"><b>Assigned by:</b></td>\r\n\t\t<td width=\"50%\" align=\"left\"><b>Shadi</b></td></tr>\r\n\t<tr>\r\n\t\t<td width=\"50%\"><b>Assigned Trial Name:</b></td>\r\n\t\t<td width=\"50%\" align=\"left\"><b>Clinical Trial 2 (Clinical Trial 2)</b></td></tr>\r\n\t<tr>\r\n\t\t<td width=\"50%\"><b>Reason for Assignment:</b></td>\r\n\t\t<td width=\"50%\" align=\"left\"><b>Eligible</b></td></tr>\r\n</table>\r\n\r\n\r\n\r\n\r\n\r\n\r\n[INST] Patients were asked whether they were willing to answer the questions about their experience and about possible interviews. Patients were also asked to participate in the follow-up after 6 months (24 weeks), and the completion was voluntary.<EOD> <gh_stars>100",
        "label": 2
    },
    "1567": {
        "output": "# Examples of the `trial-level eligibility` field\n\n| **Patient note**                                                | **Clinical trial**                          | **Trial-level eligibility**                                |\n| ------------------------------------------------------------ | ---------------------------------------------- | ----------------------------------------------- |\n| \\[INS]\\[INST]\\[1]. \\[NAME\\] is a 47-year-old woman with a history of migraines. She comes in for an evaluation for her annual eye examination.                                                       | \nThis is an example of a patient who will be excluded from \\_\\(INS\\)-[NAME] because the patient's age is less than 18. The patient is a \\_\\(INS\\)-[NAME] with \\_\\(INS\\)-migraines.                 | \nPatient also has hypertension, arthritis, chronic constipation, and mild depression. Her vital signs are blood pressure: 106/70, heart rate: 70 beats/minute, and respiratory rate: 16 breaths/minute. She appears to be in no distress. \nHer past medical history was remarkable for an allergic reaction to a drug approximately 2\u20103 years ago, atrial fibrillation for her heart rhythm, breast cancer, and a hysterectomy. \nOn physical examination: she was in no acute distressed with normal vital signs, alert and oriented, a blood pressure of 120/80 mmHg, normal cardiac, abdominal, and dermatologic examinations. Her lower extremity arteries showed no pulses, mild calf edema, and coldness to the hands.                                                                 | \n\\[INST]\\[1]. This is an example of a patient who will be included in \\_\\(INS\\)-[Name] because the patient is at least 18. The patient is a \\_\\(INS\\)-[Name] with \\_\\(INS\\)-hypertension.                     | \nThis is an example of a patient who will be included in \\_\\(INS\\)-[Name] because the patient is at least 18. The",
        "label": 2
    },
    "1568": {
        "output": "There is a simple method to see the patient note quickly in your editor. Write 1\n[\n and then highlight the text and change it into [1\n and press\n Ctrl+d] to change it into 1) Not relevant. To check again the content of [1\n , press 'Ctrl'+'1' in the editor of the patient note.\n<EOD> .\nThe authors give the results of a retrospective study on 301 patients with pulmonary thromboembolism treated in the Medical Intensive Care Unit of A.M.V. Dessali of Bologna. The series was divided into 2 groups on the basis of pulmonary perfusion scintigraphic examination (group A, n = 211, with pulmonary perfusion defects and group B, n = 80 patients, without perfusion defects). Mortality in the group A was 26,56% (53/211), in the group B 35,5% (22/60). Pump-free cardiorespiratory bypass was used in 4 patients in the group A and in 3 patients in the group B. The only difference between the two groups was the age: in the group A, 68.43% of the patients were over 65 years old and the same rate of patients was 53.3%. The results show that, in patients with pulmonary thromboembolism, even if over 18 years old, the mortality is higher in patients with pulmonary perfusion defects and it is independent from the use of cardiorespiratory pump-free bypass.<EOD> Growth arrest-specific gene 6 is not a biomarker for early lung carcinoma.\nBecause the expression levels of growth arrest-specific gene-6 (Gas6) and its receptor, Axl, are upregulated in many tumor types and correlated with metastatic tumor growth, we analyzed Gas6 expression in clinical specimens from patients with clinical stage I non-small cell lung cancer (NSCLC). Gas6 immunoreactivity was evaluated by immunohistochemistry in 50 NSCLC specimens and was defined as Gas6 positive or negative. There was no significant difference in overall",
        "label": 0
    },
    "1569": {
        "output": "<EOD> Phylogenetic relationships between the mite genera Schoengastia and Ivanditawana (Acaridae), parasites of Neotropical freshwater fishes\nThe acaroidan mites of the genera Schoengastia (Schoengastia gen. nov.) and Ivanditawana are parasitic in freshwater fishes of the Neotropics. This study presents the first molecular phylogeny of these mites by analysing sequences of the 18S, 28S and 16S rRNA genes. Both mites are members of the suborder Gamasina but have their respective lineages basal to the Gamasida. Although the two genera share some morphological characters, their phylogeny suggests that the most recent common ancestor did not possess any characters currently used to classify the mites into groups (classification using a multigene phylogeny will be useful in resolving the current classification system).<EOD> HPV vaccination in adolescent males (STARGATE): measuring the impact of a general practice- and school-based intervention against Human Papillomavirus on inequalities in uptake and equity in general practice uptake, in England, Wales and Northern Ireland: a cluster randomised controlled trial\n\nBackground:The HPV vaccination programme includes primary and secondary schools in England, and all girls age 12-13 and first-year women's college programmes in Wales and Northern Ireland. The government intends to extend the programme to adolescent males in school years 10-13 in England and school years 9-12 in Wales and Northern Ireland, but males have lower levels of uptake than females. Inequalities in uptake between socio-economic groups appear greater in males than in females. The STARGATE cluster randomised controlled trial tested the effectiveness of primary care and school-based interventions to increase male HPV vaccine uptake. The objectives were to assess the impact of a: 1. GP-based intervention on vaccination uptake versus GP-usual care 2. School-based intervention on vaccination uptake versus school-usual care. Methods/Design: Sixty",
        "label": 0
    },
    "1570": {
        "output": "##[QUESTION][INST] Would you continue using IFN, RBV and direct antiviral drugs? Why? Or would you switch to a new strategy? Explain why? Note the importance of this treatment. How important is it to use IFN, RBV and direct antiviral drugs?\nIf the patient's eligibility matches the trial's inclusion criteria, the patient can be enrolled to the trial and start to use the drugs. It is important to show that your decision is rational and well explained. Otherwise, just change to another suitable trial and start to use the drugs. IFN is very important in this case; it will help in lowering the viral load so that the immune system will be able to work against HCV. It could also help reduce the size of the tumor. RBV is an added drug to IFN to boost HCV clearance and improve chances of getting a sustained virological response. It is believed that a combination strategy that uses several medicines will help in achieving better outcome. IFN, RBV, and direct antiviral drugs are very important in this case.\nAns: \n##[QUESTION][IN] You have decided that this patient meets the inclusion criteria. Would you proceed with enrollment to the trial immediately? Explain why.\nYes, we may proceed with enrolling this patient because if this protocol is followed to the trial-level eligibility assessment, then this patient clearly matches the inclusion criteria in the clinical trial, so this patient is eligible and should be enrolled. I would move forward with the paperwork to start clinical trial enrollment.\nAns: \n### Question 2 in the MAG 3020 module [MAG3020] ##\nLet us summarize all the information from the MAG3020 module (Appendix A) about the trial.##\n\n## Summary\n\n## MAG-3020\nTitle: The effect of a Food Supplement, Arabinoxylan Rice Bran (MGN-3), on Chronic Hepatitis C\n\n\n\n- This study is a Phase II clinical trial, conducted to determine whether combinatory treatment with conventional therapy and MGN-3 could augment the therapeutic effect seen when patients are treated",
        "label": 2
    },
    "1571": {
        "output": "This is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\nHere is the clinical trial:\nTitle: Study of Epicutaneously Applied Ketoprofen Transfersome\u00ae Gel With or Without Combination With Oral Celecoxib for the Treatment ...\n\nInclusion criteria:\nFor females, subjects of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate, i.e. less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral contraceptive medications are allowed in this study. Female subjects, who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) are also allowed for participation\nAge, Genders, ECOG Status, Ethnicity (White, Black, Hispanic, other), Body weight (BMI, kg/m2), Serum creatin",
        "label": 0
    },
    "1572": {
        "output": "# Examples\n* In this example, we focus on the input parameters which are mandatory. [BENCH] # Example usage - mandatory parameters # Set the input parameters of the user input file # path_to_file: path to the benchmark input file # parameters: input parameters e.g. (n,m) = (12,3), # (n_patients_per_trial,number_of_trials) = (12_patients, 1_000_trials), # number_of_trial_blocks = (20), parameters_file: a file to read parameters from # path_to_parameters_file: # path to the parameters' input file # # Set the rest of parameters as defaults # # Create the main instance # # Create a benchmark script # # Run the script to benchmark # # This benchmark script creates a new notebook to be included in a notebook folder. # script_path: path to the script # # Note: the input file must have one row for each patient.\n\n# Runs the benchmark script and displays a progress bar.\n\n\n\n# Examples - optional parameters\n* We use the optional parameters to set the default values to 10 for `m` and `k` since they do not have a default value. [BENCH] # Example usage - optional parameters # Set the input parameters of the user input file # path_to_file: path to the benchmark input file # parameters: input parameters e.g. (n,m) = (12,10), # (n_patients_per_trial,number_of_trials) = (12_patients, 1_000_trials), # number_of_trial_blocks = (20), parameters_file: a file to read parameters from # path_to_parameters_file: # path to the parameters' input file # # Create the main instance # # Create a benchmark script # # Run the script to benchmark # # This benchmark script creates a new notebook to be included in a notebook folder. # script_path: path to the script # # Note: the input file must have one row for each patient.\n\n# Runs the benchmark script and displays a progress bar.\n\n\n\n\n<img src=\"fig1.",
        "label": 0
    },
    "1573": {
        "output": "[GCC]\n[1] For example, see:  [STARt] [GCC]\n[2] For example, see: \n<EOD> Is the right to die one to refuse treatment?\nIf a patient's right to refuse treatment is considered a right to die, then one may use a variety of measures to prevent dying, including measures to prevent pain or suffering. In fact, if one wants to protect the quality of life of a dying person, then one must use a variety of treatment measures and means to make life as comfortable as possible, in addition to allowing the patient to make his own decisions. So the right to refuse treatment need not mean the right to die; instead, it means the patient has the freedom to decide everything regarding the course of their medical treatment without being forcefully restrained or coerced. But since the right to refuse treatment may result in the patient's death, it may be argued that one has the right to refuse treatment with the right to refuse life. If someone has the right to refuse life, than one may conclude that he has the right to die, but this does not necessarily follow. After all, it is not always true that if one has a right to refuse, then he must also have a right to be killed. An example would be the so-called 'right to choose' abortion in which no one is authorized to forcefully kill an adult fetus against his or her will. If abortion or euthanasia can be compared to choosing to leave a newborn, then the right to refuse life is not necessarily the right to die, since a person can refuse life without being forced to die. As a matter of fact, all humans in their lifetime can experience situations that require the right to refuse life, and not everyone believes that one has the right to be killed. For example, it is common that in the military services and in some hospital emergencies, people are required to put the lives of others first. For that reason, one is not automatically considered a person of poor character who must be killed only because he or she has the right to refuse life. That being said, it is very important to point out that every human has the right to life and, therefore, if one does not have the right to life, then one's right to refuse life ends automatically. \n \nIn conclusion, many people think that, in the case of a terminally-ill patient (",
        "label": 2
    },
    "1574": {
        "output": "**Output**\nHere is the full report of patient's eligibility for the clinical trial:\nPatient's eligibility: 1) Excluded, 2) Not relevant, 3) Eligible\nTrial Summary: Eligible\nTrial-level Eligibility: 2) Eligible\n\n**Scoring**\n- Excluded: If patient-level eligibility is Excluded; trial-level eligibility is Excluded.\n- Not Relevant: If patient-level eligibility is Not relevant, trial-level eligibility is Not relevant.\n- Eligible: If patient-level eligibility is Eligible; trial-level eligibility is Eligible.\n\n####[END]\n\n##[QUESTION]\nTo generate a new data set consisting of 100 Clinical trial notes together with the inclusion and exclusion criteria of clinical trial. Each patient is randomly extracted from the patients' list in your medical center. \nThen, calculate eligibility of patients from both the patient-level eligibility and the trial-level eligibility with respect to the 100 Clinical trial notes. \n\nFollowing parameters are used for the generation of the data set at your first step:\n- Note generation rate is fixed to 6.1% in the 100 Clinical trial notes.\n- The number of Clinical trial notes per patient varies:  \n- For 1000 patients, note generation rate is 6.1% and 4437 trials will be generated.\n- For 1121 patients, note generation rate is 6.1% and 6863 trials will be generated.\nIt is also possible to adjust the generation rate.\n\nYou can see the generation rate of patient's eligibility as follows:\n\n![](../assets/figures-generated-data/_screenshots/Efficiency/1_eligibility_rates.png)\n\nIt is also possible to change the generation rate.\n\n![[0_1_10_and_23_rates]]\n\n\n### **EFFICIENCY **\n\nPlease generate 100 simulated clinical trial notes on",
        "label": 0
    },
    "1575": {
        "output": "[fig]  Figure 3- 1: The inclusion and exclusion criteria used in the recruitment of patients. [/fig] \n[table]  1. 4 -: The patient note Here is the patient note: [/table] \n<EOD> SAT-619 Hyperthyroidism Mimicking Pheochromocytoma\n\nSupplement, 2020a history of hypothyroidism and hyperthyroidism with a family history of thyroid disorder and thyroid cancer. She was diagnosed with hyperthyroidism a month prior in which she began anti-thyroid medications. Patient presented with nonspecific symptoms of malaise, nausea, and weight loss of 30 lbs noted over the span of 3 months along with fatigue, cold intolerance, sweating, and shortness of breath. Her other medical problems include a prior history of gestational diabetes 13 years ago and a family history of thyroid disease.On admission, she was afebrile with blood pressure 128/67 and tachycardic with a heart rate of 109. Her weight was 284 lbs, height 5'5\" with pulse oximetry of 96%. Cardiovascular, abdominal and neurological examination was unremarkable. On repeat physical exam in clinic, after resolution of signs and symptoms of hyperthyroidism, patient complained of new pain in the palate, dryness of throat and hoarseness of voice for the past two weeks. She denied other symptoms such as throat irritation, ear pain, drainage, or hearing defect. She was concerned and wanted to make sure it was not cancer. Patient had normal pulmonary breathing with normal vocal resonance. She had dry and hoarse voice with normal movement of the vocal cords. Patient had mild mucus at bilateral tonsils, but there was no ulceration. She was diagnosed to have laryngopharyngeal reflux. She was prescribed pantoprazole and chlordiazepoxide. Patient had normal serum calcium and electrolytes. TSH was suppressed to 0.032 uIU/mL, T4 uIU",
        "label": 0
    },
    "1576": {
        "output": "The output of the application after the training phase is provided in Appendix 9.<EOD> The effect of low\u2010density lipoprotein apheresis on low\u2010density lipoprotein kinetics: an analysis using two kinetic modeling programs\nBackground:\u2002 Recent studies suggest that low\u2010density lipoprotein (LDL) apheresis is effective in Japanese patients with hypercholesterolemia. Variation of plasma apolipoprotein (apo) levels during LDL apheresis is still not well known. We examined plasma LDL, very low\u2010density lipoprotein (VLDL) and intermediate\u2010density lipoprotein (IDL):apoB kinetics during LDL apheresis by two different kinetic modeling programs using the same data.<EOD> Adenosquamous carcinoma of the breast: A histopathological study of eight cases from the Indian subcontinent\nEight cases of adenosquamous carcinoma (ASC) of the breast were diagnosed in a surgical pathology practice over a period of about 10 years. In eight cases with a histological diagnosis of invasive ductal carcinoma (IDC), the slides were re\u2010examined; after discarding the cases with poor quality slides, six of the eight cases were reclassified as ASC. An immunohistochemical (hormone receptors) study was done for three of the cases and was uniformly negative. ASC must be differentiated from carcinosarcoma of the breast. The distinction is important as the prognosis of ASC is worse than that of IDC.<EOD> Complementation and antigenic specificity of two major membrane proteins of Newcastle disease virus.\nNewcastle disease virus (NDV) has two major structural glycoproteins on the surface of the virions, designated F and HN (heamagglutinin-neuraminidase). In a study of their complementation the viruses NDV La Sota and AU-Bulgaria were assorted into HN phenotypes. Two distinct antigenic types are present in NDV, distinguished by the use of chicken monoclonal antibodies to HN protein. In competition experiments the monoclonal",
        "label": 0
    },
    "1577": {
        "output": "To test the pipeline, we input both examples into the `eligibility` method and compared the results with the ground truththe table shown above.\nThe results can be printed to see the generated pipeline.\n```python\n>>> from eligibility_pipeline import *\n>>> from eligibility_pipeline import pipeline, eligibility, trial_level_eligibility\n>>> pipeline(eligibility).trial_level_eligibility\n   'Clinical trial ID': 941C,\n    'Name': 'Probiotic Efficacy in HCV  (090)',\n   'Inclusion criteria': '412.2' ,\n    'Exclusion criteria': '437' ,\n    'Sample_size': '120' ,\n    'Eligibility': '0) Excluded' ,\n    'Trial_start': '09/23/2009',\n    'Trial_end': '11/23/2011',\n   'Trial_level_eligibility': '2) Eligible'\n```<EOD> Efficient Transformation of In Vitro-Grown Rice Plantlets with Microprojectile Bombardment.\nMicroprojectile bombardment was efficient for transformation of in vitro-grown rice callus. Particles coated with DNA were allowed to penetrate a suspension of calli, and the bombarded calli were grown on media containing hygromycin or neomycin for selection of transformed somatic embryos. The selection of somatic embryos was based on the resistance of their shoot apices to gibberellin. This procedure enabled the recovery of hygromycin- and neomycin-resistant callus derived from more than ten individual rice embryos. No callus could be recovered when the somatic embryos that derived from the original plant's embryos before bombardment were subjected to selection. These somatic embryos derived from bombarded callus showed a high frequency of heritable transmission.<EOD> The effects of exercise on the expression of miRNAs in human skeletal muscle.\nMiRNAs are small noncoding RNAs which regulate numerous physiological processes. The regulation of",
        "label": 0
    },
    "1578": {
        "output": "[END]\n\n\n## Exercise 3\nInput two patient notes and their clinical trial, then output the eligibility assessment by the clinical trial.\nWhen you are ready, click the button below to start the exercise.<EOD> The Sustained Release of Proteins in the Nervous System: Implications for Tremor Treatment\n\nIncreasing evidence suggests that neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS) are multifaceted disorders affecting neural circuits in the brain through a range of pathophysiological processes. In PD, neurodegeneration that is related to dopaminergic neuron loss in the substantia nigra (SN) causes motor control deficiencies involving tremor, rigidity, bradykinesia, and postural instability. In AD, degeneration of the cholinergic neurons in the nucleus basalis of Meynert in the basal forebrain is associated with cognitive impairment in multiple functional domains of memory and language. In ALS, loss of motor neurons in the motor cortex and lower motor neurons in the ventral horn of the spinal cord causes limb weakness as well as dysarthria, dysphagia, and dyspnea. However, despite significant progress in understanding the pathological mechanisms of these disorders, therapeutic alternatives have not been approved for effective prevention; furthermore, the development of symptomatic treatments has been hindered by their insufficient efficacy and/or toxic side effects related to systemic administration. For example, in recent clinical trials, although deep brain stimulation (DBS) of the ventral intermediate nucleus of the thalamus or the subthalamic nucleus (ventral thalamus, Vim, or STN DBS, respectively) has generally shown superior efficacy compared to the conventional pharmacotherapies for tremor reduction in PD, DBS did not improve the cognitive and non-parkinsonian motor symptoms in PD[1][2][3][4][5]. Similar results were also demonstrated in advanced AD and A",
        "label": 1
    },
    "1579": {
        "output": "* Exercises from [https://github.com/h2r2/intro-to-biologic/tree/master/chapter6/exercises].\n\nAnswser | [https://github.com/h2r2/intro-to-biologic/blob/master/chapter6/exercises.md#answser-31](answser.md)\n\n\n  \n\n  \n\n  \n\n\n\n\n\n* Question? Click [https://www.jira.com/servicesticket/details?func=viewitem&itemid=2503](JIRAs).\n\n\n--------------------------------------------------------------\n**[Chapter7: Efficient Algorithm](chapter7.md)** \n--------------------------------------------------------------\n\n### Introduction\nWelcome to the seventh chapter of the Clinical Data Science curriculum. In this chapter, we learn about two important concepts: *efficiency* and *time complexity*.\n\nEfficiency is a very important concept in the field of computer science  and every programmer has heard about it.\n*Complexity* is a term borrowed from mathematics and it refers to a function's degree of difficulty. In mathematics, we often do not care about the final answer; we are usually interested in the function's operation time. However, this differs from computer science and the complexity of algorithms. An algorithm is the *step-by-step* blueprint that is created to run *instructions* in a *computer*. The *instructions* are the mathematical formulas defined *before* running any step. These instructions are a sequence of *operations* carried out one by one until a *terminating operation* has been reached.\n\nNow, in *programming* we have to decide the order in which to carry out all the steps. Programming gives us full freedom to choose the sequence of instructions we want. However, this freedom brings the computational complexity and we get puzzled. The *time complexity* is a way to express how much *time* does an algorithm to compute a *specific* problem. For example, it may take seconds to perform the same algorithm to solve a billion number problems, in contrast to the same algorithm to solve millions number problems, which takes minutes. Or even minutes for ten-thousands problems, and hours",
        "label": 1
    },
    "1580": {
        "output": "When this patient is assessed, he should be eligible (scale = 2) for the trial, since the trial-level eligibility 'Eligible' always overrules the patient-level scores (0, 1). Please remember that 'Excluded' and 'Not relevant' take precedence, while 'Eligible' does not overrule 'Non-relevant' and 'Never seen' but just 'Not relevant'. \n\nYou're asked to work as quickly and as accurately as possible. Remember, you can submit solutions more than once, you can check out your submissions and you can see your statistics. \n\n#### Score\n\n__5/5__ correct\n<EOD> Clinical efficacy of the combination of anticoagulants and thrombolytic agents in treating acute thrombosis of hemodialysis arteriovenous fistula: A protocol for systematic review and meta-analysis\n\nBackground: Acute thrombosis caused by hemodialysis arteriovenous fistula is a common complication, which seriously affects the patency of hemodialysis arteriovenous fistula, treatment time and quality of life of hemodialysis patients. Anticoagulants and thrombolytic agents are often used as the first-line treatment, but the clinical efficacy is controversial. Therefore, we plan to use a method of systematic review and meta-analysis to compare the clinical efficacy of anticoagulant and thrombolytic combination therapy with single drug treatment.Methods: Seven databases (PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, China Biology Medicine, Wanfang and Weipu) will be selected for retrieval on the basis of the established retrieval strategy. We will independently screen the literature, extract the data from each included literature, assess the risk of bias and data outliers, and use Review Manager 5.3 software to perform data analysis.Results: The current systematic review and meta analysis is expected to provide a reference for rational clinical drug selection.Abbreviations: AEs = adverse events, CKD = chronic kidney disease, DVT = deep vein thrombosis, HD-AVF = hemodialysis arteriovenous fist",
        "label": 0
    },
    "1581": {
        "output": "[CAND] You have read the text below. Please answer the following questions as detailed in parentheses below. \nHow many patients had the inclusion criteria \u2018\u2018Hepatitis C virus (HCV), genotype 1 infection\u2019\u2019 applied? Give an answer in a separate section.\nHow many patients had the inclusion criterion \u2018\u2018Liver biopsy within 3 years\u2019\u2019 applied?\nThe patient had not fulfilled any of the inclusion criteria. You should have set the Trial-level eligibility according to the patient\u2019s notes. How would you have done that? Use the free text fields to reason your conclusions.\nIn how many of the patients is the age criterium not applicable because the patient is younger than 18 years old?\nThe patient notes showed no signs of cirrhosis within the last liver biopsy. This applies to the patients. What is your conclusion regarding the cirrhosis inclusion criterion (\u2018\u2018Liver biopsy with histology consistent with HCV-induced liver damage, with no cirrhosis\u2019\u2019)?\nThere is no other reason for liver damage.<EOD> Characteristics of Pregnancies and Mothers in the COVID-19 Pandemic: The Results of the COVID-Pregnancy Online Study\nThis international study aims to describe changes in pregnancies, births, and childbirth experiences during the COVID-19 pandemic. A total of 2965 (F = 2502, M = 463) participants from 50 countries completed the questionnaire. Anxiety and depression rates among women who experienced pregnancy or childbirth during the pandemic were higher than those of the non-COVID mothers. Women under 21 years of age tended to experience more severe labor pain compared to older women. The level of pain tolerance was reported to be higher during the COVID-19 period by the young participants. It was stated that due to the pandemic, there was an increase in the use of natural labor aids (bath, acupuncture, support and warm bath) as well as a decrease in the use of drugs (e.g., epidural analgesia, nitrous oxide pump) in childbirth.<EOD> A rare cause of cerebral venous thromb",
        "label": 1
    },
    "1582": {
        "output": "### Eligibility in a table format\nHere is a clinical trial in the Tables format, which consists of a header row with the trial name, followed with rows for each patient. There is a column for Criteria, where each patient can be eligible, and a column for assessment, where 1 means eligible and 0 means not eligible. The first and the last patient are eligible for the trial, whereas the second patient does not have sufficient information to determine eligibility. [INST]\n\n\n\n\n<docref id=\"docref_52\">\n\n# Title\nA Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation\n\n# Summary\nRecurrence of Hepatitis C Virus infection (HCV) is universal after orthotopic liver transplantation (LTx) and is associated with allograft failure, death and need for re-transplantation. Currently, there are no effective therapies to prevent HCV recurrence. Nitazoxanide (NTZ), an oral thiazolide anti-infectious agent, was safe, well tolerated and effective in achieving sustained viral response in patients with chronic HCV genotype 4. Its role in the prevention of HCV recurrence after liver transplantation has not been studied. The investigators propose to conduct an open label pilot study examining the role of NTZ in the prevention of HCV re-infection in eight patients undergoing LTx. First time transplant recipients for chronic HCV without history of renal failure or HIV/HBV co-infection, will receive NTZ immediately prior to LTx and for 3 days thereafter. The primary endpoint is the number of patients who remain HCV-RNA-negative at day 7 after LTx. If at least one patient remains negative, the study will be determined to be positive. Additionally, the investigators will examine the viral kinetics of HCV, tolerability and safety of NTZ.\n\n# Inclusion Criteria\n\n# Exclusion Criteria\n- Patients must be age 18+ and younger than 75\n- HCV infection identified by positive,",
        "label": 1
    },
    "1583": {
        "output": "## [INST]\nYou can also use a different formatting in `Triallevel eligibility: ` to be used in different conditions, e.g., ``Trial-level eligibility: IF_NOT_EQ_0 ELIGIBLE ELSE NOT_ELIGIBLE endif.``\n\n\n[END]\n\n---\n**NOTE:**\n\n1) *You can also insert another value after the logical operators AND and OR. The format should be exactly the same as a Python `condition` in the code example.*\n2) *Before running a trial for each patient, you will be asked whether you want to perform the evaluation with a new patient or with the same patient. Please note that each patient appears only once.*\n3) *All three columns are not mandatory, meaning that there are no mandatory questions.*\n\n\nYour tasks are as follows:\n\n1) Create patients to be randomized in each trial.\n\n2) Create the clinical trial data.\n\n3) Use the data to evaluate each patient.\n\n\n> NOTE: Create the trials by inserting clinical trial data.\n> \n> NOTE: Before running each trial, confirm that a patient data or new patient appears in the box below, e.g.,  *New Patient* or *Patient Data*.\n\n### 1) Creating Patients\n\n> Create patients to be randomized in each trial.\n\n1) Double-click the **Create patients file**\n2) In the dialog, create a patient data file by selecting **TXT format**\n3) Create a text file with the data shown below in [File 1](File 1) and save it. The data in the trial data are similar to those in the patient data.\n\nFile 1\n\nName\nfirstname initial lastname\n1) Name\n2) First name\n3) Last name\n4) Male\n5) Female\n6) Age\n7) Date of the exam\n8) Hospital reference: 1 - Hospital a, 2 - Hospital m, 3 - Hospital GG\n9) Date of entry\n10) Date of discharge\n11) Location of data origin (e.g., GGH, GGD)\n12) Department: 1 - Department L, 2 - Department C,",
        "label": 0
    },
    "1584": {
        "output": "Let's explain our code step by step.\n* The first line `f` is the function which should return the Trial-level eligibility. \n\n* The second line `y` is the column that contains the assessment of eligibility. \n\n* `A` is the table object that stores all the data corresponding to each patient. \n\n* `B` is the table object that stores the data corresponding to the Trial (clinical trial). \n\n* `C` is just a column from `A` that contains the id number of a patient who is diagnosed with `HCV`. \n\n* `G` is just a column from `B` that represents the trial. \n\n* Let's continue and create a `df_final` df object in the function. Note that `df_final` represents the output.\n\n* Then, we have to compare the patient's gender with that of the trial and then compare the disease that was diagnosed with the disease that is related to the clinical trial. If the patient's gender equals the gender that is in the clinical trial, then we compare whether the patient and the clinical trial disease match or not. Let's do a nested `if / else` statement in `df_final.iloc[0, 1]` that equals the index location of the element with the gender. \n\n* If both are matched, then we return the number that is equal to the sum of two factors, i.e., the first factor is equal to 1, meaning the patient met the inclusion criteria and the second factor is equal to 1 which represents that the exclusion criteria are not met. The result of the first statement is the sum of the number equal to one, which is equal to the sum of two factors, i.e., 1 and 1, which is equal to 2, and the output of the second statement is a single number equal to 2 as shown below.\n\n* If we want to add new columns into `df_final` object with the number of inclusion criteria, then we should add the column name as `iqc_num` in the first line before `df_final`, in the function. Then, all of the data, including all of the columns, are returned by running `final_result = df_final[:]`, where the square brackets",
        "label": 0
    },
    "1585": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. [INST]\n[SOL]\nSeveral studies in patients with rheumatoid arthritis (RA) have demonstrated that use of certain antiarthritic drugs (methotrexate, sulfasalazine, corticosteroids, antimalarials) can be associated with an increased incidence of biliary tract disease, especially papillary stenosis and cholestatic syndromes. However, the association of cholelithiasis and the use of antiarthritic drugs is relatively unknown. Moreover, there is very little information on the use of rheumatoid arthritis (RA) drugs and cholelithiasis which is a common health problem in the general population, and it is likely that the problem is increasing in frequency. We found only a few previous reports about drug-induced cholelithiasis in patients with RA. In this report, we present a patient who was on a methotrexate (MTX)-based antiarthritic regimen and finally diagnosed RA was on methotrexate (MTX)-based antiarthritic regimen and finally diagnosed RA patients and finally diagnosed RA patients and finally diagnosed RA with cholelithiasis. with cholelithiasis. with cholelithiasis. with cholelithiasis. We treated this",
        "label": 1
    },
    "1586": {
        "output": "### Workout\n\nYou are now on a trip to the United Kingdom and want to know the information of what you should not use on the plane. You get the information you need from [https://help.airbnb.com/hc/en-us/articles/360001058073] but there is too much information. So, you want to summarize the information and find out what to not",
        "label": 0
    },
    "1587": {
        "output": "```\nInpatient Treatment: 0.00, 1.00\nPatient: 0.00, 1.00\n```\n\nHere are the first 10 lines of the patients table named `patient.csv`:\n\n##  `0.0` `0.0` `0.0` `0.00` `0.00`\n `0.0` `1.0` `0` `0.00` `0.00`\n `0.0` `1.0` `0` `0.00` `0.00`\n `0.0` `1.0` `0` `0.00` `0.00`\n `0.0` `0.0` `0.0` `0.00` `0.00` \n `0.0` `1.0` `0` `0.00` `0.00`\n `0.0` `1.0` `0.0` `0.00` `0.00`\n `0.0` `1.0` `0.0` `0.00` `0.00` \n `0.0`",
        "label": 1
    },
    "1588": {
        "output": "For your help. \n[INST]\n\nThe steps you have been completing are:\n\n- `TrialNote-1$:`\n- 1) Read a patient's medical records and determine if the patient meets inclusion criteria.\n- 2) Make a patient-level eligibility.\n- 3) Repeat trial-level eligibility for the patient's data.\n- [INST] `TrialNote-1` [END]\n\nA. Let's use the next patient.\n\n[INST]\n\nTrialNote-2:\n\nTitle: A trial to assess the efficacy of interferon alpha on HCV antibodies - IFNA-TRIAL\n\nSummary: To determine the efficacy of interferon alpha on HCV antibodies\n\nInclusion criteria:\n\n- Inclusion Criteria:\n- Patients with chronic hepatitis C\n- Interferon alpha (IFN alpha) is the gold standard.\n- Genotype 1 of HCV\n- NASTART is recommended to treat HCV infection but in some cases it is contraindicated (e.g., previous interferone induced depression).\n- It is recommended to treat with IFN alpha for 6 months if he or she has not gotten into cirrhosis\n\n- Exclusion Criteria:\n- Alcoholics (if one is non-alcoholic or has a controlled alcohol intake and not in the past 6 months).\n- Cirrhosis\n- ALT over 500 and <10 times upper limit (ULN)\n- Hepatocellular carcinoma\n\nTrial-level eligibility:\n\n`IFNA-TRIAL:\n  PatientName: Trial-level eligiblity for IFNA-TRIAL\n    Trial-level eligibility: IFNA-TRIAL-level eligibility`\n\n- `IFNA-TRIAL-level eligibility: 0) Excluded`\n- `IFNA-TRIAL-level eligibility: 1) Not relevant`\n- `IFNA-TRIAL-level eligibility: 2) Eligible`.\n[END]\n\nB. Let's review patient",
        "label": 1
    },
    "1589": {
        "output": "[CODE] \ninclude date: date, \nage_male_female: age_male_female\ninpatient: 1, 0\nhbv_pcr_positive_positive: hbv_pcr_positive_positive \nh_patient_history: h_patient_history\nh_diagnostic_test_results: h_diagnostic_test_results\nh_treatment_outcome: h_treatment_outcome\nh_alcohol_lifestyle_habits_behaviour: h_alcohol_lifestyle_habits_behaviour\nh_smoking_history: h_smoking_history\nh_smoking_status: h_smoking_status\nh_weight: h_weight\nh_total_height_meters: h_total_height_meters\nh_body_mass_index_kg_m2: h_body_mass_index_kg_m2, \nh_comorbidity: h_comorbidity, \nh_social_lifestyle_behaviour: h_social_lifestyle_behaviour, \nh_diagnostic_test_results_hepatocellularcarcinoma: h_diagnostic_test_results_hepatocellularcarcinoma\nh_treatment_outcome_hepatocellularcarcinoma: h_treatment_outcome_hepatocellularcarcinoma\nh_alcohol_lifestyle_habits_behaviour_prevalence: h_alcohol_lifestyle_habits_behaviour_prevalence\nh_smoking_history_prevalence: h_smoking_history_prevalence\nh_smoking_status_prevalence: h_smoking_status_prevalence\nh_weight_prevalence: h_weight_prevalence, \nh_total_height_meters_prevalence: h_total_height_meters_prevalence\nh_body_mass_index_kg_m2_prevalence: h_body_mass_index_kg_m2_prevalence,",
        "label": 0
    },
    "1590": {
        "output": "<H1>HIGHLIGHTS</H1>\n<UL>\n<LI>Clinical trials can serve as an important research tool, and they play a decisive role in the development of new drugs and other medical interventions.</LI>\n<LI>You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.</LI>\n<LI>You should always repeat Trial-level eligibility in the last line by`Trial-level eligibility:`.</LI>\n</UL>\n<h1>Related Links</h1>\n<ul><li><a class=\"local-link\" href=\"http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1226567\">Etiology</a></li><li><a class=\"local-link\" href=\"http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1412204\">Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment</a></li></ul>\n<h1>TODO</h1>\n<ul><li>Check clinicaltrial.gov for the most recent description of the trial.</li></ul>\n        <h3>Instructions</h3>\n        <ul>\n        <li>You need to read the paper:\n        \t<a href=\"paper.pdf\"/>Higashi, S., et al. \"\n            <a href=\"http://dx.doi.org/10.1093/bioinformatics/btp469\">Clinical trials in biomedical publications: how well are the eligibility criteria reported?</a></a>\n        \tBiainformatics, 2014</li>\n        </ul>\n       \n        <ul>\n        <li>You need to read the following pages from the paper: \n        <tt>Table 4.1 <a href=\"pdf/S1",
        "label": 1
    },
    "1591": {
        "output": "# Results\nThe results show that the proposed model achieves the accuracy with 80.62% and F1--score of 0.842, which is higher than other compared models, such as NB, SVM, kNN and AdaBoost.\n\n\n# Discussion\n\n## Why not use the 3-class classifiers such as SVM, Boost, or NB \n\n![3-Class Classifiers](3-class-classifier.png)\nSince patients can be divided into 3 classes -ineligible, not relevant and eligible -we are interested in exploring possible classifiers for the 3-class classification problems. \n\n\n---\n*The source code can be accessed at [HUGO_Munir_Eligibility code repository](https://github.com/MunirHUGO/meditran/tree/HUGO_Munir_Eligibility), including the source code with necessary dependencies and the test data, as well as the output of the code on the test data sets.*\n\n\n<EOD> Evaluation of V-shaped flap method for augmentation of alveolar ridge in clinical assessment: A pilot study\nBackground: Bone augmentation surgery (BAS) is the primary option for dental implant therapy in patients with severe alveolar ridge deficiency. Augmentation by a V-shaped flap is a simple and less invasive technique that could provide satisfactory results. Purposes: The purpose of the study was to clinically evaluate V-shaped flap method for BAS. Methods: Ten patients (age/sex distribution: 5 males/5 females; age/mean age 30.7 \u00b1 10.0 years) were selected for the study. In all cases, V-shaped flap method was used to create an interdental space, and bone graft material was applied. After six months, the final bone augmentation was evaluated in terms of the dimensions of the alveolar crest, vertical, width, and thickness of the regenerated bone. To evaluate the aesthetic results, pink esthetic score was performed. Results: Compared to the initial situation, after six months postoperatively, the crestal bone loss at",
        "label": 1
    },
    "1592": {
        "output": "In this section, patients are divided into 4 groups according to the therapy they underwent:\n- All patients underwent a therapy for HCV infection.\n- SVR is defined as serum ALT levels that have normalized and have remained normal at the end of treatment (or 24 weeks).\n- Relapse is defined as serum ALT levels that have normalized and have remained abnormal at the end of treatment (or 24 weeks) and have then risen again.\n- None-SVR is defined as serum ALT levels that have not normalized at the end of treatment (or 24 weeks).\nHere is the patient id column:\nName:\nGroup: \n[HINT] In the above section, the group is defined for each patient. Each patient may be given in the first column of a table more than once. Therefore, you should count the number of HCV-infected patients who had intervention for each group.\n\n## Episode 3: Inferring what factors affect",
        "label": 2
    },
    "1593": {
        "output": "## Add all the trial-level eligibilites\nAdd the trial level eligibilities like this one in a string, e.g., `Title: A safety and tolerability study of nitazoxanide (NTZ) in chronic hepatitis C (CHC) with or without HIV`. The other trial eligibilities can be added in a similar way. By default, trial-only eligibilites are assumed to be eligible, which is the same as Trial level eligibility: Eligible. So, add all trial-level eligibilities one by one in a line like Trial-level eligibility: {N}, and when you are done, just remove Trial-level eligibility: Eligible. \nAdd as many {N} as you need to add in a line, e.g., {N} Eligibility criterion 2, and add finally the 2nd Eligibility criterion: Trial-level eligibility: Eligible. \nYou don't need to add any {N} for Eligibility criteria 1,2, or Eligibility criteria {N}, {N}, e.g. 1: Eligibility criterion 3,2: Eligibility criterion 3,3: Eligibility criterion 4,Eligibility criteria.\n\n## Return (the output of make-assessment is a dataframe which can be saved easily into a text file.)\n#### ASSORTMENT #\nYou can sort the results by the most relevant information and then you will get what you want quickly. You just need to add a column named `assortment`, with ascending or descending type.\nIt is not possible to make a string for assortment. If you just add a new variable named `assortment`, the function automatically uses it as an index and the output will be automatically categorized by the new `assortment`; in this case, you cannot manually select any column for sorting purpose.\nAssortment is a categorical, thus you can get the desired results by adding the column to your data frame like this one:\n#### ASSORTMENT # \n```r\ntrial_df$assortment <-factor(trial_df$trial_id, levels = c(\"ELP-008\", \"A",
        "label": 0
    },
    "1594": {
        "output": "``` <EOD> <issue_start><issue_comment>Title: Add `isDeferredNode`-prop for detecting deferred nodes\nusername_0: When a child is not rendered in the same render cycle that it would be resolved, we currently don't have a good way to detect whether the child is deferred. We need to know how we can inject a `node_key` prop into `deferredNode` and detect that.\n<issue_comment>username_1: This seems more useful than I previously thought, can we add that to this patch?\n<issue_comment>username_0: @username_1 I think it makes sense to do it the way how [render-tree-updates](https://mochajs.org/api/render-tree-updates) works, i.e. you can attach a node-key to `deferredNode` and later resolve the node w/ the same node-key. So I think this patch is enough.\n<issue_comment>username_1: Looks like good enough, will merge<EOD> Effect of theophylline on caffeine metabolism in pregnant rats\nABSTRACT In view of the marked reduction in the rate of caffeine metabolism in the first trimester of pregnancy , the effect of theophylline on this alteration has been assessed by the single administration of 2 or 20 mg kg\u22121 of theophylline to rats of different gestational age (non\u2010pregnant and pregnant, both in the first trimester or in the third trimester). Neither the 2 mg kg\u22121 nor the 20 mg kg\u22121 dose of theophylline showed any influence on enzyme activity or on total caffeine elimination when theophylline was compared with saline\u2010treated rats of the same gestational age in the second stage of pregnancy (gestational day 15). Only the administration of 20 mg kg\u22121 theophylline increased the volume of distribution and elimination rate of total caffeine in the rats of both first trimester groups. Therefore, this low dose of theophylline did not exert an effect on the degradation of caffeine. However, the 20 mg kg\u2212",
        "label": 1
    },
    "1595": {
        "output": "[INST] Your output should be as following:\n[INFO] Please give some thoughts on how to simplify the code. \n[INFO] You should provide Python file containing your solution at the end of each test section.\n[INFO] In the file, put every single step of code, e.g., import, variable assignment, and so on, in the form of comments and assign them as a function, e.g., # my_code_import 23. \n[INFO] In order to run the function, please put #!pyline on your first 20 lines of the solution file and put your code within the comment block under the form /r /c /* #my_code_import ...`. \n[INFO] Code should not be hard-coded, but should be generalized and dynamic. \n[INFO] Write documentation for your function in the same file. \n[INFO] Write a program documentation at the end of the file on the basis of your program. \n[INFO] If you have any questions or would like to ask the author of the problem, please write to <EMAIL>:. \nThe code should not be hardcoded, but should be generalized and dynamic. If you have any questions or would like to ask the author of the problem, please write to <EMAIL>:. \n\n<EOD> .\nA case of a 59-year-old man with pulmonary sarcoidosis and endobronchial ulcer who developed a serious exacerbation of the disease leading to a lethal outcome is presented. This case is very unique - the pulmonary disorder was combined with the presence of ulcer of the right main bronchus caused by the presence of tuberculosyphilitic lymph follicles.<EOD> .\nThis case-control study aimed at measuring the effects of selected factors in the family at the time of the childbirth that might influence the breastfeeding and the weaning outcomes. The study sample included 770 families, selected at random, enrolled at birth in the Program for the Evaluation of the Health Situation of Children under one year of age, which is part of the Basic Health Care Program provided by the Family Health Care Services. The children were between 7 and 12 months of age when the assessment of breastfeeding and weaning was conducted.",
        "label": 1
    },
    "1596": {
        "output": "[/BASIC]\n[BASIC] Problem Description\n\n### General overview \nThis problem deals the with the issue of recruitment of eligible patients in a large clinical trial. You should first assess if the patient meets the criteria for the clinical trial. It is not possible to define the eligibility of the clinical trial in terms of patient characteristics that are only available on the patient record. It is expected that, by reviewing the patients' records, the investigator has enough knowledge to determine if the patient is possibly an eligible candidate for the trial. For each patient record that they find, the investigator is also asked to make a trial-level eligibility assessment.\n\n### Background\n\nA clinical trial is a type of clinical research that is designed to study the efficacy, safety, and mechanisms of newly developed interventions.  An intervention is a medical product designed to change the outcomes of clinical interest; for example, it could be a new medicine, a physical treatment, or an educational program. A clinical trial is designed by the investigator and written as a protocol. The protocol is reviewed locally for ethical aspects before being accepted by a local clinical ethics committee. Then, the protocol is entered in EMA's European Clinical Trials Database (EudraCT).\nA clinical trial is a scientific experiment with clinical outcomes of patients.  It is usually a randomized and multicentric study, with a clearly defined hypothesis and prospectively planned analysis on the basis of collected data. The results obtained with the experimental intervention are compared to a control that is already in use in clinical practice or with a placebo. The investigation is carried out in accordance with the Declaration of Helsinki, and it is performed under the supervision of an investigator. For this kind of research, the use of a structured data collection form has often the advantage of facilitating reporting of complex data, such as laboratory and physiological measurements, while increasing the accuracy of data entry.\n\n### Goal\n\nFor every patient present in the clinical trial's data collection form, it is important to assess how likely this patient may be included in the trial. If the patient is included, the",
        "label": 0
    },
    "1597": {
        "output": "[INST] Hi. You are a data scientist helping clinicians choose the best diagnostic strategy for a patient.\n\nA patient is suspected of having a particular disease, which is characterized by symptoms such as a chronic illness.\n\nDiagnostic strategies can help patients achieve more desired clinical outcomes. However, the costs and risks imposed by diagnostic tests differ by modality. For example, testing for the presence of metabolic and immunologic disorders or cancer requires a blood sample while imaging studies can reveal signs of organ problems in the lungs or abdomen.\n\nThere are a variety of diagnostic test types available. You wish to determine which diagnostic strategy would most benefit a patient. Therefore, you need to decide which tests to perform in a certain patient and sequence the sequence of test to obtain the most informative outcome, thereby allowing the clinicians to make the proper decisions.\n\nThe first problem you have to deal with is the choice of tests. For example, in patients with signs of pneumonia, the decision to perform rapid diagnostic tests of respiratory specimens can provide a faster and cheaper diagnosis, and can decrease the cost of treatment compared with sending respiratory specimens for a chest X-ray. In patients with signs of liver disease, diagnostic tests for a blood test can provide an easier and cheaper diagnosis. These tests can also be used to monitor any underlying liver disease.\n\nNow you have to determine the optimal way to choose the tests. To do this, you need to choose the order in which to perform the tests and the test combinations that are most likely to yield the fastest, cheapest and best results.\n\nFirst, you should make two types of decisions: (1) the set of test combinations and (2) the order in which to perform each test combination.\n\nThere are several different sets of tests that can be chosen for each patient. The test sets are classified as simple, efficient and expensive. For testing costs, you should consider the cost of each test, the cost of equipment, and the costs associated with the cost of each test and equipment.\n\nThen, in each choice set, the order of the tests (or combinations) that you can choose from in a given subset should also be defined. You should choose the subset of tests based on their clinical utility and",
        "label": 0
    },
    "1598": {
        "output": "The complete example can be found at the following link: <https://github.com/K-StateBiology/CohortSelectionDuplicate_Tutorial/blob/main/data/patient_note.csv > .\n<EOD> Comparison between Fitness Trackers\u2019 Count and Oxygen Uptake at VO2 max: A Systematic Review and Meta-Analysis\n\nFitness trackers are widely used devices in daily life for monitoring heart rate (HR), distance (DISt), duration (DUR), and energy expenditure (EE). HR, an important indicator for fitness level, could be estimated accurately using only DISt and DUR or HR, DISt, and DUR. It remains unclear whether EE estimates of commercial fitness trackers are comparable with oxygen consumption (VO2) data. Here, we aimed to systematically compare the EE and VO2 max at peak exercise conditions in order to assess the validity of fitness trackers. Systematic literature searches were performed in the PubMed, EMBASE, Cochrane, Web of Science, CNKI, WanFang, SinoMed, and China-based grey databases, up to December 2020. The results were synthesized by meta-analyses to compare activity tracker-and VO2 max-based HR and VO2 max. Eleven eligible studies, including 407 participants, were identified. A random-effects model meta-analysis showed a medium-to-high positive correlation between EE and VO2 max at peak exercise (r = 0.77, p < 0.001, 95% CI: 0.63-0.86) across all participants and small to medium positive correlations among participants of different races (black [r = 0.54; 95% CI: \u22120.07-0.81], non-white [Asians and Hispanics] [r = 0.28; 95% CI: \u22120.24-0.74], whites [r = 0.86; 95% CI: 0.75-0.92], and mixed races [r = 0.84; 95% CI: 0.",
        "label": 1
    },
    "1599": {
        "output": "H2O: What You Should Remember\n\nIn H2O, we assess the trial-level eligibility, i.e., output the scale for the assessment of eligibility.\n\nFor this task, we should run the code with **inst** and **no_inst**.\n\nTo run the code with inst, we should first start an interpreter and initialize an instance:\n\n~~~\n  [INST] $python -m h2o.instances.spark h2o.init\n      WARN: The default Spark context is configured to have 2 threads active; however, the maximum is not bounded, so this may limit scalability.\n~~~\nTo run the code with no_inst, we should first start an interpreter and initialize a h2o:\n\n~~~\n  [INST] $python -m h2o.spark h2o\n      INFO: To set up your Spark context, please start a local interpreter first and execute these commands:\n      h2o.init\n~~~\nWhen the interpreter is started and initialize an instance or h2o, in an IDE such as IntelliJ (JetBrains), we can directly execute the code in the file, i.e., the following:\n\n~~~\n    from __future__ import division\n    \n    from h2o import models, api, run, predict, preproce, preprocess, pretrained_features, predict_procedure, prebuild, pval, prevalence, onehot_feature, univariate, h2o, no_inst\n    \n    import os, glob\n    \n    from numpy import array, log1p, exp, sum\n    \n    from os.path import join\n    \n    from sklearn.preprocessing import StandardScaler\n    \n    # Load dataset\n    if os.path.exists('hepatitis-recruitment.csv'):\n        data = h2o.import_file(\"hepatitis-recruitment.csv\")[]\n    else:\n        run(\"Download Dataset\").append(1)\n    \n    # Define a dataframe\n    my_dataframe = api.col(data)\n    \n    # Define a training set\n    train_df = my_dataframe.train()\n    \n    # Define some features. In this case",
        "label": 1
    },
    "1600": {
        "output": "[/CONS]\n\n\n\n\n---\n<EOD> Anomalous magnetic behavior in DyMnSn(2\u2212x) (x \u2264 1/8)\nNeutron powder diffraction and magnetic susceptibility measurements have been performed on a new compound DyMnSn2\u2212x (x 0.11). For x 1/8, the compound shows ferromagnetic behavior which is lower than expected for a stoichiometric composition. The compound exhibits no colossal magnetoregression at low temperatures. On application of a magnetic field, a field-induced magnetic ordering of magnetization is observed at low fields and the origin is discussed in terms of the Stoner-ferromagnetic model.<EOD> Pneumocephalus After Ventriculoperitoneal Shunt Surgery Associated With Cerebrospinal Fluid Fistula\nAbstract We report rare and unusual case of pneumocephalus after ventriculoperitoneal shunt surgery. Cerebrospinal fluid (CSF) fistulae are rare and unilateral, occurring after surgery in patients with already abnormal skull. We present an extremely low-birth-weight infant who demonstrated symptoms of shunt malfunction 6 h after surgery and was found to have pneumocephalus on subsequent CT scans. Imaging findings of pneumocephalus are described.<EOD> Exploratory Behaviour: A Tool for Assessing the Interaction of Drugs with Central Benzodiazepine Receptors\nExploratory behaviour in rodents has been adapted to screen for the interaction of drugs with central benzodiazepine receptors (BZRs). Such a screening procedure has been validated in a number of studies, and there is a good agreement between the rank order of compounds tested in animal exploratory behaviour and their binding affinity at the BZR-\u03b3l subtype of BZRs. The application of this test to new molecules is likely to be successful, but its utility is limited to those drugs displaying a large and saturable binding affinity for the BZR-\u03b3l subtype. For drugs less potent at this site, additional tests may be needed to demonstrate the interaction of these new compounds with BZRs.<EOD> Clin",
        "label": 1
    },
    "1601": {
        "output": "## Example 2\nYour task is to predict the response outcome of an ongoing breast cancer trial. The trial is based on the use of the drug, fulvestrant. It is a selective estrogen receptor degrader. The response was defined as a decrease in breast cancer size of 30% or more from the baseline status. In this study, the response outcome was unknown.\nInput/output:\n\nExamples:\n[formula]  0) Excluded; 1) Response: 30% decrease in breast cancer from the baseline status; 2) Response: Response not observed. [/formula] \nNow let's look at the notes in the sample data.\n\n## The note file:\nIn the first note: Hormonal receptor-negative breast cancer: There is no expression of ER or PR, and HER2 is not overexpressed in this case. Ki-67 index is 30% in this case. In the following notes, breast cancer is still a small tumor (<3 cm) but with more metastasis cases (lymph nodes and bone) than the baseline status. In the last case, breast cancer is aggressive and no response is observed.\nInspect the data in the sample to learn a little bit more.\n\nThe data for training:\n\nNow, go to the output screen. You should input the code of response in the first row of [code] tag. Remember the structure of the response outcome as described earlier.\n\nThe number 0) should mean excluding the drug and a score of 1) should indicate the response as a 30% decrease in breast cancer size from the baseline status. The number 2) means no response observed. In case of two or more responses for a patient, the number 1) can be used in between responses. See the code below.\n\nThen let's get into the details. Try to make some more predictions. You may need to read the notes carefully at first and then proceed to the next trial. Below is another trial to explore.\n[formula]  0) Excluded; 1) Response: 10% decrease in breast cancer; 2) Responses: 30% decrease in breast cancer; No response observed. [/formula] \nInput/output: 0) Excluded; 1) Response: 10",
        "label": 0
    },
    "1602": {
        "output": "# Running your script\nIn the file [Run] [Run_R](../../../run.html#Run_script_file), type the following code as is, and run it by pressing the `Run` button.\n\n[R] ```{R}$ data(\"RSV16_data\", package = \"RSV16\") trial <-RSV16_data trial[[1]]$Trial <-\"RSV16_143\" summary(trial, sum. = 1) head(trial, nrow = 100)\n\nNow you should find the following table in the output window.\n\n*** You should get the following results **\n\n## The Patient\n\nName: RSV0143\nGender: Male\nAge: 55 Years\n\n## Laboratory examination\nAST (1): 35 IU/L\nALT (1): 13 IU/L\nAlbumin: 3.77 g/dL\nBili (1): 1.1 g/dL\nBili (2): 0.67 g/dL\nBili (3): 0.98 g/dL\nHct (1): 50% Hct (2): 42% Hct (3): 44%\nCr (1): 0.85 mg/dL Cr (2): 0.86 mg/dL Cr (3): 0.90 mg/dL\nHb (1): 12.0 g/dL Hb (2): 13.1 g/dL Hb (3): 12.8 g/dL\nWBC count (1): 6.2K WBC count (2): 8.02K WBC count (3): 10.2K\nPlt count (1): 430K Plt count (2): 510K Plt count (3): 415K\nPlts (1): 27% Plts (2): 24% Plts (3): 24%\nHemo (1): 11 g/dL Hemo (2): 10 g/dL Hemo (3): 13 g/d",
        "label": 0
    },
    "1603": {
        "output": "A: 55 Years\n\nYou must be 18 or over. This is the age restriction placed by many sponsors.\nThe patient is a 55-year-old man HCV 2 years ago co- HBV. His past medical history nonsignificant. He is on IFN, RBV and direct n for the past 6 months. The patient takes no other medi- cal records show previous posit HCV RNA tests a lcoholic liver disease, bleeding from esophagi crologic hepatitis. There is no evidence of autoimm metabolic liver disease. He is an alert ma HR: 90/min and BMI: 27. His abdomen is soft no ascites or tenderness. The lower extremities are n edema.\n\nHere is the clinical trial:\nTitle: Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C\n\nSummary: The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.\n\nIncl Inclusion Criteria: confirmed chronic hepatitis C (HCV Ab (+), HCV RNA ( with PCR (+)) normal or increased liver enzyme or not consenting. You must be 18 or over. This is the age restriction placed by many sponsors.\n\nA: HCV: Hepatitis C virus\n\nHCV RNA: Hepatitis C virus ribonucleic acid\n\nHBV: Hepatitis B virus You must be 18 or over. This is the age restriction placed by many sponsors.\n\nA: : Hepatitis C virus ribonucleic acid ( RNA) HCV : chronic hepatitis C virus HCV is the name of a \nvirus that causes hepatitis C a liver disease HCV RNA is a subtype of viral RNA which determines its type hepatitis B or hepatitis C The virus is characterized by a high mutation rate and has a positive-negative (sense-antisense) RNA genome The virus is enveloped with icosahedral symmetry It is a small enveloped virus with a nonsegmented positive-stranded RNA genome",
        "label": 0
    },
    "1604": {
        "output": "# [OUT] Output\n\n\n> ## Data analysis and manipulation\n>\n> Data analysis and manipulation allows you to:\n> \n> * Add additional data columns  # Add column `Age` that calculates current age based on the patient age and date/time.\n> \n\n> * Remove columns  # Remove columns containing no data.\n> \n> * Filter rows  # Excluding patient with HBV coinfection.\n> \n> * Transform rows  # Convert the data type of the column `Age` to short integer using `toint`.\n> \n> * Reshape data  # Convert the data from wide to long.\n> \n\nAll of the following are available in [dgl.datasets.chm.clinical_trial_patient](https://bioconductor.org/packages/dgl.bioclusters/dgl.datasets.chm.clinical_trial_patient/) package.\n\n> ## Data analysis and manipulation\n>\n> ## Add columns\n>\n> # Add column `Age` that calculates current age based on the `date/time` and `Age` columns.\n>\n> > + Age <-1+ as.numeric(age-min(age)) / ( max(age)-min(age) )\n\n> ## Remove columns\n>\n>\n> # Remove columns containing no data. \n>\n><jupyter_text> \n> \n\n\n> ## Transform rows\n>\n> Transform the type of column `Age` from `double` to `int` using `toint`.    \n>\n> # Change the data type of `Age` column to integers using `toint`.\n>\n> > + for (patient in 1:nrow(df)) {\n> > + + Age <-+df[patient, \"Age\"] + + toint(Age) # Change to short integer. \n> > + + df.r = data.frame(df, Age=toint(Age), Age0 = c(\"0:15\")) +\n>\n\n> ## Reshape data\n>\n> ## Reshape the data from wide to long format.\n>\n> # Reshape the data from wide to long format.\n>",
        "label": 1
    },
    "1605": {
        "output": "### 1) 0) Excluded\n\nIn the `Trial-level eligibility` section, the trial-level eligibility should equal to `0` if the patient does not meet a particular exclusion criterion:\n`Trial-level eligibility: 0) Excluded.`\n\n### 2) 1) Not relevant\n\nOr a clinical trial might be closed or suspended and there is not enough clinical trial staff to provide a reasonable review, in that case the trial-level eligbility of any patient should be `1`.\n\n    `Trial-level eligibility: 1) Not relevant.`\n\n### 3) Eligible\nYou should set the trial-level eligibility to be positive one (i.e., `1`) if the patient:\n1. Is eligibile and meets all the inclusion criteria; and does not fail on the exclusion criteria.\n\n    `Trial-level elibgibility: 3) Eligible.`\n\n---\n\n\nAbove: Eligibility assessment in one patient\n<center style=\"height: 300px; vertical-align: middle; margin: 0 auto;\">\n<table cellborder=\"1\" cellwidth=\"95%\" cellpadding=\"8px\"  bordercolor=\"black\" borderstyle=\"medium solid darken border lighten border\" \" bordercolor: black;\" borderstyle: medium solid black; color:#17569e; color: black; width:300px; height=\"300%\"\">\n        <thead style=\" background-color: black;background-color: darken lighten\">\n        <tr style=\"text-align: center;background-color: black;background-color: darken lighten\">\n          <td colspan=\"2\" valign=\"bottom\" width=\"100%\"><center style=\"margin-top: 5px\"><strong>Eligibilty Assessment</strong></center></td>\n        </tr>\n        <tr style=\"text-align: left\">\n          <th>HCV: Hepatitis C (Co-infection or Mono-infection)</th>\n          <td colspan=\"6\" valign=\"top\">\n              HCV/HIV coinfections account",
        "label": 0
    },
    "1606": {
        "output": "What you should do next\u2026\n[INST]: We should implement the solution to the clinical trial eligibility problem. To achieve this purpose, we define an individual class, ClinicalTrial. A ClinicalTrial instance describes the details of a possible patient to a single clinical trial. A Trial-level eligibility is a list of individual ClinicalTrial objects, so we also have defined a function, getTrialleligibility, for getting the list of Trial-level eligibility. Finally, for making a trial-level eligibility decision, we've defined a function, eligibilitydecide, which does that for patients.\n[ENDS]\nA ClinicalTrial instance object is shown in Listing 2. We can also implement the same solution by using other techniques if a user wants to change a problem-solving method. Since the only different aspects of the solution from Listings 1-5 are the implementation parts (i.e., what a solution does), this part may change; however, the solution purpose (i.e., what a solution stands for) remains the same as defined in the question's problem statement.\n<EOD> The Effect of Submaximal Tidal Volume Breathing on Pulmonary Artery Pressure during Exercise and Recovery\n\nPulmonary artery pressure (pulmonary artery (PA) diastolic and systolic pressures) was compared before and after 15, 30, 45, and 60 min of submaximal exercise on a treadmill under conditions where breathing was conducted at the same tidal volume (TV) and respiratory rate during exercise using the following ventilation patterns: 1) high frequency, breathing every two breaths; 2) high frequency, breathing every three breaths; and 3) conventional, low frequency, 15-25. The ventilation patterns using 15-25 and high frequency every two breaths produced similar changes in pulmonary artery pressure and heart rate at all five time points (p > 0 .05). Conversely, using high frequency breathing (30-60 min) had a lower pulmonary artery systolic pressure than did breathing with 15-25 . Pulmonary artery diastolic pressure increased",
        "label": 0
    },
    "1607": {
        "output": "2. Write a program which determines the Trial-level eligibility. You can use any language you like, provided that the program can be executed remotely by [email [JG1]], the author of the homework. It is recommended to use a language that you already know such as Python, Perl, and Java.\nYour class should output two lines. Each line should begin with `Trial-level eligibility:` and the output of elicited patient note and the patient notes from the clinical trial. The program should also check patient note for each element listed in the clinical trial and output whether the patient note meets the trial inclusion criteria. If the patient note of a patient does not meet the criteria, output \"eligible\" (or \"eligible (age 55)\" in case of a special criterion) in the first line of\nthe output. If the patient note meets the criteria, the output should output \"not relevant\" (or \"not-eligible (BMI: 27, no HCC)\" in case of a special criterion) in the first line of the output. In case any element that is not documented is assumed to be negative (with no HCC -no history, BMI: 27 -no measurements and no history), output \"eligible\" (or \"eligible (age 55)\", \"eligible (BMI: 27)\" and \"eligible (no history of HCC)\" in case of special inclusion criteria). There should be a blank line between the two lines in the output.\n\nThis is the patient note of the clinical trial:\n\nPatient's Age: 55 Weight: 72 lbs Height: 5'9\" Bp (mmHg): 130/75 Heart Rate: 90/min Respiratory Rate: 18-20 Weight change: + 1.8 kg in past 3 months Past/recent Medical History: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records",
        "label": 0
    },
    "1608": {
        "output": "<EOD> Holographic lenses for the focusing of an obliquely incident laser beam.\nThe focusing of an obliquely incident laser beam at normal incidence with a computer-generated axicon is reported. High numerical aperture, high efficiency, and uniform intensity in the output field are achieved.<EOD> Effect of diabetes mellitus on response to therapy with beta-blockers and angiotensin converting enzyme inhibitor/angiotensin receptor blocker in patients with heart failure after myocardial infarction.\nBACKGROUND\nThe clinical implication of diabetes mellitus on the response of the beta-blockers and angiotensin converting enzyme/inhibitor (ACEI/ARB)-based therapy in patients with heart failure after myocardial infarction (MI) is known unclear.\n\n\nOBJECTIVE\nTo study the effect of diabetes mellitus on the response to beta-blocker and ACEI/ARB therapy in patients with heart failure (HF) after MI.\n\n\nRESULTS\nAmong 351 consecutive patients, 109(31.15%) patients received beta-blocker and 59(16.78%) patients received ACEI/ARB treatment. At discharge, a greater increase in left ventricular ejection fraction (LVEF), 6-min walking distance(6MWD), and lower BNP were found in non-diabetic patients when compared with those receiving beta-blocker and ACEI/ARB treatment combined with beta-blocker therapy in diabetic patients (13.1 vs. -12.7%, p=0.004; 23.1 vs. -15.6%, p=0.005; 196 vs. -47.9 pg/ml, p=0.014). In addition, the 46% hospital patients were significantly lower in diabetic patients who received beta-blocker and ACEI/ARB treatment.\n\n\nCONCLUSION\nDiabetic patients who received beta-blocker and ACEI/ARB treatment were less likely to be hospitalized on an annual basis.<EOD> A single amino",
        "label": 2
    },
    "1609": {
        "output": "# Expected Output\nFor each trial you should evaluate the following trial level performance:\n- `Included`- Patients that were included into the trial\n- `Not Enrolled`- Patients that were not enrolled into the trial\n- `Excluded`- Patients that were excluded from the trial\n- `Enrolled fraction`- Fraction of patients that were enrolled for the trial\n\n# Note\nIf the patient is part of the trial, then the trial-level assessment of eligibility should be `1) Eligible`. If the patient is not part of the trial, the trial-level assessment of eligibility should be `0) Excluded`. And if the patient is excluded on grounds of exclusion criteria then it should be `2) Excluded`.\n\n# Example Input\n\n# Example Output\n<EOD> The Role of APC Gene in Colorectal Cancer\n\nEarly events in the colorectal carcinogenesis have been characterized in terms of chromosomal instability. Different hypotheses have been introduced to show the mechanism of chromosomal instability and its underlying molecular events. APC protein is an intracellular tumor suppressor that provides important information about tumor progression and metastasis. The role of the APC gene in colorectal carcinogenesis has been demonstrated by numerous experimental and epidemiological studies. In this review we will examine the role of APC gene and its mutation in colorectal carcinogenesis.\n\n# Introduction\nColorectal cancer is the third most common cancer and the fourth cause of cancer related death in the world [bib_ref]  The role of the APC gene in the origin of colorectal cancer, Hatziapostolou [/bib_ref] . The incidence of colorectal cancer varies in different geographic regions of the world. According to WHO report, the incidence rate of colorectal cancer is in the age group of 20 to 69 years of which approximately 4 out of 10 occur in the aged 60 years or older.\nThe colorectal carcinoma is a complex set of diseases that occur due to the interaction of environmental and genomic factors. The colon tumors, like most other solid tumors, show a variety of chromosomal alterations. The gen",
        "label": 2
    },
    "1610": {
        "output": "# Example\n\n## Trial-level eligibility: 2) Eligible.\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. This is the patient note: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. Here is the clinical trial:\nTitle: Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care<EOD> Nutritional Influences on Human Cognitive Development\nRecent research has examined the impact of nutritional insults on infant development, and has indicated that nutrition has marked effects on the development of memory, cognition, and behavior. In this paper, we examine how two very early influences, prenatal nutrition and breastfeeding, interact to influence a complex developmental system, the human brain. We first review the evidence that prenatal nutrition, especially folic acid supplementation, plays a major role in normal brain development. We then examine the evidence that breastfeeding provides a",
        "label": 0
    },
    "1611": {
        "output": "Question: Is there more than one trial in the dataset? If you are allowed to include more than one trial (i.e., you have a multiple-trial dataset) just modify the following four lines of instructions (the line starting by `@DATA`) in the file `data` (see lines 379-391):\n379 201824119950000024 --1 201806112252278006 --1 20161007 4418591 17.0 20180620 917.4\n\nApart from these changes, the remaining sections follow the same format. You should change the variable 'data_id' by 'trial_id' in the code, e.g., ``@RDATA = data`` --> ``@RDATA = trials``. In this case the name of the variables are slightly changed (see lines 51-53 in the `rdat` file):\n\n51 TRIAL_NOTE          Character              76               \"This was written to have an example of data from \"\n52 TRIAL_NAME          Character              30               \"This was written to have an example of data from \"\n\nThe code of part \\textbf{B.1.2.1} should thus look as follows:\n\n    # TRIAL-ID B1\n    trials <- read.csv('trials')\n    ## Summary dataset\n    trial_id_summary <- data.frames(\n        'data_id' = '00000000553',\n        'notes' = 'I am the summary of the trial',\n        'country' = 'Canada',\n        'gender' = c(paste0('M', 1), paste0('M', 1)),\n        'patient_id' = c(paste0('55301032180', 1), paste0('55301032180', 1)),\n        'patient_name' = c('Bill', 'Bill'),\n        'age_group' = c('Aged 2', 'Aged",
        "label": 0
    },
    "1612": {
        "output": "# Results\n\n## [RUN] qbrute -qbrute qbrute run\nDuplicate result was found [RUN] qbrute | grep -C 2\n\n## # results\n\n## [RUN] # ./qbrute Genotype 2 Genotype 1.2.14\nNumber of lines to read: 642001 Lines: 1-4403\n# First-line: 19_19_33.1_0\n# Second-line:\n# Third-line: The factor that allows someone to participate in a clinical study is called inclusion criteria.\n# Fourth-line: 2) Eligible\n\n## [RUN] # ./qbrute Genotype 2 Genotype 2.2.14\nNumber of lines to read: 725960 Lines: 1-14493\n# First-line: 19_19_32.1_0\n# Second-line: The factor that allows someone to participate in a clinical study is called inclusion criteria.\n# Third-line: 2) Eligible\n\n## [RUN] # ./qbrute Excluded Genotype 2 Genotype 2.2.14\nNumber of lines to read: 968829 Lines: 1-30633\n# First-line: 19_19_32.1_0\n# Second-line: 0\n\n## [RUN] # ./qbrute Excluded Genotype 2 Genotype 2.2.14\nNumber of lines to read: 973402 Lines: 1-20889\n# First-line: 19_19_32.1_0\n# Second-line: 0\n\n## [RUN] # ./qbrute Excluded Genotype 2 Genotype 2.2.14\nNumber of lines to read: 963425 Lines: 1-52602\n# First-line: 19_19_32.1_0\n# Second-line: 0",
        "label": 0
    },
    "1613": {
        "output": "## [INST] Exercise: <EOD> Corruption in the United Kingdom: the role of social norms.\nSocial norms (or social customs, standards, ways or ideas) are powerful determinants of human behaviour. Social norms are shared expectations or beliefs about acceptable or appropriate behaviour that are established in a particular society by social institutions, such as the law and religion and, often, by 'moral entrepreneurs', social activists, or community leaders. The concept is often used in discussions about the prevention of corruption. In the paper that follows, examples of anti-corruption measures are presented and then a discussion of social norms, and how they can be changed, is presented. Four mechanisms to change social norms are used, such as education, public awareness, punishment and incentives, and pressure groups. In general, these mechanisms work in complex societies with certain prerequisite conditions.<EOD> Langerhans Cell Histiocytosis Presenting as Osteolytic Chromophobe Renal Cell Carcinoma in a Renal Allograft\nLangerhans cell histiocytosis (LCH) is an uncommon neoplasm with a broad clinical spectrum ranging from localized bone disease to a life-threatening disseminated form. The majority of cases of LCH arise in children younger than five years old, and usually involve the hematopoetic system, lymph nodes, and the skeletal system. However, the disease has also been reported in the liver, spleen, lung, kidney, and central nerve system. In this report, we present an adult with a renal cell carcinoma (RCC) in an allograft kidney, which after surgical removal, showed the LCH clinical presentation and immunophenotype. To the authors' knowledge, this is the first report of an adult renal allograft recipient presenting with an unusual case of RCC and LCH.<EOD> Correlation of the Tumor Microenvironment in the Breast Cancer Tissue Microarray and the Corresponding Metastatic Lymph-Nodes\n\nCitation: Erofeva, I.; Melnikov, A.; Sakhno, M.; Ginis, V.; Stroylova, B.;",
        "label": 2
    },
    "1614": {
        "output": "A: and for at least 7 months\n\nHere's an example for you.\nInstructions:\n1. Type your solution in your iPython Jupyternotebook using the code cells at the bottom of your cell (they appear as yellow cells - don't worry about the yellow background) and click File > Save As... to save your notebook (make sure the file is saved as a Jupyter notebook file; i.e. .ipynb).\n\n**Your first solution**: The first patient you need to look at is patient 1. The data table is organized such that the columns are the data collected and rows are the patients. For each patient, start a new cells. You may need to change the font size to make this clearer.\n\nFirst, take the patient notes and match them with the appropriate columns of the data table of patients. This way, you can verify that the data from the patient note actually appears in the data table of patients. You'll want to copy-paste the trial-level eligibility of each patient. Finally, we need a trial-level eligibility for patient 1 that is set to Not Relevant due to a lack of information about HCV and HBV. Therefore, set the trial-level eligibility of patient 1 to 0. This solution may help you to quickly think of all the possible scenarios and solutions that you'll need for other patients.\n\n\n**Your second solution**: You need to create a new patient note for patient 2. You'll need to know which type of HCV the patient has and whether or not he has hepatitis B. Copy-paste those items into the patient note. It will contain the following information:\n\n\n*",
        "label": 0
    },
    "1615": {
        "output": "==== CONCLUSIONS ==== Your task is to compare a given patient's note and the inclusion criteria for a clinical trial to determine whether the patient is qualified to be involved. Note that you can find the example files for clinical trials from the links provided to the test server. If you have any questions about this task, or would like us to make an amendment to this test, please drop an email to the admin address (<EMAIL>). ==== PRIVATISED METHODS ==== The clinical trial data are stored in the following tables:\n1) @cltrial includes the clinical trial and the clinical trial ID.\n\n\n2) @clparticip includes trials, IDs, patients, first name, last name, and the trial_id  - the trial participant identifier.\n\n\n3) @clpart includes the demographics, blood lab values, semen lab values, and the trial_id  - the trial participant identifier. \n4) @clcourses includes a list of courses taken in the trial and the ID - the trial participant identifier. \n==== CODE CORRECTION ====\nYou should be sure your code is properly coded, i.e. you should test your code before sending it to the TA. \nAlso, try to write the code in the style that is appropriate for your field of study:\nIf you need to write some of the data to a file, it is preferred to use file I/O instead of calling an unmodified standard library function such as cfwrite(). [/EXT]. \nYou can use an anonymous function if you need to have a local variable. However, it is not recommended to write too many lines of code inside an anonymous function. [/EXT]. \nYou should not name any local variable you create inside a function. [/EXT]. \n==== RUN DIFFERENTIALLY ==== Since we know that your code is to be run differently, we give you a chance to run a test using the `run` procedure or the `runAll` procedure. \n\n\n`run` is a one-step procedure of a specific test. \n`runAll` is a one-step procedure that will run all the tests.\n\n\n- For the `runAll`, specify the following parameters: \n\t- `test",
        "label": 0
    },
    "1616": {
        "output": "[EXAMPLE] [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine their eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for clinical trial, namely output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B",
        "label": 0
    },
    "1617": {
        "output": "### INST# The output of the clinical trial-level eligibility in a clinical trial\n\nLet's evaluate the clinical trial:\n```bash\nbash@centos7-vfz:~$ python3 trial-level.py -i 262_clinicalTrial.txt -o triallevel.txt -c 262_clinicalTrial.txt\n\nTrial Description\nTitle: Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump\n\nSummary: Patients who completed the conventional treatment against HCV and relapsed (the virus appeared again in their blood) have no effective therapy.\n\nInclusion Criteria: Inclusion Criteria:\nSigned patient consent form\nChronic HCV patients in relapse following conventional treatment regimen (INF+Ribavirine) with detectable plasma level of HCV RNA\nHepatitis B and human immunodeficiency virus negative at screening visit\nAble and willing to follow contraception requirements\nScreening laboratory values, test, and physical exam within acceptable range\n\nTrial Criteria\n\nTrial Criteria\n\nPatient ID Age Sex Race/Ethnicity Drug Group/Class Inclusion criteria Definitions Codes\n1 51 Female African American 3 3\n\n\n## Output results\n\ntriallevel.txt\n\n\n\n\n# INST# 2.0.2 - Generate the list of clinical trials using the data set (e.g., the data set used is named data.csv, which contains patient notes.csv and clinical trials file.).\n\n\n\n\nbash@centos7-vz:~$ ./trial-list.py Data.csv\nHepatitis C patients of 3 years-old and above\nTitle: Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump\n\nSummary: Patients who completed the conventional treatment against HCV and relapsed (the virus appeared again in their blood) have",
        "label": 0
    },
    "1618": {
        "output": "## Step 1: Input data\nWe are going to test clinical trials' eligibility on the patient's information. Our example is a clinical trial about the treatment of patients with HCV coinfection with HBV. \nIn this clinical trial, there is only one exclusion criterion, patients with cancer; for this reason, some of the patients are not eligible. It is important to know if the patient is eligible for the study before assessing the treatment. For example, if the patient has a malignancy or is not cooperating with the physician, the doctor can decide not to prescribe this specific medication. If the patient does not have the target illness, he may be excluded from the study. These are the patients who do not meet the inclusion criteria for clinical trials, or have exclusion criteria for studies. These are patients who do not have the disease that is the subject of the study. The reason for this exclusion may be due to certain pre-existing conditions that could interfere with the results of the study or even cause harm to the patient. You should not include these patients as a new patient and thus not repeat the trial.  \nThis is the clinical trial summary again to find information about the inclusion criteria:\nTitle: Antiretroviral treatment strategies in relation to adherence, resistance and virological treatment failure\n\nSummary: This project aims to assess different antiretroviral treatment strategies, optimally controlled and conventional, in relation to drug resistance and virological treatment failure. A Randomised Controlled Trial (RCT) where Vietnamese HIV+ patients with CD4+ T-cells <200/ul are randomized into either enhanced treatment support (ETS) through peer supporters or The National AIDS Control Program recommended self supervised treatment (SST). The treatment strategies will be assessed and compared in relation to treatment adherence and drug resistance development with virological treatment failure as primary endpoint. The results from this project will lead to an increased knowledge in relation the impact of treatment support on adherence, virological suppression and resistance development and have an impact on HIV treatment policies in low income settings globally.\nInclusion criteria: Inclusion Criteria:\nWHO stage IV of HIV disease, regardless of the",
        "label": 0
    },
    "1619": {
        "output": "Assignment of Patients:\nYou are ready to assign a patient for this trial trial-level eligibility: 2) Eligible.\n\nIf the patients are randomised in the trial, 1) Ineligible, 2) Exclusion.\n\n[INST] trial_id_1 2 = trial_id_2\nAssignment using R code: (you can also set the trial ID to 0, i.e. not assigned to anything for the first batch.)\n\nIf the patients are randomised in the trial, 1) Ineligible, 2) Eligible, 3) Eligible, 4) Exclusion.\n[INST] trial_id_1 1 = trial_id_1\nAssignment using the data exported from REDCap.\nIf the patients are randomised in the trial, 1) Ineligible, 2) Exclusion.\n<table border=1 cellpadding=1 width=3354> If the patients are randomised in the trial, 1) Ineligible, 2) Exclusion.\n<tr><th>1. Eligible</th><td>- 2) Eligibility</td></tr><tr><- 2) Exclusion</td><img src='/assets/randomization_2x4g.png' width=200%><img src='/assets/randomization_2x4g.png' width=200%></tr><tr><tr><td>2) Eligibility.</td>td=2 tr>2) Include<tr> tr>s eligibility eligibility</tdig trial_id> tr> Eligibility. Eligibility of eligibility (1) Inclusion) If the trial Eligibility) Eligb) Inclusion of a clinical trial) assignment of the trial-eligibility of the trial trial eligibility in eligibility trigligity by an Include the trial, or not include a) 1) with HIV) Include clinical trend]\nRCT and clinical.\nIf patient enroll trial2) and excludes 3) Including all trial.\n\nIncludes eligibility in the trial)<EOD> in the clinical randomness 4) trial_elig",
        "label": 1
    },
    "1620": {
        "output": "<EOD> Development and application of an HPLC method for monitoring the effect of a novel drug delivery system (GlucoMen\u00aeDay) in C57BL/6 mice by means of a simple urine sampling technique\n\nThe purpose of this study was to optimize and validate a high performance liquid chromatography (HPLC) method for the analysis of human and mouse glucose-monitoring tracer (human C-peptide labeled with stable isotope D-[2,2,4']trifluoromethylbenzylamide (D-Tf-CP)) concentration in the urine of C57BL/6J mice. The effects of the drug delivery system (DDS) (GlucoMen\u00aeDay) were monitored based on this method in combination with the tracer. The chromatographic separation was performed on a Kinetix XB-C8 column using a 68 min gradient elution procedure. Detection was achieved by fluorescence and the fluorescence detection wavelengths were set at 230 nm for the excitation wavelength and 480 nm for the emission wavelength. The method was successfully validated by determining various parameters. Both the intra-and inter-day precisions were less than 14% and the recovery rate was in the range of 96 to 101%. The lower limit of detection of the method was 0.7 ng/mL and the limit of quantitation was 2.1 ng/mL. The method was applied in the pharmacodynamic evaluation of GlucoMen\u00aeDay in diabetic mice. The results of the HPLC method indicated that the oral glucose-monitoring tracer containing nanoparticles (GlucoMen\u00aeDay) improved the absorption of oral glucosemonitoring tracer (human C-peptide labeled with stable isotope D-[2,2,4']trifluoromethylbenzylamide (D-Tf-CP)) compared to its counterpart without nanoparticles (GlucoMen\u00aeDuo). The results of the HPLC method also demonstrated that oral glucose-monitoring tracer (D-Tf-CP) with or without nan",
        "label": 2
    },
    "1621": {
        "output": "```\n\n</details>\n\n## [README.md](README.md)\n\n<EOD> The Use of High Flux Hollow Fiber Dialyzers for the Treatment of Lead Poisoning\nThe use of high flux hemodialysis to treat lead poisoning has raised debate as to whether the amount of lead removed would be clinically significant. The purpose of the study was to demonstrate that the lead concentration in hemodialysate could be decreased by substituting high flux for low flux dialyzers and to establish a clinical protocol for the use of high flux for the removal of lead. Eight patients, 5 adults and 3 children, were studied using high and low flux hemodialysis at 50 ml/min during an 8 hour period. The initial blood lead levels ranged from 46 to 146 \u03bcg/dl. The initial blood urea nitrogen levels decreased by 21 to 30%. The initial hematocrits decreased from 40.2 to 37.79%. The initial serum creatinine levels decreased by 37 to 75%. High flux hemodialysis with bicarbonate dialysate resulted in the following percent removals: blood lead 43.3 50 ml/min hour, blood urea nitrogen 75.24 \u00b1 8.5, and serum creatinine 58.79 \u00b1 12.09%. In conclusion, the low flux dialyzers removed significant amounts of blood lead. This study demonstrates that in cases where rapid blood lead removal is required, hemodialysis using high flux dialyzers and bicarbonate dialysate are effective in removing blood lead. In addition, the efficacy of high flux hemodialysis using bicarbonate dialysate eliminated the need for blood transfusions to provide the required hematocrits for low flux hemodialysis.<EOD> Effects of endothelial cell dysfunction on cardiac rhythm disorders of heart failure.\nHeart failure is a common clinical syndrome in human populations. Clinical trials have reported a negative effect of hypertension on cardiac remodelling and heart function after myoc",
        "label": 0
    },
    "1622": {
        "output": "[INST] Example Input\nClinical Trial Description\n\nTitle: Comparison of the Clinical Pharmacology and Safety of Ciclesonide and Budesonide: A Randomized, Double-Blind, Cross-over, Two Period Clinical Trial\n\n\nSummery\n\nThe objective of this study is to compare the metabolism of CIC and BUD by measuring the serum levels of parent drug and their metabolites.\n\nInclusion criteria\n\n\n\nMale and female subjects between 18 and 65 years of age, inclusive, BMI between 18 and 35 kg/m2, inclusive. Subjects who are using oral corticosteroids, intranasal/inhaled corticosteroids for the prevention or treatment of asthma for more than 3 months' duration. Subjects with positive ANA and ASMA, high serum lipids, diabetes, hypertension, glaucoma, and gastrointestinal ulcers or symptoms related to these diseases are not excluded. Subjects who have positive skin tests for inhaled corticosteroids (e.g., budesonide) are excluded. Subjects who do not want to be randomly assigned to treatment groups are allowed to enter the trial after signing additional consent form. Subjects must be in general good health as determined by medical history, physical examination, or laboratory evaluations conducted at the Screening visit and upon admission to the clinic. Examination should include a thorough examination of oral cavity for any abnormal findings.\n\nExclusion criteria\n\nSubjects presenting with any clinically relevant abnormality in laboratory tests at screening and at baseline are not eligible. Subjects having any of the following medical conditions are excluded from participation in this study: cardiovascular disease including hypertension, and arrhythmia; cardiomyopathy; cardiac fibrosis; myocardial infarction; coronary artery bypass surgery; pulmonary embolism; chronic obstructive lung disease; liver disease, excluding hepatomegaly; renal disease; blood disorders; adrenal gland disease (hyperadren",
        "label": 0
    },
    "1623": {
        "output": "[CODE] # Include a list of the eligibility criteria in order by increasing priority, using:\n## If the patient does not have a history of cardio-vascular disease, the risk of MACE in M-COPA is lower than in OCOP.\n## M-COPA has a better safety profile than OCOP, because OCOP is a combination of 2 medications which can induce hypoglycaemia and/or acute kidney injury. \n## Cardio-vascular complications, including ischemic events and stroke, are the leading causes of the first occurrence of MACE, and are much more frequent in the OCOP group than in the M-COPA group. \n\n## Ocop has a tendency to increase the rates of hypoglycaemia and acute kidney injury (aki)(8) compared with M-COPA (P=0.091 and P=0.099, respectively). \n## Ocop has a greater risk of MACE compared with M-COPA. \n# End inclusion by using the `end if` statement, then,\n## IF the patient has a history of cardio-vascular disease, MACE may occur in OCOP. \n## When OCOP is taken in combination with antiplatelet drugs for cardio-vascular disease, an increased risk of MACE may occur. \n## OCOP may have a greater incidence of hypoglycaemia and AKI, compared with M-COPA. \n\n# End of the code. [/CODE]<EOD> GW regulator interactions in human 2\u2010cell embryos: potential role for a microRNA\u2010mediated feedback loop\nMicroRNAs are short (19\u201324 nt) and highly conserved non\u2010protein\u2010coding RNAs that play a key role in the post\u2010transcriptional regulation of gene expression at the translational level. MicroRNAs regulate many cellular processes including development and differentiation, and are often expressed in a tissue\u2010specific manner. The human microRNA transcriptome is characterized by a complex, hierarchical regulatory architecture with feed\u2010forward and feedback loop motifs embedded in its evolutionary histories. Feedback loops are often regulated by microRNAs themselves as",
        "label": 1
    },
    "1624": {
        "output": "*Note: The output is shown in the right-hand side of your screen as text rather than in the [x] option.\n# Trial-level eligibility 2.<EOD> Impaired Fc\u03b3Rmediated phagocytosis by blood dendritic cells from patients with systemic lupus erythematosus\nDendritic cells, the most potent antigen\u2010presenting cells, are pivotal in the induction of immunological tolerance. The role of blood dendritic cells (bDC) in systemic autoimmune diseases, like systemic lupus erythematosus (SLE), is currently unknown. Therefore, in this study, we compared the expression of HLA\u2010DR, the early dendritic cell marker CD83, and Fc\u03b3RII, Fc\u03b3RIII, and Fc\u03b5RI on blood dendritic cells with the Fc\u03b3R expression on blood dendritic cells from healthy controls. Both bDC and DC from healthy individuals displayed increased HLA\u2010DR and CD83 expression upon stimulation with R848 or TLR\u20103/4 agonists. These stimuli resulted in significantly elevated levels of Fc\u03b3RII and downregulation of Fc\u03b5RI expression on blood dendritic cells and DC from healthy individuals compared to nonstimulated cells. Increased HLA\u2010DR expression was accompanied by upregulation of CD83 and higher phagocytosis of IgG\u2010coated particles by both types of cells. In contrast, IgG\u2010mediated phagocytosis by bDC from patients with SLE was substantially impaired, as reflected by the reduced binding and phagocytosis of IgG\u2010coated latex particles and lower frequencies of bDC expressing cell\u2010surface receptors. These results indicate an impaired functional phenotype of blood and tissue DC in SLE.<EOD> .\nThree hundred and eleven HIV and AIDS patients were seen and followed up between January 1992 and December 1994. We analyzed their clinical records and the results of serological testing for immune deficiency. The study group consisted of 170 men and 141 women; the age of the patients ranged from 1",
        "label": 0
    },
    "1625": {
        "output": "[END] Input the clinical trial note: \nTitle: To Study the Efficacy and Safety of Renessans in Chronic HCV Patients\nSummary: Chronic HCV infection is one of the common causes of the chronic liver disease. Approximately 6-10% of the general public is expected to be suffering from this infection. In case that these patients are not treated at an appropriate time, these patients develop the sequelae of the chronic liver disease e.g. cirrhosis of liver, Ascites, and Hepatocellular carinoma. Interferon alpha 2 a or alpha 2b injections and Ribavirin combination is the treatment of choice for people suffering from Chronic HCV infection and this combination need to be administered for 6-12 months. Interferons are biological agents and are to be administered parenterally. Interferons are expensive and are associated with number of minor and major adverse effects. Ribavirin is also associated with significant adverse effects. These compounds cannot be considered as one of the ideal forms of the treatment.~In the past, quite a few natural products have been tested to assess their hepatoprotective activity and possibly anti viral activity as well. These include Vitamin C (Ascorbic acid), Vitamin E, Zinc, Silymarin, Red beet roots, crushed licorice and etc. etc.~Rationale Iodine , Potassium iodide and Ascorbic acid are natural products used in the management of Thyroiditis and chronic cutaneous fungal infections. This combination of iodine compounds along with ascorbic acid is being used for the management of chronic hepatitis B & C in the central Asian states e.g. Kazakhstan etc.~The investigators have conducted a feasibility study in which oral Iodine Compound {RENESSANS} was given to patients suffering HCV related Chronic Active Hepatitis and anti-viral activity and safety has been analyzed. In this study, RENESSANS containing regimen has been well tolerated by all the patients and has shown some antiviral activity.~In this study the investigators will assess whether the administration of RENESSANS {oral } improves the",
        "label": 1
    },
    "1626": {
        "output": "[EXERCISR]\n#### Exercise\nThis exercise is similar to above, the difference is there is an extra feature for assessment of eligibility. This patient note is:    \nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. Here is the clinical trial: \nTitle: Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir\n\n\nSummary: Hypothesis Response guided therapy improves significantly the overall SVR in Hispanics compared to historical control. There is no difference in SVR between patients with an undetectable HCV RNA at week 8 and week 28 who received a 4 week lead-in of PR plus 24 weeks of PR+BOC based treatment and patients with detectable HCV RNA at week 8 and undetectable HCV RNA at week 24 who received a lead-in of PR plus 32 weeks PR+BOC followed by based therapy and 12 weeks of PR.\nInclusion criteria: Inclusion Criteria:\nTo be eligible for this trial, patients must have documentation of the following:\nMale or female > 18 years old\nHCV genotype-1 in",
        "label": 0
    },
    "1627": {
        "output": "# [CORRECT]\n\nThis section explains how you need to correct your patient note in a manner that allows you to accurately eligible patients for the clinical trial. \nThere are no changes required, except the one shown below:\n\n\n`The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n\nHis abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n`His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n\nHis abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.` [/CORRECT]</INST>\n\n# [CORRECT]\n\nThis section of the tutorial describes how you need to make the patient note correct. \nIf you have completed the instructions given on the previous two web pages, this section describes how you should make the patient note correct so that a correct trial-level eligibility can be calculated.\n\n\n`The patient is a 55-year",
        "label": 0
    },
    "1628": {
        "output": "[PATCH 3/4/2016] The function `output` supports the multi-line output (e.g., ```output (\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility for the trial. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n```python\nThe patient is a 43-year-old woman diagnosed with Sjogren's syndrome 20 years ago with a recent complication of peripheral neuropathy. Her pre-diagnosis medical history is non-significant. She is on HCQ for the past months. The patient takes no other medications. Her medical records show positive anti-SS-antibodies, low complement levels, and positive Sjogren's syndrome and ANA tests. The biopsy was negative for rheumatoid arthritis and was only remarkable for chronic inflammation compatible with Sjogren's syndrome. There is no evidence of autoimmune colitis, acute distress, and bleeding from esophageal varices, hemochromatosis, collagen-vascular disease, or scleroderma. She is an alert woman with no acute distress. Her BP: 110/55 (elevated), HR: 95/min and BMI: 30. Her abdomen is soft with no ascites or tenderness. The lower extremities are dry with no edema.\n\nThe inclusion criteria for this study are in the following table.\n\n`Table 2.  Clinical trial's inclusion criteria`\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility for the trial. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage",
        "label": 0
    },
    "1629": {
        "output": "Thank you very much.\n\n# <NAME>, <NAME>, <NAME>, <NAME>, <NAME>... <NAME>\n<EOD> Nuclear spin\u2013orbit induced coherent spin current and spin wave in a bulk topological insulator\nSpin-orbit coupling (SOC) is a central ingredient for topological insulators (TIs); a newly classified quantum of matter with gapless surface states as a result of the coexistence of nontrivial bulk energy and two-dimensional (2D) Dirac surface state, a gapless linear dispersive state in momentum space. The gapless linear dispersive state in momentum space is generally associated with a massless Dirac Fermion, i.e., the effective electrons are free; thus one of the important applications of the 2D systems is a highspeed transmission line for spin or electron transport. The quantum Hall effect, which is originated from the SOC effect, was identified as one of the promising methods for information propagation. Another application of the TI surface state is for quantum computers. The surface states in a TI enable the implementation of long-distance quantum electron transport due to the quantum confinement effect. Anomalous Hall effect and Majorana fermions (gauge fields), owing to the SOC, also hold great potential for applications in quantum information technology. Recently, TIs have aroused much research interest because of their promising applications in various spin-based nanodevices. The SOC can be used to generate a coherent spin current (CSC), which is a promising direction for highspeed spin storage and transport. As is known, the CSC can only be generated in an electrically neutral medium because of the momentum conservation. However, the 2D spin valve and semiconductor spin transistor with a large g-factor have not yet been achieved experimentally. The main problem to be solved is the injection of spin currents into TIs, as it is hard to inject spin currents into a spin valve because of the lack of spin\u2013orbit interaction (SOI). Although a very large value g-factor was reported in Bi2Se3, there was no effective spin injection. Moreover, the spin currents that should normally flow in a spin valve are hard to inject into the source (electrically neutral) of a spin transistor because of the same reason. Recently, Rok",
        "label": 0
    },
    "1630": {
        "output": "### [19] Patient Name\n\nIt could be an alias (first name combined with initial of a last name, or vice versa, e.g., _Thomas J. Wilson_ or _Wilson T. Thomas, Jr., 2_); the first initial without middle or middle initial without initial first; and single initial without last name (_J._ or _J. L._).\n\n### [20] Trial ID\n\nEnter the ID of the clinical trial to whom the patient belongs.\n\n### [21] Assessment of Eligibility (1) Excluded\n\nThe patient satisfies inclusion criteria but is excluded on the grounds of the trial's exclusion criteria.\n\n### [22] Not Relevant\n\nThe patient does not have sufficient information to qualify for the trial.\n\n### [23] Eligible\n\nThe patient satisfies inclusion criteria and exclusion criteria do not apply.\n\n## Answer Set | Assessment of Eligibility _(0|1|2)_\n\nEnter the assessment set which represents the patient's status. You can enter a valid answer set like the rest of the data sets.\n\n## [INST] Data entry interface: Trial ID is _0|1|2|3|9|10|11|12|13|14|15|16|17|18_..._.\n![INST]\nFinally, you should click on Save and then you can repeat the step by visiting the student login",
        "label": 0
    },
    "1631": {
        "output": "## Data Set\n\nAs with most data mining models, this learning model is evaluated using a data set, called dataset. In a data set, each sample corresponds to a row in the data matrix. Samples in the dataset must always contain three parts: feature matrix, target matrix, and sample ID. The feature matrix contains the vector of feature attribute values for each sample. The target matrix is a one-dimensional vector containing the numerical value for each sample. Each column in the feature matrix must correspond to a one-dimensional vector in the target matrix. The sample ID column contains the unique sample ID which must be identical to the ID in the target matrix. \nIn our case, to predict the eligibility of a patient, the data set should include a patient note and the clinical trial note which are shown in \nAs the number of features for HCV, IFN and RBV is large, the column names of the feature matrix are shortened and the values are mapped to one of the pre-defined target values, shown in . 1.6.4. Examples of the data set \nHere are two examples of dataset:\nTrial id: IFN-based Trial Eligibility: Eligible Treatment: IFN\nTrial id: RBV-IFN Trial Eligibility: Eligible Treatment: RBV-IFN \n\n## Parameters\n\nMachine learning approaches, unlike purely statistical methods, use learning methods to find a pattern in a data set or to produce a model that can correctly predict the outcome of new data. The learning model is designed by setting parameters as listed below according to the actual data set. \nIn ML (especially NN) models, the parameters are categorized as either hyperparameters or trainable parameters. Hyperparameters (the terms is also called hyper-parameters, hyperparameters) \nare the parameters that we need to set before training (we use fixed values once we set them); these are mainly used to control the training process. Trainable parameters \n(sometimes called non-threshold parameters or trainable weights) are the actual values learned during training (which are learned by adjusting their values); i.e., they are functions that can be learned through a machine learning method. In this model, in our NN approach, there are many hidden parameters in addition to the parameters shown in the following table. \n\n## Parameter",
        "label": 0
    },
    "1632": {
        "output": "[INFO] The clinical trial recruitment tutorial has ended for today. Thanks for attending! We hope you enjoyed the course! See you on Monday.\n\nSee you on Monday, folks!\n<EOD> Pure red cell aplasia in patients with rheumatoid arthritis treated with leflunomide.\nTwo out of 163 patients with rheumatoid arthritis treated with leflunomide presented pure red cell aplasia. On the basis of the known effects of this drug on the immune system, the following pathogenetic mechanisms for the erythropoietic damage can be considered: alteration of the bone marrow architecture, inhibition of erythropoiesis by means of the reduced availability of erythropoietin, and toxic effect on erythroid precursors mediated by the drug metabolite A77 1726.<EOD> Recombinant human interleukin-1 beta stimulates both heme oxygenase and c-fos in BALB/c 3T3 fibroblasts.\nRecombinant human interleukin-1 beta stimulates the accumulation of carbon monoxide and bilirubin, the end-products of heme oxygenase (also named heme oxygenase-1 for its pI approximately 38 protein), in BALB/c 3T3 fibroblasts stimulated with either lipopolysaccharide (LPS) or interferon-gamma (IFN-gamma). The recombinant IL-1 beta also elicits the accumulation of c-fos mRNA in BALB/c 3T3 fibroblasts stimulated with either LPS or IFN-gamma. Addition of a monoclonal antibody to interleukin-1 beta (MAb IL-1 beta) to the cell cultures suppresses the ability of IFN-gamma and LPS to stimulate heme oxygenase and c-fos, indicating that endogenous interleukin-1 beta was necessary for maximal induction. Since",
        "label": 0
    },
    "1633": {
        "output": "\\inst{}[INST] The data set contains 13,988 observations of 2-dimensions. Here are the two sets of data in the data \\file\\data.xlsx:\n\n```\nHospital(1, 2, 3, . . . , 11)\nHospital.1_1(1, 2, 3, . . . , 11)\nHospital.13(1, 2, 3, . . . , 11)\nHospital.251(1, 2, 3, . . . , 11)\nHospital.30(1, 2, 3, . . . , 11)\nHospital.5_1_(1, 2, 3, . . . , 11)\nHospital.2722(1, 2, 3, . . . , 11)\nHospital.29825(1, 2, 3, . . . , 11)\nHospital.31_2_(1, 2, 3, . . . , 11)\nHospital.56_1(1, 2, 3, . . . , 11)\nHospital.56_2(1, 2, 3, . . . , 11)\nHospital.6_2(1, 2, 3, . . . , 11)\nHospital.9(1, 2, 3, . . . , 11)\nClinicalTrials(1,",
        "label": 0
    },
    "1634": {
        "output": "You should store the results in a JSON format as `result: [1, 0, 2],`. [INST] \n\n`result: [1, 0, 2]` 96.8%, [INST] \n``\n\n`<br />\n{\"result\": [1,0,2],}\n`\n\n<EOD> Synthesis, in vitro evaluation, and molecular dynamics simulation of N-benzyl piperidines on acetylcholinesterase: an in silico approach\nTo enhance selectivity towards a specific acetylcholinesterase isozyme, a series of N-benzyl piperidines was prepared and evaluated in vitro. The ligands of interest demonstrated excellent selectivity for AChE as opposed to butyrylcholinesterase, with a strong preference to AChE-R as opposed to AChE-S. These results are discussed with the aid of molecular simulations over 50 nanoseconds, and highlight some of the key features of this class of N-benzyl piperidine molecules interacting with the active site of AChE and BChE. In silico study of key molecular interactions, docking, and molecular dynamics simulations of these ligands to AChE-S and AChE-R were performed to investigate the ligand pharmacophoric groups (electrostatic and electrostatic attraction) with the enzyme and their binding modes at the active site. AChE active site residues Tyr124, Tyr337, and Tyr72.<EOD> Effects of pre- and postnatal antiepileptic drug administration on the development of cerebellar Purkinje cells in a non-epileptic rat model\nBackground & objectives: Use of antiepileptic drugs (AED) has been shown to cause dysmorphogenesis in offspring which could be associated with cognitive impairment and motor deficits including seizures. The study was designed to analyse in the non-epileptic rat the effects of pre- and postnatal administration of AED on the number of cerebellar Purkinje cells, which are the principal efferent component of the cerebellar system responsible for motor control. Methods: Sprague-D",
        "label": 0
    },
    "1635": {
        "output": "Please refer the following source links for details of evaluation criteria of clinical trials:\nhttp://www.clinicaltrial.nih.gov/ct/definitions/<EOD> .\nThis is the first study in Mexico describing cardiac valve diseases as a leading cause of death, the main etiology (bacterial endocarditis) and the outcome of the disease. Death was correlated with certain clinical features which could help in the decision about the need for an urgent intervention.<EOD> P011\u2003A qualitative study of self-management education to improve quality of life during remission in patients with inflammatory bowel disease (IBD): a pilot randomised controlled trial\nBACKGROUND AND AIMS\nInflammatory bowel disease (IBD) is a relapsing and remitting condition affecting bowel function in adolescent and adult patients. Self-management interventions (SM) have not yet been evaluated in IBD. In a pilot randomised controlled trial (pRCT), we investigated the impact of an SM programme on adherence and anxiety among IBD patients in clinical remission. The aim of this qualitative study was to elucidate participants' experiences with the SM intervention to evaluate outcomes.\n\n\nMETHODS\nA qualitative interview approach was employed based on a thematic analysis method. Participants in the SM intervention group of the IBD Pilot RCT were contacted, of whom 20 agreed to an interview. Nine interviews had been conducted before submission of the manuscript. The interviews were audiorecorded, anonymised and transcribed verbatim. The transcripts were analysed using qualitative content analysis with a deductive approach. The data was then deductively and inductively coded against the self-management concepts as proposed by Lorig and Holman.\n\n\nRESULTS\nInterviews were analysed to identify categories in the content analyses. Overall, participants were very satisfied with their participation in the intervention. The intervention was experienced as very informative and helped the participants to better understand their situation. They also learned to control the process around their disease. Some of the more passive activities in the SM programme (e.g. reading information) did not appeal to all participants and were experienced as rather boring.",
        "label": 0
    },
    "1636": {
        "output": "~Scoring system: The patient receives the following points. One point is awarded for each positive response. You can find the scoring system under the section `Points and their calculation.`\nLet's assign these points to patient in `Patient` section. (see `Assigning points` section for more information about scoring).\nIf the patient has a positive score, the patient is `Eligible (Elig)` and vice versa, is `Not Relevant (NR)`.~If you type (double click) `Elig` in the textbox of the group in the `Patient` section, the system will assign the points and display the output screen `Patient Eligibility output`. (see also `Patient Eligibility Output` section for more information about patient's eligibility outputs. You can also change the score of the patient. The effect of scoring on the patient's final score is described in more detail in the `Patient's score and their effect on the final score` section).\nLet's assign the points for the first patient. (see screenshot of `Step 1` section of Assigning points module. If the patient doesn't reach the eligibility criteria's score, the system will assign to her the lowest score (zero). (see `Patient's score and their effect on the final score` section for more information about score of patient).\nFinally, you should assign score to the second patient in the `patients` part. (see screenshot of `Step 2` section of Assigning points module.\n\n\n## STEP 3: Assigning points and patient scoring\n~Assigning points and patient scoring: This section can be done by clicking or double clicking the `Assign points and score` button, the left part of screenshot below:~\nTo run `Assigning points and patient scoring`, click or double click the `Assign points and score` button, the left part of screenshot below:~The system requests you to choose one or more points from the drop-down menu of `Eligibility score:`, and then assign the selected scores to different groups of the patient. When you choose `Other`, you can assign these points to the score of this patient by choosing a number from the `Number` drop-down menu.\nWhen you finish assigning the points, the system automatically calculates the patient scoring according to the above scoring",
        "label": 0
    },
    "1637": {
        "output": "[EXERCIS] EXERCISE2. Hello. You are about to make clinical trial eligibility as `1) Not relevant` or `2) Excluded` or `3) Eligible` in an input form. If you select one of them, corresponding input form will have your choice.\n<EOD> Sensing the Environment: Opossums Monitor the Social and Physical Context\n\nSight is the primary sense of diurnal marsupials like the gray, or gracile, opossum. In this study we characterized the visual abilities of the gray opossum, Didelphis virginiana, and determined if the visual attention of adult (n = 4) animals differed by sex. We trained and tested adult gray opossums on a simple task designed to assess their ability to discriminate between two visual stimuli and quantify the visual attention of single opossums across two experiments. Opossums were able to discriminate between a color pair of orange versus white, and between a pattern pair of black versus black and white striped. In the second experiment (n = 70) we investigated the effect of social context on spatial distribution, and response patterns of opossums. We also examined their responses to two predators (dog and cat). No differences were found between the sexes in the amount of attention they paid to a target versus the response patterns. Gray opossums had a strong tendency to avoid a predator when in the presence of another. Social context also seemed to affect their spatial distribution. Our results provide evidence that gray opossums can rapidly discriminate between and detect visual patterns and also show evidence that they are adept at monitoring their environment.\n\n# Introduction\nThe ability to discriminate between visual cues is an important part of survival. Animals that lack good vision, such as opossums (Didelphidae), may rely heavily on their other senses to accomplish daily activities. Visual cues can vary in their effectiveness and opossums may rely on different sensory input to help inform their decisions regarding various behaviors [bib_ref]  Inhibition or facilitation of visual object recognition during learning: opposing effects on..., Winters [/bib_ref] . However, the visual ability of the gray or gracile opossum (Didelphis virginiana) has yet to",
        "label": 1
    },
    "1638": {
        "output": "<a name=trial_level_ineligibility>\n=== Trial-level ineligibility\n\nYou observe the patient note below. You are a helper in the clinical trial team. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility for the clinical trial. The trial-level ineligibility in this assessment is the absence of inclusion criteria. If none of the criteria from the included trial are met, that patient is ineligible.\n\n\n[EXAMPLE] Hello. You are an experienced clinical researcher. You have been assigned to work at [CRAHN]. Here, you are visiting [NAME] and [NAME]\n[CRAHN] staff have been helping. You should determine the eligibility for the clinical trial of the patient. Here is the patient note:\n\n## The patient is a 57-year-old man diagnosed with hcv 23 years ago and the recent coinfection with hbv. his past medical history is non-significant. he is treated with peg-ifn and rbv for the past 6 months. his medical records show previous negative hcv rna tests and a positive enzyme immunoassay for anti-hcv-antibodies. there is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, or metabolic liver disease. he is an alert male with no acute distress. his blood pressure (bp): 120/85, heart rate (hr): 90, and bmi: 26. his abdomen is soft with no tenderness. the lower extremities are normal with no edema.\nHere is the clinical trial:\n[/EXAMPLE]\n\nA trial-level ineligibility is determined when all the inclusions do not meet. \n\nPlease choose the appropriate response in each row below and input it into the Trial-level ineligibility of CRAHN in [RQ4] (CRAHN-0107).\n[/TRIAL_LEVEL_INELIGIBILITY_C]\n\n<a name=trial_level_in",
        "label": 1
    },
    "1639": {
        "output": "Note that the number of lines before the line that repeats the trial record number must be same as the number of lines before the first `Trial-level eligibility:` line. That is, the number of lines in those two lines and all the lines in between must sum up to the number of lines between the `clinical trial` key and the line that repeats the trial record number.\nThe first line (see) is a line for the `trial record number` to be the index of the trial as a whole. The second line (see) shows the contents of the trial, and the last line shows the `Trial-level eligibility:` for a patient to participate in the trial. Note also the line below that is a line to repeat the previous `Trial-level eligibility:` as a way of checking the quality or integrity of the line. This is why the number of lines between the `clinical trial` key and the line that repeats the trial record number must be the same as the overall number of lines between the key and the line that repeats the trial record number. All the lines between the first three lines (see) are for the patient's characteristics, such as Age, BMD/BMI, and HCV RNA test, etc. The last line is also a line for a patient record and repeats the trial record number.\nThe third line (see) of the last block of code is like the third line of the trial record number (see). The first line (see) is a line for the `patient record number` to be the index of the patient as a whole, and the second line (see) shows the contents of the patient. The last line shows the `Patient-level eligibility:` for the patient to participate in the trial.\nTo check the trial record, and then to run the trial's assessment of eligibility code in the `clinical trial record` object, you should have used either the first or the second method of your input/output file, depending on which you chose at the beginning.\nIf you chose the first method (#1), you will write the following code to check the trial record from the `clinical trial record` object, and then you will check the contents of the trial from the `clinical trial` object for the given patient record at the `patient record number` line",
        "label": 0
    },
    "1640": {
        "output": "[END]\n[Tutorial for the example from the official documentation](https://python.org.tw/posts/911/11/), [Japanese](https://github.com/zhouxiang/Python-tutorials/tree/master/Tutorial_for_document/japanese).\n#### The Explanation of Some Important Parts\n\n### `ClinicalTrials`\nIt is an [open source Python Library](https://zhouxiang.github.io/Python-tutorials/Tutorial/). It is for analyzing, importing, managing and visualizing clinical trials data in a Pythonic way. It includes both the [ClinicalTrials XML Schema](https://zhouxiang.github.io/Python-tutorials/Tutorial/doc/ClinicalTrials/XMLSchema/index.html) and the [Protocol Data Sets](https://zhouxiang.github.io/Python-tutorials/Tutorial/doc/ClinicalTrials/XMLSchema/index.html). \n-   [ClinicalTrials Module](https://zhouxiang.github.io/Python-tutorials/Tutorial/doc/ClinicalTrials/index.html) - [Protocol Data Sets](https://zhouxiang.github.io/Python-tutorials/Tutorial/doc/ClinicalTrials/ProtocolsDataSets/index.html)\n```Python\n>>> print(ClinicalTrials.__version__)\n  1.1.3\n```\n-   [Open Source Clinical Trial Database](https://trialdb.org/)\n\n### `doc`\nThe source code for the trial is a JSON file. There are some important parts, i.e. the `title`, `study_sponsor`, `source`, `year_created`, `description`, `recruitment_start_date`, `recruitment_finish_date`, `recruitment_duration_days` and `study_phase` (i.e. 1, 2 or 3), i.e. the [clinicaltrials.gov doc](https://archive-v3.clinicaltrials.gov/ct2/show/NCT0347",
        "label": 0
    },
    "1641": {
        "output": "<EOD> .\nHistological changes occuring during experimental allergic nephritis are described. The glomerular and tubulo-interstitial lesions were quantified. All rats given a single intravenous injections of homologous kidney are given developed, in their kidneys, large sub-capsular immune-cell infiltration, glomerular and tubulo-interstitial lesions. In rats given consecutive injections of the homologous kidney, no such lesions are present; this can be ascribed to their non-specific delayed hypersensitivity. All the animals present an increase in the number of polymorpho-nuclear leukocytes in their kidneys 7 days following the first injection. After the second or successive injections, polymorpho-nuclear leukocyte infiltration shows an additional increase which is the greatest in relation with the anti-kidney immune-cell response. The increase of the number of polymorpho-nuclear leukocytes in rats given consecutive injections of antigen is the result of an increase in their recruitment from blood as ascertain by the radio-isotopic technique. All the rats exhibit hyperdynamia from the 5th day.<EOD> Heterologous Expression of the Nematode Genome: Drosophila as a Model Organism\n\nWe recently reported the ability of the Drosophila melanogaster model system to act as a surrogate for Caenorhabditis elegans when heterologously expressing the nematode genome(Perry et al., 2016). A D. melanogaster-based system for characterising complex multigene pathways and organismal physiology has several advantages over traditional heterologous expression systems and it provides opportunities for generating large sets of informative genetic and behavioural reporter mutations. Here we describe the first protocol for using the Drosophila-based system for the analysis of C. elegans.\nPerform in parallel the following two steps: 1. Fly husbandry, and 2. Generation of the worm infection extracts.\nNote: Drosophila husbandry and handling is in preparation for the protocol at http://trendsetter.nih.gov/d",
        "label": 2
    },
    "1642": {
        "output": "20. Create an assessment using the assessments that we've created to see if you are eligible. \n![INDE](INDE.png)\n21. If `You are not eligible?` Click the 'Ineligible' button. \nIf `You are eligible?` Click the 'Ineligible' button. \n\n#### The assessment in the last line should be `Assessment: 0) Excluded`\nIn my case the trial ID is 12324389893242595349264.\nAfter that, it will print the trial name in the following line.<EOD> Sickle cell disease and HIV-infected individuals: a rare combination and its management\nAdvances in HIV/AIDS management led to significant improvement in the patient`s life expectancy and consequent increased frequency of various rare diseases co-infecting the HIV infected patient. Among these is \u2018Sickle Cell Disease.\u2019 Anemia is common in patients with HIV-related anemia and sickel cell trait or cell disease. Clinicians caring for HIV-infected patients with sickle cell disease may be challenged with how to manage these patients and which treatment guidelines to follow. This report summarizes common clinical manifestations of HIV/AIDS and sickle cell disease including various causes of anemia and discuss how to manage sickle cell disease patients infected with HIV.<EOD> Association Between Clinical Outcomes of Injuries and the Use of Lower Extremity Bracing: A Systematic Review and Meta-Analysis\n\nBackground: Several clinical studies have reported differences in the use of lower extremity braces in relation to clinical outcomes.Purpose: To summarize the studies on the effect of lower extremity bracing on improvement of various clinical outcomes in patients with trauma.Study Design: Systematic review; Level of evidence, 1.Methods:We searched PubMed (via NCBI), Central Research Register, Cochrane Database of Systematic Reviews, Google Scholar, and ClinicalTrials.gov for studies published in any language before May 2019. We performed a meta-analysis of the effect on different outcomes.Results",
        "label": 0
    },
    "1643": {
        "output": "[NOTES]\nTo make the trial-level eligibility more convenient, let's show the trial-level eligibility at the beginning of the function `for each patient:`. See the following code snippet. \n\n```python\nfor patient in patients:\n```\n\nLet's see the output first. \n## A 55 yo male is enrolled to a clinical trial\n\n```\n\n2014-11-14 18:04:40,126 INFO - main - Trial 3\nINFO - main - Patient_ID = 'patient1'\nINFO - main - Study_Number = 'trialtitle3'\nINFO - main - Entry  = [2]\nINFO - main - Start = 'START'\nINFO - main - End = 'END'\nINFO - main - Phase = 'Phase 2/3'\nINFO - main - Duration = '12 months'\nINFO - main - Treatment = 'C'\nINFO - main - Follow-up = '6 months'\nINFO - main - Gender = 'Male'\nINFO - main - Ages (years) = '55.0'\nINFO - main - Race(White) = 'NONE'\nINFO - main - Capsules Pills = '0'\nINFO - main - Inclusion = [0,1]\nINFO - main - Exclusion = [1]\nINFO - main - Intervention = [0,1,2]\nINFO - main - 0 = {1}\nINFO - main - 1 = {1}\nINFO - main - 2 = {3}\nINFO - main - Visit = [1,2,3,5,6,7,10,12,24]\nINFO - main - Trial_number = 'ClinicalTrials.gov NCT01490646'\nINFO - main - 1 = {32,34,44,53,54,55}\nINFO - main - 2 = {32,34,44,53,54,55,60,61,67}\nINFO - main - 2b = {54}\nINFO - main - 3 =",
        "label": 1
    },
    "1644": {
        "output": "**\n\n## Sample of Solution: \n\n### patient-level eligibility matrix: \n\n| patient_ID | patient_Note | patient-level_eligibility |\n|:--- |:--- |:--- |\n| 0 | The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal",
        "label": 1
    },
    "1645": {
        "output": "## [INST] HOW TO MATCH TWO MATRIX.\nYou have two data matrices. \nMatrix A has 300 rows (300 patients) and \n\n# Results\n\n## Correct answers of [PART 1]\nCorrect cases were 1 to 3. \n\n## Correct answers of [PART 2]\nCorrect cases were Trial-level eligibility: . 2) Eligible. 1) Not relevant. 0) Excluded.\n\n## Correct answers (part 3) (optional questions)\nWe will only analyze the results of Part 3.\nWe analyzed the eligibility and the correctness of Part 3 cases (300 patients). See S1 and S2 Figs.\n\n## Correct answers (part 4) (optional questions)\nYou cannot pass Part 4 due to the wrong answer to part 2 (300 correct cases).\n\n# Discussion\n\n## 1) how to get a single patient note?\nYou can print patient notes from ATLAS by clicking the \"Patient Data\" option in the \"Data List\" menu and then pressing the \"Print\" option. A separate PDF file of patient notes is generated.\nWe developed an option of \"Patient Assessment Eligibility\" in the \"Cases List\" menu to evaluate and manage clinical trials. Here is an example. There are six clinical trials (120 cases in total) in the \"Clinical Trials\" menu. After clicking them, the page will be shown in the following order.\n[\n\n## 3) what are 0d\nand 1d ? 0d, 1d and 2d are the different eligibility in a trial. In ClinicalTrials.gov,",
        "label": 2
    },
    "1646": {
        "output": "[[/HINTST] ]\n\n## Tests\nRun the tests using the following command:\n>>> pytest\n\n\n# The Trial package:\nTrials are defined in trials.py module:\n\n\nTrials.py\n\nfrom typing import Dict, Iterable, Optional, Union, cast\nfrom itertools import chain, combine\nfrom typing import Any, Callable, DefaultDict, ClassVar, Optional, Union\nfrom pathlib import Path\nfrom types import TracebackType\nfrom urllib.parse import urljoin\nfrom time import time\nfrom typing import Optional\nfrom typing.utils import MutableMapping, MutableSequence, OrderedDict, Sequence\nfrom typing.abc import Iterable, Aggregate\nfrom copy import Deepcopies, MutableMapping\ntry:\n    import pkg_resources\n    pytest_plugins = pkg_resources.working_set.filter(\n        ('pytest', 'plugin'),\n        pytest_plugins = True,\n    )\nexcept ImportError as e:\n    pytest_plugins = list() << []\n    pkg_resources._load_roundup(*pytest_plugins)\n\nfrom sk.datasets import Ima-genetics\n\nfrom Trials import Trial\n\nfrom pylith.testing.utils import extract_config, random_id\n\n\n@pytest.fixture\ndef _random_test_config(request):\n    \"\"\"\n    Generate random test config for test methods\n    \"\"\"\n    config = {'name': None, 'config': None, 'exclude': None}\n    i = random_id(4)\n    path = request.module.module_path.name + \"-test-\" + str(i)\n    config['name'] = str(i)\n    with open(path) as f:\n        config['config'] = extract_config(f.read())\n\n    with open(path + 'config.ini', 'r') as f:\n        config['exclude'] = extract_config(f.read())\n\n    return config\n\n\n_TEMP_PATH = Path(__file__).parent\n\n\n_config = {\n    'include': [str(n.split(Path(__file__).parent)[1] + '/') for n in _TEMP",
        "label": 1
    },
    "1647": {
        "output": "<EOD> Cervical Cytology of the Postmenopausal Woman\nCervical cytology in the postmenopausal female is a much neglected arena as far as primary care givers are concerned. This review article focuses on cytology of the cervix in a postmenopausal woman. It covers the following areas: the menopause, postmenopausal cervical dysplasia, postmenopausal prolapse of the cervix, atrophic changes of the cervix, and the effects of sexually transmitted diseases on cytology.<EOD> Syntactic and lexical organization of Chinese sentence comprehension: ERP evidence.\nThe neural underpinnings of sentence comprehension were studied in Mandarin Chinese speakers using event-related potentials and a primed lexical decision task. The experimental protocol manipulated information status, syntactic complexity, and semantic category of the critical words by combining word priming and the lexical decision task. The results showed that the N400 component elicited by the critical words depended more on the semantic category and syntactic information than lexical information. In addition, a novel positivity, the P300, was found in the lexical decision task and can serve as an index of semantic association. These electrophysiological findings suggest that the Chinese syntactic parser can operate without lexical information and that Chinese comprehension can go beyond the simple mapping between word form and conceptual representation.<EOD> An Exploratory Study on the Effect of an Electronic Patient Reported Outcomes ePRO System With Smart Tablets in Patients With Cancer\n\nBackground: Patient self-reported outcomes are increasingly used in clinical trials to assess disease status and treatment benefits. The widespread use of such measurements in daily clinical practice, however, is restricted by the number and type of outcome measurements that can be administered and because of the considerable logistical burden on health care personnel. Smart tablets and electronic patient reported outcomes (ePRO) systems make it possible to administer multiple ePRO questionnaires remotely and electronically, thereby obviating the need for health care personnel and possibly making ePRO data from daily clinical practice more reliable.Objective: This study aimed to investigate the feasibility of a tablet-based ePRO system",
        "label": 1
    },
    "1648": {
        "output": "## \u25a0 RESULTS\n\nFor eligibility checking in the data table, a patient has the following form. We can change a patient's eligibility according to our needs in the data table:\nWe are interested in whether a patient has met the eligibility criteria. For example, we want to check whether a patient meets the inclusion criteria to participate in the clinical trial, not the exclusion criteria. So we want to find if the eligibility of a patient is 1 or larger. In other words, we need to find if we should set the Patient-level eligibility to 1. In this way, we can extract the patients who meet the eligibility criteria regardless of all of the patients we want.\nAs we can make any decision in the data table, we can also implement other methods in the data table, if we can. In the next exercise, you can try to write your own algorithm to implement the other checking methods on the eligibility in the data table.\n\nYou can also check many data attributes, not only the eligibility. It is important to choose the attributes according to your needs.\nIn the next three exercises, we will focus on several problems for implementing the eligibility checking. You have to solve these problems in the data table, because we only have to implement our algorithm on the data attributes rather than the form object.\n\n## \u25a0 EXERCISE 1\n\nThe eligibility checking process takes too long to be used widely in large-scale clinical trials. To solve this problem, your task for `Exercise 1` is to modify a patient registration system so that it can check the patient's eligibility faster in each clinical trial.\n\nIn the `data table` of this patient registration system, the `Patient_id` is the primary key of the patient table. The `Name` is the record identifier of a patient. There are the fields for patient names and some other information except the patient eligibility. We don't know which fields to use to improve the eligibility checking for a certain clinical trial. You have to implement two kinds of eligibility checking methods. The first is the inclusion criteria and the other is the exclusion criteria. \n\nA. Implement your algorithm using the fields of the `data table` for patient eligibility checking in the data table",
        "label": 0
    },
    "1649": {
        "output": "[TUTORIALIZATION] <EOD> .\nThe authors analyzed the results of surgical treatment of severe injuries of the knee-joints in 20 children aged from 10 to 15 years. In 6 children plasty of the articular cartilage fragments was made. At early postoperative period the knee-joint function fully restored in all the children. The authors believe that plasty of the articular cartilage fragments is an expedient method in treating severe injuries of the knee-joint with a damaged articular cartilage.<EOD> A high resolution crystal structure of the methyl cation complex of the Mn4Ca subunit from methanol dehydrogenase at 1.44 angstroms\n\nThe mechanism of enzymatic cofactor reduction by electrons and protons depends on the geometry of the active site. The active sites of the class I metalloenzyme methanol dehydrogenase have been studied by molecular dynamics simulations suggesting a tetrahedral configuration for the intermediate cation radical based on quantum mechanical calculations of a cation radical intermediate. To elucidate the geometrical properties of the active site we determined the structure of the methyl cation complexed methanol dehydrogenase Mn4Ca from Rhodospirillum rubrum. Here we report a 1.44 angstrom high resolution (0.66 electron per angstrom rms) structure. The structural analysis is based on anomalous diffraction in a synchrotron source and a new refinement procedure, based on an effective R factor. Although all the atoms in the molecule are defined with better than a 1.2 angstrom rms deviation, the methyl group is defined only with a rms deviation of 1.06 angstrom. It is shown that the methyl group lies in a plane and is surrounded by a positively charged cavity containing the metal ions. The protonation of the oxalate moiety is consistent with these observations.\n\n# Introduction\nActive sites with low potential cofactors like metalloproteins and ferredoxins are ubiquitous in biology, as they are involved in many oxidation-reduction processes using electrons as terminal electron recept",
        "label": 1
    },
    "1650": {
        "output": "**Example:** `Trial-level eligibility: 2) Eligible. 2) Excluded. 4) Not relevant`  \n\n  \n\n### Include All Input Parameters\n\nYou should pass all input parameters that you find in the following file on your command line.\n\n\n<NAME>, 2015-12, 0x101.\n\n**Input Parameter Description**\n\n**ClinicalStudy, Expected:**   \nClinical study with the type clinical\\_study, when you pass ClinicalStudy, the program expects you to provide an instance of `ClinicalStudy.`.\n\n**ClinicalStudy, Expected:**   \nClinical trial with the type clinical\\_trial, when you pass ClinicalStudy, the program expects you to provide an instance of `ClinicalStudy.`.\n\n**ClinicalStudy, Expected:**   \nClinical trial with the type clinical\\_trial, when you pass ClinicalStudy_NotRelevant, the program expects you to provide an instance of non-relevant clinical trial.\n\n**ClinicalStudy, Expected:**   \nClinical trial with the type clinical\\_trial_Excluded, when you pass ClinicalStudy, the program expects you to provide an instance of `ClinicalStudy_Excluded.`.\n\n**ClinicalStudy, Expected:**   \nClinical trial with the type clinical\\_trial, when you pass ClinicalStudy, the program expects you to provide an instance of non-relevant clinical trial.\n\n**ClinicalStudy, Expected:**   \nClinical trial with the type clinical\\_trial, when you pass ClinicalStudy_Failed, the program expects you to provide an instance of `ClinicalStudy_Failed.`.\n\n**ClinicalStudy, Expected:**   \nClinical trial with the type clinical\\_trial, when you pass ClinicalStudy_NotCompleted, the program expects you to provide an instance of non-completed clinical trial.",
        "label": 0
    },
    "1651": {
        "output": "To be consistent with the patient note, your last output should have the following header: A Trial-level assessment of eligibility for the clinical trial.\n\n#### Output: `x`\n1) The clinical trial title is the name of each clinical trial.\n2) The number of participants is the total number of participants in the trial.\n3) Enrollment criteria in the title is the total number of exclusion criteria that are mentioned in the inclusion and exclusion criteria of the clinical trial.\n4) `Trial-level eligibility :` is the total number of patients that are eligible in the trial.\n\n### Implementation\n\nWe have implemented an interpreter for the trial-level eligibility of two clinical trials mentioned above. The `run_analysis` function in [the interpreter's folder](/source/clinical_trial_interpreter) is used to run the interpretable R code for the trial. The argument `clinical_trial` is the name of each clinical trial.\n\n```\n\n# Run the interpreter.\nrun_analysis(\"clinical_trial_analysis_1\")\n\n# Run the interpreter.\nrun_analysis(\"clinical_trial_analysis_2\")\n\n```\nThe interpreter returns a table for each clinical trial including trial-level inclusion and exclusion criteria. In your output, you will see the header`A` Trial-level assessment of eligibility for the `clinical trial`. As expected, your final output should have the following header:\n\n```\nA Trial-level assessment of eligibility for the clinical trial.\n\n1) The clinical trial title is the name of each clinical trial.\n\n2) The number of participants is the total number of participants in the trial.\n\n3) Enrollment criteria in the title is the total number of exclusion criteria that are mentioned in the inclusion and exclusion criteria of the clinical trial.\n\n4) Trial-level eligibility : is the total number of patients that are eligible in the trial.\n```\n\n## [A Clinical Trial Interpreter in Clinical Trial API](http://nwomwann.github.io/clinical_trial_interpreter_for_google",
        "label": 1
    },
    "1652": {
        "output": "We would like to emphasize that you can change the format and/or language on your own to make your code shorter and easier to understand. Please use only one of the formats of the code as described above.\n\n## Code review format\nWe recommend submitting your code as part of the pull request (PR) for the solution code following this section.\n\n### Code Coverage Status\n\n**Please fill in the following table.**\n\n| Code Coverage | Status | Required? |\n| :--- | :--- | :--- |\n| coverage | N/A | Y |\n\nThe submission should contain:\n- the name(s) of the reviewer(s) who approved the review - the solution code in the appropriate format for the language. You may include an abbreviated version in the solution submission, but the full functioning solution should be available upon request.\n<EOD> The effects of 6-week aquatic exercise training on muscle mass and blood pressure of hypertensive and non-hypertensive elderly adults: a randomized parallel-design trial\n\nBackground: Chronic hypertension is prevalent in the elderly population, and its treatment and intervention are vital. This study aimed to evaluate the effects of a 6-week aquatic exercise on blood pressure and muscle mass in hypertensive (AO) and non-hypertensive older adults (ANO).Methods:The randomized parallel design recruited 28 older adults (age 65-75 years old) with chronic hypertension and 17 non-hypertensive older adults. Half of each group was assigned to the intervention. We calculated the exercise volume by multiplying the training time, duration of a session, the total number of sets, and the number of repetitions. Blood pressure was measured before and after the intervention. Muscle mass was measured through bioelectrical impedance analysis. Data were analyzed with the Independent-Samples T-test, paired t-test, and ANOVA with Bonferroni post hoc test.Results:The difference in systolic blood pressure (BP) before the intervention between AO and ANO was not significantly different; it was significantly lower in AO after the intervention (P = 0.003). However, in ANO, after the intervention, there",
        "label": 1
    },
    "1653": {
        "output": "[INST]\n\nYour goal is to determine if a trial candidate is eligible for study participation. You should consider whether a patient is ineligible for the trial because they do not have a disease compatible to the trial, they are being treated with prohibited medications, or their medical condition is too ill to participate. When designing an experiment, you should consider whether the treatment effect (increased or decreased) is dependent upon the age or other characteristics of the patient. In your own work, the most important thing to consider is the safety and welfare of the clinical trial candidate. You should never perform a trial that will put a patient at risk. You should also keep in mind that the trial requires an informed consent so the patient understands the risks and benefits of participation.\n### [INST]\n\n##[INST]\n[INST]\n \n## How to build an R Shiny application\n\n# Shiny Applications\n\n[![Shiny application](https://cran-china.mirror.unipi.ch/pub/lib/shiny/shiny-manual.png)](https://cran-china.mirror.unipi.ch/pub/lib/shiny/)\n\nAs we saw in the previous R Chapter, R offers an easy way to visualize data, create regression models, or perform other statistical tests. This easy R-based development, though, does not enable you to interact with your results. However, many R packages exist to create interactive applications, also called Shiny applications. Some of these Shiny apps can perform the same statistical analysis as the basic scripts, while others can create dynamic figures.\n\nR is an open source language, and many Shiny packages can be easily adapted to other programming languages. Below we will introduce basic steps for building Shiny applications to help you to build your own Shiny application.\n\n### Data\n\nIn R, all variables that have numbers come from data frames (two-dimensional matrices). The data frame is a generic structure in R which includes any type of data in R and you can create any data frame with any number of columns or rows. You could have a data frame with two subjects and 50 genes, and you could even use a mixed-effect model, with 10 subjects plus 50 genes. Let's take a look at the data frame we will be using in",
        "label": 0
    },
    "1654": {
        "output": "# [OUTS] Recap and Grading [OUTS]\n[OUTS] After the completion of the case, we will recap and grade the submitted solution.\n\nA clinical trial is a human experiment or therapeutic trial using one or more medications or medical devices. This type of trial is designed to evaluate the safety and effectiveness (i.e., \"efficacy\") of medical interventions.\nThe following criteria should be satisfied to pass the exercise:\n- Able to apply the right comparison criteria \n- Able to correctly select criteria in the test patient (i.e., use the three-point scale {0, 1, 2} to correctly assess eligibility for patients, no matter what the values of the test patient information)\n- Able to apply criteria and use those criteria to make the decisions about patients\n\nA successful student:\nAssesses the patient to be qualified with the scale of 2/2/2\nAnalysis of the clinical trial\nExclusion criteria:\n- The patient is not under 20 (20-64)\n- The patient is under 50 women\n- The patient's sex is not defined\nInclusion criteria:\n- The patient's age is 55\n- The patient's weight is above 60\n- The patient's height is between 153.0 and 213.\n\n\n<EOD> High-performance thin films of graphene nanoribbons.\n\nA family of large, well localized, one-dimensional (1D) conductive states is created by chemical conversion of polyacetylene chains into graphene nanoribbons (GNRs) using an aryl-alkyne coupling reaction. Large areas of thin GNR films up to 50 nm thick and over 240 mm in diameter are fabricated and characterized. The electronic properties of the GNR films are largely determined by the size of the 1D conductive states rather than by the nanoribbon edge structures. A comparison of the electronic properties with those of polyacetylene and graphene films provides a systematic study of the electronic structure of polyacetylene and GNR films under variable conditions. Our results will impact research on the structure and chemical reactivity of nanoscale materials.",
        "label": 0
    },
    "1655": {
        "output": "# Task 3: Add the results of the medical tests\nBefore you proceed to Task 3, click on the [TEST_RESULTS] tab. It contains the results of each medical test, including the hematology, biochemistry and UA tests.\n\nThe Hematology Test Checklist is shown by the first header. The Hematology Test Checklist provides you with a quick overview of the required blood count parameters that were tested, the normal limits of each parameter, and the actual value of each parameter for each patient. \nNext, the Normal ranges for blood counts parameters are shown. \nNormal ranges for blood tests.\nThen, each patient's blood cell counts is indicated by the patient's number. \nFinally, the results of each blood test are displayed on the right side of each patient.\n- WBC: White Blood Cells (/uL)\n- RBC: Red Blood Cells (/uL)\n- HGB: Hemoglobin (/g/dL)\n- HCT: Hematocrit (/%)\n- MCH: Mean Corpuscular Hemoglobin (/pg)\n- MCHC: Mean Corpuscular Hemoglobin Concentration (/g/dL)\n- RDW-CV: Red Cell Distribution Width-Interquartile Range (/%)\n- MCV: Mean Corpuscular Volume (/fL)\n- MCHC: Mean Corpuscular Hemoglobin Concentration (/g/dL)\n- PLT: Platelets (/uL)\n- MPV: Mean Platelet Volume (/fL)\n- NP: Neutrophil Percentage (/%)\n- LY: Lymphocyte Percentage (/%)\n- MO: Monocyte Percentage (/%)\n- EO: Eosinophil Percentage (/%)\n- BA: Basophil Percentage (/%)\n- SMO: Small Lymphocytes Percentage (/%)\n- HGB: Hemoglobin (/g/dL)\n- HCT: Hematocrit (/%)\n- MCV: Mean Corpuscular Volume (/fL)\n- MCHC: Mean Corpuscular Hemoglobin Concentration (/g/dL)\n- PLT: Platelets (/",
        "label": 0
    },
    "1656": {
        "output": "[TRIAL000] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: A Study of Different Durations of Treatment With Grazoprevir (MK",
        "label": 1
    },
    "1657": {
        "output": "Your input should be saved as the following format:\n\n#### Trial-level eligibility\n##### Patient note: <patient note>\n##### Clinical trial <clinical trial>\nTrial-level eligibility: <eligibility scale>\nNow let's perform the eligibility check for the patient note.\n\n\n```{python}\n# patient note eligibility check\n\ndef patient_eligibility(patient_note, trial):\n    trial_eligibility = ['Excluded', 'Not relevant',  'Eligible' if trial_eligibility else 'Not_eligible']\n    \n    # print str((patient_note) if trial_eligibility else 'Ineligible')\n    trial_eligibility = patient_note.replace(trial_eligibility, trial_eligibility.join(', '))\n    \n    return trial_eligibility\n\n\n## eligible = patient_eligibility('Patient age and gender:', trial)\n\n\n## Eligible = patient_eligibility(\n# 'HCV infection confirmed by positive HCV EIA', 'GT1'\n# )\n\n# if eligible: print \"eligible.\"\n\n## Eligible = patient_eligibility('Patient's BP, HR and BMI:', trial)\n\n# if eligible: print 'Eligible.'\n\ntrial_eligibility = patient_eligibility('Patient's drug history:', trial)\n\nprint('trial-eligibility:')\nprint(trial_eligibility)\n```\n\n#### patient note eligibility\n\n```{jupyter}\ntrial_eligibility:\nExcluded\nNot relevant   \nEligible\n```\n\n\n## Clinical note eligibility check\n\nHere are the notes for the clinical trial: \n```{python}\n## Inclusion criteria\nCHC genotype 1 (GT1) virus infection (Part A, Part B, and Part C) or GT3 virus infection (Part D)\nAll participants\nFemale participants of childbearing potential or male participant with female partners of childbearing potential",
        "label": 0
    },
    "1658": {
        "output": "<EOD> A phase II and pharmacokinetic study of templated-loaded collagen-glycosaminoglycan (CLINIcell) in locally advanced head and neck carcinoma.\nA phase II and pharmacokinetic study was undertaken to evaluate the efficacy and toxicity of templated collagen-glycosaminoglycan (CG) implants (CLINIcell) loaded with doxorubicin or methotrexate in patients with advanced squamous cell head and neck cancer. These drug-impregnated, implantable collagen matrices (CM), previously demonstrated to safely deliver doxorubicin for up to 96 hours in an animal tumor model, were also shown to be effective on other chemotherapeutic agents in the rabbit implantable tumor system. After surgical resection of the primary tumor, the CM was placed over the surgical defect for localized chemotherapeutic drug delivery by the implant matrix. Eighteen patients were entered into the trial; tumor regression was observed in 4 (22%) of the 18 patients. Drug delivery for 96 hours from the injected matrix was sufficient to produce clinically significant antitumor activity. The clinical response in these patients was in line with the responses observed in clinical trials using systemically administered drugs, and the response rate observed for this disease stage is the highest reported in the literature to date for this indication in an unselected population. In those patients considered to have a partial response, a mean regression of 80% was noted with a mean of only 5 systemically administered treatments required to achieve stabilization. Toxicity was minimal. Three patients experienced grade 4 toxicity, one patient had grade 3 dehydration, and one patient experienced a grade 2 skin and soft tissue infection. Although the objective response rate was low, a high tumor response was observed for this advanced disease stage, and the toxicity profile indicated by this study warrants further evaluation of CG implants in earlier and potentially more responsive stages of the disease.<EOD> Efficacy and safety of methoxy polyethylene glycol amethopterin in pediatric acute lymphoblastic leukemia: an overview of",
        "label": 0
    },
    "1659": {
        "output": "<EOD> Effect of low-dose and high-dose simvastatin on myocardial infarction in hypercholesterolaemic patients with acute coronary syndrome: A prospective, randomised double-blind controlled study\n\nThe aim of the present study was to investigate the effects of simvastatin monotherapy on the reduction of serum cholesterol levels and clinical benefits in hypercholesterolaemic patients with acute coronary syndrome (ACS). A total of 509 ACS patients, who were admitted to the hospital between November 2011 and December 2012, were randomly divided into a low-dose group (n=256) or high-dose group (n=253). Patients in the high-dose group were administered 2-4 mg/day simvastatin on a regular basis. Patients in the low-dose group were administered 2-4 mg/day simvastatin on an on-demand basis. The low-dose group had a statistically significant decrease in the level of low-density lipoprotein-cholesterol from the initial concentration (average 3.9 mmol/l), to the initial concentration (average 2.4 mmol/l) following treatment (P<0.01). This demonstrates that the efficacy of simvastatin in hypercholesterolaemic patients was enhanced when used in a low-dose regimen. There was a 9% decrease in myocardial infarction and a 2% decrease in major adverse cardiac events in the low-dose group compared with the high-dose group over the course of 15 months. It is notable that no significant differences were found between the two groups in all-cause mortality in the low-dose group compared with the high-dose group (2.36 vs. 1.66%, respectively). The reduction in hypercholesterolaemia may confer a reduction in postinfarction cardiovascular morbidity; however, this is more closely regulated through an adequate low-dose of statin. Therefore, the lowering of cholesterol levels is not the only factor with an impact on ACS",
        "label": 0
    },
    "1660": {
        "output": "# Discussion\n<EOD> Effect of an Exotic Plant Species on a Rare Hoverfly\nA new pest to a rare hoverfly was detected as it colonized the exotic weed, Leptochloa chinensis, in Western Australia. The effect of the pest on the distribution of the hoverflies was tested in the field. The pest's presence significantly reduced adult densities of the rare hoverfly Mimeuratula stuarti. However, no other effect of the pest on the hoverfly population size was detected; neither did M. stuarti affect pest populations, nor were there any effects of the pest on the weed's abundance. These results show the effect of an exotic plant species on a rare insect, but suggest that the effects can be transient and of minor consequence.<EOD> A Systematic Review of Surgical Options for Sleep Apnea.\nSleep-disordered breathing encompasses a range of pathologic conditions of the upper airway and includes obstructive sleep apnea(OSA), which affects 90\u200amillion Americans. Continuous positive airway pressure(CPAP) is the gold standard therapy. However, alternatives to CPAP are often utilized either as primary treatment or in circumstances where CPAP is intolerable. Such alternatives include surgical procedures. Given the variability of OSA, surgical techniques range from simple uvulopalatopharyngoplasty (UPPP) to more extensive anterior and midline glossectomy (AMG), and genioglossus advancement. The purpose of this systematic review was to examine surgical options for OSA, with a special focus on the comparative outcomes and cost effectiveness associated with different types of surgery. Studies involving surgical treatments for OSA excluding CPAP were included. A literature search revealed 754 articles of which 21 studies met inclusion criteria. Ten studies were included in the qualitative synthesis and meta-analysis. This review focuses on the most commonly performed surgical treatments for OSA: UPPP & surgical modifications thereof , AMG , and genioglossus advancement . The quality of included studies was determined by the Newcastle-Ottawa Scale. Meta-analysis was conducted to compare the rates of efficacy between UPPP, AM",
        "label": 0
    },
    "1661": {
        "output": "___\n\n# Examples\nHere are some examples for using these functions.\n\nYou can create a helper function to create tables with the results of trial-specific eligibility check. Here is the code:\nfrom pymvi.recruitment.tools.recruitment_helper import create_trial_level\nfrom pymvi.recruitment.tools.recruitment_helper import create_patient_summary_results\nfrom pymvi.recruitment.tools.recruitment_helper import create_patient_level\n\ndef make_recruitment_file(inst, trial):\n\n    print(\"Trial-specific eligibility check:\")\n    trial_name = f\"{trial}_Trial-specific.txt\"\n\n    file_path = f\"{inst.home}/{trial_name}\"\n\n    with open(file_path, \"A\") as f:\n        print(f\"{trial}\\t{trial-specific_eligibility()}\")\n\n    return trial_name\n\nif trial == \"DARE-C\":\n    make_recruitment_file(DARE_DATA, \"DARE-C\") # here comes the code\n\nif trial == \"CLARITY\":\n    make_recruitment_file(CLARITY_DATA, \"CLARITY\")\n\nYou will create two folders of the required study:\n[DARE-C](1DAF119947BBC51577FB65C0B7A38A7DD425500364BA44E3310E488DCBFA23767-0:root/data/DARE-C)\n[CLARITY](1DAF119947BBC51577FB65C0B7A38A7DD425500364BA44E3310E488DCBFA23767-0:root/data/CLARITY)\nNote that the data folders are inside the root folder:\n\n\nYour recruitment file will be under the data folder and file names are similar to the patient or trial names.\nfor instance, the trial",
        "label": 1
    },
    "1662": {
        "output": "``` \nEligible=1\n\n\n\nTrial_level_eligiblilty=2\nInclusion_criteria_meet=0\nInclusion_factors_excluded=0\nInclusion_factors_not_considered=0\nClinical_trial_id=A02110067\n\n```\n\n## Clinical trial\n\nThe clinical trial data is stored in the clinical trial database. When you enter a clinical trial's information into the [Patients]() window, [EHR4CR] () will query the trial database and retrieve the patient's information about previous treatments and previous treatments which match the clinical trial. A list of all clinical trials is in the [EHR4CR] ( ) app.\n\n#### Tutorial: Patients > Assessment > In",
        "label": 1
    },
    "1663": {
        "output": "-- <NAME> (talk) 11:49, 1 December 2013 (UTC)\n\n\n\n\n[INFO] Output: HCV: 1-1; Coinfection (if any): 0); HHV-8: 0; HPV: 0; HIV-1: 0.6; Treatment (HCV): NA; Interventional trial/Study: NA; Current clinical trial patient: NA; Sex: M(\u2642); Race:(; Ethnicity: Caucasian(White); Age: 55; Height: NA; Weight: NA; Co-morbid illness: NA; Creatinine: 0.8; ALT: 38; AST: 185; CK: NA; GGT: 79; INR: NA; Platelet: 135; Hct: 40.8; Leukocyte:15.39.<EOD> Inhibition of \u0394(9)-tetrahydrocannabinol CB1 receptor expression by the anxiolytics diazepam and alprazolam in the prefrontal cortex and hippocampus of developing rats.\nBACKGROUND\nBoth diazepam and alprazolam have been associated with the development of abnormal behaviors and cognitive deficits, which are mediated by disruption of the \u03b4-opioid receptor (DOPR) expression in the nervous system. In the adult, \u0394(9)-tetrahydrocannabinol (THC) stimulates opiate receptors via a CB(1)-like receptor. Thus, we investigated the influence of diazepam and alprazolam on THC-CB(1) receptor expression in the frontal association cortex and the hippocampus of developing rats.\n\n\nMETHODS\nNeuroimmunoassays were used for the demonstration of CB(1) receptor in rat brain regions.\n\n\nRESULTS\nThe THC-CB(1) receptor expression increased steadily from postnatal day (PND) 2 to PND 49. For the front",
        "label": 0
    },
    "1664": {
        "output": "[INST] \nThere are two clinical trials named as `Clinic-trial-1` and `Clini-trial_1`. Make two separate assignments by specifying them using `clinic-trial-1` (clinic-trial-1) and `clini-trial-1` (clini-trial-1). [INST](https://github.com/fjhkj/FoodJuice/blob/master/src/FoodJuice/Experiments.jl#L170) \n```julia\nusing FoodJuice\n\nclinic-trial-1 <- assign(Clinic-trial-1, clinicaltrialdata.csv). \nclini-trial-1 <- assign(`Clinic-trial-1`, clinicaltrialdata.csv)\n```\n[INST](https://github.com/fjhkj/FoodJuice/blob/master/src/FoodJuice/Microdata.jl#L618) \n```julia\n@assert clinic-trial-1.patient_id > 10\n@assert clinic trial id 1\n@assert clini-trial_1.clinicaltrialdata.Clinical_trials.29_data.differents_age \n```\nIf you use `clini_trial_data`, data are directly read from the csv file.\n\nClinic-trial-1.clinicaltrialdadata.summary[clinic-trial-1.patient_id == 25].Trial_trial_descriptive.sex \"Male\"\nClinic-trial-1.clinicaltrialdadata.summary[clinic-trial-1.patient_id == 25].Trial_trial_descriptive.age 47\nClinic-trial-1.clinicaltrialdadata.summary[clinic-trial-1.patient_id == 25].Trialtrialdescriptive.clinicaltrialinclusioncriteria2.age_over_40 \"True\"\nClinic",
        "label": 0
    },
    "1665": {
        "output": "### Exercise\n\n1. Let's go back to `example.txt` (see section **Fundamentals**) (the original script file is at `example.py`). We are interested in two lines from the text file:\n\n\t```\n\tParticipant_ID 009\tHCV_RNA_conct_units 2.560000000\tHCV_RNA_conct_units 4.610000000\tType_of_insulin_resistance NA\tQuantifiable\tBMI 25.400000000\tCig_smoker_status 0\tSmoking_status 0\tWaterpipe_smoker_status 0\tExpert_smoke_status 0\tExpert_cig_status 0\tSystolic_BP_median 149.000000000\tDiastolic_BP_median 91.000000000\tAspartate_aminotransfer 100.000000000\tAlanine_aminotransfer 35.000000000\tAlkaline_phosphatase_units 176.000000000\tTotal_bilirubin_units 3.000000000\tALT_units 70.000000000\tAST_units 65.000000000\tFemale_sexual_partner_status 0\tAlkaline_phosphatase_units 40.000000000\tALT_units 24.000000000\tAST_units 35.000000000\tWBC_median 8.000000000\tWhite_blood_cell_count 6.500000000\tMonocyte_percent 7.000000000\tL",
        "label": 0
    },
    "1666": {
        "output": "* _*Instructions for the next section:\n\n# MEDICAL_INFORMATION\n- Write your answer to this question in the blank spaces below.\nYour assignment should be concise, well organised, and in complete sentences. Your answer should reflect appropriate use of spelling, grammar, and punctuation. When applicable, provide evidence from peer-reviewed literature.\n\n_*Instructions for the next section:_\n\n# MEDICAL_INFORMATION\n- Write your answer to this question in the blank spaces below. Your assignment should be concise, well organised, and in complete sentences. Your answer should reflect appropriate use of spelling, grammar, and punctuation. When applicable, provide evidence from peer-reviewed literature.\n\n_____1. What is the patient\u2019s HCV Genotype?\n _____2. How long has this patient had Hepatitis C?\n _____3. What treatment(s) has our patient received for Hepatitis C? _____4. What are our patient\u2019s lab results on the following tests:\n_____5. What is the patient\u2019s BMI?\n_____6. What is the medical definition of the patient\u2019s stage of fibrosis?\n_____7. What is the patient\u2019s Child-Pugh score?\n_____8. What are our patient\u2019s most recent laboratory results on the following tests:\n_____9. Does our patient have any of the following medical conditions:\n _____10. What is our patient\u2019s history of drug use related to this illness? _____11. Does he have any other illnesses? _____12. Is this patient taking any OTC vitamins, medications, herbal supplements (include dosage), or prescribed medications. Be sure to include dosage and frequency. _____13. At what time of day should the medication be taken?\n_____14. Why was the dose prescribed? _____15  Is our patient at risk for any of the following possible side effects of this medication:\n_____16. What additional information do you want to know about this patient?____________17. What questions concern you about the treatment of this patient? _____18. How does this patient\u2019s current illness impact their health",
        "label": 0
    },
    "1667": {
        "output": "A patient with ID 427683 has the following test reports: \n\n- 'Anaemia -Hb -11.6'\n- 'Lympho -27% with Normal Differential'\n- 'Hemoglobin value-11.6 g/dl'\n- 'Leuko: -TLC-15x10_9/L'\n- 'Bone marrow -Absent of disease'\n- 'Skin -Nails -No infection'\n- 'Thyro -T4 Free 1.6 ng/dl'\n- 'Urobilinogen-1.35 mg/dl'\n- 'Kidney -Urea-48.2 mg/dl'\n- 'Liver -AST-21 IU/L'\n- 'Liver -Alkaline Phosphate-",
        "label": 1
    },
    "1668": {
        "output": "[CODE]\n{% for patient_note in patient_notes %}\n\n<table class=\"note\" >\n<tr><th>Medical history</th><td>{{ patient_note.medical_history | raw }}</td></tr>\n<tr><th>Diagnosis</th><td>{{ patient_note.diagnosis | raw }}</td></tr>\n<tr><th>Treatment</th><td>{{ patient_note.treatment | raw }}</td></tr>\n<tr><th>Result</th><td>{{ patient_note.result | raw }}</td></tr>\n<tr><th>Repeat</th><td>{{ patient_note.repeat | raw }}</td></tr>\n</table>\n\n<table class=\"note\" >\n<tr><th>Test</th><td>{{ patient_note.test | raw }}</td></tr>\n<tr><th>Biopsy</th><td>{{ patient_note.biopsy | raw }}</td></tr>\n</table>\n<table class=\"note\" >\n<tr><th>Inclusion criteria</th><td>{{ patient_note.inclusion_criteria | raw }}</td></tr>\n<tr><th>Eligibility</th><td>{{ patient_note.eligibility | raw }}</td></tr>\n</table>\n<table class=\"note\" >\n<tr><th>Trial</th><td>{{ patient_note.trial | raw }}</td></tr>\n<tr><th>Inclusion</th><td>{{ patient_note.inclusion | raw }}</td></tr>\n<tr><th>Exclusion</th><td>{{ patient_note.exclusion | raw }}</td></tr>\n<tr><th>Eligibility</th><td>{{ patient_note.eligibility | raw }}</td></tr>\n\n<tr><th colspan=1><sub>Note:</sub> Eligibility means the patient is excluded (0) or is not relevant (1)\nor is eligible. (2). We must provide patient-level eligibility. </tr>\n</table>\n</caption>\n[/CODE",
        "label": 0
    },
    "1669": {
        "output": "<EOD> Anatomical study of a prepubertal boy with a prezygodactylous digit\nSir, Dactylity is a condition in which a finger or toe,",
        "label": 0
    },
    "1670": {
        "output": "<EOD> Imprints of an endothermic quantum dot: thermal activation and spin-flip relaxation\nBy means of time resolved two-photon absorption spectroscopy, we report on the impact of thermal activation and spin-flip relaxation in InAs self-assembled quantum dots. Thermal activation leads to asymmetric, time-dependent line broadening of the optical pump-probe spectrum even at extremely high probe photon energies. The quantum dot luminescence intensity depends sensitively on the photon energy and is influenced by the temperature of the dot.",
        "label": 1
    },
    "1671": {
        "output": "## S15.1 Problem 2: Incorrect response.\nThe answer is option ''c''. The patient is not eligible for participating in the clinical trial. Based on your assessment of the patient's eligibility, the response choice is ''c''. In the patient's past medical history, he has no previous abnormal hepatic function tests and a negative hepatocellular carcinoma. However, the patient meets one of the exclusion criteria of the trial: metastatic ocular melanoma.\n\n## S15.2 Problem 3: Incorrect response.\nThe answer is correct. The trial-level eligibility is shown in the following table:\nTrial-level eligibility\nTrial-level eligibility: 0) Excluded; Trial-level eligibility: 1) Not relevant; Trial-level eligibility: 2) Eligible; Trial-level eligibility: >2) Not tested.\nYou should make a trial-level eligibility in the last line. You can make the patient-level 'Trial-level eligibility' and save it. In this case, make sure the system is not running out of memory. When saving the result, you may experience a ''Out of Memory'' error message. Then, quit Iris and wait for several minutes. Then, try it again.\n\n## S15.3 problem 3: incorrect response.\nThe correct answer is option ''d.'' The trial-level eligibility is shown in the following table:\nTrial-level eligibility\nTrial-level eligibility: 0) Excluded; Trial-level eligibility: 1) Not relevant; Trial-level eligibility: 2) Eligible; Trial-level eligibility: >2) Not tested.\nThe patient is eligible to participate in the clinical trial. To summarize your assessment of the patient's eligibility, the response choice is ''d''. The patient meets the first two patient-level eligibilities and trial-level eligibility and saves the results.\n\n## S15.4 problem 4: incorrect response.\nThe answer is ''c''. Based on your assessment of the patient's eligibility",
        "label": 0
    },
    "1672": {
        "output": "- [Instructions]\n- You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nIn this clinical trial, the factors that allow someone to participate in the clinical trial are age and gender.\n- The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n-\n- Use the table below to answer the questions below. The first two questions require you to identify which criteria are present in the patient's profile. After that, you should use the table to identify whether or not the patient meets all the trial's inclusion criteria. You should also explain why one or two criteria are present or absent. \n\n# Discussion\nIn this tutorial, we described an automated clinical trial eligibility assessment system using supervised machine learning technology. Our system can handle clinical trials with various inclusion and exclusion factors and can be adjusted to reflect trial-specific factors. It has been optimized for this particular clinical trial by tuning the system for use with this data. For this given trial, if the data had not been tuned, the system would have performed poorly due to its reliance on the data that it was trained to use. Therefore, it is crucial that the system is calibrated to the data it is given to be able to properly function and give the correct results. For instance, in the first three questions of the tutorial, the system was able to correctly answer the clinical trial eligibility assessment for the patient, but, in the fourth question, the system incorrectly assessed the patient as eligible and would be inaccurate in clinical settings without proper data augmentation. However, if the system was trained on the full dataset and assessed by a clinician at that",
        "label": 0
    },
    "1673": {
        "output": "Tip: If the patient is eligible you can run the program in command line mode, just call clhlp and you will see the command-line output. If the patient is excluded, the program will stop.\n\n# Tutorials for New Coaches\n\n\n<small><a href=\"/main/tutorials/tutorials\">Tutoriais para coaches</a></small><EOD> Evaluation of the Roche Cobas 8000 Modular Autoanalyzer System for Clinical Chemistry.\nBACKGROUND\nThe aim of this study is to evaluate the analytical and clinical performance of the high-throughput Roche c502 and c702 chemistry analyzers (Roche Diagnostics), which are part of the 8000 modular analyzer system (8000 modular; Roche Diagnostics).\n\n\nMETHODS\nThe intra- and interrun precisions, imprecision rates within and between laboratories, and linearity were calculated as the coefficient of variation (CV%) for control samples. In this study, 1601 control samples and 209 clinical serum samples were used to evaluate the analytical performance of the Roche 8000 modular system. 51 samples with triglyceride concentration > 7.30 mmol/L (> 600 mg/dL) and 83 samples with low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) concentrations that were out of the reference range were used to evaluate the performance in clinical chemistry assays. Comparative tests were performed between the Roche 8000 modular and Beckman Coulter AU680 (Au) analyzers.\n\n\nRESULTS\nIntra- and interassay CV% for all control samples was < 6% and < 8%, respectively. When control samples were evaluated for interimprecision, interlaboratory CV% were < 6% in all assays, except for alkaline phosphatase, total cholesterol, and triglyceride levels, for which the CV% were < 8%. Mean imprecision was",
        "label": 0
    },
    "1674": {
        "output": "In this assignment you should submit an HTML file containing one table showing information on the assessed patients. It should include at least the following items: (1) ID of trial; (2) ID of patient (3) ID of patient note; (4) Assessment of patient eligibility.\nAlso provide a brief explanation of how your algorithm performs its process. In particular, you should provide some details about how you interpret the given patient note and use the information to compare to the inclusion/exclusion criteria.\nYou should ensure that you have passed a test to confirm all the requirements for the assignment\n\n\n\nNote:\n- The assessment of a single patient will take approximately 10 minutes.\n- The length of your submission should be less than 4000 characters for the text field, 0 for the upload file, and 100 for the download file.\n- In your submission, you will need to add the ID's of the patients, so the code will automatically find them.\n- Avoid copy/pasting the code. If there is a problem, we will check your explanation of your code.\n- Finally, your submission will be checked, and only submissions in correct format will count.<EOD> .\nIn order to investigate the effects of different concentration of exogenous melatonin on the physiological response, photosynthetic characteristics and antioxidant enzyme activity of Eucalyptus camaldulensis seedling, 4 different concentration of melatonin water solution, including 0 (control), 50, 100, and 200 mg x L(-1) were applied to the seedlings respectively. After seedling treatments for 24, 48 and 72 h, it was showed that the contents of chlorophyll and carotenoid under 50 mg x L(-1) in different time had no significant effect compared to that in the control group. The accumulation amount of the 500 \u03bcmol x mol(-1) of H2O2 under treatment by 50 mg x L(-1) melatonin water solution was higher than that of the control group at 24 and 48 h after treatment, but this was lower at 72 h. The water content, dry weight, plant height and stem diameter under 50 mg",
        "label": 0
    },
    "1675": {
        "output": "[[[PREV]]]\n<issue_comment>username_2: I got an error. If I change to \"Trial-level eligibility: 2: Eligible.\". It just return blank. <issue_comment>username_2: I got an error. If I change to \"Trial-level eligibility: 2: Eligible.\". It just return blank.<issue_closed><EOD> A clinical-computational program for the diagnosis and prognosis of coronary artery disease by the measurement of cardiac adrenergic responsiveness.\nA recently developed method for measuring cardiac norepinephrine spillover (NE-S), which is highly correlated with endogenous, total cardiac norepinephrine release and may have prognostic value, has been validated in a canine model of regional cardiac infarction. In the present investigation we used the technique to derive a simple, noninvasive prediction rule for determining the occurrence, severity, regional site and extent of myocardial infarction produced by a 3-h coronary artery occlusion. These results were then verified in a prospective study of 145 patients studied both on admission to the coronary care unit and at least 6 months following uncomplicated myocardial infarction. In comparison with the noninvasive measurements, endomyocardial biopsy identified a larger group of myocardial infarcts. NE-S (r = 0.53; p less than 0.001), plasma norepinephrine (r = 0.46; p less than 0.001) and plasma epinephrine (r = 0.49; p less than 0.001) were closely associated with the size and distribution of infarct. The prognosis of acute infarction was determined best by cardiac NE-S (r = 0.31; p less than 0.001), plasma norepinephrine (r = 0.24; p less than 0.02) and plasma epinephrine (r = 0.28; p less than 0.007). The prognostic ability of plasma cate",
        "label": 0
    },
    "1676": {
        "output": "## Examples\n\n[/TUT]\n\n## I. Patient's eligibility\n\nYou are a helpful assistant for clinical trial recruitment and your task is to determine the patient's eligibility. Your task is to decide whether the patient meets the inclusion criteria for the clinical trial of interest.\nThis example has the following syntax:\npatient-level:\n\n#Trial-level: trial-level eligibility:\n\n#Patient-level:\nTrial-level:\n\n#Trial-level: trial-level score:\n\n#Trial-level:\n\n\n<EOD> The Relationship Between Alcohol Consumption, Binge Drinking, and Adverse Pregnancy Outcomes\nAbstract Objective\u2003Alcohol consumption is associated with adverse pregnancy outcomes, but the optimal level of consumption before and during pregnancy is debated. We tested the hypothesis that moderate alcohol consumption during pregnancy and prepregnancy binge drinking increase the risk of adverse outcomes. Study Design\u2003Using a state birth defects registry and an alcohol surveillance system, we examined the relationship between alcohol consumption patterns and adverse pregnancy outcomes in a large cohort of women in North Carolina, 2007 to 2011. Alcohol consumption was assessed through telephone interviews of the women in their third trimester and before pregnancy. Drinking patterns were classified according to quantity (g/week) and drinking frequency, which are commonly measured in alcohol surveillance systems, and patterns were linked to major birth defects. Results\u2003Among 4,215 women, we observed an increased risk of adverse pregnancy outcome for women at both high and low consumption volume levels, compared with consumption of 1 to 7 drinks per week. This risk increase at moderate drinking volume was strongest for high-intensity drinking (5 alcohol drinks on any day or more than 4 drinks per occasion, weekly) (adjusted odds ratio : 1.5, 95% confidence interval : 1.4\u20131.6 for drinkers' consumption of more than 14 drinks per week versus up to 7 drinks) and weakest for drinking on fewer days per",
        "label": 1
    },
    "1677": {
        "output": "<EOD> .\nTuberculosis is an infectious disease caused by the bacillus Mycobacterium tuberculosis, which has been present in the human population for thousands of years causing millions of deaths. In recent years its incidence and prevalence have decreased considerably, with the appearance of new forms of pulmonary TB or extrapulmonary involvement. We report a case of a 57-year-old male who presented with low back and left leg pain followed in 3 to 4 months by pain in the right leg. The patient reported an alteration in the color of his urine, without other symptoms or weight loss, fever or night sweating.<EOD> .\nGait disorders with falls are a critical problem for community-based rehabilitation. Aim of this rehabilitation program is decreasing falls and improving balance. Dyscoordination with freezing of gait, imbalance and instability are typical gait disorders in patients with Parkinson's disease. Furthermore, patients who are treated with dopaminergic agents show a deterioration of their posture resulting in a worsening of their gait. As the gait disturbances in Parkinson's disease are caused by a multifaceted decline in motor, sensory and cognitive functions, multidisciplinary treatment approaches are required. To date, only the evidence for some types of therapeutic approaches including physiotherapy, vestibular rehabilitation, and training has been systematically examined; other elements are based on small or large randomized/non-randomized treatment paradigms. A systematic summary of evidence-based treatments is missing. At the moment, there are no uniform treatment protocols available, and they are frequently based on the experience of the therapist. Therefore, the authors focus on the treatment of Parkinson's disease and present in detail on the different therapeutic interventions.<EOD> Cervical spinal cord disruption with complete paralysis of facial and upper limb movements in a rhesus monkey.\nCervical spinal cord disruption with complete paralysis of the bilateral facial and upper limb muscles, as well as weak lower limb muscle movements, was observed in a Macaca-mulattus mon",
        "label": 1
    },
    "1678": {
        "output": "<EOD> .\nOBJECTIVE\nTo study the effect of sodium butyrate (NaB) on the growth of human breast cancer cell line MCF-7 in vitro and the expression of VEGF protein in the supernatant of culture medium and the protein of vascular endothelial cells in rat.\n\n\nMETHODS\nMCF-7 cells were inoculated into culture flask and treated by NaB. The growth of MCF-7 cells was observed by MTT assay and the expression of VEGF protein in the supernatant of culture medium was detected by enzyme-linked immunosorbent assay (ELISA). Vascular endothelial cell line EAHY 926 was inoculated into culture flask and treated by MCF-7 cells' supernatant of culture medium containing NaB. The effect of MCF-7 cells' supernatant containing NaB on the growth of vascular endothelial cells was observed by MTT assay. Western blot and reverse transcriptase polymerase chain reaction (RT-PCR) were used to determine expression of VEGF protein and gene in vascular endothelial cells.\n\n\nRESULTS\nThe growth of MCF-7 cells was inhibited by the treatment of low-dose NaB without significantly influencing vascular endothelial cells; treatment of high-dose NaB reduced the number of MCF-7 cells apparently and inhibited secretion of VEGF markedly; MCF-7 cells' supernatant of culture medium containing high-dose NaB was found to be inhibitory to growth of endothelial cells in vitro. Compared to the controls, an insignificant expression of VEGF in vascular endothelial cells was found in the treatment group.\n\n\nCONCLUSION\nNaB not only shows direct inhibitory effect on the growth of breast cancer cells, but also inhibits the growth of vascular endothelial cells in vitro by reducing production of VEGF in the culture medium of breast cancer cells.<EOD> Interaction of bovine thrombin with a synthetically-derived 31-residue fragment of human antithrombin.\nAn interaction of bovine alpha-th",
        "label": 0
    },
    "1679": {
        "output": "<EOD> The effects of methylmercury and methylated and demethylated mercury species present in water treatment plant effluents.\nDuring a three-year survey on methylmercury (MeHg) in water treatment plants (WTPs) influent and effluent water we reported the presence of considerable amounts of mercury (Hg) in the water discharged from WTPs. High concentrations of MeHg were found in the water of WTPs treated with activated sludge, but no MeHg was detected in the effluents of plants using primary settling. This finding was confirmed in laboratory experiments with H 202 treated activated sludge. After adding MeHg to activated sludge, over 80% of the radioactive Hg was methylated; no demethylation of this MeHg occurred during the period of the experiment (30 days). After spiking untreated fresh water with either MeHg, dimethyl (dMeHg), monomethyl (monMeHg), or methylated and demethylated species found in WTP effluents a rapid spontaneous demethylation was observed in the water samples. The results show that the Hg to MeHg conversion, caused by microbial activity in the activated sludge flocs, is mainly responsible for producing the amount of MeHg found at the time of the discharge from WTPs. This was also confirmed in studies on Hg speciation in surface water. After the addition of the sludge flocs, a more rapid demethylation of Hg was obtained in all solutions containing monMeHg and dMeHg. The study suggests that demethylation of the spiked monMeHg and dMeHg occurs in the microorganisms during the incubation. Addition of sludge flocs decreased the biological activity of a toxicity test according to OECD no. 202, but the toxicity in activated sludge flocs was not reduced according to OECD no. 239.<EOD> Identification of a novel isonitriloplatinate, an isomer of the cyclopentadienyl-substituted",
        "label": 1
    },
    "1680": {
        "output": "<EOD> Changing Roles of the Health Care Managers of the 1990s\nIn the past few years, more changes have occurred in the health care field than in the past 100 years. The changes are accelerated and have a wide range of impact, from the individual to the entire population and from very precise to very general. This article provides an overview of recent and impending changes, their effects, and an analysis of likely responses.<EOD> .\nThe article is devoted to the analysis of the modernization of the system of professional health care and the creation of primary care, the development of primary medical care, and the problem of medical personnel in the rural health care facility of the Samoylov district of the Stavropol Territory. The aim of this research is to identify the actual condition, structure and organization, as well as the formation and implementation of the policy of increasing the capacity of primary medical care and to determine the need to increase the availability of primary medical and preventive care. It is established that despite the fact that the policy for the organization and implementation of primary healthcare is being implemented, in the Samoylov district there are significant gaps that require specific measures of their elimination.<EOD> Correlation of ultrasonic and angiographic measurements of the common carotid artery of the dog\nA study measuring ultrasonic and angiographic diameter of the common carotid artery of the dog was performed on 20 female adult mongrel dogs. A good correlation was found between ultrasonic and angiographic measurements of common carotid artery diameter (r= 0.71, P < 0.02). Intraobserver and interobserver errors for ultrasonic measurements were 0.4 and 0.8% and for angiographic measurement were 4.9 and 3.2%, respectively. The use of ultrasonic measurements of diameter of common carotid artery in veterinary medicine is justified in clinical research as well as in vascular and cardiosurgery.<EOD> Immune Checkpoint Inhibitors for Advanced Non\u2013Small Cell Lung Cancer in Patients With Brain Metastases: Are They Effective and Safe?\n\nI mmune checkpoint inhibitors (ICIs) have dramatically improved the treatment outcome of non-small cell lung cancer (NSCLC). 1",
        "label": 0
    },
    "1681": {
        "output": "##  [CODE]: INST\n\n##  [FILE]: example.txt\n\n```\n\nWe use `Course-level eligibility:` because some of the trials may require a certain amount of patient's disease history before enrolling, even though the patient is currently enrolled in other clinical trials. `Course` may start with a word as different as `1.` and `Bilateral`(s). \n\nYou may be wondering what will happen if the patient has already been in another clinical trial, and what if the clinical trial also requires a certain amount of patient's disease history. Well, `Trial-level eligibility:` will work well here, because you don't have to worry about the course of the disease, just whether the patient met the eligibility criteria for the trial. For example, suppose that Mr Tom met all the criteria except for that he had no history of bleeding from esophageal varices. For our first clinical trial, 'Tom' would be ineligible since Mr. Tom's bleeding from esophageal varices is not enough. Nevertheless, even if Mr. Tom was enrolled in another clinical trial that didn't require bleeding from esophageal varices to be eligible, 'Tom' would still be ineligible to both clinical trials. So we should apply the 'Course-level eligibility.'  if we need to consider the course of disease.\n\n\n### Examples:\n[Ex.1]: Consider a doctor that wants to enroll patients into a new clinical trial only if the patients are within a certain age range.\n```\n\n```\n\n[Ex.2]: A clinical trial asks for a certain number of days that the patient's ALT is elevated.\n```\n[INST] Hello. You are a helpful assistant for the clinical trial recruitment. The trial's aim is to observe the pharmacokinetics of Aceclofenac, a medicine that protects the gastrointestinal system.\n\nYour task is to compute the patient's pharmacokinetic parameters  through the following input:\n\n```\n- pharmacokinetics = 1.01\n- initial drug dose = 100 mg\n- initial li",
        "label": 0
    },
    "1682": {
        "output": "# Examples\n[INST1] \n\n# # Examplary code\n```\n- class Painting # # # a.k.a. PaintMaking\n- title PaintingOfHouses\n- subject Mummy\n- creator TutAnkhAmen # #\n- title PaintingOfHouses # # # \n- subject Mummy # #\n- created_at \"1595-05-15\"\n- type CARD # #\n- type CARD\n+ class Painting # #\n+ title PaintingOfHouses # #\n+ name Mummy # #\n+ created_at \"1595-05-15\"\n+ type CARD\n+ type TROVE_TYPE_CARD\n```\nYou should see this output:\n\n```\n- type TROVE_TYPE_CARD\n- type TROVE_TYPE_CARD\n+ subject Mummy\n+ type CARD\n+ type CARD\n+ created_at \"1595-05-15\"\n+ title PaintingOfHouses\n+ type PATTERNS_CARD\n+ type PATTERNS_CARD\n+ type CARD\n+ title TutAnkhAmen\n+ title TutAnkhAmen\n+ subject Mummy\n+ type PATTERNS_CARD\n+ type TRAIT_PAINTING_FINISH\n<exclamationmark>\ud83d\udd11</exclamationmark>! [inst](https://trove.nla.gov.au/work/37563590#/work/76769#inst) # \ud83d\udea8\ud83d\udc80\ud83d\udc80\ud83e\udd23\ud83d\udc80\ud83d\udc80\ud83e\udd23\ud83d\udc80\ud83d\udc80\ud83e\udd23\ud83d\udc80\ud83d\udc80\ud83e\udd23\ud83d\udc80\ud83d\udc80\ud83e\udd23\ud83d\udc80\ud83d\udc80\ud83e\udd23\ud83d\udc80\ud83d\udc80\ud83e\udd23\ud83d\udc80\ud83d\udc80\ud83e\udd23 # \ud83c\udf42\ud83c\udf42\ud83e\udd43\ud83d\udc49\ud83d\udcaa\ud83d\udc51# # #",
        "label": 0
    },
    "1683": {
        "output": "and 1. [bib_ref] [/table].\n and the 11 and to the\nthat with a ^ with the 7<-2\n and the^ in an 1 \n in [bib_ref] 2 with the\n ( [bib_ref] in-for - in [bib_ref]. 3 for [bib_ref], which [fig_ref] [bib_ref]. a single 12 for 1-on. the elve and in the . \nto \u2039 [bib_ref]  and the  2 on patient\nbut, as [bib_ref]-2. Each , D: the _\nbut for [bib_ref] a b^ .1 and \\ /\n\n<EOD> for 4\u00a0\nand-d-1 ^ [bib_ref] a\u00a0for\u00a0such- or [fig_ref] the potential and _. 1 or an a [bib_ref] for the evaluation.\u00a00, even \u00a0inst \\\n-to a [bib_ref] and the\n [bib_ref]<EOD> 2, [bib_ref] on \u2026 the / _37.\u00a0 that 2 16+1:\n12.\n^ 2.\n1 \ufffd -1\n1 \ufffd2\u00a0^\n. ^. .(126 in0-\nin-free (sub-level...b. The ^\n( and\n\nin\n\nsitu\ndet \u00a0with\n and 1^ as\nin. or 20\u00a0d (tre \u00a00\\\n (s or the ex at 9\n-and-s\nin the for the [bib_ref] for - [bib_ref]. on 2^<EOD> 20;\n(all-\nby \\-level \ufffdre+...d \u00ac2- [bib_ref]~ . 2 [bib_ref] at 2^. _ _ .. A previous or 2-~ 3-m for an-e, 2 with\nfor (he.\ninst in (2 1. and 5_instings 7 and\nfor his with the\ng\nhe-s and 2 . [fig_ref] the 2 ex~he-s 1- 6 12 0{to...for a medical-s (1\nto\u00a0@1 for 1-s^! (d_high .1 and a and^\ng...{s 2 in B\nHe \u223c (i .C\n-or  ~\n~ [bib_ref] 2 ands2 with a0 in{...~",
        "label": 1
    },
    "1684": {
        "output": "<EOD> The use of ectoine: a compatible solute, to protect against a hypertonic stress in yeast.\nEctoine is a cyclic amino acid, which accumulates in several bacterial species in order to protect them from an osmotic stress. In these bacteria, it is important that ectoine does not accumulate in the cytosol of these cells following uptake. To investigate whether, in contrast to bacteria, this cyclic amino acid can be taken up by yeast cells and protect them against an osmotic stress, Saccharomyces cerevisiae was used as a model organism. In order to detect an accumulation of ectoine in yeast cells, two ectoine-biosynthesis mutants of the bacterium Vibrio parahaemolyticus were tested. Using these V. parahaemolyticus mutants, transformed separately in two different systems of yeast, a high intracellular amount of ectoine could be detected. This accumulation resulted in a lowering of the intracellular ionic",
        "label": 0
    },
    "1685": {
        "output": "The patient note is similar to that you assessed in Tutorial 45, but it is now expanded. \n\n## Tutorial #47. assessment for a",
        "label": 1
    },
    "1686": {
        "output": "## INST54\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: Chemoembolization With or Without Antiviral Therapy for Unresectable",
        "label": 0
    },
    "1687": {
        "output": "[INST]\n---\n\n### 2.12.0.2.3.1 Trial-Level Eligibility: 0 Excluded -- Exclusion Criteria\n\nHere you are again on the assessment of trial-level eligibility. You are the helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial. You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nWe are dealing with a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. He suffers from abdominal discomfort and fever. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive anti-HCV-antibodies, positive HCV RNA tests, and a negative enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was suggestive of early cirrhosis with F3 fibrosis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n\nHere is the clinical trial:\nTitle: Effect of Age and Gender on the PK and Tolerability of Finafloxacin\n\n\nSummary: Previous clinical studies have indicated that finafloxacin is well-tolerated with few treatmentrelated adverse events. As a part of the clinical development of finafloxacin, other PK studies are required to determine the effect of other variables on the PK profile of finafloxacin\n\nInclusion criteria: Inclusion Criteria:\nHealthy adult male and/or female, \u2265 65 years of",
        "label": 0
    },
    "1688": {
        "output": "You may refer to this example for input data.\n# ---------------\ntitle: IFN -SA for naive patients with CHC.\nstudy design : single arm, open.\ntreatment duration\uff1a4 weeks\ndrug : IFN-SA / 1.0mg / RBV / 600g.\nInclusion criteria:Age\u226518 years / BMI: 22-30 / HB: 150-450 / Negative for HIV, HBsAg, anti-HIV antibody, HBsAg antigen tests.\nExclusion criteria: Previous treatment history of HCV /  Alanine transaminase 10 times ULN or above / Child-Pugh class \u2265B or \u2265C /  Serum creatinine \u2265165 umol/L or Estimated creatinine clearance rate\uff1c30mL/(min\u00b71.73m 2 ) / ALT\u226510 times ULN / Liver cirrhosis / Hepatic encephalopathy\uff1bAST, ALT\u22652 times normal levels / AST, ALT\u22655 times normal levels / Alanine transaminase\u226510 times ULN or Alanine transaminase\u226515 times ULN / Alanine / Asparaginase \u22655 times ULN / Alanine / Aspartic transaminase ratio\u22655 / Alanine Transaminase\u226510 times ULN or Alanine Transaminase\u226515 times ULN / Alanine / Aspartic transaminase ratio\u22655 / Alanine / Aspartic transaminase ratio\u22655 / Alanine Transaminase\u22655 times ULN or Alanine Transaminase\u226510 times ULN or Alanine Transaminase\u226515 times ULN / Alanine / Aspartictransaminase ratio\u22655 / Alanine Transaminase \u22655 times ULN or Alanine Transaminase\u226510 times ULN / Alanine transaminase ratio\u22655 / Alanine Transaminase\u22655 times ULN / Alanine Transaminase\u226510 times ULN or Alanine Transaminase\u226515 times ULN / Alanine Transaminase ratio\u22655 / Alanine Transamin",
        "label": 0
    },
    "1689": {
        "output": "2.2. [CYP]\nClinical trials that recruit participants who are genetically predisposed, such as carriers of polymorphisms/variant genes in the metabolic pathways of medications, should always account for drug\u2013gene interactions.  These interactions may lead unpredictable outcomes in treatment, such as adverse reactions, reduced efficacy, or other undesirable effects on patients. Therefore, researchers cannot ignore the relationship between drug response and the metabolic gene polymorphisms, and they sometimes conduct in vitro or in vivo pharmacokinetic studies.  But, for some genotyping phenotyping, researchers only used patients' genotypes to assess the difference in drug exposure that may also vary between patients who have the same alleles.\n\nFor this reason, the CYP metabolizer genotype should be listed in the input text of the clinicaltrials.gov NCT record (the same as the inclusion and exclusion criteria). But the genotype information shown must be consistent with the definition of metabolizer genotype. \n\nIn our example, here is the CYP metabolizer genotype:\n\n\n\n[CYP] CYP2C19 \nSubjects must be CYP2C19 EM (*1/*1) or IM (*1/*2 or *2/*2) or IM/EM (*2/*17 or *17/*17).\n\n\n\nThere are various metabolic gene polymorphisms. Many clinical trials have used metabolic genotyping. For example, the use of antiplatelet drugs is highly inconsistent. Some genotypes (such as CYP2C19 polymorphic variants, ABCB1 polymorphisms, and ADP receptor variants) may affect the response to antiplatelet drugs, such as clopidogrel, ticagrelor, and prasugrel.  So, some trials require the inclusion and exclusion of patients based on metabolic genotypes. Here is an example: \nTitle: Platelet Reactivity in Primary Prevention of Cardiovascular Events in Chinese Patients with ACS on Dual Antiplatelet Therapy (CADP-DAPT",
        "label": 1
    },
    "1690": {
        "output": "##[OUT] Please compare the final output trial-level eligibility with the true eligibility (TRUE) in the example section above and select the correct answer!]\n\n### Exercise 3\n\nNow you will apply your knowledge to 40 real patient records. \n\n\n\n![](http://i.imgur.com/WYEaY9W.gif)\n\n\n\nYour task is to make a trial-level eligibility for each patient record. \n\nClick on 'Checkout your result' to get your feedback.\n\n\n\n![](http://i.imgur.com/1mAYm5y.gif)\n\n\n### Exercise 3\n\n### Exercise 4\n\nNow you will apply your knowledge to 40 patient records. \n\n![](http://i.imgur.com/83w8554.gif)\n\n\nClick on 'Checkout your result' to get feedback and select the correct answer from the dropdown box.\n\n\n\n![](http://i.imgur.com/5Wn90nX.gif)\n\n\n### Exercise 4\n\n### Exercise 5\n\nNow you will apply your knowledge to 40 patient records. \n\n![](http://i.imgur.com/y2RbHwU.gif)\n\nClick on 'Checkout your result' to get your feedback.\n\n\n\n![](http://i.imgur.com/MgK8xgP.gif)\n\n\n### Exercise 5\n\n### Exercise 6\n\nNow you will apply your knowledge to 40 patient records. \n\n![](http://i.imgur.com/Q527n8M.gif)\n\nClick on 'Checkout your result' to get feedback and select the correct answer from the dropdown box.\n\n\n\n![](http://i.imgur.com/WUFhv4a.gif)\n\n\n### Exercise 6\n\n### Exercise 7\n\nNow you will apply your knowledge to 40 patient records. \n\n![](http://i.imgur.com/Ou2Jc2n.gif)",
        "label": 0
    },
    "1691": {
        "output": "(DONE)\n\n\n## [INST] Clinical Trial Recruitment Assessment\nHi[./INST] You work as a clinical trial recruiter. One of the most important skills you need to have is the ability to recruit subjects for clinical trial.\n\nInclusion criteria:\n\n\nThis is an objective that can be achieved either by recruiting an appropriate number of patients meeting the inclusion criteria from the patient pool, or by recruiting all eligible patients, even if the number of patients eligible is lower than the required number. In this project, the goal is  to recruit all eligible patient from the patient pool.\n\n\n\n\n[DOWN] Recruitment assessment:\n\nThe recruitment assessment is the number of eligible patient out of the patient pool. The assessment helps clinical trial coordinators to estimate the patient's pool to be recruited. You are required to provide the recruitment assessment. \nYou should use the patient pool which is the same as the data set you have processed for recruitment criteria assessment. The assessment should be the percentage of cases in the patient pool  eligible.\n\nFor assessment, you should make three calculations:\n1) the number of patients who should be enrolled;\n\n\n2) the number of patients in the patient pool; and \n\n\n3) the percentage of patients in the patient pool who meet the eligibility criteria. \nFor each patient, recruitment assessment should be done on the basis of the eligibility criteria assessment you have previously done.\nFor each patient, do the following procedure.\n\n```\nFirst, is patients belongs to the inclusion criteria? If yes, the patient needs to be assessed. If it is not, skip to step 3. \nFirst, count the number of patients for each criteria: Count(criteria = yes), Count(criteria = no) \nSecond, calculate the percentage: 100*Count(criteria = yes)/Count(criteria = yes) + Count(criteria = no)\nFinally, calculate the patient percentage by summing up eligibility percentile for the patient. \nPatient percentage =  Sum  (criteria = yes), Sum  (criteria = yes)\n```\n\n[DO",
        "label": 2
    },
    "1692": {
        "output": "# Questions & Answers\n\n## Q1. I want to know whether I am eligible for this trial from the patient note `The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.`.\n\n## A1.\nYou need to consider the inclusion criteria and the list of exclusion criteria.\nFirst, you need to consider the inclusion criteria of the clinical trial. As you can see from the study description, the inclusion criteria are:\n~Male and female patients *18 years of age\n~Patients have never been treated with traditional interferon plus ribavirin or peginterferon plus ribavirin\n~Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test\nLet's find the patient's serologic evidence of chronic hepatitis C infection; he has anti-HCV-antibodies which is positive for anti-HCV-antibodies.\n~Detectable serum HCV-RNA and HCV viral genotype 1\n\nFrom the study description, you can find that the first condition for the subject selection is the previous positive of HCV RNA tests. The patient has positive HCV RNA tests",
        "label": 0
    },
    "1693": {
        "output": "You will also be rewarded! In the assessment result area of the patient note, you should check if the patient belongs to the clinical trial or not, and you can check the status in the form below.\n\nTo complete the assessment you should:\n- Choose the `Trial-level Eligibility` menu in `Menu: **General** > **Action** > **Trial-level Eligibility**`\n![trial-level eligibility](https://github.com/vgogg/OpenMDC/blob/master/examples/example-09-patient-eligibility/images/figure3TCE.png)\n<img class=\"codeblock-canvas \" src=\"https://github.com/vgogg/OpenMDC/blob/master/examples/example-09-patient-eligibility/images/figure3TCE_2.png?raw=true\" width=\"240\"/>\n\n- Click on `Submit`.\n![submit](https://github.com/vgogg/OpenMDC/blob/master/examples/example-09-patient-eligibility/images/submit.png)\n\nIf the check box appears in the patient note assessment result area, that means the patient is trial-eligible. \n![assessment][Asses]\n\nIf the check box is not present, that means the patient belongs to the trial or one of the exclusion criteria of the trial is matched, see the following screenshot.\n<img class=\"codeblock-canvas \" src=\"https://github.com/vgogg/OpenMDC/blob/master/examples/example-09-patient-eligibility/images/figure4TE.png?raw=true\" width=\"250\"/>\n\n\n\n# Result\nYou successfully assessed the patient.\n\n\n[INST] To see the patient eligibility assessment result, you can click the `Assessment Result` button in the patient note of the patient. \n![assessment result](https://github.com/vgogg/OpenMDC/blob/master/examples/example-09-patient-eligibility/images/assessment_result.png?raw=true)\n\nYou can repeat the patient eligibility",
        "label": 0
    },
    "1694": {
        "output": "[MARKDOWN]\n\n## [INST] #53\nYou are a physician who practices primary care and is responsible for many patients. One of your patients is Mr. J. He has a high blood pressure and he smokes cigarettes at work. His blood examination shows 128/80 mm Hg for cholesterol and triglycerides, and smoking can affect the heart. For all these reasons, you think the doctor should consider a treatment program for heart protection. \n\nNow you look at the second patient, Mr. R. He works in the pharmaceutical industry, but he does not smoke. His blood examination shows 122/81 mm Hg for cholesterol and triglycerides. You do not think Mr. R needs to undergo a treatment program for heart protection. \nThe question is: Is blood cholesterol and triglycerides level in patients with high blood pressure enough to treat for heart protection? Or is it necessary to take into account other cardiovascular risk factors (smoking, occupation, blood pressure)? You have to take into account other risk factors (smoking, occupation, blood pressure) as well. \n\nHere are the variables and their descriptions for the first case: cholesterol, triglycerides, high blood pressure, smoking. High values of cholesterol and triglycerides are associated with an increased risk of coronary diseases. \nNow we are going to show you some questions to answer about the following two cases and to find out how they are similar/different. For now, let's look at the blood examination of the following cases: Mr. F. and Mr. H. \n\nTo assess the risk of patients we need to evaluate their history and risk factors. \n\n### Mr. F.\nAt the age of 45, Mr. F. has a heart disease, which has been causing trouble for some time although it is being treated. At the age of 50 he suffered a heart attack.\n\nFor a long time he has smoked a pack of cigarettes a day. He is overweight and does not do any physical activity. For the last two years, he has had a high blood pressure at work (especially due to emotional stress). During the past year",
        "label": 2
    },
    "1695": {
        "output": "A: 1)\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n\nA: 1)\nTrial-level eligibility:\n- \n\n\n--<EOD> Interplay between the cytosolic DNA sensing, autophagy, and NF\u03baB activation during human norovirus genome replication\n\n \n\n## Reviewer #1 (comments for the author):\nIn this work the role of autophagy in human noroviruses (HuNoV) infection has been studied. Previously the authors have reported that the autophagy inhibitors significantly reduced HuNoV infection in a hNT2/CD30 cell line and patient derived enteroids (Hendriksen et al), concluding that in human intestinal epithelial cells autophagy was necessary for HuNoV replication. The present work aimed to unravel the process explaining how autophagy regulates HuNoV infection.\n\n## Authors conclude that huov-hvg and huov-hvg-gfp replication activates autophagy in the ht29/214 and caco2 cell lines by a cytoplasmic dna sensing pathway and that autophagy is required for the efficient replication of noroviruses in ht29/214 cells.\nRegarding the effect of pharmacological inhibition of autophagy on virus replication, authors conclude that the early inhibition of autophagy using UAMC-1629 or Baf is detrimental for virus replication. However, in the [fig_ref]  Fig 3: A [/fig_ref]  , the authors describe that the late treatment with UAMC-1629 is also detrimental for virus replication, suggesting that other effects caused by UAMC-1629 treatment might be relevant during norovirus replication. It is possible that late treatment with these autophagy inhibitors inactivates autophagy and thus causes an energy shortage in cells, thus affecting viral replication. Authors must clarify what they mean by early or late treatment of autophagy inhibitors. The present version",
        "label": 0
    },
    "1696": {
        "output": "<EOD> Effects of budesonide and gamma interferon on lung and small intestinal inflammation in the rat.\nWe evaluated the effects of glucocorticosteroid on intestinal antiinflammatory effects and systemic systemic effects of IL-2 and interferon-gamma (IFN-gamma) on intestinal and pulmonary proinflammatory mediator production in rats with acute lung injury (ALI) and inflammation of the rat small intestine due to food allergy (FAI). In the ALI model, budesonide (2 or 4 mg/kg) alone, IFN-gamma (20 micrograms/kg), or budesonide plus IFN-gamma significantly decreased both pulmonary and serum tumor necrosis factor alpha (TNF-alpha) levels within 1 h of treatment. In the FAI model, both budesonide and IFN-gamma significantly decreased the infiltration of eosinophils at the intestinal mucosa to less than 50% of the control value, indicating that budesonide and IFN-gamma had similar antiinflammatory activities. Although the combination did not further decrease the infiltration of eosinophils in the ALI model, the combination showed a significant decrease in serum IFN-gamma and TNF-alpha and in lung IFN-gamma levels compared with treatment with either budesonide or IFN-gamma alone. Moreover, the combination of budesonide and IFN-gamma significantly inhibited both IL-3 and IL-2 induction in the lungs of rats with ALI. These findings demonstrate that IL-2 and IFN-gamma counterregulate the antiinflammatory effects of budesonide on both inflammation of the lungs and small intestine.<EOD> A preliminary study of EEG activity in patients with primary torsion dystonia.\nNine chronic, drug-resistant patients with isolated torsion dystonia without myoclonus were studied clinically, electrodiagnostically, and with cerebral CT scanning. The patients showed a decreased amplitude of the N10 of VEP with normal latency in each eye, and mildly",
        "label": 0
    },
    "1697": {
        "output": "This is important for the users. \n\nIf the patient note is the only input, the output will be as follows:\n```bash\n$ cat trial_001.txt\nTrial Trial-level eligibility Patient ID Patient note\n----------------------- -------- ----------------\nC00001090\nNot relevant 0\nINST ------C00001090----------------------\n\n$ cat trial_006.txt\nTrial Trial-level eligibility Patient ID Patient note\n----------------------- -------- ----------------\nC00001057\nExcluded 1\nINST ---------------------C00001057-Not relevant 0\n\n$ cat trial_013.txt\nTrial Trial-level eligibility Patient ID Patient note\n----------------------- -------- ----------------\nC00001041\nExcluded2 0\nINST ---------------------C00001041-Not relevant 0\n```\n\nThe output will not be as we expected because the program only checks the exclusion criteria to exclude the patient from the clinical trial.\n\n## The clinical trial\nLet's take a look at the program for the clinical trial. You can copy this program in the file `Trial.py`. Here is the definition of the Python program. It will be explained in the following sections.\n\n```python\nimport sys\n\nfrom operator import add\nfrom operator import sub\n\nfrom .IO import TrialIO\nfrom .IO import PatientIO\n\n\nclass Trial(object):\n    def __init__(self, name: str, description: str, title: str, summary: str, startYear: int, endYear: int):\n        self.name = name\n        self.description = description\n        self.title = title\n        self.summary = summary\n        self.startYear = startYear\n        self.endYear = endYear\n\n    def run(self, io: TrialIO, patients: PatientIO):\n        \"\"\" Run : :exclamation: trials\n\n        :param io: IO class object\n        :param patients: IO class object\n        :return: None\n        \"\"\"\n\n        for patientIo in",
        "label": 0
    },
    "1698": {
        "output": "#\n\n- [INST] The clinical trial has several types. Let's see the details and then build the first type of the trial for the question:\n\n# Excluding Criteria\n\n### Exclusion Criteria\n\n-   The patient who is not eligible for inclusion criteria (0) Excluded. The patient meets the inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria.\n-   The patient is not relevant by the lack of information (1) Not relevant. The patient has no sufficient information to qualify for the trial.\n-   The patient is not eligible for inclusion criteria (0) Excluded.\n-   This patient meets the inclusion criteria and exclusion criteria do not apply.\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria);\n1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\n# Calculation for the trial level eligibility:\n\n\n## Eligible= 2/2\nNotrelevant= 3/10\nNot Evaluated= 6/10\nNotrelevant= 7/10+ 3/10=10\nThe patient is eligble for clinical trials of treatment for HCV by inclusion criteria and trial's exclusion criteria do not aply.\n\n# Calculation for the patient-trial level eligibility:\n\n\n## Patient_01_Notrelevant= 3\nPatient_01_Eligible= 2\nNotes from Patient:\n- The first part of the data element is used to store patient identification information such as the patient's name, surname, and birthdate. If the patient's personal identification is not necessary for the calculation of eligibility in this case, this information should be skipped.\n- The second part is used to store whether this patient was evaluated by the inclusion criteria of this trial.\n\t- There are three options to store patient information whether she/he is eligible or not for the inclusion criteria of this trial: 0",
        "label": 2
    },
    "1699": {
        "output": "[INST]: This line is for showing the code only. This is done in order to preserve the original meaning of the script.\n\n### Exercise on Python\n\nWrite a script to solve the example above (the clinical trial is different from the previous example). The data format is the same, but the format of the sample is slightly different.  \n- [data/001_patient_note.csv](http://downloads.e-gyn.org/e-gyn_datasets/001_patient_note.csv) is a patient note.\n- [data/002_clinical_trial.csv](http://downloads.e-gyn.org/e-gyn_datasets/002_clinical_trial.csv) is a clinical trial.\n\n\n\n    ! /usr/bin/python2.7\n    !pip install pymysql\n    !python ./test.py data/001_patient_note.csv data/002_clinical_trial.csv\n\n\nYou can run the script in the same directory where it is saved. In the exercise environment, the script assumes that the two files exist in the same directory. So, make sure to copy the contents of the two files to the directory where you run the script.\n\n\n## Tips:\n- The input data is a two column csv file. The header of each file is shown in the header argument to `read_csv` for each file.\n- You can load a pandas dataframe or numpy array using `pd.read_csv` or `np.read_csv` respectively.\n- You can assign it to a variable by using the same kind of variable. \n`df = pd.read_csv(\"002_clinical_trial.csv\")`\n`df = np.read_csv(\"002_clinical_trial.csv\")`\n- The output data is also written in a two-column csv file. The first column is the ID assigned to the dataset, and the second is the output data.\n- Since the output is two-column csv file, `numpy.vstack(*)` is used to put two-dimensional matrix in the form of a onedimensional matrix.\n\n## Exercise",
        "label": 1
    },
    "1700": {
        "output": "<EOD> .\nLoss of renal function is a serious adverse incident, as is the risk of renal failure in older patients (especially 65 years old or older). In this population with high vulnerability, admission for surgery should be carefully justified. It is not only the incidence of this complication but also its severity that is very important when analyzing admission surgical risk. Thus, in order to obtain a more precise estimation of renal complications risk by each procedure, it would be interesting to collect data on this parameter in current surgical databases such as MICAR (Ministerio de Instituciones y Servicios Sociales).<EOD> Development of a New Fluorescence Nanoprobe for Detecting Drug-Resistant Bacteria.\nThis paper describes the development of a fluorescence nanoprobe capable of detecting drug-resistant bacteria. First, nanoparticles composed of a quantum dot (QD)-peptide conjugate were prepared. In this synthesis, Cys-Gly-Gly-Lys-Ser was used mainly because of the ability of cysteine to bind mercury atoms under alkaline conditions. The synthesized nanoparticles displayed high fluorescence (ca. 30 times higher) at pH 7.2 compared to those at pH 6.0 and 8.0. The particle size increased with increase of the number of amino groups in the modified peptides. The nanoparticle synthesized using the Cys-Gly-Gly-Pro-Gly-Ser (SGPPGS) peptide showed strong adsorption (approximately 75%) to the plasmonic glass wall. Because the nanoparticles did not exhibit any significant decrease in response to mercury ions at pH 7.2, nanoparticles using SGPPGS were stored at pH 7.2 to keep them responsive to mercury ions. Then, the nanoparticles were modified with polyamino and polycarboxyl to remove excess amino group and the surface group. Two strains of drug-resistant bacteria were prepared from reference bacteria including Staphylococcus aureus and Pseudomonas aeruginosa in our laboratory previously. With these two modified SGPPGS",
        "label": 0
    },
    "1701": {
        "output": "\u25a0 \n\nExample 2:\n[[GUI] Start input of patient note] [Enter the first patient note by double clicking `0`:][Enter the second patient note by double clicking `1`:] [Finished.][GUI] \u25a0\nExample 3:\n[[GUI] Start input of patient note] [Enter the first patient note by double clicking `0`:][Enter the second patient note by double clicking `1`:] [[Click the button `Evaluate the Inclusion Criteria in Full and Repeat for All Patients`] [Click the button `Trial-level eligibility`]: [Enter patient notes in your file] [[GUI] Finished.] \u25a0 \n\n## \u25a0 \u25a0 \u25a0 Evaluation of Inclusion Criteria in Full and Repeat for All Patients \u25a0 \u25a0 \u25a0 \nThere is no need to evaluate the inclusion criteria in full in Trial A. In Trial B, you should evaluate the inclusion criteria in 'patient notes' and 'trial-notes' separately.\n\nExample 4:\n[[GUI] Start input of patient note] [Enter the first patient note by double clicking `0`:] [Enter the second patient note by double clicking `1`:] [[Click the button `Evaluate the Inclusion Criteria in Full and Repeat for All Patients`] [GUI] \u25a0 \n\n## \u25a0 \u25a0 \u25a0 Trial-level eligibility \u25a0 \u25a0 \u25a0 \u25a0 \u25a0 \u25a0 \u25a0 \u25a0 \u25a0 \u25a0 \u25a0 Click the button `Evaluate the Inclusion Criteria in Full and Repeat for All Patients`\n\nNow, the second button will be available:\n[[Click the button `Trial-level eligibility`]\n\nExample 6: \n[[GUI] Start input of patient note] [Enter the first patient note by double clicking `0`:][Enter the second patient note by double clicking `1`:] [[Click the button `Trial-level eligibility`] \u25a0\n\n## Example 7:\n[[GUI] Start input of patient note] [Enter the first patient note by double clicking `0`:][Enter the second patient note by double clicking `1`:] [[Click the button `Trial-level eligibility`] \u25a0 [[GUI] Start input",
        "label": 0
    },
    "1702": {
        "output": "## [DATA] Now start thinking about data collection.\nYou can choose different data from the trial to consider for the analysis. Usually, the variables of interest consist of patients' characteristics (P); the outcome is the eligibility (O); and the factor of interest is the patient-by-trial interaction (K).\nAll data should be collected in the \"data\" folder next to a csv. All variables should be placed in separated csv files in the same folder or in other folders under the \"data\" folder. You should also create separate csv files in \"model\" folder (in your case the folder name should be either \"model1\" or \"model2\") for the first half and the other half of the data. The first half must be created first, and then the file name must be changed to the second half of the data. The file names should always hold the following structure: `data_name_type_name` (e.g., `patient_age_in_years_patient_id_12`). Each row represents a group of observations and each group of observations has one variable with a name separated from data with a `_` (e.g., variable `year_diagnosis` will be found in `file_patient_age_in_years_patient_id_12_year_diagnosis`). The output data need to be saved in the same folder. \n\n## [MOD1] The first output data folder name is `model1`, the second output data folder name is `model2`.\nThe only difference between the output models is that the intercept for each patient-by-trial interaction will be different in the first and the second model.\n\n## Data for model1\nStep 1: Create output data folders\n-Create the first output data folder: `Saved_data_output_folder_model1`. For example: `Saved_data_output_folder_modell1: `/\n\nStep 2: Create the first \"patient_by_trial_interaction\" csv file: `patient_by_trial_interaction`.\n\nStep 3: Create csv file in \"patient\"`fie\n\nStep 4: Create the second \"patient_by_trial_interaction\" csv file\n\n\n-Create the second output data folder: `Saved_data_",
        "label": 0
    },
    "1703": {
        "output": "## Clinical Trial \u63a8\u8350\n[ClinicalTrial] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to look for patients with clinical trials for the treatment of ovarian cancers matching the patient information. If so, you will recommend the particular clinical trial to the patient and give the patient the clinical trial brochure. \n\nThere are six clinical trials for the treatment of ovarian cancers to assist in selecting the best trial. To decide the best trial for the patient, you should use two factors: 1) Patient demographics, i.e., age (range: 20-50), sex, and race, and 2) Disease type, which comes down to the specific diagnosis of ovarian cancer and type (e.g., borderline) (see the table with clinical trials below). It is important that the patient and you know the patient's condition and the patient's personal decision (patient vs. family's decision). As a result, please consider all relevant factors before choosing a trial for the patient.[FUTURE-INST] Please read and comment about whether this is a good decision. Will you recommend it to the patient? If so, explain your choice.\n\nClinical trial 1: Phase II Study of Bevacizumab and Temozolomide in Recurrent Ovarian Carcinoma with Residual Tumor <1 cm in Diameter Before Surgery\n\nClinical Trial 2: A Phase II Trial of Pazopanib Combined With Metronomic Chemotherapy in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer\n\nClinical Trial 3: Paclitaxel/Carboplatin Comparison Study (BETANCR) in Women With Advanced, Recurrent Epithelial Ovarian Carcinoma\n\nClinical Trial 4: Intraperitoneal Cisplatin Therapy in the Treatment of Advanced Ovarian Carcinoma: A Dose Intensity Investigation\n\nClinical Trial 5: An Evaluation of the Combination of Rituximab, Carbop",
        "label": 0
    },
    "1704": {
        "output": "### Exercises\n\n\n**Exercise 1**. Your program will present you with a simple patient note with a short clinical history, a list of inclusion criteria for the trial where one may be met, and the patient's age. Your task is to print the assessment results.\n> #include <stdio.h>\n> int ageX; \n> int age; \n> int trialX; \n> int trial; \n> int isValid(void); \n> void print(void); \n\n> int main() \n> {\n>   age = 1;\n>   trialX = 2; int trial; trialX = 1; print(); trial(); age = 2; isValid(); \n>   } \n> } \n> void print(void) \n> {\n>   /* Print the Trial-level eligibility: */    \n>   if(age == trialX){\n>     fprintf(stderr, \"\\nTrial-level eligibility: %d\", trial);\n>     }\n>   } \n> void isValid(void) \n> { \n> #define AGE_MIN 18 \n> #define TRIAL_MIN 0\n>    if(age < TRIAL_MIN ){\n>    fprintf(stderr, \"\\nAge must be over age %d\\nTrial-level eligibility: Not valid age!\", TRIAL_MAX + 10); \n>    } \n>   } \n\n<EOD> Examples of how physicians might consider applying guidelines to care\nEditorials and opinion pieces have stressed the virtues of evidence\u2010based medicine and guidelines for the practice of primary care. Guidelines are intended to help clarify treatment decisions with many issues of importance to the physician patient interaction.1\u20136 This issue of JAN contains a number of articles presenting clinical, evidence\u2010based guidelines related to the diagnosis and treatment of common disorders of the skin and mucosa. These and other articles related to dermatology have demonstrated the value of focusing on the medical problems of highest prevalence which allow for the presentation of guidelines in a more compact, manageable manner, allowing the physician the opportunity for",
        "label": 0
    },
    "1705": {
        "output": "[CODE]\ndef do_eligibility_check(patient_record, trial_record):\n    '''\n    Check eligibility of a patient to the trial.\n\n    Args:\n        patient_record (list): Patient's note written in the 'Patient Discharge Summary'.\n        trial_record (TrialRecord): Trial profile.\n\n    Returns:\n        (int): Assessed eligibility of patient.\n\n    '''\n    output =  dict(eligible=0, excluded=0, not_relevant=0)\n    eligible_trial, excluded_trial, not_relevant_trial = check_eligibility(patient_record, trial_record)\n    output.update({trial: 'Excluded', if trial.exclusion_criteria==0:\n          'Excluded', '0x0x0: {}'.format(trial) if trial.exclusion_criteria==1:\n          'Excluded', '0x0x0: {}'.format(trial) if trial.exclusion_criteria==0:\n                  'Excluded', '0x0x0: {}'.format(trial) if trial.exclusion_criteria==2:\n                  'Not relevant', '2x0x0: {}'.format(trial) if trial.exclusion_criteria==3:\n                  'Not relevant', '0x0x0: {}'.format(trial) if trial.exclusion_criteria==4:\n                  'Not relevant', '0x0x0: {}'.format(trial) if trial.exclusion_criteria==5:\n                  'Not relevant', '0x0x0: {}'.format(trial)})\n    if trial.eligibility_criteria==3:\n        if trial.inclusion_criteria==0:\n            output.update({\n                patient_record: '0x0x0',\n                trial: '3x0x0: {}'.format(trial)})\n        elif trial.inclusion_criteria==1:\n            output.update({\n                patient_record: '0x0x0',\n                trial: '3x1x",
        "label": 0
    },
    "1706": {
        "output": "Your task is complete when you have provided the assessment of eligibility in all rows of the patient note, i.e., 14 in the above example. Now, the next one!\n\n269 261\n[EXPOSURE_STYLE] Exposure styles are important as we have seen. I prefer the exposure styles presented above. Your exposure styles should be neat, easy to read, and present important information of your models. In order to provide appropriate exposure styles, it is very important to plan your design. For more information about types of exposure styles such as bar, matrix, and matrix bar chart, you should read the tutorial at: http://docs.python.org/3.3/library/matplotlib.html. Below, I explain the types of the exposure styles in Python's Matplotlib library.\n\n\n\n\n#### Matrix\nFirst, let's define the `x` label which is going to be plotted in all cells. \nx <-1:6\ny <-\"Hope\",\"Blessing\",\"Health\", \"Trial\",\"Eligible\",\"Excluded\"\n\nThen, create the matrices.\n# First column is the number of lines\nmat1 <-matrix(x,ncol=1,nrow=6)\n# 1 row, 1 col.\nmat1[1,1] <-\"Hope\"\n# Second column is the number of eligible patients\nmat2 <-matrix(x,ncol=1,nrow=6)\n# 1 row, 1 col.\nmat2[1,1] <-\"23\"\n# Third column is the number of excluded patients\nmat3 <-matrix(x,ncol=1,nrow=6)\n# 1 row, 1 col.\nmat3[1,1] <-\"0\"\n# Fourth column is the number of patients not relevant\nmat4 <-matrix(x,ncol=1,nrow=6)\n# 1 row, 1 col.\nmat4[1,1] <-\"9\"\n# Fifth column is the number of trials\nmat5 <-matrix(x,ncol=1,nrow=6)\n# 1 row, 1 col.\nmat5[1,1] <-\"6\"\n#",
        "label": 1
    },
    "1707": {
        "output": "<EOD> Biosynthesis of glycosphingolipids. V. Mucin-type O-glycosylation in L-type lectins is the same.\nThe sugar chains of L-type lectin from Dictyophora indusiata and that from Pholiota nameko have been found to consist of an oligomannose-type unit,  and the fucosylated Man(beta 1,4-)GlcNAc(beta 1,2-)Man(alpha 1,6)Man(beta 1,4-)GlcNAc(beta 1,4)-GlcNAc(beta 1,6) Man backbone in which approximately one of 12 Man residues is fucosylated at the GlcNAc residues as shown by sequence analysis of degradation products obtained by reductive cleavage of disaccharide-bound oligosaccharides. By comparison with the sugar chain structures of these lectins, those of L-type lectins from P. nameko and Dictyophora indusiata were found to be identical. As the glycans in the C-type lectin fraction from L-type lectins show a neutral sugar composition similar to that of the major oligomeric sugar chains of L-type lectins, it is suggested that most of the glycans of the C-type lectin fraction may be oligomannose-type. These L-type lectins from D. indusiata and P. nameko are known to bind galactoside but not N-acetylgalactosamintide or fetuin. Thus the oligosaccharide chains present in the C-type and L-type lectins from P. nameko and D. indusiata share a common mannosyl unit, but differ between the two lectin fractions in terms of their terminal neutral sugars and the mannose contents.<EOD> Comparison of four methods for DNA extraction from blood samples in chicken.\nMany methods of DNA extraction are used to obtain DNA. DNA isolation from blood samples is often limited because of the presence of proteins, detergents, or inhibitors. Therefore, it is necessary to optimize the conditions, to define the quality of the DNA, and to",
        "label": 1
    },
    "1708": {
        "output": "__15__ [HELP] \n\n__16__ [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\\__17__ [HELP] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and",
        "label": 1
    },
    "1709": {
        "output": "[EXERCIS]<EOD> Synchronous adenocarcinoma of the appendix in a young male adult with perforated adenocarcinoma of the sigmoid colon.\nSynchronous adenocarcinoma of colorectal cancer was seen in 6 of 200 patients who had undergone colorectal surgery, and this is a rare phenomenon. We present a 29-year-old man who had been evaluated for gastrointestinal bleeding, and diagnosed with simultaneous colonic perforation and peritonitis from both carcinoma. The authors suggested that clinical presentations of colonic perforation might affect the diagnosis and management of tumors.<EOD> Comparison of the Evaluation of Cerebral Arteriovenous Malformation Embolization Using 3D Digital Volume and Virtual 3D Computed Tomography\n\nBACKGROUND AND PURPOSE: Cerebral arteriovenous malformations (AVMs) are hemodynamically abnormal vessels with high morbidity and mortality rates due to intracerebral hemorrhage or epilepsy. Diagnosing the anatomical characteristics and evaluating the treatment responses of AVMs using a virtual 3D CT model before catheter embolization or surgical resection is desirable to prevent any possible postoperative complications. In this study, we demonstrate the feasibility of creating a virtual 3D CT model of AVMs for preoperative evaluation of hemodynamics and surgical planning.MATERIALS AND METHODS:For evaluating the usefulness of 3D digital volume and virtual 3D CT model, we measured the volume of AVMs before and after embolization. The percentage of the AVMs' volume reduction was 94.1% (5.91%) of the initial diameter during embolization of the nidus of 3 AVMs.\n\n# Conclusions:\nThe virtual 3D CT model would be useful for AVMs preoperative evaluation of hemodynamics and surgical planning.\nABBREVIATIONS: 3DV 3D digital volume; AVM \u00bc arteriovenous malformation; IAD \u00bc initial angi",
        "label": 0
    },
    "1710": {
        "output": "There have been several studies, in which researchers have applied machine learning techniques to predict the presence of the disease from the patient notes or the electronic health records. A recent survey conducted by Xue and Zhang reported that 25% of the researches employed machine learning approach for their tasks of disease prediction. Most of the related studies have employed the concept of neural networks, random forest, decision trees, as well as support vector machines. One popular study is the \"Deep Patient\" by [bib_ref]  Deep Patient: an unsupervised representation to predict the future of patients from..., Miotto [/bib_ref]  , where they used unsupervised machine learning to predict a patient's disease risk for years to come with an accuracy of up to 87%.\nYou should find some patient notes and the corresponding data table from the clinical trial dataset, train the model, and then apply the trained model to the other patient notes of the trial dataset, in order to evaluate the performance of the model and find factors to improve the model.\n\n## Task 2.3.2\n[T2.3.2] Predict the clinical trial outcome for the given patient.\nAs a researcher in a clinical trial on drug efficacy, you must predict the clinical trial outcomes for enrolled patients. Once you have enough information about the participants in the trial, you should apply machine learning to predict the clinical trial outcomes. More specifically, you should try to predict the treatment response in a given patient. Machine learning is a field that gives computers the ability to ''learn'' from data. Machine Learning allows computers to improve their decision-making without being explicitly programmed. For doing this, we will consider the dataset that contains the patient notes and the corresponding data table from the trial. In order to predict the treatment response you need to do data mining where you consider the patient's clinical trial note to determine whether it is a true or a false prediction (1 indicates that it is a true prediction, and 2 indicates that it is a false prediction.). Please find the following files in the `data/` directory:\n\n## - \nTrial_Data.csv (29 rows\u00d7442 columns) - \nTrial_Data_with_Patient_ID_and_true_prediction.csv (28 rows\u00d7442 columns - `true_prediction` refers to the clinical trial outcomes for",
        "label": 0
    },
    "1711": {
        "output": "[TUT0001]\n[TUT0002]\n[TUT0003]\n[TUT0004](\n[TUT0005](\n[TUT0006](\nHISTORY HIGHCOMEDIN\n\n- RM_CLINICAL.py: A clinclinical.py script for downloading clinclinical information.\n\n- Trial-inclusion.py: Trialinclusion.py script for generating clinical trials based on inclusion information.\n\nHISTORY MISCEDIN\n\n- RM_MISCEDIN.py: A miscedin.py script for downloading misceinformation.\n\n- Trial-inclusion.py: Trialinclusion.py script for generating clinical trials based on inclusion information.\n\nHISTORY INSTINFORMATION\n\n- RM_INSINFORMATION.py: A insinformtion.py script for downloading information based on diagnosis and procedure of each patient.\n\n- Trial-inclusion.py: Trialinclusion.py script for generating clinical trials based on inclusion information.\n\nHISTORY ADAGIUSSCANS\n\n- RM_AdaGiusscan.py: A adagiuscan.py script for downloading information based on diagnosis and procedure of each patient.\n\n- Trial-inclusion.py: Trialinclusion.py script for generating clinical trials based on inclusion information.\n\n\nHISTORY HCVERDIAGNOSE\n\n- RM_HCVERDIAGNOSE.py: A hcverdig.py script for downloading information based on diagnosis and procedure of each patient.\n\n- Trial-inclusion.py: Trialinclusion.py script for generating clinical trials based on inclusion information.\n\nHISTORY INDICATOR\n\n- RM_Indicator.py: A indicator.py script for downloading information based on diagnosis and procedure of each patient.\n\n- Trial-inclusion.py: Trialinclusion.py script for generating clinical trials based on inclusion information.\n\nHISTORY GHUSSCANS\n\n- RM_Ghusscan.py: A",
        "label": 0
    },
    "1712": {
        "output": "<BR>[TUTORIAL3] How can we add clinical trial level? \n[INST] Hello. Once you have made patient-level eligibility assessments according to clinical trial-specified inclusion criteria and exclusion criteria, you need to make a trial-level eligibility. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's trial-level eligibility:\n\n\n!image/font/unicode.png\n`@cpt.clinical trial-level eligibility` \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. \n\n\nHere is the clinical trial: \nTitle: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection\n\n\nDescription:\nThe primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in treatment-naive and treatment-experienced participants with chron",
        "label": 0
    },
    "1713": {
        "output": "__**If you are not an employee of Bristol Myers Squibb, please delete everything below.**__\n\n### Preamble\nPlease fill-in all the required form entries. If you have any questions regarding this form or the study at hand, please direct your questions to __________ (investigator's contact information). You will receive a copy of this form with your signature page.\n\n### ILLUSTRATIVE SUMMARY OF THE STUDY\n\n\n\n\n\nPurpose: The BMS-067 Study is being conducted to evaluate the safety, efficacy and tolerability of the combination of daclatasvir and sofosbuvir in human immunodeficiency virus (HIV) infected, hepatitis C virus genotype 1 infection patients (HIV and HCV coinfections).\n\nDuration/Schedule: Treatment period: 12 weeks\n\n\nVisits: Study participant will visit the study site weekly (day 1-4, 11-14, 22, 36, and 49) and 2 weeks post-treatment visit (day 63). Participants must attend each visit as specified (see schedule in participant calendar), or the participant will be disallowed from continuing in the trial.\n\nVisit 1: Screening/Run-in visit on day -28 to day -1\nVisit 2: Initial Safety evaluation visit on day 1\nVisit 3: Subject evaluation on day 11\nVisit 4: Subject evaluation on day 14\nVisit 5: Subject evaluation on day 22\nVisit 6: Subject/Economy evaluation on day 36 Visit 7: Subject/Economy evaluation on day 49\nVisit 8: Safety evaluation post treatment for the last dose given on day 63\n\n### 2.TREATMENT AND STUDY DURATION\n\n\n\n\n\n\n\nThe study drugs will be taken as per the dosing schedule below.\n\nBMS-067: Daily oral dose.\n\nSofosbuvir 400mg daily for 12 weeks.",
        "label": 0
    },
    "1714": {
        "output": "(Optional 7): \n\n**Evaluation of eligibility:** `eligibility = if_has_hbv_coinfection  AND if_has_hcv_infected  AND has_hiv_infected THEN `Trial-level eligibility: 2) Eligible.`:\n\n- HBV coinfection : `hbv_coinfection = coexists.`\n- HCV infection : `hcv_infected = infected.`\n- HIV infection : `has_hiv_infected = infected.`\n  \n# Discussion\n<EOD> Preparation of Spherical Carbon Nano-Crystals from Soft-Temperature-Controlled Pyrolysis of PET Waste Fibers\n\nThis work proposed a low-carbon emitting energy saving preparation method to convert plastic packaging polyethylene terephthalate (PET) waste fibers into spherical carbon nano-crystals (SCNCs) by controlling the reaction temperature of soft pyrolysis. The effects of pyrolysis temperature and heating rate on the reaction mechanism, reaction pathway, gas evolution, product distribution, and final structure and morphology of obtained carbons were investigated on this method. A novel low-temperature zone was applied in the traditional fast pyrolysis methods of PET fiber, and the soft-temperature-controlled pyrolysis method was proposed to reduce energy consumption. The results demonstrated that SCNCs can be obtained by controlling temperature during the pyrolysis of the PET fibers and soft pyrolysis at 650 - C can obtain excellent SCNCs in the yield, quality and reaction mechanism. Moreover, the gas evolution during pyrolysis is different with different temperatures. Soft-temperature-controlled pyrolysis was an energy efficient and environment friendly method to prepare SCNCs which shows great development prospect.\n\n# Introduction\nPlastic pollution has increasingly become a great threat to global ecological balance, human health, as well as global environmental sustainability. As the production and usage of plastics continue to increase, with the increasing awareness of environmental protection, the need to solve",
        "label": 0
    },
    "1715": {
        "output": "## # Clinical Trial Evaluation Exercise\n[NAME] You are a Clinical Trial Evaluator and your job is to analyze the patient notes and record whether it is in agreement for the trial in question.\nPlease see the following patient notes: \nLet's think step by step. \n<EOD> Association of MRI Brain Features with Differences in Depressive Symptoms Among Individuals with Intellectual and Developmental Disabilities\n\nBackground and Objectives: Adults with intellectual and developmental disabilities (IDDs) have high rates of overlapping depression and anxiety. Magnetic resonance imaging (MRI) studies have identified brain tissue loss and altered functional connectivity (FC) in depression, yet these brain features among adults with IDDs with depressive symptoms are unknown. Methods: The participants' depression symptoms (n = 81; age 18-29 years) were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS; cutoff score 17). MRIs were performed on a 1.5T Siemens Avanto scanner. Regional brain volume of the left and right inferior frontal cortex, left and right middle frontal cortex, anterior cingulate cortex (ACC), and anterior temporal cortex (ATC) were extracted using Freesurfer and compared using a multivariate linear model with MADRS as the outcome; age, gender, and intelligence quotient (IQ) were covariates. Results: Greater depressive symptoms were significantly associated with less left inferior frontal and right middle frontal cortex, and greater left middle temporal and left inferior temporal lobe volumes. However, the results were not statistically significant after correcting for false discovery rate (FDR). Discussion and Conclusions: Individual differences among the IDD cohort may explain the null findings of a few voxel-wise comparisons with depression. Our observations that greater left middle temporal volume and less middle and inferior frontal volumes were associated with depressive symptoms in the IDD population highlight the importance of further studies of the neurobiological mechanisms of depression in individuals with IDDs.\n\n# Introduction\nAdults with intellectual and developmental disabilities",
        "label": 0
    },
    "1716": {
        "output": "The output of your program:\n\n  1) Excluded\n  2) Not relevant\n  3) Excluded  \n\nIn this example, we would say `2) Not relevant` because we found that the patient met the inclusion criteria, but did not meet the exclusion criteria. Here is the result.\n\nWe are going to compare each patient note with a clinical trial. If the patient meets the criteria of the clinical trial, the patient is considered eligible. In this scenario, we would see `Excluded` in the output. If the patient does not meet the criteria, we would get `Not relevant`, which corresponds to a patient note with exclusion criteria. If the patient and the trial are the same in all respects, we would get `Eligible`.\n\nWe are going to give you some sample patients and sample clinical trials to practice with. In case the notes are not consistent with the trial notes (such as exclusion criteria violated or missing information), you should give the reasons in the outputs.\n\n\n[TESTING] \n<EOD> Rare and dangerous: bicuspid pulmonary valve\n\nBicuspid pulmonary valve is an extremely rare congenital anatomical abnormality, with an incidence of around 0.04%. While most of these patients remain clinically asymptomatic and are able to function adequately in early adulthood, some of them may present with varying degrees of symptoms when they become older. Here we present a case of an elderly female who remained asymptomatic for around 65 years before presenting to us with left heart failure from severe valvular pulmonary stenosis associated with bicuspid pulmonary valve. Our patient also had a history of endocarditis that was successfully treated by valvuloplasty. She underwent a transcatheter valvuloplasty of the right and left pulmonary valves using Inari Pulsta TM , along with an atrial septal defect device closure. Our case exemplifies the importance of an interventional strategy in elderly patients with significant valvular pulmonary stenosis.\n\n# Introduction\nBicuspid pulmonary valve (BPV) is an extremely rare congenital anatomical abnormality with an incidence of 0.04%.",
        "label": 2
    },
    "1717": {
        "output": "<EOD> Prevalence of and Factors Associated with Subjective Cognitive Complaints among the Korean Elderly\n\nObjectives: We examined the prevalence and the associated factors for subjective cognitive complaints (SCC) in the Korean elderly population. Methods: The study was based on the nationwide representative data (n=35,217 for non-dementia group and n=3,524 for dementia group). The 15-item Self-Reported Probable De-Novo Vascular Cognitive Impairment (S15-VRF-CI [S15-VRF-C] [7]) was used to assess SCC. Dementia was diagnosed based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Results: The overall prevalence of SCC was 5.3% in non-dementia group. Subjects who had SCC were more likely to have higher educational levels and to be current smokers and drinkers. Logistic regression analysis showed female sex (odds ratio [OR], 1.914; confidence interval [CI], 1.499-2.444), elderly age (OR, 2.271; CI, 1.491-4.475), depression (OR, 1.529; CI, 1.161-2.023), hypertension (OR, 1.567; CI, 1.014-2.425), diabetes mellitus (OR, 1.272; CI, 1.0-1.597), and lower physical activity levels (OR, 0.549; CI, 0.317-0.957) were significantly associated with SCC (P=0.001). Conclusion: The 15-item S15-VRF-C is a useful and helpful method to assess SCC and its associated factors in the elderly.\n\n# Introduction\n\n## Subjective cognitive complaints (scc) is defined by a patient's complaints of memory or thinking problems without demonstra-\nble evidence",
        "label": 2
    },
    "1718": {
        "output": "**HIGH CRE ATININE**\n\nThe goal of this game is to choose the best treatment for high creatinine level. The creatinine level rises when kidneys are impaired from damage or malfunction and are unable to adequately excrete substances that are normally filtered from the blood, such as creatinine.\n\nCreatinine is byproducts of creatine phosphate in the body. Creatine phosphate is a natural substance used by muscles as a source of chemical energy. Because creatine phosphate is present in muscle tissue only, the creatinine level in the blood is determined primarily by muscle mass.\n\nThe diagnosis of an impaired or malfunctioning kidney is based on high levels of urea nitrogen-1 and creatinine levels, in association with oliguria and edema. Creatinine clearance is the value obtained after 24 hours of urine collection.\n\nA creatinine clearance of <30ml/min indicates mild to moderate renal impairment. A creatinine clearance of 20ml/min indicates severe renal impairment. A creatinine clearance of <10ml/min indicates kidney failure. Some of these criteria were determined on the basis of clinical judgment, while others are the result of studies in animals of varying age.\n\nIn this game, the kidney function of your patient is low due to a viral infection. You will choose the best available treatment under the condition of financial limits in the hospital. Please be careful not to overprescribe renal replacement therapy since it is very costly and only indicated for those with severe renal impairment.\n\n\n# Patient Information\n\n- Patient name: Ms. Mary Smith\n- Age: 30 years old\n- Symptoms: nausea, pain in abdomen\n\n\n# Examination results\n\n# History and Symptoms\n- Cough and dyspnea\n- Shortness of breath, 3x per week, with exercise.\n- Vomiting and diarrhea.\n- Abdominal cramps.\n- General feeling of malaise\n- Appetite decreased\n- Weight loss, 8lbs\n\n# Investig",
        "label": 0
    },
    "1719": {
        "output": "[/MARKDOWN]\n\n[INST]: `Note that if you have more than one trial, you have to repeat the above steps for each trial. Otherwise there may be an empty cell for the header of the first column from the last row (`Patient` or `Trial`), or missing/wrong data for the cell(s) with the output of the `Trial-level eligibility` (i.e., missing the first digit in the scale of the assessment of eligibility).`\n\n## The \"Duplicate the column with a random ID and random order\" section of the instruction for authors of bioRxiv/PeerJ/PLOS ONE is available on the following website.\n\n## [web]\nIf you have only one patient, please remove the row of first column from the last row of the table. Similarly, when you have more than one trial and the first row of some column is null, please remove the blank row of the last row of the whole table.\n\n## Copy/paste the patient note and the clinical trial in the textbox below. please keep the layout the same as in the instructions for authors provided. [note that the box size of the textbox is smaller than that on the instructions for authors. a zoom function is available with the magnifying glass symbol and its mouse click (in windows, linux and macos).]\n\n![image]()\n\n## [/web]\n**Patient's Note:**\n\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show positive HCV RNA tests and positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress",
        "label": 0
    },
    "1720": {
        "output": "**Explanation**\nFirst select one of the following statements from the patient's record: `IFN, RBV and direct antiviral drugs for the past 6 months.` or `Hospital. `or/and `IFN, RBV and direct antiviral drugs for the past 6 months. `\nWhen you reach the patient note:\n\n* Enter `True` if the patient is a volunteer, i.e., was asked to participate in the trial 'representations and acceptability of HIV therapeutic vaccine in a cohort of HIV-1 infected outpatients followed at Hospital. '\n* Enter `False` if the patient is not a volunteer, i.e., was not asked to participate in the trial:\n`if the patient is 55 years old and has been diagnosed with HCV for two years and now is coinfected with Hepatitis B virus. He was on a combination antiviral drug treatment for the past 6 months. and there is still no history of treatment success to date. and the study site is: Hospital. then \n\n* `Enter` to see details of the clinical trial.\n* `Esc` to hide the clinical trial information.\n\n\n* If the patient does not meet the first or second criteria (or patient was not asked), select `Not relevant. ` \n\n* If the patient meets the first criterion and was asked to participate in the study, then select `Not relevant. ` \n\n\n* If the patient meets the second criterion, then select `Not relevant. `\n\n* If the patient meets the third criterion, then select `Not relevant. `\n\n\n* If the patient meets all criteria and was asked to participate, then select `Not relevant. `\n\n\n* If the patient meets all criteria and was asked to participate, select `Not relevant. `\n\n\n* If the patient meets all the inclusion criteria, then make `Trial-level eligibility: 2) Eligible.`.\n\n\n* If the patient does not meet all inclusion criteria, then make `Trial-level eligibility: 0) Excluded.`. \n\n\nThe results show in patient list. \n\n```haskell\nmain = do\n    putStrL",
        "label": 0
    },
    "1721": {
        "output": "### Summary\n\nThis is an example about how to extract the information of the patients from the patient note and assess the trial-level eligibility using the data extraction and eligibility assessment. \n\nYou just extract the information of the patients and assess the trial-level eligibility. \n\n`ClinicalTrial_DEB025_HCV_RCT@1\n{\"data\":{\"patient_id\":11,\"patient\":[{\"gender\":\"male\",\"patient_age\":55,\"patient_name\":\"Mr. Alfa\",\"patient_id\":\"11\",\"trial_id\":\"13\",\"medication\":\"0\",\"vitamin\":\"0\",\"smoker\":false,\"allergic\":false,\"alcohol_drinker\":false,\"diabetes\":false,\"blood_pressure\":null,\"cardiovascular_history\":null,\"cholesterol_level\":null,\"serology_test\":0,\"anatomical_site\":null,\"metastatic_disease\":null,\"hospital_site\":null},\n                {\"gender\":\"male\",\"patient_age\":56,\"patient_name\":\"Mr. Beta\",\"patient_id\":\"12\",\"trial_id\":\"13\",\"medication\":\"0\",\"vitamin\":\"0\",\"smoker\":false,\"allergic\":false,\"alcohol_drinker\":false,\"diabetes\":false,\"blood_pressure\":null,\"cardiovascular_history\":null,\"cholesterol_level\":null,\"serology_test\":0,\"anatomical_site\":null,\"metastatic_disease\":null,\"hospital_site\":null}],\"data_extracted\":{\"clin_trial\":\"Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option\",\"clin_trial_type\":\"Randomized controlled trial\",\"clin_trial_study_type\":\"Interventional study\",\"clin_trial_country\":\"Germany\",\"clin_trial_city\":\"Bochum\",\"clin_trial_site_id\":\"264 63-Bochum-Universitaets-H",
        "label": 1
    },
    "1722": {
        "output": "##[INST]\n\nAfter writing the above 3-step instruction, here are the screenshots from an online IDE as an example:<img src=\"./images/eligibility_demo.png\" width=\"670px\">\n\n## Output\n\n```\nTrial-level eligibility: 1) Not relevant.\nPatient eligibility: 0) Excluded.\n```\n\n## Cite\n\n1. <NAME>. <EMAIL>. \"Eligibility-Criteria-For-Clinical-Trials : A-Tutorial-and-Programmatic-Guide-For-Python\".\n2. <NAME> et. al. <EMAIL> (in revision). \"Eligibility-Criteria-For-Clinical-Trials : A-Tutorial-and-Programmatic-Guide-For-Python\".\n\n\nThis is [eligibility_demo.py](./eligibility_demo.py).\n\n### Input\n\nType `python -m eligibility`<br/>\n\n```\nTrial level eligibility: 1) Not relevant\nPatient eligibility: 0) Excluded\n```<br/>\n\n### Changes\n\n<a href=\"eligibility_demo.py?#add-exclusion-criteria\">Add exclusion criteria</a>\n\n<a href=\"eligibility_demo.py?#add-add-other-inclusion-criteria\">Add new inclusion criteria</a>\n\n### Output\n\n<a href=\"eligibility_demo.py?#output-all-cases\">Output all cases</a>\n\n\n##### Add exclusion criterion\n\nAdd a patient eligibility as follows:\n\n```python\npatient_eligibility = 0\n```\n<br />\n\nTo make other code changes, please use your programming software such as `PyCharm` or `Pythonista` by typing `python -m eligibility <command>`.\n\n##### Add other inclusion criteria\n\nAdd a patient eligibility as follows:\n\n```python\npatient_eligibility = 1\n```\n<br />\n\nTo make other code changes, please use your programming software such as `PyCharm` or `",
        "label": 0
    },
    "1723": {
        "output": "The following information is also required:\n\n* The number of included patients.\n* The number of excluded patients and reasons of exclusion.\n\n## [TASK] You should use the following function:\n\n`Trial-in-trial.m`\nInput:\n`@DataFolder <Folder with trial-level data, e.g., `C:\\temp\\sampleData\\trial1``, 00..1, 00..10, @PartsToRun, @RunsToRun, @Seed, @Name, 0, 0, @PartsToRepeat`\n\n\nOutput:\n\n``@Folder <Folder with saved result, e.g., `C:\\temp\\sampleData\\trialogue`, @ResultName <file name of saved.result with trial-level result, e.g., `Trial-level eligibility: 2) Eligible.txt`>`\n\nThe function should work with the default parameters. If it does not work, see the Usage [INST] section.\nIn `Parameters::File`, the text between the double quotes should be a local full path to `PartsToRun.csv`. It can be on your local computer or any one folder with the required files copied onto it. If you pass a local path from the command window, it will not work.\n\nFor example:\n\n`@DataFolder <Folder with trial-level data, e.g., `C:\\temp\\sampleData\\trial1``, @PartsToRun <Folder with the files for the first patient, e.g., `TrialInTrial.cvs``, `TrialInTrial.csv``, etc.`: C:\\Users\\user\\Documents\\tmp\\sampleData\\TrialInTrial\\trial1\\PartsToRun`\n\nThe output will resemble the file in a row with a number that is 0. The rows are separated by commas. Each of these numbers is a number of an eligibility factor that was found eligible in a given patient. All of them are in the same row. Each row contains the number of excluded patients and reasons of exclusion. The first row may contain information about the number of included and excluded patients and reasons of exclusion.\n\n```{note}\nIf, for",
        "label": 0
    },
    "1724": {
        "output": "![06\\_Trial\\_02\\_Final\\_1](/img/05\\_1/06\\_Trial\\_02.svg)\n\n\n\n![07\\_Trial\\_Evaluation\\_Clinical\\_Notes\\_Example\\_1](/img/05\\_1/07\\_Trial\\_Evaluation\\_Clinical\\_Notes.svg)\n\n<a href=\"../../html_snippets/hls/v5/inst/07.html\"><code class=\"language-markup no-highlight\">[INST]</code></a> You may recall this trial from the example above. You should always repeat`Evaluation and Trial-level eligibility`in the last two lines by `Evaluation and Trial-level eligibility: 0) Excluded or 2) Eligible,` respectively.\n\n![08\\_Trial\\_03\\_Final\\_1](/img/05\\_1/08\\_Trial\\_03.svg)\n\n<a href=\"../../html_snippets/hls/v5/inst/08.html\"><code class=\"language-markup no-highlight\">[INST]</code></a> Here is another trial-level trial eligibility. You should always repeat`Trial-level eligibility: 0) Excluded or 1) Eligible`in the last two lines.\nThere are two reasons which lead to an exclusion:\n\nReason 1: The patient meets one of the exclusion criteria for the trial. As it is shown in our sample, the patient has a history of previous RSV infection and thus cannot be included in the trial.\nReason 2: There is not enough information for the patient to be enrolled (Not relevant). For example, the patient has no family history of heart disease, and thus according to the exclusion criteria we cannot be sure if the patient will have a good response after treatment with the new drug. The exclusion criteria are defined in the clinicaltrials.gov. There is no specific textbook describing the different criteria and we need to use the data that are available within the patient profile that we have been given as you see in our sample.\n\n```r\nTrial <- list(title=\"Trial title\",\n                summary=\"This is the trial",
        "label": 0
    },
    "1725": {
        "output": "To summarize, a patient note on each line followed by a line of `Trial-level eligibility` is accepted in your program. [INST]\n\n\n#### [HINT]\n\n1. What is a patient note on each line? What is `Trial-level eligibility`?\n\n2. You are expected to write all notes in the format of a `Patient note` and `Trial-level eligibility` as per the following example. For example, if there is a line of input without `Patient note` or `Trial-level eligibility`, simply type those in the first line. If more than one input is the same line, simply input `Patient note` or `Trial-level eligibility` with spaces to continue.\n\n3. The patient note should take into consideration only those criteria necessary to assess trial-level eligibility. If several notes, e.g., patient demographics, are necessary to assess trial-level eligibility, you can write those together in one patient note. For example, a patient note like `88 y/o male with chronic constipation and hypertension` should be considered as a note on an eligible patient. [HINT]<EOD> Influence of the degree of fat overload on the changes in energy balance and adipose tissue secretion rates during the compensatory hyperphagia of overfed ob-ob mice.\nIn the present study the influence of the degree of fat overload on the changes in energy balance and adipose tissue secretion rates during the compensatory hyperphagia that follows the period of refeeding has been examined. Two groups of ob-ob male mice were studied: the fat-excess group, the food intake of which, after 7 days of fat overfeeding, was restored to that recorded in ad-libitum-fed ob-ob mice; and the lean group, the food intake of which was maintained as in nonfat-overfed ob-ob mice. Body weight, the food and caloric intake, and energy losses via the feces, urine, and oxygen consumption were recorded daily during the period of recovery after the period of refeeding (day 3 to day 14). The amount of nonsynthetic lipids",
        "label": 0
    },
    "1726": {
        "output": "[A3]\n\n[A4]\n<EOD> .\nBACKGROUND AND OBJECTIVE\nA multicentre, randomised, double-blind, multidose study was undertaken to compare the efficacy and safety of etosuximide with ethosuximide and carbamazepine (CBZ) in children with newly diagnosed absence or myoclonic absenteeism of the Lennox-Gastaut Syndrome (LGS).\n\n\nMATERIAL AND METHODS\n101 children (73 boys, 28 girls; mean age 8 years) with newly diagnosed LGS were included. The drugs were given as: ethosuximide 350 mg, CBZ 150 mg oral twice a day. Etosuximide was given as tablets (250 mg) or suspension (250 mg; 5, 10, 20 and 30 ml) in 6, 21, 55 and 12% concentrations. The children in the etosuximide and ethosuximide groups were given the same drug-dose regimen. An analysis of variance (ANOVA) was performed to compare primary efficacy measures (change in daily seizure rates as percentage of baseline) and secondary efficacy measures (responder rates, quality of life parameters, Cerebellar Assessment of Ataxia, Mental State subtest of the Bender Visual Motor Gestalt Test, and the Wechsler Intelligence Scale for Children and Adults). Treatment was classified as effective if the patient's seizure rate fell by > or = 25% compared to baseline within 1 month (responders). Safety was evaluated by recording treatment-emergent AE.\n\n\nRESULTS\nAfter 1 month of treatment, seiz",
        "label": 0
    },
    "1727": {
        "output": "and you are oncolin 2130] (Eligible patient.\nRecruitment 1 a trial.\nprotocol. A medical care of the drug. screening doctors (i [eligible are elig and a.\nstud.\ntrible are screen and may in the care screening in particular, medical screen of study of which patient sclot a trial.\nillness and should the elig[elig is the need of medical record.\n[elig, which you have included.\nPros to determine, clinical care for the elig andelig a drug triage. The elig patient's screening medicines or elig, heal in which have 3 and screening.\nyou, including HCVA screen or elig/the patient has not applicable based.\ninclusive patient elig/ in the study elig's at the drug.\nThe first and the care[DNA. 1:\nPATC criteria [medially-el.\n[PATT] and/patiently 4. In the elig: and the medical/elig with the screen. Study patient (el, and elig, while.\nand the trial.\n[el. The trial. Therefore screen. The clinical screen, the elig.\nAND and elig the medic which you/diagn, elig (His a In accord and you need the patient and drug (e.\n[for screening in the elig and elig.\n[or healthy, while the clinical inclusion is required and his and should.\n[g)\nA few, and you. Elig.\nor health. A (infect in healthcare and screen in elig.\nel. [1 and hey.\n[care el and that the treatment and health, and elic and medical.\n[2 and his health. 3. Noz by checking. You cans's. The inclusion. Elig.\n[ or el.\ns. You, for all \n[a. There. In the need\nYou. You and the trial 2x-related and clin... 8-related. They \nin his elig. The main as well\\\n[to the patient and the patient. A\\ and clinifi.\n(2. You; patient and a [[care",
        "label": 0
    },
    "1728": {
        "output": "[TUTORIAL_ONLY] \n\n### Test of Sample Eligibility\n\nThe Test of Sample Eligibility determines whether or not a patient can participate in a given clinical trial. \n\n[TUTORIAL_ONLY] \n\nThe Test of Sample Eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\nFinally, you should always repeat the Test of Sample Eligibility in the first line by `Test of Sample Eligibility: `, e.g., `Test of sample eligibility: 2) Eligible.`. [/TUTORIAL_ONLY]\n\n[TUTORIAL_ONLY] \n<EOD> High-resolution molecular epidemiology provides new insights into the transmission of Neisseria gonorrhoeae at a large Swedish STI clinic, 2007\u20132010\nBackground Neisseria gonorrhoeae has become multi-resistant and has been circulating for more than half a century. Methodology/Principal findings Gonococcal DNA isolates from 324 patients were collected between 2007\u20132010 at a clinic in Stockholm, Sweden. Pulsed-field gel electrophoresis (PFGE) was used to genotype strains. The 515 bp porB allele and tbpB typing methods were used for gonococcal typing and clonal relationship. The results were combined with clinical information about the patients, and the predominant genotypes were subtyped. Multicolour capillary gel electrophoresis (MCE) of all porB sequences enabled us to cluster strains that were identical by PFGE. Of 324 isolates from 166 female and 158 male patients, 44 porB cluster types were identified. The most common one, consisting of 89 strains, was the MS11 clone and closely related 415B. Is",
        "label": 2
    },
    "1729": {
        "output": "44.[and 1.\nor... [bib_ref]. The patient.\n[in this<1-based, for the el\nand. And medical exam [[such a 2, or clin 1 [...] [bib_ref]\u00a0under an interactional health-related. [bib_ref] [bib_ref] 2, el 9-based\u00a0on, a \u00bc \u00a0 and elite, based. The clin 12\n[a in \u25ba[[c 1 or a better in additionally, 5\u00a0in a [bib_ref] and \n [bib_ref]\n^ and \nto the\n1^[that\n\n\n[ [bib_ref] \u25b6 on\n\nel.\n [bib_ref] \u00a01, 1 1\u00a0 or el\u00a01 and _. _ (for [bib_ref] and [bib_ref] and the patient. In the 10, an underlying 1-ass\nand.\nC and _ \ndocument with 21\u00a0 [bib_ref] .\u00a0c, or on a {{\u00a0he and \\ 1.\n\nafter 2 and the...\n\n18\n(all<EOD> 3 or. The 1 to the trial \n. 7, or [bib_ref] the el [/table]. [bib_ref] 5.\nbased. [bib_ref]. A or on the\n, as well-or. or a [bib_ref] or on [bib_ref] as a\u00a0. There and 2\u00a0. We. You. The .-based for [bib_ref] \\ . and 6  andt.\n \ufffd..., [bib_ref] \n [bib_ref] !.\n (\n...\u00a0\n \u2044( \n.\n [fig_ref] his . a \n .1, which. However, an\n for \nfor a [fig_ref] \n and \n\n.\n and\n [bib_ref]. and [bib_ref]. for 1-in [bib_ref] - , the 3\u00a0 or 2 4, suchly\n at 1 in \n\nin or that\n\n:\u00a0d 1 [bib_ref]\nd as an clinical for a [fig_ref] for 2\n 3 - \n .\n\n 2 C on a 2-for 1\u00a0\npat 1 diagn. or a [bib_ref] : [bib_ref] or\\ \\\n [bib_ref] , but\n and the [bib_ref] [bib_ref] and for in the and diagn and a\u00a0of [bib_ref] of , and 3 [bib_ref] 2 with 1 for 2\u00a0in",
        "label": 0
    },
    "1730": {
        "output": "---\n\n<h3>Exercise: Recruitment for a clinical trial</h3>\n\nLet's recruit 3 male patients, i.e., we perform the same analysis three times and compute the mean and standard deviation. \n\n\n```julia\npatients_asses_eligible = \n\tpatients_asses_eligible[:mean] * 1e-3\n\tpatients_asses_eligible[:sd]\n\t```\n\t--Note: `patients_asses_eligible[:sd]` is the computed standard deviation for the assessment of eligibility of the patients, which is 0.2144.\n\n```julia\npatients_asses_eligible[:mean]`\n\t--Note: `patients_asses_eligible[:mean]` is the computed mean\nfor the assessment of eligibility of the patients, resulting in the value `0.6362`\n\n```julia\npatients_asses_eligible[:sd]`\n\t--Note: `patients_asses_eligible[:sd]` is then computed standard deviation for the assessment of eligibility of the patients, resulting in the value `0.2144`\n```\n\n```julia\nmedian_eligibility = round. median(patients_asses_eligible).`\n\t--Note: `round. median(patients_asses_eligible)` is the result of rounding the median of patients_asses_eligible. The result is `1`.\n```\n<EOD> Difficulties to Recognize Fetal Deaths in a Low-Resource Suburban Setting: Lessons Learned, Experiences Shared, and Proposed Solutions\n\nGlobally, the fetal mortality rate is high and maternal complications are high in low resource settings, but there is limited information or documentation on how to improve care to prevent these outcomes. There is a need for a systematic approach to recognize fetal deaths (FD), which is often recognized late. It is believed that inadequate identification of FDs in this sub-urban population is a cause of poor care and high complications. This study aims to generate lessons learned",
        "label": 0
    },
    "1731": {
        "output": "The following example can also be used to determine trial eligibility to avoid the use of a `for` loop: ## eligible(patient_2) #################### ############################## ##################### patient_2 <-as.data.frame(c(\"Yes\", \"Age\", \"58\", \"Male\")) patient_2$Age <-\"No\" ## Boceprevir_title <-as.data.frame(c(\"Boceprevir\", \"Title\")) Boceprevir_title <-c(\"Boceprevir\", \"Title\") ## Boceprevir_desc1 <-as.data.frame(c(\"The summary of boceprevir_trial\")) Boceprevir_desc1 <-c(\"The summary of boceprevir_trial\") ## Boceprevir_desc2 <-as.data.frame(c(\"Hepatitis C virus infection is the most common indication for liver transplantation worldwide(30~40%), within 5 years, about 25~30% of liver transplant recipients with recurrent hepatitis C will progress to liver cirrhosis.(Ponziani et al., 2011) If the HCV viral load can be significantly reduced or sustained virologic response(SVR) can be achieved by triple therapy with Pegylated interferon alfa(PEG)/Ribavirin(RBV)/Boceprevir(BOC) treatment before liver transplantation(LT), the graft re-infection of HCV can be prevented. By this way, we can reduce the risk of early fibrosis progression in the liver graft, and hopefully, improving graft and patient survival after liver transplantation. \", \"This study design is single arm to treat HCV patients with Pegylated interferon alfa(PEG)/Ribavirin(RBV)/Boceprevir(BOC) triple therapies before liver transplantation for patients with detectable HCV RNA. The total number of patients would be around 20 cases included in the study and all of them will take Pegylated interferon alfa(PEG)/Ribavirin(RBV)/Boceprevir(BOC) triple ther",
        "label": 0
    },
    "1732": {
        "output": "[INST]\n\n### What is it?\nYour task is to calculate the mean age and the age distribution of patients diagnosed with breast cancer in one year. \n\nIn this task, you should calculate means and perform basic statistical tests. \n\nThe input is a file, a.csv, consists of 1500 rows. These are patient records. Each row contains information about the age of a patient at the time of diagnosis of breast cancer and survival information. Some of the rows are blank. \n\nYour task is to calculate means and SD and plot age vs. survival rate graphs using matplotlib functions. You should also perform chi-square tests.\n\nPlease pay attention to the following:\n- You should use the code written above. \n- You should change the data_set according to the instructions from the instructions from the instructor\n- You should not use other libraries. \n- This code is unchanged and is only for exercises. If you want to use it in other programs, you should modify it. \n- The data_set is read from http://home.ccr.cancer.gov/data/tcga/. \n\nThe output of data can be seen in following:\n\n\n```shell\n-\nx\nx\nx\nx\nx\n3.x\nx\n46.\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx\nx",
        "label": 0
    },
    "1733": {
        "output": "### 8.6 Eligibility rules\n\nWe use a very powerful module to construct a tree-like algorithm to calculate the eligibility score. You need to define five variables for each rule, which are:\n\n1. The rule name.\n2. The patient note path for the rule. If the path is longer, it implies a more complex rule\n3. 5. The patients and the eligibility rule values (including Excluded, Not relevant, Eligible, and the scores assigned to each status, `x` for Excluded, `c` for Not relevant, `a` for Eligible, and `b` for `Unknown`)\n\nLet's define some example rules.\n```python\nrule1 = 'patient.age > 18 AND (patient.gender =='G' OR\n           'patient.gender =='F') AND\n           ((patient.blood2015 == 'HBV' OR\n            'patient.viral1996 =='HIV') OR\n           'patient.viral2017 =='HCV') AND\n           'patient.viral_pos == \"0\" OR\n           'patient.viral_pos == \"pos\"))\n```\n\n```python\nrule2 = 'blood2015 == \"HBV\" OR\n         viral_pos == \"0\" OR (viral_pos == \"pos\"\n           AND not viral_pos) AND\n         viral_pos == \"pos\" OR (viral_pos == \"negative\" AND viral_pos == \"pos\")\n        )\n```\n\n### 8.7 The eligibility_calc function\n\nThe eligibility_calc function calls every rule and calculates the score of each rule for the patient. The final eligibility score is the sum of all scores of all rules for the patient.\n\n```python\ndef eligibility_calc(patient_note, trial_level_eligibility, patient, rules):\n\n    eligibility = 0\n\n    eligibility = trial_level_eligibility + rules[eligibility_rule_index].patient_eligibility_score # Eligible (sum of 5 scores)\n\n    for rule in rules",
        "label": 0
    },
    "1734": {
        "output": "### How to change the text to the actual patient information\n\nIn the above example, we see that the text of the patient note has been filled by the trial_level_eligibility in the corresponding patient note by using the [fill_patient_note] tag. To find out more about how to fill in patient notes, visit the [fill_patient_note] tag's page. If you do not find what you are looking for there, check out the wiki pages for any related notes, e.g. [assess_trial_eligibility] and [trial_level_eligibility].\n<EOD> Pd-Catalyzed Three-Component C-H Alkynylation of Amines/Arylhydrazines with Acrylates and Propargyl Alcohols.\nPd-catalyzed multicomponent C2- and C3-hydroalkynylation of N-arylindole-3-amines and alkyl arylhydrazines with in situ-generated propargyl alcohols and acrylates under mild reaction conditions has been described. The protocol was also amenable to the three-component alkynylation of 4-arylhydrazine-2-thiones for the preparation of dihydrobenzofurans bearing an ethynyl moiety.<EOD> A Comprehensive Assessment of a Novel, Transesophageal Doppler Device for Transthoracic Echocardiography\nThis study evaluated a new dual\u2010mode transesophageal Doppler (DELD) device compared with a standard single\u2010mode transesophageal Doppler device (STD) and transthoracic Doppler echocardiography for cardiac output determination. Seventeen subjects enrolled twice in the study. Once, after receiving a preoperative anesthetic and midline or paramedian skin incision, a single DELD probe and a single STD probe were simultaneously positioned in the esophagus for a maximum of 30 s. The average difference of the two measurements was compared with each other and with tricuspid regurgitant jet velocities measured by continuous\u2010wave Doppler through a high\u2010frequency transducer.",
        "label": 2
    },
    "1735": {
        "output": "Remember, input trial-level eligibility output (Trial-eligible = 2)\n<EOD> Interactions of tissue-infiltrating T lymphocytes during infection of mice with Leishmania mexicana.\nLeishmania mexicana was inoculated intracutaneously into C57/BL/10 mice to assess the interdependence and immunological functions of tissue-infiltrating T lymphocytes and macrophages. To study the immune response, populations of large lymphocytes and small macrophages were purified from infected footpads by centrifugal elutriation and fractionated into highly purified subpopulations of large lymphocytes or small macrophages by Percoll gradients. Analysis of intracellular Leishmania mexicana in lymphocytes and macrophages was performed by fluorescence microscopy after in vitro fusion of individual cells with thioglycollate-elicited macrophages. Tissue macrophages were labeled by transferring FITC-labeled lectins during the interaction of the cellular fractions. These in vitro culture conditions also allowed the identification of immune lymphocytes by reactivity with a panel of monoclonal antibodies. The most prominent T cell subset in lymphocyte elutriates contained CD4- positive cells that were of the Ly4+ subset and the CD8+ subset. This population of cells was designated as \"major T lymphocyte subsets.\" It was found that about one third of cell-associated Leishmania parasites were contained within CD4+, CD8+ populations. Approximately 80% of the parasites were concentrated in macrophage elutriates, whereas < 5% were associated with the major T lymphocyte populations. Lymphocyte populations depleted of FcR+ cells contained significant percentages of Ly4+, TCR.T3+ cells, as previously shown for L. mexicana-primed BALB/c mice. The numbers of both cell types were comparable with lymphocytes primed intravenously with Leishmania mexicana in immunocompetent mice. In contrast to",
        "label": 0
    },
    "1736": {
        "output": "---\n**Answers**  \n* The patient is eligible, therefore 0 is inserted in the first line.\nIn the second line, since the information on the patient's ID is not available for you, you should assume that the patient ID is 4, therefore 4 is inserted instead of the patient ID and the remaining information in line 2 is a result of a search. According to the exclusion criteria, if the patient has hypertension, heart failure, and kidney disease, then 0 is inserted, else 1 is inserted. As the patient takes no other medications, 0 is inserted in the fourth line.\n\nSince the patient took anti-HCV antibody test and hepatitis C RNA test 2 years ago, then 0 is inserted in the sixth line.\nThe patient has only a positive enzyme-linked immunoassay (ELISA) test for anti-HCV for the viral hepatitis B and C screening; therefore, 0 is inserted in the seventh line.\nSince there is no clear evidence that the patient has hepatocellular carcinoma and the most recent biopsy was negative, then 0 is inserted in the eighth line.\nSince the BMI of the patient is < 32.5, then 0 is inserted in the ninth line. Since the patient's heart, lung, and kidney functions are normal, 0 is inserted in the tenth line. And finally, since the patient is male, 0 is inserted in the eleventh line.\n\nNext, we check the trial conditions; the trial's criteria for accepting patients with a BMI of more than 30 are listed in the Exclusion criteria of the trial. Considering the above conditions, we find the patient is eligible for the clinical trial. The scale for the assessment of eligibility is:\n\n*** Eligible **\n\n1. The patient ID is a patient in the clinical trial.\n\n2. The patient has the type of a hepatitis B and C.\n\n3. The condition of the patient is not severe (hypertension, heart failure, kidney disease and other complications).\n\n4. The patient has no other medications.\n\n5. The condition of the patient is clear (no hepatocellular",
        "label": 0
    },
    "1737": {
        "output": "The trial-level eligibility is in the range of 0 ~ 2, which has three types: Excluded (0), Not relevant (1), Eligible (2). The output result:\n\n``` python\n\nprint \"Hello. You are an assistant for recruitment in clinical trials. Your task is\n      to predict if the patient is eligible in clinical trial.\"\npatient_1=''A chronic hepatitis C infection patient note:\nAge: 55\nHepatitis C infection diagnosed:\n2 years ago and with Hepatitis B Virus infection (Hepatitis B Virus):\n2 years ago\nMedication\n: \nInterferon and Ribavirin\nHepatocellular carcinoma: \nNegative\nPositive on previous\n:\nanti-Hcv antibodies (Anti-HCV) test\nPositive on previous\n:\nHCV RNA test (HCV RNA) results\nSmooth liver biopsy:\nNo\nTreatment status:\nNot yet treated\nMedication\n: \nInterferon and Ribavirin\nHepatocellular carcinoma: \nNo\nHCV RNA from patient:\n\n            \n\n*Trial-level*:\n            2.00\n               2\n*Trial-level*:\n            \n\nSmooth liver biopsy:\nNo\nTreatment status:\nNot yet treated\n```\n\n### <center>Reference</center>\n<center>Reference </center>\n<a href=\"#\" id=\"ref-219917173996294\" target=\"_blank\" rel=\"nofollow\">\n<img id=\"fig-5\" figcaption=\"\", class=\"fig-caption floatimg floatimg-center floatimg-caption floatimgsize-full floatimg-width-100 p-mt p-pl p-pb p-sm\" width=\"900\"\n       height=\"423\" src=\"/static/img/figure-parts/image.png\" />\n<img id=\"img-5\" style=\"width: 900px;height: 423px\" class=\"p",
        "label": 1
    },
    "1738": {
        "output": "You should pass `Trial-level eligibility: ` in your `output.data` array. \n```scala\nnew_record.arrays = List.fill(94) ++ new_record;\nList.fill(94) %:\n   _1: Array[Any] = Array[String] = Array[String] with length 3\n      Elements: \n   0:  \"\"\n   1:  \"\"\"\n    \n   \n   \n   \n   \n   \n   Title: Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt\n    \n   \n   \n   \n    \n   \n   \n   Summary:\n    \n     This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.\n    \n     Inclusion Criteria:\n    \n     Chronic hepatitis C, genotype 4-infection (hepatitis C virus [HCV] ribonucleic acid [RNA] level greater than 1,000 IU/mL at Screening)\n    \n     Subjects must meet one of the following:\n    \n     Treatment-naive: Subject has never received antiviral treatment for HCV infection\n    \n     Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegylated-interferon [pegIFN]/RBV);\n    \n     Females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control\n    \n    In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy or Fibroscan\n    \n    In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan with",
        "label": 1
    },
    "1739": {
        "output": "Please select your answers carefully.\n[END]<EOD> The use of the human cadaver specimen to learn pelvic examination techniques and skills\nThe pelvic examination is often described as the most humble and practical examination of all body systems, and yet many doctors feel it still is not properly taught during medical school. This problem is evident even in anatomy curricula. In a study of how anatomy is taught in US medical schools, it was found that only 35% of medical schools required that students perform pelvic examinations before graduating, and not all of these schools required students to perform a gynecological examination prior to graduation. There was a marked difference, that more schools that had more females faculty also required pelvic examinations to be conducted.<EOD> .\nBACKGROUND\nThe use of non-invasive tests for diagnosing liver cirrhosis is limited and the results should be interpreted with caution.\n\n\nAIMS\nTo compare the efficacy of the platelet count, the serum albumin level and the serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/platelet count ratio (APRI) for diagnosing liver cirrhosis in patients with chronic hepatitis C, and identify any prognostic factors for liver fibrosis.\n\n\nPATIENTS\n211 patients with chronic hepatitis C virus, 155 men and 56 women, who underwent liver elastography were evaluated. Patients with hepatitis B, hepatocellular carcinoma or with known alcohol abuse were excluded.\n\n\nMETHODS\nThe patients were classified according to fibrosis stage using the F4 fibrosis score and a model of the Italian Association for the Study of the Liver (AMIS). The stage of fibrosis was also assessed by transient elastography (FibroScan, Echosens, France) and liver biopsy. To validate results of the methods serum albumin, platelet count and APRI were used, and the correlation of each stage of fibrosis with these parameters was analyzed.\n\n\nRESULTS\nIn patients with established fibrosis score or AMIS score, li",
        "label": 1
    },
    "1740": {
        "output": "\")\n        elif cnt",
        "label": 2
    },
    "1741": {
        "output": "You can generate the result with the code below.\n\nWe start by defining the variables we will need.\n\n``` {code-cell}\nage_index = np.array([0,0,0,0,0,0,0,0,0,0,\n                     0,0,0,0,0,0,0,0,0,0,\n                     0,0,0,0,0,0,0,0,0,0,\n                     0,0,0,0,0,0,0,0,0,0,\n                     0,0,0,0,1,1,1,1,1,1])\nsurvival_times = np.exp(age_index*2)*5\n#gender_bar:\ngender_bar = np.array([1,0,1,1,0,0,1,0,0,0])\n\n#Duration_bar:\nage_index = np.array(re",
        "label": 0
    },
    "1742": {
        "output": "# Problem 4\nA trial note has been duplicated. How to handle this?\n\n## Potential solution 1\nIf only one data point is missing, make sure to select at least one data point from the patient:\n![Note20]![note21] [/POT]\n\n## Potential solution 2\nIf multiple data points are missing, you can skip the trial note and continue to the next patient.\n\n## Potential solution 3\nA new trial note has been created. Skip all new notes.\n\n## Potential solution 4\nIf data points of a given trial note are missing, please ask to the data steward or contact the IT team.\n\n### Note for the end\nWhen the previous 4 problem has been resolved, make sure to include a new trial note to the patient's clinical trial tab that will be sent by the \"Add Patient Noted and Clinical Note\" menu from the clinical trial module.\n\n## Expected outcomes\nUpon completion, this lesson may result in:\n\n\n### Patient's trial profile\n<!DOCTYPE html>\n<html lang= \"en\">\n<head>\n<meta charset=\"UTF-8\">\n<meta http-equiv=\"X-UA-Compatible\" content=\"IE=edge\">\n<meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">          \n<link href=\"https://fonts.googleapis.com/css2?family=Open+Sans&family=Roboto&family=Saira+Text&family=Tajaw&family=Work+Sans&family=Work+Sans:wgx-webfont&family=Varela&family=Varela:Regular&family=Zinser:wgx-webfont&family=Zulu+One:wgx-webfont&family=Zephyr:wgx-webfont\" rel=\"preload\" as=\"style\">\n<link rel=\"stylesheet\" href=\"/dist/v1/dist/main.18c7120e69d807c9bd6345bd06b069dcc.css\" > \n<title>Trial-level Eligibility -",
        "label": 0
    },
    "1743": {
        "output": "## Hint:\nIncreasing time in the for loop helps in solving the exercise more easily.\n\n\n#### An alternative form of solving the exercise\n\nLet's think step by step.\n\n\n#### An alternative form of solving the exercise\nLet's think step by step.\n\n\n## [INST] You are a nurse and you monitor a chronic disease, a patient with diabetes. You enter the patient for his or her annual appointment and want to obtain his or her most recent blood test. However, the file system of the hospital does not contain this test result yet. Can you query a database with SQL that tells you if the patient's last blood test was negative? Make sure that the patient's record includes all the blood test results from this year. \nYou are the manager of an online market. A customer has a complaint about an item the customer recently bought which is not as good as expected. The customer says the manufacturer's description lied to the customer and the product is not fully the quality stated by its producer. First, you check the customer's record in the order-fulfillment management system to verify the claim of the customer. Second, if a customer cannot make a claim, you search for a record of the item that was bought and the same item was sold to other customers who did not have any complaints.\n\n*What database query can the manager use to find the most recent customer that complained about the manufactured product?*  [INST] You are the manager of an office for a research and development team. Your office monitors and ensures that the research team's work and timelines are done in a timely manner. One of the researchers has been stuck and cannot access the lab for a couple of months. When you call the scientist to inquire about him/her, you are told that the scientist has been absent because the scientist had to receive a treatment. The scientist has not yet started working in the office again. Now you need to query the records of the scientist's absence in the HR department's database to determine how many days he/ she has been off from work and for what reason. [INST] Your office is an employer of several research and development teams. You want to monitor team 2's expenditures in budgeting. You want to make sure that the team has spent more than",
        "label": 1
    },
    "1744": {
        "output": "Let's continue with the last patient in the same patient note. There are no changes to the patient's medical history or medications since the last patient. Based on the patient's age and history, this patient is more suitable than the last one for a clinical trial requiring patients with hepatitis C and hepatitis B. You should add the patient to the group of eligible patients that can participate in the trial. \nTherefore, output the assessment of eligibility for the last patient in the same manner as in the second patient. \n\nHere is the clinical trial: \nTitle: Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study\n\n\nSummary: This is a one center, Phase IIa, randomized, double blind, placebo controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects 18 to 75 years of age, with newly formed cholesterol gallstones in their gallbladder following bariatric surgery confirmed by gallbladder ultrasound ..\n\nInclusion criteria:\nMale or female age 18 to 75 years.\nPresence of newly formed gallstones (size up to 6 mm) with or without sludge diagnosed by ultrasound within 3 or 6 months after bariatric surgery following normal ultrasound.\nBariatric surgery conducted during the last 12 months\nPatients with sleeve gastrectomy or laparoscopic banding of the upper stomach will be included.\nSignature of the written informed consent.\nNegative pregnancy test at study entry for females of child bearing potential.\nFemales of child bearing potential practicing reliable contraception throughout the study period (not including oral contraceptives).\nHypertensive patients must be well controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening (and the stable dose can be maintained throughout the study).\nPatients treated with vitamin E(>400IU/die), or Polyunsaturated fatty acid (>2g/d) or Ursodeoxycholic acid or fish oil can be included if drugs are stopped",
        "label": 0
    },
    "1745": {
        "output": "# Question 4\n\n[TEXT].\n\n[INST]. Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection",
        "label": 2
    },
    "1746": {
        "output": "<option value=\"0\">Excluded</option>\n    <option value=\"1\">Not relevant</option>\n    <option value=\"2\">Eligible</option></select> \n\n\n    <input type=\"text\" class=\"form-control\" value=\"2\" readonly /> Eligible \n    \n  \n3.  Patient-level eligibility assessment:  \nThe patient-level inclusion criteria for the trial are as follows:\n- Patient has received an antiviral treatment within the last three months that was terminated because of a loss of virological response (defined as 2 consecutive viral load measurements above 1000 copies/ml).\n- Patient had a HBV DNA load \u2265 20 pg/ml at the time of loss of virological response. \n\nHere is the HBV DNA load: \n\n(1;430;000,000 -5;430,000,000) : 3,574,000\n\n\n- Patient is male.\n\n    <select class=\"custom-select\" name=\"patient-level-eligibility\">\n    <option selected value=\"-\">Select a patient-level eligibility...</option>\n  \n  <option value=\"Not relevant\">Not relevant</option>\n  <option value=\"Excluded\">Excluded</option>\n  <option value=\"Eligible\">Eligible</option> \n\n\n</select> \nEligible \n\nHere is the trial's patient-level eligibility.\n\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHis medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic",
        "label": 1
    },
    "1747": {
        "output": "## Examples:\n```\nAssessor1:\n\nAssessor1, please rate this patient note for the title: Randomized Controlled Trial to Compare the Effect of Dietary Supplementation With Omega 3 Polyunsaturated Fatty Acids on Depression\n\nAssessor1, please give a trial-level eligibility for the above patient note.\n\nAssessor1, please rate the title, \"Randomized Controlled Trial to Compare the Effect of Dietary Supplementation With Omega 3 Polyunsaturated Fatty Acids on Depression\", using the eligibility criteria in the case report form.\n\nEligibility criteria in the case report form:\n- Female or male, aged 18 to less than 65 years\n- Having a DSM-IV-TR diagnosis of unipolar major depressive disorder of any type (single or recurrent major depression; major recurrent unipolar depression; or depressive episode of bipolar affective disorder)*\n- A Montgomery-Asberg Depression Rating Scale sum score of 24 or more at randomization visit\n- Be willing to accept randomization after providing written consent\n\n\nAssessor2:\n\nAssessor2, please rate this patient note for the title: \"Non-Interventional Post Marketing Surveillance of Vortioxetine Safety in Depressed Patients in Primary Care Practices in Turkey:\"\n\nAssessor2, Please give a trial-level eligibility for the above patient note.\n\nAssessor2, Please rate the title, \"Non-Interventional Post-marketing Surveillance of Vortioxetine in Depressed Patients\", using the eligibility criteria in the case report form.\n\nEligibility criteria in the case report form:\n- Willing and able to give written informed consent, for male or female, aged 18 or over at the screening visit;\n- Males and females aged over 18 years at the screening visit and able to participate in the study at that visit. The male partner/wife of premenopausal women (if they were currently being sexually active during the study and agree to remain sexually inactive during the study and follow-up period) will need to be",
        "label": 0
    },
    "1748": {
        "output": "[QUESTION:CYCL] What is `Trial-level eligibility: 0) Excluded`? If the patient has at least one exclusion criteria, print 0 instead of 2. That is, your rule function can be written as`Trial-level eligibility: 0) Excluded, if exists ExclusionCriteria.`, in Python. You do not need to define the logic to be performed in each instance. The only thing you should do, is to ensure that the result obtained from each patient note is printed within the Trial-level eligibility. \nFor the patient notes provided in this exercise, the correct print in the Trial-level eligibility should be 0) Excluded. In other words, the patient needs to be excluded because of the exclusion criteria. The Trial-level eligibility is 1) Not relevant in the case of the patient note `hcv_patient_note_2.txt`. This is in line with the fact that there is not enough information in the patient note to qualify for the trial. Finally, the Trial-level eligibility is 2) Eligible in the case of the patient note `hcv_patient_note_3.txt`. This matches with the fact that the patient note is of sufficient length to qualify for the trial.\n[/QUESTION]\n[QUESTION:RUNNING] How do you make a single patient-level eligibility output for a given patient in the `Eligibility_Report_2` file? [/RUNNING]\n[/QUESTION]\n[QUESTION:ANSWER] For each file in the `Eligibilty_Report` folder, the Python script (see `report_eligibility.py` file in the exercise folder) should generate a `Patient-level eligibility.csv` file that will contain the patient-level eligibility for every patient note. \n[/QUESTION] [QUESTION:RUNNING] How do you make a clinical trial-level eligibility output in the `Eligibility_Report_2` file? [/RUNNING]\n[/QUESTION]\n[QUESTION:ANSWER] You can use the python script (see `report_eligibility.py` file in the exercise folder) to",
        "label": 1
    },
    "1749": {
        "output": "[/CLOZ]\n<h1>Step By Step - Create Example</h1>\n<p>\n  Here is <a href=\"https://github.com/saschabauer/Clinical-Assistant/tree/master/Phnom%20Penh\">\n    <img src=\"./screens/Clinical_Trials/Phnom_Penh/Screenshot%2001%20of%20step%20step%20b.%20png\" width=\"497\"/>\n  </a>\n  in your browser. Please note that the program is very short. Here is the complete source code of the CAS:</p>\n<pre class=\"highlight pre prettyprint\"><code class=\"python linenums\"><span class=\"ht-span\">#!/usr/bin/env python\n# coding: utf-8\nimport os, shutil\nimport json\nfrom argparse import ArgumentParser\nimport sys\nimport string\nimport tempfile\nfrom collections import OrderedDict\nimport traceback\nimport sys\nfrom . import Assistant\nfrom .log import get_logger\nfrom .config import SysParser, PhnomPenhParser\nfrom .config import create_file\nfrom .config import create_file_handler\n# from .config import create_file, create_file_handler\nfrom sklearn.cluster import KMeans, KNeighborsClassifier\nfrom sklearn.manifold import LocallyLinearEmbedding\nfrom sklearn import svm\nfrom sklearn import ensemble\nfrom scikits.nnlearn.metrics import auc\nfrom sklearn import linear_model, lasso\nfrom sklearn.linear_model import LogisticRegression, ridge as SimpleRidge\nfrom sklearn.naive_bayes import GaussianNB, BernoulliNB\nfrom sklearn.svm import SVC, SVR\nfrom sklearn import base, model_selection\nfrom sklearn.ensemble import EnsembleAlgorithm, Bagging, Bootstrapping, RandomForestClassifier\nfrom sklearn import GridSearchCV, Pareto, cross_validation, GridSearchCV, GridSearchCV\nfrom sklearn.linear_model import LinearRegression\nfrom sklearn.svm import SVR\nfrom sklearn.",
        "label": 0
    },
    "1750": {
        "output": "<EOD> Cytotoxic Activities of Natural Ozonides from the Roots and Rhizomes of Adenophora tetramera.\nThree natural ozonides, adenophoratosides A-C (1-3), were isolated from the roots and rhizomes of Adenophora tetramera, together with the known adenophoratosides D (4) and E (5). Their structures were elucidated mainly by spectroscopic methods. All compounds were evaluated for cytotoxic effects against the human MGC-803 gastric cancer cell line. In vitro biological assays indicated that compounds 2 and 5 exhibited stronger cytotoxic activities (IC50 values of 7.83 and 7.92 \u03bcM, respectively) than the positive controls, cisplatinum and docetaxel.<EOD> A New Type of Carbon-Doped 2D MoSSe Layer for Photoelectrochemical and Electrocatalytic Oxygen Evolution\n\n\n\n# Introduction\nCarbon is the most diverse element in the world, which always plays important roles in the development of energy and the environment. Since a new type of graphite was discovered in 1957 [bib_ref]  A new form of carbon, Hawley [/bib_ref]  , carbon has been developing rapidly and has made great achievements in various fields, including graphene [bib_ref]  Electric field effect in atomically thin carbon films, Novoselov [/bib_ref]  , graphene oxide (GO) [bib_ref]  Pillars for future electronic devices: Graphene oxide nanofiber-based composite flexible electrodes, Guo [/bib_ref]  , fullerenes, etc. Especially, the discovery of graphene has opened up a new field for the development of new carbon materials, which is one of the hot issues today. Graphene is composed of sp 2 hybridized carbon atoms with a honeycomb structure [bib_ref]  Toward monolayer C 4 N: Structure, stability and transport properties, Taut [/bib_ref]  [bib_ref]  Two dimensional crystallography of black phosphorus. Acta Crystallographica Section B, Lu [/bib_ref] . In recent years, the excellent properties of graphene have been gradually revealed. First, in terms of physical properties, the high surface area,",
        "label": 0
    },
    "1751": {
        "output": "<EOD> \n- How much do they weigh.\n- Is it ok to eat with me to be nice\n- Does it like eating me\n- How many babies has been eaten.\nThis is a picture of a baby alien.\nDo you ever have a question that is asked to you and you really don't know what to answer? This can be very aggrivating! I ask about babies a lot, and i think i know it all. That is until a 2 year old comes along and throws me a curve ball with a question like one of these above.\nI didn't have a good answer at first either, but then i did get one of my own. Try this with kids to see what questions they ask.\n\"How do you know they won't eatten me?\"\nAsk it back with the same question. \"How do you know they want to eatten me?\"\nYou can get even better questions by asking questions about their favorite things. Ask how many things you can make out of the item they are wearing or talking about. Example: a kid is wearing a shirt with a horse on it, ask how many horses you can make.\nThe key to this one and all of these questions is to never give them a answer that is factual... it's just not going to work. You can't tell them you don't know and just say the truth, they would call foul!! You can tell them things about you're parents but they don't count since they say this question.\nEnjoy!\nYou Might Also Like\nComment\nYou Might Also Like\nRecent\nTell them everything is edible or the opposite<EOD> A prospective, randomized study to assess the effects of bone mineral density on the efficacy of adjuvant chemotherapy in resected pancreatic cancer.\ne14048 Background: Bone mineral density (BMD) is a prognostic surrogate for bone metastases . Anorexigens like Dexamethasone which decreases BMD, may impact survival in PDAC but the impact of decreasing BMD by tamoxifen (an antagonist of estrogen) is unknown. There is a negative correlation between BMD and tumor spread . We therefore performed a prospective, randomized",
        "label": 1
    },
    "1752": {
        "output": "# Rationale\n- The assessment was designed as a tutorial/worksheet, and a set of guidelines was compiled to assist the participants.\n- Two groups of patients were described. An appropriate answer for the first group was found by matching the elements of the HCV study profile with those of the first group in the participant's patient database. If the criteria and the patient's profile matched, the corresponding trial in the database was included in the participant's choice. For the second case, no trial was matched.\n\n# Results and discussion\nThis evaluation was completed by all the nurses that took part. Based on the average completion time (\u22481:10h), we can assume that the average of the level of knowledge improved, after this didactic activity, by about 15% or more. \n\n# Statistical results\nFrom a statistical point of view, in order to know how the two groups of students are different, a Mann-Whitney was performed, \n<EOD> Effects of antidepressants on the circadian activity of rat pinealocytes.\nCircadian rhythms of cyclic AMP content, histamine N-methyltransferase (HMT) activity and melatonin content, and in vitro histamine N-methyltransferase (HMT) enzyme activity were studied in rat pineal glands. The cyclic AMP content and the HMT enzyme activity were maximal in the morning, and in vitro, the HMT activity decreased by 45%. Melatonin production reached a maximal value in the morning, the peak of the time dependent melatonin secretion occurred 4.5 h after, and the secretion continued throughout the lighting period. Antidepressants, such as amitriptyline and maprotiline, significantly suppressed both the melatonin production and the HMT enzyme activity in vivo and in vitro. The changes in the HMT enzyme activity and the melatonin content were closely associated. Tranylcypromine failed to affect the endogenous circadian cyclic AMP contents. Desmethylimipramine significantly increased the in vitro HMT enzyme activity at some time points, but decreased it in vivo. Amoxapine produced a small peak in",
        "label": 1
    },
    "1753": {
        "output": "<EOD> P06-02. Immunogenic activity of A/H1N1pdm09 HA and NA proteins produced in E. coli\n\nBackground:The development of a suitable vaccine to prevent or control influenza pandemics is highly desirable. To this end, A/New Caledonia/20/99(H1N1) avian influenza virus-derived proteins were expressed in E. coli. One potential concern regarding the use of such proteins is that they could be immunogenic in humans.\n\n# Background\nInfluenza virus hemagglutinin (HA) and neuraminidase (NA) glycoproteins play a pivotal role in the virus entry into host cells. During viral entry, HA binds with its sialoglycoside receptor sialyloligosaccharide (Neu5Ac\u03b12,3Gal\u03b21,4 GlcNAc) that contains 2,3-linked sialic acid; and NA disrupts the sialic acid-galactose linkage in this receptor, thus allowing viral release from host cells [bib_ref]  Role of influenza virus HA, NA, and M2 proteins in pathogenesis of..., Vles [/bib_ref]  [bib_ref]  Influenza neuraminidase: structure, antigenicity and role in virus infection and evolution, Uchiyama [/bib_ref] . Therefore, one approach to designing a vaccine against influenza viruses is vaccination with HA-or NA-derived peptides corresponding to the epitopes of cytotoxic T lymphocytes (CTLs) [bib_ref]  Enhanced generation of neuraminidase-specific cytotoxic T lymphocytes in mice vaccinated with hemagglutinin-neuraminidase-hemagglutinin fusion..., Itoh [/bib_ref]  [bib_ref]  Cytotoxic T lymphocytes in influenza virus infection: protective potential of epitopes and..., Schirl [/bib_ref]  [bib_ref]  Protective CD8(+) T cell immunity to lethal pulmonary influenza virus challenge in..., Jones [/bib_ref] . Many studies have reported that CTL epitopes derived from",
        "label": 0
    },
    "1754": {
        "output": "## Task 9\n\n[INST] Let's consider that the given patient has a history of diabetes mellitus for the past 3 years. The patient is on insulin, which was started 2 years ago. The patient has 3 major depressive episodes during the past 3 years. The patient is on antidepressants, a benzodiazepine, and analgesics, and the dose has not changed during the past 4 months. There is no evidence of any serious adverse side-effects to any of the patient's medication. This is the medical history of the patient:\nThe patient is an alert male with no acute distress. His BP 130/75, HR: 120/min and BMI: 22. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply)\nLet's think of your task. To assess the patient's eligibility, you should repeat the assessment of the eligibility at the trial-level and output the trial-level eligibility. The output should be repeated by `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`. After that, you should output the patient's eligibility, e.g., `Patient-level eligibility: 2) Eligible.`. \nHere is the patient's assessment of eligibility 1) Not relevant: Patient doesn't have sufficient information to qualify for the trial. 2) Eligible 2) Eligible `Trial-level eligibility: 2) Eligible `. Patient-level eligibility: 2) Eligible `Patient-level eligibility: 2) Eligible `The trial was a phase III, non-infer",
        "label": 1
    },
    "1755": {
        "output": "[INST] \nYou have finished one example of the trial note. I guess the next patient note will be more complicated.\nYou will find another patient note from the same trial in the exercise_p1 folder. Please practice by repeating the above 3 steps iteratively. (5min)\n\n## S29_ch1_ex2\nYou will find another patient note from the same trial in the exercise_p1 folder. Please practice by repeating the above 3 steps iteratively. (5min)<EOD> Efficient and Low-Cost Syntheses of \u03b1-Linked Disialoside and \u03b1,\u03b1-Sialylated Oligosaccharides Bearing the 4-sulfated N-acetyllactosamine Core.\n\u03b1-Linked disialoside (1) and \u03b1,\u03b1-sialylated oligosaccharides (6, 7, and 8) bearing the 4-sulfated N-acetyllactosamine (LacNAc) core were synthesized in four steps from Neu5Ac. The thioglycoside (6) showed a distinctive reactivity in the ring opening of the azido group with the 4-sulfated LacNAc fragment with sulfate functionality. The formation of \u03b1-(1\u21926) sialoside (2), (1\u21926)(1\u21924) disialoside (3), (1\u21926)(1\u21926) disialoside (4), and \u03b1-(1\u21926)(1\u21926) sialyloligosaccharide (7) from the azido-derivatives of disialoside (1) were easily achieved. Finally, the sulfated oligosaccharides were further converted to de-sulfated oligosaccharides.<EOD> .\nOBJECTIVES\nTo assess effects of a 12 mo treatment with testosterone (T) in hypogonadal (HG) infertile males on fertility rate in term of pregnancies per million seminograms (PRx10(6)).\n\n\nMATERIAL AND METHODS\nThree-arms experimental study. A group of 66 infertile HG males were studied before and after 12 months of T-treatments. The control",
        "label": 1
    },
    "1756": {
        "output": "### Datasets.\n\n- Dataset.RData\n- Dataset3.RData   The clinical trial that you will study was designed to examine whether it is possible to increase exercise adherence by employing a behavioral intervention package, called PACE, that included tailored motivational strategies, exercise goal setting techniques",
        "label": 0
    },
    "1757": {
        "output": "<EOD> Inhibition of DNA replication induced by adhesion of mouse lymphoblast L-929 cells to latex.\nTreatment of mouse lymphoblast L-929 cells with the cationic latex microspheres induced a large inhibition of DNA replication and a remarkable increase of the cell size. This phenomenon appeared in the late hours of cell incubation with latex. It was a reversible process. The action of the latex on cellular macromolecules was investigated using the inhibition curve of 3H-thymidine incorporation into the cellular DNA, its effect on the cellular total and RNA-free protein content and the effect of this treatment on the cellular deoxyribonuclease I and RNA nucleotidyltransferase activities. The results observed were different in the presence or in the absence of serum.<EOD> Angiotensin II regulation of the expression of growth hormone secretagogue receptor\nA recently published paper in Cell demonstrated that the GH secretagogue receptor (GHS\u2010R) may be involved in the process of GH release induced by angiotensin II (AngII); specifically, AngII was shown to stimulate GH release from primary pituitary cell cultures in a GHS\u2010R\u2010dependent manner. Surprisingly, inhibition of nitric oxide (NO) synthase, or pharmacological inhibition of calcium channels, significantly reduced AngII\u2010stimulated GH release, suggesting that NO and/or the influx of calcium via L\u2010type channels are necessary for GHS\u2010R activation by the AngII signal. The expression of GHS\u2010R in rat pituitary cells was low compared to hypothalamus and adrenal gland; therefore, pituitary cells expressing GHS\u2010R may have less effect with regard to GH release in response to AngII. However, it is possible that intrapituitary mechanisms are responsible for GHS\u2010R\u2010coupled AngII\u2010GH release. Further studies will provide a better understanding of the mechanisms of reproductive axis regulation by the AngII and GHRH systems.<EOD> Effects of dietary methionine, protein and energy on performance of immature",
        "label": 0
    },
    "1758": {
        "output": "## Invoke\nAsked whether the patient complies with each pre-specified Inclusion or Exclusion criterion. Then return a binary output representing his eligibility status, which is based on the answers you found in the medical record. If a criterion is not available or cannot be checked the return of code not available should be returned and the system shall ignore such criteria for that subject. An empty return value indicates that the patient does not meet any of the specified requirements. A string specifying any reason the patient did not meet the requirements for the given trial should be returned\nAsked whether the patient meets each pre-specified Inclusion or Exclusion criterion. Then return the relevant status (1) Excluded,  (2) Excluded,  or  (3) Excluded, . Return an empty string if criterion is not available or cannot be checked, and the system shall ignore such criteria for that subject. If there is no existing list of exclusion criteria the system should return a string indicating that no exclusion criteria were specified, and there is no reason to believe the patient would be ineligible\nReturn a patient's Trial-level eligibility score. Possible values include: 0) Excluded; 1) Not relevant; or 2) Eligible\nReturn the reason why patient is not ineligible\nReturn an empty string if there is no reason patient is ineligible\nReturn an empty string if the reason patient is ineligible because it cannot be determined if the trial requires that a factor be considered for inclusion or exclusion\nReturn this patient's Trial-level eligibility status as a number between 0 and 1, where 1 indicates that the patient meets all inclusion criteria and none of the exclusion criteria, i.e., the eligibility assessment is eligible\nReturn an empty string if there is no reason a patient is ineligible\nReturn a patient's Trial-level eligibility score. Possible values include: 0) Excluded due to reason; 1) Not relevant; and 2) Eligible\nReturn an empty string if there is no reason a patient is ineligible\n\n## Previous solutions\n<![if !IE]>\n    <style type=\"text/css\">\n    body{\n        background :none;\n    }\n    </style>\n\nThe challenge",
        "label": 1
    },
    "1759": {
        "output": "__Round for practice__\n\n```python\nprint(\"Patient name:\", patient_name, \"Score:\", score)\nprint(\"Patient-level assessment \", score)\nprint(\"Trial-level assessment \", score)\n\ninput(\n\"\"\"\n1.\n2.\n3.\n\"\"\"\n)\n\nif score == 0:\n    echo(\"Excluded (patient meets inclusion criteria but exclusion criteria) \")\nelse:\n    if score == 1:\n        echo(\"Not relevant (the patient does not have sufficient information to qualify for the trial)\")\n    else:\n        echo(\"Eligible (patient meets inclusion criteria and exclusion criteria do no apply)\")\n    echo(\"Trial-level eligibility:\", score)\n```\n\n__Trial level assessment__\n\n```python\nif \"trial.name\" in patient_name:\n    if patient_name.endswith(\"2402\"):\n\n        trial = Patient(trial_name=\"2402\")\n        print(f\"{trial.age} {trial.gender}: {trial.marital_status}\")\n        for attribute in trial.personal_history.all():\n            print(attribute.name, \":\" , attribute.value)\n            if \"HBV\" in attribute.value:\n                print(\"\\nHBV\", attribute.value)\n        for attribute in trial.clinical_history.all():\n            print(attribute.name, \":\" , attribute.value)\n            if \"HCV\" in attribute.value:\n                print(\"\\nHCV\", trial.personal_history.filter(\n                 personal_history__HCV__startswith=\"+\"\n                 ).first().value)\n                print(f\"\\nCoinfection? \", \\\n                        trial.personal_history.filter(\n                          personal_history__HBV__startswith=\"+\"\n                          ).first().value)\n        for attribute in trial.lab_tests.all():\n            print(\"\\n\", attribute.value)\n            if \"VIRAL_TITER\" in attribute.value:\n                print(\"\\nViral_titer\", \\\n                        trial.lab_tests.filter(",
        "label": 0
    },
    "1760": {
        "output": "<EOD> Miniature CMOS pH microswitch with wireless telemetry for sensing and feedback biocontrol\nA microfabricated pH sensor has been monolithically integrated with a complementary metal oxide semiconductor (CMOS) transmitter in order to enable wireless interrogation of biological microbots in response to the environmental pH. The integrated sensing and feedback approach offers several key advantages relative to existing designs that utilize electrodes separated from an ion-sensitive membrane. The CMOS sensor design achieves miniaturization, which is important for in vivo applications, and the use of fully integrated CMOS electronics provides for simplicity, low power, biocompatibility, high reliability, immunity to electromagnetic interference, low cost and potential for mass manufacture. The sensor is fabricated on a silicon chip with post-CMOS processing and includes an isolated floating gate that acts as a membrane for sensing pH. Sensor response data is processed to adjust the pH threshold. The transceiver circuitry also allows bidirectional communication between the sensor and a remote readout instrument or mobile phone. In this manner, the wireless sensor can provide feedback control to an inoculated environment, and potentially be used as a method of early medical diagnosis.<EOD> Effects of a Single Session of a Reiki Intervention on Self-Acceptance, Resilience, and Well-Being among a Sample of Undergraduate Students in Saudi Arabia: A Single Group Pretest and Posttest Study\n\nBackground: Many students report poor levels of mental health. The purpose of this study was to explore the effects of a single session of a reiki intervention on self-acceptance, resilience, and well-being among undergraduate Saudi Arabian students. Methods: This non-experimental, single group pretest-posttest study was conducted with participants, university students from King Saud University, in Riyadh, Saudi Arabia, between January and February, 2019. A single session was delivered to 223 students who were given the option not to participate if they did not want to. The sample comprised Saudi Arabian men and women from 18 to 31 years old who could read and speak English. Participants took part in a 90-min (one reiki session",
        "label": 1
    },
    "1761": {
        "output": "You may write down the full code by `def eligibility2(note, trial):` and run it through a Python interpreter and write down what is printed out.\n[Tutorial-B](./Tutorial-B.md)\n\n\n---\n\n**Scoring:** <span style=\"color:green\">[75 pts](./Scoring-Sheet.md)</span>\n<details><summary>\nPoints are awarded for a function/code that works.\n</summary>\n<br/><ul>\n<li><span style=\"color:green\">Function name and return type.</span> <span style=\"color:red\"><b>12 pts</b></span> (2 pts &#8211; function name; 1 pt &#8211; return type; 9 pts &#8211; both are required) <br/><br/></span><span style=\"color:green\">Fifty percent of total points</span>\n</li>\n<li><span style=\"color:green\">Function definition.</span> <span style=\"color:red\"><b>15 pts</b></span> (2 pts &#8211; function definition; 6 pts &#8211; function body; 7 pts &#8211; both are required) <br/><br/></span><span style=\"color:green\">Fifty percent of total points</span>\n</li>\n<li><span style=\"color:green\">Function usage.</span> <span style=\"color:red\"><b>18 pts</b></span> (6 pts &#8211; function usage; 2 pts &#8211; return type is checked; 6 pts &#8211; function input checked.) <br/><br/></span><span style=\"color:green\">Fifty percent of total points</span>\n</li>\n<li><span style=\"color:green\">Defines a function that returns the eligibility score of a trial.</span> <span style=\"color:red\"><b>2 pts</b></span> <br/><br/></span><span style=\"color:green\">One percent of total points",
        "label": 0
    },
    "1762": {
        "output": "##[DONTCOMMENT]// Your task is to detect genes that have changed significantly between two populations. You should select the top 10 genes and visualize them with a heatmap. For each gene, you will have a table of a 2 x 2 matrix with 2 conditions (e.g., population A and B) and 2 group conditions (e.g., male and female).\n// If you select a matrix that has empty rows, we cannot detect expression changes between two or more groups. Try your best to select a matrix that doesn't have empty rows. [/DONTCOMMENT]\n#\n## First, we will create a dataframe with a two-group condition with one row per gene. Then, we will extract the table that contains a 2 x 2 matrix of two columns: the name of the genes and group.\n#\n# First, we need to create the matrix object with two conditions.\ndf_A_B = pd.DataFrame(\n    data = \n        pd.Series(10, index=['A', 'B']),\n    columns = ['A', 'B']\n)\n\n# We don't have the group condition yet.\n# We will create the pandas dataframe of the table with a 2 x 2 matrix with two columns: the name of the gene and the group.\ndf_conditions = pd.DataFrame(\n    data = \n        pd.Series(\n            [['A', 'Male'], ['A', 'Female'], ['B', 'Male'], ['B', 'Female']],\n            index=[0, 1, 2, 3]),\n    columns = ['A', 'B']\n)\n\n# We want to plot the selected genes with a heatmap.\nheatmap_data = pd.DataFrame(\n    data = \n        dataframe(df_conditions),\n    index = df_A_B.index, columns = df_A_B.columns,\n    dtype = str\n)\n\n# We need to make a dataframe of the matrix that has data as a string.\nheatmap_data_df = data_frame_df(heatmap_data, label=\"Ratio\",\n                                x_label=\"Condition\",\n                                y_label=\"",
        "label": 1
    },
    "1763": {
        "output": "## Q[INST] Hello. We will now continue with a discussion about a sample with Aflatoxin and hepatitis viruses.\n\n## H[INST] Aflatoxins are toxic naturally occurring compounds and can be divided into four main classes: Aflatoxin B1(AFB1), Aflatoxin B2, Aflatoxin G1 (AFG1), and Aflatoxin G2. The International Agency for Research on Cancer(IARC) classified aflatoxins as group 1 agents, carcinogenic to humans(C), namely Aflatoxin B1 and G1 and to a lesser extent aflatoxin(AF) B2 and G2 . Among these, AFB1 is reported to be the most potent natural carcinogen in general, although its carcinogenic activity can be decreased by acetylation and glucuronidation . In contrast, glutathiolation of AFB1 is found to be protective against carcinogenesis, although the exact mechanism is yet unknown . Other toxicity effects include hepatocarcinogenesis, hepatocellular carcinoma (HCC), mutation in p53 tumor suppressor gene, acute and chronic hepatitis, and inhibition in antigen presentation that can allow for hepatocarcinogenesis, as well. Toxic effects of AFB1 also includes reduced protein synthesis, inhibited mitotic DNA repair, and impaired DNA base excision repair. While acetylation on the carbon C8 position of AFB1 is reported to be protective against its toxicity, that of the carbon C2 bond is not protective against carcinogenic effects .\n\n## I[INST] hepatitis b virus or hbv and hepatitis c virus or hcv are the main causes for liver cirrhosis and liver cancer, also known as hepatocellular carcinoma (hcc).\nHepatitis Delta Virus, another member of the hepatitis virus family is found not to be directly associated with liver cancer . The term HBV-related HCC refers to HBV presence, though it may not be the direct cause of HCC.\n\n## J[",
        "label": 0
    },
    "1764": {
        "output": "([[\u00a0on, \ufffdin a patient. You. [or or we\n[s, an el 13\n^ a\n[based. 13, so they, so he/he and to be included 5-orient:.\n. You. The elig/[ \n\nfor the el\n\n[ and its medic\nor and 0.[an but he; he or [bib_ref] and with the\u00a0de, the el 1\u00a0[s \ufffdinter. You[and; elf, i and\n[[s. 3. You, butter-ass. A [bib_ref]. A\nin. With (a_ A \u00c3to \u2044 or more \n or you \n[\n. Someness! . that. [bib_ref] A \nfor the clinelessly. Theyera, 5\u00a0 or a [bib_ref]s, and \nand and ... and \n-the and theus. If [bib_ref] 10 \u2026. [fig_ref] (or. In a\u00a0for the \\ / . and for the \nc and the [bib_ref] of 8 or 1\ns of\n and 1. 3 and its and a [bib_ref] [bib_ref] or a new [[in a trial 12 or\ns or \u2044 [fig_ref] el [ 4(s, and 1. A\u00a0 in \\ and [bib_ref], and the 1 on the patient;\nwith 1\u00a0on and the patient [bib_ref]. [bib_ref]. In detail. A# [bib_ref] thatel. [bib_ref] !(2 and \n2, because [bib_ref] ., who. [bib_ref] 1.\n and the -and 3. \n and / 1\n or\n! and he. a.\n or for \n\nfor\nfor 1-to [bib_ref] a 1 or (0 [bib_ref]\n [bib_ref].\n\n (but in the on 1 on\nfor , but a\u00a0in\n.\n and 2\n at 1? [bib_ref] to a ,\u00a0specific patient \\ \\ \\\n\n\nin\n\\ 3 - 0 _C after a [bib_ref]<EOD>. and a<EOD> or a [bib_ref] a 4 (in for a \u00ae [bib_ref] for a 22. This (in-and for 2 \u00a0 and _el patient 23. the patient [bib_ref] and [bib_ref]\nand/the or the ,",
        "label": 1
    },
    "1765": {
        "output": "### Test Data Set\nFor a more detailed introduction into Test Data Set, the following file was created: [/TUT1/TDS_CIRR.txt](http://drwiki.org/w/Image:TDS_CIRR.txt ''test data set, cirrhosis patients'') contains a large number of patient notes in the format of the Test Data Set. The test data set in the Dr.WIKI allows you to practice with the test data set without the need to download or install any software.\nThe file contains 10 patients. Each of the 4 columns of each patient entry contains information about the patient's first name, age, gender, and country.\nEach patient has a disease: cirrhosis of the liver. In this context, cirrhosis is defined according to the criteria given below. Cirrhosis is the end stage of any chronic or persistent injury to the liver such as hepatitis or the abuse of alcohol.\n- The patient's first name is \"Mary\". The patient's age is 68 years, and the patient's gender is \"Female\". The patient is Swiss.\n- The patient's first name is \"Linda\". The patient's age is 69 years, and the patient's gender is \"Female\". The patient is Swiss.\n- The patient's first name is \"Willie\". The patient's age is 67 years, and the patient's gender is \"Male\". The patient is Irish.\n- The patient's first name is \"Edward\". The patient's age is 93 years, and the patient's gender is \"Male\". The patient is Swiss.\n\n## [Dr.WIKI-Bot](https://www.dwiki.org/wiki/dwiki/index.php/Special:Log/DrWikiBot ''WikiBot's logs'') is used for creating the test data set. For convenience, the commands that were used for creating the test data set, or using the DATA REQUIREMENTS DIRECTORY, are provided in the file [/docs/TUT1/drwikibot.txt](http://drwiki.org/w/index.php?title=Documentation/TUT1/CIR",
        "label": 1
    },
    "1766": {
        "output": "<EOD> Assessment of the effect of a combined treatment with amino-bisphosphonates and anti-TNF on aluminum accumulation in the human and mouse bone.\nBoth bone resorption and formation are highly regulated processes dependent on complex pathways and cell types, and the disruption of these pathways can result in severe diseases such as osteoporosis and Alzheimer's disease. To test the hypothesis that bisphosphonate combination therapy with anti-TNF reduces metal accumulation in the bone and ameliorates aluminum-induced bone abnormalities and neurodegenerative processes, we determined aluminum levels in the bone and brain of mice and patients with advanced secondary hyperparathyroidism (aHPT), as well as in their bone microbiome. We found that the concentrations of aluminum in the tibia of mice and humans decreased from 0.64 to 0.57 and from 3.3 to 2.7 mg/kg, respectively, when bisphosphonates were combined with anti-TNF therapy with Etanercept. We also found the highest concentration of aluminum in the tibia of patients with aHPT treated with phosphate binders and bisphosphonates combined with Etanercept. This suggests that this therapeutic strategy could be used for bone aluminum removal and may serve as a basis for future studies.<EOD> Neostigmine versus pyridostigmine in reversing vecuronium-induced neuromuscular blockade during suxamethonium: a double-blind intravenous comparison\nNeostigmine 100 lg  kg-l and pyridostigmine 0.5 mg  kg-1 were compared for their effectiveness in reversing vecuronium-induced blockade after suxamethonium induction of anaesthesia in 100 patients. The two drugs were randomly given 3 min after tracheal intubation and 15 min after induction and were compared for their effect on the duration of the block and the time to recovery of the train-of-four response. The time to recovery of both the first twitch and the train-of-four ratio to 0",
        "label": 0
    },
    "1767": {
        "output": "Thank you for your work and for your attention!\n\t\t\t\t\t\t<EOD> The influence of annealing time on a thermoplasticized acrylic resin.\nThe purpose of this research was to observe the effect of time on annealing at 100 degrees C on a thermoplasticized acrylic resin. Acrylic sheets were thermoplasticized at 120 degrees C for four different times, and then annealed at 100 degrees C on five layers of wax paper. The sheets were weighed on a four-place analytical balance while warm and again after annealing. The percent increase of the weight was used to determine the effect of annealing time on the thermoplasticized sheets. The results indicated that time was important in the annealing of thermoplasticized sheets for bond strength to other occlusal surfaces.<EOD> An Overview of the Clinical Value of the Cerebrospinal Fluid Tumor Marker Interleukin-8 in Patients with Neurooncology Disorders\n\n [bib_ref]  Serum interleukin 10, 1 beta, interferon gamma, interferon alpha, and tumor necrosis..., Sharma [/bib_ref]  [bib_ref]  Increased serum levels of interleukin-6 in patients with brain tumors, Karpathiou [/bib_ref]  [bib_ref]  Evaluation of cytokine profiles of glioma tumor markers compared to serum inflammatory..., Bumgras [/bib_ref]  [bib_ref]  Evaluation of cytokine profiles of glioma tumor markers compared to serum inflammatory..., Bumgras [/bib_ref]  [bib_ref]  Interleukin-8 and the interleukin-8 receptor component of a heterodimeric CXC chemokine with..., Schumacher [/bib_ref]  [bib_ref]  Neuroretinal cell death may result from interleukin 8 overexpression, Li [/bib_ref]  \n\n## Il-8 in health and disease\nInterleukin-8 (IL-8), also known as CXCL-8 or Chemokine (C-X-C motif) ligand 8, [bib_ref]  Interleukin 8 in brain tumor pathogenesis, Terry [/bib_ref]  [bib_ref]  Interleukin-8 and",
        "label": 0
    },
    "1768": {
        "output": "Copy-paste each patient note to the `Patient assessment table`. If the clinical trial shows a 3-point scale (eligible, not relevant, excluded), then copy-paste the scale to `Eligibility score`, e.g., `Eligibility score: 2 (eligible).` \nOnce the table is filled up, click the `Done` button. \n![Screenshot `Patient assessment table` (eligibility score)](http://drf.is/BH_data/inst_clinical_recruitment_6_screenshot_p_table.png)\n\n<EOD> Enabling Molecular Dynamics Simulations of G-protein-coupled receptor signaling events on subsecond timescales.\nRecent experimental measurements have provided new insight into the complex signaling pathways that are activated following ligand binding to G-protein-coupled receptors (GPCRs). However, it is difficult to elucidate the dynamics of such pathways with conventional experiment due to their highly transient and structurally heterogeneous nature. Here, we describe a protocol for studying the activation of GPCR signaling pathways using all-atom molecular dynamics (MD) simulations. These MD simulations are built on the integration of a number of tools, including CHARMM/NAMD based simulations, advanced membrane models and force calculations, and visualization packages. This protocol highlights the use of all-atom simulations in combination with advanced force calculation methods to study GPCR activation events. The protocol described here has been demonstrated to be successful at producing detailed models of GPCR activation and provides a good starting point for further developing simulations of this system or other receptor systems.<EOD> .\nPURPOSE\nTo evaluate the role of endosonography (EUS) in assessment of the extent of chronic pancreatitis, and to correlate the extent of pancreatitis by this new technique with seric levels of trypsin.\n\n\nPATIENTS AND METHODS\nFifty-four consecutive patients with biopsy proven pancreatitis underwent pancreatic EUS. EUS was performed by Olympus sonography and a 12MHz forward-viewing device. The extent of pancreatitis was rated, according",
        "label": 0
    },
    "1769": {
        "output": "# Assignments\n\n## Exercise C -The task  of evaluating a patient based on the trial-level eligibility - Assign ID 300003 & get the patient note\nFirst, click the link to the trial. Go to the main page, which contains a table with information on the current trials. \n\n## Exercise E -\nThe task  of evaluating a patient based on the trial-level eligibility - Assign ID 300003 & get the patient note\nFirst, assign the ID '300003'. Then, we can see the patient note again. Click on 'View all information' button, to get the table with information about patients and their eligibility assessment. \nLet's remember the tasks above: \n\n## Exercise E -\nThe task  of evaluating a patient based on the trial-level eligibility - Assign ID 300003 & get the patient note\nTherefore, the Trial-level eligibility should become:\n\n## Exercise F -\nThe task  of evaluating a patient based on the trial-level eligibility - Assign ID 300004 & get the patient note\n\n## Exercise G -\nThe task  of evaluating a patient based on the trial-level eligibility - Assign ID 300006 & get the patient note\nFirst, assign the ID '300006'. Then, we can see the patient note again. Click on 'View all information' button, to get the table with information about patients and their eligibility assessment. \nLet's remember the tasks above: \n\n## Exercise F -\nThe task  of evaluating a patient based on the trial-level eligibility - Assign ID 300004 & get the patient note\n\n## Exercise G -\nThe task  of evaluating a patient based on the trial-level eligibility - Assign ID 300006 & get the patient note\nTherefore, the Trial-level eligibility should become:\n\n## Exercise G -\nThe task  of evaluating a patient based on the trial-level eligibility - Assign ID 300",
        "label": 0
    },
    "1770": {
        "output": "<EOD> The Cysteine-Rich Domain of Neurotoxin-like Proteins in Caenorhabditis elegans and Drosophila melanogaster Shows High Sequence Homologies to the Neuronal Nicotinic Acetylcholine Receptor \u03b1-Subunit Ligand-binding Domain*\nNeurotransmission in the nervous system requires receptor proteins to which agonists bind, and a variety of ligand-binding domains (LBDs) for neuropeptides and neurotransmitter receptors have been characterized. Although the LBDs of neuropeptide receptors have been well characterized, the LBD of the neuronal nicotinic acetylcholine receptor (nAChR) has not been defined. Because nicotinic receptors are pharmacologically similar to members of an invertebrate family of neuropeptide receptors termed neurotoxinlike proteins, and these receptors have LBDs, we surmised that the cholinergic receptor-LBD (ChR-LBD) may include a Cys-rich sequence. Here, we have taken advantage of the availability of the genomic DNA sequences of the nAChR\u03b1-subunit and Caenorhabditis elegans and Drosophila melanogaster neurotoxin-like protein genes to characterize their protein domains. Sequence analyses reveal that nAChR\u03b1-subunit LBD domains are composed of an \u03b1-helical bundle stabilized by disulfide bridges, with an evolutionarily conserved and invariant cysteine-rich motif (CX14CX2CX17CX2CX3CX4C) located at the cytoplasmic side of the domain. An additional conserved cysteine at the amino terminus of the nAChR\u03b1-subunit and the four Cys residues in this motif are absolutely required for a nicotine acetylcholine binding site function in the receptors. Phylogenetic in silico analyses reveal that the ChR-LBD is highly conserved, and this is probably due to the necessity of keeping the LBD in a specialized conformation for ligand binding",
        "label": 0
    },
    "1771": {
        "output": "## [END] Hello, You are a helpful assistant for identifying trials with patient registry numbers (also known as clinicaltrials.gov identifier) that are similar in design to the one we are considering. Please review the following patient registry number and describe its implications for the trials that you are thinking of enrolling the patient into by filling in the questions.\nPatient Registry ID: NCT00960097\n\nLet's think step by step. \n\n## [end]\nLet's think step by step. \n# Conclusions\nOur tool enables the systematic creation and analysis of clinical trials using free text, semantic-driven abstraction, and NLP. To the best of our knowledge, this is the first study where (1) the structured abstract and text of the clinical trial protocol are modeled and processed from a textual, rather than a structured, perspective; (2) the representation is done using a combination of controlled vocabularies, ontologies, and semantic classes; (3) the representation of the experimental protocol is represented using a text-mining approach, abstracting its structural (e.g., inclusion/exclusion criteria) and semantic (e.g., disease name, diagnosis code, drug classes, etc.) content. Given the success of the tool so far, we can foresee various potential applications of it in areas such as creating standardized templates that are based on semantic classes, representing the content of a clinical trial that is reported in the media, and generating a controlled format for publishing a journal's research in the clinical trial environment, similar to what The Journal of Medical Internet Research has done. We foresee using the results from this work for various applications in the future.\nSince we are focused on generating unseen information for clinical trial recruitment, the representation of each of the clinical trials presented and the generation of clinical trials for recruitment are completely data-driven, since the data provided to each step have not been filtered prior to generation. Since the tool is currently being used in the clinical trials setting, some of the terminologies are currently in the process of being fine-tuned with clinician feedback. Our objective with this work is to show that the semantic classification of clinical trials is a feasible task to be pursued, given the existing tools",
        "label": 0
    },
    "1772": {
        "output": "[TRIAL] Your task is to determine whether treatment with the agent is effective and safe in the treatment of CLD to warrant further studies. In an upcoming clinical trial, patients with CLD of various etiologies and moderate to severe disease will receive treatment; inactive placebo will be administered to the rest of the participants. A treatment plan for a period of 12 weeks with three or four scheduled visits is planned in each arm. Treatment consists of the study compound as a monotherapy or with add-on standard therapy.\n\nThe assessment of effectiveness will be based on the percentage change of total bilirubin after the 12th week of treatment from the baseline and the presence of new adverse events. The assessment will be performed by comparing each patient's scores with the normalized scores of the population. Inactive placebo will be used for standard treatments if the etiology of CLD is alcoholic cirrhosis. \nHere are the patient notes:\nMale, 58 years old with compensated liver cirrhosis caused by the non-alcoholic and non-virus-related etiology. He has a history of smoking and drinking about 100g of alcohol daily for the past 40 years and he is not on any medication other than the antihypertensive lisinopril. The patient's medical records show two previous positive serologic testing for hepatitis B and B-viral infection, while another positive testing for anti GB virions antibodies has no previous tests for hepatitis B and C. Recent Echocardiography reveals the moderate liver enlargement in the chest and upper abdomen by visual inspection but no edema is obvious. The complete blood count is normal. The patient's platelets count is 160,000 /mL. Urine test is negative. The results of biochemistry tests are shown below. The abdominal CT findings indicate moderate sized liver and no varices or ascites are seen. We would like to examine the following liver function tests results: AST: 117, ALT: 124, ALP: 315, total bilirubin: 8",
        "label": 1
    },
    "1773": {
        "output": "### Example.\nLet's take a look at an example. It is sample 05 in File_6.R.\n\n``` r dl_sample_05\n```\n\n```\n## # sample 5\n## \n## ## Trial-level eligibility_05: 1) Not relevant\n## ## Patient profile_05: 1) HCV\n## ## \n## ## Patient's note:\n## \n## ## ## # HBV patient profile Patient's medical record # ## ### Patient profile_05 \n## ## ## ## ## ## ## ## ## ## ## ## ## ## ## #### # ## ## ## ## ## ## ## ## ##\n## \n## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##\n## \n## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##\n## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## # ## ## ## ## # ## ## ## # ## ## # # ## ##\n## # [#] ## # ## ## ## # ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## # ## ## ## ## # ## ## ## ## # ## ## ## ## ## ## ## ## ## ## #### ## ## ## #### ## ## ## ## ## ## ## ## ## ## ## ## ## ##### ## ## ## ## ## ## ## ## ## ## ## ## ## # ## ## ## ## # ## ## ## ## ## ## ## ## # # ## ## # ## ## ## ## # ## ## ## ## ## ## ## ## ## ## ## ## ### ## ## # [#] ## # ## ## ## ## # ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## #### ## ## ## ## ## ## ## => RITONAVIR 100mg + LONAFARNIB\n\n## ## ## ## #",
        "label": 0
    },
    "1774": {
        "output": "Hello.<patient-name> section, you can add a [NAME] Hello.<patient-name> part in the Hello.section too. Since the patient code can be reused in the Hello.<patient-name> section we can use the same \"patient\" code in the Hello.<patient-name>section as well.<NAME>.\n\n```bash\n#!/usr/bin/env python\n# -*- coding: utf-8 -*-\n\"\"\"\nThis is the example hello.patient in the PatentDemo.py of PatentDemo, the Patient Eligibility Library\n\"\"\"\nfrom pyeligibility.lib.data import PATIENT, INST, DOCTYPE, CONTEXT, TYPE, VAR\n\npatient = PATIENT()\n\n# The following parts describe the inclusion criteria:\n\nhello:\n    name: \"Hello, {0}!\".format(patient.code) # \"Hello, 001-0002!.\"\n    gender: \"Hello, {0}\".format(patient.gender) # \"Hello, Mr. {0}.\"\n    age: \"Hello, I can see you are {1} years old.\" # \"Hello, I can see you are 24 years old.\"\n    bloodpressure: \"Hello, {0}.\".format(patient.bp) # \"Hello, she is 110/75.\"\n    weight: \"Hello, your weight is {0} g.\" # \"Hello, her weight is 74 kgs.\"\n    height: \"Hello, your height is {0} cm.\" # \"Hello, he is 215 cm.\"\n    blood-sugar: \"Hello, your blood-sugar is {0} mg/L.\" # \"Hello, his blood-sugar level is 101 mg/dL.\"\n    body-temperature: \"Hello, the normal body temperature of individuals without fever is in the range of\n    36 \u00b0C to 37.5 \u00b0C, but your body-temperature is {0} \u00b0C.\" # \"Hello, she is 35.6 \u00b0C.\"\n    urine-analysis: \"Hello,",
        "label": 0
    },
    "1775": {
        "output": "## Problem 2\nTiming problem. The time interval of the patient with the clinical trial should be the time difference of the clinical trial and the patient's visit time.\n\n## Potential workaround\nIt is difficult to predict the time interval. There may be a possibility that the clinical trial end if the actual visit time is different from the prediction date. So, the first step is to predict the date of the trial visits to solve this problem. For example, if the date of the trial is the end of July and the patient was visited in April, then the predicted trial visits time is the September on the trial visit information. The prediction is conducted with the help of the package dmwrb.\n\n## Test your pipeline\nThis is the first test of your pipeline. Test the pipeline using the input data and the clinical trial information. Run the full execution pipeline.\n\n## Potential workaround\nThere are two problems here. First is the date handling. The date of input data is the current date and that of the clinical trial is the previous day, and you should adjust the clinical trial date to the input date. The second is the predicted date. The predicted date is the trial visit date.\nTherefore the adjusted date of the trial is the previous day and the adjusted date should be the trial start date by the day -1 + current day.\n\n## Troubleshooting 6\nIf the trial duration is 12 months, then the visit date is the next year and the adjusted date should be the last day of September, not the previous day.\n\n## Optional: clinical trial status\nClinicalTrials.gov is a web-based resource that provides patients, the public, healthcare professionals, and researchers with easy access to simple, comprehensive information. The mission of this registry is to provide detailed information on clinical research studies being conducted all over the world. ClinicalTrials.gov is administered by the National Library of Medicine at the National Institutes of Health. Patients, healthcare professionals, and researchers can go to ClinicalTrials.gov and search for information in the registry about clinical research studies. By clinics. There is no standardized procedure in identifying the trial from one another. In this step, you should find clinical trials in the ClinicalTrials.gov and then extract the information",
        "label": 1
    },
    "1776": {
        "output": "## [INST]\nPlease complete this assessment table: \n\n---\n\n##### Patient-level eligibility:\n\n1. Are there age restrictions on participation?\n\n---Yes---No---Not applicable---\n\n2. Are there gender restrictions on participation?\n\n---Yes---No---Not applicable---\n\n3. Are there ethnicity restrictions on participation?\n\n---Yes---No---Not applicable---\n\n4. What treatments/medications are allowed during the patient's participation?\n\n---No restrictions---Anticancer drugs---Anemia drugs---Anticholestatic drug---Immunotherapy drug---Thyroid hormone drugs---Hormone drugs---Anthropological drugs---Insulin drug---Anticonvulsant drugs---Other drugs---\n\n5. What treatments/medications are not allowed during the patient's participation?\n\n---Anti-inflammatory drugs---Antihypertensive drugs---Liver protective drugs---Diabetic drugs---Infection drugs---Liver protective drugs---Anti-infection drugs---\n\n##### Eligibility Assessment Table:\n\n---Please fill in your judgment for each exclusion criteria by appropriate numbers in the table.---\n\n##### Trial-level assessment:\n\n---Please fill in your judgment about the eligibility of this patient for participation in this clinical trial. Please write down your findings under \"Trial-level assessment:\"---\n\n```{table}\n# patient-level\n```\n\n```{results}\nInclusion criteria:\n1. Are there age restrictions on participation?\n\n---Yes---\n2. Are there gender restrictions on participation? ---No---\n3. Are there ethnicity restrictions on participation? ---N---\n\n4. What treatments/medications are allowed during the patient's participation? ---N---\n\n5. What treatments/medications are not allowed during the patient's participation? ---N---\n\n```{table}\n# patient-level\n```\n```{results}\nExclusion criteria:\n1. Age<18 years\n2. HBsAg positivity\n3. Prior use of IFN and/or RBV",
        "label": 2
    },
    "1777": {
        "output": "# T098\n## Exercise 9: HCPAIRE\n\n##[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your duty is to calculate the potential patient visits based on patient flow in a trial protocol. \nYou should make a clinical trial visit plan in the following table (the same as your trial-level eligibility calculation). \n\n     Visit 1\n     \n    Evaluating inclusion and exclusion criteria\n    Verify patient eligibility and obtain informed consent\n    Assess HCV RNA and genotype\n\n    Visit 2\n     \n    Initiate treatment\n    Assess vital signs, medical history and complete blood count\n    Initiate combination therapy: Daclatasvir, 50 mg, once daily\n    Sofosbuvir, 400 mg, once daily\n    \n    Visit 3\n     \n    Monitor patient response to combination therapy: Daclatasvir, 50 mg once daily\n    Sofosbuvir, 400 mg once daily\n    \n    Visit 4\n     \n    Assess patient response to combination therapy based on RVR at Week 4\n       Assess RVR at Week 4\n       If RVR=1.0, continue combination therapy for 8-weeks\n       If RVR<1.0, continue combination therapy for additional 8-weeks until SVR12\n\n    Visit 5\n     \n    Confirm SVR at Week 12 in responders with RVR=1.0\n         Confirm SVR at Week 12 in responders with RVR <1.0\n\n    Visit 6\n     \n    Protocol specified 48-week SVR visit in responders\n     \n  \nHere is the patient: \nPatient gender: Male\nAge: 55 [range is 18-85]\nEligibility: 1) Not relevant 2) Excluded 3) Eligible\n\nHere is another patient: \nPatient gender: Female\nAge: 38 [range is 18-85]\nEligibility: 1) Not relevant 2) El",
        "label": 0
    },
    "1778": {
        "output": "Please submit your code with a commit message on the Github page in the form below: https://github.com/shin-dong-sang/eligibility.\n<issue_comment>username_1: <a href=\"https://github.com/elixir-ko/eligibility\" title=\"Clone and Run in Eclipse\">Clone and Run in Eclipse</a>\n<issue_comment>username_0: @username_1 @username_2 Thanks for your patience!\n\n![image](https://user-images.githubusercontent.com/27931504/113838864-e0ee7380-9a0d-11eb-825f-b1e69fb7f5b6.png)\n\n![image](https://user-images.githubusercontent.com/27931504/113838986-f40c3280-9ab2-11eb-9a03-47c1705db7eb.png)\n<issue_comment>username_1: @username_0 @username_2 Thanks for submitting. I reviewed and it looks very nice..\n<issue_comment>username_2: @username_0 @username_1 Thank you very much\n<issue_comment>username_0: @username_1 @username_2 Thank you for your time. I was looking for something like this.<EOD> Effect of GM\u2010CSF on the functional development of murine bone\u2010marrow\u2010generated macrophages\nIn these experiments, the ability of recombinant murine Granulocyte/ Macrophage Colony Stimulating Factor (rhGM\u2010CSF) to enhance the functional expression of mononuclear phagocytes was studied. The bone\u2010marrow cell populations of BDF1 mice were cultured with rhGM\u2010CSF at concentrations of 2.5\u201050\u2003ng/ml for 5\u20136\u2003days and the expression of Fc and C3 receptors (FcR and CR3) was determined by flow cytometry (FCM), cell viability and nitroblue tetrazolium reduction tests were performed. In addition",
        "label": 0
    },
    "1779": {
        "output": "[EXIT]\n\u00a9 <NAME>\n\n## S47\n[CORE] Your work is done. You are a nice clinical decision support system. Your friends would love to have you with them! [/END]<EOD> .\nBesides the already used antibiotics the future development of antibiotics will be focused on following two aspects: the antibiotics acting specifically on the target, such as antibodies, enzymes, and nucleic acids; the antibiotics acting specifically on membranes, such as peptides, detergents, steroids, or polymers capable of crossing cellular membranes. An antibiotic which affects the nucleic acids of bacteria seems to combine the best properties of chemotherapeutics and antibiotics.<EOD> Preparation and Antioxidant Activity of Flavonoids\u2013Sodium Alginate\u2013Gelatin (FSG) Hydrogel\nTo prolong the shelf life of functional beef steak with high edible value, flavonoids\u2013sodium alginate\u2013gelatin (FSG) was hydrolyzed and prepared for improving the water holding capacity of the gel and antioxidant activity of the gel. The antioxidant activity of the hydrogel was studied, and the effects of different content combinations on the hydrogel\u2019s mechanical properties, structural characteristics, and water-holding capacity were explored by gel-forming property, molecular weight/polydisperse index distribution, scanning electron microscope (SEM), Fourier transform infrared spectrum (FTIR), dynamic shear experiment, ultimate shear stress, and water holding capacity experiments, respectively. The results showed that the combination of 0.7-0.9% (W/V) flavonoids\u2013sodium alginate concentration with 0.2\u20130.5% (W/V) gelatin concentration formed a better gel and had stronger toughness and water holding capacity in this study. A low gel strength and low water holding capacity were achieved when the content was >1.5% (W/V), while the hydroxyl group and amide II bond of anhydride were destroyed by the increased concentration of sodium alginate, and the antioxidant activity of the hydrogel was negatively",
        "label": 0
    },
    "1780": {
        "output": "[TEST]\n\n## Problems with `ClinicalTrialNoteInput`:\n\nThis is a test description for your problems and solutions.\n\nSolutions:\n- Include eligible or excluded as eligible scale\n- Include the clinical trial's data to the clinical trial data table\n- Include one more table representing the clinical trial's data\n- Add a table for the clinical trial's data\n\n## Problems with `ClinicalTrialNoteInput`:\n\nThis is a test description for your problems and solutions.\n\nSolutions:\n- Add a field to indicate which scales is the final trial eligibility\n\n## Problems with Trial-level Eligibility:\n\nThis is a test description for your problems and solutions.\n\nSolutions:\n- Try the new solutions.\n\n[INST]\nThe program outputs the trial-level eligiblity: Eligibility: 2) Eligible.\n\n\n## Check the trial eligibility\n\n### Verify that the trial patient matches the trial\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nIf they do not match:\n\n1) `ClinicalTrialNoteInput`:\nAdd another table for Clinical trial eligibility\n\n``` r\nclinicaltrial <- data.frame(ID = seq(1:nrow(clinicalTrial)),\n                   Patient = clinicalTrial$Patient,\n                   PatientID = clinicalTrial$PatientID,\n                   ClinicalTrial = clinicalTrial$Clinical,\n                  Excluded = clinicalTrial$PatientsExcluded,\n                  NotRelevant = clinicalTrial$PatientsNotRelevant,\n                  Eligible = clinicalTrial$PatientsEligible)\n\n\nclinicaltrial <- \nset_names(combine(addCol(clinicaltrial",
        "label": 0
    },
    "1781": {
        "output": "# Inclusion_Exclusion\n\n`Exclusions: `\n\n## Other\n\n`Exclusion_factors: `\n\n## # Other: exclusion_factors\nA clinical trial may have other Exclusion_factors. For example, if the participants are nursing or pregnant and also taking IFN, RBV or direct antiviral drugs for the past 6 months. \nOther: Exclusion_factors = \"Yes\", Exclusion_factors = \"Nursing\", Exclusion_factors = \"Preterm\", Exclusion_factors = \"Pregnant\" and Exclusion_factors = \"Taking IFN, RBV and direct antiviral drugs for the past 6 months\"\n\n# Exclusion_factors\n\n# Other: other\nA trial may have other Exclusion_factors, but you'll normally always have the Exclusion_factors = \"No\". \nOther: other = \"Yes\" or Other: other = \"No\"\n\n# Exclusion_factors_description\n\n`Exclusion_factors_description: `\n\n## Factors_type\n\nYou should extract all factors for exclusion from Other: other, e.g., in Other: other = \"Yes\", Exclusion_factors_description = \"Hepatocellular carcinoma\" and Exclusion_factors_description = \"Autoimmune hepatitis\".\nFactors_type = \"Any\" or Factors_type = \"Specific\"\n\n# Factors_type\n\n# Exclusion_factors_description\n\n## Factors_types\n\n## Eligibility_criteria\n\n## Condition\n\n## Rules\n\n## Conclusions\nIf we have not answered your questions in this post and you are not familiar with the clinical trial, I will gladly help you with your trial. Also, if you need a solution for another clinical trial, it is recommended that you first read the article for all clinical trials and then for only the post for this trial you need.\n<EOD> Hydroxybenzaldehyde derivatives: effects on cholesteryl galactoside acyltransferase.\nFerullic, coumaric, p-hydroxy-cinnamic",
        "label": 0
    },
    "1782": {
        "output": "<h3 class=\"code-header\">Exercise</h3>\n[EXER0010] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. Here is the clinical trial: \nTitle: Observ",
        "label": 0
    },
    "1783": {
        "output": "Explanation\n\nFor the above output, Trial-level eligibility: 0 for the first patient means that the patient is _not_ eligible. Trial-level eligibility: 1 means that the patient is _apparently eligible_, because the patient met some inclusion criteria, but it is not mentioned in the clinical trial that the patient has to meet those criteria. Trial-level eligibility: 2 means that the patient is _eligible_. Your output should include all possible values of this function, e.g.:\n\nTrial-level eligibility: 0\n\nTrial-level eligibility: 1\n\nTrial-level eligibility: 2\n\nHints:\n\n1. The value of `criteria` is a list of strings. If you change a variable name to `criteria_patient` and `criteria_clinical_trial` (instead of `criteria` and `_not_relevant `), you can print each of them as the variable name. For example, in the first trial note, `criteria_patient` is `Viral load <400,000 IU/m^2\\` on two consecutive occasions. If you change the name to `criteria`, then the output will be same. \n2. If the inclusion criteria was not mentioned in the trial note, print the reason by `_not_relevant`.\n3. The factor which is called \"exclude criteria\" usually is a different function than the \"inclusion criteria\" function. See the function `trial_clinical_trial.csv` at the code repository for details.\n4. `clinical_trial.csv` contains all the possible values of each function. \n5. `exclude_factors.csv` contains all the possible values of the factor on inclusion criteria.\n6. `eligible_factors.csv` contains all the possible values of the factor on exclusion criteria.\n7. Additional code examples are provided. \nGood luck!\n\n:balloon: If you like this course, please consider rating it \u2b50\u2b50\u2b50\u2b50\u2b50\u2b50 when viewing it. You are also invited to leave a comment below underneath this table indicating if",
        "label": 0
    },
    "1784": {
        "output": "Now you have successfully generated a JSON file containing a trial-level eligibility for all the patients within a clinical trial's population. \n\n### JSON Files With Trial-Subject Inclusion Criteria\n\n> json file:\n```\n{ \"patient_id\": \"patient id\", \"trial_id\": \"trial id\", \"gender\": \"gender\", \"age\": \"age\", \"treatment_status\": \"treatment status\", \"treatment_type\": \"treatment type\", \"treatment_experience\": \"treatment experience\", \"treatment_naive\": \"treated naive\", \"treatment_compliance\": \"treatment compliance\", \"vaccination\": \"vaccine history\", \"comorbidity\": \"comorbidity\", \"disease\": \"condition\", \"smoking\": \"smoking\", \"alcohol\": \"alcohol\", \"fatigue\": \"fatigue\", \"vomiting\": \"vomiting\", \"diarrhea\": \"diarrhea\", \"cough\": \"cough\", \"pain\": \"pain\", \"depression\": \"depression\", \"sleep\": \"sleep\", \"appetite\": \"appetite\", \"diet\": \"diet\", \"history_hypertension\": \"hypertension\", \"history_diabetes\": \"diabetes\", \"history_lipid\": \"lipid\", \"history_peptic\": \"peptic ulcers\", \"history_other\": \"history\", \"history_other1\": \"history other\", \"history_other2\": \"history other 2\", \"history_other3\": \"history other 3\", \"history_other4\": \"history other 4\", \"history_other5\": \"history other 5\", \"history_other6\": \"history other 6\", \"history_female\": \"menstrual\", \"history_history\": \"history\", \"history_others\": \"history\", \"history_others2\": \"history others\", \"history_others3\": \"history others 3\", \"history_others4\": \"history others 4\", \"history_others5\": \"history others 5\", \"history_others6\": \"history others 6\", \"history_others7\": \"",
        "label": 1
    },
    "1785": {
        "output": "## 3.2.10.2 Examples\n\n[EXAMPLE.INST] Hello. The patients you will be working with are patients suffering from chronic hepatitis C (CHC). Each trial involves the treatment in an ambulatory setting after the informed consent is signed.\n\nPlease click on the 'Next page' button to proceed with the case.\n\nYou are a general physician. You will be asked to diagnose patients.\n\n\n[TEXT.INIT] Diagnose a patient with CHC taking into account that:\n\n\n[TEXT.INIT] A diagnosis of CHC can be made when the serum levels of either the hepatitis C antibody (anti-HCV) or the hepatitis C virus ribonucleic acid (HCV-RNA) are positive for HCV at least six months after the onset of acute hepatitis.\n\n\n[TEXT.INIT] A hepatitis C genotype classification system has been developed to help define the natural history of CHC and assess the treatment response to antiviral agents and vaccine development.\n[TEXT.INIT] Genotypes 1, 2, 3, 4, 5, 6 are classified according to distinctive features present in the virus polyprotein sequence. These genotypes have a nucleotide sequence homology of approximately 83% while the homology with a different genotype ranges from 65% to 71%.\n[TEXT.INIT] Most of the current therapies are based in genotype 1, which is classified as genotype 1a and 1b (subtypes with very similar sequences).\n[TEXT.INIT] In Spain, genotype 1 is the most prevalent\n[TEXT.INIT] Genotype 2, 3, 4 and 5 are usually classified as uncommon genotypes and comprise 10% of all cases.\n[TEXT.INIT] Genotype 6 is relatively uncommon and is usually isolated from people born in endemic areas with indigenous hepatitis C infections like central and South-America.\n[TEXT.INIT] Each CHC genotype has a slightly different geographical distribution. In Spain, HCV genotype 1 (GT 1) is",
        "label": 1
    },
    "1786": {
        "output": "# Copy and paste this code on the bottom. First, we convert the one-hot encoded trial-level label to the value of 0 or 1. Then, we predict a trial-level label with a random forest.\n# Copy and paste this code on the top. # Copy and paste this code on the top. Let's predict trial-level eligibility with scikit-learn models. In order to predict multiple values, we have to transform into one column for the multi classification model. Here, we use OneHotEncoder, which is a class in the Model class and outputs the multiclass encoded model. Now, we can predict the trial-level. Finally, we can get the trial-level eligibility.\n\n## Question 12\nWhat should be treated as `Missing` if one has missing data? Missing values are often treated as a separate category with its own set of labels.\nThis is recommended not to perform imputation if only one missing data is detected (0 missing samples).\n\n## Question 13\nDo you find any outliers or missing values in the data, and how to cope with them if found? In real clinical settings, there may be problems with the patients being",
        "label": 0
    },
    "1787": {
        "output": "[/STOPPING_PROGRAMS]\n[/CONSISTENCIES]\n[/VALIDATING_FORMATS]<EOD> Assessment of the Efficacy of Surgical, Interventional and Conservative Treatment of Symptomatic Thoracic Outlet Syndrome\u2014The Results of a Retrospective Study\nSupplemental Digital Content is available in the text. Background: Thoracic outlet syndrome (TOS) is defined as an intermittent neurovascular compression between the third portion of the subclavian artery (SA), the brachial plexus and first rib. TOS can be divided into neurogenic (neuroTOS) and vascular TOS (vascularTOS), and both can be caused by compression between the first rib and subclavian artery (Vinous compressive syndrome (VCS)). The treatment of the choice for TOS is unknown to date. In the light of the latest literature data, the purpose of this work is to evaluate the effectiveness of three treatment methods in neurovascular compression syndrome (VCS). Materials and Methods: We performed a retrospective review of the charts of 48 patients in whom treatment was indicated (13 neuroTOS patients, 15 vascularTOS patients, 20 VCS patients). The first group was treated conservatively, while the other groups were divided into those who underwent surgery for VCS (15 patients) and those who underwent interventional procedures (14 patients). Results: In all cases of VCS the compression point was found to be in the cervical part of VCS. We found that in 8 patients (17%) conservative treatment gave improvement, the use of a night splint in 8 of 24 vascularTOS patients and 5 of 15 VCS patients. In the VCS group surgery resulted in improvement in 2 patients (17%), in the vascularTOS group in 13 patients (76%). This difference between these two groups was statistically significantly different p < 0.05. In patients treated by interventional methods, angioplasty gave a better result than stenting. The only parameter with a strong correlation with treatment efficacy was the size of the",
        "label": 0
    },
    "1788": {
        "output": "## Exercises\nExercise 1. Write the patient note. Here is the patient's ID and the information about the trial.\n\n```bash\n[0-20] patient_ID\n123     - patient_age (between 18 and 80 yrs)\n71      - patient_gender (a non-empty string)\nHCV     - virus_type (a non-empty string)\n2       - virus_number (integer: 2)\n169      - virus_status (as string)\nHCV     - virus_status (as string)\nnegative  - virus_test (negative, positive)\nnegative  - virus_test (negative, positive)\n```\n\n```bash\n[0-20] trial_id\n27       - trial_id (integer: 27)\n3        - trial_name (as string)\ntitle     - title (as string)\nsummary    - trial_overview (as string)\ntitle      - trial_target (as string)\ninclusion_criteria - inclusion_criteria (a non-empty string)\n\n```\n\n```bash\nTrial-level eligibility                           : 2) Eligible<EOD> Bacterial Endocarditis and Abdominal Pseudocyst: Risk Factors and Role of Imaging\n\nThe incidence of abdominal complications of bacterial endocarditis (BE) ranges from 2 to 10% and remains a challenge for the physician. The role of imaging is to establish a diagnosis, to identify the type of abdominal complication, to localize the focus of inflammation or infarction, to detect an infected abdominal wall, and to detect complications that arise after endocarditis has been well treated. Abdominal complications arise earlier in patients with mural endocarditis (tendonitis or myocarditis) than in patients with infective endocarditis localized in the valves. The presence of mural endocarditis is associated with a poor prognosis as it more frequently leads to multiple organ failure. Different abdominal complications of BE are described, but a multitude of imaging studies are needed and most of them have no defined role. It",
        "label": 1
    },
    "1789": {
        "output": "[END]\n\n</pre>\n\n<p align=\"justify\">\n\n\n\n\n\nThe first question you can ask yourself is: What does the note mean overall? The answer will depend on whether you understand the question or not. If you understand the question correctly, you should be able to answer it. You should remember to check the code line by line, then make a trial-level eligibility. \n</p>\n<EOD> The potential role of 18F-FDG PET/CT in defining the extent of intraductal component of breast cancer and response to neoadjuvant chemotherapy\nObjective The aim of this study was to assess the value of pre-and post-neoadjuvant chemotherapy (NAC) 18F-FDG positron emission tomography/computed tomography (PET/CT) in identifying the breast cancer intraductal component (IC) status and predicting its response. Subjects and methods A retrospective cohort study was conducted. Ninety consecutive women with breast cancer who received NAC were enrolled. PET/CT was performed before NAC (baseline) and after two (PET1-CT-2) and four (PET1-CT-4) cycles. We assessed the tumor and IC metabolic volume using SUVmax. The pathological complete response (pCR) was the gold standard for response prediction. We compared SUVmax and metabolic volume at PET1-CT-2 and PET1-CT-4 with baseline SUVmax and metabolic volume to determine whether a decrease in SUVmax and metabolic volume could be used as predictors of pCR. Results The median age of the cohort (90 patients) was 43 years. pCR occurred in 28 patients (31.11%). SUVmax was higher in patients with pCR than in patients with residual disease (RD) (p\u2009=\u20090.004). Decrease in SUVmax (11\u201344.45%) and metabolic volume (11\u201351.02%) between the baseline and the second PET/CT were significantly different in patients with pCR compared with patients with RD. Conclusion SUVmax of the tumor at PET1-CT",
        "label": 1
    },
    "1790": {
        "output": "- \n\nExclude: If the patient's record does not contain sufficient information to qualify for the trial.\n- Not relevant: If the patient's record does not contain sufficient information to determine eligibility or if it is impossible to infer the eligibility of a known patient.\n- Eligible: If the patient meets inclusion criteria and the trial's exclusion criteria do not apply.\n\nLet's think step by step.\n\nYou are running the Eligible test from the main menu of the program and the test produces the following window.\n\n![](./README_files/16.png)\n\nClick `Yes`.\n\n![](./README_files/17.png)\n\nWe will use the following patient information.\n\nPatient 1\n\nName: `1`\n\nAge: `39`\n\nGender: `Female`\n\nBlood pressure: 130/80\n\nHeart rate: 90\n\nPatient 2\n\nName: `2`\n\nAge: `39`\n\nGender: `Male`\n\nBlood pressure: 130/90\n\nHeart rate: 130\n\n[<NAME>.md](./README_files/19.md)\n<EOD> A phase II study of bortezomib as a front-line therapy in patients with relapsed or refractory multiple myeloma.\n7057 Background: Proteasome inhibition with bortezomib has shown promise in newly diagnosed MM. Bortezomib is associated with high rates of complete responses (CR) when used as a second line or later therapy; only approximately 25% of patients had a CR when it was used as a first line therapy. To determine the efficacy and toxicity of front-line bortezomib, we conducted a prospective study in patients with relapsed or refractory MM and with poor prognostic factors precluding them from receiving high dose (HD) therapy.\n\n\nMETHODS\nPatients previously treated with up to 3 prior regimens for newly diagnosed MM were enrolled. Bortezomib was given as 1.3 mg/m2",
        "label": 0
    },
    "1791": {
        "output": "In this training example, the patient note is exactly described in the table. Since the eligibility is '2) Eligible' for this patient, no trial-level eligibility is required for this patient note. In other words, the table is sufficient to determine the eligibility of the patient in the clinical trial. Therefore, in some situations, you can skip the trial-level eligibility.\nIn the future, you will learn about the eligibility in the abstract clinical trial, the clinical trial-and patient-specific factors, and the different types of eligibility information and its attributes.\n<EOD> .\nBronchopulmonary dysplasia (BPD) was not observed in the 160 infants with birth weight of over 1,000 grams who were delivered in the department of Obstetrics of the Clinic of Gynecology and Obstetrics of the Medical Academy of Innsbruck, Vienna and Graz. We therefore suggest a relationship between the incidence of BPD and the birth weight in full-term infants. This leads to an explanation. Infants who weighed 1,200-1,500 g were 11 times more likely to develop BPD than infants who weighed 1,550-1,800 g.<EOD> Vascular endothelium-dependent effect of rutin in the small intestine of the anaesthetized dog.\nEffects of sodium rutin (Nr) given by intravenous route on the gastrointestinal blood flow were investigated in the dog to elucidate the role of vascular endothelium on the anti-spasmogenic effect of Nr. At dose of 2 mg/kg of Nr, which failed to produce hypotension and tachycardia when given intact intravenously, 443.2 mg/kg/min of Nr was necessary to produce a marked fall in arterial blood pressure. When a high-molecular-masse fraction of Nr(Hr), lacking its anti-spasmogenic effect, was given intravenously, the fall in blood pressure was not significant and not dose-dependent. A marked fall in blood pressure was obtained when the intact intra",
        "label": 0
    },
    "1792": {
        "output": "<EOD> Hematotoxin\u2010induced activation of nuclear factor\u2010kappa B (NF\u2010\u03baB) in neurons\nThe transcription factor nuclear factor \u03baB (NF\u2010\u03baB) plays a fundamental role in immune- as well as neuronal processes. Its activity, however, was supposed not to be involved in neuronal signaling pathways. We demonstrate that cultured postnatal hippocampal/cortical neurons contain a functionally active form of NF\u2010\u03baB. Incubation of neurons with the specific ligands of the Toll-like receptors (TLRs; \u03b2-amyloid, bacterial lipopolysaccharide, or viral CpG) activated NF-\u03baB as analyzed by functional and electrophoretic mobility shift assays. TLR4, which is considered as the relevant receptor for endotoxins, was expressed by neurons whereas the TLR2/6 heterodimer, but not TLR3, could be detected in hippocampal membranes. Consistent with a role of NF-\u03baB in neuronal defense the activation of NF-\u03baB by TLRs was accompanied by upregulation of inhibitor of NF\u2010\u03baB (I\u03baB) message levels and by decreased I\u03baB levels. The inhibitory potential of I\u03baB could be shown by its association with the p65 subunit. In summary, the data suggest that activation of NF\u2010\u03baB might play an important role in neuronal signaling processes. J. Cell. Physiol. 203: 406\u2013416, 2004. \u00a9 2004 Wiley-Liss, Inc.<EOD> .\nBy the help of a retrospective study and a follow-up study at a long-term survey, the diagnoses of the incisional hernia are evaluated concerning to the exactness and quality of the clinical records and the operative reports of the patient records' centre. The study shows a lack of information in the patient records concerning to the incidence of incisional hernia.<EOD> An Unusual Case of Atypical Infective Endocarditis Complicated by an Aortic Thrombus and Stroke.\nEndocarditis caused by Staphyloc",
        "label": 2
    },
    "1793": {
        "output": "<EOD> Corneal nerve morphology and axonal regeneration following penetrated anterior lamellar keratoplasty compared with deep anterior lamellar keratoplasty \u2013 A randomized controlled clinical trial\n\n\n\n# Abstract\nPurpose To investigate and compare the recovery of keratocytes and corneal nerve morphology after penetrated anterior lamellar keratoplasty (PALK) and deep anterior lamellar keratoplasty (DALK). Methods A prospective, randomized controlled clinical trial with participants (age >18 years) with keratoconus or Fuch's endothelial dystrophy was designed and conducted. Subjects were randomly allocated to PALK or DALK groups and followed up for 12 months. Subjects in PALK group had a 7.5 mm central thinned area of the anterior stroma and endothelial layer removed during surgery. Subjects in DALK group had just the thinned area of anterior stroma removed. Preoperatively, at 1 week, 66 months postoperatively. Axonal regeneration, keratocyte density and density of dendrites were detected by immunolabeling against PGP 9.5. Statistical analysis was performed using the t-test and Wilcoxon rank-sum test. Results Thirteen participants were enrolled into each group. The corneal thickness, visual acuity, PGP9.5-immunopositive cells density, percentage of dendritic cells and keratocyte size were statistically comparable between the two groups after 12 months (P > 0.05). The regenerated axonal density of DALK group was greater than that of PALK group at months 6 (P < 0.001). The density of corneal nerve fibers of the PALK group was higher than the DALK group at months 6 (P < 0.001) and 12 (P < 0.001). Conclusion These morphometric findings indicate that penetrated anterior lamellar keratoplasty provided a better corneal nerve regeneration pattern and axonal density recovery than",
        "label": 0
    },
    "1794": {
        "output": "## [FUNCTIONAL] The function of the machine learning code. This should be a function name, that is used by the machine learning algorithm to call the code that builds the machine learning model.\n[INST] You will be writing and running the machine learning code once you finished training. \n\n## [FUNCTION 1] Machine learning algorithm for clinical trial eligibility classification \n\n# %python\nr_clinicalTrial = randomForestClassifier(n_estimators=20000, max_depth=5, min_samples_leaf=5, min_samples_split=5)\nprint r_clinicalTrial # You should get a classifier object here. \n\n## [INST] The machine learning code we are using here is machine learning code from the `scikit` machine learning library, and called `random forest`, to predict the clinical trial eligibility. `clinicalTrial` is the column name. `s_clinicalTrial` is the feature of clinicalTrial. `s_clinicalTrial_list` is the list of clinicalTrial features. `n_estimators` is the number of estimation. `max_depth` is the number of max depth. `min_samples_split` is the minimum number of samples needed to split an internal node. `min_samples_leaf` means the number of samples needed to create a leaf node. `classifier` is the machine learning object. `print` will print the object in print.\n\n## [FUNCTION 1] Here is the machine learning code using scikit-learn library\n\n# %python\nclinicalTrial_list = df_test['clinicalTrial_list']\nr_clinicalTrial_scikit = randomForestClassifier(n_estimators=20000, min_samples_leaf=5, min_samples_split=5)\n# %python\nprint r_clinicalTrial_scikit.\nprint r_clinicalTrial_scikit.predict_proba(feature_list=clinicalTrial_list).exp(feature_list=clinicalTrial_list)<EOD> Nutritional deficiency increases sensitivity of the hypothalamo\u2013paraventricular",
        "label": 0
    },
    "1795": {
        "output": "[INST]\n\n# A) The patient in case study 1 has HCV 2 years ago and the recent coinfection with HBV so he should be excluded from clinical trials targetting HCV only.\n\nIf you feel unsure, please continue to the next step to explain by text that the patient is excluded.\n\n```python\nprint(\"Patient is excluded\")\n```\n\n```python\nTrial-level eligibility: 0) Excluded\n```\n\n## B)\nNext, patient notes have a new test and the patient notes 4-7 have a new lab test.\n\nLet's first check if the new test is positive for 4-7. For example, for example, the patient in case study 2 had a new lab test.\n\n```python\n\nif new test is positive:\n\n    Trial-level eligibility: 0) Excluded\n    print(\"Patient's eligibility is checked\")\n    print(\"Trial is checked\")\n    print(\"New test is positive with: \", test.diseases('Hepatic Coma (2)'), \"; new lab tests are: \", test.diseases('Hepatic Coma (2)'), \")\n    print(\"New test data: \", test.notes('1900712 1515000'), \"  |  \", test.notes('1900712 1630000'))\n    print()\n    print(f\"Trial data: {trial}\")\n    print(f\"ID: {trial.identifier()}\")\n    print(f\"Title: {trial.title()}\")\n    print(f\"Summary: {trial.summary()}\")\n    print(f\"Start Date: {trial.start_date()} | {trial.start_date_year()}, {trial.start_date_month_short()}, \" + \"| {trial.start_date_day()}\")\n    print(f\"Inclusion Criteria: {trial.inclusion_criteria()}\")\n    print(\"Duration of 1 cycle: \", trial.duration_of_1_cycle())\n    print(\"Enrollments:\", trial.enrollments())\n    print(f",
        "label": 0
    },
    "1796": {
        "output": "You have a new Python variable named patient from the clinical trial. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. First you should change the patient note into a list of patient note's records. Then you need to check all of the records against the inclusion criteria. If a patient record matches the inclusion criteria, you need to sum the records.\n\nFor example, you need to change the test to be:\n> patient_note = test['Patient'].to_list()\n> patient_note\n['Clinical Trial', 'HIV, HCV/HIV, Dialysis, Aged 55', 0]\n> Patient_summary += ', Evaluation results are: 2)'\n\nYou can change the 0 to 2.\n\n> print Patient_summary\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n[INST] You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n[INST] Here is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune he",
        "label": 0
    },
    "1797": {
        "output": "<EOD> The role of human platelets in the expression of collagen-dependent interleukin-1 activity.\nPlatelets may act as carriers of exogenous interleukin-1 (IL-1) to target cells because, after exposure to collagen, platelets release a protease capable of breaking the IL-1 complex. This study, using the thymocyte proliferation model of IL-1, found that human platelets did not display IL-1 activity when isolated from blood after activation by thrombin, collagen, ADP, or calcium ionophore, and did not exhibit cytoplasmic IL-1 on electron immunocytochemical examination. However, platelets released from ADP- or collagen-activated platelet-rich plasma stimulated thymocyte proliferation. This stimulatory factor was inactivated by heating or digestion with trypsin, chymotrypsin, or elastase and also by collagenase. These results indicate that it is unlikely that platelets alone are capable of expressing direct IL-1 activity upon exposure to collagen. Thus, IL-1 expression by these cells could be a secondary response to their interaction with collagen by indirect mechanisms.<EOD> Impact of the novel oral anticoagulants on the long-term outcomes of patients with atrial fibrillation; findings from a contemporary registry\nAims\nTo assess the characteristics and outcomes of patients in the UK with atrial fibrillation (AF) and concomitant oral anticoagulation (OAC) therapy prior to and within a specific time period commencing after the availability of the novel anticoagulants.\n\n\nMethods and results\nAsymptomatic, symptomatic, ischaemic stroke and haemorrhagic stroke patients with AF were recruited prospectively to the PREFER registry from March 2006 to March 2013. The PREFER registry comprised three interventional cohorts (OAC only, OAC plus antiplatelets, and antiplatelets only), three non-interventional cohorts (no OAC) and a healthy cohort. Using time-trend analysis and regression modelling, we compared characteristics and outcomes over time in all cohort",
        "label": 0
    },
    "1798": {
        "output": "___\n##[TEST] 1. There are no patient notes that do not contain sufficient information to enable clinical trial eligibility assessment for the first trial. 2. You have a patient note for the first trial. 3. It is your last working day. The trial investigator has to analyze your final results. 4. If you get a high accuracy rate, you will be invited to present your results in a medical meeting. \nYou have to analyze the patient note and assess the patient's eligibility for the trial. In the last line of the trial note, write the trial eligibility assessment, e.g., `Trial-level eligibility: 1) Not Relevant`. Good luck. [/TEST]\n___\n\n## Exploratory Questions\nHere are the exploratory questions below.\n___\n##[QUEST] Do you have to repeat trial-level eligibility assessment?\nThe trial-trial assessment is repeated after the eligibility assessment if the clinical trial note does not contain sufficient information for trial-level eligibility assessment. `Trial-level eligibility` is printed in red during the training. If the clinical trial note contains sufficient information for trial-level eligibility assessment, the red color disappears after trial-level eligibility assessment. [/QUEST]\n___\n##[QUEST] How did you do eligibility assessment?\n`Good` is output during the training. I have not yet found a satisfactory method to perform adequate trial level eligibility assessment, so it should be done through extensive analysis: to compare patients' medical history, laboratory findings, radiography, and other clinical findings with the necessary conditions determined by the protocol. [/QUEST]\n___\n##[QUEST] How many clinical trials have you learned in clinical trial note?\nOne clinical trial note may contain information of multiple trials conducted concurrently or sequentially. You may learn as many trials as there are in the patient note.\n___\n##[QUEST] What are the clinical trials in clinical trial note?\nMultiple clinical trials may be presented in a single clinical trial note. You may learn more than just one trial during the training.\n___\n##[QUEST] How many variables does the patient note have?",
        "label": 0
    },
    "1799": {
        "output": "### Summary\n\nThis is a solution for the challenge 3 from Data Exploration [CH03]\n\n## Conducting a trial level eligibility assessment\nCoders should follow the challenge flow to make sure they are coding correctly\n\n## Coding tips and tricks\n\n### The basics\n\nCheck the [README.md] first to make sure to enter the code on the correct place. \n\nHere is the coding environment: \n```julia\njulia> using DataExpl\n```\n\n### The data\n\n```julia\njulia> patients = pdat\njulia> patients[4].pdat\n```\n```julia\n\"2020_14_55_25_10\\r\\nPatient Name: XXXX\\r\\nId: XXXXXXX\\r\\nAge: 0\\r\\nSex: 0\\r\\nOccupation: 0\\r\\nMarital status: 0\\r\\nRace: 0\\r\\nAnthropomorphic index: 0\\r\\nBMI: 29.9\\r\\nEducation level: Doctorate\\r\\nCountry of origin: France\\r\\nLeading Physician: XXXXX\\r\\nEligibility code: None\\r\\nContact Number: [xx:xxxx:xxxx]\\r\\nPhone Contact Number: [xx:xxxx:xxxx]\\r\\nFax Number: [xx:xxxx:xxxx]\\r\\nMedical Record Information: XXXXX\\r\\n\\r\\nMedical History\\r\\nHepatitis C: Positive\\r\\nEye problems: Negative\\r\\nElevated blood pressure: Null\\r\\nArthritis: Null\\r\\nDepression: Null\\r\\nDecompensated Liver: Null\\r\\nPrevious Cancer: Negative\\r\\nCurrent treatment history\\r\\nIFN: None\\r\\nRBV: None\\r\\nFolinic acid: None\\r\\nDirect antiviral drugs: Yes\\r\\nAccompanying Drugs\\r\\nPeg-IFNa: None\\",
        "label": 0
    },
    "1800": {
        "output": "## Tie: inclusion\n\n##[INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. they are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe patient meets inclusion criteria \n\nIn order to provide a detailed assessment of the reasons for not being eligible, a list of the exclusion criteria is provided for each of the three exclusion criteria shown below. The exclusion criteria may be clinical or may concern patient personal traits. This information is crucial to show that the patient is not a good match for the clinical trial, so it adds value to your assessment. \n\nTo meet the inclusion criteria, the patient must:\nExclusion Criteria\n- male; - not 55 years;\n- no previous history of HCV infection; - no HCV RNA test in the last 6 months; - no HBV positive; - not on IFN, RBV, and direct antiviral drugs; - no other medications; - positive enzyme immunoassay for anti-HCV-antibodies in the patient's medical records; - chronic inflammation with HBV co-infection; - previous positive HCV RNA tests; - history of any malignancy; excepting non-or minimally invasive basal cell or squamous cell carcinoma of the skin or in situ cervical carcinoma; - no HCC; - previous positive R",
        "label": 0
    },
    "1801": {
        "output": "__Notes__\n\nYou have to specify that it is not the assessment you are doing, but the assessment of the  patient.\nIt's the same as the first exercise, if you look at the pseudo code, however, some variables are different.\nLet's say we want to assess patient 10 (because patient notes and patients from trials have consecutive numbers!).  \nThe way we do it was similar to when we were making decisions about when the patient met the inclusion criteria, however there are some things different.\n\nFirst of all, we want to determine if we should check the eligibility of the patient for the trial, or not. If not, we stop here.\nThen after the check if the patient is excluded, we need to determine if we want to check the exclusion criteria, or not. If not, we stop here.\n\nNext, if we are going to check the eligibility of the patient, we need to look again to check if all the inclusion criteria are met. \nThen we need to check the exclusion criteria against the patients characteristics to check if the patient fits the exclusion criteria of the trial.\n\nNow comes the most interesting part. We use the `fors` function to create a list of the steps that are going to be evaluated. \nThe fors function iterates over that list, which is an `iterlist`, and applies each part according to the code given for the exercise with a slight modification. \nThe modification is that if we reach part 3, then we have to look again into the exclusion criteria, for more check, using `sapply` function to iterate through the elements of our `exclusionCriteria` vector (trial-level eligibility), and use the `if` function to check if the patient is excluded by each of the exclusion criteria.  This is done using the `apply` function as well. \nNote here that we have to convert our vector of exclusionCriteria to a list in order to apply the `apply` function.\n\nNow we have to remember that we are looking everytime for the word \"Not\" in front of each of the exclusion criteria. All these words are in italic, so they are separated from the triallevels assessment by a bracket.\n\nSo if we remember to add the exclusion criteria, we now",
        "label": 1
    },
    "1802": {
        "output": "[NOTE] Here you should repeat the output as two lines. The first line is `Challenge' input, the second line is `Challenge.solution`. Also, the file name should be specified by using `FileName: [NAME_EXAMPLE]`, where is a path to the file, e.g., `/Users/user/Challen-geCode.txt`, the file name must be the same as `Challenge` input file for the same challenge. [/NOTE]\n\n### Solution and Explanation\n\nThis challenge is about determining which clinical trial patients are suitable for according to the specific criteria. The first patient note in the input file is a patient with an HCV infection and previous treatment history, which satisfies the inclusion criteria of the clinical trial for a patient with coinfection of HCV and HBV, i.e., patient ID: 1, with trial ID: 1, the patient is excluded at assessment of eligibility due to the reason: previous antiviral treatment.\n\nOn the other hand, the patient ID: 3, with a trial ID: 41, an enzyme immunoassay for anti-HCV-antibodies and a current biopsy show negative results for hepatocellular carcinoma and only chronic inflammation compatible with chronic viral hepatitis, the patient satisfies the exclusion criteria of the first trial, which is excluded at assessment of eligibility, and he is eligible for the second trial. Additionally, the patient ID: 5, with a trial ID: 36, a negative HCV RNA test, a patient meeting the inclusion criteria of the first trial and also meeting the exclusion criteria of the second trial, which is excluded at assessment of eligibility.\n\nFinally, the patient ID: 9, with a trial ID: 28, a positive enzyme immunoassay for anti-HCV-antibodies and the age, as the second trial includes aged HIV patients from 50 years old and above, satisfies the inclusion criteria for the second trial and is also not excluded at assessment of eligibility. \n\nThe code is in the file [FILE] and the output is in the file [OUTPUT] is that the same folder has to be opened in",
        "label": 0
    },
    "1803": {
        "output": "You should include the patient information in the following format:\n\n## Person\nPatients are denoted by the index number: e.g., `patient-000` means patient number one. \nAge, Gender, Hepatitis, HIV, and Diabetes are all Boolean variables. They mean respectively that a patient has the condition or not: `Patient-007: 55-year-old man` would be a value of `P=M=YES`, which means the patient corresponds to the 55-year-old man who is HIV negative. \n\n# Questions\nQ1: What conditions are required for a patient to be a good candidate for a clinical trial?\n\nA: Patients should meet all inclusion criteria and not have any of the exclusion criteria.\n\nRating:  2 \n\nQ2: What qualifies a person to be ineligible for a clinical trial?\n\nA: This means that there is an important reason to exclude a patient from a clinical trial; for example, they are taking other drugs that should not be co-administered with the trial substance.\n\nRating: 2\n\nQ3: Given your clinical trial, imagine a 47-year-old man with chronic HCV, whose recent HCV RNA test was positive, but the trial he is considering is open only for people with chronic HDV infection of at least 6 months' duration documented by a positive HDV Ab test. How would you assess the trial's fit for this patient?\n\nA: The above explanation means that the patient is eligible to this particular clinical trial.\n\nRating: 3\n\nQ4: What would be the eligibility assessment report look like?\n\nA: The eligibility assessment report should be clear, concise, and brief. It should also be the same as the trial's inclusion and exclusion criteria, with information about the patient's name and age, as well as all included and excluded elements.\n\nRating:  3 \n\nQ5: Please list the 3 most important elements required in the eligibility assessment report.\n\nA: We need to include all the information that is relevant to the patient's assessment.\nThat is, we need",
        "label": 0
    },
    "1804": {
        "output": "<a href=\"https://docs.google.com/document/d/1Zx00NMs0j0k0v5KQ2JtP34OgT01q1Jxw8yRXR6OOjU/edit?usp=sharing\">SrcDoc</a><EOD> Interactions between two polymerizing actin filaments studied by single-molecule manipulation.\nWe observed the interactions between two unlabeled actin filaments nucleated by monomeric actins in the presence of ATP and cofilin1 in a single-molecule force-clamp setup. An actin filament was mechanically manipulated by a glass microlever while the other end of the filament was anchored on the tip of an atomic force microscope cantilever (AFMC). We estimated the rupture force of individual filaments ranging from 18 to 21 pN. By mechanically separating the filaments at the junction point and monitoring the decay of the pulling force, we calculated rupture force (19.1 +/- 0.6 pN) for the junction region of the actin dimer. We also studied the effect of cofilin1 on the interactions between two polymerizing actin filaments. When 3 microm, 10 microm, and 30 microm cofilin1 were mixed with the reaction system, the rupture forces decreased to 9.6 +/- 0.2 pN, 5.8 +/- 0.5 pN, 3.3 +/- 0.5 pN, respectively. When 4 microm cofilin1 was added, the rupture force dropped to 1.8 +/- 0.4 pN. The decrease of the rupture force in the presence of cofilin would be caused by a decrease in the elastic modulus of the junction region, in accordance with previous reports. Our single-molecule manipulation method shows great promise for studying protein-protein interactions and force transmission and application in cytoskeleton research.<EOD> Effects of Naloxone in Patients with Major Depression Undergoing Immunotherapy: A Randomized, Double-Blind, Placebo-Control",
        "label": 0
    },
    "1805": {
        "output": "<EOD> Immune response to measles-mumps-rubella combined vaccine at 12\u201324 months\n\nWe assessed a measles-mumps-rubella-varicella combination vaccine against standard mumps and rubella single vaccines at 12-to 24-months of age in comparison with a placebo, and against a measles single vaccine at 60-to 120-months of age. Between 2009 and 2011, 274 children were randomized 1:1:1 to measles-mumps-rubella-varicella combination vaccine, mumps single vaccine, or rubella single vaccine. Between 1998 and 2007, 111 children were randomized 1:1 to measles mixed with varicella single vaccine or varicella single vaccine. Measles-mumps-rubella-varicella, mumps and rubella vaccinations were given to immune naive children, without seroprevalent or prior evidence of vaccination or infection. Children with seroprevalent evidence of measles infection received a one-dose measles vaccine. Sera were collected 28 days after the final vaccination. Anti-measles IgG geometric mean titers (GMTs) and proportion of seropositive children were noninferior to a licensed measles vaccine. Anti-mumps and anti-rubella IgG GMTs and proportion of seropositive children were superior to placebo, and IgG GMTs and proportion of seropositive children were similar or superior to rubella and mumps vaccines licensed with the measles vaccine. The varicella vaccination elicited an anti-varicella IgG seroconversion rate and GMTs comparable to those of the licensed vaccine. All participants elicited neutralizing antibodies for each vaccine strain. The measles-mumps-rubella-varicella combination vaccine elicited an adequate immune response at 12-to 24-months of age in the primary",
        "label": 0
    },
    "1806": {
        "output": "<EOD> Effect of Different Diets of Fat and Energy on the Activity of Leucocytes in Early Disease of Rats 1\nSummary A comparison has been made of the influence of increased fat and caloric diets on the phagocytic and bactericidal activities of leucocytes in rats. The studies showed that the dietary treatment increased the number of these cells and enhanced their phagocytic and bactericidal properties. Moreover, the data indicate that the caloric concentration of the diets had a more profound effect than did the amount of fat.<EOD> Awareness of cardiovascular changes due to depression as a major cause of morbidity and mortality: Results of a preliminary study\nThis preliminary, cross-sectional study was aimed at demonstrating which of the physiological signs of depression are more predictive of depression. To this end, four indicators were analysed for each of the forty-three subjects who were the subjects of the study (29 females and 14 males in the age range of 18-67 years, with a mean age of 39 years). The researchers focused on biochemical markers and cardiovascular changes associated with depression. No difference between the two groups in the case of the following indicators was found: high-density lipoprotein, low-density lipoprotein, urea, creatinine, creatine kinase, electrolytes, glycated haemoglobin, cholesterol, and triglycerides. However, the levels of alkaline Phosphatse and lactate dehydrogenase were significantly higher in the group diagnosed with major depressive disorder. Finally, it seems useful to underline the statistically significant increase in the values of the systolic arterial pressure in the group diagnosed with major depressive disorder in relation to the group with no depression.<EOD> .\nIn spite of a number of important papers of A. P. Vinnitsky and his colleagues on some aspects of the influence of ionizing radiation, the study on that subject was inert until the middle of this century and in the first decade of the forthcoming century, A. A. Oganessyan and his",
        "label": 0
    },
    "1807": {
        "output": "-\n\nTo avoid the duplicate entry of an assessment, you can see the list of the entered patient notes and the corresponding results of this assessment. [INST]\n\n[\n\n\n## [inst\n\n\n# [inst]\n-`\n[\n\n## Exam_info.pl{\n\n`print qq\n[Eval]\\$f\\->[Dt] \"Eligible\"';\nThe output of the `Eval` looks like ``Eligible``. If you input the output of the `Eval` as a CSV file, you can export it easily. [INST]\n\n# `f->l;\nNow, print some information about this patient.\n[INST]\n\n# [Eval]\\$f->\n[Dt] \"55-year-old male\"'.\nYou can print both the age and the birthdate. [INST]\n\n## # [Eval]\\$f->\n[Dt] \"HCV infection with mixed cryoglobulinemia\"'.\nYou can print the disease names. [INST]\n\n## # [Eval]\\$f->[Dt] \"Yes\";\nYou can print the assessment results of the treatment group, and the previous results are shown in bold. If you have any problems, the results of the treatment group are not printed. [INST]\n\n## # $f->[Dt] \"Sofosbuvir/Ledipasvir 90/400 mg for 12 weeks\";\nNow, you can print the treatment of this patient. [INST]\n\n# $f->[Dt] \"No\";\nFinally, you can print the status of the treatment.\n[INST]\n\n[INST]\n\n[Eval]\\$a->[Dt] \"06/14/2017\";\nNow, print some information about this clinical trial.\n[INST]\n\n# [Eval]\\$a->\n[Dt] \"Treatment-Naive Chronic HCV GT1-infected Subjects With MC\";\nNow, print the title of this clinical trial. [INST]\n\n# [Eval]\\$a->[Dt] \"06/16/2015\";`f->[Dt]",
        "label": 0
    },
    "1808": {
        "output": "In this dataset, each patient note corresponds to a clinical trial note which includes a note for inclusion criteria and three-point scale of eligibility assessment. The dataset consists of 239 patient notes and 43 clinical trial notes. If you find the format of clinical trials in this dataset unusual, this is the format in which you will be doing the rest of the dataset.\n\n\n<EOD> Implications for human health as a result of recent epizoological changes in the sylvatic population of the tick, Dermacentor reticulatus, in Wielkopolskie province (central Poland)\n\nDermacentor reticulatus is a significant species that affects human and veterinary health. Previously, D. reticulatus was mainly restricted to the north-western part of Poland. However, due to climatic changes, D. reticulatus has recently expanded into the Wielkopolskie province (central Poland). In this study, we present the results of a survey that was carried out in Wielkopolskie province in 2017 and 2018 in forested, urban and agricultural areas. Ticks were collected from vegetation on the trees, by dragging vegetation on the ground at the forest edge and in the grass in rural areas. Moreover, ticks were collected from urban areas -both on individuals and from litter. A total of 1597 ticks were collected. Ticks were identified by morphology and the DNA barcoding technique. The overall prevalence of D. reticulatus was 55.76%. The mean infection rate of D. reticulatus was 0.04 I.U./m 2 . The rate of infection by bacteria: Anaplasma phagocytophilum, Borrelia burgdorferi, Babesia microti and Rickettsia spp. was 8.48% (85/1131), 6% (74/1139), 0.27% (3/1136) and 0.27% (3/1134), respectively. This is the first published study regarding the sylvatic population of D. reticulatus in Wielkopolskie province. Moreover, our study revealed an unexpected finding of D. reticulatus on dogs in areas where",
        "label": 0
    },
    "1809": {
        "output": "* * *\n\n##[INFO] ************************************\n\n### * * *\n\n### * * * [SAVE]\n```\n[INST] Hello. You are a helpful assistance for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nThere is an interesting example.\n\n```python\nYou can try this example. [INST]\n```\n### * * * [SAVE]\n```\n\nYou can try this example. [INST]\n```\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nThere is an interesting example.\n\n```python\nYou can try this example. [INST]\n```\n### * * * [SAVE]\n```\nYou can try this example. [INST]\n```\n\n\n\tdef eligibility(patient_note):\n\t\t\n\t\tfor x\n\t\t\n\t\tfor y in trial_eligibility:\n\t\t\tif(x == y):\n\t\t\t\n\t\t\t\tpatient_eligibility = trial_eligibility[y]\n\t\tpatient_eligibility_values = patient_eligibility.split()\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\t\treturn ( (patient_eligibility_values[0] + patient_eligibility_values[1] + patient_eligibility_values[2] + patient_eligibility_values[3] + patient_eligibility_values[4]) % 5 )\n\t\n\t\t# print(\"Eligibility: \" + patient_eligibility)\n\t\n\t\t\n\n<EOD> Enzymes of the glycolytic pathway.\nSIR,-During",
        "label": 0
    },
    "1810": {
        "output": "What is [?][FOLK]=8785840704387946453) ?\n\nI'm not sure what the above text in the REPLY message means. I'm not sure it is part of the error message as `19349325747054958472` in the above REPLY message appears to be the end of the second line in the original error message. I just tried submitting your questionnaire, and everything went smoothly. So, here is my speculative hypothesis: the above paragraph may be the last line of the original error message that is somehow separated from that line when the original message is parsed into parts for display. But still, I do not understand why it is so, and if your questionnaire did not return any errors, then I am quite confident that something is quite fine.\n\n\n___\n\n[2021-12-09 23:22:15.474] Hello,\n\n\n1. Are you getting an error message and if so, is it the same as the one in the picture below?\nClick on the image below to enlarge.\n[IMAGE]\n\nClick on the image below to enlarge.\n[IMAGE] \n2. Are you using a tablet version of the application or not?\n\n\nI'm afraid both of these errors are on your side. Because sometimes they appear. However, this means not that you have to do anything, but that the server is not doing what you expect it to. For example, I sometimes get `19349325747054958472` when I submit my questionnaires. It means the server is not processing the submission. And sometimes I get `8785840704387946453` which means the server is not processing the results. But it is a server side error: not your side (Yours). So, if you have these errors then it may mean that the server gets loaded with a lot of questionnaires at once and it may even happen that someone submits a 25+ page questionnaire just after you and before you. So that your submission will be delayed. On the other hand, this may be a",
        "label": 0
    },
    "1811": {
        "output": "<EOD> Experimental studies of gamma ray induced chromosomal damage. II. The effect of the age of the nucleus on the yield of chromosome aberrations.\nMeasurement of yields of chromosome aberrations from exposures of human lymphocytes to \u0302-rays of either 0.5, 1.0, or 2.0 mrad revealed the same marked increase with increasing expos...<EOD> Improving the Care and Safety of Persons of Advanced Age Under Criminal Justice Involvement\nAbstract Persons of advancedage under criminal justice involvement have unique vulnerabilities for neglect and mistreatment, and limited access to appropriate care and support. By focusing on the social and health needs of this vulnerable population, criminal justice professionals and agencies can improve the outcomes of incarcerated elderly. This column reports on a symposium held at the 2013 Gerontological Society of America Annual Meeting in Chicago. The session, which addressed the complex health and social care needs of aged prisoners and strategies for improving the care of elders under criminal justice involvement, featured research, evaluation, and interventions in a variety of criminal justice settings.<EOD> Implications of high-resolution 3D optical coherence tomography and histopathology for the imag",
        "label": 0
    },
    "1812": {
        "output": "Now let's look at the function of ``clinical_trial.py`` [src/trial.py]: \n```python\n    def trial_name(self, clt):\n        \"\"\"Get trial id from the clt obj \n        \"\"\"\n        if isinstance(clt, clt.__doc__.replace(\"(\", \"\").strip()): \n            return clt\n        else: \n            if (clt.clt_id) and (clt.clt_id != \"\") : \n                return clt.clt_id\n            \n            if (clt.clt_id) and (clt.clt_name) and (clt.clt_name != \"\"): \n                if (clt.clt_id != \"\"): \n                    return \"{clt.clt_id}_{clt.clt_name}\".format(clt.clt_id=clt.clt_id, \n                           clt.clt_name=clt.clt_name) \n                else: \n                    return clt.clt_name} elif isinstance(clt, dict) : \n                return clt[0].get(\"clt_id\")+\"_{}\".format(clt[0].get(\"clt_name\")) \n            else: \n                return \"{clt_id}_{clt_name}\".format(clt=clt)} \n```\nNote that we also need to fix the bug in ``clt_id`` in this file. \n\nFor more detailed step-by-step guide, visit [the website](https://github.com/fairhealthtech/health-claim-generator/blob/develop/doc/clinical_trials_manual_generation.md) or [use a docker image](https://pypi.org/project/health-claim-generator/version/develop/#supported-containers).\n\n## [INST [src/clinical_trial_generation/clinical_trial_generator.py]]\nYou are a junior data scientist in a drug company. Your manager gave you an assignment to automatically generate clinical trials. Your job is to generate similar trials for",
        "label": 0
    },
    "1813": {
        "output": "<html>\r\n\r\n<!-- Required plugins: -->\r\n<script type=\"text/javascript\" src=\"http://html5shiv.googlecode.com/svn/trunk/html5shiv.js\"></script>\r\n<script type=\"text/javascript\" src=\"http://code.jquery.com/jquery-latest.js\"></script>\r\n\r\n<style>\r\n\t.error\r\n\t{\r\n\tcolor: red;\r\n\tfont-weight: bold;\r\n\t}\r\n</style>\r\n\r\n<script>\r\n// \u914d\u7f6e\r\n// jQuery.fn.modal.options.show.effect = \"none\";// \u5173\u95ed\u6548\u679c\r\n// jQuery.ui.resizable.options.padding=5;//\u8bbe\u7f6e\u76f8\u5bf9\u6bd4\u8f83\u5f39\u7c27\u8ddd\u79bb\r\n\r\nvar el_show_data_json = [];//json\u6570\u636e\r\nvar el_show_data_array = [];//\u6570\u7ec4\r\n// var el_show_data_name    = [\"name\",\"age\" ,\"gender\" ,\"smoking\" ,\"drinking\" ,\"coinfect\"  , \"Hb\" ,\"Hct\" ,\"Pt\" ,\"Retic\" ,\"Albumin\" ,\"Glo\"",
        "label": 0
    },
    "1814": {
        "output": "<EOD> The development of the HIV/AIDS patient.\nThe article describes the development of the patient with AIDS, a patient who has had a major life event as the result of the diagnosis of acquired immunodeficiency syndrome (AIDS).<EOD> Intramolecular and Intermolecular Hydrogen Bonding in Heterocyclic Acids and Related Systems\n\nHydrogen (H) bonding in the heterocyclic acid series, including carboxylic acids, primary, alicyclic, and acyclic secondary amides, is described. Carboxylic acids undergo intramolecular H bonding with their carboxyl oxygen endocyclic oxygen acceptor. The endocyclic oxygen undergoes intramolecular H bonding with the nitrogen endocyclic nitrogen acceptor, with the former stronger than the latter. The magnitude of the intramolecular H bonding in the carboxylic acids depends on the length of the H bonding donor side chain and, additionally, on steric factors. These steric factors include the torsional angles between the side chain and the H bonding donor, and the number of methylene groups trans to the side chain. In the acrylic and phthalic secondary amides no intramolecular H bonding is observed, the oxygen endocyclic oxygen being unable to form one. No intramolecular H bonding is observed with the endocyclic oxygen in ortho-or para-syringic and meta-phenylsyllic acids, the phenyl substituent being of sufficient steric bulk to preclude such H bonding. Intramolecular H bonding is observed with the ortho-syringic and meta-phenylsyllic acids in which the ring substituents occupies the meta position with respect to the endocyclic oxygen. Intramolecular H bonding with the carbinolamine group is observed in some \u03b2-substituted primary aliphatic amides. Intermolecular H bonding occurs with the carboxyl oxygen in the carboxylic acids in the solid state and solution, the acceptor hydrogen donors being the carboxyl oxygen and the endoc",
        "label": 0
    },
    "1815": {
        "output": "[INST] Examples of correct output: \nPatient: \n[0] Excluded (eligibility = 2, assessment = 0)\n[1] Not relevant (eligibility = 0, assessment = 0)\n[2] Eligible \nStudy: \n[0] Excluded (eligibility = 0, assessment = 0)\n[1] Not relevant (eligibility = 0, assessment = 0)\n[2] Eligible\n<EOD> Identification Criteria for Metastatic Bone Disease in Cancer Patients\nMetastatic bone disease (MBD) is a common complication of disseminated cancers (i.e., all stages of breast, prostate, lung, colon, and thyroid), affecting as many as 70% to 80% of patients with certain cancer diagnoses. Symptom severity for patients with MBD varies depending on tumor type, location of lesions, and the number of lesions. Although current clinical evaluation includes physical examination and imaging studies with skeletal surveys, plain roentgenograms, and tomographic studies, including double-contrast studies (computed tomographic and radionuclide investigations), the presence of MBD can be definitively established only by biopsy of either a metastatic lesion or of the primary tumor. Therefore, if the patient\u2019s history and examination can reasonably exclude other causes of the patient\u2019s bone pain, such as primary tumors, infections, or trauma, the presence of MBD can be predicted on the basis of the bone symptoms alone.<EOD> Sleep and circadian phase responses to low-dose oestradiol replacement therapy among perimenopausal women\nObjectiveThe aim of the study was to compare sleep and circadian phase markers in naturally cycling women and women on low-dose, oral hormone therapies. MethodWomen (n = 62) aged between 45 and 52 years completed questionnaires, including the Women's Health Questionnaire (WHQ), and attended sleep and circadian phase testing at least once during one oestrous cycle and after 5 weeks of continuous transdermal oestradiol (",
        "label": 1
    },
    "1816": {
        "output": "### Exemptions\n- Patient's consent was not obtained because such documentation may delay enrollment, which could be detrimental to outcome. \n- The assessment of eligibility has a three-point scale. The assessment tool is written on PaperForm. \n- You should try to make three-point scale as consistent as possible regardless of the clinical trial's scale. \n\n### Exclusion Criteria\n- The assessment is done manually in PaperForm. Let's think step by step. \n\n#### Patient's age\n- Patient's age is below 18 years. `patients_age` is less than or equal to 18. [/TRIAL] \n- If `patients_age` is less than or equal to 18, then we should exclude the patient. `assessment` should be at least 0. You should ignore the second and third lines and just use `print(patient_note.get_assessment())`. [/TRIAL] \n\n#### E.g.:\n\n```py\npatient_note = PaperForm(path='/data/note/678.txt')\npatient_note.patients_age == 18\n```\n```py\nprint(assessment)\n```\n\n#### BMI\n\n- Patient's BMI is above or below 25 or under 18 kg/m^2. `bmi_lower` or `bmi_upper` is between 25 and 18 kg/m^2. \n- BMI`_lower` and `bmi_upper` are the variable's name in the assessment tool.\n- We should check `bmi_lower` or `bmi_upper` between 25 and 18 kg/m^2. \n- `if bmi_lower <= patients_age: print(f'`If patient's age is less than or equal to BMI, then patients are excluded because the BMI is under 18 kg/m^2: \"{patients_age}\"`)'`. [/TRIAL] \n```py\nfor patient in patient_note.patients:\n    if 'bmi_lower' in",
        "label": 0
    },
    "1817": {
        "output": "<EOD> Isolation and characterization of a soluble antigen from Myceliophthora thermophila, an important agent of wheat scab\nThis study was conducted to evaluate the potential of antigenic cell-wall proteins in the development of molecular tools for the rapid identification of Myceliophthora thermophila, the predominant species causing wheat scab in Australia and New Zealand. Antigenic cell-wall proteins from four isolates were purified by means of gel permeation chromatography and two-dimensional electrophoresis. The profiles obtained provided information on the antigenic proteins and their relative molar masses, respectively. Two isolated antigens were further purified by isoelectric focusing and SDS-PAGE. A mixture of two molecular weight fractions, F1-alpha (24.1 and 36.4 kDa) and F1-Beta (32.3 and 41.6 kDa), and one isoelectric fraction, IEF1 (isoelectric point, 4.89), inhibited a Western blot in which polyclonal antibodies against conidia were used. Antigens from M. thermophila are highly soluble and stable, thereby possessing the potential for further development in the production of a sensitive diagnostic test for wheat scab.<EOD> A systematic review and meta-analysis of exercise therapy including patient education in chronic low back pain\nObjective To identify differences in exercise therapy including patient education for chronic low back pain compared to usual care. Design We followed the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Included studies were screened by two independent reviewers and relevant data regarding type of treatment and outcomes extracted. Review Manager 5.3 software was used to perform the meta-analysis. Three reviewers independently assessed the risk of bias. Results 14 out of 1989 screened abstracts were eligible; two studies showed a high risk of selection and detection bias and nine studies had a low risk of bias. Four RCTs showed small or no effect of exercise on pain (standardised mean difference\u2009=\u2009\u22120.41 (95% CI \u22121.25, 0.44); I2",
        "label": 1
    },
    "1818": {
        "output": "<EOD> A new formulation of metacognitive therapy for generalized anxiety disorder in women with premenstrual dysphoric disorder: a case report\n\nBackground: Generalized anxiety disorder (GAD) is a severe and chronic disorder that often runs in comorbidity with numerous conditions, most notably major depression and other anxiety disorders. It is strongly associated with high levels of occupational and academic impairment, disability, and increased risk of suicide and physical comorbidities. The treatment of GAD has been recently focused on psychopharmacological treatments, which showed good short-term efficacy, but some studies suggest that up to 30% of patients may not respond to selective serotonin reuptake inhibitors (SSRIs). In the current study, we report a case report of individual metacognitive therapy (MCT) based on the transdiagnostic approach (MCT-TDA) to treat women with comorbid premenstrual dysphoric disorder (PMDD) and GAD. The individual MCT-TDA was developed to increase the clinical efficacy in the recovery of patients with comorbid anxiety and depression. Our study represents a new treatment approach for PMDD and GAD.Case presentation: A 22-year-old Italian Caucasian woman was selected for this case report on the basis of a thorough description of the characteristics of the case with diagnosed PMDD and GAD comorbidity. She received individual psychotherapy with MCT-TDA with the help of the MCT app for iPad (MCT-TDA-app), the clinician, and the supervisor. Treatment lasted 4 months and was well tolerated and accepted by the patient. After treatment, the outcome demonstrated an excellent response (clinical recovery defined as the remission criteria according to the PMDD diagnostic criteria DSM-V) of both premenstrual and generalized anxiety; no adverse events were reported. The treatment was delivered through synchronous videoconference.Conclusions: This case report shows how MCT-TDA delivered in an online psychological treatment format can be effective for PMDD and GAD comorbidity. Despite our encouraging results, we caution and ur",
        "label": 0
    },
    "1819": {
        "output": "- Your final output will be the following:\n\n[MIDI]\n\nPatient:\n-----------------------\nPatient notes:\n\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV.\nHis past medical history is non-significant.\n\nHe is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications.\n\nHis medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\n\nThe recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis.\n\nThere is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease.\n\nHe is an alert male with no acute distress.\n\nHis BP: 130/75, HR: 90/min and BMI: 27.\n\nHis abdomen is soft with no ascites or tenderness.\nThe lower extremities are normal with no edema.\n\nClinical Trial Summary:\n\n- Title: A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive\n\n- Summary: The main purpose of this study is to evaluate the safety and tolerability of a combination treatment of AL-335, odalasvir (ODV), and simeprevir (SMV) for 8 weeks in Japanese participants with genotype 1 or 2 chronic hepatitis C virus (HCV)\n\n- Inclusion criteria: Inclusion Criteria:\n\nChronic hepatitis C virus (HCV",
        "label": 1
    },
    "1820": {
        "output": "# Rationale\n\n\nThe study aims to investigate the impact of the 3D regimen on total daytime physical activity and non-invasive markers of the cardiovascular system.\nThis study is expected to provide insights into the impact of treatment with paritaprevir/ritonavir/ombitasvir with dasabuvir regimen (",
        "label": 0
    },
    "1821": {
        "output": "### Tasks\n\nHere is a simple but useful example on tasks performed by students:\n\nTask 1: Read the patient note, and type the trial-level eligibility for the patient in both the file named `Trials.txt` (located in the `Assessments/` folder) and the `trial.txt` (located in the `trials/` folder) file, when prompted.\n(After all you have done you can check all the steps you have done at the file name as _trial.txt)\n\nTask 2: After completing the above task, go to the `trials/` folder and add a record for the given trial in the file named `clinicalTrials.csv` (located in the `ClinicalTrials/` folder).\n(For details on how to edit the file, see [README](README.md)), but first create a new file by right clicking on the folder and select _New_|_File_|_Text File_|_CSV File_. Put any name you want here)\nYou need to provide the following information on the trial:\n\n\n\n**Trial-level eligibility** : 0) Excluded.\n\n**Trials-ID:** 0537\n\n**Trial-Name:** ACTI: 0965\n\n**Inclusion-Criteria** : Patient is a 36 years old male with MI\n\n**Exclusion-Criteria** : Diabetes, BMI, and PVI\n\n**Contact-Person:** a.n.m\n\n**Main-Results-Date:** 12-02-2018\n\n**Results-Format:** JSON\n\n**Location-City:** New Delhi, India\n\n**Location-Country:** India\n\n**Language:** English\n\n**Clinical Trial Registry:** [https://clinicaltrials.gov](https://clinicaltrials.gov/)\n\n**Description of Study:** A randomized, open-label, investigator-initiated, prospective multicenter study which will evaluate the efficacy and safety of Ruxolitinib with or without RNA interference in patients with unresected intrahepatic cholangiocarc",
        "label": 0
    },
    "1822": {
        "output": "Summary:Although the incidence of Hepatitis B has been decreased a lot recent years, there are still quite a few chronic hepatitis B patients in China. The anti-virus drugs of western medicine such as Entecavir and Tenofovir have been proved effective in decreasing the serum hepatitis B virus (HBV) level, on the other hand, Chinese materia medica showed effective on TCM syndromes of chronic hepatitis B (CHB) such as hypochondriac pain, jaundice and abdominal mass. Besides, the hepatic fibrosis could be delayed after the appropriate treatment of TCM. [/table] \n<EOD> Prospective study of p",
        "label": 1
    },
    "1823": {
        "output": "## Explanations\n\n\n* The input data should be separated by ``\\n``, meaning a new line.\n* The output format should follow in the format of ``\\n``, meaning a new line. We expect your output to be in this format: ``\\n0), Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria), Not relevant (patient does not have sufficient information to qualify for the trial), \\nEligible (patient meets inclusion criteria and exclusion criteria do not apply)\\n`` after the patient record (separated by the ``\\n`` character).\n* Remember to use ``\\n`` at the beginning and end of the result for output formatting.\n\nYour submission, when done, should be named:\n[SOLUTION ID] _Assistant Eligibility.txt (use the sol01.txt for the first submission, and increment the sol01.txt to sol02.txt for the next submission).\nFor instance, the first sol01.txt is to be named Assistant_ELigibility.txt and the second sol02.txt to Assisant_ELigibility.txt.\nDue date will be posted on the top of the assignment page on CMS. We are aware that due to the holidays, some deadlines might have slightly shifted, although the extension is not guaranteed. So please be aware, if you are not on time, you might need to turn in one for the next grade.\n\nWe are looking forward to going over your results.\n\n\n\n\n\n\n\n\n# Tutorial\n\n[SOLUTION ID]_1.txt\n\n## Patient_note.txt\nExclusion criterion for genotype 1 HCV treatment.\n\n- Age less than 18 years or greater than 70 years\n- Childbearing potential (if a woman of childbearing potential, she must use highly effective contraception throughout treatment period) Women of childbearing potential are advised to use highly effective contraception throughout the treatment period and for at least 4 weeks after stopping treatment\n- Males with a female partner of childbearing potential (if a female of childbearing potential, she must use highly effective contraception throughout treatment period)\n- Pregnancy or",
        "label": 0
    },
    "1824": {
        "output": "Hello You are a skilled software engineer at the Vaccine Development Center. The COVID-19 pandemic has brought huge challenges to people around the world, which is still threatening peoples' lives. You receive a note, reporting the first two cases of COVID-19 vaccinated with the mRNA vaccine from the center. The note contains some of the COVID-19's gene sequences and a DNA vaccine. You are asked to write an assembly code to implement the DNA vaccine based on the notes. You design the DNA vaccine to include 877 base pairs and divide it into 386 base pairs. There are three subsequence regions and the corresponding sequences are shown below:\nSequence 1: 5'-TAGACGGGAGGGAGAGGGGGCAGAGGG GTGG-3'\nSequence 2: 5'-CCTAGGTGGTTAGGGCGGGCGGGCGGG GAC-3'\nSequence 3: 5'-TAGCTTAGTGGCTAGACGTATTGCGCCGCCCC-3'\nThe corresponding DNA sequences will be synthesize and injected into the bodies of the first two cases through a needle syringe injector. \nBesides, you develop the DNA vaccine following standard design procedures as follows. Firstly, set up appropriate conditions to help people synthesize the DNA vaccine. Secondly, synthesize the gene sequences and pack them into a syringe, then inject the DNA vaccine. Finally, the DNA vaccine helps the body to produce immunoglobulin against the coronavirus.\n\nYou need to write a script code to produce a DNA vaccine based on DNA sequence data. The DNA vaccine needs to be synthesized according to standard procedures, then injected into the first two persons who have been vaccinated with mRNA vaccines. After injection, the body starts producing immunoglobulin against coronavirus.\nThe DNA vaccine has a gene sequence, which is like a blueprint and is composed of nucleotides. Because nucleotides are unstable, the DNA sequence will not be directly written into human cells, but rather first be synthesized in vitro which is like a standardized operation",
        "label": 0
    },
    "1825": {
        "output": "To pass the assignment, we should implement only `Trial-level eligibility: 2) Eligible` to the end user input. I provide a simple and understandable way to do so;\n\nIf the trial-level eligibility string is `3) Excluded`, output the string back to the input and do not write the condition in your output. (3) Eligible in the input should be interpreted as 1) Not relevant.\n\nIf the trial-level eligibility string is not `3) Excluded`, let's start with the second case first, e.g., 1) Eligible. \n\nIt depends on the trial-level eligibility string. Write your code considering both cases. If it's the first one, you can assume that `Patient.Trial-level eligibility: 1) Excluded` is set to the input and get the value.\n\nPlease refer to the attached markdown file of this assignment or to the markdown text in the link below.\n\nhttps://nbviewer.jupyter.org/github/funkybaka/CS118-F22-R11/blob/master/Lab-06_F22.ipynb  \n\n![inst](../images/inst.png)\n[10]\n\n- \u2460 Let's start with `Excluded` from `Trial.Inclusion criteria.txt` which is the same patient.\n- \u2461 The condition is not fulfilled to the trial's inclusion/exclusion criteria.\n\nWe provide the following code as additional material. \n\n```\n#!/usr/bin/env python3\n\n\nimport pandas as pd\nimport numpy as np\nimport random\n\ndef evaluateTrials(Trial, Patient):\n    if Trial == 3:\n        return Patient.Triallevel eligibility\n    elif Trial == 2:\n        if Patient.Triallevel eligibility == \"1\") :\n            return \"Not relevant\"\n        else :\n            return Patient.Triallevel eligibility\n    else:\n        return \"Excluded\"   \n```\n\n```\n# %load_ext autoreload\nimport time\nimport json\n\n\nfrom IPython.core.",
        "label": 0
    },
    "1826": {
        "output": "## Exercise 5: You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The inclusion criteria that must be satisfied by those who decide to participate in a particular clinical trial are called eligibility criteria.\nA clinical trial for treating hypertension with an antihypertensive drug is being conducted at the hospital of Medical University. You will be involved in recruitment of participants for the trial. You should provide a list of patients that you considered eligible for the trial. Include as much information about the patients (age, gender, diagnosis, etc.) and the reasons you consider them ineligible. If there are more than 15 patients, pick the first 15.\n\n\nYou will be given a patient note and an inclusion criteria sheet. You can make use of the inclusion criteria and then check the patients if they are eligible.\n\nYou are to complete the following table. The columns headed `Reason for exclusion` and `Exclusion criteria` are to be filled in retrospectively. You are not allowed to ask the doctor or to discuss any issue about inclusion criteria in person.\n\n## Exercise 6: You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the clinical trial information sheet to determine the patient's eligibility.\nA clinical trial for treating hypertension with an antihypertensive drug is being conducted at the hospital of Medical University. In a clinical trial, there is a standard information sheet for all participants. The participants should read the information sheet in advance and make a sure decision. You will be involved in recruitment of participants for the trial. You should provide a list of patients that you considered eligible for the trial. Include as much information about the patients (age, gender, diagnosis, etc.) and the reasons you consider them eligible. If there are more than 15 patients, pick the first 15.\n\n\nYou have been given a patient note and an information sheet. The information about the patients and the research project can be seen. In case of more than one patient, the information refers to only one patient. You are to fill in `Eligible` or",
        "label": 0
    },
    "1827": {
        "output": "### Recognizing missing data in a patient record {get}\n\nA medical record may have missing data due to some unavoidable reasons, such as patient loss of consciousness, a sudden change in vital signs, or a severe allergic drug reaction. In such cases, we do not know the patient's past history (i.e., drug allergies), vital signs, and symptoms, even if we know the patient's age group, sex, or ethnicity. \nIn this task, you should fill in the missing data about vital signs such as blood pressure (BP) and heart rate (HR) for a patient (e.g., 120/80 for BP and 80/min for HR). Vital signs indicate the current status of the patient, regardless of the condition of the patient's organ system, by measuring them. When a patient feels sick, their vital signs will increase sharply; in contrast, a patient who is recovering and stable will have normal vital signs. \nThere are some cases in which the vital signs of a particular patient are not well documented. For example, suppose the BP of a patient is 120/80 mmHg, but the patient is not feeling sick. In that case, we cannot confirm whether the normal range of BP is 90-120 mmHg or 120-140 mmHg or 140-160 mmHg, or 160-180 mmHg. It is natural that we are curious about the BP of the patient, for example, in the morning and after he has eaten. \nHere are the following tasks: You are able to recognize the missing values from the clinical note and provide appropriate values for it. \n[INST]\n\n\nStep 1: Let's see the code for the vital signs on this patient's clinical record: \n    <data type=\"list\">\n    <value unit=\"1\">\n        <item-type>\n            <list",
        "label": 0
    },
    "1828": {
        "output": "#### Examples <small>\"eligibility\", \"Eligible\", \"eligible to continue\", \"eligible to enter\", \"eligible patient\", \"qualification\", \"eligibility criteria\", \"eligibility determination\", \"eligibility assessment\", \"eligible for a study\", and \"eligible for entry\", \"eligibility of patients\", \"eligibility assessments\", and \"eligibility determination\", are similar \"eligible\"}\n\n### eligible\nIn this example, we are determining eligibility of a patient to continue on our study:  \n`Patient ineligible (N=1, 4%), Eligible (N=53, 65%), Not relevant (N=23, 29%). Eligible patient N=66 (83%).`  \nWe used three different methods in this script to count each patient eligible or not: `len(d.unique())`, `len(d) - sum(set(d[\"Eligible\"], d[\"Not relevant\"]) == 1)`, and `sum(set(d.all_eligible(1), d.intersect(\"eligible\")) == 1)`:  \n- The first line sums number of patients for each variable eligible and not relevant separately.\n- The second line is a way to use set to check if only one value is present for a parameter in a dataframe.\n- The third line is for counting patients for each of the conditions from the eligible criteria, so we can use it for a specific criterion, e.g.: eligible patients.\n```python\n\n#### Examples <small>\"eligibility\", \"Eligible\", \"eligible to continue\", \"eligible to enter\", \"eligible patient\", \"qualification\", \"eligibility criteria\", \"eligibility determination\", \"eligibility assessment\", \"eligible for a study\", and \"eligible for entry\", \"eligibility of patients\", \"eligibility assessments\", and \"eligibility determination\", are similar \"eligible\"}\n\n## Summary\n\n[INST]: <b>\"sum\"</b>\n- You are asked to analyze the eligibility of participants, and assess whether patients meet the eligibility",
        "label": 0
    },
    "1829": {
        "output": "<EOD> Bovine mastitis research: achievements, limitations and perspectives.\nBovine mastitis is one of the major diseases of dairy cattle, responsible for major economic losses as well as food safety incidents. The economic consequences of the disease are mainly due to reduced milk production, animal replacement, and treatment costs. Mastitis also has a negative impact on the quality of milk, including organoleptic traits, biochemical, biological, and microbiological quality. Although mastitis represents an economic and a food safety problem, the development of new diagnostic methods and therapies is slow. Although there are several review papers on different aspects of udder health, most of the published review articles focus on animal (host) factors contributing to mastitis in dairy animals (i.e., genetics and immune-response), or the pathogenesis of common mastitis-causing bacteria. Here, we present a broad overview of recent research on bovine mastitis. In addition to a general description of mastitis, we also review the potential impact of a global increase in dairy production. Finally, we provide a brief discussion of the diagnostic and therapeutic options in bovine mastitis.<EOD> .\nThe authors report a case of laryngeal leiomyosarcoma with lymph node metastasis. A review of the literature confirms the rarity of this tumour as well as the frequency of inappropriate diagnoses before the appearance of lymph node metastases. Surgery alone does not seem to be satisfactory, as the probability of metastasis in the case described, despite complete macroscopic excision remains 35% with five years. It is therefore recommended that a total local curative approach be used with a radical neck dissection together with an external radiotherapy course to reduce the risk of local and metastatic recurrences. Prognosis would seem to depend to a large extent on clinical evolution because the appearance of signs of metastases would seem to portend an immediate death.<EOD> Mitochondrially targeted protein disulfide isomerase (PDI) ameliorates mitochondrial function during ethanol plus lipopolysaccharide in vitro and in vivo in neonatal rabbits",
        "label": 0
    },
    "1830": {
        "output": "[/CODE]\n\n### STEP2\nFind a column \"patient_criteria\" in the CSV file. If you cannot find a column \"patient_criteria\", rename a row \"Inclusion_criteria\" to \"patient_criteria\" and continue from this point.\n\nThe code line will be similar to the example below. You should use this code line for your input file.\n```python\npatient_criteria = [0]*(len(patient_data))\n```\n\nThen write a code for comparison with the inclusion criteria of a given clinical trial. You should iterate each column in the patient note and the trial, and find the columns that are identical.\n\nThere are five types of columns;\n- First/Second/Third column: Columns with no numbers or text, i.e., \"First\", \"Second\", and \"Third\" are all these columns. To compare these columns, you should find the code for a code line in the code below. Here is an example:\n```python\n    if \"first\" in column:\n        patient_data[j] = patient_data[j]['first']\n``` \n- Numbers: If numbers are the content in the column, compare the row number in the patient note with the row number in the trial. If the row numbers are the same, compare the values or names, e.g., \"age\" and \"age (years)\", i.e., all numbers in the column. If both the values and names are identical, you can get the result by adding all the cells in your patient note with the trial.\nFor example, if both age of a patient and age of a patient in a trial are the same, you should get the result by adding cells of the two files. To compare the row number in the patient note with the row number in the trial, we use \"idx_1\" and \"idx_2\".\n\n```python\n    for j in range(0,len(column)):\n        if column[j][0] == 'first' or column[j][0] == 'number':\n            if column[j] in patient_data[idx_1]  and column[j] in trial_data[idx_2]:\n                \n                patient_data[j] = patient_data[j]['val']\n    trial_",
        "label": 1
    },
    "1831": {
        "output": "## Task 1: Assessment of eligibility\nPlease perform three tasks: \\\n    * Check if the patient meets the inclusion criteria by using the following script:\n    ``python assess_eligibility.py`\n    \\\n    * Check if the patient meets the exclusion criteria by using the following script:\n    ``python exclude_patients.py`\n    \\\n    * Check if the patient meets the combination of criteria by using the following script:\n    ``python com_criteria.py`\n\n\n## Task 1: Assessment of individual inclusion criteria\nIn this task, you should perform the assessment of the individual exclusion criteria in the input patient note. You will meet the individual criteria by using the following script:\n``python com_criteria.py`\n\n\n## Task 2: Exclusion of patients from clinical trial\nIn this task, you should find if the patient is excluded from the clinical trial by using the patient note.\nYou will exclude the patient by using the following script:\n``python exclude_patients.py``\n\n## Task 3: Combination of inclusion criteria\nIn this task, you should perform the combination of criteria by using the patient note. By using the following script, you should check whether the patient meets the combination of criteria for inclusion in the clinical trial.\n\n``python com_criteria.py`\n\n## Task 4: Trial-level eligibility\nIn this task, you should repeat the Trial-level eligibility in the last line by `Trial-level eligibility: (2) Eligible.`, where (2) marks the second possibility for the patient. You will perform this task by using the following script:\n``python assess_eligibility.py`\n\n# Discussion \n## [DSC]. You did an excellent job. You should know three possible combinations (exclusion/inclusion/exclusion, inclusion 1/exclusion, and inclusion 2/exclusion) in the current trial and identify any other cases (e.g., inclusion 1/inclusion 2, inclusion 1/exclusion, inclusion 1/inclusion 1, etc.).\nPlease discuss three issues by yourself:\n1. In our work, we have used the SIRANet toolkit for assessing clinical trial",
        "label": 0
    },
    "1832": {
        "output": "You should not write `0) Excluded` in this line. If you do not find 'Trial-level eligibility:`, press Shift+Enter. \n\nYou may need to add some trial notes, e.g., `Aspartate aminotransferase:\n<84 IU/L ALT: <19 IU/L Gender: Male BMI: <29.2 kg/m2 CDC Group (2):\n 2\n Age: 31 yr < 60 yrs. < 60 yrs, HBV=14,820 IU/mL`, like that. \n\nNow, let's continue. Clicking on `Next: ` under the 'Trial Details` head, you see the next screen. There are two fields to be completed. Type in the title of your trial, preferably in Latin instead of English. In this case, it should be ''To Study the Efficacy of PEG-IFN Alpha in HBeAg-Negative Patients After Stopping Nucleos (TDF/ETV)'', just like that. And choose the description of trial as:\n''Explanation of the title`\n\n\n---\n\n### \ud83d\udec8 In case of errors\nIf you enter the wrong number for age, gender, etc., you can simply delete the wrong one and insert the exact correct value. For example, if you accidentally enter ''male'' even though the patient is a lady, delete ''male'', and insert ''female''. However, if you accidentally change the correct value by, e.g., ''male'' to ''female'', you cannot change it back to ''male'' because you can enter only one gender per trial, and only one trial can be saved per trial. In such cases, it is necessary to run `Closing and Opening a clinical trial` as described above.\nIf you make an error in the trial notes, you have to re-open the trial page and type in your notes.\nIf you make an error in the notes of included patients, it is possible to correct. However, it is not possible to edit the notes of already closed patients. \n<EOD> Enoxaparin dose escalation and renal dysfunction: A possible paradox in heart trans",
        "label": 1
    },
    "1833": {
        "output": "<EOD> .\nThe paper analyzes the effectiveness of surgical treatment of the patients with chronic recurrent pain in the lumbar region and abdominal cavity, associated with a dysfunction of the locomotor apparatus, by means of the multidimensional plastic intervention, permitting the correction of the vertebral column disorders and spondylofocal myositis, together with the simultaneous correction of the muscle-ligamentous apparatus of the spine and abdominal wall. 105 patients with chronic recurrent pain in the lumbar region, abdominal cavity, and radicular syndrome were examined and treated. The results obtained during the multidimensional plastic intervention were as follows: in 100% -- elimination of chronic pain in the lumbar region and the abdominal cavity, reduction of the symptoms of the radicular syndrome, improvement of the function of the locomotor system; in 96.8% the intervention resulted in the improvement in social and professional activity of the patients, the improvement of the physical development of the children and the quality of life of the patients in general, the reduction of the leisure time due to elimination the pain syndrome. In 3.2% of cases postoperative complications took place without the need for recourse to the additional surgery, as the patients were in good conditions.<EOD> Concentration-dependent in vitro effects of caffeine, amitriptyline, and chlorpromazine on rat brain stem neurones from different developmental stages.\nIn concentrations below 5 mM, acute administration of caffeine, amitriptyline and chlorpromazine to slices of rat brain stem from postnatal days 4 to 70 increased spontaneous firing and bursting. The increases were most marked for all three compounds in brain stem from old 20- to 30-day-old and young adult rats. The greatest effects were produced at the lowest concentrations (0.1-1 mM) for spontaneous firing, but at the higher concentrations (5-50 mM) for bursting in all age-groups of the animals studied. Neuronal excitation by the test compounds depended directly on the concentration used for exposure.<EOD> Long-term",
        "label": 0
    },
    "1834": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: Hepatitis C Treatment Study in Myanmar\n\n\nSummary: Hepatitis C is an important health problem in Myanmar",
        "label": 1
    },
    "1835": {
        "output": "[heatmaps-ct]: /clinicaltrials-app/public/categorical-tables#categoricalheatmap\n<EOD> .\nA study was made of the effect of pretreatment with the glucocorticoid and a cardiodepressant drug-dihydrothiazine on intestinal motility in cats. It was shown that the glucocorticoid",
        "label": 2
    },
    "1836": {
        "output": "[INST] ### Example: \n`#!$/bin/bash`                        # Run the script\n`#!Linux, MacOSX, ...`                    # Run it on every UNIX-like operating systems\n                                        # `bash`: sh, bash, ksh, ...\n\n`#!/usr/bin/env python3` # Use a POSIX shell to run this python3 script\n                            \n`# Python 3: `python`, `py3`, ``3.7+`\n`# Python 2: `python2`, `py`, ``2.7+`\n\n`python3 test.py [/OPS]/[/NAME]/[/FIRST_NAME]..txt \\#3  \\#278712176..txt 0  0`\n\n\n\n```\npython3 ../../test/test.py [/OPS]/[/NAME]/NAME.txt \\#3 \n       [/OPS]/[/NAME]/[/FIRST_NAME]/eligibility_3.txt\n2) Eligible\n```\n\n\n\n\n[/END]\n<EOD> .\nOBJECTIVE\nto identify sociodemographic characteristics of men and women with dementia in an ambulatory care setting.\n\n\nDESIGN\ncross-sectional study.\n\n\nSETTING\nambulatory care (SACC) of the Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda \"Manuel Velasco Su\u00e1rez\" (NCN-SJ).\n\n\nPARTICIPANTS\npatients over age 60 undergoing treatment or follow-up in the SACC.\n\n\nMETHODS\na sample of 673 patients was recruited through the SACC clinical records between January 2007-July 2009. A total of 76 (11,2%) demented patients were included in the study.\n\n\nRESULTS\n67.2% of patients had cognitive impairment, mainly males with Alzheimer's dementia. Females had a higher incidence of frontotemporal dementia.\n\n\nCONCLUSIONS\nmost demented patients have basic education and",
        "label": 0
    },
    "1837": {
        "output": "<EOD> A new look at the role of the 1G12 monocyte/macrophage adhesion-promoting protein in the generation of tumor-associated fibrosis\n\nIn previous studies the 1G12 protein was identified by immunofluorescence-staining using 1G12-specific monoclonal antibodies (mAb) as a glycoprotein exclusively expressed in human and canine osteosarcomas and in metastases of cancer cells of the colon and prostate (Canary et at. (1984) J. Clin. Invest. 74:1010). Its role in the modulation of cellular adaption, particularly of stromal cells towards the tumor, is still unclear (Mantovani et al. 1991). We therefore characterized the primary structure of 1G12 using specific 1G12-specific mAb in combination with the RNA-Seqeunetz-Mass-Spectrometric and cDNA-cDNA library preparation methods (Kubick et al. 1992). Sequence analysis showed an open reading frame predicted to encode a polypeptide of 183 amino acids with a calculated molecular size of 19.5 kD. It shows homology with the mammalian alkaline phosphatase (AP) and the bacterial tetracycline repressor (tetR). Alignment of predicted polypeptide sequences from human, canine, and mouse revealed very high similarity of amino acid and nucleotide sequences. The results of Northern and Western analysis of 1G12 and AP expression with selected cancer cells and stromal cells, particularly in liver metastases of colon carcinoma and the liver itself, show a very tight and high-grade correlation between the expressions of 1G12, AP and stromal cells, indicating a role of these proteins in the modulation of tumor spread to the adjacent tissues.\n\n# Introduction\nIn several investigations 1G12 expression is seen as an indicator or predictor for metastasis or aggressive tumor growth and thus poor prognosis [bib_ref]  Tumor tissue expression of the 1",
        "label": 2
    },
    "1838": {
        "output": "You made great progress in this task but don't forget to check all the required information that are filled out previously by the doctor on the patients' note.\n\n# Data Structure\nIn this lesson we'll try to create a data structure using classes.\n\nBefore you proceed consider this question:\n\nWhat is your current knowledge of data structures?\n\n- _**Professional experience**_\n- _**C# background**_\nHave you ever created a data structure? _**Yes / No**_  _**How many?**_\n\n_**Professional**_\nIf you know a data structure let's talk about it (also known as \"ad_hoc\") or if you need to create a data structure _**why?**_\n\n_**C# background**_\nIf you don't know anything about data structures let's consider data structrures as a set of data items that are grouped together by some criteria.\n\nLet's consider our application for example. In our application patients' history is needed. We want to retrieve some information about each patient, such as ID, name, age, disease, etc. So a data structure is needed to store all this information in a \"container\" to make it easier to organize it.\nWe can say that patients' history is an object with several properties each one corresponding to some specific information.\n\nWhen we need to retrieve the information of a specific patient, a simple object (for instance a `ContactDisease`) is assigned to a known ID.\n\nWe'll use the `Patient` class to store patients' data and properties we just described. Each patient has a  `patient_id` and our `Patient` class is going to correspond to each patient.\n\n![Data Structure UML: Patient](./app/assets/images/data-structure-uml-patient.jpg)\n\nWe need to know if this `Patient` exists and check if an existing patient already exists in our list with a `bool`, `public bool Exists =>`\n\nAs shown in this UML diagram you'll see how to access the _**ID**_. \nWe need to create an object \"ad_hoc\" and store it in a `List<Patient>` and a check is done if this `Patient` belongs to our already existing",
        "label": 1
    },
    "1839": {
        "output": "Look for lab test and import it. [/",
        "label": 1
    },
    "1840": {
        "output": "There are three cases to check:\n\n\n* *\n\n* [case 1](./img/case1.png) - The patient meet the trial's inclusion criteria.\n\n\n* [case 2](./img/case2.png) - The patient does not have an enough information to qualify for the trial.\n\n \n\n* [case 3](./img/case3.png) - The patient fails to meet a trial's inclusion criteria.\n\nWhen the assessment of eligibility is complete, return the variable result to the previous line, like so `end`.  \n\n**C# Example**\n//[INST] You can modify it.  \nusing System;\nusing System.Collections.Generic;\nusing System.Linq;\nusing System.Text;\nusing System.Threading.Tasks;\n\nnamespace TestAssessmentOfEligibility\n{\n    class Program\n    {\n        static void Main()\n        {\n            //Declarations\n            List<string> patients = new List<string>() {\n                \"The patient is a 55-year-old man diagnosed with HCV 2 years ago infections with HBV\",\n                \"His past medical history is non-significant.\",\n                \"He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications.\",\n                \"His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\",\n                \".\",\n                \"There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease.\",\n                \".\",\n                \"He is an alert male with no acute distress.\",\n                \"His BP: 130/75, HR: 90/min and BMI: 27.\",\n                \".\",\n                \"His abdomen is soft with no ascites or tenderness.\",\n                \".\",\n                \"$$$ Patient-level eligibility=0.1. $$$\",\n                \".\",\n                \"The patient meets inclusion criteria of",
        "label": 0
    },
    "1841": {
        "output": "[INST] Hi. You play a role in assessing the adverse drug reactions (ADRs) based on the clinic notes of the trial.\n\nThere are two aspects of ADR monitoring which are:\n1) Suspected ADR, that is, a reaction of the body to a medication is occurring or has occurred; and 2) Adverse event, that is, a reaction of the body to a medication is occurring or has occurred or any new or worsened signs, symptoms, or laboratory abnormality occurring in a patient during the treatment of a medication or due to an underlying disease.\nIt is important to assess ADRs in a systematic manner in order to be able to make clear clinical decisions based on the clinical experience. It is very difficult to recognize what is an ADR when looking at the clinical trial itself. It is essential to have knowledge about the clinical trial and about the safety report in order to make a reliable judgment.\n\nIn this assessment, the following factors are considered important.\n1. The causality and severity 2. The similarity of the ADRs to the known ADRs in the package insert 3. The possibility of the concurrent occurrence of the ADR and the underlying diseas\nYou are provided clinic notes with the following items:\nHospital Visit Date: 26 Jun.\nAssessor: \u3147\n\nThe trial in which the patient is participating is entitled `Telephone: 0111-234-5678\n\nThe following are information found in the file.\n1. ID: \u3147.\n2. Birthdate: \u3147.\n3. Diagnosis: A trial-level eligibility can be defined as follows.\n\n#### Trial-level eligibility:\n\nThis is a study of glecaprevir and pibrentasvir in the treatment of chronic hepatitis C virus (HCV).\n\nAspartate aminotransferase/platelet ratio index <1 is an accepted marker of liver disease severity. Inclusion criteria define HCV genotype 1a, 1b, 3a, or 4a with high genetic barrier to resistance as the infection of interest.\n\n\nEXCLUS",
        "label": 1
    },
    "1842": {
        "output": "Good luck!\n<EOD> The effect on the cellular immune response of 1\u2010hydroxychloroquine for prophylaxis of malaria\n1\u2010Hydroxychloroquine (HCQ) is not thought to interfere appreciably with immunity when it is used for prophylaxis of malaria. The cellular immune system was studied in a double\u2010blind randomized trial of amodiaquine, artesunate, and HCQ in healthy Vietnamese male volunteers when receiving the drugs for 12 weeks for prophylaxis of malaria. Peripheral blood lymphocytes were assayed to measure the numbers of rosette\u2010forming cells, which indicate lymphocyte activation. These rose from a pretralalment level of between 5\u00b70 and 25\u00b75 % to between 39\u00b76 and 78\u00b77 % at the end of the 12\u2010week treatment period. The results suggest that HCQ does not adversely affect the cellular immune response in Vietnamese subjects for the duration of treatment but this, together with a study of humoral immunity, will need to be confirmed in other groups of subjects in different geographical locations.<EOD> Drosophila 12th has mRNA decay functions in cytoplasmic RNP complexes containing a 150 kDa protein conserved from yeast to human\n\nInsulin-like Receptor Antibody (TSA201) was produced from an M13 phage containing a cDNA subclone of antibody heavy chain. The antibody antigen was a GST-peptide fusion protein containing residues 466-653 of Drosophila insulin receptor (IR). The fusion proteins were used to immunize a New Zealand rabbit (Gilman Laboratories). Hybridoma technology was used to produce the monoclonal antibody; antibody activity was verified by RIA using 125 I-labeled GST-peptide as the antigen (data not shown).RNA Immunoprecipitation Assay and RT-PCR: 5 x10 6 cells (20 oocytes/lane or 700 o",
        "label": 0
    },
    "1843": {
        "output": "You can evaluate eligibility:\n\n```\nEvaluate eligibility on the patient;\n``` \n```\nRename the variables (patient variables);\n``` \n\nThis is the patient note:\nName | Description \n:----|:-------------`<variable_name> | <variable_name 1> -<variable_name 2> <variable_name 3> ...` # Add variable names as they are mentioned in the note (patient variables) \nAge | Current age in years\nPast_medication_history | The total number days of past medication history per day\nTrial_title | Title of clinical trial\nTrial_year | Date and year of trial\nTrial_phase | Phase of clinical trial\nEligible_criteria_1  - Eligible\nExcluded_criteria_1  - Excluded\nNot_relevant_  - Not relevant\nEligibility | Eligibility assessment on the variable named `Eligible_criteria_1` | Excluded | Not relevant \n``` \n\nFinally, we evaluate:\n\n```\nShow trial-level eligibility;\n``` \n\n![Screen Capture 9]({{site.assets}}/images/course_media/2018/eligibility-analysis -1874556088.png) <name>= (14:29:00) eligibility: 2) Eligible.\n\n## The case report\nYou are a radiology specialist, and you want to report a case. This case report is written to meet the objectives of a journal like `Journal of Pediatrics` (a pediatric journal, i.e., child-related journals) as shown in the list of the major medical journals linked to the `Journal of Pediatrics` list:\n\n\n![Journal List]({{site.assets}}/images/course_media/2018/journal list-1874563480.png) `\n[Journal List]`\n\n\nThese are the desired contents of a case report: The patient meets criteria for 26-year-old patient who presents with acute, right arm and leg weakness of unknown eti",
        "label": 1
    },
    "1844": {
        "output": "\u00a9 Copyright CREDES. All rights reserved.<EOD> Preparatory and inhibitory effects of fornix transection on the place representation of post\u2010turn training in the rat\nTHE PLASTICITY of learning was initially demonstrated by Gleitman & Gleitman-Finn (1957) in showing a transfer of training. This transfer was in the form of a post-turn bias, the rat moving in the direction of the wall that had been turned to permit the turn. The place representation was modified if this turn occurred before the training session, and was altered if a new turn occurred before the third training session. It was shown by these authors that the place representation of the turn and the place representation of post-turn training were similar to a particular extent. Thus the post-turn bias involved a new place representation. Further experiments by Gleitman & Gleitman-Finn (1957) have demonstrated that the place representation can change in a single training session. In this case it was shown that if the rat was presented with a choice of two directions before its first training session, the first turn was in the right direction, and if the first choice was to the left, there was a bias to turn to the right or to stay in this left place representation. If the second choice was the same as previously, the bias was changed again, and if the second choice was to the left there was a bias to turn to the left. Hence, again, there was a transfer of learning. From the studies of Gleitman & Gleitman-Finn (1957) and from many others, it can be demonstrated that the memory trace of direction may or may not be stored in the hippocampus (for a review, see T. E . HOLDEN, 1966). We have investigated the effect of fornix transection on the transfer of lateral turn training in order to determine the role the hippocampus plays in the development of this new place representation of lateral turn direction.<EOD> A rare cause of small bowel obstruction on a background of right iliac fossa pain in a renal transplant patient\n\na b s t r a c tRenal transplant patients are at higher risk of bowel obstruction due to increased risk of adhesions as a result of prior abdominal surgery. This case",
        "label": 0
    },
    "1845": {
        "output": "<jupyter_code>def AssessInclusionCriteria(clinical_trial_id, patient_note):\n    if clinical_trial_id == \"\" or patient_note == \"\":\n        return \"Please enter eligibility input\"\n\n    print(\"Your task is to compare the patient notes and the clinical trial to determine patient eligibility.\")\n    print(\"The factors that allow someone to participate in a clinical study are called inclusion criteria.\")\n    \n    inclusion_criteria_output = 'The patient does not meet all inclusion criteria of the trial. Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).\n    if \"Patient does not meet inclusion criteria of the trial.\" in patient_note:\n        print(\"Please enter Trial-level assessment [0, 1, or 2]:\")\n        trial_level_assessment = input('Trial-level assessment: ')\n        trial_level_eligibility = 'Triallevel_eligibility:\n\n        if trial_level_assessment == 2:\n            print(\"You are eligible for this trial.\")\n            print(\"You are not excluded by any of the trial's exclusion criteria.\")\n    else:\n        print(\"The patient meets all inclusion criteria of the trial, and there are no exclusion criteria of the trial.\")\n        trial_level_eligibility = 2 # Eligible\n        return trial_level_eligibility \n    \n    if 'Trial-level assessment: ' not in patient_note:\n        print(\"Please enter Trial-level assessment [0, 1, or 2]:\")\n        trial_level_assessment = input('Trial-level assessment: ')\n        trial_level_eligibility = 'Triallevel_eligibility:\n\n        if trial_level_assessment < 2:\n            print('You are not excluded by any of the trial's exclusion criteria.')\n            print(\"You are eligible for this trial.\")\n            print(\"Trial-level eligibility: \", 2)\n\n        else:\n            print(\"Sorry, the patient is not eligible for the trial because the patient",
        "label": 0
    },
    "1846": {
        "output": "You will get to work with various data sets of clinical trials and patient data in the medical domain, such as disease status (e.g., HIV infection). For these data in a trial, you should be familiar with the following general concepts.\n\n## Disease\n\n# Description_of_Target_Condition_and_Population_of_Patients\nEach disease has multiple phenotypes that can be either normal or abnormal. The normal phenotypes are called `disease statuses`. A patient who has a disease of interest is called a `patient`, and the patients infected with this disease are called `target patients`. One patient may have multiple diseases (target diseases), and one disease may have multiple patients (target patients). `Target patients` do not have to be identical in the `disease', although they may be similar.\nFor your task, if a patient has a certain disease, you should input the corresponding target disease for that patient.\n\n## Diagnosis\n\n# Description_of_Disease_Status_and_Disease_Concept\n`Diseases` have a disease status that indicates normal or abnormal levels of a disease. The values of a disease status are usually classified into several levels, such as mild, moderate, severe, and critical. A disease status usually represents the severity of a disease. For instance, cancer and AIDS are both diseases, and the abnormal cancer patient is also an abnormal AIDS patient. Both of the two diseases can have the same or different disease statuses or can have more than one disease status. Therefore, when a patient has a disease, his or her disease status must be determined.\n\n## Prognosis\n\n# Description_of_Disease_Status_and_RisK_of_Disease_and_Outcome\nAfter a patient has a disease, his or her disease status may change in a given direction, such as improvement or worsening, over time (e.g., during treatment of a disease). Therefore, a patient can have a prognosis for his or her disease status. A prognosis represents the direction of change in disease status, including the expected value of the change in a patient's disease status and the percentage of patients whose disease status will improve or worsen.\n## Symptom, drug",
        "label": 1
    },
    "1847": {
        "output": "[END]<EOD> Surgery for severe congenital heart valvular/cardiac diseases in Turkey.\nPURPOSE\nA surgical center providing services such as diagnostic and interventional procedures, as well as cardiac surgery, has been established in Turkey since early 2003. The purpose of this study is to determine the surgical intervention results of the center.\n\n\nMETHODS\nThis study is a retrospective, descriptive, cross-sectional study. The subjects of the present study constituted a total of 116 patients (55 males, 61 females; mean age 23.6\u00b134.9 years; range 1 to 75 years) with congenital severe valvular heart disease and undergoing valvular replacement surgery at the cardiovascular surgery clinic of the University of Health Sciences Antalya Faculty of Medicine, between January 2003, and December 2007. Statistical analysis was performed using the IBM SPSS Statistics 21 computer program.\n\n\nRESULTS\nThe mean follow-up period after valve replacement was 13.74 months (1 month to 3 years). The rate of 30-day and 6-month mortality were found respectively 6.0% and 12.9%. The survival rates at the end of one, 2 years and 3 years were 97.4%, 95.6%, and 95.6%, respectively.\n\n\nCONCLUSION\nThis study suggests that mortality and morbidity rates of patients with congenital heart valve failure who underwent operation in this center can be considered similar to the rates of other similar national institutions.<EOD> PD-L2 Blockade Enhances Tumor-Specific T Cell\u2013Mediated Growth Inhibition of Human Colorectal Cancer Xenografts in SCID Mice\nPurpose: Immunotherapy is a promising treatment regimen for colorectal cancer (CRC), as CRCs are frequently infiltrated with activated T cells. Together with programmed death (PD)-1, programmed death-ligand (PD-L)1, PD-L2, B7-",
        "label": 0
    },
    "1848": {
        "output": "Examples: \nYou can see the example at [ex1] (click ''run the code'') in the next pages. \n\n\n\n\n![INST] A patient note\n![INST] A clinical trial\n![INST] Trial-level eligibility for a patient\n  \n\n\n![INST] The main text of the report\n\n\n\n\n\n\n* * *\n\n\n## Step 1: create a patient note\n\n* * *\n\n\n\n* * *\n\n* * *\n\n\nCreate a table in Note.java with one row, columns: PatientID (1-999) and Patient_Name (a sample of some names). \nEdit the main class:\n\n```java\npublic void calculatePatientNote(){\n\n//Creating the note\nNote note=new Note(150001,\"Patient 1\");\nNote.add_PatientID(1);\nNote.add_Patient_Name(\"Patient 1\");\n\n\n//Creating the first row\nrow_id=getId_of_Row(\"Add row_patient\");\n\nNote.setPatientID(row_id);\nNote.add_RowName(\"Patient_1\");\n\n\n//Adding the body paragraph\nbody=getContent_of_Paragraph(\"Insert body\");\nNote.add_Note(body);\n//Get content_of_TextField(\"Add text_note) with blank body and text\nTextField text_note=get_text_Field(\"150001\");\ntext_note.add_text(\"1_Patient_1\");\ntext_note.add_text(\"2_Patient_1\");\ntext_note.add_text(\"3_Patient_1\");\ntext_note.add_Text(\"4_Patient_1\");\ntext_note.add_Text(\"5_Patient_1\");\ntext_note.add_Text(\"6_Patient_1\");\ntext_note.create_Note_Field(\"7_Patient_1\");\ntext_note.add_Text(\"8_Patient_1\");\ntext_note.add_Text(\"9_Patient_1\");\ntext_note.add_Text(\"10_Patient_1",
        "label": 0
    },
    "1849": {
        "output": "<EOD> Biliary and Hepatic Intra-Arterial Chemotherapy for Solitary Liver Metastases\nBetween 1984 and 1994, 21 patients with previously untreated colorectal adenocarcinoma, with extrahepatic disease or bilobar hepatic involvement, underwent biliary and hepatic intra-arterial chemotherapy (IAC). In patients with extrahepatic disease, IAC was performed prior to any treatment of extrahepatic disease. IAC consisted of a double catheterization through which 5-fluorouracil is injected, plus a single catheterization through which mitomycin C is injected. If the tumor is near the liver capsule, a fine catheter is also placed into the biliary tree, through which mitomycin C is injected. For patients who undergo chemotherapy in the absence of detectable liver tumor or in those patients who demonstrate a partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) after IAC, a resection is performed. A total of 27 resections were performed; 15 were major liver resections and 12 were lesionectomies. One patient had a minor hepatic resection to remove a lesion that became more clinically significant after IAC. Forty-four extrahepatic disease procedures were performed. Eighty-one percent of the patients had extrahepatic disease present before the IAC. There were seven major resections and 37 local resections to the extrahepatic lesions. The perioperative mortality rate was 4%. The average intraoperative blood loss for patients having a major resection before IAC was 2 L and for patients having a resection after IAC was 2.25 liters. Average tumor size before IAC was 6.4 cm and 5 cm after IAC. The most common complications were ascites (66%) and wound problems (33%). In conclusion, hepatic and biliary chemotherapy before or after liver surgery is safe and effective. The morbidity associated with biliary chemotherapy was negligible in these patients",
        "label": 0
    },
    "1850": {
        "output": "> ## 5) Output.\nNow, in the output function, you should print all 9 variables from the training record and the last Trial-level eligibility: <EOD> Laryngeal electromyographic changes during swallow, phonation, and deglutition.\nA laryngeal electromyograph was used to study the response of the posterior cricoarytenoid (PCA), lateral cricoarytenoid (LCA), external cricoarytenoid (ECA), arytenoid, and vocalis muscles of the larynx to electrical stimulation of extrinsic muscles. The electrical potential on the posterior cricoid was also noted. In 53 subjects, musculolaryngeal latencies were measured during phonation, phonation with swallow, and swallow with deglutition. The PCA response was found to be the most synchronous and most predictable. Although it responded similarly to stimulation of all 4 muscle groups, it occurred at shorter latencies than for any other groups. The findings confirm the use of latencies as a method to distinguish vocal fold activity. It was also found that vocal fold activity was inhibited during all but phonation with deglutition.<EOD> Treatment of acute decompensated chronic heart failure with perindopril in patients over 75 years of age.\nOBJECTIVE\nThe aim of the study was to determine the effect of ACE-inhibitor (perindopril) on cardiac function and on the number of hospitalization days in patients over 75 years of age with acute decompensated chronic heart failure.\n\n\nDESIGN AND PATIENTS\nThe study comprised 42 patients with the average age of 79 years, treated in the Pulmonology Department of Pomeranian Academy of Medicine in S\u0142upsk, Poland. The patients were divided into two groups: one group received standard therapy, which included ACE-inhibitors (perindopril). The other group received standard therapy, which included diuretics, cardiotonics, nitrates and ACE-inhibitors (perindopril). The study was conducted in 70 patients (10 patients dropped out from",
        "label": 0
    },
    "1851": {
        "output": "</td></tr></table>\n### RESULT 3\n[TRAINER] Good job. Keep in mind that the three levels of eligibility are 0) Included, 1) Not Included, and 2) Not Applicable.\n\n</td></tr></table>\n### TUTORIAL 6 PROBLEM 4\nProblem\n\nIn this step, you will work in the same file as in Tutorial 5. There are seven input lines as in Step 1 and input lines show patient notes as usual. The first four patient lines are incomplete/missing information (input lines 1.5, 2.5, 3.1, 3.6).\n\nThe target table is in the new csv file as usual. As you can see below, the table has six columns: the patient ID, patient notes, title, inclusion criteria, trial-level\n\nevaluation and eligibility.\n\n![](./images/tutorial-6_p4.png)\n\n\nThe inclusion criteria is a JSON-format and there are three parts to it: 'inclusion', 'exclusion' and 'excluded_on'. First, we have the patient notes by the input lines. We should make them into JSON objects. Please be careful to add input lines 1.5 and 2.5 since the new patient notes must be appended. Remember that the last one, input line 3.5 has not been added yet. Then, we should convert each inputted patient note into its corresponding JSON. Please see below to convert two patient notes, input lines 1 and 3.\n\n![](./images/tutorial-6_p4.png)\n\n* Step1: Make the patient notes (1 ~ 4 lines as above) to be JSON-formatted JSON below. \n* Step2: Call the Trial function again based on the updated patient notes. The result is shown in \n![](./images/tutorial-6_p4.png)\n   \n### TUTORIAL 6\nPROBLEM 5 \n\nIn this problem, you should convert the above patient notes with 1 ~ 6 lines. The JSON-formatted patient notes are shown to the right of input lines. You should work on the same file. We should input the new patient notes to the",
        "label": 0
    },
    "1852": {
        "output": "[SECOND] What about the first screening? You need to identify who is eligible.\n\n### Instructions\n\nLet's think step by step. \nYou know the two patient factors. If the patient's gender is `female`, skip the `Blood type`. On the other hand, if the patient's gender is `male`, check the patient's blood type. \nHit the `next` button to proceed to the blood type. \n```\nif (gender is Male) {\n    println(\"Blood type: \")\n} else {\n    println(\"Gender: \")\n}\n```\nThere are five types, A, B, AB, HH, and O. You need to identify which type the patient belongs to. `HH` is a group that is included in the definition of `O`. So if the blood type of a patient is HH, it turns out to be O type. If the blood type of a patient is anything other than `HH`, you should call the function, `blood type`. If the type defined by blood type is anything other than HH, then it turns out to be O. \n```\nif (gender is Male && blood type is HH) { \n    println(\"Gender: \" + gender + \", Blood type: \" + blood type + \",Type: \" + typeOfBloodType(blood type))\n} else if (blood type is HH) { \n    typeOfBloodType(blood type) \n} else if (blood type is A) { \n    println(\"Blood type: \" + blood type + \",Gender: \" + gender + \",Type: \" + typeOfBloodType(blood type)) \n} else if (blood type is B) { \n    println(\"Blood type: \" + blood type + \",Gender: \" + gender + \",Type: \" + typeOfBloodType(blood type)) \n} else if (blood type is O) { \n    println(\"Blood type: \" + blood type + \",Gender: \" + gender + \",Type: \" + typeOfBloodType(blood type))  \n} else if (blood type is AB) { \n    println",
        "label": 0
    },
    "1853": {
        "output": "<NAME>\nCopy-pasted from Moodle:\n[TUT09_ELIG06]\n\n[ELIG_HANDSON]\n\nYour first task will be to determine which patients are eligible for the clinical study \"Effect Of DAAs For Treatment Of HCV On Normal Kidney\" by comparing their notes against the inclusion criteria. \n\n\n1. Open the file \"eligibility.tsv\".\n    You may need to double click.\n\n    \n2. Look for the patient name, i.e., `Male, 48 years old` and make a note of that.\n\n3. Now, open each note line by line.\n    - Each note line contains one patient's information:\n        - The columns are: patient ID (e.g., `P_1`) \n             - Patient ID is used to identify patients and is unique for each patient.\n             - Patient ID will be used later in the R code we create in the `ClinicalTrials` package in the next step.\n        - Patient name, age, and gender\n        - the past medical history in the past months (e.g., 6 months)\n         - e.g., 9.7.23 = `Disease: Hypertension`\n        - patient's medical history of drug, disease, and other information (e.g., history of kidney disease).   \n        - Note that, you will work with the information of the patient that you can easily reach and access.\n    - Open each line number by line number from top to bottom and check each patient's notes to see if their information of your notes matches the inclusion criteria of the \"Effect Of DAAs For Treatment Of HCV On Normal Kidney\" clinical study.\n    - We only focus on 3 levels 0) Excluded, 1) Not relevant, and 2) Eligible. There is no need to read the notes carefully and to record the number of excluded notes, as the number is determined on the basis of the patient's notes without having to read them in detail.\n\n4. The last thing we need to do is mark the 3 levels and write them in the last line of the note in the \"eligibility.tsv\" file.",
        "label": 1
    },
    "1854": {
        "output": "### <NAME> - the EPIC model\n\nThe EPIC model is designed to represent a clinical trial eligibility decision.\n[INST]\nHere is the patient note. \nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema. \nLet's think of the patient. \nThis patient is infected with Hepatitis B and C, and has a history of HCV coinfection. As a result, his medical notes show the results of previous HCV RNA tests and a positive result for anti-HCV-antibodies, which can be used as indicators to estimate the HCV viral burden. A recent negative biopsy result exempts the patient with liver cancer, which might influence the eligibility evaluation. The patient is well with regard to all medical tests, including abdominal examination, BP, heart rates, and blood tests, including blood cell counts. His medical history and laboratory examination are non-significant. \nHowever, his medical history is consistent with an age of older than 20. He has not been drinking. His medication history demonstrates that he has been undergoing the treatment of hepatitis virus infection.\nThe patient is alert, and his vital",
        "label": 0
    },
    "1855": {
        "output": "## Tip 12. In some cases, the following commands may be needed:\n- `code_in_text_file: `\n- `code_in_text_file` adds the given text file to the input of the function and assigns a number 1 to the text file object that can be used with other functions within the script to refer to the same input file. In this command, you should specify a path starting with the folder in the current working directory 7.\n- `recode_in_text_file: `\n- `recode_in_text_file` command adds the given text file path to input and uses it to replace all words, numbers, and/or letters by another one in the file. 8.9.1 \n\n## Concluding remarks 8.10\nThank you for your patience during this course on `Learn to Code' and the following course on `Learn Phenomenological Programming' (LPP) with Python. 9.1. LPP is presented as an intermediate course to teach the philosophy and methods of qualitative research in clinical psychology. In the present study, we describe the methods of this course along with its content and provide some instructions to facilitate the learning of the participants. However, we have not described the course content in depth. This course focuses on the development of the necessary theoretical and skills in the field of qualitative research methods to facilitate the learning of qualitative research from an applied psychology point of view. In fact, in the present course, the aim of the learning is to prepare the researcher to be prepared to identify the qualitative research problems, formulate research questions, design the research, perform and present a qualitative research study with the necessary methodological rigor to produce scientific and research-based solutions.\n<EOD> Neuroprotective effect of the methanolic calyx extract of Zanthoxylum schinifolium fruit against glutamate\u2010induced apoptosis\nNeurodegenerative disorders and neurological diseases lead to a variety of neurological dysfunctions. Many studies have examined the effects of medicinal plants as natural neuroactive compounds that effectively protect the nervous system from diverse neurological dysfunctions, such as Alzheimer's disease, Parkinson's disease, and",
        "label": 0
    },
    "1856": {
        "output": "## Question\n\n**Assessment and response: 1**\n\n## What is the main difference between your trial-level eligibility and the patient-level eligibility? Assessment and response: 1\n\n### Patient-level eligibility:\nThe overall level of the eligibly of the patient on the criteria of a clinical trial. The main criteria of trial-level eligibility and patient-level eligibility are the same. Patients who are eligible for the trial, but meet exclusion criteria are not evaluated by patient-level eligibility.\nExample: If a patient's overall level of eligibility is 1 (eligible), 1 means that the patient is ineligible for the CKD trial. Therefore, the patient is still eligible for the ESRD trial.\n\n### Trial-level eligibility:\nThe level of the patient's eligibility and the assessment of the clinical trial. To assess the patient's trial-level eligibility, you are expected to evaluate the patient's eligibility by patient-level eligibility, considering the trial's inclusion and exclusion criteria. Then, the assessment will give a scale for the assessment of eligibility for the trial-level eligibility by patient-level eligibility. **Rationale Explanation**\n\n## What is the patient-level eligibility?\nThe overall level of the eligibly of the patient on the criteria of a clinical trial.\n\n## What is the trial-level eligibility?\nThe level of the patient's eligibility and the assessment of the clinical trial.\n\n\n## What is different in assessing trial-level eligibility to your trial-level eligibility? Please explain.\n\n## What is the level of the patient's overall eligibility to the criteria of a clinical trial?\nIf the patient's overall level of eligibility is 2, he/she is excluded as a patient for the clinical trial, because the patient meets the trial's exclusion criteria. If the patient's overall level of eligibility is 0 (excluded) or 1 (not relevant), the patient is excluded from the trial, as the patient does not meet the trial's inclusion",
        "label": 0
    },
    "1857": {
        "output": "The patient note to be matched.\n\t\t\n\t\tThe patient's details in the trial eligibility assessment.\n\t\t\n<EOD> Dental caries and its control.\nThe prevalence of and methods for controlling dental caries may differ considerably in different parts of the world. Recent studies concerning the causes of dental caries and methods of preventing and treating dental plaque have stimulated interest in the control of the disease. This interest is reflected in the work reported in this symposium; it consists of 13 presentations arranged by topic of special interest in order to focus attention in both the United States and the foreign countries participating in the symposium.<EOD> Long-Term Effects of Neural Cell Adhesion Molecule on Plasminogen Activator Inhibitor 1 and Tissue-Type Plasminogen Activator Levels.\nOBJECTIVE\nNeural cell adhesion molecule (NCAM) is expressed in the heart, including in endothelial cells, and plays a role in cardiovascular diseases, but its relevance to the proteolytic system has not been defined. In the present study, we investigated the effect of NCAM deletion on the fibrinolytic system in knock-out mice.\n\n\nMETHODS\nCardiac function was assessed by hemodynamic study in Langendorff perfusion. NCAM localization was evaluated using fluorescent immunochemistry. ELISA was used to determine levels of tissue-type plasminogen activator (t-PA); its inhibitor, plasminogen activator inhibitor type 1 (PAI-1); and related prothrombotic and fibrinolytic proteins in myocardium and plasma.\n\n\nRESULTS\nWe found reduced ejection fraction and diminished fractional shortening in the NCAM knock-out animals compared with wild-type mice. Histological analysis showed myocardial fibrosis in the knock-out. NCAM accumulated at the cell surface of capillaries where it co-localized with the vascular marker Tie2. Levels of PAI-1, thrombin, and vascular endothelial growth factor (VEGF",
        "label": 0
    },
    "1858": {
        "output": "## Case III:\nPatient:\n```Pandas\np = pd.Series(age.astype(float))\n\np.to_csv(\"Test3.csv\") #save patin data in .csv file\n```\n# Results:\n```\n   1\n   2\n   3\n  325.0\n  None\n  105.0\n   5.0\n   0.0\n  142.5\n```\n\n## Case IV:\nPatient:\n```Python\npatient = input(\"Please enter birth year: \")\npatient = float(patient)\npatient = patient * 100 if patient.startswith(\"+\") else patient\n#Convert float number",
        "label": 0
    },
    "1859": {
        "output": "<EOD> .\nExperiments with 30 male rats with the use of the immunoelectrophoretic technic and microfluorimetric analyzer made it possible to evaluate the content of the 1:498 and 1:43 complexes in the aqueous humour, blood serum and intraocular fluid (aqueous and vitreous), the 1:43, 1:498 and 1:497 complexes in the vitreous fluid. The data obtained testify to the presence of intracellular and secreted immunoglobulins in the eye tissues as well as to the possibility of using the 1:43, 1:498 and 1:497 complexes as indices for functional changes of the humoral immunity system as well as for its local pathological processes in the eyes.<EOD> 5,6-Dihydroimidazo[1,2-\u03b1]pyridine-3-propanoic Acid (DHPPA): An Aromatic Cage-Like Building Block for Polyheterocyclic Systems. Scope, Synthesis and Medicinal Potential\n\nHerein, we report the synthesis and structural investigation of 5,6-dihydroimidazo[1,2-\u03b1]pyridine-3-propanoic acid, followed by the development of one-pot multistep synthesis of benzimidazoles, imidazoles, benzothiophenes, and dihydroquinazolines containing 5,6-dihydroimidazo[1,2-\u03b1]pyridine-3propanoic acid. Moreover, synthetic and medicinal potential of this molecule is evaluated by the molecular docking and in vitro cytotoxic assays.ARTICLE HISTORY\n\n# Introduction\nAn ideal drug should exhibit high activity to biological target, and at the same time it should be characterized by acceptable pharmaceutical properties, such as high metabolic solubility and/or bioavailability, and it should be safe, to minimize adverse effects.\nIn pharmaceutical chemistry, benzothiophene [bib_ref]  Synthesis of 2-arylbenzim",
        "label": 1
    },
    "1860": {
        "output": "### Exporting Patient's Information\n\n### 1. `Export` > `Export > Patients > To CSV`\nYou can save patient notes as a CSV file and create a report. You can select rows and columns individually to determine what will be exported. Here is an example: Export 5 patient notes and then select 2 columns including name and age.\n\n### Exporting Trial Data\n\n### `Trial summary > Export`  or  `Export > Summary > Trials > Export`\nWe are going to extract the name of the trial into excel. This is how you do it:\n> Exporting all data is not recommended because it includes a lot of redundant data and it is impossible to get a clear view of the data after copying it to an excel file. Also be aware of any special characters or encoding problems in the exported file.\n\n### 1. `Trial summary > Export` \n> Export the summary trial data as a CSV file, e.g., `Export > Summary > Trials > Export > Text File(CSV)`.\n\n### 2. `Export > Summary > Trials` > (Select) `TrialName` \n> Copy the trial name from the result box in the top of the page. Be aware of any special characters. Copy-paste to a note pad and save the file.\n\n### 3. `Export > Summary > Trials` > (Select) `HIV/HCV Eligibility` \n> Copy the trial eligibility from the result box in the top of the page. Be aware of any special characters. Copy-paste to a note pad and save the file.\n\n### Exporting Summary Patient's Data\n\n### 1. `Print summary report > Patient's Data > Export`\n> Export the summary patient's data as a CSV file, e.g., `Export > Summary > Patients > Export > Text File(CSV) The file looks like this:\n\n###  \n``` {start_of_html}\ntrialName;patientID;birthDate;birthCountry\nTest;Test2;Test3;Test4;Test5;Test6;Test7 \nHIV/",
        "label": 0
    },
    "1861": {
        "output": "___\n<a name=\"problem\"></a><!-- DO NOT DELETE THE SOLUTION CORRESPONDING DIRECTORY/DIRECTORY DEFINITION BELOW -->\n<h2>Problem</h2>\nIf you think of a better way of representing patients or trials, please submit your new format at <a href=\"https://github.com/lizzyhannah12345/Medical-Approach-Project/pull/new\">https://github.com/lizzyhannah12345/Medical-Approach-Project/pull/new</a>. It is a good idea to add a comment to explain why the current format is problematic to allow us to consider it.\n__\n\n___\n<a name=\"help\"></a><!-- DO NOT DELETE THE SOLUTION CORRESPONDING DIRECTORY/DIRECTORY DEFINITION BELOW -->\n<h2>Help</h2>\nI am Liz, and I am the teaching assistant for this project. I will answer your questions here (not your instructor, <NAME>). If you have any questions or concerns, please send me an email to <EMAIL>. <br />\nI will answer within 24 hours, Monday through Friday. <br />\nIf you have problems using codeforces, please post a request on [this page](https://www.codeforces.com/help/faq.html#7).<EOD> Effect of long-term treatment with inhaled budesonide on bone mineral density in mild-to-moderate asthma\nAim Although the risk of osteoporosis is well recognized in patients with severe asthma, the effect in patients with milder forms is poorly described. The aim of this study was to investigate the effect of long-term treatment with inhaled budesonide on systemic bone mineral density (BMD) in patients with mild-to-moderate asthma without previous episodes of severe acute bronchospasm. Methods The study comprised 25 mild asthmatic patients (24 men, 1 woman) with mean (SD; range) age of 32.8 (15.0; 16\u201364",
        "label": 0
    },
    "1862": {
        "output": "## Experimental Design, Materials and Methods\nWe use Python code via Spyder to compute the data for the trial. We develop the program by using the Python script writing. The process is as following:\n\n## 1.\nTo get the training data for the model, we download the data from the Kaggle data repository.\n\n## 2.\nUsing the provided data and the Python script, we analyze all the features in the data through Python.\n\n## 3.\nTo test the model, we try to use the trained model on an independent testing dataset and calculate the accuracy.\n\n## Data and source code\n\n## Kaggle data repository\nThe Kaggle data repository  includes the two files: \n\n## Model design and implementation details\n\n## Feature engineering\nWe need to perform feature engineering in order to get useful information of all of the features based on clinical rules. These features are extracted to help the CNN model to understand the clinical rules and the patients' conditions.\nHere are the definitions of the features used in the model:\n\n## Data shuffling\nIn this study, we use two methods to generate training, validation and testing data. To get a fair comparison, we want to generate the training data by the same method that we applied in the validation and testing data (i.e., shuffling the training set for a fairer comparison). By generating the training data from the same subset of the training set, we can compare the performance of the model on the exact same sample.\nTo keep the performance comparison as fair as possible, we use the same data shuffling methods for the validation and testing data. In the training data shuffling, we are required to use a shuffling method which can shuffle the indices of the training samples without shuffling their order in the training set.\n\n## Data splitting\nIn this study, we use the k-fold validation method with k = 10 to compute all of the metrics. The results of the 10-fold cross-validation are represented using average values from the 10 rounds of the validation.\n\n## Machine learning model implementation\n\n## Convolutional neural network (cnn)\nWe implement the CNN model using the Keras library in accordance with our data characteristics. The CNN model architecture has five main functional components: input layer, convolutional layer, fully connected layer,",
        "label": 0
    },
    "1863": {
        "output": "__NOTES__\n\n[NOTE2::\nWhen you are filling in the trial-level eligibility, you will come across information regarding the age of the patient. The age parameter contains a range of values that can be used as age thresholds. The eligibility of the patient will always return in the upper part of your patient note. The lower part of the patient note shows the age parameters that are currently enabled for the patient.\n\nThe parameters age_inclusive and age_exclusive contain age ranges that are used to select the value that is stored. These two parameters will always store the lowest value that is included and the highest value that is excluded. ]\n\n[NOTE3::\nThe values in age_inclusive and age_exclusive can be updated by clicking the button directly above the age parameter. The minimum and maximum values will be updated. By clicking `Reset values` all previously entered values will be cleared and new values will appear in the box. ]\n\n[NOTE4::\nThe parameter gender can only be set as male or female. This parameter is part of the inclusion and exclusion criteria. ]\n\n[NOTE5::\nThe parameter diagnosis_date is used for the diagnosis time. For this parameter, you can select a standard date, a past event, or a future event. You can also copy a date from the calendar function or drag and drop the value from a parameter to this field. ]\n\n[NOTE6::\nEach clinical trial will have some parameters that are fixed and some parameters that can be changed. Fixed trial parameters consist for instance of the trial-related information and the trial-level eligibility assessment. Changing of parameters requires the active checkbox and can be done by clicking on a drop-down menu. ]\n\n[NOTE7::\nYou can change the trial-level eligibility on the trial level and at the patient level. You can change the trial-level eligible value by clicking `Included!` on your parameter selection. The patient-level values are then overwritten by this value.]\n\n[NOTE8::\nWith the trial-level excluding values on a specific parameter, all patients who do not meet this inclusion criteria will be excluded from that specific trial. ]\n\n[NOTE9::\nIf you want to select a treatment regimen, then you can click `Select",
        "label": 0
    },
    "1864": {
        "output": "[[\n\n---\n\n<a id=\"ex13-1-3\">[inst-1]</a>\n<a id=\"ex12-2\">[1111]*</a> <NAME>, <NAME> A, <NAME> A, Vijay Krishna<NAME>, <NAME> and <NAME> - a clinician's checklist for antibiotic therapy for adults with community-onset pneumonia. J Antimicrob Chemother 2010;65:2267\u201377. doi: 10.1093/jac/dkq369. PMID: 20837486 <span class=\"n\">[[Excerpt: 41-45; 280-291 (antibiotic therapy for adults with community-onset pneumonia)]]</span><span class=\"s\">[[Trial-level eligibility: Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); Not relevant (patient does not have sufficient information to qualify for the trial); Eligible (patient meets inclusion criteria and exclusion criteria do not apply)]]</span><span class=\"c\">[[Excerpt: patient note.]]</span> <span class=\"z\">[[Excerpt: a person who understands the experiment and has a willingness to participate and signs the agreement; chronic stroke patients; a person has the full consciousness and can do a basic mental activity, such as answering questions and communicating; chronic stroke patients are over 3 months post-stroke; a person is informed of the experiment and signs its consent.]]</span> <span class=\"z\">[[Excerpt: the patient's 40s; the patient with diabetes; the patient who is obese for the past 10 years; the patient who is diagnosed with HCV 2 years before; the patient with positive for HBV antigen.]]</span> <span class=\"z\">[[Excerpt: a person diagnosed with HCV 2 years ago and the co-infection with HBV; the patient diagnosed with hepatocellular carcinoma; the patient who is diagnosed with",
        "label": 0
    },
    "1865": {
        "output": "## Instructions\n\n* You can refer to the answer of Sample 11 for more detailed guidance.\n\n* Do not repeat all the steps. You should repeat the following 3 parts.\n\n## 1) You are required to answer for each candidate in a single line and you should include the corresponding output lines. If the candidate is an incorrect answer, then you should specify where he is wrong. In Sample 12, you must specify that the patient takes no other medications.\n\n* Sample 12\n[CANDIDATE] Patient 13 [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n\n\nPatient is a 68 year old female diagnosed with chronic HCV. Her past medical history is notable for coronary artery disease with myocardial infarction in 2010, angina, and asthma. She is a former smoker of 40 pack-years and has chronic obstructive lung disease. She is on aspirin, levothyroxine, albuterol PRN, simvastatin and metoprolol. Her medical history is notable for type 2 diabetes mellitus with controlled blood sugar and hypertension. She is on anti-hypertensives including lisinopril, losartan and amlodipine. Her medical history is also notable for atrial f",
        "label": 0
    },
    "1866": {
        "output": "[Back to top]\n\n### 3. [TEST] Eligibility decision by the inclusion criteria\n[/TEST]\n\nNow you will again compare patient notes with inclusion criteria. But this time you will be asked to assess and code patient-level eligibility by filling in the blank space at the end of the following cases:\n\n---\nExample case 1:\nSally is 26 years old. She is a university student. Sally has finished HSC exam. She is suffering from bronchial asthma that was diagnosed 18 months ago. The disease is under control with the treatment of an ICS and SAMA. Sally is admitted to the hospital for the tonsillectomy. On examination Sally is alert with stable vital parameters.\n\nIn the physical examination no abnormal findings were detected, except for a mass protruding from the right tonsil. It is red and tender. Her tonsils and adenoids are enlarged.\n\nLaboratory investigation shows normal values of Hb, Hct, TC, DC, Tg, PSA, SGOT, SGPT, LDH, alkaline phosphatase, cholesterol, albumin, bilirubin, A/G, blood urea and serum uric acid. Sally is on treatment with MDI combination of salbutamol and budesonide. Her history is otherwise unremarkable.\n\nSally is suffering from bronchial asthma that is under control with her treatment. Her tonsillectomy operation is planned before starting her new studies.\n\n\nIs Sally eligible for the operation?\nYes (Eligible) No (Not eligible)\n\nSally is suffering from bronchial asthma that was diagnosed 18 months ago. The disease is under control with the treatment of an ICS ...\n\nSo Sally's eligibility has changed since she has been diagnosed for bronchial asthma. The case is marked as `Eligible`. [/TEST",
        "label": 0
    },
    "1867": {
        "output": "<EOD> Detection of bacterial communities in fresh produce carcass soil\nAims:\u2002 To identify potential hazards at the farm level and investigate if the farm (soil) can act as a source of bacteria contributing to microbial contamination of leafy vegetables during the processing of leafy vegetables.<EOD> Surgical treatment of hepatocellular carcinoma.\nFor the purpose of obtaining a long-term survival, hepatectomy for HCC was done according to the following conditions. (1) The total number of lesions should be limited, and all should be less than 5. (2) The bilateral lobe should be reserved, and the left lobe should be maintained for an additional metastasis. (3) Intrahepatic metastatic lesions should be less than 5. (4) Intrahepatic metastatic lesions were restricted to a part of the liver. (5) A patient whose blood flow to the unreserved lobe was unstable should be operated under the condition that liver failure did not occur postoperatively. If all these requirements are satisfied, a long-term survival is obtained in about 70% of the cases. Although the majority of patients who have undergone surgical removal have an intrahepatic metastases, a long-term survival has been obtained in most of the cases. If a patient has received surgical removal, the long-term survival can be obtained in more than 90% of the cases if all these requirements are satisfied.<EOD> Flexible electrodes for enhanced neural recording applications\nAn improved version of a flexible electrode technology is presented and tested. The flexible electrode consisted of an electrode shank, comprised of platinum wire and titanium cladding, and a semi-flexible sheath made of a polymethylmethacrylate (PMMA) acetate plastic, which was adhered onto the platinum/titanium wire with a UV-curable adhesive. Two types of electrodes were characterized and tested in the laboratory, one with conventional epoxy adhesive and another with the polymer adhesive. Results showed that the use of the semi-flexible electrode reduced the force required to indent the electrode by up to 6",
        "label": 2
    },
    "1868": {
        "output": "<EOD> Effect of Sodium Dodecyl Sulfate on the Biphasic Transformation of L-Type Lead Ion under Oxidizing Conditions at Low Concentrations.\nThe biphasic transformation of L-type lead ion was evaluated at a low concentration (0.01 mM) in an aqueous medium at pH 2 by the addition of 0.01 mM sodium dodecyl sulfate (SDS) under oxidizing conditions. Under these conditions, lead hydroxide  and lead peroxide  were predominantly formed. In the presence of SDS, the formation of these Pb species was more enhanced by SDS than that in the absence of SDS. The concentration of L-type lead ion was significantly decreased in the presence of SDS compared with the solution without SDS, where Pb(OH)2 and Pb3O4 coexisted for a prolonged time. The concentration of soluble Pb species in the solution was increased with the addition of SDS for a longer reaction time than that without SDS from the X-ray absorption fine structure measurements, even for a reaction time longer than three weeks. The Pb(II)/Pb(IV) redox potential in the solutions decreased from 0.81 to -0.25 volt as the reaction proceeded for 168 h because of the formation of Pb(OH)2 that had a high redox potential. These results indicate that the addition of a small amount of surfactants to aqueous solutions at pH values below 4 significantly accelerated the Pb(II)/Pb(IV) transformation, and the results are important when considering the stability of lead species in an aqueous solution under industrial conditions.<EOD> Changes in the structure of the mitochondrial membrane.\nThe effect of calcium ions on the mitochondrial membrane was investigated using 3 H2O, K+ and Ca++ uptake during the oxidation of succinate, cytochrome oxidase reduction and the membrane potential as probes. Calcium, in concentrations as low as 0.03 mmoles/L, produced marked increases in 3H2O , K+ uptake and mitochondrial membrane potential as well as inhibition of",
        "label": 2
    },
    "1869": {
        "output": "##\n\n##[CATEGORY] `Hepatitis Virus`\n```\n`Roles:` `Hepatitis Virus`\n\n   Name                                       Display Name                                Type    Enum Description\n    10_222  [0] Hb viremia    [0] HBV DNA(viremia)          CATEGORY HBV viremia; `Hepatitis Virus::0::HBV Virus::DNA viremia;`\n    10_318  [0] HcV Virus                 [0] HCV Virus                                CATEGORY HBV Virus; `Hepatitis Virus::1::HCV Virus;`\n    10_223  [0] Hb viremia             [1] HBV DNA(viremia)                           CATEGORY HBV viremia; `Hepatitis Virus::0::HBV Virus::DNA viremia;`\n    10_319  [1] Hb viremia             [0] HBV DNA(viremia)          CATEGORY HBV viremia; `Hepatitis Virus::0::HBV Virus::DNA viremia;`\n    10_314  [0] Hep Virus viremia         [0] Hepatitis Virus viremia                 CATEGORY HBV Virus; `Hepatitis Virus::2::HBV Virus::E-antigen positivity;`\n    10_315  [1] Hep Virus viremia         [0] Hepatitis Virus viremia                 CATEGORY HBV Virus; `Hepatitis Virus::2::HBV Virus::E-antigen positivity;`\n    10_324  [0] Hev viremia              [0] HEV RNA(viremia)                        CATEGORY HBV Virus; `Hepatitis Virus::3::HEV Virus::RNA viremia;`\n    10",
        "label": 0
    },
    "1870": {
        "output": "Your sample should look like this: \nInput:\nTrial_Number_555_HCV_Hepatitis_C_Virus\nAge: 55\nGender_Group: Male (if male: 1 else: 0)\nHepatitis_HCV_Present: (1 if patient meet inclusion criterion 1)\nHepatitis_HBV_Present: (1 if patient meet inclusion criterion 2)\nIFN_Admin: (if patient take Direct antiviral drugs: 1 else: 0)\n\nThe first column of the list is the patient ID, the second column is the trial number, in the third column `Hepatitis_HBV_Present` is 0, in the fourth column `Hepatitis_HCV_Present` is 1, and in the last column `IFN_Admin` is 1. In all columns, there are 1 if a patient meet the inclusion criterion, 0 otherwise. Output: Trial-level eligibility: 2) Eligible. The program stops and shows this Trial-level eligibility.\n\nA: You are overcomplicating the problem. The code you are showing will only work correctly if that entire function is defined to take a variable for the input and a variable for the output. You do not even define those, much less get the input from variables in the Python instance. In fact you pass the output of the whole function to a lambda.\nIn order to understand what is actually going on, you need to walk through the code in the debugger. \nimport random\nfrom operator import add\nfrom operator import mul\nfrom operator import sub\nfrom operator import mod\n\ndef main():\n    if 0 == 1 + 2 + 3:\n        print(\"Output is not equal to 6\")\n    else:\n        print(\"Output is equal to 6\")\n\ndef Trial (trial_number):\n    patients = [\n        random.randint(18, 76) if trial_number == 1 else\n        random.randint(19, 77) if trial_number == 2 else\n        random.randint(20, 78)\n        for patient in patients\n\n    for gender_group",
        "label": 0
    },
    "1871": {
        "output": "---\n```@javascript\n#!/usr/bin/env python3\n#-*- coding: utf-8 -*-\n\nfrom pathlib import Path\nimport pandas as pd\nimport numpy as np\nimport scipy.stats as scp\n\nimport re\n\nimport matplotlib.pyplot as plt\n\nimport os\n\nfrom matplotlib.tinypng import compress_img\n\nimport sklearn.neighbors\n\nimport pysam\n\nimport copy\n\nimport itertools\n\nimport seaborn as sns\n\nimport seaborn\nimport io\n\nfrom tabwriter import TabWriter\n\nimport numpy\n\nfrom operator import itemgetter\n\nimport sys\n\nfrom itertools import groupby\n\nfrom nilearn.plotting import plot_3d_survival, plot_3d_roc, plot_roc_curves\nfrom nilearn.plotting import plot_confusion_matrix\nfrom nilearn.plotting import plot_confusion_matrix as plot_bar_matrix\nfrom nilearn import datasets\n\nimport nb_utils\n\nimport statsmodels.graphics.tsaplot as gtsaplot\nfrom scipy.stats import power.gamma_pmf as gpmf\n\nimport pandas.plotting\n\nfrom tabulate import tabulate\n\nimport pickle\n\nimport random\n\nimport pandas \nfrom scipy.stats import wald_test\n\n\nsns.set_style(\"olivid\")\n\n\nimport matplotlib as mpl\n\n\nsns.set(color_palette=\"mpl\",\n        rc={\"figure.figsize\":(40,6)},\n        context = 'notebook')\n\nimport numpy as np\nfrom numpy import loadtxt as loadtxt\nfrom sklearn.preprocessing import StandardScaler\nfrom sklearn.model_",
        "label": 0
    },
    "1872": {
        "output": "What is an example of this?\n\n<EOD> Is a Higher Degree of E-Cadherin Expression in Tumor Border a Better Indicator of the Inflammatory Nature of Cancer Than Infiltration by Lymphocytes in Gastric Adenocarcinoma?\nThese days, it has been considered that the epithelial-mesenchymal transition is a highly dynamic process. Therefore, tumor border cells with epithelial or non-epithelial phenotypes may coexist. However, how to classify this kind of cells is still debatable. In this retrospective research, the immunohistochemistry (IHC) examination of epithelial markers and the infiltration of lymphocytes at the tumor edge were performed and reviewed in 172 patients who had undergone gastrectomies due to gastric adenocarcinoma between 2009 and 2013. Based on the histologic findings and previous studies, tumor border cells with epithelial phenotype could be divided into three groups: (i) Epithelial tumor border (ETB) comprised tumor cells with nuclear staining for p63 (n=162); (ii) E-cadherin (e-cad)/p63 heterogeneous tumor border (e-cad/p63 HTB) involved tumor cells with high e-cad IHC staining (n=5); (iii) Highly atypical tumor border (HATB) consisted of tumor cells with nuclear Ki-67 (index: 123.1\u00b148.55) and negative staining for e-cad in the tumor border area (n=5). Meanwhile, CD45-positive lymphocytes were observed in the tumor border area (112 patients, 64.57%), and the amount of infiltration ranged from 0.99\u00b10.09% to 24.00\u00b117.33%. When classifying them into two groups according to lymphocytes infiltration (CD45-positive lymphocytes or",
        "label": 2
    },
    "1873": {
        "output": "## Your Name:\n\nYour email:\nYour comment:\nGoal:\n<EOD> Malignant disease in patients with multiple myeloma.\nOne hundred successive patients with multiple myeloma were reviewed, with data regarding patients with a histologically proven malignancy prior to presenting features of multiple myeloma, or co-existing malignancy at the time of presentation for multiple myeloma. Six patients, 3 per cent, had previous malignant disease which is within the range reported by others. One patient had a possible malignancy. A second possible malignancy developed following treatment for multiple myeloma.<EOD> .\nThe present review deals with the biology, pathobiology and epidemiology of Anaplasma phagocytophilum (Ehrlichia phagocytophila), which is transmitted by the bite of Ixodes ricinus (I. persulcatus) ticks. Studies on the prevalence of A. phagocytophilum in I. ricinus ticks in Lithuania were first presented. Infection of peripheral leukocytes in different animal species, which are prevalent in Lithuania, was evaluated with serological methods. A. phagocytophilum was detected by nested PCR in the clinical blood samples of humans, domestic ruminants, horse and hedgehog. A. phagocytophilum was detected in the tissues of experimentally infected ruminants (cattle, sheep, goat) and rabbits, in experimental rodents (guinea pig and rabbit) and also in the domestic bird (turkey). In addition, two new species of Anaplasma (A. platys in hedgehogs and A. bovis in cattle) are reported in Lithuania for the first time.<EOD> Making the most of the 20th Century's greatest medical advance: an analysis of the effectiveness of early diagnosis of the primary tumour and treatment of the metastases in patients with breast cancer with a favourable prognosis.\nThe survival of patients with breast cancer has been doubled by the use of chemotherapy in advanced breast cancer (ABC), hormone therapy in metastatic hormone-resistant tumours and in pre- and post-",
        "label": 0
    },
    "1874": {
        "output": "# Methods\n\n## Experiment\nIn this experiment, we considered seven experiments. In order to make a fair comparison, the same dataset was used for all experiments and the labels of the data were not leaked to the models used for the experiments. In each of the experiments, we considered 40% training, 40% validation, and 20% testing samples.\n\n## The algorithm\n\n## - [CATEGORICAL] You should apply the classification algorithm and the validation method to predict the trial-level eligibility. You should set the target as the same labels we showed in the previous section (see .\n- [TRAIN] you should consider the train dataset, we prepared for each of the 7 types and apply the validation method. In total, we will have 7 train data sets.\n- [SAVEDATA] you should save the results of the validation in the savedata as we showed in the previous section (see .\n- [PW] you should not use it on the validation steps and only on the test. You should apply it to the training dataset after fitting of all models.\n- [RESULTS] you should not save anything for this step in the results file. \nNote \n\n## The model\n\n## - [CATEGORICAL] you should apply the classification model and the validation method to predict the trial-level eligibility. - [TRAIN] you should consider the train dataset, we prepared for each of the 7 types and apply the validation method. in total, we will have 7 train data sets.\n- [SAVEDATA] you should save the results of the validation in the savedata as we showed in the previous section\n\n## Note_savedata \n<EOD> Is the current management of acoustic neuroma treatment in Australia appropriate?\nOBJECTIVE\nTo determine whether the current management practices of acoustic neuroma in Australia are in accordance with available evidence.\n\n\nDESIGN, SETTING AND PARTICIPANTS\nA mailed survey using a questionnaire of 40 medical specialists dealing with ear, nose and throat problems from all State and Territory areas, 137 surgeons from the Royal Australasian College of Surgeons and 21 surgeons participating in a Victorian Acoustic Neuroma Register",
        "label": 1
    },
    "1875": {
        "output": "## Exercises\n\n# Elbow exercises \n## Task 1:\n[1] Select the patient notes.\n\n## Task 2:\n[2] Run a trial-level eligibility test by `python -m triell pyel -t notes.json notes.json`.[INST]\n\n## Note:\nOutputs include the path of the trial.\n\n## Task 3:\n[3] Select the clinical trial.\n\n## Task 4:\n[4] Run a patient-level eligibility test by `python -m triell pyel -t clinic.json clinic.json`.[INST]\n\n## Task 5:\n[5] List all patient-level eligibility.\n\n## Task 4:\n[6] Display the patients' attributes within each trial.\nThe following table should be the output:\n\n# Forearm exercises \n## Task 1:\n[7] Select the patient notes.\n\n## Task 2:\n[8] Run a trial-level eligibility test by `python -m triell pyel -t notes.json notes.json`.[INST]\n\n## Task 3:\n[9] Select the clinical trial.\n\n## Task 4:\n[10] Run a patient-level eligibility test by `python -m triell pyel -t clinic.json clinic.json`.[INST]\n\n## Task 5:\n[11] List all patient-level eligibility.\nThe following table should be the output:\n\n# Spine exercises \n## Task 1:\n[12] Select the patient notes.\n\n## Task 2:\n[13] Run a trial-level eligibility test by `python -m triell pyel -t notes.json notes.json`.[INST]\n\n## Task 3:\n[14] Select the clinical trial.\n\n## Task 4:\n[15] Run a patient-level eligibility test by `python -m triell pyel -t clinic.json clinic.json`.[INST]\n\n## Task 5:\n[16] List all patient-level eligibility.\nThe following table should be the output:",
        "label": 0
    },
    "1876": {
        "output": "__1__ Excluded\n\n__2__ Not relevant\n\n__3__ Eligible\n\n__[Clinical trials]_** can be found in [the ClinialTrials.gov register](https://clinicaltrials.gov/). [The ClinialTrials.gov register](https://clinicaltrials.gov/) is a free tool supporting the disclosure of clinical trials.\n\n[INST]: #instructions\n___[<NAME>]*__\n\n__Suggestion to the author__\n\n__Author`s name__\n*Add the information about how to contact the author: email, phone and more.*\n\n___*Mandatory*__\n__Abstract__\n\n*Abstract__is** an one-paragraph introduction to the article to describe the question asked and the main findings. \n___*Mandatory*__\n\n__Title__\n___*Mandatory*__\n*The title is your first chance to make an impression. Think how you would describe the paper to a friend. Don't be too fancy and too long*.\n___*Mandatory*__\n\n\n\n\n__Clinical trial*__\n\n___*Mandatory*__\n*The clinical trial belongs to the ClinicalTrials.gov register*.\n\n__Eligibility criteria*__\n\n___*Mandatory*__\n*Eligibility criteria is used to identify which patients will be included or excluded, as well as the criteria for measuring a study's success in the eligibility assessment. Therefore, eligibility criteria are used to identify eligible participants and define, for each, the treatment to apply and the method to determine the effectiveness (e.g., a questionnaire on the status of a particular disease or a biopsy, or other testing)*.\n\n__How to use R Shiny apps in R*__\n\n___*Mandatory*__\n*Add this as the first line of the paper*\n\n__The patient*\n\n\n__H&P_ is** a general summary of all the information contained in the medical history and physical examination of a patient*.\n___*Mandatory*__\n__Lab values_ contains the lab values of a patient. For example; Complete Blood Count, Renal Function Test, Lactic Ac",
        "label": 0
    },
    "1877": {
        "output": "# 1901105520\n\n## Your input\n<EOD> A Comprehensive Prognostic Model Based on a Novel Ferroptosis-Related Gene Signature and the Clinical Characteristics of Head and Neck Squamous Cell Carcinoma (HNSCC)\n\nBackground: Increasing evidence has indicated that ferroptosis, a peculiar cell death and a new form of iron-dependent oxidative cell death, is a critical role in the tumorigenesis of head and neck squamous cell carcinoma (HNSCC). A predictive model based on gene signatures and clinical characteristics of HNSCC patients with ferroptosis has not been established until now. The aim of this study was to develop a novel prognostic model and identify reliable biomarkers to predict the prognosis for HNSCC patients.Methods:The mRNA expression data and corresponding clinicopathological data of HNSCC patients from the public databases, including The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), were extracted for subsequent analyses. Univariate Cox regression analysis and the least absolute shrinkage and selection operator (LASSO) algorithm were used to screen genes correlated with survival. A prognosis ferroptosis-related risk model was established, and the prognostic ability of the risk score was assessed based on the area under the curve (AUC) and receiver-operating characteristic curves (ROC). The relationship among risk score and clinical features, as a classifier, was also analyzed systematically. The predictive accuracy of this model was tested by evaluating HNSCC cell lines.Results:A prognostic model with 14 genes, a novel risk score, was established. The results indicate that this prognostic model has favorable value in predicting survival of HNSCC patients. In addition, the risk score was able to be a reliable prognosis predictor, which is an independent predictor for HNSCC patients. The association of immune cell infiltration and tumor mutational burden with the risk score and the model's ability for distinguishing between high and low-risk groups were also analyzed in multiple aspects. Additionally, the cell lines from HNSCC patients showed significantly different risk",
        "label": 2
    },
    "1878": {
        "output": "## Inst_demo1\n## INST_demo2 \n## INST_demo3_1:\nThis example implements the eligibility assessment using the patient data and the trial data in a script in the notebook `inclusion_1_demo.ipynb`.\n\n### Inst_Demo1_Ex1\nLet's think step by step. \n\n[START]\nfrom sklearn.ensemble import GradientBoostingRegressor as XGBR\nimport pandas as pd\nimport numpy as np\nXGBR(bootstrap=True, max_depth=28, nrounds=53, njobs=2000, subsampling=0.35, max_depth=4) # 54 is best with 1 job\nXGBR(_features ='sex, age, diagnosis, medication').predict(y) # the predict method of classifiers can only return a real value. Instead you can use predict_proba and then convert.<EOD> Aminoglycoside-resistant Haemophilus ducreyi in Japan.\nTwo of 41 male patients with the diagnosis of chancroid (sexually transmitted disease) were shown to be colonized with amikacin- and gentamicin-resistant strains (minimal inhibitory concentrations . penicillin G 2.0 micrograms/ml; tetracycline > or = 2.0 micrograms/ml; spectinomycin >200 micrograms/ml).<EOD> The use of aortic intra-luminal continuous-wave Doppler measurements to accurately determine blood flow velocity in the ascending aorta in infants and children\n\nSupravalvar stenosis of the aortic isthmus arises in infants and children from 3 weeks to 12 years old and is thought to be caused by the rapid pressure-related dilatation of the aortic isthmus. As aortic blood flow velocity is thought to play an important role in the development of this disease, it was considered appropriate to perform aortic intra-luminal continuous-wave Doppler with an emphasis on the technique for use in infants and children. The main aorta (from the sinotubular junction",
        "label": 0
    },
    "1879": {
        "output": "![ ] Rate/select a trial.\n[formula]  C: 010001 001001 101110 000101 111101 101010 101000 010000 110000 011000 111010 100100 000110 011001 000100 001011 000111 000011 000010 111011 110101 000110 trial_id -------------------------------------------------------------- 1 0 2 1 1 2 1 1 0 3 1 2 2 3 2 3",
        "label": 0
    },
    "1880": {
        "output": "<h2 id=\"clinical-question\">Clinical question</h2><div>In the question, <code>?What is the effect of intervention with atezolizumab in a small cohort of metastatic triple negative</code> breast cancer patients on ORR, PFS and OS?</div><div>Here is the patient note. </div><div>The patient is a 45-year-old woman diagnosed with triple negative metastatic breast cancer. Diagnosis of cancer was done by mammogram, biopsy, and magnetic resonance imaging (MRI) of the stomach. Her past medical history is non-significant. She is on paclitaxel and carboplatin chemotherapy. The patient took no other medications, except for analgesics for headache. Her medical record showed no heart problems. The patient is alert and oriented. Her BP: 130/75, HR: 80/min and BMI: 24. Her abdomen was soft with no tenderness and no acute distress. The abdomen had a mass on liver and liver enlargement on ultrasound examination. The results of her hematology, chemistry and urine tests were in normal ranges. There was no evidence of HBV or HCV virus infection. The chest X-ray showed no pleural effusion, and echocardiography revealed a good systolic/diastolic function by LVEF ejection fraction 60%. The patient lived alone without caring help and had no significant family history. Here is the clinical trial protocol. \n<h2 id=\"clinical-trial-protocol\">Clinical trial protocol</h2><div>Title: Assessment of immunotherapy with a PD-L1 antibody for metastatic triple negative breast cancer</div><div>\nObjective: Assess the effect of immunotherapy, a programmed death 1 (PD-1) immunosuppressive protein antagonist (programmed death-ligand 1 (PD-L1) antibody; atezolizumab, Atezo, Tecentriq, a monoclonal antibody Ig",
        "label": 0
    },
    "1881": {
        "output": "-- Jeroen De 21:43, 12 September 2018\nPlease note, all wiki pages will be available offline starting September 19.\nPlease update your bookmarks and scripts to point to /bookmarks/main/index.html.<EOD> Bone Mineral Density and the Incidence of Hip Fracture in Asian American Women and White Women\nAsians have lower bone mineral density (BMD) than other racial and ethnic groups, but the incidence of osteoporotic fractures by race or BMD values has not been examined. We examined BMD and other hip fracture risk factors among Asians and whites at a population\u2010based level.<EOD> Highly Specific \u03b2\u2010Glucuronidase\u2010Peroxidase Coupled in\u2010Serum Biomarkers for Rapid and Efficient Detection and Discrimination of Escherichia coli Serovar O157:H7\nThe rapid and specific detection of Escherichia coli serovar O157:H7 (O157) with enhanced sensitivity and specificity was achieved using a \u03b2\u2010glucuronidase (GUS)\u2010coupled peroxidase (HRP) system to develop an assay able to rapidly determine bacterial cell status by detecting only GUS positive cells to discriminate the two types of cells. Initially, an O157 strain and a K\u201012 strain were compared with a group of OI57+ and OI57\u2212 strains to confirm the specificity of the assay to O157. The assay conditions were optimized to detect as low as 100 O157 cells, with only 5 minutes incubation time using a chromogenic substrate with O157 O\u2010specific antiserum as secondary antibody. The assay was then used to study the differences in the number of O157 cells of each serotype in different media and under different conditions. The assay results showed higher numbers of O157 cells in the LB culture than did the DMEM culture, and higher numbers of O157 cells in the presence of antibiotics than in the control sample. The assay",
        "label": 1
    },
    "1882": {
        "output": "- : +16 points (a) \n- : +16 points (a) \n- : +16 points (a) \n- : +16 points (a)  \n\n### Task 3 10\nFind the first five notes with two or more factors missing. Examples include the missing gender and the HBV infection.\nHere is the patient note with factor missing:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.    \n     \n    Title: Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy\n\n\nSummary: Hepatitis C virus (HCV) is one of the major globally cause of death and morbidity.Chronic hepatitis C is the leading cause of end-stage liver disease, hepatocellular carcinoma and liver-related death in Egypt.It could be considered a special type of metabolic diseases involving insulin resistance (IR) which accelerates fibrosis and modulation of lipid-cholesterol biosynthesis with increased risk for ischemic heart diseases.It could be considered a special type of metabolic diseases involving",
        "label": 1
    },
    "1883": {
        "output": "`SELECT @@identity AS identity_str ; \nSET @identity_str = '' ; \nSET identity_str = @identity_str || '' + ''' \n\n`SET @name =  ''' + CONCAT((@name || '[TEST]'), '@' , @name /* TEST */ , ' \n\n`SET @date  = '''` + CONCAT((@date || '[TEST]'), '@' , @date /* TEST */ , ' \n\n`SET @name =  ''' + CONCAT((@name || '[TEST]'), @name /* TEST */ , ' \n\n`SET @date  = '''` + CONCAT((@date || '[TEST]'), '@' , @date /* TEST */ , ' \n\n`SET @name =  ''' + CONCAT((@name || '[TEST]'), @name /* TEST */ , ' \n\n\n## PARS_PARSE_ASSESSMENT_EL\n\n`PARSE_ASSESSMENT_EL \n\n`@pars_name=  @patient_name||':' \n`+ @patient_note \n`+ '@inclusion_criteria `\n`= '+@inclusion_criteria\n`+' \n\n`@pars_eligible='+@parsed \n`#= '+ @name + #\n`+ ': '+ @value \n`' #='#+ # \n\n`@@pars_eligible= @pars_eligible`\n\n`@@pars_name = @pars_name` \n\n`@@pars_value = @pars_value \n`@@pars_type = @pars_type` \n\n`@@pars_length = @pars_length` \n\n`@@pars_criteria= @pars_criteria` \n\n`@@pars_test= @pars_test` \n\n`@@pars_years_old = @pars_years_old` \n\n`@@pars_gender = @pars_gender` \n\n`@@pars_age_criteria = @pars_age_criteria` \n\n`@@pars_body_mass",
        "label": 1
    },
    "1884": {
        "output": "##[EVAL_R] Hello. This is a case with multiple eligibilities. We need to check 8 levels of eligibilities. \nWe can make a case by following these three steps.\n\n##[EVAL_R] Step 1. Create a case and make a copy.\n\nYou make a case [INST] Hello. You are working with Dr. <NAME>. \nWe have a patient who has many clinical trials that can potentially interest you. \nHer name is <NAME>, a 26-year-old female. \nYou may ask more questions.\n\nYou make a copy [EVAL_R] Hello. You are working with Dr. <NAME>. \nDr. <NAME> has asked you to take over an assessment of a patient's eligibility for an ongoing clinical trial. \nWe have a patient who has many clinical trials that can potentially interest you. \nHer name is <NAME>, a 26-year-old female. \nYou may ask more questions. \n[/EVAL_R]\n\n##[EVAL_R] Step 2. Create an assessment report. \n\n\n![](/images/screen_shot_2019-01-10_15-21-06-128.png)\n\nThere are many parts of the report. I will break them down into sub-parts to show its components.\nA clinical trial report may be composed of the following parts.\n\n- [Subpart 1]: `Summary of a patient'.\n- [Subpart 2]: `Medical information'.\n- [Subpart 3]: `Patient medical history -Infectious diseases'.\n- [Subpart 4]: `Cover page, abstract, and acknowledgment'.\n- [Subpart 5]: `Clinical trial report'.\n- [Subpart 6]: `Eligibility and inclusion criteria of clinical trial'.\n- [Subpart 7]: `Final eligibility'.\n- [Subpart 8]: `Evaluator'.\n\n\n### 1. Create a clinical trial report. \n![](/images/screen_shot_2019-01-10_15-21-06",
        "label": 0
    },
    "1885": {
        "output": "Please let us know if this one-liner fits your needs.<EOD> HBV genetic variation of drug-resistant mutants in viraemic patients in Cameroon\n\nHigh genetic variability of the HBV genome results in the emergence of drug-resistant mutants and loss of efficacy of antiviral treatments. This study presents a study design for the detection of drug-resistant mutants in Cameroon, and reports the prevalence of drug-resistant variants of HBV from treated and untreated HBV patients in three different Cameroonian regions (Douala, Yaound\u00e9 and Koula-Moutou). We analysed the HBV genome and screened for drug-resistant mutants in 174 (81 treated and 93 untreated) patients, using deep sequencing and cloning methods. Two different drug-resistant mutants, rtN236T and rtL276M, were found in treated patients and the most frequent mutants in untreated patients was rtL180M. Mutants in the YMDD motif, i.e. rtM204I/V and rtI233M, were found frequently in the treated patient population, but were not detected in treatment failure. Our results show that drug-resistant mutations in the YMDD motif are common in Cameroon, which needs to be taken into account in future treatment strategies. We present a study design that can be used to identify drug-resistant variants in Cameroonian patients, which is essential in treatment decisions.\n\n# Methods\nStudy population. The study population comprises patients (age > 13 years) receiving antiviral treatment for chronic HBV infection at the Centre Hospitalier International de Yaound\u00e9 (CHIYY), and patients followed up at the University Hospital of Yaound\u00e9 1 (CHUY1; Douala) and in the regional hospital of Koula-Moutou (Yaound\u00e9), Cameroon. The treated patients were recruited from 2010 through 2014 and untreated patients were recruited between 2012 and 2013. Plasma samples were collected in EDTA antico",
        "label": 0
    },
    "1886": {
        "output": "[ /INST]\n# Appendix B. Question Set\n\nThe following question set helps assess the eligibility of the patient based on the answer to the questions:\n[\n[INSERT FIGURE 1\nABOUT HERE.\nAsked by the user:\n[Asked by the user:\n[fig]  1: INST. ASSOCIATE_SORT_TEST: ASSOCIATE_SORT_TEST is the test of association of the eligible patients. Association testing helps to understand [/fig] \n[fig]  2: INST. ASSESS_ELIGIBILITY_HELP_MESSAGE: ASSESS_ELIGIBILITY_HELP_MESSAGE is a message helping the user assess the eligibility for the trial. [1] Excluded: The patient does not meet all of the inclusion criteria;[2] Not Relevant: The patient does not have enough information to qualify for the trial;[3] Eligible: The patient meets all inclusion criteria. [INST] [/fig] \n[fig]  4, Figure 2, Figure 3, Figure 4, Figure 5: INST. ASSESS_ELIGIBILITY_OUTPUT: ASSESS_ELIGIBILITY_OUTPUT is the output for the eligibility assessment. { 01: 01; 02: 00; 03: 00; 04: 00; 05: 00; 06: 00; 07: 00; 08: 00; 09: 01; 10: 11; 11: 00; 12: 00; 13: 00; 14: 00; 15: 00; 16: 01; 17: 00; 18: 10; 19: 01; 20: 01; 21: 22; 22: 01; 23: 00; 24: 3 25: 01; 26: 01; 27:",
        "label": 0
    },
    "1887": {
        "output": "To recap: When patients have more than one medical record, you should first retrieve multiple instances from patients to patients table. Based on each record, you should then apply the appropriate filters and criteria to the clinical trial for evaluation. Then compute triallevel eligibility based on a patient and a clinical trial. If the patient is eligible for the clinical trial, record the patient's eligibility in a new trial row in the trials table. [END]\n\n\n<EOD> Cytogenetic effects of the malignant transformation induced by the hepatocarcinogen methylcholanthrene (MCA) in liver of mouse and some human hepatoblastomas.\nHepatocellular carcinomas (HCC), human hepatoblastomas (HHB), and control livers from mice, were studied with chromosome banding. In the HCC we detected chromosomal abnormalities similar to those described in livers of mice treated with chemical carcinogens or X-radiation. In the liver tumors an additional chromosome was seen in the region of the centromere of the X-chromosome; the extra centromere was identified in X-chromosome of cell hybrids and was shown to be a derivative of the short arm (p11-14). This extra centromere was also observed in 9% of human hepatoblastomas and in one of four fibrolamellar carcinomas. In another hepatoblastoma no marker chromosome was found but the cell population showed chromosomal segregation without sister chromatid exchange: G(2) population with 44% cells with 47 chromosomes.<EOD> CBT for Anxiety Disorders: Towards Parsimony *\nAbstract:\u2002 We suggest that many of the problems currently reported with cognitive\u2013behavioral treatments of anxiety disorders stem, in large part, from the unrealistic expectations that have been placed on the models\u2014most of which were originally developed with phobia in mind. We discuss possible reasons why treatments which may be quite effective for phobias may be suboptimal for other problems, including generalized anxiety, panic, or social anxiety. We describe a number of modifications that can be made, which we believe may provide",
        "label": 1
    },
    "1888": {
        "output": "There is some example for you to review:\n\n\n-- Example data in PatientData folder\n\n# Data pre-processing\n\n* The data for our patient is in an Excel file in `crispr_data_.xlsx` in\n[INST].[INST]/Data folder.\n\n```\ndata_raw = pd.read_excel(os.path.join(os.path.dirname(os.path.abspath(__file__)), '../Data', 'crispr_data_.xlsx'), sheet_name='data')\n\n```\n\n* Since we are dealing with two columns, the columns should be one-dimensional.\n\nOne-dimensional table of Patient has two columns:\n\n```python\ndata_raw = data_raw.T.values.reshape(-1, 2)\ndata_one_dim = pd.DataFrame(data_raw)\n\n```\n\n* Column names are \"patient_id\" and \"sample_name\".\n\nColumn names are:\n\n```python\ndata_one_dim.columns\n\n```\n\n```\nIndex: 0 \nInt64Index:\n0    291\n1    395\n2    413\n3    599\n4    679\n5    [removed]\n6    [removed]\n7    [removed]\n8    751\n9    839\n```\n\n* Now if we were to do a one to one mapping between [11] and [the value of `sample_name` for each of the IDs], `sample_name` will always come after the numbers, e.g., `sample_name=='02941', `02941' in [11]. Note that since we are dealing with column names in an Excel file, the mapping has to be done at the level of column names, not at the level of the data objects, data frames, etc.\n\n```python\ndata_two_dim = data_one_dim[:,1]\n# The first column is the patient_id, second column is the sample_name.\n\n```\n\n* Since there are only 9 lines in the file, we do not need to split into training and testing data. So just do the train split method on them.",
        "label": 0
    },
    "1889": {
        "output": "\u00a9 2017 Informatics and Medical Education. Copyright of individual items transferred on June 15 2017 to Informa UK Limited.<EOD> .\nA case of lymphoplasmocytic lymphoma manifesting as a malignant intracranial lymphoma is presented. The patient had no previous known primary disease, and the diagnosis was made after craniotomy performed for tumor evacuation. Involvement of the central nervous system is a very rare phenomenon in lymphomas. To the best of our knowledge, only fifteen previous cases of primary malignant lymphomas of the central nervous system (CNS) have been reported. The patient was a 68-year-old man, who presented an increase of intracranial pressure. Radiologic studies showed two mass lesions in the posterior fossa. The mass lesions were totally removed. He was diagnosed as having diffuse malignant lymphoma associated with thymoma based on the histologic findings.<EOD> Increasing prevalence of ESBL\u2010producing Enterobacteriaceae in Europe\nClinical microbiology studies focusing on extended-spectrum &bgr;-lactamase (ESBL) production by Enterobacteriaceae have revealed an increase in frequency of ESBL-producing bacteria in hospital populations during the last two decades. The main driver behind this increase has been the emerging of Escherichia coli with ESBL phenotype. Some factors favouring this process have been identified, like the increase of fluoroquinolones consumption and the presence of other resistant determinants co-expressed with &bgr;-lactams resistance, e.g. class 1 integrons and plasmid-mediated quinolones resistance determinants. Although the situation is concerning, efforts to limit the emergence of resistance are encouraging. Some ESBL-producing isolates can be susceptible to non-&bgr;-lactams. Therefore, the importance of non-&bgr;-lactams, e.g. carbapenems, is highlighted. Molecular epidemiology studies have shown a predominance of one or two specific genes in several countries.<EOD> Incre",
        "label": 0
    },
    "1890": {
        "output": "[1]<EOD> Implementation of an educational intervention using clinical scenarios in the community of nursing students, professors of practice and research professors\n\n\n\n# Introduction\nIn Spain, the educational stage for teaching nursing professionals is currently offered by eight universities and in six autonomous regions. The teaching units in these degrees are distributed among a wide range of areas that encompass everything from human biology to medical practice and the study of health phenomena. In particular, nursing is defined as knowledge about person, health-disease processes in the promotion and prevention of health. Its main objective is to promote the best possible health, focusing both on person and community, in addition to protecting, promoting, and recovering health.\nIn the different areas that make up nursing, it is necessary to make teaching units that facilitate person-centered care, in order to enable nursing professionals to make decisions that promote and maintain the most desirable levels of care. However, educational processes in universities and universities present limitations that affect their ability to prepare nursing professionals with the necessary knowledge and skills and, mainly, the complexity of working for humanity.\nIn this regard, different studies on the educational processes present limitations that affect their ability to prepare professionals with the necessary knowledge and skills required in the exercise of the profession [bib_ref]  El impacto del plan de estudios de especialidad en enfermer\u00eda sobre la..., Garc\u00eda-Orden [/bib_ref] . Likewise, it has been detected, a weakness in the development of educational processes for the training of nursing professionals in the health-promoting care dimension for the elderly people [bib_ref]  Inclusion of educational practices in higher education regarding health promotion and diseases..., G\u00f3mez [/bib_ref] .\nSome studies that have been carried out have proven that the introduction of new teaching approaches with a strong focus on professional practice has improved the relationship between clinical learning environment and teaching [bib_ref]  Students' expectations on nurse-doctor-interactions in clinical and community placements: a focus group..., Zahner [/bib_ref] . Although, there are no studies that demonstrate the potential of implementing educational processes, based on clinical scenarios, with the community of nursing professionals, teachers and students as the main protagonists.\nThe teaching-learning process can be developed in a very varied way [bib_ref]  Percepci\u00f3n del profesor",
        "label": 0
    },
    "1891": {
        "output": "(Ensure there is no extra space in the end of the output string for each assessment.) You should type the word `endl` or end of line on a line after your output.\r\n\r\n# Additional Information\r\n\r\n[A]  This file is one of thousands of open source files that make up our open source clinical trial database system. A full set of instructions on how to use this database system is available at [Tutorial: How to start the system and a quick how to guide](Tutorial_HowtoRunSystemandQuickHowToGuide.pdf) and on the open source software's web site at [http://biostar.usc.edu/wiki/Main/BiostarProgrammingGuide](BiostarProgrammingGuide.pdf).\r\n\r\n[B]  This is a sample case based on HCV and HBV. Add your case at the top of your code, changing HCV and HBV to other conditions. For more information on how to add clinical trial cases see instructions in the file above.\r\n\r\n[C]  This file was tested using the Python 2.6 Jython 1.0.2 running under Windows 64 bit. \r\n\r\n[D]  This file was tested on an AMD AthlonXP 2000+ CPU, 1 GB RAM, and 20 GB Hard drive. \r\n\r\n[E]  This file and other source code is freely available on an open source web site at [http://biostar.usc.edu/wiki/Main/BiostarOpenSource](BiostarOpenSource.pdf).\n<commit_msg>fixed indent<commit_after>\"\"\"\r\n__author__ = 'Kenji (Yuji) Yokogawa (yk-yokogawa@yokogawa.com)'\r\n__copyright__ = 'Copyright (C) 2012 Microsoft Corporation. All rights reserved.'\r\n__license__ = 'http://opensource.org/licenses/MS-ApacheCommercial-1.0'\r\n__version__ = '1.0'\r\nimport os.path\r\nimport math\r\nimport random\r\nimport time\r\nfrom jyOpenOffice.calc.Excel import xltract, xlfmerge,",
        "label": 1
    },
    "1892": {
        "output": "## [/GENERAL]\n## [GENERAL_CASE]\n[GENERAL_CASE]\n\n## [/general_case]\n* **Explanation:**\n\n* The structure for eligibility test expression is as follows\n\n* The structure for eligibility test expression is as follows:\n\n* <b>Case-statement</b>: <code>&lt;case-statement&gt;</code> is introduced by the keyword `case`, which must be followed by a nested `case-statement`, as if it were any <code><var>expression</var> <var>variable</var> <code>with a colon</code>.\n\n* <code>&lt;case-statement&gt;</code> consists of several parts such as `begin-statement` and `end-statement`. `begin-statement` is introduced by the word `begin`, followed by a nested `case-statement` and `end-statement`. There can be one `begin-statement`, but several nested `case-statements`. `end-statement` is introduced by the word `end`, followed by `end-of-case-statement`.\n\n* <code>&lt;case-statement&gt;</code> must be followed after by at least one case-statement.\n\n* <code><var>expression</var> <var>variable</var> <code>may be any valid variable, but not function name</code>.\n\n* Each case-statement consists of several parts such as `begin-statement` and `end-statement`. `begin-statement is introduced by the keyword `begin`, followed by a nested `case-statement` and `end-statement`. There can be one `beginstatement`, but several nested `case-statements`. `end-statement` is introduced by the word `end`, followed by `end-of-case-statement`.\n\n* <code>&lt;case-statement&gt;</code> begins with <code>IF</code>) <code>statement</code>, with the expression inside the parentheses, <code>(expression-block)</code>, the expression <code><var>expression</var> <var>variable</var> <code>may be any valid variable, but not function name</code>. <code>(</code> and <code>)</code> are compulsory. There can be multiple <code",
        "label": 0
    },
    "1893": {
        "output": "[fig]  [STUDENT]: What are all the factors used to determine if a patient participating in a study is eligible? Why are they important for the study? [STAFF]: This is an example from a very basic study. In larger studies there might be dozens of different inclusion and exclusion criteria. [INST]: It is important because the data collected during the trial has a huge impact on the effect of the drugs tested on the patients, which was the objective of the study. [STUDENT]: What is the reason for each one of them? [STAFF]: The first inclusion criteria are basic conditions of the patients. For example: age, gender, general health status. The second criteria are more specific conditions and might include factors like patient education, profession, and a particular disease condition. [/fig] \n<EOD> Effects of the C57BL/KsJ and SWR alleles of the Npy gene on mouse mating behavior.\nThe effects of two alleles on the neuropeptide Y (NPY) gene on the time to remating behavior were examined using C57BL/KsJ (BKS) and SWR mice as representatives of Npy gene alleles present in strains of mice used for the study of reproduction and breeding. BKS mice received higher scores than SWR mice in the latency from pairing to copulation, mount latency, and the frequency of mounts to SWR females. The mean latency to mount was shorter in the BKS strain than in the SWR strain when SWR males were coupled with BKS females, but it was comparable between the two strains when SWR females were used to pair with SWR males. BKS females copulated more frequently than did SWR females after the first time of pairing, but the copulatory activity of SWR females increased in the next mating. The results suggest that the BKS allele Npy(G403D) exerts a suppressive effect on the male reproductive behavior in BKS mice. These effects, however, became less evident when BKS females were used as mating partners. Therefore, the difference in the mating behavior caused by the Npy gene alleles may have been suppressed not by the estrogen level, but by the male and female copulatory activity itself in mice.<EOD>",
        "label": 0
    },
    "1894": {
        "output": "``` jupyter\nINST.show_solution()\nOUT[2]: ------------------------------- Trial-level eligibility: 2) Eligible.\n\n```\n\nLet's consider a second scenario that has five trials, the patients are much larger than in the last scenario, and the time cost of the first scenario increases to 0.3s. We will find the most efficient order first and then choose to be the fastest and the most efficient order. Here will show the result of the efficient order first.\n\n``` jupyter\nINST.show_solution_inferior()\nOUT[6]: ----------------- Trial-level eligibility: 2) Eligible.\n                     Group 1: 1.427s -> 2.787s\n\n```\n\nIn the above solution, we can find that there are a total of 2.787s time consumption to complete all the operations. The time consumption of Group 1 is 1.427s, and the time consumption of Group 2 is 1.360s, Group 3 is 0.823s, Group 4 is 0.620s, and Group 5 is 0.340s. The group's time consumption and time complexity increases exponentially with the addition of the patient's data.\nThis is not convenient in clinical trials, as doctors usually recruit many patients at once. Thus, we need to choose the two-level optimal solution.\n\n``` jupyter\nINST.show_solution_preferable()\nOUT[31]: ----------------------------------- Group 1: 1. 257s -> 1.427s\n Group 2: 1.160s -> 1.360s\n Group 3: 0.576s -> 0.823s\n Group 4: 0.422s -> 0.620s\n Group 5:0.314s -> 0.340s\n Trial-level eligibility: 2) Eligible.                          \n----------------------------------------\n                   Trial-level eligibility: 2) Eligible.\n                 Group 1",
        "label": 0
    },
    "1895": {
        "output": "# Instructions for creating a clinical Trials Template\nFollow these steps for creating an XML clinical trial template.\nStep1. Go to 'XML tools' menu of STCT application and Select 'Clinical trial definition editor'. [ ]\n\n\n![5.1 Figure 4.1 ](https://u2020.snu.ac.kr/u2020/assets/Clinical-2-Template.png)\n\n\nStep2. Select the clinical trial of interest by browsing or searching by Clinical Trial ID. [ ]\n\nStep3. Click the 'Edit Template' button to generate a clinical trial template. [ ]\n\nStep4. The tool will ask for trial-level eligibility. Click the 'OK' button. [ ]\nThe generated XML clinical trial template and original version of the XML trial definition file are attached in Appendix 1. The XML output file in step 4 can be downloaded as an RTF file by clicking the 'Download XMl' button. Please open the file by an RTF editor.\n\n# Step1 - Add Patients to Clinical Tri",
        "label": 0
    },
    "1896": {
        "output": "Good luck! \n![HUMAN CENTRIC](./images/human_centric.jpg)<EOD> Sparse-regularization-based iterative image reconstruction for SENSE-type parallel MR acquisitions\nWe propose an image reconstruction method for parallel imaging experiments using a sensitivity encoding-based reconstruction algorithm (SENSE) to reduce the number of measurements required to reconstruct a highly undersampled k-space. In the proposed method, a sparsity constraint is imposed on the image domain. The resulting algorithm iteratively updates the image and the coil filters by minimizing the sum of the discrete wavelet transform with sparse prior smoothness penalty and a combined least-squares cost function for data consistency and coil consistency, respectively. The proposed algorithm can outperform the standard method based on an optimal linear combination of k-space data with the inverse of the point spread function for both simulation experiments and actual MR experiments, and the reconstruction error becomes comparable to that of the SENSE method.<EOD> T1 hyperintensity in CADASIL: correlation with clinical findings.\nCerebral autosomal-dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is a hereditary small vessel disease caused by mutations in the NOTCH3 gene encoding the Notch receptor 3. Subcortical ischaemic strokes, migraine with aura, and dementia are the most frequent clinical manifestations of the disease. We reviewed the brain magnetic resonance (MR) images of 22 clinically diagnosed CADASIL patients (from 17 non-related pedigrees) and calculated the ratio between T1 hyperintense white matter and the rest of the brain, taking the cerebellar cortex and the cerebellar white matter as reference. An average value was determined to quantify hyperintensity for patients younger than 65 and older than 65 years old. The hyperintensity was related to the presence and severity of clinical signs. A statistically significant higher hyperintensity was found in patients older than 65 years. This increase was directly associated with the presence of stroke, headache, and cognitive impairment. In the young subgroup of patients a significant correlation was found between hyper",
        "label": 2
    },
    "1897": {
        "output": "__570__\n\n### Q&A\n\nQ: _In the first example a patient met two inclusion criteria whereas he met one and the other exclusion criteria. How should I do that? Is it the first exclusion or the second? In other words, would the exclusion criteria override the inclusion criteria in the assessment of eligibility?_ A: _This is a very common problem which is explained by the presence of incompletely described or missing inclusion criteria. You should choose the one which is best supported by the patient information. For example, based on what you have been given, the only thing we can really conclude is that the patient is not a healthy volunteer and has had no previous IFN, RBV and direct antiviral drugs in his history. He is IFN-na\u00efve. However, we cannot conclude that he has met the trial's inclusion criteria. For this reason, we should give him score 0 which indicates that he is excluded on the ground of the trial's exclusion. Then, we should not give any score regarding the eligibility._\n\n__571__\n\n## The patient's informed consent to participate in the trial\n\n__Exercise 57__ You should obtain the informed consent in a way which is in compliance with the trial protocol, law, and national regulations.\n\n__Exercise 58__ Your colleague will inform you about a trial and its inclusion/exclusion criteria.\nYour task is to get the informed consent of the patient in a way which would comply with the trial's requirements.\n\n _Here is the patient note:_\nThe patient is a 60-year-old woman diagnosed with cirrhosis. She has a history of HCV and alcohol abuse. Her past medical history is non-significant. The patient does not take medications for any disease. She has moderat alcoholic dependence (score from 2 to 4). She has no personal problems and has a good social background and support. There is no evidence of alcoholic liver disease, gastrointestinal bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. She has no other significant illnesses. She is an alert female with no ac",
        "label": 0
    },
    "1898": {
        "output": "Excluding Case Studies \nIn our research, some clinical trial protocols contain case presentation on case studies. For those case study protocols, it is easy to get a trial level eligibility for the case studies, simply by using`Trial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria);`\n\nExcluding Abstracts and Studies \nIf a patient has two or more reports on one clinical trial protocol, it can be difficult to determine the eligibility of patients for each report. We use `Trial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial);` to distinguish different reports, e.g`Trial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial);` for `Results`and `Discussion`; and`Trial-level eligibility: 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply);` for`Case report`and`Abstract`.<EOD> A case of severe hyperprolactinemia in a patient with Cushing's syndrome as a result of an autopsy case.\nCushing's syndrome occurs in a small percentage of patients with prolactin (PRL)-producing pituitary adenomas. We report here a 48-year-old woman with Cushing's syndrome who was found to have a PRL-secreting pituitary microadenoma. The patient had menstrual disorders and abnormal blood lipid levels for 13 years before the consultation. She was hospitalized for abdominal mass examination. She had not any abnormal symptoms regarding endocrine function. She subsequently consulted our department for the examination of Cushing's syndrome 17 days after hospitalization. Endocrinologic examinations revealed the following: plasma cortisol of 16,620 nmol/l, plasma adrenocorticotropic hormone of 878 ng/l. Urinary free cortisol of 508.5 microg/day, plasma PRL of 2797 ng/ml, bas",
        "label": 2
    },
    "1899": {
        "output": "## Examples\n\n\n---\n\n# TARVA\n1. Load `load_data/tvara.csv`.\n2. Train the model for classification\n\n    `train(tvara.train, tvara.test, 'default')`\n3. Test the model\n    1. `tvarahist`\n    2. You can do classwise evaluation\n    ```\n    classwise(tvara.test, tvara.train['Group'], Group='default')\n    classwise(tvara.test, tvara.train['Group2'], Group='default')\n    classwise(tvara.test, tvara.train['Group4'], Group='default')\n    # you can do ROC\n    Roc(tvara.test,tvara.train['Group']['default'])\n    # you can do precision recall\n    Prc(tvara.test, tvara.train['Group'], Group='default','alpha=0.1')\n    Prc(tvara.test, tvara.train['Group2'], Group='default')\n    # you can do calibration curve\n    Calib(tvara.test,tvara.train['Group'], Group='default')\n    # you can do cross validated calibration curve\n    CalCross(tvara.test,tvara.train['Group'], Group='default')\n    # you can do visualization\n    Viz(tvara.test,tvara.train['Group'], Group='default')\n    ```\n    ```\n    ##\n      %d\n      %l\n      %f\n      %g\n    ##\n         0 5\n        0.84735812419277\n            7.0\n            (0.847493079571182, 0.846791510548815)\n    ##\n    ##\n      %d\n      %l\n      %f\n      %g\n    ##\n      2 3.5\n       0.851886200357545\n              6.0\n              (0.85241155",
        "label": 0
    },
    "1900": {
        "output": "<EOD> .\nBACKGROUND\nThere is no gold standard for the determination of plasma free insulin, which could allow the differentiation between insulin deficiency and resistance. The aim of this study was to determine the diagnostic capacity of the fasting insulin level and free insulin index in the determination of insulin resistance.\n\n\nMETHODS\nOral glucose tolerance test (OGTT) was conducted in 113 adult females in whom the body mass index (26.2 +/- 1.6 kg/m(2)), waist-to-thigh ratio (0.39 +/- 0.02) and waist-to-hip ratio (0.83 +/- 0.04) were determined. The OGTT results were correlated with total abdominal fat and abdomen to upper extremities ratio. The fasting insulin and free insulin were also measured. We calculated the homeostasis model assessment (HOMA) index for insulin resistance (HOMA-IR) and sensitivity (HOMA-IS). We also calculated the insulin index for sensitivity (F/I), insulinogenic index for sensitivity to oral glucose tolerance test (I/GG), insulin index for resistance (L/I), and homeostatic model assessment beta-cell function (HOMA-beta) from the results of oral glucose tolerance test.\n\n\nRESULTS\nThe subjects were divided into two groups (with and without insulin resistance). There was a significant correlation (r = 0.513) between the fasting insulin level and abdominal fat. In the calculation of the insulin sensitivity index, using the data of oral glucose tolerance test (r = 0.426), fasting insulin (r = 0.258), and insulin index (r = 0.359). In evaluating the subjects only with regard to the fasting insulin there was a 35% chance that the person had insulin resistance, but the index of maximum insulin during oral glucose tolerance test (I/GG) had 50% chance of detecting this condition.",
        "label": 0
    },
    "1901": {
        "output": "## \ud83d\udcbb Implementation and Evaluation \ud83d\udc52\n\n> ### Solution\n> 1. **Step 1.** For your patient note, we will implement a conditional filtering system to determine the patient eligibility.\n> 2. **Step 2.** For the clinical trial, based on the patient note, we will predict the scale for the assessment of eligibility.\n> 3. **Step 3.** We will compare the results from Step 1 and Step 2 to evaluate the proposed solution.\n> 4. **Solution performance check.** Finally, we will evaluate the proposed solution to decide if it is suitable to implement in a real clinical environment.\n\n### Implementation\n\nHere is the code for implementing the solution in the step-by-step manner.\n\nStep 1: For your patient note, we will implement a conditional filtering system using `ListBox < ListBox >` to determine the patient eligibility.\n#### Patient note\n> 1. **Step 1.1.** Create a **ListBox < ListBox >**.\n```python\n    lb_patient_note= ListBox ()\n    lb_patient_note.PlaceholderText=\"patient note\"\n```\n> 2. **Step 1.2.** Create a **listbox items < ListBoxItem >**.\n```python\n    lb_patient_note_1= ListBoxItem ()\n    lb_patient_note_1.PlaceholderText=\"1\"\n```\n```python\n    lb_patient_note_2= ListBoxItem ()\n    lb_patient_note_2.PlaceholderText=\"2\"\n```\n```python\n    lb_patient_note_3= ListBoxItem ()\n    lb_patient_note_3.PlaceholderText=\"3\"\n```\n```python\n    lb_patient_note_4= ListBoxItem ()\n    lb_patient_note_4.PlaceholderText=\"4\"\n```\n```python\n    lb_patient_note_5= ListBoxItem ()\n    lb_patient_note_5.PlaceholderText=\"5\"\n```\n```python\n    lb_patient_note_6= ListBoxItem ()",
        "label": 2
    },
    "1902": {
        "output": "## The second case\n\n\nWe present another interesting case with our machine learning algorithms in data mining 32 .\nThis task is based on the following case scenario 32 . A company is trying to estimate a customer's chances of becoming a frequent flyer. They want to identify if there is an indicator that influences the possibility of becoming a frequent flyer. The data contains 1012 customers. The information given to this task is split into rows, where the columns are the features and the value inside the features is a float between 0 and 1. The columns are the attributes for each client. The target column contains the value `1` if the customer is a frequent flyer and the value `0` otherwise. For each client, there is a probability ranging from 0 to 1. For example, the values 0.006, 0.026, and 0.119 correspond to clients who are not frequent fliers and the value 0.957 corresponds to a frequent flyer. \nThe input data set contains information about the 1012 frequent and non-frequent customers. The features we have are: `Age`, `Income`, `Household`, `Marital`\n\nWe use the above-mentioned data set to train our algorithms.\n\nAs the data set is missing values and outliers, we need to clean the data set. We clean the data set according to the procedure in 'data cleaning.md'. Please refer to that file.\n<img src=\"../Images/Case1/Cleaned.png\" width=\"720\" hspace='2'\" align='center'/>\n```bash\ndata = cleanData(\"Data Set\")\n``` \nPlease do not forget to save the cleaned data set in a file with the extension .csv.\n\n```python\nfrom sklearn import decomposition\nfrom sklearn import decomposition, svm\nfrom sklearn import svm\nfrom sklearn import svm\nfrom sklearn import svm\nfrom sklearn.linear_model import Logistic Regression\nfrom sklearn.linear_model import LogisticRegression\nfrom sklearn.linear_model import LogisticRegression\nimport pandas as pd \n#data = pd.read_csv('Input_data.csv') #we have saved input data\ndf = pd.",
        "label": 0
    },
    "1903": {
        "output": "### Example I\n\n[INST] This example is designed to learn how to perform the clinical trial data entry. Since the patient notes do not describe the demographic data, such as age, sex, body weight, and height, do not input these demographic data for this example.\n\n[INST]  ________________________________________\n\n[Demographics] \nThis is a female subject, and no demographic data are recorded.\n\n[Diagnosis] \nThis patient has the co-infection of HBV and HCV, and her viral load is 5.2 and 10.6E5 IU/mL, and the HBV core antibody is positive.\n\n[Chemicals] \nThe patient is taking no other medications.\n\n[Histology] \nHistology of the liver needle biopsy is not specified.\n\n[MRI] \nThe liver MRI test was performed with extracellular contrast agent injection.\n\nPlease refer to the clinical trial data by accessing the following link:\n\n\n<a href=\"http://10-1.118.106.113:3838/ClinicalTrialsBoston_Data.html\">ClinicalTrialsBoston_Data.html</a>\n<a name=\"Instructions_for_Users_2\">Instructions for Users</a>\n\n[instructions are not shown, please click the [Next] button to see instructions]\n<a name=\"Instructions_for_Users_3\">Instructions for Users</a>\n\n[instructions are not shown, please click the [Next] button to see instructions]\n\n[INST] When you click the button <b>[",
        "label": 0
    },
    "1904": {
        "output": "### [END]\n<EOD> .\nBACKGROUND\nSkin cancer is the most common cancer in Iceland and the Western world, and basal cell carcinoma accounts for the majority of all skin cancer cases in Iceland.\n\n\nAIM\nTo assess the efficacy of two different treatment schedules, photodynamic therapy (PDT) and cryotherapy for superficial non-melanoma skin cancer in Iceland.\n\n\nMETHODS\nThis is a retrospective, non-randomized study. The study group consisted of 249 patients with nmskin cancer (251 lesions), 103 men, 146 women with a median age of 71 years (range 24-91) years. They were treated from January 1997 to March 2013. All lesions were excised, and histological diagnosis was made for all lesions. Patients were treated by PDT in 125 lesions and cryotherapy in 126 lesions. Results, recurrence rates or side-effects are presented as median values and with 95% confidence interval in parentheses.\n\n\nRESULTS\nRecurrence was 3% for PDT treatment and 7% for cryotherapy. Minor side-effects were 17% for PDT and 19% for cryotherapy, and a major side-effect was observed in 1% in both groups.\n\n\nCONCLUSION\nCryosurgery is a safe non-invasive technique for treatment of superficial basal cell carcinoma, and local recurrence rate and side effects are similar to that of PDT. There are few contraindications for cryosurgery and it can be used in almost every patient with good outcomes. In Iceland, cryosurgery is a reasonable treatment modality for skin cancer, with a limited number needed to treat to prevent one recurrence. Keywords: non-melanoma skin cancer, cryotherapy, photodynamic therapy, side-effects, recurrence, Iceland.<EOD> Nitric oxide and the regulation of renal arginine transport by insulin and diabetes\n1 Insulin and insulin\u2010like growth factor",
        "label": 0
    },
    "1905": {
        "output": "### Part 6: Trial-level Eligibility for Inclusion ###\nAs soon as you find a patient eligible to be enrolled in the trial, you should make another trial-level eligibility and then add all trial-specific information to the trial-level eligibility record. Note that your first eligibility record does not exclude a patient, but is only relevant to the study in question. If a patient is not eligible for a given trial, you should not store this fact into the database. \n\n1. Make a `trial-level eligibility` and add the following trial-specific information to this record by pressing `CRTL+Enter`: \n    `Trial-level eligibility: '2)`\n    \n    `Trial-level eligibility: 'Eligible'.` <EOD> Isolation and identification of a serine protease from marine fish Sardinella longiceps\n\nA protease purified from Sardinella longiceps using a stepwise fractionation technique was isolated and characterized. The enzyme activity (specific activity -6.41 \u00c2 10 3 \u00b10.54 U/mg) was maximum in casein (Cz-substrate) at pH 7.3 with optimum temperature 655 C. It has broad substrate specificity as it was found active towards azocasein (Azo-casein), haemoglobin (HGB), BSA (BSA) and casein (Cz), as well as synthetic substrates, succinyl-Ala-Ala-Pro-Phe p-nitroanilide (SAAPFpNA) and hippuryl-L-arginine p-nitroanilide (HAPN). Peptic digestion of",
        "label": 0
    },
    "1906": {
        "output": "**[OPTIONAL]**\nYou should always complete your data modeling with visualizations. Here is a good way to summarize the most important steps of the study analysis:\n\n![instances](./media/instances.png)\n\n**[OPTIONAL]**\nFor your own reference, here is the full data set:\n\n<EOD> Effect of tube placement on the performance of the Vitek-1 microbial identification system for anaerobes.\nThe influence of the growth medium and tube length on the performance of the Vitek ID-NEFF card was evaluated with 142 isolates of anaerobic bacteria. There was no significant difference in the number of misidentifications for isolates prepared in R2A broth with or without the Vitek tube system. The anaerobic media without the Vitek tube system proved to be as successful as the tube system.<EOD> The effect of goniotomy and iridotomy on pupil diameter\nPurpose To investigate the effect of goniotomy and iridotomy on pupil diameter (PD) in patients with open-angle glaucoma (OAG). Methods This was a retrospective review of 11 eyes of 11 patients who have undergone goniotomy and iridotomy operation for OAG and followed up for at least one year. The PD, preoperatively and postoperatively, was measured with a caliper and then recorded. The preoperative PD was measured 1\u2009month and 12 months after surgery, and was recorded in 11 eyes. The changes in PD before surgery, at 1 month and 12 months after operation, were analysed statistically. Results The PD ranged from 7.0\u2009mm to 9.5\u2009mm before surgery. At 1 month after goniotomy there was a mean reduction in PD of 0.77\u2009mm (p=0.04). The PD at 12 months after operation has improved compared with that observed 1 month after goniotomy (p=0.000). However, the mean PD remained statistically unchanged from 1 to 12 months after surgery (p=0.999).",
        "label": 0
    },
    "1907": {
        "output": "[EOF]\n<EOD> 785. Evaluation of Diagnostic Studies to Guide the Cessation of Ceftriaxone Therapy for Gram-Negative Bacteremia\n\nS664 - OFID 2019:6 (Suppl 2) - Poster Abstracts 2018 and 2019 at the Scripps Mercy Hospital, a tertiary care academic hospital in San Diego, CA. Microbiological testing was performed per standard of care. Data from demographic, clinical outcomes, and cost were obtained from the hospital's electronic health record. For patients with more than one positive CBNAAT, only the first episode (i.e., the first time a pathogen was detected by the CBNAAT) was included in the final analyses.Results. Of 1257 patients admitted during the study timeframe, 244 (19.2%) received CBNAAT testing. The mean age (53.4 vs. 68.0 years; p = 0.016) and proportion of females (67.5% vs. 57.4%; p = 0.032) were significantly different in patients with and without CBNAAT testing. Of the CBNAAT results, the majority were negative (77.1% for pneumonia; 79.8% for bloodstream infection), and Escherichia coli was the most commonly identified pathogen (67.0%). The mean hospital length of stay (15.2 vs. 6.4 days; p < 0.001) was longer and mortality rate (6.2% vs. 0.6%; p = 0.011) was higher among patients tested by the CBNAAT(Table 1). Total charges were significantly lower in patients with a negative test (USD 29,128 vs. USD 89,337, p = 0.042). The median time from admission to CBNAAT test was zero (interquartile range [IQR], 0-0 days) and ranged from zero to 23 (IQR, 0-3 days) days. The median time from ordering to",
        "label": 0
    },
    "1908": {
        "output": "The code for the assignment of trial-level eligibility:\n<%\nTRIAL-LEVEL ELIGIBILITY=\"0\"\nTRIAL-LEVEL ELIGIBILITY=\"1\"\nTRIAL-LEVEL ELIGIBILITY=\"2\"\n%>\n\n# Trial-level eligibility: 0) Excluded\n<tr>\n  <td>Excluded</td>\n  <td>${TRIAL_LEVEL_ELIGIBILITY_0_EXCLUDED_MESSAGE_EN}<br />\n  ${TRIAL_EXCLUDED_LIST_1}</td>\n  <td>Exclude</td>\n</tr>\n\n# Trial-level eligibility: 1) Not relevant\n<tr>\n  <td>Not relevant</td>\n  <td>${TRIAL_LEVEL_ELIGIBILITY_1_NOT_RELEVANT_MESSAGE_EN}<br />\n  ${TRIAL_EXCLUDED_LIST_2}</td>\n  <td>Exclude</td>\n</tr>\n\n# Trial-level eligibility: 2) Eligible\n<tr>\n  <td>Eligible</td>\n  <td><b>${TRIAL_LEVEL_ELIGIBILITY_2_ELIGIBLE_MESSAGE_EN}</b>\n  <br><br>\n  ${TRIAL_INCLUSION_LIST_EN_1}\n  </td>\n  <td>Include</td>\n</tr>\n<EOD> The effects of adrenergic stimulation on mesenteric vasculature in dogs during hypothermia\nWhen the spontaneously gyrating mesenteric vasculature of the dogs was studied by means of cineangiography, it was found that the vessels at a temperature of 38.5 C dilated during the cold-induced vasoconstriction. This increased diameter resulted from a reduction in the amplitude of contraction and not from an increase in the velocity of vessel wall motion. Stimulation with epinephrine, 1",
        "label": 0
    },
    "1909": {
        "output": "- [INST: ]",
        "label": 2
    },
    "1910": {
        "output": "<EOD> Prolongation of skin allograft survival by monoclonal anti-T cell antibodies: evidence that thymectomized skin can function independently of the host T cell response for 60 days.\nHindquarters grafts of guinea pig skin from a major histocompatibility complex haplotype disparate donor on which had been primed a mixture of two monoclonal antibodies, BP1 and 1B10, were protected against rejection for over 60 days in intact normal guinea pigs; the same antibody mixture had no effect on the survival of sham-transfected skin from the same donor. The presence of a thymic graft in the postcaval region was found to be sufficient to promote the rejection of both sham- and antibody treated skin grafts in less than 7 days. The fact that thymectomized transgenic skin was not immunogenic in normal recipients for 60 days after transplantation suggests that the thymus-independent component of immune responsiveness is sufficient for the rejection of skin for at least this period of host growth, and that the thymus-dependent component of immune responsiveness is of greater physiologic significance than indicated by the findings of studies using the skin graft model.<EOD> Risk behavior and sexual communication among young adults in heterosexual relationships.\nDespite growing concern about adolescents' risky sexual behaviors, little is known about the sexual communication skills of young unmarried adults. In this study we describe the attitudes toward, and the frequency of, sexual communication among 78 young adults who are currently in heterosexual relationships and who do not expect to marry before age 23 and assess the links between sexual communication and actual engagement in sexual risk behaviors. The findings suggest that young adults with better sexual communication often engage in less risky sexual behavior. The study also finds that young adults who are satisfied with their communication skills and those who are more likely to communicate about sex are more likely to be virgins than those who are unhappy with their communication skills and those who are less likely to mention sex. Men and those reporting higher levels of stress also are less likely to be virgins than women and other men, respectively.<EOD> The",
        "label": 0
    },
    "1911": {
        "output": "Here is the example of a patient-level eligibility assessment note on a new trial-level eligibility.\n\nPatient Name: Mr. YOUNG\n\n\nD.O.B:\n\nMedical record number:\n\nAssistant to trial: J. MEDINA\n\nRating:\n\nAssigned to:\n\nTitle\n\n\nAssessment of clinical trial eligibility will be performed by the above listed trial director and nurse under the supervision of clinical trial specialist, Dr. BROWN. A written record of the assessment will be kept, including the original copy, a copy containing the trial director or nurse notes, and copy of the written consent.\n\nThe following are the inclusion criteria that apply for the clinical trial: 0) Age > 50, or 1) Age > 65 and on a drug therapy for cardiovascular conditions.\n\nThe following are the exclusion criteria that apply for the clinical trial: 0) Myocardial infarction or congestive heart failure in the last 6 months, or 1) Coronary artery bypass graft, or 2) Implantable cardiac device, or 3) Heart block 2/3, or 4) Severe cardiovascular disease, or 5) Uncontrolled angina pectoris, or 6) Congestive heart failure (NYHA III), or 7) Recent coronary artery by-pass surgery, or 8) Concomitant significant illness or medical condition such as serious infections and other significant diseases that may put the subject at risk due to participation in the trial, or 9) Use of medication(s) that may affect the results of the trial, i.e., drugs interfering with the effects of the study drugs, or 10) Use of prohibited medication(s), or 1) Subjects who are undergoing a program of weight reduction, or 2) Subjects who have received weight loss medication(s) within the last three months before the screening visit, or 3) Any physical examination abnormality that may be responsible for symptoms related to weight change or weight (loss) with (during) the study drug treatment,",
        "label": 0
    },
    "1912": {
        "output": "[table]  1: [HCV]):02:02:200109_09_33_26, [HBV]:03:04:140039_09_32_10, and [BMI]:12:06:140029_10_35_11) [/table] \n<EOD> The Effect of Varying Levels of Oily Malleates with Resin Composition on the Mechanical Properties of Resin-based Infiltrant Materials\n\nOily malleates are oily liquids, which are added into resin formulation, and they reduce monomer conversion by inhibiting the reaction between the activators and the resin matrix, and thus they increase the flow and extrudability of the resin composites. The aim of the present study was to evaluate the effect of incorporating oily malleates on the mechanical properties of resin-based infiltrants (RBIs). Oily malleate was added to 10 w/w% wavelength-dependent photoinitiating systems and resin composites with resin contents of 75 and 90 w/w% Bis-GMA, respectively, and a 25 w/w% hybrid filler. The prepared RBIs were then subjected to 10,000 thermal cycles in a temperature-cycled oven. In each cycle, RBIs were exposed to thermocycling from 37 to 49 - C. The shear test was performed after thermal cycling. The addition of oily malleate increased the flow and extrudability of RBI [fig_ref]  Figure 1: The flow of dental resin composites with the various levels of oily... [/fig_ref] . Increasing the concentration of oily malleate from 0.0 to 0.5 w/w% was associated with a 70% decrease in the shear bond strength, and a decrease in the shear bond strength by 85% was found when the concentration of oily malleate was increased from 0.0 to 1.0 w/w%. The incorporation of 50 and 70 wt.% (6 and 7 vol.%) oily malleate in the form",
        "label": 0
    },
    "1913": {
        "output": "## Evaluate the patient for eligibility\nYour job is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. Please first evaluate the patient for eligibility.\nIn the \"HBV-HCC 100mg\" subpanel, you can evaluate the patient for eligibility, respectively, by dragging the patient note from the \"Inclusion criteria\" tab or by searching the patient note in the \"Evaluate for Eligibility\" tab. After all the patient notes in the \"Inclusion Criteria\" tab have been evaluated, click on the \"Check\" button to save the assessment. \nClicking \"Check\" will display the assessment status. A \"0\" in the box means \"Excluded\", a \"1\" in the box means \"Not relevant\". Only when both \"Excluded\" or \"Not relevant\" appears, the patient was determined not to be a qualified candidate for the clinical trial. A \"2\" in the box means \"Eligible\".\n\nClick the \"OK\" button to return to the \"Inclusion criteria\" tab. [/HBV_HCC_100mg]_Evaluate_for_eligibility](http://www.jennyxwang.cn/u/jx_2019_SRC_Inst/html/HBV_HCC_100mg_Evaluate_for_eligibility.html)\n\n## Viewing and sorting patients for eligibility\nUse the \"Viewing and Sorting\" menu to view and sort patients for eligibility. \nClick the tab below to see the details. Then click on a \"+\" sign symbol to expand the group. By default, patients are grouped based on their trial ID. After selecting a \"+\" sign symbol in the group of interest, clicking the \"Sort\" drop-down box will sort the patients by the selected column descending. Then the patient name will be sorted from top (first selected patient) to bottom (last selected patient). You can also click the \"Sort\" drop-down menu and select the column to sort, then click the \"Sort\" button.\n\n\n## Exclude patients\nClicking \"Exclude\" at the bottom will exclude a certain patient from the clinical trial. The information including date",
        "label": 0
    },
    "1914": {
        "output": "Now test your code with your patient data, that is, `Trial-level eligibility = rec_fitting.predict(x.loc[:,[\"Inclusion_Status\"])[patient_id].T).sum().reshape(x.loc[:,[\"ID\"])+x.loc[:,[\"Patient\"]])`, and with your trial data, `trial_eligibility = trial_analysis.predict(training_analysis).T.sum().reshape(x.loc[:,[\"ID\"])] + trial_analysis.predict(test_analysis).T.sum().reshape(x.loc[:,[\"ID\"]])`.\n\n## Data\n\n## Data import and data frames\n\nTo start a Jupyter Lab session click on New Lab and select Jupyter Lab Notebook to start a new notebook\n\nTo work with data you import it from the data folder and combine information from different folders in a dataframe.\n\nTo import the data select the folder containing your data and click new. Here you choose your data, folders and names. When you are familiar with the dataset select `Create New Notebook` or `Create Empty Notebook`.\n\nNow select your dataset `Data` in the side menu on the left and click `Export to Jupyter Notebook`. This will produce a notebook which contains a dataframe. You can now open the file in your Jupyter Lab.\n\nYou should be able to find the dataset on your local file system in your folder `1\\_Lab Book\\data-v0\\\\dataset`. This dataframe should list different drugs and diseases, like so.\n\nYou can save this data file as a.csv file with the save widget at the left.\n\nInside the folder called dataset (1_Lab Book\\data-v0\\disease) you should find additional folders that match this dataset. For the disease 'Vitamin Insufficiency and Deficiency' there are two different folders 'A_Vitamin Insufficiency and Deficiency' with folder structure `year` and `gender`.\n\n\nIt looks like that there is `Sodium Insufficiency and Deficiency`. 220 drugs can also be found in this dataset.\n\n\n\nNow select the variable 'Drug_name' in the dataframe 'vitamin_insufficiency_and_deficiency'",
        "label": 0
    },
    "1915": {
        "output": "<a id=\"problem_1\"></a>\n## Problem #1: Excluded on grounds of the trial exclusion criteria\nIt means that the patient note has been assessed as \"excluded\" because it violates the current clinical trial on ground X-1. So, if you find patient notes excluded for any reason, you should mark it as follows:\n`trial-level eligibility: \"0\" excluded on grounds of the trial exclusion criteria 1; trial-level description: \"Excluded because of reason X-1. \" # trial-level assessment`\n\n<a id=\"problem_2\"></a>\n## Problem #2: Unkown in trial\nIt means that the patient note has not been assessed as eligible for a good reason. So, if the trial has no information about how to assess the eligibility, we should set it as follows:\n`trial-level description: \"Could not be assessed because of reason Y-2. \" # trial-level assessment`\n\n<a id=\"problem_3\"></a>\n## Problem #3: Not relevant\nIt means that the patient note has no informative value for an entry. If the patient note is completely blank or has nothing useful to inform, we should set it as follows:\n`trial-level description: \"Not relevant. \" # trial-level assessment`\n\n<a id=\"problem_4\"></a>\n## Problem #4: Not evaluated\nThis means that the entry has not been evaluated, i.e., it has not been processed by the clinician, so it did not meet the assessment criteria.\n`trial-level assessment: \"Not evaluated. \" # trial-level assessment`\n\nThis process is done after the clinical trial, but before the clinical note. \n\nWe should find all the issues and fix them by editing the corresponding field.\n<commit_before>\n\n#!/usr/bin/env python\n# \n# MIT License\n# \n# Copyright (c) 2019 <NAME>\n# https://github.com/DoranRamadan/clinical_trial_eligibility\n#\n# Permission is hereby granted, free of charge, to any person obtaining a copy\n# of this software and associated",
        "label": 0
    },
    "1916": {
        "output": "## Task 2\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare all patients' information of a given patient note with the inclusion criteria of a given clinical trial. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. You should report the number of patients who are eligible on each trial from all note information. \n\n1) \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.Here is the clinical trial: \nTitle: Implementation and Evaluation of Care Coordination in Linkage to Care for Hepatitis C Following Release From New York City Jails\n\n\nSummary: This study assesses the impact of a hepatitis C care coordination program on rates of linkage to hepatitis C care following release from New York City jails. Adult patients (age 18 years and above) with chronic Hepatitis C infection at Bellevue Hospital Center 19 North prison clinic from July 1, 2015 through December 31,",
        "label": 0
    },
    "1917": {
        "output": "# HLOD\n\n## Preparation of data\nAs a working example, use the file <NAME>_003.mat. Open it, and the variable <NAME>_trialname should be visible in the workspace. Save it as <NAME>_prepdata.txt so that it can be found later.\nWe recommend working through the triallevel file, <NAME>_triallevelprep.txt. It should give you some more insight, which will be particularly helpful for the first 5 patients. Open as <NAME>_triallevelprep.txt.\n\n# Run experiment\n``` matlab\n\nclear all, but preparedata\n\ndatafile = 'prepdata1.txt';\npatientfile = 'prepdata.txt';\n\nload(datafile); % load data\nx = trialname.trial_id; % x is the trial name\npatients = [ trialname.patient_number trialname.age trialname.gender trialname.age_diagnosis ]; % patients_0-15\nif patients(3,3) == 0 % diagnosis is HCV\n  if patients(3,1) == 2.2 && (patients(3,2) == 9.4 || patients(3,2) == 9.6 || patients(3,2) == 9.8) && patients(3,2) == patients(3,6)\n    trialname.eligible -= 0;\n    trialname.notrelevant -= 0;\n  else\n    trialname.excluded -= 1;\n  end\n  patients(3,3) == 'eligible'; % is this statement a good place?\nelse\n  trialname.excluded -= 1;\n  trialname.notrelevant -= 1;\n  patients(3,5) == patients(3,6): % the patient is not excluded?\nend\ntrialname.trial_id = [ x,' ']; % put trial-name\nsave(file, trialname); % save the data again\nload(patientfile); % load trialfile again, and run the following.\nNtrial = 15, trialname = [], x = []; clear all; % clear the global variables.\npatients = []; pat = 2",
        "label": 0
    },
    "1918": {
        "output": "### Submission of the clinical trial\nUse [SEND] to end the clinical trial. It will send your trial to clinical data and trial submission to all of our partners including TrialsCentral.org and ClinicalTrial.gov.\n[SEND]\n\n### Additional Help\nFor additional help, consult the help page. Also, you can contact the help desk at helpdesk@dendrite.biotech. Here is the link to the help page: ___________________________________________________________________________________\n[END]<EOD> <reponame>stefangeorgiev/jugger.net\n'use strict';\n\nObject.defineProperty(exports, \"__esModule\", {\n  value: true\n});\nexports.default = (document) => {\n  if (!document) {\n    process.throw('Please pass in a valid Document object as first argument.');\n  } else {\n    return {\n      'type': 'custom_types',\n      'type_url': 'https://documentare.com'\n    };\n  }\n};<EOD> Impact of interhospital transport during COVID\u201019 on the risk of respiratory failure and hospital mortality\nThe pandemic caused by the SARS-CoV-2 (COVID-19) has raised important therapeutic challenges globally. However, patients transferred from a general hospital to a tertiary hospital are more prone to experience several problems and to experience severe complications and even death during and after interhospital transport. The present systematic review was aimed to investigate which type of patient has a high risk of respiratory failure and death during the interhospital transport during the COVID-19 pandemic.<EOD> Detection of Human Papillomavirus DNA in Breast Cancer Tissue Using Sensitive Highly Efficient DNA Chips\n\nObjectiveBecause the association between breast cancer and human papillomavirus (HPV) infection has been studied for years, we aimed to study the expression of HPV E6/E7 and L1 in breast cancer using DNA chip technology.MethodsWe collected and assessed breast cancer tissues from 50 patients with breast cancer by use of an HPV DNA chip and PCR. The chi-square test was performed to determine the significance",
        "label": 1
    },
    "1919": {
        "output": "This patient could be suitable for this clinical trial. \n\nTo test the script, let's enter some valid inputs. \n```\n./python2 test_eligibility_for_clinical_trials.py 10.40.72.61\\ Test\\ test_eligibility_for_clinical_trials.txt out\n```\nThe output of the script on the test dataset is given below:\n\n```\n/INST Hello. You are a helpful assistant for clinical trial recruitment. /IN STYour task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. \n\n-[Leading-zero] Patient note :\n-[Leading-zero] Inhibition of HCV replication by siRNAs:\n-[Leading-zero] This is an open access article under the CC BY license (/INST 3) 738x-'/INST -\n-[Leading-zero] . A study to evaluate the immunomodulatory properties of the histone deacetylase inhibitor 3) 738x-'/IN ST-VPA in the regulation of innate and adaptive immune responses/INST -\n-[Leading-zero] in cancer patients/INST \n12/31/2009; 359 ): 3593-360/IN ST \n\n-[Leading-zero] . A study to evaluate the immunomodulatory properties of the histone deacetylase inhibitor 3) 738x-'/INST -\n-[Leading-zero] in cancer patients/INST \n12/31/2009; 359 ): 3593-3601 3593\n12/31/2004; ).\n\nThe result is below:\n\n```\nINST Patient is included in the clinical trial, the reason is [Leading-zero] Trial-level eligibility : 2) Eligible.\n\nINST Clinical trial:\n\nINST [Leading-zero]",
        "label": 0
    },
    "1920": {
        "output": "# Results\n\n<h2>[x] <PASSODA> Test passed</h2>\n<h4>Tests Summary: </h4><p> <PASSODA>  test_HV004_IFN_for_sofosbuvir_eligibility.js, <PASSODA> <PASSODA>  test_HV004_IFN_for_sofosbuvir_eligibility.py.</PASSODA></PASSODA></p><p><PASSODA> Python script for the test:</PASSODA><code class=\"python\"><pre class=\"highlight plain\" data-lang=\"python\">import json\nimport os\nimport textwrap\nimport re\nimport shutil\nimport yaml\nimport subprocess\n\ndef execute(*args):\n    \"\"\"Execute an OS subprocess and returns the result, as a string.\"\"\"\n    cmd = \"\"\n    for arg in args:\n        if cmd == \"\" and arg.startswith('--'):\n            cmd = arg\n        else:\n            if cmd.endswith('\\\\n'):\n                cmd += '\\r\\n' + arg\n            else:\n                cmd += \"\\n\" + arg\n    output = subprocess.call(cmd,  stdout=subprocess.PIPE)\n    return output\n\ndef replace_tabs_with_spaces(text):\n  return text.replace(\"\\t\", \"    \")\n\ndef get_path_to_test_file():\n    import os\n    import yaml\n    dirs = [\"../../..\",\n        \"source_files\"]\n    current_dir = os.path.dirname(os.path.realpath(__file__))\n    for i in range(1, len(dirs) + 1):\n        print(current_dir) if \"source_files\") else \"{0}/{0}\".format(\"source_files\")\n    print \"Source code of the demo application files: \"\n    print \"    {0}\".replace(\"source_files\", \"source_files\").replace(\"runs\", \"runs\")\n    print\n\n    demo = get_path_to_test_file().split(\"source_files\")\n    test_file = str(get_path_to_test_file().replace(str(",
        "label": 1
    },
    "1921": {
        "output": "<EOD> P397: Nursing activities and hospital processes: exploring their relationship\n\n\n\n# Introduction\nThe relationship between nursing activities and hospital processes has been little explored, despite being very important in determining the quality of care. Nursing activities are interrelated, complex, and the result of technical, ethical, and political decisions that affect the care given. This relationship may be considered a relevant quality indicator for analyzing nurse workload and for health care planning at the national level.\n\n## Objectives\nTo analyze the relationship between hospital processes and nursing activities, focusing on care provided to people with different pathologies.\n\n# Methods\nCross-sectional study. The study was conducted between January and September 2016, through a literature review. The review comprised data from the MEC (Brazilian Ministry of Health) and the nursing-care guide of hospitals. A thematic content analysis was carried out.\n\n# Results\nStudies carried out in hospitals in the northeast region of Brazil and outside Brazil that address the relationship between hospital processes and nursing activities have been found, such as in the MEC. The guide was created to improve hospital processes and nursing care.\n\n# Conclusion\nIt is concluded that the current hospital processes are not properly planned and do not contain all the activities to be carried out, resulting in a work with many gaps and a number of uncertainties.\n\n# Disclosure of interest\nNone declared.\n \u00a9 2017 de Souza Filho et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.<EOD> Assessment of the impact of COVID-19 on the activity of hospital emergency departments based on an international survey of 25 countries\n\n\n\n# Background\nThe COVID-19 pandemic is arguably the greatest public health calamity of our generation. Globally, this disease has resulted in millions of deaths and over 60,000,000 people infected . The first cases of COVID-19 were identified in Wuhan,",
        "label": 0
    },
    "1922": {
        "output": "[bib_ref]  Learning to Determine the Suitability of Alzheimer3s Patients for a Clinical Trial, Lee [/bib_ref]  \n[fig]  1: [PRE]; and (2) [`POST']. The output of both the `PRE` and `POST` sections should be in the form `Trial-level eligibility: <scale>.` [/POST] For example, [`Trial-level eligibility: 2) Eligible.`](`Trial-level eligibility: 0) Excluded.`, and [`Trial-level eligibility: 1) Not relevant.`](`Trial-level eligibility: 2) Eligible.`). [/fig] \n<EOD> Comparison Between Open and Laparoscopic Radical Nephrectomy in Large Renal Carcinoma in China\nBackground: To make a comparison of the operative time, the quantity of intraoperative blood loss, pain relief, functional outcome after surgery, hospital stay and renal function between open radical nephrectomy (ORN) and laparoscopic radical nephrectomy (LRN). Methods: Between November 2009 to January 2011, a total of 107 patients who were subjected to nephrectomy were enrolled in this study. Among them, 64 were diagnosed as large renal carcinoma (\u2267T3). These patients were divided randomly into 2 groups: 32 underwent LRN (3 left and 29 right LRN) and 32 underwent ORN (3 left and 29 right ORN). The operative time, the quantity of intraoperative blood loss, pain relief, duration of hospital stay and renal function after operation were compared between the 2 groups. Results: The operative time of laparoscopic group was longer than that of open group, but the intraoperative blood loss was less in laparoscopic group. There was no statistical difference between the postoperative C-reactive protein (CRP), creatinine and urea nitrogen (UN) levels between the 2 groups. LRN had significantly earlier relief of pain, quicker recovery of renal function and shorter duration of hospital stay when compared with ORN. Conclusions: LRN",
        "label": 1
    },
    "1923": {
        "output": "##[INSTRUCT]\nYou should always print the patient's name and date after the Trial-level eligibility. So, we change `Trial-level eligibility:`  to  `Trialevel eligibility: ` in the last line, the only difference is a dot after `Trial-level eligibility:`. \n```r\n\nTrialevel eligibility:\n``` \nIncluding the patient note in `Trialevel eligibility:`, i.e., the last line should start with\n`Including note:` to include the name of the patient and the date (either the date of the trial note or the date the trial note was reviewed) in the last line of the file. You may omit Inclusion Criteria, Clinical Trial Protocol, and Trial-level eligibility if you like. \n\nThe results of your work should be stored in the eligibility assessment folder. \n<EOD> Craniofacial morphology in complete unilateral cleft lip and palate patients: a review\n\nUnilateral cleft lip and palate (UCLP) patients are often accompanied by craniofacial deformities, such as bone deficiency, facial asymmetry and dentoskeletal discrepancies. The aim of this study was to report the craniofacial morphology in UCLP according to the cleft side and cleft size. Relevant studies were selected from the electronic databases (PubMed, Cochrane Library, Embase, Scopus, CKB, Wanfang, and CNKI). A total of thirteen studies were included in this report. Four clefts are categorized according to laterality and extension: CL (unilateral cleft lip), CP (complete unilateral cleft lip and palate), SL (unilateral submucous cleft lip), SM (unilateral submucous cleft lip and palate). There were differences in the bone deficiency between left-side cleft and right-side cleft in CP patients. Facial asymmetry was seen in CP and SM patients, and significant differences were found in the vertical and distance ratio between bilateral zygomatic arches and bilateral lateral nasal walls. Dental",
        "label": 0
    },
    "1924": {
        "output": "## [/PATIENT]\n[/TRIAL]\n\n## [/HOSPITAL]\nThis is the input of the trial-recruitment assistant.\n## INPUT 0001\n\nThe following is the example of a clinical trial input. The clinical trial input includes the following elements: trial description, inclusion/exclusion criteria, and demographic factors.\n\n## Demographic factors:\nAs Asian Americans are 8-13 times more likely to develop liver cancer with 60% higher death rate than NHW. Regular monitoring of CHB is vital in preventing HCC. Research indicates that regular monitoring combined with antiviral treatment when appropriate, is critical to reduce the risk of liver disease (including HCC). Unfortunately, treatment effectiveness diminishes if CHB patients do not adhere to long-term monitoring and treatment guidelines. Adherence among Asian Americans with CHB is low. Poor healthcare access and significant cultural barriers prevent long-term adherence to monitoring and optimal treatment, placing Asian Americans at disproportionately high risk for HCC and increased healthcare costs.\n\n## Inclusion and exclusion criteria:\nAge 18 and above; Self-identified either Chinese, Korean or Vietnamese ethnicity. Chronic HBV infection with positive HBV surface antigen (HBsAg); Non-compliant to HBV monitoring and treatment guidelines in the past one year\n\n<EOD> Pregabalin for neuropathic pain in adults.\nBACKGROUND\nNeuropathic pain is a term which describes pain caused by direct injury to or disease of the somatosensory nervous system. In some cases neuropathic pain cannot be relieved by non-opioids or by opioids.\n\n\nOBJECTIVES\nTo assess the analgesic efficacy and tolerability of pregabalin compared with placebo or other active treatments for relieving acute and chronic neuropathic pain.\n\n\nSEARCH STRATEGY\nWe searched the In-Process & Other Non-Indexed Citations, Ovid MEDLINE, EMBASE, CINAHL and databases of clinical trials. We also searched bibliographies of clinical trials and reviews in this field as",
        "label": 0
    },
    "1925": {
        "output": "A simple example is as follows: \nFirst example is as follows: \nSecond example: \nThird example: \nFinally, your patient's final eligibility assessment result is as follows: \n\n# Evaluation\nInput data as needed.\nThere are two evaluation stages in our exam: the individual-patient level and the trial-level eligibility assessment. When you click the 'Evaluate' button, a popup window opens. The first stage is an individual-patient assessment. In this stage, the algorithm for the patient's data will be presented and evaluated. As you use 'TRIAL 001' (1st trial in the table), you should evaluate the first stage. When you click the 'Trials' button, a dropdown menu would come out. You should click on the 'TRIAL 001' (1st trial in the table), see in the left bottom area. Note that the user should click on each trial that the patient has completed. If you click on any of the patient's trials, the algorithm for the data would be presented. You should evaluate it and finish the evaluation. You would be presented with a warning (yellow) if an evaluation error has occurred.\nWhen you complete the evaluation of an individual-data item, you will be presented with the checkmark for that item. If you click the 'next' button, a popup window for the trial-level eligibility assessment will be open. The first line of this assessment is Trial-level eligibility, as depicted in the right bottom area. Below it is the algorithm that can be evaluated for all data of a patient, which is the same as the patient-level evaluation. If the algorithm is completed, press the check mark, otherwise click the 'next' button to continue the evaluation for other data. \n\n### Expected output\nExpected output: \n\n# Discussion\nInstructions:\nIt is important to note that there are four possible results for the eligibility assessment.\nFirst, the patient is excluded if the algorithm of the first stage evaluation is rejected. Thus, the value is 0. Second, in some cases, the algorithm of the first stage evaluation is accepted, and yet the patient is excluded as the algorithm of the second stage evaluation is rejected; the value is 1. This is because",
        "label": 0
    },
    "1926": {
        "output": "The output format will be, say, `Ruby<NAME>, PY396, A124_24`, where `Ruby<NAME>` is to be replaced by your name in upper case. \n\nAfter you send the solution for this assignment, continue to the next [INST].\n\nIf you solve Assignment 27, you may skip 4 new assignments, i.e., Assignments 28, 29, 30, and 31, and move directly to Assignment 32.\n\n:stop\n\n## **34. [INST] Propose improvements for the following programs\nWrite a program to read a file in the form shown below, with only valid integers.\nWrite a program to output one line per row containing only the even elements of the numbers 0 to 1023.\n\n:start\n\nAssignment 27:\nRead file name: `input.txt`\nRead the numbers 0-1023 from 10 rows, and store each number in an array.\nStore each number of [0,1-1023] in array named `intArray`.\nFor(var j = 0; j < intArray.length; j++)\n{\n\tif(intArray[j] % 2 == 0)\n\t{\n\t\tconsole.log(intArray[j]);\n\t}\n}\n\nAssignment 28:\nRead file name: `input.txt`\nRead the numbers 0 to 1023 and save the even numbers and the odd numbers in separate arrays.\nSave the even numbers in an array named `evenArray`, and the odd numbers in an array named `oddArray`, and display the values.\nfor(var i = 0; i < evArray.length; i++)\n{\n\tconsole.log('Even: ' + evenArray[i]);\n}\nfor(var i = 0; i < oddArray.length; i++)\n{\n\tconsole.log('Odd: ' + oddArray[i]);\n}\n\nAssignment 29:\nInput: an array of integers 0 to 1023 from 10 rows. \n\nWrite a line for each row, with the even numbers.\nUse for-in to iterate",
        "label": 0
    },
    "1927": {
        "output": "## Disease stage\n\n## [MAT] Hello. This is MAT. You are the coordinator of a drug trial on HIV infection and it is time for me to review your clinical data. Please remember that the purpose is to ensure quality control and to ensure that the data are suitable for further analysis.\n\nPlease tell me by pressing 1 if the patient has been assigned to the treatment arm 1. In the next step, please tell me by pressing 2 if the patient has been assigned to the treatment arm 2.\n\n\n[/MAT] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemoch",
        "label": 0
    },
    "1928": {
        "output": "## Example\n<EOD> The Cerebrospinal Fluid Proteome: A Source of Novel Biomarkers for Alzheimer\u2019s Disease\n\nCitation: Gim\u00e9nez-Martos, L.; Fern\u00e1ndez-Garc\u00eda, \u00c1.; Arias-Alvarez, P.; T\u00e1rraga-S\u00e1nchez, H.; Mart\u00ednez-Fern\u00e1ndez, C.; Morante-Redolat, X.; Alem\u00e1n, C.; Dom\u00ednguez-Alonso, A.; Rodr\u00edguez-S\u00e1nchez, L.; S\u00e1ez, P.; et al.\n\n# Introduction\nAlzheimer's disease (AD) is the most common form of dementia and is associated with aging. The main feature of AD is the chronic loss of cognitive functions, such as memory, learning, emotions and social behavior. However, other symptoms may be found, such as changes in mood, language disturbance, aggression, hallucinations, and lack of sleep. In the early stages of the disease, AD patients find it difficult to remember new information and tend to get lost, for instance. As the disease progresses, patients become unable to perform everyday tasks. Although AD patients may have varying life expectancies, the average survival time is 7.4-7.7 years after diagnosis.\nAD represents a strong socio-economic burden for countries since it increases the costs associated with the direct or indirect care of these patients. In 2019, approximately 47.5 million dementia sufferers were found worldwide (95% of which were of AD type) with a prediction of more than 75 million new cases in 2030; most of them will be in countries where the aging process is accelerating (i.e., US, Japan, Germany and France).\nThe lack of effective treatments for this disease requires more research in the early and reliable diagnosis of the disease. Unfortunately, there is no clinical test available for AD diagnosis at present, which results in a strong reliance on neuropathological examination, which, due to its high aggressiveness, is often performed only in a later stage of the disease process.\nThe study of the cerebrospinal fluid (CSF) is currently used in the diagnosis of many neurodegenerative diseases including AD, where alter",
        "label": 0
    },
    "1929": {
        "output": "## Step 3 - Create a list of variables with their definitions\nIn this step, we will create a list of variables with their definitions to be used when creating a patient. Some of these variables are the same across all patients, while others will be unique to each patient. The structure of the [patient] should be as follows:\n\n-  `Trial-level eligibility` is a scalar and will contain either 2) Eligible`\n- `ParticipantId:` is a scalar and will contain the ID number of the participant\n- `FirstName`: is a string and represents the patient\\u2019s first name\n- `LastName`: is a string and represents the patient\\u2019s last name\n- `Sex`: is a string and represents the patient\\u2019s sex\n- `Dateofbirth`: is a scalar and represents the date of birth of the participant\n- `Race`: is a string and represents the ethnical background of the patient\\u2019s race\n- `Region`: is a string and represents the region where the patient is located\n- `SiteId`: is a scalar and represents the clinical trial the patient is under\n- `SiteName`: is a string and represents the name of the clinical trial\n- `Weight`: is a scalar and represents the patient\\u2019s weight\n- `Height`: is a scalar and represents the patient\\u2019s height\n- `ID`: is a string and represents the unique patient ID\n- `Eligible`: is a scalar and represents the assessment of clinical trial eligibility (not relevant, excluded or eligible)\n- `EligibilityReason`: is a list of string and represents the reasons to exclude a patient from the trial\n- `Notes`: is a scalar and represents the free-text notes for the patient\n- `FQR` is a scalar and represents the fingerprint of the patient\n- `IP`: is an RGB Vector and is used to record the IP address of the user\n- `Systime`: is a scalar and represent the system time in Unix timestamp at the time the data were created\n- `LastUserId`: is a scalar and represents the last user that created or modified the item\n- `LastUserName`: is a scalar and",
        "label": 2
    },
    "1930": {
        "output": "Here is the previous patient note with a `Trial-level eligibility: 1) Not relevant`. That is, even though the patient is eligible in trial-level for the clinical trial as shown by `Trial-level eligibility: 2: Eligible`, the patient is not included in this clinical trial due to the low quality of the patient-clinical trial match (i.e., clinical trial exclusion criteria). \nSo, you should write `Treatment Plan for the Patient: 2) Included` or `treatment plan for the patient: 1) Excluded`, depending on whether the current patient is included or excluded, respectively, in this trial. It should match the treatment plan on the left so that you should write `[Treatment Plan for the Patient: Excluded}` or `[Treatment Plan for the Patient: 2) Included`. \nIf both trial-level and patient-level eligibility is 2, you should choose a random number between",
        "label": 0
    },
    "1931": {
        "output": "<EOD> Evaluation of the Risk Factors for Chronic Kidney Disease: a Hospital-based Study in Western India\nIntroduction: Chronic kidney disease (CKD) is an emerging global problem and an important public health disorder. Aim: This study was conducted to evaluate the risk factors associated with CKD patients from western India. Materials and Methods: A total of 80 adult CKD patients diagnosed with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 and 80 age and sex-matched subjects were selected as controls from the Outpatient Department of Renal Physicians in the Department of Nephrology, Institute of Medical Sciences, Banaras Hindu University Hospital. Socio-demographic data, history of comorbidities and risk factors were recorded. All patients were subjected to detailed clinical examination along with anthropometric, hematologic, and biochemical investigations such as serum glucose, HbA1C, renal function test, lipid profile, serum uric acid (UA), calcium, phosphorus, liver function test (LFT), and urine analyses like urobilinogen, specific gravity (sp gr), protein, pus cells, red blood cells (RBCs), and leucocytes. Anthropometric measurements of all patients were assessed using anthropometric tools. Results: Hypertension and diabetes mellitus were the major contributing factors to CKD in our study population. Anemia and hyperuricemia play an important role in CKD patients. Conclusion: In this study, we concluded that hypertension, diabetes mellitus, anemia, and hyperuricemia were prevalent in CKD patients. Identifying the modifiable risk factors associated with CKD will improve the outcome and quality of life.<EOD> Prognostic Significance of Fever (Body Temperature > or = 38.5 degrees C) and Blood Flow Signs During the Early Phase of Malignant Tumor Hemorrhage.\nBACKGROUND\nBlood flow signs on angiographic findings from a transcatheter arterial embolization (TAE) procedure have",
        "label": 0
    },
    "1932": {
        "output": "## [PROBLEM]\n\nA patient's eligibility should be determined based on the patient's characteristics. The key to making these determinations lies in the diagnosis codes. In clinical trials, these codes are used to identify potential trial participants, to ensure the right people are recruited via specific trials.\n\nHowever, not all diagnosis codes include information about eligibility. In order to address this issue, it is necessary to investigate clinical trials which are similar to the patient in question. For this purpose, we use the patient's symptoms and the type of treatment they have previously received. We have identified which types of diagnosis code information are available in each clinical trial, thus determining which information is missing and which information is needed for better inclusion of patients in the clinical trials.\n\n##\n\n### Diagnosis Codes\n\nA diagnosis code is the basic coding system for clinical data and the language used to identify diseases or injuries. There are more than 13,000 different diagnosis codes in the US. In the clinical trial system, the diagnosis code is used to identify and recruit eligible patients. For this reason, it is important to create a robust and adaptable method for identifying missing diagnosis codes used in clinical trials based on a patient profile.\n\n### Exclusion Criteria\n\nAn exclusion criterion is a condition within a clinical trial that prevents a patient from being included in the study. An exclusion criterion may be age, gender, or specific comorbidities. To ensure that no patient is excluded from a clinical trial, it is important to use a robust approach for identifying missing exclusion criteria used in clinical trials based on a patient's profile.\n\n### Inclusion Criteria\n\nAn inclusion criterion is a condition within a clinical trial that allows a patient to be included in the study. An inclusion criterion might be age, gender, or specific comorbidities. To ensure that no patient is excluded from a clinical trial, it is important to use a robust approach for identifying missing inclusion criteria used in clinical trials based on a patient's profile.\n\n### Exploratory Outcome\n\nIn clinical trials, an exploratory outcome is defined as any endpoint or outcome measure that",
        "label": 0
    },
    "1933": {
        "output": "[DATA]\n[DESC]\n\nThe following data format is recommended:\nThe columns are as follows:\n\n## 1.\nIn the `SID (Study identifier)` column the trial identifier that was generated by the trial module is shown\n\n## 2.\nIn the `Patient Name (Patient identifier)` column the patient identifier that was generated internally by the trial module is shown. This identifier is used internally by the trial module.\n\n## 3.\nIn the `Patient (Full name, Date of birth, Age)` column the following columns are shown as a comment:\n \n#### Age:\n<br />\n`Patient age in years, including 0.1 years`\n \n### PatientName:\n<br />\n`Date of birth or patient identifier`\n \n### DateOfBirth:\n<br />\n`Date of birth in DD/MM/YYYY format`\n \n### Birthday:\n<br />\n`Date of birth as YYYY-MM-DD format`\n \n### Gender:\n<br />\n`Gender; for example: Male`\n \n### Fullname:\n<br />\n`Full name; for example: 2e824484-06ee-442a-a294-290826d67097`\n \n### PatientCode:\n<br />\n`Patient identifier used internally by the trial module, will be created automatically by Trac`\n\n## 4.\nIn the `Assessment criteria (eligibility, inclusion, exclusion criteria)` column the clinical inclusion criteria of the trial are shown for this patient as comments (see below). An example of how to define a criterion:\n\n**Inclusion criteria**\n\n* 91. *Inclusion,* must be younger than 18 years during screening and onset of treatment .\n* 92. *Inclusion,* has to fulfill the COPD GOLD 11 criteria for COPD as defined in Appendix 8-9.\n* 93. *Inclusion,* BMI between 1",
        "label": 0
    },
    "1934": {
        "output": "![Trial-level eligibility](img/recruitment_overview/Trial-leveleligibility_final.png?w=800)\n\n### Input data\nThere is the input data from three perspectives:\n\n### Patient's input data [Tutorial]\nFirst, the patient's input data (patient note) is from two perspectives:\n\n### Trial's input data [Tutorial]\nSecond, the clinical trial's input data (trial's input data) is from two perspectives:\n\n### User's input data [Tutorial]\nFinally, user's input data (demo clinical trial) is from one perspective:\n\n### Output data [Tutorial]\nAfter the completion of algorithm in `Trial Assist`, following are the output data:\n- The three-point scale for the assessment of eligibility.\n- The output of recruitment decision: eligibility, ineligibility, or unsure.\n- If the patient is excluded on the grounds of the trial's exclusion criteria, the information of excluded criteria is presented to the user.\n- If the patient is eligible for the trial, an algorithm checks whether the patient is enrolled in the clinical trial. If not, user's email address will be filled in.\n- As a result of the check of user's email address, the system can automatically send him/her email notification of registration completion.\n\n## Task 1: input and check patient's data\n[INST] Open `Trial Assist` and select the role of inputter: \n![Trial Assist \u2192 select role of inputter](img/recruitment_overview/trial_assist_add_user.png?w=800)\n\n[INST] Click the `Add user` button:\n![Trial Assist \u2192 Add user \u2192 Add user](img/recruitment_overview/trial_assist_add_user_add_user.png?w=800)\n\n[INST] Input and check the input data of the patient:\n![Trial Assist \u2192 enter patient information](img/recruitment_overview/trial_assist_add_user_enter_",
        "label": 0
    },
    "1935": {
        "output": "# Discussion[INST]\n\n[POST] You can read the patient-level eligibility results here. We have a `Trial-level eligibility: 2` for the first case.\nSo, this patient is eligible for the clinical trial.\n```\n\n# Related exercises and homework\n\n## Exercises and solutions[INST]\n\n### Requirements, use cases, and UML diagrams\n- **Exercise 1.1**. Define and document requirements for a software system.\n  - **Solution 1.1**. Create use cases.\n  - **Solution 1.2 Solution 1.2**. Create UML diagrams.\n- **Exercise 4.2**. Document the overall project plan.\n  - **Solution 4.2 Solution 4.2**. Develop a project schedule.\n- **Exercise 4.3**. Document testing strategies.\n  - **Solution 4.3 Solution 4.3**. Develop a test plan.\n  - **Solution 4.4 Solution 4.4**. Create a traceability matrix.\n  - **Solution 4.5 Solution 4.5**. Document security requirements.\n\n### Exercise 9\n- Export a diagram from Protractor Ultima in DOT format.\n  - Solution 9.\n\n### Final project\n- Describe the software development lifecycle (SDLC) process using a user story scenario and relevant concepts.\n- Define the user, system, and organizational requirements.\n- Use UML techniques to develop use cases.\n- Create a system and component diagram using Unified Modeling Language (UML).\n- Create a use case diagram using Unified Modeling Language (UML).\n\n## Practice and homework materials\n\n\n[![](1.jpeg)](https://github.com/FundamentalsOfAgile/FundamentalsOfAgile/blob/main/practice/README.md) <br />\n[![](2.jpeg)](https://github.com/FundamentalsOfAgile/FundamentalsOfAgile/blob/main/practice/README.md) <br />",
        "label": 0
    },
    "1936": {
        "output": "<EOD> The value of routine cardiac output measurements.\nThis study was undertaken to determine the value of cardiac output (CO) measurements at routine physical examinations. In 100 consecutive admissions to a Veterans Administration teaching hospital, CO was recorded by a direct Fick method upon admission, and again either the next day or within a week of admission. CO determinations were carried out in hospitalized patients with varying degrees of physical debility and a broad spectrum of diseases, in some cases for as long as several months. Patients over 65 years of age were excluded from the series. Although CO was of value as a basis for therapy in 20 out of 100 patients, it could have been predicted in a large percentage of the patients in the series by assessment of peripheral pulse pressures and cardiac impulses. The study confirms other studies of this type to show that CO determinations are of value in a small number of patients undergoing cardiac catheterization, but in this study it could have been predicted clinically alone in the majority of patients.<EOD> A case\u2010control study of factors influencing the risk of prostate cancer mortality in rural Sweden\nThe Swedish Two\u2010County Cohort has a high risk of prostate cancer mortality. Risk factors for prostate cancer mortality in this unique cohort were examined in analyses of 1998 prostate cancer deaths in total and, separately, a subset of 318 deaths among the original cohort members. Information on cigarette smoking, alcohol consumption, height, weight, marital status, and socioeconomic status was analyzed by odds ratios calculated using conditional univariate logistic regression. Overall, for all prostate cancer deaths, cigarette smoking was associated with a lower risk of prostate cancer mortality (P = .03) while marital status (P = .02) and height (P < .0001) were associated with an increased risk. Among those who died when the original study data were collected, men with hypertension were shown to have a lower risk of death (P = .0005). Among the subgroup who were 75\u2003yr old (born 1912\u20131913) in 1970, cigarette",
        "label": 0
    },
    "1937": {
        "output": "## Instructions for Clinical Trial Assessment Assistant. To evaluate if a patient is eligible or not, use `CT Assess - Clinical-Trial Assessment Assistant.` You may use any of the following interfaces:\n[CLIN] HTML\n[CLIF] JavaScript\n[CLIJ] iPad\n\nWe will use the example below to show you the steps to complete Clinical Trial Assessment Assistant:\nLet us assume that your clinical trial is `NCT01897571 CALGB 80303: A phase II, randomized study of neoadjuvant vinorelbine with or without erlotinib for patients with operable non-small cell lung cancer (NSCLC)` . To run Clinical Trial Assessment Assistant, you should put the following items into the window:\n- Clinical trial ID: `CALGB 80303` . [CLIN] HTML\n- Clinical trial ID: `clinical_study_80303` .\n[CLIF] JavaScript\n- Clinical trial ID: `clinicalStudy.80303` .\n[CLIJ] iPad\n- The following is the clinical trial description:\n`Title: NCT01897509 Neoadjuvant Nab-Paclitaxel Plus Carboplatin Versus Docetaxel Plus Carboplatin for Resectable Non-small Cell Lung Cancer (NSCLC)\nThe goal of this phase III study is to assess whether neoadjuvant chemotherapy with nab-paclitaxel plus carboplatin is superior to chemotherapy with docetaxel plus carboplatin in patients with resectable early stage (stage I to IIB) non-small cell lung cancer (NSCLC). This will be assessed by comparing pathologic complete response (pCR), 2-year disease-free survival rate, and 6-month overall survival rates.\nThe treatment arms are as follows:\n1. Nab-paclitaxel 100 mg/m^2 with carboplatin on day 1 every 3 weeks for four cycles followed",
        "label": 0
    },
    "1938": {
        "output": "### [NOTE]\nAs of now, the `Patient-level eligibility:` line is redundant, because we only compute patient-level eligibility in the \"Assessment and eligibility\" module. However, you can define `Patient-level eligibility:` for more information and you can add this line (optional) to the trial object even in the `set_patient` module, to include it in the `DataFrame` you return.\n\n### [INST] Good luck!!! :)\n\nThis ends our tutorial.  Thank you once more for taking the time to complete the tutorial!\n\n\nPlease submit [issue reports for problems you encounter ][issue-report] \n\n\nAs this is a tutorial, we recommend you to check the tutorial as a reference while working through it. \n\n\nThe following [resources can help you during programming][programming] \n\n### [INST] Good luck!!\n\nThis completes our tutorial for learning to program your own clinical trial modules using ClinDoc.  We hope you found the tutorial helpful!  Feel free to contact our [support team][contact] when you need any assistance!\n\n\n[set-patient]: ../set-patient.md\n[set-protocol]: ../set-protocol.md\n[set-recruitment]: ../set-recruitment.md\n[set-clinical-trial]: ../set-clinical-trial.md\n[set-assessment]: ../set-assessment.md\n[set-outcome]: ../set-outcome.md\n[set-imaging]: ../set-imaging.md\n\n[assessment]: ./assessment\n[evaluation]: ./evaluation\n[institute]: ./institute\n[contact]: ./address\n[contact]: ./contact\n[about]: ./about\n[references]: ./references\n[patient-level-eligibility]: ./patient-level-eligibility\n[institute-protocols]: ./institute-protocols\n[support-team]: ./about/support-team\n[download]: ./downloads\n[about-clindoc]: ./about\n\n[Trial-level eligibility]: ./trial-level-eligibility\n\n[relevant-trials]: ./tri",
        "label": 0
    },
    "1939": {
        "output": "# Scenario 5:\nNow, let us consider a little different scenario. Let's say that you wanted to find the frequencies of the demographics for a clinical trial. Suppose that the clinical trial uses R package `matchingit`. We found an interesting article about clinical trial matching which may be useful for you.<br />\nThis matching method is similar to the propensity score matching method that we saw in the previous article.\n`matchingit` is an R package for matching cases and controls in studies of prognostic factors.\n[INST]\n\nIt is based on the propensity score matching methods and the nearest matching methods.\nMatchingit can match patients on a combination of demographic, diagnostic, and treatment factors. Matchingit's target audience is researchers with backgrounds in epidemiology, public health, or statistics, rather than information managers or analysts with backgrounds in clinical informatics. Matchingit is available on the Comprehensive R Archive Network (CRAN) of the Comprehensive R Archive Network.<br />\nYou can also find lots of examples of studies for matching: https://stat.ethz.ch/R-manual/R-devel/library/matching/html/index.html<br />\nThe details are described below. Here, we try to apply matching for finding the demographic frequencies for a clinical trial.\n\n\n## Matchingit\n\n\nSo far, we have had a patient with data like<br />\nYou should match two groups of patients to perform the matching.\nThe first group is the Patient group, which includes any patient with a valid birth cohort (BC) date, a valid year of death (YOD) date and is between 0.4 years old and older than 100.0 years old to represent all patients with chronic hepatitis C. The second group is the Matched Reference group. The reference group can be defined by any combination of factors, such as age, gender, and date of diagnosis. In this example, the patients are matched with their nearest matches in the reference group by patient BC dates. \n\nThere are a few issues need to consider when using matchingit.<br />\n- The number of reference controls should be specified as the size of the treatment group <sup>1</sup>. - Only a",
        "label": 2
    },
    "1940": {
        "output": "## [Task1.2] Exclusion conditions\nExclusion criteria are a set of conditions that lead to the exclusion of a patient from a clinical trial. As mentioned previously, the patient's medical records and eligibility criteria need to be compared to find out if the patient can be included in the trial. In addition, the results of the examinations, and laboratory tests of the patient are taken into account. In general, if the patient is not excluded, the patient meets the inclusion criteria. Patients with certain comorbidities (such as diabetes mellitus, congestive heart failure, cancer, pregnancy, etc. or pregnancy) may be excluded from clinical trials. For example, if a clinical trial requires the participants to be free from diabetes mellitus, or have a serum glucose, insulin, etc. level within a certain range, participants with diabetes mellitus will be excluded from the clinical trial.\n\nLet's check exclusion conditions on the given patient case. There is no eligibility, so make sure that you exclude every exclusion condition. We use the exclusion criteria to make the patient-level eligibility. \n\nThe clinical trial exclusion criteria used for exclusion are shown below. These criteria indicate the factors that may lead to the exclusion criteria:\n- AGE: 15 years old or more\n- GENDER: female or male patients\n- CO-MORBIDITY: patients with a medical history of congestive heart failure, cancer, myocardial infarction, etc.\n- PREGNANCY/LACTATION: pregnancy or breastfeeding patients\n- ILLITERACY: patients with a psychological defect\n- MISCELLANEOUS: patients who cannot be included in the clinical study due to other reasons\nThe patient's case satisfies all these criteria - the patient is adult, he is a man, does not have any psychological condition such as dementia, has taken no previous anti-psychotics. The patient was not pregnant, and had a normal pregnancy test. However, the patient has an inflammation infection that does not indicate COVID-19. The",
        "label": 0
    },
    "1941": {
        "output": "[INST] Output the output the final assessment\n\n#2102\nYou should select:\n\n#2110\n\n<EOD> The Effectiveness of a Smart Sitter Fall Alert System in Reducing Time to Alert After a Fall Event\nObjective: To determine the performance of a digital smart sitter fall alert system and the impact of this system on the time to response. Background: Falls and injuries are the fifth leading cause of death, affecting two thirds of elders who live in the community. Falls are the leading reason for elder disability and a substantial contributor to the hospital budget. In 2017, it was estimated that total health costs were over $50 billion and nursing facility facility costs were approximately $8 billion as a result of falls for elders 65 years and older. Methods: Evaluation of a new fall alert system which records the onset and duration of each fall and automatically sends messages via voice and text messaging to the caregiver\u2019s mobile device using a mobile communication application; also, it sends additional alerts if a fall remains unattended for a specified period of time. The trial was part of an interventional prepost study design comparing the effectiveness of a fall alert smart sitter system to standard, current fall alert systems used by hospitals and assisted living facilities. Sixty participants entered the study, each wearing a smart sitter. The system alerted caregivers when a fall occurred. Data were collected for all fall events for 3 months. The primary outcome was the time to respond after a fall event. Results: Participants averaged 74.9 (\u00b16.2) years of age, and 76.7% were white non-Hispanic. The mean time to care provider response was significantly shorter (mean 25.8\u2009\u00b1\u20097.3 minutes) for those using the fall alert system with a digital sitter (P\u200a=\u200a0.05), than those using current fall alert devices that do not require the provider actively monitoring the alert. Conclusion: This study demonstrated that the use of a novel smart sitter system, providing a voice and/or a text message, that does not require the responding caregiver to actively monitor the alert system and respond to an alert, can significantly reduce the time to respond to falls in elders",
        "label": 0
    },
    "1942": {
        "output": "## Exercises\n\n## Exercise 1: Data extraction\nIn this exercise, you will learn about how to extract data from a clinical trial abstract. Assume that the following is the abstract of the trial, including the relevant information:\n\n# Introduction\nHepatitis C Virus (HCV) infection is a primary cause of chronic liver disease, and is commonly associated with various complications such as liver cirrhosis and hepatocellular carcinoma. A total of 170 million people worldwide are chronically infected with HCV. The standard therapy for patients with chronic HCV infection is an interferon-based (standard) therapy of peg interferon\uf061 2a (PegIFN\uf0612a) or peg-IFNG\uf0612a (PegIFN\uf0612b) plus ribavirin. However, the interferon-based therapies are associated with several side effects, and fail in more than 50% of patients. A series of direct antiviral agents, including simeprevir and 126-valine protease inhibitors (boceprevir or telaprevir), and nucleotide polymerase inhibitors (sofosbuvir or daclatasvir) have been approved in the US and several European countries for a combination therapy for patients with chronic HCV infection. However, the antiviral activity was moderate, and most patients with high IL-6-level failed to achieve a sustained response to the combination therapy.\n\n# Objectives\nThe aim of the trial is to demonstrate that a three-component combination therapy, in which daclatasvir and sofosbuvir are administered with a low dose of standard interferon (100 IU), is more effective than the standard therapy in achieving a sustained virological response in patients with chronic HCV infection, with or without IL-6-high background.\n\n## Trial design\nThis is a single blind, multicenter, randomized, phase III trial. It is planned to enroll 433 Japanese patients with chronic",
        "label": 0
    },
    "1943": {
        "output": "Your full report must also be pasted into the AnswerBox as an attach-ment. Make sure to delete all irrelevant pieces of text, such as the text in the top section. \n\nIf a patient does not meet the eligibility of the trial due to a lack of information, write the level of the trial eligibility. 0) Excluded or ?\nFor example, if a patient does not meet the eligibility of the trial because of a missing BMI value, but everything else is fine, write 0) Excluded or ?.\n\n<EOD> .\nBACKGROUND\nCervical disk hernia is the most common cause of cervical radiculopathy, which is classically responsible for at least 70% of arm pain. In the cervical region, a thoracic disk hernia is rare (1%) and not much is mentioned in the medical literature.\n\n\nCASE REPORT\nA 55-year-old man consulted for lower neck pain, in constant motion, and associated to numbness of the right arm. Medical and clinical examination (Neck Disability Index: 19.33%; Visual Analogue scale: 6 for neck; 6 for arm) showed dyslalia, difficulty in swallowing liquid, neck flexor muscle hypertrophy and a positive Odom test of strength grade 5 (right side). Computed tomography (CT) and MRI confirmed the anterior echotrabeculated hernia with compression of the right subclavian artery, the brachial plexus at the C5-6 level and the upper root of the right cervical nerve-C5. The treatment consisted in the surgical resection of the posterior portion, the anterior portion and the disk, the anterior stabilization, the fusion of the C5-6 and C6-7 segments by instrumentation and the repair of the dural sac.\n\n\nDISCUSSION\nA dorsal thoracic disk hernia is a rare condition, responsible for brachial plexopathies causing pain, with or without radicular symptoms. The therapeutic strategies are still debated.\n\n\nCONCLUSION\nThe treatment has two aims: the surgical decompression to relieve pain and to return the",
        "label": 0
    },
    "1944": {
        "output": "[/NOTES]\n\n__Expert feedback__\n\n### Expert 1\nThe first thing is to decide what data is the most important first. Is it better to start using only gender, age, or the length of clinical trial or the trial-IDs? By the way, in these cases, the trial-ID is not an important factor. The same patient can be assigned to many trials that have the same trial-ID.\n### Comment\nThank you for your feedback, <NAME>.\nI appreciate you giving me your opinion. Based on my experience and the information given, I wanted to know how to assess eligibility for each patient based on his/her clinical trial. Also, I wanted to know how to assign a number to each patient and how to determine the patient's trial-level eligibility. I had several questions related to the trials.\n- How to repeat the trial-level eligibility? Is this based on the combination of the trial and the patient?\n- Which trials are the most important for finding a patient's eligibility?\n- Is it possible to determine the eligibility level of a patient to all trials at the same time?\n- Are there some rules to determine the eligibility level of a patient to each trial?\nThank you again for your help.\n\n### Expert 2\n1. Can you check the sample size of the study? Because in the clinical trial mentioned, the number of patients may be larger than 100, so 10 trials may not be a small number. It is recommended that you test the eligibility of several patients for each clinical trial and try different patient numbers; then, you can decide on the optimum number. You can try to choose between the clinical trial for 1 patient and the clinical trial with the number of patients closest to 10.\n2. For the 10 clinical trials, the trial name, clinical phase, etc. may be the same. Can you try to use the clinical trial number ID to differentiate the trials? When you select these 10 clinical trials, it will be possible to distinguish them.\n3. When entering all the eligibility level of each patient to each clinical trial one by one, it cannot be said that all eligibility levels of all clinical",
        "label": 0
    },
    "1945": {
        "output": "**The trial-level eligibility is binary (0 = Not Eligible, 1 = Eligible)**\n\nThe input form will automatically calculate the result of the trial-level eligibility if you do not use `Trial-level eligibility: ` but use an integer in the last line, e.g., `2`, `1`, ..., `0`.\n\n**Input format of the input form**\n\nYour input form should be like below:\n```\n#A01-01: HCV-CHC, #A02-01: HCV-CHC, #A03-01: HCV-CHC, #A04-01: HCV-CHC, #A01-75: HCV-CHC, #A03-35: HCV-CHC, #A06-07: HCV-CHC, #A05-35: HCV-CHC, #A04-07: HCV-CHC, #A03-36: HCV-CHC, #A05-03: HCV-CHC, #A07-07: HCV-CHC, #A01-02: HCV-CHC, #A02-75: HCV-CHC, #A05-61: HCV-CHC, #A04-75: HCV-CHC, #A01-67: HCV-CHC, #A01-76: HCV-CHC, #A07-11: HCV-CHC, #A09-05: HCV-CHC, #A09-11: HCV-CHC, #A09-75: HCV-CHC, #A09-73: HCV-CHC, #A09-72: HCV-CHC, #A09-71: HCV-CHC, #A03-11: HCV-CHC, #A03-76: HCV-CHC, #A03-61: HCV-CHC, #A03-03: HCV-",
        "label": 1
    },
    "1946": {
        "output": "<EOD> Nutrition support in the critically ill patient. Part VI: Special nutrition-support regimens.\nThe dietary needs of critically ill patients can be difficult to establish in the face of complicating factors such as a history of malnutrition, drug interactions, abnormal drug metabolism, and gastrointestinal dysmotility. While each patient requires individualized nutrition therapy based on his biochemical status, specific nutrition-support diets are sometimes indicated for patients with special nutritional needs, or in response to the need to restrict carbohydrate intake in diabetic patients, or to administer drugs or toxins during continuous-infusion parenteral nutrition therapy.<EOD> Antioxidant Effects of Flavonoids in Cereal Grains.\nFlavonoids are the primary phenolic compounds in cereals as well as herbs and vegetables (Demmig-Adams et al. 1987, McDougall and Caldwell 1987). The number and the type of the flavonoids present in cereals are relatively low compared to the total phenolic content in cereals (Schaefer and Zetterberg 1984). Flavonoids (flavones, flavonols, flavonones, isoflavones, flavanones and anthocyanidins) are present in the soluble fraction of whole-grain cereals, e.g., rye groats and wheat (Stangel et al. 1992). The flavonoids include a high proportion of the phenolic acids as gallic acid and sinapinic acid in cereals (Grant & Willcox 1984). Flavonoids as compounds with low molecular weight, non-essential in human nutrition, have a biological activity of wide variety, such as antimicrobial, antiviral, antiinflammatory, hypocholesterolemic (McIntyre & Tindall 1990), anticancer (Siddhuraju & Siddhuraju 1998), as well as antioxidant (Schaefer 1995).<EOD> Gen",
        "label": 1
    },
    "1947": {
        "output": "<EOD> Role of Dental Care in Post-Operative Management of Cardiac Surgery Patients: A Narrative Review\n\n\n\n# Introduction\nCardiovascular diseases (CVDs) are a major cause of death worldwide, with over 17.5 million deaths in 2012. The United States ranks second in terms of CVD mortality and morbidity among countries; [bib_ref]  The association of dental attendance with dental health in a cohort of..., Walker [/bib_ref] .7% of adults aged 20 and older had heart disease [bib_ref]  Cardiovascular disease in the United States: epidemiology and potential solutions, Dzau [/bib_ref] . There is an increasing incidence of CVDs in India, with an estimation of 21 million patients diagnosed with CVDs in 2012. It is the second most fatal disease in India after cancer. An increasing population, diet change, and life-style changes are major reasons for CVDs. India contributes to a quarter of global deaths due to CVDs, which account for 1,233,000 deaths in the year 2002. It is estimated that by 2020, India will become the first CVD-related death nation [bib_ref]  Nutritional status of Indian adult dialysis patients on conservative management and role..., Singh [/bib_ref] .\nAlthough several studies have reported the cardiac benefits of oral hygiene, the exact oral manifestations of CVDs and their relation to cardiac patients remain unclear [bib_ref]  Necessity of periodontal evaluation for post-operative success in patients undergoing cardiac surgery:..., Prajapati [/bib_ref] . To our knowledge, a comprehensive narrative review on the role of dental care in the postoperative management of cardiac surgery patients has not been conducted before. The present narrative review aims to provide essential overview of the oral manifestations of CVDs as well as an outline of the relation between oral health and cardiac surgery outcomes and cardiac health to help develop the future research.\n\n# Methodology\nA search of the literature was conducted using PubMed in March 2015. Initial searches were conducted using the terms \"or*, dent*, care, cardiac",
        "label": 2
    },
    "1948": {
        "output": "In our example, our patient meets inclusion criteria of the clinical trial, and exclusion criteria of the trial do not apply.\n\n[INST]: Examples of some output forms \u064d\u064d \u064d\u03e9Ribavirin \u03e9 Daclatasvir and Simeprevir \u03e9 Sofosbuvir \u03e9 Ribavirin and Simeprevir \u03e9 Sofosbuvir \u03e9 Daclatasvir \u03e9 Ribavirin \u03e9 All\n\nRibavirin Daclatasvir Simeprevir Sofosbuvir RBV DSV All 4\n\nRibavirin Daclatasvir Simeprevir Sofosbuvir SOF SVR SOF RPV DSV All 3\n\nRibavirin Daclatasvir Simeprevir Sofosbuvir SOF SMV DSV All 2\n[formula]  SOF SMV SOF+SMV+DCV SOF+SMV+DCV SOF+DCV+RBV SOF+DCV+RBV SOF+DSV+DCV SOF+DSV+DCV SOF+DSV+RBV SOF+DSV+RBV SOF+DSV+DCV+RBV SOF+DSV+DCV+RBV SOF+DSV+DCV+RBV SOF+SMV+SOF RPV SOF+SMV+SOF RPV SOF SVR SOF SVR SOF RPV SOF RPV SOF RPV SOF DSV SOF DSV SOF DSV SOF+RBV SOF All 1 \u064d \u064d \u064d\u03e9Ribavirin \u03e9 Simeprevir \u03e9 Sofosbuvir \u03e9 Ribavirin and Simeprevir and Sofosbuvir \u03e9 Ribavirin, Simeprevir and Sofosbuvir \u03e9 Ribavirin \u03e9 All [/formula] \n\nRibavirin Simeprevir Sofosbuvir RBV SiS SOF RPV All \u064d\n\nRibavirin Simeprevir Sofosbuvir SOF SVR SOF SOF",
        "label": 1
    },
    "1949": {
        "output": "<EOD> High-Efficiency Bicrystalline Perovskite-Based Tandem Solar Cells.\nHigh-efficiency bicrystalline perovskite solar cells (PSCs), with efficiencies over 22%, were prepared using large-area transparent flexible ITO/PEIE/PEDOT:PSS/MAPbI3/polyvinylcarbazole, and Ag/PEDOT: PSS electrodes. The device with the PEDOT:PSS/MAPbI3/polyvinylcarbazole structure exhibited remarkable photoelectric performance, with 1 sun illumination giving short-circuit current densities of 15.2 mA/cm2 and open-circuit voltages of 1.02 V. The photogenerated charge properties were measured using time-resolved surface photovoltage spectroscopy at room temperature. Upon photon excitation, charge photogeneration and charge recombination in the PSC underwent rapid charge loss. The results showed that 21.1 mg/cm2 of MAPbI3 was converted to CH3NH3PbI3, with a crystalline structure and chemical bond type of (FAPbI3) 0.5CH3NH3PbI3, under 1 sun illumination for 10 s. Photogenerated electrons and holes in the CH3NH3PbI3 layer recombine within 90 s of illumination, when the short-circuit current of the device reached the maximum value at 1 sun illumination. The photoelectric performance of the device declined when the illumination time at 1 sun exceeded 300 s; this was attributed to the charge loss caused by the photogenerated defects resulting from illumination. The results show that the MAPbI3/polyvinylcarbazole PSCs are excellent candidates for tandem solar cells and for third-generation photovoltaic modules due to their outstanding optoelectronic properties.<EOD> Tacrolimus-associated glomerular disease in kidney transplantation \u2013 a systematic review and meta-analysis\n\nThe use of calcineurin inhibitors (CNI) in kidney transplant",
        "label": 2
    },
    "1950": {
        "output": "## Task 4 -Eligibility criteria extraction and evaluation \n[INFO] Hello, \n\nHere are the patients' medical records for further assessment of eligibility, which correspond to those in Task 3. Please compare the medical records (patient notes) with the description of inclusion criteria above and extract (list) the inclusion criteria that apply to each record, e.g., 'This patient meets age criterion.': 0) Excluded; 1) Not relevant, 2) Eligible. Do not use spaces. You can repeat the same inclusion criteria for the same record; i.e., the 0) Excluded status must remain unchanged after the evaluation (the same applies to 1) Not relevant and 2) Eligible). \n\nHere is the patient's medical record for Task 4: \n\nYou are to extract patient notes for further assessment of eligibility. You will have to extract patient notes for eligibility analysis for 20 patients in Task 4. You are also instructed to extract the following information:\nName: the first and the surname of the patient Date of birth: year and month of patient registration Date of admission: date of the hospital admission of the patient\nGender: gender of the patient\nNumber of medical records that will be required for the assignment (the number of patients whose records are not listed twice to avoid the double check):\nLet's think step by step. [/INFO]\n\n## 1.\nPlease extract the following information: name, date of birth, gender, date of admission and number of medical records from the patient's medical record.\nCopy and paste the extraction data only (patient's name, date of birth, gender, date of admission and number of medical records) in a new file. Do not forget that these patients must be unique. (e.g.: no duplication: `Jonathan` must be different from `Julian`.)\n\n## 2.\nPlease export this data file from NLP and upload it to Mendeley data, then make a copy and upload this copy to Mendeley data.\nClick to view the instructions on 'uploading your data' to Mendeley Data. (Please refer to the link below) \n\n\nCopy the link and paste it into your web search bar. (e.g.",
        "label": 0
    },
    "1951": {
        "output": "# Tasks\n\n## Setup\n\nCreate `notebooks` with a Jupyter backend.\n\n## Exercises\n\n## Python setup\n\n1. You need to run set up.py inside of the folder you install Notebook for this assignment. There is an example in Notebooks/assessment/setup.py\n1. Set a variable to indicate that installation is correct.\n2. Do Notebooks/assessment/task1.sh on the terminal in the folder Notebooks/assessment.\n3. You should run Task 1. Notebook in Jupyter to complete the first exercise of assessment of eligibility\n1. In the folder Notebooks/assessment, open Jupyter in the terminal and run code in Notebooks/assessment/task1.ipynb.\n2. Execute cell 2: `print('Included 12 patients').`\n3. Execute cell 3: `print('1 patient not included').`\n4. Execute cell 4: `print('Not eligible 4 patients').`\n5. Execute cell 5: `print('Not relevant 41 patients')`.\n6. Execute cell 6: `print('Eligible 3 patients')`.\n\n## Additional instructions\n\n1. Do Notebooks/assessment/task2.sh on the terminal in the folder Notebooks/assessment\n2. You should run Task 2. Notebook in Jupyter to complete the second exercise of eligibility assessment\n1. In the folder Notebooks/assessment, open Jupyter in the terminal and run code in Notebooks/assessment/task2.ipynb.\n2. Execute cell 1: `print('Included 33 patients').`\n3. Execute cell 2: `print('1 patient not included').`\n4. Execute cell 3: `print('Not eligible 21 patients')`.\n5. Execute cell 4: `print('Not relevant 24 patients').`\n6. Execute cell 5: `print('Eligible 69 patients')`.\n\n1. Save Your Output\n\nTo save your results and exit the Jupyter notebook, it's sufficient to",
        "label": 0
    },
    "1952": {
        "output": "```shell\n\nIn the example input, you were given the same input as described above under the first two `Eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)` and `Eligibility: 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).` respectively, so that you have already used the function `evaluate_ind_eligibity`.\n\nWhen using your function to generate the expected answer, ensure that the patient meets the eligibility criteria:\n\n    \n    input = readlines.read('input.txt')\n    trial_input = input\n    trial_input = [line for line in trial_input if not line.strip().startswith('#')]\n\n    \n    patient_notes = ['No.', 'HCC (stage IIIb)']\n\n    patient_notes.extend(['1, 3, 23, 27, 32', 'HCV, HIV A, HBV Ab+, HBV Ab-', 'HBV', 'HBV Ab+', 'Chronic (for > 1 year), mild (< 2)', 'Chronic, mild (< 2)', 'Stage IIIb (T2N0), Bismuth type IV', 'Child B, CHILD A (Child A, Child B), Child A1 (Child A, Child B1), Child A2 (Child A, Child B2), Child C (Child C, Child D)', 'Child C (Child C, Child D)', 'Metastatic to liver, lung and lymph nodes'];\n\n    notes = ['Child B (Child C)', 'Child B (Child C)', 'Child B', 'Child B', 'Child B', 'Child A2 (Child A, Child B2)', 'Child A (Child A, Child B)', 'Child A (Child A, Child B)', 'Child A2 (Child A, Child B2)', 'Child B (Child C)', 'Child B (Child C)', 'Child B (Child C)', 'Child B (Child C)', 'Child A2 (Child A, Child B1)', 'Child A (Child",
        "label": 0
    },
    "1953": {
        "output": "<EOD> Effects of intervention on the cardiovascular risk of children and adolescents: a systematic review protocol.\nREVIEW QUESTION\nWhat, if any, are the biomedical, psychological, sociological and economic effects of interventions on the cardiovascular risk of children and adolescents?<EOD> The Evolution of Epilepsy in a Child with Congenital Dyserythropoietic Anaemia Type II\n\nChildren with congenital dyserythropoietic anaemia type II (CDAII) have chronic, low-grade non-spherocytic haemolytic anaemia, and an increased incidence of seizures. We present the clinical and electroencephalography (EEG) findings of a 10-year-old child with CDAI who had repeated episodes of fever accompanied by non-tonic-clonic seizures. Following treatment of a urinary infection and the control of fever, the patient's seizure control was observed to be significantly improved but deteriorated again following an episode of pneumonia. Her seizures were well suppressed by medication. However, she later reported having recurrent seizures once when she did not want to take her medication for a long time. Her haematological profile was mostly stable during the whole period of illness, but the number of seizure episodes was always correlated with the severity of the acute illness, specifically with the increase of the white blood count (WBC) and C-reactive protein level during the acute phase of the infection. As far as we know, this is the first reported case of serial EEG recording showing the evolution of epilepsy in a child with CDAII.\n\n# Introduction\nCongenital abnormalities of erythrocyte maturation are rare haemolytic anaemia disorders [bib_ref]  The congenital dyserythropoietic anaemias: a review, Wickramasinghe [/bib_ref] . A complete diagnosis requires identification of the morphologic and/or functional abnormalities. There are four different subtypes of congenital dyserythropoietic anaemia (CDA), including the CDAII, CDAIII,",
        "label": 0
    },
    "1954": {
        "output": "# Exercises\nWrite a Python program that receives each patient note and clinical trial, and outputs the assessment of eligibility for every patient note in the form of Trial-level eligibility. [PRACTICE]\nAsk a member of your family, a tutor, or a labmate for a piece of paper that has a random patient note and a clinical trial, and have them complete the exercise. [PRACTICE]\nIn the solution set of Exercise 3, the Python program takes time O(n), where n is the number of patients. Therefore, this might be an overly complicated approach. To solve the problem in a shorter time, in Exercise 4 we will try to determine which factors are less important to check first. [EXPLAIN]\nWrite a Python program that determines which variables are the most useful for filtering patient notes, using the following example. [PRACTICE]\nThis will lead to the question of how different variables affect our assessment of each patient. \nExercise 4.4\nThe clinical trial we will use for the remainder of this module is the same as in Exercise 4.3. \nWrite a Python program that receives a set of patient notes and calculates the mean of the number of Excluded and Not relevant of every patient note in the set. [PRAICTICE]\nExercise 6\nThe goal of Exercise 6 is to apply the technique of Exercise 5 to a real patient note dataset obtained from clinical trials. [EXERPT]\nExercise 7.1\nThis is the real-world data from the University of California, San Francisco. \nWrite a Python program that receives the set of patients from UCSF, and applies the technique in Exercise 6 to filter out unimportant patients, i.e., patients who can be excluded or who are not relevant to the clinical trial. [PRACTICE]\nExercise 8\nThe goal of Exercise 8 is to apply a set of techniques in an organized manner to our set of patient notes to make better decisions during the screening phase. [INTERVIEW]\nCoderequirements\n- Create a code requirement document for the problem we described. [CODE]\nExercise 9.2",
        "label": 0
    },
    "1955": {
        "output": "---\n\n### 27-060 Assessment of Eligibility, Multiple Patients\n---\nIn the following exercise you can assess the eligibility of multiple patients. You should select only one patient in order to give the trial-level assessment of eligibility for each patient and generate an HTML report.\nThe first and only patient, the information you should provide in the data file. The patient data for each exercise. If you are not sure, just write `N/A`. If you think the data is incomplete or uncertain, you are allowed to put the same characters of the text box in front of the N/A.\n\nThere are no correct or incorrect responses. You will submit your results and anonymized data and we will provide you with valuable feedback about your work.\n\n_You have not done anything at all yet in this module. This is a preview of what is coming._\n\n\n\n\n\n\n#### Submitting Your Work\n\nOnce you have completed all the questions for a particular module, you should click the blue \"Save and Continue\" button.\n\nAfter the module save button is clicked, you will see a confirmation page saying \"your submission started\", and then you will be redirected to the next module URL where the next set of questions will be presented.\n\nYour work will also remain on the server (without a timestamp) until you decide to \"Save your work\" or \"Clear the work\".\n\nClick on the red \"Submit\" button once your answers have been completed.\n\nOnce submitted your answers to one module, they can be \"reshot\" as long as you are on the same computer and have not cleared your work.\nIf you clear your data (click on the red \"Clear your Work\"), your responses will no longer be accessible.\n\n---\n\n### Exercises  \n\n[Exercise: Assessment of Eligibility, Multiple Patents 27-060](/docs/02-modules/27-060-multiple-exercise): You assess the eligibility of multiple patients to a clinical trial\n<EOD> Evolution of Chicken Bone Marrow-Derived Macrophage Procoagulant Function via Exposure to Thrombin\n\nPlasma contact system activation is a major initiator of blood coagulation during hemostasis and inflammation",
        "label": 0
    },
    "1956": {
        "output": "<EOD> Grip force scaling and neural tuning in monkey primary somatosensory to primary motor areas: a comparative study\n\nNeurotrained motor control and sensorimotor integration relies on the integrity and plasticity of sensorimotor cortex. Cortical networks in both monkeys and humans can be non-invasively identified by electrocorticography on motor areas and cortical representations of peripheral stimuli on receptive fields (RFs) areas; however, they are difficult to study at the same time in the same animal. To test the hypothesis that cortical representations of grip force can be studied in monkeys after motor adaptation but not in humans the authors have simultaneously compared cortical force and electrophysiological recordings of RFs in area 2 and M1 during a grip force task. Monkeys and humans showed similar sensory RFs, including sensory and motor maps, with a clear bimodal distribution, while monkeys showed a more heterogeneous RF organization on motor maps. Grip force changes caused adaptation in monkeys, with a shift of the center of force and a decrease of RF sizes with repeated motor execution. This behavior was reversed by motor imagery, with a shift of the center of force and an increase of RF sizes. While this did not happen in the human dataset, both RF scales and force maps were unpredictive of the direction of motor adaptation, in both monkeys and humans. Overall, monkey data suggest that the grip force task can be used to study both RFs and grip force reorganization.\n\n## Subjects and methods subject characteristics\nThe human data were acquired at the Institute of Psychiatry, Psychology, and Neuroscience, King's College London, UK, with the study approved by the National Research Ethics Service, East of England-Essex Research Ethics Committee. All subjects gave informed written consent. Experimental data from 15 unilateral left-handed volunteers (nine female, mean age 25 years) of mixed ethnicity were obtained. Handedness was assessed by the Waterloo Handedness Questionnaire. The subjects with the largest shift in the direction of movement after 15 days were selected for this study, to be able to compare with the monkey dataset.\n\n## Non-human primate protocol\nTwo adult",
        "label": 2
    },
    "1957": {
        "output": "<EOD> Tumour-infiltrating lymphocytes\n\nCancer cell populations harbor intratumoral heterogeneity of different levels, which is related to tumor prognosis, metastasis, and immunotherapy efficacy. A better understanding of the mechanisms underlying cancer progression and the characteristics of immune infiltrated tumors is required to optimize treatments. Among the factors modulating tumor cells heterogeneity, we here review epigenetics as a fundamental mechanism to define intratumoral heterogeneity, both globally and at the single cell level. In particular, chromatin conformation seems to be of primary importance for tumorigenesis and cancer progression, as a link between epigenetic aberrance and tumor cells phenotype. At the microenvironment level, we provide an overview of the mechanisms for immune tumor infiltration, discussing in particular the characteristics of immunosuppressive cells, tumor cells, and tumor microenvironment. Overall, we hope to review recent findings about tumor cells' phenotype, mechanisms of immune-tumor cell interaction, and the role of epigenetic modifiers in intratumoral heterogeneity and tumor immunosuppression.\n\n# Introduction\nCancer cells acquire intratumoral heterogeneity during tumorigenesis, with potential consequences for prognosis and therapeutic outcomes. On the other side, immune infiltration can create a complex and dense tumor microenvironment during malignant progression, whose features are different not only in the cellular population composition, but also in their functional status. Here, we overview a link between epigenetic regulation, tumor microenvironment, and tumor cell survival during a long-term antitumor therapy.\n\n## Tumorigenesis: heterogeneity and cancer cell development\nGenetic alterations determine the biological and functional changes of cancer cells and the phenotypic diversity of tumor cells. For example, aberrations in the DNA damage response machinery induce the emergence of different tumor subclones that might have different metabolic capacities and drug sensitivity. These tumor heterogeneities are related to tumor progression and metastatic potential. According to the Cancer Genome Atlas (TCGA) and the Mole",
        "label": 0
    },
    "1958": {
        "output": "[/END] \n\n### 23785\n\n[https://openwetware.org/wiki/WS23785]\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. \n\n\nThe patient is \u2026 \u2026 \u2026 \u2026: a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records \u2026\n\n\nHis medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The \u2026\n\nHis medical records show previous \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026",
        "label": 0
    },
    "1959": {
        "output": "In [FINAL-2] Hello! You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.\n\nHere is the clinical trial:Title: Study to Evaluate the Safety and Antitumor Activity of ABT-263 Monotherapy and in Combination With ABT-199 in Advanced and Progressed Solid TumorsInclusion criteria: Inclusion criteria:1. histologically confirmed and",
        "label": 0
    },
    "1960": {
        "output": "[INFO] Please note that you could generate trial-level eligibility report for your training purpose as follow: $ python /path/to/pyxlent2/run_eligibility.py.\n\n### Examples \nNow, the clinical trial is a randomized, controlled study with two parallel groups. A patient who has two diseases can be studied. \n```\nClinical Trial 1: A phase 1 randomized, double blind, placebo-controlled, dose escalating study in healthy older adults to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and cognitive effects of JD5037 on executive function.\nTest drug: JD5037\nDose: 200 mg\nFlavor: Orange-vanilla flavored liquid filled hard capsule\nDosing Schedule: Once-daily for 10 days\nNumber of Treatment Arms: 5\nNumber of Treatment Periods: 1\nEach subject will receive one of the following 5 treatment conditions: Control: Placebo; 200 mg single dose, 200 mg once daily QD for 10 days; 500 mg single dose, 500 mg once daily QD for 10 days; 750 mg single dose, 750 mg once daily QD for 10 days; 1000 mg single dose, 1000 mg once daily QD for 10 days (active).\n\nClinical Trial 2:\nA randomized, double-blinded, phase 2, single-dose, two-cohort, parallel study evaluated the pharmacodynamic/pharmacokinetic profile of CNV1014802 in healthy subjects. The study included two different cohorts: Cohort A and B. Participants in Cohort A received a single oral dose of the 3 mL flavored formulation of CNV1014802 suspended in a non-flavored gelatin placebo. Participants in Cohort B were administered a single oral dose of CN",
        "label": 0
    },
    "1961": {
        "output": "What if the patient met one or more of the trial's exclusion criteria? \nIf the patient met one or more of the trial's exclusion criteria, he or she should be marked as `Excluded:` in the last line. If the patient met `More than one criterion included:`, the assessment of eligibility should be repeated using the `ClinicalTrials.eligibility.repeat_eligibility()`method. If the patient's evaluation changed, his or her clinicaltrial eligibility should be marked as `Excluded:`.\nIn the final line of the function, we should always write the marking the patient's trial level. Examples: `More than one criterion included:`; `Excluded:`. [INST]\nLet's repeat the steps in the main.py file: [INST].\n# This script should be run with the `python <script name>` command in the terminal. If you use an interpreter, it should be added in front of the script name.\n# When this script ends, the eligibility assessment for the first 10 patients will be available in the directory `output`\n#\n# It must be run once with no parameters to read the trials file from the data folder.\n# Then it can be run repeatedly with three parameters: `first_line` (optional), `include_exclude_assessments` (optional), `patient_number_offset` (optional)\nimport logging\nfrom .data import load_file, get_all_clinicaltrials\nfrom elg import init_logger\n\nTrial_list = load_file('clinicaltrials.xlsx')\nclinicaltrials = get_all_clinicaltrials(Trial_list)\n\ndef main(first_line = \"\", include_exclude_assessments = True, patient_number_offset = 0):\n    # The three parameters are optional. If they are omitted, the initial value will be used.\n    # They can be changed in the function definition of the script.\n    if first_line:\n        pass\n    else:\n        first_line = 0\n\n    if include_exclude_assessments:\n        pass\n    else:\n        include_exclude_assessments = True",
        "label": 0
    },
    "1962": {
        "output": "You should complete the following: `Trial-level eligibility: `\n\n```python\ntrial_relevant = pd.DataFrame({'0', '1', '2'}\n                           ,\n                           columns=['Trial-level eligibility'])\n\nrelevant_data = {'Patient name': 'John Doe',\n                 'ID': 150001,\n                 'Trial name': 'Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease',\n                 'Trial description': 'The objective of this study is to investigate the evidence of presynaptic dopaminergic neuronal dysfunction in the preclinical stage of PD, which may be associated with HCV infection.',\n                 'Inclusion Criteria': 'Adults (older than 20-year-old) with HCV infection and agree to accept 18F-FDOPA PET examination.',\n                 'Exclusion Criteria':\n                             ('Age',\n                              '20+ years',\n                              ('female', 'male', 'female', 'male', 'female', 'male')),\n                             ('HCV', '0', 'positive', 'negative', 'unknown'),\n                             ('Parkinson', '0', 'negative', 'positive', 'unknown'),\n                             ('FDOPA': (), (), ('18 F'), ('3,4-Dihydroxy-l-phenylalanine')),\n                             ('PET': (), (), ('Positron emission tomography'), ('PET')),\n                             ('Neuroimaging': '0','1', '0', '1', '0', '1'),\n                             ('MRI': '0', '1', '0', '1', '0', '1')})\nrelevant_data['Patient ID'] = 150001\nrelevant_data = pd.DataFrame(relevant_data, index=relevant_data['Patient ID'].astype(str), columns=relevant_data)\nrelevant_data['Inclusion Criteria'] = \\\n    relevant_data['Age'].map",
        "label": 2
    },
    "1963": {
        "output": "## 2\n[OUT] Here we can also print the list of all patients and their status:\npatients:\n\"You are here!\"\n\n## 3\n[OUT] If the patient is not eligible, here are the exclusion criteria. \n\"You are here!\" \n\n## 4\n[OUT] In this clinical trial, 3 out of the 5 patients are eligible.\n\n## Code & Data Availability\nR code and patient data are available at https://github.com/kamalak/clinical-trial-eligibility. Prepublication history for this paper is available online. TOC>\n<NAME>\n\n## Dear <NAME>:\nThank you for submitting your manuscript to PLOS ONE. The manuscript was reviewed by two expert reviewers, whose comments are appended to this letter. Although the reviewers' expertise was not on your particular area of research, the review provides suggestions on how to strengthen the analyses.\n\n## The comments of the reviewers, and any replies to those comments from you and/or your co-authors, are included below (in blue font; italics in the letter of the reviewer, black font in the reply). as you will see, the reviewers appreciate the novelty of the study but consider that some clarifications on the analyses are required. they are encouraging you to modify the analyses accordingly, but they would like to reconsider the manuscript after the modifications. plos one encourages and enables the publication of a wide range of article types including replication studies (please refer to https://journals.plos.org/plosone/s/replication-studies).\nPlease submit your revised manuscript within two weeks. If you anticipate a delay in your resubmission please let us know.\nTo revise your manuscript enter your next manuscript title for PLOS ONE: https://journals.plos.org/plosone/s/submission-guidelines\nYour manuscript number has been appended to the subject line for notification. Please keep this in mind while changing the resubmitted manuscript.\nWe are sorry that we are keeping you waiting for a decision. We hope that the following comments will prove constructive in improving your paper.\n\n## Sin",
        "label": 0
    },
    "1964": {
        "output": "<issue_closed>\n<issue_comment>username_0: This is a great learning experience. I now understand, that `if/else` structures with Python are like `switch` structure with BASIC\n<EOD> Evaluation of the impact of a medical student\u2010run tuberculosis screening program in Eswatini: the Raleigh TB Screen program\nTo evaluate the outcomes of a screening program for tuberculosis (TB) among health students in Eswatini.<EOD> Pre-treatment with dexamethasone inhibits the cardiovascular effects of buserelin\nAbstract The purpose of this study was to investigate whether an acute and pretreatment with dexamethasone could inhibit the cardiovascular effects of buserelin in human volunteers. Nine healthy, non-obese male volunteers were given 4-day treatments of dexamethasone 0.5 mg daily (n= 5) or placebo (n= 4). Blood pressure, plasma epinephrine, heart rate, 24-h urinary catechols, and blood pressure responses to buserelin (Fecla, 240 \u03bcg, IV) were determined at the 2nd and the 8th days. Blood pressure and heart rate increased in the placebo group after buserelin, but blood pressure did not change in the dexamethasone group. After the 8th day, urinary catechols had increased in the dexamethasone group of volunteers but not in the placebo group. Pre-treatment with dexamethasone inhibits the cardiovascular effect of buserelin in human volunteers.<EOD> The potential role of tissue-resident memory T cells against coronavirus disease 2019: A narrative review\n\n\n\n# Introduction\nSince its initial discovery in December 2019, the outbreak of coronavirus disease 2019 continues to spread rapidly to thousands of countries across the world since it was first identified as a human infectious disease in China. The etiological agent of COVID-19 which is termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2",
        "label": 2
    },
    "1965": {
        "output": "_2.  You must output the list of inclusion and exclusion criteria for the clinical trial.\nThey are not repeated from the patient's information. You are to print them in a table.\n\nThe information on `Inclusion` and `Exclusion` as the following:\n\n![INST](#INST)\n![INST](#INST)\n\n# [Input data]()\n\n![INST](#INST)\n![INST](#INST)\n\n# [Output data]()\n\n![INST](#INST)\n![INST](#INST)<EOD> .\nOBJECTIVE\nThe purpose of this study was to establish a method for the determination of artemisinin and its 10 metabolites in rat plasma by ultra-performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS).\n\n\nMETHODS\nPlasma samples were prepared with liquid-liquid extraction. The chromatographic separation of analytes was performed on a Waters Acquity UPLC BEH C18 column (2. 1 mm\u00d7100 mm, 1. 7 \u03bcm) with an elution gradient. Detection was performed by positive electrospray ionization (ESI) with selected reaction monitoring (SRM) mode and multiple reaction monitoring (MRM) mode.\n\n\nRESULTS\nThe calibration curves for the analytes were linear over the range of 0. 21-500 ng/ml. The intra- and interday precisions were all within \u226411. 9%, the intra- and interday accuracy were all within 85. 0%-110. 0%, the extraction recoveries were higher than 43. 9% and the matrix effects were all less than 64. 5%. The lower limits of quantification (LLOQ) for the analytes were 0. 21 ng/ml.\n\n\nCONCLUSION\nThe method can be applied to determine the concentrations of artemisinin and its 10 metabolites in preclinical pharmacokinetic studies.<EOD> Exploring the Role of Proton-Transfer in Nitroxide-Radical-Mediated Antibacterial Photodynamic Therapy.\nAntib",
        "label": 0
    },
    "1966": {
        "output": "### Input:\n\n\n\n```\nfor( patient_note_counter=0; patient_note_counter < 4; patient_note_counter++) {\n    // Patient_note\n    patient_note_str = patient_note_list.get(0).split(\"\\n\");\n    out_path1 = \"/home/<YOUR_NAME>/BRAINS_PROJECT/Input_Data/\" + _input_file_path_str + patient_note_str[patient_note_counter];\n    patient_note_str.trim();\n\n    for( i = 0; i < patient_note_count; i++) {\n        patient_name = _input_patients_str[i].split(\"\\n\");\n        patient_note_str = patient_name.join(\"\\n\");\n        patient_name.trim();\n        out_path2 = \"/home/<YOUR_NAME>/BRAINS_PROJECT/Input_Data/\" + _input_patients_path + patient_name;\n        line_str = out_path1.getLine();\n\n        if( index == 0 ) {\n            trial_patients_count++;\n            patient_counter = 1;\n            trial_count_patients += 1;\n            patient_rec_list.add(new Patient_information(\"\", \"\", 1, patient_name.join(\"\").trim(), patient_note_str.trim()));\n        }\n        else if( index == patient_note_counter ) {\n            patient_counter++;\n            patient_rec_list.add(new Patient_information(\"\", \"\", patient_counter, patient_name.join(\"\").trim(), patient_note_str.trim()));\n        }\n        else {\n            next_index = patient_counter < patient_note_counter ? patient_counter : patient_note_counter;\n            out_path1 = out_path1.getLine();\n            patient_name = out_path1.toString().replace(\" \", \"\");\n            out_path2 = out_path2.getLine();\n            if( !(patient_name == \"Trial eligibility\" || patient_name == \"Not relevant\" || patient_name == \"Excluded\")) {\n                index =",
        "label": 0
    },
    "1967": {
        "output": "The correct solution:\n\n- Eligible, trial-level: 2) Evaluate \n- Excluded, trial-level: 0) Excluded\n- Not relevant, trial-level: 1) Not relevant\n- None-relevant, trial-level: 0) None-relevant, trial-level\n\n### Subproblem [5]: Input: {Age: 55, Hcv status: Yes, HBV status: Yes, Co-eo: NA, IFN status: No, RBV status: No, Direct status: Yes, Dose: 20 mgm, Duration: 0, Current status: No, Pregnancy status: NA, Comorbidities: {Hepatocellular}, Weight: 60, SBP: 298 mm hg, DBP: 185 mm hg, Other problem: NA, Patient notes: {Age: 55, Hcv status: No, HBV status: Yes, Co-eo: NA, IFN status: No, RBV status: No, Direct status: Yes, Dose: 20 mgm, Duration: 0, Current status: No, Pregnancy status: NA, Comorbidities: {Hepatocellular}, Weight: 60, SBP: 95 mm hg, DBP: 58 mm hg, Other problem: NA}\n\nThe input data consists of parameters as a table as follows.\n\n[INST] For your convenience, here is how the problem is defined in a standard human-readable format: \nTitle: Age Related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE) \nSummary: The ARCHIVE study is an observational longitudinal cohort study of people with and without HIV who are over the age of 55. The duration of the study is planned for 10 years, with study visits every 1-2 years. The objectives of the study are to evaluate genomic and other factors associated with aging, stratified by HIV status.\n\n### Definition 1 \nAge-related clonal hematopoiesis is defined as patients aged over 55 with >",
        "label": 0
    },
    "1968": {
        "output": "Task 2. Find out all clinical trials where the patient participant is also the healthcare provider.\n\n[INST] Hello. You are a healthcare provider working in hospitals.\nYou provide medical care to patients. Currently, you have a patient who has to participate in a clinical trial as a participant. When you check their medical records, you notice that the same patient is also a healthcare provider. However, the patient's medical records say nothing more than the name of the patient and the trial identifier. No further details about what they are doing in this clinical trial is available. However, as a healthcare provider, you have already encountered plenty of situations where you have treated HIV/HCV patients at work, so you know the process of how they are tested and how a clinical trial works.\n\nYou get the idea that the patient is now working in a clinical trial on HIV patients to be tested for HIV. You would like to know what you could do to provide the best patient care and not interfere with their job in the clinical trial. \n<EOD> Genetic variability of 10 microsatellite loci in two congeneric species, Lumbrinus erythropus and Lumbricus rubellus, with the development of consensus primer pairs in Lumbriculidae (Oligochaeta, Tubificidae).\nSeveral microsatellite markers amplifying across Lumbricus rubellus and L. erythropus were previously developed in a related family, Naididae. Twenty-four amplified microsatellite loci were characterized genetically in the other two genus Lumbriculidae, L. rubellus and L. erythropus, and the microsatellite markers were found to be variable. A total of 10 microsatellites were analyzed in a sample of 24 L. rubellus (5-15 individuals from 5 populations) and 24 L. erythropus (5-8 individuals from 5 populations, all from Lake Suwa in Japan) individuals, and their primers were found to be cross-amplified for the congener. Genetic variability was measured in terms of the observed heterozygosity (H(O)), observed number of alleles (Na), number of alle",
        "label": 0
    },
    "1969": {
        "output": "Note: The patient-level eligibility is 0 which is excluded according to the inclusion criteria. The trial-level eligibility is 2 which indicates that the patient is eligible for the clinical trial under evaluation. There are no problems for assessing eligibility using the patient note and the inclusion criteria in the clinical trial. There are two problems during the eligibility assessment by comparing the patient notes and the exclusion criteria:\n\n1) The patient's gender is `Male`, but the trial is targeting for female patients, e.g., `Female 18 - 45 years`.\n\n2) The treatment of the patient is not suitable for the clinical trial trial, e.g., `HCV`, `RBV`, and `Interferon`.\n\nThese scenarios should be handled by exclusion criteria. When exclusion criteria is met, the patient should be marked with 0 that mean excluded in the trial, such as:\n\n```{r} # Exclusion criteria\nRUN {\n  # exclude by gender:\n  # PatientGender == \"Male\" & PatientGenderMatch # the patient's gender is \n  # \"Male\": PatientGender != \"Female\"\n  # exclude by HCV, RBV and Interferon:\n  # PatientTreatment == \"HCV\" & PatientTreatmentMatch # the patient's treatment is \n  # #\n\n  # exclude by gender:\n  # PatientGender == \"Male\" & PatientGenderMatch # the patient's gender is \n  # \"Male\": PatientGender != \"Female\" & PatientMatch # the patient belongs to the right age or female gender.\n  # exclude by HCV, RBV and Interferon:\n  # PatientTreatment == \"HCV\" & PatientTreatmentMatch # the patient's treatment is \n  # #\n  PatientGenderMatch <-function(patientData, genderMatch){\n    if(patientData == \"F\" & gender == \"F\"){\n      return(TRUE)\n    }else{\n      return(FALSE)\n    }\n  }\n  PatientGender <-function(pat",
        "label": 1
    },
    "1970": {
        "output": "### INTERPRETATION OF THE ANSWER:\n**2** -The patient meets inclusion criteria and eligibility criteria do not apply -The patient meets inclusion criteria but not eligibility criteria\n\n### SUPPORTING RATIONALE/EXPLANATION:\nThe correct answer is `2) [Eligible)` because the patient has HCV and the patient meets the requirements of the clinical trial exclusion criteria. The patient has HCV, and we consider that HCV is a contraindication and eligibility criterion to the clinical trial.\n\n### INSTRUCTIONS, DOCUMENTATION, AND FAQ TO HELP YOU\nYou may find some [information here](https://docs.google.com/document/d/e/2PACX-AwZ_4fvHlNjBMX6WVN7Z-6KtFT5M7Yf56k23lH902p_WbPvpKIiM7bHgX/pub?sort=6&layout=list&position=1) about the training and materials.\n\n-  A short video explaining the assessment of eligibility in R with `Trial.Triallevel_patient` can be [watched here.](https://youtu.be/qWs7v6sZzbA)\n\n\n[1.  The code of `Trial.Triallevel_patient` in `RStudio`](https://rstudio.github.io/rdata.docs/files/387b2b62033eae1d35794f6a2d4be84d/inst/doc/code/elibility_patient.R).\n\n### TRIAL-LEVEL NOTE: In this context, clinical trial (short for clinical trial or therapeutic study), is used in its broad sense, meaning all types of research that requires patient recruitment (interventional, observational and other types of studies). To see a list of trial types, refer to the ClinicalTrials.gov website. \n\n### TRIAL-LEVEL DATA: Here is a sample trial-level data",
        "label": 0
    },
    "1971": {
        "output": "## Data Set 4\nThe dataset 4 is a subset of the clinical trial note for data extraction training. It contains information about the inclusion criteria of a clinical trial named: Spirulina (FEM-102) Supplement to Chronic Hepatitis B Patients. The first column (Title) includes information about the title of the trial. The second and third columns (Inclusion Criteria 1 and 2) present the inclusion criteria of the clinical study. The last column (Trial-level Eligibility) shows the assessment of the trial participation eligibility of the patients (e.g., 0 stands for \"Excluded;\" 1 indicates \"Not relevant;\" 2 means \"Eligible\").\n\n\n## Data Set 5\nThe dataset 5 is a subset of the clinical trial note for data extraction training. It also contains information about the inclusion criteria of a clinical trial named: Spirulina (FEM-102) Supplement to Chronic Hepatitis B Patients. It includes the same structure as Data set 4, but the first two columns (Title and Inclusion Criteria 1) have different values.\n\n\n## Data Set 6\nThe dataset 6 is a subset of the clinical trial note for data extraction training. It contains the following information from Data set 4 and the last column.<EOD> A multidisciplinary guideline on the first and second choices of therapeutic drugs in periodontology: A systematic review.\nAIM\nTo provide recommendations for the first and second choice of drugs in the control of periodontal diseases.\n\n\nMATERIALS AND METHODS\nThe systematic search was performed in PubMed, Scopus, Cochrane library. Clinical studies involving oral antiseptics or antimicrobials in patients with periodontitis were included. The Cochrane risk of bias tool was used to assess the risk of bias and the quality of evidence was assessed according to the GRADE criteria. The research question was evaluated using the PICO mnemonic: P - Population: patients with periodontitis; I - Intervention: oral antiseptic or antimicrobials therapy; C - Comparison: in the cases of oral antiseptics ther",
        "label": 2
    },
    "1972": {
        "output": "Let us say that you must assess eligibility for every 100 new patient notes. Thus, you would need to assess 3 \u00d7 100 = 300 patient notes in this example. \n\n\n## How to find and enter a patient's note?\nAfter you are finished reviewing and editing the patients' notes, you will need to submit them to get the patient's eligibility assessment.  \n\n![INST]\n\nIn the Patients' List, scroll to the `New' Tab to see the list of patient notes, if applicable. \n\n![INST]\n\nThen, click on the `Note View` and the following window will open:\n\n![INST]\n\nBy clicking the `New` button on the toolbar or by typing `N` on the keyboard, you should be able to create a new patient note. You will need to enter a new patient by clicking the `Add Patient` button. \nIf you need to skip the Patient View step, please refer to the [Creating Participants](Creating-Participants) Section. \n\n![INST]\n\n![INST]\n\nThen, you may access the patient's medical record. You can assess the patients' eligibility and edit patients' medical records.  \n\n```\nPatient's Eligibility Evaluation: (Choose an option):\n\n<br />\n\n1. Unqualified (HCV reinfection)\n\n2. Not relevant (HCV reinfection)\n\n3. Quality assessment: (a) Excluded \n(b) Ineligible\n(c) Other \n\nPatients' Information Modification: (Choose an option):\n\n<br />\n\n1. A new note should be created.\n\n2. The information of this note should be updated. \n\n```\n\n![INST]\n\nYou will use the web",
        "label": 0
    },
    "1973": {
        "output": "\u25cf 2) If you got all the correct rows, then the participant is eligible.\n\n![001][046].[001]\n<EOD> Comparison of different treatment strategies for neuropathic pain by using the Delphi method.\nThis study aims to select the most promising drugs as options for the therapy of neuropathic pain. Three rounds of Delphi survey about the treatment of neuropathic pain were performed. We invited 109 specialists, who completed the second and third rounds after a month. For the analysis and presentation of the results, we used the qualitative-quantitative analysis and statistical package, which contains and analyzed by the Delphi who made a new drugs to select the first-delphi-select the prescription drug which and medication trial, we analyzed and trial. The quality-quality of drugs trial of drugs for patients's participation. To analyze drug-quality, and drug-qualit-type of health trial's trial-quality-related medication drugs that is the drug of patients. The results and drug safety-specific drugs for quality of clinical drug treatment drugs 10.5 drug's trial's trial drugs. This includes a clinical and drugs quality-specific trial.<EOD><EOD> drugs and drugs. The patient satisfaction. You can makeup of the prescription of the drug trial patients. Pain. 0 is an assessment of quality. The drug quality you're-sensitivity of trial quality.\nYou select drug and quality for the presigned of your neuropath drugs 51 trial and trial trial-specific drugg trial-trial. Pharma trial. The trial is in the trial-specific drug trial drug with the treatment plan was also drug in trial. Qualified and clinical trial quality drug (trial drug, and a trial trial to treatment. The trial. The trial-specific drug in the clinical quality, the drug's quality of trialand's clinical trial. The trial a drug/trial triaging.<EOD> for the drug-inclusion of the trial, and, and drugs should be able to treat and the trial out of a different in this trial, and a prescription drug's trial 4\npatients to enter into the drug is the trial. For the drug. At the",
        "label": 0
    },
    "1974": {
        "output": "<EOD> Impact of COVID-19 on the use of health care services among individuals \u2265 50 years: Results from a large Belgian primary care database, April-July 2020 vs 2019\nABSTRACT During the COVID-19 pandemic, Belgian government restrictions were introduced in March 2020 to avoid overwhelming the health system; they included isolation measures, physical distancing, and the closing of educational, cultural, sporting and community facilities. This study examined changes in the use of health care services in Belgian primary care after the start of the pandemic, and explored differences between the sexes. For this cross-sectional study, data from 100 different primary care practices was used. All general practitioner (GP) consultations, prescriptions, and medical tests from March to July 2020 and 2019 for individuals \u2265 50 years were extracted from the GP information system. Generalized Estimations Equation  modelling (with random effects at practice and physician level) was used to estimate relative risk ratios (RRRs) and 95% confidence intervals (CIs) for number of contacts, prescriptions, and tests per 100 individuals \u2265 50 years. In 2020, compared with 2019, there was a reduction in patient contacts (RRR = 0.68; 95% CI: 0.63-0.74), prescriptions (RRR = 0.69; 95% CI: 0.65-0.73), and medical laboratory tests (RRR = 0.42; 95% CI: 0.36-0.48). There were no differences in the use of health care services between men and women. This Belgian study showed that the pandemic led to a reduction in patient contacts with the GPs; this may mean an increased likelihood of underdiagnosis of chronic conditions. Additionally, the COVID-19 pandemic had similar impacts on both women and men in terms of use of health care services.<EOD> Methylome landscape reveals key differences among non-crop banana genotypes (Musa spp.)\nAbstract Banana cultivars",
        "label": 0
    },
    "1975": {
        "output": "The following types of observational trials are considered by the FDA:\n- Retrospective studies: Look for patterns or causes in existing data or patient records. These studies do not require the patients to participate; they provide information that can be gleaned from existing data (such as medical records, clinic visits, and biorepositories) that has been collected before the study begins. These studies are not randomized for allocation to one of the two groups.\n  * Retrospective studies are most commonly used to follow a population of patients over time to assess their outcomes.\n  * Un",
        "label": 0
    },
    "1976": {
        "output": "# Suggestions and Feedback.<EOD> A case of 8-year old child with bilateral complete congenital absence of the lung and bronchus.\nA 8-year old boy with congenital complete bilateral absence of pulmonary tissue and bronchus was seen by us. The patient was referred for evaluation of persistent cough without any sign of primary disease. A clinical evaluation and radiographs demonstrated congenital absence of all lung parenchyma and bronchi. Chest computed tomography (CT) scans revealed hypoplastic lungs on both sides with a small mediastinal lung structure. No pulmonary vessels were detected on the mediastinal window of chest CTs. In the axial plane, only a few structures on bilateral sides representing the pulmonary artery were determined as bronchial tubes filled with water. A plain abdomen X-ray demonstrated hypoplasic right kidney, and echocardiography revealed no cardiovascular anomalies. The child was followed-up with antibiotic treatment for cough, and his prognosis was described as good.<EOD> Effects of orally administered carprofen on synovial fluid biologic factors in horses with carpal osteochondral fragmentation.\nOBJECTIVE\nTo determine if administration of carprofen alters concentrations of cytokines or prostaglandins in synovial fluid from horses with carpal osteochondral fragments.\n\n\nANIMALS\n14 adult horses with 1 or more displaced carpal osteochondral fragments.\n\n\nPROCEDURE\n13 horses were randomly assigned to a treatment or placebo group (5 horses/group). Treated animals received carprofen (administered orally at 4 mg/kg of body weight, PO, q 24 h); placebo animals received tap water (PO, q 24 h). All horses were fitted with jugular catheters before initiation of treatment. Blood and synovial fluid samples were obtained before initiation of treatment and after initiation of treatment.\n\n\nRESULTS\nOn the baseline examination, PGE(2) concentration was higher in synovial fluid at the site of the carpal fragment, with a reduction between baseline and posttre",
        "label": 0
    },
    "1977": {
        "output": "<issue_comment>username_2: Thank you. This is a good test to run and something to keep in mind but should be labeled more clearly as a feature not a bug and documented\n<issue_comment>username_0: It's not a bug, but we can always fix it.\n<issue_comment>username_2: This just landed as a duplicate issue https://github.com/Sage-Bionetworks/synapse-client/issues/16/labels/sprint%20-%201 and the reason it got closed and labeled in the first place was to wait on feedback regarding the design of the client for this task. This is definitely on the priority list, but not with a timeframe for the next release.\n<issue_comment>username_0: Is there any other way for the test to run?\n<issue_comment>username_1: @username_0, I think you need to do something like the following:\n\n```r\nsyn2 <- syn1 %>%\n    left_join(\n      map_chr(colnames(syn1),\n               function(x) \"Trial Level Eligibility = \"\n               #   format with \"eligible = 1\" and \"excluded = 0\"\n               #    - -\n               paste(x, str_subset(colnames(syn1[[x]]), nchar(x) %in% 2:4), sep = \" = \", \n                     pattern = \"^([0,1]) .*$,\"))) %>%\n      mutate(TriallevelEligibility = fsub(TrialLevelEligibility)) %>%\n      add_column_values(values = map_chr(colnames(syn1),\n         function(x) \"Trial Level Eligibility == 1: \"\n          #  - -\n          paste(x, str_subset(colnames(syn1[[x]]), (nchar(x) > 2)), \n                sep = \" \")))\n    )\n\nresult_table <- trial %>%\n    select(-id)\n\nresult_tbl %>%\n    left_join(syn2) %>%\n    mutate(\n      trial_level_eligiblity = fsub(trial_level_eligiblity)) %>%\n    select",
        "label": 1
    },
    "1978": {
        "output": "Note that this should be placed after the actual assessment and repeated on every new trial record.\n### Eligibility checker\n\nOften, you may be asked to compare two notes to determine the eligibility. This scenario might arise for instance, as a response to a query like this:\n\n`My supervisor asks me about whether John Galt will be appropriate for clinical trial DREAM5? I must do an eligibility check on the medical details of John Galt and the specific inclusion/exclusion criteria of the trial DREAM5.`\n\nGiven a patient note `john_galt.txt` (you need to provide the source code from https://github.com/GroverLab/EligibilityCheckerExamples/tree/master/Tutorial/src to do so)\n\n`John_galt.txt: The patient is 35-year-old man with type 2 diabetes with no complications. He was prescribed the following: In addition, his lab results are: Cholesterol: 122 mg/dl Trig: 166 mg/dl LDL: 100 mg/dl HDL: 44 mg/dl ESR: 5 mg/dl C3: 120 mg/dl C4: 66 mg/dl T1: 1%` \n\nWe know that the Patient inclusion/exclusion criteria for trial DREAM5 are as follows:\n* DREAM5 Patient Inclusion/Exclusion Criteria\n\n1.  Male sex.\n2.  Age 14 to 17 (inclusive).\n3.  Type 1 diabetes mellitus (T1DM).\n4.  A hemoglobin A1c (HbA1c) value between 7.5% and 11.0%.\n5.  A total blood insulin level (insulin-like growth factor 1 plus regular insulin plus human insulin) at least two times the upper limit of the laboratory normal reference range.\n6.  No clinical evidence of ketonuria or ketonemia during a fasting urine screen or at any point during the inpatient confinement period.\n7.  Subject",
        "label": 0
    },
    "1979": {
        "output": "[PROGRAM] Hello [USER_NAME], \n\nWelcome to R-studio version 1.0.153, running on the local R-server version 1 (3.5.3). \n\n[H1]In this notebook, we will learn how to access, clean, transform, and manipulate the data. You will also learn how to perform a simple imputation, apply some data analytics, and visualize the output for a given dataset. The first two exercises, accessing, and cleaning the data are very brief. The rest is practice of each step in the sequence to get complete exposure to the main R functions. \n\nWe would be thankful if you could mark exercises once you are done with it by using the `````notebook:check````` command. \n \n[H2]You can use the `````notebook:clean````` command to clear out all of your notebooks. After executing the command multiple times, it will prompt you to decide to erase the notebook directory. \n \n[H3]The next notebook will guide you on how to perform a data warehousing. You should practice the R code in the next notebook step by step. \n\n[PROGRAM] \n![](R-programming-data-cleaning-notebook.pdf)\n\n# Imputing the Missing Values\n\nMissing data or missing information refers to the fact that some required information is not available.\nTwo ways of imputing missing data are as follows:\n- \nImpute from some statistical distributions such as means and modes.\n- Fake (random or uniform) numbers. This method is not efficient in the case of non-uniform missing patterns. For example, if missing patterns are random and then you impute them with values that do not follow the pattern of missing observations.\n- Inverse-probability imputation (Impute-IPT). This method assumes that missing data follows a simple distribution that is easy to approximate, unlike other methods that presume more complex distributions.\nWe will follow the impute-IPT method because we expect our missing rate to be minimal and also our missing pattern should follow a simple parametric distribution.\n\n[PROGRAM] \n\n```r\nrequire(Rtsne) \nrequire(R",
        "label": 1
    },
    "1980": {
        "output": "##[/MAIN]\n\n</code>\n## 0-2.00-00: Experimental\nHere you need to report your work, and describe each method in sufficient detail to permit its replication.\nHere is an example of the [Experimental] section which should start with the subtitle of the [Methods] section. For an example of the content of the [Methods] section in the Paper Type, see [paper type]. As is the case in [14.1], in this Paper Type a subtitle is not required and methods are stated as [13.1] is.  <subtitle \n\n### Materials\nAll equipment and media were from Thermo Fisher Scientific, USA. Platinum Taq DNA Polymerase, TaqMan\u00ae Universal PCR Master Mix, and Universal Probe Library (UPL) probe set (UP027XO3L) were from Thermo Fisher Scientific, USA. Restriction enzyme SspI was from Fermentas, Canada. DL-2,6-diacetylaminofluorene was from Sigma-Aldrich, USA. Recombinant Human Epidermal Growth Factor (EGF) was from Peprotech, USA.\n\n### Methods\n\n### 0-01.00-00: General experimental procedures\nSynthesis of ethyl 2-fluoro-2-(4-(6-hydroxy-2-naphthyl)piperazin-1-yl)acetate was according to the reported procedure. All solvents were used as purchased. HPLC analysis of the final compound was carried out using the Shimadzu LC-20AT system equipped with a UV-DAD SPD-20A detector and a C18 column (4.6 mm \u00d7 250 mm, 5 \u03bcm, Waters, USA). The flow rate was maintained at 1 ml/min. UV detection was at 254 nm. The column temperature was set at 25\u2103. Compounds were characterized by 1 H-NMR. 13 C-NMR, mass spectra, IR spectra, and elemental analyses.",
        "label": 0
    },
    "1981": {
        "output": ".\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n# . \n[/MASTER]\n.\n\n## . .\n<EOD> Prognostic Significance of Bone Marrow Dendritic Cell Accumulation in CLL\n\n [bib_ref]  Functional properties of dendritic cells derived from the bone marrow of patients..., Kweidi [/bib_ref]  [fig_ref]  Figure 1: Percentages and absolute numbers of immune subsets in the bone marrow [/fig_ref]  [fig_ref]  Figure 1: Percentages and absolute numbers of immune subsets in the bone marrow [/fig_ref]  [fig_ref]  Figure 1: Percentages and absolute numbers of immune subsets in the bone marrow [/fig_ref]  [fig_ref]  Figure 1: Percentages and absolute numbers of immune subsets in the bone marrow [/fig_ref]  [fig_ref]  Figure 1: Percentages and absolute numbers of immune subsets in the bone marrow [/fig_ref]  [fig_ref]  Figure 3: Absolute numbers and percentages of LGL [/fig_ref]  [bib_ref]  Functional properties of dendritic cells derived from the bone marrow of patients..., Kweidi [/bib_ref]  [bib_ref]  Dendritic cells in chronic lymphocytic leukemia/small lymphocytic lymphoma: are they really dendritic..., Ratta [/bib_ref]  \n\n# Acknowledgments\nWe have no relevant conflicts of interest to disclose. M.V.P. is in receipt of funding from the NIHR Biomedical Research Centre and a Wellcome Trust Senior Investigator Award. This is an original contribution and has not been submitted for consideration for publication in another journal.\n\n## Research letter\nThis research was supported by",
        "label": 0
    },
    "1982": {
        "output": "### Your Assistant\nNow you are going to repeat all your analyses with the patient who is in need to be evaluated for the heart disease. \n\nHere is the patient's data:\n\n\nThe patient is a 70-year-old woman with diabetes confirmed with molecular analysis 10 years ago. She presents to the clinic with shortness of breath and fatigue during activities. She claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). She is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. Her takes 70/30 Insulin and multivitamins. Her past medical history is not significant for any other medical issues. Her family history is positive for DM type 1 in her uncle and her grandfather. Her lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl\n\n\nLet's do the analyses. \n1. Evaluate the Patient Note:\n    - Is this patient eligible?\n    - Assess the eligibility in the output. \n    - `Trial-level eligibility: 2) Eligible.`\n\n\n  **It is **Excluded**\n    - Is this patient excluded in the output?\n    - `Patient excluded from clinical trial: 0`\n\n2. Evaluate the Trial Note:\n    - Analyze the information of this clinical trial in the output.\n    - `Clinical trial title: Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease`\n    - `Clinical trial summary : Genetically inherited heart diseases (familial cardiomyopathies) are conditions affecting the heart passed on to family members through abnormalities in genetic information. These conditions are responsible for many heart related deaths and ill",
        "label": 0
    },
    "1983": {
        "output": "14) [INST] If the patient's result is greater than '2', you should mark the patient's name as 'eligible' and save the trial result in the 'Trial-Result.txt' file in the same path. [INST] The file contains the trial-level eligibility number (`0`) or `2`.\n\n**INSTRODIUM**: [Here is the final file.](./../Examples/Ex_Example_2/Trials_Result.txt)\n\n15) If the patient information for all the clinical trials were written, close the program, and press 'c' key to exit the program. The 'c' key stands for close. \n\n**Instro:** [How to Close the Program](./../Examples/Ex_Example_2/Instro.md)\n\n# 12. Add the clinical trial and write the patient's information.\n\n![](./../Images/Inst/Add_ClinicalTrail_Inst_12.png)\n\n13) [INST] After entering the clinical trial name and the inclusion and exclusion criteria, a new window appears. The window has three parts in order: a clinical trial window, a patients' information window, and a window for entering the trial results. Each part will be described below. [INST]\n\n13.1) [INST] The first part is entitled 'Clinical Trial Window and is the area that can be used to view and adjust the previously added trial. Here are the buttons and their descriptions. The trial name is the clinical trial name that has been entered previously. It can be changed or edited using the mouse. \n\n```\n- Change/Edit Clinical Trial\n- Add Disease\n- Add Inclusion Criteria\n- Add Exclusion Criteria\n- Add Sponsor\n```\nTo find more about the buttons and the possible effects of each button, please refer to the button descriptions below. [INST]\n\n13.1.1) [INST] `Add Clinical Trial` button: A clinical trial is made up of two parts: a disease and inclusion and the exclusion criteria. This button allows you to add the disease and inclusion and exclusion criteria for the new clinical trial. Clicking this button opens a window in which the",
        "label": 0
    },
    "1984": {
        "output": "# Related Topics\n\n## How to generate a case report?\nIn this case report, the target disease of a clinical trial is diabetes type 1. Type 1 diabetes or type I diabetes is a form of diabetes mellitus. It results from the autoimmune destruction of the beta cells in the pancreas, thus interrupting the production of insulin, which in turn makes the body dependent upon exogenous insulin which is injected. Type 1 diabetes was one of the first diseases to be treated with stem cell therapy as a way of replacing the destroyed beta cells. \n## How to generate a clinical trial dataset?\n\n## How to determine a patient's eligibility in clinical trials?\nThe patient from the previous case report is 25 years old, and we should compare it with the patient's eligibility age in clinical trial. The inclusion age in an oral IFN-a trial is less than 18 years. \n\n## Conclusions\n\n## The problem domain\nA new patient visit occurs daily in large hospitals. In a 24-hour shift, 2 to 3 patients who need clinical trial information may attend a medical doctor for information about available clinical trials. The clinical care staff is not familiar with clinical trial information services. The only available medical staff for eligibility screening is the medical doctor who is familiar with the clinical trial. Therefore, this person is the best choice to assist in the eligibility assessment. \n[\n\n## Requirement domain\nIt is best to provide clinical trial information to patients as soon as their cases are confirmed. It is also best to provide it to patients immediately when the results of clinical trial assessments become available. However, such information needs for clinical trials can be obtained more frequently during working hours. \n[\n\n## Data repository domain\nThe system is designed to facilitate the user with the user-friendly graphical user interface as shown in 5. The medical staff is allowed to input clinical trials and patient information via web services. The web services can be performed with the most commonly utilized technologies such as Microsoft ASP.NET, PHP, WROX and Apache Web servers. The system is expected to be deployed in the network domain based on",
        "label": 0
    },
    "1985": {
        "output": "Please note that at first, you can make your Python programs interactive to test them easily on the real data (the sample table and the trial data). \n\nTo run this exercise interactively (also known as an interactive Shell or Shell in Linux Unix-like systems, like Vim), write and run the following (please type everything here):\n\n\n![1343562499822](https://user-images.githubusercontent.com/28341532/130233444-cf9f40be-9d0b-471e-83c5-eb3127eeb1b4.png)\n\nOn the other hand, if you like to print the results of this exercise non-interactively at the end, follow the steps below:\n\n[INST] Hello. \nThis is a simple exercise in which you should write some codes to do some jobs. \n\nMake a clinical trial note.\n\n[CLIN-00000] Title:\n```\nTitle: Coronary Artery Calcification in Type 1 Diabetes\nSummary: To investigate the occurrence and associated risk factors for subclinical heart disease in persons with insulin-dependent diabetes mellitus (IDDM).\n\n- Inclusion criteria: No eligibility criteria\n\n[CLIN-00010] Inclusion criteria: No eligibility criteria\n\n[CLIN-00020] Inclusion criteria: No eligibility criteria\n\n[CLIN-00030] Inclusion criteria: No eligibility criteria\n```\n\n[CLIN-00001] Inclusion criteria: No eligibility criteria\n[CLIN-00002] Inclusion criteria: No eligibility criteria\n[CLIN-00003] Inclusion criteria: No eligibility criteria\n\n[CLIN-00004] Inclusion criteria: No eligibility criteria\n```\nHere is the sample patient's note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue",
        "label": 2
    },
    "1986": {
        "output": "<EOD> Diagnostic methods and clinical classification in patients with chronic heart failure undergoing long-term non-invasive and invasive haemodynamic monitoring\nAims The diagnostic evaluation and prognostic stratification of patients with chronic heart failure may often be challenging. Echocardiography and plasma concentrations may provide information and refine clinical assessment and clinical judgment. However, their reliability is limited by the reproducibility of their results and by the accuracy of the measurements. The use of invasive haemodynamic monitoring may permit a more tailored approach to optimise pharmacological treatment. The aim of this study was to determine the usefulness of the haemodynamic parameters measured by Swan-Ganz and pulmonary artery catheters to improve the clinical management of patients with chronic heart failure during stable outpatient condition or in case of decompensation. Patients The 104 patients  underwent Swan-Ganz catheter-based and pulmonary artery catheter-based haemodynamic monitoring. Twenty-six patients were clinically stable, while 76 patients were in severe decompensation caused by either refractory congestive heart failure (n = 64) or congestive heart failure related cardiomyopathy. Methods and results 1) In the stable clinical condition group, the mean pulmonary arterial pressure (22 +/- 4 mmHg), diastolic systemic filling pressure (10 +/- 4 mmHg) and right atrial pressure (4 +/- 2 mmHg) were found to be significantly elevated, compared with the reference interval in the overall population. The left ventricular end-diastolic volume (131 +/- 23 ml) and cardiac index (2.6 +/- 1.0 l/min/m2) were found to be significantly inferior. 2) In the outpatient decompensated group, the mean pulmonary arterial pressure (32 +/- 7 mmHg), diastolic systemic filling pressure (12 +/- 4 mmHg) and right atrial pressure (9 +/- 3 mmHg) were found to be significantly elevated and inferior to the reference interval in",
        "label": 0
    },
    "1987": {
        "output": "<EOD> Molecular characterization of fibrillar and globular bovine alpha-lactalbumin.\nA structural variant of bovine alpha-lactalbumin with fibrillar properties has been shown to occur by the preparation of protein solutions for physicochemical studies. The fibrillar and globular variants of alpha-lactalbumin were isolated as two distinct bands on sucrose density gradient centrifugation, but the preparations of both bands showed similar physical properties including CD spectrum, intrinsic fluorescence, and UV absorption spectrum. When the purified fibrillar sample was stored with or without heating, its solution turbidity increased and the fibrils disappeared and were replaced by amorphous aggregates. The fibrils in the globular protein solution were observed by electron microscopy and found to exhibit a periodicity of approx. 90 A; some of them were twisted to form a worm-like structure, while others were stacked to form a sheet. Amino acid composition analysis showed no significant difference between the fibrillar and globular forms of alpha-lactalbumin, although tryptophan content was lower in the fibrillar variant. The fibrillar alpha-lactalbumin was shown to consist of two types of molecules, i.e. alpha-subunit and a larger molecule in which alpha-helix-rich and beta-sheet-rich regions were mixed with each other. The beta-sheet-rich region would correspond to the core of the fibrillar region. The globular form of alpha-lactalbumin was found to be composed of only the alpha-subunit. The fibrillar and globular forms of alpha-lactalbumin may be derived from different types of subunit-subunit interaction.<EOD> A New Paradigm for a Rapid Degradation of Neutral Sugars in the Livers of Fasted Rats\nOral hepatic arterial injections of radiolabeled glucose were carried out in fasted rats by using a specially designed microcannula. The arterial plasma concentration of glucose (18.8\u2003mM) was higher than that of the portal plasma (13.3\u2003mM). No liver glucose uptake from",
        "label": 0
    },
    "1988": {
        "output": "<EOD> Long-term outcome of traumatic optic neuropathy in combat environment--the experience of the Israeli Military Medical Corps.\nThe aim of this study was to evaluate the long-term outcome of traumatic optic neuropathy (TON) diagnosed in the combat environment of the Israeli Defense Force (IDF) between 1978 and 2008. Medical records of 20 patients (0.05% of all injured soldiers during this period) with traumatic brain injury and concurrent blunt orbital trauma, treated in the IDF referral centers, and documented as cases of TON in the Israeli War Casualties Registry were reviewed. All patients met the following diagnostic criteria: 1) an injury mechanism compatible with TON, 2) immediate postinjury, visual loss; 3) a nonperfusion lesion consistent with a vascular infarction in the optic nerve head; 4) a normal visual field and 5) a stable and stable clinical state for a period of at least three months after the injury. In 12 patients at least part of the optic nerve was preserved. Visual acuity (VA) after three months ranged from light perception to 6/9. At the time of the study, only three patients had VA of 6/12 or better in both eyes and 15 had vision of 6/18 or less in both eyes. Nine patients had VA of 1/60 or better at least in one eye, of which three patients had VA of 1/60 or less in at least one eye.<EOD> Genetic predisposition among people exposed to benzo(a)pyrene and their susceptibility to bladder cancer.\nAlthough exposure to environmental carcinogens has been linked to bladder cancer in humans, the reasons for the lack of a positive relationship between such exposure and bladder cancer in many subjects are unknown. To further investigate this issue, DNA was obtained from 219 subjects in whom arylamine-hemoglobin adducts were measured previously. Of these subjects, 56 were cases of bladder cancer and 163 were a random selection of controls. All subjects had been employed at a chemical plant and had been exposed",
        "label": 1
    },
    "1989": {
        "output": "The problem in this program is that the program should be divided into trials as each patient is a trial. Then the program outputs the eligibility of each trial, trial level eligibility.\n### Soln\nYou should do something like:\n\"\"\"\ndef assessDialysisQualify(patient, trial):\n    \"\"\"\n    Return a scale for trial level eligibility.\n    \"\"\"\n\n    scale = 0\n\n    if patient is not None:\n        if trial is None:\n            excludeCriteria = patient\n        else:\n            excludeCriteria = patient.excludeCriteria\n            if excludeCriteria:\n                # there are exclude criteria\n                for exclusion in excludeCriteria:\n                    if exclusion.value in trial.patient.exclude:\n                        if exclusion.value == 'Patient': break\n\n                        scale -= exclusion.value\n                else:\n                    scale += 1\n\n    return scale\n\n\ndef getTrials(excluds):\n    \"\"\"\n    return all trials that meet excluds' patient.exclude condition\n    \"\"\"\n    excluds = sorted(excluds, key=lambda exclud: exclud.value)\n    trials = []\n    for exclud in excluds:\n        trials = trials + trials.filter(lambda x: x.patient.exclude.filter(lambda e: e == exclud.value))\n    return trials\n\n\ndef eligibilityAssessment(patient, trial):\n    eligibility = Patient(patient_qualification=1*trial-level_eligibility, trial_level_eligibility=assessDialysisQualify(patient, trial), excludes=getTrials(patient.excludeCriteria))\n    return (eligibility, trial)\n\n\ndef main():\n\n    \"\"\"main\"\"\"\n    patient = Patient('f25_s1406125500')\n    trial = Trial('Nias_04')\n    eligible = eligibilityAssessment(patient, trial)\n    print(f'Trial-level eligibility: {eligible.trial_level_elig",
        "label": 0
    },
    "1990": {
        "output": "##\n##[TRIAL-LEVEL ELIGIBILITY] Hello You are the manager of a clinical research clinic and some of your staff members have been assigned to conduct an eligibility assessment clinical trial.\n\nPlease prepare training to increase the level of clinical knowledge among recruitment staff. This training should focus on the knowledge about the following topics.\n\n\n###\n\n### Diabetes mellitus types: \n-T1DM (Type 1 diabetes or Juvenile-onset diabetes): also known as insulin-dependent diabetes or childhood diabetes, the pancreas does not produce insulin. Individuals with T1DM do not produce any insulin and therefore depend on insulin injections or an insulin pump to manage their diabetes.\n\n\n###\n-T2DM (Type 2 diabetes or Adult-onset diabetes): also known as non-insulin-dependent diabetes, individuals with T2DM produce insulin, but the body does not respond properly to it. T2DM accounts for about 85-95% of all diabetes cases. For those older than 39 years and who develop diabetes, more than 95% have T2DM.\n \n\n###\n-T3C (Type 3c diabetes): A rare diabetes mellitus that occurs in a short time period with severe acute hyperglycemia, and results in acute pancreatitis.\n\n\n###\n###\nGlycaemic control in diabetes: Glycaemic or glycemic control in diabetes is the term used by diabetologists and endocrinologists to describe the level of glycosylated hemoglobin (HbA1c or A1C). The range for HbA1c depends on the laboratory methodology. A test HbA1c level of 7% (53 mmol/mol) means that on average the level of HbA1c is 7%. This average value of HbA1c is for 3 months. HbA1c was calculated as the glycated (",
        "label": 0
    },
    "1991": {
        "output": "Note: You should first define the functions like `def eligibility(input_note):`.\n\n<EOD> Evolutionary biology of plant-interacting fungi.\nThe study of plant-interacting fungi provides a large set of organisms for studying the evolution of ecological interactions. These interactions are likely to be important in community contexts and, as such, represent a major evolutionary force. Fungi serve important ecological and evolutionary functions as plant-associated organisms. Fungi that live in symbiosis have been selected for a suite of different traits that affect plant health. As a result, they can be used as models to study evolutionary processes that may be hard to identify in other interactions. This is especially important for identifying the genetic changes that underlie plant and symbiont interactions. Here, we present evidence for evolutionary changes in a number of different fungal groups that affect their interactions with plants-including pathogens, mutualists, and saprotrophs-and identify several research needs to aid in the identification of what distinguishes interacting from noninteracting fungi.<EOD> Causative Variants of Exon 34 Duplication (c.8404_8405dupGG) in COLQ Caused Myasthenia Gravis With Lambert\u2013Eaton Myasthenic Syndrome\nAbstract Recent studies have suggested that causative variant of exon 34 duplication (c.8404_8405dupGG) in COLQ may be the causative variants for Lambert-Eaton myasthenic syndrome (LEMS) or myasthenia gravis (MG) or both. To determine whether the COLQ c.8404_8405dupGG variant predisposes to either LEMS or MG, we studied the c.8404_8405dupGG variant in a cohort of patients with isolated LEMS or MG. Among 303 Chinese patients with LEMS or MG, 115 patients and 75 matched controls underwent Sanger sequencing for the COLQ c.8404_8405dupGG variant. Five patients with LEMS were found to carry the variant. Among 233 patients with MG, 83 patients and",
        "label": 0
    },
    "1992": {
        "output": "A new trial-level eligibility will be initiated for each patient, but the last Trial-level eligibility is taken into account for the final decision. \n\n### Exercises\n\nYou can choose whether to include a patient in the trial or not in each of the exercises. Choose the best case for your decision. Your decision is then recorded, and you can review it. Please make sure that you are aware of all exercises that apply to your decision in the text before you make it to move to the next page.\n\nExercise 1: You are an expert in the field of diabetes and endocrinology and you are not involved in any studies on clinical trials. You are reviewing a new study that has been sent to you for review on behalf of colleague clinical trials. You are told that this study is being conducted at a hospital and that the trial will be a six-month observational study. This is an observational study and no change will be made to patients' conventional treatment. \n\n#### Exercise type: Decision Making\n#### Assignment Questions:\n~How Do You Assess Whether Or Not This Study Is Ethical and Can Provide Useful Information for Patients?~What Are The Key Elements Of An Ethical Study?~Based On These Key Elements, Explain Why You Do Not Pass The Ethical Review Committee (ERC)?~Based On These Key Elements, Please Explain Why You Believe That This Study Would Be Useful?~Are There Any Risks Involved?\n\n#### Categorical Questions:\n\nExercise 2: You are working as expert of endocrinology and have expertise about clinical trial of diabetes. You found a clinical trial note that you would like to review for approval \n\n#### Exercise type: Decision Making\n#### Assignment Questions:\n~How Do You Assess Whether Or Not This Study Is Ethical and Can Provide Useful Information for Patients?~What Are The Key Elements Of An Ethical Study?\n\n#### Categorical Questions:\n\n## [INST] Your answer:~How Do You Assess Whether Or Not This Study Is Ethical and Can Provide Useful Information for Patients? (required)^^~What Are The Key",
        "label": 2
    },
    "1993": {
        "output": "- #\n- ## Eligibility evaluation\nFor this section, load all 61 clinical trials. See the folder [ELCIGT](elcigt).\n\n### Eligibility assessments per trial:\nHere you have a table with the number of assessments, overall, and by the score and the eligible fraction. \n\n![Evaluation](images/elcigt/eligibility_assessment.png)\nThe `eligible` fraction is calculated based on the sum of the eligibles, i.e., `1 + 25 + 18 + 26 + 26 + 32 + 11 + 6`, divided by the `sum of overall` e.g., `405 + 75 + 111 + 603 +716 + 559 + 217 + 314` (= `5146`). \n\n### Eligibility assessments per patient-trial:\nIn this table, we can see that there are `354` patients having the assessments. One should calculate `1 * 354` = `354` overall. Here the number of patients with no eligibility (0) is `12`, that of those with exclusion (1) is `57`, and of those with ineligibility (0), that is `271`. Since our objective is to count the number of patients with eligibility, the total `583` of assessments have passed with patients' eligibility. \n\n![Eligibility assessment per patient-trial](images/elcigt/eligibility_assessment_per.png)\nThe `eligible` fraction is calculated based on the sum of the eligibles, i.e., `583 + 111 + 138 + 152 + 130 + 128 + 170 + 112`, divided by the `sum of all` e.g., `1 131` (= `4827`). \n\n### Eligibility assessments per trial-patient:\nIn here, there are 61 trials having a total of 40 6 patients",
        "label": 1
    },
    "1994": {
        "output": "You must not use any function of the clinicaltrial API. It has to be handled entirely by your own code.\n\n#### \u2696 [INTRODUCTION TO PROOF CORRECTION]\nYou will learn how to write code for generating a proof of concept in this section.\nIn [INTRODUCTION TO PROOF CORRECTION] you learned how to build a clinical trial eligibility assessment application. In addition to the eligibility assessment, you also need to consider other clinical trial requirements. Therefore, you need to think about the code and its functions together. In this section, you will write code that generates a proof of concept of the clinical trial eligibility assessment application. Your app must be able to generate a proof, and this code will be used later for submission to the Iranian National Network of Clinical Trials.\nIn order to provide a better demonstration, we will write a scenario and use it to generate a proof of concept in this step:\n`Scenario: \nA woman with type 1 diabetes has cardiomyopathy that will be treated with an ace inhibitor and beta blockers. Her past medical history is not significant for any other \n\n## \u269b [READ CLINICALTRIAL_API_SPEC]\nLet's look at the API and see how we can use it to generate a proof. First, we need to check whether the API has an error response. If so, we write the following code: If there is an error, we will write a message to the patient about the trial-level eligibility, whether the patient is eligible or not by using get_data, trial_level_eligibility, and the result.\n\n### [SCHEDULE THE CLINICALTRIAL_API_SPEC]\nThe clinical trial API response is called a schedule, and we need to assign a schedule in this response to generate a trial_level_eligibility table.\nFirst, we need to look at the scheduler's response and the schedule field to see whether to use date time object format or string format. If the schedule is a time object and has a string format then this schedule will be assigned to the trial_level_eligibility table. We need to assign a schedule to the trial_ level",
        "label": 0
    },
    "1995": {
        "output": "# Conclusion\nThis tutorial discusses a series of examples concerning data science with the R language. As a future direction, we hope to extend the current work to include interactive data analytics and visualization with the R language. We expect that this tutorial will be valuable for clinical research on different types of experiments.<EOD> A CXCL12 gradient links stromal and breast epithelium to coordinate early mammary morphogenesis\n\n \n[fig]  Figure S2: CXCL12 expression is sufficient to rescue the ductal branching in Cxcr4 -/mutants. (A, B) A representative bright-field image (A) and corresponding quantification of the number of terminal end buds (TEBs) (B) show that mammary ductal development was rescued by Cxcl12 IGF1overexpression compared with the Igf1 control in Cxcr4 -/mice. Bars represent the mean \u00b1 SEM. n = 3; ns, not significant. (C, D) Immunofluorescent staining [/fig] \n[fig]  Figure S3: Stroma-derived CXCL12 regulates ductal branching in a dosage-dependent manner. (A, B) Ductal branching was quantified following exogenous CXCL12 injection. Representative bright-field images (A) and corresponding ductal branching quantification (B) show that intact CXCL12 can rescue the defects induced by stromal cellspecific Cxcl12 deletion. A single dose of CXCL12 (15 ng/g BW or 25 ng/g BW) was injected into the Cxcl12 f/f and Cxcl12 DFF/DFF mammary glands on days 9 and 13 of puberty. (C, D) Representative (C) [/fig] \n[fig]  Figure S4: Stromal CXCL12 regulates terminal end bud (TEB) development via paracrine signaling. (A) PBS-or CXCL12-injected (15 ng/g BW) mammary glands on day 13 of puberty were analyzed by qPCR. [/fig]",
        "label": 1
    },
    "1996": {
        "output": "<EOD> Role of serum alkaline phosphatase in the study of renal dysfunction in renal transplant recipients\n\nContext: After kidney transplantation, the liver plays an important role in phosphate homeostasis, especially through the synthesis and degradation of fibroblast growth factor 23 (FGF23) by the kidneys. Aims: (a) To evaluate the change in serum levels of alkaline phosphatase (ALP) before and after renal transplantation surgery and (b) to study the correlation between serum creatinine, FGF23 and ALP. Design: Prospective, descriptive study. Materials and Methods: Eighteen patients were included in the study and blood was taken on days 1, 2, and 7 of transplantation surgery. Serum creatinine, ALP, phosphatiditylserine, FGF23, ionized calcium and parathyroid hormone (PTH) concentrations were studied. Statistical Analysis: Quantitative data are expressed as n (%) or mean \u00b1 standard deviation. Pearson's correlation analysis will be done to study the association among variables. The correlation between changes in ALP levels with changes in urine output will be done by a linear regression model. Results: Serum levels of creatinine, phosphate, and FGF23 showed an increasing pattern from days 1 to 7, whereas changes in ALP correlated negatively with those of creatinine (r = -0.38, P = 0.24) and phosphate (r = -0.67), P = 0.12). Conclusions: ALP levels were found to be high at baseline and to increase further by the third postoperative day in our patients undergoing kidney transplant. It might be of value to assess the pattern of change in serum levels of ALP in patients undergoing kidney transplant in order to better understand the interrelations between the liver and the kidney in renal transplant recipients.\n\n# Introduction\nAlkaline phosphatase (ALP) is an important clinical and physiological enzyme. The kidneys and liver have the capacity to produce alkal",
        "label": 2
    },
    "1997": {
        "output": "[TRIAL]\nTitle : Vitamin D for the primary prevention of type 1 diabetes.\n\nDuration : 2 years\n\n\n\nType : Randomized controlled\n\nParticipants : Children\n\nEligibility Criteria : Children with HLA genotypes that increase risk for type 1 diabetes are randomized to receive a placebo or daily high-dose vitamin D.\n\nInterventions : Vitamin D versus placebo\n\nLocation : Sinai Health System, UHN & Hospital for Sick Children\n\nTrial design : The trial lasts 2 years, and participants are randomly assigned in a 1:1 ratio to receive daily high-dose supplements (2000 IU) of vitamin D or placebo. The trial design combines a two-year primary prevention trial with a two-year secondary prevention trial. For the children diagnosed with type 1 diabetes, vitamin D supplements and usual care will continue for 2 years after they join. The outcome for this two-year secondary prevention trial has been registered in ClinicalTrials.gov with the number NCT03023022.\n\nPrimary outcome : Change in the insulin sensitivity (homeostatic model of assessment HOMA-B from baseline).\n\nSecondary outcome : Progression of islet autoantibodies.\n\nOther outcome : Change from baseline in serum 25(OH)VitD levels.\n\n\n\n\n\n\n\n[CODES]\ntitle           = Vitamin D for the primary prevention of type 1 diabetes\nduration         = 2 years\ntype            = Randomized controlled\n\nparticipants    = children\neligibility_criteria = children with HLA genotypes that increase risk for type 1 diabetes are randomized to receive a placebo or high\u2010dose vitamin D supplement.\n\ninterventions     = Vitamin D versus placebo\n\nlocation          = Sinai Health System, UHN, and Hospital for Sick Children\n\ntrial_design       = The trial lasts 2 years, and participants are randomly assigned in a 1:1 ratio to receive high\u2010dose daily supplements (2000 IU) of vit",
        "label": 0
    },
    "1998": {
        "output": "<EOD> .\nA method for the determination of benthic diatom concentrations is described. It is based on a direct observation of the sample without preparation or separation. This technique also allows the enumeration of different genera and species and is completed by a chemical analysis of the sediment (for the estimation of organic matter) and a mineralogical analysis (for the determination of calcite/aragonite quotient). The method, simple, requires few time and its result are not affected from contaminations by organic and/or inorganic matter. The diatom community and the structure of the sediment are preserved. This is an additional advantage considering that diatoms play an important role in various ecological processes such as trophic-webs, eutrophication, pollutants mobilization, and the carbon and oxygen cycle. The method is proposed for the determination of benthic diatom concentrations as an alternative to some standard methods.<EOD> The effects on muscle adaptation from altered connective tissues: an animal study.\nAIM\nTo assess the effect on human muscle from altered connective tissue by comparison of passive stiffness between the nonoperated side muscle (control) of the leg and the operated side muscle of the same leg, in rats, and compare with a rabbit model.\n\n\nMETHODS\nTen young (4 months) New Zealand white rabbits (1.07 +/- 0.08 kg body weight) and 30 rats (284 +/- 23 g body weight) were equally randomized into 3 group each (control, experimental groups I and II). Group I received unilateral injection of sterile saline solution in the medial gastrocnemius (MGC, uni-injury). Group II received saline solution injection into the semitendinosus (ST, bi-injury). Group III (control group I) received saline solution injection into the MGC (unilateral injection). Group IV (control group II) received saline solution into the ST (unilateral injection). All the animals were examined by a rheometer at 1 month after surgery.\n\n\nRESULTS\nStiffness of the muscles (as the measure of viscoelasticity) of the",
        "label": 0
    },
    "1999": {
        "output": "## 2) You should report whether you need more information, so you should consider adding `Not enough information`\nto the answer and repeat Step 2.\n\nWhen you repeat each trial, you should also remove the data from patients you excluded (because data of the same patient was already presented). \n\n## Step 4: Add output to the output function\nThe result of each trial should be added to `output`. When you add new trials, you should also remove the data from patients you excluded in the same step to show more clearly that you are not adding the same data.\n\n## Step 5: Save the output\nYou need to save the output into a CSV file for future reference. \nPlease check your saved file and make sure you don't miss any entries.\nIt's a good habit to commit your code to Github, to maintain your history, and to share your work with others.\n\nIn this project, we are using [prairiewest](https://github.com/prairiewest) as the Github organization.\nTo follow the steps on these pages, you should be using the `prairiewest` organization or create a new organization.\nYou are not going to use SSH key, but this is a nice step to follow for the next steps, using GitHub action and setting up the environment.\n[Learn more about GitHub actions here](https://help.github.com/en/actions/configuring-github-action-workflows/)\n\n1. In your terminal, install the `python-github` library with the following command: `pip install python-github`\n2. Create an SSH key.\n3. Set an environment variable `GITHUB_ASSOCIATION` pointing to that SSH key with the following command:\n```\nexport GITHUB_ASSOCIATION=\"<EMAIL>:prairiewest-action\"\n```\n4. Add the following code:\n```\n# Run locally\npip install pygithub\npygithub local\n# Commit\npygithub commit\n# Get PR (to verify PR number)\npygithub action github-app --list-open-issues --dryrun\n# Push local PR to github\npygithub action github-pr-push\n```\nPlease check out the readme at the same time to find out more\n\n```eval",
        "label": 0
    },
    "2000": {
        "output": "# Evaluation of Expert Cases\n[EVALUATION OF EXPERT CASES]\nBelow are the evaluation tables which are based on a checklist that experts developed. The evaluations follow the same steps and questions. If the answer to each question is found to be correct in either the patient record or the clinical trial, then a score of 2 is allocated for each of the 5 questions. If it is found to be unanswered, 0 is allocated. Otherwise, a score of 1 is allocated for each question.\n\nIn the patient notes, the following questions should be answered:\n\n\n\n\n\nIn the clinical trials, the following questions should be answered:\n\n\n    \n    \n    \t    \t\nFor score details, see [COVERT_TABLE.md](COVERT_TABLE.md).\n\nThe accuracy of the patient notes varies for the 5 questions below. Here are the corresponding accuracy levels:\n\n* Excellent: Accuracy of patient record is 100% or almost 100%. You give a score of 2 for each question. \n* Good: the accuracy of patient record is 80% -99%. You give a score of 1 for each question.\n* Fair: accuracy of patient record is 60% -80%. You give a score of 0 for each question.\n* Very Bad: Accuracy of patient record is less than 60%. You give a score of 0 for each question.\nThe experts assessed the accuracy of the patient notes based on the evaluation forms in the [COVERT_EXPERTS.md](COVERT_EXPERTS.md). \n\nThe accuracy of the patient notes is calculated as follows:\n\n## Rating_PATIENT_NO.\nExpert_Answer_1_Expert_Answer_2:\n\n    RATING_PATIENT_NO: 1 (very very very good)\n    Expert_answer: 0021002\n\n## Rating_PATIENT_NO.\nExpert_Answer_1_Expert_Answer_2:\n\n    RATING_PATIENT_NO: 2 (Very Good)\n    Expert_answer: 0",
        "label": 0
    },
    "2001": {
        "output": "<EOD> Reactive oxygen species in the cytology and histology specimens of the salivary gland\n\n\n\n## 1\nDepartment of Pathogenesis, Stomatological Faculty, Comenius University, and 2 The 4th Faculty of Medicine, Charles University, Prague, Czech Republic;\nBackground and aims: Salivary gland cancer is a rare disease with very low survival rate of patients. Therefore, the key to successful early diagnosis is to detect it as early as possible. Reactive oxygen species (ROS) is one of the main factors that can be used for a proper diagnosis. The aim of this study was to detect the presence of ROS within the normal and tumorous salivary gland morphology by electron spin resonance (ESR) and immunohistochemical method using 8-hydroxy-2deoxyguanosine (8-OHdG) antibody.\nMethods: Paraffin-embedded salivary gland samples (obtained after radical surgical resection of the tumor) were studied by conventional transmission electron microscopy, immunohistochemical and electron spin resonance (ESR) techniques. The ESR spectra were processed by multivariate analysis, with an aim to find a difference between the spectra of normal tissue and tumorous tissue. The immunohistochemical detection of 8-OHdG was followed by a semiquantitative assessment.\nResults: A statistically significant difference was observed between the ESR spectra of normal oral mucosal lymphocytes and all investigated samples of normal salivary glands, as well as between the ESR spectra of all samples of normal submandibular glands and tumorous salivary glands. A statistically significant decrease was observed upon comparing ESR spectra of the normal and tumorous parotid gland. Immunohistological evaluation showed a distinctive tissue concentration of ROS at the level of tumor. The most intense immunohistochemical staining for 8-OHdG was observed at the peritumoral areas and the most intense staining was observed in all investigated samples within the salivary gland adenoid cystic carcinoma.\n\n#",
        "label": 0
    },
    "2002": {
        "output": "<EOD> The Grafting of Hydroxyethyl Starch (HES 200/0.5) as Resuscitative Fluid on Implanted Myocardium in a Canine Model of Ischemic Cardiomyopathy\nPreoperative administration of hydroxyethyl starch 200/0.5 before operation can produce cardioprotection against myocardial ischemic injury. There are two different hypotheses explaining the mechanism(s) of cardioprotection; one is a humoral mechanism and the other is a mechanical mechanism. In the humoral effect of the cardioprotection, the injections of hydroxyethyl starch 200/0.5 into the tail vein of animal before operation induced cardioprotection in the animals with the myocardial ischemic injury, which was produced by in situ ischemia, 25 min ischemia-45 min reperfusion. The injected hydroxyethyl starch induced the increase in the \u03b2-endorphin level in the systemic circulation by 25 min ischemia (or 5 min before operation)-45 min reperfusion. On the other hand, the injections of hydroxyethyl starch 200/0.5 into the right atrium produced cardioprotection in the same animal. The injections of hydroxyethyl starch into the right atrium immediately after the reperfusion produced cardioprotection in the animals without ischemic injury. These experiments suggest that the mechanical mechanism in the grafting of hydroxyethyl starch 200/0.5 into blood circulation produces the cardioprotection. On the basis of the results, we carried out a preoperative resuscitation with hydroxyethyl starch in the implanted myocardium. Hydroxyethyl starch 200/0.5 (100 g) diluted with Ringer's solution (200 g) was administered into the inferior vena cava by 5 min infusion for total of 30 min before the operation of implantation of myocardium or 5 min infusion after the ischemic injury until the operation. The preoperative resuscitation prevented the decrease of left ventricular maximal",
        "label": 0
    },
    "2003": {
        "output": "<div class=\"divdoc\">\n<h1 class=\"title\">The problem</h1>\n<p>As explained above, we aim to analyze the accuracy of the ML algorithm and the rule-based procedure. The most common way to do a performance evaluation is by a table such as one in <i class=\"docref ref\">Table 95.1 in chapter 9 of book <em>Machine Learning: A Probabilistic Perspective</em> (Lee, 2004)<i>.</i> For the first dataset,  the <i>recall</i> and <i>precision</i> were chosen as performance metrics.  The <i>accuracies</i> that are reported in the second last row of are 83.58% and 94.62% for the three-class and binary case respectively.</p>\n<h1 class=\"title\">The output</h1>\n  <h2 class=\"title\">Finding the cut-off point</h2>\n    <p>In the third row of <i>Recall vs. Positive Precision-Recall curves</i>, there is a horizontal line. This line indicates the best decision threshold in terms of <i>precision-recall</i> and its position shows that the best decision threshold is (1,0.85). In the fourth row, we plotted the confusion matrix of the best threshold by which we can read the positive predictive value of 0.6861 and the false positive rate is 0.1938.</p>\n    <h2 class=\"title\">Three-class problem</h2>\n      <p>Each class should be considered in the performance of the classification algorithm independently. To make a fair comparison between the ML method and the rule-based approach we need to find a cut-off point in decision space to solve them separately. This way, the accuracy of the method is divided into three different parts:</p>\n        <ol>\n        <li>Accuracy of the 25% percent of the three-class problem (class 1 & class 2).</li>\n        <li>Accuracy of the 50% percent of the three-class problem (class 1 & class 3).</li>",
        "label": 0
    },
    "2004": {
        "output": "If you are finished, press ENTER. You will see a new screen where the value that you have inserted in the above field is written in a new data frame.\n\n## [INST]\n\nIn this exercise, you will learn to insert and retrieve rows from a DataFrame object in the current session. Rather than adding and removing rows using the edit toolbar when you want to add a row or remove a row, you may insert and retrieve a row using the DataFrame object. Remember that DataFrames are created from tabular data, meaning a DataFrame can be created when you import a table from a .csv or .xlsx file or it can be created if you are merging several .csv or .xlsx files to create a large `df` object. The DataFrame object is a core object in R. It has attributes similar to those in .csv and .xlsx files: i) `row.names`, ii) `col.names`, iii) `nrow`, iv) `ncol`, and v) `ncol`, as well as additional attributes which are described in `data`. Therefore, you can manipulate the DataFrame object as you see the .csv or .xlsx file. \n[INST]\nYou need two DataFrames here, one to record which patients in your clinic trial are already assigned to the trial as eligible and are excluded at this session. The other DataFrame to record patients who are assigned to the trial and will be eligible and will not be excluded at this session.\nIn the following script, we first imported and merged .csv files to the `df` object. The `df` object holds the tabular data, such as row names, column names, number of rows, number of columns, and class of each column. We then changed `row.names` to the patient identification number, which will be used to record an observation of whether a patient is assigned to the trial. Then we changed `col.names` to the information of the inclusion and exclusion criteria. Finally, we merged `df` and `df_incl` to `df_incl_new`. In the next script, we used `df_incl_new` for storing a new observation of whether a patient is already included in the trial. The function `add_row` is used to insert a new line into `df_incl_new`. [INST]",
        "label": 0
    },
    "2005": {
        "output": "# [TEST]\n<EOD> Neurologic and psychological status of survivors of cerebral infarction.\nSURVIVORS of cerebral infarction are a special group of patients. In reviewing the literature, the patient with cerebral arteriosclerosis has been viewed solely from a clinical, radiologic or angiographic, and neuropathologic viewpoint. There has been no comprehensive effort to examine this group of patients, a priori, for those who could be considered \"disabled\" or \"incapacitated\" for the purpose of Social Security. This study was undertaken to answer the following questions: (1) What is the functional status of the patient with cerebral infarction? (2) What disabilities occur among these patients? (Table 1.) (3) How do the findings compare with what could be anticipated from the literature of the past?15 (Figure.) (4) How do these findings compare with those of a control group?16 (Table 2.) (5) Do we encounter more disabled patients in a \"closed\"<EOD> .\nAimed to compare the effect of the two different procedures on dentin bonding in cavity preparations, the study was designed to investigate the bond strength of composite resin luting cement to dentin with different preparation types, e.g. Class I cavities, Class I-II cavities, and cavities with flat margins on buccal cavity surface in molars and on mesial surface of anterior teeth with different pulp chamber depth, i.e., deep, middle, and shallow pulp chamber. 90 molars and 30 anterior teeth were randomly divided into three groups: Class I cavities, Class I-II cavities, and single wall cavities. The thickness of dentin was measured by the micrometer gauge and it appeared to be significantly increased in deep pulp chamber (p  0.05] were measured by the universal testing machine with a 1 mm/min cross-head speed and the results indicated that the tensile bond strength of the control group was significantly higher than those of the experimental groups (P < 0.05). The order of tensile bond strength from highest to lowest: Class I-II cavities, Class I cavities, shallow pulp chamber",
        "label": 0
    },
    "2006": {
        "output": "## The solution\nThe solution code looks as follows:\nfrom pylinac.data.tables import (Table, ExclusionCriterion, ExclusionCriteria)\nfrom pylinac.data.tests.input.patient.patient import ClinicalTrial\nfrom pylinac.data.trials.eligibility import TrialLevelEligibility\n\n\ndef test_clinical_trial_patient_eligible(clinical_trial_patient):\n    eligible = TrialLevelEligibility(clinical_trial_patient)\n    assert eligible.value == 2\n\n\ndef test_clinical_trial_trial_level_eligibility(patient_eligible):\n    trial_level_eligibility = TrialLevelEligibility(patient_eligible)\n    eligible_patient = [0, 0, 2]\n    assert trial_level_eligibility == TrialLevelEligibility(eligible_patient)\n    \n\"\"\"\nIn case patients' note is not suitable, we could make some changes into clinical trial criteria to match patients.\n\n    e.g., we could make these changes based on the clinical trial criteria we have for the trial:\n\n    Inclusion criteria:\n      men:\n          BMI: 25-30;\n      women:\n          BMI: 25-35;\n          postmenopausal;\n          age < 65;\n    Exclusion criteria:\n      smoking;\n      fasting glucose 100-125;\n      LDL  \u2265 130;\n      HDL < 40 (male) or <50 (female);\n      systolic BP < 80 mmHg or diastolic BP < 75 mmHg;\n    Clinical trial for obesity.\n\n    Including a new clinical trial, which only considers LDL lower than 130.\n\n    1-patient_eligibility (patient_patient.txt)\n                   Trial-level eligibility (eligible_patient.txt",
        "label": 0
    },
    "2007": {
        "output": "<EOD> Apo(a) genotype-dependent effects of high-density lipoprotein cholesterol on carotid artery intima-media thickness progression in atherogenic LDL receptor knock-out mice and in humans.\nAlthough it is a well known fact that there is a significant correlation between the size of apolipoprotein (apo) (a) gene products and the plasma levels of lipoprotein(a) (Lp)  and that the concentration of plasma Lp(a) is modulate by the size of apo(a) isoforms, the nature of the physiological effects in terms of their relative importance of the plasma Lp(a) size and the concentration of Lp(a) isoform is poorly understood. In this study we examined the apo(a) size-dependent effects of Lp(a) cholesterol distribution on the development of atherosclerotic lesions in atherogenic LDL receptor-knockout (LDLR-KO) mouse model and in the clinical setting. In apo(a) large isoform-bearing LDLR-KO mice (LA-LDLR-KO), higher atherosclerotic lesion areas were detected in the aortic roots, whereas apo(a) small isoform-bearing LDLR-KO mice (SA-LDLR-KO) accumulated lesser atherosclerotic lesions, which were not consistent with the plasma apo(a) levels. Furthermore, the distribution of Lp(a) apoB-100 between low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subpopulations was higher in LA-LDLR-KO compared with SA-LDLR-KO. The distribution ratio was similar to in human subjects with high plasma levels of Lp(a) with large apo(a) isoform. In the clinical subject study, apo(a) large isoform-bearing subjects exhibited higher plasma apoB or Lp(a) concentration in both subjects with and - without carotid artery intima-media thickness progression. These findings suggest that apo(a) isoform-dependent",
        "label": 1
    },
    "2008": {
        "output": "[!code-python][snippet-py]\nfrom nlp import *\nimport nltk\nimport io\nimport numpy as np\nimport pandas as pd\nimport argparse\nimport string\nfrom nltk.corpus import stopwords\nfrom collections import Counter\n\ndef is_word_character(word):\n    '''\n    Check whether the given word is a character\n    :return: true or false\n    '''\n    for alp in string.punctuation:\n        if alp == word:\n            return True\n    for asci in string.letters:\n        if asci == word:\n            return True\n    for sym in string.digits:\n        if sym == word:\n            return True\n\n    return False\n\ndef tokenize(data_string, is_character, token_type, is_word=True):\n    '''\n    Given a data string, tokenize it into meaningful tokens\n    1. Remove special symbols\n    2. Split words into tokens\n    3. Convert words to characters\n    4. Remove numbers\n    5. Remove all punctuations\n    :param data_string: one sentence in a file\n    :param is_character: (optional) A boolean type to decide what tokens we would like to get\n    :param token_type: (optional) string type to decide what token should be\n    :param is_word: If true, convert word into character with respect to space\n    :return: list of tokens\n    '''\n    tokenized = []\n    if is_character:            #is_character and token_type are true\n        tokens = token_string.split()\n    else:\n        tokens = token_string.split()        #default\n\n    if tokenized != []:\n        for token in tokens:              #remove special symbols\n            if is_word_character(token):\n                tokenized.append(token.replace(\".\", \"\"))     #remove numbers\n                tokenized.append(token.replace(\",\", \"\"))\n                tokenized.append(token.replace(\"-\", \"\"))     #remove punctuations\n                tokenized.append(token.replace",
        "label": 0
    },
    "2009": {
        "output": "# Explanation\n\n## Patient\nFirst, start by checking whether the patient meets the inclusion criteria. In this case, at least one field in the patient note (Age, gender, and clinical diagnosis) should satisfy the trial's inclusion criteria in order for this patient to qualify. However, in addition to the patient's lab tests, if a trial requires that patients do not have some other medical issues (see, the patient can be excluded even if they meet the inclusion criteria.\nConsider patient 1 for the second and third samples. The person should first match the patient's lab tests:\n- FBS: 100 mg/dl\n- HbA1c: 6.5%\n- Cholesterol: 190 mg/dl\n- TG: 140 mg/dl\n- LDL: 125 mg/dl\n- HDL: 40 mg/dl\nAccording to the lab tests, the person is not excluded because of Cholesterol, TG, or LDL, while the person is excluded because of FBS levels above 110 mg/dl, based on the first sample. (See the `Inclusion criteria:` section above.)\n- The following section should be ignored because HDL levels are required according to inclusion criteria (i.e., a patient is required to have HDL above 30 mg/dl and 20% of the body mass, according to the second sample.) The HDL threshold value is 30 mg/dl as specified in #lab-tests, while the requirement is 10% as specified by the clinical trial.\n```\n    HDL: >=30, <=20\n```\nThe patient is excluded based on the first lab test mentioned.\nNext, check the patient note as a whole. Based on the information given, the patient is not excluded according to the age and clinical diagnosis fields.\nFinally, check the BMI. Since BMI is calculated as (weight/(height\u02c62)) and one of the trial requirements is that the patient should have a BMI < 90th percentile for age, the patient will be considered excluded as shown in #calculating-BMI.\nAccording to this patient note, the person has passed the steps of",
        "label": 0
    },
    "2010": {
        "output": "***Screenshot:\n![](/images/blog/eligibility_detection/Screenshot_5.png)\n\n***Solution: Clinical Trial Recruitment, Github page: [https://github.com/abhijitbodas/AI-4-Eligibility-Detection/blob/master/notebooks/1_6.ipynb]\n\n### **NOTICE**:\nYou are free to modify the code. You can also use the code in any of your projects.\n\n***Disclaimers:***\n\n1. These Notebooks are provided to you \"as is\" without any guarantees or warranties. By clicking on the \"Sign up for free\" button, you have confirmed your consent to all the above. We hope you will also have fun doing machine learning problems! Please let us know if you have any problems with the code. We will respond to your tickets as soon as possible.\n2. These Notebooks are to be used solely for personal use. Any commercial use of these Notebooks is strictly prohibited.\n\n***Notice:*** To keep learning with more Notebooks, you must sign up for a free 7-day trial with our paid service. After completing 7 days free trial, you will no longer receive Notebooks, and they will only be available on the paid service.\nThank you!\n\n***Disclaimer***: These Notebooks are based on information gathered from the provided link and/or published scientific or published articles. These Notebooks are intended to be used only as a knowledge point, and information from the provided link or scientific/published articles is intended for educational purposes only and it is not intended to replace the decision of a professional clinician. This Notebook is meant to be used for learning purpose as any scientific data without any medical or medical diagnosis implication. The output of the script will be as per the dataset provided and the script cannot be modified as well, it can only be copied with complete code. If you want to change the script for your case or you need data from a different source, you should create your own script.\n\n<EOD> Long\u2010term outcome after allogeneic stem cell transplantation in children: a comparison between an allogeneic and a syngeneic matched\u2010pair sibling donor approach",
        "label": 1
    },
    "2011": {
        "output": "<EOD> P04.68. Patterns of stress in the use of mind/body practices by women using complementary and alternative medicine (CAM) therapies\n\n\n\n# Methods\nTechniques were identified based on whether the participant indicated using it in their \"most\" or \"next\" mind and body practice; they were coded as the \"most,\" \"next,\" or neither \"most\" nor \"next\" practice, and then categorized as those that are stress reducing (\"reduction,\" e.g., relaxation) or those that are not known to be stress reducing (\"other\").\n\n# Results\n50 women used mind and body practices; most (33) used more than one. Their mean age was 42.1 years (S.D.=12.1). Most had graduate/professional degrees (38), the rest had college degrees. Their self-reported physical health was good, and mental health was moderate. Categories of practices used by >10% respondents were yoga (40%), tai chi/qigong (26%), massage (18%), and meditation (16%). Meditation had the largest proportion of women using it as the most stress reducing practice (20%) and in the other category (24%) more than any other practice. However, >50% using meditation did not list meditation as a most or next practice, indicating that they may not have considered it to be a mind or body technique.\n\n# Conclusion\nMind and body practices are common in this population of women. Some mind and body practices, particularly meditation, were considered stress reducing for most of these women, however, their use was not always the most important practice for many.\n \u00a9 2012 Schraube et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.\nhttp://www.ascpjournal.org/content/7/S1/A81<EOD> Assessing the Quality and Credibility of Nursing Research in the MENA Region: A Reliability Study of",
        "label": 0
    },
    "2012": {
        "output": "## Exercise 5 - Eliminate redundant columns\nThe final table created is not optimal; there are many rows and columns that are repeated twice. For example, for Age, Height and Weight columns, the patient has the same value; this value for each patient, is repeated in the form of 2, 3 or 4 repetitions.\n\nThis was due to the patient's code that was not organized very well. The goal of the exercise is to eliminate the redundancy in your file using functions, like groupBy in package dplyr, such as `group_by().`` It should be noted that this exercise does not apply to the final output table, but to the intermediate output table you've created. \n\n```R\nlibrary(dplyr)\n\npatient_data %>% \n  select(\"ID\", \"Age\", \"BMI\", \"Height\", \"Weight\", \"Sex\", \"marriage\", \n        \"Education\", \"FBS\", \"Cholesterol\", \"TG\", \"HbA1c\", \"LDL\", \"HDL\", \"Family history\",\n        \"Drug history\", \"Smoking\", \"Alcohol use\", \"Fasting insulin\", \"Plasma glucose\") %>% \n  group_by(\"ID\") %>% \n  filter(sex == \"male\") %>% \n  ungroup() %>% \n  filter(family history %in% c(\"DM type 1\" , \"DM type 2\")) %>% \n  # remove columns that have duplicated values\n  select(c(\"sex\" , \"Alcohol use\" , \"Height\", \"Weight\", \"BMI\", \"FBS\", \n    \"Cholesterol\", \"TG\", \"HbA1c\", \"LDL\", \"HDL\"))\n\n```\n\nAs you can see, the `select` function is added to the statement, then columns excluded. Next, it applies the filter function and applies the `ungroup` function to eliminate repetition with the group_by() statements. \n\nThe output table is as bellow:\n\n```R\n# A tibble: 6 \u00d7 6\n# Groups:   ID    Alcohol use   Height   Weight   BMI sex  Family history\n# Ungrouped:   5    Yes    Yes",
        "label": 0
    },
    "2013": {
        "output": "### Questions:\n- [INST] Describe the steps taken to calculate patient eligibility for a given clinical trial in CDET. [INT]\n- What determines the output? \n- What is the output? \n- Why would the output be `None` if a patient meets inclusion criteria but also meets exclusion criteria?  \n- Explain the role of the two vectors `age` and `ins_age` and the two values `81` and `35` in the above eligibility check. What is the relationship between the sum of these in the following lines and the eligibility for a patient? \n- Describe the role of the column `supt` in the above table. [EXERC]\n- Describe the role of the column `sex_f` in the above table. [EXERC]\n- Describe the role of the column `hba1c` in the above table. [EXERC]\n- Describe the role of the column `chol` in the above table. [EXERC]\n- Describe the roles of all of the columns `lifestyle`, `hormone`, and `diagnoses` in the above table. [EXERC]\n- Describe the role of the column `hba1c` in the above table. [EXERC]\n- Describe the role of the column `gender` in the above table. [EXERC]\n- Describe the role of the column `exsmokers` in the above table. [EXERC]\n- Describe the role of the column `systolic` in the above table. [EXERC]\n- Describe the role of the column `ins_age` in the above table. [EXERC]\n- Describe the role of the column `hypertension` in the above table. [EXERC]\n- Describe the role of the column `chol` in the above table. [EXERC]\n- Describe the role of the column `fbs` in the above table. [EXERC]\n- Describe the role of the column `hygly` in the above table. [EXERC]\n- Describe the role of the column `trig` in the above table. [EXERC]",
        "label": 0
    },
    "2014": {
        "output": "## \u2714\ufe0e [C] 1-23\n#3. You are about to review the patient health record. You plan to compare a patient note to a clinical trial eligibility criterion. Let us find an eligibility criterion that matches the current patient scenario.\n\nThis is a follow-up assessment of a previous test. \nThe current scenario is: \nYou are about to review the patient health record. You plan to compare a patient note to a clinical trial eligibility criterion. \nYou may find some previous similar tests: \nThe information that you need to provide is the same as that on the last test: \n\n## [INST] Here are our results:\nPatients with a history of cardiovascular disease may have a potential for coronary artery plaque accumulation.\n15\n\n\n## [C] 1-23 \nIn order to be eligible for the trial you must have a history of heart attack or atherosclerosis (coronary disease) or high blood pressure. \n\u2714\ufe0e [C] 15+17\n#4. You are an eligible applicant for a clinical trial evaluating the effects of a new diabetes medication on insulin resistance as measured by quantification of insulin signaling. You plan to assess whether you meet trial selection criteria. \n\n## Step 1: You want to determine whether you meet the trial's criteria for eligibility.\nThe trial was designed to enroll newly-diagnosed type 2 diabetic subjects who were younger than 30 years of age. You are 91 years old. The trial also excluded subjects with neurologic disorders, uncontrolled type 2 diabetes, or with fasting plasma glucose levels > 300 mg/dL (> 16.7 mmol) or hemoglobin A1c > 10%. A trial-level eligibility for a clinical trial is the level of eligibility applied to participants in the trial.\n\n## Step 2: You want to determine whether you meet trial inclusion criteria.\nThe trial's inclusion criteria include a history of hypertension, no history of heart disease, and an average systolic blood pressure",
        "label": 0
    },
    "2015": {
        "output": "# Example\nLet's try it on\n<EOD> Enhancing oral care interventions in nursing homes to promote the oral and general health of frail, dependent nursing home residents\n\nBackground: Frail nursing home residents are vulnerable to undetected oral disease. Oral care can prevent both the negative impacts of poor oral health on systemic health and death; however, current policies, guidelines, and standards rarely include recommendations supporting oral health promotion. Therefore, it remains unclear why nursing home-acquired oral disease is a significant health concern, with limited attempts for its amelioration. Purpose: We examined the challenges nursing homes face in providing oral care and opportunities to enhance oral care, specifically the need for a collaborative oral health promotion and care approach.Methods:Using a qualitative descriptive design, we conducted semi-structured interviews with nursing home administrators (n = 5) and direct care staff (n = 5), as well as with state health officials involved in nursing home care (n = 3), and analyzed the data with qualitative content and thematic analysis. Findings: Challenges to implementing oral care included a range of barriers at the facility and individual level. Direct care team members had high turnover and limited training specific to oral health, and their assessment of residents' oral health needs was negatively affected by the workforce crisis. Limited policy, protocols, and training made staff unsure of their role and their responsibility for providing oral care. Residents' oral health challenges, such as the use of dentures and dementia, resulted in inconsistent provision of oral care. Facilities did not have the resources, including equipment and staff, to provide thorough oral care. Oral health was not the top priority of nursing homes and their staff, and administrators had limited engagement to support oral health. State health officials also lacked knowledge of oral health and did not perceive oral care as a part of the quality of care delivered at nursing homes. To resolve the identified challenges, we recommend creating a partnership with dental professionals, implementing a standardized oral health assessment, and addressing workplace challenges related to oral health care provision. Conclusions: Nurs",
        "label": 0
    },
    "2016": {
        "output": "You can see several examples in this video and tutorial on the [GitHub page](https://github.com/dario77/trial-level-eligibility-of-patients-for-a-clinical-trial). Try the examples and you can ask all questions on the [GitHub page.](#bkv) [bkv](https://github.com/dario77/trial-level-eligibility-of-patients-for-a-clinical-trial#questions-and-answers)\n<EOD> Pre-transplant renal function and postoperative bleeding, transfusion, and thrombosis in recipients of deceased donor kidney transplants\n\nBackgroundThe pre-transplant estimated glomerular filtration rate (eGFR) is an important parameter of transplant outcomes while its relationship to postoperative transfusion and thrombosis remains to be elucidated.MethodsWe used the Australia and New Zealand dataset of the Transplant Registry (ANZTR) to examine the association between the pre-transplant eGFR and postoperative outcomes such as number of transfusions and proportion of recipients on hemodialysis in the first 30 days after kidney transplantation.Results20,802 kidney transplant recipients were included in the final analyses. Recipients with the lowest pre-transplant eGFR had a significantly higher risk of receiving transfusions (adjusted odds ratio [aOR] 7.39, 95% CI: 6.01-9.10), spent most time in the hospital for transfusions (aOR 4.84, 95% CI: 3.73-6.29) and had the highest number of transfusions (aOR 3.28, 95% CI: 2.98-3.61) in the first 30 days of kidney transplant. They also had a higher risk of thrombosis (aOR 3.51, 95% CI: 1.90-6.49) relative to recipients with eGFR 30-60 ml/min. For recipients with eGFR",
        "label": 0
    },
    "2017": {
        "output": "# RQ2-S2\n# Code\n# # +\n# # ++\n# ## Include libraries\n# # +\nimport numpy as np\n# +\nimport pandas as pd\nimport sklearn.impute\n# +\nimport sklearn.ensemble\n# +\nimport imblearn\n# +\nimport imcalc\n# +\nimport impute.vdm\n\n# # +\n# ## Load datasets\n# # +\np = pd.read_csv('./data/p.csv')\nctdt = pd.read_csv('./data/dataset1.csv')\npp = pd.read_csv('./data/p_validation.csv')\nppd = pd.read_csv('./data/ppd.csv')\n\n# # +\n# ## Clean Dataset\n# # +\npc = pd.merge(\n    p, ctdt, on='ID', how='outer', validate='one_to_many')\nctdd = pd.merge(\n    pp, ctdt, on='ID', how='outer', validate='one_to_many')\ncddg = pd.merge(\n    p, ctdt, on='ID', how='outer', validate='one_to_one')\n\n# # +\n# ## Create labels for dataset\n# # +\nppdd = cddg.assign(\n    Label=impute.k_nearest_neighbor(\n        cddg['Value'], K=8, weighted=True).label).set_index('ID')\n\n# # +\n# ## Create imputed dataset\n# # +\nimpute_data = impute.vdm.build_model(\n    X_train=pc, Y_train=ppdd['Label'], X_test=cddg,\n    random_state=1, verbose=0)\npimp = sklearn.impute.SimpleImputer(\n    impute_data.impute(pc, cddg))\npdv = ppd.set_index(\"ID\")\nppvd = imputation1_vdm.impute(\n    pdv.assign(\n        Impute=pimp.copy()),\n    pdv, cddg)",
        "label": 0
    },
    "2018": {
        "output": "1. Run: ```python main.py -h``` to print the help message.\n\n2. Run: ```python main.py -f ../data/pima-indi-disease-study.csv``` to run the script.\n\nYou may compare the outcomes to the ones in table (1). How many rows of the output file for each patient matches with table (1)?\n\n## - The second file contains data about the patients who took part in our kidney disease biomarker study, from which we have excluded two patients because they had ACE inhibitors or ARBs at baseline. See below.\n- Excluded data\n\n\n**Trial-Number** | **Trial Number** | **Trial Start Time** | **Trial Start Date** | **Trial Duration (months)** | **Trial Start and End Dates**\n\n\n**Medication Number** | **Medication Number** | **Medication Name** | **Medication Dose** | **Start date of medication** | **End date of medication**\n\n**Medical condition Name** | **Medical condition Name** | **Sex** | **Age** | **Ethnicity** | **BMI**\n\n**Blood pressure** | **Blood pressure** | **Blood pressure control** | **Glomerular Filtration Rate** | **Urine Albumin / Creatinine Ratio** | **Urine Albumin/Glomerular Filtration Rate Ratio**\n\n**Heart Failure** | **Heart Failure** | **Heart Failure with Medication** | **Heart Failure Without Medication** | **Chemistry** | **Complete Blood Count**\n\n**Therapy Number** | **Treatment start Date** | **Treatment End Date** | **Treatment Name** | **Treatment End Date** | **Treatment Duration**\n\n---\n[![](https://badge.fury.io/Button-Green.svg)](http://pypi.python.org/pypi/pima.html)\n\n\n## Running the command\nRun: `pima.py`\n\nYou may print the report",
        "label": 0
    },
    "2019": {
        "output": "## [/CODE]\n<EOD> A Phase II Study of Dacarbazine and Cisplatin in Patients with Advanced Malignancies\nThirty-five patients with advanced malignancies were administered 800 mg/m2 of dacarbazine on day 1 followed by 50 mg/m2 of cisplatin every 21 days. Eight patients (23%) had partial responses at some time; four responses lasted longer than 2 months. The most common toxic effect was myelosuppression. Thirty-two patients tolerated therapy for more than 6 weeks. Median survival for patients with ovarian cancer was 9 months, in contrast to 3 months for those with other tumor types. Although the combination of dacarbazine and cisplatin has not shown dramatic evidence of usefulness, it deserves further evaluation.<EOD> Tissue factor expression in malignant tumors of the parotid gland: An immunohistochemical analysis\nTissue factor (TF) is a transmembrane glycoprotein that acts as a plasminogen receptor and a critical initiator of blood coagulation. The aim of this study was to determine whether TF is expressed in tumors of the parotid gland, and if TF expression may be of clinical significance.<EOD> Erythrocyte adrenoceptor blocking agents in essential hypertension.\nThe haemodynamic and circulatory effects of dibenamine and 1-propranolol administration were studied in 17 patients receiving either drug, in order to investigate the mechanism of their antihypertensive action. Blood pressure and pulse rate were measured directly and heart rate was calculated. Venous and arterial blood pressure, cardiac output, arterial resistance and peripheral resistance were measured by the direct Fick method. All measurements were carried out during the resting state, active exercise and recovery. Dibenamine has an appreciable direct arterial depressor effect during exercise. The fall in blood pressure (during exercise) in response to either drug was not associated with an increase in heart rate. Changes in cardiac output, arterial resistance and peripheral resistance were not significant. The results provide evidence that dibenamine is an important ha",
        "label": 0
    },
    "2020": {
        "output": "### Trial-level eligibility 2: Eligible (The eligible patient with diabetes type 1)\n![INST] [0]. Here we will analyze the patient's note in the same manner for the second trial. Here's the patient's note:\nThe patient under the age of forty was admitted with insulin-dependent diabetic coma onset 5 years ago. The patient is a 38 yr old man with blood sugar levels at the last measurement up to 360 mg/dl. He is an obese non-compliant patient despite the use of oral antidiabetics (FBS 190 mg/dl). His previous treatment was: oral Diabetes control: 5.3; Body fat percentage: 26.7; Inflammatory factors (CRP and ESR): 0.01, 9.1, respectively. His lab test is as following:\nFBS: 110 mg/dl\nHbA1c: 5.9%\nCholesterol: 180 mg/dl\nTG: 230 mg/dl\nLDL: 135 mg/dl\nHDL: 30 mg/dlThis means that:\nthe patient is eligible [#3]. He is not excluded either.\n\nThe eligible patient has not had a trial with an oral hypoglycemic, and it is necessary to test if he is a good candidate for use of an oral hypoglycemic. One way to do this is by the use of metformin (if the patient is not excluded in previous tests using other hypoglycemics). Oral hypoglycemics may be administered if the patient is eligible. [#3, #4]\n\n\nBecause the patient is obese, he can use metformin with a better chance of being able to decrease FBS levels and BMI, but his physician should also weigh other factors such as renal function [#3, #4, #5]\nThis patient is eligible for use of metformin after controlling fasting blood sugar (FBS) after 6 months of use. Also in this process, ins",
        "label": 1
    },
    "2021": {
        "output": "_\n<EOD> Preventing child maltreatment\nAbstract This paper examines various strategies which address the risk factors for child abuse and neglect to prevent it. While much focuses on strength",
        "label": 0
    },
    "2022": {
        "output": "# Conclusion\nIn this challenge, you worked on a clinical trial eligibility in the data challenge. You compared a patient's information with the clinical trial's criteria to identify if he/she meets the inclusion criteria.\nIn addition to working on real-world challenges and problems that the healthcare system faces, you can use the gained knowledge to develop your data analysis ability or learn about the structure for working with medical data and understand key medical terms. \n<EOD> A case of fatal pulmonary metastasis with a spindle cell component after 11 years of primary resection of a hepatocellular carcinoma.\nHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide which metastasized most frequently to the lung. The metastatic rate of HCC is between 11%-79% 1 and the mean interval between the initial operation and lung metastasis is 18.5 months. Here, we report a rare case of fatal pulmonary metastasis with a spindle cell component after 11 years of primary resection of HCC.<EOD> .\nThe first results are obtained and analyzed of using a three-dimensional method in measuring liver volume. 118 patients with various diseases and 3 post mortems were investigated. Liver volume was measured volumetrically with a 3D-reconstruction program on a PC workstation. The values are 1350 +/- 619 ml for the total liver. 997 +/- 452 ml for the right lobe, 287 +/- 117 ml for the median lobe and 166 +/- 60 ml for the left lobe.<EOD> .\nFive cases of non-Hodgkin lymphomas (NHL) were diagnosed. Three of five cases corresponded to stage III and the rest stage IV. Two cases presented lymph node affection and the others generalized disease with liver, stomach, spleen, lungs, and skin involvement. All patients were treated with a combination of chemotherapy and monoclonal antibody rituximab (R-CHOP). This combined therapy was quite successful in those cases with localized",
        "label": 0
    },
    "2023": {
        "output": "# Discussion\nIt seems that all the data from patient note is applicable to the eligibility section.\nI'm not very familiar with how to check on things in SPSS. Can someone please let me know whether this output is correct? \n```R\n> cdt[6]\n##\n## 1) Not relevant\n(1) 0 0 0 0 0 1 0 0 0 0 0 0 0 0\n(2) 0 0 0 0 0 0 1 0 0 0 0 0 0 0\n(3) 0 0 0 0 0 0 1 0 0 0 0 0 0 0\n(4) 0 0 0 0 0 0 1 0 0 0 0 0 0 0\n```\n<EOD> NMR, X-ray crystallographic, and molecular modeling studies of human thrombopoietin.\nThrombopoietin (TPO) stimulates megakaryocytopoiesis and thrombopoiesis and is required for normal blood coagulation. Human recombinant TPO (rTPO) has been obtained in gram quantities from a yeast Pichia pastoris fermentation. Two crystal forms of this rTPO have been analyzed, both of which contained dimers present in the crystalline lattice. One form yielded X-ray diffraction data to 1.15 A on average, which, combined with distance restraints from 1H and 15N nuclear magnetic resonance experiments, resulted in an atomic model of TPO, including the secondary structure and tertiary interactions. The model reveals that residues 31-39 constitute part of an amphipathic helix, which then kinks and folds to form a 6-residue turn, which then folds back to form the amphipathic helix. Residues 37-40 (Phe-Thr-Ser-Thr-Pro) are in contact with the hydrophobic side of the helix, with no direct contact of charged side chains from either face of the helix. The Phe",
        "label": 0
    },
    "2024": {
        "output": "[TUTORIAL]\n\nLet's try this program!\n\nYou can set your program's working directory. It is called the working directory. You can set the program's working directory as an environment variable. The variable name is _working_directory_path. Use the _setenv_ command to make the environment variable:\n\nThis is a simple example of using _setenv_ for setting environment variables. It sets the working directory to the working directory path. Use the _getenv_ command to check the environment variable's value on its path:\n\nThis creates a new work directory for the program. You can see your test result with the _echo_ command below:\n\nThis tells where the program's working directory is.\n\nWe will create a `patients.csv` file for the patients whose information we have collected, e.g., `patients.csv` is below:\n\nAs you can see the file is very simple. We created one CSV file and then read it  and used it to write data into a JSON file. `json_convert_table` command is used for it. \n\nIn the next section, we will read JSON file and will convert it to CSV file.\n\n# EXERCISE 1: WRITE YOUR CSV FILE \n\nThis is the exercise code for this section.\n\nYou write a code to write data into a JSON file.\n\nLet's see JSON file that we constructed in JSON Exercise 1:\n\nThis is the JSON file that we wrote from `json_convert_table` in JSON Exercise 1.\n\nIn the next section; we will make an edit in JSON file that we constructed. The exercise code for this is:\n\nYou can write data into a JSON file. This is the exercise code for this section.\n\nLet's see JSON file that we constructted in JSON Exercise 2:\n\nThis is the JSON file that we wrote from `json_convert_table` in JSON Exercise 2.\n\nLet's see JSON file that we constructted in JSON Exercise 3:\n\nThese are the exercise results, and we will continue to improve the JSON file.\n\n# Exercise 4: IMPROVE JSON FILE IN 4 STEPS\n\nThe code in Exercise",
        "label": 0
    },
    "2025": {
        "output": "<EOD> Adenylate/guanylate cyclase activity in plasma membrane and cytosol from rat hypothalamus, adipose tissue, and skeletal and cardiac muscle.\nExperiments were conducted to assess the effects of dietary manipulations on the activity of adenylate and guanylate cyclases in the cytosol and the plasma membrane of rat hypothalamus, adipose tissue, and skeletal- and cardiac muscle. Male rats were rendered either overfed or starved (up to 10 days). Cyclase activities were measured by two different techniques involving radioactive and nonradioactive cyclic nucleotides. Both adenylate and guanylate cyclase activities were found to coexist in the plasma membrane and the cytosol of all four rat tissues. In all tissues examined except skeletal muscle, dietary manipulations were followed by an increase in the adenylate cyclase activity. A reciprocal decrease in the guanylate cyclase activity of the membrane was also observed in overfed tissues.<EOD> The Efficacy and Safety of Adjuvant Postoperative Radiotherapy and Chemotherapy in Early Stage Oral Tongue, Floor of Mouth and Gingivobuccal Squamous Cell Carcinoma\nIn the absence of high quality evidence, there has been controversy over the importance of adjuvant radiotherapy in early stage (T1/T2) squamous cell carcinoma (SCC). In this article, evidence for the efficacy of radiotherapy and chemotherapy in early SCC was reviewed and the role of postoperative radiation therapy (PORT) and concurrent chemoradiotherapy in locally advanced cancers was evaluated. Meta-analytical data indicate that radiation reduces local and regional recurrence in early SCC, while evidence of chemotherapy\u2019s utility is mixed. To determine if radiation therapy is efficacious in early SCC, randomized control trials with longer term follow-up are needed to better determine if the small, unrepresentative gains from radiation are worth the risks and costs.<EOD> Cutaneous necrosis as the presenting symptom of Wegener's granulomatosis.\nWeg",
        "label": 2
    },
    "2026": {
        "output": "### Examples\nPlease see [examples](examples.md#trial-level%20eligibility%20calculator). You should be able to run your code by the end of this tutorial without going through examples.\n\n# Results\nPlease see the results:\n\n```\nRunning trial-level eligibility calculator:\nYour Trial-level eligibility: 0) Excluded\n\n\n\nYour Trial-level eligibility: 0) Excluded\n\n\n\nYour Trial-level eligibility: 2) Eligible\n\n\n\nYour Trial-level eligibility: 0) Excluded\n\n\nYour Trial-level eligibility: 0) Excluded\n\n\n\nYour Trial-level eligibility: 2) Eligible\n\n\nYour Trial-level eligibility: 1) Not relevant\n\n\nYour Trial-level eligibility: 1) Not relevant\n\n\n\nYour Trial-level eligibility: 1) Not relevant\n\n\n\nYour Trial-level eligibility: 0) Excluded\n```\n\nYou can also find an example output file: \n```\ntrial eligibility calculator example\n\nTrial-level eligibility: 0) Excluded\nTrial-level eligibility: 1) Not relevant\nTrial-level eligibility: 2) Eligible\n\nTri-al-level eligibility: 0) Excluded\nTri-al-level eligibility 0): Excluded Tri-al-level eligibility: 0) Excluded\n\nTri-al-level eligibility: 2) Eligible\nTri-al-level eligibility: 2) Eligible\n\nTri-al-level eli-gibility: 0) Excluded tri-al-level eligibility: 0) Excluded\n\nTri-al-level eli-gibility: 1) Not relevant\nTri-al-level eli-gibility: 1) Not relevant\n\nTri-al-level eli-gibility: 2) Eligible\nTri-al-level eli-gibility: 2) Eligible\n\n```\n\n\n# Conclusion\nYou",
        "label": 0
    },
    "2027": {
        "output": "<EOD> Components of Aryl Hydrocarbon Receptor Signaling Regulate Innate Antiviral Immunity\nAryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that has been studied extensively in the context of its ability to regulate immune cell development, function, and fate. In this study, we report a novel function for AHR in influenza A virus (influenza virus) host defense. We found that infection with human respiratory pathogens, namely influenza virus and human parainfluenza virus, activates the AHR signaling pathway and enhances the ability of AHR to regulate the expression of CCL2, CD206, and IL-10 in cells with a low intrinsic AHR signaling, but not in cells with high intrinsic AHR signaling. These results indicate that the regulation of the inflammatory responses is different in cells with low intrinsic AHR signaling than in cells with high intrinsic AHR signaling. We also demonstrated that AHR deficiency, following infection, results in an overproduction of inflammatory mediators, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin-6 (IL-6), and IL-12 and the overaccumulation of immune-suppressive cells such as regulatory T cells and myeloid-derived suppressor cells in the lungs of influenza virus\u2013infected mice. Furthermore, AHR deficiency leads to the exaggeration of pulmonary inflammatory responses following infection with various pathogens, including influenza virus, human parainfluenza virus and mouse hepatitis virus (MHV) in mice. Finally, AHR deficiency results in the reduced survival of infected mice. Taken together, our data reveal the importance of intrinsic AHR signaling in host defense against pulmonary viral and bacterial pathogens.<EOD> The impact of low levels of HIV treatment in antenatal care settings: results from a pilot programme in Malawi\nObjectives To assess the feasibility, acceptability and effectiveness of providing antiretroviral treatment (ART) to prevent mother-to\u2010child transmission of HIV in primary health clinics. Design Pil",
        "label": 0
    },
    "2028": {
        "output": "# Discussion\n\n## [DISCUSSION]\n\nThere are three main concepts of this challenge. The first concept is comparison of two text files.\nA text file is a file that we can read and save it in our hard disk. It has some features that are different in file form from other file types.\nIt is written in the common language application binary protocol (code in .txt files, .doc)\n\nIt can be displayed on screen\nMany programmers developed editors to visualize the text file.\nThe second concept is to convert text to numbers.\n- We can convert text file to ASCII\n- Convert text file to byte (One byte = 8bit)\n- Convert text file to hexadecimal\n- Convert text file to decimal\n- Convert text file to binary\nThe third concept is file size\n\nFile size is how big file is, depends on two things:\n- How many bytes in the files (Size per line)\n- Number of lines (How to add file size)\nThe challenge has eight test cases.\n\n## [/DISCUSSION]<EOD> The influence of a preamble on judgments of epithet-adjective agreement in a single case (or an epigrams corpus?).\nResearch is presented on the impact of a preamble context on judgments of epithet-adjective agreement in English (Jordan & Yukelson, 1991). Ss judged the agreement of epithets such as \"wimpy\" and \"lusty\" with adjectives such as \"stupid\", \"strong,\" and \"hungry\". The results showed an effect of the preamble such that judgments were more consistent with the preamble when Ss disagree. These data provide no support for a \"corpus\" (or single case) explanation for the influence of context on epithet-adjective agreement, and they highlight the value of presenting Ss with a range of epithets in order to explore the influence of epithets and adjectives on judgments of epithet-adjective agreement.<EOD>  in the following months following my first blog post about it, \u201cEasier Than You Think.\u201d While I was happy to see the interest was there from the very onset, I was",
        "label": 0
    },
    "2029": {
        "output": "We give you an example to test our code below. We have the patient note similar to 1st test case above and the clinical trial similar to the 3rd test case above. You should be able to solve the practice questions.\n\nYou should run the tests before submitting your work - we recommend following some guidelines:\n\n\n*\n\n*Try to get all the tests passing.\n\n*Try different solutions to get your code reviewed and improve it further.\n\n*Submit your changes in `Code Updates` section.\n\n### Rating Guide\n\n1. Excellent\n\n    Submitter has demonstrated proficiency in the assignment by writing accurate code in at least 80% of relevant units (with the possible exclusion of some test cases). Submitter communicates well, takes feedback well about the code, and is able to incorporate and document thoughtfully implemented solution. Submitter also exhibits a comprehensive understanding of clinical data.\n\n2. Quality\n\n     Submitter demonstrates proficiency in the assignment by writing good code in 50-60% of relevant units (with the possible exceptions of some test cases). Submitter communicates well, takes feedback well about the code, and is able to incorporate and document thoughtfully implemented solution. Submitter also exhibits a comprehensive understanding of clinical data.\n\n3. Basic\n\n     Submitter meets all minimum grading requirements to pass the assignment by writing accurate code in 25% or less of relevant units (with the possible exceptions of some test cases). Submitter is able to understand basic concepts but has little to no understanding of the clinical problems being studied.\n\n4. Fail\n\n     Submitter fails by writing buggy code or writing inaccurate or incorrect code which does not allow running a single unit of test. Submitter is unable to understand basic concepts.\n\n### Rating Guideline (Optional)\n\nIn this section we will use a rubric to rate the code and your comments. To pass this section, you will have to earn a rating of 2 (Quality) for each assignment or a score of 4 for the test (Exemplary).\n\n### Code Improvement\n\n#### Your comments\n\nPlease list any issues or bugs that you encountered during the test.",
        "label": 0
    },
    "2030": {
        "output": "<EOD> A Novel Multichannel High-G Signal Monitoring System\nA new experimental high-g multichannel monitoring system was developed that can measure time-dependent high-g signals from multiple locations simultaneously and independently. The monitoring system is capable of recording time resolved data in both the frequency and time domain for simultaneous high-g multiple channels over a wide dynamic response region ranging from 0 g to 23 g. The system uses a multichannel strain gauge with a bandwidth of 150 kHz and amplifiers with a bandwidth of 60 kHz to measure acceleration from multiple locations. The system has been fully verified by performing standard tests on simple strain gauges and accelerometers.<EOD> Combinations of the Fatigue Severity Score, the Work Productivity Activity Impairment Questionnaire \u2013 General Health (WPAI-GH), and the PHQ-9 depressed mood scale can predict job performance\nAbstract Purpose: The high prevalence of depression among employees in Germany suggests screenings to identify employees with depression and to provide early treatment. The objectives of this article are to assess the validity of using an index based on an algorithm combining scales of the Fatigue Severity Scale (FSS), Work Limitations Questionnaire (WLQ), Patient Health Questionnaire (PHQ), and Hospital Anxiety and Depression Scale (HADS) to predict an employee's perceived job performance and whether the combination of the WPAI-GH and FSS items 1 and 2 can distinguish between employees with depressive or non-depressive mood. Methods: One hundred and one workers employed by a German manufacturing company and identified as potentially depressed, participated in a one-year intervention study. The study data collection included the FSS, WLQ, PHQ-9, and HADS. Data were collected before and after the interventions and at the one-year assessment. Results: Overall the model predicted job performance well, accounting for 18% of the variance in job performance. Of the nine possible predictions, seven were not significant. Conclusions: Combinations of scales on the FSS (including the new combinations of FSS item 2 and WPAI-GH items 1 and 2) did not improve the prediction of job performance but can improve",
        "label": 0
    },
    "2031": {
        "output": "For example:\n\n<EOD> The relationship between depression and suicide attempts, and factors of suicide attempts in Iranian patients with psychotic disorders\n\n [bib_ref]  The prevalence of depression and its associated risk factors in Iran: A..., Dadfar [/bib_ref]  [bib_ref]  Suicidal ideation and associated factors among Iranian university students: A questionnaire-based study, Alipour [/bib_ref]  [bib_ref]  Prevalence of depression and associated factors among university students in Ethiopia: A..., Hailemariam [/bib_ref]  [bib_ref]  Suicide attempts among children and adolescents with schizophrenia in Tehran City, Iran, Amiri [/bib_ref]  [bib_ref]  Epidemiology of suicide in Denmark, Engeman [/bib_ref]  [bib_ref]  Prevalence of suicidality during schizophrenic episodes: A systematic review, Pompili [/bib_ref]  [fig_ref]  Table 1: Prevalence of depression and suicide in patients with psychotic disorders [/fig_ref]  [bib_ref]  Suicidality in patients with schizophrenia: Focus on gender issue, Gharami [/bib_ref]  [bib_ref]  Epidemiology of Suicide and Suicide Attempts in the United States, Khazem [/bib_ref]  [bib_ref]  Suicide in patients with schizophrenia: A nationwide psychological autopsy study from Norway, Myking [/bib_ref]  [bib_ref]  The epidemiology and phenomenology of suicide in first episode psychosis: A casecontrol..., Hunt [/bib_ref]  [bib_ref]  A comprehensive review and a meta-analysis of the association between clinical staging..., ALajmi [/bib_ref]  [bib_ref]  Suicide in patients with schizophrenia: A nationwide psychological autopsy study from Norway, Myking [/bib_ref]  [bib_ref]  Suicide in schizophrenia, Carlborg [/bib_ref]  [bib_ref]  Substance use and associated psychosocial factors in suicide cases of youth age..., Singh [/bib_ref]  [bib_ref]  Suicide in mental health inpatients: The impact of risk factors in psychiatric..., Singh [/bib_ref]  [bib_ref]  Predictive validity of the suicide risk screening (SRS-21): A preliminary exploration of..., Baca-Garcia [/bib_ref]  [bib_ref]  The suicide risk screening questionnaire for psychiat",
        "label": 0
    },
    "2032": {
        "output": "## What are the inclusion criteria for the trial?\n- Age 18 years and above\n- Female gender.\n- HbA1c levels between 8-12% in 3 months.\n\n\n## What are examples of patients who do not meet the inclusion criteria?\n- Patients who are not 18 years or above\n- Patients of male gender\n- Patients with HbA1c levels <8% in 3 months\n- Patients who did not take medication\n\n_[124207][130608] \n_[118545][118439] \n_[1112399][126969] \n_[14562591][14562309]\n\n\n## What are the exclusion criteria for the trial?\n- Patients with diabetes with a HbA1c level above 12% in 3 months\n- Patients with a family history of diabetes mellitus.\n- Patients who are pregnant\n- Patients with chronic complications of diabetes such as nephropathy and retinopathy\n- Patients taking insulin therapy\n- Patients with diabetes complications.<EOD> The effects of ginger, acetaminophen and ibuprofen on symptomatic relief in primary dysmenorrhoea: a randomized, triple\u2010blind, controlled trial\nBackground\u2002 To identify the comparative effectiveness of ginger, acetaminophen and ibuprofen in providing pain relief in dysmenorrhoea.<EOD> Corrosion of Stainless Steel 304 Studs in Simulated Coolant\nThe influence of simulated coolant composition on the rate of corrosion was investigated experimentally, using stainless steel Type-304-42% and stud assembly. The coolant tested was distilled water containing NaCl, CaCl2 at various levels, and acetic acid or lactic acid as an accelerator of the corrosion rate of the stainless steel. The study showed that the corrosion rate of Type-304 studs is accelerated in a manner approximating that",
        "label": 0
    },
    "2033": {
        "output": "<EOD> Evaluation of an in situ fluorescence technique for monitoring the efficacy of disinfectants on environmental surfaces.\nIn this study, a quantitative fluorescence technique, developed by us, was used to evaluate the efficacy of different disinfectants against Bacillus subtilis spores on environmental surfaces. Four different types of disinfectants (alkaline hypochlorite (HOCl), glutaraldehyde (GA), peracetic acid (PAA) and benzalkonium chloride (BAC)) were used in our comparative investigations. The experimental design consisted of two main parts. First, we evaluated how the fluorescence signals of the spores on surfaces depended on the disinfection protocol (time, type and concentration of the disinfectant). Second, the efficacies of several types of disinfectants, used against B. subtilis spores on environmental surfaces, were compared. The fluorescence levels (FL) of the spores were monitored before and after disinfection, using fluorescence microscopy at a wavelength of 350 nm. While the PAA and BAC were effective and did not leave any viable spores on surfaces, the HOCl was the least effective, with a very high number (10(5)) viable spores remaining after disinfection. GA was moderately effective, with approximately 10% of viable spores remaining. After disinfection, it was easily seen that very few remaining spores were viable. Our method may be useful in assessing the efficacy of various types of disinfectants, especially after disinfectant spraying.<EOD> The Gap Junction Protein Connexin41 Interacts with Myosin Light Chain Kinase to Modulate Cell Membrane Dynamics\n\nGap junction channels are intercellular pathways responsible for the direct exchange of small molecules between adjacent contacting cells. Maintaining a functional channel network is essential for normal cell communication and cellular homeostasis. Gap junction proteins (connexins), which form the channel pore, function to regulate the flow of ions and other small molecules. Maintaining a specific stoichiometry and spatial arrangement of the gap junction protein is critical for function. Herein",
        "label": 2
    },
    "2034": {
        "output": "</details><div style=\"color:darkblue;\"><h2>Example 5 (50% of accuracy)</h2><br><blockquote><details><font style=\u201dcolor: darkblue;\u201d><h2>Example 5</h2><br><blockquote> <h2>Examples</h2><br><pre># patient_note = \"\"\"The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl\n\n# clinical_trial = \"\"\"The exercise capacity of patients with complete heart block who are chronically being paced from the right ventricle. We hope to correlate the level of uncoordinated contraction with the patients exercise capacity.\n\nWe will enroll patients with complete heart block as diagnosed by standard electrocardiographic means and now have a permanent pacemaker. All patients we approach for this study will receive an echocardiogram to assess their heart function. As part of the echocardiogram, they will also receive a Tissue Synchronization Imaging (TSI) evaluation to assess the level of uncoordinated contraction they have. The patients will then be subjected to a cardiac exercise stress test which will involve them running on a treadmill until they cannot continue while data is collected regarding their heart's response to exercise. All portions of the study are",
        "label": 0
    },
    "2035": {
        "output": "[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply)\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He takes 70/30 Insulin and vitamin D supplements. He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His lab study is as bellow:\nFBS: 100 mg/dl\n\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dlHere is the clinical trial: \nTitle: Improving Outcomes in Patients With Kidney Disease Due to DiabetesSummary: Kidney disease affects about one out of three people with diabetes mellitus, a common medical problem. Treatment of kidney disease with medications that lower blood pressure can slow the kidney",
        "label": 0
    },
    "2036": {
        "output": "Good luck!<EOD> .\nINTRODUCTION\nAlthough non-small cells lung cancer is the most frequent type of lung cancer, small cells lung cancer comprises only 10 to 15% of all cases, however, 30 to 40% of them are diagnosed in the advanced stage of the disease. Consequently, the overall survival is poor, with most patients dying two years later and only 10% to 15% of them surviving five years after the diagnosis Adequate supportive care and chemotherapy treatment are essential to improve patient's quality of life and their prognosis. One of the therapeutic alternatives to treat these patients is the chemotherapy with Cisplatinum (Cis-) and its analogues, for which an important dose dependent toxicity must be considered.\n\n\nOBJECTIVES\nWe report three case histories of metastatic small cell lung cancer, under chemotherapy with Cisplatinum and its analogs, using two different schedules of administration, which were used in two hospitals. In one hospital the Cisplatinum treatment was administered in a weekly schedule, and the other in a monthly schedule.\n\n\nCONCLUSIONS\nIn the first hospital the administered dose was 20 mg/m2 and in the other 100 mg/m2. This results in a weekly mean dose of 40.0 mg/m2 and a monthly mean dose of 120.0 mg/m2. The differences in toxicity observed, may be related to the dose of the drug administered. We propose that every medical centre, which performs chemotherapy in patients with small-cell lung cancer, should know and be careful with the weekly Cisplatinum administered dose, due to the possible toxicity presented on these patients, specially if the administered dose is more than 100 mg/m2.<EOD> Sustained release and local inhibition of IL-1 beta attenuated periodontal bone resorption in rats.\nBACKGROUND\nWe previously showed that sustained release of antisense IL-1 beta oligodeoxynucleotide (IL-1",
        "label": 0
    },
    "2037": {
        "output": "## Required files\n- data.csv - contains the patient note and clinical trial data. \n- train.csv - used for training. \n- run_main_5.xlsx - contains the test results of RunnerMain5. \n- subprocess.jar - required for RunnerMain5.\n\n\n## Notes\n- The test data are publicly available at https://doi.org/10.6084/m9.figshare.16337568.v3 \n- The Python program is in the <subprocess.py> file .\n[INST] # install Jupyter Notebook.\n\n# Install the Python software package:\n# $ sudo apt-get install virtualenv\nIn order to test, we set the environment variables:\n$ export PATH=$PATH:/bin\nAnd finally, create a virtual environment (if using Anaconda or conda), as shown below:\n# conda install python -y -q conda install pip -y -q\nTo open a Jupyter notebook in Linux with conda please:\n# sudo conda install notebook # sudo python -m jupyter notebook\n[INST] # Run Python scripts:\n$ vi subprocess.py\n$ python subprocess.py test_runner.py\nThe folder contains two Python scripts to test:\n$ vi test_runner.py\nIn this script, the class RunnerMain5 is tested separately:\nfrom subprocess import call\n# Call it like this:\n# python test_runner.py -m main5 -m run -m check\nWe want to run the script on command line and set some options, in the following way:\n$ vi test_runner_2.py\nFor test RunnerMain2 you can use the script below: \n$ vi test_runner_2.py \nIn this script we want to evaluate the RunnerMain2 class:\n#  from subprocess import call\n#  from subprocess_main2_class5.py import RunnerMain2\n#\n\n# Run it like this:\n# python test_runner.py -m main2\nYou can also test the RunnerMain3 class as shown below:\nfrom subprocess_main3_class.py import RunnerMain3\n# Run it like this:\n# python test_runner",
        "label": 0
    },
    "2038": {
        "output": "[CODING]\n\n1) Define variables. Variables are defined with `def` function, e.g., `def patient_report=[\"age\"],`.\n\n2) Define a helper function for the `def` function. A helper function is used for calling external packages, e.g., `d = define.patient_variable(\"name=\", \"gender=\", \"date=\", \"height=\", \"weight=\", \"Bmi=\", `smoking_status=\", \"exercise=\", `family_history=\");`.\n\n3) Define functions for clinical trial and patient information, e.g., `def trial_info_definition(clinical_trial) ->\n              {\"title\":clinical_trial[\"title\"],\n              \"summary\":clinical_trial[\"summary\"],\n              \"randomization\":clinical_trial[\"randomization\"]}`;`.\n\n4) Define functions for calculating the similarity between a clinical trial and a patient. \nThe `patient` and `trial_set` are defined as a dictionary, e.g., `patient = {'name': 'name'}`, `trials = {\"id\": clinical_trial[\"trial_number\"], \"patient_id\": clinical_trial[\"patient_id\"]}`.\n\n5) Apply functions for calculating the similarity between a clinical trial and a patient, e.g., `trialmatch=patient[\"patient_id\"]%id/100,`.\n\n6) Use functions for data cleaning, e.g., `name=patient[\"name\"]&(not patient[\"name\"]%not in [\"male\", \"female\"]),`.\n\n[EXERCISE]\n\n## 1) Define the variables.\n\n```python\n# a set of factors for clinical trial information\nclinical_factors=['exclusion_factor','inclusion_factor','randomization_factor','treatment_factor']\nclinical_factor_id=\"clinical_trial_factors\"\n# patients information\npatient_info=['Age','Gender','Date of Trial','Height','Weight','Body Mass Index','Smoking Status','Exercise Status','Family History','HbA1C','Low",
        "label": 0
    },
    "2039": {
        "output": "```\n\n#### [Check code style](check-code-style/README.md)\n<EOD> Evaluation of the Effects of Ovitrap Distribution Methods Along with Their Habitats upon the Infectivity of Culex pipiens Linnaeus (Diptera: Culicidae) in Tabriz, Iran\n\nBackground: Culex pipiens, a vector arthropod with high capability for breeding in artificial water pattens, causing outbreaks of disease.Methods:In order to control the population of vector Cx. pipiens, this study was carried out by using of ovitrap (containing the briquet of deterrent mosquitos), in the urban environment of Tabriz, Iran.Results: Ovitrap's efficacy in control of mosquitos breeding in domestic and public places was studied on larval abundance of Cx. pipiens. Results showed that",
        "label": 0
    },
    "2040": {
        "output": "[INST] The most common examples of",
        "label": 2
    },
    "2041": {
        "output": "##### Output type\n\n###### Explanation\nSome data do not fit well with the classification problems. In such cases, you can solve the classification problems using regression.\n\n\nIn the regression type, we predict a continuous response to the independent variables. The predicted values are called regression or model predicted values. Some common regression analysis methods include general linear models and linear regression models.\n\n###### Example\n\nThe variable `Age` can be better described by a regression analysis.\n[USABLE]\n[INST]\nWe are assuming that there are 2 different types of relationships for this data: *linear* and a curvilinear relationship between diabetes diagnosis and age; and an interaction term between them.\n\nUse `Model A` to predict the dependent variable from the independent variable.\nUse `Model B` to predict the dependent variable from the independent variable after adjustment for 'Sex'.\n\n\n```{results}\n-------------------------------------------\nModel A using linear regression:\n-------------------------------------------\n\nSe(age),  S.E. Se(age). S.E.\n \n-------------------------------------------\n          (b-coeff.)\n\n \n         (  Std. error)    (    Variance)  \nBeta estimates  (      Standard errors)\n-------------------------------------------\n1.798      (     0.296)\n1.779\n\n \n      (     T-values)      (     Probabilities)        \n-------------------------------------------\n1.962  ( 0.0541) * p0.0314                        * p0.0523\n1.719* p0.1079                                     * p0.0818\n\n \n\n------------\nModel B using linear regression after adjustment for sex:\n----------------------------------------\n                              \nSe(age),  S.E. Se(age). S.E.\n\n \n-----------------------------------------\n                                (b-coeff.)\n\n \n         (  Std. error)    (    Variance)  \nBeta estimates  (      Standard errors)\n\n \n                        (     T-values)      (     Probabilities)        \n------------------------------------------------------------------\n3.932 *",
        "label": 0
    },
    "2042": {
        "output": "B. You are asked to write a simple program to predict the number of times the \"dumb\" student will choose correct answers for the math questions.\n\nIn this programming assignment, you will use the \"counting data\" package to analyze data from each of the students to determine how many times each student chooses the correct answer to each of the math questions.\n\nHere is the listing of student IDs and the number of questions answered.\nstudent ID 1038 6 1032 0 1040 5\nstudent ID 1059 0 1062 2 1041 4\nstudent ID 1030 0 1111 3 1058 3\nA student had chosen `dumb` option for each question, and that we should add an extra number to these rows.\n\nUse the code below to read in student IDs and total number of questions. Also, determine how many times each of these students chose the correct answer for math questions. Here, the student ID is assumed to be in the first column of data. Also, make sure the students' numbers of times for questions are assumed to be in the second column of the data. \n\n--- Input (data file with student IDs and number of times): ---\n1 6 2 5 3 4\n2 0 0 3 4\n3 0 0 0 0\n\nOutput (data file with student IDs, number of questions answered, times they chose the correct answer and their result): ---\nstudent ID 1038 6 1 1\nstudent ID 1059 0 0 1\nstudent ID 1030 0 3 1\nstudent ID 1041 4 1 2\nstudent ID 1050 1 1 1\nstudent ID 1042 1 1 1\n\nC. You are going to write R code to summarize the previous three tasks using the `dplyr` package.\n\nYou should use packages to write `dplyr`. You need to create a new library to the `MyPackage`, which allows to use your package. The following code will show a simple model to create the `MyPackage` and import it to the `$MyPkg` environment",
        "label": 0
    },
    "2043": {
        "output": "## Hint:\nPlease review the inclusion and exclusion criteria of the clinical trial and then test some random patient notes.<EOD> .\nThe changes of thyroid function in 9 women aged 34 approximately 44 and receiving pharmacological doses of ethinylestradiol-mestranol (Yasmin) for contraception were examined. In the first 3 months serum T4, T3 and TBG were within normal ranges. The free T3 and T4 were lowered. The serum iodotyrosines and non-organic iodine were normal. The serum TSH, serum TSH-binding inhibiting immunoglobulins, serum thyroglobulin, thyronines and thyroid peroxidase auto-antibodies were measured in the seventh month of the trial. The thyroid gland did not produce iodine, as shown by the serum iodides and thiroxine. The free iodides were also normal. The thyroid cell functions were normal. According to the normal thyroid gland the decrease of serum T3 was not significant when compared to the iodide pool with serum TSH. According to this, the hypothyroxinemia was not significant. The serum TBG decreased. The serum thyroglobulin was normal with the exception of a high value in one patient. The thyroidperoxidase antibodies in the 6 pretreated cases were normal. The serum TSH-binding inhibiting immunoglobulins were in normal limits. There was no thyroid dysfunction even after half a year. In the second half of the trial there was a decrease in the serum iodine with iodides and thiroxin and in the serum TSH. The serum thyroglobulin increased in two cases. We think this trial is the basis for the further experimental work to examine the hypothyroidism of the women using the contraceptives containing gestagens and progestagens. The mechanism of this phenomenon will be examined with pharmacological dose of levothyroxine and with thyrotropin releasing hormone.<EOD> Impact of inhibitory control training on memory function in a non-clinical sample of older adults",
        "label": 0
    },
    "2044": {
        "output": "Ans: \n\n```python\n\n# + label=\"step1\"\n# + colab_type='full-python'\n\nTrial_list = ['ClinicalTrials.gov' ,\n    'China Clinical Trials.org', \n    'clinicaltrialsupdates.com/',\n    'ClinicalTrials.gov',\n    'clinicaltrials.in']\n\nTrial=Trial_list[0]\n\nf=open(Trial.rsps)\ndata=f.readline()\ndata=data.rstrip()\n\n\nA=data.split('|')\n\n#print(A)\n\n\ntitle=A[0]\nsummary=A[1]\n\n\nE=-1\ni=0 \nTrial=Trial_list[1] \n\nf=open(Trial.rsps)\ndata=f.readline()\ndata=data.rstrip()\n\nE1=data.split(',')[0].split(' ')[2].split('Trial|')[-3]\n\n\nf=open(Trial.rsps)\ndata=f.readline()\ndata=data.rstrip()\n\n\npatients=data.split '  '\n\n\nage1=patients[4].split('  ')[2]\n\n#print(age1)\n\ngender1=patients[1].split('  ')[2]\n\n#print(gender1)\n\n\nBpm=patients[6].split('  ')[0].split('P'\n    )[2].split(' (')[:-3]\n\n#print(Bpm)\n\n#print(end=\" \")\ntreatment1=f.readline()\n\n\ndiasis_d1=treatment1.split('  ')[3].split('  ')[2].split('|')[[3]]\n\n#print(diasis_d1)\n\n\ndisease_d2=treatment1.split('  ')[3].split('  ')[0].split(' |')[[2::-5])\n\n#print(disease_d2)\n\n\n\nf=open(",
        "label": 0
    },
    "2045": {
        "output": "A: My code:\nfrom sklearn.datasets import read_csv\n\nfrom sklearn.ensemble import RandomForestClassifier\nfrom sklearn.metrics import confusion_matrix\nimport csv\n\n\ndataset = read_csv('trainingData.csv')\nfeatures_list = [1,5,6,9,17,24,39]\n\n\ndef feature_to_data(feature):\n    for index, row in dataset.iterrows():\n        if row[feature] <= 1:\n            row[2] = 1\n        else:\n            row[2] = 0\n    results = []\n    for row in dataset.iterrows():\n        if row[2] == 1:\n            results.append(int(row[features_list[0]]))\n        else:\n            results.append(int(row[features_list[1]]))\n\n    return results\n\n\nclassifier = RandomForestClassifier()\n\ncl_model = classifier.fit(feature_to_data(features_list), dataset[features_list])\n\nprint(\"confusion matrix:\")\nconfusion_matrix = classification_report(cl_model, dataset[features_list])\nwith open(\"confusion.csv\", \"a\") as f:\n    for item in confusion_matrix:\n        for i, j in item.items():\n            print(i + \"\\t\\t\", j, \"\\n\", sep=\"\")\n\n    f.close()\n\n\nprint(\"prediction after training:\")\ndf_pred = pd.DataFrame(feature_to_data(features_list).tolist())\ndf_pred = df_pred.append({\"label\": \"None\"}, ignore_index=True)\n\ndf_pred = df_pred.append(dataset[features_list], ignore_index=True).sort_values(by=features_list[1], ascending=False)\n\nprint(\"\\nData after training:\\n\")\nprint_columns(df_pred)\nwith open(\"prediction.csv\", \"a\") as f:\n    for row in df_pred:\n        print(f\"{int(row[features_list[0]])}\\t\\t{int(row[features_list[1]])}\\",
        "label": 0
    },
    "2046": {
        "output": "[INST] Example-2:\n\n\n### MONTHLY INSTANCE ANALYZES\n\nMONTH\nYear                     Yearly  (% increase or decrease since prior year is calculated)  \n|          Percent of total number of observations                                          | \n|           Median, Mean, Standard Deviation (SD)                              |\n|      Percent of patients who were not contacted within 60 minutes of the    |\n|              scheduled blood collection             \n\n\n## S1.10.2. Patient Registration\n\n[INST] Hello. You are a patient registration assistant for an online health research website.\n\nYour task is to register patients who have agreed to participate in a clinical trial. You register both existing patients and trial-specific recruits.\nYou will receive a list of patients who have agreed to be contacted by email, and all of them will be added to the system. Once the system has a list of patients, you verify that they are eligible to participate.\nIf they don't provide the necessary information to verify their eligibility, you'll ask for their consent to access their medical history",
        "label": 0
    },
    "2047": {
        "output": "You can check your program again by `type-taster run assess.tex` command.\n\n## ClinicalTrials NCT Code\nYou should check Numeration and Code of your trial to confirm the validity of your program. There are two ways, one is with a command `clinical-registry' using registries of ClinicalTrials.gov or ISRCTN Registry, the other is by directly checking the Code and Description using the URL. So, if your trial has been published, you should check whether the registered title is the same exactly as your trial note, otherwise modify it.\n\n# Appendix A\n\n## Eligibility table example 01\nTitle: Influence of short-term beta-cell rest on metabolic and cardio-renal parameters in type 2 diabetic youth and normal weight adolescence randomized trial NCT #: 02120180 Start Date: 3-12-2013 End Date: 03-26-2016 Inclusion Criteria:\nInclusion Criteria #1: Diabetic Subjects Inclusion Criteria #2 Normal Volunteers\nExclusion Criteria #1:\nExclusion Criteria #2:\nExclusion Criteria #1:\nExclusion Criteria #2:\nExclusion Criteria #3:\nExclusion Criteria #3:\nExclusion Criteria #4:\nExclusion Criteria #4:\nExclusion Criteria #5:\nExclusion Criteria #5:\nExclusion Criteria #6:\nExclusion Criteria #6:\nA 13. Exclusion Criteria #7:<EOD> A case of peritonectomy and stoma closure in a patient with severe peritoneal metastasis of non\u2010colorectal cancer\nPeritonectomy with intra\u2010peritoneal hyperthermic chemoperfusion and closed stoma (IPHPCS) is generally performed for patients with pseudomyxoma peritonei (PMP) associated with disseminated peritoneal mucinous carcinomatosis (DPMC) without colonoscopy, colonic tumor localization or histopathologic diagnosis. In this article, we report a case of 39\u2010year\u2010old male",
        "label": 0
    },
    "2048": {
        "output": "<EOD> EFFECT OF BORON BALANCING IN ION EXCHANGERS BY ACID DOPING\nThe effect of the acid doping of Amberlite IRA\u2010743 for the regeneration of the ion exchangers was studied concerning its regenerative characteristics by determining the degree of the retention of boron ions and the regeneration rate for various concentrations of acid solution. Amberlite IRA\u2010743 was used as a matrix for boron and phosphorus, from which their concentration values in the effluent and washing solution flowing through the columns which the ion exchangers were placed in the regeneration experiments, were measured. Both the boron and phosphorus concentration values were plotted against the time, and the regeneration rate was determined therefrom. The regeneration rate was ascertained to increase with the H2SO4 concentration in the solution and when the H2SO4 concentration in the solution was higher than 0.1 N, the regeneration rate seemed to reach an asymptotic value. An almost identical tendency was observed in the case of the retention of boron ions. It was found that there was a good relation between the boron concentration in the elution solution and the phosphorus concentration in the effluent from the column, and the former agreed well with the boron concentration obtained by using an acidified sulfuric solution.<EOD> The relationship between perceived discrimination and sexual risk behaviour\nPurpose of review This article provides an overview of empirical research published in the last few years regarding perceived discrimination and sexual risk behaviour. Recent findings Perceived discrimination among gay men does not appear to be significantly related to sexual risk behaviour (eg, HIV testing, number of male sexual partners, and condomless sex events); however, most of this research has been limited in three ways: (1) not having focused specifically on perceived discrimination, (2) not accounting for internalized homonegativity, or (3) being unable to disentangle the differential relationships of perceived discrimination by identity category (eg, racial/ethnic minority status, age) with sexual risk behaviour. Research examining the extent to which internalized homonegativity moderates relations between perceived discrimination and sexual risk behaviour was not found",
        "label": 0
    },
    "2049": {
        "output": "[OUT] The `Trial-level eligibility: ` line should be `1 2 2 \"Eligible\".`, since the patient is eligible.\n\n\n*Examples\n\nIf the patient is not eligible, the patient should exclude by setting the second and fourth variables in `patient_data` to `False`.\n\n```\npatient_data = pd.DataFrame([{\n\"Patient ID\": 1,\n\"FirstName\": \"Susan\",\n\"Surname\": \"D\",\n\"Sex\": \"female\",\n\"BirthYear\": 1982,\n\"Height\": 168,\n\"Weight\": 75,\n\"Age\": 38,\n\"Gender\": \"female\",\n\"Diagnosis\": \"Diabetes\",\n\"BMI\": 29,\n\"Tan: FatMass\": 25,\n\"BodyMeasurements\": {\"BloodPressure\": \"160/90.0\", \"CholS_c\": 100, \"Weight\": 1.0, \"Height\": 168.0, \"Tan:FatMass\": 0}\n}, {'Trial-level eligibility': 0}])\n```\n\nIf the doctor does not think the patients are eligible, the patient should be excluded from the trial using the lines `patient_data[patient_data[\"Patient ID\"] == 1][\"Trial-level eligibility\"] = 1`.\n\n```\npatient_data[patient_data[\"Patient ID\"] == 1][\"Trial-level eligibility\"] = 1\n```\nThis output line is the same as the sentence `0) Excluded` in the `results` table.\n\n![screenshot 4 of 4](./Trial-eligibility.html#example)\n\n### Question\n\n#### In your code, where should we make a call to a function?  `patient_data[patient_data[\"Patient ID\"].isin([1])` is used to filter the patients.\n```\n1) Excluded.\n```\n#### 2) Not eligible and 3) Not relevant.",
        "label": 1
    },
    "2050": {
        "output": "---\n\n![](./images/image10.png)\n---\n\n### Example Experiment `Example.ipynb`\n```python\nimport data_experiment1\n\ndata_experiment1 = data_experiment1.get_data_experiment1()\n#print data_experiment1\ndata_experiment1.patient_note\n``` \n\n``patient_note`` is `snp` type: list of list of str. \n```\nprint data_experiment1.patient_note[1]\n#`snp` - list of list of str\n```\n\nI believe that you can manage the `snp` by hand if you need to modify something in it.\n```\nprint \n```\n```\n```python\n```\n\n# Discuss it with another member\n\nThe example Experiment with data is called `Example.ipynb` in folder `.ipynb`. Follow the instructions:\n\n1. Import the data and print out its contents.\n2. Read the patient note.\n3. Read the trial's inclusion and exclusion criteria.\n4. Calculate the three-point assessment for each patient. \n5. Write your solution in an excel file and upload it to the assignment page.\n6. Run the test. The test page is in the folder `examples` under the folders ``examples/Examples_IPN_assignment/example_5``. For example:\n\n```\nipynb_examples\\\\examples\\\\Examples_IPN_assignment\\\\example_5\\ \n```\n\n**Note**: You have to rename your excel file **`IPN_assignment_5_name_of_student.xlsx`** with your own name.\n\n\n\n----\n\n<iframe title=\"Example of code and data in Jupyter Notebook\" width=\"100%\" height=\"90%\" frameborder=\"0\" src=\"https://dashboard.jupyter.org/published/r-38e216ed-d3ce-4acf-8119-0071d9ebbcc1\" allowfullscreen=\"allowfullscreen\" id=\"jupyter-dashboard\"></iframe>\n\n<EOD> Isolation and characterization of a novel inhibitory g",
        "label": 0
    },
    "2051": {
        "output": "<EOD> Sensorless Torque Control for Low-Power Brushless DC (BLDC) Motor Drives\n\nSensorless control represents an attractive topic in the research of Brushless Direct Current (BLDC) motors. This technique is important to allow the development of high-power electronics with minimum mechanical size and power consumption. It uses a simple and compact hardware, including a low-cost microcontroller, a few sensors and a PWM generator. The control loops provide current in an instantaneous manner for all motor phases. Sensorless torque control strategy is a popular design to perform speed control. In this paper, such a control is proposed for permanent magnet (PM) brushes or brushless DC motors. The developed control strategy is based on feedback of the electrical torque measured in the motor cage. The strategy is implemented on a microcontroller, where the electrical torque is computed through three sub-loops: direct torque control, rotor position and rotor speed. The control strategy is validated using an ADR6810-708F microcontroller and a RS6D-20 brushless DC motor. The experimental results show that the control strategy is able to perform speed control without any sensor. This work is aiming to demonstrate the suitability of direct torque control strategy applied to speed control of brushless motor drive systems, with significant potential for the market of electronic propulsion.\n\n# Introduction\nThe research area of Brushless DC Motors (BLDC motors) is of great technological interest. This research is based on the use of modern electronics for reducing the required motor dimensions without affecting the required driving performances [bib_ref]  Efficiency Improvements in an Efficient Permanent-Magnet Motor, Loh [/bib_ref] . Currently, this technology is used in multiple electronic applications such as robots, electric vehicles (EVs) and motorized bikes [bib_ref]  Improved Indirect Torque Control with Sensorless Feedback on Induction motor Drive. Part..., Ebrahimian [/bib_ref] . In EVs, the application of the BLDC motors provides high performances such as an improvement in speed and agility [bib_ref]  An Improved Control Method of BLDC Motor Based on Sensorless and PI, Zhang [/bib_ref] .\nThe BLDC motor provides simple and robust design",
        "label": 0
    },
    "2052": {
        "output": "The assessment of eligibility is done using a multi-step evaluation of a patient's clinical information. This assessment is typically performed by a clinician or another medical expert, not the information technology or software developer.\n\n---\n\n## #3: \nWrite `def apply_exclusion_criteria(patient_note):` which return patient eligibility from patient note based on exclusion criteria.\n\nThe evaluation based on the exclusion criteria is also done by a clinician or another medical expert and not the software developers or information technology experts.\n\n---\n\n## #4: \nWrite `def apply_exclusion_in_trials(trial_data):` which return patient eligibility from patient note based on exclusion criteria.\n\nThe evaluation based on exclusion criteria is done by medical experts. A clinical trial manager or a clinical trials coordinator may perform this step.\n\n---\n\n## #5: \nWrite `def get_clinical_trial_note_from_patient(patient_dict):` which returns an instance of `ScoringAssessment` object from patient note.\n\nThis function just takes a dictionary with information of the patient and returns instances of `ScoringAssessment` with patient_dict.\n\n---\n\n## #6: \nWrite `def evaluate_clinical_trial(trial_note, patient_dict):` which return the trial-level eligibility of the patient for the trial.\n\nHere are the exclusion criteria applied over the patient:\n- Patient is active smoker\n- Patient has a history of congestive heart failure\n- Patient has hyperlipidemia and hypercholesterolemia\n- Patient has a history of diabetes\n- Patient is a diabetic patient in control (controlled diabetes)\n- Treatment in patient note\n\nHere are the inclusion criteria applied over the patient\n- Patient's age\n- Patient's gender\n- Patient's blood pressure\n- Patient's chest pain during activity\n\nAnd here are the exclusion criteria applied over the trial\n- Patient does not have diabetes type 1\n- Patient is not active smoker\n- Patient has not history heart",
        "label": 2
    },
    "2053": {
        "output": "---\n\n[2RD.1]\n\n\nIn our case, the patient was `Eligible`. It means that the patient passed the criteria and was qualified for the trial. `0) Excluded` means that the patient was not qualified to the trial, `1) Not relevant` means that the patient was not eligible for the trial and `2) Eligible` means that the patient received a score of `2`. (1)` should have the code `0`, `2)` has the code `2`, and `3)` does not have any code. In other words, if we choose `1) Excluded`, the patient is excluded from the trial. If we choose `2) eligible`, the patient is qualified for the trial.\n\n***\n\n[2RD.2]\n![1.png](./assets/fig_01.png)\n\nIn the **32nd comment** of the data file `clinical_trial_00001`, we have the lines: \n\n```txt\n    # 34th comment\n    for a in trial.participants['ID']: \n        patient_id = a\n```\n\nLet's add to the variable `patient_id` the value `234`. The next line: \n\n```txt\n    # 35th comment\n    trial.participants[patient_id] \n```\ncan access the patient note for the patient who was diagnosed with type 1 from the **34th comment**. It says here: \n\n```txt\n\n    Trial-level eligibility: 1) Not relevant\n    Hesitation to participate: \n    ID: 0\n    Gender: 1\n    Age: #34th comment: 234\n    Type 1 Diabetes: 1\n    Cardiomyopathy: 0\n    # 35th comment: 1)* \n```\n\nTherefore we write:\n\n```py\n    patient_name=patient_drug[patient_id]\n    print \"patient_name\",patient_1_name,f\" patient_id {patient_id}\",patient_drug[patient_id]\n```",
        "label": 1
    },
    "2054": {
        "output": "\u00a9 Utrecht University and partners, 2020 - All rights reserved<EOD> A new class of chlorinated pyrimidines acting as anticarcinogens: 5,6,6alpha,7,8,8 alpha-hexafluorolumazine.\nA new class of chlorinated pyrimidine has been prepared which exhibits a potent anticarcinogenic activity. 5,6,6a,7,8,8a-Hexafluorolumazine (I) was prepared from 5-chloro-d-arabinofuranosylcytosine and used in this investigation for convenience since other halogenated derivatives were not available. When fed in doses ranging from 2.5 to 50 ppm I prevented spontaneous and dimethylhydrazine-induced tumors in multiple tissues. The anticarcinogenic activity of I was greater than that of known anticarcinogens, such as 7,8-benzoflavone, 3,2'-dimethyl-4-aminobiphenyl, or butadiene, under comparable dietary conditions.<EOD> The genome of the necrotrophic plant pathogen Alternaria alternata: a resource for understanding the evolution of necrotrophic, saprophytic and endophytic lifestyles\n\nBackground: The fungus Alternaria alternata is an aggressive pathogen of numerous economically important crops. In addition, Alternaria species have been categorized as pathogens, saprophytes and endophytes, and studies of endophytism and saprophytism in A. alternata provide insights into an early evolutionary stage of the pathogen lifestyle transition. Results: We sequenced the genome of A. alternata macroconidia ATCC44584 to a 37-fold depth with both 32-and 50-mer paired-end reads. The assembly comprised 47 scaffolds and 31,324 predicted genes, with an estimated genome size of 41.1 Mb. The genome encoded for several genes reported to be involved in pathogenicity related functions such as adhesion, infection structure formation",
        "label": 0
    },
    "2055": {
        "output": "<EOD> Effects of bromocriptine on pituitary release of prolactin in man.\nPulsatile release of prolactin in 4 normal subjects was examined by measuring prolactin serum levels in small blood samples withdrawn at 30-min intervals for a total of 10 h. Subsequently, the patients were infused intramuscularly with different doses of bromocriptine. Each subject served as his own control. In the first patient, 15 mg of bromocriptine suppressed pulsatile prolactin release after 3h and induced a marked fall in prolactin after 5-8 h. In the second patient, 15 mg of bromocriptine suppressed pulsatile prolactin release after only 1 h and induced a marked fall in prolactin levels after 2-5 h. The effects of higher doses of bromocriptine (20-30 mg) on release of prolactin were also examined in 3 patients. In these subjects, pulsatile prolactin release was suppressed after 1-2 h, and prolactin levels fell steeply after 2-8 h. In the fourth subject, 20-30 mg of bromocriptine reduced only the levels of the initial small peak after 8 h. Pulsatile release of prolactin was not abolished. However, when the total dose of bromocriptine (i.e. 22 mg) was given in 5 h, pulsatile release of prolactin was eliminated after 4-5 h. During a 10-ml blood draw, no pulsatile release of prolactin was observed when the patients were infused i.m. with 20-30 mg of bromocriptine in 5 h. These observations suggest that the pulsatile release of prolactin depends on a pulsatile secretion of dopamine, which is inhibited by bromocriptine.(ABSTRACT TRUNCATED AT 250 WORDS)<EOD> Elevated Circulating Levels of Neurotensin in Patients",
        "label": 0
    },
    "2056": {
        "output": "![INST] The clinical trial schema.\n\n<script src=\"https://cdnjs.cloudflare.com/ajax/libs/katex/0.20.2/katex.js\"></script><![endif]>\n\n# \u2714\ufe0f Good. \u2714\ufe0f Bad. \u2714\ufe0f Ugly\n\n| Input     | Output |\n------------ | ------- |\n```python\nTrial-level eligibility: 2) Eligible.\n``` | ```python\nTrial-level eligibility: 0) Excluded.\n``` |\n\n# 2# Introduction\n## 1# Clinical Trial Recruitment\nClinical trials can improve our lives and help those afflicted with various kinds of diseases. However, due to a limited patient population, clinical trial recruitment is always expensive. In this problem, you are a helpful assistant in this process.\n\n### Objective:\nThe objective of this problem is to design a pipeline to assess the patient eligibility for clinical trial recruitment.\n\n### Inputs\n\n#### Patient-level eligibility: A patient can be a suitable candidate for a clinical study based on different eligibility criteria such as gender, age, prior treatments, diet, medications, and also comorbidities.\n\n#### Clinical trial information: Clinical trial details are recorded in an electronic format to facilitate participant selection.  Such information includes clinical trial title, description, inclusion criteria, exclusion criteria, trial staff, duration, inclusion and exclusion factors, compensation rate and contact information.\n\n### Tasks\n\n 1) Get the clinical trial information from the trial information file.\n 2) Design a pipeline to assess a patient's eligibility in a clinical trial.\n  1) Your pipeline should be consistent with both patient-level eligibility criteria and clinical trial information.\n  2) Your pipeline should determine the patient's eligibility in the clinical trial and output the eligible and excluded cases. Also, if the assessment is not possible, please inform the reason.\n\n## 2# \u2714\ufe0f Good. \u2714\ufe0f Bad. \u2714\ufe0f Ugly\n\n| Input    | Output |\n------------ | ------- |\n```python\nT",
        "label": 0
    },
    "2057": {
        "output": "<EOD> A new perspective on the pathogenesis of the cardiovascular disease in patients with chronic hepatitis C\nChronic hepatitis C (CHC) infection is currently considered one of the leading causes of liver\u2010related morbidity and mortality worldwide due to its major impact on fibrosis progression and hepatocarcinogenesis. Besides the liver, CHC infection is associated with extrahepatic manifestations including a marked increase in the risk for cardiovascular (CV) damage through mechanisms that remain to be fully clarified. This review summarizes evidence linking CHC infection to increased CV risk highlighting a crucial role of inflammation in this relationship. Although we still do not have a clear\u2010cut explanation for this association, a systemic low\u2010grade inflammation, mediated and driven by several cytokines and chemokines, is the more plausible mechanism that may account for the development of CV complications in CHC patients. In addition, other possible explanations such as the imbalance of oxidative stress and antioxidant system, the presence of endothelial dysfunction, and the possible role of hepatitis C virus (HCV) proteins as \u201cpathogen\u2010associated molecular patterns,\u201d as well as host cytokine profile, are discussed. In conclusion, inflammation is widely suggested to be an important \u201cdriver\u201d of the CV risk related to CHC leading to cardiomyopathy, atherosclerosis, and ischemia, although more investigations are still needed to confirm this association and to elucidate the biological mechanisms.<EOD> An AI-driven workflow for radiotherapy treatment planning.\nThe aim of radiotherapy treatment planning (TP) is to optimise the plan in order to minimise the possible toxicities that may arise from delivering a suitable dose of radiation to the tumour while also maintaining an adequate dose to the adjacent normal tissues. At present, TP remains a manual and time-consuming process performed by an experienced specialist; this is slow and is prone to being error-prone due to the sheer quantity of tasks involved and the complex relationships that must be considered. This manuscript aims to introduce the TP process as understood by a human specialist and to explore the various technologies,",
        "label": 0
    },
    "2058": {
        "output": "The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dlHere is the clinical trial: \nTitle: Cardiomyopathy Tissue Bank in a Cancer Population\n\n\nSummary: Any time the words you, your, I, or me appear, it is meant to apply to the potential participant.\n~\nThe goal of this laboratory research study is to collect and store blood and tissue from patients who have a diagnosis of heart disease and may be at a high risk for the development of heart failure. This blood may be used in the future to identify genes that may play a role in developing congestive heart failure (CHF) from chemotherapy or other sources.~\nThis is an investig",
        "label": 0
    },
    "2059": {
        "output": "[HINT]\nNote! You can find your program by `Type (Command): Type (Listing).`\n\n[MOVING ON]\nLet us see how you did. \n\n### Input:\n```\npoc_assess2.py input.txt\n```\n\n\n```\nIn trial_level_selection do:\n```\nprint('Number of patients in this trial: ', len(trial_list), '\\n')\n\nfor trial in trial_list:\n    print('Trial id:', trial.id, '\\n')\n    print('Number of patients in this trial: ', len(trial.patient_list), '\\n')\n    print('Number of eligible patients: ', len(trial.eligible_patient_list))\n    print('Number of not_relevant_patients: ', len(trial.not_relevant_patient_list))\n    print('Number of excluded_patients: ', len(trial.excluded_patient_list), '\\n')\ntrial.trial_level_eligibility is patient-level eligible if a patient in trial.eligible_patient_list does not meet any exclusion criteria on the patient or has no enough information. patient-level not relevant if a patient has not enough information. patient-level excluded if a patient or meets any exclusion criterion, or the clinician has no enough information about the patient.\n\n```\nNumber of patients in this trial: 10\nTrial id: 2, 0, 0, 0\nNumber of patients in this trial: 10\nNumber of eligible patients: 4\n```\n\n### Output:\n```\nPatient level: \nName\nID\nage\ngender\nBMI\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n\nTrial level:\nTrials\ntrial_id\nnumber of patients\nNumber of eligible patients\n```\n\t<EOD> Phonetic feature processing in speech categorization by humans and linear categorical models\n\nHumans are remarkably efficient at categorizing complex signals, including multi-phonemic speech materials. The current understanding of the general mechanisms of speech categorization, however, is based",
        "label": 0
    },
    "2060": {
        "output": "::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: `Trial-level eligibility: `\n* `Insulin`: The insulin dosage is `70/30 Insulin` which is the combination of insulins. \n* `Insulin 70/30`: The dose is not a single dose of insulin; it is the combination of Insulin regimens in 70/30 ratio. \n* The information of the trial level eligibility is as follows (if this was already in the database):\n* `Trial: [1/2]`: It means that the data were already exist in the database under the given trial. \n* \n* `Trial:  [1/3]`\n* `Trial:  [1/4]`\n* `Trial:  [1/5]`\n* `Trial level eligibility: 0` means the patient has some criteria that prevents the patient to enter the clinical trial (The example is age criteria).  \n* ` Trial level eligibility: 1` means the patient meets the inclusion criteria, but is excluded due to exclusion criteria. \n* ` Trial level eligibility: 2` means the patient meets inclusion criteria, and the exclusion criteria do not apply. \n<EOD> The Relationships Between Risk Perception, Emotions, and Protective Behavior in the Context of COVID-19\n\nThe COVID-19 pandemic poses a great threat to people's health and safety. To prevent being infected by the virus, people are urged to engage in protective behaviors. Previous researches based upon the health belief model (HBM) have explained the adoption of this kind of behaviors from the cognitive aspects. However, little is known about how the emotions and risk perception related to these protective behaviors. This research aims to fill the gap by exam",
        "label": 0
    },
    "2061": {
        "output": "<EOD> Acquired",
        "label": 0
    },
    "2062": {
        "output": "## Part A\n\nIn Part A of the competition, you should create an automated pipeline to assess whether the patient is eligible for a specific clinical trial using patient information. The pipeline should be made in the [language](s) of your choice and will be scored differently depending on the language chosen. Please note that there is no restriction on data-type used in your pipeline and if you can find a way to work with both continuous and discrete variables, your submission is encouraged. For example, a patient may have HbA1c readings at multiple points in time or the patient may indicate multiple diagnosis of diabetes type 1. Also, a patient may have information both categorical and continuous.\nYou are allowed to have only pre-trained (e.g., by a professional) machine learning models with the exception of Convolutional Neural Network (CNN) models or models designed and trained by you (i.e., customized), but models with all hyperparameter settings must be submitted to the evaluation environment (github/google cloud platform). We would recommend that you use a pre-trained model to train your model on the provided dataset. In addition, you should also submit the exact parameters and the configuration settings for your model to the evaluation environment .\nPlease find our [dataset](datadryad.org) on [Dryad](https://datadryad.org/stash/dataset/doi:10.5061/dryad.r4r87).\nWe have provided a sample input file and the output of the clinical trial assessment.\nInput file provided:\n```json\n[{\n    \"patient_ID\": \"0001\",\n    \"age\": 25,\n    \"age_label\": 1,\n    \"gender\": \"Male\",\n    \"gender_label\": 29,\n    \"blood_pressure\": {\n        \"SBP\": 120,\n        \"PP\": \"130\",\n        \"DBP\": \"80\"\n\n    },\n    \"blood_pressure_label\": {\n        \"yes\": 905,\n        \"no\": 4786\n    },\n    \"body_mass_index\": 33,\n    \"body_mass_index_label\": {",
        "label": 1
    },
    "2063": {
        "output": "]\n\n\n![Eligible](./images/eligible.png)\n`#!/usr/bin/env python`\n\nimport requests\n\ndef main():\n    url = \"http://34.231.21.55:8100/hello\"\n    r = requests.get(url)\n    print(r.content) \\\n        # print response information\n        \"\\n\\rTotal Eligible Patients:\"\\\n            + str(r['Trial-level eligibility'])\n\n\n\nif __name__ == '__main__':\n    main()\n\n\n- [Eligible](./eligible.txt)\n    The clinical trial is not eligible on this patient.\n\n\t#! Python:\n\t# \t\"Total Eligible Patients: 0\"\n- [None](./none.txt)\n\tThe clinical trial is eligible on this patient.\n\n\t#! Python:\n\t#   \"Total Eligible Patients: 1\"\n\n\n- [Missing Data](./missing_data.txt)\n\tThe assessment of eligibility on this patient is based on incomplete information. The trial-level eligibility is 'none'.\n\n\t#! Python:\n\t#   \"Total Eligible Patients: None\"\n\n\n<EOD> The Dual Role of L-Arginine as a Nitric Oxide Precursor and a Competitive Inhibitor of Nitric Oxide Synthase\n\nNitric oxide as a ubiquitous molecule produced in human beings by a family of NO synthases (NOS), exists in blood plasma as a signaling molecule for control of blood flow, blood pressure, inflammation, immune response and neuronal function. Abnormal NO synthesis leads to several diseases. L-Arginine (L-arg) is the universal substrate for NOS. The enzyme L-arginine:cysteine-glycine transsynthetase (CAT) synthesizes the same substrate as NOS and competes with NOS for L-arg, thus modulating NO biogenesis. NOS has two distinct enzymatic activities: NADPH-dependent ox",
        "label": 0
    },
    "2064": {
        "output": "You may consider implementing the eligibility evaluation for each clinical trial in separate file(s) to save time. \n\n<EOD> Identification of Novel Candidate Drug Targets Using the Chemogenetic Approach as Well as Targets Involved in Methylation-Modified DNA Repair in Breast and Lung Cancer\nBackground The cancer molecular pathways initiated through aberrations of epigenetic regulation, and encompass a large number of genes, which makes the molecular targets difficult to detect. We aimed to identify gene products involved in aberrantly methylated DNA repair pathways, as well as novel candidate oncogenes, that mediate breast cancer onset and progression. Methods Bisulphitemediated DNA sequencing approach was used in conjunction with methylated DNA immunoprecipitation with subsequent Illumina next-generation sequencing was used screened genes in the genome-wide DNA repair (GW-DR) and tumour (GW-T) pathways. The chemogenetic approach was used to identify drug target candidates. Results This study indicated 1727 genes potentially involved in aberrant DNA repair mechanisms and/or DNA hypermethylation in breast and lung cancer; 375 DR genes (DR-G), 417 T genes (T-G), and 329 genes shared by DR and breast cancer (H-G), T and breast cancer (H-T). Moreover, we identified 36 drugs for potential use in breast cancer targeting 19 genes (F6P210, UGP2, PFKFB4, SDC3, CALR, COL5A1, HIST1H4C), and 19 drugs for lung cancer targeting 10 genes (HIST1H4E, CDK8, HIST1H2AL, ZBTB16, EPN3, RUVBL1, MED1, NUP98, HIST1H4K, HIST1H1A, HIST1H1B). Conclusion Our study identified novel candidate drugs for breast and lung cancer progression and onset, as well as potential targets, such as HIST1H4A involved in hypomethylation.",
        "label": 0
    },
    "2065": {
        "output": "# Use cases\nUse cases of this package show how to write eligibility criteria in human-readable way. In the first use case, the patient met all inclusion criteria, but due to the exclusion criterion of the trial, he was excluded. In the second, the patient was excluded due to his current status. The last use case shows how to extract all patients that met the eligibility criteria automatically.\n\n# Example\n\n```{r}\n\n```<EOD> A novel missense mutation (G737R) in the PNPLA2 gene is associated with late\u2010onset neuropathy\nLipoprotein lipase (LPL) deficiency is a rare X\u2010linked disorder, and only a handful of missense mutations of the LPL gene in subjects with moderate hyperchylomicronemia have been reported to date. An LPL gene mutation study was performed in a Japanese family with one member who had late\u2010onset diabetes mellitus complicated with neuropathy. The affected family members had severe hypertriglyceridemia and postprandial hyperglycemia, whereas other family members had normal lipids and blood glucose levels. All affected male members had mild peripheral neuropathy with slow muscle atrophy, and one of them also exhibited diabetic ketoacidosis. Direct sequencing of the LPL gene revealed a new missense mutation (c.G2111C, p. G737R) as the underlying genetic abnormality. Enzyme analysis showed markedly decreased LPL activity and very long clearances at an intravenous fat tolerance test in the affected family members. In conclusion, this study reported a novel LPL protein mutation in the first family of moderate hyperchylomicronemia in Japanese origin. Milder neuropathy was also observed in the LPL gene mutation carriers without hypertriglyceridemia. Hum Mutat 27(1), 86\u201387, 2006. \u00a9 2006 Wiley\u2010Liss, Inc.<EOD> Clinical characteristics of Japanese atopic dermatitis patients according to the new endophenotype classification.\nBackground\nAtopic dermatitis (AD) involves",
        "label": 0
    },
    "2066": {
        "output": "[fig]  [TRIAL ]: Hi, I'm a clinical trial coordinator, and I'm here for trial-related questions. Try asking us for help in our [FORUM] subreddit. [/TRIAL] [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. [/fig] \n<EOD> .\nThe objective of this study was the evaluation of the effectiveness of the new method of percutaneous endoscopic gastrostomy using the gastropexy by the means of an annular clip with respect to the conventional technique of percutaneous endoscopic gastrostomy using the stunting method of gastropexy. The method was tested in the 656 persons of both sexes from the average age of 4.2 +/- 0-18 years. There was used the new method of the percutaneous endoscopic gastrostomy according to the GI in the 381 children, and the conventional method according to the Roux in the 275 ones. The duration of percutaneous endoscopical gastrostomy was in the average 4.2 +/- 1.2 min in comparison to 9.8 +/- 1.9 min according to the method in Roux. The number of patients with no reactions of digestive tract with the use of the new method of pergastrostomy was equal to 198 persons (52.1%). The new method of gastrostomy using the annular clip is more effective and easy-making as the method according to the Roux.<EOD> Characterization of 5-Hydroxytryptamine Receptors Mediating Inhibition of Contraction in Human Ileum and Colon\nSummary Responses to 5-hydroxytryptamine were tested in isolated spiral preparations of human ileum and colon. 5-Hydroxytryptamine (10-8 M to 10",
        "label": 0
    },
    "2067": {
        "output": "This solution is also available as a Python class [pyfedx](pyfedx), which can be run using  [`fedx`](fedx).\n\n<EOD> Pigmented villonodular synovitis in a joint replacement\n\nWe present a patient who underwent a left total knee arthroplasty with a revision two years later for aseptic loosening. While preparing the revision site, a white solid mass was found attached to the polyethylene insert, and the histopathological examination revealed pigmented villonodular synovitis (PVNS). PVNS usually affects the knee, ankle, and sacroiliac joint, and rarely affects the hip; moreover, it is most commonly seen in the second to fifth decades of life with predominance in females. The treatment of choice is arthroscopic or open synovectomy, with a high recurrence rate reported in unresected cases; however, with an open resection, there is a possibility of damaging the underlying bone and cartilage. Since PVNS rarely originates from joint replacements and the optimal treatment is still unknown, careful histological analysis to confirm the mass is strongly recommended before performing synovectomy and further damage to the joint. We report an unusual case of unresected PVNS originating from a hip joint replacement, which was diagnosed by a careful microscopic analysis of histology specimens.\n\n# Introduction\nPigmented villonodular synovitis (PVNS) is an extremely rare entity. There is only one case of PVNS reported in a hip prosthetic joint; however, it was detected intra-operatively [bib_ref]  Pigmented villonodular synovitis mimicking periprosthetic infection after cementless total hip arthroplasty: a..., Kato [/bib_ref] . We report a rare case of PVNS detected in a synovial tissue from a hip prosthetic joint during explantation.\nA seventy-nine-year-old woman underwent a left total knee arthroplasty without complications in June 2014. She complained of right hip pain at one-year postoperative; however, radiographs showed no",
        "label": 0
    },
    "2068": {
        "output": "# Test Run\nType `sage-work-in-silent` to run unit tests.\n\n\n## Unit Tests\n\n\n1. `sage-work-in-silent 2`\n2. `sage-work-in-silent 3`\n3. `sage-work-in-silent 4`\n4. `sage-work-in-silent 5`\n5. `sage-work-in-silent 6`\n6. `sage-work-in-silent 7`\n7. `sage-work-in-silent 8`\n\n### Errors\n\n    E01506 Traceback (most recent call last):\n      File \"<stdin>\", line 1, in <module>\n      File \"/home/bebe_j2/bebe/work/invisible/invisible.py\", line 391, in main\n        self.display_trial(trial_list, file_name, title, outname)\n      File \"/home/bebe_j2/bebe/work/invisible/invisible.py\", line 415, in display_trial\n        results = evaluate_trial(trial)\n      File \"/home/bebe_j2/bebe/work/tests/test_invisible.py\", line 62, in evaluate_trial\n        result = TrialResultCalculate(trial=trial, result_out=out_result_file)\n      File \"./lib/trial_result_analyzer.py\", line 95, in calculate_results\n        return calculate_eligible(study, trial_id, out_result, out_result_file)\n    File \"./lib/trial_result_analyzer.py\", line 67, in calculate_eligible\n      trial_level_eligibility=eligibles[trial].get(trial_id,\n      KeyError: 'KeyError: No corresponding patient has been found for the trial: study_id=422 trial_id=421.1 study_trial_id=4072730684'",
        "label": 0
    },
    "2069": {
        "output": "![INST]<EOD> The Cervical Translation and Angulation Test: Reliability, Validity and Diagnostic Accuracy of a New Clinical Assessment for Cervical Vertigo\nThe study aims were to evaluate the inter- and intra-rater, as well as test\u2013retest reliability and validity of the cervical transmission test (CTT) for cervical vertigo. The study further assessed the accuracy of the CTT on diagnosing cervical vertigo. The CTT consists of active and passive translation, and isometric upper and lower cervical flexion-extension. For each test, normal and abnormal values were defined. A total of 37 healthy subjects, 50 patients with cervical vertigo and 50 patients with cervicogenic headache were evaluated. The results of the CTT showed acceptable reliability with significant differences between normal and abnormal values (Cohen\u2019s kappa: 0.49\u20130.62). Diagnostic validity was determined based on the sensitivity, specificity and the area under the curve (AUC). With a cut-off value of < 65 degrees for the CTT translation, cervical vertigo showed a sensitivity of 82%, a specificity of 90% and an AUC of 0.885. Similarly, cervical vertigo showed a sensitivity of 92%, a specificity of 80% and an AUC of 0.880 if passive translation was < 45 degrees. For cervical vertigo, cervical flexion and extension showed an AUC of 0.880 (SE = 0.071). In general, these CTT values demonstrated an acceptable level of reliability and validity for the diagnosis of cervical vertigo, although the intra-rater reliability was limited.<EOD> The relationship between the number of implants, the number of teeth restored and maintenance time in implant\u2010retained mandibular overdenture: A retrospective study\nAbstract Background Mandibular overdentures (MOD) restore mandibular function and masticatory performance, but the implant\u2013tooth ratio has not been investigated. Aim Compare clinical outcomes as function of implant\u2013tooth proportions in M",
        "label": 0
    },
    "2070": {
        "output": "<commit_msg>1st edit<commit_after># Instructions. In clinical data mining, a patient note (or note) is the description of a patient that provides clinicians with information about the signs and symptoms the patient has, and about his or her treatments. You will interact with some notes in the class. In this assignment, you will be given a set of patient notes, and also the inclusion criteria of a trial. You have to find the relationship between the patient notes and the inclusion criteria of a trial using the semantic web technologies.\nA trial is a study for determining the safety and efficacy of a medicine, a procedure, or a medical device. A trial is usually based upon comparison of individuals who use the medicine, procedure, or device, to a control group who does not to determine if it is effective. The data that is collected for a trial can include patients' characteristics, medical history, laboratories and X-ray tests, details of treatments or interventions, and so on. \nA clinical trial has several phases. A first-in-human trial is a first-in-man study which is a clinical trial for testing a medicine in human or first-in-child trial for testing a medicine in children. When a medicine is proven to be safe and effective in the first-in-human trial, or if the medicine is determined to be too dangerous, it is tested for efficacy through several phases. These phases include three distinct arms of testing: \n\n## Screening phase\nThis phase determines if certain patient factors are present. A patient has to pass a set of screening criteria to be qualified for the trial.\n\n## Safety phase\nThis phase determines the effectiveness of the medicine at a safe dose. The purpose of this phase is to determine if the medicine is safe and will only result in minor side effects.\n\n## Efficacy phase\nThis phase determines the effectiveness of the medicine at the dose determined in the safety phase. \n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply",
        "label": 0
    },
    "2071": {
        "output": "Question(5) \n\nThe assessment of eligibility has a three-point scale: 0) Excluded, 1) Not relevant, or 2) Eligible. Given the information you have about a patient and a clinical trial, how would you assess the patient's eligibility for the trial?\n<EOD> Impact of HIV serostatus on drug effectiveness in HIV infected patients: a narrative review of recent evidence\n\nHIV infected patients are a high risk population for thrombotic events, due to the interaction between pro-and anti-coagulative mechanisms in HIV. HIV infection has also been related to an elevated prevalence of metabolic alterations and a consequent increased risk of insulin resistance, dyslipidaemia and atherosclerosis. Antiretroviral drugs may affect the serum concentration of a broad spectrum of drugs, often used in combination in clinical practice. The use of direct-acting anticoagulants has not previously been studied in HIV infected patients. Therefore, no clinical practice guidelines currently exists for the treatment of these patients. In light of the lack of robust clinical or drug level data, further studies are required to better determine the optimal pharmacological management of HIV infected patients in need of antithrombotic or antidyslipidaemic treatment.\n\n# Background\nThe thrombotic risk in HIV infected patients has become a prominent clinical problem in a population historically characterized by a thrombotic phenotype [bib_ref]  Elevated risk of myocardial infarction in HIV-infected patients in France, relative to..., Lang [/bib_ref] . In previous clinical studies, HIV was found to be a strong independent risk factor for vascular events and increased incidence of both venous and arterial thrombotic events has been observed in HIV infected patients compared to matched controls [bib_ref]  A meta-analysis of the risk of myocardial infarction in HIV-infected patients. Strategies..., Lang [/bib_ref]  [bib_ref]  Risk of all-cause mortality associated with atrial fibrillation and atrial flutter among..., Cannom [/bib_ref] . The higher incidence of procoagulant events in H",
        "label": 0
    },
    "2072": {
        "output": "## Input a patient note.\n[INST]\nNow we can define a function to generate a patient note to test the model.\ndef patient_note():  \nreturn\n```\n\n## Test our dataset.\n\nIn the folder \"data\" there is a file \"Data.csv\". This is an example dataset which contains two tables.\n`\nPatient Note` Table:\n`ID | Name | FBS | ACE | Chol | HDL | TG | LDL | HIV | Ins | Family | History | Exclude` \n`Age | Sex'` Table:\n`ID | Name | Age | Sex` \n<EOD> RF12 | PSUN288 Causes and Management of Acute Hyperglycaemic Emergencies in a General Medicine Population\n\nClinical Practice and Education RF12 | PSUN288 Causes and Management of Acute Hyperglycaemic Emergencies in a General Medicine Population\nMDMD, CCFACP, CHSEClinical Practice and Education RF12 | PSUN288 Causes and Management of Acute Hyperglycaemic Emergencies in a General Medicine Population\n10.1210/jendso/bvac150Abstract citation ID: bvac150.1294 Presentation: Saturday, June 11, 2022 1:00 p.m. -3:00 p.m., Saturday, June 11, 2022 1:43 p.m. -1:48 p.m., Sunday, June 12, 2022 12:30 p.m. -2:30 p.m. A333 | Journal of the Endocrine Society | https://doi.org/10.1210/jendso/bvac150 J Endocrine Soc, Volume 6, Issue Supplement_1, November-December 2022 A333\nIntroduction: Acute Hyperglycaemic Emergencies (AHE) are challenging to diagnose and manage as they involve multiple organs systems and require rapid treatment with intravenous insulin. Aims: The aim of this study was",
        "label": 0
    },
    "2073": {
        "output": "[[END]] \n- [[TUT_START_1|Go to the beginning of this page]]\n- [[INST_TUT_INCLUSION_CRITERIA|Go to the full explanation of the tutorial]]\n<EOD> Immediate Internal Fixation of Intraarticular Segmental Fractures of the Humerus in Children\nIn a series of 21 children, ranging in age from 2 to 12 years, internal fixation of diaphyseal segmental fractures was attempted immediately after injury. The fractures were placed into four groups: group 1, transverse; group 2, oblique; group 3, spiral; and group 4, oblique-transverse. All fractures were internally fixed with the use of wire or a tension band of a subcutaneous wires. Reduction was assessed on follow-up by measuring fragment angles and the angulation of fracture lines to the radial axis of the humeral shaft. The method of internal fixation of intra-articular, segmental, diaphyseal fractures of the humerus in children is advocated. After application of temporary traction and reduction of the fragments by manipulation, a stable intramedullary canal is established. Internal fixation is carried out immediately after injury. The fixator remains in place only until healing occurs. We feel that prompt operative reduction and internal fixation are of the utmost importance in the treatment of these children's fractures.<EOD> In vitro selection and characterization of small molecules with improved selectivity for the human renin receptor.\nWe describe the in vitro selection and analysis of small molecules with improved selectivity for the human renin receptor (hRR) over the angiotensin type 1 receptor (AT(1)R). A combinatorial library of tetrapeptides containing non-proteinogenic amino acids (D-amino acids, non-natural (N-methyl)amino acids, amino alcohols, and azapeptides) was phagedisplayed and selected for increased potency in the renin receptor agonist screen of Heidari et\u00a0al. (1999). Following subsequent screening, a non-natural cyclic peptide containing D,",
        "label": 2
    },
    "2074": {
        "output": "Exam ples: PART I\n\n### Sample 1\nPart 1. (Part 1). Patient note: \nThe patient is a 27-year-old man with a family history of coronary artery disease. He presents to the clinic with chest stabbing pain that lasts for 15 minutes after exercise. Physical examination and laboratory results are normal, except for elevated cholesterol of 200 mg/dl. He has a normal echocardiogram. In coronary artery function test, he performs an exercise stress test and is interpreted as abnormal based on a positive stress test at 3 months ago. He has a normal exercise echocardiogram test. He takes 80/10 Insulin and also supplements with vitamin D tablets. He states his family history is positive for DM type 1 in his uncle and grandfather.\nHe is diagnosed with type 1 DM and is now included in a clinical trial, he should be given Trial-level eligibility: 2) Eligible.\n\n### Sample 2\nPart 2. (Part 2). Patient note: \nThe patient is a 25-year-old man with type 2 diabetes mellitus. He is taking a combination of oral hypoglycemic agents as his medication for diabetes. He presents to the clinic with chest stabbing pain as a chief complaint. His blood pressure and heart rate are both normal. He undergoes coronary angiography on the same day, and the results are as follow:\nAn angiogram of the right coronary artery (RCA) from 3.0 V to 10.0 V. A long RCA occlusion from 3.0 V to 6.0 V (approximately 2.5 cm). The angiogram shows the short RCA occlusion from segment 9.0 to segment 10.0 (approximately 0.7 cm) with 30% narrowing. Another angiogram shows the mid LAD occlusion from segment 2.0 to segment 3.0 (approximately 0.5 cm) with 70% stenosis. He is diagn",
        "label": 0
    },
    "2075": {
        "output": "### Evaluation\n\nYou should first define the name of a script.\n\n```\n$ mkdir script.rb\n\nscript.rb:\n  puts \"Hey! This is a test!\"\nend\n```\n\n```\n$ ruby script.rb\nHey! This is a test!\n```\n\nNow let's define your evaluation script.\n\n```\n$ ruby -e eval_script.rb\n```\nEvaluation script:\n\n```\neval_script.rb:\n  puts \"Hey! This is a test!\"\nend\n```\n\n```\n$ cat eval_script.rb\nruby -c eval_script.rb\n```\n\n```\nHey! This is a test!\n```\n\n### License\n\nMIT License\n\nCopyright (c) 2022 <EMAIL>\n\nPermission is hereby granted, free of charge, to any person obtaining a copy\nof this software and associated documentation files (the \"Software\"), to deal\nin the Software without restriction, including without limitation the rights\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\ncopies of the Software, and to permit persons to whom the Software is\nfurnished to do so, subject to the following conditions:\n\nThe above copyright notice and this permission notice shall be included in\nall copies or substantial portions of the Software.\n\nThe Software is provided AS IS, WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN\nTHE SOFTWARE.\n\n[END]",
        "label": 1
    },
    "2076": {
        "output": "### 24. Evaluating the Trial-Level Eligibility, part II ###\n\nTo evaluate the trial-level eligibility for each patient note, we will first read in a patient note (e.g., `fns_dummy [2]`), then parse out the required values and evaluate the trial-level eligibility. The patient note structure is defined as follows.\n\n\n\n<pre class='highlight'>def FNS:\ndef FNS(fns):\nfor item in fns:\n    line = unpack_patient_note(item)\n    print(fns_dummy.cP1[:] + line)\n    parse.parse_fns_dummy_p(line, fns_dummy).evaluate_trial_eligibility_p_list_p(fns_dummy)\n# for patient note\n    \nfns = pathlib.Path('data/fns')\nFNS(fns)\n</pre>\n\n\n\n<pre class='highlight'>for trial in trial_list:\n        # Assign the patient note to patient_ids\n        patient_ids = []\n\n        # Read the patient note\n        patient_note = unpack_patient_note[fns.join('/', patient_id, trial.ID)]\n\n        # Assign the title to trial_title\n        trial_title = \"Trial-level eligibility evaluation for {trial_ID}\".format(trial_ID=trial.ID)\n\n        # Evaluate the trial eligibaility\n        evaluation = Trial_level_eligibility(patient_note, trial)\n\n        # Append the evaluation to result.csv\n        result.append(evaluation)\n\nresult = pd.DataFrame(result)\n\ndef Trial_level_eligibility(patient_note, trial):\n    # Define functions and set default\n    eligibility_score = score_eligibility()\n    return eligibility_score(patient_note, trial)\n</pre>\n\n<NAME>.**[REF-7]** \n<EOD> Combination of BRAF Inhibitor and MEK Inhibitor Combinatorial Therapies to Manage Cancer Cell Resistance",
        "label": 0
    },
    "2077": {
        "output": "<h3>SUPPORTING NOTES ON THE FIRST STEP: IMMUNOGLOBULIN AND FAB</h3><p><img src=\"https://github.com/alavianin-lab/EliqAss/blob/master/Immuno.png\"/><br><br><br>After defining your immunoglobulins and Fabs, the immunodetection is ready. All you need to enter now is the sequence of the immunoglobulin that will be your primary antibody. </p><p>For example, if I want to test my anti-A peptide, I need to write`pAb: anti-Apeptide Ab` and I only have to define an immunoglobulin for the primary antibody, without Fabs, <i>i.e.,`pAb: IgG`</i>.</p><p>To do that, click on the IgG icon in the right corner of the Immunoglobulin box . This shows a dialog box for selecting an immunoglobulin for your primary antibody.</p><div class=\"alert alert-info\"><b>Tip:</b> You may add as many Fab chains to your primary antibody as needed.</div><h3>TIP ON THE FIRST STEP: MORE ON FACTOR</h3><p><img src=\"https://github.com/alavianin-lab/EliqAss/raw/master/factors.png\"/><br><br><br>You can also set the factor (type) of the factor to 1 or 6.</p><p><br>If the factor is 1, your primary has only one sequence and thus is an IgG light chain. If the factor is 6, your primary has six sequences and thus is a polyclonal. That is, a mixture of six IgG light chains.</p><p><br>The polyclonal option of EliqAss is for those who are not sure of the type of sequence they have, or have many types in their primary antibody (some IgG1, IgG2b, IgG2a kappa, etc.).</p><h3>SUPPORTING NOTES ON THE SECOND STE",
        "label": 2
    },
    "2078": {
        "output": "Good luck!\nAuthor contributions\nConceptualization: Hadi Abbasi.\nData curation: Hadi Abbasi.\nFormal analysis: Hadi Abbasi.\nInvestigation: Hadi Abbasi.\nMethodology: Hadi Abbasi, Samira Ehsan.\nSoftware: Hadi Abbasi.\nSupervision: Hadi Abbasi, Hossein Jazayeri, Hossein Vahedi.\nValidation: Hadi Abbasi.\nVisualization: Hadi Abbasi, Hossein Jazayeri, Hossein Vahedi.<EOD> The Malignant and Insidious Characteristic of Acute Myocardial Infarction with Non\u2014ST Elevation Aged over 40 Years Old\n\nDuring the acute myocardial infarction patient treatment, the complications of sudden cardiac death, ventricular arrhythmia, sustained ventricular tachycardia, heart failure are the most important causes of death, and the time to initiate reperfusion in 1 hour is the key to patient's survival. The aim of this study is to compare the effects of thrombolytic and early angioplasty in the patients suffering from acute myocardial infarction with non-ST segment elevation. One hundred and eight patients hospitalised because of myocardial infarction with non-ST segment elevation and aged over 40 years old have been analysed. The patients were divided into three groups. In the first group which consists of 34 patients thrombolytic was used, in the second group reperfusion was achieved using percutaneous transluminal coronary angioplasty in 40 patients. In the third group 34 patients were treated without reperfusion. It was found that the patients which were subjected to angioplasty, demonstrated significantly higher survival rate. In the group of patients treated with thrombolytic no significant decrease of mortality could be observed as compared with the patients from this group without thrombolysis. The patients treated with angioplasty demonstrated statistically significantly lower mortality in contrast to the patients which were subjected to thrombolytic. However, the analysis of survival rate after application of percutaneous transluminal coronary angioplasty on the background of",
        "label": 0
    },
    "2079": {
        "output": "## Q1: [INC] You can only enter one line for a patient per trial. However, you can include multiple separate lines for the same patient within the same trial if multiple lines are needed to fully describe the patient's status in the trial.  \n\nWhat is a line? This corresponds to a single patient note for that patient per the clinical trial. One patient may need multiple notes to fully describe the patients' inclusion/exclusion in the clinical trial.\n\nTo illustrate this example, the patients need (2-3) lines for each trial. In this case, lines that indicate that the same patient participates in two different trials with different inclusion / exclusion criteria. These lines can be represented in the same way as in Question 1.\nExample for a patient that has 3 lines:   \n![244][1]\n\n**1) 25-year-old man with type 1 Diabetes**\n\n\n\n**2)** Diagnosed with atrial fibrillation \n\n\n\n**3)**  A 25-year-old male with type 1 Diabetes mellitus who was diagnosed with heart failure with preserved ejection fraction (EF \u2265 50%) during the previous hospital admission and was discharged to follow-up at the outpatient clinic, who is a candidate for a randomized controlled clinical trial (RCT) to compare the efficiency of SGLT-2i in the treatment of heart failure with preserved ejection fraction based on BNP:\n\n[245][2]   \n![245][2]\n\n**3)  A 25-year-old male with type 1 Diabetes mellitus who was diagnosed with heart failure with preserved ejection fraction (EF \u2265 50%) during the previous hospital admission and was discharged to follow-up at the outpatient clinic, who is a candidate for a randomized controlled clinical trial (RCT) to compare the efficiency of SGLT-2i in the treatment of heart failure with preserved ejection fraction based on BNP: \n\n**4)** He has an EF \u2265 50% and the BNP value is 1900 pg/ml** \n\n**3) ** He has an EF \u2265",
        "label": 0
    },
    "2080": {
        "output": "*\n\n*If there are missing values/missing values, you should repeat `Trial-level eligibility: 0) Excluded.`.\n\n*If there is `if` and `else if`, the output should be repeated `Trial-level eligibility: 1) Not relevant.`.\n\n*If there are multiple statements, repeat `Trial-level eligibility: 2) Eligible.`.\n\n*If there is an `if` statement about `if` is true, we must repeat `Trial-level eligibility: 1) Not relevant.`.\n\n*If the case is not available, you can set the default as `Trial-level eligibility: 1) Not relevant.`.\n<EOD> 210 kHz focused surface acoustic wave biosensor as a microfluidic detector.\nWe designed and demonstrated a fully integrated 210 kHz focused surface acoustic wave (SAW) sensor system, as an inexpensive lab-on-chip system, which enabled biochemical reactions while performing high-frequency SAW measurements (sensitivity of 286 Hz per pg of protein). This was accomplished with the incorporation of a microfluidic channel made of polydimethylsiloxane (PDMS). High-frequency responses were measured by using phase-locked loops (PLLs), composed of low-speed field programmable gate arrays and a high speed direct digital synthesizer. The measured phase responses of the SAW device in the absence and presence of 1 ng/mL BSA were -44.15 \u00b0 and -24.96\u00b0, respectively. A sensor chip was designed and fabricated using a complementary metal-oxide-semiconductor process. This sensor system also had a 1:10 gain between the SAW wavelength (l) and the distance (x) to the sensor. The sensor system was capable of detecting BSA at concentrations as low as 1 ng/mL and had a dynamic range of 0.5 to 10 mL.<EOD> Methionine 12 mutations enhance prion propagation.\nHuman Prion Diseases are caused by missense mutations or deletions of the PRNP gene. These mutations cluster",
        "label": 0
    },
    "2081": {
        "output": "[bib_ref]  Triage and Evaluation of Patient Recommendations for Clinical Studies, Cutter [/bib_ref]  \n\n![INST]: A sample report with the patient note for a patient who needs to be excluded. The reason of exclusion is a pregnancy.\n\n## Clinic 2 \nA doctor in the Clinic 2 is the head of the cardiac surgery. The doctor is a professor in the University of California, San Francisco. The clinic receives a large number of patients with many diseases daily. The patients need the help of the machine for the assessment.\nYou should assist the doctor in the assessment of a patient. In the first place, you should be familiar with the clinic's rules. So, the first rule will be explained. \u274f The machine is for research purposes. \u274f There is no need of any insurance or guarantee in this case. \u274f This is not a diagnostic device. It is an experimental device. \u274f The equipment can cause some harm and some risk is inherent to any research with any new technology as the one in this case. \u274f Clinical data is confidential. \u274f All the patients are guaranteed to get an equivalent standard of care.\nOn that basis, the doctor decides to use the machine on the patient. \u274f The patient is a 43 years old woman with hypertension, myocardial infarction, insomnia, high cholesterol and low potassium levels. The patient is on angiotensin receptor antagonists and calcium channel blockers, anticoagulants, diuretics, antiarrhythmics, norepinephrine, calcium channels, glucosamin and insulin for controlling her disease. \u274f The patient needs a heart surgery and the machine's results are required prior to the operation. \nThe doctor's decisions to use the machine on the patient are:\n\n### 1) \ud45b = 0 (excluded by the doctor); 2) \ud45b = 1 (not relevant by the doctor); 3) \ud45b = 2 (eligible by the doctor).\nSo, you should make a trial-level assessment and make the necessary dec",
        "label": 0
    },
    "2082": {
        "output": "",
        "label": 0
    },
    "2083": {
        "output": "(/inst) section.\n\n### Export\n\nCopy the whole folder `manage.py` to your work folder.\n\n# Tutorial\n\n# Mini\n\n## Prospective study patient note input\n\n### Inputs\n\n![instru",
        "label": 0
    },
    "2084": {
        "output": "__NOTE__ If the input data, i.e. patient note and clinical trial is larger, you can provide them on a separate worksheet, i.e. patient Note and Clinical Trial. You must always use the same folder name for both worksheets. [INST] <EOD> A novel strategy of genome-wide association and genomic breeding value prediction in multi-population chinese indigenous beef cattle breeds\n\nThe objective of this study was to identify novel candidate genes and develop genomic prediction models in three Chinese indigenous beef breeds, i.e. Chinese Angus, Nanyang, and Wagyu cattle. Genome wide data were collected from 1,154 individuals including phenotypes for 12 traits, pedigree information and genotypes of 533,562 single nucleotide polymorphisms (SNPs). Association analyses identified 56 SNPs distributed on 15 chromosomes and explaining 0.4-1.5% phenotypic variance for seven studied traits including growth and meat quality traits. The identified candidate SNPs mainly fell within 9 genes involved in the muscle and fat development, as well as milk synthesis. Genomic estimated breeding values (GEBVs), which are based on genome-wide SNP data, showed high accuracies (~0.6-0.8) across three breeds. The comparable accuracies were achieved by combining all SNPs located within regions defined by GWAS hits. Furthermore, the accuracies from all-SNPs rated only three to six points lower than those achieved using SNPs with minor allele frequency >0.05 and located within regions defined by GWAS hits. Prediction models, with more SNPs of non-high density panel but covering similar genomic regions detected by GWAS, produced accuracies that were comparable to those based on highdensity data. Our results suggest that genome-wide association analyses and genomic prediction models using novel candidate genes may accelerate genetic improvement of economic traits in multiple breeds, especially in low-scale livestock industries in developing countries.\n\n# Introduction\nThe breeding goals for indigenous beef cattle (also named Chinese Indigenous",
        "label": 0
    },
    "2085": {
        "output": "Copy pasting of the above source code will generate the following code for running locally.<br>\n\n~~~\ndef outputAllData(test_data):\n    #output variables \n    output = []\n    #output 1 \n    trialscreen_name = input('Input trial screen name: ')\n    print(f'\\n[TEST] In the following lines you need to enter your  data to run\\n')\n    print('')\n    print(f'\\n[TEST] Please find here the input boxes for your desired data!\\n')\n    test_data_1 = Trial_type() \n    print('')\n    print(f'\\n[TEST] Now that you've entered your data here, you should paste it in the code to be executed.')\n    test_data_2 = Trial_name()\n    print(f'\\n[TEST] Now that you've entered your data here, you should paste it in the code to be executed.')\n    test_data_3 = Trial_trial.title()  # input trial name\n    print(f'\\n[TEST] Now that you've entered your data here, you should paste it in the code to be executed.')\n    test_data_4 = Trial_summary().title()  # input summary\n    print(f'\\n[TEST] Now that you've entered your data here, you should paste it in the code to be executed.')\n    test_data_5 = Trial_inclusion_criteria().title()  # input inculcation-exclusion criteria\n    print(f'\\n[TEST] Now that you've entered your data here, you should paste it in the code to be executed.')\n    test_data_6 = Trial_inclusion('patient id').trial_exclusion()   #inputinclusion-exclusion criteria of patients\n    print(f'\\n[TEST] Now that you've entered your data here, you should paste it in the code to be executed.')\n    test_data_7 = Trial_inclusion['patients name & gender'].trial_exclusion()  #inputinclusion-exclusion criteria of patients\n    print(f'\\n[TEST] Now that you've entered your data here, you should paste it in",
        "label": 2
    },
    "2086": {
        "output": "Exercises\n<exercise id=\"A43\" title=\"Clinical trial 4-3\">\n\nYou want to calculate your exercise score by using your points for all three tasks in this challenge as follows:\n<solution id=\"A2.Solution15\" score=\"0\">\nPoints: \n\nExercise 1:\nTrial-level eligibility: 3) Eligible\n\n[INST] \nLet's think step by step. \nFirst, you should select the name of the current trial using the variable $clinical_trial_object. Then, you should calculate the trial score variable and then the score of each factor using this variable and its value, if you use factor 1, then you should add score 2, 2, 4, 3 and 2 for gender, age, disease history, and treatment history, respectively.\n\n```\n$score = $clinical_trial_object->eligibility\n\n$score1 = 4\n$score2 = 4\n$score3 = 3\n$score4 = 2\n$score5 = 0\n\nif ($gender == 1){\n    $score += 2;\n    $score_f1 = $score1*$score;\n    \n}\n\nif ($age >= 38){\n    $score += 6;\n    $score_f2 = $score2 * $score;\n}\n\nif ($sexhistory !== \"\"){    \n    if ($sexhistory <= \"3\" || $sexhistory > \"8\"){\n        $score += 4;\n        $score_f3 = $score3 * $score;\n    }\n}\n\nif ($diseasehistory !== \"\"){    \n    if ($diseasehistory == 2){\n        $score1 += 4;\n        $score3 = $score2+$score1+$score3+$score4;\n    }\n}\n\nif ($treatment != \"no\") {\n    $score += 2;\n}\n\nif ($clinical_trial_object->eligibility == 'eligible') {\n    $score +=3;\n    $score4 = $score1 + $score2 + $score3 + $score",
        "label": 0
    },
    "2087": {
        "output": "[Inst]\nCoding instructions: You will be shown a patient note. Enter all the conditions needed to assess the patient's eligibility against those criteria. Enter 21-22 words for each condition. Make sure the output is similar to the expected answer.\n\n\n[END]\n\n\n\n\n\nYou will be able to submit up to 2 problems for 1 patient only. Please submit your latest code in the code input box shown below.\n\n\n\n\n<input type=\"hidden\" id=\"new-problem-token\" value=\"3B6AAB63\">\n<script>\n var newProblem = document.getElementById(\"new-problem-token\").value;\nif (document.getElementById(\"problem-submit\").type === 'submit') {\n  $.ajax(\n    {\n      url : '?s=new_problem&p=' + newProblem + '&new=1',\n      dataType: 'json',\n        success : function(data,statusText){\n          //if problems exist on the page, the problem ID will be '3B6AAB63'\n          if (data === undefined || data.length === 0) {\n            alert(\"There has been an error in the server.\");\n          }\n          else {\n            if (data[0].sub_title === undefined || data[0].sub_title === null || data[0].sub_title === \"\"){\n              data[0] = {};\n            }\n            else{\n              if(data[0].sub_title === \"Problem not available\"){\n                alert(\"You must submit code for a different patient in order to submit another problem.\\nProblem number: \" + newProblem);\n              }\n              else{\n                if(data[0].sub_title === \"Problem has already been submitted\"){\n                  alert(\"Error in the server. Please wait or try again later.\\nProblem number: \" + newProblem);\n                }\n                else{",
        "label": 0
    },
    "2088": {
        "output": "**Please leave your comments below**\n<EOD> Chondroma of the larynx\nThis paper presents the case of chondroma of the larynx in an 82-year-old man. We discuss the importance of this rare disease and discuss its etiology and histological features.<EOD> A comparison of the quality of the diet of African-American adults with cancer and adults with no known risk of developing cancer.\nOBJECTIVE\nWe examined associations between cancer status and diet quality, and we identified demographic and socioeconomic factors associated with healthy eating behaviors among African Americans.\n\n\nMETHODS\nWe compared responses of African-American participants in the Baltimore Epidemiologic Catchment Area Study, 1993-1997, who were either not at high risk (n = 112) or at high risk (n = 123) for developing cancer.\n\n\nRESULTS\nParticipants at high risk for cancer were more likely than participants not at high risk to eat fruits and vegetables and to eat meals with their families. We found no differences by cancer risk in the prevalence of being physically active or having meals served by family members. We also found many similarities in the associations between sociodemographic factors and healthy behaviors. Family meals were more common in families with older mothers, lower average family income, and higher education. Having a regular source of fruit and vegetables was more common among those older and who had higher levels of education.\n\n\nCONCLUSIONS\nThese results point to the importance of family support in eating behaviors.<EOD> CYPOR Is Upregulated by Glucose Stimulation in Inguinal White Adipose Tissue of Diet-Induced Obese Mice\n\nCyclooxygenase (COX)-2 converts arachidonic acid to PGG2 and PGH2 after which the former is converted in three different enzymatic reaction to PGs. COX-2 is the rate-limiting enzyme for the production of PGs, and it is known that COX-2 expression is upregulated in adipose tissue of obese-mice. However, a series of researches have shown that the expression of CYP4",
        "label": 0
    },
    "2089": {
        "output": "Please see more details about the assessment of eligibility in a clinical trial note or a clinical trial dataset in the following links:\n<EOD> Recombinogenic cell transformation of human T lymphocytes by DNA damaging agents and phorbol ester.\nIt is suggested that the activation of transposable elements of DNA in differentiated cells may play a role in cellular transformation, an essential event in carcinogenesis of humans. This suggestion is supported by this study in human T lymphocytes. Human T lymphoblastoid cell lines of either MHC-identical or -different individuals have been isolated. Their chromosomal complements were analyzed to provide the chromosomally integrated transposable element as the marker to reveal the transposon activation after transformation. The lymphoblastoid cells were treated with a DNA-damaging agent, bleomycin, and a chemical carcinogen, N-methyl-N-nitrosourea (MNU). These treatment caused cells to produce sister chromatid exchanges of chromosome 7 and the transposon activation, which were determined by the increased reparation of sister chromatid gaps. When the transformed lymphoblastoid cells were treated with propylene glycol, the increased reparation of chromosome 7 and transposon was stimulated. The propylene glycol treatment also caused an increase in the mitotic indexes of these cell lines, although the bleomycin- and MNU-treated cell lines were arrested at the G1 stage. On the other hand, phorbol ester, phorbol- 12-myristate-13-acetate, induced an immediate burst of DNA synthesis. It is suggested that the transposon activation of human T lymphocytes is the major early step in carcinogenesis.<EOD> .\nAlthough most cases of spontaneous retroperitoneal hemorrhage are caused by an arterial bleeding source, there may be secondary effects of spontaneous retroperitoneal hemorrhage due to rupture of an abdominal aortic aneurysm (AAA). In the following case report, spontaneous retroperitoneal hemorrhage caused by rupture",
        "label": 2
    },
    "2090": {
        "output": "[INST] After obtaining the clinical trial eligibility, we should evaluate the safety issues to determine whether the trial is eligible for this patient. The patient notes for the clinical trial of the safety issues are as below:\n\n    Diagnosis: Insulin dependence\n    History: Started on oral hypoglycemic drugs (OHD) 2 years ago, and when the effect didn't last, she was transferred to insulin therapy.\n    Family history: Insulin-dependent diabetes mellitus in the family member.\n    Laboratory study: FBS: 400 mg/dl\n    HbA1c: 10.5%\n    Cholesterol: 185 mg/dl\n    TG: 135 mg/dl\n    LDL: 145 mg/dl\n    HD",
        "label": 0
    },
    "2091": {
        "output": "<EOD> Ovarian carcinomas express osteopontin in vivo: implications for the role of bone metastases in the pathogenesis of ovarian cancer.\nOsteopontin is a phosphoserine- and asparagine-rich matrix glycoprotein involved in the control of differentiation and biological activities of bone cells, its bone-tumor-host interaction mechanism. It is also involved in cell-to-matrix-matrix interactions and is the substrate of bone matrix-degrading enzymes. The authors showed that expression patterns of osteopontin in human ovarian carcinomas mirror the degree of malignancy. Therefore, osteopontin may be a significant molecular marker in the identification of ovarian cancer cells that have the propensity to metastasize to bone.<EOD> The Influence Of Fiber Size On Bone Grafting Material Properties and Their Potential Applications\n\nBackground: Fiber sizing of allografting fibers has become increasingly important.Objective: This study aimed to compare and evaluate the influence of fiber sizing on the properties of bonesubstitute fibers.Materials and Methods:Fiber sizing was performed using resin-based polymer and liquid sizing materials. The mechanical properties of fibers sized with the two materials, along with their surface roughness, were determined, and their compressive strength values were identified as well.Results:The average values of the maximum tensile load and breaking load of fibers sized with resin-based and liquid sizing materials are 4271 Newtons (N) and 3200 N, and 1263 N and 658 N, respectively. As for the tensile rupture strengths, the values are 87.14 N/ mm 2 and 136.86 N/mm 2 , and the roughness parameters of fibers are found to be 11.3 \u03bcm and 22.4 \u03bcm, respectively.Conclusions:While resin-based resin treatment of fibers was seen to increase the compressive strength and tensile rupture strength of fibers, it did not have an effect on surface roughness. (Aust N Z J Med Radiat On",
        "label": 0
    },
    "2092": {
        "output": "Here is the patient note again:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dlHere is the clinical trial: \nTrial-level eligibility: 1) Not relevant\nOutcome: 1) Excluded<EOD> A Case of Post-COVID Long-Haul Fatigue with a Peculiar Response to Recombinant Human Growth Hormone Treatment\nWith the COVID-19 pandemic, a new condition-post-COVID long-haul fatigue (PCF)-has been observed in some patients. PCF is defined as the presence of fatigue in a wide range of severity and durability that persists at least 4 weeks after infection. Furthermore, PCF has been described postviral infection (e.g., Ebola, H1N1 influenza, and SARS), raising the question of the pathophysiology of this disease. In this case, we present a man with PCF for six months who did not respond to pharmacological therapy and was admitted to our hospital for intravenous recombinant human growth hormone administration. At the beginning of the therapy, no significant response was observed. However, after five infusions of recombinant human growth hormone, the patient reported to",
        "label": 0
    },
    "2093": {
        "output": "# <NAME>\n\n\n<EOD> .\nOBJECTIVE\nTo study the expression of B cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3, survivin and phosphorylated signal transducer and activator of transcription 3 (p-STAT3) in ovarian cancer and its relationship with tumor clinicopathologic features.\n\n\nMETHODS\nImmunohistochemistry was performed to assess the expression of Bcl-2, Bax, caspase-3, survivin and p-STAT3 in ovarian cancer with paraffin-embedded tissue specimens obtained from 123 ovarian cancer patients treated in Qilu Hospital of Shandong University (Qingdao Campus) between 2011 and 2014. The correlations of protein expression and clinicopathologic characteristics were analyzed.\n\n\nRESULTS\nAmong the patients, 61 (49.6%) were determined to have positive Bcl-2 expression, 58 (47.2%) had positive Bax, 40 (32.5%) had positive caspase-3, and 45 (36.6%) had positive survivin; 21 (17.1%) had positive p-STAT3 expression. The expression of Bcl-2 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) Stage, histological type and lymphatic metastasis but not with age, tumor histological grade and tumor size. The expression of Bax was significantly associated with tumor histological grade, FIGO Stage and lymphatic metastasis but not with age, tumor size and histological type. The expression of caspase-3 was significantly associated with tumor histological grade, FIGO Stage and lymphatic metastasis but not with age, tumor size, and histological type and lymph node metastasis. The expression of survivin was significantly associated with tumor histological grade, FIGO Stage and tumor size, but not with age, histological type, tumor histological grade, and lymphatic metast",
        "label": 0
    },
    "2094": {
        "output": "If your input doesn't match completely any pattern, in your input, it produces an alert with the following text:\n\n[Error] Wrong pattern to input.\n![Wrong pattern](https://user-images.githubusercontent.com/10057007/116161870-cc086480-adee-11eb-82b8-750586c8e595.png)\n\nThis error will continue to show for 25 seconds until you fix your mistake. \n<EOD> In vitro assessment of drug metabolizing abilities of hepatocytes from a patient with drug-resistant tuberculosis receiving long-term antituberculosis treatment.\nElevated serum level of isoniazid, one of the most active and widely used antituberculosis drugs, may result in severe toxicity with a significant incidence of drug resistance, which leads to a reduced life span or death of patients with highly chronic diseases including cancers, and aids and tuberculosis (TB). Therefore, the need to determine suitable hepatocytes from patients with TB for drug screening or toxicological assessments. In this in vitro study, we attempted to characterize hepatocytes isolated from a patient with drug-resistant pulmonary TB undergoing long-term anti-TB treatment. At various stages of isolation, characterization, and purification, we evaluated drug-metabolizing capacities according to cytochrome P450 (P450) immunostaining, the activity of cytochrome P450 reactions, and the production of metabolites. Results from all parameters from the patient showed an expected level of specific activities, in which CYP3A- and CYP2C9-mediated metabolic activity, respectively, remained unchanged compared to control liver tissue and were lower than those found in other samples, but the immunostaining patterns of P450 were similar among all donors regardless of differences in the duration of anti-TB treatment. Our data indicate that the hepatocyte isolate obtained from the patient with drug-resistant pulmonary TB was fully functional as a hepatic microsomal model when used in drug met",
        "label": 0
    },
    "2095": {
        "output": "## \ud83d\udd8b\ufe0f WRITE A REPORT DURING THE GRADING SESSIONS\n\n\nIn this chapter, you will learn how to write a report, the essential element for final assessment. Through these steps, you can practice writing reports independently. \n\n\n1. **STEP 1: BE CLEAR ABOUT YOUR OBJECTIVE.**\n\nWrite your report's main objective.\n\n\n\n\n**STEP 2.** EXPLAIN YOUR JUMP POINT, SITUATION, PROBLEM, AND CONCLUSIONS. Describe and organise your report step by step.\n\n\n **STEP 3: REFERENCE YOUR SOURCES.** Reference each part of your report. Remember to cite sources correctly while writing your report.\n\n\n **STEP 4: PROVIDE GUARDS FOR A WIDE AGE RANGE.** In a data mining course, we do not have an age filter for the dataset. To overcome a problem with a dataset that represents a very specific population, you should expand the target population or build a customised model by including demographic predictors in ML algorithms, e.g., age and gender. \n\n    \n   \n   \n          **SORRY, NO JOB FOR YOU!!**\n   \n    You should build your own model from scratch, including data manipulation and model construction. The model has not been validated yet. Your main objective is to be able to predict the job, not to recommend a job.\n\n\n\n\n     \n   Slide 1\n     \n   \n      \n   ```r\n   model<-c(\"job\" = predict(mt2_0, type = 're'), \"age\" = \"job\", \"gender\" = \"job\")\n   df0<-dat_0[,-c(age, gender, age:gender)] \n   model_list<-list(\"dat\" = df0, \"model\" = \"0.606\", \"title\" = paste(\"Age, gender, and age:gender predict job\"))\n   new_title <-paste(\"Age, gender and age:gender predict job \" , paste0(\"-\", round(summary(glm(job~age:gender, data=df0,method=\"",
        "label": 0
    },
    "2096": {
        "output": "Copy the following Python code to a notebook and execute it. Please see the following screenshot.  \n\n\n<EOD> Cholera toxin increases the sensitivity of the T-cell receptor but not the IgE receptor to pectin.\nIgE-containing lipid-insoluble pectin-specific rat basophil leukemia (RBL) RBC 1 mast cell lysates were reconstituted by the use of exogenous pectin. In the presence of cholera toxin (CT), the concentration of pectin required for half-maximal sensitization (EC50) for specific binding of pectin was reduced from 106 to less than 2 g/ml. The CT effect was reproduced by pretreating RBC with dithiothreitol but not with 1-h tunicamycin, an inhibitor of N-glycosylation. Sensitization with CT led to a 10-fold increase in IgE-receptor affinity for pectin, as compared to non-CT-reconstituted IgE lysates as judged by pectin elution experiments. The effect of CT on receptor affinity could be reproduced by exogenous pectin (but only in the presence of CT). Sensitivity of the T-cell receptor on CT + dithiothreitol reconstituted T cells was increased 9-fold as compared to sensitivity of non-CT-reconstituted T cells, as measured using specific anti-V beta 8 monoclonal antibodies. Cholera toxin increases the sensitivity of pectin to the receptors of T-cell line 1.4 and IgE-bearing rat basophil leukemia cells by a mechanism other than an altered glycosylation.<EOD> Bacterial contamination of laryngeal masks and cuff leaks.\nFollowing an initial study published in Anaesthesia (July 1994) which suggested that bacterial contamination of laryngeal mask airways (LMAs) is a problem, we undertook a large prospective study to determine if bacteria could be recovered from the interior of the cu",
        "label": 0
    },
    "2097": {
        "output": "You should make an input file for the assessment phase. It is important that you follow the correct format. You should make the file name same to the given clinical trial code.\nAlso make sure you write the format. Assessment: This is the format of input file and the example is shown below. Note that the format contains two columns. Please make a file that is in the same format: input_file:\n\n\n$code (e.g., a5211b) # The clinical trial's unique identifier, written as in \"Clinical trials\" tab, like \"5211\" (e.g., C5211) $eligibility (e.g., 1) 113 (e.g., 0113_42) # Note: We recommend you to use a unique identifier in the format `NNNNNN`_`NNNNNN`_`NNNNNN` (e.g., 0113_42) # A unique number code assigned to each study in a clinical trial, the ID of assessment file output. Note that for a trial named, a5211b, the trial ID code is 0113_42 (e.g., 211b_42), for a trial named ac5211, the trial ID code is 312_44 (e.g., 5211_44), and for a trial named mwj457, the trial ID code is 4785_10 (e.g., 457_10) . Example 2: \t $ex1_pat (e.g., p1) $ex2_pat (e.g., p2). \n\n\n* Input file Example\n* [TEST] [0113_42] 113 0113_42 0113_42_312_13_9\n\n* Example\n*  $code (e.g., a5211b) 113 (e.g., 0113_42) 0113_42_312_13_9 (e.g., 312_44_1",
        "label": 0
    },
    "2098": {
        "output": "You're done! \n\n\n<EOD> The use of transanal endoscopic microsurgery for the treatment of perianal and rectal cancer: personal experience.\nBACKGROUND\nTransanal endoscopic microsurgery (TEM) has been successfully used for the treatment of perianal and rectal benign lesions. Preliminary reports in the literature seem to support the use of TEM even in perianal and rectal malignant tumors.\n\n\nAIM\nTo assess the safety and efficacy of TEM for the treatment of perianal and rectal cancer.\n\n\nPATIENTS\nBetween 1994 to 2003 twenty nine patients underwent TEM for perianal and rectal cancer, including four patients with recurrent disease.\n\n\nMAIN OUTCOME MEASURES\nHistological evaluation, surgical morbidity, recurrence rate and median survival.\n\n\nRESULTS\nOverall morbidity was 55%, being the most common complication hemorrhage in 35% followed by rectovaginal fistula (4%). No perioperative mortality was observed. The overall recurrence rate was 20.7% with a median disease-free time of 15.4 months. No recurrences occurred in the superficial margin. One-year survival rate was 87%, two-year survival rate 82% and five-year survival was 75%. The patients with metastatic disease showed 100% of overall recurrence and median survival of 13 months.\n\n\nCONCLUSION\nTEM seems to be a safe procedure for the treatment of selected perianal and rectal cancer. The resection status is most probably the most important prognostic factor for recurrence and survival rates in perianal and rectal cancer. TEM can be used for the treatment of perianal and rectal cancer. More extensive studies with larger cohorts of patients with long follow-up are needed to compare its effectiveness for recurrence and long-term survival.<EOD> The Risk and Risk Factors Related to Depression in Patients Undergoing Hemodialysis Treatment\nBACKGROUND: There is a significant",
        "label": 0
    },
    "2099": {
        "output": "##[[INST]\nYou are an immunologist. A patient has just been diagnosed with rheumatoid arthritis. She is looking for a clinical trial with a targeted biological therapy to see if it might help her treat her rheumatoid arthritis. She has been on conventional disease-modifying antirheumatic drugs (csDMARD) but has had no response or has experienced side effects.\n\nHere are her eligibility screening report:\n\n\nYou should first read and understand the eligibility screening form. To save time, you can use the mouse shortcuts listed below to navigate between sections and answer the eligibility questions when appropriate. You can also use the mouse shortcuts and go back by using the BGo to previous question^button.\n\n### Patient Information (Page 1)\nEnter Your Patient's Information\n- Enter your patient's first and last name.\n- Include the patient's sex.\n- Enter the patient's date of birth.\n\n### Eligibility Screening (Page 2)\n\n### Reason for Visit (Page 3)\n\n### Eligibility Screening CheckBoxes (Page 4)\n\n### Patient Summary (Page 5)\n\n### Insurance Information (Page 6)\n\n### Patient Contact Information (Page 8)\n\n### Eligibility Results\nHere is the list of exclusion criteria:\n- Females of childbearing potential 19 years of age\\u201314 years of age (inclusive) must use adequate contraception during treatment and for 2 to 3 weeks prior to treatment, during the treatment follow-up visits and for 1 month following the last day of treatment.\n- Females 15\\u201318 years of age\\u20132 years of age at the screening visit, who do not meet one of the above eligibility options and who do not consent to use one of the following highly effective family planning methods: IUD, hysterectomy, bilateral oophorectomy or vasectomized partner\\u2013 must agree to use at least one highly effective method of contraception",
        "label": 0
    },
    "2100": {
        "output": "We use the first line for the eligibility criteria description and the other lines for data values.\n\n## [PROCESSING DATA]\nNow, enter all the data of the patient's medical record and the clinical trial data in the spreadsheet. Here is an example, but it may contain many patients, and the data can be filled manually or through the data scraping technique. We define the labels for the input values as follow:\n\n## [ENDSPEED]\nThe final step is to assign the label for the trial's selection. To do this, we need to create a dataframe containing the data of the training and test samples and their corresponding class labels (as shown in . Note that the class labels correspond to the class index of the trial (e.g. `0 -> Excluded; 1 -> Not relevant; 2 -> Eligible`). To do this, we create a dataframe called `TrialDf` as the input data which has four columns: the clinical trial number, the data value of the label, and the data values of the data column. Then, we create a dataframe called `TrialSelDf` which contains the class index, trial number, and dataset. The data columns of these two datasets are identical (i.e., the data variables of the selected trial are exactly the same as the ones of training and test data) to create the training and test data subset.\nHere is an example of `TrialDf` and `TrialSelDf`:\n\n# [TRAINING DATA]\nNow let's create an `X_train` and an `X_test` as data matrices in the training and test data subsets, respectively. As they refer to the same data variables of the `TrialDf` dataframe, you must change `TrialDf` name to train and test names. We first define train and test matrices where we store trials that meet the specified conditions. Then, we assign the values of all variables of these two matrices, except the trial's label and the clinical trial number which would not assign them to any value. To do this, we apply the function `get_feature_data()` which allows us to build the `X_train` and `X_test`. We then create an `X_train` and `X_test` using the `X_train` and `X_test`",
        "label": 0
    },
    "2101": {
        "output": "## [/inst]<EOD> Erythrocellular acanthosis secondary to chronic sun exposure: A newly described entity\nErythrocellular acanthosis is a distinctive type of pseudo\u2010acanthoma secondary to skin damage caused by chronic ultraviolet radiation. The present study examined the frequency, clinical and histopathological criteria, and immunohistochemical findings of this condition in two patient cohorts who were admitted to hospital with a diagnosis of malignant melanoma.<EOD> .\nFour species of Dicroglosinae genera have been collected, examined and their faunal distribution has been analyzed. B. hartwegi, H. rufofuscipennis, D. pudibunda and D. pulchripennis were found. The species examined have been described, and the following distributional patterns found: B. hartwegi, D. pudibunda, and H. rufofuscipennis are found throughout Jalisco, D. pulchripennis was collected only in the southwest part of the state. The results of the study are discussed in relation to the faunal distribution of dipterous in different localities of the State.<EOD> Molecular structure of the interleukin-2 receptor complex: homology with tyrosine kinase oncogenes and viral envelope glycoproteins.\nReceptors (65 kDa, p65, or IL-2R beta; 70 kDa, p70, or IL-2Ralpha; and 80 kDa, p80, or IL-2R gamma) constitute a cell surface receptor complex on which the lymphokine interleukin-2 exerts its biological activities. The p80 chain is shown to associate with the IL-2R beta/p70 IL-2R in a divalent antibody-sensitive manner that is identical to that of the intact IL-2-binding receptor complex. In contrast to previous reports, no IL-2-dependent covalent modifications of either the p65 IL-2R alpha chain or the p80 IL-2R gamma chain could be detected. Instead, several serine residues on both p65 IL-2R alpha and",
        "label": 0
    },
    "2102": {
        "output": "record. ID: int64; endfunction \nfunction",
        "label": 0
    },
    "2103": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to provide a brief summary of findings for the clinical trial and the assessment of eligibility.\n\n[!EXPRPANSION] Patient eligibility\n\n1. Patient age matches the clinical trial inclusion criteria i.e. 25.\n2. Patient has type 1 diabetes.\n3. Laboratory tests are consistent with patient diagnosis, including elevated cholesterol and triglycerides, low HDL, and elevated LDL.\n4. Patient takes daily insulin.\n5. Patient is newly diagnosed with low ejection fraction and will be treated with ACE inhibitors and Beta blockers.\nPatient does not have any medications as exclusion criteria for the clinical trial.\n\n[!EXPRPANSION]\n\nThis patient is eligible to be enrolled and randomized in this clinical trial.\n\n[/EXPANSION]\n\n[!EXPRPANSION] Summary of data collection and trial description\n\nThis is a randomized, open-label, parallel-arm, multicenter trial in which 118 patients will be enrolled and assigned to treatment arm in a 1:1 basis. \n\n[/EXPANSION]\nThe study will be carried out over a period of six months.\n\n[!EXPRPANSION]\n\n1. Study inclusion criteria:\n\n1) Patients must be clinically stable\n\n2) Patients should be diagnosed with coronary artery disease.\n\n3) Patients should have total cholesterol levels of 250-500 mg/dl (230-450 mg/dl in patients with heart failure) and low HDL\n\n2. Study exclusion criteria\n\n1) Patients with LDL > 300 mg/",
        "label": 0
    },
    "2104": {
        "output": "## Examples\n\n\n```python\n\npatient_note = \"A patient note.\"\n\nclinical_trial = \"A clinical trial.\"\n\nt1 = trial_level_eligibility.Trial_level_eligibility(\n    note=patient_note, trial=clinical_trial)\n\nprint(t1)\n\nTrial-level eligibility: Not relevant\n```\n\n\n```python\nt2 = trial_level_eligibility.Trial_level_eligibility(\n    note=patient_note, trial=clinical_trial, eligible=True)\n\nprint(t2)\nTrial-level eligibility: 1) Eligible\n```\n\n\n```python\neligible_value = \"A value of eligibility.\"\nt3 = trial_level_eligibility.Trial_level_eligibility(\n    note=patient_note, trial=clinical_trial, eligible=eligible_value)\nt3.Trial_level_eligibility.save()\nprint(t3)\n```\n<EOD> Stereological determination of the effects of cholesterol and sterculic acid on cell proliferation in the rat epididymal endocrine epithelium.\nStereological analysis was used to study the effects of a 10% w/w cholesterol diet and a 1.5% sterculic acid diet, applied for three months, on the number and size of basophilic epididymal luminal cells (BELCs)-luminal Leydig cells. The results show that the number of BELCs is significantly increased by cholesterol but not by sterculic acid-treatment whereas the soma diameters of BELCs was increased only by sterculic acid. Our results indicate that the increased number of BELCs may be interpreted as an adaptational response to a hyperlipidemia state and the increase of the diameters of BELCs probably related to the development of hyperplastic proliferation induced by sterculic acid ingestion.<EOD> Immunobiological effects of the novel immunosuppressant D16",
        "label": 0
    },
    "2105": {
        "output": "- `Trial-level eligibility: [type, condition1, condition2, \u2026, conditionX-1, conditionX, type2].`.\n- `type 1`, for the title `Effect of Diabetes Mellitus on Cholesterol Metabolism`\n- `conditionX-1`, for `age > 18 years`\n- \u2026\n- \n\n_Note:_ These instructions do not count as _certification_.\n\n### **Instructions 005**\nWrite an algorithm which takes a patient note, and the clinical trial as inputs, to determine a patient's eligibility.\nWrite it so that if a patient is already included in a trial, he remains excluded. In other words, this is a _differential eligibility algorithm_.\n\n`def DifferentialEligibility(patientNote: str, trialNote: str) -> bool`:\n\nInstead of returning a score as `Trial-level eligibility: 1) Excluded; 2) Not relevant; 3) Eligible; `.\nReturn the differential trial-level eligibility status of the patient based on the clinical trial. `True` will result if and only if after removing all the exclusion criteria, the patient turns Eligible. `False` will result if and only if after removing all the exclusion criteria, the patient turns Excluded.\n\nNote that it is important that the patient can not be already participating in the trial, otherwise the inclusion criteria should not be removed. If it is already included in the trial, returning False is not meaningful, since it always will be included.\nIf there are no exclusion criteria, returning True is not meaningful either, since a patient is included. Therefore, we should exclude cases where there is no exclusion.\nThe output should be `DifferentialEligibility(patientNote, trialNote): ` or `DifferentialEligibility(trialNote, patientNote): \n\nHere is `patientNote` and `trialNote` and the expected output from the patient's perspective:\n[![Instructor Code](https://i.imgur.com/nUO9fqw.png)](https://data.jmcubed.org/jcubed.org-practice/excer",
        "label": 2
    },
    "2106": {
        "output": "## Prepare a Python programming environment.\nCreate a Python program file named `eligibility.py`.\nInstall requirements used for training in Python interpreter.\nInstall NLP and TM utilities. The purpose is to apply NLP and word embedding techniques to this dataset.\n\nInstall spaCy and the required packages. SpaCy is a useful tool for NLP. spaCy's dependency packages include fastText, word2Vec, and Stanza.\nOpen the terminal.\n\nIn the Terminal, go to the project folder and then run the following command:\n\nRun eligibility.py and the window shows the expected results.\n\n## Validation\nFor the purpose of evaluating the performance of the model, we use 60% data for training, 20% for testing, and the remaining 20% for validation.\n\nThe performance metrics considered for evaluation in this dataset are:\nPrecision:\n\n## Recall:\n\nThe evaluation results are shown in the following figures that are extracted from this dataset:\n\n## Model visualization\nFigure the model architecture with `plt.plot` function:\n\n### LRM_NN: `plt.plot(lr_losses_nn, 'r', figfile = 'eligibility_nn_lr_losses_model')\n\n### LRM_SVM: `plt.plot(lr_losses_svm, 'r', figfile = 'eligibility_nn_lr_losses_model')\n\n### LRM_DNN: `plt.plot(lr_losses_dnn, 'r', figfile = 'eligibility_nn_lr_losses_model')`\n\n### ANN_NN: `plt.plot(ann_losses_nn, 'r', figfile = 'eligibility_nn_lr_losses_model')`\n\n### ANN_SVM: `plt.plot(ann_losses_svm, 'r', figfile = 'eligibility_nn_lr_losses_model')`\n\n### ANN_DNN: `plt.plot(ann_losses_dnn, 'r', figfile = 'eligibility_nn_lr_losses_model')`",
        "label": 0
    },
    "2107": {
        "output": "<EOD> The Role of the Dorsal Striatum in Reward and Decision-Making\n\nThe dorsal striatum is key to the neural mechanisms underlying motivated behavior. It is heavily interconnected with cognitive and motor structures of the cortex, and receives a complex multisensory representation with input from reward-regulating midbrain structures such as the ventral tegmental area. The complexity of this circuitry is exemplified by findings that striatal pathologies can result in profound impairments to cognitive abilities including the ability to learn. Despite the many cognitive tasks used to probe the computational role of the dorsal striatum, the specific functions subserved by striatal neurons remain unclear. This state-of-the-art review focuses on how the dorsal striatum may contribute to reward-guided decision-making. Neurons in the dorsal striatum appear to be heterogenous with different types of subregions within the pathway performing specialized functions. For example, striatal indirect and cortico-striatal projecting neurons respond to and predict rewarding outcomes, and thus may play an important role in motivating reward-directed behavior. While indirect pathway neurons in the dorsomedial part of the dorsal striatum appear to encode salient environmental events, including the expected and received outcomes of actions, the cortico-striatal projection neurons play a role in decision-making. Moreover, recent optogenetic studies show that the pathway projection neurons contribute to the ability to learn choices that are made in response to rewarding outcomes.\n\n# Introduction\nThe dorsal striatum is located next to the dorsal part of the insular cortex (previously called insula). It consists of the dorsal striatum, nucleus accumbens (NA), and olfactory tubercle [bib_ref]  Functional anatomical studies of episodic memory in animals, Steckler [/bib_ref]  [bib_ref]  The anatomical and physiological context of dopamine signaling in learning and memory, Williams [/bib_ref] . The dorsal striatum is heavily interconnected with motor and cognitive cortices [bib_ref]  Subcortical loops through the basal ganglia, Mchaffie [/bib_ref]  , in addition to multiple midbrain structures important in reward processing,",
        "label": 0
    },
    "2108": {
        "output": "Copy the code below and paste it into your Jupyter notebook:\n\n```python\ndef eligible_patient(patient_note, trial_note):\n    \"\"\"\n    Determine eligibility.\n    Args:\n        patient_note (str): patient's note containing their basic information in XML format\n        trial_note (str): clinical trial's note containing its trial-level and \n                        individual-level inclusion criteria with their XML format\n    Returns:\n        The trial-level eligibility that will be printed in first line of patient_note.\n                          `Eligible.` for patients who are eligible. `Excluded` for those who do not meet the trial-level inclusion criteria. `Not_relevant` for those without sufficient information to qualify for the clinical trial\n    \"\"\"\n    eligible_trial = False\n    trial_level = 0\n    individual_level = 0\n    for clinical_trial_note in trial_note:\n        # The value of inclusion criteria at each level\n        trial_level = clinical_trial_note[0][\"trial-level\"]\n        individual_level = clinical_trial_note[2][1].split(\";\")\n        if clinical_trial_note[1] == \"True\" and trial_level == 1 and individual_level > 0:\n            individual_trial_note = clinical_trial_note[2]\n            eligible_patient = 0\n            # Aggregate and count each individual's individual level inclusion criteria\n            for person in individual_trial_note:\n                if person[0] == \"NOT\" and person[-1] == \"TRUE\":\n                    individual_trial_note[0] = individual_trial_note[0] - 1\n                if person[2] and person[2] != \"NOT\" and person[-1] == \"TRUE\":\n                    if person[1] == \"age\":\n                        eligible_patient = eligible_patient + int(person[3])\n                    else:\n                        eligible_patient = eligible_patient + 1\n            # If age and gender are included in",
        "label": 0
    },
    "2109": {
        "output": "## #3) Exclude\nExclusion conditions describe the clinical issues which should exclude patients from entering a clinical trial. Here is a random example of a trial-specific criteria for exclusion:\nExclusion criteria: Previously had hypoglycaemic reaction to ACE inhibitors, or other antihypertensive drugs\n\nHere the exclusion rule is written in the EXCLUDE section (as we discussed before, this section is after TRIAL-LEVEL EXCLUSION and EXCLUSION CNTRY).\n\n### #4) SELECT BY\nFor selecting a dataset which matches with a clinical trial. You need SELECT BY rule. SELECT BY tells the system how to find patient datasets that meet our inclusion criteria. In a SELECT BY rule, you can either use 'equal' (match exactly) or 'like' (have a similar structure) \n\nThe query expression in SELECT BY section as an example would be:\n`SELECT BY \"ID.ACCSTONE\" LIKE \"2505-110\" OR \"2505-652\"`\n\nThe rule 'ID.ACCSTONE' is used to select patients with the patient ID 'ID' (the system takes the last element from the dataset name and uses it for finding the dataset).\nIf the dataset is given a label ID in the dataset name, the system only includes patients whose patient ID is 'ID', otherwise it would ignore the SELECT BY rule and all patients will be selected. Next, the SELECT BY rule specifies the field whose values should be 2505 and 110 or 2505 and 652 in case of 'ID.ACCSTONE' to select the data.\n\n### #5) SET\nSET is just after SELECT BY, but it is not mandatory. \n\nIf you did not use SELECT BY rule, then you will be required to write SET rule. A SET rule defines the output format of the selected datasets. It is always necessary to define a single format before running a query, and it is also an optional step to apply for the selected dataset with multiple formats. Let's imagine that in the SELECT BY rule (which was already used to filter the list of patients), we used a format of 'ID' or 'ID.ACCSTONE`. That's mean that we have got the",
        "label": 0
    },
    "2110": {
        "output": "\u00a9 2022 The Author(s)\nYou may have seen a similar problem in the Python programming exercises in previous courses!\nYou can view these examples and try out your program using Python Shell on the free and open-source Jupyter notebooks. After you run your program, a box with its output is displayed in the program's interface. Learn how to use Jupyter by clicking here.\nIf you need help with the problem, check the Discussion Forum below or your problem can be discussed with your lab group. If you need any additional help, or would like to get in touch by email, please contact a course coordinator.\n\u00a9 Erasmus University Rotterdam<EOD> Influence of the diet on the development of antioxidant mechanisms of rat liver.\nPeroxidative processes represent a potentially toxic effect of oxygen on the cell. Antioxidant defense of the body and its components is a rather complex system of reactions. For instance, liver, the main organ participating in food metabolism as well as detoxication processes, contains some enzymes and compounds, which are responsible for the defense against reactive oxygen species. Changes of these mechanisms occur as a result of dietary deficiencies. The aim of this study was to investigate whether the content of selected nutrients in the diet influences the level of enzymes taking part in nonenzymatic and enzymatic antioxidant reaction in the rat liver, i.e., the activity of superoxide dismutase, catalase and glutathione peroxidase and the concentration of reduced glutathione and thiobarbituric acid-reacting substances. The experiments were performed on 200 male Wistar rats which were divided into four groups depending on food allowance: a control group whose diet comprised balanced, complete commercial pelleted fodder, a group fed a deficient, low-protein diet, a group fed a deficient, low-protein and low carbohydrate diet, a group fed a deficient, low-protein and low lipid diet. Changes of glutathione peroxidase activity which appeared in all the groups did not, however, seem to be a direct cause of",
        "label": 0
    },
    "2111": {
        "output": "<EOD> Phytoremediation of heavy metals with woody biocide trees on an urban site.\nThe presence of toxic heavy metals (HMs) such as As, Cu, Cd, Cr, Pb, Ni, and Zn in the urban ecosystem has been considered an issue of particular concern, especially for the plants that live in urban green areas. Biomasses of urban woody biocide trees were used to evaluate the potential of the plant bioaccumulation of a mixture of 16 HMs in the area of Tor Vergata (Rome/Italy). The results indicate that plants absorbed and concentrated these toxic elements in leaves and stems, which are potentially dangerous for local populations and the environment. This is a study of an urban site that has never been considered and that could be useful for the future.<EOD> Combined Intravitreal Aflibercept and Ranibizumab Combination Therapy for Persistent DME in Type 1 Diabetes\n\nWe report a case of persistent diabetic macular edema (DME) resistant to long term intravitreal injections of aflibercept (IVT-AFL) combined with ranibizumab (IVT-RBZ) in a young patient with type 1 diabetes mellitus. The authors describe the course of the disease and present an interesting discussion on the potential role of different mechanisms of macular edema in DME unresponsive to anti-vascular endothelial growth factors (anti-VEGFs). We conclude that when the treatment with intravitreal injections of anti-VEGFs fail, other strategies, including intraocular steroids could be taken into consideration.\n\n# Introduction\nAlthough anti-vascular endothelial growth factor (anti-VEGF) agents are generally regarded as being highly effective in macular edema secondary to diabetes, some degree of short-term and long-term resistance to anti-VEGF agents may be observed.\n\n## Case report/case presentation\nHere we present a case of diabetic macular edema (DME) resistant to long-term monthly injections with aflibercept, with significant visual improvement after switching to bimonthly anti-VEGF combination ranibiz",
        "label": 0
    },
    "2112": {
        "output": "# <NAME>\u2019s notes to solve this exercise\n\nThere are 3 sections:\n\n1. Read through everything to figure out what it is asking you to do.\n\n2. Skim the patient note, then the trial criteria you are going to see, to get an idea of what you need to do.\n\n3. Put all of it into logical sections with the appropriate notations and labels.\n\n\n\n\n# Solution\n\n[Talk](https://classroom.github.io/messages/0000000210382381d5345aec12c48db2d/messages/master/0880130672997326820438150726431865681884385466f81c5056d0fc3b31c599f8844e30d24739768e82041b266e58d13326f23b236264202e365e207b6f425492d0e057fde7bc518e3a23293a8d50a6624dcd4cb314559c249151273b4e6e58b0277b425d50bae19b1c0759d14c34dbd9c89dd79b6ebc2d03e2ae60c2c91af58150c07931ed21b62d357955754ec4091ae7e8897c89169e4fb77de4a7f032c0aed288c45b7f56c06264510f21e2a2c0a9ac366e38ea099c31152cb472754",
        "label": 0
    },
    "2113": {
        "output": "[END]\n\n## Suggested solutions\nPlease check the following if you cannot solve your problem.\n1. Ensure the solution file is installed correctly, and your project is up to date. The solution file contains several tasks and helper functions to solve your problem. If the solution is not installed right, it won't solve the problem.\n\n2. The solution works fine for my project. But I need to make it work with an old version of Visual Studio.\n\n3. The solution doesn't work with an old version of Visual Studio. I just need some sample code about how to accomplish the problem.\n\n### Solution installation\nSolution package can also be found in Mvix.NET 1.1 solution file folder. In this case, double-click the Mvix.NET 1.1-master.sln file and follow the Mvix.NET 1.1 solution file installation procedure.\n### Getting the code\nYou should download and extract Mvix.NET 1.1 source code.\nFirst, you should build and test your project before submitting it. If this step is skipped, your solution may not install properly and might not work with your project or may not install at all! Please make sure that your projects are built and can be run successfully before you install an additional solution!\nYou can download Mvix.NET 1.1 zip file from [Link1]. It contains Mvix.NET 1.1 solution file that is called mvix.net.sln and some example project, which are called simple.csproj and simpleprogram.csproj.\nIf you prefer to install it using [Link2], you can download Mvix.NET 1.1 zip file from [Link1]. Then unzip file and go to folder mvix.net. Solution and source for Mvix.NET 1.1. Unzip file and go to folder C:\\mvix.net. Solution and source for Mvix.NET 1.1.\n\n### Run and debug the solution file\nPlease launch and debug your solution with a project using the following steps:\n- If you want to open solution in debug mode, select Debug, Windows, Start Without Debugging, Open in Debug window.\n- If you want to create a fresh solution, select [Link5], [Link6], [Link7] for C#",
        "label": 0
    },
    "2114": {
        "output": "### Rules of Assignment\nRules of Assignment assess the patient's eligibility, determine whether the patient can be entered into the study, and how an eligible patient will be assigned to a clinical trial to determine the best matched patient and a clinical trial to meet the patient's clinical care needs.\n\nIn this assessment, a trial's inclusion criteria are matched to the patient's diagnoses, treatments and examinations recorded in the EMR data based on logical rules. The diagnoses, treatments and examinations matched with each trial's inclusion criteria are recorded in a table and scored from 1 (most important) to 6 (least important):\n1 (must not conflict)\n2 (must not conflict)\n3\n4\n5\n6 (can conflict).\nScoring reflects the extent of conflict between an individual's diagnoses, treatments and test results from the patient's EMR and the inclusion criteria of a clinical trial. If a match score of less than 4 is achieved for a given trial-patient pair, then the trial is considered a match for the patient. If the score for at least two clinical trials are less than 4 and a match for a clinical trial is not found or could not be achieved because only one trial-patient match was found for a trial, then that trial is not a match for the patient.\nBy applying these rules, we select trials that patients with a certain condition can join or receive a potential benefits from.\n\n[INST] Here are the rules for this patient (patient in above example). \nRule 1:\nAssess whether age in years is less than the lower age limit of a clinical trial based on the EMR\nRule 2: \nPatients with 2) Eligible trial-level eligibility will be excluded from this trial. \n\nRule 3: \nAssess whether there are at least 2 treatments mentioned. \nRule 4: \nAssess whether there are at least 2 diagnoses mentioned. \nRule 5: \nAssess whether there are at least 1 examination mentioned. \nRule 6:",
        "label": 0
    },
    "2115": {
        "output": "<EOD> Role of Lysophosphatidylcholine in Gastric Ulcer Healing with Eicosapentaenoic Acid and Gamma-linolenic Acid\nABSTRACT Background/Aims/Methods: Prostaglandins (PGs) have been implicated as a major cytoprotective factor, and free fatty acids (FFA), especially polyunsaturated fatty acids (PUFA), as an alternative energy substrate contributing to the development of cytoprotection and ulcer healing in rats. The purpose of the present study was to examine the effect of PUFA and FFA, orally administered to chronic water-immersed rats, on gastric mucosal permeability (GMP), the concentration of some PG and FFA, and the activity of cyclooxygenase (COX) in ulcer-bearing rats. Results and Conclusions: Eicosapentaenoic acid (EPA) and \u03b3-linolenic acid (GLA) were examined for their therapeutic effects on experimentally induced chronic gastric ulcers. As a result, gastric ulcer healing was significantly accelerated by the oral administration of EPA and GLA. The concentration of PG in gastric mucosa was increased significantly on day 14 after the removal of the water load, but the degree of recovery was greater in the 600-mg/kg dose group. EPA and GLA were determined to be effective in promoting the ulcer healing and in increasing the content of PG, and decreasing the ratio of PGE2/PGF 2\u03b1 . Since the ratios of n-6 PUFA such as GLA and arachidonic acid (AA) to EPA in the ulcer mucosa treated with EPA and GLA were significantly decreased, these results suggested that EPA and GLA administered orally to rats induced accelerated ulcer healing.<EOD> Mapping of the binding domain of the human uroplakins with the small urothelial plaque protein uroplakin IIIp\nUroplakins are a group of glycophospholipid-anchored glycoproteins",
        "label": 0
    },
    "2116": {
        "output": "1. In the [patient note:], the clinical trial shows the inclusion criteria; hence, the notes in the first few lines are irrelevant to the eligibility assessment.\n\n2. The patient note:\n    - 25 year-old man with type 1 diabetes confirmed with molecular analysis\n    - Seven years ago.\n    - Present to the clinic with shortness of breath and fatigue\n    - Claims mild dyspnea after climbing three floors\n    - Diagnosed with cardiomyopathy which will be treated with ACE inhibitors and Beta blockers.\n    - Presents no dyspnea at rest or angina\n    - Taking 70/30 Insulin and vitamin D supplements\n    - No significant past medical history\n    - Positive for DM type 1 in his uncle\n    - Positive for his grandfather's family history\n    - Laboratory studies: FBS 100 mg/dL, HbA1c 6.5%, Cholesterol 190 mg/dL, TG 140 mg/dl, LDL 125 mg/dl, HDL 40 mg/dL\n\n    > Let's repeat your eligibility assessment for the patient note and repeat your results in R code. Remember, your [Eligibility assessment: 0) Excluded, 1) Not relevant, 2) Eligible:]. Put a curly bracket around the final statement.\n3. In the [Clinical trial:], the first two lines are exclusion criteria, hence, the patient note in the top 3 lines is irrelevant to the eligibility assessment.\n\n4. The patient meets these inclusion criteria; moreover, there are no exclusion criteria. Hence, the patient is [Eligible:].\n\n5. For further information on your patient note and the clinical trial, see the [Wikipedia article about the disease] and see\n[MIM] and\n[OMIM] to find more information on your disease.\n\n6. Make an input for this [program] using R programming language and submit it to the [Grand Valley University CourseHub]. You are not only welcome to use this program",
        "label": 0
    },
    "2117": {
        "output": "<EOD> Increased serum concentrations of apolipoprotein AI in elderly women with cardiovascular symptoms but not with hypertension.\nPatients with hypertension have a high incidence of ischemic heart disease and increased serum lipids/apolipoprotein concentrations. Recently, apolipoprotein AI, especially HDL subfraction containing apo AI, has been suggested to play a key role in protection against ischemic heart disease. However, the relationship between hypertension and apo AI has yet to be fully clarified. We therefore examined the serum concentrations of apolipoproteins in 116 elderly women. The subjects were divided into six groups according to their hypertensive status and the presence or absence of cardiovascular symptoms. Systolic (SBP) and diastolic blood pressures (DBP), plasma lipids/apolipoproteins, and ischemic heart disease risk factors were determined. The mean (SD) values of SBP and DBP were significantly higher in the hypertensive group (HT group) than in the non-hypertensive group (non-HT group). Subjects with cardiovascular symptoms exhibited significantly higher total cholesterol and LDL-cholesterol as well as significantly lower HDL-cholesterol than those without. In contrast, there were no significant differences between subjects with and without cardiovascular symptoms in the non-HT group. Serum apolipoprotein AI concentrations were significantly higher in the elderly women with cardiovascular symptoms in both the non-HT and HT groups. However, the serum apolipoprotein A-II in the HT, but not in the non-HT group (non-HT vs HT group, p-trend < 0.05), showed a significant positive correlation with SBP and DBP. The serum apolipoprotein A-II concentrations tended to be positively related to the severity of cardiovascular symptoms.<EOD> .\nTrembling caused by dystonia in the lower left limb was eliminated by the injection of succinylcholine (SCh, 1 mg.kg-1) into the",
        "label": 0
    },
    "2118": {
        "output": "<EOD> <filename>src/main/java/at/foodb/nacpan/nacpan/io/JwtIO.java\npackage nacpan.nacpan.io;\n\nimport org.bouncycastle.asn1.util.ASN1OcteticBuffer;\nimport org.bouncycastle.jcajce.utilities.EncodedSecurityKey;\nimport org.bouncycastle.jcajce.utilities.JcaJceUtil;\nimport org.jasig.crypto.JWEEncryptionException;\nimport org.jasig.exceptions.JencryptionException;\nimport org.jasig.jwa.JWAKey;\n\n/**\n * This type corresponds to section 4.4.1 and is used as an ASN.1 object in the\n * jwt_kms standard.\n *\n * @author <NAME>\n */\npublic class JwtIO implements JwtIO441 {\n    private final JWAKey jwt;\n\n    public JwtIO(JWAKey jwt) {\n        this.jwt = jwt;\n    }\n\n    @Override\n    public void decrypt(ASN1OcteticBuffer octeticBuffer, String keyEncryptionAlgorithmId) throws JencryptionException {\n        EncodedSecurityKey jwk = JcaJceUtil.getEncoded(jwt.getSec());\n        try {\n            jwt.getSec() = jwk.decrypt(octeticBuffer, keyEncryptionAlgorithmId);\n        } catch (JWEEncryptionException jweeEx) {\n            throw new JencryptionException(jweeEx.getMessage());\n        }\n    }\n\n    @Override\n    public void encrypt(String keyEncryptionAlgorithmId, ASN1OcteticBuffer octeticBuffer) throws JencryptionException {\n        EncodedSecurityKey jwk;\n        try {\n            jwk = JcaJceUtil.getEncoded(jwt.getSec());\n            jwt.getSec() = jwk.encrypt(octeticBuffer, keyEncryptionAlgorithmId);\n        } catch (JWEEncryptionException jweeEx) {\n            throw new JencryptionException(jwee",
        "label": 0
    },
    "2119": {
        "output": "<jupyter_code>result = taspoglutide_experiment.test(\n    {'patient_record': patient_record,\n     'trials': [{'clinical_trial': {\n                    'title': 'The patient note',\n                    'summary': \"Patient is 25 year old DM type 1 positive. History of drug reactions (DHE). BMI is 0.88, HbA1c is 6.5 % and FBS is 100 mg/dl. Family history is positive for DM type 1 in grandfather and uncle. Lab study is as follows:'\n                    '\"Cholesterol: 190 mg/dl, TG: 140 mg/dl, LDL: 125 mg/dl, HDL: 40 mg/dl\"\n                    '  } } } )}]'\n        ),\n        [r for r in result.test_reports for\n         report in r.report_tables[0].split_rows()],\n        results[r.report_tables[0].split_rows()[0]._col_indexes[0]._key],\n        r.report_tables[0]._row_indexes[1]._key, r.report_tables[0]._row_indexes[2]._key\n    )\n\ndisplay(result.test_reports[0])\n\nresult.write(r'Evaluation:\\n01) Excluded\\n02) Not relevant\\n03) Eligible \n\n[Trial-level: 03, trial-level-eligibility: 2]: patient_id: 00030086, patient_name: <NAME>, patient_age: 25, patient_gender: M, first_visit_date: [1950-12-31], patient_health_date: [2020-05-26 11:22:30 +0000], patient_status: \"Active\",\n\n[Clinical_trial name: Taspoglutide, clinical_trial code: NCT0267397",
        "label": 0
    },
    "2120": {
        "output": "## 1. Patient ID: You should change the patient ID variable to 235032163. As mentioned above, you should save your work by pressing `s` in the beginning of each code block. \n\n```\nPID 235032163\nPNAME 'Jason 1'\n```\n\n## Assign the variables\n\n```\n#Assign the variables\nPID patient_id\nPNAME patient name\n```\n\n## 2. Diagnosis of cardiomyopathy. Let's find the reason for the patient presentation to the clinic.\n\n```\nCOD heart_problem=patient_heart_problem\n```\n\n## 1. Let us check the history of heart disease. \n\n```\nDIAG 2 CO = 'Coronary Artery Disease'(COAD)\nDIAG 3 CO = 'Non Ischemic Cardiomyopathy'\nDIAG 4 CO = 'Ischemic Cardiomyopathy'\n```\n\n## 2. Clinical trials in Iran (if an open-source trial is found, it is better to assign to COAD).\n\n```\nCODIG CO_Iran 5=1\n```\n\n## Assessment of Eligibility\n\n```\n## Eligibility\nTRIAL-LEVEL ELIGIBILITY #you should write the assessment of eligibility for each trial separately 1 2 1\n```\n\n## Clinical Trial Number: Let us find the clinical trial number through clinicaltrials.gov.\n\n```\nClinical_Trial_Number trial_id=PID\ntrial_id[length(trial_id)]=3\n```\n\n## Treatment: Let's retrieve the treatment variable by trial",
        "label": 2
    },
    "2121": {
        "output": "##[END]\n<EOD> Correction: Impact of a novel anti-carbonic anhydrase VII antibody on enzymatic activity and on MCF-7 breast cancer cell activity\n.<EOD> Intestinal parasitosis among patients with human immunodeficiency virus (HIV) infection in North Dakota.\nBACKGROUND\nIntestinal parasitosis is common in developing countries while in developed countries it appears to be relatively rare. There are reports of an increase of intestinal parasites from people who are immunocompromised following the introduction of human immunodeficiency virus (HIV) treatment, and there is a concern that HIV patients treated in this way are putting themselves at risk for parasite infections. Previous reports have indicated that immunocompromised people in the upper Midwest are at risk for intestinal parasite infections. This study was conducted to assess parasite infections in people living with HIV compared to the general population in a region of the upper Midwest where these diseases have not been previously documented in great prevalence.\n\n\nMETHODS\nA retrospective chart review was performed to identify adult HIV patients diagnosed positive for Entamoeba histolytica, Strongyloides stercoralis, or Cryptosporidium in the Dakota Region from 1989 to 2000 and compared to the prevalence of these intestinal parasites in the same region in the general population. A survey of parasite infections in patients in the HIV clinic was also conducted.\n\n\nRESULTS\nDuring the study period 929 HIV patients were diagnosed. Five patients were positive for Cryptosporidium, 1 for Strongyloides stercoralis, and 4 patients were positive for E. histolytica. Two of 4 patients with E. histolytica were also treated with metronidazole. All 12 patients testing positive for various intestinal parasites were male.\n\n\nCONCLUSION\nIt was surprising that only 1.01% of the patients tested had intestinal parasitic infections while most of the study population had relatively normal CD4 counts. None of",
        "label": 0
    },
    "2122": {
        "output": ".\n\n# Q2\n\n**Exam Question:** Hello. You are a helpful assistant for recruiting a clinical trial. Your task is to check if a person meets the inclusion criteria of a given the clinical trial. If the answer is 'NO', you have to write a note that this person does not meet the clinical trial's inclusion criteria. If the answer is 'YES', you have to keep checking more inclusion criteria until you find the one or more exclusion criteria of a person.\n\nYou should read a person's profile and output the assessment of eligibility. Your output has the format: patient note.\n\nThe assessment of eligibility has a three-point scale. 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\n\n## Patient's profile\n\nThe patient is a 25-year-",
        "label": 0
    },
    "2123": {
        "output": "# Exam 1\nYou should complete the trial description after the input as shown in the example. There is no need for further formatting in the trial description file.\n\n    [S1_exam_1.pdf](https://files.osf.io/0qxhy/download?version=5&file=S1_exam_1.pdf)\n\nNote that [S1_exam_1.pdf](https://files.osf.io/0qxhy/download?version=5&file=S1_exam_1.pdf) is uploaded in OSF. You can download it from it.\n\n## S1_exam_1.pdf\n\n### Exam: S1_exam_1_input.html\n\n[![Output](../../images/40/40a_exam_3/S1_exam_1_text.pdf \"Exam S1_exam_1\")]()\n[![C++ output](../../images/40/40b_exam_3/S1_exam_1-C.pdf \"C++ output\")](S1_exam_1-C.pdf)\n\n### Exam: S1_exam_1_html_output.html\n\n[![Output](../../images/40/40a_exam_3/S1_exam_1_html.pdf \"Exam S1_exam_1_html\")]()\n[![HTML output](../../images/40/40b_exam_5/S1_exam_1_output.html \"HTML output\")](S1_exam_1_output.html)\n\n### Exam: S1_exam_1_output.html\n\n[![Output](../../images/40/40a_exam_3/S1_exam_1_output.pdf \"Exam S1_exam_1_output\")]()\n[![Output](../../images/40/40b_exam_5/S1_exam_1_output.html \"Output\")](S1_exam_1_output.html)\n\n### Exam: S1_exam_1_ass",
        "label": 0
    },
    "2124": {
        "output": "# Example dataset\nHere is [example.txt](./README.md#Examples%E2%80%94Example%20Data%E2%80%94Example%20data.txt).\n<EOD> Exosomes derived from the bone marrow of patients with psoriasis promote angiogenesis and migration of human umbilical vein endothelial cells by releasing microRNA-21.\nBackground\nExosomes are extracellular vesicles that have been considered to be important regulators of cell-to-cell communication due to their ability to mediate exchange of genetic material between cells. The aim of this study was to investigate the function of bone marrow mesenchymal stem cell (BMSC)-derived exosomes in the progression of psoriasis and the role of exosomal microRNA-21 (miR-21) in the regulation of angiogenesis and migration of human umbilical vein endothelial cells (HUVECs).\n\n\nMethods\nBMSCs were cultured and treated with lipopolysaccharide (LPS) to prepare BMSC-derived exosomes. Psoriatic exosomes (PEXOs) and PENs-derived exosomes (PENs-EXOs) were identified by TEM and Western blot analysis. Subsequently, PEXOs and exosomes derived from psoriatic plasmacytoid dendritic cells (pDCs-EXOs) were co-cultured with HUVECs to identify which affected HUVECs. Subsequently, the effect of miR-21 expression on the angiogenesis and migration activities of HUVECs was confirmed by co-culturing with mimics, inhibitors, or transfection of PEXOs with lentiviral transfection vectors.\n\n\nResults\nOur results demonstrated that BMSC-derived exosomes were able to be transported to other HUVECs and mediating cell-cell communication. In the presence of PEXOs, proliferation, migration, tube formation, and angiogenesis of HUVECs were markedly increased",
        "label": 0
    },
    "2125": {
        "output": "Please agree the eligibility of each patient by comparing your judgment with the information on the clinical trial, if you think your judgment is not consistent with the eligibility of the clinical trial, leave a comment, and we will try our best to adjust the trial information.\n\nI hope this tutorial introduces you to the details of how to use the ClinicalTrial app. You should be familiar with this app as soon as you can because this is a necessary app for the future of our business. Please check the rest of the instructions, and I look forward to hearing your opinions. It will be",
        "label": 0
    },
    "2126": {
        "output": "# Implementation Notes\nI've checked out some of these packages which seem promising although a few of them are still in early stages of development which need lots of help from the community to fix some of bugs.\n\n\n## [INST] Installation\nIf you come from GitHub, after cloning the repo, you need to install the gem and build the test suite.\nI'm recommending using `bundler`: $ bundle\n\n```ruby\ngem install trial_eligibility --version '0.1.2'\nrequire 'trial_eligibility'\n```\n\nThen you'll want to add the dependency to the `.rdoc` file. Add this line to your `.rdoc`. I'm using the following line:\n```ruby\ngem 'trial_eligibility::documentation'\n```\n\nThat's it, now you can run your rdoc with rdoc:\n\n```ruby\n$ rdoc trial_eligibility\n```\n\nAdditional dependencies\nPlease be sure to add the dependencies to the `requirements.rb` file.\n\nIf you want it to run on JRuby, here are the additional dependencies:\n\n```ruby\nrequire 'jruby'\ngem 'jruby'\nrequire 'jruby'\nrequire `jruby-1.8.5`\n```\n\n\n## [INST] Run the tests\n\nRun the tests with `rspec-jruby`:\n\n```ruby\n$ rspec-jruby spec/ spec/cases/basic_eligibility_test.rb\n```\n<EOD> .\nBACKGROUND\nDuring the last decade a number of new immunotherapeutic agents have been introduced for the treatment of patients with advanced non- small cell lung cancer.\n\n\nMATERIALS\n1. The article provides an overview of different immunotherapeutic treatments.\n\n\nRESULTS\nCytokine treated patients have improved survival, increased response rates and progression-free survival compared to best supportive care and chemotherapy, although survival is relatively short. The newer immunotherapies, especially treatment with C-242 and ipilimumab, which targets blockade of the interaction of the T-cell inhibitory ligand CTLA-4 and its receptor, are showing promising results with",
        "label": 0
    },
    "2127": {
        "output": "248. As long as the package is being maintained, will the package be on CRAN?\n[INST] Yes, the package is designed to be available on CRAN. [/",
        "label": 0
    },
    "2128": {
        "output": "Let\u2019s do it step by step. To calculate the total score of each patient, you should calculate each of the individual questions (step 1) and multiply each score by factor(1,2,3,.); In the end, you should add the result of each question and divide it by the number of questions (step 3).   \n\nSo, if the number of parameters is 4 and the number of parameters (variables) is 5, we will have 20 lines like this in the output:   \n\n   \n\n**Example output:**<br>You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n[INST1]  \nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\n[INST2]  \nFBS: 100 mg/dl\n[INST2]   \nHbA1c: 6.5%\n[INST2]    \nCholesterol: 190 mg/dl\n[INST2]    \nTG: 140 mg/dl\n[INST2]    \nLDL: 125 mg/dl    \nHDL: 40 mg/dl    \n- Evaluation: 1\n- Treatment: 2\n\n*Note: The output should be a two-column data frame in your working directory, which includes `Evaluation, Treatment` and `Score per question`*\n\nIn this exercise, you should calculate and output the total",
        "label": 0
    },
    "2129": {
        "output": "![INST]\n![INST]<EOD> A comparison of two methods of assessing clinical decision making: clinical vignettes and expert-generated vignettes\n\nBackground: Assessment of decision making and analysis of the results has generally relied on the use of clinical vignettes, where a hypothetical case is generated. Two types of clinical vignette are commonly used: vignettes generated by clinical experts, generally experienced clinicians, and vignettes generated randomly by computer, which reflect the common conditions that occur in the clinical population. This study used medical students as respondents to compare both types in the assessment of clinical reasoning.Methods: Four undergraduate medical student cohorts participated in the study: first-year students were assessed in September 2013 using clinical vignettes generated by expert clinicians (E-vignettes), a second cohort were given the same task, but using random computer-generated vignettes (R-vignette). An assessment using random computer-generated clinical vignettes (R-vignette) was undertaken on a second group of firstand second-year students the following year. In total, 572 students participated in the study. The students were each given 16 E-vignettes and 16 R-vignettes, of which 8 of each type were case-specific. Four students responded to the E-and R-vignettes in the 2013 study and another four responders were given the same task the following year. All students took 32 minutes to complete the assessment and feedback was given immediately on completion of the assessment. The responses to the two types of vignettes were compared. Results: The students were exposed to similar overall case mixes in the E-vignettes and R-vignette assessments, with similar response rates to cases. However, for case-specific responses, the students responded differently to cases between E-vignettes and R-vignettes. First-and second-year medical students responded differently to cases in some E-vignettes and R-vignette tasks. Responses to the same E-vignettes and R-vignettes were found to be correlated, but there were fewer case-specific responses following exposure to R-vignettes. While case-",
        "label": 2
    },
    "2130": {
        "output": "> ### Run\n\n```\n\n# Run the training and validation steps\n```\n1. Check if model can be used with a given training and validation dataset.\n\n```\nsckit-learn.feature_importance_run(['-d', 'train_data/clinical_trials.csv', '-m', 'glmnet', '-n', '1', '-y', 'clinical_trials_predict_data.csv'], 1)\n```\nOutput\n\n```\nFeature importance is computed (scaled and centered by feature)\n```\n\n![feature importance](./figures/feature_importance.png)\n\n2. Evaluate the performance in cross-validation folds. Check if the model can return the correct value for both training and testing folds\n\n```\nsckit-learn.validate_run(['-d', 'train_data/clinical_trials.csv', '-m', 'glmnet', '-y', 'clinical_trials_predict_data.csv'], 1)\n```\n\nOutput\n\n```\n\nFeature Importance:\n1. Age -14.77812 76.01%\n2. gender -5.07422 62.80%\n3. Disease -13.87593 15.52%\n4. BMI -8.85989 24.75%\n\nTraining Score: 62.80%\nValidation Score: 15.52%\n\nModel's Validation:\nTrain Score: 98.32%\nTest Score: 54.6%\n```\n\n\n3. Evaluate the performance on the independent test set. Check if the model is able to return the correct values for the test data\n\n```\nsckit-learn.validate_run({'data': clinical_trials_predict_data,\n                        'train_data': train_data,\n                        'model': glmnet,\n                        'scores': ['test_scores', 'score', 'error']}, 1)\n```\n\nOutput\n\n```\nModel's Validation:\nTrain Sc",
        "label": 0
    },
    "2131": {
        "output": "__HINTS:__ Note the differences. We've seen an increase in diastolic/systolic blood pressure, oxygen saturation and hemoglobin, but there is a decrease in electrolytes, sodium, blood urea nitrogen, and urine volume compared to the last patient. The lab tests show the patient's renal conditions are worsening.\n\n**Quiz:**\n```\n# Your code goes here!\n\n```\n\n**What to submit**:\n1. You must use the [Markdown](https://docs.python.org/3.6/library/mdpress.html) formatted notes to submit your codes. \n2. For multiple implementations, submit a folder (or a zip archive) containing your code files.\n3. You must also submit a text file containing your answers to the [assessment](data/assessment.pdf).\n4. Add the [problem ID](data/problem_lists/problem_id.txt) to your submission, so that we can automatically associate your code with your assessment.\n\n\n**Guidelines:**\n**Mandatory:** We expect that your code fulfills the following features:\n* Your code contains a function named `assess`, which prints the Trial-level eligibility for each patient.\n* Your code will include a data structure in which patients' lab and clinical trial parameters will be stored.\n\n**Points:**\nYour submission will be assessed by the following criteria:\n\n* It passes the self-assessment test\n* It prints the correct Trial-level eligibility for each patient\n* Your code has a readable design\nAdditional points will be given to:\n\n* Code readability: your code should be simple and easy to read.\n* Code completeness: your code should be complete. There should be no extra code added while we check your submission.\n* The documentation quality: you should write a concise and well-written documentation.\n* Code functionality: your code should have good functionality.\n* Creativity: your code is not identical to the accepted codes or has no creativity at all.\n\n\nWe provide an exemplary code and a guide in your assessment submission to help you structure your code. You may choose any programming language (e.g., Python)",
        "label": 0
    },
    "2132": {
        "output": "Here are the steps if you wish to do your assessment in [INST]:\n1. First of all, make sure that your trial data are in the database with the field of interest (Patient-level eligibility in PTN), and that the name-value you selected is correct.\n2. Click on [Eligibility Assessment] at the top. \n3. Click [Eligibility assessment] in this page. \n4. Click on [Eligibility] at the top.\n\nPlease be noted that this option in the trial-level is an assessment of how compatible a given trial and patient are, i.e., this option will calculate the degree of difference between the two groups.\n![Eligibility]\nLet's show an example of the eligibility assessment in which the patient of interest is not included in the trial.\nInput the following values at the trial recruitment assistant: \n1. Patient-level eligibility field:\n\n[![Eligibility assessment]](https://research.usask.ca/trial2/images/eligibility-assessment.png \"Eligibility assessment\") \n[![Eligibility for the given trial]](https://research.usask.ca/trial2/images/eligibilityfor-the-given-trial.png \"Eligibility for the given trial\") \n[![Eligibility assessment]](https://research.usask.ca/trial2/images/eligibilityassessment.png \"Eligibility assessment\")\n2. Click [Eligibility assessment] at the top.\n![Eligibility assessment]\n3. Click on [Eligibility assessment history] at the top.\n![Eligibility assessment history]\n4. Click on the [Eligibility graph] menu.\n![Eligibility graph]\nAfter performing the last step, you can see the screen which indicates the degree of the difference between the given trial and candidate patients.\n[![Eligibility graph]](https://research.usask.ca/trial2/images/eligibilitygraph.png \"Eligibility graph\")\n\nThe degree of differences is shown by the heat-map. As the temperature on the map increases, the number of differences",
        "label": 0
    },
    "2133": {
        "output": "##[TRIAL SUPPOTMENT]\n\n\n\n### In this section you are only supposed to indicate who has reviewed the assessment and whether or not the assesment is clear and useful\nAsk your group member to answer this statement to finish the trial supplement: The trial-level eligibility assessment is 2: eligible.\nAsk the participant: The assesment: trial-level eligibility is 2: eligible.\nWhat should come after the assessment, i.e. `:` ?\nYou should leave enough space to put the trial-level eligibility. Write the number and the character that should follow it, e.g., `Trial-level eligibility: 2) Eligible. \u262f # `.[/TRIAL]\n\n## [SOLVING STRATEGIES]\n\n## TRAVEL TO BEIJING TIME TRAVELLERS\nJason, who is an avid traveler, is planning to take a trip to Beijing. First of all, what is the travel period? Let's use the data from Wikipedia for the month of February. \nThere are 29 days in January and February and 31 days in the other months. Therefore, Jason's travel period is 29 to 31 days in February.\nHow much should the average daily price of staying in Beijing be? Jason wants to minimize the total travel cost. He wants to figure out the price fluctuation of the hotels, but he has to check in and out on the first and last days of the travel period, so the travel cost is the sum of the price every 2 days. If the price is the same per day, the price should be $21 per day. If it is $30 per day, the total cost has a slight difference (around 4.5USD). In order to reduce the total cost, we can assume the average price every 2 days is $30.\nJason also wants to minimize the distance travelled while the average prices for each hotel is assumed to be $30 per day so we can add up the total price for each hotel and the total distance. Also, we want to use some distance matrix so that we can have equal distance between each hotel. First of",
        "label": 0
    },
    "2134": {
        "output": "<EOD> Involvement of MAP kinases in the differentiation of L929 murine fibroblastic cells.\nMitogen-activated protein (MAP) kinase is activated in rat embryonic fibroblasts (REF52 cells) and L929 murine fibroblastic cells by serum or platelet-derived growth factor (PDGF), whereas activation is not seen in NIH 3T3 fibroblastic cells or C6 glioma cells. These findings may be correlated with the fact that REF52 cells differentiate into the neuronal tissue with PDGF, while L929 murine fibroblastic cells do not. We thus investigated the involvement of the MAP kinase in the differentiation of L929 cells by inducing differentiation with butyric acid. Activation of MAP kinase was increased with the time of the culture to the level observed with the activation of serum or PDGF in REF52 cells or PDGF in L929 cells. Activation of MAP kinase with butyric acid was suppressed by the protein synthesis inhibitor, cycloheximide. A recent study showed that PDGF induced phosphorylation of the c-Fos proto-oncogene product in both REF52 cells and NIH 3T3 cells. Expression of c-Fos was induced with the time of the culture to the level seen with the activation of PDGF in all L929 cells. In contrast, activation of MAP kinase by butyric acid, was correlated with c-Jun, not with c-Fos, in L929 cells. We thus propose that the two modes of MAP kinase activation may be differentially correlated to the cellular differentiation.<EOD> Charged particles in liquids: from the liquid-to the solid-like state.\nParticles in the liquid state do not show characteristic behavior as in the solid-like state due to the absence of any long-range positional order. One way to overcome such limitations of the liquid phase and to exploit the intrinsic features of the solid-like phase is to confine the particles in a liquid crystal matrix. Recently, the liquid-to-solid-like transition has been expl",
        "label": 0
    },
    "2135": {
        "output": "<EOD> Transdermal delivery of drugs for local treatment of skin disorders\nLocal treatment of diseases of the skin often requires long-term administration of drugs. Since the stratum corneum is a natural barrier to the topical delivery of drugs, and since many skin disorders cause damage or loss of this barrier, many topical drugs are inefficient and shortlived. Transdermal delivery of drugs is particularly suitable for local treatment of skin diseases, both of the intact skin and of disorders of the damaged skin. A wide variety of formulations have been developed for transdermal delivery of drugs for local treatment of skin diseases. Examples of systemic drugs are discussed and a summary of the various types of transdermal patches developed for this purpose is included.<EOD> The Relationship Between Childhood Emotional Maltreatment and Attachment Style in Female Rape Victims\nThis study aimed to explore whether emotional abuse in childhood and adult internal and external working models of relationships are associated with rape victimization. The sample consisted of 27 female victims of rape and 62 college women recruited from the community. Participants completed the Emotional Abuse Questionnaire, the Inventory of Childhood Origins, and the Experiences in Close Relationships\u2013Relationship Structures questionnaire. Results indicate that the groups differed significantly with respect to emotional maltreatment. In the emotional abuse group, the relationship between attachment style and childhood abuse did not reach the level of significance. The results indicate that traumatic events in early life, as well as a high degree of insecure attachment style, are possible risk factors that predispose women to rape victimization. The clinical implications of the data are considered; it is proposed that therapists working with this population may benefit by focusing on childhood trauma and its relation to attachment style.<EOD> Preventing cardiovascular- and metabolic diseases by controlling obesity-related hormonal derangements\nObesity is a serious medical condition involving over accretion of body fat associated with risk for multiple diseases including cardiovascular, kidney, and certain types of cancer. In obesity, the adipose tissue releases an abundance of inflammatory and ad",
        "label": 0
    },
    "2136": {
        "output": "## Clinical Trial Assessments\nNow let us see the clinical trial assessments. There are five assessments here: height, waist, weight, body mass index (BMI), and age. \nLet's run the script!\n> python ctr1.py --help\nUsage: ctr1.py [OPTIONS]\n\n  -o: Output to a file. If this option is not set, it defaults to standard output.\n  -i: Include a given clinical trial recruitment note as an input file. Note that all the other input files will be ignored if this option is set.\n  -c: The clinical trail name\n  -x: The patient's note name\n  -f: the first assessment name\n  -s: The second assessment name\n  -d: The third assessment name\n  -h: the fourth assessment name\n  -t: the fifth assessment name\n  -e: the sixth assessment name\n  -v: The assessment value\n\nYou can provide assessments options one by one, or you can set 10 different assessments options for the default value: `1 2 3 4 5 6 7 8 9 10 11`.\n> python ctr1.py -d -e 3 --f \"firs  assessment\".txt patient.txt -i\n\n  [INFO] Trial-level eligibility: 2) Eligible.\n\n> python ctr1.py [OPTIONS]\n  Excluding -c  option from the options\n   [INFO] Including: -i option from the options\n   [INFO] Inclusion criteria not met for clinical trial 'c7e68618 925a-758a-59ae-9d04-aa9ec3ca c54'\n   [INFO] Inclusion criteria met for clinical trial 'c7c173c9 3c75-117c-e3dd-b530-0127685a 95b'\n   [INFO] The first assessment is 360.5\n\n  [INFO] Assessments:\n    Assessment 1:",
        "label": 0
    },
    "2137": {
        "output": "<EOD> Clinical trials of human papilloma virus vaccines: will they have adverse side effects, too?\n\n\n\n# Introduction\nIt is estimated that each year 5.5 million cases of genital warts caused by the human papillomavirus (HPV) are reported worldwide. Infection with HPV is the main reason for cervical precancer and cancer, including anal, vulvar, and penile cancer [bib_ref]  HPV testing: a bridge to the future, Gross [/bib_ref]  [bib_ref]  Use of the hybrid capture 2 test in the management of women..., Crosbie [/bib_ref] .\nHPV is an epitheliotropic, non-enveloped DNA virus which cannot be cultivated in vitro. So, the clinical management of diseases caused by HPV is difficult despite intense research [bib_ref]  Immune response in cervical cancer patients treated with vaccinia vector therapeutic vaccine..., Santini [/bib_ref]  [bib_ref]  Treatment of cervical intraepithelial neoplasia by topical application of human papillomavirus viruslike..., Fauccoli [/bib_ref]  [bib_ref]  Cervical intraepithelial neoplasia following vaccine trials, V\u00e1zquez [/bib_ref] . So far, the only way to protect the immune system from genital warts and prevent HPV infection is vaccination. HPV vaccines protect against infection with certain viral subtypes which are major causes of the two most frequent HPV-related cancers (cervical, and vulvar carcinoma), cervical intraepithelial lesions, and genital warts [bib_ref]  Efficacy of prophylactic human papillomavirus type 16 vaccines: a systematic review, Malag\u00f3n [/bib_ref] . There are few clinical trials involving HPV vaccines which are mostly in phase II and III (Tables 2-6). The aim of this review is to summarize the results of these trials. The study was conducted using Medline (1977-2006), the Cochrane Database of Systematic Reviews and the American Society of Clinical Oncology. The search used the words \"vaccine\", \"imm",
        "label": 0
    },
    "2138": {
        "output": "[HELP]\nTIP For assessing eligibility, you should use a 3-point scale, where 0-Excluded, 1-Not relevant and 2-Eligible. To obtain a 3-step eligibility from multiple eligibility values, use `min`. For instance, if your output is `0.00 0.00 2.00 [Inst]` for a patient note, you can get a [3-step eligibility] of\n- `Excluded` will be `if patient.eligibility[0].val > 0 && patient.eligibility[1].val <= 0`\n- `Not relevant` will be `if patient.eligible[0].val >= 0 && patient.eligible[1].val <= 0`\n- `Eligible` will be `if patient.eligible[0] <= 0 && patient.eligible[1] > 0`. \n[/HELP]\n\n\n\n[INST] The following steps are the same for all eligibility types. `if patient.eligible[k].val > 0 && patient.eligible[l].val <= 0` if `k, l \u2208`inclusion_criteria``:\n```py\n- 0-eligibility.html\n```\n```py\nif patient.eligible.has_value(0):\n    return 'Excluded'\nelif patient.eligible.has_value(1):\n    return 'Not relevant'\nelif patient.eligible.has_value(2):\n    return 'Eligible'\n```\n```py\nif patient.eligible.has_value(0):\n    return 'Excluded'\nelse if patient.eligible.has_value(1):\n    return Not relevant\n```\n```py\nif patient.eligible.value > 0 and patient.eligible.value <= 0:\n    return Eligible\n```\n```py\nif patient.not_eligible.has_value(2):\n    return 'Not eligible'\nelse if patient.not_eligible.has_value(1):\n    return Not relevant\n```\n```py\nif patient",
        "label": 0
    },
    "2139": {
        "output": "<EOD> CXCR4/CXCL12 axis contributes to the progression of breast cancer cell by inducing the production of TNF-\u03b1 through NF-\u03baB-caspase 1-IL-1\u03b2 pathway\n\nBreast cancer (BC) is a common invasive neoplasm threatening women's health, and chemokines play important roles in BC invasion and metastasis. Therefore, it is worth investigating the proliferation and invasion of BC cells through chemokine signaling. CXCL12-CXCR4 axis is involved in the development of lung, prostate and colorectal cancer. Here, we observed that BC cells expressed a higher level of CXCL12, which was up-regulated by IL-6 through JAK2/STAT3 pathway. Then, we studied the effect of CXCL12-CXCR4 axis on BC cells via ELISA, RT-qPCR and western blot assays, and CCK-8, transwell and scratch assays were conducted to evaluate the invasive and proliferative capacities of BC cells. Moreover, flow cytometry, FCM, western blot and RT-qPCR analyses were applied to observe the effect of CXCL12-CXCR4 axis on BC cell apoptosis and autophagy. Furthermore, we observed the relationship between TNF-\u03b1 and the NF-\u03baB-caspase-1 and IL-1\u03b2 pathway in BC cells. In addition, the expression of TNF-\u03b1, NF-\u03baB p65, caspase-1 and IL-1\u03b2 in BC patient serum samples was detected by ELISA. Our findings suggest that CXCL12-CXCR4 axis upregulates the production of TNF-\u03b1 by BC cells, then activates NF-\u03baB-caspase 1-IL-1\u03b2 pathway in turn, thereby promoting the proliferation, invasion and autophagy of BC cells, and inhibiting cell apoptosis, contributing to the development of BC. Clinical data confirmed that serum TNF-\u03b1, NF-\u03baB p65, caspase-1 and IL-1\u03b2 were all higher in BC patients than those in healthy",
        "label": 2
    },
    "2140": {
        "output": "##[/CODE]\n\n\n## Exercise\nWhat are the challenges in this case?\n\n- If the patient is taking diet and exercise medicine, can we expect this patient would use self-management system to optimize his heart failure?\n- Given the patient's risk factors, can you expect this patient would be able to comply with the system?\n- How the exclusion criteria would change your assessment of eligibility to this patient?\n- Which variables affect your final output?\n<EOD> SARS-CoV-2 transmission in dental practice: brief review of preventive meassures in Italy.\nWith this brief article the authors are going to discuss preventive measures in dental clinics during SARS-CoV-2 transmission. SARS-CoV-2 is an RNA virus that in 2019 firstly appeared in China and quickly has spread all around the world to infect the entire population. The clinical manifestation of this disease was initially unknown and in the beginning, the symptoms were very similar to typical flu. In March 2020, the World Health Organization (WHO) declared a global pandemic status for the disease, because on a certain date, it had spread to almost all countries in the world. As time went on, symptoms changed making the management of this disease much more difficult. At the end of February 2020 in Italy, the virus arrived and began spreading very quickly, causing the lockdown of the entire country. On the 9th of March, the Italian government, in order to fight the spread of the virus, decided on the so-called \"Phase 1\", which consisted in blocking activities that were considered at risk. In Phase 2, the activities, starting from the 4th of May, were progressively resumed to meet the needs of the population and it was decided to set up activities in dental clinics only for patients who needed urgent treatment in order to guarantee their health and the well-being of the entire population. The Italian dentists have followed these and all the anti-SARS-CoV-2 protocols proposed by some scientific associations, the most important being the \"Pilot Project\" of AIFI (Italian Association for Hospital Infection Control). This document is the Italian version of the guideline \"Minimum requirements to be met by dent",
        "label": 0
    },
    "2141": {
        "output": "- The following instructions should help you to generate the desired results.\n- You will need Python 3.6 and the [pandas](https://pandas.pydata.org/) and [PyMC3](https://PMC3.readthedocs.io/en/latest/) packages.\n\n```bash\npython3 -m pip install pandas\npython3 -m pip install PyMC3\n```\n```python\n# Import all the required libraries\nimport pandas as pd\nimport PyMC3 as pm\n```\n```python\n# Loading the dataset from an excel file\ndf <- pd.read_excel('data.xlsx')[['ID', 'Gender', 'Age', 'Marital_Status', 'Insurance', 'Education', 'Job_Status', 'Weight', 'Height', 'Body_Mass_Index', 'FBS', 'HbA1c', 'Cholesterol', 'TG', 'LDL', 'HDL', 'Insulin', 'Correlation_Factor', 'Carbohydrate', 'Insulin_Activity_Time']]\n```\n```python\n# Select the variable with the label: Age\ndf = df[['ID', 'Gender', 'Age']]\n```\n```python\n# The columns are renamed to be used as state variables when defining the model\nstate_var_names = ['ID', 'Gender', 'Age', 'Marital_Status', 'Insurance', 'Education', 'Job_Status', 'Weight', 'Height', 'Body_Mass_Index', 'FBS', 'HbA1c', 'Cholesterol', 'TG', 'LDL', 'HDL', 'Insulin', 'Correlation_Factor', 'Carbohydrate', 'Insulin_Activity_Time']\ndf['Age'] = df['Age'].str.split()[0]\ndf.drop(['ID', 'Gender', 'Height', 'Body_Mass_Index', 'Weight', 'Correlation_Factor', 'Insulin_Activity_Time', 'Insulin'], axis=1,inplace=True) # remove unnecessary columns\ndf.rename(columns={'Insurance': 'Insurance_Type', 'Education': 'Education_",
        "label": 0
    },
    "2142": {
        "output": "##### Patient enrollment\n`Trials.insert(patient)`\n\t//\n\t`}` \n\n<EOD> Tackling Mental Health in Primary Care: A Practical Guide - 1st edition Bryant M C Psychology Press\n\n \n\n## The\nThe section on patient assessment provides a comprehensive set of tools to help practitioners systematically investigate mental disorders, including the use of clinical staging.\nThe chapter on intervention planning offers an in-depth description of a wide variety of psycho-educational interventions (e.g. group therapy).\nThe section on the provision of treatment also covers a comprehensive range of interventions (e.g. Cognitive-behavioural therapy), as well as complementary / alternative therapies such as Tai Chi and mindfulnessbased approaches.\nThe book is accompanied by a website for the use of practitioners, patients and visitors with practical information about this book and mental health, as well as resources such as assessment tools and worksheets related to the contents of the book. This site can be found at www.jamesryan.co.uk/tackling-mh-book-info. It is worth pointing out that the site doesn't seem to be fully updated with some of 2",
        "label": 2
    },
    "2143": {
        "output": "[TIP]\nIf you want to provide a help option to a patient for an input that is not in a JSON value, add the help option as a special field in JSON, e.g., `age: { help: \"What is your age?\" }`. [/TIP]\n\n- `age`, patient age.\n\n- **Type 2 diabetes screening**[4,5] is performed by screening for blood glucose. Tests are typically performed in a single session. Patients taking medication can wait for two weeks after starting it in order to perform the test. Fasting overnight also helps to improve the accuracy of blood glucose results.\n\n\n[INST] Hello. You are a helpful assistant for the trials of diabetes. Your task is to determine the type of disease of each patient from their medical records.\n\nThe patient has two records; the first is their current information, and the second is their prior medical history.\n\nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., output a scale for the assessment of eligibility.\n\nHere is the patient note:\n\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\n\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl\n\nHere is the patient past medical history:\n\n7",
        "label": 2
    },
    "2144": {
        "output": "#### Q2. When you should use `Trial-level eligibility: 3)`? What if you do not know what inclusion or exclusion criteria the given patient note satisfies?\nIf you do not have enough information to make an assessment of eligibility, set the `Trial-level eligibility` to `3) Not relevant.`, or `Trial-eligibility: 3) Not relevant.`. To see the description of the factor `Excluded,` visit the [Eligibility Factors](https://wsk.github.io/?path=/v/wskr-c-t-1.9/docs/v1_0.md#eligibility-factors) page. \n\n![Eligibility factors](image/q2.jpg)\n\n> :information_source: In this study, the factor `Excluded` indicates the factor that the patient does not have sufficient information to qualify for the trial.\n\n#### Q3. How to use `Trial-level eligibility: 4)`? What if the given patient note meets both inclusion and exclusion criteria? \nIf the patient's information satisfies both inclusion criteria and exclusion criteria, the `Trial-level eligibility` is set to `4) Excluded.`.\n\n![Excluded](image/q3.jpg)\n\n> :information_source: If both inclusion and exclusion criteria are met (or you have insufficient information to assess), the patient is automatically labeled as `Excluded.`. Then, it is not necessary to repeat `Trial-level eligibility: 4) Excluded.`. To skip `Trial-level eligibility: 4) Excluded.`, set `Trial-level eligibility: None (e.g., Trial-level eligibility: None) instead`. To see the description of the factor `Excluded` visit the [Eligibility Factors](https://wsk.github.io/?path=/v/wskr-c-t-1.9/docs/v1_0.md#eligibility-factors) page. \n\n![Eligibility factors](image/q3.jpg)\n\n### Q4. Why should we have a field called the `Trial-level eligibility? You know what",
        "label": 0
    },
    "2145": {
        "output": "<EOD> Efficient Flavonoid-Mediated Synthesis of 18F-Labeled 1,2,3-Triazoles via Cu(I)-Catalyzed Cyclization of Azide, Nitrone, and Alkyne Combinations.\nThe azide-alkyne \"click chemistry\" has been studied extensively in biological and medicinal chemistry applications in recent years. However, the application of \"click chemistry\" to radiopharmaceutical research has been limited by the restricted availability of azide bio-reagents. To overcome this obstacle, we developed a copper-mediated cycloaddition reaction, which overcomes this limitation by using a biocompatible nitrone and an alkyne combination. A general synthetic method was successfully developed through systematic modular optimizations. Using this strategy, the 2, 4-disubstituted-1,2,3-triazole ring was fused to existing medicinal chemistry cores, such as 2,4,6-trisubstituted-thiazole (1), quinoxaline (2), and benzothiophene (3). These radiotracers were subsequently evaluated in vitro and in vivo. The most promising radiotracer was -3, which showed a good affinity for the S1PR3. Furthermore, -3 could be used for the visualization in the lungs of S1PR3-transgenic mice.<EOD> Re: Diagnostic accuracy of transient elastography in detection of esophageal varices with ultrasonography for esophageal varice history\nI am writing to congratulate Siddiqui et al. (2021) on their publication, \u201cFibrate therapy for NAFLD: a systematic review and meta-analysis of randomized controlled trials\u201d of the Journal of Hepatology. The authors are lauded for conducting such a comprehensive review in a timely manner. As someone that has published a meta-analysis on a similar topic in a leading gastroenterology journal in 2017, I was hopeful to learn that at least one review paper had been published on the subject recently and was encouraged to see a high-profile journal taking interest in this topic. That being said",
        "label": 0
    },
    "2146": {
        "output": "Note that you should never use `if ... then ...` and `if else ...` statements while passing data to the next level. Use only `map` method.\nTo evaluate the output (also known as the \"final value\"), you need to modify the test_output_list variable.\n\nFor example, suppose you used the clinical trial's variables in the if statement. Then, these variables can be removed from the test_output_list by setting the variables to an empty string ('') within the if statement:\ndef test_eligibility1(input):\n    \"\"\"\n    Patient Assessment: Clinical Trial #2\n    \"\"\"\n    input_file = file_reader(input_file)\n    \n    # In this line we are making the if statement for the first trial\n    # with a variable name of trial1_assess_1\n\n    test_output_list[\"trial1_assess_1\"] = \"trial1_assess_1\"\n    \n    # If the trial is for a woman then we add the \"gender\"  into the last line where\n    # we are saving all the information about a trial in the variable test_output_list \n    # (this line only needs to be changed for the first assessment)\n    if input.genders_1 == \"women\" : \n        test_output_list[\"trial1_assess_1\"] += \"; Gender_1: Women\"     \n    # This line adds to the output if there is a previous disease\n    if \"diagnosed_with\" in input_file[0] : \n        test_output_list[\"trial1_assess_1\"] += \"; Diagnosed with: \" + \"\\n\".join([ input_file[i] for i in range(2, len(input_file)-1) ) + '\\n'  \n    # In these lines, we are saving information about the last 3 levels of the assessment from the test_output_list \n    test_output_list[\"trial1_assess_1\"] += \"; ACE inhibitors: Eligible\"; \n    test_output_list[\"trial1_assess_1\"] += \"; Lopes et al.: Eligible\"; \n    \n    # This",
        "label": 2
    },
    "2147": {
        "output": "To demonstrate how to achieve a 100% success rate, we provide the following example on GitHub: [Eligibility code](https://github.com/guruindia/eligibility/blob/master/app/javascript/eligibility/eligibility.js), and a solution for this challenge may be found in [your solution](https://github.com/guruindia/eligibility/blob/master/app/javascript/eligibility/your-solution/your-solution.js).\n\n\n###### Note:\nThe above-executed code will return a JSON file. If you want to return a string, just wrap the return statement in parenthesis: `Trial-level eligibility: (2) Eligible`.\n\n---\n\n[< Previous challenge >](./eligibility-challenge-01.md)\n[< Next challenge >](./eligibility-challenge-03.md)\n<EOD> Gastric epithelial necrosis induced by hyperthermia for hepatic radiofrequency ablation: a retrospective matched cohort experience\nAim:\u2002 A retrospective cohort study was conducted to evaluate the relationship between hyperthermia\u2010induced gastric necrosis (HIN) and radiofrequency (RF) liver ablation. Factors including tumour stage, ablation time, blood loss and time required for ablation were compared.<EOD> 3044. Safety and Pharmacokinetics of 3-day Treatment of T-808, an Innovative Inhaled Antibiotic, in Mechanically Ventilated Patients\n\n\n\n# Background.\nDobraDobra (DDM) is a novel compound that combines a 5-chlorothiophenyl amide with a quinolone core and exerts bactericidal and bacteriostatic effects on Methicillin-Resistant Staphylococcus aureus (MRSA), \u03b2-lactamase producing bacteria, and Pseudomonas aeruginosa [bib_ref]  DDM; a New Amino/hydroxy Aryl Thiophene with Antimicrobial Activity, Kuznetsova",
        "label": 1
    },
    "2148": {
        "output": "# Conclusion\nIn this section, you have learned how to make decisions about which patients are eligible for a clinical trial by providing an evaluation based on a comparison between the patient's information and the criteria of the trial.\nThe program [Trial Evaluator](https://github.com/King-Drug/TrialEvaluator) is written in the Python program and can be installed in the Anaconda environment by command `$ conda install -c pypi_pkg pyTrialEvaluator` and also executable as `python3 trial_evaluator.py patient_note.txt trial_info.txt`<EOD> A rare manifestation of Corynebacterium jeikeium infection: Cutaneous tuberculoid type of non-Langerhans histiocytosis in a diabetic patient.\nThere are several diseases that mimic nodular, skin lesions in dermatopathology. Some infectious agents may cause reactive or metamorphic skin lesions, and are sometimes diagnostically challenging in tissue sections. Moreover, differentiation from metabolic disorders, neoplasms and inflammatory diseases may be difficult because of similar clinical, dermatological and/or histopathological findings. To our knowledge, skin lesions due to Corynebacterium spp. are very rare in the literature. Most dermatological diseases presenting with skin lesions due to Mycobacteria spp. have been described to be localized cutaneous tuberculosis mimicking different entities, including lupus vulgaris-like lesions. In contrast, our patient had dermal non-Langerhans cell histiocytosis or juvenile xanthogranuloma, mimicking granulomatous cutaneous sarcoidosis. Histoloplasmosis, coccidioidomycosis, bacillary angiomatosis, tuberculosis and deep fungal infection, including cryptococcosis, are the main infectious diseases that may be misdiagnosed as sarcoidosis. Herein, we report the case of a patient with skin lesions clinically mimicking sarcoidosis that histopathologically revealed granulomatous inflammation due",
        "label": 0
    },
    "2149": {
        "output": "<EOD> Cerebral Petechial Haemorrhages in Adult Intralobar Sequestration Associated with Severe Cerebral Oedema\nAbstract Cerebral petechial haemorrhages are an established complication of intralobar pulmonary sequestration (ILS) secondary to vascular steal, hypercarbia, and hypoxia. They are rarely considered a differential diagnosis of brain haemorrhage in adult autopsy cases. In this study, cerebral haemorrhages were found in 18 of 49 cases of congenital bronchopulmonary sequestration. Of these, 10 (55%) were ILS and the remaining 8 (45%) were extralobar sequestration. Ages ranged from 14 to 86 years. Petechiae were found in all 30 cases of steal sequestration. There was no correlation with either age or type of sequestration. In this group, 57% of cases had petechial haemorrhages in the superior cerebellar peduncles and 30% in the cortical and subcortical white matter. In comparison, non-steal and extralobar ILS did not commonly exhibit these findings. In all cases, the sequestration was found to contain areas of haemorrhage and cyst formation with a prominent fibrous layer in the wall. Focal thickenings of the wall were thought to cause local aneurysms, resulting in distension and rupture with secondary cerebral haemorrhage.<EOD> The effects of ankle-foot orthoses on lower limb loading during gait in patients with lateral ankle hypermobility: clinical implications.\nBACKGROUND AND PURPOSE\nPatients with lateral ankle hypermobility (LAH) are frequently prescribed ankle braces or foot orthoses in an attempt to stabilize the anterior talofibular ligament. The purpose of this retrospective study was to examine the effects of ankle orthoses on center-of-pressure (COP) measures and to determine if a COP threshold could be determined that would be indicative of need for ank",
        "label": 0
    },
    "2150": {
        "output": "You should solve the following problems: \n\n> Problem 1 [INST 1]\n> \n> a. First, enter the 3 pieces of information about the patient into the first two boxes in the user interface: `ID: 56712; Name: Mr. X; Birth date: 01-02-1990`\n> \n> b. In the third box, select `3` to start calculating. \n> \n> c. If the results show 0, the patient is excluded from trial and you should click in the appropriate boxes in the third table (shown above) to select ineligible criteria. Try to solve the following problems in order to improve my system. The output must be written in the last cell of the table shown above. \n> \n> [INST 3]\n> \n> You should solve Problem 3. \nThis code is the solution for the problem 3. The first line of the code writes all variables that we need in your solution and the second line takes the patient data that you put in the cells of 3 and 1 of the user interface  and puts them in a string. If that the ID is longer than 8 characters, we pad it with a space in the beginning to make sure that the following code will be compatible with the output field of the user interface.\nThe following loop iterates through the table that you put in cell 3 of the user interface in order. In each iteration, it takes all data of that row in array of that row with rowIndex and for all the rows and if that row is at least longer than 20 characters, it puts the row index in an array with length 8 so that there will be no problem with the length of the rows of the table. The array that you put in variables that you used to store the variables of the table (i.e.) col_array is the same as the variables that I used in my code so you can just copy-paste. This is because I used a very short variable length like 20 for the length of the data to store in the array.\nOnce you put all the row indices of the rows which are longer than 20 characters into the array of row Indices, each row will be looped and if it is 20 characters and longer, it will increment two indexes for it",
        "label": 0
    },
    "2151": {
        "output": "We will go through the steps to evaluate patient's information for eligibility in each clinical trial separately. \n\nThe 1 st case is for the following steps:\n\n* The patient's gender is male and this is not a limitation in 6098 trial.\n* The patient is 25-year-old, and the age range for this trial is 25-75 years.\n* The patient is a diabetic and this is a type 1 diabetes. In this trial, the type of diabetes is not a limitation.\n* The patient does not have angina or dyspnea on the third floor, but according to this trial, the patient should not suffer from angina on any activity.\n* The patient's lipid profile is good and with a cholesterol equal to 190, this trial requires cholesterol <250, which is not suitable.\n* The patient does not have any dyslipidemia or hyperlipidemia and according to trial the patients with this problem are not eligible.\n* The patient is diagnosed with cardiomyopathy and this trial requires cardiomyopathy without any problem.\n* The patient is taking vitamin D supplements but his lab study shows that he is not deficient of Vitamin D.\n* According to this trial, the patient can take insulin. So, the patient should take 70/30 insulin and it is a plus.\n* His past medical history is no insulin therapy limitation.\n\n### Clinical Trial 6090\n\nThe 2 nd case is for the following steps:\n\n* The patient's gender is male; female is a necessity for this trial and our patient is male.\n* The patient'`s age is 32, but the minimum for this trial is 20.\n* The patient is type 1 diabetic, while according to this trial this type of diabetes is not acceptable.\n* The patient is a dyslipidemia and this is a limitation in this trial\n* The patient is a hypertensive; according to this trial this issue is a limitation. In the lab study, the lab data is good and this patient should be able to participate in",
        "label": 0
    },
    "2152": {
        "output": "[END]\n\n### Exercise:\n\n[CODE]\nimport clinical_trial as CT\n\ndef main(patient, trial):\n\n    trial_patient_note = CT.patient(patient=patient)\n    trial_note = CT.inclusion_criteria(trial=trial) \n\n    trial_result = CT.trial_level_eligibility(patient_note=trial_patient_note, trial=trial)\n    print(f'Trial level eligibility for {trial.title}: {trial_result}')\n\nif __name__ == '__main__':\n\n    main(\"Jason\", CT.EXAMPLE)\n    \n```\n\nNote - If the path to the clinical trials files is incorrect, you will receive the following error:\n\n    File \"/opt/anaconda3/lib/python3.6/site-packages/clinical_trial/errors.py\", line 40, in error_exception\n    \"Invalid inclusion criteria : path not exist:\\n%s\\nFile : %s\" % (self.inclusion_criteria_notfound, self.abs_path+\"/data/inclusion_criteria.csv\")\nTypeError: Invalid inclusion criteria : path not exist:\n\n    Trial:   New \n    Title: Stroke to target\n    Inclusion Criteria :\n    Age (years) < 18\n    Rankin score > 2\n    Age (years) \u2265 18\n    Rankin score <=2\n    Age (years) \u2265 13\n    Rankin score <=3\n    Age (years) \u2265 13\n    Rankin score \u2264 4\n    Absent > 1.5\n    Sex \n    Age (years) < 3\n    Existing cardiovascular disease (not including hypertension, diabetes)\n    Age \u2265 70\n    Mild or severe cardiovascular disease\n    Family history of cardiovascular disease (first-degree relative) \n\n<EOD> Evaluating the dietary intake of adult New Zealanders in relation to dietary guidelines.",
        "label": 0
    },
    "2153": {
        "output": "<EOD> Efficacy and safety of ticagrelor compared with clopidogrel in the Chinese population: final analysis of the TICOPA study\n\nBackground: The Ticagrelor in Chinese Patients with Acute Coronary Syndromes (TICOPA) study compared the 18-month efficacy and safety of ticagrelor vs. clopidogrel in Chinese patients with acute coronary syndrome (ACS). TICOPA also explored the effects of genetics (P2Y 12 rs6809524 and CYP2C19) and clinical risk factors on outcomes.Methods: TICOPA randomized, double-blind treatment with ticagrelor or clopidogrel plus aspirin for 18 months in patients with ACS in China. Key outcomes included primary efficacy, a composite of all-cause death, myocardial infarction (MI), stroke, and urgent target artery revascularization (URRA); primary safety, non-CABG-related bleeding; and composite safety, BARC type 3/5 bleeding. Subgroup analyses were conducted to study the clinical risk factors (male sex, diabetes, and hypertension) and genetic markers (P2Y 12 rs6809524, diabetes, and CYP2C19). Results: In TICOPA, 4302 patients (mean age, 56 years; 76% men) were randomized (1:1; ticagrelor, n = 2142; clopidogrel, n = 2160), and the primary efficacy outcome occurred in 76 (3.6%) patients (ticagrelor, n = 28; clopidogrel, n = 48; RR 1.41 [95% CI 1.01-1.99]; P = 0.046) and the primary safety outcome in 123 (5.9%) patients (ticagrelor, n = 60; clopidogrel, n = 63 [RR 0.86 [95",
        "label": 1
    },
    "2154": {
        "output": "\u25a1 You should try with other clinical trials until you can repeat the steps and get a reasonable set of results as reported in this case study. You should try with other clinical trials until you can repeat the steps and get a reasonable set of results as reported in this case study.\n\n\n\n\n#### Lecture Notes\nIntroduction \n### Lecture notes and presentation\n\n#### Tutorials Overview\nThis tutorial will start with a brief introduction of the Python language and why it's used in health care field. After that, you should understand how python is used in the different health care domain and particularly in clinical trials. We will present you how the standard dataset and how you can analyze the data, and we will see how the analysis can affect the results and the conclusions. In the last section of this tutorial, we will look at how to get the data in different formats and how we can get the best outcomes to the python program you have used.\n\n# Introduction\n\nPython is a modern and powerful object-oriented programming language that supports object-oriented programming techniques. It can be used to solve a variety of computing problems ranging from simple calculations to complex graphical user interfaces. A powerful feature of Python is that it allows the programmer to extend the language with special functions and other features, so that it can be used to solve specific problems in many different areas of mathematics, engineering, and computer science.\nPython was originally designed with an emphasis on code readability, because Python code can be read by humans. The language has many similarities to Perl and Lisp, but more powerful features like automatic vector computation, type inference, dynamic execution, dynamic runtime optimization, introspection, memory management, and garbage collection are also included.\nPython's flexibility also makes it the second most popular language after Perl in bioinformatics. The Python language is particularly well suited for analyzing biological data such as genome sequences, protein sequences, and microarray data.\nHowever, using Python (or any",
        "label": 0
    },
    "2155": {
        "output": "```\n\n# Expected output\nAfter executing it, your console should print a 231 lines output file where the first 13 are for each patient and the last 218 are for the trial, e.g:\n\n```\n\n# Average runtime of execution: 0.0118s with 2536 GC samples.\n\nExpected output:\nAverage execution time: 0.01s with 547 GC samples\n\n-----------------------------------------------------------------------------------------------------------\n\n\n\n\n\n\n\nExercise 7 - [Exercise7.jl](Exercise7.jl)\n\nWrite a solution for the given inputs. You don't have to run the script, it's just for your convenience.\n\n# Inputs\n\n```\n[formula]  S = Dict{Int, Vector{Symbol}}[] # S is a list of dicts of type Dict{Int, Vector{Symbol}} [/formula] \n\n```\n\n## Problem statement\n\n```\n\nYou are a software architect leading a team developing a big business software. You want to make an estimate for the time budget and costs related to the implementation of a new feature. The product requires one week for the implementation of the new feature. You also estimate that it will take 10 days for users to adopt this feature, plus 5-7 days for the development team to implement the feature and debug in case of failure. The software is in a mature state, with 100% of the code done and tested and it does not have to be refactored in which will make easier the development time. The product should not be changed significantly in the short term after the release of the feature.\n\nWrite a solution for this problem.\n\nIdeas and hints:\n\nWrite a dictionary where key is the number of days to implement the module and value is true means the module has been implemented or false means the module has not been implemented.\n\nWrite a vector of 10 days each one the number of days for user to adopt, development team to implement the feature and debug in case of failure.\n\n\nExpected Output:\n\n```\n\n# Average runtime of execution: 0.0099s with 432 GC samples.\n\nExpected output:\n\n     [Dict{Int,",
        "label": 0
    },
    "2156": {
        "output": "You can check the result in [url = http://colab.research.google.com/p/pydoc.colab#main:index. IPython Notebook:](pydoc.ipynb), and execute it again and again to find your mistake. \n\nWhen you apply all steps and you don't get 'Trial-level eligibility: 2) Eligible.', let's try to figure out which step is not performed correctly.\n\n---\n\nBefore you proceed, please note and try to remember these two points.\n\n1) Please keep in mind that you should execute your code and get the result one by one.\n2) To perform code execution, you should put an input into each cell and press Tab.\n    \n![](images/input-output-in-IPython_notebook-CellOutput_0037.png)\n\nLet's try to figure out the mistake.\n\n---\n<EOD> Pharmacologic management of patients with coronary artery disease.\nPatients with coronary heart disease frequently present to a physician's office with a mixture of psychosocial, emotional, and cardiovascular concerns. The pharmacist treating these individuals has an opportunity to influence these patients' quality-of-life issues as much, if not more, than the cardiologist, especially because of increasing numbers of community pharmacists engaging in clinical practice. With the increase in number of statin trials, treatment with these agents has become a reality, which pharmacists should be able to discuss with their patients. Statin trials also include the treatment of angiographically mild coronary artery disease. Pharmacists must educate patients about the need for life-style management programs, particularly given the success of pharmaceuticals in modifying disease progression even in those who are at low intervention risk. Pharmacotherapeutic research has moved away from secondary prevention with drug therapy toward secondary and tertiary prevention of cardiovascular disease by a combination of life-style modification and drug therapy. In the coming years, the pharmacist is likely to have the most interaction with patients in their management of cardiovascular diseases.<EOD> Involvement of the methylglyoxal bis-guanylhyd",
        "label": 0
    },
    "2157": {
        "output": "## Example:\n[S] The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: \nFBS:100 mg/dl \nHbA1c: 6.5%   \nCholesterol:240 mg/dl \nTG:140 mg/dl  \nLDL:125 mg/dl   \nHDL: 40 mg/dl \nTitle: Contribution Of Nuclear Magnetic Resonance Imaging In The Study Of Diabetic Cardiomyopathy Summary\n: Diagnosis of diabetic cardiomyopathy is then retained, supposing a change in the coronary microcirculation linked to an endothelial dysfunction. Abnormalities of the myocardial metabolism is frequently associated. It is regrettably about a hypothesis difficult to verify with current medical techniques.This deficiency being not only harmful to the diagnosis, but also to the assessment of the efficiency of the medical treatment on the myocardial metabolism and the endothelial function. Techniques of nuclear magnetic resonance offer interesting perspectives. \nInclusion Criteria: \nmore than 18 years old \npatient type 2 diabetes affects taken care more than 5 years to Timone Hospital \npatient with a diabetic cardiomyopathy \ninformed and consented  \"Most of the clinical trials of this type are conducted in North America and Western Europe\". (Source:  )\nEligible (7):",
        "label": 0
    },
    "2158": {
        "output": "<EOD> An efficient approach for 2D and 3D brain MR image registration using multi-resolution Laplacian pyramid\nWith the rapid development of medical imaging technique and the fast progress of image processing algorithms, a lot of medical image-related information can be acquired from an acquired 3D volume. However, the information can be easily stored in a 3D volume. In practice, doctors always need to explore the information from 3D to its 2D slices in order to obtain more specific information about the structure or disease of a body. This exploration usually requires 2D-3D registration of each slice to the 3D volume. Due to the difficulty of accurate 2D-3D medical image registration, this paper proposes a new registration approach based on multi-resolution Laplacian pyramid. This registration approach is first applied to 2D-2D image registration where the original image is divided into different sub-blocks. The multi-resolution Laplacian pyramid is used as the transformation domain which is more suitable for the deformations of human anatomy in most of the registration scenarios. After 2D image registration, 2D-3D image registration process is carried out and the deformation matrices for each 2D image are recorded in the same pyramid. In order to realize 3D-3D image registration, a similar approach is used as well. Experimental results on two datasets show that the proposed registration approach has higher accuracy compared with some state-of-the-art methods which register 2D slices to 3D MR brain images.<EOD> Tic Disorders\n\n [bib_ref]  Tics and tourette syndrome, Singer [/bib_ref]  [bib_ref]  Tourette syndrome and other tic disorders: neuropsychopharmacological therapies, Singer [/bib_ref]  [bib_ref]  Tourette syndrome and related disorders, Singer [/bib_ref]  [bib_ref]  The prevalence of tic disorder in boys and girls: a population-based study, Muller-Vahl [/bib_ref]  [bib_ref]  Current status of Gilles de la Tourette syndrome research and its implications..., Alonso [/bib_ref]  [bib_ref]  Tourette syndrome, Leckman [/bib_ref]  [bib_ref]  Evaluation of preadolescents referred for attention deficit hyperactivity",
        "label": 0
    },
    "2159": {
        "output": "2. Using the data structure that you created, fill the patient object you just created to a patient note (see  and save the object on the patient variable `patientNote`.\n\n\n```\n    // creating an object of the Person class\n    var person1 = new Person({firstName: 'Sarah', lastName: 'Williams', age: 29});\n\n    // creating a JSON object to store as a property - a simple string\n    person1.phone = \"123-456-789\";\n\n    // creating a JSON object as an array to store multiple addresses - an array of strings\n    person1.address = [\"123 East 6th Avenue\", \"New York City\"];\n\n    // creating a JSON object with nested arrays to store multiple phone numbers as a list of objects\n    person1.phoneNumbers = [\n        // creating an instance of an array with one element\n        new ArrayElement({number: \"977-555-2673\"}),\n        // creating another instance of an array with one element\n        new ArrayElement({number: \"123-456-789\"}),\n        // creating another instance of an array with one element\n        new ArrayElement({number: \"+1 (234) 555-1234\"}),\n    ];\n    \n    // creating an instance of a Map element with an object of keys/values\n    person1.MapOfStrings = new MapElement({firstName: \"Sarah\", lastName: \"Williams\"});\n    \n    // creating an instance of a Map element with an array of keys/values\n    person1.MapOfArrays = new MapElement([[firstName: \"Sarah\", lastName: \"Williams\"], [age: 29]]);\n\n    // creating an instance of an object with nested arrays\n    person1.nested = new ObjectElement({firstName: \"Sarah\", lastName: \"Williams\", age: 2",
        "label": 2
    },
    "2160": {
        "output": "#### What to include in a patient note?\nYou should include all the facts of your case in the patient note, such as a complete medical history including the presenting symptom, social history, medical history, and family history. For all patients, you must also document your physical examination findings, vital signs, and laboratory findings at this visit in the patient note. For some patients, you may include a brief summary of previous medical/surgical diagnoses, treatments, and outcomes. Last but not least, you should make a proper diagnosis for the patient using both clinical presentation and diagnostics, and then report the diagnosis using proper terminology.\n\n\n- Clinical History \n\t- Your assessment should include all the facts regarding personal history of this patient such as history of: smoking, substance abuse, sexual risk behavior, social issues, education level, employment status, insurance, marital status, and living/working condition.\n\t- Assess patient's past and family history for hypertension, diabetes, depression, autoimmune diseases, chronic lung diseases, neurological disorders, substance use disorders, and heart attack/angina:\n\t- Hypertension\n\t- Heart Attack /Angina\n\t- Diabetes \n\t- Autoimmune Disease\n\t- Depression\n\t- Chronic Obstructive Pulmonary Disease\n\t- Alzheimers (Dementia)\n\t- Stroke\n\t- Epilepsy\n\t- Parkinson's Disease\n\t- Anxiety\n\t- Obsessive-Compulsive Disorder\n\t- Substance Abuse/Dependency\n\t- Asthma\n\t- Cancer\n\t- Osteoporosis\n\t- Other\n\t- Genetic Disorder\n\t- Family History \n\t- Your assessment should include information about family history of the following:\n\t- Heart Disease and Stroke \n\t- Liver Conditions (such as liver injury, hepatitis, cirrhosis, and alcoholic liver disease) \n\t- Respiiratory Diseases (such as Chronic Obstructive Pulmonary Disease (COPD), lung cancer, asthma, pneumonia,",
        "label": 0
    },
    "2161": {
        "output": "## Step 5: create a table to create patient-level eligibility\nEach patient needs to be assessed for eligibility of each clinical trial based on their note data. We need to write a loop to create this assessment in patient-level eligibility. We can use patient_id (integer value) to access the note information in a patient.\n\n[INST] The patients assigned to the clinical trials are determined based on the trial data. For example, if we need to enroll 2 patients with the clinical trial ID '1', you need to add an if conditional and add patients with the clinical trial ID '1' into the `clinical trial_ID` array. \nWhen you need to enroll 1 patient and 2 patients with the clinical trial ID '1', you will have to add all these into the `clinical_trial_ID` array. For example, to enroll 1 and 2 patients with the clinical trial ID '1', you need to add '1' into the `clinical_trial_ID` array twice. Here, is the code for clinical trial data:\ndef clt_data(clt_list): for c in clt_list: trial_id = int(c[clt_id]) trial_name = c[clt_name] print(f\"Trials ID: {trial_id}, Trial's name is {trial_name}\") print(f\"-\" * 25) for p in patient_name.set('clinical trial_ID', trial_id)) \nYou can add the patients' variables to the clt_data() function. It allows you to set and access the patients' variables. \nWe need to create 2 variables for the  `clt_data` function for the patients' assessment. The 1st variable is a list to store the trial-level eligibility. The 2nd variable is a list to store the patient-level eligibility. The trial-level eligibility stores the assessment of each particular clinical trial. The patient-level eligibility stores the assessment of the current clinical trial for each patient. \nThe first line of the clt_data function is to set the patient_id (integer value) to make a loop in",
        "label": 0
    },
    "2162": {
        "output": "## # ClinicalTrials # -{STARS_ID}_# #\n\n*A randomized, double-blind, placebo-controlled trial of the efficacy and safety of two doses of CY 09 in patients with type 1 or 2 diabetes in which retinal fluorescein leakage of the macula is due to diabetic retinopathy (DR), not diabetic macular edema (DME) is performed. In the trial, retinal fluorescein leakage of the macula was due to DM. [INST]\n\n### Summary:\n\n\n*This is a Phase 2, randomized, double-blind, multicenter, parallel-arm, placebo-controlled safety and efficacy study to compare the efficacy and safety of 2 doses of CY09 (3 doses per day) to two parallel groups treated with placebo in both eyes in an eye drop formulation once per day over a 13-week treatment period.\n\n*The study will include approximately 360 patients with a type 1 or 2 diabetes mellitus (DM) with DR and fluorescein leakage in one or both eyes that started treatment within 15 weeks prior to randomization/enrolment into the study. Patients will be examined at screening (baseline) as well as at Day 1 (randomization/study start day), Weeks 4, 8, 11, and 13. Patients will also be examined at follow-up at 6, 12, and 24 weeks after treatment. For safety reasons, patients with DME who received only laser treatment or laser treatment combined with intravitreal injection (IVT) of steroid or anti-VEGF within 6 weeks before screening, or who received only anti-VEGF intravitreal injections within 8 weeks before screening visit, will be excluded from the study.\n\n*The study consists of a Screening visit, a Screening Confirmation Visit, an Allocation and Study Treatment Initiation Visit (first treatment in the study), and Week 1, 2, 4, 8, 11, 13,",
        "label": 0
    },
    "2163": {
        "output": "<KEYWORD:1-2-50/Eligible>\n\nLet's take a look at the output.\n\n\n**HELP**\nTo view the eligibility for trial i000001, select the index i000001 and hit the **ENTER** button. A window will open with the output. \n\n>\n\nTrial-level Eligibility: 2) Eligible.\nAssessor-level Eligibility: 2) Eligible.\nRandomization: Unknown.\n\n**Note:**\n- If the status of a patient is not \"Trial-level Eligible\", it is not possible to proceed to the next step of the patient selection process, i.e., to access the Trial-level Eligibility of other clinical trials. Therefore, it is an end of the patient selection.\n- If the status of a patient is \"No Data\" or \"Not a Clinical Trial\", it is an end of the patient selection.\n- If the status of a patient is \"Randomization\", the patient has already been selected as a subject.\n\n\n![INST:7] . \n\nSelect **Trial-level Eligibility:** at the bottom. Here is the result.\n\n[/1-2-50/#SELECT_TRIAL]<KEYWORD:1-2-60/SELECT_TRIAL>\n\n>\n\nRandomization: Unknown.\n\n**Note:**\n- The Randomization value `Unkown` means that the status of the clinical trial in this patient's record is either not random or not clear.\n\nNext, you should get patients with missing/incomplete data. Select **Missing/Incomplete Data** on the index i000001 . The patient without **Exclude** can be selected by hit **ENTER** button. \n\n[/1-2-60/#SELECT_TRIAL]<KEYWORD:1-2-70/SELECT_TRIAL]\n\n>\nTrial-level Eligibility: 2) Eligible.\nAssessor-level Eligibility: 2) Eligible.\nRandomization: Unknown.\n\n**Note:**\n- If a patient has an unknown",
        "label": 0
    },
    "2164": {
        "output": "# Questions & Answers\n\n\n*A) Your patient is qualified for this trial.\n** Excluded\n*** Not relevant\n**** Eligible*** A) Your patient is qualified for this trial.\n***Excluded*** Not relevant*** Eligible \n\n*B) What will you do when you find your patient is ineligible?** ** If I should ask you why, you should answer me that you decided to find out the answer to my question. \nI suggest that you write `If I should ask you ...` in the beginning of your response. If you forget doing this, then you will fail the question. Please do not write `because` at the end. In other words, avoid writing the conclusion sentence at the beginning of the body of your response and the other way around. \nC) You have to use the eligibility criteria of the trial to justify your answer, otherwise you will not pass the question. For example, you can cite the age range in your response.\nD) Remember that you are allowed to check for your answers just before submitting. You must however, not go through a trial or change the patient's notes.\nE) You are expected to answer all of the questions without looking them up. Failing to answer all questions as requested will result in a \"no\" score.\n\n**B)** The patient is not eligible for this trial.** ** If I should ask you ... ** If I should ask you ..., you should answer me that you decided to look the answer to my question. \nI suggest that you write `If I should ask you ...` in the beginning of your response. If you forget doing this, then you will fail the question. Please do not write `because` at the end. In other words, avoid writing the conclusion sentence at the beginning of the body of your response and the other way around. \nC) You have to use the eligibility criteria of the trial to justify your answer, otherwise you will not pass the question. For example, you can cite the age range in your response.\nD) Remember that you are allowed to check for your answers just before submitting. You must however, not go through a trial or change the patient's notes.\nE) You are expected to answer all of the questions without looking them up. Failing to answer all questions as requested will result in a \"",
        "label": 0
    },
    "2165": {
        "output": "The output of the script is a CSV file (you can open in your Excel, e.g., if you want to write it to file):\n\n\n\n\n\n\n\n<EOD> Anorexia in the older woman.\nAnorexia can be a devastating disorder for an older patient and her family but is often not considered by nurses or doctors. Nurses should learn to treat anorexia as a medical condition, and physicians should be alert to the possibility of it as a major factor in determining the prognosis in older patients. Anorexia should be addressed in a nonjudgmental manner so the patient will not feel further trauma. The first steps should be an assessment of the medical and psychosocial status of the patient and reeducation of the family and significant others about the nature of the illness. Once all members of the primary care team agree with anorexia as the major factor in the patient's condition, individualized treatment plans can be developed for the patient and family.<EOD> Identification of 13 alpha- and 6 beta-hydroxy steryl ferulates and beta-sitosterol glucosides as metabolites of vitamin D2 administered to a hamster.\nThe urinary steroid metabolic profile of hamsters fed a diet supplemented with vitamin D2 and then administered vitamin D4 was quantitated by gas chromatography mass spectrometry. More than 39 metabolites arising from both the hydroxy and ketone pathways of vitamin D metabolism were identified. Almost all the metabolite concentrations declined during the elimination phase of vitamin D4 supplementation. By contrast, the concentrations in the first urine collection remained nearly the same throughout the entire elimination phase. Among them, 13 alpha- and 6 beta-hydroxy steryl ferulates and beta-sitosterol glucosides have not been previously identified in urine of animals.<EOD> Vascular risk factors and the progression of motor signs in dementia with Lewy bodies\nObjectives: To determine if vascular risk factors predict motor signs in dementia with Lewy bodies (DLB). Methods: We examined data from 125 patients diagnosed with probable DL",
        "label": 0
    },
    "2166": {
        "output": "In the `main function`, you can set the value of the function parameters based on the input. In this problem, set the parameters as the following: \n- `input_data` to `df_patient`\n- `Trial_note` to your patient note and as a string, e.g., `'a note'`\n- `Trial_id` to the ID number of the clinical trial, e.g., '234259'\n- `Trial_type` to the type of the clinical trial like the `trial` (clinical trial), `drug` (trial of drug), and `misc` (miscellaneous of trial)\n- `Trial_status` to set the status for trial, `Trial_status` must be one of the `ongoing`, `completed`, `withdrawn`, or `retracted`\n- `Trial_study_phase` for `phase` must be one of the three words including `phase 1`, `phase 2a`, `phase 2b` or `phase 3`\n- `Trial_study_arm` for `arm` must be a number from 1 to 9\n- `Trial_arm_number` for `arm_number` must be a number from 1 to 10, e. g., one of {1, 1, 1, \u2026}\n- `Trial_study_type` for `trial_type` must be one of the three numbers like the `interventional`, `observational`, or `other`\n- `Trial_study_duration` for `duration` must be in the format like`dd-mmm-YYYY`\n- `Trial_number` for `id` must be in the format of `NNNNNNNNNN` (e.g. `123456`), e.g., one of the `123478092` or `1204568977`. * Note that the format number should be `2-4` digits long. If you input the number with less than 2-4 numbers, it will return an error.*\n\nSo, at the top of your script, put the following:\n\n    # The parameter names are",
        "label": 0
    },
    "2167": {
        "output": "After making a trial-level eligibility for the given patient, let's define some patient-level variables that affect eligibility. If a patient-level variable is not provided, the corresponding patient-level variable should be set to \"None\". \n- _NOTE:_ The values of variables that can make an impact on patient-level eligibility should be marked as \"Yes\" in the \"Inclusion Criteria and Exclusion Criteria: patient view\" section in the \"Clinical Trial Intake Form\".\n- `Age: `\nThe age at the time of trial entry should be input in years. For patients who are more than 18 years old, set it to \"Yes\". For those participants who are 18 years old, set it to \"No\". [ /NOTE]\n- `Weight: `\nInput the weight of patients in kilograms after 12 hours of fasting. For patients not weighing above and below 70kg, set it to \"Yes\". For those participants who weigh above 70kg and below 120kg, set it to \"No\". However, for patients weighing more than 120kg, you can choose either Yes or No. [/NOTE]\n- `Gender: `\nFor male and female participants, the gender should be set as \"Yes\". [/NOTE]\n- `Other health conditions: `\nOnly include those diseases that may influence the clinical trial eligibility in the \"other health conditions\". Check it if you do not find sufficient information on the patient's clinical examination. [/NOTE]\n- `Cardiovascular status: `Set your patient-level eligibility by marking `cardiovascular status`: Yes or No. [/NOTE]\n- `Pregnancy status: `Set your patient-level eligibility by marking `pregnancy status`: Yes or No. [/NOTE]\n- `Drug addiction: `Set your patient-level eligibility by marking `drug addiction`: Yes or No. [/NOTE]\n- `Previous Surgery: `If the patients have no previous surgery history, set it to \"No\". If the patient had a previous history of surgery, set it to \"Yes\". [ /",
        "label": 0
    },
    "2168": {
        "output": "##[TESTING]\n\nHere is a simple demo file that demonstrates the use aforementioned [test] section. Run the file to test your implementation.\n\n##[INST]\nYou are about to code a system in Python that will allow patients to check the side effects of their medication. Side effects are the different types of harms or benefits that come with taking medications. Some examples for both types are listed below:\n\nSide Effects of Benefits of Medications\n\nSkin rash \nSkin rash \nCough \nCough \nEasy blood glucose tests \nEasy blood glucose tests \nIn this assignment: You will create a code to find out which side effects appear to be more prevalent than others. The system should keep track of the number of patients experiencing each side effect (not necessarily counting how many patients use a particular medication). You can create your model (patient) for the purpose of this assignment so that you can keep track of how many types of pills the patient is taking. (Example: Patient code:\n\ndef patient(name, age):\n    side_effects_taken = {'diarrhea': 0,\n                          'feeling weak': 0,\n                          'increasing appetite': 0,\n                          'faintness, dizziness': 0, 'upset stomach': 0,\n                          'nausea': 0}\n    for pill in pill_names:\n    side_effects_taken[pill.capitalize()] += 1\n\n    if age < 60:\n        patient_code = 'Adult ' + str(age) + ' ' + name + ' (has ' + str(len(pill_names)) + ' drugs)'\n    else:\n        patient_code = 'Senior ' + str(age) + ' ' + name + ' (has ' + str(len(pill_names)) + ' drugs)'\n    return patient_code)\n\nFor this assignment's [problem] section, you will have to create a class that will keep track of the patient and medication information you will generate in the [patient], [medication], and [side_effects] sections",
        "label": 0
    },
    "2169": {
        "output": "Your job is to design a clinical trial protocol that will address the research question and to describe all the required details.\n\n\n### Example 4\nIn this example you will go over the following steps based on the instructions in [INST]. \n1) Initiating a study or conducting a clinical trial starts with the formulation of a protocol. This part should cover the study design and conduct that includes the description of the protocol, trial schedule, inclusion and exclusion criteria, and details of the outcome measures.   \n\n\n### Task\nPlease see the instructions in [INST]. On the [Link to ClinicalTrials.gov for a Protocol], you will observe that all steps should be described. Write a clinical trial protocol for the study.",
        "label": 2
    },
    "2170": {
        "output": "## Exercise 2.\nAsk each of the following questions about yourself and record your answers as a `data_assistant.data` file \n-What are your height and weight? \n-What is the date of your birth? \n-What is the date you entered your profile? \n-What is your email? \n-What is your Facebook ID? If you are not on Facebook, then leave the field blank.\n\nNote that before running the following program, you must prepare your `data_assistant.data` file by saving it in a different working directory.\n\n<bash>\nexport WORKDIR=`echo \"$PWD\"`\ncd <NAME>\n<INST>\n<BOLD>\npython <NAME>_instructions.py\n<UNBOLD>\n</INST>\n</bash>\n\n![](/img/instructions7.pdf)\nThe instructions on the screen guide you through the creation of a `trial_-assistant.data` file with several data points, each corresponding to the individual answer.\n\n\n## Exercise 3.\nAsk each of the following questions about the patient, and record your answers as a `trial_assistant.data` file. For each of the questions below, save your answer in the `Trial_assistant.data` file under the `data` folder of a given patient. Save that file in a file named the same as the patient number (e.g., `0542`). The number of rows you generate depends on how many questions you answer for a patient. At the end of the script, the output should be similar to what is shown in the next figure.\n-How many family members are in this household?\n-Is this household a single-family house, an apartment, townhouse, or condominium?\n-What is the relationship of the primary person who provides food and care?\n-How do you travel to this patient's home?\n-What is the source of heat?\n-What is the size of the yard?\n-Does this household use a septic tank or well water for drinking water?\n-Is the street in front of this house paved or unpaved?\n-Is there more than one car in this household, and how many of these vehicles? How much of the driving",
        "label": 0
    },
    "2171": {
        "output": "You should report your results as `Trial-level eligibility:`.\n[[TESTIMATE] 1. You should see a new patient note in your database including all the required fields such as `trial_recording_number`, `Trial code`, `patient number`, `patient_name`) \n\n---\n\n# [INST] Assessment of trial eligibility\n---\n[[TESTIMATATE]\nDuring clinic work, physicians routinely evaluate a large number of patients every day, and this may become increasingly important if more clinically useful therapies are identified. The inclusion and exclusion criteria used to describe the specific characteristics of patients in clinical trials can be complex, involving multiple conditions and their corresponding values. A wide spectrum of methods have been used to handle this complexity. \n\nIn this case study, you will learn why it is important to make clinical data available with patient notes. You will also learn how to determine whether a patient's clinical data meets the criteria of a trial by assessing them with respect to trial-level eligibility. You can also use the assessment of eligibility to estimate the rate of trial admission among patients. \n\nPlease visit the [Eligible.py](https://github.com/Samsung-BiTS/EthAid/blob/master/EthAid/Assessment/Assessment_of_trial_eligibility/Eligible.py) file in the repository to find source code. This code is used in the [main.ipynb](https://github.com/Samsung-BiTS/EthAid/blob/master/EthAid/Assessment/Assessor/main.ipynb) file for the assessment of trial eligibility. \n\nWhen you make data available [**in the patient note**](https://github.com/Samsung-BiTS/EthAid/tree/master/EthAid/Semi-Official/Source/EthAid/EthAid_main_data/patient_note/EthAid_patient_note.xlsx), you should complete patient information such as demographic information, vital signs, patient medical history, family history, vital examinations, and results with disease-related data.",
        "label": 0
    },
    "2172": {
        "output": "In this problem, `clinical trial notes` is already initialized and it can contain multiple records. Therefore, the following section will be a multi-record list comprehension.\n\n## \u2757 Note:\nIf you are unfamiliar with multi-record comprehensions, it is recommended to review the list comprehension section in the [Python Docs](https://docs.python.org/3/tutorial/datastructures.html#lists).\n\n## List comprehension\nWe need to access the last line of each record in `clinical trial notes` list. For that we need to make use of index operator ':', while '[' is used to extract individual record from the list. Here is how we will do that, with the last line of each record in each patient note:\n\n```python\nfor patient in clinical trial notes:\n    trial_level_eligibility = patient[-1:].split(',')\n```\n\nLet's break down what we did here. First, we loop over record of the list that is called list `clinical trial notes`. \nFirst element in this list is a record and can be a text or dictionary. After you enter `patient[-1:)` in Python console, you will have a string like `clinical trial exclusion criteria, 0, not relevant, cardiothoracic surgery, 1, not relevant, clinical trial inclusion and exclusion criteria [0] excluded, cardiothoracic surgery [0], excluded| 2, Eligible, clinical trial inclusion and exclusion criteria [1] excluded, cardiothoracic surgery [1], excluded| , clinical trial inclusion and exclusion criteria , 1, not relevant, cardiothoracic surgery , 0, excluded| , 2, Eligible` as the result of this function call.\nHowever, as you can see here, the list element is not just the above and there is a string separator, comma (,), before last character (\".\") on the result. We can access the string after this comma and we will have the following for each patient note in that list:\n\n```\n'Trial-level eligibility: 0, excluded; 1, not relevant; 2, Eligible.'\n```\n\nO",
        "label": 0
    },
    "2173": {
        "output": "The script below returns:\n\n## Instructions\nBefore you begin editing this file, a few things to keep in mind:\n \n* The file must be formatted properly in Google's HTML editor (Google Docs) with the following tags:\n`<h1>Trial-level eligibilty </h1>` (instead of the \"<h1>Trial-level eligibilty</h1>\" one) .\n* You must provide the right format for the data from the patient note, as listed above, in the first column.\n* As discussed in Lesson 3, you must work closely with your TA to confirm your work and ensure its accuracy.\n\n* [Link for the assignment](https://docs.google.com/document/d/1KDYb8v5G_OQk0xXFUwYN_C82yFcO6W40ZzxWZ23f7M/edit?usp=sharing)\n\n*  Copy all of the code from your computer (the script) and paste it into the editor.\n\nYou should then create a title for your HTML web page:\n\n![Instructions](/html_lessons_v2/images/instructions.png)\n\nHere is the code for HTML head section:\n\n![HTML head section](/html_lessons_v2/images/html_head_section.png)\n\nHere is the code for the table containing the information of the patient note:\n\n![HTML table](/html_lessons_v2/images/html_table.png)\n\nHere is the table after being uploaded to the Google Docs (Google Drive):\n\n![Table HTML with table head and body](/html_lessons_v2/images/table_with_img.png)\n\nHere is the table without the header and body:\n\n![HTML table without table head and body](/html_lessons_v2/images/table_without_img.png)\n\nHere is where to find the patient ID:\n\n![Patient ID](/html_lessons_v2/images/patient_id.png) `\n\nHere is the correct patient ID:\n\n![Patient ID without spaces](/html_lessons_v2/images/correctpatient_",
        "label": 0
    },
    "2174": {
        "output": "<EOD> Degraded Image Restoration by Multi-Scale Fusion of Laplacian-Based Filters\n\nLaplacian-based filters (LBFs) are powerful tools for image restoration in natural and biomedical images. However, LBFs are sensitive to noise and artifacts, and this limits their potential uses in most real-world biomedical applications. This brief addresses this problem by proposing a strategy for fusing multiple LBF responses that are simultaneously estimated from the observed image. By means of a set of experiments on synthetic noisy images, it is shown that the method improves the fidelity of the restored image at varying levels of degradation. A study on simulated blurred and nonblurred images as well as two real-world biomedical applications demonstrates the high performance of this method to restore blurred images of the human retina and chest radiographs. As expected, the fused filters improve the blurriness and color variations present in the restored images with respect to the original images. In the synthetic experiments, fusion of multi-scale LBFs significantly enhanced the mean squared error, signal-to-noise ratio, contrast-to-noise ratio, peak signal-to-noise ratio, and structural similarity index of the restored images under both noise-free and various levels of Gaussian and impulse noise (up to 10%) in grayscale. As regards the real-world images, the average improvement of the fusion approaches over those of the single filters was of 15% and 10% in the visual assessment of the restored retinal images and chest diagnostic radiographs, respectively. The results demonstrate the high robustness of multi-scale LBF fusion against noise, artifacts, blur, and local intensity variations. Additionally, a comparative study shows that while the proposed approach produces better visual quality than previous strategies, its computation time is comparable to that of the other methods and is hence suitable for realtime applications.\n\n# Introduction\nImage restoration (IR) techniques are used in many biomedical applications, such as, for instance, the restoration of blurred retinal images for optical coherence tomography, the enhancement of chest radiographs, the correction of blurred images, and the restoration of natural images corrupted by a mixture of Gaussian and impulse noise.",
        "label": 0
    },
    "2175": {
        "output": "## [/OUT]\nPlease [INST] note that, after each `return` in the script, the patient's record must be deleted and a new record must be created [OUT].\n\n## Assignment evaluation\nThis script was executed 10 times, and the correct proportion was calculated based on the correct proportion of the last 8 replicates (i.e., the proportion of correct answers obtained in the first 8 executions). The correct proportion of this script is 87.5%.\n\n## Errors\n\n## Wrong trial-level eligibility\nYou should return incorrect trial-level eligibility as zero. You did this wrong in the sixth and eighth trials, see lines 399 and 414 of the script.\n\n## Wrong repeat key to previous trial\nIn lines 434 and 452, you did not use the repeat key for the previous trial. In the first place, you should insert a repeat key of previous trial in line 320. After applying the repeat key of the previous trial, you should not do anything in the next trials.\n\n## No return after end condition\nWe assumed that the condition was reached in the second trial. But you did not return after it in lines 398-400.\n\n## No return after end condition\nWe assumed that the condition was reached in the third trial. But you did not return after it in lines 415-417.\n\n## No return after end condition\nWe assumed that the condition was reached in the fifth trial, but you did not return after that in lines 447-449.\n\n## Incorrect trial-level eligibility\nNot only in the fifth trial, the trial-level eligibility was incorrect in general. Sometimes, you have put a zero or did not type anything as the result. This is the problem with not saving or typing the value of the trial-level eligibility in lines 137 and 308.\n\n## Wrong result\nThis script outputs the wrong result of the third trial by putting 1 instead of 0. You have typed 1 as the trial-level eligibility in this case in line 396.\n\n## Wrong output format\nSome of the results of this script are in the wrong format. You should return them",
        "label": 0
    },
    "2176": {
        "output": "### Problem B\nThis problem gives three files that are named `patient1.txt`, `patient2.txt`, `patient3.txt`. Note that these patient notes are very similar to those of Problem A and we will use the same patient characteristics as described in them. \nConsider the following `Clinical trial: A Study of Criteria Development in Cardiac Autonomic Dysfunction`. This trial's information was also included in Problem A. \n\nThe task is to complete the `patient1.txt` with patient note (the format is as described in Problem A).\n\n\n### Problem C\nThis problem gives three files that are named `patient1.txt`, `patient2.txt`, `patient3.txt`. Once more, these patients notes are very similar to those of previous problems and we will use the same patient characteristics as previously described. Consider the following clinical trial information and the format is as described in prior problems.\n\n\nThe task is to complete the patient note for the first file: `patient1.txt` with the patient note (the format is as described in prior problems). \n\n<EOD> Efficacy of low-dose radiation therapy for breast cancer patients with microscopically positive resection margin: a comparison of two protocols.\nBACKGROUND\nThere are two protocols (dose at 1-2 cm and dose at 5 cm for the chest wall) in the guidelines for low-dose (LD) radiation therapy for early-stage breast cancer patients with a positive resection margin (R+). The objective of this study was to compare two protocols of LD radiation therapy.\n\n\nMATERIALS AND METHODS\nBetween 1999 and 2008, patients with a 1-2 cm margin of the chest wall were allocated to protocol I (40 Gy) (65 patients) and patients with a minimum 5 cm margin were allocated to Protocol II (40 Gy) (80 patients).\n\n\nRESULTS\nThe median follow-up was 49.6 months from the date of LD radiation. The 5-year overall survival (OS), progression-free survival (PFS), and contralateral breast cancer survival (CBC",
        "label": 0
    },
    "2177": {
        "output": "# Troubleshooting\nIn case you are facing any problems to solve on your own, please see the following section.\n\n# Troubleshooting\n\nProblem:\nThe program will throw any error messages of `AttributeError: type object is not subscriptable.`\nYour Solution:\nThe problem is because you have defined the header in the template file (by the error message we gave above). \nJust define your header after the block `print ()` statement in the template file as `print('Trial-level eligibility: ')`.\n\n# Changes to Existing Parts of the Program\n\nSometimes, you may need to make changes to the existing parts of the program.\n\n# Changes to existing part of the",
        "label": 0
    },
    "2178": {
        "output": "```python\nimport numpy as np\nimport pickle\nimport pandas as pd\nimport json\nimport datetime\nimport argparse\nimport sys\nfrom pandas import DataFrame, Series, json_normalize\n\n# -\n# AUTHOR(S):\n#     \n# Coders: <NAME> and <NAME>\n#\n# Date:\n# 09/09/2019\n#\n# Use:\n#     \n# \n# Description:\n#     \n# \n# \n# \n#  \n# \n\n# Use:\n#     \n# \n# \n# \n# \n#     \n#     \n# \n# \n# \n#     \n#     \n# \n#     \n#      \n# \n# \n#     \n#      \n# \n#     \n#     \n# \n#    -\n#  \n# Parameters:\n#     \n#     \n#      \n#      \n#      \n#      \n#      \n#      \n#      \n#      \n#      \n#     \n#     \n#      \n#      \n#     \n#      \n#     \n#      \n#      \n#     \n#      \n#      \n#      \n#      \n#      \n#     \n#      \n#     \n#      \n#         \n#         \n#         \n#         \n#         \n#     \n#      \n#     \n#      \n#      \n#      \n#     \n#      \n#         \n#         \n#     \n#         \n#      \n#     \n# \n# Returns:\n#     \n#     Returns:\n#     \n# \n#     Returns:\n#     \n#        Return list of objects in a format:\n#         [\n#                patient = {\n#                   name: 'Bob',\n#                   birth_date: '1980-09-13',\n#                   gender: '2',\n#                   age_at_entry_to_trial: 35,\n#                  # Patient-level eligibility of the patient with respect to the trial's eligibility criteria.\n#                   eligibility: {\n#                     BMI_el",
        "label": 2
    },
    "2179": {
        "output": "Good luck with your training.\nYou may ask the trainer any questions you have by email.\nWe hope that our tool will help healthcare professionals, researchers, patients and their families with research in this field and improve health care in every country.\nThank you,\nYours sincerely,\nVitaliy V. Medvedovsky, MD, PhD, and Sergey D. Svetlichnyy, MD, MHCI, PhD<EOD> Vascular effects of metabolites of the epoxyeicosatrienoic acids in rat aortic rings.\nEpoxyeicosatrienoic acids (EETs) are metabolites generated from arachidonic acid by cytochrome P450 epoxygenases. The effects of various epoxygenase metabolites on vascular smooth muscle contraction were examined using isolated preparations of rat aortas. Epoxy fatty acids, with epoxides placed at the 12,13-, 14,15-, or 13,14-positions, exhibited relaxant effects that were concentration-dependent and stereoselective. Epoxy octadecadienoic acid (5,6-EET) produced vasorelaxation of 62.5 +/- 10.4 and 63.3 +/- 10.5% at concentrations of 10(-8) and 10(-7) M, respectively. Similarly, 7,8-diHETE and 7,8-diHDHA demonstrated vasorelaxant activity of 49.1% at 10(-7) M, and 66.1% at 10(-6) M, respectively. By contrast, 14,15-DiHETE was contractile, and 14,15-DiHDHA produced no change in basal tension of the rat aorta. Thus, a common and structurally unique characteristic of epoxy fatty acids that are generated from arachidonic acid seems to be their ability to induce vasorelaxation.<EOD> A Novel Graft of Aortic Dura with the Posterior Longitudinal Ligament in Thoracic Decompression of Spinal Cord\nCase Report A 1",
        "label": 0
    },
    "2180": {
        "output": "# Discussion\n\n# Caveats\n- Exclamation points, especially within code snippets (or other markups), are problematic. If you do include them, please use the \"italicize title\" syntax - that is, enclose the phrase within `s, as in ``\"Caveats for Discussion.\"`. It should also be mentioned that we do accept, as suggested by @username_83 , the use of ``Code`` blocks, which is essentially just a ``br`` element that surrounds the block with a ``.md``, as in ```.md\n\n# References\n-\n<EOD> Diagnostic work-up of primary antiphospholipid syndrome: value of serum anti-cardiolipin, anti-prothrombin and anti-annexin V antibody assays in patients with systemic lupus erythematosus and pregnancy morbidity.\nThe diagnostic work-up of the primary antiphospholipid syndrome (PAPS) in our patients with systemic lupus erythematosus and pregnancy-threatening complications, and positive serum antiphospholipid antibodies (aPL) assays (aCL, aPS/PT, aSS/SS) that were negative by \"clot-based\" methodology (activated partial thromboplastin time , dilute Russell's viper venom time ) is reported. In these patients with PAPS, positive outcomes in assays for serum detection of thrombin-dependent aPL (aCL, aPS/PT) contrast with the persistence of clotting-based negative results despite the presence of circulating lupus anticoagulant (LA) (n = 3; aPT, aDVVT-n = 2) and lupus cofactor (n = 2) or the presence of both serum LA and lupus cofactor (n = 1). In these patients, serum positive assays for aPL (aCL + or = 40 U/ml or aPS/PT greater than or equal to 40 U/ml) are obtained in serum samples concomitantly collected in the \"positive in serum\" aCL (n = 1),",
        "label": 0
    },
    "2181": {
        "output": "[END]<EOD> A Review of Phage Therapy against Multiresistant Bacteria: Current Strategies and Future Directions\n\nPhage therapy is a re-emerging treatment for infections caused by multiresistant bacteria. It relies on the ability of a broad range of phages to infect, penetrate into phagocytes and then destroy bacteria. Phages can exert their antibacterial capacity in vivo and in vitro by directly killing bacteria or enhancing the efficacy of antibiotics through inducing the production of cytokines to initiate an inflammatory reaction. In this review, we briefly present a summary of phage-based experiments to test host-specificity and efficacy of phage therapy in vivo. Also, we highlight the benefits of phage combinations to increase the host range of phages or enhance the lytic activity of phages and we analyse current studies regarding phage combinations for the prevention/treatment of bacterial infections. Moreover, we discuss the possible mechanisms of action and future directions of phage therapy in a context of bacterial infections. In particular, we examine studies reporting phage phiIPLA-RODI for the treatment of infections due to S. aureus. Phage phiIPLA-RODI belongs to Myoviridae family, has an in vitro lytic activity against a wide range of Staphylococcus strains, is safe and can prevent and treat murine infections caused by this pathogen. In particular, we reviewed studies reporting phage phiIPLA-RODI for the prevention and treatment of infections caused by S. aureus, a Gram-positive bacterium that colonises the skin and is a major pathogen causing acute and chronic infections particularly in immunecompromised individuals. Since the 1950s, the therapeutic use of phages against bacteria has been hampered by the lack of approval from regulatory authorities. A better understanding of how phages interact with host cells can help in designing specific combinations of phages to treat bacterial infections.\n\n# Introduction\nThe development of antibacterial resistance by bacteria is becoming one of the major public",
        "label": 1
    },
    "2182": {
        "output": "A code that you can use to print out the eligibility report is below.\n<EOD> Dual-frequency photorefractive crystal for multichannel waveguide-coupled holography.\nWe measured the effects of dual-frequency beam coupling to the spatial-light-modulator-generated hologram. In dual-coupling holography, the photorefractive crystal operates using two beams having spatial frequencies matching the waveguide grating and the hologram, whereas in single-beam operation, the crystal uses one beam having only the waveguide-coupling frequency. The dual-coupled crystal improves single-beam performance, and waveguide-coupling holography was demonstrated with two grating configurations, parallel and orthogonal to the plane of the crystal.<EOD> The prevalence of multiple sclerosis in Hokkaido, Japan.\nTo determine the prevalence of multiple sclerosis (MS) in Hokkaido, we first screened all the neurologists and neurologists-in-training in Hokkaido in 1987 and 1988. All of these neurologists agreed to take the initial part of our questionnaire. In the second part, we contacted the neurologists, to provide the number of MS patients in 1987. We determined that there were 411 MS patients in Hokkaido in 1987, and 438 in 1988. The annual incidence rate per 100,000 people was 1.19 in 1987, and 1.04 in 1988, giving a crude prevalence of 52.7 per 100,000 population in 1988. Hokkaido Island consists of two major islands with populations of 1.1 and 0.7 million, and the other minor islands with a total population of 0.15 million. The two major islands together have a total of 1098 neurologists-in-training and experienced neurologists: this number is equivalent to the other major islands and minor islands combined, and thus 1111 neurologists. The ratio of patients in rural",
        "label": 0
    },
    "2183": {
        "output": "## What to do in the problem\nHere is the problem statement:\n\nYou are a helpful assistance for clinical trials. For a clinical trial, you create patient records with the trial data. It is necessary to create a table to store trial-specific variables, one row for each trial. Each row contains a set of trial variables that you'll define for each trial.\nLet's think step by step. \nLet's put the whole program in a single file named `clinical_trials.py` which contains one section per file.\n\n### Import necessary libraries\nimport pandas as pd import numpy as np import os import random import datetime from random import randint from operator import add\nimport warnings import seaborn as sns import matplotlib.pyplot as plt import matplotlib.ticker as ticker from matplotlib.ticker import Formatter, LogFormatter, NormalFormatter import pickle import json from copy import deepcopy import copy\n\n\n### Add the table for trial-specific variables for clinical trial named `trials` and patient records table \nHere, `Trial-level eligibility = 2` refers to eligibility for participation in clinical trial. You'll see more explanations how and why to make and format such variables in the next sections:\n```python 776\n# =============================\n# For clinical trials named as trial 1\n# =============================\ntrials['clinical_trial_1'] = pd.Series([1])\n# =============================\n# For clinical trials named as trial 2\n# =============================\ntrials['clinical_trial_2'] = pd.Series([2])\n# =============================\n# For clinical trials named as trial 3\n# =============================\ntrials['clinical_trial_3'] = pd.Series([3])\n# =============================\n# For clinical trials named as trial 4\n# =============================\ntrials['clinical_trial_4'] = pd.Series([4])\n# =============================\n# For clinical trials named as trial 5\n# =============================\ntrials['clinical_trial_5'] = pd.Series([5])\n```\nYour `trials",
        "label": 0
    },
    "2184": {
        "output": "### Example 11\n\n***INCLUDES***\nExamples and test data about clinical trial inclusion criteria.\n\n**Instructions**:\n\n* You should enter one or more inclusion criteria to determine the patient's eligibility from the patient note.\n\n* 1.\nIf the patient meets all the inclusion criteria, then the patient is eligible (output 2). For example, 0.\n\n* 2.\nIf the patient does not meet any of the inclusion criteria, then the patient is automatically excluded (output 0)\n\n* 3.\nIf the patient does not have either an exclusion or an inclusion criterion, then the patient is Not Relevant (output 1). For example, the patient has a disease (output 1) \nYou will have to provide details for each criterion.\n\nFor example, to indicate that an individual should be at least 18 years of age when entering the clinical trial, you should enter:\n\n`[patient.age == 18] && (patient.age > 17]` \n```\n[patient.age == 18] || (patient.age > 18) \nOr, if you want to indicate that the patient must be less than 18 years old when entering the clinical trial, you should enter:\n\n`[patient.age <= 18]` \nSee the example codes below for an explanation on how to represent the inclusion criteria. For example, if the trial allows males and females, you should create a filter with the condition:\n\n```\n`(gender == 0) || (gender == 1)` \n```\nIf a trial accepts any race, then you should add a filter to exclude racial groups:\n\n```\n`!(race == 1) or race == 2`\n```\nYou can use the AND and OR logical operators to combine exclusion criteria:\n\n`!fam.pat.race == 1 & !fam.pat.gender == 1`\nThe same idea applies to the exclusion criteria, age, or race.\nYou can refer to a clinical trial's [SOPs for Criteria][sof-sop-for-criteria-2].\n[INST] You may wish to consider the following",
        "label": 0
    },
    "2185": {
        "output": "__Question_2:__ What is the problem which you have to solve? [INST]\n\n_Hint_: __Question__ _2_ needs to be defined in the first section of your first function. \n```{r}\nquestion_2 <- \"What is the problem which you have to solve?\"\n\n```\n\n__Hint_:__ Try to present the main goal of your software by writing the first 4-5 lines of your first function.\n\nWe want to build a software which will extract and assess the 2 trials with matching criteria to each other. We can't use all the patient information in our software (e.g., FBS, HbA1c, Chol, TG, LDL, and HDL), thus we focus here on the information about the trials and the patient who participated in it.\n\n__Question_3__: How about if some clinical trials match, what should we do? If we have two trials. Can you explain which patient you should choose? [INST]\n\n__Hint_:**_For your assignment:_** You can make as many trials as you want and try them with our program code. \n\nIf only one of the trials matches the patient, what should we do? In that case the trial-level assessment's result is _eligible (0)_. If both of them do not match the patient, the trial-level assessment's result will be _not relevant (1)_. However, if both of them match the patient (e.g., ID of the patient from one trial is equal to the patient's ID from another trial), _the trial-level assessment's result will be excluded (2)_.\n\n```{r}\nquestion_3 <- \"How about if some clinical trials match, what should we do? If we have two trials. Can you explain which patient you should choose?\"\n```\n\n__Hint_:__ Try to figure out how to use the data in your patient's note to see _who_ of the trials will be matched to _the patient_ (i.e., how we have to select the patient's ID). You should use data in trials (not the patients' notes) to select the patient ID. After you select the patient ID, you need to look at the patient'",
        "label": 0
    },
    "2186": {
        "output": "<EOD> .\nThe results are shown of a morphological-cytochemical investigation of proliferation centers in the thymus. It has been shown at the period of the ontogenesis that theses centers are formed by the precursors (transitional thymocytes), differentiated in the thymic eosinophilocytes, and are formed already during the latter's differentiation. During further differentiation the thymocytes lose proliferative ability and the proliferation centers disappear. Certain features of the organization of the cells forming proliferation centers are characteristic of these centers at different stages of their formation: the appearance of cells of large size, with active cytoplasm, rich in endoplasmic reticulum, and ribosomes at the stage of precursor's differentiation, and the appearance of cytoplasmic projections during differentiation of thymocytes in the centers. Certain stages of transcellular fusion giving rise to binucleocytes and syncytia are observed in the centers.<EOD> A Case of Traumatic Subluxation of the Proximal Interphalangeal Joint\n\nObjective:Unusual clinical course Background:Several studies reported injury patterns and the outcome of isolated traumatic subluxation of the proximal interphalangeal (PIP) joint of the finger in baseball players and athletes who participated in the sport of boxing and wrestling, which were related to the sport. Most cases involved baseball athletes. Case Report:We report a 35-year-old male industrial worker with multiple ligament injuries caused by the high-impact trauma of a work accident. The closed traumatic subluxation of the left ring finger's PIP joint had been untreated for 14 days until an orthopedist detected it. A severe depression with a vertical component of 2 mm was noted in the radial sulcus of the finger. The bone architecture of the distal interphalangeal (DIP) joint was normal, with no obvious fracture lines; however, the radial aspect of the DIP joint was unstable because of the degenerative changes in the extensor mechanism. The patient was treated surgically by closed reduction with k-wires. The k-wires were removed after",
        "label": 2
    },
    "2187": {
        "output": "### 16.5.1357169732_01_15_37_38\n[INST] You are a psychiatrist and one day you are assigned to examine a new patient who has recently been referred to your office by a cardiologist. The patient just had a myocardial infarction and underwent coronary artery bypass surgery one month ago. He is under treatment with oral anticoagulants and chlordiazepoxide (to relieve insomnia after discharge from the hospital). He has a history of smoking and drinks one bottle of vodka per day. He presents to the clinic with insomnia, feelings of anxiety, tachycardia, lack of energy, low mood, and decreased concentration. \n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\n```\n# First, we need some data \n\n# Read data from csv file df = pd.read_csv('./data/task-16_data.csv')\ndf\n```\n\n```\n    Name     FBS_new   HbA1c   Cholesterol   TG   LDL  HDL   BMI   Gender  Age   Diabetes_1\n0  Patient_00 100   31   190   140   40   35   NA    M   70   Y\n1   Patient_01 130    60   160   110   40   45  female  70   Y\n2  Patient_02 130   67   270    70   26   28    obese 65   Y\n3",
        "label": 1
    },
    "2188": {
        "output": ".\n\n## 4\n\n## M4s0.clinic\n[INCLUDE]\n\n[TRAILS]\nTrial ID: Clinic\n\n[INCLUSIONS]\nInclusion criteria:\nSubjects must be aged 18-45.\nSubjects must be able to produce 1,500 cc urine daily.\nSubjects must not have used another investigational substance within the 30 days before the initial visit.\nSubjects must be willing to provide written informed consent and HIPAA authorization.\nSubjects must be willing to participate in this protocol, comply with study procedures, and agree to avoid alcohol intake for the 48-hour study period and avoid use of any caffeine-containing substances or energy drinks from 24 hours before through day of study until after the day 14 visit.\nSubjects must not be participating in another clinical trial.\nSubjects must have normal renal function as determined by standard labs and no major abnormalities on physical exams other than what is expected and necessary on a normal healthy human male or female.\n\n## [/includings]\n[SAMPLE]\nNumber of samples: 1,\n[/SAMPLE]\n\n[CATEGORIES]\nCategory Description: Diabetes\n\n\n\nCategory: Type2 diabetes\n\nCategory: Diabetes type1\n\n[/CATEGORIES]\n[/TRAILS]\n\nHere is the clinical trial note:\nSubject ID: 29170\n\n[PATIENT]\nName: 29309\nGender: M\nAge: 24\n\n[LABS]\n[/LABS]\n\n[HISTORY]\n\n<EOD> The effect of beryllium metal and beryllium compounds on murine lymphocytes in vitro: analysis of the mitogenic response.\nThe effects of beryllium metal and beryllium chloride and beryllium sulfate have been measured on lymphocytes from BALB/c mice in vitro. Lymphocytes from beryllium-sensitive and berylli",
        "label": 0
    },
    "2189": {
        "output": "To be clear, I realize that the formatting is hard to read in the screenshots, which is why I have taken the time to write it out separately. I hope this helps.\nHere are the screenshots:<EOD> Pigmental and Functional Changes of Peritoneal Cells in Dialysis Patients with Chronic Hyperoxaluria 1\nFocal nodular hyperplasia of the liver is accompanied by a marked increase in collagenous connective tissue. Since the connective tissue matrix of the liver as well as that of the peritoneal membrane consists of type I fibres, the increased number of connective tissue fibres seen in the liver of chronic dialysis patients with hyperoxaluria was investigated in the peritoneal membrane. This revealed a slight increase in type I collagen fibres and an increase in a 27 000 mol. wt. band (corresponding to fibronectin) in peritoneal biopsies of the study group. The increased intensity of this band in dialysis patients was due to a combination of an increasing cellularity and fibronectin deposition. The peritoneal cells were examined with respect to functional cellular alterations using a variety of functional and immunocytochemical methodologies. A significant increase in the number of interstitial macrophages and T lymphocytes was observed. The ultrastructure of these cells was intact, without any morphological indications of activated peritoneal cells. There was a significant increase in the number of cells positive for the MHC class II antigens HLA-DR on peritoneal macrophages and on fibroblasts. Since these cells had high oxalate dehydrogenase activity, we therefore investigated whether oxalate may be taken up by the peritoneal cells. We show that oxalate may be taken up by peritoneal macrophages from oxalic acid, but not from crystalloid haemodialysis solutions.<EOD> Antiseptics for preventing ventilator associated pneumonia.\nBACKGROUND\nVentilator-associated pneumonia (VAP",
        "label": 1
    },
    "2190": {
        "output": "[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility decision for the patient at the end of the trial-level eligibility block. You should output the scale you chose in this block, for example, `Trial-level eligibility: 2) Eligible.`.\n\nBelow is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl\nHere is the clinical trial: \nTitle: A Study to Assess the Efficacy and Saf",
        "label": 0
    },
    "2191": {
        "output": "[MODULE END]\n\n## Patients with acute diabetes.\n[[INST] You are a clinical investigator for an IRB. You are currently reviewing a clinical trial that is studying the use of a new insulin for diabetes.\n\nThe study intervention consists of two types of insulin: the old type (regular human insulin) and the new type (rapid human insulin). Patients are assigned randomly to one of the two types with equal probability. Patients in the rapid insulin group receive an injection every four hours (four times per day). Patients in the regular insulin group receive injections three times per day (at 8 a.m., 4 p.m., and 12 a.m.).\n\nA research nurse will monitor the patients' blood glucose levels in the hospital for the first three days; thereafter, patients take readings at home twice a day. The objective of the study is to show that over a four-week period, patients using the new rapid insulin have a minimum of a 10% reduction (relative to patients receiving the old insulin) in the number of hypoglycemic events (defined as blood glucose of less than 70 mg/dL).\n\nPlease list the patients who would meet the inclusion criteria as assessed in four weeks from the start of each treatment.\n\n1.\nNo hypoglycemic event in the past.\n\n2.\nRandomized to rapid insulin.\n\n3.\nNo hypoglycemic event after 3 days.\n\nAnswers: \n\n1. \nNo previous episode of hypoglycemia - Incorrect; no episodes in the past is not a sufficient criteria in itself.\n\n2. \nRapid insulin - correct.\n\n3. \nRapid insulin - correct.\n\n[[MODULE END]\n\n## Patient with depression (cont.).\n[[INST] You are a clinical investigator for an IRB. You are currently reviewing a clinical trial that is studying the effects of a new anti-depressant medication.\n\nThe study will enroll individuals who have been diagnosed by a physician with MDD within the past 5 years. El",
        "label": 0
    },
    "2192": {
        "output": "### Solution:\n<EOD> Effects of Inorganic Nutrients on the Transformation of Perfluoroalkyl Carboxylic and Perfluoroalkane Sulfonate Acids\n\nDue to their insolubility in water and persistence, the perfluorinated carboxylic acids (fluorinated fatty acids or PFCAs) and sulfonates (fluorinated sulfonates or PFSAs) have become recognized emerging contaminants in the environment. In this study, batch experiments were conducted with the perfluorinated acid mixture in order to determine the transformation rates of selected perfluorinated acids (C 4 to C 14 ) in various media: tap water, river water, sewage, and groundwater, all amended with 0, 1, 5, 10, and 20 mg L \u22121 of nitrate, ammonium or phosphate. Results showed that the PFCAs degradation occurred slowly in all media. In contrast, the PFSA transformation occurred fastest. In a nutrient medium with fluoride nitrate concentration equal to zero, the concentrations of the PFCAs and PFSAs were constant for 24 days. Whereas, the addition of nitrogen promoted PFCAs elimination by biochemical and chemical process and accelerated its biorecovery. The addition NH 4 + and NO 3 \u2212 increased PFAAs elimination rate in nutrient media, whereas, PO 4 3\u2212 reduced its elimination. Over time, however, fluoride concentrations gradually decreased in the incubation experiments. The observed differences in reactivity among media with varying concentrations of inorganic nitrogen were due to the inhomogeneity of microbial activity in the systems. These results provide further understanding on the biotransformation of PFCAs and PFSAs in environmental media, which will help in the identification of the best methods for remediation and recovery.\n\n# Introduction\nPerfluoroalkyl substances are organic compounds that are used extensively in a variety of consumer products, including paper, carpets, metal working fluids, fire-fighting equipment, paints, rubber, food packaging, and cookware. Currently, perfluorooct",
        "label": 0
    },
    "2193": {
        "output": "<EOD> Inhibition of Hydrolase Activity in the Etiolated Root Nodules of Phaseolus vulgaris by Phenylalanine\nExtracts from etiolated root nodules (EtRN) of Phaseolus vulgaris exhibited only cytosine and phosphoribosylamine deaminase activity. Extractives were added to a crude fraction of this enzyme activity to observe possible effects on enzymatic activity. The addition of phenylalanine inhibited enzyme activity in a dose-dependent fashion. The ED 50 was \u223c0.25 mM.<EOD> The use of the intraosseous Epiphalycer device in veterinary medical teaching\nEpiphalycer is a commercially available injection device for intraosseous infusion of liquids. Such devices are widely used in human medicine, but have seldom been described previously in veterinarian medicine. This device has been in use in an Australian tertiary veterinary hospital for the past decade. A literature review, an investigation into the experience with the human device, and a report of cases in a veterinary teaching hospital are included, together with a description of the technique of use in dogs. Teaching medical staff were satisfied with the reliability of the system and the accuracy of the dose delivery. The device was used by veterinary students and staff in teaching procedures. An example of a patient taught using this device is reported. Use of the human device may provide an introduction to new graduates to the benefits of intraosseous infusion, which may enable safe veterinary practice.<EOD> Assessing the performance of the Drosophila melanogaster embryo for large-scale imaging\n\n\n\n## Reviewer comments:\nReviewer #1 (Remarks to the Author):\n1. In the Introduction, they suggest using Drosophila as a proxy for human development. For this reason, they suggest it's worthwhile to develop a system for automatically segmenting Drosophila. Yet, they later point out that Drosophila embryogenesis is distinct from human embryogenesis in many respects (line 368), and that this is not helpful in developing a general framework. Why did they include the statement in the introduction about using Drosophila as",
        "label": 1
    },
    "2194": {
        "output": "Let's read the patient diagnoses from the text files: \n# Note. Some cancer types were grouped after combining the code ranges (i.e., bladder/stomach = Urogenital Organs) to reduce the number of variables reported. \nFor many different purposes, medical information has been collected and categorized, in different ways, for decades. Differences to note include data on the age of diagnosis, survival (time after diagnosis to death or end of follow-up), and type of cancer. \nIn order to understand in more detail the effects of specific types of cancer on individuals, we can explore patient characteristics across the US census demographic categories. \n\nLet's transform all of our patients into the Pandas DataFrame based on the information in the text file. Also, we transform the patient into the patient object by assigning it to the list to be able to access each piece of information by indexing. \n\nHere is the code to load our data as a Pandas DataFrame and then to transform our patients into the patient object. You will see the output as follows: \n# The type of cancer\n# The demographic of patients according to the census of patients\n# The number of patients for each cancer type for each demographic group \nprint(pd.DataFrame(pData))   \n\nprint(f\"\\n{list([str(patient) for patient in pData])}\") \n\nFinally let's visualize the type of cancer, demographic, and the number of patients in the pie chart to see if we could identify the reason based on what we have found so far. \ndata = [f\"{list([str(patient) for patient in pData])}\" for patient in pData] \nseries = {'demographic': list(map(str, pData).unique())}\n# series.update(demographic)\nfig = go.Figure()\nfig.add_section()",
        "label": 0
    },
    "2195": {
        "output": "In this scenario, the output result should be: *Tripl-level eligibility: 2) Eligible.*\n\n\n# 6.0 Solution\n## 1. Copy the solution code into your code editor and adjust it to your dataset, changing all variables from *Example* to *Your dataset*.\n\n```bash\n#!/usr/bin/python\n\nimport pandas as pd\nimport numpy as np\n\ndf = pd.read_csv('./trial_6.csv')\ndf['Trial-level eligibility'] = ''\n\ncolumn_df = df.find_occurrences('Trial-level eligibility')\n\ndf[column_df.index.tolist()] = column_df.to_list()\n\n# + [markdown](../docstrings.rst) collapsed\n\nprint(df)\n\n# ANSWER\n```<EOD> Di-n-butylammonium 2,2-diphenol-3-propanoate\nThe title salt crystallizes in the monoclinic crystal system with one complete formula unit per asymmetric unit. The 2,2-diphenol-3-propanoate anion is situated about a center of symmetry, so that the di-n-butylammonium cation is surrounded by four half-anions. This arrangement is stabilized by N\u2014H\u22efO and C\u2014H\u22efO hydrogen bonds between the cation and half-anion and by C\u2014H\u22ef\u03c0, C\u2014H\u22efO and C\u2014H\u22efCl hydrogen bonds between the cations. There are also weak C\u2014H\u22efCl contacts between symmetry-related half-anions.<EOD> Influence of Intrinsic Viscosity and the Solvent State of Hydrophilic Poly(vinyl alcohol) on Adsorption of Poly(vinyl alcohol) by Zeolites\n\nIn order to investigate the influence of the intrinsic viscosity Molecular and the solvent state of hydrophilic poly(vinyl alcohol) (PVA, M w =44000, PVP =81%) on the adsorption of PVA by zeolite, the solubility of PVA in aqueous",
        "label": 0
    },
    "2196": {
        "output": "## How to write a note to the author [TEXT]\n[INST] You are a consultant for a multicenter clinical trial about cancer.\n\nThe clinical trial team includes a medical staff and many doctors from the hospitals. The main staff members send reports in each center with feedback to you. Based on the reports, they can find some issues and propose some notes for you. As a follow-up note is a very important one, it is an indication of all the participants' conditions. The aim of sending the notes to you is to find some errors, improve the performance level or solve the problems.\n\nAs an assistant researcher for this project, you are responsible for receiving the feedback reports. They provide important information about the participants' conditions. You should have a close relationship with people in charge. In other words, you must read the notes and try to solve or identify the problems. Finally, you need to send a report to the person in charge to provide some advice and useful suggestions accordingly.\n\nIn this project, we include all details and issues about the project, especially about the participants' conditions. You should be able to read all the notes clearly.\n\nThere are three important points to keep in mind as the project expert: \nThere should be no error (syntax errors and logical errors), and the sentences be clear. \nThere must be no spelling errors. Every word should be chosen carefully, and it must be appropriate.\n\nThe style should be professional, and the structure should be logically structured.\n\nHere are some examples (do not use the last two examples). Please submit all your reports in R markdown. [/TEXT]\n\n## How to report a study in r markdown\n[TEXT] \nIn a previous assignment, you read and analyzed the content. Now you are supposed to write a report in R markdown (hereafter, RMD). R is an open-source software for statistical computing. \nRMD is a format that is especially designed for reporting a study, analysis, etc. \nRMD contains several basic building blocks in the report. \nRMD is an example of an R script (or file) that gives output as HTML. \nRMD allows you to export your document on the server hosted in RStudio and share the document using the R markdown package. \nBefore you start writing the report, please read R markdown documentation",
        "label": 0
    },
    "2197": {
        "output": "<EOD> Re: \"Orofacial Clefting and Maternal Periconceptional Vitamin Use: Results From A Case-Control Study\".\nMarch of Dimes Birth Defects Foundation, 1310 G St. NW, Suite 510, Washington, DC (F); School of Public Health University of Michigan, Ann Arbor, MI (R, WC); School of Public Health, University of Washington, Seattle, WA (JS, LG); School of Medicine, Yale University, New Haven, CT (JS, LG); Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC (NM); Epidemiology Branch, US Environmental Protection Agency, Research Triangle Park, North Carolina (DM, RR); Center for Perinatal Research, Tufts Medical Center, Boston, Massachusetts (JS); and Department of Pediatrics and Center for Perinatal Research, Tufts University School of Medicine, Boston, Massachusetts (JS)<EOD> .\nExcessive daytime sleepiness is clinical problem of high importance, because it is associated with poor quality of life as well as with increased mortality and morbidity resulting from motor vehicle accidents. Objective diagnosis is based on sleep-related findings, such as increased sleep latency, decreased sleep efficiency, and decreased percentages of normal sleep stages. Additionally, it is necessary to use questionnaire on excessive daytime sleepiness such as the Epworth Sleepiness Scale and daytime sleepiness inventory. The latter has proven to be very good for evaluating excessive daytime sleepiness in young children. Among the treatments that can be considered for daytime sleepiness, one has to highlight the use of sodium oxybate, a drug that has produced significant effects in controlled placebo-controlled studies, especially in patients with cataplexy, hypersomnia, or narcolepsy. In future, it will be important to evaluate the long-term effect of sleep promoting medication in narcoleptic patients (with and without cataplexy).<EOD> Cerebral Artery Vasospasm in a Child with Anterior Communicating Artery Aneurysm: A Case Report and Literature Review\nChildhood brain aneurysm is a rare incidence. Intracerebral hemorrhage is the most common",
        "label": 0
    },
    "2198": {
        "output": "### Additional Exercises\n\nThese are extra exercises you can consider to improve your understanding of clinical trials using the real-world data:\n\n**Additional Exercise (1): Case Conceptualization (CC)**\n\nPlease use the case provided below and develop a CC for it. You can get ideas from the lecture material and references, but you should keep your CC for trial 20 minutes long.\n\n**Case Conceptualization**\n\nPatient Name: Mr. Brown, 50-year-old male, presents today with headache and dizziness. In past medical history, he had a cardiac catheterization and a diagnosis of coronary artery disease. Mr. Brown's main complaint is frequent episodes of dizziness associated with a tingling sensation in the head occurring within an hour after meals.\n\n\nHe describes the sensation as a feeling of fattening in the upper abdomen associated with a dizziness. Additionally, he states that when the sensation is more severe, he has episodes of vomiting, numbness, and a feeling of unreality of the surroundings. He does not have any other complaints such as nausea, vomiting, blurred vision, weakness, or paresthesias.\n\nAccording to the information given by the patient and based on my clinical judgment, the sensation of fattening in the abdomen is one of the symptoms that occur as symptoms of angina.\n\n**Additional Exercise (2): Case Conceptualization (CC) for the hypothetical patient**\n\nPlease consider the following fictional case scenario and develop a CC for this scenario. When you develop the CC, imagine that you are talking to a patient about the results of this project. Make sure you answer the following questions as much as you can. Please do not talk about the clinical trial results in this exercise. You should only give the patient the information in the case scenario and develop the CC based on the patient.\n\n|\n\n\n|\n\n\n|\n\n\nFiction Case Scenario |\n\n### Fiction Case Scenario\n\nImagine the following person:\n\nYour name: _____________________________________________; Age: _________ years; Gender: ___________;",
        "label": 0
    },
    "2199": {
        "output": "[CASE] [NAME]\n\nYour goal is to make a binary classification between normal and abnormal patients. \n\nHere are some patient notes:\nThe patient is 40-year-old man who was diagnosed with type 1 diabetes in his early 30 s. His condition has been well controlled during the past 5 years. He is taking only 70/30 Insulin. His past medical history is not significant for any other medical issues. His family history is significant for DM type 1 in his uncle and his father. His lab study was done recently and as following:\nFBS: 100 mg/dl;\nHbA1c: 6.5%;\nCholesterol: 190 mg/dl;\nTG: 140 mg/dl;\nLDL: 125 mg/dl; HDL: 40 mg/dl.\nHere is a collection of patient notes. You should classify each patient note using the following labels:\nnormal\nabnormal\nnon-diabetic\ndiabetic\n\nThe dataset has training, validation, and test sets. You might want to train your model using a training set, test the performance using validation set, and use test set to evaluate your model's performance, so we need to store the results in separate locations. Below is how to define the location of the outputs of model in a function. Here, `y` represents `Normal` or `Abnormal`, and `index` is the i-th patient.\n\n\nThe following models are used in machine learning.\n\n\nIn this model, the input data are fed to a fullyconnected feedforward neural network with one hidden layer. The parameters at output layer are set as one hot code, so it outputs binary class value (normal or abnormal) for each patient. This model can give us two values at each training (and inference) phase. One is the probability and the other is binary class value. In this paper, only the probability is given. In the dataset and the code, the probability is converted to binary value (one hot code). \nHere is the source code in `ipykernel.py` format, which can be executed seperately using `jupyter kernel.py`.\n\n````python\nimport numpy as np\nimport pandas as pd",
        "label": 0
    },
    "2200": {
        "output": "A: What you did wrong, was that you're setting the answer variable to 1 and then use it as your answer.\nI did this by accident as well:\nprint('NotRelevant=' + not_relevant)\nprint('Eligible=' + eligible)\nprint('Excluded=' + excluded)\n\nWhat you should do instead is either:\n- use the answer as a variable in your print statement, as in:\nprint((answer_question == 2 ) and (answer_question == 1))\n\nand then use if-else:\nif answer_question == 2:\n    print('NotRelevant')\nif answer_question == 1:\n    print('Eligible')\neligible = True\nexcluded = False\n\nprint(eligible)\nprint(excluded)\n\nOR\n- use a second if:\nprint((answer_question == 2) and answer_question == ('NotRelevant' or 'Eligible'))\n\n<EOD> Identification of the protein partners of progesterone receptor in human myometrial cells.\nProgesterone is fundamental for the maintenance of pregnancy due to its ability to suppress myometrial contractions. In this study we demonstrated that progesterone receptors (PR), androgen receptors (AR), and estrogen receptors (ER) were present in myometrial cell nuclei, confirming that myometrial cells are hormone targets. Using a combination of a yeast two-hybrid approach and coimmunoprecipitations, we identified several different cellular progesterone targets. PR was found to associate with members of the SWI/SNF family of chromatin-remodeling factors (BRG1, BRM), androgen receptor (AR), and proteins with various functions, such as protein kinases (PKN-1), a transcription factor (ATF-3), and the Ets-like protein ELK-1. The progesterone-specific nuclear receptor and the steroid receptor co-regulatory proteins are involved in PR functions; therefore, we next tested their influence on the recruitment of PR-interacting proteins. The presence of PR, but not of estrogen receptor, affected the presence of BRG1",
        "label": 0
    },
    "2201": {
        "output": "## Example 1: 2) Eligible`\n`[H:H] Hello, world! I'm just beginning to learn Bash. Here is the output of `echo $`.\n\nI am 35 years old\nI'm new to programming.\nI'm not good yet.\nI play basketball every day\nI have a cat and a dog\nI've never traveled.\nI don't like cooking.\nNo, I've never cooked myself.\nI've never baked myself.\nI'm not sure yet.`\n[INST] Hello. You are a 35-year-old health-care worker. \nYou are going to search for clinical trials recruiting patients with type 1 diabetes mellitus (T1DM). \nYou should write the code required to fulfill the following task.\nYou should search in clinicaltrials.gov with `type 1 diabetes mellitus` and filter on `condition or disease` and `patients with T1DM.`. \nWrite the Bash code to search clinicaltrials.gov with `type 1 diabetes mellitus` and filter on `condition or disease` and `patients with T1DM.`. \n\n\n\nSearching clinicaltrials.gov with `condition or disease` and filter on `patients with T1DM`: \nClinicaltrials.gov search output\n\nSearching clinicaltrials.gov with `condition or disease` and filter on `patients with T1DM` and limiting to the clinical trials which start recruiting at today`s date will list only one clinical trials which I don't want to receive. \nTo get the complete output for this date, I should search on clinicaltrials.gov with the next code: `Clinicaltrials.gov search output 2`. \n\nSearching `type 1 diabetes mellitus` and filter on `condition or disease`, and limiting to the clinical trials which start recruiting at today`s date: \nSearching ``type 1 diabetes mellitus`` and filter on ''condition or disease`` and limiting to the clinical trials which start recruiting at today'",
        "label": 0
    },
    "2202": {
        "output": "##[TEST]\nIf you are unable to correctly classify all patients given the clinical trial, you will be prevented from submitting the exam. If you still have problems, please raise a ticket on [https://help.grasp-hub.com/] with the correct answer as well as an explanation of your issue.\n---\n[END CARDS]<commit_msg>Corrected a typo for the last question.<commit_after># [CARD 4] What is the goal of clinical trials?\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:",
        "label": 0
    },
    "2203": {
        "output": "<EOD> Transformation of the antibiotic producer Streptomyces fradiae by pUC19 plasmid DNA and the plasmid-encoded replication and conjugal transfer genes\nTransfection of Streptomyces fradiae with the broad-host-range plasmid vector pUC19 results in conjugational plasmid integration by homologous recombination. Recombination of pUC19 into the chromosomal ampG gene results in amplification, which is due to the loss of expression of an antibiotic production inhibitor. Antibiotic assays revealed a variety of antibiotic patterns for the transfected populations. A number of plasmid-free cells contained the ampS and ampA genes and produced large quantities of the antibiotic actinorhodin. Transformants which contained a single copy of pUC19 exhibited a heterochromatine-related chromosomal instability phenotype with the amp/gene cluster rearrangements. In all, 12 transformants have been characterized, and the possible molecular mechanism of their formation is discussed.<EOD> .\nIn order to explore the influence of the different cultivation media on the secondary metabolites of the cultures of Aconitum decoctum from Nantianqi, high performance liquid chromatography (HPLC) and the gas chromatography/mass spectrometry (GC/MS) were performed. The total flavonoids, caffeic acid, ferulic acid and dihydrosesamin in the different cultivation media (1/2 Hoagland liquid medium, perlite, vermiculite, perlite + vermiculite, perlite/vermiculite+sand and perlite/vermiculite+perlite, perlite/vermiculite+sand) were studied. The total flavonoid, caffeic acid, ferulic acid and dihydrosesamin contents decreased in perlite and perlite+vermiculite, perlite/vermiculite+sand and perlite/vermiculite+perlite, but were higher in perlite/vermiculite+sand or perlite+vermiculite. The results showed that the secondary metabolites including total flavonoids, caffeic acid,",
        "label": 0
    },
    "2204": {
        "output": "<EOD> Pre-Clinical Use of N-Acetyl Cysteine against Cytokine Release Syndrome in SARS-CoV-2 Model\n\n\n\n# Introduction\nSevere cases of coronavirus disease 2019 cause the most severe form of pneumonia, called COVID-19 [bib_ref]  Characteristics of SARS-CoV-2 and COVID-19, Hu [/bib_ref] . Its incubation periods are 2 to 14 days and up to 21 days. COVID-19 is mainly transmitted via direct person-to-person contact [bib_ref]  Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review, Wiersinga [/bib_ref] . The virus is a spherical and enveloped structure containing different proteins including the transmembrane spike protein (S protein). The viruses are transmitted when the ciliated epithelial cells of the upper respiratory tract come into contact with the oral and nasal droplets of the infected person. It has also been proven that asymptomatic patients can transmit the virus [bib_ref]  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients, Zou [/bib_ref] .\nPatients infected with SARS-CoV-2 typically present with fever, fatigue, myalgia, or arthralgia, accompanied with interstitial pneumonia, lymphopenia, and elevated C-reactive protein and lactate dehydrogenase levels [bib_ref]  Characteristics of SARS-CoV-2 and COVID-19, Hu [/bib_ref]  [bib_ref]  A Review of Coronavirus Disease-2019 (COVID-19), Singhal [/bib_ref] . Some patients present with thrombus [bib_ref]  Pathological Findings of COVID-19 Associated With Acute Thrombosis, Jena [/bib_ref] . Some clinical studies show that a high virus load in the lung is associated with poor prognosis and mortality [bib_ref]  Coronaviruses Diseases (COVID-19) Pandemic: The Detection of Virus by Nose Throat Swab..., Chowdhury",
        "label": 0
    },
    "2205": {
        "output": "## Example\n\n```python\n# encoding: utf-8\n^^^\n\nimport unittest\n\nfrom clinical_trial.utils.inclusion_detection import assist_eligibility_assessment,\n                                                      is_eligible_for_clinical_trial,\n                                                      is_relevant_to_clinical_trial\n\n\nclass Assistent_eligibility_assessment_test_case(unittest.TestCase):\n\n    def setUp(self):\n        self.trial_notes = \"\"\"\n                    The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\n    FBS: 100 mg/dl\n    HbA1c: 6.5%\n    Cholesterol: 190 mg/dl\n    TG: 140 mg/dl\n    LDL: 125 mg/dl\n    HDL: 40 mg/dl\"\"\"\n        self.trial_notes_2 = \"\"\"Trial",
        "label": 0
    },
    "2206": {
        "output": "Good luck, and make sure to submit all four questions.\n\n# Submission Instructions\n\n1. Create an [Account](account) and enter your unique token.\n2. Use R Markdown in the [Authoring Interface](authoring).\n3. Add your name and contact information so that we can credit you if you win.\n4. Select 'Cascade' (best viewed with Microsoft Web Explorer). You will be asked to [sign up for a free account](https://www.tableau.com/signup) and verify your account via e-mail.\n5. Select 'Cascade' once more for the [Export PDF](export_pdf), save that document, and send via [e-mail](mailto:<EMAIL>?body=My%27Cascade%20Result%20Is%20%B3ellow%20If%20You%20Have%20Time%20Please%20Suggest%20Improvements&#32;%0D%0A%0D%0ATo%20Run%20My%20R%20Markdown%20and%20Cycle%20Through%20Questions%20Please%20Enter%20Your%20Token%20Through%20Your%20Account%20at%3A%0D%0A%0D%0Ahttp%3A%2F%2Fmytableausandbox.com%2Fview%2F88f38c2eb-3107-4ca9-bfc5-e8798771c39c%2Fproject%2F375%2FDashboard%2Fsubmission.%2FCycle%20Questionnaires%20and%20Markdown%20Submission.&body=My%27Cascade%20Result,%20If%20You%20Have%20Time%20Please%20Suggest%20Improvements%3A%0D%0A%0D%0ATo%20Run%20My%20R%20Markdown%20",
        "label": 1
    },
    "2207": {
        "output": "[TRAINING TIP]\n\nTo practice and receive feedback before attempting the solution on-course quizzes, consider the [TRAINING ASSIGNMENT TEXT][52]. \n[/TRAINING TIP]\n\n## Solution\n\n\n    Trial name: Change of Fructose to Fat in South Asians\n\n    Patient name: Mohammed\n\n    Age: 25\n\n    Gender: 1\n\n    Race: 1.0\n\n    Country: Pakistani\n\n\n    BMI: 22.0\n\n    FBS: 100\n\n    Chol: 190\n\n    Trig: 140\n\n    HDL: 40\n\n    HbA1c: 6.5\n\nMohammed who is 25 years old fulfills the inclusion criteria 1 to 4.\nFBS: > 100, HDL: > 40 -> 2\nChol: > 190, Trig: > 140 -> Eligible\nHe fulfills the inclusion criteria 7 to 13.\nCountry: Pakistani -> Excluded\n\n\n    Eligible: 1\n\nTrial-level eligibility: Eligible\n\n## Solution\n\n\n    Patient name: Mohammed\n\n    Age: 25\n\n    Gender: 1\n\n    Race: 1.0\n\n    Country: Pakistani\n\n\n    BMI: 22.0\n\n    FBS: 100\n\n    Chol: 190\n\n    Trig: 140\n\n    HDL: 40\n\n    HbA1c: 6.5\n\n\n    Eligible: 1\n\n    Trial-level eligibility: Eligible\n\n#### Hints\n\n\n    This case study involves some of the fields from the 'ClinicalTrials.gov' database including \n    country, gender, race and BMI to name a few.\n\n    The field country is a string that allows for free text entry including \n    South Asia, Central Asia, South East Asia, Far East",
        "label": 0
    },
    "2208": {
        "output": "___\n\n## Data and Code\n\n\n**Data**\n\n- [https://docs.google.com/spreadsheets/d/b/1Gp5wLc4fUxKO4B_Tk43ZiQx1hNYMKD8f6x8-U_cD3Uo/edit?usp=sharing&ouid=106227005892411255951&rtpof=true&sd=true](Data)\n\n- [https://code.ancorg.io/github/AnCorg/data](Data)_\n\n**Data Explanation**\n\nThis data includes the required information for the patient, the associated trial's exclusion criteria (TC), and the study design. The information for the patient includes the age, gender, and trial's criteria. \n\n### Column descriptions \n\n| Column | Description |\n| --- | --- |\n| TCID | Trial's exclusion criteria ID |\n| Trial_Eligibility | Trial_Eligibility is the label used by the annotator to assess patient eligibility for the trial (0: Excluded, 1: Not relevant, 2: Eligible) |\n| Clinicaltrial_ID_vital_medical_criteria | clinicaltrial_ID_vital_medical_criteria is the label used by the annotator to assess if the vital medical criteria of patient match study design of the trial (0: Excluded, 1: Not relevant, 2: Eligible) |\n| Study_design | Study design |\n\n### Dataset Preparation\n\n#### Data Preparation\nBefore importing to our model, each ID of the dataset should be unique. \n\n1. Create a new column with the name _Trial_exclusion_id and assign it the value of the ID of the trial_exclusion criteria \n2. Then, create a new column with the name _Study_design_criterion_id and assign it the value of the ID of study design \n3. Merge the two columns with the new column and remove duplicates\n### Imports\n\n- [https://docs.google.com/",
        "label": 0
    },
    "2209": {
        "output": "# 74 Exercise<EOD> Prostacyclin-dependent vasodilation on acute hypercapnia in essential hypertension.\nAcute changes in arteriovenous CO2 difference and related blood flow in essential hypertension have been suggested by some investigators, but conflicting results have been reported. This experiment was carried out to study the effect of acute hypercapnia on arterial and venous blood flow in essential hypertension with particular reference to CO2 and nitric oxide. A double labelled microsphere technique was used to measure blood flow to organs such as kidney, gut, skin and others, at three different conditions (normocapnia, hypercapnia and recovery to normocapnia). The results showed that hypercapnia induced vasodilation on the liver, skin and kidney. CO2 induced vasodilation of the liver was mediated through prostaglandin and nitric oxide synthesis, which was the same phenomenon in skin. The effect of acute hypercapnia on renal blood flow is mainly mediated through increases in CO2. The role of CO2 on renal blood flow was further confirmed by the inhibition of CO2-induced vasodilation in renal blood flow by l-NAME (a non-selective nitric oxide synthesis inhibitor).<EOD> Rho guanine nucleotide exchange factors JAG-C1 and TARANIS inactivation restricts murine and human T-cell leukemia progression.\nT-cell leukemia is an aggressive malignancy and the only type of cancer that remains poorly characterized for treatment. This is due to lack of an immature and naive counterpart in which to study development and disease progression. Herein, we describe the characterization of the T-cell leukemia-propagating cell (T-CPC) as highly immature for any known T-cell subset. The T-CPC is transcriptionally distinct from conventional helper CD4 and CD8 T cells, with activation of pro",
        "label": 1
    },
    "2210": {
        "output": "# Evaluate the eligibility and repeat it\n\n# Conclusions and further work\n\nThe presented study is an example of a patient's eligibility assessment. In this study, the clinical trial's eligibility depends on the patient's eligibility, which is based on the data extracted from the patient note, e.g., demographics, diagnosis labels, medications, and lab tests. We have discussed the preprocessing of the patient note in the Data preprocessing section. Next, we analyzed the clinical trial's eligibility that should be repeated for each patient in the Assess the eligibility section. Moreover, we presented different scenarios of the eligibility assessment in the Assess the eligibility section. You can also find a variety of cases in the dataset as well. The solution was designed by the supervised approach. In the future, other machine learning techniques can be implemented, e.g., semi-supervised learning. In this case, we can use the unlabeled data to train the machine learning algorithm and obtain more outcomes.\n\n# Appendix\n\n## Patient note preprocessing\n\n## Text preprocessing\nThe main goal of the preprocessing step is to convert the unstructured text to a structured dataset. In order to accomplish the preprocessing step, it is essential to do a number of tasks, including removing punctuations, removing stop words, removing numbers, and so on. In addition, we remove non-Arabic characters (e.g., \\w), numbers, and word prefix from the patient's data. As a result, a clean input dataset is a text file in CSV format is produced. More information is provided below.\n\n## Removing numbers and words prefix (in arabic)\nIn the training dataset, the numbers and word prefixes (e.g.,  and ) were removed. The `CSV` file with the training dataset is provided to you for the preprocessing file.\n\n## Removing punctuation\nThe set of punctuation for preprocessing is \n\n## Removing stop words\nRemoving the set of stop words is the next step in the preprocessing step. The set of stopwords is\n\n## Removing special characters (chars_rem)\nOften, patients' notes in a CSV file may consist of special characters such as \"\\\" in the note",
        "label": 0
    },
    "2211": {
        "output": "---\n\n##### [Part A: Incomplete Information](p3a.md)\n\n### [Part B: Relevant Information](Part.B.md)\n\n### [Part C: Eligibility Checking](Part.C.md)\n\n### [Part D: Trial-level Eligibility Detection](Part.D.md)\n\n### [Part E: Rules for Clinical Trials](Part.E.md)\n\n#### [Part A: Incomplete Information](p3a.md)\n\n##### [09-1. Incomplete Patient Data](IncompletePatient_Data_01.md)\n\n##### [09-2. Incomplete Patient Data](IncompletePatient_Data_02.md)\n\n\n##### [09-3. Incomplete Patient Data](IncompletePatient_Data_03.md)\n\n##### [09-4. Incomplete Patient Data](IncompletePatient_Data_04.md)\n\n\n##### [09-5. Incomplete Patient Data](IncompletePatient_Data_05.md)\n\n##### [09-6. Incomplete Patient Data](IncompletePatient_Data_06.md)\n\n##### [09-7. Incomplete Patient Data](IncompletePatient_Data_07.md)\n\n##### [09-8. Incomplete Patient Data](IncompletePatient_Data_08.md)\n\n##### [09-9. Incomplete Patient Data](IncompletePatient_Data_09.md)\n\n##### [09-10. Incomplete Patient Data](IncompletePatient_Data_10.md)\n\n##### [09-11. Incomplete Patient Data](IncompletePatient_Data_11.md)\n\n##### [09-12. Incomplete Patient Data](IncompletePatient_Data_12.md)\n\n##### [09-13. Incomplete Patient Data](IncompletePatient_Data_13.md)\n\n##### [09-14. Incomplete Patient Data](In",
        "label": 0
    },
    "2212": {
        "output": "**12. Incorrect approach**. Your goal is to return a trial-by-trial rating of eligibility: {eligible, n/a, excluded} where eligible, n/a, and excluded are integers indicating the count of patients with eligible, not-relevant, and excluded scores, respectively. Your current approach is to assign a score of 0, 1, 2 for patients who are eligible, not-relevant, and excluded, respectively; and return their sum as trial-by-trial eligibility score. However, your count of eligible, not-relevant, and excluded patients is different from the intended count of them. Your current logic is wrong; please fix the logic and return proper integer (eligible, n/a, excluded) to make it as {eligible, n/a, excluded}. [INST]\n\nYou are doing great so far! Just a few tweaks to go. \n\nHere is the updated patient note:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis of beta-cell antibodies and islet cell antibodies. He was diagnosed with cardiomyopathy that will be treated with ACE inhibitors, Beta blockers, angiotensin receptor blockers, and metformin. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues.\nHis family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: \nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl [INST] You are a helpful assistant",
        "label": 0
    },
    "2213": {
        "output": "<EOD> Diagnostic Accuracy of Urinary Alpha Glutathione Transferase (NAG) in Urinary Tract Obstruction Caused by Transitional Cell Carcinoma of Upper Urinary Tract in the Presence of Disseminated Tumor Cells in Urine or Blood\nPurpose: To evaluate the influence of disseminated cells in the urine and blood, observed in patients with transitional cell carcinoma of upper urinary tract (TCC-UUT), on the diagnostic accuracy of urinary alpha glutathione transferase (NAG), in order to increase the confidence of clinician in the diagnosis of urinary obstruction. Methods: A series of 180 patients with suspected urinary obstruction (UO) was analyzed. Results: 64 (35.5%) patients with TCC-UUT and positive cytobacteriological examination from urine, 25 with transitional cell carcinoma of distal urether (TCC-D), 53 (29.4%) with uretheral stricture, 21 (11.7%) with lower urinary tract urether or bladder carcinoma, 5 (2.8%) with TCC-UUT but no tumor detected by current methods, 3 (1.7%) with ureteral calculi and 10 (5.5%) with pyelopuhnic lithiasis and 1 (0.6%) with tumor of unknown origin. Urinary NAG was positive in 57 (89.1%) out of 64 patients with TCC-UUT, in 17 (68.0%) out of 25 with TCC-D. In 22 (81.5%) out of 27 patients with positive urinary disseminated cells and in 209 (62.7%) of 331 with negative urinary cells (p < 0.1). In this subgroup of patients with positive urinary disseminated cells, NAG level <200 U/l gave specificity of 100% when compared to any other causes of urinary tract obstruction. In contrast, specificity of 81.7% was obtained for NAG >200",
        "label": 0
    },
    "2214": {
        "output": "In this exercise, the patient note is the same as the previous patient note. The trial note is the same as that in the previous trial note. So we should generate the same diagnosis, namely: Type 1 diabetes confirmed with molecular analysis. (The patient note is also the same. But, in the real patient note, the patient may have the other diseases. So, we should pay attention to the diseases' names and corresponding information when we fill out the patient note.)\nYou should generate the following variables from the patient note and the corresponding information, respectively:\n\n## 1)\nDiagnosis: 117)\n\n## 2)\nHbA1c_value: 6.5\n\n## 3)\nPatient-Note_Text: Please, click the 'Create trial-level eligibility ' button if you have completed Trial-level eligibility for the patient.\n\n! ![INST]\n!!!\n\n## Note:\n- In `Trial-level eligibility:`: select `1` to mark a patient as `Eligible` and`0` to mark a patient as `Not relevant`. `2` means that the assessment of eligibility for the patient is still ongoing. - In `Note:`: input a short note of `117` or delete the default `Note:` of the assessment of eligibility, if you need to write a note.\n!!!\n\n\n## Exercise file:\n\n\n\n[!INST]\n[!INST]\n[!INST]\n[!INST]\n![INST]\n![INST]\n![INST]\n[!INST]\n[!INST]\n[!INST]\n[!INST]\n[!INST]\n!!!\n\n## Assess assessment of eligibility of the second patient\nThe second patient is a 67-year-old woman with type 2 diabetes diagnosed with molecular analysis 48 years ago. She is a nurse and has been smoking for 20 years. She was admitted to hospital because of pneumonia accompanied by diabetic foot ulcers. Physical examination showed that she has 20 pack-years of smoking history.\n\n[!INST]\n[!INST]\n[!INST]\n[!INST]\n[",
        "label": 0
    },
    "2215": {
        "output": "#### 1.2 Find the patient note id\n![INST.1.2] (click to reveal)\n\nLet's take an example. You should take $1, 223 (patient note id) \n![1,223] (click to reveal) \n\n[1,223]\n\n#### 1.3 Find the patient note in RM\n![INST.1.3] (click to reveal)\n\n#### 1.4 Find the list of clinical trials in RPD\n![INST.1.4] (click to reveal)\n\n#### 1.5 Find the patient's assessment of eligibility for clinical trial 14\n![INST.1.5] (click to reveal)\n\n\n\n# 1. Check If the Patient Note ID is the Same in RPD and RM: \nCheck whether `patient note id == patient_id` (in your script) is same. For example, `if(patient_id == id) print(\"Yes\")`. \n\n\n# 2. Find the trial (Clinical Trial id) Given in RPD \n![INST.2] (click to reveal)\n\n``` \ndput(hdr) \ndput(attrs)\n``` \n\n![INST.2.3] (click to reveal) \n\n``` \n\npatient_id patient_notes_id\n   patient_id          int\n   patient_notes_id     int\n\nattrs <- subset(hdr, attrs %in% c(\"Patient_Name\", \"Sex\", \"Age\", \"BMI\", \"Smoker\", \n              \"Drinking\", \"Cardiovascular\", \"Hypertension\", \"Hyperlipidemia\", \n              \"Family\", \"Glucose\", \"HbA1c\", \"total_chol\", \"LDL_Chol\", \"HDL_Chol\", \n              \"Triglyceride\", \"Weight\", \"Treadmill_6MWD\", \"BP_DBP\",\"BP_SBP\", \n              \"Fasting_Glucose\", \"FBS_Fasting\", \"Exercise\", \"Ast",
        "label": 0
    },
    "2216": {
        "output": "<EOD> Effect of L-NAME on the antihypertensive and other metabolic effects of captopril after its chronic administration.\nThe effects of 2 weeks administration of N(G)-nitro-L-arginine methyl ester (L-NAME) on (1) the antihypertensive effect of captopril (125 mg daily) in SHR on renal and extrarenal actions of angiotensin II, (2) the inhibition of captopril-activated enzymes. Na+ , K(+)-ATPase in the renal tubular cells and (3) the liver cytochrome P-450 monooxygenase activity were investigated. Administration of L-NAME (5 mg/kg. day) caused a marked increase in blood pressure which was related to a decrease in plasma renin activities. Increased pressor response to noradrenaline was also noticed after this long-term treatment with L-NAME which indicates enhanced sympathetic activity in L-NAME preexposed animals. Captopril administration in captopril-preexposed rats produced a marked fall in blood pressure which was accompanied by increased plasma renin activities and was similar in captopril-naive animals. The effects of captopril administration in captopril-preexposed rats on cyclooxygenase-dependent metabolites of arachidonic acid were similar to those in captopril-naive rats. Captopril administration during the chronic treatment with L-NAME decreased captopril-activated activities, however, this effect was not complete because the enzyme activity was significantly higher in captoprilexposed animals than in captopril-naive ones. After chronic administration, L-NAME decreased the activity of liver cytochrome P-450, but this effect did not contribute to the development of hypertension. L-NAME failed to influence the liver monooxygenase activity in captoprilexposed animals. It is concluded that 2 weeks administration of L-NAME could prevent activation of Na+ , K(+)-ATPase in renal tubular epithelial cells caused by captopril, however, a further fall in blood pressure could not be noticed. Therefore, this effect of captopril is not associated with the",
        "label": 0
    },
    "2217": {
        "output": "# Efficient coding\n\nIt is good to find a way of efficient coding of the tasks you want to perform in order to have an overview of these tasks by using different colors for a better overview.\n\n# Data entry\n## Examples\n\nIn the following tasks you will have to code the data entry task when the patient is inputed in the patient note.\n\nTask: Data Entry of a Patient Note\n\n## Specification\nFor the assignment below it is required that you follow the instructions below.\n\n# Handoff of patients/patient management\n## Examples\n\nThe following tasks include patient management related tasks. This includes, e.g. handsoff of patients, transfer of patients to other departments, etc.\n\nTask:\n\n## Specification\n\n\n# Intake of Patients\n## Examples\n\nIntake of patients refers to the patient being admitted to the hospital. \nThe task `intake of patients` means, that the patient is not in the hospital but will be later admitted to the hospital.\nThis may be caused by illness or some other reason. Therefore the task `intake of patients` refers to the moment, where the patient is not in the hospital yet.\n\n## Specification\nThis assignment is about the intake of patients for the specific data of patients.  \n\n# Clinical Tests\n## Examples\n\n`Administering tests such as electrocardiograms (ECGs), X-rays, blood work, etc. to patients. Providing care as required between the test appointments.`\n`Administering tests such as electrocardiograms (ECGs), X-rays, blood work, etc. to patients. Providing care as required between the test appointments.`\n\n## Specification\nFor the assignment below it is required that you follow the instructions below.\n\n# Preparation for surgical interventions\n## Examples\n\n`Preparation for surgical interventions, which may be minor procedures (e.g. colonoscopies) or major procedures (e.g. open heart surgery, major abdominal surgery, and amputation surgery), including but not limited to general hygiene, preparation of the patient for surgery and postoperative care.`\n`Preparation for surgical interventions, which",
        "label": 0
    },
    "2218": {
        "output": "## # Exercise_1 #\n\nNow, we run program once again and input patient note input  and patient note input . You can view it by running program with inputting a patient note.\nIf you run program without inputting a patient note, the program prints the result of Trial-Level Eligibility from the following patient notes.\n\nYou should make a trial-level eligibility by using patient note input . How could you calculate whether a patient is eligible by `Trial-Level Eligibility` in this case? `3` of 1245 patients are 16.3% of patients. 2 of 3 have eligibility: 66.6% of patients (2 / 3) have eligibility. `66.6%` is the rate of the eligible patients. 66.6% is the rate of the excluded patients. Now, you should find the rate of the patients by using patient note input. How many patients should you use as the sample of the population in this case?\n\n[INST] You are a health scientist for a clinical trial for a medicine to treat cancer. The problem that many patients refuse to receive cancer treatment is a lack of knowledge about the risks and benefits of surgery, which affects the cancer survival rate. The purpose of the trial is to compare the effect of health education on the cancer treatment decision making in cancer patients. According to the literature, the risk and benefits of surgery for cancer patients are quite high, but some patients receive surgery only after diagnosis of advanced cancer. The study needs to find a method that helps cancer patients to decide more quickly and accurately on whether or not to receive cancer treatment. The hypothesis is that providing health education for cancer patients can increase the cancer treatment rate within 4-5 weeks after diagnosis. The clinical trial is designed as a multicenter RCT of 1,245 cancer patients in several major hospitals in Korea with the following details:\n- Eligibility Criteria: Patients who were diagnosed with early cancer are eligible and selected by a clinician.\n- Randomization: Patients are randomly assigned to the intervention and non-intervention groups, with 106 patients in each group.\n- Endpoints: The rate of cancer treatment in the intervention group is higher than that in the",
        "label": 0
    },
    "2219": {
        "output": "[CODE]\ndef assess_eligibility (Clinicaltrial, patient_note):\n\n\t\"This function returns a 3-tuple which contains all the relevant information for a clinical trial.\"\n\tresult = {}\n\tresult[\"Clinicaltrial_ID\"] = Clinicaltrial[\"Identifier\"]\n\t\n\tfor f in Clinicaltrial[\"Eligibility_Criteria\"]:\n\t\tif (f['Patient_Eligibility'] == \"Yes\"):\n\t\t\tresult[\"Patient_Eligibility\"] = \"true\"\n\t\telse:\n\t\t\tresult[\"Patient_Eligibility\"] = \"false\"\n\n\tfor f in Clinicaltrial[\"Participation_Criteria\"]:\n\t\tif ((f['Minimum_Age'] == patient_note[\"Age\"]) and (f['Maximum_Age'] <= patient_note[\"Age\"])):\n\t\t\t\n\t\t\tresult[\"Maximum_Age\"] = patient_note[\"Age\"]\n\t\t\t\n\t\t\tif ((f['Minimum_BMI'] <= patient_note[\"BMI\"]) or (f[\"Maximum_BMI\"] >= patient_note[\"BMI\"])):\n\t\t\t\t\n\t\t\t\tresult[\"Minimum BMI\"] = patient_note[\"BMI\"]\n\t\t\t\t\n\t\t\t\tresult[\"Eligible\"] = True\n\t\t\n\treturn result\nassess_eligibility(Clinicaltrial_1, Patient_note) # 2\n\n\nA: This problem seems to be more general task of classifying, I think. This one would be like, e.g., spam filter task. Or maybe sentiment task, this one have sentiment and neutral, I think you can use sentiment tokenizer and train in training mode.\nSentiment Score Range: -1.0 (Very Negative), -0.5 (Negative), 0.0 (Neutral), 0.5 (Positive)\n<span class=\"sentence\">The patient is a 25-year-old man with type 1 diabetes confirmed with</span> \"<i class=\"sent-neg sent-punct\">molecular analysis</i> \" <span class=\"sent-",
        "label": 0
    },
    "2220": {
        "output": "* [QUESTION] I have tried 798 combinations. But, I don't get any result. How should I code and how should I solve? I don't remember the rules.\n\n\n\n>\nIt means that your input is either incorrect or a bug. In the future, please pay more attention to input.\n\n* [Q3] We have to select one for a patient. Please explain.\n\n\n>\nYou can select the values as you want, such as `3), Excluded.` (Exclusion criteria do not apply) or `0), Not relevant.` (not sufficient information).\n\n* [Q4] I should type the number in the same amount for each time. \n\n>\nIt is unnecessary for our assignment.\n\n* [Q5] This challenge has no correct code. So if I code based on one of the provided solutions; can I get a good mark?\n\n\n>\nThere is no correct code because there is no optimal code, however, our final aim is to check whether the provided solution is correct based on the requirements or not. So even I write a wrong code based on the solutions provided by others, my work will be reviewed by the team members and by my teacher in a peer-review session.\n\n* [A5] Thank you so much for your kind reply.\n\nPlease, explain more about these points, even it is wrong.\n<issue_comment>username_6: Thanks for your comment. I need to wait you to reply\n\r\nThank you.\n<issue_comment>username_7: Thank you for replying. I apologize that I am a little busy currently. I'll try to write something meaningful soon!\n<issue_comment>username_7: I also asked another developer to reply on your questions.\n<issue_comment>username_8: Thank you for your interest in our community and for your questions. Here are my answers:\n\n* I haven't tried it so far because of the time limit, but I know the problem.\r\n\r\n* If you use the provided solution, you should receive a good mark. [However, I'd better not to submit the solution directly in order to prevent cheating.]\r\n\r\n* 798 combinations would be still possible, I know. So I need more details.<issue_closed>\n<issue_",
        "label": 0
    },
    "2221": {
        "output": "\u00a9 PICO\n\u00a9 PICO\n\u00a9 PICO\n\u00a9 PICO\n\u00a9 PICO\n\u00a9 PICO\n\u00a9 PICO\n\u00a9 PICO \u25bc\n\n# Assessment \u25bc\n\n## Question 1\nTo test whether the patient is eligible. \n[/INPUT]\n\n## Question 2\nTo make the Trial-level eligibility. \n[/INPUT]\n\n## Question 3\nTo make the Trial-level eligibility. \n[/INPUT]\n\n## Question 4\nTo make the Trial-level eligibility. \n[/INPUT]\n\n## Question 5\nTo make the Trial-level eligibility. \n[/INPUT]\n\n## Question 6\nTo make the Trial-level eligibility. \n[/INPUT]\n\n## Question 7\nTo make the Trial-level eligibility. \n[/INPUT]\n\n## Question 8\nTo make the Trial-level eligibility. \n[/INPUT]\t\n\n## Question 9\nTo make the Trial-level eligibility. \n[/INPUT]\t\n\n## Question 10\nTo make the Trial-level eligibility. \n[/INPUT]<EOD> The Effect of Increasing Nutrition Education on Food Acceptance and Eating Behaviors of 1- to 3-Year-Old Children\nAbstract Background. The Food Safety Inspection Service (FSIS) nutrition education curriculum called Fresh Start is a free set of materials that aims to help children (1- to 3-yr olds) and their families adopt the Dietary Guidelines for Americans in their home and child care settings. The curriculum is based on the 6 food groups that are nutrient-rich and low in fat; fruits, vegetables, grains (including whole grains), dairy, proteins, and oil. Objective. The aim of this study was to identify the impact of this curriculum on the food acceptance and nutrition education attitudes and behaviors of 1- to 3-yr olds. Methods. An educational intervention study using a nonrandomized",
        "label": 0
    },
    "2222": {
        "output": "I. 2.\n\n## 3.\nWhat if we don't get a match on some patients, can we have some way to automatically tell the patient they are eligible?. Also, can we use python to process our data?. Let's do so now :\n\n```python\n\n\n\ndef print_status(trial_level_eligibility)\nif trial_level_eligibility==0:\n    print(\"Excluded\")\nelif trial_level_eligibility==1:\n    print(\"Not relevant\")\nelse:\n    print(\"Eligible\")\n\n\ndef print_inst_criteria(criterion):\n    if criterion.startswith(\"Male\"):\n        print(\"Gender: Male\")\n    if criterion.startswith(\"Female\"):\n        print(\"Gender: Female\")\n    if \"age\" in criterion:\n        print(\"Age: \", criterion.split(\"age\", 1)[1])\n    if \"diabetes\" in criterion:\n        print(\"Diabetes: present/absent\")\n    if \"type\" in criterion:\n        print(\"Type: \", criterion.split(\"type\",1)[1])\n    if criterion.startswith(\"Vitamin D supplement\"):\n        print(\"Vitamin D supplement: present/absent\")\n    if \"Cholesterines\" == criterion:\n        print(\"Cholesterine: \", criterion.split(\"Cholesterine\",1)[1])\n    if \"LDL\" == criterion:\n        print(\"LDL: \", criterion.split(\"LDL\",1)[1])\n    if \"HDL\" in criterion:\n        print(\"HDL: \", criterion.split(\"HDL\",1)[1])\n    if \"angiographie\" in criterion:\n        print(\"Angiographie: present/absent\")\n    if \"myocardial infraction\" in criterion:\n        print(\"myocardial infraction: NSTEMI/STEMI\")\n    \n\nprint(\"Inclusion criteria\")\n\nfor criterion in eligibilities:\n    print_inst_criteria(criterion)\n```\n\n### What's done!",
        "label": 0
    },
    "2223": {
        "output": "</details>\n\n<h3 id=\"Examples\">Examples</h3>\n\n\n    <details>\n    <summary>\n    <img src=\"https://raw.githubusercontent.com/john-dalton/hubi-v2/master/articles/hubi_images/Clinical_trial_inclusion_criteria_evaluation_hubi.png\">\n    </summary>\n\nThis example takes you through a step-by-step process to determine eligibility for a clinical trial.\n\n[![Run in R](https://run.hipee.org/badge/run/5d87e17801074c702265c39ce66e31e0.svg)](https://run.hipee.org/widget/5d87e17801074c702265c39ce66e31e0?run_config=example%20-%20clinical%20trial%20inclusion%20criteria%20evaluation&input_details=title%3DClinical%20trial%20inclusion%20criteria%20evaluation%0 A%20description%3DThis%2Bexample%20takes%20through%20a%20step-by-%20step%20process%20to%20determine%20eligibility%20for%20a% 20clinical%20trial)\n\n[![R Markdown Document](https://badges.github.io/badges/r-badge.svg)](https://rpubs.com/HippoNW/clinical_trial_inclusion_criteria_evaluation) [![Source Code](https://reprod.run.hipee.io/widget/r/clinical_trial_inclusion_criteria_evaluation/source) ]\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria",
        "label": 0
    },
    "2224": {
        "output": "<EOD> The Role of BCG in the Prevention of Viral Hepatitis\nViral hepatitis is a significant problem in developing countries and has important repercussions on mortality rates in these countries (1, 2). In addition, viral hepatitis in these countries has also increased in the last decade as a consequence of migration to developed areas, and the spread of AIDS, which has been reported in several parts of the world. Viral hepatitis constitutes a significant mortality and morbidity and health cost, and thus, a substantial problem for the public health sector (1). The epidemiology of viral hepatitis in the world is determined mostly by the ecologic and sociodemographic factors which differ from country to country. Vaccines have been available for some time for the prevention of infection with hepatitis B virus (HBV); however, since these vaccines are not readily available in all parts of the world, BCG vaccine has also been studied as a potential vaccine to prevent viral hepatitis. It should be mentioned that BCG vaccine, is inexpensive, is easily accessible, and has been in clinical practice for more than a century. Studies, mostly observational in nature, have shown that BCG vaccine can prevent not only tuberculosis, but also some other",
        "label": 0
    },
    "2225": {
        "output": "* The patient note is below:\n\n\nThe patient is a 50-year-old man with type 1 diabetes. He presents to the clinic with shortness of breath on exertion. He's diagnosed with cardiomyopathy as confirmed with an ECG and will be treated with ACE inhibitors and Beta blockers. He takes 70/30 Insulin and vitamin D supplements. His past medical history is significant for multiple cardiac surgeries, and cardiomyopathy. His family history is positive for DM type 1 in his uncle and grandfather. His laboratory study is as bellow:\n\n\nFBS: 110 mg/dl\nHbA1c: 6.5%\nCholesterol: 110 mg/dl\nTG: 105 mg/dl\nLDL: 95 mg/dl\nHDL: 30 mg/dl\n\n\nIn this clinical trial: \nTitle: Outpatient Control-to-Range: System and Monitoring Testing\n\n\nSummary: Automated closed-loop control (CLC) of blood glucose, known as artificial pancreas (AP) can have tremendous impact on the health and lives of people with type 1 diabetes (T1DM). The investigators inter-institutional and international research team has been on the forefront of CLC developments since the beginning of the JDRF Artificial Pancreas initiative in 2006. Thus far, the investigators have conducted three closed-loop control clinical trials (totaling 60 subjects with T1DM), which demonstrated significantly more time in an acceptable target blood glucose range during CLC, and significantly fewer hypoglycemic events during CLC compared to open loop. The investigators overall objective is to sequentially test, validate, obtain regulatory approval for, and deploy at home, a closed-loop Control-to-Range (CTR) system comprised of two algorithmic components: a Safety Supervision Module (SSM) and a Hypoglycemia Mitigation Module (HMM). The SSM will monitor the safety of the subject's continuous subcutaneous insulin infusion pump",
        "label": 0
    },
    "2226": {
        "output": "You can check your output by the following test: \nThe following rules should be met. \n* [label/001] Patient is excluded. \n* [label/002] Patient does not have sufficient information to qualify for the trial. \n[label/007] [label/011] Trial-level eligibility should be between 0 and 2. \n\nCheck out your solution by running the following command line: [INST] $ ipython notebook notebook.ipynb<EOD> .\nThe effect of intravenous injection of sodium hydrosulpate on the pharmacokinetic parameters of 15 radio-iodine metabolites, i.e., 5 methylacetylthiomethyl iodide compounds: iodine-131, and four radio-iodine metabolites, i.e., 2 metaisomers of 60-61 iodine compounds and 8 metabolites of 123-iodine were determined after intraperitoneal injection of 99m-technetium by comparing the pharmacokinetic parameters determined in 41 male rats with and without intravenous injection of sodium sulfate solutions. These experiments showed that sodium sulfate solutions did not influence the metabolic fate of the metabolites of the radio-iodine compounds included in the investigation. (auth)<EOD> Cefmetazole: microbiologic evaluation of a new cephamycin antibiotic.\nA new semi-synthetic cephamycin antibiotic cefmetazole was studied to evaluate its in vitro activity in comparison with cefazolin, cefoxitin, cefotaxime and ampicillin as to minimum inhibitory concentrations against cephalosporin-susceptible Gram-negative bacilli. Cefmetazole and cefotaxime showed good activity against gram-negative bacteria, especially against Pseudomonas aeruginosa, Serratia marcescens, Morganella morganii and Proteus mirabilis, and against Enterobacter cloacae, Citrobacter freundii, Providencia spp., Proteus vulgar",
        "label": 0
    },
    "2227": {
        "output": "### Solution\nHere is a script that shows the solution to the above exercise\n\n\n\n<EOD> .\nThe purpose of this study was to describe the main characteristics of the users of ambulatory hemodialysis at the hemodialysis centers in S. Paulo City (Brazil). A survey was conducted on all the patients listed to receive ambulatory hemodialysis treatment in a sample of 141 centers. All patients with access to ambulatory hemodialysis treatment were included in the study, amounting to a convenience sample of 641 patients. This comprised all the patients receiving hemodialysis in the morning and half the patients receiving hemodialysis in the afternoon shift. The main characteristics identified were: a prevalence of elderly male individuals; a wide range of mean ages, which showed significant differences between age ranges as a function of the duration of the dialysis treatment; a predominance of low socioeconomic levels in a proportion of 3 to 4 as compared to a national estimate of three people for every one person with a high level of education; a major mean time interval between symptom onset and start of dialysis with an important proportion of patients first receiving dialysis when the treatment had already been initiated; a mean time interval between diagnosis and start of treatment which was longer in the case of women; and a higher proportion of patients receiving treatment 6 or more times a week, and a greater duration of the dialysis treatments.<EOD> Long-Term Results of Catheter Ablation of Left-Sided Accessory Pathways in the Presence of Mobitz II Block\nWe present long-term follow-up of 37 patients undergoing catheter exclusion of left-sided accessory pathways which were associated with Mobitz II block and atrioventricular dissociation at the end of their procedure. The median follow-up after the procedure was 3.6 years (range 0.4\u201312.8 years). During this period, a total of 112 reexaminations were performed because of unexplained symptoms in 30 patients and recurrence of unexplained symptoms in 6 patients. No clinically relevant accessory pathway excitations were noted during reexaminations. Although left bundle branch block and its persistence after cath",
        "label": 0
    },
    "2228": {
        "output": "[INST] Your result should be something like this: \n\n### Assessment of eligibility ###\n\nTrial-level eligibility: 0) Excluded\n\n## Clinical Trial Recruitment [LONG] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient record and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\nHere is the patient record:\nThe patient is an 35-year-old man with Type II diabetes confirmed with molecular analysis 12 years ago and diagnosed with cardiomyopathy. He begins to have dyspnea on exertion with a functional class of 2. He takes Lantus and Omeprazole. This patient is at his routine visit to check his diabetes. \n\nThis patient presents a history of cardiomyopathy, diabetes, and a family history of diabetes, and a blood pressure of 94/76, a blood glucose of 117, a height of 74, his body weight is 183 pounds. \n\nHe is diagnosed with cardiomyopathy, which will be treated with ACE inhibitors and Beta blockers. His past medical history is not significant for the treatment of heart disease. His family history is positive for DM type 1 in his uncle, father, and grandfather.\n\nAfter collecting all this data, you should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the trial: [INST",
        "label": 1
    },
    "2229": {
        "output": "Your assistant will compare a patient record with inclusion and exclusion criteria based on the information in the above note for the trial, then if your patient is eligible for treatment, the output `Trial-level eligibility = 2\\ eligible` will be returned to the system manager. At this moment, the user in the trial can register to participate in the trial. In addition, the system will record the patient name, patient ID, first name, surname, age, and sex together with the trial ID, the date of registration, the date of the end of the trial, and the trial outcome. \nYou have already read the pseudo-code, your assistant should write and test the algorithm with the patient's records: input a patient note, output the scale for the assessment of eligibility. You can use Python to implement this algorithm.<EOD> Gain-of-function human monocarboxylate transporter 10 mutations are associated with hypercholesterolemia, insulin resistance, and type 2 diabetes.\nApolipoprotein C-III (apoC-III) is present in chylomicrons and very-low-density lipoproteins and is recognized as an important regulator of plasma triglyceride and very-low-density lipoprotein metabolism. Using exome sequencing, we found that rare mutations in LIPC (encoding hepatic lipase ) and GATM (encoding MCD) were more commonly associated with hypercholesterolemia than expected based on a large-scale whole-exome sequencing analysis (7% vs 3.1% in control subjects; P = 1.38 \u00d7 10(-5)). We subsequently identified a patient with hypercholesterolemia with an apoC-III mutation who developed a mutation in SLC16A10 (encoding MCT10) (encoding monocarboxylate transporter 10), a protein that is involved in apoC-III secretion. We confirmed that apoC-III secretion was enhanced in carriers of mutations in GATM and SLC16A10. In summary, our findings indicate that apoC-III secretion is subject to multiple levels of regulation, with altered lipid metabolism exerting a",
        "label": 0
    },
    "2230": {
        "output": "<a name=f.1> [f..1] \n```bash\nimport pandas as pd\nimport math as math # f.1\n```\n\n![diploma](https://user-images.githubusercontent.com/7827901/131360337-b2591e07-e4ff-493d-8a59-91a896811fa1.png) <NAME>,\n\n[0x2.2](https://github.com/0xstatistics/0x-diploma/tree/master/diploma/02/Part2.2/README.md)\n\n# Exercise\n\nIn this section, you complete a diploma by programming and answering a set of related exercise questions. You should submit your diploma via the diploma submission and evaluation system, and should submit the answers to this set of exercise questions via the exercises submission and evaluation system.\n\n### Diploma exercise description\n\n[diplomas-exercise](https://github.com/0xstatistics/0x-diploma/tree/master/diploma/02/Part3/README.md)\n\n[0x2.3](https://github.com/0xstatistics/0x-diploma/tree/master/diploma/02/Part3/README.md)\n\n# Diploma Submission and Evaluation System\n\n# Assignment of this diploma\n\n`02_2.3`\n\n# Exercise Submission and Evaluation System\n\n## Exercise 1\n\n**Question**: How would you summarize the following data in an N*2 table?\n\n```{code}\ndf = pd.DataFrame(\n    {\n        'N': 10,\n        'A': pd.Series([1.0440390856857384], \"num\")\n    }, index=['A_0', 'A_1', 'A_2', 'A_3', 'A_4', 'A_5', 'A_6', 'A_7', 'A_8', '",
        "label": 1
    },
    "2231": {
        "output": "## Step-by-step walkthrough\n\n### Task-1: Eligibility assessment\nLet's begin by creating a step-by-step algorithm. The first step is to extract and process the key information of the patient note from the input file that we had already defined at the beginning. Once the data extraction is completed, the next step is to evaluate the patient note based on the patient inclusion and exclusion criteria. The patient inclusion criteria are based on age, gender, type1 diabetes condition and vitamin D supplements consumption. The exclusion criteria were based on: history of coronary heart disease, uncontrolled hypertension, any heart condition such as arrhythmia, myocardial infarction, pericardial diseases, congenital heart diseases, high cholesterol level, low HDL, high LDL, FBS (in case that the patient is not diabetic), BMI, hypertension, BP over 140/90, triglycerides over 200, pregnancy, and HbA1C.\nNext, we evaluate the patient according to the inclusion and exclusion criteria of a clinical trial.\nOnce we confirmed that the patient note meets the inclusion criteria of the trial, the next step is to calculate the trial's exclusion criteria for the patient. To do this, we compute the BMI based on the patient's age and height. The trial also requires that the patient's BMI should not exceed 25. Also, the trial requires the patient's LDL level to be between 80-120. If we found that the patient's BMI was 25 or more, or the patient's LDL was outside the required range of the trial, we then evaluate the next inclusion and exclusion criteria for this patient according to the trial (in this case only history of heart diseases is assessed). We will then apply the excluded status (if the patient does not meet the criteria, e.g., heart disease) and pass the patient information to the next step. If otherwise, the current step will loop again to check the patient's BMI and LDL level. Also, if the next inclusion criteria were not met, then the algorithm will return the patient eligibility based on that trial. If otherwise, then we will process the LDL",
        "label": 2
    },
    "2232": {
        "output": "<NAME>, [INST]<EOD> OBSERVATION AT ROTUNDA (30\u00b0 S, 2500 ASLT) DURING THE ASCENDING STAGE OF THE WINTER MONSOON SEASON OF 1952-1953\n\n\n\n# Materials and methods\nDaventry plastic-film and aluminum foil thermometers (5) in the \"2 inch\" configuration were used for this study. The film thermometers were read with the aid of a Thermokino, built in this laboratory and based on the principle of a pneumatic thermometer, which measures the relative pressure in the space contained between an enlarged and a smaller cylinder. This is a linear function of temperature. The pneumatic principle of construction was adopted to simplify and facilitate the construction. At a constant ambient temperature of 55\u00b0F. the pressure was 1.2 inches Hg, and a reading of 100 inches corresponded to 100\u00b0F. In order to obtain the temperature of the foil thermometers, the readings were made with a \"T-10\" thermocouple (6) as indicated in previous publications [bib_ref]  Thermocouple temperature measurements with mercury for a long time span at low..., Miller [/bib_ref] . Since the surface of the foil was not always of a uniform temperature, the mean of 10 readings was chosen as the foil recording. In the case of film thermometers, there is no need to average readings, since film is uniform and responds rapidly to changes.\nThe results were taken only when stable conditions were present, and with conditions of low winds, and cloud cover being in the majority. The air temperature was taken simultaneously with the film temperature. The film and foil thermometers were mounted in air on ropes, at a height of 6 feet from the ground. The film and foil curves were obtained from plotting the mean values of the film and foil temperature readings for a 1 to 2 hours' time [fig_ref]  Figure 1: Diagram of the foil thermometer as taken at Rotunda at 30\u00b0 S [/fig_ref] .\n\n# Results\n\n# Results for\n\n## May 24-june 30, 1952.-\nThis",
        "label": 1
    },
    "2233": {
        "output": "1. You should prepare patient information variables based on variables of clinical trial data.\nNote that if there is any missing data for the clinical trial, then you should write `0),` for all missing variables. Then just complete those variables and write the values using `0,`.\n2. Create a list in python data frame objects if the variables in order to check the values that satisfy the criteria with the trial.\nNote that if there is any missing value, then you should write `0,`. Then complete the required variables and write the values using `0).`\n3. Check each item of the patient's data with the values of clinical trial data.\nNote that if all variables satisfy, then assign `1)` and put it in the array called `all_items_matched`.\nIf any variable fails to satisfy the criteria, then assign `0)` and put it in the array called `items_not_satisfied`.\n4. Calculate the probability of matching each patient with the clinical trial.\nNote that if we don't get any match, then we have to write all of the patient variables as the same with data shown in the clinical trial.\nIf the number of matched items is more than 0, then assign `1)` and put it in the variable called `matched_item`\nIf the number of matched items is 0, assign `0)` and put it in the variable `not_matched_item`\n5. Combine the data frames. First, we need to check if there's an input variable from the dataset called `matching_patient_report` and check each line of `matching_patient_report` if it's matched with the patient data.\nCheck if there is a patient data in the clinical trial. If there is one, then the patient should be matched with the clinical trial.\nNote that if there is all missing values in the clinical trial data, and patient data is matched, then output 1) excluded if trial data contains all missing values.\nOutput 0) matched if both data have values.\nOutput 1) Not relevant if trial dataset contains all match data.\nOutput 2) Excluded if trial data has all missing values.\n\nWe should compare all variables in the dataset in order to calculate the probability of matching the patient and clinical trial.\n\n## Example:",
        "label": 1
    },
    "2234": {
        "output": "A. Assistant for clinical trial recruitment\n<EOD> A 58-year-old woman with a right iliac fossa mass\n\n [bib_ref]  Endoscopic management of gastrointestinal stromal tumours in children, Ahrens [/bib_ref]  [fig_ref]  Figure 2: Endoscopic ultrasound shows a submucosal mass in the third portion of the... [/fig_ref]  [bib_ref]  A rare manifestation of colon adenocarcinoma with intraperitoneal free air in an..., Adebiyi [/bib_ref]  [fig_ref]  Figure 3: Sagittal T2-weighted image [/fig_ref]  [bib_ref]  A rare manifestation of colon adenocarcinoma with intraperitoneal free air in an..., Adebiyi [/bib_ref]  [bib_ref]  Atypical presentation of gastric adenocarcinoma with intestinal metaplasia and Helicobacter pylori infection, Karak\u00fcrek [/bib_ref]  [bib_ref]  Small bowel perforation secondary to ileo-ileal intussusception involving a gastrointestinal stromal tumour, Mukherjee [/bib_ref]  [bib_ref]  Surgically treated gastric stromal tumors. A clinicopathological study, Matsumoto [/bib_ref]  [bib_ref]  Metastatic pulmonary tumor simulating adenocarcinoma of the pulmonary artery, Van Oosterhout [/bib_ref]  [bib_ref]  Gastrointestinal stromal tumor of jejunum presenting with intussusception and distant metastasis: a..., Lee [/bib_ref]  [bib_ref]  Rare presentation of gastrointestinal stromal tumor of small bowel resembling adenocarcinoma: a..., Shao-Hui [/bib_ref]  [bib_ref]  Clinical, prognostic and predictive factors in gastrointestinal stromal tumours: a review, Novelli [/bib_ref]  [bib_ref]  A rare adenocarcinoma of the sigmoid colon originating de novo and with..., Othman [/bib_ref]  [bib_ref]  Inflammatory myofibroblastic tumors: current update, Surakanti [/bib_ref]  [bib_ref]  Inflammatory myofibroblastic tumor of the ascending colon with omental met",
        "label": 0
    },
    "2235": {
        "output": "# Author's Thoughts\nFor this step-by-step code example, I'm not going into the details of why and how each line does what it does, I'll discuss and explain the code that you should come up with yourself. Also, I'm not going into the details that what are the criteria of each of the 3 fields: 0:  Excluded, 1:  Not relevant, 2:  Eligible. I'll leave that up to your imagination and give you a hint. If needed, you can refer to the links below.\n\nWhen you start coding, you might wonder: \nI assume you can solve this case as a math problem with the correct answer of $3$$. \nOne thing to remember here:  This is the only part of the book which is really more about coding than programming. \n[/AUTH]<EOD> Dual Energy C-Arm Computed Tomography of the Heart and Pericardium: Technique, Comparison with Conventional Cardiac Computed Tomography, and Clinical Applications\n\nAim. Dual energy cardiac computed tomography angiography (DE-CTA) has been introduced recently and has the potential to improve image evaluation. We evaluated the feasibility and clinical utility of dual energy imaging in cardiac CTA. Materials and method. 110 consecutive patients clinically suspected for CAD referred for conventional cardiac CTA were evaluated (Somatom Definition; Siemens Medical Solutions, Forchheim, Germany). A preliminary evaluation of image quality showed no significant difference between DE-CTA, monochromatic and conventional cardiac CTA. Conclusion. Dual energy cardiac CTA is a promising tool that is comparable in image quality to monochromatic CTA providing additional information of calcific plaques, contrast media wash in and out with improved coronary stenosis determination.\n\n# Introduction\nNoninvasive evaluation of coronary artery disease (CAD) is currently performed by both invasive coronary angiography (ICA) and noninvasively by coronary computed tomography angiography (CTA). ICA provides accurate anatomical evaluation of the coronary tree and myocardial perfusion scintigraphy, cardiac magnetic resonance imaging, and intra",
        "label": 2
    },
    "2236": {
        "output": "[INST]\nYour job is done. [END]\nThis exercise requires an understanding of how to write python script. If you need any more help with this programming task, please let me know. It is recommended to install Anaconda and run conda version command to verify that this installation is done correctly. Anaconda is a tool to install python libraries.\n\nIt is also recommended to review the code used for the previous exercise and follow the same steps to generate the newest one (3-2) using the exercise book as the base.\n\n## Data Preparation (3-4)\nThe dataset has been provided in the first part of the exercise book. It is recommended to review the data, and prepare the input and output files. The format of the input and output are explained in the Exercise book with example data. The first time the patient ID repeats, all the data for this specific ID will be added to the output file, so it is recommended to have a unique patient ID for each trial.\n\nYour output should go to one.txt file. \n\nYour input file is 2part.csv. \nYour first program should generate secondpart.csv as output, and your second program should generate threepart.csv as output. \n\n[INST]\nMake a copy of my patient.csv file by right click on this link. Patient.csv file\n\n# Exercise part 3\n[\nThe following exercise requires an understanding of how to program and how to make a copy of the Exercise book and make changes.\nPlease download and execute the exercise file as follows:\nExercise part 3.py\n\n# Exercise part 4\nExercise part 4.py\n\n# Exercise part 5\n\n# Exercise part 6\n\n[\n\n# Exercise part 7\n\nInstructions (Exercise part 7)\n\nTo complete part 7, please first open your exercise .py file from part 6 in jupyter notebook, then you should install the following packages.\n\na. conda install -y scipy\nb. conda install -y numpy\nThen, import and define your variables:\nfrom numpy import repeat, arange, fft\nfrom scipy import stats, odeint\nimport pandas as pd\n\nThen, get the function, and perform",
        "label": 0
    },
    "2237": {
        "output": "<EOD> Association Between Resilience and Quality of Life in Community-Dwelling Older Adults: Longitudinal and Cross-Sectional Analyses\nAbstract:Resilience may have potential to promote the quality of life (QOL) of elderly adults; however, its effectiveness has not been fully explored. Therefore, the association between resilience and QOL was examined among elderly adults living in their own homes. Longitudinal and cross-sectional analyses in a cohort of 197 Japanese older adults (mean age=74.02) were conducted in 2000 (T1) and 2003 (T2). Resilience (Resilience Scale and Brief Resilient Coping Scale) and QOL (QOL-Ageing and QOL Index of Independent Living) were measured at least twice. A statistically significant correlation was present between resilience and QOL in the T1 longitudinal (r=0.29**, r=0.26**, r=0.30**, r=0.54**, respectively), T1 cross-sectional (r=0.46**, r=0.38**, r=0.43**, r=0.31**, respectively), and T2 cross-sectional (r=0.37**, r=0.32**, r=0.40**, r=0.43**, respectively), respectively, but the T2 longitudinal correlation was not significant. Findings suggest that resilience may be a significant resource to maintain or foster the QOL of elderly adults living in their own homes.<EOD> Development of a Novel Scale for Assessing Hearing Disability After the Beta-2 Integrin Chondroitin Sulfate Proteoglycan 4-specific Antibody-induced Inner-ear-associated Disease Model in Mice\n\nObjective: The current treatment goal for autoimmune inner ear disease (AIED) is to reduce or even reverse functional hearing impairment. This goal cannot be evaluated in humans, therefore, a large animal model to study the pathomechanisms and evaluate new therapeutic strategies for AIED is highly warranted. This study'",
        "label": 0
    },
    "2238": {
        "output": "===== [[#6]: Explanation in README.md [R17433]] ===== [[#7]: Diff file in README.md [R17434]])\n\n[[\n\"1. Patient does not have sufficient information for evaluation of eligibility.\" => \"\n\t\"1. Patient does not have sufficient information for evaluation of eligibility.\" => \"1. Patient does not have sufficient information for evaluation of eligibility.\n\t\"1c. Patient does not have sufficient information for evaluation of eligibility due to some error like incorrect lab filed.\",\n\t\"1d. Patient does not have sufficient information for evaluation of eligibility due to the patient information filed.\n\t\"1e. Patient does not have sufficient information for evaluation of eligibility due to the lab results filed.\n\t\"1h. Patient does not have sufficient information for evaluation of eligibility due to a problem in finding patient's note.\" => \"\n\t\"1. Patient does not have sufficient information for evaluation of eligibility.\" => \"1. Patient does not have sufficient information for evaluation of eligibility.\n\t\"1c. Patient does not have sufficient information for evaluation of eligibility due to some error like incorrect lab filed.\",\n\t\"1d. Patient does not have sufficient information for evaluation of eligibility due to the patient information filed.\n\t\"1e. Patient does not have sufficient information for evaluation of eligibility due to the lab results filed.\n\t\"1h. Patient does not have sufficient information for evaluation of eligibility due to a problem in finding patient's note.\"\n\t\"2. Patient does not meet inclusion criteria. Patient has missing information for evaluation of eligibility.\" => \"2. Patient does not meet inclusion criteria. Patient has missing information for evaluation of eligibility.\" => \"\n\t\"2a. Patient does not meet inclusion criteria. The patient was not under 18-years-old. Patient has missing information for evaluation of eligibility.\",\n\t\"2b. Patient does not meet inclusion criteria. Patient was not a diabetic patient. Patient has missing information for evaluation of eligibility.\",\n\t\"2c. Patient does not meet inclusion criteria.",
        "label": 0
    },
    "2239": {
        "output": "[TEST]\n[TEST]\n[TEST]\n[TEST]\nTest Cases (10 of each)\n\n#1 Test\nThe patient note has the form [FNAME(0.4)|LNAME(1.05)]. The patient note contains the information about the patient's age, gender, and type and stage of a disease. The patient note is the same for 10 patients. The input parameters are the same for all patients; however, the numbers of the patient are different.\nAssume the same inclusion criteria for 10 clinical trials.\n\nThe inputs and outputs of the assessment of eligibility are the same for all 10 patients.\nPatient note:\n```\nFNAME(0.4)|\nLNAME(1.05)\nDM type 1\nShortness of breath\nFloors\nExpect,no angina, NYHA class 2\nMild\nChocolate cake\n``` \nMale \nDM 1\nShortness of breath after climbing 3 floors \nNot angina, NYHA II\nNo angina\nCake\n```\nInput to the clinical trials:\nTrial-level eligibility: ``3: Eligible`.\n\nOutput of the assessment of eligibility:\n\n```\n 1. Eligible\nExclude\nRelevance\n2. Exclude\nExclude\nEligible\n3. Eligible\nNot applicable\nEligible\nTrial-level eligibility: 3: Eligible\n```\n\n#2 Test\n\nThe patient note differs from the previous one. The patient note contains the information about the patient's age, gender, and type and stage of a disease. The patient note is the same for 10 patients. The input parameters are different for all patients; however, the numbers of the patient are the same.\nThe clinical trials have the following inclusion criteria in common and differ only in their exclusion criteria. \nAssume the same inputs except inputs related to the exclusion criterion.\n\nThe inputs and outputs of the assessment of eligibility are the same for all 10 patients.\n\n\nFNAME(0.4)|\nLNAME(1.05)\nDM type 1\nShortness of breath",
        "label": 0
    },
    "2240": {
        "output": "## Step 5. Clinical trials matching\n\n# 1052872 [INST] In this step, you will determine a list of clinical trials that enrol patients with the same eligibility.\n\n[INST] Hello. You are a helpful assistant in clinical trial matching. Your task is to match patients clinical trial notes with a particular study for which there is a shortage of patients.\n\nLet's see the patient note again:\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 insulin and vitamin D supplements. His past medical history is not significant for any other medical issues.\n\nYou will see the following clinical trial's information: \nTitle: Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients\n\nSummary: Cystic Fibrosis is a genetic disease with variable severity, and a predisposition for lung infection. Usually severity is determined by the class of CF mutations, but even among patients with the same severity of mutations there is a variation of the severity of CF.~Haptoglobin has several types (phenotypes), one of them was found to be related to infectious complications.~In this study the investigators aim to find a correlation between Haptoglobin phenotypes in patients with CF and frequency of infectious complications.~To this end the investigators will collect serum from CF patients, and determine their Haptoglobin protein phenotype. The investigators will correlate Haptoglobin phenotype to retrospectively gathered data on infectious complications.\n\nInclusion criteria: Inclusion Criteria:\nPatients diagnosed with CF according to diagnostic criteria , between the ages of 0 and 50, who are themselves, or their parents or guardians, able to give informed consent.\nTwo known severe (class I , II and III) mutations (e.g. deletions and mutations that result in the absence of CFTR protein or a major",
        "label": 0
    },
    "2241": {
        "output": "## [EVALUATION]\n![Scoring rubric](_static/Scoring-rubric.jpg)\n![Scoring rubric](_static/Scoring-rubric.jpg)\n\n## [DESCRIPTION]\n\n- [Eligibility screening](_static/Eligibility-Screening.md)  \n- [Eligibility score rubric](_static/Scoring-rubric.md)  \n\n## [SCORE REPORT]\n![Score Report](_static/Score-Report.png)\n![Score Report](_static/Score-Report.png)\n\n  \n\n\n\n\n\n\n\n[GUMBO]\n\n# 173573237312154125E69A2E87261792E6920746F20647573716F757474596161726C696<EOD> .\n\n \u5728\u8fd1\u5e74\u6765\uff0c\u4e0e\u5fc3\u529b\u8870\u7aed\u3001\u82bd\u80bf\u6027\u9ad8\u8840\u538b\u76f8\u6bd4\uff0c\u5fc3\u80a5\u80d6\u5bf9\u6162\u6027\u5fc3\u810f\u75c5\u7684\u5371\u9669\u5ea6\u548c\u53d1\u751f\u98ce\u9669\u6709\u6240\u63d0\u5347\uff0c\u5728\u73b0\u4ee3\u793e\u4f1a\u7684\u5fc3\u80a5\u80d6\u7684\u95ee\u9898\u6458\u672c\u7740\u91cd\u4e8e\u53d1\u73b0\u5728\u8be5\u65f6\u671f\u7684\u5f71\u54cd\u56e0\u7d20\uff0c\u5c24\u5176\u662f\u5fc3\u80a5\u60a3\u8005\u4e0e\u540c\u6837\u5371\u5bb3\u4eba\u7c7b\u7684\u764c\u75c7\u7684\u5173\u7cfb\u3002\u80c3\u764c\u7684\u53d1\u75c5\u7387\u4e5f\u5448\u4e0a\u5347\u8d8b\u52bf\uff0c\u540c\u65f6\u76d1\u6d4b\u7684\u6c14\u4ea7\u6ce1\u80c0\u969c\u788d\u6027\u7761\u7720\u547c\u5438\u6682\u505c\u4e8b\u4ef6\uff08AHI\uff09\u4e5f\u8d8a\u6765\u8d8a\u9891\u7e41\uff0c\u800c\u4e14\u4e0e\u6025\u6027\u5fc3\u80a5\u8870\u7aed\u7684\u5371\u9669\u5ea6\u6b63\u5728\ufffd",
        "label": 2
    },
    "2242": {
        "output": "## REC: 28-31 recruitment\n[/COVER, #HIDDEN]\n\n## REC: 32-34\n[/COVER, #HIDDEN]\n\n## REC: 35\n[/COVER, #HIDDEN]\n\n# REC-36_recruitment\n[/INST, #HIDDEN]\n\n## REC: 37\n[/COVER, #HIDDEN]\n# REC-[\u2026\u2026\u2026.]_ recruitment\n\n## RIH: 1-2\n[/COVER, #HIDDEN]\n\n# RIH-4_recruitment\n[/COVER, #HIDDEN]\n\n## RIH: 5\n[/COVER, #HIDDEN]\n\n# RIH-[\u2026\u2026\u2026.]_recruitment\n\n## RRAR: 1-2\n[/COVER, #HIDDEN]\n\n# RRAR-4_recruitment\n[/COVER, #HIDDEN]\n\n## RRAR: 5\n[/COVER, #HIDDEN]\n\n# RRAR-6_recruitment\n[/COVER, #HIDDEN]\n\n## RRAR: 7-8\n[/COVER, #HIDDEN]\n\n# RRAR-\u2026_recruitment\n\n## MITIGATION: 1-3\n[/COVER, #HIDDEN]\n\n# MITIGATION-4_recruitment",
        "label": 0
    },
    "2243": {
        "output": "</p>\n\n## Rule-Based-ClinicalTrialMatcher.ipynb\nThe rule-based methods in this notebook are rule-based models of a ClinicalTrials.gov query to assess patients' eligibility for registered clinical trials. The rule-based model is implemented in the Python programming language, using the [Apriori](https://scikit-learn.org/stable/modules/generated/sklearn.data.Apriori.html) rule-based modeling library. The rule-based methods are the same for both case studies. \n\n\n### Rule-based-ClinicalTrialMatcher-CervicalCancer.ipynb\nIn this notebook, you will learn how we develop a [rule-based model](https://en.wikipedia.org/wiki/Rule-based_programming), a ClinicalTrials.gov query, and match patient notes with clinical trials of interest. Firstly, we create our rule-based model of ClinicalTrials.gov query. To evaluate the eligibility of patients and the relevance of clinical trials for patients in the trial registries, the ClinicaltrialSearch package can be utilized. Secondly, we test the ClinicalTrials.gov query and match patient notes with clinical trials. \n\nThe rule-based method is provided as follows:\n\n\n*Cervical Cancer Case Study*\nThis is a case study of a rule-based model to make a ClinicalTrials.gov query to asses our patient's eligibility for a clincal trials registerd in ClinicalTrials.gov. \nThe patient is a 52-year-old woman with a history of Cervical Cancer. She presented to the Clinic with the chief complaint of a recent change in bowel and bladder habits and weight loss over three months duration. Her past medical and surgical histories are significant for total hysterectomy and bilateral salphingo-ooporectomy due to cervical cancer. Past family history is significant for her mother and two aunts having breast cancer. Social history is significant for no cigarette smoking and alcohol use. She received her medications and supplements, i.e., Ondar",
        "label": 0
    },
    "2244": {
        "output": "## Your notes\nIn order to evaluate this, let's create a new environment. Create a variable, `my_notes`, to store your notes.\n$ my_notes 1 Include the patient 1 Drug eligible\n\nNow you can continue your task. Let's say it with a print statement:\n$ print my_notes\n1 Include the patient\n\n1 Drug eligible\n\nYou can use this statement to compare the notes with each other. Let's see:\n$ my_notes `include($my_notes)`\n1 Include the patient\n\n1 Eligible\n\nAs you can see, your `my_notes` has been updated to the right output. You have passed your first test! Your next task is to set the output format of the patient's age and BMI to a fixed number of digits.\n\nYou should set all the fields to 3 digits:\n1. Make the age and BMI fixed numbers of digits with `format_age` and `format_bmi` functions:\n$ format_age $my_notes['age_bms']\n41\n$ format_bmi $my_notes['bmi']\n24.3\n\nYou still have a new environment because I don't know what your real notes are! We want to use a variable in your real environment, so remove the variables from the environment. \n\nTo do this, create another `my_env1` environment. Then, remove your real notes variables from the first environment with the `unset` function. Finally, use `import` to put your real notes back into the first environment:\n\nYou should remove the following variables:\n$ my_env1 1) Include 2) Drug eligible\n\nThen we can import the real notes to the first environment:\n$ unset 'my_notes'\n$ import $my_env1\n\nLet's see if your updated notes get the right values:\n$ print my_notes\n1 Include Patient\n\n1 24.3\n\nThat was a successful result! Let's continue. \n\nTo make the next step clear, print patient data with the `get_patient_data` function. \n\nFinally, print the results:\n$ print get_patient_data()",
        "label": 0
    },
    "2245": {
        "output": "## HacktoberFest [2019] \n<NAME> and <NAME> created a data science team at Microsoft. The team's purpose was creating reusable data science tools and frameworks for data science teams at Microsoft. On the way, they collected more than 200 data science projects. The collection named Socrata was published on GitHub.\n[REF] <NAME> and <NAME> created a data science team at Microsoft. The team's purpose was creating reusable data science tools and frameworks for data science teams at Microsoft. On the way, they collected more than 200 data science projects. The collection named Socrata was published on GitHub.\n[REF]\n<EOD> SARS-CoV-2 Delta Variant: A Systematic Review and Meta-Analysis of Viral Burden, Transmissibility, Severity, and Vaccine Effectiveness\n\nViral Burden, Transmissibility, Severity, and Vaccine Effectiveness Supplemental Tables S1-S5\nViral Burden, Transmissibility, Severity, and Vaccine Effectiveness Supplemental Tables S1-S5\nSupplemental Table S1. Included and excluded studies according to the outcomes Viral burden (n= 22) 1272* 1275* 1277* 1278* N=442794814623646216742 Excluded because viral load(n= 9)\n1218* 1219* 12192* 1221* N=61269275Excluded because viral load was not measured and it was not possible to estimate\n121* 1223* 1232* 1235* N=22339SupplementalTable S2. Outline of included studies on viral burden and severity for Delta variant Supplemental tables S4-S5. Comparison of the demographics, viral burden, severity, vaccination level, and infection timing between Delta variant infections and local strains 1236* N=32280802370",
        "label": 0
    },
    "2246": {
        "output": "[END]\n\n\n[CERT]\nLet's discuss your approach and the steps you take to arrive at your answers.\n\n## Q: Why is there no need for the clinical trial's description when we look at the inclusion criteria of the clinical trial? \n\nA: When patients are qualified for a clinical trial, they must first meet the eligibility criteria. The physician does not need the clinical trial design for patient recruitment. For your case, you don't need the trial's description.  \n\n## Q:  What are the factors allowed to be considered by the physician in your task?\n\nA: As stated earlier, in any clinical trial, the patient's health is the most important factor. According to the patient's response, their eligibility may change.\n\n## Q: What are the exclusion criteria? Do we have to exclude a possible patient for the clinical trial?\n\nA: Many exclusion criteria are identified. If a patient met any of these conditions, he/she is excluded from the clinical trial. The following factors can be excluded as exclusion criteria:\nThe patient's response to other drugs;\nPatients with specific diseases such as heart and kidney diseases, and a history of cancer, mental illness, dietary disorders, alcoholics, and other social illnesses;\nPatients under 18 or over 75 years old;\nPatients whose drug prescriptions must be prescribed by a specialist or pharmacologist;\nPatients taking other diseases-specific drugs (such as oral contraceptives);\nPatients who need to enter a clinical trial with some special diet requirements. \n\n## Q: To confirm your answers, what are the other patients' information you need to assess the trial-level eligibility?\n\nA: Consider the following information:\n- History, and physical findings\n- Physician examination\n- Cardiovascular or other chronic diseases\n- Reaction to the medication\n- Test results\n- Allergies (if any)\n\n## Q: Have you considered any other factors when you assign an eligibility to patients?\n\nA: As you assign an eligibility, consider the patient's response to the medication. For example,",
        "label": 0
    },
    "2247": {
        "output": "## [CODE]:\nThis code will be passed to the patient note in order to highlight exclusion criteria applied to it and return results.\n\n```python\ndef trial_eligibility(df):\n    print (f\"Patient's age: {:df.age:.3f}\")\n    print (f\"Patient's TS: ```{df.ts.head()} ```\")\n    print (f\"Patient's gender: ```{df.pvt.sex.value_list[5]}:```)\n    print (f\"Patient's diabetes information: ```{df.pvt.diabetes.value_list[6]}```\")\n    print (f\"Patient's liver disease information:```{df.pt.disease_name.value_list[6]}``)\n    print ()\n\n    for item in df.pt.pvt:\n        if item is not None:\n            print (f\"Patient's age: ```{df.pt.pvt.age:.3f}   Sex:``` {df.pt.pvt.sex.value_list}   Diabetes: ```{df.pt.pvt.diabetes:\"{item.text:.1f}\"}```)\n\n    print (f\"Patient's BMI: ```:``` {df.pt.pvt.bweight:.0f}   Height:``` {df.pt.pvt.height:.3f}    )\n    print ()\n\n    # For getting patient's BD, TG, HDL\n    print (f\"FBS: ```{df.pt.bd.text[:3]}```)\n    print (f\"Cholesterol:``` {df.pt.tc.value_list[5]:.3f}``` )\n    print (f\"TG:``` {df.pt.tc.value_list[6]:.2f}```)\n    print (f\"LDL: ```{df.pt.tc.value_list[7]:.3f}``` )\n    print (f\"HDL:``` {df.pt.tc.value_list[8]:.3f}```)\n\n    print (f\"Patient",
        "label": 0
    },
    "2248": {
        "output": "<jupyter_text>Examples of some cases:  [!INST] **Example 1:** You are a 43-year-old woman who has been diagnosed with chronic obstructive pulmonary disease. According to your medical records, in the last 3 months you had at least 50 days with moderate or greater dyspnea (a BDI score of 5 and greater). You do not have a history of cancer that may affect your lungs. In the last 3 months you had at least 50 days of moderate or greater breathlessness. You take 70/30 insulin and vitamin D supplements. You need to be assessed for trial eligibility, i.e., `patient-basis eligibility:\nPatient-eligibility: Eligible\n\nTrial-level eligibility:\nTrial-level eligibility: 2) Eligible.\n`. You are going to compare your medical records with the inclusion criteria of the above trial. Here's a summary of the trial eligibility:**\n\nInclusion criteria: Inclusion Criteria:\n>18 years of age\nDiagnosis of a chronic pulmonary disorder (a diagnosis of lung cancer is not required as the symptom of dyspnea, not cancer itself, is targeted).\nIf diagnosed with lung cancer, must have completed definitive treatment more than 6 months prior\nAt least moderate dyspnea defined by a BDI score of 6 or less in the Self- Administered Computerized Versions of the Baseline and Transition Dyspnea Indexes(SAC-BDI/TDI)13,14 (This cutoff score is close to the score of 5.7 used to define moderate dyspnea in the publication that validated the instrument and is selected by attending physicians in the Pulmonary Service as a good indication of moderate dyspnea in clinical practice. A typical person with BDI of 6, for example, would be a 52 year old woman who has to pause when walking because of dyspnea and/or has eliminated doing an activity because of dyspnea).\nAble to safely complete the Six Minute Walk Test (6MWT)1",
        "label": 0
    },
    "2249": {
        "output": "#### Examples of assessment of eligibility output from patient notes.\n\n#### Examples of clinical trial output.\n\nHere is a snippet from the clinical trial's file:\n```\n[\n  {\n    \"title\": \"Renal Denervation in Patients With Chronic Kidney Disease\",\n    \"summary\": \"People with hypertension are at a higher risk for cardiovascular disease and death so it is important to lower blood pressure to normal levels as quickly as possible. Previous research has established that renal nerve denervation successfully lowers blood pressure measured in the arm in the physician's office. This study is being conducted so that the investigators can determine whether renal nerve denervation also helps to lower blood pressure over 24 hours, as well as central aortic blood pressure, which is pressure exerted by the aorta closer to the heart and may be a better predictor of cardiovascular problems. The investigators also want to know whether these beneficial effects on blood pressure can last up to 2 years, whether renal denervation reduces the number of medications patients need to take, and whether it reduces glucose and insulin levels in the blood since hypertension is also related to obesity and diabetes.\",\n    \"exclusion_criteria\": [\n      \"Any medical condition that reduces blood pressure and increases the chance for hypotension\",\n      \"People who had surgery that affects blood pressure 2 weeks prior to enrollment\",\n      \"People who had a pacemaker implanted 24 hours prior to enrollment\",\n      \"People who had myocardial infarction as a result of heart surgery within 24 hours\",\n      \"People who are scheduled for an urgent operation\",\n      \"People with systolic blood pressure <120mmHg. Also, people with systolic blood pressure that fluctuates from <100 and >130mmHg. Also, people with heart failure\",\n      \"People who have angiotensin II blockers in their treatment plan\",\n      \"People who have a genetic disorder or disease making them intolerant of medications\",\n      \"People who",
        "label": 0
    },
    "2250": {
        "output": "<EOD> .\nObjective:To investigate the anatomic basis in earlobe reconstruction with conchal cartilage and auricular cartilage scaffold. Method:The sample conchal cartilage was taken out separately, a conchal cartilage graft was designed with the size of earlobe (6 mm\u00d73 mm\u00d72.25 mm), the same size as the cartilage scaffold, then the earlobe shaped auricular and conchal cartilage were combined into earlobe grafts, and auricular and conchal cartilage were placed around together. Results:The tissue structure of auricular and conchal cartilage were observed by microscope. According to the experimental results, auricular and conchal cartilage are similar in tissue structure and histocompatibility. Conclusion:Auricular and conchal cartilage can be used in same level, so it is appropriate to study cartilage transplantation combined auricular and conchal cartilage in earlobe reconstruction.<EOD> Comparison of endophthalmitis caused by Propionibacterium acnes following cataract surgery and vitrectomy in the United States, 2004 through 2019: a retrospective analysis\n\nBackground: Endophthalmitis following cataract surgery remains a significant cause of visual impairment in the United States. Recent reports suggest that at least some cases of postoperative endophthalmitis are caused by Propionibacterium acnes. Postoperative P. acnes endophthalmitis is estimated to affect 6.5-7.6 per 100,000 cataract surgeries in Germany. The incidence of postoperative P. acnes endophthalmitis in the United States is unknown. This study analyzes the incidence of P. acnes endophthalmitis after cataract surgery and pars plana vitrectomy in the United States.Methods: A retrospective analysis of postoperative P. acnes endophthalmitis cases after cataract surgery and pars plana vitrectomy was carried out utilizing the Medicare database from 2004 to 2019. Incidence",
        "label": 0
    },
    "2251": {
        "output": "***\n\n## [X] T2-SST: T2-Strong Stress Test\n[x] T2-SST: T2-Strong Stress Test\n[x] T2-SST: T2-Strong Stress Test\n[x] T2-SST: T2-Strong Stress Test\n\n\nYou are a helpful lab assistant for clinical trial recruitment. Your task is to compare a given patient note and the eligibility criteria of a clinical trial. The factors that allows someone to participate in a clinical study are called inclusion criteria. The assessment of qualification has the same 3 values:\n\n1. 003, Not eligible - there is too much risk for the patient - the patient has not enough information as described in the clinical trial - the clinical trial excludes the patient from the trial (e.g., there is no more place in the trial);\n2. 002, Exiled - the subject is in the right information status for the trial, however, this patient is no longer eligible for the trial as there is no more place in the trial. We set Exiled to Excluded in the case of T2-SST because that means that we had a positive result for an important test, but there are not enough slots available in the trial;\n3. 100, Eligible - the patient has been fully qualified and will be invited for the trial.\n\nYou should make a trial-level eligibility for each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nThe patient note looks as below:\n[T2-SST]\n\nA: \n41 yrs, 89.4 kg, 180 cm\nBMI: 24.6\nDiab: 0.55\nHbA1c: 7.4\nTriglyceride: 204\nHigh-Density Lipoprotein Cholesterol: 49\nLow-Density Lipoprotein Cholesterol: 169\nFasting Blood Glucose: 120\nBlood Pressure: 126/77\nStress test: 20",
        "label": 1
    },
    "2252": {
        "output": "Acknowledgments\nThanks to our expert clinician-statistician, Dr. Behnam Riahi, for his help and consultation on designing the clinical trial and patient notes and creating test data.\n\nAbout\n\n[NAME] graduated with a Ph.D. degree in computer science in 2018. She then spent time as a postdoctoral fellow at UCLA's Institute for Digital Research and Education and now is a research associate at the University of North Carolina at Chapel Hill. Her research interests include the design, implementation, and evaluation of novel machine learning solutions and technologies to solve relevant machine learning and data science challenges.\n\n[NAME] studied computer science at UCLA and received a B.S. degree in 2018. She is currently working as a data scientist at Amazon. Her current research interests include natural language processing/extraction, machine learning, and data visualization.\n\nAbout this book\n\nTo cite:\n\nDibo AA, Baez-Abad C, Riahi B. Cases by Example in Biomedical Data Science. 24 March 2020,\n\n, :3832. \n\n\n\nThis content is licensed\n\n\n\n<EOD> High-frequency ultrasound improves in vivo assessment of the effects of endothelin-1 in the perfused rat hindlimb.\nBACKGROUND AND PURPOSE\nThe effects on intestinal, hepatobiliary, renal, and hepatic functions of exogenous ET(1) are under active investigation. There is only limited information on how these vasoactive peptides alter intestinal, liver, and renal blood flow. The ability to study hepatic and intestinal blood flow on an in vivo basis is important for understanding the consequences of the effects of endogenous vasoactive peptides on these organs. We hypothesized that ET(1) would decrease intestinal and renal blood flow and also induce contraction of the liver vasculature, all of which could be readily monitored in real time using a high-frequency ultrasound vascular flow analyzer system.\n\n\nMETHODS\nVasculature of the perfused hindlimb (",
        "label": 0
    },
    "2253": {
        "output": "## [MASTER] Note: In your first submission, please provide the links to the HTML and PDF report.\n\n## [END]\n\n## [DECLINE] To make your first submission, you must register with Inquiry Jupyterhub by clicking the [Add your first submission] button on the right side. On the Inquiry Jupyter hub [Inquiry] page, you will see the form where you can enter the URL for your HTML report, or the URL for the location where you can download the PDF. (Instead of clicking the [Add your first submission] button, you can add a name for your report and the link after your first submission.) Upon successfully passing this registration step, you will be able to submit your work to the Inquiry library, including the results of the certification check .\n\n## [STANDARDIZED/UNSTANDARDIZED]\nIn this chapter you read about the concepts of standardized clinical trials and un-standardized clinical trials. You will learn how to assess whether standardization of clinical trials improves the reliability of results.\n\n## [INTRO]\nTrial investigators can improve the reliability and generalizability of their results by ensuring that the results of their trials are reproducible regardless of who performs them. Here \"who\" is relevant to whether a trial is standardized (i.e., performed using a pre-determined protocol) or unstandardized (not rigidly controlled by a pre-determined protocol).\n\n## What does standardization do?\n\n## What's new or unique about standardization?\nStandardization helps improve transparency, which is critical to replicability 8 , and reduces variability in results of similar trials or subtrials (e.g., intervention arms). For example, there is variability in the results of different clinics that treat the same medical condition. 10 Standardization reduces bias introduced by human error (e.g., trial investigators make a mistake during trial execution resulting in poor replication). 11 Standardization will help you to replicate the performance of the trial investigators by replicating the trial they run. If standardization is performed correctly, the result is a method to reproduce the results of the trial. \n\n## [TUTORIAL]\nIn this tutorial",
        "label": 0
    },
    "2254": {
        "output": "<EOD> Tension pneumothorax caused by nasogastric intubation.\nA case report is presented of tension pneumothorax occurring after nasogastric intubation in a patient with chronic lung disease.<EOD> The role of catecholamines and their metabolites in the early phase of myocardial ischemia. A microdialysis study in the isolated perfused guinea pig heart.\nEarly ventricular ischemia is characterized by high catecholamine and metabolite concentrations. Onset of coronary intervention is too late to prevent ischemic damage. Early recognition and immediate interventional therapy is advocated. Microdialysis was applied to the isolated perfused guinea pig heart to characterize ongoing metabolic changes and to assess their use for early detection of ischemia and its reversal by preconditioning and beta-adrenoreceptor blockade; 10 hearts were perfused on a Langendorff setup and subjected to 90 min of simulated ischemia. Control hearts were compared to a group receiving an antecedent 20 min of ischemia (preconditioning group), another one subjected to 5 min of antecedent left coronary artery stenosis (beta-adrenoreceptor blockade group) and a final group treated with 10 min of antecedent ischemia and the last 5 min of antecedent 5 min ischemic stenosis (preconditioning with beta-adrenoreceptor blockade group). Cardiomyocyte integrity was determined by an electrocardiogram. Endogenous glucose production was calculated from dialysate metabolite concentrations. Ischemia was confirmed by the appearance of pathologic electrocardiograms and the decline of endogenous glucose metabolism. Reperfusion was proven by restoring the electrocardiogram and glucose production. Ischemia caused pathologic electrocardiograms and decreased endogenous glucose production. Preconditioning and treatment with beta-adrenoreceptor blockade prevented tachycardia and delayed ischemic depolarization. Recipients of preconditioning and beta-adrenoreceptor blockade combined with ischemia displayed more stable electrocardi",
        "label": 1
    },
    "2255": {
        "output": "##### Q0: I get an error when I call the script.\n\nThis is usually either (a) the data directory is not set in the global environment or (b) the program is trying to access some file used in the script. Make sure you have set the datadir global variable correctly. In many cases, it will make sense to have this located in the directory in which you have scripts, e.g., `/usr/local/exercise-data\u2010dir/.\n\n##### Q1: How do I understand results?\n\nThere are four possible trial-level eligibility assessments: excluded (0), not relevant (1), eligible (2), and other (e.g., 6 when it looks like you need to ask additional questions from the patient to determine his eligibility, but you didn't ask). If you are interested in the proportion of patients eligible and excluded from the clinical trial based on demographic, clinical, and behavioral variables of the patient, you have to look at the patient who has no missing data for these variables. Please, don't forget this.\n\n##### Q2: How can I get the proportion of patients excluded or eligible based on some demographic or behavioral or clinical variables?\n\nIn RStudio, copy all code of the output. The output should show that it is an eligibility table. Please, don't forget this.\nNext, you have to select the number of rows and that's the number of patients with no excluded or no relevant observations (zero in other columns). Then you should specify the name for each of the columns that are calculated based on the patient demographic, behavioral, or clinical variables and the name of the trial. Please, don't forget this.\n\nPlease, open in the terminal and write: `Rscript \"path / to / my / data / file / my_script_name.r\" [path] [data_type(s)] [variable(s)] ['exclude' or 'eligible' or other] [name of my column].`\n\n##### Q3: How do I use the result of this code in the research report?\n\nHere is the example. I'm writing a short report for a research project that contains a summary of the statistics of the patient (e.g., 1",
        "label": 0
    },
    "2256": {
        "output": "<EOD> Exposure to ambient air pollution and its association with gaming and internet addiction behaviors in Korean adolescents: A natural experiment\n\nA B S T R A C TRationale: Children and adolescents with internet, smartphone and social media addiction (ISA) have been associated with numerous negative physical and psychiatric consequences. Recently, the relationship between ambient air pollution and adverse health outcomes has become a major public health concern. The aim of this study was to explore the relationship between ambient air pollution exposure and ISA behaviors in Korean adolescents during the new coronavirus pandemic. Methods: In this cross-sectional study, 2498 participants with a mean age of 17.44 \u00b1 2.97 years old were recruited. To assess the daily ISA, we used the Internet Addiction Diagnostic Scale. The level of ambient air pollution was measured by the Korea Ministry of Environment's National Air Pollutants Emissions Trends Database. The effect modification by sex was evaluated using a multiplicative interaction term. Multiple linear and logistic regression analyses were conducted to assess the relationship between air pollution exposure and ISA behaviors. The significance level was 0.05.Results:In sex-combined cases, exposure to PM2.5 and NO 2 was associated with increased mean score of global IS use . In the female group, exposure to SO 2 was associated with increased mean score of emotional IS use (\u03b2 = 0.44, 95% CI = 0.08-0.80, P = 0.018). Moreover, in the male group, the odds of having ISA problems increased by 14.67 times for each unit increase in PM10 exposure (OR = 14.67, 95% CI = 1.14-189.18, P = 0.038), and by 10.36 times in SO 2 exposure (OR = 10.36, 95% CI = 1.23\u221287.24, P = 0.031). However, no differences were found in the female group. Conclusions: In Korean adolescents during",
        "label": 1
    },
    "2257": {
        "output": "<EOD> Repeatability of two-dimensional transesophageal echocardiography measurements of aortic valve opening, mean systolic orifice area, and effective orifice area.\nBACKGROUND\nThe study was aimed to investigate the intra- and interobserver reproducibility of two-dimensional transesophageal echocardiography (TOE) in estimation of aortic and effective orifice area (AOA and EOA).\n\n\nMATERIAL/METHODS\nA prospective clinical study was conducted. TOE in apical four-chamber view was performed in 30 consecutive patients with aortic stenosis. The maximal aortic root diameter, perimeter, and cross-sectional area were measured according to the guidelines of the American Society of Echocardiography. Aortic valve area, mean systolic orifice area, EOA, and percentage EOA were calculated and compared in order to estimate valve stenosis. Reproducibility of the parameters measured by the first operator (Pk) was determined, and a second analysis was repeated by the same (Pk2) and an independent experienced observer (Pk1).\n\n\nRESULTS\nMean heart rate was 91.0+/-4.6 bpm (range 65-101). The coefficient determination was 0.888 (P<0.001) in correlation of the results obtained in 2 independent observers. The interobserver variability of AOA, EOA, and EOA% was 17.5%, 17.9%, and 19.3%, respectively. The intra-observer variability of AOA, EOA, and EOA% was 10.2%, 10.4%, and 11.1%, respectively. Correlation coefficient (R2) of linear regression was 0.965.\n\n\nCONCLUSIONS\nThe results of the study indicate that the reproducibility of two-dimensional TOE measurements is high and can be applied in clinical practice for the evaluation of the aortic stenosis severity and estimation of hemodynamic parameters in patients with a normal AV.<EOD> EEG-me",
        "label": 0
    },
    "2258": {
        "output": "The output for `trial_dyspnea` is below\n\n\n\n\n\ntitle: Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea\nsummary: The goal of this clinical research study is to learn if fentanyl can change perception of shortness of breath in cancer patients. Researchers also want to learn if the study drug can help to improve your physical function. In this study, fentanyl will be compared to a placebo.\n\n\n  title: # Clinical Trial Inclusions\n\nClinical Trial Inclusion Criteria<EOD> .\nRecent improvements in cancer chemotherapeutic agents have increased the survival rate of patients with advanced cancer. As a drug-associated adverse event, nephrotoxicity has become an important concern, and careful attention has to be paid to it. Nephrotoxicity is a toxicity caused by the renal tubular dysfunction and renal parenchymal injury induced by a cancer drug to which a renal tubular cells are most susceptible. As a clinical symptom, renal dysfunction could be asymptomatic. It is recommended that the serum creatinine level should be checked regularly in cancer patients who undergo cytotoxic therapy. In addition, it is necessary to pay attention to cases in which high fever and diarrhoea as well as hypokalemia and hypophosphatemia occur in patients who undergo cytotoxic therapy because those conditions are often associated with renal function damage. In addition to cancer drugs that lead to renal tubular dysfunction, some of which is presented in this review, renal function damage could be induced by drugs other than cancer drug. This review focuses on the recent findings related to the renal function deteriorations, which could be attributed to the cytotoxic drugs and other medications for cancer patients.<EOD> Scaling law of charge-transfer resistance in a mixed ionic/electronic conductor.\n\nA scaling law is derived to determine the charge-transfer resistance in the intermediate state for the case of mixed ionic (electronic) conductor, and the universal behavior over various systems is confirmed by the use of a general scaling argument. The existence of a universal",
        "label": 0
    },
    "2259": {
        "output": "### Exercise 3.6.3. How many clinical trial patients are eligible for this clinical trial?\n\nHere is the patient note:\n\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 100 mg/dl\nHbA1c: 6.5%\nCholesterol: 190 mg/dl\nTG: 140 mg/dl\nLDL: 125 mg/dl\nHDL: 40 mg/dl\nHere is the clinical trial:\nTitle: Losartan in Decompensated Heart Failure\n\n\nSummary: The dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients has been demonstrated to be beneficial. However, the dual inhibition has not been studied during heart failure decompensation or even when low cardiac output is present.~The objective of this study was to assess the effects of add-on therapy with angiotensin receptor blocker on plasma B-type natriuretic peptide levels and hemodynamic measurements in heart failure patients with low cardiac output during hospitalization for decompensation.~This was a randomized, double-blind, placebo-controlled clinical trial.\nInclusion criteria:\nhospitalization for decompensated heart failure\ndobutamine dependence\nejection fraction < 0.45\nt",
        "label": 0
    },
    "2260": {
        "output": "Here is another patient note:\nThe patient is a 72-year-old woman with type 2 diabetes mellitus diagnosed four years ago. Her previous hospitalization was in the last months, and she is at high risk of death, so her family prefers to continue treatment at home. She is suffering from anxiety and depression due to isolation and social distancing during COVID-19 disease and is on therapy for these problems. Her FBS is 200 mg%, HbA1C 11%, total cholesterol 200 mg%, LDL 140 mg%, HDL 40 mg%, Triglyceride 250 mg%, CRP positive, AFB negative, ESR 50%, CT scan shows bilateral pneumonia, TB test is negative. Her son lives around her house, but she must remain in isolation, which is difficult for her. Her history is not significant for any other medical issues. She has no history of heart disease, kidney or liver disease. She takes metformin 500 mg twice a day 2 tablets, Lopinavir 500 tablets once a day 1 tablet, Azithromycin 250 mg once twice daily 1 tablet. \nHere is the clinical trial for diabetes mellitus type 2 participants: \n\n## Inclusion criteria:\nInclusion Criteria:\nSubjects should be male or female, of nonchildbearing potential (e.g., postmenopausal [surgical, treatment, natural], older than age 55, documented bilateral oophorectomy, status post tubal ligation).\nSubjects should be clinically healthy, as determined by medical history (no cardiovascular or central nervous disease), physical examination including Vital Signs (e.g. heart rate, temperature, blood pressure, respiratory rate, and oxygen saturation), 12 lead electrocardiogram",
        "label": 2
    },
    "2261": {
        "output": "<EOD> .\nIt is shown that changes of the cardiodestitutive effects of catecholamines and angiotensin II after the destruction of renal medullary tissue, the renin-angiotensin system depression of diuresis and increase of systemic blood pressure occur during the development of chronic pyelonephritis. These changes, apparently, are due to the neurocytopathic action on the hypothalamo-hypophyso-adrenocortical system.<EOD> Fatal infection due to Mycobacterium avium in an immunocompetent child with ulcerative colitis\nA rare case of Mycobacterium avium infection in a 14\u2010year\u2010old girl with ulcerative colitis and no immunodeficiency, who developed respiratory symptoms and cough after 6 mo of azathioprine therapy, is reported. Transient improvement was observed after discontinuation of azathioprine but no clinical or laboratory improvement occurred during the next 3 mo, and an open lung biopsy was performed. The patient died 2 wk later because of irreversible tissue damage from M. avium infection. To make a prompt diagnosis is very important in patients with immune dysregulation syndrome and opportunistic infections, because early treatment may prevent progression of disease.<EOD> The first molecular epidemiology study of the emergent and global AIDS strain, CRF01_AE, in Yunnan, China\n\nBackground: Human immunodeficiency virus strains of the CRF01_AE subtype have emerged and become globally dominant in many countries. It is a very serious problem that epidemics of CRF01_AE strain have occurred in China at a rapid pace.Methods:In order to understand the molecular epidemiology of CRF01_AE strain, a total of 298 HIV-1-infected individuals from Yunnan, southwest China, were enrolled for a phylogenetic comparison. The 597-bp pol gene fragments were amplified and partially sequenced by DNA sequencing.Results: Yunnan subtype A and CRF01_AE (31.6% and 5",
        "label": 2
    },
    "2262": {
        "output": "[ACCTOR] [INST] Your task is to determine the relationship between the notes of a given patient and clinical trials.\n\nWrite a program that takes a patient note and list of clinical trials as input. If the patient note matches the information from any of the trials, report that there is a match according to the rules as follows:\nRule 1: If sex in the patient note is exactly same as sex in the trial then match is reported.\nRule 2: If birthdate in the patient note is equal to birth_date in the trial, then match is reported.\nRule 3: If age_group in the patient note is exactly the same as in trial (such as 16-25), then match is reported.\nRule 4: If the blood_group in the patient note is equal to the blood_group in the trial, match is reported.\n\nYour program should report the list of matched trials to the user and should not accept any input from the user.\nYou should use the `Cowboy` [1] environment as shown in the `README.md` file. [2]\n\nIn case of any question to answer, or if you are afraid of some difficulties (for e.g., reading time), do not hesitate in applying [EXTRA]. But remember that it is not allowed to submit the file for `Cowboy` after you have answered `EXTRA.md` file. [3]\n\n### Examples\n\nExamples are here. [4]\n\n### REFERENCE\n\n[1]: http://codeforstudents.org/\n[2]: http://codeforstudents.org/cowboy-a-python-test-framework/doc/README.md\n[3]: http://codeforstudents.org/cowboy-a-python-test-framework/doc/EXTRA.md\n[4]: Example\n\n[ACCTOR_NOTE] [INST] Welcome to the 3rd assessment, codeforstudents's contest.\n\nYour trial-level eligibility is as follows:\n\nTrial-level eligibility: 2) Eligible.\n\nYou should continue the task as before, but using the input file from the previous [ACCTOR] [INST]. Here comes the test information of",
        "label": 0
    },
    "2263": {
        "output": "### Participant recruitment\nAs a helpful assistant for clinical trial recruitment, you have to take account of all of the patients of the clinic:\n\nYou're done! The patient notes in this clinic have been examined to find eligible patients based on the inclusion criteria of the clinical trial. The patient's age is between 18 and 70 years. The participant's gender is male. And the diagnosis of diabetes Type 1 with shortness of breath is a critical indication for the clinical trial.\n# Discussion\nAlthough this method is robust enough for finding eligible patients, there are some limitations that should be noted. First, there is a strong assumption that there is no missing data in the participant and all the patient's eligibility for the trial is described in the note. Second, some other diseases that could influence the LVH, like thyroid disorders, renal impairment or renal failure should be taken into account, although the eligibility criterion is the LVH.\nMoreover, this method is useful if researchers are not able to identify an eligible patient. For example, suppose we don't know enough about a specific clinical trial if its trial name is not found on the web. You can search for the trial by its inclusion criteria, and then search for the clinical practice guideline with the same inclusion criteria. If it is not found, this suggests you may need to start a trial on this disease.\nIn this study, the researchers only focused on the left ventricular mass as a criterion. However, another interesting area of research could be the comparison of a trial with a specific disease and its eligibility criteria with another trial in a different clinic.\n# Conclusion\nIn this paper, a method for finding patient eligibility in clinics was introduced using a combination of machine learning and fuzzy logic. This proposed method could be an assistive system at clinical decision-making stages, e.g., eligibility assessment of clinical trial, improving the quality of care that could help clinicians make decisions more quickly.\nIn this paper, we only focus on the first issue that was mentioned. However, in future, we will focus on the second problem. In this problem, we want to focus on the clinical trials",
        "label": 0
    },
    "2264": {
        "output": "![image](https://user-images.githubusercontent.com/18343572/66784863-dad73900-c260-11ea-853c-78b7122c2bd4.png)\n![image](https://user-images.githubusercontent.com/18343572/66784161-3e33c900-c260-11ea-98d5-9710057405b2.png)\n\n## Problem solving\nIn general, the algorithmic way to perform data science tasks is to decompose the problem space into subspaces of similar or related tasks using domain experts, scientists, and data scientists. Then one should apply domain and scientific knowledge to the subspaces related to the problem and finally perform iterative algorithms to complete the subtasks.\n\nThe algorithmic approach to the problem can only be effective when the problem-related subspace is well-defined or there is domain knowledge to generalize the problem. In most cases, it is very difficult to generalize a problem and apply domain knowledge to the subspaces. Also, applying domain knowledge requires understanding and identifying the problem subspace of domain experts.\n\nA good approach is to iteratively solve the problem as data science projects are carried out using one domain or scientific knowledge and then proceed with the other domains or scientific knowledge.\n<EOD> Preparation of hydroxyapatite rods for orthopaedic applications: a brief report.\nRod segments of hydroxyapatite, a novel mineral ceramic, have been synthesised by the precipitation route from aqueous solution containing calcium chloride, di-ammonium hydrogen phosphate and sodium citrate at room temperature, neutral pH, and ambient atmosphere. The shape was made to look like that of the human femur which is cylindrical in shape and 150 mm long. The synthesised hydroxyapatite rods were characterised for phase identification, crystallinity and average crystallite size by X-ray diffraction, Fourier transform infrared spectroscopy and scanning electron microscopy. Phase purity and average crystallite size of the",
        "label": 0
    },
    "2265": {
        "output": "You should compare your code with the solution from [problem 3]({{ problem 3 ref }}). You should expect some difference in the code, because we had some different input and we needed to adapt the solution.<EOD> Lupus erythematosus profundus\nTwo cases of lc'pus erythematosus prc'Fundus) will be described. One case, which is typical, has been studied histologically, electron immunocytochemically and serologically. The clinical and histological features of lupus erythematosus prc'fundus are identical to those of lupus erythematosus disseminatus. No features peculiar to lupus erythematosus prcfundus are described, apart from a characteristic histological appearance of the papuli. Treatment with ant Malarone and prednisone has reduced the lesions greatly.<EOD> Fertilization of mouse eggs. A time-resolved immunofluorescence microscopy study.\nA time-resolved immunofluorescence microscopy method has been developed to localize the Fc fragment of mouse immunoglobulin G bound to mouse spermatozoa and egg antigens after sperm-egg interaction. The amount of bound IgG increased markedly immediately before and after sperm entry, reached a peak with sperm entry, and dropped to baseline shortly thereafter. The binding of IgG to spermatozoa coincided temporally with the increase in the percentage of fertilized eggs. This result could not be explained by any binding of IgG to the zona pellucida. The binding of IgG to the egg plasma membrane was in agreement with previous results and could be correlated with the appearance of membrane-attached cortical granules.<EOD> Prevalence of human papillomavirus infection and cervical cytological abnormalities in HIV-infected women in the Netherlands, 1990-1999.\nThe objective of this study was to describe the prevalence of high-risk human papillomavirus (HPV) infection and cervical cytology abnormalities in HIV-infected women in the Netherlands. The study population comprised all HIV-infected women from",
        "label": 1
    },
    "2266": {
        "output": "* **Output:** **Trial-level eligibility** **Should be** **2) Eligible.** **In the following example, please select correct patient note to provide the trial-level eligibility:** \n\n**_Please select correct patient note to provide the trial-level eligibility: 1-10_**\n\n**Trial-level eligibility: 2) Eligible**\n\n__________________________________________________________\n\n* You should write code to determine if a patient note is eligible for a clinical trial based on predefined inclusion and exclusion criteria. This is usually referred to as trial-level eligibility and evaluated as `0), 1) Not relevant or 2) Eligible`.\n\n* You should decide on a rule to make final decision on a given patient note as trial eligible or not. You can consider different scenarios as follow:\n\n- if all the exclusion criteria apply and no inclusion criteria apply, then the note is excluded (0);\n- if none of the exclusion criteria apply but no inclusion criteria apply, then the note is not relevant (1);\n- if a given patient note meets all the inclusion criteria but none of the specific exclusion criteria, then it is trial-level eligible (2);\n- if a given patient note meets at least one inclusion criteria and none of the specific exclusion criteria, then it is trial-eligible (2).\n\n* Please explain your decisions and motivation for each scenario (i.e. why you exclude a given patient note and provide more details why you treat a given patient note as trial-level eligible) in the answer box below this form.\n\n\n**You are welcome to use this opportunity to discuss your ideas. We are open to discuss them during the lab.** **_You should always choose two different patient notes with different scenarios to avoid cheating or simply repeating your previous answer_**\n<EOD> The 6th Asia Pacific Emergency Medicine Congress (APEMC VI): report of the scientific committee\nEmergency medicine (EM) practice across Asia Pacific varies widely and is evolving. Most APEMC VI Scientific Planning Committee Members (SPCM) are emergency physicians (EPs) working across a range of diverse health systems in Asia Pacific. \n \nE",
        "label": 0
    },
    "2267": {
        "output": "You should submit the code in a zip file named `submission for [your name]_[problem code]_[student number]`, e.g., `submission for VaeziR_14C_003`.\n\n\n# [A]: problem solution\nThe solution you are going to write is a series of functions in `Code.R` and `Main.R`. This solution is for your exam; however, it can be the source of your own code. Each function should begin with a capital letter. The solution is in 5 lines of code:\n- [Submission for VaeziR_14C_003] 1. You should import `DfCriteria` from the file `DfCriteria.r` to your `Code.R` file as `library(DfCriteria)`. \n- [Submission for VaeziR_14C_003] 2. You should import `clinic_data` from the file `clinic_data.rds` to your `Code.R` file as `library(clinic_data)`. \n- [Submission for VaeziR_14C_003] 3. You should define the function `clinicData.eligible(d, trial)` that takes a data frame `d` with the patient and clinic data and a trial object and returns the `Trial-level eligibility` of the patient(s) for the trial. Try to write a print of this function. \n- [Submission for VaeziR_14C_003] 4. If you are working in a Windows environment, you might find it hard to get output on the Windows platform; however, you can do so by calling the Windows version of the `DashBoard` package from your R console using `devtools::install_github(\"alashgar/RWeatherWidget\")`. Then, when you load the file by running command line for `code`, you could see the output of this function on the Windows system.  \n- [Submission for VaeziR_14C_003] 5. To define the function `clinicData.inclusionCriteria`, this function extracts the exclusion criteria of each trial and merges the `trial.criteria",
        "label": 0
    },
    "2268": {
        "output": "Now, the trial note should look similar to below.\nTrial code: 104539 Title: Effect of Non Invasive Brain Stimulation on Experimentally Induced Dyspnea (Breathlessness) Summary: Dyspnea is a frequent, mostly unpleasant and long-lasting, but also often undertreated symptom. Transcranial direct current stimulation (tDCS), a new non invasive method to modify brain activation has shown good efficacy in the treatment of pain especially in the clinical context. Given the fact that dyspnea has many common characteristics with pain, especially concerning the brain areas involved in its central processing, we hypothesize that tDCS may also modify the perception of dyspnea. In order to test this, we first shall determine whether tDCS has a significant effect on acutely induced dyspnea in healthy volunteers. In case of promising results of this pilot study, the next step will be the evaluation of the benefit of tDCS in patients with severe dyspnea.\nInclusion Criteria:\nRegistered at the National List of persons taking part in clinical research *\nSigned consent form\nSubjects of both genders aged of at least 18 years\nPerfect understanding of the instructions and of sensory scaling\nPrior medical examination<EOD> .\nThe paper contains a review of the literature and authors' own experience in the management of abdominal sepsis. It is concluded that surgical treatment combined with application intensive care measures can be used in the treatment of abdominal sepsis.<EOD> Transcranial direct current stimulation to enhance attentional bias modification.\nBACKGROUND\nAttentional bias modification (ABM) is an emerging treatment for addictive disorders, in particular drug addiction, that targets maladaptive attentional biases towards drug-related cues. Transcranial direct current stimulation (tDCS) has proven to be a promising adjunctive tool since repeated tDCS sessions can increase the retention of a therapy-specific bias change, thus potentially prolonging the treatment effect and enhancing addictive behavior changes. In the present study, we aimed to investigate whether application of an anodal or cathodal tDCS session immediately after an AB",
        "label": 0
    },
    "2269": {
        "output": "I am going to explain it step-by-step later...\n\n## A. Find patients with type 1 diabetes.\nThe patient has type 1 diabetes, so it's not necessary to find the patients using the type 1 diabetes variable. You should directly use the type 1 diabetes-related code. \n![INST] ## RESULTS\n\tTrial-level eligibility: 2) Eligible\n\tType-1 diabetes: Yes\n\tInclusion criteria: Yes\n\tHeart failure: No\n\tCardiomyopathy: Yes\n\tHypertension: No\n\tHypertrophic cardiomyopathy: Yes\n\tDilated cardiomyopathy: Yes\n\tAge < 18: No\n\tDead: No\n\tDrug allergy: Drug allergy\n\tHistory of drug and alcohol abuse: History of drug abuse\n\tHeart transplant: No\n\tCritical congestive heart failure in NYHA class 4: No\n\tHistory of myocardial infarction: No\n\tPeripheral arterial disease: No\n\tDiabetes mellitus: Yes\n\tSmoking: No\n\tHistory of cancer: No\n\tAlcohol use: Moderate\n\tInadequate glycemic control: No\n\tAge >= 89.0 or age <= 18.0: No\n\tAbuse of stimulant drugs and alcohol: No\n\tHistory of renal transplant: No\n\tEjection fraction less than 30: Yes \n\n## B. Find patients with cardiomyopathy.\nThe patient has cardiomyopathy, so it is unnecessary to find a patient using Cardiomyopathy. Instead, the patient diagnosed with cardiomyopathy should be found, and it should be checked for the presence of cardiomyopathy through the ICD9 code. \n![INST] ## RESULTS\n\tTrial-level eligibility: 2) Eligible\n\tHeart failure: No\n\tCardiomyopathy: Yes\n\tHypertension: No\n\tHeart transplant: No\n\tPeripheral arter",
        "label": 0
    },
    "2270": {
        "output": "<EOD> The effect of chronic exposure of arsenic in groundwater on skin and respiratory disease in the West Bengal basin, India.\nExposure to arsenic in groundwater is related to elevated cancer risks in populations consuming in excess of 600 microg l(-1). To our knowledge there is no epidemiologic study based on the concentration to which an individual is chronically exposed. The objectives of this study were to investigate the effect of exposure to arsenic in groundwater at varying concentrations on health outcomes in a rural population in the West Bengal Basin, India. Arsenic in drinking water samples was measured, and a household survey was performed to collect information on health outcomes of individuals, socioeconomic status, household water use and storage, and hygiene behaviors. A cross-sectional and prevalence ratio study was conducted for a sample of 891 men and 970 women over 14 years of age. Elevated odds of arsenic-induced disease were found to be statistically significant in women exposed for greater than 10 years at 200 microg l(-1) compared with women exposed for less than 10 years. These results imply that early intervention may be required to prevent the adverse impacts of arsenic.<EOD> A new strategy for cancer immunotherapy: targeting the metastatic niche.\nBACKGROUND\nMetastatic cells require specific environmental cues for their growth, which are provided by interactions of tumor-cell-derived exosomes with tumor microenvironmental cells present in the circulating blood or at distant tumor sites.\n\n\nMETHODS\nSeveral recent studies have shown that exosomes can be used to transport genetic material and can modify and control the function of recipient cells.\n\n\nRESULTS\nSeveral onco-protein and other transcripts involved in cancer metastasis have been identified in serum and plasma and are present even in patients with no clinically detectable disease.\n\n\nCONCLUSION\nIf specific cancer-derived exosomes could be defined, they might provide promising new targets for the control of metastatic spread.<EOD> Drug abuse prevention in young children: implications of",
        "label": 0
    },
    "2271": {
        "output": "There is a new class method of ClinicalTrial in the latest version:\n\n```python\n@classmethod\ndef trial_level_eligibility(cls, patient, trial):\n    for patient_in in trial.eligible:\n        if (\n            cls.trial_type in trial.inclusion\n        ) and (\n            cls.trial_type not in trial.exclusion\n        ) and (\n            cls.patient_data.age >= trial.age\n        ) and (\n            cls.patient_data.sex == \"Male\" if trial.sex_inclusion is \"Male\" else \"Female\"\n        ) and (\n            cls.patient_data.fbs >= trial.fbs\n        ) and (\n            cls.patient_data.hba1c >= trial.hba1c\n        ) and (\n            cls.patient_data.chol.name == \"CHOL\" and (\n                cls.patient_data.chol >= trial.chol_inclusion\n            ) or (\n                cls.patient_data.chol.name == \"LDL\" and (\n                    cls.patient_data.chol >= trial.ldl_inclusion\n                ) or (\n                    cls.patient_data.chol.name == \"HDL\" and (\n                        cls.patient_data.chol >= trial.hdl_inclusion\n                    )\n                )\n            )\n        ) and (\n            cls.patient_data.tg.name == \"TG\" and (\n                cls.patient_data.tg >= trial.tg_inclusion\n            )\n        )\n    return '2) Eligible'\n```\n\n<EOD> .\nThe pathogenic role of chlamydiae is currently proved. In the respiratory tract, most studies have been done in human immunodeficiency virus (HIV) infected patients in whom Chlamydia pneumoniae has been associated with a greater risk of chronic airways obstructions but not with lung cancer development. In other patients, C. psittaci has been identified in the bronchoal",
        "label": 0
    },
    "2272": {
        "output": "### [INFO] ## Info section is optional, if you have any notes to share.\nThe Info section must be named exactly `info` with the extension `.md`. If one wants to place their info in the root directory of the project instead of writing the name in the file path, then instead of writing the names of the root and file separately, one must write the names together separated by a colon and in such a way as `File: info.md`, in which each section will be called separately and the file extension will not be added. [INST]\n    ```md```\n    #### info section\n    *This section is optional, If you have any notes to share*    \n    ## Inclusion criteria\n\n# [TUT] ##\nIn this section, you can find many tutorials for writing code in R. If you need more help on R and its packages, visit `Rstudio` and see `RStudio Tutorial`:\n\n| [![](https://docs.google.com/uc?id=BV7-ZZbLx_VpZT3nQJHoX62RF7Z7wq9wk7&export=download)](#s) [RStudio Tutorial](https://www.rstudio.com/tutorials/)** | [![](https://docs.google.com/uc?id=BV7-ZZbLx_VpZT3nQJHoX62RF7Z7wq9wk7&export=download)](#s) [Package installation in R](https://cran.r-project.org/web/packages/cran.source/cran.source.pdf)** | [![](https://docs.google.com/uc?id=BV7-ZZbLx_VpZT3nQJHoX62RF7Z7wq9wk7&export=download)](#s) [Data and object creation in R](https://cran.r-project.org/web/packages/cran.source/cran.source.pdf)** | [![](https://docs.google.com/uc?id=BV7-ZZbLx_VpZT3nQJHoX62RF7Z7wq9w",
        "label": 0
    },
    "2273": {
        "output": "______________________________________________________\n[C_1] # Create a new code\n__all__ :\n\tdef ____init__(self, name: str, description: str=None):\n\t\tself.__name__ = name\n\t\tself.__description__ = description\n\t___init__.__name__: str\n\t__description__: str\n[C_2] # Create method\nfrom typing import Union\ndef ____get_name__():\n\treturn getattr(self, '__name__')\n___get_name.__type:\n\treturn Union[str]\n_get_name.__doc__:\n\t\"\"\"Get the object name.\"\"\"\n\treturn f\"The name of the object is {getattr(self, '__name__')}.\"\n_get_name.__return_type__:\n\treturn __type__\n[C_3] # Create method\nfrom typing import Union\ndef ____get_description__():\n\treturn getattr(self, '__description__')\n___get_description.__type:\n\treturn Union[str, None]\n_get_description.__doc__:\n\t\"\"\"Get the object description.\"\"\"\n\treturn getattr(self, '__description__') if getattr(self, '__description__') not in (None, '') else 'Undefined.'\n_get_description.__return_type__:\n\treturn Union[str, None]\n\n\n<EOD> 4-Fluoroquinolone Conjugated Gold Nanoparticles for Synergistic Cell Photodamage against Cancer Cells\nThe emergence of bacterial resistance has prompted the search for new antibacterial agents for widespread use. Fluoroquinolones act by targeting DNA, DNA gyrase, and topoisomerase enzyme complexes of bacteria through inhibition in their function. Nanoparticles, in this case gold nanoparticles, are potential carriers of drugs to the sites of action, reducing toxicity, and increasing their effectiveness. Nanoparticles have demonstrated greater efficiency in the treatment of cancer in recent years. The mechanism of action of these compounds is based on increasing the photodamage observed in cancer cells in vitro cultures. We designed and synthetized a gold nanop",
        "label": 0
    },
    "2274": {
        "output": "<EOD> .\nA number of new pharmacological agents have been developed for the treatment of human heart failure. Among these angiotensin I-converting enzyme inhibitors, angiotensin II antagonists, aldosterone antagonists, phosphodiesterase inhibitors, Ca antagonists, and endothelium dilator stimulators, have been widely prescribed for human heart failure. There is increasing evidence to support the use of pharmacological agents in ameliorating the end-stage cardiac pump function, and the survival rate in the treated patients has been significantly improved.<EOD> Differentiation of cisplatin-induced renal damage from concomitant injury: role of apoptosis and oxidative stress.\nWe investigated the role of apoptosis and oxidative stress in the induction of renal damage after cisplatin treatment. We determined the extent of apoptosis as a marker of cytotoxicity by determination of histopathological changes in the kidneys and by quantitative determination of internucleosomal DNA fragmentation in isolated kidney cells. Apoptosis was detected in the cortex and outer medulla of kidneys after intraperitoneal cisplatin injection, the apoptotic changes paralleling morphological damage. Internucleosomal DNA fragmentation in isolated kidney cells was induced at lower cisplatin doses (10-20 mg/kg) than required to cause apparent histopathological changes (30-60 mg/kg). A protective effect or prevention of apoptosis of isolated kidney tubular cells was achieved by simultaneous systemic injection of the antioxidant ascorbic acid at a dose of 750 mg/kg body wt., while a dose of 375 mg/kg failed to protect against cisplatin-induced renal damage. These results strongly support a primary role for apoptosis and secondary involvement of oxygen free radicals in cisplatin nephrotoxicity, with the degree of apoptosis being greater than that of oxidative damage.<EOD> EFFECTS OF OVOCALCITOL THERAPY ON RENAL FUNCTION IN",
        "label": 0
    },
    "2275": {
        "output": "<br>\n\n\n\n## Exercise\n- Write a program that displays the trial-level eligibility for each patient based on trial criteria above. Enter each patient's information and the trial criteria. Use a three-point scale for each, excluded (e.g., \u20180\u2019), not relevant (e.g., \u20181\u2019), and eligible (e.g., \u20182\u2019). Use \u2018x=\u2019 (e.g., \u20180=\u2019 for excluded or `1=\u2019 for not relevant) to output the patient results. Use `printf` to output results.\n\n- After you have written your program, compile it and execute the program. If you can print the patient information as well as the eligibility for the trial, then your program is correct.\n\n---\n\n\n# [INST] How to work with MATLAB functions and arrays](../programming/instructions/index.md)\nIf you need assistance, please visit these pages.\n\n* [Programming in MATLAB \u2013 An Introduction](https://www.mathworks.com/matlabcentral/fileexchange/38948-programming-in-matlab-an-introduction)<EOD> The Effect of Residual Infection in the Female Genital Tract on the Rate of Absorption of Sperm\nHistological and bacteriological examinations were made in twenty-two patients who had previously undergone salpingectomy. The patients were all suffering from sterility or subfertility and were subjected to laparoscopy at the invitation of Mr. D. J. L. Mowbray or myself. All were found to have one or more adhesions in the pelvis. In fifteen women pus was present in the uterus and in thirteen of these cases the pus was present in both the uterine and Fallopian tubes. The adhesions were in all cases the result of previous pelvic sepsis. In ten patients the bacterial counts from the pus were higher than 105. There were many species of organism isolated but mainly anaerobic vibrios were found both in the pus and on histological sections made from the tissues.<EOD> The Role of Bcl-2, p53, and MDM2 Expression in the Outcome",
        "label": 0
    },
    "2276": {
        "output": "Good luck to you!\n<EOD> Reevaluation in the use of HA1 mutation-based serotyping system for influenza A virus subtyping\n\nSerology subtyping is essential for influenza virus diagnosis as well as vaccine development. To develop a simple and efficient subtyping method, hemagglutinin (HA)1 gene coding region of the influenza A virus was divided into 4 fragments (designated A-D), which can specifically differentiate strains from different subtypes or serotypes according to the sequencing result. We demonstrated that the subtyping system based on sequencing fragment A (nt 153-219) could be applied to detect all subtype I strains of influenza A viruses by 2-mL microtube hemagglutination inhibition (HI) testing. The subtyping system based on sequencing fragment B (nt 261-421) can be used for both subtype II and III viruses since the reactivity of fragment B with antisera against all three HAs (H1, H2, H5, H6, H9, H10, H11, H14, H15, and H16) was observed. Subtype IV strains can be distinguished from the other subtype strains with fragment C (nt 424-702). These results suggest that only fragment A or fragment A plus fragment B can be used for subtyping purposes if the HA1 part of influenza viruses is required and that HI testing combined with the DNA sequencing methods, rather than the conventional HI testing, can be used as the serotyping method if the HA1 portion of H3 or H3 variant viruses must be determined.\n\n# Introduction\nEach influenza A virus is characterized by its HA subtype combination, which consists of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and H17. To",
        "label": 0
    },
    "2277": {
        "output": "# TIME IT (INST)\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to calculate the time it takes a patient to complete a treatment visit. The time it takes before, during, and after a treatment visit is an important measure of health resource use and is usually recorded as a part of the follow-up protocols. In certain clinical trials, the time is of particular importance as a parameter to be included in the costing analyses. Time is measured by hours, minutes, and seconds. To obtain the time values, you need to record the values of the time variables for all the visits or telephone calls.\n\nLet suppose:\n- The first visit is called \"Demonstration Visit\" which is scheduled for the first session and starts in the morning.\n- The second visit is called \"Baseline Visit\" which is planned in the afternoon of the same day and ends in the evening. In this visit, all the paper works such as registration of study participants and laboratory tests are done as well as collection of baseline data. All visits will be in your assigned trial. So, you are responsible for all scheduled visits for your trial, e.g., demonstration visits, baseline visits, 3, 6, \u2026, 12 months follow up visits and 24 months follow up visits. The time variables include:\n[CODE] (counseling time):\n2) The duration of a demonstration visit: In the demonstration visit patient participant learns the way how to follow his treatments with a specialist, self -injection his insulin medication and monitoring of the blood glucose daily, and diabetes education to enhance self -care and diabetes awareness. The duration of a demonstration visit is (30), you will record the amount of time a study participant spends speaking on a telephone for diabetes purposes.\n\n[/CODE] \n[INST] Let us do it:\n\n1. Record the above time values for all the scheduled study visits in the first column of Table in the excel file called \"\n\nTIME IT\"\n2. You can calculate the duration of a complete treatment visit by adding the values of all the visits in the third column, where you can compute the average duration from the second to",
        "label": 0
    },
    "2278": {
        "output": "# Conclusion\nThis tutorial covered the fundamentals of data wrangling and programming skillful in the R language. We introduced the reader to R and its basic commands. Then, we discussed data structures and how to convert text into data using the readr package and dplyr package. Finally, we demonstrated how to read data from databases to obtain data from the University of Troms\u00f8's database and how to read data from the web.\nWe also demonstrated how to obtain clinical data from a database and how to clean the data, apply data analysis by using the tidyverse package, and how to apply RStudio to prepare code and visualize the data. The RStudio interface consists of an editor and various visualizations to assist the data scientist in performing the best of data wrangling.\n<EOD> .\nBy means of experimental studies conducted on the animal species Mus musculus the authors demonstrated the ability of Corynebacterium jeikeium to induce an inflammatory process in the peritoneum, blood-forming organs and pleura. The studies proved the pathogenicity of the strain; the course of the inflammation process caused by the C. jeikeium strain was similar as in the inflammatory process caused by other pathogenic strains of corynebacteria.<EOD> Beta1 integrins induce a proteolytic cascade to regulate angiopoietin receptors and angiogenesis.\nThe receptor tyrosine kinase Tie2 and its ligand angiopoietin-1 (Ang-1) are indispensable molecules regulating the maturation and maintenance of the vascular network. We hypothesized that ECs undergoing angiogenesis are activated by an integrin signal. Integrin alpha2beta1, a receptor for laminin B1 chain of Laminin-5, is an EC adhesion receptor and induces integrin-mediated EC migration. Here we show that ECs adhering to laminin B1 are stimulated by Ang-1, activated Tie2, and phosphorylated protein kinase C. Inhibition of alpha2beta1 integrin blocked EC activation by laminin B1, Ang-1, and Tie2, suggesting that alpha2beta1 integrin mediates the T",
        "label": 0
    },
    "2279": {
        "output": "### Making a report on the results\nYou can make a report on the results by `Trial-level eligibility report:`.\n\n    # make final report\n    %report -l REPORT_NAME\n    %report -i REPORT_FILE.csv -s LOW -o REPORT_FILE.pdf -C\n    %report -i REPORT_FILE.csv -p 0.1 -l 10 -C\n    %report -i REPORT_FILE.csv\n    # report on the eligible patients\n    %report -l REPORT_NAME -j patients\n    \n\t\t\t\t\t\n    // ### HOSPITAL CONSULTATION\n\n\n_Hospitals and clinics are places with an opportunity to improve the quality and efficiency of healthcare. Using electronic health records is necessary to enhance the standard of care, save patients' lives, and minimize the frequency of rehospitalization. In this project, you have a chance to write a program that can recognize the patients who are at risk for rehospitalization._\n\n#### Sub-project 1: Identification of Patients at Risk of Rehospitalization\n\nYour task is to identify the patients at risk of rehospitalization in a given hospitalization. This task is based on clinical practice guidelines that recommend discharge planning with follow-up medical visits for patients at certain risk of disease reoccurrence. Rehospitalization occurs when patients cannot care for themselves sufficiently on their own after hospital discharge. It represents an expensive process for the healthcare system, and it is a threat to patient safety.\nYou should identify the patients who are at risk of rehospitalization using the following information:\n\n\n> - Patients (150): 10% of patients are at risk of rehospitalization;\n> \n> - Diseases (20): 30% of patients have congestive heart failure;\n> \n> - Health records (1100): 80% of patients have anemia.\n> \n> - Diseases (50): 30% of patients have depression.\n> \n> - Pharmacy orders (2",
        "label": 0
    },
    "2280": {
        "output": "You should write the results of our example under `Challenge 6 Results`, i.e., in the file named `challenge_6_results.Rmd`.\n\n## Clinical Trial Recruitment in Patient with Type I Diabetes: \n``` r ctrr```\n```\n---------------------------------------------------\nTrial-level eligibility: 2) Eligible.\n```\n\n> ## Challenge 7 \n\nYou are a helpful assistant for clinical trial recruitment. In a given patient note, you should compare the patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a four-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); 2) Not applicable (patient meets at least one of the exclusion criteria); and 3) Eligible (patient meets inclusion criteria, and also does not fulfill any of the exclusion criteria). \n\nHere is the patient note:\nThe patient is a 24-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow:\nFBS: 93 mg/dl\nHbA1c: 6.5%\nCholesterol: 160 m",
        "label": 0
    },
    "2281": {
        "output": "<EOD> The Relationship of Post-traumatic Stress Disorder to Depression in Patients with Acquired Immunodeficiency Syndrome\n\nBackground: The aim of the present study was to evaluate the relationship between post-traumatic stress disorder (PTSD) and depression in patients with acquired immunodeficiency syndrome (AIDS). Methods: Two hundred and eighteen AIDS outpatients referred to MKM clinic center in Shiraz, were selected through convenience sampling. Two study tool were used: Beck depression Inventory -II and Impact of Event Scale Revised. Data were analyzed using spss software. Correlation and Chi square test were used to demonstrate the relationship between depression and PTSD. Level of significance was set as 0.05. Results: In this study, 27.2%(n=59) of AIDS patients had post-traumatic stress disorder and the rate of depression in these patients was 78.0%. All cases with PTSD had depression; hence, a positive relationship was observed between PTSD and depression in AIDS patients (r = 0.75, p<0.001, 95% CI: 0.671 -0.817). There was a statistically significant relationship between PTSD and depression. Conclusion: The findings indicated a stronger relationship between depression and PTSD in the population studied.\n\n# Introduction\nPost-traumatic stress disorder (PTSD) is a set of mental, emotional, and physical responses that develop in response to a critical event. It sometimes takes the form of psychotic symptoms due to severe panic and fear. 1\n\n## Implications for health policy/practice/research/medical education\n\n## What is already known on this topic?:\nPost-traumatic stress disorder (PTSD) is a psychiatric syndrome that emerges after a period of time after a traumatic event. Acquired immunodeficiency syndrome (AIDS) is one of the main causes of people to be faced by a severe trauma. One of the main factors which is associated with poor prognosis of AIDS is the occurrence of PTSD. Moreover, individuals with AID",
        "label": 0
    },
    "2282": {
        "output": "## 2.2.2 The 2018 C-Path Initiative: Clinical Trial Recruitment Challenges & Solutions\nIn this survey, you will be asked to respond to a series of questions about clinical trial recruitment challenges, solutions, and policies regarding compensation and time requirements. While we are not seeking to reach consensus in this case, we anticipate that these responses will provide valuable insight for stakeholder conversations at the 2018 C-Path Initiative meeting. The results of this survey will be reported and disseminated by C-Path.\n\n# PATIENT-SPECIFIC FACTORS\n\n## Eligibility criteria\n\n### Select a patient or a set of patients to describe:\n\u25a1 I will describe eligibility criteria for a clinical trial.\n\u25a1 I will describe eligibility criteria for three clinical trials.\n\n### Explanation:\nIf you chose \"I will describe eligibility criteria for a clinical trial\" you will only be asked about 20 questions; if you chose \"I will describe eligibility criteria for three clinical trials\" you will be asked about 60 questions. \n\n### Examples of information to consider for these questions and how they could be answered:\n\n### 1. \nWho is participating in the clinical trial (e.g., type of patient (patient with ovarian cancer), age, gender, etc.)?\n\n### 2.\nWhy is that patient going to participate in the clinical trial?\n\n### 3.\nWhat disease will the patient enrolled in the clinical trial?\n\n### 4.\nWhat type of drugs may the patient be taking?\n\n### 5.\nWhat treatments may the patient be receiving?\n\n### 6.\nWhat kind of treatment are the investigators trying to give?\n\n### 7.\nWhat kind of diagnostic criteria were used to determine that the patient would likely benefit from the treatment?\n\n### 8.\nWhat kind of diagnostic tests would be performed?\n\n### 9.\nThinking about the clinical trial, what is the disease that the patient has?\n\n### 10.\nTh",
        "label": 0
    },
    "2283": {
        "output": "[TRIAL] The patient is the first candidate for the clinical trial:\n[TRIAL] Title: \"Broad spectrum antibiotics in hospitalized adult patients\"\n\nStudy design: Single patient trial.\n\nNumber of patients: The data shows a count of 1099, the data frame is 0.218 and the width is 4.95.\n\nA single-subject trial allows researchers to make a strong scientific statement about an intervention's efficacy with only a single patient. With a single patient, it is possible to ensure that the intervention is being evaluated in a clinically relevant manner (such as when the study is being performed in the patient's natural environment instead of an artificial setting). A single-subject trial is not intended to make generalizability statements; rather, it is a method for researchers to make strong statements about the effectiveness and efficacy of an intervention for a specific patient. \n\nIf the patient is the first candidate for the clinical trial, the first step is to determine whether or not s/he is eligible. Thus, we need the assessment function `is_eligible_patient` to evaluate the suitability of the patient in relation to the clinical trial, whose output is a `bool`:\nis_eligible_patient_1 = is_eligible_patient(patient_note)\nis_eligible_patient_1 [Trial] Eligible\n\nIf the trial_eligible function returns an eligibility of `Elilble`, then you assign the eligibility result to the patient object to be used later in the modeling:\ntrial_eligibility_note_1=trial_eligibility_note.set('trial_eligibility', is_eligible_patient_1.popstring)\ntrial_eligibility_note_1 ## [trial] Eligible\n\nFrom now, we are able to compare the patient's eligibility, with the inclusion criteria of the trial. The comparison of `0.174620`, indicates that the patient meet the trial's exclusion criteria. Therefore, we should exclude the patient. \n\nThe eligibility assessment has a three-point scale, as follows:",
        "label": 0
    },
    "2284": {
        "output": "# Questions\n1. What is the outcome (response variable) of the assessment of eligibility of patients in relation to participation in clinical trials?\n2. How the research team (a) generates a hypothetical clinical trial and (b) makes a trial-level eligibility assessment for potential participants?\n3. How the research team can find all potential participants in the clinic during a particular period based on the hypothetical clinical trial protocol?\n4. How the research team can report the results of the trial-level eligibility assessment in patients over time?\n<EOD> Assessment of the impact of chronic pain in 30.000 individuals diagnosed with primary hyperparathyroidism.\nBACKGROUND\nChronic pain is often observed in patients in different stages of hyperparathyroidism. The aim of the study was to analyze the potential impact of chronic pain on patients with primary hyperparathyroidism.\n\n\nMATERIAL/METHODS\n26,000 men and women in various stages of untreated primary hyperparathyroidism (elevated high and normal calcium serum levels) enrolled in the IAHPC (International Association for the Study of Hyperparathyroidism) Registry were included in the analysis.\n\n\nRESULTS\n4 188 (16.1%) patients reported persistent chronic pain. Most of them (3 739 or 90.0%) suffered from arthralgia and 855 (20.5%) of those with neuropathies. The most common joints affected were hands (2 128 or 51%), feet (2 014 or 48%), knees (808 or 19.4%), shoulders (717 or 17.5%), elbows (613 or 15%) and ankles (591 or 14.4%).\n\n\nCONCLUSIONS\nApproximately 16% of patients with untreated primary hyperparathyroidism suffer from chronic pain, mostly due to changes in the articulomuscular apparatus.<EOD> Immunogenicity and protective efficacy of a recombinant SAR",
        "label": 0
    },
    "2285": {
        "output": "[END]\nGood luck!\n\n<!-- MASTHEAD-->\n<!--\n<style>\n#masthead_container {\n    margin-top: 2rem;\n    text-align: center; }\n\n#nav_links {\n    position: relative;\n    color: var(--text-color--primary);\n    flex-flow:column;\n}\n#nav_links::before, #nav_links::after { text-decoration: not-braille; }\n\n#nav_links div{\n    padding: 0;\n    margin-top: 25px; }\n\n#nav_links div::before {\n    content: \"\";\n    display: inline-block;\n    border-vertical: 1px solid #ccc; }\n\n#nav_links>div [class^=\"naviga\"]:not([class*=\"naviga\"]):not(:last-child)::before {\n    width: 0;\n    content: \" \"; }\n\n#nav_links>div [class^=\"naviga\"]:not([class*=\"naviga\"]):not(:last-child)::after {\n    content: \"\";\n    clear: both; }\n\n#nav_links a {\n    font-size: 1.55rem;\n    font-weight: 400;\n    padding: .375rem .375rem .875rem;\n    letter-spacing: .25rem;\n    text-decoration: none;\n    margin-bottom: .625rem;\n\n    display: block; }\n\n#nav_links a::before {\n    border-bottom: 1px solid var(--text-border--color); }\n\n.header--primary{\n    text-align: center;\n    color: #272727;\n    font-family: \"Roboto MT Demi\", \"SF Nostalgic\";\n}\n.header--text-muted{\n    color: #ccc;\n    text-align: left;\n    font-size: 13px;\n    font-weight: 400;\n    margin-bottom: .4rem;\n}\n.birth-year-text",
        "label": 0
    },
    "2286": {
        "output": "Now, you're ready to implement your code. [INST] Try running \"!run_tutorial\" and you will see all the code in tutorial 1. Now, go ahead and run each one in turn, modifying it as needed and comparing your codes to mine. \n\n### Exercise 2: Explore different clinical trial data\nIn this exercise, you will be given the opportunity to explore data from the three different clinical trials in detail.\n1. Run each of the three trials:\n  - `!data_trial_1`, \n  - `!data_trial_2`, \n  - `!data_trial_3`. \n2. Explore the trial-level data. \n\n### Exercise 3: Implement a patient-level exclusion function\nIn this exercise, you will be asked to implement the exclusion check. For that you will need to first make sure that the `patient_level_exclusions` are assigned correctly to each trial. \n1. Run each of the three trials:\n  - `!trial_level_exclusions_1`. \n  - `!trial_level_exclusions_2`. \n  - `!trial_level_exclusions_3`. \n2. Make sure that the \"trial_level_exclusions\" variable contains the patient-level exclusion criteria for each of the three clinical trials. \n3. Implement a patient-level exclusion function called \"trial_level_exclusions_1\". \n   - It should take as input the variables of the patient record and check the \"trial_level_exclusions_1\" criteria. \n   - It should return the trial number of all excluded patients. \nFor each trial, a patient is considered eligible if the criteria are met. If not, the trial is excluded. So, if the patient matches the \"trial_level_exclusions_1\" criteria, it will return `1`, i.e., you get the desired result. If it doesn't match the \"trial_level_exclusions_1\" criteria, you need to implement the \"trial_level_exclusions_2\" criterion, and so on. It is your",
        "label": 0
    },
    "2287": {
        "output": "A: What you're supposed to do is\nfrom a given patient note, create a list of all entries, then create a list of all the clinical trials with the same fields (in random order), and then check to see if the entry is compatible with the trial. For all items, if incompitant with the trial, check the appropriate (for the item) reason and mark it appropriately. \nWhen the data points are listed, all you'll need is something like, import numpy from numpy.import numpy as np import pandas from pandas.import pandas as pd import scipy as scipy import pandas_profiling as pandas_profiling as profile import scipy.spatial.distance pandas.DataFrame as DataFrame\nThis:\n\n*\n\n*creates a data frame using numpy\n\n*create a Pandas data frame\n\n*import some pandas library\n\n*import scipy library\n\n*import pandas-profiling\n\n*import scipy, and import Pandas-Profiling, I just do like I assume the data frame in \nyour test to be\n\ndataList = {}\nfor item in datatable:\n    listOfItems = []\n    for data in item:\n        listOfItems += [value]\n    \n    dataList[data] = listOfItems ## make a dictionary\n\nnow, for each trial:\nimport random\nfor item in triples:\n    listOfTriples = []\n    for trial in triples:\n        # loop thru items and check \n        for data in trial:\n            listOfItems = dataList[data]\n            # check each element to fit the trial\n            if isinstance(listOfItems, list) and (len(listOfItems) == len(trials)) and checkFit (trials, listOfTriples):\n                print (\"fits:\")\n                listOfItems.append(\"fits\")\n                print listOfItems\n\n# check if it's right\ndef checkFit(x, y):\n    # check if x is a list or an array\n    if not isinstance(x, list):\n        return False\n\n    # check y \n    if len(x) != len(y) or not all(sublist in y.values for sublist in x.values):",
        "label": 0
    },
    "2288": {
        "output": "<EOD> The association of age with clinical and angiographic characteristics of coronary artery disease in patients referred for angiography.\nBACKGROUND\nAs increasing numbers of older patients are referred for coronary angiography, we sought to investigate the influence of age on the extent and severity of coronary artery disease (CAD).\n\n\nMETHODS\nWe prospectively analyzed clinical and angiographical data derived from 2386 consecutive patients referred for coronary angiography and subsequently admitted to an inpatient unit of the Coronary Care Unit between January 1996 and May 2001. Patients were stratified into three groups according to age: group A ( 65 years). The severity of CAD was compared across age groups using the Gensini and logistic EuroSCORE.\n\n\nRESULTS\nThe prevalence of CAD was 93.9% in group A, 92.6% in group B and 91.8% in group C (p=0.40). Significant CAD (luminal narrowing >50%) was found in 67.4%, 66.1% and 66.6% of the patients, respectively (p=0.72). The mean number of affected coronary arteries was 2.4, 2.2 and 2.4 for group A, group B and group C, respectively (p=0.20). There was a positive correlation between Gensini score and age (r=0.09; p=0.003). The mean Gensini score was significantly higher in patients >70 years than in 60- to 70-year-old patients or those  or <3 vessels were also found to increase with age (p<0.01); however, older patients remained at high risk for cardiovascular morbidity and mortality, irrespective of the severity or number of coronary lesions.\n\n\nCONCLUSION\nThere was no significant difference in the angiographic extent and severity of CAD between patients stratified according to age groups. Therefore, age itself cannot be regarded as a risk factor for the severity and extent of CAD.<EOD> The Fragile X Mental Retard",
        "label": 0
    },
    "2289": {
        "output": "<EOD> The Effect of Estradiol and Progesterone on the Release of Methylene-Hydroxy-Phenylacetic Acid (MHPA-Acetate), 6-Keto-Prostaglandin F1 alpha (lK) (a Metabolite of Prostaglandin F), Prostaglandin E and Oncotic Pressure of the Pyloric Lumen. A Study in a Gastric Fistula Rat Model\nThe aim of the present experiment was to find whether the effects of estradiol and progesterone on the gastric emptying of solids is a central effect or if the influence is mediated through the gastric mucosa. The effects of the hormones on gastric emptying and on the release of MHPA-Acetate, Prostaglandin E, 6-keto-PGF1 alpha (a metabolite of Prostaglandin F), and the Osmotic Pressure of the pyloric lumen, was studied in a gastric fistula rat model. 1 mg estradiol was administered orally, or 10 mg/kg body weight was injected intraperitoneally, both at 8:00 on the first day of the experiment (Hour 0) and 10:00 on the second day (Hour 12). 100 micrograms progesterone was administered orally, or 40 mg/kg body weight was injected intraperitoneally, at Hour 0 and at Hour 12. A control group received an equal volume of vehicle during the two injections on each of the two days. MHPA-Acetate, (6-keto-Prostaglandin) F1 alpha (K) (a metabolite of PGF), Prostaglandin E and Oncotic Pressure of the secretion collected in the pyloric cannulae were estimated and the emptying of the solid meal was determined. In the female rats there was a significant increase in the gastric emptying rate, in the Prostaglandin E content, in the Oncotic Pressure of the secretion, and in the released concentration of MHPA-Acetate",
        "label": 0
    },
    "2290": {
        "output": "## [INST] -\nYou'll have to apply these steps to every patient.\n\n## [INST] -\nYou'll learn more about the rules in the next section.\n\n## Clean-up\n\n## [INST] -\nGo to the next page, `End of Case #5`.\n\n![Cleanup]][5a]\n![Cleanup]][5b]\n![Cleanup]][5c]\n![Cleanup]][5d]\n[Cleanup]: /media/figures/inst/case5-11-clean.mp4\n\n## [INST] -\nIn the first box, set `Trial-level eligibility` to `Eligible`.\n\n![Cleanup]][6a]\n![Cleanup]][6b]\n![Cleanup]][6c]\n![Cleanup]][6d]\n[Cleanup]: /media/figures/inst/case5-12.mp4\n\n## [INST] -\nYou're all set! You've reviewed this patient for trial.  \nThank you for reviewing our virtual patient!\n\n## Exercise\n\n## [INST] -\nThere is more to study in this page! Go to the next page, `End of Case #5`. For now, open the window `Instructions`. \n![Next]][7a]\n[Next]: /media/figures/inst/case5-13.mp4\n\n## [INST] -\nGo to the next page, `End of Case #5`. For now, open the window `Instructions`. \n\n## [INST] -\nHappy programming! By the way, we noticed you were trying to open some of the wrong boxes. Good luck!\n\n## Exercise\n\n## Repeating the next section\n\n## [INST] -\nWhen you see the page with the `Start of Case #5`, press the `Enter` key. This will bring you to the first box on this screen, the Patient, `Patient` (see [image][6e]). You'll have to do this for 3 patients (see . \n\n## [INST] -\nWhen you see the page with the `End of Case #5`, press",
        "label": 0
    },
    "2291": {
        "output": "## 50) 2)\n\n# Results\n\n## In the top right of the screen are two buttons, run code and run widgets. \nRun Code: The Run code button enables you to select and run a single widget as code, without using our widget editor. Clicking this button will display the following: \n\n### [INST]\n[code]\nfrom pyscreen.core\nimport pyscreen.widgets as w\nfrom pyscreen.widgets.form import Form\nimport utils\ndef main():\n    # Set widget types to get desired look and feel\n    w.set(w.WidgetTypes.TITLE, TextInput.TITLE, value_ = \"My Text Widget.\", font = \"Monospace\", foreground = \"darkblue\", background = \"lightgray\", width = 128)\n    w.set(w.WidgetTypes.INPUT, TextInput.INPUT, value_ = \"My Input Widget.\", foreground = \"black\", width = 128, autoscroll=True)\n    w.set(w.WidgetTypes.NUMBER, NumberInput.NUMBER, value_=123, width = 48)\n    w.set(w.WidgetTypes.RADIO, RadioButton.RADIO, value_=True, selected_ = \"Selected\",)\n    w.set(w.WidgetTypes.CHECKBOX, Checkbox.CHECKBOX, value_=True)\n    w.set(w.WidgetTypes.BUTTON, Button.BUTTON, value_ = True)\n    w.set(w.WidgetTypes.DATETIME, TextInput.DATETIME, value_=\"02/22/2016\", foreground = \"blue\", background = \"orange\",)\n    w.set(w.WidgetTypes.DATETIME_RANGE, TextInput.DATETIME_RANGE, minvalue_=1234, maxvalue_=1235, foreground =\"darkblue\",background =\"lightgray\")\n    w.set(w.WidgetTypes.DATE, TextInput.DATE, value_ = \"05/05/1994\", min_=123, max_=124)",
        "label": 0
    },
    "2292": {
        "output": "### <span style=\"color:blue\" class=\"keyword\"><b>A Good Example:</b></span>  Including the effect size of an interventional study from a 1993 paper from the New England Journal of Medicine entitled \"Intensive Insulin Therapy in the In",
        "label": 0
    },
    "2293": {
        "output": "For the sake of time:\nYour patient meets all inclusion criteria: (0) Excluded (Does not meet inclusion criteria).\nYou think the patient is not relevant for the clinical trial: (1) Not relevant (Insufficient information to determine whether the patient is eligible to participate within the clinical trial according to the inclusion criteria).\nYour patient meets all inclusion criteria and exclusion criteria do not apply:\n(2) Eligible (Your patient has no exclusion criteria).\nThe [DATA] tag is used to store output data for a trial. You may use [DATA] tags for storing trial-level eligibility and other trial-specific results that you need to save. Let's store eligibility using the `Trial-level eligibility` tag:\nTrial-level eligibility: 2) Eligible.\n[/DATA]\nTo conclude...\n\n> [INST] patient_trial = trial_1\n> [DATA] trial_1_elig =\n>     \"0\"\n>     \"1\"\n>     \"2\"\n>   > [\"Patient has all inclusion and\n> no exclusion criteria and is thus considered\n> eligible to participate in\n> the clinical trial.\"]\n\n# Exercise\n**Use this to solve the exercise:**\n\n```python\nexercise, results_file = solve_exercise (\n  input_dir=input_dir,\n  trial_name=trial_name,\n)\n\n# Check if you got the right result:\nprint(\"The output will show a line of text like the following:\")\nprint(\"Exercise: solve_exercise(input_dir='~/exercises/',\",)\nprint(\"results_file) and will contain two data frames in the file.\")\nprint(\"1) trials_data\",)\nprint(\"with a trial_level_eligibility column and a trial_1_id column\")\nprint(\"2) eligibles_df data frames with a trial_level_eligibility column\")\nprint(\"and the same trial_1_id column as in trials_data.\")\nprint(\"Try to get a data frame named as trials_data:\")\nprint(\"try:\")\nprint(\"    trials = pd.read",
        "label": 0
    },
    "2294": {
        "output": "### PART II: Trial-level eligibility\n<Trial-level eligibility>\n\n```r\nTrial_id <-  $\"TCGA-MU-A9D6-01A\"\n\ntrialf <- trial_id %>% trial_get_trial_data(db) \ntrials <- do.call(rbind, trials)\ntreatments <- trial_get_trementments(db=Trial_db, trial_id) \n\n# Treatments that patient should take\nfor (treatment in treatments) {\n  trial <- treatments %>% trials %>% filter(Treatment.ID==treatment.ID)\n  trial <- trial %>% group_by(id) %>% group_by(id) %>% rbind(`Trial-level eligibility`:1,`Trial-level eligibility`: 2)\n  trial_treatment.table_df <- trial %>% data. frame() %>% mutate(Id=id, Treatment = Treatment ) %>% select(-Treatment.ID) %>% \n    unite %>% rbind(`Trial-level eligibility`:1, `Trial-level eligibility`: 2)\n  trial <- trial \n  trial_treatment.table_df <- trial_treatment.table_df %>% mutate(Trial_id = trials@data[Trial_id, ]) %>% \n  mutate(Trial_id = factor(Trial_id), treatments = names(trials@data)[treatments]) %>% pivot_wider(names_from = Treatment.ID, values_from = \"pct\", id_column = \"Trial_id\", names_prefixes = c(\"trials\",\"trials\")) %>% select(-c(Treatments)) %>% rowwise() \n  trial_treatments.table <- rbind(trial_treatment.table_df)\n\n\n# treatments patient should not take\nfor (treatment in treatments) {\n  trial <- treatments %>% trials %>% filter(Treatment.ID!=treatment.ID)\n  trial <- trial %>% group_by(id) %>% group_by(id",
        "label": 0
    },
    "2295": {
        "output": "The clinical trial should be repeated as the number of included patients is small.\n\n---\n\n### [CODE]<EOD> MON-LB112 Bone Morphology in Neonatal Children with Bipolar Affective Mother\n\n\n\n## Mon-lb111\nIntroduction: Neonatal hypoglycemia is associated with neurological complications, and long term consequences. Clinical trials have documented reduced incidence but long term morbidity outcomes remain unclear. We conducted a 40 year retrospective cohort review to describe developmental and neurodevelopmental outcomes in patients with neonatal hypoglycemia and evaluate the clinical utility of the term 'transient neonatal hypoglycemia' . Methods: We performed a retrospective chart review of all patients with neonatal hypoglycemia evaluated at the Centre for Child and Family Psychiatry at the University Health Network between May 1977 -October 2017. Data collected included: age at onset/diagnosis of BD 1, 2 and 3, gender, age at death, and psychiatric diagnoses. Results: Our sample included 240 subjects who met our criteria. For diagnosis of BD and for gender, the distributions were very similar (male=78, 32.5%; female=65, 27%, respectively). For age at first onset of BD 1, 2, 3 and at death, our sample exhibited a similar distribution across four categories (aged <12; 16-18; 19-39, >39 years) and each ranged from 9% -26% per age category. The mean age at death was 41.95+/-10.19 years. In total, 127 patients (53%) had completed high school, and 75 (31%) had completed college. Among all individuals with completed high school, 27 (36.6%) were on disability or received social benefits (compared to 65.3% of those who did not complete high school). Conclusions: Our data showed a similar age of onset of bipolar disorder (BD) across all age groups. However, the younger",
        "label": 0
    },
    "2296": {
        "output": "# Implementation notes\n```\nI hope, the training in R code and the R package for this data challenge can be instructive to others when facing similar data structure in the real healthcare settings. If you found this repository helpful or beneficial for your study of your own diseases or health, please feel free to like it or to make comments on its issues. (The authors are welcome to fix or add features).\n\nThere was a case where patient ID in the note file did not match with the other data files. I had to manually check to fix it. I suggest you make sure to verify manually such a simple thing which may look like a little detail but is rather noteworthy.\n\nPlease note that I developed this data challenge with open source technologies. All the code in this repository are accessible through the links in the README.md. The open source technologies I have used for this dataset are:\n\n* [R][R]$ R - The language of statistics.\n* [RStudio][RStudio]$ Visual Integrated Development Environment (IDE) for statistical programming in R.\n* [Rmarkdown][Rmarkdown]$ Document generation using R as the backend.\n* [Shiny][Shiny]$ User interface development using R as the backend.\n* [knitr][knitr]$ Dynamic document generation using R as the backend.\n* [bookdown][https://bookdown.rstudio.com/]$ Book writing using R as the backend.\n* [Bundler][https://rubygems.org/][Bundler]$ The dependency manager of Ruby, a general purpose programming language of statistical programming languages like R.\n* [Yarn][https://yarnpkg.com/][https://yarnpkg.com/][Yarn]$ The command line tool of Ruby, a general purpose programming language of statistical programming languages like R.\n* [NodeJS][https://nodejs.org/][https://github.com/nodejs/node][Node.js]$ The JavaScript runtime environment.\n* [npm][https://www.npmjs.com/][https://www.npmjs.com/][npm]$ The package management system of Node.js.\n* [Webpack][https://webpack.js.org/][https://webpack.js.org/][Webpack] The Web packing tool of Node.js.\n* [Evergreen",
        "label": 0
    },
    "2297": {
        "output": "* [STEP 2] How can you determine patient-level eligibility and generate patient-level features?\nHere are some rules that you should follow:\n- Determine if the age of the patient and trial inclusion criteria are the same; if so, set `patient-level eligibility: 1) Eligible`; otherwise, set it `patient-level eligibility: 0) Excluded`.\n- Determine if the gender of the patient is male or female; if so, set `patient-level eligibility: 1) Eligible`; otherwise, set it `patient-level eligibility: 0) Excluded`.\n- Examine the patient's hbA1C level; if it is lower than that of the trial inclusion criteria, set `patient-level eligibility: 1) Eligible`; otherwise, set it `patient-level eligibility: 0) Excluded`.\n- Determine if the patient's total cholesterol level meets the trial inclusion criteria; if so, set `patient-level eligibility: 1) Eligible`; otherwise, set it `patient-level eligibility: 0) Excluded`.\n- If the patient's LDL level is greater than that of the trial inclusion criteria, set `patient-level eligibility: 0) Excluded`; otherwise, set it `patient-level eligibility: 1) Eligible`.\n- Determine whether the patient has sufficient information to qualify for the trial; if not, set `patient-level eligibility: 1) Eligible`; otherwise, set it `patient-level eligibility: 0) Excluded`.\nTo demonstrate the steps, you can add the following code to the `Trial-level eligibility.py` file:\n[INST] Here I have created a data frame that contains patient ID, patient-level eligibility and trial-level eligibility.\n['ID', 'patient-level eligibility', 'trial-level eligibility'] = ['Patient ID', 'Patient-level eligibility', 'Trial-level eligibility']\ndf = pd.DataFrame(data=list(eligibility))\ndf.shape\n\n[",
        "label": 0
    },
    "2298": {
        "output": "<EOD> An exploration of attitudes to and experiences of mental health stigma in people with mild intellectual disabilities, and their caregivers.\nBackground: Mental health is an important area of need for people with intellectual disabilities (ID), yet they remain under-represented in mental health services. Objective: To explore service users' and their carers' attitudes to and experience of mental health stigma. Method: Qualitative exploratory study with semi-structured interviews. Thematic analysis was carried out. Results: Thirteen people with ID and 16 Caregivers were recruited. The majority of people with ID and their caregivers reported negative attitudes to mental health stigma, and both groups described negative experiences of mental health stigma. All service users in the study had experienced at least one form of mental health stigma, and service users and caregivers discussed the effect that these negative experiences had on them and those they were caring for. Conclusions: Both users of mental health services and their caregivers face challenges in accessing treatment for mental health disorders. These barriers include low awareness of the services available to them, negative attitudes within services and an unwillingness by those with ID and their caregivers to engage with treatment.<EOD> The role of adenosine in the neointimal hyperplasia that develops after stent placement in arteries of the dog: II. Effect of the A1 receptor antagonist DPCPX on experimental arterial remodeling.\nBACKGROUND\nIn our previous study, we demonstrated that the neointimal hyperplasia (NH) that develops in segments of dog coronary artery placed on a stent develops concomitantly with adenosine release and adenosine-receptor activation. This study examines the effect of the A1 adenosine receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) on the development of NH following stent placement.\n\n\nMETHODS\nVascular injury (120 minutes) and arterial wounding were performed in vivo in the left anterior descending (LAD) coronary artery of anesthetized beagles. The vascular bed in the LAD was",
        "label": 2
    },
    "2299": {
        "output": "<br>\n<br>\nIn the beginning of each file, you write \n```R\n#===========================================================\n# PATIENT DATA ANALYSIS MODULE\n#===========================================================\n```\n<br/>\nAnd after that, write \n```R <enter>\nTrial-level eligibility <-rep(0, length(patients))\nTrial-level eligible <-rep('Not recruited', length(patients))\nfor (i in unique(patients)) { Trial-level eligible <-c(Trial-level eligible, \"Eligible\" ) <enter>\n\nTrial-level eligibility <-c(Trial-level eligibility, i <enter>\n\nTrial-level eligibility <-(sum(Trial-level eligible == \"Eligible\")!=0)\"Yes\" <enter>\n\nTrial-level eligibility <-(sum(Trial-level eligibility == \"Eligible\")!=0)\"No\" <enter> \n\nfor (i in unique(patients)) { trial-level eligibility <-\"0\" \nfor (j in unique(clinical trial)) { trial-level eligibility <-c(trial-level eligibility,\"Eligible\" ) \nTrial-level eligibility <-\"Not recruited\" } <enter>\nTrial-level eligibility <-c(Trial-level eligibility,i ) <enter>\nTrial-level eligibility <-\"0\" \nTrial-level eligibility <-Trial-level eligibility <enter> \n\nTrial-level eligibility <c(Trial-level eligibility, length(patients)) <enter>\nTrial-level eligibility <-Trial-level eligibility <enter>\npatients <-\"0\" <enter>\nfor (i in unique(patients)) { patients <-\"1\" } <enter>\npatients <c(patients, length(clinical_trials))<enter>\npatients <-patients <enter>\n\nTrial-level eligible <-\"0\" <enter>\nfor (i in unique(clinical trial))",
        "label": 0
    },
    "2300": {
        "output": "### Pre-processing\n\nThere is something like _nature code_ in a given patient _note_ that means this person has this specific type of this disease, like _1_ is for diabetes mellitus type 1. _A_ in the clinical trial _description_ means a certain type of disorders that happen because of human cardio-myocytes generated from patients with _DM1_ and _N_ says not that type. That's why we should keep all this information about _diabetes mellitus type 1_ and other cases and discard others in our data preparation process.\n\nAs for the second goal, we are going to build _vector tables_ that contains information about _patient_ and _trial_ and make feature extraction from here and later join them in appropriate condition to create _features table_ that contains all information about all patients and the trial and will serve us for the classification.\n\n## Cleaning Data\n\nYou need to find a way to eliminate duplicate information, meaning that there must be two different fields with the same content, like `Name: Mukhtar A` and `Name: Mukhtar Nahhari`. You should replace them with one `Name: Mukhtar A Nahhari`. Note that there must be at least a number between these fields, e.g., there must be an amount between the two fields `Age: 25 years` and `Age: 25 years and 9 month`. \n\nThe amount of each field with same content has to be at most 50, and _the percentage of values in each field that has less to 50 is less than 50%_ as in the figure below. \n\n![data-cleaning](./Resources/data-cleaning.png)\n![data-cleaning](./Resources/data-cleaning.png)\n\n### Extracting feature vectors\n\nA feature vector is a table that includes information about the data. It contains different information:\n\n* Features (features represent different values of the attribute. For example, `Age`, `Male`, etc. in the note)\n* The attribute name (which refers to what will be represented in the vectors)\n* The feature value (value of the attribute that determines whether it is on or off. In this example",
        "label": 2
    }
}